PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fargali, S; Garcia, AL; Sadahiro, M; Jiang, C; Janssen, WG; Lin, WJ; Cogliani, V; Elste, A; Mortillo, S; Cero, C; Veitenheimer, B; Graiani, G; Pasinetti, GM; Mahata, SK; Osborn, JW; Huntley, GW; Phillips, GR; Benson, DL; Bartolomucci, A; Salton, SR				Fargali, Samira; Garcia, Angelo L.; Sadahiro, Masato; Jiang, Cheng; Janssen, William G.; Lin, Wei-Jye; Cogliani, Valeria; Elste, Alice; Mortillo, Steven; Cero, Cheryl; Veitenheimer, Britta; Graiani, Gallia; Pasinetti, Giulio M.; Mahata, Sushil K.; Osborn, John W.; Huntley, George W.; Phillips, Greg R.; Benson, Deanna L.; Bartolomucci, Alessandro; Salton, Stephen R.			The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure	FASEB JOURNAL			English	Article						adrenal; chromaffin granule; CG; large dense core vesicle; LDCV; norepinephrine	GRANULE-LIKE STRUCTURES; DENSE-CORE GRANULES; NERVE GROWTH-FACTOR; CHROMOGRANIN-A; TARGETED ABLATION; NEUROPEPTIDE-Y; MESSENGER-RNA; NEUROENDOCRINE; PEPTIDE; EXPRESSION	Secretion of proteins and neurotransmitters from large dense core vesicles (LDCVs) is a highly regulated process. Adrenal LDCV formation involves the granin proteins chromogranin A (CgA) and chromogranin B (CgB); CgA- and CgB-derived peptides regulate catecholamine levels and blood pressure. We investigated function of the granin VGF (nonacronymic) in LDCV formation and the regulation of catecholamine levels and blood pressure. Expression of exogenous VGF in nonendocrine NIH 3T3 fibroblasts resulted in the formation of LDCV-like structures and depolarization-induced VGF secretion. Analysis of germline VGF-knockout mouse adrenal medulla revealed decreased LDCV size in noradrenergic chromaffin cells, increased adrenal norepinephrine and epinephrine content and circulating plasma epinephrine, and decreased adrenal CgB. These neurochemical changes in VGF-knockout mice were associated with hypertension. Germline knock-in of human VGF(1-615) into the mouse Vgf locus rescued the hypertensive knockout phenotype, while knock-in of a truncated human VGF(1-524) that lacks several C-terminal peptides, including TLQP-21, resulted in a small but significant increase in systolic blood pressure compared to hVGF(1-615) mice. Finally, acute and chronic administration of the VGF-derived peptide TLQP-21 to rodents decreased blood pressure. Our studies establish a role for VGF in adrenal LDCV formation and the regulation of catecholamine levels and blood pressure.Fargali, S., Garcia, A. L., Sadahiro, M., Jiang, C., Janssen, W. G., Lin, W.-J., Cogliani, V., Elste, A., Mortillo, S., Cero, C., Veitenheimer, B., Graiani, G., Pasinetti, G. M., Mahata, S. K., Osborn, J. W., Huntley, G. W., Phillips, G. R., Benson, D. L., Bartolomucci, A., Salton, S. R. The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure.	[Fargali, Samira; Garcia, Angelo L.; Sadahiro, Masato; Jiang, Cheng; Janssen, William G.; Lin, Wei-Jye; Cogliani, Valeria; Elste, Alice; Mortillo, Steven; Pasinetti, Giulio M.; Huntley, George W.; Phillips, Greg R.; Benson, Deanna L.; Salton, Stephen R.] Ichan Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA; [Salton, Stephen R.] Ichan Sch Med Mt Sinai, Dept Geriatr, New York, NY 10029 USA; [Pasinetti, Giulio M.] Ichan Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Garcia, Angelo L.; Sadahiro, Masato; Jiang, Cheng] Ichan Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA; [Pasinetti, Giulio M.; Huntley, George W.; Phillips, Greg R.; Benson, Deanna L.; Salton, Stephen R.] Ichan Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Cero, Cheryl; Veitenheimer, Britta; Osborn, John W.; Bartolomucci, Alessandro] Univ Minnesota, Dept Integrat Biol & Physiol, Minneapolis, MN USA; [Graiani, Gallia] Univ Parma, Dept Internal Med & Biomed Sci, I-43100 Parma, Italy; [Mahata, Sushil K.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Mahata, Sushil K.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Minnesota System; University of Minnesota Twin Cities; University of Parma; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego	Salton, SR (corresponding author), Ichan Sch Med Mt Sinai, Dept Neurosci, Box 1065,1 Gustave L Levy Pl, New York, NY 10029 USA.	stephen.salton@mssm.edu	Jiang, Cheng/O-6217-2017; Mahata, Sushil/AAF-8781-2021; Lin, Wei-Jye/AGW-1054-2022	Jiang, Cheng/0000-0003-4583-3295; Huntley, George W./0000-0003-3645-6192; Lin, Wei-Jye/0000-0002-6057-7325; Graiani, Gallia/0000-0003-1926-7568; Cero, Cheryl/0000-0003-0513-8669; Benson, Deanna/0000-0001-7037-1147; Salton, Stephen/0000-0003-4087-8427; Pasinetti, Giulio/0000-0002-1524-5196	American Psychological Association Diversity Program in Neuroscience predoctoral fellowship; U.S. National Institutes of Health (NIH) Endocrine Training grant [5T32DK07645]; NIH grant [RO1 DK071308, RO1 MH086499, R21/R33 MH083496, R01 HL076312]; Diabetes Action Research and Education Foundation; Minnesota Partnership for Biotechnology and Medical Genomics, Decade of Discovery in Diabetes grant; U.S. Department of Veterans Affairs Research Career Scientist Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL116476, R01HL076312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071308, T32DK007645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH096678, R33MH083496, R01MH086499, R21MH083496] Funding Source: NIH RePORTER	American Psychological Association Diversity Program in Neuroscience predoctoral fellowship; U.S. National Institutes of Health (NIH) Endocrine Training grant; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Diabetes Action Research and Education Foundation; Minnesota Partnership for Biotechnology and Medical Genomics, Decade of Discovery in Diabetes grant; U.S. Department of Veterans Affairs Research Career Scientist Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank director Kevin Kelley and staff of the Mouse Genetics Core Facility (Icahn School of Medicine at Mount Sinai) for their assistance with Vgf gene targeting in ES cells and the generation of humanized VGF-knock-in mouse lines. This work was supported by an American Psychological Association Diversity Program in Neuroscience predoctoral fellowship (A. L. G.), U.S. National Institutes of Health (NIH) Endocrine Training grant 5T32DK07645 (S. F.), NIH grant RO1 DK071308 (S. R. S.), NIH grant RO1 MH086499 (S. R. S.), NIH grant R21/R33 MH083496 (S. R. S.), the Diabetes Action Research and Education Foundation (S. R. S.), a Minnesota Partnership for Biotechnology and Medical Genomics, Decade of Discovery in Diabetes grant (A. B.), NIH grant R01 HL076312 (J.W.O.), and a U.S. Department of Veterans Affairs Research Career Scientist Award (S. K. M.).	Bartolomucci A, 2006, P NATL ACAD SCI USA, V103, P14584, DOI 10.1073/pnas.0606102103; Bartolomucci A, 2011, ENDOCR REV, V32, P755, DOI 10.1210/er.2010-0027; Beuret N, 2004, J BIOL CHEM, V279, P20242, DOI 10.1074/jbc.M310613200; Bozdagi O, 2008, J NEUROSCI, V28, P9857, DOI 10.1523/JNEUROSCI.3145-08.2008; Canu N, 1997, GENOMICS, V45, P443, DOI 10.1006/geno.1997.4945; Chakraborty TR, 2006, BRAIN RES, V1089, P21, DOI 10.1016/j.brainres.2006.02.124; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; Courel M, 2010, J BIOL CHEM, V285, P10030, DOI 10.1074/jbc.M109.064196; Courel M, 2006, J BIOL CHEM, V281, P38038, DOI 10.1074/jbc.M604037200; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; D'Amato F, 2008, J ENDOCRINOL, V197, P359, DOI 10.1677/JOE-07-0346; Diaz-Vera J, 2012, FASEB J, V26, P430, DOI 10.1096/fj.11-181941; Diaz-Vera J, 2010, J NEUROSCI, V30, P950, DOI 10.1523/JNEUROSCI.2894-09.2010; Elste AM, 2006, J COMP NEUROL, V495, P324, DOI 10.1002/cne.20876; Esler M, 2006, HYPERTENSION, V48, P787, DOI 10.1161/01.HYP.0000242642.42177.49; Fargali S, 2012, J ENDOCRINOL, V215, P313, DOI 10.1530/JOE-12-0172; Fujihara H, 2012, ENDOCRINOLOGY, V153, P1377, DOI 10.1210/en.2011-1539; Garcia AL, 2005, J BIOL CHEM, V280, P41595, DOI 10.1074/jbc.M509122200; Gentile F, 2004, EXP CELL RES, V295, P269, DOI 10.1016/j.yexcr.2004.01.010; Grabner CP, 2005, J NEUROPHYSIOL, V94, P2093, DOI 10.1152/jn.00316.2005; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hahm S, 1999, NEURON, V23, P537, DOI 10.1016/S0896-6273(00)80806-5; Hahm S, 2002, J NEUROSCI, V22, P6929; Hanson HH, 2010, MICROSC MICROANAL, V16, P747, DOI 10.1017/S1431927610094092; Helle KB, 2004, BIOL REV, V79, P769, DOI 10.1017/S146479310400644X; Hendy GN, 2006, MOL ENDOCRINOL, V20, P1935, DOI 10.1210/me.2005-0398; Hotta K, 2009, J ENDOCRINOL, V202, P111, DOI 10.1677/JOE-08-0531; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; Hunsberger JG, 2007, NAT MED, V13, P1476, DOI 10.1038/nm1669; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Inomoto C, 2007, J HISTOCHEM CYTOCHEM, V55, P487, DOI 10.1369/jhc.6A7110.2007; Jethwa PH, 2007, ENDOCRINOLOGY, V148, P4044, DOI 10.1210/en.2007-0038; Kim T, 2005, J NEUROSCI, V25, P6958, DOI 10.1523/JNEUROSCI.1058-05.2005; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; Loh YP, 2012, J MOL NEUROSCI, V48, P347, DOI 10.1007/s12031-012-9728-2; Loh YP, 2004, J MOL NEUROSCI, V22, P63, DOI 10.1385/JMN:22:1-2:63; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Malosio ML, 2004, J CELL SCI, V117, P743, DOI 10.1242/jcs.00934; Montero-Hadjadje M, 2009, J BIOL CHEM, V284, P12420, DOI 10.1074/jbc.M805607200; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; Obermuller S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008936; Ozawa H, 1995, CELL STRUCT FUNCT, V20, P415, DOI 10.1247/csf.20.415; Possenti R, 1999, ENDOCRINOLOGY, V140, P3727, DOI 10.1210/en.140.8.3727; Possenti R, 2012, BIOCHEM J, V441, P511, DOI 10.1042/BJ20111165; SALTON SRJ, 1991, MOL CELL BIOL, V11, P2335, DOI 10.1128/MCB.11.5.2335; Salton SRJ, 2000, FRONT NEUROENDOCRIN, V21, P199, DOI 10.1006/frne.2000.0199; Snyder SE, 2003, J ENDOCRINOL, V179, P227, DOI 10.1677/joe.0.1790227; Stephens SB, 2012, CELL METAB, V16, P33, DOI 10.1016/j.cmet.2012.05.011; Stettler H, 2009, BIOCHEM J, V418, P81, DOI 10.1042/BJ20071382; Thakker-Varia S, 2007, J NEUROSCI, V27, P12156, DOI 10.1523/JNEUROSCI.1898-07.2007; Toshinai K, 2010, AM J PHYSIOL-ENDOC M, V299, pE394, DOI 10.1152/ajpendo.00768.2009; Trani E, 2002, J NEUROCHEM, V81, P565, DOI 10.1046/j.1471-4159.2002.00842.x; TRANI E, 1995, J NEUROCHEM, V65, P2441; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Veitenheimer B, 2011, AM J PHYSIOL-REG I, V300, pR460, DOI 10.1152/ajpregu.00371.2010; Watson E, 2005, ENDOCRINOLOGY, V146, P5151, DOI 10.1210/en.2005-0588; Watson Elizabeth, 2009, BMC Physiology, V9, P19, DOI 10.1186/1472-6793-9-19; Yamaguchi H, 2007, J BIOL CHEM, V282, P26354, DOI 10.1074/jbc.M701665200; Zhang KX, 2014, J NEUROCHEM, V129, P48, DOI 10.1111/jnc.12527; Zhang KX, 2011, CURR HYPERTENS REP, V13, P36, DOI 10.1007/s11906-010-0170-y; Zhang KX, 2009, CIRC-CARDIOVASC GENE, V2, P46, DOI 10.1161/CIRCGENETICS.108.785659	63	33	33	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2120	2133		10.1096/fj.13-239509	http://dx.doi.org/10.1096/fj.13-239509			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24497580	Green Published			2022-12-28	WOS:000335336000016
J	Jing, D; Baik, AD; Lu, XL; Zhou, B; Lai, XH; Wang, LY; Luo, EP; Guo, XE				Jing, Da; Baik, Andrew D.; Lu, X. Lucas; Zhou, Bin; Lai, Xiaohan; Wang, Liyun; Luo, Erping; Guo, X. Edward			In situ intracellular calcium oscillations in osteocytes in intact mouse long bones under dynamic mechanical loading	FASEB JOURNAL			English	Article						lacunocanalicular system; purinergic receptor; mechanotransduction; fluorescence recovery after photobleaching; endoplasmic reticulum; shear stress	FLUID-FLOW; SOLUTE TRANSPORT; STRAIN AMPLIFICATION; OSTEOBLASTIC CELLS; SHEAR-STRESS; ACTIVATION; INCREASES; MODEL; ATP; CALVARIA	Osteocytes have been hypothesized to be the major mechanosensors in bone. How in situ osteocytes respond to mechanical stimuli is still unclear because of technical difficulties. In vitro studies have shown that osteocytes exhibited unique calcium (Ca2+) oscillations to fluid shear. However, whether this mechanotransduction phenomenon holds for in situ osteocytes embedded within a mineralized bone matrix under dynamic loading remains unknown. Using a novel synchronized loading/imaging technique, we successfully visualized in real time and quantified Ca2+ responses in osteocytes and bone surface cells in situ under controlled dynamic loading on intact mouse tibia. The resultant fluid-induced shear stress on the osteocyte in the lacunocanalicular system (LCS) was also quantified. Osteocytes, but not surface cells, displayed repetitive Ca2+ spikes in response to dynamic loading, with spike frequency and magnitude dependent on load magnitude, tissue strain, and shear stress in the LCS. The Ca2+ oscillations were significantly reduced by endoplasmic reticulum (ER) depletion and P-2 purinergic receptor (P2R)/phospholipase C (PLC) inhibition. This study provides direct evidence that osteocytes respond to in situ mechanical loading by Ca2+ oscillations, which are dependent on the P2R/PLC/inositol trisphosphate/ER pathway. This study develops a novel approach in skeletal mechanobiology and also advances our fundamental knowledge of bone mechanotransduction.-Jing, D., Baik, A. D., Lu, X. L., Zhou, B., Lai, X., Wang, L., Luo, E., Guo, X. E. In situ intracellular calcium oscillations in osteocytes in intact mouse long bones under dynamic mechanical loading.	[Jing, Da; Luo, Erping] Fourth Mil Med Univ, Dept Biomed Engn, Xian 710032, Shaanxi, Peoples R China; [Jing, Da; Baik, Andrew D.; Lu, X. Lucas; Zhou, Bin; Guo, X. Edward] Columbia Univ, Dept Biomed Engn, Bone Bioengn Lab, New York, NY 10027 USA; [Lu, X. Lucas; Lai, Xiaohan; Wang, Liyun] Univ Delaware, Dept Mech Engn, Newark, DE 19716 USA	Air Force Military Medical University; Columbia University; University of Delaware	Guo, XE (corresponding author), Columbia Univ, 351 Engn Terrace,Mail Code 8904, New York, NY 10027 USA.	ed.guo@columbia.edu	lu, xl/HDO-8340-2022		U.S. National Institutes of Health [R21 AR052417, R01 AR052461, RC1 AR058453, R01 AR054385]; China Scholarship Council; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052461, RC1AR058453, R21AR052417, R01AR054385] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Keith Yeager, Bin Wang, and Wen Li for their technical help in the experiments; Genevieve Brown and Andrea Morrell for their help in drafting the manuscript; and Andrea Morrell for her help in performing the ionomycin experiments. This work was supported by the U.S. National Institutes of Health (grants R21 AR052417, R01 AR052461, and RC1 AR058453 to X.E.G. and R01 AR054385 to L.W.). D.J. thanks the China Scholarship Council for its partial financial support. The authors declare no conflicts of interest.	Adachi T, 2009, J BIOMECH, V42, P2507, DOI 10.1016/j.jbiomech.2009.07.006; Ajubi NE, 1999, AM J PHYSIOL-ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Brodt MD, 2010, J BONE MINER RES, V25, P2006, DOI 10.1002/jbmr.96; Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756-3282(96)00028-2; Burra S, 2010, P NATL ACAD SCI USA, V107, P13648, DOI 10.1073/pnas.1009382107; Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989; De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022; Fritton JC, 2005, BONE, V36, P1030, DOI 10.1016/j.bone.2005.02.013; Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136; Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021; Grimston SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044222; Guo YH, 1999, AM J PHYSIOL-LUNG C, V276, pL1018, DOI 10.1152/ajplung.1999.276.6.L1018; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Heinemann A, 1999, BRIT J PHARMACOL, V128, P313, DOI 10.1038/sj.bjp.0702808; Henriksen Z, 2006, CELL CALCIUM, V39, P435, DOI 10.1016/j.ceca.2006.01.012; Himeno-Ando A, 2012, BIOCHEM BIOPH RES CO, V417, P765, DOI 10.1016/j.bbrc.2011.12.031; Huang LP, 2004, J PHARMACOL EXP THER, V309, P193, DOI 10.1124/jpet.103.060814; Hung CT, 1997, AM J PHYSIOL-CELL PH, V272, pC1611, DOI 10.1152/ajpcell.1997.272.5.C1611; Huo B, 2010, CELL CALCIUM, V47, P234, DOI 10.1016/j.ceca.2009.12.005; Hutchins BI, 2008, J NEUROSCI, V28, P143, DOI 10.1523/JNEUROSCI.4548-07.2008; Ishihara Y, 2013, BONE, V53, P204, DOI 10.1016/j.bone.2012.12.002; Ishihara Y, 2012, BONE, V50, P842, DOI 10.1016/j.bone.2012.01.021; Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev-bioeng-070909-105302; Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021-9290(98)00114-6; Jing D, 2013, BONE, V53, P531, DOI 10.1016/j.bone.2013.01.008; Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200; Jorgensen NR, 2000, J BONE MINER RES, V15, P1024, DOI 10.1359/jbmr.2000.15.6.1024; Judex S, 2009, ORTHOD CRANIOFAC RES, V12, P94, DOI 10.1111/j.1601-6343.2009.01442.x; Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200; Li P, 2012, ANN BIOMED ENG, V40, P1874, DOI 10.1007/s10439-012-0554-z; Lu XL, 2012, BONE, V51, P466, DOI 10.1016/j.bone.2012.05.021; Lu XL, 2012, J BONE MINER RES, V27, P563, DOI 10.1002/jbmr.1474; Lynch ME, 2010, J APPL PHYSIOL, V109, P685, DOI 10.1152/japplphysiol.00210.2010; Moriishi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040143; Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452; Price C, 2011, J BONE MINER RES, V26, P277, DOI 10.1002/jbmr.211; Robling AG, 2009, CRIT REV EUKAR GENE, V19, P319, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.50; Rochefort GY, 2010, OSTEOPOROSIS INT, V21, P1457, DOI 10.1007/s00198-010-1194-5; Silva MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034980; Sipma H, 1996, EUR J PHARMACOL, V305, P207, DOI 10.1016/0014-2999(96)00167-7; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Thi MM, 2012, J MEMBRANE BIOL, V245, P401, DOI 10.1007/s00232-012-9462-2; Turner CH, 2005, J BONE MINER METAB, V23, P16, DOI 10.1007/BF03026318; Turner CH, 2002, CALCIFIED TISSUE INT, V70, P435, DOI 10.1007/s00223-001-1024-z; Vatsa A, 2008, BONE, V43, P452, DOI 10.1016/j.bone.2008.01.030; Wang B, 2013, J BONE MINER RES, V28, P1075, DOI 10.1002/jbmr.1804; Wang LY, 2005, P NATL ACAD SCI USA, V102, P11911, DOI 10.1073/pnas.0505193102; Wang N, 2012, MOL ENDOCRINOL, V26, P142, DOI 10.1210/me.2011-1083; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Yoshida J, 2003, EUR J PHARMACOL, V472, P23, DOI 10.1016/S0014-2999(03)01831-4; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; You LD, 2001, J BIOMECH, V34, P1375, DOI 10.1016/S0021-9290(01)00107-5; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516	60	77	85	0	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1582	1592		10.1096/fj.13-237578	http://dx.doi.org/10.1096/fj.13-237578			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24347610	Green Published			2022-12-28	WOS:000335344300007
J	Sharma, V; Nayak, J; DeRossi, C; Charbono, A; Ichikawa, M; Ng, BG; Grajales-Esquivel, E; Srivastava, A; Wang, L; He, P; Scott, DA; Russell, J; Contreras, E; Guess, CM; Krajewski, S; Del Rio-Tsonis, K; Freeze, HH				Sharma, Vandana; Nayak, Jonamani; DeRossi, Charles; Charbono, Adriana; Ichikawa, Mie; Ng, Bobby G.; Grajales-Esquivel, Erika; Srivastava, Anand; Wang, Ling; He, Ping; Scott, David A.; Russell, Joseph; Contreras, Emily; Guess, Cherise M.; Krajewski, Stan; Del Rio-Tsonis, Katia; Freeze, Hudson H.			Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice	FASEB JOURNAL			English	Article						eye defects; congenital disorder of glycosylation; lens; MPI-CDG	6-PHOSPHATE RECEPTORS; CONGENITAL DISORDERS; LENS DEVELOPMENT; TRANSGENIC MICE; GLYCOSYLATION; MOUSE; EYE; DEFICIENCY; GROWTH; METABOLISM	Patients with congenital disorder of glycosylation (CDG), type Ib (MPI-CDG or CDG-Ib) have mutations in phosphomannose isomerase (MPI) that impair glycosylation and lead to stunted growth, liver dysfunction, coagulopathy, hypoglycemia, and intestinal abnormalities. Mannose supplements correct hypoglycosylation and most symptoms by providing mannose-6-P (Man-6-P) via hexokinase. We generated viable Mpi hypomorphic mice with residual enzymatic activity comparable to that of patients, but surprisingly, these mice appeared completely normal except for modest (similar to 15%) embryonic lethality. To overcome this lethality, pregnant dams were provided 1-2% mannose in their drinking water. However, mannose further reduced litter size and survival to weaning by 40 and 66%, respectively. Moreover, similar to 50% of survivors developed eye defects beginning around midgestation. Mannose started at birth also led to eye defects but had no effect when started after eye development was complete. Man-6-P and related metabolites accumulated in the affected adult eye and in developing embryos and placentas. Our results demonstrate that disturbing mannose metabolic flux in mice, especially during embryonic development, induces a highly specific, unanticipated pathological state. It is unknown whether mannose is harmful to human fetuses during gestation; however, mothers who are at risk for having MPI-CDG children and who consume mannose during pregnancy hoping to benefit an affected fetus in utero should be cautious.-Sharma, V., Nayak, J., DeRossi, C., Charbono, A., Ichikawa, M., Ng, B. G., Grajales-Esquivel, E., Srivastava, A., Wang, L., He, P., Scott, D. A., Russell, J., Contreras, E., Guess, C. M., Krajewski, S., Del Rio-Tsonis, K., Freeze, H. H. Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice.	[Sharma, Vandana; Nayak, Jonamani; DeRossi, Charles; Charbono, Adriana; Ichikawa, Mie; Ng, Bobby G.; Srivastava, Anand; Wang, Ling; He, Ping; Scott, David A.; Russell, Joseph; Contreras, Emily; Guess, Cherise M.; Krajewski, Stan; Freeze, Hudson H.] SBMRI, La Jolla, CA 92037 USA; [Grajales-Esquivel, Erika; Del Rio-Tsonis, Katia] Miami Univ, Dept Biol, Oxford, OH 45056 USA	University System of Ohio; Miami University	Freeze, HH (corresponding author), SBMRI, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hudson@sanfordburnham.org		Scott, David/0000-0002-8668-2449; Grajales-Esquivel, Erika/0000-0001-8423-416X; Freeze, Hudson/0000-0001-6316-0501	U.S. National Institutes of Health [R01-DK55615]; Children's Heart Fund; Rocket Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055615, T32DK007202] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Heart Fund; Rocket Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the U.S. National Institutes of Health (R01-DK55615), the Children's Heart Fund, and the Rocket Fund (to H. H. F.). The authors thank Dr. Peter Westenskow [The Scripps Research Institute (TSRI), La Jolla, CA, USA] for sharing some of the antibodies. The authors also thank Dr. Amanda Roberts (TSRI mouse behavioral assessment core) for providing access to the optic drum. The authors greatly appreciate Guillermina Garcia and Robbin Newlin [Sanford-Burnham Medical Research Institute (SBMRI) histology core facility] for exceptional technical support with histology. The authors thank the SBMRI animal facility staff for setting up the mouse breeding and taking care of the animals and Buddy Charbono for technical support. The authors also acknowledge technical support provided by Jamie Smolin in their laboratory.	ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; Beebe DC, 2000, DEV BIOL, V220, P424, DOI 10.1006/dbio.2000.9638; Bode L, 2008, J CLIN INVEST, V118, P229, DOI 10.1172/JCI32335; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; BREITMAN ML, 1989, DEVELOPMENT, V106, P457; BUCHANAN T, 1985, J CLIN INVEST, V75, P1927, DOI 10.1172/JCI111908; Cantagrel V, 2010, CELL, V142, P203, DOI 10.1016/j.cell.2010.06.001; Chu J, 2013, DIS MODEL MECH, V6, P95, DOI 10.1242/dmm.010116; Cline A, 2012, MOL BIOL CELL, V23, P4175, DOI 10.1091/mbc.E12-05-0411; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; COULOMBRE AJ, 1965, EXP EYE RES, V4, P302, DOI 10.1016/S0014-4835(65)80045-8; CROSSLEY JR, 1977, BRIT MED J, V1, P428, DOI 10.1136/bmj.1.6058.428-a; Davis JA, 2002, GLYCOBIOLOGY, V12, P435, DOI 10.1093/glycob/cwf060; Davis JA, 2001, BBA-GEN SUBJECTS, V1528, P116, DOI 10.1016/S0304-4165(01)00183-0; de Lonlay P, 2009, BBA-MOL BASIS DIS, V1792, P841, DOI 10.1016/j.bbadis.2008.11.012; de Lonlay P, 1999, J PEDIATR-US, V135, P379, DOI 10.1016/S0022-3476(99)70139-3; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DeRossi C, 2006, J BIOL CHEM, V281, P5916, DOI 10.1074/jbc.M511982200; Donthi Rajakumar V., 2007, V139, P151; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; GENISGAL.JM, 1966, NATURE, V210, P209, DOI 10.1038/210209a0; GITZELMANN R, 1967, EXP EYE RES, V6, P1, DOI 10.1016/S0014-4835(67)80047-2; GRACY RW, 1968, J BIOL CHEM, V243, P3161; Halket JM, 2003, EUR J MASS SPECTROM, V9, P1, DOI 10.1255/ejms.527; Hellbusch CC, 2007, J BIOL CHEM, V282, P10762, DOI 10.1074/jbc.M700314200; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; KINOSHITA JIN H., 1965, INVEST OPHTHALMOL, V4, P786; Kranjcec B, 2014, WORLD J UROL, V32, P79, DOI 10.1007/s00345-013-1091-6; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; Marek KW, 1999, GLYCOBIOLOGY, V9, P1263; Marklova E, 2007, CLIN CHIM ACTA, V385, P6, DOI 10.1016/j.cca.2007.07.002; MATZNER U, 1992, DEVELOPMENT, V114, P965; Michelakakis H, 2009, CLIN CHIM ACTA, V401, P81, DOI 10.1016/j.cca.2008.11.024; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; Price NPJ, 2004, ANAL CHEM, V76, P6566, DOI 10.1021/ac049198m; Saika S, 2006, LAB INVEST, V86, P106, DOI 10.1038/labinvest.3700375; Schneider A, 2012, NAT MED, V18, P71, DOI 10.1038/nm.2548; Sharma V, 2011, J BIOL CHEM, V286, P39431, DOI 10.1074/jbc.M111.285502; Sharma V, 2011, J BIOL CHEM, V286, P10193, DOI 10.1074/jbc.M110.194241; SOLS A, 1960, SCIENCE, V131, P297, DOI 10.1126/science.131.3396.297; Thiel C, 2006, MOL CELL BIOL, V26, P5615, DOI 10.1128/MCB.02391-05; VARMA SD, 1979, INVEST OPHTH VIS SCI, V18, P236; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; Wilt SD, 1999, EXP EYE RES, V69, P405, DOI 10.1006/exer.1999.0714; Yamamoto Y, 2000, SCIENCE, V289, P631, DOI 10.1126/science.289.5479.631; Zhu AP, 2009, ANAL BIOCHEM, V388, P97, DOI 10.1016/j.ab.2009.02.009	49	16	16	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1854	1869		10.1096/fj.13-245514	http://dx.doi.org/10.1096/fj.13-245514			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24421398	Green Published			2022-12-28	WOS:000335344300030
J	Bonnot, A; Guiot, E; Hepp, R; Cavellini, L; Tricoire, L; Lambolez, B				Bonnot, Agnes; Guiot, Elvire; Hepp, Regine; Cavellini, Laetitia; Tricoire, Ludovic; Lambolez, Bertrand			Single-fluorophore biosensors based on conformation-sensitive GFP variants	FASEB JOURNAL			English	Article						green fluorescent protein; chromophore; genetically encoded indicators; intracellular second messengers; fluorescence lifetime imaging; high-resolution microscopy	GREEN-FLUORESCENT PROTEIN; KINASE-A; CALCIUM INDICATORS; DENDRITIC SPINES; ENERGY-TRANSFER; QUANTUM YIELD; IN-VIVO; FRET; MECHANISM; MEMBRANE	The -strands of GFP form a rigid barrel that protects the chromophore from external influence. Herein, we identified specific mutations in -strand 7 that render the chromophore sensitive to interactions of GFP with another protein domain. In the process of converting the FRET-based protein kinase A (PKA) sensor AKAR2 into a single-wavelength PKA sensor containing a GFP and a quencher, we discovered that the quencher was not required and that the sensor response relied on changes in GFP intrinsic fluorescence. The identified mutations in -strand 7 render GFP fluorescence intensity and lifetime sensitive to conformational changes of the PKA-sensing domain. In addition, sensors engineered from the GCaMP2 calcium indicator to incorporate a conformation-sensitive GFP (csGFP) exhibited calcium-dependent fluorescence changes. We further demonstrate that single GFP sensors report PKA dynamics in dendritic spines of neurons from brain slices on 2-photon imaging with a high signal-to-baseline ratio and minimal photobleaching. The susceptibility of GFP variants to dynamic interactions with other protein domains provides a new approach to generate single wavelength biosensors for high-resolution imaging.Bonnot, A., Guiot, E., Hepp, R., Cavellini, L., Tricoire, L., Lambolez, B. Single-fluorophore biosensors based on conformation-sensitive GFP variants.	[Bonnot, Agnes; Guiot, Elvire; Hepp, Regine; Cavellini, Laetitia; Tricoire, Ludovic; Lambolez, Bertrand] Univ Paris 06, Ctr Natl Rech Sci CNRS, Unite Mixte Rech UMR 7102, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Lambolez, B (corresponding author), UPMC, NPA UMR7102, 9 Quai St Bernard, F-75005 Paris, France.	bertrand.lambolez@snv.jussieu.fr		Cavellini, Laetitia/0000-0003-1743-2689; lambolez, bertrand/0000-0002-0653-480X; Tricoire, Ludovic/0000-0003-3345-1468; HEPP, regine/0000-0002-7683-7451	Centre National de la Recherche Scientifique (CNRS); UPMC-P6; Ecole des Neurosciences de Paris (Network for Viral Transfer); Fondation pour la Recherche sur le Cerveau/Rotary Club de France; Region Ile de France	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); UPMC-P6; Ecole des Neurosciences de Paris (Network for Viral Transfer); Fondation pour la Recherche sur le Cerveau/Rotary Club de France; Region Ile de France(Region Ile-de-France)	The authors thank Drs. Michael J. O'Donovan, J. Woodland Hastings, and Carl H. Johnson for helpful comments on the manuscript. The authors thank the Universite Pierre et Marie Curie (UPMC) IFR83 Cell Imaging Facility for valuable assistance. The authors thank Melanie Cohen and Valerie Pichon [Physicochimie des Electrolytes, Colloides et Sciences Analytiques (PECSA) laboratory, Unite Mixte de Recherche (UMR) 7195, Ecole Superieure de Physique et de Chimie Industrielles (ESPCI)-ParisTech, Paris, France] for giving access to the spectrofluorometer. This work was supported by Centre National de la Recherche Scientifique (CNRS), UPMC-P6, and by grants from Ecole des Neurosciences de Paris (Network for Viral Transfer), Fondation pour la Recherche sur le Cerveau/Rotary Club de France, and Region Ile de France. L. T. was a U.S. National Institutes of Health/CNRS European Career Transition Award Fellow.	Akerboom J, 2009, J BIOL CHEM, V284, P6455, DOI 10.1074/jbc.M807657200; Bae JH, 2003, J MOL BIOL, V328, P1071, DOI 10.1016/S0022-2836(03)00364-4; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Barondeau DP, 2003, P NATL ACAD SCI USA, V100, P12111, DOI 10.1073/pnas.2133463100; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; Castro LRV, 2010, J NEUROSCI, V30, P6143, DOI 10.1523/JNEUROSCI.5851-09.2010; Chinga G, 2007, NORD PULP PAP RES J, V22, P441, DOI 10.3183/npprj-2007-22-04-p441-446; Cotlet M, 2001, J PHYS CHEM B, V105, P4999, DOI 10.1021/jp003813i; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; Depry C, 2011, MOL BIOSYST, V7, P52, DOI 10.1039/c0mb00079e; Drobac E, 2010, J NEUROSCI RES, V88, P695, DOI 10.1002/jnr.22249; Gallopin T, 2006, CEREB CORTEX, V16, P1440, DOI 10.1093/cercor/bhj081; Ganesan S, 2006, P NATL ACAD SCI USA, V103, P4089, DOI 10.1073/pnas.0509922103; Gervasi N, 2007, J NEUROSCI, V27, P2744, DOI 10.1523/JNEUROSCI.5352-06.2007; Goedhart J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1738; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hepp R, 2007, J NEUROCHEM, V102, P1875, DOI 10.1111/j.1471-4159.2007.04657.x; Hu E., 2010, DYN NEOCORT CEREB CO, V21, P708; Kirchhofer A, 2010, NAT STRUCT MOL BIOL, V17, P133, DOI 10.1038/nsmb.1727; Kummer AD, 1998, CHEM PHYS, V237, P183, DOI 10.1016/S0301-0104(98)00245-6; Lelimousin M, 2009, BIOCHEMISTRY-US, V48, P10038, DOI 10.1021/bi901093w; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Leray A, 2009, MICROSC RES TECHNIQ, V72, P371, DOI 10.1002/jemt.20665; Mao T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001796; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305; Murakoshi H, 2008, BRAIN CELL BIOL, V36, P31, DOI 10.1007/s11068-008-9024-9; Mutoh H, 2011, EXP PHYSIOL, V96, P13, DOI 10.1113/expphysiol.2010.053942; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Nguyen QT, 2006, J NEUROSCI METH, V156, P351, DOI 10.1016/j.jneumeth.2006.03.001; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Seifert MH, 2002, J AM CHEM SOC, V124, P7932, DOI 10.1021/ja0257725; Suzuki N, 2010, ACTA CRYSTALLOGR D, V66, P1059, DOI 10.1107/S0907444910032944; Tallini YN, 2006, P NATL ACAD SCI USA, V103, P4753, DOI 10.1073/pnas.0509378103; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Thomas Philip, 2005, Journal of Pharmacological and Toxicological Methods, V51, P187, DOI 10.1016/j.vascn.2004.08.014; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VanEngelenburg SB, 2008, CURR OPIN CHEM BIOL, V12, P60, DOI 10.1016/j.cbpa.2008.01.020; Villoing A, 2008, BIOCHEMISTRY-US, V47, P12483, DOI 10.1021/bi801400d; Wilson T, 1998, ANNU REV CELL DEV BI, V14, P197, DOI 10.1146/annurev.cellbio.14.1.197; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2005, NATURE, V437, P569, DOI 10.1038/nature04140; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798; Zhang J, 2007, MOL BIOSYST, V3, P759, DOI 10.1039/b706628g	47	17	17	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1375	1385		10.1096/fj.13-240507	http://dx.doi.org/10.1096/fj.13-240507			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24334549	Green Published			2022-12-28	WOS:000335324800029
J	Lagoda, G; Sezen, SF; Hurt, KJ; Cabrini, MR; Mohanty, DK; Burnett, AL				Lagoda, Gwen; Sezen, Sena F.; Hurt, K. Joseph; Cabrini, Marcelo R.; Mohanty, Dillip K.; Burnett, Arthur L.			Sustained nitric oxide ( NO)-releasing compound reverses dysregulated NO signal transduction in priapism	FASEB JOURNAL			English	Article						sickle cell; oxidative stress; NO bioavailability	SICKLE-CELL-DISEASE; MEDIATES PENILE ERECTION; SMOOTH-MUSCLE-CELLS; NADPH OXIDASE; MICROVASCULAR DYSFUNCTION; OXIDATIVE STRESS; MOUSE PENIS; SYNTHASE; MICE; PATHOPHYSIOLOGY	We evaluated the therapeutic potential of a sustained nitric oxide (NO)-releasing compound to correct the molecular hallmarks and pathophysiology of priapism, an important but poorly characterized erectile disorder. 1,5-Bis-(dihexyl-N-nitrosoamino)-2,4-dinitrobenzene (C6) and an inactive form of the compound [1,5-bis-(dihexylamino)-2,4-dinitrobenzene (C6)] were tested in neuronal cell cultures and penile lysates for NO release (Griess assay) and biological activity (cGMP production). The effect of local depot C6 or C6 was evaluated in mice with a priapic phenotype due to double neuronal and endothelial NO synthase deletion (dNOS(-/-)) or human sickle hemoglobin transgenic expression (Sickle). Changes in NO signaling molecules and reactive oxygen species (ROS) surrogates were assessed by Western blot. The physiological response after C6 treatment was assessed using an established model of electrically stimulated penile erection. C6 generated NO, increased cGMP, and dose dependently increased NO metabolites. C6 treatment reversed abnormalities in key penile erection signaling molecules, including phosphodiesterase type 5, phosphorylated endothelial nitric oxide synthase, and phosphorylated vasodilator-stimulated phosphoprotein. In Sickle mice, C6 also attenuated the increased ROS markers gp91(phox), 4-hydroxynonenal, and 3-nitrotyrosine. Finally, C6 corrected the excessive priapic erection response of dNOS(-/-) mice. Exogenous sustained NO release from C6 corrects pathological erectile signaling in mouse models of priapism and suggests novel approaches to human therapy.Lagoda, G., Sezen, S. F., Hurt, K. J., Cabrini, M. R., Mohanty, D. K., Burnett, A. L. Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism.	[Lagoda, Gwen; Sezen, Sena F.; Cabrini, Marcelo R.; Burnett, Arthur L.] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA; [Lagoda, Gwen; Cabrini, Marcelo R.; Burnett, Arthur L.] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA; [Hurt, K. Joseph] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO USA; [Mohanty, Dillip K.] Cent Michigan Univ, Dept Chem, Mt Pleasant, MI 48859 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; Central Michigan University	Burnett, AL (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, 600 N Wolfe St,Marburg 407, Baltimore, MD 21287 USA.	aburnett@jhmi.edu	Sezen, Sena/AAK-5264-2021; Cabrini, Marcelo/I-6676-2016; Hurt, K. Joseph/J-8266-2019	Cabrini, Marcelo/0000-0002-6081-3412; Hurt, K. Joseph/0000-0001-6906-350X	U.S. National Institutes of Health [HL090515, R01-DK067223, R15-HL106600]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL090515, R15HL106600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067223] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants HL090515, R01-DK067223 (to A. L. B.), and R15-HL106600 (to D.K.M.).	Adeyoju AB, 2002, BJU INT, V90, P898, DOI 10.1046/j.1464-410X.2002.03022.x; Andersson KE, 2011, PHARMACOL REV, V63, P811, DOI 10.1124/pr.111.004515; Andersson KE, 2001, PHARMACOL REV, V53, P417; Bivalacqua TJ, 2012, J SEX MED, V9, P79, DOI 10.1111/j.1743-6109.2011.02288.x; Bivalacqua TJ, 2009, J SEX MED, V6, P2494, DOI 10.1111/j.1743-6109.2009.01359.x; Burnett AL, 2006, UROLOGY, V67, P1043, DOI 10.1016/j.urology.2005.11.045; Burnett AL, 2003, INT J IMPOT RES, V15, pS80, DOI 10.1038/sj.ijir.3901077; Burnett AL, 2002, J ANDROL, V23, pS20; Burnett Arthur L, 2006, J Clin Hypertens (Greenwich), V8, P53; Burnett AL, 2012, J SEX MED, V9, P104, DOI 10.1111/j.1743-6109.2011.02411.x; Champion HC, 2005, P NATL ACAD SCI USA, V102, P1661, DOI 10.1073/pnas.0407183102; Cheah JH, 2006, NEURON, V51, P431, DOI 10.1016/j.neuron.2006.07.011; Chen J, 1999, BJU INT, V83, P269; Claudino MA, 2009, J SEX MED, V6, P2187, DOI 10.1111/j.1743-6109.2009.01337.x; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; Han TH, 2003, P NATL ACAD SCI USA, V100, P12504, DOI 10.1073/pnas.2133409100; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Hurt KJ, 2006, P NATL ACAD SCI USA, V103, P3440, DOI 10.1073/pnas.0511326103; Hurt KJ, 2002, P NATL ACAD SCI USA, V99, P4061, DOI 10.1073/pnas.052712499; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Kanika ND, 2010, INT J IMPOT RES, V22, P363, DOI 10.1038/ijir.2010.27; Kato GJ, 2012, J SEX MED, V9, P70, DOI 10.1111/j.1743-6109.2011.02287.x; Kato Gregory J, 2008, Hematology Am Soc Hematol Educ Program, P186, DOI 10.1182/asheducation-2008.1.186; Lagoda G, 2013, J UROLOGY, V189, P762, DOI 10.1016/j.juro.2012.08.198; Mack AK, 2006, INT J BIOCHEM CELL B, V38, P1237, DOI 10.1016/j.biocel.2006.01.010; Mi T, 2008, J CLIN INVEST, V118, P1491, DOI 10.1172/JCI33467; Morris Claudia R, 2008, Hematology Am Soc Hematol Educ Program, P177, DOI 10.1182/asheducation-2008.1.177; Munarriz R, 2003, UROLOGY, V62, P760, DOI 10.1016/S0090-4295(03)00484-9; Musicki B, 2012, J SEX MED, V9, P1980, DOI 10.1111/j.1743-6109.2012.02798.x; Musicki B, 2011, J SEX MED, V8, P419, DOI 10.1111/j.1743-6109.2010.02123.x; Muzaffar S, 2004, CIRCULATION, V110, P1140, DOI 10.1161/01.CIR.0000139851.50067.E4; Naghavi N, 2013, SMALL, V9, P22, DOI 10.1002/smll.201200458; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Wang J, 2009, POLYM J, V41, P715, DOI 10.1295/polymj.PJ2008335; Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179; Wood KC, 2005, FASEB J, V19, P989, DOI 10.1096/fj.04-3218fje; Wood KC, 2006, FREE RADICAL BIO MED, V40, P1443, DOI 10.1016/j.freeradbiomed.2005.12.015; Yang YM, 2009, AM J PHYSIOL-HEART C, V297, pH1829, DOI 10.1152/ajpheart.00230.2009; Yu H, 2011, CHEM BIOL DRUG DES, V78, P527, DOI 10.1111/j.1747-0285.2011.01174.x; Zhou Z, 2012, CURR VASC PHARMACOL, V10, P756, DOI 10.2174/157016112803520738	44	29	30	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					76	84		10.1096/fj.13-228817	http://dx.doi.org/10.1096/fj.13-228817			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24076963	Green Published			2022-12-28	WOS:000333526100010
J	Garreta, A; Val-Moraes, SP; Garcia-Fernandez, Q; Busquets, M; Juan, C; Oliver, A; Ortiz, A; Gaffney, BJ; Fita, I; Manresa, A; Carpena, X				Garreta, Albert; Val-Moraes, Silvana P.; Garcia-Fernandez, Queralt; Busquets, Montserrat; Juan, Carlos; Oliver, Antonio; Ortiz, Antonio; Gaffney, Betty J.; Fita, Ignacio; Manresa, Angels; Carpena, Xavi			Structure and interaction with phospholipids of a prokaryotic lipoxygenase from Pseudomonas aeruginosa	FASEB JOURNAL			English	Article						lipid peroxidation; protein-phospholipid complexes; enzyme mechanisms; membrane interaction; host-pathogen interactions	CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MEMBRANES; FLUORESCENCE; OXYGENATION; TRYPTOPHAN; MECHANISM; SUGGESTS; BINDING; DOMAIN	Lipoxygenases (LOXs), which are essential in eukaryotes, have no confirmed function in prokaryotes that are devoid of polyunsaturated fatty acids. The structure of a secretable LOX from Pseudomonas aeruginosa (Pa_LOX), the first available from a prokaryote, presents significant differences with respect to eukaryotic LOXs, including a cluster of helices acting as a lid to the active center. The mobility of the lid and the structural variability of the N-terminal region of Pa_LOX was confirmed by comparing 2 crystal forms. The binding pocket contains a phosphatidylethanolamine phospholipid with branches of 18 (sn-1) and 14/16 (sn-2) carbon atoms in length. Carbon atoms from the sn-1 chain approach the catalytic iron in a manner that sheds light on how the enzymatic reaction might proceed. The findings in these studies suggest that Pa_LOX has the capacity to extract and modify unsaturated phospholipids from eukaryotic membranes, allowing this LOX to play a role in the interaction of P. aeruginosa with host cells.	[Garreta, Albert; Val-Moraes, Silvana P.; Manresa, Angels] Univ Barcelona, Fac Farm, Microbiol Lab, E-08028 Barcelona, Spain; [Busquets, Montserrat] Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Barcelona, Spain; [Garreta, Albert; Garcia-Fernandez, Queralt; Fita, Ignacio; Carpena, Xavi] CSIC, Inst Biol Mol IBMB, Barcelona, Spain; [Juan, Carlos; Oliver, Antonio] Hosp Univ Son Espases, Microbiol Serv, Palma De Mallorca, Spain; [Ortiz, Antonio] Univ Murcia, Fac Vet, Dept Biochem & Mol Biol A, Murcia, Spain; [Gaffney, Betty J.] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA	University of Barcelona; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Hospital Universitari Son Espases; University of Murcia; State University System of Florida; Florida State University	Carpena, X (corresponding author), Inst Mol Biol, Parc Cient Barcelona,Baldiri Reixac 10, Barcelona 08028, Spain.	xcvcri@ibmb.csic.es	Oliver, Antonio/E-4048-2012; Juan, Carlos/AAB-2183-2020; Fita, Ignasi/R-4515-2019; Gaffney, Betty J/C-9666-2015; Carpena, Xavi/J-5877-2017; Oliver, Antonio/V-5541-2019; Ortiz, Antonio/K-5592-2017	Oliver, Antonio/0000-0001-9327-1894; Juan, Carlos/0000-0002-1402-3516; Fita, Ignasi/0000-0002-7521-2679; Carpena, Xavi/0000-0002-8646-0440; Oliver, Antonio/0000-0001-9327-1894; Manresa, Angeles/0000-0003-2337-9060	Ministerio de Ciencia e Innovacion (MICINN) [CTQ2010-21283-C02/01/PPQ, HBP2006-0027]; Generilitat de Catalunya [2009SGR819]; MICINN [BFU2012-36827]; Generalitat de Catalunya [SGR2009-00327]; U.S. National Institutes of Health [R01GM065268]; Ministerio de Economia y Competitividad-Instituto de Salud Carlos III of Spain [SAF2012-38539, CP12/03324, RD12/0015]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065268] Funding Source: NIH RePORTER	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Generilitat de Catalunya; MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Generalitat de Catalunya(Generalitat de Catalunya); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministerio de Economia y Competitividad-Instituto de Salud Carlos III of Spain(Spanish Government); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Special thanks go to S. Rodriguez-Puente, J. Linacero, J. Pous, and A. Guasch [Plataforma Automatitzada de Cristal.lografia (PAC), Parc Cientific de Barcelona, Barcelona, Spain] for valuable help with crystal preparation. The authors thank T. Bates for carefully revising the manuscript. This work was supported by grants CTQ2010-21283-C02/01/PPQ, HBP2006-0027 from the Ministerio de Ciencia e Innovacion (MICINN) and 2009SGR819 from the Generilitat de Catalunya to A. M.; grants BFU2012-36827 from MICINN and SGR2009-00327 from the Generalitat de Catalunya to I. F.; grant R01GM065268 from the U.S. National Institutes of Health to B. J. G.; and grants SAF2012-38539, CP12/03324, and RD12/0015 from the Ministerio de Economia y Competitividad-Instituto de Salud Carlos III of Spain to C. J. and A.Ol.	Bateman A, 1999, CURR BIOL, V9, pR588, DOI 10.1016/S0960-9822(99)80380-7; Bianconi ML, 2007, BIOPHYS CHEM, V126, P59, DOI 10.1016/j.bpc.2006.05.017; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Bricogne G, 2011, BUSTER 2 10 0; Bushnell EAC, 2013, J BIOL INORG CHEM, V18, P343, DOI 10.1007/s00775-013-0978-4; Callis PR, 2004, J PHYS CHEM B, V108, P4248, DOI 10.1021/jp0310551; Choi J, 2008, PROTEINS, V70, P1023, DOI 10.1002/prot.21590; Coffa G, 2004, P NATL ACAD SCI USA, V101, P15579, DOI 10.1073/pnas.0406727101; DeLano W.L, PYMOL MOL GRAPHICS S; Eek P, 2012, J BIOL CHEM, V287, P22377, DOI 10.1074/jbc.M112.343285; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Feussner I, 1997, FEBS LETT, V406, P1, DOI 10.1016/S0014-5793(97)00218-4; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gaffney BJ, 1996, ANNU REV BIOPH BIOM, V25, P431, DOI 10.1146/annurev.bb.25.060196.002243; GAFFNEY BJ, 1993, BIOPHYS J, V64, P773, DOI 10.1016/S0006-3495(93)81438-3; Gilbert NC, 2012, FASEB J, V26, P3222, DOI 10.1096/fj.12-205286; Gilbert NC, 2011, SCIENCE, V331, P217, DOI 10.1126/science.1197203; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Haeggstrom JZ, 2011, CHEM REV, V111, P5866, DOI 10.1021/cr200246d; Harrison EM, 2010, INFECT IMMUN, V78, P1437, DOI 10.1128/IAI.00621-09; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Kessler A, 2004, SCIENCE, V305, P665, DOI 10.1126/science.1096931; Kulkarni AP, 2001, CELL MOL LIFE SCI, V58, P1805, DOI 10.1007/PL00000820; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Montes LR, 2007, BBA-BIOMEMBRANES, V1768, P2365, DOI 10.1016/j.bbamem.2007.04.024; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neau DB, 2009, BIOCHEMISTRY-US, V48, P7906, DOI 10.1021/bi900084m; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oursel D, 2007, RAPID COMMUN MASS SP, V21, P3229, DOI 10.1002/rcm.3177; Oursel D, 2007, RAPID COMMUN MASS SP, V21, P1721, DOI 10.1002/rcm.3013; Pande AH, 2005, BIOPHYS J, V88, P4084, DOI 10.1529/biophysj.104.056788; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; Schneider C, 2007, CHEM BIOL, V14, P473, DOI 10.1016/j.chembiol.2007.04.007; Shaver CM, 2006, MICROBIOL-SGM, V152, P143, DOI 10.1099/mic.0.28368-0; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Su C, 1998, J BIOL CHEM, V273, P13072, DOI 10.1074/jbc.273.21.13072; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Vance RE, 2004, P NATL ACAD SCI USA, V101, P2135, DOI 10.1073/pnas.0307308101; Vidal-Mas J, 2005, ANTON LEEUW INT J G, V87, P245, DOI 10.1007/s10482-004-4021-1; Xu S, 2012, STRUCTURE, V20, P1490, DOI 10.1016/j.str.2012.06.003; Youn B, 2006, PROTEINS, V65, P1008, DOI 10.1002/prot.21182	45	56	58	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4811	4821		10.1096/fj.13-235952	http://dx.doi.org/10.1096/fj.13-235952			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23985801	Green Published			2022-12-28	WOS:000329999000016
J	Mitsuhashi, M; Taub, DD; Kapogiannis, D; Eitan, E; Zukley, L; Mattson, MP; Ferrucci, L; Schwartz, JB; Goetzl, EJ				Mitsuhashi, Masato; Taub, Dennis D.; Kapogiannis, Dimitrios; Eitan, Erez; Zukley, Linda; Mattson, Mark P.; Ferrucci, Luigi; Schwartz, Janice B.; Goetzl, Edward J.			Aging enhances release of exosomal cytokine mRNAs by A beta(1-42)-stimulated macrophages	FASEB JOURNAL			English	Article						membrane vesicle; T cells; immunosenescence; neural proteinopathy; dementia	CELL-DERIVED EXOSOMES; AMYLOID-BETA-PEPTIDE; ALZHEIMERS-DISEASE; TNF-ALPHA; IMMUNE-RESPONSES; MIGRATION; BLOOD; INDIVIDUALS; MEMBRANE; PROFILES	Amyloid-beta(1-42) (A beta) peptide effects on human models of central nervous system (CNS)-patrolling macrophages (Ms) and CD4 memory T-cells (CD4-Tms) were investigated to examine immune responses to A beta in Alzheimer's disease. A beta and lipopolysaccharide (LPS) elicited similar M cytokine and exosomal mRNA (ex-mRNA) responses. A beta- and LPS-stimulated Ms from 20 >= 65-yr-old subjects generated significantly more IL-1, TNF-alpha, and IL-6, but not IL-8 or IL-12, and significantly more ex-mRNAs for IL-6, TNF-alpha, and IL-12, but not for IL-8 or IL-1, than Ms from 20 matched 21- to 45-yr-old subjects. CD4-Tm generation of IL-2, IL-4, and IFN-gamma and, for young subjects, IL-10, but not IL-6, evoked by A beta was significantly lower than with anti-T-cell antigen receptor antibodies (Abs). Abs significantly increased all CD4-Tm ex-mRNAs, but only IL-2 and IL-6 ex-mRNAs were increased by A beta. There were no significant differences between cytokine and ex-mRNA responses of CD4-Tms from the old compared to the young subjects. M-derived serum exosomes from the old subjects had significantly higher IL-6 and IL-12 ex-mRNA levels than those from the young subjects, whereas there were no differences for CD4-Tm-derived serum exosomes. An A beta level relevant to neurodegeneration elicited broad M cytokine and ex-mRNA responses that were significantly greater in the old subjects, but only narrow and age-independent CD4-Tm responses.	[Mitsuhashi, Masato] Hitachi Chem Res Ctr, Irvine, CA USA; [Taub, Dennis D.; Kapogiannis, Dimitrios; Eitan, Erez; Zukley, Linda; Mattson, Mark P.; Ferrucci, Luigi; Goetzl, Edward J.] NIA, NIH, Baltimore, MD 21224 USA; [Schwartz, Janice B.; Goetzl, Edward J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Schwartz, Janice B.; Goetzl, Edward J.] Univ Calif San Francisco, Geriatr Res Labs, San Francisco, CA 94143 USA	Hitachi Limited; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), UCSF Geriatr Res Ctr, 1719 Broderick St, San Francisco, CA 94115 USA.	edward.goetzl@ucsf.edu	Schwartz, Janice/K-6354-2019; Kapogiannis, Dimitrios/AAW-4934-2020	Kapogiannis, Dimitrios/0000-0003-2181-3118	Jewish Home of San Francisco; Intramural Research Program of the U.S. National Institute on Aging; Edward A. Dickson Professorship at the University of California, San Francisco; NATIONAL INSTITUTE ON AGING [ZIAAG000975] Funding Source: NIH RePORTER	Jewish Home of San Francisco; Intramural Research Program of the U.S. National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Edward A. Dickson Professorship at the University of California, San Francisco; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by endowment fund income of the Jewish Home of San Francisco, by the Intramural Research Program of the U.S. National Institute on Aging, and by funds from the Edward A. Dickson Professorship at the University of California, San Francisco. The authors are grateful to Judith H. Goetzl for expert preparation of the graphic illustrations. Dr. Charles Hesdorffer (Veterans Affairs Medical Center, Washington, DC, USA) provided constant support for the research.	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Baril L, 2004, NEUROSCI LETT, V355, P226, DOI 10.1016/j.neulet.2003.10.071; Bhatnagar S, 2007, J BIOL CHEM, V282, P25779, DOI 10.1074/jbc.M702277200; Bonotis K, 2008, J NEUROIMMUNOL, V193, P183, DOI 10.1016/j.jneuroim.2007.10.020; Britschgi M, 2007, INT REV NEUROBIOL, V82, P205, DOI 10.1016/S0074-7742(07)82011-3; Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V121, P255, DOI 10.1046/j.1365-2249.2000.01281.x; Bruunsgaard H, 2000, LIFE SCI, V67, P2721, DOI 10.1016/S0024-3205(00)00851-1; Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753; Giubilei F, 2003, DEMENT GERIATR COGN, V16, P35, DOI 10.1159/000069991; Goetzl EJ, 2010, FASEB J, V24, P3580, DOI 10.1096/fj.10-160911; Grubeck-Loebenstein B, 2002, ADV IMMUNOL, V80, P243, DOI 10.1016/S0065-2776(02)80017-7; Huang MC, 2011, CLIN IMMUNOL, V138, P201, DOI 10.1016/j.clim.2010.11.002; Jozwik A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033276; Kirwan JP, 2001, AM J PHYSIOL-ENDOC M, V281, pE1137, DOI 10.1152/ajpendo.2001.281.6.E1137; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Lombardi VRM, 1999, J NEUROIMMUNOL, V97, P163, DOI 10.1016/S0165-5728(99)00046-6; Lugini L, 2012, J IMMUNOL, V189, P2833, DOI 10.4049/jimmunol.1101988; Lutter D, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-100; Miscia S, 2009, NEUROBIOL AGING, V30, P394, DOI 10.1016/j.neurobiolaging.2007.07.011; Mitsuhashi M, 2010, J IMMUNOL METHODS, V363, P95, DOI 10.1016/j.jim.2010.10.002; Monsonego A, 2003, J CLIN INVEST, V112, P415, DOI 10.1172/JCI200318104; Montecino-Rodriguez E, 2013, J CLIN INVEST, V123, P958, DOI 10.1172/JCI64096; Mueller SN, 2013, ANNU REV IMMUNOL, V31, P137, DOI 10.1146/annurev-immunol-032712-095954; Naslund TI, 2013, J IMMUNOL, V190, P2712, DOI 10.4049/jimmunol.1203082; Pedersen M, 2003, MECH AGEING DEV, V124, P495, DOI 10.1016/S0047-6374(03)00027-7; Pellicano M, 2010, J ALZHEIMERS DIS, V21, P181, DOI 10.3233/JAD-2010-091714; Rea IM, 2000, CYTOKINE, V12, P156, DOI 10.1006/cyto.1999.0537; Richartz-Salzburger E, 2007, J PSYCHIATR RES, V41, P174, DOI 10.1016/j.jpsychires.2006.01.010; Smyth L. A., 2013, EUR J IMMUNOL; Stansley B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-115; Streit WJ, 2009, ACTA NEUROPATHOL, V118, P475, DOI 10.1007/s00401-009-0556-6; Strohmeyer R, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-18; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Trieb K, 1996, NEUROBIOL AGING, V17, P541; Turola E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00149; Verdier Y, 2004, CURR PROTEIN PEPT SC, V5, P19, DOI 10.2174/1389203043486937; Wahlgren J, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks463; Walters SB, 2013, J IMMUNOL, V190, P669, DOI 10.4049/jimmunol.1201856; Zhang HF, 2011, CELL MOL IMMUNOL, V8, P23, DOI 10.1038/cmi.2010.59	40	48	50	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5141	5150		10.1096/fj.13-238980	http://dx.doi.org/10.1096/fj.13-238980			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24014820	Green Published			2022-12-28	WOS:000329999000046
J	Baek, AE; Kanthi, Y; Sutton, NR; Liao, H; Pinsky, DJ				Baek, Amy E.; Kanthi, Yogendra; Sutton, Nadia R.; Liao, Hui; Pinsky, David J.			Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3)	FASEB JOURNAL			English	Article						vascular homeostasis; endothelium; cAMP	CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ENDOTHELIAL-CELLS; INTERMITTENT CLAUDICATION; PLATELET-AGGREGATION; EXTRACELLULAR ATP; ADENOSINE UPTAKE; CILOSTAZOL; INHIBITION; MILRINONE; DIPHOSPHOHYDROLASE	The ectoenzyme CD39 suppresses thrombosis and inflammation by suppressing ATP and ADP to AMP. However, mechanisms of CD39 transcriptional and post-translational regulation are not well known. Here we show that CD39 levels are modulated by inhibition of phosphodiesterase 3 (PDE3). RAW macrophages and human umbilical vein endothelial cells (HUVECs) were treated with the PDE3 inhibitors cilostazol and milrinone, then analyzed using qRT-PCR, immunoprecipitation/Western blot, immunofluorescent staining, radio-thin-layer chromatography, a malachite green assay, and ELISA. HUVECs expressed elevated CD39 protein (2-fold [P<0.05] for cilostazol and 2.5-fold [P<0.01] for milrinone), while macrophage CD39 mRNA and protein were both elevated after PDE3 inhibition. HUVEC ATPase activity increased by 25% with cilostazol and milrinone treatment (P<0.05 and P<0.01, respectively), as did ADPase activity (47% and 61%, P<0.001). There was also a dose-dependent elevation of soluble CD39 after treatment with 8-Br-cAMP, with maximal elevation of 60% more CD39 present compared to controls (1 mM, P<0.001). Protein harvested after 8-Br-cAMP treatment showed that ubiquitination of CD39 was decreased by 43% compared to controls. A DMSO or PBS vehicle control was included for each experiment based on solubility of cilostazol, milrinone, and 8-Br-cAMP. These results indicate that PDE3 inhibition regulates endothelial CD39 at a post-translational level.Baek, A. E., Kanthi, Y., Sutton, N. R., Liao, H., Pinsky, D. J. Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3).	[Baek, Amy E.; Pinsky, David J.] Univ Michigan, Med Ctr, Div Cardiovasc Med, Dept Mol & Integrat Physiol, Ann Arbor, MI USA; [Kanthi, Yogendra; Sutton, Nadia R.; Liao, Hui; Pinsky, David J.] Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Baek, AE (corresponding author), 7240 Med Sci Res Bldg 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	abaek@umich.edu	liao, hui/GSE-5758-2022	Kanthi, MD, Yogendra/0000-0002-5660-5194; Sutton, Nadia/0000-0002-0968-3085	Taubman Medical Research Institute of the University of Michigan; U.S. National Institutes of Health Multidisciplinary Cardiovascular Research Training [T32 HL007853]; American Heart Association; Ruth professorship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER	Taubman Medical Research Institute of the University of Michigan; U.S. National Institutes of Health Multidisciplinary Cardiovascular Research Training; American Heart Association(American Heart Association); Ruth professorship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by the Taubman Medical Research Institute of the University of Michigan (D.J.P.), a Ruth professorship (D.J.P.), U.S. National Institutes of Health Multidisciplinary Cardiovascular Research Training grant T32 HL007853 (D.J.P., N.S., Y.K.), and an American Heart Association predoctoral fellowship (A.E.B.).	Adelstein R S, 1980, Ann N Y Acad Sci, V356, P142, DOI 10.1111/j.1749-6632.1980.tb29607.x; ANDERSON JL, 1987, J AM COLL CARDIOL, V9, P711, DOI 10.1016/S0735-1097(87)80223-1; Ansermot N, 2010, ARCH INTERN MED, V170, P529, DOI 10.1001/archinternmed.2010.26; Atabakhsh E, 2009, MOL CANCER RES, V7, P1962, DOI 10.1158/1541-7786.MCR-09-0098; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Bramer SL, 1999, CLIN PHARMACOKINET, V37, P1, DOI 10.2165/00003088-199937002-00001; Bruno O, 2011, BRIT J PHARMACOL, V164, P2054, DOI 10.1111/j.1476-5381.2011.01524.x; Cone J, 1999, J CARDIOVASC PHARM, V34, P497, DOI 10.1097/00005344-199910000-00004; Dawson DL, 1998, CIRCULATION, V98, P678, DOI 10.1161/01.CIR.98.7.678; Dindyal Shiva, 2009, Recent Pat Cardiovasc Drug Discov, V4, P6; Elkind MSV, 2010, STROKE, V41, pS3, DOI 10.1161/STROKEAHA.110.594945; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Fujiwara Y, 2011, J TOXICOL SCI, V36, P155, DOI 10.2131/jts.36.155; Goncalves DAP, 2009, ENDOCRINOLOGY, V150, P5395, DOI 10.1210/en.2009-0428; Gorcideski EZ, 2009, CIRC-HEART FAIL, V2, P320, DOI 10.1161/CIRCHEARTFAILURE.108.839076; Hyman MC, 2009, J CLIN INVEST, V119, P1136, DOI 10.1172/JCI36433; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; KIMURA Y, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1144; KOGA S, 1995, AM J PHYSIOL-CELL PH, V268, pC1104, DOI 10.1152/ajpcell.1995.268.5.C1104; Koziak K, 1999, THROMB HAEMOSTASIS, V82, P1538; Kramer S, 2005, ONCOGENE, V24, P938, DOI 10.1038/sj.onc.1208257; Liao H, 2010, J BIOL CHEM, V285, P14791, DOI 10.1074/jbc.M110.116905; Lira EC, 2011, MUSCLE NERVE, V44, P371, DOI 10.1002/mus.22066; Liu YG, 2000, J CARDIOVASC PHARM, V36, P351, DOI 10.1097/00005344-200009000-00011; Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x; Marcus AJ, 2005, SEMIN THROMB HEMOST, V31, P234, DOI 10.1055/s-2005-869528; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Minami N, 1997, LIFE SCI, V61, pPL383, DOI 10.1016/S0024-3205(97)00986-7; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Netherton SJ, 2005, MOL PHARMACOL, V67, P263, DOI 10.1124/mol.104.004853; Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701; Rosen RC, 2003, AM J CARDIOL, V92, p9M, DOI 10.1016/S0002-9149(03)00824-5; Schror K, 2002, DIABETES OBES METAB, V4, pS14, DOI 10.1046/j.1463-1326.2002.0040s2s14.x; Stull J T, 1980, Adv Cyclic Nucleotide Res, V13, P39; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6; Wang L, 2012, MOL CELL BIOCHEM, V359, P83, DOI 10.1007/s11010-011-1002-3; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x; Wu Y, 2006, BIOCHEM J, V396, P23, DOI 10.1042/BJ20051568; Yano M, 2000, AM J PHYSIOL-HEART C, V279, pH1898, DOI 10.1152/ajpheart.2000.279.4.H1898; Zhang W, 2002, MOL PHARMACOL, V62, P514, DOI 10.1124/mol.62.3.514; Zhong XT, 2001, J BIOL CHEM, V276, P41518, DOI 10.1074/jbc.M104415200	45	19	19	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4419	4428		10.1096/fj.13-234625	http://dx.doi.org/10.1096/fj.13-234625			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23901069	Green Published, Green Submitted			2022-12-28	WOS:000329937500010
J	Versari, S; Longinotti, G; Barenghi, L; Maier, JAM; Bradamante, S				Versari, Silvia; Longinotti, Giulia; Barenghi, Livia; Maier, Jeanette Anne Marie; Bradamante, Silvia			The challenging environment on board the International Space Station affects endothelial cell function by triggering oxidative stress through thioredoxin interacting protein overexpression: the ESA-SPHINX experiment	FASEB JOURNAL			English	Article						microgravity; spaceflight; microarray; human umbilical vein endothelial cells; focal adhesion	GENE-EXPRESSION; DISTURBED FLOW; SHEAR-STRESS; MICROGRAVITY; GENOMICS; GROWTH; CYTOSKELETON; MECHANISMS; MICRORNAS; COMPLEX	Exposure to microgravity generates alterations that are similar to those involved in age-related diseases, such as cardiovascular deconditioning, bone loss, muscle atrophy, and immune response impairment. Endothelial dysfunction is the common denominator. To shed light on the underlying mechanism, we participated in the Progress 40P mission with Spaceflight of Human Umbilical Vein Endothelial Cells (HUVECs): an Integrated Experiment (SPHINX), which consisted of 12 in-flight and 12 ground-based control modules and lasted 10 d. Postflight microarray analysis revealed 1023 significantly modulated genes, the majority of which are involved in cell adhesion, oxidative phosphorylation, stress responses, cell cycle, and apoptosis. Thioredoxin-interacting protein was the most up-regulated (33-fold), heat-shock proteins 70 and 90 the most down-regulated (5.6-fold). Ion channels (TPCN1, KCNG2, KCNJ14, KCNG1, KCNT1, TRPM1, CLCN4, CLCA2), mitochondrial oxidative phosphorylation, and focal adhesion were widely affected. Cytokine detection in the culture media indicated significant increased secretion of interleukin-1 and interleukin-1. Nitric oxide was found not modulated. Our data suggest that in cultured HUVECs, microgravity affects the same molecular machinery responsible for sensing alterations of flow and generates a prooxidative environment that activates inflammatory responses, alters endothelial behavior, and promotes senescence.Versari, S., Longinotti, G., Barenghi, L., Maier, J. A. M., Bradamante, S. The challenging environment on board the International Space Station affects endothelial cell function by triggering oxidative stress through thioredoxin-interacting protein overexpression: the ESA-SPHINX experiment.	[Versari, Silvia; Longinotti, Giulia; Barenghi, Livia; Bradamante, Silvia] CNR, ISTM, I-20133 Milan, Italy; [Maier, Jeanette Anne Marie] Univ Milan, Dept Biomed & Clin Sci, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze e Tecnologie Molecolari (ISTM-CNR); University of Milan	Bradamante, S (corresponding author), CNR, ISTM, Via Golgi 19, I-20133 Milan, Italy.	silvia.bradamante@istm.cnr.it	Maier, Jeanette Anne Marie/H-4820-2012	Maier, Jeanette Anne Marie/0000-0002-6326-9221; Barenghi, Livia/0000-0001-7493-5798	ESA-ESTEC [4200014651]; Italian Space Agency (ASI) [I/048/10/0]	ESA-ESTEC(European Space Agency); Italian Space Agency (ASI)(Agenzia Spaziale Italiana (ASI))	The authors thank the European Space Research and Technology Centre (ESTEC) Life Science Instrumentation Laboratory, User Support Operation Centre (USOC; Zurich, Switzerland); Thales Alenia Space (Turin, Italy); Kayser Italia (Livorno, Italy); S. P. Korolyov Rocket and Space Corp. Energia (Moscow, Russia); and European Space Agency (ESA) Office (Moscow, Russia) for technical and logistic support. This work was supported by the ESA-ESTEC (contract 4200014651) and by the Italian Space Agency (ASI; contract I/048/10/0).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernardini D, 2005, BBA-MOL CELL RES, V1745, P265, DOI 10.1016/j.bbamcr.2005.06.013; Biggar KK, 2011, J MOL CELL BIOL, V3, P167, DOI 10.1093/jmcb/mjq045; Biolo G, 2003, CURR OPIN CLIN NUTR, V6, P31, DOI 10.1097/00075197-200301000-00006; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Boonstra J., 2011, LAB SCI SPACE DATA, P107; Silvia B, 2010, BBA-MOL CELL RES, V1803, P1376, DOI 10.1016/j.bbamcr.2010.07.007; Buravkova L, 2005, ACTA ASTRONAUT, V57, P67, DOI 10.1016/j.actaastro.2005.03.012; Buravkova LB, 2001, ACTA ASTRONAUT, V48, P647, DOI 10.1016/S0094-5765(01)00023-6; Carlsson SIM, 2003, BBA-MOL CELL RES, V1642, P173, DOI 10.1016/j.bbamcr.2003.08.003; Carlsson Sofia I M, 2002, J Gravit Physiol, V9, pP273; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chien S, 2007, AM J PHYSIOL-HEART C, V292, pH1209, DOI 10.1152/ajpheart.01047.2006; Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Collins C, 2011, EXP GERONTOL, V46, P185, DOI 10.1016/j.exger.2010.09.010; Cotrupi Sabrina, 2004, J Gravit Physiol, V11, pP173; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dikalov SI, 2012, ANTIOXID REDOX SIGNA; Downey T, 2006, METHOD ENZYMOL, V411, P256, DOI 10.1016/S0076-6879(06)11013-7; DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112; Dunn LL, 2010, ARTERIOSCL THROM VAS, V30, P2089, DOI 10.1161/ATVBAHA.110.209643; Griffoni C, 2011, J CELL BIOCHEM, V112, P265, DOI 10.1002/jcb.22921; Grosse J, 2012, FASEB J, V26, P639, DOI 10.1096/fj.11-194886; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hirase T, 2012, AM J PHYSIOL-HEART C, V302, pH499, DOI 10.1152/ajpheart.00325.2011; Hoffman BD, 2011, NATURE, V475, P316, DOI 10.1038/nature10316; Hsiai T. K, 2010, HEMODYNAMICS MECHANO, P1; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; Infanger M, 2007, J CELL BIOCHEM, V101, P1439, DOI 10.1002/jcb.21261; Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597; Janmey PA, 2011, J CELL SCI, V124, P9, DOI 10.1242/jcs.071001; Klein-Nulend J, 2003, ADV SPACE RES-SERIES, V32, P1551, DOI 10.1016/S0273-1177(03)90395-4; Kliche K, 2011, PFLUG ARCH EUR J PHY, V462, P209, DOI 10.1007/s00424-011-0929-2; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu DS, 2011, J R SOC INTERFACE, V8, P1379, DOI 10.1098/rsif.2011.0177; Mammoto A, 2012, J CELL SCI, V125, P3061, DOI 10.1242/jcs.093005; Mariotti M, 2009, MICROGRAVITY SCI TEC, V21, P141, DOI 10.1007/s12217-008-9066-8; Martinon F, 2010, EUR J IMMUNOL, V40, P616, DOI 10.1002/eji.200940168; Morbidelli L, 2005, BIOCHEM BIOPH RES CO, V334, P491, DOI 10.1016/j.bbrc.2005.06.124; Muid S., 2010, GRAVIT SPACE BIOL S, V23, pS1; Ng MKC, 2007, ARTERIOSCL THROM VAS, V27, P106, DOI 10.1161/01.ATV.0000251517.98396.4a; Nichols HL, 2006, PHYSIOL GENOMICS, V26, P163, DOI 10.1152/physiolgenomics.00323.2005; Pedersen SF, 2011, J AM SOC NEPHROL, V22, P1587, DOI 10.1681/ASN.2010121284; Pop C, 2009, J BIOL CHEM, V284, P21777, DOI 10.1074/jbc.R800084200; Salminen A, 2012, CELL MOL LIFE SCI, V69, P2999, DOI 10.1007/s00018-012-0962-0; Sanford GL, 2002, IN VITRO CELL DEV-AN, V38, P493; Santarpia L, 2010, ENDOCR-RELAT CANCER, V17, pF51, DOI 10.1677/ERC-09-0222; Schulze PC, 2004, J BIOL CHEM, V279, P30369, DOI 10.1074/jbc.M400549200; Sukharev S, 2012, J CELL SCI, V125, P3075, DOI 10.1242/jcs.092353; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tomasini R, 2005, ONCOGENE, V24, P8093, DOI 10.1038/sj.onc.1208951; Tretter L, 2004, NEUROCHEM RES, V29, P569, DOI 10.1023/B:NERE.0000014827.94562.4b; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; van Raam BJ, 2012, BBA-PROTEINS PROTEOM, V1824, P113, DOI 10.1016/j.bbapap.2011.06.005; Vasto S, 2007, MECH AGEING DEV, V128, P83, DOI 10.1016/j.mad.2006.11.015; Vecchione A, 2010, ENDOCR-RELAT CANCER, V17, pF37, DOI 10.1677/ERC-09-0163; Vernikos J, 1996, BIOESSAYS, V18, P1029, DOI 10.1002/bies.950181215; Vernikos J, 2010, GERONTOLOGY, V56, P157, DOI 10.1159/000252852; Versari S, 2007, BBA-MOL CELL RES, V1773, P1645, DOI 10.1016/j.bbamcr.2007.05.014; Walther I, 1996, J BIOTECHNOL, V47, P113, DOI 10.1016/0168-1656(96)01375-2; Wang E, 1999, FASEB J, V13, pS167; Wang XQ, 2012, CIRC RES, V110, P560, DOI 10.1161/CIRCRESAHA.111.256362; World C, 2011, ARTERIOSCL THROM VAS, V31, P1890, DOI 10.1161/ATVBAHA.111.226340; Wu MZ, 2011, AGEING RES REV, V10, P1, DOI 10.1016/j.arr.2009.11.002; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Yoshioka J, 2004, CIRCULATION, V109, P2581, DOI 10.1161/01.CIR.0000129771.32215.44; Zschauer TC, 2011, ARTERIOSCL THROM VAS, V31, P650, DOI 10.1161/ATVBAHA.110.218982	70	88	92	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4466	4475		10.1096/fj.13-229195	http://dx.doi.org/10.1096/fj.13-229195			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23913861				2022-12-28	WOS:000329937500014
J	Takeda, S; Hashimoto, T; Roe, AD; Hori, Y; Spires-Jones, TL; Hyman, BT				Takeda, Shuko; Hashimoto, Tadafumi; Roe, Allyson D.; Hori, Yukiko; Spires-Jones, Tara L.; Hyman, Bradley T.			Brain interstitial oligomeric amyloid beta increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						in vivo microdialysis; apolipoprotein E	A-BETA; APOLIPOPROTEIN-E; SYNAPTIC PLASTICITY; SECRETED OLIGOMERS; PRECURSOR PROTEIN; DEPOSITION; METABOLISM; PLASMA; E4	There is a growing body of evidence that soluble oligomeric forms of amyloid (A) play a critical role in Alzheimer's disease (AD). Despite the importance of soluble A oligomers as a therapeutic target for AD, the dynamic metabolism of these A species in vivo has not been elucidated because of the difficulty in monitoring brain A oligomers in living animals. Here, using a unique large pore-sized membrane microdialysis, we characterized soluble A oligomers in brain interstitial fluid (ISF) of awake, freely moving APP/PS1 transgenic and control WT mice. We could detect high-molecular-weight (HMW) and low-molecular-weight (LMW) A oligomers in the brain ISF of living animals, which increased dramatically in an age-dependent manner (5- to 8-fold increase, 4 vs. 17-18 mo). Notably, HMW A decreased more slowly than other forms of A after acute -secretase inhibition [% decrease from the baseline (HMW vs. LMW) was 36.9 vs. 74.1% (A(40), P<0.05) and 25.4 vs. 88.0% (A(42), P<0.01)], suggesting that HMW A oligomers clear more slowly than other forms from the brain. These data reveal the dynamic metabolism of neurotoxic A oligomers in AD brain and could provide new insights into A-targeted therapies for AD.Takeda, S., Hashimoto, T., Roe, A. D., Hori, Y., Spires-Jones, T. L., and Hyman, B. T. Brain interstitial oligomeric amyloid increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease.	[Takeda, Shuko; Hashimoto, Tadafumi; Roe, Allyson D.; Hori, Yukiko; Spires-Jones, Tara L.; Hyman, Bradley T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab,Dept Neurol,MassGen Inst N, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab,Dept Neurol,MassGen Inst N, Bldg 114,16th St, Charlestown, MA 02129 USA.	bhyman@partners.org	Spires-Jones, Tara/AAR-7697-2020	Spires-Jones, Tara/0000-0003-2530-0598; Hashimoto, Tadafumi/0000-0001-5442-4800	U.S. National Institutes of Health [P50AG05134]; Japan Society for the Promotion of Science (JSPS); NATIONAL INSTITUTE ON AGING [P50AG005134] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research is supported by U.S. National Institutes of Health grant P50AG05134 (B. T. H.). S. T. is supported by a fellowship from the Japan Society for the Promotion of Science (JSPS). The authors also thank Dr. Alberto Serrano-Pozo for valuable discussions. The authors declare no conflicts of interest.	Bero AW, 2011, NAT NEUROSCI, V14, P750, DOI 10.1038/nn.2801; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Cao CH, 2009, J ALZHEIMERS DIS, V17, P681, DOI 10.3233/JAD-2009-1071; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Cirrito JR, 2003, J NEUROSCI, V23, P8844; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Fukumoto H, 2010, FASEB J, V24, P2716, DOI 10.1096/fj.09-150359; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hashimoto T, 2012, J NEUROSCI, V32, P15181, DOI 10.1523/JNEUROSCI.1542-12.2012; Holtzman DM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002369; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hong SY, 2011, J NEUROSCI, V31, P15861, DOI 10.1523/JNEUROSCI.3272-11.2011; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Klein William L, 2006, Alzheimers Dement, V2, P43, DOI 10.1016/j.jalz.2005.11.003; Koffie RM, 2012, BRAIN, V135, P2155, DOI 10.1093/brain/aws127; Koffie RM, 2009, P NATL ACAD SCI USA, V106, P4012, DOI 10.1073/pnas.0811698106; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012; Savonenko A, 2005, NEUROBIOL DIS, V18, P602, DOI 10.1016/j.nbd.2004.10.022; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 1999, J CLIN INVEST, V104, P1169, DOI 10.1172/JCI8508; Takeda S, 2011, NEUROSCIENCE, V186, P110, DOI 10.1016/j.neuroscience.2011.04.035; Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Xia WM, 2009, ARCH NEUROL-CHICAGO, V66, P190, DOI 10.1001/archneurol.2008.565; Yamada K, 2009, J NEUROSCI, V29, P11393, DOI 10.1523/JNEUROSCI.2021-09.2009	32	47	50	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3239	3248		10.1096/fj.13-229666	http://dx.doi.org/10.1096/fj.13-229666			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23640054	Green Published			2022-12-28	WOS:000329877600029
J	Zhang, GH; Lin, RK; Kwon, YT; Li, YP				Zhang, Guohua; Lin, Ren-Kuo; Kwon, Yong Tae; Li, Yi-Ping			Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2	FASEB JOURNAL			English	Article						cachexia; p38; MAPK; C; EBP; gene regulation	SKELETAL-MUSCLE ATROPHY; END RULE PATHWAY; C/EBP-BETA; CANCER CACHEXIA; PROTEIN-DEGRADATION; PROTEASOME PATHWAY; ACTIVATION; ATROGIN1/MAFBX; EXPRESSION; MAPK	The N-end rule pathway contributes significantly to accelerated muscle proteolysis mediated by the ubiquitin-proteasome pathway in various catabolic conditions. UBR2 (aka E3-II) is the only known E3 ubiquitin ligase of the N-end rule pathway that is up-regulated by cachectic stimuli including proinflammatory cytokines and tumors. However, the signaling mechanism through which UBR2 is up-regulated remains undetermined. Here we identify a signaling pathway that mediates tumor cell-induced up-regulation of UBR2. UBR2 expression in C2C12 myotubes was up-regulated by conditioned medium from Lewis lung carcinoma cells or C26 colon adenocarcinoma cells, which was blocked by a pharmacological inhibitor of p38/ mitogen-activated protein kinase (MAPK), SB202190. Similarly, SB202190 administration (i.p.) abolished UBR2 up-regulation in the tibialis anterior of LLC tumor-bearing mice. Genetic gain and loss of function assays in C2C12 myotubes indicated that tumor-induced activation of the p38 isoform is sufficient and necessary for UBR2 up-regulation. In addition, UBR2 up-regulation required p38-mediated phosphorylation of CCAAT/enhancer binding protein (C/EBP)- Thr-188, which was critical to C/EBP binding to the UBR2 promoter. Furthermore, luciferase reporter assay revealed that the C/EBP binding motif in the UBR2 promoter is a functional C/EBP-responsive cis-element that enhances the promoter activity on activation by p38. Finally, genetic ablation of C/EBP blocked UBR2 up-regulation in LLC tumor-bearing mice. These results suggest that UBR2 up-regulation in cachectic muscle is mediated by the p38-C/EBP signaling pathway responsible for the bulk of tumor-induced muscle proteolysis.Zhang, G., Lin, R.-K., Kwon, Y. T., Li, Y.-P. Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2.	[Zhang, Guohua; Lin, Ren-Kuo; Li, Yi-Ping] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Kwon, Yong Tae] Univ Pittsburgh, Ctr Pharmacogenet, Pittsburgh, PA USA; [Kwon, Yong Tae] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Kwon, Yong Tae] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, World Class Univ Program, Seoul, South Korea; [Kwon, Yong Tae] Seoul Natl Univ, Coll Med, Seoul, South Korea	University of Texas System; University of Texas Health Science Center Houston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Seoul National University (SNU); Seoul National University (SNU)	Li, YP (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.	yi-ping.li@uth.tmc.edu	Li, Yi-Ping/ABF-9245-2020; Zhang, Guohua/AFR-1220-2022		U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR052511]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052511] Funding Source: NIH RePORTER	U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by an R01 grant from the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases to Y.-P.L. (AR052511). The authors thank Peter Johnson (National Cancer Institute, Bethesda, MD, USA) for sharing the C/EBP beta<SUP>-/-</SUP> mice, Jiahuai Han (Scripps Research Institute, La Jolla, CA, USA) for sharing the adenovirus encoding MKK6bE, and David Engelberg (Hebrew University, Jerusalem, Israel) for sharing plasmids encoding the constitutively active mutants of p38 MAPK isoforms.	Avitzour M, 2007, FEBS J, V274, P963, DOI 10.1111/j.1742-4658.2007.05644.x; Baltgalvis KA, 2009, PFLUG ARCH EUR J PHY, V457, P989, DOI 10.1007/s00424-008-0574-6; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bostrom P, 2010, CELL, V143, P1072, DOI 10.1016/j.cell.2010.11.036; Cao PR, 2005, INT J BIOCHEM CELL B, V37, P2088, DOI 10.1016/j.biocel.2004.11.010; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052; Csibi A, 2009, J BIOL CHEM, V284, P4413, DOI 10.1074/jbc.M807641200; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; Di Giovanni S, 2004, ANN NEUROL, V55, P195, DOI 10.1002/ana.10811; Doyle A, 2011, FASEB J, V25, P99, DOI 10.1096/fj.10-164152; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011; Fielitz J, 2007, J CLIN INVEST, V117, P2486, DOI 10.1172/JCI32827; Gallagher IJ, 2012, CLIN CANCER RES, V18, P2817, DOI 10.1158/1078-0432.CCR-11-2133; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Kwak KS, 2004, CANCER RES, V64, P8193, DOI 10.1158/0008-5472.CAN-04-2102; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Lagirand-Cantaloube J, 2008, EMBO J, V27, P1266, DOI 10.1038/emboj.2008.52; Lagirand-Cantaloube J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004973; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Leger B, 2006, FASEB J, V20, P583, DOI 10.1096/fj.05-5249fje; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; Mancini A, 2007, ONCOGENE, V26, P1020, DOI 10.1038/sj.onc.1209853; Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; O'Gorman P, 1999, NUTR CANCER, V35, P127, DOI 10.1207/S15327914NC352_5; Ottenheijm CAC, 2006, AM J RESP CRIT CARE, V174, P997, DOI 10.1164/rccm.200605-721OC; Penna F, 2010, INT J CANCER, V127, P1706, DOI 10.1002/ijc.25146; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; Staiger J, 2009, CARCINOGENESIS, V30, P832, DOI 10.1093/carcin/bgn273; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673; Zhang GH, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-20; Zhang GH, 2011, EMBO J, V30, P4323, DOI 10.1038/emboj.2011.292	44	30	30	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2893	2901		10.1096/fj.12-222711	http://dx.doi.org/10.1096/fj.12-222711			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23568773	Green Published			2022-12-28	WOS:000328841000037
J	Luo, SL; Zhangsun, DT; Schroeder, CI; Zhu, XP; Hu, YY; Wu, Y; Weltzin, MM; Eberhard, S; Kaas, Q; Craik, DJ; McIntosh, JM; Whiteaker, P				Luo, Sulan; Zhangsun, Dongting; Schroeder, Christina I.; Zhu, Xiaopeng; Hu, Yuanyan; Wu, Yong; Weltzin, Maegan M.; Eberhard, Spencer; Kaas, Quentin; Craik, David J.; McIntosh, J. Michael; Whiteaker, Paul			A novel alpha 4/7-conotoxin LvIA from Conus lividus that selectively blocks alpha 3 beta 2 vs. alpha 6/alpha 3 beta 2 beta 3 nicotinic acetylcholine receptors	FASEB JOURNAL			English	Article						nuclear magnetic resonance spectroscopy; cholinergic; ligand-gated ion channel receptor; molecular modeling	SPIN COUPLING-CONSTANTS; DISULFIDE BOND ISOMERS; ALPHA-CONOTOXIN-MII; SUBUNIT COMPOSITION; PROTEIN; ALPHA-9-ALPHA-10; BINDING; PEPTIDES; TARGETS; TOOLS	This study was performed to discover and characterize the first potent alpha 3 beta 2-subtype-selective nicotinic acetylcholine receptor (nAChR) ligand. A novel alpha 4/7-conotoxin, alpha-CTxLvIA, was cloned from Conus lividus. Its pharmacological profile at Xenopus laevis oocyte-expressed rat nAChR subtypes was determined by 2-electrode voltage-clamp electrophysiology, and its 3-dimensional (3D) structure was determined by NMR spectroscopy. alpha-CTx LvIA is a 16-aa C-terminally-amidated peptide with 2-disulfide bridges. Using rat subunits expressed in Xenopus oocytes, we found the highest affinity of alpha-CTxLvIA was for alpha 3 beta 2 nAChRs (IC50 8.7 nM), where blockade was reversible within 2 min. IC50 values were > 100 nM at alpha 6/alpha 3 beta 2 beta 3, alpha 6/alpha 3 beta 4, and alpha 3 beta 4 nAChRs, and >= 3 mu M at all other subtypes tested. alpha 3 beta 2 vs. alpha 6 beta 2 subtype selectivity was confirmed for human-subunit nAChRs with much greater preference (300-fold) for alpha 3 beta 2 over alpha 6 beta 2 nAChRs. This is the first alpha-CTx reported to show high selectivity for human alpha 3 beta 2 vs. alpha 6 beta 2 nAChRs. alpha-CTxLvIA adopts two similarly populated conformations water: one (assumed to be bioactive) is highly structured, whereas the other is mostly random coil in nature. Selectivity differences with the similarly potent, but less selective, alpha 3 beta 2 nAChR antagonist alpha-CTx PeIA probably reside within the three residues, which differ in loop 2, given their otherwise similar 3D structures. alpha 4/7-CTx LvIA is a new, potent, selective alpha 3 beta 2 nAChR antagonist, which will enable detailed studies of alpha 3 beta 2 nAChR structure, function, and physiological roles.-Luo, S., Zhangsun, D., Schroeder, C. I., Zhu, X., Hu, Y., Wu, Y., Weltzin, M. M., Eberhard, S., Kaas, Q., Craik, D. J., McIntosh, J. M., Whiteaker, P. A novel alpha 4/7-conotoxin LvIA from Conus lividus that selectively blocks alpha 3 beta 2 vs. alpha 6/alpha 3 beta 2 beta 3 nicotinic acetylcholine receptors.	[Luo, Sulan; Zhangsun, Dongting; Zhu, Xiaopeng; Hu, Yuanyan; Wu, Yong] Hainan Univ, Minist Educ, Key Lab Trop Biol Resources, Key Lab Marine Drug Haikou, Haikou 570228, Hainan, Peoples R China; [Schroeder, Christina I.; Kaas, Quentin; Craik, David J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Weltzin, Maegan M.; Whiteaker, Paul] Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA; [Eberhard, Spencer] Brigham Young Univ, Dept Biol, Rexburg, ID USA; [McIntosh, J. Michael] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA; [McIntosh, J. Michael] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; [McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Hainan University; University of Queensland; Barrow Neurological Institute; Brigham Young University; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Luo, SL (corresponding author), Hainan Univ, Minist Educ, Key Lab Trop Biol Resources, Haikou 570228, Hainan, Peoples R China.	luosulan2003@163.com	Craik, David/B-1695-2010; Schroeder, Cristina I./K-2042-2014; Kaas, Quentin/J-8727-2014	Craik, David/0000-0003-0007-6796; Schroeder, Cristina I./0000-0002-6737-6374; Kaas, Quentin/0000-0001-9988-6152	National Natural Science Foundation of China [81160503, 41366002]; State High-Tech Research and Development Project (863) of the Ministry of Science and Technology of China [2012AA021706]; Program for International Science and Technology Cooperation Program of China [2011DFR31210]; Changjiang Scholars and Innovative Research Team in University (PCSIRT) [IRT1123]; U.S. National Institutes of Health [DA012242, GM103801, GM48677]; Australian Research Council [1093115]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677, R01GM103801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012242] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State High-Tech Research and Development Project (863) of the Ministry of Science and Technology of China; Program for International Science and Technology Cooperation Program of China; Changjiang Scholars and Innovative Research Team in University (PCSIRT)(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian Research Council(Australian Research Council); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported, in part, by the National Natural Science Foundation of China, grants 81160503 and 41366002; State High-Tech Research and Development Project (863) of the Ministry of Science and Technology of China, grant 2012AA021706; Program for International Science and Technology Cooperation Program of China, grant 2011DFR31210; and Changjiang Scholars and Innovative Research Team in University, grants PCSIRT and IRT1123. This work was also supported by U.S. National Institutes of Health grants DA012242, GM103801, and GM48677, and Australian Research Council grant 1093115. D.J.C. is an Australian National Health and Medical Research Council Professorial Fellow (APP1026501). A preliminary account of some of this work was presented in the patent literature (76).	Armishaw CJ, 2010, BIOPOLYMERS, V94, P307, DOI 10.1002/bip.21360; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cierpicki T, 2001, J BIOMOL NMR, V21, P249, DOI 10.1023/A:1012911329730; Clark RJ, 2006, J BIOL CHEM, V281, P23254, DOI 10.1074/jbc.M604550200; Clark RJ, 2010, ANGEW CHEM INT EDIT, V49, P6545, DOI 10.1002/anie.201000620; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; Corpuz GP, 2005, BIOCHEMISTRY-US, V44, P8176, DOI 10.1021/bi047541b; Daly NL, 2011, J BIOL CHEM, V286, P10233, DOI 10.1074/jbc.M110.196170; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dowell C, 2003, J NEUROSCI, V23, P8445; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; Dutton JL, 2001, CURR MED CHEM, V8, P327, DOI 10.2174/0929867013373453; Franco A, 2012, BIOCHEM PHARMACOL, V83, P419, DOI 10.1016/j.bcp.2011.11.006; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Gotti C, 2006, NEUROBIOL DIS, V23, P481, DOI 10.1016/j.nbd.2006.04.005; Gotti C, 2009, BIOCHEM PHARMACOL, V78, P703, DOI 10.1016/j.bcp.2009.05.024; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Halai R, 2009, J BIOL CHEM, V284, P20275, DOI 10.1074/jbc.M109.015339; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; Hogg RC, 1999, J BIOL CHEM, V274, P36559, DOI 10.1074/jbc.274.51.36559; Hone AJ, 2012, MOL PHARMACOL, V82, P972, DOI 10.1124/mol.112.080853; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Jacobsen RB, 1999, BIOCHEMISTRY-US, V38, P13310, DOI 10.1021/bi9907476; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jin AH, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-28; Kaas Q, 2008, BIOINFORMATICS, V24, P445, DOI 10.1093/bioinformatics/btm596; Kaas Q, 2012, NUCLEIC ACIDS RES, V40, pD325, DOI 10.1093/nar/gkr886; Kasheverov IE, 2009, CURR PHARM DESIGN, V15, P2430, DOI 10.2174/138161209788682316; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1; Letchworth SR, 2011, BIOCHEM PHARMACOL, V82, P862, DOI 10.1016/j.bcp.2011.06.022; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Lukas RJ, 1999, PHARMACOL REV, V51, P397; Luo S., 2012, Chinese Pat. Lit. CN, Patent No. [201210347966. 3, 2012103479663]; Luo Su-lan, 2004, Zhongguo Haiyang Yaowu, V23, P21; Luo SL, 2013, J BIOL CHEM, V288, P894, DOI 10.1074/jbc.M112.427898; Luo SL, 2010, J BIOL CHEM, V285, P12355, DOI 10.1074/jbc.M109.079012; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; McClure-Begley TD, 2012, J NEUROCHEM, V122, P48, DOI 10.1111/j.1471-4159.2012.07759.x; McIntosh JM, 2005, J BIOL CHEM, V280, P30107, DOI 10.1074/jbc.M504102200; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; McIntosh JM, 2002, J BIOL CHEM, V277, P33610, DOI 10.1074/jbc.M205102200; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Muttenthaler M, 2011, CURR PHARM DESIGN, V17, P4226, DOI 10.2174/138161211798999384; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; Nevin ST, 2007, MOL PHARMACOL, V72, P1406, DOI 10.1124/mol.107.040568; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Nielsen KJ, 2002, J BIOL CHEM, V277, P27247, DOI 10.1074/jbc.M201611200; Norton RS, 2006, TOXICON, V48, P780, DOI 10.1016/j.toxicon.2006.07.022; Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Peng C, 2009, ACTA BIOCH BIOPH SIN, V41, P858, DOI 10.1093/abbs/gmp077; Quik M, 2011, BIOCHEM PHARMACOL, V82, P873, DOI 10.1016/j.bcp.2011.06.001; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santos AD, 2004, J BIOL CHEM, V279, P17596, DOI 10.1074/jbc.M309654200; Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606; Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z; SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015; Sondergaard CR, 2011, J CHEM THEORY COMPUT, V7, P2284, DOI 10.1021/ct200133y; Talley TT, 2006, J BIOL CHEM, V281, P24678, DOI 10.1074/jbc.M602969200; Teichert RW, 2006, BIOCHEMISTRY-US, V45, P1304, DOI 10.1021/bi052016d; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Vincler M, 2006, P NATL ACAD SCI USA, V103, P17880, DOI 10.1073/pnas.0608715103; WAGNER G, 1990, PROG NUCL MAG RES SP, V22, P101, DOI 10.1016/0079-6565(90)80003-Z; Whiteaker P, 2000, MOL PHARMACOL, V57, P913; Whiteaker P, 2002, J NEUROSCI, V22, P2522, DOI 10.1523/JNEUROSCI.22-07-02522.2002; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Young T, 2008, BRAIN RES, V1229, P118, DOI 10.1016/j.brainres.2008.06.086; Yu RL, 2013, J MED CHEM, V56, P3557, DOI 10.1021/jm400041h; Yu RL, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002011; [郑晓冬 ZHENG Xiaodong], 2011, [生物技术, Biotechnology], V21, P40	80	47	53	1	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1842	1853		10.1096/fj.13-244103	http://dx.doi.org/10.1096/fj.13-244103			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24398291	Green Published			2022-12-28	WOS:000335344300029
J	Kavitha, JV; Rosario, FJ; Nijland, MJ; McDonald, TJ; Wu, GY; Kanai, Y; Powell, TL; Nathanielsz, PW; Jansson, T				Kavitha, Jovita V.; Rosario, Fredrick J.; Nijland, Mark J.; McDonald, Thomas J.; Wu, Guoyao; Kanai, Yoshikatsu; Powell, Theresa L.; Nathanielsz, Peter W.; Jansson, Thomas			Down-regulation of placental mTOR, insulin/IGF- I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon	FASEB JOURNAL			English	Article						fetal growth restriction; trophoblast; nonhuman primate	AMINO-ACID TRANSPORTER; INTRAUTERINE GROWTH RESTRICTION; 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 AND-2; MAMMALIAN TARGET; GLUCOCORTICOID SENSITIVITY; NUTRITIONAL MANIPULATION; DEVELOPMENTAL-CHANGES; UNCOUPLING PROTEIN-2; TROPHOBLAST CELLS; GLUT-1 EXPRESSION	The mechanisms by which maternal nutrient restriction (MNR) causes reduced fetal growth are poorly understood. We hypothesized that MNR inhibits placental mechanistic target of rapamycin (mTOR) and insulin/IGF-I signaling, down-regulates placental nutrient transporters, and decreases fetal amino acid levels. Pregnant baboons were fed control (ad libitum, n=11) or an MNR diet (70% of controls, n=11) from gestational day (GD) 30. Placenta and umbilical blood were collected at GD 165. Western blot was used to determine the phosphorylation of proteins in the mTOR, insulin/IGF-I, ERK1/2, and GSK-3 signaling pathways in placental homogenates and expression of glucose transporter 1 (GLUT-1), taurine transporter (TAUT), sodium-dependent neutral amino acid transporter (SNAT), and large neutral amino acid transporter (LAT) isoforms in syncytiotrophoblast microvillous membranes (MVMs). MNR reduced fetal weights by 13%, lowered fetal plasma concentrations of essential amino acids, and decreased the phosphorylation of placental S6K, S6 ribosomal protein, 4E-BP1, IRS-1, Akt, ERK-1/2, and GSK-3. MVM protein expression of GLUT-1, TAUT, SNAT-2 and LAT-1/2 was reduced in MNR. This is the first study in primates exploring placental responses to maternal undernutrition. Inhibition of placental mTOR and insulin/IGF-I signaling resulting in down-regulation of placental nutrient transporters may link maternal undernutrition to restricted fetal growth.Kavitha, J. V., Rosario, F. J., Nijland, M. J., McDonald, T. J., Wu, G., Kanai, Y., Powell, T. L., Nathanielsz, P. W., Jansson, T. Down-regulation of placental mTOR, insulin/IGF-I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon.	[Kavitha, Jovita V.; Rosario, Fredrick J.; Nijland, Mark J.; McDonald, Thomas J.; Powell, Theresa L.; Nathanielsz, Peter W.; Jansson, Thomas] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA; [McDonald, Thomas J.; Wu, Guoyao] Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA; [Kanai, Yoshikatsu] Osaka Univ, Grad Sch Med, Dept Pharmacol, Div Biosyst Pharmacol, Osaka, Japan	University of Texas System; University of Texas Health San Antonio; Texas A&M University System; Texas A&M University College Station; Osaka University	Rosario, FJ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Ctr Pregnancy & Newborn Res, Mail Code 7836,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	josephf@uthscsa.edu	Rosario, Fredrick Joseph/I-2835-2019; Powell, Theresa/AAE-4249-2020	Nathanielsz, Peter/0000-0001-8410-6280; Powell, Theresa/0000-0001-7410-1080	U.S. National Institutes of Health [P01HD21350]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021350] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011133] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by U.S. National Institutes of Health grant P01HD21350.	Antonow-Schlorke I, 2011, P NATL ACAD SCI USA, V108, P3011, DOI 10.1073/pnas.1009838108; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Barry JS, 2006, EXP BIOL MED, V231, P566; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Bodner J, 1999, PLACENTA, V20, P677, DOI 10.1053/plac.1999.0431; Brodsky Dara, 2004, J Intensive Care Med, V19, P307, DOI 10.1177/0885066604269663; Carter AM, 2007, PLACENTA, V28, pS41, DOI 10.1016/j.placenta.2006.11.002; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Choi J, 2011, AM J PHYSIOL-REG I, V301, pR757, DOI 10.1152/ajpregu.00051.2011; Coan PM, 2010, J PHYSIOL-LONDON, V588, P527, DOI 10.1113/jphysiol.2009.181214; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Cox LA, 2006, J PHYSIOL-LONDON, V572, P67, DOI 10.1113/jphysiol.2006.106872; Dandrea J, 2001, REPRODUCTION, V122, P793, DOI 10.1530/rep.0.1220793; Desforges M, 2006, AM J PHYSIOL-CELL PH, V290, pC305, DOI 10.1152/ajpcell.00258.2005; DESOYE G, 1994, HISTOCHEMISTRY, V101, P277, DOI 10.1007/BF00315915; Di Simone N, 2009, J CELL MOL MED, V13, P388, DOI 10.1111/j.1582-4934.2008.00337.x; Fang JG, 1997, PEDIATR RES, V41, P258, DOI 10.1203/00006450-199702000-00017; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Ganguly A, 2012, ENDOCRINOLOGY, V153, P3995, DOI 10.1210/en.2011-1973; Glazier JD, 1997, PEDIATR RES, V42, P514, DOI 10.1203/00006450-199710000-00016; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Gnanalingham MG, 2007, REPRODUCTION, V134, P615, DOI 10.1530/REP-06-0369; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; ILLSLEY NP, 1990, BIOCHIM BIOPHYS ACTA, V1029, P218, DOI 10.1016/0005-2736(90)90157-J; Jansson N, 2003, J CLIN ENDOCR METAB, V88, P1205, DOI 10.1210/jc.2002-021332; Jansson N, 2006, J PHYSIOL-LONDON, V576, P935, DOI 10.1113/jphysiol.2003.550004; Jansson N, 2013, J CLIN ENDOCR METAB, V98, P105, DOI 10.1210/jc.2012-2667; Jansson T, 2006, PLACENTA, V27, pS91, DOI 10.1016/j.placenta.2005.11.010; Jansson T, 1998, PEDIATR RES, V44, P532, DOI 10.1203/00006450-199810000-00011; JANSSON T, 1993, J CLIN ENDOCR METAB, V77, P1554, DOI 10.1210/jc.77.6.1554; Jansson T, 2002, DIABETES, V51, P2214, DOI 10.2337/diabetes.51.7.2214; Jansson T, 1999, AM J OBSTET GYNECOL, V180, P163, DOI 10.1016/S0002-9378(99)70169-9; Jansson T, 2007, CLIN SCI, V113, P1, DOI 10.1042/CS20060339; Jansson T, 2013, CLIN OBSTET GYNECOL, V56, P591, DOI 10.1097/GRF.0b013e3182993a2e; Jones HN, 2009, AM J PHYSIOL-CELL PH, V297, pC1228, DOI 10.1152/ajpcell.00195.2009; Jones HN, 2010, DIABETES, V59, P1161, DOI 10.2337/db09-0824; KARL PI, 1995, J CELL PHYSIOL, V165, P83, DOI 10.1002/jcp.1041650111; KARL PI, 1992, AM J PHYSIOL, V262, pC834, DOI 10.1152/ajpcell.1992.262.4.C834; Kawabata K, 2006, FEBS LETT, V580, P5288, DOI 10.1016/j.febslet.2006.08.072; Lesage J, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740037; Li C, 2007, PLACENTA, V28, P1200, DOI 10.1016/j.placenta.2007.06.011; Ling R, 2001, BBA-BIOMEMBRANES, V1512, P15, DOI 10.1016/S0005-2736(01)00310-8; Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; MAHENDRAN D, 1993, PEDIATR RES, V34, P661; Malandro MS, 1996, AM J PHYSIOL-CELL PH, V271, pC295, DOI 10.1152/ajpcell.1996.271.1.C295; Nijland MJ, 2010, J PHYSIOL-LONDON, V588, P1349, DOI 10.1113/jphysiol.2009.184168; Norberg S, 1998, PEDIATR RES, V44, P233, DOI 10.1203/00006450-199808000-00016; Nord M., 2010, HOUSEHOLD FOOD SECUR; Park SY, 2005, ARCH PHARM RES, V28, P421, DOI 10.1007/BF02977671; Pepe GJ, 2001, ENDOCRINOLOGY, V142, P4496, DOI 10.1210/en.142.10.4496; Pepe GJ, 2001, ENDOCRINOLOGY, V142, P68, DOI 10.1210/en.142.1.68; Rodriguez JS, 2012, REPROD SCI, V19, P493, DOI 10.1177/1933719111424439; Roos S, 2009, AM J PHYSIOL-CELL PH, V297, pC723, DOI 10.1152/ajpcell.00191.2009; Roos S, 2009, AM J PHYSIOL-CELL PH, V296, pC142, DOI 10.1152/ajpcell.00330.2008; Roos S, 2007, J PHYSIOL-LONDON, V582, P449, DOI 10.1113/jphysiol.2007.129676; Rosario FJ, 2013, J PHYSIOL-LONDON, V591, P609, DOI 10.1113/jphysiol.2012.238014; Rosario FJ, 2011, ENDOCRINOLOGY, V152, P1119, DOI 10.1210/en.2010-1153; Roseboom TJ, 2011, PLACENTA, V32, P395, DOI 10.1016/j.placenta.2011.03.001; Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J; Schlabritz-Loutsevitch NE, 2004, J MED PRIMATOL, V33, P117, DOI 10.1111/j.1600-0684.2004.00067.x; Sferruzzi-Perri AN, 2007, AM J PHYSIOL-ENDOC M, V292, pE668, DOI 10.1152/ajpendo.00320.2006; Sibley CP, 2005, PEDIATR RES, V58, P827, DOI 10.1203/01.PDR.0000181381.82856.23; TAVARE JM, 1989, CELL SIGNAL, V1, P55, DOI 10.1016/0898-6568(89)90020-X; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Whorwood CB, 2001, ENDOCRINOLOGY, V142, P2854, DOI 10.1210/en.142.7.2854; Wu GY, 1997, J NUTR, V127, P2342, DOI 10.1093/jn/127.12.2342; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Yiallourides M, 2009, REPRODUCTION, V138, P601, DOI 10.1530/REP-09-0043; Yung HW, 2008, AM J PATHOL, V173, P451, DOI 10.2353/ajpath.2008.071193; Zhu MJ, 2007, PLACENTA, V28, P1192, DOI 10.1016/j.placenta.2007.05.004; Zhu MJ, 2010, AM J PHYSIOL-REG I, V299, pR1224, DOI 10.1152/ajpregu.00309.2010	77	99	102	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1294	1305		10.1096/fj.13-242271	http://dx.doi.org/10.1096/fj.13-242271			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24334703	Green Published			2022-12-28	WOS:000335324800022
J	Padler-Karavani, V; Hurtado-Ziola, N; Chang, YC; Sonnenburg, JL; Ronaghy, A; Yu, H; Verhagen, A; Nizet, V; Chen, X; Varki, N; Varki, A; Angata, T				Padler-Karavani, Vered; Hurtado-Ziola, Nancy; Chang, Yung-Chi; Sonnenburg, Justin L.; Ronaghy, Arash; Yu, Hai; Verhagen, Andrea; Nizet, Victor; Chen, Xi; Varki, Nissi; Varki, Ajit; Angata, Takashi			Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates	FASEB JOURNAL			English	Article						sialic acids; N-acetylneuraminic acid; N-glycolylneuraminic acid; innate immunity	SIALIC ACIDS; INNATE IMMUNITY; RECEPTOR; GANGLIOSIDES; MACROPHAGES; DIVERSITY; INTERACT; PATHOGEN; REVEALS; CLONING	Siglecs are sialic acid-binding Ig-like lectins that recognize sialoglycans via amino-terminal V-set domains. CD33-related Siglecs (CD33rSiglecs) on innate immune cells recognize endogenous sialoglycans as self-associated molecular patterns (SAMPs), dampening immune responses via cytosolic immunoreceptor tyrosine-based inhibition motifs that recruit tyrosine phosphatases. However, sialic acid-expressing pathogens subvert this mechanism through molecular mimicry. Meanwhile, endogenous host SAMPs must continually evolve to evade other pathogens that exploit sialic acids as invasion targets. We hypothesized that these opposing selection forces have accelerated CD33rSiglec evolution. We address this by comparative analysis of major CD33rSiglec (Siglec-3, Siglec-5, and Siglec-9) orthologs in humans, chimpanzees, and baboons. Recombinant soluble molecules displaying ligand-binding domains show marked quantitative and qualitative interspecies differences in interactions with strains of the sialylated pathogen, group B Streptococcus, and with sialoglycans presented as gangliosides or in the form of sialoglycan microarrays, including variations such as N-glycolyl and O-acetyl groups. Primate Siglecs also show quantitative and qualitative intra- and interspecies variations in expression patterns on leukocytes, both in circulation and in tissues. Taken together our data explain why the CD33rSiglec-encoding gene cluster is undergoing rapid evolution via multiple mechanisms, driven by the need to maintain self-recognition by innate immune cells, while escaping 2 distinct mechanisms of pathogen subversion.Padler-Karavani, V., Hurtado-Ziola, N., Chang, Y.-C., Sonnenburg, J. L., Ronaghy, A., Yu, H., Verhagen, A., Nizet, V., Chen, X., Varki, N., Varki, A., Angata, T. Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates.	[Padler-Karavani, Vered; Hurtado-Ziola, Nancy; Sonnenburg, Justin L.; Verhagen, Andrea; Varki, Ajit; Angata, Takashi] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Padler-Karavani, Vered; Hurtado-Ziola, Nancy; Sonnenburg, Justin L.; Verhagen, Andrea; Varki, Ajit; Angata, Takashi] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Chang, Yung-Chi; Nizet, Victor] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Ronaghy, Arash; Varki, Nissi] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Yu, Hai; Chen, Xi] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Davis	Varki, A (corresponding author), Univ Calif San Diego, 9500 Gilman Dr, La Jolla, CA 92093 USA.	a1varki@ucsd.edu	Chen, Xi/H-1811-2018; Nizet, Victor/AAF-3190-2019; PADLER-KARAVANI, VERED/AAC-6055-2022	Chen, Xi/0000-0002-3160-614X; PADLER-KARAVANI, VERED/0000-0002-4761-3571; Nizet, Victor/0000-0003-3847-0422	University of California at San Diego Program of Excellence in Glycosciences (U.S. National Institutes of Health) [P01HL107150]; Mathers Foundation of New York; International Sepharadic Education Foundation postdoctoral fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107150] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011132] Funding Source: NIH RePORTER	University of California at San Diego Program of Excellence in Glycosciences (U.S. National Institutes of Health); Mathers Foundation of New York; International Sepharadic Education Foundation postdoctoral fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Yerkes Primate Research Center (Atlanta, GA, USA), Zoo Atlanta (Atlanta, GA, USA), the San Diego Zoo (San Diego, CA, USA), the Lincoln Park Zoo (Chicago, IL, USA), the Primate Foundation of Arizona (Mesa, AZ), and the Southwest Primate Research Center (San Antonio, TX, USA), for providing nonhuman primate blood samples. The laboratories of A.V. and V.N. are supported by the University of California at San Diego Program of Excellence in Glycosciences (U.S. National Institutes of Health grant P01HL107150). A.V. is also supported by the Mathers Foundation of New York. V.P.-K. was partially supported by an International Sepharadic Education Foundation postdoctoral fellowship. The authors declare no conflicts of interest.	Altevogt BM, 2011, CHIMPANZEES IN BIOMEDICAL AND BEHAVIORAL RESEARCH: ASSESSING THE NECESSITY, P1; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2002, BBA-GEN SUBJECTS, V1572, P294, DOI 10.1016/S0304-4165(02)00316-1; Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Angata T, 2004, P NATL ACAD SCI USA, V101, P13251, DOI 10.1073/pnas.0404833101; Angata T, 2006, FASEB J, V20, P1964, DOI 10.1096/fj.06-5800com; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Baker CJ, 2013, VACCINE, V31, pD3, DOI 10.1016/j.vaccine.2013.02.030; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Cao H, 2008, EUR J IMMUNOL, V38, P2303, DOI 10.1002/eji.200738078; Cao HA, 2011, IMMUNOLOGY, V132, P18, DOI 10.1111/j.1365-2567.2010.03368.x; Carlin AF, 2007, J BACTERIOL, V189, P1231, DOI 10.1128/JB.01155-06; Carlin AF, 2009, J EXP MED, V206, P1691, DOI 10.1084/jem.20090691; Carlin AF, 2009, BLOOD, V113, P3333, DOI 10.1182/blood-2008-11-187302; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Crocker PR, 2012, ANN NY ACAD SCI, V1253, P102, DOI 10.1111/j.1749-6632.2011.06449.x; Esko JD, 2009, ESSENTIALS GLYCOBIOL, P489; Ghaderi D, 2011, P NATL ACAD SCI USA, V108, P17743, DOI 10.1073/pnas.1102302108; Guo JP, 2011, AM J RESP CELL MOL, V44, P238, DOI 10.1165/rcmb.2010-0007OC; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Khatua B, 2012, J LEUKOCYTE BIOL, V91, P641, DOI 10.1189/jlb.0511260; Lehr HA, 1997, J HISTOCHEM CYTOCHEM, V45, P1559, DOI 10.1177/002215549704501112; Liu Y, 2009, TRENDS IMMUNOL, V30, P557, DOI 10.1016/j.it.2009.09.006; Martin MJ, 2005, P NATL ACAD SCI USA, V102, P12819, DOI 10.1073/pnas.0503819102; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Nguyen DH, 2006, P NATL ACAD SCI USA, V103, P7765, DOI 10.1073/pnas.0510484103; Padler-Karavani V, 2012, J BIOL CHEM, V287, P22593, DOI 10.1074/jbc.M112.359323; Paulson JC, 2012, ANN NY ACAD SCI, V1253, P37, DOI 10.1111/j.1749-6632.2011.06362.x; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Rich SM, 2009, P NATL ACAD SCI USA, V106, P14902, DOI 10.1073/pnas.0907740106; Severi E, 2007, MICROBIOL-SGM, V153, P2817, DOI 10.1099/mic.0.2007/009480-0; SJOBERG ER, 1995, J BIOL CHEM, V270, P2921, DOI 10.1074/jbc.270.7.2921; SONG Y, 1995, GLYCOBIOLOGY, V5, P207, DOI 10.1093/glycob/5.2.207; Sonnenburg JL, 2004, GLYCOBIOLOGY, V14, P339, DOI 10.1093/glycob/cwh039; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Varki A, 2011, GLYCOBIOLOGY, V21, P1121, DOI 10.1093/glycob/cwr087; Varki A, 2010, P NATL ACAD SCI USA, V107, P8939, DOI 10.1073/pnas.0914634107; Varki A, 2009, P NATL ACAD SCI USA, V106, P14739, DOI 10.1073/pnas.0908196106; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Wang XX, 2012, P NATL ACAD SCI USA, V109, P9935, DOI 10.1073/pnas.1119459109; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483	46	53	54	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1280	1293		10.1096/fj.13-241497	http://dx.doi.org/10.1096/fj.13-241497			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24308974	Green Published			2022-12-28	WOS:000335324800021
J	Zhang, L; Hou, XJ; Ma, RJ; Moley, K; Schedl, T; Wang, Q				Zhang, Liang; Hou, Xiaojing; Ma, Rujun; Moley, Kelle; Schedl, Tim; Wang, Qiang			Sirt2 functions in spindle organization and chromosome alignment in mouse oocyte meiosis	FASEB JOURNAL			English	Article						sirtuin; infertility; acetylation	ACETYLATED ALPHA-TUBULIN; HISTONE DEACETYLASE; MATERNAL AGE; CELL-CYCLE; CALORIC RESTRICTION; H4-K16 ACETYLATION; HUMAN ANEUPLOIDY; IN-VITRO; MICROTUBULES; MICE	Sirtuins have been widely reported to be involved in multiple biological processes; however, their function in oocyte meiosis has not been. Here, by confocal scanning and quantitative analysis, we show that specific depletion of Sirt2 in mouse oocytes results in spindle defects and chromosome disorganization (35.5 +/- 8.7 vs. 9.6 +/- 3.8% control; P<0.05), with impaired microtubule-kinetochore interaction. Moreover, knockdown and overexpression experiments reveal that Sirt2 modulates the acetylation status of histone H4K16 and -tubulin in oocytes, which may in part mediate the defective phenotypes described above by influencing microtubule dynamics and kinetochore function. Finally, we find lower Sirt2 protein level in oocytes from aged mice by immunoblotting and that maternal age-associated meiotic defects can be ameliorated through overexpression of Sirt2 (33.2 +/- 5.1% old vs.12.7 +/- 5.2% old+Sirt2; P<0.05), providing support for the hypothesis that decreased Sirt2 is one of a number of factors contributing to oocyte age-dependent deficits. In summary, our data indicate a role for Sirt2 during oocyte meiosis and uncover a striking beneficial effect of increased Sirt2 expression on aged oocytes.Zhang, L., Hou, X., Ma, R., Moley, K., Schedl, T., Wang, Q. Sirt2 functions in spindle organization and chromosome alignment in mouse oocyte meiosis.	[Zhang, Liang; Ma, Rujun] Nanjing Agr Univ, Coll Anim Sci & Technol, Nanjing, Jiangsu, Peoples R China; [Zhang, Liang; Hou, Xiaojing; Ma, Rujun; Wang, Qiang] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China; [Moley, Kelle; Schedl, Tim] Washington Univ, Sch Med, St Louis, MO USA	Nanjing Agricultural University; Nanjing Medical University; Washington University (WUSTL)	Wang, Q (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.	qwang2012@njmu.edu.cn			National Natural Science Foundation of China [31271541, 31301181]; Nanjing Medical University [2012RC04]; U.S. National Institutes of Health [GM100756]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100756] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nanjing Medical University; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Professor Dong Zhang (Nanjing Medical University) for technical assistance, particularly with the kinetochore detection. This work was supported by the National Natural Science Foundation of China (31271541 and 31301181), Nanjing Medical University Startup Funding (2012RC04), and the U.S. National Institutes of Health (GM100756; T. S.). The authors declare no conflicts of interest.	Akiyama T, 2006, P NATL ACAD SCI USA, V103, P7339, DOI 10.1073/pnas.0510946103; Battaglia DE, 1996, HUM REPROD, V11, P2217; Beirowski B, 2011, P NATL ACAD SCI USA, V108, pE952, DOI 10.1073/pnas.1104969108; Bobrowska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034805; Chiang T, 2010, CURR BIOL, V20, P1522, DOI 10.1016/j.cub.2010.06.069; Choy JS, 2011, GENETICS, V189, P11, DOI 10.1534/genetics.111.130781; CUEVA JG, 2012, CURR BIOL, V22, P1066, DOI [DOI 10.1016/j.cub.2012.05.012, DOI 10.1016/J.CUB.2012.05.012]; DEPENNART H, 1988, BIOL CELL, V64, P375, DOI 10.1016/0248-4900(88)90012-3; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Eppig JJ, 1996, MOL REPROD DEV, V44, P260, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;260::AID-MRD17&gt;3.0.CO;2-6; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; HENDERSON SA, 1968, NATURE, V218, P22, DOI 10.1038/218022a0; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Hunt PA, 2008, TRENDS GENET, V24, P86, DOI 10.1016/j.tig.2007.11.010; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857; Inoue T, 2007, CELL CYCLE, V6, P1011, DOI 10.4161/cc.6.9.4219; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108; Kawamura Y, 2010, J CLIN INVEST, V120, P2817, DOI 10.1172/JCI42020; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kwak SS, 2012, THERIOGENOLOGY, V78, P1597, DOI 10.1016/j.theriogenology.2012.07.006; Li WB, 2007, J NEUROSCI, V27, P2606, DOI 10.1523/JNEUROSCI.4181-06.2007; Liu MY, 2013, HUM REPROD, V28, P707, DOI 10.1093/humrep/des437; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Luke B, 2012, NEW ENGL J MED, V366, P2483, DOI 10.1056/NEJMoa1110238; Ma PP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003377; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Nagaoka SI, 2012, NAT REV GENET, V13, P493, DOI 10.1038/nrg3245; Nakagawa T, 2011, J CELL SCI, V124, P833, DOI 10.1242/jcs.081067; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; NAVOT D, 1994, FERTIL STERIL, V61, P97; Nezi LG, 2009, CURR OPIN CELL BIOL, V21, P785, DOI 10.1016/j.ceb.2009.09.007; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784; Pandithage R, 2008, J CELL BIOL, V180, P915, DOI 10.1083/jcb.200707126; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Robbins AR, 2005, CELL CYCLE, V4, P717, DOI 10.4161/cc.4.5.1690; Robinson PJJ, 2008, J MOL BIOL, V381, P816, DOI 10.1016/j.jmb.2008.04.050; ROBSON SJ, 1989, CELL MOTIL CYTOSKEL, V12, P273, DOI 10.1002/cm.970120408; SCHATTEN G, 1988, DEV BIOL, V130, P74, DOI 10.1016/0012-1606(88)90415-0; Selesniemi K, 2011, P NATL ACAD SCI USA, V108, P12319, DOI 10.1073/pnas.1018793108; Serrano L, 2013, GENE DEV, V27, P639, DOI 10.1101/gad.211342.112; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Sudo H, 2010, J NEUROSCI, V30, P7215, DOI 10.1523/JNEUROSCI.0048-10.2010; Topalidou I, 2012, CURR BIOL, V22, P1057, DOI 10.1016/j.cub.2012.03.066; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; van den Berg IM, 2011, HUM REPROD, V26, P1181, DOI 10.1093/humrep/der030; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang Q, 2007, REPROD FERT DEVELOP, V19, P1, DOI 10.1071/RD06103; Wang Q, 2012, ENDOCRINOLOGY, V153, P1984, DOI 10.1210/en.2011-1815; Zhang D, 2004, BIOL REPROD, V71, P740, DOI 10.1095/biolreprod.104.028282; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813	66	78	88	3	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1435	1445		10.1096/fj.13-244111	http://dx.doi.org/10.1096/fj.13-244111			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24334550	Green Published			2022-12-28	WOS:000335324800034
J	Ljubicic, V; Burt, M; Jasmin, BJ				Ljubicic, Vladimir; Burt, Matthew; Jasmin, Bernard J.			The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets	FASEB JOURNAL			English	Review						AMPK; PPAR beta/delta; SIRT1; PGC-1 alpha; utrophin A	ACTIVATED PROTEIN-KINASE; SMALL-MOLECULE ACTIVATORS; UTROPHIN GENE-EXPRESSION; FATTY-ACID OXIDATION; MDX MOUSE; PPAR-DELTA; MITOCHONDRIAL BIOGENESIS; AMPK ACTIVATION; GLUCOSE-UPTAKE; INSULIN SENSITIVITY	Duchenne muscular dystrophy (DMD) is a life-limiting, neuromuscular disorder that causes progressive, severe muscle wasting in boys and young men. Although there is no cure, scientists and clinicians can leverage the fact that slower, more oxidative skeletal muscle fibers possess an enhanced degree of resistance to the dystrophic pathology relative to their faster, more glycolytic counterparts, and can thus use this knowledge when investigating novel therapeutic avenues. Several factors have been identified as powerful regulators of muscle plasticity. Some proteins, such as calcineurin, peroxisome proliferator-activated receptor (PPAR) coactivator 1 (PGC-1), PPAR/, and AMP-activated protein kinase (AMPK), when chronically stimulated in animal models, remodel skeletal muscle toward the slow, oxidative myogenic program, whereas others, such as receptor-interacting protein 140 (RIP140) and E2F transcription factor 1 (E2F1), repress this phenotype. Recent studies demonstrating that pharmacologic and physiological activation of targets that shift dystrophic muscle toward the slow, oxidative myogenic program provide appreciable molecular and functional benefits. This review surveys the rationale behind, and evidence for, the study of skeletal muscle plasticity in preclinical models of DMD and highlights the potential therapeutic opportunities in advancing a strategy focused on remodeling skeletal muscle in patients with DMD toward the slow, oxidative phenotype.Ljubicic, V., Burt, M., Jasmin, B. J. The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets.	[Jasmin, Bernard J.] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Ctr Neuromuscular Dis, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa	Jasmin, BJ (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.	jasmin@uottawa.ca			Muscular Dystrophy Association (MDA); Canadian Institutes of Health Research (CIHR); Muscular Dystrophy Canada, Jesse's Journey: The Foundation for Gene and Cell Therapy, l'Association Francaise contre les Myopathies; Canadian Space Agency; Natural Science and Engineering Research Council of Canada; CIHR Fellowship programs; MDA Development Grant program	Muscular Dystrophy Association (MDA)(Muscular Dystrophy Association); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Muscular Dystrophy Canada, Jesse's Journey: The Foundation for Gene and Cell Therapy, l'Association Francaise contre les Myopathies; Canadian Space Agency(Canadian Space Agency); Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR Fellowship programs(Canadian Institutes of Health Research (CIHR)); MDA Development Grant program	Work in the B.J.J. laboratory is funded by the Muscular Dystrophy Association (MDA), the Canadian Institutes of Health Research (CIHR), Muscular Dystrophy Canada, Jesse's Journey: The Foundation for Gene and Cell Therapy, l'Association Francaise contre les Myopathies, and the Canadian Space Agency. V. L. receives support from the Natural Science and Engineering Research Council of Canada and CIHR Fellowship programs, as well as from the MDA Development Grant program. The authors apologize to the many excellent scientists working in relevant areas whose work they could not include in their review due solely to restrictions on space and references.	Amat R, 2009, J BIOL CHEM, V284, P21872, DOI 10.1074/jbc.M109.022749; Angus LM, 2005, AM J PHYSIOL-CELL PH, V289, pC908, DOI 10.1152/ajpcell.00196.2005; Ansved T, 2001, ACTA PHYSIOL SCAND, V171, P359, DOI 10.1046/j.1365-201x.2001.00839.x; Babraj JA, 2009, AM J PHYSIOL-ENDOC M, V296, pE1042, DOI 10.1152/ajpendo.90811.2008; Baltgalvis KA, 2012, MED SCI SPORT EXER, V44, P1671, DOI 10.1249/MSS.0b013e31825703f0; Barre L, 2007, AM J PHYSIOL-ENDOC M, V292, pE802, DOI 10.1152/ajpendo.00369.2006; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2012, NAT REV DRUG DISCOV, V11, P443, DOI 10.1038/nrd3738; Bays HE, 2011, J CLIN ENDOCR METAB, V96, P2889, DOI 10.1210/jc.2011-1061; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Blanchet E, 2012, HUM MOL GENET, V21, P3910, DOI 10.1093/hmg/dds219; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Boon H, 2008, DIABETOLOGIA, V51, P1893, DOI 10.1007/s00125-008-1108-7; Bosselaar M, 2011, J CLIN PHARMACOL, V51, P1449, DOI 10.1177/0091270010382912; Brasnyo P, 2011, BRIT J NUTR, V106, P383, DOI 10.1017/S0007114511000316; Breen DM, 2008, BIOCHEM BIOPH RES CO, V374, P117, DOI 10.1016/j.bbrc.2008.06.104; Bueno CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045699; Bushby K, 2010, LANCET NEUROL, V9, P177, DOI 10.1016/S1474-4422(09)70272-8; Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474-4422(09)70271-6; Call JA, 2008, J APPL PHYSIOL, V105, P923, DOI 10.1152/japplphysiol.00028.2008; Call JA, 2010, MUSCLE NERVE, V42, P871, DOI 10.1002/mus.21764; Canto C, 2010, CELL MOL LIFE SCI, V67, P3407, DOI 10.1007/s00018-010-0454-z; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Centeno-Baez C, 2011, AM J PHYSIOL-ENDOC M, V301, pE922, DOI 10.1152/ajpendo.00530.2010; Chakkalakal JV, 2006, HUM MOL GENET, V15, P1423, DOI 10.1093/hmg/ddl065; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chung SW, 2010, ARCH BIOCHEM BIOPHYS, V501, P79, DOI 10.1016/j.abb.2010.05.003; Crandall JP, 2012, J GERONTOL A-BIOL, V67, P1307, DOI 10.1093/gerona/glr235; Cuthbertson DJ, 2007, DIABETES, V56, P2078, DOI 10.2337/db06-1716; Davies KE, 2006, NAT REV MOL CELL BIO, V7, P762, DOI 10.1038/nrm2024; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DIXON R, 1991, J CLIN PHARMACOL, V31, P342, DOI 10.1002/j.1552-4604.1991.tb03715.x; Dolinsky VW, 2012, J PHYSIOL-LONDON, V590, P2783, DOI 10.1113/jphysiol.2012.230490; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Drew BG, 2008, EXPERT OPIN PHARMACO, V9, P2137, DOI [10.1517/14656566.9.12.2137, 10.1517/14656566.9.12.2137 ]; DupontVersteegden EE, 1996, J APPL PHYSIOL, V80, P734, DOI 10.1152/jappl.1996.80.3.734; DUPONTVERSTEEGDEN EE, 1994, J APPL PHYSIOL, V77, P1736, DOI 10.1152/jappl.1994.77.4.1736; Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2; Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012; Ehrenborg E, 2009, PHARMACOL REV, V61, P373, DOI 10.1124/pr.109.001560; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; Fairclough RJ, 2012, CURR GENE THER, V12, P206; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fillmore N, 2010, J APPL PHYSIOL, V109, P511, DOI 10.1152/japplphysiol.00126.2010; Frier BC, 2011, J APPL PHYSIOL, V111, P688, DOI 10.1152/japplphysiol.00279.2011; Fritah A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032520; Fujii N, 2007, DIABETES RES CLIN PR, V77, pS92, DOI 10.1016/j.diabres.2007.01.040; Gan ZJ, 2011, GENE DEV, V25, P2619, DOI 10.1101/gad.178434.111; Garcia-Roves PM, 2008, J BIOL CHEM, V283, P35724, DOI 10.1074/jbc.M805078200; Gaudel C, 2008, AM J PHYSIOL-ENDOC M, V295, pE297, DOI 10.1152/ajpendo.00581.2007; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Godin Richard, 2012, J Physiol, V590, P5487, DOI 10.1113/jphysiol.2012.240390; Gordon BS, 2013, CLIN NUTR, V32, P104, DOI 10.1016/j.clnu.2012.06.003; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Guevel L, 2011, J PROTEOME RES, V10, P2465, DOI 10.1021/pr2001385; Gurd BJ, 2011, APPL PHYSIOL NUTR ME, V36, P589, DOI [10.1139/h11-070, 10.1139/H11-070]; Gurd BJ, 2009, J PHYSIOL-LONDON, V587, P1817, DOI 10.1113/jphysiol.2008.168096; Hallberg M, 2008, MOL CELL BIOL, V28, P6785, DOI 10.1128/MCB.00504-08; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Hardie DG, 2011, AM J CLIN NUTR, V93, p891S, DOI 10.3945/ajcn.110.001925; Hawley JA, 2009, NUTR REV, V67, P172, DOI 10.1111/j.1753-4887.2009.00185.x; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Hayes A, 1996, J APPL PHYSIOL, V80, P670, DOI 10.1152/jappl.1996.80.2.670; HAYES A, 1993, P ROY SOC B-BIOL SCI, V253, P19, DOI 10.1098/rspb.1993.0077; Hayes A, 1998, AM J PHYSIOL-CELL PH, V274, pC1138, DOI 10.1152/ajpcell.1998.274.4.C1138; Hayes A, 1997, J APPL PHYSIOL, V82, P435, DOI 10.1152/jappl.1997.82.2.435; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hoffman EP, 2011, AM J PATHOL, V179, P12, DOI 10.1016/j.ajpath.2011.03.050; Hollinger K, 2013, AM J PHYSIOL-REG I, V305, pR13, DOI 10.1152/ajpregu.00221.2012; Hori YS, 2011, J PHARMACOL EXP THER, V338, P784, DOI 10.1124/jpet.111.183210; Hoshino D, 2012, AM J PHYSIOL-REG I, V302, pR373, DOI 10.1152/ajpregu.00183.2011; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jahnke VE, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-16; Jansen M, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-55; Jiang LQ, 2010, AM J PHYSIOL-ENDOC M, V298, pE8, DOI 10.1152/ajpendo.00403.2009; Jorgensen SB, 2007, AM J PHYSIOL-ENDOC M, V292, pE331, DOI 10.1152/ajpendo.00243.2006; Jucker BM, 2007, AM J PHYSIOL-ENDOC M, V293, pE1256, DOI 10.1152/ajpendo.00218.2007; Kaczor JJ, 2007, FREE RADICAL BIO MED, V43, P145, DOI 10.1016/j.freeradbiomed.2007.04.003; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; Kleiner S, 2009, J BIOL CHEM, V284, P18624, DOI 10.1074/jbc.M109.008797; Kleopa KA, 2006, HUM MOL GENET, V15, P1623, DOI 10.1093/hmg/ddl083; Kotelnikova E, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002365; Kramer DK, 2007, J BIOL CHEM, V282, P19313, DOI 10.1074/jbc.M702329200; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; LATEUR BJD, 1979, AM J PHYS MED REHAB, V58, P26; Leick L, 2010, AM J PHYSIOL-ENDOC M, V299, pE456, DOI 10.1152/ajpendo.00648.2009; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lira VA, 2010, AM J PHYSIOL-ENDOC M, V299, pE145, DOI 10.1152/ajpendo.00755.2009; Ljubicic V, 2013, TRENDS MOL MED, V19, P614, DOI 10.1016/j.molmed.2013.07.002; Ljubicic V, 2012, AM J PHYSIOL-CELL PH, V302, pC110, DOI 10.1152/ajpcell.00183.2011; Ljubicic V, 2011, HUM MOL GENET, V20, P3478, DOI 10.1093/hmg/ddr265; Long YC, 2008, AM J PHYSIOL-ENDOC M, V295, pE545, DOI 10.1152/ajpendo.90259.2008; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Mangano DT, 2006, J AM COLL CARDIOL, V48, P206, DOI 10.1016/j.jacc.2006.04.044; Markert CD, 2012, MUSCLE NERVE, V45, P746, DOI 10.1002/mus.23244; Markert CD, 2011, MUSCLE NERVE, V43, P464, DOI 10.1002/mus.21987; Matsakas A, 2013, FASEB J, V27, P4004, DOI 10.1096/fj.13-228296; Mendell JR, 2012, NEUROSCI LETT, V527, P90, DOI 10.1016/j.neulet.2012.04.078; Meng ZX, 2013, NAT MED, V19, P640, DOI 10.1038/nm.3144; Menzies KJ, 2013, J BIOL CHEM, V288, P6968, DOI 10.1074/jbc.M112.431155; Michel RN, 2007, APPL PHYSIOL NUTR ME, V32, P921, DOI 10.1139/H07-093; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Minor RK, 2011, SCI REP-UK, V1, DOI 10.1038/srep00070; Miura P, 2009, HUM MOL GENET, V18, P4640, DOI 10.1093/hmg/ddp431; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Momken I, 2011, FASEB J, V25, P3646, DOI 10.1096/fj.10-177295; Moorwood C, 2011, PLOS ONE, V6; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; O'Neill HM, 2013, MOL CELL ENDOCRINOL, V366, P135, DOI 10.1016/j.mce.2012.06.019; O'Neill HM, 2011, P NATL ACAD SCI USA, V108, P16092, DOI 10.1073/pnas.1105062108; Olson EJ, 2012, ARTERIOSCL THROM VAS, V32, P2289, DOI 10.1161/ATVBAHA.112.247890; Park CE, 2007, EXP MOL MED, V39, P222, DOI 10.1038/emm.2007.25; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Parsons SA, 2007, J BIOL CHEM, V282, P10068, DOI 10.1074/jbc.M609368200; Pauly M, 2012, AM J PATHOL, V181, P583, DOI 10.1016/j.ajpath.2012.04.004; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Perez-Schindler J, 2012, MOL CELL BIOL, V32, P4913, DOI 10.1128/MCB.00877-12; Perkins KJ, 2007, MOL BIOL CELL, V18, P2864, DOI 10.1091/mbc.E06-12-1069; Peters JM, 2011, CANCER METAST REV, V30, P619, DOI 10.1007/s10555-011-9320-1; Philp A, 2011, J BIOL CHEM, V286, P30561, DOI 10.1074/jbc.M111.261685; Pichavant C, 2011, MOL THER, V19, P830, DOI 10.1038/mt.2011.59; Pold R, 2005, DIABETES, V54, P928, DOI 10.2337/diabetes.54.4.928; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; REN JM, 1995, PFLUG ARCH EUR J PHY, V430, P389, DOI 10.1007/BF00373914; Riserus U, 2008, DIABETES, V57, P332, DOI 10.2337/db07-1318; Rockl KSC, 2007, DIABETES, V56, P2062, DOI 10.2337/db07-0255; Safdar A, 2011, J BIOL CHEM, V286, P10605, DOI 10.1074/jbc.M110.211466; Schenk S, 2011, J CLIN INVEST, V121, P4281, DOI 10.1172/JCI58554; Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003; Scott O M, 1981, Physiotherapy, V67, P174; Selsby JT, 2013, J APPL PHYSIOL, V115, P660, DOI 10.1152/japplphysiol.00252.2013; Selsby JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030063; Seth A, 2007, CELL METAB, V6, P236, DOI 10.1016/j.cmet.2007.08.004; Stupka N, 2006, J PHYSIOL-LONDON, V575, P645, DOI 10.1113/jphysiol.2006.108472; Suwa M, 2006, J APPL PHYSIOL, V101, P1685, DOI 10.1152/japplphysiol.00255.2006; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Timmers S, 2012, AGING-US, V4, P146, DOI 10.18632/aging.100445; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; VIGNOS PJ, 1983, MUSCLE NERVE, V6, P323, DOI 10.1002/mus.880060502; VIGNOS PJ, 1966, J AMER MED ASSOC, V197, P843, DOI 10.1001/jama.197.11.843; Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386; von Maltzahn J, 2012, P NATL ACAD SCI USA, V109, P20614, DOI 10.1073/pnas.1215765109; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; White AT, 2013, DIABETOLOGIA, V56, P1629, DOI 10.1007/s00125-013-2912-2; Williams DB, 2009, AM J PHYSIOL-ENDOC M, V296, pE1400, DOI 10.1152/ajpendo.90913.2008; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wineinger MA, 1998, AM J PHYS MED REHAB, V77, P20, DOI 10.1097/00002060-199801000-00004; Witczak CA, 2008, CELL MOL LIFE SCI, V65, P3737, DOI 10.1007/s00018-008-8244-6; Yamamoto H, 2011, CELL, V147, P827, DOI 10.1016/j.cell.2011.10.017; Yoshino J, 2012, CELL METAB, V16, P658, DOI 10.1016/j.cmet.2012.09.015; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	166	50	52	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					548	568		10.1096/fj.13-238071	http://dx.doi.org/10.1096/fj.13-238071			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24249639				2022-12-28	WOS:000331072200004
J	Perez-Aso, M; Fernandez, P; Mediero, A; Chan, ES; Cronstein, BN				Perez-Aso, Miguel; Fernandez, Patricia; Mediero, Aranzazu; Chan, Edwin S.; Cronstein, Bruce N.			Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3	FASEB JOURNAL			English	Article						fibrosis; intracellular signaling	PROTEIN-KINASE-A; MATRIX METALLOPROTEINASE-1; PHARMACOLOGICAL BLOCKADE; DERMAL FIBROBLASTS; PROSTAGLANDIN E-2; DOWN-REGULATION; MURINE MODEL; TGF-BETA; ACTIVATION; EPAC	Activation of adenosine A2A receptor (A(2A)R) promotes fibrosis and collagen synthesis. However, the underlying mechanism is still unclear, not least because cAMP, its principal effector, has been found to inhibit TGF1-induced collagen synthesis. Here, we show that in primary normal human dermal fibroblasts, A(2A)R stimulation with CGS21680 elicits a modest cAMP increase (150 +/- 12% of control; EC50 54.8 nM), which stimulates collagen1 (Col1) and collagen3 (Col3), but maximal cAMP resulting from direct activation of adenylyl cyclase by forskolin (15,689 +/- 7038% of control; EC50 360.7 nM) inhibits Col1 and increases Col3. Similar to Col1 expression, fibroblast proliferation increased following physiological cAMP increases by CGS21680 but was inhibited by cAMP increases beyond the physiological range by forskolin. The A(2A)R-mediated increase of Col1 and Col3 was mediated by AKT, while Col3, but not Col1, expression was dependent on p38 and repressed by ERK. TGF1 induced phosphorylation of Smad2/3 and increased Col3 expression, which was prevented by Smad3 depletion. In contrast, CGS21680 did not activate Smad2/3, and Smad2/3 knockdown did not prevent CGS21680-induced Col1 or Col3 increases. Our results indicate that cAMP is a concentration-dependent switch for collagen production via noncanonical, AKT-dependent, Smad2/3-independent signaling. These observations explain the paradoxical effects of cAMP on collagen expression.Perez-Aso, M., Fernandez, P., Mediero, A., Chan, E. S., and Cronstein, B. N. Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3.	[Perez-Aso, Miguel; Mediero, Aranzazu; Chan, Edwin S.; Cronstein, Bruce N.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Fernandez, Patricia] NCI, NIH, Bethesda, MD 20892 USA	New York University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cronstein, BN (corresponding author), NYU, Sch Med, Dept Med, 550 First Ave, New York, NY 10016 USA.	bruce.cronstein@nyumc.org	Mediero, Aranzazu/AAA-8362-2020	Pintor, Jesus/0000-0002-9191-7679; Perez-Aso, Miguel/0000-0002-4703-4182; Cronstein, Bruce/0000-0002-4295-7383; Mediero, Aranzazu/0000-0002-5368-574X	U.S. National Institutes of Health (NIH) [AR56672, AR54897]; New York University (NYU)-Health and Hospitals Corporation Clinical and Translational Science Institute [UL1RR029893]; NYU Cancer Institute (Center Support grant); NIH/National Cancer Institute [5 P30CA16087-31]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056672, R01AR054897, R56AR056672] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New York University (NYU)-Health and Hospitals Corporation Clinical and Translational Science Institute; NYU Cancer Institute (Center Support grant); NIH/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by grants from the U.S. National Institutes of Health (NIH; AR56672 and AR54897), the New York University (NYU)-Health and Hospitals Corporation Clinical and Translational Science Institute (UL1RR029893), the NYU Cancer Institute (Center Support grant), and the NIH/National Cancer Institute (5 P30CA16087-31).	Bujor AM, 2008, J INVEST DERMATOL, V128, P1906, DOI 10.1038/jid.2008.39; BUTKOWSKI RJ, 1982, METHOD ENZYMOL, V82, P410; Chan ESL, 2006, ARTHRITIS RHEUM-US, V54, P2632, DOI 10.1002/art.21974; Chan ESL, 2006, BRIT J PHARMACOL, V148, P1144, DOI 10.1038/sj.bjp.0706812; Chan ESL, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4229; Che J, 2007, MOL PHARMACOL, V72, P1626, DOI 10.1124/mol.107.038760; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Cho HJ, 2007, CELL BIOL INT, V31, P1225, DOI 10.1016/j.cellbi.2007.04.006; D'Souza KM, 2011, J BIOL CHEM, V286, P15507, DOI 10.1074/jbc.M111.218263; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Fernandez P, 2008, AM J PATHOL, V172, P1675, DOI 10.2353/ajpath.2008.070952; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Goffin L, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2991; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hayashi T, 2006, J INVEST DERMATOL, V126, P990, DOI 10.1038/sj.jid.5700227; Huang SK, 2008, AM J RESP CELL MOL, V39, P482, DOI 10.1165/rcmb.2008-0080OC; Insel PA, 2012, BRIT J PHARMACOL, V166, P447, DOI 10.1111/j.1476-5381.2012.01847.x; Jun JB, 2005, J INVEST DERMATOL, V124, P298, DOI 10.1111/j.0022-202X.2004.23559.x; Katebi M, 2008, INFLAMMATION, V31, P299, DOI 10.1007/s10753-008-9078-y; Lazarova T, 2004, BIOCHEMISTRY-US, V43, P12945, DOI 10.1021/bi0492051; Lazzerini PE, 2012, J MOL MED, V90, P331, DOI 10.1007/s00109-011-0824-5; Lipshtat A, 2010, P NATL ACAD SCI USA, V107, P1247, DOI 10.1073/pnas.0908647107; Liu XQ, 2006, MOL PHARMACOL, V70, P1992, DOI 10.1124/mol.106.028951; Liu XQ, 2004, AM J PHYSIOL-CELL PH, V286, pC1089, DOI 10.1152/ajpcell.00461.2003; Milne GR, 2011, THESCIENTIFICWORLDJO, V11, P320, DOI 10.1100/tsw.2011.22; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Montesinos MC, 1997, J EXP MED, V186, P1615, DOI 10.1084/jem.186.9.1615; Moore SW, 2006, J NEUROSCI, V26, P2419, DOI 10.1523/JNEUROSCI.5419-05.2006; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2009, J IMMUNOL, V183, P5487, DOI 10.4049/jimmunol.0901247; Okunishi K, 2011, J BIOL CHEM, V286, P32231, DOI 10.1074/jbc.M111.235606; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Park CH, 2010, J INVEST DERMATOL, V130, P2049, DOI 10.1038/jid.2010.62; Peng Z, 2008, FASEB J, V22, P2263, DOI 10.1096/fj.07-100685; Perez-Aso M., 2013, PURINERG SIGNAL, DOI 10.1007/s11302-013-9368-1; Perez-Aso M, 2012, FASEB J, V26, P4254, DOI 10.1096/fj.12-209627; Rentz TJ, 2007, J BIOL CHEM, V282, P22062, DOI 10.1074/jbc.M700167200; Schiller M, 2010, J BIOL CHEM, V285, P409, DOI 10.1074/jbc.M109.038620; Shi GX, 2006, MOL CELL BIOL, V26, P9136, DOI 10.1128/MCB.00332-06; Stadelmann WK, 1998, AM J SURG, V176, p26S, DOI 10.1016/S0002-9610(98)00183-4; Thevenin D, 2005, BIOCHEMISTRY-US, V44, P16239, DOI 10.1021/bi051422u; Victor-Vega C, 2002, INFLAMMATION, V26, P19, DOI 10.1023/A:1014417728325; Villarreal F, 2009, AM J PHYSIOL-CELL PH, V296, pC1178, DOI 10.1152/ajpcell.00291.2008; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Yano N, 2007, J BIOL CHEM, V282, P18819, DOI 10.1074/jbc.M610537200; Yokoyama U, 2008, P NATL ACAD SCI USA, V105, P6386, DOI 10.1073/pnas.0801490105	49	42	43	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					802	812		10.1096/fj.13-241646	http://dx.doi.org/10.1096/fj.13-241646			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24200882	Green Published			2022-12-28	WOS:000331072200027
J	Portelli, MA; Siedlinski, M; Stewart, CE; Postma, DS; Nieuwenhuis, MA; Vonk, JM; Nurnberg, P; Altmuller, J; Moffatt, MF; Wardlaw, AJ; Parker, SG; Connolly, MJ; Koppelman, GH; Sayers, I				Portelli, Michael A.; Siedlinski, Mateusz; Stewart, Ceri E.; Postma, Dirkje S.; Nieuwenhuis, Maartje A.; Vonk, Judith M.; Nurnberg, Peter; Altmuller, Janine; Moffatt, Miriam F.; Wardlaw, Andrew J.; Parker, Stuart G.; Connolly, Martin J.; Koppelman, Gerard H.; Sayers, Ian			Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels	FASEB JOURNAL			English	Article						GWAS; proteolysis; respiratory disease; HBECs; cellular proliferation and wound repair	PLASMINOGEN-ACTIVATOR RECEPTOR; UROKINASE RECEPTOR; PLAUR POLYMORPHISMS; NEUTROPHIL ELASTASE; CELL-PROLIFERATION; LUNG-FUNCTION; ASSOCIATION; SYSTEM; AIRWAY; MEMBRANE	The soluble cleaved urokinase plasminogen activator receptor (scuPAR) is a circulating protein detected in multiple diseases, including various cancers, cardiovascular disease, and kidney disease, where elevated levels of scuPAR have been associated with worsening prognosis and increased disease aggressiveness. We aimed to identify novel genetic and biomolecular mechanisms regulating scuPAR levels. Elevated serum scuPAR levels were identified in asthma (n=514) and chronic obstructive pulmonary disease (COPD; n=219) cohorts when compared to controls (n=96). In these cohorts, a genome-wide association study of serum scuPAR levels identified a human plasma kallikrein gene (KLKB1) promoter polymorphism (rs4253238) associated with serum scuPAR levels in a control/asthma population (P=1.17x10(-7)), which was also observed in a COPD population (combined P=5.04x10(-12)). Using a fluorescent assay, we demonstrated that serum KLKB1 enzymatic activity was driven by rs4253238 and is inverse to scuPAR levels. Biochemical analysis identified that KLKB1 cleaves scuPAR and negates scuPAR's effects on primary human bronchial epithelial cells (HBECs) in vitro. Chymotrypsin was used as a proproteolytic control, while basal HBECs were used as a control to define scuPAR-driven effects. In summary, we reveal a novel post-translational regulatory mechanism for scuPAR using a hypothesis-free approach with implications for multiple human diseases.Portelli, M. A., Siedlinski, M., Stewart, C. E., Postma, D. S., Nieuwenhuis, M. A., Vonk, J. M., Nurnberg, P., Altmuller, J., Moffatt, M. F., Wardlaw, A. J., Parker, S. G., Connolly, M. J., Koppelman, G. H., Sayers, I. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.	[Portelli, Michael A.; Stewart, Ceri E.; Sayers, Ian] Univ Nottingham, Queens Med Ctr, Div Resp Med, Nottingham NG7 2UH, England; [Siedlinski, Mateusz; Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen Res Inst Asthma & COPD GRIAC,Dept Epide, Groningen, Netherlands; [Postma, Dirkje S.; Nieuwenhuis, Maartje A.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen Res Inst Asthma & COPD GRIAC,Dept Pulmo, Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen Res Inst Asthma & COPD GRIAC,Dept Paedi, Groningen, Netherlands; [Nurnberg, Peter; Altmuller, Janine] Univ Cologne, Cologne Ctr Genom, D-50931 Cologne, Germany; [Moffatt, Miriam F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Wardlaw, Andrew J.] Univ Leicester, Inst Lung Hlth Immun & Inflammat, Leicester, Leics, England; [Parker, Stuart G.] Univ Sheffield, Sheffield, S Yorkshire, England; [Connolly, Martin J.] Univ Auckland, Freemasons Dept Geriatr Med, Auckland 1, New Zealand	University of Nottingham; University of Groningen; University of Groningen; University of Groningen; University of Cologne; Imperial College London; University of Leicester; University of Sheffield; University of Auckland	Portelli, MA (corresponding author), Univ Nottingham, Queens Med Ctr, Div Resp Med, Nottingham NG7 2UH, England.	michael.portelli@nottingham.ac.uk	Siedlinski, Mateusz/ABF-4244-2021; Koppelman, Gerard/AAG-9187-2020; Vonk, Judith M/ABA-3009-2020; Portelli, Michael/U-7671-2019; Vonk, Judith/K-8477-2019	Siedlinski, Mateusz/0000-0001-7682-6122; Vonk, Judith M/0000-0001-7531-4547; Portelli, Michael/0000-0003-0821-4575; Vonk, Judith/0000-0001-7531-4547; Parker, Stuart/0000-0002-8675-6276; Sayers, Ian/0000-0001-5601-5410; Altmuller, Janine/0000-0003-4372-1521; Stewart, Ceri/0000-0002-6214-2237; Koppelman, Gerard/0000-0001-8567-3252; Wardlaw, Andrew/0000-0001-6583-0791	STEPS (Malta) scholarship; European Union; University Medical Center Groningen; Netherlands Asthma Foundation [AF 95.09, AF 98.48, AF 3.2.02.51, AF 3.2.07.015]; Asthma UK [08/01]; National Institute for Health Research [NF-SI-0512-10030] Funding Source: researchfish; Asthma UK [08/017] Funding Source: researchfish	STEPS (Malta) scholarship; European Union(European Commission); University Medical Center Groningen; Netherlands Asthma Foundation; Asthma UK; National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	The authors thank all participants who contributed to this study and acknowledge Dr. Charlotte Ruse (Sheffield Institute for Studies on Aging, University of Sheffield) for her help in setting up the COPD cohort utilized in this study. The authors also thank Benjamin Willson (Centre for Biomolecular Science, University of Nottingham) for his modification of the CellProfiler pipeline. Support came from the STEPS (Malta) scholarship, financed in part by the European Union, European Social Fund (ESF), under Operational Programme II, Cohesion Policy 2007-2013, Empowering People for More Jobs and a Better Quality of Life; the University Medical Center Groningen; the Netherlands Asthma Foundation, grants AF 95.09, AF 98.48, AF 3.2.02.51, and AF 3.2.07.015; and Asthma UK, grant 08/01.	Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Andersen O, 2008, J MED VIROL, V80, P209, DOI 10.1002/jmv.21114; Andolfo A, 2002, THROMB HAEMOSTASIS, V88, P298; Barnes PJ, 2000, CHEST, V117, P10; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, P1391, DOI 10.1016/j.jaci.2009.03.014; Beaufort N, 2006, BIOL CHEM, V387, P217, DOI 10.1515/BC.2006.029; Beaufort N, 2004, J IMMUNOL, V172, P540, DOI 10.4049/jimmunol.172.1.540; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Blasi F, 2011, CURR PHARM DESIGN, V17, P1911, DOI 10.2174/138161211796718206; Blasi F, 2010, FEBS LETT, V584, P1923, DOI 10.1016/j.febslet.2009.12.039; Bruneau N, 2011, CURR PHARM DESIGN, V17, P1914, DOI 10.2174/138161211796718198; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Davies Donna E, 2009, Proc Am Thorac Soc, V6, P678, DOI 10.1513/pats.200907-067DP; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Eugen-Olsen J, 2010, J INTERN MED, V268, P296, DOI 10.1111/j.1365-2796.2010.02252.x; Fink E, 2007, BIOL CHEM, V388, P957, DOI 10.1515/BC.2007.104; Ge DL, 2008, GENOME RES, V18, P640, DOI 10.1101/gr.071571.107; Gutova M, 2008, STEM CELLS, V26, P1406, DOI 10.1634/stemcells.2008-0141; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Haupt TH, 2012, CRIT CARE, V16, DOI 10.1186/cc11434; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; LaRusch GA, 2010, BLOOD, V115, P5111, DOI 10.1182/blood-2009-08-236430; Lilla JN, 2009, J BIOL CHEM, V284, P13792, DOI 10.1074/jbc.M900508200; Lund LR, 2006, EMBO J, V25, P2686, DOI 10.1038/sj.emboj.7601173; Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522; Mazzieri R, 2005, THROMB HAEMOSTASIS, V93, P641, DOI 10.1160/TH05-01-0021; MILES LA, 1983, THROMB RES, V29, P407, DOI 10.1016/0049-3848(83)90244-X; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; Newgard CB, 2010, NAT MED, V16, P388, DOI 10.1038/nm0410-388; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; PLESNER T, 1994, BLOOD, V83, P808; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Postma Dirkje S, 2006, Proc Am Thorac Soc, V3, P434, DOI 10.1513/pats.200601-006AW; Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Raghu H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-647; Savva A, 2011, J INFECTION, V63, P344, DOI 10.1016/j.jinf.2011.07.016; Schmaier AH, 1999, THROMB HAEMOSTASIS, V82, P226; Sidenius N, 2000, BLOOD, V96, P4091; Stewart CE, 2013, LUNG, V191, P215, DOI 10.1007/s00408-013-9450-z; Stewart CE, 2012, THORAX, V67, P477, DOI 10.1136/thoraxjnl-2011-200508; Stewart CE, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-112; Stewart CE, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-75; Tan XD, 2006, INT J ONCOL, V28, P369; Team RC, 2012, R LANG ENV STAT COMP; Thuno M, 2009, DIS MARKERS, V27, P157, DOI [10.1155/2009/504294, 10.3233/DMA-2009-0657]; Verweij N, 2013, HYPERTENSION, V61, P602, DOI 10.1161/HYPERTENSIONAHA.111.203117; WACHTFOGEL YT, 1983, J CLIN INVEST, V72, P1672, DOI 10.1172/JCI111126; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411; Wei Y, 2007, J BIOL CHEM, V282, P3929, DOI 10.1074/jbc.M607989200; Wilcox-Adelman SA, 2000, CELL ADHES COMMUN, V7, P477, DOI 10.3109/15419060009040305; Wilhelm OG, 1999, J CELL PHYSIOL, V180, P225, DOI 10.1002/(SICI)1097-4652(199908)180:2<225::AID-JCP10>3.0.CO;2-2; Xiao W, 2005, CHEST, V128, P2316, DOI 10.1378/chest.128.4.2316; Xu J, 2010, CLIN SCI, V119, P353, DOI 10.1042/CS20100151	63	30	30	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					923	934		10.1096/fj.13-240879	http://dx.doi.org/10.1096/fj.13-240879			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24249636	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000331072200037
J	Turnbull, IC; Karakikes, I; Serrao, GW; Backeris, P; Lee, JJ; Xie, CQ; Senyei, G; Gordon, RE; Li, RA; Akar, FG; Hajjar, RJ; Hulot, JS; Costa, KD				Turnbull, Irene C.; Karakikes, Ioannis; Serrao, Gregory W.; Backeris, Peter; Lee, Jia-Jye; Xie, Chaoqin; Senyei, Grant; Gordon, Ronald E.; Li, Ronald A.; Akar, Fadi G.; Hajjar, Roger J.; Hulot, Jean-Sebastien; Costa, Kevin D.			Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium	FASEB JOURNAL			English	Article						cardiomyocyte development; contractile function; drug discovery; stem cell	CELL-DERIVED CARDIOMYOCYTES; SCAFFOLD-FREE; IN-VITRO; STEM; HEART; MATURATION; MUSCLE; TRANSPLANTATION; GENERATION; CALCIUM	Cardiac experimental biology and translational research would benefit from an in vitro surrogate for human heart muscle. This study investigated structural and functional properties and interventional responses of human engineered cardiac tissues (hECTs) compared to human myocardium. Human embryonic stem cell-derived cardiomyocytes (hESC-CMs, >90% troponin-positive) were mixed with collagen and cultured on force-sensing elastomer devices. hECTs resembled trabecular muscle and beat spontaneously (1.18 +/- 0.48 Hz). Microstructural features and mRNA expression of cardiac-specific genes (-MHC, SERCA2a, and ACTC1) were comparable to human myocardium. Optical mapping revealed cardiac refractoriness with loss of 1:1 capture above 3 Hz, and cycle length dependence of the action potential duration, recapitulating key features of cardiac electrophysiology. hECTs reconstituted the Frank-Starling mechanism, generating an average maximum twitch stress of 660 N/mm(2) at L-max, approaching values in newborn human myocardium. Dose-response curves followed exponential pharmacodynamics models for calcium chloride (EC50 1.8 mM) and verapamil (IC50 0.61 M); isoproterenol elicited a positive chronotropic but negligible inotropic response, suggesting sarcoplasmic reticulum immaturity. hECTs were amenable to gene transfer, demonstrated by successful transduction with Ad.GFP. Such 3-D hECTs recapitulate an early developmental stage of human myocardium and promise to offer an alternative preclinical model for cardiology research.Turnbull, I. C., Karakikes, I., Serrao, G. W., Backeris, P., Lee, J.-J., Xie, C., Senyei, G., Gordon, R. E., Li, R. A., Akar, F. G., Hajjar, R. J., Hulot, J.-S., Costa, K. D. Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium.	[Turnbull, Irene C.; Karakikes, Ioannis; Serrao, Gregory W.; Backeris, Peter; Lee, Jia-Jye; Xie, Chaoqin; Senyei, Grant; Li, Ronald A.; Akar, Fadi G.; Hajjar, Roger J.; Hulot, Jean-Sebastien; Costa, Kevin D.] Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, New York, NY 10029 USA; [Gordon, Ronald E.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Li, Ronald A.] Univ Hong Kong, Li Ka Shing Fac Med, Stem Cell & Regenerat Med Consortium, Pokfulam, Hong Kong, Peoples R China; [Li, Ronald A.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Pokfulam, Hong Kong, Peoples R China; [Li, Ronald A.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Physiol, Pokfulam, Hong Kong, Peoples R China; [Hulot, Jean-Sebastien] Univ Paris 06, Unit Mixte Rech Sante UMRS 956, Paris, France	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Hong Kong; University of Hong Kong; University of Hong Kong; UDICE-French Research Universities; Sorbonne Universite	Costa, KD (corresponding author), Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, Cardiovasc Cell & Tissue Engn Lab, 1 Gustave L Levy Pl,POB 1030, New York, NY 10029 USA.	kevin.costa@mssm.edu	Hulot, Jean-Sébastien/A-2278-2016; Senyei, Grant/GQZ-4020-2022	Hulot, Jean-Sébastien/0000-0001-5463-6117; Karakikes, Ioannis/0000-0002-4348-600X	U.S. National Institutes of Health (NIH)/National Center for Research Resources; NIH/National Center for Advancing Translational Sciences [UL1RR029887]; NIH/National Heart Lung and Blood Institute Program of Excellence in Nanotechnology Award [HHSN268201000045C]; Research Grant Council of Hong Kong [TRS T13-706/11]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007824] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/National Center for Advancing Translational Sciences; NIH/National Heart Lung and Blood Institute Program of Excellence in Nanotechnology Award; Research Grant Council of Hong Kong(Hong Kong Research Grants Council); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Timothy Cashman for technical assistance. Confocal laser scanning microscopy was performed at the Mount Sinai Microscopy Shared Resource Facility. This project was supported by the U.S. National Institutes of Health (NIH)/National Center for Research Resources and the NIH/National Center for Advancing Translational Sciences through grant UL1RR029887; an NIH/National Heart Lung and Blood Institute Program of Excellence in Nanotechnology Award, contract HHSN268201000045C; and the Research Grant Council of Hong Kong, grant TRS T13-706/11.	Akar FG, 2004, CIRC RES, V95, P717, DOI 10.1161/01.RES.0000144125.61927.1c; BOHM M, 1991, CIRC RES, V68, P689, DOI 10.1161/01.RES.68.3.689; Boudou T, 2012, TISSUE ENG PT A, V18, P910, DOI [10.1089/ten.TEA.2011.0341, 10.1089/ten.tea.2011.0341]; Cain BS, 1998, ANN THORAC SURG, V65, P1065, DOI 10.1016/S0003-4975(98)00093-9; Carlsson L, 2006, J INTERN MED, V259, P70, DOI 10.1111/j.1365-2796.2005.01590.x; Caspi O, 2007, CIRC RES, V100, P263, DOI 10.1161/01.RES.0000257776.05673.ff; Chang MG, 2006, CIRCULATION, V113, P1832, DOI 10.1161/CIRCULATIONAHA.105.593038; COOPER IC, 1990, J MOL CELL CARDIOL, V22, P439, DOI 10.1016/0022-2828(90)91479-Q; Didie M, 2013, J CLIN INVEST, V123, P1285, DOI 10.1172/JCI66854; Domian IJ, 2009, SCIENCE, V326, P426, DOI 10.1126/science.1177350; Engler AJ, 2008, J CELL SCI, V121, P3794, DOI 10.1242/jcs.029678; Eschenhagen T, 2012, AM J PHYSIOL-HEART C, V303, pH133, DOI 10.1152/ajpheart.00007.2012; Foldes G, 2011, J MOL CELL CARDIOL, V50, P367, DOI 10.1016/j.yjmcc.2010.10.029; FRANZ MR, 1988, J CLIN INVEST, V82, P972, DOI 10.1172/JCI113706; Fulbright JM, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/942090; GODT RE, 1991, CAN J PHYSIOL PHARM, V69, P1692, DOI 10.1139/y91-251; GWATHMEY JK, 1991, J CLIN INVEST, V87, P1023, DOI 10.1172/JCI115061; Hansen A, 2010, CIRC RES, V107, P35, DOI 10.1161/CIRCRESAHA.109.211458; Hasenfuss G, 1996, CIRCULATION, V94, P3155, DOI 10.1161/01.CIR.94.12.3155; HASENFUSS G, 1994, J MOL CELL CARDIOL, V26, P1461, DOI 10.1006/jmcc.1994.1165; Holubarsch C, 1996, CIRCULATION, V94, P683, DOI 10.1161/01.CIR.94.4.683; Jacot JG, 2008, BIOPHYS J, V95, P3479, DOI 10.1529/biophysj.107.124545; Karakikes I., 2013, STEM CELLS TRANSL ME, DOI 10.5966/sctm.2013-0110; Kensah G, 2013, EUR HEART J, V34, P1134, DOI 10.1093/eurheartj/ehs349; Kraehenbuehl TP, 2011, NAT METHODS, V8, P731, DOI 10.1038/nmeth.1671; Lesman A, 2010, TISSUE ENG PT A, V16, P115, DOI [10.1089/ten.tea.2009.0130, 10.1089/ten.TEA.2009.0130]; Liang HM, 2010, CELL PHYSIOL BIOCHEM, V25, P459, DOI 10.1159/000303051; Liau B, 2011, BIOMATERIALS, V32, P9180, DOI 10.1016/j.biomaterials.2011.08.050; Liu J, 2009, AM J PHYSIOL-CELL PH, V297, pC152, DOI 10.1152/ajpcell.00060.2009; Ludwig TE, 2006, NAT METHODS, V3, P637, DOI 10.1038/NMETH902; Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135; Naito H, 2006, CIRCULATION, V114, pI72, DOI 10.1161/CIRCULATIONAHA.105.001560; Narmoneva DA, 2004, CIRCULATION, V110, P962, DOI 10.1161/01.CIR.0000140667.37070.07; Nirmalanandhan VS, 2009, J BIOMOL SCREEN, V14, P755, DOI 10.1177/1087057109336591; Peng S, 2010, J PHARMACOL TOX MET, V61, P277, DOI 10.1016/j.vascn.2010.01.014; PETERS NS, 1994, CIRCULATION, V90, P713, DOI 10.1161/01.CIR.90.2.713; Pillekamp F, 2012, STEM CELLS DEV, V21, P2111, DOI 10.1089/scd.2011.0312; Radisic M, 2008, J BIOMED MATER RES A, V86A, P713, DOI 10.1002/jbm.a.31578; Razeghi P, 2001, CIRCULATION, V104, P2923, DOI 10.1161/hc4901.100526; Rossman EI, 2004, J MOL CELL CARDIOL, V36, P33, DOI 10.1016/j.yjmcc.2003.09.001; Schaaf S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026397; SCHWINGER RHG, 1990, J CARDIOVASC PHARM, V15, P892, DOI 10.1097/00005344-199006000-00006; SCHWINGER RHG, 1992, AM HEART J, V123, P116, DOI 10.1016/0002-8703(92)90755-K; Serrao GW, 2012, TISSUE ENG PT A, V18, P1322, DOI [10.1089/ten.tea.2011.0278, 10.1089/ten.TEA.2011.0278]; Song H, 2010, P NATL ACAD SCI USA, V107, P3329, DOI 10.1073/pnas.0905729106; SONNENBL.EH, 1966, CIRC RES, V19, P980, DOI 10.1161/01.RES.19.5.980; Stevens KR, 2009, P NATL ACAD SCI USA, V106, P16568, DOI 10.1073/pnas.0908381106; Stevens KR, 2009, TISSUE ENG PT A, V15, P1211, DOI 10.1089/ten.tea.2008.0151; Tiburcy M, 2011, CIRC RES, V109, P1105, DOI 10.1161/CIRCRESAHA.111.251843; Tulloch NL, 2011, CIRC RES, V109, P47, DOI 10.1161/CIRCRESAHA.110.237206; WHITE M, 1994, CIRCULATION, V90, P1225, DOI 10.1161/01.CIR.90.3.1225; Wiegerinck RF, 2009, PEDIATR RES, V65, P414, DOI 10.1203/PDR.0b013e318199093c; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Zhang DH, 2013, BIOMATERIALS, V34, P5813, DOI 10.1016/j.biomaterials.2013.04.026	54	115	118	1	42	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					644	654		10.1096/fj.13-228007	http://dx.doi.org/10.1096/fj.13-228007			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24174427	Green Published			2022-12-28	WOS:000331072200012
J	Filant, J; Lydon, JP; Spencer, TE				Filant, Justyna; Lydon, John P.; Spencer, Thomas E.			Integrated chromatin immunoprecipitation sequencing and microarray analysis identifies FOXA2 target genes in the glands of the mouse uterus	FASEB JOURNAL			English	Article						ChIP-Seq; development; function; transcription factor	LEUKEMIA INHIBITORY FACTOR; BETA-CATENIN; TRANSCRIPTION FACTORS; ENDOMETRIAL GLANDS; RECEPTOR-ALPHA; PROGESTERONE; IMPLANTATION; EXPRESSION; BINDING; MORPHOGENESIS	Uterine glands and their secretions are indispensable for endometrial function and fertility; however, the mechanisms regulating their development and function are not well understood. Forkhead transcription factor box A2 (FOXA2) is uniquely expressed in the glandular epithelial (GE) cells of the uterus, and conditional deletion of Foxa2 after birth impedes uterine gland development. An integrative approach was used here to define the FOXA2 cistrome in the murine uterus. Genome-wide mapping of FOXA2 binding sites was combined with transcriptomic analyses of isolated GE and Foxa2-deleted uteri. ChIP-Seq analyses found the number of FOXA2 target genes was substantially greater in the adult (8893) than neonatal uterus (1101). In the neonatal uterus, FOXA2-bound and GE-expressed genes (469) were enriched for developmentally related processes, including cell cycle, cell junction, focal adhesion, and WNT signaling. In the adult uterus, FOXA2-bound and GE-expressed genes (3730) were enriched for functional processes, including metabolic pathways, focal adhesion, bacterial invasion of epithelial cells, and WNT signaling. Analysis of the uterine FOXA2 cistrome provides novel insights into mechanisms governing endometrial gland development and function, which are important to understand fundamental aspects of uterine differentiation, regeneration and disease. Filant, J., Lydon, J. P., Spencer, T. E. Integrated chromatin immunoprecipitation sequencing and microarray analysis identifies FOXA2 target genes in the glands of the mouse uterus.	[Filant, Justyna; Spencer, Thomas E.] Washington State Univ, Dept Anim Sci, Pullman, WA 83843 USA; [Filant, Justyna; Spencer, Thomas E.] Washington State Univ, Ctr Reprod Biol, Pullman, WA 83843 USA; [Lydon, John P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Washington State University; Washington State University; Baylor College of Medicine	Spencer, TE (corresponding author), Washington State Univ, Dept Anim Sci, 1815 Ferdinands Lane,VMRB 175, Pullman, WA 83843 USA.	thomas.spencer@wsu.edu	Spencer, Thomas/AAD-6434-2020	Spencer, Thomas/0000-0003-2815-766X	NICHD NIH HHS [R21 HD076347] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andrew DJ, 2010, DEV BIOL, V341, P34, DOI 10.1016/j.ydbio.2009.09.024; Bazer FW, 2012, J REPROD DEVELOP, V58, P180, DOI 10.1262/jrd.2011-019; Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024; Burton GJ, 2011, J REPROD IMMUNOL, V89, P118, DOI 10.1016/j.jri.2011.02.005; Burtscher I, 2009, DEVELOPMENT, V136, P1029, DOI 10.1242/dev.028415; Cha JY, 2012, NAT MED, V18, P1754, DOI 10.1038/nm.3012; Chen W, 2010, CELL TISSUE RES, V341, P441, DOI 10.1007/s00441-010-1013-5; Cooke PS, 2013, MOL HUM REPROD, V19, P547, DOI 10.1093/molehr/gat031; Cooke PS, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.097188; Cummings M, 2011, ANAL BIOCHEM, V416, P123, DOI 10.1016/j.ab.2011.05.009; Diao HL, 2010, FERTIL STERIL, V94, P2808, DOI 10.1016/j.fertnstert.2010.06.034; Dimitriadis E, 2006, J REPROD IMMUNOL, V69, P53, DOI 10.1016/j.jri.2005.07.004; Dunlap KA, 2011, BIOL REPROD, V85, P386, DOI 10.1095/biolreprod.111.091769; Filant J, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.113.107631; Filant J, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.097089; Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6; Gonzalez IM, 2012, DEV BIOL, V361, P286, DOI 10.1016/j.ydbio.2011.10.021; Gray CA, 2002, REPRODUCTION, V124, P289, DOI 10.1530/rep.0.1240289; Hawkins SM, 2011, MOL ENDOCRINOL, V25, P821, DOI 10.1210/me.2010-0371; Hewitt SC, 2012, MOL ENDOCRINOL, V26, P887, DOI 10.1210/me.2011-1311; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huo L, 2001, MOL CELL BIOL, V21, P644, DOI 10.1128/MCB.21.2.644-654.2001; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeong JW, 2006, J ENDOCRINOL, V189, P473, DOI 10.1677/joe.1.06747; Jeong JW, 2009, ONCOGENE, V28, P31, DOI 10.1038/onc.2008.363; Jeong JW, 2010, BIOL REPROD, V83, P396, DOI 10.1095/biolreprod.109.083154; K Deb, 2005, PLACENTA TROPHOBLAST, V121; Kaestner KH, 2010, CURR OPIN GENET DEV, V20, P527, DOI 10.1016/j.gde.2010.06.005; Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83; LUDWIG H, 1991, ANN NY ACAD SCI, V622, P28, DOI 10.1111/j.1749-6632.1991.tb37848.x; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; Niklaus AL, 2006, ENDOCRINOLOGY, V147, P3375, DOI 10.1210/en.2005-1665; O'Sullivan CM, 2002, MOL REPROD DEV, V62, P328, DOI 10.1002/mrd.10142; Rubel CA, 2012, MOL ENDOCRINOL, V26, P1428, DOI 10.1210/me.2011-1355; Sekiya T, 2007, MOL CELL, V28, P291, DOI 10.1016/j.molcel.2007.10.002; Shelton DN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040312; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Spencer TE, 2012, MOL CELL ENDOCRINOL, V354, P34, DOI 10.1016/j.mce.2011.09.035; STEWART CL, 1994, ANN NY ACAD SCI, V734, P157, DOI 10.1111/j.1749-6632.1994.tb21743.x; Tan YF, 2006, REPROD NUTR DEV, V46, P641, DOI 10.1051/rnd:2006037; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Villacorte M, 2013, ONCOGENE, V32, P3477, DOI 10.1038/onc.2012.376; Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439; Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhang S, 2013, MOL ASPECTS MED, V34, P939, DOI 10.1016/j.mam.2012.12.011; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	47	31	33	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					230	243		10.1096/fj.13-237446	http://dx.doi.org/10.1096/fj.13-237446			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24025729	Green Published			2022-12-28	WOS:000333526100023
J	Ishikawa, K; Yoshida, S; Nakao, S; Nakama, T; Kita, T; Asato, R; Sassa, Y; Arita, R; Miyazaki, M; Enaida, H; Oshima, Y; Murakami, N; Niiro, H; Ono, J; Matsuda, A; Goto, Y; Akashi, K; Izuhara, K; Kudo, A; Kono, T; Hafezi-Moghadam, A; Ishibashi, T				Ishikawa, Keijiro; Yoshida, Shigeo; Nakao, Shintaro; Nakama, Takahito; Kita, Takeshi; Asato, Ryo; Sassa, Yukio; Arita, Ryoichi; Miyazaki, Masanori; Enaida, Hiroshi; Oshima, Yuji; Murakami, Noboru; Niiro, Hiroaki; Ono, Junya; Matsuda, Akira; Goto, Yoshinobu; Akashi, Koichi; Izuhara, Kenji; Kudo, Akira; Kono, Toshihiro; Hafezi-Moghadam, Ali; Ishibashi, Tatsuro			Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy	FASEB JOURNAL			English	Article						wound healing; fibrosis; extracellular matrix	TGF-BETA; GROWTH-FACTOR; INCREASED EXPRESSION; GENE-EXPRESSION; RPE CELLS; IN-VIVO; ADHESION; DIFFERENTIATION; MAINTENANCE; INVOLVEMENT	Proliferative vitreoretinopathy (PVR) is a severe, vision-threatening disorder characterized by the fibrous membrane formation that leads to tractional retinal detachment. There has been no effective therapeutic approach other than vitreoretinal surgery. In this study, DNA microarray analysis of the fibrous membranes revealed significant up-regulation of periostin. We also found increased periostin expression in the vitreous and retinal pigment epithelial (RPE) cells from fibrous membranes of PVR patients. In vitro, periostin increased proliferation, adhesion, migration, and collagen production in RPE cells through integrin V-mediated FAK and AKT phosphorylation. Periostin blockade suppressed migration and adhesion induced by TGF2 and PVR vitreous. In vivo, periostin inhibition had the inhibitory effect on progression of experimental PVR in rabbit eyes without affecting the viability of retinal cells. These results identified periostin as a pivotal molecule for fibrous membrane formation as well as a promising therapeutic target for PVR.Ishikawa, K., Yoshida, S., Nakao, S., Nakama, T., Kita, T., Asato, R., Sassa, Y., Arita, R., Miyazaki, M., Enaida, H., Oshima, Y., Murakami, N., Niiro, H., Ono, J., Matsuda, A., Goto, Y., Akashi, K., Izuhara, K., Kudo, A., Kono, T., Hafezi-Moghadam, A., Ishibashi, T. Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy.	[Ishikawa, Keijiro; Yoshida, Shigeo; Nakao, Shintaro; Nakama, Takahito; Kita, Takeshi; Asato, Ryo; Sassa, Yukio; Arita, Ryoichi; Miyazaki, Masanori; Enaida, Hiroshi; Oshima, Yuji; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 8128582, Japan; [Murakami, Noboru; Niiro, Hiroaki; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 8128582, Japan; [Ono, Junya] Shino Test Corp, Kanagawa, Japan; [Matsuda, Akira] Juntendo Univ, Sch Med, Dept Ophthalmol, Tokyo 113, Japan; [Goto, Yoshinobu] Int Univ Hlth & Welf, Fac Rehabil, Dept Occupat Therapy, Fukuoka, Japan; [Izuhara, Kenji] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga, Japan; [Kudo, Akira] Tokyo Inst Technol, Dept Biol Informat, Yokohama, Kanagawa 227, Japan; [Kono, Toshihiro] Fukuoka Univ, Chikushi Hosp, Dept Ophthalmol, Fukuoka 81401, Japan; [Hafezi-Moghadam, Ali] Brigham & Womens Hosp, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA; [Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Kyushu University; Kyushu University; Shino Test Corporation; Juntendo University; International University of Health & Welfare; Saga University; Tokyo Institute of Technology; Fukuoka University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Yoshida, S (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 8128582, Japan.	yosida@eye.med.kyushu-u.ac.jp	Kudo, Akira/C-7340-2015; Matsuda, Akira/A-9981-2010	Kudo, Akira/0000-0001-6289-3391; Matsuda, Akira/0000-0002-0792-3663; Hafezi-Moghadam, Ali/0000-0002-5336-0697	Ministry of Education, Science, Sports and Culture, Japan; Japan Society for the Promotion of Science	Ministry of Education, Science, Sports and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors thank the staff of the Research Support Center (Graduate School of Medical Sciences, Kyushu University) for technical support and Ms. Mari Imamura and Ms. Masayo Eto (Kyushu University) for their excellent technical assistance. This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture, Japan (T. I. and S.Y.). K. Ishikawa is supported by a fellowship from The Japan Society for the Promotion of Science Postdoctoral Fellowships. The authors declare no conflicts of interest.	Agrawal RN, 2007, NAT PROTOC, V2, P67, DOI 10.1038/nprot.2007.4; Andrews A, 1999, INVEST OPHTH VIS SCI, V40, P2683; Arima M, 2012, INVEST OPHTH VIS SCI, V53, P6495, DOI 10.1167/iovs.12-9684; Asano Y, 2004, J IMMUNOL, V172, P7123, DOI 10.4049/jimmunol.172.11.7123; Asato R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054191; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Banerjee S, 2007, INVEST OPHTH VIS SCI, V48, P2203, DOI 10.1167/iovs.06-1358; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; Conway SJ, 2008, CURR GENOMICS, V9, P548, DOI 10.2174/138920208786847917; Cui J, 2009, EXP EYE RES, V88, P438, DOI 10.1016/j.exer.2008.10.020; Dangaria SJ, 2009, DIFFERENTIATION, V78, P79, DOI 10.1016/j.diff.2009.03.005; Elliott CG, 2012, J CELL SCI, V125, P121, DOI 10.1242/jcs.087841; ELNER SG, 1995, CURR EYE RES, V14, P1045, DOI 10.3109/02713689508998529; FASTENBERG DM, 1982, AM J OPHTHALMOL, V93, P565, DOI 10.1016/S0002-9394(14)77370-2; Gillan L, 2002, CANCER RES, V62, P5358; Hamasaki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042655; Harada C, 2006, PROG RETIN EYE RES, V25, P149, DOI 10.1016/j.preteyeres.2005.09.001; He SK, 2008, INVEST OPHTH VIS SCI, V49, P4078, DOI 10.1167/iovs.07-1302; HILTON G, 1983, OPHTHALMOLOGY, V90, P121, DOI 10.1016/s0161-6420(83)34588-7; Hinton DR, 2002, EYE, V16, P422, DOI 10.1038/sj.eye.6700190; Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Ikuno Y, 2000, INVEST OPHTH VIS SCI, V41, P3107; Ishikawa K, 2010, INVEST OPHTH VIS SCI, V51, P4307, DOI 10.1167/iovs.09-4605; Ito S, 1999, GRAEF ARCH CLIN EXP, V237, P691, DOI 10.1007/s004170050298; Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324; Kawahara S, 2008, DIABETES, V57, P2784, DOI 10.2337/db08-0302; Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105; Lei HT, 2011, INVEST OPHTH VIS SCI, V52, P5016, DOI 10.1167/iovs.11-7442; Li GH, 2006, ATHEROSCLEROSIS, V188, P292, DOI 10.1016/j.atherosclerosis.2005.11.002; LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477; Maharaj ASR, 2008, J EXP MED, V205, P491, DOI 10.1084/jem.20072041; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Norris RA, 2009, DEV DYNAM, V238, P1052, DOI 10.1002/dvdy.21933; Ontsuka K, 2012, EXP DERMATOL, V21, P331, DOI 10.1111/j.1600-0625.2012.01454.x; Parapuram SK, 2009, INVEST OPHTH VIS SCI, V50, P5965, DOI 10.1167/iovs.09-3621; Pennock S, 2011, AM J PATHOL, V179, P2931, DOI 10.1016/j.ajpath.2011.08.043; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Saika S, 2008, PROG RETIN EYE RES, V27, P177, DOI 10.1016/j.preteyeres.2007.12.002; Schwartz MA, 2001, J CELL SCI, V114, P2553; Shimazaki M, 2008, J EXP MED, V205, P295, DOI 10.1084/jem.20071297; Smith CL, 2011, CIRC RES, V108, pE15, DOI 10.1161/CIRCRESAHA.110.235531; Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517; Walshe TE, 2011, NEUROSCIENCE, V189, P123, DOI 10.1016/j.neuroscience.2011.05.020; Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yoshida S, 2011, INVEST OPHTH VIS SCI, V52, P5670, DOI 10.1167/iovs.10-6625	52	51	56	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					131	142		10.1096/fj.13-229740	http://dx.doi.org/10.1096/fj.13-229740			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24022401				2022-12-28	WOS:000333526100015
J	Hawkins, TD; Bradley, BJ; Davy, SK				Hawkins, Thomas D.; Bradley, Benjamin J.; Davy, Simon K.			Nitric oxide mediates coral bleaching through an apoptotic-like cell death pathway: evidence from a model sea anemone-dinoflagellate symbiosis	FASEB JOURNAL			English	Article						Symbiodinium; zooxanthellae; heat stress; innate immunity	HEAT-STRESS; THERMAL-STRESS; SYMBIODINIUM-MICROADRIATICUM; SYNTHASE ACTIVITY; OXIDATIVE STRESS; CYTOCHROME-C; NO; MITOCHONDRIA; MECHANISMS; AUTOPHAGY	Coral bleaching (involving the loss of symbiotic algae from the cnidarian host) is a major threat to coral reefs and appears to be mediated at the cellular level by nitric oxide (NO). In this study, we examined the specific role of NO in bleaching using the sea anemone Aiptasia pulchella, a model system for the study of corals. Exposure of A. pulchella to high-temperature shock (26-33 degrees C over <1 h) or an NO donor (S-nitrosoglutathione) resulted in significant increases in host caspase-like enzyme activity. These responses were reflected in the intensities of bleaching, which were significantly higher in heat-or NO-treated specimens than in controls maintained in seawater at 26 C. Notably, the inhibition of caspase-like activity prevented bleaching even in the presence of an NO donor or at elevated temperature. The additional use of an NO scavenger controlled for effects mediated by agents other than NO. We also exposed A. pulchella to a more ecologically relevant treatment (an increase from 26 to 33 degrees C over 6-7 d). Again, host NO synthesis correlated with the activation of caspase-like enzyme activity. Therefore, we conclude that NO's involvement in cnidarian bleaching arises through the regulation of host apoptotic pathways.	[Hawkins, Thomas D.; Bradley, Benjamin J.; Davy, Simon K.] Victoria Univ Wellington, Sch Biol Sci, Wellington 6140, New Zealand	Victoria University Wellington	Davy, SK (corresponding author), Victoria Univ Wellington, Sch Biol Sci, Wellington 6140, New Zealand.	simon.davy@vuw.ac.nz		Davy, Simon/0000-0003-3584-5356	Victoria University of Wellington; Wellington Botanical Society; Commonwealth scholarship	Victoria University of Wellington; Wellington Botanical Society; Commonwealth scholarship	The authors thank Dr. Paul Fisher and Daniel Logan for assistance with experimental setups and confocal laser scanning microscopy, respectively. The authors also thank members of the S. K. D. Laboratory and two anonymous reviewers for their insightful and constructive comments on this manuscript. This work was supported by Victoria University of Wellington funding to S. K. D and Wellington Botanical Society grants to T. D. H. This study fulfills part of the requirements for a Ph.D. funded by a Commonwealth scholarship to T. D. H.	Bhagooli R, 2001, AM ZOOL, V41, P1391; BOTTGER A, 2003, GENETICS APOPTOSIS, P145; Bouchard JN, 2008, PLANT CELL PHYSIOL, V49, P641, DOI 10.1093/pcp/pcn037; Bouchard JN, 2009, MAR BIOL, V156, P2209, DOI 10.1007/s00227-009-1249-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Buxton L, 2002, INTEGR COMP BIOL, V42, P1205; Carmen JC, 2007, MOL MICROBIOL, V64, P904, DOI 10.1111/j.1365-2958.2007.05714.x; Catala M, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-297; Davidson SK, 2004, CELL MICROBIOL, V6, P1139, DOI 10.1111/j.1462-5822.2004.00429.x; De'ath G, 2012, P NATL ACAD SCI USA, V109, P17995, DOI 10.1073/pnas.1208909109; Detournay O, 2012, DEV COMP IMMUNOL, V38, P525, DOI 10.1016/j.dci.2012.08.008; Detournay O, 2011, BIOL BULL-US, V221, P261, DOI 10.1086/BBLv221n3p261; Downs CA, 2010, ECOTOXICOLOGY, V19, P171, DOI 10.1007/s10646-009-0403-5; Dunn SR, 2007, P ROY SOC B-BIOL SCI, V274, P3079, DOI 10.1098/rspb.2007.0711; Dunn SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039024; Dunn SR, 2004, CELL DEATH DIFFER, V11, P1213, DOI 10.1038/sj.cdd.4401484; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Ghasemi A., 2007, JMSR, V2, P29; GOREAU TJ, 1990, CORAL REEFS, V8, P211, DOI 10.1007/BF00265013; Hawkins TD, 2013, J EXP BIOL, V216, P3185, DOI 10.1242/jeb.087510; Hawkins TD, 2012, PLANT CELL PHYSIOL, V53, P1889, DOI 10.1093/pcp/pcs127; Hoegh-Guldberg O, 2007, SCIENCE, V318, P1737, DOI 10.1126/science.1152509; Kumar S., 2003, GENETICS APOPTOSIS, P31; Kuranaga E, 2007, TRENDS CELL BIOL, V17, P135, DOI 10.1016/j.tcb.2007.01.001; Lasi M., 2010, CELL RES, V1, P1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McClanahan TR, 2004, MAR BIOL, V144, P1239, DOI 10.1007/s00227-003-1271-9; Meyer E, 2012, BIOL BULL-US, V223, P44, DOI 10.1086/BBLv223n1p44; Middlebrook R, 2010, J EXP BIOL, V213, P1026, DOI 10.1242/jeb.031633; Nagano T, 2002, CHEM REV, V102, P1235, DOI 10.1021/cr010152s; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nussler AK, 2006, NAT PROTOC, V1, P2223, DOI 10.1038/nprot.2006.341; Pannebakker BA, 2007, P NATL ACAD SCI USA, V104, P213, DOI 10.1073/pnas.0607845104; Perez S, 2006, J EXP BIOL, V209, P2804, DOI 10.1242/jeb.02309; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Richier S, 2006, FEBS J, V273, P4186, DOI 10.1111/j.1742-4658.2006.05414.x; Sarkar S, 2011, MOL CELL, V43, P19, DOI 10.1016/j.molcel.2011.04.029; Schwarz JA, 2008, VIE MILIEU, V58, P141; Shen C, 2013, ARTHRITIS RHEUM-US, V65, P287, DOI 10.1002/art.37730; Singh R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059631; Snyder CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007059; Suggett DJ, 2008, J PHYCOL, V44, P948, DOI 10.1111/j.1529-8817.2008.00537.x; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Trapido-Rosenthal H, 2005, BIOL BULL-US, V208, P3, DOI 10.2307/3593094; Trapido-Rosenthal HG, 2001, AM ZOOL, V41, P247, DOI 10.1668/0003-1569(2001)041[0247:NOACDS]2.0.CO;2; van Hooidonk R, 2013, NAT CLIM CHANGE, V3, P508, DOI [10.1038/NCLIMATE1829, 10.1038/nclimate1829]; Vidal-Dupiol Jeremie, 2009, BMC Physiology, V9, P14, DOI 10.1186/1472-6793-9-14; Wang JT, 2011, MAR ECOL PROG SER, V422, P51, DOI 10.3354/meps08913; Wang YL, 2011, CELL MICROBIOL, V13, P518, DOI 10.1111/j.1462-5822.2011.01576.x; Weis VM, 2008, J EXP BIOL, V211, P3059, DOI 10.1242/jeb.009597; Weis VM, 2008, TRENDS ECOL EVOL, V23, P369, DOI 10.1016/j.tree.2008.03.004; Wiens M, 2003, BBA-MOL CELL RES, V1593, P179, DOI 10.1016/S0167-4889(02)00388-9; Yamasaki H, 2001, NITRIC OXIDE-BIOL CH, V5, P261, DOI 10.1006/niox.2001.0353	58	42	43	0	54	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4790	4798		10.1096/fj.13-235051	http://dx.doi.org/10.1096/fj.13-235051			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23934282				2022-12-28	WOS:000329999000014
J	Babich, V; Vadnagara, K; Di Sole, F				Babich, Victor; Vadnagara, Komal; Di Sole, Francesca			The biophysical and molecular basis of intracellular pH sensing by Na+/H+ exchanger-3	FASEB JOURNAL			English	Article						electroneutral transport; patch clamp; epithelial cells; G-protein-coupled receptors	OPOSSUM KIDNEY-CELLS; CALCINEURIN HOMOLOGOUS PROTEIN; PARATHYROID-HORMONE; CYTOPLASMIC DOMAIN; PROXIMAL TUBULE; NHE3 PHOSPHORYLATION; ESSENTIAL COFACTOR; MEMBRANE PATCHES; PLASMA-MEMBRANE; GENE FAMILY	Epithelial Na+/H+ exchanger-3 (NHE3) transport is fundamental for renal and intestinal sodium reabsorption. Cytoplasmic protons are thought to serve as allosteric modifiers of the exchanger and to trigger its transport through protein conformational change. This effect presupposes an intracellular pH (pH(i)) dependence of NHE3 activity, although the biophysical and molecular basis of NHE3 pH(i) sensitivity have not been defined. NHE3, when complexed with the calcineurin homologous protein-1 (CHP1), had a shift in pH(i) sensitivity (0.4 units) toward the acidic side in comparison with NHE3 alone, as measured by oscillating pH electrodes combined with whole-cell patch clamping. Indeed, CHP1 interaction with NHE3 inhibited NHE3 transport in a pH(i) -dependent manner. CHP1 binding to NHE3 also affected its acute regulation. Intracellular perfusion of peptide from the CHP1 binding region (or pH(i) modification to reduce the CHP1 amount bound to NHE3) was permissive and cooperative for dopamine inhibition of NHE3 but reversed that of adenosine. Thus, CHP1 interaction with NHE3 apparently establishes the exchanger set point for pH(i), and modification in this set point is effective in the hormonal stimuli-mediated regulation of NHE3. CHP1 may serve as a regulatory cofactor for NHE3 conformational change, dependent on intracellular protonation.Babich V., Vadnagara K., Di Sole, F. The biophysical and molecular basis of intracellular pH sensing by the Na+/H+ exchanger-3.	[Babich, Victor; Di Sole, Francesca] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Babich, Victor; Vadnagara, Komal; Di Sole, Francesca] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Southwestern Medical Center Dallas	Babich, V (corresponding author), Univ Maryland, Sch Med, Dept Med, 20 Penn St,HSFII,Suite S005, Baltimore, MD 21201 USA.	vbabich@medicine.umaryland.edu			U.S. National Institutes of Health [R01HL092196-05, R01DK041612]; Simmons Family Foundation; Charles and Jane Pak Center of Mineral Metabolism; American Society of Nephrology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041612] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Simmons Family Foundation; Charles and Jane Pak Center of Mineral Metabolism; American Society of Nephrology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Drs. Pedro A. Jose (University of Maryland School of Medicine, Baltimore, MD, USA), Orson W. Moe (University of Texas Southwestern Medical Center, Dallas, TX, USA), Donald W. Hilgemann (University of Texas Southwestern Medical Center), and Peter B. Gahan (King's College, London, UK) for valuable discussions. This work was supported by U.S. National Institutes of Health grants R01HL092196-05 and R01DK041612, the Simmons Family Foundation, and the Charles and Jane Pak Center of Mineral Metabolism. F. D. was supported by a Carl W. Gottschalk Research Scholar Award from the American Society of Nephrology.	Albrecht FE, 2000, AM J PHYSIOL-REG I, V278, pR1064, DOI 10.1152/ajpregu.2000.278.4.R1064; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; Ben Ammar Y, 2006, EMBO J, V25, P2315, DOI 10.1038/sj.emboj.7601145; Bobulescu IA, 2010, AM J PHYSIOL-RENAL, V298, pF1205, DOI 10.1152/ajprenal.00708.2009; Bobulescu IA, 2009, PFLUG ARCH EUR J PHY, V458, P5, DOI 10.1007/s00424-008-0595-1; Bobulescu IA, 2005, CURR OPIN NEPHROL HY, V14, P485, DOI 10.1097/01.mnh.0000174146.52915.5d; Brett CL, 2005, AM J PHYSIOL-CELL PH, V288, pC223, DOI 10.1152/ajpcell.00360.2004; Brown D, 2012, J AM SOC NEPHROL, V23, P774, DOI 10.1681/ASN.2012010029; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Cha B, 2003, J MEMBRANE BIOL, V191, P49, DOI 10.1007/s00232-002-1044-2; Di Sole F, 2004, J BIOL CHEM, V279, P2962, DOI 10.1074/jbc.M306838200; Di Sole F, 2003, J AM SOC NEPHROL, V14, P1720, DOI 10.1097/01.ASN.0000072743.97583.DB; Di Sole F, 1999, J PHYSIOL-LONDON, V515, P829, DOI 10.1111/j.1469-7793.1999.829ab.x; Di Sole F, 2012, AM J PHYSIOL-RENAL, V303, pF165, DOI 10.1152/ajprenal.00628.2011; Di Sole F, 2009, J AM SOC NEPHROL, V20, P1776, DOI 10.1681/ASN.2008121255; Dibrov P, 2000, BIOSCIENCE REP, V20, P185, DOI 10.1023/A:1005567519792; Donowitz M, 2007, PHYSIOL REV, V87, P825, DOI 10.1152/physrev.00030.2006; Donowitz M, 2013, MOL ASPECTS MED, V34, P236, DOI 10.1016/j.mam.2012.05.001; Donowitz M, 2009, J EXP BIOL, V212, P1638, DOI 10.1242/jeb.028605; Fine M, 2011, J GEN PHYSIOL, V137, P137, DOI 10.1085/jgp.201010469; Fuster D, 2004, P NATL ACAD SCI USA, V101, P10482, DOI 10.1073/pnas.0403930101; Fuster D, 2008, J GEN PHYSIOL, V132, P465, DOI 10.1085/jgp.200810016; Girardi ACC, 2012, AM J PHYSIOL-CELL PH, V302, pC1569, DOI 10.1152/ajpcell.00017.2012; Guzman-Perez A, 2001, BIOORG MED CHEM LETT, V11, P803, DOI 10.1016/S0960-894X(01)00059-2; Hayashi H, 2002, ANN NY ACAD SCI, V976, P248; HELMLEKOLB C, 1993, PFLUG ARCH EUR J PHY, V425, P34, DOI 10.1007/BF00374501; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; Inoue BH, 2012, AM J PHYSIOL-REG I, V302, pR166, DOI 10.1152/ajpregu.00127.2011; Kang TM, 2003, J GEN PHYSIOL, V121, P325, DOI 10.1085/jgp.200208777; Kocinsky HS, 2007, AM J PHYSIOL-RENAL, V293, pF212, DOI 10.1152/ajprenal.00042.2007; Li XX, 2000, AM J PHYSIOL-REG I, V278, pR931, DOI 10.1152/ajpregu.2000.278.4.R931; Marala RB, 2002, EUR J PHARMACOL, V451, P37, DOI 10.1016/S0014-2999(02)02193-3; Matsushita M, 2007, AM J PHYSIOL-CELL PH, V293, pC246, DOI 10.1152/ajpcell.00464.2006; Mishima M, 2007, J BIOL CHEM, V282, P2741, DOI 10.1074/jbc.M604092200; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; Naoe Y, 2005, J BIOL CHEM, V280, P32372, DOI 10.1074/jbc.M503390200; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Pang TX, 2004, BIOCHEMISTRY-US, V43, P3628, DOI 10.1021/bi0360004; Pang TX, 2002, J BIOL CHEM, V277, P43771, DOI 10.1074/jbc.M208313200; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Shcheynikov N, 2004, J BIOL CHEM, V279, P21857, DOI 10.1074/jbc.M313323200; Srivastava J, 2007, PHYSIOLOGY, V22, P30, DOI 10.1152/physiol.00035.2006; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 2003, J BIOL CHEM, V278, P43580, DOI 10.1074/jbc.M306690200; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; Wang TM, 2008, J GEN PHYSIOL, V132, P51, DOI 10.1085/jgp.200709950; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; Wiederkehr MR, 2001, KIDNEY INT, V59, P197, DOI 10.1046/j.1523-1755.2001.00480.x; Xu J, 2000, HYPERTENSION, V36, P395, DOI 10.1161/01.HYP.36.3.395; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004; Zaun HC, 2008, J BIOL CHEM, V283, P12456, DOI 10.1074/jbc.M800267200; Zaun HC, 2012, J BIOL CHEM, V287, P36883, DOI 10.1074/jbc.M112.394700	59	10	10	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4646	4658		10.1096/fj.12-225466	http://dx.doi.org/10.1096/fj.12-225466			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23934281	Green Published			2022-12-28	WOS:000329937500029
J	Zheng, J; Zhang, L; Zhang, JB; Wang, XX; Ye, KQ; Xi, Z; Du, Q; Liang, ZC				Zheng, Jie; Zhang, Lei; Zhang, Junbin; Wang, Xiaoxia; Ye, Keqiong; Xi, Zhen; Du, Quan; Liang, Zicai			Single modification at position 14 of siRNA strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation	FASEB JOURNAL			English	Article						RNA immunoprecipitation; AGO; computational modeling	CRYSTAL-STRUCTURE; CHEMICAL-MODIFICATIONS; MAMMALIAN-CELLS; COMPLEX; IMPROVEMENTS; THERAPEUTICS; ARGONAUTE2; RNAS; DNA	Normally siRNA has to be chemically stabilized in therapeutic applications. It is a challenge to obtain optimal stabilizing effects while maintaining full silencing activity due to a lack of understanding of how different chemical modifications would influence the efficacy of siRNA. In the current study, the effect of single 2-sugar modifications was profiled across the length of the siRNA guide strand. This led to the surprising finding that a single 2-OMe modification at position 14 of the siRNA guide strand substantially compromised its gene-silencing activity in a manner that was independent of the nucleotide identity at this site or the sequence context around it. We found that modification at position 14 of the siRNA guide strand reduced its RNA-induced silencing complex (RISC) loading tremendously, whereas the loading of the siRNA sense strand was only marginally affected. When comparing the silencing potency of 14th position-modified siRNA (transfected at 16.7 nM) and native control (transfected at 1 nM) at equivalent Ago2 loading levels, the silencing potency of modified siRNA was much lower, even lower than the level of native siRNA transfected at 0.1 nM. These data indicated that modification at position 14 of the siRNA guide strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation. Using a computational modeling approach, we demonstrated an intimate interaction between the 14th nucleotide of guide strand and the amino acid Q675 in the AGO protein, which is located in a highly conserved loop of PIWI domain. In addition to gaining insights into siRNA-AGO interactions, this study of structure-activity relationship further established a general principle for siRNA modification in siRNA drug development.Zheng, J., Zhang, L., Zhang, J., Wang, X., Ye, K., Xi, Z., Du, Q., Liang, Z. Single modification at position 14 of siRNA strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation.	[Zheng, Jie; Zhang, Lei; Wang, Xiaoxia; Du, Quan; Liang, Zicai] Peking Univ, Inst Mol Med, Sch Pharmaceut Sci, Beijing 100871, Peoples R China; [Du, Quan] Peking Univ, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci, Beijing 100871, Peoples R China; [Zhang, Junbin; Xi, Zhen] Nankai Univ, State Key Lab Elementoorgan Chem, Tianjin 300071, Peoples R China; [Ye, Keqiong] Natl Inst Biol Sci, Beijing, Peoples R China	Peking University; Peking University; Nankai University; National Institute of Biological Sciences, Beijing	Liang, ZC (corresponding author), Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.	zhenxi@nankai.edu.cn; liangz@pku.edu.cn			National Natural Science Foundation of China [81273422]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [31221002]; National High-Tech R&D Program of China [2012AA022501]; National Basic Research Program of China [2011CBA01100]; National Drug Program [2011ZX09102-011-12, 2012ZX09102301-006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High-Tech R&D Program of China(National High Technology Research and Development Program of China); National Basic Research Program of China(National Basic Research Program of China); National Drug Program	This work was supported by the National Natural Science Foundation of China (81273422), the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (31221002), the National High-Tech R&D Program of China (2012AA022501), the National Basic Research Program of China (2011CBA01100), and the National Drug Program (2011ZX09102-011-12, 2012ZX09102301-006).	Boland A, 2011, P NATL ACAD SCI USA, V108, P10466, DOI 10.1073/pnas.1103946108; Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758; Clark PR, 2008, NUCLEIC ACIDS RES, V36, P1081, DOI 10.1093/nar/gkm630; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; Dowler T, 2006, NUCLEIC ACIDS RES, V34, P1669, DOI 10.1093/nar/gkl033; Du Q, 2004, BIOCHEM BIOPH RES CO, V325, P243, DOI 10.1016/j.bbrc.2004.09.222; Elkayam E, 2012, CELL, V150, P100, DOI 10.1016/j.cell.2012.05.017; Elmen J, 2005, NUCLEIC ACIDS RES, V33, P439, DOI 10.1093/nar/gki193; Hong J, 2008, BIOCHEM BIOPH RES CO, V368, P703, DOI 10.1016/j.bbrc.2008.01.116; Kraynack BA, 2006, RNA, V12, P163, DOI 10.1261/rna.2150806; Prakash TP, 2005, J MED CHEM, V48, P4247, DOI 10.1021/jm050044o; Schirle NT, 2012, SCIENCE, V336, P1037, DOI 10.1126/science.1221551; Shukla S, 2010, CHEMMEDCHEM, V5, P328, DOI 10.1002/cmdc.200900444; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Wang YL, 2008, NATURE, V456, P209, DOI 10.1038/nature07315; Wang YL, 2009, NATURE, V461, P754, DOI 10.1038/nature08434; Wang YL, 2008, NATURE, V456, P921, DOI 10.1038/nature07666	17	22	24	2	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4017	4026		10.1096/fj.13-228668	http://dx.doi.org/10.1096/fj.13-228668			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23771927				2022-12-28	WOS:000329747100016
J	Zhang, F; Dai, M; Neng, LL; Zhang, JH; Zhi, ZW; Fridberger, A; Shi, XR				Zhang, Fei; Dai, Min; Neng, Lingling; Zhang, Jin Hui; Zhi, Zhongwei; Fridberger, Anders; Shi, Xiaorui			Perivascular macrophage-like melanocyte responsiveness to acoustic trauma-a salient feature of strial barrier associated hearing loss	FASEB JOURNAL			English	Article						mouse cochlea; endothelial cell; instrastrial fluid-blood barrier; paracellular permeability; acoustic trauma	EPITHELIUM-DERIVED FACTOR; BLOOD-LABYRINTH BARRIER; CELL-ADHESION MOLECULE; ENDOLYMPHATIC HYDROPS; BRAIN-BARRIER; GROWTH-FACTOR; NITRIC-OXIDE; INNER-EAR; VASCULARIS; MOUSE	Tissue perivascular resident macrophages (PVM/Ms), a hybrid cell type with characteristics of both macrophages and melanocytes, are critical for establishing and maintaining the endocochlear potential (EP) required for hearing. The PVM/Ms modulate expression of tight- and adherens-junction proteins in the endothelial barrier of the stria vascularis (intrastrial fluid-blood barrier) through secretion of a signaling molecule, pigment epithelium growth factor (PEDF). Here, we identify a significant link between abnormalities in PVM/Ms and endothelial barrier breakdown from acoustic trauma to the mouse ear. We find that acoustic trauma causes activation of PVM/Ms and physical detachment from capillary walls. Concurrent with the detachment, we find loosened tight junctions between endothelial cells and decreased production of tight- and adherens-junction protein, resulting in leakage of serum proteins from the damaged barrier. A key factor in the intrastrial fluid-blood barrier hyperpermeability exhibited in the mice is down-regulation of PVM/M modulated PEDF production. We demonstrate that delivery of PEDF to the damaged ear ameliorates hearing loss by restoring intrastrial fluid-blood barrier integrity. PEDF up-regulates expression of tight junction-associated proteins (ZO-1 and VE-cadherin) and PVM/M stabilizing neural cell adhesion molecule (NCAM-120). These studies point to the critical role PVM/Ms play in regulating intrastrial fluid-blood barrier integrity in healthy and noise-damaged ears.Zhang, F., Dai, M., Neng, L., Zhang, J.H., Zhi, Z., Fridberger, A., Shi, X. Perivascular macrophage-like melanocyte responsiveness to acoustic trauma a salient feature of strial barrier associated hearing loss.	[Zhang, Fei; Dai, Min; Neng, Lingling; Zhang, Jin Hui; Shi, Xiaorui] Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Dept Otolaryngol Head & Neck Surg, Portland, OR 97239 USA; [Zhi, Zhongwei] Univ Washington, Biophoton & Imaging Lab BAIL, Seattle, WA 98195 USA; [Fridberger, Anders] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden	Oregon Health & Science University; University of Washington; University of Washington Seattle; Karolinska Institutet	Shi, XR (corresponding author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	shix@ohsu.edu	zhang, jin/GXV-9154-2022; Zhi, Zhongwei/H-4175-2015; zhang, jinhui/GXF-6528-2022; Fridberger, Anders/E-8977-2010	Zhi, Zhongwei/0000-0001-8995-7287; Fridberger, Anders/0000-0002-7960-1559	U.S. National Institutes of Health (NIH) [NIH NIDCD DC008888-02A1, NIH NIDCD DC008888-02S1, NIH NIDCD R21 DC012398, NIH NIDCD R01-DC010844, NIHP30-DC005983]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010844, P30DC005983, R21DC012398, R03DC008888] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by U.S. National Institutes of Health (NIH) grants NIH NIDCD DC008888-02A1 (X. R. S.), NIH NIDCD DC008888-02S1 (X. R. S.), NIH NIDCD R21 DC012398 (X. R. S.), NIH NIDCD R01-DC010844 (X. R. S.), NIHP30-DC005983. The authors declare no conflicts of interest.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Bush WD, 2007, PIGM CELL RES, V20, P134, DOI 10.1111/j.1600-0749.2007.00362.x; CABLE J, 1992, HEARING RES, V64, P6, DOI 10.1016/0378-5955(92)90164-I; Cohen-Salmon M, 2007, P NATL ACAD SCI USA, V104, P6229, DOI 10.1073/pnas.0605108104; Dai M, 2010, AM J PATHOL, V177, P3089, DOI 10.2353/ajpath.2010.100340; DOI K, 1992, ACTA OTO-LARYNGOL, V112, P667, DOI 10.3109/00016489209137457; DRAGER UC, 1985, P NATL ACAD SCI USA, V82, P6716, DOI 10.1073/pnas.82.19.6716; Francavilla C, 2007, J CELL SCI, V120, P4388, DOI 10.1242/jcs.010744; HE HT, 1987, J CELL BIOL, V105, P2489, DOI 10.1083/jcb.105.6.2489; Hinsby AM, 2004, FRONT BIOSCI-LANDMRK, V9, P2227, DOI 10.2741/1393; Hirose K, 2003, JARO, V4, P339, DOI 10.1007/s10162-002-3036-4; HUKEE MJ, 1985, ANN OTO RHINOL LARYN, V94, P297; Juhn S K, 2001, Int Tinnitus J, V7, P72; JUHN SK, 1981, ACTA OTO-LARYNGOL, V91, P529, DOI 10.3109/00016488109138538; Kellerhals B, 1972, Adv Otorhinolaryngol, V18, P91; Klein M, 2008, INFECTION, V36, P2, DOI 10.1007/s15010-007-7153-1; Lin DW, 1997, OTOLARYNG HEAD NECK, V117, P530, DOI 10.1016/S0194-5998(97)70026-3; Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101; Liu JT, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/871272; MCMENOMEY SO, 1992, OTOLARYNG HEAD NECK, V106, P288; Murillo-Cuesta S, 2010, PIGM CELL MELANOMA R, V23, P72, DOI 10.1111/j.1755-148X.2009.00646.x; Neng L., 2012, JARO-J ASSOC RES OTO, V14, P175; Neng LL, 2013, NAT PROTOC, V8, P709, DOI 10.1038/nprot.2013.033; Ni C, 2013, PIGM CELL MELANOMA R, V26, P78, DOI 10.1111/pcmr.12030; Ohlemiller KK, 2009, HEARING RES, V249, P1, DOI 10.1016/j.heares.2008.12.005; Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10; Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014; Plonka PM, 2009, EXP DERMATOL, V18, P799, DOI 10.1111/j.1600-0625.2009.00912.x; Prat A, 2001, GLIA, V36, P145, DOI 10.1002/glia.1104; Salt AN, 2004, JARO-J ASSOC RES OTO, V5, P203, DOI 10.1007/s10162-003-4032-z; Sheikpranbabu S, 2010, BIOCHIMIE, V92, P1040, DOI 10.1016/j.biochi.2010.05.004; Shi XR, 2011, HEARING RES, V282, P10, DOI 10.1016/j.heares.2011.08.006; Shi XR, 2009, AM J PATHOL, V174, P1692, DOI 10.2353/ajpath.2009.080739; Shi XR, 2002, HEARING RES, V172, P73, DOI 10.1016/S0378-5955(02)00513-0; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x; Slominski A, 2009, EXP DERMATOL, V18, P760, DOI 10.1111/j.1600-0625.2009.00892.x; STEEL KP, 1989, DEVELOPMENT, V107, P453; STEEL KP, 1980, NATURE, V288, P159, DOI 10.1038/288159a0; STEEL KP, 1983, BEHAV NEUROSCI, V97, P381, DOI 10.1037/0735-7044.97.3.381; Sulaimon SS, 2003, VET DERMATOL, V14, P57, DOI 10.1046/j.1365-3164.2003.00327.x; Suzuki M, 2002, HEARING RES, V164, P12, DOI 10.1016/S0378-5955(01)00397-5; Tachibana M, 1999, PIGM CELL RES, V12, P344, DOI 10.1111/j.1600-0749.1999.tb00518.x; Tan ZJ, 2010, P NATL ACAD SCI USA, V107, P9873, DOI 10.1073/pnas.1003480107; Trowe MO, 2011, DEV BIOL, V359, P95, DOI 10.1016/j.ydbio.2011.08.030; Ueda S, 2010, CURR MOL MED, V10, P279, DOI 10.2174/156652410791065291; Yang Y., 2011, PLOS ONE, V6; Zhang WJ, 2012, P NATL ACAD SCI USA, V109, P10388, DOI 10.1073/pnas.1205210109; Zheng GL, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-71	51	30	37	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3730	3740		10.1096/fj.13-232892	http://dx.doi.org/10.1096/fj.13-232892			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729595	Green Published			2022-12-28	WOS:000328840500031
J	Li, WJ; Nicola, JP; Amzel, LM; Carrasco, N				Li, Wenjing; Nicola, Juan Pablo; Amzel, L. Mario; Carrasco, Nancy			Asn441 plays a key role in folding and function of the Na+/I+ symporter (NIS)	FASEB JOURNAL			English	Article						plasma membrane targeting; helix capping; interhelical interaction; congenital hypothyroidism; protein folding	IODIDE TRANSPORT DEFECT; N-CAPPING BOX; SODIUM/IODIDE SYMPORTER; POSTTRANSCRIPTIONAL REGULATION; MOLECULAR CHARACTERIZATION; CONGENITAL HYPOTHYROIDISM; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; MUTATION; EXPRESSION	The Na+/I- symporter (NIS) is a plasma membrane glycoprotein that mediates active I- transport in the thyroid, the first step in the biosynthesis of the iodine-containing thyroid hormones T-3 and T-4. Several NIS mutants have been identified as a cause of congenital I- transport defect (ITD), and their investigation has yielded valuable mechanistic information on NIS. Here we report a thorough characterization of the ITD-causing NIS mutation in which the sixth intracellular loop residues 439-443 are missing. This mutant protein was intracellularly retained, incompletely glycosylated, and intrinsically inactive. Engineering 5 Ala at positions 439-443 partially recovered cell surface targeting and activity (approximate to 15%). Strikingly, NIS with the sequence 439-AANAA-443, in which Asn was restored at position 441, was targeted to the plasma membrane and exhibited approximate to 95% the transport activity of WT NIS. Based on our NIS homology model, we propose that the side chain of N441, a residue conserved throughout most of the SLC5 family, interacts with the main chain amino group of G444, capping the -helix of transmembrane segment XII and thus stabilizing the structure of the molecule. Our data provide insight into a critical interhelical interaction required for NIS folding and activity.Li, W., Nicola, J. P., Amzel, L. M., Carrasco, N. Asn441 plays a key role in folding and function of the Na+/I- symporter (NIS).	[Li, Wenjing; Carrasco, Nancy] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Nicola, Juan Pablo; Carrasco, Nancy] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; [Amzel, L. Mario] Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD USA	Yeshiva University; Albert Einstein College of Medicine; Yale University; Johns Hopkins University; Johns Hopkins Medicine	Carrasco, N (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06510 USA.	nancy.carrasco@yale.edu	Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162; Amzel, L. Mario/0000-0002-0129-9572	Yale University School of Medicine; U.S. National Institutes of Health [DK-41544]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544] Funding Source: NIH RePORTER	Yale University School of Medicine; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Sabine Costagliola (Free University of Brussels, Brussels, Belgium) for providing the anti-human NIS VJ1 monoclonal antibody. The authors are grateful to Dr. George Rose (Johns Hopkins University, Baltimore, MD, USA) for his insightful comments and to the members of the N.C. laboratory for critical reading of the manuscript. J.P.N. was supported by the Brown-Coxe postdoctoral fellowship from Yale University School of Medicine. This work was supported by U.S. National Institutes of Health grant DK-41544 (N.C.). The authors declare no conflicts of interest.	Altorjay A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-5; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DE la Vieja A, 2000, PHYSIOL REV, V80, P1083, DOI 10.1152/physrev.2000.80.3.1083; De la Vieja A, 2005, MOL ENDOCRINOL, V19, P2847, DOI 10.1210/me.2005-0162; De la Vieja A, 2007, J BIOL CHEM, V282, P25290, DOI 10.1074/jbc.M700147200; De la Vleja A, 2004, J CELL SCI, V117, P677, DOI 10.1242/jcs.00898; Dohan O, 2001, J CLIN ENDOCR METAB, V86, P2697, DOI 10.1210/jc.86.6.2697; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Dohan O, 2002, MOL ENDOCRINOL, V16, P1893, DOI 10.1210/me.2002-0071; Dohan O, 2000, TRENDS ENDOCRIN MET, V11, P99, DOI 10.1016/S1043-2760(00)00237-X; Dohan O, 2007, P NATL ACAD SCI USA, V104, P20250, DOI 10.1073/pnas.0707207104; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Faham S, 2008, SCIENCE, V321, P810, DOI 10.1126/science.1160406; Fujiwara H, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122a; Gallo M, 2005, INT J IMMUNOPATH PH, V18, P95, DOI 10.1177/039463200501800111; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; Krishnamurthy H, 2009, NATURE, V459, P347, DOI 10.1038/nature08143; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Levy O, 1998, FEBS LETT, V429, P36, DOI 10.1016/S0014-5793(98)00522-5; Narayana N, 2006, J MOL BIOL, V362, P414, DOI 10.1016/j.jmb.2006.06.086; Neumann JM, 2008, TRENDS BIOCHEM SCI, V33, P314, DOI 10.1016/j.tibs.2008.05.001; Nicola JP, 2009, AM J PHYSIOL-CELL PH, V296, pC654, DOI 10.1152/ajpcell.00509.2008; Nicola JP, 2012, J PHYSIOL-LONDON, V590, P6013, DOI 10.1113/jphysiol.2012.241307; Nicola JP, 2011, J CLIN ENDOCR METAB, V96, pE1100, DOI 10.1210/jc.2011-0349; Nicola JP, 2010, MOL ENDOCRINOL, V24, P1846, DOI 10.1210/me.2010-0102; Nicola JP, 2009, ENDOCRINOLOGY, V150, P500, DOI 10.1210/en.2008-0345; Paroder V., 2013, J CELL SCI IN PRESS; Paroder V, 2006, P NATL ACAD SCI USA, V103, P7270, DOI 10.1073/pnas.0602365103; Paroder-Belenitsky M, 2011, P NATL ACAD SCI USA, V108, P17933, DOI 10.1073/pnas.1108278108; Pohlenz J, 2000, J CLIN ENDOCR METAB, V85, P2366, DOI 10.1210/jc.85.7.2366; Purtell K, 2012, FASEB J, V26, P3252, DOI 10.1096/fj.12-206110; Reed-Tsur MD, 2008, ENDOCRINOLOGY, V149, P3077, DOI 10.1210/en.2008-0027; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Riedel C, 2001, J BIOL CHEM, V276, P21458, DOI 10.1074/jbc.M100561200; Schulz A, 2000, J BIOL CHEM, V275, P37860, DOI 10.1074/jbc.M006709200; Spitzweg C, 2010, MOL CELL ENDOCRINOL, V322, P56, DOI 10.1016/j.mce.2010.02.007; STANBURY JB, 1960, LANCET, V1, P1162; Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630; Tonacchera M, 2003, CLIN ENDOCRINOL, V59, P500, DOI 10.1046/j.1365-2265.2003.01877.x; Wapnir IL, 2003, J CLIN ENDOCR METAB, V88, P1880, DOI 10.1210/jc.2002-021544; WOLFF J, 1983, ENDOCR REV, V4, P240, DOI 10.1210/edrv-4-3-240; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; ZHUKOVSKY EA, 1994, BIOCHEMISTRY-US, V33, P9856, DOI 10.1021/bi00199a006	45	24	24	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3229	3238		10.1096/fj.13-229138	http://dx.doi.org/10.1096/fj.13-229138			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23650190	Green Published			2022-12-28	WOS:000329877600028
J	Stavenuiter, F; Gale, AJ; Heeb, MJ				Stavenuiter, Fabian; Gale, Andrew J.; Heeb, Mary J.			Phosphorylation of protein S by platelet kinases enhances its activated protein C cofactor activity	FASEB JOURNAL			English	Article						blood coagulation regulation; vitamin K-dependent protein	FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY; FACTOR-VA; ANTICOAGULANT ACTIVITY; C4B-BINDING PROTEIN; APOPTOTIC CELLS; FACTOR XA; BINDING; COAGULATION; DOMAIN	Protein S (PS) is a multifunctional plasma protein of the hemostatic and inflammatory pathways, although mechanisms for its regulation are poorly understood. Since certain plasma proteins are regulated through extracellular phosphorylation, we investigated whether the anticoagulant activity of PS is regulated through phosphorylation by platelet-secreted kinases. PS was phosphorylated on exposure to activated platelets or their releasates, as judged by immunoblotting for phospho-amino acids and PS. PS phosphorylation was reduced by specific inhibitors of casein kinase 1 (CK1) and casein kinase 2 (CK2) (10 mu M D4476, 100 mu M CK2-inhibitory peptide YNLKSKSSEDIDESS). Involvement of CKs in PS phosphorylation was confirmed using purified CK1/CK2. Phosphorylation of PS by purified CK1 did not affect its activated protein C (APC) cofactor activity in activated partial thromboplastin time assays in PS-depleted plasma. However, phosphorylation of PS by CK2 or by CK1/CK2 increased PS cofactor activity similar to 1.5-fold (158.7 +/- 4.8%, P < 0.01) or similar to 2-fold (191.5 +/- 6.4%, P < 0.0001), respectively. The APC cofactor activity of PS in PS-depleted plasma exposed to platelet-secreted kinases was enhanced, while CK2 but not CK1 inhibitors reduced APC cofactor activity. Mass spectrometry revealed a phosphorylated CK2 site at Thr37 within the N-terminal Gla-domain. Thus, platelet-mediated extracellular phosphorylation of PS is a potential mechanism by which its activity is regulated.Stavenuiter, F., Gale, A. J., Heeb, M. J. Phosphorylation of protein S by platelet kinases enhances its activated protein C cofactor activity.	[Stavenuiter, Fabian; Gale, Andrew J.; Heeb, Mary J.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Heeb, MJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM276,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	heeb@scripps.edu			U.S. National Institutes of Health [RO1 HL088375]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088375] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was partly supported by grant RO1 HL088375 from the U.S. National Institutes of Health. The authors thank Prof. John Griffin (Scripps Research Institute, La Jolla, CA, USA) for providing the CK2-inhibitory peptide. F.S., M.J.H., and A.G. designed the study and analyzed results; F. S. performed experiments; and F. S. and M.J.H. wrote the article. The authors declare no conflicts of interest.	ABE K, 1991, BIOCHEM BIOPH RES CO, V176, P1123, DOI 10.1016/0006-291X(91)90401-R; Ahnstrom J, 2011, BLOOD, V117, P6685, DOI 10.1182/blood-2010-11-317099; Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Andersson HM, 2010, BLOOD, V115, P4878, DOI 10.1182/blood-2009-11-256610; Burstyn-Cohen T, 2009, J CLIN INVEST, V119, P2942, DOI 10.1172/JCI39325; Dahlback B, 2005, FEBS LETT, V579, P3310, DOI 10.1016/j.febslet.2005.03.001; Ekdahl KN, 1997, ARTHRITIS RHEUM, V40, P2178, DOI 10.1002/art.1780401212; Ekdahl KN, 1999, THROMB HAEMOSTASIS, V82, P1283; Ekdahl KN, 1999, J IMMUNOL, V162, P7426; Fernandes N, 2010, J THROMB HAEMOST, V8, P1976, DOI 10.1111/j.1538-7836.2010.03919.x; FURMANIAKKAZMIERCZAK E, 1993, BLOOD, V81, P405; GRINNELL BW, 1990, BLOOD, V76, P2546; Hackeng TM, 2000, BIOCHEM J, V349, P757, DOI 10.1042/bj3490757; Hackeng TM, 2006, P NATL ACAD SCI USA, V103, P3106, DOI 10.1073/pnas.0504240103; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; Hansson K, 2005, J THROMB HAEMOST, V3, P2633, DOI 10.1111/j.1538-7836.2005.01478.x; He XH, 1998, J BIOL CHEM, V273, P27449, DOI 10.1074/jbc.273.42.27449; Heeb MJ, 2009, FASEB J, V23, P2244, DOI 10.1096/fj.08-123174; Heeb MJ, 1999, J BIOL CHEM, V274, P36187, DOI 10.1074/jbc.274.51.36187; Heeb MJ, 2004, J THROMB HAEMOST, V2, P1766, DOI 10.1111/j.1538-7836.2004.00901.x; HOSKINS J, 1987, P NATL ACAD SCI USA, V84, P349, DOI 10.1073/pnas.84.2.349; HOYT CH, 1994, BLOOD, V83, P3517; KALAFATIS M, 1993, BLOOD, V81, P704; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kalafatis M, 1998, J BIOL CHEM, V273, P8459, DOI 10.1074/jbc.273.14.8459; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Long GL, 1998, J BIOL CHEM, V273, P11521, DOI 10.1074/jbc.273.19.11521; MARTIN SC, 1989, BIOCHEM J, V261, P1051, DOI 10.1042/bj2611051; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Mille-Baker B, 2003, BLOOD, V101, P1416, DOI 10.1182/blood-2002-08-2353; MITCHELL CA, 1987, J CLIN INVEST, V79, P374, DOI 10.1172/JCI112822; Morboeuf O, 2000, THROMB HAEMOSTASIS, V84, P604, DOI 10.1055/s-0037-1614075; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; RAND MD, 1994, BLOOD, V83, P2180; Rezende SM, 2004, BLOOD, V103, P1192, DOI 10.1182/blood-2003-05-1551; Saller F, 2005, BLOOD, V105, P122, DOI 10.1182/blood-2004-06-2176; Saller F, 2009, BLOOD, V114, P2307, DOI 10.1182/blood-2009-03-209031; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1985, BLOOD, V66, P1452; Stavenuiter F, 2013, THROMB HAEMOSTASIS, V109, P229, DOI 10.1160/TH12-08-0622; Villoutreix BO, 1997, J COMPUT AID MOL DES, V11, P293, DOI 10.1023/A:1007912929828; Webb JH, 2002, J IMMUNOL, V169, P2580, DOI 10.4049/jimmunol.169.5.2580	43	9	9	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2918	2925		10.1096/fj.12-225961	http://dx.doi.org/10.1096/fj.12-225961			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23580615	Green Published			2022-12-28	WOS:000328841000040
J	Bisaglia, M; Greggio, E; Beltramini, M; Bubacco, L				Bisaglia, Marco; Greggio, Elisa; Beltramini, Mariano; Bubacco, Luigi			Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies	FASEB JOURNAL			English	Review						dopamine metabolism; dopaminergic pathways; neurotransmission; oxidative stress	CATECHOL-O-METHYLTRANSFERASE; AMINO-ACID DECARBOXYLASE; GTP-CYCLOHYDROLASE I; TYROSINE-HYDROXYLASE; MONOAMINE-OXIDASE; SUBSTANTIA-NIGRA; MESSENGER-RNA; GENE-THERAPY; OXIDATIVE STRESS; TRANSPORTER	Parkinson's disease is the second most common neurodegenerative disorder and, at present, has no cure. Both environmental and genetic factors have been implicated in the etiology of the disease; however, the pathogenic pathways leading to neuronal degeneration are still unclear. Parkinson's disease is characterized by the preferential death of a subset of neurons in the mesencephalon that use dopamine as neurotransmitter for synaptic communication. Dopamine is a highly reactive molecule that can lead to cytotoxicity if not properly stored and metabolized. Targeting any of the pathways that tightly control this neurotransmitter holds great therapeutic expectations. In this article we present a comprehensive overview of the cellular pathways that control dopamine fate and discuss potential therapeutic approaches to counteract or slow Parkinson's disease onset and progression.	[Bisaglia, Marco; Greggio, Elisa; Beltramini, Mariano; Bubacco, Luigi] Univ Padua, Mol Physiol & Biophys Unit, Dept Biol, I-35121 Padua, Italy	University of Padua	Bisaglia, M (corresponding author), Univ Padua, Mol Physiol & Biophys Unit, Dept Biol, Via Ugo Bassi 58B, I-35121 Padua, Italy.	marco.bisaglia@unipd.it	Bubacco, Luigi/B-5602-2012; Greggio, Elisa/H-6119-2013	Bubacco, Luigi/0000-0001-7927-9208; Greggio, Elisa/0000-0002-8172-3598	University of Padova [PRAT2010-CPDA103503]; Italian Ministry of Education, University, and Research [PRIN2010-M2JARJ]	University of Padova; Italian Ministry of Education, University, and Research(Ministry of Education, Universities and Research (MIUR))	This work was supported by grants from the University of Padova (PRAT2010-CPDA103503) and the Italian Ministry of Education, University, and Research (PRIN2010-M2JARJ).	Afonso-Oramas D, 2009, NEUROBIOL DIS, V36, P494, DOI 10.1016/j.nbd.2009.09.002; Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Anderson DW, 2011, BRAIN RES, V1408, P81, DOI 10.1016/j.brainres.2011.06.051; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Bademci G, 2010, HUM MUTAT, V31, pE1767, DOI 10.1002/humu.21351; Bankiewicz KS, 2006, MOL THER, V14, P564, DOI 10.1016/j.ymthe.2006.05.005; BARTHOLINI G, 1967, NATURE, V215, P852, DOI 10.1038/215852b0; Belluzzi E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038026; BIRKMAYER W, 1977, LANCET, V1, P439; Bisaglia M, 2007, J BIOL CHEM, V282, P15597, DOI 10.1074/jbc.M610893200; Bisaglia M, 2010, BIOCHEM BIOPH RES CO, V394, P424, DOI 10.1016/j.bbrc.2010.03.044; Bonifacio MJ, 2007, CNS DRUG REV, V13, P352, DOI 10.1111/j.1527-3458.2007.00020.x; Bowling KM, 2008, J BIOL CHEM, V283, P31449, DOI 10.1074/jbc.M802552200; CALNE DB, 1969, BRIT J PHARMACOL, V37, P57, DOI 10.1111/j.1476-5381.1969.tb09522.x; CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0; Caudle WM, 2008, TRENDS NEUROSCI, V31, P303, DOI 10.1016/j.tins.2008.02.010; Caudle WM, 2007, J NEUROSCI, V27, P8138, DOI 10.1523/JNEUROSCI.0319-07.2007; Chinta SJ, 2005, INT J BIOCHEM CELL B, V37, P942, DOI 10.1016/j.biocel.2004.09.009; Choi HJ, 2006, NEUROCHEM INT, V48, P255, DOI 10.1016/j.neuint.2005.10.011; Choi HJ, 2005, NEUROCHEM INT, V46, P329, DOI 10.1016/j.neuint.2004.10.009; COLPAERT FC, 1987, NEUROPHARMACOLOGY, V26, P1431, DOI 10.1016/0028-3908(87)90110-9; Cookson MR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009415; Da Prada M, 1988, J Neural Transm Suppl, V26, P31; Daadi MM, 2006, NEUROREPORT, V17, P201, DOI 10.1097/01.wnr.0000198952.38563.05; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; delaCruz CP, 1996, FREE RADICAL BIO MED, V20, P53, DOI 10.1016/0891-5849(95)02025-X; Eiden LE, 2004, PFLUG ARCH EUR J PHY, V447, P636, DOI 10.1007/s00424-003-1100-5; Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1; Elbaz A, 2007, J NEUROL SCI, V262, P37, DOI 10.1016/j.jns.2007.06.024; Fan DS, 1998, HUM GENE THER, V9, P2527, DOI 10.1089/hum.1998.9.17-2527; Feng LR, 2010, CNS DRUGS, V24, P177, DOI 10.2165/11533740-000000000-00000; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Fumagalli F, 1999, J NEUROSCI, V19, P2424; Furukawa Y, 2001, NEUROLOGY, V56, P260, DOI 10.1212/WNL.56.2.260; Galter D, 2003, NEUROBIOL DIS, V14, P637, DOI 10.1016/j.nbd.2003.09.001; Girotto S, 2012, J BIOL CHEM, V287, P18738, DOI 10.1074/jbc.M111.311589; Glatt CE, 2006, HUM MOL GENET, V15, P299, DOI 10.1093/hmg/ddi445; Goldstein DS, 2011, EUR J NEUROL, V18, P703, DOI 10.1111/j.1468-1331.2010.03246.x; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Haavik J, 1997, J NEUROCHEM, V68, P328; Hauser RA, 2009, PARKINSONISM RELAT D, V15, pS17, DOI 10.1016/S1353-8020(09)70772-2; ICHINOSE H, 1994, J NEURAL TRANSM-PARK, V8, P149, DOI 10.1007/BF02250926; Jankovic J, 2012, CURR OPIN NEUROL, V25, P433, DOI 10.1097/WCO.0b013e3283542fc2; Jankovic J, 2011, EXPERT REV NEUROTHER, V11, P1509, DOI [10.1586/ERN.11.149, 10.1586/ern.11.149]; Jarraya B, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000130; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jinsmaa Y, 2011, CHEM-BIOL INTERACT, V192, P118, DOI 10.1016/j.cbi.2011.01.006; KAPLAN GP, 1979, BRAIN RES, V167, P241, DOI 10.1016/0006-8993(79)90819-9; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; Kelada SNP, 2006, HUM MOL GENET, V15, P3055, DOI 10.1093/hmg/ddl247; Kenney Christopher, 2006, Expert Rev Neurother, V6, P7, DOI 10.1586/14737175.6.1.7; Kotraiah V, 2013, J ENZYM INHIB MED CH, V28, P489, DOI 10.3109/14756366.2011.653353; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; Ludecke B, 1996, HUM MOL GENET, V5, P1023, DOI 10.1093/hmg/5.7.1023; LUNDSTROM K, 1991, DNA CELL BIOL, V10, P181, DOI 10.1089/dna.1991.10.181; Mandel RJ, 1998, J NEUROSCI, V18, P4271; Mandel RJ, 2008, EXP NEUROL, V209, P58, DOI 10.1016/j.expneurol.2007.08.008; Marchitti SA, 2007, PHARMACOL REV, V59, P125, DOI 10.1124/pr.59.2.1; Marshall FJ, 2006, NEUROLOGY, V66, P366, DOI 10.1212/01.wnl.0000198586.85250.13; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438; Mooslehner KA, 2001, MOL CELL BIOL, V21, P5321, DOI 10.1128/MCB.21.16.5321-5331.2001; Nagatsu T, 1997, J NEURAL TRANSM-SUPP, P203; NEAR JA, 1986, MOL PHARMACOL, V30, P252; PIETRUSZKO R, 1984, Alcohol, V1, P363, DOI 10.1016/0741-8329(84)90004-1; Pogson JH, 2011, CURR NEUROL NEUROSCI, V11, P283, DOI 10.1007/s11910-011-0187-x; Przedborski S, 2000, RESTOR NEUROL NEUROS, V16, P135; Rajput AH, 2002, MOVEMENT DISORD, V17, P289, DOI 10.1002/mds.10031; Richardson JR, 2005, TOXICOL SCI, V88, P193, DOI 10.1093/toxsci/kfi304; Riederer Peter, 2011, Exp Neurobiol, V20, P1, DOI 10.5607/en.2011.20.1.1; Ritz BR, 2009, ENVIRON HEALTH PERSP, V117, P964, DOI 10.1289/ehp.0800277; Senthil K, 2004, CLIN CHIM ACTA, V339, P27, DOI 10.1016/j.cccn.2003.08.017; Shen Y, 2000, HUM GENE THER, V11, P1509, DOI 10.1089/10430340050083243; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Sulzer D, 2011, NEURON, V69, P628, DOI 10.1016/j.neuron.2011.02.010; TENHUNEN J, 1994, EUR J BIOCHEM, V223, P1049, DOI 10.1111/j.1432-1033.1994.tb19083.x; Truong JG, 2004, EUR J PHARMACOL, V492, P143, DOI 10.1016/j.ejphar.2004.03.060; Truong JG, 2003, EUR J PHARMACOL, V474, P223, DOI 10.1016/S0014-2999(03)02080-6; UHL GR, 1994, ANN NEUROL, V35, P494, DOI 10.1002/ana.410350421; Varrone A, 2012, Q J NUCL MED MOL IM, V56, P68; Vasiliou Vasilis, 2005, Human Genomics, V2, P138; Vergo S, 2007, BRAIN RES, V1185, P18, DOI 10.1016/j.brainres.2007.09.028; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; Wey MCY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031522; Xu YM, 1998, J NEUROSCI RES, V54, P691, DOI 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F; Yang WS, 2005, J TOXICOL ENV HEAL A, V68, P1939, DOI 10.1080/15287390500226987; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Youdim MBH, 2006, NAT REV NEUROSCI, V7, P295, DOI 10.1038/nrn1883	93	35	39	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2101	2110		10.1096/fj.12-226852	http://dx.doi.org/10.1096/fj.12-226852			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23463698				2022-12-28	WOS:000319667600002
J	Koeberl, DD; Austin, S; Case, LE; Smith, EC; Buckley, AF; Young, SP; Bali, D; Kishnani, PS				Koeberl, Dwight D.; Austin, Stephanie; Case, Laura E.; Smith, Edward C.; Buckley, Anne F.; Young, Sarah P.; Bali, Deeksha; Kishnani, Priya S.			Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease	FASEB JOURNAL			English	Article						mannose-6-phosphate receptor; acid -glucosidase; acid maltase; glycogen storage disease type II	ACID-ALPHA-GLUCOSIDASE; BECKER MUSCULAR-DYSTROPHY; MOUSE MODEL; EFFICACY; GLYCOGEN; MASS; RECOMBINANT; DUCHENNE; VECTOR; TRIAL	Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased CI-MPR-mediated uptake of recombinant human acid--glucosidase during ERT in mice with Pompe disease following addition of albuterol therapy. Currently we have completed a pilot study of albuterol in patients with late-onset Pompe disease already on ERT for >2 yr, who were not improving further. The 6-min walk test (6MWT) distance increased in all 7 subjects at wk 6 (30 +/- 13 m; P=0.002), wk 12 (34 +/- 14 m; P=0.004), and wk 24 (42 +/- 37 m; P=0.02), in comparison with baseline. Grip strength was improved significantly for both hands at wk 12. Furthermore, individual subjects reported benefits; e.g., a female patient could stand up from sitting on the floor much more easily (time for supine to standing position decreased from 30 to 11 s), and a male patient could readily swing his legs out of his van seat (hip abduction increased from 1 to 2+ on manual muscle testing). Finally, analysis of the quadriceps biopsies suggested increased CI-MPR at wk 12 (P=0.08), compared with baseline. With the exception of 1 patient who succumbed to respiratory complications of Pompe disease in the first week, only mild adverse events have been reported, including tremor, transient difficulty falling asleep, and mild urinary retention (requiring early morning voiding). Therefore, this pilot study revealed initial safety and efficacy in an open label study of adjunctive albuterol therapy in patients with late-onset Pompe disease who had been stable on ERT with no improvements noted over the previous several years.Koeberl, D. D., Austin, S., Case, L. E., Smith, E. C., Buckley, A. F., Young, S. P., Bali, D., Kishnani, P. S. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.	[Koeberl, Dwight D.; Austin, Stephanie; Young, Sarah P.; Bali, Deeksha; Kishnani, Priya S.] Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27710 USA; [Case, Laura E.] Duke Univ, Med Ctr, Dept Community & Family Med, Div Phys Therapy, Durham, NC 27710 USA; [Smith, Edward C.] Duke Univ, Med Ctr, Dept Pediat, Div Pediat Genet, Durham, NC 27710 USA; [Buckley, Anne F.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Koeberl, DD (corresponding author), Duke Univ, Med Ctr, Box 103856, Durham, NC 27710 USA.	koebe001@mc.duke.edu		Case, Laura/0000-0002-2941-2186; Buckley, Anne/0000-0003-1209-5791	Duke University Medical Center	Duke University Medical Center	This study was funded by a Bridge Funding grant from the Duke University Medical Center. The authors express appreciation to Dr. Y.-T. Chen for discussions regarding study design and therapy in Pompe disease. In addition, the authors deeply appreciate Ms. Songtao Li and Ms. Jian Dai for their outstanding technical support of this project, and Ms. Carla Johnson for logistical support.	Amalfitano A, 1999, P NATL ACAD SCI USA, V96, P8861, DOI 10.1073/pnas.96.16.8861; Angelini EPC, 2004, BASIC APPL MYOL, V14, P71; Cardone Monica, 2008, Pathogenetics, V1, P6, DOI 10.1186/1755-8417-1-6; CARUSO JF, 1995, MED SCI SPORT EXER, V27, P1471; Fowler EG, 2004, NEUROLOGY, V62, P1006, DOI 10.1212/01.WNL.0000118530.71646.0F; Kissel JT, 2001, NEUROLOGY, V57, P1434, DOI 10.1212/WNL.57.8.1434; Koeberl DD, 2012, MOL GENET METAB, V105, P221, DOI 10.1016/j.ymgme.2011.11.005; Koeberl DD, 2011, MOL GENET METAB, V103, P107, DOI 10.1016/j.ymgme.2011.02.006; Li ST, 2013, FASEB J, V27, P34, DOI 10.1096/fj.12-207472; Matsumoto T, 2006, ARCH ORAL BIOL, V51, P603, DOI 10.1016/j.archoralbio.2006.01.003; McVie-Wylie AJ, 2008, MOL GENET METAB, V94, P448, DOI 10.1016/j.ymgme.2008.04.009; Raben N, 2005, MOL THER, V11, P48, DOI 10.1016/j.ymthe.2004.09.017; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Skura CL, 2008, NEUROLOGY, V70, P137, DOI 10.1212/01.WNL.0000287070.00149.a9; Sun BD, 2005, MOL THER, V11, P57, DOI 10.1016/j.ymthe.2004.10.004; van der Ploeg AT, 2010, NEW ENGL J MED, V362, P1396, DOI 10.1056/NEJMoa0909859; Young SP, 2009, GENET MED, V11, P536, DOI 10.1097/GIM.0b013e3181a87867; Young SP, 2003, ANAL BIOCHEM, V316, P175, DOI 10.1016/S0003-2697(03)00056-3; Zhu YX, 2009, MOL THER, V17, P954, DOI 10.1038/mt.2009.37	20	26	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2171	2176		10.1096/fj.13-241893	http://dx.doi.org/10.1096/fj.13-241893			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24443373	Green Submitted			2022-12-28	WOS:000335336000020
J	Li, M; Andersson-Lendahl, M; Sejersen, T; Arner, A				Li, Mei; Andersson-Lendahl, Monika; Sejersen, Thomas; Arner, Anders			Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment	FASEB JOURNAL			English	Article						Danio rerio; Duchenne muscular dystrophy; skeletal muscle; therapy	DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; NONSENSE MUTATIONS; MDX MOUSE; MODEL; SUPPRESSION; PATHOLOGY; EMBRYO; PTC124; GENE	Sapje zebrafish carry a mutation in the dystrophin gene, which results in a premature stop codon, and a severe muscle phenotype. They display several of the structural characteristics of Duchenne muscular dystrophy (DMD). Ataluren (PTC124) is proposed to cause readthrough of premature stop codons and has been introduced as a potential treatment of genetic disorders. Clinical trials in DMD have shown promise, although with complex dose dependency. We have established physiology techniques, enabling high resolution of contractile function in skeletal muscle of zebrafish larvae. We aimed to provide a mechanical analysis of sapje larval muscle and examine effects of ataluren. Homozygous 5 d postfertilization (dpf) sapje larvae exhibited structural defects with 50% decrease in active tension. Ataluren (0.1-1 mu M, 3-5 dpf) improved contractile function (similar to 60% improvement of force at 0.5 mu M) and dystrophin expression. Controls were not affected. Higher doses (5 mu M, 35 mu M) impaired contractile function, an effect also observed in controls, suggesting unspecific negative effects at high concentrations. In summary, Sapje larvae exhibit impaired contractile performance and provide a relevant DMD model for functional studies. Ataluren significantly improves skeletal muscle function in the sapje larvae, most likely reflecting an observed increase in dystrophin expression. The bell-shaped dose dependence in sapje resembles that previously reported in clinical DMD studies.-Li, M., Andersson-Lendahl, M., Sejersen, T., Arner, A. Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment.	[Li, Mei; Arner, Anders] Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; [Andersson-Lendahl, Monika] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; [Sejersen, Thomas] Karolinska Inst, Dept Womens & Childrens Hlth, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Li, M (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Von Eulers 5 8, SE-17177 Stockholm, Sweden.	anders.arner@ki.se	Andersson Lendahl, Monika/ABE-5981-2021	Sejersen, Thomas/0000-0001-5961-7097; Andersson Lendahl, Monika/0000-0002-5690-8515	Swedish Research Council [2009-4302]; Association Francaise Contre les Myopathies [16304]; Strategic Research Programme in Stem Cells and Regenerative Medicine (StratRegen; Karolinska Institutet); PTC Therapeutics	Swedish Research Council(Swedish Research CouncilEuropean Commission); Association Francaise Contre les Myopathies(Association Francaise contre les Myopathies); Strategic Research Programme in Stem Cells and Regenerative Medicine (StratRegen; Karolinska Institutet); PTC Therapeutics	This study was supported by grants from the Swedish Research Council (2009-4302), the Association Francaise Contre les Myopathies (16304), and the Strategic Research Programme in Stem Cells and Regenerative Medicine (StratRegen; Karolinska Institutet). T.S. has received economic support from PTC Therapeutics to perform a part of an initial phase 2b study of ataluren for DMD, and he is currently a member of the scientific advisory board for a PTC Therapeutics phase 3 study of ataluren for DMD. The authors appreciate the competent help with zebrafish handling and breeding from Mr. Kent Ivarsen (CMB zebrafish facility, Karolinska Institutet).	Aartsma-Rus A, 2006, MUSCLE NERVE, V34, P135, DOI 10.1002/mus.20586; ANDERSON JE, 1988, J MUSCLE RES CELL M, V9, P499, DOI 10.1007/BF01738755; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Bassett D, 2004, CLIN EXP PHARMACOL P, V31, P537, DOI 10.1111/j.1440-1681.2004.04030.x; Bassett DI, 2003, DEVELOPMENT, V130, P5851, DOI 10.1242/dev.00799; BEGGS AH, 1991, AM J HUM GENET, V49, P54; Berger J, 2010, NEUROMUSCULAR DISORD, V20, P826, DOI 10.1016/j.nmd.2010.08.004; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CULLEN MJ, 1975, J NEUROL SCI, V24, P179, DOI 10.1016/0022-510X(75)90232-4; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; Dou Y, 2008, J GEN PHYSIOL, V131, P445, DOI 10.1085/jgp.200809982; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Finkel RS, 2010, J CHILD NEUROL, V25, P1158, DOI 10.1177/0883073810371129; Granato M, 1996, DEVELOPMENT, V123, P399; Howard MT, 2000, ANN NEUROL, V48, P164, DOI 10.1002/1531-8249(200008)48:2<164::AID-ANA5>3.3.CO;2-2; Kawahara G, 2011, P NATL ACAD SCI USA, V108, P5331, DOI 10.1073/pnas.1102116108; LEV AA, 1987, J BIOL CHEM, V262, P15817; Li M, 2013, J GEN PHYSIOL, V141, P335, DOI 10.1085/jgp.201210915; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; O'Brien KF, 2001, MOL GENET METAB, V74, P75, DOI 10.1006/mgme.2001.3220; Peltz SW, 2013, ANNU REV MED, V64, P407, DOI 10.1146/annurev-med-120611-144851; Pichavant C, 2011, MOL THER, V19, P830, DOI 10.1038/mt.2011.59; Sparrow J, 2008, ADV EXP MED BIOL, V642, P192; Sztal TE, 2012, HUM MOL GENET, V21, P4718, DOI 10.1093/hmg/dds312; Tan L, 2011, J INHERIT METAB DIS, V34, P443, DOI 10.1007/s10545-010-9265-5; TANABE Y, 1986, ACTA NEUROPATHOL, V69, P91, DOI 10.1007/BF00687043; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Zucconi E, 2010, NEUROMUSCULAR DISORD, V20, P64, DOI 10.1016/j.nmd.2009.10.011	30	35	35	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1593	1599		10.1096/fj.13-240044	http://dx.doi.org/10.1096/fj.13-240044			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371125	Bronze			2022-12-28	WOS:000335344300008
J	Sato, K; Iemitsu, M; Matsutani, K; Kurihara, T; Hamaoka, T; Fujita, S				Sato, Koji; Iemitsu, Motoyuki; Matsutani, Kenji; Kurihara, Toshiyuki; Hamaoka, Takafumi; Fujita, Satoshi			Resistance training restores muscle sex steroid hormone steroidogenesis in older men	FASEB JOURNAL			English	Article						aging; muscle strength; skeletal muscle; exercise	METABOLIC SYNDROME; TESTOSTERONE; EXERCISE; DHEA; DEHYDROEPIANDROSTERONE; STRENGTH; PATHWAY	Skeletal muscle can synthesize testosterone and 5 alpha-dihydrotestosterone (DHT) from dehydroepiandrosterone (DHEA) via steroidogenic enzymes in vitro, but hormone levels and steroidogenic enzyme expression decline with aging. Resistance exercise has been shown to increase in plasma sex steroid hormone levels. However, it remains unclear whether resistance training can restore impaired steroidogenic enzyme expressions in older individuals. Six young and 13 older men were recruited, and muscle biopsies were taken from the vastus lateralis at basal state. The same group of older subjects underwent resistance training involving knee extension and flexion exercises for 12 wk, and post-training biopsies were performed 4-5 d after the last exercise session. Muscular sex steroid hormone levels and sex steroidgenesis-related enzyme expressions were significantly lower in older subjects than younger ones at baseline, but 12 wk of resistance training significantly restored hormone levels (DHEA: 432 +/- 26 at baseline, 682 +/- 31 pg/mu g protein, DHT: 6.2 +/- 0.9 at baseline, 9.8 +/- 1.4 pg/mu g protein). Furthermore, the steroidogenesis-related enzymes such as 3 beta-hydroxysteroid dehydrogenase (HSD), 17 beta-HSD, and 5 alpha-reductase expressions were significantly restored by resistance training. We conclude progressive resistance training restores age-related declines in sex steroidogenic enzyme and muscle sex steroid hormone levels in older men.-Sato, K., Iemitsu, M., Matsutani, K., Kurihara, T., Hamaoka, T., Fujita, S. Resistance training restores muscle sex steroid hormone steroidogenesis in older men.	[Sato, Koji; Iemitsu, Motoyuki; Matsutani, Kenji; Kurihara, Toshiyuki; Hamaoka, Takafumi; Fujita, Satoshi] Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Shiga 5258577, Japan	Ritsumeikan University	Fujita, S (corresponding author), Ritsumeikan Univ, 1-1-1 Nojihigashi, Kusatsu, Shiga 5258577, Japan.	safujita@fc.ritsumei.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [23700849, 24300235, 22680050]; Yamaha Motor Foundation for Sports; Grants-in-Aid for Scientific Research [25560378, 23300217] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Yamaha Motor Foundation for Sports; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors specially thank Dr. Noboru Mesaki for supporting this study. This work was supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (23700849, 24300235, and 22680050). This work was also funded by the Yamaha Motor Foundation for Sports (to K. S., S. F., and M. I.). The authors declare no conflicts of interest.	Aizawa K, 2007, AM J PHYSIOL-ENDOC M, V292, pE577, DOI 10.1152/ajpendo.00367.2006; Aizawa K, 2010, STEROIDS, V75, P219, DOI 10.1016/j.steroids.2009.12.002; Akishita M, 2010, ATHEROSCLEROSIS, V210, P232, DOI 10.1016/j.atherosclerosis.2009.10.037; Belanger A., 2005, J CLIN ENDOCR METAB, V79, P1086; Caron Marc-Andre, 2011, BMC Res Notes, V4, P488, DOI 10.1186/1756-0500-4-488; Copeland JL, 2002, J GERONTOL A-BIOL, V57, pB158, DOI 10.1093/gerona/57.4.B158; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; Fujita S, 2009, DIABETOLOGIA, V52, P1889, DOI 10.1007/s00125-009-1430-8; Hawkins VN, 2008, MED SCI SPORT EXER, V40, P223, DOI 10.1249/mss.0b013e31815bbba9; Jubrias SA, 2001, J APPL PHYSIOL, V90, P1663, DOI 10.1152/jappl.2001.90.5.1663; Labrie F, 2005, J ENDOCRINOL, V187, P169, DOI 10.1677/joe.1.06264; Li CY, 2010, DIABETES CARE, V33, P1618, DOI 10.2337/dc09-1788; Lo JC, 2006, AM J MED, V119, P69, DOI 10.1016/j.amjmed.2006.07.009; Muller M, 2005, J CLIN ENDOCR METAB, V90, P2618, DOI 10.1210/jc.2004-1158; Pollanen E, 2011, AGING CELL, V10, P650, DOI 10.1111/j.1474-9726.2011.00701.x; Pollanen E, 2010, GROWTH HORM IGF RES, V20, P372, DOI 10.1016/j.ghir.2010.07.003; Sato K, 2008, AM J PHYSIOL-ENDOC M, V294, pE961, DOI 10.1152/ajpendo.00678.2007; Sato K, 2011, AM J PHYSIOL-ENDOC M, V301, pE274, DOI 10.1152/ajpendo.00564.2010; Sattler FR, 2009, J CLIN ENDOCR METAB, V94, P1991, DOI 10.1210/jc.2008-2338; Sheffield-Moore M, 2011, J CLIN ENDOCR METAB, V96, pE1831, DOI 10.1210/jc.2011-1262; Sinha-Hikim I., 2001, AM J PHYSIOL-ENDOC M, V283, pE154; Taekema DG, 2011, EUR J ENDOCRINOL, V164, P189, DOI 10.1530/EJE-10-0703; Villareal DT, 2006, AM J PHYSIOL-ENDOC M, V291, pE1003, DOI 10.1152/ajpendo.00100.2006; Vingren JL, 2010, SPORTS MED, V40, P1037, DOI 10.2165/11536910-000000000-00000; Vingren JL, 2008, J APPL PHYSIOL, V105, P1754, DOI 10.1152/japplphysiol.91235.2008; White JP, 2013, MOL CELL ENDOCRINOL, V365, P174, DOI 10.1016/j.mce.2012.10.019	26	47	49	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1891	1897		10.1096/fj.13-245480	http://dx.doi.org/10.1096/fj.13-245480			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24443372				2022-12-28	WOS:000335344300033
J	Chandrashekran, A; Sarkar, R; Thrasher, A; Fraser, SE; Dibb, N; Casimir, C; Winston, R; Readhead, C				Chandrashekran, Anil; Sarkar, Rupa; Thrasher, Adrian; Fraser, Scott E.; Dibb, Nicholas; Casimir, Colin; Winston, Robert; Readhead, Carol			Efficient generation of transgenic mice by lentivirus-mediated modification of spermatozoa	FASEB JOURNAL			English	Article						lentiviral vectors; transgenesis; male germ cells; in vitro fertilization	C-KIT RECEPTOR; RETROVIRAL TRANSDUCTION; STEM-CELLS; GENE-TRANSFER; VECTORS; TRANSMISSION; EXPRESSION; INTEGRATION; PROTEINS; HIV-1	Transgenic technologies conventionally rely on the oocyte as a substrate for genetic modification. Owing to their accessibility, however, male germ cells, including mature sperm, have material advantages for use in transgenesis. Here we have exploited lentiviruses to generate transgenic animals via the male germline. When pseudotyped lentiviral vectors encoding green fluorescent protein (GFP) were incubated with mouse spermatozoa, these sperm were highly successful in producing transgenics. Lentivirally transduced mouse spermatozoa were used in in vitro fertilization (IVF) studies, and when followed by embryo transfer, 42% of founders were found to be transgenic for GFP. Inverse PCR strategy for integration site analysis demonstrated integration of at least 1 or 2 copies of GFP in the transgenics, mapping to different chromosomes. GFP expression was detected in a wide range of murine tissues, including testis and the transgene was stably transmitted to a third generation of transgenic animals. This relatively simple, yet highly efficient, technique for generating transgenic animals by transducing spermatozoa with lentiviral vectors in vitro is a powerful tool for the study of fertilization/preimplantation development, vertical viral gene transmission, gene function and regulation, and epigenetic inheritance.Chandrashekran, A., Sarkar, R., Thrasher, A., Fraser, S. E., Dibb, N., Casimir, C., Readhead, C., Winston, R. Efficient generation of transgenic mice by lentivirus-mediated modification of spermatozoa.	[Chandrashekran, Anil; Sarkar, Rupa; Dibb, Nicholas; Winston, Robert] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Dept Surg & Canc, Div Canc, London, England; [Thrasher, Adrian] UCL, Inst Child Hlth, Mol Immunol Unit, London, England; [Fraser, Scott E.; Readhead, Carol] CALTECH, Beckman Inst, Biol Imaging Ctr, Pasadena, CA 91125 USA; [Casimir, Colin] Middlesex Univ, Sch Sci & Technol, Dept Nat Sci, London N17 8HR, England	Imperial College London; University of London; University College London; California Institute of Technology; Middlesex University	Chandrashekran, A (corresponding author), Royal Vet Coll, Dept Vet Clin Sci, Hawkshead Ln, N Mymms AL9 7TA, England.	achandrashekran@rvc.ac.uk	Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223; Sarkar, Rupa/0000-0003-0014-2239; Chandrashekran, Anil/0000-0002-7037-7693	Institute of Obstetrics and Gynaecology Trust; London, UK; Atazoa Ltd. (London, UK); Genesis Research Trust; UK Biotechnology and Biological Resources Research Council	Institute of Obstetrics and Gynaecology Trust; London, UK; Atazoa Ltd. (London, UK); Genesis Research Trust; UK Biotechnology and Biological Resources Research Council	The authors thank Malcolm Parker and Ilpo Huhtaniemi (Imperial College London) for critically reading the manuscript. The authors also thank Aura Keeter, Natasha Bouey, and Joaquin Gutierrez (California Institute of Technology), and Ihsan Isa (Imperial College London), for their dedicated technical assistance; and Naveenan Navaratnam and Geok Chin Tan (Imperial College London) for helpful discussion and support. The authors thank Amy Cutler and Zoe Webster (Transgenic and Embryonic Stem Cell Laboratory, Medical Research Council-Clinical Sciences Centre, London, UK) for assistance with IVF followed by embryo transfer to obtain transgenic animals, and their maintenance and welfare. The authors thank Luigi Naldini [San Raffaele Telethon Institute for Gene Therapy (TIGET), San Raffaele Scientific Institute, Milan, Italy] for providing the PGK-GFP encoded lentiviral vector and Rusty Landsford (California Institute of Technology, Pasadena, CA, USA) for the vectors containing H2Bcherry reporters. This work was supported by Atazoa Ltd. (London, UK) and by the Genesis Research Trust (previously known as the Institute of Obstetrics and Gynaecology Trust; London, UK). R.S. was supported by a Case Ph. D. studentship from the UK Biotechnology and Biological Resources Research Council. Author contributions: A. C. and C. R. designed and performed experiments and analyzed the data; R. S. performed experiments; C. C., S.E.F., A.T., N.D., and R.W. contributed reagents, lent support and advice on experiments, and contributed to the writing and editing of the manuscript; A.C. and C.R. wrote the manuscript. R.W. and C.R. are joint senior authors. Conflicts of interest: C.R., N.D., and R. W. are directors of a commercial enterprise, Atazoa Ltd., which hopes to exploit novel techniques for animal transgenesis. A.C. is a former employee of Atazoa Ltd.	Baccetti B, 1999, J ACQ IMMUN DEF SYND, V21, P355; Baup D, 2010, TRANSGENIC RES, V19, P399, DOI 10.1007/s11248-009-9318-4; Brinster RL, 2002, SCIENCE, V296, P2174, DOI 10.1126/science.1071607; Chandrashekran A, 2004, J GENE MED, V6, P1189, DOI 10.1002/jgm.625; Chandrashekran A, 2004, BLOOD, V104, P2697, DOI 10.1182/blood-2003-10-3717; Dhup S, 2008, NAT METHODS, V5, P601, DOI 10.1038/nmeth.1225; Dufait I., 2012, SCIENTIFICA CAIRO, V2012, DOI 10.6064/2012/694137; Emeagi PU, 2013, CURR MOL MED, V13, P602; Escors D, 2010, ARCH IMMUNOL THER EX, V58, P107, DOI 10.1007/s00005-010-0063-4; Feng HL, 1998, MOL REPROD DEV, V49, P317, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;317::AID-MRD12&gt;3.0.CO;2-T; Galimi F, 2002, CURR TOP MICROBIOL, V261, P245; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; Gur Y, 2006, GENE DEV, V20, P411, DOI 10.1101/gad.367606; Hiripi L, 2010, TRANSGENIC RES, V19, P799, DOI 10.1007/s11248-009-9356-y; Hofmann A, 2003, EMBO REP, V4, P1054, DOI 10.1038/sj.embor.7400007; Honaramooz A, 2008, FASEB J, V22, P374, DOI 10.1096/fj.07-8935com; Howe Steven J, 2012, Methods Mol Biol, V891, P85, DOI 10.1007/978-1-61779-873-3_5; Kanatsu-Shinohara M, 2004, BIOL REPROD, V71, P1202, DOI 10.1095/biolreprod.104.031294; Landazuri N, 2006, BIOTECHNOL BIOENG, V93, P146, DOI 10.1002/bit.20697; Li C, 2010, BIOL REPROD, V82, P331, DOI 10.1095/biolreprod.109.078501; Liechtenstein T, 2013, VIRUS RES, V176, P1, DOI 10.1016/j.virusres.2013.05.007; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lyall J, 2011, SCIENCE, V331, P223, DOI 10.1126/science.1198020; Michalkiewicz M, 2007, AM J PHYSIOL-HEART C, V293, pH881, DOI 10.1152/ajpheart.00060.2007; Monne M, 2011, BIOL REPROD, V85, P661, DOI 10.1095/biolreprod.111.092098; Nagano M, 2001, P NATL ACAD SCI USA, V98, P13090, DOI 10.1073/pnas.231473498; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Prather RS, 2007, ADV EXP MED BIOL, V591, P1; Sandlow JI, 1997, UROLOGY, V49, P494, DOI 10.1016/S0090-4295(96)00494-3; Sasaki E, 2009, NATURE, V459, P523, DOI 10.1038/nature08090; Sastry L, 2002, GENE THER, V9, P1155, DOI 10.1038/sj.gt.3301731; Sato Y., 2010, PLOS ONE, V5; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Sehgal L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021975; Smith K, 2005, BIOESSAYS, V27, P551, DOI 10.1002/bies.20211; Smolenski RT, 2007, CARDIOVASC RES, V73, P143, DOI 10.1016/j.cardiores.2006.10.027; Watson Deborah J, 2004, Methods Mol Biol, V246, P413; Zhang Y., 2012, PLOS ONE, V7; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	39	14	14	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					569	576		10.1096/fj.13-233999	http://dx.doi.org/10.1096/fj.13-233999			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24297703				2022-12-28	WOS:000331072200005
J	Puppa, MJ; Gao, S; Narsale, AA; Carson, JA				Puppa, Melissa J.; Gao, Song; Narsale, Aditi A.; Carson, James A.			Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia	FASEB JOURNAL			English	Article						inflammation; cancer; STAT3; protein turnover; C2C12 myotube; IL-6	CANCER CACHEXIA; KAPPA-B; IL-6; INHIBITION; EXPRESSION; CYTOKINES; ANTIBODY; ATROPHY; GROWTH; GP130	Chronic inflammation is associated with cachexia-induced skeletal muscle mass loss in cancer. Levels of IL-6 cytokine family members are increased during cancer-related cachexia and induce intracellular signaling through glycoprotein130 (gp130). Although muscle STAT3 and circulating IL-6 are implicated in cancer-induced muscle wasting, there is limited understanding of muscle gp130's role in this process. Therefore, we investigated the role of skeletal muscle gp130 (skm-gp130) in cancer-induced alterations in the regulation of muscle protein turnover. Lewis lung carcinoma (LLC) cells were injected into 8-wk-old skm-gp130-knockout (KO) mice or wild-type mice. Skeletal muscle loss was attenuated by 16% in gp130-KO mice, which coincided with attenuated LLC-induced phosphorylation of muscle STAT3, p38, and FOXO3. gp130 KO did not restore mTOR inhibition or alter AMP-activated protein kinase (AMPK) expression. The induction of atrogin expression and p38 phosphorylation in C2C12 myotubes exposed to LLC-treated medium was attenuated by gp130 inhibition, but mTOR inhibition was not restored. STAT signaling inhibition in LLC-treated myotubes did not attenuate the induction of p38 or AMPK phosphorylation. We concluded that, during LLC-induced cachexia, skm-gp130 regulates muscle mass signaling through STAT3 and p38 for the activation of FOXO3 and atrogin, but does not directly regulate the suppression of mTOR.Puppa, M. J., Gao, S., Narsale, A. A., Carson, J. A. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.	[Puppa, Melissa J.; Gao, Song; Narsale, Aditi A.; Carson, James A.] Univ S Carolina, Dept Exercise Sci, Integrat Muscle Biol Lab, Columbia, SC 29208 USA; [Carson, James A.] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Carson, JA (corresponding author), Univ S Carolina, Dept Exercise Sci, Publ Hlth Res Ctr, Room 405,921 Assembly St, Columbia, SC 29208 USA.	carsonj@mailbox.sc.edu	Carson, James/Q-5693-2019; Narsale, Aditi/U-4643-2019	Carson, James/0000-0003-3733-8796; Puppa, Melissa/0000-0003-3826-0003; Narsale, Aditi/0000-0002-1421-5104	U.S. NIH/NCI [R01 CA121249]; NATIONAL CANCER INSTITUTE [R01CA121249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103336] Funding Source: NIH RePORTER	U.S. NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Ms. Tia Davis and Dr. Marj Pena for technical assistance with the animal breeding. The skeletal muscle-specific Cre-expressing mice were a gift from Dr. Steven Burden (New York University, New York, NY, USA). The gp130 fl/fl mice were a gift from Drs. Colin Stuart [Laboratory of Cancer and Developmental Biology, National Cancer Institute (NCI), U. S. National Institutes of Health (NIH), Frederick, MD, USA] and Lothar Hennighausen (Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA). The research described in this report was supported by U.S. NIH/NCI research grant R01 CA121249 to J.A.C.	Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Ando K, 2013, J CLIN ONCOL, V31, pE69, DOI 10.1200/JCO.2012.44.2020; Argiles JM, 2003, CURR OPIN CLIN NUTR, V6, P401, DOI 10.1097/01.mco.0000078983.18774.cc; Baeza-Raja B, 2004, MOL BIOL CELL, V15, P2013, DOI 10.1091/mbc.E03-08-0585; Baltgalvis KA, 2008, AM J PHYSIOL-REG I, V294, pR393, DOI 10.1152/ajpregu.00716.2007; Barton BE, 2001, CYTOKINE, V16, P251, DOI 10.1006/cyto.2001.0968; Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012; Bonetto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022538; Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruera E, 1997, BRIT MED J, V315, P1219, DOI 10.1136/bmj.315.7117.1219; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Dworzak F, 1998, CANCER, V82, P42, DOI 10.1002/(SICI)1097-0142(19980101)82:1<42::AID-CNCR5>3.0.CO;2-M; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Febbraio MA, 2007, J CLIN INVEST, V117, P841, DOI 10.1172/JCI30453; Fortunati N, 2007, ONCOL REP, V18, P1521; Frost RA, 2011, PHYSIOLOGY, V26, P83, DOI 10.1152/physiol.00044.2010; Frost RA, 2009, J CELL BIOCHEM, V108, P1192, DOI 10.1002/jcb.22349; Goodman CA, 2011, J PHYSIOL-LONDON, V589, P5485, DOI 10.1113/jphysiol.2011.218255; Goodman CA, 2011, CELL SIGNAL, V23, P1896, DOI 10.1016/j.cellsig.2011.07.013; Goodman CA, 2011, FASEB J, V25, P1028, DOI 10.1096/fj.10-168799; Hariri G, 2010, CLIN CANCER RES, V16, P4968, DOI 10.1158/1078-0432.CCR-10-0969; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirata H, 2013, J PAIN SYMPTOM MANAG, V46, pE9, DOI 10.1016/j.jpainsymman.2013.01.009; Ho RC, 2005, AM J PHYSIOL-CELL PH, V289, pC794, DOI 10.1152/ajpcell.00632.2004; Kamoshida S, 2006, BIOMED RES-TOKYO, V27, P275, DOI 10.2220/biomedres.27.275; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Lantier L, 2010, FASEB J, V24, P3555, DOI 10.1096/fj.10-155994; MATTHYS P, 1991, EUR J CANCER, V27, P182, DOI 10.1016/0277-5379(91)90483-T; MORI M, 1991, CANCER RES, V51, P6656; Murphy KT, 2011, AM J PHYSIOL-REG I, V301, pR716, DOI 10.1152/ajpregu.00121.2011; Muscaritoli M, 2010, CLIN NUTR, V29, P154, DOI 10.1016/j.clnu.2009.12.004; Nai YJ, 2007, JPEN-PARENTER ENTER, V31, P18, DOI 10.1177/014860710703100118; Pfeilschifter W, 2010, NEUROCHEM RES, V35, P1391, DOI 10.1007/s11064-010-0197-0; Puppa MJ, 2012, J CACHEXIA SARCOPENI, V3, P117, DOI 10.1007/s13539-011-0047-1; Puppa MJ, 2011, BBA-MOL BASIS DIS, V1812, P1601, DOI 10.1016/j.bbadis.2011.08.010; Reed SA, 2012, FASEB J, V26, P987, DOI 10.1096/fj.11-189977; Rose-John S, 2012, INT J BIOL SCI, V8, P1237, DOI 10.7150/ijbs.4989; Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-4; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tazaki E, 2011, EXP THER MED, V2, P887, DOI 10.3892/etm.2011.286; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; Toledo-Corral CM, 2012, ACTA HISTOCHEM, V114, P159, DOI 10.1016/j.acthis.2011.04.003; Washington TA, 2011, ACTA PHYSIOL, V202, P657, DOI 10.1111/j.1748-1716.2011.02281.x; Watt MJ, 2006, NAT MED, V12, P541, DOI 10.1038/nm1383; White JP, 2013, AM J PHYSIOL-ENDOC M, V304, pE1042, DOI 10.1152/ajpendo.00410.2012; White JP, 2013, MOL CELL ENDOCRINOL, V365, P174, DOI 10.1016/j.mce.2012.10.019; White JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024650; White J, 2012, ITE J, V82, P14; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zhang GH, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-20; Zhang GH, 2011, EMBO J, V30, P4323, DOI 10.1038/emboj.2011.292; Zhao L, 2004, J BIOL CHEM, V279, P44093, DOI 10.1074/jbc.M313131200	58	95	95	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					998	1009		10.1096/fj.13-240580	http://dx.doi.org/10.1096/fj.13-240580			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24145720	Green Published			2022-12-28	WOS:000331072200043
J	de la Garza-Rodea, AS; Baldwin, DM; Oskouian, B; Place, RF; Bandhuvula, P; Kumar, A; Saba, JD				de la Garza-Rodea, Anabel S.; Baldwin, Dianna M.; Oskouian, Babak; Place, Robert F.; Bandhuvula, Padmavathi; Kumar, Ashok; Saba, Julie D.			Sphingosine phosphate lyase regulates myogenic differentiation via S1P receptor-mediated effects on myogenic microRNA expression	FASEB JOURNAL			English	Article						myogenesis; sphingolipid; C2C12; Spns2	SKELETAL-MUSCLE REGENERATION; C2C12 MYOBLASTS; SATELLITE CELLS; SPHINGOSINE-1-PHOSPHATE LYASE; CYTOSKELETAL REORGANIZATION; SPHINGOLIPID METABOLISM; TARGET GENES; 1-PHOSPHATE; MIR-206; PROLIFERATION	S1P lyase (SPL) catalyzes the irreversible degradation of sphingosine-1-phosphate (S1P), a bioactive lipid whose signaling activities regulate muscle differentiation, homeostasis, and satellite cell (SC) activation. By regulating S1P levels, SPL also controls SC recruitment and muscle regeneration, representing a potential therapeutic target for muscular dystrophy. We found that SPL is induced during myoblast differentiation. To investigate SPL's role in myogenesis at the cellular level, we generated and characterized a murine myoblast SPL-knockdown (SPL-KD) cell line lacking SPL. SPL-KD cells accumulated intracellular and extracellular S1P and failed to form myotubes under conditions that normally stimulate myogenic differentiation. Under differentiation conditions, SPL-KD cells also demonstrated delayed induction of 3 myogenic microRNAs (miRNAs), miR-1, miR-206, and miR-486. SPL-KD cells successfully differentiated when treated with an S1P(1) agonist, S1P(2) antagonist, and combination treatments, which also increased myogenic miRNA levels. SPL-KD cells transfected with mimics for miR-1 or miR-206 also overcame the differentiation block. Thus, we show for the first time that the S1P/SPL/S1P-receptor axis regulates the expression of a number of miRNAs, thereby contributing to myogenic differentiation.de la Garza-Rodea, A. S., Baldwin, D. M., Oskouian, B., Place, R. F., Bandhuvula, P., Kumar, A., Saba, J. D. Sphingosine phosphate lyase regulates myogenic differentiation via S1P receptor-mediated effects on myogenic microRNA expression.	[de la Garza-Rodea, Anabel S.; Baldwin, Dianna M.; Oskouian, Babak; Place, Robert F.; Bandhuvula, Padmavathi; Kumar, Ashok; Saba, Julie D.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; [Baldwin, Dianna M.] San Francisco State Univ, San Francisco, CA 94132 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; California State University System; San Francisco State University	Saba, JD (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	jsaba@chori.org			U.S. National Institutes of Health [GM66954]; Muscular Dystrophy Association [MDA217712]; Minority Biomedical Research Support-Research Initiative for Scientific Enhancement (MBRS-RISE) [5R25GM59298-12]; California Institute of Regenerative Medicine (CIRM) Bridges grant [TB1-01194]; CIRM clinical fellowship [TG2-01164]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066954, R25GM059298] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Minority Biomedical Research Support-Research Initiative for Scientific Enhancement (MBRS-RISE); California Institute of Regenerative Medicine (CIRM) Bridges grant; CIRM clinical fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are grateful to Abeer Eltanawy, Julia Weisbrod, and Rashed Abu-Alia for technical support and N. Cronen for expert administrative assistance. These studies were supported by U.S. National Institutes of Health grant GM66954, Muscular Dystrophy Association grant MDA217712 and Minority Biomedical Research Support-Research Initiative for Scientific Enhancement (MBRS-RISE) grant 5R25GM59298-12 (to J.D.S.), California Institute of Regenerative Medicine (CIRM) Bridges grant TB1-01194 (to D. B.), and CIRM clinical fellowship TG2-01164 (to A.S.G.R.)	Anderson C, 2006, NUCLEIC ACIDS RES, V34, P5863, DOI 10.1093/nar/gkl743; Bandhuvula P, 2009, BIOCHEM BIOPH RES CO, V380, P366, DOI 10.1016/j.bbrc.2009.01.106; Becciolini L, 2006, BBA-MOL CELL BIOL L, V1761, P43, DOI 10.1016/j.bbalip.2006.01.006; Bektas M, 2010, J BIOL CHEM, V285, P10880, DOI 10.1074/jbc.M109.081489; Bruni P., 2013, HDB EXP PHARM, V216, P457, DOI [10.1007/978-3-7091-1511-4_23, DOI 10.1007/978-3-7091-1511-4_23]; Calhabeu F, 2013, ONCOGENE, V32, P651, DOI 10.1038/onc.2012.73; Calise S, 2012, BBA-MOL CELL RES, V1823, P439, DOI 10.1016/j.bbamcr.2011.11.016; Chen JF, 2010, J CELL BIOL, V190, P867, DOI 10.1083/jcb.200911036; Chu CY, 2007, J CELL PHYSIOL, V213, P412, DOI 10.1002/jcp.21230; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Danieli-Betto D, 2010, AM J PHYSIOL-CELL PH, V298, pC550, DOI 10.1152/ajpcell.00072.2009; Dey BK, 2011, MOL CELL BIOL, V31, P203, DOI 10.1128/MCB.01009-10; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; Donati C, 2007, FEBS LETT, V581, P4384, DOI 10.1016/j.febslet.2007.08.007; Formigli L, 2005, J CELL SCI, V118, P1161, DOI 10.1242/jcs.01695; Fyrst H, 2008, BBA-MOL CELL BIOL L, V1781, P448, DOI 10.1016/j.bbalip.2008.05.005; Fyrst H, 2010, NAT CHEM BIOL, V6, P489, DOI [10.1038/NCHEMBIO.392, 10.1038/nchembio.392]; Fyrst H, 2009, CANCER RES, V69, P9457, DOI 10.1158/0008-5472.CAN-09-2341; Germinario E, 2012, J APPL PHYSIOL, V113, P707, DOI 10.1152/japplphysiol.00300.2012; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Goljanek-Whysall K, 2012, J CELL SCI, V125, P3590, DOI 10.1242/jcs.101758; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Hisano Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038941; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449; Kelly RF, 2010, BASIC RES CARDIOL, V105, P763, DOI 10.1007/s00395-010-0125-0; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Kim RH, 2009, BBA-MOL CELL BIOL L, V1791, P692, DOI 10.1016/j.bbalip.2009.02.011; Kumar A, 2011, CELL SIGNAL, V23, P1144, DOI 10.1016/j.cellsig.2011.02.009; Kumar A, 2009, EXPERT OPIN THER TAR, V13, P1013, DOI 10.1517/14728220903039722; Loh KC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037218; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Meacci E, 2003, BBA-MOL CELL BIOL L, V1633, P133, DOI 10.1016/S1388-1981(03)00106-9; Nagata Y, 2006, J CELL BIOL, V174, P245, DOI 10.1083/jcb.200605028; Oskouian B, 2004, SEMIN CELL DEV BIOL, V15, P529, DOI 10.1016/j.semcdb.2004.05.009; Oskouian B, 2005, J BIOL CHEM, V280, P18403, DOI 10.1074/jbc.M410928200; Rapizzi E, 2008, MOL CELL BIOCHEM, V314, P193, DOI 10.1007/s11010-008-9780-y; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Sassoli C, 2011, J CELL MOL MED, V15, P2498, DOI 10.1111/j.1582-4934.2010.01250.x; Serra M, 2010, ADV ENZYME REGUL, V50, P349, DOI 10.1016/j.advenzreg.2009.10.024; Siehler S, 2001, J BIOL CHEM, V276, P48733, DOI 10.1074/jbc.M011072200; Siow DL, 2010, J LIPID RES, V51, P2546, DOI 10.1194/jlr.M004374; Small EM, 2010, P NATL ACAD SCI USA, V107, P4218, DOI 10.1073/pnas.1000300107; Spiegel S, 2012, ONCOGENE, V31, P537, DOI 10.1038/onc.2011.267; Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974; SULLARDS MC, 2001, SCI STKE, V67, P1; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Wang F, 1999, CANCER RES, V59, P6185; Zammit PS, 2006, J CELL SCI, V119, P1824, DOI 10.1242/jcs.02908; Zanin M, 2008, AM J PHYSIOL-CELL PH, V294, pC36, DOI 10.1152/ajpcell.00164.2007; Zhang K, 2007, EMBO J, V26, P1094, DOI 10.1038/sj.emboj.7601565	53	15	15	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					506	519		10.1096/fj.13-233155	http://dx.doi.org/10.1096/fj.13-233155			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24158395	Green Published			2022-12-28	WOS:000333526100047
J	Liu, CH; Ren, JQ; Liu, CM; Liu, PK				Liu, Christina H.; Ren, Jiaqian; Liu, Charng-Ming; Liu, Philip K.			Intracellular gene transcription factor protein-guided MRI by DNA aptamers in vivo	FASEB JOURNAL			English	Article						AP1 knockout; attention; monoamine oxidase A; stress; transgenic mice	LIVING BRAINS; CELL TRACKING; LIVE ANIMALS; ACUTE STRESS; EXPRESSION; PROBES; AMPHETAMINE; CONTRAST; EXPOSURE; DELIVERY	The mechanisms by which transcription factor (TF) protein AP-1 modulates amphetamine's effects on gene transcription in living brains are unclear. We describe here the first part of our studies to investigate these mechanisms, specifically, our efforts to develop and validate aptamers containing the binding sequence of TF AP-1 (5ECdsAP1), in order to elucidate its mechanism of action in living brains. This AP-1-targeting aptamer, as well as a random sequence aptamer with no target (5ECdsRan) as a control, was partially phosphorothioate modified and tagged with superparamagnetic iron oxide nanoparticles (SPIONs), gold, or fluorescein isothiothianate contrast agent for imaging. Optical and transmission electron microscopy studies revealed that 5ECdsAP1 is taken up by endocytosis and is localized in the neuronal endoplasmic reticulum. The results of magnetic resonance imaging (MRI) with SPION-5ECdsAP1 revealed that neuronal AP-1 TF protein levels were elevated in neurons of live male C57black6 mice after amphetamine exposure; however, pretreatment with SCH23390, a dopaminergic receptor antagonist, suppressed this elevation. As studies in transgenic mice with neuronal dominant-negative A-FOS mutant protein, which has no binding affinity for the AP-1 sequence, showed a completely null MRI signal in the striatum, we can conclude that the MR signal reflects specific binding between the 5ECdsAP1 aptamer and endogenous AP-1 protein. Together, these data lend support to the application of 5ECdsAP1 aptamer for intracellular protein-guided imaging and modulation of gene transcription, which will thus allow investigation of the mechanisms of signal transduction in living brains.Liu, C. H., Ren, J., Liu, C.-M., Liu, P. K. Intracellular gene transcription factor protein-guided MRI by DNA aptamers in vivo.	[Liu, Christina H.; Ren, Jiaqian; Liu, Charng-Ming; Liu, Philip K.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Liu, PK (corresponding author), Massachusetts Gen Hosp, CNY149 2301 Thirteenth St, Charlestown, MA 02129 USA.	philipl@nmr.mgh.harvard.edu		Liu, Christina/0000-0002-5723-177X	U.S. National Institutes of Health (NIH) [R01DK43351, R01DK57521]; National Institute on Drug Abuse [R01DA029889]; National Institute of Biomedical Imaging and Bioengineering [R01EB013768]; National Center for Alternative Medicine of the NIH [AT004974]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT004974] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR014075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB013768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521, P30DK043351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA029889] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); National Center for Alternative Medicine of the NIH; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Dr. M. Schwartzchild for allowing them to use the locomotion detection device. The authors also thank Dr. C. Vinson (National Cancer Institute, Frederick, MD, USA) for use of the double-transgenic A-FOS mutant mouse strain, Dr. H. Prentice for reading and critical evaluation, and Ms. N. Eusemann for assistance with editing the manuscript. The authors appreciate the help of M. McKee with TEM and the availability of the Massachusetts General Hospital Microscopy Core [supported by U.S. National Institutes of Health (NIH) grants R01DK43351 and R01DK57521]. This project was supported by research grants from the National Institute on Drug Abuse (R01DA029889), the National Institute of Biomedical Imaging and Bioengineering (R01EB013768), and the National Center for Alternative Medicine (AT004974) of the NIH.	BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; Berman SC, 2011, MAGN RESON MED, V65, P564, DOI 10.1002/mrm.22613; Bonovich M, 2002, CANCER GENE THER, V9, P62, DOI 10.1038/sj/cgt/7700409; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; Brody SA, 2003, PSYCHOPHARMACOLOGY, V169, P240, DOI 10.1007/s00213-003-1421-2; Bulte JWM, 2004, METHOD ENZYMOL, V386, P275; Fitzgerald ML, 2007, J LIPID RES, V48, P621, DOI 10.1194/jlr.M600449-JLR200; Hogemann D, 2000, BIOCONJUGATE CHEM, V11, P941, DOI 10.1021/bc000079x; Ichikawa T, 2002, NEOPLASIA, V4, P523, DOI 10.1038/sj.neo.7900266; Komatsu T, 2011, MECH AGEING DEV, V132, P103, DOI 10.1016/j.mad.2011.01.002; Lind K, 2002, J DRUG TARGET, V10, P221, DOI 10.1080/10611860290022651; Liu CH, 2004, MAGN RESON MED, V51, P978, DOI 10.1002/mrm.20047; Liu CH, 2008, FASEB J, V22, P1193, DOI 10.1096/fj.07-9557com; Liu CH, 2007, FASEB J, V21, P3004, DOI 10.1096/fj.07-8203com; Liu CH, 2007, J NEUROSCI, V27, P713, DOI 10.1523/JNEUROSCI.4660-06.2007; Liu CH, 2013, FASEB J, V27, P712, DOI 10.1096/fj.12-220061; Liu CH, 2012, FASEB J, V26, P1652, DOI 10.1096/fj.11-199547; Liu CH, 2009, J NEUROSCI, V29, P10663, DOI 10.1523/JNEUROSCI.2167-09.2009; Liu PK, 2008, NEUROSCIENTIST, V14, P503, DOI 10.1177/1073858407309746; LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405; MULDOON LL, 1995, AM J PATHOL, V147, P1840; Paletzki RF, 2008, NEUROSCIENCE, V152, P1040, DOI 10.1016/j.neuroscience.2008.01.045; Soliman A, 2012, J NEUROSCI, V32, P17120, DOI 10.1523/JNEUROSCI.2091-12.2012; SORENSEN AG, 1995, AM J NEURORADIOL, V16, P1753; Sterrenburg L, 2012, J NEUROSCI RES, V90, P179, DOI 10.1002/jnr.22737; Strome EM, 2002, P NATL ACAD SCI USA, V99, P15749, DOI 10.1073/pnas.232480899; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; Zhang ZM, 2001, NEUROIMAGE, V14, P1159, DOI 10.1006/nimg.2001.0902; Zhu XM, 2012, INT J NANOMED, V7, P953, DOI 10.2147/IJN.S28316; ZIMMER C, 1995, RADIOLOGY, V196, P521, DOI 10.1148/radiology.196.2.7617871	30	16	16	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					464	473		10.1096/fj.13-234229	http://dx.doi.org/10.1096/fj.13-234229			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24115049	Green Published			2022-12-28	WOS:000333526100043
J	Jiang, Y; Gong, P; Madak-Erdogan, Z; Martin, T; Jeyakumar, M; Carlson, K; Khan, I; Smillie, TJ; Chittiboyina, AG; Rotte, SCK; Helferich, WG; Katzenellenbogen, JA; Katzenellenbogen, BS				Jiang, Yan; Gong, Ping; Madak-Erdogan, Zeynep; Martin, Teresa; Jeyakumar, Muthu; Carlson, Kathryn; Khan, Ikhlas; Smillie, Troy J.; Chittiboyina, Amar G.; Rotte, Sateesh C. K.; Helferich, William G.; Katzenellenbogen, John A.; Katzenellenbogen, Benita S.			Mechanisms enforcing the estrogen receptor beta selectivity of botanical estrogens	FASEB JOURNAL			English	Article						chromatin binding; gene regulation; proliferation; breast cancer cells	BREAST-CANCER CELLS; MILD COGNITIVE IMPAIRMENT; THYROID-HORMONE RECEPTOR; HEALTH INITIATIVE MEMORY; POSTMENOPAUSAL WOMEN; PLUS PROGESTIN; ER-BETA; COACTIVATOR BINDING; DISSOCIATION RATE; RANDOMIZED-TRIAL	Because little is known about the actions of botanical estrogens (BEs), widely consumed by menopausal women, we investigated the mechanistic and cellular activities of some major BEs. We examined the interactions of genistein, daidzein, equol, and liquiritigenin with estrogen receptors ER and ER, with key coregulators (SRC3 and RIP140) and chromatin binding sites, and the regulation of gene expression and proliferation in MCF-7 breast cancer cells containing ER and/or ER. Unlike the endogenous estrogen, estradiol (E2), BEs preferentially bind to ER, but their ER-potency selectivity in gene stimulation (340- to 830-fold vs. E2) is enhanced at several levels (coregulator recruitment, chromatin binding); nevertheless, at high (0.1 or 1 M) concentrations, BEs also fully activate ER. Because ER drives breast cancer cell proliferation and ER dampens this, the relative levels of these two ERs in target cells and the BE dose greatly affect gene expression and proliferative response and will be crucial determinants of the potential benefits vs. risks of BEs. Our findings reveal key and novel mechanistic differences in the estrogenic activities of BEs vs. E2, with BEs displaying patterns of activity distinctly different from those seen with E2 and provide valuable information to inform future studies.Jiang, Y., Gong, P., Madak-Erdogan, Z., Martin, T., Jeyakumar, M., Carlson, K., Khan, I., Smillie, T. J., Chittiboyina, A. G., Rotte, S. C. K., Helferich, W. G., Katzenellenbogen, J. A., Katzenellenbogen, B. S. Mechanisms enforcing the estrogen receptor selectivity of botanical estrogens.	[Jiang, Yan; Gong, Ping; Madak-Erdogan, Zeynep; Katzenellenbogen, Benita S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; [Martin, Teresa; Jeyakumar, Muthu; Carlson, Kathryn; Katzenellenbogen, John A.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Helferich, William G.] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; [Khan, Ikhlas; Smillie, Troy J.; Chittiboyina, Amar G.; Rotte, Sateesh C. K.] Univ Mississippi, Natl Ctr Nat Prod Res, Oxford, MS USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Mississippi	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.	katzenel@illinois.edu	Chittiboyina, Amar G/F-4898-2016; Khan, Ikhlas/AAA-1490-2020; Khan, Ikhlas/AAA-1829-2020	Chittiboyina, Amar G/0000-0002-7047-5373; Madak-Erdogan, Zeynep/0000-0003-2607-1643	U.S. National Institutes of Health (NIH) from the National Center for Complementary and Alternative Medicines (NCCAM) [P50AT006268]; Office of Dietary Supplements (ODS); National Cancer Institute (NCI); NIH [T32ES007326]; National Center for Complementary & Integrative Health [P50AT006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007326] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) from the National Center for Complementary and Alternative Medicines (NCCAM); Office of Dietary Supplements (ODS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This project was made possible by U.S. National Institutes of Health (NIH) grant P50AT006268 (to W. G. H., I. K., B. S. K., and J.A.K.) from the National Center for Complementary and Alternative Medicines (NCCAM), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, ODS, NCI, or NIH. Partial support to Z.M.E. and T. M. was from NIH T32ES007326.	Allred CD, 2001, CANCER RES, V61, P5045; Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; Barnett DH, 2008, CANCER RES, V68, P3505, DOI 10.1158/0008-5472.CAN-07-6151; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Butler LM, 2010, AM J CLIN NUTR, V91, P1013, DOI 10.3945/ajcn.2009.28572; Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l; Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Charn TH, 2010, MOL ENDOCRINOL, V24, P47, DOI 10.1210/me.2009-0252; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Choi I, 2001, MOL CELL ENDOCRINOL, V181, P139, DOI 10.1016/S0303-7207(01)00492-0; Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269; Gruvberger-Saal SK, 2007, CLIN CANCER RES, V13, P1987, DOI 10.1158/1078-0432.CCR-06-1823; Gunther JR, 2009, J BIOMOL SCREEN, V14, P181, DOI 10.1177/1087057108329349; Harrington WR, 2006, ENDOCRINOLOGY, V147, P3843, DOI 10.1210/en.2006-0358; Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459; Hartman J, 2012, STEROIDS, V77, P1262, DOI 10.1016/j.steroids.2012.07.002; Heemstra JM, 2006, ORG LETT, V8, P5441, DOI 10.1021/ol0620444; Hilakivi-Clarke L, 2010, J NUTR, V140, p2326S, DOI 10.3945/jn.110.124230; Hsieh CY, 1998, CANCER RES, V58, P3833; Huntley AL, 2004, MATURITAS, V47, P1, DOI 10.1016/S0378-5122(03)00221-4; Jeyakumar M, 2008, BIOCHEMISTRY-US, V47, P7465, DOI 10.1021/bi800393u; Jeyakumar M, 2009, ANAL BIOCHEM, V386, P73, DOI 10.1016/j.ab.2008.11.039; Jeyakunnar M, 2011, J BIOL CHEM, V286, P12971, DOI 10.1074/jbc.M110.205112; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; KATZENELLENBOGEN JA, 1973, BIOCHEMISTRY-US, V12, P4092, DOI 10.1021/bi00745a011; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Levis S, 2011, ARCH INTERN MED, V171, P1363, DOI 10.1001/archinternmed.2011.330; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Madak-Erdogan Z, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.28; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Mersereau JE, 2008, MOL CELL ENDOCRINOL, V283, P49, DOI 10.1016/j.mce.2007.11.020; Muthyala RS, 2004, BIOORGAN MED CHEM, V12, P1559, DOI 10.1016/j.bmc.2003.11.035; Nilsson S, 2011, NAT REV DRUG DISCOV, V10, P778, DOI 10.1038/nrd3551; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Paruthiyil S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006271; Peterson TG, 1998, AM J CLIN NUTR, V68, p1505S, DOI 10.1093/ajcn/68.6.1505S; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Pitkin Joan, 2012, Menopause Int, V18, P20, DOI 10.1258/mi.2012.012001; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Sacks FM, 2006, CIRCULATION, V113, P1034, DOI 10.1161/CIRCULATIONAHA.106.171052; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Saji S, 2005, CANCER CHEMOTH PHARM, V56, pS21, DOI 10.1007/s0028-005-0107-3; Sareddy GR, 2012, MOL CANCER THER, V11, P1174, DOI 10.1158/1535-7163.MCT-11-0960; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Simmler C, 2013, J AGR FOOD CHEM, V61, P2146, DOI 10.1021/jf304445p; Siow RCM, 2007, FREE RADICAL BIO MED, V42, P909, DOI 10.1016/j.freeradbiomed.2007.01.004; Speirs V, 2004, LANCET ONCOL, V5, P174, DOI 10.1016/S1470-2045(04)01413-5; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Taku K, 2012, MENOPAUSE, V19, P776, DOI 10.1097/gme.0b013e3182410159; Tamrazi A, 2002, MOL ENDOCRINOL, V16, P2706, DOI 10.1210/me.2002-0250; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; Wong JMW, 2012, AM J CLIN NUTR, V95, P564, DOI 10.3945/ajcn.111.017418	60	74	75	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4406	4418		10.1096/fj.13-234617	http://dx.doi.org/10.1096/fj.13-234617			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23882126	Green Published			2022-12-28	WOS:000329937500009
J	Fullston, T; Teague, EMCO; Palmer, NO; DeBlasio, MJ; Mitchell, M; Corbett, M; Print, CG; Owens, JA; Lane, M				Fullston, Tod; Teague, E. Maria C. Ohlsson; Palmer, Nicole O.; DeBlasio, Miles J.; Mitchell, Megan; Corbett, Mark; Print, Cristin G.; Owens, Julie A.; Lane, Michelle			Paternal obesity initiates metabolic disturbances in two generations of mice with incomplete penetrance to the F-2 generation and alters the transcriptional profile of testis and sperm microRNA content	FASEB JOURNAL			English	Article						nongenetic transmission; epigenetic alteration; methylation; DNA damage; ROS	BODY-MASS INDEX; HIGH-FAT DIET; SEMEN QUALITY; REPRODUCTIVE HORMONES; HUMAN SPERMATOZOA; MIRNA EXPRESSION; GENE-EXPRESSION; RNA; IMPACT; TIME	Obesity is highly prevalent, and its incidence is increasing. The previous study showing a major effect of paternal obesity on metabolic health of offspring is confounded by comorbidity with diabetes. Therefore, we investigated the effect of diet-induced paternal obesity, in the absence of diabetes, on the metabolic health of two resultant generations and the molecular profiles of the testes and sperm. Founder (F-0) male C57BL6 mice were fed either a high-fat diet (HFD) or a control diet (CD); n = 10/diet for a period of 10 wk. Testis expression of mRNA/microRNAs was analyzed by microarray and qPCR and sperm microRNA abundance by qPCR. Two subsequent generations were generated by mating F-0 and then F-1 mice to CD mice, and their metabolic health was investigated. All mice, other than F-0 males, were maintained on a CD. HFD feeding induced paternal obesity with a 21% increase in adiposity, but not overt diabetes, and initiated intergenerational transmission of obesity and insulin resistance in two generations of offspring. This distinct phenotypic constellation is either partially or fully transmitted to both female and male F-1 offspring and further transmitted through both parental lineages to the F-2 generation, with a heightened effect on female F-1 offspring (+67% in adiposity) and their F-2 sons (+24% in adiposity). Founder male obesity altered the testes expression of 414 mRNAs by microarray and 11 microRNAs by qPCR, concomitant with alterations in sperm microRNA content and a 25% reduction in global methylation of germ cell DNA. Diet-induced paternal obesity modulates sperm microRNA content and germ cell methylation status, which are potential signals that program offspring health and initiate the transmission of obesity and impaired metabolic health to future generations. This study implicates paternal obesity in the transgenerational amplification of obesity and type 2 diabetes in humans.Fullston, T., Ohlsson Teague, E. M. C., Palmer, N. O., DeBlasio, M. J., Mitchell, M., Corbett, M., Print, C. G., Owens, J. A., Lane, M. Paternal obesity initiates metabolic disturbances in two generations of mice with incomplete penetrance to the F-2 generation and alters the transcriptional profile of testis and sperm microRNA content.	[Fullston, Tod; Teague, E. Maria C. Ohlsson; Palmer, Nicole O.; DeBlasio, Miles J.; Mitchell, Megan; Owens, Julie A.; Lane, Michelle] Univ Adelaide, Discipline Obstet & Gynaecol, Adelaide, SA 5005, Australia; [Corbett, Mark] Univ Adelaide, Discipline Paediat, Sch Paediat & Reprod Hlth, Robinson Inst, Adelaide, SA 5005, Australia; [Print, Cristin G.] Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand; [Print, Cristin G.] Univ Auckland, New Zealand Bioinformat Inst, Auckland 1, New Zealand; [Lane, Michelle] Repromed, Adelaide, SA, Australia	University of Adelaide; Robinson Research Institute; University of Adelaide; University of Auckland; University of Auckland	Fullston, T (corresponding author), Univ Adelaide, Level 3 Med Sch South, Adelaide, SA 5005, Australia.	tod.fullston@adelaide.edu.au	Mitchell, Megan/CAG-5875-2022; De Blasio, Miles/D-5460-2011; Corbett, Mark/A-8063-2010; Mitchell, Megan/CAG-5838-2022; De Blasio, Miles J/GQB-1536-2022; Owens, Julie A/C-9744-2009; De Blasio, Miles/AAB-7234-2019	Mitchell, Megan/0000-0002-4284-2201; Corbett, Mark/0000-0001-9298-3072; Mitchell, Megan/0000-0002-4284-2201; De Blasio, Miles J/0000-0002-4797-5193; Owens, Julie A/0000-0002-7498-1353; De Blasio, Miles/0000-0002-4797-5193; Print, Cristin/0000-0001-8345-7812	National Health and Medical Research Council (NHMRC); M. S. McLeod Research Fund Fellowship	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); M. S. McLeod Research Fund Fellowship	The authors acknowledge the intellectual input of Hassan W. Bakos at the conception of the study and the technical contributions of Samantha Schulz and Verity Bell (School of Pediatrics and Reproductive Health, University of Adelaide). The authors also thank Daniel Hurley and Vicky Fan (University of Auckland) for bioinformatic support. This work was supported by a National Health and Medical Research Council (NHMRC) program grant awarded to M.L. ML. is the recipient of an NHMRC Senior Research Fellowship. T.F. is the recipient of an NHMRC Early Career Research Fellowship. M.C. is a recipient of an M. S. McLeod Research Fund Fellowship. The authors declare no conflicts of interest. T.F., E.M.C.O.T., N.O.P., M.M., J.A.O., and M.L. designed the experiments. T.F., E.M.C.O.T., N.O.P., M.J.D. and M.L. executed the experiments. All authors contributed to data analysis and interpretation. T.F., J.A.O., and M.L. prepared the manuscript. All authors reviewed and approved the final manuscript.	Abd El Naby WS, 2013, ZYGOTE, V21, P31, DOI 10.1017/S0967199411000566; Abu-Halima M, 2013, FERTIL STERIL, V99, P1249, DOI 10.1016/j.fertnstert.2012.11.054; Adiga SK, 2010, FERTIL STERIL, V93, P2486, DOI 10.1016/j.fertnstert.2009.06.015; Bakos HW, 2011, INT J ANDROL, V34, P402, DOI 10.1111/j.1365-2605.2010.01092.x; Bakos HW, 2011, FERTIL STERIL, V95, P1700, DOI 10.1016/j.fertnstert.2010.11.044; Bedzhov I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002609; Begg S., 2007, BURDEN DIS INJURY AU; Bhat GK, 2006, J ANDROL, V27, P302, DOI 10.2164/jandrol.05133; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Chavarro JE, 2010, FERTIL STERIL, V93, P2222, DOI 10.1016/j.fertnstert.2009.01.100; Chen YX, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-407; Chong MMW, 2010, GENE DEV, V24, P1951, DOI 10.1101/gad.1953310; Danielzik S, 2002, EUR J NUTR, V41, P132, DOI 10.1007/s00394-002-0367-1; Dar AA, 2011, J BIOL CHEM, V286, P16606, DOI 10.1074/jbc.M111.227611; Das S, 2013, ONCOGENE, V32, P2927, DOI 10.1038/onc.2012.311; De Blasio MJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE75, DOI 10.1152/ajpendo.00689.2006; Dunn GA, 2011, ENDOCRINOLOGY, V152, P2228, DOI 10.1210/en.2010-1461; Dunn GA, 2011, HORM BEHAV, V59, P290, DOI 10.1016/j.yhbeh.2010.05.004; Dunn GA, 2009, ENDOCRINOLOGY, V150, P4999, DOI 10.1210/en.2009-0500; El Hajj N, 2011, SEX DEV, V5, P60, DOI 10.1159/000323806; Fall CHD, 2011, ANN HUM BIOL, V38, P410, DOI 10.3109/03014460.2011.592513; Fejes I, 2005, ANDROLOGIA, V37, P155, DOI 10.1111/j.1439-0272.2005.00671.x; Freeman E, 2012, INT J OBESITY, V36, P12, DOI 10.1038/ijo.2011.198; Fullston T, 2012, HUM REPROD, V27, P1391, DOI 10.1093/humrep/des030; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghanayem BI, 2010, BIOL REPROD, V82, P96, DOI 10.1095/biolreprod.109.078915; Git A, 2010, RNA, V16, P991, DOI 10.1261/rna.1947110; Gong ZW, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/320482; Grandjean V, 2009, GYNECOL OBSTET FERTI, V37, P558, DOI 10.1016/j.gyobfe.2009.04.005; Grandjean V, 2009, DEVELOPMENT, V136, P3647, DOI 10.1242/dev.041061; Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100; Hammoud AO, 2008, FERTIL STERIL, V90, P2222, DOI 10.1016/j.fertnstert.2007.10.011; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Howie GJ, 2009, J PHYSIOL-LONDON, V587, P905, DOI 10.1113/jphysiol.2008.163477; Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300; Iimura T, 2007, DEV GROWTH DIFFER, V49, P265, DOI 10.1111/j.1440-169x.2007.00928.x; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jensen TK, 2004, FERTIL STERIL, V82, P863, DOI 10.1016/j.fertnstert.2004.03.056; Kort HI, 2006, J ANDROL, V27, P450, DOI 10.2164/jandrol.05124; Krawetz SA, 2005, NAT REV GENET, V6, P633, DOI 10.1038/nrg1654; Lane M, 2002, HUM REPROD, V17, P2686, DOI 10.1093/humrep/17.10.2686; Leibel NI, 2006, J CLIN ENDOCR METAB, V91, P1275, DOI 10.1210/jc.2005-1707; Li L, 2009, AM J CLIN NUTR, V89, P551, DOI 10.3945/ajcn.2008.26759; Lin CC, 2008, INT J OCCUP ENV HEAL, V14, P112, DOI 10.1179/oeh.2008.14.2.112; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Liu WM, 2012, P NATL ACAD SCI USA, V109, P490, DOI 10.1073/pnas.1110368109; Ma J, 2010, CURR BIOL, V20, P265, DOI 10.1016/j.cub.2009.12.042; MacDonald AA, 2010, HUM REPROD UPDATE, V16, P293, DOI 10.1093/humupd/dmp047; Madison-Villar MJ, 2011, J MOL EVOL, V73, P316, DOI 10.1007/s00239-011-9478-8; Magnusdottir EV, 2005, HUM REPROD, V20, P208, DOI 10.1093/humrep/deh569; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Marczylo EL, 2012, EPIGENETICS-US, V7, P432, DOI 10.4161/epi.19794; Mitchell M, 2011, FERTIL STERIL, V95, P1349, DOI 10.1016/j.fertnstert.2010.09.038; Morey JS, 2006, BIOL PROCED ONLINE, V8, P175, DOI 10.1251/bpo126; NASRESFAHANI MH, 1990, DEVELOPMENT, V109, P501; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Nguyen DM, 2010, GASTROENTEROL CLIN N, V39, P1, DOI 10.1016/j.gtc.2009.12.014; Ning HX, 2009, DIFFERENTIATION, V78, P253, DOI 10.1016/j.diff.2009.07.009; Ogus S, 2003, ENDOCRINOLOGY, V144, P2865, DOI 10.1210/en.2002-0178; Ostermeier GC, 2005, J ANDROL, V26, P70; Ostermeier GC, 2004, NATURE, V429, P154, DOI 10.1038/429154a; Palmer NO, 2012, AM J PHYSIOL-ENDOC M, V302, pE768, DOI 10.1152/ajpendo.00401.2011; Palmer NO, 2011, REPROD FERT DEVELOP, V23, P929, DOI 10.1071/RD10326; Piovan C, 2012, MOL ONCOL, V6, P458, DOI 10.1016/j.molonc.2012.03.003; Pradervand S, 2010, BIOTECHNIQUES, V48, P219, DOI 10.2144/000113367; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Rassoulzadegan M, 2010, ORGANOGENESIS, V6, P33, DOI 10.4161/org.6.1.11094; Santulli G, 2012, DIABETES, V61, P692, DOI 10.2337/db11-1027; Smith ZD, 2012, NATURE, V484, P339, DOI 10.1038/nature10960; Suh N, 2010, CURR BIOL, V20, P271, DOI 10.1016/j.cub.2009.12.044; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Tanic M, 2012, BREAST CANCER RES TR, V134, P41, DOI 10.1007/s10549-011-1905-4; Tripurani SK, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-25; Tunc O, 2011, ANDROLOGIA, V43, P121, DOI 10.1111/j.1439-0272.2009.01032.x; Tunc O, 2009, J ASSIST REPROD GEN, V26, P537, DOI 10.1007/s10815-009-9346-2; van der Heijden GW, 2006, DEV BIOL, V298, P458, DOI 10.1016/j.ydbio.2006.06.051; Wagner KD, 2008, DEV CELL, V14, P962, DOI 10.1016/j.devcel.2008.03.009; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Ward WS, 2010, MOL HUM REPROD, V16, P30, DOI 10.1093/molehr/gap080; Whitaker KL, 2010, AM J CLIN NUTR, V91, P1560, DOI 10.3945/ajcn.2009.28838; Yamauchi Y, 2011, ASIAN J ANDROL, V13, P31, DOI 10.1038/aja.2010.75; Yauk C, 2008, P NATL ACAD SCI USA, V105, P605, DOI 10.1073/pnas.0705896105; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Youngson NA, 2011, ASIAN J ANDROL, V13, P195, DOI 10.1038/aja.2010.163	85	365	380	2	76	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4226	4243		10.1096/fj.12-224048	http://dx.doi.org/10.1096/fj.12-224048			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23845863				2022-12-28	WOS:000329747100033
J	Michel, PP; Toulorge, D; Guerreiro, S; Hirsch, EC				Michel, Patrick P.; Toulorge, Damien; Guerreiro, Serge; Hirsch, Etienne C.			Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease	FASEB JOURNAL			English	Review						calcium; electrical activity; neurodegeneration	CALCIUM-CHANNEL BLOCKERS; NIGRA-PARS-COMPACTA; NOCICEPTIN/ORPHANIN FQ RECEPTOR; PROGRESSIVE SUPRANUCLEAR PALSY; CA2+-ACTIVATED K+ CHANNELS; MIDBRAIN SLICE CULTURES; P-CONTAINING NEURONS; SUBSTANTIA-NIGRA; PEDUNCULOPONTINE NUCLEUS; ENDOPLASMIC-RETICULUM	Parkinson disease (PD) is a degenerative brain disorder characterized by motor symptoms that are unequivocally associated with the loss of dopaminergic (DA) neurons in the substantia nigra (SN). Although our knowledge of the mechanisms that contribute to DA cell death in both hereditary and sporadic forms of the disease has advanced significantly, the nature of the pathogenic process remains poorly understood. In this review, we present evidence that neurodegeneration occurs when the electrical activity and excitability of these neurons is reduced. In particular, we will focus on the specific need these neurons may have for stimulation in order to survive and on the molecular and cellular mechanisms that may be compromised when this need is no longer met in PD.Michel, P. P., Toulorge, D., Guerreiro, S., Hirsch, E. C. Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease.	[Michel, Patrick P.; Toulorge, Damien; Guerreiro, Serge; Hirsch, Etienne C.] Univ Paris 06, Inst Cerveau & Moelle Epiniere, Ctr Rech, UMR S975, Paris, France; [Michel, Patrick P.; Toulorge, Damien; Guerreiro, Serge; Hirsch, Etienne C.] INSERM, UMR 975, Paris, France; [Michel, Patrick P.; Toulorge, Damien; Guerreiro, Serge; Hirsch, Etienne C.] CNRS, UMR 7225, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Michel, PP (corresponding author), Hop La Pitie Salpetriere, Inst Cerveau & Moelle Epiniere, 47 Bd Hop, F-75013 Paris, France.	patrick-pierre.michel@upmc.fr	Michel, Patrick Pierre/J-5248-2019; Hirsch, Etienne/AAC-7655-2019	Michel, Patrick Pierre/0000-0001-5607-3119; Hirsch, Etienne/0000-0003-4823-276X; Toulorge, Damien/0000-0002-9651-8132; Guerreiro, Serge/0000-0003-1744-6351	Institut National de la Sante et de la Recherche Medicale; Fondation pour la Recherche Medicale; program Investissements d'Avenir [ANR-10-IAIHU- 06]; Association France Parkinson	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); program Investissements d'Avenir(French National Research Agency (ANR)); Association France Parkinson	Recent work by the authors mentioned in this review received financial support from Institut National de la Sante et de la Recherche Medicale and Fondation pour la Recherche Medicale (to D.T.). P.P.M. gratefully acknowledges support from the program Investissements d'Avenir (ANR-10-IAIHU- 06) and Association France Parkinson.	Adams DJ, 2012, BRIT J PHARMACOL, V166, P486, DOI 10.1111/j.1476-5381.2011.01781.x; Alvarez-Fischer D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061700; Aumann T, 2012, J NEUROCHEM, V121, P497, DOI 10.1111/j.1471-4159.2012.07703.x; Bao L, 2005, J NEUROSCI, V25, P10029, DOI 10.1523/JNEUROSCI.2652-05.2005; BOLAM JP, 1990, BRAIN RES, V529, P57, DOI 10.1016/0006-8993(90)90811-O; Brosenitsch TA, 2001, J NEUROSCI, V21, P2571, DOI 10.1523/JNEUROSCI.21-08-02571.2001; Cali T, 2012, J BIOL CHEM, V287, P18478, DOI [10.1074/jbc.M111.304733, 10.1074/jbc.M111.302794]; Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030; Choi YM, 2009, NEUROSCIENCE, V160, P587, DOI 10.1016/j.neuroscience.2009.02.067; Chu JMT, 2011, NEUROPHARMACOLOGY, V61, P1389, DOI 10.1016/j.neuropharm.2011.08.027; Corti O, 2011, PHYSIOL REV, V91, P1161, DOI 10.1152/physrev.00022.2010; Counts SE, 2002, J NEUROCHEM, V83, P442, DOI 10.1046/j.1471-4159.2002.01148.x; Dagher A, 2009, NEURON, V61, P502, DOI 10.1016/j.neuron.2009.01.031; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; Domanskyi A, 2011, FASEB J, V25, P2898, DOI 10.1096/fj.11-181958; Doo AR, 2010, NEUROL RES, V32, pS88, DOI 10.1179/016164109X12537002794282; Douhou A, 2001, J NEUROCHEM, V78, P163, DOI 10.1046/j.1471-4159.2001.00401.x; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; Evans RM, 2010, J BIOL CHEM, V285, P1032, DOI 10.1074/jbc.M109.040634; Ferrer I, 2011, J NEURAL TRANSM, V118, P821, DOI 10.1007/s00702-010-0482-8; GAI WP, 1991, BRAIN, V114, P2253, DOI 10.1093/brain/114.5.2253; GONON FG, 1985, NEUROSCIENCE, V14, P765, DOI 10.1016/0306-4522(85)90141-1; Good CH, 2011, FASEB J, V25, P1333, DOI 10.1096/fj.10-173625; GRACE AA, 1984, J NEUROSCI, V4, P2866; Grillner P, 2002, BEHAV BRAIN RES, V130, P149, DOI 10.1016/S0166-4328(01)00418-1; Guerreiro S, 2008, MOL PHARMACOL, V74, P980, DOI 10.1124/mol.108.048207; Guerreiro S, 2009, J NEUROCHEM, V109, P1118, DOI 10.1111/j.1471-4159.2009.06040.x; HALLIDAY GM, 1990, NEUROSCIENCE, V39, P81, DOI 10.1016/0306-4522(90)90223-Q; He XB, 2011, STEM CELLS, V29, P1861, DOI 10.1002/stem.739; Hernan MA, 2002, ANN NEUROL, V52, P276, DOI 10.1002/ana.10277; Herrik KF, 2010, J NEUROPHYSIOL, V104, P1726, DOI 10.1152/jn.01126.2009; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; HIRSCH EC, 1987, P NATL ACAD SCI USA, V84, P5976, DOI 10.1073/pnas.84.16.5976; Holmes A., 2006, CNS & Neurological Disorders-Drug Targets, V5, P225, DOI 10.2174/187152706776359600; JELLINGER K, 1988, J NEUROL NEUROSUR PS, V51, P540, DOI 10.1136/jnnp.51.4.540; Jeyarasasingam G, 2002, NEUROSCIENCE, V109, P275, DOI 10.1016/S0306-4522(01)00488-2; Kann O, 2007, AM J PHYSIOL-CELL PH, V292, pC641, DOI 10.1152/ajpcell.00222.2006; Karachi C, 2010, J CLIN INVEST, V120, P2745, DOI 10.1172/JCI42642; Katsuki H, 2003, NEUROSCI LETT, V341, P123, DOI 10.1016/S0304-3940(03)00176-9; Katsuki H, 2001, NEUROSCI LETT, V300, P166, DOI 10.1016/S0304-3940(01)01570-1; Kim SR, 2011, NEUROBIOL DIS, V44, P215, DOI 10.1016/j.nbd.2011.07.003; KITA T, 1986, BRAIN RES, V372, P21, DOI 10.1016/0006-8993(86)91454-X; Lannuzel A, 2008, MOVEMENT DISORD, V23, P2122, DOI 10.1002/mds.22300; Lasaga M, 2011, PEPTIDES, V32, P1972, DOI 10.1016/j.peptides.2011.07.009; Lee CR, 2009, J NEURAL TRANSM-SUPP, P71, DOI 10.1007/978-3-211-92660-4_6; Li W, 2007, J CELL PHYSIOL, V212, P348, DOI 10.1002/jcp.21007; Li XT, 2010, J NEUROSCI, V30, P1788, DOI 10.1523/JNEUROSCI.5604-09.2010; Liss B, 2005, NAT NEUROSCI, V8, P1742, DOI 10.1038/nn1570; Liu Y, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-98; Livingstone PD, 2009, BIOCHEM PHARMACOL, V78, P744, DOI 10.1016/j.bcp.2009.06.004; Luscher C, 2010, NAT REV NEUROSCI, V11, P301, DOI 10.1038/nrn2834; Lyng GD, 2007, BRAIN RES, V1133, P1, DOI 10.1016/j.brainres.2006.11.053; Marinelli M, 2000, J NEUROSCI, V20, P8876; Marras C, 2012, ANN NEUROL, V71, P362, DOI 10.1002/ana.22616; Martel P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020402; Marti M, 2005, J NEUROSCI, V25, P9591, DOI 10.1523/JNEUROSCI.2546-05.2005; Marti M, 2004, J NEUROSCI, V24, P6659, DOI 10.1523/JNEUROSCI.0987-04.2004; Marti M, 2010, MOVEMENT DISORD, V25, P1723, DOI 10.1002/mds.23271; Mena MA, 2006, EXPERT OPIN DRUG SAF, V5, P759, DOI 10.1517/14740338.5.6.759; Meredith Gloria E, 2008, Parkinsonism Relat Disord, V14 Suppl 2, pS112, DOI 10.1016/j.parkreldis.2008.04.012; Michel P. P., 2006, SCI STKE, V2006, ppe19; MICHEL PP, 1990, J NEUROCHEM, V54, P1102, DOI 10.1111/j.1471-4159.1990.tb01935.x; Michel PP, 1999, J NEUROCHEM, V72, P2074, DOI 10.1046/j.1471-4159.1999.0722074.x; NEDERGAARD S, 1993, J PHYSIOL-LONDON, V466, P727; Parain K, 2003, BRAIN RES, V984, P224, DOI 10.1016/S0006-8993(03)03195-0; Pasternak B, 2012, AM J EPIDEMIOL, V175, P627, DOI 10.1093/aje/kwr362; Patel JC, 2009, J NEUROSCI, V29, P6568, DOI 10.1523/JNEUROSCI.0181-09.2009; Quik M, 2012, MOVEMENT DISORD, V27, P947, DOI 10.1002/mds.25028; Ramirez-Latorre JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051610; REID MS, 1991, J NEUROCHEM, V57, P970, DOI 10.1111/j.1471-4159.1991.tb08245.x; Rice ME, 2011, NEUROSCIENCE, V198, P112, DOI 10.1016/j.neuroscience.2011.08.066; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Saad M, 2011, HUM MOL GENET, V20, P615, DOI 10.1093/hmg/ddq497; Salthun-Lassalle B, 2005, MOL PHARMACOL, V68, P1214, DOI 10.1124/mol.105.015453; Salthun-Lassalle B, 2004, J NEUROSCI, V24, P5922, DOI 10.1523/JNEUROSCI.5668-03.2004; Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485; Sato A, 2006, J CELL PHYSIOL, V209, P172, DOI 10.1002/jcp.20719; Schapira AH, 2011, MOVEMENT DISORD, V26, P1049, DOI 10.1002/mds.23732; Schulz JB, 2007, PARKINSONISM RELAT D, V13, pS306, DOI 10.1016/S1353-8020(08)70021-X; Selvaraj S, 2012, J CLIN INVEST, V122, P1354, DOI 10.1172/JCI61332; Selvaraj S, 2010, CNS NEUROL DISORD-DR, V9, P94, DOI 10.2174/187152710790966650; Sun HS, 2006, J NEUROPHYSIOL, V95, P2590, DOI 10.1152/jn.00970.2005; Suzuki S, 2013, J NEUROSCI RES, V91, P462, DOI 10.1002/jnr.23160; Teive WAG, 2004, PARKINSONISM RELAT D, V10, P243, DOI 10.1016/j.parkreldis.2003.12.004; Thacker EL, 2007, NEUROLOGY, V68, P764, DOI 10.1212/01.wnl.0000256374.50227.4b; Thompson AA, 2012, NATURE, V485, P395, DOI 10.1038/nature11085; Thomsen MS, 2012, J NEUROIMMUNOL, V251, P65, DOI 10.1016/j.jneuroim.2012.07.006; Toulorge D, 2011, FASEB J, V25, P2563, DOI 10.1096/fj.11-182824; Toulorge D, 2010, J NEUROCHEM, V114, P553, DOI 10.1111/j.1471-4159.2010.06785.x; Tsuneki H, 2000, EUR J NEUROSCI, V12, P2475, DOI 10.1046/j.1460-9568.2000.00138.x; Uslaner JM, 2012, NEUROPHARMACOLOGY, V62, P1413, DOI 10.1016/j.neuropharm.2010.11.015; Vassort G, 2006, CELL CALCIUM, V40, P205, DOI 10.1016/j.ceca.2006.04.025; Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004; Visanji NP, 2006, NEUROPHARMACOLOGY, V51, P506, DOI 10.1016/j.neuropharm.2006.04.015; Webling Kristin E B, 2012, Front Endocrinol (Lausanne), V3, P146, DOI 10.3389/fendo.2012.00146; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; Xu K, 2010, NEUROSCIENCE, V167, P475, DOI 10.1016/j.neuroscience.2010.02.020; Xu L, 2009, MOL PHARMACOL, V76, P872, DOI 10.1124/mol.109.057596; ZWEIG RM, 1989, ANN NEUROL, V26, P41, DOI 10.1002/ana.410260106	102	51	53	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3414	3423		10.1096/fj.12-220418	http://dx.doi.org/10.1096/fj.12-220418			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23699175				2022-12-28	WOS:000328840500001
J	Mu, XD; Usas, A; Tang, Y; Lu, AP; Wang, B; Weiss, K; Huard, J				Mu, Xiaodong; Usas, Arvydas; Tang, Ying; Lu, Aiping; Wang, Bing; Weiss, Kurt; Huard, Johnny			RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice	FASEB JOURNAL			English	Article						ROCK; mdx; utrophin; -SUP; intramyocellular lipid accumulation	DUCHENNE MUSCULAR-DYSTROPHY; FACTOR-KAPPA-B; INTRAMYOCARDIAL LIPID-ACCUMULATION; FATTY-ACID METABOLISM; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; SKELETAL-MUSCLE; INSULIN-RESISTANCE; PPAR-GAMMA; MDX MICE	Heterotopic ossification (HO) and fatty infiltration (FI) often occur in diseased skeletal muscle and have been previously described in various animal models of Duchenne muscular dystrophy (DMD); however, the pathological mechanisms remain largely unknown. Dystrophin-deficient mdx mice and dystrophin/utrophin double-knockout (dKO) mice are mouse models of DMD; however, mdx mice display a strong muscle regeneration capacity, while dKO mice exhibit a much more severe phenotype, which is similar to patients with DMD. Our results revealed that more extensive HO, but not FI, occurred in the skeletal muscle of dKO mice versus mdx mice, and RhoA activation specifically occurred at the sites of HO. Moreover, the gene expression of RhoA, BMPs, and several inflammatory factors were significantly up-regulated in muscle stem cells isolated from dKO mice; while inactivation of RhoA in the cells with RhoA/ROCK inhibitor Y-27632 led to reduced osteogenic potential and improved myogenic potential. Finally, inactivation of RhoA signaling in the dKO mice with Y-27632 improved muscle regeneration and reduced the expression of BMPs, inflammation, HO, and intramyocellular lipid accumulation in both skeletal and cardiac muscle. Our results revealed that RhoA represents a major molecular switch in the regulation of HO and muscle regeneration in dystrophic skeletal muscle of mice.Mu, X., Usas, A., Tang, Y., Lu, A., Wang, B., Weiss, K., Huard, J. RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice.	[Mu, Xiaodong; Usas, Arvydas; Tang, Ying; Lu, Aiping; Wang, Bing; Weiss, Kurt; Huard, Johnny] Univ Pittsburgh, Dept Orthopaed Surg, Stem Cell Res Ctr, Pittsburgh, PA 15219 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huard, J (corresponding author), Univ Pittsburgh, Dept Orthopaed Surg, Stem Cell Res Ctr, Bridgeside Point 2,Ste 206,450 Technol Dr, Pittsburgh, PA 15219 USA.	jhuard@pitt.edu			Henry J. Mankin endowed chair at the University of Pittsburgh; William F. and Jean W. Donaldson endowed chair at the Children's Hospital of Pittsburgh; NATIONAL INSTITUTE ON AGING [P30AG024827, P01AG043376] Funding Source: NIH RePORTER	Henry J. Mankin endowed chair at the University of Pittsburgh; William F. and Jean W. Donaldson endowed chair at the Children's Hospital of Pittsburgh; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported, in part, by the Henry J. Mankin endowed chair at the University of Pittsburgh, and the William F. and Jean W. Donaldson endowed chair at the Children's Hospital of Pittsburgh. The authors also thank Ms. Bria King and Mr. James Cummins for their editorial assistance in completing this manuscript.	Aghajanian A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008045; Ahmad N, 2010, J ULTRAS MED, V29, P367, DOI 10.7863/jum.2010.29.3.367; Amin RH, 2010, AM J PHYSIOL-ENDOC M, V298, pE28, DOI 10.1152/ajpendo.00446.2009; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Axelsen LN, 2010, AM J PHYSIOL-REG I, V298, pR1560, DOI 10.1152/ajpregu.00392.2009; Banovac K, 2004, SPINAL CORD, V42, P707, DOI 10.1038/sj.sc.3101628; Beqaj S, 2002, J CELL BIOL, V156, P893, DOI 10.1083/jcb.200107049; Bowerman M, 2010, HUM MOL GENET, V19, P1468, DOI 10.1093/hmg/ddq021; Castellani L, 2006, J BIOL CHEM, V281, P15249, DOI 10.1074/jbc.M601390200; Charrasse S, 2006, MOL BIOL CELL, V17, P749, DOI 10.1091/mbc.E05-04-0284; Ciaraldi TP, 2002, ANN NY ACAD SCI, V967, P66; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; Cox FM, 2011, RHEUMATOLOGY, V50, P1153, DOI 10.1093/rheumatology/ker001; Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635-200405000-00001; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Demer LL, 2002, INT J EPIDEMIOL, V31, P737, DOI 10.1093/ije/31.4.737; Duan DS, 2006, HUM MOL GENET, V15, pR253, DOI 10.1093/hmg/ddl180; Finsterer J, 2003, CARDIOLOGY, V99, P1, DOI 10.1159/000068446; Fromigue O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873; Gharaibeh B, 2008, NAT PROTOC, V3, P1501, DOI 10.1038/nprot.2008.142; Goto K, 2009, J PHARMACOL SCI, V110, P437, DOI 10.1254/jphs.09081FP; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Greenberg AS, 2011, J CLIN INVEST, V121, P2102, DOI 10.1172/JCI46069; HOLNESS CL, 1993, BLOOD, V81, P1607; Hosoyama T, 2009, DIFFERENTIATION, V77, P350, DOI 10.1016/j.diff.2008.11.001; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hulver MW, 2004, P NUTR SOC, V63, P375, DOI 10.1079/PNS2004351; IONASESCU V, 1981, J NEUROL SCI, V50, P249, DOI 10.1016/0022-510X(81)90171-4; Isaac C, 2013, J ORTHOP RES, V31, P343, DOI 10.1002/jor.22236; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]; Kikkawa N, 2009, CELL STRUCT FUNCT, V34, P77, DOI 10.1247/csf.08039; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177; Lu AP, 2012, MOL THER, V20, P661, DOI 10.1038/mt.2011.261; Marcus RL, 2010, J NUTR HEALTH AGING, V14, P362, DOI 10.1007/s12603-010-0081-2; Mavrogenis AF, 2011, ORTHOPEDICS, V34, DOI 10.3928/01477447-20110124-08; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Mei M, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-110; Messina S, 2006, AM J PATHOL, V168, P918, DOI 10.2353/ajpath.2006.050673; Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611; Miljkovic-Gacic I, 2008, OBESITY, V16, P1854, DOI 10.1038/oby.2008.280; Momose M, 2001, NEUROMUSCULAR DISORD, V11, P464, DOI 10.1016/S0960-8966(01)00191-2; Monici MC, 2003, NEUROLOGY, V60, P993, DOI 10.1212/01.WNL.0000049913.27181.51; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, pS162, DOI 10.1016/S0960-8966(02)00101-3; Nakayama Y, 2009, BIOCHEM BIOPH RES CO, V379, P288, DOI 10.1016/j.bbrc.2008.12.040; Neal B., 2000, COCHRANE DATABASE SY; Nguyen F, 2002, J COMP PATHOL, V126, P100, DOI 10.1053/jcpa.2001.0526; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ruberg FL, 2007, CIRCULATION, V116, P1110, DOI 10.1161/CIRCULATIONAHA.107.721860; Saini-Chohan HK, 2012, J LIPID RES, V53, P4, DOI 10.1194/jlr.R012120; Salisbury E, 2011, J CELL BIOCHEM, V112, P2748, DOI 10.1002/jcb.23225; Santos A, 2010, CYTOTHERAPY, V12, P924, DOI 10.3109/14653241003774011; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Schulze PC, 2009, J LIPID RES, V50, P2137, DOI 10.1194/jlr.R001115; Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X; Sharma S, 2004, FASEB J, V18, P1692, DOI 10.1096/fj.04-2263com; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; Starkey JD, 2011, J HISTOCHEM CYTOCHEM, V59, P33, DOI 10.1369/jhc.2010.956995; Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003; Tahallah N, 2008, J LIPID RES, V49, P438, DOI 10.1194/jlr.M700421-JLR200; Thibaud JL, 2007, NEUROMUSCULAR DISORD, V17, P575, DOI 10.1016/j.nmd.2007.03.013; VALENTINE BA, 1990, J NEUROL SCI, V97, P1, DOI 10.1016/0022-510X(90)90095-5; Vasileiadis GI, 2011, ORTHOPEDICS, V34, P467, DOI 10.3928/01477447-20110427-23; Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293; Ye JM, 2001, DIABETES, V50, P411, DOI 10.2337/diabetes.50.2.411; Zhou H, 2011, ACTA PHARMACOL SIN, V32, P999, DOI 10.1038/aps.2011.54; Zhou Y, 2013, J CLIN INVEST, V123, P1096, DOI 10.1172/JCI66700	72	28	31	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3619	3631		10.1096/fj.13-233460	http://dx.doi.org/10.1096/fj.13-233460			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23704088	Green Published			2022-12-28	WOS:000328840500021
J	Naville, D; Pinteur, C; Vega, N; Menade, Y; Vigier, M; Le Bourdais, A; Labaronne, E; Debard, C; Luquain-Costaz, C; Begeot, M; Vidal, H; Le Magueresse-Battistoni, B				Naville, Danielle; Pinteur, Claudie; Vega, Nathalie; Menade, Yoan; Vigier, Michele; Le Bourdais, Alexandre; Labaronne, Emmanuel; Debard, Cyrille; Luquain-Costaz, Celine; Begeot, Martine; Vidal, Hubert; Le Magueresse-Battistoni, Brigitte			Low-dose food contaminants trigger sex-specific, hepatic metabolic changes in the progeny of obese mice	FASEB JOURNAL			English	Article						BPA; DEHP; persistent organic pollutant; estrogen sulfotransferase; cholesterol biosynthesis	ENDOCRINE-DISRUPTING CHEMICALS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ESTROGEN SULFOTRANSFERASE; ENVIRONMENTAL CHEMICALS; DEVELOPMENTAL ORIGINS; GENE-EXPRESSION; BISPHENOL-A; RECEPTOR; LIVER; EXPOSURE	Environmental contaminants are suspected to be involved in the epidemic incidence of metabolic disorders, food ingestion being a primarily route of exposure. We hypothesized that life-long consumption of a high-fat diet that contains low doses of pollutants will aggravate metabolic disorders induced by obesity itself. Mice were challenged from preconception throughout life with a high-fat diet containing pollutants commonly present in food (2,3,7,8-tetrachlorodibenzo-p-dioxin, polychlorinated biphenyl 153, diethylhexyl phthalate, and bisphenol A), added at low doses in the tolerable daily intake range. We measured several blood parameters, glucose and insulin tolerance, hepatic lipid accumulation, and gene expression in adult mice. Pollutant-exposed mice exhibited significant sex-dependent metabolic disorders in the absence of toxicity and weight gain. In males, pollutants increased the expression of hepatic genes (from 36 to 88%) encoding proteins related to cholesterol biosynthesis and decreased (40%) hepatic total cholesterol levels. In females, there was a marked deterioration of glucose tolerance, which may be related to the 2-fold induction of estrogen sulfotransferase and reduced expression of estrogen receptor (25%) and estrogen target genes (>34%). Because of the very low doses of pollutants used in the mixture, these findings may have strong implications in terms of understanding the potential role of environmental contaminants in food in the development of metabolic diseases.Naville, D., Pinteur, C., Vega, N., Menade, Y., Vigier, M., Le Bourdais, A., Labaronne, E., Debard, C., Luquain-Costaz, C., Begeot, M., Vidal, H., Le Magueresse-Battistoni, B. Low-dose food contaminants trigger sex-specific, hepatic metabolic changes in the progeny of obese mice.	[Naville, Danielle; Pinteur, Claudie; Vega, Nathalie; Menade, Yoan; Vigier, Michele; Le Bourdais, Alexandre; Labaronne, Emmanuel; Debard, Cyrille; Luquain-Costaz, Celine; Begeot, Martine; Vidal, Hubert; Le Magueresse-Battistoni, Brigitte] INSERM, U1060, Cardiovasc Metab Diabetol & Nutr CarMeN Lab, Oullins, France; [Naville, Danielle; Pinteur, Claudie; Vega, Nathalie; Menade, Yoan; Vigier, Michele; Le Bourdais, Alexandre; Labaronne, Emmanuel; Debard, Cyrille; Luquain-Costaz, Celine; Begeot, Martine; Vidal, Hubert; Le Magueresse-Battistoni, Brigitte] Inst Natl Rech Agron INRA U1362, Oullins, France; [Naville, Danielle; Pinteur, Claudie; Vega, Nathalie; Menade, Yoan; Vigier, Michele; Le Bourdais, Alexandre; Labaronne, Emmanuel; Debard, Cyrille; Luquain-Costaz, Celine; Begeot, Martine; Vidal, Hubert; Le Magueresse-Battistoni, Brigitte] Univ Lyon 1, F-69622 Villeurbanne, France; [Luquain-Costaz, Celine; Vidal, Hubert] Inst Natl Sci Appl INSA Lyon, IMBL, Villeurbanne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National des Sciences Appliquees de Lyon - INSA Lyon	Le Magueresse-Battistoni, B (corresponding author), INSERM U1060 CarMeN, Fac Med Lyon Sud, 165 Chemin Grand Revoyet, F-69921 Oullins, France.	brigitte.lemagueresse@inserm.fr	Tuomisto, Jouko/J-7450-2012; Naville, Danielle/N-1200-2017; Le Magueresse-Battistoni, Brigitte/M-6927-2017; Vidal, Hubert/M-6674-2017; Le Magueresse-Battistoni, Brigitte/AAZ-5601-2021	Naville, Danielle/0000-0003-2615-6161; Le Magueresse-Battistoni, Brigitte/0000-0002-7247-4403; Vidal, Hubert/0000-0002-9467-0317; Le Magueresse-Battistoni, Brigitte/0000-0002-7247-4403; Labaronne, Emmanuel/0000-0001-6314-7809	Institut Benjamin Delessert; Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement et du Travail (ANSES; Programme National Environnement-Environnement-Sante-Travail) [EST-2010/2/2007]; European Foundation of the Study of Diabetes (EFSD/Novo Nordisk)	Institut Benjamin Delessert; Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement et du Travail (ANSES; Programme National Environnement-Environnement-Sante-Travail)(French National Research Agency (ANR)); European Foundation of the Study of Diabetes (EFSD/Novo Nordisk)	The authors thank Michel Beylot for the indirect calorimetry measurement. This work was supported by grants from Institut Benjamin Delessert (2010), Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement et du Travail (ANSES; Programme National Environnement-Environnement-Sante-Travail, EST-2010/2/2007), and the European Foundation of the Study of Diabetes (EFSD/Novo Nordisk, program 2011). The authors declare no conflicts of interest.	Alonso-Magdalena P, 2011, NAT REV ENDOCRINOL, V7, P346, DOI 10.1038/nrendo.2011.56; Anton R, 2005, EFSA J, V3, DOI 10.2903/j.efsa.2005.204/full; Baars AJ, 2004, TOXICOL LETT, V151, P51, DOI 10.1016/j.toxlet.2004.01.028; Barker DJP, 2005, HORM RES, V64, P2, DOI 10.1159/000089311; Barouki R, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-42; Barros RPA, 2006, TRENDS MOL MED, V12, P425, DOI 10.1016/j.molmed.2006.07.004; Beylot M, 2012, METABOLISM, V61, P415, DOI 10.1016/j.metabol.2011.07.019; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boutros PC, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-419; Carpenter David O., 2008, Reviews on Environmental Health, V23, P59; Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200; Croutch CR, 2005, TOXICOL SCI, V85, P560, DOI 10.1093/toxsci/kfi106; Della Torre S, 2011, CELL METAB, V13, P205, DOI 10.1016/j.cmet.2011.01.002; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dorne JLCM, 2010, TOXICOLOGY, V268, P156, DOI 10.1016/j.tox.2009.11.004; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Fromenty B, 2013, J HEPATOL, V58, P824, DOI 10.1016/j.jhep.2012.12.018; Gao H, 2008, MOL ENDOCRINOL, V22, P10, DOI 10.1210/me.2007-0121; Gao J, 2012, DIABETES, V61, P1543, DOI 10.2337/db11-1152; Gout J, 2010, MOL CELL ENDOCRINOL, V319, P99, DOI 10.1016/j.mce.2010.01.021; Grun F, 2007, REV ENDOCR METAB DIS, V8, P161, DOI 10.1007/s11154-007-9049-x; He JH, 2011, EXP BIOL MED, V236, P1116, DOI 10.1258/ebm.2011.011128; Heindel JJ, 2009, MOL CELL ENDOCRINOL, V304, P90, DOI 10.1016/j.mce.2009.02.025; Hevir N, 2013, MOL CELL ENDOCRINOL, V367, P74, DOI 10.1016/j.mce.2012.12.019; Ibrahim MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025170; Jacobsen PR, 2012, REPROD TOXICOL, V34, P237, DOI 10.1016/j.reprotox.2012.05.099; Koch HM, 2009, PHILOS T R SOC B, V364, P2063, DOI 10.1098/rstb.2008.0208; Lee DH, 2006, DIABETES CARE, V29, P1638, DOI 10.2337/dc06-0543; LEITER EH, 1994, J CLIN INVEST, V93, P2007, DOI 10.1172/JCI117194; Marmugi A, 2012, HEPATOLOGY, V55, P395, DOI 10.1002/hep.24685; Martens K, 2008, BBA-MOL CELL BIOL L, V1781, P694, DOI 10.1016/j.bbalip.2008.07.010; Mauvais-Jarvis F, 2012, DIABETES, V61, P1353, DOI 10.2337/db12-0357; Mauvais-Jarvis F, 2011, TRENDS ENDOCRIN MET, V22, P24, DOI 10.1016/j.tem.2010.10.002; Moraes RC, 2003, ENDOCRINOLOGY, V144, P4773, DOI 10.1210/en.2003-0456; Nadal A, 2013, NAT REV ENDOCRINOL, V9, P9, DOI 10.1038/nrendo.2012.205; Nault R, 2013, TOXICOL APPL PHARM, V267, P184, DOI 10.1016/j.taap.2012.11.028; Naville D, 2011, TOXICOL LETT, V207, P251, DOI 10.1016/j.toxlet.2011.09.019; Pageaux JF, 1996, ARCH BIOCHEM BIOPHYS, V327, P142, DOI 10.1006/abbi.1996.0102; Riant E, 2009, ENDOCRINOLOGY, V150, P2109, DOI 10.1210/en.2008-0971; Ruzzin J, 2010, ENVIRON HEALTH PERSP, V118, P465, DOI 10.1289/ehp.0901321; Schafer KS, 2002, J EPIDEMIOL COMMUN H, V56, P813, DOI 10.1136/jech.56.11.813; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Silins I, 2011, INT J ENV RES PUB HE, V8, P629, DOI 10.3390/ijerph8030629; Stubbins RE, 2012, DIABETES OBES METAB, V14, P58, DOI 10.1111/j.1463-1326.2011.01488.x; Taxvig C, 2012, MOL CELL ENDOCRINOL, V361, P106, DOI 10.1016/j.mce.2012.03.021; Thayer KA, 2012, ENVIRON HEALTH PERSP, V120, P779, DOI 10.1289/ehp.1104597; van Leeuwen FXR, 2000, CHEMOSPHERE, V40, P1095, DOI 10.1016/S0045-6535(99)00358-6; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Wagner M, 2011, HEPATOLOGY, V53, P1023, DOI 10.1002/hep.24148; Wahlang B, 2013, J NUTR BIOCHEM, V24, P1587, DOI 10.1016/j.jnutbio.2013.01.009; Waxman DJ, 2009, MOL PHARMACOL, V76, P215, DOI 10.1124/mol.109.056705; Wei J, 2011, ENDOCRINOLOGY, V152, P3049, DOI 10.1210/en.2011-0045; WHO, 2003, 55 WHO CONC INT CHEM; Xi W, 2012, ENVIRON SCI POLLUT R, V19, P2515, DOI 10.1007/s11356-012-0827-y; Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007; Zhao CY, 2010, J ENDOCRINOL, V204, P233, DOI 10.1677/JOE-09-0271; Zhou XD, 2012, J NUTR BIOCHEM, V23, P532, DOI 10.1016/j.jnutbio.2011.02.008	58	41	42	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3860	3870		10.1096/fj.13-231670	http://dx.doi.org/10.1096/fj.13-231670			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23756648	Green Submitted			2022-12-28	WOS:000328840500043
J	Lin, HY; Su, YF; Hsieh, MT; Lin, SR; Meng, R; London, D; Lin, C; Tang, HY; Hwang, J; Davis, FB; Mousa, SA; Davis, PJ				Lin, Hung-Yun; Su, Yee-Fun; Hsieh, Meng-Ti; Lin, Sharon; Meng, Ran; London, David; Lin, Cassie; Tang, Heng-Yuan; Hwang, Jaulang; Davis, Faith B.; Mousa, Shaker A.; Davis, Paul J.			Nuclear monomeric integrin alpha v in cancer cells is a coactivator regulated by thyroid hormone	FASEB JOURNAL			English	Article						thyroxine; gene expression; angiogenesis; carcinogenesis	ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; GROWTH-FACTOR; SERINE PHOSPHORYLATION; MEMBRANE-RECEPTOR; SURFACE RECEPTOR; EPITHELIAL-CELLS; GLIOMA-CELLS; IN-VITRO; ALPHA-V-BETA-3	Thyroid hormone induces tumor cell and blood vessel cell proliferation via a cell surface receptor on heterodimeric integrin v3. We investigated the role of thyroid hormone-induced internalization of nuclear integrin v monomer. Physiological concentration of thyroxine (free T-4, 10(-10) M), but not 3,5,3-triiodo-l-thyronine (T-3), induced cellular internalization and nuclear translocation of integrin v monomer in human non-small-cell lung cancer (H522) and ovarian carcinoma (OVCAR-3) cells. T-4 did not complex with integrin v monomer during its internalization. The v monomer was phosphorylated by activated ERK1/2 when it heterodimerized with integrin 3 in vitro. Nuclear v complexed with transcriptional coactivator proteins, p300 and STAT1, and with corepressor proteins, NCoR and SMRT. Nuclear v monomer in T-4-exposed cells, but not integrin 3, bound to promoters of specific genes that have important roles in cancer cells, including estrogen receptor-, cyclooxygenase-2, hypoxia-inducible factor-1, and thyroid hormone receptor 1 in chromatin immunoprecipitation assay. In summary, monomeric v is a novel coactivator regulated from the cell surface by thyroid hormone for the expression of genes involved in tumorigenesis and angiogenesis. This study also offers a mechanism for modulation of gene expression by thyroid hormone that is adjunctive to the nuclear hormone receptor (TR)-T-3 pathway.Lin, H.-Y., Su, Y.-F., Hsieh, M.-T., Lin, S., Meng, M., London, D., Lin, C., Tang, H.-Y., Hwang, J., Davis, F. B., Mousa, S. A., and Davis, P. J. Nuclear monomeric integrin v in cancer cells is a coactivator regulated by thyroid hormone.	[Lin, Hung-Yun; Su, Yee-Fun; Hsieh, Meng-Ti] Taipei Med Univ, Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Lin, Sharon; Meng, Ran; London, David; Lin, Cassie; Tang, Heng-Yuan; Davis, Faith B.; Mousa, Shaker A.; Davis, Paul J.] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Albany, NY USA; [Hwang, Jaulang] Taipei Med Univ, Sch Med, Dept Biochem, Taipei, Taiwan; [Davis, Paul J.] Albany Med Coll, Dept Med, Albany, NY 12208 USA	Taipei Medical University; Albany College of Pharmacy & Health Sciences; Taipei Medical University; Albany Medical College	Lin, HY (corresponding author), Taipei Med Univ, Inst Canc Biol & Drug Discovery, 250 Wu Shin St, Taipei, Taiwan.	linhy@tmu.edu.tw; pdavis.ordwayst@gmail.com	Mousa, Shaker A/A-7151-2017	Mousa, Shaker A/0000-0002-9294-015X	Taipei Medical University	Taipei Medical University	The authors appreciate the support from M. Frank and Margaret D. Rudy for conducting some of the studies described here. This work was also supported, in part, by the startup fund of Taipei Medical University.	Arnaout MA, 2007, CURR OPIN CELL BIOL, V19, P495, DOI 10.1016/j.ceb.2007.08.002; Beber EH, 2009, CALCIFIED TISSUE INT, V84, P324, DOI 10.1007/s00223-009-9230-1; Belmadani S, 2008, AM J PHYSIOL-HEART C, V295, pH69, DOI 10.1152/ajpheart.00341.2008; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cai Weibo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; Cao HJ, 2009, ENDOCR RES, V34, P31, DOI 10.1080/07435800902911810; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Cody V, 2007, STEROIDS, V72, P165, DOI 10.1016/j.steroids.2006.11.008; D'Arezzo S, 2004, ENDOCRINOLOGY, V145, P5694, DOI 10.1210/en.2004-0890; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Davis FB, 2004, CIRC RES, V94, P1500, DOI 10.1161/01.RES.0000130784.90237.4a; Davis PJ, 2011, ANNU REV PHARMACOL, V51, P99, DOI 10.1146/annurev-pharmtox-010510-100512; Davis PJ, 2000, J BIOL CHEM, V275, P38032, DOI 10.1074/jbc.M002560200; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dijkgraaf I, 2007, INT J CANCER, V120, P605, DOI 10.1002/ijc.22297; Furuya F, 2007, MOL CELL BIOL, V27, P6116, DOI 10.1128/MCB.00900-07; Glinskii AB, 2009, CELL CYCLE, V8, P3562, DOI 10.4161/cc.8.21.9963; Jang ER, 2010, BIOCHEM BIOPH RES CO, V397, P637, DOI 10.1016/j.bbrc.2010.05.060; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Lazar Mitchell A, 2003, Nucl Recept Signal, V1, pe001; Leonard JL, 1997, THYROID, V7, P147, DOI 10.1089/thy.1997.7.147; Lim JY, 2012, J CELL PHYSIOL, V227, P1081, DOI 10.1002/jcp.22824; Lin HY, 2008, CARCINOGENESIS, V29, P62, DOI 10.1093/carcin/bgm239; Lin HY, 2007, STEROIDS, V72, P180, DOI 10.1016/j.steroids.2006.11.014; Lin HY, 2006, FASEB J, V20, P1742, DOI 10.1096/fj.06-5743fje; Lin HY, 2012, DISCOV MED, V14, P199; Lin HY, 2011, DISCOV MED, V11, P337; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lin HY, 2009, J STEROID BIOCHEM, V113, P182, DOI 10.1016/j.jsbmb.2008.12.010; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014, DOI 10.1152/ajpcell.1999.276.5.C1014; Lin HY, 1998, J IMMUNOL, V161, P843; Meissner JD, 2011, NUCLEIC ACIDS RES, V39, P5907, DOI 10.1093/nar/gkr162; Meng R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027547; Moeller LC, 2005, MOL ENDOCRINOL, V19, P2955, DOI 10.1210/me.2004-0542; Mousa SA, 2006, INT ANGIOL, V25, P407; Mousa SS, 2010, CLIN APPL THROMB-HEM, V16, P288, DOI 10.1177/1076029609348315; Odrljin TM, 2001, AM J RESP CELL MOL, V24, P12, DOI 10.1165/ajrcmb.24.1.3992; Rae MT, 2007, J CLIN ENDOCR METAB, V92, P322, DOI 10.1210/jc.2006-1522; Riis ALD, 2008, J CLIN ENDOCR METAB, V93, P3999, DOI 10.1210/jc.2008-0550; Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004; Shih A, 2001, BIOCHEMISTRY-US, V40, P2870, DOI 10.1021/bi001978b; Tang HY, 2006, MOL CANCER THER, V5, P2034, DOI 10.1158/1535-7163.MCT-06-0216; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Varlakhanova N, 2011, MOL CELL ENDOCRINOL, V332, P180, DOI 10.1016/j.mce.2010.10.010; Visser WE, 2011, MOL ENDOCRINOL, V25, P1, DOI 10.1210/me.2010-0095; Watson PJ, 2012, MOL CELL ENDOCRINOL, V348, P440, DOI 10.1016/j.mce.2011.08.033; Wojciak JM, 2009, EMBO J, V28, P948, DOI 10.1038/emboj.2009.30; Yalcin M, 2010, J CLIN ENDOCR METAB, V95, P1972, DOI 10.1210/jc.2009-1926; Yonkers MA, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-20; Zhang Y, 2011, ARTERIOSCL THROM VAS, V31, P2897, DOI 10.1161/ATVBAHA.111.237453	53	54	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3209	3216		10.1096/fj.12-227132	http://dx.doi.org/10.1096/fj.12-227132			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23640055				2022-12-28	WOS:000329877600026
J	Alcaniz, L; Vega, A; Chacon, P; El Bekay, R; Ventura, I; Aroca, R; Blanca, M; Bergstralh, DT; Monteseirin, J				Alcaniz, Lorena; Vega, Antonio; Chacon, Pedro; El Bekay, Rajaa; Ventura, Inmaculada; Aroca, Rocio; Blanca, Miguel; Bergstralh, Dan T.; Monteseirin, Javier			Histamine production by human neutrophils	FASEB JOURNAL			English	Article						antigens; IgE; histidine decarboxylase	FC-EPSILON-RI; PERIPHERAL-BLOOD NEUTROPHILS; EOSINOPHIL CATIONIC PROTEIN; L-HISTIDINE DECARBOXYLASE; HIGH-AFFINITY RECEPTOR; RHEUMATOID-ARTHRITIS; DEPENDENT INDUCTION; ALLERGEN EXPOSURE; IMMUNE REGULATION; LATE-PHASE	Histamine is an important mediator in the development of allergic reactions. Only a small subset of human cell types is able to produce histamine. No previous studies have shown that human neutrophils are among them. The present work was undertaken to analyze whether human neutrophils produce histamine, and to determine what agonists are involved in histamine production by human neutrophils. The expression of histidine decarboxylase in human neutrophils was established by quantitative PCR, Western blotting, and flow cytometry analysis. The activity of the enzyme was determined by ELISA, which measured histamine in the culture supernatant of neutrophils stimulated with a set of classical agonists. Human neutrophils are bona fide histamine-producing cells. Neutrophils store approximate to 0.29 pg/cell and release approximate to 50% of the histamine content in an antigen-dependent manner and on stimulation with other neutrophil agonists. Basal expression of histidine decarboxylase, the rate-limiting enzyme in histamine production, is higher in neutrophils from patients with allergies than from healthy donors. Our results cannot be ascribed to cell contamination for several reasons. LPS failed to induce histamine release by basophils, whereas it induced histamine release by neutrophils; and we did not detect basophils, monocytes, or lymphocytes in our neutrophil preparations. Eosinophils, albeit detected, were only 0.001-0.004% of the final cell population, and they did not store or release histamine on antigen or LPS stimulation. Antigens to which patients with allergies were sensitized stimulated release of histamine from neutrophils. These observations represent a novel view of neutrophils as possible source of histamine in the allergic diseases.Alcaniz, L., Vega, A., Chacon, P., El Bekay, R., Ventura, I., Aroca, R., Blanca, M., Bergstralh, D. T., Monteseirin, J. Histamine production by human neutrophils.	[Alcaniz, Lorena; Vega, Antonio; Chacon, Pedro; Ventura, Inmaculada; Aroca, Rocio; Monteseirin, Javier] Hosp Univ Virgen Macarena, Serv Reg Inmunol & Alergia, Seville, Spain; [Monteseirin, Javier] Univ Seville, Fac Med, Dept Med, Seville, Spain; [Chacon, Pedro] Consejo Super Invest Cient CABIMER CSIC, Ctr Andaluz Biol Mol & Med Regenerat, Cell Signaling Dept, Seville, Spain; [El Bekay, Rajaa] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER Fisiopatol Obesidad &, Malaga, Spain; [El Bekay, Rajaa] Hosp Clin Virgen de la Victoria, Lab Invest Biomed, Fdn Inst Mediterraneo Avance Biotecnol & Invest S, Malaga, Spain; [Blanca, Miguel] Carlos Haya Hosp FDN IMABIS, Res Lab, Malaga, Spain; [Vega, Antonio; Bergstralh, Dan T.] Gurdon Inst, Cambridge, England	Hospital Universitario Virgen Macarena; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; Hospital Carlos Haya	Monteseirin, J (corresponding author), Calle Asunc 27,3 Izda, Seville 41011, Spain.	fmonteseirinm@meditex.es	Bekay, Rajaa El/AAZ-3959-2020; El Bekay, RAJAA/AGN-6069-2022	El Bekay, RAJAA/0000-0003-3332-3431; Chacon Fernandez, Pedro Jose/0000-0003-0925-814X; Vega Rioja, Antonio/0000-0003-4698-9697; Bergstralh, Dan/0000-0003-1689-3715	Junta de Andalucia (Ayudas Grupos de Investigacion); Fundacion de la Sociedad Espanola de Alergia e Inmunologia Clinica; Fundacion Sanitaria Virgen Macarena; Fondo de Investigacion Sanitaria (FIS)-Thematic Networks and Cooperative Research Centres Red de Investigacion de Reacciones Adversas a Alergenos y Farmacos (RIRAAF) [RD07-0064]; Fundacion Alergol, Spain; Ministerio de Ciencia y Tecnologia and Fundacion Alergol, Spain; Federation of European Biochemical Societies (FEBS); Ministerio de Educacion y Ciencia, Spain [FIS-2007, CP07/00288, SAF2003-00200]	Junta de Andalucia (Ayudas Grupos de Investigacion)(Junta de Andalucia); Fundacion de la Sociedad Espanola de Alergia e Inmunologia Clinica; Fundacion Sanitaria Virgen Macarena; Fondo de Investigacion Sanitaria (FIS)-Thematic Networks and Cooperative Research Centres Red de Investigacion de Reacciones Adversas a Alergenos y Farmacos (RIRAAF); Fundacion Alergol, Spain; Ministerio de Ciencia y Tecnologia and Fundacion Alergol, Spain; Federation of European Biochemical Societies (FEBS); Ministerio de Educacion y Ciencia, Spain(Spanish Government)	The authors are grateful to Cristina Chamorro and Elisa Gomez for their technical assistance. This work was supported by grants from the Junta de Andalucia (Ayudas Grupos de Investigacion), Fundacion de la Sociedad Espanola de Alergia e Inmunologia Clinica, Fundacion Sanitaria Virgen Macarena, Fondo de Investigacion Sanitaria (FIS)-Thematic Networks and Cooperative Research Centres Red de Investigacion de Reacciones Adversas a Alergenos y Farmacos (RIRAAF; RD07-0064), and Fundacion Alergol, Spain. A.V. and P.C. were supported by fellowships from the Ministerio de Ciencia y Tecnologia and Fundacion Alergol, Spain. In addition, A. V. was the recipient of a Federation of European Biochemical Societies (FEBS) long-term postdoctoral fellowship, and P. C. was the recipient of a Sara Borell postdoctoral grant from the Ministerio de Educacion y Ciencia, Spain. R.E. is the recipient of a Miguel Servet postdoctoral grant (FIS-2007, CP07/00288, SAF2003-00200) from the Ministerio de Educacion y Ciencia, Spain. D. T. B. is the recipient of a Marie Curie postdoctoral fellowship. J.M. is under the Programa de Intensificacion de la Actividad Investigadora del Sistema Nacional de Salud. The authors declare no conflicts of interest.	Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Alphonse M. P., 2005, THESIS U MANITOBA; Alphonse MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001921; ANDERSSON M, 1994, MEDIAT INFLAMM, V3, P171, DOI 10.1155/S0962935194000220; Barret K. E., 1993, IMMUNOPHARMACOLOGY M, P29; Benoni G, 2001, INT J IMMUNOPATH PH, V14, P161; BUSSE WW, 1989, J ALLERGY CLIN IMMUN, V84, P658, DOI 10.1016/0091-6749(89)90293-5; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Chacon P, 2005, EUR J IMMUNOL, V35, P2313, DOI 10.1002/eji.200425572; Dehlink E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012204; Edwards SW, 2003, CHEM IMMUNOL, V83, P204; GABOURY JP, 1995, J IMMUNOL, V154, P804; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; GRAHAM HT, 1955, BLOOD, V10, P467, DOI 10.1182/blood.V10.5.467.467; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HOLGATE ST, 1994, CLIN REV ALLERG, V12, P65; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Kita H, 1999, J IMMUNOL, V162, P6901; KRAUSS S, 1968, BLOOD, V31, P699, DOI 10.1182/blood.V31.6.699.699; Kubes P, 1996, CARDIOVASC RES, V32, P699, DOI 10.1016/S0008-6363(96)00118-6; Laszlo V, 2001, INFLAMM RES, V50, P428, DOI 10.1007/PL00000266; Liu FT, 1996, BIOCHEMISTRY-US, V35, P6073, DOI 10.1021/bi952716q; Monteseirin J, 2005, CLIN EXP ALLERGY, V35, P1204, DOI 10.1111/j.1365-2222.2005.02320.x; Monteseirin J, 2009, J INVEST ALLERG CLIN, V19, P340; Monteseirin J, 2004, J LEUKOCYTE BIOL, V76, P692, DOI 10.1189/jlb.0903441; Monteseirin J, 2007, J IMMUNOL, V179, P2634, DOI 10.4049/jimmunol.179.4.2634; Moreno AN, 2003, INT ARCH ALLERGY IMM, V132, P221, DOI 10.1159/000074303; Naclerio RM, 1996, J ALLERGY CLIN IMMUN, V98, P721, DOI 10.1016/S0091-6749(96)70118-5; Nakajima T, 2004, J ALLERGY CLIN IMMUN, V113, P528, DOI 10.1016/j.jaci.2003.12.036; Nishimura M, 2003, TRANSFUSION MED, V13, P141, DOI 10.1046/j.1365-3148.2003.00434.x; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; OH C, 1988, IMMUNOLOGY, V65, P143; Porcherie A, 2011, J EXP MED, V208, P2225, DOI 10.1084/jem.20110845; Saffar AS, 2007, J IMMUNOL, V178, P2535, DOI 10.4049/jimmunol.178.4.2535; Saini S, 2004, J ALLERGY CLIN IMMUN, V114, P768, DOI 10.1016/j.jaci.2004.06.015; SAXENA SP, 1989, SCIENCE, V243, P1596, DOI 10.1126/science.2928797; Schmidt T, 2012, J LEUKOCYTE BIOL, V91, P791, DOI 10.1189/jlb.0911483; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; Schramm R, 2004, INFLAMM RES, V53, P644, DOI 10.1007/s00011-004-1307-8; Schroeder J. T., 2003, MIDDLETONS ALLERGY P, P347; Shiraishi M, 2000, IMMUNOLOGY, V99, P600, DOI 10.1046/j.1365-2567.2000.00986.x; Smuda C, 2011, IMMUNOL LETT, V141, P102, DOI 10.1016/j.imlet.2011.08.002; SUGITA N, 1993, J PERIODONTAL RES, V28, P363, DOI 10.1111/j.1600-0765.1993.tb01080.x; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715; Szeberenyi JB, 2001, INFLAMM RES, V50, pS112; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; Tanaka S, 2004, EUR J IMMUNOL, V34, P1472, DOI 10.1002/eji.200324636; Tani K, 2000, J LEUKOCYTE BIOL, V67, P585, DOI 10.1002/jlb.67.4.585; Torsteinsdottir I, 1999, SCAND J IMMUNOL, V50, P433, DOI 10.1046/j.1365-3083.1999.00602.x; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; TRUONG MJ, 1994, ANN NY ACAD SCI, V725, P234, DOI 10.1111/j.1749-6632.1994.tb39806.x; Uddin M, 2010, THORAX, V65, P684, DOI 10.1136/thx.2009.120741; Vega A, 2007, J CELL SCI, V120, P2328, DOI 10.1242/jcs.000331; Vega A, 2006, J LEUKOCYTE BIOL, V80, P152, DOI 10.1189/jlb.0705411; Vella A, 1999, INFLAMMATION, V23, P471, DOI 10.1023/A:1021969127489; Vonakis BM, 2008, BLOOD, V111, P1789, DOI 10.1182/blood-2007-07-104364; Xu XA, 2006, J EXP MED, V203, P2907, DOI 10.1084/jem.20061232; Xu X, 2012, J LEUKOCYTE BIOL, V91, P275, DOI 10.1189/jlb.0711356; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yamaoka KA, 1996, INT IMMUNOL, V8, P479, DOI 10.1093/intimm/8.4.479; Yang EJ, 2012, J CELL PHYSIOL, V227, P2567, DOI 10.1002/jcp.22995; Yoon J, 2007, J IMMUNOL, V179, P8454, DOI 10.4049/jimmunol.179.12.8454	63	35	39	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2902	2910		10.1096/fj.12-223867	http://dx.doi.org/10.1096/fj.12-223867			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23572231				2022-12-28	WOS:000328841000038
J	Barsoum, IB; Kaur, J; Ge, RS; Cooke, PS; Yao, HHC				Barsoum, Ivraym B.; Kaur, Jaspreet; Ge, Renshan S.; Cooke, Paul S.; Yao, Humphrey Hung-Chang			Dynamic changes in fetal Leydig cell populations influence adult Leydig cell populations in mice	FASEB JOURNAL			English	Article						hedgehog pathway; spermatogenesis; steroidogenic factor 1; testis	HEDGEHOG DHH GENE; DESERT-HEDGEHOG; MOUSE TESTIS; GONADAL-DYSGENESIS; PROGENITOR CELLS; SERTOLI-CELLS; DIFFERENTIATION; IDENTIFICATION; MUTATION; PROLIFERATION	Testes contain two distinct Leydig cell populations during development: fetal and adult Leydig cells (FLCs and ALCs, respectively). ALCs are not derived from FLCs, and it is unknown whether these two populations share common progenitors. We discovered that hedgehog (Hh) signaling is responsible for transforming steroidogenic factor 1-positive (SF1(+)) progenitors into FLCs. However, not all SF1(+) progenitors become FLCs, and some remain undifferentiated through fetal development. We therefore hypothesized that if FLCs and ALCs share SF1(+) progenitors, increased Hh pathway activation in SF1(+) progenitor cells could change the dynamics and distribution of SF1(+) progenitors, FLCs, and ALCs. Using a genetic model involving constitutive activation of Hh pathway in SF1(+) cells, we observed reduced numbers of SF1(+) progenitor cells and increased FLCs. Conversely, increased Hh activation led to decreased ALC populations prepubertally, while adult ALC numbers were comparable to control testes. Hence, reduction in SF1(+) progenitors temporarily affects ALC numbers, suggesting that SF1(+) progenitors in fetal testes are a potential source of both FLCs and ALCs. Besides transient ALC defects, adult animals with Hh activation in SF1(+) progenitors had reduced testicular weight, oligospermia, and decreased sperm mobility. These defects highlight the importance of properly regulated Hh signaling in Leydig cell development and testicular functions.Barsoum, I. B., Kaur, J. Ge, R. S., Cooke, P. S., Yao, H. H.-C. Dynamic changes in fetal Leydig cell populations influence adult Leydig cell populations in mice.	[Barsoum, Ivraym B.; Kaur, Jaspreet; Cooke, Paul S.; Yao, Humphrey Hung-Chang] Univ Illinois, Coll Vet Med, Dept Comparat Biosci, Urbana, IL USA; [Ge, Renshan S.] Populat Council, New York, NY 10021 USA; [Cooke, Paul S.] Univ Florida, Coll Vet Med, Dept Physiol Sci, Gainesville, FL 32610 USA; [Yao, Humphrey Hung-Chang] NIEHS, Dev Reprod Biol Grp, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA	University of Illinois System; University of Illinois Urbana-Champaign; Population Council; State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yao, HHC (corresponding author), NIEHS, 111 TW Alexander Dr,Maildrop C4-10, Res Triangle Pk, NC 27709 USA.	humphrey.yao@nih.gov	Barsoum, Ivraym/AAJ-3493-2020; Yao, Hung-Chang Humphrey/B-4795-2010	Yao, Hung-Chang Humphrey/0000-0003-2944-8469; Cooke, Paul/0000-0002-9370-4896	U.S. National Institutes of Health [HD-059961]; U.S. National Institutes of Health (National Institute of Environmental Health Sciences) [ES-102965]; Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH [U54-HD28934]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD059961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES102965] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Institutes of Health (National Institute of Environmental Health Sciences)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors are grateful for the assistance and support of H.H.-C.Y. laboratory members. This study was funded by the U.S. National Institutes of Health (grant HD-059961 to H.H.-C.Y. and P. S. C., and National Institute of Environmental Health Sciences Intramural Research Fund ES-102965 to H.H.-C.Y.). The authors dedicate this study to their collaborator and friend, Dr. Keith Parker, who passed away on December 13, 2008. The authors also thank the University of Virginia (UVA) Center for Research and Reproduction Ligand Assay and Analysis Core (Charlottesville, VA, USA) for hormone measurement. The UVA Center is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH (Specialized Cooperative Centers Program in Reproduction and Infertility Research) grant U54-HD28934.	Barsoum I, 2006, TRENDS ENDOCRIN MET, V17, P223, DOI 10.1016/j.tem.2006.06.009; Barsoum IB, 2010, J ANDROL, V31, P11, DOI 10.2164/jandrol.109.008318; Barsoum IB, 2009, DEV BIOL, V329, P96, DOI 10.1016/j.ydbio.2009.02.025; Bingham NC, 2006, GENESIS, V44, P419, DOI 10.1002/dvg.20231; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Brennan J, 2003, GENE DEV, V17, P800, DOI 10.1101/gad.1052503; Buki A, 2000, J HISTOCHEM CYTOCHEM, V48, P153; Canto P, 2005, MOL HUM REPROD, V11, P833, DOI 10.1093/molehr/gah216; Canto P, 2004, J CLIN ENDOCR METAB, V89, P4480, DOI 10.1210/jc.2004-0863; Clark AM, 2000, BIOL REPROD, V63, P1825, DOI 10.1095/biolreprod63.6.1825; Davidoff MS, 2004, J CELL BIOL, V167, P935, DOI 10.1083/jcb.200409107; DeFalco T, 2011, DEV BIOL, V352, P14, DOI 10.1016/j.ydbio.2011.01.011; Ge RS, 2006, P NATL ACAD SCI USA, V103, P2719, DOI 10.1073/pnas.0507692103; Habert R, 2001, MOL CELL ENDOCRINOL, V179, P47, DOI 10.1016/S0303-7207(01)00461-0; Haider SG, 2004, INT REV CYTOL, V233, P181, DOI 10.1016/S0074-7696(04)33005-6; HARDY MP, 1989, ENDOCRINOLOGY, V124, P762, DOI 10.1210/endo-124-2-762; Hatano O, 1996, GENES CELLS, V1, P663, DOI 10.1046/j.1365-2443.1996.00254.x; Hu GX, 2010, J ANDROL, V31, P379, DOI 10.2164/jandrol.109.008680; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Karl J, 1998, DEV BIOL, V203, P323, DOI 10.1006/dbio.1998.9068; Kawai Y, 2011, REPRODUCTION, V141, P217, DOI 10.1530/REP-10-0006; Kim Y, 2006, DEV DYNAM, V235, P2292, DOI 10.1002/dvdy.20894; Kroft TL, 2001, BIOL REPROD, V65, P1663, DOI 10.1095/biolreprod65.6.1663; Mayerhofer A, 1996, J ANDROL, V17, P223; Merchant-Larios H, 1998, EXP CELL RES, V244, P230, DOI 10.1006/excr.1998.4215; ORTH JM, 1982, ANAT REC, V203, P485, DOI 10.1002/ar.1092030408; Park SY, 2007, ENDOCRINOLOGY, V148, P3704, DOI 10.1210/en.2006-1731; Pierucci-Alves F, 2001, BIOL REPROD, V65, P1392, DOI 10.1095/biolreprod65.5.1392; Schmahl J, 2000, DEVELOPMENT, V127, P65; Shima Y, 2012, ENDOCRINOLOGY, V153, P417, DOI 10.1210/en.2011-1407; Szczepny A, 2006, DEV DYNAM, V235, P3063, DOI 10.1002/dvdy.20931; Szczepny A, 2009, BIOL REPROD, V80, P258, DOI 10.1095/biolreprod.108.067926; Tang H, 2008, DEVELOPMENT, V135, P3745, DOI 10.1242/dev.024786; Umehara F, 2000, AM J HUM GENET, V67, P1302, DOI 10.1016/S0002-9297(07)62958-9; Wennemuth G, 2003, DEVELOPMENT, V130, P1317, DOI 10.1242/dev.00353; Yao HHC, 2002, DEV BIOL, V246, P356, DOI 10.1006/dbio.2002.0663; Yao HHC, 2002, GENE DEV, V16, P1433, DOI 10.1101/gad.981202; Yazawa T, 2006, ENDOCRINOLOGY, V147, P4104, DOI 10.1210/en.2006-0162	39	35	35	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2657	2666		10.1096/fj.12-225060	http://dx.doi.org/10.1096/fj.12-225060			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23568777	Green Published			2022-12-28	WOS:000328841000015
J	Lagrange, J; Li, ZL; Fassot, C; Bourhim, M; Louis, H; Cat, AND; Parlakian, A; Wahl, D; Lacolley, P; Jaisser, F; Regnault, V				Lagrange, Jeremy; Li, Zhenlin; Fassot, Celine; Bourhim, Mustapha; Louis, Huguette; Cat, Aurelie Nguyen Dinh; Parlakian, Ara; Wahl, Denis; Lacolley, Patrick; Jaisser, Frederic; Regnault, Veronique			Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice	FASEB JOURNAL			English	Article						aldosterone; thrombin; SP1; smooth muscle cell; transcriptional regulation	MYOCARDIAL-INFARCTION; PLATELET ACTIVATION; HEART-FAILURE; ALDOSTERONE; CELLS; GENERATION; PLASMA; GENE; RATS; DYSFUNCTION	Previous studies have shown that aldosterone, which activates the mineralocorticoid receptor (MR), promotes thrombosis in animal models. Our objective was to determine whether MR activation/expression in the vascular endothelium could modify thrombotic risk in vivo and to examine thrombin generation at the surface of aortic endothelial cells (HAECs). MR was conditionally overexpressed in vivo in vascular endothelial cells in mice (MR-EC mice) or stimulated with aldosterone in HAECs. Thrombosis after ferric chloride injury was delayed in MR-EC mice compared with controls as well as in wild-type FVB/NRj mice treated with aldosterone (60 g/kg/d for 21 d). Thrombin generation in platelet-poor plasma did not differ between MR-EC mice and controls. In MR-EC mice, aortic endothelial cell protein C receptor (EPCR) expression was increased. Aldosterone (10(-8) M) attenuated thrombin generation at the surface of cultured HAECs, and this effect was associated with up-regulation of expression of EPCR, which promotes formation of activated protein C. Aldosterone increases EPCR expression via a transcriptional mechanism involving interaction of MR with the specificity protein 1 site. These findings demonstrate that MR activation acts on endothelial cells to protect against thrombosis in physiological conditions and that MR-mediated EPCR overexpression drives this antithrombotic property through enhancing protein C activation.Lagrange, J., Li, Z., Fassot, C., Bourhim, M., Louis, H., Nguyen Dinh Cat, A., Parlakian, A., Wahl, D., Lacolley, P., Jaisser, F., Regnault, V. Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice.	[Lagrange, Jeremy; Bourhim, Mustapha; Louis, Huguette; Wahl, Denis; Lacolley, Patrick; Regnault, Veronique] Fac Med, INSERM, U1116, F-54500 Vandoeuvre Les Nancy, France; [Lagrange, Jeremy; Bourhim, Mustapha; Louis, Huguette; Wahl, Denis; Lacolley, Patrick; Regnault, Veronique] Univ Lorraine, Nancy, France; [Li, Zhenlin; Fassot, Celine; Cat, Aurelie Nguyen Dinh; Parlakian, Ara; Jaisser, Frederic] Univ Paris 06, Paris, France; [Fassot, Celine; Cat, Aurelie Nguyen Dinh; Jaisser, Frederic] INSERM, U872, Ctr Rech Cordeliers, Paris, France; [Wahl, Denis; Lacolley, Patrick; Jaisser, Frederic; Regnault, Veronique] Ctr Hosp Univ CHU Nancy, Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Universite de Lorraine; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Nancy	Regnault, V (corresponding author), Fac Med, INSERM, U1116, 9 Ave Foret Haye, F-54500 Vandoeuvre Les Nancy, France.	veronique.regnault@inserm.fr	Lacolley, Patrick/G-3118-2013; lagrange, jeremy/AAQ-2538-2021; Lagrange, Jeremy/AAB-4505-2020; Fassot, Celine/K-1494-2015; CAT, Aurelie NGUYEN DINH/H-8182-2013; Regnault, Veronique/H-9138-2016; Li, Zhenlin/E-3937-2016; REGNAULT, Veronique/AAY-1711-2020; Jaisser, Frederic/P-4287-2017	Lagrange, Jeremy/0000-0002-0811-565X; REGNAULT, Veronique/0000-0001-6418-5022; Jaisser, Frederic/0000-0001-9051-1901; LI, Zhenlin/0000-0002-3706-4505; ARA, PARLAKIAN/0000-0002-0928-2185	Agence Nationale de la Recherche (ANR) Blanc program [NT09_450866]; Region Lorraine; Communaute Urbaine du Grand Nancy (Nancy, France)	Agence Nationale de la Recherche (ANR) Blanc program(French National Research Agency (ANR)); Region Lorraine(Region Grand-Est); Communaute Urbaine du Grand Nancy (Nancy, France)	The authors thank Christos Chatzantoniou and Sandrine Placier for assistance in setting up the arterial thrombosis model. The authors are grateful to Sebastien Hupont (FR 3209) for his participation. The authors thank Mary Osborne-Pellegrin and Peter Lenting for helpful discussion and comments on the manuscript, and Simon N. Thornton for manuscript editing. This study was supported by the Agence Nationale de la Recherche (ANR) Blanc program NT09_450866. J.L. is supported by the Region Lorraine and the Communaute Urbaine du Grand Nancy (Nancy, France).	Barr JD, 2013, BLOOD, V121, P3733, DOI 10.1182/blood-2012-11-468983; Bodary PF, 2006, ARTERIOSCL THROM VAS, V26, P233, DOI 10.1161/01.ATV.0000195782.07637.44; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; Burger D, 2012, J AM SOC HYPERTENS, V6, P85, DOI 10.1016/j.jash.2011.11.003; Cat AND, 2010, FASEB J, V24, P2454, DOI 10.1096/fj.09-147926; Centelles MN, 2010, THROMB HAEMOSTASIS, V103, P1239, DOI 10.1160/TH09-11-0750; Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859; Ducros E, 2008, BIOCHEM BIOPH RES CO, V373, P192, DOI 10.1016/j.bbrc.2008.05.185; Esmon CT, 2004, CRIT CARE MED, V32, pS298, DOI 10.1097/01.CCM.0000126128.64614.81; Funder JW, 2004, TRENDS ENDOCRIN MET, V15, P139, DOI 10.1016/j.tem.2004.03.006; Gromotowicz A, 2011, J RENIN-ANGIO-ALDO S, V12, P430, DOI 10.1177/1470320310397405; Hackeng TM, 1996, BIOCHEM J, V319, P399, DOI 10.1042/bj3190399; Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636; Itoh Y, 2010, ARTERIOSCL THROM VAS, V30, P1725, DOI 10.1161/ATVBAHA.110.207365; Jeong Y, 2009, P NATL ACAD SCI USA, V106, P3782, DOI 10.1073/pnas.0804037106; Kolkhof P, 2012, MOL CELL ENDOCRINOL, V350, P310, DOI 10.1016/j.mce.2011.06.025; Li W, 2005, J THROMB HAEMOST, V3, P1351, DOI 10.1111/j.1538-7836.2005.01385.x; Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840; Lidegaard O, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6423; Mao XQ, 2012, CARDIOVASC RES, V96, P513, DOI 10.1093/cvr/cvs274; McCurley A, 2012, MOL CELL ENDOCRINOL, V350, P256, DOI 10.1016/j.mce.2011.06.014; Meinel S, 2013, NUCLEIC ACIDS RES, V41, P8045, DOI 10.1093/nar/gkt581; Messaoudi S, 2012, MOL CELL ENDOCRINOL, V350, P266, DOI 10.1016/j.mce.2011.06.038; Messaoudi S, 2009, FASEB J, V23, P2176, DOI 10.1096/fj.08-125302; Mollica LR, 2006, BLOOD, V108, P1251, DOI 10.1182/blood-2006-02-001461; Newfell BG, 2011, ARTERIOSCL THROM VAS, V31, P1871, DOI 10.1161/ATVBAHA.111.229070; Parlakian A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009299; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Qu D, 2007, J THROMB HAEMOST, V5, P395, DOI 10.1111/j.1538-7836.2007.02347.x; REGNAULT V, 1991, THROMB RES, V63, P629, DOI 10.1016/0049-3848(91)90089-F; REGNAULT V, 1995, THROMB HAEMOSTASIS, V73, P1365; Regnault W, 2004, THROMB RES, V114, P539, DOI 10.1016/j.thromres.2004.06.017; Schafer A, 2003, THROMB HAEMOSTASIS, V89, P1024, DOI 10.1055/s-0037-1613404; Schafer A, 2010, J PHYSIOL PHARMACOL, V61, P45; SIMPSON SA, 1953, EXPERIENTIA, V9, P333, DOI 10.1007/BF02155834; Skott O, 2006, PHARMACOL THERAPEUT, V111, P495, DOI 10.1016/j.pharmthera.2005.10.010; Stankiewicz A, 2007, THROMB HAEMOSTASIS, V98, P697, DOI 10.1160/TH07-03-0237; Tchaikovski SN, 2007, J THROMB HAEMOST, V5, P2079, DOI 10.1111/j.1538-7836.2007.02719.x; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; Weiler H, 2011, HAMOSTASEOLOGIE, V31, P185, DOI 10.5482/ha-1166; Wu CQ, 2013, BJOG-INT J OBSTET GY, V120, P801, DOI 10.1111/1471-0528.12210; Zannad F, 2011, NEW ENGL J MED, V364, P11, DOI 10.1056/NEJMoa1009492; Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427	43	19	19	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2062	2072		10.1096/fj.13-238188	http://dx.doi.org/10.1096/fj.13-238188			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24451386				2022-12-28	WOS:000335336000011
J	Wolff, NA; Ghio, AJ; Garrick, LM; Garrick, MD; Zhao, L; Fenton, RA; Thevenod, F				Wolff, Natascha A.; Ghio, Andrew J.; Garrick, Laura M.; Garrick, Michael D.; Zhao, Lin; Fenton, Robert A.; Thevenod, Frank			Evidence for mitochondrial localization of divalent metal transporter 1 (DMT1)	FASEB JOURNAL			English	Article						adenine nucleotide translocator; early endosomal antigen 1; kiss-and-run; lysosome-associated membrane protein; transferrin	KIDNEY PROXIMAL TUBULE; CYTOCHROME-C-OXIDASE; IRON-METABOLISM; SUPEROXIDE-DISMUTASE; MEMBRANE-PROTEINS; EPITHELIAL-CELLS; ION TRANSPORTER; OUTER-MEMBRANE; RAT-KIDNEY; TRAFFICKING	In mammalian cells, mitochondria receive most incoming iron, yet no entry pathway for iron at the outer mitochondrial membrane (OMM) has been characterized. Our results show that the divalent metal transporter 1 (DMT1) occurs in the OMM. Immunoblots detected DMT1 in mitochondria from a pneumocyte cell model in their OMM. Using the split-ubiquitin yeast 2-hybrid system, we found that cytochrome c oxidase subunit II (COXII) and the translocase of OMM 6-kDa subunit (Tom6) homologue interact with DMT1. COXII coimmunoprecipitates with DMT1. There are 4 DMT1 isoforms that differ at the N and C termini. Using HEK293 cells that inducibly express all of the 4 ends of DMT1, we found all of them in the OMM, as detected by immunoblots after cell fractionation, and in isolated mitochondria, as detected by immunofluorescence. Immunoblot analysis of purified cell fractions from rat renal cortex confirmed and extended these results to the kidney, which expressed high levels of DMT1. Immunogold labeling detected DMT1 colocalization in mitochondria with the voltage-dependent anion-selective channel protein-1, which is expressed in the OMM. We suggest that DMT1 not only exports iron from endosomes, but also serves to import the metal into the mitochondria.Wolff, N. A., Ghio, A. J., Garrick, L. M., Garrick, M. D., Zhao, L., Fenton, R. A., Thevenod, F. Evidence for mitochondrial localization of divalent metal transporter 1 (DMT1).	[Wolff, Natascha A.; Thevenod, Frank] Univ Witten Herdecke, Dept Physiol & Pathophysiol, D-58453 Witten, Germany; [Wolff, Natascha A.; Thevenod, Frank] Univ Witten Herdecke, Ctr Biomed Educ & Res ZBAF, D-58453 Witten, Germany; [Ghio, Andrew J.] US EPA, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Chapel Hill, NC USA; [Garrick, Laura M.; Garrick, Michael D.; Zhao, Lin] SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; [Fenton, Robert A.] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Fenton, Robert A.] Aarhus Univ, Interact Prot Epithelial Transport InterPrET Ctr, Aarhus, Denmark	Witten Herdecke University; Witten Herdecke University; United States Environmental Protection Agency; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Aarhus University; Aarhus University	Thevenod, F (corresponding author), Univ Witten Herdecke, Dept Physiol & Pathophysiol, Stockumer Str 12, D-58453 Witten, Germany.	natascha.wolff@uni-wh.de; frank.thevenod@uni-wh.de	Fenton, Robert/AFR-6983-2022; Fenton, Robert A/ABD-9824-2021	Fenton, Robert/0000-0003-1623-199X; Garrick, Michael/0000-0001-7342-6983	Deutsche Forschungsgemeinschaft (DFG) [TH345/11-1]; Center for Biomedical Education and Research (ZBAF; University of Witten/Herdecke, Witten, Germany); Laura and Michael Garrick Fund; Danish Medical Research Council; Lundbeck Foundation	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Center for Biomedical Education and Research (ZBAF; University of Witten/Herdecke, Witten, Germany); Laura and Michael Garrick Fund; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden)	The authors thank Dr. Sabine Brast and Dr. Giuliano Ciarimboli for advice regarding the split-ubiquitin yeast 2-hybrid system, Tobias Dreser and Else-Merete Locke for technical assistance, and Dr. Funmei Yang (University of Texas at San Antonio, San Antonio, TX, USA) for assistance in performing the immunoblot in Fig. 1. Access to the Zeiss AxioImager fluorescence microscope was provided by the State University of New York (SUNY) Buffalo Confocal Microscopy Facility (Buffalo, NY, USA). Financial support was obtained from Deutsche Forschungsgemeinschaft (DFG) grant TH345/11-1, The Center for Biomedical Education and Research (ZBAF; University of Witten/Herdecke, Witten, Germany), the Laura and Michael Garrick Fund, the Danish Medical Research Council, and the Lundbeck Foundation. The hDMT1-1A/+IRE plasmids were provided by Dr. Matthias Hentze [European Molecular Biology Laboratory (EMBL), Heidelberg, Germany].	Abouhamed M, 2006, AM J PHYSIOL-RENAL, V290, pF1525, DOI 10.1152/ajprenal.00359.2005; Abouhamed M, 2007, AM J PHYSIOL-RENAL, V293, pF705, DOI 10.1152/ajprenal.00198.2007; Becker T, 2012, TRENDS BIOCHEM SCI, V37, P85, DOI 10.1016/j.tibs.2011.11.004; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breuer W, 2008, INT J BIOCHEM CELL B, V40, P350, DOI 10.1016/j.biocel.2007.03.010; Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005; Chen CY, 2012, BBA-MOL CELL RES, V1823, P1459, DOI 10.1016/j.bbamcr.2012.01.003; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Christensen EI, 2012, PHYSIOLOGY, V27, P223, DOI 10.1152/physiol.00022.2012; Colombini M, 2012, BBA-BIOMEMBRANES, V1818, P1457, DOI 10.1016/j.bbamem.2011.12.026; De Pinto V, 2010, FEBS LETT, V584, P1793, DOI 10.1016/j.febslet.2010.02.049; Dunn LL, 2007, TRENDS CELL BIOL, V17, P93, DOI 10.1016/j.tcb.2006.12.003; Ferguson CJ, 2001, AM J PHYSIOL-RENAL, V280, pF803, DOI 10.1152/ajprenal.2001.280.5.F803; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Garrick MD, 2006, BIOCHEM J, V398, P539, DOI 10.1042/BJ20051987; Garrick MD, 2009, BBA-GEN SUBJECTS, V1790, P309, DOI 10.1016/j.bbagen.2009.03.018; Goldsteins G, 2008, J BIOL CHEM, V283, P8446, DOI 10.1074/jbc.M706111200; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Grefen C., 2007, CURR PROTOC NEUROSCI, V41; Griparic L, 2005, METHOD ENZYMOL, V404, P620, DOI 10.1016/S0076-6879(05)04054-1; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Kato H, 2008, BIOCHEM BIOPH RES CO, V369, P958, DOI 10.1016/j.bbrc.2008.02.150; Kuo HC, 2004, J NEUROSCI RES, V76, P497, DOI 10.1002/jnr.20112; Lill R, 2012, BBA-MOL CELL RES, V1823, P1491, DOI 10.1016/j.bbamcr.2012.05.009; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; Mackenzie B, 2006, PFLUG ARCH EUR J PHY, V451, P544, DOI 10.1007/s00424-005-1494-3; Martines AMF, 2013, NAT REV NEPHROL, V9, P385, DOI 10.1038/nrneph.2013.98; Moeller HB, 2009, KIDNEY INT, V75, P295, DOI 10.1038/ki.2008.505; Norden AGW, 2001, KIDNEY INT, V60, P1885, DOI 10.1046/j.1523-1755.2001.00016.x; Obrdlik P, 2004, P NATL ACAD SCI USA, V101, P12242, DOI 10.1073/pnas.0404467101; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradkar PN, 2009, MOL CELL BIOL, V29, P1007, DOI 10.1128/MCB.01685-08; Porcelli AM, 2005, BIOCHEM BIOPH RES CO, V326, P799, DOI 10.1016/j.bbrc.2004.11.105; Richardson DR, 2010, P NATL ACAD SCI USA, V107, P10775, DOI 10.1073/pnas.0912925107; RICHMOND VS, 1972, BRIT J HAEMATOL, V23, P605, DOI 10.1111/j.1365-2141.1972.tb07095.x; Roth JA, 2000, J NEUROSCI, V20, P7595; Roth JA, 2010, J NEUROCHEM, V113, P454, DOI 10.1111/j.1471-4159.2010.06607.x; Salazar J, 2008, P NATL ACAD SCI USA, V105, P18578, DOI 10.1073/pnas.0804373105; Sarraf SA, 2013, NATURE, V496, P372, DOI 10.1038/nature12043; Sheftel AD, 2007, BLOOD, V110, P125, DOI 10.1182/blood-2007-01-068148; Shvartsman M, 2012, BIOMETALS, V25, P711, DOI 10.1007/s10534-012-9529-7; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Smith CP, 2009, BBA-GEN SUBJECTS, V1790, P724, DOI 10.1016/j.bbagen.2008.10.010; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Tabuchi M, 2000, J BIOL CHEM, V275, P22220, DOI 10.1074/jbc.M001478200; Tchernitchko D, 2002, BIOCHEM J, V363, P449, DOI 10.1042/0264-6021:3630449; Thevenod F, 2003, BIOCHEM BIOPH RES CO, V300, P546, DOI 10.1016/S0006-291X(02)02871-1; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Veuthey T, 2008, AM J PHYSIOL-RENAL, V295, pF1213, DOI 10.1152/ajprenal.90216.2008; Walther DM, 2009, BBA-MOL CELL RES, V1793, P42, DOI 10.1016/j.bbamcr.2008.04.013; Wang XC, 2002, AM J PHYSIOL-LUNG C, V282, pL987, DOI 10.1152/ajplung.00253.2001; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Wolff NA, 2011, TOXICOL LETT, V203, P210, DOI 10.1016/j.toxlet.2011.03.014; Wolff NA, 2011, J CELL MOL MED, V15, P209, DOI 10.1111/j.1582-4934.2009.00985.x; Xu WJ, 2013, CELL METAB, V17, P319, DOI 10.1016/j.cmet.2013.02.004; Zhang AS, 2009, J BIOL CHEM, V284, P711, DOI 10.1074/jbc.R800017200	57	40	41	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2134	2145		10.1096/fj.13-240564	http://dx.doi.org/10.1096/fj.13-240564			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24448823				2022-12-28	WOS:000335336000017
J	Xiao, WD; Feng, YJ; Holst, JJ; Hartmann, B; Yang, H; Teitelbaum, DH				Xiao, Weidong; Feng, Yongjia; Holst, Jens J.; Hartmann, Bolette; Yang, Hua; Teitelbaum, Daniel H.			Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition	FASEB JOURNAL			English	Article						proliferation; epithelial barrier function; taste receptor; metabotropic glutamate receptor	BITTER TASTE RECEPTORS; RAT SMALL-INTESTINE; GASTROINTESTINAL-TRACT; BARRIER FUNCTION; EPITHELIAL-CELLS; GROWTH-FACTOR; UMAMI TASTE; MONOSODIUM GLUTAMATE; POTENTIAL MECHANISM; MULTIPLE RECEPTORS	Small intestine luminal nutrient sensing may be crucial for modulating physiological functions. However, its mechanism of action is incompletely understood. We used a model of enteral nutrient deprivation, or total parenteral nutrition (TPN), resulting in intestinal mucosal atrophy and decreased epithelial barrier function (EBF). We examined how a single amino acid, glutamate (GLM), modulates intestinal epithelial cell (IEC) growth and EBF. Controls were chow-fed mice, T1 receptor-3 (T1R3)-knockout (KO) mice, and treatment with the metabotropic glutamate receptor (mGluR)-5 antagonist MTEP. TPN significantly changed the amount of T1Rs, GLM receptors, and transporters, and GLM prevented these changes. GLM significantly prevented TPN-associated intestinal atrophy (2.5-fold increase in IEC proliferation) and was dependent on up-regulation of the protein kinase pAkt, but independent of T1R3 and mGluR5 signaling. GLM led to a loss of EBF with TPN (60% increase in FITC-dextran permeability, 40% decline in transepithelial resistance); via T1R3, it protected EBF, whereas mGluR5 was associated with EBF loss. GLM led to a decline in circulating glucagon-like peptide 2 (GLP-2) during TPN. The decline was regulated by T1R3 and mGluR5, suggesting a novel negative regulator pathway for IEC proliferation not previously described. Loss of luminal nutrients with TPN administration may widely affect intestinal taste sensing. GLM has previously unrecognized actions on IEC growth and EBF. Restoring luminal sensing via GLM could be a strategy for patients on TPN.Xiao, W., Feng, Y., Holst, J. J., Hartmann, B., Yang, H., Teitelbaum, D. H. Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition.	[Xiao, Weidong; Feng, Yongjia; Teitelbaum, Daniel H.] Univ Michigan, Pediat Surg Sect, Dept Surg, Sch Med, Ann Arbor, MI 48109 USA; [Xiao, Weidong; Feng, Yongjia; Teitelbaum, Daniel H.] Univ Michigan, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA; [Xiao, Weidong; Yang, Hua] Third Mil Med Univ, Xinqiao Hosp, Dept Gen Surg, Chongqing, Peoples R China; [Holst, Jens J.; Hartmann, Bolette] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen, Denmark	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Army Medical University; University of Copenhagen	Teitelbaum, DH (corresponding author), Univ Michigan, Pediat Surg Sect, Mott Childrens Hosp F3970, Ann Arbor, MI 48109 USA.	dttlbm@umich.edu	Holst, Jens/AAA-8022-2022	Holst, Jens Juul/0000-0001-6853-3805; Hartmann, Bolette/0000-0001-8509-2036	Ajinomoto Co. Inc. (Tokyo, Japan); U.S. National Institutes of Health [2R01AI-44076-14]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044076] Funding Source: NIH RePORTER	Ajinomoto Co. Inc. (Tokyo, Japan); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank P. J. Browner and Drs. R. Sueyoshi, M. W. Ralls, and R. S. Herman for assistance with mouse care, sample collection, and the Ussing chamber experiment, and H. K. Yoon for technical assistance. This work was supported by Ajinomoto Co. Inc. (Tokyo, Japan) and U.S. National Institutes of Health grant 2R01AI-44076-14. The authors declare no conflicts of interest.	Agency for Healthcare Research and Quality, 2010, DAT PN EN US; Akiba Y, 2011, ACTA PHYSIOL, V201, P77, DOI 10.1111/j.1748-1716.2010.02149.x; Akiba Y, 2011, DIGESTION, V83, P25, DOI 10.1159/000323401; Akiba Y, 2009, AM J PHYSIOL-GASTR L, V297, pG781, DOI 10.1152/ajpgi.90605.2008; Akiba Y, 2009, AM J CLIN NUTR, V90, p826S, DOI 10.3945/ajcn.2009.27462U; Amagase K, 2012, J PHARMACOL SCI, V118, P131, DOI 10.1254/jphs.11R03FM; Bezencon C, 2007, CHEM SENSES, V32, P41, DOI 10.1093/chemse/bjl034; Chance WT, 2006, PEPTIDES, V27, P883, DOI 10.1016/j.peptides.2005.09.012; Conigrave AD, 2006, AM J PHYSIOL-GASTR L, V291, pG753, DOI 10.1152/ajpgi.00189.2006; Delay ER, 2006, CHEM SENSES, V31, P351, DOI 10.1093/chemse/bjj039; Dockray G J, 2003, J Physiol Pharmacol, V54 Suppl 4, P9; Feng YJ, 2012, ANN NY ACAD SCI, V1258, P71, DOI 10.1111/j.1749-6632.2012.06572.x; Feng YJ, 2010, AM J PHYSIOL-GASTR L, V298, pG833, DOI 10.1152/ajpgi.00030.2010; Feng YJ, 2009, J PHYSIOL-LONDON, V587, P641, DOI 10.1113/jphysiol.2008.162719; Finger Thomas E, 2011, F1000 Biol Rep, V3, P20, DOI 10.3410/B3-20; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Janssen S, 2011, P NATL ACAD SCI USA, V108, P2094, DOI 10.1073/pnas.1011508108; Kaji I, 2009, AM J PHYSIOL-GASTR L, V296, pG971, DOI 10.1152/ajpgi.90514.2008; Kinnamon SC, 2009, AM J CLIN NUTR, V90, p753S, DOI 10.3945/ajcn.2009.27462K; Kondoh T, 2009, AM J CLIN NUTR, V90, p832S, DOI 10.3945/ajcn.2009.27462V; Krug SM, 2009, MOL BIOL CELL, V20, P3713, DOI 10.1091/mbc.E09-01-0080; Kubera C, 2012, NEUROSCIENCE, V219, P271, DOI 10.1016/j.neuroscience.2012.05.064; Li XD, 2009, AM J CLIN NUTR, V90, p733S, DOI 10.3945/ajcn.2009.27462G; Liu XW, 2006, AM J CLIN NUTR, V84, P1142, DOI 10.1093/ajcn/84.5.1142; Mace OJ, 2007, J PHYSIOL-LONDON, V582, P379, DOI 10.1113/jphysiol.2007.130906; Mace OJ, 2009, J PHYSIOL-LONDON, V587, P195, DOI 10.1113/jphysiol.2008.159616; Mayer EA, 2011, NAT REV NEUROSCI, V12, P453, DOI 10.1038/nrn3071; Negri R, 2011, J PEDIATR GASTR NUTR, V53, P601, DOI 10.1097/MPG.0b013e3182309641; Nelson DW, 2008, AM J PHYSIOL-REG I, V294, pR1175, DOI 10.1152/ajpregu.00238.2007; Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003; Nguyen CA, 2012, CURR MED CHEM, V19, P28; Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533; Nochi R, 2012, EUR J NEUROSCI, V36, P2273, DOI 10.1111/j.1460-9568.2012.08128.x; Nose K, 2010, J INTERF CYTOK RES, V30, P67, DOI 10.1089/jir.2009.0046; Reeds PJ, 2000, J NUTR, V130, p978S, DOI 10.1093/jn/130.4.978S; Rozengurt E, 2006, AM J PHYSIOL-GASTR L, V291, pG171, DOI 10.1152/ajpgi.00073.2006; Schunemann DP, 2010, PATHOL ONCOL RES, V16, P285, DOI 10.1007/s12253-009-9223-4; Sharp CD, 2003, AM J PHYSIOL-HEART C, V285, pH2592, DOI 10.1152/ajpheart.00520.2003; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Shin YJ, 2010, NEUROCHEM RES, V35, P1628, DOI 10.1007/s11064-010-0223-2; Sternini C, 2007, AM J PHYSIOL-GASTR L, V292, pG457, DOI 10.1152/ajpgi.00411.2006; Sun XY, 2008, AM J PHYSIOL-GASTR L, V294, pG139, DOI 10.1152/ajpgi.00386.2007; Sun XY, 2006, JPEN-PARENTER ENTER, V30, P474, DOI 10.1177/0148607106030006474; Swartz TD, 2012, BRIT J NUTR, V107, P621, DOI 10.1017/S0007114511003412; Vermeulen MAR, 2011, WORLD J GASTROENTERO, V17, P1569, DOI 10.3748/wjg.v17.i12.1569; Wang JH, 2011, J PHARMACOL EXP THER, V339, P464, DOI 10.1124/jpet.111.184788; Wauson EM, 2012, MOL CELL, V47, P851, DOI 10.1016/j.molcel.2012.08.001; Wildhaber BE, 2005, J SURG RES, V123, P8, DOI 10.1016/j.jss.2004.06.015; Wildhaber BE, 2002, PEDIATR SURG INT, V18, P570, DOI 10.1007/s00383-002-0869-1; Wildhaber BE, 2003, J SURG RES, V112, P144, DOI 10.1016/S0022-4804(03)00160-4; Yang H, 2003, AM J PHYSIOL-GASTR L, V284, pG629, DOI 10.1152/ajpgi.00290.2002; Yang H, 2008, ANN SURG, V248, P849, DOI 10.1097/SLA.0b013e31818a1522; Yang H, 2009, ANN NY ACAD SCI, V1165, P338, DOI 10.1111/j.1749-6632.2009.04026.x; Yasumatsu K, 2012, J PHYSIOL-LONDON, V590, P1155, DOI 10.1113/jphysiol.2011.211920; Yasumatsu K, 2009, AM J CLIN NUTR, V90, p747S, DOI 10.3945/ajcn.2009.27462J; Young RL, 2009, GUT, V58, P337, DOI 10.1136/gut.2008.148932; Zhang CJ, 2009, J NUTR, V139, P1315, DOI 10.3945/jn.108.096669; Zhang J, 2013, AMINO ACIDS, V45, P1169, DOI 10.1007/s00726-013-1573-2; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4; Zhao L, 2011, NEUROSCIENCE, V192, P185, DOI 10.1016/j.neuroscience.2011.06.044; Znalesniak EB, 2010, CELL PHYSIOL BIOCHEM, V25, P533, DOI 10.1159/000303057	61	31	35	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2073	2087		10.1096/fj.13-238311	http://dx.doi.org/10.1096/fj.13-238311			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24497581	Green Published, Green Submitted			2022-12-28	WOS:000335336000012
J	Wexler-Cohen, Y; Stevens, GC; Barnoy, E; van der Bliek, AM; Johnson, PJ				Wexler-Cohen, Yael; Stevens, Grant C.; Barnoy, Eran; van der Bliek, Alexander M.; Johnson, Patricia J.			A dynamin-related protein contributes to Trichomonas vaginalis hydrogenosomal fission	FASEB JOURNAL			English	Article						organelle division; evolution; parasitology	SINGLE DYNAMIN; GENOME SEQUENCE; MITOCHONDRIAL; MEMBRANE; ENDOCYTOSIS; TINIDAZOLE; ORGANELLES; EVOLUTION; DIVISION; VESICLE	Trichomonas vaginalis is a highly divergent, unicellular eukaryote of the phylum Metamonada, class Parabasalia, and the source of a common sexually transmitted infection. This parasite lacks mitochondria, but harbors an evolutionarily related organelle, the hydrogenosome. We explored the role of dynamin-related proteins (DRPs) in the division of the hydrogenosome. Eight DRP homologues [T. vaginalis DRPs (TvDRPs)], which can be grouped into 3 subclasses, are present in T. vaginalis. We examined 5 TvDRPs that are representative of each subclass, by introducing dominant negative mutations analogous to those known to interfere with mitochondrial division in yeast, worms, and mammals. Microscopic and cell fractionation analyses of parasites expressing one of the mutated TvDRPs (TVAG_350040) demonstrated that this protein localizes to hydrogenosomes. Moreover, these organelles were found to be increased in size and reduced in number in cells expressing this dominant negative protein, relative to parasites expressing the corresponding wild-type TvDRP, the other 4 mutant TvDRPs, or an empty vector control. Our data indicate a role for a TvDRP in the fission of T. vaginalis hydrogenosomes, similar to that described for peroxisomes and mitochondria. These findings reveal a conservation of core components involved in the division of diverse eukaryotic organelles across broad phylogenetic distances.Wexler-Cohen, Y. Stevens, G. C., Barnoy, E. van der Bliek, A. M., Johnson, P. J. A dynamin-related protein contributes to Trichomonas vaginalis hydrogenosomal fission.	[Wexler-Cohen, Yael; Stevens, Grant C.; Johnson, Patricia J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA; [van der Bliek, Alexander M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90024 USA; [Barnoy, Eran] Univ Calif Los Angeles, Dept Biol Stat, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Johnson, PJ (corresponding author), Univ Calif Los Angeles, 609 Charles E Young Dr E,1602 Mol Sci Bldg, Los Angeles, CA 90024 USA.	johnsonp@ucla.edu			U.S. National Institutes of Health [AI27857, GM051866]; Long-Term European Molecular Biology Organization (EMBO) fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027857, R29AI027857, R01AI027857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051866] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Long-Term European Molecular Biology Organization (EMBO) fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Sirus Kohan for assistance with electron microscopic analyses performed at the Electron Microscopy Services Center of the University of California-Los Angeles Brain Research Institute and their colleagues, Dr. Gil Lustig, Angelica Riestra, Olivia Twu, Dr. Clea Mantini, and Dr. Brian Janssen for assistance, support, and insightful comments. This work was funded by U.S. National Institutes of Health grants AI27857 (to P.J.J.) and GM051866 (to A.M.V.) and a Long-Term European Molecular Biology Organization (EMBO) fellowship (to Y.W.-C.).	Benchimol M, 2008, CURR PHARM DESIGN, V14, P872, DOI 10.2174/138161208784041114; Benchimol M, 2008, TISSUE CELL, V40, P61, DOI 10.1016/j.tice.2007.09.006; Benchimol M, 2009, TISSUE CELL, V41, P151, DOI 10.1016/j.tice.2009.01.001; Bui HT, 2012, J CELL BIOL, V199, P613, DOI 10.1083/jcb.201207079; Carlton JM, 2007, SCIENCE, V315, P207, DOI 10.1126/science.1132894; Chanez AL, 2006, J CELL SCI, V119, P2968, DOI 10.1242/jcs.03023; Delgadillo MG, 1997, P NATL ACAD SCI USA, V94, P4716, DOI 10.1073/pnas.94.9.4716; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; DIAMOND LS, 1957, J PARASITOL, V43, P488, DOI 10.2307/3274682; Dyall SD, 2000, CURR OPIN MICROBIOL, V3, P404, DOI 10.1016/S1369-5274(00)00112-0; Dyall SD, 2004, NATURE, V431, P1103, DOI 10.1038/nature02990; Embley TM, 2006, NATURE, V440, P623, DOI 10.1038/nature04546; Fung HB, 2005, CLIN THER, V27, P1859, DOI 10.1016/j.clinthera.2005.12.012; Gaechter V, 2008, TRAFFIC, V9, P57, DOI 10.1111/j.1600-0854.2007.00657.x; Gandre-Babbe S, 2008, MOL BIOL CELL, V19, P2402, DOI 10.1091/mbc.E07-12-1287; Hirt RP, 2011, ADV PARASIT, V77, P87, DOI 10.1016/B978-0-12-391429-3.00006-X; Johnston VJ, 2008, CURR OPIN INFECT DIS, V21, P56, DOI 10.1097/QCO.0b013e3282f3d999; Koirala S, 2013, P NATL ACAD SCI USA, V110, pE1342, DOI 10.1073/pnas.1300855110; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lackner LL, 2009, BBA-MOL BASIS DIS, V1792, P1138, DOI 10.1016/j.bbadis.2008.11.011; Mears JA, 2008, METHOD CELL BIOL, V88, P237, DOI 10.1016/S0091-679X(08)00413-5; Morgan GW, 2004, J BIOL CHEM, V279, P10692, DOI 10.1074/jbc.M312178200; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; Narcisi EM, 1996, ANTIMICROB AGENTS CH, V40, P1121, DOI 10.1128/AAC.40.5.1121; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300; Rahaman A, 2008, CURR BIOL, V18, P1227, DOI 10.1016/j.cub.2008.07.042; Ryan CM, 2011, ESSAYS BIOCHEM, V51, P161, DOI [10.1042/BSE0510161, 10.1042/bse0510161]; Schwebke JR, 2004, CLIN MICROBIOL REV, V17, P794, DOI 10.1128/CMR.17.4.794-803.2004; Shiflett AM, 2010, ANNU REV MICROBIOL, V64, P409, DOI 10.1146/annurev.micro.62.081307.162826; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wakabayashi J, 2009, J CELL BIOL, V186, P805, DOI 10.1083/jcb.200903065	36	14	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1113	1121		10.1096/fj.13-235473	http://dx.doi.org/10.1096/fj.13-235473			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24297697	Green Published			2022-12-28	WOS:000335324800008
J	Okunishi, K; DeGraaf, AJ; Zaslona, Z; Peters-Golden, M				Okunishi, Katsuhide; DeGraaf, Angela J.; Zaslona, Zbigniew; Peters-Golden, Marc			Inhibition of protein translation as a novel mechanism for prostaglandin E2 regulation of cell functions	FASEB JOURNAL			English	Article						protein kinase A; ribosomal protein S6; mammalian target of rapamycin; fibroblasts; macrophages	LUNG FIBROBLASTS; E-PROSTANOID-2 RECEPTOR; MAMMALIAN TARGET; DNA METHYLATION; CYCLIC-AMP; S6 KINASE; COLLAGEN; CAMP; GROWTH; EXPRESSION	Prostaglandin E-2 (PGE(2)) regulates numerous biological processes by modulating transcriptional activation, epigenetic control, proteolysis, and secretion of various proteins. Scar formation depends on fibroblast elaboration of matrix proteins such as collagen, and this process is strongly suppressed by PGE(2) through activation of cAMP-dependent protein kinase A (PKA). However, the actual mechanism by which PGE(2)-PKA signaling inhibits collagen expression in fibroblasts has never been delineated, and that was the objective of this study. PGE(2) unexpectedly induced a rapid reduction in procollagen I protein expression in adult lung fibroblasts, with a half-maximum effect at 1.5 h. This effect reflected its inhibition of translation rather than transcription. Global protein synthesis was also inhibited by PGE(2). This action was mediated by PKA and involved both activation of ribosomal protein (rpS6) and suppression of mammalian target of rapamycin (mTOR). Similar effects of PGE(2) were demonstrated in mouse peritoneal macrophages (PMs). These findings identify inhibition of translation as a new mechanism by which PGE(2) regulates cellular function and a novel example of translational inhibition mediated by opposing actions on two distinct translational control pathways. Translational inhibition would be expected to contribute to dynamic alterations in cell function that accompany the changing PGE(2) levels observed in disease states and with various pharmacotherapies.Okunishi K., DeGraaf, A. J., Zasona, Z., Peters-Golden, M. Inhibition of protein translation as a novel mechanism for prostaglandin E-2 regulation of cell functions.	[Okunishi, Katsuhide; DeGraaf, Angela J.; Zaslona, Zbigniew; Peters-Golden, Marc] Univ Michigan Hlth Syst, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Peters-Golden, M (corresponding author), 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	petersm@umich.edu		Zaslona, Zbigniew/0000-0003-3361-4140	American Lung Association; Deutsche Forschungsgemeinschaft (German Research Foundation); U.S. National Institutes of Health [HL094311]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL094311] Funding Source: NIH RePORTER	American Lung Association; Deutsche Forschungsgemeinschaft (German Research Foundation)(German Research Foundation (DFG)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Scott H. Wettlaufer for technical contributions, Teresa M. Murphy and Sally Przybranowski for general technical assistance, and members of the laboratory of M.P.-G. for constructive input. This work was supported by an American Lung Association Senior Research Training Fellowship (K.O.), Japanese Grants-in-Aid for Scientific Research (K.O.), Deutsche Forschungsgemeinschaft (German Research Foundation; Z.Z.), and U.S. National Institutes of Health grant HL094311 (M.P.-G.).	af Forselles KJ, 2011, BRIT J PHARMACOL, V164, P1847, DOI 10.1111/j.1476-5381.2011.01495.x; Bauman KA, 2010, J CLIN INVEST, V120, P1950, DOI 10.1172/JCI38369; BITTERMAN PB, 1986, J CLIN INVEST, V77, P700, DOI 10.1172/JCI112364; BOROK Z, 1991, AM REV RESPIR DIS, V144, P1080, DOI 10.1164/ajrccm/144.5.1080; Canetti C, 2006, J LEUKOCYTE BIOL, V79, P1234, DOI 10.1189/jlb.0705374; ELIAS JA, 1985, AM REV RESPIR DIS, V131, P94; FINE A, 1989, J BIOL CHEM, V264, P16988; FINE A, 1992, BIOCHIM BIOPHYS ACTA, V1135, P67, DOI 10.1016/0167-4889(92)90167-A; Gilroy DW, 2001, AM J PHYSIOL-CELL PH, V281, pC188, DOI 10.1152/ajpcell.2001.281.1.C188; Goc A, 2011, J CELL PHYSIOL, V226, P3004, DOI 10.1002/jcp.22648; Gordon S, 2007, EUR J IMMUNOL, V37, pS9, DOI 10.1002/eji.200737638; Hetzel M, 2005, LUNG, V183, P225, DOI 10.1007/s00408-004-2534-z; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Huang S, 2007, AM J PHYSIOL-LUNG C, V292, pL405, DOI 10.1152/ajplung.00232.2006; Huang SK, 2008, AM J RESP CELL MOL, V39, P482, DOI 10.1165/rcmb.2008-0080OC; Huang SK, 2012, FASEB J, V26, P3703, DOI 10.1096/fj.11-203323; Huang SK, 2009, FASEB J, V23, P4317, DOI 10.1096/fj.08-128801; Hulmes DJS, 2002, J STRUCT BIOL, V137, P2, DOI 10.1006/jsbi.2002.4450; Jensen LT, 1997, CARDIOVASC RES, V33, P535, DOI 10.1016/S0008-6363(96)00247-7; Ji R, 2012, BRIT J PHARMACOL, V166, P1033, DOI 10.1111/j.1476-5381.2011.01817.x; Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029; Kim HW, 2010, MOL CELL BIOL, V30, P5406, DOI 10.1128/MCB.00217-10; Kohyama T, 2001, AM J PHYSIOL-LUNG C, V281, pL1257, DOI 10.1152/ajplung.2001.281.5.L1257; Kolodsick JE, 2003, AM J RESP CELL MOL, V29, P537, DOI 10.1165/rcmb.2002-0243OC; Larsson O, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003220; LAURENT GJ, 1987, AM J PHYSIOL, V252, pC1, DOI 10.1152/ajpcell.1987.252.1.C1; Liu XQ, 2004, AM J PHYSIOL-CELL PH, V286, pC1089, DOI 10.1152/ajpcell.00461.2003; Mavrakis M, 2006, HUM MOL GENET, V15, P2962, DOI 10.1093/hmg/ddl239; Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5; Misra UK, 2009, J CELL BIOCHEM, V108, P998, DOI 10.1002/jcb.22333; Moore CEJ, 2009, J MOL BIOL, V389, P480, DOI 10.1016/j.jmb.2009.04.020; Peters-Golden M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.275pe37; Poulalhon N, 2006, J BIOL CHEM, V281, P33045, DOI 10.1074/jbc.M606366200; Rennard S. I., 1982, J INVESTIGATIVE D S1, V79, p77S; Rocchi S, 2000, BIOCHEM J, V352, P483, DOI 10.1042/0264-6021:3520483; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Schweda F, 2004, AM J PHYSIOL-RENAL, V287, pF427, DOI 10.1152/ajprenal.00072.2004; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Serezani CHC, 2005, BLOOD, V106, P1067, DOI 10.1182/blood-2004-08-3323; Tanaka T, 2002, EUR RESPIR J, V20, P359, DOI 10.1183/09031936.02.00252602; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Valdez PA, 2012, IMMUNITY, V36, P668, DOI 10.1016/j.immuni.2012.02.013; White ES, 2005, AM J RESP CELL MOL, V32, P135, DOI 10.1165/rcmb.2004-0126OC; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Xia DR, 2012, NAT MED, V18, P224, DOI 10.1038/nm.2608; Xie JL, 2011, CELL SIGNAL, V23, P1927, DOI 10.1016/j.cellsig.2011.06.025; Zhu Y, 2001, Respir Res, V2, P300, DOI 10.1186/rr73; Zito CI, 2007, J BIOL CHEM, V282, P6946, DOI 10.1074/jbc.M608338200; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	50	13	13	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					56	66		10.1096/fj.13-231720	http://dx.doi.org/10.1096/fj.13-231720			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24072780	Green Published, Green Submitted			2022-12-28	WOS:000333526100008
J	Hishikawa, D; Shindou, H; Harayama, T; Ogasawara, R; Suwabe, A; Shimizu, T				Hishikawa, Daisuke; Shindou, Hideo; Harayama, Takeshi; Ogasawara, Rie; Suwabe, Akira; Shimizu, Takao			Identification of Sec14-like 3 as a novel lipid-packing sensor in the lung	FASEB JOURNAL			English	Article						phospholipid; lipid binding protein; lipid transport; alveolar surfactant	LAMELLAR BODY BIOGENESIS; TRANSFER PROTEIN; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; MEMBRANE CURVATURE; CRYSTAL-STRUCTURE; GENE-EXPRESSION; ACYL-COA; II CELLS; BINDING; SECRETION	Pulmonary surfactant, a complex composed primarily of lipids and associated proteins, is synthesized in alveolar type II (ATII) cells and secreted into alveoli to prevent collapse during respiration. Although numerous studies have clarified the fundamental roles of pulmonary surfactant, the molecular mechanisms of transport and secretion of pulmonary surfactant remain totally unknown. Thus, we screened candidate genes by comparing genes with the expressed sequence tag (EST) libraries of embryonic and adult lungs by using the digital differential display method in the National Center for Biotechnology Information (NCBI) database. We identified Sec14-like 3 (Sec14L3) as a new class of lipid-associated proteins highly expressed in ATII cells. We found that Sec14L3 expression is >100-fold increased during the perinatal period in the lung. Furthermore, Sec14L3 bound to small-sized liposomes (30 nm in diameter), but not to large-sized liposomes (100 nm diameter), through its Sec14 domain. Because of the increased curvature, lipid-packing defects are more likely to occur in small-sized liposomes than in large-sized liposomes. Based on these results, we conclude that Sec14L3 is a new class of lipid-packing sensor. Sec14L3 may play important roles in the lung, such as intracellular lipid transport, surfactant maturation, and endo/exocytosis.	[Hishikawa, Daisuke; Shindou, Hideo; Harayama, Takeshi; Shimizu, Takao] Natl Ctr Global Hlth & Med, Dept Lipid Signaling, Res Inst, Tokyo 1628655, Japan; [Ogasawara, Rie; Suwabe, Akira] Iwate Med Univ, Sch Med, Dept Lab Med, Morioka, Iwate 020, Japan; [Shimizu, Takao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan	National Center for Global Health & Medicine - Japan; Iwate Medical University; University of Tokyo	Shindou, H (corresponding author), Natl Ctr Global Hlth & Med, Tokyo 1628655, Japan.	hshindou-tky@umin.net	Shimizu, Takao/AAV-7052-2021; Harayama, Takeshi/AAD-8852-2022	Harayama, Takeshi/0000-0003-2255-4197	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan; MEXT [22790270, 24790805]; Cell Science Research Foundation	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cell Science Research Foundation(Cell Science Research Foundation, Japan)	The authors thank Drs. T. Hashidate, M. Tarui, M. Eto, K. Yanagida, and William Valentine (Japan National Center for Global Health and Medicine), Y. Kita, S. M. Tokuoka, and K. Kuniyeda (University of Tokyo) for suggestions and Y. Takahashi (National Center for Global Health and Medicine) for his valuable technical supports. The authors also thank Dr. William Valentine for critical reading of the manuscript. This work was supported by a Grant-in-Aid for Scientific Research (S) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (T. S.) and a Grant-in-Aid for Young Scientists (B) from the MEXT (D. H., 22790270; T. H., 24790805). H. S. was supported by a Grant-in-Aid for Young Scientists (B) from the MEXT and by the Cell Science Research Foundation.	Ali Mehboob, 2010, Proteome Sci, V8, P34, DOI 10.1186/1477-5956-8-34; Anantharaman V, 2002, GENOME BIOL, V3; Ban N, 2007, J BIOL CHEM, V282, P9628, DOI 10.1074/jbc.M611767200; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bankaitis VA, 2010, TRENDS BIOCHEM SCI, V35, P150, DOI 10.1016/j.tibs.2009.10.008; BATENBURG JJ, 1992, AM J PHYSIOL, V262, pL367, DOI 10.1152/ajplung.1992.262.4.L367; Bhatia VK, 2009, EMBO J, V28, P3303, DOI 10.1038/emboj.2009.261; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2012, DEV CELL, V23, P886, DOI 10.1016/j.devcel.2012.10.009; Bridges JP, 2010, J CLIN INVEST, V120, P1736, DOI 10.1172/JCI38061; Carvalho-Oliveira IM, 2009, J PROTEOME RES, V8, P3606, DOI 10.1021/pr900021m; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; Cheong N, 2007, J BIOL CHEM, V282, P23811, DOI 10.1074/jbc.M703927200; Curwin AJ, 2008, FUTURE LIPIDOL, V3, P399, DOI 10.2217/17460875.3.4.399; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; Ghosh R, 2011, BIOFACTORS, V37, P290, DOI 10.1002/biof.180; Habermehl D, 2005, BIOCHEM BIOPH RES CO, V326, P254, DOI 10.1016/j.bbrc.2004.11.021; Haque R, 2009, PROTEOME SCI, V7, DOI 10.1186/1477-5956-7-12; Harayama T, 2008, J BIOL CHEM, V283, P11097, DOI 10.1074/jbc.M708909200; Hishikawa D, 2008, P NATL ACAD SCI USA, V105, P2830, DOI 10.1073/pnas.0712245105; Itoh T, 2009, PROG LIPID RES, V48, P298, DOI 10.1016/j.plipres.2009.05.002; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kempna P, 2003, FREE RADICAL BIO MED, V34, P1458, DOI 10.1016/S0891-5849(03)00173-4; Kono N, 2013, SCIENCE, V340, P1106, DOI 10.1126/science.1233508; Li XM, 2002, J CELL BIOL, V157, P63, DOI 10.1083/jcb.200201037; Merkulova M, 2005, FEBS J, V272, P5595, DOI 10.1111/j.1742-4658.2005.04955.x; Merkulova MI, 1999, FEBS LETT, V450, P126, DOI 10.1016/S0014-5793(99)00470-6; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; Perez-Gil J, 2010, PHYSIOLOGY, V25, P132, DOI 10.1152/physiol.00006.2010; Proud D, 2008, AM J RESP CRIT CARE, V178, P962, DOI 10.1164/rccm.200805-670OC; Saito K, 2007, BBA-MOL CELL BIOL L, V1771, P719, DOI 10.1016/j.bbalip.2007.02.010; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Shan LH, 2012, INFLAMMATION, V35, P702, DOI 10.1007/s10753-011-9363-z; Shan LH, 2009, EUR J PHARMACOL, V616, P293, DOI 10.1016/j.ejphar.2009.06.055; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Shindou H, 2009, J BIOL CHEM, V284, P1, DOI 10.1074/jbc.R800046200; Stocker A, 2002, STRUCTURE, V10, P1533, DOI 10.1016/S0969-2126(02)00884-5; SUWABE A, 1991, AM J RESP CELL MOL, V5, P80, DOI 10.1165/ajrcmb/5.1.80; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; Vanni S, 2013, BIOPHYS J, V104, P575, DOI 10.1016/j.bpj.2012.11.3837; Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500; Wong TA, 2005, P NATL ACAD SCI USA, V102, P12777, DOI 10.1073/pnas.0506156102; Zhang XL, 2010, PHYSIOL GENOMICS, V41, P1, DOI 10.1152/physiolgenomics.00167.2009; Zhao Y, 2008, J BIOL CHEM, V283, P8258, DOI 10.1074/jbc.M710422200	45	13	13	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5131	5140		10.1096/fj.13-237941	http://dx.doi.org/10.1096/fj.13-237941			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24018064				2022-12-28	WOS:000329999000045
J	Vasconcelos, JF; Souza, BSF; Lins, TFS; Garcia, LMS; Kaneto, CM; Sampaio, GP; de Alcantara, AC; Meira, CS; Macambira, SG; Ribeiro-dos-Santos, R; Soares, MBP				Vasconcelos, Juliana F.; Souza, Bruno S. F.; Lins, Thayse F. S.; Garcia, Leticia M. S.; Kaneto, Carla M.; Sampaio, Geraldo P.; de Alcantara, Adriano C.; Meira, Cassio S.; Macambira, Simone G.; Ribeiro-dos-Santos, Ricardo; Soares, Milena B. P.			Administration of granulocyte colony-stimulating factor induces immunomodulation, recruitment of T regulatory cells, reduction of myocarditis and decrease of parasite load in a mouse model of chronic Chagas disease cardiomyopathy	FASEB JOURNAL			English	Article						Trypanosoma cruzi; cytokine therapy; inflammation; fibrosis; Th1 modulation	BONE-MARROW; G-CSF; DENDRITIC CELLS; IFN-GAMMA; IN-VITRO; EXPRESSION; INDUCTION; TRANSPLANTATION; MACROPHAGES; GENERATION	Chagas disease, caused by Trypanosoma cruzi infection, is a leading cause of heart failure in Latin American countries. In a previous study, we showed beneficial effects of granulocyte colony-stimulating factor (G-CSF) administration in the heart function of mice with chronic T. cruzi infection. Presently, we investigated the mechanisms by which this cytokine exerts its beneficial effects. Mice chronically infected with T. cruzi were treated with human recombinant G-CSF (3 courses of 200 mu g/kg/d for 5 d). Inflammation and fibrosis were reduced in the hearts of G-CSF-treated mice, compared with the hearts of vehicle-treated mice, which correlated with decreased syndecan-4, intercellular adhesion molecule-1, and galectin-3 expressions. Marked reductions in interferon-gamma and tumor necrosis factor-alpha and increased interleukin-10 and transforming growth factor-beta were found after G-CSF administration. Because the therapy did not induce a Th1 to Th2 immune response deviation, we investigated the role of regulatory T (T-reg) cells. A significant increase in CD3(+)Foxp3(+) cells was observed in the hearts of G-CSF-treated mice. In addition, a reduction of parasitism was observed after G-CSF treatment. Our results indicate a role of T-reg cells in the immunosuppression induced by G-CSF treatment and reinforces its potential therapeutic use for patients with Chagas disease.	[Vasconcelos, Juliana F.; Souza, Bruno S. F.; Lins, Thayse F. S.; Meira, Cassio S.; Macambira, Simone G.; Soares, Milena B. P.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil; [Vasconcelos, Juliana F.; Souza, Bruno S. F.; Garcia, Leticia M. S.; Kaneto, Carla M.; Sampaio, Geraldo P.; de Alcantara, Adriano C.; Macambira, Simone G.; Ribeiro-dos-Santos, Ricardo; Soares, Milena B. P.] Hosp Sao Rafael, Ctr Biotecnol & Terapia Celular, Salvador, BA, Brazil; [Kaneto, Carla M.] Univ Estadual Santa Cruz, Ilheus, BA, Brazil; [Macambira, Simone G.] Univ Fed Bahia, Salvador, BA, Brazil	Fundacao Oswaldo Cruz; Universidade Estadual de Santa Cruz; Universidade Federal da Bahia	Soares, MBP (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.	milena@bahia.fiocruz.br	Souza, Bruno/AAO-4601-2021; Vasconcelos, Juliana/AAN-5274-2021; Soares, Milena B. P./O-3771-2018; de Alcântara, Adriano Costa/A-6333-2011	Souza, Bruno/0000-0003-3771-0439; de Alcântara, Adriano Costa/0000-0003-0115-4987; Vasconcelos, Juliana/0000-0003-4553-0315; Soares, Milena/0000-0001-7549-2992	Brazilian Ministry of Sciences and Technology (MCT); Conselho Nacional de Pesquisas (CNPq); Financiadora de Estudos e Projetos (FINEP); Fundacao Oswaldo Cruz (FIOCRUZ); Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB); Coordination for the Improvement of Higher Education Personnel (CAPES) doctoral scholarship from Universidade Estadual de Feira de Santana/Programa de Pos-graduacao em Biotecnologia (UEFS/PPgBIOTEC); Rede Nordeste de Biotecnologia (RENORBIO) graduate programs; CNPq; FAPESB	Brazilian Ministry of Sciences and Technology (MCT); Conselho Nacional de Pesquisas (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Financiadora de Estudos e Projetos (FINEP)(Financiadora de Inovacao e Pesquisa (Finep)); Fundacao Oswaldo Cruz (FIOCRUZ); Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB); Coordination for the Improvement of Higher Education Personnel (CAPES) doctoral scholarship from Universidade Estadual de Feira de Santana/Programa de Pos-graduacao em Biotecnologia (UEFS/PPgBIOTEC); Rede Nordeste de Biotecnologia (RENORBIO) graduate programs; CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESB(Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB))	The authors thank Kyan Allahdadi for careful review of the article. This work was supported by grants from the Brazilian Ministry of Sciences and Technology (MCT), Conselho Nacional de Pesquisas (CNPq), Financiadora de Estudos e Projetos (FINEP), Fundacao Oswaldo Cruz (FIOCRUZ), and Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB). J.F.V. and A. C. D. A. were recipients of a Coordination for the Improvement of Higher Education Personnel (CAPES) doctoral scholarship from the Universidade Estadual de Feira de Santana/Programa de Pos-graduacao em Biotecnologia (UEFS/PPgBIOTEC) and Rede Nordeste de Biotecnologia (RENORBIO) graduate programs, respectively. B. S. F. S. holds a CNPq doctoral scholarship, and C. S. M. holds a FAPESB master scholarship. M. B. P. S. and R.R.-D.-S. are recipients of CNPq senior fellowships.	Angeli FS, 2010, CARDIOVASC DRUG THER, V24, P409, DOI 10.1007/s10557-010-6263-7; Bahia-Oliveira LMG, 1998, BRAZ J MED BIOL RES, V31, P127, DOI 10.1590/S0100-879X1998000100017; Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x; Bocchi EA, 1996, ANN THORAC SURG, V61, P1727, DOI 10.1016/0003-4975(96)00141-5; Boneberg EM, 2002, INFLAMM RES, V51, P119, DOI 10.1007/PL00000283; Campos SV, 2008, J HEART LUNG TRANSPL, V27, P597, DOI 10.1016/j.healun.2008.02.017; de Araujo FF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000992; FEDERICI EE, 1964, AM J TROP MED HYG, V13, P272, DOI 10.4269/ajtmh.1964.13.272; Ferrari R, 1999, PHARMACOL RES, V40, P97, DOI 10.1006/phrs.1998.0463; Fontt EO, 1998, INFECT IMMUN, V66, P2722, DOI 10.1128/IAI.66.6.2722-2727.1998; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Franco-Paredes Carlos, 2007, BMC Int Health Hum Rights, V7, P7, DOI 10.1186/1472-698X-7-7; Franco-Paredes C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000470; Galhardo M C, 1999, Rev Soc Bras Med Trop, V32, P291, DOI 10.1590/S0037-86821999000300011; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003; Hamon M, 2004, GLYCOBIOLOGY, V14, P311, DOI 10.1093/glycob/cwh038; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; HARTUNG T, 1995, BLOOD, V85, P2482, DOI 10.1182/blood.V85.9.2482.bloodjournal8592482; Higuchi T, 2008, ANN THORAC SURG, V85, P1367, DOI 10.1016/j.athoracsur.2007.12.053; Hill GR, 2010, BLOOD, V116, P819, DOI 10.1182/blood-2009-11-256495; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, P1, DOI DOI 10.1371/J0UR-NAL.PNTD.0000270; Ishiguro K, 2002, GLYCOCONJUGATE J, V19, P315, DOI 10.1023/A:1025308702966; Itoh M, 1999, J IMMUNOL, V162, P5317; Iwanaga K, 2004, BIOCHEM BIOPH RES CO, V325, P1353, DOI 10.1016/j.bbrc.2004.10.149; Joo HG, 2001, J LEUKOCYTE BIOL, V69, P555; Kared H, 2005, DIABETES, V54, P78, DOI 10.2337/diabetes.54.1.78; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Macambira SG, 2009, FASEB J, V23, P3843, DOI 10.1096/fj.09-137869; Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630; Morris ES, 2004, BLOOD, V103, P3573, DOI 10.1182/blood-2003-08-2864; Soares MBP, 2010, J INFECT DIS, V202, P416, DOI 10.1086/653481; Rabinovich GA, 2002, CELL DEATH DIFFER, V9, P661, DOI 10.1038/sj.cdd.4401009; Reifenberg K, 2007, AM J PATHOL, V171, P463, DOI 10.2353/ajpath.2007.060906; Rossetti M, 2010, EUR J IMMUNOL, V40, P3097, DOI 10.1002/eji.201040659; Rutella S, 2005, J IMMUNOL, V175, P7085, DOI 10.4049/jimmunol.175.11.7085; Rutella S, 2004, EUR J IMMUNOL, V34, P1291, DOI 10.1002/eji.200324651; Rutella S, 2002, BLOOD, V100, P2562, DOI 10.1182/blood-2001-12-0291; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Schijman AG, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000931; Sharma UC, 2004, CIRCULATION, V110, P3121, DOI 10.1161/01.CIR.0000147181.65298.4D; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Sloand EM, 2000, BLOOD, V95, P2269, DOI 10.1182/blood.V95.7.2269.007k37_2269_2274; Soares MBP, 2001, AN ACAD BRAS CIENC, V73, P547, DOI 10.1590/S0001-37652001000400008; Soares MBP, 2001, AM J PATHOL, V159, P703, DOI 10.1016/S0002-9440(10)61741-5; Soares MBP, 2011, CELL CYCLE, V10, P1448, DOI 10.4161/cc.10.9.15487; Tadokoro CE, 2001, IMMUNOL LETT, V77, P31, DOI 10.1016/S0165-2478(01)00197-3; Urry Z, 2012, EUR J IMMUNOL, V42, P2697, DOI 10.1002/eji.201242370; Vitelli-Avelar DM, 2005, SCAND J IMMUNOL, V62, P297, DOI 10.1111/j.1365-3083.2005.01668.x; von Aulock S, 2004, J PHARMACOL EXP THER, V308, P754, DOI 10.1124/jpet.103.058198; World Health Organization, CHAG DIS; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786; Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008-5472.CAN-04-1987	55	27	28	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4691	4702		10.1096/fj.13-229351	http://dx.doi.org/10.1096/fj.13-229351			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964077	Green Published			2022-12-28	WOS:000329999000005
J	Ou, O; Allen-Redpath, K; Urgast, D; Gordon, MJ; Campbell, G; Feldmann, J; Nixon, GF; Mayer, CD; Kwun, IS; Beattie, JH				Ou, Ou; Allen-Redpath, Keith; Urgast, Dagmar; Gordon, Margaret-Jane; Campbell, Gill; Feldmann, Joerg; Nixon, Graeme F.; Mayer, Claus-Dieter; Kwun, In-Sook; Beattie, John H.			Plasma zinc's alter ego is a low-molecular-weight humoral factor	FASEB JOURNAL			English	Article						atherosclerosis; microarray; smooth muscle; zinc deficiency	IMMUNE-SYSTEM; DIETARY ZINC; DEFICIENCY; INFLAMMATION; METALLOTHIONEIN; ATHEROSCLEROSIS; APOPTOSIS; ARTHRITIS; PROTEINS; CELLS	Mild dietary zinc deprivation in humans and rodents has little effect on blood plasma zinc levels, and yet cellular consequences of zinc depletion can be detected in vascular and other tissues. We proposed that a zinc-regulated humoral factor might mediate the effects of zinc deprivation. Using a novel approach, primary rat vascular smooth muscle cells (VSMCs) were treated with plasma from zinc-deficient (<1 mg Zn/kg) or zinc-adequate (35 mg Zn/kg, pair-fed) adult male rats, and zinc levels were manipulated to distinguish direct and indirect effects of plasma zinc. Gene expression changes were analyzed by microarray and qPCR, and incubation of VSMCs with blood plasma from zinc-deficient rats strongly changed the expression of >2500 genes, compared to incubation of cells with zinc-adequate rat plasma. We demonstrated that this effect was caused by a low-molecular-weight (approximate to 2-kDa) zinc-regulated humoral factor but that changes in gene expression were mostly reversed by adding zinc back to zinc-deficient plasma. Strongly regulated genes were overrepresented in pathways associated with immune function and development. We conclude that zinc deficiency induces the production of a low-molecular-weight humoral factor whose influence on VSMC gene expression is blocked by plasma zinc. This factor is therefore under dual control by zinc.Ou, O., Allen-Redpath, K., Urgast, D., Gordon, M.-J., Campbell, G., Feldmann, J., Nixon, G. F., Mayer, C.-D., Kwun, I.-S., and Beattie, J. H. Plasma zinc's alter ego is a low-molecular-weight humoral factor.	[Ou, Ou; Gordon, Margaret-Jane; Campbell, Gill; Beattie, John H.] Univ Aberdeen, Rowett Inst Nutr & Hlth, Aberdeen AB21 9SB, Scotland; [Allen-Redpath, Keith; Nixon, Graeme F.] Univ Aberdeen, Sch Med Sci, Aberdeen AB21 9SB, Scotland; [Urgast, Dagmar; Feldmann, Joerg] Univ Aberdeen, Trace Element Speciat Lab, Aberdeen AB21 9SB, Scotland; [Mayer, Claus-Dieter] Biomath & Stat Scotland, Aberdeen, Scotland; [Kwun, In-Sook] Andong Natl Univ, Dept Food Sci & Nutr, Andong, Kyungbook, South Korea	University of Aberdeen; University of Aberdeen; University of Aberdeen; James Hutton Institute; Andong National University	Beattie, JH (corresponding author), Univ Aberdeen, Rowett Inst Nutr & Hlth, Greenburn Rd, Aberdeen AB21 9SB, Scotland.	j.beattie@abdn.ac.uk	Feldmann, Jörg/AAT-3703-2020; Mayer, Claus-Dieter/L-9353-2013	Mayer, Claus-Dieter/0000-0001-8788-3149; Feldmann, Joerg/0000-0002-0524-8254; Nixon, Graeme/0000-0002-9581-3332	Rural and Environment Science and Analytical Services of the Scottish Government; National Research Foundation of Korea [NRF 220-2008-1-F00013]; University of Aberdeen	Rural and Environment Science and Analytical Services of the Scottish Government; National Research Foundation of Korea(National Research Foundation of Korea); University of Aberdeen	The work was supported by the Rural and Environment Science and Analytical Services of the Scottish Government to J.H.B, M.J.G., G. C., and C.-D.M., and by the National Research Foundation of Korea (grant NRF 220-2008-1-F00013) to O.O., K.A.-R., D. U., J.H.B., G.F.N., J.F. and I. S. K., with funding in part from the University of Aberdeen.	BALOGH Z, 1980, ANN RHEUM DIS, V39, P329, DOI 10.1136/ard.39.4.329; Bao B, 2011, BIOCHEM BIOPH RES CO, V407, P703, DOI 10.1016/j.bbrc.2011.03.084; Beattie JH, 2004, BRIT J NUTR, V91, P177, DOI 10.1079/BJN20031072; Beattie JH, 2008, PROTEOMICS, V8, P2126, DOI 10.1002/pmic.200700784; Beattie JH, 2012, MOL NUTR FOOD RES, V56, P1097, DOI 10.1002/mnfr.201100776; Breuner CW, 2002, J ENDOCRINOL, V175, P99, DOI 10.1677/joe.0.1750099; Cho Young-Eun, 2007, Nutr Res Pract, V1, P29, DOI 10.4162/nrp.2007.1.1.29; Croxford TP, 2011, J NUTR, V141, P359, DOI 10.3945/jn.110.131318; Eide DJ, 2011, METALLOMICS, V3, P1124, DOI 10.1039/c1mt00064k; FERNLEY RT, 1977, CLIN EXP PHARMACOL P, V4, P267, DOI 10.1111/j.1440-1681.1977.tb02624.x; Fraker PJ, 2004, ANNU REV NUTR, V24, P277, DOI 10.1146/annurev.nutr.24.012003.132454; Fukada T, 2011, J BIOL INORG CHEM, V16, P1123, DOI 10.1007/s00775-011-0797-4; Gibson RS, 2008, BRIT J NUTR, V99, pS14, DOI 10.1017/S0007114508006818; Guo BL, 2012, MOL CELL BIOCHEM, V361, P209, DOI 10.1007/s11010-011-1105-x; Haase H, 2006, BIOGERONTOLOGY, V7, P421, DOI 10.1007/s10522-006-9057-3; Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610; Johnson HM, 2006, CELL MOL BIOL, V52, P71, DOI 10.1170/T700; Kim JY, 2007, J AM COLL NUTR, V26, P1; King JC, 2010, INT J VITAM NUTR RES, V80, P300, DOI 10.1024/0300-9831/a000037; Kwon CS, 2007, BRIT J NUTR, V97, P247, DOI 10.1017/S0007114507328614; Maret W, 2012, J INORG BIOCHEM, V111, P110, DOI 10.1016/j.jinorgbio.2011.11.018; Mburu ASW, 2010, EUR J CLIN NUTR, V64, P510, DOI 10.1038/ejcn.2010.33; Nagata M, 2011, J NUTR BIOCHEM, V22, P172, DOI 10.1016/j.jnutbio.2010.01.003; Nixon G F, 1993, Blood Press, V2, P221, DOI 10.3109/08037059309077555; Patrushev N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033211; Prasad AS, 2012, J TRACE ELEM MED BIO, V26, P66, DOI 10.1016/j.jtemb.2012.04.004; Radek K, 2007, SEMIN IMMUNOPATHOL, V29, P27, DOI 10.1007/s00281-007-0064-5; Reeves PG, 2003, J NUTR BIOCHEM, V14, P232, DOI 10.1016/S0955-2863(03)00006-8; ROFE AM, 1992, BIOL TRACE ELEM RES, V34, P237, DOI 10.1007/BF02783679; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Strand TA, 2004, AM J CLIN NUTR, V79, P451; Takeda A, 2012, BEHAV BRAIN RES, V226, P259, DOI 10.1016/j.bbr.2011.09.026; Takeda A, 2009, BRAIN RES REV, V62, P33, DOI 10.1016/j.brainresrev.2009.09.003; Taylor KM, 2012, CELL CYCLE, V11, P1863, DOI 10.4161/cc.20414; Taylor KM, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002585; WALRAVENS PA, 1989, PEDIATRICS, V83, P532; Wilson M, 2012, J BIOL CHEM, V287, P9322, DOI 10.1074/jbc.C111.320796; Wong CP, 2012, MOL NUTR FOOD RES, V56, P77, DOI 10.1002/mnfr.201100511	39	9	9	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3672	3682		10.1096/fj.13-228791	http://dx.doi.org/10.1096/fj.13-228791			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729592				2022-12-28	WOS:000328840500026
J	Wang, N; Robaye, B; Gossiel, F; Boeynaems, JM; Gartland, A				Wang, Ning; Robaye, Bernard; Gossiel, Fatima; Boeynaems, Jean-Marie; Gartland, Alison			The P2Y(13) receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development	FASEB JOURNAL			English	Article						knockout; bone phenotype; purinergic; ADP	HUMAN ARTICULAR CHONDROCYTES; NORADRENALINE RELEASE; MINERAL METABOLISM; DIETARY PHOSPHATE; P2Y13 RECEPTOR; ADP RECEPTOR; P2 RECEPTORS; GROWTH; EXPRESSION; ATP	Purinergic signaling mediates many cellular processes, including embryonic development and regulation of endocrine signaling. The ADP P2Y(13) receptor is known to regulate bone and stem cells activities, although relatively little is known about its role in bone development. In this study we demonstrate, using contemporary techniques, that deletion of the P2Y(13) receptor results in an age-dependent skeletal phenotype that is governed by changes in phosphate metabolism and hormone levels. Neonatal and postnatal (2 wk) P2Y(13) receptor-knockout (KO) mice were indistinguishable from their wild-type (WT) littermate controls. A clear bone phenotype was observed in young (4-wk-old) KO mice compared WT controls, with 14% more trabecular bone, 35% more osteoblasts, 73% fewer osteoclasts, and a 17% thicker growth plate. Mature (>10 wk of age) KO mice showed the opposite bone phenotype, with 14% less trabecular bone, 22% fewer osteoblasts, and 10% thinner growth plate. This age-dependent phenotype correlated with serum fibroblast growth factor-23 (FGF-23) and phosphorus levels that were 65 and 16% higher, respectively, in young KO mice but remained unchanged in mature mice. These findings provide novel insights for the role of the P2Y(13) receptor in skeletal development via coordination with hormonal regulators of phosphate homeostasis.Wang, N., Robaye, B., Gossiel, F., Boeynaems, J.-M., Gartland, A. The P2Y(13) receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development.	[Wang, Ning; Gossiel, Fatima; Gartland, Alison] Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Sheffield S10 2RX, S Yorkshire, England; [Robaye, Bernard; Boeynaems, Jean-Marie] Univ Libre Bruxelles, Inst Interdisciplinary Res, IRIBHM, Gosselies, Belgium; [Boeynaems, Jean-Marie] Free Univ Brussels, Erasme Hosp, Dept Med Chem, B-1050 Brussels, Belgium	University of Sheffield; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Gartland, A (corresponding author), Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	a.gartland@sheffield.ac.uk	Gartland, Alison/A-2152-2012	Gartland, Alison/0000-0002-3712-2437; WANG, NING/0000-0002-2663-7515	European Commission [202231]	European Commission(European CommissionEuropean Commission Joint Research Centre)	Funding Source: European Commission under the 7th Framework Programme (proposal 202231) performed as a collaborative project among the members of the ATPBone Consortium (Copenhagen University, Copenhagen, Denmark; University College London, London, UK; University of Maastricht, Maastricht, The Netherlands; University of Ferrara, Ferrara, Italy; University of Liverpool, Liverpool, UK; University of Sheffield, Sheffield, UK; and Universite Libre de Bruxelles, Brussels, Belgium), and is a substudy under the main study, "Fighting osteoporosis by blocking nucleotides: purinergic signaling in bone formation and homeostasis." The authors declare no conflicts of interest.	Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; Bacic D, 2003, PFLUG ARCH EUR J PHY, V446, P52, DOI 10.1007/s00424-002-0969-8; Bailey MA, 2009, PURINERG SIGNAL, V5, P473, DOI 10.1007/s11302-009-9149-z; Beck GR, 2003, J CELL BIOCHEM, V90, P234, DOI 10.1002/jcb.10622; Ben-Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409; Biber J, 2009, PFLUG ARCH EUR J PHY, V458, P39, DOI 10.1007/s00424-008-0580-8; Biver G, 2013, STEM CELLS, V31, P2747, DOI 10.1002/stem.1411; Boyan BD, 2002, CRIT REV ORAL BIOL M, V13, P143, DOI 10.1177/154411130201300205; Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Burnstock G, 2011, CELL MOL LIFE SCI, V68, P1369, DOI 10.1007/s00018-010-0614-1; CASWELL AM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P151, DOI 10.1016/0304-4165(91)90054-K; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Csolle C, 2008, J NEUROCHEM, V106, P347, DOI 10.1111/j.1471-4159.2008.05391.x; Fabre AC, 2010, HEPATOLOGY, V52, P1477, DOI 10.1002/hep.23897; Farrow EG, 2010, J ENDOCRINOL, V207, P67, DOI 10.1677/JOE-10-0181; Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004-1039; Fumagalli M, 2004, BIOCHEM PHARMACOL, V68, P113, DOI 10.1016/j.bcp.2004.02.038; Grimm I, 2009, J CELL SCI, V122, P2524, DOI 10.1242/jcs.044891; HATORI M, 1995, J CELL PHYSIOL, V165, P468, DOI 10.1002/jcp.1041650304; Heinrich A, 2008, NEUROPHARMACOLOGY, V54, P375, DOI 10.1016/j.neuropharm.2007.10.013; Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692; Hung CT, 1997, AM J PHYSIOL-CELL PH, V272, pC1611, DOI 10.1152/ajpcell.1997.272.5.C1611; Inscho EW, 2009, AM J PHYSIOL-RENAL, V297, pF1166, DOI 10.1152/ajprenal.00506.2009; Juppner H, 2010, J BONE MINER RES, V25, P2091, DOI 10.1002/jbmr.170; Kaplan AD, 1996, ENDOCRINOLOGY, V137, P4757, DOI 10.1210/en.137.11.4757; Knight MM, 2009, J ANAT, V214, P275, DOI 10.1111/j.1469-7580.2008.01021.x; Koolpe M, 1999, ARTHRITIS RHEUM, V42, P258, DOI 10.1002/1529-0131(199902)42:2<258::AID-ANR7>3.0.CO;2-O; Krajisnik T, 2007, J ENDOCRINOL, V195, P125, DOI 10.1677/JOE-07-0267; Lanske B, 2007, CURR OPIN NEPHROL HY, V16, P311, DOI 10.1097/MNH.0b013e3281c55eca; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mackenzie NCW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032177; Marionneau C, 2005, J PHYSIOL-LONDON, V562, P223, DOI 10.1113/jphysiol.2004.074047; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Perwad F, 2005, ENDOCRINOLOGY, V146, P5358, DOI 10.1210/en.2005-0777; Pinter O., 2007, END ABSTR, V14, P617; Praetorius HA, 2010, ANNU REV PHYSIOL, V72, P377, DOI 10.1146/annurev-physiol-021909-135825; Queiroz G, 2003, J PHARMACOL EXP THER, V307, P809, DOI 10.1124/jpet.103.054809; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Rhees BK, 2000, J EXP ZOOL, V288, P151, DOI 10.1002/1097-010X(20000815)288:2&lt;151::AID-JEZ6&gt;3.0.CO;2-6; Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200; Segawa H, 2002, J BIOL CHEM, V277, P19665, DOI 10.1074/jbc.M200943200; Shalhoub V, 2011, CALCIFIED TISSUE INT, V89, P140, DOI 10.1007/s00223-011-9501-5; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Sondergaard M, 2003, AM J PHYSIOL-ENDOC M, V285, pE427, DOI 10.1152/ajpendo.00573.2002; Stubbs JR, 2012, J BONE MINER RES, V27, P38, DOI 10.1002/jbmr.516; Unwin RJ, 2003, NEWS PHYSIOL SCI, V18, P237, DOI 10.1152/nips.01436.2003; Vallon V, 2008, AM J PHYSIOL-RENAL, V294, pF10, DOI 10.1152/ajprenal.00432.2007; van der Eerden BCJ, 2003, ENDOCR REV, V24, P782, DOI 10.1210/er.2002-0033; Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200; Wang H, 2008, J BONE MINER RES, V23, P939, DOI 10.1359/JBMR.080220; Wang LW, 2005, CIRC RES, V96, P189, DOI 10.1161/01.RES.0000153670.07559.E4; Wang N, 2013, J BONE MINER RES, V28, P1446, DOI 10.1002/jbmr.1877; Wang N, 2012, MOL ENDOCRINOL, V26, P142, DOI 10.1210/me.2011-1083; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Yoshiko Y, 2007, BONE, V40, P1565, DOI 10.1016/j.bone.2007.01.017; Zhang FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/jpet.301.2.705	59	23	24	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2249	2259		10.1096/fj.13-243626	http://dx.doi.org/10.1096/fj.13-243626			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24487286	Green Published			2022-12-28	WOS:000335336000027
J	Jove, M; Moreno-Navarrete, JM; Pamplona, R; Ricart, W; Portero-Otin, M; Fernandez-Real, JM				Jove, Mariona; Maria Moreno-Navarrete, Jose; Pamplona, Reinald; Ricart, Wifredo; Portero-Otin, Manuel; Manuel Fernandez-Real, Jose			Human omental and subcutaneous adipose tissue exhibit specific lipidomic signatures	FASEB JOURNAL			English	Article						insulin resistance; metabolism; systems biology	FATTY-ACID-COMPOSITION; INSULIN SENSITIVITY; HUMAN ADIPOCYTES; GENE-EXPRESSION; IN-VITRO; DIFFERENTIATION; OBESITY; CELLS; BIOSYNTHESIS; CHOLESTEROL	Despite their differential effects on human metabolic pathophysiology, the differences in omental and subcutaneous lipidomes are largely unknown. To explore this field, liquid chromatography coupled with mass spectrometry was used for lipidome analyses of adipose tissue samples (visceral and subcutaneous) selected from a group of obese subjects (n=38). Transcriptomics and in vitro studies in adipocytes were used to confirm the pathways affected by location. The analyses revealed the existence of obesity-related specific lipidome signatures in each of these locations, attributed to selective enrichment of specific triglycerides, glycerophospholipids, and sphingolipids, because these were not observed in adipose tissues from nonobese individuals. The changes were compatible with subcutaneous enrichment in pathways involved in adipogenesis, triacylglyceride synthesis, and lipid droplet formation, as well as increased -oxidation. Marked differences between omental and subcutaneous depots in obese individuals were seen in the association of lipid species with metabolic traits (body mass index and insulin sensitivity). Targeted studies also revealed increased cholesterol (56%) and cholesterol epoxide (34%) concentrations in omental adipose tissue. In view of the effects of cholesterol epoxide, which induced enhanced expression of adipocyte differentiation and -oxidation genes in human omental adipocytes, a novel role for cholesterol epoxide as a signaling molecule for differentiation is proposed. In summary, in obesity, adipose tissue exhibits a location-specific differential lipid profile that may contribute to explaining part of its distinct pathogenic role.Jove, M., Moreno-Navarrete, J. M., Pamplona, R., Ricart, W., Portero-Otin, M., Fernandez-Real, J. M. Human omental and subcutaneous adipose tissue exhibit specific lipidomic signatures.	[Jove, Mariona; Pamplona, Reinald; Portero-Otin, Manuel] Inst Recerca Biomed Lleida IRBLLEIDA UdL, Nutricio Envelliment NUTREN Nutrigen, Cientif Tecnolg Agroalimentari Lleida PCiTAL, Lleida, Spain; [Maria Moreno-Navarrete, Jose; Ricart, Wifredo; Manuel Fernandez-Real, Jose] Inst dInvestigacio Biomed Girona IdIBGi, Dept Diabet, Centro Investigac Biomed Red Fisiopatologia Obesi, Endocrinol & Nutr, Girona, Spain; [Jove, Mariona; Pamplona, Reinald; Portero-Otin, Manuel] Inst Recerca Biomed Lleida IRBLLEIDA UdL Cient &, Nutr & Envelliment NUTREN Nutrigen, Lleida, Spain; [Maria Moreno-Navarrete, Jose; Ricart, Wifredo; Manuel Fernandez-Real, Jose] Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Dept Diabet Endocrinol & Nutr, Inst Invest Biomed Girona IdIBGi, Girona, Spain; [Maria Moreno-Navarrete, Jose; Ricart, Wifredo; Manuel Fernandez-Real, Jose] Inst Salud Carlos III, Girona, Spain	Institut de Recerca Biomedica - IRB Lleida; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Institut de Recerca Biomedica - IRB Lleida; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Instituto de Salud Carlos III	Fernandez-Real, JM (corresponding author), Hosp Girona Dr Josep Trueta, Sect Diabet Endocrinol & Nutr, Carretera de Franca S-N, Girona 17007, Spain.	jmfreal@idibgi.org	Fernández-Real, Jose Manuel/AGH-3599-2022; Jové, Mariona/M-9104-2016; Portero-Otin, Manuel/B-7122-2009; Moreno-Navarrete, José María/H-9772-2015; Pamplona, Reinald/A-7359-2010; Moreno-Navarrete, José María/ABG-5548-2021	Fernández-Real, Jose Manuel/0000-0002-7442-9323; Jové, Mariona/0000-0001-5577-6162; Portero-Otin, Manuel/0000-0002-1823-0299; Moreno-Navarrete, José María/0000-0002-2883-511X; Pamplona, Reinald/0000-0003-4337-6107; Moreno-Navarrete, José María/0000-0002-2883-511X; Ricart, Wifredo/0000-0002-3452-9098	Spanish Ministry of Science and Innovation (INNPRONTA Program) [BFU2009-11879/BFI, AGL2006-1243]; Autonomous Government of Catalunya [2009SGR-735]; Autonomous Government of Catalunya (ACC1O program); Spanish Ministry of Health [FIS 08-1843, 11-01532]; COST B-35 Action; Instituto Tomas Pascual para la Nutricion y Salud; Ministerio de Educacion y Ciencia [SAF2011-0214]	Spanish Ministry of Science and Innovation (INNPRONTA Program); Autonomous Government of Catalunya; Autonomous Government of Catalunya (ACC1O program); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); COST B-35 Action; Instituto Tomas Pascual para la Nutricion y Salud; Ministerio de Educacion y Ciencia(Spanish Government)	Work performed in the Institut de Recerca Biomedica de Lleida-Cientific i Tecnologic Agroalimentari de Lleida (IRBLLEIDA-PCiTAL) was supported by the Spanish Ministry of Science and Innovation (INNPRONTA Program, BFU2009-11879/BFI and AGL2006-1243) the Autonomous Government of Catalunya (2009SGR-735, ACC1O program), and the Spanish Ministry of Health (FIS 08-1843 and 11-01532]. This work was also supported by the COST B-35 Action, Instituto Tomas Pascual para la Nutricion y Salud, and partially supported by research grants from the Ministerio de Educacion y Ciencia (SAF2011-0214). Centro de Investigacion Biomedica en Red-Fisiopatologia de la Obesidad y la Nutricion (CIBERobn) is an initiative from the Instituto de Salud Carlos III (Girona, Spain). M.P.-O. and J.M.F.-R. designed the experiment; M.J. and J.M.M-N. performed research; R.P. and W.R. analyzed data; M.J., M.P.-O., and J.M.F.-R. wrote the paper. The authors declare no conflicts of interest.	Arner P, 2002, DIABETES-METAB RES, V18, pS5, DOI 10.1002/dmrr.254; BAS P, 1992, LIPIDS, V27, P470, DOI 10.1007/BF02536391; Davies JD, 2005, J BIOL CHEM, V280, P3911, DOI 10.1074/jbc.M410075200; Dwyer JR, 2007, J BIOL CHEM, V282, P8959, DOI 10.1074/jbc.M611741200; Fox CS, 2007, CIRCULATION, V116, P39, DOI 10.1161/CIRCULATIONAHA.106.675355; Garcia-Serrano S, 2011, MOL MED, V17, P273, DOI 10.2119/molmed.2010.00078; Gesta S, 2006, P NATL ACAD SCI USA, V103, P6676, DOI 10.1073/pnas.0601752103; Gomez-Ambrosi J, 2004, FASEB J, V18, P215, DOI 10.1096/fj.03-0591fje; Guo L, 2010, J BIOL CHEM, V285, P25438, DOI 10.1074/jbc.M110.119933; Hodson L, 2008, PROG LIPID RES, V47, P348, DOI 10.1016/j.plipres.2008.03.003; Horl G, 2011, J BIOL CHEM, V286, P17338, DOI 10.1074/jbc.M111.234534; Johnson JS, 2011, J CELL BIOCHEM, V112, P1673, DOI 10.1002/jcb.23082; Jung HR, 2011, BBA-MOL CELL BIOL L, V1811, P925, DOI 10.1016/j.bbalip.2011.06.025; Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115; Kim JK, 2009, METHODS MOL BIOL, V560, P221, DOI 10.1007/978-1-59745-448-3_15; Kim WK, 2007, J BONE MINER RES, V22, P1711, DOI 10.1359/JBMR.070710; Kobayashi A, 2006, J LIPID RES, V47, P1791, DOI 10.1194/jlr.M500546-JLR200; Kolak M, 2007, DIABETES, V56, P1960, DOI 10.2337/db07-0111; Laaksonen R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000097; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; LAU WF, 1995, EXPERIENTIA, V51, P731, DOI 10.1007/BF01941271; Leemand J, 2012, EXP DIABETES RES, DOI 10.1155/2012/242984; Machann J, 2013, NMR BIOMED, V26, P232, DOI 10.1002/nbm.2849; MacLaren R, 2008, J LIPID RES, V49, P308, DOI 10.1194/jlr.M700199-JLR200; Moreno-Navarrete JM, 2011, DIABETES, V60, P168, DOI 10.2337/db10-0805; Marwarha G, 2012, CELL SIGNAL, V24, P484, DOI 10.1016/j.cellsig.2011.09.029; Meex RCR, 2009, AM J PHYSIOL-REG I, V297, pR913, DOI 10.1152/ajpregu.91053.2008; *NAT I GEN MED SCI, 2010, LIP MET PATHW STRAT; Ortega FJ, 2010, INT J OBESITY, V34, P487, DOI 10.1038/ijo.2009.263; Ortiz A, 2012, NEW ENGL J MED, V366, P668, DOI 10.1056/NEJMc1114201; Otani H, 2011, ANTIOXID REDOX SIGN, V15, P1911, DOI 10.1089/ars.2010.3739; Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314; Perez-Perez R, 2009, J PROTEOME RES, V8, P1682, DOI 10.1021/pr800942k; Perrini S, 2008, DIABETOLOGIA, V51, P155, DOI 10.1007/s00125-007-0841-7; Perrini S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057892; Quehenberger O, 2011, NEW ENGL J MED, V365, P1812, DOI 10.1056/NEJMra1104901; Roberts LD, 2009, PHYSIOL GENOMICS, V39, P109, DOI 10.1152/physiolgenomics.90365.2008; Samad F, 2006, DIABETES, V55, P2579, DOI 10.2337/db06-0330; Samad F, 2011, ADV EXP MED BIOL, V721, P67, DOI 10.1007/978-1-4614-0650-1_5; Sandra K, 2010, J CHROMATOGR A, V1217, P4087, DOI 10.1016/j.chroma.2010.02.039; Sato D, 2012, METABOLISM, V61, P92, DOI 10.1016/j.metabol.2011.05.012; Ulven SM, 2005, PROSTAG LEUKOTR ESS, V73, P59, DOI 10.1016/j.plefa.2005.04.009; Virtanen KA, 2002, J CLIN ENDOCR METAB, V87, P3902, DOI 10.1210/jc.87.8.3902; WAHLE KWJ, 1991, EUR J CLIN NUTR, V45, P195; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356; Zheng W, 2006, BBA-BIOMEMBRANES, V1758, P1864, DOI 10.1016/j.bbamem.2006.08.009	46	38	39	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1071	1081		10.1096/fj.13-234419	http://dx.doi.org/10.1096/fj.13-234419			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24265485				2022-12-28	WOS:000335324800005
J	Vigna, SR; Shahid, RA; Liddle, RA				Vigna, Steven R.; Shahid, Rafiq A.; Liddle, Rodger A.			Ethanol contributes to neurogenic pancreatitis by activation of TRPV1	FASEB JOURNAL			English	Article						acute pancreatitis; AMG9801; palmitoleic acid; TRP channel	ALCOHOLIC PANCREATITIS; VANILLOID RECEPTOR; INFLAMMATION; METABOLITES; TOXICITY; INJURY; RATS; MICE	Alcohol abuse is a major cause of pancreatitis in people, but the mechanism is unknown. It has been recently demonstrated that transient receptor potential vanilloid 1 (TRPV1) activation causes neurogenic inflammation and plays an important role in acute pancreatitis. Moreover, TRPV1 is activated by ethanol. We examined the direct effects of ethanol on acute pancreatitis. Acute inflammation of the pancreas was produced by injection of ethanol and palmitoleic acid (POA), a nonoxidative metabolite of ethanol, in wild-type C57BL/6J mice and Trpv1-knockout C57BL/6J mice. Inflammatory indexes were analyzed 24 h later. Injection of ethanol + POA produced acute pancreatitis indicated by significant increases in histopathological damage, serum amylase levels, and pancreatic MPO concentrations (P<0.05-0.001). All parameters of pancreatitis were blocked by pretreatment with the TRPV1 antagonist drug AMG9810. In addition, ethanol + POA administration to Trpv1knockout mice did not produce pancreatic inflammation. Treatment with vehicle, ethanol alone, or POA alone had no inflammatory effects. TRPV1 partially mediates inflammation induced by ethanol + POA in the mouse pancreas, consistent with the ability of ethanol to activate TRPV1. We propose that ethanol may contribute to alcohol-induced pancreatitis by a neurogenic mechanism.Vigna, S. R., Shahid, R. A., and Liddle, R. A. Ethanol contributes to neurogenic pancreatitis by activation of TRPV1.	[Vigna, Steven R.; Shahid, Rafiq A.; Liddle, Rodger A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Vigna, Steven R.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; [Liddle, Rodger A.] Durham Vet Affairs Med Ctr, Durham, NC USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Liddle, RA (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 103211, Durham, NC 27710 USA.	rodger.liddle@duke.edu			U.S. National Institutes of Health [R01 DK-064213]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064213] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. D. Julius (University of California, San Francisco, CA, USA) for the generous gift of Trpv1<SUP>-/-</SUP> mice. This work was supported by U.S. National Institutes of Health grant R01 DK-064213.	BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Criddle DN, 2004, P NATL ACAD SCI USA, V101, P10738, DOI 10.1073/pnas.0403431101; Dawra R, 2008, PANCREAS, V37, P62, DOI 10.1097/MPA.0b013e3181607761; Gavva NR, 2007, J NEUROSCI, V27, P3366, DOI 10.1523/JNEUROSCI.4833-06.2007; Gavva NR, 2005, J PHARMACOL EXP THER, V313, P474, DOI 10.1124/jpet.104.079855; Gerasimenko JV, 2009, P NATL ACAD SCI USA, V106, P10758, DOI 10.1073/pnas.0904818106; Huang W, 2010, PANCREAS, V39, P1324; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; Liddle RA, 2004, PANCREATOLOGY, V4, P551, DOI 10.1159/000082180; Liddle RA, 2007, BBA-MOL BASIS DIS, V1772, P869, DOI 10.1016/j.bbadis.2007.02.012; Long D. J., J PHARM EXP THER, V332, P525; Nathan JD, 2005, GASTROENTEROLOGY, V128, P717, DOI 10.1053/j.gastro.2004.11.052; Romac JMJ, 2008, PANCREAS, V36, P394, DOI 10.1097/MPA.0b013e318160222a; SPORMANN H, 1989, PATHOL RES PRACT, V184, P507, DOI 10.1016/S0344-0338(89)80143-8; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; Werner J, 1997, GASTROENTEROLOGY, V113, P286, DOI 10.1016/S0016-5085(97)70106-9; Werner J, 2002, AM J PHYSIOL-GASTR L, V283, pG65, DOI 10.1152/ajpgi.00419.2001; Werner J, 2001, SURGERY, V129, P736, DOI 10.1067/msy.2001.113891	23	17	18	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					891	896		10.1096/fj.13-236208	http://dx.doi.org/10.1096/fj.13-236208			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24221085	Green Published			2022-12-28	WOS:000331072200034
J	Casadevall, A; Fang, FC				Casadevall, Arturo; Fang, Ferric C.			Is the Nobel Prize good for science?	FASEB JOURNAL			English	Article							DISCOVERY; CONTROVERSY; DEBATE; CREDIT; STREPTOMYCIN; NOMINATIONS; INJUSTICE; PROTEST; REFORMS; CHAGAS	The Nobel Prize is arguably the best known and most prestigious award in science. Here we review the effect of the Nobel Prize and acknowledge that it has had many beneficial effects on science. However, ever since its inaugural year in 1901, the Nobel Prize has also been beset by controversy, mostly involving the selection of certain individuals and the exclusion of others. In this regard, the Nobel Prize epitomizes the winner-take-all economics of credit allocation and distorts the history of science by personalizing discoveries that are truly made by groups of individuals. The limitation of the prize to only 3 individuals at a time when most scientific discovery is the result of collaborative and cooperative research is arguably the major cause of Nobel Prize controversies. A simple solution to this problem would be to eliminate the restriction on the number of individuals who could be awarded the prize, a measure that would recognize all who contribute, from students to senior investigators. There is precedent for such a change in the Nobel Peace Prize, which has often gone to organizations. Changing the Nobel Prize to more fairly allocate credit would reduce the potential for controversy and directly benefit the scientific enterprise by promoting cooperation and collaboration of scientists within a field to reduce the negative consequences of competition between individual scientists.	[Casadevall, Arturo] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; [Casadevall, Arturo] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Fang, Ferric C.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; [Fang, Ferric C.] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Casadevall, A (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	arturo.casadevall@einstein.yu.edu		Fang, Ferric/0000-0002-3243-110X				Abad-Santos A., 2012, ATLANTIC; Abbadessa G, 2009, SCIENCE, V323, P206, DOI 10.1126/science.323.5911.206; Abbott A, 2009, NATURE, V458, P564, DOI 10.1038/458564a; Al-Khalili J., 2012, GUARDIAN; Allison JP, 2011, NATURE, V479, P178, DOI 10.1038/479178a; [Anonymous], 2012, Sci Am, V307, P12; [Anonymous], 1980, NATURE, V287, P667; [Anonymous], 1983, NATURE, V305, P750; [Anonymous], 1999, NAT CELL BIOL, V1, pE169, DOI 10.1038/15602; [Anonymous], 1975, NATURE, V254, P277; [Anonymous], 1971, PHYS TODAY, V24, P69; Baloh RW, 2002, NEUROLOGY, V58, P1094, DOI 10.1212/WNL.58.7.1094; Baumeister W, 2004, SCIENCE, V306, P1290, DOI 10.1126/science.306.5700.1290; Benson AA, 2010, PHOTOSYNTH RES, V105, P209, DOI 10.1007/s11120-010-9592-2; Bestetti RB, 2013, INT J CARDIOL, V168, P2328, DOI 10.1016/j.ijcard.2013.01.048; Blow NS, 2012, BIOTECHNIQUES, V52, P11, DOI 10.2144/000113792; Bots M, 2006, NATURE, V443, P906, DOI 10.1038/443906a; Broad W., 1982, BETRAYERS TRUTH; BROAD WJ, 1980, SCIENCE, V207, P37, DOI 10.1126/science.6985744; BROAD WJ, 1982, SCIENCE, V218, P549, DOI 10.1126/science.218.4572.549; BROAD WJ, 1982, SCIENCE, V217, P1120, DOI 10.1126/science.7051287; Casadevall A, 2012, SCI AM, V307, P13, DOI 10.1038/scientificamerican0812-13; Casadevall A, 2012, INFECT IMMUN, V80, P891, DOI 10.1128/IAI.06183-11; Casadevall A, 2012, NAT IMMUNOL, V13, P21, DOI 10.1038/ni.2184; Casadevall A, 2009, INFECT IMMUN, V77, P4177, DOI 10.1128/IAI.00757-09; Christianson G. E., 1996, E HUBBLE MARINER NEB; Coffey P., 2008, CATHEDRALS SCI; Coles H, 1997, NATURE, V389, P529, DOI 10.1038/39120; Coutinho M, 1999, MEM I OSWALDO CRUZ, V94, P123, DOI 10.1590/S0074-02761999000700012; Crawford N, 1996, NATURE, V382, P393; Doherty P. C., 2011, CONVERSATION    1003; Dreizen P, 2004, LANCET, V363, P78, DOI 10.1016/S0140-6736(03)15182-3; Eisenberg L, 2005, AM J PSYCHIAT, V162, P1760, DOI 10.1176/appi.ajp.162.9.1760; Eisenberg R L, 1992, AJR Am J Roentgenol, V159, P996; Engineering and Public Policy Committee on Science, 2004, FAC INT RES; Faerstein E, 2010, EPIDEMIOLOGY, V21, P158, DOI 10.1097/EDE.0b013e3181c308e0; Fang FC, 2012, INFECT IMMUN, V80, P897, DOI 10.1128/IAI.06184-11; Feldman Burton, 2000, NOBEL PRIZE HIST GEN; Feynman RP, 1999, PLEASURE FINDING THI; FLETCHER H, 1982, PHYS TODAY, V35, P43, DOI 10.1063/1.2915126; Friedman R. M., 2001, POLITICS EXCELLENCE; Goodman S, 2001, NATURE, V414, P239, DOI 10.1038/35104765; Goodstein D, 2001, AM SCI, V89, P54, DOI 10.1511/2001.14.724; Gozum M, 2009, SCIENCE, V323, P207, DOI 10.1126/science.323.5911.207; Guillen JBL, 1998, NATURE, V396, P614, DOI 10.1038/25215; Habashi F, 2004, CIM BULL, V97, P77; Hargittai M, 2012, PHYS WORLD, V25, P38; HEILBRON JL, 1987, NATURE, V330, P694, DOI 10.1038/330694a0; Helmuth L, 2001, SCIENCE, V291, P567, DOI 10.1126/science.291.5504.567; HOLDEN C, 1989, SCIENCE, V243, P471, DOI 10.1126/science.243.4890.471-a; Holley J., 2005, WASHINGTON POST; Howlett R, 1998, NATURE, V395, P625, DOI 10.1038/27019; Jamieson V., 2008, NEW SCI; Johnson G., 2007, NY TIMES; Judson H. F., 2004, GREAT BETRAYAL FRAUD; Kahn CR, 2004, J CLIN INVEST, V114, P1051, DOI 10.1172/JCI20042316; KANTHA S S, 1991, Keio Journal of Medicine, V40, P35; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; Lawrence P.A., 2012, CURR BIOL, V22, pR214; Lawrence PA, 2002, NATURE, V415, P835, DOI 10.1038/415835a; Lloyd E., 2004, PITTMED, P17; Macchia RJ, 2007, J UROLOGY, V178, P783, DOI 10.1016/j.juro.2007.05.019; Martin Douglas, 2011, NY TIMES; Mazloumian A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018975; McElheny V. K., 2004, WATSON DNA MAKING SC; Meyers Morton, 2012, PRIZE FIGHT RACE RIV; Moss AJ, 2007, ANN NONINVAS ELECTRO, V12, P79, DOI 10.1111/j.1542-474X.2007.00141.x; Nair P, 2011, P NATL ACAD SCI USA, V108, P15043, DOI 10.1073/pnas.1111960108; NEWMARK P, 1989, NATURE, V342, P329, DOI 10.1038/342329b0; Nobel A, 2007, ANN NONINVAS ELECTRO, V12, P81; Palmer B., 2012, SLATE           1008; Piqueras M, 2009, INT MICROBIOL, V11, P227, DOI 10.2436/20.1501.01.65; Ploegh H, 2012, NATURE, V486, P318, DOI 10.1038/486318a; Portugal F, 2010, PERSPECT BIOL MED, V53, P558, DOI 10.1353/pbm.2010.0014; Pringle P, 2012, EXPT 11 DARK SECRETS; Purkis C., 2012, SWEDISH BOOK REV, V2; Rablen MD, 2008, J HEALTH ECON, V27, P1462, DOI 10.1016/j.jhealeco.2008.06.001; Reich ES, 2010, NATURE, V468, P486, DOI 10.1038/468486a; Reichard P, 2002, J BIOL CHEM, V277, P13355, DOI 10.1074/jbc.R200002200; Rhodes R, 1998, DEADLY FEASTS; Rosenfeld L, 2002, CLIN CHEM, V48, P2270; Satir P, 1997, J CELL BIOL, V138, P223; Saxon W, 1989, NY TIMES; Service RF, 2001, SCIENCE, V294, P503; Service RF, 2008, SCIENCE, V322, P361, DOI 10.1126/science.322.5900.361; Singh R, 2001, NOTES REC ROY SOC, V55, P267, DOI 10.1098/rsnr.2001.0143; Stolt CM, 2004, ADV CANCER RES, V92, P1, DOI 10.1016/S0065-230X(04)92001-5; Townes CH, 2007, NATURE, V447, P654, DOI 10.1038/447654a; WADE N, 1975, SCIENCE, V189, P358, DOI 10.1126/science.189.4200.358; Wagner H, 2012, EUR J IMMUNOL, V42, P1089, DOI 10.1002/eji.201242404; Wainwright M, 2005, J HIST MED ALL SCI, V60, P218, DOI 10.1093/jhmas/jri024; WAINWRIGHT M, 1991, HIST PHIL LIFE SCI, V13, P97; WAINWRIGHT M, 1989, NATURE, V342, P336, DOI 10.1038/342336d0; Wilford J. N., 2007, NY TIMES; Wright P., 2002, GUARDIAN; Zuckerman H., 1977, SCI ELITE NOBEL LAUR	96	23	25	2	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4682	4690		10.1096/fj.13-238758	http://dx.doi.org/10.1096/fj.13-238758			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24008752				2022-12-28	WOS:000329999000004
J	Franzosa, JA; Bugel, SM; Tal, TL; La Du, JK; Tilton, SC; Waters, KM; Tanguay, RL				Franzosa, Jill A.; Bugel, Sean M.; Tal, Tamara L.; La Du, Jane K.; Tilton, Susan C.; Waters, Katrina M.; Tanguay, Robert L.			Retinoic acid-dependent regulation of miR-19 expression elicits vertebrate axis defects	FASEB JOURNAL			English	Article						microRNAs; somitogenesis; zebrafish	LEFT-RIGHT ASYMMETRY; CYP26 ENZYMES; METABOLIZING ENZYME; MICRORNA EXPRESSION; GENOME DUPLICATION; SEGMENTATION; SKELETAL; SOMITOGENESIS; HINDBRAIN; CLUSTER	Retinoic acid (RA) is involved in multifarious and complex functions necessary for vertebrate development. RA signaling is reliant on strict enzymatic regulation of RA synthesis and metabolism. Improper spatiotemporal expression of RA during development can result in vertebrate axis defects. microRNAs (miRNAs) are also pivotal in orchestrating developmental processes. While mechanistic links between miRNAs and axial development are established, the role of miRNAs in regulating metabolic enzymes responsible for RA abundance during axis formation has yet to be elucidated. Our results uncovered a role of miR-19 family members in controlling RA metabolism through the regulation of CYP26A1 during vertebrate axis formation. Global miRNA expression profiling showed that developmental RA exposure suppressed the expression of miR-19 family members during zebrafish somitogenesis. A reporter assay confirmed that cyp26a1 is a bona fide target of miR-19 in vivo. Transient knockdown of miR-19 phenocopied axis defects caused by RA exposure. Exogenous miR-19 rescued the axis defects induced by RA exposure. Taken together, these results indicate that the teratogenic effects of RA exposure result, in part, from repression of miR-19 expression and subsequent misregulation of cyp26a1. This highlights a previously unidentified role of miR-19 in facilitating vertebrate axis development via regulation of RA signaling.	[Franzosa, Jill A.; Bugel, Sean M.; Tal, Tamara L.; La Du, Jane K.; Tanguay, Robert L.] Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97333 USA; [Franzosa, Jill A.; Bugel, Sean M.; Tal, Tamara L.; La Du, Jane K.; Tanguay, Robert L.] Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97333 USA; [Tilton, Susan C.; Waters, Katrina M.] Pacific NW Natl Lab, Richland, WA USA	Oregon State University; Oregon State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Tanguay, RL (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, 28645 East HWY 34, Corvallis, OR 97333 USA.	robert.tanguay@oregonstate.edu	Tal, Tamara/O-5414-2019	Tal, Tamara/0000-0001-8365-9385; Waters, Katrina/0000-0003-4696-5396	U.S. National Institute of Environmental Health Sciences (NIEHS) Environmental Health Sciences Core Center [P30 ES000210]; NIEHS [T32 ES007060, P42 ES016465]; Oregon State University Linus Pauling Institute; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210, T32ES007060, P42ES016465] Funding Source: NIH RePORTER	U.S. National Institute of Environmental Health Sciences (NIEHS) Environmental Health Sciences Core Center; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Oregon State University Linus Pauling Institute; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Leah Wehmas for her experimental and technical assistance. The authors are grateful to Cari Buchner, Carrie Barton, and the staff at the Sinnhuber Aquatic Research Laboratory (Oregon State University) for exemplary fish husbandry and technical expertise. The authors thank Dr. James Patton (Vanderbilt University, Nashville, TN, USA) for sharing the pCS2-GFP vector. The authors appreciate the critical comments on the manuscript provided by Britton Goodale, Katerine Saili, Michael Simonich, and R. L. T. laboratory members. This work was supported by U.S. National Institute of Environmental Health Sciences (NIEHS) Environmental Health Sciences Core Center grant P30 ES000210, NIEHS Training grant T32 ES007060, and an Oregon State University Linus Pauling Institute grant to R. L. T., and by NIEHS Superfund Basic Research Program grant P42 ES016465 to R. L. T. and K. M. W. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest. J.A.F., S. M. B., T. L. T., and R. L. T designed the research; J.A.F., S. M. B., J.K.L., and T. L. T. performed the research; S. C. T. and K. M. W. contributed analytic tools; J.A.F., S. M. B., T. L. T., S. C. T., K. M. W., and R. L. T. analyzed data; and J.A.F. and R. L. T. wrote the paper.	Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Aulehla A, 2004, GENE DEV, V18, P2060, DOI 10.1101/gad.1217404; Aulehla A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000869; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bonauer A, 2009, CELL CYCLE, V8, P3866, DOI 10.4161/cc.8.23.9994; Brend T, 2009, SEMIN CELL DEV BIOL, V20, P472, DOI 10.1016/j.semcdb.2008.11.009; Campo-Paysaa F, 2011, EVOL DEV, V13, P15, DOI 10.1111/j.1525-142X.2010.00452.x; Campo-Paysaa F, 2008, GENESIS, V46, P640, DOI 10.1002/dvg.20444; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chaulk SG, 2011, RNA BIOL, V8, P1105, DOI 10.4161/rna.8.6.17410; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; COOKE J, 1975, NATURE, V254, P196, DOI 10.1038/254196a0; Cordes R, 2004, DEVELOPMENT, V131, P1221, DOI 10.1242/dev.01030; Crist CG, 2009, P NATL ACAD SCI USA, V106, P13383, DOI 10.1073/pnas.0900210106; Darnell DK, 2006, DEV DYNAM, V235, P3156, DOI 10.1002/dvdy.20956; de Pontual L, 2011, NAT GENET, V43, P1026, DOI 10.1038/ng.915; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Diez del Corral R, 2003, NEURON, V40, P65; Diez del Corral R, 2004, BIOESSAYS, V26, P857, DOI 10.1002/bies.20080; Dubrulle J, 2004, DEVELOPMENT, V131, P5783, DOI 10.1242/dev.01519; Duester Gregg, 2007, Birth Defects Research, V81, P84, DOI 10.1002/bdrc.20092; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Eckalbar WL, 2012, WIRES DEV BIOL, V1, P401, DOI 10.1002/wdev.34; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Emoto Y, 2005, DEV BIOL, V278, P415, DOI 10.1016/j.ydbio.2004.11.023; FELL HB, 1952, J PHYSIOL-LONDON, V116, P320, DOI 10.1113/jphysiol.1952.sp004708; Flynt AS, 2007, NAT GENET, V39, P259, DOI 10.1038/ng1953; Giampietro PF, 2009, ANN NY ACAD SCI, V1151, P38, DOI 10.1111/j.1749-6632.2008.03452.x; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Goljanek-Whysall K, 2011, P NATL ACAD SCI USA, V108, P11936, DOI 10.1073/pnas.1105362108; Halilagic A, 2007, DEV BIOL, V303, P362, DOI 10.1016/j.ydbio.2006.11.021; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; HE L, 2004, NAT REV GENET, V5, P522; He XJ, 2011, DEV BIOL, V357, P463, DOI 10.1016/j.ydbio.2011.07.014; Heimberg AM, 2008, P NATL ACAD SCI USA, V105, P2946, DOI 10.1073/pnas.0712259105; Hernandez RE, 2007, DEVELOPMENT, V134, P177, DOI 10.1242/dev.02706; Hoesel B, 2010, GENE EXPR PATTERNS, V10, P265, DOI 10.1016/j.gep.2010.06.002; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Hsu RJ, 2010, NUCLEIC ACIDS RES, V38, P4384, DOI 10.1093/nar/gkq148; Hu P, 2008, DEV DYNAM, V237, P3798, DOI 10.1002/dvdy.21801; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; Jevnaker AM, 2011, J CELL PHYSIOL, V226, P2257, DOI 10.1002/jcp.22562; Kawakami Y, 2005, NATURE, V435, P165, DOI 10.1038/nature03512; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lee LMY, 2012, P NATL ACAD SCI USA, V109, P13668, DOI 10.1073/pnas.1200872109; Levin M, 2005, MECH DEVELOP, V122, P3, DOI 10.1016/j.mod.2004.08.006; Li N, 2011, DEVELOPMENT, V138, P1817, DOI 10.1242/dev.056697; Liu N, 2007, P NATL ACAD SCI USA, V104, P20844, DOI 10.1073/pnas.0710558105; LOHNES D, 1994, DEVELOPMENT, V120, P2723; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Mathew LK, 2007, J BIOL CHEM, V282, P35202, DOI 10.1074/jbc.M706640200; McGlinn E, 2009, P NATL ACAD SCI USA, V106, P18610, DOI 10.1073/pnas.0910374106; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Meyer A, 2005, BIOESSAYS, V27, P937, DOI 10.1002/bies.20293; Mishima Y, 2009, GENE DEV, V23, P619, DOI 10.1101/gad.1760209; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2008, NAT REV GENET, V9, P541, DOI 10.1038/nrg2340; O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032; Pennimpede T, 2010, BIRTH DEFECTS RES A, V88, P883, DOI 10.1002/bdra.20709; Peterson KJ, 2009, BIOESSAYS, V31, P736, DOI 10.1002/bies.200900033; Pourquie O, 2011, CELL, V145, P650, DOI 10.1016/j.cell.2011.05.011; Rathjen T, 2009, FEBS LETT, V583, P1422, DOI 10.1016/j.febslet.2009.03.048; Raya A, 2004, CURR OPIN GENET DEV, V14, P575, DOI 10.1016/j.gde.2004.07.011; Rhinn M, 2012, DEVELOPMENT, V139, P843, DOI 10.1242/dev.065938; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Saga Y, 2001, NAT REV GENET, V2, P835, DOI 10.1038/35098552; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Sempere LF, 2006, J EXP ZOOL PART B, V306B, P575, DOI 10.1002/jez.b.21118; Shah AR, 2007, BIOINFORMATICS, V23, P906, DOI 10.1093/bioinformatics/btm031; Shkumatava A, 2009, GENE DEV, V23, P466, DOI 10.1101/gad.1745709; Sirbu IO, 2006, NAT CELL BIOL, V8, P271, DOI 10.1038/ncb1374; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Sweetman D, 2006, DEV DYNAM, V235, P2185, DOI 10.1002/dvdy.20881; Tal TL, 2012, FASEB J, V26, P1452, DOI 10.1096/fj.11-194464; Tanzer A, 2004, J MOL BIOL, V339, P327, DOI 10.1016/j.jmb.2004.03.065; Thatcher JE, 2009, EXPERT OPIN DRUG MET, V5, P875, DOI 10.1517/17425250903032681; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Vermot J, 2005, SCIENCE, V308, P563, DOI 10.1126/science.1108363; Vermot J, 2005, NATURE, V435, P215, DOI 10.1038/nature03488; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Woltering JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001396; Yekta S, 2008, NAT REV GENET, V9, P789, DOI 10.1038/nrg2400; Zakany J, 2001, CELL, V106, P207, DOI 10.1016/S0092-8674(01)00436-6; Zhang Z, 2011, DEV BIOL, V351, P254, DOI 10.1016/j.ydbio.2011.01.005	96	10	11	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4866	4876		10.1096/fj.12-225524	http://dx.doi.org/10.1096/fj.12-225524			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23975936	Green Published			2022-12-28	WOS:000329999000021
J	Menegazzo, L; Albiero, M; Millioni, R; Tolin, S; Arrigoni, G; Poncina, N; Tessari, P; Avogaro, A; Fadini, GP				Menegazzo, Lisa; Albiero, Mattia; Millioni, Renato; Tolin, Serena; Arrigoni, Giorgio; Poncina, Nicol; Tessari, Paolo; Avogaro, Angelo; Fadini, Gian Paolo			Circulating myeloid calcifying cells have antiangiogenic activity via thrombospondin-1 overexpression	FASEB JOURNAL			English	Article						stem cells; atherosclerosis; inflammation; endothelial cells	MIGRATION INHIBITORY FACTOR; ENDOTHELIAL GROWTH-FACTOR; MYOCARDIAL-INFARCTION; TUMOR-GROWTH; MACROPHAGE; NEOVASCULARIZATION; ATHEROSCLEROSIS; ATHEROGENESIS; ANGIOGENESIS; OSTEOGENESIS	Myeloid calcifying cells (MCCs) represent a subpopulation of human monocytes with procalcific potential and are characterized by coexpression of osteocalcin (OC) and bone alkaline phosphatase (BAP). Herein, an in-depth proteomic investigation of MCCs based on fluorescence-activated cell sorting, protein extraction and digestion, isobaric tag for relative and absolute quantitation labeling, fractionation, and analysis on matrix-assisted laser desorption/ionization-time of flight/time of flight and LTQ Orbitrap mass spectrometers identified and quantified more than 700 proteins and revealed pathways activated in OC(+)BAP(+) MCCs compared with those in OC(-)BAP(-) cells. Among proteins referable to angiogenesis, the thrombospondin-1 pathway was markedly up-regulated in MCCs vs. control cells. Up-regulation of the thrombospondin-1 pathway was confirmed by a genome-wide transcriptional analysis. Using in vitro and in vivo angiogenesis assays, we found that freshly isolated MCCs and cultured MCCs display an antiangiogenic function by means of both paracrine activity (conditioned medium) and altered spatial localization in cocultures with endothelial cells. Thrombospondin-1 inhibition by antibody-mediated neutralization or gene knockdown restored the angiogenic activity of OC(+)BAP(+) MCCs toward normal values and abolished the antiangiogenic effects of MCC conditioned medium. These data indicate that circulating MCCs exert antiangiogenic activity by virtue of their overexpression of thrombospondin-1. The study highlights the successful identification and validation of a pathogenic pathway by a gold standard proteomic/transcriptomic analysis of blood cells.Menegazzo, L., Albiero, M., Millioni, R., Tolin, S., Arrigoni, G., Poncina, N., Tessari, P., Avogaro, A., Fadini, G. P. Circulating myeloid calcifying cells have antiangiogenic activity.	[Menegazzo, Lisa; Millioni, Renato; Poncina, Nicol; Tessari, Paolo; Avogaro, Angelo; Fadini, Gian Paolo] Univ Padua, Dept Med, Padua, Italy; [Arrigoni, Giorgio] Univ Padua, Dept Biomed Sci, Padua, Italy; [Menegazzo, Lisa; Albiero, Mattia; Tolin, Serena; Arrigoni, Giorgio; Poncina, Nicol; Avogaro, Angelo; Fadini, Gian Paolo] Venetian Inst Mol Med, Padua, Italy; [Tolin, Serena; Arrigoni, Giorgio] Univ Padua, Prote Ctr, Padua, Italy	University of Padua; University of Padua; Veneto Institute Molecular Medicine; University of Padua	Fadini, GP (corresponding author), Univ Hosp Padova, Div Metab Dis, Dept Med, Via Giustiniani 2, I-35100 Padua, Italy.	gianpaolo.fadini@unipd.it	Fadini, Gian Paolo/M-4575-2019; Albiero, Mattia/AAG-4257-2019; Avogaro, Angelo/S-3808-2016; Millioni, Renato/ABG-1799-2020; Arrigoni, Giorgio/A-3535-2014	Fadini, Gian Paolo/0000-0002-6510-2097; Albiero, Mattia/0000-0003-4142-9738; Arrigoni, Giorgio/0000-0002-4103-2733; AVOGARO, ANGELO/0000-0002-1177-0516	European Foundation for the Study of Diabetes/AstraZeneca Young Investigator Award	European Foundation for the Study of Diabetes/AstraZeneca Young Investigator Award	The authors acknowledge the technical assistance of Stefano Ciciliot (Venetian Institute of Molecular Medicine) for gene silencing and of Silvio Bicciato and Emilia Maria Cristina Mazza (Center for Genome Research, Department of Life Sciences, University of Modena and Reggio Emilia) for analysis of microarray data. This work was supported by a European Foundation for the Study of Diabetes/AstraZeneca Young Investigator Award (to G. P. F). L. M. and M. A. performed research and analyzed data; R. M. and S. T. designed research, performed research, and analyzed data; G. A. designed research and analyzed data; N.P. performed research and analyzed data; P. T. designed research; A. A. designed research and wrote manuscript; and G. P. F. designed research, analyzed data, and wrote manuscript. The authors declare no conflicts of interest.	Bento CF, 2011, DIABETOLOGIA, V54, P1946, DOI 10.1007/s00125-011-2191-8; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Dutta P, 2012, NATURE, V487, P325, DOI 10.1038/nature11260; Ehara S, 2004, CIRCULATION, V110, P3424, DOI 10.1161/01.CIR.0000148131.41425.E9; Fadini GP, 2012, CIRCULATION, V125, P2772, DOI 10.1161/CIRCULATIONAHA.112.090860; Fadini GP, 2011, CIRC RES, V108, P1112, DOI 10.1161/CIRCRESAHA.110.234088; Gossl M, 2010, JACC-CARDIOVASC IMAG, V3, P32, DOI 10.1016/j.jcmg.2009.10.009; Hellings WE, 2010, CIRCULATION, V121, P1941, DOI 10.1161/CIRCULATIONAHA.109.887497; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; Kishuku M, 2009, J IMMUNOL, V183, P8176, DOI 10.4049/jimmunol.0803849; Kocher T, 2009, J PROTEOME RES, V8, P4743, DOI 10.1021/pr900451u; Lawler PR, 2012, COLD SPRING HARB PER, V2; Ley K, 2011, ARTERIOSCL THROM VAS, V31, P1506, DOI 10.1161/ATVBAHA.110.221127; Matsumoto T, 2006, AM J PATHOL, V169, P1440, DOI 10.2353/ajpath.2006.060064; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Shoji T, 2010, LAB INVEST, V90, P637, DOI 10.1038/labinvest.2010.39; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Urbich C, 2003, CIRCULATION, V108, P2511, DOI 10.1161/01.CIR.0000096483.29777.50; Zernecke A, 2008, CIRCULATION, V117, P1594, DOI 10.1161/CIRCULATIONAHA.107.729125	21	18	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4355	4365		10.1096/fj.12-223719	http://dx.doi.org/10.1096/fj.12-223719			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23901071				2022-12-28	WOS:000329937500004
J	Dillon, J; Andrianakis, I; Mould, R; Ient, B; Liu, W; James, C; O'Connor, V; Holden-Dye, L				Dillon, James; Andrianakis, Ioannis; Mould, Richard; Ient, Ben; Liu, Wei; James, Christopher; O'Connor, Vincent; Holden-Dye, Lindy			Distinct molecular targets including SLO-1 and gap junctions are engaged across a continuum of ethanol concentrations in Caenorhabditis elegans	FASEB JOURNAL			English	Article						electrophysiology; pharynx; anesthesia; intoxication; alcohol; calcium-activated K+ channel	ELECTRICAL-ACTIVITY; PHARYNGEAL MUSCLE; CHANNEL; SENSITIVITY; NEMATODE; EXPOSURE; GENETICS; BEHAVIOR; CCA-1	Ethanol (alcohol) interacts with diverse molecular effectors across a range of concentrations in the brain, eliciting intoxication through to sedation. Invertebrate models including the nematode worm Caenorhabditis elegans have been deployed for molecular genetic studies to inform on key components of these alcohol signaling pathways. C. elegans studies have typically employed external dosing with high (>250 mM) ethanol concentrations: A careful analysis of responses to low concentrations is lacking. Using the C. elegans pharyngeal system as a paradigm, we report a previously uncharacterized continuum of cellular and behavioral responses to ethanol from low (10 mM) to high (300 mM) concentrations. The complexity of these responses indicates that the pleiotropic action of ethanol observed in mammalian brain is conserved in this invertebrate model. We investigated two candidate ethanol effectors, the calcium-activated K+ channel SLO-1 and gap junctions, and show that they contribute to, but are not sole determinants of, the low- and high-concentration effects, respectively. Notably, this study shows cellular and whole organismal behavioral responses to ethanol in C. elegans that directly equate to intoxicating through to supralethal blood alcohol concentrations in humans and provides an important benchmark for interpretation of paradigms that seek to inform on human alcohol use disorders.Dillon, J., Andrianakis, I., Mould, R., Ient, B., Liu, W., James, C., O'Connor, V., Holden-Dye, L. Distinct molecular targets including SLO-1 and gap junctions are engaged across a continuum of ethanol concentrations in Caenorhabditis elegans.	[Dillon, James; Mould, Richard; Ient, Ben; O'Connor, Vincent; Holden-Dye, Lindy] Univ Southampton, Ctr Biol Sci, Southampton SO17 1BJ, Hants, England; [Andrianakis, Ioannis; James, Christopher] Univ Southampton, Inst Sound & Vibrat Res, Southampton SO17 1BJ, Hants, England; [Liu, Wei] Univ Southampton, Southampton Stat Sci Res Inst, Southampton SO17 1BJ, Hants, England; [Liu, Wei] Univ Southampton, Sch Math, Inst Life Sci, Southampton SO17 1BJ, Hants, England	University of Southampton; University of Southampton; University of Southampton; University of Southampton	Holden-Dye, L (corresponding author), Univ Southampton, Ctr Biol Sci, Inst Life Sci, Southampton SO17 1BJ, Hants, England.	lmhd@soton.ac.uk	James, Christopher/AAV-4770-2020	Holden-Dye, Lindy/0000-0002-9704-1217; O'Connor, Vincent/0000-0003-3185-5709; Dillon, James/0000-0003-3244-7483; Liu, Wei/0000-0002-4719-0345	Biotechnology and Biological Sciences Research Council (BBSRC), UK [BB/E022251/1]; Gerald Kerkut Charitable Trust; U.S. National Institutes of Health (NIH) Office of Research Infrastructure Programs [P40 OD010440]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010440] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BB/E022251/1] Funding Source: researchfish; BBSRC [BB/E022251/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council (BBSRC), UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Gerald Kerkut Charitable Trust; U.S. National Institutes of Health (NIH) Office of Research Infrastructure Programs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported in part by grant BB/E022251/1 from the Biotechnology and Biological Sciences Research Council (BBSRC), UK. B.I. received funding from the Gerald Kerkut Charitable Trust. C. elegans slo-1(js379) was provided by the Caenorhabditis elegans Genetics Center (Minneapolis, MN, USA), funded by the U.S. National Institutes of Health (NIH) Office of Research Infrastructure Programs (P40 OD010440).	Adermark L, 2004, NEUROCHEM INT, V45, P971, DOI 10.1016/j.neuint.2004.06.007; Altun ZF, 2009, DEV DYNAM, V238, P1936, DOI 10.1002/dvdy.22025; Anonymous, 2006, P173; Atkinson NS, 2009, J NEUROGENET, V23, P293, DOI 10.1080/01677060802572937; Avery L, 1995, METHOD CELL BIOL, V48, P251; Avery L, 2003, J EXP BIOL, V206, P2441, DOI 10.1242/jeb.00433; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; AVERY L, 1993, J EXP BIOL, V175, P283; Bettinger JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035192; Blednow YA, 2003, P NATL ACAD SCI USA, V100, P277, DOI 10.1073/pnas.012682399; BRENNER S, 1974, GENETICS, V77, P71; Castro PV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029984; Chiang JTA, 2006, J EXP BIOL, V209, P1859, DOI 10.1242/jeb.02165; Cook A, 2006, ELECTROPHYSIOLOGICAL; COVARRUBIAS M, 1993, P NATL ACAD SCI USA, V90, P6957, DOI 10.1073/pnas.90.15.6957; Crowder CM, 2004, TRENDS NEUROSCI, V27, P579, DOI 10.1016/j.tins.2004.07.006; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Cutter AD, 2010, MOL ECOL, V19, P798, DOI 10.1111/j.1365-294X.2009.04491.x; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; Davis JR, 2008, ALCOHOL CLIN EXP RES, V32, P853, DOI 10.1111/j.1530-0277.2008.00639.x; Dillon J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008482; Felix MA, 2010, CURR BIOL, V20, pR965, DOI 10.1016/j.cub.2010.09.050; Franks Christopher J., 2006, Invertebrate Neuroscience, V6, P105, DOI 10.1007/s10158-006-0023-1; Franks CJ, 2002, J NEUROPHYSIOL, V87, P954, DOI 10.1152/jn.00233.2001; Graham ME, 2009, MOL BIOL CELL, V20, P43, DOI 10.1091/mbc.E08-07-0689; Harris RA, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.128re7; Kwon JY, 2004, GENOMICS, V83, P600, DOI 10.1016/j.ygeno.2003.10.008; Lin CH, 2013, ALCOHOL CLIN EXP RES, V37, pE190, DOI 10.1111/j.1530-0277.2012.01856.x; Liu JX, 2013, MOL PHARMACOL, V83, P235, DOI 10.1124/mol.112.081240; Mitchell PH, 2007, PHARMACOGENOMICS J, V7, P411, DOI 10.1038/sj.tpj.6500440; Mitchell P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010422; Morgan M., 2010, ALCOHOL HLTH; Morgan PG, 1995, ALCOHOL CLIN EXP RES, V19, P1423, DOI 10.1111/j.1530-0277.1995.tb01002.x; Pemberton DJ, 2001, MOL PHARMACOL, V59, P1037, DOI 10.1124/mol.59.5.1037; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; Sagar GDV, 2006, J CELL BIOCHEM, V98, P1543, DOI 10.1002/jcb.20870; Scholz H, 2013, CURR TOP BEHAV NEURO, V13, P433, DOI 10.1007/7854_2011_128; Shtonda B, 2005, J EXP BIOL, V208, P2177, DOI 10.1242/jeb.01615; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; Steffensen SC, 2011, SYNAPSE, V65, P695, DOI 10.1002/syn.20885; Steger KA, 2005, J EXP BIOL, V208, P2191, DOI 10.1242/jeb.01616; TWOMBLY DA, 1990, J PHARMACOL EXP THER, V254, P1029; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; Yuan C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026468	44	12	13	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4266	4278		10.1096/fj.11-189340	http://dx.doi.org/10.1096/fj.11-189340			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23882127	Green Published			2022-12-28	WOS:000329747100036
J	Matsakas, A; Yadav, V; Lorca, S; Narkar, V				Matsakas, Antonios; Yadav, Vikas; Lorca, Sabina; Narkar, Vihang			Muscle ERR gamma mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming	FASEB JOURNAL			English	Article						estrogen-related receptors; fiber type; nuclear receptors; muscle degenerative diseases	SKELETAL-MUSCLE; OXIDATIVE-PHOSPHORYLATION; TRANSCRIPTIONAL CONTROL; DEFICIENT MUSCLES; NOS TRANSGENE; FULL-LENGTH; MDX MICE; EXPRESSION; UTROPHIN; RECEPTOR	Treatment of Duchenne muscular dystrophy (DMD) by replacing mutant dystrophin or restoring dystrophin-associated glycoprotein complex (DAG) has been clinically challenging. Instead, identifying and targeting muscle pathways deregulated in DMD will provide new therapeutic avenues. We report that the expression of nuclear receptor estrogen-related receptor- (ERR), and its metabolic and angiogenic targets are down-regulated (50-85%) in skeletal muscles of mdx mice (DMD model) vs. wild-type mice. Corelatively, oxidative myofibers, muscle vasculature, and exercise tolerance (33%) are decreased in mdx vs. wild-type mice. Overexpressing ERR selectively in the dystrophic muscles of the mdx mice restored metabolic and angiogenic gene expression compared with control mdx mice. Further, ERR enhanced muscle oxidative myofibers, vasculature, and blood flow (by 33-66%) and improved exercise tolerance (by 75%) in the dystrophic mice. Restoring muscle ERR pathway ameliorated muscle damage and also prevented DMD hallmarks of postexercise muscle damage, hypoxia, and fatigue in mdx mice. Notably, ERR did not restore sarcolemmal DAG complex, which is thus dispensable for antidystrophic effects of ERR. In summary, ERR-dependent metabolic and angiogenic gene program is defective in DMD, and we demonstrate that its restoration is a potential strategy for treating muscular dystrophy.Matsakas, A., Yadav, V., Lorca, S., Narkar, V. Muscle ERR mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming.	[Matsakas, Antonios; Yadav, Vikas; Lorca, Sabina; Narkar, Vihang] Univ Texas Med Sch Houston, Ctr Metab & Degenerat Dis, Inst Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Narkar, V (corresponding author), Univ Texas Med Sch Houston, Ctr Metab & Degenerat Dis, Brown Fdn Inst Mol Med, IMM SRB 430F,1825 Pressler St, Houston, TX 77030 USA.	vihang.a.narkar@uth.tmc.edu	Antonios Matsakas, SFHEA/I-6565-2019	Antonios Matsakas, SFHEA/0000-0003-0746-0088	University of Texas Medical School at Houston intramural funds; Muscular Dystrophy Association [MDA 174408]; American Heart Association [AHA 11SDG7600213]; American Diabetes Association [ADA 1-13-BS-127]	University of Texas Medical School at Houston intramural funds; Muscular Dystrophy Association(Muscular Dystrophy Association); American Heart Association(American Heart Association); American Diabetes Association(American Diabetes Association)	The authors thank Ron Evans (Salk Institute, La Jolla, CA, USA) for generously providing the muscle-specific ERR gamma transgenic mice for this study. The authors also thank Drs. Eun Ran Kim and Qingchun Tong, at the Institute of Molecular Medicine, for help with Comprehensive Lab Animal Monitoring System to measure spontaneous ambulatory activity. This work was supported by University of Texas Medical School at Houston intramural funds, as well as grants from the Muscular Dystrophy Association (MDA 174408), the American Heart Association (AHA 11SDG7600213), and the American Diabetes Association (ADA 1-13-BS-127).	Alaynick WA, 2007, CELL METAB, V6, P13, DOI 10.1016/j.cmet.2007.06.007; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106; Chakkalakal JV, 2005, FASEB J, V19, P880, DOI 10.1096/fj.04-1956rev; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chinsomboon J, 2009, P NATL ACAD SCI USA, V106, P21401, DOI 10.1073/pnas.0909131106; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Deasy BM, 2009, MOL THER, V17, P1788, DOI 10.1038/mt.2009.136; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Fairclough RJ, 2011, EXP PHYSIOL, V96, P1101, DOI 10.1113/expphysiol.2010.053025; Faist V, 2001, ANN NUTR METAB, V45, P58, DOI 10.1159/000046707; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Goyenvalle A, 2011, HUM MOL GENET, V20, pR69, DOI 10.1093/hmg/ddr105; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Grounds MD, 2008, NEUROBIOL DIS, V31, P1, DOI 10.1016/j.nbd.2008.03.008; Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jahnke VE, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-16; Khairallah RJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002829; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Kobayashi YM, 2008, NATURE, V456, P511, DOI 10.1038/nature07414; Kuznetsov AV, 1998, MOL CELL BIOCHEM, V183, P87, DOI 10.1023/A:1006868130002; Li S, 2006, HUM MOL GENET, V15, P1610, DOI 10.1093/hmg/ddl082; Ljubicic V, 2011, HUM MOL GENET, V20, P3478, DOI 10.1093/hmg/ddr265; Matsakas A, 2012, CIRC RES, V110, P1087, DOI 10.1161/CIRCRESAHA.112.266478; Matsakas A, 2012, EXP PHYSIOL, V97, P125, DOI 10.1113/expphysiol.2011.063008; Matsakas A, 2010, J MUSCLE RES CELL M, V31, P111, DOI 10.1007/s10974-010-9214-9; Messina S, 2007, FASEB J, V21, P3737, DOI 10.1096/fj.07-8459com; Miura P, 2009, HUM MOL GENET, V18, P4640, DOI 10.1093/hmg/ddp431; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Murray J, 2013, FASEB J, V27, P135, DOI 10.1096/fj.12-212290; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Narkar VA, 2011, CELL METAB, V13, P283, DOI 10.1016/j.cmet.2011.01.019; Neuhaus P, 2003, MOL CELL BIOL, V23, P6037, DOI 10.1128/MCB.23.17.6037-6048.2003; Pauly M, 2012, AM J PATHOL, V181, P583, DOI 10.1016/j.ajpath.2012.04.004; Percival JM, 2013, HUM MOL GENET, V22, P153, DOI 10.1093/hmg/dds415; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Porter JD, 1998, J CELL SCI, V111, P1801; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; Rangwala SM, 2010, J BIOL CHEM, V285, P22619, DOI 10.1074/jbc.M110.125401; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; RYDERCOOK AS, 1988, EMBO J, V7, P3017, DOI 10.1002/j.1460-2075.1988.tb03165.x; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Selsby JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030063; Shiao T, 2004, HUM MOL GENET, V13, P1873, DOI 10.1093/hmg/ddh204; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tidball JG, 2004, MOL GENET METAB, V82, P312, DOI 10.1016/j.ymgme.2004.06.006; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; Tinsley JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019189; Wang SCM, 2010, MOL CELL ENDOCRINOL, V315, P146, DOI 10.1016/j.mce.2009.07.012; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110	59	45	46	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4004	4016		10.1096/fj.13-228296	http://dx.doi.org/10.1096/fj.13-228296			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23781095				2022-12-28	WOS:000329747100015
J	Eckle, T; Hughes, K; Ehrentraut, H; Brodsky, KS; Rosenberger, P; Choi, DS; Ravid, K; Weng, TT; Xia, Y; Blackburn, MR; Eltzschig, HK				Eckle, Tobias; Hughes, Kelly; Ehrentraut, Heidi; Brodsky, Kelley S.; Rosenberger, Peter; Choi, Doo-Sup; Ravid, Katya; Weng, Tingting; Xia, Yang; Blackburn, Michael R.; Eltzschig, Holger K.			Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury	FASEB JOURNAL			English	Article						A(2B); dipyridamole; hypoxia-inducible factor; CD73; CD39; apyrase; ecto-nucleotidase	HYPOXIA-INDUCIBLE FACTOR; CEREBRAL-BLOOD-FLOW; HIF-1-DEPENDENT REPRESSION; EXTRACELLULAR ADENOSINE; TRANSGENIC MOUSE; IMAGE-ANALYSIS; ATP RELEASE; KAPPA-B; INFLAMMATION; MECHANISM	The signaling molecule adenosine has been implicated in attenuating acute lung injury (ALI). Adenosine signaling is terminated by its uptake through equilibrative nucleoside transporters (ENTs). We hypothesized that ENT-dependent adenosine uptake could be targeted to enhance adenosine-mediated lung protection. To address this hypothesis, we exposed mice to high-pressure mechanical ventilation to induce ALI. Initial studies demonstrated time-dependent repression of ENT1 and ENT2 transcript and protein levels during ALI. To examine the contention that ENT repression represents an endogenous adaptive response, we performed functional studies with the ENT inhibitor dipyridamole. Dipyridamole treatment (1 mg/kg; EC50=10 M) was associated with significant increases in ALI survival time (277 vs. 395 min; P<0.05). Subsequent studies in gene-targeted mice for Ent1 or Ent2 revealed a selective phenotype in Ent2(-/-) mice, including attenuated pulmonary edema and improved gas exchange during ALI in conjunction with elevated adenosine levels in the bronchoalveolar fluid. Furthermore, studies in genetic models for adenosine receptors implicated the A(2B) adenosine receptor (Adora2b) in mediating ENT-dependent lung protection. Notably, dipyridamole-dependent attenuation of lung inflammation was abolished in mice with alveolar epithelial Adora2b gene deletion. Our newly identified crosstalk pathway between ENT2 and alveolar epithelial Adora2b in lung protection during ALI opens possibilities for combined therapies targeted to this protein set.	[Eckle, Tobias; Hughes, Kelly; Ehrentraut, Heidi; Brodsky, Kelley S.; Eltzschig, Holger K.] Univ Colorado, Sch Med, Mucosal Inflammat Program, Dept Anesthesiol, Aurora, CO 80045 USA; [Rosenberger, Peter] Univ Hosp, Dept Anesthesiol & Intens Care Med, Tubingen, Germany; [Choi, Doo-Sup] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Coll Med, Rochester, MN USA; [Ravid, Katya] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Ravid, Katya] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Weng, Tingting; Xia, Yang; Blackburn, Michael R.] Univ Texas Med Sch Houston, Dept Biochem & Mol Biol, Houston, TX USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Mayo Clinic; Boston University; Boston University; University of Texas System; University of Texas Health Science Center Houston	Eltzschig, HK (corresponding author), Univ Colorado, Sch Med, Mucosal Inflammat Program, Dept Anesthesiol, 12700 E 19th Ave,Mailstop B112,Res Complex 2,Room, Aurora, CO 80045 USA.	holger.eltzschig@ucdenver.edu	Choi, Doo-Sup/G-9474-2012; Eckle, Tobias/AAE-6705-2020	Choi, Doo-Sup/0000-0002-6796-9938; Eckle, Tobias/0000-0002-6065-4669; Ravid, Katya/0000-0002-9918-3024; Blackburn, Michael/0000-0002-1394-9966	U.S. National Heart Institute [R01-DK097075, R01-HL0921, R01-DK083385, R01-HL098294, P01-HL114457-01, K08-HL102267, R01-HL070952]; Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070952, P01HL114457, R01HL098294, K08HL102267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK097075, R01DK083385] Funding Source: NIH RePORTER	U.S. National Heart Institute; Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge Kristann Magee, Stephanie Bonney, and Megan Bonney for technical assistance. This research was supported by U.S. National Heart Institute grants R01-DK097075, R01-HL0921, R01-DK083385, R01-HL098294, and P01-HL114457-01 to H. K. E.; K08-HL102267 to T. E.; and R01-HL070952 to M. R. B.; and by a Crohn's and Colitis Foundation of America grant to H.K.E.	Aherne CM, 2012, GUT, V61, P695, DOI 10.1136/gutjnl-2011-300012; Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Cagnina RE, 2009, AM J PHYSIOL-LUNG C, V297, pL467, DOI 10.1152/ajplung.90553.2008; Casanello P, 2005, CIRC RES, V97, P16, DOI 10.1161/01.RES.0000172568.49367.f8; Chaudary N, 2004, CARDIOVASC RES, V61, P780, DOI 10.1016/j.cardiores.2003.11.031; Choi DS, 2004, NAT NEUROSCI, V7, P855, DOI 10.1038/nn1288; CRONSTEIN BN, 1994, ADV EXP MED BIOL, V370, P411; Cronstein BN, 1997, RHEUM DIS CLIN N AM, V23, P739, DOI 10.1016/S0889-857X(05)70358-6; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7; Dixon BS, 2009, NEW ENGL J MED, V360, P2191, DOI 10.1056/NEJMoa0805840; Eckle T, 2008, AM J PHYSIOL-LUNG C, V295, pL718, DOI 10.1152/ajplung.90298.2008; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2008, CIRCULATION, V118, P166, DOI 10.1161/CIRCULATIONAHA.107.758516; Eckle T, 2008, BLOOD, V111, P2024, DOI 10.1182/blood-2007-10-117044; Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Eckle T, 2009, PHYSIOLOGY, V24, P298, DOI 10.1152/physiol.00022.2009; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2008, TRENDS CARDIOVAS MED, V18, P103, DOI 10.1016/j.tcm.2008.01.006; Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70; Eltzschig HK, 2006, METH MOL B, V341, P73; Eltzschig HK, 2006, BLOOD, V108, P1602, DOI 10.1182/blood-2006-02-001016; Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Eltzschig HK, 2009, ANESTHESIOLOGY, V111, P904, DOI 10.1097/ALN.0b013e3181b060f2; Faigle M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002801; Grenz A, 2008, PLOS MED, V5, P968, DOI 10.1371/journal.pmed.0050137; Grenz A, 2012, J CLIN INVEST, V122, P693, DOI 10.1172/JCI60214; Grenz A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014812; Hart ML, 2008, GASTROENTEROLOGY, V135, P1739, DOI 10.1053/j.gastro.2008.07.064; Hart ML, 2008, FASEB J, V22, P2784, DOI 10.1096/fj.07-103911; Hart ML, 2008, ARTERIOSCL THROM VAS, V28, P1477, DOI 10.1161/ATVBAHA.108.169219; Hart ML, 2011, J IMMUNOL, V186, P4367, DOI 10.4049/jimmunol.0903617; Hart ML, 2010, J IMMUNOL, V184, P4017, DOI 10.4049/jimmunol.0901851; Hart ML, 2009, J IMMUNOL, V182, P3965, DOI 10.4049/jimmunol.0802193; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Jackson EK, 2013, AM J PHYSIOL-RENAL, V304, pF49, DOI 10.1152/ajprenal.00571.2012; Jackson EK, 2010, HYPERTENSION, V56, P151, DOI 10.1161/HYPERTENSIONAHA.110.152454; Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876; Kim HH, 2008, J CEREBR BLOOD F MET, V28, P1285, DOI 10.1038/jcbfm.2008.24; KO KR, 1990, AM J PHYSIOL, V259, pH1703, DOI 10.1152/ajpheart.1990.259.6.H1703; Koeppen M, 2013, MUCOSAL IMMUNOL, V6, P762, DOI 10.1038/mi.2012.114; Koeppen M., 2011, JOVE-J VIS EXP, V51, P2525; Koeppen M, 2012, ANESTHESIOLOGY, V116, P1245, DOI 10.1097/ALN.0b013e318255793c; Lahm A, 2004, ARCH ORTHOP TRAUM SU, V124, P431, DOI 10.1007/s00402-004-0701-6; Lehr HA, 1997, J HISTOCHEM CYTOCHEM, V45, P1559, DOI 10.1177/002215549704501112; Loffler M, 2007, ARTERIOSCL THROM VAS, V27, P1004, DOI 10.1161/ATVBAHA.106.126714; Lu Q, 2010, AM J PHYSIOL-LUNG C, V298, pL755, DOI 10.1152/ajplung.00330.2009; Martin TR, 2002, J CLIN INVEST, V110, P1603, DOI 10.1172/JCI200217302; Morabito L, 1998, J CLIN INVEST, V101, P295, DOI 10.1172/JCI1554; Morote-Garcia JC, 2008, BLOOD, V111, P5571, DOI 10.1182/blood-2007-11-126763; Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Oliver KM, 2012, J BIOL CHEM, V287, P14004, DOI 10.1074/jbc.M112.347971; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701; Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Schingnitz U, 2010, J IMMUNOL, V184, P5271, DOI 10.4049/jimmunol.0903035; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sitkovsky MV, 2008, BLOOD, V111, P5424, DOI 10.1182/blood-2008-03-143990; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Taylor CT, 2008, J PHYSIOL-LONDON, V586, P4055, DOI 10.1113/jphysiol.2008.157669; Taylor CT, 2011, J PHYSIOL-LONDON, V589, P797, DOI 10.1113/jphysiol.2010.201467; Taylor CT, 2010, PHYSIOLOGY, V25, P272, DOI 10.1152/physiol.00029.2010; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Tsukamoto H, 2012, BLOOD, V119, P4554, DOI 10.1182/blood-2011-09-375899; Van Linden A, 2007, EXPERT OPIN BIOL TH, V7, P1437, DOI 10.1517/14712598.7.9.1437; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Zhou Y, 2011, J IMMUNOL, V186, P1097, DOI 10.4049/jimmunol.1002907; Zhou Y, 2009, J IMMUNOL, V182, P8037, DOI 10.4049/jimmunol.0900515	86	75	76	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3078	3089		10.1096/fj.13-228551	http://dx.doi.org/10.1096/fj.13-228551			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603835	Green Published			2022-12-28	WOS:000329877600015
J	Magne, J; Aminoff, A; Sundelin, JP; Mannila, MN; Gustafsson, P; Hultenby, K; Wernerson, A; Bauer, G; Listenberger, L; Neville, MJ; Karpe, F; Boren, J; Ehrenborg, E				Magne, Joelle; Aminoff, Anna; Sundelin, Jeanna Perman; Mannila, Maria Nastase; Gustafsson, Peter; Hultenby, Kjell; Wernerson, Annika; Bauer, Greta; Listenberger, Laura; Neville, Matt J.; Karpe, Fredrik; Boren, Jan; Ehrenborg, Ewa			The minor allele of the missense polymorphism Ser251Pro in perilipin 2 (PLIN2) disrupts an alpha-helix, affects lipolysis, and is associated with reduced plasma triglyceride concentration in humans	FASEB JOURNAL			English	Article						lipid droplets; lipid accumulation; lipid metabolism; HEK293 cells; macrophages	DIFFERENTIATION-RELATED PROTEIN; CYTOSOLIC LIPID DROPLETS; LOW-DENSITY-LIPOPROTEIN; HUMAN MACROPHAGES; HIGH-RISK; SECRETION; INSULIN; TRIACYLGLYCEROL; METABOLISM; INCREASES	Perilipin 2 (PLIN2) is the most abundant lipid droplet (LD)-associated protein in nonadipose tissue, and its expression correlates with intracellular lipid accumulation. Here we identified a missense polymorphism, Ser251Pro, that has major effect on protein structure and function, along with an influence on human plasma triglyceride concentration. The evolutionarily conserved Ser251Pro polymorphism was identified with the ClustalW program. Structure modeling using 3D-JigSaw and the Chimera package revealed that the Pro251 allele disrupts a predicted -helix in PLIN2. Analyses of macrophages from individuals carrying Ser251Pro variants and human embryonic kidney 293 (HEK293) cells stably transfected with either of the alleles demonstrated that the Pro251 variant causes increased lipid accumulation and decreased lipolysis. Analysis of LD size distribution in stably transfected cells showed that the minor Pro251 allele resulted in an increased number of small LDs per cell and increased perilipin 3 protein expression levels as compared with cells carrying the major Ser251 allele. Genotyping of 2113 individuals indicated that the Pro251 variant is associated with decreased plasma triglyceride and very low-density lipoprotein concentrations. Altogether, these data provide the first evidence of a polymorphism in PLIN2 that affects PLIN2 function and may influence the development of metabolic and cardiovascular diseases.	[Magne, Joelle; Aminoff, Anna; Mannila, Maria Nastase; Gustafsson, Peter; Ehrenborg, Ewa] Karolinska Univ Hosp, Atherosclerosis Res Unit, Ctr Mol Med, Dept Med, SE-17176 Stockholm, Sweden; [Hultenby, Kjell] Karolinska Inst, Div Clin Res Ctr, Dept Lab Med, Stockholm, Sweden; [Wernerson, Annika] Karolinska Inst, Div Renal Med, Dept Clin Sci Technol & Intervent, Stockholm, Sweden; [Sundelin, Jeanna Perman; Boren, Jan] Univ Gothenburg, Wallenberg Lab, Sahlgrenska Ctr Cardiovasc & Metab Res, Gothenburg, Sweden; [Bauer, Greta; Listenberger, Laura] St Olaf Coll, Dept Biol & Chem, Northfield, MN 55057 USA; [Neville, Matt J.; Karpe, Fredrik] Univ Oxford, Radcliffe Dept Med, OCDEM, Oxford, England; [Neville, Matt J.; Karpe, Fredrik] Oxford Univ Hosp Trust, Oxford Biomed Res Ctr, Natl Inst Hlth Res, OCDEM,Churchill Hosp, Oxford, England	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; University of Gothenburg; Saint Olaf College; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford	Ehrenborg, E (corresponding author), Karolinska Univ Hosp, Atherosclerosis Res Unit, Ctr Mol Med, L8 03, SE-17176 Stockholm, Sweden.	ewa.ehrenborg@ki.se		Saliba-Gustafsson, Peter/0000-0002-7807-9009; Ehrenborg, Ewa/0000-0003-1993-2468; magne, joelle/0000-0003-0316-4046; Karpe, Fredrik/0000-0002-2751-1770; Wernerson, Annika/0000-0003-2792-0010	Swedish Research Council [12659]; Swedish Heart-Lung Foundation; Swedish Diabetes Foundation; Swedish Foundation for Strategic Research; Karolinska Institutet Funds; Research Corporation for Science Advancement; Novo Nordisk Fonden [NNF13OC0004973] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Diabetes Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Karolinska Institutet Funds; Research Corporation for Science Advancement(Research Corporation for Science Advancement); Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank professor Mai-Lis Hellenius (Karolinska Institutet) for clinical expertise and Olivera Werngren (Karolinska Institutet) and Anastasia Hains (St. Olaf College) for excellent technical support. This work was supported by the Swedish Research Council (grant no. 12659), the Swedish Heart-Lung Foundation, the Swedish Diabetes Foundation, the Swedish Foundation for Strategic Research, Karolinska Institutet Funds, and the Research Corporation for Science Advancement. The authors declare no conflicts of interest.	ANDERSSON M, 1994, J LIPID RES, V35, P535; Bell M, 2008, DIABETES, V57, P2037, DOI 10.2337/db07-1383; Bickel PE, 2009, BBA-MOL CELL BIOL L, V1791, P419, DOI 10.1016/j.bbalip.2009.04.002; Bosma M, 2012, DIABETES, V61, P2679, DOI 10.2337/db11-1402; Bostrom P, 2007, NAT CELL BIOL, V9, P1286, DOI 10.1038/ncb1648; Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Buers I, 2009, ARTERIOSCL THROM VAS, V29, P767, DOI 10.1161/ATVBAHA.108.182675; Bulankina AV, 2009, J CELL BIOL, V185, P641, DOI 10.1083/jcb.200812042; Chang BHJ, 2010, J LIPID RES, V51, P2132, DOI 10.1194/jlr.M004515; Chapman MJ, 2011, EUR HEART J, V32, P1345, DOI 10.1093/eurheartj/ehr112; Chong BM, 2011, J BIOL CHEM, V286, P23254, DOI 10.1074/jbc.M110.217091; Contreras-Moreira B, 2002, BIOINFORMATICS, V18, P1141, DOI 10.1093/bioinformatics/18.8.1141; Faleck DM, 2010, AM J PHYSIOL-ENDOC M, V299, pE249, DOI 10.1152/ajpendo.00646.2009; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; Homan R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; Imai Y, 2012, PHYSIOL GENOMICS, V44, P1125, DOI 10.1152/physiolgenomics.00045.2012; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Johansen CT, 2011, J LIPID RES, V52, P189, DOI 10.1194/jlr.R009720; Krahmer N, 2011, CELL METAB, V14, P504, DOI 10.1016/j.cmet.2011.07.013; Larigauderie G, 2004, ARTERIOSCL THROM VAS, V24, P504, DOI 10.1161/01.ATV.0000115638.27381.97; Larigauderie G, 2006, FEBS J, V273, P3498, DOI 10.1111/j.1742-4658.2006.05357.x; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Ledmyr H, 2002, J LIPID RES, V43, P51; Lehner R, 2012, ARTERIOSCL THROM VAS, V32, P1087, DOI 10.1161/ATVBAHA.111.241497; Li L, 2006, J LIPID RES, V47, P67, DOI 10.1194/jlr.M500424-JLR200; Listenberger LL, 2007, J LIPID RES, V48, P2751, DOI 10.1194/jlr.M700359-JLR200; Listenberger LL, 2007, CURR PROTOC CELL BIO, DOI [DOI 10.1002/0471143030.CB2402S35, 10.1002/0471143030.cb2402s35]; Llorente-Cortes V, 2007, J LIPID RES, V48, P2133, DOI 10.1194/jlr.M700039-JLR200; Magnusson B, 2006, ARTERIOSCL THROM VAS, V26, P1566, DOI 10.1161/01.ATV.0000223345.11820.da; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; McIntosh AL, 2012, AM J PHYSIOL-CELL PH, V303, pC728, DOI 10.1152/ajpcell.00448.2011; Nakamura N, 2003, BIOCHEM BIOPH RES CO, V306, P333, DOI 10.1016/S0006-291X(03)00979-3; Narayanaswami V, 2010, COMP BIOCHEM PHYS A, V155, P123, DOI 10.1016/j.cbpa.2009.09.009; Nuotio K, 2007, STROKE, V38, P1791, DOI 10.1161/STROKEAHA.106.478867; Paul A, 2008, CIRC RES, V102, P1492, DOI 10.1161/CIRCRESAHA.107.168070; Perman JC, 2011, J CLIN INVEST, V121, P2625, DOI 10.1172/JCI43068; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rader DJ, 2005, CELL METAB, V1, P223, DOI 10.1016/j.cmet.2005.03.005; Robenek H, 2006, J CELL SCI, V119, P4215, DOI 10.1242/jcs.03191; Rydberg EK, 2003, ATHEROSCLEROSIS, V170, P245, DOI 10.1016/S0021-9150(03)00302-2; Spencer C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001337; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Sztalryd C, 2006, J BIOL CHEM, V281, P34341, DOI 10.1074/jbc.M602497200; Tan GD, 2006, DIABETOLOGIA, V49, P158, DOI 10.1007/s00125-005-0044-z; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Watts GF, 2011, HEART, V97, P350, DOI 10.1136/hrt.2010.204990; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; Wolins NE, 2006, FEBS LETT, V580, P5484, DOI 10.1016/j.febslet.2006.08.040; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Zechner R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200	54	30	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3090	3099		10.1096/fj.13-228759	http://dx.doi.org/10.1096/fj.13-228759			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603836				2022-12-28	WOS:000329877600016
J	Yan, CG; Ward, PA; Wang, XM; Gao, HW				Yan, Chunguang; Ward, Peter A.; Wang, Ximo; Gao, Hongwei			Myeloid depletion of SOCS3 enhances LPS-induced acute lung injury through CCAAT/enhancer binding protein delta pathway	FASEB JOURNAL			English	Article						C/EBP; LPS	KAPPA-B ACTIVATION; C/EBP-BETA; GENE-EXPRESSION; MESSENGER-RNA; MURINE MODEL; MICE LACKING; CYTOKINE; SUPPRESSOR; IL-6; INDUCTION	Although uncontrolled inflammatory response plays a central role in the pathogenesis of acute lung injury (ALI), the precise molecular mechanisms underlying the development of this disorder remain poorly understood. SOCS3 is an important negative regulator of IL-6-type cytokine signaling. SOCS3 is induced in lung during LPS-induced lung injury, suggesting that generation of SOCS3 may represent a regulatory product during ALI. In the current study, we created mice lacking SOCS3 expression in macrophages and neutrophils (LysM-cre SOCS3(fl/fl)). We evaluated the lung inflammatory response to LPS in both LysM-cre SOCS3(fl/fl) mice and the wild-type (WT) mice (SOCS3(fl/fl)). LysM-cre SOCS3(fl/fl) mice displayed significant increase of the lung permeability index (lung vascular leak of albumin), neutrophils, lung neutrophil accumulation (myeloperoxidase activity), and proinflammatory cytokines/chemokines in bronchial alveolar lavage fluids compared to WT mice. These phenotypes were consistent with morphological evaluation of lung, which showed enhanced inflammatory cell influx and intra-alveolar hemorrhage. We further identify the transcription factor, CCAAT/enhancer-binding protein (C/EBP) as a critical downstream target of SOCS3 in LPS-induced ALI. These results indicate that SOCS3 has a protective role in LPS-induced ALI by suppressing C/EBP activity in the lung. Elucidating the function of SOCS3 would represent prospective targets for a new generation of drugs needed to treat ALI.	[Yan, Chunguang; Wang, Ximo; Gao, Hongwei] Harvard Univ, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury,Med Sch, Boston, MA 02115 USA; [Ward, Peter A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Wang, Ximo] Nankai Univ, Tianjin Union Med Ctr, Dept Surg, Affiliated Hosp, Tianjin 300071, Peoples R China	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Michigan System; University of Michigan; Nankai University	Gao, HW (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury,Med Sch, 20 Shattuck St, Boston, MA 02115 USA.	wangximo@126.com; hgao@zeus.bwh.harvard.edu	Yan, Chunguang/ABE-5021-2021		U.S. National Institutes of Health [5R01HL092905-04, 3R01HL092905-02S1, 5R01GM029507-30]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by U.S. National Institutes of Health grants 5R01HL092905-04 and 3R01HL092905-02S1 (H.G.) and 5R01GM029507-30 (P.A.W.). The authors declare no conflicts of interest.	Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Albina JE, 2005, SHOCK, V23, P168, DOI 10.1097/01.shk.0000148054.74268.e2; Babon JJ, 2012, GROWTH FACTORS, V30, P207, DOI 10.3109/08977194.2012.687375; Babon JJ, 2012, IMMUNITY, V36, P239, DOI 10.1016/j.immuni.2011.12.015; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Cao XH, 2004, J IMMUNOL, V172, P4851, DOI 10.4049/jimmunol.172.8.4851; Cappelletti M, 1996, CELL DEATH DIFFER, V3, P29; Cassatella MA, 1999, BLOOD, V94, P2880, DOI 10.1182/blood.V94.8.2880.420k31_2880_2889; Chopra M, 2009, EXP BIOL MED, V234, P361, DOI 10.3181/0811-MR-318; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Croker BA, 2012, IMMUNOL CELL BIOL, V90, P124, DOI 10.1038/icb.2011.29; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf; Gao HW, 2006, J IMMUNOL, V177, P612, DOI 10.4049/jimmunol.177.1.612; Gao HW, 2002, J BIOL CHEM, V277, P38827, DOI 10.1074/jbc.M206224200; Gomez-Guerrero C, 2004, J IMMUNOL, V172, P6969, DOI 10.4049/jimmunol.172.11.6969; Gorgoni B, 2002, J IMMUNOL, V168, P4055, DOI 10.4049/jimmunol.168.8.4055; Heeg K, 2003, VACCINE, V21, pS61, DOI 10.1016/S0264-410X(03)00202-0; Hilberath JN, 2011, FASEB J, V25, P1827, DOI 10.1096/fj.10-169896; Howden BP, 2005, EUR J CLIN MICROBIOL, V24, P100, DOI 10.1007/s10096-004-1261-y; Hu HM, 1998, J IMMUNOL, V160, P2334; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Kabir K, 2002, SHOCK, V17, P300, DOI 10.1097/00024382-200204000-00010; Kinjyo I, 2006, J EXP MED, V203, P1021, DOI 10.1084/jem.20052333; Koay MA, 2002, AM J RESP CELL MOL, V26, P572, DOI 10.1165/ajrcmb.26.5.4748; Kozawa O, 2002, CELL SIGNAL, V14, P311, DOI 10.1016/S0898-6568(01)00248-0; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Lee YJ, 2012, J LEUKOCYTE BIOL, V91, P921, DOI 10.1189/jlb.0611289; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu X, 2008, MOL IMMUNOL, V45, P1405, DOI 10.1016/j.molimm.2007.08.018; Lu YC, 2009, J IMMUNOL, V182, P7212, DOI 10.4049/jimmunol.0802971; Moriwaki A, 2011, AM J RESP CELL MOL, V44, P448, DOI 10.1165/rcmb.2009-0051OC; Nakaya M, 2011, INT IMMUNOL, V23, P195, DOI 10.1093/intimm/dxq472; Okugawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC399, DOI 10.1152/ajpcell.00026.2003; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Qin H, 2007, J IMMUNOL, V179, P5966, DOI 10.4049/jimmunol.179.9.5966; Qin HW, 2006, J IMMUNOL, V177, P7761, DOI 10.4049/jimmunol.177.11.7761; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI200113568; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Strieter RM, 2002, J CLIN INVEST, V109, P699, DOI 10.1172/JCI200215277; Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741; Veenbergen S, 2008, ARTHRITIS RHEUM-US, V58, P3742, DOI 10.1002/art.24072; Ward PA, 1999, ARCH SURG-CHICAGO, V134, P666, DOI 10.1001/archsurg.134.6.666; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Wong PKK, 2006, J CLIN INVEST, V116, P1571, DOI 10.1172/JCI25660; Yan CG, 2013, AM J PATHOL, V182, P420, DOI 10.1016/j.ajpath.2012.10.013; Yan CG, 2010, J BIOL CHEM, V285, P37227, DOI 10.1074/jbc.M110.132084; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Yoshimura Akihiko, 2009, Keio Journal of Medicine, V58, P73	56	40	42	3	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2967	2976		10.1096/fj.12-225797	http://dx.doi.org/10.1096/fj.12-225797			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23585399	Green Submitted, Green Published			2022-12-28	WOS:000329877600005
J	Calzada, C; Vericel, E; Colas, R; Guillot, N; El Khoury, G; Drai, J; Sassolas, A; Peretti, N; Ponsin, G; Lagarde, M; Moulin, P				Calzada, Catherine; Vericel, Evelyne; Colas, Romain; Guillot, Nicolas; El Khoury, Graziella; Drai, Jocelyne; Sassolas, Agnes; Peretti, Noel; Ponsin, Gabriel; Lagarde, Michel; Moulin, Philippe			Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia	FASEB JOURNAL			English	Article						metabolic disease; vitamin E; lipid peroxidation; hydroxylated fatty acids	APOLIPOPROTEIN-A-I; FAMILIAL HYPOBETALIPOPROTEINEMIA; OXIDATIVE STRESS; TRANSFER PROTEIN; ACTIVATION; ATHEROSCLEROSIS; DISEASE; HDL; EXPRESSION; TARGET	There is evidence that high-density lipoproteins (HDLs) may regulate platelet function, but disparate results exist regarding the effects of oxidized HDLs on platelets. The objective of our study was to determine the role of in vivo oxidized HDLs on platelet aggregation. Platelet aggregation and redox status were investigated in 5 patients with abetalipoproteinemia (ABLP) or homozygous hypobetalipoproteinemia, two rare metabolic diseases characterized by the absence of apolipoprotein B-containing lipoproteins, compared to 5 control subjects. Platelets isolated from plasma of patients with ABLP aggregated 4 to 10 times more than control platelets, depending on the agonist. By contrast, no differences in the extent of platelet aggregation were observed between ABLP platelet-rich plasma (PRP) and control PRP, suggesting the presence of a protective factor in ABLP plasma. ABLP HDLs inhibited agonist-induced platelet aggregation by binding to SR-BI, while control HDLs had no effect. On the other hand, lipoprotein-deficient plasma from patients with ABLP did not inhibit platelet aggregation. Severe oxidative stress was evidenced in patients with ABLP. Compared to control HDLs, ABLP HDLs showed a 40% decrease of -tocopherol and an 11-fold increased malondialdehyde concentration. These results demonstrate that in vivo oxidized HDLs do not lose their antiaggregatory properties despite oxidation.Calzada, C., Vericel, E., Colas, R., Guillot, N., El Khoury, G., Drai, J., Sassolas, A., Peretti, N., Ponsin, G., Lagarde, M., Moulin, P. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.	[Calzada, Catherine; Vericel, Evelyne; Colas, Romain; Guillot, Nicolas; El Khoury, Graziella; Drai, Jocelyne; Sassolas, Agnes; Peretti, Noel; Ponsin, Gabriel; Lagarde, Michel; Moulin, Philippe] Univ Lyon 1, INSERM, Cardiovasc Metab Diabetol & Nutr CarMeN Lab, Inst Natl Sci Appl Lyon INSA Lyon,IMBL,UMR 1060, F-69622 Villeurbanne, France; [Moulin, Philippe] Hosp Civils Lyon, Lyon Bron, France; [Peretti, Noel] Hosp Civils Lyon, Serv Gastroenterol & Nutr, Lyon Bron, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Lyon	Calzada, C (corresponding author), Univ Lyon, INSERM, UMR 1060, INSA Lyon,IMBL, Bat Louis Pasteur,20 Av Albert Einstein, F-69621 Villeurbanne, France.	catherine.calzada@insa-lyon.fr	Vericel, Evelyne/M-4187-2018	El Khoury, Graziella/0000-0003-1902-390X; Calzada, Catherine/0000-0001-8858-6752; Guillot, Nicolas/0000-0003-1096-6960	Institut National de la Sante et de la Recherche Medicale; Agence Nationale de la Recherche (ANR) [ANR-05-COD-D019-01]; Centre National de la Recherche Scientifique	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS))	The authors are grateful to the patients for their reliable cooperation, to the control subjects for their participation, and to the nurses from Hospices Civils de Lyon for their expert blood drawing. The authors greatly thank Prof. Alain Lachaux for medical cooperation and Mathilde Di Filippo for scientific contribution. This work was supported by Institut National de la Sante et de la Recherche Medicale and Agence Nationale de la Recherche (ANR; grant ANR-05-COD-D019-01). C.C. is supported by the Centre National de la Recherche Scientifique.	ARDLIE NG, 1989, ATHEROSCLEROSIS, V76, P117, DOI 10.1016/0021-9150(89)90094-4; Assinger A, 2008, FEBS LETT, V582, P778, DOI 10.1016/j.febslet.2008.02.001; AVIRAM M, 1985, ATHEROSCLEROSIS, V57, P313, DOI 10.1016/0021-9150(85)90043-7; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BOUKHCHACHE D, 1982, BIOCHIM BIOPHYS ACTA, V713, P386, DOI 10.1016/0005-2760(82)90257-0; BOWYER DE, 1963, BIOCHIM BIOPHYS ACTA, V70, P423, DOI 10.1016/0926-6542(63)90061-1; Brodde MF, 2011, ATHEROSCLEROSIS, V215, P374, DOI 10.1016/j.atherosclerosis.2010.12.026; Calkin AC, 2009, CIRCULATION, V120, P2095, DOI 10.1161/CIRCULATIONAHA.109.870709; Calzada C, 2007, J CLIN ENDOCR METAB, V92, P1961, DOI 10.1210/jc.2006-2045; Clarke MW, 2006, CLIN CHEM, V52, P1339, DOI 10.1373/clinchem.2006.068692; Colas R, 2011, DIABETOLOGIA, V54, P2931, DOI 10.1007/s00125-011-2272-8; Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014; Di Leo E, 2008, CLIN GENET, V74, P267, DOI 10.1111/j.1399-0004.2008.01023.x; Gao DT, 2010, J BIOL CHEM, V285, P4447, DOI 10.1074/jbc.M109.082800; Granot E, 2004, AM J CLIN NUTR, V79, P226; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Imachi H, 2003, ARTERIOSCL THROM VAS, V23, P898, DOI 10.1161/01.ATV.0000067429.46333.7B; Kontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1; LAGARDE M, 1980, THROMB RES, V17, P581, DOI 10.1016/0049-3848(80)90098-5; LINTON MF, 1993, J LIPID RES, V34, P521; Macdonald DL, 2003, ARTERIOSCL THROM VAS, V23, P1583, DOI 10.1161/01.ATV.0000085840.67498.00; Nakano T, 2003, J LAB CLIN MED, V141, P378, DOI 10.1016/S0022-2143(03)00026-X; Nofer JR, 2011, CURR OPIN LIPIDOL, V22, P277, DOI 10.1097/MOL.0b013e32834701de; Nofer JR, 2010, CLIN EXP PHARMACOL P, V37, P726, DOI 10.1111/j.1440-1681.2010.05377.x; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; Rye KA, 2009, J LIPID RES, V50, pS195, DOI 10.1194/jlr.R800034-JLR200; SHASTRI KM, 1980, J LIPID RES, V21, P467; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SURYA II, 1991, THROMB HAEMOSTASIS, V65, P306; Takahashi Y, 1996, BIOCHEM BIOPH RES CO, V222, P453, DOI 10.1006/bbrc.1996.0765; Valiyaveettil M, 2008, BLOOD, V111, P1962, DOI 10.1182/blood-2007-08-107813; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	33	12	12	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2855	2861		10.1096/fj.12-225169	http://dx.doi.org/10.1096/fj.12-225169			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23507868				2022-12-28	WOS:000328841000033
J	Dalli, J; Zhu, M; Vlasenko, NA; Deng, B; Haeggstrom, JZ; Petasis, NA; Serhan, CN				Dalli, Jesmond; Zhu, Min; Vlasenko, Nikita A.; Deng, Bin; Haeggstrom, Jesper Z.; Petasis, Nicos A.; Serhan, Charles N.			The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A(4) hydrolase (LTA(4)H), and shifts macrophage phenotype	FASEB JOURNAL			English	Article						inflammation resolution; leukocytes; n-3 omega essential fatty acids; proresolving mediators; DHA	PRO-RESOLVING MEDIATORS; FATTY-ACIDS; INFLAMMATION; RESOLUTION; ENZYME; D1; INACTIVATION; LEUKOCYTES; DISEASE; INJURY	Maresins are produced by macrophages from docosahexaenoic acid (DHA) and exert potent proresolving and tissue homeostatic actions. Maresin 1 (MaR1; 7R,14S-dihydroxy-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid) is the first identified maresin. Here, we investigate formation, stereochemistry, and precursor role of 13,14-epoxy-docosahexaenoic acid, an intermediate in MaR1 biosynthesis. The 14-lipoxygenation of DHA by human macrophage 12-lipoxygenase (hm12-LOX) gave 14-hydro(peroxy)-docosahexaenoic acid (14-HpDHA), as well as several dihydroxy-docosahexaenoic acids, implicating an epoxide intermediate formation by this enzyme. Using a stereo-controlled synthesis, enantiomerically pure 13S,14S-epoxy-docosa-4Z,7Z,9E,11E,16Z,19Z-hexaenoic acid (13S,14S-epoxy-DHA) was prepared, and its stereochemistry was confirmed by NMR spectroscopy. When this 13S,14S-epoxide was incubated with human macrophages, it was converted to MaR1. The synthetic 13S,14S-epoxide inhibited leukotriene B-4 (LTB4) formation by human leukotriene A(4) hydrolase (LTA(4)H) approximate to 40% (P<0.05) to a similar extent as LTA(4) (approximate to 50%, P<0.05) but was not converted to MaR1 by this enzyme. 13S,14S-epoxy-DHA also reduced (approximate to 60%; P<0.05) arachidonic acid conversion by hm12-LOX and promoted conversion of M1 macrophages to M2 phenotype, which produced more MaR1 from the epoxide than M1. Together, these findings establish the biosynthesis of the 13S,14S-epoxide, its absolute stereochemistry, its precursor role in MaR1 biosynthesis, and its own intrinsic bioactivity. Given its actions and role in MaR1 biosynthesis, this epoxide is now termed 13,14-epoxy-maresin (13,14-eMaR) and exhibits new mechanisms in resolution of inflammation in its ability to inhibit proinflammatory mediator production by LTA(4) hydrolase and to block arachidonate conversion by human 12-LOX rather than merely terminating phagocyte involvement.Dalli, J., Zhu, M., Vlasenko, N. A., Deng, B., Haeggstrom, J. Z., Petasis, N. A., Serhan, C. N. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A(4) hydrolase (LTA(4)H) and shifts macrophage phenotype.	[Dalli, Jesmond; Deng, Bin; Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; [Dalli, Jesmond; Deng, Bin; Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA USA; [Zhu, Min; Vlasenko, Nikita A.; Petasis, Nicos A.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; [Zhu, Min; Vlasenko, Nikita A.; Petasis, Nicos A.] Univ So Calif, Loker Hydrocarbon Res Inst, Los Angeles, CA 90089 USA; [Haeggstrom, Jesper Z.] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Southern California; University of Southern California; Karolinska Institutet	Serhan, CN (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur,HIM 829, Boston, MA 02115 USA.	petasis@usc.edu; cnserhan@zeus.bwh.harvard.edu	Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446; Dalli, Jesmond/0000-0001-6328-3640	U.S. National Institutes of Health [P01GM095467]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM095467] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Mary Halm Small for expert assistance in manuscript preparation. This study was supported by U.S. National Institutes of Health grant P01GM095467. The C.N.S. and N.A.P. laboratories contributed equally to this study.	Ariel A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00004; Calder PC, 2011, EUR J PHARMACOL, V668, pS50, DOI 10.1016/j.ejphar.2011.05.085; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Dalli J, 2012, BLOOD, V120, pE60, DOI 10.1182/blood-2012-04-423525; De Caterina R, 2011, NEW ENGL J MED, V364, P2439, DOI 10.1056/NEJMra1008153; Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902; Giera M, 2012, BBA-MOL CELL BIOL L, V1821, P1415, DOI 10.1016/j.bbalip.2012.07.011; Hellmann J, 2011, FASEB J, V25, P2399, DOI 10.1096/fj.10-178657; Ingersoll MA, 2011, TRENDS IMMUNOL, V32, P470, DOI 10.1016/j.it.2011.05.001; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; Lu Y, 2010, J LIPID RES, V51, P923, DOI 10.1194/jlr.M000059; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Oh SF, 2011, J CLIN INVEST, V121, P569, DOI 10.1172/JCI42545; OHISHI N, 1987, J BIOL CHEM, V262, P10200; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; Samuelsson B, 2012, J BIOL CHEM, V287, P10070, DOI 10.1074/jbc.X112.351437; Serhan CN, 2012, FASEB J, V26, P1755, DOI 10.1096/fj.11-201442; Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Serhan CN., 2010, FUNDAMENTALS INFLAMM, DOI 10.1017/CBO9781139195737; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Stables MJ, 2011, BLOOD, V118, pE192, DOI 10.1182/blood-2011-04-345330; Tian HB, 2012, STEM CELLS DEV, V21, P1187, DOI 10.1089/scd.2011.0220; Tian HB, 2011, J BIOL CHEM, V286, P4443, DOI 10.1074/jbc.M110.100388; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; WEISSMANN G, 1978, HOSP PRACT, V13, P53, DOI 10.1080/21548331.1978.11707397; Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364; Yang R, 2011, CURR PROTOC IMMUNOL, V95, P14261; Zhang MJ, 2012, ANNU REV NUTR, V32, P203, DOI 10.1146/annurev-nutr-071811-150726	31	186	195	4	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2573	2583		10.1096/fj.13-227728	http://dx.doi.org/10.1096/fj.13-227728			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23504711	Green Published			2022-12-28	WOS:000328841000007
J	Lee, JH; Kim, TH; Oh, SJ; Yoo, JY; Akira, S; Ku, BJ; Lydon, JP; Jeong, JW				Lee, Jae Hee; Kim, Tae Hoon; Oh, Seo Jin; Yoo, Jung-Yoon; Akira, Shizuo; Ku, Bon Jeong; Lydon, John P.; Jeong, Jae-Wook			Signal transducer and activator of transcription-3 (Stat3) plays a critical role in implantation via progesterone receptor in uterus	FASEB JOURNAL			English	Article						animal model; early pregnancy; steroid hormone; transcription factor	LEUKEMIA INHIBITORY FACTOR; EMBRYO IMPLANTATION; EARLY-PREGNANCY; RETINOIC ACID; MICE LACKING; B ISOFORM; EXPRESSION; MOUSE; GENE; INTERLEUKIN-11	Recent studies have shown that activation of the signal transducer and activator of transcription-3 (Stat3) is required for decidualization, interacting with progesterone receptor (PR) in uterus. Based on previous reports, we hypothesized that crosstalk between STAT3 and PR signaling is required for successful implantation. To identify the interaction between STAT3 and PR isoforms, we performed immunoprecipitation following transient cotransfection and found that STAT3 physically interacted with PR-A, which is known to be important for uterine development and function, but not with PR-B. To further investigate the role of Stat3 in uterine function, Stat3 was conditionally ablated only in the PR-positive cells (PR(cre/+)Stat3(f/f); Stat3(d/d)). Our studies revealed that ovarian function and uterine development of Stat3(d/d) mice were normal. However, Stat3(d/d) female mice were infertile due to defective embryo implantation. Unlike Stat3(f/f) mice, Stat3(d/d) mice exhibited an unclosed uterine lumen. Furthermore, uteri of Stat3(d/d) mice were unable to undergo a well-characterized hormonally induced decidual reaction. The expression of stromal PR was decreased during decidualization and preimplantation period in Stat3(d/d) mice, and PR target genes were significantly down-regulated after progesterone induction. Our results suggest that STAT3 and PR crosstalk is required for successful implantation in the mouse uterus.Lee, J. H., Kim, T. H., Oh, S. J., Yoo, J.-Y., Akira, S., Ku, B. J., Lydon, J. P., Jeong, J.-W. Signal transducer and activator of transcription-3 (Stat3) plays a critical role in implantation via progesterone receptor in uterus.	[Lee, Jae Hee; Kim, Tae Hoon; Oh, Seo Jin; Yoo, Jung-Yoon; Jeong, Jae-Wook] Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI 49503 USA; [Akira, Shizuo] Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 565, Japan; [Ku, Bon Jeong] Chungnam Natl Univ, Sch Med, Dept Internal Med, Taejon, South Korea; [Lydon, John P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Jeong, Jae-Wook] Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Biotechnol, World Class Univ WCU Biomodulat Program, Seoul, South Korea	Michigan State University; Michigan State University College of Human Medicine; Osaka University; Chungnam National University; Baylor College of Medicine; Seoul National University (SNU)	Jeong, JW (corresponding author), Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, 333 Bostwick Ave NE,Ste 4024, Grand Rapids, MI 49503 USA.	jaewook.jeong@hc.msu.edu		Yoo, Jung-Yoon/0000-0001-9366-3863	U.S. National Institutes of Health [R01HD057873]; World Class University (WCU) program through the National Research Foundation of Korea [R31-10056]; Ministry of Education, Science, and Technology; Lalor Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057873] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); World Class University (WCU) program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Lalor Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Francesco J. DeMayo and CheMyong Jay Ko for invaluable discussions and Susan D. Ferguson, Sharra A. Poncil, and Thuy L. Tran for manuscript preparation. This work was supported by U.S. National Institutes of Health grant R01HD057873; the World Class University (WCU) program (R31-10056) through the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology (J. W. J.); and the Lalor Foundation's postdoctoral fellowship program (J. H. L). The authors declare no conflicts of interest.	Attia GR, 2000, J CLIN ENDOCR METAB, V85, P2897, DOI 10.1210/jc.85.8.2897; Chen JR, 2000, ENDOCRINOLOGY, V141, P4365, DOI 10.1210/en.141.12.4365; Cheng JG, 2001, P NATL ACAD SCI USA, V98, P8680, DOI 10.1073/pnas.151180898; Conneely OM, 2003, STEROIDS, V68, P771, DOI 10.1016/S0039-128X(03)00126-0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; Dimitriadis E, 2006, ENDOCRINOLOGY, V147, P3809, DOI 10.1210/en.2006-0264; Dimitriadis E, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-44; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Evers JLH, 2002, LANCET, V360, P151, DOI 10.1016/S0140-6736(02)09417-5; FINN CA, 1972, BIOL REPROD, V7, P82, DOI 10.1093/biolreprod/7.1.82; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; Franco HL, 2012, FASEB J, V26, P1218, DOI 10.1096/fj.11-193334; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Han BC, 2010, J CELL PHYSIOL, V223, P471, DOI 10.1002/jcp.22056; Jeong JW, 2005, ENDOCRINOLOGY, V146, P3490, DOI 10.1210/en.2005-0016; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KRAUS WL, 1993, MOL ENDOCRINOL, V7, P1603, DOI 10.1210/me.7.12.1603; Lee KY, 2004, REPRODUCTION, V128, P679, DOI 10.1530/rep.1.00340; Liu TY, 2002, BIOL REPROD, V67, P114, DOI 10.1095/biolreprod67.1.114; Lydon JP, 1996, J STEROID BIOCHEM, V56, P67, DOI 10.1016/0960-0760(95)00254-5; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Marwood M, 2009, ENDOCRINOLOGY, V150, P2915, DOI 10.1210/en.2008-1538; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nakamura H, 2006, FEBS LETT, V580, P2717, DOI 10.1016/j.febslet.2006.04.029; Sharkey AM, 2003, BEST PRACT RES CL OB, V17, P289, DOI 10.1016/S1521-6934(02)00130-X; Smith S, 2003, JAMA-J AM MED ASSOC, V290, P1767, DOI 10.1001/jama.290.13.1767; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Teng CB, 2004, MOL REPROD DEV, V69, P1, DOI 10.1002/mrd.20149; Teng CB, 2004, REPRODUCTION, V128, P197, DOI 10.1530/rep.1.00053; Vermot J, 2000, ENDOCRINOLOGY, V141, P3638, DOI 10.1210/en.141.10.3638; von Wolff M, 2000, MOL HUM REPROD, V6, P627; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	73	77	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2553	2563		10.1096/fj.12-225664	http://dx.doi.org/10.1096/fj.12-225664			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23531596	Green Published			2022-12-28	WOS:000328841000005
J	Pan, Z; Fukuoka, S; Karagianni, N; Guaiquil, VH; Rosenblatt, MI				Pan, Zan; Fukuoka, Shima; Karagianni, Natalia; Guaiquil, Victor H.; Rosenblatt, Mark I.			Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea	FASEB JOURNAL			English	Article						wound healing; nerve regeneration; neurotrophic; receptor; eye; neurofluorescent thy1-YFP mice	TRIGEMINAL GANGLION NEURONS; DIABETIC-NEUROPATHY; FACTOR VEGF; IN-VITRO; NEOVASCULARIZATION; EXPRESSION; OUTGROWTH; RECEPTOR; FLT-1	Peripheral nerve injury is a major neurological disorder that can cause severe motor and sensory dysfunction. Neurogenic effects of vascular endothelial growth factor (VEGF) have been found in the central nervous system, and we examined whether VEGF could promote anatomical and functional recovery of peripheral nerves after injury using an avascular corneal nerve injury model. We found that VEGF enhanced neurite elongation in isolated trigeminal ganglion neurons in a dose-dependent manner. This effect was suppressed by neutralizing antibodies for VEGF receptor (VEGFR) 1 and 2 or neuropilin receptor 1 or by VEGFR2 inhibitors (SU 1498 and Ki 8751). In vivo, mice receiving sustained VEGF via implanted pellets showed increased corneal nerve regeneration after superficial injury compared with those receiving vehicle. VEGF injected subconjunctivally at the time of injury accelerated reinnervation, the recovery of mechanosensation, and epithelial wound healing. Endogenous VEGF expression was up-regulated in the corneal epithelium and stroma after wounding. Thus, VEGF can mediate peripheral neuron growth but requires the activation of multiple VEGF receptor types. In addition, VEGF can accelerate the return of sensory and trophic functions of damaged peripheral nerves. Wounding induces the expression of VEFG, which may modulate physiological nerve repair.Pan, Z., Fukuoka, S., Karagianni, N., Guaiquil, V. H., Rosenblatt, M. I. Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea.	[Pan, Zan; Fukuoka, Shima; Karagianni, Natalia; Guaiquil, Victor H.; Rosenblatt, Mark I.] Weill Cornell Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10065 USA	Cornell University	Rosenblatt, MI (corresponding author), Weill Cornell Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, E-301,1300 York Ave, New York, NY 10065 USA.	mar2058@med.cornell.edu			U.S. National Eye Institute/U.S, National Institutes of Health [R01EY018594, K08EY015829]; Research to Prevent Blindness Career Development Award; NATIONAL EYE INSTITUTE [K08EY015829, R01EY018594] Funding Source: NIH RePORTER	U.S. National Eye Institute/U.S, National Institutes of Health; Research to Prevent Blindness Career Development Award(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by the U.S. National Eye Institute/U.S, National Institutes of Health (grants R01EY018594 and K08EY015829) and by a Research to Prevent Blindness Career Development Award.	BAKER KS, 1993, INVEST OPHTH VIS SCI, V34, P137; Bates BD, 2010, PAIN, V149, P522, DOI 10.1016/j.pain.2010.03.024; Callaghan BC, 2012, LANCET NEUROL, V11, P521, DOI 10.1016/S1474-4422(12)70065-0; de Castro F, 1998, EUR J NEUROSCI, V10, P146, DOI 10.1046/j.1460-9568.1998.00037.x; Ebihara N, 2011, INVEST OPHTH VIS SCI, V52, P8549, DOI 10.1167/iovs.11-7956; FORBES DJ, 1987, CURR EYE RES, V6, P507, DOI 10.3109/02713688709025207; GARCIAHIRSCHFELD J, 1994, EXP EYE RES, V59, P597, DOI 10.1006/exer.1994.1145; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Khaibullina AA, 2004, DEV BRAIN RES, V148, P59, DOI 10.1016/j.devbrainres.2003.09.022; Kirchmair R, 2007, MOL THER, V15, P69, DOI 10.1038/sj.mt.6300019; Li ZR, 2012, CORNEA, V31, P1028, DOI 10.1097/ICO.0b013e31823f8b40; Li ZJ, 2011, AM J PATHOL, V178, P1106, DOI 10.1016/j.ajpath.2010.12.001; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Lunn JS, 2009, DEV NEUROBIOL, V69, P871, DOI 10.1002/dneu.20747; Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461; Marfurt CF, 2010, EXP EYE RES, V90, P478, DOI 10.1016/j.exer.2009.12.010; Margaritescu O, 2011, ROM J MORPHOL EMBRYO, V52, P1283; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nishida T, 2009, CURR OPIN OPHTHALMOL, V20, P276, DOI 10.1097/ICU.0b013e32832b758f; Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368; Rosenberg ME, 2002, CORNEA, V21, P265, DOI 10.1097/00003226-200204000-00006; Sathasivam S, 2008, NEUROSCI RES, V62, P71, DOI 10.1016/j.neures.2008.06.008; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Ueno H, 2012, INVEST OPHTH VIS SCI, V53, P867, DOI 10.1167/iovs.11-8438; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Yu CQ, 2008, INVEST OPHTH VIS SCI, V49, P3870, DOI 10.1167/iovs.07-1418; Yu CQ, 2007, INVEST OPHTH VIS SCI, V48, P1535, DOI 10.1167/iovs.06-1192; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com; Zochodne DW, 2012, J PERIPHER NERV SYST, V17, P1, DOI 10.1111/j.1529-8027.2012.00378.x	37	49	54	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2756	2767		10.1096/fj.12-225185	http://dx.doi.org/10.1096/fj.12-225185			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23568776	Green Published			2022-12-28	WOS:000328841000024
J	Balmaceda, V; Cuchillo-Ibanez, I; Pujadas, L; Garcia-Ayllon, MS; Saura, CA; Nimpf, J; Soriano, E; Saez-Valero, J				Balmaceda, Valeria; Cuchillo-Ibanez, Inmaculada; Pujadas, Lluis; Garcia-Ayllon, Maria-Salud; Saura, Carlos A.; Nimpf, Johannes; Soriano, Eduardo; Saez-Valero, Javier			ApoER2 processing by presenilin-1 modulates reelin expression	FASEB JOURNAL			English	Article						Reelin; transcription; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; DENSITY-LIPOPROTEIN RECEPTOR; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; GAMMA-SECRETASE; EPIGENETIC REGULATION; INTRACELLULAR DOMAIN; SIGNALING PATHWAY; VLDL RECEPTOR; KNOCKOUT MICE	The reelin signaling protein and its downstream components have been associated with synaptic plasticity and neurotransmission. The reelin signaling pathway begins with the binding of reelin to the transmembrane lipoprotein receptor apolipoprotein E receptor 2 (ApoER2), which in turns induces the sequential cleavage of ApoER2 by the sequential action of alpha- and gamma-secretases. Using conditional-knockout mice of the catalytic component of the gamma-secretase complex, presenilin 1 (PS1), we demonstrated increased brain ApoER2 and reelin protein and transcript levels, with no changes in the number of reelin-positive cells. Using the human SH-SY5Y neuroblastoma cell line, we showed that ApoER2 processing occurs in the presence of PS1, producing an intracellular ApoER2 C-terminal fragment. In addition, the pharmacologic inhibition of gamma-secretase in SH-SY5Y cells led to increased reelin levels. Overexpression of ApoER2 decreased reelin mRNA levels in these cells. A luciferase reporter gene assay and nuclear fractionation confirmed that increased amounts of intracellular fragment of ApoER2 suppressed reelin expression at a transcriptional level. Chromatin immunoprecipitation experiments corroborated that the intracellular fragment of ApoER2 bound to the RELN promoter region. Our study suggests that PS1/gamma-secretase-dependent processing of the reelin receptor ApoER2 inhibits reelin expression and may regulate its signaling.-Balmaceda, V., Cuchillo-Ibanez, I., Pujadas, L., Garcia-Ayllon, M.-S., Saura, C. A., Nimpf, J., Soriano, E., Saez-Valero, J. ApoER2 processing by presenilin-1 modulates reelin expression.	[Balmaceda, Valeria; Cuchillo-Ibanez, Inmaculada; Garcia-Ayllon, Maria-Salud; Saez-Valero, Javier] Univ Miguel Hernandez, Inst Neurociencias Alicante, CSIC, E-03550 Sant Joan dAlacant, Spain; [Balmaceda, Valeria; Cuchillo-Ibanez, Inmaculada; Pujadas, Lluis; Garcia-Ayllon, Maria-Salud; Saura, Carlos A.; Soriano, Eduardo; Saez-Valero, Javier] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Pujadas, Lluis; Soriano, Eduardo] Inst Recerca Biomed IRB Barcelona, Barcelona, Spain; [Pujadas, Lluis; Soriano, Eduardo] Univ Barcelona, Dept Cell Biol, Barcelona, Spain; [Garcia-Ayllon, Maria-Salud] Fdn Fomento Invest Sanitaria & Biomed Comunitat V, Hosp Gen Univ Elche, Unidad Invest, Elche, Spain; [Saura, Carlos A.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Inst Neurociencies, Bellaterra, Spain; [Nimpf, Johannes] Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, Vienna, Austria	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); CIBERNED; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Autonomous University of Barcelona; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Saez-Valero, J (corresponding author), Univ Miguel Hernandez, Inst Neurociencias Alicante, CSIC, Av Ramon & Cajal S-N, E-03550 Sant Joan dAlacant, Spain.	j.saez@umh.es	PUJADAS, LLUÍS/AAE-1595-2020; Saura, Carlos A/AFM-9239-2022; cuchillo, inmaculada/P-2975-2019; Pujadas, Lluís/O-7442-2015; Soriano, Eduardo/AAB-3216-2019; Sáez, Javier/K-5756-2014; GARCIA-AYLLON, MARIA-SALUD/M-4387-2019; Saura, Carlos/D-2727-2011	PUJADAS, LLUÍS/0000-0003-3890-8279; Pujadas, Lluís/0000-0003-3890-8279; Soriano, Eduardo/0000-0002-3204-9285; Sáez, Javier/0000-0001-7480-320X; Garcia-Ayllon, Maria-Salud/0000-0001-5140-9752; Saura, Carlos/0000-0003-3692-5657; /0000-0002-3689-5518; Nimpf, Johannes/0000-0002-9273-3492	Fondo de Investigaciones Sanitarias [PS09/00684, PI12/00593]; Fundacion Ramon Areces; Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III; Ministerio de Ciencia e Innovacion [SAF2010-20925]; CSIC, Spain; Fondo Social Europeo (FSE), European Community; Austrian Science Fund (FWF) [P 24767] Funding Source: researchfish	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Ramon Areces; Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); CSIC, Spain; Fondo Social Europeo (FSE), European Community; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The authors thank Drs. W. Rebeck (Georgetown University, Washington, DC, USA), D. Grayson (University of Illinois College of Medicine, Chicago, IL, USA), J. Herz (University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA), G. Evin (Department of Pathology, University of Melbourne, Melbourne, VIC, Australia), and A. Barco and J. Galceran [Instituto de Neurociencias de Alicante, Universidad Miguel Hernandez-Consejo Superior de Investigaciones Cientificas (CSIC), Sant Joan d'Alacant, Spain] for generously providing cDNAs, antibodies, and technical advice. This work was supported by grants from Fondo de Investigaciones Sanitarias (PS09/00684; PI12/00593); Fundacion Ramon Areces; Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III; and Ministerio de Ciencia e Innovacion (SAF2010-20925, to C.A.S.). V.B. is supported by a Junta para la Ampliacion de Estudios (JAE) predoctoral fellowship from the CSIC, Spain, cofinanced by the Fondo Social Europeo (FSE), European Community. The authors declare no conflicts of interest.	Balthazart J, 2008, NEUROSCIENCE, V153, P944, DOI 10.1016/j.neuroscience.2008.02.020; Bar I, 1999, NATURE, V399, P645, DOI 10.1038/21340; Becker J, 2012, INT J ONCOL, V41, P681, DOI 10.3892/ijo.2012.1488; Beffert U, 2006, J NEUROSCI, V26, P2041, DOI 10.1523/JNEUROSCI.4566-05.2006; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Botella-Lopez A, 2006, P NATL ACAD SCI USA, V103, P5573, DOI 10.1073/pnas.0601279103; Botella-Lopez A, 2010, NEUROBIOL DIS, V37, P682, DOI 10.1016/j.nbd.2009.12.006; Chen Y, 2002, NUCLEIC ACIDS RES, V30, P2930, DOI 10.1093/nar/gkf401; Cooper JA, 1999, CELL, V97, P671, DOI 10.1016/S0092-8674(00)80778-3; Cuchillo-Ibanez I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072297; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; De Gasperi R, 2008, DEV DYNAM, V237, P2405, DOI 10.1002/dvdy.21661; de Rouvroit CL, 1999, EXP NEUROL, V156, P214, DOI 10.1006/exnr.1998.7007; De Strooper B, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006304; Deguchi K, 2003, J NEUROPATH EXP NEUR, V62, P676, DOI 10.1093/jnen/62.6.676; Duit S, 2010, J BIOL CHEM, V285, P4896, DOI 10.1074/jbc.M109.025973; Dumanis SB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017203; Forster E, 2010, EUR J NEUROSCI, V31, P1511, DOI 10.1111/j.1460-9568.2010.07222.x; Gan HT, 2011, J NEUROCHEM, V117, P565, DOI 10.1111/j.1471-4159.2011.07227.x; Hibi T, 2009, FEBS LETT, V583, P1299, DOI 10.1016/j.febslet.2009.03.024; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hisanaga A, 2012, FEBS LETT, V586, P3349, DOI 10.1016/j.febslet.2012.07.017; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Hoe HS, 2005, MOL BRAIN RES, V137, P31, DOI 10.1016/j.molbrainres.2005.02.013; Hoe HS, 2007, J NEUROSCI, V27, P10895, DOI 10.1523/JNEUROSCI.3135-07.2007; Hoe HS, 2006, J BIOL CHEM, V281, P35176, DOI 10.1074/jbc.M602162200; Hoe HS, 2009, J NEUROSCI, V29, P7459, DOI 10.1523/JNEUROSCI.4872-08.2009; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Jossin Y, 2007, J NEUROSCI, V27, P4243, DOI 10.1523/JNEUROSCI.0023-07.2007; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; Krstic D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047793; Kubo K, 2002, NEUROSCI RES, V43, P381, DOI 10.1016/S0168-0102(02)00068-8; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; Levenson JM, 2008, BBA-GENE REGUL MECH, V1779, P422, DOI 10.1016/j.bbagrm.2008.01.001; Lleo A, 2011, CURR TOP MED CHEM, V11, P1513, DOI 10.2174/156802611795861004; Lugli G., 2003, BMC BIOCH, V7, P4; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mayer H, 2006, MOL CELL BIOL, V26, P19, DOI 10.1128/MCB.26.1.19-27.2006; Muller T, 2008, PROG NEUROBIOL, V85, P393, DOI 10.1016/j.pneurobio.2008.05.002; Parisiadou L, 2007, NEUROBIOL AGING, V28, P377, DOI 10.1016/j.neurobiolaging.2005.12.015; Pesold C, 1998, P NATL ACAD SCI USA, V95, P3221, DOI 10.1073/pnas.95.6.3221; Polavarapu R, 2008, AM J PATHOL, V172, P1355, DOI 10.2353/ajpath.2008.070975; Rochette MJ, 2002, MOL NEUROBIOL, V26, P81, DOI 10.1385/MN:26:1:081; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Saura CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019430; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Silveyra M. X., 2012, NEUROBIOL AGING, V33; Sinagra M, 2008, NEURON GLIA BIOL, V4, P189, DOI 10.1017/S1740925X09990214; Smalheiser NR, 2000, P NATL ACAD SCI USA, V97, P1281, DOI 10.1073/pnas.97.3.1281; Squarzoni S, 1998, NEUROMUSCULAR DISORD, V8, P338, DOI 10.1016/S0960-8966(98)00031-5; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Trotter JH, 2011, J NEUROSCI, V31, P14413, DOI 10.1523/JNEUROSCI.3135-11.2011; Utsunomiya-Tate N, 2000, P NATL ACAD SCI USA, V97, P9729, DOI 10.1073/pnas.160272497; Wagner T, 2012, EXP BRAIN RES, V217, P377, DOI 10.1007/s00221-011-2876-8; Wicher G, 2006, J NEUROSCI RES, V83, P864, DOI 10.1002/jnr.20774; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang H, 2012, J NEUROCHEM, V120, P9, DOI 10.1111/j.1471-4159.2011.07519.x	67	27	27	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1543	1554		10.1096/fj.13-239350	http://dx.doi.org/10.1096/fj.13-239350			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24344333	Green Submitted			2022-12-28	WOS:000335344300004
J	Spitali, P; van den Bergen, JC; Verhaart, IEC; Wokke, B; Janson, AAM; van den Eijnde, R; den Dunnen, JT; Laros, JFJ; Verschuuren, JJGM; 't Hoen, PAC; Aartsma-Rus, A				Spitali, Pietro; van den Bergen, Janneke C.; Verhaart, Ingrid E. C.; Wokke, Beatrijs; Janson, Anneke A. M.; van den Eijnde, Rani; den Dunnen, Johan T.; Laros, Jeroen F. J.; Verschuuren, Jan J. G. M.; 't Hoen, Peter A. C.; Aartsma-Rus, Annemieke			DMD transcript imbalance determines dystrophin levels	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; exon skipping; antisense oligonucleotides; transcript stability	DUCHENNE MUSCULAR-DYSTROPHY; MESSENGER-RNA; NONSENSE MUTATIONS; SKELETAL-MUSCLE; GENE; DISEASE; PTC124	Duchenne and Becker muscular dystrophies are caused by out-of-frame and in-frame mutations, respectively, in the dystrophin encoding DMD gene. Molecular therapies targeting the precursor-mRNA are in clinical trials and show promising results. These approaches will depend on the stability and expression levels of dystrophin mRNA in skeletal muscles and heart. We report that the DMD gene is more highly expressed in heart than in skeletal muscles, in mice and humans. The transcript mutated in the mdx mouse model shows a 5' to 3' imbalance compared with that of its wild-type counterpart and reading frame restoration via antisense-mediated exon skipping does not correct this event. We also report significant transcript instability in 22 patients with Becker dystrophy, clarifying the fact that transcript imbalance is not caused by premature nonsense mutations. Finally, we demonstrate that transcript stability, rather than transcriptional rate, is an important determinant of dystrophin protein levels in patients with Becker dystrophy. We suggest that the availability of the complete transcript is a key factor to determine protein abundance and thus will influence the outcome of mRNA-targeting therapies.	[Spitali, Pietro; Verhaart, Ingrid E. C.; den Dunnen, Johan T.; Laros, Jeroen F. J.; 't Hoen, Peter A. C.; Aartsma-Rus, Annemieke] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands; [van den Bergen, Janneke C.; Wokke, Beatrijs; Verschuuren, Jan J. G. M.] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands; [Janson, Anneke A. M.; van den Eijnde, Rani] Prosensa Therapeut, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; BioMarin Pharmaceutical Inc.; Prosensa	Aartsma-Rus, A (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, POB 9600, NL-2300 RC Leiden, Netherlands.	a.m.rus@lumc.nl	dunnen, johan den/ABH-4228-2020; Hoen, Peter A 't/D-3950-2018; Verhaart, Ingrid/Y-2588-2018; Spitali, Pietro/Y-2948-2018	dunnen, johan den/0000-0002-6304-1710; Hoen, Peter A 't/0000-0003-4450-3112; Verhaart, Ingrid/0000-0001-7348-7989; Spitali, Pietro/0000-0003-2783-688X; Laros, Jeroen F.J./0000-0002-8715-7371; Verschuuren, Jan/0000-0002-4572-1501; Aartsma-Rus, Annemieke/0000-0003-1565-654X	Prinses Beatrix Foundation; ZonMw	Prinses Beatrix Foundation; ZonMw(Netherlands Organization for Health Research and Development)	The authors acknowledge Ron Wolterbeek for help with statistical analysis and Maarten van Iterson for helping with the Affy probe mapping. This work was supported by the Prinses Beatrix Foundation and ZonMw.	Aartsma-Rus A, 2004, GENE THER, V11, P1391, DOI 10.1038/sj.gt.3302313; Aartsma-Rus A, 2009, HUM MUTAT, V30, P293, DOI 10.1002/humu.20918; Arechavala-Gomeza V, 2007, HUM GENE THER, V18, P798, DOI 10.1089/hum.2006.061; Arechavala-Gomeza V, 2010, NEUROMUSCULAR DISORD, V20, P295, DOI 10.1016/j.nmd.2010.03.007; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Bovolenta M, 2012, HUM MUTAT, V33, P572, DOI 10.1002/humu.22017; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Finkel RS, 2010, J CHILD NEUROL, V25, P1158, DOI 10.1177/0883073810371129; Goemans NM, 2011, NEW ENGL J MED, V364, P1513, DOI 10.1056/NEJMoa1011367; Hamed SA, 2006, AM J MED GENET B, V141B, P44, DOI 10.1002/ajmg.b.30234; Hamed SA, 2005, CLIN GENET, V68, P69, DOI 10.1111/j.1399-0004.2005.00455.x; Haslett JN, 2003, NEUROGENETICS, V4, P163, DOI 10.1007/s10048-003-0148-x; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Heemskerk H, 2009, ANN NY ACAD SCI, V1175, P71, DOI 10.1111/j.1749-6632.2009.04973.x; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; Muntoni F, 2003, LANCET NEUROL, V2, P731, DOI 10.1016/S1474-4422(03)00585-4; Norwood FLM, 2009, BRAIN, V132, P3175, DOI 10.1093/brain/awp236; Pescatori M, 2007, FASEB J, V21, P1210, DOI 10.1096/fj.06-7285com; Spitali P, 2010, LAB INVEST, V90, P1396, DOI [10.1038/labinvest.2010.98, 10.1038/labinvest.labinvest201098]; Tennyson CN, 1996, NUCLEIC ACIDS RES, V24, P3059, DOI 10.1093/nar/24.15.3059; TENNYSON CN, 1995, NAT GENET, V9, P184, DOI 10.1038/ng0295-184; Tuffery-Giraud S, 2009, HUM MUTAT, V30, P934, DOI 10.1002/humu.20976; van Putten M, 2010, NEUROMUSCULAR DISORD, V20, P273, DOI 10.1016/j.nmd.2010.02.004; Verhaart I. E. C., 2012, PLOS CURR, V4, DOI 10.1371/currents.md.597d7 00f92eaa70de261ea0d91821377.; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756	27	19	20	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4909	4916		10.1096/fj.13-232025	http://dx.doi.org/10.1096/fj.13-232025			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23975932				2022-12-28	WOS:000329999000025
J	Qiao, HS; Chen, XQ; Xu, LF; Wang, JJ; Zhao, GY; Hou, YY; Ge, HM; Tan, RX; Li, EG				Qiao, Haishi; Chen, Xiaoqing; Xu, Lanfang; Wang, Jingjing; Zhao, Guoyan; Hou, Yayi; Ge, Hui Ming; Tan, Ren-Xiang; Li, Erguang			Antitumor effects of naturally occurring oligomeric resveratrol derivatives	FASEB JOURNAL			English	Article						stilbenoid; p53; apoptosis; senescence	CANCER-CELL-LINES; TUMOR SUPPRESSION; PROTEIN-KINASES; P53; APOPTOSIS; SENESCENCE; STILBENOIDS; OLIGOSTILBENOIDS; RESTORATION; HOPEAHAINOL	This study was designed to evaluate and characterize the molecular basis of antitumor activity of naturally occurring resveratrol (RES; 3,5,4-trihydroxy-trans-stilbene) derivatives. The compounds were isolated from plants in previous studies and characterized spectroscopically. The antitumor activities of 31 RES derivatives, including dimers, trimers, and tetramers of RES, were evaluated using cell-based assays and validated on a murine model. Several trimeric and a tetrameric stilbenoids induced tumor cell apoptosis or growth arrest of several tumor cell lines with IC50 values (2.8-19.7 M), significantly lower than that of RES (IC50>70 M). Using pauciflorol B (PauB) as an example, we showed that the compound induced apoptosis p53 dependently, inducing p53 accumulation and p53-modulated gene expression in cells with wild-type p53, but not in those with nonfunctional p53. Reexpression of p53 in p53-null cells rescued cell death response. In parallel, the MAPK/p38 was activated and critical for PauB-induced killing. Interestingly, activation of p38 in p53 deficient cells was sufficient to drive cells into senescence via the p16-pRb pathway. Finally, PauB dose-dependently inhibited tumor growth on nude mice. Naturally occurring trimeric and tetrameric stilbenoids are potent antitumor agents. Those compounds exert antitumor effect through p53-dependent induction of apoptosis or senescence.Qiao, H., Chen, X., Xu, L., Wang, J., Zhao, G., Hou, Y., Ge, H. M., Tan, R-X., Li, E. Antitumor effects of naturally occurring oligomeric resveratrol derivatives.	[Qiao, Haishi; Chen, Xiaoqing; Xu, Lanfang; Wang, Jingjing; Zhao, Guoyan; Hou, Yayi; Li, Erguang] Nanjing Univ, Sch Med, Nanjing 210093, Jiangsu, Peoples R China; [Qiao, Haishi; Chen, Xiaoqing; Xu, Lanfang; Wang, Jingjing; Zhao, Guoyan; Hou, Yayi; Li, Erguang] Nanjing Univ, Jiangsu Lab Mol Med, Nanjing 210093, Jiangsu, Peoples R China; [Qiao, Haishi; Chen, Xiaoqing; Xu, Lanfang; Wang, Jingjing; Zhao, Guoyan; Hou, Yayi; Ge, Hui Ming; Tan, Ren-Xiang; Li, Erguang] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China; [Ge, Hui Ming; Tan, Ren-Xiang] Nanjing Univ, Coll Life Sci, Nanjing 210093, Jiangsu, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University	Tan, RX (corresponding author), Nanjing Univ, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China.	rxtan@nju.edu.cn; erguang@nju.edu.cn	Li, Erguang/C-2782-2013; Li, Erguang/N-7676-2019; qiao, haishi/ABE-5765-2021; Wang, Jingjing/GLS-7536-2022	Li, Erguang/0000-0002-3065-1336; Li, Erguang/0000-0002-3065-1336; Wang, Jingjing/0000-0003-2347-7824	National Natural Science Foundation of China (NSFC) [81121062, 90813036, 81071859]; Jiangsu Innovation Programs for Graduate Students	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Jiangsu Innovation Programs for Graduate Students	The authors thank Ms. Ziying Yang and Chunmin Yan for technical assistance, and Dr. Guang Yang for English editing. The work was supported financially by grants from the National Natural Science Foundation of China (NSFC; 81121062, 90813036, 81071859). X. Q. C. and J.J.W. are recipients of Predoctoral Fellowship from Jiangsu Innovation Programs for Graduate Students. The authors declare no conflict of interest.	Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Barjot C, 2007, LIFE SCI, V81, P1565, DOI 10.1016/j.lfs.2007.08.047; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Brumatti G, 2008, METHODS, V44, P235, DOI 10.1016/j.ymeth.2007.11.010; Carlsson J, 2009, FEBS J, V276, P4142, DOI 10.1111/j.1742-4658.2009.07124.x; Chen XQ, 2012, ANTIVIR RES, V95, P30, DOI 10.1016/j.antiviral.2012.05.001; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Demidenko ZN, 2010, P NATL ACAD SCI USA, V107, P9660, DOI 10.1073/pnas.1002298107; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Donnez D, 2009, TRENDS BIOTECHNOL, V27, P706, DOI 10.1016/j.tibtech.2009.09.005; El-Subbagh HI, 2000, J MED CHEM, V43, P2915, DOI 10.1021/jm000038m; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; da Costa DCF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048746; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Ge HM, 2008, CHEM-EUR J, V14, P376, DOI 10.1002/chem.200700960; Ge HM, 2006, J NAT PROD, V69, P1800, DOI 10.1021/np060242y; Ge HM, 2010, CHEM-EUR J, V16, P6338, DOI 10.1002/chem.201000230; Ge HM, 2009, J AGR FOOD CHEM, V57, P5756, DOI 10.1021/jf900756d; Gonzalez-Barrio R, 2006, J AGR FOOD CHEM, V54, P4222, DOI 10.1021/jf060160f; Gonzalez-Sarrias A, 2011, J AGR FOOD CHEM, V59, P8632, DOI 10.1021/jf201561e; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ito T, 2003, CARCINOGENESIS, V24, P1489, DOI 10.1093/carcin/bgg105; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jeandet P, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/579089; Kitazumi I, 2011, FEBS J, V278, P427, DOI 10.1111/j.1742-4658.2010.07975.x; Levav-Cohen Y, 2012, ONCOGENE, V31, P2199, DOI 10.1038/onc.2011.402; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mishima Satoshi, 2003, J Exp Ther Oncol, V3, P283, DOI 10.1111/j.1533-869X.2003.01102.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Padayatty SJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0011414, 10.1371/journal.pone.0015288]; Qin YH, 2011, RSC ADV, V1, P135, DOI 10.1039/c1ra00007a; Riviere C, 2012, NAT PROD REP, V29, P1317, DOI 10.1039/c2np20049j; Schilder YDC, 2009, FREE RADICAL BIO MED, V46, P1598, DOI 10.1016/j.freeradbiomed.2009.03.013; Senturk Emir, 2013, Methods Mol Biol, V962, P113, DOI 10.1007/978-1-62703-236-0_9; She QB, 2001, CANCER RES, V61, P1604; Shen T, 2009, NAT PROD REP, V26, P916, DOI 10.1039/b905960a; Singh N., 2012, PLOS ONE, V7; Snyder SA, 2012, ANGEW CHEM INT EDIT, V51, P4080, DOI 10.1002/anie.201107730; Snyder SA, 2011, NATURE, V474, P461, DOI 10.1038/nature10197; SOTHEESWARAN S, 1993, PHYTOCHEMISTRY, V32, P1083, DOI 10.1016/S0031-9422(00)95070-2; Srinivasan S, 2007, CANCER RES, V67, P246, DOI 10.1158/0008-5472.CAN-06-2430; Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006; Takaoka M., 1939, NIPPON KAGAKU KAISHI, V60, P1090, DOI [10.1246/nikkashi1921.60.1090, DOI 10.1246/NIKKASHI1921.60.1090]; Tang HY, 2006, MOL CANCER THER, V5, P2034, DOI 10.1158/1535-7163.MCT-06-0216; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yan T, 2012, PLANTA MED, V78, P1015, DOI 10.1055/s-0031-1298623; Zhou CX, 1999, PLANTA MED, V65, P480, DOI 10.1055/s-2006-960821	56	8	8	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4561	4571		10.1096/fj.13-231613	http://dx.doi.org/10.1096/fj.13-231613			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23925653				2022-12-28	WOS:000329937500022
J	Johnson, A; DiPietro, LA				Johnson, Ariel; DiPietro, Luisa Ann			Apoptosis and angiogenesis: an evolving mechanism for fibrosis	FASEB JOURNAL			English	Review						wound healing; scar formation; liver; lung; allograft vasculopathy	HEPATIC STELLATE CELLS; IDIOPATHIC PULMONARY-FIBROSIS; GROWTH-FACTOR; ENDOTHELIAL-CELLS; LIVER FIBROSIS; SCAR FORMATION; LUNG FIBROSIS; EXPRESSION; TISSUE; MYOFIBROBLASTS	Fibrosis, seen in the liver, lung, heart, kidney, and skin, is a significant global disease burden. Currently, therapeutic treatment is limited, and the number of cases continues to grow. Apoptosis has been identified as a potential initiator and propagator of fibrosis. This review specifically examines the correlation between the presence of apoptotic cells and their effect on fibroblast phenotype and collagen metabolism in several different experimental models of fibrosis. Fibrosis in these models is generally preceded by robust angiogenesis and vascular regression, suggesting that the vascular apoptotic burden may be important to fibrotic outcomes. This review considers the emerging evidence that angiogenesis or vascular regression contributes to fibrosis and identifies initial vascular outgrowth or vascular apoptotic cell presence as possible regulators of fibrosis. A further understanding of the cellular mechanisms of fibrosis may suggest novel methods for the reduction of the fibrotic response and promotion of regeneration.Johnson, A., DiPietro, L. A. Apoptosis and angiogenesis: an evolving mechanism for fibrosis.	[Johnson, Ariel; DiPietro, Luisa Ann] Univ Illinois, Ctr Wound Healing & Tissue Regenerat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	DiPietro, LA (corresponding author), Univ Illinois, Coll Dent, Ctr Wound Healing & Tissue Regenerat MC 859, 801 S Paulina,Rm 401B, Chicago, IL 60612 USA.	ldipiet@uic.edu			U.S. National Institutes of Health [R01-GM50875, T32 DE018381]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE018381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050875] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health grants R01-GM50875 andT32 DE018381. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Benjamin LE, 2000, CANCER METAST REV, V19, P75, DOI 10.1023/A:1026552415576; Berger AC, 2000, J SURG RES, V91, P26, DOI 10.1006/jsre.2000.5890; Cailhier JF, 2006, AM J TRANSPLANT, V6, P247, DOI 10.1111/j.1600-6143.2005.01165.x; Canbay Ali, 2005, Turk J Gastroenterol, V16, P1; Chen CC, 2010, J CELL COMMUN SIGNAL, V4, P63, DOI 10.1007/s12079-009-0080-4; Chen CZC, 2009, FIBROGENESIS TISSUE, V2, DOI 10.1186/1755-1536-2-7; Chen FP, 2006, EUR J PHARMACOL, V536, P287, DOI 10.1016/j.ejphar.2006.03.011; Cheresh DA, 2008, ONCOGENE, V27, P6285, DOI 10.1038/onc.2008.304; Choy JC, 2004, AM J PATHOL, V165, P127, DOI 10.1016/S0002-9440(10)63281-6; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cosgrove GP, 2004, AM J RESP CRIT CARE, V170, P242, DOI 10.1164/rccm.200308-1151OC; de Fijter JW, 2010, KIDNEY INT, V78, pS38, DOI 10.1038/ki.2010.421; Denton M D, 2000, Pediatr Transplant, V4, P252, DOI 10.1034/j.1399-3046.2000.00031.x; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Diao JS, 2010, BURNS, V36, P1136, DOI 10.1016/j.burns.2010.01.014; Dimmeler S, 2000, CIRC RES, V87, P434; Dulauroy S, 2012, NAT MED, V18, P1262, DOI 10.1038/nm.2848; Ebina M, 2004, AM J RESP CRIT CARE, V169, P1203, DOI 10.1164/rccm.200308-1111OC; El-Tanani MK, 2006, CYTOKINE GROWTH F R, V17, P463, DOI 10.1016/j.cytogfr.2006.09.010; Farkas L, 2011, AM J RESP CELL MOL, V45, P1, DOI 10.1165/rcmb.2010-0365TR; Fraisl P, 2009, DEV CELL, V16, P167, DOI 10.1016/j.devcel.2009.01.003; Greenhalgh DG, 1998, INT J BIOCHEM CELL B, V30, P1019, DOI 10.1016/S1357-2725(98)00058-2; Gurtl B, 2009, INT J EXP PATHOL, V90, P338, DOI 10.1111/j.1365-2613.2009.00647.x; Hagimoto N, 1997, AM J RESP CELL MOL, V16, P91, DOI 10.1165/ajrcmb.16.1.8998084; Hagimoto N, 1997, AM J RESP CELL MOL, V17, P272, DOI 10.1165/ajrcmb.17.3.2893; Hannivoort RA, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-1; Hartlapp I, 2001, FASEB J, V15, P2215, DOI 10.1096/fj.01-0049com; Havasi A, 2011, KIDNEY INT, V80, P29, DOI 10.1038/ki.2011.120; Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246; Horowitz JC, 2006, AM J PHYSIOL-LUNG C, V290, pL415, DOI 10.1152/ajplung.00276.2005; Huibers M, 2011, TRANSPL IMMUNOL, V25, P124, DOI 10.1016/j.trim.2011.07.001; Jang YC, 1999, WOUND REPAIR REGEN, V7, P375, DOI 10.1046/j.1524-475X.1999.00375.x; Johnson A., 2013, ADV WOUND C IN PRESS; Khanna S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009539; King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4; Kisseleva T, 2008, EXP BIOL MED, V233, P109, DOI 10.3181/0707-MR-190; Kisseleva T, 2012, P NATL ACAD SCI USA, V109, P9448, DOI 10.1073/pnas.1201840109; Kuwano K, 2001, AM J PHYSIOL-LUNG C, V280, pL316, DOI 10.1152/ajplung.2001.280.2.L316; Lai WK, 2005, J HEPATOL, V42, P7, DOI 10.1016/j.jhep.2004.11.008; Laplante P, 2010, CELL DEATH DIFFER, V17, P291, DOI 10.1038/cdd.2009.124; Lee JI, 2003, J HEPATOL, V39, P960, DOI 10.1016/S0168-8278(03)00411-2; Lemos QT, 2010, MEM I OSWALDO CRUZ, V105, P611, DOI 10.1590/S0074-02762010000500002; Maher JJ, 2001, SEMIN LIVER DIS, V21, P417, DOI 10.1055/s-2001-17555; Mathai SK, 2010, LAB INVEST, V90, P812, DOI 10.1038/labinvest.2010.73; Meltzer EB, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-8; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Murray LA, 2011, INT J BIOCHEM CELL B, V43, P154, DOI 10.1016/j.biocel.2010.10.013; Noble PW, 2004, CLIN CHEST MED, V25, P749, DOI 10.1016/j.ccm.2004.04.003; Novo E, 2006, GUT, V55, P1174, DOI 10.1136/gut.2005.082701; Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427; Pardo Annie, 2006, Proc Am Thorac Soc, V3, P383, DOI 10.1513/pats.200601-012TK; Povero D, 2010, HISTOL HISTOPATHOL, V25, P1075, DOI 10.14670/HH-25.1075; Rai Nirendra K, 2005, Int J Low Extrem Wounds, V4, P138, DOI 10.1177/1534734605280018; Razzaque MS, 2003, PATHOL INT, V53, P133, DOI 10.1046/j.1440-1827.2003.01446.x; Reinders MEJ, 2006, J AM SOC NEPHROL, V17, P932, DOI 10.1681/ASN.2005121250; Reinders MEJ, 2003, TRANSPLANTATION, V76, P224, DOI 10.1097/01.TP.0000071363.55007.D0; Renzoni EA, 2003, AM J RESP CRIT CARE, V167, P438, DOI 10.1164/rccm.200202-135OC; RIOU JPA, 1992, AM J SURG, V163, P324, DOI 10.1016/0002-9610(92)90014-I; Sarrazy V, 2011, WOUND REPAIR REGEN, V19, pS10, DOI 10.1111/j.1524-475X.2011.00708.x; Schmauss D, 2008, CIRCULATION, V117, P2131, DOI 10.1161/CIRCULATIONAHA.107.711911; Shimizu A, 2002, KIDNEY INT, V61, P1867, DOI 10.1046/j.1523-1755.2002.00309.x; Song BQ, 2009, WOUND REPAIR REGEN, V17, P559, DOI 10.1111/j.1524-475X.2009.00514.x; Stoneman VEA, 2009, J CARDIOVASC PHARM, V53, P100, DOI 10.1097/FJC.0b013e318198fe60; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Szpaderska AM, 2005, J DENT RES, V84, P309, DOI 10.1177/154405910508400403; Taylor DO, 2006, J HEART LUNG TRANSPL, V25, P869, DOI 10.1016/j.healun.2006.05.002; Tzortzaki EG, 2007, RESP MED, V101, P1821, DOI 10.1016/j.rmed.2007.02.006; Uhal BD, 2008, EUR RESPIR REV, V17, P138, DOI 10.1183/09059180.00010906; van der Veer WM, 2011, WOUND REPAIR REGEN, V19, P292, DOI 10.1111/j.1524-475X.2011.00692.x; van der Veer WM, 2009, BURNS, V35, P15, DOI 10.1016/j.burns.2008.06.020; Wang LY, 2006, AM J PHYSIOL-LUNG C, V290, pL695, DOI 10.1152/ajplung.00245.2005; Wang RQ, 2000, J CELL PHYSIOL, V185, P253; Wang WL, 2002, J BIOL CHEM, V277, P21723, DOI 10.1074/jbc.M202224200; Wang XS, 2010, PATHOLOGY, V42, P457, DOI 10.3109/00313025.2010.493864; Wilgus TA, 2008, LAB INVEST, V88, P579, DOI 10.1038/labinvest.2008.36; Wolfram D, 2009, DERMATOL SURG, V35, P171, DOI 10.1111/j.1524-4725.2008.34406.x; World Health Organization, 2008, GLOBAL BURDEN DIS; Wynes MW, 2004, J LEUKOCYTE BIOL, V76, P1019, DOI 10.1189/jlb.0504288; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487	80	97	107	2	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3893	3901		10.1096/fj.12-214189	http://dx.doi.org/10.1096/fj.12-214189			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23783074	Green Published			2022-12-28	WOS:000329747100004
J	Xu, H; Belkacemi, L; Jog, M; Parrent, A; Hebb, MO				Xu, Hu; Belkacemi, Louiza; Jog, Mandar; Parrent, Andrew; Hebb, Matthew O.			Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson's disease	FASEB JOURNAL			English	Article						neurodegeneration; transplantation	MESENCHYMAL STEM-CELLS; ADULT HUMAN BRAIN; SUBCORTICAL WHITE-MATTER; NEURODEGENERATIVE DISEASES; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; PROGENITOR CELLS; NERVOUS-SYSTEM; GENE-TRANSFER; GLIAL-CELLS	Cell-based therapies offer promise for patients with Parkinson's disease (PD); however, durable and effective transplantation substrates need to be defined. This study characterized the feasibility and growth properties of primary cultures established from small-volume brain biopsies taken during deep brain stimulation (DBS) surgery in patients with PD. The lineage and expression of neurotrophic factors with known beneficial actions in PD-affected brain circuitry were also evaluated. Nineteen patients with PD undergoing DBS surgery consented to brain biopsies prior to electrode implantation. Cultures from these samples exhibited exponential and plateau phases of growth and were readily expanded throughout multiple passages. There was robust expression of progenitor markers and the unexpected colocalization of neural and mesenchymal proteins. The oligodendrocyte transcription factor, Olig1, and the myelin-specific sphingolipid, galactocerebroside, were coexpressed with each of glial-derived neurotrophic factor, brain-derived neurotrophic factor, and cerebral dopamine neurotrophic factor. Fluorescence-activated cell sorting demonstrated homogeneous expression of both nestin and Olig1 throughout the expanded cultures. Cells remained viable after a year in cryostorage. These findings confirm the feasibility of small brain biopsies as an expandable source of autologous cell substrate in living patients and demonstrate the complex phenotype of these cells, with implications for therapeutic application in PD and other neurological diseases. Xu, H., Belkacemi, L., Jog, M., Parrent, A., Hebb. M. O. Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson's disease.	[Xu, Hu; Belkacemi, Louiza; Jog, Mandar; Parrent, Andrew; Hebb, Matthew O.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada	Western University (University of Western Ontario)	Hebb, MO (corresponding author), Univ Western Ontario, Dept Clin Neurol Sci Neurosurg, 339 Windermere Rd,C7-134, London, ON N6A 5A5, Canada.	mhebb@uwo.ca			Michael J. Fox Foundation for Parkinson's Research	Michael J. Fox Foundation for Parkinson's Research	The authors thank Drs. Marco and Vania Prado for their generous provision of technical resources. This work was supported by The Michael J. Fox Foundation for Parkinson's Research.	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Aron L, 2011, TRENDS NEUROSCI, V34, P88, DOI 10.1016/j.tins.2010.11.001; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Barker RA, 2013, LANCET NEUROL, V12, P84, DOI 10.1016/S1474-4422(12)70295-8; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Bernstein JJ, 1996, INT J DEV NEUROSCI, V14, P681, DOI 10.1016/0736-5748(95)00096-8; Bjorklund A, 2010, PROG BRAIN RES, V184, P237, DOI 10.1016/S0079-6123(10)84013-0; Blandini F, 2010, CELL TRANSPLANT, V19, P203, DOI 10.3727/096368909X479839; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brunet JF, 2002, LAB INVEST, V82, P809, DOI 10.1097/01.LAB.0000017166.26718.BB; Dass B, 2006, NEUROLOGY, V66, pS89, DOI 10.1212/WNL.66.10_suppl_4.S89; Defer GL, 1996, BRAIN, V119, P41, DOI 10.1093/brain/119.1.41; Dupin E, 2012, DEV BIOL, V366, P83, DOI 10.1016/j.ydbio.2012.02.035; Frischknecht R, 2012, ADV EXP MED BIOL, V970, P153, DOI 10.1007/978-3-7091-0932-8_7; Glavaski-Joksimovic A, 2010, J NEUROSCI RES, V88, P2669, DOI 10.1002/jnr.22435; Gris P, 2007, GLIA, V55, P1145, DOI 10.1002/glia.20537; Hayashi T, 2013, J CLIN INVEST, V123, P272, DOI 10.1172/JCI62516; Hickey P, 2013, EXPERT OPIN BIOL TH, V13, P137, DOI 10.1517/14712598.2013.754420; Hubmacher D, 2013, CURR OPIN RHEUMATOL, V25, P65, DOI 10.1097/BOR.0b013e32835b137b; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Ibanez CF, 2012, TRENDS NEUROSCI, V35, P431, DOI 10.1016/j.tins.2012.03.007; Kells AP, 2012, NEUROBIOL DIS, V48, P228, DOI 10.1016/j.nbd.2011.10.004; KOSAKA K, 1984, CLIN NEUROPATHOL, V3, P185; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; L'Episcopo F, 2010, CNS NEUROL DISORD-DR, V9, P349, DOI 10.2174/187152710791292639; Lescaudron L, 2012, CURR MED CHEM, V19, P6018; Li HL, 2007, J NEUROSCI, V27, P14375, DOI 10.1523/JNEUROSCI.4456-07.2007; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lindholm P, 2010, DEV NEUROBIOL, V70, P360, DOI 10.1002/dneu.20760; Ma YL, 2010, J NUCL MED, V51, P7, DOI 10.2967/jnumed.109.066811; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; MAPSTONE TB, 1992, PEDIATR NEUROSURG, V17, P169, DOI 10.1159/000120590; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Mendez I, 2002, J NEUROSURG, V96, P589, DOI 10.3171/jns.2002.96.3.0589; Moloney TC, 2010, BRAIN RES, V1359, P33, DOI 10.1016/j.brainres.2010.08.040; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; NORTON WT, 1988, GLIA, V1, P403, DOI 10.1002/glia.440010608; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Okun MS, 2013, NEW ENGL J MED, V368, P483, DOI 10.1056/NEJMc1214078; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Othman A, 2011, GLIA, V59, P914, DOI 10.1002/glia.21163; PERZELOVA A, 1993, GLIA, V7, P237, DOI 10.1002/glia.440070307; Perzelova A, 2007, BIOLOGIA, V62, P633, DOI 10.2478/s11756-007-0123-3; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; Ren LQ, 2000, MOL PHARMACOL, V58, P1303, DOI 10.1124/mol.58.6.1303; Roessler R., 2012, STEM CELL REV, DOI 10.1007/s12015-012-9369-4; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Ruozi B, 2012, INT REV NEUROBIOL, V102, P207, DOI 10.1016/B978-0-12-386986-9.00009-0; RUTKA JT, 1986, LAB INVEST, V55, P71; Sadan O, 2009, EXPERT OPIN BIOL TH, V9, P1487, DOI 10.1517/14712590903321439; Sadan O, 2009, STEM CELLS DEV, V18, P1179, DOI 10.1089/scd.2008.0411; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Skaper SD, 2008, CNS NEUROL DISORD-DR, V7, P46, DOI 10.2174/187152708783885174; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Uccelli A, 2011, LANCET NEUROL, V10, P649, DOI 10.1016/S1474-4422(11)70121-1; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; Wolters EC, 2009, PARKINSONISM RELAT D, V15, pS6, DOI 10.1016/S1353-8020(09)70770-9; ZHANG ET, 1990, J ANAT, V170, P111; Zuccato C, 2009, NAT REV NEUROL, V5, P311, DOI 10.1038/nrneurol.2009.54	61	12	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4157	4168		10.1096/fj.12-226555	http://dx.doi.org/10.1096/fj.12-226555			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825231				2022-12-28	WOS:000329747100027
J	Bombardier, E; Smith, IC; Gamu, D; Fajardo, VA; Vigna, C; Sayer, RA; Gupta, SC; Bal, NC; Periasamy, M; Tupling, AR				Bombardier, Eric; Smith, Ian C.; Gamu, Daniel; Fajardo, Val A.; Vigna, Chris; Sayer, Ryan A.; Gupta, Subash C.; Bal, Naresh C.; Periasamy, Muthu; Tupling, A. Russell			Sarcolipin trumps beta-adrenergic receptor signaling as the favored mechanism for muscle-based diet-induced thermogenesis	FASEB JOURNAL			English	Article						calcium cycling; energy expenditure; skeletal muscle; obesity	SKELETAL-MUSCLE; UNCOUPLING PROTEIN-3; HEAT-PRODUCTION; INDUCED OBESITY; CA2+-ATPASE; TRANSPORT; ABLATION; CA2+; UCP1; ATP	Sarcolipin (SLN) regulates muscle-based nonshivering thermogenesis and is up-regulated with high-fat feeding (HFF). To investigate whether other muscle-based thermogenic systems compensate for a lack of Sln and to firmly establish SLN as a mediator of diet-induced thermogenesis (DIT), we measured muscle and whole-body energy expenditure in chow- and high-fat-fed Sln(-/-) and wild-type (WT) mice. Following HFF, resting muscle metabolic rate (Vo(2), l/g/s) was increased similarly in WT (0.28 +/- 0.02 vs. 0.31 +/- 0.03) and Sln(-/-) (0.23 +/- 0.03 vs. 0.35 +/- 0.02) mice due to increased sympathetic nervous system activation in Sln(-/-) mice; however, whole-body metabolic rate (Vo(2), ml/kg/h) was lower in Sln(-/-) compared with WT mice following HFF but only during periods when the mice were active in their cages (WT, 2894 +/- 87 vs. Sln(-/-), 2708 +/- 61). Treatment with the -adrenergic receptor (-AR) antagonist propranolol during HFF completely prevented muscle-based DIT in Sln(-/-) mice; however, it had no effect in WT mice, resulting in greater differences in whole-body metabolic rate and diet-induced weight gain. Our results suggest that -AR signaling partially compensates for a lack of SLN to activate muscle-based DIT, but SLN is the primary and more effective mediator.Bombardier, E., Smith, I. C., Gamu, D., Fajardo, V. A., Vigna, C., Sayer, R. A., Gupta, S. C., Bal, N. C., Periasamy, M., Tupling, A. R. Sarcolipin trumps -adrenergic receptor signaling as the favored mechanism for muscle-based diet-induced thermogenesis.	[Bombardier, Eric; Smith, Ian C.; Gamu, Daniel; Fajardo, Val A.; Vigna, Chris; Sayer, Ryan A.; Tupling, A. Russell] Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; [Gupta, Subash C.; Bal, Naresh C.; Periasamy, Muthu] Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; [Periasamy, Muthu] Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	University of Waterloo; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Tupling, AR (corresponding author), Univ Waterloo, Dept Kinesiol, 200 Univ Ave W,Ext 33652, Waterloo, ON N2L 3G1, Canada.	rtupling@uwaterloo.ca	Gupta, Subash/AAF-2563-2019	Gupta, Subash/0000-0002-0418-1940; Periasamy, Muthu/0000-0001-8834-5975; Tupling, A. Russell/0000-0002-3895-6767; Smith, Ian/0000-0001-5269-1710	Canadian Institutes of Health Research (CIHR) [MOP 86618, MOP 47296]; U.S. National Institutes of Health [R01 HL-080551]; Natural Sciences and Engineering Research Council of Canada; CIHR; American Physiological Society; American Heart Association [10POST3360007]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); CIHR(Canadian Institutes of Health Research (CIHR)); American Physiological Society; American Heart Association(American Heart Association)	The authors thank Marg Burnett for excellent technical assistance. This work was supported in part by research grants from the Canadian Institutes of Health Research (CIHR; MOP 86618 and MOP 47296 to A. R. T.) and the U.S. National Institutes of Health (R01 HL-080551 to M. P.). E. B., I. C. S., and C. V. were supported by postgraduate scholarship doctoral awards from the Natural Sciences and Engineering Research Council of Canada. V. F. was supported by a doctoral award from CIHR. R. A. S. was supported by master's postgraduate scholarship awards from CIHR and from the Natural Sciences and Engineering Research Council of Canada. N.C.B. was supported by a postdoctoral fellowship from the American Physiological Society and the American Heart Association (10POST3360007). Author contributions: A. R. T. and E. B. conceived of the study idea and designed the experiments; I. C. S. conducted the resting muscle VO<INF>2</INF> TIOX studies; E. B. and R. A. S. conducted the HFD feeding and treadmill exercise experiments, glucose tolerance tests, adiposity and serum chemistry analyses; E. B. and D. G. conducted the propranolol experiments; E. B., C. V., and R. A. S. conducted the whole-body VO<INF>2</INF> CLAMS measurements; V. A. F. conducted the Western blot analyses on UCP-1; S. C. G. conducted the Western blot analyses on SLN; M. P. generated the Sln<SUP>-/-</SUP> mouse model; A. R. T., E. B., I. C. S., V. A. F., S. C. G., and N.C.B. analyzed the data and assembled the figures; A. R. T., E. B., and D. G. wrote the article. The authors declare no conflicts of interest.	Anunciado-Koza R, 2008, J BIOL CHEM, V283, P27688, DOI 10.1074/jbc.M804268200; Babu GJ, 2007, P NATL ACAD SCI USA, V104, P17867, DOI 10.1073/pnas.0707722104; Babu GJ, 2007, J MOL CELL CARDIOL, V43, P215, DOI 10.1016/j.yjmcc.2007.05.009; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Bal NC, 2012, NAT MED, V18, P1575, DOI 10.1038/nm.2897; Barclay CJ, 2007, J MUSCLE RES CELL M, V28, P259, DOI 10.1007/s10974-007-9116-7; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; de Meis L, 2001, BIOSCIENCE REP, V21, P113, DOI 10.1023/A:1013640006611; Dulloo AG, 2002, SCIENCE, V297, P780, DOI 10.1126/science.1074923; Feldmann HM, 2009, CELL METAB, V9, P203, DOI 10.1016/j.cmet.2008.12.014; GREEN HJ, 1991, CAN J PHYSIOL PHARM, V69, P1222, DOI 10.1139/y91-179; Kozak LP, 2010, CELL METAB, V11, P263, DOI 10.1016/j.cmet.2010.03.009; Lehnart SE, 2004, ANN NY ACAD SCI, V1015, P144, DOI 10.1196/annals.1302.012; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Mall S, 2006, J BIOL CHEM, V281, P36597, DOI 10.1074/jbc.M606869200; Masuo K, 2010, CURR DIABETES REV, V6, P58, DOI 10.2174/157339910790909396; Primeau V, 2011, INT J OBESITY, V35, P971, DOI 10.1038/ijo.2010.216; Roatta S, 2010, EXERC SPORT SCI REV, V38, P31, DOI 10.1097/JES.0b013e3181c5cde7; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Smith WS, 2002, BIOCHEM J, V361, P277, DOI 10.1042/0264-6021:3610277; Son C, 2004, DIABETOLOGIA, V47, P47, DOI 10.1007/s00125-003-1272-8; Szentesi P, 2001, J PHYSIOL-LONDON, V531, P393, DOI 10.1111/j.1469-7793.2001.0393i.x; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; Tseng YH, 2010, NAT REV DRUG DISCOV, V9, P465, DOI 10.1038/nrd3138; Tupling AR, 2011, AM J PHYSIOL-CELL PH, V301, pC841, DOI 10.1152/ajpcell.00409.2010	27	39	39	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3871	3878		10.1096/fj.13-230631	http://dx.doi.org/10.1096/fj.13-230631			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23752204	Green Published			2022-12-28	WOS:000328840500044
J	Ishigami, T; Abe, K; Aoki, I; Minegishi, S; Ryo, A; Matsunaga, S; Matsuoka, K; Takeda, H; Sawasaki, T; Umemura, S; Endo, Y				Ishigami, Tomoaki; Abe, Kaito; Aoki, Ichiro; Minegishi, Shintaro; Ryo, Akihide; Matsunaga, Satoko; Matsuoka, Kazuhiro; Takeda, Hiroyuki; Sawasaki, Tatsuya; Umemura, Satoshi; Endo, Yaeta			Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels	FASEB JOURNAL			English	Article						autoimmune; cytokine; coronary heart disease; peripheral artery disease	PRENYLATED RAB ACCEPTOR; KINASE-C-ZETA; STIMULATED GLUT4 TRANSLOCATION; LOW-DENSITY-LIPOPROTEIN; CYCLIN D2 EXPRESSION; SNARE PROTEINS; 3T3-L1 ADIPOCYTES; BETA-CATENIN; AGGRAVATES ATHEROSCLEROSIS; REGULATED EXOCYTOSIS	Atherosclerotic diseases, such as coronary artery disease and peripheral artery disease, are systemic disorders and among the leading causes of mortality and morbidity throughout the world. However, the exact pathophysiological mechanisms underlying the development of atherosclerosis remain unknown; currently, atherosclerosis is thought to involve an inflammatory process. Systemic inflammatory reactions and accumulation of immune cells in atherosclerotic lesions in situ are considered essential. We have comprehensively analyzed autoantibodies in patients with atherosclerosis by means of a newly developed high-throughput autoantibody analysis system. A wide range of autoantibodies was found in sera from patients with atherosclerosis. After we statistically analyzed the titers of each autoantibody with conventional techniques, the results underwent text-mining analyses based on natural language processing. Combinatory analysis revealed a close association between anti-interleukin (IL)-5 antibody and atherosclerosis. Titers of anti-IL-5 antibodies and serum IL-5 concentrations were also closely associated with other risk factors, such as low-density lipoprotein cholesterol, serum creatinine, fasting plasma glucose, gender, and age, suggesting that suppressed IL-5 function mediated by autoantibodies in patients with atherosclerosis plays an important role in the disease process. To validate the clinical significance of these findings, we computed the specificity and sensitivity of titers of anti-IL-5 autoantibodies for human atherosclerosis. When antibody titers of 1.49 were assumed to predict the presence of atherosclerosis, the sensitivity was 95.0% and the specificity 91.0%, with an area under the curve of 0.940. Our results provide important clues to understanding the role of autoantibody-mediated immune reactions in human atherosclerosis and suggest novel therapeutic opportunities for management of the disease.Ishigami, T., Abe, K., Aoki, I., Minegishi, S., Ryo, A., Matsunaga, S., Matsuoka, K., Takeda, H., Sawasaki, T., Umemura, S., and Endo, Y. Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels.	[Ishigami, Tomoaki; Abe, Kaito; Minegishi, Shintaro; Umemura, Satoshi] Yokohama City Univ, Dept Med Sci & Cardiorenal Med, Grad Sch Med, Yokohama, Kanagawa 2360004, Japan; [Aoki, Ichiro] Yokohama City Univ, Dept Mol Pathol, Grad Sch Med, Yokohama, Kanagawa 2360004, Japan; [Ryo, Akihide; Matsunaga, Satoko] Yokohama City Univ, Dept Microbiol, Grad Sch Med, Yokohama, Kanagawa 2360004, Japan; [Matsuoka, Kazuhiro; Takeda, Hiroyuki; Sawasaki, Tatsuya; Endo, Yaeta] Ehime Univ, Cell Free Sci & Technol Res Ctr, Div Proteomed Sci, Matsuyama, Ehime 790, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Ehime University	Ishigami, T (corresponding author), Yokohama City Univ, Dept Med Sci & Cardiorenal Med, Grad Sch Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	tommmish@hotmail.com	Kaito, Abe/CAG-2336-2022; Matsuoka, Kazuhiro/N-8419-2015	Kaito, Abe/0000-0003-2152-2572; Sawasaki, Tatsuya/0000-0002-7952-0556	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [0018590898]; Takeda Science Foundation; Novartis Foundation for Gerontological Research; Yokohama Foundation for Advancement of Medical Science; Grants-in-Aid for Scientific Research [25117719, 23591221] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Novartis Foundation for Gerontological Research(Novartis Foundation for Gerontological Research); Yokohama Foundation for Advancement of Medical Science; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We greatly appreciate Dr. Takai (Tokyo Medical and Dental University Graduate School of Medicine, Department of Computational Biology and Bioinfomatics) for her help and assessment in bioinformatics for our work. We also greatly appreciate Dr. Yamakado (The Center for Multiphasic Health Testing and Services of Mitsui Memorial Hospital) for providing sera from the age-matched control subjects. T.I. is supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) no. 0018590898, Takeda Science Foundation, Novartis Foundation for Gerontological Research, and Yokohama Foundation for Advancement of Medical Science.	Baluchamy S, 2005, VIRUS RES, V108, P69, DOI 10.1016/j.virusres.2004.08.004; Bazzoni G, 2005, J CELL SCI, V118, P623, DOI 10.1242/jcs.01661; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; Bhatt D. L., JAMA, V304, P1350; Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180; Binder CJ, 2005, J LIPID RES, V46, P1353, DOI 10.1194/jlr.R500005-JLR200; Binder CJ, 2004, J CLIN INVEST, V114, P427, DOI 10.1172/jci200420479; Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Bowcock AM, 2005, ANNU REV GENOM HUM G, V6, P93, DOI 10.1146/annurev.genom.6.080604.162324; Braiman L, 2001, MOL CELL BIOL, V21, P7852, DOI 10.1128/MCB.21.22.7852-7861.2001; Bucci C, 2001, BIOCHEM BIOPH RES CO, V286, P815, DOI 10.1006/bbrc.2001.5466; Butterworth AS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002260; Calero M, 2002, BIOCHEM BIOPH RES CO, V290, P676, DOI 10.1006/bbrc.2001.6242; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chapman WW, 2009, J BIOMED INFORM, V42, P757, DOI 10.1016/j.jbi.2009.09.001; Chen GL, 2003, FEBS LETT, V534, P54, DOI 10.1016/S0014-5793(02)03774-2; Cho S, 2009, J NEUROCHEM, V109, P126, DOI 10.1111/j.1471-4159.2009.05801.x; Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800; Cornelis F, 1998, P NATL ACAD SCI USA, V95, P10746, DOI 10.1073/pnas.95.18.10746; CRUTE BE, 1992, J NEUROCHEM, V59, P2017; Cutlip DE, 2004, CIRCULATION, V110, P1226, DOI 10.1161/01.CIR.0000140721.27004.4B; Daugherty A, 2004, J CLIN INVEST, V114, P317, DOI 10.1172/jci200422561; Drachman DB, 2003, J CLIN INVEST, V111, P797, DOI 10.1172/JCI200318180; Dubois T, 2002, EUR J BIOCHEM, V269, P909, DOI 10.1046/j.0014-2956.2001.02725.x; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Duran A, 2004, EMBO J, V23, P4595, DOI 10.1038/sj.emboj.7600468; Endo Y, 2006, CURR OPIN BIOTECH, V17, P373, DOI 10.1016/j.copbio.2006.06.009; Esnault S, 2007, J ALLERGY CLIN IMMUN, V120, P1082, DOI 10.1016/j.jaci.2007.06.024; ESPEL E, 1983, BIOCHEM BIOPH RES CO, V117, P817, DOI 10.1016/0006-291X(83)91670-4; Evans DT, 2002, J VIROL, V76, P327, DOI 10.1128/JVI.76.1.327-337.2002; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Foster LJ, 2000, TRAFFIC, V1, P512, DOI 10.1034/j.1600-0854.2000.010609.x; Fritzius T, 2007, FEBS J, V274, P1552, DOI 10.1111/j.1742-4658.2007.05702.x; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Gougeon PY, 2002, J BIOL CHEM, V277, P36408, DOI 10.1074/jbc.M205026200; Gutierrez R, 2005, PLANT CELL PHYSIOL, V46, P166, DOI 10.1093/pcp/pci007; Hansson GK, 2009, ATHEROSCLEROSIS, V202, P2, DOI 10.1016/j.atherosclerosis.2008.08.039; Hao JC, 1997, J NEUROSCI, V17, P1596; Horton LE, 1997, ONCOGENE, V14, P491, DOI 10.1038/sj.onc.1200851; Huang TJ, 2001, BRIT J PHARMACOL, V134, P1029, DOI 10.1038/sj.bjp.0704344; Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; Jawaheer D, 2001, AM J HUM GENET, V68, P927, DOI 10.1086/319518; Jiang XZ, 2006, BIOCHEM BIOPH RES CO, V345, P1497, DOI 10.1016/j.bbrc.2006.05.055; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; Ke B, 2007, J BIOL CHEM, V282, P21786, DOI 10.1074/jbc.M701661200; Kearney PM, 2008, LANCET, V371, P117, DOI 10.1016/S0140-6736(08)60104-X; Kida A, 2007, ONCOGENE, V26, P6630, DOI 10.1038/sj.onc.1210490; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; Kinoshita S, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S1-S4; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lawson K, 2005, MOL CELL BIOCHEM, V274, P103, DOI 10.1007/s11010-005-3066-4; LEHRICH RW, 1994, J BIOL CHEM, V269, P32446; Lin JL, 2001, J BIOL CHEM, V276, P41733, DOI 10.1074/jbc.M103475200; Ling SZ, 2003, J PHYSIOL-LONDON, V553, P65, DOI 10.1113/jphysiol.2003.051631; Logan MR, 2002, J ALLERGY CLIN IMMUN, V109, P299, DOI 10.1067/mai.2002.121453; Macaulay SL, 1997, BIOCHEM J, V324, P217, DOI 10.1042/bj3240217; Mallat Z, 2009, J LIPID RES, V50, pS364, DOI 10.1194/jlr.R800092-JLR200; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Matsuoka K, 2010, J PROTEOME RES, V9, P4264, DOI 10.1021/pr9010553; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Methe H, 2005, J AM COLL CARDIOL, V45, P1939, DOI 10.1016/j.jacc.2005.03.040; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868; Min SH, 2005, NEUROCHEM RES, V30, P955, DOI 10.1007/s11064-005-6177-0; Miyamoto-Sato E, 2005, GENOME RES, V15, P710, DOI 10.1101/gr.3510505; Miyao Y, 2009, BIOINFORMATICS, V25, P394, DOI 10.1093/bioinformatics/btn631; Miyashita H, 2003, ONCOL REP, V10, P1045; Ohmura-Hoshino M, 2004, VACCINE, V22, P3751, DOI 10.1016/j.vaccine.2004.03.034; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; PALVIMO J, 1988, BIOCHIM BIOPHYS ACTA, V952, P172, DOI 10.1016/0167-4838(88)90113-6; Perez-Branguli F, 1999, FEBS LETT, V458, P60, DOI 10.1016/S0014-5793(99)01120-5; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Ray KK, 2009, LANCET, V373, P1765, DOI 10.1016/S0140-6736(09)60697-8; Reikhardt B A, 2003, Neurosci Behav Physiol, V33, P799, DOI 10.1023/A:1025101516128; Rosas M, 2006, J LEUKOCYTE BIOL, V80, P186, DOI 10.1189/jlb.1105636; Saito T, 2003, J BIOL CHEM, V278, P36718, DOI 10.1074/jbc.M305114200; Sampi M, 2008, J AM COLL CARDIOL, V52, P1370, DOI 10.1016/j.jacc.2008.06.047; Sanchez MDP, 2002, PLANT MOL BIOL, V50, P167, DOI 10.1023/A:1016029001537; Sawasaki T, 2002, P NATL ACAD SCI USA, V99, P14652, DOI 10.1073/pnas.232580399; Sawasaki T, 2005, METH MOL B, V310, P131; Shimada K, 2009, CIRC J, V73, P994, DOI 10.1253/circj.CJ-09-0277; St-Denis Jean-Francois, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P153; Sun HC, 2005, J CANCER RES CLIN, V131, P284, DOI 10.1007/s00432-004-0645-9; Takai K, 2010, NAT PROTOC, V5, P227, DOI 10.1038/nprot.2009.207; TAKATSU K, 1994, ADV IMMUNOL, V57, P145, DOI 10.1016/S0065-2776(08)60673-2; Takatsu K, 2009, ADV IMMUNOL, V101, P191, DOI 10.1016/S0065-2776(08)01006-7; Takuma T, 2002, J BIOCHEM, V132, P729, DOI 10.1093/oxfordjournals.jbchem.a003280; Takuma T, 2000, ARCH ORAL BIOL, V45, P369, DOI 10.1016/S0003-9969(00)00004-2; Tanabe L, 2002, BIOINFORMATICS, V18, P1124, DOI 10.1093/bioinformatics/18.8.1124; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Tran GT, 2012, BLOOD, V119, P4441, DOI 10.1182/blood-2011-12-396101; Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; Wang CC, 2007, MOL BIOL CELL, V18, P1056, DOI 10.1091/mbc.E06-10-0974; Wang Y, 2007, FEBS LETT, V581, P3069, DOI 10.1016/j.febslet.2007.05.072; Weir ML, 2001, BIOCHEM BIOPH RES CO, V286, P616, DOI 10.1006/bbrc.2001.5437; Widberg CH, 2003, J BIOL CHEM, V278, P35093, DOI 10.1074/jbc.M304261200; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zhang X, 2005, J CLIN NEUROSCI, V12, P166, DOI 10.1016/j.jocn.2004.03.036; Zhou XH, 2000, CIRCULATION, V102, P2919; Zhou XH, 2006, ARTERIOSCL THROM VAS, V26, P864, DOI 10.1161/01.ATV.0000206122.61591.ff	114	15	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3437	3445		10.1096/fj.12-222653	http://dx.doi.org/10.1096/fj.12-222653			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23699176				2022-12-28	WOS:000328840500004
J	Matsumura, T; Imamichi, Y; Mizutani, T; Ju, YF; Yazawa, T; Kawabe, S; Kanno, M; Ayabe, T; Katsumata, N; Fukami, M; Inatani, M; Akagi, Y; Umezawa, A; Ogata, T; Miyamoto, K				Matsumura, Takehiro; Imamichi, Yoshitaka; Mizutani, Tetsuya; Ju, Yunfeng; Yazawa, Takashi; Kawabe, Shinya; Kanno, Masafumi; Ayabe, Tadayuki; Katsumata, Noriyuki; Fukami, Maki; Inatani, Masaru; Akagi, Yoshio; Umezawa, Akihiro; Ogata, Tsutomu; Miyamoto, Kaoru			Human glutathione S-transferase A (GSTA) family genes are regulated by steroidogenic factor 1 (SF-1) and are involved in steroidogenesis	FASEB JOURNAL			English	Article						transcriptional regulation; chromatin structure; gene cluster; isomerase activity	MESENCHYMAL STEM-CELLS; TRANSCRIPTION; RECEPTOR; DIFFERENTIATION; ESTABLISHMENT; ENHANCERS; PROMOTER; HORMONES; PATHWAY; ENZYMES	Steroidogenic factor 1 (SF-1) is a master regulator for steroidogenesis. In this study, we identified novel SF-1 target genes using a genome-wide promoter tiling array and a DNA microarray. SF-1 was found to regulate human glutathione S-transferase A (GSTA) family genes (hGSTA1-hGSTA4), a superfamily of detoxification enzymes clustered on chromosome 6p12. All hGSTA genes were up-regulated by transduction of SF-1 into human mesenchymal stem cells, while knockdown of endogenous SF-1 in H295R cells down-regulated all hGSTA genes. Chromatin immunoprecipitation assays, however, revealed that SF-1 bound directly to the promoters of hGSTA3 and weakly of hGSTA4. Chromosome conformation capture assays revealed that the coordinated expression of the genes was based on changes in higher-order chromatin structure triggered by SF-1, which enables the formation of long-range interactions, at least between hGSTA1 and hGSTA3 gene promoters. In steroidogenesis, dehydrogenation of the 3-hydroxy group and subsequent (5)-(4) isomerization are thought to be enzymatic properties of 3-hydroxysteroid dehydrogenase (3-HSD). Here, we demonstrated that, in steroidogenic cells, the hGSTA1 and hGSTA3 gene products catalyze (5)-(4) isomerization in a coordinated fashion with 3-HSD II to produce progesterone or (4)-androstenedione from their (5)-precursors. Thus, hGSTA1 and hGSTA3 gene products are new members of steroidogenesis working as Delta(5)-Delta(4) isomerases.	[Matsumura, Takehiro; Imamichi, Yoshitaka; Mizutani, Tetsuya; Ju, Yunfeng; Yazawa, Takashi; Kawabe, Shinya; Kanno, Masafumi; Miyamoto, Kaoru] Univ Fukui, Fac Med Sci, Dept Biochem, Fukui 9101193, Japan; [Matsumura, Takehiro; Inatani, Masaru; Akagi, Yoshio] Univ Fukui, Fac Med Sci, Dept Ophthalmol, Fukui 9101193, Japan; [Imamichi, Yoshitaka; Mizutani, Tetsuya; Yazawa, Takashi; Kawabe, Shinya; Miyamoto, Kaoru] Univ Fukui, Translat Res Ctr, Org Life Sci Adv Programs, Fukui 9101193, Japan; [Imamichi, Yoshitaka] Univ Fukui, Fukui 9101193, Japan; [Ayabe, Tadayuki; Katsumata, Noriyuki; Fukami, Maki] Natl Res Inst Child Hlth & Dev, Dept Mol Endocrinol, Tokyo, Japan; [Umezawa, Akihiro] Natl Res Inst Child Hlth & Dev, Dept Reprod Biol, Tokyo, Japan; [Ogata, Tsutomu] Hamamatsu Univ Sch Med, Dept Pediat, Shizuoka, Japan	University of Fukui; University of Fukui; University of Fukui; University of Fukui; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; Hamamatsu University School of Medicine	Mizutani, T (corresponding author), Univ Fukui, Fac Med Sci, Dept Biochem, Fukui 9101193, Japan.	mizutani@u-fukui.ac.jp	Fukami, Maki/ABE-4694-2020; Yazawa, Takashi/AEZ-6785-2022	Fukami, Maki/0000-0001-9971-4035; Yazawa, Takashi/0000-0003-4526-6585; Ogata, Tsutomu/0000-0001-7178-9991	Health and Labor Sciences Research grant; Japan Ministry of Education, Culture, Sports, Science, and Technology; Smoking Research Foundation; Kanzawa Medical Research Foundation; Takeda Science Foundation; Grants-in-Aid for Scientific Research [23390249, 22227002, 25861481] Funding Source: KAKEN	Health and Labor Sciences Research grant(Ministry of Health, Labour and Welfare, Japan); Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Smoking Research Foundation; Kanzawa Medical Research Foundation(Kanzawa Medical Research Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors are grateful to Dr. T. Yanase (Fukuoka University, Fukuoka, Japan) for providing KGN cells, Dr. H. Takemori (National Institute of Biomedical Innovation, Osaka, Japan) for providing H295R cells, Dr. J. Toguchida (Kyoto University, Kyoto, Japan) for providing hMSC-hTERT-E6/E7 cells, and Dr. K. Morohashi (University of Kyushu, Fukuoka, Japan) for providing anti-Ad4BP/SF-1 antibody. The authors also thank K. Matsuura, H. Fujii, Y. Yamazaki, and Y. Usami for technical assistance and Y. Inoue for administrative assistance. This work was supported by a Health and Labor Sciences Research grant; a grant from the Japan Ministry of Education, Culture, Sports, Science, and Technology; the Smoking Research Foundation; the Kanzawa Medical Research Foundation; and the Takeda Science Foundation.	Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Eskiw CH, 2011, J CELL SCI, V124, P3676, DOI 10.1242/jcs.087981; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hirai H, 2010, INT J DEV BIOL, V54, P1589, DOI 10.1387/ijdb.103194hh; Johansson AS, 2001, J BIOL CHEM, V276, P33061, DOI 10.1074/jbc.M104539200; Ju YF, 2012, ENDOCRINOLOGY, V153, P5522, DOI 10.1210/en.2012-1334; Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014; Mishiro T, 2009, EMBO J, V28, P1234, DOI 10.1038/emboj.2009.81; Mizutani T, 2000, J BIOL CHEM, V275, P22512, DOI 10.1074/jbc.M001631200; Mizutani T, 2001, MOL ENDOCRINOL, V15, P1693, DOI 10.1210/me.15.10.1693; Mizutani T, 2010, J BIOL CHEM, V285, P28240, DOI 10.1074/jbc.M110.129510; Montavon T, 2011, CELL, V147, P1132, DOI 10.1016/j.cell.2011.10.023; Morel F, 2002, PHARMACOGENETICS, V12, P277, DOI 10.1097/00008571-200206000-00003; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006-291X(02)00661-7; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003-0030; Prasad M, 2012, J BIOL CHEM, V287, P9534, DOI 10.1074/jbc.M111.333278; RAINEY WE, 1993, J CLIN ENDOCR METAB, V77, P731, DOI 10.1210/jc.77.3.731; Rajapaksha M, 2011, BIOCHEMISTRY-US, V50, P11015, DOI 10.1021/bi2016102; Schoenfelder S, 2010, NAT GENET, V42, P53, DOI 10.1038/ng.496; Simard J, 2005, ENDOCR REV, V26, P525, DOI 10.1210/er.2002-0050; Yazawa T, 2006, ENDOCRINOLOGY, V147, P4104, DOI 10.1210/en.2006-0162; Yazawa T, 2010, MOL ENDOCRINOL, V24, P485, DOI 10.1210/me.2009-0352; Yazawa T, 2009, ENDOCRINOLOGY, V150, P3885, DOI 10.1210/en.2008-1310	28	22	22	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3198	3208		10.1096/fj.12-222745	http://dx.doi.org/10.1096/fj.12-222745			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23650189				2022-12-28	WOS:000329877600025
J	Schallreuter, KU; Salem, MAEL; Holtz, S; Panske, A				Schallreuter, Karin U.; Salem, Mohammed A. E. L.; Holtz, Sarah; Panske, A.			Basic evidence for epidermal H2O2/ONOO--mediated oxidation/nitration in segmental vitiligo is supported by repigmentation of skin and eyelashes after reduction of epidermal H2O2 with topical NB-UVB-activated pseudocatalase PC-KUS	FASEB JOURNAL			English	Article						FT-Raman spectroscopy; ROS; RNS; MSRA; MSRB; thioredoxin reductase	METHIONINE-SULFOXIDE-REDUCTASE; HYDROGEN-PEROXIDE H2O2; AFFECTS IMMUNE-RESPONSE; L-TRYPTOPHAN METABOLISM; FT-RAMAN SPECTROSCOPY; FENTON CHEMISTRY; OXIDATIVE STRESS; IN-VITRO; MELANOCYTES; MELATONIN	Nonsegmental vitiligo (NSV) is characterized by loss of inherited skin color. The cause of the disease is still unknown despite accumulating in vivo and in vitro evidence of massive epidermal oxidative stress via H2O2 and peroxynitrite (ONOO-) in affected individuals. The most favored hypothesis is based on autoimmune mechanisms. Strictly segmental vitiligo (SSV) with dermatomal distribution is a rare entity, often associated with stable outcome. Recently, it was documented that this form can be associated with NSV (mixed vitiligo). We here asked the question whether ROS and possibly ONOO- could be players in the pathogenesis of SSV. Our in situ results demonstrate for the first time epidermal biopterin accumulation together with significantly decreased epidermal catalase, thioredoxin/thioreoxin reductase, and MSRA/MSRB expression. Moreover, we show epidermal ONOO- accumulation. In vivo FT-Raman spectroscopy reveals the presence of H2O2, methionine sulfoxide, and tryptophan metabolites; i.e., N-formylkynurenine and kynurenine, implying Fenton chemistry in the cascade (n=10). Validation of the basic data stems from successful repigmentation of skin and eyelashes in affected individuals, regardless of SSV or segmental vitiligo in association with NSV after reduction of epidermal H2O2 (n=5). Taken together, our contribution strongly supports H2O2/ONOO-mediated stress in the pathogenesis of SSV. Our findings offer new treatment intervention for lost skin and hair color.	[Schallreuter, Karin U.; Salem, Mohammed A. E. L.; Holtz, Sarah; Panske, A.] Ernst Moritz Arndt Univ Greifswald, Inst Pigmentary Disorders, Greifswald, Germany; [Schallreuter, Karin U.] Univ Bradford, Sch Life Sci, Ctr Skin Sci, Bradford BD7 1DP, W Yorks, England	Ernst Moritz Arndt Universitat Greifswald; University of Bradford	Schallreuter, KU (corresponding author), Univ Bradford, Sch Life Sci, Ctr Skin Sci, Bradford BD7 1DP, W Yorks, England.	k.schallreuter@bradford.ac.uk			American Vitiligo Research Foundation (Clearwater, FL, USA)	American Vitiligo Research Foundation (Clearwater, FL, USA)	The authors thank the patients who participated in this study. This study has been supported by the American Vitiligo Research Foundation (Clearwater, FL, USA) and by private donations. The authors declare no conflict of interest.	BOLOGNIA JL, 1994, J AM ACAD DERMATOL, V31, P157, DOI 10.1016/S0190-9622(94)70143-1; Cartaxo SB, 2010, ACTA CIR BRAS, V25, P351, DOI 10.1590/S0102-86502010000400010; Chavan B, 2006, J INVEST DERMATOL, V126, P2481, DOI 10.1038/sj.jid.5700425; Dell'Anna ML, 2006, PIGM CELL RES, V19, P406, DOI 10.1111/j.1600-0749.2006.00333.x; ELMOFTY AM, 1980, INT J DERMATOL, V19, P237; Ezzedine K, 2012, BRIT J DERMATOL, V166, P539, DOI 10.1111/j.1365-2133.2011.10709.x; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Gibbons NQ, 2006, J INVEST DERMATOL, V126, P2576, DOI 10.1038/sj.jid.5700612; Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151; Happle R, 2007, J AM ACAD DERMATOL, V57, P690, DOI 10.1016/j.jaad.2007.06.039; Hasse S, 2004, J INVEST DERMATOL, V122, P307, DOI 10.1046/j.0022-202X.2004.22230.x; Huggins RH, 2005, ACTA DERMATOVEN ALP, V14, P137; Jung S, 2002, FEBS LETT, V527, P91, DOI 10.1016/S0014-5793(02)03171-X; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; KOGA M, 1988, BRIT J DERMATOL, V118, P223, DOI 10.1111/j.1365-2133.1988.tb01778.x; KOGA M, 1977, BRIT J DERMATOL, V97, P255, DOI 10.1111/j.1365-2133.1977.tb15180.x; Kruger C, 2012, INT J DERMATOL, V51, P1206, DOI 10.1111/j.1365-4632.2011.05377.x; Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099; Manga P, 2006, AM J PATHOL, V169, P1652, DOI 10.2353/ajpath.2006.050769; Maresca V, 1997, J INVEST DERMATOL, V109, P310, DOI 10.1111/1523-1747.ep12335801; Neiers F, 2004, J BIOL CHEM, V279, P42462, DOI 10.1074/jbc.M407464200; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Ogawa Fumihide, 2006, Nihon Rinsho Meneki Gakkai Kaishi, V29, P349; Pey AL, 2006, FASEB J, V20, P2130, DOI 10.1096/fj.06-5835fje; Picardo M, 2012, BRIT J DERMATOL, V166, P472, DOI 10.1111/j.1365-2133.2012.10839.x; Rokos H, 2008, J RAMAN SPECTROSC, V39, P1214, DOI 10.1002/jrs.1968; Salem MMAEL, 2009, FASEB J, V23, P3790, DOI 10.1096/fj.09-132621; Schallreuter KU, 2008, EXP DERMATOL, V17, P139, DOI [10.1111/j.1600-0625.2007.00666_1.x, 10.1111/j.1600-0625.2007.00666.x]; Schallreuter KU, 2008, INT J DERMATOL, V47, P743, DOI 10.1111/j.1365-4632.2008.03660.x; Schallreuter KU, 2008, J INVEST DERMATOL, V128, P808, DOI 10.1038/sj.jid.5701100; Schallreuter KU, 2007, ARCH DERMATOL RES, V299, P225, DOI 10.1007/s00403-007-0748-7; Schallreuter KU, 2012, FASEB J, V26, P2471, DOI 10.1096/fj.11-201897; Schallreuter KU, 2012, FASEB J, V26, P2457, DOI 10.1096/fj.11-197137; Schallreuter KU, 2011, AUTOIMMUNE DISEASES OF THE SKIN: PATHOGENESIS, DIAGNOSIS, MANAGEMENT, THIRD EDITION, P435, DOI 10.1007/978-3-211-99225-8_19; SCHALLREUTER KU, 1991, J INVEST DERMATOL, V97, P1081, DOI 10.1111/1523-1747.ep12492612; SCHALLREUTER KU, 1995, DERMATOLOGY, V190, P223, DOI 10.1159/000246690; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; Schallreuter KU, 2006, BIOCHEM BIOPH RES CO, V342, P145, DOI 10.1016/j.bbrc.2006.01.124; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schallreuter KU, 2001, J PHOTOCH PHOTOBIO B, V64, P179, DOI 10.1016/S1011-1344(01)00235-4; SCHALLREUTER KU, 1992, BIOCHEM BIOPH RES CO, V189, P72, DOI 10.1016/0006-291X(92)91527-W; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007; Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Spencer JD, 2007, J INVEST DERMATOL, V127, P411, DOI 10.1038/sj.jid.5700538; Taieb A, 2008, PIGM CELL MELANOMA R, V21, P646, DOI 10.1111/j.1755-148X.2008.00511.x; Taieb A, 2007, PIGM CELL RES, V20, P27, DOI 10.1111/j.1600-0749.2006.00355.x; Thiele JJ, 1999, J INVEST DERMATOL, V113, P335, DOI 10.1046/j.1523-1747.1999.00693.x; Thody AJ, 1999, ANN NY ACAD SCI, V885, P217, DOI 10.1111/j.1749-6632.1999.tb08679.x; Tobin DJ, 2000, J PATHOL, V191, P407; van Geel N, 2013, BRIT J DERMATOL, V168, P56, DOI 10.1111/bjd.12013; Wink DA, 2011, J LEUKOCYTE BIOL, V89, P873, DOI 10.1189/jlb.1010550; Wood JM, 2009, FASEB J, V23, P2065, DOI 10.1096/fj.08-125435	57	30	31	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3113	3122		10.1096/fj.12-226779	http://dx.doi.org/10.1096/fj.12-226779			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23629861				2022-12-28	WOS:000329877600018
J	Esse, R; Imbard, A; Florindo, C; Gupta, S; Quinlivan, EP; Davids, M; Teerlink, T; de Almeida, IT; Kruger, WD; Blom, HJ; Castro, R				Esse, Ruben; Imbard, Apolline; Florindo, Cristina; Gupta, Sapna; Quinlivan, Eoin P.; Davids, Mariska; Teerlink, Tom; de Almeida, Isabel Tavares; Kruger, Warren D.; Blom, Henk J.; Castro, Rita			Protein arginine hypomethylation in a mouse model of cystathionine beta-synthase deficiency	FASEB JOURNAL			English	Article						homocystinuria; S-adenosylhomocysteine; H4R3me2a; methylarginines	MYELIN BASIC-PROTEIN; S-ADENOSYLHOMOCYSTEINE; DNA METHYLATION; LIQUID-CHROMATOGRAPHY; ASYMMETRIC DIMETHYLARGININE; MICE DEFICIENT; HISTONE H4; PLASMA; ADENOSYLMETHIONINE; ATHEROSCLEROSIS	Accumulation of the homocysteine (Hcy) precursor S-adenosylhomocysteine (AdoHcy) may cause cellular hypomethylation in the setting of hyperhomo-cysteinemia because of cystathionine beta-synthase (CBS) deficiency, an inborn error of metabolism. To test this hypothesis, DNA and protein arginine methylation status were assessed in liver, brain, heart, and kidney obtained from a previously described mouse model of CBS deficiency. Metabolite levels in tissues and serum were determined by high-performance liquid chromatography or liquid chromatography-electrospray ionization-tandem mass spectrometry. Global DNA and protein arginine methylation status were evaluated as the contents of 5-methyldeoxycytidine in DNA and of methylarginines in proteins, respectively. In addition, histone arginine methylation was assessed by Western blotting. CBS-deficient mice exhibited increased (>6fold) Hcy and AdoHcy levels in all tissues examined compared with control levels. In addition, global DNA methylation status was not affected, but global protein arginine methylation status was decreased (10-35%) in liver and brain. Moreover, asymmetric dimethylation of arginine 3 on histone H4 (H4R3me2a) content was markedly decreased in liver, and no differences were observed for the other histone arginine methylation marks examined. Our results show that CBS-deficient mice present severe accumulation of tissue Hcy and AdoHcy, protein arginine hypomethylation in liver and brain, and decreased H4R3me2a content in liver. Therefore, protein arginine hypomethylation arises as a potential player in the pathophysiology of CBS deficiency.	[Esse, Ruben; Imbard, Apolline; Davids, Mariska; Teerlink, Tom; Blom, Henk J.] Vrije Univ Amsterdam, Med Ctr, Metab Unit, Dept Clin Chem, Amsterdam, Netherlands; [Esse, Ruben; Florindo, Cristina; de Almeida, Isabel Tavares; Castro, Rita] Univ Lisbon, Inst Med & Pharmaceut Sci iMed UL, P-1699 Lisbon, Portugal; [de Almeida, Isabel Tavares] Univ Lisbon, Fac Pharm, Dept Biochem & Human Biol, P-1699 Lisbon, Portugal; [Imbard, Apolline] Hop Robert Debre, AP HP, Serv Biochim Hormonol, F-75019 Paris, France; [Gupta, Sapna; Kruger, Warren D.] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA; [Quinlivan, Eoin P.] Univ Florida, Biomed Mass Spectrometry Lab, Gainesville, FL USA; [Blom, Henk J.] Univ Hosp, Lab Clin Biochem & Metab, Dept Gen Pediat, Ctr Pediat & Adolescent Med, D-79106 Freiburg, Germany	Vrije Universiteit Amsterdam; Universidade de Lisboa; Universidade de Lisboa; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Fox Chase Cancer Center; State University System of Florida; University of Florida; University of Freiburg	Blom, HJ (corresponding author), Univ Hosp, Lab Clin Biochem & Metab, Dept Gen Pediat, Ctr Pediat & Adolescent Med, Mathildenstr 1, D-79106 Freiburg, Germany.	henk.blom@uniklinik-freiburg.de	Quinlivan, Eoin/AAJ-1979-2021; iMed.ULisboa, MetGen/B-5293-2014; Quinlivan, Eoin P/B-8454-2008; de Almeida, Isabel Tavares/F-8319-2014; Castro, Rita/J-7672-2019; Kruger, Warren/Y-2541-2018	Quinlivan, Eoin/0000-0002-0908-1762; Quinlivan, Eoin P/0000-0002-0908-1762; Castro, Rita/0000-0002-4585-0741; kruger, warren/0000-0002-4990-3695; Tavares de Almeida, Isabel/0000-0002-4024-8305; , Ruben/0000-0002-8381-0628; Blom, Henk/0000-0001-5202-9241	Fundacao para a Ciencia e a Tecnologia, Portugal [PTDC/SAU-ORG/112683/2009, SFRH/BD/48585/2008, SFRH/BD/41970/2007]; Hempling Foundation for Homocystinuria Research; U.S. National Institutes of Health [CA06927, R01GM098772]; Commonwealth of Pennsylvania; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK101404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098772] Funding Source: NIH RePORTER	Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology); Hempling Foundation for Homocystinuria Research; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Commonwealth of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors acknowledge Sigrid de Jong and Rob Barto for their excellent technical assistance. This work was financially supported by the Fundacao para a Ciencia e a Tecnologia, Portugal (grants PTDC/SAU-ORG/112683/2009, SFRH/BD/48585/2008, and SFRH/BD/41970/2007), the Hempling Foundation for Homocystinuria Research, the U.S. National Institutes of Health (grants CA06927 and R01GM098772), and an appropriation from the Commonwealth of Pennsylvania.	Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Baric I, 2004, P NATL ACAD SCI USA, V101, P4234, DOI 10.1073/pnas.0400658101; Castro R, 2003, CLIN CHEM, V49, P1292, DOI 10.1373/49.8.1292; Caudill MA, 2001, J NUTR, V131, P2811, DOI 10.1093/jn/131.11.2811; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Cheng XD, 2007, MUTAT RES-FUND MOL M, V618, P102, DOI 10.1016/j.mrfmmm.2006.05.041; Chittka A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013807; Choumenkovitch SF, 2002, J NUTR, V132, P2157, DOI 10.1093/jn/132.8.2157; Clarke S., 2011, HOMOCYSTEINE HLTH DI, P63; Cosgrove MS, 2005, BIOCHEM CELL BIOL, V83, P468, DOI 10.1139/O05-137; Davids M, 2012, J CHROMATOGR B, V900, P38, DOI 10.1016/j.jchromb.2012.05.025; de Jong S, 2006, ANAL BIOCHEM, V353, P287, DOI 10.1016/j.ab.2006.03.010; Esse R, 2013, BBA-MOL BASIS DIS, V1832, P1708, DOI 10.1016/j.bbadis.2013.05.013; Esse R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055483; Esse Ruben, 2012, METHYLATION DNA RNA, DOI [10.5772/51984, DOI 10.5772/51984]; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Fleck C, 2001, KIDNEY INT, V59, pS14, DOI 10.1046/j.1523-1755.2001.59780014.x; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Grillo MA, 2008, AMINO ACIDS, V34, P187, DOI 10.1007/s00726-007-0500-9; Guo AL, 2014, MOL CELL PROTEOMICS, V13, P372, DOI 10.1074/mcp.O113.027870; Gupta S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027598; Gupta S, 2009, FASEB J, V23, P883, DOI 10.1096/fj.08-120584; Handy DE, 2011, CIRCULATION, V123, P2145, DOI 10.1161/CIRCULATIONAHA.110.956839; Heil SG, 2007, MOL GENET METAB, V91, P55, DOI 10.1016/j.ymgme.2007.01.008; HOFFMAN DR, 1979, CAN J BIOCHEM CELL B, V57, P56, DOI 10.1139/o79-007; Hong E, 2012, BIOGERONTOLOGY, V13, P329, DOI 10.1007/s10522-012-9379-2; James SJ, 2002, J NUTR, V132, p2361S, DOI 10.1093/jn/132.8.2361S; Kim S, 1997, INT J BIOCHEM CELL B, V29, P743, DOI 10.1016/S1357-2725(97)00009-5; Li XG, 2010, BLOOD, V115, P2028, DOI 10.1182/blood-2009-07-236059; Lin KY, 2002, CIRCULATION, V106, P987, DOI 10.1161/01.CIR.0000027109.14149.67; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lund G, 2004, J BIOL CHEM, V279, P29147, DOI 10.1074/jbc.M403618200; Marliss EB, 2006, DIABETOLOGIA, V49, P351, DOI 10.1007/s00125-005-0066-6; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Orendac M, 2003, J INHERIT METAB DIS, V26, P761, DOI 10.1023/B:BOLI.0000009963.88420.c2; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Quinlivan EP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn534; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Schiza V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003805; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Struys EA, 2000, CLIN CHEM, V46, P1650; Surtees R, 1998, EUR J PEDIATR, V157, pS118, DOI 10.1007/PL00014296; TEERLINK T, 1994, CLIN CHEM, V40, P245; Teerlink T, 2007, J CHROMATOGR B, V851, P21, DOI 10.1016/j.jchromb.2006.07.024; Teerlink T, 2009, PHARMACOL RES, V60, P448, DOI 10.1016/j.phrs.2009.08.002; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; UELAND PM, 1982, PHARMACOL REV, V34, P223; Vaes BLT, 2010, BONE, V46, P514, DOI 10.1016/j.bone.2009.09.033; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang LQ, 2005, HUM MOL GENET, V14, P2201, DOI 10.1093/hmg/ddi224; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; Zaina S, 2005, J NUTR, V135, P5, DOI 10.1093/jn/135.1.5	53	21	22	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2686	2695		10.1096/fj.13-246579	http://dx.doi.org/10.1096/fj.13-246579			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24532665	Green Published			2022-12-28	WOS:000339883600026
J	Dumont, M; Stack, C; Elipenahli, C; Jainuddin, S; Launay, N; Gerges, M; Starkova, N; Starkov, AA; Calingasan, NY; Tampellini, D; Pujol, A; Beal, MF				Dumont, Magali; Stack, Cliona; Elipenahli, Ceyhan; Jainuddin, Shari; Launay, Nathalie; Gerges, Meri; Starkova, Natalia; Starkov, Anatoly A.; Calingasan, Noel Y.; Tampellini, Davide; Pujol, Aurora; Beal, M. Flint			PGC-1 alpha overexpression exacerbates beta-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						cell death; mitochondria; behavior; Tg19959 mice	GAMMA COACTIVATOR 1-ALPHA; HUNTINGTONS-DISEASE; OXIDATIVE STRESS; MITOCHONDRIAL BIOGENESIS; NEURODEGENERATIVE DISORDERS; TRANSCRIPTIONAL COACTIVATOR; PARKINSONS-DISEASE; MUSCLE ATROPHY; A-BETA; EXPRESSION	The peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha) interacts with various transcription factors involved in energy metabolism and in the regulation of mitochondrial biogenesis. PGC-1 alpha mRNA levels are reduced in a number of neurodegenerative diseases and contribute to disease pathogenesis, since increased levels ameliorate behavioral defects and neuropathology of Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis. PGC-1 alpha and its downstream targets are reduced both in postmortem brain tissue of patients with Alzheimer's disease (AD) and in transgenic mouse models of AD. Therefore, we investigated whether increased expression of PGC-1 alpha would exert beneficial effects in the Tg19959 transgenic mouse model of AD; Tg19959 mice express the human amyloid precursor gene (APP) with 2 familial AD mutations and develop increased beta-amyloid levels, plaque deposition, and memory deficits by 2-3 mo of age. Rather than an improvement, the cross of the Tg19959 mice with mice overexpressing human PGC-1 alpha exacerbated amyloid and tau accumulation. This was accompanied by an impairment of proteasome activity. PGC-1 alpha overexpression induced mitochondrial abnormalities, neuronal cell death, and an exacerbation of behavioral hyperactivity in the Tg19959 mice. These findings show that PGC-1 alpha overexpression exacerbates the neuropathological and behavioral deficits that occur in transgenic mice with mutations in APP that are associated with human AD.-Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Launay, N., Gerges, M., Starkova, N., Starkov, A. A., Calingasan, N. Y., Tampellini, D., Pujol, A., Beal, M. F. PGC-1 alpha overexpression exacerbates beta-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.	[Dumont, Magali; Stack, Cliona; Elipenahli, Ceyhan; Jainuddin, Shari; Gerges, Meri; Starkova, Natalia; Starkov, Anatoly A.; Calingasan, Noel Y.; Beal, M. Flint] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA; [Launay, Nathalie; Pujol, Aurora] Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Inst Neuropathol, Neurometabol Dis Lab, Barcelona, Spain; [Launay, Nathalie; Pujol, Aurora] ISCIII, Ctr Biomed Res Rare Dis CIBERER, U579, Valencia, Spain; [Tampellini, Davide] Univ Paris Sud, Hosp Kremlin Bicetre, INSERM, UMR 788, F-94275 Le Kremlin Bicetre, France; [Pujol, Aurora] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain	Cornell University; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; ICREA	Dumont, M (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, 525 East 68th St,Rm A569A, New York, NY 10065 USA.	mad2138@med.cornell.edu	Pujol, Aurora/N-4990-2014; Starkov, Anatoly/B-2688-2012; Launay, Nathalie/G-1387-2016	Pujol, Aurora/0000-0002-9606-0600; Starkov, Anatoly/0000-0002-1334-4828; Tampellini, Davide/0000-0003-3188-0293; Launay, Nathalie/0000-0002-7498-217X; DUMONT, MAGALI/0000-0001-9990-6512	U.S. National Institutes of Health (NIH) [5P01 (AG14930)]; Spanish National Institute of Health Carlos III [FIS PI11/01043]; Catalan Government Group of Excellence [2009SGR85]; Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), an initiative of Instituto de Salud Carlos III (ISCIII); NATIONAL INSTITUTE ON AGING [P01AG014930] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish National Institute of Health Carlos III(Instituto de Salud Carlos III); Catalan Government Group of Excellence; Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), an initiative of Instituto de Salud Carlos III (ISCIII); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); ICREA(ICREA)	This work was supported by the U.S. National Institutes of Health (NIH), grant 5P01 (AG14930). The work performed at the Neurometabolic Diseases Laboratory was carried out thanks to grants from the Spanish National Institute of Health Carlos III (FIS PI11/01043) and the Catalan Government Group of Excellence (2009SGR85) to A.P. N.L. holds a postdoctoral fellowship from Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), an initiative of Instituto de Salud Carlos III (ISCIII). The authors thank Peter Davies (Albert Einstein College of Medicine, New York, NY, USA), Rakez Kayed (University of Texas Medical Branch, Galveston, TX, USA), and Wenjie Luo (Weill Cornell Medical College, New York, NY, USA) for providing the tau (CP13 and DA9), amyloid (OC), and PS1 antibodies, respectively. The authors declare no conflicts of interest.	ARRIGONI O, 1962, NATURE, V193, P1256, DOI 10.1038/1931256a0; Beal MF, 2009, PARKINSONISM RELAT D, V15, pS189, DOI 10.1016/S1353-8020(09)70812-0; Brault JJ, 2010, J BIOL CHEM, V285, P19460, DOI 10.1074/jbc.M110.113092; Chaturvedi RK, 2010, HUM MOL GENET, V19, P3190, DOI 10.1093/hmg/ddq229; Chaturvedi RK, 2009, HUM MOL GENET, V18, P3048, DOI 10.1093/hmg/ddp243; Cheroni C, 2005, NEUROBIOL DIS, V18, P509, DOI 10.1016/j.nbd.2004.12.007; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciron C, 2012, HUM MOL GENET, V21, P1861, DOI 10.1093/hmg/ddr618; Cripps D, 2006, J BIOL CHEM, V281, P10825, DOI 10.1074/jbc.M512786200; Du H, 2012, ANTIOXID REDOX SIGN, V16, P1467, DOI 10.1089/ars.2011.4277; Dumont M., NEUROCHEM INT, V56, P345; Dumont M, 2009, FASEB J, V23, P2459, DOI 10.1096/fj.09-132928; Dumont M, 2009, J NEUROCHEM, V109, P502, DOI 10.1111/j.1471-4159.2009.05970.x; ESPOSTI MD, 1993, BIOCHEM BIOPH RES CO, V190, P1090, DOI 10.1006/bbrc.1993.1161; Geng TY, 2011, AM J PATHOL, V178, P1738, DOI 10.1016/j.ajpath.2011.01.005; Go YM, 2010, ANTIOXID REDOX SIGN, V13, P489, DOI 10.1089/ars.2009.3021; Gong B, 2010, AGING CELL, V9, P1018, DOI 10.1111/j.1474-9726.2010.00632.x; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Higgins GC, 2010, J ALZHEIMERS DIS, V20, pS453, DOI 10.3233/JAD-2010-100321; Hishiya A, 2006, EMBO J, V25, P554, DOI 10.1038/sj.emboj.7600945; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Johri A, 2012, HUM MOL GENET, V21, P1124, DOI 10.1093/hmg/ddr541; Katsouri L, 2011, J ALZHEIMERS DIS, V25, P151, DOI 10.3233/JAD-2011-101356; Keeney PM, 2009, HUM GENE THER, V20, P897, DOI 10.1089/hum.2009.023; Kim J, 2010, HUM MOL GENET, V19, P3919, DOI 10.1093/hmg/ddq306; Launay N, 2013, BRAIN, V136, P891, DOI 10.1093/brain/aws370; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Liang H, 2009, AM J PHYSIOL-ENDOC M, V296, pE945, DOI 10.1152/ajpendo.90292.2008; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Ma Q, 2010, PHARMACOL THERAPEUT, V125, P376, DOI 10.1016/j.pharmthera.2009.11.004; McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Miura S, 2006, AM J PATHOL, V169, P1129, DOI 10.2353/ajpath.2006.060034; Morais VA, 2010, J ALZHEIMERS DIS, V20, pS255, DOI 10.3233/JAD-2010-100345; Muller WE, 2010, MOL NEUROBIOL, V41, P159, DOI 10.1007/s12035-010-8141-5; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Qin WP, 2009, ARCH NEUROL-CHICAGO, V66, P352, DOI 10.1001/archneurol.2008.588; Ren QG, 2007, FEBS LETT, V581, P1521, DOI 10.1016/j.febslet.2007.02.065; Rona-Voros K, 2010, CURR DRUG TARGETS, V11, P1262, DOI 10.2174/1389450111007011262; Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB; Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006; Sheng BY, 2012, J NEUROCHEM, V120, P419, DOI 10.1111/j.1471-4159.2011.07581.x; Shi QL, 2007, ALZ DIS ASSOC DIS, V21, P276, DOI 10.1097/WAD.0b013e31815721c3; Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tsunemi T., SCI TRANSL MED, V4; Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106; Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yao J, 2011, J NEUROSCI, V31, P2313, DOI 10.1523/JNEUROSCI.4717-10.2011; Zhai WG, 2005, CELL, V123, P1241, DOI 10.1016/j.cell.2005.10.030; Zhao W, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-51; Zheng B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001059	61	34	34	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1745	1755		10.1096/fj.13-236331	http://dx.doi.org/10.1096/fj.13-236331			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24398293	Green Published			2022-12-28	WOS:000335344300021
J	Gupta, P; Giri, J; Srivastav, S; Chande, AG; Mukhopadhyaya, R; Das, PK; Ukil, A				Gupta, Purnima; Giri, Jayeeta; Srivastav, Supriya; Chande, Ajit G.; Mukhopadhyaya, Robin; Das, Pijush K.; Ukil, Anindita			Leishmania donovani targets tumor necrosis factor receptor-associated factor (TRAF) 3 for impairing TLR4-mediated host response	FASEB JOURNAL			English	Article						signalosome; ubiquitination; macrophage	EXPERIMENTAL VISCERAL LEISHMANIASIS; NF-KAPPA-B; TOLL-LIKE RECEPTORS; IMMUNE-RESPONSE; PROTEIN; UBIQUITINATION; ACTIVATION; INFECTION; TOLL-LIKE-RECEPTOR-4; PROMASTIGOTES	Intramacrophage pathogen Leishmania donovani escapes host immune response by subverting Toll-like receptor (TLR) signaling, which is critically regulated by protein ubiquitination. In the present study, we identified tumor necrosis factor receptor-associated factor (TRAF) 3, degradative ubiquitination of which is essential for TLR4 activation, as a target for Leishmania to deactivate LPS-mediated TLR4 signaling. We used LPS-treated RAW 264.7 cells and compared the TLR4-mediated immune response in these cells with L. donovani and L. donovani + LPS costimulated macrophages. TRAF3, which was ubiquitinated (2.1-fold over control) at lys 48 position and subsequently degraded following LPS treatment, persisted in L. donovani and L. donovani + LPS costimulated cells due to defective lys 48 ubiquitination. Lys 63-linked ubiquitination of upstream proteins in the cascade (cIAP1/2 and TRAF6), mandatory for TRAF3 degradation, was also reduced postinfection. This may be attributed to reduced association between ubiquitin-conjugating enzyme Ubc13 and TRAF6 during infection. Inhibition of TRAF3 before infection by shRNA in Balb/c mice showed enhanced IL-12 and TNF-alpha (10.8- and 8.1-fold over infected control) and decreased spleen parasite burden (61.3% suppression, P < 0.001), thereby marking reduction in disease progression. Our findings identified TRAF3 as a novel molecular regulator exploited by Leishmania for successful infection.-Gupta, P., Giri, J., Srivastav, S., Chande, A. G., Mukhopadhyaya, R., Das, P. K., Ukil, A. Leishmania donovani targets tumor necrosis factor receptor-associated factor (TRAF) 3 for impairing TLR4-mediated host response.	[Gupta, Purnima; Giri, Jayeeta; Ukil, Anindita] Univ Calcutta, Dept Biochem, Kolkata 700019, India; [Srivastav, Supriya; Das, Pijush K.] Indian Inst Chem Biol, CSIR, Infect Dis & Immunol Div, Kolkata, India; [Chande, Ajit G.; Mukhopadhyaya, Robin] Tata Mem Hosp, ACTREC, Virol Lab, Kharghar, Navi Mumbai, India	University of Calcutta; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital	Ukil, A (corresponding author), Univ Calcutta, Dept Biochem, 35 Ballygunge Circular Rd, Kolkata 700019, India.	aninditau@yahoo.com	Chande, Ajit/K-5031-2014; Gupta, Purnima/AAP-8717-2020	Chande, Ajit/0000-0003-2210-5180; GIRI, JAYEETA/0000-0002-2688-7274; Gupta, Purnima/0000-0003-4389-3024	Department of Science and Technology (DST); University Grants Commission (UGC); Department of Biotechnology (DBT); Council of Scientific and Industrial Research (CSIR), Government of India	Department of Science and Technology (DST)(Department of Science & Technology (India)); University Grants Commission (UGC)(University Grants Commission, India); Department of Biotechnology (DBT)(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research (CSIR), Government of India(Council of Scientific & Industrial Research (CSIR) - India)	This work was supported by the Department of Science and Technology (DST), University Grants Commission (UGC), Department of Biotechnology (DBT), and Council of Scientific and Industrial Research (CSIR), Government of India.	ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; Ball WB, 2011, J IMMUNOL, V187, P1322, DOI 10.4049/jimmunol.1004237; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Depledge DP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000829; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Faria Marilia S., 2012, Journal of Parasitology Research, P930257, DOI 10.1155/2012/930257; Flandin JF, 2006, EUR J IMMUNOL, V36, P411, DOI 10.1002/eji.200535079; Gallego C, 2011, INFECT IMMUN, V79, P2871, DOI 10.1128/IAI.01388-10; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Kar S, 2010, J LEUKOCYTE BIOL, V88, P9, DOI 10.1189/jlb.0909644; Karin M, 2009, IMMUNOL REV, V228, P225, DOI 10.1111/j.1600-065X.2008.00755.x; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Komander D, 2009, BIOCHEM SOC T, V37, P937, DOI 10.1042/BST0370937; Kropf P, 2004, INFECT IMMUN, V72, P1920, DOI 10.1128/IAI.72.4.1920-1928.2004; Kropf P, 2004, J LEUKOCYTE BIOL, V76, P48, DOI 10.1189/jlb.1003484; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muraille E, 2003, J IMMUNOL, V170, P4237, DOI 10.4049/jimmunol.170.8.4237; MURRAY HW, 1993, J IMMUNOL, V151, P929; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Olivier M, 2005, CLIN MICROBIOL REV, V18, P293, DOI 10.1128/CMR.18.2.293-305.2005; Pei Y, 2006, NAT METHODS, V3, P670, DOI 10.1038/NMETH911; Ruhland A, 2007, CELL MICROBIOL, V9, P84, DOI 10.1111/j.1462-5822.2006.00769.x; Ruse M, 2006, IMMUNOL RES, V34, P33, DOI 10.1385/IR:34:1:33; Santhosh CV, 2008, BIOCHEM BIOPH RES CO, V371, P546, DOI 10.1016/j.bbrc.2008.04.106; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Shibolet O, 2007, AM J PHYSIOL-GASTR L, V292, pG1469, DOI 10.1152/ajpgi.00531.2006; Silverman JM, 2012, FRONT CELL INFECT MI, V1, DOI 10.3389/fcimb.2011.00026; Srivastav S, 2012, J IMMUNOL, V189, P924, DOI 10.4049/jimmunol.1102845; Sun SC, 2008, NAT REV IMMUNOL, V8, P501, DOI 10.1038/nri2337; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tseng PH, 2010, NAT IMMUNOL, V11, P70, DOI 10.1038/ni.1819; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5	36	25	26	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1756	1768		10.1096/fj.13-238428	http://dx.doi.org/10.1096/fj.13-238428			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24391131				2022-12-28	WOS:000335344300022
J	Keuper, M; Jastroch, M; Yi, CX; Fischer-Posovszky, P; Wabitsch, M; Tschop, MH; Hofmann, SM				Keuper, Michaela; Jastroch, Martin; Yi, Chun-Xia; Fischer-Posovszky, Pamela; Wabitsch, Martin; Tschoep, Matthias H.; Hofmann, Susanna M.			Spare mitochondrial respiratory capacity permits human adipocytes to maintain ATP homeostasis under hypoglycemic conditions	FASEB JOURNAL			English	Article						glycolysis; lactate secretion; oxidative phosphorylation; hyperglycemic	INSULIN-RESISTANCE; ADIPOSE-TISSUE; LACTATE RELEASE; OBESITY; CELLS; DIFFERENTIATION; ROSIGLITAZONE; BIOLOGY; STRESS; MICE	Mitochondrial dysfunction in white adipose tissue plays a key role in the pathogenesis of type 2 diabetes. Emerging evidence specifically suggests that altered oxidative phosphorylation in adipocytes may have a relevant effect on systemic glucose homeostasis, requiring understanding of adipocyte bioenergetics. We analyzed energetic flux of an intact human adipocyte cell model by plate-based respirometry and extracellular acidification. During differentiation, we discovered that glycolytic ATP production was increasingly replaced by mitochondrial oxidative metabolism (from 20 to 60%). This observation was corroborated by simultaneous up-regulation of canonical mitochondrial gene programs, such as peroxisome proliferator-activated receptor coactivator (PGC1; 150-fold) and cytochrome c-1 (CytC; 3-fold). Mimicking diabetic phenotypes by exposure to various glucose levels (0, 5, and 25 mM) resulted in immediate adjustments of glycolytic and mitochondrial activity that aimed to maintain intracellular ATP. We conclude that ATP deficits by mitochondrial failure are compensated by glycolytic ATP production, resulting in inefficient conversion of glucose to cellular ATP. Metabolic inefficiency may enhance glucose uptake, therefore improving systemic glucose homeostasis. Notably, mature adipocytes developed a high spare respiratory capacity (increased by 6-fold) permitting rapid adaptation to metabolic changes. Spare respiratory capacity may also allow additional metabolic scope for energy dissipation, potentially offering new therapeutic targets for the treatment of metabolic disease.Keuper, M., Jastroch, M., Yi, C.-X., Fischer-Posovszky, P., Wabitsch, M., Tschop, M. H., Hofmann, S. M. Spare mitochondrial respiratory capacity permits human adipocytes to maintain ATP homeostasis under hypoglycemic conditions.	[Keuper, Michaela; Hofmann, Susanna M.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Diabet & Regenerat Res, D-85764 Neuherberg, Germany; [Jastroch, Martin; Yi, Chun-Xia; Tschoep, Matthias H.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Diabet & Obes, D-85764 Neuherberg, Germany; [Jastroch, Martin; Yi, Chun-Xia; Tschoep, Matthias H.] Tech Univ Munich, D-80290 Munich, Germany; [Fischer-Posovszky, Pamela; Wabitsch, Martin] Univ Ulm, Med Ctr, Dept Pediat & Adolescent Med, Div Pediat Endocrinol & Diabet, D-89069 Ulm, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Ulm University	Keuper, M (corresponding author), German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Diabet & Regenerat Res, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	michaela.keuper@helmholtz-muenchen.de	Hofmann, Susanna/F-2654-2014; Tschoep, Matthias H/I-5443-2014; Jastroch, Martin/I-7494-2017; Yi, Chun-Xia/J-4068-2016	Hofmann, Susanna/0000-0001-7682-5840; Yi, Chun-Xia/0000-0003-1184-4615; Fischer-Posovszky, Pamela/0000-0003-3402-9840; Keuper, Michaela/0000-0003-0319-3509; Tschoep, Matthias/0000-0002-4744-371X	Helmholtz Alliance ICEMED (Imaging and Curing Environmental Metabolic Diseases) through the Initiative and Network Fund of the Helmholtz Association	Helmholtz Alliance ICEMED (Imaging and Curing Environmental Metabolic Diseases) through the Initiative and Network Fund of the Helmholtz Association	This work was funded (in part) by the Helmholtz Alliance ICEMED (Imaging and Curing Environmental Metabolic Diseases) through the Initiative and Network Fund of the Helmholtz Association. The authors declare no conflicts of interest.	Affourtit C, 2011, FREE RADICAL BIO MED, V50, P609, DOI 10.1016/j.freeradbiomed.2010.12.020; Bottcher H, 1996, INT J OBESITY, V20, P874; Brand MD, 2005, BIOCHEM SOC T, V33, P897, DOI 10.1042/BST0330897; Choo HJ, 2006, DIABETOLOGIA, V49, P784, DOI 10.1007/s00125-006-0170-2; Collins JM, 2011, J LIPID RES, V52, P1683, DOI 10.1194/jlr.M012195; Crawford SO, 2010, INT J EPIDEMIOL, V39, P1647, DOI 10.1093/ije/dyq126; de Heredia FP, 2010, PFLUG ARCH EUR J PHY, V459, P509, DOI 10.1007/s00424-009-0750-3; Ducluzeau PH, 2011, J PHYSIOL BIOCHEM, V67, P285, DOI 10.1007/s13105-011-0074-6; Fischer-Posovszky P, 2008, OBESITY FACTS, V1, P184, DOI 10.1159/000145784; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Guo X, 2012, ACTA PHARM SIN B, V2, P358, DOI 10.1016/j.apsb.2012.06.002; Jastroch M, 2012, BBA-BIOENERGETICS, V1817, P1660, DOI 10.1016/j.bbabio.2012.05.014; Juraschek S. P., 2013, PLOS ONE, V8; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Keuper Michaela, 2011, Front Endocrinol (Lausanne), V2, P89, DOI 10.3389/fendo.2011.00089; Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472; Kita T, 2009, J BIOCHEM, V146, P787, DOI 10.1093/jb/mvp124; Kusminski CM, 2012, NAT MED, V18, P1539, DOI 10.1038/nm.2899; Newton BW, 2011, J PROTEOME RES, V10, P4692, DOI 10.1021/pr200491h; Nicholls DG, 2009, BIOCHEM SOC T, V37, P1385, DOI 10.1042/BST0371385; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Qvisth V, 2007, AM J PHYSIOL-ENDOC M, V292, pE709, DOI 10.1152/ajpendo.00104.2006; Si Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007000; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Vernochet C, 2012, CELL METAB, V16, P765, DOI 10.1016/j.cmet.2012.10.016; von Heimburg D, 2005, RESP PHYSIOL NEUROBI, V146, P107, DOI 10.1016/j.resp.2004.12.013; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Wang T, 2010, OBESITY, V18, P1493, DOI 10.1038/oby.2009.456; Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003; Yehuda-Shnaidman E, 2010, DIABETES, V59, P2474, DOI 10.2337/db10-0245; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855	32	53	53	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					761	770		10.1096/fj.13-238725	http://dx.doi.org/10.1096/fj.13-238725			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24200885				2022-12-28	WOS:000331072200023
J	Pinto, VI; Senini, VW; Wang, YQ; Kazembe, MP; McCulloch, CA				Pinto, Vanessa I.; Senini, Vincent W.; Wang, Yongqiang; Kazembe, Mwayi P.; McCulloch, Christopher A.			Filamin A protects cells against force-induced apoptosis by stabilizing talin-and vinculin-containing cell adhesions	FASEB JOURNAL			English	Article						periodontal ligament; mechanoprotection; cell death; anoikis; integrins	PERIODONTAL-LIGAMENT; TOOTH MOVEMENT; INTEGRIN BINDING; ACTIN; PHOSPHORYLATION; STRETCH; FILGAP; DEATH; EXPRESSION; MECHANISM	In mechanically loaded tissues such as weight-bearing joints, myocardium, and periodontal ligament, pathophysiological forces can disrupt cell-matrix contacts, which can induce cell death, leading to tissue and organ dysfunction. Protection against force-induced cell death may be mediated by filamin A (FLNa), an actin-binding protein that regulates 1 integrin-mediated cell adhesion. We examined the affect of filamin expression on collagen distribution and cell death in the periodontal ligament, a force-loaded tissue. Conditional deletion of FLNa in fibroblasts was associated with 2-fold increase of acellular areas in periodontal ligament and 7-fold higher proportions of apoptotic cells. In cultured fibroblasts with FLNa knockdown, we examined the affect of supraphysiological forces (1 pN/m(2) cell area; applied through the 1 integrin) on recruitment of talin and vinculin to focal adhesions and on apoptosis. Compared with the wild type, FLNa-knockdown cells exhibited 3-fold increases in floating cells after overnight force application and a 2-fold increase in cell detachment. Force induced time-dependent reductions (P<0.05) in the numbers of activated 1 integrin-, talin-, and vinculin-stained adhesions in FLNa-knockdown compared with those in wild-type cells. We conclude that FLNa protects against apoptosis in force-loaded cells, and this protection is mediated by enhanced formation and maturation of matrix adhesions.Pinto, V. I., Senini, V. W., Wang, Y., Kazembe, M. P., McCulloch, C. A. Filamin A protects cells against force-induced apoptosis by stabilizing talin and vinculin-containing cell adhesions.	[Pinto, Vanessa I.; Senini, Vincent W.; Wang, Yongqiang; Kazembe, Mwayi P.; McCulloch, Christopher A.] Univ Toronto, Fac Dent, Matrix Dynam Grp, Toronto, ON M5S 3E2, Canada	University of Toronto	Pinto, VI (corresponding author), Univ Toronto, Room 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	v.pinto@utoronto.ca			Canadian Institute of Health Research [MOP-490422]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	The authors gratefully acknowledge Cheung Lo for his assistance in the mandible dissections and explant cultures. Research was supported by Canadian Institute of Health Research operating grant MOP-490422 to C.A.M.	ATRIZADEH F, 1971, Journal of Periodontal Research, V6, P159, DOI 10.1111/j.1600-0765.1971.tb00604.x; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Carisey A, 2013, CURR BIOL, V23, P271, DOI 10.1016/j.cub.2013.01.009; Chen HS, 2009, BIOPHYS J, V97, P3095, DOI 10.1016/j.bpj.2009.08.059; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Choi CK, 2008, NAT CELL BIOL, V10, P1039, DOI 10.1038/ncb1763; Das M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026355; del Rio A, 2009, SCIENCE, V323, P638, DOI 10.1126/science.1162912; Ehrlicher AJ, 2011, NATURE, V478, P260, DOI 10.1038/nature10430; Feng YY, 2006, P NATL ACAD SCI USA, V103, P19836, DOI 10.1073/pnas.0609628104; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Glogauer M, 1997, J CELL SCI, V110, P11; Goult BT, 2013, J BIOL CHEM, V288, P8238, DOI 10.1074/jbc.M112.438119; Grashoff C, 2010, NATURE, V466, P263, DOI 10.1038/nature09198; Hao Y, 2009, ARCH ORAL BIOL, V54, P864, DOI 10.1016/j.archoralbio.2009.05.012; Hsieh MH, 2005, INT REV CYTOL, V245, P45, DOI 10.1016/S0074-7696(05)45003-2; Janmey PA, 2004, TRENDS BIOCHEM SCI, V29, P364, DOI 10.1016/j.tibs.2004.05.003; Jeon PD, 1999, AM J ORTHOD DENTOFAC, V115, P267, DOI 10.1016/S0889-5406(99)70328-8; Kainulainen T, 2002, J BIOL CHEM, V277, P21998, DOI 10.1074/jbc.M200715200; Kiema T, 2006, MOL CELL, V21, P337, DOI 10.1016/j.molcel.2006.01.011; Kim C., ANN REV CELL DEV BIO, V27, P321; Kim C, 2011, ANNU REV CELL DEV BI, V27, P321, DOI 10.1146/annurev-cellbio-100109-104104; Kim H, 2008, EXP CELL RES, V314, P834, DOI 10.1016/j.yexcr.2007.11.022; Kim H, 2010, EXP CELL RES, V316, P1829, DOI 10.1016/j.yexcr.2010.02.007; Kurol J, 1998, ANGLE ORTHOD, V68, P161; Lee HS, 2013, MOL BIOL CELL, V24, P1354, DOI 10.1091/mbc.E12-09-0695; Lee SE, 2008, BIOPHYS J, V95, P2027, DOI 10.1529/biophysj.107.124487; LINDSKOG S, 1985, Endodontics and Dental Traumatology, V1, P96; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; Mak BC, 2008, J BIOL CHEM, V283, P23462, DOI 10.1074/jbc.M803194200; MCCULLOCH CAG, 1989, CELL TISSUE RES, V255, P129; MCCULLOCH CAG, 1983, J PERIODONTAL RES, V18, P339, DOI 10.1111/j.1600-0765.1983.tb00369.x; MCCULLOCH CAG, 1983, AM J ANAT, V167, P43, DOI 10.1002/aja.1001670105; McCulloch CAG, 2000, PERIODONTOL 2000, V24, P56, DOI 10.1034/j.1600-0757.2000.2240104.x; Mohammad I, 2012, FASEB J, V26, P3260, DOI 10.1096/fj.11-202051; Naveh GRS, 2013, J STRUCT BIOL, V181, P108, DOI 10.1016/j.jsb.2012.10.008; Ohta Y, 2006, NAT CELL BIOL, V8, P803, DOI 10.1038/ncb1437; Pentikainen U, 2009, J MOL BIOL, V393, P644, DOI 10.1016/j.jmb.2009.08.035; Rajshankar D, 2012, FASEB J, V26, P4429, DOI 10.1096/fj.12-207381; REITAN K, 1967, AMER J ORTHODONTICS, V53, P721, DOI 10.1016/0002-9416(67)90118-2; Ritter N, 2007, CELL TISSUE RES, V328, P537, DOI 10.1007/s00441-007-0382-x; Rygh P, 1974, Nor Tannlaegeforen Tid, V84, P352; Shifrin Y, 2012, BIOCHEM J, V445, P57, DOI 10.1042/BJ20112119; Shifrin Y, 2009, MOL BIOL CELL, V20, P1269, DOI 10.1091/mbc.E08-08-0872; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Shyu KG, 2009, CLIN SCI, V116, P377, DOI 10.1042/CS20080163; Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000; Trombetta JM, 2010, J HISTOCHEM CYTOCHEM, V58, P871, DOI 10.1369/jhc.2010.956144; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Verborgt O, 2002, J BONE MINER RES, V17, P907, DOI 10.1359/jbmr.2002.17.5.907; Verderio EAM, 2003, J BIOL CHEM, V278, P42604, DOI 10.1074/jbc.M303303200; Von Bohl M, 2004, ANGLE ORTHOD, V74, P16; Wang Q, 2006, J BIOL CHEM, V281, P31093, DOI 10.1074/jbc.M606392200; Wehrle-Haller B, 2012, CURR OPIN CELL BIOL, V24, P116, DOI 10.1016/j.ceb.2011.11.001; Zhong W, 2008, ORAL DIS, V14, P270, DOI 10.1111/j.1601-0825.2007.01375.x	59	26	26	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					453	463		10.1096/fj.13-233759	http://dx.doi.org/10.1096/fj.13-233759			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24097310	Green Submitted			2022-12-28	WOS:000333526100042
J	Wolfs, IMJ; Stoger, JL; Goossens, P; Pottgens, C; Gijbels, MJJ; Wijnands, E; van der Vorst, EPC; van Gorp, P; Beckers, L; Engel, D; Biessen, EAL; Kraal, G; van Die, I; Donners, MMPC; de Winther, MPJ				Wolfs, Ine M. J.; Stoger, J. Lauran; Goossens, Pieter; Pottgens, Chantal; Gijbels, Marion J. J.; Wijnands, Erwin; van der Vorst, Emiel P. C.; van Gorp, Patrick; Beckers, Linda; Engel, David; Biessen, Erik A. L.; Kraal, Georg; van Die, Irma; Donners, Marjo M. P. C.; de Winther, Menno P. J.			Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis	FASEB JOURNAL			English	Article						immune modulation; monocytes; inflammation; schistosome; mouse	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SCHISTOSOMA-MANSONI ANTIGENS; TRICHURIS-SUIS THERAPY; SOLUBLE EGG ANTIGEN; IMMUNE-RESPONSE; TH2 RESPONSES; IN-VIVO; MICE; ACTIVATION; DISEASE	Atherosclerosis is a lipid-driven inflammatory disease of the vessel wall, characterized by the chronic activation of macrophages. We investigated whether the helminth-derived antigens [soluble egg antigens (SEAs)] could modulate macrophage inflammatory responses and protect against atherosclerosis in mice. In bone marrow-derived macrophages, SEAs induce anti-inflammatory macrophages, typified by high levels of IL-10 and reduced secretion of proinflammatory mediators. In hyperlipidemic LDLR-/- mice, SEA treatment reduced plaque size by 44%, and plaques were less advanced compared with PBS-injected littermate controls. The atheroprotective effect of SEAs was found to be mainly independent of cholesterol lowering and T-lymphocyte responses but instead could be attributed to diminished myeloid cell activation. SEAs reduced circulating neutrophils and inflammatory Ly6C(high) monocytes, and macrophages showed high IL-10 production. In line with the observed systemic effects, atherosclerotic lesions of SEA-treated mice showed reduced intraplaque inflammation as inflammatory markers [TNF-, monocyte chemotactic protein 1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and CD68], neutrophil content, and newly recruited macrophages were decreased. We show that SEA treatment protects against atherosclerosis development by dampening inflammatory responses. In the future, helminth-derived components may provide novel opportunities to treat chronic inflammatory diseases, as they diminish systemic inflammation and reduce the activation of immune cells.Wolfs, I. M. J., Stoger, J. L., Goossens, P., Pottgens, C., Gijbels, M. J. J., Wijnands, E., van der Vorst, E. P. C., van Gorp, P., Beckers, L., Engel, D., Biessen, E. A. L., Kraal, G., van Die, I., Donners, M. M. P. C., de Winther, M. P. J. Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis.	[Wolfs, Ine M. J.; Stoger, J. Lauran; Goossens, Pieter; Pottgens, Chantal; Gijbels, Marion J. J.; van der Vorst, Emiel P. C.; van Gorp, Patrick; Donners, Marjo M. P. C.; de Winther, Menno P. J.] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Mol Genet, Maastricht, Netherlands; [Wolfs, Ine M. J.; Gijbels, Marion J. J.; Wijnands, Erwin; Beckers, Linda; Engel, David; Biessen, Erik A. L.; Donners, Marjo M. P. C.] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Pathol, Maastricht, Netherlands; [Pottgens, Chantal] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Physiol, Maastricht, Netherlands; [Stoger, J. Lauran; Gijbels, Marion J. J.; Beckers, Linda; de Winther, Menno P. J.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands; [Goossens, Pieter] Aix Marseille Univ, Ctr Immunol Marseille Luminy, Marseille, France; [Kraal, Georg; van Die, Irma] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands	Maastricht University; Maastricht University; Maastricht University; University of Amsterdam; Academic Medical Center Amsterdam; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Vrije Universiteit Amsterdam	de Winther, MPJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Rm L01-146-2,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.dewinther@amc.uva.nl	van Gorp, Patrick/L-9580-2018; van Gorp, Patrick/S-3892-2019; Stöger, Lauran/AAE-9667-2021; Stoger, Lauran/AAX-5117-2021	van Gorp, Patrick/0000-0002-0355-5349; van Gorp, Patrick/0000-0002-0355-5349; Stöger, Lauran/0000-0002-4705-4837; Goossens, Pieter/0000-0002-7269-6372; Biessen, Erik/0000-0002-6454-8548; de Winther, Menno/0000-0002-4038-6636	Netherlands Heart Foundation [2007T034, 2012T079, 2007T067]; Nederlandse Organisatie voor Wetenschappelijk Onderz (NWO)-Vidi [917.066.329]	Netherlands Heart Foundation(Netherlands Heart Foundation); Nederlandse Organisatie voor Wetenschappelijk Onderz (NWO)-Vidi	M.M.P.C.D. and M.P.J.D.W. are supported by The Netherlands Heart Foundation (Dr. E. Dekker postdoctoral fellow grants 2007T034 and 2012T079 to M. M. P. C. D.; Dr. E. Dekker investigator grant 2007T067 to M.P.J.D.W.) and Nederlandse Organisatie voor Wetenschappelijk Onderz (NWO)-Vidi grant 917.066.329 (to M.P.J.D.W.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest.	ASSAADKHALIL SH, 1992, ANN BIOL CLIN-PARIS, V50, P697; Atochina O, 2006, EXP DERMATOL, V15, P461, DOI 10.1111/j.1600-0625.2006.00431.x; Atochina O, 2008, IMMUNOLOGY, V125, P111, DOI 10.1111/j.1365-2567.2008.02826.x; Bhargava P, 2012, NAT MED, V18, P1665, DOI 10.1038/nm.2962; BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488; Bouhlel MA, 2008, J INTERN MED, V263, P28, DOI 10.1111/j.1365-2796.2007.01892.x; Boyle J. J., 2005, Current Vascular Pharmacology, V3, P63, DOI 10.2174/1570161052773861; Burton OT, 2010, EUR J IMMUNOL, V40, P2221, DOI 10.1002/eji.200939998; Cooke A, 1999, PARASITE IMMUNOL, V21, P169, DOI 10.1046/j.1365-3024.1999.00213.x; Correale J, 2009, J IMMUNOL, V183, P5999, DOI 10.4049/jimmunol.0900897; Doenhoff MJ, 2002, PARASITOLOGY, V125, P415, DOI 10.1017/S0031182002002275; Dunne DW, 2005, NAT REV IMMUNOL, V5, P420, DOI 10.1038/nri1601; Eefting D, 2007, ATHEROSCLEROSIS, V193, P335, DOI 10.1016/j.atherosclerosis.2006.09.032; Everts B, 2009, J EXP MED, V206, P1673, DOI 10.1084/jem.20082460; Feig JE, 2011, CIRCULATION, V123, P989, DOI 10.1161/CIRCULATIONAHA.110.984146; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Fu GX, 2012, ENDOCRINE, V42, P676, DOI 10.1007/s12020-012-9675-2; Goh F, 2009, IMMUNOLOGY, V127, P326, DOI 10.1111/j.1365-2567.2008.02979.x; Goossens P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022327; Goossens P, 2010, CELL METAB, V12, P142, DOI 10.1016/j.cmet.2010.06.008; GRZYCH JM, 1991, J IMMUNOL, V146, P1322; Han XB, 2010, FASEB J, V24, P2869, DOI 10.1096/fj.09-148155; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Harnett W, 2010, NAT REV IMMUNOL, V10, P278, DOI 10.1038/nri2730; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Khallou-Laschet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008852; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; Kuijk LM, 2010, IUBMB LIFE, V62, P303, DOI 10.1002/iub.304; La Flamme AC, 2007, PARASITE IMMUNOL, V29, P259, DOI 10.1111/j.1365-3024.2007.00942.x; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Nagayama Y, 2004, J IMMUNOL, V173, P2167, DOI 10.4049/jimmunol.173.3.2167; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Pancre V, 1999, IMMUNOLOGY, V98, P525, DOI 10.1046/j.1365-2567.1999.00887.x; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Pearce EJ, 1996, INT IMMUNOL, V8, P435, DOI 10.1093/intimm/8.4.435; Potteaux S, 2011, J CLIN INVEST, V121, P2025, DOI 10.1172/JCI43802; Schramm G, 2010, MICROBES INFECT, V12, P881, DOI 10.1016/j.micinf.2010.06.001; Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Smith P, 2007, J IMMUNOL, V178, P4557, DOI 10.4049/jimmunol.178.7.4557; Stoger JL, 2012, ATHEROSCLEROSIS, V225, P461, DOI 10.1016/j.atherosclerosis.2012.09.013; Summers RW, 2005, INFLAMM BOWEL DIS, V11, P783, DOI 10.1097/01.MIB.0000179316.50002.f3; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Thomas PG, 2005, J IMMUNOL, V175, P2082, DOI 10.4049/jimmunol.175.4.2082; van der Valk FM, 2012, CURR OPIN LIPIDOL, V23, P532, DOI 10.1097/MOL.0b013e3283587543; van Die I, 2010, GLYCOBIOLOGY, V20, P2, DOI 10.1093/glycob/cwp140; Weinstock JV, 2012, NATURE, V491, P183, DOI 10.1038/491183a; Zaccone P, 2003, EUR J IMMUNOL, V33, P1439, DOI 10.1002/eji.200323910; Zaccone P, 2011, EUR J IMMUNOL, V41, P2709, DOI 10.1002/eji.201141429; Zaccone P, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/795210; Zaccone P, 2009, EUR J IMMUNOL, V39, P1098, DOI 10.1002/eji.200838871; Zheng XP, 2008, J NEUROIMMUNOL, V194, P107, DOI 10.1016/j.jneuroim.2007.12.001	57	61	66	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					288	299		10.1096/fj.13-235911	http://dx.doi.org/10.1096/fj.13-235911			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24043262	Green Submitted			2022-12-28	WOS:000333526100028
J	Hakim, A; Barnes, PJ; Adcock, IM; Usmani, OS				Hakim, Amir; Barnes, Peter J.; Adcock, Ian M.; Usmani, Omar S.			Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity	FASEB JOURNAL			English	Article						inflammation; hydrogen peroxide; oxidative stress; Ran-GTP; chronic obstructive pulmonary disease	FACTOR-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY INFLAMMATION; HYDROGEN-PEROXIDE; TRANSPORT; ASTHMA; CORTICOSTEROIDS; LOCALIZATION; INHIBITION; PROTEINS	Some patients with severe inflammatory disease fail to respond to glucocorticoids, and oxidative stress contributes to this insensitivity. Importin receptors are associated with nuclear translocation of the glucocorticoid receptor (GR), which is essential for glucocorticoid function. We hypothesized that importin-7 is central to GR nuclear translocation and glucocorticoid sensitivity. We investigated the effects of importin-7 siRNA on fluticasone propionate (FP)-induced GR nuclear localization and suppression of IL-1-induced CXCL8 and the effects of hydrogen peroxide (H2O2) plus IL-1 costimulation on importin-7 expression, function, and glucocorticoid responsiveness in a human macrophagecell line (U937). H2O2 significantly reduced FP-induced GR nuclear localization (3.4 +/- 0.51- vs. 5.7 +/- 0.85-fold increase, P<0.05) and suppression of IL-1-induced CXCL8 (62.3 +/- 2.3 vs. 85.1 +/- 7.0%, P<0.05). Knockdown of importin-7 by 38.4 +/- 11.5% (compared with control siRNA) significantly reduced FP-mediated GR nuclear localization (3.5 +/- 0.5- vs. 5.7 +/- 0.85-fold increase, P<0.05) and suppression of IL-1-induced CXCL8 expression (40.2 +/- 16.1 vs. 68.4 +/- 3.0%, P<0.05). H2O2 plus IL-1 had no direct effect on importin-7 but caused a significant loss (61.2 +/- 12.6% compared with baseline) of nuclear RanGTP, an essential cofactor for importin-7-mediated nuclear import of cargo proteins. The importin-7 complex is essential for glucocorticoid function, and the expression of its cofactor RanGTP is reduced during oxidative stress-induced glucocorticoid insensitivity.Hakim, A., Barnes, P. J., Adcock, I. M., Usmani, O. S. Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Royal Brompton Hosp, London SW3 6LY, England	Imperial College London; Royal Brompton Hospital	Hakim, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, Dovehouse St, London SW3 6LY, England.	a.hakim08@imperial.ac.uk	Adcock, Ian/L-3217-2019	Barnes, Peter/0000-0002-5122-4018; hakim, amir/0000-0002-4884-3141; Adcock, Ian/0000-0003-2101-8843	UK National Institute for Health Research (NIHR); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London; Medical Research Council [G1000758B, MC_PC_13033, G1000758] Funding Source: researchfish; National Institute for Health Research [CDF-2011-04-053, NF-SI-0611-10148] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish; MRC [MC_PC_13033] Funding Source: UKRI	UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	O.S.U. is a recipient of a UK National Institute for Health Research (NIHR) Career Development Fellowship. This article was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.	Adcock Ian M., 1996, Biochemical Society Transactions, V24, p267S; Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771, DOI 10.1164/ajrccm.154.3.8810618; Balfour-Lynn I. M., 2001, COCHRANE DB SYST REV, DOI DOI 10.1021/4651858; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Barnes PJ, 2006, EUR J PHARMACOL, V533, P2, DOI 10.1016/j.ejphar.2005.12.052; Chung KF, 2010, ANN NY ACAD SCI, V1203, P85, DOI 10.1111/j.1749-6632.2010.05600.x; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Davies Huw R, 2002, Am J Respir Med, V1, P211; Dekhuijzen PNR, 1996, AM J RESP CRIT CARE, V154, P813, DOI 10.1164/ajrccm.154.3.8810624; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Enesa K, 2008, J BIOL CHEM, V283, P18582, DOI 10.1074/jbc.M801312200; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Gagliardo R, 2011, J ALLERGY CLIN IMMUN, V128, P635, DOI 10.1016/j.jaci.2011.03.045; Galigniana MD, 2010, NUCLEUS-PHILA, V1, P299, DOI 10.4161/nucl.1.4.11743; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hattotuwa KL, 2002, AM J RESP CRIT CARE, V165, P1592, DOI 10.1164/rccm.2105025; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042, DOI 10.1164/ajrccm.158.4.9710091; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Isajevs S, 2011, RESPIRATION, V81, P362, DOI 10.1159/000322560; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Kirkham P, 2006, PHARMACOL THERAPEUT, V111, P476, DOI 10.1016/j.pharmthera.2005.10.015; Kodiha M, 2004, CELL DEATH DIFFER, V11, P862, DOI 10.1038/sj.cdd.4401432; Kodiha Mohamed, 2012, J Signal Transduct, V2012, P208650, DOI 10.1155/2012/208650; Lee KY, 2012, EUR RESPIR J, V40, P863, DOI 10.1183/09031936.00146811; Makris D, 2008, RESPIRATION, V75, P138, DOI 10.1159/000106377; Marin-Corral J, 2009, EUR RESPIR J, V33, P1309, DOI 10.1183/09031936.00072008; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Mercado N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041582; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; Patel PS, 2002, J INTERF CYTOK RES, V22, P427, DOI 10.1089/10799900252952217; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Raby BA, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-67; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Stochaj U, 2000, FASEB J, V14, P2130, DOI 10.1096/fj.99-0751fje; Strambio-De-Castillia C, 2010, NAT REV MOL CELL BIO, V11, P490, DOI 10.1038/nrm2928; Suissa S, 2009, EUR RESPIR J, V34, P13, DOI 10.1183/09031936.00190908; Tao T, 2006, AM J RESP CELL MOL, V35, P668, DOI 10.1165/rcmb.2006-0073OC; Tchen CR, 2010, J BIOL CHEM, V285, P2642, DOI 10.1074/jbc.M109.037309; To Y, 2010, AM J RESP CRIT CARE, V182, P897, DOI 10.1164/rccm.200906-0937OC; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; Vandevyver S, 2012, TRAFFIC, V13, P364, DOI 10.1111/j.1600-0854.2011.01288.x; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Wagstaff KM, 2009, TRAFFIC, V10, P1188, DOI 10.1111/j.1600-0854.2009.00937.x	52	33	36	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4510	4519		10.1096/fj.12-222604	http://dx.doi.org/10.1096/fj.12-222604			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23934279	Bronze			2022-12-28	WOS:000329937500018
J	Boccardi, V; Barbieri, M; Rizzo, MR; Marfella, R; Esposito, A; Marano, L; Paolisso, G				Boccardi, Virginia; Barbieri, Michelangela; Rizzo, Maria Rosaria; Marfella, Raffaele; Esposito, Antonietta; Marano, Luigi; Paolisso, Giuseppe			A new pleiotropic effect of statins in elderly: modulation of telomerase activity	FASEB JOURNAL			English	Article						aging; health span; cellular senescence	ENDOTHELIAL PROGENITOR CELLS; CARDIOVASCULAR-DISEASE; STRESS; SENESCENCE; COMPONENT; THERAPY; LENGTH; SPAN; RISK; GENE	Recent evidence suggests a link between statins and telomere biology. Whether statin treatment may modulate telomerase activity and affect telomere erosion rate is unknown. We aimed at investigating the potential impact of statin therapy on peripheral blood mononuclear cells telomerase activity, its implication on LTL variability, and its association with telomere shortening rates along with aging. The cross-sectional study was conducted in 230 subjects (age range: 30-86 y) stratified according to statins treatment. LTL was measured by quantitative polymerase chain reaction and telomerase activity by a PCR-ELISA protocol. Subjects on statin treatment showed higher telomerase activity (P<0.0001) and longer LTL (P=0.028) levels compared to the nonstatin group. Statin therapy was associated with higher telomerase activity independently of multiple covariates, including age, gender, smoking habits, lipid, systemic inflammation, glucose, and blood pressure levels (P=0.019). Indeed, subjects on statin treatment showed significant lower telomere erosion along with aging. Every 1 y increment in age, LTL decreases by 0.058 Kb in no statin and 0.033 Kb in statin groups, respectively, as well as the major difference in telomere attrition between groups was found after the age of 65 yr (P<0.0001). In summary, statins, modulating telomerase activity, affect telomere erosion along with aging.Boccardi, V., Barbieri, M., Rizzo, M. R., Marfella, R., Esposito, A., Marano, L., Paolisso, G. A new pleiotropic effect of statins in elderly: modulation of telomerase activity	[Boccardi, Virginia; Barbieri, Michelangela; Rizzo, Maria Rosaria; Marfella, Raffaele; Esposito, Antonietta; Marano, Luigi; Paolisso, Giuseppe] Univ Naples 2, Dept Internal Med Surg Neurol Metab Dis & Geriatr, I-80138 Naples, Italy	Universita della Campania Vanvitelli	Paolisso, G (corresponding author), Univ Naples 2, Dept Internal Med Surg Neurol Metab Dis & Geriatr, Div Internal Med 6, Pzza Miraglia 2, I-80138 Naples, Italy.	giuseppe.paolisso@unina2.it	Boccardi, Virginia/K-2630-2016; Rizzo, Maria Rosaria/AHH-3649-2022; Marano, Luigi/K-4944-2013; paolisso, giuseppe/AAP-8516-2020; Rizzo, Maria/HGD-6576-2022; Barbieri, Michelangela/K-2192-2016; rizzo, maria rosaria R/J-1968-2016; Marfella, Raffaele/AAH-2595-2019	Boccardi, Virginia/0000-0003-2134-1122; Rizzo, Maria Rosaria/0000-0002-1023-4260; Marano, Luigi/0000-0002-9777-9588; paolisso, giuseppe/0000-0002-2137-455X; Barbieri, Michelangela/0000-0002-9223-5792; rizzo, maria rosaria R/0000-0002-1023-4260; Marfella, Raffaele/0000-0003-3960-9270				Assmus B, 2003, CIRC RES, V92, P1049, DOI 10.1161/01.RES.0000070067.64040.7C; de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245; de Jesus BB, 2011, AGING CELL, V10, P604, DOI 10.1111/j.1474-9726.2011.00700.x; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boccardi V, 2012, EMBO MOL MED, V4, P685, DOI 10.1002/emmm.201200246; Brouilette SW, 2007, LANCET, V369, P107, DOI 10.1016/S0140-6736(07)60071-3; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Daubenmier J, 2012, PSYCHONEUROENDOCRINO, V37, P917, DOI 10.1016/j.psyneuen.2011.10.008; Epel ES, 2006, PSYCHONEUROENDOCRINO, V31, P277, DOI 10.1016/j.psyneuen.2005.08.011; Garcia-Cao I, 2006, EMBO REP, V7, P546, DOI 10.1038/sj.embor.7400667; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Hewitt G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1708; Ludman A, 2009, PHARMACOL THERAPEUT, V122, P30, DOI 10.1016/j.pharmthera.2009.01.002; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Muezzinler A, 2013, AGEING RES REV, V12, P509, DOI 10.1016/j.arr.2013.01.003; Saliques S, 2011, ATHEROSCLEROSIS, V219, P753, DOI 10.1016/j.atherosclerosis.2011.09.011; Satoh M, 2009, CLIN SCI, V116, P827, DOI 10.1042/CS20080404; Serrano AL, 2004, CIRC RES, V94, P575, DOI 10.1161/01.RES.0000122141.18795.9C; Silvestre D. C., 2010, GENOME DYN, V7, P29; Spindler S. R., 2012, PLOS ONE, V7; Spyridopoulos I, 2004, CIRCULATION, V110, P3136, DOI 10.1161/01.CIR.0000142866.50300.EB; Taylor F, 2011, COCHRANE DATABASE SY, V19, DOI 10.1002/14651858.CD004816.pub5; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	28	44	49	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3879	3885		10.1096/fj.13-232066	http://dx.doi.org/10.1096/fj.13-232066			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23748973				2022-12-28	WOS:000328840500045
J	Nishimura, T; Zhao, XM; Gan, HX; Koyasu, S; Remold, HG				Nishimura, Tomoyasu; Zhao, Xiaomin; Gan, Huixian; Koyasu, Shigeo; Remold, Heinz G.			The prostaglandin E-2 receptor EP4 is integral to a positive feedback loop for prostaglandin E-2 production in human macrophages infected with Mycobacterium tuberculosis	FASEB JOURNAL			English	Article						cyclooxygenase 2; Toll-like receptor 2; p38 mitogen-activated protein kinase	ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; PROSTANOID RECEPTORS; DENDRITIC CELLS; UP-REGULATION; NITRIC-OXIDE; E SYNTHASE; EXPRESSION; CYCLOOXYGENASE-2; PGE(2)	Prostaglandin E-2 (PGE(2)) is an important biological mediator involved in the defense against Mycobacterium tuberculosis (Mtb) infection. Previously, we reported that in macrophages (M phi s), infection with avirulent Mtb H37Ra resulted in inhibition of necrosis by an inhibitory effect on mitochondrial permeability transition via the PGE(2) receptor EP2. However, human M phi s also express EP4, a PGE(2) receptor functionally closely related to EP2 that also couples to stimulatory guanine nucleotide binding protein, but the functional differences between EP2 and EP4 in Mtb-infected M phi s have been unclear. EP4 antagonist addition to H37Ra-infected M phi s inhibited the expression of cyclooxygenase 2 (COX2) and microsomal prostaglandin E synthase-1 (mPGES-1), which are involved in PGE(2) production. Moreover, H37Ra infection induced PGE(2) production through the Toll-like receptor (TLR) 2/p38 mitogen-activated protein kinase (MAPK) signaling pathway. Induction of COX2 and mPGES-1 expression by TLR2 stimulation or Mtb infection was increased after additional stimulation with EP4 agonist. Hence, in Mtb-infected M phi s, PGE(2) production induced by pathogen recognition receptors/p38 MAPK signaling is up-regulated by EP4-triggered signaling to maintain an effective PGE(2) concentration.Nishimura, T., Zhao, X., Gan, H., Koyasu, S., and Remold, H. G. The prostaglandin E-2 receptor EP4 is integral to a positive feedback loop for prostaglandin E-2 production in human macrophages infected with Mycobacterium tuberculosis.	[Nishimura, Tomoyasu; Zhao, Xiaomin; Gan, Huixian; Remold, Heinz G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy,Dept Med, Boston, MA 02115 USA; [Nishimura, Tomoyasu; Koyasu, Shigeo] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan; [Nishimura, Tomoyasu] Keio Univ, Sch Med, Div Pulm Med, Dept Med, Tokyo, Japan; [Koyasu, Shigeo] RIKEN Res Ctr Allergy & Immunol, Lab Immune Cell Syst, Yokohama, Kanagawa, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Keio University; Keio University; RIKEN	Remold, HG (corresponding author), Brigham & Womens Hosp, Smith Bldg,526B,1 Jimmy Fund Way, Boston, MA 02115 USA.	hremold@partners.org	Koyasu, Shigeo/J-5583-2015	Koyasu, Shigeo/0000-0001-9585-3038	U.S. National Institutes of Health [AI072143]; Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (Japan Society of the Promotion of Science); Grants-in-Aid for Scientific Research [22229004] Funding Source: KAKEN; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072143] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (Japan Society of the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors are grateful to Dr. Eileen Remold-O'Donnell for helpful discussions. H. G. R. and T.N. conceived of and designed the experiments, analyzed the data and wrote the article; T.N. did the experiments with assistance from H. G. and X.Z.; S. K. provided intellectual input. The authors declare no conflicts of interest. This work is funded by the U.S. National Institutes of Health (grant AI072143). T.N. is supported by Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (Japan Society of the Promotion of Science).	Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Bansal K, 2009, J LEUKOCYTE BIOL, V85, P804, DOI 10.1189/jlb.0908561; Basu S, 2007, J BIOL CHEM, V282, P1039, DOI 10.1074/jbc.M604379200; Caws M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000034; Chen M, 2008, ARTHRITIS RHEUM, V58, P1354, DOI 10.1002/art.23453; Chen MJ, 2006, J IMMUNOL, V176, P3707, DOI 10.4049/jimmunol.176.6.3707; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; Diaz-Munoz MD, 2012, BIOCHEM J, V443, P451, DOI 10.1042/BJ20111052; Diaz-Munoz MD, 2010, CELL SIGNAL, V22, P1427, DOI 10.1016/j.cellsig.2010.05.011; Drage MG, 2009, CELL IMMUNOL, V258, P29, DOI 10.1016/j.cellimm.2009.03.008; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Ferronato S, 2011, EUR J VASC ENDOVASC, V41, P358, DOI 10.1016/j.ejvs.2010.11.019; FORSTERMANN U, 1983, J PHARM PHARMACOL, V35, P724; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Gan HX, 2008, NAT IMMUNOL, V9, P1189, DOI 10.1038/ni.1654; Gan HX, 2005, J INFECT DIS, V191, P1292, DOI 10.1086/428906; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Hiraiwa H, 2011, INFLAMM RES, V60, P1039, DOI 10.1007/s00011-011-0365-y; Inada M, 2006, J IMMUNOL, V177, P1879, DOI 10.4049/jimmunol.177.3.1879; Iona E, 2012, MICROBES INFECT, V14, P959, DOI 10.1016/j.micinf.2012.04.003; Katsuyama M, 1998, BIOCHEM BIOPH RES CO, V251, P727, DOI 10.1006/bbrc.1998.9540; Khan KMF, 2012, J IMMUNOL, V188, P1970, DOI 10.4049/jimmunol.1102383; Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310; Krutzik SR, 2004, SEMIN IMMUNOL, V16, P35, DOI 10.1016/j.smim.2003.10.005; Legler DF, 2010, INT J BIOCHEM CELL B, V42, P198, DOI 10.1016/j.biocel.2009.09.015; Martin CJ, 2012, CELL HOST MICROBE, V12, P289, DOI 10.1016/j.chom.2012.06.010; Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894; Medeiros AI, 2009, J EXP MED, V206, P61, DOI 10.1084/jem.20082058; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825; Oikawa A, 2007, J PERIODONTAL RES, V42, P367, DOI 10.1111/j.1600-0765.2006.00959.x; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; Park JS, 2006, J LEUKOCYTE BIOL, V79, P80, DOI 10.1189/jlb.0505250; Quesniaux V, 2004, MICROBES INFECT, V6, P946, DOI 10.1016/j.micinf.2004.04.016; Rand L, 2009, J IMMUNOL, V182, P5865, DOI 10.4049/jimmunol.0801935; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Serezani CH, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002448; Shoji M, 2006, LIFE SCI, V78, P2012, DOI 10.1016/j.lfs.2005.09.019; Sohn H, 2009, SCAND J IMMUNOL, V69, P43, DOI 10.1111/j.1365-3083.2008.02188.x; Stenger S, 2002, CURR OPIN IMMUNOL, V14, P452, DOI 10.1016/S0952-7915(02)00355-2; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Tabata H, 2002, BIOCHEM BIOPH RES CO, V298, P398, DOI 10.1016/S0006-291X(02)02455-5; Thuong NTT, 2007, GENES IMMUN, V8, P422, DOI 10.1038/sj.gene.6364405; Vichai V, 2005, INFLAMM RES, V54, P163, DOI 10.1007/s00011-004-1338-1; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Wilson RJ, 2004, EUR J PHARMACOL, V501, P49, DOI 10.1016/j.ejphar.2004.08.025; Zaslona Z, 2012, BLOOD, V119, P2358, DOI 10.1182/blood-2011-08-374207	51	33	36	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3827	3836		10.1096/fj.13-228858	http://dx.doi.org/10.1096/fj.13-228858			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23759445	Green Published			2022-12-28	WOS:000328840500040
J	Pasiakos, SM; Cao, JJ; Margolis, LM; Sauter, ER; Whigham, LD; McClung, JP; Rood, JC; Carbone, JW; Combs, GF; Young, AJ				Pasiakos, Stefan M.; Cao, Jay J.; Margolis, Lee M.; Sauter, Edward R.; Whigham, Leah D.; McClung, James P.; Rood, Jennifer C.; Carbone, John W.; Combs, Gerald F., Jr.; Young, Andrew J.			Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial	FASEB JOURNAL			English	Article						recommended dietary allowance; fractional synthesis rate; nitrogen balance; skeletal muscle; postprandial; energy deficit	RESTING ENERGY-EXPENDITURE; BODY-COMPOSITION; RESISTANCE EXERCISE; ENDURANCE EXERCISE; NITROGEN-BALANCE; OVERWEIGHT; REQUIREMENTS; CARBOHYDRATE; RESTRICTION; METABOLISM	The purpose of this work was to determine the effects of varying levels of dietary protein on body composition and muscle protein synthesis during energy deficit (ED). A randomized controlled trial of 39 adults assigned the subjects diets providing protein at 0.8 (recommended dietary allowance; RDA), 1.6 (2x-RDA), and 2.4 (3x-RDA) g kg(-1) d(-1) for 31 d. A 10-d weight-maintenance (WM) period was followed by a 21 d, 40% ED. Body composition and postabsorptive and postprandial muscle protein synthesis were assessed during WM (d 9-10) and ED (d 30-31). Volunteers lost (P<0.05) 3.2 +/- 0.2 kg body weight during ED regardless of dietary protein. The proportion of weight loss due to reductions in fat-free mass was lower (P<0.05) and the loss of fat mass was higher (P<0.05) in those receiving 2x-RDA and 3x-RDA compared to RDA. The anabolic muscle response to a protein-rich meal during ED was not different (P>0.05) from WM for 2x-RDA and 3x-RDA, but was lower during ED than WM for those consuming RDA levels of protein (energy x protein interaction, P<0.05). To assess muscle protein metabolic responses to varied protein intakes during ED, RDA served as the study control. In summary, we determined that consuming dietary protein at levels exceeding the RDA may protect fat-free mass during short-term weight loss.Pasiakos, S. M., Cao, J. J., Margolis, L. M., Sauter, E. R., Whigham, L. D., McClung, J. P., Rood, J. C., Carbone, J. W., Combs, G. F., Jr., Young, A. J. Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial.	[Pasiakos, Stefan M.; Margolis, Lee M.; McClung, James P.; Young, Andrew J.] US Army Res Inst Environm Med, Mil Nutr Div, Natick, MA 01760 USA; [Cao, Jay J.; Whigham, Leah D.; Combs, Gerald F., Jr.] ARS, Grand Forks Human Nutr Res Ctr, USDA, Grand Forks, ND USA; [Sauter, Edward R.] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA; [Rood, Jennifer C.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Carbone, John W.] Eastern Michigan Univ, Sch Hlth Sci, Ypsilanti, MI 48197 USA	United States Department of Defense; United States Army; United States Department of Agriculture (USDA); University of North Dakota Grand Forks; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Eastern Michigan University	Pasiakos, SM (corresponding author), US Army Res Inst Environm Med, Mil Nutr Div, 15 Kansas St,Bldg 42, Natick, MA 01760 USA.	stefan.pasiakos@us.army.mil	McClung, James P/A-1989-2009; Pasiakos, Stefan M/E-6295-2014; Rood, Jennifer/N-1989-2017	Pasiakos, Stefan M/0000-0002-5378-5820; Rood, Jennifer/0000-0001-5848-2987; Whigham, Leah/0000-0002-5376-8967; Margolis, Lee/0000-0003-1697-825X; , Lee/0000-0002-0652-1304	U.S. Army Medical Research and Material Command; U.S. Department of Defense; U.S. Department of Agriculture, Agricultural Research Service [58-1950-7-707]	U.S. Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); U.S. Department of Defense(United States Department of Defense); U.S. Department of Agriculture, Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	First, the authors thank the volunteers that participated in this research experiment. The authors acknowledge Doreen Rolshoven, LuAnn Johnson, Bonita Hoverson, Angela Scheett, Debbie Krause, and the dietary kitchen staff, Emily Nielson, Jackie Nelson, Jean Hager, and Dr. William Siders (U. S. Department of Agriculture Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA) for their significant contributions to study management and conduct, data collection, and analysis. The authors acknowledge William Mills, Matthew Dickson, Bryan Wiley, Michael Stanger, Lauren Thompson, Philip Niro, and Dr. Hedrick Porrata (U. S. Army Research Institute of Environmental Medicine, Nantick, MA, USA) for their significant contributions to data collection and assistance with manuscript layout and design. Finally, the authors sincerely thank Nancy Murphy (U. S. Army Research Institute of Environmental Medicine) for her significant contributions to data collection, management, and analysis. The study was supported by the U. S. Army Medical Research and Material Command and the U. S. Department of Agriculture, Agricultural Research Service. Author contributions: S. M. P. performed project conception, development of overall research plan, study oversight, research, data analysis, and manuscript preparation, and had primary responsibility for final content; L. M. M., J.J.C., L. D. W., J.P.M., J.W.C., G. F. C., and A.J.Y. assisted with project conception, development of research plan, study implementation and management, data analysis, and manuscript preparation; E. R. S. performed muscle biopsies, provided medical oversight, and assisted in manuscript preparation; J.C.R. performed stable isotope and urinary nitrogen analysis. S. M. P. reports that his institution received a grant from the Dairy Research Institute for work outside this publication. E. R. S. reports that his institution received a grant and travel support from the U. S. Department of Agriculture for work associated with this publication. E. R. S. also reports that he is a consultant for Halo Health, has received royalties for book editorship, and has received a patent. J.P.M. reports that his institution received a grant from the U.S. Army Medical Research and Material Command for work outside this publication. J.C.R. reports that her institution received a grant from the U.S. Department of Defense for work associated with this publication. The other authors report no conflicts of interest. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement of approval of the products or services of these organizations. This material is based on work supported by the U.S. Department of Agriculture, Agricultural Research Service, under agreement No. 58-1950-7-707. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U. S. Department of Agriculture. This trial was registered at http://www.clinicaltrials.gov as NCT01292395.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Artioli GG, 2010, MED SCI SPORT EXER, V42, P436, DOI 10.1249/MSS.0b013e3181ba8055; Atherton PJ, 2010, AM J CLIN NUTR, V92, P1080, DOI 10.3945/ajcn.2010.29819; Baradel LA, 2009, PREV MED, V49, P158, DOI 10.1016/j.ypmed.2009.06.030; Bohe J, 2003, J PHYSIOL-LONDON, V552, P315, DOI 10.1113/jphysiol.2003.050674; Bolster DR, 2005, AM J PHYSIOL-ENDOC M, V289, pE678, DOI 10.1152/ajpendo.00060.2005; Bray GA, 2012, INT J OBESITY, V36, P448, DOI 10.1038/ijo.2011.173; Bray GA, 2012, JAMA-J AM MED ASSOC, V307, P47, DOI 10.1001/jama.2011.1918; Burd Nicholas A, 2011, Nutr Metab (Lond), V8, P15, DOI 10.1186/1743-7075-8-15; CALLOWAY DH, 1954, AM J CLIN NUTR, V2, P405; CALLOWAY DH, 1975, J NUTR, V105, P914, DOI 10.1093/jn/105.7.914; Campbell WW, 2009, OBESITY, V17, P1332, DOI 10.1038/oby.2009.2; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; de Jonge L, 2012, OBESITY, V20, P2384, DOI 10.1038/oby.2012.127; Ebbeling CB, 2012, JAMA-J AM MED ASSOC, V307, P2627, DOI 10.1001/jama.2012.6607; Farnsworth E, 2003, AM J CLIN NUTR, V78, P31, DOI 10.1093/ajcn/78.1.31; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; Food and Nutrition Board of the National Academy of Sciences, 2005, DIET REF INT EN CARB; Friedlander AL, 2005, AM J PHYSIOL-ENDOC M, V289, pE446, DOI 10.1152/ajpendo.00001.2005; FRIEDMAN JE, 1989, INT J SPORTS MED, V10, P118, DOI 10.1055/s-2007-1024886; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; GOODMAN MN, 1984, AM J PHYSIOL, V246, pE383, DOI 10.1152/ajpendo.1984.246.5.E383; Greenhaff PL, 2008, AM J PHYSIOL-ENDOC M, V295, pE595, DOI 10.1152/ajpendo.90411.2008; JOHNSON MJ, 1994, MED SCI SPORT EXER, V26, P235, DOI 10.1249/00005768-199402000-00015; Johnston CS, 2004, J NUTR, V134, P586, DOI 10.1093/jn/134.3.586; KASCH FW, 1976, J APPL PHYSIOL, V40, P982, DOI 10.1152/jappl.1976.40.6.982; Katan MB, 2009, NEW ENGL J MED, V360, P923, DOI 10.1056/NEJMe0810291; KEYS A, 1946, FED PROC, V5, P55; Keys A, 1950, BIOL HUMAN STARVATIO; Layman DK, 2005, J NUTR, V135, P1903, DOI 10.1093/jn/135.8.1903; Layman DK, 2003, J NUTR, V133, P411, DOI 10.1093/jn/133.2.411; Layman DK, 2009, J NUTR, V139, P514, DOI 10.3945/jn.108.099440; Mettler S, 2010, MED SCI SPORT EXER, V42, P326, DOI 10.1249/MSS.0b013e3181b2ef8e; Moore DR, 2009, AM J CLIN NUTR, V89, P161, DOI 10.3945/ajcn.2008.26401; Pasiakos SM, 2011, AM J CLIN NUTR, V94, P809, DOI 10.3945/ajcn.111.017061; Pasiakos SM, 2010, INT J SPORT NUTR EXE, V20, P282, DOI 10.1123/ijsnem.20.4.282; Pasiakos SM, 2010, J NUTR, V140, P745, DOI 10.3945/jn.109.118372; Pasiakos SM, 2008, METABOLISM, V57, P458, DOI 10.1016/j.metabol.2007.11.006; Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99; Phillips SM, 2008, MED SCI SPORT EXER, V40, P503, DOI [10.1249/mss.0b013e3181629a44, 10.1249/MSS.0b013e3181629a44]; Pikosky MA, 2008, MED SCI SPORT EXER, V40, P505, DOI [10.1249/mss.0b013e31815f6643, 10.1249/MSS.0b013e31815f6643]; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Rodriguez NR, 2008, AM J CLIN NUTR, V87, p1551S, DOI 10.1093/ajcn/87.5.1551S; ROZA AM, 1984, AM J CLIN NUTR, V40, P168, DOI 10.1093/ajcn/40.1.168; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867; STEIN TP, 1991, METABOLISM, V40, P478, DOI 10.1016/0026-0495(91)90228-O; Tharion WJ, 2005, APPETITE, V44, P47, DOI 10.1016/j.appet.2003.11.010; Villareal DT, 2012, OBESITY, V20, P1780, DOI 10.1038/oby.2011.280; Weinheimer EM, 2010, NUTR REV, V68, P375, DOI 10.1111/j.1753-4887.2010.00298.x; Yaemsiri S, 2011, INT J OBESITY, V35, P1063, DOI 10.1038/ijo.2010.229	52	169	173	3	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3837	3847		10.1096/fj.13-230227	http://dx.doi.org/10.1096/fj.13-230227			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23739654				2022-12-28	WOS:000328840500041
J	Ohkubo, H; Ito, Y; Minamino, T; Mishima, T; Hirata, M; Hosono, K; Shibuya, M; Yokomizo, T; Shimizu, T; Watanabe, M; Majima, M				Ohkubo, Hirotoki; Ito, Yoshiya; Minamino, Tsutomu; Mishima, Toshiaki; Hirata, Mitsuhiro; Hosono, Kanako; Shibuya, Masabumi; Yokomizo, Takehiko; Shimizu, Takao; Watanabe, Masahiko; Majima, Masataka			Leukotriene B-4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment	FASEB JOURNAL			English	Article						BLT1; regeneration; neutrophil; sinusoid	ENDOTHELIAL-GROWTH-FACTOR; ISCHEMIA-REPERFUSION INJURY; CELL-GROWTH; REGENERATION; MICE; ANGIOGENESIS; NEUTROPHIL; FIBROSIS; PATHWAY; ATHEROSCLEROSIS	Recruited macrophages play a critical role in liver repair after acute liver injury. Leukotriene B-4 (LTB4) is a potent chemoattractant for macrophages. In this study, we investigated the role of LTB4 receptor type 1 (BLT1) in liver repair during hepatic ischemia/reperfusion (I/R) injury. BLT1-knockout mice (BLT1-/-) or their wild-type counterparts (WT) were subjected to partial hepatic I/R. Compared with WT, BLT1-/- exhibited delayed liver repair and hepatocyte proliferation accompanied by a 70% reduction in the recruitment of macrophages and a 70-80% attenuation in hepatic expression of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and VEGF receptor 1 (VEGFR1). Disruption of BLT1 signaling also reduced the expression of EGF by 67% on recruited macrophages expressing VEGFR1 in the injured liver. Treatment of WT mice with an EGF-neutralizing antibody delayed liver repair and reduced macrophage recruitment, compared with control immunoglobulin G (IgG). BLT1 signaling enhanced the expression of VEGF, VEGFR1, and EGF in isolated peritoneal macrophages in vitro. These results indicate that BLT1 signaling plays a role in liver repair after hepatic I/R through enhanced expression of EGF in recruited macrophages and that the development of a specific agonist for BLT1 could be useful for liver recovery from acute liver injury.Ohkubo, H., Ito, Y., Minamino, T., Mishima, T., Hirata, M., Hosono, K., Shibuya, M., Yokomizo, T., Shimizu, T., Watanabe, M., Majima, M. Leukotriene B-4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment.	[Ohkubo, Hirotoki; Hosono, Kanako; Majima, Masataka] Kitasato Univ, Dept Pharmacol, Sch Med, Sagamihara, Kanagawa 2520374, Japan; [Ohkubo, Hirotoki; Ito, Yoshiya; Mishima, Toshiaki; Hirata, Mitsuhiro; Watanabe, Masahiko] Kitasato Univ, Dept Surg, Sch Med, Sagamihara, Kanagawa 2520374, Japan; [Minamino, Tsutomu] Kitasato Univ, Dept Gastroenterol, Sch Med, Sagamihara, Kanagawa 2520374, Japan; [Shibuya, Masabumi] Jobu Univ, Gakubunkan Inst Physiol & Med, Gunma, Japan; [Yokomizo, Takehiko] Juntendo Univ, Sch Med, Dept Biochem, Tokyo 113, Japan; [Shimizu, Takao] Natl Ctr Global Hlth & Med, Tokyo, Japan	Kitasato University; Kitasato University; Kitasato University; Juntendo University; National Center for Global Health & Medicine - Japan	Majima, M (corresponding author), Kitasato Univ, Dept Pharmacol, Sch Med, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	mmajima@med.kitasato-u.ac.jp	Yokomizo, Takehiko/P-5673-2016; Majima, Masataka/ABH-3063-2021; Shimizu, Takao/AAV-7052-2021	Yokomizo, Takehiko/0000-0002-5219-1553; 	High-Tech Research Center of the Ministry of Education, Culture, Sports, Science and Technology, Japan; Integrative Research Program of the Graduate School of Medical Science, Kitasato University	High-Tech Research Center of the Ministry of Education, Culture, Sports, Science and Technology, Japan; Integrative Research Program of the Graduate School of Medical Science, Kitasato University	The authors thank Michiko Ogino, Kyoko Yoshikawa, and Mieko Hamano for technical assistance. This work was supported by research grants from the High-Tech Research Center of the Ministry of Education, Culture, Sports, Science and Technology, Japan. This study was also supported by the Integrative Research Program of the Graduate School of Medical Science, Kitasato University. The authors declare no conflicts of interest.	Back M, 2011, PHARMACOL REV, V63, P539, DOI 10.1124/pr.110.004184; Barone S, 2005, AM J PHYSIOL-CELL PH, V289, pC826, DOI 10.1152/ajpcell.00629.2004; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Brancato S. K., AM J PATHOL, V178, P19; Clavien PA, 2008, SWISS MED WKLY, V138, P361, DOI 2008/25/smw-12231; Ding BS, 2010, NATURE, V468, P310, DOI 10.1038/nature09493; Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Fujita M, 2005, CARCINOGENESIS, V26, P271, DOI 10.1093/carcin/bgh324; Hasegawa T, 2007, AM J PHYSIOL-GASTR L, V292, pG1385, DOI 10.1152/ajpgi.00246.2006; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Holt MP, 2008, J LEUKOCYTE BIOL, V84, P1410, DOI 10.1189/jlb.0308173; Hosono K, 2011, ARTERIOSCL THROM VAS, V31, P1049, DOI 10.1161/ATVBAHA.110.222356; HUGHES H, 1992, PROSTAG LEUKOTR ESS, V45, P113, DOI 10.1016/0952-3278(92)90226-9; Ito S, 2008, SHOCK, V30, P87, DOI 10.1097/SHK.0b013e31815d06a1; Jaeschke H, 2006, AM J PHYSIOL-GASTR L, V290, pG1083, DOI 10.1152/ajpgi.00568.2005; Jala VR, 2004, TRENDS IMMUNOL, V25, P315, DOI 10.1016/j.it.2004.04.003; Karlmark KR, 2009, HEPATOLOGY, V50, P261, DOI 10.1002/hep.22950; Kato T, 2011, TOXICOL SCI, V120, P218, DOI 10.1093/toxsci/kfq366; Katoh H, 2010, AM J PATHOL, V176, P1469, DOI 10.2353/ajpath.2010.090607; Kinoshita M, 2010, J HEPATOL, V53, P903, DOI 10.1016/j.jhep.2010.04.037; Koyama S, 2001, AM J PHYSIOL-LUNG C, V280, pL1203, DOI 10.1152/ajplung.2001.280.6.L1203; Laskin DL, 2009, CHEM RES TOXICOL, V22, P1376, DOI 10.1021/tx900086v; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Mancuso P, 2010, INFECT IMMUN, V78, P2264, DOI 10.1128/IAI.01323-09; Matsukawa A, 1999, J IMMUNOL, V163, P6148; Michalopoulos GK, 2007, J CELL PHYSIOL, V213, P286, DOI 10.1002/jcp.21172; Minamino T, 2012, TOXICOL APPL PHARM, V259, P104, DOI 10.1016/j.taap.2011.12.013; Murakami M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood-2006-04-016030; Natarajan A, 2007, P NATL ACAD SCI USA, V104, P17081, DOI 10.1073/pnas.0704126104; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Saiman Y, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00213; Saiwai H, 2010, AM J PATHOL, V176, P2352, DOI 10.2353/ajpath.2010.090839; Sanchez-Galan E, 2009, CARDIOVASC RES, V81, P216, DOI 10.1093/cvr/cvn277; Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Spite M, 2011, J IMMUNOL, V187, P1942, DOI 10.4049/jimmunol.1100196; Teoh N, 2004, HEPATOLOGY, V39, P412, DOI 10.1002/hep.20035; Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217; Titos E, 2003, FASEB J, V17, P1745, DOI 10.1096/fj.02-1157fje; Van Sweringen HL, 2011, HEPATOLOGY, V54, P1445, DOI 10.1002/hep.24457; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	46	17	19	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3132	3143		10.1096/fj.13-227421	http://dx.doi.org/10.1096/fj.13-227421			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23629862				2022-12-28	WOS:000329877600020
J	Rancourt, RC; Harris, HR; Barault, L; Michels, KB				Rancourt, Rebecca C.; Harris, Holly R.; Barault, Ludovic; Michels, Karin B.			The prevalence of loss of imprinting of H19 and IGF2 at birth	FASEB JOURNAL			English	Article						allele-specific expression; DNA methylation; genomic; cohort	BECKWITH-WIEDEMANN-SYNDROME; UNIPARENTAL DISOMY; CHROMOSOME 11P15; GENE-EXPRESSION; WILMS-TUMOR; METHYLATION; BREAST; REGION; LOCUS; HYPOMETHYLATION	Imprinted genes are monoallelically expressed according to the parent of origin and are critical for proper placental and embryonic development. Disruption of methylation patterns at imprinted loci resulting in loss of imprinting (LOI) may lead to serious imprinting disorders (e.g., Beckwith-Wiedemann syndrome) and is described in some cancers (e.g., Wilms' tumor). As most research has focused on children with cancer or other abnormal phenotypes, the imprinting status in healthy infants at birth has not been characterized. We examined the prevalence of H19 and IGF2 LOI at birth by allele-specific expression assays analysis on 114 human individuals. Overall expression and methylation analyses were performed on a subset of samples. We found that LOI of H19 was observed for 4% of individuals in cord blood and 3.3% in placenta, and for IGF2 of 22% of individuals in the cord blood and 0% in placenta. Interestingly, LOI status did not correspond to aberrant methylation levels of the imprinted DMRs or with changes in overall gene expression for the majority of individuals. Our observations suggest that LOI is present in phenotypically healthy infants. Determining a normal human epigenotype range is important for discovering factors required to maintain a healthy pregnancy and embryonic development.Rancourt, R. C., Harris, H. R., Barault, L., Michels, K. B. The prevalence of loss of imprinting of H19 and IGF2 at birth.	[Rancourt, Rebecca C.; Harris, Holly R.; Barault, Ludovic; Michels, Karin B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; [Rancourt, Rebecca C.; Michels, Karin B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Harris, Holly R.] Karolinska Inst, Natl Inst Environm Med, Div Nutr Epidemiol, Stockholm, Sweden	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Karolinska Institutet	Michels, KB (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr,Dept Obstet Gyneco, 221 Longwood Ave, Boston, MA 02115 USA.	kmichels@research.bwh.harvard.edu	Harris, Holly/AAK-6844-2020; Barault, Ludovic/J-2472-2016	Harris, Holly/0000-0002-2572-6727; Barault, Ludovic/0000-0001-5227-5047; Rancourt, Rebecca/0000-0003-2696-7220	National Cancer Institute, U.S. National Institutes of Health [5R21CA128382]; NATIONAL CANCER INSTITUTE [R21CA128382] Funding Source: NIH RePORTER	National Cancer Institute, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors gratefully acknowledge the Epigenetic Birth Cohort participants. The authors thank Joelle Perkins for genotyping analyses and Eliza Gardiner, Michelle Peters, and Seema Sannesy for help with data and specimen collection. The authors also thank members of the K. B. M. laboratory for helpful discussions of the project: Amy Non, Alexandra Binder, Timothy Barrow, and Benedetta Izzi. This project was supported by Public Health Research grant 5R21CA128382 from the National Cancer Institute, U.S. National Institutes of Health (principal investigator: K. B. M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest.	Ahmadian A, 2000, ANAL BIOCHEM, V280, P103, DOI 10.1006/abio.2000.4493; Apostolidou S, 2007, J MOL MED, V85, P379, DOI 10.1007/s00109-006-0131-8; Barault L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055896; Brown KW, 2008, MOL CANCER RES, V6, P1114, DOI 10.1158/1541-7786.MCR-08-0002; Catchpoole D, 2000, J MED GENET, V37, P212, DOI 10.1136/jmg.37.3.212; Charalambous Marika, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P3, DOI 10.1097/MED.0b013e328013daa2; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Cui HM, 2002, CANCER RES, V62, P6442; DAVIES SM, 1994, CANCER RES, V54, P2560; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Diplas AI, 2009, EPIGENETICS-US, V4, P235, DOI 10.4161/epi.9019; Edwards CA, 2007, CURR OPIN CELL BIOL, V19, P281, DOI 10.1016/j.ceb.2007.04.013; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; Frost J. M., 2010, PLOS ONE, V5; Gicquel C, 2005, NAT GENET, V37, P1003, DOI 10.1038/ng1629; Guo L, 2008, DEV BIOL, V320, P79, DOI 10.1016/j.ydbio.2008.04.025; Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163; Kagami M, 2012, EPIGENETICS-US, V7, P1142, DOI 10.4161/epi.21937; Lambertini L, 2008, EPIGENETICS-US, V3, P261, DOI 10.4161/epi.3.5.6755; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Mancini-DiNardo D, 2006, GENE DEV, V20, P1268, DOI 10.1101/gad.1416906; Michels KB, 2006, INT J CANCER, V119, P2007, DOI 10.1002/ijc.22004; Michels KB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025254; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; Monk D, 2006, P NATL ACAD SCI USA, V103, P6623, DOI 10.1073/pnas.0511031103; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Murrell A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001849; Prawitt D, 2005, P NATL ACAD SCI USA, V102, P4085, DOI 10.1073/pnas.0500037102; Radford EJ, 2011, FEBS LETT, V585, P2059, DOI 10.1016/j.febslet.2011.05.063; Rancourt RC, 2012, HUM REPROD, V27, P2208, DOI 10.1093/humrep/des151; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Sparago A, 2004, NAT GENET, V36, P958, DOI 10.1038/ng1410; Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096; Tabano S, 2010, EPIGENETICS-US, V5, P313, DOI 10.4161/epi.5.4.11637; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Temple IK, 2007, J MED GENET, V44, P637, DOI 10.1136/jmg.2007.050807; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; Weksberg R, 2005, AM J MED GENET C, V137C, P12, DOI 10.1002/ajmg.c.30058; Williamson CM, 2006, NAT GENET, V38, P350, DOI 10.1038/ng1731; Wong HL, 2006, BIOTECHNIQUES, V41, P734, DOI 10.2144/000112305	46	25	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3335	3343		10.1096/fj.12-225284	http://dx.doi.org/10.1096/fj.12-225284			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23620526	Green Published			2022-12-28	WOS:000329877600038
J	Chambliss, AB; Wu, PH; Chen, WC; Sun, SX; Wirtz, D				Chambliss, Allison B.; Wu, Pei-Hsun; Chen, Wei-Chiang; Sun, Sean X.; Wirtz, Denis			Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution	FASEB JOURNAL			English	Article						epigenetics; high-throughput; microscopy	HISTONE ACETYLATION; CANCER; EPIGENETICS; INHIBITORS; TUMOR	Heterogeneity of cellular phenotypes in asynchronous cell populations placed in the same biochemical and biophysical environment may depend on cell cycle and chromatin modifications; however, no current method can measure these properties at single-cell resolution simultaneously and in situ. Here, we develop, test, and validate a new microscopy assay that rapidly quantifies global acetylation on histone H3 and measures a wide range of cell and nuclear properties, including cell and nuclear morphology descriptors, cell-cycle phase, and F-actin content of thousands of cells simultaneously, without cell detachment from their substrate, at single-cell resolution. These measurements show that isogenic, isotypic cells of identical DNA content and the same cell-cycle phase can still display large variations in H3 acetylation and that these variations predict specific phenotypic variations, in particular, nuclear size and actin cytoskeleton content, but not cell shape. The dependence of cell and nuclear properties on cell-cycle phase is assessed without artifact-prone cell synchronization. To further demonstrate its versatility, this assay is used to quantify the complex interplay among cell cycle, epigenetic modifications, and phenotypic variations following pharmacological treatments affecting DNA integrity, cell cycle, and inhibiting chromatin-modifying enzymes.Chambliss, A. B., Wu, P.-H., Chen, W.-C., Sun, S. X., Wirtz, D. Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution.	[Chambliss, Allison B.; Wu, Pei-Hsun; Chen, Wei-Chiang; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Chambliss, Allison B.; Wu, Pei-Hsun; Chen, Wei-Chiang; Sun, Sean X.; Wirtz, Denis] Johns Hopkins Univ, Phys Scioncol Ctr, Baltimore, MD 21218 USA; [Chambliss, Allison B.; Wu, Pei-Hsun; Chen, Wei-Chiang; Sun, Sean X.; Wirtz, Denis] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Sun, Sean X.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, 3400 N Charles St,NEB 116, Baltimore, MD 21218 USA.	wirtz@jhu.edu	Sun, Sean X/C-6755-2009; Sun, Sean/M-7208-2019	Sun, Sean X/0000-0002-9077-7088; Sun, Sean/0000-0002-9077-7088; Chambliss, Allison/0000-0002-0461-8137	U.S. National Institutes of Health [R01CA174388, U54CA143868]; Achievement Rewards for College Scientists (ARCS) Foundation fellowship; NATIONAL CANCER INSTITUTE [R01CA174388, U54CA143868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075305] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Achievement Rewards for College Scientists (ARCS) Foundation fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Prof. Jonathan Licht (Northwestern University, Chicago, IL, USA) for fruitful conversations and Dr. Sean Hanlon (U. S. National Cancer Institute, Bethesda, MD, USA) for important suggestions and editing the manuscript. This work was supported by U.S. National Institutes of Health grants R01CA174388 and U54CA143868. A. B. C. is supported by an Achievement Rewards for College Scientists (ARCS) Foundation fellowship.	Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Chang J, 2012, BRIT J CANCER, V106, P116, DOI 10.1038/bjc.2011.532; Chavez-Blanco A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-22; Chen WC, 2013, INTEGR BIOL-UK, V5, P523, DOI 10.1039/c2ib20246h; Dasgupta AR, 2006, IEEE SPECTRUM, V43, P8; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; HEPPNER GH, 1984, CANCER RES, V44, P2259; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P2268, DOI 10.1073/pnas.71.6.2268; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Ronzoni S, 2005, CYTOM PART A, V66A, P52, DOI 10.1002/cyto.a.20151; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Wu PH, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/1/015005; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615	22	20	20	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2667	2676		10.1096/fj.12-227108	http://dx.doi.org/10.1096/fj.12-227108			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23538711	Green Published			2022-12-28	WOS:000328841000016
J	Kang, J; Shen, ZL; Lim, JM; Handa, H; Wells, L; Tantin, D				Kang, Jinsuk; Shen, Zuolian; Lim, Jae-Min; Handa, Hiroshi; Wells, Lance; Tantin, Dean			Regulation of Oct1/Pou2f1 transcription activity by O-GlcNAcylation	FASEB JOURNAL			English	Article						Gadd45a; Lamin B	GLCNAC MODIFICATION; P53-INDEPENDENT INDUCTION; COORDINATE REGULATION; INTERACTION NETWORK; FACTORS OCT-1; GADD45; STRESS; PROTEINS; PROMOTER; BINDING	The Oct1 transcription factor is a potent regulator of stress responses, metabolism, and tumorigenicity. Although Oct1 is regulated by phosphorylation and ubiquitination, the presence and importance of other modifications is unknown. Here we show that Oct1 is modified by O-linked -N-acetylglucosamine (O-GlcNAc) moieties. We map two sites of O-GlcNAcylation at positions T255 and S728 within human Oct1. Under anchorage-independent overgrowth conditions, Oct1 associates 3-fold more strongly with the Gadd45a promoter and mediates transcriptional repression. Increased binding correlates with quantitative reductions in Oct1 nuclear periphery-associated puncta, and a reduced association with lamin B1. The O-GlcNAc modification sites are important for both Gadd45a repression and anchorage-independent survival. In contrast to chronic overgrowth conditions, following acute nutrient starvation Oct1 mediates Gadd45a activation. The O-GlcNAc sites are also important for Gadd45a activation under these conditions. We also, for the first time, identify specific Oct1 ubiquitination sites. The findings suggest that Oct1 integrates metabolic and stress signals via O-GlcNAc modification to regulate target gene activity.Kang, J., Shen, Z., Lim, J.-M., Handa, H., Wells, L., Tantin, D. Regulation of Oct1/Pou2f1 transcription activity by O-GlcNAcylation.	[Kang, Jinsuk; Shen, Zuolian; Tantin, Dean] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA; [Lim, Jae-Min; Wells, Lance] Univ Georgia, Dept Biochem & Mol Biol, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; [Handa, Hiroshi] Tokyo Inst Technol, Integrated Res Inst, Yokohama, Kanagawa 227, Japan	Utah System of Higher Education; University of Utah; University System of Georgia; University of Georgia; Tokyo Institute of Technology	Tantin, D (corresponding author), Univ Utah, Sch Med, Dept Pathol, JMRB 5700B, Salt Lake City, UT 84112 USA.	dean.tantin@path.utah.edu	Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363	Integrated Technology Resource for Biomedical Glycomics [P41RR018502]; National Cancer Institute [1R21CA141009]; NATIONAL CANCER INSTITUTE [R21CA141009] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR018502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103490] Funding Source: NIH RePORTER	Integrated Technology Resource for Biomedical Glycomics; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank D. Stillman, K. Ullman, D. Ayer, and J. Rutter for critical reading of the manuscript. The authors thank J. Shaw for use of laboratory equipment and technical advice, and D. McClain for advice and reagents. This work was funded by the Integrated Technology Resource for Biomedical Glycomics (P41RR018502, to L.W.) and the National Cancer Institute (1R21CA141009, to D.T.).	Dalvai M, 2010, CELL CYCLE, V9, P3933, DOI 10.4161/cc.9.19.13154; Ding JJ, 2012, CELL RES, V22, P155, DOI 10.1038/cr.2011.179; Duggan SP, 2006, CARCINOGENESIS, V27, P319, DOI 10.1093/carcin/bgi211; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Fong JJ, 2012, J BIOL CHEM, V287, P12195, DOI 10.1074/jbc.M111.315804; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Housley MP, 2009, J BIOL CHEM, V284, P5148, DOI 10.1074/jbc.M808890200; Imai S, 1997, MOL BIOL CELL, V8, P2407, DOI 10.1091/mbc.8.12.2407; Issad T, 2008, TRENDS ENDOCRIN MET, V19, P380, DOI 10.1016/j.tem.2008.09.001; Jang H, 2012, CELL STEM CELL, V11, P62, DOI 10.1016/j.stem.2012.03.001; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019063; Kang JS, 2009, TRENDS BIOCHEM SCI, V34, P491, DOI 10.1016/j.tibs.2009.06.003; Kang JS, 2009, GENE DEV, V23, P208, DOI 10.1101/gad.1750709; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Liebermann Dan A., 2011, Critical Reviews in Oncogenesis, V16, P129; Maddox J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003048; Malhas AN, 2009, J CELL BIOL, V184, P45, DOI 10.1083/jcb.200804155; Mancini M, 2012, LEUKEMIA RES, V36, P1028, DOI 10.1016/j.leukres.2012.03.025; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Pardo M, 2010, CELL STEM CELL, V6, P382, DOI 10.1016/j.stem.2010.03.004; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Pombo A, 1998, EMBO J, V17, P1768, DOI 10.1093/emboj/17.6.1768; Reddy KL, 2008, NATURE, V452, P243, DOI 10.1038/nature06727; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schild-Poulter C, 2007, ONCOGENE, V26, P3980, DOI 10.1038/sj.onc.1210165; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Shakya A, 2011, J BIOL CHEM, V286, P450, DOI 10.1074/jbc.M110.174045; Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840; Shimi T, 2011, GENE DEV, V25, P2579, DOI 10.1101/gad.179515.111; Takahashi S, 2001, CANCER RES, V61, P1187; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Tolkunova E, 2007, J MOL BIOL, V374, P1200, DOI 10.1016/j.jmb.2007.09.081; Tront JS, 2010, CANCER RES, V70, P9671, DOI 10.1158/0008-5472.CAN-10-2177; van den Berg DLC, 2010, CELL STEM CELL, V6, P369, DOI 10.1016/j.stem.2010.02.014; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Webster DM, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-28; Wells L, 2011, AMINO ACIDS, V40, P877, DOI 10.1007/s00726-010-0709-x; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zhao P, 2011, J PROTEOME RES, V10, P4088, DOI 10.1021/pr2002726; Zhao R, 2009, CURR OPIN GENET DEV, V19, P172, DOI 10.1016/j.gde.2009.02.007	45	17	18	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2807	2817		10.1096/fj.12-220897	http://dx.doi.org/10.1096/fj.12-220897			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23580612	Green Published			2022-12-28	WOS:000328841000029
J	Takayama, Y; Shibasaki, K; Suzuki, Y; Yamanaka, A; Tominaga, M				Takayama, Yasunori; Shibasaki, Koji; Suzuki, Yoshiro; Yamanaka, Akihiro; Tominaga, Makoto			Modulation of water efflux through functional interaction between TRPV4 and TMEM16A/anoctamin 1	FASEB JOURNAL			English	Article						choroid plexus; cerebrospinal fluid; calcium-activated chloride channel; hyposmosis; temperature	HEAT-EVOKED ACTIVATION; CATION CHANNEL; ATP RELEASE; ION-CHANNEL; EXPRESSION; LOCALIZATION; TEMPERATURE; TMEM16A; KLOTHO; INFLUX	Transient receptor potential vanilloid 4 (TRPV4), a calcium-permeable channel, is highly expressed in the apical membrane of choroid plexus epithelial cells (CPECs) in the brain. The function of TRPV4 is unknown. Here, we show physical and functional interaction between TRPV4 and anoctamin 1 (ANO1) in HEK293T cells and CPECs. Chloride currents induced by a TRPV4 activator (GSK1016790A) were markedly increased in an extracellular calcium-dependent manner in HEK293T cells expressing TRPV4 with ANO1, but not with ANO4, ANO6, or ANO10, the mRNAs of which were expressed in the choroid plexus. We also found physical interaction between TRPV4 and ANO1 in both HEK293T cells and choroid plexus. We observed that ANO1 was activated at a warm temperature (37 degrees C) in HEK293T cells and that the heat-evoked chloride currents were markedly enhanced after GSK1016790A application in CPECs. Simultaneous stimulation by warmth and hyposmosis induced chloride current activation in wild-type, but not in TRPV4-deficient, CPECs. Cell volume changes were induced by ANO1-mediated chloride currents in parallel with membrane potential changes, and the cell volume was significantly decreased at negative membrane potentials by TRPV4-induced ANO1 activation. Thus, physical and functional interactions between TRPV4 and ANO1 can modulate water transport in the choroid plexus.Takayama, Y., Shibasaki, K., Suzuki, Y., Yamanaka, A., Tominaga, M. Modulation of water efflux through functional interaction between TRPV4 and TMEM16A/anoctamin 1.	[Takayama, Yasunori; Suzuki, Yoshiro; Tominaga, Makoto] Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Natl Inst Physiol Sci, Div Cell Signaling, Okazaki, Aichi 4448787, Japan; [Shibasaki, Koji] Gunma Univ, Dept Mol & Cellular Neurobiol, Maebashi, Gunma 371, Japan; [Suzuki, Yoshiro; Tominaga, Makoto] Grad Univ Adv Studies, Dept Physiol Sci, Okazaki, Aichi, Japan; [Yamanaka, Akihiro] Nagoya Univ, Environm Med Res Inst, Dept Neurosci 2, Nagoya, Aichi 464, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); Gunma University; Graduate University for Advanced Studies - Japan; Nagoya University	Tominaga, M (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Natl Inst Physiol Sci, Div Cell Signaling, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan.	tominaga@nips.ac.jp	Takayama, Yasunori/AAG-1133-2021; Yamanaka, Akihiro/AAD-8641-2021; Shibasaki, Koji/U-8674-2018	Yamanaka, Akihiro/0000-0001-6099-7306; Shibasaki, Koji/0000-0003-2330-1749; SUZUKI, YOSHIRO/0000-0003-0010-1867	Ministry of Education, Culture, Sports, Science, and Technology in Japan (Brain Environment); Salt Science Research Foundation; Grants-in-Aid for Scientific Research [26640041] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology in Japan (Brain Environment); Salt Science Research Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dr. Uhtaek Oh (Seoul National University, Seoul, South Korea) for providing anoctamin plasmid DNAs and an anti-ANO1 antibody. The authors also thank Dr. Bernd Nilius (KU Leuven, Leuven, Belgium), Dr. Kenji F. Takana (Keio University, Tokyo, Japan), Dr. Akihiro Imura (Institute of Biomedical Research and Innovation Laboratory, Kobe, Japan) and Dr. Kaori Sato-Numata (National Institute for Physiological Sciences, Okazaki, Japan) for their technical advice and the generous gifts of materials. This work was supported by a grant-in-aid for scientific research to M. T. from the Ministry of Education, Culture, Sports, Science, and Technology in Japan (Brain Environment) and by The Salt Science Research Foundation. Y.T., a Research Fellow of the Japan Society for the Promotion of Science, was supported by a grant-in-aid.	Almaca J, 2009, J BIOL CHEM, V284, P28571, DOI 10.1074/jbc.M109.010074; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; Cho H, 2012, NAT NEUROSCI, V15, P1015, DOI 10.1038/nn.3111; Damkier HH, 2010, PHYSIOLOGY, V25, P239, DOI 10.1152/physiol.00011.2010; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Guler AD, 2002, J NEUROSCI, V22, P6408; Imura A, 2007, SCIENCE, V316, P1615, DOI 10.1126/science.1135901; Kunzelmann K, 2013, PFLUGERS ARCH; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200; Lorenzo IM, 2008, P NATL ACAD SCI USA, V105, P12611, DOI 10.1073/pnas.0803970105; MASUZAWA T, 1985, BRAIN, V108, P625, DOI 10.1093/brain/108.3.625; Mihara H, 2011, J PHYSIOL-LONDON, V589, P3471, DOI 10.1113/jphysiol.2011.207829; Millar Ian D, 2007, Cerebrospinal Fluid Res, V4, P8, DOI 10.1186/1743-8454-4-8; Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206; Moore C, 2013, P NATL ACAD SCI USA, V110, P15502, DOI 10.1073/pnas.1315603110; Namkung W, 2011, J BIOL CHEM, V286, P2365, DOI 10.1074/jbc.M110.175109; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; Praetorius J, 2007, PFLUG ARCH EUR J PHY, V454, P1, DOI 10.1007/s00424-006-0170-6; Ryskamp DA, 2011, J NEUROSCI, V31, P7089, DOI 10.1523/JNEUROSCI.0359-11.2011; Schreiber R, 2010, J BIOL CHEM, V285, P7838, DOI 10.1074/jbc.M109.065367; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Shibasaki K, 2007, J NEUROSCI, V27, P1566, DOI 10.1523/JNEUROSCI.4284-06.2007; Shukla AK, 2010, J BIOL CHEM, V285, P30115, DOI 10.1074/jbc.M110.141549; Sidhaye VK, 2006, P NATL ACAD SCI USA, V103, P4747, DOI 10.1073/pnas.0511211103; Sokabe T, 2010, J BIOL CHEM, V285, P18749, DOI 10.1074/jbc.M110.103606; Speake T, 2003, BBA-BIOMEMBRANES, V1609, P80, DOI 10.1016/S0005-2736(02)00658-2; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki J, 2010, NATURE, V468, P834, DOI 10.1038/nature09583; Tian YM, 2012, J CELL SCI, V125, P4991, DOI 10.1242/jcs.109553; Tian YM, 2011, FASEB J, V25, P1058, DOI 10.1096/fj.10-166884; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Willette RN, 2008, J PHARMACOL EXP THER, V326, P443, DOI 10.1124/jpet.107.134551; Xiao QH, 2011, P NATL ACAD SCI USA, V108, P8891, DOI 10.1073/pnas.1102147108; Yang HH, 2012, CELL, V151, P111, DOI 10.1016/j.cell.2012.07.036; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313	42	61	64	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2238	2248		10.1096/fj.13-243436	http://dx.doi.org/10.1096/fj.13-243436			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24509911	Bronze			2022-12-28	WOS:000335336000026
J	Martens, W; Sanen, K; Georgiou, M; Struys, T; Bronckaers, A; Ameloot, M; Phillips, J; Lambrichts, I				Martens, Wendy; Sanen, Kathleen; Georgiou, Melanie; Struys, Tom; Bronckaers, Annelies; Ameloot, Marcel; Phillips, James; Lambrichts, Ivo			Human dental pulp stem cells can differentiate into Schwann cells and promote and guide neurite outgrowth in an aligned tissue-engineered collagen construct in vitro	FASEB JOURNAL			English	Article						cellular hydrogel; neural regeneration; nerve repair; myelination; glial cell	MARROW STROMAL CELLS; FUNCTIONALLY ACTIVE NEURONS; CRANIAL NEURAL CREST; NERVE REGENERATION; SPINAL-CORD; NEUROTROPHIC FACTORS; PLASTIC COMPRESSION; PERIPHERAL-NERVES; REPAIR; GUIDANCE	In the present study, we evaluated the differentiation potential of human dental pulp stem cells (hDPSCs) toward Schwann cells, together with their functional capacity with regard to myelination and support of neurite outgrowth in vitro. Successful Schwann cell differentiation was confirmed at the morphological and ultrastructural level by transmission electron microscopy. Furthermore, compared to undifferentiated hDPSCs, immunocytochemistry and ELISA tests revealed increased glial marker expression and neurotrophic factor secretion of differentiated hDPSCs (d-hDPSCs), which promoted survival and neurite outgrowth in 2-dimensional dorsal root ganglia cultures. In addition, neurites were myelinated by d-hDPSCs in a 3-dimensional collagen type I hydrogel neural tissue construct. This engineered construct contained aligned columns of d-hDPSCs that supported and guided neurite outgrowth. Taken together, these findings provide the first evidence that hDPSCs are able to undergo Schwann cell differentiation and support neural outgrowth in vitro, proposing them to be good candidates for cell-based therapies as treatment for peripheral nerve injury.-Martens, W., Sanen, K., Georgiou, M., Struys, T., Bronckaers, A., Ameloot, M., Phillips, J., Lambrichts, I. Human dental pulp stem cells can differentiate into Schwann cells and promote and guide neurite outgrowth in an aligned tissue-engineered collagen construct in vitro.	[Martens, Wendy; Struys, Tom; Bronckaers, Annelies; Lambrichts, Ivo] Hasselt Univ, Biomed Res Inst BIOMED, Dept Funct Morphol, Diepenbeek, Belgium; [Sanen, Kathleen; Ameloot, Marcel] Hasselt Univ, Biomed Res Inst BIOMED, Dept Biophys, Diepenbeek, Belgium; [Georgiou, Melanie; Phillips, James] Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes MK7 6AA, Bucks, England; [Georgiou, Melanie] UCL, Eastman Dent Inst, Dept Biochem Engn, London, England; [Phillips, James] UCL, Eastman Dent Inst, Dept Biomat & Tissue Engn, London, England	Hasselt University; Hasselt University; Open University - UK; University of London; University College London; University of London; University College London	Martens, W (corresponding author), Biomed Res Inst, Histol Lab, Campus Diepenbeek,Bldg C,Off C011, B-3590 Diepenbeek, Belgium.	wendy.martens@uhasselt.be	Lambrichts, Ivo/CAJ-1727-2022	Bronckaers, Annelies/0000-0001-8969-873X; Lambrichts, Ivo/0000-0001-7520-0021; Phillips, James/0000-0001-8117-3074	Hasselt University [05G02BOF]; Research Foundation Flanders [Fonds Wetenschappelijk Onderzoek (FWO)] [K200713N]; Interreg Euregio Meuse-Rhine IV-A consortium BioMIMedics; FWO [GO29112FWO]; Boehringer Ingelheim Fonds	Hasselt University; Research Foundation Flanders [Fonds Wetenschappelijk Onderzoek (FWO)](FWO); Interreg Euregio Meuse-Rhine IV-A consortium BioMIMedics; FWO(FWO); Boehringer Ingelheim Fonds(Boehringer Ingelheim)	The authors are grateful to Dr. Constantinus Politis and Dr. Luc Vrielinck (Ziekenhuis Oost Limburg, Genk Diepenbeek, Belgium) for providing dental pulp tissue and to Marc Jans for excellent tissue processing for transmission electron microscopy. This research was supported by multiple grants to W.M. and K.S. K.S. acknowledges funding from Hasselt University (05G02BOF), a travel grant from Research Foundation Flanders [Fonds Wetenschappelijk Onderzoek (FWO), grant K200713N] and funding by the Interreg Euregio Meuse-Rhine IV-A consortium BioMIMedics. W.M. benefits from a grant via FWO (GO29112FWO) and via the Boehringer Ingelheim Fonds.	Arthur A, 2008, STEM CELLS, V26, P1787, DOI 10.1634/stemcells.2007-0979; Arthur A, 2009, STEM CELLS, V27, P2229, DOI 10.1002/stem.138; Aurand ER, 2012, NEUROSCI RES, V72, P199, DOI 10.1016/j.neures.2011.12.005; Bell JHA, 2012, TISSUE ENG PART B-RE, V18, P116, DOI [10.1089/ten.teb.2011.0498, 10.1089/ten.TEB.2011.0498]; BRETSCHNEIDER A, 1981, AM J CLIN PATHOL, V76, P450; Brown RA, 2005, ADV FUNCT MATER, V15, P1762, DOI 10.1002/adfm.200500042; BROWN RA, 2004, Patent No. 2004087231; Brown RA, 2007, INT REV CYTOL, V262, P75, DOI 10.1016/S0074-7696(07)62002-6; Chai Y, 2000, DEVELOPMENT, V127, P1671; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Deumens R, 2010, PROG NEUROBIOL, V92, P245, DOI 10.1016/j.pneurobio.2010.10.002; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; East E, 2010, TISSUE ENG PT A, V16, P3173, DOI 10.1089/ten.tea.2010.0017; East E, 2009, J TISSUE ENG REGEN M, V3, P634, DOI 10.1002/term.209; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Geckil H, 2010, NANOMEDICINE-UK, V5, P469, DOI 10.2217/NNM.10.12; Georgiou M, 2013, BIOMATERIALS, V34, P7335, DOI 10.1016/j.biomaterials.2013.06.025; Graham A, 2004, DEV DYNAM, V229, P5, DOI 10.1002/dvdy.10442; Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; Gu XS, 2011, PROG NEUROBIOL, V93, P204, DOI 10.1016/j.pneurobio.2010.11.002; HALL SM, 1986, NEUROPATH APPL NEURO, V12, P401, DOI 10.1111/j.1365-2990.1986.tb00151.x; Huang AHC, 2008, STEM CELLS, V26, P2654, DOI 10.1634/stemcells.2008-0285; Ibarretxe G., 2012, STEM CELLS INT, V2012, DOI DOI 10.1155/2012/103503; Ichihara S, 2008, INJURY, V39, pS29, DOI 10.1016/j.injury.2008.08.029; Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Kiraly M, 2009, NEUROCHEM INT, V55, P323, DOI 10.1016/j.neuint.2009.03.017; Lietz M, 2006, BIOMATERIALS, V27, P1425, DOI 10.1016/j.biomaterials.2005.08.007; Mantovani Cristina, 2012, Methods Mol Biol, V916, P47, DOI 10.1007/978-1-61779-980-8_5; Martens W, 2013, CLIN ORAL INVEST, V17, P1969, DOI 10.1007/s00784-013-1030-3; Miletich Isabelle, 2004, Birth Defects Res C Embryo Today, V72, P200, DOI 10.1002/bdrc.20012; Nectow AR, 2012, TISSUE ENG PART B-RE, V18, P40, DOI [10.1089/ten.teb.2011.0240, 10.1089/ten.TEB.2011.0240]; Nosrat IV, 2004, EUR J NEUROSCI, V19, P2388, DOI 10.1111/j.0953-816X.2004.03314.x; Nosrat IV, 2001, DEV BIOL, V238, P120, DOI 10.1006/dbio.2001.0400; Papaccio G, 2006, J CELL PHYSIOL, V208, P319, DOI 10.1002/jcp.20667; Phillips JB, 2011, METHODS MOL BIOL, V695, P183, DOI 10.1007/978-1-60761-984-0_12; Phillips JB, 2005, TISSUE ENG, V11, P1611, DOI 10.1089/ten.2005.11.1611; Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88; Ren ZW, 2012, REV NEUROSCIENCE, V23, P135, DOI 10.1515/revneuro-2011-0069; Ribeiro-Resende VT, 2009, BIOMATERIALS, V30, P5251, DOI 10.1016/j.biomaterials.2009.07.007; Ross JJ, 2008, PHILOS T R SOC B, V363, P199, DOI 10.1098/rstb.2006.2021; Sakai K, 2012, J CLIN INVEST, V122, P80, DOI 10.1172/JCI59251; Sherman DL, 2005, NAT REV NEUROSCI, V6, P683, DOI 10.1038/nrn1743; Struys T, 2011, CELLS TISSUES ORGANS, V193, P366, DOI 10.1159/000321400; Terenghi G, 2009, INT REV NEUROBIOL, V87, P393, DOI 10.1016/S0074-7742(09)87021-9; Thesleff I, 1999, BONE, V25, P123, DOI 10.1016/S8756-3282(99)00119-2; Wei YJ, 2009, CELL TISSUE RES, V337, P361, DOI 10.1007/s00441-009-0836-4; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wright KE, 2009, BRIT J CANCER, V101, P658, DOI 10.1038/sj.bjc.6605197	52	120	125	5	52	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1634	1643		10.1096/fj.13-243980	http://dx.doi.org/10.1096/fj.13-243980			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24352035	Green Accepted, Green Published			2022-12-28	WOS:000335344300012
J	Roosjen, M; McColl, B; Kao, B; Gearing, LJ; Blewitt, ME; Vadolas, J				Roosjen, Mark; McColl, Bradley; Kao, Betty; Gearing, Linden J.; Blewitt, Marnie E.; Vadolas, Jim			Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal beta-like globin genes	FASEB JOURNAL			English	Article						RNA interference; beta-hemoglobinopathies; molecular mechanism; epigenetic repressor	CAUSES HEREDITARY PERSISTENCE; GAMMA-GLOBIN; THERAPEUTIC TARGET; NUCLEAR RECEPTORS; HEMOGLOBIN; DIFFERENTIATION; EXPRESSION; GENERATION; INDUCTION; HBS1L-MYB	The clinical symptoms of hemoglobin disorders such as beta-thalassemia and sickle cell anemia are significantly ameliorated by the persistent expression of gamma-globin after birth. This knowledge has driven the discovery of important regulators that silence gamma-globin postnatally. Improved understanding of the gamma- to beta-globin switching mechanism holds the key to devising targeted therapies for beta-hemoglobinopathies. To further investigate this mechanism, we used the murine erythroleukemic (MEL) cell line containing an intact 183-kb human beta-globin locus, in which the (G)gamma- and beta-globin genes are replaced by DsRed and eGFP fluorescent reporters, respectively. Following RNA interference (RNAi)-mediated knockdown of two key transcriptional regulators, Myb and BCL11A, we observed a derepression of gamma-globin, measured by DsRed fluorescence and qRT-PCR (P < 0.001). Interestingly, double knockdown of Myb and DNA methyltransferase 1 (DNMT1) resulted in a robust induction of epsilon-globin, (up to 20% of total beta-like globin species) compared to single knockdowns (P < 0.001). Conversely, double knockdowns of BCL11A and DNMT1 enhanced gamma-globin expression (up to 90% of total beta-like globin species) compared to single knockdowns (P < 0.001). Moreover, following RNAi treatment, expression of human beta-like globin genes mirrored the expression levels of their endogenous murine counterparts. These results demonstrate that Myb and BCL11A cooperate with DNMT1 to achieve developmental repression of embryonic and fetal beta-like globin genes in the adult erythroid environment.-Roosjen, M., McColl, B., Kao, B., Gearing, L. J., Blewitt, M. E., Vadolas, J. Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal beta-like globin genes.	[Roosjen, Mark] Van Hall Larenstein Univ Appl Sci, Leeuwarden, Netherlands; [Roosjen, Mark; McColl, Bradley; Kao, Betty; Vadolas, Jim] Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Grp, Melbourne, Vic, Australia; [Gearing, Linden J.; Blewitt, Marnie E.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Mol Med, Parkville, Vic 3050, Australia; [Kao, Betty; Vadolas, Jim] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Gearing, Linden J.; Blewitt, Marnie E.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Blewitt, Marnie E.] Univ Melbourne, Dept Genet, Melbourne, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; University of Melbourne; University of Melbourne	Vadolas, J (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Grp, Flemington Rd, Parkville, Vic 3052, Australia.	jim.vadolas@mcri.edu.au		Kao, Betty/0000-0003-0202-8018; Gearing, Linden/0000-0003-3508-3056; Blewitt, Marnie/0000-0002-2984-1474; Vadolas, Jim/0000-0002-3072-3512	Australia National Health and Medical Research Council; Murdoch Childrens Research Institute; Victorian Government's Operational Infrastructure Support Program, Thalassaemia Australia; Thalassaemia Society of New South Wales; Greek Conference	Australia National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Murdoch Childrens Research Institute; Victorian Government's Operational Infrastructure Support Program, Thalassaemia Australia; Thalassaemia Society of New South Wales; Greek Conference(Greek Ministry of Development-GSRT)	The Australia National Health and Medical Research Council, the Murdoch Childrens Research Institute, the Victorian Government's Operational Infrastructure Support Program, Thalassaemia Australia, the Thalassaemia Society of New South Wales, and the Greek Conference supported this work. The authors declare no conflicts of interest.	Akpan I, 2010, EXP HEMATOL, V38, P989, DOI 10.1016/j.exphem.2010.08.001; Amaya M, 2013, BLOOD, V121, P3493, DOI 10.1182/blood-2012-11-466227; Atweh GF, 1999, BLOOD, V93, P1790; Banzon V, 2011, EXP HEMATOL, V39, P26, DOI 10.1016/j.exphem.2010.10.003; Bianchi E, 2010, BLOOD, V116, pE99, DOI 10.1182/blood-2009-08-238311; Boosalis MS, 2011, BLOOD CELL MOL DIS, V47, P107, DOI 10.1016/j.bcmd.2011.04.008; Borg J, 2010, NAT GENET, V42, P801, DOI 10.1038/ng.630; Bradner JE, 2010, P NATL ACAD SCI USA, V107, P12617, DOI 10.1073/pnas.1006774107; Chan KSK, 2012, FASEB J, V26, P1736, DOI 10.1096/fj.11-199356; Costa FC, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003155; Cui SAY, 2011, MOL CELL BIOL, V31, P3298, DOI 10.1128/MCB.05310-11; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Funnell APW, 2013, MOL CELL BIOL, V33, P2976, DOI 10.1128/MCB.00074-13; Gonda TJ, 2008, EXPERT OPIN BIOL TH, V8, P713, DOI [10.1517/14712598.8.6.713, 10.1517/14712598.8.6.713 ]; Higgs DR, 2012, LANCET, V379, P373, DOI 10.1016/S0140-6736(11)60283-3; Jiang J, 2006, BLOOD, V108, P1077, DOI 10.1182/blood-2006-01-008912; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Mabaera R, 2008, EXP HEMATOL, V36, P1057, DOI 10.1016/j.exphem.2008.06.014; Majewski IJ, 2008, PLOS BIOL, V6, P796, DOI 10.1371/journal.pbio.0060093; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Olivieri NF, 1998, HUM MOL GENET, V7, P1655, DOI 10.1093/hmg/7.10.1655; Papadopoulos P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051272; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips JD, 2007, BLOOD, V109, P2618, DOI 10.1182/blood-2006-06-022848; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; Rees DC, 2011, HAEMATOL-HEMATOL J, V96, P488, DOI 10.3324/haematol.2011.041988; Sankaran VG, 2011, P NATL ACAD SCI USA, V108, P1519, DOI 10.1073/pnas.1018384108; Sankaran VG, 2010, ANN NY ACAD SCI, V1202, P64, DOI 10.1111/j.1749-6632.2010.05574.x; Shi LH, 2013, NAT MED, V19, P291, DOI 10.1038/nm.3101; Siatecka M, 2011, BLOOD, V118, P2044, DOI 10.1182/blood-2011-03-331371; Stadhouders R, 2012, EMBO J, V31, P986, DOI 10.1038/emboj.2011.450; Suzuki M, 2013, MOL CELL BIOL, V33, P1687, DOI 10.1128/MCB.01617-12; Tallack MR, 2013, CURR OPIN HEMATOL, V20, P193, DOI 10.1097/MOH.0b013e32835f59ba; Tanabe O, 2002, EMBO J, V21, P3434, DOI 10.1093/emboj/cdf340; Tanabe O, 2007, EMBO J, V26, P2295, DOI 10.1038/sj.emboj.7601676; Thein SL, 2007, P NATL ACAD SCI USA, V104, P11346, DOI 10.1073/pnas.0611393104; Uda M, 2008, P NATL ACAD SCI USA, V105, P1620, DOI 10.1073/pnas.0711566105; van Dijk TB, 2010, BLOOD, V116, P4349, DOI 10.1182/blood-2010-03-274399; Xu J, 2013, P NATL ACAD SCI USA, V110, P6518, DOI 10.1073/pnas.1303976110; Xu J, 2011, SCIENCE, V334, P993, DOI 10.1126/science.1211053; Xu J, 2010, GENE DEV, V24, P783, DOI 10.1101/gad.1897310; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	45	26	32	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1610	1620		10.1096/fj.13-242669	http://dx.doi.org/10.1096/fj.13-242669			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371119				2022-12-28	WOS:000335344300010
J	Aven, L; Paez-Cortez, J; Achey, R; Krishnan, R; Ram-Mohan, S; Cruikshank, WW; Fine, A; Ai, XB				Aven, Linh; Paez-Cortez, Jesus; Achey, Rebecca; Krishnan, Ramaswamy; Ram-Mohan, Sumati; Cruikshank, William W.; Fine, Alan; Ai, Xingbin			An NT4/TrkB-dependent increase in innervation links early-life allergen exposure to persistent airway hyperreactivity	FASEB JOURNAL			English	Article						smooth muscle; ASM; childhood asthma; innervation; contractility; lung slice	TRK RECEPTORS; MURINE MODEL; ASTHMA; CELLS; HYPERRESPONSIVENESS; INFLAMMATION; INDUCTION; SIGNALS; MUSCLE; MICE	Children who are exposed to environmental respiratory insults often develop asthma that persists into adulthood. In this study, we used a neonatal mouse model of ovalbumin (OVA)-induced allergic airway inflammation to understand the long-term effects of early childhood insults on airway structure and function. We showed that OVA sensitization and challenge in early life led to a 2-fold increase in airway smooth muscle (ASM) innervation (P<0.05) and persistent airway hyperreactivity (AHR). In contrast, OVA exposure in adult life elicited short-term AHR without affecting innervation levels. We found that postnatal ASM innervation required neurotrophin (NT)-4 signaling through the TrkB receptor and that early-life OVA exposure significantly elevated NT4 levels and TrkB signaling by 5- and 2-fold, respectively, to increase innervation. Notably, blockade of NT4/TrkB signaling in OVA-exposed pups prevented both acute and persistent AHR without affecting baseline airway function or inflammation. Furthermore, biophysical assays using lung slices and isolated cells demonstrated that NT4 was necessary for hyperreactivity of ASM induced by early-life OVA exposure. Together, our findings show that the NT4/TrkB-dependent increase in innervation plays a critical role in the alteration of the ASM phenotype during postnatal growth, thereby linking early-life allergen exposure to persistent airway dysfunction.Aven, L., Paez-Cortez, J., Achey, R., Krishnan, R., Ram-Mohan, S., Cruikshank, W. W., Fine, A., Ai X. An NT4/TrkB-dependent increase in innervation links early-life allergen exposure to persistent airway hyperreactivity.	[Aven, Linh; Paez-Cortez, Jesus; Achey, Rebecca; Cruikshank, William W.; Fine, Alan; Ai, Xingbin] Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; [Krishnan, Ramaswamy; Ram-Mohan, Sumati] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA	Boston University; Harvard University; Beth Israel Deaconess Medical Center	Ai, XB (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 72 East Concord St, Boston, MA 02118 USA.	aix@bu.edu			U.S. National Institutes of Health [HL112619, CA122737, HL007035]; Parker Francis Foundation; American Asthma Foundation [12-0086]; NATIONAL CANCER INSTITUTE [R01CA122737] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL116163, T32HL007035, R21HL112619] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker Francis Foundation; American Asthma Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. David Ginty (Johns Hopkins University, Baltimore, MD, USA) for the TrkB<SUP>F616A/F616A</SUP> mouse line; Dr. Janice Weinberg for statistical analysis; Kavon Kaboli for airway resistance assay by Flexivent; and Kelsi Radzikinas, Kruti Patel, and Kavitha Rajendran for technical assistance. This work was supported by grants to X. A. and A. F. (HL112619) and W. C. (CA122737) and a T32 training grant to L. A. (HL007035) from the U.S. National Institutes of Health; a grant from The Parker Francis Foundation to R. K.; and a grant to X. A. from the American Asthma Foundation (12-0086). The authors declare no conflicts of interest.	Ai XB, 2007, DEVELOPMENT, V134, P3327, DOI 10.1242/dev.007674; Aven L, 2013, ORGANOGENESIS, V9, P194, DOI 10.4161/org.24842; Bai Y, 2006, AM J PHYSIOL-LUNG C, V291, pL208, DOI 10.1152/ajplung.00494.2005; Belvisi MG, 2002, CURR OPIN PHARMACOL, V2, P211, DOI 10.1016/S1471-4892(02)00145-5; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Butler JP, 2002, AM J PHYSIOL-CELL PH, V282, pC595, DOI 10.1152/ajpcell.00270.2001; Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106; Chen X, 2005, NEURON, V46, P13, DOI 10.1016/j.neuron.2005.03.009; Chevrel G, 2006, MUSCLE NERVE, V33, P462, DOI 10.1002/mus.20444; de Vries A, 2006, CLIN EXP ALLERGY, V36, P1192, DOI 10.1111/j.1365-2222.2006.02549.x; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Garcia-Suarez O, 2009, RESP PHYSIOL NEUROBI, V167, P281, DOI 10.1016/j.resp.2009.06.001; Gelfand EW, 2012, CURR OPIN IMMUNOL, V24, P713, DOI 10.1016/j.coi.2012.08.011; Ghosh S, 2011, J BIOL CHEM, V286, P22678, DOI 10.1074/jbc.M111.241224; Giuditta A, 2002, TRENDS NEUROSCI, V25, P400, DOI 10.1016/S0166-2236(02)02188-4; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Kc P, 2010, RESP PHYSIOL NEUROBI, V173, P213, DOI 10.1016/j.resp.2010.03.020; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Knox SM, 2010, SCIENCE, V329, P1645, DOI 10.1126/science.1192046; Krishnan R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005486; Langsdorf A, 2011, AM J RESP CELL MOL, V44, P293, DOI 10.1165/rcmb.2009-0462OC; Larson SD, 2004, TOXICOL APPL PHARM, V194, P211, DOI 10.1016/j.taap.2003.09.025; LIU X, 1995, NATURE, V375, P238, DOI 10.1038/375238a0; Luther JA, 2009, AUTON NEUROSCI-BASIC, V151, P46, DOI 10.1016/j.autneu.2009.08.009; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Martinez FD, 2009, ALLERGOL IMMUNOPATH, V37, P249, DOI 10.1016/j.aller.2009.06.008; Morgan RK, 2007, J IMMUNOL, V178, P8081, DOI 10.4049/jimmunol.178.12.8081; Nassenstein C, 2006, J ALLERGY CLIN IMMUN, V118, P597, DOI 10.1016/j.jaci.2006.04.052; Nekrep N, 2008, DEVELOPMENT, V135, P2151, DOI 10.1242/dev.015859; Paez-Cortez J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074469; Radzikinas K, 2011, J NEUROSCI, V31, P15407, DOI 10.1523/JNEUROSCI.2745-11.2011; Rogerio AP, 2012, J IMMUNOL, V189, P1983, DOI 10.4049/jimmunol.1101665; Shuler MG, 2004, J COMP NEUROL, V472, P183, DOI 10.1002/cne.11017; SPRINGALL DR, 1987, J AUTONOM NERV SYST, V20, P155, DOI 10.1016/0165-1838(87)90113-5; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Szczepankiewicz A, 2012, EUR RESPIR J, V39, P1035, DOI 10.1183/09031936.00136611; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Tortorolo L, 2005, AM J RESP CRIT CARE, V172, P233, DOI 10.1164/rccm.200412-1693OC; Wu ZX, 2012, AM J PHYSIOL-LUNG C, V302, pL152, DOI 10.1152/ajplung.00071.2011; Wu ZX, 2009, ENVIRON HEALTH PERSP, V117, P1434, DOI 10.1289/ehp.0800511; Yu M, 2008, J ALLERGY CLIN IMMUN, V122, P640, DOI 10.1016/j.jaci.2008.04.038; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895	43	31	34	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					897	907		10.1096/fj.13-238212	http://dx.doi.org/10.1096/fj.13-238212			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24221086	Green Published			2022-12-28	WOS:000331072200035
J	Vorselen, D; Roos, WH; MacKintosh, FC; Wuite, GJL; van Loon, JJWA				Vorselen, Daan; Roos, Wouter H.; MacKintosh, Fred C.; Wuite, Gijs J. L.; van Loon, Jack J. W. A.			The role of the cytoskeleton in sensing changes in gravity by nonspecialized cells	FASEB JOURNAL			English	Review						mechanosensing; mechanotransduction; actin; tubulin	MICROTUBULE SELF-ORGANIZATION; REACTION-DIFFUSION PROCESSES; MESENCHYMAL STEM-CELLS; ALTERED GRAVITY; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; MICROGRAVITY	A large body of evidence indicates that single cells in vitro respond to changes in gravity, and that this response might play an important role for physiological changes at the organism level during spaceflight. Gravity can lead to changes in cell proliferation, differentiation, signaling, and gene expression. At first glance, gravitational forces seem too small to affect bodies with the size of a cell. Thus, the initial response to gravity is both puzzling and important for understanding physiological changes in space. This also offers a unique environment to study the mechanical response of cells. In the past 2 decades, important steps have been made in the field of mechanobiology, and we use these advances to reevaluate the response of single cells to changes in gravity. Recent studies have focused on the cytoskeleton as initial gravity sensor. Thus, we review the observed changes in the cytoskeleton in a microgravity environment, both during spaceflight and in ground-based simulation techniques. We also evaluate to what degree the current experimental evidence supports the cytoskeleton as primary gravity sensor. Finally, we consider how the cytoskeleton itself could be affected by changed gravity. To make the next step toward understanding the response of cells to altered gravity, the challenge will be to track changes quantitatively and on short timescales.Vorselen, D., Roos, W. H., MacKintosh, F. C., Wuite, G. J. L., van Loon, J. J. W. A. The role of the cytoskeleton in sensing changes in gravity by nonspecialized cells.	[Vorselen, Daan; Roos, Wouter H.; MacKintosh, Fred C.; Wuite, Gijs J. L.] Vrije Univ Amsterdam, Dept Phys & Astron, Amsterdam, Netherlands; [Vorselen, Daan; Roos, Wouter H.; MacKintosh, Fred C.; Wuite, Gijs J. L.] Vrije Univ Amsterdam, LaserLab Amsterdam, Amsterdam, Netherlands; [Vorselen, Daan; van Loon, Jack J. W. A.] Univ Amsterdam, Acad Ctr Dent Amsterdam ACTA, Dept Oral Cell Biol, Amsterdam, Netherlands; [Vorselen, Daan; van Loon, Jack J. W. A.] Vrije Univ Amsterdam, MOVE Res Inst Amsterdam, Amsterdam, Netherlands; [van Loon, Jack J. W. A.] VU Univ Med Ctr Amsterdam, Dept Oral & Maxillofacial Surg Oral Pathol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	van Loon, JJWA (corresponding author), Acad Ctr Dent Amsterdam ACTA, Dept Oral Cell Biol, Off 11N15,Gustav Mahler Laan 3004, NL-1081 LA Amsterdam, Netherlands.	j.vanloon@vumc.nl	Roos, Wouter/L-8346-2014; MacKintosh, Frederick/AAB-9332-2021; MacKintosh, Fred C/A-9450-2008	Roos, Wouter/0000-0002-5104-0139; MacKintosh, Frederick/0000-0002-2607-9541; MacKintosh, Fred C/0000-0002-2607-9541; wuite, gijs/0000-0002-5706-043X; van Loon, Jack/0000-0001-9051-6016	Netherlands Organisation for Scientific Research (NWO) [MG-10-07]; Netherlands Space Office (NSO); NWO-Vidi grant	Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Netherlands Space Office (NSO); NWO-Vidi grant(Netherlands Organization for Scientific Research (NWO))	This work is subsidized by the Netherlands Organisation for Scientific Research (NWO), grant MG-10-07 (D.V.) through the Netherlands Space Office (NSO), and by a NWO-Vidi grant (W.H.R.). The authors thank Prof. James Tabony for providing the panels for Fig. 2.	Alberts B., 2007, MOL BIOL CELL, P903; Albrecht-Buehler G, 1991, ASGSB Bull, V4, P25; Ando J, 2009, CIRC J, V73, P1983, DOI 10.1253/circj.CJ-09-0583; Blancaflor EB, 2013, AM J BOT, V100, P143, DOI 10.3732/ajb.1200283; Boonstra J, 1999, FASEB J, V13, pS35, DOI 10.1096/fasebj.13.9001.s35; Brangwynne CP, 2008, J CELL BIOL, V183, P583, DOI 10.1083/jcb.200806149; Briegleb W., 1992, AGSGB B, V5, P24; Buravkova LB, 2001, ACTA ASTRONAUT, V48, P647, DOI 10.1016/S0094-5765(01)00023-6; Carlsson SIM, 2003, BBA-MOL CELL RES, V1642, P173, DOI 10.1016/j.bbamcr.2003.08.003; Chebli Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058246; Chebli Y, 2011, FRONT PLANT SCI, V2, DOI 10.3389/fpls.2011.00056; Cogoli A, 1997, Adv Space Biol Med, V6, P33, DOI 10.1016/S1569-2574(08)60077-5; COGOLI A, 1993, J LEUKOCYTE BIOL, V54, P259, DOI 10.1002/jlb.54.3.259; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cogoli A., 2006, FUNDAMENTALS SPACE B, P121; Cortes S, 2006, BIOPHYS CHEM, V120, P168, DOI 10.1016/j.bpc.2005.11.002; Crawford-Young SJ, 2006, INT J DEV BIOL, V50, P183, DOI 10.1387/ijdb.052077sc; del Rio A, 2009, SCIENCE, V323, P638, DOI 10.1126/science.1162912; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Footer MJ, 2007, P NATL ACAD SCI USA, V104, P2181, DOI 10.1073/pnas.0607052104; Gaboyard S, 2002, NEUROREPORT, V13, P2139, DOI 10.1097/00001756-200211150-00030; Galkin VE, 2012, CURR BIOL, V22, pR96, DOI 10.1016/j.cub.2011.12.010; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Gershovich P.M., 2009, CELL TISS BIOL, V3, P423, DOI [10.1134/S1990519X09050046, DOI 10.1134/S1990519X09050046]; Glade N, 2006, BIOPHYS CHEM, V121, P1, DOI 10.1016/j.bpc.2005.12.001; Glansdorf P, 1971, THERMODYNAMIC THEORY; Grenon SM, 2013, SCI REP-UK, V3, DOI 10.1038/srep01494; Grimm D, 2011, EXPERT REV PROTEOMIC, V8, P13, DOI 10.1586/EPR.10.105; Grosse J, 2012, FASEB J, V26, P639, DOI 10.1096/fj.11-194886; Hammond TG, 2001, AM J PHYSIOL-RENAL, V281, pF12, DOI 10.1152/ajprenal.2001.281.1.F12; Hanggi P, 2002, CHEMPHYSCHEM, V3, P285, DOI 10.1002/1439-7641(20020315)3:3<285::AID-CPHC285>3.0.CO;2-A; Hayakawa K, 2008, J CELL SCI, V121, P496, DOI 10.1242/jcs.022053; Hijken PJ, 1991, ADV SPACE RES, V12, P145; Hoffman BD, 2011, NATURE, V475, P316, DOI 10.1038/nature10316; HORNECK G, 1992, NUCL TRACKS RAD MEAS, V20, P185; Huang Y, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-87; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Infanger M, 2006, CELL TISSUE RES, V324, P267, DOI 10.1007/s00441-005-0142-8; Ingber D, 1999, FASEB J, V13, pS3; Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kacena MA, 2004, MICROGRAVITY SCI TEC, V15, P28, DOI 10.1007/BF02870949; Kiss JZ, 1996, PHYSIOL PLANTARUM, V97, P237, DOI 10.1034/j.1399-3054.1996.970205.x; Kondepudi D K, 1991, ASGSB Bull, V4, P119; Kraft TFB, 2000, PLANTA, V211, P415, DOI 10.1007/s004250000302; Kuznetsov OA, 1996, PLANTA, V198, P87; Leitz G, 2009, PLANT CELL, V21, P843, DOI 10.1105/tpc.108.065052; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Li J, 2009, PROTOPLASMA, V238, P23, DOI 10.1007/s00709-009-0068-1; Limbach C, 2005, PLANT PHYSIOL, V139, P1030, DOI 10.1104/pp.105.068106; Margadant F, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001223; Marie PJ, 2000, CALCIFIED TISSUE INT, V67, P2, DOI 10.1007/s00223001088; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; Meloni MA, 2006, PROTOPLASMA, V229, P243, DOI 10.1007/s00709-006-0210-2; Meloni MA, 2011, CYTOSKELETON, V68, P125, DOI 10.1002/cm.20499; Meng R, 2011, ACTA BIOCH BIOPH SIN, V43, P133, DOI 10.1093/abbs/gmq121; MESLAND DAM, 1992, ADV SPACE RES-SERIES, V12, P15, DOI 10.1016/0273-1177(92)90259-Z; Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611; Moes MJA, 2011, MICROGRAVITY SCI TEC, V23, P249, DOI 10.1007/s12217-010-9185-x; Monici M, 2006, MICROGRAVITY SCI TEC, V18, P234, DOI 10.1007/BF02870417; Moore SW, 2010, DEV CELL, V19, P194, DOI 10.1016/j.devcel.2010.07.018; Morbidelli L, 2009, MICROGRAVITY SCI TEC, V21, P135, DOI 10.1007/s12217-008-9067-7; Morita MT, 2010, ANNU REV PLANT BIOL, V61, P705, DOI 10.1146/annurev.arplant.043008.092042; Nichols HL, 2006, PHYSIOL GENOMICS, V26, P163, DOI 10.1152/physiolgenomics.00323.2005; Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006; Pache C, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3377960; Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597; POLLARD EC, 1965, J THEOR BIOL, V8, P113, DOI 10.1016/0022-5193(65)90097-4; Puchner EM, 2012, ANNU REV BIOPHYS, V41, P497, DOI 10.1146/annurev-biophys-050511-102301; Roca-Cusachs P, 2012, J CELL SCI, V125, P3025, DOI 10.1242/jcs.095794; Rosner H, 2006, PROTOPLASMA, V229, P225, DOI 10.1007/s00709-006-0202-2; Schwarzenberg M, 1999, ADV SPACE RES, V24, P793, DOI 10.1016/S0273-1177(99)00075-7; Sciola L, 1999, ADV SPACE RES, V24, P801, DOI 10.1016/S0273-1177(99)00078-2; Searby ND, 2005, AM J PHYSIOL-CELL PH, V289, pC148, DOI 10.1152/ajpcell.00524.2003; Stanga J, 2009, PLANT SIGNAL BEHAV, V4, P933, DOI 10.4161/psb.4.10.9470; Suresh S, 2007, ACTA MATER, V55, P3989, DOI 10.1016/j.actamat.2007.04.022; TABONY J, 1994, SCIENCE, V264, P245, DOI 10.1126/science.8146654; TABONY J, 1992, P NATL ACAD SCI USA, V89, P6948, DOI 10.1073/pnas.89.15.6948; Todd P, 1989, ASGSB Bull, V2, P95; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; TYLER A, 1966, J THEOR BIOL, V11, P59, DOI 10.1016/0022-5193(66)90039-7; Ulbrich C, 2011, CELL PHYSIOL BIOCHEM, V28, P185, DOI 10.1159/000331730; Uva BM, 2002, BRAIN RES, V934, P132, DOI 10.1016/S0006-8993(02)02415-0; Van Loon JJWA, 2009, J MICROSC-OXFORD, V233, P234, DOI 10.1111/j.1365-2818.2009.03113.x; van Loon J.J.W.A., 2007, BIOL SPACE LIFE EART, P17; van Loon JJWA, 2007, ADV SPACE RES, V39, P1161, DOI 10.1016/j.asr.2007.02.016; van Loon JJWA, 2009, MICROGRAVITY SCI TEC, V21, P159, DOI 10.1007/s12217-008-9065-9; Vassy J., 2001, FASEB Journal, V15, P1104; Versari S, 2007, BBA-MOL CELL RES, V1773, P1645, DOI 10.1016/j.bbamcr.2007.05.014; Wan QQ, 2013, J BONE MINER METAB, V31, P520, DOI 10.1007/s00774-013-0449-6; Wang JHC, 2006, BIOMECH MODEL MECHAN, V5, P1, DOI 10.1007/s10237-005-0012-z; Wang N, 2009, NAT REV MOL CELL BIO, V10, P75, DOI 10.1038/nrm2594; Wehland M, 2013, CELL PHYSIOL BIOCHEM, V31, P432, DOI 10.1159/000343380; Wiese C, 2006, J CELL SCI, V119, P4143, DOI 10.1242/jcs.03226; Williams D, 2009, CAN MED ASSOC J, V180, P1317, DOI 10.1503/cmaj.090628; Yamamoto K, 2002, PLANT PHYSIOL, V128, P669, DOI 10.1104/pp.010804; Yang C, 2008, ACTA ASTRONAUT, V63, P923, DOI 10.1016/j.actaastro.2008.03.002; Yang F, 2008, CHINESE SCI BULL, V53, P1185, DOI 10.1007/s11434-008-0167-y; Yang F, 2010, MICROGRAVITY SCI TEC, V22, P45, DOI 10.1007/s12217-008-9103-7; Zayzafoon M, 2005, IMMUNOL REV, V208, P267, DOI 10.1111/j.0105-2896.2005.00330.x	105	104	110	1	64	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					536	547		10.1096/fj.13-236356	http://dx.doi.org/10.1096/fj.13-236356			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24249634				2022-12-28	WOS:000331072200003
J	Goldklang, MP; Perez-Zoghbi, JF; Trischler, J; Nkyimbeng, T; Zakharov, SI; Shiomi, T; Zelonina, T; Marks, AR; D'Armiento, JM; Marx, SO				Goldklang, Monica P.; Perez-Zoghbi, Jose F.; Trischler, Jordis; Nkyimbeng, Takwi; Zakharov, Sergey I.; Shiomi, Takayuki; Zelonina, Tina; Marks, Andrew R.; D'Armiento, Jeanine M.; Marx, Steven O.			Treatment of experimental asthma using a single small molecule with anti-inflammatory and BK channel-activating properties	FASEB JOURNAL			English	Article						airway smooth muscle; airway contractility; MAP kinases; ERK	AIRWAY SMOOTH-MUSCLE; KINASE-C-DELTA; HOUSE-DUST MITE; N-TERMINAL KINASE; PROTEIN-KINASES; MOUSE MODEL; INTRACELLULAR CA2+; POTASSIUM CHANNELS; T-CELLS; INFLAMMATION	Large conductance voltage- and calcium-activated potassium (BK) channels are highly expressed in airway smooth muscle (ASM). Utilizing the ovalbumin (OVA) and house dust mite (HDM) models of asthma in C57BL/6 mice, we demonstrate that systemic administration of the BK channel agonist rottlerin (5 mu g/g) during the challenge period reduced methacholine-induced airway hyperreactivity (AHR) in OVA-and HDM-sensitized mice (47% decrease in peak airway resistance in OVA-asthma animals, P<0.01; 54% decrease in HDM-asthma animals, P<0.01) with a 35-40% reduction in inflammatory cells and 20-35% reduction in Th2 cytokines in bronchoalveolar lavage fluid. Intravenous rottlerin (5 mu g/g) reduced AHR within 5 min in the OVA-asthma mice by 45% (P<0.01). With the use of an ex vivo lung slice technique, rottlerin relaxed acetylcholine-stimulated murine airway lumen area to 87 +/- 4% of the precontracted area (P<0.01 vs. DMSO control). Rottlerin increased BK channel activity in human ASM cells (V-50 shifted by 73.5 +/- 13.5 and 71.8 +/- 14.6 mV in control and asthmatic cells, respectively, both P<0.05 as compared with pretreatment) and reduced the frequency of acetylcholine-induced Ca2+ oscillations in murine ex vivo lung slices. These findings suggest that rottlerin, with both anti-inflammatory and ASM relaxation properties, may have benefit in treating asthma.	[Goldklang, Monica P.; Shiomi, Takayuki; Zelonina, Tina; D'Armiento, Jeanine M.] Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA; [Goldklang, Monica P.; D'Armiento, Jeanine M.] Columbia Univ, Coll Phys & Surg, Div Pulm Allergy & Crit Care, New York, NY 10032 USA; [Zakharov, Sergey I.; Marx, Steven O.] Columbia Univ, Coll Phys & Surg, Div Cardiol, Dept Med, New York, NY 10032 USA; [Trischler, Jordis; Nkyimbeng, Takwi; Marks, Andrew R.; D'Armiento, Jeanine M.] Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; [Zakharov, Sergey I.; Marx, Steven O.] Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; [Perez-Zoghbi, Jose F.] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Dept Cell Physiol & Mol Biophys, Lubbock, TX 79430 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Marx, SO (corresponding author), Columbia Univ, 630 West 168th St,P&S 9-420, New York, NY 10032 USA.	arm42@columbia.edu; jmd12@columbia.edu; sm460@columbia.edu	Shiomi, Takayuki/A-2228-2014; Zakharov, Sergey/L-8511-2014; Zakharov, Sergey/O-2896-2019	Shiomi, Takayuki/0000-0002-4250-1204; Zakharov, Sergey/0000-0001-9864-8304; Zakharov, Sergey/0000-0001-9864-8304; Goldklang, Monica/0000-0002-7019-3130; Perez-Zoghbi, Jose Francisco/0000-0002-7554-6468	U.S. National Institutes of Health [UL1 TR000040]; American Asthma Foundation; U.S. National Institute of Heart, Lung, and Blood [P01-HL-081172, R01-HL-086936, T32-HL-007854, T32-HL-007343]; American Heart Association [11SDG5670050]; American Lung Association [RG-196192-N]; Flight Attendant Medical Research Institute Young Clinical Scientist Award [103236]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086936, T32HL007854, P01HL081172, T32HL007343] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation; U.S. National Institute of Heart, Lung, and Blood; American Heart Association(American Heart Association); American Lung Association; Flight Attendant Medical Research Institute Young Clinical Scientist Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Yong-Xiao Wang and members of the Wang laboratory at Albany Medical College (Albany, NY, USA) for help with the isolation of murine ASM cells. The authors thank Drs. Charles Emala and Elizabeth Townsend for providing human ASM cells and for thoughtful critiques of this work. The authors thank Jacquelyn Trice for assistance with the lung slice experiments, Sarah Marks for assistance with cell culture and histology, and Dr. Amy Simon for advice about the HDM model. The authors thank Drs. Tiffany Thomas and Serge Cremers (Columbia University Biomarkers Core Lab, Irving Institute for Clinical and Translational Research; U.S. National Institutes of Health grant UL1 TR000040) for assistance with the liquid chromatography-mass spectrometry work. This study was supported by funds from an American Asthma Foundation grant (to A. R. M.); U.S. National Institute of Heart, Lung, and Blood grants P01-HL-081172 (to S.O.M., A. R. M., and J.M.D.), R01-HL-086936 (to J.M.D.), T32-HL-007854 (to M. P. G.), and T32-HL-007343 (to M. P. G.); American Heart Association grant 11SDG5670050 (to J.F.P.-Z.); American Lung Association grant RG-196192-N (to J.F.P.-.Z); and Flight Attendant Medical Research Institute Young Clinical Scientist Award 103236 (to J.M.D. and M. P. G.). Columbia University, on behalf of S.O.M., S.I.Z., A. R. M., and J.M.D., has filed a patent for the use of rottlerin in activating BK channels and treating asthma.	Alrashdan YA, 2012, AM J PHYSIOL-LUNG C, V302, pL1118, DOI 10.1152/ajplung.00232.2011; BARNES PJ, 1985, BRIT J CLIN PHARMACO, V20, pS289, DOI 10.1111/j.1365-2125.1985.tb02815.x; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Ben-Chaim Y, 2003, J BIOL CHEM, V278, P22482, DOI 10.1074/jbc.M301146200; Blacquiere MJ, 2010, INT ARCH ALLERGY IMM, V153, P173, DOI 10.1159/000312635; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cho SH, 2004, J ALLERGY CLIN IMMUN, V114, P1085, DOI 10.1016/j.jaci.2004.07.035; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Eynott PR, 2003, BRIT J PHARMACOL, V140, P1373, DOI 10.1038/sj.bjp.0705569; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Fattouh R, 2011, AM J RESP CRIT CARE, V183, P179, DOI 10.1164/rccm.200905-0736OC; Goplen N, 2012, FASEB J, V26, P1934, DOI 10.1096/fj.11-196477; Grunstein MM, 2005, J ALLERGY CLIN IMMUN, V116, P94, DOI 10.1016/j.jaci.2005.03.046; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GUJRAL M. L., 1960, INDIAN JOUR MED RES, V48, P52; Hallsworth MP, 2001, AM J RESP CRIT CARE, V164, P688, DOI 10.1164/ajrccm.164.4.2011004; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Jaffar Z, 2004, J IMMUNOL, V172, P3842, DOI 10.4049/jimmunol.172.6.3842; Janssen LJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1757, DOI 10.1152/ajpcell.1997.272.6.C1757; Janssen LJ, 2004, AM J PHYSIOL-LUNG C, V287, pL852, DOI 10.1152/ajplung.00130.2004; Janssen LJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-123; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; Kotlikoff MI, 1996, ANNU REV PHYSIOL, V58, P115, DOI 10.1146/annurev.ph.58.030196.000555; KUME H, 1995, AM J PHYSIOL-LUNG C, V268, pL221, DOI 10.1152/ajplung.1995.268.2.L221; Langlois A, 2009, J LEUKOCYTE BIOL, V85, P656, DOI 10.1189/jlb.0808492; Lee JH, 2001, AM J PHYSIOL-LUNG C, V280, pL1019, DOI 10.1152/ajplung.2001.280.5.L1019; Lee JS, 2008, CYTOKINE, V42, P365, DOI 10.1016/j.cyto.2008.03.010; Liu CQ, 2005, AM J PHYSIOL-LUNG C, V289, pL574, DOI 10.1152/ajplung.00134.2005; Liu QH, 2009, P NATL ACAD SCI USA, V106, P11418, DOI 10.1073/pnas.0813307106; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Mehra D, 2010, AM J PHYSIOL-LUNG C, V298, pL189, DOI 10.1152/ajplung.00042.2009; Miura K, 1999, J IMMUNOL, V162, P4198; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Naureckas ET, 1999, AM J RESP CRIT CARE, V160, P2062, DOI 10.1164/ajrccm.160.6.9903131; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Perez JF, 2005, J GEN PHYSIOL, V125, P535, DOI 10.1085/jgp.200409216; Perez-Zoghbi JF, 2010, J GEN PHYSIOL, V135, P247, DOI 10.1085/jgp.200910365; Roose JP, 2005, MOL CELL BIOL, V25, P4426, DOI 10.1128/MCB.25.11.4426-4441.2005; Sanderson MJ, 2003, METHOD ENZYMOL, V360, P447; Schubl S, 2009, J SURG RES, V153, P181, DOI 10.1016/j.jss.2008.04.032; Seibold MA, 2008, HUM MOL GENET, V17, P2681, DOI 10.1093/hmg/ddn168; Semenov I, 2006, AM J PHYSIOL-LUNG C, V291, pL802, DOI 10.1152/ajplung.00104.2006; Semenov I, 2011, J PHYSIOL-LONDON, V589, P1803, DOI 10.1113/jphysiol.2010.204347; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Soltoff SP, 2007, TRENDS PHARMACOL SCI, V28, P453, DOI 10.1016/j.tips.2007.07.003; Springael C, 2007, BIOCHEM PHARMACOL, V73, P515, DOI 10.1016/j.bcp.2006.10.034; Tan X, 2013, AM J PHYSIOL-LUNG C, V304, pL790, DOI 10.1152/ajplung.00356.2012; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Townsend EA, 2010, AM J PHYSIOL-LUNG C, V298, pL521, DOI 10.1152/ajplung.00287.2009; Wang JM, 2000, J IMMUNOL, V165, P4051, DOI 10.4049/jimmunol.165.7.4051; Zakharov SI, 2005, J BIOL CHEM, V280, P30882, DOI 10.1074/jbc.M505302200; Zhang DH, 2007, J PHARMACOL EXP THER, V322, P913, DOI 10.1124/jpet.107.124669; Zhou XB, 2008, J BIOL CHEM, V283, P21036, DOI 10.1074/jbc.M800447200	56	25	26	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4975	4986		10.1096/fj.13-235176	http://dx.doi.org/10.1096/fj.13-235176			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23995289	Green Published			2022-12-28	WOS:000329999000031
J	Lim, JX; Iyer, A; Liu, LG; Suen, JY; Lohman, RJ; Seow, V; Yau, MK; Brown, L; Fairlie, DP				Lim, Junxian; Iyer, Abishek; Liu, Ligong; Suen, Jacky Y.; Lohman, Rink-Jan; Seow, Vernon; Yau, Mei-Kwan; Brown, Lindsay; Fairlie, David P.			Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism	FASEB JOURNAL			English	Article						protease-activated receptor; adipocyte; macrophage; biomarker; inhibitor	PROTEINASE-ACTIVATED RECEPTOR-2; TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; TISSUE; ADIPOCYTE; PALMITOYLATION; PROTEINASE-ACTIVATED-RECEPTOR-2; CELLS; DEFICIENCY; PROTECTS	Excessive uptake of fatty acids and glucose by adipose tissue triggers adipocyte dysfunction and infiltration of immune cells. Altered metabolic homeostasis in adipose tissue promotes insulin resistance, type 2 diabetes, hypertension, and cardiovascular disease. Inflammatory and metabolic processes are mediated by certain proteolytic enzymes that share a common cellular target, protease-activated receptor 2 (PAR2). This study showed that human and rat obesity correlated in vivo with increased expression of PAR2 in adipose tissue, primarily in stromal vascular cells (SVCs) including macrophages. PAR2 was expressed more than other PARs on human macrophages and was increased by dietary fatty acids (palmitic, stearic, and myristic). A novel PAR2 antagonist, GB88 (5-isoxazoyl-Cha-Ile-spiroindene-1,4-piperidine), given orally at 10 mg/kg/d (wk 8-16) reduced body weight by similar to 10% in obese rats fed a high-carbohydrate high-fat (HCHF) diet for 16 wk, and strongly attenuated adiposity, adipose tissue inflammation, infiltrated macrophages and mast cells, insulin resistance, and cardiac fibrosis and remodeling; while reversing liver and pancreatic dysfunction and normalizing secretion of PAR2-directed glucose-stimulated insulin secretion in MIN6 beta cells. In summary, PAR2 is a new biomarker for obesity, and its expression is stimulated by dietary fatty acids; PAR2 is a substantial contributor to inflammatory and metabolic dysfunction; and a PAR2 antagonist inhibits diet-induced obesity and inflammatory, metabolic, and cardiovascular dysfunction.	[Lim, Junxian; Iyer, Abishek; Liu, Ligong; Suen, Jacky Y.; Lohman, Rink-Jan; Seow, Vernon; Yau, Mei-Kwan; Fairlie, David P.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Brown, Lindsay] Univ So Queensland, Dept Biol & Phys Sci, Toowoomba, Qld 4350, Australia	University of Queensland; University of Southern Queensland	Fairlie, DP (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	lindsay.brown@usq.edu.au; d.fairlie@imb.uq.edu.au	Lim, Junxian/J-2275-2017; Lohman, Rink-Jan/F-5733-2011; liu, ligong/B-1690-2010; Fairlie, David P/F-8865-2014; Iyer, Abishek/C-9767-2017; Suen, Jacky/G-4077-2015	Lim, Junxian/0000-0002-8309-0704; Lohman, Rink-Jan/0000-0001-6387-0992; liu, ligong/0000-0002-2693-1896; Fairlie, David P/0000-0002-7856-8566; Iyer, Abishek/0000-0001-9533-5265; Suen, Jacky/0000-0002-0309-2524; Yau, Mei-Kwan/0000-0002-5620-8359	Australian National Health and Medical Research Council [1000745, 1047759, 631534]; Senior Principal Research Fellowship [1027369]; Australian Research Council [FF0668733]; grant for GPCR research [DP1093245]; Queensland Government	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Senior Principal Research Fellowship; Australian Research Council(Australian Research Council); grant for GPCR research; Queensland Government	The authors thank the Australian National Health and Medical Research Council for grant support (1000745, 1047759, 631534) and a Senior Principal Research Fellowship to D. P. F. (1027369), the Australian Research Council for a Federation Fellowship to D. P. F. (FF0668733) and a grant for GPCR research (DP1093245), and the Queensland Government for a 2012 Co-Investment Fund (CIF) grant. The authors thank Jon Whitehead (Mater Medical Research Institute, Brisbane, QLD, Australia) for human adipose RNA and SGBS cells, Brad Marsh (Institute for Molecular Bioscience, Brisbane, QLD, Australia) for MIN6 cells, the Australian Red Cross for providing the buffy coat for human monocyte isolation, and the Australian Cancer Research Foundation (ACRF) Cancer Biology Imaging Facility (Brisbane, QLD, Australia) for the use of confocal microscopes. The authors have filed patents on PAR2 antagonists and their uses, which are owned by The University of Queensland. The authors declare no other conflicts of interest.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Adams MN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028018; Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Antoniak S, 2010, ARTERIOSCL THROM VAS, V30, P2136, DOI 10.1161/ATVBAHA.110.213280; Badeanlou L, 2011, NAT MED, V17, P1490, DOI 10.1038/nm.2461; Barry GD, 2010, J MED CHEM, V53, P7428, DOI 10.1021/jm100984y; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Bucci M, 2013, BRIT J PHARMACOL, V168, P411, DOI 10.1111/j.1476-5381.2012.02205.x; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497; Dulon S, 2005, AM J RESP CELL MOL, V32, P411, DOI 10.1165/rcmb.2004-0274OC; Dulon S, 2003, AM J RESP CELL MOL, V28, P339, DOI 10.1165/rcmb.4908; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Han CY, 2010, DIABETES, V59, P386, DOI 10.2337/db09-0925; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Iyer A, 2012, DIABETES, V61, P2320, DOI 10.2337/db11-1179; Iyer A, 2010, NAT REV ENDOCRINOL, V6, P71, DOI 10.1038/nrendo.2009.264; Jin H, 1997, EUR J PHARMACOL, V324, P109, DOI 10.1016/S0014-2999(97)00059-9; Johnson EJ, 2006, AM J CLIN NUTR, V83, p1494S, DOI 10.1093/ajcn/83.6.1494S; Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kanke T, 2009, BRIT J PHARMACOL, V158, P361, DOI 10.1111/j.1476-5381.2009.00342.x; Kawate N, 1997, MOL CELL ENDOCRINOL, V127, P211, DOI 10.1016/S0303-7207(97)04010-0; Kelso EB, 2007, ARTHRITIS RHEUM, V56, P765, DOI 10.1002/art.22423; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Lim J, 2013, FASEB J, V27, P822, DOI 10.1096/fj.12-220582; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Lohman RJ, 2012, FASEB J, V26, P2877, DOI 10.1096/fj.11-201004; Lohman RJ, 2012, J PHARMACOL EXP THER, V340, P256, DOI 10.1124/jpet.111.187062; McLarty JL, 2011, HYPERTENSION, V58, P264, DOI 10.1161/HYPERTENSIONAHA.111.169417; Naour N, 2010, J CLIN ENDOCR METAB, V95, P1861, DOI 10.1210/jc.2009-1894; Newell FS, 2006, FASEB J, V20, P2615, DOI 10.1096/fj.05-5710fje; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Ohtsubo K, 2011, NAT MED, V17, P1067, DOI 10.1038/nm.2414; Panchal SK, 2011, J CARDIOVASC PHARM, V57, P611, DOI [10.1097/FJC.0b013e3181feb90a, 10.1097/FJC.0b013e31821b1379]; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Rallabhandi P, 2008, J BIOL CHEM, V283, P24314, DOI 10.1074/jbc.M804800200; Ramachandran R, 2011, J BIOL CHEM, V286, P24638, DOI 10.1074/jbc.M110.201988; Regard JB, 2007, J CLIN INVEST, V117, P4034, DOI 10.1172/JCI32994; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Samad F, 2001, BLOOD, V98, P3353, DOI 10.1182/blood.V98.12.3353; Sams-Dodd F, 2005, DRUG DISCOV TODAY, V10, P139, DOI 10.1016/S1359-6446(04)03316-1; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011; Suen JY, 2012, BRIT J PHARMACOL, V165, P1413, DOI 10.1111/j.1476-5381.2011.01610.x; Suen JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013809; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Wang P, 2010, BMC BIOCHEM, V11, DOI 10.1186/1471-2091-11-36; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wentworth JM, 2010, DIABETES, V59, P1648, DOI 10.2337/db09-0287; Yau MK, 2013, J MED CHEM, V56, P7477, DOI 10.1021/jm400638v	56	80	83	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4757	4767		10.1096/fj.13-232702	http://dx.doi.org/10.1096/fj.13-232702			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964081				2022-12-28	WOS:000329999000011
J	Magnifico, S; Saias, L; Deleglise, B; Duplus, E; Kilinc, D; Miquel, MC; Viovy, JL; Brugg, B; Peyrin, JM				Magnifico, Sebastien; Saias, Laure; Deleglise, Berangere; Duplus, Eric; Kilinc, Devrim; Miquel, Marie-Christine; Viovy, Jean-Louis; Brugg, Bernard; Peyrin, Jean-Michel			NAD(+) acts on mitochondrial SirT3 to prevent axonal caspase activation and axonal degeneration	FASEB JOURNAL			English	Article						microfluidic; apoptosis; sirtuin	WALLERIAN DEGENERATION; SIRT3-MEDIATED DEACETYLATION; LYSINE ACETYLATION; SELF-DESTRUCTION; DNA-DAMAGE; IN-VIVO; APOPTOSIS; SYNAPSES; SIRTUINS; WLD(S)	In chronic degenerative syndromes, neuronal death occurs over long periods, during which cells progressively lose their axons and, ultimately, their cell bodies. Although apoptosis is recognized as a key event in neuronal death, the molecular mechanisms involved in CNS axons degeneration are poorly understood. Due to the highly polarized phenotypes of CNS neurons, the different neuronal subcompartments are likely to be targeted by light repetitive and localized aggression. Such locally initiated deleterious signal transduction pathways could theoretically spread through the cytoplasm. However, where axon-degenerative signals initiate, what these early signals are, and how they lead to axon degeneration are unanswered questions that limit our understanding of neurodegenerative diseases and our ability to identify novel therapeutic targets. Using a microfluidic culture device adapted to CNS primary neurons, allowing specific access to the axonal and somatodendritic compartments, we analyzed the molecular pathways involved in axonal degeneration of differentiated neurons. We show here that local application of proapoptotic stimuli on the somatodentritic compartment triggers a dying-back pattern involving caspase-dependent axonal degeneration. Using complementary pharmacological and genetic approaches, we further demonstrate that NAD(+) and grape wine polyphenols prevent axonal apoptosis and act via mitochondrial SirT3 activation in axons.	[Magnifico, Sebastien; Deleglise, Berangere; Duplus, Eric; Kilinc, Devrim; Brugg, Bernard; Peyrin, Jean-Michel] CNRS, Unite Mixte Rech UMR 7102, Paris, France; [Magnifico, Sebastien; Saias, Laure; Deleglise, Berangere; Duplus, Eric; Kilinc, Devrim; Miquel, Marie-Christine; Viovy, Jean-Louis; Brugg, Bernard; Peyrin, Jean-Michel] Univ Paris 06, F-75005 Paris, France; [Saias, Laure; Viovy, Jean-Louis] Inst Curie, CNRS, UMR 168, F-75231 Paris, France; [Miquel, Marie-Christine] Toulouse Univ, CNRS, UMR 5541, Ctr Dev Biol, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE)	Peyrin, JM (corresponding author), Univ Paris 06, CNRS, UMR 7102, 9 Quai St Bernard,Bat B,6Eme Etage, F-75005 Paris, France.	jean-michel.peyrin@upmc.fr	Kilinc, Devrim/E-8733-2011; Kilinc, Devrim/I-4180-2019; DUPLUS, Eric/F-2969-2013	Kilinc, Devrim/0000-0003-3321-5203; Kilinc, Devrim/0000-0003-3321-5203; Peyrin, Jean-Michel/0000-0002-8705-8672; Peyrin, Jean-Michel/0000-0002-0108-1266; Miquel, Marie-Christine/0000-0002-9332-2572; Viovy, Jean-Louis/0000-0002-8223-4040; DUPLUS, Eric/0000-0003-1954-4836	Agence Nationale de la Recherche (ANR) Neuroscience research grant, ANR Bornaphosphopath, Plan Alzheimer; French Ministere de l'Enseignement Superieur et de la Recherche	Agence Nationale de la Recherche (ANR) Neuroscience research grant, ANR Bornaphosphopath, Plan Alzheimer(French National Research Agency (ANR)); French Ministere de l'Enseignement Superieur et de la Recherche	The authors thank Vincent Setola and Etienne Jacotot for critical reading of the manuscript. This project was funded by the Agence Nationale de la Recherche (ANR) Neuroscience research grant, ANR Bornaphosphopath, Plan Alzheimer. B. D., S. M., and M. S. received Ph.D. fellowships from the French Ministere de l'Enseignement Superieur et de la Recherche. The authors declare no conflicts of interest.	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Alvarez S, 2008, EXP NEUROL, V212, P166, DOI 10.1016/j.expneurol.2008.03.022; Arendt T, 2009, ACTA NEUROPATHOL, V118, P167, DOI 10.1007/s00401-009-0536-x; Awasaki T, 2006, NEURON, V50, P855, DOI 10.1016/j.neuron.2006.04.027; Babetto E, 2010, J NEUROSCI, V30, P13291, DOI 10.1523/JNEUROSCI.1189-10.2010; Bao JJ, 2010, J CELL BIOCHEM, V110, P238, DOI 10.1002/jcb.22531; Barnat M, 2010, J NEUROSCI, V30, P7804, DOI 10.1523/JNEUROSCI.0372-10.2010; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Beirowski B, 2009, J NEUROSCI, V29, P653, DOI 10.1523/JNEUROSCI.3814-08.2009; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; Borsello T, 2000, NEUROSCIENCE, V95, P163; Brichese L, 2004, CELL CYCLE, V3, P1312, DOI 10.4161/cc.3.10.1166; Brooks C, 2007, P NATL ACAD SCI USA, V104, P11649, DOI 10.1073/pnas.0703976104; Coleman M, 2011, ADV GENET, V73, P185, DOI 10.1016/B978-0-12-380860-8.00005-7; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Courchesne SL, 2011, J NEUROSCI, V31, P1624, DOI 10.1523/JNEUROSCI.3347-10.2011; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Feng Y, 2010, PROTEIN CELL, V1, P237, DOI 10.1007/s13238-010-0021-2; Finn JT, 2000, J NEUROSCI, V20, P1333; Fritz KS, 2012, J PROTEOME RES, V11, P1633, DOI 10.1021/pr2008384; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Glass JD, 2002, J NEUROL SCI, V196, P9, DOI 10.1016/S0022-510X(02)00013-8; Hafner AV, 2010, AGING-US, V2, P914, DOI 10.18632/aging.100252; Hirschey MD, 2011, COLD SH Q B, V76, P267, DOI 10.1101/sqb.2011.76.010850; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Karbowski M, 2010, ADV EXP MED BIOL, V687, P131; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kilinc D, 2011, NEUROTOX RES, V19, P149, DOI 10.1007/s12640-010-9152-8; Kim SH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014731, 10.1371/journal.pone.0026214]; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kuo CT, 2006, NEURON, V51, P283, DOI 10.1016/j.neuron.2006.07.014; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Louneva N, 2008, AM J PATHOL, V173, P1488, DOI 10.2353/ajpath.2008.080434; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Miller BR, 2009, NAT NEUROSCI, V12, P387, DOI 10.1038/nn.2290; Nakagawa T, 2011, J CELL SCI, V124, P833, DOI 10.1242/jcs.081067; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; Park SH, 2011, INT J MOL SCI, V12, P6226, DOI 10.3390/ijms12096226; Paul D, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3569946; Pfister JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004090; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Schoenmann Z, 2010, J NEUROSCI, V30, P6375, DOI 10.1523/JNEUROSCI.0922-10.2010; Song WJ, 2013, NEUROBIOL DIS, V51, P72, DOI 10.1016/j.nbd.2012.07.004; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Wang J, 2009, CELL ADHES MIGR, V3, P77, DOI 10.4161/cam.3.1.7483; Wen YH, 2011, MOL CELL NEUROSCI, V48, P1, DOI 10.1016/j.mcn.2011.05.002; Whitmore AV, 2003, CELL DEATH DIFFER, V10, P260, DOI 10.1038/sj.cdd.4401147; Yahata N, 2009, J NEUROSCI, V29, P6276, DOI 10.1523/JNEUROSCI.4304-08.2009; Yankner BA, 2009, J BIOL CHEM, V284, P4754, DOI 10.1074/jbc.R800018200; Yu W, 2012, J BIOL CHEM, V287, P14078, DOI 10.1074/jbc.M112.355206; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002	59	32	35	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4712	4722		10.1096/fj.13-229781	http://dx.doi.org/10.1096/fj.13-229781			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23975935				2022-12-28	WOS:000329999000007
J	Wang, P; Guan, PP; Guo, C; Zhu, F; Konstantopoulos, K; Wang, ZY				Wang, Pu; Guan, Pei-Pei; Guo, Chuang; Zhu, Fei; Konstantopoulos, Konstantinos; Wang, Zhan-You			Fluid shear stress-induced osteoarthritis: roles of cyclooxygenase-2 and its metabolic products in inducing the expression of proinflammatory cytokines and matrix metalloproteinases	FASEB JOURNAL			English	Review						PGE(2); 15d-PGJ(2); inflammation; apoptosis; chondrocytes	TUMOR-NECROSIS-FACTOR; ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; PROTEIN-KINASE-A; HUMAN CHONDROCYTES; GENE-EXPRESSION; FACTOR-ALPHA; ARTICULAR-CARTILAGE; SIGNALING PATHWAYS; TISSUE INHIBITOR	The mechanical overloading of cartilage is involved in the pathophysiology of osteoarthritis (OA) by both biochemical and mechanical pathways. The application of fluid shear stress to chondrocytes recapitulates the earmarks of OA, as evidenced by the release of proinflammatory cytokines (PICs), matrix metalloproteinases (MMPs), and apoptotic factors. Dysregulations or mutations in these genes might directly cause OA in addition to determining the stage at which OA becomes apparent, the joint sites involved, and the severity of the disease and how rapidly it progresses. However, the underlying mechanisms remain unknown. In this review, we propose that the dysregulation of cyclooxygenase-2 (COX-2) is associated with fluid shear stress-induced OA via its metabolic products at different stages of the disease. Indeed, high fluid shear stress rapidly induces the production of PICs and MMPs via COX-2-derived prostaglandin (PG)E-2 at the early stage of OA. In contrast, prolonged shear exposure (>12 h) aggravates the condition by concurrently up-regulating the expression of proapoptotic genes and down-regulating the expression of antiapoptotic genes in a 15-deoxy-Delta (12,14)-prostaglandin J(2) (15d-PGJ(2))-dependent manner at the late stage of disease. These observations may help to resolve long-standing questions in OA progression and provide insight for development of strategies to treat and combat OA.	[Wang, Pu; Guan, Pei-Pei; Guo, Chuang; Wang, Zhan-You] Northeastern Univ, Coll Life & Hlth Sci, Shenyang 110004, Peoples R China; [Wang, Pu; Guan, Pei-Pei; Zhu, Fei; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Inst NanoBio Technol, Baltimore, MD USA	Northeastern University - China; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wang, ZY (corresponding author), Northeastern Univ, Coll Life & Hlth Sci, Shenyang 110004, Peoples R China.	kkonsta1@jhu.edu; wangzy@mail.neu.edu.cn	Konstantopoulos, Konstantinos/A-7045-2011	Wang, Zhan-You/0000-0003-0807-9916	U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [RO1 (AR053358)]; Fundamental Research Funds of China [N120520001, N120320001]; Liaoning Province High School Talent Support Program of China [LJQ2013029]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053358] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Fundamental Research Funds of China; Liaoning Province High School Talent Support Program of China; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported, in whole or in part, by the U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grant RO1 (AR053358), Fundamental Research Funds of China (N120520001 and N120320001), and Liaoning Province High School Talent Support Program of China (LJQ2013029).	Abulencia JP, 2003, J BIOL CHEM, V278, P28388, DOI 10.1074/jbc.M301378200; Afzal S, 2011, PAK J PHARM SCI, V24, P217; Alaaeddine N, 1999, CYTOKINE, V11, P1020, DOI 10.1006/cyto.1999.0505; Alfranca A, 2008, BLOOD, V112, P1120, DOI 10.1182/blood-2007-09-112268; Alleva DG, 2002, J LEUKOCYTE BIOL, V71, P677; Alshihabi SN, 1996, BIOCHEM BIOPH RES CO, V224, P808, DOI 10.1006/bbrc.1996.1104; Alves CF, 2011, BRIT J PHARMACOL, V162, P623, DOI 10.1111/j.1476-5381.2010.01057.x; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Baici A, 1998, BIOL CHEM, V379, P1007; Boileau C, 2005, ANN RHEUM DIS, V64, P891, DOI 10.1136/ard.2004.026906; Brenn D, 2007, ARTHRITIS RHEUM, V56, P351, DOI 10.1002/art.22282; Buckwalter JA, 2006, BIORHEOLOGY, V43, P603; Carroll GT, 2009, CELL MOL BIOENG, V2, P591, DOI 10.1007/s12195-009-0089-z; Carter DR, 2004, CLIN ORTHOP RELAT R, pS69, DOI 10.1097/01.blo.0000144970.05107.7e; Chadjichristos C, 2003, J BIOL CHEM, V278, P39762, DOI 10.1074/jbc.M303541200; Chen BC, 2006, J IMMUNOL, V177, P681, DOI 10.4049/jimmunol.177.1.681; Cheng M, 2007, BIORHEOLOGY, V44, P349; Chiba T, 2009, INT ARCH ALLERGY IMM, V149, P77, DOI 10.1159/000211377; Choi YA, 2004, EXP MOL MED, V36, P226, DOI 10.1038/emm.2004.31; Cippitelli M, 2003, J IMMUNOL, V170, P4578, DOI 10.4049/jimmunol.170.9.4578; Dahlberg L, 2000, ARTHRITIS RHEUM, V43, P673, DOI 10.1002/1529-0131(200003)43:3<673::AID-ANR25>3.0.CO;2-8; Fahmi H, 2002, OSTEOARTHR CARTILAGE, V10, P100, DOI 10.1053/joca.2001.0485; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Felson DT, 2006, NEW ENGL J MED, V354, P841, DOI 10.1056/NEJMcp051726; Fleenor DL, 2003, INVEST OPHTH VIS SCI, V44, P3494, DOI 10.1167/iovs.02-0757; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Glossop JR, 2009, GENE EXPR PATTERNS, V9, P381, DOI 10.1016/j.gep.2009.01.001; Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926-000-0021-y; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; GUERNE PA, 1990, J IMMUNOL, V144, P499; Harizi H, 2006, CELL MOL IMMUNOL, V3, P271; HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306; Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg; HUANG A, 1993, BIOTECHNIQUES, V14, P730; Ishiguro N, 1999, ARTHRITIS RHEUM, V42, P129, DOI 10.1002/1529-0131(199901)42:1<129::AID-ANR16>3.0.CO;2-4; Jacques C, 1999, REV RHUM, V66, P701; Jiang JX, 2013, J PHARMACOL EXP THER, V344, P360, DOI 10.1124/jpet.112.200444; Jiang ZH, 2004, J VASC SURG, V40, P345, DOI 10.1016/j.jvs.2004.03.048; Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002; Kobayashi M, 2005, ARTHRITIS RHEUM-US, V52, P128, DOI 10.1002/art.20776; Krizanac-Bengez L, 2006, J CELL PHYSIOL, V206, P68, DOI 10.1002/jcp.20429; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Laine L, 2008, SEMIN ARTHRITIS RHEU, V38, P165, DOI 10.1016/j.semarthrit.2007.10.004; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; Lems WF, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3084; Li L, 2008, BIOCHEM BIOPH RES CO, V370, P159, DOI 10.1016/j.bbrc.2008.03.051; Liang Feng, 2005, Zhonghua Nei Ke Za Zhi, V44, P421; Liang Feng, 2002, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V19, P667; Liang KC, 2007, J CELL PHYSIOL, V211, P759, DOI 10.1002/jcp.20992; Liu JJ, 2005, ANN ONCOL, V16, P455, DOI 10.1093/annonc/mdi077; LOTZ M, 1992, J IMMUNOL, V148, P466; Lowe GN, 1996, ENDOCRINOLOGY, V137, P2208, DOI 10.1210/en.137.6.2208; Ma B, 2012, ARTHRITIS RHEUM-US, V64, P2589, DOI 10.1002/art.34425; Martel-Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049-0172(03)00134-3; Martinez Alma E., 2012, Inflammation & Allergy Drug Targets, V11, P58; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Messer RLW, 2008, J BIOMED MATER RES A, V87A, P229, DOI 10.1002/jbm.a.31730; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Mohtai M, 1996, J ORTHOP RES, V14, P67, DOI 10.1002/jor.1100140112; Murphy G, 2008, NAT CLIN PRACT RHEUM, V4, P128, DOI 10.1038/ncprheum0727; Naito K, 1999, RHEUMATOLOGY, V38, P510, DOI 10.1093/rheumatology/38.6.510; Nishida K, 2008, PPAR RES, V2008, DOI 10.1155/2008/250568; Nishitani K, 2010, J CELL BIOCHEM, V109, P425, DOI 10.1002/jcb.22421; Ohta S, 1998, LAB INVEST, V78, P79; Okada M, 2010, J VET MED SCI, V72, P735, DOI 10.1292/jvms.09-0582; Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-144; Piva R, 2005, BLOOD, V105, P1750, DOI 10.1182/blood-2004-04-1360; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Pustovrh MC, 2009, EUR J CLIN INVEST, V39, P1082, DOI 10.1111/j.1365-2362.2009.02200.x; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Rola-Pleszczynski M, 1992, Mediators Inflamm, V1, P5, DOI 10.1155/S0962935192000024; Roman-Blas JA, 2006, OSTEOARTHR CARTILAGE, V14, P839, DOI 10.1016/j.joca.2006.04.008; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; Schuligoi R, 2005, BIOCHEM BIOPH RES CO, V335, P684, DOI 10.1016/j.bbrc.2005.07.130; Shan ZZ, 2004, J BIOL CHEM, V279, P37939, DOI 10.1074/jbc.M402424200; Sottile A, 1996, IMMUNOPHARM IMMUNOT, V18, P27, DOI 10.3109/08923979609007108; Storer PD, 2005, J NEUROSCI RES, V80, P66, DOI 10.1002/jnr.20413; Stove J, 2000, PATHOBIOLOGY, V68, P144, DOI 10.1159/000055915; Sweeney NV, 2004, CARDIOVASC RES, V63, P625, DOI 10.1016/j.cardiores.2004.05.008; TAJIMA S, 1983, J BIOL CHEM, V258, P73; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Todhunter PG, 1996, AM J VET RES, V57, P1080; Towle CA, 1997, OSTEOARTHR CARTILAGE, V5, P293, DOI 10.1016/S1063-4584(97)80008-8; VILLIGER PM, 1993, J CLIN INVEST, V91, P1575, DOI 10.1172/JCI116363; VILLIGER PM, 1992, J CLIN INVEST, V90, P488, DOI 10.1172/JCI115885; Wang HF, 2011, J CELL PHYSIOL, V226, P1044, DOI 10.1002/jcp.22427; Wang P, 2012, J BIOL CHEM, V287, P31877, DOI 10.1074/jbc.M112.362731; Wang P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027630; Wang P, 2011, FASEB J, V25, P3401, DOI 10.1096/fj.11-184861; Wang P, 2010, J BIOL CHEM, V285, P24793, DOI 10.1074/jbc.M110.110320; Wang P, 2010, AM J PHYSIOL-CELL PH, V298, pC1445, DOI 10.1152/ajpcell.00508.2009; Westacott CI, 1996, SEMIN ARTHRITIS RHEU, V25, P254, DOI 10.1016/S0049-0172(96)80036-9; Yokota H, 2003, J BIOL CHEM, V278, P47275, DOI 10.1074/jbc.M304652200; YU CL, 1994, IMMUNOPHARMACOLOGY, V27, P207, DOI 10.1016/0162-3109(94)90017-5; Zayed N, 2008, ARTHRITIS RHEUM-US, V58, P3530, DOI 10.1002/art.23958; Zhang RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032356; Zheng LS, 2012, J BIOMECH, V45, P2368, DOI 10.1016/j.jbiomech.2012.07.013; Zhu F, 2010, CELL DEATH DIFFER, V17, P1325, DOI 10.1038/cdd.2010.13; Zhu F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015174	100	50	52	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4664	4677		10.1096/fj.13-234542	http://dx.doi.org/10.1096/fj.13-234542			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964078	Green Published			2022-12-28	WOS:000329999000002
J	Zhang, ZH; Zhang, Y; Wang, F; Wang, XH; Xu, YY; Yang, HY; Yu, GH; Yuan, CG; Ma, JY				Zhang, Zhihong; Zhang, Yi; Wang, Fei; Wang, Xinhe; Xu, Yuanyuan; Yang, Huaiyi; Yu, Guohua; Yuan, Chonggang; Ma, Jiyan			De novo generation of infectious prions with bacterially expressed recombinant prion protein	FASEB JOURNAL			English	Article						sPMCA; recombinant PrP; bioassay	MISFOLDING CYCLIC AMPLIFICATION; IN-VITRO; NEURODEGENERATIVE DISEASES; LIPID INTERACTION; MAMMALIAN PRIONS; CONFORMATION; FIBRILLIZATION; AGGREGATION; REPLICATION; MEMBRANES	The prion hypothesis is strongly supported by the fact that prion infectivity and the pathogenic conformer of prion protein (PrP) are simultaneously propagated in vitro by the serial protein misfolding cyclic amplification (sPMCA). However, due to sPMCA's enormous amplification power, whether an infectious prion can be formed de novo with bacterially expressed recombinant PrP (rPrP) remains to be satisfactorily resolved. To address this question, we performed unseeded sPMCA with rPrP in a laboratory that has never been exposed to any native prions. Two types of proteinase K (PK)-resistant and self-perpetuating recombinant PrP conformers (rPrP-res) with PK-resistant cores of 17 or 14 kDa were generated. A bioassay revealed that rPrP-res(17kDa) was highly infectious, causing prion disease in wild-type mice with an average survival time of about 172 d. In contrast, rPrP-res(14kDa) completely failed to induce any disease. Our findings reveal that sPMCA is sufficient to initiate various self-perpetuating PK-resistant rPrP conformers, but not all of them possess in vivo infectivity. Moreover, generating an infectious prion in a prion-free environment establishes that an infectious prion can be formed de novo with bacterially expressed rPrP.	[Zhang, Zhihong; Zhang, Yi; Xu, Yuanyuan; Yu, Guohua; Yuan, Chonggang; Ma, Jiyan] E China Normal Univ, Sch Life Sci, Shanghai Key Lab Brain Funct Genom, Key Lab Brain Funct Genom,Minist Educ, Shanghai 200062, Peoples R China; [Zhang, Yi; Wang, Fei; Wang, Xinhe; Ma, Jiyan] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Yang, Huaiyi] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China	East China Normal University; University System of Ohio; Ohio State University; Chinese Academy of Sciences; Institute of Microbiology, CAS	Ma, JY (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 1645 Neil Ave,Rm 457A Hamilton Hall, Columbus, OH 43210 USA.	ma.131@osu.edu	zhang, zh/GWV-4677-2022	Ma, Jiyan/0000-0001-7150-1898	National Natural Science Foundation of China [31172347, 30871369]; Ministry of Education of China [985]; U.S. National Institutes of Health [R01 NS071035, R01 NS 060729]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071035, R01NS060729] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Man-Sun Sy (Case Western Reserve University, Cleveland, OH, USA) and Dr. Surachai Supattapone (Dartmouth Medical School, Hanover, NH, USA) for providing reagents used in this study. Financial support for this study was provided by the National Natural Science Foundation of China, projects 31172347 and 30871369; the Ministry of Education of China, project 985; and the U.S. National Institutes of Health, grants R01 NS071035 and R01 NS 060729.	Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Aguzzi A, 2009, NEURON, V64, P783, DOI 10.1016/j.neuron.2009.12.016; Aguzzi A, 2009, NATURE, V459, P924, DOI 10.1038/459924a; Barria MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000421; Brundin P, 2010, NAT REV MOL CELL BIO, V11, P301, DOI 10.1038/nrm2873; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Castilla J, 2005, NAT MED, V11, P982, DOI 10.1038/nm1286; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Closewood L. C., 2009, BIOSAFETY MICROBIOLO, P282; Colby DW, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000736; Cosseddu GM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002370; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; Deleault NR, 2012, P NATL ACAD SCI USA, V109, pE1938, DOI 10.1073/pnas.1206999109; Deleault NR, 2012, P NATL ACAD SCI USA, V109, P8546, DOI 10.1073/pnas.1204498109; Feraudet C, 2005, J BIOL CHEM, V280, P11247, DOI 10.1074/jbc.M407006200; Geoghegan JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000535; Gomes MPB, 2008, J BIOL CHEM, V283, P19616, DOI 10.1074/jbc.M802102200; Gonzalez-Romero D, 2008, FEBS LETT, V582, P3161, DOI 10.1016/j.febslet.2008.08.003; Imamura M, 2011, J VIROL, V85, P2582, DOI 10.1128/JVI.02098-10; Kang HE, 2012, J BIOL CHEM, V287, P37219, DOI 10.1074/jbc.M112.395921; Kazlauskaite J, 2005, BIOCHEM SOC SYMP, V72, P211, DOI 10.1042/bss0720211; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Kim JI, 2010, J BIOL CHEM, V285, P14083, DOI 10.1074/jbc.C110.113464; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Ma JY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002589; Makarava N, 2008, J BIOL CHEM, V283, P15988, DOI 10.1074/jbc.M800562200; Makarava N, 2010, ACTA NEUROPATHOL, V119, P177, DOI 10.1007/s00401-009-0633-x; Morales R, 2012, NAT PROTOC, V7, P1397, DOI 10.1038/nprot.2012.067; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Polymenidou M, 2012, J EXP MED, V209, P889, DOI 10.1084/jem.20120741; Polymenidou M, 2011, CELL, V147, P498, DOI 10.1016/j.cell.2011.10.011; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Prusiner SB, 2012, SCIENCE, V336, P1511, DOI 10.1126/science.1222951; Saa P, 2006, J BIOL CHEM, V281, P35245, DOI 10.1074/jbc.M603964200; Saa P, 2006, SCIENCE, V313, P92, DOI 10.1126/science.1129051; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Soto C, 2012, CELL, V149, P968, DOI 10.1016/j.cell.2012.05.007; Tamguney G, 2008, J GEN VIROL, V89, P1777, DOI 10.1099/vir.0.2008/001255-0; Wang F, 2007, BIOCHEMISTRY-US, V46, P7045, DOI 10.1021/bi700299h; Wang F, 2013, ACTA BIOCH BIOPH SIN, V45, P485, DOI 10.1093/abbs/gmt038; Wang F, 2012, J VIROL, V86, P1874, DOI 10.1128/JVI.06216-11; Wang F, 2011, METHODS, V53, P208, DOI 10.1016/j.ymeth.2010.12.013; Wang F, 2010, BIOCHEMISTRY-US, V49, P8169, DOI 10.1021/bi101146v; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748; Wang XH, 2009, BBA-MOL BASIS DIS, V1792, P555, DOI 10.1016/j.bbadis.2009.02.014; Yin SM, 2007, P NATL ACAD SCI USA, V104, P7546, DOI 10.1073/pnas.0610827104	48	46	46	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4768	4775		10.1096/fj.13-233965	http://dx.doi.org/10.1096/fj.13-233965			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23970796	Green Published			2022-12-28	WOS:000329999000012
J	Zhao, HL; Ning, JL; Savage, S; Kang, HC; Lu, KZ; Zheng, X; George, AJT; Ma, DQ				Zhao, Hailin; Ning, Jiaolin; Savage, Sinead; Kang, Heechan; Lu, Kaizhi; Zheng, Xia; George, Andrew J. T.; Ma, Daqing			A novel strategy for preserving renal grafts in an ex vivo setting: potential for enhancing the marginal donor pool	FASEB JOURNAL			English	Article						xenon; ischemic injury; organ preservation; organ transplantation; renoprotection	ISCHEMIA/REPERFUSION INJURY; INDUCED APOPTOSIS; CARBON-MONOXIDE; IN-VIVO; XENON; MITOCHONDRIA; ISCHEMIA; DONATION; DYNAMICS; PROTECTS	Renal transplantation remains the best treatment option for patients with end-stage renal failure. However, the shortage of renal grafts remains a big challenge. Renal graft ischemic injuries that occur before and after graft retrieval have a devastating effect on graft survival, especially on grafts from marginal donors. This study was conducted to assess the protective effect against ischemic injury of a preservative solution supplemented with xenon (Xe), when used on ex vivo kidney grafts in a rat renal transplant model, and to explore the underlying mechanisms in vitro. Lewis rat renal grafts were stored in Soltran preservative solution at 4 C, saturated with nitrogen (N-2) or Xe gas (70% Xe or N-2, with 5% CO2 balanced with O-2) for 24 or 48 h. Grafts stored in Xe-saturated preservative solution demonstrated significantly less severe histopathologic changes, together with enhanced B-cell lymphoma (Bcl)-2 and heat shock protein (HSP)-70 expression. After engraftment in the Lewis rat recipient, renal function was significantly improved in the Xe-treated grafts, and macrophage infiltration and fibrosis were reduced. Xe exposure enhanced Bcl-2 and HSP-70 expression in human renal tubular epithelial (HK-2) cells and prevented mitochondrial and nuclear damage. The release of the apoptogenic factors cytochrome c, apoptosis-inducing factor (AIF), and proinflammatory high-mobility group protein B1 (HMGB-1) was effectively suppressed. This study thus demonstrated for the first time that Xe confers renoprotection on renal grafts ex vivo and is likely to stabilize cellular structure during ischemic insult. The current study has significant clinical implications, in which the use of Xe ex vivo could enhance the marginal donor pool of renal grafts by preventing graft loss due to ischemia.	[Zhao, Hailin; Ning, Jiaolin; Savage, Sinead; Kang, Heechan; Zheng, Xia; Ma, Daqing] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Surg & Canc, Sect Anaesthet Pain Med & Intens Care,Fac Med, London SW10 9NH, England; [Ning, Jiaolin; Lu, Kaizhi] Third Mil Med Univ, Southwest Hosp, Dept Anesthesiol, Chongqing, Peoples R China; [George, Andrew J. T.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Sect Mol Immunol, London SW10 9NH, England	Imperial College London; Army Medical University; Imperial College London	Ma, DQ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Surg & Canc, Fac Med, 369 Fulham Rd, London SW10 9NH, England.	lukaizhi@163.net; d.ma@imperial.ac.uk	Ma, Daqing/GLT-2735-2022	Ma, Daqing/0000-0003-1235-0537; Ma, Daqing/0000-0002-0688-2097; George, Andrew/0000-0002-2866-0241	British Medical Research Council (MRC); Developmental Pathway Funding Scheme (DPFS) program [G802392]; National Natural Science Foundation (Beijing, China) [81170414]; Medical Research Council [G0802392] Funding Source: researchfish; MRC [G0802392] Funding Source: UKRI	British Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Developmental Pathway Funding Scheme (DPFS) program; National Natural Science Foundation (Beijing, China)(National Natural Science Foundation of China (NSFC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the British Medical Research Council (MRC), the Developmental Pathway Funding Scheme (DPFS) program (project grant G802392), and the National Natural Science Foundation (Beijing, China; 81170414).	Aydin Z, 2007, NEPHROL DIAL TRANSPL, V22, P342, DOI 10.1093/ndt/gfl690; Benard G, 2007, J CELL SCI, V120, P838, DOI 10.1242/jcs.03381; Brooks C, 2009, J CLIN INVEST, V119, P1275, DOI 10.1172/JCI37829; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Gueler F, 2004, KIDNEY INT, V66, P523, DOI 10.1111/j.1523-1755.2004.761_11.x; Hamar P, 2004, P NATL ACAD SCI USA, V101, P14883, DOI 10.1073/pnas.0406421101; Herrero-Fresneda I, 2003, AM J PATHOL, V162, P127, DOI 10.1016/S0002-9440(10)63804-7; Honda HM, 2005, ANN NY ACAD SCI, V1047, P248, DOI 10.1196/annals.1341.022; Jassem W, 2004, KIDNEY INT, V66, P514, DOI 10.1111/j.1523-1755.2004.761_9.x; Jassem W, 2002, TRANSPLANTATION, V73, P493, DOI 10.1097/00007890-200202270-00001; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawai A, 2001, J CELL SCI, V114, P3565; Kosieradzki M, 2008, TRANSPL P, V40, P3279, DOI 10.1016/j.transproceed.2008.10.004; LACHMANN B, 1990, LANCET, V335, P1413; Limatola V, 2010, NEUROSCIENCE, V165, P874, DOI 10.1016/j.neuroscience.2009.10.063; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2009, J AM SOC NEPHROL, V20, P713, DOI 10.1681/ASN.2008070712; Ma DQ, 2006, J CEREBR BLOOD F MET, V26, P199, DOI 10.1038/sj.jcbfm.9600184; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Manara AR, 2012, BRIT J ANAESTH, V108, pI108, DOI 10.1093/bja/aer357; Mapa K, 2010, MOL CELL, V38, P89, DOI 10.1016/j.molcel.2010.03.010; Moers C, 2010, NEPHROL DIAL TRANSPL, V25, P666, DOI 10.1093/ndt/gfp717; Nakao A, 2008, KIDNEY INT, V74, P1009, DOI 10.1038/ki.2008.342; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Perico N, 2004, LANCET, V364, P1814, DOI 10.1016/S0140-6736(04)17406-0; Pratschke J, 2005, TRANSPLANT INT, V18, P15, DOI 10.1111/j.1432-2277.2004.00018.x; Pratschke Johann, 2004, Ann Transplant, V9, P78; Rawat S, 2010, ANESTH ANALG, V110, P101, DOI 10.1213/ANE.0b013e3181be0e17; Sanders RD, 2004, BRIT MED BULL, V71, P115, DOI 10.1093/bmb/ldh034; Schmidt M, 2005, ANESTHESIOLOGY, V102, P929, DOI 10.1097/00000542-200505000-00011; Shah N, 2010, J AM SOC NEPHROL, V21, P888, DOI 10.1681/ASN.2010040415; Siedlecki A, 2011, AM J TRANSPLANT, V11, P2279, DOI 10.1111/j.1600-6143.2011.03754.x; Siriussawakul A, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/819382; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Weber NC, 2005, BRIT J PHARMACOL, V144, P123, DOI 10.1038/sj.bjp.0706063; Weber NC, 2008, ANESTH ANALG, V107, P1807, DOI 10.1213/ane.Ob013e31818874bf; Wu HL, 2007, J CLIN INVEST, V117, P2847, DOI 10.1172/JCI31008; Wu HL, 2010, J AM SOC NEPHROL, V21, P1878, DOI 10.1681/ASN.2009101048; Yoshida J, 2010, AM J TRANSPLANT, V10, P763, DOI 10.1111/j.1600-6143.2010.03040.x; Zhao HL, 2013, FASEB J, V27, P4076, DOI 10.1096/fj.13-232173	43	12	14	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4822	4833		10.1096/fj.13-236810	http://dx.doi.org/10.1096/fj.13-236810			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23934278				2022-12-28	WOS:000329999000017
J	Mustafi, D; Kevany, BM; Genoud, C; Bai, XD; Palczewski, K				Mustafi, Debarshi; Kevany, Brian M.; Genoud, Christel; Bai, Xiaodong; Palczewski, Krzysztof			Photoreceptor phagocytosis is mediated by phosphoinositide signaling	FASEB JOURNAL			English	Article						lincRNA; retina; RNA-Seq; RPE	REV-ERB-ALPHA; ROD OUTER SEGMENTS; CIRCADIAN CLOCK; DIACYLGLYCEROL KINASE; PHOSPHOLIPASE-C; NONCODING RNAS; ROYAL-COLLEGE; GENE; TRANSCRIPTION; EXPRESSION	Circadian oscillations in peripheral tissues, such as the retinal compartment of the eye, are critical to anticipating changing metabolic demands. Circadian shedding of retinal photoreceptor cell discs with subsequent phagocytosis by the neighboring retinal pigmented epithelium (RPE) is essential for removal of toxic metabolites and lifelong survival of these postmitotic neurons. Defects in photoreceptor phagocytosis can lead to severe retinal pathology, but the biochemical mechanisms remain poorly defined. By first documenting a 2.8-fold burst of photoreceptor phagocytosis events in the mouse eye in the morning compared with the afternoon by serial block face imaging, we established time points to assess transcriptional readouts by RNA sequencing (RNA-Seq). We identified 365 oscillating protein-coding transcripts that implicated the phosphoinositide lipid signaling network mediating the discrete steps of photoreceptor phagocytosis. Moreover, examination of overlapping cistromic sites by core clock transcription factors and promoter elements of these effector genes provided a functional basis for the circadian cycling of these transcripts. RNA-Seq also revealed oscillating expression of 16 long intergenic noncoding RNAs and key histone modifying enzymes critical for circadian gene expression. Our phenotypic and genotypic characterization reveals a complex global landscape of overlapping and temporally controlled networks driving the essential circadian process in the eye.Mustafi, D., Kevany, B. M., Genoud, C., Bai, X., Palczewski, K. Photoreceptor phagocytosis is mediated by phosphoinositide signaling.	[Mustafi, Debarshi; Kevany, Brian M.; Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Bai, Xiaodong] Case Western Reserve Univ, Ctr RNA Mol Biol, Cleveland, OH 44106 USA; [Genoud, Christel] Friedrich Miescher Inst Biomed Res, Electron Microscopy Facil, Basel, Switzerland	Case Western Reserve University; Case Western Reserve University; Friedrich Miescher Institute for Biomedical Research	Palczewski, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu		Mustafi, Debarshi/0000-0002-9164-7488; genoud, christel/0000-0002-0933-9911	National Eye Institute of the U.S. National Institutes of Health (NIH) [R01-EY-008061, R01-EY-019478, R01-EY-022606, R01-EY-022326, P30-EY-11373]; Research to Prevent Blindness Foundation; Foundation Fighting Blindness, Fight for Sight; Ohio Lions Eye Research Foundation; Maurice E. Muller Foundation of Switzerland; CWRU Medical Scientist Training Program from NIH [T32GM007250]; Visual Sciences Training Program from NIH [T32EY007157]; NATIONAL EYE INSTITUTE [T32EY007157, R01EY019478, R01EY008061, R01EY022606, P30EY011373, R01EY022326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	National Eye Institute of the U.S. National Institutes of Health (NIH); Research to Prevent Blindness Foundation(Research to Prevent Blindness (RPB)); Foundation Fighting Blindness, Fight for Sight; Ohio Lions Eye Research Foundation; Maurice E. Muller Foundation of Switzerland; CWRU Medical Scientist Training Program from NIH; Visual Sciences Training Program from NIH; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Leslie T. Webster, Jr. [Case Western Reserve University (CWRU)] for valuable comments on the manuscript. The authors thank Neil Molyneaux, Simone Edelheit, and Milena Rajak (CWRU) for technical assistance and Dr. Ahmad Khalil (CWRU) for helpful discussions. Research reported in this work was supported by the National Eye Institute of the U.S. National Institutes of Health (NIH) under awards R01-EY-008061, R01-EY-019478, R01-EY-022606, R01-EY-022326, and P30-EY-11373, and the Research to Prevent Blindness Foundation, Foundation Fighting Blindness, Fight for Sight, and the Ohio Lions Eye Research Foundation. D. M. was supported in part by the CWRU Medical Scientist Training Program (T32GM007250) and Visual Sciences Training Program (T32EY007157) training grants from the NIH as well as the Maurice E. Muller Foundation of Switzerland. K. P. is John H. Hord Professor of Pharmacology.	Abruzzi KC, 2011, GENE DEV, V25, P2374, DOI [10.1101/gad.178079.111, 10.1101/gad.174110.111]; Alenghat T, 2008, NATURE, V456, P997, DOI 10.1038/nature07541; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Almena M, 2011, TRENDS BIOCHEM SCI, V36, P593, DOI 10.1016/j.tibs.2011.06.005; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Asher G, 2011, CELL METAB, V13, P125, DOI 10.1016/j.cmet.2011.01.006; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Botelho RJ, 2009, J BIOL CHEM, V284, P28522, DOI 10.1074/jbc.M109.009514; Burstyn-Cohen T, 2012, NEURON, V76, P1123, DOI 10.1016/j.neuron.2012.10.015; Carrasco S, 2004, MOL BIOL CELL, V15, P2932, DOI 10.1091/mbc.E03-11-0844; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; Chowers I, 2004, INVEST OPHTH VIS SCI, V45, P2098, DOI 10.1167/iovs.03-0863; Coon SL, 2012, P NATL ACAD SCI USA, V109, P13319, DOI 10.1073/pnas.1207748109; Crandall DL, 2000, J CLIN ENDOCR METAB, V85, P2609, DOI 10.1210/jc.85.7.2609; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; Denk W, 2004, PLOS BIOL, V2, P1900, DOI 10.1371/journal.pbio.0020329; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Feng D, 2012, MOL CELL, V47, P158, DOI 10.1016/j.molcel.2012.06.026; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416; Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Gregory GD, 2007, MOL CELL BIOL, V27, P8466, DOI 10.1128/MCB.00993-07; Hall MO, 1996, INVEST OPHTH VIS SCI, V37, P1473; HETH CA, 1994, INVEST OPHTH VIS SCI, V35, P409; HETH CA, 1995, INVEST OPHTH VIS SCI, V36, P984; Hogenesch JB, 2011, NAT REV GENET, V12, P407, DOI 10.1038/nrg2972; Huang WY, 2011, J CLIN INVEST, V121, P2133, DOI 10.1172/JCI46043; Hughes ME, 2012, GENOME RES, V22, P1266, DOI 10.1101/gr.128876.111; Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511; Jeon H, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-149; Katada S, 2010, NAT STRUCT MOL BIOL, V17, P1414, DOI 10.1038/nsmb.1961; Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009; Koike N, 2012, SCIENCE, V338, P349, DOI 10.1126/science.1226339; Kolko M, 2007, INVEST OPHTH VIS SCI, V48, P1401, DOI 10.1167/iovs.06-0865; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; Lee HS, 2003, NAT NEUROSCI, V6, P111, DOI 10.1038/nn1006; Lehner B, 2013, NAT REV GENET, V14, P168, DOI 10.1038/nrg3404; Liu X., 2012, PLOS ONE, V7, DOI rg/10.1371/journal.pone.0040345; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200; Maemura K, 2000, J BIOL CHEM, V275, P36847, DOI 10.1074/jbc.C000629200; Masri S, 2010, NAT NEUROSCI, V13, P1324, DOI 10.1038/nn.2668; MOISSEIEV J, 1990, INVEST OPHTH VIS SCI, V31, P1070; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mustafi D, 2013, HUM MOL GENET, V22, P2992, DOI 10.1093/hmg/ddt156; Mustafi D, 2012, J CLIN INVEST, V122, P2989, DOI 10.1172/JCI64427; Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767; Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Park YJ, 2008, P NATL ACAD SCI USA, V105, P11784, DOI 10.1073/pnas.0801394105; Posor Y, 2013, NATURE, V499, P233, DOI 10.1038/nature12360; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Regier DS, 2005, P NATL ACAD SCI USA, V102, P7595, DOI 10.1073/pnas.0500663102; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rey G, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000595; Ruggiero L, 2012, P NATL ACAD SCI USA, V109, P8145, DOI 10.1073/pnas.1121101109; Ryeom SW, 1996, J CELL SCI, V109, P387; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schoenhard JA, 2003, J MOL CELL CARDIOL, V35, P473, DOI 10.1016/S0022-2828(03)00051-8; Shelby SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053964; Steinckwich N, 2011, J IMMUNOL, V186, P2182, DOI 10.4049/jimmunol.1001338; Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129; Swanson JA, 2008, NAT REV MOL CELL BIO, V9, P639, DOI 10.1038/nrm2447; Takeda Y, 2011, NUCLEIC ACIDS RES, V39, P4769, DOI 10.1093/nar/gkq1335; TERMAN JS, 1993, BRAIN RES, V605, P256; Todt JC, 2004, J LEUKOCYTE BIOL, V75, P705, DOI 10.1189/jlb.0903439; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 2007, FASEB J, V21, P3866, DOI 10.1096/fj.07-8371com; Tovin A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003116; Valekunja UK, 2013, P NATL ACAD SCI USA, V110, P1554, DOI 10.1073/pnas.1214168110; van den Bout I, 2007, EXP CELL RES, V313, P1260, DOI 10.1016/j.yexcr.2007.01.005; Vollmers C, 2012, CELL METAB, V16, P833, DOI 10.1016/j.cmet.2012.11.004; Wang J, 2006, J BIOL CHEM, V281, P33842, DOI 10.1074/jbc.M607873200; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zhang EE, 2009, CELL, V139, P199, DOI 10.1016/j.cell.2009.08.031	88	33	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4585	4595		10.1096/fj.13-237537	http://dx.doi.org/10.1096/fj.13-237537			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23913857	Green Published			2022-12-28	WOS:000329937500024
J	Chen, H; Zhang, LJ; Zhang, HB; Xiao, Y; Shao, LJ; Li, HR; Yin, H; Wang, RY; Liu, GW; Corley, D; Yang, ZZ; Zhao, Y				Chen, Hui; Zhang, Lianjun; Zhang, Hongbing; Xiao, Yi; Shao, Lijuan; Li, Hongran; Yin, Hui; Wang, Ruoyu; Liu, Guangwei; Corley, Douglas; Yang, Zhongzhou; Zhao, Yong			Disruption of TSC1/2 signaling complex reveals a checkpoint governing thymic CD4(+)CD25(+)Foxp3(+), regulatory T-cell development in mice	FASEB JOURNAL			English	Article						mTOR; thymus; Rictor	TUMOR-SUPPRESSOR TSC1; MAMMALIAN TARGET; RAPAMYCIN; MTOR; DIFFERENTIATION; CYCLOSPORINE; QUIESCENCE; EXPRESSION; MAINTAINS; SURVIVAL	Thymic-derived CD4(+)CD25(+)Foxp3(+) natural regulatory T (nT(reg)) cells are essential for the maintenance of peripheral immune tolerance. Signaling pathways that drive immature thymic progenitors to differentiate into CD4(+)CD25(+)Foxp3(+) nT(reg) cells need to be elucidated. The precise role of the TSC1/2 complex, a critical negative regulator of mammalian target of rapamycin (mTOR), in thymic CD4(+)CD25(+)Foxp3(+) nT(reg)-cell development remains elusive. In the present study, we found that the percentage and cell number of thymic CD4(+)CD25(+)Foxp3(+) nT(reg) cells were significantly increased in T-cell-specific TSC1-knockout (TSC1KO) mice. Nevertheless, the levels of CD4(+)CD25(+)Foxp3(-) nT(reg) precursors in TSC1KO thymus were indistinguishable from those in wild-type mice. TSC1KO CD4(+)CD25(+)Foxp3(+) nT(reg) cells showed normal cell death but enhanced proliferative response to IL-2 in a STAT5-dependent manner. Rapamycin (Rapa) treatment failed to rescue but rather increased the frequency of CD4(+)CD25(+)Foxp3(+) nT(reg) cells in TSC1KO and RictorKO mice. The percentage and cell number of thymic CD4(+)CD25(+)Foxp3(+) nT(reg) cells were significantly increased in T-cell-specific RictorKO mice but not in PtenKO mice. Collectively, our studies suggest that TSC1 plays an important role in regulating thymic CD4(+)CD25(+)Foxp3(+) nT(reg)-cell development via a Rapa-resistant and mTORC2-dependent signaling pathway.Chen, H, Zhang, L., Zhang, H., Xiao, Y., Shao, L., Li, H., Yin, H., Wang, R., Liu, G., Corley, D., Yang, Z., Zhao, Y. Disruption of TSC1/2 signaling complex reveals a checkpoint governing thymic CD4(+)CD25(+)Foxp3(+) regulatory T-cell development in mice.	[Chen, Hui; Zhang, Lianjun; Xiao, Yi; Li, Hongran; Yin, Hui; Liu, Guangwei; Corley, Douglas; Zhao, Yong] Chinese Acad Sci, Inst Zool, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100101, Peoples R China; [Zhang, Hongbing] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Physiol & Pathophysiol, Natl Lab Med Mol Biol, Beijing 100730, Peoples R China; [Zhang, Hongbing] Chinese Acad Med Sci, Sch Basic Med, Beijing 100730, Peoples R China; [Zhang, Hongbing] Peking Union Med Coll, Beijing 100021, Peoples R China; [Shao, Lijuan; Wang, Ruoyu] Dalian Univ, Dept Oncol, Affiliated Zhongshan Hosp, Dalian 116012, Peoples R China; [Yang, Zhongzhou] Nanjing Univ, Minist Educ Key Lab Model Anim Dis Study, Model Anim Res Ctr, Nanjing 210008, Jiangsu, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Dalian University; Nanjing University	Zhao, Y (corresponding author), Chinese Acad Sci, Transplantat Biol Res Div, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beichen West Rd 1-5, Beijing 100101, Peoples R China.	zhongzhouyang@nju.edu.cn; zhaoy@ioz.ac.cn	Zhang, Lianjun/AAE-6795-2020; Coll, Lluis Fajas/C-8567-2014	Liu, Guangwei/0000-0002-6008-2891	Ministry of Science and Technology of China [2010CB945301, 2011CB710900, 2009CB522203]; National Natural Science Foundation [C81072396, C81130055]; Chinese Academy of Sciences for Distinguished Young Scientists [KSCX2-EW-Q-7]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences for Distinguished Young Scientists	The authors thank Dr. Yuzhu Hou for critical reading of the manuscript. This work was supported by grants from the Ministry of Science and Technology of China (2010CB945301 and 2011CB710900 to Y.Z.; 2009CB522203 to H.Z.), the National Natural Science Foundation (C81072396 and C81130055 to Y.Z.), and the Chinese Academy of Sciences for Distinguished Young Scientists (KSCX2-EW-Q-7 to G.L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors are grateful for Feng Zu for flow cytometric sorting. The authors declare no conflicts of interest. Author contributions: H.C. and L.Z. designed and performed the study, analyzed data, and wrote the paper; H.Z. provided TSC1KO mice and revised the paper; Y.X. performed genotyping and flow cytometry; L.S., H.L., and H.Y. performed flow cytometry and analyzed data; R.W. analyzed data and revised the paper; G.L. and D.C. performed flow cytometry and revised the paper; Z.Y. provided RictorKO mice and revised the paper; Y.Z. designed the study, analyzed data, and wrote the paper.	Akimova T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024226; Basu S, 2008, J IMMUNOL, V180, P5794, DOI 10.4049/jimmunol.180.9.5794; Bushell A, 2007, AM J TRANSPLANT, V7, P759, DOI 10.1111/j.1600-6143.2006.01716.x; Chang X, 2012, EUR J IMMUNOL, V42, P1639, DOI 10.1002/eji.201142066; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Coenen JJA, 2007, BONE MARROW TRANSPL, V39, P537, DOI 10.1038/sj.bmt.1705628; Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005; Dujardin HC, 2004, P NATL ACAD SCI USA, V101, P14473, DOI 10.1073/pnas.0403303101; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Goto J, 2011, P NATL ACAD SCI USA, V108, pE1070, DOI 10.1073/pnas.1106454108; Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Juntilla MM, 2007, P NATL ACAD SCI USA, V104, P12105, DOI 10.1073/pnas.0705285104; Li RB, 2007, J IMMUNOL, V179, P5191, DOI 10.4049/jimmunol.179.8.5191; Lio CWJQ, 2008, IMMUNITY, V28, P100, DOI 10.1016/j.immuni.2007.11.021; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; Ma JH, 2011, J GENET GENOMICS, V38, P533, DOI 10.1016/j.jgg.2011.10.002; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Neuman NA, 2011, EMBO MOL MED, V3, P189, DOI 10.1002/emmm.201100131; Nunes-Cabaco H, 2011, EUR J IMMUNOL, V41, P3604, DOI 10.1002/eji.201141614; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Powell JD, 2010, IMMUNITY, V33, P301, DOI 10.1016/j.immuni.2010.09.002; Qu YY, 2007, TRANSPL IMMUNOL, V17, P153, DOI 10.1016/j.trim.2007.01.002; Rao RR, 2010, IMMUNITY, V32, P67, DOI 10.1016/j.immuni.2009.10.010; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shevach EM, 2011, ADV IMMUNOL, V112, P137, DOI 10.1016/B978-0-12-387827-4.00004-8; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shin HJ, 2011, BLOOD, V118, P2342, DOI 10.1182/blood-2010-10-313684; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; Uraushihara K, 2003, J IMMUNOL, V171, P708, DOI 10.4049/jimmunol.171.2.708; Vang KB, 2008, J IMMUNOL, V181, P3285, DOI 10.4049/jimmunol.181.5.3285; Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x; Wang HJ, 2006, TRANSPLANTATION, V82, P1484, DOI 10.1097/01.tp.0000246312.89689.17; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wu Q, 2011, J IMMUNOL, V187, P1106, DOI 10.4049/jimmunol.1003968; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xie DL, 2012, P NATL ACAD SCI USA, V109, P14152, DOI 10.1073/pnas.1119744109; Yang K, 2011, NAT IMMUNOL, V12, P888, DOI 10.1038/ni.2068; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang L, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/678107	47	34	36	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3979	3990		10.1096/fj.13-235408	http://dx.doi.org/10.1096/fj.13-235408			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23882125				2022-12-28	WOS:000329747100013
J	Thuringer, D; Jego, G; Wettstein, G; Terrier, O; Cronier, L; Yousfi, N; Hebrard, S; Bouchot, A; Hazoume, A; Joly, AL; Gleave, M; Rosa-Calatrava, M; Solary, E; Garrido, C				Thuringer, Dominique; Jego, Gaetan; Wettstein, Guillaume; Terrier, Olivier; Cronier, Laurent; Yousfi, Nadhir; Hebrard, Sophie; Bouchot, Andre; Hazoume, Adonis; Joly, Anne-Laure; Gleave, Martin; Rosa-Calatrava, Manuel; Solary, Eric; Garrido, Carmen			Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3	FASEB JOURNAL			English	Article						tubulogenesis; chorioallantoic membrane; autocrine VEGFR2 activation; microvascular endothelial cell; endocytosis; NF-B pathway; VEGF release	ENDOTHELIAL GROWTH-FACTOR; KAPPA-B; PROTEIN; VEGF; ACTIVATION; TLR3; RNA; PHOSPHORYLATION; INTERLEUKIN-8; EXPRESSION	The heat-shock protein 27 (HSP27) is up-regulated in tumor cells and released in their microenvironment. Here, we show that extracellular HSP27 has a proangiogenic effect evidenced on chick chorioallantoic membrane. To explore this effect, we test the recombinant human protein (rhHSP27) at physiopathological doses (0.1-10 g/ml) onto human microvascular endothelial cells (HMECs) grown as monolayers or spheroids. When added onto HMECs, rhHSP27 dose-dependently accelerates cell migration (with a peak at 5 g/ml) and favors spheroid sprouting within 12-24 h. rhHSP27 increases VEGF gene transcription and promotes secretion of VEGF-activating VEGF receptor type 2. Increased VEGF transcription is related to NF-B activation in 30 min. All of these effects are initiated by rhHSP27 interaction with Toll-like receptor 3 (TLR3). Such an interaction can be detected by immunoprecipitation but does not seem to be direct, as we failed to detect an interaction between rhHSP27 and monomeric TLR3 by SPR analysis. rhHSP27 is rapidly internalized with a pool of TLR3 to the endosomal compartment (within 15-30 min), which is required for NF-B activation in a cytosolic Ca2+-dependent manner. The HSP27/TLR3 interaction induces NF-B activation, leading to VEGF-mediated cell migration and angiogenesis. Such a pathway provides alternative targets for antiangiogenic cancer therapy.Thuringer, D., Jego, G., Wettstein, G., Terrier, O., Cronier, L., Yousfi, N., Hebrard, S., Bouchot, A., Hazoume, A., Joly, A.-L., Gleave, M., Rosa-Calatrava, M., Solary, E., and Garrido, C. Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3.	[Thuringer, Dominique; Jego, Gaetan; Wettstein, Guillaume; Yousfi, Nadhir; Hebrard, Sophie; Hazoume, Adonis; Joly, Anne-Laure; Solary, Eric; Garrido, Carmen] Univ Burgundy, INSERM, U866, F-21000 Dijon, France; [Jego, Gaetan; Garrido, Carmen] Univ Burgundy, Fac Med Pharm, F-21000 Dijon, France; [Terrier, Olivier; Rosa-Calatrava, Manuel] Univ Lyon 1, Fac Med, Lab Virol & Pathol Humaine VirPath EA4610, F-69365 Lyon, France; [Cronier, Laurent] Univ Poitiers, CNRS, FRE3511, IPBC, Poitiers, France; [Bouchot, Andre] IFR100, Fac Med, Dijon, France; [Gleave, Martin] Univ British Columbia, Dept Urol, Vancouver, BC V5Z 1M9, Canada; [Solary, Eric] Univ Paris 11, INSERM, U1009, Inst Gustave Roussy, Villejuif, France; [Garrido, Carmen] CHU Dijon, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Universite de Bourgogne; University of British Columbia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; CHU Dijon Bourgogne	Thuringer, D (corresponding author), INSERM, U866, Fac Med, 7 Blvd Jeanne dArc, F-21000 Dijon, France.	dominique.thuringer@u-bourgogne.fr	Thuringer, Dominique/AAA-7448-2020; Rosa-calatrava, Manuel/M-7263-2014; Terrier, Olivier/B-6301-2009; Garrido, Carolina/GWM-5557-2022; jego, gaetan/N-7226-2018; Garrido, carmen/G-1633-2018	Terrier, Olivier/0000-0001-9393-7684; jego, gaetan/0000-0003-0376-9299; Garrido, carmen/0000-0003-1368-1493; CRONIER, Laurent/0000-0002-5088-9325; Gleave, Martin/0000-0003-4235-0167; Rosa-calatrava, Manuel/0000-0002-7559-9527; Solary, Eric/0000-0002-8629-1341	Centre National de la Recherche Scientifique (CNRS); INSERM; Conseil Regional de Bourgogne (Faber Program); European Commission Seventh Framework Programme [SPEDOC 248835]; Ligue Nationale contre le Cancer (Label); Agence Nationale de la Recherche; Institut National du Cancer (INCa)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Conseil Regional de Bourgogne (Faber Program)(Region Bourgogne-Franche-Comte); European Commission Seventh Framework Programme(European Commission); Ligue Nationale contre le Cancer (Label)(Institut National du Cancer (INCA) France); Agence Nationale de la Recherche(French National Research Agency (ANR)); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France)	The authors are grateful to Christine Arnould [Centre Microbiologie du Sol et de l'Environnement (CMSE), Institut National de Recherche Agronomique, Dijon, France] for confocal microscopy and to Amandine Bataille and Eric Fourmaux for technical assistance. The authors thank Dr. Mike Maillasson [Platform Molecular Interactions Proteins Microarrays Activities(IMPACT) Biogenouest, Centre de Recherche en Cancerologie Nantes/Angers (CRCNA), Institut National de la Sante et de la Recherche Medicale (INSERM) U892, Nantes, France] for analysis of agonist/receptor interaction using the surface plasmon resonance technique. The authors thank Dr. Dominique Chevrier (InvivoGen, Toulouse, France) for cell assays using HEK 293T cells overexpressing or not overexpressing TLR3. Stably transfected human cell lines MCA205/OVA<SUP>+/-</SUP> shTRIF or sh lamin were kindly provided by Dr. Dalil Hannani (Institut Gustave Roussy, INSERM U1015, Villejuif, France). This work was supported by Centre National de la Recherche Scientifique (CNRS), by INSERM, by Conseil Regional de Bourgogne (Faber Program), and the European Commission Seventh Framework Programme (SPEDOC 248835 to C.G.). C.G. and E.S. are supported by grants from Ligue Nationale contre le Cancer (Label), Agence Nationale de la Recherche, and Institut National du Cancer (INCa).	Banerjee S, 2011, CANCER RES, V71, P318, DOI 10.1158/0008-5472.CAN-10-1778; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106; Crawford Y, 2009, CELL TISSUE RES, V335, P261, DOI 10.1007/s00441-008-0675-8; De AK, 2000, J IMMUNOL, V165, P3951, DOI 10.4049/jimmunol.165.7.3951; Didelot C, 2006, HANDB EXP PHARM, V172, P171; DOUKAS J, 1994, AM J PATHOL, V145, P137; Durupt F, 2012, CANCER GENE THER, V19, P58, DOI 10.1038/cgt.2011.68; Evans IM, 2008, CELL SIGNAL, V20, P1375, DOI 10.1016/j.cellsig.2008.03.002; Fanelli MA, 1998, CANCER EPIDEM BIOMAR, V7, P791; Feng JT, 2005, PROTEOMICS, V5, P4581, DOI 10.1002/pmic.200401309; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663; Fischer S, 2007, BLOOD, V110, P2457, DOI 10.1182/blood-2006-08-040691; Fischer S, 2009, FASEB J, V23, P2100, DOI 10.1096/fj.08-121608; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Ghayour-Mobarhan M, 2012, CLIN CHIM ACTA, V413, P15, DOI 10.1016/j.cca.2011.04.005; Goutagny N, 2012, TARGET ONCOL, V7, P29, DOI 10.1007/s11523-012-0213-1; Grote K, 2011, THESCIENTIFICWORLDJO, V11, P981, DOI 10.1100/tsw.2011.92; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Kampinga HH, 2012, INT J BIOCHEM CELL B, V44, P1706, DOI 10.1016/j.biocel.2012.06.005; Kawamura H, 2008, BLOOD, V112, P3638, DOI 10.1182/blood-2007-12-125856; Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577; Kelly RJ, 2009, TARGET ONCOL, V4, P297, DOI 10.1007/s11523-009-0126-9; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765; Koff JL, 2008, AM J PHYSIOL-LUNG C, V294, pL1068, DOI 10.1152/ajplung.00025.2008; Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200; Moon Su-Jin, 2010, Korean Journal of Internal Medicine, V25, P429, DOI 10.3904/kjim.2010.25.4.429; Paone A, 2010, NEOPLASIA, V12, P539, DOI 10.1593/neo.92106; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Pohar J, 2013, J BIOL CHEM, V288, P442, DOI 10.1074/jbc.M112.413922; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Salaun B, 2011, CANCER RES, V71, P1607, DOI 10.1158/0008-5472.CAN-10-3490; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Vercammen E, 2008, CLIN MICROBIOL REV, V21, P13, DOI 10.1128/CMR.00022-07; Wang Y, 2010, J BIOL CHEM, V285, P36836, DOI 10.1074/jbc.M110.167973; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Winston WM, 2007, P NATL ACAD SCI USA, V104, P10565, DOI 10.1073/pnas.0611282104; Yamashita M, 2012, J IMMUNOL, V188, P2825, DOI 10.4049/jimmunol.1103220	43	74	76	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4169	4183		10.1096/fj.12-226977	http://dx.doi.org/10.1096/fj.12-226977			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23804239				2022-12-28	WOS:000329747100028
J	Wang, XT; Wang, L; Guo, SC; Bao, Y; Ma, YY; Yan, FY; Xu, K; Xu, ZY; Jin, L; Lu, DR; Xu, JB; Wang, JC				Wang, Xiaotian; Wang, Lei; Guo, Shicheng; Bao, Yang; Ma, Yanyun; Yan, Fengyang; Xu, Kuan; Xu, Zhiyun; Jin, Li; Lu, Daru; Xu, Jibin; Wang, Jiu-Cun			Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lund cancers	FASEB JOURNAL			English	Article						BSP; MSP	LEUKEMIA ZINC-FINGER; ACID RECEPTOR-ALPHA; PROMYELOCYTIC LEUKEMIA; DNA-BINDING; PROTEIN PLZF; GROWTH; GENE; TRANSCRIPTION; METHYLATION; DIFFERENTIATION	Deregulation of promyelocytic leukemia zinc finger protein (PLZF), a tumor suppressor gene, was reported in different types of solid tumors. This study for the first time explored the reduced expression of PLZF and its effects in non-small-cell lung cancer (NSCLC) carcinogenesis. PLZF was found to be down-regulated by 62.8% in 87.1% of 154 paired NSCLC samples by quantitative real-time PCR, and its expression was found to be associated with the sex of the patient (P=0.02). Further analysis showed that down-regulation of PLZF in 35.6% NSCLC samples (31 out of 87) was triggered by hypermethylation in the promoter region. This was validated by demethylation analysis using the A549 cell line. Dual-luciferase reporter assay indicated that CTCF binding to the promoter region could activate PLZF transcription. Overexpression of PLZF in both A549 and LTEP lung cancer cell lines was found to inhibit proliferation and increase apoptosis. Therefore, reduced expression of PLZF was found to be common in NSCLC. PLZF down-regulation was partially correlated with hypermethylation in the promoter region. Decreased levels of PLZF expression may contribute to the pathogenesis of NSCLC by promoting cell survival. Therefore, the restoration of PLZF expression may serve as a new strategy for NSCLC therapy.Wang, X., Wang, L., Guo, S., Bao, Y., Ma, Y., Yan, F., Xu, K., Xu, Z., Jin, L., Lu, D., Xu, J., Wang, J.-C. Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers.	[Wang, Xiaotian; Wang, Lei; Guo, Shicheng; Ma, Yanyun; Yan, Fengyang; Jin, Li; Lu, Daru; Wang, Jiu-Cun] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Wang, Xiaotian; Guo, Shicheng; Ma, Yanyun; Yan, Fengyang; Jin, Li; Lu, Daru; Wang, Jiu-Cun] Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China; [Wang, Lei] Peoples Liberat Army, Hosp 455, Dept Cardiothorac Surg, Shanghai, Peoples R China; [Bao, Yang] Yangzhou 1 Peoples Hosp, Yangzhou, Peoples R China; [Xu, Kuan] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Xu, Zhiyun; Xu, Jibin] Second Mil Med Univ, Dept Cardiothorac Surg, Changhai Hosp Shanghai, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University; Naval Medical University	Wang, JC (corresponding author), Fudan Univ, Natl Minist Educ, Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 200433, Peoples R China.	jibinx@yahoo.com; jcwang@fudan.edu.cn	Wang, Jiucun/J-8744-2012; Jin, Li/M-5063-2019; Guo, Shicheng/A-1204-2016; Jin, Li/C-1468-2009; MA, YAN/HHN-2912-2022	Wang, Jiucun/0000-0003-2765-0620; Guo, Shicheng/0000-0002-7047-9972; Jin, Li/0000-0002-4546-2415; 	National Science Foundation of China (NSFC) [81172228]; National S&T Major Special Project [2011ZX09102-010-01]; National Science Foundation of China [81270120, 31271338]	National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National S&T Major Special Project; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors thank Prof. Jian Yu (State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Cancer Institute, Shanghai, China) for providing MBD-Seq data of NSCLC and normal lung tissues. This study was partially supported by the grants from the National Science Foundation of China (NSFC; 81172228), and National S&T Major Special Project (2011ZX09102-010-01). J.-C.W. and L.J. were supported by the grants from the National Science Foundation of China (81270120, 31271338).	Atienza JM, 2005, J BIOMOL SCREEN, V10, P795, DOI 10.1177/1087057105279635; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brunner G, 2008, CANCER BIOTHER RADIO, V23, P451, DOI 10.1089/cbr.2008.0473; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; Chen Wanqing, 2010, Zhongguo Fei Ai Za Zhi, V13, P488, DOI 10.3779/j.issn.1009-3419.2010.05.20; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheung M, 2010, ONCOGENE, V29, P1633, DOI 10.1038/onc.2009.455; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; De la Rosa-Velazquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024; Doulatov S, 2009, GENE DEV, V23, P2076, DOI 10.1101/gad.1788109; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; Goldman M, 2013, NUCLEIC ACIDS RES, V41, pD949, DOI 10.1093/nar/gks1008; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kikugawa T, 2006, PROSTATE, V66, P1092, DOI 10.1002/pros.20443; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Renda M, 2007, J BIOL CHEM, V282, P33336, DOI 10.1074/jbc.M706213200; Rho SB, 2006, FEBS LETT, V580, P4073, DOI 10.1016/j.febslet.2006.06.047; Rottmann S, 2006, CURR TOP MICROBIOL, V302, P63; Rottmann S, 2005, J BIOL CHEM, V280, P15489, DOI 10.1074/jbc.C400611200; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shiraishi K, 2007, ONCOGENE, V26, P339, DOI 10.1038/sj.onc.1209800; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Xu JB, 2007, LUNG CANCER, V58, P36, DOI 10.1016/j.lungcan.2007.04.019; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861; Yu NC, 2006, ANAL CHEM, V78, P35, DOI 10.1021/ac051695v	35	21	22	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4194	4203		10.1096/fj.13-229070	http://dx.doi.org/10.1096/fj.13-229070			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23804241				2022-12-28	WOS:000329747100030
J	Ghazi-Visser, L; Laman, JD; Nagel, S; van Meurs, M; van Riel, D; Tzankov, A; Frank, S; Adams, H; Wolk, K; Terracciano, L; Melief, MJ; Sabat, R; Gunthert, U				Ghazi-Visser, Lizette; Laman, Jon D.; Nagel, Sabine; van Meurs, Marjan; van Riel, Debby; Tzankov, Alexandar; Frank, Stephan; Adams, Heiner; Wolk, Kerstin; Terracciano, Luigi; Melief, Marie-Jose; Sabat, Robert; Guenthert, Ursula			CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells	FASEB JOURNAL			English	Article						multiple sclerosis; apoptosis; Th1	CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; EXPRESSION; INDUCTION; APOPTOSIS; ANTIBODY; DISEASE; LESIONS; CNS; INFLAMMATION	CD44 variant (CD44(v)) isoforms play important roles in the development of autoimmune disorders, including colitis and arthritis, but their role in multiple sclerosis (MS) has been explored only to a limited extent. We determined the functional relevance of CD44(v) isoforms in MS and its animal model, experimental autoimmune encephalomyelitis (EAE). Genetic ablation of CD44(v7) and CD44(v10) isoforms significantly reduced the clinical EAE burden, as well as the number of inflammatory infiltrates. CD44(v7) and CD44(v10) expression on both memory T and antigen-presenting cells, participated in the development of adoptive transfer EAE. Significantly reduced mRNA expression of Th1 signature genes was detected in the brains of CD44(v10-/-) mice compared with those of CD44(WT) mice. Furthermore, forkhead transcription factor 3 (Foxp3), Bcl-2, and inducible nitric oxide synthase (iNOS) levels were reduced in CD44(v10-/-) brains, whereas active caspase-3 was elevated. Brain-infiltrating CD4(hi)CD44(v10+) T cells preceded EAE onset and paralleled disease severity in wild-type but not in CD44(v7-/-) and CD44(v10-/-) mice. CD44(v7) and CD44(v10) expression contributed to EAE by increasing the longevity of autoreactive CD4(hi)panCD44(hi) T cells. Accordingly, the absence of CD44(v7) and CD44(v10) led to increased apoptosis in the inflammatory infiltrates and reduced Th1 responses, resulting in marked disease reduction. Although absent in noninflamed human brains, we detected CD44(v3), CD44(v7), and CD44(v10) isoforms on glial cells and on perivascular infiltrating cells of MS lesions. We conclude that CD44(v7) and CD44(v10), expressed on autoreactive CD4(hi)panCD44(hi) T cells, are critically involved in the pathogenesis of classic EAE by increasing their life span. Targeting these short CD44(v) isoform regions may reduce inflammatory processes and clinical symptoms in MS.Ghazi-Visser, L., Laman, J. D., Nagel, S., van Meurs, M., van Riel, D., Tzankov, A., Frank, S., Adams, H., Wolk, K., Terracciano, L., Melief, M.-J., Sabat, R., Gunthert, U. CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells.	[Ghazi-Visser, Lizette; Laman, Jon D.; van Meurs, Marjan; van Riel, Debby; Melief, Marie-Jose] Univ Med Ctr Rotterdam, Dept Immunol, Rotterdam, Netherlands; [Ghazi-Visser, Lizette; Laman, Jon D.; van Meurs, Marjan; van Riel, Debby; Melief, Marie-Jose] Univ Med Ctr Rotterdam, Multiple Sclerosis MS Ctr ErasMS, Erasmus Med Ctr, Rotterdam, Netherlands; [Nagel, Sabine; Tzankov, Alexandar; Frank, Stephan; Adams, Heiner; Terracciano, Luigi; Guenthert, Ursula] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland; [Wolk, Kerstin; Sabat, Robert] Univ Hosp Charite, Interdisciplinary Grp Mol Immunopathol, Berlin, Germany	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Basel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gunthert, U (corresponding author), Univ Basel Hosp, Inst Pathol, Schonbeinstr 40, CH-4031 Basel, Switzerland.	ursula.guenthert@unibas.ch	Terracciano, Luigi M./AAB-5335-2022; Wolk, Kerstin/O-1205-2013; Tzankov, Alexandar/H-5656-2019	Terracciano, Luigi M./0000-0002-9393-9660; Tzankov, Alexandar/0000-0002-1100-3819; van Riel, Debby/0000-0001-9753-3564; Wolk, Kerstin/0000-0002-7689-4130	Swiss National Fund [3100-067084.01]; Dutch MS Research Foundation; European Commission COST consortium Neurinfnet [BM0603]	Swiss National Fund(Swiss National Science Foundation (SNSF)); Dutch MS Research Foundation; European Commission COST consortium Neurinfnet	The authors thank Drs. P. Ruiz (Charite University Medicine, Berlin, Germany), I. Zlobec (Institute of Pathology, Basel, Switzerland), U. Eriksson (University Hospitals, Basel and Zurich, Switzerland), and R. Q. Hintzen (Erasmus MC, Rotterdam, The Netherlands) for critical reading of the manuscript and valuable comments; H. Kohler (cell sorting facility of the Basel Institute for Immunology, now Friedrich Miescher Institute, Basel, Switzerland) for expert cell sorting; U. Muller (transgenic unit of the Basel Institute for Immunology, now Friedrich Miescher Institute, Basel, Switzerland), B. Johansson, P. Hirschmann, S. Schneider, A. Mielgo, and P. Schmidt for excellent technical support; T. van Os for microphotography; and K. Stauffer and S. Eckervogt (Basel) for expert animal care. Human brain tissue was obtained from the Netherlands Brain Bank (Amsterdam, The Netherlands). This work was supported by the Swiss National Fund (3100-067084.01). Work at the MS Center ErasMS is supported by the Dutch MS Research Foundation and the European Commission COST consortium Neurinfnet (BM0603). The authors declare no conflicts of interest.	Aheng C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022841; Baaten BJG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00023; Boven LA, 2006, BRAIN, V129, P517, DOI 10.1093/brain/awh707; Braitch Manjit, 2010, Inflammation & Allergy Drug Targets, V9, P249; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Chu CQ, 2000, J EXP MED, V192, P123, DOI 10.1084/jem.192.1.123; Crispin JC, 2010, ARTHRITIS RHEUM-US, V62, P1431, DOI 10.1002/art.27385; Domingues HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015531; Elyaman W, 2008, AM J PATHOL, V173, P411, DOI 10.2353/ajpath.2008.080142; Engelhardt B, 2010, CLIN EXP NEUROIMMUNO, V1, P79, DOI DOI 10.1111/J.1759-1961.2010.009.X; Garin T, 2007, J NEUROL SCI, V258, P17, DOI 10.1016/j.jns.2007.01.079; Ghosh SC, 2012, EXPERT OPIN THER TAR, V16, P635, DOI 10.1517/14728222.2012.687374; GIRGRAH N, 1991, J NEUROPATH EXP NEUR, V50, P779, DOI 10.1097/00005072-199111000-00009; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Guan HB, 2011, J IMMUNOL, V186, P6955, DOI 10.4049/jimmunol.1004043; HAEGEL H, 1993, J CELL BIOL, V122, P1067, DOI 10.1083/jcb.122.5.1067; Haegel-Kronenberger H, 1998, J IMMUNOL, V161, P3902; Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018; Hoffmann U, 2007, CELL DEATH DIFFER, V14, P1542, DOI 10.1038/sj.cdd.4402153; Huss DJ, 2011, EUR J IMMUNOL, V41, P2987, DOI 10.1002/eji.201141666; Johnson Pauline, 2009, Inflammation & Allergy Drug Targets, V8, P208; Kaaijk P, 1997, J NEUROIMMUNOL, V73, P70, DOI 10.1016/S0165-5728(96)00167-1; Kandagaddala LD, 2012, EXP TOXICOL PATHOL, V64, P109, DOI 10.1016/j.etp.2010.07.002; Kleine TO, 2006, CYTOM PART A, V69A, P147, DOI 10.1002/cyto.a.20225; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Laman JD, 1998, MULT SCLER, V4, P147, DOI 10.1177/135245859800400312; Laman JD, 1998, J NEUROIMMUNOL, V86, P30, DOI 10.1016/S0165-5728(98)00024-1; Li J, 2007, J NEUROIMMUNOL, V192, P57, DOI 10.1016/j.jneuroim.2007.09.004; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Maniati E, 2008, J PATHOL, V214, P190, DOI 10.1002/path.2270; Masuko K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029728; McFarland HF, 2007, NAT IMMUNOL, V8, P913, DOI 10.1038/ni1507; Michel L, 2008, J CLIN INVEST, V118, P3411, DOI 10.1172/JCI35365; Mielgo A, 2006, CELL DEATH DIFFER, V13, P465, DOI 10.1038/sj.cdd.4401763; Mix E, 2010, PROG NEUROBIOL, V92, P386, DOI 10.1016/j.pneurobio.2010.06.005; Murugaiyan G, 2008, J IMMUNOL, V181, P7480, DOI 10.4049/jimmunol.181.11.7480; Mycko MP, 2003, BRAIN, V126, P1048, DOI 10.1093/brain/awg107; Nandi A, 2004, IMMUNITY, V20, P455, DOI 10.1016/S1074-7613(04)00077-9; Naor D, 2007, ANN NY ACAD SCI, V1110, P233, DOI 10.1196/annals.1423.025; O'Connor RA, 2008, J NEUROIMMUNOL, V193, P1, DOI 10.1016/j.jneuroim.2007.11.016; Rothhammer V, 2011, J EXP MED, V208, P2465, DOI 10.1084/jem.20110434; Runnels HA, 2010, ADV THER, V27, P168, DOI 10.1007/s12325-010-0010-0; Schwarzler C, 2001, EUR J IMMUNOL, V31, P2997, DOI 10.1002/1521-4141(2001010)31:10<2997::AID-IMMU2997>3.0.CO;2-J; Seiter S, 1999, J INVEST DERMATOL, V113, P11, DOI 10.1046/j.1523-1747.1999.00635.x; Soilu-Hanninen M, 2005, J NEUROIMMUNOL, V166, P189, DOI 10.1016/j.jneuroim.2005.05.008; Steinman L, 2009, NAT REV IMMUNOL, V9, P440, DOI 10.1038/nri2548; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; van der Valk P, 2000, NEUROPATH APPL NEURO, V26, P2, DOI 10.1046/j.1365-2990.2000.00217.x; Visser L, 2002, J NEUROIMMUNOL, V132, P156, DOI 10.1016/S0165-5728(02)00306-5; Weimann TK, 2001, J INVEST DERMATOL, V117, P949, DOI 10.1046/j.0022-202x.2001.01467.x; Wittig B, 1997, IMMUNOL LETT, V57, P217, DOI 10.1016/S0165-2478(97)00060-6; Wittig B, 1999, LAB INVEST, V79, P747; Wittig BM, 2000, J EXP MED, V191, P2053, DOI 10.1084/jem.191.12.2053; Wittig BM, 2002, PATHOBIOLOGY, V70, P184, DOI 10.1159/000068152; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Yoshinari C, 1999, MELANOMA RES, V9, P223, DOI 10.1097/00008390-199906000-00003; ZEINE R, 1992, J NEUROIMMUNOL, V40, P57, DOI 10.1016/0165-5728(92)90213-5; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455; Zhu B, 2008, J EXP MED, V205, P2295, DOI 10.1084/jem.20080187; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	61	12	12	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3683	3701		10.1096/fj.13-228809	http://dx.doi.org/10.1096/fj.13-228809			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23752202	Green Submitted			2022-12-28	WOS:000328840500027
J	Novo, CL; Polese, C; Matheus, N; Decottignies, A; Londono-Vallejo, A; Castronovo, V; Mottet, D				Novo, Clara Lopes; Polese, Catherine; Matheus, Nicolas; Decottignies, Anabelle; Londono-Vallejo, Arturo; Castronovo, Vincent; Mottet, Denis			A new role for histone deacetylase 5 in the maintenance of long telomeres	FASEB JOURNAL			English	Article						cancer; chromatin	HOMOLOGOUS RECOMBINATION; MAMMALIAN TELOMERES; DNA; POSITION; CELLS; LENGTH; RNA; CANCER; HETEROCHROMATIN; INHIBITION	Telomeres are major regulators of genome stability and cell proliferation. A detailed understanding of the mechanisms involved in their maintenance is of foremost importance. Of those, telomere chromatin remodeling is probably the least studied; thus, we intended to explore the role of a specific histone deacetylase on telomere maintenance. We uncovered a new role for histone deacetylase 5 (HDAC5) in telomere biology. We report that HDAC5 is recruited to the long telomeres of osteosarcoma- and fibrosarcoma-derived cell lines, where it ensures proper maintenance of these repetitive regions. Indeed, depletion of HDAC5 by RNAi resulted in the shortening of longer telomeres and homogenization of telomere length in cells that use either telomerase or an alternative mechanism of telomere maintenance. Furthermore, we present evidence for the activation of telomere recombination on depletion of HDAC5 in fibrosarcoma telomerase-positive cancer cells. Of potential importance, we also found that depletion of HDAC5 sensitizes cancer cells with long telomeres to chemotherapeutic drugs. Cells with shorter telomeres were used to control the specificity of HDAC5 role in the maintenance of long telomeres. HDAC5 is essential for the length maintenance of long telomeres and its depletion is required for sensitization of cancer cells with long telomeres to chemotherapy. Novo, C. L., Polese, C., Matheus, N., Decottignies, A., Londono-Vallejo, A., Castronovo, V., Mottet, D. A new role for histone deacetylase 5 in the maintenance of long telomeres.	[Novo, Clara Lopes; Polese, Catherine; Matheus, Nicolas; Castronovo, Vincent; Mottet, Denis] Univ Liege Sart Tilman, Grp Interdisciplinaire Genoproteom Appl GIGA, Metastasis Res Lab, Pathol Inst B23, Liege, Belgium; [Decottignies, Anabelle] Catholic Univ Louvain, Fac Pharm & Biomed Sci, de Duve Inst, Brussels, Belgium; [Londono-Vallejo, Arturo] Labellise Ligue Canc Inst Curie, Telomeres & Canc Lab, Paris, France; [Londono-Vallejo, Arturo] Univ Paris 06, Paris, France	University of Liege; Universite Catholique Louvain; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite	Mottet, D (corresponding author), Univ Liege, GIGA Canc, Pathol Inst B23, Metastasis Res Lab, B-4000 Liege, Sart Tilman, Belgium.	dmottet@ulg.ac.be	Londono-Vallejo, Arturo/ABH-5555-2020; Novo, Clara Lopes/J-8975-2014	Londono-Vallejo, Arturo/0000-0003-3535-7563; Novo, Clara Lopes/0000-0003-1435-4136	National Fund for Scientific Research (FNRS; Belgium); Televie; Centre Anti-Cancereux, Fonds Leon Fredericq; Fonds Speciaux de Recherche pres de l'Universite de Liege	National Fund for Scientific Research (FNRS; Belgium)(Fonds de la Recherche Scientifique - FNRS); Televie; Centre Anti-Cancereux, Fonds Leon Fredericq; Fonds Speciaux de Recherche pres de l'Universite de Liege	The authors thank the Groupe Interdisciplinaire de Genoproteomique Appliquee (GIGA) Cell Imaging and Flow Cytometry core facility for their help with microscopy and imaging analysis as well as Dr. Paul Peixoto and Dr. Christian Herens (Genetics Department, GIGA, University of Liege) for technical assistance. The authors also thank both Dr. Olivier Peulen and Laurence Seidel for their helpful assistance for statistical analyses. This work was supported by grants from the National Fund for Scientific Research (FNRS; Belgium), Televie, the Centre Anti-Cancereux, Fonds Leon Fredericq, and Fonds Speciaux de Recherche pres de l'Universite de Liege. D. M. and A. D. are research associates at FNRS. C. P. is a FNRS-Televie fellow. N. M. is FRIA fellow. P. P. is a FNRS-TELEVIE postdoctorate scholar. C. L. N., C. P., and N. M. performed the experiments; C. L. N. supervised C. P.; C. L. N., A. L. V., A. D., V. C., and D. M. conceived the study, performed data analysis, and wrote the manuscript. The authors declare no conflicts of interest.	ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; Baker AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019124; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Bothmer A, 2011, MOL CELL, V42, P319, DOI 10.1016/j.molcel.2011.03.019; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Burgio G, 2011, J CELL SCI, V124, P2041, DOI 10.1242/jcs.078261; Chapman JR, 2012, J CELL SCI, V125, P3529, DOI 10.1242/jcs.105353; Chueh AC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000354; Cristofari G, 2006, EMBO J, V25, P565, DOI 10.1038/sj.emboj.7600952; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dechat T, 2008, GENE DEV, V22, P832, DOI 10.1101/gad.1652708; Draskovic I, 2009, P NATL ACAD SCI USA, V106, P15726, DOI 10.1073/pnas.0907689106; Drosopoulos WC, 2012, J CELL BIOL, V197, P253, DOI 10.1083/jcb.201112083; Feng ZH, 2012, NUCLEIC ACIDS RES, V40, P726, DOI 10.1093/nar/gkr748; Galati A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034386; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; Lee H, 2006, MOL CELL BIOL, V26, P5259, DOI 10.1128/MCB.01971-05; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; Loyola A, 2006, MOL CELL, V24, P309, DOI 10.1016/j.molcel.2006.08.019; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Michishita E, 2009, CELL CYCLE, V8, P2664, DOI 10.4161/cc.8.16.9367; Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377; Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160; Pedram M, 2006, MOL CELL BIOL, V26, P1865, DOI 10.1128/MCB.26.5.1865-1878.2006; Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3; Pickett HA, 2012, CELL CYCLE, V11, P1309, DOI 10.4161/cc.19632; Poschke H, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002960; Schoeftner S, 2008, NAT CELL BIOL, V10, P228, DOI 10.1038/ncb1685; Sfeir A, 2009, CELL, V138, P90, DOI 10.1016/j.cell.2009.06.021; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Tilman G, 2009, ONCOGENE, V28, P1682, DOI 10.1038/onc.2009.23; Uziel O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009132; Waltregny D, 2005, FASEB J, V19, P966, DOI 10.1096/fj.04-2303fje; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; Ward RJ, 2005, MOL PHARMACOL, V68, P779, DOI 10.1124/mol.105.011494; Wong LH, 2007, GENOME RES, V17, P1146, DOI 10.1101/gr.6022807; Wong LH, 2009, GENOME RES, V19, P404, DOI 10.1101/gr.084947.108; Wu GK, 2003, CANCER RES, V63, P2589; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zaug AJ, 2005, P NATL ACAD SCI USA, V102, P10864, DOI 10.1073/pnas.0504744102	51	13	13	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3632	3642		10.1096/fj.12-224204	http://dx.doi.org/10.1096/fj.12-224204			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729589	Green Submitted			2022-12-28	WOS:000328840500022
J	Shih, DM; Shaposhnik, Z; Meng, YH; Rosales, M; Wang, XP; Wu, J; Ratiner, B; Zadini, F; Zadini, G; Lusis, AJ				Shih, Diana M.; Shaposhnik, Zory; Meng, Yonghong; Rosales, Melenie; Wang, Xuping; Wu, Judy; Ratiner, Boris; Zadini, Filiberto; Zadini, Giorgio; Lusis, Aldons J.			Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice	FASEB JOURNAL			English	Article						bile acid; intestinal cholesterol absorption; low-density lipoprotein; high-density lipoprotein; reverse cholesterol transport	HYDROPHILIC BILE-ACIDS; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; URSODEOXYCHOLIC ACID; CHOLESTEROL LEVELS; BRACHIOCEPHALIC ARTERY; CARDIOVASCULAR-DISEASE; OXIDIZED PHOSPHOLIPIDS; HYOCHOLIC ACID; AORTIC ROOT	We examined the effects of a natural secondary bile acid, hyodeoxycholic acid (HDCA), on lipid metabolism and atherosclerosis in LDL receptor-null (LDLRKO) mice. Female LDLRKO mice were maintained on a Western diet for 8 wk and then divided into 2 groups that received chow, or chow + 1.25% HDCA, diets for 15 wk. We observed that mice fed the HDCA diet were leaner and exhibited a 37% (P<0.05) decrease in fasting plasma glucose level. HDCA supplementation significantly decreased atherosclerotic lesion size at the aortic root region, the entire aorta, and the innominate artery by 44% (P<0.0001), 48% (P<0.01), and 94% (P<0.01), respectively, as compared with the chow group. Plasma VLDL/IDL/LDL cholesterol levels were significantly decreased, by 61% (P<0.05), in the HDCA group as compared with the chow diet group. HDCA supplementation decreased intestinal cholesterol absorption by 76% (P<0.0001) as compared with the chow group. Furthermore, HDL isolated from the HDCA group exhibited significantly increased ability to mediate cholesterol efflux ex vivo as compared with HDL of the chow diet group. In addition, HDCA significantly increased the expression of genes involved in cholesterol efflux, such as Abca1, Abcg1, and Apoe, in a macrophage cell line. Thus, HDCA is a candidate for antiatherosclerotic drug therapy.Shih, D. M., Shaposhnik, Z., Meng, Y., Rosales, M., Wang, X., Wu, J., Ratiner, B., Zadini, F., Zadini, G., Lusis, A. J. Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice.	[Shih, Diana M.; Shaposhnik, Zory; Meng, Yonghong; Rosales, Melenie; Wang, Xuping; Wu, Judy; Lusis, Aldons J.] Univ Calif Los Angeles, Div Cardiol, Dept Med, Los Angeles, CA 90095 USA; [Shaposhnik, Zory] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Lusis, Aldons J.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; [Ratiner, Boris; Zadini, Filiberto; Zadini, Giorgio] AtheroNova Inc, Irvine, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Shih, DM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, 10833 Le Conte Ave,A2-237 CHS, Los Angeles, CA 90095 USA.	dshih@mednet.ucla.edu			AtheroNova, Inc.; U.S. National Heart, Lung, and Blood Institute [1R01-HL-094322-04, 2-P01-HL-030568-26A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL094322, P01HL030568] Funding Source: NIH RePORTER	AtheroNova, Inc.; U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Lawrence Castellani, Sarada Charugundla, Yu-Rong Xia, Carmen Volpe, and Zhiqiang Zhou for excellent technical support. The authors thank Balbir Brar for critical reading of the manuscript. This study was supported in part by AtheroNova, Inc., and by U.S. National Heart, Lung, and Blood Institute grants 1R01-HL-094322-04 (to A.J.L.) and 2-P01-HL-030568-26A1 (to D.M.S.).	BACHRACH WH, 1982, DIGEST DIS SCI, V27, P737, DOI 10.1007/BF01393771; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Barter P, 2011, TRENDS PHARMACOL SCI, V32, P694, DOI 10.1016/j.tips.2011.07.004; Batta AK, 2004, METABOLISM, V53, P556, DOI 10.1016/j.metabol.2003.12.003; Beltroy EP, 2007, J LIPID RES, V48, P869, DOI 10.1194/jlr.M600488-JLR200; Bennett BJ, 2009, ARTERIOSCL THROM VAS, V29, P348, DOI 10.1161/ATVBAHA.108.176685; BROUGHTON G, 1994, AM J MED SCI, V307, P54, DOI 10.1097/00000441-199401000-00011; Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312; COHENSOLAL C, 1995, BBA-LIPID LIPID MET, V1257, P189, DOI 10.1016/0005-2760(95)00073-L; Couture P, 2013, CURR OPIN LIPIDOL, V24, P227, DOI 10.1097/MOL.0b013e3283613a55; Davidson MH, 2011, CURR ATHEROSCLER REP, V13, P95, DOI 10.1007/s11883-010-0151-2; Digby JE, 2012, ARTERIOSCL THROM VAS, V32, P582, DOI 10.1161/ATVBAHA.111.236315; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Eyssen HJ, 1999, APPL ENVIRON MICROB, V65, P3158; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689; KOOPMAN BJ, 1984, CLIN CHIM ACTA, V142, P103, DOI 10.1016/0009-8981(84)90105-0; KRAUSS RM, 1987, LANCET, V2, P62; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; Navab M, 2001, J LIPID RES, V42, P1308; Orozco LD, 2007, CIRC RES, V100, P1703, DOI 10.1161/CIRCRESAHA.107.151720; PEDERSEN TR, 1994, LANCET, V344, P1383; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; QIAO JH, 1994, ARTERIOSCLER THROMB, V14, P1480, DOI 10.1161/01.ATV.14.9.1480; Rader DJ, 2006, J CLIN INVEST, V116, P3090, DOI 10.1172/JCI30163; Ramachandran S, 2005, ATHEROSCLEROSIS, V178, P33, DOI 10.1016/j.atherosclerosis.2004.08.010; Sato H, 2008, J MED CHEM, V51, P1831, DOI 10.1021/jm7015864; Sehayek E, 2001, J LIPID RES, V42, P1250; Shao BH, 2010, J BIOL CHEM, V285, P18473, DOI 10.1074/jbc.M110.118182; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; SINGHAL AK, 1984, J LIPID RES, V25, P539; SINGHAL AK, 1984, J LIPID RES, V25, P564; Song C, 2000, STEROIDS, V65, P423, DOI 10.1016/S0039-128X(00)00127-6; Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216-003-2224-3; Teupser D, 2004, P NATL ACAD SCI USA, V101, P17795, DOI 10.1073/pnas.0408096101; Teupser D, 2003, ARTERIOSCL THROM VAS, V23, P1907, DOI 10.1161/01.ATV.0000090126.34881.B1; Thomas C, 2008, NAT REV DRUG DISCOV, V7, P678, DOI 10.1038/nrd2619; Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tsimikas S, 2000, ARTERIOSCL THROM VAS, V20, P689, DOI 10.1161/01.ATV.20.3.689; Uy MC, 2008, OBES SURG, V18, P1532, DOI 10.1007/s11695-008-9587-7; VANDEHEIJNING BJM, 1994, J LIPID RES, V35, P1002; VanderLaan PA, 2004, ARTERIOSCL THROM VAS, V24, P12, DOI 10.1161/01.ATV.0000105054.43931.f0; Wang DQH, 2003, AM J PHYSIOL-GASTR L, V285, pG494, DOI 10.1152/ajpgi.00156.2003; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Watson CE, 2011, J LIPID RES, V52, P361, DOI 10.1194/jlr.M011098; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	54	27	31	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3805	3817		10.1096/fj.12-223008	http://dx.doi.org/10.1096/fj.12-223008			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23752203	Green Published			2022-12-28	WOS:000328840500038
J	Gandy, KAO; Adada, M; Canals, D; Carroll, B; Roddy, P; Hannun, YA; Obeid, LM				Gandy, K. Alexa Orr; Adada, Mohamad; Canals, Daniel; Carroll, Brittany; Roddy, Patrick; Hannun, Yusuf A.; Obeid, Lina M.			Epidermal growth factor-induced cellular invasion requires sphingosine-1-phosphate/sphingosine-1-phosphate 2 receptor-mediated ezrin activation	FASEB JOURNAL			English	Article						radixin; moesin; actin cytoskeleton; polarization	SPHINGOSINE KINASE-1 EXPRESSION; EGF RECEPTOR; ERM PROTEINS; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; TARGETED THERAPY; PROSTATE-CANCER; CELLS; PHOSPHORYLATION; MIGRATION	Ezrin, radixin, and moesin (ERM) proteins link cortical actin to the plasma membrane and coordinate cellular events that require cytoskeletal rearrangement, including cell division, migration, and invasion. While ERM proteins are involved in many important cellular events, the mechanisms regulating their function are not completely understood. Our laboratory previously identified reciprocal roles for the sphingolipids ceramide and sphingosine-1-phosphate (S1P) in the regulation of ERM proteins. We recently showed that ceramide-induced activation of PP1 leads to dephosphorylation and inactivation of ERM proteins, while S1P results in phosphorylation and activation of ERM proteins. Following these findings, we aimed to examine known inducers of the SK/S1P pathway and evaluate their ability to regulate ERM proteins. We examined EGF, a known inducer of the SK/S1P pathway, for its ability to regulate the ERM family of proteins. We found that EGF induces ERM c-terminal threonine phosphorylation via activation of the SK/S1P pathway, as this was prevented by siRNA knockdown or pharmacological inhibition of SK. Using pharmacological, as well as genetic, knockdown approaches, we determined that EGF induces ERM phosphorylation via activation of S1PR2. In addition, EGF led to cell polarization in the form of lamellipodia, and this occurred through a mechanism involving S1PR2-mediated phosphorylation of ezrin T567. EGF-induced cellular invasion was also found to be dependent on S1PR2-induced T567 ezrin phosphorylation, such that S1PR2 antagonist, JTE-013, and expression of a dominant-negative ezrin mutant prevented cellular invasion toward EGF. In this work, a novel mechanism of EGF-stimulated invasion is unveiled, whereby S1P-mediated activation of S1PR2 and phosphorylation of ezrin T567 is required.	[Gandy, K. Alexa Orr] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29425 USA; [Roddy, Patrick] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Adada, Mohamad; Canals, Daniel; Carroll, Brittany; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Obeid, Lina M.] Northport Vet Affairs Med Ctr, Northport, NY USA	Medical University of South Carolina; Medical University of South Carolina; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Obeid, LM (corresponding author), SUNY Stony Brook, Dept Med, Hlth Sci Ctr, L-4,179, Stony Brook, NY 11794 USA.	lina.obeid@stonybrookmedicine.edu	Canals, Daniel/AAW-1998-2021; Canals, Daniel/AAJ-8176-2021	Canals, Daniel/0000-0002-9293-5123; obeid, lina/0000-0002-0734-0847; Adada, Mohamad/0000-0002-2988-2081	Office of Research and Development, Department of Veterans Affairs [BX000156-01A1]; Ralph H. Johnson Veterans Affairs Medical Center (Charleston, SC, USA); U.S. Department of Education Graduate Assistance in Areas of National Need (GAANN) in Lipid Biology and New Technologies [P200A070596]; U.S. National Institutes of Health (NIH) [HL-007260]; National Cancer Institute [R01-CA87584, PO1-CA97132]; NIH National Institute of General Medical Sciences [R01-GM062887]; Cancer Center Support Grant [P30 CA138313]; NATIONAL CANCER INSTITUTE [P01CA097132, P30CA138313, R01CA087584] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887, T32GM008444, R01GM097741] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000156] Funding Source: NIH RePORTER	Office of Research and Development, Department of Veterans Affairs(US Department of Veterans Affairs); Ralph H. Johnson Veterans Affairs Medical Center (Charleston, SC, USA); U.S. Department of Education Graduate Assistance in Areas of National Need (GAANN) in Lipid Biology and New Technologies; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This article is based on work supported in part by Merit Award BX000156-01A1 (L.M.O.) from the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center (Charleston, SC, USA); U.S. Department of Education Graduate Assistance in Areas of National Need (GAANN) in Lipid Biology and New Technologies grant P200A070596 (K.A.O.G.); U.S. National Institutes of Health (NIH) grant HL-007260 (K.A.O.G.); National Cancer Institute grants R01-CA87584 (Y.A.H.) and PO1-CA97132 (Y.A.H. and L.M.O.), and NIH National Institute of General Medical Sciences grant R01-GM062887 (L.M.O.). The imaging facilities for this research were supported, in part, by Cancer Center Support Grant P30 CA138313 to the Hollings Cancer Center (Medical University of South Carolina). The content of this material does not represent the views of the U.S. Department of Veterans Affairs or the U.S. Government.	Adyshev DM, 2011, CELL SIGNAL, V23, P2086, DOI 10.1016/j.cellsig.2011.08.003; Anelli V, 2008, J BIOL CHEM, V283, P3365, DOI 10.1074/jbc.M708241200; Antoine-Bertrand J, 2011, MOL BIOL CELL, V22, P3734, DOI 10.1091/mbc.E10-11-0917; Asghar U, 2010, CLIN COLORECTAL CANC, V9, P274, DOI 10.3816/CCC.2010.n.040; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Bao MY, 2012, LIVER INT, V32, P331, DOI 10.1111/j.1478-3231.2011.02666.x; Batus M, 2010, EXPERT REV ANTICANC, V10, P1589, DOI 10.1586/ERA.10.104; Baumgartner M, 2006, P NATL ACAD SCI USA, V103, P13391, DOI 10.1073/pnas.0605950103; Brakch N, 2010, EUR HEART J, V31, P67, DOI 10.1093/eurheartj/ehp387; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Canals D, 2012, J BIOL CHEM, V287, P10145, DOI 10.1074/jbc.M111.306456; Canals D, 2010, J BIOL CHEM, V285, P32476, DOI 10.1074/jbc.M110.141028; Chen Y, 2011, CANCER RES, V71, P1721, DOI 10.1158/0008-5472.CAN-09-4683; Chen ZC, 2001, CANCER-AM CANCER SOC, V92, P3068, DOI 10.1002/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO;2-5; Cheng L, 2011, FUTURE ONCOL, V7, P519, DOI [10.2217/FON.11.25, 10.2217/fon.11.25]; Cui YZ, 2010, CANCER INVEST, V28, P242, DOI 10.3109/07357900903124498; Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001; Domingo G, 2010, EXPERT REV ANTICANC, V10, P1577, DOI [10.1586/era.10.141, 10.1586/ERA.10.141]; Donati C, 2007, FEBS LETT, V581, P4384, DOI 10.1016/j.febslet.2007.08.007; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Estrada-Bernal A, 2011, J NEURO-ONCOL, V102, P353, DOI 10.1007/s11060-010-0345-z; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; French KJ, 2003, CANCER RES, V63, P5962; Gorshkova I, 2008, J BIOL CHEM, V283, P11794, DOI 10.1074/jbc.M800250200; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200; Kagesawa T, 2008, MECH DEVELOP, V125, P1020, DOI 10.1016/j.mod.2008.08.001; Kahsai AW, 2010, BBA-MOL CELL RES, V1803, P300, DOI 10.1016/j.bbamcr.2009.11.002; Kharel Y, 2011, BIOCHEM J, V440, P345, DOI 10.1042/BJ20110817; Kim S, 2011, ANTICANCER RES, V31, P3767; Kruser TJ, 2010, EXP CELL RES, V316, P1083, DOI 10.1016/j.yexcr.2010.01.009; Kunda P, 2012, CURR BIOL, V22, P231, DOI 10.1016/j.cub.2011.12.016; Li Junwei, 2007, Zhongguo Fei Ai Za Zhi, V10, P183, DOI 10.3779/j.issn.1009-3419.2007.03.05; Li MH, 2009, J UROLOGY, V181, P1347, DOI 10.1016/j.juro.2008.10.140; Libotte T, 2001, EXP CELL RES, V270, P129, DOI 10.1006/excr.2001.5339; Lopez-Perez M, 2006, INT J BIOCHEM CELL B, V38, P1716, DOI 10.1016/j.biocel.2006.04.001; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Lynch JA, 2010, CURR BIOL, V20, P1042, DOI 10.1016/j.cub.2010.04.023; Medlin MD, 2010, ARTERIOSCL THROM VAS, V30, P1779, DOI 10.1161/ATVBAHA.110.209395; Musial Jacek, 2007, Polish Journal of Pathology, V58, P235; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Neisch AL, 2011, CURR OPIN CELL BIOL, V23, P377, DOI 10.1016/j.ceb.2011.04.011; Nunes J, 2012, BRIT J CANCER, V106, P909, DOI 10.1038/bjc.2012.14; Orr Gandy K. A., 2012, BIOCHEM J, V449, P661; Paugh BS, 2008, FASEB J, V22, P455, DOI 10.1096/fj.07-8276com; Pullar CE, 2006, MOL BIOL CELL, V17, P4925, DOI 10.1091/mbc.E06-05-0433; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; Rodgers A, 2009, STEM CELLS DEV, V18, P1319, DOI 10.1089/scd.2009.0023; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Schenten V, 2011, J LEUKOCYTE BIOL, V89, P587, DOI 10.1189/jlb.0510304; Spassieva S, 2007, METHOD ENZYMOL, V434, P233, DOI 10.1016/S0076-6879(07)34012-3; Stiess M, 2011, DEV NEUROBIOL, V71, P430, DOI 10.1002/dneu.20849; Sukocheva O, 2006, J CELL BIOL, V173, P301, DOI 10.1083/jcb.200506033; Takeuchi K, 2010, FEBS J, V277, P316, DOI 10.1111/j.1742-4658.2009.07450.x; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Van Brocklyn JR, 2002, CANCER LETT, V181, P195, DOI 10.1016/S0304-3835(02)00050-2; Wang Longyun, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P969, DOI 10.3969/j.issn.1672-7347.2010.09.012; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yotsumoto F, 2009, ANTICANCER RES, V29, P4879; Young N, 2009, MOL CANCER RES, V7, P23, DOI 10.1158/1541-7786.MCR-08-0061; Zeidan YH, 2008, J CELL BIOL, V181, P335, DOI 10.1083/jcb.200705060; Zhai Jian-Wen, 2010, Chin J Cancer, V29, P317	64	26	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3155	3166		10.1096/fj.13-228460	http://dx.doi.org/10.1096/fj.13-228460			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23629860	Green Published			2022-12-28	WOS:000329877600022
J	Bezawork-Geleta, A; Saiyed, T; Dougan, DA; Truscott, KN				Bezawork-Geleta, Ayenachew; Saiyed, Tamanna; Dougan, David A.; Truscott, Kaye N.			Mitochondrial matrix proteostasis is linked to hereditary paraganglioma: LON-mediated turnover of the human flavinylation factor SDH5 is regulated by its interaction with SDHA	FASEB JOURNAL			English	Article						organelle; assembly factor; protein degradation; AAA+ protease; succinate dehydrogenase	SUCCINATE-DEHYDROGENASE; COMPLEX-II; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; GENE; MUTATIONS; MEMBRANE; CELLS; ELECTROPHORESIS	Mutations in succinate dehydrogenase (SDH) subunits and assembly factors cause a range of clinical conditions. One such condition, hereditary paraganglioma 2 (PGL2), is caused by a G78R mutation in the assembly factor SDH5. Although SDH5(G78R) is deficient in its ability to promote SDHA flavinylation, it has remained unclear whether impairment to its import, structure, or stability contributes to its loss of function. Using import-chase analysis in human mitochondria isolated from HeLa cells, we found that the import and maturation of human SDH5(G78R) was normal, while its stability was reduced significantly, with similar to 25% of the protein remaining after 180 min compared to similar to 85% for the wild-type protein. Notably, the metabolic stability of SDH5(G78R) was restored to wild-type levels by depleting mitochondrial LON (LONM). Degradation of SDH5(G78R) by LONM was confirmed in vitro; however, in contrast to the in organello analysis, wild-type SDH5 was also rapidly degraded by LONM. SDH5 instability was confirmed in SDHA-depleted mitochondria. Blue native PAGE showed that imported SDH5(G78R) formed a transient complex with SDHA; however, this complex was stabilized in LONM depleted mitochondria. These data demonstrate that SDH5 is protected from LONM-mediated degradation in mitochondria by its stable interaction with SDHA, a state that is dysregulated in PGL2.-Bezawork-Geleta, A., Saiyed, T., Dougan, D. A., Truscott, K. N. Mitochondrial matrix proteostasis is linked to hereditary paraganglioma: LON-mediated turnover of the human flavinylation factor SDH5 is regulated by its interaction with SDHA.	[Bezawork-Geleta, Ayenachew; Saiyed, Tamanna; Dougan, David A.; Truscott, Kaye N.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Melbourne, Vic 3086, Australia	La Trobe University	Truscott, KN (corresponding author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Melbourne, Vic 3086, Australia.	d.dougan@latrobe.edu.au; k.truscott@latrobe.edu.au	dougan, david/B-3359-2010	dougan, david/0000-0001-9313-1904; Bezawork-Geleta, Ayenachew/0000-0001-5404-5093; Bezawork-Geleta, Ayenachew/0000-0003-2739-8023; Truscott, Kaye/0000-0002-5352-9835	Australian Research Council [DP110103936, FT0992033]; La Trobe University; Cooperative Research Centre	Australian Research Council(Australian Research Council); La Trobe University; Cooperative Research Centre(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme)	This work was supported by Australian Research Council fellowships to D.A.D (DP110103936) and K.N.T. (FT0992033), a La Trobe University postgraduate research scholarship to A.B-G., and a Cooperative Research Centre postgraduate award to T.S. Protein sequencing was performed by the Australian Proteome Analysis Facility (North Ryde, NSW, Australia). The authors thank N. Hoogenraad and M. Ryan (La Trobe University) for anti-HSP60 and anti-NDUFA9 antisera, respectively.	Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Catanzariti AM, 2004, PROTEIN SCI, V13, P1331, DOI 10.1110/ps.04618904; Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Eletsky A, 2012, BIOCHEMISTRY-US, V51, P8475, DOI 10.1021/bi301171u; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Granot Z, 2007, MOL ENDOCRINOL, V21, P2164, DOI 10.1210/me.2005-0458; Gur Eyal, 2013, Subcell Biochem, V66, P3, DOI 10.1007/978-94-007-5940-4_1; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Hoekstra AS, 2013, BBA-BIOENERGETICS, V1827, P543, DOI 10.1016/j.bbabio.2012.11.005; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lim K, 2005, PROTEINS, V58, P759, DOI 10.1002/prot.20337; Lowth BR, 2012, J STRUCT BIOL, V179, P193, DOI 10.1016/j.jsb.2012.06.001; Lu B, 2013, MOL CELL, V49, P121, DOI 10.1016/j.molcel.2012.10.023; Mossmann D, 2012, BBA-GENE REGUL MECH, V1819, P1098, DOI 10.1016/j.bbagrm.2011.11.007; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Ninnis RL, 2009, EMBO J, V28, P1732, DOI 10.1038/emboj.2009.134; Rutter J, 2010, MITOCHONDRION, V10, P393, DOI 10.1016/j.mito.2010.03.001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Stojanovski D, 2007, METHOD CELL BIOL, V80, P783, DOI 10.1016/S0091-679X(06)80036-1; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Tatsuta Takashi, 2007, Methods Mol Biol, V372, P343, DOI 10.1007/978-1-59745-365-3_25; Tian Q, 2011, J BIOL CHEM, V286, P26424, DOI 10.1074/jbc.M110.215772; Truscott KN, 2010, BIOCHEM CELL BIOL, V88, P97, DOI [10.1139/O09-167, 10.1139/o09-167]; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Vogtle FN, 2009, CELL, V139, P428, DOI 10.1016/j.cell.2009.07.045; Voos Wolfgang, 2013, Subcell Biochem, V66, P223, DOI 10.1007/978-94-007-5940-4_9; Yamaguchi Y, 2011, ANNU REV GENET, V45, P61, DOI 10.1146/annurev-genet-110410-132412; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	37	33	33	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1794	1804		10.1096/fj.13-242420	http://dx.doi.org/10.1096/fj.13-242420			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24414418				2022-12-28	WOS:000335344300025
J	Liu, L; Kim, H; Casta, A; Kobayashi, Y; Shapiro, LS; Christiano, AM				Liu, Liang; Kim, Hyunmi; Casta, Alex; Kobayashi, Yuki; Shapiro, Lawrence S.; Christiano, Angela M.			Hairless is a histone H3K9 demethylase	FASEB JOURNAL			English	Article						epigenetics; ChIP-Seq	METHYLATION; RECEPTOR; GENE; DIFFERENTIATION; ACTIVATION; PROTEINS; MUTATION; ATRICHIA; DISEASE; PLAYS	The hairless (HR) protein contains a Jumonji C (JmjC) domain that is conserved among a family of proteins with histone demethylase (HDM) activity. To test whether HR possesses HDM activity, we performed a series of in vitro demethylation assays, which demonstrated that HR can demethylate monomethylated or dimethylated histone H3 lysine 9 (H3K9me1 or me2). Moreover, ectopic expression of wild-type HR, but not JmjC-mutant HR, led to pronounced demethylation of H3K9 in cultured human HeLa cells. We also show that two missense mutations in HR, which we and others described in patients with atrichia with papular lesions, abolished the demethylase activity of HR, demonstrating the role of HR demethylase activity in human disease. By ChIP-Seq analysis, we identified multiple new HR target genes, many of which play important roles in epidermal development, neural function, and transcriptional regulation, consistent with the predicted biological functions of HR. Our findings demonstrate for the first time that HR is a H3K9 demethylase that regulates epidermal homeostasis via direct control of its target genes.-Liu, L., Kim, H., Casta, A., Kobayashi, Y., Shapiro, L. S., Christiano, A. M. Hairless is a histone H3K9 demethylase.	[Liu, Liang; Kim, Hyunmi; Casta, Alex; Kobayashi, Yuki; Christiano, Angela M.] Columbia Univ, Dept Dermatol, New York, NY 10032 USA; [Christiano, Angela M.] Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; [Shapiro, Lawrence S.] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Christiano, AM (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Dermatol, Russ Berrie Med Sci Pavil,1150 St Nicholas Av, New York, NY 10032 USA.	amc65@columbia.edu	Shapiro, Lawrence/AAE-7172-2019		U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR47338]; Columbia University Skin Disease Research Center [P30AR44535]; NIH [T32AR007605]; Center for Environmental Health in Northern Manhattan [P30 ES009089]; American Skin Association; Dermatology Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047338, T32AR007605, P30AR044535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Columbia University Skin Disease Research Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Environmental Health in Northern Manhattan; American Skin Association; Dermatology Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank M. Zhang, J. Shimazu, and R. Du for their excellent technical assistance. The authors also thank Drs. Timothy Bestor, Yutaka Shimomura, and the members of the A.M.C. laboratory for helpful discussions and comments. This work was supported by U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01AR47338 to A.M.C. and Columbia University Skin Disease Research Center grant P30AR44535. H.K was supported by NIH grant T32AR007605. L.L. is supported in part by a pilot grant from the Center for Environmental Health in Northern Manhattan (P30 ES009089), a Research Scholar Award from the American Skin Association, and a research grant from the Dermatology Foundation.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Ahmad W, 1998, SCIENCE, V279, P720, DOI 10.1126/science.279.5351.720; Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Chuma M, 2012, BIOL PHARM BULL, V35, P582, DOI 10.1248/bpb.35.582; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Djabali K, 2001, J CELL SCI, V114, P367; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; Kim BK, 2012, J BIOL CHEM, V287, P16681, DOI 10.1074/jbc.M111.320770; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Klein I, 2002, J INVEST DERMATOL, V119, P920, DOI 10.1046/j.1523-1747.2002.00268.x; Kleine-Kohlbrecher D, 2010, MOL CELL, V38, P165, DOI 10.1016/j.molcel.2010.03.002; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Lien WH, 2011, CELL STEM CELL, V9, P219, DOI 10.1016/j.stem.2011.07.015; Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; O'Shaughnessy RFL, 2004, J INVEST DERMATOL, V123, P613, DOI 10.1111/j.0022-202X.2004.23410.x; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Qi HH, 2010, NATURE, V466, P503, DOI 10.1038/nature09261; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thompson Catherine C, 2009, Nucl Recept Signal, V7, pe010, DOI 10.1621/nrs.07010; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Trojer P, 2007, CELL, V129, P915, DOI 10.1016/j.cell.2007.03.048; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; Eswar Narayanan, 2007, Curr Protoc Protein Sci, VChapter 2, DOI [10.1002/cpbi.3, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/0471140864.ps0209s50]; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zarach JM, 2004, DEVELOPMENT, V131, P4189, DOI 10.1242/dev.01303; Zlotogorski A, 2002, J INVEST DERMATOL, V118, P881, DOI 10.1046/j.1523-1747.2002.01740.x	32	31	33	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1534	1542		10.1096/fj.13-237677	http://dx.doi.org/10.1096/fj.13-237677			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24334705	Green Published			2022-12-28	WOS:000335344300003
J	Ng, SF; Lin, RCY; Maloney, CA; Youngson, NA; Owens, JA; Morris, MJ				Ng, Sheau-Fang; Lin, Ruby C. Y.; Maloney, Christopher A.; Youngson, Neil A.; Owens, Julie A.; Morris, Margaret J.			Paternal high-fat diet consumption induces common changes in the transcriptomes of retroperitoneal adipose and pancreatic islet tissues in female rat offspring	FASEB JOURNAL			English	Article						chronic degenerative disorder; olfactory receptor genes; obesity; premature aging; developmental programming	PROTEIN-KINASE-C; LOW-BIRTH-WEIGHT; BODY-MASS INDEX; MISSING HERITABILITY; INDUCED OBESITY; OLFACTORY-BULB; EPISTASIS; DISEASE; NORMALIZATION; INFLAMMATION	We previously showed that paternal high-fat diet (HFD) consumption programs beta-cell dysfunction in female rat offspring, together with transcriptome alterations in islets. Here we investigated the retroperitoneal white adipose tissue (RpWAT) transcriptome using gene and pathway enrichment and pathway analysis to determine whether commonly affected network topologies exist between these two metabolically related tissues. In RpWAT, 5108 genes were differentially expressed due to a paternal HFD; the top 5 significantly enriched networks identified by pathway analysis in offspring of HFD fathers compared with those of fathers fed control diet were: mitochondrial and cellular response to stress, telomerase signaling, cell death and survival, cell cycle, cellular growth and proliferation, and cancer. A total of 187 adipose olfactory receptor genes were down-regulated. Interrogation against the islet transcriptome identified specific gene networks and pathways, including olfactory receptor genes that were similarly affected in both tissues (411 common genes, P < 0.05). In particular, we highlight a common molecular network, cell cycle and cancer, with the same hub gene, Myc, suggesting early onset developmental changes that persist, shared responses to programmed systemic factors, or crosstalk between tissues. Thus, paternal HFD consumption triggers unique gene signatures, consistent with premature aging and chronic degenerative disorders, in both RpWAT and pancreatic islets of daughters.-Ng, S.-F., Lin, R. C. Y., Maloney, C. A., Youngson, N. A., Owens, J. A., Morris, M. J. Paternal high-fat diet consumption induces common changes in the transcriptomes of retroperitoneal adipose and pancreatic islet tissues in female rat offspring.	[Ng, Sheau-Fang; Maloney, Christopher A.; Youngson, Neil A.; Morris, Margaret J.] Univ New S Wales, Sch Med Sci, Dept Pharmacol, Sydney, NSW 2052, Australia; [Lin, Ruby C. Y.] Univ New S Wales, Ramaciotti Ctr Genom, Sydney, NSW 2052, Australia; [Lin, Ruby C. Y.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; [Ng, Sheau-Fang] Natl Univ Malaysia, Fac Med, Dept Paediat, Kuala Lumpur, Malaysia; [Owens, Julie A.] Univ Adelaide, Sch Paediat & Reprod Hlth, Adelaide, SA, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Universiti Kebangsaan Malaysia; University of Adelaide	Morris, MJ (corresponding author), Univ New S Wales, Sch Med Sci, Dept Pharmacol, Sydney, NSW 2052, Australia.	m.morris@unsw.edu.au	Youngson, Neil/AAB-7389-2019; Morris, Margaret J/J-4285-2013; Owens, Julie A/C-9744-2009; Maloney, Christopher/AAG-8599-2019; Lin, Ruby CY/A-1636-2009	Owens, Julie A/0000-0002-7498-1353; Maloney, Christopher/0000-0002-9193-2369; Lin, Ruby CY/0000-0003-4163-511X; Morris, Margaret/0000-0003-2285-5117; Youngson, Neil/0000-0003-0690-4580	National Health and Medical Research Council (NHMRC) of Australia; New South Innovations [University of New South Wales (UNSW)]; Ministry of Higher Education; National University of Malaysia; UNSW	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); New South Innovations [University of New South Wales (UNSW)]; Ministry of Higher Education(Science and Technology Development Fund (STDF)Ministry of Higher Education & Scientific Research (MHESR)); National University of Malaysia; UNSW	This work was supported by a project grant of the National Health and Medical Research Council (NHMRC) of Australia (to M.J.M) and funding from New South Innovations [University of New South Wales (UNSW)]. S.F.N. was supported by the Ministry of Higher Education and the National University of Malaysia. R.C.Y.L. is supported by the UNSW Vice-Chancellor Postdoctoral Fellowship.	Affymetrix, 2006, AFF GENECHIP EXPR AN; Anderson LM, 2006, NUTRITION, V22, P327, DOI 10.1016/j.nut.2005.09.006; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bakos HW, 2011, INT J ANDROL, V34, P402, DOI 10.1111/j.1365-2605.2010.01092.x; Binder NK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052304; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Braunschweig M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030583; Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Choi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056610; Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579; Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809; FORMAN HJ, 1974, BIOCHEM BIOPH RES CO, V60, P1044, DOI 10.1016/0006-291X(74)90418-5; Fullston T, 2013, FASEB J, V27, P4226, DOI 10.1096/fj.12-224048; Gardano L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00146; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hypponen E, 2003, BMJ-BRIT MED J, V326, P19, DOI 10.1136/bmj.326.7379.19; Inoguchi T, 2003, J AM SOC NEPHROL, V14, pS227, DOI 10.1097/01.ASN.0000077407.90309.65; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; JENSEN PK, 1966, BIOCHIM BIOPHYS ACTA, V122, P157, DOI 10.1016/0926-6593(66)90057-9; Jin CC, 2013, J ALLERGY CLIN IMMUN, V132, P287, DOI 10.1016/j.jaci.2013.06.022; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Le Bacquer O, 2006, M S-MED SCI, V22, P514, DOI 10.1051/medsci/2006225514; Lehner B, 2007, J EXP BIOL, V210, P1559, DOI 10.1242/jeb.002311; Lehner B, 2011, TRENDS GENET, V27, P323, DOI 10.1016/j.tig.2011.05.007; Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967; Lindsay RS, 2000, DIABETES, V49, P445, DOI 10.2337/diabetes.49.3.445; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; Meseguer M, 2008, FERTIL STERIL, V89, P1191, DOI 10.1016/j.fertnstert.2007.05.005; Moore JH, 2005, BIOESSAYS, V27, P637, DOI 10.1002/bies.20236; Morris Margaret J, 2009, Expert Rev Endocrinol Metab, V4, P625, DOI 10.1586/eem.09.45; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Okser S, 2013, BIODATA MIN, V6, DOI 10.1186/1756-0381-6-5; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Perry JRB, 2009, DIABETES, V58, P1463, DOI 10.2337/db08-1378; Power C, 2003, J EPIDEMIOL COMMUN H, V57, P969, DOI 10.1136/jech.57.12.969; Primeaux SD, 2013, DIGEST DIS SCI, V58, P72, DOI 10.1007/s10620-012-2421-z; Pyo CW, 2013, BBA-GEN SUBJECTS, V1830, P5316, DOI 10.1016/j.bbagen.2013.07.030; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Skinner MK, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R91, 10.1186/gb-2012-13-10-r91]; Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007; Son YO, 2013, TOXICOL APPL PHARM, V271, P239, DOI 10.1016/j.taap.2013.04.036; Tormos AM, 2013, FREE RADICAL RES, V47, P905, DOI 10.3109/10715762.2013.821200; Tucker K, 2012, J NEUROENDOCRINOL, V24, P1087, DOI 10.1111/j.1365-2826.2012.02314.x; Tucker K, 2010, RESULTS PROBL CELL D, V52, P147, DOI 10.1007/978-3-642-14426-4_12; Tzanetakou IP, 2012, AGEING RES REV, V11, P220, DOI 10.1016/j.arr.2011.12.003; Vucenik I, 2012, ANN NY ACAD SCI, V1271, P37, DOI 10.1111/j.1749-6632.2012.06750.x; Wang Y, 2013, AUTOPHAGY, V9, P272, DOI 10.4161/auto.23628; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Youngson NA, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2011.0337; Zhang CB, 2013, AM J PHYSIOL-ENDOC M, V305, pE530, DOI 10.1152/ajpendo.00640.2012; Zuk O, 2012, P NATL ACAD SCI USA, V109, P1193, DOI 10.1073/pnas.1119675109	54	99	104	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1830	1841		10.1096/fj.13-244046	http://dx.doi.org/10.1096/fj.13-244046			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24421403				2022-12-28	WOS:000335344300028
J	Fardini, Y; Masson, E; Boudah, O; Ben Jouira, R; Cosson, C; Pierre-Eugene, C; Kuo, MS; Issad, T				Fardini, Yann; Masson, Elodie; Boudah, Ouassila; Ben Jouira, Rania; Cosson, Camille; Pierre-Eugene, Cecile; Kuo, Mei-Shiue; Issad, Tarik			O-GlcNAcylation of FoxO1 in pancreatic beta cells promotes Akt inhibition through an IGFBP1-mediated autocrine mechanism	FASEB JOURNAL			English	Article						insulin-like growth factor-binding protein 1; PI3K signaling; glucotoxicity; Forkhead transcription factor O1; apoptosis	STIMULATED INSULIN-SECRETION; FACTOR-BINDING PROTEIN-1; TRANSCRIPTIONAL ACTIVITY; N-ACETYLGLUCOSAMINE; GLCNAC MODIFICATION; GROWTH; ACTIVATION; GLYCOSYLATION; INCREASES; APOPTOSIS	O-GlcNAcylation on serine/threonine is a post-translational modification that controls the activity of nucleocytoplasmic proteins according to glucose availability. We previously showed that O-GlcNAcylation of FoxO1 in liver cells increases its transcriptional activity. In the present study, we evaluated the potential involvement of FoxO1 O-GlcNAcylation in the context of pancreatic -cell glucotoxicity. FoxO1 was O-GlcNAcylated in INS-1 832/13 cells and isolated rat pancreatic islets. O-GlcNAcylation of FoxO1 resulted in a 2-fold increase in its transcriptional activity toward a FoxO1 reporter gene and a 3-fold increase in the expression of the insulin-like growth factor-binding protein 1 (Igfbp1) gene at the mRNA level, resulting in IGFBP1 protein oversecretion by the cells. Of note, increased IGFBP1 in the culture medium inhibited the activity of the insulin-like growth factor 1 receptor (IGF1R)/phosphatidyl inositol 3 kinase (PI3K)/Akt pathway. We reveal in this report a novel mechanism by which O-GlcNAcylation inhibits Akt activity through an autocrine mechanism. However, although inhibition of IGFBP1 expression using siRNA restored the PI3 kinase/Akt pathway, it did not rescue INS-1 832/13 cells from high-glucose- or O-glcNAcylation-induced cell death. In contrast, FoxO1 down-regulation by siRNA led to 30 to 60% protection of INS-1 832/13 cells from death mediated by glucotoxic conditions. Therefore, whereas FoxO1 O-GlcNAcylation inhibits Akt through an IGFBP1-mediated autocrine pathway, the deleterious effects of FoxO1 O-GlcNAcylation on cell survival appeared to be independent of this pathway.Fardini, Y., Masson, E., Boudah, O., Ben Jouira, R., Cosson, C., Pierre-Eugene, C., Kuo, M.-S., Issad, T. O-GlcNAcylation of FoxO1 in pancreatic cells promotes Akt inhibition through an IGFBP1-mediated autocrine mechanism.	Univ Paris 05, Inst Cochin, CNRS, Unite Mixte Rech UMR 8104, Paris, France; INSERM, Unite U1016, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Issad, T (corresponding author), Inst Cochin, Dept Diabet Endocrinol & Metab, 22 Rue Mechain, F-75014 Paris, France.	tarik.issad@inserm.fr		MASSON, Elodie/0000-0001-6312-0913; FARDINI, Yann/0000-0002-6800-1777; Issad, Tarik/0000-0002-2638-6330; Ben Jouira, Rania/0000-0001-6999-4566	Agence Nationale de la Recherche (ANR) grant (ANR Geno-path Diab-O-Glyc); Societe Francophone du Diabete (SFD-Alfediam); Cardiovasculaire-Obesite-Rein-Diabete Domaine d'Interet Majeur (CORDDIM) Ile-de-France	Agence Nationale de la Recherche (ANR) grant (ANR Geno-path Diab-O-Glyc)(French National Research Agency (ANR)); Societe Francophone du Diabete (SFD-Alfediam); Cardiovasculaire-Obesite-Rein-Diabete Domaine d'Interet Majeur (CORDDIM) Ile-de-France	The authors thank Dr. C. B. Newgard (Duke University Medical Center, Durham, NC, USA) for providing INS-1 832/13 cells and Dr. Gaelle Filhoulaud for useful technical advice for rat islet isolation. This work was supported by an Agence Nationale de la Recherche (ANR) grant (ANR Geno-path Diab-O-Glyc) and the Societe Francophone du Diabete (SFD-Alfediam). Y.F. was supported by a postdoctoral fellowship from the Cardiovasculaire-Obesite-Rein-Diabete Domaine d'Interet Majeur (CORDDIM) Ile-de-France. The authors declare no conflicts of interest.	Andrali SS, 2007, J BIOL CHEM, V282, P15589, DOI 10.1074/jbc.M701762200; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Buteau J, 2007, J BIOL CHEM, V282, P287, DOI 10.1074/jbc.M606118200; Cetinbas N, 2006, BIOCHEMISTRY-US, V45, P3835, DOI 10.1021/bi052370b; Cifarelli V, 2012, MOL ENDOCRINOL, V26, P1213, DOI 10.1210/me.2011-1276; Cooksey RC, 2006, AM J PHYSIOL-ENDOC M, V290, pE334, DOI 10.1152/ajpendo.00265.2005; D'Alessandris C, 2004, FASEB J, V18, P959, DOI 10.1096/fj.03-0725fje; Filhoulaud G, 2009, J BIOL CHEM, V284, P24583, DOI 10.1074/jbc.M109.025288; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Glauser DA, 2007, J ENDOCRINOL, V193, P195, DOI 10.1677/JOE-06-0191; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guinez C, 2011, DIABETES, V60, P1399, DOI 10.2337/db10-0452; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; ISSAD T, 1995, EUR J BIOCHEM, V234, P108, DOI 10.1111/j.1432-1033.1995.108_c.x; Issad T, 2010, DIABETES METAB, V36, P423, DOI 10.1016/j.diabet.2010.09.001; Issad T, 2008, TRENDS ENDOCRIN MET, V19, P380, DOI 10.1016/j.tem.2008.09.001; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kang ES, 2008, EXP CELL RES, V314, P2238, DOI 10.1016/j.yexcr.2008.04.014; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kuo M, 2008, BIOCHIMIE, V90, P679, DOI 10.1016/j.biochi.2008.03.005; Kuo M, 2008, FEBS LETT, V582, P829, DOI 10.1016/j.febslet.2008.02.010; Lacasa D, 2005, MOL PHARMACOL, V67, P1206, DOI 10.1124/mol.104.009514; Lefebvre T, 2009, BIOCHIM BIOPHYS ACTA, V1800, P67; Lewitt MS, 2008, DIABETOLOGIA, V51, P1135, DOI 10.1007/s00125-008-1016-x; Liu JF, 1998, EUR J BIOCHEM, V258, P271, DOI 10.1046/j.1432-1327.1998.2580271.x; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Okamoto H, 2006, J CLIN INVEST, V116, P775, DOI 10.1172/JCI24967; Omae N, 2012, MOL CELL ENDOCRINOL, V348, P297, DOI 10.1016/j.mce.2011.09.013; Ruan W., ACTA DIABETOL, V47, P5; Soesanto YA, 2008, AM J PHYSIOL-ENDOC M, V295, pE974, DOI 10.1152/ajpendo.90366.2008; Strobel A, 1999, DIABETOLOGIA, V42, P527, DOI 10.1007/s001250051190; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998	38	27	28	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					1010	1021		10.1096/fj.13-238378	http://dx.doi.org/10.1096/fj.13-238378			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24174424				2022-12-28	WOS:000331072200044
J	Katada, R; Akdemir, G; Asavapanumas, N; Ratelade, J; Zhang, H; Verkman, AS				Katada, Ryuichi; Akdemir, Gokhan; Asavapanumas, Nithi; Ratelade, Julien; Zhang, Hua; Verkman, A. S.			Greatly improved survival and neuroprotection in aquaporin-4-knockout mice following global cerebral ischemia	FASEB JOURNAL			English	Article						water channel; brain swelling; astrocyte; neuroscience	CAROTID-ARTERY OCCLUSION; EXTRACELLULAR-SPACE; WATER TRANSPORT; COGNITIVE IMPAIRMENT; BRAIN EDEMA; LACKING; MODEL; DEATH; VULNERABILITY; OUTCOMES	Aquaporin-4 (AQP4), the principal water channel in astrocytes, is involved in brain water movement, inflammation, and neuroexcitation. In this study, there was strong neuroprotection in mice lacking AQP4 in a model of global cerebral ischemia produced by transient, bilateral carotid artery occlusion (BCAO). Survival and neurological outcome were greatly improved in the AQP4(-/-)vs. AQP4(+/+) mice after occlusion, with large and robust differences in both outbred (CD1) and inbred (C57bl/6) mouse strains without or with mechanical ventilation. Improved survival was also seen in mice lacking the scaffold protein -syntrophin, which manifest reduced astrocyte water permeability secondary to defective AQP4 plasma membrane targeting. Intracranial pressure elevation and brain water accumulation were much reduced in the AQP4(-/-)vs. AQP4(+/+) mice after carotid artery occlusion, as were blood-brain barrier (BBB) disruption and neuronal loss. Brain slices from AQP4(-/-) mice showed significantly reduced cell swelling and cytotoxicity in response to oxygen-glucose deprivation, compared with slices from AQP4(+/+) mice. Our findings suggest that the neuroprotective effect of AQP4 deletion in global cerebral ischemia involves reduced astrocyte swelling and brain water accumulation, resulting in reduced BBB disruption, inflammation, and neuron death. AQP4 water transport inhibition may improve survival and neurological outcome after cardiac arrest and in other conditions associated with global cerebral ischemia.Katada, R., Akdemir, G., Asavapanumas, N., Ratelade, J., Zhang, H., Verkman, A. S. Greatly improved survival and neuroprotection in aquaporin-4 knockout mice following global cerebral ischemia.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, 1246 Hlth Sci East Tower,Box 0521, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu		Akdemir, Gokhan/0000-0002-1852-9442; Asavapanumas, Nithi/0000-0002-5362-2124; Ratelade, Julien/0000-0001-7968-5409	U.S. National Institutes of Health (Bethesda, MD, USA) [DK35124, EY13574, EB00415, DK72517]; Guthy-Jackson Charitable Foundation; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, P30DK072517, R37DK035124] Funding Source: NIH RePORTER	U.S. National Institutes of Health (Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Guthy-Jackson Charitable Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants DK35124, EY13574, EB00415, and DK72517 from the U.S. National Institutes of Health (Bethesda, MD, USA) and grants from the Guthy-Jackson Charitable Foundation.	Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Chen MK, 2001, J NEUROSCI, V21, P6512, DOI 10.1523/JNEUROSCI.21-17-06512.2001; Cho SG, 2004, NEUROCHEM INT, V45, P117, DOI 10.1016/j.neuint.2003.11.012; Datta SC, 2008, J NEUROSCI METH, V175, P119, DOI 10.1016/j.jneumeth.2008.08.007; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Duffy S, 1996, J NEUROSCI, V16, P71; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; FUJIOKA M, 1994, STROKE, V25, P2091, DOI 10.1161/01.STR.25.10.2091; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; Hinson SR, 2012, P NATL ACAD SCI USA, V109, P1245, DOI 10.1073/pnas.1109980108; Huber VJ, 2007, BIOORG MED CHEM LETT, V17, P1270, DOI 10.1016/j.bmcl.2006.12.010; Huber VJ, 2009, BIOORGAN MED CHEM, V17, P418, DOI 10.1016/j.bmc.2007.12.038; Jin BJ, 2013, J GEN PHYSIOL, V141, P119, DOI 10.1085/jgp.201210883; Jiwa NS, 2010, J NEUROCHEM, V115, P814, DOI 10.1111/j.1471-4159.2010.06958.x; Kim DH, 2010, NEUROSCI LETT, V475, P74, DOI 10.1016/j.neulet.2010.03.046; KIRINO T, 1985, PROG BRAIN RES, V63, P39; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Li LH, 2011, FASEB J, V25, P1556, DOI 10.1096/fj.10-177279; Lu DC, 2008, FASEB J, V22, P3216, DOI 10.1096/fj.07-104836; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Magnus T, 2012, CURR OPIN NEUROL, V25, P334, DOI 10.1097/WCO.0b013e328352ede6; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MICKEL HS, 1990, STROKE, V21, P1641, DOI 10.1161/str.21.11.1641c; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Murakami K, 1998, BRAIN RES, V780, P304, DOI 10.1016/S0006-8993(97)01217-1; Murakami Y, 2005, J NEUROCHEM, V93, P1616, DOI 10.1111/j.1471-4159.2005.03163.x; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nielsen S, 1997, J NEUROSCI, V17, P171; Ouyang YB, 2007, J NEUROSCI, V27, P4253, DOI 10.1523/JNEUROSCI.0211-07.2007; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; Ratelade J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027412; Rossi A, 2012, GLIA, V60, P2027, DOI 10.1002/glia.22417; Soares LM, 2013, BEHAV BRAIN RES, V249, P28, DOI 10.1016/j.bbr.2013.04.010; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Thiagarajah JR, 2005, J NEUROSCI RES, V80, P293, DOI 10.1002/jnr.20439; Walker EJ, 2010, J NEUROSCI RES, V88, P764, DOI 10.1002/jnr.22257; Yamamoto Y, 2009, BRAIN RES, V1295, P218, DOI 10.1016/j.brainres.2009.07.081; Yang BX, 2008, BIOORGAN MED CHEM, V16, P7489, DOI 10.1016/j.bmc.2008.06.005; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9; Yao XM, 2008, J NEUROSCI, V28, P5460, DOI 10.1523/JNEUROSCI.0257-08.2008; Zhang H, 2011, ANN NEUROL, V70, P943, DOI 10.1002/ana.22551; Zhang H, 2010, BIOPHYS J, V99, P1284, DOI 10.1016/j.bpj.2010.06.023; Zhen G, 2007, J NEUROSCI METH, V166, P73, DOI 10.1016/j.jneumeth.2007.06.029	49	58	66	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					705	714		10.1096/fj.13-231274	http://dx.doi.org/10.1096/fj.13-231274			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24186965	Green Published			2022-12-28	WOS:000331072200018
J	Kryza, T; Achard, C; Parent, C; Marchand-Adam, S; Guillon-Munos, A; Iochmann, S; Korkmaz, B; Respaud, R; Courty, Y; Heuze-Vourc'h, N				Kryza, Thomas; Achard, Carole; Parent, Christelle; Marchand-Adam, Sylvain; Guillon-Munos, Audrey; Iochmann, Sophie; Korkmaz, Brice; Respaud, Renaud; Courty, Yves; Heuze-Vourc'h, Nathalie			Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway	FASEB JOURNAL			English	Article						proteolysis; processing; extracellular matrix; vascular endothelial growth factor; hypoxia	REGULATE PERICYTE RECRUITMENT; INTEGRAL MEMBRANE-PROTEINS; CELL LUNG-CANCER; GENE-EXPRESSION; PDGF-B; ENDOTHELIAL-CELLS; BREAST-CANCER; LYMPHATIC METASTASIS; PROTEOLYTIC CLEAVAGE; SYSTEMIC-SCLEROSIS	KLK12, a kallikrein peptidase, is thought to take part in the control of angiogenesis. Our analysis of the secretome of endothelial cells (ECs) that had been treated with KLK12 showed that KLK12 converts the extracellular matrix- or membrane-bound precursor of platelet-derived growth factor B (PDGF-B) into a soluble form. Both PDGF-B and vascular endothelial growth factor A (VEGF-A) take part in the induction of angiogenesis by KLK12 in a coculture model of angiogenesis that mimics endothelial tubule formation. We used a cellular approach to analyze the interplay between KLK12, PDGF-B, and VEGF-A and showed that release of PDGF-B by KLK12 leads to the fibroblast-mediated secretion of VEGF-A. This then stimulates EC differentiation and the formation of capillary tube-like structures. Thus, KLK12 favors the interaction of ECs and stromal cells. The released PDGF-B acts as a paracrine factor that modulates VEGF-A secretion by stromal cells, which ultimately leads to angiogenesis. Moreover, the genes encoding KLK12 and PDGFB are both expressed in ECs and up-regulated in tumor cells kept under hypoxic conditions, which is consistent with the physiological involvement of KLK12 in PDGF-B maturation.Kryza, T., Achard, C., Parent, C., Marchand-Adam, S., Guillon-Munos, A., Iochmann, S., Korkmaz, B., Respaud, R., Courty, Y., Heuze-Vourc'h, N. Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway.	[Kryza, Thomas; Parent, Christelle; Iochmann, Sophie; Heuze-Vourc'h, Nathalie] Univ Tours, Equipe Accueil EA 6305, Tours, France; [Marchand-Adam, Sylvain] Univ Tours, Unite Mixte Rech UMR 1100, Tours, France; [Marchand-Adam, Sylvain; Iochmann, Sophie; Korkmaz, Brice; Courty, Yves] Univ Tours, Inst Univ Technol IUT Tours, Tours, France; [Respaud, Renaud] Univ Tours, EA 6306, Tours, France; [Kryza, Thomas; Parent, Christelle; Marchand-Adam, Sylvain; Guillon-Munos, Audrey; Iochmann, Sophie; Korkmaz, Brice; Courty, Yves; Heuze-Vourc'h, Nathalie] Ctr Etud Pathol Resp, UMR 1100, Tours, France; [Kryza, Thomas; Parent, Christelle; Marchand-Adam, Sylvain; Guillon-Munos, Audrey; Iochmann, Sophie; Korkmaz, Brice; Courty, Yves; Heuze-Vourc'h, Nathalie] Ctr Etud Pathol Resp, EA 6305, Tours, France; [Achard, Carole] INSERM, UMR 892, Tours, France; [Achard, Carole] CNRS, UMR 6299, Nantes, France; [Achard, Carole] Univ Nantes, Nantes, France; [Marchand-Adam, Sylvain; Korkmaz, Brice; Courty, Yves] INSERM, UMR 1100, Tours, France; [Marchand-Adam, Sylvain] CHRU Tours, Serv Pneumol, Tours, France; [Respaud, Renaud] CHRU Tours, Serv Pharm, Tours, France	Universite de Tours; Universite de Tours; Universite de Tours; Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Tours; CHU Tours	Heuze-Vourc'h, N (corresponding author), Fac Med Tours, CEPR INSERM U1100, EA 6305, 10 Blvd Tonnelle, F-37032 Tours, France.	nathalie.vourch@med.univ-tours.fr	Kryza, Thomas/AAX-7681-2020; Respaud, Renaud/E-8858-2017; HEUZE-VOURC'H, Nathalie/P-8081-2016	Kryza, Thomas/0000-0003-1668-8551; Respaud, Renaud/0000-0003-0515-7165; IOCHMANN, Sophie/0000-0002-4877-895X; Heuze-Vourc'h, Nathalie/0000-0003-4929-5068; Courty, Yves/0000-0003-3694-8517; marchand-adam, sylvain/0000-0002-9522-3738; KORKMAZ, BRICE/0000-0002-5159-8706; Parent, Christelle/0000-0001-8086-4690	Region Centre (KalliCaP); Ligue Contre le Cancer (Indre, Indre-et-Loire, ME-et-Loire, Morbihan, and Sarthe)	Region Centre (KalliCaP)(Region Centre-Val de Loire); Ligue Contre le Cancer (Indre, Indre-et-Loire, ME-et-Loire, Morbihan, and Sarthe)	The authors thank Christophe Epinette (Universite de Tours, Tours, France) for technical assistance with HPLC and the Plateforme de Spectrometrie de Masse et Proteomique du Centre de Biophysique Moleculaire (Orleans, France) for mass spectrometry analysis. The English text was edited by Dr. Owen Parkes. N.H.-V. and Y.C. hold grants from the Region Centre (KalliCaP, 2009-2011) and the Ligue Contre le Cancer (Indre, Indre-et-Loire, ME-et-Loire, Morbihan, and Sarthe).	Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bertolotti E, 2013, J MORPHOL, V274, P956, DOI 10.1002/jmor.20155; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Betsholtz C, 2004, CURR OPIN NEPHROL HY, V13, P45, DOI 10.1097/00041552-200401000-00007; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bishop E T, 1999, Angiogenesis, V3, P335, DOI 10.1023/A:1026546219962; Borgono CA, 2007, J BIOL CHEM, V282, P2405, DOI 10.1074/jbc.M608348200; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Distler JHW, 2003, Q J NUCL MED, V47, P149; Donnem T, 2008, J THORAC ONCOL, V3, P963, DOI 10.1097/JTO.0b013e3181834f52; Donnem T, 2011, CLIN LUNG CANCER, V12, P106, DOI 10.1016/j.cllc.2011.03.005; Donovan D., 2001, Angiogenesis, V4, P113, DOI 10.1023/A:1012218401036; Eissa A, 2011, J BIOL CHEM, V286, P687, DOI 10.1074/jbc.M110.125310; Emanueli C, 2004, CIRCULATION, V110, P1638, DOI 10.1161/01.CIR.0000142051.36244.83; Etulain J, 2013, BRIT J PHARMACOL, V170, P255, DOI 10.1111/bph.12250; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Furuya M, 2005, VASC HEALTH RISK MAN, V1, P277, DOI 10.2147/vhrm.2005.1.4.277; Gabant G, 2008, METHODS, V46, P54, DOI 10.1016/j.ymeth.2008.10.021; Giusti B, 2005, ARTHRITIS RHEUM-US, V52, P3618, DOI 10.1002/art.21383; Giusti B, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2002; Guillon-Munos A, 2011, J BIOL CHEM, V286, P25505, DOI 10.1074/jbc.M110.213231; Hamilton BS, 2013, J BIOL CHEM, V288, P17399, DOI 10.1074/jbc.M112.440362; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Horii K, 2007, MOL CANCER RES, V5, P383, DOI 10.1158/1541-7786.MCR-06-0226; Hughes CCW, 2008, CURR OPIN HEMATOL, V15, P204, DOI 10.1097/MOH.0b013e3282f97dbc; Kawai T, 1997, LAB INVEST, V77, P431; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Kodama M, 2010, CANCER SCI, V101, P1984, DOI 10.1111/j.1349-7006.2010.01639.x; Kryza T, 2013, BIOL CHEM, V394, P385, DOI 10.1515/hsz-2012-0291; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; Lederle W, 2006, AM J PATHOL, V169, P1767, DOI 10.2353/ajpath.2006.060120; Lin YS, 2011, SPECTROCHIM ACTA A, V79, P1552, DOI 10.1016/j.saa.2011.04.087; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Lu Y, 2008, BIOL CHEM, V389, P695, DOI 10.1515/BC.2008.080; Lundwall A, 2008, CELL MOL LIFE SCI, V65, P2019, DOI 10.1007/s00018-008-8024-3; Matei D, 2007, J BIOL CHEM, V282, P445, DOI 10.1074/jbc.M607012200; McGinnis LM, 2012, NAT MED, V18, P22, DOI 10.1038/nm.2623; Memari N, 2007, BIOL CHEM, V388, P427, DOI 10.1515/BC.2007.049; Mukhopadhyay D, 2004, SEMIN CANCER BIOL, V14, P123, DOI 10.1016/j.semcancer.2003.09.019; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; Oikonomopoulou K, 2006, BIOL CHEM, V387, P817, DOI 10.1515/BC.2006.104; Reinke JM, 2012, EUR SURG RES, V49, P35, DOI 10.1159/000339613; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Scarisbrick IA, 2006, J NEUROIMMUNOL, V178, P167, DOI 10.1016/j.jneuroim.2006.05.022; Scarisbrick IA, 2008, BIOL CHEM, V389, P739, DOI 10.1515/BC.2008.085; Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Senger D.R., 2011, COLD SPRING HARB PER, V3; Shaw JLV, 2007, CLIN CHEM, V53, P1423, DOI 10.1373/clinchem.2007.088104; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Sotiropoulou G, 2010, BIOL CHEM, V391, P321, DOI 10.1515/BC.2010.036; Sotiropoulou G, 2009, J BIOL CHEM, V284, P32989, DOI 10.1074/jbc.R109.027946; SOYOMBO AA, 1994, J BIOL CHEM, V269, P17734; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stratman AN, 2010, BLOOD, V116, P4720, DOI 10.1182/blood-2010-05-286872; Talieri M, 2012, TUMOR BIOL, V33, P1075, DOI 10.1007/s13277-012-0347-x; van Hinsbergh VWM, 2006, ARTERIOSCL THROM VAS, V26, P716, DOI 10.1161/01.ATV.0000209518.58252.17; Veveris-Lowe TL, 2007, SEMIN THROMB HEMOST, V33, P87, DOI 10.1055/s-2006-958467; Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575; Yao YY, 2013, LAB INVEST, V93, P577, DOI 10.1038/labinvest.2013.48; Yoshida D, 2006, J NEURO-ONCOL, V76, P13, DOI 10.1007/s11060-005-3279-0; Yousef GM, 2000, GENOMICS, V69, P331, DOI 10.1006/geno.2000.6346; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zhao EH, 2012, WORLD J GASTROENTERO, V18, P6597, DOI 10.3748/wjg.v18.i45.6597	69	24	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					740	751		10.1096/fj.13-237503	http://dx.doi.org/10.1096/fj.13-237503			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24225148				2022-12-28	WOS:000331072200021
J	Kubota, T; Arita, M; Isobe, Y; Iwamoto, R; Goto, T; Yoshioka, T; Urabe, D; Inoue, M; Arai, H				Kubota, Tadafumi; Arita, Makoto; Isobe, Yosuke; Iwamoto, Ryo; Goto, Tomomi; Yoshioka, Takeshi; Urabe, Daisuke; Inoue, Masayuki; Arai, Hiroyuki			Eicosapentaenoic acid is converted via omega-3 epoxygenation to the anti-inflammatory metabolite 12-hydroxy-17,18-epoxyeicosatetraenoic acid	FASEB JOURNAL			English	Article						bioactive lipid; metabolomics	POLYUNSATURATED FATTY-ACIDS; INFLAMMATION; OMEGA-3-FATTY-ACIDS; IDENTIFICATION; NEUTROPHIL; RESOLUTION	Eicosapentaenoic acid (EPA) has beneficial effects in many inflammatory disorders. In this study, dietary EPA was converted to 17,18-epoxyeicosatetraenoic acid (17,18-EpETE) by -3 epoxygenation in the mouse peritoneal cavity. Mediator lipidomics revealed a series of novel oxygenated metabolites of 17,18-EpETE, and one of the major metabolites, 12-hydroxy-17,18-epoxyeicosatetraenoic acid (12-OH-17,18-EpETE), displayed a potent anti-inflammatory action by limiting neutrophil infiltration in murine zymosan-induced peritonitis. 12-OH-17,18-EpETE inhibited leukotriene B-4-induced neutrophil chemotaxis and polarization in vitro in a low nanomolar range (EC50 0.6 nM). The complete structures of two natural isomers were assigned as 12S-OH-17R,18S-EpETE and 12S-OH-17S,18R-EpETE, using chemically synthesized stereoisomers. These natural isomers displayed potent anti-inflammatory action, whereas the unnatural stereoisomers were essentially devoid of activity. These results demonstrate that 17,18-EpETE derived from dietary EPA is converted to a potent bioactive metabolite 12-OH-17,18-EpETE, which may generate an endogenous anti-inflammatory metabolic pathway.Kubota, T., Arita, M., Isobe, Y., Iwamoto, R., Goto, T., Yoshioka, T., Urabe, D., Inoue, M., Arai, H. Eicosapentaenoic acid is converted via -3 epoxygenation to the anti-inflammatory metabolite 12-hydroxy-17,18-epoxyeicosatetraenoic acid.	[Kubota, Tadafumi; Arita, Makoto; Isobe, Yosuke; Arai, Hiroyuki] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Tokyo 1130033, Japan; [Isobe, Yosuke; Iwamoto, Ryo; Goto, Tomomi; Yoshioka, Takeshi] Univ Tokyo, Grad Sch Pharmaceut Sci, Business Acad Collaborat Lab, Tokyo 1130033, Japan; [Goto, Tomomi; Urabe, Daisuke; Inoue, Masayuki] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Integral Analyt Chem, Tokyo 1130033, Japan; [Arita, Makoto] Japanese Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan; [Goto, Tomomi; Yoshioka, Takeshi] Shionogi & Co Ltd, Shionogi Res Labs, Osaka 553, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Shionogi & Company Limited	Arita, M (corresponding author), Univ Tokyo, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	marita@mol.f.u-tokyo.ac.jp		Arita, Makoto/0000-0001-9902-0463; Yoshioka, Takeshi/0000-0002-8658-8081	Japanese Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO); Ministry of Education, Culture, Sports, Science, and Technology of Japan; program for Promotion of Basic and Applied Research for Innovations in Bio-Oriented industry; Grants-in-Aid for Scientific Research [23227004] Funding Source: KAKEN	Japanese Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); program for Promotion of Basic and Applied Research for Innovations in Bio-Oriented industry; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Michiko Kamio and Mie Honda for skillful technical assistance. This study was supported by the Japanese Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO; to M.A.), a Grant in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to M.A.), and the program for Promotion of Basic and Applied Research for Innovations in Bio-Oriented industry (to H.A.).	Arita M, 2005, BIOCHEM BIOPH RES CO, V338, P149, DOI 10.1016/j.bbrc.2005.07.181; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2012, J BIOCHEM, V152, P313, DOI 10.1093/jb/mvs092; Arnold C, 2010, J BIOL CHEM, V285, P32720, DOI 10.1074/jbc.M110.118406; Capdevila JH, 1996, J BIOL CHEM, V271, P22663, DOI 10.1074/jbc.271.37.22663; Fergus GJ, 2007, NAT CELL BIOL, V9, P86, DOI 10.1038/ncb1517; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Isobe Y, 2012, J BIOL CHEM, V287, P10525, DOI 10.1074/jbc.M112.340612; Kunisaki Y, 2006, J CELL BIOL, V174, P647, DOI 10.1083/jcb.200602142; Lucas D, 2010, J LIPID RES, V51, P1125, DOI 10.1194/jlr.M003061; Newman JW, 2005, PROG LIPID RES, V44, P1, DOI 10.1016/j.plipres.2004.10.001; Oh SF, 2011, J CLIN INVEST, V121, P569, DOI 10.1172/JCI42545; Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004; Schwarz D, 2004, BIOCHEM PHARMACOL, V67, P1445, DOI 10.1016/j.bcp.2003.12.023; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248; Szczur K, 2009, BLOOD, V114, P4527, DOI 10.1182/blood-2008-12-195164; Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720; Tjonahen E, 2006, CHEM BIOL, V13, P1193, DOI 10.1016/j.chembiol.2006.09.011; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7	25	34	35	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					586	593		10.1096/fj.13-236224	http://dx.doi.org/10.1096/fj.13-236224			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24128889				2022-12-28	WOS:000331072200007
J	Hwang, JW; Sundar, IK; Yao, HW; Sellix, MT; Rahman, I				Hwang, Jae-Woong; Sundar, Isaac K.; Yao, Hongwei; Sellix, Michael T.; Rahman, Irfan			Circadian clock function is disrupted by environmental tobacco/cigarette smoke, leading to lung inflammation and injury via a SIRT1-BMAL1 pathway	FASEB JOURNAL			English	Article						oxidative stress; cytokines; chronic obstructive pulmonary disease; locomotor activity; emphysema; mouse	OBSTRUCTIVE PULMONARY-DISEASE; CIGARETTE-SMOKE; GENE-EXPRESSION; SIRT1; DEPRESSION; PROTEIN; EMPHYSEMA; DEACETYLASE; BMAL1; SUSCEPTIBILITY	Patients with obstructive lung diseases display abnormal circadian rhythms in lung function. We determined the mechanism whereby environmental tobacco/cigarette smoke (CS) modulates expression of the core clock gene BMAL1, through Sirtuin1 (SIRT1) deacetylase during lung inflammatory and injurious responses. Adult C57BL6/J and various mice mutant for SIRT1 and BMAL1 were exposed to both chronic (6 mo) and acute (3 and 10 d) CS, and we measured the rhythmic expression of clock genes, circadian rhythms of locomotor activity, lung function, and inflammatory and emphysematous responses in the lungs. CS exposure (100-300 mg/m(3) particulates) altered clock gene expression and reduced locomotor activity by disrupting the central and peripheral clocks and increased lung inflammation, causing emphysema in mice. BMAL1 was acetylated and degraded in the lungs of mice exposed to CS and in patients with chronic obstructive pulmonary disease (COPD), compared with lungs of the nonsmoking controls, linking it mechanistically to CS-induced reduction of SIRT1. Targeted deletion of Bmal1 in lung epithelium augmented inflammation in response to CS, which was not attenuated by the selective SIRT1 activator SRT1720 (EC50=0.16 M) in these mice. Thus, the circadian clock, specifically the enhancer BMAL1 in epithelium, plays a pivotal role, mediated by SIRT1-dependent BMAL1, in the regulation of CS-induced lung inflammatory and injurious responses. Hwang, J.-W., Sundar, I. K., Yao, H., Sellix, M. T., Rahman, I. Circadian clock function is disrupted by environmental tobacco/cigarette smoke, leading to lung inflammation and injury via a SIRT1-BMAL1 pathway.	[Hwang, Jae-Woong; Sundar, Isaac K.; Yao, Hongwei; Rahman, Irfan] Univ Rochester, Med Ctr, Dept Environm Med, Lung Biol & Dis Program, Rochester, NY 14642 USA; [Sellix, Michael T.] Univ Rochester, Med Ctr, Dept Med, Div Endocrinol & Metab, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Rahman, I (corresponding author), Univ Rochester, Med Ctr, Dept Environm Med, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	irfan_rahman@urmc.rochester.edu	Yao, Hongwei/G-6444-2010; Sundar, Isaac K/F-8764-2012	Sundar, Isaac K/0000-0001-6742-3460	U.S. National Institutes of Health [1R01HL097751, 1R01HL092842]; National Institute of Environmental Health Sciences (NIEHS) Environmental Health Science Center [P30-ES01247]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097751, R01HL092842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences (NIEHS) Environmental Health Science Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Dr. Thomas J. Mariani (University of Rochester, Rochester, NY) for providing the Cre recombinase transgenic mice with CC10 promoter, Dr. Michael McBurney (University of Ottawa, Ottawa, ON, Canada) for providing SIRT1-knockout mice (SIRT1-deficient mice), Dr. Leonard Guarente (Massachusetts Institutes of Technology, Cambridge, MA, USA) and Dr. Wei Gu (Columbia University, New York, NY, USA) for providing Tg mice overexpressing Sirt1 (SIRT1 Tg mice), and Dr. Sangwoon Chung, Katherine Bachmann, Lindsay Marchetti, Zachary Murphy, Drew Phillips, Suzanne Bellanca, and Stephanie Uhrinek (University of Rochester, Rochester, NY, USA) for technical assistance. This study was supported by grants from the U.S. National Institutes of Health (1R01HL097751, 1R01HL092842) to I. R. and a grant from the National Institute of Environmental Health Sciences (NIEHS) Environmental Health Science Center (P30-ES01247). The authors declare no conflicts of interest. Author contributions: J.H. performed mouse studies, cell counts, immunoblotting, real-time PCR analysis, ELISA, and manuscript writing; I. S. K. performed cell counts, real-time PCR analysis, ELISA, mean linear intercept (Lm) analysis, immunoblotting, immunoprecipitation, and overall data collection and analysis; J.H. and I. S. K. performed: data analysis for circadian experiments and cell counts; H.Y., I. S. K., M. T. S., and I. R. performed: interpretation of results and manuscript editing; M. T. S. performed wheel running activity assay and, PER2:: luciferase assays; I. R. performed study design and manuscript writing.	Agusti A, 2011, EUR RESPIR REV, V20, P183, DOI 10.1183/09059180.00004311; Antoniu SA, 2011, EXPERT REV RESP MED, V5, P333, DOI [10.1586/ers.11.30, 10.1586/ERS.11.30]; Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Bechtold DA, 2010, TRENDS PHARMACOL SCI, V31, P191, DOI 10.1016/j.tips.2010.01.002; Belden WJ, 2008, CELL, V134, P212, DOI 10.1016/j.cell.2008.07.010; Bellet MM, 2013, P NATL ACAD SCI USA, V110, P3333, DOI 10.1073/pnas.1214266110; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; BOYSEN PG, 1979, CHEST, V76, P536, DOI 10.1378/chest.76.5.536; Caito S, 2010, FASEB J, V24, P3145, DOI 10.1096/fj.09-151308; Casale R, 1997, RESPIRATION, V64, P251, DOI 10.1159/000196682; Castanon-Cervantes O, 2010, J IMMUNOL, V185, P5796, DOI 10.4049/jimmunol.1001026; Cavadini G, 2007, P NATL ACAD SCI USA, V104, P12843, DOI 10.1073/pnas.0701466104; Chang HC, 2013, CELL, V153, P1448, DOI 10.1016/j.cell.2013.05.027; Chen CY, 2008, AM J PHYSIOL-HEART C, V295, pH632, DOI 10.1152/ajpheart.91535.2007; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Divo M, 2012, AM J RESP CRIT CARE, V186, P155, DOI 10.1164/rccm.201201-0034OC; Foronjy RF, 2005, EXP LUNG RES, V31, P547, DOI 10.1080/019021490951522; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gebel S, 2006, TOXICOL SCI, V93, P422, DOI 10.1093/toxsci/kfl071; Gentner NJ, 2012, AM J PHYSIOL-HEART C, V302, pH818, DOI 10.1152/ajpheart.00852.2011; Gibbs JE, 2009, ENDOCRINOLOGY, V150, P268, DOI 10.1210/en.2008-0638; Gibbs JE, 2012, P NATL ACAD SCI USA, V109, P582, DOI 10.1073/pnas.1106750109; Gierisch JM, 2012, J GEN INTERN MED, V27, P351, DOI 10.1007/s11606-011-1915-2; Grimaldi B, 2009, INT J BIOCHEM CELL B, V41, P81, DOI 10.1016/j.biocel.2008.08.035; Guerassimov A, 2004, AM J RESP CRIT CARE, V170, P974, DOI 10.1164/rccm.200309-1270oc; Hadden H, 2012, J APPL PHYSIOL, V113, P385, DOI 10.1152/japplphysiol.00244.2012; Hanania NA, 2011, AM J RESP CRIT CARE, V183, P604, DOI 10.1164/rccm.201003-0472OC; Hida A, 2012, J PHYSIOL ANTHROPOL, V31, DOI 10.1186/1880-6805-31-7; Hoegh SV, 2010, IMMUNOBIOLOGY, V215, P314, DOI 10.1016/j.imbio.2009.05.001; Hwang JW, 2011, J IMMUNOL, V187, P987, DOI 10.4049/jimmunol.1001861; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Leone MJ, 2012, CHRONOBIOL INT, V29, P715, DOI 10.3109/07420528.2012.682681; Keller M, 2009, P NATL ACAD SCI USA, V106, P21407, DOI 10.1073/pnas.0906361106; Khapre RV, 2011, CELL CYCLE, V10, P4162, DOI 10.4161/cc.10.23.18381; Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206; Kwon I, 2006, MOL CELL BIOL, V26, P7318, DOI 10.1128/MCB.00337-06; Laurin C, 2012, AM J RESP CRIT CARE, V185, P918, DOI 10.1164/rccm.201105-0939PP; Lewis D A, 2001, Curr Opin Pulm Med, V7, P105, DOI 10.1097/00063198-200103000-00008; Logan RW, 2012, MOL CELL ENDOCRINOL, V349, P82, DOI 10.1016/j.mce.2011.06.039; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; Mortola JP, 2002, RESP PHYSIOL NEUROBI, V131, P91, DOI 10.1016/S1569-9048(02)00040-X; Murphy JM, 2003, AM J PSYCHIAT, V160, P1663, DOI 10.1176/appi.ajp.160.9.1663; Mykletun A, 2008, EUR PSYCHIAT, V23, P77, DOI 10.1016/j.eurpsy.2007.10.005; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Narasimamurthy R, 2012, P NATL ACAD SCI USA, V109, P12662, DOI 10.1073/pnas.1209965109; Okada K, 2008, J SURG RES, V145, P5, DOI 10.1016/j.jss.2007.01.010; Oster H, 2006, J BIOL RHYTHM, V21, P350, DOI 10.1177/0748730406293053; PETTY TL, 1988, AM J MED, V85, P21, DOI 10.1016/0002-9343(88)90237-9; Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708-1269OC; Silver AC, 2012, IMMUNITY, V36, P251, DOI 10.1016/j.immuni.2011.12.017; Simon DM, 2006, FASEB J, V20, P1507, DOI 10.1096/fj.05-5410fje; Spengler CM, 2000, AM J RESP CRIT CARE, V162, P1038, DOI 10.1164/ajrccm.162.3.9911107; Spengler ML, 2012, P NATL ACAD SCI USA, V109, pE2457, DOI 10.1073/pnas.1206274109; Sukumaran S, 2011, J APPL PHYSIOL, V110, P1732, DOI 10.1152/japplphysiol.00079.2011; Tamaru T, 2003, GENES CELLS, V8, P973, DOI 10.1046/j.1365-2443.2003.00686.x; Thomas A, 1993, Pneumologie, V47, P526; Tsai CL, 2007, CHRONOBIOL INT, V24, P699, DOI 10.1080/07420520701535753; Vasu VT, 2009, INTEGR CANCER THER, V8, P321, DOI 10.1177/1534735409352027; Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006; Yao HW, 2008, AM J PHYSIOL-LUNG C, V294, pL1174, DOI 10.1152/ajplung.00439.2007; Yao HW, 2008, AM J PATHOL, V172, P1222, DOI 10.2353/ajpath.2008.070765; Yao HW, 2012, J CLIN INVEST, V122, P2032, DOI 10.1172/JCI60132; Yao HW, 2011, TOXICOL APPL PHARM, V254, P72, DOI 10.1016/j.taap.2009.10.022; Yao HW, 2010, P NATL ACAD SCI USA, V107, P15571, DOI 10.1073/pnas.1007625107; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Yoon JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044053; Zheng X, 2007, P NATL ACAD SCI USA, V104, P15899, DOI 10.1073/pnas.0701599104	70	97	100	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					176	194		10.1096/fj.13-232629	http://dx.doi.org/10.1096/fj.13-232629			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24025728	Green Published			2022-12-28	WOS:000333526100019
J	Muller, S; Faulhaber, A; Sieber, C; Pfeifer, D; Hochberg, T; Gansz, M; Deshmukh, SD; Dauth, S; Brix, K; Saftig, P; Peters, C; Henneke, P; Reinheckel, T				Mueller, Sabrina; Faulhaber, Anja; Sieber, Carolin; Pfeifer, Dietmar; Hochberg, Tanja; Gansz, Martina; Deshmukh, Sachin D.; Dauth, Stephanie; Brix, Klaudia; Saftig, Paul; Peters, Christoph; Henneke, Philipp; Reinheckel, Thomas			The endolysosomal cysteine cathepsins L and K are involved in macrophage-mediated clearance of Staphylococcus aureus and the concomitant cytokine induction	FASEB JOURNAL			English	Article						proteases; lysosome; innate immune system; phagocyte; nonoxidative killing	TOLL-LIKE RECEPTORS; ACTIVATION; PROTEASES; RECOGNITION; TRANSCRIPTION; PHAGOCYTOSIS; PROTEOLYSIS; INFECTION; CLEAVAGE	Cysteine cathepsins are endolysosomal cysteine proteases highly expressed in macrophages; however, their individual contributions to the elimination of bacteria and bacteria-induced cytokine production by macrophages are unknown. We assessed the contribution of cysteine cathepsins to macrophage defense pathways against Staphylococcus aureus by using chemical inhibitors and by infecting primary bone marrow-derived macrophages deficient in 1 of 7 major macrophage-expressed endolysosomal cysteine proteases. We show that cysteine cathepsins are involved in the phagocytosis and killing of S. aureus. Cathepsin L was identified as an executor of nonoxidative killing. Moreover, microarray data revealed cysteine cathepsins to be important for the maximal induction of certain proinflammatory genes, such as IL6, in response to S. aureus. Cysteine cathepsin's contribution to IL6 production was dependent on phagocytosis, and cathepsin K was identified to be a critical protease in this process. Analysis of macrophages with impaired trafficking of endolysosomal Toll-like receptors (TLRs) to the acidic compartment revealed that they were not involved in cathepsin-dependent IL6 induction. Because IL6 production was completely dependent on the TLR-adaptor protein myeloid differentiation primary response gene 88 (MyD88), it appears that other TLRs are involved. In summary, lysosomal cysteine proteases are functionally linked to the complex bactericidal and inflammatory activities of macrophages. Muller, S., Faulhaber, A., Sieber, C., Pfeifer, D., Hochberg, T., Gansz, M., Deshmukh, S. D., Dauth, S., Brix, K., Saftig, P., Peters, C., Henneke, P., Reinheckel, T. The endolysosomal cysteine cathepsins L and K are involved in macrophage-mediated clearance of Staphylococcus aureus and the concomitant cytokine induction.	[Mueller, Sabrina; Faulhaber, Anja; Sieber, Carolin; Hochberg, Tanja; Gansz, Martina; Peters, Christoph; Reinheckel, Thomas] Univ Freiburg, Inst Mol Med & Cell Res, D-79106 Freiburg, Germany; [Peters, Christoph; Reinheckel, Thomas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Mueller, Sabrina; Deshmukh, Sachin D.; Henneke, Philipp; Reinheckel, Thomas] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Pfeifer, Dietmar] Univ Med Ctr Freiburg, Dept Internal Med 1, Core Facil Genom, Freiburg, Germany; [Henneke, Philipp] Univ Med Ctr Freiburg, Ctr Paediat & Adolescent Med, Div Pediat Infect Dis & Rheumatol, Freiburg, Germany; [Mueller, Sabrina; Gansz, Martina] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany; [Dauth, Stephanie; Brix, Klaudia] Jacobs Univ Bremen, Res Ctr Mol Life Sci, Sch Sci & Engn, D-28759 Bremen, Germany; [Saftig, Paul] Univ Kiel, Inst Biochem, Kiel, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Jacobs University; University of Kiel	Reinheckel, T (corresponding author), Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.	thomas.reinheckel@uniklinik-freiburg.de	Saftig, Paul/A-7966-2010; Reinheckel, Thomas/AAL-9761-2021; Brix, Klaudia/F-5072-2013	Reinheckel, Thomas/0000-0001-9866-9105; Brix, Klaudia/0000-0002-4476-0357	Excellence Initiative of the German Federal and State Governments [EXC 294]; CAU Kiel; Deutsche Forschungsgemeinschaft [SFB 850, B7, SFB 877, SPP 1580]; Centre of Chronic Immunodeficiency (CCI) Freiburg [TP8]	Excellence Initiative of the German Federal and State Governments; CAU Kiel; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Centre of Chronic Immunodeficiency (CCI) Freiburg	The authors thank H. A. Chapman (University of California, San Francisco, CA, USA) and J. Joyce (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) for kindly providing cathepsin S-deficient mice, M. A. Freudenberg (Max-Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany) for kindly providing TLR9- and Unc93B1-deficient mice, J. Potempa (Jagiellonian University, Krakow, Poland) for the S. aureus Newman strain, M. Bogyo (Stanford University, Stanford, CA, USA) for the JPM-OEt protease inhibitor, and Susanne Dollwet-Mack, Lars Ellenrieder, and Ulrike Reif (Albert Ludwigs University, Freiburg, Germany) and Bernhard Kremer (University Medical Center, Freiburg, Germany) for outstanding technical assistance. This study was supported by the Excellence Initiative of the German Federal and State Governments (EXC 294), Inflammation at Interfaces, CAU Kiel, the Deutsche Forschungsgemeinschaft SFB 850 Project B7, SFB 877, and SPP 1580, and the Centre of Chronic Immunodeficiency (CCI) Freiburg grant TP8.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Avalos AM, 2013, J IMMUNOL, V190, P695, DOI 10.4049/jimmunol.1202342; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Beers C, 2003, J EXP MED, V197, P169, DOI 10.1084/jem.20020978; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blander JM, 2012, NAT REV IMMUNOL, V12, P215, DOI 10.1038/nri3167; Buxade M, 2012, J EXP MED, V209, P379, DOI 10.1084/jem.20111569; Callewaert L, 2010, J BIOSCIENCES, V35, P127, DOI 10.1007/s12038-010-0015-5; Chapman HA, 2006, CURR OPIN IMMUNOL, V18, P78, DOI 10.1016/j.coi.2005.11.011; D'Angelo ME, 2010, J BIOL CHEM, V285, P20514, DOI 10.1074/jbc.M109.094573; Dahl SW, 2001, BIOCHEMISTRY-US, V40, P1671, DOI 10.1021/bi001693z; Deshmukh SD, 2012, J IMMUNOL, V188, P774, DOI 10.4049/jimmunol.1101383; Deshmukh SD, 2011, EMBO REP, V12, P71, DOI 10.1038/embor.2010.189; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Ewald SE, 2008, NATURE, V456, P658, DOI 10.1038/nature07405; Ewald SE, 2011, J EXP MED, V208, P643, DOI 10.1084/jem.20100682; Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128; Garcia-Cattaneo A, 2012, P NATL ACAD SCI USA, V109, P9053, DOI 10.1073/pnas.1115091109; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Grimm S, 2012, FREE RADICAL BIO MED, V52, P1011, DOI 10.1016/j.freeradbiomed.2011.12.021; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Houghton AM, 2009, NATURE, V460, P637, DOI 10.1038/nature08181; Ip WKE, 2008, J EXP MED, V205, P169, DOI 10.1084/jem.20071164; Ip WKE, 2010, J IMMUNOL, V184, P7071, DOI 10.4049/jimmunol.1000110; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kaplan A, 2012, J IMMUNOL, V189, P4537, DOI 10.4049/jimmunol.1201111; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lennon-Dumenil AM, 2002, J EXP MED, V196, P529, DOI 10.1084/jem.20020327; Liu GY, 2009, PEDIATR RES, V65, p71R, DOI 10.1203/PDR.0b013e31819dc44d; Liu WL, 2012, J IMMUNOL, V189, P2460, DOI 10.4049/jimmunol.1103179; Marre ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012871; Matthews SP, 2010, J IMMUNOL, V184, P2423, DOI 10.4049/jimmunol.0901486; Muller S, 2012, BBA-PROTEINS PROTEOM, V1824, P34, DOI 10.1016/j.bbapap.2011.07.003; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Park B, 2008, NAT IMMUNOL, V9, P1407, DOI 10.1038/ni.1669; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Rivera-Marrero CA, 2004, INFECT IMMUN, V72, P5712, DOI 10.1128/IAI.72.10.5712-5721.2004; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Rybicka JM, 2010, P NATL ACAD SCI USA, V107, P10496, DOI 10.1073/pnas.0914867107; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sander LE, 2011, NATURE, V474, P385, DOI 10.1038/nature10072; Sepulveda FE, 2009, IMMUNITY, V31, P737, DOI 10.1016/j.immuni.2009.09.013; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Shimada T, 2010, CELL HOST MICROBE, V7, P38, DOI 10.1016/j.chom.2009.12.008; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; VanderVen BC, 2009, TRAFFIC, V10, P372, DOI [10.1111/j.1600-0854.2008.00877.x, 10.1111/j.1600-0854.2009.00877.x]; Wolf AJ, 2011, J IMMUNOL, V187, P6002, DOI 10.4049/jimmunol.1100232	57	34	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					162	175		10.1096/fj.13-232272	http://dx.doi.org/10.1096/fj.13-232272			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24036885				2022-12-28	WOS:000333526100018
J	Tan, JTM; Prosser, HCG; Vanags, LZ; Monger, SA; Ng, MKC; Bursill, CA				Tan, Joanne T. M.; Prosser, Hamish C. G.; Vanags, Laura Z.; Monger, Steven A.; Ng, Martin K. C.; Bursill, Christina A.			High- density lipoproteins augment hypoxia-induced angiogenesis via regulation of post- translational modulation of hypoxia- inducible factor 1 alpha	FASEB JOURNAL			English	Article						scavenger receptor BI; phosphatidylinositol 3-kinase; PI3K; Akt pathway; prolyl hydroxylase domain proteins; Siah ubiquitin ligases; endothelial cells	ENDOTHELIAL PROGENITOR CELLS; RANDOMIZED CONTROLLED-TRIAL; B TYPE-I; CORONARY ATHEROSCLEROSIS; PROLYL HYDROXYLATION; GROWTH-FACTOR; LENTIVIRUS VECTOR; HIF-ALPHA; A-I; EXPRESSION	Increasing evidence suggests that high-density lipoproteins (HDLs) promote hypoxia-induced angiogenesis. The hypoxia-inducible factor 1 (HIF-1)/vascular endothelial growth factor (VEGF) pathway is important in hypoxia and is modulated post-translationally by prolyl hydroxylases (PHD1-PHD3) and E3 ubiquitin ligases (Siah1 and Siah2). We aimed to elucidate the mechanisms by which HDLs augment hypoxia-induced angiogenesis. Preincubation (16 h) of human coronary artery endothelial cells with reconstituted high-density lipoprotein (rHDL) containing apolipoprotein A-I (apoA-I) and phosphatidylcholine (20 M, final apoA-I concentration), before hypoxia, increased Siah1 (58%) and Siah2 (88%) mRNA levels and suppressed PHD2 (32%) and PHD3 (45%) protein levels compared with hypoxia-induced control levels. After Siah1/2 small interfering RNA knockdown, rHDL was unable to suppress PHD2/3 and failed to induce HIF-1, VEGF, and tubulogenesis in hypoxia. Inhibition of the upstream phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway also abrogated the effects of rHDL. Furthermore, knockdown of the scavenger receptor SR-BI attenuated rHDL-induced elevations in Siah1/2 and tubulogenesis in hypoxia, indicating that SR-BI plays a key role. Finally, the importance of VEGF in mediating the ability of rHDL to drive hypoxia-induced angiogenesis was confirmed using a VEGF-neutralizing antibody. In summary, rHDL augments the HIF-1/VEGF pathway via SR-BI and modulation of the post-translational regulators of HIF-1 (PI3K/Siahs/PHDs). HDL-induced augmentation of angiogenesis in hypoxia may have implications for therapeutic modulation of ischemic injury.Tan, J. T. M., Prosser, H. C. G., Vanags, L. Z., Monger, S. A., Ng, M. K. C., Bursill, C. A. High-density lipoproteins augment hypoxia-induced angiogenesis via regulation of post-translational modulation of hypoxia inducible factor 1.	[Tan, Joanne T. M.; Prosser, Hamish C. G.; Vanags, Laura Z.; Monger, Steven A.; Ng, Martin K. C.; Bursill, Christina A.] Heart Res Inst, Sydney, NSW, Australia; [Tan, Joanne T. M.; Prosser, Hamish C. G.; Vanags, Laura Z.; Ng, Martin K. C.; Bursill, Christina A.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Ng, Martin K. C.] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia	University of Sydney; Heart Research Institute; University of Sydney; University of Sydney	Tan, JTM (corresponding author), Heart Res Inst, 7 Eliza St, Newtown, NSW 2042, Australia.	joanne.tan@hri.org.au	Tan, Joanne Tsui Ming/Y-4423-2019; Tan, Ming-Jen/A-3862-2011	Tan, Joanne Tsui Ming/0000-0003-1875-4882; Tan, Ming-Jen/0000-0002-3583-1723; Bursill, Christina/0000-0002-0682-8760	Australia National Health and Medical Research Council [632512]; Heart Foundation [CR07S3331, PB12S6959]; Bushell Foundation	Australia National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Heart Foundation; Bushell Foundation	This work was supported by Australia National Health and Medical Research Council Project grant 632512 (to C. A. B and M.K.C.N), Heart Foundation Career Development Fellowship CR07S3331 and a Bushell Foundation grant (to C. A. B), and Heart Foundation Postgraduate Scholarship PB12S6959 (to L.Z.V).	Al-Khalili F, 2002, J INTERN MED, V252, P561, DOI 10.1046/j.1365-2796.2002.01070.x; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; BERGE KG, 1982, CIRCULATION, V66, P1176, DOI 10.1161/01.CIR.66.6.1176; Boden WE, 2011, NEW ENGL J MED, V365, P2255, DOI 10.1056/NEJMoa1107579; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Coulon C, 2010, ARTERIOSCL THROM VAS, V30, P2331, DOI 10.1161/ATVBAHA.110.214106; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feng Y, 2008, ARTERIOSCL THROM VAS, V28, P278, DOI 10.1161/ATVBAHA.107.158741; Feng YM, 2009, BLOOD, V113, P755, DOI 10.1182/blood-2008-06-161794; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fox SB, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2825; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JENKINS PJ, 1978, BMJ-BRIT MED J, V2, P388, DOI 10.1136/bmj.2.6134.388; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mineo C, 2007, TRENDS CARDIOVAS MED, V17, P156, DOI 10.1016/j.tcm.2007.03.005; Miura S, 2003, ARTERIOSCL THROM VAS, V23, P802, DOI 10.1161/01.ATV.0000066134.79956.58; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nakayama K, 2009, J BIOCHEM, V146, P757, DOI 10.1093/jb/mvp167; Nakayama K, 2009, MOL CANCER RES, V7, P443, DOI 10.1158/1541-7786.MCR-08-0458; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Prosser H. C., 2012, ARTERIOSCLER THROMB, V32, pA392; Ryan HE, 2000, CANCER RES, V60, P4010; Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797; Seetharam D, 2006, CIRC RES, V98, P63, DOI 10.1161/01.RES.0000199272.59432.5b; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Sumi M, 2007, ARTERIOSCL THROM VAS, V27, P813, DOI 10.1161/01.ATV.0000259299.38843.64; Tardif JC, 2007, JAMA-J AM MED ASSOC, V297, P1675, DOI 10.1001/jama.297.15.jpc70004; Tsuzuki Y, 2000, CANCER RES, V60, P6248; van der Vorst EPC, 2013, FASEB J, V27, P1413, DOI 10.1096/fj.12-212753; Ware JA, 1997, NAT MED, V3, P158, DOI 10.1038/nm0297-158; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591; Yao YC, 2008, ARTERIOSCL THROM VAS, V28, P2266, DOI 10.1161/ATVBAHA.108.176958; Zhang QH, 2010, EXP BIOL MED, V235, P1082, DOI 10.1258/ebm.2010.010060; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	45	37	40	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					206	217		10.1096/fj.13-233874	http://dx.doi.org/10.1096/fj.13-233874			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24022405				2022-12-28	WOS:000333526100021
J	Escudero-Esparza, A; Kalchishkova, N; Kurbasic, E; Jiang, WG; Blom, AM				Escudero-Esparza, Astrid; Kalchishkova, Nikolina; Kurbasic, Emila; Jiang, Wen G.; Blom, Anna M.			The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly	FASEB JOURNAL			English	Article						innate immunity; cancer progression	SQUAMOUS-CELL CARCINOMA; C4B-BINDING PROTEIN; HOMOZYGOUS DELETION; ALPHA-CHAIN; BREAST; CANCER; SYSTEM; HEAD; NECK; IMMUNOLOGY	CUB and Sushi multiple domains 1 (CSMD1) is a transmembrane protein containing 15 consecutive complement control protein (CCP) domains, which are characteristic for complement inhibitors. We expressed a membrane-bound fragment of human CSMD1 composed of the 15 C-terminal CCP domains and demonstrated that it inhibits deposition of C3b by the classical pathway on the surface of Chinese hamster ovary cells by 70% at 6% serum and of C9 (component of membrane attack complex) by 90% at 1.25% serum. Furthermore, this fragment of CSMD1 served as a cofactor to factor I-mediated degradation of C3b. In all functional assays performed, well-characterized complement inhibitors were used as positive controls, whereas Coxsackie adenovirus receptor, a protein with no effect on complement, was a negative control. Moreover, attenuation of expression in human T47 breast cancer cells that express endogenous CSMD1 significantly increased C3b deposition on these cells by 45% at 8% serum compared with that for the controls. Furthermore, by expressing a soluble 17-21 CCP fragment of CSMD1, we found that CSMD1 inhibits complement by promoting factor I-mediated C4b/C3b degradation and inhibition of MAC assembly at the level of C7. Our results revealed a novel complement inhibitor for the classical and lectin pathways.	[Escudero-Esparza, Astrid; Kalchishkova, Nikolina; Kurbasic, Emila; Blom, Anna M.] Lund Univ, Sect Med Prot Chem, Dept Lab Med Malmo, Malmo, Sweden; [Jiang, Wen G.] Cardiff Univ, Sch Med, Inst Canc & Genet, Metastasis & Angiogenesis Res Grp, Cardiff CF10 3AX, S Glam, Wales	Lund University; Cardiff University	Blom, AM (corresponding author), Skane Univ Hosp, Dept Lab Med Malmo, Sect Med Prot Chem, Wallenberg Lab, Inga Marie Nilssons Gata 53, S-20502 Malmo, Sweden.	anna.blom@med.lu.se	jiang, wen/GYI-9662-2022; Blom, Anna/AFS-7369-2022; Jiang, Wen G./AAF-1876-2020; Jiang, Wen G/B-1293-2010; Blom, Anna/B-9607-2009	Jiang, Wen G./0000-0002-3283-1111; Jiang, Wen G/0000-0002-3283-1111; Blom, Anna/0000-0002-1348-1734	Cancerfonden; Swedish Research Council [K2012-66X-14928-09-5]; Royal Physiographic Society in Lund; Cancer Research Wales; Foundation of Osterlund; Foundation of Greta and Johan Kock; Foundation of King Gustav V's 80th Anniversary; Foundation of Knut and Alice Wallenberg; Foundation of Inga-Britt; Foundation of Arne Lundberg; ALF; Skane University Hospital	Cancerfonden(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Royal Physiographic Society in Lund; Cancer Research Wales; Foundation of Osterlund; Foundation of Greta and Johan Kock; Foundation of King Gustav V's 80th Anniversary; Foundation of Knut and Alice Wallenberg(Knut & Alice Wallenberg Foundation); Foundation of Inga-Britt; Foundation of Arne Lundberg; ALF; Skane University Hospital	The authors thank Dr. Marcin Okroj, Dr. Linda Mark, and Dr. Steven B. Scholnick for help in the initial stages of this project and Dr. Jane Lane for proofreading the article. This work was supported by the Cancerfonden, the Swedish Research Council (K2012-66X-14928-09-5), the Royal Physiographic Society in Lund, Cancer Research Wales (WGJ), the Foundations of Osterlund, Greta and Johan Kock, King Gustav V's 80th Anniversary, Knut and Alice Wallenberg, Inga-Britt and Arne Lundberg, and grants for clinical research from ALF and Skane University Hospital. The authors declare no conflicts of interest.	Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; Blom AM, 2003, J BIOL CHEM, V278, P43437, DOI 10.1074/jbc.M306620200; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; Escudero-Esparza A, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-43; Farrell CL, 2008, CANCER BIOL THER, V7, P609, DOI 10.4161/cbt.7.4.5623; Happonen KE, 2009, J IMMUNOL, V182, P1518, DOI 10.4049/jimmunol.182.3.1518; Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641; Kamal M, 2010, BREAST CANCER RES TR, V121, P555, DOI 10.1007/s10549-009-0500-4; Kraus DM, 2006, J IMMUNOL, V176, P4419, DOI 10.4049/jimmunol.176.7.4419; Lundwall A, 2002, MOL HUM REPROD, V8, P805, DOI 10.1093/molehr/8.9.805; Ma CQ, 2009, CANCER BIOL THER, V8, P907, DOI 10.4161/cbt.8.10.8132; Mark L, 2007, J VIROL, V81, P4166, DOI 10.1128/JVI.02069-06; Midorikawa Y, 2009, HEPATOLOGY, V49, P513, DOI 10.1002/hep.22698; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 2004, GENE CHROMOSOME CANC, V39, P185, DOI 10.1002/gcc.10309; Nilsson SC, 2009, EUR J IMMUNOL, V39, P310, DOI 10.1002/eji.200838702; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; Okroj M, 2012, J BIOL CHEM, V287, P20100, DOI 10.1074/jbc.M111.324913; Okroj M, 2009, J BIOL CHEM, V284, P505, DOI 10.1074/jbc.M806669200; Richter TM, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-29; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rutkowski MJ, 2010, MOL CANCER RES, V8, P1453, DOI 10.1158/1541-7786.MCR-10-0225; Scholnick SB, 2003, GENE CHROMOSOME CANC, V38, P281, DOI 10.1002/gcc.10279; Scholnick SB, 1996, J NATL CANCER I, V88, P1676, DOI 10.1093/jnci/88.22.1676; Sigbjornsdottir BI, 2000, J MED GENET, V37, P342, DOI 10.1136/jmg.37.5.342; Spiller OB, 2003, J BIOL CHEM, V278, P9283, DOI 10.1074/jbc.M211579200; Sun PC, 2001, GENOMICS, V75, P17, DOI 10.1006/geno.2001.6587; Tang MR, 2012, APOPTOSIS, V17, P927, DOI 10.1007/s10495-012-0727-0; Toomes C, 2003, GENE CHROMOSOME CANC, V37, P132, DOI 10.1002/gcc.10191; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620	35	61	62	0	71	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5083	5093		10.1096/fj.13-230706	http://dx.doi.org/10.1096/fj.13-230706			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964079				2022-12-28	WOS:000329999000040
J	Andrianifahanana, M; Wilkes, MC; Gupta, SK; Rahimi, RA; Repellin, CE; Edens, M; Wittenberger, J; Yin, XQ; Maidl, E; Becker, J; Leof, EB				Andrianifahanana, Mahefatiana; Wilkes, Mark C.; Gupta, Shiv K.; Rahimi, Rod A.; Repellin, Claire E.; Edens, Maryanne; Wittenberger, Joshua; Yin, Xueqian; Maidl, Elizabeth; Becker, Jackson; Leof, Edward B.			Profibrotic TGF beta responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases	FASEB JOURNAL			English	Article						EGF; pulmonary fibrosis	GROWTH-FACTOR-BETA; INDUCED PULMONARY-FIBROSIS; IMATINIB MESYLATE; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; ACTIVATION; LUNG; MECHANISMS; EXPRESSION; INDUCTION	Transforming growth factor (TGF) has significant profibrotic activity both in vitro and in vivo. This reflects its capacity to stimulate fibrogenic mediators and induce the expression of other profibrotic cytokines such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF/ErbB) ligands. Here we address both the mechanisms by which TGF induced ErbB ligands and the physiological significance of inhibiting multiple TGF-regulated processes. The data document that ErbB ligand induction requires PDGF receptor (PDGFR) mediation and engages a positive autocrine/paracrine feedback loop via ErbB receptors. Whereas PDGFRs are essential for TGF-stimulated ErbB ligand up-regulation, TGF-specific signals are also required for ErbB receptor activation. Subsequent profibrotic responses are shown to involve the cooperative action of PDGF and ErbB signaling. Moreover, using a murine treatment model of bleomycin-induced pulmonary fibrosis we found that inhibition of TGF/PDGF and ErbB pathways with imatinib plus lapatinib, respectively, not only prevented myofibroblast gene expression to a greater extent than either drug alone, but also essentially stabilized gas exchange (oxygen saturation) as an overall measure of lung function. These observations provide important mechanistic insights into profibrotic TGF signaling and indicate that targeting multiple cytokines represents a possible strategy to ameliorate organ fibrosis dependent on TGF.Andrianifahanana, M., Wilkes, M. C., Gupta, S. K., Rahimi, R. R., Repellin, C. E., Edens, M., Wittenberger, J., Yin, X., Maidl, E., Becker, J., Leof, E. B. Profibrotic TGF responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.	[Andrianifahanana, Mahefatiana; Wilkes, Mark C.; Gupta, Shiv K.; Edens, Maryanne; Wittenberger, Joshua; Yin, Xueqian; Maidl, Elizabeth; Becker, Jackson; Leof, Edward B.] Mayo Clin, Dept Biochem & Mol Biol, Coll Med, Thorac Dis Res Unit,Div Pulm & Crit Care Med, Rochester, MN 55905 USA; [Rahimi, Rod A.] Johns Hopkins Med Ctr, Baltimore, MD USA; [Repellin, Claire E.] Stanford Res Inst, Menlo Pk, CA USA	Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; SRI International; Stanford University	Leof, EB (corresponding author), Mayo Clin, Stabile 858,200 1st St SW, Rochester, MN 55905 USA.	leof.edward@mayo.edu		Wilkes, Mark/0000-0002-9600-6831	U.S. Public Health Service from the National Institute of General Medical Sciences [GM-55816, GM-54200]; Scleroderma Foundation; Mayo Foundation; Fraternal Order of Eagles Cancer Research Fund (Rochester, MN, USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK084567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065841, R01GM055816, R37GM055816, R01GM054200] Funding Source: NIH RePORTER	U.S. Public Health Service from the National Institute of General Medical Sciences; Scleroderma Foundation; Mayo Foundation; Fraternal Order of Eagles Cancer Research Fund (Rochester, MN, USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. Public Health Service grants GM-55816 and GM-54200 from the National Institute of General Medical Sciences, the Scleroderma Foundation, and the Mayo Foundation (to E. B. L.). M. A. received a Fraternal Order of Eagles Cancer Research Fund (Rochester, MN, USA) fellowship grant. The authors declare no conflicts of interest.	ADAMSON IYR, 1974, AM J PATHOL, V77, P185; Akhmetshina A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1734; Andrianifahanana M, 2010, CANCER RES, V70, P7421, DOI 10.1158/0008-5472.CAN-10-0232; Aono Y, 2005, AM J RESP CRIT CARE, V171, P1279, DOI 10.1164/rccm.200404-531OC; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Beyer C, 2012, CURR OPIN RHEUMATOL, V24, P274, DOI 10.1097/BOR.0b013e3283524b9a; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Chaudhary NI, 2006, AM J RESP CRIT CARE, V173, P769, DOI 10.1164/rccm.200505-717OC; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Cho MC, 2008, BIOCHEM BIOPH RES CO, V377, P832, DOI 10.1016/j.bbrc.2008.10.053; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Daniels CE, 2010, AM J RESP CRIT CARE, V181, P604, DOI 10.1164/rccm.200906-0964OC; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Distler O., 2010, ARTHRITIS RHEUM S10, V62, P560, DOI DOI 10.1002/ART.28329; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; GOUSTIN AS, 1986, CANCER RES, V46, P1015; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hong M, 2011, J BIOL CHEM, V286, P17841, DOI 10.1074/jbc.M111.233676; Ishii Y, 2006, AM J RESP CRIT CARE, V174, P550, DOI 10.1164/rccm.200509-1534OC; Khanna D, 2011, ARTHRITIS RHEUM-US, V63, P3540, DOI 10.1002/art.30548; Kolosova I, 2011, J CELL PHYSIOL, V226, P1248, DOI 10.1002/jcp.22448; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Magro L, 2008, BONE MARROW TRANSPL, V42, P757, DOI 10.1038/bmt.2008.252; Meng XM, 2010, J AM SOC NEPHROL, V21, P1477, DOI 10.1681/ASN.2009121244; MOSELEY PL, 1986, J CLIN INVEST, V78, P1150, DOI 10.1172/JCI112695; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Nakerakanti Sashidhar, 2012, Open Rheumatol J, V6, P156, DOI 10.2174/1874312901206010156; Olivieri A, 2009, BLOOD, V114, P709, DOI 10.1182/blood-2009-02-204156; Phanish MK, 2006, BIOCHEM J, V393, P601, DOI 10.1042/BJ20051106; Pope J, 2011, ARTHRITIS RHEUM-US, V63, P3547, DOI 10.1002/art.30549; Prud'homme GJ, 2007, LAB INVEST, V87, P1077, DOI 10.1038/labinvest.3700669; Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501; Rahimi RA, 2009, CANCER RES, V69, P84, DOI 10.1158/0008-5472.CAN-08-2146; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sime PJ, 2001, CLIN IMMUNOL, V99, P308, DOI 10.1006/clim.2001.5008; Sivakumar P, 2012, CURR OPIN PULM MED, V18, P462, DOI 10.1097/MCP.0b013e328356800f; Spiera RF, 2011, ANN RHEUM DIS, V70, P1003, DOI 10.1136/ard.2010.143974; Steele MP, 2013, ANNU REV MED, V64, P265, DOI 10.1146/annurev-med-042711-142004; Suzuki K, 2007, CANCER RES, V67, P3673, DOI 10.1158/0008-5472.CAN-06-3211; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Todd NW, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-11; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Wilkes MC, 2006, J BIOL CHEM, V281, P27846, DOI 10.1074/jbc.M603721200; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xie T, 2011, PHYSIOL GENOMICS, V43, P479, DOI 10.1152/physiolgenomics.00222.2010; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhao JS, 2002, AM J PHYSIOL-LUNG C, V282, pL585, DOI 10.1152/ajplung.00151.2001	60	38	42	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4444	4454		10.1096/fj.12-224907	http://dx.doi.org/10.1096/fj.12-224907			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23913859	Green Published			2022-12-28	WOS:000329937500012
J	Dangel, A; Ackermann, N; Abdel-Hadi, O; Maier, R; Onder, K; Francois, P; Muller, CW; Pane-Farre, J; Engelmann, S; Schrenzel, J; Heesemann, J; Lindermayr, C				Dangel, Alexandra; Ackermann, Nikolaus; Abdel-Hadi, Omar; Maier, Richard; Oender, Kamil; Francois, Patrice; Mueller, Carsten W.; Pane-Farre, Jan; Engelmann, Susanne; Schrenzel, Jacques; Heesemann, Juergen; Lindermayr, Christian			A de novo-designed antimicrobial peptide with activity against multiresistant Staphylococcus aureus acting on RsbW kinase	FASEB JOURNAL			English	Article						sigma B transcription factor; NanoSIMS; DNA binding	SIGMA-FACTOR SIGMA(B); RECOMBINATIONAL CLONING; BIOFILM FORMATION; GENOME SEQUENCE; CELL; VIRULENCE; RESISTANCE; EVOLUTION; MEMBRANE; MICROORGANISMS	Antimicrobial peptides are a promising complement to common antibiotics, development of resistance to which is a growing problem. Here we present a de novo-designed peptide, SP1-1 (RKKRLKLLKRLL-NH2), with antimicrobial activity against multiresistant Staphylococcus aureus (minimal inhibitory concentration: 6.25 M). Elucidation of the mode of action of this peptide revealed a strong interaction with RsbW kinase (K-d: 6.01 +/- 2.73 nM), a serine kinase negatively regulating the activity of the transcription factor sigma B (SigB). SP1-1 binding and functional modulation of RsbW were shown in vitro by a combination of biochemical, molecular, and biophysical methods, which were further genetically evidenced in vivo by analysis of S. aureus sigB deletion mutants. Intracellular localization of the peptide was demonstrated using nanometer-scaled secondary ion mass spectrometry. Moreover, microarray analysis revealed that transcription of numerous genes, involved in cell wall and amino acid metabolism, transport mechanisms, virulence, and pigmentation, is affected. Interestingly, several WalR binding motif containing genes are induced by SP1-1. In sum, the designed peptide SP1-1 seems to have multiple modes of action, including inhibition of a kinase, and therefore might contribute to the development of new antibacterial compounds, giving bacterial kinase inhibition a closer inspection.Dangel, A., Ackermann, N., Abdel-Hadi, O., Maier, R., onder, K., Francois, P., Muller, C. W., Pane-Farre, J., Engelmann, S., Schrenzel, J., Heesemann, J., Lindermayr, C. A de novo-designed antimicrobial peptide with activity against multiresistant Staphylococcus aureus acting on RsbW kinase.	[Dangel, Alexandra; Lindermayr, Christian] Helmholtz Ctr Munich, Inst Biochem Plant Pathol, Neuherberg, Germany; [Ackermann, Nikolaus; Heesemann, Juergen] Univ Munich, Max von Pettenkofer Inst Hyg & Med Microbiol, Munich, Germany; [Abdel-Hadi, Omar; Maier, Richard; Oender, Kamil] Paracelsus Med Univ Salzburg, Dept Dermatol, Salzburg, Austria; [Francois, Patrice; Schrenzel, Jacques] Univ Hosp Geneva, Genom Res Lab, Geneva, Switzerland; [Mueller, Carsten W.] Tech Univ Munich, Dept Soil Sci, Freising Weihenstephan, Germany; [Pane-Farre, Jan; Engelmann, Susanne] Ernst Moritz Arndt Univ Greifswald, Inst Microbiol, Greifswald, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Paracelsus Private Medical University; University of Geneva; Technical University of Munich; Ernst Moritz Arndt Universitat Greifswald	Lindermayr, C (corresponding author), Helmholtz Zentrum Munich, Land Str, D-85764 Munich, Germany.	lindermayr@helmholtz-muenchen.de	Lindermayr, Christian/M-7338-2014; Schrenzel, Jacques/AAC-5685-2021; francois, patrice/AAL-5583-2020; Mueller, Carsten W/C-2679-2012; Schrenzel, Jacques/P-8525-2017; Dangel, Alexandra/Y-8811-2019	Lindermayr, Christian/0000-0002-9343-4996; Schrenzel, Jacques/0000-0001-5464-7764; Mueller, Carsten W/0000-0003-4119-0544; Schrenzel, Jacques/0000-0001-5464-7764; Dangel, Alexandra/0000-0001-6737-5681; francois, patrice/0000-0002-0540-750X				Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Andres E, 2012, EUR J CLIN MICROBIOL, V31, P881, DOI 10.1007/s10096-011-1430-8; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Baba T, 2008, J BACTERIOL, V190, P300, DOI 10.1128/JB.01000-07; Behrens S, 2012, ENVIRON MICROBIOL, V14, P2851, DOI 10.1111/j.1462-2920.2012.02724.x; Bischoff M, 2004, J BACTERIOL, V186, P4085, DOI 10.1128/JB.186.13.4085-4099.2004; Brandner CJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-321; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Bulet P, 2004, IMMUNOL REV, V198, P169, DOI 10.1111/j.0105-2896.2004.0124.x; Cameca, 2009, NANOSIMS 50 50L INST; Cebrian G, 2009, J APPL MICROBIOL, V107, P187, DOI 10.1111/j.1365-2672.2009.04194.x; Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200; Charbonnier Y, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-95; Chen H, 2011, PLOS ONE, V6; Chen ZJ, 2011, APPL MICROBIOL BIOT, V89, P281, DOI 10.1007/s00253-010-2864-0; COUTO MA, 1993, INFECT IMMUN, V61, P2991, DOI 10.1128/IAI.61.7.2991-2994.1993; Delaune A, 2012, INFECT IMMUN, V80, P3438, DOI 10.1128/IAI.00195-12; Diemond-Hernandez B, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-68; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Dubrac S, 2007, J BACTERIOL, V189, P8257, DOI 10.1128/JB.00645-07; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Giachino P, 2001, J BACTERIOL, V183, P1843, DOI 10.1128/JB.183.6.1843-1852.2001; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Gillaspy A. F., 2007, STAPHYLOCOCCUS AUREU; Giuliani A, 2007, CENT EUR J BIOL, V2, P1, DOI 10.2478/s11535-007-0010-5; Gotoh Y, 2010, CURR OPIN MICROBIOL, V13, P232, DOI 10.1016/j.mib.2010.01.008; Guerquin-Kern JL, 2005, BBA-GEN SUBJECTS, V1724, P228, DOI 10.1016/j.bbagen.2005.05.013; Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000; Hecker M, 2007, ANNU REV MICROBIOL, V61, P215, DOI 10.1146/annurev.micro.61.080706.093445; Hecker M, 2009, RES MICROBIOL, V160, P245, DOI 10.1016/j.resmic.2009.03.008; Herbert S, 2010, INFECT IMMUN, V78, P2877, DOI 10.1128/IAI.00088-10; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; Kim JY, 2011, AMINO ACIDS, V40, P183, DOI 10.1007/s00726-010-0632-1; King-Scott J, 2011, STRUCTURE, V19, P56, DOI 10.1016/j.str.2010.11.010; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Knobloch JKM, 2004, INFECT IMMUN, V72, P3838, DOI 10.1128/IAI.72.7.3838-3848.2004; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Kullik I, 1998, J BACTERIOL, V180, P4814, DOI 10.1128/JB.180.18.4814-4820.1998; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lauderdale KJ, 2009, INFECT IMMUN, V77, P1623, DOI 10.1128/IAI.01036-08; Laverty G, 2011, INT J MOL SCI, V12, P6566, DOI 10.3390/ijms12106566; Livermore DM, 2004, CLIN MICROBIOL INFEC, V10, P1, DOI 10.1111/j.1465-0691.2004.1004.x; Maier RH, 2008, BIOTECHNIQUES, V45, P235, DOI 10.2144/000112897; Mangoni ML, 2011, CELL MOL LIFE SCI, V68, P2157, DOI 10.1007/s00018-011-0709-3; Markossian KA, 2004, BIOCHEMISTRY-MOSCOW+, V69, P1082, DOI 10.1023/B:BIRY.0000046881.29486.51; Miyazaki E, 1999, J BACTERIOL, V181, P2846, DOI 10.1128/JB.181.9.2846-2851.1999; Musat N, 2012, FEMS MICROBIOL REV, V36, P486, DOI 10.1111/j.1574-6976.2011.00303.x; Musat N, 2008, P NATL ACAD SCI USA, V105, P17861, DOI 10.1073/pnas.0809329105; Nguyen LT, 2011, TRENDS BIOTECHNOL, V29, P464, DOI 10.1016/j.tibtech.2011.05.001; Otvos L, 2000, BIOCHEMISTRY-US, V39, P14150, DOI 10.1021/bi0012843; Pane-Farre J, 2006, INT J MED MICROBIOL, V296, P237, DOI 10.1016/j.ijmm.2005.11.011; Pane-Farre J, 2009, J BACTERIOL, V191, P2561, DOI 10.1128/JB.01514-08; Park CB, 1996, BIOCHEM BIOPH RES CO, V218, P408, DOI 10.1006/bbrc.1996.0071; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002; Peschel A, 2006, NAT REV MICROBIOL, V4, P529, DOI 10.1038/nrmicro1441; Pietiainen M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-429; Scherl A, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-296; Schneider T, 2010, SCIENCE, V328, P1168, DOI 10.1126/science.1185723; Senn MM, 2005, J BACTERIOL, V187, P8006, DOI 10.1128/JB.187.23.8006-8019.2005; Sinha B, 2010, INT J MED MICROBIOL, V300, P170, DOI 10.1016/j.ijmm.2009.08.019; Stapleton MR, 2007, J BACTERIOL, V189, P7316, DOI 10.1128/JB.00734-07; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Wang GS, 2012, ANTIMICROB AGENTS CH, V56, P845, DOI 10.1128/AAC.05637-11; Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521; Wilke MH, 2010, EUR J MED RES, V15, P571, DOI 10.1186/2047-783X-15-12-571; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zeng XC, 2012, PEPTIDES, V33, P44, DOI 10.1016/j.peptides.2011.11.012	72	17	18	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4476	4488		10.1096/fj.13-234575	http://dx.doi.org/10.1096/fj.13-234575			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23901070	Green Published			2022-12-28	WOS:000329937500015
J	Prado, GN; Romero, JR; Rivera, A				Prado, Gregory N.; Romero, Jose R.; Rivera, Alicia			Endothelin-1 receptor antagonists regulate cell surface-associated protein disulfide isomerase in sickle cell disease	FASEB JOURNAL			English	Article						erythrocytes; Gardos channel; redox reactions; Berkeley transgenic SCD mice	ERYTHROCYTE DEHYDRATION; THROMBUS FORMATION; PLASMA-MEMBRANE; CL-COTRANSPORT; K+ TRANSPORT; MOUSE MODEL; CHANNEL; ACTIVATION; PHOSPHORYLATION; EXPRESSION	Increased endothelin-1 (ET-1) levels, disordered thiol protein status, and erythrocyte hydration status play important roles in sickle cell disease (SCD) through unresolved mechanisms. Protein disulfide isomerase (PDI) is an oxidoreductase that mediates thiol/disulfide interchange reactions. We provide evidence that PDI is present in human and mouse erythrocyte membranes and that selective blockade with monoclonal antibodies against PDI leads to reduced Gardos channel activity (1.6 +/- 0.03 to 0.56 +/- 0.02 mmol center dot 10(13) cell(-1)center dot min(-1), P<0.001) and density of sickle erythrocytes (D-50: 1.115 +/- 0.001 to 1.104 +/- 0.001 g/ml, P=0.012) with an IC50 of 4 ng/ml. We observed that erythrocyte associated-PDI activity was increased in the presence of ET-1 (3.1 +/- 0.2 to 5.6 +/- 0.4%, P<0.0001) through a mechanism that includes casein kinase II. Consistent with these results, in vivo treatment of BERK sickle transgenic mice with ET-1 receptor antagonists lowered circulating and erythrocyte associated-PDI activity (7.1 +/- 0.3 to 5.2 +/- 0.2%, P<0.0001) while improving hematological parameters and Gardos channel activity. Thus, our results suggest that PDI is a novel target in SCD that regulates erythrocyte volume and oxidative stress and may contribute to cellular adhesion and endothelial activation leading to vasoocclusion as observed in SCD.-Prado, G. N., Romero, J. R., Rivera, A. Endothelin-1 receptor antagonists regulate cell surface-associated protein disulfide isomerase in sickle cell disease.	[Prado, Gregory N.; Rivera, Alicia] Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; [Prado, Gregory N.; Rivera, Alicia] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Prado, Gregory N.; Romero, Jose R.] Harvard Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Hypertens,Brigham & Women, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rivera, A (corresponding author), Boston Childrens Hosp, Dept Lab Med, Bader 7,300 Longwood Ave, Boston, MA 02115 USA.	alicia.rivera@childrens.harvard.edu		Romero, Jose Ricardo/0000-0001-8225-0772	U.S. National Institutes of Health [NIH HL090632, HL096518]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096518, R01HL090632] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	A preliminary report of these findings was presented in abstract form (63). The authors thank Jessica Alves for her technical assistance; Dr. Gary Bradwin [Manager, Clinical and Epidemiologic Laboratory (CERLab), Boston Children's Hospital] for his kind assistance in setting the ELISA measurements; and Dr. Mary E. Fabry for her invaluable support and contribution with the development of the sickle cell mouse colony. This work was supported by U.S. National Institutes of Health grants NIH HL090632 (to A. R.) and HL096518 (to J.R.R.). Study conception and design was performed by A. R. and J.R.R. Collection and/or assembly of data were performed by G.N.P., J.R.R., and A. R. Data analysis and interpretation were performed by G.N.P., J.R.R., and A. R. Manuscript writing was done by G.N.P., J.R.R., and A. R. Final approval of manuscript was provided by G.N.P., J.R.R, and A. R. The authors declare no conflict of interest.	AKAGI S, 1988, J HISTOCHEM CYTOCHEM, V36, P1069, DOI 10.1177/36.8.3292644; Bailey MA, 2010, J GEN PHYSIOL, V136, P367, DOI 10.1085/jgp.201010430; Bartolucci P, 2012, BLOOD, V120, P3136, DOI 10.1182/blood-2012-04-424184; Belcher JD, 2005, AM J PHYSIOL-HEART C, V288, pH2715, DOI 10.1152/ajpheart.00986.2004; Cai S, 1997, J MEMBRANE BIOL, V158, P147, DOI 10.1007/s002329900252; Chang JS, 2010, BLOOD, V116, P1779, DOI 10.1182/blood-2009-12-260513; CHENG SY, 1986, P NATL ACAD SCI USA, V83, P947, DOI 10.1073/pnas.83.4.947; Cho J, 2008, J CLIN INVEST, V118, P1123, DOI 10.1172/JCI34134; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; DEFRANCESCHI L, 1995, AM J PHYSIOL-CELL PH, V269, pC899, DOI 10.1152/ajpcell.1995.269.4.C899; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; Donoghue N, 2000, PROTEIN SCI, V9, P2436, DOI 10.1110/ps.9.12.2436; Durpes MC, 2011, J BIOL CHEM, V286, P3057, DOI 10.1074/jbc.M110.173229; Essex DW, 2004, BLOOD, V104, P1383, DOI 10.1182/blood-2004-03-1097; FRELINGER AL, 2013, PLATELETS; FUHRMANN GF, 1985, BIOCHIM BIOPHYS ACTA, V820, P223, DOI 10.1016/0005-2736(85)90116-6; Gallina A, 2002, J BIOL CHEM, V277, P50579, DOI 10.1074/jbc.M204547200; Graido-Gonzalez E, 1998, BLOOD, V92, P2551, DOI 10.1182/blood.V92.7.2551.2551_2551_2555; HALLIWELL B, 1984, LANCET, V1, P1396; Hatae N, 2007, MOL ENDOCRINOL, V21, P1192, DOI 10.1210/me.2006-0343; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hotchkiss KA, 1998, BBA-PROTEIN STRUCT M, V1388, P478, DOI 10.1016/S0167-4838(98)00211-8; Jasuja R, 2010, BLOOD, V116, P4665, DOI 10.1182/blood-2010-04-278184; Joiner CH, 2004, BLOOD, V104, P2954, DOI 10.1182/blood-2004-01-0112; Kaul DK, 2006, AM J PHYSIOL-HEART C, V291, pH167, DOI 10.1152/ajpheart.01096.2005; KAUL DK, 1983, J CLIN INVEST, V72, P22, DOI 10.1172/JCI110960; Klein H, 2007, J GEN PHYSIOL, V129, P299, DOI 10.1085/jgp.200609726; KRONING H, 1994, SCAND J IMMUNOL, V39, P346, DOI 10.1111/j.1365-3083.1994.tb03384.x; Kutlar A, 2012, AM J HEMATOL, V87, P536, DOI 10.1002/ajh.23147; Laurindo FRM, 2008, ANTIOXID REDOX SIGN, V10, P1101, DOI 10.1089/ars.2007.2011; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; Michael JR, 1997, AM J PHYSIOL-LUNG C, V273, pL768, DOI 10.1152/ajplung.1997.273.4.L768; Muzyamba MC, 2003, J PHYSIOL-LONDON, V547, P903, DOI 10.1113/jphysiol.2002.036467; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Pojoga LH, 2012, AM J HYPERTENS, V25, P243, DOI 10.1038/ajh.2011.197; Prado GN, 2010, BLOOD, V116, P121, DOI 10.1182/blood.V116.21.265.265; RANK BH, 1985, J CLIN INVEST, V75, P1531, DOI 10.1172/JCI111857; Raturi A, 2005, BIOCHEM J, V391, P351, DOI 10.1042/BJ20050770; Raturi A, 2007, FREE RADICAL BIO MED, V43, P62, DOI 10.1016/j.freeradbiomed.2007.03.025; RICEEVANS C, 1986, BIOCHEM J, V237, P265, DOI 10.1042/bj2370265; Rivera A, 2002, BLOOD, V99, P357, DOI 10.1182/blood.V99.1.357; Rivera A, 1999, AM J PHYSIOL-CELL PH, V277, pC746, DOI 10.1152/ajpcell.1999.277.4.C746; Rivera A, 2007, AM J PHYSIOL-CELL PH, V293, pC960, DOI 10.1152/ajpcell.00530.2006; Rivera A, 2013, PHYSIOL GENOMICS, V45, P343, DOI 10.1152/physiolgenomics.00143.2012; Romero JR, 2002, BLOOD, V99, P1103, DOI 10.1182/blood.V99.4.1103; Romero JR, 2004, BLOOD, V103, P2384, DOI 10.1182/blood-2003-01-0237; Rybicki AC, 1998, BLOOD, V92, P2594, DOI 10.1182/blood.V92.7.2594.2594_2594_2596; RYSER HJP, 1999, PLASMA MEMBRANE REDO; Sabaa N, 2008, J CLIN INVEST, V118, P1924, DOI 10.1172/JCI33308; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Shartava A, 1999, AM J HEMATOL, V62, P19, DOI 10.1002/(SICI)1096-8652(199909)62:1<19::AID-AJH4>3.0.CO;2-C; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Sheng K, 1998, BLOOD, V91, P3467, DOI 10.1182/blood.V91.9.3467.3467_3467_3470; Swiatkowska M, 2010, J BIOL CHEM, V285, P29874, DOI 10.1074/jbc.M109.092486; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; Torrecilla I, 2007, J CELL BIOL, V177, P127, DOI 10.1083/jcb.200610018; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890	63	17	17	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4619	4629		10.1096/fj.13-228577	http://dx.doi.org/10.1096/fj.13-228577			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23913858	Green Published			2022-12-28	WOS:000329937500027
J	Khan, MAH; Liu, J; Kumar, G; Skapek, SX; Falck, JR; Imig, JD				Khan, Md Abdul Hye; Liu, Jing; Kumar, Ganesh; Skapek, Stephen X.; Falck, John R.; Imig, John D.			Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity	FASEB JOURNAL			English	Article						chemotherapeutics; acute kidney injury; eicosanoids	SOLUBLE EPOXIDE HYDROLASE; ENDOPLASMIC-RETICULUM STRESS; RENAL INJURY; KIDNEY; INHIBITION; APOPTOSIS; CELLS; MECHANISMS; EXPRESSION; PROTECTS	Nephrotoxicity severely limits the use of the anticancer drug cisplatin. Oxidative stress, inflammation, and endoplasmic reticulum (ER) stress contribute to cisplatin-induced nephrotoxicity. We developed novel orally active epoxyeicosatrienoic acid (EET) analogs and investigated their prophylactic effect in cisplatin-induced nephrotoxicity in rats. Cisplatin-induced nephrotoxicity was manifested by increases in blood urea nitrogen, plasma creatinine, urinary N-acetyl--(d)-glucosaminidase activity, kidney injury molecule 1, and histopathology. EET analogs (10 mg/kg/d) attenuated cisplatin-induced nephrotoxicity by reducing these renal injury markers by 40-80% along with a 50-70% reduction in renal tubular cast formation. This attenuated renal injury is associated with reduced oxidative stress, inflammation, and ER stress evident from reduction in related biomarkers and in the renal expression of genes involved in these pathways. Moreover, we demonstrated that the attenuated nephrotoxicity correlated with decreased apoptosis that is associated with 50-90% reduction in Bcl-2 protein family mediated proapoptotic signaling, reduced renal caspase-12 expression, and a 50% reduction in renal caspase-3 activity. We further demonstrated in vitro that the protective activity of EET analogs does not compromise the anticancer effects of cisplatin. Collectively, our data provide evidence that EET analogs attenuate cisplatin-induced nephrotoxicity by reducing oxidative stress, inflammation, ER stress, and apoptosis without affecting the chemotherapeutic effects of cisplatin.	[Khan, Md Abdul Hye; Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Imig, John D.] Med Coll Wisconsin, Cardiovasc Ctr, Milwaukee, WI 53226 USA; [Liu, Jing; Skapek, Stephen X.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Kumar, Ganesh; Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Imig, JD (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jdimig@mcw.edu	Falck, John R/B-3030-2011	Falck, John R/0000-0002-9219-7845; Imig, John/0000-0002-9668-2899; Khan, Md Abdul Hye/0000-0001-5940-9300	U.S. National Institutes of Health (NIH) [HL59699, DK38226]; Robert A. Welch Foundation [GL625910]; NIH [DK38226, GM31278]; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059699, R29HL059699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	These studies were supported by U.S. National Institutes of Health (NIH) grants HL59699 and DK38226 to J.D.I.; Robert A. Welch Foundation grant GL625910 and NIH grants GM31278 and DK38226 to J.R.F.; and a postdoctoral fellowship from the Midwest Affiliate of the American Heart Association to Md.A.H.K.	Batchu SN, 2011, BRIT J PHARMACOL, V162, P897, DOI 10.1111/j.1476-5381.2010.01093.x; Benoehr P, 2005, J AM SOC NEPHROL, V16, P452, DOI 10.1681/ASN.2004030225; Bongers ML, 2012, PHARMACOECONOMICS, V30, P17, DOI 10.2165/11595000-000000000-00000; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cribb AE, 2005, DRUG METAB REV, V37, P405, DOI 10.1080/03602530500205135; El-Beshbishy HA, 2011, EUR J PHARMACOL, V668, P278, DOI 10.1016/j.ejphar.2011.06.051; Elmarakby AA, 2011, AM J PHYSIOL-REG I, V301, pR1307, DOI 10.1152/ajpregu.00759.2010; Falck JR, 2009, J MED CHEM, V52, P5069, DOI 10.1021/jm900634w; Falck JR, 2003, BIOORG MED CHEM LETT, V13, P4011, DOI 10.1016/j.bmcl.2003.08.060; Faubel S, 2007, J PHARMACOL EXP THER, V322, P8, DOI 10.1124/jpet.107.119792; Gross GJ, 2008, AM J PHYSIOL-HEART C, V294, pH2838, DOI 10.1152/ajpheart.00186.2008; Hanigan MH, 2005, AM J PHYSIOL-RENAL, V288, pF125, DOI 10.1152/ajprenal.00041.2003; Imig JD, 2009, US Patent, Patent No. [7,550,617, 7550617]; Imig JD, 2012, PHYSIOL REV, V92, P101, DOI 10.1152/physrev.00021.2011; Imig JD, 2010, FRONT PHYSIOL, V1, DOI 10.3389/fphys.2010.00157; Imig JD, 2010, J CARDIOVASC PHARM, V56, P329, DOI 10.1097/FJC.0b013e3181e96e0c; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Inagi R, 2009, NEPHRON EXP NEPHROL, V112, pE1, DOI 10.1159/000210573; Jia ZJ, 2011, KIDNEY INT, V79, P77, DOI 10.1038/ki.2010.331; Kaergel E, 2002, HYPERTENSION, V40, P273, DOI 10.1161/01.HYP.0000029240.44253.5E; King Lorraine M, 2005, Pharmacogenet Genomics, V15, P7, DOI 10.1097/01213011-200501000-00002; Kintzel PE, 2001, DRUG SAFETY, V24, P19, DOI 10.2165/00002018-200124010-00003; Levy AR, 2011, CURR MED RES OPIN, V27, P2253, DOI 10.1185/03007995.2011.633989; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V270, pF700, DOI 10.1152/ajprenal.1996.270.4.F700; Liu L, 2011, J PHARMACOL EXP THER, V339, P451, DOI 10.1124/jpet.111.180505; Liu YM, 2012, J PHARMACOL EXP THER, V341, P725, DOI 10.1124/jpet.111.191247; Ma H, 2010, CLIN EXP PHARMACOL P, V37, P460, DOI 10.1111/j.1440-1681.2009.05323.x; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Manhiani M, 2009, AM J PHYSIOL-RENAL, V297, pF740, DOI 10.1152/ajprenal.00098.2009; Marino JP, 2009, CURR TOP MED CHEM, V9, P452, DOI 10.2174/156802609788340805; Miller RP, 2010, TOXINS, V2, P2490, DOI 10.3390/toxins2112490; Morisseau C, 2005, ANNU REV PHARMACOL, V45, P311, DOI 10.1146/annurev.pharmtox.45.120403.095920; Mukhopadhyay P, 2012, FREE RADICAL BIO MED, V52, P497, DOI 10.1016/j.freeradbiomed.2011.11.001; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Olearczyk JJ, 2009, CLIN SCI, V116, P61, DOI 10.1042/CS20080039; Pabla N, 2008, KIDNEY INT, V73, P994, DOI 10.1038/sj.ki.5002786; Park MS, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134858; Parrish AR, 2009, CELL BIOL TOXICOL, V25, P217, DOI 10.1007/s10565-008-9071-0; Perazella MA, 2010, SEMIN NEPHROL, V30, P570, DOI 10.1016/j.semnephrol.2010.09.005; Peyrou M, 2007, TOXICOL SCI, V99, P346, DOI 10.1093/toxsci/kfm152; Rabik CA, 2008, J PHARMACOL EXP THER, V327, P442, DOI 10.1124/jpet.108.141291; Ramesh G, 2002, J CLIN INVEST, V110, P835, DOI 10.1172/JCI200215606; Sanchez-Gonzalez PD, 2011, CRIT REV TOXICOL, V41, P803, DOI 10.3109/10408444.2011.602662; Seubert JM, 2007, PROSTAG OTH LIPID M, V82, P50, DOI 10.1016/j.prostaglandins.2006.05.017; Sodhi K, 2009, J PHARMACOL EXP THER, V331, P906, DOI 10.1124/jpet.109.157545; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wei Q, 2007, KIDNEY INT, V72, P53, DOI 10.1038/sj.ki.5002256; Yang BC, 2001, MOL PHARMACOL, V60, P310, DOI 10.1124/mol.60.2.310; Zhang B, 2007, KIDNEY INT, V72, P37, DOI 10.1038/sj.ki.5002242; Zhao G, 2012, HUM GENE THER, V23, P688, DOI 10.1089/hum.2011.135; Zhao G, 2012, J LIPID RES, V53, P456, DOI 10.1194/jlr.M017319	51	60	62	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2946	2956		10.1096/fj.12-218040	http://dx.doi.org/10.1096/fj.12-218040			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603837	Green Published			2022-12-28	WOS:000329877600003
J	Crowder, SW; Horton, LW; Lee, SH; McClain, CM; Hawkins, OE; Palmer, AM; Bae, H; Richmond, A; Sung, HJ				Crowder, Spencer W.; Horton, Linda W.; Lee, Sue Hyun; McClain, Colt M.; Hawkins, Oriana E.; Palmer, Amanda M.; Bae, Hojae; Richmond, Ann; Sung, Hak-Joon			Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia	FASEB JOURNAL			English	Article						aging; reactive oxygen species; p53; experimental models	DOWN-REGULATION; TUMOR INVASION; P53; DIFFERENTIATION; SENESCENCE; CULTURE; PROLIFERATION; EXPRESSION; PHENOTYPE; APOPTOSIS	Bone marrow-derived human mesenchymal stem cells (hMSCs) either promote or inhibit cancer progression, depending on factors that heretofore have been undefined. Here we have utilized extreme hypoxia (0.5% O-2) and concurrent treatment with metal carcinogen (nickel) to evaluate the passage-dependent response of hMSCs toward cancerous transformation. Effects of hypoxia and nickel treatment on hMSC proliferation, apoptosis, gene and protein expression, replicative senescence, reactive oxygen species (ROS), redox mechanisms, and in vivo tumor growth were analyzed. The behavior of late passage hMSCs in a carcinogenic hypoxia environment follows a profile similar to that of transformed cancer cells (i.e., increased expression of oncogenic proteins, decreased expression of tumor suppressor protein, increased proliferation, decreased apoptosis, and aberrant redox mechanisms), but this effect was not observed in earlier passage control cells. These events resulted in accumulated intracellular ROS in vitro and excessive proliferation in vivo. We suggest a mechanism by which carcinogenic hypoxia modulates the activity of three critical transcription factors (c-MYC, p53, and HIF1), resulting in accumulated ROS and causing hMSCs to undergo cancer-like behavioral changes. This is the first study to utilize carcinogenic hypoxia as an environmentally relevant experimental model for studying the age-dependent cancerous transformation of hMSCs.Crowder, S. W., Horton, L. W., Lee, H. H., McClain, C. M., Hawkins, O. E., Palmer, A. M. Bae, H., Richmond, A., Sung, H.-J. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia.	[Crowder, Spencer W.; Lee, Sue Hyun; Palmer, Amanda M.; Sung, Hak-Joon] Vanderbilt Univ, Med Ctr, Dept Biomed Engn, Nashville, TN 37235 USA; [Crowder, Spencer W.; Sung, Hak-Joon] Vanderbilt Univ, Med Ctr, Ctr Stem Cell Biol, Nashville, TN 37235 USA; [Horton, Linda W.; Hawkins, Oriana E.; Richmond, Ann] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37235 USA; [McClain, Colt M.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37235 USA; [Horton, Linda W.; Hawkins, Oriana E.; Richmond, Ann] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA; [Bae, Hojae; Sung, Hak-Joon] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Biomed Engn, Seoul, South Korea	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Kyung Hee University	Sung, HJ (corresponding author), Vanderbilt Univ, Dept Biomed Engn, VU Stn B, Box 351631, Nashville, TN 37235 USA.	hak-joon.sung@vanderbilt.edu	Richmond, Ann/A-3048-2014	bae, hojae/0000-0003-3057-4999; RICHMOND, ANN/0000-0002-9580-900X	Vanderbilt Start-Up; U.S. National Institutes of Health [HL091465]; National Cancer Institute [CA34590-30]; U.S. Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA034590, R01CA116021, T32CA119925, R23CA034590] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL091465] Funding Source: NIH RePORTER	Vanderbilt Start-Up; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful for technical help from Dae Kwang Jung. This research is supported by Vanderbilt Start-Up, the U.S. National Institutes of Health (HL091465), the National Cancer Institute (CA34590-30; A.R.), and a Senior Research Career Scientist Award from the U.S. Department of Veterans Affairs (A.R.).	Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Basciano L, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-12; Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555-010-9222-7; Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557; Cameron Keyuna S., 2011, Reviews on Environmental Health, V26, P81, DOI 10.1515/REVEH.2011.012; Chacko SM, 2010, AM J PHYSIOL-CELL PH, V299, pC1562, DOI 10.1152/ajpcell.00221.2010; Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509; Choumerianou DM, 2008, CELL PROLIFERAT, V41, P909, DOI 10.1111/j.1365-2184.2008.00559.x; Das R, 2010, TISSUE ENG PART B-RE, V16, P159, DOI 10.1089/ten.TEB.2009.0296; Estrada JC, 2012, CELL DEATH DIFFER, V19, P743, DOI 10.1038/cdd.2011.172; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959; Grayson WL, 2007, BIOCHEM BIOPH RES CO, V358, P948, DOI 10.1016/j.bbrc.2007.05.054; Heo JY, 2009, STEM CELLS, V27, P1455, DOI 10.1002/stem.54; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Klopp AH, 2011, STEM CELLS, V29, P11, DOI 10.1002/stem.559; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-60; Li N, 2009, CANCER-AM CANCER SOC, V115, P4795, DOI 10.1002/cncr.24519; Listenberger LL, 2007, CURR PROTOC CELL BIO, DOI [DOI 10.1002/0471143030.CB2402S35, 10.1002/0471143030.cb2402s35]; Lu CL, 2010, BLOOD, V115, P221, DOI 10.1182/blood-2009-06-228494; Nelson KK, 2004, FREE RADICAL BIO MED, V37, P768, DOI 10.1016/j.freeradbiomed.2004.06.008; Oller AR, 1997, TOXICOL APPL PHARM, V143, P152, DOI 10.1006/taap.1996.8075; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; RANI AS, 1993, CARCINOGENESIS, V14, P947, DOI 10.1093/carcin/14.5.947; Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood-2006-10-051060; Rodriguez R, 2012, CELL RES, V22, P62, DOI 10.1038/cr.2011.157; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Serena E, 2009, EXP CELL RES, V315, P3611, DOI 10.1016/j.yexcr.2009.08.015; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002; Sung HJ, 2007, AM J PHYSIOL-CELL PH, V293, pC87, DOI 10.1152/ajpcell.00585.2006; Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007; Torsvik A, 2010, CANCER RES, V70, P6393, DOI 10.1158/0008-5472.CAN-10-1305; Tsai CC, 2011, BLOOD, V117, P459, DOI 10.1182/blood-2010-05-287508; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Wagner W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005846; Yu Q, 2000, GENE DEV, V14, P163	46	23	25	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2788	2798		10.1096/fj.13-228288	http://dx.doi.org/10.1096/fj.13-228288			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23568779	Green Published			2022-12-28	WOS:000328841000027
J	Armstrong, DA; Lesseur, C; Conradt, E; Lester, BM; Marsit, CJ				Armstrong, David A.; Lesseur, Corina; Conradt, Elisabeth; Lester, Barry M.; Marsit, Carmen J.			Global and gene-specific DNA methylation across multiple tissues in early infancy: implications for children's health research	FASEB JOURNAL			English	Article						cord blood; epigenetic epidemiology; placenta; saliva	GLUCOCORTICOID-RECEPTOR; CORD BLOOD; IN-UTERO; EPIGENETIC REGULATION; CYTOSINE METHYLATION; TRANSCRIPTION FACTOR; EXPOSURE; BINDING; LEPTIN; EXPRESSION	An increasing number of population studies are assessing epigenetic variation in relation to early-life outcomes in tissues accessible to epidemiologic researchers. Epigenetic mechanisms are highly tissue specific, however, and it is unclear whether the variation observed in one of the tissue types is representative of other sources or whether the variation in DNA methylation is distinct, reflecting potential functional differences across tissues. To assess relations between DNA methylation in various samples from newborns and children in early infancy, we measured promoter or gene-body DNA methylation in matched term placenta, cord blood, and 3-6 mo saliva samples from 27 unrelated infants enrolled in the Rhode Island Child Health Study. We investigated 7 gene loci (KLF15, NR3C1, LEP, DEPTOR, DDIT4, HSD11B2, and CEBPB) and global methylation, using repetitive region LINE-1 and ALUYb8 sequences. We observed a great degree of interlocus, intertissue, and interindividual epigenetic variation in most of the analyzed loci. In correlation analyses, only cord blood NR3C1 promoter methylation correlated negatively with methylation in saliva. We conclude that placenta, cord blood, and saliva cannot be used as a substitute for one another to evaluate DNA methylation at these loci during infancy. Each tissue has a unique epigenetic signature that likely reflects their differential functions. Future studies should consider the uniqueness of these features, to improve epigenetic biomarker discovery and translation.Armstrong, D. A., Lesseur, C., Conradt, E., Lester, B. M., Marsit, C. J. Global and gene-specific DNA methylation across multiple tissues in early infancy: implications for children's health research.	[Armstrong, David A.; Lesseur, Corina; Marsit, Carmen J.] Dartmouth Coll, Geisel Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; [Marsit, Carmen J.] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Sect Biostat & Epidemiol, Hanover, NH 03755 USA; [Conradt, Elisabeth; Lester, Barry M.] Brown Alpert Med Sch, Brown Ctr Study Children Risk, Providence, RI USA; [Conradt, Elisabeth; Lester, Barry M.] Brown Univ, Women & Infants Hosp, Providence, RI USA	Dartmouth College; Dartmouth College; Brown University; Brown University; Women & Infants Hospital Rhode Island	Marsit, CJ (corresponding author), Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	carmen.j.marsit@dartmouth.edu	Lesseur, Corina/W-1034-2019	Lesseur, Corina/0000-0001-6744-6750; Marsit, Carmen/0000-0003-4566-150X	National Institute of Environmental Health Sciences (NIEHS) [P01 ES022832/EPA RD83544201, R01ES022223]; National Institute of Mental Health (NIMH) [R01MH094609]; U.S. National Institutes of Health (Bethesda, MD, USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES022832, R01ES022223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH094609] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); U.S. National Institutes of Health (Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank Joyce Lee (Department of Pediatrics, Women's and Infants Hospital) for her efforts in sample collection and Susan Simon (Media Learning Technologist, Jones Media Center, Dartmouth College Library) for assistance with figure preparation. The study was funded by grants from the National Institute of Environmental Health Sciences (NIEHS; P01 ES022832/EPA RD83544201 and R01ES022223) and the National Institute of Mental Health (NIMH; R01MH094609), U.S. National Institutes of Health (Bethesda, MD, USA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647; Appleton AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074691; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bocklandt S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014821; Boeke CE, 2012, EPIGENETICS-US, V7, P253, DOI 10.4161/epi.7.3.19082; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Bouchard L, 2010, DIABETES CARE, V33, P2436, DOI 10.2337/dc10-1024; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Bromer C, 2013, DEV PSYCHOBIOL, V55, P673, DOI 10.1002/dev.21061; Burris HH, 2014, J APPL TOXICOL, V34, P113, DOI 10.1002/jat.2904; Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445; Chapman K, 2013, PHYSIOL REV, V93, P1139, DOI 10.1152/physrev.00020.2012; Choi SH, 2009, INT J CANCER, V125, P723, DOI 10.1002/ijc.24384; Christensen B. C., 2012, EPIGENETIC EPIDEMIOL, P197; Conradt E, 2013, EPIGENETICS-US, V8, P1321, DOI 10.4161/epi.26634; Davies MN, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r43; De Bustos C, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-7; De Matteis R, 2002, J ANAT, V201, P363, DOI 10.1046/j.0021-8782.2002.00106.x; Eckmann-Scholz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039014; Edelman S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048597; Fenton Tanis R, 2003, BMC Pediatr, V3, P13; Filiberto AC, 2011, EPIGENETICS-US, V6, P566, DOI 10.4161/epi.6.5.15236; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Groom A, 2012, DIABETES, V61, P391, DOI 10.2337/db11-1039; Haggarty P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068896; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herbstman JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072824; Hogg K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062969; Hogg K, 2013, MOL CELL ENDOCRINOL, V367, P64, DOI 10.1016/j.mce.2012.12.018; Ikegame T, 2013, NEUROSCI RES, V77, P208, DOI 10.1016/j.neures.2013.08.004; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Kim JH, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-33; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Koestler DC, 2013, ENVIRON HEALTH PERSP, V121, P971, DOI 10.1289/ehp.1205925; Lesseur C, 2013, MOL CELL ENDOCRINOL, V381, P160, DOI 10.1016/j.mce.2013.07.024; Marsit C, 2013, ADV EXP MED BIOL, V754, P233, DOI 10.1007/978-1-4419-9967-2_12; Marsit CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033794; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Mehta D, 2013, P NATL ACAD SCI USA, V110, P8302, DOI 10.1073/pnas.1217750110; Michels K. B., 2012, EPIGENETIC EPIDEMIOL, P105; Mill J, 2013, NAT REV GENET, V14, P585, DOI 10.1038/nrg3405; Mparmpakas D, 2012, CLIN SCI, V122, P349, DOI 10.1042/CS20110378; Mueller B., 1928, INT J LEGAL MED, V11, P211; Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423; Ng J. W., 2012, GENOME BIOL, V13, P1; Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034; Ollikainen M, 2010, HUM MOL GENET, V19, P4176, DOI 10.1093/hmg/ddq336; Papageorgiou EA, 2009, AM J PATHOL, V174, P1609, DOI 10.2353/ajpath.2009.081038; Parle-McDermott A, 2011, ADV NUTR, V2, P463, DOI 10.3945/an.111.001008; Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055; Pilsner JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037147; R Core Team, 2013, LANG ENV STAT COMP; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Ronn T, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003572; SALAHUDDIN SZ, 1981, BLOOD, V58, P931; Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001; Slotkin RK, 2007, NAT REV GENET, V8, P272, DOI 10.1038/nrg2072; Solomon SS, 2008, LIFE SCI, V83, P305, DOI 10.1016/j.lfs.2008.06.024; Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Tyrka AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030148; Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Wilhelm-Benartzi CS, 2012, ENVIRON HEALTH PERSP, V120, P296, DOI 10.1289/ehp.1103927	72	59	60	2	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2088	2097		10.1096/fj.13-238402	http://dx.doi.org/10.1096/fj.13-238402			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24478308	Green Published			2022-12-28	WOS:000335336000013
J	Bibee, KP; Cheng, YJ; Ching, JK; Marsh, JN; Li, AJ; Keeling, RM; Connolly, AM; Golumbek, PT; Myerson, JW; Hu, G; Chen, JJ; Shannon, WD; Lanza, GM; Weihl, CC; Wickline, SA				Bibee, Kristin P.; Cheng, Ya-Jian; Ching, James K.; Marsh, Jon N.; Li, Allison J.; Keeling, Richard M.; Connolly, Anne M.; Golumbek, Paul T.; Myerson, Jacob W.; Hu, Grace; Chen, Junjie; Shannon, William D.; Lanza, Gregory M.; Weihl, Conrad C.; Wickline, Samuel A.			Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function	FASEB JOURNAL			English	Article						perfluorocarbon; Duchenne; cardiomyopathy; nanomedicine; drug delivery	SKELETAL-MUSCLE; MDX MICE; CORTICOSTEROID TREATMENT; THERAPEUTIC TARGET; STEROID-THERAPY; SIROLIMUS; PHARMACOKINETICS; ATHEROSCLEROSIS; NANOSTRUCTURES; DYSFUNCTION	Duchenne muscular dystrophy in boys progresses rapidly to severe impairment of muscle function and death in the second or third decade of life. Current supportive therapy with corticosteroids results in a modest increase in strength as a consequence of a general reduction in inflammation, albeit with potential untoward long-term side effects and ultimate failure of the agent to maintain strength. Here, we demonstrate that alternative approaches that rescue defective autophagy in mdx mice, a model of Duchenne muscular dystrophy, with the use of rapamycin-loaded nanoparticles induce a reproducible increase in both skeletal muscle strength and cardiac contractile performance that is not achievable with conventional oral rapamycin, even in pharmacological doses. This increase in physical performance occurs in both young and adult mice, and, surprisingly, even in aged wild-type mice, which sets the stage for consideration of systemic therapies to facilitate improved cell function by autophagic disposal of toxic byproducts of cell death and regeneration.Bibee, K. P., Cheng, Y.-J., Ching, J. K., Marsh, J. N., Li, A. J., Keeling, R. M., Connolly, A. M., Golumbek, P. T., Myerson, J. W., Hu, G., Chen, J., Shannon, W. D., Lanza, G. M., Weihl, C. C., Wickline, S. A. Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function.	[Bibee, Kristin P.; Cheng, Ya-Jian; Marsh, Jon N.; Li, Allison J.; Myerson, Jacob W.; Hu, Grace; Chen, Junjie; Lanza, Gregory M.; Wickline, Samuel A.] Washington Univ, Sch Med, Ctr Translat Res Adv Imaging & Nanomed, St Louis, MO 63110 USA; [Bibee, Kristin P.; Cheng, Ya-Jian; Marsh, Jon N.; Li, Allison J.; Myerson, Jacob W.; Hu, Grace; Chen, Junjie; Shannon, William D.; Lanza, Gregory M.; Wickline, Samuel A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Ching, James K.; Keeling, Richard M.; Connolly, Anne M.; Golumbek, Paul T.; Weihl, Conrad C.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Wickline, SA (corresponding author), Washington Univ, Sch Med, Dept Med, Ctr Translat Res Adv Imaging & Nanomed, 660 South Euclid Ave, St Louis, MO 63110 USA.	saw@wuphys.wustl.edu	Connolly, Anne/GYD-3128-2022	Connolly, Anne/0000-0002-9193-2457	U.S. National Institutes of Health (NIH) [R01 AR056223, HL073646]; NIH [HL112518, HL113392, NS073457ss, K02 AG042095]; Muscular Dystrophy Association; American Heart Association [12PRE9310044]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113392, R42HL112518, R01HL073646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K02AG042095, R01AG031867] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors acknowledge contributions of other colleagues to this study: Kefeng Wang (statistical analysis); John Allen, Cordelia Caradine, and Xiaoxia Yang (animal preparation); Huiying Zhang and Noriko Yanaba (histology); and Ralph W. Fuhrhop, Michael J. Scott, and Angana Senpan (NP formulation). This work was supported by U.S. National Institutes of Health (NIH) grants R01 AR056223 and HL073646 (S.A.W.); NIH HL112518, HL113392, and NS073457ss (G.M.L.); and NIH K02 AG042095 (C.C.W.); the Muscular Dystrophy Association (C.C.W., A.M.C., and P.T.G.); and American Heart Association graduate fellowship award 12PRE9310044 (Y.-J.C.).	Adelman SJ, 2010, CURR PHARM DESIGN, V16, P4002; Ahern GP, 1997, NEUROSCI LETT, V225, P81, DOI 10.1016/S0304-3940(97)00193-6; Ashford MW, 2005, CIRCULATION, V112, P2462, DOI 10.1161/CIRCULATIONAHA.104.516716; Avila G, 2005, CELL CALCIUM, V38, P35, DOI 10.1016/j.ceca.2005.05.001; Avila G, 2003, J BIOL CHEM, V278, P22600, DOI 10.1074/jbc.M205866200; Balaban B, 2005, AM J PHYS MED REHAB, V84, P843, DOI 10.1097/01.phm.0000184156.98671.d0; Bellinger AM, 2009, NAT MED, V15, P325, DOI 10.1038/nm.1916; Biggar WD, 2006, NEUROMUSCULAR DISORD, V16, P249, DOI 10.1016/j.nmd.2006.01.010; Cheng YJ, 2012, AM J PHYSIOL-HEART C, V303, pH559, DOI 10.1152/ajpheart.00321.2012; Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3; Crowe A, 1999, DRUG METAB DISPOS, V27, P627; Cyrus T, 2008, ARTERIOSCL THROM VAS, V28, P820, DOI 10.1161/ATVBAHA.107.156281; De Palma C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.159; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; DOLBER PC, 1987, STAIN TECHNOL, V62, P23, DOI 10.3109/10520298709107961; Eghtesad S, 2011, MOL MED, V17, P917, DOI 10.2119/molmed.2010.00256; Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013; Ferron GM, 1997, J CHROMATOGR B, V703, P243, DOI 10.1016/S0378-4347(97)00415-5; FLAIM SF, 1994, ARTIF CELL BLOOD SUB, V22, P1043, DOI 10.3109/10731199409138801; Flynn JM, 2013, AGING CELL, V12, P851, DOI 10.1111/acel.12109; Goemans NM, 2011, NEW ENGL J MED, V364, P1513, DOI 10.1056/NEJMoa1011367; Grumati P, 2010, NAT MED, V16, P1313, DOI 10.1038/nm.2247; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Ju JS, 2009, AUTOPHAGY, V5, P511, DOI 10.4161/auto.5.4.7761; Keeling RM, 2007, MUSCLE NERVE, V35, P43, DOI 10.1002/mus.20646; Kinali M, 2009, LANCET NEUROL, V8, P918, DOI 10.1016/S1474-4422(09)70211-X; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lien CF, 2012, J BIOL CHEM, V287, P41374, DOI 10.1074/jbc.M112.400044; Markham LW, 2005, PEDIATR CARDIOL, V26, P768, DOI 10.1007/s00246-005-0909-4; Morawski AM, 2004, MAGN RESON MED, V52, P1255, DOI 10.1002/mrm.20287; Mouisel E, 2010, MUSCLE NERVE, V41, P809, DOI 10.1002/mus.21624; Moxley RT, 2005, NEUROLOGY, V64, P13, DOI 10.1212/01.WNL.0000148485.00049.B7; Napoli KL, 1997, CLIN BIOCHEM, V30, P135, DOI 10.1016/S0009-9120(96)00157-9; Neubauer AM, 2008, MAGN RESON MED, V60, P1353, DOI 10.1002/mrm.21795; O'Reilly T, 2010, CANCER CHEMOTH PHARM, V65, P625, DOI 10.1007/s00280-009-1068-8; Palladino M, 2013, ARTERIOSCL THROM VAS, V33, P2867, DOI 10.1161/ATVBAHA.112.301172; Pan H, 2012, METHOD ENZYMOL, V508, P17, DOI 10.1016/B978-0-12-391860-4.00002-1; Pauly M, 2012, AM J PATHOL, V181, P583, DOI 10.1016/j.ajpath.2012.04.004; Schram G, 2013, J AM COLL CARDIOL, V61, P948, DOI 10.1016/j.jacc.2012.12.008; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r; Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842; Stepkowski SM, 2003, TRANSPLANT P, V35, p219S, DOI 10.1016/S0041-1345(03)00222-7; Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546; van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108; Vidal B, 2012, HUM MOL GENET, V21, P1989, DOI 10.1093/hmg/dds012; VILQUIN JT, 1995, TRANSPLANTATION, V59, P422, DOI 10.1097/00007890-199502150-00020; Wickline SA, 2006, ARTERIOSCL THROM VAS, V26, P435, DOI 10.1161/01.ATV.0000201069.47550.8b; Wickline SA, 2010, MOL IMAGING PRINCIPL, P542; WILLIAMS DA, 1990, J PHYSIOL-LONDON, V428, P243, DOI 10.1113/jphysiol.1990.sp018210; Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; ZEMAN RJ, 1986, BIOCHEM J, V240, P269, DOI 10.1042/bj2400269; Zhang HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026385	55	47	48	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2047	2061		10.1096/fj.13-237388	http://dx.doi.org/10.1096/fj.13-237388			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24500923	Green Published			2022-12-28	WOS:000335336000010
J	Zarco-Zavala, M; Morales-Rios, E; Mendoza-Hernandez, G; Ramirez-Silva, L; Perez-Hernandez, G; Garcia-Trejo, JJ				Zarco-Zavala, Mariel; Morales-Rios, Edgar; Mendoza-Hernandez, Guillermo; Ramirez-Silva, Leticia; Perez-Hernandez, Gerardo; Garcia-Trejo, Jose J.			The zeta subunit of the F1FO-ATP synthase of alpha-proteobacteria controls rotation of the nanomotor with a different structure	FASEB JOURNAL			English	Article						Paracoccus denitrificans; regulation	EPSILON-SUBUNIT; PARACOCCUS-DENITRIFICANS; INHIBITOR PROTEIN; ATP SYNTHASE; THERMOPHILIC F-1-ATPASE; ESCHERICHIA-COLI; OXIDATIVE-PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; REGULATORY PROTEIN; MITOCHONDRIA	The subunit is a novel natural inhibitor of the -proteobacterial F1FO-ATPase described originally in Paracoccus denitrificans. To characterize the mechanism by which this subunit inhibits the F1FO nanomotor, the subunit of Paracoccus denitrificans (Pd-) was analyzed by the combination of kinetic, biochemical, bioinformatic, proteomic, and structural approaches. The subunit causes full inhibition of the sulfite-activated PdF1-ATPase with an apparent IC50 of 270 nM by a mechanism independent of the epsilon subunit. The inhibitory region of the subunit resides in the first 14 N-terminal residues of the protein, which protrude from the 4--helix bundle structure of the isolated subunit, as resolved by NMR. Cross-linking experiments show that the subunit interacts with rotor () and stator (, ) subunits of the F-1-ATPase, indicating that the subunit hinders rotation of the central stalk. In addition, a putatively regulatory nucleotide-binding site was found in the subunit by isothermal titration calorimetry. Together, the data show that the subunit controls the rotation of F1FO-ATPase by a mechanism reminiscent of, but different from, those described for mitochondrial IF1 and bacterial epsilon subunits where the 4--helix bundle of seems to work as an anchoring domain that orients the N-terminal inhibitory domain to hinder rotation of the central stalk.Zarco-Zavala, M., Morales-Rios, E., Mendoza-Hernandez, G., Ramirez-Silva, L., Perez-Hernandez, G., Garcia-Trejo, J. J. The subunit of the F1FO-ATP synthase of -proteobacteria controls rotation of the nanomotor with a different structure.	[Zarco-Zavala, Mariel; Garcia-Trejo, Jose J.] Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Coyoacan, Mexico; [Mendoza-Hernandez, Guillermo; Ramirez-Silva, Leticia] Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Coyoacan, Mexico; [Morales-Rios, Edgar] MRC, Mitochondrial Res Unit, Cambridge, England; [Perez-Hernandez, Gerardo] Univ Autonoma Metropolitana Mexico, Tlalpan, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Autonoma Metropolitana - Mexico	Garcia-Trejo, JJ (corresponding author), Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Lab 206, Circuito Escolar S-N,Edificio F,Ciudad Univ, Mexico City 04510, DF, Mexico.	jjgartre@unam.mx		ZARCO-ZAVALA, MARIEL/0000-0002-9892-0758; Morales-Rios, Edgar/0000-0003-1139-2292; Perez-Hernandez, Gerardo/0000-0003-3290-4875	Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)-Direccion General Asuntos del Personal Academico (DGAPA; UNAM) [IN213809, IN211012]; Consejo Nacional de Ciencia y Tecnologia (CONACyT) grant [CB-2011-01-167622]; CONACyT grant [47310013, 105532]; PAPIIT-DGAPA (UNAM) grant [IN215912]; CONACyT Ph.D. Fellowship [299475]	Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)-Direccion General Asuntos del Personal Academico (DGAPA; UNAM); Consejo Nacional de Ciencia y Tecnologia (CONACyT) grant; CONACyT grant(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); PAPIIT-DGAPA (UNAM) grant; CONACyT Ph.D. Fellowship(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	The authors gratefully acknowledge Marietta Tuena de Gomez-Puyou and Armando Gomez-Puyou [Institute of Cell Physiology (IFC), Universidad Nacional Autonoma de Mexico (UNAM)] for critical review of this work. The authors also thank John E. Walker (Medical Research Council, Mitochondrial Biology Unit, Cambridge, UK) for important suggestions in the first draft of the article. The authors also thank Blanca Barquera (Rensselaer Polytechnic Institute, Troy, NY, USA) and Roderick A. Capaldi (University of Oregon, Eugene, OR, USA) for important suggestions to improve the final text of this article. The technical assistance of Raquel Ortega is gratefully acknowledged. This project was supported by the following grants to J.J.G.-T.: Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)-Direccion General Asuntos del Personal Academico (DGAPA; UNAM) grants IN213809 and IN211012, and Consejo Nacional de Ciencia y Tecnologia (CONACyT) grant CB-2011-01-167622. G. P.-H. was supported by CONACyT grants 47310013 and 105532 and L. R-S. by PAPIIT-DGAPA (UNAM) grant IN215912. The authors are grateful to Dr. Pedro Serrano and Prof. Kurt Wuthrich for initial collaborative work in the resolution of the NMR structure of the Pd-zeta subunit, for permission to show the resolved Pd-zeta structure (PDB_id 2LL0; Fig. 6 and Supplemental Movie S1) and to cite the nucleotide binding properties of the zeta subunit, and for providing plasmids expressing the truncated and full Js-zeta subunits for functional studies (Pedro Serrano, M. G. Biswaranjan Mohanty, and Kurt Wuthrich; to be submitted; private communication by the authors). M. Z.-Z. was supported by CONACyT Ph.D. Fellowship 299475; this work is part of her Ph.D. thesis at the Postgraduate Studies in Biomedical Sciences of UNAM [Doctorado en Ciencias Biomedicas (PDCB)] carried out at the UNAM Facultad de Quimica (Faculty of Chemistry) with J.J.G.-T. as Ph.D. advisor. Author contributions: M. Z.-Z. carried out most of the experiments, including protein purification, cross-linking, CD, calorimetry, limited proteolysis, ATPase activity, WB, and 2D-SDS-PAGE gels, designed research, made gene constructions, and analyzed the data; E. M. R. carried out preliminary biochemical experiments shown in Supplemental Material, designed the primers for protein constructions and carried out the phylogenetic analysis of the zeta gene in the alpha-proteobacterial class, wrote part of Materials and Methods, and contributed key expertise in the cloning and protein purification protocols; G. M.-H. carried out the mass spectrometry sequencing of the full WT Pd-zeta subunit and also protein constructs and proteolytic fragments obtained by limited proteolysis; L. R-S. carried out the CD experiments and helped with the calculation of secondary structure content of the Pd-zeta subunit; G. P.-H. carried out ITC of ATP binding to Pd-zeta and helped with the data fitting to estimate the K<INF>d</INF> for ATP; J.J.G.-T. designed research, carried out cross-linking experiments, ATPase assays, and protein purification experiments and contributed to molecular biology constructions and cloning, helped with curve fitting to estimate the IC<INF>50</INF> of Pd-zeta during inhibitory titration, carried out 2D-SDS-PAGE gels, constructed phylogenetic trees and protein sequence alignments, and wrote the manuscript. The authors declare no conflicts of interest.	Bason J. V., J MOL BIOL, V406, P443; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Cabezon E, 2003, NAT STRUCT BIOL, V10, P744, DOI 10.1038/nsb966; Cingolani G, 2011, NAT STRUCT MOL BIOL, V18, P701, DOI 10.1038/nsmb.2058; Castillo DD, 2011, J BIOL CHEM, V286, P23911, DOI 10.1074/jbc.M111.252056; DEJESUSGARCIA J, 1995, J BIOENERG BIOMEMBR, V27, P127, DOI 10.1007/BF02110340; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; Garcia-Trejo JJ, 2008, J BIOL PHYS, V34, P197, DOI 10.1007/s10867-008-9114-z; Gledhill JR, 2007, P NATL ACAD SCI USA, V104, P15671, DOI 10.1073/pnas.0707326104; Gupta RS, 2005, CRIT REV MICROBIOL, V31, P101, DOI 10.1080/10408410590922393; HALFMAN CJ, 1982, BIOCHEM J, V203, P339, DOI 10.1042/bj2030339; Iino R, 2009, J BIOL CHEM, V284, P17457, DOI 10.1074/jbc.M109.003798; Kato S, 2007, J BIOL CHEM, V282, P37618, DOI 10.1074/jbc.M707509200; Kato-Yamada Y, 2003, J BIOL CHEM, V278, P36013, DOI 10.1074/jbc.M306140200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebowitz MS, 1996, ARCH BIOCHEM BIOPHYS, V330, P342, DOI 10.1006/abbi.1996.0261; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Margulis L, 1970, ORIGIN EUKARYOTIC CE; Masaike T, 2006, BIOCHEM BIOPH RES CO, V342, P800, DOI 10.1016/j.bbrc.2006.02.017; Minauro-Sanmiguel F, 2002, J BIOENERG BIOMEMBR, V34, P433, DOI 10.1023/A:1022514008462; Mizumoto J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073888; Morales-Rios E, 2010, FASEB J, V24, P599, DOI 10.1096/fj.09-137356; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10518, DOI 10.1021/bi00498a014; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Robinson GC, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120164; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHWERZMANN K, 1982, J BIOL CHEM, V257, P9555; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; VANHEEKE G, 1993, BIOCHEMISTRY-US, V32, P10140, DOI 10.1021/bi00089a033; vanRaaij MJ, 1996, BIOCHEMISTRY-US, V35, P15618, DOI 10.1021/bi960628f; Walker JE, 2013, BIOCHEM SOC T, V41, P1, DOI 10.1042/BST20110773; Williams KP, 2007, J BACTERIOL, V189, P4578, DOI 10.1128/JB.00269-07; Yagi H, 2007, P NATL ACAD SCI USA, V104, P11233, DOI 10.1073/pnas.0701045104; Zarco-Zavala M, 2013, BBA-BIOENERGETICS, V1827, P60, DOI 10.1016/j.bbabio.2012.09.010; Zharova TV, 2006, BBA-BIOENERGETICS, V1757, P304, DOI 10.1016/j.bbabio.2006.03.001; Zharova TV, 2004, J BIOL CHEM, V279, P12319, DOI 10.1074/jbc.M311397200	41	27	27	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2146	2157		10.1096/fj.13-241430	http://dx.doi.org/10.1096/fj.13-241430			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24522203				2022-12-28	WOS:000335336000018
J	Fry, CS; Lee, JD; Jackson, JR; Kirby, TJ; Stasko, SA; Liu, HL; Dupont-Versteegden, EE; McCarthy, JJ; Peterson, CA				Fry, Christopher S.; Lee, Jonah D.; Jackson, Janna R.; Kirby, Tyler J.; Stasko, Shawn A.; Liu, Honglu; Dupont-Versteegden, Esther E.; McCarthy, John J.; Peterson, Charlotte A.			Regulation of the muscle fiber microenvironment by activated satellite cells during hypertrophy	FASEB JOURNAL			English	Article						extracellular matrix; Tcf4; Pax7; myogenic progenitor cells; fibroblast	CONNECTIVE-TISSUE FIBROBLASTS; SKELETAL-MUSCLE; EXTRACELLULAR-MATRIX; TRANSFORMING GROWTH-FACTOR-BETA-1; LATERAL TRANSMISSION; MYONUCLEAR ADDITION; COLLAGEN; RAT; EXPRESSION; CULTURES	Our aim in the current study was to determine the necessity of satellite cells for long-term muscle growth and maintenance. We utilized a transgenic Pax7-DTA mouse model, allowing for the conditional depletion of > 90% of satellite cells with tamoxifen treatment. Synergist ablation surgery, where removal of synergist muscles places functional overload on the plantaris, was used to stimulate robust hypertrophy. Following 8 wk of overload, satellite cell-depleted muscle demonstrated an accumulation of extracellular matrix (ECM) and fibroblast expansion that resulted in reduced specific force of the plantaris. Although the early growth response was normal, an attenuation of hypertrophy measured by both muscle wet weight and fiber cross-sectional area occurred in satellite cell-depleted muscle. Isolated primary myogenic progenitor cells (MPCs) negatively regulated fibroblast ECM mRNA expression in vitro, suggesting a novel role for activated satellite cells/MPCs in muscle adaptation. These results provide evidence that satellite cells regulate the muscle environment during growth.-Fry, C. S., Lee, J. D., Jackson, J. R., Kirby, T. J., Stasko, S. A., Liu, H., Dupont-Versteegden, E. E., McCarthy, J. J., Peterson, C. A. Regulation of the muscle fiber microenvironment by activated satellite cells during hypertrophy.	[Fry, Christopher S.; Lee, Jonah D.; Jackson, Janna R.; Liu, Honglu; Dupont-Versteegden, Esther E.; Peterson, Charlotte A.] Univ Kentucky, Coll Hlth Sci, Dept Rehabil Sci, Lexington, KY 40536 USA; [Kirby, Tyler J.; Stasko, Shawn A.; McCarthy, John J.; Peterson, Charlotte A.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Peterson, CA (corresponding author), Univ Kentucky, 900 S Limestone,CTW 105, Lexington, KY 40536 USA.	cpete4@uky.edu	Fry, Christopher/U-2216-2019	Kirby, Tyler/0000-0002-0210-3826	Jeane B. Kempner Postdoctoral Scholar Award; Ellison Medical Foundation/American Federation of Aging Research Fellow EPD [12102]; U.S. National Institutes of Health (NIH) [AG-34453, AR-60701]; NIH [T32-HL-086341]; National Center for Advancing Translational Sciences, NIH [UL1-TR-000117]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000117] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL086341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K12DE023574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG034453] Funding Source: NIH RePORTER	Jeane B. Kempner Postdoctoral Scholar Award; Ellison Medical Foundation/American Federation of Aging Research Fellow EPD; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences, NIH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors acknowledge Ben Lawson and Ken Campbell (Center of Muscle Biology Single Fiber Function core services, University of Kentucky). Research was supported by the Jeane B. Kempner Postdoctoral Scholar Award (to C.S.F.); Ellison Medical Foundation/American Federation of Aging Research Fellow EPD 12102 (to J.D.L.); and U.S. National Institutes of Health (NIH) grants AG-34453 (to C.A.P.) and AR-60701 (to C.A.P. and J.J.M.). S.A.S. was supported by NIH grant T32-HL-086341. The project described was also partially supported by the National Center for Advancing Translational Sciences, NIH grant UL1-TR-000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Adams GR, 2002, AM J PHYSIOL-CELL PH, V283, pC1182, DOI 10.1152/ajpcell.00173.2002; BERNASCONI P, 1995, J CLIN INVEST, V96, P1137, DOI 10.1172/JCI118101; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Bruusgaard JC, 2010, P NATL ACAD SCI USA, V107, P15111, DOI 10.1073/pnas.0913935107; CALDWELL CJ, 1990, NEUROPATH APPL NEURO, V16, P225, DOI 10.1111/j.1365-2990.1990.tb01159.x; Campbell KS, 2006, BIOPHYS J, V90, P1288, DOI 10.1529/biophysj.105.067504; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHEEK DB, 1965, B JOHNS HOPKINS HOSP, V116, P378; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; Cosgrove BD, 2009, DIFFERENTIATION, V78, P185, DOI 10.1016/j.diff.2009.08.004; Ferreira LF, 2012, J APPL PHYSIOL, V112, P1538, DOI 10.1152/japplphysiol.01269.2011; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; Goetsch SC, 2003, PHYSIOL GENOMICS, V14, P261, DOI 10.1152/physiolgenomics.00056.2003; Gordon SE, 2001, AM J PHYSIOL-ENDOC M, V280, pE150, DOI 10.1152/ajpendo.2001.280.1.E150; Hidestrand M, 2008, J GERONTOL A-BIOL, V63, P566, DOI 10.1093/gerona/63.6.566; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Kaariainen M, 2000, SCAND J MED SCI SPOR, V10, P332, DOI 10.1034/j.1600-0838.2000.010006332.x; Kay EP, 1998, CURR EYE RES, V17, P286, DOI 10.1076/ceyr.17.3.286.5212; Kirkpatrick LJ, 2010, J HISTOCHEM CYTOCHEM, V58, P317, DOI 10.1369/jhc.2009.954792; Kjaer M, 2004, PHYSIOL REV, V84, P649, DOI 10.1152/physrev.00031.2003; KUHL U, 1982, DEV BIOL, V93, P344, DOI 10.1016/0012-1606(82)90122-1; Lepper C, 2011, DEVELOPMENT, V138, P3639, DOI 10.1242/dev.067595; Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002-9440(10)63188-4; LIPTON BH, 1977, DEV BIOL, V61, P153, DOI 10.1016/0012-1606(77)90288-3; Mathew SJ, 2011, DEVELOPMENT, V138, P371, DOI 10.1242/dev.057463; McCarthy JJ, 2011, DEVELOPMENT, V138, P3657, DOI 10.1242/dev.068858; Murphy MM, 2011, DEVELOPMENT, V138, P3625, DOI 10.1242/dev.064162; NOBLE EG, 1983, PFLUG ARCH EUR J PHY, V396, P260, DOI 10.1007/BF00587864; Petrella JK, 2008, J APPL PHYSIOL, V104, P1736, DOI 10.1152/japplphysiol.01215.2007; Petrella JK, 2006, AM J PHYSIOL-ENDOC M, V291, pE937, DOI 10.1152/ajpendo.00190.2006; Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Ramaswamy KS, 2011, J PHYSIOL-LONDON, V589, P1195, DOI 10.1113/jphysiol.2010.201921; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rocheteau P, 2012, CELL, V148, P112, DOI 10.1016/j.cell.2011.11.049; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; ROY RR, 1985, J APPL PHYSIOL, V59, P639, DOI 10.1152/jappl.1985.59.2.639; Sambasivan R, 2011, DEVELOPMENT, V138, P3647, DOI 10.1242/dev.067587; SANDERSON RD, 1986, J CELL BIOL, V102, P740, DOI 10.1083/jcb.102.3.740; SASSE J, 1981, DEV BIOL, V83, P79, DOI 10.1016/S0012-1606(81)80010-3; Sato K, 2003, MUSCLE NERVE, V28, P365, DOI 10.1002/mus.10436; SCHIAFFINO S, 1976, VIRCHOWS ARCH B, V21, P113; Strutz F, 2001, KIDNEY INT, V59, P579, DOI 10.1046/j.1523-1755.2001.059002579.x; Taylor-Jones JM, 2002, MECH AGEING DEV, V123, P649, DOI 10.1016/S0047-6374(01)00411-0; Uezumi A, 2011, J CELL SCI, V124, P3654, DOI 10.1242/jcs.086629; Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014; Urciuolo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2964; Verdijk LB, 2009, J GERONTOL A-BIOL, V64, P332, DOI 10.1093/gerona/gln050; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Zammit PS, 2006, J HISTOCHEM CYTOCHEM, V54, P1177, DOI 10.1369/jhc.6R6995.2006; Zanotti S, 2007, MATRIX BIOL, V26, P615, DOI 10.1016/j.matbio.2007.06.004; Zhang C, 2012, J BIOMECH, V45, P2001, DOI 10.1016/j.jbiomech.2012.04.026; Zhang Y, 2010, DEV GROWTH DIFFER, V52, P725, DOI 10.1111/j.1440-169X.2010.01209.x; Zou Y, 2008, J NEUROPATH EXP NEUR, V67, P144, DOI 10.1097/nen.0b013e3181634ef7	55	180	183	2	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1654	1665		10.1096/fj.13-239426	http://dx.doi.org/10.1096/fj.13-239426			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24376025	Green Published			2022-12-28	WOS:000335344300014
J	Kiss, G; Konrad, C; Pour-Ghaz, I; Mansour, JJ; Nemeth, B; Starkov, AA; Adam-Vizi, V; Chinopoulos, C				Kiss, Gergely; Konrad, Csaba; Pour-Ghaz, Issa; Mansour, Josef J.; Nemeth, Beata; Starkov, Anatoly A.; Adam-Vizi, Vera; Chinopoulos, Christos			Mitochondrial diaphorases as NAD(+) donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition	FASEB JOURNAL			English	Review						adenine nucleotide translocase; DT-diaphorase; reducing equivalent; succinyl-CoA ligase	KETOGLUTARATE DEHYDROGENASE COMPLEX; ADENINE-NUCLEOTIDE TRANSLOCASE; REDUCED PYRIDINE NUCLEOTIDE; SUCCINYL-COA SYNTHETASES; GUINEA-PIG HEART; DT-DIAPHORASE; COENZYME-Q; OXIDATIVE-PHOSPHORYLATION; LIPOAMIDE DEHYDROGENASE; CYTOCHROME-C	Substrate-level phosphorylation mediated by succinyl-CoA ligase in the mitochondrial matrix produces high-energy phosphates in the absence of oxidative phosphorylation. Furthermore, when the electron transport chain is dysfunctional, provision of succinyl-CoA by the alpha-ketoglutarate dehydrogenase complex (KGDHC) is crucial for maintaining the function of succinyl-CoA ligase yielding ATP, preventing the adenine nucleotide translocase from reversing. We addressed the source of the NAD(+) supply for KGDHC under anoxic conditions and inhibition of complex I. Using pharmacologic tools and specific substrates and by examining tissues from pigeon liver exhibiting no diaphorase activity, we showed that mitochondrial diaphorases in the mouse liver contribute up to 81% to the NAD(+) pool during respiratory inhibition. Under these conditions, KGDHC's function, essential for the provision of succinyl-CoA to succinyl-CoA ligase, is supported by NAD(+) derived from diaphorases. Through this process, diaphorases contribute to the maintenance of substrate-level phosphorylation during respiratory inhibition, which is manifested in the forward operation of adenine nucleotide translocase. Finally, we show that reoxidation of the reducible substrates for the diaphorases is mediated by complex III of the respiratory chain.-Kiss, G., Konrad, C., Pour-Ghaz, I., Mansour, J. J., Nemeth, B., Starkov, A. A., Adam-Vizi, V., Chinopoulos, C. Mitochondrial diaphorases as NAD(+) donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition.	[Kiss, Gergely; Konrad, Csaba; Pour-Ghaz, Issa; Mansour, Josef J.; Nemeth, Beata; Adam-Vizi, Vera; Chinopoulos, Christos] Semmelweis Univ, Dept Med Biochem, Hungarian Acad Sci, SE Lab Neurobiochem, H-1094 Budapest, Hungary; [Starkov, Anatoly A.] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA	Hungarian Academy of Sciences; Semmelweis University; Cornell University	Chinopoulos, C (corresponding author), Semmelweis Univ, Dept Med Biochem, 37-47 Tuzolto St, H-1094 Budapest, Hungary.	chinopoulos.christos@eok.sote.hu	Starkov, Anatoly/B-2688-2012	Starkov, Anatoly/0000-0002-1334-4828; Pour-Ghaz, Issa/0000-0001-6404-1213; Mansour, Josef/0000-0001-5324-8286; Chinopoulos, Christos/0000-0003-0183-4149; Adam-Vizi, Vera/0000-0002-8350-8701	Orszagos Tudomanyos Kutatasi Alapprogram (OTKA) [81983]; Hungarian Academy of Sciences [02001]; Astellas Pharma Kft.-Kerpel-Fronius Odon Tehetseggondozo Program; U.S. National Institutes of Health/National Institute on Aging [AG014930]; MTA-SE Lendulet Neurobiochemistry Research Division [95003]; OTKA NNF [78905]; OTKA [NNF2 85658, K 100918]; EC; NATIONAL INSTITUTE ON AGING [P01AG014930] Funding Source: NIH RePORTER	Orszagos Tudomanyos Kutatasi Alapprogram (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Hungarian Academy of Sciences(Hungarian Academy of Sciences); Astellas Pharma Kft.-Kerpel-Fronius Odon Tehetseggondozo Program; U.S. National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MTA-SE Lendulet Neurobiochemistry Research Division; OTKA NNF(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); EC(European CommissionEuropean Commission Joint Research Centre); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by Orszagos Tudomanyos Kutatasi Alapprogram (OTKA) grant 81983 and Hungarian Academy of Sciences grant 02001 (to V.A.-V.); a student grant from Astellas Pharma Kft.-Kerpel-Fronius Odon Tehetseggondozo Program (to G.K.); grant AG014930 from the U.S. National Institutes of Health/National Institute on Aging (to A.A.S.); and grants MTA-SE Lendulet Neurobiochemistry Research Division 95003, OTKA NNF 78905, OTKA NNF2 85658, and OTKA K 100918 (to C.C). Cyb5r2 transgenic mice were provided by the European Mouse Mutant Archive (EMMA) service project, funded by the EC FP7 Capacities Specific Program. The authors declare no conflicts of interest.	AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Bando Y., 1992, J NUTR SCI VITAMINOL, P453; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; Bianchet MA, 2004, METHOD ENZYMOL, V382, P144; Chan TS, 2002, FREE RADICAL RES, V36, P421, DOI 10.1080/10715760290021270; CHANCE B, 1960, NATURE, V185, P666, DOI 10.1038/185666a0; Chapple SJ, 2012, INT J BIOCHEM CELL B, V44, P1315, DOI 10.1016/j.biocel.2012.04.021; CHICK WL, 1968, AM J PHYSIOL, V215, P1107, DOI 10.1152/ajplegacy.1968.215.5.1107; Chinopoulos C, 2013, J NEUROSCI RES, V91, P1030, DOI 10.1002/jnr.23196; Chinopoulos C, 2011, J NEUROSCI RES, V89, P1897, DOI 10.1002/jnr.22659; Chinopoulos C, 2011, FEBS LETT, V585, P1255, DOI 10.1016/j.febslet.2011.04.004; Chinopoulos C, 2010, FEBS J, V277, P3637, DOI 10.1111/j.1742-4658.2010.07755.x; Chinopoulos C, 2010, FASEB J, V24, P2405, DOI 10.1096/fj.09-149898; Chinopoulos C, 2010, BBA-MOL BASIS DIS, V1802, P221, DOI 10.1016/j.bbadis.2009.08.008; Chinopoulos C, 2009, BIOPHYS J, V96, P2490, DOI 10.1016/j.bpj.2008.12.3915; CLARK JB, 1979, PHARMACOL THERAPEUT, V7, P351, DOI 10.1016/0163-7258(79)90036-6; COLPABOONSTRA JP, 1958, BIOCHIM BIOPHYS ACTA, V27, P122, DOI 10.1016/0006-3002(58)90298-1; CONOVER TE, 1963, BIOCHIM BIOPHYS ACTA, V67, P268; CONOVER TE, 1960, BIOCHEM BIOPH RES CO, V2, P26, DOI 10.1016/0006-291X(60)90258-8; CONOVER TE, 1962, BIOCHIM BIOPHYS ACTA, V58, P189, DOI 10.1016/0006-3002(62)90998-8; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; DANIELSON L, 1962, NATURE, V194, P155, DOI 10.1038/194155a0; DANIELSON L, 1960, ACTA CHEM SCAND, V14, P1837, DOI 10.3891/acta.chem.scand.14-1837; DEDUKHOVA V I, 1986, Biokhimiya, V51, P567; Dong HB, 2013, BIOCHEM BIOPH RES CO, V435, P727, DOI 10.1016/j.bbrc.2013.05.051; EDLUND C, 1982, BIOSCIENCE REP, V2, P861, DOI 10.1007/BF01114891; Eliasson M, 1999, BIOCHEM PHARMACOL, V58, P1287, DOI 10.1016/S0006-2952(99)00185-9; ERNSTER L, 1960, BIOCHEM BIOPH RES CO, V2, P88, DOI 10.1016/0006-291X(60)90193-5; ERNSTER L, 1958, FED PROC, V17, P216; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; ERNSTER L, 1958, ACTA CHEM SCAND, V12, P595, DOI 10.3891/acta.chem.scand.12-0595; ERNSTER L, 1969, EUR J BIOCHEM, V9, P299, DOI 10.1111/j.1432-1033.1969.tb00609.x; ERNSTER L, 1962, BIOCHIM BIOPHYS ACTA, V58, P171, DOI 10.1016/0006-3002(62)90997-6; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; ESTABROOK RW, 1958, J BIOL CHEM, V233, P1014; Faig M, 2001, STRUCTURE, V9, P659, DOI 10.1016/S0969-2126(01)00636-0; FLATMARK T, 1967, J BIOL CHEM, V242, P2454; Freeman HC, 2006, DIABETES, V55, P2153, DOI 10.2337/db06-0358; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; GIUDITTA A, 1961, BIOCHIM BIOPHYS ACTA, V48, P10, DOI 10.1016/0006-3002(61)90509-1; GIUDITTA A, 1959, J NEUROCHEM, V5, P50, DOI 10.1111/j.1471-4159.1959.tb13332.x; GIUDITTA A, 1963, BIOCHIM BIOPHYS ACTA, V67, P316; Gomez-Diaz C, 2003, PROTOPLASMA, V221, P11, DOI 10.1007/s00709-002-0067-y; GOPAL D, 1988, J BIOL CHEM, V263, P11652; Haefeli RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017963; HARRIS EJ, 1977, BIOCHEM J, V168, P129, DOI 10.1042/bj1680129; HODNICK WF, 1993, CANCER RES, V53, P4907; HUNTER FE, 1949, J BIOL CHEM, V177, P361; IDE S, 1967, J BIOL CHEM, V242, P54; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kiss G, 2013, FASEB J, V27, P2392, DOI 10.1096/fj.12-220202; Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011; Klyachko NL, 2005, J BIOL CHEM, V280, P16106, DOI 10.1074/jbc.M414285200; Kolesova G M, 1993, Biokhimiia, V58, P1630; KOLESOVA G M, 1987, Biokhimiya, V52, P715; KOLESOVA G M, 1989, Biokhimiya, V54, P103; KOLESOVA G M, 1991, Biokhimiya, V56, P1779; KOLI AK, 1969, J BIOL CHEM, V244, P621; Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200; LENAZ G, 1985, DRUG EXP CLIN RES, V11, P547; LIND C, 1990, METHOD ENZYMOL, V186, P287; LIND C, 1981, ARCH BIOCHEM BIOPHYS, V207, P217, DOI 10.1016/0003-9861(81)90027-8; Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3; MAERKI F, 1961, BIOCHEM Z, V334, P293; MARTIUS C, 1954, BIOCHEM Z, V326, P24; MARTIUS C, 1953, BIOCHIM BIOPHYS ACTA, V12, P134, DOI 10.1016/0006-3002(53)90132-2; MASSEY V, 1960, BIOCHIM BIOPHYS ACTA, V37, P314, DOI 10.1016/0006-3002(60)90239-0; Metelkin E, 2009, FEBS J, V276, P6942, DOI 10.1111/j.1742-4658.2009.07394.x; Miyadera H, 2003, P NATL ACAD SCI USA, V100, P473, DOI 10.1073/pnas.0237315100; NICHOLLS DG, 1977, EUR J BIOCHEM, V75, P601, DOI 10.1111/j.1432-1033.1977.tb11560.x; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; PENNEY DG, 1970, BIOCHEM J, V118, P221, DOI 10.1042/bj1180221; PEUHKURINEN KJ, 1983, AM J PHYSIOL, V244, pH281, DOI 10.1152/ajpheart.1983.244.2.H281; Phillips D, 2009, BIOCHEMISTRY-US, V48, P7140, DOI 10.1021/bi900725c; PISARENKO O, 1987, BIOMED BIOCHIM ACTA, V46, pS568; PISARENKO O, 1988, BIOCHIM BIOPHYS ACTA, V934, P55, DOI 10.1016/0005-2728(88)90119-3; PISARENKO OI, 1985, BASIC RES CARDIOL, V80, P126, DOI 10.1007/BF01910459; PREUSCH PC, 1991, FREE RADICAL BIO MED, V11, P77, DOI 10.1016/0891-5849(91)90191-5; PREUSCH PC, 1990, FREE RADICAL RES COM, V8, P401, DOI 10.3109/10715769009053374; RANDALL HM, 1966, AM J PHYSIOL, V211, P493, DOI 10.1152/ajplegacy.1966.211.2.493; REED L J, 1968, Brookhaven Symposia in Biology, V21, P397; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Sack MN, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013102; SANADI DR, 1963, BIOCHEMISTRY-US, V2, P523, DOI 10.1021/bi00903a023; SANBORN T, 1979, AM J PHYSIOL, V237, pH535, DOI 10.1152/ajpheart.1979.237.5.H535; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAEGTMEYER H, 1978, CIRC RES, V43, P808, DOI 10.1161/01.RES.43.5.808; TAEGTMEYER H, 1977, J BIOL CHEM, V252, P5010; TEDESCHI G, 1995, J BIOL CHEM, V270, P1198, DOI 10.1074/jbc.270.3.1198; Toye AA, 2005, DIABETOLOGIA, V48, P675, DOI 10.1007/s00125-005-1680-z; Traver RD, 1997, BRIT J CANCER, V75, P69, DOI 10.1038/bjc.1997.11; Tretter L, 2007, J NEUROSCI RES, V85, P3471, DOI 10.1002/jnr.21405; Tyler D. D., 1967, METHOD ENZYMOL, V10, P75, DOI DOI 10.1016/0076-6879(67)10014-1; VALLE VGR, 1986, BIOCHEM BIOPH RES CO, V135, P189, DOI 10.1016/0006-291X(86)90961-7; Vasiliou Vasilis, 2006, Human Genomics, V2, P329; Vaubel RA, 2011, J BIOL CHEM, V286, P40232, DOI 10.1074/jbc.M111.274415; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Weinberg JM, 2000, AM J PHYSIOL-RENAL, V279, pF927, DOI 10.1152/ajprenal.2000.279.5.F927; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826; WILLIAMS CH, 1959, BIOCHIM BIOPHYS ACTA, V32, P568, DOI 10.1016/0006-3002(59)90643-2; WILSON MA, 1970, BIOCHIM BIOPHYS ACTA, V216, P54, DOI 10.1016/0005-2728(70)90158-1; Winski SL, 2002, CANCER RES, V62, P1420; WOSILAIT WD, 1954, J BIOL CHEM, V206, P271; WOSILAIT WD, 1960, J BIOL CHEM, V235, P1196; WOSILAIT WD, 1954, J BIOL CHEM, V206, P255; Wu KB, 1997, ARCH BIOCHEM BIOPHYS, V347, P221, DOI 10.1006/abbi.1997.0344; Yue Y, 2001, AM J PHYSIOL-HEART C, V281, pH590, DOI 10.1152/ajpheart.2001.281.2.H590; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669	111	28	30	3	48	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1682	1697		10.1096/fj.13-243030	http://dx.doi.org/10.1096/fj.13-243030			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24391134	Green Published			2022-12-28	WOS:000335344300016
J	Matsuoka, K; Asano, Y; Higo, S; Tsukamoto, O; Yan, Y; Yamazaki, S; Matsuzaki, T; Kioka, H; Kato, H; Uno, Y; Asakura, M; Asanuma, H; Minamino, T; Aburatani, H; Kitakaze, M; Komuro, I; Takashima, S				Matsuoka, Ken; Asano, Yoshihiro; Higo, Shuichiro; Tsukamoto, Osamu; Yan, Yi; Yamazaki, Satoru; Matsuzaki, Takashi; Kioka, Hidetaka; Kato, Hisakazu; Uno, Yoshihiro; Asakura, Masanori; Asanuma, Hiroshi; Minamino, Tetsuo; Aburatani, Hiroyuki; Kitakaze, Masafumi; Komuro, Issei; Takashima, Seiji			Noninvasive and quantitative live imaging reveals a potential stress-responsive enhancer in the failing heart	FASEB JOURNAL			English	Article						transcriptional regulation; in vivo assessment; natriuretic peptide	ATRIAL-NATRIURETIC-PEPTIDE; PROTEIN-KINASE-C; CARDIAC-HYPERTROPHY; FACTOR EXPRESSION; FACTOR GENE; SEQUENCES; MICE; ANF; IDENTIFICATION; VERTEBRATE	Recent advances in genome analysis have enabled the identification of numerous distal enhancers that regulate gene expression in various conditions. However, the enhancers involved in pathological conditions are largely unknown because of the lack of in vivo quantitative assessment of enhancer activity in live animals. Here, we established a noninvasive and quantitative live imaging system for monitoring transcriptional activity and identified a novel stress-responsive enhancer of Nppa and Nppb, the most common markers of heart failure. The enhancer is a 650-bp fragment within 50 kb of the Nppa and Nppb loci. A chromosome conformation capture (3C) assay revealed that this distal enhancer directly interacts with the 5 '-flanking regions of Nppa and Nppb. To monitor the enhancer activity in a live heart, we established an imaging system using the firefly luciferase reporter. Using this imaging system, we observed that the novel enhancer activated the reporter gene in pressure overload-induced failing hearts (failing hearts: 5.7 +/- 1.3-fold; sham-surgery hearts: 1.0 +/- 0.2-fold; P < 0.001, repeated-measures ANOVA). This method will be particularly useful for identifying enhancers that function only during pathological conditions.-Matsuoka, K., Asano, Y., Higo, S., Tsukamoto, O., Yan, Y., Yamazaki, S., Matsuzaki, T., Kioka, H., Kato, H., Uno, Y., Asakura, M., Asanuma, H., Minamino, T., Aburatani, H., Kitakaze, M., Komuro, I., and Takashima, S. Noninvasive and quantitative live imaging reveals a potential stress-responsive enhancer in the failing heart.	[Matsuoka, Ken; Asano, Yoshihiro; Higo, Shuichiro; Matsuzaki, Takashi; Kioka, Hidetaka; Minamino, Tetsuo; Komuro, Issei; Takashima, Seiji] Osaka Univ, Grad Sch Med, Inst Expt Anim Sci, Dept Cardiovasc Med, Suita, Osaka 5650871, Japan; [Matsuoka, Ken; Asano, Yoshihiro; Higo, Shuichiro; Tsukamoto, Osamu; Yan, Yi; Kioka, Hidetaka; Kato, Hisakazu; Takashima, Seiji] Osaka Univ, Grad Sch Med, Inst Expt Anim Sci, Dept Med Biochem, Suita, Osaka 5650871, Japan; [Uno, Yoshihiro] Osaka Univ, Grad Sch Med, Inst Expt Anim Sci, Lab Reprod Engn, Suita, Osaka 5650871, Japan; [Yamazaki, Satoru] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Cell Biol, Suita, Osaka, Japan; [Asakura, Masanori; Kitakaze, Masafumi] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Clin Res & Dev, Suita, Osaka, Japan; [Asanuma, Hiroshi] Kyoto Prefectural Univ, Sch Med, Dept Cardiovasc Sci & Technol, Kyoto 606, Japan; [Aburatani, Hiroyuki] Univ Tokyo, Res Ctr Adv Sci & Technol, Genome Sci Div, Tokyo, Japan	Osaka University; Osaka University; Osaka University; National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan; Kyoto Prefectural University; University of Tokyo	Asano, Y (corresponding author), Osaka Univ, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	asano@cardiology.med.osaka-u.ac.jp		Kato, Hisakazu/0000-0003-4619-3680; Tsukamoto, Osamu/0000-0002-9504-8001	Japan Society for the Promotion of Science (JSPS) through the Funding Program for Next Generation World-Leading Researchers (NEXT Program); Council for Science and Technology Policy (CSTP); Ministry of Health, Labor, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Japan Society for the Promotion of Science; Japan Heart Foundation; Japan Cardiovascular Research Foundation; Japan Medical Association; Japan Intractable Diseases Research Foundation; Uehara Memorial Foundation; Takeda Science Foundation; Ichiro Kanehara Foundation; Inoue Foundation for Science; Mochida Memorial Foundation; Heart Foundation/Novartis Grant for Research Award on Molecular and Cellular Cardiology; Japan Foundation of Applied Enzymology; Naito Foundation; Banyu Foundation; Showa Houkoukai	Japan Society for the Promotion of Science (JSPS) through the Funding Program for Next Generation World-Leading Researchers (NEXT Program)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Council for Science and Technology Policy (CSTP)(Council for Science and Technology Policy (CSTP)); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Heart Foundation; Japan Cardiovascular Research Foundation; Japan Medical Association; Japan Intractable Diseases Research Foundation; Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Ichiro Kanehara Foundation; Inoue Foundation for Science(Inoue Foundation for Science); Mochida Memorial Foundation; Heart Foundation/Novartis Grant for Research Award on Molecular and Cellular Cardiology; Japan Foundation of Applied Enzymology(Japan Foundation of Applied Enzymology); Naito Foundation(Naito Memorial Foundation); Banyu Foundation; Showa Houkoukai	This research was supported by the Japan Society for the Promotion of Science (JSPS) through the Funding Program for Next Generation World-Leading Researchers (NEXT Program), which was initiated by the Council for Science and Technology Policy (CSTP); grants-in-aid from the Ministry of Health, Labor, and Welfare of Japan; grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and grants-in-aid from the Japan Society for the Promotion of Science. This research was also supported by grants from the Japan Heart Foundation, the Japan Cardiovascular Research Foundation, the Japan Medical Association, the Japan Intractable Diseases Research Foundation, the Uehara Memorial Foundation, the Takeda Science Foundation, the Ichiro Kanehara Foundation, the Inoue Foundation for Science, the Mochida Memorial Foundation, a Heart Foundation/Novartis Grant for Research Award on Molecular and Cellular Cardiology, the Japan Foundation of Applied Enzymology, the Naito Foundation, the Banyu Foundation, and Showa Houkoukai. The authors thank Hiroshi Kimura for antibodies, Seitaro Nomura for the ChIP-seq analysis, Saori Ikezawa and Eri Takata for technical assistance, and Yuko Okada and Hiromi Fujii for secretarial support.	Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Blow MJ, 2010, NAT GENET, V42, P806, DOI 10.1038/ng.650; Burley DS, 2007, BASIC RES CARDIOL, V102, P529, DOI 10.1007/s00395-007-0672-1; Chien KR, 2008, SCIENCE, V322, P1494, DOI 10.1126/science.1163267; de Lange FJ, 2003, GENESIS, V37, P1, DOI 10.1002/gene.10220; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Felsenfeld G, 2004, COLD SPRING HARB SYM, V69, P245, DOI 10.1101/sqb.2004.69.245; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; Horsthuis T, 2008, CIRC RES, V102, P849, DOI 10.1161/CIRCRESAHA.107.170571; Iaccarino G, 1999, HYPERTENSION, V33, P396, DOI 10.1161/01.HYP.33.1.396; Kitakaze M, 2007, LANCET, V370, P1483, DOI 10.1016/S0140-6736(07)61634-1; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; Koch F, 2008, TRENDS BIOCHEM SCI, V33, P265, DOI 10.1016/j.tibs.2008.04.006; Li P, 2008, CIRC RES, V102, P185, DOI 10.1161/CIRCRESAHA.107.157677; Liao YL, 2002, AM J PHYSIOL-HEART C, V282, pH1703, DOI 10.1152/ajpheart.00238.2001; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; Shen Y, 2012, NATURE, V488, P116, DOI 10.1038/nature11243; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Small EA, 2003, DEV BIOL, V261, P116, DOI 10.1016/S0012-1606(03)00306-3; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Szutorisz H, 2005, TRENDS BIOCHEM SCI, V30, P593, DOI 10.1016/j.tibs.2005.08.006; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; Vecchione C, 2002, CIRCULATION, V105, P1700, DOI 10.1161/01.CIR.0000012750.08480.55; Warren SA, 2011, MOL CELL BIOL, V31, P4633, DOI 10.1128/MCB.05940-11; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	38	9	9	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1870	1879		10.1096/fj.13-245522	http://dx.doi.org/10.1096/fj.13-245522			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24391132				2022-12-28	WOS:000335344300031
J	Armando, I; Villar, VM; Jones, JE; Lee, H; Wang, XY; Asico, LD; Yu, PY; Yang, J; Escano, CS; Pascua-Crusan, AM; Felder, RA; Jose, PA				Armando, Ines; Villar, Van Anthony M.; Jones, John E.; Lee, Hewang; Wang, Xiaoyan; Asico, Laureano D.; Yu, Peiying; Yang, Jian; Escano, Crisanto S., Jr.; Pascua-Crusan, Annabelle M.; Felder, Robin A.; Jose, Pedro A.			Dopamine D3 receptor inhibits the ubiquitin-specific peptidase 48 to promote NHE3 degradation	FASEB JOURNAL			English	Article						renal proximal tubule cells; kidney; blood pressure; C57Bl; 6 mice	NA+/H+ EXCHANGER NHE3; PROTEIN-COUPLED RECEPTOR; MEDIATED INHIBITION; ANGIOTENSIN-II; BLOOD-PRESSURE; HYPERTENSION; MECHANISMS; EXPRESSION; GENE; NATRIURESIS	The dopamine D-3 receptor (D3R) is crucial in the regulation of blood pressure and sodium balance, in that Drd3 gene ablation in mice results in hypertension and failure to excrete a dietary salt load. The mechanism responsible for the renal sodium retention in these mice is largely unknown. We now offer and describe a novel mechanism by which D3R decreases sodium transport in the long term by inhibiting the deubiquitinylating activity of ubiquitin-specific peptidase 48 (USP48), thereby promoting Na+-H+ exchanger (NHE)-3 degradation. We found that stimulation with the D3R-specific agonist PD128907 (1 M, 30 min) promoted the interaction and colocalization among D3R, NHE3, and USP48; inhibited USP48 activity (-35 +/- 6%, vs. vehicle), resulting in increased ubiquitinylated NHE3 (+140 +/- 10%); and decreased NHE3 expression (-50 +/- 9%) in human renal proximal tubule cells (hRPTCs). USP48 silencing decreased NHE3's half-life (USP48 siRNA t(1/2)=6.1 h vs. vehicle t(1/2)=12.9 h), whereas overexpression of USP48 increased NHE3 half-life (t(1/2)=21.8 h), indicating that USP48 protects NHE3 from degradation via deubiquitinylation. USP48 accounted for approximate to 30% of the total deubiquitinylating activity in these cells. Extending our studies in vivo, we found that pharmacologic blockade of D3R via the D3R-specific antagonist GR103691 (1 g/kg/min, 4 d) in C57Bl/6J mice increased renal NHE3 expression (+310 +/- 15%, vs. vehicle), whereas an innovative kidney-restricted Usp48 silencing via siRNA (3 g/d, 7 d) increased ubiquitinylated NHE3 (+250 +/- 30%, vs. controls), decreased total NHE3 (-23 +/- 2%), and lowered blood pressure (-24 +/- 2 mm Hg), compared with that in control mice that received either the vehicle or nonsilencing siRNA. Our data demonstrate a crucial role for the dynamic interaction between D3R and USP48 in the regulation of NHE3 expression and function.Armando, I., Villar, V. A. M., Jones J. E., Lee, H., Wang, X., Asico L. D., Yu, P., Yang, J., Escano, C. S. Jr., Pascua-Crusan, A. M., Felder, R. A., Jose, P. A. Dopamine D3 receptor inhibits the ubiquitin-specific peptidase 48 to promote NHE3 degradation.	[Armando, Ines; Villar, Van Anthony M.; Jones, John E.; Lee, Hewang; Wang, Xiaoyan; Asico, Laureano D.; Yu, Peiying; Yang, Jian; Escano, Crisanto S., Jr.; Pascua-Crusan, Annabelle M.; Jose, Pedro A.] Univ Maryland, Div Nephrol, Dept Med, Sch Med, Baltimore, MD 21201 USA; [Felder, Robin A.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA	University System of Maryland; University of Maryland Baltimore; University of Virginia	Villar, VM (corresponding author), Univ Maryland, Div Nephrol, Dept Med, Sch Med, 20 Penn St,HSF 2,Ste S003C, Baltimore, MD 21201 USA.	vvillar@medicine.umaryland.edu	Wang, Xiaoyan/GOK-1663-2022; Asico, Laureano/AAM-6321-2020	Wang, Xiaoyan/0000-0001-7406-5008; Lee, Hewang/0000-0003-1338-2573	U.S. National Institutes of Health [P01HL074940, P01HL068686, R01HL092196, R37HL023081, R01DK039308, R01DK090918]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068686, R01HL092196, P01HL074940, R01HL023081, R37HL023081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090918, R01DK039308] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by U.S. National Institutes of Health grants P01HL074940, P01HL068686, R01HL092196, R37HL023081, R01DK039308, and R01DK090918. The authors declare no conflicts of interest.	Asico LD, 1998, J CLIN INVEST, V102, P493, DOI 10.1172/JCI3685; Brismar H, 2000, CLIN EXP HYPERTENS, V22, P303, DOI 10.1081/CEH-100100079; Carey RM, 2001, HYPERTENSION, V38, P297, DOI 10.1161/hy0901.096422; CHEN CJ, 1992, CLIN EXP HYPERTENS A, V14, P615, DOI 10.3109/10641969209036211; Cuevas S, 2012, HYPERTENSION, V59, P446, DOI 10.1161/HYPERTENSIONAHA.111.185744; Day CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034923; Di Sole F, 2011, KIDNEY INT, V80, P822, DOI 10.1038/ki.2011.229; Donowitz M, 2007, PHYSIOL REV, V87, P825, DOI 10.1152/physrev.00030.2006; Felder RA, 2002, P NATL ACAD SCI USA, V99, P3872, DOI 10.1073/pnas.062694599; FELDER RA, 1990, HYPERTENSION, V15, P560, DOI 10.1161/01.HYP.15.6.560; Felder RA, 2006, NAT CLIN PRACT NEPHR, V2, P637, DOI 10.1038/ncpneph0301; Fernandez-Montalvan A, 2007, FEBS J, V274, P4256, DOI 10.1111/j.1742-4658.2007.05952.x; Flegelova H, 2006, BBA-GEN SUBJECTS, V1760, P504, DOI 10.1016/j.bbagen.2006.01.014; Gomes P, 2002, AM J PHYSIOL-RENAL, V283, pF114, DOI 10.1152/ajprenal.00244.2001; Harris RC, 2012, CURR OPIN NEPHROL HY, V21, P61, DOI 10.1097/MNH.0b013e32834de2cb; Hu MC, 2013, AM J PHYSIOL-RENAL, V304, pF1169, DOI 10.1152/ajprenal.00630.2012; Hussain T, 2003, EXP BIOL MED, V228, P134, DOI 10.1177/153537020322800202; Jose PA, 1998, PHARMACOL THERAPEUT, V80, P149, DOI 10.1016/S0163-7258(98)00027-8; KANEKO S, 1990, J AUTON PHARMACOL, V10, pS53, DOI 10.1111/j.1474-8673.1990.tb00228.x; KANEKO S, 1992, AM J PHYSIOL, V263, pR631, DOI 10.1152/ajpregu.1992.263.3.R631; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kessler BM, 2011, CELL BIOCHEM BIOPHYS, V60, P21, DOI 10.1007/s12013-011-9176-6; Klisic J, 2002, AM J PHYSIOL-RENAL, V283, pF532, DOI 10.1152/ajprenal.00365.2001; Ladasky JJ, 2006, J IMMUNOL, V177, P6172, DOI 10.4049/jimmunol.177.9.6172; Ladines CA, 2001, AM J PHYSIOL-REG I, V281, pR1071, DOI 10.1152/ajpregu.2001.281.4.R1071; Li HW, 2008, J CLIN INVEST, V118, P2180, DOI 10.1172/JCI33637; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Lockhart PJ, 2004, DNA SEQUENCE, V15, P9, DOI 10.1080/10855660310001638197; Luippold G, 1998, N-S ARCH PHARMACOL, V358, P690, DOI 10.1007/PL00005314; Luippold G, 2001, J AM SOC NEPHROL, V12, P2272, DOI 10.1681/ASN.V12112272; McDonough AA, 2010, AM J PHYSIOL-REG I, V298, pR851, DOI 10.1152/ajpregu.00002.2010; Mikhalyov I, 2011, BBA-BIOMEMBRANES, V1808, P1930, DOI 10.1016/j.bbamem.2011.04.002; Moe OW, 1997, CURR OPIN NEPHROL HY, V6, P440, DOI 10.1097/00041552-199709000-00006; Morales Patricio, 2007, Soc Reprod Fertil Suppl, V65, P269; Murtazina R, 2006, J BIOL CHEM, V281, P17845, DOI 10.1074/jbc.M601740200; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Nogueira C, 2008, AM J PHYSIOL-RENAL, V294, pF1232, DOI 10.1152/ajprenal.00025.2007; Ortiz PA, 2001, HYPERTENSION, V38, P621, DOI 10.1161/hy09t1.093361; Pedrosa R, 2004, AM J PHYSIOL-RENAL, V287, pF1059, DOI 10.1152/ajprenal.00139.2004; Pedrosa R, 2004, BRIT J PHARMACOL, V142, P1343, DOI 10.1038/sj.bjp.0705893; Queiroz-Leite GD, 2011, BIOCHEM BIOPH RES CO, V409, P470, DOI 10.1016/j.bbrc.2011.05.028; Quesada V, 2004, BIOCHEM BIOPH RES CO, V314, P54, DOI 10.1016/j.bbrc.2003.12.050; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Sibley DR, 1999, ANNU REV PHARMACOL, V39, P313, DOI 10.1146/annurev.pharmtox.39.1.313; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Ueda A, 2003, AM J HYPERTENS, V16, P853, DOI 10.1016/S0895-7061(03)01013-6; Villar VAM, 2013, FASEB J, V27, P1808, DOI 10.1096/fj.12-208439; Villar VM, 2013, J BIOL CHEM, V288, P152, DOI 10.1074/jbc.M112.428458; Villar VM, 2009, J BIOL CHEM, V284, P21425, DOI 10.1074/jbc.M109.003665; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Yang ZW, 2006, AM J PHYSIOL-REG I, V290, pR96, DOI 10.1152/ajpregu.00434.2005; Yao T, 2008, MOL CELL, V31, P909, DOI 10.1016/j.molcel.2008.08.027; Yu Peiying, 2013, Methods Mol Biol, V964, P15, DOI 10.1007/978-1-62703-251-3_2; Zeng CY, 2008, KIDNEY INT, V74, P750, DOI 10.1038/ki.2008.247; Zeng CY, 2008, AM J PHYSIOL-HEART C, V294, pH551, DOI 10.1152/ajpheart.01036.2007; Zeng CY, 2006, CURR HYPERTENS REV, V2, P247, DOI 10.2174/157340206778132563; Zeng CY, 2006, CIRC RES, V99, P494, DOI 10.1161/01.RES.0000240500.96746.ec; Zhang YR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038745	59	16	16	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1422	1434		10.1096/fj.13-243840	http://dx.doi.org/10.1096/fj.13-243840			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24308971	Green Published			2022-12-28	WOS:000335324800033
J	Lee, KL; Hoey, DA; Spasic, M; Tang, T; Hammond, HK; Jacobs, CR				Lee, Kristen L.; Hoey, David A.; Spasic, Milos; Tang, Tong; Hammond, H. Kirk; Jacobs, Christopher R.			Adenylyl cyclase 6 mediates loading-induced bone adaptation in vivo	FASEB JOURNAL			English	Article						mechanotransduction; mechanical loading; fluid flow	PRIMARY CILIA; OSTEOBLAST DIFFERENTIATION; FLUID-FLOW; INTRACELLULAR CALCIUM; PARATHYROID-HORMONE; PRIMARY OSTEOCYTES; MECHANICAL-STRESS; SIGNALING PATHWAY; INTERMITTENT PTH; MC3T3-E1 CELLS	Primary cilia are single, nonmotile, antenna-like structures extending from the apical membrane of most mammalian cells. They may mediate mechanotransduction, the conversion of external mechanical stimuli into biochemical intracellular signals. Previously we demonstrated that adenylyl cyclase 6 (AC6), a membrane-bound enzyme enriched in primary cilia of MLO-Y4 osteocyte-like cells, may play a role in a primary cilium-dependent mechanism of osteocyte mechanotransduction in vitro. In this study, we determined whether AC6 deletion impairs loading-induced bone formation in vivo. Skeletally mature mice with a global knockout of AC6 exhibited normal bone morphology and responded to osteogenic chemical stimuli similar to wild-type mice. Following ulnar loading over 3 consecutive days, bone formation parameters were assessed using dynamic histomorphometry. Mice lacking AC6 formed significantly less bone than control animals (41% lower bone formation rate). Furthermore, there was an attenuated flow-induced increase in COX-2 mRNA expression levels in primary bone cells isolated from AC6 knockout mice compared to controls (1.3 +/- 0.1- vs. 2.6 +/- 0.2-fold increase). Collectively, these data indicate that AC6 plays a role in loading-induced bone adaptation, and these findings are consistent with our previous studies implicating primary cilia and AC6 in a novel mechanism of osteocyte mechanotransduction.Lee, K. L., Hoey, D. A., Spasic, M., Tang, T., Hammond, H. K., Jacobs, C. R. Adenylyl cyclase 6 mediates loading-induced bone adaptation in vivo.	[Lee, Kristen L.; Hoey, David A.; Spasic, Milos; Jacobs, Christopher R.] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Hoey, David A.] Royal Coll Surgeons Ireland, Dept Anat, Dublin 2, Ireland; [Hoey, David A.] Univ Limerick, Dept Mech Aeronaut & Biomed Engn, Ctr Appl Biomed Engn Res, Mat & Surface Sci Inst, Limerick, Ireland; [Spasic, Milos] Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA; [Tang, Tong; Hammond, H. Kirk] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Tang, Tong; Hammond, H. Kirk] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	Columbia University; Royal College of Surgeons - Ireland; University of Limerick; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Jacobs, CR (corresponding author), Columbia Univ, 351 Engn Terr,1210 Amsterdam Ave,Mail Code 8904, New York, NY 10027 USA.	crj2111@columbia.edu	Hoey, David/X-9231-2019; Hoey, David/A-7587-2012	Hoey, David/0000-0001-5898-0409	U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health [AR054156, AR062177, 5P01HL066941, HL081741, HL088426]; American Heart Association [11GRNT7610059]; National Science Foundation [GRFP 0707425]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088426, P01HL066941, R01HL081741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR054156, R01AR062177] Funding Source: NIH RePORTER	U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health; American Heart Association(American Heart Association); National Science Foundation(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank J. Christopher Fritton, Alesha B. Castillo, Sara Temiyasathit, and Ron Kwon for valuable discussions; Julia C. Chen and An M. Nguyen for technical assistance and helpful input; and Bin Zhou and Ji Wang for conducting microCT imaging and analyses. This publication was made possible by grants from the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health (AR054156 and AR062177, to C.R.J.; 5P01HL066941, HL081741, and HL088426, to H.K.H.), the American Heart Association (grant-in-aid 11GRNT7610059 to T.T.), and the National Science Foundation (GRFP 0707425 to K.L.L.).	Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Cheng SL, 2001, CALCIFIED TISSUE INT, V68, P87, DOI 10.1007/BF02678146; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003; Elis S, 2010, J BONE MINER RES, V25, P2051, DOI 10.1002/jbmr.100; Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004-1282; Gu GL, 2006, CELL TISSUE RES, V323, P263, DOI 10.1007/s00441-005-0066-3; Guillou JL, 1999, J BIOL CHEM, V274, P35539, DOI 10.1074/jbc.274.50.35539; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Husse B, 2010, HEART INT, V5, P10, DOI 10.4081/hi.2010.e3; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev-bioeng-070909-105302; Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017; Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037; Jin XJ, 2014, CELL MOL LIFE SCI, V71, P2165, DOI 10.1007/s00018-013-1483-1; Kaiser E, 2003, BIOCHEM BIOPH RES CO, V305, P573, DOI 10.1016/S0006-291X(03)00820-9; Klein-Nulend J, 2007, CLIN REV BONE MINER, V5, P195, DOI 10.1007/s12018-008-9014-6; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; Kotttgen M, 2008, J CELL BIOL, V182, P437, DOI 10.1083/jcb.200805124; Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09-148007; Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013; Lee KCL, 2002, BONE, V31, P407, DOI 10.1016/S8756-3282(02)00842-6; Lee KL, 2010, CLIN REV BONE MINER, V8, P201, DOI 10.1007/s12018-010-9078-y; Liedert A, 2006, BIOCHEM BIOPH RES CO, V349, P1, DOI 10.1016/j.bbrc.2006.07.214; Litzenberger JB, 2009, CELL MOL BIOENG, V2, P416, DOI 10.1007/s12195-009-0068-4; Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104; Masi L, 2005, J Endocrinol Invest, V28, P37; Masyuk AI, 2008, AM J PHYSIOL-GASTR L, V295, pG725, DOI 10.1152/ajpgi.90265.2008; Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200; McGlashan SR, 2010, CELL BIOL INT, V34, P441, DOI 10.1042/CBI20090094; Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706; Mullender M, 2004, MED BIOL ENG COMPUT, V42, P14, DOI 10.1007/BF02351006; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560-6568.2004; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232-002-1042-4; Qiu N, 2012, J CELL SCI, V125, P1945, DOI 10.1242/jcs.095893; Sabsovich I, 2008, BONE, V42, P439, DOI 10.1016/j.bone.2007.09.041; Salih E, 1996, J BONE MINER RES, V11, P1461; Saunders MM, 2001, AM J PHYSIOL-CELL PH, V281, pC1917, DOI 10.1152/ajpcell.2001.281.6.C1917; Schmidt C, 1997, EUR J CELL BIOL, V72, P191; Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876; Su S, 2013, NAT METHODS, V10, P1105, DOI [10.1038/NMETH.2647, 10.1038/nmeth.2647]; Tang T, 2008, CIRCULATION, V117, P61, DOI 10.1161/CIRCULATIONAHA.107.730069; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; Temiyasathit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033368; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; Tuson M, 2011, DEVELOPMENT, V138, P4921, DOI 10.1242/dev.070805; Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006-291X(02)02124-1; Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104; Wann AKT, 2012, FASEB J, V26, P1663, DOI 10.1096/fj.11-193649; Werthmann RC, 2009, J PHYSIOL-LONDON, V587, P4091, DOI 10.1113/jphysiol.2009.172957; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; Willoughby D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002299; Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; You LD, 2001, J BIOMECH, V34, P1375, DOI 10.1016/S0021-9290(01)00107-5	59	27	30	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1157	1165		10.1096/fj.13-240432	http://dx.doi.org/10.1096/fj.13-240432			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24277577	Green Published			2022-12-28	WOS:000335324800012
J	Gholami, S; Chen, CH; Lou, E; Belin, LJ; Fujisawa, S; Longo, VA; Chen, NG; Gonen, M; Zanzonico, PB; Szalay, AA; Fong, YM				Gholami, Sepideh; Chen, Chun-Hao; Lou, Emil; Belin, Laurence J.; Fujisawa, Sho; Longo, Valerie A.; Chen, Nanhai G.; Goenen, Mithat; Zanzonico, Pat B.; Szalay, Aladar A.; Fong, Yuman			Vaccinia virus GLV-1h153 in combination with I-131 shows increased efficiency in treating triple-negative breast cancer	FASEB JOURNAL			English	Article						symporter; radiation therapy	SODIUM-IODIDE SYMPORTER; DIFFERENTIATED THYROID-CARCINOMA; RADIOIODINE THERAPY; GENE-EXPRESSION; BONE METASTASES; NUDE-MICE; IN-VITRO; PAPILLARY; AGENT; LUNG	We investigated the therapeutic efficacy of a replication-competent oncolytic vaccinia virus, GLV-1h153, carrying human sodium iodide symporter (hNIS), in combination with radioiodine in an orthotopic triple-negative breast cancer (TNBC) murine model. In vitro viral infection was confirmed by immunoblotting and radioiodine uptake assays. Orthotopic xenografts (MDA-MB-231 cells) received intratumoral injection of GLV-1h153 or PBS. One week after viral injection, xenografts were randomized into 4 treatment groups: GLV-1h153 alone, GLV-1h153 and I-131 (approximate to 5 mCi), I-131 alone, or PBS, and followed for tumor growth. Kruskal-Wallis and Wilcoxon tests were performed for statistical analysis. Radiouptake assay showed a 178-fold increase of radioiodine uptake in hNIS-expressing infected cells compared with PBS control. Systemic I-131-iodide in combination with GLV-1h153 resulted in a 6-fold increase in tumor regression (24 compared to 146 mm(3) for the virus-only treatment group; P<0.05; d 40). We demonstrated that a novel vaccinia virus, GLV-1h153, expresses hNIS, increases the expression of the symporter in TNBC cells, and serves both as a gene marker for noninvasive imaging of virus and as a vehicle for targeted radionuclide therapy with I-131.Gholami, S., Chen, C-H., Lou, E., Belin, L. J., Fujisawa, S., Longo, V. A. Chen, N. G., Gonen, M., Zanzonico, P. B., Szalay, A. A., Fong, Y. Vaccinia virus GLV-1h153 in combination with I-131 shows increased efficiency in treating triple-negative breast cancer.	[Gholami, Sepideh; Chen, Chun-Hao; Belin, Laurence J.; Fong, Yuman] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Fujisawa, Sho] Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10065 USA; [Longo, Valerie A.] Mem Sloan Kettering Canc Ctr, Small Anim Imaging Core Facil, New York, NY 10065 USA; [Goenen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Zanzonico, Pat B.] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10065 USA; [Zanzonico, Pat B.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA; [Lou, Emil] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; [Chen, Nanhai G.; Szalay, Aladar A.] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, Dept Radiat Oncol, San Diego, CA 92103 USA; [Chen, Nanhai G.; Szalay, Aladar A.] Genelux Corp, San Diego, CA USA; [Szalay, Aladar A.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97070 Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Dept Biochem, D-97070 Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Inst Mol Infect Biol, D-97070 Wurzburg, Germany	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego; University of Wurzburg; University of Wurzburg; University of Wurzburg	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.	Fongy@mskcc.org	Gonen, Mithat/E-4826-2012	Gonen, Mithat/0000-0001-8683-8477; Lou, Emil/0000-0002-1607-1386	William H. and Alice Goodwin; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center; Flight Attendant's Medical Research Institute (FAMRI); Cycle for Survival; NATIONAL CANCER INSTITUTE [T32CA009501] Funding Source: NIH RePORTER	William H. and Alice Goodwin; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center; Flight Attendant's Medical Research Institute (FAMRI); Cycle for Survival; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Jason Aguilar and Mesruh Turkekul for their excellent technical assistance. Technical services provided by the Research Animal Resource Center (RARC), the Molecular Cytology facilities, and the Small-Animal Imaging Core facilities at Memorial Sloan-Kettering Cancer Center are gratefully acknowledged. This work is supported by the William H. and Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center, the Flight Attendant's Medical Research Institute (FAMRI), and Cycle for Survival.	ALLWEISS P, 1984, J NUCL MED, V25, P755; Barton KN, 2011, MOL THER, V19, P1353, DOI 10.1038/mt.2011.89; BITTON R, 1993, J CLIN ENDOCR METAB, V77, P1423, DOI 10.1210/jc.77.5.1423; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Farina G P, 2000, G Chir, V21, P469; Gentschev I, 2009, CANCER GENE THER, V16, P320, DOI 10.1038/cgt.2008.87; Gholami S, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3404; Gholami S, 2012, ANN SURG, V256, P437, DOI 10.1097/SLA.0b013e3182654572; Gholami S, 2011, SURGERY, V150, P1040, DOI 10.1016/j.surg.2011.09.010; Haddad D, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-36; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; Kelly KJ, 2008, HUM GENE THER, V19, P774, DOI 10.1089/hum.2008.036; Kelly KJ, 2009, INT J CANCER, V124, P911, DOI 10.1002/ijc.24037; Lee YJ, 2004, THYROID, V14, P889; Lin SF, 2007, SURGERY, V142, P976, DOI 10.1016/j.surg.2007.09.017; Lin SF, 2008, J CLIN ENDOCR METAB, V93, P4403, DOI 10.1210/jc.2008-0316; MAXON HR, 1990, ENDOCRIN METAB CLIN, V19, P685, DOI 10.1016/S0889-8529(18)30317-7; Mazzaferri EL, 2001, J CLIN ENDOCR METAB, V86, P1447, DOI 10.1210/jc.86.4.1447; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; Mazzaferri EL, 1997, THYROID, V7, P265, DOI 10.1089/thy.1997.7.265; Rajecki M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032871; Renier C, 2009, ANN SURG ONCOL, V16, P962, DOI 10.1245/s10434-008-0280-9; Robbins RJ, 2005, J NUCL MED, V46, p28S; SAMAAN NA, 1985, J CLIN ENDOCR METAB, V60, P376, DOI 10.1210/jcem-60-2-376; SCHLUMBERGER M, 1986, J CLIN ENDOCR METAB, V63, P960; Schlumberger M, 1996, J NUCL MED, V37, P598; SHERMAN SI, 1994, J CLIN ENDOCR METAB, V78, P629, DOI 10.1210/jc.78.3.629; Spitzweg C, 1998, J CLIN ENDOCR METAB, V83, P1746, DOI 10.1210/jc.83.5.1746; Spitzweg C, 2007, HUM GENE THER, V18, P916, DOI 10.1089/hum.2007.081; SWEENEY DC, 1995, ENDOCRIN METAB CLIN, V24, P803, DOI 10.1016/S0889-8529(18)30022-7; U.S. National Institutes of Health, 2008, SAF STUD GL ONC1 ONC; VANNOSTRAND D, 1986, J NUCL MED, V27, P1519; Wapnir IL, 2003, J CLIN ENDOCR METAB, V88, P1880, DOI 10.1210/jc.2002-021544; Yu YA, 2009, MOL CANCER THER, V8, P141, DOI 10.1158/1535-7163.MCT-08-0533; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146	35	24	25	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					676	682		10.1096/fj.13-237222	http://dx.doi.org/10.1096/fj.13-237222			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24186964	Green Published			2022-12-28	WOS:000331072200015
J	Ma, X; Pietsch, J; Wehland, M; Schulz, H; Saar, K; Hubner, N; Bauer, J; Braun, M; Schwarzwalder, A; Segerer, J; Birlem, M; Horn, A; Hemmersbach, R; Wasser, K; Grosse, J; Infanger, M; Grimm, D				Ma, Xiao; Pietsch, Jessica; Wehland, Markus; Schulz, Herbert; Saar, Katrin; Huebner, Norbert; Bauer, Johann; Braun, Markus; Schwarzwaelder, Achim; Segerer, Juergen; Birlem, Maria; Horn, Astrid; Hemmersbach, Ruth; Wasser, Kai; Grosse, Jirka; Infanger, Manfred; Grimm, Daniela			Differential gene expression profile and altered cytokine secretion of thyroid cancer cells in space	FASEB JOURNAL			English	Article						growth factors; microgravity; protein kinases; extracellular matrix	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; SIMULATED MICROGRAVITY; CARCINOMA CELLS; EXTRACELLULAR-MATRIX; ANTITUMOR-ACTIVITY; BIOLOGICAL FUNCTIONS; INCREASES APOPTOSIS; TISSUE INHIBITORS; HUMAN-LYMPHOCYTES	This study focuses on the effects of short-term [22 s, parabolic flight campaign (PFC)] and long-term (10 d, Shenzhou 8 space mission) real microgravity on changes in cytokine secretion and gene expression patterns in poorly differentiated thyroid cancer cells. FTC-133 cells were cultured in space and on a random positioning machine (RPM) for 10 d, to evaluate differences between real and simulated microgravity. Multianalyte profiling was used to evaluate 128 secreted cytokines. Microarray analysis revealed 63 significantly regulated transcripts after 22 s of microgravity during a PFC and 2881 after 10 d on the RPM or in space. Genes in several biological processes, including apoptosis (n=182), cytoskeleton (n=80), adhesion/extracellular matrix (n=98), proliferation (n=184), stress response (n=268), migration (n=63), angiogenesis (n=39), and signal transduction (n=429), were differentially expressed. Genes and proteins involved in the regulation of cancer cell proliferation and metastasis, such as IL6, IL8, IL15, OPN, VEGFA, VEGFD, FGF17, MMP2, MMP3, TIMP1, PRKAA, and PRKACA, were similarly regulated under RPM and spaceflight conditions. The resulting effect was mostly antiproliferative. Gene expression during the PFC was often regulated in the opposite direction. In summary, microgravity is an invaluable tool for exploring new targets in anticancer therapy and can be simulated in some aspects in ground-based facilities.Ma, X., Pietsch, J., Wehland, M., Schulz, H., Saar, K., Hubner, N., Bauer, J., Braun, M., Schwarzwalder, A., Segerer, J., Birlem, M., Horn, A., Hemmersbach, R., Wa ss er, K., Grosse, J., Infanger, M., Grimm, D. Differential gene expression profile and altered cytokine secretion of thyroid cancer cells in space.	[Ma, Xiao; Grosse, Jirka; Grimm, Daniela] Aarhus Univ, Inst Biomed, Dept Pharmacol, DK-8000 Aarhus C, Denmark; [Pietsch, Jessica; Wehland, Markus; Infanger, Manfred] Univ Magdeburg, Clin Plast Aesthet & Hand Surg, D-39106 Magdeburg, Germany; [Schulz, Herbert; Saar, Katrin; Huebner, Norbert] Max Delbruck Ctr Mol Med, Berlin, Germany; [Bauer, Johann] Max Planck Inst Biochem, D-82152 Martinsried, Germany; [Braun, Markus] Univ Bonn, Inst Mol Physiol & Biotechnol Plants IMBIO, Gravitat Biol Grp, Bonn, Germany; [Schwarzwaelder, Achim; Segerer, Juergen; Birlem, Maria; Horn, Astrid] Astrium European Aeronaut Def & Space EADS, Immenstaad, Germany; [Hemmersbach, Ruth; Wasser, Kai] Deutsch Zentrum Luft & Raumfahrt DLR, Inst Aerosp Med, Cologne, Germany; [Grosse, Jirka] Univ Regensburg, Dept Nucl Med, D-93053 Regensburg, Germany	Aarhus University; Otto von Guericke University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; University of Bonn; Airbus; Helmholtz Association; German Aerospace Centre (DLR); University of Regensburg	Grimm, D (corresponding author), Aarhus Univ, Inst Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus C, Denmark.	daniela.grimm@farm.au.dk		Wehland, Markus/0000-0002-8160-859X; Grimm, Daniela/0000-0002-4991-3105; Saar, Kathrin/0000-0002-4483-1557	DLR [Bundesministerium fur Wirtschaft und Technologie (BMWi)] [50WB0824, 50WB1124]; Aarhus University (Aarhus, Denmark)	DLR [Bundesministerium fur Wirtschaft und Technologie (BMWi)]; Aarhus University (Aarhus, Denmark)	The authors thank Heidi Skou Knudsen for excellent technical assistance and Associate Professor Chun Yang (Tsinghua University, Beijing, China) for providing laboratory facilities and help during preparation for the space mission. The authors especially thank the Chinese Manned Space Engineering Office (CMSEO) and Professor Gunter Ruyters and Dr. Peter Preu [Deutsches Zentrum fur Luft- und Raumfahrt (DLR) Administration, Bonn, Germany] for providing the opportunity to participate in the Shenzhou 8 mission. This study was supported by the DLR [Bundesministerium fur Wirtschaft und Technologie (BMWi) grants 50WB0824 and 50WB1124; D. G.] and Aarhus University (Aarhus, Denmark; D. G.). The authors thank the team of PRS & EJE (Letchworth Garden City, UK) for academic proofreading of the manuscript.	Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Antonelli A, 2009, ENDOCR-RELAT CANCER, V16, P1299, DOI 10.1677/ERC-08-0337; Bailey CM, 2006, J CELL PHYSIOL, V209, P617, DOI 10.1002/jcp.20782; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Basak GW, 2008, ONCOL REP, V19, P1173; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Belbin TJ, 2005, ARCH OTOLARYNGOL, V131, P10, DOI 10.1001/archotol.131.1.10; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boonyaratanakornkit JB, 2005, FASEB J, V19, P2020, DOI 10.1096/fj.05-3778fje; Borst AG, 2009, MICROGRAVITY SCI TEC, V21, P287, DOI 10.1007/s12217-008-9043-2; Briese J, 2010, ANTICANCER RES, V30, P1681; Castellone MD, 2004, ONCOGENE, V23, P2188, DOI 10.1038/sj.onc.1207322; Chakraborty S, 2012, BBA-REV CANCER, V1826, P129, DOI 10.1016/j.bbcan.2012.03.008; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Cui YZ, 2009, INT J CANCER, V124, P1614, DOI 10.1002/ijc.24163; DAVIES DL, 1979, IEEE T PATTERN ANAL, V1, P224, DOI 10.1109/TPAMI.1979.4766909; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Elliott BE, 2005, BREAST CANCER RES, V7, pR365, DOI 10.1186/bcr1006; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gauglhofer C, 2011, HEPATOLOGY, V53, P854, DOI 10.1002/hep.24099; Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945-053X(00)00108-6; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Goretzki P E, 1990, Recent Results Cancer Res, V118, P48; Grenon SM, 2013, SCI REP-UK, V3, DOI 10.1038/srep01494; Griffoni C, 2011, J CELL BIOCHEM, V112, P265, DOI 10.1002/jcb.22921; Grimm D, 2002, FASEB J, V16, P604, DOI 10.1096/fj.01-0673fje; Grimm D, 2011, EXPERT REV PROTEOMIC, V8, P13, DOI 10.1586/EPR.10.105; Grimm D, 2010, TISSUE ENG PT A, V16, P1559, DOI [10.1089/ten.tea.2009.0524, 10.1089/ten.TEA.2009.0524]; Grimm D, 2009, CURR VASC PHARMACOL, V7, P347, DOI 10.2174/157016109788340640; Grimm D, 2009, TISSUE ENG PT A, V15, P2267, DOI 10.1089/ten.tea.2008.0576; Grosse J, 2013, CELL PHYSIOL BIOCHEM, V32, P154, DOI 10.1159/000350132; Grosse J, 2012, FASEB J, V26, P5124, DOI 10.1096/fj.12-215749; Grosse J, 2012, FASEB J, V26, P639, DOI 10.1096/fj.11-194886; Guarino V, 2005, J CLIN ENDOCR METAB, V90, P5270, DOI 10.1210/jc.2005-0271; Heer R, 2004, J PATHOL, V204, P578, DOI 10.1002/path.1668; Hoelting T, 1997, CANCER LETT, V119, P1, DOI 10.1016/S0304-3835(97)00242-5; Hsueh C, 2011, J SURG ONCOL, V103, P395, DOI 10.1002/jso.21844; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hughes-Fulford M, 2011, FASEB J, V25, P2858, DOI 10.1096/fj.11-0902ufm; Huigsloot M, 2011, AM J HUM GENET, V88, P488, DOI 10.1016/j.ajhg.2011.03.002; Infanger M, 2005, J VASC RES, V42, P202, DOI 10.1159/000085176; Infanger M, 2004, BURNS, V30, P305, DOI 10.1016/j.burns.2003.12.006; Infanger M, 2008, ANN VASC SURG, V22, P273, DOI 10.1016/j.avsg.2007.11.002; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kimura K, 2000, CANCER IMMUNOL IMMUN, V49, P71, DOI 10.1007/s002620050604; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Kossmehl P, 2006, APOPTOSIS, V11, P347, DOI 10.1007/s10495-006-4350-9; Kossmehl P, 2003, ENDOCRINOLOGY, V144, P4172, DOI 10.1210/en.2002-0171; Kraiem Z, 2000, THYROID, V10, P1061, DOI 10.1089/thy.2000.10.1061; Lannetti A, 2008, P NATL ACAD SCI USA, V105, P14058, DOI 10.1073/pnas.0710846105; LaPorta CAM, 1997, CLIN EXP METASTAS, V15, P568, DOI 10.1023/A:1018447531813; Lee YY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.76; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levina V, 2009, CLIN CANCER RES, V15, P2647, DOI 10.1158/1078-0432.CCR-08-2024; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007; Maccarrone M, 2003, J LEUKOCYTE BIOL, V73, P472, DOI 10.1189/jlb.0602295; Marastoni S, 2008, CONNECT TISSUE RES, V49, P203, DOI 10.1080/03008200802143190; Maruoka Y, 1998, MECH DEVELOP, V74, P175, DOI 10.1016/S0925-4773(98)00061-6; Mori M, 2006, J CLIN INVEST, V116, P395, DOI 10.1172/JCI20797; Murooka TT, 2005, CANC TREAT, V126, P15, DOI 10.1007/0-387-24361-5_2; Nersita R, 2012, CLIN ENDOCRINOL, V76, P142, DOI 10.1111/j.1365-2265.2011.04183.x; Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562; Ornitz DM, 2001, GENOME BIOL, V2; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Pietsch J, 2011, CURR MOL MED, V11, P350, DOI 10.2174/156652411795976600; Pietsch J, 2013, BIOMATERIALS, V34, P7694, DOI 10.1016/j.biomaterials.2013.06.054; Pietsch J, 2010, PROTEOMICS, V10, P904, DOI 10.1002/pmic.200900226; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Rollins BJ, 2006, EUR J CANCER, V42, P760, DOI 10.1016/j.ejca.2006.01.002; Rothermund L, 2002, AM J HYPERTENS, V15, P644, DOI 10.1016/S0895-7061(02)02956-4; Sarrio D, 2006, BREAST CANCER RES TR, V98, P71, DOI 10.1007/s10549-005-9133-4; Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442; Ulbrich C, 2008, J CELL BIOCHEM, V104, P1324, DOI 10.1002/jcb.21710; Ulbrich C, 2011, CELL PHYSIOL BIOCHEM, V28, P185, DOI 10.1159/000331730; Ulbrich C, 2010, CELL PHYSIOL BIOCHEM, V25, P551, DOI 10.1159/000303059; Uva BM, 2002, EUR J HISTOCHEM, V46, P209; van Loon JJWA, 2007, ADV SPACE RES, V39, P1161, DOI 10.1016/j.asr.2007.02.016; Villagra A, 2007, J BIOL CHEM, V282, P35457, DOI 10.1074/jbc.M701719200; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Volpe V, 2013, J CLIN ENDOCR METAB, V98, P228, DOI 10.1210/jc.2012-2528; Wehland M, 2013, CELL PHYSIOL BIOCHEM, V31, P432, DOI 10.1159/000343380; White RJ, 2001, NATURE, V409, P1115, DOI 10.1038/35059243; Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xu JS, 2000, DEVELOPMENT, V127, P1833; Xu JS, 1999, MECH DEVELOP, V83, P165, DOI 10.1016/S0925-4773(99)00034-9; Yu P, 2010, CLIN CANCER RES, V16, P6019, DOI 10.1158/1078-0432.CCR-10-1966; Zeng J, 2012, COMB CHEM HIGH T SCR, V15, P276, DOI 10.2174/138620712799218608; Zhang ML, 2009, P NATL ACAD SCI USA, V106, P7513, DOI 10.1073/pnas.0902637106; Zhu AX, 2009, J CLIN ONCOL, V27, P3027, DOI 10.1200/JCO.2008.20.9908; Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	98	97	97	4	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					813	835		10.1096/fj.13-243287	http://dx.doi.org/10.1096/fj.13-243287			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24196587				2022-12-28	WOS:000331072200028
J	Ortica, S; Tarantino, N; Aulner, N; Israel, A; Gupta-Rossi, N				Ortica, Sara; Tarantino, Nadine; Aulner, Nathalie; Israel, Alain; Gupta-Rossi, Neetu			The 4 Notch receptors play distinct and antagonistic roles in the proliferation and hepatocytic differentiation of liver progenitors	FASEB JOURNAL			English	Article						CDK inhibitors; hepatoblasts; polyploidy; paralogs; bipotential stem cells	HUMAN HEPATOCELLULAR-CARCINOMA; BILE-DUCT DEVELOPMENT; ALAGILLE-SYNDROME; CELL LINES; HUMAN HOMOLOG; HUMAN JAGGED1; KINASE 1; MUTATIONS; TRANSCRIPTION; HYPERPLASIA	The Notch signaling pathway is involved in liver development and regeneration. Here, we investigate the role of the 4 mammalian Notch paralogs in the regulation of hepatoblast proliferation and hepatocytic differentiation. Our model is based on bipotential mouse embryonic liver (BMEL) progenitors that can differentiate into hepatocytes or cholangiocytes in vitro and in vivo. BMEL cells were subjected to Notch antagonists or agonists. Blocking Notch activation with a -secretase inhibitor, at 50 M for 48 h, reduced cell growth by 50%. S-phase entry was impaired, but no apoptosis was induced. A systematic paralog-specific strategy was set using lentiviral transduction with constitutively active forms of each Notch receptor along with inhibition of endogenous Notch signaling. This assay demonstrates that proliferation of BMEL cells requires Notch2 and Notch4 activity, resulting in significant down-regulation of p27(Kip1) and p57(Kip2) cyclin-dependent kinase inhibitors. Conversely, Notch3-expressing cells proliferate less and express 3-fold higher levels of p57(Kip2). The Notch3 cells present a hepatocyte-like morphology, enhanced multinucleation, and a ploidy shift. Moreover, Notch3 activity is conducive to hepatocytic differentiation in vitro, while its paralogs impede this fate. Our study provides the first evidence of a functional diversity among the mammalian Notch homologues in the proliferation and hepatocytic-lineage commitment of liver progenitors.Ortica, S., Tarantino, N., Aulner, N., Israel, A., Gupta-Rossi, N. The 4 Notch receptors play distinct and antagonistic roles in the proliferation and hepatocytic differentiation of liver progenitors.	[Ortica, Sara; Tarantino, Nadine; Israel, Alain; Gupta-Rossi, Neetu] Inst Pasteur, CNRS, Unite Rech Associee URA 2582, Unite Signalisat Mol & Activat Cellulaire, F-75724 Paris 15, France; [Aulner, Nathalie] Inst Pasteur, Imagopole, F-75724 Paris 15, France; [Ortica, Sara] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Gupta-Rossi, N (corresponding author), Inst Pasteur, CNRS, URA 2582, Unite Signalisat Mol & Activat Cellulaire, 25 Rue Dr Roux, F-75724 Paris 15, France.	neetu.gupta@pasteur.fr	Gupta-Rossi, Neetu/AAE-3117-2022	Gupta-Rossi, Neetu/0000-0003-0043-264X	French National Research Agency [ANR 10-INSB-04-01]; Soutien aux Equipes Scientifiques pour l'Acquisition de Moyens Experimentaux (SESAME); Conseil de la Region Ile-de-France; Fondation pour la Recherche Medicale (FRM); Domaine d'Interet Majeur (DIM)-Stem Cells and Cell Therapy (STEM)-Pole (Ile-de-France); U.S. National Institute of Child Health and Human Development; University of Iowa (Iowa City, IA, USA)	French National Research Agency(French National Research Agency (ANR)); Soutien aux Equipes Scientifiques pour l'Acquisition de Moyens Experimentaux (SESAME); Conseil de la Region Ile-de-France(Region Ile-de-France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Domaine d'Interet Majeur (DIM)-Stem Cells and Cell Therapy (STEM)-Pole (Ile-de-France)(Region Ile-de-France); U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); University of Iowa (Iowa City, IA, USA)	The authors thank Mary Weiss and Helene Strick-Marchand (Institut Pasteur, Paris, France) for the kind gift of bipotential mouse embryonic liver cells and helpful discussions. The authors are grateful to M. Bocchetta (Loyola University Medical Center, Chicago, IL, USA), I. Screpanti (Sapienza University of Rome, Rome, Italy), J. Kitajewski (Columbia University Medical Center, New York, NY, USA), Y. Jacob and E. Birlouez (Institut Pasteur, Paris, France), and M. X. Ilagan (Washington University School of Medicine, St. Louis, MO, USA) for constructs. The authors thank S. Cairo, P. Falanga, P. Mourikis, S. Yennek, F. Logeat, D. Ndiaye, and D. Kachaner (Institut Pasteur) for materials and advice. The authors especially thank P. H. Commere and A. Danckaert (Imagopole, Institut Pasteur). The authors acknowledge the Imagopole-Plateforme d'Imagerie Dynamique (PFID) France-BioImaging infrastructure, supported by the French National Research Agency (ANR 10-INSB-04-01, Investments for the Future), for advice and access to the Opera system. The Imagopole was sponsored by the Soutien aux Equipes Scientifiques pour l'Acquisition de Moyens Experimentaux (SESAME) 2007 program, Conseil de la Region Ile-de-France, and by a grant from the Fondation pour la Recherche Medicale (FRM). S.O. was supported by grants from the Domaine d'Interet Majeur (DIM)-Stem Cells and Cell Therapy (STEM)-Pole (Ile-de-France) and the FRM. Notch2 (Artavanis- Tsakonas) antibody was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the U.S. National Institute of Child Health and Human Development and maintained by the University of Iowa (Iowa City, IA, USA).	Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bellavia D, 2008, ONCOGENE, V27, P5092, DOI 10.1038/onc.2008.230; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; Croquelois A, 2005, HEPATOLOGY, V41, P487, DOI 10.1002/hep.20571; Diermeier-Daucher S., 2010, CURR PROTOC CELL BIO, V48; Dill MT, 2013, HEPATOLOGY, V57, P1607, DOI 10.1002/hep.26165; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fitz JG, 2002, SEMIN LIVER DIS, V22, P241, DOI 10.1055/s-2002-34502; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Funahashi Y, 2008, CANCER RES, V68, P4727, DOI 10.1158/0008-5472.CAN-07-6499; Gentric G, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/282430; Giovannini C, 2006, ANTICANCER RES, V26, P2123; Giovannini C, 2012, AM J PATHOL, V181, P413, DOI 10.1016/j.ajpath.2012.04.019; Goessling W, 2008, DEV BIOL, V320, P161, DOI 10.1016/j.ydbio.2008.05.526; Gramantieri L, 2007, LIVER INT, V27, P997, DOI 10.1111/j.1478-3231.2007.01544.x; Guo H, 2011, CARCINOGENESIS, V32, P1897, DOI 10.1093/carcin/bgr220; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Gupta-Rossi N, 2011, J BIOL CHEM, V286, P18720, DOI 10.1074/jbc.M110.190769; Haapasalo A, 2011, J ALZHEIMERS DIS, V25, P3, DOI 10.3233/JAD-2011-101065; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; Kamath BM, 2012, J MED GENET, V49, P138, DOI 10.1136/jmedgenet-2011-100544; Kitamoto T, 2010, STEM CELLS, V28, P2205, DOI 10.1002/stem.547; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Lasagni L, 2010, STEM CELLS, V28, P1673, DOI 10.1002/stem.492; Lemaigre FP, 2008, HEPATOLOGY, V48, P358, DOI 10.1002/hep.22480; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Litten JB, 2011, PEDIATR DEVEL PATHOL, V14, P378, DOI 10.2350/10-09-0900-OA.1; Liu HD, 2010, GENE DEV, V24, P2395, DOI 10.1101/gad.1975210; Loomes KM, 2002, AM J MED GENET, V112, P181, DOI 10.1002/ajmg.10592; Margall-Ducos G, 2007, J CELL SCI, V120, P3633, DOI 10.1242/jcs.016907; McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Mizuguchi T, 2001, J CELL PHYSIOL, V189, P106, DOI 10.1002/jcp.1136; Mok WC, 2012, WORLD J GASTROENTERO, V18, P3527, DOI 10.3748/wjg.v18.i27.3527; Mourikis P, 2012, STEM CELLS, V30, P243, DOI 10.1002/stem.775; NADAL C, 1966, EXP CELL RES, V42, P99, DOI 10.1016/0014-4827(66)90324-7; Ochsner SA, 2007, STEM CELLS, V25, P2476, DOI 10.1634/stemcells.2007-0101; Oda T, 1997, GENOMICS, V43, P376, DOI 10.1006/geno.1997.4820; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ou YY, 2002, J CELL SCI, V115, P1825; Rogler LE, 1997, AM J PATHOL, V150, P591; Ryan MJ, 2008, HEPATOLOGY, V48, P1989, DOI 10.1002/hep.22538; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Shiojiri N, 1997, MICROSC RES TECHNIQ, V39, P328, DOI 10.1002/(SICI)1097-0029(19971115)39:4<328::AID-JEMT3>3.0.CO;2-D; Si-Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Sparks EE, 2010, HEPATOLOGY, V51, P1391, DOI 10.1002/hep.23431; Strick-Marchand H, 2004, P NATL ACAD SCI USA, V101, P8360, DOI 10.1073/pnas.0401092101; Strick-Marchand H, 2002, HEPATOLOGY, V36, P794, DOI 10.1053/jhep.2002.36123; Suwanjunee S, 2008, ANTI-CANCER DRUG, V19, P477, DOI 10.1097/CAD.0b013e3282fc6cdd; Tanimizu N, 2007, MOL BIOL CELL, V18, P1472, DOI 10.1091/mbc.E06-09-0848; Tchorz JS, 2009, HEPATOLOGY, V50, P871, DOI 10.1002/hep.23048; Ullah Z, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-10; van Zijl F, 2010, WORLD J HEPATOL, V2, P1, DOI 10.4254/wjh.v2.i1.1; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Wang CM, 2009, J BIOL CHEM, V284, P16183, DOI 10.1074/jbc.M109.002105; Wang L, 2009, HEPATOLOGY, V49, P268, DOI 10.1002/hep.22579; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140	64	25	27	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					603	614		10.1096/fj.13-235903	http://dx.doi.org/10.1096/fj.13-235903			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24145721				2022-12-28	WOS:000331072200009
J	Spaethling, JM; Piel, D; Dueck, H; Buckley, PT; Morris, JF; Fisher, SA; Lee, J; Sul, JY; Kim, J; Bartfai, T; Beck, SG; Eberwine, JH				Spaethling, Jennifer M.; Piel, David; Dueck, Hannah; Buckley, Peter T.; Morris, Jacqueline F.; Fisher, Stephen A.; Lee, JaeHee; Sul, Jai-Yoon; Kim, Junhyong; Bartfai, Tamas; Beck, Sheryl G.; Eberwine, James H.			Serotonergic neuron regulation informed by in vivo single-cell transcriptomics	FASEB JOURNAL			English	Article						RNA-Seq; GPCR; electophysiology; histamine; dorsal raphe	HISTAMINE H-3 RECEPTOR; DORSAL RAPHE NEURONS; RAT-BRAIN; EXPRESSION; MICE; OXYTOCIN; LIGANDS; NUCLEUS; ANXIETY; GENES	Despite the recognized importance of the dorsal raphe (DR) serotonergic (5-HT) nuclei in the pathophysiology of depression and anxiety, the molecular components/putative drug targets expressed by these neurons are poorly characterized. Utilizing the promoter of an ETS domain transcription factor that is a stable marker of 5-HT neurons (Pet-1) to drive 5-HT neuronal expression of YFP, we identified 5-HT neurons in live acute slices. We isolated RNA from single 5-HT neurons in the ventromedial and lateral wings of the DR and performed single-cell RNA-Seq analysis identifying >500 G-protein coupled receptors (GPCRs) including receptors for classical transmitters, lipid signals, and peptides as well as dozens of orphan-GPCRs. Using these data to inform our selection of receptors to assess, we found that oxytocin and lysophosphatidic acid 1 receptors are translated and active in costimulating, with the (1)-adrenergic receptor, the firing of DR 5-HT neurons, while the effects of histamine are inhibitory and exerted at H3 histamine receptors. The inhibitory histamine response provides evidence for tonic in vivo histamine inhibition of 5-HT neurons. This study illustrates that unbiased single-cell transcriptomics coupled with functional analyses provides novel insights into how neurons and neuronal systems are regulated.Spaethling, J. M., Piel, D., Dueck, H., Buckley, P. T., Morris, J. F., Fisher, S. A., Lee, J., Sul, J.-Y., Kim, J., Bartfai, T., Beck, S. G., Eberwine, J. H. Serotonergic neuron regulation informed by in vivo single-cell transcriptomics.	[Spaethling, Jennifer M.; Buckley, Peter T.; Morris, Jacqueline F.; Lee, JaeHee; Sul, Jai-Yoon; Eberwine, James H.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; [Dueck, Hannah; Fisher, Stephen A.; Kim, Junhyong] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Piel, David; Beck, Sheryl G.] Childrens Hosp Philadelphia, Res Inst, Dept Anesthesiol, Philadelphia, PA 19104 USA; [Bartfai, Tamas] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Scripps Research Institute	Eberwine, JH (corresponding author), Univ Penn, 37 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	eberwine@upenn.edu			U.S. National Institutes of Health [MH075047, DP1OD004117]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH075047] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD004117] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded in part by U.S. National Institutes of Health grants MH075047 (to S.B.) and DP1OD004117 (to J.E).	Allen MC, 1998, EUR J PHARMACOL, V361, P261, DOI 10.1016/S0014-2999(98)00719-5; Aman TK, 2007, J PHARMACOL EXP THER, V320, P376, DOI 10.1124/jpet.106.111690; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Artigas F, 2001, TRENDS PHARMACOL SCI, V22, P224, DOI 10.1016/S0165-6147(00)01682-5; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; Bartfai T, 2012, TRENDS PHARMACOL SCI, V33, P9, DOI 10.1016/j.tips.2011.09.006; Blake JA, 2011, NUCLEIC ACIDS RES, V39, pD842, DOI 10.1093/nar/gkq1008; Bosch OJ, 2011, HORM BEHAV, V59, P202, DOI 10.1016/j.yhbeh.2010.11.012; Boudaba C, 2006, AM J PHYSIOL-REG I, V291, pR102, DOI 10.1152/ajpregu.00795.2005; Buckley PT, 2011, NEURON, V69, P877, DOI 10.1016/j.neuron.2011.02.028; Calizo LH, 2011, NEUROPHARMACOLOGY, V61, P524, DOI 10.1016/j.neuropharm.2011.04.008; Crawford LK, 2013, ACS CHEM NEUROSCI, V4, P200, DOI 10.1021/cn300238j; Crawford LK, 2010, J NEUROPHYSIOL, V103, P2652, DOI 10.1152/jn.01132.2009; Drutel G, 2001, MOL PHARMACOL, V59, P1; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Eberwine J., 2001, CURR PROTOC NEUROSCI, V5; Eberwine J, 2011, PHARMACOL THERAPEUT, V129, P241, DOI 10.1016/j.pharmthera.2010.09.010; Grant GR, 2011, BIOINFORMATICS, V27, P2518, DOI 10.1093/bioinformatics/btr427; Hardoy Maria Carolina, 2010, Clin Pract Epidemiol Ment Health, V6, P1, DOI 10.2174/1745017901006010001; Hendricks T, 1999, J NEUROSCI, V19, P10348; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; JANSEN FP, 1994, BRIT J PHARMACOL, V113, P355, DOI 10.1111/j.1476-5381.1994.tb16995.x; Johnson PL, 2004, ANN NY ACAD SCI, V1018, P58, DOI 10.1196/annals.1296.006; Kim MA, 2004, BRAIN RES, V1026, P56, DOI 10.1016/j.brainres.2004.08.022; LAKOSKI JM, 1984, EUR J PHARMACOL, V103, P153, DOI 10.1016/0014-2999(84)90202-4; Larsen PJ, 1996, NEUROSCIENCE, V70, P963, DOI 10.1016/0306-4522(95)00415-7; Lowry CA, 2008, ANN NY ACAD SCI, V1148, P86, DOI 10.1196/annals.1410.004; Machado-Vieira R, 2010, PHARMACEUTICALS, V3, P19, DOI 10.3390/ph3010019; Perez-Garcia C, 1999, PSYCHOPHARMACOLOGY, V142, P215, DOI 10.1007/s002130050882; Pillot C, 2002, NEUROSCIENCE, V114, P173, DOI 10.1016/S0306-4522(02)00135-5; Rawson NE, 2000, J NEUROCHEM, V75, P185, DOI 10.1046/j.1471-4159.2000.0750185.x; Ring RH, 2006, PSYCHOPHARMACOLOGY, V185, P218, DOI 10.1007/s00213-005-0293-z; Rizk A, 2004, EUR J NEUROSCI, V19, P1992, DOI 10.1111/j.1460-9568.2004.03251.x; Roberts C, 2005, NEUROCHEM RES, V30, P371, DOI 10.1007/s11064-005-2611-6; Sakai K, 2000, NEUROREPORT, V11, P3237, DOI 10.1097/00001756-200009280-00037; Sakai K, 2001, NEUROSCIENCE, V104, P1141, DOI 10.1016/S0306-4522(01)00103-8; Santin LJ, 2009, GENES BRAIN BEHAV, V8, P772, DOI 10.1111/j.1601-183X.2009.00524.x; Scott MM, 2005, P NATL ACAD SCI USA, V102, P16472, DOI 10.1073/pnas.0504510102; Sharman JL, 2011, NUCLEIC ACIDS RES, V39, pD534, DOI 10.1093/nar/gkq1062; Skoura A, 2009, J LIPID RES, V50, pS293, DOI 10.1194/jlr.R800047-JLR200; Souza RP, 2010, INT J NEUROPSYCHOPH, V13, P793, DOI 10.1017/S1461145710000167; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Takei H, 2012, NEUROSCI LETT, V518, P55, DOI 10.1016/j.neulet.2012.04.056; Team RC., 2022, LANG ENV STAT COMP; Templin JS, 2012, BRAIN RES, V1457, P1, DOI 10.1016/j.brainres.2012.03.066; Terenzi MG, 2005, NEUROSCIENCE, V134, P345, DOI 10.1016/j.neuroscience.2005.04.004; Threlfell S, 2004, J NEUROSCI, V24, P8704, DOI 10.1523/JNEUROSCI.2690-04.2004; van der Goot H, 2000, EUR J MED CHEM, V35, P5, DOI 10.1016/S0223-5234(00)00101-X; Warnes GR, 2012, GPLOTS VARIOUS R PRO; Woclawek-Potocka I, 2009, EXP BIOL MED, V234, P986, DOI 10.3181/0901-RM-36; Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009	52	43	46	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					771	780		10.1096/fj.13-240267	http://dx.doi.org/10.1096/fj.13-240267			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24192459	Green Published, Bronze			2022-12-28	WOS:000331072200024
J	Daniels, SI; Soule, EE; Davidoff, KS; Bernbaum, JG; Hu, DS; Maeda, K; Stahl, SJ; Naiman, NE; Waheed, AA; Freed, EO; Wingfield, P; Yarchoan, R; Davis, DA				Daniels, Sarah I.; Soule, Erin E.; Davidoff, Katharine S.; Bernbaum, John G.; Hu, Duosha; Maeda, Kenji; Stahl, Stephen J.; Naiman, Nicole E.; Waheed, Abdul A.; Freed, Eric O.; Wingfield, Paul; Yarchoan, Robert; Davis, David A.			Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide	FASEB JOURNAL			English	Article						retrovirus; cytochalasin D; cellular uptake; endocytosis	HUMAN-IMMUNODEFICIENCY-VIRUS; THERAPEUTIC AGENTS; HIV-1 REPLICATION; TYPE-1 PROTEASE; VIRAL VECTORS; PROTEINS; DELIVERY; CELLS; INHIBITION; BETA	A 27-aa peptide (P27) was previously shown to decrease the accumulation of human immunodeficiency virus type 1 (HIV-1) in the supernatant of chronically infected cells; however, the mechanism was not understood. Here, we show that P27 prevents virus accumulation by inducing macropinocytosis (MPC). Treatment of HIV-1- and human T-cell lymphotropic virus type 1 (HTLV-1)-infected cells with 2-10 M P27 caused cell membrane ruffling and uptake of virus and polymerized forms of the peptide into large vacuoles. As demonstrated by electron microscopy, activation of MPC did not require virus or cells infected with virus, as P27 initiated its own uptake in the absence of virus. Inhibitors of MPC, Cytochalasin D and amiloride, decreased P27-mediated uptake of soluble dextran and inhibited P27-induced virus uptake by >60%, which provides further evidence that P27 induces MPC. In CD4(+) HeLa cells, HIV-1 infection was enhanced by P27 up to 4-fold, and P27 increased infection at concentrations as low as 20 nM. The 5-aa C-terminal domain of P27 was necessary for virus uptake and may be responsible for the polymerization of P27 into fibrils. These forms of P27 may play a key role in triggering MPC, making this peptide a useful tool for studying virus uptake and infection, as well as MPC of other macromolecules.Daniels, S.I., Soule, E.E., Davidoff, K.S., Bernbaum, J.G., Hu, D., Maeda, K., Stahl, S.J., Naiman, N.E., Waheed, A.E., Freed, E.O., Wingfield, P., Yarchoan, R., Davis. D.A. Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.	[Daniels, Sarah I.; Soule, Erin E.; Davidoff, Katharine S.; Hu, Duosha; Maeda, Kenji; Naiman, Nicole E.; Yarchoan, Robert; Davis, David A.] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, Frederick, MD 21701 USA; [Waheed, Abdul A.; Freed, Eric O.] NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, Frederick, MD 21701 USA; [Stahl, Stephen J.; Wingfield, Paul] NIAMSD, Prot Express Lab, NIH, Bethesda, MD 20892 USA; [Bernbaum, John G.] NIAID, Supporting Integrated Res Facil, Div Clin Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Davis, DA (corresponding author), NIH, 10 Ctr Dr,Bldg 10,Rm 6N106,MSC 1868, Bethesda, MD 20892 USA.	dadavis@helix.nih.gov	Maeda, Kenji/B-7708-2019	Maeda, Kenji/0000-0002-9424-1491; Naiman, Nicole/0000-0002-6116-555X; Wingfield, Paul/0000-0002-9515-4752	Intramural Research Program of the Center for Cancer Research; National Cancer Institute; U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; NATIONAL CANCER INSTITUTE [ZIABC010775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER	Intramural Research Program of the Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Intramural Research Program of the Center for Cancer Research, the National Cancer Institute, the U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Allergy and Infectious Diseases. The authors thank Yuki Takamatsu and Philippe Kieffer for technical help with flow cytometry and flow cytometry analysis.	Aghi M, 2005, CURR OPIN MOL THER, V7, P419; Amand HL, 2008, BIOCHEM BIOPH RES CO, V371, P621, DOI 10.1016/j.bbrc.2008.04.039; Amyere M, 2000, MOL BIOL CELL, V11, P3453, DOI 10.1091/mbc.11.10.3453; Asai D, 2010, J CONTROL RELEASE, V141, P52, DOI 10.1016/j.jconrel.2009.08.025; Borgmann K, 2011, AIDS RES HUM RETROV, V27, P853, DOI [10.1089/aid.2010.0295, 10.1089/AID.2010.0295]; Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001; Davis DA, 1999, J VIROL, V73, P1156, DOI 10.1128/JVI.73.2.1156-1164.1999; Davis DA, 2006, ANTIVIR RES, V72, P89, DOI 10.1016/j.antiviral.2006.03.015; Davis DA, 2009, BIOCHEM J, V419, P497, DOI 10.1042/BJ20082068; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; Ganguly S, 2008, OLIGONUCLEOTIDES, V18, P277, DOI 10.1089/oli.2008.0140; Glorioso JC, 2003, J NEUROVIROL, V9, P165, DOI 10.1080/13550280390193984; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600-0854.2009.00878.x; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Lim JP, 2011, IMMUNOL CELL BIOL, V89, P836, DOI 10.1038/icb.2011.20; Liu NQ, 2002, J VIROL, V76, P6689, DOI 10.1128/JVI.76.13.6689-6700.2002; Maeda K, 2001, J BIOL CHEM, V276, P35194, DOI 10.1074/jbc.M105670200; Mandel RJ, 2006, MOL THER, V13, P463, DOI 10.1016/j.ymthe.2005.11.009; Mandrekar S, 2009, J NEUROSCI, V29, P4252, DOI 10.1523/JNEUROSCI.5572-08.2009; Marechal V, 2001, J VIROL, V75, P11166, DOI 10.1128/JVI.75.22.11166-11177.2001; Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509-510; Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046; Morozov VA, 1999, VIROLOGY, V255, P279, DOI 10.1006/viro.1998.9578; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris SJ, 2002, ARCH VIROL, V147, P961, DOI 10.1007/s00705-001-0779-x; Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014; NAGY K, 1983, INT J CANCER, V32, P321, DOI 10.1002/ijc.2910320310; Nakase I, 2009, MOL THER, V17, P1868, DOI 10.1038/mt.2009.192; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; Norbury CC, 2006, IMMUNOLOGY, V117, P443, DOI 10.1111/j.1365-2567.2006.02335.x; Overmeyer JH, 2008, MOL CANCER RES, V6, P965, DOI 10.1158/1541-7786.MCR-07-2036; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Raghu H, 2009, J VIROL, V83, P4895, DOI 10.1128/JVI.02498-08; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Sandgren KJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000866; Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P6837, DOI 10.1093/nar/gki991; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; WINGFIELD PT, 1991, BIOCHEMISTRY-US, V30, P7527, DOI 10.1021/bi00244a023; Wojtowicz WM, 2002, J BIOL CHEM, V277, P35019, DOI 10.1074/jbc.M203518200; Zhang H, 2008, J MOL BIOL, V378, P565, DOI 10.1016/j.jmb.2008.02.066	48	2	2	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					106	116		10.1096/fj.13-238113	http://dx.doi.org/10.1096/fj.13-238113			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24097312	Green Published			2022-12-28	WOS:000333526100013
J	Lee, TK; Clarke, IJ; St John, J; Young, IR; Leury, BL; Rao, A; Andrews, ZB; Henry, BA				Lee, T. Kevin; Clarke, Iain J.; St John, Justin; Young, I. Ross; Leury, Brian L.; Rao, Alexandra; Andrews, Zane B.; Henry, Belinda A.			High cortisol responses identify propensity for obesity that is linked to thermogenesis in skeletal muscle	FASEB JOURNAL			English	Article						stress; energy expenditure; hypothalamic-pituitary-adrenal axis; postprandial	PITUITARY-ADRENAL AXIS; FOOD-INTAKE; ADIPOSE-TISSUE; MALIGNANT HYPERTHERMIA; MITOCHONDRIAL-FUNCTION; INSULIN SENSITIVITY; OVARIECTOMIZED EWES; STRESS REACTIVITY; FAT DISTRIBUTION; ARCUATE NUCLEUS	Subjects characterized as cortisol high responders (HRs) consume more calories after stress, but it is unknown whether cortisol responsiveness predicts a propensity for obesity. Female sheep with either high or low cortisol responses to adrenocorticotropin (ACTH) were identified. Body composition was similar in HRs and cortisol low responders (LRs), but the HRs had greater (P<0.01) adiposity than did the LRs (40.5 +/- 0.7 vs. 35.8 +/- 1.4%) after high-energy feeding, despite comparable food intake. Postprandial thermogenesis in muscle temperature was 0.8 +/- 0.08 degrees C higher in the LRs than in the HRs (P<0.01), whereas feeding-induced changes in fat temperature were similar. Leptin and insulin sensitivity were similar in the HRs and LRs. Feeding lowered (P<0.001) the respiratory control ratio in muscle (HRs 9.2 +/- 0.8-5.2 +/- 1.2; LRs 8.4 +/- 0.5-5.2 +/- 0.7), indicative of increased uncoupled respiration. Also in muscle, the feeding-induced increases in uncoupling protein (UCP)-3 (fold increase: HRs, 2.4; LRs, 2.0), ryanodine 1 receptor (RyR1; fold increase: HRs 3.1; LRs 2.1), and sarcoendoplasmic reticulum Ca2+-dependent ATPase (fold increase: HRs 1.5; LRs 1.6) were equivalent in the HRs and LRs. Sequencing of mitochondrial DNA revealed no haplotypic differences between the 2 groups. We conclude that predisposition to obesity can be predicted by cortisol responsiveness to an ACTH challenge and that the response is due to innate differences in muscle thermogenesis.Lee, T. K., Clarke, I. J., St. John, J., Young, I. R., Leury, B. L., Rao, A., Andrews, Z. B., Henry, B. A. High cortisol responses identify propensity to obesity that is linked to thermogenesis in skeletal muscle.	[Lee, T. Kevin; Clarke, Iain J.; Young, I. Ross; Rao, Alexandra; Andrews, Zane B.; Henry, Belinda A.] Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia; [St John, Justin] Monash Med Ctr, Monash Inst Med Res, Clayton, Vic 3168, Australia; [Leury, Brian L.] Univ Melbourne, Melbourne Sch Land & Environm, Melbourne, Vic, Australia	Monash University; Monash University; University of Melbourne	Henry, BA (corresponding author), Monash Univ, Dept Physiol, Bldg 13F, Clayton, Vic 3800, Australia.	belinda.henry@monash.edu	Leury, Brian/L-6231-2019	Leury, Brian/0000-0001-9173-2730; Lee, Kevin/0000-0002-2835-8827; Clarke, Iain/0000-0002-6613-2757; Andrews, Zane B./0000-0002-9097-7944; St. John, Jus/0000-0002-3993-1449	Victorian Government; Australia National Health and Medical Research Council [1005935]	Victorian Government; Australia National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Bruce Doughton, Lynda Morrish, and Elaine Chase for animal husbandry and technical assistance. This work was supported by the Victorian Government's Operational Infrastructure Support Program and by an Australia National Health and Medical Research Council project grant (1005935) to B.A.H.	Adam TC, 2007, PHYSIOL BEHAV, V91, P449, DOI 10.1016/j.physbeh.2007.04.011; Anukulkitch C, 2007, AM J PHYSIOL-REG I, V292, pR242, DOI 10.1152/ajpregu.00417.2006; Bal NC, 2012, NAT MED, V18, P1575, DOI 10.1038/nm.2897; Balog EM, 2001, BIOPHYS J, V81, P2050, DOI 10.1016/S0006-3495(01)75854-7; BERGMAN RN, 1979, AM J PHYSIOL, V236, pE667, DOI 10.1152/ajpendo.1979.236.6.E667; BOCKING AD, 1986, J DEV PHYSIOL, V8, P237; BRAY GA, 1992, AM J PHYSIOL, V262, pE32, DOI 10.1152/ajpendo.1992.262.1.E32; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Christoffersen B, 2009, AM J PHYSIOL-REG I, V297, pR1195, DOI 10.1152/ajpregu.90851.2008; Clarke IJ, 2001, REPROD FERT DEVELOP, V13, P577, DOI 10.1071/RD01087; Clarke IJ, 2001, ENDOCRINOLOGY, V142, P2725, DOI 10.1210/en.142.6.2725; Clarke IJ, 2000, J NEUROENDOCRINOL, V12, P1105, DOI 10.1046/j.1365-2826.2000.00570.x; Clarke SD, 2013, ENDOCRINOLOGY, V154, P184, DOI 10.1210/en.2012-1758; Clarke SD, 2012, AM J PHYSIOL-REG I, V303, pR1071, DOI 10.1152/ajpregu.00036.2012; Clarke SD, 2012, ENDOCRINOLOGY, V153, P123, DOI 10.1210/en.2011-1634; Curioni CC, 2005, INT J OBESITY, V29, P1168, DOI 10.1038/sj.ijo.0803015; de Meis L, 2005, BIOSCIENCE REP, V25, P181, DOI 10.1007/s10540-005-2884-7; Duclos M, 2001, CLIN ENDOCRINOL, V55, P447, DOI 10.1046/j.1365-2265.2001.01384.x; Epel E, 2001, PSYCHONEUROENDOCRINO, V26, P37, DOI 10.1016/S0306-4530(00)00035-4; Feldkircher KM, 1996, INT J OBESITY, V20, P232; George SA, 2010, PSYCHONEUROENDOCRINO, V35, P607, DOI 10.1016/j.psyneuen.2009.09.017; Harper ME, 2002, DIABETES, V51, P2459, DOI 10.2337/diabetes.51.8.2459; Henry BA, 2010, DOMEST ANIM ENDOCRIN, V38, P46, DOI 10.1016/j.domaniend.2009.07.006; Henry BA, 1999, ENDOCRINOLOGY, V140, P1175, DOI 10.1210/en.140.3.1175; Henry BA, 2000, ENDOCRINOLOGY, V141, P1506, DOI 10.1210/en.141.4.1506; Henry BA, 2008, ENDOCRINOLOGY, V149, P2019, DOI 10.1210/en.2007-1311; Henry BA, 2011, ENDOCRINOLOGY, V152, P2609, DOI 10.1210/en.2011-0143; Henry BA, 2010, AM J PHYSIOL-REG I, V299, pR907, DOI 10.1152/ajpregu.00809.2009; Kadarmideen HN, 2007, PHYSIOL GENOMICS, V29, P57, DOI 10.1152/physiolgenomics.00144.2006; Knott SA, 2008, DOMEST ANIM ENDOCRIN, V34, P261, DOI 10.1016/j.domaniend.2007.07.002; Kurose Y, 2005, J NEUROENDOCRINOL, V17, P331, DOI 10.1111/j.1365-2826.2005.01318.x; Lanner JT, 2012, ADV EXP MED BIOL, V740, P217, DOI 10.1007/978-94-007-2888-2_9; Lincoln GA, 2001, AM J PHYSIOL-REG I, V281, pR76, DOI 10.1152/ajpregu.2001.281.1.R76; Louis CF, 2001, BIOSCIENCE REP, V21, P155, DOI 10.1023/A:1013644107519; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MacLean PS, 2011, AM J PHYSIOL-REG I, V301, pR581, DOI 10.1152/ajpregu.00755.2010; Makimura H, 2000, DIABETES, V49, P1917, DOI 10.2337/diabetes.49.11.1917; Murani E, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-74; PASQUALI R, 1993, J CLIN ENDOCR METAB, V77, P341, DOI 10.1210/jc.77.2.341; Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434; SECHEN SJ, 1990, AM J PHYSIOL, V258, pE582, DOI 10.1152/ajpendo.1990.258.4.E582; SULLIVAN KM, 1991, ELECTROPHORESIS, V12, P17, DOI 10.1002/elps.1150120105; Sumithran P, 2011, NEW ENGL J MED, V365, P1597, DOI 10.1056/NEJMoa1105816; Symonds ME, 2012, P NUTR SOC, V71, P363, DOI 10.1017/S0029665112000584; Touma C, 2008, PSYCHONEUROENDOCRINO, V33, P839, DOI 10.1016/j.psyneuen.2008.03.013; Udden J, 2003, J INTERN MED, V253, P225, DOI 10.1046/j.1365-2796.2003.01099.x	46	13	13	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					35	44		10.1096/fj.13-238345	http://dx.doi.org/10.1096/fj.13-238345			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24022403				2022-12-28	WOS:000333526100006
J	Gattu, AK; Swenson, ES; Iwakiri, Y; Samuel, VT; Troiano, N; Berry, R; Church, CD; Rodeheffer, MS; Carpenter, TO; Chung, CH				Gattu, Arijeet K.; Swenson, E. Scott; Iwakiri, Yasuko; Samuel, Varman T.; Troiano, Nancy; Berry, Ryan; Church, Christopher D.; Rodeheffer, Matthew S.; Carpenter, Thomas O.; Chung, Chuhan			Determination of mesenchymal stem cell fate by pigment epithelium-derived factor (PEDF) results in increased adiposity and reduced bone mineral content	FASEB JOURNAL			English	Article						metabolic syndrome; osteogenesis imperfecta type VI	OSTEOGENESIS IMPERFECTA; INSULIN-RESISTANCE; OSTEOBLAST; ADIPOCYTE; IDENTIFICATION; ADIPOGENESIS; DIFFERENTIATION; PROLIFERATION; SUPPRESSES; INHIBITION	Pigment epithelium-derived factor (PEDF), the protein product of the SERPINF1 gene, has been linked to distinct diseases involving adipose or bone tissue, the metabolic syndrome, and osteogenesis imperfecta (OI) type VI. Since mesenchymal stem cell (MSC) differentiation into adipocytes vs. osteoblasts can be regulated by specific factors, PEDF-directed dependency of murine and human MSCs was assessed. PEDF inhibited adipogenesis and promoted osteoblast differentiation of murine MSCs, osteoblast precursors, and human MSCs. Blockade of adipogenesis by PEDF suppressed peroxisome proliferator-activated receptor- (PPAR), adiponectin, and other adipocyte markers by nearly 90% compared with control-treated cells (P<0.001). Differentiation to osteoblasts by PEDF resulted in a common pathway that involved PPAR suppression (P<0.01). Canonical Wnt--catenin signaling results in a MSC differentiation pattern analogous to that seen with PEDF. Thus, adding PEDF enhanced Wnt--catenin signal transduction in human MSCs, demonstrating a novel Wnt agonist function. In PEDF knockout (KO) mice, total body adiposity was increased by >50% compared with controls, illustrating its systemic role as a negative regulator of adipogenesis. Bones from KO mice demonstrated a reduction in mineral content recapitulating the OI type VI phenotype. These results demonstrate that the human diseases associated with PEDF reflect its ability to modulate MSC differentiation.Gattu, A. K., Swenson, E. S., Iwakiri, Y., Samuel, V. T., Troiano, N., Berry, R., Church, C. D., Rodeheffer, M. S., Carpenter, T. O., Chung, C. Determination of mesenchymal stem cell fate by pigment epithelium-derived factor (PEDF) results in increased adiposity and reduced bone mineral content.	[Gattu, Arijeet K.; Swenson, E. Scott; Iwakiri, Yasuko; Samuel, Varman T.; Chung, Chuhan] Yale Univ, Sch Med, Dept Med, Comparat Med Sect, New Haven, CT 06510 USA; [Troiano, Nancy] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, Comparat Med Sect, New Haven, CT 06510 USA; [Berry, Ryan; Church, Christopher D.; Rodeheffer, Matthew S.] Yale Univ, Sch Med, Dept Mol Cellular & Dev Biol, Comparat Med Sect, New Haven, CT 06510 USA; [Carpenter, Thomas O.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Chung, Chuhan] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA	Yale University; Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Chung, CH (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Digest Dis, 1080 LMP, New Haven, CT 06510 USA.	chuhan.chung@yale.edu			U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P30-AR46032]; NIH [DK34989]; NIH/National Institute of Diabetes and Digestive and Kidney Diseases [DK082600]; U.S. Department of Veteran's Affairs merit grant; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082600, P30DK034989, R01DK090489] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); U.S. Department of Veteran's Affairs merit grant; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Drs. Ben-Hua Sun and Joshua Van Houten (Yale University School of Medicine) for assistance with the microCT images and Dr. Fred S. Gorelick (Yale University School of Medicine) for a thorough reading of the manuscript. This work was supported by U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant P30-AR46032 to the Yale Core Center for Musculoskeletal Disorders (C. C., T. C.), NIH grant DK34989 to the Yale Liver Center Core (C. C.), NIH/National Institute of Diabetes and Digestive and Kidney Diseases grant DK082600 (Y.I.), and a U.S. Department of Veteran's Affairs merit grant (C. C.). The authors declare no conflicts of interest.	Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978-1-61779-415-5_2; Becker J, 2011, AM J HUM GENET, V88, P362, DOI 10.1016/j.ajhg.2011.01.015; Bohm A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034035; Bogan R, 2013, J BONE MINER RES, V28, P1531, DOI 10.1002/jbmr.1892; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chung C, 2008, J HEPATOL, V48, P471, DOI 10.1016/j.jhep.2007.10.012; Chung CH, 2009, GASTROENTEROLOGY, V136, P331, DOI 10.1053/j.gastro.2008.09.065; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Crowe S, 2009, CELL METAB, V10, P40, DOI 10.1016/j.cmet.2009.06.001; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; Doyon G, 2009, J BIOL CHEM, V284, P25220, DOI 10.1074/jbc.M109.022632; DuBose KB, 2012, BIOCHEM BIOPH RES CO, V422, P488, DOI 10.1016/j.bbrc.2012.05.020; Glorieux FH, 2002, J BONE MINER RES, V17, P30, DOI 10.1359/jbmr.2002.17.1.30; Gonzalez R, 2010, P NATL ACAD SCI USA, V107, P3552, DOI 10.1073/pnas.0914019107; Grippo PJ, 2012, GUT, V61, P1454, DOI 10.1136/gutjnl-2011-300821; Ho TC, 2010, AM J PATHOL, V177, P1798, DOI 10.2353/ajpath.2010.091085; Homan EP, 2011, J BONE MINER RES, V26, P2798, DOI 10.1002/jbmr.487; Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200; Kang YY, 2009, STEM CELLS DEV, V18, P77, DOI 10.1089/scd.2008.0026; Kaur S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01673; Koli K, 2008, BONE, V43, P679, DOI 10.1016/j.bone.2008.06.016; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lecka-Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376; Liu WZ, 2012, J BIOL CHEM, V287, P7213, DOI 10.1074/jbc.M111.286724; Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209; Matsumoto K, 2004, HEPATOLOGY, V40, P252, DOI 10.1002/hep.20259; Moreno-Navarrete J. M., 2013, INT J OBES LOND, DOI 10.1038/ijo.2012.223; Nie J, 2009, J BIOL CHEM, V284, P1279, DOI 10.1074/jbc.M808285200; Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10; Prockop DJ, 2012, NEW ENGL J MED, V367, P2353, DOI 10.1056/NEJMcibr1210178; Ramirez-Castillejo C, 2006, NAT NEUROSCI, V9, P331, DOI 10.1038/nn1657; Rauch F, 2012, J CLIN ENDOCR METAB, V97, pE1550, DOI 10.1210/jc.2012-1827; Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sabater M, 2010, J CLIN ENDOCR METAB, V95, P4720, DOI 10.1210/jc.2010-0630; Schmitz JC, 2011, AM J PATHOL, V179, P2990, DOI 10.1016/j.ajpath.2011.08.009; Venturi G, 2012, J BONE MINER RES, V27, P723, DOI 10.1002/jbmr.1480; Wang M, 2009, AM J PHYSIOL-ENDOC M, V297, pE1378, DOI 10.1152/ajpendo.00252.2009; Wang P, 2008, EUR J ENDOCRINOL, V159, P713, DOI 10.1530/EJE-08-0521; Yamagishi S, 2006, J CLIN ENDOCR METAB, V91, P2447, DOI 10.1210/jc.2005-2654; Yasui N, 2003, BIOCHEMISTRY-US, V42, P3160, DOI 10.1021/bi0206558	46	65	69	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4384	4394		10.1096/fj.13-232900	http://dx.doi.org/10.1096/fj.13-232900			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23887690	Green Published			2022-12-28	WOS:000329937500007
J	Lazrak, A; Fu, LW; Bali, V; Bartoszewski, R; Rab, A; Havasi, V; Keiles, S; Kappes, J; Kumar, R; Lefkowitz, E; Sorscher, EJ; Matalon, S; Collawn, JF; Bebok, Z				Lazrak, Ahmed; Fu, Lianwu; Bali, Vedrana; Bartoszewski, Rafal; Rab, Andras; Havasi, Viktoria; Keiles, Steve; Kappes, John; Kumar, Ranjit; Lefkowitz, Elliot; Sorscher, Eric J.; Matalon, Sadis; Collawn, James F.; Bebok, Zsuzsanna			The silent codon change I507-ATC -> ATT contributes to the severity of the Delta F508 CFTR channel dysfunction	FASEB JOURNAL			English	Article						ABC protein; channel gating; patch-clamp; single-nucleotide polymorphism; sSNP; cotranslational folding	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; MESSENGER-RNA; QUALITY-CONTROL; SYNONYMOUS MUTATIONS; SECONDARY STRUCTURE; SIDE-CHAIN; EXPRESSION; PROTEIN; STABILITY	The most common disease-causing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene is the out-of-frame deletion of 3 nucleotides (CTT). This mutation leads to the loss of phenylalanine-508 (F508) and a silent codon change (SCC) for isoleucine-507 (I507-ATCATT). F508 CFTR is misfolded and degraded by endoplasmic reticulum-associated degradation (ERAD). We have demonstrated that the I507-ATCATT SCC alters F508 CFTR mRNA structure and translation dynamics. By comparing the biochemical and functional properties of the I507-ATT and I507-ATC F508 CFTR, we establish that the I507-ATCATT SCC contributes to the cotranslational misfolding, ERAD, and to the functional defects associated with F508 CFTR. We demonstrate that the I507-ATC F508 CFTR is less susceptible to the ER quality-control machinery during translation than the I507-ATT, although 27 degrees C correction is necessary for sufficient cell-surface expression. Whole-cell patch-clamp recordings indicate sustained, thermally stable cAMP-activated Cl- transport through I507-ATC and unstable function of the I507-ATT F508 CFTR. Single-channel recordings reveal improved gating properties of the I507-ATC compared to I507-ATT F508 CFTR (NPo=0.45 +/- 0.037 vs. NPo=0.09 +/- 0.002; P<0.001). Our results signify the role of the I507-ATCATT SCC in the F508 CFTR defects and support the importance of synonymous codon choices in determining the function of gene products.Lazrak, A., Fu, L., Bali, V., Bartoszewski, R., Rab, A., Havasi, V., Keiles, S., Kappes, J., Kumar, R., Lefkowitz, E., Sorscher, E. J., Matalon, S., Collawn, J. F., Bebok, Z. The silent codon change I507-ATCATT contributes to the severity of the F508 CFTR.	[Lazrak, Ahmed; Matalon, Sadis] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA; [Fu, Lianwu; Bali, Vedrana; Rab, Andras; Collawn, James F.; Bebok, Zsuzsanna] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA; [Kappes, John; Sorscher, Eric J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Kappes, John; Kumar, Ranjit; Lefkowitz, Elliot] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Fu, Lianwu; Havasi, Viktoria; Kappes, John; Sorscher, Eric J.; Matalon, Sadis; Collawn, James F.; Bebok, Zsuzsanna] Univ Alabama Birmingham, Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; [Keiles, Steve] Ambry Genet, Aliso Viejo, CA USA; [Bartoszewski, Rafal] Med Univ Gdansk, Dept Biol & Pharmaceut Bot, Gdansk, Poland	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Fahrenheit Universities; Medical University Gdansk	Bebok, Z (corresponding author), Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, 1918 Univ Blvd,MCLM 350A, Birmingham, AL 35294 USA.	bebok@uab.edu	Rab, András/AAR-7804-2021; Rab, Andras/AAI-9402-2021; Havasi, Viktoria/B-1309-2009; Bartoszewski, Rafal A/D-6311-2011	Rab, András/0000-0003-2154-0017; Bartoszewski, Rafal A/0000-0002-2864-6757; Fu, Karl/0000-0001-5386-9429; Sorscher, Eric J./0000-0001-9341-3354; Lefkowitz, Elliot/0000-0002-4748-4925; Lazrak, Ahmed/0000-0002-4127-1937	U.S. National Institutes of Health [HL076587, DK060065, 5U01ES015676, 5R01HL031197, GM095639]; North American Cystic Fibrosis Foundation [Sorsch05xx0, CFF R464, CFF DELUCA03G0]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000165] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031197, R01HL076587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES015676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM095639] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); North American Cystic Fibrosis Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This publication was made possible by U.S. National Institutes of Health grants HL076587 (Z.B.), DK060065 (J.F.C.), 5U01ES015676 and 5R01HL031197 (A. L. and S. M.), GM095639 (J.C.K.), University of Alabama at Birmingham Center for Clinical and Translational Science UL1TR000165 (National Center for Advancing Translational Sciences and National Center for Research Resources; R. K. and E. L.), P30 DK07248Z, and North American Cystic Fibrosis Foundation grants Sorsch05xx0, CFF R464 (E.J.S.), and CFF DELUCA03G0 (J.C.K). The authors thank Ms. Nancy Brissie for her outstanding technical support in organizing, maintaining, and preparing the cell clones used in these studies.	Aleksandrov AA, 2012, J MOL BIOL, V419, P41, DOI 10.1016/j.jmb.2012.03.001; Bartoszewski R, 2008, J BIOL CHEM, V283, P12154, DOI 10.1074/jbc.M707610200; Bartoszewski R, 2011, J BIOL CHEM, V286, P41862, DOI 10.1074/jbc.M111.304956; Bartoszewski RA, 2010, J BIOL CHEM, V285, P28741, DOI 10.1074/jbc.M110.154575; Brodsky JL, 2009, CURR OPIN CELL BIOL, V21, P516, DOI 10.1016/j.ceb.2009.04.006; Cai ZW, 2003, J GEN PHYSIOL, V122, P605, DOI 10.1085/jgp.200308921; Chen R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013574; Cui L, 2006, J PHYSIOL-LONDON, V572, P347, DOI 10.1113/jphysiol.2005.099457; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; Diatchenko L, 2006, PAIN, V123, P226, DOI 10.1016/j.pain.2006.04.015; Diatchenko L, 2006, AM J MED GENET B, V141B, P449, DOI 10.1002/ajmg.b.30324; Dong Q, 2012, P NATL ACAD SCI USA, V109, P917, DOI 10.1073/pnas.1120065109; Fu LW, 2012, BIOCHEM J, V441, P633, DOI 10.1042/BJ20111566; GRAY MA, 1993, AM J PHYSIOL, V264, pC591, DOI 10.1152/ajpcell.1993.264.3.C591; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; Henderson MJ, 2010, J BIOL CHEM, V285, P11314, DOI 10.1074/jbc.M109.044057; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jih KY, 2011, J PHYSIOL-LONDON, V589, P2719, DOI 10.1113/jphysiol.2010.202861; Jurkuvenaite A, 2010, AM J RESP CELL MOL, V42, P363, DOI 10.1165/rcmb.2008-0434OC; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kirk KL, 2011, J BIOL CHEM, V286, P12813, DOI 10.1074/jbc.R111.219634; Kleizen B, 2005, MOL CELL, V20, P277, DOI 10.1016/j.molcel.2005.09.007; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Lazrak A, 2012, AM J RESP CELL MOL, V46, P342, DOI 10.1165/rcmb.2011-0309OC; Lazrak A, 2011, AM J PHYSIOL-LUNG C, V301, pL557, DOI 10.1152/ajplung.00094.2011; Lazrak A, 2009, FASEB J, V23, P3829, DOI 10.1096/fj.09-135590; Liu XH, 2012, BIOCHEMISTRY-US, V51, P5113, DOI 10.1021/bi300018e; Londino JD, 2013, AM J PHYSIOL-LUNG C, V304, pL582, DOI 10.1152/ajplung.00314.2012; Loo TW, 2011, BIOCHEMISTRY-US, V50, P4393, DOI 10.1021/bi2004813; Lukacs GL, 2012, TRENDS MOL MED, V18, P81, DOI 10.1016/j.molmed.2011.10.003; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Mathews D. H., 2007, CURRENT PROTOCOLS NU; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Morito D, 2008, MOL BIOL CELL, V19, P1328, DOI 10.1091/mbc.E07-06-0601; MORRAL N, 1994, NAT GENET, V7, P169, DOI 10.1038/ng0694-169; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Muanprasat C, 2004, J GEN PHYSIOL, V124, P125, DOI 10.1085/jgp.200409059; Nackley AG, 2006, SCIENCE, V314, P1930, DOI 10.1126/science.1131262; Nackley AG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005237; Okiyoneda T, 2010, SCIENCE, V329, P805, DOI 10.1126/science.1191542; Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rotin D, 2011, PFLUG ARCH EUR J PHY, V461, P1, DOI 10.1007/s00424-010-0893-2; Roxo-Rosa M, 2006, P NATL ACAD SCI USA, V103, P17891, DOI 10.1073/pnas.0608312103; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Sharp PM, 2010, PHILOS T R SOC B, V365, P1203, DOI 10.1098/rstb.2009.0305; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Thibodeau PH, 2010, J BIOL CHEM, V285, P35825, DOI 10.1074/jbc.M110.131623; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Tosoni K, 2013, BIOCHEM J, V449, P295, DOI 10.1042/BJ20121240; Tsai CJ, 2008, J MOL BIOL, V383, P281, DOI 10.1016/j.jmb.2008.08.012; Tsao D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024287; Tsao D, 2011, NUCLEIC ACIDS RES, V39, P6201, DOI 10.1093/nar/gkr165; Tseng SC, 2011, PHARMACOGENOMICS, V12, P1147, DOI [10.2217/PGS.11.66, 10.2217/pgs.11.66]; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; Varga K, 2008, BIOCHEM J, V410, P555, DOI 10.1042/BJ20071420; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Wang W, 2011, J BIOL CHEM, V286, P41937, DOI 10.1074/jbc.M111.296061; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7; Zuker M, 2000, CURR OPIN STRUC BIOL, V10, P303, DOI 10.1016/S0959-440X(00)00088-9; Zuker M, 1998, RNA, V4, P669, DOI 10.1017/S1355838298980116; ZUKER M, 1995, NUCLEIC ACIDS RES, V23, P2791, DOI 10.1093/nar/23.14.2791	78	45	47	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4630	4645		10.1096/fj.13-227330	http://dx.doi.org/10.1096/fj.13-227330			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23907436	Green Published			2022-12-28	WOS:000329937500028
J	Su, H; Liu, BC; Frohlich, O; Ma, HP; Sands, JM; Chen, GP				Su, Hua; Liu, Bingchen; Froehlich, Otto; Ma, Heping; Sands, Jeff M.; Chen, Guangping			Small GTPase Rahl4 down-regulates UT-A1 urea transport activity through enhanced clathrin-dependent endocytosis	FASEB JOURNAL			English	Article						protein interaction; membrane protein; inner medulla	EPITHELIAL SODIUM-CHANNEL; RENAL COLLECTING DUCT; RAB GTPASES; AQUAPORIN-2 TRAFFICKING; MEMBRANE TRAFFICKING; BINDING-PROTEINS; APICAL MEMBRANE; PLASMA-MEMBRANE; WATER CHANNELS; CELLS	The UT-A1 urea transporter plays an important role in the urinary concentration mechanism. However, the molecular mechanisms regarding UT-A1 trafficking, endocytosis, and degradation are still unclear. In this study, we identified the small GTPase Rab14 as a binding partner to the C terminus of UT-A1 in a yeast 2-hybrid assay. Interestingly, UT-A1 binding is preferential for the GDP-bound inactive form of Rab14. Coinjection of Rab14 in Xenopus oocytes results in a decrease of UT-A1 urea transport activity, suggesting that Rab14 acts as a negative regulator of UT-A1. We subsequently found that Rab14 reduces the cell membrane expression of UT-A1, as evidenced by cell surface biotinylation. This effect is blocked by chlorpromazine, an inhibitor of the clathrin-mediated endocytic pathway, but not by filipin, an inhibitor of the caveolin-mediated endocytic pathway. In kidney, Rab14 is mainly expressed in IMCD epithelial cells with a pattern identical to UT-A1 expression. Consistent with its role in participating in clathrin-mediated endocytosis, Rab14 localizes in nonlipid raft microdomains and codistributes with Rab5, a marker of the clathrin-mediated endocytic pathway. Taken together, our study suggests that Rab14, as a novel UT-A1 partner, may have an important regulatory function for UT-A1 urea transport activity in the kidney inner medulla.Su, H., Liu, B., Frohlich, O., Ma, H., Sands, J. M., Chen, G. Small GTPase Rab14 down-regulates UT-A1 urea transport activity through enhanced clathrin-dependent endocytosis.	[Su, Hua; Liu, Bingchen; Froehlich, Otto; Ma, Heping; Sands, Jeff M.; Chen, Guangping] Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; [Sands, Jeff M.; Chen, Guangping] Emory Univ, Sch Med, Div Renal, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Chen, GP (corresponding author), Emory Univ, Sch Med, Dept Physiol, 615 Michael St, Atlanta, GA 30322 USA.	gchen3@emory.edu	LIU, BING-CHEN/AAG-9141-2020		U.S. National Institutes of Health [R01-DK087838, R01-DK041707]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087838, R01DK041707] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors greatly acknowledge Richard Scheller (Genentech, South San Francisco, CA, USA) for the Rabl 4 antibody and pGEX-KG-Rabl 4 construct. This work was supported by U.S. National Institutes of Health grants R01-DK087838 (to G.C.) and R01-DK041707 (to J M.S.).	Bradford AD, 2001, AM J PHYSIOL-RENAL, V281, pF133, DOI 10.1152/ajprenal.2001.281.1.F133; Butterworth MB, 2007, J BIOL CHEM, V282, P37885, DOI 10.1074/jbc.M707989200; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Chen G, 2008, AM J PHYSIOL-RENAL, V295, pF1528, DOI 10.1152/ajprenal.90482.2008; Chen GP, 2006, J BIOL CHEM, V281, P27436, DOI 10.1074/jbc.M605525200; Chen GP, 2011, FASEB J, V25, P4531, DOI 10.1096/fj.11-185991; Feng XY, 2009, AM J PHYSIOL-RENAL, V296, pF1514, DOI 10.1152/ajprenal.00068.2009; Fenton RA, 2004, P NATL ACAD SCI USA, V101, P7469, DOI 10.1073/pnas.0401704101; Huang HD, 2010, AM J PHYSIOL-RENAL, V299, pF1389, DOI 10.1152/ajprenal.00718.2009; Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009; Junutula JR, 2004, MOL BIOL CELL, V15, P2218, DOI 10.1091/mbc.E03-10-0777; Kitt KN, 2008, TRAFFIC, V9, P1218, DOI 10.1111/j.1600-0854.2008.00752.x; KNEPPER MA, 1993, AM J PHYSIOL, V265, pF214, DOI 10.1152/ajprenal.1993.265.2.F214; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; Linford A, 2012, DEV CELL, V22, P952, DOI 10.1016/j.devcel.2012.04.010; Liu GY, 2008, MOL BIOL REP, V35, P201, DOI 10.1007/s11033-007-9071-9; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mistry AC, 2007, J BIOL CHEM, V282, P30097, DOI 10.1074/jbc.M705866200; Mistry AC, 2009, AM J PHYSIOL-RENAL, V297, pF292, DOI 10.1152/ajprenal.00196.2009; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; NIELSEN S, 1993, AM J PHYSIOL, V265, pF204, DOI 10.1152/ajprenal.1993.265.2.F204; Noda Y, 2004, BIOCHEM BIOPH RES CO, V322, P740, DOI 10.1016/j.bbrc.2004.07.195; Noda Y, 2004, FEBS LETT, V568, P139, DOI 10.1016/j.febslet.2004.05.021; Noda Y, 2008, J CELL BIOL, V182, P587, DOI 10.1083/jcb.200709177; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Pfeffer SR, 2005, J BIOL CHEM, V280, P15485, DOI 10.1074/jbc.R500003200; Procino G, 2008, J CELL SCI, V121, P2097, DOI 10.1242/jcs.022210; Proikas-Cezanne T, 2006, FEBS LETT, V580, P5241, DOI 10.1016/j.febslet.2006.08.053; Rodman JS, 2000, J CELL SCI, V113, P183; Sands JM, 2004, CURR OPIN NEPHROL HY, V13, P525, DOI 10.1097/00041552-200409000-00008; Sands JM, 2003, J MEMBRANE BIOL, V191, P149, DOI 10.1007/s00232-002-1053-1; Saxena S, 2005, BIOCHEM BIOPH RES CO, V337, P1219, DOI 10.1016/j.bbrc.2005.09.186; Saxena SK, 2006, BIOCHEM BIOPH RES CO, V341, P184, DOI 10.1016/j.bbrc.2005.12.170; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Shakor ABA, 2012, CELL SIGNAL, V24, P677, DOI 10.1016/j.cellsig.2011.10.016; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Su H, 2012, AM J PHYSIOL-RENAL, V303, pF1325, DOI 10.1152/ajprenal.00248.2012; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Valenti G, 2005, ENDOCRINOLOGY, V146, P5063, DOI 10.1210/en.2005-0868; van de Graaf SFJ, 2006, MOL CELL BIOL, V26, P303, DOI 10.1128/MCB.26.1.303-312.2006; Xu G, 2012, AM J PHYSIOL-CELL PH, V302, pC1012, DOI 10.1152/ajpcell.00440.2011; Zuk PA, 2000, J BIOL CHEM, V275, P26754	45	11	11	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4100	4107		10.1096/fj.13-229294	http://dx.doi.org/10.1096/fj.13-229294			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23796783	Green Published			2022-12-28	WOS:000329747100022
J	Wissing, MD; Mendonca, J; Kortenhorst, MSQ; Kaelber, NS; Gonzalez, M; Kim, E; Hammers, H; van Diest, PJ; Carducci, MA; Kachhap, SK				Wissing, Michel D.; Mendonca, Janet; Kortenhorst, Madeleine S. Q.; Kaelber, Nadine S.; Gonzalez, Matthew; Kim, Eunice; Hammers, Hans; van Diest, Paul J.; Carducci, Michael A.; Kachhap, Sushant K.			Targeting prostate cancer cell lines with polo-like kinase 1 innibitors as a single agent and in combination with histone deacetylase inhibitors	FASEB JOURNAL			English	Article						Plk1; HDAC; synergy; mitotic kinases; spindle assembly checkpoint	AURORA-A; PHASE-I; DOSE-ESCALATION; VALPROIC ACID; BI 6727; PLK1; MECHANISMS; LOCALIZATION; CHECKPOINT; EXPRESSION	Combinations of anticancer therapies with high efficacy and low toxicities are highly sought after. Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat. IC(50)s of Plk1 inhibitors BI 2536 and BI 6727 were determined in prostate cancer cells by MTS assays. Morphological and molecular changes were assessed by immunoblotting, immunofluorescence, flow cytometry, real-time RT-PCR, and pulldown assays. Efficacy of combination therapy was assessed by MTS and clonogenic assays. IC50 values in DU145, LNCaP, and PC3 cells were 50, 75, and 175 nM, respectively, for BI 2536 and 2.5, 5, and 600 nM, respectively, for BI 6727. Human prostate fibroblasts and normal prostate epithelial cells were unaffected at these concentrations. While DU145 and LNCaP cells were solely arrested in mitosis on treatment, PC3 cells accumulated in G(2) phase and mitosis, suggesting a weak spindle assembly checkpoint. Combining Plk1 inhibitors with HDAC inhibitors had synergistic antitumor effects in vitro. DMSO-treated prostate cancer cells were used as controls to study the effect of Plk1 and HDAC inhibition. Plk1 inhibitors decreased proliferation and clonogenic potential of prostate cancer cells. Hence, Plk1 may serve as an important molecular target for inhibiting prostate cancer. Combining HDAC inhibitors with BI 2536 or BI 6727 may be an effective treatment strategy against prostate cancer.Wissing, M. D., Mendonca, J., Kortenhorst, M. S. Q., Kaelber, N. S., Gonzalez, M., Kim E., Hammers, H., van Diest, P. J., Carducci, M. A., Kachhap, S. K. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.	[Wissing, Michel D.; Mendonca, Janet; Kortenhorst, Madeleine S. Q.; Kaelber, Nadine S.; Kim, Eunice; Hammers, Hans; Carducci, Michael A.; Kachhap, Sushant K.] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Prostate Canc Program, Baltimore, MD 21231 USA; [Wissing, Michel D.] Leiden Univ, Dept Clin Oncol, Med Ctr, Leiden, Netherlands; [Wissing, Michel D.; Kortenhorst, Madeleine S. Q.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Gonzalez, Matthew] Boston Univ, Sch Med, Boston, MA 02118 USA	Johns Hopkins University; Johns Hopkins Medicine; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; Boston University	Kachhap, SK (corresponding author), Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB I 1M53, Baltimore, MD 21231 USA.	kachhsu@jhmi.edu	Carducci, Michael/R-8164-2019		Flight Attendant Medical Research Institute (FAMRI); NCI Specialized Programs of Research Excellence (SPORE) grant [P50CA58236]; Aegon; Prostate Cancer Foundation (Koch Award); Dr. Saal van Zwanenbergstichting; Huygens Scholarship Programme (HSP) Talentenprogramma; Leiden University; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute (FAMRI); NCI Specialized Programs of Research Excellence (SPORE) grant; Aegon; Prostate Cancer Foundation (Koch Award); Dr. Saal van Zwanenbergstichting; Huygens Scholarship Programme (HSP) Talentenprogramma; Leiden University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Boehringer Ingelheim (Ingelheim am Rhein, Get many) for the Plk1 inhibitors, Dr. Kyung S. Lee [U.S. National Cancer Institute (NCI), Bethesda, MD, USA] for providing the GST-PBIPtide-A6 vector, Eugene Kim (Johns Hopkins Medical Institutions, Baltimore, MD, USA) for his help with the Western blots, and Prof. J. W. R. Nortier (Leiden University Medical Centre, Leiden, The Netherlands) and Prof. E. Van der Wall (University Medical Centre Utrecht, Utrecht, The Netherlands) for their support and discussion. This study was supported by the Flight Attendant Medical Research Institute (FAMRI), an NCI Specialized Programs of Research Excellence (SPORE) grant (P50CA58236), Aegon, and the Prostate Cancer Foundation (Koch Award). M.W. was financially supported by fellowships from the Dr. Saal van Zwanenbergstichting, the Huygens Scholarship Programme (HSP) Talentenprogramma, and Leiden University. The authors declare no conflicts of interest. The funding sources had no role in the study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript.	Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Bahassi E, 2011, EXP BIOL MED, V236, P648, DOI 10.1258/ebm.2011.011011; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bolanos-Garcia VM, 2009, CURR CANCER DRUG TAR, V9, P131, DOI 10.2174/156800909787580980; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chan EHY, 2008, CHROMOSOMA, V117, P457, DOI 10.1007/s00412-008-0165-5; Chopra P, 2010, EXPERT OPIN INV DRUG, V19, P27, DOI 10.1517/13543780903483191; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cordoba E. V., 2013, AIDS, DOI 10.1097/QAD.0b013e328361fa4a; Crane R, 2004, BIOL CELL, V96, P215, DOI 10.1016/j.biolcel.2003.09.008; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; De Luca M, 2006, CELL CYCLE, V5, P296; Deeraksa A, 2013, ONCOGENE, V32, P2973, DOI 10.1038/onc.2012.309; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deleporte A, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3031; Gandhi L, 2009, J CLIN ONCOL, V27; Hanisch A, 2006, MOL BIOL CELL, V17, P448, DOI 10.1091/mbc.E05-08-0801; Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208; Kortenhorst MSQ, 2008, CLIN CANCER RES, V14, P6886, DOI 10.1158/1078-0432.CCR-08-0119; Lee KS, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-4; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Mross K, 2008, J CLIN ONCOL, V26, P5511, DOI 10.1200/JCO.2008.16.1547; Pandha HS, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.14547; Park JE, 2009, P NATL ACAD SCI USA, V106, P1725, DOI 10.1073/pnas.0812135106; Prystowsky MB, 2009, J PATHOL, V218, P467, DOI 10.1002/path.2554; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Rokhlin OW, 2006, MOL CANCER RES, V4, P113, DOI 10.1158/1541-7786.MCR-05-0085; Rubin EH, 2006, CLIN CANCER RES, V12, P7039, DOI 10.1158/1078-0432.CCR-06-1802; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Schmit TL, 2010, PHARM RES-DORDR, V27, P989, DOI 10.1007/s11095-010-0051-8; Schoffski P, 2012, EUR J CANCER, V48, P179, DOI 10.1016/j.ejca.2011.11.001; Schoffski P, 2010, EUR J CANCER, V46, P2206, DOI 10.1016/j.ejca.2010.03.039; Schoffski P, 2009, ONCOLOGIST, V14, P559, DOI 10.1634/theoncologist.2009-0010; Sebastian M, 2010, J THORAC ONCOL, V5, P1060, DOI 10.1097/JTO.0b013e3181d95dd4; Shabbeer S, 2007, PROSTATE, V67, P1099, DOI 10.1002/pros.20587; Stadler W.M., 2011, J CLIN ONCOL, V29, P4567; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Takaki T, 2008, CURR OPIN CELL BIOL, V20, P650, DOI 10.1016/j.ceb.2008.10.005; Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yasunaga Y, 2001, CANCER RES, V61, P5969; Yun SM, 2013, CANCER LETT, V331, P250, DOI 10.1016/j.canlet.2013.01.007	46	28	30	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4279	4293		10.1096/fj.12-222893	http://dx.doi.org/10.1096/fj.12-222893			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23884428	Green Published			2022-12-28	WOS:000329747100037
J	Chaudhuri, AD; Yelamanchili, SV; Marcondes, MCG; Fox, HS				Chaudhuri, Amrita Datta; Yelamanchili, Sowmya V.; Marcondes, Maria Cecilia G.; Fox, Howard S.			Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1	FASEB JOURNAL			English	Article						HIV; HAND; dementia; neurodegeneration; SIRT1	CHRONIC INFLAMMATORY REACTION; REPEAT LTR TRANSACTIVATION; SIRT1 EXPRESSION; DOWN-REGULATION; INHIBITION; TARGETS; MODELS; DEACETYLASE; ACTIVATION; CORRELATE	MicroRNA (miR)-142 is up-regulated in the brain in HIV and SIV encephalitis (SIVE). We identified the cell types where miR-142 is up-regulated and its relevant downstream target. Fluorescent in situ hybridization combined with immunofluorescent labeling revealed that miR-142-3p and -5p are expressed within hippocampal neurons and myeloid cells in SIVE. Sirtuin1 (SIRT1) was predicted as a potential miR-142 target by analysis of its 3-UTR and bioinformatic analysis of factors linked to altered hippocampal gene expression profile in SIVE. Overexpression of pre-miR-142 in HEK293T cells led to a 3.7-fold decrease in SIRT1 protein level. Examination of the individual effects of miR-142-5p and miR-142-3p through overexpression and inhibition studies revealed that significant effects on SIRT1 occurred only with miR-142-5p. Luciferase reporter assays revealed a 2.3-fold inhibition of expression due to interaction of miR-142 with the SIRT1 3-UTR, mutation analysis revealed that only the miR-142-5p target site was active. MiR-142 expression in primary human neurons led to a small (1.3-fold) but significant decrease in SIRT1 protein level. Furthermore, qRT-PCR revealed up-regulation of miR-142-3p (6.4-fold) and -5p (3.9-fold) and down-regulation of SIRT1 (33-fold) in macrophages/microglia from animals with SIVE. We have therefore elucidated a miR-mediated mechanism of regulation of SIRT1 expression in SIVE.Chaudhuri, A. D., Yelamanchili, S. V., Marcondes, M. C. G., Fox, H. S. Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1.	[Chaudhuri, Amrita Datta; Yelamanchili, Sowmya V.; Fox, Howard S.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA; [Marcondes, Maria Cecilia G.] Scripps Res Inst, Dept Mol & Cellular Neurosci, La Jolla, CA 92037 USA	University of Nebraska System; University of Nebraska Medical Center; Scripps Research Institute	Fox, HS (corresponding author), Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr,DRC 3008, Omaha, NE 68198 USA.	hfox@unmc.edu		Fox, Howard/0000-0003-2032-374X	U.S. National Institutes of Health [P30 MH062261, R01 MH073490, R21 DA029491]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH073490, P30MH062261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA029491] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by U.S. National Institutes of Health grants P30 MH062261 and R01 MH073490 to H. S. F., and R21 DA029491 to M. C. G. M. The authors declare no conflicts of interest. The authors thank Katy Emanuel for assisting with qRT-PCR, Benjamin Lamberty for help with lentivirus preparation, Brenda Morsey for primary human neuronal culture, Jessica Winkler for IPA, Phillip Purnell for suggestions and discussion, and members of the laboratory of H. S. F. for useful comments.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Bissels U, 2011, STEM CELLS, V29, P847, DOI 10.1002/stem.627; Blazek D, 2008, MOL CELL, V29, P539, DOI 10.1016/j.molcel.2008.02.007; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; Burdo TH, 2005, AIDS, V19, P1704, DOI 10.1097/01.aids.0000186823.76230.33; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Crews L, 2008, J NEUROVIROL, V14, P327, DOI 10.1080/13550280802132840; del Palacio M, 2012, REV MED VIROL, V22, P33, DOI 10.1002/rmv.711; Donmez G, 2012, J NEUROSCI, V32, P124, DOI 10.1523/JNEUROSCI.3442-11.2012; Donmez G, 2010, CELL, V142, P320, DOI 10.1016/j.cell.2010.06.020; Eacker SM, 2009, NAT REV NEUROSCI, V10, P837, DOI 10.1038/nrn2726; Eipper-Mains JE, 2011, RNA, V17, P1529, DOI 10.1261/rna.2775511; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Gao ZG, 2008, BIOCHEM BIOPH RES CO, V376, P793, DOI 10.1016/j.bbrc.2008.09.079; Gaudet AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-110; Gersten M, 2009, J NEUROSCI, V29, P12467, DOI 10.1523/JNEUROSCI.3180-09.2009; Gorospe M, 2008, TRENDS CELL BIOL, V18, P77, DOI 10.1016/j.tcb.2007.11.007; Jiang ML, 2012, NAT MED, V18, P153, DOI 10.1038/nm.2558; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kraft-Terry SD, 2009, NEURON, V64, P133, DOI 10.1016/j.neuron.2009.09.042; Kwon HS, 2008, CELL HOST MICROBE, V3, P158, DOI 10.1016/j.chom.2008.02.002; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Loscher CJ, 2008, EXP EYE RES, V87, P529, DOI 10.1016/j.exer.2008.08.016; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marcondes MCG, 2001, J IMMUNOL, V167, P5429, DOI 10.4049/jimmunol.167.9.5429; Merkerova M, 2008, EUR J HAEMATOL, V81, P304, DOI 10.1111/j.1600-0609.2008.01111.x; Mildner A, 2013, BLOOD, V121, P1016, DOI 10.1182/blood-2012-07-445999; Min H, 2010, EXP MOL MED, V42, P233, DOI 10.3858/emm.2010.42.4.032; Min SW, 2010, NEURON, V67, P953, DOI 10.1016/j.neuron.2010.08.044; Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857; Nishiyama T, 2012, BIOCHEM BIOPH RES CO, V425, P755, DOI 10.1016/j.bbrc.2012.07.148; Noorbakhsh F, 2010, FASEB J, V24, P1799, DOI 10.1096/fj.09-147819; Pagans S, 2005, PLOS BIOL, V3, P210, DOI 10.1371/journal.pbio.0030041; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pena JTG, 2009, NAT METHODS, V6, P139, DOI [10.1038/NMETH.1294, 10.1038/nmeth.1294]; Quintas A, 2012, EXP GERONTOL, V47, P198, DOI 10.1016/j.exger.2011.11.010; Rom S, 2010, FASEB J, V24, P2292, DOI 10.1096/fj.09-143503; Schug TT, 2010, MOL CELL BIOL, V30, P4712, DOI 10.1128/MCB.00657-10; Takeda-Watanabe A, 2012, BIOCHEM BIOPH RES CO, V427, P191, DOI 10.1016/j.bbrc.2012.09.042; Tatro ET, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010337; Thakur BK, 2012, BIOCHEM BIOPH RES CO, V424, P245, DOI 10.1016/j.bbrc.2012.06.084; Wang X, 2009, JOVE-J VIS EXP, V32, pe1499, DOI DOI 10.3791/1499; WATRY D, 1995, AM J PATHOL, V146, P914; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Wojcik M, 2009, MINI-REV MED CHEM, V9, P386, DOI 10.2174/1389557510909030386; Wu D, 2011, NEUROSCIENCE, V190, P386, DOI 10.1016/j.neuroscience.2011.06.017; Xie J, 2013, PHARMACOL RES, V67, P60, DOI 10.1016/j.phrs.2012.10.010; Yelamanchili SV, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.56; Yelamanchili SV, 2010, J NEUROIMMUNE PHARM, V5, P63, DOI 10.1007/s11481-009-9172-4; Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008; Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006; Yoshizaki T, 2009, MOL CELL BIOL, V29, P1363, DOI 10.1128/MCB.00705-08; Yu ZP, 2012, J BIOL CHEM, V287, P22560, DOI 10.1074/jbc.M112.357582; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029; Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001; Zhang HS, 2012, FEBS LETT, V586, P4203, DOI 10.1016/j.febslet.2012.10.023; Zhang HS, 2012, BBA-MOL CELL RES, V1823, P1017, DOI 10.1016/j.bbamcr.2012.02.014; Zhang HS, 2009, VIRUS RES, V146, P51, DOI 10.1016/j.virusres.2009.08.005	64	55	55	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3720	3729		10.1096/fj.13-232678	http://dx.doi.org/10.1096/fj.13-232678			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23752207	Green Published, Bronze			2022-12-28	WOS:000328840500030
J	Jung, JI; Ladd, TB; Kukar, T; Price, AR; Moore, BD; Koo, EH; Golde, TE; Felsenstein, KM				Jung, Joo In; Ladd, Thomas B.; Kukar, Thomas; Price, Ashleigh R.; Moore, Brenda D.; Koo, Edward H.; Golde, Todd E.; Felsenstein, Kevin M.			Steroids as gamma-secretase modulators	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid; A beta; cholesterol metabolites	AMYLOID PRECURSOR PROTEIN; A-BETA; ALZHEIMERS-DISEASE; TRANSMEMBRANE DOMAIN; PLAQUE-FORMATION; PEPTIDE; DEPOSITION; A-BETA-42; PRESENILIN; TARGET	Aggregation and accumulation of A(42) play an initiating role in Alzheimer's disease (AD); thus, selective lowering of A(42) by -secretase modulators (GSMs) remains a promising approach to AD therapy. Based on evidence suggesting that steroids may influence A production, we screened 170 steroids at 10 M for effects on A(42) secreted from human APP-overexpressing Chinese hamster ovary cells. Many acidic steroids lowered A(42), whereas many nonacidic steroids actually raised A(42). Studies on the more potent compounds showed that A(42)-lowering steroids were bonafide GSMs and A(42)-raising steroids were inverse GSMs. The most potent steroid GSM identified was 5-cholanic acid (EC50=5.7 M; its endogenous analog lithocholic acid was virtually equipotent), and the most potent inverse GSM identified was 4-androsten-3-one-17-carboxylic acid ethyl ester (EC50=6.25 M). In addition, we found that both estrogen and progesterone are weak inverse GSMs with further complex effects on APP processing. These data suggest that certain endogenous steroids may have the potential to act as GSMs and add to the evidence that cholesterol, cholesterol metabolites, and other steroids may play a role in modulating A production and thus risk for AD. They also indicate that acidic steroids might serve as potential therapeutic leads for drug optimization/development.Jung, J. I., Ladd, T. B., Kukar, T., Price, A. R., Moore, B. D., Koo, E. H., Golde, T. E., Felsenstein, K. M. Steroids as -secretase modulators.	[Jung, Joo In; Ladd, Thomas B.; Price, Ashleigh R.; Moore, Brenda D.; Golde, Todd E.; Felsenstein, Kevin M.] Univ Florida, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32610 USA; [Jung, Joo In; Ladd, Thomas B.; Price, Ashleigh R.; Moore, Brenda D.; Golde, Todd E.; Felsenstein, Kevin M.] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; [Kukar, Thomas] Emory Univ, Sch Med, Dept Pharmacol & Neurol, Atlanta, GA USA; [Koo, Edward H.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Emory University; University of California System; University of California San Diego	Felsenstein, KM (corresponding author), Univ Florida, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32610 USA.	kfelsenstein0@ufl.edu	Kukar, Thomas/AAW-2612-2021	Moore, Brenda/0000-0002-9685-6561; Kukar, Thomas/0000-0002-3750-6262; Visconti, Ashleigh/0000-0002-7371-136X	U.S. National Institutes of Health [AG-20206]; Coins for Alzheimer's Research Trust; Rotarians in the southeastern United States; NATIONAL INSTITUTE ON AGING [P01AG020206, R00AG032362] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Coins for Alzheimer's Research Trust; Rotarians in the southeastern United States; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	These studies were supported by funds from U.S. National Institutes of Health grant AG-20206 and the Coins for Alzheimer's Research Trust, supported by Rotarians in the southeastern United States. The authors are extremely grateful to Dr. Rong Wang (Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA) for the use of the PE Biosystems Voyager DE STR MALDI-TOF mass spectrometer. The authors also thank Dr. Yong Ran for technical support in performing the notch inhibition assay. The authors are also grateful to Gideon Shapiro and Kristi Ayers for critical reading of the manuscript.	Amtul Z, 2010, NEUROSCIENCE, V169, P781, DOI 10.1016/j.neuroscience.2010.05.031; BARLTROP JA, 1991, BIOORG MED CHEM LETT, V1, P611, DOI 10.1016/S0960-894X(01)81162-8; Barrett PJ, 2012, SCIENCE, V336, P1168, DOI 10.1126/science.1219988; Beel AJ, 2010, BBA-MOL CELL BIOL L, V1801, P975, DOI 10.1016/j.bbalip.2010.03.008; Bhattacharyya R, 2010, BBA-MOL CELL BIOL L, V1801, P960, DOI 10.1016/j.bbalip.2010.04.003; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Chang D, 1997, ADV EXP MED BIOL, V429, P261; Crump CJ, 2011, ACS CHEM NEUROSCI, V2, P705, DOI 10.1021/cn200098p; De Strooper B, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006304; Ebke A, 2011, J BIOL CHEM, V286, P37181, DOI 10.1074/jbc.C111.276972; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Fukuchi J, 2005, J STEROID BIOCHEM, V94, P311, DOI 10.1016/j.jsbmb.2004.11.012; Gijsen HJ, 2012, INT J ALZHEIMERS DIS, V2012; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; Golde TE, 2001, DRUG DISCOV TODAY, V6, P1049, DOI 10.1016/S1359-6446(01)01965-1; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hall A, 2010, BIOORG MED CHEM LETT, V20, P1306, DOI 10.1016/j.bmcl.2009.08.072; Haskell SG, 1997, J CLIN EPIDEMIOL, V50, P1249, DOI 10.1016/S0895-4356(97)00169-8; Hubbs JL, 2012, J MED CHEM, V55, P9270, DOI 10.1021/jm300976b; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jayaraman A, 2012, ENDOCRINOLOGY, V153, P5467, DOI 10.1210/en.2012-1464; Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kounnas MZ, 2010, NEURON, V67, P769, DOI 10.1016/j.neuron.2010.08.018; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kukar T, 2008, CURR TOP MED CHEM, V8, P47, DOI 10.2174/156802608783334042; Kukar TL, 2008, NATURE, V453, P925, DOI 10.1038/nature07055; Kukar TL, 2011, J BIOL CHEM, V286, P39804, DOI 10.1074/jbc.M111.274696; Lessard C., 2012, SOC NEUR ANN M, V750, pE66; Li XC, 2013, NATURE, V493, P56, DOI 10.1038/nature11801; Loureiro RM, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt173; Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; McLendon C, 2000, FASEB J, V14, P2383; Moore BD, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt121; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Nunes AF, 2012, MOL NEUROBIOL, V45, P440, DOI 10.1007/s12035-012-8256-y; Oehlrich D, 2011, J MED CHEM, V54, P669, DOI 10.1021/jm101168r; Ohki Y, 2011, EMBO J, V30, P4815, DOI 10.1038/emboj.2011.372; Popp J, 2012, J NEUROCHEM, V123, P310, DOI 10.1111/j.1471-4159.2012.07893.x; Prasanthi JRP, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-1; Richter L, 2010, P NATL ACAD SCI USA, V107, P14597, DOI 10.1073/pnas.1003026107; Rivkin A, 2010, BIOORG MED CHEM LETT, V20, P1269, DOI 10.1016/j.bmcl.2009.11.101; Russo C, 1997, FEBS LETT, V409, P411, DOI 10.1016/S0014-5793(97)00564-4; Sagi SA, 2011, J BIOL CHEM, V286, P39794, DOI 10.1074/jbc.M111.277228; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Steven G. Y., J PHYSL, V92, P289; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Suzuki T, 2008, J PHARMACOL SCI, V107, P285, DOI 10.1254/jphs.08006FP; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; Tognolini M, 2012, CHEMMEDCHEM, V7, P1071, DOI 10.1002/cmdc.201200102; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wang RS, 2006, J BIOL CHEM, V281, P15330, DOI 10.1074/jbc.M512574200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yue X, 2005, P NATL ACAD SCI USA, V102, P19198, DOI 10.1073/pnas.0505203102; Zall A, 2011, BIOORGAN MED CHEM, V19, P4903, DOI 10.1016/j.bmc.2011.06.062	65	32	33	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3775	3785		10.1096/fj.12-225649	http://dx.doi.org/10.1096/fj.12-225649			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23716494	Green Published			2022-12-28	WOS:000328840500035
J	Nicholas, LM; Rattanatray, L; MacLaughlin, SM; Ozanne, SE; Kleemann, DO; Walker, SK; Morrison, JL; Zhang, S; Muhlhausler, BS; Martin-Gronert, MS; McMillen, IC				Nicholas, Lisa M.; Rattanatray, Leewen; MacLaughlin, Severence M.; Ozanne, Susan E.; Kleemann, Dave O.; Walker, Simon K.; Morrison, Janna L.; Zhang, Song; Muhlhaeusler, Beverley S.; Martin-Gronert, Malgorzata S.; McMillen, Isabella C.			Differential effects of maternal obesity and weight loss in the periconceptional period on the epigenetic regulation of hepatic insulin-signaling pathways in the offspring	FASEB JOURNAL			English	Article						pregnancy; embryo; fetus; diabetes; programming; microRNAs	11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; CARBOXYKINASE GENE-TRANSCRIPTION; LATE-GESTATION; DIABETES-MELLITUS; GLUCOSE-TOLERANCE; POSTNATAL LAMB; ADIPOSE-TISSUE; BIRTH-WEIGHT; DB/DB MICE; EXPRESSION	Our aim was to determine the effect of exposure to maternal obesity or to maternal weight loss around conception on the programming of hepatic insulin signaling in the offspring. We used an embryo transfer model in sheep to investigate the effects of exposure to either maternal obesity or to weight loss in normal and obese mothers preceding and for 1 wk after conception on the expression of hepatic insulin-signaling and gluconeogenic factors and key miRNAs involved in insulin signaling in the offspring. We found that exposure to maternal obesity resulted in increased hepatic miR-29b (P<0.05), miR-103 (P<0.01), and miR-107 (P<0.05) expression, a decrease in IR (P<0.05), phopsho-Akt (P<0.01), and phospho-FoxO1 (P<0.01) abundance, and a paradoxical decrease in 11HSD1 (P<0.05), PEPCK-C (P<0.01), and PEPCK-M (P<0.05) expression in lambs. These changes were ablated by a period of moderate dietary restriction imposed during the periconceptional period. Maternal dietary restriction alone also resulted in decreased abundance of a separate subset of hepatic insulin-signaling molecules, namely, IRS1 (P<0.05), PDK1 (P<0.01), phospho-PDK1 (P<0.05), and aPKC (P<0.05) and in decreased PEPCK-C (P<0.01) and G6Pase (P<0.01) expression in the lamb. Our findings highlight the sensitivity of the epigenome to maternal nutrition around conception and the need for dietary interventions that maximize metabolic benefits and minimize metabolic costs for the next generation.Nicholas, L. M., Rattanatray, L., MacLaughlin, S. M., Ozanne, S. E., Kleemann, D. O., Walker, S. K., Morrison, J. L., Zhang, S., Muhlhausler, B. S., Martin-Gronert, M. S., McMillen, I. C. Differential effects of maternal obesity and weight loss in the periconceptional period on the epigenetic regulation of hepatic insulin-signaling pathways in the offspring.	[Nicholas, Lisa M.; Rattanatray, Leewen; MacLaughlin, Severence M.; Morrison, Janna L.; Zhang, Song; Muhlhaeusler, Beverley S.; McMillen, Isabella C.] Univ S Australia, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia; [Rattanatray, Leewen] Univ Adelaide, Discipline Physiol, Sch Mol & Life Sci, Adelaide, SA, Australia; [Ozanne, Susan E.; Martin-Gronert, Malgorzata S.] Univ Cambridge, Addenbrookes Hosp, Metab Res Labs, Inst Metab Sci, Cambridge CB2 2QQ, England; [Kleemann, Dave O.; Walker, Simon K.] South Australian Res & Dev Inst, Turretfield Res Ctr, Rosedale, SA, Australia	University of South Australia; University of Adelaide; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; South Australian Research & Development Institute (SARDI)	McMillen, IC (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	caroline.mcmillen@newcastle.edu.au	McMillen, Isabella Caroline/N-5540-2019; Morrison, Janna/B-8308-2009	Morrison, Janna/0000-0002-8602-8519; Nicholas, Lisa/0000-0003-1976-1953; Ozanne, Susan/0000-0001-8753-5144	Brailsford Robertson Trust; Australia National Health and Medical Research Council (CMcM); MRC [G0600717] Funding Source: UKRI; British Heart Foundation [FS/09/029/27902] Funding Source: researchfish; Medical Research Council [G0600717, G0600717B, MC_UU_12012/5/B] Funding Source: researchfish	Brailsford Robertson Trust; Australia National Health and Medical Research Council (CMcM); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Brailsford Robertson Trust and the Australia National Health and Medical Research Council (CMcM). The authors gratefully acknowledge the expert assistance provided by Bernard Chuang, Laura O'Carroll, and Pamela Sim (Early Origins of Adult Health Research Group) and Dr. Jen Kelly and Skye Rudiger (Turretfield Research Centre) during the course of this study.	AFRC (Agricultural and Food Research Council), 1993, EN PROT REQ RUM ADV, P100; AIELLO RJ, 1987, COMP BIOCHEM PHYS B, V88, P193, DOI 10.1016/0305-0491(87)90100-3; Beale EG, 2007, CELL BIOCHEM BIOPHYS, V48, P89, DOI 10.1007/s12013-007-0025-6; Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808; Catalano PM, 2002, AM J PHYSIOL-ENDOC M, V282, pE522, DOI 10.1152/ajpendo.00124.2001; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950; Cohen AW, 2003, AM J PHYSIOL-ENDOC M, V285, pE1151, DOI 10.1152/ajpendo.00324.2003; de Rooij SR, 2006, DIABETES CARE, V29, P1897, DOI 10.2337/dc06-0460; DORNER G, 1994, HORM METAB RES, V26, P213, DOI 10.1055/s-2007-1001668; Forhead AJ, 2008, J PHYSIOL-LONDON, V586, P2393, DOI 10.1113/jphysiol.2007.149237; Greenwood PL, 2000, REPROD FERT DEVELOP, V12, P149, DOI 10.1071/RD00053; Hall RK, 2007, MOL ENDOCRINOL, V21, P550, DOI 10.1210/me.2006-0307; Hanson RW, 2009, J BIOL CHEM, V284, P27021, DOI 10.1074/jbc.R109.040519; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; He AB, 2007, MOL ENDOCRINOL, V21, P2785, DOI 10.1210/me.2007-0167; Jordan SD, 2011, NAT CELL BIOL, V13, P434, DOI 10.1038/ncb2211; Kakar MA, 2005, THERIOGENOLOGY, V64, P1090, DOI 10.1016/j.theriogenology.2004.12.017; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Krebs M, 2005, DIABETES OBES METAB, V7, P621, DOI 10.1111/j.1463-1326.2004.00439.x; Kumanyika SK, 2008, CIRCULATION, V118, P428, DOI 10.1161/CIRCULATIONAHA.108.189702; Liu YJ, 2005, DIABETES, V54, P32, DOI 10.2337/diabetes.54.1.32; Long NM, 2010, J ANIM SCI, V88, P3546, DOI 10.2527/jas.2010-3083; Luo J, 2005, J CELL BIOL, V170, P455, DOI 10.1083/jcb.200503088; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Mora A, 2005, BIOCHEM J, V385, P639, DOI 10.1042/BJ20041782; Muhlhausler BS, 2006, FASEB J, V20, P1257, DOI 10.1096/fj.05-5241fje; Muhlhausler BS, 2007, ENDOCRINOLOGY, V148, P6157, DOI 10.1210/en.2007-0770; Muhlhausler BS, 2009, ENDOCRINOLOGY, V150, P4287, DOI 10.1210/en.2009-0462; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nijland MJ, 2010, J PHYSIOL-LONDON, V588, P1349, DOI 10.1113/jphysiol.2009.184168; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; Pandey AK, 2011, MOL CELL ENDOCRINOL, V332, P125, DOI 10.1016/j.mce.2010.10.004; Postic C, 2004, DIABETES METAB, V30, P398, DOI 10.1016/S1262-3636(07)70133-7; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rattanatray L, 2010, ENDOCRINOLOGY, V151, P5195, DOI 10.1210/en.2010-0501; RUSSEL AJF, 1981, J AGR SCI, V97, P723, DOI 10.1017/S0021859600037096; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Smith NA, 2010, ANIM REPROD SCI, V121, P94, DOI 10.1016/j.anireprosci.2010.05.001; Staab CA, 2010, J STEROID BIOCHEM, V119, P56, DOI 10.1016/j.jsbmb.2009.12.013; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Todd SE, 2009, PEDIATR RES, V65, P409, DOI 10.1203/PDR.0b013e3181975efa; Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112; Waterland RA, 2009, HORM RES, V71, P13, DOI 10.1159/000178030; Whitaker RC, 2004, PEDIATRICS, V114, pE29, DOI 10.1542/peds.114.1.e29; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang S, 2010, FASEB J, V24, P2772, DOI 10.1096/fj.09-154294	50	85	86	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3786	3796		10.1096/fj.13-227918	http://dx.doi.org/10.1096/fj.13-227918			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729590				2022-12-28	WOS:000328840500036
J	Terrando, N; Gomez-Galan, M; Yang, T; Carlstrom, M; Gustavsson, D; Harding, RE; Lindskog, M; Eriksson, LI				Terrando, Niccolo; Gomez-Galan, Marta; Yang, Ting; Carlstrom, Mattias; Gustavsson, Daniel; Harding, Ralph E.; Lindskog, Maria; Eriksson, Lars I.			Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline	FASEB JOURNAL			English	Article						inflammation; resolution; long-term potentiation; astrocytes; dementia	LONG-TERM POTENTIATION; INFLAMMATION-RESOLUTION; LIPID MEDIATORS; CIRCUITS; INTERLEUKIN-1-BETA; NEUROINFLAMMATION; INFECTION; MEMORY	Hospitalization for major surgery or critical illness often associates with cognitive decline. Inflammation and dysregulation of the innate immune system can exert broad effects in the periphery and central nervous system (CNS), yet the mechanisms underlying memory impairment after surgery remain poorly understood and without effective therapy. Endogenous regulation of acute inflammation is providing novel approaches to treat several disease states including sepsis, pain, obesity and diabetes. Resolvins are potent endogenous lipid mediators biosynthesized during the resolution phase of acute inflammation that display immunoresolvent actions. Here, using a mouse model of surgery-induced cognitive decline we report that orthopedic surgery affects hippocampal neuronal-glial function, including synaptic transmission and plasticity. Systemic prophylaxis with aspirin-triggered resolvin D1 (AT-RvD1: 7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, as little as 100 ng dose per mouse) improved memory decline following surgery and abolished signs of synaptic dysfunction. Moreover, delayed administration 24 h after surgery also attenuated signs of neuronal dysfunction postoperatively. AT-RvD1 also limited peripheral damage by modulating the release of systemic interleukin (IL)-6 and improved other clinical markers of tissue injury. Collectively, these results demonstrate a novel role of AT-RvD1 in modulating the proinflammatory milieu after aseptic injury and protecting the brain from neuroinflammation, synaptic dysfunction and cognitive decline. These findings provide novel and safer approaches to treat postoperative cognitive decline and potentially other forms of memory dysfunctions.Terrando, N., Gomez-Galan, M., Yang, T., Carlstrom, M., Gustavsson, D., Harding, R. E., Lindskog, M., Eriksson, L. I. Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline.	[Terrando, Niccolo; Gomez-Galan, Marta; Yang, Ting; Carlstrom, Mattias; Gustavsson, Daniel; Eriksson, Lars I.] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; [Gomez-Galan, Marta; Lindskog, Maria] Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; [Harding, Ralph E.] Carl Vinson Vet Affairs Med Ctr, Dept Surg, Dublin, GA USA; [Eriksson, Lars I.] Karolinska Univ Hosp, Dept Anesthesiol Surg Serv & Intens Care Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Terrando, N (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Nanna Svart Vag 2, S-17177 Stockholm, Sweden.	niccolo.terrando@ki.se	Lindskog, Maria/F-1729-2011; Carlström, Mattias/E-7350-2015; Terrando, Niccolo/Y-4349-2019	Lindskog, Maria/0000-0002-4178-2825; Carlström, Mattias/0000-0001-9923-8729; Terrando, Niccolo/0000-0003-1803-5853; Gomez-Galan, Marta/0000-0002-8355-9795	European Society of Anaesthesiology; Karolinska Institutet Foundations; Thorsten Soderberg Foundation (Stockholm, Sweden); Stockholm County Council (Stockholm, Sweden); Research Council for Medicine, Sweden	European Society of Anaesthesiology; Karolinska Institutet Foundations(Karolinska Institutet); Thorsten Soderberg Foundation (Stockholm, Sweden); Stockholm County Council (Stockholm, Sweden)(Stockholm County Council); Research Council for Medicine, Sweden	The authors thank Michel Goiny and Anette Ebberyd for excellent technical support; Lena Sandlund for assistance with the liver enzymes measurement. This work was funded by a research grant program of the European Society of Anaesthesiology; Research Council for Medicine, Sweden; Karolinska Institutet Foundations; Thorsten Soderberg Foundation (Stockholm, Sweden); and the Stockholm County Council (Stockholm, Sweden).	Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Barrientos RM, 2012, J NEUROSCI, V32, P14641, DOI 10.1523/JNEUROSCI.2173-12.2012; Ben Menachem-Zidon O, 2011, BRAIN BEHAV IMMUN, V25, P1008, DOI 10.1016/j.bbi.2010.11.007; Carlstrom M, 2013, ACTA PHYSIOL, V207, P732, DOI 10.1111/apha.12079; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Cibelli M, 2010, ANN NEUROL, V68, P360, DOI 10.1002/ana.22082; Fong TG, 2009, NAT REV NEUROL, V5, P210, DOI 10.1038/nrneurol.2009.24; Gomez-Galan M, 2013, MOL PSYCHIATR, V18, P582, DOI 10.1038/mp.2012.10; Halassa MM, 2010, ANNU REV PHYSIOL, V72, P335, DOI 10.1146/annurev-physiol-021909-135843; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Liu Guanghao, 2012, Am J Neurodegener Dis, V1, P60; Mas E, 2012, CLIN CHEM, V58, P1476, DOI 10.1373/clinchem.2012.190199; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Norling LV, 2011, J IMMUNOL, V186, P5543, DOI 10.4049/jimmunol.1003865; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2012, FASEB J, V26, P1755, DOI 10.1096/fj.11-201442; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Tang JXX, 2013, ANN SURG, V257, P439, DOI 10.1097/SLA.0b013e318269d623; Terrando N, 2011, ANN NEUROL, V70, P986, DOI 10.1002/ana.22664; Terrando N, 2011, MAYO CLIN PROC, V86, P885, DOI 10.4065/mcp.2011.0332; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123; Zhang MJ, 2012, ANNU REV NUTR, V32, P203, DOI 10.1146/annurev-nutr-071811-150726	41	107	109	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3564	3571		10.1096/fj.13-230276	http://dx.doi.org/10.1096/fj.13-230276			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23709617				2022-12-28	WOS:000328840500016
J	Wei, L; Wu, J; Liu, H; Yang, HL; Rong, MQ; Li, DS; Zhang, PH; Han, JY; Lai, R				Wei, Lin; Wu, Jing; Liu, Han; Yang, Hailong; Rong, Mingqiang; Li, Dongsheng; Zhang, Pinghu; Han, Junyou; Lai, Ren			A mycobacteriophage-derived trehalose-6,6 '-dimycolate-binding peptide containing both antimycobacterial and anti-inflammatory abilities	FASEB JOURNAL			English	Article						Mycobacterium tuberculosis; cord factor; immunoregulative effects; cytokine; mouse model	TUBERCULOSIS; GENE; EXPRESSION; INITIATION; GRANULOMA	Bacteriophages, the viruses of eubacteria, have developed unique mechanisms to interact with their host bacteria. They have been viewed as potential antibacterial therapeutics. Mycobacteriophage-derived compounds may interact with Mycobacterium tuberculosis (MTB) and/or its components, such as the cord factor, trehalose-6,6'-dimycolate (TDM), which is the most abundant glycolipid produced on the surface of MTB. TDM emulsion injected intravenously into mice induces lung immunopathology that mimics many aspects of MTB infection. Thus, TDM is an important target for anti-MTB agent development. On the basis of genomics information of mycobacteriophages, 200 peptides were synthesized. Their effects on MTB, their interactions with TDM, and anti-inflammatory activities were tested. One of them (PK34) showed MTB-killing activity with a minimal inhibitory concentration of 50 g/ml and TDM-binding ability. In a mouse model, PK34 showed comparable ability to clear MTB as rifampin did in vivo. It also exerted strong activity to inhibit MTB or TDM-induced inflammation in vivo. PK34 significantly inhibited inflammatory cytokines secretions by inactivating MAPK and PKB signals while it maintained certain proinflammatory cytokine production. It is possible to prospect for TDM-binding and/or anti-MTB peptides by mining the mycobacteriophages genome. In addition to its direct MTB-killing ability, PK34 might be a useful adjunct in the treatment of granulomatous inflammation occurring during mycobacterial infection or a template for developing antituberculosis (TB) agents because of its immunoregulative effects. As a TDM-binding peptide, PK34 may be a promising tool to study TDM's interactions with corresponding receptors and signal pathways.	[Wei, Lin; Wu, Jing; Liu, Han; Yang, Hailong; Rong, Mingqiang; Li, Dongsheng; Lai, Ren] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming, Peoples R China; [Wei, Lin; Wu, Jing; Liu, Han; Yang, Hailong; Rong, Mingqiang; Li, Dongsheng; Lai, Ren] Kunming Inst Zool, Kunming, Peoples R China; [Wei, Lin; Lai, Ren] Nanjing Agr Univ, Minist Agr, Key Lab Microbiol Engn Agr Environm, Life Sci Coll, Nanjing, Jiangsu, Peoples R China; [Wu, Jing; Liu, Han] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; [Zhang, Pinghu] China Pharmaceut Univ, Jiangsu Ctr New Drug Screening, Nanjing, Jiangsu, Peoples R China; [Zhang, Pinghu] China Pharmaceut Univ, Natl Drug Screening Lab, Nanjing, Jiangsu, Peoples R China; [Han, Junyou] Jilin Univ, Changchun 130023, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Kunming Institute of Zoology; Ministry of Agriculture & Rural Affairs; Nanjing Agricultural University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; China Pharmaceutical University; China Pharmaceutical University; Jilin University	Han, JY (corresponding author), 32 East Jiaochang Rd, Kunming 650223, Yunnan, Peoples R China.	han_junyou@126.com; rlai@mail.kiz.ac.cn	Wei, Lin/AAE-3043-2022; yang, hailong/GXH-9625-2022	Wei, Lin/0000-0003-3359-2471; 	Chinese National Natural Science Foundation [30830021, 31025025, 31070701, 31000960, U1132601]; Ministry of Science and Technology [2010CB529800, 2009ZX09103-1/091, 2011ZX09102-002-10]; Ministry of Agriculture [2009ZX08009-159B]; Yunnan Province [Y103951111]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Ministry of Agriculture(Gida Tarim Ve Hayvancilik Bakanligi); Yunnan Province	This work was supported by the Chinese National Natural Science Foundation (30830021, 31025025, 31070701, 31000960, 31025025, U1132601), the Ministry of Science and Technology (2010CB529800, 2009ZX09103-1/091, 2011ZX09102-002-10), the Ministry of Agriculture (2009ZX08009-159B), and Yunnan Province (Y103951111).	BEKIERKUNST A, 1969, J BACTERIOL, V100, P95, DOI 10.1128/JB.100.1.95-102.1969; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P301; Chan J, 2004, CLIN IMMUNOL, V110, P2, DOI 10.1016/S1521-6616(03)00210-9; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Co DO, 2004, CLIN IMMUNOL, V113, P130, DOI 10.1016/j.clim.2004.08.012; Cooper AM, 2008, IMMUNOL REV, V226, P191, DOI 10.1111/j.1600-065X.2008.00702.x; Figueiredo R, 2009, BIOORGAN MED CHEM, V17, P503, DOI 10.1016/j.bmc.2008.12.006; Geisel RE, 2005, J IMMUNOL, V174, P5007, DOI 10.4049/jimmunol.174.8.5007; Hatfull GF, 2010, ANNU REV MICROBIOL, V64, P331, DOI 10.1146/annurev.micro.112408.134233; Haydel SE, 2010, PHARMACEUTICALS-BASE, V3, P2268, DOI 10.3390/ph3072268; Hunter RL, 2006, ANN CLIN LAB SCI, V36, P371; Kim JH, 2008, FREE RADICAL BIO MED, V45, P885, DOI 10.1016/j.freeradbiomed.2008.06.019; Leal IS, 1999, INFECT IMMUN, V67, P5747, DOI 10.1128/IAI.67.11.5747-5754.1999; Lee WB, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002614; Li JX, 2007, MOL CELL PROTEOMICS, V6, P882, DOI 10.1074/mcp.M600334-MCP200; Liu J, 2004, NAT BIOTECHNOL, V22, P185, DOI 10.1038/nbt932; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; Ma YF, 2010, GENOMICS, V95, P66, DOI 10.1016/j.ygeno.2009.09.004; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; Matsunaga I, 2009, J EXP MED, V206, P2865, DOI 10.1084/jem.20092533; McNerney R, 2005, J APPL MICROBIOL, V99, P223, DOI 10.1111/j.1365-2672.2005.02596.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Odegrip R, 2000, J VIROL, V74, P4057, DOI 10.1128/JVI.74.9.4057-4063.2000; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; ORSINI G, 1993, J BACTERIOL, V175, P85, DOI 10.1128/JB.175.1.85-93.1993; Paige C, 2010, CELL MICROBIOL, V12, P301, DOI 10.1111/j.1462-5822.2009.01424.x; Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273; Schoolnik GK, 2004, NAT BIOTECHNOL, V22, P505, DOI 10.1038/nbt0504-505; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; Welsh KJ, 2010, TRANSL RES, V156, P207, DOI 10.1016/j.trsl.2010.06.001; Yoong P, 2006, J BACTERIOL, V188, P2711, DOI 10.1128/JB.188.7.2711-2714.2006	33	16	18	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3067	3077		10.1096/fj.13-227454	http://dx.doi.org/10.1096/fj.13-227454			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603838				2022-12-28	WOS:000329877600014
J	Zhu, M; Van Dyke, TE; Gyurko, R				Zhu, Min; Van Dyke, Thomas E.; Gyurko, Robert			Resolvin E1 regulates osteoclast fusion via DC-STAMP and NFATc1	FASEB JOURNAL			English	Article						osteoimmunology; inflammation resolution; lipid mediator	BONE-RESORPTION; CELL-FUSION; INFLAMMATION; RESOLUTION; RECEPTOR; MECHANISMS; IMMUNE; DIFFERENTIATION; ACTIVATION; RANKL	Interactions between the immune and skeletal systems in inflammatory bone diseases are well appreciated, but the underlying molecular mechanisms that coordinate the resolution phase of inflammation and bone turnover have not been unveiled. Here we investigated the direct actions of the proresolution mediator resolvin E1 (RvE1) on bone-marrow-cell-derived osteoclasts in an in vitro murine model of osteoclast maturation and inflammatory bone resorption. Investigation of the actions of RvE1 treatment on the specific stages of osteoclast maturation revealed that RvE1 targeted late stages of osteoclast maturation to decrease osteoclast formation by 32.8%. Time-lapse vital microscopy and migration assays confirmed that membrane fusion of osteoclast precursors was inhibited. The osteoclast fusion protein DC-STAMP was specifically targeted by RvE1 receptor binding and was down-regulated by 65.4%. RvE1 did not affect the induction of the essential osteoclast transcription factor nuclear factor of activated T cells c1 (NFATc1) or its nuclear translocation; however, NFATc1 binding to the DC-STAMP promoter was significantly inhibited by 60.9% with RvE1 treatment as shown in electrophoresis mobility shift assay. Our findings suggest that proresolution mediators act directly on osteoclasts, in addition to down-regulation of inflammation, providing a novel mechanism for modulating osteoclast signaling in osteolytic inflammatory disease.Zhu, M., Van Dyke, T. E., Gyurko, R. Resolvin E1 regulates osteoclast fusion via DC-STAMP and NFATc1.	[Zhu, Min; Gyurko, Robert] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA; [Van Dyke, Thomas E.] Forsyth Inst, Dept Periodontol, Cambridge, MA USA	Boston University; Harvard University; Forsyth Institute	Gyurko, R (corresponding author), Boston Univ, 650 Albany St,Rm X-344A, Boston, MA 02118 USA.	gyurko@bu.edu		Gyurko, Robert/0000-0003-1457-6812	U.S. Public Health Service from the National Institutes of Dental and Craniofacial Research [DE19938]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019938] Funding Source: NIH RePORTER	U.S. Public Health Service from the National Institutes of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Dr. B. S. Nikolajczyk and Dr. V. Trinkaus-Randall for technical support and discussion. RvE1 was kindly provided by Dr. C. N. Serhan, (Brigham and Women's Hospital, Boston, MA, USA). This work was supported by U.S. Public Health Service grant DE19938 from the National Institutes of Dental and Craniofacial Research. M.Z. designed and carried out experiments, analyzed data, and wrote the manuscript; T. E. V. D. was involved in experimental design and provided reagents, data analysis, and preparation of the manuscript; R. G was involved in experimental design, data analysis, and manuscript preparation. Conflicts of interest: T. E. V. D. is an inventor on patents (resolvins) assigned to Boston University and licensed to Resolvyx Pharmaceuticals. T. E. V. D. is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company. T.E.V.D.'s interests were reviewed and managed by Boston University and now the Forsyth Institute in accordance with their conflict of interest policies.	Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711; Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Ariel A, 2006, NAT IMMUNOL, V7, P1209, DOI 10.1038/ni1392; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140-6736(11)60243-2; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499; Cheng YLJ, 2012, DIABETES CARE, V35, P1686, DOI 10.2337/dc12-0046; El-Gabalawy H, 2010, J RHEUMATOL, V37, P2, DOI 10.3899/jrheum.091461; Feng X, 2011, ANNU REV PATHOL-MECH, V6, P121, DOI 10.1146/annurev-pathol-011110-130203; Fierro IM, 2002, J PHARMACOL EXP THER, V300, P385, DOI 10.1124/jpet.300.2.385; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Gao L, 2013, J IMMUNOL, V190, P689, DOI 10.4049/jimmunol.1103688; Garcia C, 1996, J BONE MINER RES, V11, P1619; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hartgers FC, 2000, EUR J IMMUNOL, V30, P3585, DOI 10.1002/1521-4141(200012)30:12<3585::AID-IMMU3585>3.3.CO;2-P; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005; Herrera BS, 2008, BRIT J PHARMACOL, V155, P1214, DOI 10.1038/bjp.2008.367; Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003; Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106; Hwang SY, 2011, BBA-MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002; Ishii M, 2008, MOD RHEUMATOL, V18, P220, DOI 10.1007/s10165-008-0051-2; Izumi Y, 2000, PERIODONTOL, V56, P166; Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007; Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007-0237; Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518; Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514; Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007-0038; Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875-009-9316-6; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Negishi-Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600-065X.2009.00821.x; Ohira T, 2010, J BIOL CHEM, V285, P3451, DOI 10.1074/jbc.M109.044131; Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8; Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087; Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2011, FASEB J, V25, P1441, DOI 10.1096/fj.11-0502ufm; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Takahashi N, 2011, FRONT BIOSCI-LANDMRK, V16, P21, DOI 10.2741/3673; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Van Dyke TE, 2008, J PERIODONTOL, V79, P1601, DOI 10.1902/jop.2008.080173; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401; Yuan JZ, 2010, PROSTAG OTH LIPID M, V92, P85, DOI 10.1016/j.prostaglandins.2010.04.001	55	38	38	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3344	3353		10.1096/fj.12-220228	http://dx.doi.org/10.1096/fj.12-220228			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23629863	Green Published			2022-12-28	WOS:000329877600039
J	Polyak, MJ; Vivithanaporn, P; Maingat, FG; Walsh, JG; Branton, W; Cohen, EA; Meeker, R; Power, C				Polyak, Maria J.; Vivithanaporn, Pornpun; Maingat, Ferdinand G.; Walsh, John G.; Branton, William; Cohen, Eric A.; Meeker, Rick; Power, Christopher			Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence	FASEB JOURNAL			English	Article						HIV-1; FIV; type 1 interferon; tetherin; CD317; BST-2; microglia	FELINE IMMUNODEFICIENCY VIRUS; ENHANCES MACROPHAGE TROPISM; IN-SITU HYBRIDIZATION; AFRICAN-GREEN MONKEYS; NERVOUS-SYSTEM; LENTIVIRUS INFECTION; MESSENGER-RNA; ENVELOPE GLYCOPROTEIN; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING	The lentiviruses, human and feline immunodeficiency viruses (HIV-1 and FIV, respectively), infect the brain and cause neurovirulence, evident as neuronal injury, inflammation, and neurobehavioral abnormalities with diminished survival. Herein, different lentivirus infections in conjunction with neural cell viability were investigated, concentrating on type 1 interferon-regulated pathways. Transcriptomic network analyses showed a preponderance of genes involved in type 1 interferon signaling, which was verified by increased expression of the type 1 interferon-associated genes, Mx1 and CD317, in brains from HIV-infected persons (P < 0.05). Leukocytes infected with different strains of FIV or HIV-1 showed differential Mx1 and CD317 expression (P < 0.05). In vivo studies of animals infected with the FIV strains, FIVch or FIVncsu, revealed that FIVch-infected animals displayed deficits in memory and motor speed compared with the FIVncsu-and mock-infected groups (P < 0.05). TNF-alpha, IL-1 beta, and CD40 expression was increased in the brains of FIVch-infected animals; conversely, Mx1 and CD317 transcript levels were increased in the brains of FIVncsu-infected animals, principally in microglia (P < 0.05). Gliosis and neuronal loss were evident among FIVch-infected animals compared with mock-and FIVncsu-infected animals (P < 0.05). Lentiviral infections induce type 1 interferon-regulated gene expression in microglia in a viral diversity-dependent manner, representing a mechanism by which immune responses might be exploited to limit neurovirulence.-Polyak, M. J., Vivithanaporn, P., Maingat, F. G., Walsh, J. G., Branton, W., Cohen, E. A., Meeker, R., Power, C. Differential type 1 interferon- regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence.	[Polyak, Maria J.; Maingat, Ferdinand G.; Walsh, John G.; Branton, William; Power, Christopher] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Vivithanaporn, Pornpun] Mahidol Univ, Fac Sci, Dept Pharmacol, Bangkok 10400, Thailand; [Cohen, Eric A.] Univ Montreal, Inst Rech Clin Montreal, Montreal, PQ, Canada; [Cohen, Eric A.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada; [Meeker, Rick] Univ N Carolina, Dept Neurol, Durham, NC USA	University of Alberta; Mahidol University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; University of North Carolina	Power, C (corresponding author), Univ Alberta, Dept Med Neurol, HMRC 6-11, Edmonton, AB, Canada.	chris.power@ualberta.ca		Branton, William/0000-0002-3259-2544; Power, Christopher/0000-0002-5131-9711	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	C.P. and E.A.C. hold Canada Research Chairs (Tier 1) in Neurological Infection and Immunity and Human Retrovirology, respectively. C.P. is an Alberta Innovates Health Solutions (AIHS) Senior Scholar. J.G.W. is an AIHS Fellow. These studies were supported by the Canadian Institutes of Health Research (to C.P. and E.A.C.).	Acharjee S, 2011, BRAIN, V134, P3209, DOI 10.1093/brain/awr242; Afkhami-Goli A, 2009, J NEUROVIROL, V15, P139, DOI 10.1080/13550280802534763; Andrew AJ, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-80; Arts JHE, 2007, FOOD CHEM TOXICOL, V45, P1856, DOI 10.1016/j.fct.2007.04.001; Barrett BS, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002596; BEEBE AM, 1994, J VIROL, V68, P3080, DOI 10.1128/JVI.68.5.3080-3091.1994; Blasius AL, 2006, J IMMUNOL, V177, P3260, DOI 10.4049/jimmunol.177.5.3260; Boche D, 1996, J NEUROVIROL, V2, P377, DOI 10.3109/13550289609146903; Bosinger SE, 2009, J CLIN INVEST, V119, P3556, DOI 10.1172/JCI40115; Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001; Brown JN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003664; BROWN WC, 1991, J VIROL, V65, P3359, DOI 10.1128/JVI.65.6.3359-3364.1991; BRUNNER D, 1989, J VIROL, V63, P5483, DOI 10.1128/JVI.63.12.5483-5488.1989; CALLANAN JJ, 1992, VET IMMUNOL IMMUNOP, V35, P3, DOI 10.1016/0165-2427(92)90116-8; Cao W, 2009, J EXP MED, V206, P1603, DOI 10.1084/jem.20090547; Celestino M, 2012, J VIROL, V86, P6688, DOI 10.1128/JVI.07037-11; Cheney KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013521; Clements JE, 2008, J NEUROVIROL, V14, P309, DOI 10.1080/13550280802132832; Clements JE, 1996, CLIN MICROBIOL REV, V9, P100, DOI 10.1128/CMR.9.1.100; Cocka L., 2012, 19 C RETR OPP INF; Dietrich I, 2011, J VIROL, V85, P5840, DOI 10.1128/JVI.00071-11; Dionne KR, 2011, J NEUROVIROL, V17, P314, DOI 10.1007/s13365-011-0038-1; DOW SW, 1992, VET IMMUNOL IMMUNOP, V35, P23, DOI 10.1016/0165-2427(92)90118-A; Dube M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000856; Dube M, 2009, J VIROL, V83, P4574, DOI 10.1128/JVI.01800-08; Dunfee RL, 2007, VIROLOGY, V367, P222, DOI 10.1016/j.virol.2007.05.029; Dunfee RL, 2006, P NATL ACAD SCI USA, V103, P15160, DOI 10.1073/pnas.0605513103; Elder JH, 2010, CURR HIV RES, V8, P73, DOI 10.2174/157016210790416389; ENGLISH RV, 1993, J VIROL, V67, P5175, DOI 10.1128/JVI.67.9.5175-5186.1993; Erikson E, 2011, P NATL ACAD SCI USA, V108, P13688, DOI 10.1073/pnas.1101684108; Fadel HJ, 2011, VET IMMUNOL IMMUNOP, V143, P179, DOI 10.1016/j.vetimm.2011.06.002; Fletcher NF, 2008, VET IMMUNOL IMMUNOP, V123, P134, DOI 10.1016/j.vetimm.2008.01.028; Fletcher NF, 2011, VET J, V188, P260, DOI 10.1016/j.tvjl.2010.03.022; Fritz-French C, 2012, CYTOKINE GROWTH F R, V23, P7, DOI 10.1016/j.cytogfr.2012.01.001; Gandhi N, 2009, AIDS RES HUM RETROV, V25, P691, DOI 10.1089/aid.2008.0299; Gannon P, 2011, CURR OPIN NEUROL, V24, P275, DOI 10.1097/WCO.0b013e32834695fb; Giunta Brian, 2007, Critical Reviews in Neurobiology, V19, P79; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Gupta RK, 2009, P NATL ACAD SCI USA, V106, P20889, DOI 10.1073/pnas.0907075106; Hauser H, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-85; Huang JH, 2011, J INFECT DIS, V204, P1557, DOI 10.1093/infdis/jir616; Huang JH, 2010, J VIROL, V84, P9463, DOI 10.1128/JVI.01009-10; Hughes R, 2012, REV MED VIROL, V22, P257, DOI 10.1002/rmv.1708; Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093; Jia B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000429; Johnston JB, 2000, J VIROL, V74, P7211, DOI 10.1128/JVI.74.16.7211-7220.2000; Johnston JB, 2002, J VIROL, V76, P2622, DOI 10.1128/JVI.76.6.2622-2633.2002; Johnston JB, 2002, J VIROL, V76, P3626, DOI 10.1128/JVI.76.8.3626-3636.2002; Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384; Kenyon JC, 2011, VIRUSES-BASEL, V3, P2192, DOI 10.3390/v3112192; Kirchhoff F, 2010, CELL HOST MICROBE, V8, P55, DOI 10.1016/j.chom.2010.06.004; Kolenda-Roberts HM, 2007, FRONT BIOSCI-LANDMRK, V12, P3668, DOI 10.2741/2343; KUIKEN CL, 1995, J GEN VIROL, V76, P175, DOI 10.1099/0022-1317-76-1-175; Kupzig S, 2003, TRAFFIC, V4, P694, DOI 10.1034/j.1600-0854.2003.00129.x; Lederer S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000296; Liberatore RA, 2011, P NATL ACAD SCI USA, V108, P18097, DOI 10.1073/pnas.1113694108; Lichterfeld M, 2012, J LEUKOCYTE BIOL, V91, P27, DOI 10.1189/jlb.0811442; Liner KJ, 2007, J NEUROVIROL, V13, P291, DOI 10.1080/13550280701422383; MacKinnon CD, 2007, J NEUROPHYSIOL, V97, P4368, DOI 10.1152/jn.01136.2006; Maingat F, 2010, J IMMUNOL, V184, P1566, DOI 10.4049/jimmunol.0902575; Maingat F, 2009, J NEUROSCI, V29, P8429, DOI 10.1523/JNEUROSCI.5818-08.2009; Mandl JN, 2008, NAT MED, V14, P1077, DOI 10.1038/nm.1871; Mankowski JL, 1997, J VIROL, V71, P6055, DOI 10.1128/JVI.71.8.6055-6060.1997; Mankowski JL, 2002, J INFECT DIS, V186, pS199, DOI 10.1086/344938; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Miller C, 2011, VET IMMUNOL IMMUNOP, V143, P282, DOI 10.1016/j.vetimm.2011.06.006; Moore RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019838; Na H, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-44; Neil S, 2009, J INTERF CYTOK RES, V29, P569, DOI 10.1089/jir.2009.0077; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Neil SJD, 2007, CELL HOST MICROBE, V2, P193, DOI 10.1016/j.chom.2007.08.001; NOVOTNEY C, 1990, AIDS, V4, P1213, DOI 10.1097/00002030-199012000-00005; Ohtomo T, 1999, BIOCHEM BIOPH RES CO, V258, P583, DOI 10.1006/bbrc.1999.0683; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P2448, DOI 10.1073/pnas.86.7.2448; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P8088, DOI 10.1073/pnas.86.20.8088; Park KM, 2010, CELL SIGNAL, V22, P977, DOI 10.1016/j.cellsig.2010.01.010; PAVLOVIC J, 1993, CIBA F SYMP, V176, P233; Peng G, 2006, J EXP MED, V203, P41, DOI 10.1084/jem.20051512; Power C, 1998, J VIROL, V72, P9109, DOI 10.1128/JVI.72.11.9109-9115.1998; Power C, 1995, CURR TOP MICROBIOL, V202, P89; Power C, 1998, J VIROL, V72, P9045, DOI 10.1128/JVI.72.11.9045-9053.1998; Power C, 2004, J NEUROVIROL, V10, P113, DOI 10.1080/13550280490270815; POWER C, 1994, J VIROL, V68, P4643, DOI 10.1128/JVI.68.7.4643-4649.1994; Power C, 2002, CAN J NEUROL SCI, V29, P19, DOI 10.1017/S0317167100001682; Power C, 2001, TRENDS NEUROSCI, V24, P162, DOI 10.1016/S0166-2236(00)01737-9; Pulliam L, 2011, AIDS, V25, P1721, DOI 10.1097/QAD.0b013e328349f022; Rho MB, 1995, BRAIN BEHAV IMMUN, V9, P366, DOI 10.1006/brbi.1995.1034; Robertson K, 2009, NEUROPSYCHOL REV, V19, P232, DOI 10.1007/s11065-009-9096-z; Sauter D, 2009, CELL HOST MICROBE, V6, P409, DOI 10.1016/j.chom.2009.10.004; Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; TOMPKINS MB, 1991, J AM VET MED ASSOC, V199, P1311; TORTEN M, 1991, J VIROL, V65, P2225, DOI 10.1128/JVI.65.5.2225-2230.1991; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001; Van Damme N, 2008, CELL MICROBIOL, V10, P1040, DOI 10.1111/j.1462-5822.2007.01101.x; van Marle G, 2005, J NEUROVIROL, V11, P107, DOI 10.1080/13550280590922838; van Marle G, 2002, AIDS, V16, P1905, DOI 10.1097/00002030-200209270-00007; Vivithanaporn P, 2010, NEUROLOGY, V75, P1150, DOI 10.1212/WNL.0b013e3181f4d5bb; Vivithanaporn P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012856; Weed MR, 2003, J NEUROVIROL, V9, P452, DOI 10.1080/13550280390218751; Wesselingh SL, 1997, J NEUROIMMUNOL, V74, P1, DOI 10.1016/S0165-5728(96)00160-9; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Wesselingh SL, 2000, METH MOL B, V123, P323; Wesselingh SL, 2001, CURR OPIN NEUROL, V14, P375, DOI 10.1097/00019052-200106000-00018; WESSELINGH SL, 1994, ADV NEUROIMMUNOL, V4, P199, DOI 10.1016/S0960-5428(06)80258-5; Witwer KW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008129; YAMAMOTO JK, 1989, J AM VET MED ASSOC, V194, P213; Zaritsky LA, 2012, J IMMUNOL, V188, P3876, DOI 10.4049/jimmunol.1103024; Zhang FW, 2009, CELL HOST MICROBE, V6, P54, DOI 10.1016/j.chom.2009.05.008; Zhang KY, 2003, J VIROL, V77, P6899, DOI 10.1128/JVI.77.12.6899-6912.2003; Zhang KY, 2001, VIROLOGY, V283, P19, DOI 10.1006/viro.2001.0876; Zhu Y, 2009, FASEB J, V23, P2928, DOI 10.1096/fj.08-128819; Zink MC, 2006, CURR HIV RES, V4, P293; Zink MC, 1997, AM J PATHOL, V151, P793	117	17	17	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2829	2844		10.1096/fj.13-227868	http://dx.doi.org/10.1096/fj.13-227868			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23608145	Green Accepted			2022-12-28	WOS:000328841000031
J	Moleres, A; Campion, J; Milagro, FI; Marcos, A; Campoy, C; Garagorri, JM; Gomez-Martinez, S; Martinez, JA; Azcona-Sanjulian, MC; Marti, A				Moleres, Adriana; Campion, Javier; Milagro, Fermin I.; Marcos, Ascension; Campoy, Cristina; Garagorri, Jesus M.; Gomez-Martinez, Sonia; Alfredo Martinez, J.; Cristina Azcona-Sanjulian, M.; Marti, Amelia		EVASYON Study Grp	Differential DNA methylation patterns between high and low responders to a weight loss intervention in overweight or obese adolescents: the EVASYON study	FASEB JOURNAL			English	Article						epigenetics; biomarkers; dieting response	BODY-MASS INDEX; LIFE-STYLE INTERVENTION; SPANISH ADOLESCENTS; PHYSICAL-ACTIVITY; GENE-EXPRESSION; TROPONIN-T; BLOOD; CHILDHOOD; RISK; SUSCEPTIBILITY	In recent years, epigenetic markers emerged as a new tool to understand the influence of lifestyle factors on obesity phenotypes. Adolescence is considered an important epigenetic window over a human's lifetime. The objective of this work was to explore baseline changes in DNA methylation that could be associated with a better weight loss response after a multidisciplinary intervention program in Spanish obese or overweight adolescents. Overweight or obese adolescents (n = 107) undergoing 10 wk of a multidisciplinary intervention for weight loss were assigned as high or low responders to the treatment. A methylation microarray was performed to search for baseline epigenetic differences between the 2 groups (12 subjects/group), and MALDI-TOF mass spectrometry was used to validate (n = 107) relevant CpG sites and surrounding regions. After validation, 5 regions located in or near AQP9, DUSP22, HIPK3, TNNT1, and TNNI3 genes showed differential methylation levels between high and low responders to the multidisciplinary weight loss intervention. Moreover, a calculated methylation score was significantly associated with changes in weight, BMI-SDS, and body fat mass loss after the treatment. In summary, we have identified 5 DNA regions that are differentially methylated depending on weight loss response. These methylation changes may help to better understand the weight loss response in obese adolescents.	[Moleres, Adriana; Campion, Javier; Milagro, Fermin I.; Alfredo Martinez, J.; Marti, Amelia] Univ Navarra, Dept Nutr Food Sci Physiol & Toxicol, Pamplona 31008, Navarra, Spain; [Campion, Javier; Milagro, Fermin I.; Alfredo Martinez, J.; Marti, Amelia] Inst Hlth Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain; [Marcos, Ascension; Gomez-Martinez, Sonia] Spanish Natl Res Council, Inst Frio, Inst Food Sci Technol & Nutr, Immunonutr Res Grp,Dept Metab & Nutr, Madrid, Spain; [Campoy, Cristina] Univ Granada, Dept Pediat, Sch Med, Granada, Spain; [Garagorri, Jesus M.] Univ Zaragoza, Dept Paediat Radiol & Phys Med, Zaragoza, Spain; [Cristina Azcona-Sanjulian, M.] Univ Navarra Hosp, Dept Pediat, Paediat Endocrinol Unit, Pamplona, Spain	University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia y Tecnologia de Alimentos y Nutricion (ICTAN); University of Granada; University of Zaragoza; University of Navarra	Marti, A (corresponding author), Univ Navarra, Dept Nutr Food Sci Physiol & Toxicol, C Irunlarrea S-N, Pamplona 31008, Navarra, Spain.	amarti@unav.es	Campoy, Cristina/F-4946-2017; Martinez-Gonzalez, Miguel A./AAE-7669-2019; San Julián, María Cristina Azcona/A-1160-2015; Martí, Amelia/H-1192-2017; Milagro, Fermin/F-2315-2015; Agil, Ahmad/D-9620-2014; Marti, Amelia/M-2709-2019; Sanchez, Ascension Marcos/K-4965-2014; Navas-Carretero, Santiago/L-2918-2015; Martínez, Sonia SGM Gómez/Q-2626-2017; Martinez Hernandez, J Alfredo/K-8709-2014; Warnberg, Julia/G-1390-2011	Campoy, Cristina/0000-0002-9860-6785; San Julián, María Cristina Azcona/0000-0001-5534-8758; Martí, Amelia/0000-0001-9832-7981; Milagro, Fermin/0000-0002-3228-9916; Marti, Amelia/0000-0001-9832-7981; Sanchez, Ascension Marcos/0000-0002-8022-9563; Navas-Carretero, Santiago/0000-0002-5163-2230; Martin-Bautista, Elena/0000-0002-7651-8100; Gomez_Martinez, Sonia/0000-0002-3281-0118; Campion, Javier/0000-0002-6522-8271; Martinez Hernandez, J Alfredo/0000-0001-5218-6941; Agil, Ahmad/0000-0003-0164-9648; Warnberg, Julia/0000-0002-8408-316X	Health Research Fund from the Carlos III Health Institute from Ministry of Health and Consumption, Fondo de In - vestigacion Sanitaria (FIS) [PI051579, PI051080]; Linea Especial, Nutricion y Obesidad (University of Navarra); Carlos III Health Institute [Centro de Investigacion Biomedica en Red (CIBER) project] [CB06/03/1017]; RETICS network; Navarra government; Spanish Agency for Food Security and Nutrition (AESAN) from the Spanish Ministry of Health and Consumption	Health Research Fund from the Carlos III Health Institute from Ministry of Health and Consumption, Fondo de In - vestigacion Sanitaria (FIS); Linea Especial, Nutricion y Obesidad (University of Navarra); Carlos III Health Institute [Centro de Investigacion Biomedica en Red (CIBER) project]; RETICS network; Navarra government; Spanish Agency for Food Security and Nutrition (AESAN) from the Spanish Ministry of Health and Consumption	The authors acknowledge the essential collaboration provided by all professionals of the EVASYON study group, as well as all the adolescents involved in the intervention. Research relating to this work was funded by grants from the Health Research Fund from the Carlos III Health Institute from Ministry of Health and Consumption, Fondo de In - vestigacion Sanitaria (FIS; PI051579, PI051080) for the EVASYON project; Linea Especial, Nutricion y Obesidad (University of Navarra); Carlos III Health Institute [Centro de Investigacion Biomedica en Red (CIBER) project, CB06/03/1017], and RETICS network. The scholarship to A. Moleres from the Navarra government is fully acknowledged. The EVASYON study has received the award from the Spanish Agency for Food Security and Nutrition (AESAN) from the Spanish Ministry of Health and Consumption for the best applied research project in 2009. The authors declare no conflict of interests. EVASYON study group (Coordinator: Marcos, A.): Granada: Campoy, C., Lopez-Belmonte, G., Delgado, M., Martin-Matillas, M., Aparicio, V., Carbonell, A., Agil, A., Silva, D. R., Perez-Ballesteros, C., Piqueras, M. J., Chillon, P., Tercedor, P., Martin-Lagos, J. A., Martin-Bautista, E., Perez-Exposito, M., Garofano, M., Aguilar, M. J., Fernandez-Mayorga, A., and Sanchez, P.; Madrid: Marcos, A., Warnberg, J., Puertollano, M. A., Gomez-Martinez, S., Zapatera, B., Nova, E., Romeo, J., Diaz, E. L., Pozo, T., Morande, G., Villasenor, A., Madruga, D., Munoz, R., Veiga, O. L., Villagra, A., Martinez-Gomez, D., Garcia, R. M., Vaquero, M. P., Perez-Granados, A. M., and Navas-Carretero, S.; Pamplona: Marti, A., Azcona-Sanjulian, M. C., Moleres. A., Rendo-Urteaga. T., Marques. M., and Martinez. J. A.; Santander: Redondo-Figuero, C., Garcia-Fuentes, M., DeRufino, P., Gonzalez-Lamuno, D., Amigo, T., Lanza, R., and Noriega, M. J.; Zaragoza: Garagorri, J. M., Moreno, L. A., Romero, P., De Miguel, P., Rodriguez, G., Bueno, G., Mesana, M. I., Vicente, G., Fernandez, J., Rey-Lopez, P., Muro, C., and Tomas, C.	Al-Moundhri MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015585; Barton PJR, 1999, GENOMICS, V57, P102, DOI 10.1006/geno.1998.5702; Bouchard L, 2010, AM J CLIN NUTR, V91, P309, DOI 10.3945/ajcn.2009.28085; Campion J, 2009, OBES REV, V10, P383, DOI 10.1111/j.1467-789X.2009.00595.x; Cole TJ, 2007, BMJ-BRIT MED J, V335, P194, DOI 10.1136/bmj.39238.399444.55; Cordero P, 2011, J PHYSIOL BIOCHEM, V67, P463, DOI 10.1007/s13105-011-0084-4; Ford AL, 2010, ARCH DIS CHILD, V95, P256, DOI 10.1136/adc.2009.165340; Fuemmeler BF, 2009, OBESITY FACTS, V2, P179, DOI 10.1159/000220605; Fukushima A, 2010, DIABETES, V59, P1906, DOI 10.2337/db09-1365; Geddes J, 2007, ANN CLIN BIOCHEM, V44, P391, DOI 10.1258/000456307780945750; Guerrero-Preston R, 2011, CANCER PREV RES, V4, P1061, DOI 10.1158/1940-6207.CAPR-11-0006; He Qin, 2010, Mol Cell Pharmacol, V2, P61; Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258; Kanade A, 2011, J AM COLL NUTR, V30, P216, DOI 10.1080/07315724.2011.10719963; Kussmann M, 2010, NUTR REV, V68, pS38, DOI 10.1111/j.1753-4887.2010.00326.x; Lass N, 2011, J CLIN ENDOCR METAB, V96, P3533, DOI 10.1210/jc.2011-1609; Lavebratt C, 2012, INT J OBESITY, V36, P757, DOI 10.1038/ijo.2011.178; Lee MH, 2010, TOXICOL LETT, V199, P416, DOI 10.1016/j.toxlet.2010.10.008; Lillycrop KA, 2011, INT J OBESITY, V35, P72, DOI 10.1038/ijo.2010.122; Lloyd LJ, 2010, INT J OBESITY, V34, P18, DOI 10.1038/ijo.2009.61; Marti A, 2008, P NUTR SOC, V67, P1, DOI 10.1017/S002966510800596X; Marti A, 2011, OBESITY FACTS, V4, P187, DOI 10.1159/000329847; Marti A, 2010, J NUTRIGENET NUTRIGE, V3, P157, DOI 10.1159/000324350; Martinez-Gomez D, 2011, MED CLIN-BARCELONA, V136, P13, DOI 10.1016/j.medcli.2010.05.013; Martinez-Gomez D, 2009, GAC SANIT, V23, P512, DOI 10.1016/j.gaceta.2009.02.013; Martinez-Gomez D, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-414; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Milagro FI, 2011, FASEB J, V25, P1378, DOI 10.1096/fj.10-170365; Moleres A, 2012, J PEDIATR-US, V161, P466, DOI 10.1016/j.jpeds.2012.04.004; Moreno LA, 2007, INT J OBESITY, V31, P1798, DOI 10.1038/sj.ijo.0803670; Nayak Shivananda B., 2010, Archives of Physiology and Biochemistry, V116, P21, DOI 10.3109/13813450903397638; Ohgusu Y, 2008, DRUG METAB PHARMACOK, V23, P279, DOI 10.2133/dmpk.23.279; Philibert RA, 2010, AM J MED GENET B, V153B, P619, DOI 10.1002/ajmg.b.31031; Pimenta AM, 2011, PUBLIC HEALTH NUTR, V14, P1237, DOI 10.1017/S1368980010003009; Razquin C, 2011, MOL NUTR FOOD RES, V55, P136, DOI 10.1002/mnfr.201000445; Rodriguez A, 2011, CELL CYCLE, V10, P1548, DOI 10.4161/cc.10.10.15672; Sekine Y, 2006, ONCOGENE, V25, P5801, DOI 10.1038/sj.onc.1209578; Serrano-Marco L, 2011, DIABETES, V60, P1990, DOI 10.2337/db10-0704; TANNER JM, 1986, CLIN ENDOCRINOL META, V15, P411, DOI 10.1016/S0300-595X(86)80005-6; Van der Auwera I, 2009, BRIT J CANCER, V100, P1277, DOI 10.1038/sj.bjc.6605013; Wang XL, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-87; Zhu Y, 2010, ADV EXP MED BIOL, V664, P217, DOI 10.1007/978-1-4419-1399-9_25	42	102	109	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2504	2512		10.1096/fj.12-215566	http://dx.doi.org/10.1096/fj.12-215566			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23475851	Green Submitted			2022-12-28	WOS:000319667600038
J	Righi, V; Constantinou, C; Mintzopoulos, D; Khan, N; Mupparaju, SP; Rahme, LG; Swartz, HM; Szeto, HH; Tompkins, RG; Tzika, AA				Righi, Valeria; Constantinou, Caterina; Mintzopoulos, Dionyssios; Khan, Nadeem; Mupparaju, S. P.; Rahme, Laurence G.; Swartz, Harold M.; Szeto, Hazel H.; Tompkins, Ronald G.; Tzika, A. Aria			Mitochondria-targeted antioxidant promotes recovery of skeletal muscle mitochondrial function after burn trauma assessed by in vivo P-31 nuclear magnetic resonance and electron paramagnetic resonance spectroscopy	FASEB JOURNAL			English	Article						physiology; molecular medicine; mice; mitochondria; oxidative stress	INSULIN-RESISTANCE; INDUCED APOPTOSIS; NMR-SPECTROSCOPY; DOWN-REGULATION; PEPTIDE; INJURY; ACONITASE; METABOLISM; MODULATION; DYSFUNCTION	Burn injury causes a major systemic catabolic response that is associated with mitochondrial dysfunction in skeletal muscle. We investigated the effects of the mitochondria-targeted peptide antioxidant Szeto-Schiller 31 (SS-31) on skeletal muscle in a mouse burn model using in vivo phosphorus-31 nuclear magnetic resonance (P-31 NMR) spectroscopy to noninvasively measure high-energy phosphate levels; mitochondrial aconitase activity measurements that directly correlate with TCA cycle flux, as measured by gas chromatography mass spectrometry (GC-MS); and electron paramagnetic resonance (EPR) to assess oxidative stress. At 6 h postburn, the oxidative ATP synthesis rate was increased 5-fold in burned mice given a single dose of SS-31 relative to untreated burned mice (P=0.002). Furthermore, SS-31 administration in burned animals decreased mitochondrial aconitase activity back to control levels. EPR revealed a recovery in redox status of the SS-31-treated burn group compared to the untreated burn group (P<0.05). Our multidisciplinary convergent results suggest that SS-31 promotes recovery of mitochondrial function after burn injury by increasing ATP synthesis rate, improving mitochondrial redox status, and restoring mitochondrial coupling. These findings suggest use of noninvasive in vivo NMR and complementary EPR offers an approach to monitor the effectiveness of mitochondrial protective agents in alleviating burn injury symptoms.	[Righi, Valeria; Constantinou, Caterina; Mintzopoulos, Dionyssios; Tzika, A. Aria] Harvard Univ, Sch Med, Massachusetts Gen Hosp, NMR Surg Lab,Dept Surg, Boston, MA 02114 USA; [Constantinou, Caterina; Rahme, Laurence G.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Surg Lab,Dept Surg, Boston, MA 02114 USA; [Righi, Valeria; Constantinou, Caterina; Mintzopoulos, Dionyssios; Rahme, Laurence G.; Tompkins, Ronald G.; Tzika, A. Aria] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Div Burns, Boston, MA 02114 USA; [Righi, Valeria; Mintzopoulos, Dionyssios; Tzika, A. Aria] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Massachusetts Gen Hosp, Boston, MA 02114 USA; [Righi, Valeria; Mintzopoulos, Dionyssios; Tzika, A. Aria] Harvard Univ, Sch Med, Shriners Burns Inst, Boston, MA 02114 USA; [Khan, Nadeem; Mupparaju, S. P.; Swartz, Harold M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch,Dept Diagnost Radiol, Electron Paramagnet Resonance EPR Ctr Viable Syst, Hanover, NH 03756 USA; [Szeto, Hazel H.] Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Dartmouth College; Cornell University	Tzika, AA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, NMR Surg Lab,Dept Surg, 51 Blossom St,Rm 261, Boston, MA 02114 USA.	atzika@hms.harvard.edu	Righi, Valeria/N-4821-2014; Constantinou, Caterina/D-3844-2018	Righi, Valeria/0000-0003-2394-8462; Constantinou, Caterina/0000-0003-3589-0739	U.S. National Institute Institutes of Health (NIH) [P50GM021700]; Shriner's Hospital for Children [8893, 8892]; U.S. Defense Medical Research and Development Program (DMRDP) [DM103014]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R33AI105902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700] Funding Source: NIH RePORTER	U.S. National Institute Institutes of Health (NIH); Shriner's Hospital for Children; U.S. Defense Medical Research and Development Program (DMRDP); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by a U.S. National Institute Institutes of Health (NIH) center grant (P50GM021700) to R. G. T. (A. A. T., director of the NMR core), Shriner's Hospital for Children research grants to A. A. T. (8893) and L. G. R. (8892), and a research support grant (DM103014) from the U.S. Defense Medical Research and Development Program (DMRDP). The authors thank Dr. Alan J. Fischman for his advice. The authors also thank Dr. Ann Power Smith (Write Science Right, Las Vegas, NV, USA) for editorial assistance. Disclosure: the SS peptides technology has been licensed for commercial development to Stealth Peptides Inc. (Newton Centre, MA, USA) by the Cornell Research Foundation (CRF), and both CRF and H. H. S. have financial interests.	ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; ALGER JR, 1984, Q REV BIOPHYS, V17, P83, DOI 10.1017/S0033583500005266; Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048; Apidianakis Y, 2012, FASEB J, V26, P730, DOI 10.1096/fj.11-192484; Astrakas LG, 2005, FASEB J, V19, P1431, DOI 10.1096/fj.04-2005com; BAILEY IA, 1981, BIOCHEM J, V196, P171, DOI 10.1042/bj1960171; Barret JP, 2003, ARCH SURG-CHICAGO, V138, P127, DOI 10.1001/archsurg.138.2.127; Befroy DE, 2009, METHOD ENZYMOL, V457, P373, DOI 10.1016/S0076-6879(09)05021-6; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; Bulteau AL, 2003, BIOCHEMISTRY-US, V42, P14846, DOI 10.1021/bi0353979; Carter EA, 2011, INT J MOL MED, V28, P589, DOI 10.3892/ijmm.2011.752; Cho S, 2007, J BIOL CHEM, V282, P4634, DOI 10.1074/jbc.M609388200; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Dai DF, 2011, J AM COLL CARDIOL, V58, P73, DOI 10.1016/j.jacc.2010.12.044; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; HITZIG BM, 1987, FASEB J, V1, P22, DOI 10.1096/fasebj.1.1.3301494; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Khan N, 2008, MOL MED REP, V1, P813, DOI 10.3892/mmr_00000033; KINGSLEYHICKMAN PB, 1990, J BIOL CHEM, V265, P1545; Lee HY, 2011, SHOCK, V36, P580, DOI 10.1097/SHK.0b013e3182366872; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; Min K, 2011, J APPL PHYSIOL, V111, P1459, DOI 10.1152/japplphysiol.00591.2011; Padfield KE, 2006, J TRAUMA, V61, P280, DOI 10.1097/01.ta.0000230567.56797.6c; Padfield KE, 2005, P NATL ACAD SCI USA, V102, P5368, DOI 10.1073/pnas.0501211102; Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62; Righi V, 2009, INT J MOL MED, V24, P749, DOI 10.3892/ijmm_00000288; SAKO EY, 1988, J BIOL CHEM, V263, P10600; Sheridan RL, 2004, J AM COLL SURGEONS, V198, P243, DOI 10.1016/j.jamcollsurg.2003.11.007; Shestov AA, 2012, NEUROCHEM RES, V37, P2388, DOI 10.1007/s11064-012-0782-5; Siegel MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026963; TOMERA JF, 1988, BURNS, V14, P210, DOI 10.1016/0305-4179(88)90040-X; Tzika AA, 2008, INT J MOL MED, V21, P201; Tzika AA, 2008, INT J MOL MED, V21, P825; Tzika AA, 2009, INT J MOL MED, V24, P387, DOI 10.3892/ijmm_00000244; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; Yo K, 2013, AM J PHYSIOL-ENDOC M, V304, pE331, DOI 10.1152/ajpendo.00098.2012; Yu YM, 2002, AM J PHYSIOL-ENDOC M, V282, pE247, DOI 10.1152/ajpendo.00206.2001; Yu YM, 1999, JPEN-PARENTER ENTER, V23, P160, DOI 10.1177/0148607199023003160; Zhang QH, 2006, INT J MOL MED, V18, P1223; Zhang SJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1154, DOI 10.1152/ajpcell.00110.2007; Zhao KS, 2005, BIOCHEM PHARMACOL, V70, P1796, DOI 10.1016/j.bcp.2005.08.022; Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200	45	24	25	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2521	2530		10.1096/fj.12-220764	http://dx.doi.org/10.1096/fj.12-220764			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23482635	Green Published			2022-12-28	WOS:000319667600040
J	Kuhn, ML; Prachi, P; Minasov, G; Shuvalova, L; Ruan, J; Dubrovska, I; Winsor, J; Giraldi, M; Biagini, M; Liberatori, S; Savino, S; Bagnoli, F; Anderson, WF; Grandi, G				Kuhn, Misty L.; Prachi, Prachi; Minasov, George; Shuvalova, Ludmilla; Ruan, Jiapeng; Dubrovska, Ievgeniia; Winsor, James; Giraldi, Monica; Biagini, Massimiliano; Liberatori, Sabrina; Savino, Silvana; Bagnoli, Fabio; Anderson, Wayne F.; Grandi, Guido			Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP	FASEB JOURNAL			English	Article						immunogenicity; lantibiotic; abscess; pathogenesis; epidermin leader peptide processing serine protease; vaccine	LANTIBIOTIC GENE CLUSTERS; GROUP-B STREPTOCOCCI; SERINE-PROTEASE; GROUP-A; METHICILLIN-RESISTANT; LACTOCOCCUS-LACTIS; CRYSTAL-STRUCTURE; C5A PEPTIDASE; ANTIMICROBIAL RESISTANCE; REVERSE VACCINOLOGY	Despite the global medical needs associated with Staphylococcus aureus infections, no licensed vaccines are currently available. We identified and characterized a protein annotated as an epidermin leader peptide processing serine protease (EpiP), as a novel S. aureus vaccine candidate. In addition, we determined the structure of the recombinant protein (rEpiP) by X-ray crystallography. The crystal structure revealed that rEpiP was cleaved somewhere between residues 95 and 100, and we found that the cleavage occurs through an autocatalytic intramolecular mechanism. The protein expressed by S. aureus cells also appeared to undergo a similar processing event. To determine whether the protein acts as a serine protease, we mutated the hypothesized catalytic serine 393 residue to alanine, generating rEpiP-S393A. The crystal structure of this mutant protein showed that the polypeptide chain was not cleaved and was not interacting stably with the active site. Indeed, rEpiP-S393A was shown to be impaired in its protease activity. Mice vaccinated with rEpiP were protected from S. aureus infection (34% survival, P=0.0054). Moreover, the protective efficacy generated by rEpiP and rEpiP-S393A was comparable, implying that the noncleaving mutant could be used for vaccination purposes.-Kuhn, M. L., Prachi, P., Minasov, G., Shuvalova, L., Ruan, J., Dubrovska, I., Winsor, J., Giraldi, M., Biagini, M., Liberatori, S., Savino, S., Bagnoli, F., Anderson, W. F., Grandi, G. Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP.	[Kuhn, Misty L.; Minasov, George; Shuvalova, Ludmilla; Ruan, Jiapeng; Dubrovska, Ievgeniia; Winsor, James; Anderson, Wayne F.] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Ctr Struct Genom Infect Dis, Chicago, IL 60611 USA; [Prachi, Prachi; Giraldi, Monica; Biagini, Massimiliano; Liberatori, Sabrina; Savino, Silvana; Bagnoli, Fabio; Grandi, Guido] Novartis Vaccines & Diagnost, Res Ctr, Siena, Italy	Northwestern University; Feinberg School of Medicine; Novartis	Grandi, G (corresponding author), Novartis Vaccines, Via Fiorentina 1, I-53100 Siena, Italy.	wf-anderson@northwestern.edu; guido.grandi@novartis.com	Liberatori, Sabrina/GYU-1878-2022	Liberatori, Sabrina/0000-0003-3524-0429; Minasov, George/0000-0001-5460-3462; Grandi, Guido/0000-0001-9724-2185; Winsor, James/0000-0002-9673-4839	U.S. DOE [DE-AC02-06CH11357]; Michigan Economic Development Corporation; Michigan Technology Tri-Corridor [085P100817]; U.S. National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, U.S. Department of Health and Human Services [HHSN272200700058C, HHSN272201200026C]; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER	U.S. DOE(United States Department of Energy (DOE)); Michigan Economic Development Corporation; Michigan Technology Tri-Corridor; U.S. National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, U.S. Department of Health and Human Services; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Elisabetta Sabini for her tireless efforts and organization to enable a productive collaboration between our groups. Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science by Argonne National Laboratory (Argonne, IL, USA), was supported by the U.S. DOE under contract DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and Michigan Technology Tri-Corridor (grant 085P100817). This project has been funded in whole or in part with federal funds from the U.S. National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, U.S. Department of Health and Human Services, under contracts HHSN272200700058C and HHSN272201200026C. The authors are grateful to Dr. Ravi P. N Mishra, Dr. Luigi Fiaschi, and Dr. Fabiana Falugi for their contribution in antigen identification and cloning and RNA extraction and real-time PCR experiments.	Andrews T, 2003, CLIN MICROBIOL REV, V16, P597, DOI 10.1128/CMR.16.4.597-621.2003; Arnison PG, 2013, NAT PROD REP, V30, P108, DOI 10.1039/c2np20085f; Atkins KL, 2008, MOL IMMUNOL, V45, P1600, DOI 10.1016/j.molimm.2007.10.021; AUGUSTIN J, 1992, EUR J BIOCHEM, V204, P1149, DOI 10.1111/j.1432-1033.1992.tb16740.x; Bagnoli F, 2011, OMICS, V15, P545, DOI 10.1089/omi.2010.0127; Bethe G, 2001, FEMS MICROBIOL LETT, V205, P99, DOI 10.1016/S0378-1097(01)00453-0; Bierbaum G, 2009, CURR PHARM BIOTECHNO, V10, P2, DOI 10.2174/138920109787048616; Bottomley MJ, 2009, J BIOL CHEM, V284, P1313, DOI 10.1074/jbc.M808363200; CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cheng Q, 2002, INFECT IMMUN, V70, P6409, DOI 10.1128/IAI.70.11.6409-6415.2002; Cleary PP, 2004, VACCINE, V22, P4332, DOI 10.1016/j.vaccine.2004.04.030; Comellas-Bigler M, 2004, STRUCTURE, V12, P1313, DOI 10.1016/j.str.2004.04.013; Cotter PD, 2005, NAT REV MICROBIOL, V3, P777, DOI 10.1038/nrmicro1273; Cunningham D, 2007, NAT STRUCT MOL BIOL, V14, P413, DOI 10.1038/nsmb1235; Daly KM, 2010, J BACTERIOL, V192, P1131, DOI 10.1128/JB.01375-09; Edwards RJ, 2005, J INFECT DIS, V192, P783, DOI 10.1086/432485; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; ENGELKE G, 1994, APPL ENVIRON MICROB, V60, P814, DOI 10.1128/AEM.60.3.814-825.1994; Foophow T, 2010, J MOL BIOL, V400, P865, DOI 10.1016/j.jmb.2010.05.064; Geissler S, 1996, J BACTERIOL, V178, P284, DOI 10.1128/jb.178.1.284-288.1996; Hampton EN, 2007, P NATL ACAD SCI USA, V104, P14604, DOI 10.1073/pnas.0703402104; Hidalgo-Grass C, 2004, LANCET, V363, P696, DOI 10.1016/S0140-6736(04)15643-2; Hidalgo-Grass C, 2006, EMBO J, V25, P4628, DOI 10.1038/sj.emboj.7601327; Highlander SK, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-99; Houssen WE, 2012, CHEMBIOCHEM, V13, P2683, DOI 10.1002/cbic.201200661; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; Ji YD, 1997, INFECT IMMUN, V65, P2080, DOI 10.1128/IAI.65.6.2080-2087.1997; Joo HS, 2011, J BIOL CHEM, V286, P8933, DOI 10.1074/jbc.M111.221382; Kennan RM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001210; Kies S, 2003, PEPTIDES, V24, P329, DOI 10.1016/S0196-9781(03)00046-9; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Klock Heath E., 2009, V498, P91, DOI 10.1007/978-1-59745-196-3_6; Kuhn ML, 2013, PROTEIN SCI, V22, P222, DOI 10.1002/pro.2199; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; Kuklin NA, 2006, INFECT IMMUN, V74, P2215, DOI 10.1128/IAI.74.4.2215-2223.2006; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Marsh AJ, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-679; Maskalyk J, 2002, CAN MED ASSOC J, V167, P375; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Millard CS, 2003, PROTEIN EXPRES PURIF, V29, P311, DOI 10.1016/S1046-5928(03)00063-9; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Mishra RPN, 2012, J INFECT DIS, V206, P1041, DOI 10.1093/infdis/jis463; Moore PCL, 2001, J CLIN MICROBIOL, V39, P2760, DOI 10.1128/JCM.39.8.2760-2767.2001; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otto M, 2001, RES MICROBIOL, V152, P351, DOI 10.1016/S0923-2508(01)01206-2; Palumbo E, 2012, METHODS MOL BIOL, V799, P361, DOI 10.1007/978-1-61779-346-2_21; Paton AW, 2006, NATURE, V443, P548, DOI 10.1038/nature05124; Patti JM, 2011, EXPERT REV ANTI-INFE, V9, P845, DOI [10.1586/ERI.11.99, 10.1586/eri.11.99]; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Rodriguez-Ortega MJ, 2006, NAT BIOTECHNOL, V24, P191, DOI 10.1038/nbt1179; Rybak MJ, 2001, DRUGS, V61, P1, DOI 10.2165/00003495-200161010-00001; SAHAI J, 1989, NEW ENGL J MED, V321, P1342; Santillan DA, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.003; SCHNELL N, 1992, EUR J BIOCHEM, V204, P57, DOI 10.1111/j.1432-1033.1992.tb16605.x; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; Shorr AF, 2007, PHARMACOECONOMICS, V25, P751, DOI 10.2165/00019053-200725090-00004; Siezen RJ, 1996, ANTON LEEUW INT J G, V69, P171, DOI 10.1007/BF00399422; Smith L, 2008, CURR OPIN MICROBIOL, V11, P401, DOI 10.1016/j.mib.2008.09.008; Smith TL, 1999, MICROBES INFECT, V1, P795, DOI 10.1016/S1286-4579(99)80082-3; Stranger-Jones YK, 2006, P NATL ACAD SCI USA, V103, P16942, DOI 10.1073/pnas.0606863103; Tanaka SI, 2007, J MOL BIOL, V372, P1055, DOI 10.1016/j.jmb.2007.07.027; ten Broeke-Smits NJP, 2010, NUCLEIC ACIDS RES, V38, P3263, DOI 10.1093/nar/gkq058; Turner CE, 2009, VACCINE, V27, P4923, DOI 10.1016/j.vaccine.2009.06.042; Turner DPJ, 2002, INFECT IMMUN, V70, P4447, DOI 10.1128/IAI.70.8.4447-4461.2002; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; Webb Glenn F., 2010, Journal of Biological Dynamics, V4, P115, DOI 10.1080/17513750903026411; Willey JM, 2007, ANNU REV MICROBIOL, V61, P477, DOI 10.1146/annurev.micro.61.080706.093501; Yamamoto T, 2010, J INFECT CHEMOTHER, V16, P225, DOI 10.1007/s10156-010-0045-9; Zingaretti C, 2010, FASEB J, V24, P2839, DOI 10.1096/fj.09-145631; Zinkernagel AS, 2008, CELL HOST MICROBE, V4, P170, DOI 10.1016/j.chom.2008.07.002	75	13	14	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1780	1793		10.1096/fj.13-241737	http://dx.doi.org/10.1096/fj.13-241737			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24421400	Green Published			2022-12-28	WOS:000335344300024
J	Ruiz, M; Ganfornina, MD; Correnti, C; Strong, RK; Sanchez, D				Ruiz, Mario; Ganfornina, Maria D.; Correnti, Colin; Strong, Roland K.; Sanchez, Diego			Ligand binding-dependent functions of the lipocalin NLaz: an in vivo study in Drosophila	FASEB JOURNAL			English	Article						lipid-binding proteins; aging; pheromonal signaling; metabolism regulation; oxidative stress	SWISS-MODEL REPOSITORY; EXTENDS LIFE-SPAN; APOLIPOPROTEIN-D; STRESS RESISTANCE; OXIDATIVE STRESS; ARACHIDONIC-ACID; HUMAN APOD; PROTEIN; LAZARILLO; GENE	Lipocalins are small extracellular proteins mostly described as lipid carriers. The Drosophila lipocalin NLaz (neural Lazarillo) modulates the IIS pathway and regulates longevity, stress resistance, and behavior. Here, we test whether a native hydrophobic pocket structure is required for NLaz to perform its functions. We use a point mutation altering the binding pocket (NLaz(L130R)) and control mutations outside NLaz binding pocket. Tryptophan fluorescence titration reveals that NLaz(L130R) loses its ability to bind ergosterol and the pheromone 7(z)-tricosene but retains retinoic acid binding. Using site-directed transgenesis in Drosophila, we test the functionality of the ligand binding-altered lipocalin at the organism level. NLaz-dependent life span reduction, oxidative stress and starvation sensitivity, aging markers accumulation, and deficient courtship are rescued by overexpression of NLaz(WT), but not of NLaz(L130R). Transcriptional responses to aging and oxidative stress show a large set of age-responsive genes dependent on the integrity of NLaz binding pocket. Inhibition of IIS activity and modulation of oxidative stress and infection-responsive genes are binding pocket-dependent processes. Control of energy metabolites on starvation appears to be, however, insensitive to the modification of the NLaz binding pocket.-Ruiz, M., Ganfornina, M. D., Correnti, C., Strong, R. K., and Sanchez, D. Ligand binding-dependent functions of the lipocalin NLaz: an in vivo study in Drosophila.	[Ruiz, Mario; Ganfornina, Maria D.; Sanchez, Diego] Univ Valladolid, CSIC, Inst Biol & Genet Mol, Dept Bioquim & Biol Mol & Fisiol, Valladolid 47003, Spain; [Correnti, Colin; Strong, Roland K.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Fred Hutchinson Cancer Center	Sanchez, D (corresponding author), Univ Valladolid, CSIC, Inst Biol & Genet Mol, C Sanz & Fores 3, Valladolid 47003, Spain.	lazarill@ibgm.uva.es	Ganfornina, Maria D/N-5743-2014; Sanchez, Diego/N-5990-2014; Ruiz, Mario/B-3507-2013	Ganfornina, Maria D/0000-0002-8567-4826; Sanchez, Diego/0000-0001-6296-6773; Ruiz, Mario/0000-0002-7149-6600	Junta de Castilla y Leon (JCyL) [VA180A11-2]; Ministerio de Ciencia e Innovacion (MICINN) [BFU2008-01170, BFU2011-23978]; JCyL [EDU/1708/2008]	Junta de Castilla y Leon (JCyL)(Junta de Castilla y Leon); Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); JCyL(Junta de Castilla y Leon)	The authors thank Dr. J. M. Pereda [Centro de Investigacion del Cancer (CIC), Salamanca, Spain] for providing advice on potential residues to mutate in NLaz. Gene sequencing was performed at the CIC genomic facility. Drosophila transgenesis was carried out at BestGene Inc. (Chino Hills, CA, USA). E. Martin-Tejedor provided technical assistance throughout the project. The authors also acknowledge the critical and constructive comments of two anonymous reviewers that have certainly improved the manuscript and the accuracy of data presentation and interpretation included herein. This work was supported by grants to M. D. G. and D. S. [Junta de Castilla y Leon (JCyL) grant VA180A11-2, and Ministerio de Ciencia e Innovacion (MICINN) grants BFU2008-01170 and BFU2011-23978], and M. R. was supported by a JCyL fellowship to young researchers (EDU/1708/2008). Author contributions: M. R. designed and performed the experiments, analyzed the data, and helped in writing the manuscript; D. S. and M. D. G, designed the research project and helped with experiments and analysis of results; C. C. and R. K. S. participated in the discussion and design of experiments; M. D. G., D. S. and M. R. wrote the manuscript; all authors read and approved the final manuscript.	Abergel RJ, 2008, J AM CHEM SOC, V130, P11524, DOI 10.1021/ja803524w; Ahnstrom J, 2007, J LIPID RES, V48, P1754, DOI 10.1194/jlr.M700103-JLR200; Akerstrom Bo, 2006, P1; Bajo-Graneras R, 2011, GLIA, V59, P1551, DOI 10.1002/glia.21200; Bajo-Graneras R, 2011, J NEUROCHEM, V117, P949, DOI 10.1111/j.1471-4159.2011.07266.x; Bauer J, 2010, AGING-US, V2, P298, DOI 10.18632/aging.100146; Benkert P, 2009, BMC STRUCT BIOL, V9, DOI 10.1186/1472-6807-9-35; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Bhatia S, 2012, BIOCHEM J, V442, P713, DOI 10.1042/BJ20111166; Biesalski HK, 1999, AM J CLIN NUTR, V69, P931; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; BISHOP RE, 1995, J BIOL CHEM, V270, P23097, DOI 10.1074/jbc.270.39.23097; Breustedt DA, 2006, BBA-PROTEINS PROTEOM, V1764, P161, DOI 10.1016/j.bbapap.2005.12.006; CABRAL JHM, 1995, FEBS LETT, V366, P53, DOI 10.1016/0014-5793(95)00484-Q; Charron JBF, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-86; Chiswell B, 2007, BBA-PROTEINS PROTEOM, V1774, P637, DOI 10.1016/j.bbapap.2007.03.004; Correnti C, 2012, J BIOL CHEM, V287, P13524, DOI 10.1074/jbc.R111.311829; Correnti C, 2011, STRUCTURE, V19, P1796, DOI 10.1016/j.str.2011.09.019; Curtis C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-12-r262; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; Eichinger A, 2007, J BIOL CHEM, V282, P31068, DOI 10.1074/jbc.M703552200; Elenewski JE, 2010, J PHYS CHEM B, V114, P11315, DOI 10.1021/jp104103f; Fukuhara A, 2012, BIOCHEM J, V443, P75, DOI 10.1042/BJ20111889; Ganfornina M. D., 2006, LIPOCALINS, P49; Ganfornina MD, 2008, AGING CELL, V7, P506, DOI 10.1111/j.1474-9726.2008.00395.x; Ganfornina MD, 2010, GLIA, V58, P1320, DOI 10.1002/glia.21010; Ganfornina MD, 2000, MOL BIOL EVOL, V17, P114, DOI 10.1093/oxfordjournals.molbev.a026224; GANFORNINA MD, 1995, DEVELOPMENT, V121, P123; Gasymov OK, 2010, BIOCHEMISTRY-US, V49, P582, DOI 10.1021/bi901435q; Gasymov OK, 2009, BIOCHEMISTRY-US, V48, P7219, DOI 10.1021/bi9005557; Gebauer M, 2012, METHOD ENZYMOL, V503, P157, DOI 10.1016/B978-0-12-396962-0.00007-0; Grillet M, 2006, P ROY SOC B-BIOL SCI, V273, P315, DOI 10.1098/rspb.2005.3332; Gutierrez G, 2000, BBA-PROTEIN STRUCT M, V1482, P35, DOI 10.1016/S0167-4838(00)00151-5; Hull-Thompson J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000460; Kahsai L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011480; Kalikka J, 2011, EUR BIOPHYS J BIOPHY, V40, P181, DOI 10.1007/s00249-010-0638-3; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; Kiefer Florian, 2009, Nucleic Acids Res, V37, pD387, DOI 10.1093/nar/gkn750; Kopp J, 2004, NUCLEIC ACIDS RES, V32, pD230, DOI 10.1093/nar/gkh008; Kourtis N, 2011, EMBO J, V30, P2520, DOI 10.1038/emboj.2011.162; Kumasaka T, 2009, J BIOL CHEM, V284, P22344, DOI 10.1074/jbc.M109.018341; Lee KS, 2004, J BIOL CHEM, V279, P50781, DOI 10.1074/jbc.M407842200; Lee KS, 2008, NAT CELL BIOL, V10, P468, DOI 10.1038/ncb1710; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moskalev AA, 2012, AGEING RES REV, V11, P51, DOI 10.1016/j.arr.2011.09.003; Muffat J, 2008, P NATL ACAD SCI USA, V105, P7088, DOI 10.1073/pnas.0800896105; Navarro JA, 2010, HUM MOL GENET, V19, P2828, DOI 10.1093/hmg/ddq183; Pasco MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036583; Peng Y, 2010, BBA-PROTEINS PROTEOM, V1804, P2102, DOI 10.1016/j.bbapap.2010.07.020; Ponton F, 2011, J INSECT PHYSIOL, V57, P840, DOI 10.1016/j.jinsphys.2011.03.014; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Ruiz M, 2013, FEBS J, V280, P3928, DOI 10.1111/febs.12394; Ruiz M, 2012, INSECT BIOCHEM MOLEC, V42, P776, DOI 10.1016/j.ibmb.2012.07.005; Ruiz M, 2011, EXP GERONTOL, V46, P579, DOI 10.1016/j.exger.2011.02.014; Sanchez D, 2006, CURR BIOL, V16, P680, DOI 10.1016/j.cub.2006.03.024; Sanchez D, 2003, MOL BIOL EVOL, V20, P775, DOI 10.1093/molbev/msg079; Sanchez D, 2000, INT J DEV BIOL, V44, P349; Sanchez D, 2008, J MOL RECOGNIT, V21, P312, DOI 10.1002/jmr.902; Sousa-Nunes R, 2011, NATURE, V471, P508, DOI 10.1038/nature09867; Sundaram M, 1998, BIOCHEM J, V334, P155, DOI 10.1042/bj3340155; Tcatchoff L, 2006, FEBS LETT, V580, P2102, DOI 10.1016/j.febslet.2006.03.017; Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551; Vogt M, 2001, J MOL RECOGNIT, V14, P79, DOI 10.1002/1099-1352(200101/02)14:1<79::AID-JMR521>3.0.CO;2-4; Wade NM, 2012, J EXP BIOL, V215, P343, DOI 10.1242/jeb.064592; Wang MC, 2003, DEV CELL, V5, P811, DOI 10.1016/S1534-5807(03)00323-X; Wu SC, 2012, CELL HOST MICROBE, V11, P410, DOI 10.1016/j.chom.2012.03.004; Zhang YR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036772; Zhou YY, 2010, FASEB J, V24, P4668, DOI 10.1096/fj.10-164863; Zsila F, 2002, BIOCHEM PHARMACOL, V64, P1651, DOI 10.1016/S0006-2952(02)01350-3	69	11	12	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1555	1567		10.1096/fj.13-240556	http://dx.doi.org/10.1096/fj.13-240556			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24361577	Green Submitted			2022-12-28	WOS:000335344300005
J	Stewart, A; Maity, B; Wunsch, AM; Meng, FT; Wu, Q; Wemmie, JA; Fisher, RA				Stewart, Adele; Maity, Biswanath; Wunsch, Amanda M.; Meng, Fantao; Wu, Qi; Wemmie, John A.; Fisher, Rory A.			Regulator of G-protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin-mediated activation of the 5-HT1A receptor-adenylyl cyclase axis	FASEB JOURNAL			English	Article						cAMP; animal behavior; mood disorders; SSRIs; GPCRs	ANIMAL-MODELS; EXPRESSION; COORDINATION; ASSOCIATION; HIPPOCAMPUS; INHIBITION; MODULATOR; BEHAVIOR; AGONISTS; BRAIN	Targeting serotonin (5-HT) bioavailability with selective 5-HT reuptake inhibitors (SSRIs) remains the most widely used treatment for mood disorders. However, their limited efficacy, delayed onset of action, and side effects restrict their clinical utility. Endogenous regulator of G-protein signaling (RGS) proteins have been implicated as key inhibitors of 5-HT(1A)Rs, whose activation is believed to underlie the beneficial effects of SSRIs, but the identity of the specific RGS proteins involved remains unknown. We identify RGS6 as the critical negative regulator of 5-HT1AR-dependent antidepressant actions. RGS6 is enriched in hippocampal and cortical neurons, 5-HT1AR-expressing cells implicated in mood disorders. RGS6(-/-) mice exhibit spontaneous anxiolytic and antidepressant behavior rapidly and completely reversibly by 5-HT1AR blockade. Effects of the SSRI fluvoxamine and 5-HT1AR agonist 8-OH-DPAT were also potentiated in RGS6(+/-) mice. The phenotype of RGS6(-/-) mice was associated with decreased CREB phosphorylation in the hippocampus and cortex, implicating enhanced G alpha(i)-dependent adenylyl cyclase inhibition as a possible causative factor in the behavior observed in RGS6(-/-) animals. Our results demonstrate that by inhibiting serotonergic innervation of the cortical-limbic neuronal circuit, RGS6 exerts powerful anxiogenic and prodepressant actions. These findings indicate that RGS6 inhibition may represent a viable means to treat mood disorders or enhance the efficacy of serotonergic agents.-Stewart, A., Maity, B., Wunsch, A. M., Meng, F., Wu, Q., Wemmie, J. A., Fisher, R. A. Regulator of G-protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin-mediated activation of the 5-HT1A receptor-adenylyl cyclase axis.	[Stewart, Adele; Maity, Biswanath; Meng, Fantao; Wu, Qi; Fisher, Rory A.] Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; [Wunsch, Amanda M.; Wemmie, John A.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; [Wemmie, John A.] Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Fisher, RA (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, 51 Newton Rd,BSB 2-512, Iowa City, IA 52242 USA.	rory-fisher@uiowa.edu		Fisher, Rory/0000-0003-3108-4836; Wemmie, John/0000-0001-7531-9065; Wunsch, Amanda/0000-0002-2292-439X; Stewart, Adele/0000-0003-4968-2471	U.S. National Institutes of Health [CA-161882]; U.S. Department of Veterans Affairs (Merit Award); U.S. National Institute of Mental Health [1R01MH085724-01]; U.S. National Heart, Lung, and Blood Institute [5 R01 HL113863-01]; McKnight Neuroscience of Brain Disorders Award; PhRMA Foundation; University of Iowa Graduate College; NATIONAL CANCER INSTITUTE [R01CA161882] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085724] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000741] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans Affairs (Merit Award)(US Department of Veterans Affairs); U.S. National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); McKnight Neuroscience of Brain Disorders Award; PhRMA Foundation; University of Iowa Graduate College; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Dr. Chantal Allamargot and the University of Iowa Central Microscopy Research Facility for their assistance with acquisition of confocal microscopy images. This work was supported by U.S. National Institutes of Health grant CA-161882 (R.A.F.). J.A.W. was supported by the U.S. Department of Veterans Affairs (Merit Award), the U.S. National Institute of Mental Health (1R01MH085724-01), the U.S. National Heart, Lung, and Blood Institute (5 R01 HL113863-01), and a McKnight Neuroscience of Brain Disorders Award. A.S. is the recipient of a Predoctoral Fellowship in Pharmacology/Toxicology from the PhRMA Foundation and a Presidential Fellowship from the University of Iowa Graduate College. The authors declare no conflicts of interest.	Beaudoin GMJ, 2012, NAT PROTOC, V7, P1741, DOI 10.1038/nprot.2012.099; Beaulieu JM, 2008, P NATL ACAD SCI USA, V105, P1333, DOI 10.1073/pnas.0711496105; Beyer CE, 2004, BRAIN RES, V1022, P214, DOI 10.1016/j.brainres.2004.06.073; Blendy JA, 2006, BIOL PSYCHIAT, V59, P1144, DOI 10.1016/j.biopsych.2005.11.003; Blundell J, 2008, BRAIN RES, V1190, P78, DOI 10.1016/j.brainres.2007.11.017; Chao PT, 2011, CELL METAB, V13, P573, DOI 10.1016/j.cmet.2011.02.019; Chen ACH, 2001, BIOL PSYCHIAT, V49, P753, DOI 10.1016/S0006-3223(00)01114-8; Clarke WP, 1996, J PHARMACOL EXP THER, V277, P1259; Dulawa SC, 2004, NEUROPSYCHOPHARMACOL, V29, P1321, DOI 10.1038/sj.npp.1300433; DUNN RW, 1989, EUR J PHARMACOL, V169, P1, DOI 10.1016/0014-2999(89)90811-X; Gao XJ, 2008, GENOMICS, V92, P457, DOI 10.1016/j.ygeno.2008.08.013; Ghavami A, 2004, CELL SIGNAL, V16, P711, DOI 10.1016/j.cellsig.2003.11.006; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; Gu ZL, 2007, MOL PHARMACOL, V71, P1030, DOI 10.1124/mol.106.032490; Hettema JM, 2013, PSYCHIAT GENET, V23, P92, DOI 10.1097/YPG.0b013e32835d70b3; Hohoff C, 2009, J NEURAL TRANSM, V116, P1523, DOI 10.1007/s00702-008-0097-5; Huang XY, 2006, MOL CELL BIOL, V26, P6870, DOI 10.1128/MCB.00314-06; KOSTOWSKI W, 1992, PHARMACOL TOXICOL, V71, P24, DOI 10.1111/j.1600-0773.1992.tb00515.x; Kupfer DJ, 2012, LANCET, V379, P1045, DOI 10.1016/S0140-6736(11)60602-8; Leygraf A, 2006, J NEURAL TRANSM, V113, P1921, DOI 10.1007/s00702-006-0484-8; Lifschytz T, 2012, INT J NEUROPSYCHOPH, V15, P1307, DOI 10.1017/S1461145711001453; Maity B, 2012, J BIOL CHEM, V287, P4972, DOI 10.1074/jbc.M111.297218; MATSUDA T, 1995, EUR J PHARMACOL, V280, P235, DOI 10.1016/0014-2999(95)00254-I; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Polter AM, 2010, CELL SIGNAL, V22, P1406, DOI 10.1016/j.cellsig.2010.03.019; POMPEIANO M, 1992, J NEUROSCI, V12, P440; Riad N, 2000, J COMP NEUROL, V417, P181, DOI 10.1002/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A; Richardson-Jones JW, 2011, J NEUROSCI, V31, P6008, DOI 10.1523/JNEUROSCI.5836-10.2011; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Savitz J, 2009, PROG NEUROBIOL, V88, P17, DOI 10.1016/j.pneurobio.2009.01.009; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Stratinaki M, 2013, P NATL ACAD SCI USA, V110, P8254, DOI 10.1073/pnas.1214696110; Talbot JN, 2010, P NATL ACAD SCI USA, V107, P11086, DOI 10.1073/pnas.1000003107; Terzi D, 2009, PROG MOL BIOL TRANSL, V86, P299, DOI 10.1016/S1877-1173(09)86010-9; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Yang JQ, 2010, CIRC RES, V107, P1345, DOI 10.1161/CIRCRESAHA.110.224220	38	35	37	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1735	1744		10.1096/fj.13-235648	http://dx.doi.org/10.1096/fj.13-235648			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24421401	Green Published			2022-12-28	WOS:000335344300020
J	Karki, S; Surolia, R; Hock, TD; Guroji, P; Zolak, JS; Duggal, R; Ye, T; Thannickal, VJ; Antony, VB				Karki, Suman; Surolia, Ranu; Hock, Thomas David; Guroji, Purusotham; Zolak, Jason S.; Duggal, Ryan; Ye, Tong; Thannickal, Victor J.; Antony, Veena B.			Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis	FASEB JOURNAL			English	Article						mesothelial-to-mesenchymal transition; smooth muscle actin; matrix remodeling	EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; TRANSCRIPTION FACTORS; GENE-EXPRESSION; LUNG INJURY; TGF-BETA; GROWTH; MIGRATION; INVASION; MORPHOGENESIS	Pleural mesothelial cells (PMCs), which are derived from the mesoderm, exhibit an extraordinary capacity to undergo phenotypic changes during development and disease. PMC transformation and trafficking has a newly defined role in idiopathic pulmonary fibrosis (IPF); however, the contribution of Wilms' tumor 1 (Wt1)-positive PMCs to the generation of pathognomonic myofibroblasts remains unclear. PMCs were obtained from IPF lung explants and healthy donor lungs that were not used for transplantation. Short hairpin Wt1-knockdown PMCs (sh Wt1) were generated with Wt1 shRNA, and morphologic and functional assays were performed in vitro. Loss of Wt1 abrogated the PMC phenotype and showed evidence of mesothelial-to-mesenchymal transition (MMT), with a reduced expression of E-cadherin and an increase in the profibrotic markers -smooth muscle actin (-SMA) and fibronectin, along with increased migration and contractility, compared with that of the control. Migration of PMCs in response to active transforming growth factor (TGF)-1 was assessed by live-cell imaging with 2-photon microscopy and 3D imaging, of Wt1-EGFP transgenic mice. Lineage-tracing experiments to map the fate of Wt1(+) PMCs in mouse lung in response to TGF-1 were also performed by using a Cre-loxP system. Our results, for the first time, demonstrate that Wt1 is necessary for the morphologic integrity of pleural membrane and that loss of Wt1 contributes to IPF via MMT of PMCs into a myofibroblast phenotype.Karki, S., Surolia, R., Hock, T. D., Guroji, P., Zolak, J. S., Duggal, R., Ye, T., Thannickal, V., J., Antony, V. B. Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis.	[Karki, Suman; Surolia, Ranu; Hock, Thomas David; Guroji, Purusotham; Duggal, Ryan; Thannickal, Victor J.; Antony, Veena B.] Univ Alabama Birmingham, Dept Med, Div Pulm & Crit Care, Birmingham, AL 35294 USA; [Zolak, Jason S.; Ye, Tong] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Antony, VB (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.	vantony@uab.edu	Ye, Tong/ABG-8560-2021; Ye, Tong/A-8251-2010	Ye, Tong/0000-0003-1017-6969; Ye, Tong/0000-0003-1017-6969; Guroji, Purushotham/0000-0001-9331-5711	U.S. National Insitutes of Health (NIH) [P01 HL114470]; NIH [P30AR048311]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL114470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048311] Funding Source: NIH RePORTER	U.S. National Insitutes of Health (NIH); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by U.S. National Insitutes of Health (NIH) grant P01 HL114470. The authors thank Prof. Lucas Puzzo-Miller for help in the vibratome sectioning and live imaging of mouse lung sections and the University of Alabama School of Medicine Comprehenive Flow Cytometry Core (NIH grant P30AR048311) for help in sorting the transfected cells. The authors declare no conflicts of interest.	Antony VB, 2003, EUR RESPIR J, V21, P539, DOI 10.1183/09031936.03.00403902; ANTONY VB, 1995, AM J RESP CELL MOL, V12, P581, DOI 10.1165/ajrcmb.12.6.7766422; Arlt MJE, 2012, JOVE-J VIS EXP, DOI 10.3791/4162; Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; Borok Z, 2009, J CLIN INVEST, V119, P7, DOI 10.1172/JCI38084; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Burwell EA, 2007, ONCOGENE, V26, P3423, DOI 10.1038/sj.onc.1210127; Chapman Harold A, 2012, Proc Am Thorac Soc, V9, P89, DOI 10.1513/pats.201112-053AW; Chen HY, 1997, J CELL SCI, V110, P345; Chilosi M, 2003, AM J PATHOL, V162, P1495, DOI 10.1016/S0002-9440(10)64282-4; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Cool CD, 2006, AM J RESP CRIT CARE, V174, P654, DOI 10.1164/rccm.200602-205OC; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Decologne N, 2007, J IMMUNOL, V179, P6043, DOI 10.4049/jimmunol.179.9.6043; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; Gauldie J, 2007, BIOCHEM SOC T, V35, P661, DOI 10.1042/BST0350661; Glista-Baker EE, 2012, AM J RESP CELL MOL, V47, P552, DOI 10.1165/rcmb.2012-0023OC; Hinz Boris, 2010, F1000 Biol Rep, V2, P78, DOI 10.3410/B2-78; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Humphreys BD, 2010, AM J PATHOL, V176, P85, DOI 10.2353/ajpath.2010.090517; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Ju WJ, 2006, MOL CELL BIOL, V26, P654, DOI 10.1128/MCB.26.2.654-667.2006; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Khalil N, 2004, CAN MED ASSOC J, V171, P153, DOI 10.1503/cmaj.1030055; Miller-Hodges E, 2012, J PATHOL, V226, P229, DOI 10.1002/path.2977; Misumi Shigeki, 2006, Proc Am Thorac Soc, V3, P307, DOI 10.1513/pats.200602-018TK; Morita T, 2007, J CELL BIOL, V179, P1027, DOI 10.1083/jcb.200708174; Mubarak KK, 2012, EUR RESPIR J, V39, P133, DOI 10.1183/09031936.00141010; Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440-1843.2002.00404.x; Nakamura Y, 2003, INVEST OPHTH VIS SCI, V44, P4331, DOI 10.1167/iovs.03-0068; Nasreen N, 2009, AM J PHYSIOL-LUNG C, V297, pL115, DOI 10.1152/ajplung.90587.2008; Pace E, 2008, J IMMUNOL, V181, P7292, DOI 10.4049/jimmunol.181.10.7292; Parenti R, 2013, ACTA HISTOCHEM, V115, P70, DOI 10.1016/j.acthis.2012.04.006; Phanish MK, 2006, BIOCHEM J, V393, P601, DOI 10.1042/BJ20051106; Que JW, 2008, P NATL ACAD SCI USA, V105, P16626, DOI 10.1073/pnas.0808649105; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Sakairi T, 2011, NEPHROL DIAL TRANSPL, V26, P2746, DOI 10.1093/ndt/gfr061; Sally ML, 2011, J CELL MOL MED, V15, P2095, DOI 10.1111/j.1582-4934.2010.01212.x; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Scholz H, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00004; Takeichi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057829; Thornton Emily E, 2012, Curr Protoc Cytom, VChapter 12, DOI 10.1002/0471142956.cy1228s60; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Walters Dianne M, 2008, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0546s40; Willis Brigham C, 2006, Proc Am Thorac Soc, V3, P377, DOI 10.1513/pats.200601-004TK; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou B, 2008, NATURE, V454, P109, DOI 10.1038/nature07060; Zhou B, 2012, CIRC RES, V111, pE276, DOI 10.1161/CIRCRESAHA.112.275784; Zolak JS, 2013, AM J PATHOL, V182, P1239, DOI 10.1016/j.ajpath.2012.12.030	49	66	66	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1122	1131		10.1096/fj.13-236828	http://dx.doi.org/10.1096/fj.13-236828			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24265486	Green Published			2022-12-28	WOS:000335324800009
J	Walrand, S; Short, KR; Heemstra, LA; Novak, CM; Levine, JA; Coenen-Schimke, JM; Nair, KS				Walrand, Stephane; Short, Kevin R.; Heemstra, Lydia A.; Novak, Colleen M.; Levine, James A.; Coenen-Schimke, Jill M.; Nair, K. Sreekumaran			Altered regulation of energy homeostasis in older rats in response to thyroid hormone administration	FASEB JOURNAL			English	Article						aging; food intake; spontaneous physical activity; mitochondria	SKELETAL-MUSCLE; UNCOUPLING PROTEIN-2; LABORATORY ENTITY; GENE-EXPRESSION; AGED RATS; MITOCHONDRIAL; HYPERTHYROIDISM; EXPENDITURE; METABOLISM; OBESITY	Hyperthyroidism causes increased energy intake and expenditure, although anorexia and higher weight loss have been reported in elderly individuals with hyperthyroidism. To determine the effect of age on energy homeostasis in response to experimental hyperthyroidism, we administered 200 g tri-iodothyronine (T3) in 7- and 27-mo-old rats for 14 d. T3 increased energy expenditure (EE) in both the young and the old rats, although the old rats lost more weight (147 g) than the young rats (58 g) because of the discordant effect of T3 on food intake, with a 40% increase in the young rats, but a 40% decrease in the old ones. The increased food intake in the young rats corresponded with a T3-mediated increase in the appetite-regulating proteins agouti-related peptide, neuropeptide Y, and uncoupling protein 2 in the hypothalamus, but no increase occurred in the old rats. Evidence of mitochondrial biogenesis in response to T3 was similar in the soleus muscle and heart of the young and old animals, but less consistent in old plantaris muscle and liver. Despite the comparable increase in EE, T3's effect on mitochondrial function was modulated by age in a tissue-specific manner. We conclude that older rats lack compensatory mechanisms to increase caloric intake in response to a T3-induced increase in EE, demonstrating a detrimental effect of age on energy homeostasis.Walrand, S., Short, K. R., Heemstra, L. A., Novak, C. M., Levine, J. A., Coenen-Schimke, J. M., Nair, K. S. Altered regulation of energy homeostasis in older rats in response to thyroid hormone administration.	[Walrand, Stephane; Short, Kevin R.; Heemstra, Lydia A.; Novak, Colleen M.; Levine, James A.; Coenen-Schimke, Jill M.; Nair, K. Sreekumaran] Mayo Clin, Endocrinol Res Unit, Sch Med, Rochester, MN 55905 USA	Mayo Clinic	Nair, KS (corresponding author), Mayo Clin, Endocrinol Res Unit, 200 First St SW, Rochester, MN 55905 USA.	nair.sree@mayo.edu	Short, Kevin R/AAC-2553-2020	Short, Kevin R/0000-0001-6704-9587; Novak, Colleen/0000-0002-8542-1677; Walrand, Stephane/0000-0002-4349-3664	U.S. National Institutes of Health/National Institute on Aging [R01-AG09531]; Mayo Foundation; Dole-Murdock Professorship; American Federation for Aging Research; NATIONAL INSTITUTE ON AGING [R01AG009531] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Mayo Foundation; Dole-Murdock Professorship; American Federation for Aging Research; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dawn Morse, Jane Kahl, and Kate Klaus for technical support with animal care and sample analyses. Funding was provided by U.S. National Institutes of Health/National Institute on Aging grant R01-AG09531, the Mayo Foundation, the Dole-Murdock Professorship (K.S.N.), and the American Federation for Aging Research (K.R.S.).	ACHESON K, 1984, METABOLISM, V33, P262, DOI 10.1016/0026-0495(84)90048-9; ANGERAS U, 1987, ENDOCRINOLOGY, V120, P1417, DOI 10.1210/endo-120-4-1417; Axelband F, 2011, J CELL PHYSIOL, V226, P21, DOI 10.1002/jcp.22325; Bahi L, 2005, J CELL PHYSIOL, V203, P589, DOI 10.1002/jcp.20273; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; BRAND MD, 1992, EUR J BIOCHEM, V206, P775, DOI 10.1111/j.1432-1033.1992.tb16984.x; Caiozzo V J, 1996, Exerc Sport Sci Rev, V24, P321; Coppola A, 2007, CELL METAB, V5, P21, DOI 10.1016/j.cmet.2006.12.002; da Costa VMC, 2001, J ENDOCRINOL, V171, P193, DOI 10.1677/joe.0.1710193; Dhillo WS, 2007, THYROID, V17, P433, DOI 10.1089/thy.2007.0018; EDWARDS JG, 1994, BIOCHEM BIOPH RES CO, V199, P1482, DOI 10.1006/bbrc.1994.1398; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Graier WF, 2008, CELL CALCIUM, V44, P36, DOI 10.1016/j.ceca.2008.01.001; Haddad F, 1998, J APPL PHYSIOL, V85, P2227, DOI 10.1152/jappl.1998.85.6.2227; Haddad F, 2008, AM J PHYSIOL-HEART C, V294, pH29, DOI 10.1152/ajpheart.01125.2007; Harper ME, 2008, THYROID, V18, P145, DOI 10.1089/thy.2007.0250; Horimoto M, 2004, HEPATOLOGY, V39, P386, DOI 10.1002/hep.20047; Hulbert AJ, 2000, BIOL REV, V75, P519, DOI 10.1017/S146479310000556X; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Jang IS, 2001, MECH AGEING DEV, V122, P561, DOI 10.1016/S0047-6374(01)00236-6; Johannsen DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040837; Kim B, 2008, THYROID, V18, P141, DOI 10.1089/thy.2007.0266; Krueger JJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE983, DOI 10.1152/ajpendo.2001.281.5.E983; Levine JA, 2003, J APPL PHYSIOL, V94, P165, DOI 10.1152/japplphysiol.00499.2002; Lipman RD, 1996, J GERONTOL A-BIOL, V51, pB54, DOI 10.1093/gerona/51A.1.B54; LOIREAU A, 1987, J NUTR, V117, P159, DOI 10.1093/jn/117.1.159; Long XL, 1999, J GERONTOL A-BIOL, V54, pB23, DOI 10.1093/gerona/54.1.B23; MASSOUDI M, 1983, ANN NUTR METAB, V27, P26, DOI 10.1159/000176621; Mooradian AD, 2008, DRUG AGING, V25, P371, DOI 10.2165/00002512-200825050-00002; Paradies G, 1997, BBA-BIOENERGETICS, V1319, P5, DOI 10.1016/S0005-2728(97)00012-1; Portman MA, 2005, AM J PHYSIOL-HEART C, V288, pH2484, DOI 10.1152/ajpheart.00848.2004; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Ribeiro MO, 2008, THYROID, V18, P197, DOI 10.1089/thy.2007.0288; Scarpace PJ, 2000, DIABETES, V49, P431, DOI 10.2337/diabetes.49.3.431; Scarpace PJ, 2000, NEUROPHARMACOLOGY, V39, P1872, DOI 10.1016/S0028-3908(00)00014-9; Shek EW, 2000, REGUL PEPTIDES, V92, P65, DOI 10.1016/S0167-0115(00)00151-8; Short KR, 2007, AM J PHYSIOL-ENDOC M, V292, pE642, DOI 10.1152/ajpendo.00397.2006; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Short KR, 2001, AM J PHYSIOL-ENDOC M, V280, pE761, DOI 10.1152/ajpendo.2001.280.5.E761; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; Sun ZQ, 2000, AM J PHYSIOL-ENDOC M, V278, pE302, DOI 10.1152/ajpendo.2000.278.2.E302; THOMAS FB, 1970, ANN INTERN MED, V72, P679, DOI 10.7326/0003-4819-72-5-679; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Villicev CM, 2007, J ENDOCRINOL, V193, P21, DOI 10.1677/joe.1.07066; WAHRENBERG H, 1994, J CLIN ENDOCR METAB, V78, P898, DOI 10.1210/jc.78.4.898; Weitzel JM, 2003, EXP PHYSIOL, V88, P121, DOI 10.1113/eph8802506; WIBOM R, 1990, SCAND J CLIN LAB INV, V50, P143, DOI 10.3109/00365519009089146; WINDER WW, 1977, AM J PHYSIOL, V232, pC180, DOI 10.1152/ajpcell.1977.232.5.C180; Wolden-Hanson T, 2006, PHYSIOL BEHAV, V88, P267, DOI 10.1016/j.physbeh.2006.05.032	50	11	11	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1499	1510		10.1096/fj.13-239806	http://dx.doi.org/10.1096/fj.13-239806			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24344330	Green Published			2022-12-28	WOS:000335324800040
J	Ma, XL; Hibbert, B; McNulty, M; Hu, TQ; Zhao, XL; Ramirez, FD; Simard, T; de Belleroche, JS; O'Brien, ER				Ma, Xiaoli; Hibbert, Benjamin; McNulty, Melissa; Hu, Tieqiang; Zhao, Xiaoling; Ramirez, F. Daniel; Simard, Trevor; de Belleroche, Jacqueline S.; O'Brien, Edward R.			Heat shock protein 27 attenuates neointima formation and accelerates reendothelialization after arterial injury and stent implantation: importance of vascular endothelial growth factor up-regulation	FASEB JOURNAL			English	Article						VEGF; restenosis; progenitor cell	ZOTAROLIMUS-ELUTING STENT; PROGENITOR CELLS; RE-ENDOTHELIALIZATION; MOUSE MODEL; FOLLOW-UP; HEAT-SHOCK-PROTEIN-27; APOPTOSIS; ATHEROSCLEROSIS; MIGRATION; ESTROGEN	Elevated serum heat shock protein 27 (HSP27) levels are atheroprotective; however, the role of HSP27 after arterial injury is unknown. Human endothelial progenitor cells (EPCs) were treated with recombinant (r)HSP27 (50 g/ml) or its inactive C1 terminus, and gene expression was characterized before functional studies were performed in vitro and in vivo. Vascular endothelial growth factor (VEGF) was markedly up-regulated by rHSP27 (10- and 6-fold increases in mRNA and secretion, respectively). Pretreatment of EPCs with rHSP27 resulted in a 60% reduction in reendothelialization (RE) time in a scratch assay, an effect that was blocked with VEGF-neutralizing antibodies. Mice overexpressing HSP27 demonstrated more robust mobilization of EPCs at the time of arterial injury, as well as a 67% increase in RE and a 45% reduction in neointima (NI) formation at 28 d. Implantation of rHSP27-eluting stents in rabbit carotid arteries resulted in a marked improvement in RE at 7 and 28 d and transient attenuation of NI formation by 42% at 7 d. Hence, extracellular HSP27 up-regulated VEGF and improved EPC migration in vitro. Augmented systemic or local levels of HSP27 markedly improved RE after vascular injury, an effect that is of particular relevance to the safety profile of vascular stents.Ma, X., Hibbert, B., McNulty, M., Hu, T., Zhao, X., Ramirez, F. D., Simard, T., de Belleroche, J. S., O'Brien, E. R. Heat shock protein 27 attenuates neointima formation and accelerates reendothelialization after arterial injury and stent implantation: importance of vascular endothelial growth factor up-regulation.	[Ma, Xiaoli; Hibbert, Benjamin; McNulty, Melissa; Hu, Tieqiang; Zhao, Xiaoling; Ramirez, F. Daniel; Simard, Trevor; O'Brien, Edward R.] Univ Ottawa, Inst Heart, Ottawa, ON, Canada; [de Belleroche, Jacqueline S.] Univ London Imperial Coll Sci Technol & Med, London, England; [O'Brien, Edward R.] Libin Cardiovasc Inst Alberta, Calgary, AB T2N 2T9, Canada	University of Ottawa; University of Ottawa Heart Institute; Imperial College London; Libin Cardiovascular Institute Of Alberta	O'Brien, ER (corresponding author), Libin Cardiovasc Inst Alberta, Foothills Med Ctr, Room C823,1403-29th St NW, Calgary, AB T2N 2T9, Canada.	ed.obrien@albertahealthservices.ca	O'Brien, Edward R/J-6621-2013	O'Brien, Edward R/0000-0003-1039-9425	Heart and Stroke Foundation of Ontario [T7217]; Canadian Institute for Health Research (CIHR) [ISO 110836]; Medtronic Canada [ISO 110836]; CIHR [IRC57093]; Medtronic [IRC57093]	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Medtronic Canada(Medtronic); CIHR(Canadian Institutes of Health Research (CIHR)); Medtronic(Medtronic)	This work was supported by operating grants funded by the Heart and Stroke Foundation of Ontario (T7217) and by joint funding from the Canadian Institute for Health Research (CIHR) and Medtronic Canada (ISO 110836). CIHR and Medtronic also collectively fund a peer-reviewed research chair (IRC57093) to E.R.O. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbar MT, 2003, J BIOL CHEM, V278, P19956, DOI 10.1074/jbc.M207073200; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen HF, 2009, MOL CELL BIOCHEM, V327, P1, DOI 10.1007/s11010-009-0034-4; Chen YX, 2004, CIRCULATION, V110, P3721, DOI 10.1161/01.CIR.0000146790.51331.BA; Chen YX, 2003, CAN J PHYSIOL PHARM, V81, P730, DOI 10.1139/Y03-066; Cuerrier CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055867; Douglas G., 2012, EUR HEART J, DOI 10.1093/eurheartj/ehs240; Garg S, 2009, JACC-CARDIOVASC INTE, V2, P1190, DOI 10.1016/j.jcin.2009.10.002; Hibbert B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016413; Hibbert B, 2009, CARDIOVASC RES, V83, P16, DOI 10.1093/cvr/cvp156; Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960; Hutter R, 2004, CIRCULATION, V110, P2430, DOI 10.1161/01.CIR.0000145120.37891.8A; Kato K, 2011, INT J MOL MED, V27, P423, DOI 10.3892/ijmm.2011.595; Keezer SM, 2003, CANCER RES, V63, P6405; Kirtane AJ, 2013, JACC-CARDIOVASC INTE, V6, P325, DOI 10.1016/j.jcin.2012.12.123; Kubo M., 2012, PLOS ONE, V7; Leon MB, 2010, J AM COLL CARDIOL, V55, P543, DOI 10.1016/j.jacc.2009.08.067; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Ma XL, 2010, CARDIOVASC RES, V86, P338, DOI 10.1093/cvr/cvq047; Ma XL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001894; Martin-Ventura JL, 2004, CIRCULATION, V110, P2216, DOI 10.1161/01.CIR.0000136814.87170.B1; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Miller H, 2005, ARTERIOSCL THROM VAS, V25, pE10, DOI 10.1161/01.ATV.0000156536.89752.8e; Park HK, 2006, CIRCULATION, V114, P886, DOI 10.1161/CIRCULATIONAHA.105.541219; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pourdjabbar Ali, 2011, Cardiovascular & Hematological Disorders - Drug Targets, V11, P30; Rayner K, 2008, CIRC RES, V103, P133, DOI 10.1161/CIRCRESAHA.108.172155; Rayner K, 2010, TRENDS CARDIOVAS MED, V20, P53, DOI 10.1016/j.tcm.2010.03.008; Rayner K, 2009, ARTERIOSCL THROM VAS, V29, P1751, DOI 10.1161/ATVBAHA.109.193656; Salari S, 2013, CELL STRESS CHAPERON, V18, P53, DOI 10.1007/s12192-012-0356-0; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; Seibert TA, 2013, J AM COLL CARDIOL, V62, P1446, DOI 10.1016/j.jacc.2013.05.041; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Straume O, 2012, P NATL ACAD SCI USA, V109, P8699, DOI 10.1073/pnas.1017909109; Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814; Zhao YDD, 2005, CIRC RES, V96, P442, DOI 10.1161/01.RES.0000157672.70560.7b	40	17	19	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					594	602		10.1096/fj.13-230417	http://dx.doi.org/10.1096/fj.13-230417			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24142570				2022-12-28	WOS:000331072200008
J	Chen, KH; Dasgupta, A; Ding, JH; Indig, FE; Ghosh, P; Longo, DL				Chen, Kuang-Hueih; Dasgupta, Asish; Ding, Jinhui; Indig, Fred E.; Ghosh, Paritosh; Longo, Dan L.			Role of mitofusin 2 ( Mfn2) in controlling cellular proliferation	FASEB JOURNAL			English	Article						HSG; Ras; Raf; ERK	TUMOR-SUPPRESSOR; RASSF FAMILY; APOPTOSIS; DOMAIN; EXPRESSION; MUTATIONS; PATHWAY	It has been reported that Mitofusin2 (Mfn2) inhibits cell proliferation when overexpressed. We wanted to study the role of endogenous Mfn2 in cell proliferation, along with the structural features of Mfn2 that influence its mitochondrial localization and control of cell proliferation. Mfn2-knockdown clones of a B-cell lymphoma cell line BJAB exhibited an increased rate of cell proliferation. A 2-fold increase in cell proliferation was also observed in Mfn2-knockout mouse embryonic fibroblast (MEF) cells as compared with the control wild-type cells, and the proliferative advantage of the knockout MEF cells was blocked on reintroduction of the Mfn2 gene. Mfn2 exerts its antiproliferative effect by acting as an effector molecule of Ras, resulting in the inhibition of the Ras-Raf-ERK signaling pathway. Furthermore, both the N-terminal (aa 1-264) and the C-terminal (aa 265-757) fragments of Mfn2 blocked cell proliferation through distinct mechanisms: the N-terminal-mediated inhibition was due to its interaction with Raf-1, whereas the C-terminal fragment of Mfn2 inhibited cell proliferation by interacting with Ras. The inhibition of proliferation by the N-terminal fragment was independent of its mitochondrial localization. Collectively, our data provide new insights regarding the role of Mfn2 in controlling cellular proliferation.Chen, K.-H., Dasgupta, A., Ding, J., Indig, F. E., Ghosh, P., Longo, D. L. Role of Mitofusin 2 (Mfn2) in controlling cellular proliferation.	[Chen, Kuang-Hueih; Dasgupta, Asish; Ghosh, Paritosh; Longo, Dan L.] NIA, Lymphocyte Cell Biol Unit, Genet Lab, Biomed Res Ctr,NIH, Baltimore, MD 21224 USA; [Ding, Jinhui] NIA, Bioinformat Facil, Neurogenet Lab, NIH, Baltimore, MD 21224 USA; [Indig, Fred E.] NIA, Confocal Imaging Facil, NIH, Baltimore, MD 21224 USA; [Chen, Kuang-Hueih] MedStar Res Inst, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Ghosh, P (corresponding author), NIA, Lymphocyte Cell Biol Unit, Genet Lab, NIH,Biomed Res Ctr, 251 Bayview Blvd, Baltimore, MD 21224 USA.	kuanghueihchen@yahoo.com; ghoshp@grc.nia.nih.gov	Longo, Dan L./F-6022-2011		National Institutes of Health, National Institute on Aging; NATIONAL INSTITUTE ON AGING [ZIAAG000451, ZICAG000615] Funding Source: NIH RePORTER	National Institutes of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Dr. David C. Chan (Division of Biology, California Institute of Technology, Pasadena, CA, USA) for WT and Mfn2-knockout MEFs. The authors thank Drs. Carl Sasaki and Jessica Curtis for technical assistance and Rachel Munk for help in editing the paper. The authors also thank the Flow Cytometry facility at the National Institute on Aging for help in cell cycle analysis. This research was supported (in part) by the Intramural Research Program of the National Institutes of Health, National Institute on Aging.	Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Chien KR, 2004, NAT CELL BIOL, V6, P807, DOI 10.1038/ncb0904-807; de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534; de Brito OM, 2009, MITOCHONDRION, V9, P222, DOI 10.1016/j.mito.2009.02.005; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Guo XM, 2007, CIRC RES, V101, P1113, DOI 10.1161/CIRCRESAHA.107.157644; Hernandez-Alvarez MI, 2010, DIABETES CARE, V33, P645, DOI 10.2337/dc09-1305; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Marchler-Bauer A, 2011, NUCLEIC ACIDS RES, V39, pD225, DOI 10.1093/nar/gkq1189; Misko AL, 2012, J NEUROSCI, V32, P4145, DOI 10.1523/JNEUROSCI.6338-11.2012; Park J, 2010, J BIOL CHEM, V285, P35029, DOI 10.1074/jbc.M110.165506; Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rojo M, 2002, J CELL SCI, V115, P1663; Shen T, 2007, J BIOL CHEM, V282, P23354, DOI 10.1074/jbc.M702657200; Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Wu L, 2008, MOL CANCER THER, V7, P222, DOI 10.1158/1535-7163.MCT-07-0382; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	26	79	89	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					382	394		10.1096/fj.13-230037	http://dx.doi.org/10.1096/fj.13-230037			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24081906	Green Published			2022-12-28	WOS:000333526100036
J	Fitzgerald, JC; Ugun-Klusek, A; Allen, G; De Girolamo, LA; Hargreaves, I; Ufer, C; Abramov, AY; Billett, EE				Fitzgerald, Julia C.; Ugun-Klusek, Aslihan; Allen, George; De Girolamo, Luigi A.; Hargreaves, Iain; Ufer, Christoph; Abramov, Andrey Y.; Billett, E. Ellen			Monoamine oxidase-A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins	FASEB JOURNAL			English	Article						reactive oxygen species; neurodegeneration; electron transport chain; Parkinson's disease	MAO-B ELEVATION; COMPLEX-I; SUPEROXIDE-PRODUCTION; PARKINSONS-DISEASE; OXIDATIVE STRESS; SITES; PATHOGENESIS; LOCALIZATION; INHIBITION; EXPRESSION	The study examined how the mitochondrial enzyme monoamine oxidase-A (MAO-A), which produces hydrogen peroxide as a catalytic by-product, influences death and survival mechanisms. Targeted microRNA (miRNA) was used to stably knock down MAO-A mRNA, protein, and catalytic activity by 60-70% in SH-SY5Y human neuroblastoma cells. The effects of MAO-A knockdown (KD) on ATP, oxidative stress, electron transport chain, and survival following exposure to mitochondrial toxins were assessed. In control cells, complex I inhibition resulted in caspase-mediated cell death linked with ROS production and reduced ATP, followed by up-regulation of MAO-A mRNA, protein, and enzyme activity levels. Inhibition of complex III and IV resulted in a similar increase in MAO-A expression, while up-regulation of MAO-A was lower following complex II inhibition. MAO-A KD decreased basal reactive oxygen species levels by 50% and increased levels of ATP and reduced glutathione and Bcl-2. MAO-A KD specifically increased the activity of complex I but had no effect on complex II-IV activities. Furthermore, MAO-A KD protected against inhibitors of complex I, III, and IV. In summary, endogenous MAO-A levels influence mitochondrial function, notably complex I activity, and MAO-A may be a target for protection against neurodegenerative conditions that involve oxidative stress and mitochondrial dysfunction as underlying pathogenic factors.Fitzgerald, J. C., Ugun-Klusek, A., Allen, G., De Girolamo, L. A., Hargreaves, I., Ufer, C., Abramov, A. Y., Billett, E. E. Monoamine oxidase-A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins.	[Fitzgerald, Julia C.; Ugun-Klusek, Aslihan; De Girolamo, Luigi A.; Ufer, Christoph; Billett, E. Ellen] Nottingham Trent Univ, Sch Sci & Technol, Nottingham NG11 8NS, England; [Fitzgerald, Julia C.] Hertie Inst Clin Brain Res, Funct Neurogen Lab, Tubingen, Germany; [Allen, George; Abramov, Andrey Y.] UCL, Inst Neurol, Dept Mol Neurosci, London, England; [Hargreaves, Iain] Natl Hosp Neurol & Neurosurg, Neurometab Unit, London WC1N 3BG, England; [Ufer, Christoph] Charite, Inst Biochem, D-13353 Berlin, Germany	Nottingham Trent University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Billett, EE (corresponding author), Nottingham Trent Univ, Sch Sci & Technol, Nottingham NG11 8NS, England.	ellen.billett@ntu.ac.uk	Hargreaves, Iain/AAJ-6757-2020; Abramov, Andrey Y/H-9053-2012; Abramov, Andrey/AAC-6712-2019	Abramov, Andrey Y/0000-0002-7646-7235; Abramov, Andrey/0000-0002-7646-7235; Ugun Klusek, Aslihan/0000-0002-0199-0275; Billett, Ellen/0000-0001-8245-6519	Nottingham Trent University; British Council; Deutscher Akademischer Austauschdienst (DAAD)	Nottingham Trent University; British Council(The British Council in India); Deutscher Akademischer Austauschdienst (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD))	The authors thank Hartmut Kuhn and Dr. Pavlos Chaitidis (Institute of Biochemistry, University Medicine Berlin-Charite, Berlin, Germany). Funding for this study was provided by Nottingham Trent University, British Council, and Deutscher Akademischer Austauschdienst (DAAD).	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Bongioanni P, 1996, NEURODEGENERATION, V5, P351, DOI 10.1006/neur.1996.0047; Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003; Burte F, 2011, J PROTEOME RES, V10, P1974, DOI 10.1021/pr101211k; CADENAS E, 2000, FREE RADIC BIOL MED, V29, P220; Caneda-Ferron B, 2008, J NEUROCHEM, V105, P225, DOI 10.1111/j.1471-4159.2007.05130.x; Cao X, 2009, J NEUROCHEM, V111, P101, DOI 10.1111/j.1471-4159.2009.06300.x; CHURCH RJ, 1994, P R MICROSC SOC, V29, P243; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Danielczyk M. L., 1998, ACTA PSYCHIAT SCAND, V78, P730; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Edmondson D. E., 2013, CURR PHARM DES; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fitzgerald JC, 2008, FEBS J, V275, P5758, DOI 10.1111/j.1742-4658.2008.06708.x; Fitzgerald JC, 2007, J NEUROCHEM, V103, P2189, DOI 10.1111/j.1471-4159.2007.04921.x; FOWLER CJ, 1980, J NEURAL TRANSM, V49, P1, DOI 10.1007/BF01249185; Gandhi S, 2005, HUM MOL GENET, V14, P2749, DOI 10.1093/hmg/ddi308; Gerlach M., 1993, MONOAMINE OXIDASE, P147; Gu M, 1998, J NEUROL SCI, V158, P24, DOI 10.1016/S0022-510X(98)00095-1; Hajieva P, 2009, J NEUROCHEM, V110, P118, DOI 10.1111/j.1471-4159.2009.06114.x; Hargreaves IP, 2007, MITOCHONDRION, V7, P284, DOI 10.1016/j.mito.2007.02.001; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Heo JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032629; Hu LF, 2009, MOL PHARMACOL, V75, P27, DOI 10.1124/mol.108.047985; Jiang HB, 2006, J BIOL CHEM, V281, P8591, DOI 10.1074/jbc.M510926200; JIN YZ, 1990, BIOCHEM BIOPH RES CO, V172, P1338, DOI 10.1016/0006-291X(90)91596-K; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kumar MJ, 2003, J BIOL CHEM, V278, P46432, DOI 10.1074/jbc.M306378200; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mallajosyula JK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001616; Martin I, 2011, ANNU REV GENOM HUM G, V12, P301, DOI 10.1146/annurev-genom-082410-101440; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Musatov A, 2012, FREE RADICAL RES, V46, P1313, DOI 10.3109/10715762.2012.717273; Naoi M, 2009, J NEURAL TRANSM, V116, P1371, DOI 10.1007/s00702-009-0309-7; Ou XM, 2006, P NATL ACAD SCI USA, V103, P10923, DOI 10.1073/pnas.0601515103; Perfeito R, 2012, FREE RADICAL BIO MED, V53, P1791, DOI 10.1016/j.freeradbiomed.2012.08.569; Quinlan CL, 2012, FREE RADICAL BIO MED, V53, P1807, DOI 10.1016/j.freeradbiomed.2012.08.015; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Rodriguez MJ, 2000, J HISTOCHEM CYTOCHEM, V48, P147, DOI 10.1177/002215540004800115; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schapira AHV, 2009, NEUROLOGY, V72, pS44, DOI 10.1212/WNL.0b013e3181990438; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siddiqui A, 2012, FREE RADICAL RES, V46, P1011, DOI 10.3109/10715762.2012.662277; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Tang B, 2012, MOL MED REP, V5, P1271, DOI 10.3892/mmr.2012.806; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Wang J, 2011, BIOCHEMISTRY-US, V50, P2499, DOI 10.1021/bi101722b; Wei Z, 2012, J NEURAL TRANSM, V119, P1285, DOI 10.1007/s00702-012-0779-x; Westlund K., 1994, MONOAMINE OXIDASE IN, P1; WESTLUND KN, 1988, NEUROSCIENCE, V25, P439, DOI 10.1016/0306-4522(88)90250-3; Zhou G, 2001, J NEUROL NEUROSUR PS, V70, P229, DOI 10.1136/jnnp.70.2.229; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	60	27	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					218	229		10.1096/fj.13-235481	http://dx.doi.org/10.1096/fj.13-235481			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24051032				2022-12-28	WOS:000333526100022
J	Kai, F; Duncan, R				Kai, FuiBoon; Duncan, Roy			Prostate cancer cell migration induced by myopodin isoforms is associated with formation of morphologically and biochemically distinct actin networks	FASEB JOURNAL			English	Article						PC3 cells; actin bundles; stress fibers; actomyosin; synaptopodin 2	BINDING PROTEIN; FILAMENT BUNDLES; STRESS FIBERS; ALPHA-ACTININ; SYNAPTOPODIN; FESSELIN; SUPPRESSION; EXPRESSION; MOTILITY; MYOSIN	Myopodin is an actin-binding protein that promotes cancer cell migration in response to serum stimulation and is associated with invasive tumor development. To determine whether enhanced migration reflects changes in actin cytoskeleton remodeling, fluorescence confocal microscopy was used to examine the composition and morphology of filamentous actin structures in mock-transduced cells vs. stably transduced PC3 cells expressing human myopodin isoforms, and the chemokinetic response of cells was quantified using transwell assays. The same approaches were used to analyze the effects of external migration stimuli, actin polymerization inhibitors or deletion of the isoform-specific amino- and/or carboxy termini on cell migration and actin bundle formation. Results indicate that the termini of the myopodin isoforms differentially alter the formation of morphologically distinct F-actin networks that also differ in their myosin and myopodin staining patterns. Furthermore, enhanced cell migration was reduced by >50% when actin bundle formation was impaired by myopodin-truncation, low concentrations of an actin polymerization inhibitor, or in the absence of an external migration stimulus. Human myopodin isoforms are therefore potent regulators of stress fiber formation, inducing the formation of biochemically and morphologically distinct F-actin networks in the cell body whose presence directly correlates with increased cell migration.	[Kai, FuiBoon; Duncan, Roy] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4R2, Canada; [Duncan, Roy] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4R2, Canada; [Duncan, Roy] Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4R2, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Duncan, R (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, Tupper Med Bldg,5850 Coll St,POB 15000, Halifax, NS B3H 4R2, Canada.	roy.duncan@dal.ca		Duncan, Roy/0000-0002-5162-5081	Dalhousie Medical Research Foundation (DMRF); Prostate Cancer Fight Foundation of Canada; Canadian Institutes of Health Research (CIHR); Beatrice Hunter Cancer Research Institute; Canadian Imperial Bank of Commerce as part of the Terry Fox Strategic Health Research Training Program in Cancer Research at CIHR	Dalhousie Medical Research Foundation (DMRF); Prostate Cancer Fight Foundation of Canada; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Beatrice Hunter Cancer Research Institute; Canadian Imperial Bank of Commerce as part of the Terry Fox Strategic Health Research Training Program in Cancer Research at CIHR	The authors thank Jan Gettemans (Ghent University, Belgium) for kindly providing the cDNAs for MYO1, MYO2, and MYO3. This work was funded by a grant from the Dalhousie Medical Research Foundation (DMRF) with support from the Prostate Cancer Fight Foundation of Canada, and by a grant from the Canadian Institutes of Health Research (CIHR). F. K. was supported by a trainee award from the Beatrice Hunter Cancer Research Institute with funds provided by the Canadian Imperial Bank of Commerce as part of the Terry Fox Strategic Health Research Training Program in Cancer Research at CIHR.	Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Anderson TW, 2008, MOL BIOL CELL, V19, P5006, DOI 10.1091/mbc.E08-01-0034; Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Asanuma K, 2005, J CLIN INVEST, V115, P1188, DOI 10.1172/JCI200523371; Beall B, 2001, BIOCHEMISTRY-US, V40, P14252, DOI 10.1021/bi011806u; Beqqali A, 2010, J CELL SCI, V123, P1141, DOI 10.1242/jcs.063859; Burnette DT, 2011, NAT CELL BIOL, V13, P371, DOI 10.1038/ncb2205; Claeys KG, 2009, ACTA NEUROPATHOL, V117, P293, DOI 10.1007/s00401-008-0479-7; Cramer LP, 1997, J CELL BIOL, V136, P1287, DOI 10.1083/jcb.136.6.1287; De Ganck A, 2005, FEBS LETT, V579, P6673, DOI 10.1016/j.febslet.2005.10.054; De Ganck A, 2008, BIOCHEM BIOPH RES CO, V370, P269, DOI 10.1016/j.bbrc.2008.03.086; De Ganck A, 2009, INT J ONCOL, V34, P1403, DOI 10.3892/ijo_00000268; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Kai FB, 2012, CARCINOGENESIS, V33, P2100, DOI 10.1093/carcin/bgs268; Khaymina SS, 2007, J PROTEOME RES, V6, P3648, DOI 10.1021/pr070237v; Kovac B, 2013, J CELL SCI, V126, P263, DOI 10.1242/jcs.115063; Leinweber BD, 1999, J MUSCLE RES CELL M, V20, P539, DOI 10.1023/A:1005597306671; Lin F, 2001, AM J PATHOL, V159, P1603, DOI 10.1016/S0002-9440(10)63006-4; Linnemann A, 2013, J MUSCLE RES CELL M, V34, P61, DOI 10.1007/s10974-012-9334-5; Linnemann A, 2010, EUR J CELL BIOL, V89, P681, DOI 10.1016/j.ejcb.2010.04.004; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Nemethova M, 2008, J CELL BIOL, V180, P1233, DOI 10.1083/jcb.200709134; Pellegrin S, 2007, J CELL SCI, V120, P3491, DOI 10.1242/jcs.018473; Pham M, 2006, J MUSCLE RES CELL M, V27, P45, DOI 10.1007/s10974-005-9053-2; Schmoller KM, 2009, BIOPHYS J, V97, P83, DOI 10.1016/j.bpj.2009.04.040; Schroeter M, 2004, BIOCHEMISTRY-US, V43, P13875, DOI 10.1021/bi0487490; Schroeter MM, 2008, BIOSCIENCE REP, V28, P195, DOI 10.1042/BSR20080079; Schroeter MM, 2008, BIOCHEM BIOPH RES CO, V371, P582, DOI 10.1016/j.bbrc.2008.04.134; Schroeter MM, 2005, J MUSCLE RES CELL M, V26, P183, DOI 10.1007/s10974-005-9009-6; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Thierry-Mieg D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s12; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087; Tojkander S, 2011, CURR BIOL, V21, P539, DOI 10.1016/j.cub.2011.03.007; Trudeau T, 2013, STRUCTURE, V21, P332, DOI 10.1016/j.str.2012.12.013; Ulbricht A, 2013, CURR BIOL, V23, P430, DOI 10.1016/j.cub.2013.01.064; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039; Wong JS, 2012, EMBO J, V31, P1028, DOI 10.1038/emboj.2011.464; Yu YP, 2011, ONCOGENE, V30, P4855, DOI 10.1038/onc.2011.200; Yu YP, 2006, CANCER RES, V66, P7414, DOI 10.1158/0008-5472.CAN-06-0227	42	10	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5046	5058		10.1096/fj.13-231571	http://dx.doi.org/10.1096/fj.13-231571			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24005909				2022-12-28	WOS:000329999000037
J	Cencetti, F; Bernacchioni, C; Tonelli, F; Roberts, E; Donati, C; Bruni, P				Cencetti, Francesca; Bernacchioni, Caterina; Tonelli, Francesca; Roberts, Edward; Donati, Chiara; Bruni, Paola			TGF beta 1 evokes myoblast apoptotic response via a novel signaling pathway involving S1P(4) transactivation upstream of Rho-kinase-2 activation	FASEB JOURNAL			English	Article						transforming growth factor; sphingosine 1-phosphate; S1P(4); C2C12 myoblasts; skeletal muscle cells	SPHINGOSINE KINASE TYPE-2; TGF-BETA; MYOGENIC DIFFERENTIATION; CELL-PROLIFERATION; MOUSE MODEL; T-CELLS; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; GROWTH; PROTEIN	In view of its multiple detrimental effects, transforming growth factor 1 (TGF1) is recognized as critical negative regulator of skeletal muscle repair. Apoptosis of skeletal muscle precursor cells driven by TGF1 contributes to the negative role exerted by the cytokine in tissue repair, although the underlying molecular mechanisms are still elusive. Herein we report the identification of a new signaling pathway, relying on Rho kinase-2 stimulation, subsequent to SMAD-dependent S1P(4) up-regulation and transactivation via sphingosine kinase (SK)-2, that accounts for TGF1-induced apoptosis in cultured myoblasts. S1P(4)-specific gene silencing reduced by almost 50% activation of caspase-3 and poly-ADP ribosyl transferase cleavage elicited by TGF1. Moreover, the selective S1P(4) antagonist CYM50358 also reduced the TGF1 proapoptotic effects. By employing pharmacological and molecular biological approaches, the involvement of SK2 and ROCK2 in the transmission of the TGF1 apoptotic action was also demonstrated. These results reinforce the notion that the SK/S1P axis plays a fundamental role in TGF1 mode of action in skeletal muscle cells and, by disclosing a novel mechanism by which TGF1 exerts its harmful action, pinpoint new molecular targets that in principle could be beneficial in the treatment of several skeletal muscle disorders or aging-dependent muscle atrophy.Cencetti, F., Bernacchioni, C., Tonelli, F., Roberts, E., Donati, C., Bruni, P. TGF1 evokes myoblast apoptotic response via a novel signaling pathway involving S1P(4) transactivation upstream of Rho-kinase-2 activation.	[Cencetti, Francesca; Bernacchioni, Caterina; Tonelli, Francesca; Donati, Chiara; Bruni, Paola] Univ Florence, Dipartimento Sci Biomed Sperimentali & Clin, I-50134 Florence, Italy; [Cencetti, Francesca; Bernacchioni, Caterina; Tonelli, Francesca; Donati, Chiara; Bruni, Paola] Interuniv Inst Myol, Florence, Italy; [Roberts, Edward] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	University of Florence; Scripps Research Institute	Bruni, P (corresponding author), Univ Florence, Dipartimento Sci Biomed Sperimentali & Clin, Viale GB Morgagni 50, I-50134 Florence, Italy.	paola.bruni@unifi.it	Bruni, Paola/A-1151-2008; cencetti, francesca/J-8372-2018; donati, chiara/AAN-2682-2021	donati, chiara/0000-0003-2224-4199; Bruni, Paola/0000-0002-1151-3413; Cencetti, Francesca/0000-0003-4351-2965; Bernacchioni, Caterina/0000-0002-1023-0067	Italian Ministry of University and Scientific Research; University of Florence; Fondazione Cassa di Risparmio di Pistoia e Pescia	Italian Ministry of University and Scientific Research(Ministry of Education, Universities and Research (MIUR)); University of Florence; Fondazione Cassa di Risparmio di Pistoia e Pescia	This research was supported by grants from Italian Ministry of University and Scientific Research (PRIN2009) to P. B., University of Florence (ex 60%) to C. D., and Fondazione Cassa di Risparmio di Pistoia e Pescia to P. B. The authors are indebted to K. L. Lynch and T. L. MacDonald (University of Virginia, Charlottesville, VA, USA) for the kind gift of VPC96047 and VPC96091.	Bernasconi P, 1999, NEUROMUSCULAR DISORD, V9, P28, DOI 10.1016/S0960-8966(98)00093-5; Bruni P, 2008, CELL MOL LIFE SCI, V65, P3725, DOI 10.1007/s00018-008-8236-6; Burks TN, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-19; Cencetti F, 2010, MOL BIOL CELL, V21, P1111, DOI 10.1091/mbc.E09-09-0812; Chen YW, 2005, NEUROLOGY, V65, P826, DOI 10.1212/01.wnl.0000173836.09176.c4; Chipuk JE, 2012, CELL, V148, P988, DOI 10.1016/j.cell.2012.01.038; Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ding G, 2007, J BIOL CHEM, V282, P27493, DOI 10.1074/jbc.M701641200; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; Donati C, 2007, STEM CELLS, V25, P1713, DOI 10.1634/stemcells.2006-0725; Donati C, 2009, CELL SIGNAL, V21, P228, DOI 10.1016/j.cellsig.2008.10.007; Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Golfier S, 2010, FASEB J, V24, P4701, DOI 10.1096/fj.09-141473; Gordon KJ, 2008, BBA-MOL BASIS DIS, V1782, P197, DOI 10.1016/j.bbadis.2008.01.006; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Guerrero M, 2012, BIOORG MED CHEM LETT, V22, P537, DOI 10.1016/j.bmcl.2011.10.096; Guerrero M, 2011, BIOORG MED CHEM LETT, V21, P3632, DOI 10.1016/j.bmcl.2011.04.097; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Illuzzi G, 2010, J BIOL CHEM, V285, P18594, DOI 10.1074/jbc.M109.072801; Kennedy AJ, 2011, J MED CHEM, V54, P3524, DOI 10.1021/jm2001053; Kharel Y, 2011, BIOCHEM J, V440, P345, DOI 10.1042/BJ20110817; Kim RH, 2009, BBA-MOL CELL BIOL L, V1791, P692, DOI 10.1016/j.bbalip.2009.02.011; Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC; Lebman DA, 2008, J LIPID RES, V49, P1388, DOI 10.1194/jlr.R800008-JLR200; Li X, 2009, POULTRY SCI, V88, P1725, DOI 10.3382/ps.2008-00534; Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002-9440(10)63188-4; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; MacDonald EM, 2012, CURR OPIN RHEUMATOL, V24, P628, DOI 10.1097/BOR.0b013e328358df34; Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-21; Matsuyuki H, 2006, CELL MOL IMMUNOL, V3, P429; McLennan IS, 2002, INT J DEV BIOL, V46, P559; Meacci E, 2003, BBA-MOL CELL BIOL L, V1633, P133, DOI 10.1016/S1388-1981(03)00106-9; Meacci E, 2008, J CELL PHYSIOL, V214, P210, DOI 10.1002/jcp.21187; Meinen S, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-18; Miller AV, 2008, MOL CELL BIOL, V28, P4142, DOI 10.1128/MCB.01465-07; Miyake M, 2011, J CELL PHYSIOL, V226, P1128, DOI 10.1002/jcp.22434; Nijnik A, 2012, J IMMUNOL, V189, P102, DOI 10.4049/jimmunol.1200282; Nincheri P, 2010, CELL SIGNAL, V22, P1688, DOI 10.1016/j.cellsig.2010.06.009; Ohotski J, 2012, BRIT J CANCER, V106, P1453, DOI 10.1038/bjc.2012.98; Ohsawa Y, 2012, LAB INVEST, V92, P1100, DOI 10.1038/labinvest.2012.78; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Street CA, 2011, ANTICANCER RES, V31, P3645; Taha TA, 2006, BBA-BIOMEMBRANES, V1758, P2027, DOI 10.1016/j.bbamem.2006.10.018; Takuwa Y, 2013, BBA-MOL CELL BIOL L, V1831, P185, DOI 10.1016/j.bbalip.2012.06.008; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vemula S, 2010, BLOOD, V115, P1785, DOI 10.1182/blood-2009-08-237222; Wang WG, 2005, FASEB J, V19, P1731, DOI 10.1096/fj.05-3730fje; Watterson KR, 2007, WOUND REPAIR REGEN, V15, P607, DOI 10.1111/j.1524-475X.2007.00292.x; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Zhou L, 2010, J NEUROPATH EXP NEUR, V69, P771, DOI 10.1097/NEN.0b013e3181e9a34b	57	39	41	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4532	4546		10.1096/fj.13-228528	http://dx.doi.org/10.1096/fj.13-228528			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23913862				2022-12-28	WOS:000329937500020
J	Aguer, C; Fiehn, O; Seifert, EL; Bezaire, V; Meissen, JK; Daniels, A; Scott, K; Renaud, JM; Padilla, M; Bickel, DR; Dysart, M; Adams, SH; Harper, ME				Aguer, Celine; Fiehn, Oliver; Seifert, Erin L.; Bezaire, Veronic; Meissen, John K.; Daniels, Amanda; Scott, Kyle; Renaud, Jean-Marc; Padilla, Marta; Bickel, David R.; Dysart, Michael; Adams, Sean H.; Harper, Mary-Ellen			Muscle uncoupling protein 3 overexpression mimics endurance training and reduces circulating biomarkers of incomplete beta-oxidation	FASEB JOURNAL			English	Article						fatty acid oxidation; acylcarnitines; oxidative stress; exercise mimetic; mitochondria	OXYGEN SPECIES PRODUCTION; FATTY-ACID OXIDATION; MOUSE SKELETAL-MUSCLE; INSULIN-RESISTANCE; SUPEROXIDE-DISMUTASE; CARNITINE ACETYLTRANSFERASE; CELL-FREE; EXERCISE; MITOCHONDRIA; INCREASES	Exercise substantially improves metabolic health, making the elicited mechanisms important targets for novel therapeutic strategies. Uncoupling protein 3 (UCP3) is a mitochondrial inner membrane protein highly selectively expressed in skeletal muscle. Here we report that moderate UCP3 overexpression (roughly 3-fold) in muscles of UCP3 transgenic (UCP3 Tg) mice acts as an exercise mimetic in many ways. UCP3 overexpression increased spontaneous activity (approximate to 40%) and energy expenditure (approximate to 5-10%) and decreased oxidative stress (approximate to 15-20%), similar to exercise training in wild-type (WT) mice. The increase in complete fatty acid oxidation (FAO; approximate to 30% for WT and approximate to 70% for UCP3 Tg) and energy expenditure (approximate to 8% for WT and 15% for UCP3 Tg) in response to endurance training was higher in UCP3 Tg than in WT mice, showing an additive effect of UCP3 and endurance training on these two parameters. Moreover, increases in circulating short-chain acylcarnitines in response to acute exercise in untrained WT mice were absent with training or in UCP3 Tg mice. UCP3 overexpression had the same effect as training in decreasing long-chain acylcarnitines. Outcomes coincided with a reduction in muscle carnitine acetyltransferase activity that catalyzes the formation of acylcarnitines. Overall, results are consistent with the conclusions that circulating acylcarnitines could be used as a marker of incomplete muscle FAO and that UCP3 is a potential target for the treatment of prevalent metabolic diseases in which muscle FAO is affected.Aguer, C., Fiehn, O., Seifert, E. L., Bezaire, V., Meissen, J. K., Daniels, A., Scott, K., Renaud, J.-M., Padilla, M., Bickel, D. R., Dysart, M., Adams, S. H., Harper, M.-E. Muscle uncoupling protein 3 overexpression mimics endurance training and reduces circulating biomarkers of incomplete beta-oxidation.	[Aguer, Celine; Seifert, Erin L.; Daniels, Amanda; Padilla, Marta; Bickel, David R.; Dysart, Michael; Harper, Mary-Ellen] Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON K1H 8M5, Canada; [Scott, Kyle; Renaud, Jean-Marc] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; [Padilla, Marta; Bickel, David R.; Harper, Mary-Ellen] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON K1H 8M5, Canada; [Fiehn, Oliver; Meissen, John K.] Univ Calif Davis, West Coast Metabol Ctr, Davis, CA 95616 USA; [Fiehn, Oliver; Meissen, John K.] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; [Adams, Sean H.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [Adams, Sean H.] ARS, Obes & Metab Res Unit, USDA, Western Human Nutr Res Ctr, Davis, CA 95616 USA; [Bezaire, Veronic] Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada	University of Ottawa; University of Ottawa; University of Ottawa; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Agriculture (USDA); Carleton University	Harper, ME (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	sean.h.adams@ars.usda.gov; mharper@uottawa.ca	Aguer, Celine/U-7848-2019; Bickel, David/ABF-7206-2021; ADAMS, SEAN/N-9262-2018	Aguer, Celine/0000-0001-8828-8472; Bickel, David/0000-0002-9623-3946; ADAMS, SEAN/0000-0002-9515-2319; Harper, Mary-Ellen/0000-0003-3864-5886	Canadian Institutes of Health Research (Institute of Nutrition, Metabolism and Diabetes grant); U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grant [R01DK078328-01]; U.S. Department of Agriculture-Agricultural Research Service Intramural Projects [5306-51530-016-00D, 5306-51530-019-00]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078328] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (Institute of Nutrition, Metabolism and Diabetes grant); U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grant; U.S. Department of Agriculture-Agricultural Research Service Intramural Projects; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Linda Jut for muscle fiber typing, Mahmoud Salkhordeh, Jian Xuan, Jaehoon Kim, Mine Palazoglu, Massud Atta, Kristie Cloos, and Wan Tan for their excellent technical assistance, Trina Knotts (Mouse Metabolomic Phenotyping Center, University of California, Davis, CA, USA) for ANCOVA analyses, and Dolors Serra (University of Barcelona, Barcelona, Spain) for her generous gift of anti-CrAT antibody. This work was supported by the Canadian Institutes of Health Research (Institute of Nutrition, Metabolism and Diabetes grant to M.E.H.), U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK078328-01 (to S.H.A., M.E.H., and O.F.), and U.S. Department of Agriculture-Agricultural Research Service Intramural Projects 5306-51530-016-00D and 5306-51530-019-00 (to S.H.A.). C.A., O.F., S.H.A., and M.-E.H. conceived the experiments; CA., O.F., E.L.S., V.B., S.H.A., and M.-E.H. designed the experiments; C.A., E.L.S., V.B., J.K.M., A.D., K.S., and M.D. performed experiments; C.A., O.F., E.L.S., V.B., J.K.M., A.D., K.S., J.-M.R., M.P., D.R.B., and M.D. analyzed data; C.A. wrote the article; and V.B., E.L.S., S.H.A., and M.-E.H. edited the article. The authors declare no conflicts of interest.	Adams SH, 2009, J NUTR, V139, P1073, DOI 10.3945/jn.108.103754; Aguer C, 2010, DIABETOLOGIA, V53, P1151, DOI 10.1007/s00125-010-1708-x; Anderson EJ, 2007, J BIOL CHEM, V282, P31257, DOI 10.1074/jbc.M706129200; Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Baillet L, 2000, J BIOL CHEM, V275, P36766, DOI 10.1074/jbc.M008265200; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Bickel DR, 2013, STAT APPL GENET MOL, V12, P529, DOI 10.1515/sagmb-2013-0003; BICKEL DR, 2004, STAT APPL GENET MOL, V3; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Calvo JA, 2008, J APPL PHYSIOL, V104, P1304, DOI 10.1152/japplphysiol.01231.2007; Choi CS, 2007, J CLIN INVEST, V117, P1995, DOI 10.1172/JCI13579; Cifelli C, 2007, J PHYSIOL-LONDON, V582, P843, DOI 10.1113/jphysiol.2007.130955; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Costford SR, 2006, AM J PHYSIOL-ENDOC M, V290, pE1304, DOI 10.1152/ajpendo.00401.2005; Pimenta AD, 2007, EUR J APPL PHYSIOL, V102, P119, DOI 10.1007/s00421-007-0542-4; Dekany M, 2006, INT J SPORTS MED, V27, P112, DOI 10.1055/s-2005-865634; Di Meo S, 2001, BIOL SIGNAL RECEPT, V10, P125; Efron B, 2004, J AM STAT ASSOC, V99, P96, DOI 10.1198/016214504000000089; Efron B., 2010, LARGE SCALE INFERENC; Efron B., 2011, LOCFDR COMPUTES LOCA; Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012; Estey C, 2012, EXP GERONTOL, V47, P361, DOI 10.1016/j.exger.2012.02.008; Gerrits MF, 2010, J LIPID RES, V51, P2394, DOI 10.1194/jlr.P005298; GLATZ JFC, 1984, BIOCHIM BIOPHYS ACTA, V794, P454, DOI 10.1016/0005-2760(84)90012-2; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Hitomi Y, 2008, REDOX REP, V13, P213, DOI 10.1179/135100008X308894; Hollander J, 2001, PFLUG ARCH EUR J PHY, V442, P426, DOI 10.1007/s004240100539; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Jaudzems K, 2009, J ENZYM INHIB MED CH, V24, P1269, DOI 10.3109/14756360902829527; JONES RE, 1981, BIOCHIM BIOPHYS ACTA, V666, P120, DOI 10.1016/0005-2760(81)90097-7; JORGENSEN TG, 1976, SCAND J CLIN LAB INV, V36, P771, DOI 10.3109/00365517609081936; Kim JK, 2002, METABOLISM, V51, P460, DOI 10.1053/meta.2002.31326; Kitzmann M, 2011, BBA-MOL BASIS DIS, V1812, P423, DOI 10.1016/j.bbadis.2010.12.007; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Lehmann R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011519; Leick L, 2008, AM J PHYSIOL-ENDOC M, V294, pE463, DOI 10.1152/ajpendo.00666.2007; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Mailloux RJ, 2012, FASEB J, V26, P363, DOI 10.1096/fj.11-189639; Mailloux RJ, 2011, BIOCHEM J, V437, P301, DOI 10.1042/BJ20110571; Majerczak J, 2010, J PHYSIOL PHARMACOL, V61, P743; Muoio DM, 2012, CELL METAB, V15, P764, DOI 10.1016/j.cmet.2012.04.005; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Padilla M, 2012, STAT APPL GENET MOL, V11, DOI 10.1515/1544-6115.1807; Pecqueur C, 2001, J MOL MED, V79, P48, DOI 10.1007/s001090000150; Pedersen BK, 2006, SCAND J MED SCI SPOR, V16, P3, DOI 10.1111/j.1600-0838.2006.00520.x; Powers SK, 2007, J APPL PHYSIOL, V102, P2389, DOI 10.1152/japplphysiol.01202.2006; Seifert EL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009834; Senese R, 2011, PFLUG ARCH EUR J PHY, V461, P153, DOI 10.1007/s00424-010-0892-3; Steinberg J, 2002, RESP PHYSIOL NEUROBI, V130, P189, DOI 10.1016/S0034-5687(02)00002-6; Thyfault JP, 2010, AM J PHYSIOL-REG I, V299, pR926, DOI 10.1152/ajpregu.00093.2010; Toime LJ, 2010, FREE RADICAL BIO MED, V49, P606, DOI 10.1016/j.freeradbiomed.2010.05.010; VEERKAMP JH, 1983, BIOCHIM BIOPHYS ACTA, V753, P399, DOI 10.1016/0005-2760(83)90064-4	55	38	41	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4213	4225		10.1096/fj.13-234302	http://dx.doi.org/10.1096/fj.13-234302			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825224	Green Published			2022-12-28	WOS:000329747100032
J	Hong, WMC; Amara, SG				Hong, Weimin C.; Amara, Susan G.			Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons	FASEB JOURNAL			English	Article						ubiquitination; internalization; endosome sorting; fluorescence imaging	RECEPTOR TRAFFICKING; SURFACE EXPRESSION; XENOPUS OOCYTES; CELL-LINES; MEMBRANE; INTERNALIZATION; MICROSCOPY; MECHANISM; BINDING; METHAMPHETAMINE	The dopamine transporter (DAT) clears the extracellular dopamine released during neurotransmission and is a major target for both therapeutic and addictive psychostimulant amphetamines. Amphetamine exposure or activation of protein kinase C (PKC) by the phorbol ester PMA has been shown to down-regulate cell surface DAT. However, in dopamine neurons, the trafficking itinerary and fate of internalized DAT has not been elucidated. By monitoring surface-labeled DAT in transfected dopamine neurons from embryonic rat mesencephalic cultures, we find distinct sorting and fates of internalized DAT after amphetamine or PMA treatment. Although both drugs promote DAT internalization above constitutive endocytosis in dopamine neurons, PMA induces ubiquitination of DAT and leads to accumulation of DAT on LAMP1-positive endosomes. In contrast, after amphetamine exposure DAT is sorted to recycling endosomes positive for Rab11 and the transferrin receptor. Furthermore, quantitative assessment of DAT recycling using an antibody-feeding assay reveals that significantly less DAT returns to the surface of dopamine neurons after internalization by PMA, compared with vehicle or amphetamine treatment. These results demonstrate that, in neurons, the DAT is sorted differentially to recycling and degradative pathways after psychostimulant exposure or PKC activation, which may allow for either the transient or sustained inhibition of DAT during dopamine neurotransmission.	[Hong, Weimin C.; Amara, Susan G.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Amara, SG (corresponding author), NIMH, Ctr Dr, 10 Ctr Dr,Room 4N222, Bethesda, MD 20814 USA.	susan.amara@nih.gov		Amara, Susan/0000-0001-8914-1106	American Recovery and Reinvestment Act funds; U.S. National Institutes of Health [DA07595]; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA007595, R01DA007595] Funding Source: NIH RePORTER	American Recovery and Reinvestment Act funds; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Yong-Jian Liu, Alexander Sorkin, Willi Halfter, Geoff Murdoch, Mee Choi, Linton Traub, Ora Weisz, Gerald Apodaca, and Katy Baty (University of Pittsburgh, Pittsburgh, PA, USA) for valuable suggestions or various DNA constructs and antibodies. The authors also appreciate critiques from Spencer Watts, Mads Larsen, Ethan Block, Jie Jiang, and other members of the S.G.A. laboratory. This work was supported by American Recovery and Reinvestment Act funds and a U.S. National Institutes of Health grant (DA07595) to S.G.A.	Baker R., 1995, NEURAL CELL CULTURE, P25; Blot Vincent, 2008, V457, P347, DOI 10.1007/978-1-59745-261-8-26; Bogdanov Y, 2006, EMBO J, V25, P4381, DOI 10.1038/sj.emboj.7601309; Boudanova E, 2008, NEUROPHARMACOLOGY, V54, P605, DOI 10.1016/j.neuropharm.2007.11.007; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Chi LM, 2003, J PHARMACOL EXP THER, V307, P729, DOI 10.1124/jpet.103.055095; Cremona ML, 2011, NAT NEUROSCI, V14, P469, DOI 10.1038/nn.2781; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Eriksen J, 2010, J BIOL CHEM, V285, P27289, DOI 10.1074/jbc.M110.131003; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V282, P834; Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140; Foster JD, 2008, J NEUROCHEM, V105, P1683, DOI 10.1111/j.1471-4159.2008.05262.x; Furman CA, 2009, J NEUROSCI, V29, P3328, DOI 10.1523/JNEUROSCI.5386-08.2009; Garcia BG, 2005, MOL PHARMACOL, V68, P102, DOI 10.1124/mol.104.009092; German CL, 2012, J NEUROCHEM, V123, P288, DOI 10.1111/j.1471-4159.2012.07875.x; Holton KL, 2005, NAT NEUROSCI, V8, P881, DOI 10.1038/nn1478; Hong WC, 2010, J BIOL CHEM, V285, P32616, DOI 10.1074/jbc.M110.150565; Jiang M, 2006, NAT PROTOC, V1, P695, DOI 10.1038/nprot.2006.86; Johnson LA, 2005, NEUROPHARMACOLOGY, V49, P750, DOI 10.1016/j.neuropharm.2005.08.018; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Matthies HJG, 2010, J NEUROSCI, V30, P7863, DOI 10.1523/JNEUROSCI.4574-09.2010; Melikian HE, 1999, J NEUROSCI, V19, P7699; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; Miranda M, 2007, MOL BIOL CELL, V18, P313, DOI 10.1091/mbc.E06-08-0704; Moron JA, 2003, J NEUROSCI, V23, P8480; Mortensen OV, 2008, MOL BIOL CELL, V19, P2818, DOI 10.1091/mbc.E07-09-0980; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Rao A, 2012, FASEB J, V26, P1921, DOI 10.1096/fj.11-196113; Rao A, 2011, MOL CELL NEUROSCI, V46, P148, DOI 10.1016/j.mcn.2010.08.016; Sakrikar D, 2012, J NEUROSCI, V32, P5385, DOI 10.1523/JNEUROSCI.6033-11.2012; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Scott DB, 2004, J NEUROSCI, V24, P7096, DOI 10.1523/JNEUROSCI.0780-04.2004; Sekine-Aizawa Y, 2004, P NATL ACAD SCI USA, V101, P17114, DOI 10.1073/pnas.0407563101; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Sorkina T, 2006, J NEUROSCI, V26, P8195, DOI 10.1523/JNEUROSCI.1301-06.2006; Sulzer D, 2011, NEURON, V69, P628, DOI 10.1016/j.neuron.2011.02.010; Tang TTT, 2010, J BIOL CHEM, V285, P20975, DOI 10.1074/jbc.M110.102210; Wanat MJ, 2008, J PHYSIOL-LONDON, V586, P2157, DOI 10.1113/jphysiol.2007.150078; Wheeler D. S., 2011, NEUROSCIENCE; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	45	46	47	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2995	3007		10.1096/fj.12-218727	http://dx.doi.org/10.1096/fj.12-218727			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23612789	Green Published			2022-12-28	WOS:000329877600008
J	Faleri, A; Santini, L; Brier, S; Pansegrau, W; Lo Surdo, P; Scarselli, M; Buricchi, F; Volpini, G; Genovese, A; van der Veen, S; Lea, S; Tang, CM; Savino, S; Pizza, M; Finco, O; Norais, N; Masignani, V				Faleri, Agnese; Santini, Laura; Brier, Sebastien; Pansegrau, Werner; Lo Surdo, Paola; Scarselli, Maria; Buricchi, Francesca; Volpini, Gianfranco; Genovese, Alessia; van der Veen, Stijn; Lea, Susan; Tang, Christoph M.; Savino, Silvana; Pizza, Mariagrazia; Finco, Oretta; Norais, Nathalie; Masignani, Vega			Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties	FASEB JOURNAL			English	Article						mAb synergy; MenB vaccine; meningococcal antigen; hydrogen/deuterium exchange mass spectrometry	BACTERICIDAL ACTIVITY; SEROGROUP-B; PROTECTIVE ANTIGEN; VIRULENCE FACTOR; VACCINE; COMPLEMENT; RESPONSES; SURVIVAL; SEQUENCE; GNA1870	Factor H binding protein (fHbp) is one of the main antigens of the 4-component meningococcus B (4CMenB) multicomponent vaccine against disease caused by serogroup B Neisseria meningitidis (MenB). fHbp binds the complement down-regulating protein human factor H (hfH), thus resulting in immune evasion. fHbp exists in 3 variant groups with limited cross-protective responses. Previous studies have described the generation of monoclonal antibodies (mAbs) targeting variant-specific regions of fHbp. Here we report for the first time the functional characterization of two mAbs that recognize a wide panel of fHbp variants and subvariants on the MenB surface and that are able to inhibit fHbp binding to hfH. The antigenic regions targeted by the two mAbs were accurately mapped by hydrogen-deuterium exchange mass spectrometry (HDX-MS), revealing partially overlapping epitopes on the N terminus of fHbp. Furthermore, while none of the mAbs had bactericidal activity on its own, a synergistic effect was observed for each of them when tested by the human complement serum bactericidal activity (hSBA) assay in combination with a second nonbactericidal mAb. The bases underlying fHbp variant cross-reactivity, as well as inhibition of hfH binding and cooperativity effect observed for the two mAbs, are discussed in light of the mapped epitopes.-Faleri, A., Santini, L., Brier, S., Pansegrau, W., Lo Surdo, P., Scarselli, M., Buricchi, F., Volpini, G., Genovese, A., van der Veen, S., Lea, S., Tang, C. M., Savino, S., Pizza, M., Finco, O., Norais, N., Masignani, V. Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties.	[Faleri, Agnese; Santini, Laura; Brier, Sebastien; Pansegrau, Werner; Lo Surdo, Paola; Scarselli, Maria; Buricchi, Francesca; Volpini, Gianfranco; Genovese, Alessia; Savino, Silvana; Pizza, Mariagrazia; Finco, Oretta; Norais, Nathalie; Masignani, Vega] Novartis Vaccines & Diagnost Srl, Res Ctr, I-53100 Siena, Italy; [van der Veen, Stijn; Lea, Susan; Tang, Christoph M.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Novartis; University of Oxford	Masignani, V (corresponding author), Novartis Vaccines & Diagnost Srl, Res Ctr, Via Fiorentina 1, I-53100 Siena, Italy.	vega.masignani@novartis.com	Brier, Sebastien/L-7787-2019; Lea, Susan M/B-7678-2009; Brier, Sébastien/E-8558-2019	Brier, Sebastien/0000-0003-1758-8237; Lea, Susan M/0000-0001-9287-8053; van der Veen, Stijn/0000-0002-8176-391X	Medical Research Council [G0900888] Funding Source: Medline; Wellcome Trust [102908] Funding Source: Medline; MRC [G0900888] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baerga-Ortiz A, 2002, PROTEIN SCI, V11, P1300, DOI 10.1110/ps.4670102; Bai XL, 2010, EXPERT REV VACCINES, V9, P1203, DOI 10.1586/ERV.10.116; Beernink PT, 2008, INFECT IMMUN, V76, P4232, DOI 10.1128/IAI.00367-08; Beernink PT, 2008, INFECT IMMUN, V76, P2568, DOI 10.1128/IAI.00033-08; Beernink PT, 2009, MICROBIOL-SGM, V155, P2873, DOI 10.1099/mic.0.029876-0; Beernink PT, 2009, MOL IMMUNOL, V46, P1647, DOI 10.1016/j.molimm.2009.02.021; Borrow R, 2005, CLIN DIAGN LAB IMMUN, V12, P970, DOI 10.1128/CDLI.12.8.970-976.2005; Brier S, 2012, BIOCHEMISTRY-US, V51, P6738, DOI 10.1021/bi300656w; Cantini F, 2006, J BIOL CHEM, V281, P7220, DOI 10.1074/jbc.M508595200; Cantini F, 2009, J BIOL CHEM, V284, P9022, DOI 10.1074/jbc.C800214200; Cendron L, 2011, ACTA CRYSTALLOGR F, V67, P531, DOI 10.1107/S1744309111006154; Coales SJ, 2009, RAPID COMMUN MASS SP, V23, P639, DOI 10.1002/rcm.3921; Cohn AC, 2010, CLIN INFECT DIS, V50, P184, DOI 10.1086/649209; Dunphy KY, 2011, INFECT IMMUN, V79, P353, DOI 10.1128/IAI.00849-10; Engen JR, 2001, ANAL CHEM, V73, p256A, DOI 10.1021/ac012452f; Fletcher LD, 2004, INFECT IMMUN, V72, P2088, DOI 10.1128/IAI.72.4.2088-2100.2004; Giuliani MM, 2005, INFECT IMMUN, V73, P1151, DOI 10.1128/IAI.73.2.1151-1160.2005; Giuntini S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034272; Giuntini S, 2011, INFECT IMMUN, V79, P3751, DOI 10.1128/IAI.05182-11; Huang J, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-7; Johnson S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002981; Karlsson R, 2006, ANAL BIOCHEM, V349, P136, DOI 10.1016/j.ab.2005.09.034; Konar M, 2013, J INFECT DIS, V208, P627, DOI 10.1093/infdis/jit239; Lucidarme J, 2011, CLIN VACCINE IMMUNOL, V18, P1002, DOI 10.1128/CVI.00055-11; Madico G, 2006, J IMMUNOL, V177, P501, DOI 10.4049/jimmunol.177.1.501; Malito E, 2013, P NATL ACAD SCI USA, V110, P3304, DOI 10.1073/pnas.1222845110; Marshall HS, 2012, PEDIATR INFECT DIS J, V31, P1061, DOI 10.1097/INF.0b013e31826327e4; Mascioni A, 2010, BBA-BIOMEMBRANES, V1798, P87, DOI 10.1016/j.bbamem.2009.09.021; Mascioni A, 2009, J BIOL CHEM, V284, P8729, DOI 10.1074/jbc.M808831200; Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911; McNeil LK, 2009, VACCINE, V27, P3417, DOI 10.1016/j.vaccine.2009.01.075; Nissen MD, 2013, PEDIATR INFECT DIS J, V32, P364, DOI 10.1097/INF.0b013e31827b0d24; Richmond PC, 2012, VACCINE, V30, P6163, DOI 10.1016/j.vaccine.2012.07.065; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Scarselli M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002234; Scarselli M, 2009, J MOL BIOL, V386, P97, DOI 10.1016/j.jmb.2008.12.005; Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769; Sheldon EA, 2012, HUM VACC IMMUNOTHER, V8, P888, DOI 10.4161/hv.19983; Vu DM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00341; Welsch JA, 2004, J IMMUNOL, V172, P5606, DOI 10.4049/jimmunol.172.9.5606; Welsch JA, 2008, J INFECT DIS, V197, P1053, DOI 10.1086/528994; Zimmer SM, 2004, EXPERT OPIN PHARMACO, V5, P855, DOI 10.1517/14656566.5.4.855	42	32	32	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1644	1653		10.1096/fj.13-239012	http://dx.doi.org/10.1096/fj.13-239012			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371123				2022-12-28	WOS:000335344300013
J	Morgan, JLL; Ritchie, LE; Crucian, BE; Theriot, C; Wu, HL; Sams, C; Smith, SM; Turner, ND; Zwart, SR				Morgan, Jennifer L. L.; Ritchie, Lauren E.; Crucian, Brian E.; Theriot, Corey; Wu, Honglu; Sams, Clarence; Smith, Scott M.; Turner, Nancy D.; Zwart, Sara R.			Increased dietary iron and radiation in rats promote oxidative stress, induce localized and systemic immune system responses, and alter colon mucosal environment	FASEB JOURNAL			English	Article						body iron stores; short-chain fatty acids; cytokines; injury repair; pathogen recognition	CHAIN FATTY-ACIDS; TOLL-LIKE RECEPTORS; PARTICLE RADIATION; SPACE RADIATION; GUT MICROBIOTA; SHORT-DURATION; ELECTROLYTE TRANSPORT; GENE-EXPRESSION; BONE LOSS; HIGH-LET	Astronauts are exposed to increased body iron stores and radiation, both of which can cause oxidative damage leading to negative health effects. The purpose of this study was to investigate combined effects of high dietary iron (650 mg/kg diet) and radiation exposure (0.375 Gy cesium-137 every other day for 16 d) on markers of oxidative stress, immune system function, and colon mucosal environment in male Sprague-Dawley rats (n=8/group). Control rats consumed adequate iron (45 mg/kg diet) and were not irradiated. Combined treatments increased liver glutathione peroxidase, serum catalase, and colon myeloperoxidase while decreasing total fecal short-chain fatty acid concentrations. The high-iron diet alone increased leukocyte count. Radiation decreased the T-cell CD4:CD8 ratio. Plasma iron was negatively correlated with cytokine production in activated monocytes. Genes involved in colon microbial signaling, immune response, and injury repair were altered by radiation. Genes involved with injury repair and pathogen recognition changed with dietary iron. These data demonstrate that dietary iron and radiation, alone and combined, contribute to oxidative stress that is related to immune system alterations in circulation and the colon. The model presented may help us better understand the changes to these systems that have been identified among astronauts.Morgan, J. L. L., Ritchie, L. E., Crucian, B. E., Theriot, C., Wu, H., Sams, C., Smith, S. M., Turner, N. D., Zwart, S. R. Increased dietary iron and radiation in rats promote oxidative stress, induce localized and systemic immune system responses, and alter colon mucosal environment.	[Morgan, Jennifer L. L.] Oak Ridge Associated Univ, NASA, Postdoctoral Fellowship Program, Houston, TX USA; [Crucian, Brian E.; Wu, Honglu; Smith, Scott M.] NASA, Lyndon B Johnson Space Ctr, Biomed Res & Environm Sci Div, Houston, TX 77058 USA; [Sams, Clarence] NASA, Lyndon B Johnson Space Ctr, Space & Clin Operat Div, Human Hlth & Performance Directorate, Houston, TX 77058 USA; [Ritchie, Lauren E.; Turner, Nancy D.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA; [Theriot, Corey] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Zwart, Sara R.] Univ Space Res Assoc, Div Space Life Sci, Houston, TX USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Medical Branch Galveston; Universities Space Research Association (USRA)	Zwart, SR (corresponding author), Mail Code SK3,2101 NASA Pkwy, Houston, TX 77058 USA.	sara.zwart-1@nasa.gov		Turner, Nancy/0000-0001-7737-7277; Morgan, Jennifer/0000-0002-6694-9687	NASA Human Research Program's Human Health Countermeasures Element	NASA Human Research Program's Human Health Countermeasures Element	The authors thank the staff of the NASA Johnson Space Center Nutritional Biochemistry Laboratory for their assistance in processing and analyzing the samples, and in all aspects of carrying out this project. The authors thank Jane Krauhs for editorial assistance. This study was funded by the NASA Human Research Program's Human Health Countermeasures Element.	Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Angelucci E, 2000, NEW ENGL J MED, V343, P327, DOI 10.1056/NEJM200008033430503; Arboleya L, 2013, REUMATOL CLIN, V9, P303, DOI [10.1016/j.reumae.2013.02.004, 10.1016/j.reuma.2013.02.008]; AUBAILLY M, 1991, PHOTOCHEM PHOTOBIOL, V54, P769, DOI 10.1111/j.1751-1097.1991.tb02088.x; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BAXTER CF, 1955, BRIT J HAEMATOL, V1, P86, DOI 10.1111/j.1365-2141.1955.tb05491.x; Beard J, 2003, J NUTR, V133, p1468S, DOI 10.1093/jn/133.5.1468S; Benjamini Y, 2006, BIOMETRIKA, V93, P491, DOI 10.1093/biomet/93.3.491; BIEMOND P, 1984, J CLIN INVEST, V73, P1576, DOI 10.1172/JCI111364; Bogdandi EN, 2010, RADIAT RES, V174, P480, DOI 10.1667/RR2160.1; Borlon C, 2007, ANN NY ACAD SCI, V1119, P72, DOI 10.1196/annals.1404.002; Brennan PC, 1998, INT J RADIAT BIOL, V73, P691, DOI 10.1080/095530098141942; Brint EK, 2011, AM J GASTROENTEROL, V106, P329, DOI 10.1038/ajg.2010.438; Charney AN, 1998, AM J PHYSIOL-GASTR L, V274, pG518, DOI 10.1152/ajpgi.1998.274.3.G518; Crichton RR., 2009, IRON METABOLISM MOL; Crim KC, 2008, CARCINOGENESIS, V29, P1415, DOI 10.1093/carcin/bgn144; CRONKITE EP, 1955, ANN NY ACAD SCI, V59, P815, DOI 10.1111/j.1749-6632.1955.tb45985.x; Crucian B, 2013, J CLIN IMMUNOL, V33, P456, DOI 10.1007/s10875-012-9824-7; Crucian B, 2011, AVIAT SPACE ENVIR MD, V82, P857, DOI 10.3357/ASEM.3047.2011; Crucian B, 2009, J LEUKOCYTE BIOL, V86, P1017, DOI 10.1189/jlb.0709500; Crucian BE, 2008, AVIAT SPACE ENVIR MD, V79, P835, DOI 10.3357/ASEM.2276.2008; Cucinotta FA, 2001, RADIAT RES, V156, P460, DOI 10.1667/0033-7587(2001)156[0460:SRACIA]2.0.CO;2; Cuff MA, 2002, J PHYSIOL-LONDON, V539, P361, DOI 10.1113/jphysiol.2001.014241; Cummings J H, 2003, Curr Issues Intest Microbiol, V4, P9; Davidson LA, 2004, CANCER RES, V64, P6797, DOI 10.1158/0008-5472.CAN-04-1068; Deplancke B, 2001, AM J CLIN NUTR, V73, p1131S; Donohoe DR, 2012, MOL CELL, V48, P612, DOI 10.1016/j.molcel.2012.08.033; Dostal A, 2012, J NUTR, V142, P271, DOI 10.3945/jn.111.148643; Dubois A., 1994, RAD GASTROINTESTINAL; Feinendegen L.E., 2005, BRIT J RADIOL, V45, P185, DOI [10.1259/bjr/64628752, DOI 10.1259/BJR/64628752]; Fischer JG, 2002, J NUTR, V132, P2525, DOI 10.1093/jn/132.9.2525; FOWLER JF, 1984, INT J RADIAT BIOL, V46, P103, DOI 10.1080/09553008414551181; Freeman SL, 2000, AM J PHYSIOL-GASTR L, V278, pG243, DOI 10.1152/ajpgi.2000.278.2.G243; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; GMUNDER FK, 1994, AVIAT SPACE ENVIR MD, V65, P419; Gridley DS, 2006, RADIAT RES, V165, P78, DOI 10.1667/RR3490.1; Guan J, 2004, RADIAT RES, V162, P572, DOI 10.1667/RR3249; Gueguinou N, 2009, J LEUKOCYTE BIOL, V86, P1027, DOI 10.1189/jlb.0309167; GUNTERSMITH PJ, 1986, AM J PHYSIOL, V250, pG540, DOI 10.1152/ajpgi.1986.250.4.G540; Hamilton SA, 2006, J APPL PHYSIOL, V101, P789, DOI 10.1152/japplphysiol.01078.2005; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hellweg CE, 2007, NATURWISSENSCHAFTEN, V94, P517, DOI 10.1007/s00114-006-0204-0; HENDRY JH, 1995, RADIAT ENVIRON BIOPH, V34, P59, DOI 10.1007/BF01210548; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; ILIAKIS GE, 1992, RADIAT RES, V131, P192, DOI 10.2307/3578441; Kalliomaki M, 2012, J PEDIATR GASTR NUTR, V54, P727, DOI 10.1097/MPG.0b013e318241cfa8; Kennedy AR, 2007, RADIAT ENVIRON BIOPH, V46, P201, DOI 10.1007/s00411-007-0105-4; Kiang Juliann G, 2010, Adapt Med, V2, P1, DOI 10.4247/AM.2010.ABA004; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; Kusunoki Y, 1999, RADIAT RES, V152, P539, DOI 10.2307/3580151; Larbi A, 2007, EXP GERONTOL, V42, P852, DOI 10.1016/j.exger.2007.05.004; LATELLA G, 1991, INT J COLORECTAL DIS, V6, P127, DOI 10.1007/BF00300209; Lee JY, 2006, MOL CELLS, V21, P174; Lloyd SA, 2012, BONE, V51, P756, DOI 10.1016/j.bone.2012.07.001; Lloyd SAJ, 2008, J APPL PHYSIOL, V104, P729, DOI 10.1152/japplphysiol.00632.2007; Louis P, 2009, FEMS MICROBIOL LETT, V294, P1, DOI 10.1111/j.1574-6968.2009.01514.x; Lundin A, 2008, CELL MICROBIOL, V10, P1093, DOI 10.1111/j.1462-5822.2007.01108.x; Macfarlane GT, 2009, CURR PHARM DESIGN, V15, P1528, DOI 10.2174/138161209788168146; Macnaughton WK, 2000, ALIMENT PHARM THER, V14, P523; MACNAUGHTON WK, 1994, GASTROENTEROLOGY, V106, P324, DOI 10.1016/0016-5085(94)90589-4; Manichanh C, 2008, AM J GASTROENTEROL, V103, P1754, DOI 10.1111/j.1572-0241.2008.01868.x; Mehta SK, 2000, J INFECT DIS, V182, P1761, DOI 10.1086/317624; MERRITT AJ, 1994, CANCER RES, V54, P614; Morliere P, 1997, BBA-GEN SUBJECTS, V1334, P283, DOI 10.1016/S0304-4165(96)00106-7; NELSON JM, 1992, CELL PROLIFERAT, V25, P579, DOI 10.1111/j.1365-2184.1992.tb01461.x; Pecaut MJ, 2006, RADIAT RES, V165, P68, DOI 10.1667/RR3493.1; Pierson DL, 2005, BRAIN BEHAV IMMUN, V19, P235, DOI 10.1016/j.bbi.2004.08.001; Pouget JP, 2001, EUR J NUCL MED, V28, P541, DOI 10.1007/s002590100484; Quarmby S, 2002, RADIAT RES, V157, P243, DOI 10.1667/0033-7587(2002)157[0243:DEOCGI]2.0.CO;2; Rakoff-Nahoum S, 2008, MUCOSAL IMMUNOL, V1, pS10, DOI 10.1038/mi.2008.49; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; Sener G, 2006, PHARMACOL RES, V53, P241, DOI 10.1016/j.phrs.2005.11.006; Singh VK, 2012, CYTOKINE, V58, P406, DOI 10.1016/j.cyto.2012.03.011; Smith S. M., 2009, NUTR BIOCHEMISTRY SP; Smith SM, 2002, NUTRITION, V18, P864, DOI 10.1016/S0899-9007(02)00912-7; Sprung C. N., 2013, CANC LETT IN PRESS; Stevens RG, 2000, RADIAT RES, V153, P844, DOI 10.1667/0033-7587(2000)153[0844:HHMCAR]2.0.CO;2; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; Tedelind S, 2007, WORLD J GASTROENTERO, V13, P2826, DOI 10.3748/wjg.v13.i20.2826; THAMES HD, 1984, INT J RADIAT BIOL, V45, P1, DOI 10.1080/09553008414550011; TONELLI F, 1995, DIS COLON RECTUM, V38, P974, DOI 10.1007/BF02049735; Townsend L. W., 2006, 153 NCRPM; Valyi-Nagy T, 2005, HISTOL HISTOPATHOL, V20, P957, DOI 10.14670/HH-20.957; Vijay-Kumar M, 2007, INFLAMM BOWEL DIS, V13, P856, DOI 10.1002/ibd.20142; Vozenin-Brotons MC, 2004, RADIAT RES, V161, P299, DOI 10.1667/RR3128; Wilson AJ, 1997, GASTROENTEROLOGY, V113, P487, DOI 10.1053/gast.1997.v113.pm9247468; Wilson AJ, 1999, CLIN SCI, V97, P385, DOI 10.1042/CS19980351; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Yusuf SW, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/317659; Zacharski LR, 2008, JNCI-J NATL CANCER I, V100, P996, DOI 10.1093/jnci/djn209; Zeitlin C, 2013, SCIENCE, V340, P1080, DOI 10.1126/science.1235989; Zheng HY, 2005, ARTERIOSCL THROM VAS, V25, P1577, DOI 10.1161/01.ATV.0000174126.28201.61; Zoran DL, 1997, J NUTR, V127, P2217, DOI 10.1093/jn/127.11.2217; Zwart SR, 2013, AM J CLIN NUTR, V98, P217, DOI 10.3945/ajcn.112.056465	98	14	14	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1486	1498		10.1096/fj.13-239418	http://dx.doi.org/10.1096/fj.13-239418			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24334706				2022-12-28	WOS:000335324800039
J	Walters, DM; White, KM; Patel, U; Davis, MJ; Veluci-Marlow, RM; Sunkesula, SRB; Bonner, JC; Martin, JR; Gladwell, W; Kleeberger, SR				Walters, Dianne M.; White, Kevin M.; Patel, Ushma; Davis, Martin J.; Veluci-Marlow, Roberta M.; Sunkesula, Solomon Raju Bhupanapadu; Bonner, James C.; Martin, Jessica R.; Gladwell, Wes; Kleeberger, Steven R.			Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5)	FASEB JOURNAL			English	Article						lung injury; inflammation; collagen; haplotype; mapping	MESSENGER-RNA EXPRESSION; HUMAN LUNG FIBROBLASTS; BRONCHOALVEOLAR LAVAGE; EOSINOPHIL ACTIVATION; GROWTH-FACTOR; RECEPTOR; INFLAMMATION; CANCER; INJURY; CELLS	Interstitial lung diseases (ILDs) are characterized by injury, inflammation, and scarring of alveoli, leading to impaired function. The etiology of idiopathic forms of ILD is not understood, making them particularly difficult to study due to the lack of appropriate animal models. Consequently, few effective therapies have emerged. We developed an inbred mouse model of ILD using vanadium pentoxide (V2O5), the most common form of a transition metal found in cigarette smoke, fuel ash, mineral ores, and steel alloys. Pulmonary responses to V2O5, including dose-dependent increases in lung permeability, inflammation, collagen content, and dysfunction, were significantly greater in DBA/2J mice compared to C57BL/6J mice. Inflammatory and fibrotic responses persisted for 4 mo in DBA/2J mice, while limited responses in C57BL/6J mice resolved. We investigated the genetic basis for differential responses through genetic mapping of V2O5-induced lung collagen content in BXD recombinant inbred (RI) strains and identified significant linkage on chromosome 4 with candidate genes that associate with V2O5-induced collagen content across the RI strains. Results suggest that V2O5 may induce pulmonary fibrosis through mechanisms distinct from those in other models of pulmonary fibrosis. These findings should further advance our understanding of mechanisms involved in ILD and thereby aid in identification of new therapeutic targets.Walters, D. M., White, K. M., Patel, U., Davis, M. J., Veluci-Marlow, R. M., Bhupanapadu Sunkesula, S. R., Bonner, J. C., Martin, J. R., Gladwell, W., Kleeberger, S. R. Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).	[Walters, Dianne M.; White, Kevin M.; Patel, Ushma; Davis, Martin J.; Veluci-Marlow, Roberta M.; Sunkesula, Solomon Raju Bhupanapadu] E Carolina Univ, Dept Physiol, Greenville, NC 27834 USA; [Bonner, James C.] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA; [Martin, Jessica R.; Gladwell, Wes; Kleeberger, Steven R.] NIEHS, Lab Resp Biol, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; East Carolina University; University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Walters, DM (corresponding author), E Carolina Univ, Brody Sch Med, Dept Physiol, 6N-98,600 Moye Blvd, Greenville, NC 27834 USA.	waltersd@ecu.edu	Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452	Intramural Research Program of the U.S. National Institutes of Health; NIEHS; East Carolina University; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES100512, ZIAES100513] Funding Source: NIH RePORTER	Intramural Research Program of the U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); East Carolina University; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors gratefully acknowledge the U.S. National Institute of Environmental Health Sciences (NIEHS) Histology Core facility and Joani Zary Oswald (Brody School of Medicine Histology Core, East Carolina University) for histological services, and Dr. Paul Strausbauch for pathology advice. The authors also thank Dr. Jared M. Brown for use of laboratory equipment and technical advice, and M. Anthony Phipps for technical assistance. This research was supported (in part) by the Intramural Research Program of the U.S. National Institutes of Health, NIEHS, and East Carolina University. The authors declare no conflicts of interest.	Adachi A, 1998, B ENVIRON CONTAM TOX, V61, P276, DOI 10.1007/s001289900759; Alber A, 2012, INT J EXP PATHOL, V93, P243, DOI 10.1111/j.1365-2613.2012.00833.x; Alfaro MP, 2013, LAB INVEST, V93, P81, DOI 10.1038/labinvest.2012.162; Antao-Menezes A, 2008, J IMMUNOL, V180, P4200, DOI 10.4049/jimmunol.180.6.4200; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72, DOI 10.1152/ajplung.1998.274.1.L72; Bonner JC, 2000, AM J PHYSIOL-LUNG C, V278, pL209, DOI 10.1152/ajplung.2000.278.1.L209; BOOMARS KA, 1995, THORAX, V50, P1087, DOI 10.1136/thx.50.10.1087; Brody AR, 2002, CHEST, V121, p31S, DOI 10.1378/chest.121.3_suppl.31S; Chaudhary NI, 2006, AM J RESP CRIT CARE, V173, P769, DOI 10.1164/rccm.200505-717OC; Chong IW, 2000, INFLAMMATION, V24, P505, DOI 10.1023/A:1007021322323; Chung MP, 2003, AM J RESP CELL MOL, V29, P375, DOI 10.1165/rcmb.2003-0029OC; Cohen MD, 1996, FUND APPL TOXICOL, V33, P254, DOI 10.1006/faat.1996.0163; Cohen MD, 1997, J TOXICOL ENV HEALTH, V51, P591, DOI 10.1080/009841097159854; Cohen MD, 1996, TOXICOL APPL PHARM, V138, P110, DOI 10.1006/taap.1996.0104; Cohen Mitchell D, 2004, J Immunotoxicol, V1, P39, DOI 10.1080/15476910490438360; Costabel U, 2001, Curr Opin Pulm Med, V7, P255, DOI 10.1097/00063198-200109000-00002; Cottin V, 2009, CHEST, V136, P1, DOI 10.1378/chest.09-0538; Davis Gerald S., 1998, Journal of Environmental Pathology Toxicology and Oncology, V17, P81; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dreher K, 1996, CHEST, V109, pS33, DOI 10.1378/chest.109.3_Supplement.33S-a; Emad A, 2007, J CLIN IMMUNOL, V27, P605, DOI 10.1007/s10875-007-9114-y; FUJIMOTO K, 1995, CHEST, V108, P48, DOI 10.1378/chest.108.1.48; Fulkerson PC, 2006, AM J PATHOL, V169, P2117, DOI 10.2353/ajpath.2006.060617; Gibbons MA, 2011, AM J RESP CRIT CARE, V184, P569, DOI 10.1164/rccm.201010-1719OC; Grabowski GM, 1999, TOXICOL APPL PHARM, V156, P170, DOI 10.1006/taap.1999.8642; HALLGREN R, 1989, AM REV RESPIR DIS, V139, P373; HAUSER R, 1995, AM J RESP CRIT CARE, V152, P1478, DOI 10.1164/ajrccm.152.5.7582280; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hirata H, 2008, RESPIROLOGY, V13, P788, DOI 10.1111/j.1440-1843.2008.01361.x; Howden R, 2008, AM J PHYSIOL-HEART C, V295, pH59, DOI 10.1152/ajpheart.00941.2007; Huaux F, 2005, AM J PATHOL, V167, P1485, DOI 10.1016/S0002-9440(10)61235-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ingram JL, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-34; International Agency for Cancer Research (IARC), 2006, IARC MONOGR EVAL CAR, V86, P227; Irsigler GB, 1999, AM J IND MED, V35, P366, DOI 10.1002/(SICI)1097-0274(199904)35:4<366::AID-AJIM7>3.3.CO;2-E; Jakubzick C, 2004, IMMUNOL RES, V30, P339, DOI 10.1385/IR:30:3:339; Kinder BW, 2008, CHEST, V133, P226, DOI 10.1378/chest.07-1948; KNECHT EA, 1992, J APPL TOXICOL, V12, P427, DOI 10.1002/jat.2550120611; Kodavanti UP, 1998, TOXICOL SCI, V43, P204, DOI 10.1093/toxsci/43.2.204; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Kottmann RM, 2012, AM J RESP CRIT CARE, V186, P740, DOI 10.1164/rccm.201201-0084OC; Kuwano K, 1999, AM J RESP CELL MOL, V20, P53, DOI 10.1165/ajrcmb.20.1.2941; LEES REM, 1980, BRIT J IND MED, V37, P253; Loomis-King H., CURR OPIN PHARM, V13, P377; Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109; Miyake Y, 2005, ANN OCCUP HYG, V49, P259, DOI 10.1093/annhyg/meh090; Moeller A, 2008, INT J BIOCHEM CELL B, V40, P362, DOI 10.1016/j.biocel.2007.08.011; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; National Toxicology Program, 2002, Natl Toxicol Program Tech Rep Ser, P1; NEMERY B, 1990, EUR RESPIR J, V3, P202; Ohtsuka Y, 2006, EUR RESPIR J, V28, P1013, DOI 10.1183/09031936.06.00132505; Olsen AL, 2010, BREATHING AM, P99; Paun A, 2013, AM J RESP CELL MOL, V48, P330, DOI 10.1165/rcmb.2012-0078OC; Pi LY, 2012, FASEB J, V26, P3365, DOI 10.1096/fj.11-200154; Pierce LM, 1996, TOXICOL APPL PHARM, V138, P1, DOI 10.1006/taap.1996.9999; Puxeddu I, 2006, J ALLERGY CLIN IMMUN, V117, P103, DOI 10.1016/j.jaci.2005.08.057; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; Schuler D, 2011, J TOXICOL PATHOL, V24, P149, DOI 10.1293/tox.24.149; SCHWARTZ DA, 1991, J APPL PHYSIOL, V71, P1688, DOI 10.1152/jappl.1991.71.5.1688; Shimizu Y, 2006, IMMUNOPHARM IMMUNOT, V28, P295, DOI 10.1080/08923970600809389; Shyur SD, 2008, EUR J HUM GENET, V16, P1283, DOI 10.1038/ejhg.2008.79; SJOBERG S G, 1955, AMA Arch Ind Health, V11, P505; Taskar V, 2008, SEMIN RESP CRIT CARE, V29, P670, DOI 10.1055/s-0028-1101277; Taskar Varsha S, 2006, Proc Am Thorac Soc, V3, P293, DOI 10.1513/pats.200512-131TK; Walters Dianne M, 2008, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0546s40; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438, DOI 10.1164/ajrccm.164.8.2007121; WATERS MD, 1974, TOXICOL APPL PHARM, V28, P253, DOI 10.1016/0041-008X(74)90012-X; Woodin MA, 2000, AM J IND MED, V37, P353, DOI 10.1002/(SICI)1097-0274(200004)37:4<353::AID-AJIM5>3.3.CO;2-C; World Health Organization, 2002, AIR QUAL GUID, P162; Yu DF, 2011, AM J PHYSIOL-LUNG C, V301, pL31, DOI 10.1152/ajplung.00301.2010	72	11	11	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1098	1112		10.1096/fj.13-235044	http://dx.doi.org/10.1096/fj.13-235044			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24285090	Green Published			2022-12-28	WOS:000335324800007
J	Hurtado, R; Bub, G; Herzlinger, D				Hurtado, Romulo; Bub, Gil; Herzlinger, Doris			A molecular signature of tissues with pacemaker activity in the heart and upper urinary tract involves coexpressed hyperpolarization-activated cation and T-type Ca2+ channels	FASEB JOURNAL			English	Article						smooth muscle; kidney; peristalsis; ion channels; optical mapping	SINOATRIAL NODE CELLS; SMOOTH-MUSCLE-CELLS; MOUSE RENAL PELVIS; INTERSTITIAL-CELLS; BIOLOGICAL PACEMAKER; ACTION-POTENTIALS; CALCIUM CURRENTS; EMBRYONIC HEART; EXPRESSION; CAJAL	Renal pacemakers set the origin and frequency of the smooth muscle contractions that propel wastes from the kidney to the bladder. Although congenital defects impairing this peristalsis are a leading cause of pediatric renal failure, the mechanisms underlying renal pacemaker activity remain unknown. Using ratiometric optical mapping and video microscopy, we discovered that hyperpolarization-activated cation (HCN) channel block with the specific anatagonist ZD7288 (30 m; IC50) abolished the pacemaker depolarizations that initiate murine upper urinary tract peristalsis. Optical mapping and immunohistochemistry indicate that pacemaker potentials are generated by cells expressing HCN isoform-3, and that HCN3(+) cells are coupled to definitive smooth muscle via gap junctions. Furthermore, we demonstrate that HCN3(+) cells coexpress T-type Ca2+ (TTC) channels and that TTC channel inhibition with R(-)efonidipine or NNC55-0396 decreased contractile frequency in a dose-dependent manner. Collectively, these data demonstrate that HCN3(+)/TTC+ cells are the pacemakers that set the origin and rate of upper urinary tract peristalsis. These results reveal a conserved mechanism controlling autorhythmicity in 2 distinct muscle types, as HCN and TTC channels also mediate cardiac pacemaker activity. Moreover, these findings have translational applications, including the development of novel diagnostics to detect fetal urinary tract motility defects prior to renal damage.Hurtado, R., Bub, G., Herzlinger, D. A molecular signature of tissues with pacemaker activity in the heart and upper urinary tract involves coexpressed hyperpolarization-activated cation and T-type Ca2+ channels.	[Hurtado, Romulo; Herzlinger, Doris] Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; [Bub, Gil] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England	Cornell University; University of Oxford	Herzlinger, D (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA.	daherzli@physbio-tech.net		Hurtado, Romulo/0000-0003-0865-3383	U.S. National Institutes of Health [RO1 DK45218]; British Heart Foundation Centre of Research Excellence, University of Oxford [RE/08/004]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P20DK103072, R01DK045218] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); British Heart Foundation Centre of Research Excellence, University of Oxford; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grant RO1 DK45218, awarded to D. H., and British Heart Foundation Centre of Research Excellence, University of Oxford, grant RE/08/004, awarded to G.B. The authors thank Dr. Norio Hashimoto (Nissan Chemical Industries, Minamisaitama, Japan) for the generous gift of R(-) efondipine. The authors thank Dr. Jeremy Graham and Mr. Mark Henson for providing expertise in construction of ratiometric optical mapping apparatuses; Dr. David Christini, Dr. Emre Aksay, and Dr. Willemijn Groenendaal for helpful suggestions on experimental techniques; and Dr. Harel Weinstein, Dr. Jeremy Dittman, Dr. Tom Schultheiss, Dr. Lauren Acinapura, Mr. Chad Kurylo, Ms. Lauretta Lacko, and Mr. James Mtui for helpful manuscript discussions.	Alberti C, 2012, EUR REV MED PHARMACO, V16, P213; Barbuti A, 2008, ANN NY ACAD SCI, V1123, P213, DOI 10.1196/annals.1420.024; Baruscotti M, 2010, PFLUG ARCH EUR J PHY, V460, P405, DOI 10.1007/s00424-010-0810-8; Biel M, 2009, PHYSIOL REV, V89, P847, DOI 10.1152/physrev.00029.2008; Bohn G, 2000, FEBS LETT, V481, P73, DOI 10.1016/S0014-5793(00)01979-7; BOSMITH RE, 1993, BRIT J PHARMACOL, V110, P343, DOI 10.1111/j.1476-5381.1993.tb13815.x; Bozler E, 1942, AM J PHYSIOL, V136, P9; Bramich NJ, 1996, J PHYSIOL-LONDON, V492, P185, DOI 10.1113/jphysiol.1996.sp021300; Bub G, 2003, J CARDIOVASC ELECTR, V14, pS229, DOI 10.1046/j.1540.8167.90315.x; Cain JE, 2011, J CLIN INVEST, V121, P1199, DOI 10.1172/JCI45523; Cho HC, 2007, CIRC RES, V100, P1112, DOI 10.1161/01.RES.0000265845.04439.78; Dickens EJ, 1999, J PHYSIOL-LONDON, V514, P515, DOI 10.1111/j.1469-7793.1999.515ae.x; DIXON JS, 1982, J ANAT, V135, P129; DOERR T, 1989, PFLUG ARCH EUR J PHY, V413, P599, DOI 10.1007/BF00581808; Dwyer TM, 2003, NEWS PHYSIOL SCI, V18, P1, DOI 10.1152/nips.1416.2002; ENGELMANN TW, 1969, PFLUGERS ARCH GES PH, V2, P243; Furukawa T, 2004, BRIT J PHARMACOL, V143, P1050, DOI 10.1038/sj.bjp.0705944; GOEL R, 2013, CLIN PERINATOL, V40, P43, DOI DOI 10.1016/j.pop.2012.11.002; GOSLING JA, 1970, EXPERIENTIA, V26, P769, DOI 10.1007/BF02232539; GROSS D, 1986, BIOPHYS J, V50, P339, DOI 10.1016/S0006-3495(86)83467-1; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; Hall CE, 2004, DEVELOPMENT, V131, P581, DOI 10.1242/dev.00947; Harris NC, 1995, J NEUROPHYSIOL, V74, P2366, DOI 10.1152/jn.1995.74.6.2366; Hashitani H, 1999, J PHYSIOL-LONDON, V514, P459, DOI 10.1111/j.1469-7793.1999.459ae.x; Herrmann S, 2007, EMBO J, V26, P4423, DOI 10.1038/sj.emboj.7601868; Hirota Seiichi, 2000, Journal of Gastroenterology, V35, P75; Hirst GDS, 2003, J PHYSIOL-LONDON, V550, P337, DOI 10.1113/jphysiol.2003.043299; Huang LP, 2004, J PHARMACOL EXP THER, V309, P193, DOI 10.1124/jpet.103.060814; Huizinga JD, 2009, AM J PHYSIOL-GASTR L, V296, pG1, DOI 10.1152/ajpgi.90380.2008; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Hurtado R, 2006, DEV DYNAM, V235, P2811, DOI 10.1002/dvdy.20909; Hurtado R, 2010, KIDNEY INT, V77, P500, DOI 10.1038/ki.2009.483; IRISAWA H, 1962, P JPN ACAD, V38, P171, DOI 10.2183/pjab1945.38.171; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Klemm MF, 1999, J PHYSIOL-LONDON, V519, P867, DOI 10.1111/j.1469-7793.1999.0867n.x; Knisley SB, 2000, AM J PHYSIOL-HEART C, V279, pH1421, DOI 10.1152/ajpheart.2000.279.3.H1421; Laish-Farkash A, 2010, J CARDIOVASC ELECTR, V21, P1365, DOI 10.1111/j.1540-8167.2010.01844.x; Lang RJ, 2007, J PHYSIOL-LONDON, V583, P1049, DOI 10.1113/jphysiol.2007.137034; Lang RJ, 2010, CLIN EXP PHARMACOL P, V37, P509, DOI 10.1111/j.1440-1681.2009.05226.x; Lee SE, 2009, KOREAN J PHYSIOL PHA, V13, P241, DOI 10.4196/kjpp.2009.13.3.241; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Liau J, 2004, ANN BIOMED ENG, V32, P1202, DOI 10.1114/B:ABME.0000039354.41647.1b; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Madle A, 2001, Med Sci Monit, V7, P74; MARSHALL PW, 1993, J CARDIOVASC PHARM, V21, P902, DOI 10.1097/00005344-199306000-00008; Masumiya H, 1998, EUR J PHARMACOL, V349, P351, DOI 10.1016/S0014-2999(98)00204-0; Monfredi O, 2010, PACE, V33, P1392, DOI 10.1111/j.1540-8159.2010.02838.x; Mostafa RM, 2010, WORLD J GASTROENTERO, V16, P3239, DOI 10.3748/wjg.v16.i26.3239; Nakagawa Tadashi, 2005, Journal of Smooth Muscle Research, V41, P141, DOI 10.1540/jsmr.41.141; Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a; Nishizawa H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007069; Niwa N, 2004, AM J PHYSIOL-HEART C, V286, pH2257, DOI 10.1152/ajpheart.01043.2003; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Ono K, 2010, J MOL CELL CARDIOL, V48, P65, DOI 10.1016/j.yjmcc.2009.08.021; Orbelli L, 1910, PFLUGERS ARCH GESAMT, V133, P23; Plotnikov AN, 2004, CIRCULATION, V109, P506, DOI 10.1161/01.CIR.0000114527.10764.CC; Potapova I, 2004, CIRC RES, V94, P952, DOI 10.1161/01.RES.0000123827.60210.72; Qu JH, 2003, CIRCULATION, V107, P1106, DOI 10.1161/01.CIR.0000059939.97249.2C; Roubille F, 2013, CIRCULATION, V127, P1986, DOI 10.1161/CIRCULATIONAHA.112.000145; ROUSE W, 1994, BRIT J PHARMACOL, V113, P1071, DOI 10.1111/j.1476-5381.1994.tb17102.x; SCHMIDTNIELSEN B, 1987, KIDNEY INT, V31, P621, DOI 10.1038/ki.1987.43; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Shin KS, 2001, J GEN PHYSIOL, V117, P91, DOI 10.1085/jgp.117.2.91; Silverstein DM, 2003, PEDIATR NEPHROL, V18, P216, DOI 10.1007/s00467-002-1065-1; Steriade M, 2003, NEURON, V37, P563, DOI 10.1016/S0896-6273(03)00065-5; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Tanaka H, 2004, J PHARMACOL SCI, V96, P499, DOI 10.1254/jphs.RCJ04001X; Weiss Robert M., 2006, Journal of Smooth Muscle Research, V42, P103, DOI 10.1540/jsmr.42.103; WEISS ROBERT M., 1967, INVEST UROL, V5, P42; Xiao Yong-Fu, 2007, Shengli Xuebao, V59, P562; Xu C, 2003, BIOPHYS J, V84, P2768, DOI 10.1016/S0006-3495(03)75081-4; Zhu MH, 2009, J PHYSIOL-LONDON, V587, P4905, DOI 10.1113/jphysiol.2009.176206	73	22	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					730	739		10.1096/fj.13-237289	http://dx.doi.org/10.1096/fj.13-237289			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24189942	Green Published			2022-12-28	WOS:000331072200020
J	Bhat, A; Hoch, AI; Decaris, ML; Leach, JK				Bhat, Archana; Hoch, Allison I.; Decaris, Martin L.; Leach, J. Kent			Alginate hydrogels containing cell-interactive beads for bone formation	FASEB JOURNAL			English	Article						extracellular matrix; osteogenesis; adhesion ligands; mesenchymal stem cell	MESENCHYMAL STEM-CELLS; TROPHIC FACTOR SECRETION; OSTEOBLAST-LIKE CELLS; EXTRACELLULAR-MATRIX; OSTEOGENIC DIFFERENTIATION; ADHESION PEPTIDES; SCAFFOLDS; GROWTH; MICROCARRIERS; CULTURE	Alginate hydrogels containing cell-instructive cues are the subject of intense interest for their use as cell carriers in bone tissue engineering. Peptides and proteins are chemically grafted onto these hydrophilic materials to facilitate adhesion and direct phenotype of entrapped cells. However, the presentation of a single or small number of peptides does not represent the complexity of the native extracellular matrix (ECM) of bony tissues. Mesenchymal stem cells (MSCs) secrete ECM that can be harvested and deposited on various substrata to promote osteogenic differentiation. In this study, we hypothesized that the presentation of engineered cell-secreted ECM on microbeads suspended in alginate hydrogels would promote cell adhesion and enhance osteogenic differentiation of undifferentiated MSCs without chemical incorporation of cell-adhesive peptides. Human MSCs entrapped in alginate hydrogels loaded with ECM-coated beads showed increased interaction with beads, when compared with cells suspended in hydrogels containing uncoated blank (BLK) beads. MSCs entrapped in ECM gels exhibited increased alkaline phosphatase (ALP) activity and expression of osteogenic genes in vitro compared with hydrogels modified with arginine-glycine-aspartic acid (RGD)-containing peptides. Transplantation of MSCs into an ectopic site resulted in significant increases in blood vessel density for ECM hydrogels when compared with the BLK or RGD gels. Furthermore, we observed comparable levels of bone formation at 6 wk with ECM and RGD hydrogels. These findings demonstrate that engineered ECM can be deployed in a minimally invasive manner to direct the formation of bony tissue. This strategy may provide an alternative to the engraftment of proteins or peptides onto the polymer backbone of hydrogels for directing cellular behavior.	[Bhat, Archana; Hoch, Allison I.; Decaris, Martin L.; Leach, J. Kent] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; [Leach, J. Kent] Univ Calif Davis, Sch Med, Dept Orthopaed Surg, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Leach, JK (corresponding author), Univ Calif Davis, Dept Biomed Engn, 451 Hlth Sci Dr,GBSF 3321, Davis, CA 95616 USA.	jkleach@ucdavis.edu		Hoch, Allison/0000-0002-2418-8736	Hartwell Foundation; Department of the Army [W81XWH-10-1-0984]	Hartwell Foundation; Department of the Army	The authors are grateful for financial support from The Hartwell Foundation and the Department of the Army (W81XWH-10-1-0984). The authors thank Marissa Hugh-banks and Nandor Laszik for their contributions to the work.	Alsberg E, 2001, J DENT RES, V80, P2025, DOI 10.1177/00220345010800111501; Chen MQ, 2011, BIOMATERIALS, V32, P7532, DOI 10.1016/j.biomaterials.2011.06.054; Datta N, 2006, P NATL ACAD SCI USA, V103, P2488, DOI 10.1073/pnas.0505661103; Davis HE, 2011, ACTA BIOMATER, V7, P691, DOI 10.1016/j.actbio.2010.09.007; Decaris ML, 2012, TISSUE ENG PT A, V18, P2148, DOI [10.1089/ten.tea.2011.0677, 10.1089/ten.TEA.2011.0677]; Decaris ML, 2012, ACTA BIOMATER, V8, P744, DOI 10.1016/j.actbio.2011.10.035; Decaris ML, 2011, ANN BIOMED ENG, V39, P1174, DOI 10.1007/s10439-010-0217-x; Dhoot NO, 2004, J BIOMED MATER RES A, V71A, P191, DOI 10.1002/jbm.a.30103; Diduch DR, 2000, ARTHROSCOPY, V16, P571, DOI 10.1053/jars.2000.4827; Drury JL, 2004, BIOMATERIALS, V25, P3187, DOI 10.1016/j.biomaterials.2003.10.002; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Frondoza C, 1996, BIOMATERIALS, V17, P879, DOI 10.1016/0142-9612(96)83283-2; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Grigoriou V, 2005, J BIOL CHEM, V280, P1733, DOI 10.1074/jbc.M402550200; He JW, 2010, TISSUE ENG PT A, V16, P127, DOI [10.1089/ten.tea.2009.0255, 10.1089/ten.TEA.2009.0255]; He JW, 2012, TISSUE ENG PT A, V18, P1520, DOI [10.1089/ten.tea.2011.0127, 10.1089/ten.TEA.2011.0127]; He JW, 2010, J CELL BIOCHEM, V110, P87, DOI 10.1002/jcb.22514; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Hoch AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035579; Huang NF, 2010, ACTA BIOMATER, V6, P4614, DOI 10.1016/j.actbio.2010.06.033; Kaigler D, 2005, FASEB J, V19, P665, DOI 10.1096/fj.04-2529fje; Kang YQ, 2011, BIOMATERIALS, V32, P6119, DOI 10.1016/j.biomaterials.2011.05.015; Kim J, 2010, J BIOMED MATER RES A, V95A, P673, DOI 10.1002/jbm.a.32884; Kong HJ, 2004, BIOMACROMOLECULES, V5, P1720, DOI 10.1021/bm049879r; Kozawa O, 2001, J CELL BIOCHEM, V81, P430, DOI 10.1002/1097-4644(20010601)81:3<430::AID-JCB1056>3.0.CO;2-G; Lao LH, 2008, COLLOID SURFACE B, V66, P218, DOI 10.1016/j.colsurfb.2008.06.014; Lebaron RG, 2000, TISSUE ENG, V6, P85, DOI 10.1089/107632700320720; Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x; Liao JH, 2010, BIOMATERIALS, V31, P8911, DOI 10.1016/j.biomaterials.2010.07.110; Liao JH, 2010, ACTA BIOMATER, V6, P2386, DOI 10.1016/j.actbio.2010.01.011; Lin H, 2012, BIOMATERIALS, V33, P4480, DOI 10.1016/j.biomaterials.2012.03.012; Malda J, 2006, TRENDS BIOTECHNOL, V24, P299, DOI 10.1016/j.tibtech.2006.04.009; Mosahebi A, 2003, TISSUE ENG, V9, P209, DOI 10.1089/107632703764664684; Mountziaris PM, 2012, J BIOMED MATER RES A, V100A, P1097, DOI 10.1002/jbm.a.34058; Paek HJ, 2006, TISSUE ENG, V12, P1733, DOI 10.1089/ten.2006.12.1733; Prang P, 2006, BIOMATERIALS, V27, P3560, DOI 10.1016/j.biomaterials.2006.01.053; Rezania A, 1999, BIOTECHNOL PROGR, V15, P19, DOI 10.1021/bp980083b; Rowlands AS, 2008, AM J PHYSIOL-CELL PH, V295, pC1037, DOI 10.1152/ajpcell.67.2008; Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142-9612(98)00107-0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; Shekaran A, 2011, J BIOMED MATER RES A, V96A, P261, DOI 10.1002/jbm.a.32979; Sofia S, 2001, J BIOMED MATER RES, V54, P139, DOI 10.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-7; Subramani K, 2006, BIOMED MATER, V1, P144, DOI 10.1088/1748-6041/1/3/009; Thibault RA, 2010, TISSUE ENG PT A, V16, P431, DOI [10.1089/ten.tea.2009.0583, 10.1089/ten.TEA.2009.0583]; Wu YN, 2007, BIOMATERIALS, V28, P4056, DOI 10.1016/j.biomaterials.2007.05.039	47	29	30	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4844	4852		10.1096/fj.12-213611	http://dx.doi.org/10.1096/fj.12-213611			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24005905				2022-12-28	WOS:000329999000019
J	Ock, S; Ahn, J; Lee, SH; Kang, H; Offermanns, S; Ahn, HY; Jo, YS; Shong, M; Cho, BY; Jo, D; Abel, ED; Lee, TJ; Park, WJ; Lee, IK; Kim, J				Ock, Sangmi; Ahn, Jihyun; Lee, Seok Hong; Kang, Hyun; Offermanns, Stefan; Ahn, Hwa Young; Jo, Young Suk; Shong, Minho; Cho, Bo Youn; Jo, Daewoong; Abel, E. Dale; Lee, Tae Jin; Park, Woo Jin; Lee, In-Kyu; Kim, Jaetaek			IGF-1 receptor deficiency in thyrocytes impairs thyroid hormone secretion and completely inhibits TSH-stimulated goiter	FASEB JOURNAL			English	Article						MCT8; T-4; hypertrophy; proliferation	GROWTH-FACTOR-I; THYROTROPIN; CELLS; ASSOCIATION; EXPRESSION; ABSENCE	Although thyroid-stimulating hormone (TSH) is known to be a major regulator of thyroid hormone biosynthesis and thyroid growth, insulin-like growth factor 1 (IGF-1) is required for mediating thyrocyte growth in concert with TSH in vitro. We generated mice with thyrocyte-selective ablation of IGF-1 receptor (TIGF1RKO) to explore the role of IGF-1 receptor signaling on thyroid function and growth. In 5-wk-old TIGF1RKO mice, serum thyroxine (T-4) concentrations were decreased by 30% in concert with a 43% down-regulation of the monocarboxylate transporter 8 (MCT8), which is involved in T-4 secretion. Despite a 3.5-fold increase in circulating concentrations of TSH, thyroid architecture and size were normal. Furthermore, thyrocyte area was increased by 40% in WT thyroids after 10 d TSH injection, but this effect was absent in TSH-injected TIGF1RKO mice. WT mice treated with methimazole and sodium perchlorate for 2 or 6 wk exhibited pronounced goiter development (2.0 and 5.4-fold, respectively), but in TIGF1RKO mice, goiter development was completely abrogated. These data reveal an essential role for IGF-1 receptor signaling in the regulation of thyroid function and TSH-stimulated goitrogenesis.	[Ock, Sangmi; Ahn, Jihyun; Lee, Seok Hong; Ahn, Hwa Young; Cho, Bo Youn; Kim, Jaetaek] Chung Ang Univ, Dept Internal Med, Div Endocrinol & Metab, Seoul 156755, South Korea; [Kang, Hyun] Chung Ang Univ, Dept Anesthesiol, Seoul 156755, South Korea; [Lee, Tae Jin] Chung Ang Univ, Dept Pathol, Coll Med, Seoul 156755, South Korea; [Offermanns, Stefan] Max Planck Inst Heart & Lung Res, Dept Pharmacol, Bad Nauheim, Germany; [Jo, Young Suk; Shong, Minho] Chungnam Natl Univ Hosp, Res Ctr Endocrine & Metab Dis, Dept Internal Med, Taejon, South Korea; [Jo, Daewoong] Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37212 USA; [Abel, E. Dale] Univ Utah, Sch Med, Program Mol Med, Div Endocrinol Metab & Diabet, Salt Lake City, UT USA; [Park, Woo Jin] Gwangju Inst Sci & Technol, Global Res Lab, Kwangju, South Korea; [Park, Woo Jin] Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea; [Lee, In-Kyu] Kyungpook Natl Univ, Sch Med, Div Endocrinol & Metab, Taegu, South Korea; [Lee, In-Kyu] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea; [Lee, In-Kyu] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Taegu, South Korea	Chung Ang University; Chung Ang University; Chung Ang University; Chung Ang University Hospital; Max Planck Society; Chungnam National University; Chungnam National University Hospital; Vanderbilt University; Utah System of Higher Education; University of Utah; Gwangju Institute of Science & Technology (GIST); Gwangju Institute of Science & Technology (GIST); Kyungpook National University; Kyungpook National University; Kyungpook National University	Kim, J (corresponding author), Chung Ang Univ, Dept Internal Med, Div Endocrinol & Metab, 224-1 Heuk Seok Dong, Seoul 156755, South Korea.	jtkim@cau.ac.kr	Lee, In-Kyu/AAR-6374-2021; Ahn, Jihyun/AAH-9110-2020; Kang, Hyun/AAE-7872-2020; Kim, Jaetaek/AAE-7147-2020; /H-7803-2012; Offermanns, Stefan/L-3313-2017	Kang, Hyun/0000-0003-2844-5880; Kim, Jaetaek/0000-0001-5247-0408; Offermanns, Stefan/0000-0001-8676-6805; shong, minho/0000-0002-0247-7115; Abel, E. Dale/0000-0001-5290-0738	Korea Healthcare Technology RD Project [A084811, A101749]; Korea Ministry of Health and Welfare; Basic Science Research Program through the National Research Foundation, Ministry of Education, Republic of Korea [2012R1A1A2043642]	Korea Healthcare Technology RD Project; Korea Ministry of Health and Welfare(Ministry of Health & Welfare (MOHW), Republic of Korea); Basic Science Research Program through the National Research Foundation, Ministry of Education, Republic of Korea	The authors thank Dr. Samuel Refetoff (University of Chicago) for T<INF>4</INF> and TSH measurements. This study was supported by grants of the Korea Healthcare Technology R&D Project (A084811 to J.K.; A101749 to W.J.P and J.K.), Korea Ministry of Health and Welfare, and by grants of the Basic Science Research Program through the National Research Foundation (2012R1A1A2043642 to J.A.), Ministry of Education, Republic of Korea. The authors declare no conflicts of interest.	Belfiore A, 1999, BIOCHIMIE, V81, P403, DOI 10.1016/S0300-9084(99)80088-1; Bidey SP, 1999, J ENDOCRINOL, V160, P321, DOI 10.1677/joe.0.1600321; Brewer C, 2007, CANCER RES, V67, P8002, DOI 10.1158/0008-5472.CAN-07-2471; Cadoret A, 2005, INT J CANCER, V114, P668, DOI 10.1002/ijc.20805; Cheung NW, 1996, J CLIN ENDOCR METAB, V81, P1179, DOI 10.1210/jc.81.3.1179; Cheung NW, 1997, CLIN ENDOCRINOL, V46, P545, DOI 10.1046/j.1365-2265.1997.1680985.x; Clement S, 2001, ENDOCRINOLOGY, V142, P5131, DOI 10.1210/en.142.12.5131; Derwahl M, 1999, J CLIN ENDOCR METAB, V84, P829, DOI 10.1210/jc.84.3.829; Di Cosmo C, 2010, J CLIN INVEST, V120, P3377, DOI 10.1172/JCI42113; DORMITZER PR, 1989, AM J PHYS ANTHROPOL, V78, P527, DOI 10.1002/ajpa.1330780408; Dumitrescu AM, 2006, ENDOCRINOLOGY, V147, P4036, DOI 10.1210/en.2006-0390; Eggo MC, 1990, GROWTH FACTORS, V2, P99, DOI 10.3109/08977199009071497; FIELD JB, 1973, J CLIN INVEST, V52, P2404, DOI 10.1172/JCI107430; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; Graf H., 2012, WERNER INGBARS THYRO, P635; Kasagi K, 1999, THYROID, V9, P791, DOI 10.1089/thy.1999.9.791; Kero J, 2007, J CLIN INVEST, V117, P2399, DOI 10.1172/JCI30380; Kim J, 2008, MOL ENDOCRINOL, V22, P2531, DOI 10.1210/me.2008-0265; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kogai T, 1997, ENDOCRINOLOGY, V138, P2227, DOI 10.1210/en.138.6.2227; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; Liao XH, 2011, ENDOCRINOLOGY, V152, P1180, DOI 10.1210/en.2010-0900; Maia AL, 2011, J ENDOCRINOL, V209, P283, DOI 10.1530/JOE-10-0481; Marians RC, 2002, P NATL ACAD SCI USA, V99, P15776, DOI 10.1073/pnas.242322099; Medeiros-Neto G, 2012, MED CLIN N AM, V96, P351, DOI 10.1016/j.mcna.2012.01.010; Misaki T., 1998, J CLIN ENDOCR METAB, V66, P1227; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; MIYAKAWA M, 1988, J CLIN ENDOCR METAB, V67, P973, DOI 10.1210/jcem-67-5-973; Muller K, 2011, MOL ENDOCRINOL, V25, P1867, DOI 10.1210/me.2011-0065; Nishimura M, 2008, DRUG METAB PHARMACOK, V23, P22, DOI 10.2133/dmpk.23.22; Ock S, 2011, ENDOCR J, V58, P1013, DOI 10.1507/endocrj.EJ11-0007; Ramsden JD, 2005, ENDOCRINOLOGY, V146, P2895, DOI 10.1210/en.2005-0168; Santisteban P., 2012, WERNER INGBARS THYRO, P4; Smith VE, 2012, ENDOCRINOLOGY, V153, P3526, DOI 10.1210/en.2011-2030; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TODE B, 1989, J CLIN ENDOCR METAB, V69, P639, DOI 10.1210/jcem-69-3-639; Trajkovic M, 2007, J CLIN INVEST, V117, P627, DOI 10.1172/JCI28253; Tsui S, 2008, J IMMUNOL, V181, P4397, DOI 10.4049/jimmunol.181.6.4397; Volzke H, 2007, J CLIN ENDOCR METAB, V92, P4039, DOI 10.1210/jc.2007-0816; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; Welsh GI, 2010, CELL METAB, V12, P329, DOI 10.1016/j.cmet.2010.08.015; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524	42	28	31	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4899	4908		10.1096/fj.13-231381	http://dx.doi.org/10.1096/fj.13-231381			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23982142				2022-12-28	WOS:000329999000024
J	Aiken, CE; Tarry-Adkins, JL; Ozanne, SE				Aiken, Catherine E.; Tarry-Adkins, Jane L.; Ozanne, Susan E.			Suboptimal nutrition in utero causes DNA damage and accelerated aging of the female reproductive tract	FASEB JOURNAL			English	Article						developmental programming; senescence; mitochondrial DNA; reproduction	OXIDATIVE STRESS; PROTEIN RESTRICTION; TELOMERASE ACTIVITY; MATERNAL NUTRITION; POSTNATAL-GROWTH; DEFENSE CAPACITY; COPY NUMBER; FETAL; EXPRESSION; AGE	Early life exposure to adverse environments can lead to a variety of metabolic and cardiovascular diseases in offspring. We hypothesize that female reproductive function may also be affected, with subsequent implications for fertility. We used an established maternal low-protein model where animals are born small but undergo rapid postnatal catch-up growth by suckling a control-fed dam (recuperated offspring). Markers of oxidative stress and cellular aging in reproductive tract tissues were assessed at 3 and 6 mo of age. Recuperated offspring had lower birth weight than controls (P<0.01) but caught up during lactation. 4-Hydroxynonenal (4HNE; an indicator of oxidative stress) was increased in recuperated animals compared with controls in both ovaries and oviducts at 6 mo. At 3 and 6 mo, ovaries and oviducts of recuperated offspring had increased mitochondrial (mt)DNA copy number (P<0.01). By contrast, germ-line cells showed no difference in mtDNA copy number, suggesting they were protected from suboptimal maternal nutrition. Oviduct and somatic ovarian telomere length declined more rapidly with age in recuperated animals. This accelerated cellular aging was associated with a declined ovarian reserve in developmentally programmed animals. These findings have significant clinical implications in light of worldwide trends to delayed childbearing.Aiken, C. E., Tarry-Adkins, J. L., Ozanne, S. E. Suboptimal nutrition in utero causes DNA damage and accelerated aging of the female reproductive tract.	[Aiken, Catherine E.; Tarry-Adkins, Jane L.; Ozanne, Susan E.] Univ Cambridge, Metab Res Labs, Cambridge CB2 OQQ, England; [Aiken, Catherine E.] Addenbrookes Hosp, Med Res Council Metab Dis Unit, Inst Metab Sci, Cambridge, England; [Aiken, Catherine E.] Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 OQQ, England; [Aiken, Catherine E.] Rosie Hosp, Cambridge, England; [Aiken, Catherine E.] Natl Inst Hlth Res Cambridge Comprehens Biomed Re, Cambridge, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Aiken, CE (corresponding author), Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Level 4,Box 289,Hills Rd, Cambridge CB2 OQQ, England.	cema2@cam.ac.uk		Ozanne, Susan/0000-0001-8753-5144	British Maternal Fetal Medicine Society; Gynaecological Cancer Fund; Addenbrooke's Charitable Trust; British Heart Foundation [PG/09/037/27387, FS/09/029/27902] Funding Source: researchfish; Medical Research Council [G0600717, G0600717B, MC_UU_12012/5/B, MC_UU_12012/4] Funding Source: researchfish; MRC [MC_UU_12012/5, G0600717, MC_UU_12012/4] Funding Source: UKRI	British Maternal Fetal Medicine Society; Gynaecological Cancer Fund; Addenbrooke's Charitable Trust; British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The work reported here was funded jointly by grants from the British Maternal Fetal Medicine Society, the Gynaecological Cancer Fund, and Addenbrooke's Charitable Trust. S.E.O. is a British Heart Foundation Senior Fellow and a member of the University of Cambridge Medical Research Council Metabolic Diseases Unit. The authors declare no conflicts of interest.	Albertini DF, 2012, J ASSIST REPROD GEN, V29, P577, DOI 10.1007/s10815-012-9832-9; Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7; Bentov Y, 2011, J ASSIST REPROD GEN, V28, P773, DOI 10.1007/s10815-011-9588-7; Bernal AB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015558; Botting B, 2000, Popul Trends, P32; Buhi WC, 1997, BIOL REPROD, V57, P7, DOI 10.1095/biolreprod57.1.7; Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950; Cheong AWY, 2009, BIOL REPROD, V81, P126, DOI 10.1095/biolreprod.108.071449; Chernoff N, 2009, REPROD TOXICOL, V28, P489, DOI 10.1016/j.reprotox.2009.06.006; de Bruin JP, 2004, BIOL REPROD, V70, P419, DOI 10.1095/biolreprod.103.015784; de Bruin JP, 1998, EARLY HUM DEV, V51, P39, DOI 10.1016/S0378-3782(97)00073-X; Arganaraz ME, 2012, ZYGOTE, V20, P53, DOI 10.1017/S0967199410000602; Eisenhauer KM, 1997, BIOL REPROD, V56, P1120, DOI 10.1095/biolreprod56.5.1120; Elias SG, 2003, MENOPAUSE, V10, P399, DOI 10.1097/01.GME.0000059862.93639.C1; Faddy MJ, 2000, MOL CELL ENDOCRINOL, V163, P43, DOI 10.1016/S0303-7207(99)00238-5; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; Guerin P, 2001, HUM REPROD UPDATE, V7, P175, DOI 10.1093/humupd/7.2.175; Guzman C, 2006, J PHYSIOL-LONDON, V572, P97, DOI 10.1113/jphysiol.2005.103903; Haussmann MF, 2003, P ROY SOC B-BIOL SCI, V270, P1387, DOI 10.1098/rspb.2003.2385; HIRSHFIELD AN, 1978, BIOL REPROD, V19, P597, DOI 10.1095/biolreprod19.3.597; Ibanez L, 2007, HUM REPROD, V22, P395, DOI 10.1093/humrep/del395; Igosheva N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010074; Kawanishi S, 2004, ANN NY ACAD SCI, V1019, P278, DOI 10.1196/annals.1297.047; Knudsen Thomas B, 2004, Birth Defects Res C Embryo Today, V72, P313, DOI 10.1002/bdrc.20028; Lee KF, 2002, BIOCHEM BIOPH RES CO, V292, P564, DOI 10.1006/bbrc.2002.6676; Li Q, 2012, SCI CHINA LIFE SCI, V55, P659, DOI 10.1007/s11427-012-4352-5; Lim J, 2011, BIOL REPROD, V84, P775, DOI 10.1095/biolreprod.110.088583; Liu JP, 2010, REPRODUCTION, V140, P215, DOI 10.1530/REP-10-0008; Meikle D, 2001, REPRODUCTION, V122, P437, DOI 10.1530/rep.0.1220437; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; MURRAY MK, 1995, MICROSC RES TECHNIQ, V31, P497, DOI 10.1002/jemt.1070310606; Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050; Ozanne SE, 2007, NAT CLIN PRACT ENDOC, V3, P539, DOI 10.1038/ncpendmet0531; Rae MT, 2002, ANIM REPROD SCI, V72, P63, DOI 10.1016/S0378-4320(02)00068-4; Rhind SM, 2001, REPRODUCTION, V122, P205, DOI 10.1530/rep.0.1220205; Sloboda DM, 2007, J CLIN ENDOCR METAB, V92, P46, DOI 10.1210/jc.2006-1378; Sloboda DM, 2011, HUM REPROD UPDATE, V17, P210, DOI 10.1093/humupd/dmq048; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Sullivan TM, 2009, REPROD FERT DEVELOP, V21, P773, DOI 10.1071/RD09004; Tarry-Adkins JL, 2008, FASEB J, V22, P2037, DOI 10.1096/fj.07-099523; Tarry-Adkins JL, 2013, FASEB J, V27, P379, DOI 10.1096/fj.12-218685; Tarry-Adkins JL, 2011, AM J CLIN NUTR, V94, p1765S, DOI 10.3945/ajcn.110.000620; Tarry-Adkins JL, 2006, AM J PHYSIOL-RENAL, V290, pF509, DOI 10.1152/ajprenal.00215.2005; Tatone C, 2008, HUM REPROD UPDATE, V14, P131, DOI 10.1093/humupd/dmm048; Tatone C, 2013, FERTIL STERIL, V99, P12, DOI 10.1016/j.fertnstert.2012.11.029; Yamagata Y, 2002, ENDOCR J, V49, P589, DOI 10.1507/endocrj.49.589	46	33	34	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3959	3965		10.1096/fj.13-234484	http://dx.doi.org/10.1096/fj.13-234484			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23792302				2022-12-28	WOS:000329747100011
J	Almine, JF; Wise, SG; Hiob, M; Singh, NK; Tiwari, KK; Vali, S; Abbasi, T; Weiss, AS				Almine, Jessica F.; Wise, Steven G.; Hiob, Matti; Singh, Neeraj Kumar; Tiwari, Krishna Kumar; Vali, Shireen; Abbasi, Taher; Weiss, Anthony S.			Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts	FASEB JOURNAL			English	Article						signaling; wound healing	HUMAN TROPOELASTIN; UP-REGULATION; PEPTIDES; EXPRESSION; PATHWAY; CHEMOKINES; MATRIX; PROLIFERATION; COACERVATION; INDUCTION	Following penetrating injury of the skin, a highly orchestrated and overlapping sequence of events helps to facilitate wound resolution. Inflammation is a hallmark that is initiated early, but the reciprocal relationship between cells and matrix molecules that triggers and maintains inflammation is poorly appreciated. Elastin is enriched in the deep dermis of skin. We propose that deep tissue injury encompasses elastin damage, yielding solubilized elastin that triggers inflammation. As dermal fibroblasts dominate the deep dermis, this means that a direct interaction between elastin sequences and fibroblasts would reveal a proinflammatory signature. Tropoelastin was used as a surrogate for elastin sequences. Tropoelastin triggered fibroblast expression of the metalloelastase MMP-12, which is normally expressed by macrophages. MMP-12 expression increased 1056 +/- 286-fold by 6 h and persisted for 24 h. Chemokine expression was more transient, as chemokine C-X-C motif ligand 8 (CXCL8), CXCL1, and CXCL5 transcripts increased 11.8 +/- 2.6-, 10.2 +/- 0.4-, and 8593 +/- 996-fold, respectively, by 6-12 h and then decreased. Through the use of specific inhibitors and protein truncation, we found that transduction of the tropoelastin signal was mediated by the fibroblast elastin binding protein (EBP). In silico modeling using a predictive computational fibroblast model confirmed the up-regulation, and simulations revealed PKA as a key part of the signaling circuit. We tested this prediction with 1 M PKA inhibitor H-89 and found that 2 h of exposure correspondingly reduced expression of MMP-12 (63.9 +/- 12.3%) and all chemokine markers, consistent with the levels seen with EBP inhibition, and validated PKA as a novel node and druggable target to ameliorate the proinflammatory state. A separate trigger that utilized C-terminal RKRK of tropoelastin reduced marker expression to 65.0-76.5% and suggests the parallel involvement of integrin (V3). We propose that the solubilization of elastin as a result of dermal damage leads to rapid chemokine up-regulation by fibroblasts that is quenched when exposed elastin is removed by MMP-12.Almine, J. F., Wise, S. G., Hiob, M., Kumar Singh, N. K., Tiwari, K. K., Vali, S., Abbasi, T., and Weiss, A. S. Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts.	[Almine, Jessica F.; Wise, Steven G.; Hiob, Matti; Weiss, Anthony S.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia; [Weiss, Anthony S.] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Weiss, Anthony S.] Univ Sydney, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Wise, Steven G.] Heart Res Inst, Sydney, NSW, Australia; [Singh, Neeraj Kumar; Tiwari, Krishna Kumar; Vali, Shireen] Cellworks Res India Ltd, Bangalore, Karnataka, India; [Vali, Shireen; Abbasi, Taher] Cellworks Grp, San Jose, CA USA	University of Sydney; University of Sydney; University of Sydney; University of Sydney; Heart Research Institute	Weiss, AS (corresponding author), Univ Sydney, Sch Mol Biosci G08, Sydney, NSW 2006, Australia.	tony.weiss@sydney.edu.au	Wise, Steven/AAB-8170-2021; Weiss, Anthony S/GYV-0157-2022; Weiss, Anthony S/F-8103-2010; Wise, Steven/B-1858-2009	Weiss, Anthony S/0000-0002-8106-4836; Tiwari, Krishna/0000-0002-3699-0937; Wise, Steven/0000-0001-7964-819X; Almine, Jessica/0000-0003-2260-0560	Australian Research Council; Australian Defense Health Foundation; Australian National Health and Medical Research Council; U.S. National Institutes of Health [EB014283]; Australian Postgraduate Award; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB014283] Funding Source: NIH RePORTER	Australian Research Council(Australian Research Council); Australian Defense Health Foundation; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian Postgraduate Award(Australian Government); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	A.S.W. acknowledges support from the Australian Research Council, Australian Defense Health Foundation, Australian National Health and Medical Research Council, and the U.S. National Institutes of Health (EB014283). A.S.W. is the scientific founder of Elastagen Pty. Ltd. J.F.A received an Australian Postgraduate Award. The authors thank their colleagues at Concord Hospital for the generous donation of human dermal fibroblasts; A/Prof. Gareth Denyer, Dr. Dale Hancock, Mrs. Sarah Martinez, Ms. Yannie Poon, and Ms. Kate Nieuwendyk for their technical assistance; and Dr. Suzanne Mithieux and Dr.Daniel Bax for advice on the text of this article. The authors declare no conflicts of interest.	Adair-Kirk TL, 2008, INT J BIOCHEM CELL B, V40, P1101, DOI 10.1016/j.biocel.2007.12.005; Amadeu TP, 2004, WOUND REPAIR REGEN, V12, P169, DOI 10.1111/j.1067-1927.2004.012209.x; [Anonymous], 2001, CURR PROTOC CELL BIO, DOI [10.1002/0471143030.cb0901s00, DOI 10.1002/0471143030.CB0901S00]; Antonicelli F, 2007, CURR TOP DEV BIOL, V79, P99, DOI 10.1016/S0070-2153(06)79005-6; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Cantarelli B, 2009, FEBS LETT, V583, P2385, DOI 10.1016/j.febslet.2009.06.037; Devalaraja RM, 2000, J INVEST DERMATOL, V115, P234, DOI 10.1046/j.1523-1747.2000.00034.x; Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184; Duca L, 2005, MOL PHARMACOL, V67, P1315, DOI 10.1124/mol.104.002725; Duca L, 2004, CRIT REV ONCOL HEMAT, V49, P235, DOI 10.1016/j.critrevonc.2003.09.007; Duca L, 2002, FEBS LETT, V524, P193, DOI 10.1016/S0014-5793(02)03057-0; Engelhardt E, 1998, AM J PATHOL, V153, P1849, DOI 10.1016/S0002-9440(10)65699-4; Flavell SJ, 2008, BRIT J PHARMACOL, V153, pS241, DOI 10.1038/sj.bjp.0707487; Fujimoto N, 2000, J INVEST DERMATOL, V115, P633, DOI 10.1046/j.1523-1747.2000.00117.x; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Harvey LE, 2013, SCI REP-UK, V3, DOI 10.1038/srep01232; Heinz A, 2010, FEBS J, V277, P1939, DOI 10.1111/j.1742-4658.2010.07616.x; Jawad R, 2012, PHARM RES-DORDR, V29, P511, DOI 10.1007/s11095-011-0575-6; Jones PL, 1999, J CELL SCI, V112, P435; Kamoun A, 1995, CELL ADHES COMMUN, V3, P273, DOI 10.3109/15419069509081013; Kielty CM, 2002, J CELL SCI, V115, P2817; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Murdoch C, 2000, BLOOD, V95, P3032; Nenan S, 2005, MEM I OSWALDO CRUZ, V100, P167, DOI 10.1590/S0074-02762005000900028; Pierce RA, 2006, AM J PHYSIOL-LUNG C, V291, pL391, DOI 10.1152/ajplung.00441.2004; Raghunath M, 1996, J INVEST DERMATOL, V106, P1090, DOI 10.1111/1523-1747.ep12339373; Rajendran P, 2012, J CELL PHYSIOL, V227, P2184, DOI 10.1002/jcp.22954; Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613; Roten SV, 1996, J CUTAN PATHOL, V23, P37, DOI 10.1111/j.1600-0560.1996.tb00775.x; Schultz GS, 2011, WOUND REPAIR REGEN, V19, P134, DOI 10.1111/j.1524-475X.2011.00673.x; SENIOR RM, 1982, J CLIN INVEST, V70, P614, DOI 10.1172/JCI110654; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; Smith RS, 1997, AM J PATHOL, V151, P317; Taddese S, 2009, MATRIX BIOL, V28, P84, DOI 10.1016/j.matbio.2008.12.002; Tajima S, 1997, ARCH DERMATOL RES, V289, P489, DOI 10.1007/s004030050227; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Watanabe T, 2012, ARCH ORAL BIOL, V57, P52, DOI 10.1016/j.archoralbio.2011.07.010; Waterhouse A, 2011, PHARM RES-DORDR, V28, P1415, DOI 10.1007/s11095-010-0327-z; Wise SG, 2009, INT J BIOCHEM CELL B, V41, P494, DOI 10.1016/j.biocel.2008.03.017; Wu WJ, 1999, EUR J BIOCHEM, V266, P308, DOI 10.1046/j.1432-1327.1999.00891.x; Yeo GC, 2011, ADV COLLOID INTERFAC, V167, P94, DOI 10.1016/j.cis.2010.10.003	43	29	29	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3455	3465		10.1096/fj.13-231787	http://dx.doi.org/10.1096/fj.13-231787			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23671273	Green Published			2022-12-28	WOS:000328840500006
J	Perez-Cervera, Y; Dehennaut, V; Gil, MA; Guedri, K; Mata, CJS; Olivier-Van Stichelen, S; Michalski, JC; Foulquier, F; Lefebvre, T				Perez-Cervera, Yobana; Dehennaut, Vanessa; Aquino Gil, Moyira; Guedri, Katia; Solorzano Mata, Carlos Josue; Olivier-Van Stichelen, Stephanie; Michalski, Jean-Claude; Foulquier, Francois; Lefebvre, Tony			Insulin signaling controls the expression of O-GlcNAc transferase and its interaction with lipid microdomains	FASEB JOURNAL			English	Article						lipid rafts; OGT; PI3K pathway	N-ACETYLGLUCOSAMINE TRANSFERASE; PROTEIN MODIFICATION; GLCNACYLATION; RESISTANCE; PHOSPHORYLATION; RECEPTOR; PATHWAY; CELLS; RAFTS; GLYCOSYLATION	Lipid microdomains (rafts) are cholesterol-enriched dynamic ordered lipid domains belonging to cell membranes involved in diverse cellular functions, including signal transduction, membrane trafficking, and infection. Many studies have reported relationships between insulin signaling and lipid rafts. Likewise, links between insulin signaling and O-GlcNAcylation have also been described. However, the potential connection between O-GlcNAc and raft dynamics remains unexplored. Here we show that O-GlcNAc and the enzyme that creates this modification, O-GlcNAc transferase (OGT), are localized in rafts. On insulin stimulation, we observe time-dependent increases in OGT expression and localization within rafts. We show that these processes depend on activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Inhibition of OGT does not significantly affect cholesterol synthesis and raft building but decreases insulin receptor expression and PI3K and mitogen-activated protein kinase pathway activation. Taken together, these findings indicate that O-GlcNAcylation, lipid rafts, and signaling pathways are spatiotemporally coordinated to enable fundamental cellular functions.Perez-Cervera, Y., Dehennaut, V., Aquino Gil, M., Guedri, K., Solorzano Mata, C. J., Olivier-Van Stichelen, S., Michalski, J.-C., Foulquier, F., Lefebvre, T. Insulin signaling controls the expression of O-GlcNAc transferase and its interaction with lipid microdomains.	[Perez-Cervera, Yobana; Dehennaut, Vanessa; Guedri, Katia; Solorzano Mata, Carlos Josue; Olivier-Van Stichelen, Stephanie; Michalski, Jean-Claude; Foulquier, Francois; Lefebvre, Tony] Univ Lille 1, IFR 147, Unit Struct & Funct Glycobiol, CNRS,UMR 8576, F-59655 Villeneuve Dascq, France; [Perez-Cervera, Yobana; Aquino Gil, Moyira; Solorzano Mata, Carlos Josue] UABJO, UNAM, Ctr Multidisciplinario Invest, Oaxaca, Mexico	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Universidad Autonoma Benito Juarez de Oaxaca; Universidad Nacional Autonoma de Mexico	Lefebvre, T (corresponding author), Univ Lille 1, IFR 147, Unit Struct & Funct Glycobiol, CNRS,UMR 8576, F-59655 Villeneuve Dascq, France.	tony.lefebvre@univ-lille1.fr	olivier-van stichelen, Stephanie/AAH-9328-2021; dehennaut, vanessa/I-7435-2018; Perez-Cervera, Yobana/C-4700-2018; Lefebvre, Tony/AAZ-1724-2021; FOULQUIER, FRANCOIS/AAI-1182-2021; foulquier, francois/ABE-5886-2020; Lefebvre, Tony/AAW-9169-2021	olivier-van stichelen, Stephanie/0000-0002-2033-5241; dehennaut, vanessa/0000-0001-6421-0793; Lefebvre, Tony/0000-0001-9883-2240; foulquier, francois/0000-0002-6551-3240; Foulquier, Francois/0000-0001-5084-4015; GUEDRI-IDJOUADIENE, Katia/0000-0001-8417-5489	University of Lille 1; Centre National de la Recherche Scientifique (CNRS); Franco-Mexican exchange program ECOS NORD [M09S02]; Rosalind Franklin fellowship (Instituto de Ciencia y Tecnologia del Distrito Federal)	University of Lille 1; Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Franco-Mexican exchange program ECOS NORD; Rosalind Franklin fellowship (Instituto de Ciencia y Tecnologia del Distrito Federal)	The authors thank Dr. Andrew J. Thompson for his expert advice in the preparation of DRMs, Jennifer Stallars for her technical assistance, Professor Edgar Zenteno and Dr. Xiaoyong Yang for helpful discussion and continual support, the Bioimaging Core Facility of Lille, Institut de Recherche Interdisciplinaire CNRS, Dr. Tarik Issad and Professor Ralph Schwarz for critical reading of the manuscript, and Dr. David Vocadlo (Simon Fraser University, Burnaby, BC, Canada) for English editing the manuscript and for providing Ac-5SGlcNAc. This work was supported by the University of Lille 1, the Centre National de la Recherche Scientifique (CNRS), and the Franco-Mexican exchange program ECOS NORD No. M09S02. Y.P.C. is the recipient of a Rosalind Franklin fellowship (Instituto de Ciencia y Tecnologia del Distrito Federal). The authors declare no conflicts of interest.	Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; Dehennaut V, 2008, MOL CELL PROTEOMICS, V7, P2229, DOI 10.1074/mcp.M700494-MCP200; Dehennaut V, 2008, BIOCHEM BIOPH RES CO, V369, P539, DOI 10.1016/j.bbrc.2008.02.063; Dehennaut V, 2007, J BIOL CHEM, V282, P12527, DOI 10.1074/jbc.M700444200; Dias WB, 2009, J BIOL CHEM, V284, P21327, DOI 10.1074/jbc.M109.007310; Gandy JC, 2006, FEBS LETT, V580, P3051, DOI 10.1016/j.febslet.2006.04.051; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI 10.1038/NCHEMBIO.520; Guinez C, 2006, GLYCOBIOLOGY, V16, P22, DOI 10.1093/glycob/cwj041; Guinez C, 2008, FASEB J, V22, P2901, DOI 10.1096/fj.07-102509; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Inokuchi J, 2007, YAKUGAKU ZASSHI, V127, P579, DOI 10.1248/yakushi.127.579; JARETT L, 1980, SCIENCE, V210, P1127, DOI 10.1126/science.7003710; Kang ES, 2008, EXP CELL RES, V314, P2238, DOI 10.1016/j.yexcr.2008.04.014; Ku NO, 2010, NAT CELL BIOL, V12, P876, DOI 10.1038/ncb2091; Lazarus MB, 2011, NATURE, V469, P564, DOI 10.1038/nature09638; Liu Y, 2011, J PATHOL, V225, P54, DOI 10.1002/path.2912; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Macauley MS, 2008, J BIOL CHEM, V283, P34687, DOI 10.1074/jbc.M804525200; Majumdar G, 2004, DIABETES, V53, P3184, DOI 10.2337/diabetes.53.12.3184; Olivier-Van Stichelen S, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.36; Park SY, 2005, EXP MOL MED, V37, P220, DOI 10.1038/emm.2005.30; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; Robinson KA, 2007, AM J PHYSIOL-ENDOC M, V292, pE884, DOI 10.1152/ajpendo.00569.2006; Sekine O, 2010, J BIOL CHEM, V285, P38684, DOI 10.1074/jbc.M110.155192; Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Song M, 2008, CELL SIGNAL, V20, P94, DOI 10.1016/j.cellsig.2007.09.002; Thompson AJ, 2009, PROTEOMICS, V9, P3022, DOI 10.1002/pmic.200900006; Uhles S, 2003, J CELL BIOL, V163, P1327, DOI 10.1083/jcb.200306093; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; Wang ZH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000526; Whelan SA, 2008, J BIOL CHEM, V283, P21411, DOI 10.1074/jbc.M800677200; Whelan SA, 2010, J BIOL CHEM, V285, P5204, DOI 10.1074/jbc.M109.077818; Yang WH, 2008, P NATL ACAD SCI USA, V105, P17345, DOI 10.1073/pnas.0806198105; Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668; Zeidan Q, 2010, J CELL SCI, V123, P13, DOI 10.1242/jcs.053678; Zou LY, 2009, AM J PHYSIOL-HEART C, V296, pH515, DOI 10.1152/ajpheart.01025.2008	41	38	38	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3478	3486		10.1096/fj.12-217984	http://dx.doi.org/10.1096/fj.12-217984			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23689613				2022-12-28	WOS:000328840500008
J	Zhang, YQ; Davis, C; Sakellariou, GK; Shi, Y; Kayani, AC; Pulliam, D; Bhattacharya, A; Richardson, A; Jackson, MJ; McArdle, A; Brooks, SV; Van Remmen, H				Zhang, Yiqiang; Davis, Carol; Sakellariou, George K.; Shi, Yun; Kayani, Anna C.; Pulliam, Daniel; Bhattacharya, Arunabh; Richardson, Arlan; Jackson, Malcolm J.; McArdle, Anne; Brooks, Susan V.; Van Remmen, Holly			CuZnSOD gene deletion targeted to skeletal muscle leads to loss of contractile force but does not cause muscle atrophy in adult mice	FASEB JOURNAL			English	Article						oxidative stress; regeneration; central nuclei	CU,ZN SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; ADAPTIVE RESPONSES; FIBERS; AGE; DEFICIENCY; MOUSE; IDENTIFICATION; MECHANISMS; SARCOPENIA	We have previously shown that deletion of CuZnSOD in mice (Sod1(-/-) mice) leads to accelerated loss of muscle mass and contractile force during aging. To dissect the relative roles of skeletal muscle and motor neurons in this process, we used a Cre-Lox targeted approach to establish a skeletal muscle-specific Sod1-knockout (mKO) mouse to determine whether muscle-specific CuZnSOD deletion is sufficient to cause muscle atrophy. Surprisingly, mKO mice maintain muscle masses at or above those of wild-type control mice up to 18 mo of age. In contrast, maximum isometric specific force measured in gastrocnemius muscle is significantly reduced in the mKO mice. We found no detectable increases in global measures of oxidative stress or ROS production, no reduction in mitochondrial ATP production, and no induction of adaptive stress responses in muscle from mKO mice. However, Akt-mTOR signaling is elevated and the number of muscle fibers with centrally located nuclei is increased in skeletal muscle from mKO mice, which suggests elevated regenerative pathways. Our data demonstrate that lack of CuZnSOD restricted to skeletal muscle does not lead to muscle atrophy but does cause muscle weakness in adult mice and suggest loss of CuZnSOD may potentiate muscle regenerative pathways.Zhang, Y., Davis, C., Sakellariou, G.K., Shi, Y., Kayani, A.C., Pulliam, D., Bhattacharya, A., Richardson, A., Jackson, M.J., McArdle, A., Brooks, S.V., Van Remmen, H. CuZnSOD gene deletion targeted to skeletal muscle leads to loss of contractile force but does not cause muscle atrophy in adult mice.	[Zhang, Yiqiang; Davis, Carol] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78249 USA; [Shi, Yun; Pulliam, Daniel; Bhattacharya, Arunabh; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78249 USA; [Zhang, Yiqiang; Shi, Yun; Bhattacharya, Arunabh; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78249 USA; [Richardson, Arlan; Van Remmen, Holly] South Texas Vet Hlth Syst, GRECC, San Antonio, TX USA; [Brooks, Susan V.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Sakellariou, George K.; Kayani, Anna C.; Jackson, Malcolm J.; McArdle, Anne] Univ Liverpool, Dept Musculoskeletal Biol, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; University of Michigan System; University of Michigan; University of Liverpool	Van Remmen, H (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Cellular & Struct Biol, San Antonio, TX 78249 USA.	svbrooks@umich.edu; vanremmen@uthscsa.edu	Zhang, Yiqiang/AAA-3143-2019	Brooks, Susan/0000-0003-1954-967X; Jackson, Malcolm/0000-0003-3683-8297	U.S. National Institute on Aging [AG-020591]; U.S. National Institute of Child Health and Human Development; MRC [G0700919, MR/K006312/1] Funding Source: UKRI; Medical Research Council [G0700919, MR/K006312/1] Funding Source: researchfish; NATIONAL INSTITUTE ON AGING [P30AG013283, P01AG020591] Funding Source: NIH RePORTER	U.S. National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Jose Gomez and Anne Erickson for technical assistance. The work was supported by U.S. National Institute on Aging grant AG-020591. The F1.652 antibody was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the U.S. National Institute of Child Health and Human Development and maintained by The University of Iowa, Department of Biology (Iowa City, IA, USA).	ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Barker T, 2007, J PHYSIOL-LONDON, V583, P421, DOI 10.1113/jphysiol.2007.139378; Baroffio A, 1996, DIFFERENTIATION, V60, P47, DOI 10.1046/j.1432-0436.1996.6010047.x; CAMPBELL MJ, 1973, J NEUROL NEUROSUR PS, V36, P174, DOI 10.1136/jnnp.36.2.174; Chan S, 2007, AM J PHYSIOL-CELL PH, V293, pC985, DOI 10.1152/ajpcell.00128.2007; Ciciliot S, 2010, CURR PHARM DESIGN, V16, P906, DOI 10.2174/138161210790883453; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; DOHERTY TJ, 1993, CAN J APPL PHYSIOL, V18, P331, DOI 10.1139/h93-029; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Fulle S, 2004, EXP GERONTOL, V39, P17, DOI 10.1016/j.exger.2003.09.012; Geiger PC, 2001, J APPL PHYSIOL, V90, P380, DOI 10.1152/jappl.2001.90.1.380; Jang YC, 2010, FASEB J, V24, P1376, DOI 10.1096/fj.09-146308; JOHNSON BD, 1994, J APPL PHYSIOL, V77, P481, DOI 10.1152/jappl.1994.77.1.481; Larkin L. M., 2012, AGE DORDR, DOI 10.1007/s11357-012-9441-7; Larkin LM, 2011, AM J PHYSIOL-REG I, V301, pR1400, DOI 10.1152/ajpregu.00093.2011; Leger B, 2006, J PHYSIOL-LONDON, V576, P923, DOI 10.1113/jphysiol.2006.116715; Lowe DA, 2001, AM J PHYSIOL-CELL PH, V280, pC540, DOI 10.1152/ajpcell.2001.280.3.C540; Lustgarten MS, 2009, AM J PHYSIOL-CELL PH, V297, pC1520, DOI 10.1152/ajpcell.00372.2009; Marcell TJ, 2003, J GERONTOL A-BIOL, V58, P911, DOI 10.1093/gerona/58.10.M911; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; McArdle A, 2001, AM J PHYSIOL-CELL PH, V280, pC621, DOI 10.1152/ajpcell.2001.280.3.C621; McFadden SL, 1999, J COMP NEUROL, V413, P101; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Muller FL, 2008, MUSCLE NERVE, V38, P1173, DOI 10.1002/mus.21049; Muller FL, 2006, FREE RADICAL BIO MED, V40, P1993, DOI 10.1016/j.freeradbiomed.2006.01.036; Palomero J, 2008, ANTIOXID REDOX SIGN, V10, P1463, DOI 10.1089/ars.2007.2009; Plant DR, 2001, CLIN EXP PHARMACOL P, V28, P779, DOI 10.1046/j.1440-1681.2001.03521.x; Sakellariou GK, 2011, AGING CELL, V10, P749, DOI 10.1111/j.1474-9726.2011.00709.x; Shefer Gabi, 2005, Methods Mol Biol, V290, P281; Stern-Straeter J, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-66; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Vasilaki A, 2010, AGING CELL, V9, P979, DOI 10.1111/j.1474-9726.2010.00635.x; Ward WF, 2005, J GERONTOL A-BIOL, V60, P847, DOI 10.1093/gerona/60.7.847; Weichhart T, 2012, METHODS MOL BIOL, V821, P1, DOI 10.1007/978-1-61779-430-8_1; Wu RF, 2010, AUTOPHAGY, V6, P828, DOI 10.1128/MCB.01445-09; Zong YN, 2012, GENE DEV, V26, P247, DOI 10.1101/gad.180885.111	37	48	48	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3536	3548		10.1096/fj.13-228130	http://dx.doi.org/10.1096/fj.13-228130			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729587	Green Published, Green Submitted			2022-12-28	WOS:000328840500014
J	Evani, SJ; Prabhu, RG; Gnanaruban, V; Finol, EA; Ramasubramanian, AK				Evani, Shankar J.; Prabhu, Rajesh G.; Gnanaruban, V.; Finol, Ender A.; Ramasubramanian, Anand K.			Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow	FASEB JOURNAL			English	Article						MDA-MB-231; shear; aggregation	CANCER-CELLS; MELANOMA ADHESION; TNF-ALPHA; CARCINOMA; PROGRESSION; INFLAMMATION; MACROPHAGES; EXTRAVASATION; MIGRATION; INVASION	Endothelial adhesion is necessary for the hematogenous dissemination of tumor cells. However, the metastatic breast tumor cell MDA-MB-231 does not bind to the endothelium under physiological flow conditions, suggesting alternate mechanisms of adhesion. Since monocytes are highly represented in the tumor microenvironment, and also bind to endothelium during inflammation, we hypothesized that the monocytes assist in the arrest of MDA-MB-231 on the endothelium. Using in vitro models of the dynamic shear environment of the vasculature, we show that TNF--activated THP1/primary human monocytes and MDA-MB-231 cells form stable aggregates, and that the monocytes in these aggregates mediate the adhesion of otherwise nonadherent MDA-MB-231 cells to inflamed endothelium under flow (55 +/- 2.4 vs. 1.7 +/- 0.82 at a shear stress of 0.5 dyn/cm(2), P<0.01). We also show that the hydrodynamic forces determine the size and orientation of aggregates adhered to the endothelium, and strongly favor the attachment of small aggregates with tumor cells downstream of flow (74-86% doublets at 0.5-2 dyn/cm(2), P<0.01). The 5-fold up-regulation of ICAM-1 on TNF--activated MDA-MB-231 cells through the Nf-B pathway was found to be critical in MDA-MB-231-monocyte aggregation and endothelial adhesion. Our results demonstrate that, under inflammatory conditions, monocytes may serve to disseminate tumor cells through circulation, and the tumor-monocyte-endothelial axis may represent a new therapeutic target to reduce cancer metastasis.	[Evani, Shankar J.; Prabhu, Rajesh G.; Gnanaruban, V.; Finol, Ender A.; Ramasubramanian, Anand K.] Univ Texas San Antonio, Dept Biomed Engn, San Antonio, TX 78249 USA; [Ramasubramanian, Anand K.] Univ Texas San Antonio, South Texas Ctr Emerging Infect Dis, San Antonio, TX 78249 USA	University of Texas System; University of Texas at San Antonio (UTSA); University of Texas System; University of Texas at San Antonio (UTSA)	Ramasubramanian, AK (corresponding author), Univ Texas San Antonio, Dept Biomed Engn, San Antonio, TX 78249 USA.	anand.ramasubramanian@utsa.edu	Finol, Ender/C-4585-2016; evani, shankar jaikishan/Z-3198-2019	Finol, Ender/0000-0002-0811-9482; 	Breast Cancer Research Program, U.S. Department of Defense [W81XWH-10-1-0754]; U.S. National Institutes of Health [HL112629]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [SC1HL112629] Funding Source: NIH RePORTER	Breast Cancer Research Program, U.S. Department of Defense(United States Department of Defense); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by a grant from the Breast Cancer Research Program, U.S. Department of Defense (W81XWH-10-1-0754), and partially by a grant from the U.S. National Institutes of Health (HL112629).	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Bailey C, 2007, CLIN EXP METASTAS, V24, P121, DOI 10.1007/s10585-007-9060-3; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Blot E, 2003, BRIT J CANCER, V88, P1207, DOI 10.1038/sj.bjc.6600872; Brown ER, 2008, ANN ONCOL, V19, P1340, DOI 10.1093/annonc/mdn054; Burdick MM, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00103; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Chang KC, 2000, P NATL ACAD SCI USA, V97, P11262, DOI 10.1073/pnas.200240897; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dong C, 1999, ANN BIOMED ENG, V27, P298, DOI 10.1114/1.143; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Geng Y, 2010, CELL MOL BIOENG, V3, P361, DOI 10.1007/s12195-010-0145-8; Gramling MW, 2010, EXP CELL RES, V316, P314, DOI 10.1016/j.yexcr.2009.10.024; Haidari M, 2012, J BIOL CHEM, V287, P32981, DOI 10.1074/jbc.M112.395905; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Jadhav S, 2005, BIOPHYS J, V88, P96, DOI 10.1529/biophysj.104.051029; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Julien S, 2011, CANCER RES, V71, P7683, DOI 10.1158/0008-5472.CAN-11-1139; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Konstantopoulos K, 2009, ANNU REV BIOMED ENG, V11, P177, DOI 10.1146/annurev-bioeng-061008-124949; Kumar RA, 2003, BIOPHYS J, V85, P4099, DOI 10.1016/S0006-3495(03)74822-X; Langer HF, 2009, J CELL MOL MED, V13, P1211, DOI 10.1111/j.1582-4934.2009.00811.x; Leek RD, 1996, CANCER RES, V56, P4625; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liang S, 2008, AM J PHYSIOL-CELL PH, V295, pC701, DOI 10.1152/ajpcell.00245.2008; Liang S, 2008, ANN BIOMED ENG, V36, P661, DOI 10.1007/s10439-008-9445-8; Lin EY, 2007, MOL ONCOL, V1, P288, DOI 10.1016/j.molonc.2007.10.003; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073; Mierke CT, 2011, J BIOL CHEM, V286, P40025, DOI 10.1074/jbc.M111.256172; Narasimhan M, 2008, CANCER RES, V68, P5185, DOI 10.1158/0008-5472.CAN-07-6883; Peng HH, 2007, EXP CELL RES, V313, P551, DOI 10.1016/j.yexcr.2006.10.030; Peyri N, 2009, ANTICANCER RES, V29, P2347; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179; Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070; SheenChen SM, 1997, BREAST CANCER RES TR, V43, P211, DOI 10.1023/A:1005736712307; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Zhang P, 2011, J IMMUNOL, V186, P242, DOI 10.4049/jimmunol.1000494; Zhang XH, 2004, BIOPHYS J, V87, P3470, DOI 10.1529/biophysj.104.045690	47	72	76	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3017	3029		10.1096/fj.12-224824	http://dx.doi.org/10.1096/fj.12-224824			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23616566	Green Published			2022-12-28	WOS:000329877600010
J	Wong, J; Si, XN; Angeles, A; Zhang, JC; Shi, JY; Fung, G; Jagdeo, J; Wang, TY; Zhong, ZH; Jan, E; Luo, HL				Wong, Jerry; Si, Xiaoning; Angeles, Arkhjamil; Zhang, Jingchun; Shi, Junyan; Fung, Gabriel; Jagdeo, Julienne; Wang, Tianying; Zhong, Zhaohua; Jan, Eric; Luo, Honglin			Cytoplasmic redistribution and cleavage of AUF1 during coxsackievirus infection enhance the stability of its viral genome	FASEB JOURNAL			English	Article						viral protease 3C; mRNA degradation; nuclear export	NUCLEAR-PORE COMPLEX; RIBOSOME ENTRY SITE; MESSENGER-RNA DECAY; ENCODED PROTEASE 3C(PRO); BINDING-PROTEIN; IN-VITRO; NUCLEOCYTOPLASMIC TRAFFICKING; DEPENDENT TRANSLATION; GENE-EXPRESSION; LA AUTOANTIGEN	Coxsackievirus B3 (CVB3) is a causative agent of viral myocarditis, hepatitis, pancreatitis, and meningitis in humans. The adenosine-uridine (AU)-rich element RNA binding factor 1 (AUF1) is an integral component in the regulation of gene expression. AUF1 destabilizes mRNAs and targets them for degradation by binding to AU-rich elements in the 3 untranslated region (UTR) of mRNAs. The 3-UTR of the CVB3 genome contains canonical AU-rich sequences, raising the possibility that CVB3 RNA may also be subjected to AUF1-mediated degradation. Here, we reported that CVB3 infection led to cytoplasmic redistribution and cleavage of AUF1. These events are independent of CVB3-induced caspase activation but require viral protein production. Overexpression of viral protease 2A reproduced CVB3-induced cytoplasmic redistribution of AUF1, while in vitro cleavage assay revealed that viral protease 3C contributed to AUF1 cleavage. Furthermore, we showed that knockdown of AUF1 facilitated viral RNA, protein, and progeny production, suggesting an antiviral property for AUF1 against CVB3 infection. Finally, an immunoprecipitation study demonstrated the physical interaction between AUF1 and the 3-UTR of CVB3, potentially targeting CVB3 genome toward degradation. Together, our results suggest that cleavage of AUF1 may be a strategy employed by CVB3 to enhance the stability of its viral genome.Wong, J., Si, X., Angeles, A., Zhang, J., Shi, J., Fung, G., Jagdeo, J., Wang, T., Zhong, Z., Jan, E., Luo, H. Cytoplasmic redistribution and cleavage of AUF1 during coxsackievirus infection enhance the stability of its viral genome.	[Wong, Jerry; Si, Xiaoning; Angeles, Arkhjamil; Zhang, Jingchun; Shi, Junyan; Fung, Gabriel; Luo, Honglin] Univ British Columbia, St Pauls Hosp, Providence Heart & Lung Inst, James Hogg Res Ctr, Vancouver, BC V6Z 1Y6, Canada; [Wong, Jerry; Si, Xiaoning; Angeles, Arkhjamil; Zhang, Jingchun; Shi, Junyan; Fung, Gabriel; Luo, Honglin] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada; [Jagdeo, Julienne; Jan, Eric] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6Z 1Y6, Canada; [Wang, Tianying; Zhong, Zhaohua] Harbin Med Univ, Dept Microbiol, Harbin, Peoples R China	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of British Columbia; Harbin Medical University	Luo, HL (corresponding author), Univ British Columbia, St Pauls Hosp, UBC James Hogg Res Ctr, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	honglin.luo@hli.ubc.ca	Zhong, Zhaohua/N-1659-2019; Jan, Eric/O-1923-2019; Shi, Junyan/T-1777-2019	Zhong, Zhaohua/0000-0002-0778-5053; 	Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of British Columbia and Yukon; CIHR	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of British Columbia and Yukon; CIHR(Canadian Institutes of Health Research (CIHR))	The authors thank Dr. Robert J. Schneider (New York University School of Medicine, New York, NY, USA) for his generous gift of the FLAG-tagged AUF1 plasmids. This work was partially supported by the Canadian Institutes of Health Research (CIHR; to H. L.) and the Heart and Stroke Foundation of British Columbia and Yukon (to H.L.). J.W. is a recipient of studentships from the CIHR.	Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; BECK MA, 1990, AM J PATHOL, V136, P669; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Buendia B, 1999, J CELL SCI, V112, P1743; Carthy CM, 1998, J VIROL, V72, P7669, DOI 10.1128/JVI.72.9.7669-7675.1998; Castello A, 2009, J CELL SCI, V122, P3799, DOI 10.1242/jcs.055988; Chau DHW, 2007, APOPTOSIS, V12, P513, DOI 10.1007/s10495-006-0013-0; Chen TM, 2010, NUCLEIC ACIDS RES, V38, P8061, DOI 10.1093/nar/gkq717; Gao GA, 2010, J VIROL, V84, P11056, DOI 10.1128/JVI.00008-10; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Gratacos FM, 2010, WIRES RNA, V1, P457, DOI 10.1002/wrna.26; Gustin KE, 2003, VIRUS RES, V95, P35, DOI 10.1016/S0168-1702(03)00165-5; Gustin KE, 2002, J VIROL, V76, P8787, DOI 10.1128/JVI.76.17.8787-8796.2002; Gustin KE, 2001, EMBO J, V20, P240, DOI 10.1093/emboj/20.1.240; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Huang BL, 2007, J CELL COMMUN SIGNAL, V1, P17, DOI 10.1007/s12079-007-0003-1; Huber S, 2004, VIRAL IMMUNOL, V17, P358, DOI 10.1089/vim.2004.17.358; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; Kim SM, 2004, J VIROL, V78, P13479, DOI 10.1128/JVI.78.24.13479-13488.2004; Knapinska AM, 2011, MOL CELL BIOL, V31, P1419, DOI 10.1128/MCB.00907-10; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lang C, 2008, J MOL MED-JMM, V86, P49, DOI 10.1007/s00109-007-0249-3; Liao BS, 2007, NAT STRUCT MOL BIOL, V14, P511, DOI 10.1038/nsmb1249; Lu JY, 2006, GENE DEV, V20, P3174, DOI 10.1101/gad.1467606; Lu JY, 2006, RNA, V12, P883, DOI 10.1261/rna.2308106; Luo HL, 2003, J VIROL, V77, P1, DOI 10.1128/JVI.77.1.1-9.2003; Luo HL, 2002, J VIROL, V76, P3365, DOI 10.1128/JVI.76.7.3365-3373.2002; Luo HH, 2010, CARDIOVASC RES, V85, P347, DOI 10.1093/cvr/cvp225; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Paek KY, 2008, J VIROL, V82, P12082, DOI 10.1128/JVI.01405-08; Park N, 2008, J VIROL, V82, P1647, DOI 10.1128/JVI.01670-07; Park N, 2010, J BIOL CHEM, V285, P28796, DOI 10.1074/jbc.M110.143404; Peritz T, 2006, NAT PROTOC, V1, P577, DOI 10.1038/nprot.2006.82; Rassmann A, 2013, J VIROL METHODS, V187, P190, DOI 10.1016/j.jviromet.2012.08.025; Ray PS, 2002, NUCLEIC ACIDS RES, V30, P4500, DOI 10.1093/nar/gkf583; Si XN, 2005, J VIROL, V79, P13875, DOI 10.1128/JVI.79.22.13875-13881.2005; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Tracy S, 2008, CURR TOP MICROBIOL, V323, P49; Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998; Wang LL, 2012, ANTIVIR RES, V93, P270, DOI 10.1016/j.antiviral.2011.12.004; Wang YC, 2011, AM J CHINESE MED, V39, P1219, DOI 10.1142/S0192415X11009512; Wong J, 2006, J VIROL METHODS, V133, P211, DOI 10.1016/j.jviromet.2005.11.013; Wong J, 2012, CELL RES, V22, P360, DOI 10.1038/cr.2011.114; Yalamanchili P, 1997, VIROLOGY, V239, P176, DOI 10.1006/viro.1997.8862; Yalamanchili P, 1997, J VIROL, V71, P1220, DOI 10.1128/JVI.71.2.1220-1226.1997; Zhang JC, 2011, FEBS LETT, V585, P261, DOI 10.1016/j.febslet.2010.11.056; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	50	35	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2777	2787		10.1096/fj.12-226498	http://dx.doi.org/10.1096/fj.12-226498			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23572232				2022-12-28	WOS:000328841000026
J	Zhao, J; Mialki, RK; Wei, JX; Coon, TA; Zou, CB; Chen, BB; Mallampalli, RK; Zhao, YT				Zhao, Jing; Mialki, Rachel K.; Wei, Jianxin; Coon, Tiffany A.; Zou, Chunbin; Chen, Bill B.; Mallampalli, Rama K.; Zhao, Yutong			SCF E3 ligase F-box protein complex SCFFBXL19 regulates cell migration by mediating Rac1 ubiquitination and degradation	FASEB JOURNAL			English	Article						small GTPase protein; protein stability; phosphorylation; cell motility	I-KAPPA-B; SIGNAL-INDUCED UBIQUITINATION; BRONCHIAL EPITHELIAL-CELLS; DEPENDENT PROTEOLYSIS; C-MYC; PHOSPHORYLATION; KINASE; UBIQUITYLATION; ACETYLATION; RECEPTOR	Rac1, a member of the Rho family of GTPases, regulates diverse cellular functions, including cytoskeleton reorganization and cell migration. F-box proteins are major subunits within the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligases that recognize specific substrates for ubiquitination. The role of F-box proteins in regulating Rac1 stability has not been studied. Mouse lung epithelial (MLE12) cells were used to investigate Rac1 stability and cell migration. Screening of an F-box protein library and in vitro ubiquitination assays identified FBXL19, a relatively new member of the F-box protein family that targets Rac1 for its polyubiquitination and proteasomal degradation. Overexpression of FBXL19 decreased both Rac1 active and inactive forms and significantly reduced cellular migration. Protein kinase AKT-mediated phosphorylation of Rac1 at serine(71) was essential for FBXL19-mediated Rac1 ubiquitination and depletion. Lysine(166) within Rac1 was identified as a polyubiquitination acceptor site. Rac1(S71A) and Rac1(K166R) mutant proteins were resistant to FBXL19-mediated ubiquitination and degradation. Further, ectopically expressed FBXL19 reduced cell migration in Rac1-overexpressing cells (P<0.01, Rac1 cells vs. FBXL19+Rac1 cells), but not in Rac1 lysine(166) mutant-overexpressing cells. FBXL19 diminished formation of the migratory leading edge. Thus, SCFFBXL19 targets Rac1 for its disposal, a process regulated by AKT. These findings provide the first evidence of an F-box protein targeting a small G protein for ubiquitination and degradation to modulate cell migration.Zhao, J., Mialki, R. K., Wei, J., Coon, T. A., Zou, C., Chen, B. B., Mallampalli, R. K., Zhao, Y. SCF E3 ligase F-box protein complex SCFFBXL19 regulates cell migration by mediating Rac1 ubiquitination and degradation.	[Zhao, Jing; Mialki, Rachel K.; Wei, Jianxin; Coon, Tiffany A.; Zou, Chunbin; Chen, Bill B.; Mallampalli, Rama K.; Zhao, Yutong] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Zhao, Jing; Mialki, Rachel K.; Wei, Jianxin; Coon, Tiffany A.; Zou, Chunbin; Chen, Bill B.; Mallampalli, Rama K.; Zhao, Yutong] Univ Pittsburgh, Sch Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA; [Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Zhao, YT (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, 3459 5th Ave,NW 628 MUH, Pittsburgh, PA 15213 USA.	zhaoy3@upmc.edu	Zou, Chunbin/L-7488-2019; Wei, Jianxin/P-5431-2016	Zou, Chunbin/0000-0003-1355-4726; 	U.S. National Institutes of Health [RO1 HL01916, HL112791, HL097376, HL098174, HL116472]; American Heart Association [12SDG9050005, 12SDG12040330]; Merit Review Award from the United States; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL116472, R01HL098174, R01HL091916, R01HL097376, R01HL112791] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002200] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Merit Review Award from the United States; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by U.S. National Institutes of Health grants RO1 HL01916 and HL112791 (to Y.Z.), HL097376 and HL098174 (to R. K. M.), and HL116472 (to B. B. C.); American Heart Association awards 12SDG9050005 (to J.Z.) and 12SDG12040330 (to C.Z.); and a Merit Review Award from the United States (to R. K. M.). The authors declare no conflicts of interest.	Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chen BB, 2011, CELL CYCLE, V10, P3487, DOI 10.4161/cc.10.20.17742; Chen BB, 2011, MOL CELL BIOL, V31, P1905, DOI 10.1128/MCB.00723-10; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Desai LP, 2004, AM J PHYSIOL-LUNG C, V287, pL1134, DOI 10.1152/ajplung.00022.2004; Dogan T, 2008, NAT CELL BIOL, V10, P1447, DOI 10.1038/ncb1804; Filippi MD, 2007, BLOOD, V109, P1257, DOI 10.1182/blood-2006-04-017731; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gustin C, 2008, AM J PHYSIOL-CELL PH, V295, pC905, DOI 10.1152/ajpcell.00544.2007; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ho MS, 2006, J BIOMED SCI, V13, P181, DOI 10.1007/s11373-005-9058-2; Hoeck JD, 2010, NAT NEUROSCI, V13, P1365, DOI 10.1038/nn.2644; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Klotz K, 2009, EXP CELL RES, V315, P1832, DOI 10.1016/j.yexcr.2008.11.017; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tanaka K, 2001, BIOCHIMIE, V83, P351, DOI 10.1016/S0300-9084(01)01237-8; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; ten Klooster JP, 2007, EMBO J, V26, P336, DOI 10.1038/sj.emboj.7601518; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; Wang YP, 2008, EXP MOL PATHOL, V85, P122, DOI 10.1016/j.yexmp.2008.06.001; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Zhao J, 2012, NAT IMMUNOL, V13, P651, DOI 10.1038/ni.2341; Zhao J, 2012, J BIOL CHEM, V287, P19105, DOI 10.1074/jbc.M112.339507; Zhao J, 2011, BIOCHEM J, V439, P45, DOI 10.1042/BJ20110274; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zolk O, 2006, CARDIOVASC RES, V70, P410, DOI 10.1016/j.cardiores.2005.12.021; Zou CB, 2011, J BIOL CHEM, V286, P2719, DOI 10.1074/jbc.M110.192377	45	50	51	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2611	2619		10.1096/fj.12-223099	http://dx.doi.org/10.1096/fj.12-223099			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23512198	Green Published			2022-12-28	WOS:000328841000010
J	Behring, JB; Kumar, V; Whelan, SA; Chauhan, P; Siwik, DA; Costello, CE; Colucci, WS; Cohen, RA; McComb, ME; Bachschmid, MM				Behring, Jessica B.; Kumar, Vikas; Whelan, Stephen A.; Chauhan, Pratibha; Siwik, Deborah A.; Costello, Catherine E.; Colucci, Wilson S.; Cohen, Richard A.; McComb, Mark E.; Bachschmid, Markus M.			Does reversible cysteine oxidation link the Western diet to cardiac dysfunction?	FASEB JOURNAL			English	Article						oxidative post-translational modifications; reactive oxygen and nitrogen species; obesity; metabolic heart disease	NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; OBESITY; MOUSE; HEART	Using a novel cysteine thiol labeling strategy coupled with mass spectrometric analysis, we identified and quantified the changes in global reversible cysteine oxidation of proteins in the left ventricle of hearts from mice with metabolic syndrome-associated diastolic dysfunction. This phenotype was induced by feeding a high-fat, high-sucrose, type-2 diabetogenic diet to C57BL/6J mice for 8 mo. The extent of reversible thiol oxidation in relationship to the total available (free and reducible) level of each cysteine could be confidently determined for 173 proteins, of which 98 contained cysteines differentially modified 1.5-fold by the diet. Our findings suggest that the metabolic syndrome leads to potentially deleterious changes in the oxidative modification of metabolically active proteins. These alterations may adversely regulate energy substrate flux through glycolysis, -oxidation, citric acid (TCA) cycle, and oxidative phosphorylation (oxphos), thereby contributing to maladaptive tissue remodeling that is associated with, and possibly contributing to, diastolic left ventricular dysfunction.Behring, J. B., Kumar, V., Whelan, S. A., Chauhan, P., Siwik, D. A., Costello, C. E., Colucci, W. S., Cohen, R. A., McComb M. E., Bachschmid, M. M. Does reversible cysteine oxidation link the Western diet to cardiac dysfunction?	[Behring, Jessica B.; Kumar, Vikas; Chauhan, Pratibha; Cohen, Richard A.; McComb, Mark E.; Bachschmid, Markus M.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Vasc Biol Sect, Boston, MA 02118 USA; [Siwik, Deborah A.; Colucci, Wilson S.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Myocardial Unit, Boston, MA 02118 USA; [Whelan, Stephen A.; Costello, Catherine E.; McComb, Mark E.] Boston Univ, Sch Med, Ctr Biomed Mass Spectrometry, Cardiovasc Prote Ctr, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Bachschmid, MM (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Vasc Biol Sect, Boston, MA 02118 USA.	mccomb@bu.edu; bach@bu.edu	Whelan, Stephen A/I-9502-2012; McComb, Mark E/I-3193-2014	Whelan, Stephen A/0000-0002-4740-0795; Whelan, Stephen A/0000-0002-5439-6501; Bachschmid, Markus Michael/0000-0002-0748-5528; /0000-0002-1070-6408; Costello, Catherine/0000-0003-1594-5122; /0000-0002-4249-485X; /0000-0002-7166-327X	National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), U.S. Department of Health and Human Services [HHSN268201000031C]; NIH [P01-HL-068758, R37-HL-104017, HL-064750, HL-31607]; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068758, T32HL007501, R01HL031607, R01HL064750, R37HL104017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM104603] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), U.S. Department of Health and Human Services; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank David R. Pimentel and Aaron L. Sverdlov for many helpful discussions and editing of the manuscript. This work was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), U.S. Department of Health and Human Services, under contract HHSN268201000031C, as well as by NIH grants P01-HL-068758, R37-HL-104017, HL-064750, and HL-31607, and its contents are solely the responsibility of the authors and do not represent the official views of the awarding offices. The authors declare no conflicts of interest.	Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Freeman H, 2006, CELL METAB, V3, P35, DOI 10.1016/j.cmet.2005.10.008; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Jeong J., 2011, MOL CELL PROTEOMICS, V10, P1; Kumar V, 2013, FREE RADICAL BIO MED, V58, P109, DOI 10.1016/j.freeradbiomed.2013.01.021; LOCONTE M, 2013, OXIDATIVE STRESS RED; Murray CI, 2012, CIRC RES, V111, P1253, DOI 10.1161/CIRCRESAHA.112.278721; Murray CI, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013441; Nicholson A, 2010, OBESITY, V18, P1902, DOI 10.1038/oby.2009.477; Petro AE, 2004, METABOLISM, V53, P454, DOI 10.1016/j.metabol.2003.11.018; Qin FZ, 2012, CIRCULATION, V125, P1757, DOI 10.1161/CIRCULATIONAHA.111.067801; Reisz JA, 2013, FEBS J, V280, P6150, DOI 10.1111/febs.12535; Rosiers CD, 2011, CARDIOVASC RES, V90, P210, DOI 10.1093/cvr/cvr055; Sharma V, 2010, MOL CELL BIOCHEM, V337, P223, DOI 10.1007/s11010-009-0303-2; Wu RH, 2011, NAT METHODS, V8, P677, DOI [10.1038/nmeth.1636, 10.1038/NMETH.1636]	15	28	28	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					1975	1987		10.1096/fj.13-233445	http://dx.doi.org/10.1096/fj.13-233445			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24469991	Green Published			2022-12-28	WOS:000335336000003
J	Zurkinden, L; Solca, C; Vogeli, IA; Vogt, B; Ackermann, D; Erickson, SK; Frey, FJ; Sviridov, D; Escher, G				Zurkinden, Line; Solca, Curzio; Voegeli, Isabelle A.; Vogt, Bruno; Ackermann, Daniel; Erickson, Sandra K.; Frey, Felix J.; Sviridov, Dmitri; Escher, Genevieve			Effect of Cyp27A1 gene dosage on atherosclerosis development in ApoE-knockout mice	FASEB JOURNAL			English	Article						27-hydroxycholesterol; LDL; VLDL fraction; CYP3A11	STEROL 27-HYDROXYLASE GENE; BILE-ACID BIOSYNTHESIS; CEREBROTENDINOUS XANTHOMATOSIS; SIDE-CHAIN; X-RECEPTOR; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; CHOLESTEROL EFFLUX; MECHANISM; MACROPHAGES; METABOLISM	In humans, sterol 27-hydroxylase (CYP27A1) deficiency leads to cholesterol deposition in tendons and vasculature. Thus, in addition to its role in bile acid synthesis, where it converts cholesterol to 27-hydroxycholesterol (27-OHC), CYP27A1 may also be atheroprotective. Cyp27A1-deficient (Cyp27A1(-/-)) mice were crossed with apolipoprotein E (apoE)-deficient mice. Cyp27A1(+/+)/apoE(-/-) [ApoE-knockout (KO)], Cyp27A1(+/-)/apoE(-/-) heterozygous (het), and Cyp27A1(-/-)/apoE(-/-) [double-knockout (DKO)] mice were challenged with a Western diet (WD) for 3 and 6 mo. ApoE-KO mice fed a chow diet or a WD were used as the control. The severity of atherosclerosis in DKO mice was reduced 10-fold. Compared with the control, the DKO mice had no 27-OHC, total plasma cholesterol and low-density lipoprotein and very low density lipoprotein (LDL/VLDL) concentrations were reduced 2-fold, and HDL was elevated 2-fold. Expression of hepatic CYP7A1, CYP3A, and CYP8B1 were 5- to 10-fold higher. 3-Hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) activity increased 4-fold. Fecal cholesterol was increased. In contrast, het mice fed a WD developed accelerated atherosclerosis and severe skin lesions, possibly because of reduced reverse cholesterol transport due to diminished 27-OHC production. CYP27A1 activity is involved in the control of cholesterol homeostasis and development of atherosclerosis with a distinct gene dose-dependent effect.Zurkinden, L., Solca, C., Vogeli, I. A., Vogt, B., Ackermann, D., Erickson, S. K., Frey, F. J., Sviridov, D., Escher, G. Effect of Cyp27A1 gene dosage on atherosclerosis development in ApoE-knockout mice.	[Zurkinden, Line; Solca, Curzio; Voegeli, Isabelle A.; Vogt, Bruno; Ackermann, Daniel; Frey, Felix J.; Escher, Genevieve] Univ Hosp Bern, Dept Nephrol Hypertens & Clin Pharmacol, CH-3010 Bern, Switzerland; [Zurkinden, Line; Voegeli, Isabelle A.] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Erickson, Sandra K.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Sviridov, Dmitri] Baker Heart & Diabet Inst, Melbourne, Vic, Australia	University of Bern; University Hospital of Bern; University of Bern; University of California System; University of California San Francisco; Baker Heart and Diabetes Institute	Escher, G (corresponding author), Univ Hosp Bern, Dept Nephrol Hypertens & Clin Pharmacol, CH-3010 Bern, Switzerland.	genevieve.escher@dkf.unibe.ch	Vogt, Bruno/AAS-2876-2020; Sviridov, Dmitri/E-7943-2010	Vogt, Bruno/0000-0002-1548-6387; Escher, Genevieve/0000-0002-5125-2262	Foundation Banca del Ceresio; Swiss National Foundation [310030-122133]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	Foundation Banca del Ceresio; Swiss National Foundation(Swiss National Science Foundation (SNSF)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Prof. Jurg Reichen for critical discussion of the manuscript and Ms. Beatrice Blanchard for technical help. This work was supported by grants from the Foundation Banca del Ceresio (to C.S.) and Swiss National Foundation grant 310030-122133 (to G.E.). D.S. is a fellow of the National Health and Medical Research Council of Australia.	Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Bavner A, 2010, J LIPID RES, V51, P2722, DOI 10.1194/jlr.M008326; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM I, 1994, SCAND J GASTROENTERO, V29, P68, DOI 10.3109/00365529409103629; Bjorkhem I, 2010, BIOCHEM BIOPH RES CO, V396, P46, DOI 10.1016/j.bbrc.2010.02.140; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Burkard I, 2004, J LIPID RES, V45, P776, DOI 10.1194/jlr.D300036-JLR200; CALI JJ, 1991, J BIOL CHEM, V266, P7779; Dias V, 2011, J PHARM BIOALLIED SC, V3, P453, DOI 10.4103/0975-7406.84465; Diekstra FP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035333; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Dubrac S, 2005, J LIPID RES, V46, P76, DOI 10.1194/jlr.M400219-JLR200; Erickson SK, 2003, J LIPID RES, V44, P1001, DOI 10.1194/jlr.M200489-JLR200; Escher G, 2003, J BIOL CHEM, V278, P11015, DOI 10.1074/jbc.M212780200; Goodwin B, 2003, P NATL ACAD SCI USA, V100, P223, DOI 10.1073/pnas.0237082100; Honda A, 2005, J LIPID RES, V46, P287, DOI 10.1194/jlr.M400256-JLR200; Honda A, 2001, J BIOL CHEM, V276, P34579, DOI 10.1074/jbc.M103025200; LOCKET PL, 1989, LIPIDS, V24, P221, DOI 10.1007/BF02535238; Mateos L, 2011, J BIOL CHEM, V286, P25574, DOI 10.1074/jbc.M111.236877; Monson DM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1087, DOI 10.1001/archophthalmol.2011.219; Mukhamedova N, 2008, J LIPID RES, V49, P2312, DOI 10.1194/jlr.M800095-JLR200; Norlin M, 2003, J LIPID RES, V44, P1515, DOI 10.1194/jlr.M300047-JLR200; Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816; Quattropani C, 2001, J CLIN INVEST, V108, P1299, DOI 10.1172/JCI200112745; Rafiq M, 2011, Pract Neurol, V11, P296, DOI 10.1136/practneurol-2011-000003; Reichwaldt I, 2010, J PEDIATR SURG, V45, pE9, DOI 10.1016/j.jpedsurg.2010.06.030; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; STONE BG, 1985, J CLIN INVEST, V76, P1773, DOI 10.1172/JCI112168; Verrips A, 1999, METABOLISM, V48, P233, DOI 10.1016/S0026-0495(99)90040-9	32	14	14	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1198	1209		10.1096/fj.13-233791	http://dx.doi.org/10.1096/fj.13-233791			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24327605	Green Published			2022-12-28	WOS:000335324800015
J	Blanchard, E; Zlock, L; Lao, A; Mika, D; Namkung, W; Xie, M; Scheitrum, C; Gruenert, DC; Verkman, AS; Finkbeiner, WE; Conti, M; Richter, W				Blanchard, Elise; Zlock, Lorna; Lao, Anna; Mika, Delphine; Namkung, Wan; Xie, Moses; Scheitrum, Colleen; Gruenert, Dieter C.; Verkman, Alan S.; Finkbeiner, Walter E.; Conti, Marco; Richter, Wito			Anchored PDE4 regulates chloride conductance in wild-type and Delta F508-CFTR human airway epithelia	FASEB JOURNAL			English	Article						cystic fibrosis; cyclic nucleotide phosphodiesterase; cAMP; corrector	CYSTIC-FIBROSIS; PULMONARY-DISEASE; PHOSPHODIESTERASE-4 INHIBITOR; CHANNEL ACTIVITY; CFTR EXPRESSION; IN-VITRO; CAMP; ROFLUMILAST; RESCUE; INFLAMMATION	Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) that impair its expression and/or chloride channel function. Here, we provide evidence that type 4 cyclic nucleotide phosphodiesterases (PDE4s) are critical regulators of the cAMP/PKA-dependent activation of CFTR in primary human bronchial epithelial cells. In non-CF cells, PDE4 inhibition increased CFTR activity under basal conditions (I-SC 7.1 A/cm(2)) and after isoproterenol stimulation (increased I-SC from 13.9 to 21.0 A/cm(2)) and slowed the return of stimulated CFTR activity to basal levels by >3-fold. In cells homozygous for F508-CFTR, the most common mutation found in CF, PDE4 inhibition alone produced minimal channel activation. However, PDE4 inhibition strongly amplified the effects of CFTR correctors, drugs that increase expression and membrane localization of CFTR, and/or CFTR potentiators, drugs that increase channel gating, to reach approximate to 25% of the chloride conductance observed in non-CF cells. Biochemical studies indicate that PDE4s are anchored to CFTR and mediate a local regulation of channel function. Taken together, our results implicate PDE4 as an important determinant of CFTR activity in airway epithelia, and support the use of PDE4 inhibitors to potentiate the therapeutic benefits of CFTR correctors and potentiators.Blanchard, E., Zlock, L., Lao, A., Mika, D., Namkung, W., Xie, M., Scheitrum, C., Gruenert, D.C., Verkman, A.S., Finkbeiner, W.E., Conti, M., Richter, W. Anchored PDE4 regulates chloride conductance in wild type and F508-CFTR human airway epithelia.	[Blanchard, Elise; Mika, Delphine; Xie, Moses; Scheitrum, Colleen; Conti, Marco; Richter, Wito] Univ Calif San Francisco, Inst Human Genet, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; [Zlock, Lorna; Lao, Anna; Finkbeiner, Walter E.] Univ Calif San Francisco, Dept Pathol, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA; [Namkung, Wan; Verkman, Alan S.] Univ Calif San Francisco, Dept Med, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA; [Namkung, Wan; Verkman, Alan S.] Univ Calif San Francisco, Dept Physiol, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA; [Gruenert, Dieter C.] Univ Calif San Francisco, Inst Human Genet, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA; [Namkung, Wan] Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, Inchon, South Korea	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yonsei University	Richter, W (corresponding author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 513 Parnassus Ave,Box 0556, San Francisco, CA 94143 USA.	richterw@obgyn.ucsf.edu	Mika, Delphine/Q-2808-2018	Richter, Wito/0000-0001-5588-9060	Cystic Fibrosis Foundation [RDP R613-CR11]; U.S. National Institutes of Health [HL107960, HL0927088, DK072517]; Elizabeth Nash Postdoctoral Fellowship from Cystic Fibrosis Research Inc. (CFRI); Pennsylvania Cystic Fibrosis, Inc.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL107960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517] Funding Source: NIH RePORTER	Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Elizabeth Nash Postdoctoral Fellowship from Cystic Fibrosis Research Inc. (CFRI); Pennsylvania Cystic Fibrosis, Inc.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the Cystic Fibrosis Foundation (pilot grant to W. R.; RDP R613-CR11 to A. S. V. and W. E. F.) and grants from the U.S. National Institutes of Health (HL107960 to W. R.; HL0927088 to M. C.; DK072517 to A. S. V and W. E. F.). E. B. is supported by an Elizabeth Nash Postdoctoral Fellowship from Cystic Fibrosis Research Inc. (CFRI), and D. C. G. was supported, in part, by funds from Pennsylvania Cystic Fibrosis, Inc.	Amaral MD, 2011, CURR DRUG TARGETS, V12, P683; Amaral MD, 2005, PEDIATR PULM, V39, P479, DOI 10.1002/ppul.20168; Barnes AP, 2005, J BIOL CHEM, V280, P7997, DOI 10.1074/jbc.M407521200; Bolger GB, 2006, BIOCHEM J, V398, P23, DOI 10.1042/BJ20060423; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Cantin AM, 2006, AM J RESP CRIT CARE, V173, P1139, DOI 10.1164/rccm.200508-1330OC; Cheng J, 2010, MOL BIOL CELL, V21, P1178, DOI 10.1091/mbc.E09-03-0229; Chiaw PK, 2011, ESSAYS BIOCHEM, V50, P233, DOI [10.1042/BSE0500233, 10.1042/bse0500233]; Clunes LA, 2012, FASEB J, V26, P533, DOI 10.1096/fj.11-192377; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Dransfield MT, 2013, CHEST, V144, P498, DOI 10.1378/chest.13-0274; Elizur A, 2008, CHEST, V133, P489, DOI 10.1378/chest.07-1631; Fabbri LM, 2009, LANCET, V374, P695, DOI 10.1016/S0140-6736(09)61252-6; Farinha CM, 2013, CHEM BIOL, V20, P943, DOI 10.1016/j.chembiol.2013.06.004; Francis SH, 2011, HANDB EXP PHARMACOL, V204, P47, DOI [10.1007/978-3-642-17969-3_2, 10.1007/978-3-642-13443-2_4]; Giembycz MA, 2008, BRIT J PHARMACOL, V155, P288, DOI 10.1038/bjp.2008.297; Giembycz MA, 2010, DRUG DES DEV THER, V4, P147; GRUBB B, 1993, AM J RESP CELL MOL, V8, P454, DOI 10.1165/ajrcmb/8.4.454; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Hatzelmann A, 2010, PULM PHARMACOL THER, V23, P235, DOI 10.1016/j.pupt.2010.03.011; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; Illek B, 2008, CELL PHYSIOL BIOCHEM, V22, P57, DOI 10.1159/000149783; Jin S-L Catherine, 2012, Chang Gung Med J, V35, P197; Kelley TJ, 1996, J CLIN INVEST, V98, P513, DOI 10.1172/JCI118819; KELLEY TJ, 1995, AM J RESP CELL MOL, V13, P657, DOI 10.1165/ajrcmb.13.6.7576703; Lee JH, 2007, J BIOL CHEM, V282, P10414, DOI 10.1074/jbc.M610857200; LeSimple P, 2010, J PHYSIOL-LONDON, V588, P1195, DOI 10.1113/jphysiol.2009.182246; Li CY, 2005, PHARMACOL THERAPEUT, V108, P208, DOI 10.1016/j.pharmthera.2005.04.004; Liu SS, 2005, J PHARMACOL EXP THER, V314, P846, DOI 10.1124/jpet.105.083519; Loo TW, 2006, BIOCHEM J, V395, P537, DOI 10.1042/BJ20060013; Lukacs GL, 2012, TRENDS MOL MED, V18, P81, DOI 10.1016/j.molmed.2011.10.003; McPhail GL, 2013, DRUG TODAY, V49, P253, DOI 10.1358/dot.2013.49.4.1940984; Monterisi S, 2012, J CELL SCI, V125, P1106, DOI 10.1242/jcs.089086; Nichols D, 2008, CLIN REV ALLERG IMMU, V34, P146, DOI 10.1007/s12016-007-8039-9; Nichols DP, 2008, CLIN REV ALLERG IMMU, V35, P135, DOI 10.1007/s12016-008-8081-2; Okiyoneda T, 2013, NAT CHEM BIOL, V9, P444, DOI [10.1038/NCHEMBIO.1253, 10.1038/nchembio.1253]; Page CP, 2011, HANDB EXP PHARMACOL, V204, P391, DOI 10.1007/978-3-642-17969-3_17; Penmatsa H, 2010, MOL BIOL CELL, V21, P1097, DOI 10.1091/mbc.E09-08-0655; Pettit RS, 2012, ANN PHARMACOTHER, V46, P1065, DOI 10.1345/aph.1R076; Powell K, 2002, ADV DRUG DELIVER REV, V54, P1395, DOI 10.1016/S0169-409X(02)00148-5; Ramalho AS, 2002, AM J RESP CELL MOL, V27, P619, DOI 10.1165/rcmb.2001-0004OC; Richter W, 2005, BIOCHEM J, V388, P803, DOI 10.1042/BJ20050030; Richter W, 2004, J BIOL CHEM, V279, P30338, DOI 10.1074/jbc.M312687200; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Richter W, 2008, EMBO J, V27, P384, DOI 10.1038/sj.emboj.7601968; Richter W, 2013, EXPERT OPIN THER TAR, V17, P1011, DOI 10.1517/14728222.2013.818656; Richter W, 2013, EMBO REP, V14, P276, DOI 10.1038/embor.2013.4; Rowe SM, 2010, PULM PHARMACOL THER, V23, P268, DOI 10.1016/j.pupt.2010.02.001; Schultz BD, 1999, J MEMBRANE BIOL, V170, P51, DOI 10.1007/s002329900537; Shakur Y, 2002, CARDIOVASC DRUG THER, V16, P417, DOI 10.1023/A:1022186402442; Sloane PA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039809; Srivani P, 2008, CURR PHARM DESIGN, V14, P3854, DOI 10.2174/138161208786898653; Stoltz DA, 2013, J CLIN INVEST, V123, P2685, DOI 10.1172/JCI68867; Thelin WR, 2005, J BIOL CHEM, V280, P41512, DOI 10.1074/jbc.M507308200; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Van Goor F, 2011, P NATL ACAD SCI USA, V108, P18843, DOI 10.1073/pnas.1105787108; Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106; Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780; Watson MJ, 2011, FASEB J, V25, P2996, DOI 10.1096/fj.11-186080; Xie M, 2011, MOL PHARMACOL, V80, P281, DOI 10.1124/mol.111.071134; Zhang KYJ, 2005, EXPERT OPIN THER TAR, V9, P1283, DOI 10.1517/14728222.9.6.1283; Zhang LL, 2013, AM J PATHOL, V182, P1986, DOI 10.1016/j.ajpath.2013.02.008	65	26	27	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					791	801		10.1096/fj.13-240861	http://dx.doi.org/10.1096/fj.13-240861			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24200884	Green Published			2022-12-28	WOS:000331072200026
J	Gorbatenko, A; Olesen, CW; Morup, N; Thiel, G; Kallunki, T; Valen, E; Pedersen, SF				Gorbatenko, Andrej; Olesen, Christina W.; Morup, Nina; Thiel, Gerald; Kallunki, Tuula; Valen, Eivind; Pedersen, Stine F.			ErbB2 upregulates the Na+,HCO3 (-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4	FASEB JOURNAL			English	Article						HER2; MCF-7; KLF4	TRANSCRIPTION START-SITE; PH CONTROL; RECEPTOR; SP1; NBCN1; GENE; IDENTIFICATION; ACTIVATION; EXPRESSION; PROMOTER	Misregulation of acid-base transport plays central roles in cancer development. We previously demonstrated the strong up-regulation of the Na+,HCO3- cotransporter NBCn1 (SLC4A7) in MCF-7 breast cancer cells by a truncated, constitutively active ErbB2 (HER2) receptor, NErbB2, and showed that NBCn1 expression and activity are increased in breast cancer tissue from patients. Here, we present the first in-depth characterization of an SLC4A7 promoter and identify its minimal NErbB2-sensitive region. Inhibition or siRNA-mediated knockdown of PI3K, Akt1, ERK1/2, or Src decreased the NBCn1 protein level in NErbB2-expressing MCF-7 cells by approximate to 50, 60, 30 and 35%, respectively. Further, knockdown of the transcription factor Kruppel-like factor 4 (KLF4) reduced NBCn1 protein expression by approximate to 40%, and KLF4 overexpression increased NBCn1 expression by 50-80%. In contrast, knockdown of the closely related transcription factor specificity protein 1 (Sp1) or transfection with dominant-negative Sp1 increased NBCn1 expression by approximate to 35 and approximate to 50%, respectively. NBCn1 expression was also increased by stimulation of full-length ErbB1, -2, and -3 receptors in SKBr3 cells (1.5- and 2-fold by NRG1 or EGF, respectively) or after their exogenous expression in MCF-7 cells. Finally, stimulation with NRG1 or EGF more than doubled acid extrusion capacity in SKBr3 cells. In conclusion, NBCn1 is strongly upregulated by ErbB receptor signaling in a manner involving opposite effects of KLF4 and Sp1, transcription factors with central roles in cancer development. ErbB-induced up-regulation of NBCn1-mediated acid extrusion may play important physiological and pathophysiological roles in the breast epithelium and other tissues with high ErbB receptor levels.Gorbatenko, A., Olesen, C. W., MOrup, N., Thiel, G., Kallunki, T., Valen, E., Pedersen, S. F. ErbB2 upregulates the Na+,HCO3--cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4.	[Gorbatenko, Andrej; Olesen, Christina W.; Morup, Nina; Pedersen, Stine F.] Univ Copenhagen, Dept Biol, Sect Cell & Dev Biol, DK-2100 Copenhagen, Denmark; [Thiel, Gerald] Univ Saarland, Med Ctr, Homburg, Germany; [Kallunki, Tuula] Danish Canc Soc Res Ctr, Unit Cell Death & Metab, Copenhagen, Denmark; [Valen, Eivind] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University of Copenhagen; Saarland University; Danish Cancer Society; Harvard University	Pedersen, SF (corresponding author), Univ Copenhagen, Dept Biol, 13 Univ Pk, DK-2100 Copenhagen, Denmark.	sfpedersen@bio.ku.dk	Pedersen, Stine Falsig/M-8347-2014; Pedersen, Stine Falsig/O-1133-2019; Nygaard, Nina Mørup/GSD-9456-2022; Valen, Eivind/A-8617-2011	Pedersen, Stine Falsig/0000-0002-3044-7714; Pedersen, Stine Falsig/0000-0002-3044-7714; Nygaard, Nina Mørup/0000-0002-7332-4116; Valen, Eivind/0000-0003-1840-6108; Kallunki, Tuula/0000-0002-8571-383X; Gorbatenko, Andrej/0000-0002-0077-1679	Danish Cancer Society [R2-A273-09-S2]; Danish Council for Independent Research-Medical Sciences [12-127290]; Lundbeck Foundation [R83-A8139]	Danish Cancer Society(Danish Cancer Society); Danish Council for Independent Research-Medical Sciences(Det Frie Forskningsrad (DFF)); Lundbeck Foundation(Lundbeckfonden)	UDELTA;NErbB2 and vector control MCF-7 cells and full length ErbB1-4 plasmids were kind gifts from Jesper Nylandsted (Danish Cancer Society, Copenhagen, Denmark). DN-STAT3 constructs and corresponding control plasmids were gifts from Heehyoung Lee (Beckman Research Institute, Duarte, CA, USA); PMT3, PMT3-KLF4 and TDA(WT) x2-pGL2-TATA-Luc constructs were kind gifts from Vincent Yang (Department of Medicine, Stony Brook University, Stony Brook, NY, USA); and the enhancerless Renilla luciferase control plasmid pHRG-B was a gift from Andras Kapus (University of Toronto, Toronto, ON, USA). NBCn1 antibodies were a gift from Jeppe Praetorius (Aarhus University, Aarhus, Denmark). Vibe Nylander, Anni Bech Nielsen, and Katrine Franklin Mark are gratefully acknowledged for expert technical assistance. This work was funded by the Danish Cancer Society (R2-A273-09-S2); Danish Council for Independent Research-Medical Sciences (12-127290); and the Lundbeck Foundation (R83-A8139). Part of this work has previously been presented in abstract form (60).	Al-Sarraj A, 2005, J CELL BIOCHEM, V94, P153, DOI 10.1002/jcb.20305; Allen LF, 2003, SEMIN ONCOL, V30, P65, DOI 10.1053/j.seminoncol.2003.08.009; Alroy I, 1999, MOL CELL BIOL, V19, P1961; Bae JS, 2013, J BIOL CHEM, V288, P6295, DOI 10.1074/jbc.M112.392001; Boedtkjer E, 2012, CURR PHARM DESIGN, V18, P1345, DOI 10.2174/138161212799504830; Boedtkjer E, 2013, INT J CANCER, V132, P1288, DOI 10.1002/ijc.27782; Boron WF, 2009, J EXP BIOL, V212, P1697, DOI 10.1242/jeb.028563; Brockhoff G, 2001, CYTOMETRY, V44, P338, DOI 10.1002/1097-0320(20010801)44:4<338::AID-CYTO1125>3.0.CO;2-V; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Ding Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2236; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Dreszer TR, 2012, NUCLEIC ACIDS RES, V40, pD918, DOI 10.1093/nar/gkr1055; Egeblad M, 2001, INT J CANCER, V94, P185, DOI 10.1002/ijc.1459; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Fiske WH, 2009, EXP CELL RES, V315, P583, DOI 10.1016/j.yexcr.2008.10.043; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Gorbatenko A, 2013, FASEB J, V27; Gorbatenko A, 2011, J CELL PHYSIOL, V226, P2857, DOI 10.1002/jcp.22628; Hernandez A, 2012, CURR PHARM DESIGN, V18, P1383, DOI 10.2174/138161212799504821; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Juven-Gershon T, 2010, DEV BIOL, V339, P225, DOI 10.1016/j.ydbio.2009.08.009; Kodzius R, 2006, NAT METHODS, V3, P211, DOI 10.1038/nmeth0306-211; Larsen AM, 2012, CHEMMEDCHEM, V7, P1808, DOI 10.1002/cmdc.201200335; Lauritzen G, 2010, EXP CELL RES, V316, P2538, DOI 10.1016/j.yexcr.2010.06.005; Lauritzen G, 2012, CANCER LETT, V317, P172, DOI 10.1016/j.canlet.2011.11.023; Lenhard B, 2012, NAT REV GENET, V13, P233, DOI 10.1038/nrg3163; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Long JR, 2010, CANCER EPIDEM BIOMAR, V19, P2357, DOI 10.1158/1055-9965.EPI-10-0054; Matsukawa R, 2011, J HYPERTENS, V29, P1735, DOI 10.1097/HJH.0b013e32834937d6; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Moon JS, 2011, J BIOL CHEM, V286, P23808, DOI 10.1074/jbc.M111.236737; Neri D, 2011, NAT REV DRUG DISCOV, V10, P767, DOI 10.1038/nrd3554; Niu GL, 2001, CANCER RES, V61, P3276; Odiete O, 2012, CIRC RES, V111, P1376, DOI 10.1161/CIRCRESAHA.112.267286; Parks SK, 2011, J CELL PHYSIOL, V226, P299, DOI 10.1002/jcp.22400; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Peng SH, 2011, BREAST CANCER RES TR, V127, P309, DOI 10.1007/s10549-011-1459-5; Pinheiro C, 2012, J BIOENERG BIOMEMBR, V44, P127, DOI 10.1007/s10863-012-9428-1; Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950; Poulsen KA, 2007, AM J PHYSIOL-CELL PH, V293, pC1605, DOI 10.1152/ajpcell.00012.2007; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Snead CM, 2011, EUR J ORAL SCI, V119, P136, DOI 10.1111/j.1600-0722.2011.00867.x; Soufi A, 2012, CELL, V151, P994, DOI 10.1016/j.cell.2012.09.045; Stutz AM, 2009, EUR J HUM GENET, V17, P1481, DOI 10.1038/ejhg.2009.64; Su HW, 2009, AM J PHYSIOL-CELL PH, V296, pC13, DOI 10.1152/ajpcell.00263.2008; SZOLLOSI J, 1995, CANCER RES, V55, P5400; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Valen E, 2011, TRENDS GENET, V27, P475, DOI 10.1016/j.tig.2011.08.001; VANDERHORNE VS, 2009, MOL CANCER RES, V7, P592; Yoshida Y, 2009, CELL STEM CELL, V5, P237, DOI 10.1016/j.stem.2009.08.001; Zeng FH, 2009, EXP CELL RES, V315, P602, DOI 10.1016/j.yexcr.2008.08.005; Zhang DH, 2005, MOL CELL PROTEOMICS, V4, P1686, DOI 10.1074/mcp.M400221-MCP200; Zhao YH, 2009, ONCOGENE, V28, P3689, DOI 10.1038/onc.2009.229	60	31	31	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					350	363		10.1096/fj.13-233288	http://dx.doi.org/10.1096/fj.13-233288			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24088818				2022-12-28	WOS:000333526100033
J	Carchman, EH; Whelan, S; Loughran, P; Mollen, K; Stratamirovic, S; Shiva, S; Rosengart, MR; Zuckerbraun, BS				Carchman, Evie H.; Whelan, Sean; Loughran, Patricia; Mollen, Kevin; Stratamirovic, Sladjana; Shiva, Sruti; Rosengart, Matthew R.; Zuckerbraun, Brian S.			Experimental sepsis-induced mitochondrial biogenesis is dependent on autophagy, TLR4, and TLR9 signaling in liver	FASEB JOURNAL			English	Article						lipopolysaccharide; Toll-like receptor 4; VPS34; peroxisome proliferator-activated receptor-gamma coactivator; PGC-1 alpha	NITRIC-OXIDE; IN-VITRO; INFLAMMATORY RESPONSES; ADAPTIVE IMMUNITY; INNATE; DNA; FAILURE; MICE; HEPATOCYTES; ACTIVATION	Organ injury in sepsis is initially characterized by dysfunction without cell death and structural damage, and thus with the ability to recover organ function. Adaptive metabolic responses to sepsis can prevent bioenergetic failure and death. These studies were aimed at investigating the influence of sepsis on mitochondrial homeostasis, focusing on removal of dysfunctional mitochondria and restitution of a healthy mitochondrial population. These data demonstrate decreased hepatic oxidative phosphorylation by 31 +/- 11% following murine cecal ligation and puncture (CLP) at 8 h and 34 +/- 9% following LPS treatment in vitro at 12 h (P<0.05). In addition, there was a loss of mitochondrial membrane potential. Mitochondrial density and number initially decreased (relative area per micrograph of 64 +/- 10% at baseline vs. 39 +/- 13% at 8 h following LPS; P<0.05) and was associated with an increase in autophagy and mitophagy. CLP-induced markers of mitochondrial biogenesis and mitochondrial number and density recovered over time. Furthermore, these data suggest that mitochondrial biogenesis was dependent on an autophagy and mitochondrial DNA/Toll-like receptor 9 (TLR9) signaling pathway. These results suggest that hepatocyte survival and maintenance of function in sepsis is dependent on a mitochondrial homeostasis pathway marked by mitophagy and biogenesis.	[Carchman, Evie H.; Whelan, Sean; Loughran, Patricia; Mollen, Kevin; Stratamirovic, Sladjana; Rosengart, Matthew R.; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Shiva, Sruti] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; [Shiva, Sruti; Zuckerbraun, Brian S.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA; [Carchman, Evie H.; Loughran, Patricia; Stratamirovic, Sladjana; Zuckerbraun, Brian S.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Zuckerbraun, BS (corresponding author), F1200PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.	zuckerbraunbs@upmc.edu	Loughran, Patricia/AAB-1184-2021	Mollen, Kevin/0000-0001-7629-2722	U.S. National Institutes of Health [R01 GM082830, GM082852]; U.S. Veterans Affairs Merit Award [1I01BX000566]; U.S. Department of Defense grant [DM102439]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM082830, R01GM082852] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000566] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Veterans Affairs Merit Award; U.S. Department of Defense grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work is supported by U.S. National Institutes of Health grants R01 GM082830 (B.S.Z.) and GM082852 (M. R. R.), U.S. Veterans Affairs Merit Award 1I01BX000566 (B.S.Z.), and U.S. Department of Defense grant DM102439 (B.S.Z.). Author contributions: E. H. C. and B.S.Z., study concept and design; E. H. C., S. P. W., and P. L., acquisition of data; E. H. C., M. R. R., S.Sh., K. P. M., and B.S.Z., analysis and interpretation of data; E. H. C., S. P. M., and B.S.Z., drafting of the manuscript; E. H. C. and B.S.Z., critical revision of the manuscript for important intellectual content and statistical analysis; B.S.Z., acquisition of funding; S.St., technical support. The authors declare no conflicts of interest.	Barber GN, 2011, IMMUNOL REV, V243, P99, DOI 10.1111/j.1600-065X.2011.01051.x; Bertin S, 2008, MOL CELL PROTEOMICS, V7, P2311, DOI 10.1074/mcp.M800100-MCP200; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003; Carchman EH, 2011, HEPATOLOGY, V53, P2053, DOI 10.1002/hep.24324; Carre JE, 2010, AM J RESP CRIT CARE, V182, P745, DOI 10.1164/rccm.201003-0326OC; Chaturvedi A, 2008, IMMUNITY, V28, P799, DOI 10.1016/j.immuni.2008.03.019; Collins LV, 2004, J LEUKOCYTE BIOL, V75, P995, DOI 10.1189/jlb.0703328; Creery D, 2002, CRIT CARE MED, V30, P483; Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002; Delgado M, 2009, IMMUNOL REV, V227, P189, DOI 10.1111/j.1600-065X.2008.00725.x; Deretic V, 2005, TRENDS IMMUNOL, V26, P523, DOI 10.1016/j.it.2005.08.003; Erusalimsky JD, 2007, ARTERIOSCL THROM VAS, V27, P2524, DOI 10.1161/ATVBAHA.107.151167; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Gramignoli R, 2012, CELL TRANSPLANT, V21, P1245, DOI 10.3727/096368911X600939; Imaeda AB, 2009, J CLIN INVEST, V119, P305, DOI 10.1172/JCI35958; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Lancel S, 2009, J PHARMACOL EXP THER, V329, P641, DOI 10.1124/jpet.108.148049; Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161; McBride HM, 2008, J CELL BIOL, V183, P757, DOI 10.1083/jcb.200810184; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Oka T, 2012, NATURE, V485, P251, DOI 10.1038/nature10992; Piantadosi CA, 2012, BBA-GEN SUBJECTS, V1820, P712, DOI 10.1016/j.bbagen.2011.03.008; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Plitas G, 2008, J EXP MED, V205, P1277, DOI 10.1084/jem.20080162; Reynolds CM, 2009, FREE RADICAL BIO MED, V46, P564, DOI 10.1016/j.freeradbiomed.2008.11.007; Rubartelli A, 2007, TRENDS IMMUNOL, V28, P429, DOI 10.1016/j.it.2007.08.004; Singer M, 2004, LANCET, V364, P545, DOI 10.1016/S0140-6736(04)16815-3; Stolz DB, 2002, HEPATOLOGY, V36, P81, DOI 10.1053/jhep.2002.33716; Waltz P, 2011, AUTOPHAGY, V7, P315, DOI 10.4161/auto.7.3.14044; Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211; Watanabe E, 2009, LAB INVEST, V89, P549, DOI 10.1038/labinvest.2009.8; WEST MA, 1985, INFECT IMMUN, V49, P563, DOI 10.1128/IAI.49.3.563-570.1985; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zuckerbraun BS, 2007, FASEB J, V21, P1099, DOI 10.1096/fj.06-6644com	36	52	65	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4703	4711		10.1096/fj.13-229476	http://dx.doi.org/10.1096/fj.13-229476			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23982147	Green Published			2022-12-28	WOS:000329999000006
J	Conti, L; Lanzardo, S; Arigoni, M; Antonazzo, R; Radaelli, E; Cantarella, D; Calogero, RA; Cavallo, F				Conti, Laura; Lanzardo, Stefania; Arigoni, Maddalena; Antonazzo, Roberta; Radaelli, Enrico; Cantarella, Daniela; Calogero, Raffaele A.; Cavallo, Federica			The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells	FASEB JOURNAL			English	Article						endogenous TLR2 ligands; transcriptome; NF kappa B; MyD88; BOXA; breast carcinoma	BREAST-CANCER; TLR2; INFLAMMATION; EXPRESSION; REPAIR	Cancer stem cells (CSCs) are responsible for tumor progression, metastases, resistance to therapy, and tumor recurrence. Therefore, the identification of molecules involved in CSC self-renewal is a necessary step toward more effective therapies. To this aim, through the transcription profiling of the murine ErbB2(+) tumor cell line TUBO vs. derived CSC-enriched mammospheres, Toll-like receptor 2 (TLR2) was identified as 2-fold overexpressed in CSCs, as confirmed by qPCR and cytofluorimetric analysis. TLR2 signaling inhibition impaired in vitro mammosphere generation in murine TUBO (60%) and 4T1 (30%) and human MDA-MB-231 (50%), HCC1806 (60%), and MCF7 (50%) cells. In CSC, TLR2 was activated by endogenous high-mobility-group box 1 (HMGB1), inducing I kappa B alpha phosphorylation, IL-6 and TGF beta secretion, and, consequently, STAT3 and Smad3 activation. In vivo TLR2 inhibition blocked TUBO tumor takes in 9/14 mice and induced a 2-fold reduction in lung metastases development by decreasing cell proliferation and vascularization and increasing apoptosis. Collectively, these results demonstrate that murine and human mammary CSCs express TLR2 and its ligand HMGB1; this autocrine loop plays a pivotal role in CSC self-renewal, tumorigenesis, and metastatic ability. These findings, while providing evidence against the controversial use of TLR2 agonists in antitumor therapy, lay out new paths toward the design of anticancer treatments.	[Conti, Laura; Lanzardo, Stefania; Arigoni, Maddalena; Antonazzo, Roberta; Calogero, Raffaele A.; Cavallo, Federica] Univ Turin, Ctr Mol Biotechnol, Turin, Italy; [Radaelli, Enrico] Fdn Filarete, Mouse & Anim Pathol Lab, Milan, Italy; [Radaelli, Enrico] Univ Milan, Dept Anim Pathol, Milan, Italy; [Cantarella, Daniela] IRCC, Candiolo, Italy	University of Turin; University of Milan; IRCCS Fondazione del Piemonte per l'Oncologia	Cavallo, F (corresponding author), Ctr Mol Biotechnol, Via Nizza 52, I-10126 Turin, Italy.	federica.cavallo@unito.it	Calogero, Raffaele/K-9428-2019; CONTI, LAURA/A-9005-2017; Conti, Laura/AAL-8272-2020; Cavallo, Federica/C-5666-2011	Calogero, Raffaele/0000-0002-2848-628X; CONTI, LAURA/0000-0003-1780-098X; CANTARELLA, DANIELA/0000-0001-6135-2032; Cavallo, Federica/0000-0003-4571-1060; Arigoni, Maddalena/0000-0003-4629-3841	Italian Association for Cancer Research [IG 11675]; Fondazione Ricerca Molinette Onlus; University of Turin; Compagnia di San Paolo (Progetti di Ricerca Ateneo/CSP)	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Fondazione Ricerca Molinette Onlus; University of Turin; Compagnia di San Paolo (Progetti di Ricerca Ateneo/CSP)(Compagnia di San Paolo)	This work was supported by grants from the Italian Association for Cancer Research (IG 11675), Fondazione Ricerca Molinette Onlus, the University of Turin, and the Compagnia di San Paolo (Progetti di Ricerca Ateneo/CSP). The authors thank Dr. Roberto Ruiu for his technical assistance and Dr. Dale Lawson for his revision and editing of the manuscript. The authors declare no conflicts of interest.	Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; Campana L, 2008, CURR OPIN IMMUNOL, V20, P518, DOI 10.1016/j.coi.2008.04.012; Carotenuto P, 2010, CRIT REV EUKAR GENE, V20, P17, DOI 10.1615/CritRevEukarGeneExpr.v20.i1.20; Chang ZL, 2010, INFLAMM RES, V59, P791, DOI 10.1007/s00011-010-0208-2; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chefetz I, 2013, CELL CYCLE, V12, P511, DOI 10.4161/cc.23406; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Fan Jie, 2010, Open Crit Care Med J, V2, P1; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Grange C, 2008, NEOPLASIA, V10, P1433, DOI 10.1593/neo.08902; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038890; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kim S, 2011, ANN NY ACAD SCI, V1217, P191, DOI 10.1111/j.1749-6632.2010.05882.x; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Morrison R, 2011, J ONCOL, V2011, DOI 10.1155/2011/941876; Nogueira-Machado JA, 2012, RECENT PATENTS ENDOC, V6, P201, DOI 10.2174/187221412802481784; Noh KH, 2012, CANCER RES, V72, P1717, DOI 10.1158/0008-5472.CAN-11-3758; Okano H, 2005, EXP CELL RES, V306, P349, DOI 10.1016/j.yexcr.2005.02.021; Parmigiani G, 2004, CLIN CANCER RES, V10, P2922, DOI 10.1158/1078-0432.CCR-03-0490; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Rovero S, 2001, GENE THER, V8, P447, DOI 10.1038/sj.gt.3301416; Sallustio F, 2010, FASEB J, V24, P514, DOI 10.1096/fj.09-136481; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; Shaykhiev R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001393; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Taylor T, 2010, STEM CELLS DEV, V19, P1333, DOI 10.1089/scd.2009.0484; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Wang L, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt96; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Xie WJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010850; Xie WJ, 2009, BIOCHEM BIOPH RES CO, V379, P1027, DOI 10.1016/j.bbrc.2009.01.009; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yang HZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006520	40	65	68	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4731	4744		10.1096/fj.13-230201	http://dx.doi.org/10.1096/fj.13-230201			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23970797				2022-12-28	WOS:000329999000009
J	Lee, RJ; Chen, B; Doghramji, L; Adappa, ND; Palmer, JN; Kennedy, DW; Cohen, NA				Lee, Robert J.; Chen, Bei; Doghramji, Laurel; Adappa, Nithin D.; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.			Vasoactive intestinal peptide regulates sinonasal mucociliary clearance and synergizes with histamine in stimulating sinonasal fluid secretion	FASEB JOURNAL			English	Article						allergic rhinitis; chronic rhinosinusitis; ciliary beat frequency; cystic fibrosis transmembrane conductance regulator; CFTR	CILIARY BEAT FREQUENCY; NASAL-MUCOSA; NITRIC-OXIDE; CYSTIC-FIBROSIS; MESSENGER-RNA; VIP RECEPTORS; CYCLIC-AMP; NEUROPEPTIDES; CAMP; POLYPEPTIDE	Mucociliary clearance (MCC) is the primary physical airway defense against inhaled pathogens and particulates. MCC depends on both proper fluid/mucus homeostasis and epithelial ciliary beating. Vasoactive intestinal peptide (VIP) is a neurotransmitter expressed in the sinonasal epithelium that is up-regulated in allergy. However, the effects of VIP on human sinonasal physiology are unknown, as are VIP's interactions with histamine, a major regulator of allergic disease. We imaged ciliary beat frequency, mucociliary transport, apical Cl- permeability, and airway surface liquid (ASL) height in primary human sinonasal air-liquid-interface cultures to investigate the effects of VIP and histamine. VIP stimulated an increase in ciliary beat frequency (EC50 0.5 mu M; maximal increase similar to 40% compared with control) and cystic fibrosis transmembrane conductance regulator (CFTR)-dependent and Na(+)K(+)2Cl(-) cotransporter-dependent fluid secretion, all requiring cAMP/PKA signaling. Histamine activated Ca2+ signaling that increased ASL height but not ciliary beating. Low concentrations of VIP and histamine had synergistic effects on CFTR-dependent fluid secretion, revealed by increased ASL heights. An up-regulation of VIP in histamine-driven allergic rhinitis would likely enhance mucosal fluid secretion and contribute to allergic rhinorrhea. Conversely, a loss of VIP-activated secretion in patients with CF may impair mucociliary transport, contributing to increased incidences of sinonasal infections and rhinosinusitis.	[Lee, Robert J.; Chen, Bei; Doghramji, Laurel; Adappa, Nithin D.; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Cohen, NA (corresponding author), Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.	cohenn@uphs.upenn.edu	Lee, Robert J./L-4397-2017	Lee, Robert J./0000-0001-5826-6686; Cohen, Noam/0000-0002-9462-3932	Flight Attendants Medical Research Institute	Flight Attendants Medical Research Institute	This work was supported by a grant from The Flight Attendants Medical Research Institute and a philanthropic contribution from the RLG Foundation, Inc. (to N.A.C.).	Antunes MB, 2009, IMMUNOL ALLERGY CLIN, V29, P631, DOI 10.1016/j.iac.2009.07.004; Ballard ST, 2002, AM J PHYSIOL-LUNG C, V283, pL329, DOI 10.1152/ajplung.00277.2001; Ballard ST, 2007, RESP PHYSIOL NEUROBI, V159, P271, DOI 10.1016/j.resp.2007.06.017; BARANIUK JN, 1990, J ALLERGY CLIN IMMUN, V86, P620, DOI 10.1016/S0091-6749(05)80226-X; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1993, J APPL PHYSIOL, V74, P272, DOI 10.1152/jappl.1993.74.1.272; Braiman A, 2008, RESP PHYSIOL NEUROBI, V163, P202, DOI 10.1016/j.resp.2008.05.010; Busto R, 1999, AM J PHYSIOL-LUNG C, V277, pL42, DOI 10.1152/ajplung.1999.277.1.L42; Choi JY, 2007, J CLIN INVEST, V117, P3118, DOI 10.1172/JCI31992; Cohen NA, 2006, ANN OTO RHINOL LARYN, V115, P20; Delgado M, 2008, ARTHRITIS RHEUM-US, V58, P1010, DOI 10.1002/art.23482; DEY RD, 1981, CELL TISSUE RES, V220, P231; Dickson L, 2006, ANN NY ACAD SCI, V1070, P239, DOI 10.1196/annals.1317.021; Dickson L, 2006, NEUROPHARMACOLOGY, V51, P1086, DOI 10.1016/j.neuropharm.2006.07.017; Dickson L, 2009, PHARMACOL THERAPEUT, V121, P294, DOI 10.1016/j.pharmthera.2008.11.006; DOMSCHKE S, 1978, GUT, V19, P1049, DOI 10.1136/gut.19.11.1049; Edelstein Arthur, 2010, Curr Protoc Mol Biol, VChapter 14, DOI 10.1002/0471142727.mb1420s92; Fang Sheen-Yie, 1997, Proceedings of the National Science Council Republic of China Part B Life Sciences, V21, P8; Fang SY, 1998, ACTA OTO-LARYNGOL, V118, P398; FANG SY, 1994, ACTA OTO-LARYNGOL, V114, P324, DOI 10.3109/00016489409126064; Fischer A, 2005, J OCCUP ENVIRON MED, V47, P20, DOI 10.1097/01.jom.0000150238.77663.49; FRANDSEN EK, 1978, BRIT J PHARMACOL, V62, P367, DOI 10.1111/j.1476-5381.1978.tb08471.x; GANZ P, 1986, AM J PHYSIOL, V250, pH755, DOI 10.1152/ajpheart.1986.250.5.H755; Gerelsaikhan T, 2000, J KOREAN MED SCI, V15, pS3, DOI 10.3346/jkms.2000.15.S.S3; GHATEI MA, 1982, ENDOCRINOLOGY, V111, P1248, DOI 10.1210/endo-111-4-1248; GRIDER JR, 1992, AM J PHYSIOL, V262, pG774, DOI 10.1152/ajpgi.1992.262.4.G774; Groneberg DA, 2001, LAB INVEST, V81, P749, DOI 10.1038/labinvest.3780283; Gudis DA, 2010, OTOLARYNG CLIN N AM, V43, P461, DOI 10.1016/j.otc.2010.02.007; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hasaneen NA, 2003, CHEST, V124, P1067, DOI 10.1378/chest.124.3.1067; Heppt W, 2004, CLIN EXP ALLERGY, V34, P1105, DOI 10.1111/j.1365-2222.2004.01990.x; Heppt W, 2002, J OCCUP ENVIRON MED, V44, P924, DOI 10.1097/00043764-200210000-00011; Kaiser HB, 1998, ALLERGY ASTHMA PROC, V19, P23, DOI 10.2500/108854198778557962; Kanazawa H, 1997, AM J RESP CRIT CARE, V155, P747, DOI 10.1164/ajrccm.155.2.9032223; Kim DH, 2011, AM J RHINOL ALLERGY, V25, pE44, DOI 10.2500/ajra.2011.25.3568; Lai YY, 2011, J ALLERGY CLIN IMMUN, V128, P1207, DOI 10.1016/j.jaci.2011.09.001; LAZARUS SC, 1986, AM J PHYSIOL, V251, pC115, DOI 10.1152/ajpcell.1986.251.1.C115; Lee MC, 2011, AM J OTOLARYNG, V32, P517, DOI 10.1016/j.amjoto.2010.11.003; Lee RJ, 2007, J PHYSIOL-LONDON, V582, P1099, DOI 10.1113/jphysiol.2007.131995; Lee RJ, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.412817; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Lee RJ, 2010, J CLIN INVEST, V120, P3137, DOI 10.1172/JCI42992; Lee RJ, 2010, AM J PHYSIOL-LUNG C, V298, pL210, DOI 10.1152/ajplung.00342.2009; LINDBERG S, 1986, ANN OTO RHINOL LARYN, V95, P94, DOI 10.1177/000348948609500120; LINDBERG S, 1988, OTOLARYNG HEAD NECK, V99, P401, DOI 10.1177/019459988809900409; LUNDBERG JM, 1981, P NATL ACAD SCI-BIOL, V78, P5255, DOI 10.1073/pnas.78.8.5255; Melvin JE, 2005, ANNU REV PHYSIOL, V67, P445, DOI 10.1146/annurev.physiol.67.041703.084745; Mendonca Jeferson Cedaro de, 2005, Braz J Otorhinolaryngol, V71, P123; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; Nieratschker V, 2011, EXPERT REV NEUROTHER, V11, P937, DOI [10.1586/ern.11.84, 10.1586/ERN.11.84]; Paladini F, 2009, NEUROGASTROENT MOTIL, V21, P597, DOI 10.1111/j.1365-2982.2009.01284.x; Reynolds A, 2007, J PHYSIOL-LONDON, V582, P507, DOI 10.1113/jphysiol.2007.129718; SAID SI, 1982, EXP LUNG RES, V3, P343, DOI 10.3109/01902148209069662; SAKAI N, 1991, REGUL PEPTIDES, V34, P33, DOI 10.1016/0167-0115(91)90222-3; Salathe M, 2007, ANNU REV PHYSIOL, V69, P401, DOI 10.1146/annurev.physiol.69.040705.141253; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; Schaper C, 2010, J INVEST ALLERG CLIN, V20, P214; SCHUIL PJ, 1994, EUR ARCH OTO-RHINO-L, V251, P325, DOI 10.1007/BF00171538; Sisson JH, 2003, J MICROSC-OXFORD, V211, P103, DOI 10.1046/j.1365-2818.2003.01209.x; Song YL, 2009, AM J PHYSIOL-LUNG C, V297, pL1131, DOI 10.1152/ajplung.00085.2009; Teff Z, 2008, BIOPHYS J, V94, P298, DOI 10.1529/biophysj.107.111724; Tran NP, 2011, ALLERGY ASTHMA IMMUN, V3, P148, DOI 10.4168/aair.2011.3.3.148; UDDMAN R, 1978, ACTA OTO-LARYNGOL, V86, P443, DOI 10.3109/00016487809124767; UDDMAN R, 1987, AM REV RESPIR DIS, V136, pS3, DOI 10.1164/ajrccm/136.6_Pt_2.S3; Vacic V, 2011, NATURE, V471, P499, DOI 10.1038/nature09884; Virgin FW, 2012, AM J RHINOL ALLERGY, V26, P70, DOI 10.2500/ajra.2012.26.3705; Woodworth BA, 2007, AM J RHINOL, V21, P122, DOI 10.2500/ajr.2007.21.2905; Worthington EN, 2011, METHODS MOL BIOL, V742, P77, DOI 10.1007/978-1-61779-120-8_5; Zhao KQ, 2012, FASEB J, V26, P3178, DOI 10.1096/fj.11-202184	69	32	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5094	5103		10.1096/fj.13-234476	http://dx.doi.org/10.1096/fj.13-234476			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23934280				2022-12-28	WOS:000329999000041
J	Sferruzzi-Perri, AN; Vaughan, OR; Haro, M; Cooper, WN; Musial, B; Charalambous, M; Pestana, D; Ayyar, S; Ferguson-Smith, AC; Burton, GJ; Constancia, M; Fowden, AL				Sferruzzi-Perri, Amanda N.; Vaughan, Owen R.; Haro, Maria; Cooper, Wendy N.; Musial, Barbara; Charalambous, Marika; Pestana, Diogo; Ayyar, Shruti; Ferguson-Smith, Anne C.; Burton, Graham J.; Constancia, Miguel; Fowden, Abigail L.			An obesogenic diet during mouse pregnancy modifies maternal nutrient partitioning and the fetal growth trajectory	FASEB JOURNAL			English	Article						resource allocation; developmental programming; metabolic signaling pathways; imprintome; placental phenotype	DIFFUSIONAL EXCHANGE CHARACTERISTICS; HIGH-FAT DIET; PLACENTAL PHENOTYPE; SIGNALING PATHWAYS; DOWN-REGULATION; GENE; UNDERNUTRITION; RESTRICTION; ADAPTATIONS; EXPRESSION	In developed societies, high-sugar and high-fat (HSHF) diets are now the norm and are increasing the rates of maternal obesity during pregnancy. In pregnant rodents, these diets lead to cardiovascular and metabolic dysfunction in their adult offspring, but the intrauterine mechanisms involved remain unknown. This study shows that, relative to standard chow, HSHF feeding throughout mouse pregnancy increases maternal adiposity (+30%, P<0.05) and reduces fetoplacental growth at d 16 (-10%, P<0.001). At d 19, however, HSHF diet group pup weight had normalized, despite the HSHF diet group placenta remaining small and morphologically compromised. This altered fetal growth trajectory was associated with enhanced placental glucose and amino acid transfer (+35%, P<0.001) and expression of their transporters (+40%, P<0.024). HSHF feeding also up-regulated placental expression of fatty acid transporter protein, metabolic signaling pathways (phosphoinositol 3-kinase and mitogen-activated protein kinase), and several growth regulatory imprinted genes (Igf2, Dlk1, Snrpn, Grb10, and H19) independently of changes in DNA methylation. Obesogenic diets during pregnancy, therefore, alter maternal nutrient partitioning, partly through changes in the placental phenotype, which helps to meet fetal nutrient demands for growth near term. However, by altering provision of specific nutrients, dietary-induced placental adaptations have important roles in programming development with health implications for the offspring in later life.Sferruzzi-Perri, A. N., Vaughan, O. R., Haro, M., Cooper, W. N., Musial, B., Charalambous, M., Pestana, D., Ayyar, S., Ferguson-Smith, A. C., Burton, G. J., Constancia, M., Fowden, A. L. An obesogenic diet during mouse pregnancy modifies maternal nutrient partitioning and the fetal growth trajectory.	[Sferruzzi-Perri, Amanda N.; Vaughan, Owen R.; Musial, Barbara; Charalambous, Marika; Ayyar, Shruti; Burton, Graham J.; Constancia, Miguel; Fowden, Abigail L.] Univ Cambridge, Ctr Trophoblast Res, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England; [Haro, Maria; Cooper, Wendy N.; Pestana, Diogo; Ferguson-Smith, Anne C.; Constancia, Miguel] Cambridege Biomed Res Ctr, Metab Res Labs, Dept Obstet & Gynaecol, Cambridge, England; [Haro, Maria; Cooper, Wendy N.; Pestana, Diogo; Ferguson-Smith, Anne C.; Constancia, Miguel] Cambridege Biomed Res Ctr, Natl Inst Hlth Res, Cambridge, England	University of Cambridge; University of Cambridge; University of Cambridge	Sferruzzi-Perri, AN (corresponding author), Univ Cambridge, Ctr Trophoblast Res, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.	ans48@cam.ac.uk	Constancia, Miguel/F-6654-2013	Constancia, Miguel/0000-0002-8976-1679; Sferruzzi-Perri, Amanda/0000-0002-4931-4233; Ferguson-Smith, Anne/0000-0002-7608-5894; Pestana, Diogo/0000-0001-6332-7914; Charalambous, Marika/0000-0002-1684-5783	UK Biotechnology and Biological Sciences Research Council; Centre for Trophoblast Research (CTR); C.J. Martin Overseas Biomedical Fellowship from the Australian National Health and Medical Research Council; Next Generation Fellowship from the CTR; CTR; Medical Research Council; BBSRC [BB/I014594/1] Funding Source: UKRI; MRC [G0600717, MR/J001597/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C513626/1, BB/I014594/1] Funding Source: researchfish; British Heart Foundation [FS/09/029/27902] Funding Source: researchfish; Medical Research Council [G0600717, G0600717B, MR/J001597/1, MC_UU_12012/5/B] Funding Source: researchfish; Wellcome Trust [095606/Z/11/Z] Funding Source: researchfish	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Centre for Trophoblast Research (CTR); C.J. Martin Overseas Biomedical Fellowship from the Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Next Generation Fellowship from the CTR; CTR; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Nuala Daw, Chris Cardinal, and Wendy Cassidy for technical help. This work was supported by the UK Biotechnology and Biological Sciences Research Council and the Centre for Trophoblast Research (CTR). A.N.S.-P. received a C.J. Martin Overseas Biomedical Fellowship from the Australian National Health and Medical Research Council and a Next Generation Fellowship from the CTR. O.R.V. received a Ph.D. studentship from CTR. B.M. received a Ph.D. studentship from the Medical Research Council.	Angiolini E, 2006, PLACENTA, V27, pS98, DOI 10.1016/j.placenta.2005.12.008; Angiolini E, 2011, FASEB J, V25, P1737, DOI 10.1096/fj.10-175273; Appelbe OK, 2013, MECH DEVELOP, V130, P143, DOI 10.1016/j.mod.2012.09.010; Armitage JA, 2004, J PHYSIOL-LONDON, V561, P355, DOI 10.1113/jphysiol.2004.072009; Charalambous M, 2012, CELL METAB, V15, P209, DOI 10.1016/j.cmet.2012.01.006; Charalambous M, 2010, DEV BIOL, V337, P1, DOI 10.1016/j.ydbio.2009.10.011; Coan PM, 2008, J PHYSIOL-LONDON, V586, P5023, DOI 10.1113/jphysiol.2008.157313; Coan PM, 2008, J PHYSIOL-LONDON, V586, P4567, DOI 10.1113/jphysiol.2008.156133; Coan PM, 2011, J PHYSIOL-LONDON, V589, P3659, DOI 10.1113/jphysiol.2011.208629; Coan PM, 2010, J PHYSIOL-LONDON, V588, P527, DOI 10.1113/jphysiol.2009.181214; Coan PM, 2004, BIOL REPROD, V70, P1806, DOI 10.1095/biolreprod.103.024166; Constancia M, 2005, P NATL ACAD SCI USA, V102, P19219, DOI 10.1073/pnas.0504468103; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Cordain L, 2005, AM J CLIN NUTR, V81, P341, DOI 10.1093/ajcn.81.2.341; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fowden AL, 2011, PROG BIOPHYS MOL BIO, V106, P281, DOI 10.1016/j.pbiomolbio.2010.11.005; Fowden AL, 2006, J PHYSIOL-LONDON, V572, P5, DOI 10.1113/jphysiol.2005.104141; Franko KL, 2007, J ENDOCRINOL, V192, P67, DOI 10.1677/joe.1.07063; Frias AE, 2011, ENDOCRINOLOGY, V152, P2456, DOI 10.1210/en.2010-1332; Gabory A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047986; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; Ivanova E, 2012, EPIGENETICS-US, V7, P1200, DOI 10.4161/epi.22141; Jansson N, 2006, J PHYSIOL-LONDON, V576, P935, DOI 10.1113/jphysiol.2003.550004; Jansson N, 2013, J CLIN ENDOCR METAB, V98, P105, DOI 10.1210/jc.2012-2667; Jansson T, 2012, PLACENTA, V33, pE23, DOI 10.1016/j.placenta.2012.05.010; Jones HN, 2009, FASEB J, V23, P271, DOI 10.1096/fj.08-116889; Kwong WY, 2000, DEVELOPMENT, V127, P4195; Liang CY, 2010, METABOLISM, V59, P943, DOI 10.1016/j.metabol.2009.10.015; Lim AL, 2010, SEMIN CELL DEV BIOL, V21, P201, DOI 10.1016/j.semcdb.2009.10.008; Lin Y, 2012, NUTRITION, V28, P1037, DOI 10.1016/j.nut.2012.01.002; Lin Y, 2011, BRIT J NUTR, V106, P510, DOI 10.1017/S0007114511000614; Ma Y, 2011, PLACENTA, V32, P255, DOI 10.1016/j.placenta.2011.01.007; Nadra K, 2010, ENDOCRINOLOGY, V151, P4969, DOI 10.1210/en.2010-0131; Petry CJ, 2011, EXP DIABETES RES, DOI 10.1155/2011/171376; Petry CJ, 2010, DIABETES, V59, P282, DOI 10.2337/db09-0757; Radford EJ, 2012, PLOS GENET, V8, P41, DOI 10.1371/journal.pgen.1002605; Rasmussen T, 2009, DIABETES CARE, V32, P1904, DOI 10.2337/dc09-0663; Redmer DA, 2009, REPRODUCTION, V137, P749, DOI 10.1530/REP-08-0516; Rosario FJ, 2011, ENDOCRINOLOGY, V152, P1119, DOI 10.1210/en.2010-1153; Rutland CS, 2007, PLACENTA, V28, P734, DOI 10.1016/j.placenta.2006.07.001; Samuelsson AM, 2008, HYPERTENSION, V51, P383, DOI 10.1161/HYPERTENSIONAHA.107.101477; Schieve L A, 1998, Matern Child Health J, V2, P111, DOI 10.1023/A:1022992823185; Sferruzzi-Perri AN, 2011, ENDOCRINOLOGY, V152, P3202, DOI 10.1210/en.2011-0240; Sferruzzi-Perri AN, 2009, BIOL REPROD, V81, P207, DOI 10.1095/biolreprod.108.073312; Sibley CP, 2004, P NATL ACAD SCI USA, V101, P8204, DOI 10.1073/pnas.0402508101; Sul HS, 2009, MOL ENDOCRINOL, V23, P1717, DOI 10.1210/me.2009-0160; Swan G, 2004, P NUTR SOC, V63, P505, DOI 10.1079/PNS2004381; Thorsdottir I, 2002, OBSTET GYNECOL, V99, P799, DOI 10.1016/S0029-7844(02)01946-4; Varrault A, 2006, DEV CELL, V11, P711, DOI 10.1016/j.devcel.2006.09.003; Wallace JM, 2004, BIOL REPROD, V71, P1055, DOI 10.1095/biolreprod.104.030965; Warner MJ, 2010, BIOCHEM J, V427, P333, DOI 10.1042/BJ20091861; Watkins AJ, 2008, BIOL REPROD, V78, P299, DOI 10.1095/biolreprod.107.064220; Yevtodiyenko A, 2006, DEV DYNAM, V235, P1115, DOI 10.1002/dvdy.20705; Zhu MJ, 2007, PLACENTA, V28, P1192, DOI 10.1016/j.placenta.2007.05.004; Zhu MJ, 2009, PLACENTA, V30, P405, DOI 10.1016/j.placenta.2009.02.001; Zhu MJ, 2010, AM J PHYSIOL-REG I, V299, pR1224, DOI 10.1152/ajpregu.00309.2010	57	104	104	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3928	3937		10.1096/fj.13-234823	http://dx.doi.org/10.1096/fj.13-234823			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825226				2022-12-28	WOS:000329747100008
J	Verga-Gerard, A; Porcherot, M; Meyniel-Schicklin, L; Andre, P; Lotteau, V; Perrin-Cocon, L				Verga-Gerard, Amandine; Porcherot, Marine; Meyniel-Schicklin, Laurene; Andre, Patrice; Lotteau, Vincent; Perrin-Cocon, Laure			Hepatitis C virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF-beta signaling	FASEB JOURNAL			English	Article						transforming growth factor-; hepatocellular carcinoma; EMT	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; VIRUS-INFECTION; LIVER-CANCER; EXPRESSION; RECEPTOR; ACTIVATION; TUMOR; PATHWAY; LIGASE	TGF- signaling induces epithelial to mesenchymal transition (EMT) and plays an important role in hepatocellular carcinoma (HCC) development. Clinical observations indicate that hepatitis C virus (HCV) chronic infection, which is a major cause of HCC, induces TGF- signaling perturbations. Here, we investigate the mechanisms by which HCV nonstructural proteins interfere with TGF- signaling, in human hepatoma cell lines expressing HCV subgenomic replicon. A transcriptomic study showed that TGF- stimulation of these cells resulted in a protumoral gene expression profile and in up-regulation of EMT-related genes compared to control interferon-treated cells not expressing HCV proteins. We found that the viral protease NS3-4A interacted with SMURF2, a negative regulator of TGF- signaling. In cells expressing HCV subgenomic replicon or NS3-4A, TGF- stimulation induced an increased expression of SMAD-dependent genes compared to control cells. This enhanced signaling was suppressed by SMURF2 overexpression and mimicked by SMURF2 silencing. In addition, NS3-4A expression resulted in an increased and prolonged TGF--induced phosphorylation of SMAD2/3 that was abrogated by SMURF2 overexpression. Neither NS3-4A protease activity nor SMURF2 ubiquitin-ligase activity was required to affect TGF- signaling. Therefore, by targeting SMURF2, NS3-4A appears to block the negative regulation of TGF- signaling, increasing the responsiveness of cells to TGF-. Verga-Gerard, A., Porcherot, M., Meyniel-Schicklin, L., Andre, P., Lotteau, V., and Perrin-Cocon, L. Hepatitis C virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF- signaling.	[Verga-Gerard, Amandine; Porcherot, Marine; Meyniel-Schicklin, Laurene; Andre, Patrice; Lotteau, Vincent; Perrin-Cocon, Laure] Univ Lyon, Lyon, France; [Verga-Gerard, Amandine; Porcherot, Marine; Meyniel-Schicklin, Laurene; Andre, Patrice; Lotteau, Vincent; Perrin-Cocon, Laure] Ctr Int Rech Infectiol, INSERM, U1111, F-69007 Lyon, France; [Andre, Patrice] Hosp Civils Lyon, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Perrin-Cocon, L (corresponding author), Ctr Int Rech Infectiol, INSERM, U1111, 21 Av Tony Gamier, F-69007 Lyon, France.	laure.perrin@inserm.fr	lotteau, vincent/M-8143-2014; Perrin-Cocon, Laure A/M-8099-2014; André, Patrice/M-8139-2014	Perrin-Cocon, Laure A/0000-0003-0501-6733; André, Patrice/0000-0002-5834-7395; Lotteau, Vincent/0000-0003-0997-3282	Institut National du Cancer (INCa); Association pour la Recherche contre le Cancer (ARC); Agence Nationale pour la Recherche sur le SIDA et les Hepatites Virales (ANRS) [PAIR-CHC 2009-141]; Ligue Nationale contre le Cancer and the Fondation pour la Recherche Medicale (FRM)	Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); Agence Nationale pour la Recherche sur le SIDA et les Hepatites Virales (ANRS)(ANRSFrench National Research Agency (ANR)); Ligue Nationale contre le Cancer and the Fondation pour la Recherche Medicale (FRM)	This work was funded by Institut National du Cancer (INCa), Association pour la Recherche contre le Cancer (ARC), Agence Nationale pour la Recherche sur le SIDA et les Hepatites Virales (ANRS; grant PAIR-CHC 2009-141), and Region Rhone-Alpes (SRESR 2009-cluster X), doctoral fellowship from the Ligue Nationale contre le Cancer and the Fondation pour la Recherche Medicale (FRM) to A.V.G. The authors acknowledge the contribution of the PLATIM platform, the AniRA Level 3 security laboratory and genetic analysis platforms of SFR Biosciences Gerland-Lyon Sud (UMS3444/US8; Lyon, France). The authors gratefully acknowledge the contributions of Dr. Y. Jacob (Institut Pasteur, Paris, France) and Dr. M. F. Bourgeade [Institut National de la Sante et de la Recherche Medicale (INSERM) U785, Paris, France] for helpful discussions and materials. The authors thank Prof. Ralf Bartenschlager (University of Heidelberg, Heidelberg, Germany) for providing Huh9.13 cells, and Prof. D. Lamarre (University of Montreal, Montreal, QC, Canada) for providing BILN2061. The authors also thank Lionel Tafforeau and Thibault Chantier (INSERM U851, Lyon, France), Philippe Mangeot (INSERM U1111, Lyon, France), and Benoit de Chassey (Hospices Civiles de Lyon, Lyon, France) for providing materials and expert technical assistance.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Akkari L, 2012, J HEPATOL, V57, P1021, DOI 10.1016/j.jhep.2012.06.027; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Bose SK, 2012, J VIROL, V86, P13621, DOI 10.1128/JVI.02016-12; Brass V, 2008, P NATL ACAD SCI USA, V105, P14545, DOI 10.1073/pnas.0807298105; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Choi SS, 2009, HEPATOLOGY, V50, P2007, DOI 10.1002/hep.23196; de Chassey B, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.66; de Chassey B, 2012, CURR OPIN VIROL, V2, P606, DOI 10.1016/j.coviro.2012.09.001; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Divella R, 2012, ANTICANCER RES, V32, P141; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jiang Z, 2010, BIOSCIENCE REP, V30, P383, DOI 10.1042/BSR20090129; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin ZS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043593; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Malizia AP, 2009, EXP CELL RES, V315, P1819, DOI 10.1016/j.yexcr.2009.04.001; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, GENE DEV, V14, P627; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Navratil V, 2009, NUCLEIC ACIDS RES, V37, pD661, DOI 10.1093/nar/gkn794; Nishioka M, 2013, MOL CARCINOGEN, V52, P207, DOI 10.1002/mc.21845; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; Pellet J, 2010, NUCLEIC ACIDS RES, V38, pD371, DOI 10.1093/nar/gkp1000; Ray S, 2003, J GASTROEN HEPATOL, V18, P393, DOI 10.1046/j.1440-1746.2003.02985.x; Saitoh T, 2002, INT J MOL MED, V10, P345; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Strizzi L, 2012, CANCER RES, V72, P1915, DOI 10.1158/0008-5472.CAN-11-3419; Tang LY, 2011, EMBO J, V30, P4777, DOI 10.1038/emboj.2011.393; Thibeault D, 2009, BIOCHEMISTRY-US, V48, P744, DOI 10.1021/bi801931e; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; van Zijl F, 2009, FUTURE ONCOL, V5, P1169, DOI [10.2217/fon.09.91, 10.2217/FON.09.91]; Wilson GK, 2012, J HEPATOL, V56, P803, DOI 10.1016/j.jhep.2011.11.018; Yamazaki K, 2011, DIGEST DIS, V29, P284, DOI 10.1159/000327560; Zhang P, 2012, J BIOL CHEM, V287, P21290, DOI 10.1074/jbc.M112.357202	49	13	13	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4027	4040		10.1096/fj.13-229187	http://dx.doi.org/10.1096/fj.13-229187			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23781096				2022-12-28	WOS:000329747100017
J	Braun, TP; Grossberg, AJ; Krasnow, SM; Levasseur, PR; Szumowski, M; Zhu, XX; Maxson, JE; Knoll, JG; Barnes, AP; Marks, DL				Braun, Theodore P.; Grossberg, Aaron J.; Krasnow, Stephanie M.; Levasseur, Peter R.; Szumowski, Marek; Zhu, Xin Xia; Maxson, Julia E.; Knoll, J. Gabriel; Barnes, Anthony P.; Marks, Daniel L.			Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle	FASEB JOURNAL			English	Article						adenocarcinoma; atrophy; inflammation; lipopolysaccharide; MyD88; sickness behavior; corticosterone	PITUITARY-ADRENAL AXIS; PROTEIN-DEGRADATION; UBIQUITIN-PROTEASOME; WEIGHT-LOSS; ATROPHY; RATS; ACTIVATION; RECEPTOR; MICE; LIPOPOLYSACCHARIDE	Cachexia is a wasting condition defined by skeletal muscle atrophy in the setting of systemic inflammation. To explore the site at which inflammatory mediators act to produce atrophy in vivo, we utilized mice with a conditional deletion of the inflammatory adaptor protein myeloid differentiation factor 88 (MyD88). Although whole-body MyD88-knockout (wbMyD88KO) mice resist skeletal muscle atrophy in response to LPS, muscle-specific deletion of MyD88 is not protective. Furthermore, selective reexpression of MyD88 in the muscle of wbMyD88KO mice via electroporation fails to restore atrophy gene induction by LPS. To evaluate the role of glucocorticoids as the inflammation-induced mediator of atrophy in vivo, we generated mice with targeted deletion of the glucocorticoid receptor in muscle (mGRKO mice). Muscle-specific deletion of the glucocorticoid receptor affords a 71% protection against LPS-induced atrophy compared to control animals. Furthermore, mGRKO mice exhibit 77% less skeletal muscle atrophy than control animals in response to tumor growth. These data demonstrate that glucocorticoids are a major determinant of inflammation-induced atrophy in vivo and play a critical role in the pathogenesis of endotoxemic and cancer cachexia.Braun, T. P., Grossberg, A. J., Krasnow, S. M., Levasseur, P. R., Szumowski, M., Zhu, X. X., Maxson, J. E., Knoll, J. G., Barnes, A. P., and Marks, D. L. Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.	[Braun, Theodore P.; Grossberg, Aaron J.; Krasnow, Stephanie M.; Levasseur, Peter R.; Szumowski, Marek; Zhu, Xin Xia; Knoll, J. Gabriel; Barnes, Anthony P.; Marks, Daniel L.] Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Portland, OR 97239 USA; [Maxson, Julia E.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA; [Maxson, Julia E.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Marks, DL (corresponding author), Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, 3181 SW Sam Jackson Pk Rd,Mail Code L-481, Portland, OR 97239 USA.	marksd@ohsu.edu	Grossberg, Aaron/AAD-6686-2021; Marks, Daniel/C-3712-2009	Barnes, Anthony/0000-0002-4598-9591; Grossberg, Aaron/0000-0003-4690-4948; Braun, Theodore/0000-0002-6248-2143	U.S. National Institutes of Health [DK-70333, DK-084646]; Canadian Institutes of Health Research [200948]; Rubinstein Radiation Research Scholarship; Portland Achievement Awards for College (ARCS); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070333, F30DK084646] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Rubinstein Radiation Research Scholarship; Portland Achievement Awards for College (ARCS); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funding was provided by U.S. National Institutes of Health grants DK-70333 and DK-084646, Canadian Institutes of Health Research grant 200948, the Rubinstein Radiation Research Scholarship, and the Portland Achievement Awards for College (ARCS) chapter. The authors declare no conflicts of interest.	Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Braun TP, 2011, J EXP MED, V208, P2449, DOI 10.1084/jem.20111020; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; DEWYS WD, 1986, CLINICS ONCOL, V5, P251; Doyle A, 2011, FASEB J, V25, P99, DOI 10.1096/fj.10-164152; Elander L, 2009, J NEUROSCI, V29, P1404, DOI 10.1523/JNEUROSCI.5247-08.2009; EVANS WK, 1985, CANCER RES, V45, P3347; Gilson H, 2007, ENDOCRINOLOGY, V148, P452, DOI 10.1210/en.2006-0539; GOLDBERG AL, 1988, J CLIN INVEST, V81, P1378, DOI 10.1172/JCI113466; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Gosselin C, 1997, PHYSIOL BEHAV, V62, P519, DOI 10.1016/S0031-9384(97)00010-3; HEIKINHEIMO O, 1994, HUM REPROD, V9, P40, DOI 10.1093/humrep/9.suppl_1.40; Hu ZY, 2009, J CLIN INVEST, V119, P3059, DOI 10.1172/JCI38770; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Li W, 2009, AM J PHYSIOL-CELL PH, V297, pC706, DOI 10.1152/ajpcell.00626.2008; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; Llovera M, 1996, CANCER LETT, V99, P7, DOI 10.1016/0304-3835(95)04026-9; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MATHISON JC, 1980, AM J PATHOL, V101, P245; MAY RC, 1986, J CLIN INVEST, V77, P614, DOI 10.1172/JCI112344; MEALY K, 1990, ARCH SURG-CHICAGO, V125, P42; Mealy K., 1990, ARCH SURG-CHICAGO, V125, P47; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; Ogimoto K, 2006, ENDOCRINOLOGY, V147, P4445, DOI 10.1210/en.2006-0465; Paul PK, 2010, J CELL BIOL, V191, P1395, DOI 10.1083/jcb.201006098; Rivadeneira DE, 1999, NUTR CANCER, V35, P202, DOI 10.1207/S15327914NC352_16; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001; Tan BHL, 2009, CLIN CANCER RES, V15, P6973, DOI 10.1158/1078-0432.CCR-09-1525; TANAKA Y, 1990, CANCER RES, V50, P2290; TESSITORE L, 1994, BIOCHEM J, V299, P71, DOI 10.1042/bj2990071; Tiao G, 1997, AM J PHYSIOL-REG I, V272, pR849, DOI 10.1152/ajpregu.1997.272.3.R849; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; Van Gammeren D, 2009, FASEB J, V23, P362, DOI 10.1096/fj.08-114249; Watson ML, 2012, AM J PHYSIOL-ENDOC M, V302, pE1210, DOI 10.1152/ajpendo.00512.2011; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; ZAMIR O, 1993, METABOLISM, V42, P204, DOI 10.1016/0026-0495(93)90036-N; Zamir O, 1992, Mediators Inflamm, V1, P247, DOI 10.1155/S0962935192000371	42	71	71	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3572	3582		10.1096/fj.13-230375	http://dx.doi.org/10.1096/fj.13-230375			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23733748	Green Published			2022-12-28	WOS:000328840500017
J	Coudyzer, P; Lemoine, P; Jordan, BF; Gallez, B; Galant, C; Nisolle, M; Courtoy, PJ; Henriet, P; Marbaix, E				Coudyzer, Pauline; Lemoine, Pascale; Jordan, Benedicte F.; Gallez, Bernard; Galant, Christine; Nisolle, Michelle; Courtoy, Pierre J.; Henriet, Patrick; Marbaix, Etienne			Hypoxia is not required for human endometrial breakdown or repair in a xenograft model of menstruation	FASEB JOURNAL			English	Article						mouse model; estradiol and progesterone; matrix metalloproteinases; hypoxia-induced factor 1-alpha; pimonidazole	ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; OVARIAN-STEROIDS; IMMUNODEFICIENT MICE; TISSUE BREAKDOWN; STROMAL CELLS; EXPRESSION; ANGIOGENESIS; REGENERATION; WITHDRAWAL	Menstrual endometrial breakdown induced by estradiol and progesterone withdrawal is regularly attributed to vasospasm of spiral arteries causing ischemia and hypoxia. We investigated whether hypoxia actually occurred in an in vivo model of menstruation. Three complementary approaches were used to look for signs of hypoxia in fragments of human functionalis xenografted to ovariectomized immunodeficient mice bearing pellets-releasing estradiol and progesterone, and then deprived of ovarian steroids. Hormone withdrawal 21 d after grafting induced menstrual breakdown and MMP expression within 4 d. Local partial oxygen pressure (pO(2)) was measured by electron paramagnetic resonance using implanted lithium phtalocyanine crystals. In mice with hormone maintenance until sacrifice, pO(2) was low one week after grafting (14.8 +/- 3.4 mmHg) but increased twofold from the second week when tissue was largely revascularized. After 3 wk, pO(2) was not modified by hormone withdrawal but was slightly increased on hormone reimpregnation 4 d after removal (34.7 +/- 6.1 mmHg) by comparison with hormone maintenance (27.1 +/- 8.6 mmHg). These results were confirmed using fluorescence quenching-based OxyLite measurements. In a further search for signs of hypoxia, we did not find significant HIF1-alpha immunostaining, nor pimonidazole adducts after hormone withdrawal. We conclude that hypoxia is not needed to trigger menstrual-like tissue breakdown or repair in human endometrial xenograft.Coudyzer, P., Lemoine, P., Jordan, B. F., Gallez, B., Galant, C., Nisolle, M., Courtoy, P. J., Henriet, P., and Marbaix, E. Hypoxia is not required for human endometrial breakdown or repair in a xenograft model of menstruation.	[Coudyzer, Pauline; Lemoine, Pascale; Courtoy, Pierre J.; Henriet, Patrick; Marbaix, Etienne] Catholic Univ Louvain, Cell Biol Unit, de Duve Inst, B-1200 Brussels, Belgium; [Jordan, Benedicte F.; Gallez, Bernard] Catholic Univ Louvain, Biomed Magnet Resonance Res Grp, Louvain Drug Res Inst, B-1200 Brussels, Belgium; [Galant, Christine] Catholic Univ Louvain, Dept Pathol, Inst Rech Expt & Clin, B-1200 Brussels, Belgium; [Nisolle, Michelle] Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl, Liege, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Liege	Marbaix, E (corresponding author), de Duve Inst, Cell Biol Unit, Ave Hippocrate,75 B1-75-02, B-1200 Brussels, Belgium.	etienne.marbaix@uclouvain.be		Henriet, Patrick/0000-0003-4602-8888	Fonds de la Recherche Scientifique Medicale; Concerted Research Actions, Communaute Francaise de Belgique	Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Concerted Research Actions, Communaute Francaise de Belgique	The authors thank the patients, as well as Professor J. Donnez and the staff of the Gynaecologic Department of the Cliniques Universitaires Saint-Luc, for providing endometrial tissues. The authors also thank H. P. Gaide Chevronnay for contribution to culture of endometrial explants under hypoxia. This work was supported by the Fonds de la Recherche Scientifique Medicale; Concerted Research Actions, Communaute Francaise de Belgique. P. H. and B. F. J. are research associates of the Fonds de la Recherche Scientifique (FRS-FNRS).	Battersby S, 2004, REPRODUCTION, V127, P79, DOI 10.1530/rep.1.00038; BERGQVIST A, 1985, AM J PATHOL, V121, P337; Brosens IA, 1997, AM J OBSTET GYNECOL, V176, P263, DOI 10.1016/S0002-9378(97)70482-4; CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120; Chevronnay HPG, 2008, ENDOCRINOLOGY, V149, P1015, DOI 10.1210/en.2007-0849; Chevronnay HPG, 2012, BBA-PROTEINS PROTEOM, V1824, P146, DOI 10.1016/j.bbapap.2011.09.003; Chevronnay HPG, 2010, ENDOCRINOLOGY, V151, P4515, DOI 10.1210/en.2009-1398; Chevronnay HPG, 2009, ENDOCRINOLOGY, V150, P5094, DOI 10.1210/en.2009-0750; Cornet PB, 2005, J CLIN ENDOCR METAB, V90, P1001, DOI 10.1210/jc.2004-1277; Critchley HOD, 1999, J CLIN ENDOCR METAB, V84, P240, DOI 10.1210/jc.84.1.240; Critchley HOD, 2006, ENDOCRINOLOGY, V147, P744, DOI 10.1210/en.2005-1153; Du HL, 2012, STEM CELLS DEV, V21, P3324, DOI 10.1089/scd.2011.0193; Eggermont J, 2005, FERTIL STERIL, V84, P492, DOI 10.1016/j.fertnstert.2005.03.034; Fan XJ, 2008, FASEB J, V22, P3571, DOI 10.1096/fj.08-111401; Fraser IS, 2000, STEROIDS, V65, P665, DOI 10.1016/S0039-128X(00)00188-4; Gallez B, 2004, NMR BIOMED, V17, P240, DOI 10.1002/nbm.900; Gannon BJ, 1997, HUM REPROD, V12, P132, DOI 10.1093/humrep/12.1.132; Garry R, 2010, BJOG-INT J OBSTET GY, V117, P1175, DOI 10.1111/j.1471-0528.2010.02630.x; Gonzalez MLA, 2009, HUM REPROD, V24, P2217, DOI 10.1093/humrep/dep203; Graubert MD, 2001, AM J PATHOL, V158, P1399, DOI 10.1016/S0002-9440(10)64091-6; Henriet P, 2012, MOL CELL ENDOCRINOL, V358, P197, DOI 10.1016/j.mce.2011.07.042; Jabbour HN, 2006, ENDOCR REV, V27, P17, DOI 10.1210/er.2004-0021; Ljungkvist ASE, 2000, INT J RADIAT ONCOL, V48, P1529, DOI 10.1016/S0360-3016(00)00787-2; MARKEE JE, 1978, AM J OBSTET GYNECOL, V131, P558; Masuda H, 2007, P NATL ACAD SCI USA, V104, P1925, DOI 10.1073/pnas.0604310104; Matsuura-Sawada R, 2005, HUM REPROD, V20, P1477, DOI 10.1093/humrep/deh783; Maybin JA, 2011, J CLIN ENDOCR METAB, V96, P2475, DOI 10.1210/jc.2010-2971; Maybin JA, 2011, AM J PATHOL, V178, P1245, DOI 10.1016/j.ajpath.2010.11.070; Nap AW, 2004, J CLIN ENDOCR METAB, V89, P1089, DOI 10.1210/jc.2003-031406; Popovici RM, 1999, J CLIN ENDOCR METAB, V84, P2245, DOI 10.1210/jc.84.6.2245; Pretto CM, 2008, J CLIN ENDOCR METAB, V93, P4126, DOI 10.1210/jc.2007-2636; Punyadeera C, 2006, MOL HUM REPROD, V12, P367, DOI 10.1093/molehr/gal027; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Sharkey AM, 2000, J CLIN ENDOCR METAB, V85, P402, DOI 10.1210/jc.85.1.402; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Smith SK, 2001, TRENDS ENDOCRIN MET, V12, P147, DOI 10.1016/S1043-2760(01)00379-4; Vassilev V, 2005, J CLIN ENDOCR METAB, V90, P5848, DOI 10.1210/jc.2005-0762; Zhang J, 2002, HUM REPROD, V17, P265, DOI 10.1093/humrep/17.2.265	38	16	17	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3711	3719		10.1096/fj.13-232074	http://dx.doi.org/10.1096/fj.13-232074			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729593				2022-12-28	WOS:000328840500029
J	Huang, BW; Ray, PD; Iwasaki, K; Tsuji, Y				Huang, Bo-Wen; Ray, Paul D.; Iwasaki, Kenta; Tsuji, Yoshiaki			Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4	FASEB JOURNAL			English	Article						arsenic; histone methylation; antioxidant; oxidative stress	ANTIOXIDANT-RESPONSIVE ELEMENT; OXIDATIVE STRESS; REACTIVE OXYGEN; H-GENE; HISTONE H3; INDUCED APOPTOSIS; RECEPTOR FUNCTION; IRON HOMEOSTASIS; IN-VIVO; METHYLATION	Antioxidant genes such as ferritin are transcriptionally activated in oxidative stress via the antioxidant responsive element (ARE), to which nuclear factor-E2-related factor 2 (Nrf2) binds and activates transcription. Histone modification plays a cooperative and essential role in transcriptional regulation; however, its role in antioxidant gene transcription remains elusive. Arsenic exposure activated ferritin transcription via the ARE concomitant with increased methylation of histones H4Arg3 (H4R3) and H3Arg17 (H3R17). To test our hypothesis that histone H4R3 and H3R17 methylation regulates ferritin transcription, H4R3 and H3R17 protein arginine (R) methyltransferases 1 and 4 (PRMT1 and PRMT4) were investigated. Arsenic exposure of human HaCaT keratinocytes induced nuclear accumulation of PRMT1 and PRMT4, histone H4R3 and H3R17 methylation proximal to the ARE, but not to the non-ARE regions of ferritin genes. PRMT1 or PRMT4 knockdown did not block Nrf2 nuclear accumulation but inhibited Nrf2 binding to the AREs by approximate to 40% (P<0.05), thus diminishing ferritin transcription in HaCaT and human primary keratinocytes and fibroblasts, causing enhanced cellular susceptibility to arsenic toxicity as evidenced by 2-fold caspase 3 activation. Focused microarray further characterized several oxidative stress response genes are subject to PRMT1 or PRMT4 regulation. Collectively, PRMT1 and PRMT4 regulate the ARE and cellular antioxidant response to arsenic.Huang, B.-W., Ray, P. D., Iwasaki, K., Tsuji, Y. Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4.	[Huang, Bo-Wen; Ray, Paul D.; Tsuji, Yoshiaki] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Iwasaki, Kenta] Nagoya Univ, Sch Med, Dept Appl Immunol, Nagoya, Aichi 466, Japan	University of North Carolina; North Carolina State University; Nagoya University	Tsuji, Y (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	ytsuji@ncsu.edu		Iwasaki, Kenta/0000-0003-3229-5192	U.S. National Institutes of Health (NIH) from National Institute of General Medical Sciences [R01GM088392, RO1GM095550]; NIH from National Institute of Environmental Health Sciences [T32ES007046]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM095550, R01GM088392] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) from National Institute of General Medical Sciences; NIH from National Institute of Environmental Health Sciences; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by U.S. National Institutes of Health (NIH) grants R01GM088392 and RO1GM095550 from the National Institute of General Medical Sciences to Y.T. P. D. R. was supported by NIH training grant T32ES007046 from the National Institute of Environmental Health Sciences.	ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Arosio P, 2002, FREE RADICAL BIO MED, V33, P457, DOI 10.1016/S0891-5849(02)00842-0; Barchowsky A, 1999, FREE RADICAL BIO MED, V27, P1405, DOI 10.1016/S0891-5849(99)00186-0; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen C, 2011, NAT REV MOL CELL BIO, V12, P629, DOI 10.1038/nrm3185; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Di Lorenzo A, 2011, FEBS LETT, V585, P2024, DOI 10.1016/j.febslet.2010.11.010; Feng Q, 2009, J BIOL CHEM, V284, P36167, DOI 10.1074/jbc.M109.065524; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hintze KJ, 2005, P NATL ACAD SCI USA, V102, P15048, DOI 10.1073/pnas.0505148102; Hsu CH, 2012, ONCOGENE, V31, P2335, DOI 10.1038/onc.2011.415; Huang X, 2003, MUTAT RES-FUND MOL M, V533, P153, DOI 10.1016/j.mrfmmm.2003.08.023; Iwasaki K, 2006, MOL CELL BIOL, V26, P2845, DOI 10.1128/MCB.26.7.2845-2856.2006; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Kim JH, 2013, ONCOGENE, V32, P514, DOI 10.1038/onc.2012.59; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Latham JA, 2007, NAT STRUCT MOL BIOL, V14, P1017, DOI 10.1038/nsmb1307; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lin W, 2006, J BIOCHEM MOL BIOL, V39, P304; Litt M, 2009, BIOSCIENCE REP, V29, P131, DOI 10.1042/BSR20080176; MacKenzie EL, 2008, FREE RADICAL BIO MED, V44, P1762, DOI 10.1016/j.freeradbiomed.2008.01.031; Mackenzie EL, 2008, ANTIOXID REDOX SIGN, V10, P997, DOI 10.1089/ars.2007.1893; Mackenzie EL, 2008, BIOCHEM J, V411, P107, DOI 10.1042/BJ20071544; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pi JB, 2003, EXP CELL RES, V290, P234, DOI 10.1016/S0014-4827(03)00341-0; Pi JB, 2010, J BIOL CHEM, V285, P9292, DOI 10.1074/jbc.M109.093955; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Reichard JF, 2007, NUCLEIC ACIDS RES, V35, P7074, DOI 10.1093/nar/gkm638; Reichard JF, 2010, EPIGENOMICS-UK, V2, P87, DOI [10.2217/epi.09.45, 10.2217/EPI.09.45]; Rossman TG, 2003, MUTAT RES-FUND MOL M, V533, P37, DOI 10.1016/j.mrfmmm.2003.07.009; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sakamoto K, 2009, MOL BIOL CELL, V20, P1606, DOI 10.1091/mbc.E08-07-0762; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Sun Z, 2009, MOL CELL BIOL, V29, P2658, DOI 10.1128/MCB.01639-08; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Teyssier C, 2010, TRENDS ENDOCRIN MET, V21, P181, DOI 10.1016/j.tem.2009.11.002; Theil EC, 2006, J INORG BIOCHEM, V100, P2074, DOI 10.1016/j.jinorgbio.2006.09.011; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Tsuji Y, 2005, ONCOGENE, V24, P7567, DOI 10.1038/sj.onc.1208901; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wu J, 2006, FREE RADICAL BIO MED, V40, P444, DOI 10.1016/j.freeradbiomed.2005.08.035; Wu JC, 2012, P NATL ACAD SCI USA, V109, P5675, DOI 10.1073/pnas.1114905109; Xie Y, 2009, J BIOL CHEM, V284, P9199, DOI 10.1074/jbc.M806193200; Yamagata K, 2008, MOL CELL, V32, P221, DOI 10.1016/j.molcel.2008.09.013; Zhang J, 2007, BIOCHEM J, V404, P459, DOI 10.1042/BJ20061611; Zhang JY, 2006, MOL CELL BIOL, V26, P7942, DOI 10.1128/MCB.00700-06; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907; Zhao R, 2011, ENVIRON HEALTH PERSP, V119, P56, DOI 10.1289/ehp.1002304	68	29	30	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3763	3774		10.1096/fj.12-226043	http://dx.doi.org/10.1096/fj.12-226043			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23699174	Green Published			2022-12-28	WOS:000328840500034
J	Borst, O; Munzer, P; Schmid, E; Schmidt, EM; Russo, A; Walker, B; Yang, WT; Leibrock, C; Szteyn, K; Schmidt, S; Elvers, M; Faggio, C; Shumilina, E; Kuro-o, M; Gawaz, M; Lang, F				Borst, Oliver; Muenzer, Patrick; Schmid, Evi; Schmidt, Eva-Maria; Russo, Antonella; Walker, Britta; Yang, Wenting; Leibrock, Christina; Szteyn, Kalina; Schmidt, Sebastian; Elvers, Margitta; Faggio, Caterina; Shumilina, Ekaterina; Kuro-o, Makoto; Gawaz, Meinrad; Lang, Florian			1,25( OH)(2) vitamin D-3-dependent inhibition of platelet Ca2+ signaling and thrombus formation in klotho-deficient mice	FASEB JOURNAL			English	Article						SOCE; STIM1; megakaryocytes; Orai1; NF-B	KAPPA-B PATHWAY; 1,25-DIHYDROXYVITAMIN D-3; D-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; CARDIOVASCULAR-DISEASE; DENDRITIC CELLS; DOWN-REGULATION; OLDER-ADULTS; EXPRESSION; GENE	Platelets are activated by increased cytosolic Ca2+ concentration ([Ca2+](i)) following store-operated calcium entry (SOCE) accomplished by calcium-release-activated calcium (CRAC) channel moiety Orai1 and its regulator STIM1. In other cells, Ca2+ transport is regulated by 1,25(OH)(2) vitamin D-3 [1,25(OH)(2)D-3]. 1,25(OH)(2)D-3 formation is inhibited by klotho and excessive in klotho-deficient mice (kl/kl). The present study explored the effect of klotho deficiency on platelet Ca2+ signaling and activation. Platelets and megakaryocytes isolated from WT and kl/kl-mice were analyzed by RT-PCR, Western blotting, confocal microscopy, Fura-2-fluorescence, patch clamp, flow cytometry, aggregometry, and flow chamber. STIM1/Orai1 transcript and protein levels, SOCE, agonist-induced [Ca2+](i) increase, activation-dependent degranulation, integrin (IIb3) activation and aggregation, and thrombus formation were significantly blunted in kl/kl platelets (by 27-90%). STIM1/Orai1 transcript and protein levels, as well as CRAC currents, were significantly reduced in kl/kl megakaryocytes (by 38-73%) and 1,25(OH)(2)D-3-treated WT megakaryocytes. Nuclear NF-B subunit p50/p65 abundance was significantly reduced in kl/kl-megakaryocytes (by 51-76%). Transfection with p50/p65 significantly increased STIM1/Orai1 transcript and protein levels in megakaryocytic MEG-01 cells (by 46-97%). Low-vitamin D diet (LVD) of kl/kl mice normalized plasma 1,25(OH)(2)D-3 concentration and function of platelets and megakaryocytes. Klotho deficiency inhibits platelet Ca2+ signaling and activation, an effect at least partially due to 1,25(OH)(2)D-3-dependent down-regulation of NF-B activity and STIM1/Orai1 expression in megakaryocytes.Borst, O., Munzer, P., Schmid, E., Schmidt, E.-M., Russo, A., Walker, B., Yang, W., Leibrock, C., Szteyn, K., Schmidt, S., Elvers, M., Faggio, C., Shumilina, E., Kuro-o, M., Gawaz, M., Lang, F. 1,25(OH)(2) vitamin D-3-dependent inhibition of platelet Ca2+ signaling and thrombus formation in klotho-deficient mice.	[Borst, Oliver; Elvers, Margitta; Gawaz, Meinrad] Univ Tubingen, Dept Cardiol & Cardiovasc Med, D-72076 Tubingen, Germany; [Borst, Oliver; Muenzer, Patrick; Schmid, Evi; Schmidt, Eva-Maria; Russo, Antonella; Walker, Britta; Yang, Wenting; Leibrock, Christina; Szteyn, Kalina; Schmidt, Sebastian; Shumilina, Ekaterina; Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; [Schmidt, Eva-Maria; Faggio, Caterina] Univ Tubingen, Dept Behav Neurobiol, D-72076 Tubingen, Germany; [Russo, Antonella] Univ Messina, Dept Biol & Environm Sci, Sant Agata Di Messina, Italy; [Elvers, Margitta] Univ Dusseldorf, Dept Clin & Expt Hemostasis, Dusseldorf, Germany; [Kuro-o, Makoto] Univ Texas Dallas, Dept Pathol, Dallas, TX 75230 USA	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Messina; Heinrich Heine University Dusseldorf; University of Texas System; University of Texas Dallas	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de		Borst, Oliver/0000-0003-4002-4085; faggio, caterina/0000-0002-0066-2421; Munzer, Patrick/0000-0001-5357-038X	Deutsche Forschungsgemeinschaft [KFO 274, BO 3786/1-1]; Fortune research grant [2133-0]; Tubingen Platelet Investigative Consortium (TuePIC)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fortune research grant; Tubingen Platelet Investigative Consortium (TuePIC)	This study has been supported by the Deutsche Forschungsgemeinschaft (KFO 274, Platelets-Molecular Mechanisms and Translational Implications; and BO 3786/1-1), a Fortune research grant (2133-0; to O.B.), and the Tubingen Platelet Investigative Consortium (TuePIC). The authors declare no conflicts of interest.	Aihara K, 2004, J BIOL CHEM, V279, P35798, DOI 10.1074/jbc.M404865200; Authi KS, 2009, BLOOD, V113, P1872, DOI 10.1182/blood-2008-11-185959; Bao BY, 2006, CARCINOGENESIS, V27, P1883, DOI 10.1093/carcin/bgl041; Beaulieu LM, 2011, BLOOD, V117, P5963, DOI 10.1182/blood-2010-09-304949; Bergmeier W, 2009, J THROMB HAEMOST, V7, P187, DOI 10.1111/j.1538-7836.2009.03379.x; Bergmeier W, 2009, BLOOD, V113, P675, DOI 10.1182/blood-2008-08-174516; Borst O, 2012, CIRC RES, V111, P1297, DOI 10.1161/CIRCRESAHA.112.276444; Borst O, 2012, BLOOD, V119, P251, DOI 10.1182/blood-2011-06-359976; Braun A, 2009, BLOOD, V113, P2056, DOI 10.1182/blood-2008-07-171611; Brondum-Jacobsen P, 2012, ARTERIOSCL THROM VAS, V32, P2794, DOI 10.1161/ATVBAHA.112.248039; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Deb DK, 2009, AM J PHYSIOL-RENAL, V296, pF1212, DOI 10.1152/ajprenal.00002.2009; Dong XY, 2005, P NATL ACAD SCI USA, V102, P16007, DOI 10.1073/pnas.0506516102; Dong XY, 2003, J BIOL CHEM, V278, P49378, DOI 10.1074/jbc.M308448200; Elvers M, 2012, BLOOD, V120, P1317, DOI 10.1182/blood-2011-12-398438; Eylenstein A, 2012, J BIOL CHEM, V287, P2719, DOI 10.1074/jbc.M111.275925; Fischer SS, 2010, AM J PHYSIOL-RENAL, V299, pF1171, DOI 10.1152/ajprenal.00233.2010; Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196; Geldmeyer-Hilt K, 2011, BIOCHEM BIOPH RES CO, V407, P699, DOI 10.1016/j.bbrc.2011.03.078; Giarratana N, 2004, J IMMUNOL, V173, P2280, DOI 10.4049/jimmunol.173.4.2280; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; Grosse J, 2007, J CLIN INVEST, V117, P3540, DOI 10.1172/JCI32312; Gupta S, 2012, CIRC RES, V111, P1410, DOI 10.1161/CIRCRESAHA.112.264754; Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029; Hu MC, 2013, ANNU REV PHYSIOL, V75, P503, DOI 10.1146/annurev-physiol-030212-183727; Jablonski KL, 2011, HYPERTENSION, V57, P63, DOI 10.1161/HYPERTENSIONAHA.110.160929; John GB, 2011, AM J KIDNEY DIS, V58, P127, DOI 10.1053/j.ajkd.2010.12.027; Kestenbaum B, 2011, J AM COLL CARDIOL, V58, P1433, DOI 10.1016/j.jacc.2011.03.069; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Koyama T, 1998, BLOOD, V92, P160, DOI 10.1182/blood.V92.1.160.413k16_160_167; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lang F, 2013, THROMB HAEMOSTASIS, V110, P925, DOI 10.1160/TH13-02-0176; Levin GP, 2012, JAMA-J AM MED ASSOC, V308, P1898, DOI 10.1001/jama.2012.17304; Oh J, 2009, CIRCULATION, V120, P687, DOI 10.1161/CIRCULATIONAHA.109.856070; Ohsawa M, 2000, CIRCULATION, V102, P2867; Okada S, 2000, INT IMMUNOL, V12, P861, DOI 10.1093/intimm/12.6.861; Ponda MP, 2012, CIRCULATION, V126, P270, DOI 10.1161/CIRCULATIONAHA.111.077875; Rondina MT, 2013, CIRC RES, V112, P1506, DOI 10.1161/CIRCRESAHA.113.300512; Rosen CJ, 2011, NEW ENGL J MED, V364, P248, DOI 10.1056/NEJMcp1009570; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Schmidt EM, 2013, FASEB J, V27, P2799, DOI 10.1096/fj.13-229286; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; Shumilina E, 2010, FASEB J, V24, P1989, DOI 10.1096/fj.09-142265; Silvagno F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008670; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Varga-Szabo D, 2008, J EXP MED, V205, P1583, DOI 10.1084/jem.20080302; Wallis DE, 2008, CIRCULATION, V118, P1476, DOI 10.1161/CIRCULATIONAHA.107.713339; Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127; Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683; YU XP, 1995, P NATL ACAD SCI USA, V92, P10990, DOI 10.1073/pnas.92.24.10990; Zhang W, 2011, CIRC RES, V109, P534, DOI 10.1161/CIRCRESAHA.111.246777; Zhang Z, 2007, KIDNEY INT, V72, P193, DOI 10.1038/sj.ki.5002296	53	27	31	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2108	2119		10.1096/fj.13-239277	http://dx.doi.org/10.1096/fj.13-239277			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24522202				2022-12-28	WOS:000335336000015
J	Farah, BL; Madden, L; Li, ST; Nance, S; Bird, A; Bursac, N; Yen, PM; Young, SP; Koeberl, DD				Farah, Benjamin L.; Madden, Lauran; Li, Songtao; Nance, Sierra; Bird, Andrew; Bursac, Nenad; Yen, Paul M.; Young, Sarah P.; Koeberl, Dwight D.			Adjunctive beta(2)-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease	FASEB JOURNAL			English	Article						mannose-6-phosphate receptor; gene therapy; adeno-associated virus; acid maltase; autophagy; enzyme replacement therapy	ENZYME REPLACEMENT THERAPY; ADENOASSOCIATED VIRUS VECTOR; MTORC1 SUPPRESSION; IMMUNE-RESPONSES; GENE-THERAPY; MOUSE MODEL; AUTOPHAGY; CLENBUTEROL; RECOMBINANT; EXPRESSION	Enzyme or gene replacement therapy with acid -glucosidase (GAA) has achieved only partial efficacy in Pompe disease. We evaluated the effect of adjunctive clenbuterol treatment on cation-independent mannose-6-phosphate receptor (CI-MPR)-mediated uptake and intracellular trafficking of GAA during muscle-specific GAA expression with an adeno-associated virus (AAV) vector in GAA-knockout (KO) mice. Clenbuterol, which increases expression of CI-MPR in muscle, was administered with the AAV vector. This combination therapy increased latency during rotarod and wirehang testing at 12 wk, in comparison with vector alone. The mean urinary glucose tetrasaccharide (Glc4), a urinary biomarker, was lower in GAA-KO mice following combination therapy, compared with vector alone. Similarly, glycogen content was lower in cardiac and skeletal muscle following 12 wk of combination therapy in heart, quadriceps, diaphragm, and soleus, compared with vector alone. These data suggested that clenbuterol treatment enhanced trafficking of GAA to lysosomes, given that GAA was expressed within myofibers. The integral role of CI-MPR was demonstrated by the lack of effectiveness from clenbuterol in GAA-KO mice that lacked CI-MPR in muscle, where it failed to reverse the high glycogen content of the heart and diaphragm or impaired wirehang performance. However, the glycogen content of skeletal muscle was reduced by the addition of clenbuterol in the absence of CI-MPR, as was lysosomal vacuolation, which correlated with increased AKT signaling. In summary, (2)-agonist treatment enhanced CI-MPR-mediated uptake and trafficking of GAA in mice with Pompe disease, and a similarly enhanced benefit might be expected in other lysosomal storage disorders.Farah, B. L., Madden, L., Li, S., Nance, S., Bird, A., Bursac, N., Yen, P. M., Young, S. P., Koeberl, D. D. Adjunctive 2-agonist treatment reduces glycogen independently of receptor-mediated acid -glucosidase uptake in the limb muscles of mice with Pompe disease.	[Farah, Benjamin L.; Yen, Paul M.] Duke Natl Univ Singapore Grad Med Sch, Cardiovasc & Metab Dis Program, Singapore, Singapore; [Madden, Lauran; Bursac, Nenad] Duke Univ Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA; [Li, Songtao; Nance, Sierra; Bird, Andrew; Young, Sarah P.; Koeberl, Dwight D.] Duke Univ Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27710 USA; [Yen, Paul M.] Duke Univ Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; [Yen, Paul M.] Duke Univ Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; [Yen, Paul M.] Duke Univ Med Ctr, Dept Canc Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Koeberl, DD (corresponding author), Duke Univ Med Ctr, Box 103856, Durham, NC 27710 USA.	koebe001@mc.duke.edu	Bursac, Nenad/AAU-5548-2021; Yen, Paul M/V-9857-2019	Bursac, Nenad/0000-0002-5688-6061; Yen, Paul/0000-0002-3790-8114	U.S. National Institutes of Health (NIH) from the National Heart, Lung, and Blood Institute [R01 HL081122]; NIH from the National Institute of Arthritis and Musculoskeletal and Skin Disorders [R01AR065873]; Singapore National Medical Research Council (NMRC) [NMRC/CIRG/1340/2012]; Genzyme Corp.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR065873] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) from the National Heart, Lung, and Blood Institute; NIH from the National Institute of Arthritis and Musculoskeletal and Skin Disorders; Singapore National Medical Research Council (NMRC)(National Medical Research Council, Singapore); Genzyme Corp.(Sanofi-AventisGenzyme Corporation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by U.S. National Institutes of Health (NIH) grant R01 HL081122 from the National Heart, Lung, and Blood Institute, by NIH grant R01AR065873 from the National Institute of Arthritis and Musculoskeletal and Skin Disorders, and by Singapore National Medical Research Council (NMRC) grant NMRC/CIRG/1340/2012 to P.M.Y. Muscle-specific CI-MPR-KO mice were provided courtesy of Dr. Randy Jirtle (Duke University, Durham, NC, USA). RhGAA was provided under agreement with Genzyme Corp. (Cambridge, MA, USA). The AAV8 packaging plasmid was provided courtesy of Dr. James M. Wilson (University of Pennsylvania, Philadelphia, PA, USA). D. B., D. D. K., and S.P.Y. have received research/grant support from Genzyme Corp. in the past.	Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Ashe KM, 2010, MOL GENET METAB, V100, P309, DOI 10.1016/j.ymgme.2010.05.001; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389; ENGEL AG, 1970, BRAIN, V93, P599, DOI 10.1093/brain/93.3.599; Franco LM, 2005, MOL THER, V12, P876, DOI 10.1016/j.ymthe.2005.04.024; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Iizuka Hiroyuki, 1998, Journal of Smooth Muscle Research, V34, P139; Kamalakkannan G, 2008, J HEART LUNG TRANSPL, V27, P457, DOI 10.1016/j.healun.2008.01.013; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Koeberl DD, 2012, MOL GENET METAB, V105, P221, DOI 10.1016/j.ymgme.2011.11.005; Koeberl DD, 2011, MOL GENET METAB, V103, P107, DOI 10.1016/j.ymgme.2011.02.006; Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773; Li ST, 2013, FASEB J, V27, P34, DOI 10.1096/fj.12-207472; MARTEL RR, 1977, CAN J PHYSIOL PHARM, V55, P48, DOI 10.1139/y77-007; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; McCarty DM, 2004, ANNU REV GENET, V38, P819, DOI 10.1146/annurev.genet.37.110801.143717; Nascimbeni AC, 2012, AUTOPHAGY, V8, P1697, DOI 10.4161/auto.21691; NIALS AT, 1993, BRIT J PHARMACOL, V110, P1112, DOI 10.1111/j.1476-5381.1993.tb13929.x; Nishiyama Y, 2012, MOL GENET METAB, V107, P490, DOI 10.1016/j.ymgme.2012.09.011; Oya Y, 2001, Rinsho Shinkeigaku, V41, P390; Raben N, 2005, MOL THER, V11, P48, DOI 10.1016/j.ymthe.2004.09.017; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; Raben N, 2008, HUM MOL GENET, V17, P3897, DOI 10.1093/hmg/ddn292; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schnepp BC, 2003, J VIROL, V77, P3495, DOI 10.1128/JVI.77.6.3495-3504.2003; Soraru G, 2006, AMYOTROPH LATERAL SC, V7, P246, DOI 10.1080/14660820600600558; Spampanato C, 2013, EMBO MOL MED, V5, P691, DOI 10.1002/emmm.201202176; Sun BD, 2008, MOL THER, V16, P1366, DOI 10.1038/mt.2008.133; Sun BD, 2005, MOL THER, V11, P889, DOI 10.1016/j.ymthe.2005.01.012; Sun BD, 2005, MOL THER, V11, P57, DOI 10.1016/j.ymthe.2004.10.004; Taksir TV, 2007, J HISTOCHEM CYTOCHEM, V55, P991, DOI 10.1369/jhc.7A7239.2007; Torneke K, 1998, J VET PHARMACOL THER, V21, P388, DOI 10.1046/j.1365-2885.1998.00156.x; Wylie AA, 2003, AM J PATHOL, V162, P321, DOI 10.1016/S0002-9440(10)63823-0; Ye Lan, 2012, Frontiers in Genetics, V3, P177, DOI 10.3389/fgene.2012.00177; Young SP, 2009, GENET MED, V11, P536, DOI 10.1097/GIM.0b013e3181a87867; Zhang P, 2012, HUM GENE THER, V23, P460, DOI 10.1089/hum.2011.063; Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11	38	14	14	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2272	2280		10.1096/fj.13-244202	http://dx.doi.org/10.1096/fj.13-244202			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24448824	Green Published, Green Submitted			2022-12-28	WOS:000335336000029
J	Hollinger, K; Yang, CX; Montz, RE; Nonneman, D; Ross, JW; Selsby, JT				Hollinger, Katrin; Yang, Cai X.; Montz, Robyn E.; Nonneman, Dan; Ross, Jason W.; Selsby, Joshua T.			Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin-glycoprotein complex assembly in pig skeletal muscle	FASEB JOURNAL			English	Article						BMD; animal model; Becker muscular dystrophy; Duchenne muscular dystrophy; DMD	DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT MDX MICE; THERAPEUTIC STRATEGIES; MODELS; MUTATION; MOUSE; CONTRACTION; PREDNISONE; DATABASE; RINGO	The purpose of this investigation was to determine the extent to which dystrophin insufficiency caused histomorphological changes in a novel pig model of Becker muscular dystrophy. In our procedures, we used a combination of biochemical approaches, including quantitative PCR and Western blots, along with a histological analysis using standard and immunohistological measures. We found that 8-wk-old male affected pigs had a 70% reduction in dystrophin protein abundance in the diaphragm, psoas major, and longissimus lumborum and a 5-fold increase in serum creatine kinase activity compared with healthy male littermates. Dystrophin insufficiency in the diaphragm and the longissimus resulted in muscle histopathology with disorganized fibrosis that often colocalized with fatty infiltration but not the psoas. Affected animals also had an 80-85% reduction in alpha-sarcoglycan localization in these muscles, indicating compromised assembly of the dystrophin glycoprotein complex. Controls used in this study were 4 healthy male littermates, as they are most closely related to the affected animals. We concluded that pigs with insufficient dystrophin protein expression have a phenotype consistent with human dystrophinopathy patients. Given that and their similarity in body size and physiology to humans, we further conclude that this pig line is an appropriate translational model for dystrophinopathies.-Hollinger, K., Yang, C. X., Montz, R. E., Nonneman, D., Ross, J. W., Selsby, J. T. Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin-glycoprotein complex assembly in pig skeletal muscle.	[Hollinger, Katrin; Yang, Cai X.; Montz, Robyn E.; Ross, Jason W.; Selsby, Joshua T.] Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA; [Nonneman, Dan] ARS, USDA, US Meat Anim Res Ctr, Clay Ctr, NE USA	Iowa State University; United States Department of Agriculture (USDA)	Selsby, JT (corresponding author), Iowa State Univ, Dept Anim Sci, 2356 Kildee Hall, Ames, IA 50011 USA.	jselsby@iastate.edu		Selsby, Joshua/0000-0003-3797-7539	U.S. National Institutes of Health [RR-030232, NS-079603]; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR030232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS079603] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors are grateful for insights provided by Dr. Ted Huiatt. This project was partially supported by the U.S. National Institutes of Health, grants RR-030232 (to J.W.R.) and NS-079603 (to J.T.S.). Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture (USDA).	Aartsma-Rus A, 2006, MUSCLE NERVE, V34, P135, DOI 10.1002/mus.20586; Acsadi G, 2012, J BIOL CHEM, V287, P18153, DOI 10.1074/jbc.M111.284521; Ambrosio CE, 2008, NEUROMUSCULAR DISORD, V18, P892, DOI 10.1016/j.nmd.2008.06.385; Banks GB, 2008, CURR TOP DEV BIOL, V84, P431, DOI 10.1016/S0070-2153(08)00609-1; Brereton D., 2012, PLOS CURRENTS, V4; Briguet A, 2004, NEUROMUSCULAR DISORD, V14, P675, DOI 10.1016/j.nmd.2004.06.008; Chamberlain JS, 2007, FASEB J, V21, P2195, DOI 10.1096/fj.06-7353com; COOPER BJ, 1988, NATURE, V334, P154, DOI 10.1038/334154a0; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DRACHMAN DB, 1974, LANCET, V2, P1409; duVerle David, 2010, V22, P202; ERVASTI JM, 1994, FEBS LETT, V350, P173, DOI 10.1016/0014-5793(94)00748-9; Groenen MAM, 2012, NATURE, V491, P393, DOI 10.1038/nature11622; Hamed SA, 2005, CLIN GENET, V68, P69, DOI 10.1111/j.1399-0004.2005.00455.x; Kornegay JN, 2003, NEUROMUSCULAR DISORD, V13, P493, DOI 10.1016/S0960-8966(03)00025-7; Kornegay JN, 2012, MAMM GENOME, V23, P85, DOI 10.1007/s00335-011-9382-y; LAW DJ, 1994, J CELL SCI, V107, P1477; Legardinier S, 2009, J BIOL CHEM, V284, P8822, DOI 10.1074/jbc.M805846200; Liu JMK, 2004, MUSCLE NERVE, V30, P767, DOI 10.1002/mus.20154; Mangner N, 2012, MUSCLE NERVE, V45, P544, DOI 10.1002/mus.22318; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Nonneman DJ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-233; PENA SDJ, 1987, J NEUROL SCI, V79, P337, DOI 10.1016/0022-510X(87)90240-1; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Prather RS, 2013, ANNU REV ANIM BIOSCI, V1, P203, DOI 10.1146/annurev-animal-031412-103715; Rafael JA, 2000, HUM MOL GENET, V9, P1357, DOI 10.1093/hmg/9.9.1357; Rasband W., 2006, IMAGEJ; Sacco A, 2010, CELL, V143, P1059, DOI 10.1016/j.cell.2010.11.039; Selsby JT, 2013, J APPL PHYSIOL, V115, P660, DOI 10.1152/japplphysiol.00252.2013; Spitali P, 2013, FASEB J, V27, P4909, DOI 10.1096/fj.13-232025; Tuffery-Giraud S, 2009, HUM MUTAT, V30, P934, DOI 10.1002/humu.20976; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Wells D J, 2005, Acta Myol, V24, P172; Zucconi E, 2010, NEUROMUSCULAR DISORD, V20, P64, DOI 10.1016/j.nmd.2009.10.011	36	19	19	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1600	1609		10.1096/fj.13-241141	http://dx.doi.org/10.1096/fj.13-241141			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24347611	Green Published, Green Submitted			2022-12-28	WOS:000335344300009
J	Rodrigue-Way, A; Caron, V; Bilodeau, S; Keil, S; Hassan, M; Levy, E; Mitchell, GA; Tremblay, A				Rodrigue-Way, Amelie; Caron, Veronique; Bilodeau, Stephanie; Keil, Sarah; Hassan, Meryl; Levy, Emile; Mitchell, Grant A.; Tremblay, Andre			Scavenger receptor CD36 mediates inhibition of cholesterol synthesis via activation of the PPAR gamma/PGC-1 alpha pathway and Insig1/2 expression in hepatocytes	FASEB JOURNAL			English	Article						HMG-CoA reductase; hexarelin; Insig-1/2; SREBP-2	HMG-COA REDUCTASE; ELEMENT-BINDING PROTEIN; HORMONE-RELEASING PEPTIDE; PPAR-GAMMA; DIRECT PHOSPHORYLATION; GHRELIN RECEPTOR; SKELETAL-MUSCLE; GENE-EXPRESSION; DEGRADATION; METABOLISM	The scavenger receptor CD36 plays a central role in lipid metabolism by promoting macrophage cholesterol efflux with the potential to reduce atherosclerotic lesions. However, the effect of CD36 on de novo cholesterol synthesis is not known. Here, we describe the cellular mechanism by which CD36 activation induces cholesterol depletion in HepG2 cells. Using the CD36 ligand hexarelin, we found a rapid phosphorylation of HMG-CoA reductase Ser-872 in treated cells, resulting in inactivation of the rate-limiting enzyme in sterol synthesis. Degradation of HMG-CoA reductase by the ubiquitin-proteasome pathway was also enhanced by hexarelin, through an increased recruitment of the anchor proteins insulin-induced gene (Insig)-1 and Insig-2. Genes encoding key enzymes involved in cholesterol synthesis and under the control of transcription factor sterol regulatory element-binding protein (SREBP)-2 remained unresponsive to sterol depletion, due to retention of the SREBP-2 escort protein Scap by Insig-1/2. Insig1 and Insig2 gene expression was also increased through activation of nuclear receptor peroxisome-proliferator activating receptor gamma (PPAR gamma) by CD36, which lifted the inhibitory effect of PPAR gamma 1 Ser-84 phosphorylation. Recruitment of coactivator peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1 alpha) to activated AMPK alpha was also promoted, resulting in PGC-1 alpha transcriptional activation through Sirt1-mediated deacetylation, increased recruitment of PPAR gamma, and up-regulation of Insig-1/2, revealing a regulatory role of CD36 on PGC-1 alpha signaling. Our data identify CD36 as a novel regulator of HMG-CoA reductase function and Insig-1/2 expression, 2 critical steps regulating cholesterol synthesis in hepatocytes.-Rodrigue-Way, A., Caron, V., Bilodeau, S., Keil, S., Hassan, M., Levy, E., Mitchell, G. A., Tremblay, A. Scavenger receptor CD36 mediates inhibition of cholesterol synthesis via activation of the PPAR gamma/PGC-1 alpha pathway and Insig1/2 expression in hepatocytes.	[Rodrigue-Way, Amelie; Caron, Veronique; Bilodeau, Stephanie; Keil, Sarah; Hassan, Meryl; Levy, Emile; Mitchell, Grant A.; Tremblay, Andre] St Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Rodrigue-Way, Amelie; Bilodeau, Stephanie; Keil, Sarah; Mitchell, Grant A.; Tremblay, Andre] Univ Montreal, Fac Med, Dept Biochem & Mol Med, Montreal, PQ H3C 3J7, Canada; [Mitchell, Grant A.] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada; [Tremblay, Andre] Univ Montreal, Fac Med, Dept Obstet & Gynecol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Universite de Montreal; Universite de Montreal	Tremblay, A (corresponding author), Ste Justine Hosp, Res Ctr, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	andre.tremblay.1@umontreal.ca			Canadian Institutes of Health Research [MOP102645]; Canadian Diabetes Association [OG3-12-3827]; Natural Sciences and Engineering Research Council of Canada; Fondation de l'Hopital Ste-Justine	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Diabetes Association; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Fondation de l'Hopital Ste-Justine	The authors thank Pere Puigserver (Harvard Medical School, Boston, MA, USA) for the generous gift of GCN-5 plasmid. This research was supported by the Canadian Institutes of Health Research (grant MOP102645 to A. T.) and by the Canadian Diabetes Association (grant OG3-12-3827 to A. T.). A.R.-W. was supported by a doctoral award from the Natural Sciences and Engineering Research Council of Canada, S. B. by a doctoral award from the Fondation de l'Hopital Ste-Justine, and S. K. by the Faculte des Etudes Superieures de l'Universite de Montreal. The authors declare no conflicts of interest.	Adams BD, 2009, ENDOCRINOLOGY, V150, P14, DOI 10.1210/en.2008-0984; Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Avallone R, 2006, MOL ENDOCRINOL, V20, P3165, DOI 10.1210/me.2006-0146; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; Demers A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007728; Demers A, 2008, PPAR RES, V2008, DOI 10.1155/2008/364784; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Gong Y, 2006, CELL METAB, V3, P15, DOI 10.1016/j.cmet.2005.11.014; Habets DDJ, 2009, BBA-MOL CELL BIOL L, V1791, P212, DOI 10.1016/j.bbalip.2008.12.009; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Janowski BA, 2002, P NATL ACAD SCI USA, V99, P12675, DOI 10.1073/pnas.202471599; Jeon TI, 2012, TRENDS ENDOCRIN MET, V23, P65, DOI 10.1016/j.tem.2011.10.004; Jo Y, 2011, P NATL ACAD SCI USA, V108, P20503, DOI 10.1073/pnas.1112831108; Jo Y, 2010, CRIT REV BIOCHEM MOL, V45, P185, DOI 10.3109/10409238.2010.485605; Kast-Woelbern HR, 2004, J BIOL CHEM, V279, P23908, DOI 10.1074/jbc.M403145200; Konig B, 2009, EUR J PHARMACOL, V605, P23, DOI 10.1016/j.ejphar.2009.01.009; Kojima M, 2001, TRENDS ENDOCRIN MET, V12, P118, DOI 10.1016/S1043-2760(00)00362-3; Lee JN, 2004, J BIOL CHEM, V279, P45257, DOI 10.1074/jbc.M408235200; Leff T, 2003, BIOCHEM SOC T, V31, P224; Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013; LEVY E, 1990, J LIPID RES, V31, P2009; Loirdighi N, 1997, AM J PHYSIOL-GASTR L, V273, pG62, DOI 10.1152/ajpgi.1997.273.1.G62; Luangrath V, 2008, ARTERIOSCL THROM VAS, V28, P1290, DOI 10.1161/ATVBAHA.107.161653; Marcil V, 2006, CARDIOVASC RES, V72, P473, DOI 10.1016/j.cardiores.2006.08.024; Marleau Sylvie, 2005, FASEB J, V19, P1869; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Namgaladze D, 2013, CARDIOVASC RES, V98, P479, DOI 10.1093/cvr/cvt073; Rodrigue-Way A, 2007, ENDOCRINOLOGY, V148, P1009, DOI 10.1210/en.2006-0975; Sanchez M, 2013, ONCOGENE, V32, P117, DOI 10.1038/onc.2012.19; Sauve K, 2009, CANCER RES, V69, P5793, DOI 10.1158/0008-5472.CAN-08-4924; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001; St-Laurent V, 2005, J STEROID BIOCHEM, V94, P23, DOI 10.1016/j.jsbmb.2005.02.001; Thielemans L, 2007, J RECEPT SIG TRANSD, V27, P309, DOI 10.1080/10799890701519587; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Zhou J, 2006, J BIOL CHEM, V281, P15013, DOI 10.1074/jbc.M511116200	46	24	27	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1910	1923		10.1096/fj.13-240168	http://dx.doi.org/10.1096/fj.13-240168			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371122				2022-12-28	WOS:000335344300035
J	Curtil, C; Enache, LS; Radreau, P; Dron, AG; Scholtes, C; Deloire, A; Roche, D; Lotteau, V; Andre, P; Ramiere, C				Curtil, Claire; Enache, Liviu S.; Radreau, Pauline; Dron, Anne-Gaelle; Scholtes, Caroline; Deloire, Alexandre; Roche, Didier; Lotteau, Vincent; Andre, Patrice; Ramiere, Christophe			The metabolic sensors FXR alpha, PGC-1 alpha, and SIRT1 cooperatively regulate hepatitis B virus transcription	FASEB JOURNAL			English	Article						HBV; epigenetic; metabolism; nuclear receptors	DEACETYLASE; DELETION; ELEMENTS; ENHANCER; HBV	Hepatitis B virus (HBV) genome transcription is highly dependent on liver-enriched, metabolic nuclear receptors (NRs). Among others, NR farnesoid X receptor (FXR) enhances HBV core promoter activity and pregenomic RNA synthesis. Interestingly, two food-withdrawal-induced FXR modulators, peroxisome proliferator-activated receptor- coactivator 1 (PGC-1) and deacetylase SIRT1, have been found to be associated with HBV genomes ex vivo. Whereas PGC-1 induction was shown to increase HBV replication, the effect of SIRT1 on HBV transcription remains unknown. Here, we showed that, in hepatocarcinoma-derived Huh-7 cells, combined activation of FXR by GW4064 and SIRT1 by activator 3 increased HBV core promoter-controlled luciferase expression by 25-fold, compared with a 10-fold increase with GW4064 alone. Using cell lines differentially expressing FXR in overexpression and silencing experiments, we demonstrated that SIRT1 activated the core promoter in an FXR- and PGC-1-dependent manner. Maximal activation (>150-fold) was observed in FXR- and PGC-1-overexpressing Huh-7 cells treated with FXR and SIRT1 activators. Similarly, in cells transfected with full-length HBV genomes, maximal induction (3.5-fold) of core promoter-controlled synthesis of 3.5-kb RNA was observed in the same conditions of transfection and treatments. Thus, we identified a subnetwork of metabolic factors regulating HBV replication, strengthening the hypothesis that transcription of HBV and metabolic genes is similarly controlled.Curtil, C., Enache, L. S., Radreau, P., Dron, A.-G., Scholtes, C., Deloire, A., Roche, D., Lotteau, V., Andre, P., and Ramiere, C. The metabolic sensors FXR, PGC-1, and SIRT1 cooperatively regulate hepatitis B virus transcription.	[Curtil, Claire; Enache, Liviu S.; Radreau, Pauline; Dron, Anne-Gaelle; Scholtes, Caroline; Deloire, Alexandre; Lotteau, Vincent; Andre, Patrice; Ramiere, Christophe] Univ Lyon, Ctr Int Rech Infectiol CIRI, Lyon, France; [Curtil, Claire; Enache, Liviu S.; Radreau, Pauline; Dron, Anne-Gaelle; Scholtes, Caroline; Deloire, Alexandre; Lotteau, Vincent; Andre, Patrice; Ramiere, Christophe] Inst Natl Sante & Rech Med INSERM, U1111, Lyon, France; [Curtil, Claire; Enache, Liviu S.; Radreau, Pauline; Dron, Anne-Gaelle; Scholtes, Caroline; Deloire, Alexandre; Lotteau, Vincent; Andre, Patrice; Ramiere, Christophe] Ecole Normale Super Lyon, F-69364 Lyon, France; [Curtil, Claire; Enache, Liviu S.; Radreau, Pauline; Dron, Anne-Gaelle; Scholtes, Caroline; Deloire, Alexandre; Lotteau, Vincent; Andre, Patrice; Ramiere, Christophe] Univ Lyon 1, CIRI, F-69365 Lyon, France; [Curtil, Claire; Enache, Liviu S.; Radreau, Pauline; Dron, Anne-Gaelle; Scholtes, Caroline; Deloire, Alexandre; Lotteau, Vincent; Andre, Patrice; Ramiere, Christophe] Ctr Natl Recherce Sci CNRS, Unite Mixte Rech UMR 5308, Lyon, France; [Dron, Anne-Gaelle; Scholtes, Caroline; Andre, Patrice; Ramiere, Christophe] Hosp Civils Lyon, Lyon, France; [Enache, Liviu S.] Univ Med & Pharm, Targumures, Romania; [Enache, Liviu S.] Emergency Clin Hosp, Targumures, Romania; [Roche, Didier] Edelris SAS, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon	Andre, P (corresponding author), INSERM, U1111, Ctr Int Rech Infectiol, 21 Ave Tony Garnier, F-69365 Lyon 07, France.	patrice.andre@inserm.fr	Ramière, Christophe/M-8083-2014; lotteau, vincent/M-8143-2014; Scholtès, Caroline/B-9039-2011; André, Patrice/M-8139-2014	Ramière, Christophe/0000-0002-1981-7155; Scholtès, Caroline/0000-0003-0691-8480; André, Patrice/0000-0002-5834-7395; Lotteau, Vincent/0000-0003-0997-3282; Enache, Liviu Sorin/0000-0002-0391-9982	Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS); Natheb program (French Fond Unique Interministeriel); Sectorial Operational Programme Human Resources Development (SOP HRD); European Social Fund; Romanian government [POSDRU 6/1.5/17]	Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS)(ANRSFrench National Research Agency (ANR)); Natheb program (French Fond Unique Interministeriel); Sectorial Operational Programme Human Resources Development (SOP HRD); European Social Fund(European Social Fund (ESF)); Romanian government(Romanian Government)	Work was supported by a grant from Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS) and by the Natheb program (French Fond Unique Interministeriel). L. S. E. was partly supported by the Sectorial Operational Programme Human Resources Development (SOP HRD), financed from the European Social Fund and by the Romanian government under contract POSDRU 6/1.5/17. The authors acknowledge the contribution of the AniRA level 3 security laboratory and genetic analysis platforms of SFR Biosciences Gerland-Lyon Sud (AMS3444/US8).	Bar-Yishay I, 2011, LIVER INT, V31, P282, DOI 10.1111/j.1478-3231.2010.02423.x; Belloni L, 2009, P NATL ACAD SCI USA, V106, P19975, DOI 10.1073/pnas.0908365106; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Colin L, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-111; Denu JM, 2005, CURR OPIN CHEM BIOL, V9, P431, DOI 10.1016/j.cbpa.2005.08.010; Doitsh G, 2004, MOL CELL BIOL, V24, P1799, DOI 10.1128/MCB.24.4.1799-1808.2004; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Guise AJ, 2013, VIRUSES-BASEL, V5, P1607, DOI 10.3390/v5071607; GUNTHER S, 1995, J VIROL, V69, P5437; Herbein G, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0003-5; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hubbard BP, 2013, SCIENCE, V339, P1216, DOI 10.1126/science.1231097; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Kemper JK, 2009, CELL METAB, V10, P392, DOI 10.1016/j.cmet.2009.09.009; Kwon HS, 2008, CELL HOST MICROBE, V3, P158, DOI 10.1016/j.chom.2008.02.002; Levrero M, 2009, J HEPATOL, V51, P581, DOI 10.1016/j.jhep.2009.05.022; Li L, 2009, J VIROL, V83, P1682, DOI 10.1128/JVI.02208-08; Moolla N, 2002, J VIRAL HEPATITIS, V9, P323, DOI 10.1046/j.1365-2893.2002.00381.x; Nayagam VM, 2006, J BIOMOL SCREEN, V11, P959, DOI 10.1177/1087057106294710; Ondracek CR, 2009, J VIROL, V83, P12535, DOI 10.1128/JVI.01623-09; Ondracek CR, 2009, J VIROL, V83, P12545, DOI 10.1128/JVI.01624-09; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Pagans S, 2005, PLOS BIOL, V3, P210, DOI 10.1371/journal.pbio.0030041; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Ramiere C, 2008, J VIROL, V82, P10832, DOI 10.1128/JVI.00883-08; Reese V, 2011, INT J BIOCHEM CELL B, V43, P230, DOI 10.1016/j.biocel.2009.11.016; Rodgers JT, 2008, FEBS LETT, V582, P46, DOI 10.1016/j.febslet.2007.11.034; Sambrook J., 2001, MOL CLONING LAB MANU; Shirakawa K, 2013, TRENDS MICROBIOL, V21, P277, DOI 10.1016/j.tim.2013.02.005; Shlomai A, 2006, P NATL ACAD SCI USA, V103, P16003, DOI 10.1073/pnas.0607837103; Srisuttee R, 2012, ONCOL REP, V28, P276, DOI 10.3892/or.2012.1798; Tang H, 2001, P NATL ACAD SCI USA, V98, P1841, DOI 10.1073/pnas.041479698; Wu S, 2011, CANCER LETT, V312, P33, DOI 10.1016/j.canlet.2011.07.025; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990; Zhang XY, 2011, HEPATOLOGY, V53, P1476, DOI 10.1002/hep.24195	38	34	38	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1454	1463		10.1096/fj.13-236372	http://dx.doi.org/10.1096/fj.13-236372			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24297698				2022-12-28	WOS:000335324800036
J	Lauridsen, HM; Pober, JS; Gonzalez, AL				Lauridsen, Holly M.; Pober, Jordan S.; Gonzalez, Anjelica L.			A composite model of the human postcapillary venule for investigation of microvascular leukocyte recruitment	FASEB JOURNAL			English	Article						neutrophil migration; ICAM-1; N-cadherin; pericyte; endothelial cell; inflammation; transmigration	VASCULAR ENDOTHELIAL-CELLS; TRANSENDOTHELIAL MIGRATION; PERICYTES; CADHERIN; P120-CATENIN; DIAPEDESIS; ADHESION; CULTURE; SITE; CD99	Neutrophil extravasation occurs across postcapillary venules, structures composed of endothelial cells (ECs), pericytes (PCs), and basement membrane (BM). We constructed composite models of the human postcapillary venule, combining ECs with PCs or PC-deposited BM, to better study this process. Quiescent and tumor necrosis factor (TNF-)-activated composites demonstrated in situ-like expression of cadherins, E-selectin, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), platelet-endothelial cell adhesion molecule 1 (PECAM-1), CD99, and interleukin 8 (IL-8). After TNF- activation, the ECs supported greater neutrophil adhesion (66.1 vs. 23.7% of input cells) and transmigration (35.1 vs. 7.20% of input cells) than did the PCs, but the composites behaved comparably (no significant difference) to ECs in both assays. TNF--activated EC-conditioned medium (CM) increased transmigration across the PCs, whereas TNF--activated PC-CM decreased transmigration across the ECs, and culturing on PC-derived BM decreased both adhesion to and transmigration across the ECs. Anti-very late antigen 4 (VLA-4; on neutrophils) inhibited adhesion to TNF--activated composites, but not to ECs alone. Anti-CD99 (expressed on all 3 cell types) inhibited transmigration across the composites (14.5% of control) more than across the ECs (39.0% of control), and venular shear stress reduced transmigration across the ECs (17.3% of static) more than across the composites (36.7% of static). These results provide proof of concept that our composite human EC/PC/BM venular construct can reveal new interactions in the inflammatory cascade.Lauridsen, H. M., Pober, J. S., Gonzalez, A. L. A composite model of the human postcapillary venule for investigation of microvascular leukocyte recruitment.	[Lauridsen, Holly M.; Gonzalez, Anjelica L.] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA; [Pober, Jordan S.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA	Yale University; Yale University	Gonzalez, AL (corresponding author), Yale Univ, Malone Engn Ctr 314, 55 Prospect St, New Haven, CT 06520 USA.	anjelica.gonzalez@yale.edu			U.S. National Institutes of Health [HL051014]; Dubinsky New Initiative grant; Hartwell Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051014] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dubinsky New Initiative grant; Hartwell Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Kathryn Miller-Jensen for allowing them to use the LI-COR Scanner, Dr. Thomas Manes for help with immunofluorescence, and Dr. Cheryl Maier for discussions and review of the manuscript. Facilities used were supported by the Yale Institute for Nanoscience and Quantum Engineering and National Science Foundation (NSF), Materials Research Science and Engineering Center (MRSEC), Division of Materials Research (DMR) 1119826. A.L.G. and J.S.P. were supported by U.S. National Institutes of Health grant HL051014, with additional support for A.L.G. coming from the Dubinsky New Initiative grant and The Hartwell Foundation.	Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Ayres-Sander CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060025; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bixel MG, 2010, BLOOD, V116, P1172, DOI 10.1182/blood-2009-12-256388; Brey EA, 2004, ANN BIOMED ENG, V32, P1100, DOI 10.1114/B:ABME.0000036646.17362.c4; Burns AR, 1997, J IMMUNOL, V159, P2893; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Ding ZM, 1999, J IMMUNOL, V163, P5029; Francis ME, 2008, TISSUE ENG PART B-RE, V14, P19, DOI 10.1089/teb.2007.0115; Gentil-dit-Maurin A, 2010, EXP CELL RES, V316, P2587, DOI 10.1016/j.yexcr.2010.06.015; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Hermant B, 2003, J BIOL CHEM, V278, P14002, DOI 10.1074/jbc.M300351200; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liu WF, 2005, MATER TODAY, V8, P28, DOI 10.1016/S1369-7021(05)71222-0; Lou O, 2007, J IMMUNOL, V178, P1136, DOI 10.4049/jimmunol.178.2.1136; Maier CL, 2010, MICROCIRCULATION, V17, P367, DOI 10.1111/j.1549-8719.2010.00038.x; Marin V, 2001, J IMMUNOL METHODS, V254, P183, DOI 10.1016/S0022-1759(01)00408-2; MERIMEE TJ, 1970, J CLIN INVEST, V49, P2161, DOI 10.1172/JCI106434; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; Muller WA, 2009, CIRC RES, V105, P223, DOI 10.1161/CIRCRESAHA.109.200717; Nakagawa S, 2009, NEUROCHEM INT, V54, P253, DOI 10.1016/j.neuint.2008.12.002; Nelson C, 2004, STRAD, V115, P15; Nwariaku FE, 2002, SHOCK, V18, P82, DOI 10.1097/00024382-200207000-00015; Oas RG, 2013, MOL BIOL CELL, V24, P704, DOI 10.1091/mbc.E12-06-0471; Petrie TA, 2006, BIOMATERIALS, V27, P5459, DOI 10.1016/j.biomaterials.2006.06.027; Proebstl D, 2012, J EXP MED, V209, P1219, DOI 10.1084/jem.20111622; Voisin M.-B., AM J PATHOL, V176, P482	30	16	16	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1166	1180		10.1096/fj.13-240986	http://dx.doi.org/10.1096/fj.13-240986			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24297702	Green Published			2022-12-28	WOS:000335324800013
J	van Weeghel, M; Ofman, R; Argmann, CA; Ruiter, JPN; Claessen, N; Oussoren, SV; Wanders, RJA; Aten, J; Houten, SM				van Weeghel, Michel; Ofman, Rob; Argmann, Carmen A.; Ruiter, Jos P. N.; Claessen, Nike; Oussoren, Saskia V.; Wanders, Ronald J. A.; Aten, Jan; Houten, Sander M.			Identification and characterization of Eci3, a murine kidney-specific Delta(3), Delta(2)-enoyl-CoA isomerase	FASEB JOURNAL			English	Article						fatty acid oxidation; peroxisomes; gene duplication	UNSATURATED FATTY-ACIDS; COA-BINDING PROTEIN; BETA-OXIDATION; MOUSE KIDNEY; ENOYL-COA; 3,2-TRANS-ENOYL-COA ISOMERASE; MAMMALIAN PEROXISOMES; MOLECULAR-CLONING; RAT-LIVER; METABOLISM	Oxidation of unsaturated fatty acids requires the action of auxiliary enzymes, such as (3),(2)-enoyl-CoA isomerases. Here we describe a detailed biochemical, molecular, histological, and evolutionary characterization of Eci3, the fourth member of the mammalian enoyl-CoA isomerase family. Eci3 specifically evolved in rodents after gene duplication of Eci2. Eci3 is with 79% identity homologous to Eci2 and contains a peroxisomal targeting signal type 1. Subcellular fractionation of mouse kidney and immunofluorescence studies revealed a specific peroxisomal localization for Eci3. Expression studies showed that mouse Eci3 is almost exclusively expressed in kidney. By using immunohistochemistry, we found that Eci3 is not only expressed in cells of the proximal tubule, but also in a subset of cells in the tubulointerstitium and the glomerulus. In vitro, Eci3 catalyzed the isomerization of trans-3-nonenoyl-CoA to trans-2-nonenoyl-CoA equally efficient as Eci2, suggesting a role in oxidation of unsaturated fatty acids. However, in contrast to Eci2, in silico gene coexpression and enrichment analysis for Eci3 in kidney did not yield carboxylic acid metabolism, but diverse biological functions, such as ion transport (P=7.1E-3) and tissue morphogenesis (P=1.0E-3). Thus, Eci3 picked up a novel and unexpected role in kidney function during rodent evolution.van Weeghel, M., Ofman, R., Argmann, C. A., Ruiter, J. P. N., Claessen, N., Oussoren, S. V., Wanders, R. J. A., Aten, J., Houten, S. M. Identification and characterization of Eci3, a murine kidney-specific (3),(2)-enoyl-CoA isomerase.	[van Weeghel, Michel; Ofman, Rob; Ruiter, Jos P. N.; Oussoren, Saskia V.; Wanders, Ronald J. A.; Houten, Sander M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; [Argmann, Carmen A.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands; [Claessen, Nike; Aten, Jan] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Wanders, Ronald J. A.; Houten, Sander M.] Univ Amsterdam, Dept Pediat, Emma Childrens Hosp, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam	Houten, SM (corresponding author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Icahn Inst Genom & Multiscale Biol, 1425 Madison Ave,Box 1498, New York, NY 10029 USA.	sander.houten@mssm.edu	Houten, Sander/Y-3599-2019; van Weeghel, Michel/A-2766-2010	Houten, Sander/0000-0002-6167-9147; Aten, Jan/0000-0002-0997-6777; van Weeghel, Michel/0000-0002-4916-2866	Netherlands Organisation for Scientific Research [016.086.336]	Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO))	The authors thank Sape Kinderman (Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands) for analyzing trans-3-nonenoic acid with proton NMR, Coert Zuurbier (Academic Medical Center, Amsterdam, The Netherlands) for contributing rat tissues, Elisabeth Lodder (Academic Medical Center, Amsterdam, The Netherlands) for contributing DBA/2J kidney, and Dr. H. Schulz (Department of Chemistry, The City College of the City University of New York, New York, NY, USA) for the generous gift of the polyclonal mouse Eci2 antibody. Human tissue was obtained from the U. S. National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders (University of Maryland, Baltimore, MD, USA). The role of the NICHD Brain and Tissue Bank is to distribute tissue, and therefore, it cannot endorse the studies performed or the interpretation of results. This work was supported by the Netherlands Organisation for Scientific Research (VIDI grant 016.086.336 to S. M. H.). The authors declare no conflicts of interest.	Adkins RM, 2001, MOL BIOL EVOL, V18, P777, DOI 10.1093/oxfordjournals.molbev.a003860; Chesler EJ, 2004, NAT NEUROSCI, V7, P485, DOI 10.1038/nn0504-485; Cheval L, 2011, PHYSIOL GENOMICS, V43, P161, DOI 10.1152/physiolgenomics.00093.2010; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; Gogarten JP, 1999, CURR OPIN GENET DEV, V9, P630, DOI 10.1016/S0959-437X(99)00029-5; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; Hurles M, 2004, PLOS BIOL, V2, P900, DOI 10.1371/journal.pbio.0020206; Janssen U, 2002, J BIOL CHEM, V277, P19579, DOI 10.1074/jbc.M110993200; Kaessmann H, 2010, GENOME RES, V20, P1313, DOI 10.1101/gr.101386.109; Knudsen J, 2000, J NUTR, V130, p294S, DOI 10.1093/jn/130.2.294S; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; MULLERNEWEN G, 1991, BIOL CHEM H-S, V372, P613, DOI 10.1515/bchm3.1991.372.2.613; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; Ofman R, 2006, BIOCHEM J, V393, P537, DOI 10.1042/BJ20050893; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Pravenec M, 2004, PHYSIOL RES, V53, pS15; PRAVENEC M, 1989, J HYPERTENS, V7, P217; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Ren Y, 2003, J BIOL CHEM, V278, P111, DOI 10.1074/jbc.M209261200; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; Soskine M, 2010, NAT REV GENET, V11, P572, DOI 10.1038/nrg2808; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Stoffel W, 1964, Hoppe Seylers Z Physiol Chem, V339, P167, DOI 10.1515/bchm2.1964.339.1.167; STOFFEL W, 1993, FEBS LETT, V333, P119, DOI 10.1016/0014-5793(93)80387-A; van Weeghel M, 2012, FASEB J, V26, P4316, DOI 10.1096/fj.12-206326; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329; Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439; Wang JT, 2003, NEUROINFORMATICS, V1, P299, DOI 10.1385/NI:1:4:299; Wiese S, 2007, MOL CELL PROTEOMICS, V6, P2045, DOI 10.1074/mcp.M700169-MCP200; WIRTHENSOHN G, 1986, PHYSIOL REV, V66, P469, DOI 10.1152/physrev.1986.66.2.469; Zhang DY, 2002, J BIOL CHEM, V277, P9127, DOI 10.1074/jbc.M112228200	35	7	9	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1365	1374		10.1096/fj.13-240416	http://dx.doi.org/10.1096/fj.13-240416			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24344334				2022-12-28	WOS:000335324800028
J	Gupta, S; Melnyk, SB; Kruger, WD				Gupta, Sapna; Melnyk, Stepan B.; Kruger, Warren D.			Cystathionine beta-synthase-deficient mice thrive on a low-methionine diet	FASEB JOURNAL			English	Article						osteoporosis; alopecia; homocysteine; metabolism; inborn errors	S-ADENOSYLHOMOCYSTEINE; PLASMA HOMOCYSTEINE; NATURAL-HISTORY; MOUSE MODEL; HOMOCYSTINURIA; HYPERHOMOCYSTEINEMIA; HUMANS	Cystathionine -synthase (CBS) deficiency is a recessive inborn error of metabolism characterized by elevated serum total homocysteine (tHcy). Previously, our laboratory developed a mouse model of CBS deficiency, TgI278T Cbs(-)/(-) (abbreviated as Cbs(-/-)), characterized by low weight, low adiposity, decreased Scd-1 expression, facial alopecia, and osteoporosis. To determine the potential benefit of a methionine-restricted diet (MRD), we fed Cbs(-/-) and Cbs(+/-) control mice either an MRD or a regular diet (RD) from weaning till 240 d of age. Cbs(-/-) mice fed the MRD had a 77% decrease in tHcy, 28% increase in weight, 130% increase in fat mass, 82% increase in Scd-1 expression, and 10.6% increase in bone density and entirely lacked the alopecia phenotype observed in age-matched Cbs(-/-) mice fed the RD. At the end of the study, Cbs(-/-) mice fed the MRD were phenotypically indistinguishable from Cbs(+/-) mice fed the RD. Notably, whereas the MRD diet was highly beneficial to Cbs(-/-) mice, it had nearly opposite effect on Cbs(+/-) mice. These studies show that a low-methionine diet can correct the phenotypic consequences of loss of CBS and provide a striking example of how genotype and diet can interact to influence phenotype in mammals.Gupta, S., Melnyk, S.B., Kruger, W.D. Cystathionine -synthase-deficient mice thrive on a low-methionine diet.	[Gupta, Sapna; Kruger, Warren D.] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA; [Melnyk, Stepan B.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA	Fox Chase Cancer Center; University of Arkansas System; University of Arkansas Medical Sciences	Kruger, WD (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	warren.kruger@fccc.edu	Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695	Monell Chemical Senses Center under a grant from the Pennsylvania Department of Health; Hempling Foundation for Homocystinuria Research, the U.S. National Institutes of Health [CA06927, R01GM098772]; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098772] Funding Source: NIH RePORTER	Monell Chemical Senses Center under a grant from the Pennsylvania Department of Health; Hempling Foundation for Homocystinuria Research, the U.S. National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank the staff of the genomics, laboratory animal, and biostatistics facilities of Fox Chase Cancer Center for their assistance. The authors specifically acknowledge Fang Zhu for statistical support. The authors also thank Dr. Michael Tordoff and his laboratory for help in use of the PIXimus II DEXA. This equipment was provided by funds awarded to the Monell Chemical Senses Center under a grant from the Pennsylvania Department of Health. The department specifically disclaims responsibility for any analyses, interpretations or conclusions of the study. This work was supported by grants from the Hempling Foundation for Homocystinuria Research, the U.S. National Institutes of Health (CA06927 and R01GM098772), and an appropriation from the Commonwealth of Pennsylvania.	Benight NM, 2011, AM J PHYSIOL-GASTR L, V301, pG249, DOI 10.1152/ajpgi.00076.2011; BRENTON D P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P277; Brosnan JT, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P176; CARSON NAJ, 1963, ARCH DIS CHILD, V38, P425, DOI 10.1136/adc.38.201.425; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Gupta S., 2011, PLOS ONE, V6; Gupta S, 2009, FASEB J, V23, P883, DOI 10.1096/fj.08-120584; Keating AK, 2011, MOL GENET METAB, V103, P330, DOI 10.1016/j.ymgme.2011.04.012; KOMROWER GM, 1966, ARCH DIS CHILD, V41, P666, DOI 10.1136/adc.41.220.666; Lu YH, 2012, MOL GENET METAB, V105, P590, DOI 10.1016/j.ymgme.2012.01.021; Maclean KN, 2012, J BIOL CHEM, V287, P31994, DOI 10.1074/jbc.M112.355172; Maclean KN, 2010, MOL GENET METAB, V101, P153, DOI 10.1016/j.ymgme.2010.06.010; Melnyk S, 2000, CLIN CHEM, V46, P265; MUDD SH, 1985, AM J HUM GENET, V37, P1; Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008; Perrone CE, 2010, METABOLISM, V59, P1000, DOI 10.1016/j.metabol.2009.10.023; PERRY TL, 1966, PEDIATRICS, V37, P502; REISH O, 1995, AM J HUM GENET, V57, P127; Rizki G, 2006, J LIPID RES, V47, P2280, DOI 10.1194/jlr.M600198-JLR200; Robert K, 2004, ANAT REC PART A, V280A, P1072, DOI 10.1002/ar.a.20082; SARDHARW.IB, 1968, CAN MED ASSOC J, V99, P731; STORCH KJ, 1990, AM J PHYSIOL, V258, pE790, DOI 10.1152/ajpendo.1990.258.5.E790; STORCH KJ, 1988, AM J PHYSIOL, V255, pE322, DOI 10.1152/ajpendo.1988.255.3.E322; Wang LQ, 2005, HUM MOL GENET, V14, P2201, DOI 10.1093/hmg/ddi224; Wang LQ, 2004, CIRC RES, V94, P1318, DOI 10.1161/01.RES.0000129182.46440.4a; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; Yap S, 2000, SEMIN THROMB HEMOST, V26, P335, DOI 10.1055/s-2000-8100; Yap S, 1998, J INHERIT METAB DIS, V21, P738, DOI 10.1023/A:1005445132327; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200	31	22	29	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					781	790		10.1096/fj.13-240770	http://dx.doi.org/10.1096/fj.13-240770			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24189943	Green Published			2022-12-28	WOS:000331072200025
J	Jelinic, M; Leo, CH; Uiterweer, EDP; Sandow, SL; Gooi, JH; Wlodek, ME; Conrad, KP; Parkington, H; Tare, M; Parry, LJ				Jelinic, Maria; Leo, Chen-Huei; Uiterweer, Emiel D. Post; Sandow, Shaun L.; Gooi, Jonathan H.; Wlodek, Mary E.; Conrad, Kirk P.; Parkington, Helena; Tare, Marianne; Parry, Laura J.			Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin- mediated relaxation after in vivo serelaxin treatment	FASEB JOURNAL			English	Article						RXFP1; vasodilation	SPONTANEOUSLY HYPERTENSIVE-RATS; NITRIC-OXIDE; MYOGENIC REACTIVITY; NONPREGNANT RATS; BLOOD-PRESSURE; EMERGING ROLE; PREGNANCY; FLOW; VASCULATURE; VASODILATOR	Relaxin is a potent vasodilator of small resistance arteries and modifies arterial compliance in some systemic vascular beds, yet receptors for relaxin, such as RXFP1, have only been localized to vascular smooth muscle. This study first aimed to localize RXFP1 in rat arteries and veins from different organ beds and determine whether receptors are present in endothelial cells. We then tested the hypothesis that region-specific vascular effects of relaxin may be influenced by the cellular localization of RXFP1 within different blood vessels. The aorta, vena cava, mesenteric artery, and vein had significantly higher (P<0.05) RXFP1 immunostaining in endothelial cells compared with vascular smooth muscle, whereas the femoral artery and vein and small pulmonary arteries had higher (P<0.01) RXFP1 immunostaining in the vascular smooth muscle. Male rats were treated subcutaneously with recombinant human relaxin-2 (serelaxin; 4 g/h) for 5 d; vasodilation and compliance in mesenteric and femoral arteries and veins were compared with placebo controls. Serelaxin significantly (P=0.04) reduced wall stiffness and increased volume compliance in mesenteric arteries but not in the other vessels examined. This was associated with changes in geometrical properties, and not compositional changes in the extracellular matrix. Serelaxin treatment had no effect on acetylcholine-mediated relaxation but significantly (P<0.001) enhanced bradykinin (BK)-mediated relaxation in mesenteric arteries, involving enhanced nitric oxide but not endothelium-derived hyperpolarization or vasodilatory prostanoids. In conclusion, there is differential distribution of RXFP1 on endothelial and smooth muscle across the vasculature. In rats, mesenteric arteries exhibit the greatest functional response to chronic serelaxin treatment.Jelinic, M., Leo, C-H., Post Uiterweer, E. P., Sandow, S. L., Gooi, J. H., Wlodek, M. E., Conrad, K. P., Parkington, H., Tare, M., Parry, L. J. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.	[Jelinic, Maria; Leo, Chen-Huei; Gooi, Jonathan H.; Parry, Laura J.] Univ Melbourne, Dept Zool, Parkville, Vic 3010, Australia; [Jelinic, Maria; Wlodek, Mary E.] Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia; [Uiterweer, Emiel D. Post] Univ Med Ctr Utrecht, Dept Obstet, Utrecht, Netherlands; [Sandow, Shaun L.] Univ New S Wales, Dept Physiol, Sydney, NSW, Australia; [Uiterweer, Emiel D. Post; Conrad, Kirk P.] Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL USA; [Parkington, Helena; Tare, Marianne] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia	University of Melbourne; University of Melbourne; Utrecht University; Utrecht University Medical Center; University of New South Wales Sydney; State University System of Florida; University of Florida; Monash University	Parry, LJ (corresponding author), Univ Melbourne, Dept Zool, Parkville, Vic 3010, Australia.	ljparry@unimelb.edu.au	wlodek, Mary/A-8939-2019; Gooi, Jonathan/AAS-7982-2020; leo, Chen huei/ABD-2155-2020; Gooi, Jonathan/M-2407-2016; Sandow, Shaun/N-4256-2016	wlodek, Mary/0000-0002-8490-9099; Gooi, Jonathan/0000-0002-8839-1602; leo, Chen huei/0000-0003-1424-9694; Sandow, Shaun/0000-0002-0753-2742; Jelinic, Maria/0000-0001-9773-4972; Post Uiterweer, Emiel/0000-0002-2777-3551; Parry, Laura/0000-0002-6883-3418	Novartis; Australian Research Council [LP110200543]; U.S. National Institutes of Health [HL067937]; Australian and New Zealand Medical Research and Technology in Victoria; Australian Postgraduate Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067937] Funding Source: NIH RePORTER	Novartis(Novartis); Australian Research Council(Australian Research Council); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian and New Zealand Medical Research and Technology in Victoria; Australian Postgraduate Award(Australian Government); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Dennis Stewart, the coordinator of the research partnership (Novartis Pharma AG, Basel, Switzerland) for helpful advice with the experimental design and critical analysis of the data. The authors also thank Dr. Elaine Unemori for helpful suggestions and manuscript review. The authors are grateful to Dr. Jill Verlander, Professor John Hutson, and Dr. Marc Mazzuca for their valuable contributions to this work, and Professor O. David Sherwood (University of Illinois, Urbana, IL, USA) for his generous gift of the RXFP1 antibody. The authors disclose that this project was partially funded by Novartis, which also provided the serelaxin, as conditions of an Australian Research Council Linkage grant. The research was funded by Australian Research Council Linkage grant LP110200543 (L.J.P., M. T., H. C. P., and M. E. W.), U.S. National Institutes of Health grant HL067937 (K. P. C. and L.J.P.) and an Australian and New Zealand Medical Research and Technology in Victoria grant (L.J.P.). M.J. received an Australian Postgraduate Award.	Adams J, 2012, PLOS ONE, V7; BANISACCHI T, 1995, BRIT J PHARMACOL, V116, P1589, DOI 10.1111/j.1476-5381.1995.tb16377.x; Chan S. L., 2013, FASEB J, DOI 10.1096/fj.13-230797; Chan SL, 2011, FASEB J, V25, P3229, DOI 10.1096/fj.10-175471; Conrad KP, 2011, AM J PHYSIOL-REG I, V301, pR267, DOI 10.1152/ajpregu.00156.2011; Conrad KP, 2004, AM J PHYSIOL-REG I, V287, pR250, DOI 10.1152/ajpregu.00672.2003; Conrad KP, 2004, ENDOCRINOLOGY, V145, P3289, DOI 10.1210/en.2003-1612; Danielson LA, 1999, J CLIN INVEST, V103, P525, DOI 10.1172/JCI5630; Debrah DO, 2011, J APPL PHYSIOL, V111, P260, DOI 10.1152/japplphysiol.00845.2010; Debrah DO, 2005, HYPERTENSION, V46, P745, DOI 10.1161/01.HYP.0000184230.52059.33; Dschietzig T, 2012, CARDIOVASC RES, V95, P97, DOI 10.1093/cvr/cvs149; Dschietzig T, 2009, J CARD FAIL, V15, P182, DOI 10.1016/j.cardfail.2009.01.008; Failli P, 2001, FASEB J, V15, P252, DOI 10.1096/fj.01-0569fje; Ferreira VM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004845; Fisher C, 2002, CIRCULATION, V106, P292, DOI 10.1161/01.CIR.0000025630.05387.45; Gao YJ, 2008, CAN J PHYSIOL PHARM, V86, P737, DOI 10.1139/Y08-079; Gooi JH, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.108118; Holobotovskyy V, 2013, CIRC RES, V112, P781, DOI 10.1161/CIRCRESAHA.111.300142; Jeyabalan A, 2007, ADV EXP MED BIOL, V612, P65; Kern A, 2009, ENDOCRINOLOGY, V150, P2419, DOI 10.1210/en.2008-1385; Kubota Y, 2002, MOL HUM REPROD, V8, P900, DOI 10.1093/molehr/8.10.900; Li Y, 2005, REGUL PEPTIDES, V132, P41, DOI 10.1016/j.regpep.2005.09.009; MASSICOTTE G, 1989, P SOC EXP BIOL MED, V190, P254; Mazzuca MQ, 2012, J PHYSIOL-LONDON, V590, P3375, DOI 10.1113/jphysiol.2012.230011; McGuane JT, 2011, ENDOCRINOLOGY, V152, P2786, DOI 10.1210/en.2010-1126; Novak J, 2002, AM J PHYSIOL-REG I, V283, pR349, DOI 10.1152/ajpregu.00635.2001; Novak J, 2006, FASEB J, V20, P2352, DOI 10.1096/fj.06-6263com; Sandoo A, 2010, OPEN CARDIOVASC MED, V4, P302, DOI 10.2174/1874192401004010302; Sasser JM, 2011, HYPERTENSION, V58, P197, DOI 10.1161/HYPERTENSIONAHA.110.164392; SHERWOOD OD, 1980, ENDOCRINOLOGY, V107, P691, DOI 10.1210/endo-107-3-691; STLOUIS J, 1985, LIFE SCI, V37, P1351, DOI 10.1016/0024-3205(85)90251-6; Tare M, 2000, BRIT J PHARMACOL, V130, P605, DOI 10.1038/sj.bjp.0703332; Teerlink JR, 2013, LANCET, V381, P29, DOI 10.1016/S0140-6736(12)61855-8; Teerlink JR, 2009, LANCET, V373, P1429, DOI 10.1016/S0140-6736(09)60622-X; Tse GH, 2013, APPL IMMUNOHISTO M M, V21, P464, DOI 10.1097/PAI.0b013e31827ba0e1; van Drongelen J, 2012, J APPL PHYSIOL, V112, P962, DOI 10.1152/japplphysiol.00470.2011; Drongelen J, 2011, AM J PHYSIOL-HEART C, V300, pH1609, DOI 10.1152/ajpheart.00360.2010; Vodstrcil LA, 2012, FASEB J, V26, P4035, DOI 10.1096/fj.12-210567; Xu Q, 2010, HYPERTENSION, V55, P1260, DOI 10.1161/HYPERTENSIONAHA.109.149369; Zieman SJ, 2005, ARTERIOSCL THROM VAS, V25, P932, DOI 10.1161/01.ATV.0000160548.78317.29	40	73	74	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					275	287		10.1096/fj.13-233429	http://dx.doi.org/10.1096/fj.13-233429			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24036884	Green Published			2022-12-28	WOS:000333526100027
J	Koutsokeras, A; Purkayashta, N; Rigby, A; Subang, MC; Sclanders, M; Vessillier, S; Mullen, L; Chernajovsky, Y; Gould, D				Koutsokeras, Apostolos; Purkayashta, Nirupam; Rigby, Anne; Subang, Maria C.; Sclanders, Michelle; Vessillier, Sandrine; Mullen, Lisa; Chernajovsky, Yuti; Gould, David			Generation of an efficiently secreted, cell penetrating NF-kB inhibitor	FASEB JOURNAL			English	Article						protein transduction domain; inflammation; MMP; gene therapy	KAPPA-B-ALPHA; TAT FUSION PROTEINS; GENE-THERAPY; IN-VIVO; TRANSDUCTION DOMAINS; BINDING DOMAIN; INFLAMMATION; ACTIVATION; PEPTIDE; CYTOKINES	Gene therapy is a powerful approach to treat disease locally. However, if the therapeutic target is intracellular, the therapeutic will be effective only in the cells where the therapeutic gene is delivered. We have engineered a fusion protein containing an intracellular inhibitor of the transcription factor NF-B pathway that can be effectively secreted from producing cells. This fusion protein is cleaved extracellularly by metalloproteinases allowing release of a protein transduction domain (PTD) linked to the NF-B inhibitor for translocation into neighboring cells. We show that engineered molecules can be efficiently secreted (>80%); are cleaved with matrix metalloprotease-1; inhibit NF-B driven transcription in a biological assay with a human reporter cell line; and display significant inhibition in mouse paw inflammation models when delivered by lentivirus or secreting cells. No inhibition of NF-B transcription or therapeutic effect was seen using molecules devoid of the PTD and NF-B inhibitory domains. By creating a fusion protein with an endogenous secretion partner, we demonstrate a novel approach to efficiently secrete PTD-containing protein domains, overcoming previous limitations, and allowing for potent paracrine effects.Koutsokeras, A., Purkayashta, N., Rigby, A., Subang, M. C., Sclanders, M., Vessillier, S., Mullen, L., Chernajovsky, Y., Gould, D. Generation of an efficiently secreted, cell penetrating NF-B inhibitor.	[Koutsokeras, Apostolos; Purkayashta, Nirupam; Rigby, Anne; Subang, Maria C.; Sclanders, Michelle; Vessillier, Sandrine; Mullen, Lisa; Chernajovsky, Yuti; Gould, David] Queen Mary Univ London, Bone & Joint Res Unit, Barts & London Sch Med & Dent, London EC1M 6BQ, England	University of London; Queen Mary University London	Gould, D (corresponding author), Queen Mary Univ London, Bone & Joint Res Unit, Barts & London Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	d.j.gould@qmul.ac.uk	Vessillier, Sandrine/E-2502-2013	Vessillier, Sandrine/0000-0002-9697-1834; Mullen, Lisa/0000-0001-8278-2226; Purkayastha, Nirupam/0000-0003-3870-1147	Arthritis Research UK [17428, 17559, 17208, 18401]; British Heart Foundation [PG/09/093]; Medical Research Council [G0800795]; National Multiple Sclerosis Society USA; Wellcome Trust [073271]; MRC [G0800795] Funding Source: UKRI	Arthritis Research UK(Versus Arthritis); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Multiple Sclerosis Society USA(National Multiple Sclerosis Society); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Ron Hay (Dundee University, Dundee, UK) for providing the 57A Hela cells, Adrian Thrasher (Institute of Child Health, London, UK) for providing the HRSIN-CSGW vector, and Mauro Perretti and Neil Dufton for technical assistance. The authors thank Arthritis Research UK for support of A. K., C. S., N.P., and D. G. (grants 17428, 17559, 17208, and 18401); the British Heart Foundation (grant PG/09/093) for support of S. V.; the Medical Research Council (grant G0800795) for support of L. M.; the National Multiple Sclerosis Society USA (promise 2010 program) for support of A. R. and M. S.; and the Wellcome Trust (grant 073271). Conflict of interest declaration: Y.C. is founder and director of Stealthyx Therapeutics, which develops the LAP-delivery technology.	Adams G, 2003, NAT BIOTECHNOL, V21, P1314, DOI 10.1038/nbt888; Barka T, 2004, J HISTOCHEM CYTOCHEM, V52, P469, DOI 10.1177/002215540405200405; Blackwell NM, 2004, ARTHRITIS RHEUM-US, V50, P2675, DOI 10.1002/art.20467; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; di Meglio P, 2005, ARTHRITIS RHEUM-US, V52, P951, DOI 10.1002/art.20960; Flinterman M, 2009, MOL THER, V17, P334, DOI 10.1038/mt.2008.256; Ho A, 2001, CANCER RES, V61, P474; Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587; Koutsokeras A, 2009, BBA-GEN SUBJECTS, V1790, P147, DOI 10.1016/j.bbagen.2008.11.005; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Mullen L., 2013, EXPERT OPIN IN PRESS; Mullen L., 2013, ANN RHEUM DIS; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Roomi MW, 2010, ONCOL REP, V23, P605, DOI 10.3892/or_00000675; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sambrook J., 2002, MOL CLONING LAB MANU; Schropfer A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-553; Shaw PA, 2008, BIOCHEMISTRY-US, V47, P1157, DOI 10.1021/bi701542p; Shen Y, 2011, MOL THER, V19, P903, DOI 10.1038/mt.2010.283; Strickland I, 2006, ANN RHEUM DIS, V65, P75, DOI 10.1136/ard.2006.058438; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; Tas SW, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1958; Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2; Triantaphyllopoulos KA, 1998, GENE THER, V5, P253, DOI 10.1038/sj.gt.3300570; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Vessillier S, 2004, PROTEIN ENG DES SEL, V17, P829, DOI 10.1093/protein/gzh097; Vessillier S, 2012, ANN RHEUM DIS, V71, P143, DOI 10.1136/annrheumdis-2011-200100; Zhang HG, 2000, ARTHRITIS RHEUM-US, V43, P1094, DOI 10.1002/1529-0131(200005)43:5<1094::AID-ANR20>3.0.CO;2-V	34	7	7	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					373	381		10.1096/fj.13-236570	http://dx.doi.org/10.1096/fj.13-236570			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24072781				2022-12-28	WOS:000333526100035
J	Singh, S; Saraiva, L; Elkington, PTG; Friedland, JS				Singh, Shivani; Saraiva, Luisa; Elkington, Paul T. G.; Friedland, Jon S.			Regulation of matrix metalloproteinase-1,-3, and-9 in Mycobacterium tuberculosis-dependent respiratory networks by the rapamycin- sensitive PI3K/p70(S6K) cascade	FASEB JOURNAL			English	Article						collagenase; stromelysin; gelatinase; immunopathology; epithelial cell; pulmonary; human	ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHAGOLYSOSOME BIOGENESIS; EPITHELIAL-CELLS; INHIBITION; SECRETION; MATRIX-METALLOPROTEINASE-9; EXPRESSION; AUTOPHAGY; GROWTH	This study was designed to investigate the role of the phosphatidyl inositol 3-kinase (PI3K)/AKT/p70(S6K) signaling path on regulation of primary normal human bronchial epithelial cell-derived matrix metalloproteinase (MMP)-1, -3, and -9 expression in tuberculosis (TB). These MMPs are key in pathological extracellular matrix degradation in TB. Normal human bronchial epithelials were stimulated with conditioned medium from monocytes infected with virulent TB (CoMTb) and components of the PI3K/AKT signaling pathway blocked using specific chemical inhibitors and siRNA. MMP gene expression was measured by RT-PCR and secretion by ELISA, luminex, or zymography. Phospho-p70 S6K was detected by Western blot analysis and activity blocked by rapamycin. Chemical blockade of the proximal catalytic PI3K p110 subunit augmented MMP-1 and MMP-9 in a dose-dependent manner (all P<0.001) but suppressed MMP-3 (P<0.01). Targeted siRNA studies identified the p110 isoform as key causing 5-fold increase in TB network-dependent MMP-1 secretion to 4900 +/- 1100 pg/ml. Specific inhibition of the AKT node suppressed all 3 MMPs. Phospho-p70(S6K) was identified in the cellular model, and rapamycin, a p70(S6K) inhibitor, inhibited MMP-1 (P<0.001) and MMP-3 (P<0.01) but not MMP-9. Controls were epithelial cells that were unstimulated or exposed to conditioned medium from monocytes not exposed to TB. In summary, blockade of the proximal PI3K catalytic subunit increases MMP-1 and MMP-9, whereas rapamycin decreased both MMP-1 and MMP-3. The regulation of the PI3K path in TB is complex, MMP specific, and a potential immunotherapeutic target in diseases characterized by tissue destruction.Singh, S., Saraiva, L., Elkington, P. T. G., Friedland, J. S. Regulation of matrix metalloproteinase-1, -3, and -9 in Mycobacterium tuberculosis-dependent respiratory networks by the rapamycin-sensitive PI 3-kinase/p70(S6K) cascade.	[Singh, Shivani; Saraiva, Luisa; Elkington, Paul T. G.; Friedland, Jon S.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, London W12 0NN, England	Imperial College London	Friedland, JS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, 8th Floor Commonwealth Bldg, Hammersmith Campus, London W12 0NN, England.	j.friedland@imperial.ac.uk	Singh, Shivani/M-4164-2019	Elkington, Paul/0000-0003-0390-0613; Friedland, Jonathan S/0000-0001-7789-9649	Medical Research Council (UK); UK National Institute for Health Research Biomedical Research Centres funding scheme at Imperial College London; National Institute for Health Research [DHCS/06/05/012] Funding Source: researchfish	Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute for Health Research Biomedical Research Centres funding scheme at Imperial College London; National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by a Medical Research Council (UK) Clinical Research Training Fellowship to S. S. The authors thank Abteen Mostofi (Cambridge University Hospitals, Cambridge, UK) for help with the signaling diagram and Dr. Daniel Lowther for help with the RT-PCR experiments. J.S.F. and P. E. are grateful for support from the UK National Institute for Health Research Biomedical Research Centres funding scheme at Imperial College London.	Awad AE, 2010, AM J PHYSIOL-CELL PH, V298, pC679, DOI 10.1152/ajpcell.00351.2009; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Cho JE, 2010, MOL CELLS, V29, P35, DOI 10.1007/s10059-010-0003-5; Das G, 2011, MOL CARCINOGEN, V50, P412, DOI 10.1002/mc.20723; Deretic V, 2006, CELL MICROBIOL, V8, P719, DOI 10.1111/j.1462-5822.2006.00705.x; Dragon S, 2007, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Elkington P, 2011, J CLIN INVEST, V121, P1827, DOI 10.1172/JCI45666; Elkington PT, 2007, AM J RESP CELL MOL, V37, P431, DOI 10.1165/rcmb.2007-0011OC; Elkington PTG, 2005, AM J RESP CRIT CARE, V172, P1596, DOI 10.1164/rccm.200505-753OC; Elkington PTG, 2005, J IMMUNOL, V175, P5333, DOI 10.4049/jimmunol.175.8.5333; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Huang GC, 2012, J BIOL CHEM, V287, P23196, DOI 10.1074/jbc.M112.351940; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jastrzebski K, 2007, GROWTH FACTORS, V25, P209, DOI 10.1080/08977190701779101; Jung SB, 2005, J CLIN IMMUNOL, V25, P482, DOI 10.1007/s10875-005-5431-1; Kang PB, 2005, J EXP MED, V202, P987, DOI 10.1084/jem.20051239; Kuijl C, 2007, NATURE, V450, P725, DOI 10.1038/nature06345; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lu YB, 2005, J LEUKOCYTE BIOL, V78, P259, DOI 10.1189/jlb.0904498; Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004; Nuttall RK, 2003, MOL CANCER RES, V1, P333; O'Kane CM, 2010, AM J RESP CELL MOL, V43, P465, DOI 10.1165/rcmb.2009-0211OC; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Okane CM, 2008, EUR J IMMUNOL, V38, P1321, DOI 10.1002/eji.200737855; Osman B, 2011, BIOCHEM PHARMACOL, V81, P134, DOI 10.1016/j.bcp.2010.09.011; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Pende Mario, 2006, Bull Cancer, V93, pE39; Peng XQ, 2010, ACTA PHARMACOL SIN, V31, P175, DOI 10.1038/aps.2009.190; Quiding-Jarbrink M, 2001, INFECT IMMUN, V69, P5661, DOI 10.1128/IAI.69.9.5661-5670.2001; Rand L, 2009, J IMMUNOL, V182, P5865, DOI 10.4049/jimmunol.0801935; Saleh MT, 2000, J BACTERIOL, V182, P6850, DOI 10.1128/JB.182.23.6850-6853.2000; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sauty A, 1999, J IMMUNOL, V162, P3549; Sharma M, 2007, IMMUNOL CELL BIOL, V85, P229, DOI 10.1038/sj.icb.7100037; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852; Thomas M, 2008, CURR OPIN PHARMACOL, V8, P267, DOI 10.1016/j.coph.2008.02.004; Vergne I, 2005, P NATL ACAD SCI USA, V102, P4033, DOI 10.1073/pnas.0409716102; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Volkman HE, 2010, SCIENCE, V327, P466, DOI 10.1126/science.1179663; Wang X, 2010, INT J IMMUNOGENET, V37, P97, DOI 10.1111/j.1744-313X.2010.00897.x; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948; Yang CS, 2006, CELL MICROBIOL, V8, P1158, DOI 10.1111/j.1462-5822.2006.00699.x; Zhou HY, 2006, ENDOCRINOLOGY, V147, P2557, DOI 10.1210/en.2005-1404	47	19	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					85	93		10.1096/fj.13-235507	http://dx.doi.org/10.1096/fj.13-235507			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24076964				2022-12-28	WOS:000333526100011
J	Wang, HB; Jiang, YC; Shi, D; Quilliam, LA; Chrzanowska-Wodnicka, M; Wittchen, ES; Li, DY; Hartnett, ME				Wang, Haibo; Jiang, Yanchao; Shi, Dallas; Quilliam, Lawrence A.; Chrzanowska-Wodnicka, Magdalena; Wittchen, Erika S.; Li, Dean Y.; Hartnett, M. Elizabeth			Activation of Rap1 inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization	FASEB JOURNAL			English	Article						barrier integrity; GTPase-activating proteins; p22phox; p47phox; NOX4	ENDOTHELIAL-CELL TRANSMIGRATION; MACULAR DEGENERATION; JUNCTIONAL INTEGRITY; PROTEIN; RPE; PHOSPHORYLATION; PATHOGENESIS; ASSOCIATION; VARIANT; BINDING	Activation of Rap1 GTPase can improve the integrity of the barrier of the retina pigment epithelium (RPE) and reduce choroidal neovascularization (CNV). Inhibition of NADPH oxidase activation also reduces CNV. We hypothesize that Rap1 inhibits NADPH oxidase-generated ROS and thereby reduces CNV formation. Using a murine model of laser-induced CNV, we determined that reduced Rap1 activity in RPE/choroid occurred with CNV formation and that activation of Rap1 by 2-O-Me-cAMP (8CPT)-reduced laser-induced CNV via inhibiting NADPH oxidase-generated ROS. In RPE, inhibition of Rap1 by Rap1 GTPase-activating protein (Rap1GAP) increased ROS generation, whereas activation of Rap1 by 8CPT reduced ROS by interfering with the assembly of NADPH oxidase membrane subunit p22phox with NOX4 or cytoplasmic subunit p47phox. Activation of NADPH oxidase with Rap1GAP reduced RPE barrier integrity via cadherin phosphorylation and facilitated choroidal EC migration across the RPE monolayer. Rap1GAP-induced ROS generation was inhibited by active Rap1a, but not Rap1b, and activation of Rap1a by 8CPT in Rap1b(-/-) mice reduced laser-induced CNV, in correlation with decreased ROS generation in RPE/choroid. These findings provide evidence that active Rap1 reduces CNV by interfering with the assembly of NADPH oxidase subunits and increasing the integrity of the RPE barrier.Wang, H., Jiang, Y., Shi, D., Quilliam, L. A., Chrzanowska-Wodnicka, M., Wittchen, E. S., Li, D. Y., Hartnett, M. E. Activation of Rap1 inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization.	[Wang, Haibo; Jiang, Yanchao; Hartnett, M. Elizabeth] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA; [Shi, Dallas; Li, Dean Y.] Univ Utah, Dept Cell & Dev Biol, Salt Lake City, UT 84132 USA; [Quilliam, Lawrence A.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Chrzanowska-Wodnicka, Magdalena] Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI USA; [Wittchen, Erika S.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Indiana University System; Indiana University Bloomington; Versiti Blood Center of Wisconsin; University of North Carolina; University of North Carolina Chapel Hill	Hartnett, ME (corresponding author), Univ Utah, John A Moran Eye Ctr, 65 N Mario Capecchi Dr, Salt Lake City, UT 84132 USA.	me.hartnett@hsc.utah.edu	Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Chrzanowska, Magdalena/0000-0003-4182-2126	U.S. National Institutes of Health (NIH)/National Eye Institute [R01 R01-EY015130, R01-EY017011]; NIH [R01HL111582]; American Heart Association [10SDG3430042]; NATIONAL EYE INSTITUTE [R01EY015130, P30EY014800, R01EY017011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL111582] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by U.S. National Institutes of Health (NIH)/National Eye Institute grants R01 R01-EY015130 and R01-EY017011 (M. E. H.), NIH grant R01HL111582 (M.C.-W.), and American Heart Association grant 10SDG3430042 (E.S.W.).	Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007; Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437; Boettner B, 2009, CURR OPIN CELL BIOL, V21, P684, DOI 10.1016/j.ceb.2009.06.004; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621; Campbell M, 2013, ADV EXP MED BIOL, V763, P70; Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973; Chrzanowska-Wodnicka M, 2013, EXP CELL RES, V319, P2350, DOI 10.1016/j.yexcr.2013.07.022; Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200; Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433; Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301; Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568; Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724; Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y; Katsube T, 2007, BBA-MOL CELL RES, V1773, P794, DOI 10.1016/j.bbamcr.2007.03.002; Kim JH, 2012, INT J BIOCHEM CELL B, V44, P808, DOI 10.1016/j.biocel.2012.02.005; King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1; Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200; Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164; Li Y, 2007, J IMMUNOL, V179, P8322, DOI 10.4049/jimmunol.179.12.8322; Liu JJ, 2011, MOL BIOL CELL, V22, P2509, DOI 10.1091/mbc.E11-02-0157; MALY FE, 1994, J BIOL CHEM, V269, P18743; McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986; Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006; Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878; Noda K, 2010, MOL BIOL CELL, V21, P584, DOI 10.1091/mbc.E09-07-0580; Peng SM, 2011, INVEST OPHTH VIS SCI, V52, P1392, DOI 10.1167/iovs.10-5984; Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012; Petronio MS, 2013, MOLECULES, V18, P2821, DOI 10.3390/molecules18032821; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1995, METHOD ENZYMOL, V255, P476; Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002; Sallee JL, 2006, J BIOL CHEM, V281, P16189, DOI 10.1074/jbc.R600003200; Santulli RJ, 2008, J PHARMACOL EXP THER, V324, P894, DOI 10.1124/jpet.107.131656; Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774; Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793; Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141; Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086; Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200; van Buul JD, 2005, J BIOL CHEM, V280, P21129, DOI 10.1074/jbc.M500898200; Vikstrom E, 2009, EXP CELL RES, V315, P313, DOI 10.1016/j.yexcr.2008.10.044; Wang H, 2011, EYE BRAIN, V3, P19, DOI 10.2147/EB.S24951; Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595; Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212; Wittchen E. S., 2013, PLOS ONE IN PRESS; Wittchen Erika S, 2011, Small GTPases, V2, P65; Wittchen ES, 2011, INVEST OPHTH VIS SCI, V52, P7455, DOI 10.1167/iovs.11-7295; Wittchen ES, 2005, J BIOL CHEM, V280, P11675, DOI 10.1074/jbc.M412595200; Xu HZ, 2011, INVEST OPHTH VIS SCI, V52, P2160, DOI 10.1167/iovs.10-6518; Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598; Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103	55	20	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					265	274		10.1096/fj.13-240028	http://dx.doi.org/10.1096/fj.13-240028			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24043260	Green Published			2022-12-28	WOS:000333526100026
J	Bosmann, M; Grailer, JJ; Ruemmler, R; Russkamp, NF; Zetoune, FS; Sarma, JV; Standiford, TJ; Ward, PA				Bosmann, Markus; Grailer, Jamison J.; Ruemmler, Robert; Russkamp, Norman F.; Zetoune, Firas S.; Sarma, J. Vidya; Standiford, Theodore J.; Ward, Peter A.			Extracellular histones are essential effectors of C5aR-and C5L2-mediated tissue damage and inflammation in acute lung injury	FASEB JOURNAL			English	Article						complement; cytotoxic factors	COMPLEMENT FRAGMENTS C5A; RECEPTOR C5AR; ANAPHYLATOXIN; C5L2; EXPRESSION; TRAPS; PATHOGENESIS; MEDIATORS; CELLS; DEATH	We investigated how complement activation promotes tissue injury and organ dysfunction during acute inflammation. Three models of acute lung injury (ALI) induced by LPS, IgG immune complexes, or C5a were used in C57BL/6 mice, all models requiring availability of both C5a receptors (C5aR and C5L2) for full development of ALI. Ligation of C5aR and C5L2 with C5a triggered the appearance of histones (H3 and H4) in bronchoalveolar lavage fluid (BALF). BALF from humans with ALI contained H4 histone. Histones were absent in control BALF from healthy volunteers. In mice with ALI, in vivo neutralization of H4 with IgG antibody reduced the intensity of ALI. Neutrophil depletion in mice with ALI markedly reduced H4 presence in BALF and was highly protective. The direct lung damaging effects of extracellular histones were demonstrated by airway administration of histones into mice and rats (Sprague-Dawley), which resulted in ALI that was C5a receptor-independent, and associated with intense inflammation, PMN accumulation, damage/destruction of alveolar epithelial cells, together with release into lung of cytokines/chemokines. High-resolution magnetic resonance imaging demonstrated lung damage, edema and consolidation in histone-injured lungs. These studies confirm the destructive C5a-dependent effects in lung linked to appearance of extracellular histones.	[Bosmann, Markus; Ruemmler, Robert] Univ Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany; [Bosmann, Markus] Univ Med Ctr, Dept Hematol & Oncol, Mainz, Germany; [Grailer, Jamison J.; Ruemmler, Robert; Russkamp, Norman F.; Zetoune, Firas S.; Sarma, J. Vidya; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Standiford, Theodore J.] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu		Bosmann, Markus/0000-0003-2773-1033	U.S. National Institutes of Health (NIH) [GM-29507, GM-61656, NHLBI-T32-HL007517-29]; Deutsche Forschungsgemeinschaft [571701, BO 3482/1-1, BO 3482/3-1]; German Federal Ministry of Education and Research [BMBF 01EO1003]; Marie Curie Career Integration grant of the European Union [334486]; Boehringer Ingelheim Fonds; NIH [P50CA093990]; NATIONAL CANCER INSTITUTE [P50CA093990] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517, P50HL074024, P50HL060289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R37GM029507, R01GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Marie Curie Career Integration grant of the European Union; Boehringer Ingelheim Fonds(Boehringer Ingelheim); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants GM-29507 and GM-61656 (P. A. W.) and NHLBI-T32-HL007517-29 (J.J.G.) from the U.S. National Institutes of Health (NIH), along with the Deutsche Forschungsgemeinschaft (project 571701, BO 3482/1-1, BO 3482/3-1, M. B.), the German Federal Ministry of Education and Research (BMBF 01EO1003, M. B.), a Marie Curie Career Integration grant of the European Union (project 334486, M. B.) and the Boehringer Ingelheim Fonds (N.F.R., R. R). The authors are responsible for the content of this publication. The authors declare no conflicts of interest. The authors thank Dr. Ralph Lydic and William Filbey for help with the whole-body plethysmography, Lisa K. Johnson and Dorothy Sorenson for technical assistance with the histopathology, and Amanda Welton for technical assistance with the MRI studies (all from the University of Michigan). The authors thank the Department of Radiology at the University of Michigan for the use of the Center for Molecular Imaging, which is supported in part by NIH grant P50CA093990. The authors thank Beverly Schumann, Sue Scott, and Robin Kunkel for excellent staff support.	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Allam R, 2012, J AM SOC NEPHROL, V23, P1375, DOI 10.1681/ASN.2011111077; Bamberg CE, 2010, J BIOL CHEM, V285, P7633, DOI 10.1074/jbc.M109.092106; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bosch X, 2009, NEW ENGL J MED, V361, P62, DOI 10.1056/NEJMra0801327; Bosmann M., 2012, FASEB J; Bosmann M, 2013, EUR J IMMUNOL, V43, P1907, DOI 10.1002/eji.201243075; Bosmann M, 2012, J IMMUNOL, V188, P5086, DOI 10.4049/jimmunol.1102914; Bosmann M, 2012, FASEB J, V26, P1640, DOI 10.1096/fj.11-199216; Bosmann M, 2012, ADV EXP MED BIOL, V946, P147, DOI 10.1007/978-1-4614-0106-3_9; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303; Chen NJ, 2007, NATURE, V446, P203, DOI 10.1038/nature05559; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Dunkelberger J, 2012, J IMMUNOL, V188, P4032, DOI 10.4049/jimmunol.1103141; Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf; Friggeri A, 2012, MOL MED, V18, P825, DOI 10.2119/molmed.2012.00005; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gao HW, 2006, ANNU REV PATHOL-MECH, V1, P215, DOI 10.1146/annurev.pathol.1.110304.100155; Garcia CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064443; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Gotts JE, 2011, CRIT CARE CLIN, V27, P719, DOI 10.1016/j.ccc.2011.04.004; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hakkim A, 2011, NAT CHEM BIOL, V7, P75, DOI 10.1038/NCHEMBIO.496; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; HIRSCH JG, 1958, J EXP MED, V108, P925, DOI 10.1084/jem.108.6.925; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Kanse SM, 2012, J IMMUNOL, V188, P2858, DOI 10.4049/jimmunol.1103029; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Kwan WH, 2013, J EXP MED, V210, P257, DOI 10.1084/jem.20121525; Lalli PN, 2008, BLOOD, V112, P1759, DOI 10.1182/blood-2008-04-151068; LARSEN GL, 1980, AM J PATHOL, V100, P179; Lee DY, 2009, J INVEST DERMATOL, V129, P2489, DOI 10.1038/jid.2009.106; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Li R, 2013, FASEB J, V27, P855, DOI 10.1096/fj.12-220509; Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC; Martin TR, 2011, CRIT CARE CLIN, V27, P735, DOI 10.1016/j.ccc.2011.05.013; Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331; Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Paine R, 2012, CRIT CARE MED, V40, P90, DOI 10.1097/CCM.0b013e31822d7bf0; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366; Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0; Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001; Sun L, 2009, FASEB J, V23, P3808, DOI 10.1096/fj.09-133694; Ward PA, 2003, EUR RESPIR J, V22, p22S, DOI 10.1183/09031936.03.00000703a; WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374; WEBSTER RO, 1982, J CLIN INVEST, V70, P1177, DOI 10.1172/JCI110716; WETSEL RA, 1995, IMMUNOL LETT, V44, P183, DOI 10.1016/0165-2478(94)00212-A; Xu J, 2011, J IMMUNOL, V187, P2626, DOI 10.4049/jimmunol.1003930; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhang X, 2010, J IMMUNOL, V185, P6741, DOI 10.4049/jimmunol.1000892	66	149	158	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5010	5021		10.1096/fj.13-236380	http://dx.doi.org/10.1096/fj.13-236380			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23982144	Green Published, Green Submitted			2022-12-28	WOS:000329999000034
J	Guskiewicz, KM; Goldman, SB				Guskiewicz, Kevin M.; Goldman, Sarah B.			A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics	FASEB JOURNAL			English	Editorial Material							CONCUSSION; STATEMENT		[Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Goldman, Sarah B.] US Army, Off Surgeon Gen, Rehabil & Reintegrat Div, Falls Church, VA 22042 USA	University of North Carolina; University of North Carolina Chapel Hill	Goldman, SB (corresponding author), US Army, Off Surgeon Gen, Rehabil & Reintegrat Div, 7700 Arlington Blvd,3SW128C, Falls Church, VA 22042 USA.	sarah.b.goldman.mil@mail.mil		Guskiewicz, Kevin/0000-0002-8682-2130				*ASS SECR DEF HLTH, 2007, TRAUM BRAIN INJ DEF; Berrigan L, 2011, BRAIN INJURY, V25, P742, DOI 10.3109/02699052.2011.580317; Broglio S., 2013, J ATHLETIC IN PRESS; CLARK EC, 1951, ELECTROEN CLIN NEURO, V3, P9, DOI 10.1016/0013-4694(51)90049-1; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Deputy Secretary of Defense, 2010, 09033 DTM US DEP DEF; French L., 2008, J SPEC OPER MED, V8, P67; Gardner A., 2013, BRIT J SPORT MED; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; O'Neil ME., 2013, VA DOD CLIN PRACT GU; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008	14	0	0	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4327	4329		10.1096/fj.13-1101ufm	http://dx.doi.org/10.1096/fj.13-1101ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	24179113				2022-12-28	WOS:000329937500001
J	Terrazas, CA; Alcantara-Hernandez, M; Bonifaz, L; Terrazas, LI; Satoskar, AR				Terrazas, Cesar A.; Alcantara-Hernandez, Marcela; Bonifaz, Laura; Terrazas, Luis I.; Satoskar, Abhay R.			Helminth-excreted/secreted products are recognized by multiple receptors on DCs to block the TLR response and bias Th2 polarization in a cRAF dependent pathway	FASEB JOURNAL			English	Article						CLRs; dendritic cell; mannose receptor; immunomodulation; MGL	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; C-TYPE LECTINS; DENDRITIC CELLS; TRANSCRIPTION FACTOR; SECRETED PRODUCT; IL-10 PRODUCTION; IMMUNE-RESPONSE; EGG ANTIGENS; MATURATION	Dendritic cells (DCs) recognize pathogens and initiate the T-cell response. The DC-helminth interaction induces an immature phenotype in DCs; as a result, these DCs display impaired responses to TLR stimulation and prime Th2-type responses. However, the DC receptors and intracellular pathways targeted by helminth molecules and their importance in the initiation of the Th2 response are poorly understood. In this report, we found that products excreted/secreted by Taenia crassiceps (TcES) triggered cRAF phosphorylation through MGL, MR, and TLR2. TcES interfered with the LPS-induced NFB p65 and p38 MAPK signaling pathways. In addition, TcES-induced cRAF signaling pathway was critical for down-regulation of the TLR-mediated DC maturation and secretion of IL-12 and TNF-. Finally, we show for the first time that blocking cRAF in DCs abolishes their ability to induce Th2 polarization in vitro after TcES exposure. Our data demonstrate a new mechanism by which helminths target intracellular pathways to block DC maturation and efficiently program Th2 polarization.Terrazas, C. A., Alcantara-Hernandez, M., Bonifaz, L., Terrazas, L. I., Satoskar, A. R. Helminth-excreted/secreted products are recognized by multiple receptors on DCs to block the TLR response and bias Th2 polarization in a cRAF dependent pathway.	[Terrazas, Cesar A.; Terrazas, Luis I.] Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala, Unidad Biomed, Mexico City 04510, DF, Mexico; [Terrazas, Cesar A.; Satoskar, Abhay R.] Ohio State Univ, Dept Microbiol, Med Ctr, Columbus, OH 43210 USA; [Terrazas, Cesar A.; Satoskar, Abhay R.] Ohio State Univ, Dept Pathol, Med Ctr, Columbus, OH 43210 USA; [Alcantara-Hernandez, Marcela; Bonifaz, Laura] Inst Mexicano Seguro Social IMSS, Ctr Med Siglo 21, Unidad Invest Med Inmunoquim, Mexico City, DF, Mexico	Universidad Nacional Autonoma de Mexico; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Instituto Mexicano del Seguro Social	Satoskar, AR (corresponding author), Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.	literrazas@campus.iztacala.unam.mx; abhay.satoskar@osumc.edu	Terrazas, Luis I/AAV-8858-2020; Satoskar, Abhay/AAB-7748-2019	Alcantara-Hernandez, Marcela/0000-0002-3620-1248; Terrazas, Luis I./0000-0003-1635-9467	Consejo Nacional de Ciencia y Tecnologia (CONACYT; Mexico) [167799]; Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)-Universidad Nacional Autonoma de Mexico (UNAM) [IN213512]; CONACYT-Mexico, Programa de Doctorado en Ciencias Biomedicas (PDCB) UNAM; Fulbright-Mexico-U.S. Commission for Educational and. Cultural Exchange (COMEXUS); U.S. National Institutes of Health	Consejo Nacional de Ciencia y Tecnologia (CONACYT; Mexico)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)-Universidad Nacional Autonoma de Mexico (UNAM); CONACYT-Mexico, Programa de Doctorado en Ciencias Biomedicas (PDCB) UNAM; Fulbright-Mexico-U.S. Commission for Educational and. Cultural Exchange (COMEXUS); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. Steve Oghumu for his help with experiments and critical reading of the paper. This work was supported by grant 167799 from Consejo Nacional de Ciencia y Tecnologia (CONACYT; Mexico) and Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)-Universidad Nacional Autonoma de Mexico (UNAM) IN213512, and is part of the requirements to obtain the Ph.D. degree in the Postgraduate Program in Biomedical Sciences, Facultad de Medicina, UNAM, for C. A. T., who was supported by a fellowship from CONACYT-Mexico, Programa de Doctorado en Ciencias Biomedicas (PDCB) UNAM, and Fulbright-Mexico-U.S. Commission for Educational and. Cultural Exchange (COMEXUS). The research in the A. R. S laboratory is supported by the grants from the U. S. National Institutes of Health. The authors declare no conflicts of interest.	Abdi K, 2012, J IMMUNOL, V188, P5981, DOI 10.4049/jimmunol.1102868; Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Amit P, 2011, EXP PARASITOL, V127, P687, DOI 10.1016/j.exppara.2010.11.006; Balic A, 2004, EUR J IMMUNOL, V34, P3047, DOI 10.1002/eji.200425167; Everts B, 2012, J EXP MED, V209, P1753, DOI 10.1084/jem.20111381; Gomez-Garcia L, 2006, PARASITOL RES, V99, P440, DOI 10.1007/s00436-006-0159-2; Goodridge HS, 2005, J IMMUNOL, V174, P284, DOI 10.4049/jimmunol.174.1.284; Gringhuis SI, 2007, IMMUNITY, V26, P605, DOI 10.1016/j.immuni.2007.03.012; Gringhuis SI, 2010, METHOD ENZYMOL, V480, P151, DOI 10.1016/S0076-6879(10)80008-4; Gringhuis SI, 2010, NAT IMMUNOL, V11, P419, DOI 10.1038/ni.1858; Gringhuis SI, 2009, NAT IMMUNOL, V10, P203, DOI 10.1038/ni.1692; Guasconi L, 2011, IMMUNOLOGY, V133, P386, DOI 10.1111/j.1365-2567.2011.03449.x; Hovius JWR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040031; Kane CM, 2004, J IMMUNOL, V173, P7454, DOI 10.4049/jimmunol.173.12.7454; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Lee JJ, 2005, MOL BIOCHEM PARASIT, V143, P245, DOI 10.1016/j.molbiopara.2005.06.002; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MacDonald AS, 2008, J EXP MED, V205, P13, DOI 10.1084/jem.20072665; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Napoletano C, 2012, EUR J IMMUNOL, V42, P936, DOI 10.1002/eji.201142086; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Okano M, 1999, J IMMUNOL, V163, P6712; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Poncini CV, 2010, MOL IMMUNOL, V47, P1981, DOI 10.1016/j.molimm.2010.04.016; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Qian C, 2006, BLOOD, V108, P2307, DOI 10.1182/blood-2006-03-005595; Reyes JL, 2011, INT J BIOL SCI, V7, P1323, DOI 10.7150/ijbs.7.1323; Reyes JL, 2011, CELL IMMUNOL, V267, P77, DOI 10.1016/j.cellimm.2010.11.006; Reyes JL, 2009, INFECT GENET EVOL, V9, P1115, DOI 10.1016/j.meegid.2009.05.011; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Saunders SP, 2009, INFECT IMMUN, V77, P399, DOI 10.1128/IAI.00762-08; Segura M, 2007, EUR J IMMUNOL, V37, P1887, DOI 10.1002/eji.200636553; Terrazas CA, 2011, INT J BIOL SCI, V7, P1298, DOI 10.7150/ijbs.7.1298; Terrazas CA, 2011, INT J BIOL SCI, V7, P1391, DOI 10.7150/ijbs.7.1391; Terrazas CA, 2010, INT J PARASITOL, V40, P1051, DOI 10.1016/j.ijpara.2010.02.016; Terrazas CA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/357106; Terrazas LI, 1998, J PARASITOL, V84, P74, DOI 10.2307/3284533; Terrazas LI, 2008, CURR TOP MED CHEM, V8, P383, DOI 10.2174/156802608783790848; Thomas PG, 2005, J IMMUNOL, V175, P2082, DOI 10.4049/jimmunol.175.4.2082; Thomas PG, 2003, J IMMUNOL, V171, P5837, DOI 10.4049/jimmunol.171.11.5837; Tundup S, 2012, ANN NY ACAD SCI, V1253, pE1, DOI 10.1111/j.1749-6632.2012.06618.x; van de Veerdonk FL, 2009, CELL HOST MICROBE, V5, P329, DOI 10.1016/j.chom.2009.02.006; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; van Liempt E, 2007, MOL IMMUNOL, V44, P2605, DOI 10.1016/j.molimm.2006.12.012; Van Vliet S. J., 2013, J LEUKOC BIOL, DOI 10.1189/jlb.1012520; van Vliet SJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000625; Vanhoutte F, 2007, MICROBES INFECT, V9, P1606, DOI 10.1016/j.micinf.2007.09.013; Villa OF, 1996, PARASITOLOGY, V112, P561, DOI 10.1017/S0031182000066142; Whelan M, 2000, J IMMUNOL, V164, P6453, DOI 10.4049/jimmunol.164.12.6453; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374	51	45	47	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4547	4560		10.1096/fj.13-228932	http://dx.doi.org/10.1096/fj.13-228932			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23907435	Green Published			2022-12-28	WOS:000329937500021
J	Chan, SL; Sweet, JG; Cipolla, MJ				Chan, Siu-Lung; Sweet, Julie G.; Cipolla, Marilyn J.			Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension	FASEB JOURNAL			English	Article						blood-brain barrier; inward remodeling; matrix metalloproteinase-2; spontaneous hypertensive rats; vascular endothelial growth factor	WHITE-MATTER LESIONS; ENDOTHELIAL GROWTH-FACTOR; ISCHEMIC VASCULAR-DISEASE; MECHANICAL-PROPERTIES; COGNITIVE DECLINE; NONPREGNANT RATS; FAMILY PEPTIDES; CONSCIOUS RATS; BLOOD-PRESSURE; EXPRESSION	We investigated the effect of hypertension on the function and structure of cerebral parenchymal arterioles (PAs), a major target of cerebral small vessel disease (SVD), and determined whether relaxin is a treatment for SVD during hypertension. PAs were isolated from 18-wk-old female normotensive Wistar-Kyoto (WKY) rats, spontaneous hypertensive rats (SHRs), and SHRs treated with human relaxin 2 for 14 d (4 g/h; n=8/group) and studied using a pressurized arteriograph system. Hypertension reduced PA inner diameter (58 +/- 3 vs. 49 +/- 3 m at 60 mmHg in WKY rats, P<0.05), suggesting inward remodeling that was reversed by relaxin (56 +/- 4 m, P<0.05). Relaxin also increased PA distensibility in SHRs (34 +/- 2 vs. 10 +/- 2% in SHRs, P<0.05). Relaxin was detected in cerebrospinal fluid (110 +/- 30 pg/ml) after systemic administration, suggesting that it crosses the blood-brain barrier (BBB). Relaxin receptors (RXFP1/2) were not detected in cerebral vasculature, but relaxin increased vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP-2) expression in brain cortex. Inhibition of VEGF receptor tyrosine kinase (axitinib, 4 mg/kg/d, 14 d) had no effect on increased distensibility with relaxin, but caused outward hypertrophic remodeling of PAs from SHRs. These results suggest that relaxin crosses the BBB and activates MMP-2 in brain cortex, which may interact with PAs to increase distensibility. VEGF appears to be involved in remodeling of PAs, but not relaxin-induced increased distensibility.Chan, S.-L., Sweet, J. G., Cipolla, M. J. Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension.	[Chan, Siu-Lung; Sweet, Julie G.; Cipolla, Marilyn J.] Univ Vermont, Dept Neurol Sci, Burlington, VT 05405 USA; [Cipolla, Marilyn J.] Univ Vermont, Dept Obstet Gynecol & Reprod Sci, Burlington, VT 05405 USA; [Cipolla, Marilyn J.] Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont	Chan, SL (corresponding author), Univ Vermont, Dept Neurol Sci, 149 Beaumont Ave,HSRF 416, Burlington, VT 05405 USA.	siu-lung.chan@uvm.edu	Chan, Siu-Lung/I-3023-2019	Chan, Siu-Lung/0000-0001-7564-3287	U.S. National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke [R01 NSO45940]; NIH National Heart, Lung, and Blood Institute [P01 HL095488]; Totman Medical Research Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL095488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045940] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke; NIH National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Totman Medical Research Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Dennis Stewart (Corthera, Inc., San Carlos, CA, USA) and Novartis Pharmaceuticals (Basel, Switzerland) for providing recombinant human relaxin 2. The authors also thank Dr. Ernst Rinderknecht (Corthera) for the helpful discussion. The authors thank Timothy Hunter, Mary Lou Shane, Meghann Palermo, and the Vermont Cancer Center DNA Analysis Facility (University of Vermont) for their technical expertise on qPCR studies. The authors thank Nicole Bishop (Microscopy Imaging Center, University of Vermont) for her help with VEGF immunohistochemistry and imaging. The authors also thank Sheila Russell for helping to collect CSF. The authors gratefully acknowledge the continued support from the U.S. National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (R01 NSO45940), NIH National Heart, Lung, and Blood Institute (P01 HL095488), and the Totman Medical Research Trust. Recombinant human relaxin 2 was a gift from Corthera and Novartis Phat maceuticals.	Bathgate RAD, 2013, PHYSIOL REV, V93, P405, DOI 10.1152/physrev.00001.2012; Baumbach GL, 1996, HYPERTENSION, V27, P159, DOI 10.1161/01.HYP.27.2.159; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; Chan SL, 2012, J IMMUNOASS IMMUNOCH, V33, P314, DOI 10.1080/15321819.2011.647189; Chan SL, 2011, FASEB J, V25, P3229, DOI 10.1096/fj.10-175471; Cipolla MJ, 2009, STROKE, V40, P1451, DOI 10.1161/STROKEAHA.108.535435; Conrad KP, 2011, CURR HYPERTENS REP, V13, P409, DOI 10.1007/s11906-011-0231-x; Conrad KP, 2004, ENDOCRINOLOGY, V145, P3289, DOI 10.1210/en.2003-1612; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; Danielson LA, 2003, J APPL PHYSIOL, V95, P1509, DOI 10.1152/japplphysiol.00545.2003; Debrah DO, 2006, ENDOCRINOLOGY, V147, P5126, DOI 10.1210/en.2006-0567; Debrah DO, 2011, J APPL PHYSIOL, V111, P260, DOI 10.1152/japplphysiol.00845.2010; Desouza CV, 2009, VASC PHARMACOL, V51, P162, DOI 10.1016/j.vph.2009.05.001; Dufouil C, 2009, STROKE, V40, P2219, DOI 10.1161/STROKEAHA.108.540633; Fernando MS, 2006, STROKE, V37, P1391, DOI 10.1161/01.STR.0000221308.94473.14; Godin O, 2011, CIRCULATION, V123, P266, DOI 10.1161/CIRCULATIONAHA.110.961052; Gouw AA, 2008, STROKE, V39, P3083, DOI 10.1161/STROKEAHA.108.521807; Gundlach AL, 2009, ANN NY ACAD SCI, V1160, P226, DOI 10.1111/j.1749-6632.2009.03956.x; Guo XX, 2009, HYPERTENSION, V54, P57, DOI 10.1161/HYPERTENSIONAHA.109.129700; HOFFMAN WE, 1981, BRAIN RES, V214, P196, DOI 10.1016/0006-8993(81)90454-6; Holderfield MT, 2008, CIRC RES, V102, P637, DOI 10.1161/CIRCRESAHA.107.167171; Jeyabalan A, 2006, J APPL PHYSIOL, V100, P1955, DOI 10.1152/japplphysiol.01330.2005; Jeyabalan A, 2007, ENDOCRINOLOGY, V148, P189, DOI 10.1210/en.2006-0989; Jokinen H, 2009, CEREBROVASC DIS, V27, P384, DOI 10.1159/000207442; Jokinen H, 2009, CEREBROVASC DIS, V27, P336, DOI 10.1159/000202010; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lammie GA, 2002, BRAIN PATHOL, V12, P358; Lekgabe ED, 2005, HYPERTENSION, V46, P412, DOI 10.1161/01.HYP.0000171930.00697.2f; Liao DP, 1996, STROKE, V27, P2262, DOI 10.1161/01.STR.27.12.2262; Liu Li, 2008, J Vis Exp, DOI 10.3791/960; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Markus HS, 2000, J NEUROL NEUROSUR PS, V69, P48, DOI 10.1136/jnnp.69.1.48; McGowan BMC, 2010, DIABETES OBES METAB, V12, P1090, DOI 10.1111/j.1463-1326.2010.01302.x; Moran C, 2012, INT J STROKE, V7, P36, DOI 10.1111/j.1747-4949.2011.00725.x; Nishimura N, 2007, P NATL ACAD SCI USA, V104, P365, DOI 10.1073/pnas.0609551104; Pantoni L, 1997, ANN NY ACAD SCI, V826, P92, DOI 10.1111/j.1749-6632.1997.tb48463.x; Tryggvason K, 1992, Matrix Suppl, V1, P45; van Dijk EJ, 2004, HYPERTENSION, V44, P625, DOI 10.1161/01.HYP.0000145857.98904.20; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Yan W, 2008, REPRODUCTION, V135, P705, DOI 10.1530/REP-08-0014	41	37	39	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3917	3927		10.1096/fj.13-230797	http://dx.doi.org/10.1096/fj.13-230797			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23783073	Green Published			2022-12-28	WOS:000329747100007
J	Grelard, A; Guichard, P; Bonnafous, P; Marco, S; Lambert, O; Manin, C; Ronzon, F; Dufourc, EJ				Grelard, Axelle; Guichard, Paul; Bonnafous, Pierre; Marco, Sergio; Lambert, Olivier; Manin, Catherine; Ronzon, Frederic; Dufourc, Erick J.			Hepatitis B subvirus particles display both a fluid bilayer membrane and a strong resistance to freeze drying: a study by solid-state NMR, light scattering, and cryo-electron microscopy/tomography	FASEB JOURNAL			English	Article						deuterium labeling; lipid incorporation; order parameter; lipid thickness; trapped water	BOND ORDER PARAMETERS; MAGNETIC-RESONANCE; LIPID-BILAYERS; C-C; 3-DIMENSIONAL RECONSTRUCTION; DYNAMICS; PROTEIN; CHOLESTEROL; TEMPERATURE; PHASE	Hepatitis B surface antigen (HBsAg) subvirus particles produced from yeast share immunological determinants with mature viruses, which enable the use of HBsAg as a potent antigen for human vaccination. Because the intimate structure of such pseudoviral particles is still a matter of debate, we investigated the robustness of the external barrier and its structure and dynamics using the noninvasive solid-state NMR technique. This barrier is made of 60% proteins and 40% lipids. Phospholipids represent 83% of all lipids, and chain unsaturation is of 72%. Dynamics was reported by embedding small amounts of deuterium chain-labeled unsaturated phospholipid into the external barrier of entire subviral particles, while controlling particle integrity by cryoelectron microscopy, tomography, and light scattering. Variable preparation modes were used, from mild incubation of small unilamellar vesicles to very stringent incorporation with freeze-drying. A lipid bilayer structure of 4- to 5-nm thickness was evidenced with a higher rigidity than that of synthetic phospholipid vesicles, but nonetheless reflecting a fluid membrane (50-52% of maximum rigidity) in agreement with the elevated unsaturation content. The HBsAg particles of 20- to 24-nm diameter were surprisingly found resistant to lyophilization, in such a way that trapped water inside particles could not be removed. These dual properties bring more insight into the mode of action of native subviral particles and their recombinant counterparts used in vaccines.Grelard, A., Guichard, P., Bonnafous, P., Marco, S., Lambert, O., Manin, C., Ronzon, F., and Dufourc, E. J. Hepatitis B subvirus particles display both a fluid bilayer membrane and a strong resistance to freeze drying: a study by solid-state NMR, light scattering, and cryo-electron microscopy/tomography.	[Grelard, Axelle; Bonnafous, Pierre; Lambert, Olivier; Dufourc, Erick J.] Univ Bordeaux, Inst Chem & Biol Membranes & Nanoobjects, CBMN, UMR 5248, Pessac, France; [Grelard, Axelle; Bonnafous, Pierre; Lambert, Olivier] CNRS, Inst Chem & Biol Membranes & Nanoobjects, CBMN, UMR5248, Pessac, France; [Guichard, Paul; Marco, Sergio; Dufourc, Erick J.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Guichard, Paul; Marco, Sergio] Univ Paris 11, INSERM, U759, F-91405 Orsay, France; [Manin, Catherine; Ronzon, Frederic] Sanofi Pasteur, Marcy Letoile, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay	Dufourc, EJ (corresponding author), CBMN, UMR5248, Allee Geoffroy St Hilaire, F-33600 Pessac, France.	e.dufourc@cbmn.u-bordeaux.fr	marco, SERGIO/E-4875-2017; Bonnafous, Pierre/M-7845-2014; Guichard, Paul/AAL-8603-2020; DUFOURC, Erick Joel/AAA-4992-2020	Guichard, Paul/0000-0002-0363-1049; DUFOURC, Erick Joel/0000-0002-8221-9326; GRELARD, Axelle/0000-0002-6708-2253; Lambert, Olivier/0000-0002-5651-8082	Tres Grands Equipements de Resonance Magnetique Nucleaire a Tres Haut Champ, Federation de Recherche (TGE RMN THC FR) [3050]; Sanofi Pasteur (Lyon, France)	Tres Grands Equipements de Resonance Magnetique Nucleaire a Tres Haut Champ, Federation de Recherche (TGE RMN THC FR); Sanofi Pasteur (Lyon, France)	The Aquitaine Government is thanked for supporting equipment setup in the Institute of Chemistry and Biology of Membranes and Nanoobjects/Institut Europeen de Chimie et Biologie. Financial support from the Tres Grands Equipements de Resonance Magnetique Nucleaire a Tres Haut Champ, Federation de Recherche (TGE RMN THC FR) 3050 for conducting the research is gratefully acknowledged. Tino Kreil is thanked for reading the manuscript and improving the English. This study was also funded by Sanofi Pasteur (Lyon, France).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Aussenac F, 2003, LANGMUIR, V19, P10468, DOI 10.1021/la034268q; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; BLOOM M, 1981, CHEM PHYS LETT, V80, P198, DOI 10.1016/0009-2614(81)80089-9; BOTHOREL P, 1974, CHEM PHYS LIPIDS, V12, P96, DOI 10.1016/0009-3084(74)90048-6; BOTHOREL P, 1968, CR ACAD SCI D NAT, V266, P2492; Buchoux S, 2008, BIOPHYS J, V95, P3840, DOI 10.1529/biophysj.107.128322; BULDT G, 1979, J MOL BIOL, V134, P673, DOI 10.1016/0022-2836(79)90479-0; BURNETT LJ, 1971, J CHEM PHYS, V55, P5829, DOI 10.1063/1.1675758; Cevc G., 1993, PHOSPHOLIPIDS HDB, V2ZxaucDNWHcC; CULLIS PR, 1978, NATURE, V271, P672, DOI 10.1038/271672a0; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DAVIS JH, 1983, BIOCHIM BIOPHYS ACTA, V737, P117, DOI 10.1016/0304-4157(83)90015-1; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DEULING HJ, 1976, J PHYS-PARIS, V37, P1335, DOI 10.1051/jphys:0197600370110133500; Dichtelmuller H, 2002, BIOLOGICALS, V30, P135, DOI 10.1006/biol.2002.0332; Diminsky D, 1997, VACCINE, V15, P637, DOI 10.1016/S0264-410X(96)00239-3; Douliez JP, 1998, J CHEM PHYS, V109, P2513, DOI 10.1063/1.476823; Douliez JP, 1996, J PHYS CHEM-US, V100, P17083, DOI 10.1021/jp961457r; Douliez JP, 1996, J PHYS CHEM-US, V100, P18450, DOI 10.1021/jp961220v; DOULIEZ JP, 1995, BIOPHYS J, V68, P1727, DOI 10.1016/S0006-3495(95)80350-4; Dufourc E. J., 2009, WILEY ENCY CHEM BIOL; DUFOURC EJ, 1984, BIOCHEMISTRY-US, V23, P6062, DOI 10.1021/bi00320a025; Dufourc Erick J, 2008, J Chem Biol, V1, P63, DOI 10.1007/s12154-008-0010-6; FERNANDEZPUENTE L, 1994, EUROPHYS LETT, V28, P181, DOI 10.1209/0295-5075/28/3/005; Gamier-Lhomme M, 2007, BBA-BIOMEMBRANES, V1768, P2516, DOI 10.1016/j.bbamem.2007.06.004; GARNIER M, 2006, SIGNAL TRANSDUCTION, V6, P133; Garnier-Lhomme M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004255; Garnier-Lhomme Marie, 2009, V462, P89, DOI 10.1007/978-1-60327-115-8_6; Gastaminza P, 2010, J VIROL, V84, P10999, DOI 10.1128/JVI.00526-10; Gilbert RJC, 2005, P NATL ACAD SCI USA, V102, P14783, DOI 10.1073/pnas.0505062102; Greiner VJ, 2010, BIOCHIMIE, V92, P994, DOI 10.1016/j.biochi.2010.04.014; Grelard Axelle, 2009, V462, P111, DOI 10.1007/978-1-60327-115-8_7; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HERMAN GT, 1973, J THEOR BIOL, V42, P1, DOI 10.1016/0022-5193(73)90145-8; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; ISRAELACHVILI JN, 1977, BIOCHIM BIOPHYS ACTA, V470, P185, DOI 10.1016/0005-2736(77)90099-2; Kang SM, 2009, VIRUS RES, V143, P140, DOI 10.1016/j.virusres.2009.04.005; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; Larijani B, 2006, LIPIDS, V41, P925, DOI 10.1007/s11745-006-5045-2; LEONARD A, 1991, BIOCHIMIE, V73, P1295, DOI 10.1016/0300-9084(91)90092-F; Leonard A., 1993, B MAGN RESON, V15, P124; Marassi FM, 1999, P NATL ACAD SCI USA, V96, P14336, DOI 10.1073/pnas.96.25.14336; Maringer K, 2012, J VIROL, V86, P12971, DOI 10.1128/JVI.01913-12; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MEIER P, 1987, P NATL ACAD SCI USA, V84, P3704, DOI 10.1073/pnas.84.11.3704; Messaoudil C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-288; Milhiet PE, 2011, BIOCHIMIE, V93, P254, DOI 10.1016/j.biochi.2010.09.018; Park SH, 2008, J MAGN RESON, V193, P133, DOI 10.1016/j.jmr.2008.04.033; PETERSEN NO, 1977, BIOCHEMISTRY-US, V16, P2657, DOI 10.1021/bi00631a012; POTT T, 1995, BIOPHYS J, V68, P965, DOI 10.1016/S0006-3495(95)80272-9; Raffard G, 2000, LANGMUIR, V16, P7655, DOI 10.1021/la000564g; Roberts KL, 2009, J GEN VIROL, V90, P1582, DOI 10.1099/vir.0.009092-0; Satoh O, 2000, J BIOCHEM-TOKYO, V127, P543, DOI 10.1093/oxfordjournals.jbchem.a022639; SAXTON WO, 1984, ULTRAMICROSCOPY, V13, P57, DOI 10.1016/0304-3991(84)90057-3; SCHINDLER H, 1975, BIOCHEMISTRY-US, V14, P2283, DOI 10.1021/bi00682a001; SCHMITZ G, 1991, J LIPID RES, V32, P1539; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; STERNIN E, 1983, J MAGN RESON, V55, P274, DOI 10.1016/0022-2364(83)90239-1; THURMOND RL, 1993, BIOCHEMISTRY-US, V32, P5394, DOI 10.1021/bi00071a015; Tu K, 1995, BIOPHYS J, V69, P2558, DOI 10.1016/S0006-3495(95)80126-8; Tu K, 1996, BIOPHYS J, V70, P595, DOI 10.1016/S0006-3495(96)79623-6; Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1	65	20	20	1	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4316	4326		10.1096/fj.13-232843	http://dx.doi.org/10.1096/fj.13-232843			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23839934				2022-12-28	WOS:000329747100040
J	Nilsson, MI; Dobson, JP; Greene, NP; Wiggs, MP; Shimkus, KL; Wudeck, EV; Davis, AR; Laureano, ML; Fluckey, JD				Nilsson, Mats I.; Dobson, Justin P.; Greene, Nicholas P.; Wiggs, Michael P.; Shimkus, Kevin L.; Wudeck, Elyse V.; Davis, Amanda R.; Laureano, Marissa L.; Fluckey, James D.			Abnormal protein turnover and anabolic resistance to exercise in sarcopenic obesity	FASEB JOURNAL			English	Article						fractional synthesis rates; DEPTOR; muscle; diabetes	SKELETAL-MUSCLE; ZUCKER RATS; IN-VIVO; INSULIN STIMULATION; INDUCED HYPERTROPHY; BODY-COMPOSITION; GLUCOSE-UPTAKE; MECHANISM; TISSUES; DEPTOR	Obesity may impair protein synthesis rates and cause anabolic resistance to growth factors, hormones, and exercise, ultimately affecting skeletal muscle mass and function. To better understand muscle wasting and anabolic resistance with obesity, we assessed protein 24-h fractional synthesis rates (24-h FSRs) in selected hind-limb muscles of sedentary and resistance-exercised lean and obese Zucker rats. Despite atrophied hind-limb muscles (-28% vs. lean rats), 24-h FSRs of mixed proteins were significantly higher in quadriceps (+18%) and red or white gastrocnemius (+22 or +38%, respectively) of obese animals when compared to lean littermates. Basal synthesis rates of myofibrillar (+8%) and mitochondrial proteins (-1%) in quadriceps were not different between phenotypes, while manufacture of cytosolic proteins (+12%) was moderately elevated in obese cohorts. Western blot analyses revealed a robust activation of p70S6k (+178%) and a lower expression of the endogenous mTOR inhibitor DEPTOR (-28%) in obese rats, collectively suggesting that there is an obesity-induced increase in net protein turnover favoring degradation. Lastly, the protein synthetic response to exercise of mixed (-7%), myofibrillar (+6%), and cytosolic (+7%) quadriceps subfractions was blunted compared to the lean phenotype (+34, +40, and +17%, respectively), indicating a muscle- and subfraction-specific desensitization to the anabolic stimulus of exercise in obese animals.Nilsson, M. I., Dobson, J. P., Greene, N. P., Wiggs, M. P., Shimkus, K. L., Wudeck, E. V., Davis, A. R., Laureano, M. L., Fluckey, J. D. Abnormal protein turnover and anabolic resistance to exercise in sarcopenic obesity.	[Nilsson, Mats I.; Dobson, Justin P.; Greene, Nicholas P.; Wiggs, Michael P.; Shimkus, Kevin L.; Wudeck, Elyse V.; Davis, Amanda R.; Fluckey, James D.] Texas A&M Univ, Dept Hlth & Kinesiol, Muscle Biol Lab, College Stn, TX 77843 USA; [Laureano, Marissa L.] McMaster Univ Hosp, Dept Pediat & Med, Neuromuscular Clin, Hamilton, ON, Canada	Texas A&M University System; Texas A&M University College Station; McMaster University	Fluckey, JD (corresponding author), Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX 77843 USA.	jfluckey@hlkn.tamu.edu	Nilsson, Mats/AAG-2068-2021; Greene, Nicholas/G-7399-2015; Greene, Nicholas/A-6076-2013	Nilsson, Mats/0000-0001-5656-5578; Greene, Nicholas/0000-0002-9504-9362; Greene, Nicholas/0000-0001-9621-2005	Sydney and J. L. Huffines Institute for Sports Medicine and Human Performance at Texas AM University	Sydney and J. L. Huffines Institute for Sports Medicine and Human Performance at Texas AM University	Funds were provided by the Sydney and J. L. Huffines Institute for Sports Medicine and Human Performance at Texas A&M University. The authors extend their gratitude to Dr. Scot Kimball (Penn State University, State College, PA, USA) for generously providing the eIF2B epsilon antibody.	Adeva MM, 2012, AMINO ACIDS, V43, P171, DOI 10.1007/s00726-011-1088-7; Argiles JM, 1999, J NUTR BIOCHEM, V10, P244, DOI 10.1016/S0955-2863(98)00098-9; Avignon A, 1996, DIABETES, V45, P1396, DOI 10.2337/diabetes.45.10.1396; Bacchi E, 2012, DIABETES CARE, V35, P676, DOI 10.2337/dc11-1655; Baumgartner RN, 2000, ANN NY ACAD SCI, V904, P437; Bell JA, 2006, J NUTR, V136, P1249, DOI 10.1093/jn/136.5.1249; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2003, J PHYSIOL-LONDON, V553, P213, DOI 10.1113/jphysiol.2003.047019; Cannon Christopher P, 2009, Clin Cornerstone, V9, P55; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; DOMENECH M, 1992, MOL CELL BIOCHEM, V110, P155, DOI 10.1007/BF02454192; Dryden S, 1999, CLIN SCI, V96, P307, DOI [10.1042/CS19980226, 10.1042/cs0960307]; Dufner D, 2003, CURR OPIN CLIN NUTR, V6, P511, DOI 10.1097/00075197-200309000-00004; DURSCHLAG RP, 1983, GROWTH, V47, P282; Evans WJ, 2010, AM J CLIN NUTR, V91, p1123S, DOI 10.3945/ajcn.2010.28608A; Farrell PA, 1999, J APPL PHYSIOL, V87, P1075, DOI 10.1152/jappl.1999.87.3.1075; Farrell PA, 1998, J APPL PHYSIOL, V85, P2291, DOI 10.1152/jappl.1998.85.6.2291; FELIG P, 1969, NEW ENGL J MED, V281, P811, DOI 10.1056/NEJM196910092811503; Fluckey JD, 2000, AM J PHYSIOL-ENDOC M, V279, pE182, DOI 10.1152/ajpendo.2000.279.1.E182; Fluckey JD, 2004, AM J PHYSIOL-ENDOC M, V286, pE753, DOI 10.1152/ajpendo.00155.2003; Fluckey JD, 1999, ACTA PHYSIOL SCAND, V167, P77; Fluckey JD, 1996, J GERONTOL A-BIOL, V51, pB323, DOI 10.1093/gerona/51A.5.B323; Frier BC, 2007, CELL STRESS CHAPERON, V12, P132, DOI 10.1379/CSC-233R.1; GARLICK PJ, 1988, BIOCHEM J, V254, P579, DOI 10.1042/bj2540579; Gasier HG, 2012, METABOLISM, V61, P153, DOI 10.1016/j.metabol.2011.07.001; Gasier HG, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-31; Gasier HG, 2009, COMP BIOCHEM PHYS B, V154, P235, DOI 10.1016/j.cbpb.2009.06.012; Guillet C., OBESITY REV, V13, P51; Guillet C, 2009, J CLIN ENDOCR METAB, V94, P3044, DOI 10.1210/jc.2008-2216; Haasch D, 2006, BIOCHEM BIOPH RES CO, V343, P361, DOI 10.1016/j.bbrc.2006.02.177; Halvatsiotis P, 2002, DIABETES, V51, P2395, DOI 10.2337/diabetes.51.8.2395; Heber D, 1996, AM J CLIN NUTR, V64, P472; Hernandez JM, 2000, J APPL PHYSIOL, V88, P1142, DOI 10.1152/jappl.2000.88.3.1142; Herrero MC, 1997, INT J OBESITY, V21, P698, DOI 10.1038/sj.ijo.0800464; Heshka S, 2008, INT J OBESITY, V32, P780, DOI 10.1038/sj.ijo.0803802; Holloway GP, 2009, AM J PHYSIOL-ENDOC M, V296, pE738, DOI 10.1152/ajpendo.90896.2008; Ibanez J, 2008, J DIABETES COMPLICAT, V22, P112, DOI 10.1016/j.jdiacomp.2007.06.008; Jaleel A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1255, DOI 10.1152/ajpendo.90586.2008; Johnson PR, 1997, AM J CLIN NUTR, V66, P890, DOI 10.1093/ajcn/66.4.890; Katsanos CS, 2011, OBESITY, V19, P469, DOI 10.1038/oby.2010.290; Katta A, 2009, MUSCLE NERVE, V39, P503, DOI 10.1002/mus.21255; Kazi AA, 2011, MOL MED, V17, P925, DOI 10.2119/molmed.2011.00070; Laplante M, 2012, CELL METAB, V16, P202, DOI 10.1016/j.cmet.2012.07.008; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; LOBLEY GE, 1978, P NUTR SOC, V37, pA20; Masgrau A, 2012, J PHYSIOL-LONDON, V590, P5199, DOI 10.1113/jphysiol.2012.238576; Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707; Nilsson MI, 2010, AM J PHYSIOL-ENDOC M, V299, pE466, DOI 10.1152/ajpendo.00118.2010; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Oltman CL, 2005, AM J PHYSIOL-ENDOC M, V289, pE113, DOI 10.1152/ajpendo.00594.2004; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; Paturi S, 2010, J APPL PHYSIOL, V108, P7, DOI 10.1152/japplphysiol.00330.2009; Peterson JM, 2008, AM J PHYSIOL-CELL PH, V295, pC521, DOI 10.1152/ajpcell.00073.2008; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Procaccini C, 2012, J IMMUNOL, V189, P2941, DOI 10.4049/jimmunol.1200935; Relaix F, 2012, DEVELOPMENT, V139, P2845, DOI 10.1242/dev.069088; Rennie MJ, 2004, ANNU REV PHYSIOL, V66, P799, DOI 10.1146/annurev.physiol.66.052102.134444; Sabatini D. M., 2012, COLD SPRING HARBOR P, V4; Sadiq F, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-23; Sampalis JS, 2004, OBES SURG, V14, P939, DOI 10.1381/0960892041719662; She PX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059443; Simpson S. A., 2011, BMJ, V343; Sitnick M, 2009, J PHYSIOL-LONDON, V587, P5753, DOI 10.1113/jphysiol.2009.180174; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sriwijitkamol A, 2006, AM J PHYSIOL-ENDOC M, V290, pE925, DOI 10.1152/ajpendo.00429.2005; Stenholm S, 2008, CURR OPIN CLIN NUTR, V11, P693, DOI 10.1097/MCO.0b013e328312c37d; Swift J. M., J APPL PHYSL, V109, P1600; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wang ZW, 2012, AM J PHYSIOL-ENDOC M, V303, pE163, DOI 10.1152/ajpendo.00105.2012; Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542; Waters DL, 2011, CLIN GERIATR MED, V27, P401, DOI 10.1016/j.cger.2011.03.007; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zamboni M, 2008, NUTR METAB CARDIOVAS, V18, P388, DOI 10.1016/j.numecd.2007.10.002; Zheng YB, 2009, J ENDOCRINOL, V203, P337, DOI 10.1677/JOE-09-0181	76	61	61	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3905	3916		10.1096/fj.12-224006	http://dx.doi.org/10.1096/fj.12-224006			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23804240				2022-12-28	WOS:000329747100006
J	Qi, YF; Chen, JB; Lay, A; Don, A; Vadas, M; Xia, P				Qi, Yanfei; Chen, Jinbiao; Lay, Angelina; Don, Anthony; Vadas, Mathew; Xia, Pu			Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic beta-cell death in diet-induced obese mice	FASEB JOURNAL			English	Article						apoptosis; lipotoxicity; sphingolipids; type 2 diabetes	ENDOPLASMIC-RETICULUM STRESS; INSULIN-RESISTANCE; FATTY-ACIDS; APOPTOSIS; PALMITATE; 1-PHOSPHATE; GLUCOSE; GROWTH; SPHINGOSINE-1-PHOSPHATE; CONTRIBUTES	Lipotoxic stress-induced -cell death (lipotoxicity) is recognized as a key contributor to the development of type 2 diabetes mellitus (T2DM). The current study reports a critical role of sphingosine kinase 1 (SphK1) in -cell survival under lipotoxic conditions. In an attempt to investigate the role of SphK1 in lipotoxicity in vivo, we fed Sphk1(-/-) and wild-type (WT) mice with a high-fat diet (HFD) or normal chow diet. Remarkably, while HFD-fed WT mice developed glucose intolerance and compensatory hyperinsulinemia, all HFD-fed Sphk1(-/-) mice manifested evident diabetes, accompanied by a nearly 3-fold reduction in insulin levels compared with the WT mice. Pancreatic -cell mass was increased by 140% in HFD-fed WT mice but decreased to 50% in HFD-fed Sphk1(-/-) mice, in comparison with the chow diet control groups, respectively. Accordingly, by blocking the enzyme activity, expression of a dominant negative form of SphK1 markedly promoted palmitate-induced cell death in MIN6 and INS-1 -cell lines. Moreover, primary islets isolated from Sphk1(-/-) mice exhibited higher susceptibility to lipotoxicity than WT controls. Of note, sphingosine 1-phosphate (S1P) profoundly abrogated lipotoxicity in cells or the cells lacking SphK1 activity and Sphk1(-/-) islets, highlighting a pivotal role of S1P in -cell survival under lipotoxic conditions. These findings could suggest a new therapeutic strategy for preventing -cell death and thus the onset of T2DM.Qi, Y., Chen, J., Lay, A., Don, A., Vadas, M., Xia, P. Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic -cell death in diet-induced obese mice.	[Qi, Yanfei; Chen, Jinbiao; Xia, Pu] Univ Sydney, Signal Transduct Program, Sydney, NSW 2006, Australia; [Lay, Angelina; Vadas, Mathew] Univ Sydney, Vasc Biol Program, Centenary Inst, Sydney Med Sch, Sydney, NSW 2006, Australia; [Don, Anthony] Univ New S Wales, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Don, Anthony] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Xia, Pu] Fudan Univ, Dept Endocrinol, Zhongshan Hosp, Shanghai 200433, Peoples R China	University of Sydney; University of Sydney; Centenary Institute; University of New South Wales Sydney; University of New South Wales Sydney; Fudan University	Xia, P (corresponding author), Fudan Univ, Dept Endocrinol, Zhongshan Hosp, Shanghai 200433, Peoples R China.	xiapu_fudan@163.com	Don, Anthony Simon/AAE-9687-2021; Qi, Yanfei/ABC-1242-2021; Chen, Jinbiao/J-5868-2013; Chen, Jinbiao/N-9905-2019; Xia, Pu/G-3090-2010; Vadas, Mathew/R-1378-2019	Don, Anthony Simon/0000-0003-1655-1184; Qi, Yanfei/0000-0003-1391-4111; Chen, Jinbiao/0000-0003-0339-5880; Chen, Jinbiao/0000-0003-0339-5880; Xia, Pu/0000-0003-4705-8878; 	Australian National Health and Medical Research Council (NHMRC) [349348, 571408]; Cancer Institute NSW Fellowship; Fudan University Distinguished Professorship; NHMRC scholarship	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW Fellowship; Fudan University Distinguished Professorship; NHMRC scholarship(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Dr. Richard Proia (U.S. National Institutes of Health, Bethesda, MD, USA) for providing sphk1<SUP>-/-</SUP> mouse colonies; Dr. Carol Wadham (Centenary Institute) for reviewing and editing the manuscript; Dr. Ross D. Laybutt (Garvan Institute, Darlinghurst, NSW, Australia) for technical guidance of islet isolation; and Dr. Timothy Couttas (University of New South Wales) for technical assistance. This work was supported by grants from the Australian National Health and Medical Research Council (NHMRC; project 349348 and program 571408). P.X. is funded by a Cancer Institute NSW Fellowship and a Fudan University Distinguished Professorship, and Y.Q. by an NHMRC scholarship. The authors report no conflicts of interest.	Allagnat F, 2011, CELL DEATH DIFFER, V18, P328, DOI 10.1038/cdd.2010.105; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Ashcroft FM, 2012, CELL, V148, P1160, DOI 10.1016/j.cell.2012.02.010; Bonner-Weir S, 2010, DIABETES, V59, P2340, DOI 10.2337/db10-0084; BONORA E, 1989, J CLIN ENDOCR METAB, V68, P374, DOI 10.1210/jcem-68-2-374; Boslem E, 2011, BIOCHEM J, V435, P267, DOI 10.1042/BJ20101867; Bruce CR, 2012, DIABETES, V61, P3148, DOI 10.2337/db12-0029; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cerasi E., 2011, MEDICOGRAPHIA, V33, P7; Cunha DA, 2012, DIABETES, V61, P2763, DOI 10.2337/db12-0123; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108; Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009; Ellacott KLJ, 2010, CELL METAB, V12, P10, DOI 10.1016/j.cmet.2010.06.001; Giacca A, 2011, AM J PHYSIOL-ENDOC M, V300, pE255, DOI 10.1152/ajpendo.00416.2010; Gurzov EN, 2011, TRENDS CELL BIOL, V21, P424, DOI 10.1016/j.tcb.2011.03.001; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hasan NM, 2012, ARCH BIOCHEM BIOPHYS, V518, P23, DOI 10.1016/j.abb.2011.11.016; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Laybutt DR, 2007, DIABETOLOGIA, V50, P752, DOI 10.1007/s00125-006-0590-z; Laychock SG, 2006, ENDOCRINOLOGY, V147, P4705, DOI 10.1210/en.2006-0456; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Ma MM, 2007, DIABETOLOGIA, V50, P891, DOI 10.1007/s00125-006-0589-5; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Maedler K, 2003, DIABETES, V52, P726, DOI 10.2337/diabetes.52.3.726; Martinez SC, 2008, DIABETES, V57, P846, DOI 10.2337/db07-0595; Morales A, 2007, APOPTOSIS, V12, P923, DOI 10.1007/s10495-007-0721-0; Newsholme P, 2007, CLIN SCI, V112, P27, DOI 10.1042/CS20060115; Okada T, 2007, P NATL ACAD SCI USA, V104, P8977, DOI 10.1073/pnas.0608703104; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2010, J CLIN INVEST, V120, P1429, DOI 10.1172/JCI40659; Poitout V, 2010, BBA-MOL CELL BIOL L, V1801, P289, DOI 10.1016/j.bbalip.2009.08.006; Qi YF, 2012, J BIOL CHEM, V287, P32236, DOI 10.1074/jbc.M112.362160; Sachdeva MM, 2009, P NATL ACAD SCI USA, V106, P19090, DOI 10.1073/pnas.0904849106; Sarkar S, 2005, FEBS LETT, V579, P5313, DOI 10.1016/j.febslet.2005.08.055; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sone H, 2005, DIABETOLOGIA, V48, P58, DOI 10.1007/s00125-004-1605-2; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Sukocheva O, 2006, J CELL BIOL, V173, P301, DOI 10.1083/jcb.200506033; Sukocheva O, 2009, ENDOCRINOLOGY, V150, P4484, DOI 10.1210/en.2009-0391; Taha TA, 2005, FASEB J, V19, P482, DOI 10.1096/fj.05-4412fje; Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645; Veret J, 2013, BBA-MOL CELL BIOL L, V1831, P251, DOI 10.1016/j.bbalip.2012.10.003; Wong JWH, 2012, ANAL CHEM, V84, P470, DOI 10.1021/ac2026578; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Xia P, 2011, CYTOKINE GROWTH F R, V22, P45, DOI 10.1016/j.cytogfr.2010.09.004	49	64	64	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4294	4304		10.1096/fj.13-230052	http://dx.doi.org/10.1096/fj.13-230052			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23839933				2022-12-28	WOS:000329747100038
J	Stockebrand, M; Sauter, K; Neu, A; Isbrandt, D; Choe, CU				Stockebrand, Malte; Sauter, Kathrin; Neu, Axel; Isbrandt, Dirk; Choe, Chi-un			Differential regulation of AMPK activation in leptin- and creatine-deficient mice	FASEB JOURNAL			English	Article						AGAT; AICAR; ob; ob; skeletal muscle; white adipose tissue	PROTEIN-KINASE; SKELETAL-MUSCLE; GLUCOSE-HOMEOSTASIS; METABOLIC SYNDROME; BODY-WEIGHT; FATTY-ACID; INSULIN; TISSUE; MOUSE; AICAR	AMP-activated protein kinase (AMPK) is a key sensor and regulator of energy homeostasis. Previously, we demonstrated that intracellular energy depletion by l-arginine:glycine amidinotransferase (AGAT) deficiency resulted in AMPK activation and protected from metabolic syndrome. In the present study, we show tissue-specific leptin dependence of AMPK activation by energy depletion. We investigated leptin-dependent AMPK regulation in AGAT- and leptin-deficient (d/d ob/ob) mice. Like ob/ob mice, but unlike d/d mice, d/d ob/ob mice were obese and glucose intolerant. Therefore, leptin is a prerequisite for resistance to metabolic syndrome in AGAT-deficient mice. Quantitative Western blots revealed a 4-fold increase in AMPK activation in skeletal muscle of d/d ob/ob mice (P<0.001). However, AMPK activation was absent in white adipose tissue (WAT) and liver. Compared with blood glucose levels in ob/ob mice, fasting levels were still reduced and therefore did not show leptin dependence (wild-type, 79.4 +/- 3.9 mg/dl; d/d, 68.4 +/- 3.2 mg/dl; P<0.05). In ob/ob mice and wild-type mice, 5-aminoimidazole-4-carboxamide-1--d-ribofuranoside (AICAR), in combination with leptin, augmented glucose tolerance compared with AICAR alone, whereas no improvement was found under conditions of high-fat-diet feeding. These findings reveal a previously unknown synergistic AMPK activation by leptin and intracellular energy depletion, suggesting that AMPK activation can be therapeutically effective in metabolic syndrome only if leptin sensitivity is preserved.Stockebrand, M., Sauter, K., Neu, A., Isbrandt, D., Choe, C. Differential regulation of AMPK activation in leptin- and creatine-deficient mice.	[Stockebrand, Malte; Sauter, Kathrin; Neu, Axel; Isbrandt, Dirk; Choe, Chi-un] Univ Med Ctr Hamburg Eppendorf, D-20251 Hamburg, Germany; [Choe, Chi-un] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, D-20251 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Choe, CU (corresponding author), Univ Med Ctr Hamburg Eppendorf, Ctr Mol Neurobiol, Falkenried 94, D-20251 Hamburg, Germany.	cchoe@uke.de		Neu, Axel/0000-0001-7045-7194; Isbrandt, Dirk/0000-0002-4720-1016	Else Kroner Memorial Stipendium from the Else Kroner-Fresenius-Stiftung; Deutsche Forschungsgemeinschaft (DFG) [CH872/1-1, IS63/3-1, IS63/3-2]	Else Kroner Memorial Stipendium from the Else Kroner-Fresenius-Stiftung; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank H. Voss, I. Heinsohn, and U. Wolters for expert animal care; S. Schillemeit for expert technical assistance; M. Schweizer, C. Raithore, and S. Fehr for help with histology; T. Streichert for blood chemistry (University Medical Center Hamburg-Eppendorf); D. Clausen for help with Fig. 7; and the reviewer, whose valuable comments helped to improve the paper. This work was supported by an Else Kroner Memorial Stipendium from the Else Kroner-Fresenius-Stiftung (C.U.C.) and the Deutsche Forschungsgemeinschaft (DFG; CH872/1-1 to C.U.C., A.N., and D.I., and IS63/3-1 and IS63/3-2 to D.I.).	Berglund ED, 2012, J CLIN INVEST, V122, P1000, DOI 10.1172/JCI59816; BERLET HH, 1976, BIOCHIM BIOPHYS ACTA, V437, P166, DOI 10.1016/0304-4165(76)90358-5; Ceddia RB, 2005, INT J OBESITY, V29, P1175, DOI 10.1038/sj.ijo.0803025; Choe CU, 2013, HUM MOL GENET, V22, P110, DOI 10.1093/hmg/dds407; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; Coppari R, 2005, CELL METAB, V1, P63, DOI 10.1016/j.cmet.2004.12.004; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gaidhu MP, 2011, J LIPID RES, V52, P1702, DOI 10.1194/jlr.M015354; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; Ipsiroglu OS, 2001, LIFE SCI, V69, P1805, DOI 10.1016/S0024-3205(01)01268-1; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Mackintosh JA, 2003, PROTEOMICS, V3, P2273, DOI 10.1002/pmic.200300578; Miller RA, 2010, J CLIN INVEST, V120, P2267, DOI 10.1172/JCI43661; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Miyamoto L., 2012, J BIOL CHEM; Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707; Nabuurs CI, 2013, J PHYSIOL-LONDON, V591, P571, DOI 10.1113/jphysiol.2012.241760; Nakken GN, 2010, J APPL PHYSIOL, V108, P298, DOI 10.1152/japplphysiol.00906.2009; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Rasband W., 2006, IMAGEJ; Schmidt A, 2004, HUM MOL GENET, V13, P905, DOI 10.1093/hmg/ddh112; Smith AC, 2005, J PHYSIOL-LONDON, V565, P537, DOI 10.1113/jphysiol.2004.081679; Song XM, 2002, DIABETOLOGIA, V45, P56, DOI 10.1007/s125-002-8245-8; Tanaka T, 2005, DIABETES, V54, P2365, DOI 10.2337/diabetes.54.8.2365; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Viollet B, 2010, CRIT REV BIOCHEM MOL, V45, P276, DOI 10.3109/10409238.2010.488215; Wang MY, 2005, P NATL ACAD SCI USA, V102, P18011, DOI 10.1073/pnas.0509001102; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Yu X, 2004, DIABETOLOGIA, V47, P2012, DOI 10.1007/s00125-004-1570-9; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	16	18	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4147	4156		10.1096/fj.12-225136	http://dx.doi.org/10.1096/fj.12-225136			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825223				2022-12-28	WOS:000329747100026
J	Tanaka, T; Yamaguchi, J; Higashijima, Y; Nangaku, M				Tanaka, Tetsuhiro; Yamaguchi, Junna; Higashijima, Yoshiki; Nangaku, Masaomi			Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia	FASEB JOURNAL			English	Article						HIF; cardiorenal anemia syndrome	PROXIMAL TUBULAR CELLS; CHRONIC KIDNEY-DISEASE; TUBULOINTERSTITIAL INJURY; TRANSCRIPTION FACTORS; BINDING-PROTEIN; FUNCTIONAL-ROLE; ERYTHROPOIETIN; IDENTIFICATION; FACTOR-1-ALPHA; DYSFUNCTION	Chronic hypoxia in the tubulointerstitium serves as a final common pathway in progressive renal disease. Circumstantial evidence suggests that hypoxia-inducible factor (HIF)-1 in the ischemic tubules may be functionally inhibited in a chronic kidney disease (CKD) milieu. In this study, we hypothesized that indoxyl sulfate (IS), a uremic toxin, impairs the cellular hypoxic response. In human kidney (HK-2) proximal tubular cells, IS reduced the hypoxic induction of HIF-1 target genes. This effect was not associated with quantitative changes in the HIF-1 protein, but with functional impairment of the HIF-1 C-terminal transactivation domain (CTAD). Among factors that impeded the recruitment of transcriptional coactivators to the HIF-1CTAD, IS markedly up-regulated Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) through a mechanism of post-transcriptional mRNA stabilization involving the extracellular signal-regulated kinase (ERK) 1/2 pathway. In vivo, disproportionate expression of HIF target genes was demonstrated in several CKD models, which was offset by an oral adsorbent, AST-120. Furthermore, administration of indole reduced the induction of angiogenic, hypoxia-inducible genes in rats with experimental heart failure. Results of these studies reveal a novel role of IS in modulating the transcriptional response of HIF-1 and provide insight into molecular mechanisms underlying progressive nephropathies as well as cardiovascular complications.Tanaka, T., Yamaguchi, J., Higashijima, Y., Nangaku, M. Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia.	[Tanaka, Tetsuhiro; Yamaguchi, Junna; Higashijima, Yoshiki; Nangaku, Masaomi] Univ Tokyo, Sch Med, Div Nephrol & Endocrinol, Tokyo 1138655, Japan	University of Tokyo	Tanaka, T (corresponding author), Univ Tokyo, Sch Med, Div Nephrol & Endocrinol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	tetsu-tky@umin.ac.jp; mnangaku-tky@umin.ac.jp		Higashijima, Yoshiki/0000-0002-4489-606X	Japan Society for the Promotion of Science [24390213, 22790781]; Takeda Science Foundation	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported by grants-in-aid for scientific research from the Japan Society for the Promotion of Science (24390213 to M.N. and 22790781 to T.T.), and a research grant from the Takeda Science Foundation (to T.T.).	Bernhardt WM, 2009, P NATL ACAD SCI USA, V106, P21276, DOI 10.1073/pnas.0903978106; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Ceradini DJ, 2008, J BIOL CHEM, V283, P10930, DOI 10.1074/jbc.M707451200; Chade AR, 2009, CIRCULATION, V119, P547, DOI 10.1161/CIRCULATIONAHA.108.788653; Chen Y, 2008, DEVELOPMENT, V135, P2939, DOI 10.1242/dev.021097; Chiang CK, 2011, LAB INVEST, V91, P1564, DOI 10.1038/labinvest.2011.114; Chou YT, 2006, ONCOGENE, V25, P5547, DOI 10.1038/sj.onc.1209552; Chou YT, 2006, J BIOL CHEM, V281, P18451, DOI 10.1074/jbc.M601720200; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Du JW, 2012, BLOOD, V119, P2789, DOI 10.1182/blood-2011-10-387902; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Huang Y, 2004, FASEB J, V18, P1138, DOI 10.1096/fj.04-1510fje; Ito S, 2010, J BIOL CHEM, V285, P38869, DOI 10.1074/jbc.M110.166686; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Katavetin P, 2006, J AM SOC NEPHROL, V17, P1405, DOI 10.1681/ASN.2005090918; Kawakami T, 2010, AM J PHYSIOL-RENAL, V299, pF568, DOI 10.1152/ajprenal.00659.2009; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104; Manotham K, 2004, J AM SOC NEPHROL, V15, P1277, DOI 10.1097/01.ASN.0000125614.35046.10; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Matsumoto M, 2004, J AM SOC NEPHROL, V15, P1574, DOI 10.1097/01.ASN.0000128047.13396.48; Nangaku M, 2006, J AM SOC NEPHROL, V17, P17, DOI 10.1681/ASN.2005070757; Nangaku M, 2013, CLIN EXP PHARMACOL P, V40, P148, DOI 10.1111/1440-1681.12005; Niwa T, 2011, THER APHER DIAL, V15, P120, DOI 10.1111/j.1744-9987.2010.00882.x; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Palm F, 2010, AM J PHYSIOL-RENAL, V299, pF380, DOI 10.1152/ajprenal.00175.2010; Persson H, 2011, CANCER RES, V71, P78, DOI 10.1158/0008-5472.CAN-10-1869; Qu X, 2007, EMBO J, V26, P4445, DOI 10.1038/sj.emboj.7601883; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Rosenberger C, 2008, KIDNEY INT, V73, P34, DOI 10.1038/sj.ki.5002567; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; Sakai M, 2012, NAT MED, V18, P612, DOI 10.1038/nm.2691; Sano M, 2007, NATURE, V446, P444, DOI 10.1038/nature05602; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; SHERIDAN AM, 1993, AM J PHYSIOL, V265, pF342, DOI 10.1152/ajprenal.1993.265.3.F342; Silter M, 2010, PFLUG ARCH EUR J PHY, V459, P569, DOI 10.1007/s00424-009-0748-x; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Tanaka S, 2003, PHYSIOL ENTOMOL, V28, P290, DOI 10.1111/j.1365-3032.2003.00346.x; Tanaka T, 2004, AM J PATHOL, V165, P1979, DOI 10.1016/S0002-9440(10)63249-X; Tanaka T, 2012, J BIOL CHEM, V287, P34866, DOI 10.1074/jbc.M112.374587; Tien ES, 2004, J BIOL CHEM, V279, P24053, DOI 10.1074/jbc.M401489200; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu B, 2007, DEV BIOL, V301, P130, DOI 10.1016/j.ydbio.2006.08.072; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06	52	34	35	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4059	4075		10.1096/fj.13-231837	http://dx.doi.org/10.1096/fj.13-231837			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23792300				2022-12-28	WOS:000329747100019
J	He, WJ; Mazumder, A; Wilder, T; Cronstein, BN				He, Wenjie; Mazumder, Amitabha; Wilder, Tuere; Cronstein, Bruce N.			Adenosine regulates bone metabolism via A(1), A(2A), and A(2B) receptors in bone marrow cells from normal humans and patients with multiple myeloma	FASEB JOURNAL			English	Article						osteoclast differentiation; osteoblast differentiation; osteolytic bone disease	INFLAMMATORY PROTEIN (MIP)-1-ALPHA; NUCLEOSIDE TRANSPORTER 1; PATHOLOGICAL FRACTURES; MACROPHAGE; EXPRESSION; LESIONS; ALPHA; DIFFERENTIATION; OSTEOBLASTS; MECHANISMS	Multiple myeloma (MM) is characterized by osteolytic bone lesions with uncoupled bone remodeling. In this study, we examined the effects of adenosine and its receptors (A(1)R, A(2A)R, A(2B)R, and A(3)R) on osteoblast and osteoclast differentiation of cells derived from patients with MM and healthy control subjects. Mesenchymal stem cells and bone marrow-derived mononuclear cells were isolated from bone marrow and differentiated into osteoblasts and osteoclasts, respectively. A(1)R antagonist rolofylline and A(2B)R agonist BAY60-6583 inhibit osteoclast differentiation of cells from patients with MM in a dose-dependent manner, as shown by TRAP staining (IC50: 10 and approximate to 10 nM, respectively). BAY60-6583 and dipyridamole, a nucleoside transport inhibitor, stimulate osteoblast differentiation of cells from patients with MM, as measured by ALP activity at d 14 and Alizarin Red staining at d 21 (by 1.57 +/- 0.03- and 1.71 +/- 0.45-fold, respectively), which can be blocked by A(2B)R antagonist MRS1754. Consistently, real-time PCR showed a significant increase of mRNA of osteocalcin and osterix at d 14. The effect of adenosine and its receptors is consistent in patients with MM and healthy subjects, suggesting an intrinsic mechanism that is important in both MM bone metabolism and normal physiology. Furthermore, the effect of dipyridamole on osteoblast differentiation is diminished in both A(2B)R- and CD39-knockout mice. These results indicate that adenosine receptors may be useful targets for the treatment of MM-induced bone disease.He, W., Mazumder, A., Wilder, T., Cronstein. B. N. Adenosine regulates bone metabolism via A(1), A(2A), and A(2B) receptors in bone marrow cells from normal humans and patients with multiple myeloma.	[He, Wenjie; Wilder, Tuere; Cronstein, Bruce N.] NYU, Sch Med, New York, NY 10016 USA; [Mazumder, Amitabha] NYU, Ctr Canc, New York, NY 10016 USA	New York University; New York University	Cronstein, BN (corresponding author), NYU, Sch Med, 550 1st Ave, New York, NY 10016 USA.	bruce.cronstein@nyumc.org	Cronstein, Bruce N/D-4678-2011	Cronstein, Bruce N/0000-0002-4295-7383	U.S. National Institutes of Health [AR56672, AR56672S1, AR54897]; New York University-Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute [UL1RR029893]; Vilcek Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056672, R01AR054897, R56AR056672] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New York University-Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute; Vilcek Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by grants from the U.S. National Institutes of Health (AR56672, AR56672S1 and AR54897), the New York University-Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute (UL1RR029893), and the Vilcek Foundation.	Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458; BARILLE S, 1995, BLOOD, V86, P3151; BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909; Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994; Eckle T, 2013, FASEB J; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750; Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021; Filella X, 1996, CANCER DETECT PREV, V20, P52; Gharibi B, 2012, INT J OBESITY, V36, P397, DOI 10.1038/ijo.2011.129; Gharibi B, 2011, J BONE MINER RES, V26, P2112, DOI 10.1002/jbmr.424; Goranova-Marinova V, 2007, HAEMATOLOGICA, V92, P1000, DOI 10.3324/haematol.10943; Grenz A, 2012, J CLIN INVEST, V122, P693, DOI 10.1172/JCI60214; Hashimoto T, 2004, BRIT J HAEMATOL, V125, P38, DOI 10.1111/j.1365-2141.2004.04864.x; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; He W, 2012, PURINERG SIGNAL, V8, P327, DOI 10.1007/s11302-012-9292-9; Hideshima T, 2001, SEMIN ONCOL, V28, P607, DOI 10.1053/sonc.2001.28608; Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09-147447; Kara FM, 2010, ARTHRITIS RHEUM-US, V62, P534, DOI 10.1002/art.27219; Khoa ND, 2003, J IMMUNOL, V171, P3991, DOI 10.4049/jimmunol.171.8.3991; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; King AE, 2006, TRENDS PHARMACOL SCI, V27, P416, DOI 10.1016/j.tips.2006.06.004; Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365-2141.2004.05018.x; Lust JA, 1999, HEMATOL ONCOL CLIN N, V13, P1117, DOI 10.1016/S0889-8588(05)70115-5; Mediero A., 2012, SCI TRANSL MED, V4; Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017; Melton LJ, 2005, J BONE MINER RES, V20, P487, DOI 10.1359/JBMR.041131; Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025; Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037; Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood-2002-12-3905; Pellegatti P, 2011, FASEB J, V25, P1264, DOI 10.1096/fj.10-169854; Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood-2008-01-132134; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Saad F, 2007, CANCER-AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991; Sati HIA, 1999, BRIT J HAEMATOL, V104, P350, DOI 10.1046/j.1365-2141.1999.01193.x; Sonmez M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-11; SUBBARAO K, 1977, J CLIN INVEST, V60, P936, DOI 10.1172/JCI108848; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; Takedachi M, 2012, J CELL PHYSIOL, V227, P2622, DOI 10.1002/jcp.23001; TAUBE T, 1992, EUR J HAEMATOL, V49, P192; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Uneda S, 2003, BRIT J HAEMATOL, V120, P53, DOI 10.1046/j.1365-2141.2003.04040.x; VALENTINOPRAN A, 1982, BRIT J HAEMATOL, V52, P601, DOI 10.1111/j.1365-2141.1982.tb03936.x; Warraich S, 2013, J BONE MINER RES, V28, P1135, DOI 10.1002/jbmr.1826; Young JD, 2008, XENOBIOTICA, V38, P995, DOI [10.1080/00498250801927427, 10.1080/00498250801927427 ]	45	60	61	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3446	3454		10.1096/fj.13-231233	http://dx.doi.org/10.1096/fj.13-231233			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23682121	Green Published			2022-12-28	WOS:000328840500005
J	LeMaoult, J; Daouya, M; Wu, J; Loustau, M; Horuzsko, A; Carosella, ED				LeMaoult, Joel; Daouya, Marina; Wu, Juan; Loustau, Maria; Horuzsko, Anatolij; Carosella, Edgardo D.			Synthetic HLA-G proteins for therapeutic use in transplantation	FASEB JOURNAL			English	Article						engineered molecules; immune regulation; therapy; tolerance	NATURAL-KILLER-CELLS; G EXPRESSION; INHIBITORY RECEPTOR; DENDRITIC CELLS; UP-REGULATION; G MOLECULE; G ANTIGEN; T-CELLS; CRYSTAL-STRUCTURE; PATHWAY	The human leukocyte antigen (HLA)-G is a tolerogenic molecule, whose expression by allografts is associated with better acceptance. An increasing interest in producing HLA-G as a clinical-grade molecule for therapy use is impaired by its complexity and limited stability. Our purpose was to engineer simpler and more stable HLA-G-derived molecules than the full-length HLA-G trimolecular complex that are also tolerogenic, functional as soluble molecules, and compatible with good manufacturing practice (GMP) production conditions. We present two synthetic molecules: ((3)-L)(x2) and ((1)-(3))(x2) polypeptides. We show their capability to bind the HLA-G receptor LILRB2 and their functions in vitro and in vivo. The ((1)-(3))(x2) polypeptide proved to be a potent tolerogenic molecule in vivo: One treatment of skin allograft recipient mice with ((1)-(3))(x2) was sufficient to significantly prolong graft survival, and four weekly treatments induced complete tolerance. Furthermore, ((1)-(3))(x2) was active as a soluble molecule and capable of inhibiting the proliferation of tumor cell lines, as does the full length HLA-G trimolecular complex. Thus, the synthetic ((1)-(3))(x2) polypeptide is a stable and simpler alternative to the full-length HLA-G molecule. It can be produced under GMP conditions, it functions as a soluble molecule, and it is at least as tolerogenic as HLA-G in vivo.LeMaoult, J., Daouya, M., Wu, J., Loustau, M., Horuzsko, A., Carosella, E. D. Synthetic HLA-G proteins for therapeutic use in transplantation.	[LeMaoult, Joel; Daouya, Marina; Loustau, Maria; Carosella, Edgardo D.] Commissariat Energie Atom & Energies Alternat CEA, Inst Emerging Dis & Innovat Therapies iMETI, Res Div Hematol & Immunol SRHI, Paris, France; [LeMaoult, Joel; Daouya, Marina; Loustau, Maria; Carosella, Edgardo D.] Univ Paris Diderot, Sorbonne Paris Cite, Unite Mixte Rech UMR E 5, Inst Univ Hematol,St Louis Hosp, Paris, France; [Wu, Juan; Horuzsko, Anatolij] Georgia Hlth Sci Univ, Ctr Mol Chaperone Radiobiol & Canc Virol, Augusta, GA USA	CEA; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University System of Georgia; Augusta University	LeMaoult, J (corresponding author), Hop St Louis, CEA IMETI SRHI, 1 Ave Claude Vellefaux, F-75475 Paris, France.	joel.lemaoult@cea.fr	LeMaoult, Joel/E-9583-2011	LeMaoult, Joel/0000-0002-4513-9482	Commissariat a l'Energie Atomique et aux Energies Alternatives; U.S. National Institutes of Health [R56 AI055923]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI055923] Funding Source: NIH RePORTER	Commissariat a l'Energie Atomique et aux Energies Alternatives; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by Commissariat a l'Energie Atomique et aux Energies Alternatives, and by U.S. National Institutes of Health grant R56 AI055923 (to A.H.). The authors declare no conflicts of interest.	Agaugue S, 2011, BLOOD, V117, P7021, DOI 10.1182/blood-2010-07-294389; Aractingi S, 2001, AM J PATHOL, V159, P71, DOI 10.1016/S0002-9440(10)61675-6; Bahri R, 2006, J IMMUNOL, V176, P1331, DOI 10.4049/jimmunol.176.3.1331; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P16180, DOI 10.1073/pnas.212643199; Carosella ED, 2008, BLOOD, V111, P4862, DOI 10.1182/blood-2007-12-127662; Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005; Caumartin J, 2007, EMBO J, V26, P1423, DOI 10.1038/sj.emboj.7601570; Cirulli V, 2006, DIABETES, V55, P1214, DOI 10.2337/db05-0731; Clements CS, 2005, P NATL ACAD SCI USA, V102, P3360, DOI 10.1073/pnas.0409676102; Colonna M, 1998, J IMMUNOL, V160, P3096; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Davies B, 2001, AM J REPROD IMMUNOL, V45, P103, DOI 10.1111/j.8755-8920.2001.450207.x; El Ibrahim E, 2004, INT J CANCER, V108, P243, DOI 10.1002/ijc.11456; Favier B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021011; Gonen-Gross T, 2005, J IMMUNOL, V175, P4866, DOI 10.4049/jimmunol.175.8.4866; Gonen-Gross T, 2003, J IMMUNOL, V171, P1343, DOI 10.4049/jimmunol.171.3.1343; Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872; HoWangYin KY, 2012, CELL MOL LIFE SCI, V69, P4041, DOI 10.1007/s00018-012-1069-3; Ibrahim EC, 2001, CANCER RES, V61, P6838; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Lefebvre S, 2002, J PATHOL, V196, P266, DOI 10.1002/path.1039; LeMaoult J, 2004, P NATL ACAD SCI USA, V101, P7064, DOI 10.1073/pnas.0401922101; Liang S, 2008, P NATL ACAD SCI USA, V105, P8357, DOI 10.1073/pnas.0803341105; Liang SY, 2002, EUR J IMMUNOL, V32, P2418, DOI 10.1002/1521-4141(200209)32:9<2418::AID-IMMU2418>3.0.CO;2-L; Lila N, 2000, LANCET, V355, P2138, DOI 10.1016/S0140-6736(00)02386-2; Lopes CT, 2008, TRANSPL P, V40, P856, DOI 10.1016/j.transproceed.2008.02.051; Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005; Mallet V, 1999, INT IMMUNOL, V11, P889, DOI 10.1093/intimm/11.6.889; McMaster M, 1998, J IMMUNOL, V160, P5922; Naji A, 2007, BLOOD, V110, P3936, DOI 10.1182/blood-2007-04-083139; Nuckel H, 2005, BLOOD, V105, P1694, DOI 10.1182/blood-2004-08-3335; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Polakova K, 2000, NEOPLASMA, V47, P342; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; Real LM, 1999, INT J CANCER, V81, P512; Rebmann V, 2007, SEMIN CANCER BIOL, V17, P422, DOI 10.1016/j.semcancer.2007.06.010; Ristich V, 2005, EUR J IMMUNOL, V35, P1133, DOI 10.1002/eji.200425741; Riteau B, 2001, J IMMUNOL, V166, P5018, DOI 10.4049/jimmunol.166.8.5018; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Rouas-Freiss N, 1999, SEMIN CANCER BIOL, V9, P3, DOI 10.1006/scbi.1998.0103; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P5249, DOI 10.1073/pnas.94.10.5249; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554; Shiroishi M, 2006, J BIOL CHEM, V281, P10439, DOI 10.1074/jbc.M512305200; Shiroishi M, 2006, P NATL ACAD SCI USA, V103, P16412, DOI 10.1073/pnas.0605228103; Shiroishi M, 2009, PROTEIN PEPTIDE LETT, V16, P447, DOI 10.2174/092986609787848108; Urosevic M, 2002, BLOOD, V99, P609, DOI 10.1182/blood.V99.2.609; Urosevic M, 2001, AM J PATHOL, V159, P817, DOI 10.1016/S0002-9440(10)61756-7; Verloes A, 2011, J IMMUNOL, V186, P2663, DOI 10.4049/jimmunol.1001081	49	29	36	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3643	3651		10.1096/fj.13-228247	http://dx.doi.org/10.1096/fj.13-228247			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23752205	Green Published			2022-12-28	WOS:000328840500023
J	Chaganti, LK; Kuppili, RR; Bose, K				Chaganti, Lalith K.; Kuppili, Raja Reddy; Bose, Kakoli			Intricate structural coordination and domain plasticity regulate activity of serine protease HtrA2	FASEB JOURNAL			English	Article						PDZ; serine protease domain; dynamics	DEGS PROTEASE; ACTIVATION; BINDING; PROTEINS; PDZ; IDENTIFICATION; RECOGNITION; TEMPERATURE; INHIBITOR; EFFICIENT	HtrA2, a complex trimeric pyramidal mitochondrial serine protease that regulates critical biological functions and diseases, including apoptosis and cancer, is a promising therapeutic target. It promotes apoptosis through multiple pathways, complex mechanisms of which are still elusive. The existing model of activation that emphasizes relative intramolecular movements between C-terminal PDZ and protease domains (PDZ-protease collapse in inactive and resting states) has not been able to unambiguously demonstrate dynamics of its actions. Using structure-guided design, molecular biology and protein biochemistry, we obtained various combinations of HtrA2 domains and mutants. Conformational changes and stability were characterized using molecular dynamics simulation and spectroscopic tools while functional enzymology delineated their roles in regulating enzyme catalysis. Quantitative Forster resonance energy transfer showed lesser intramolecular PDZ-protease distance in trimeric HtrA2 compared to its inactive monomeric counterpart (approximate to 21 and approximate to 22.3 angstrom, respectively, at 37 degrees C). Our findings highlight importance of N-terminal region, oligomerization, and intricate intermolecular PDZ-protease interaction in proper active-site formation, enzyme-substrate complex stabilization, and hence HtrA2 functions. These observations redefine the existing activation model and showcase a unique example of how precise interdomain coordination, plasticity, and intermolecular contacts lead to distinct functional properties and hence provide new insights into HtrA2 structure, function, and dynamics.	[Chaganti, Lalith K.; Kuppili, Raja Reddy; Bose, Kakoli] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc ACTREC, Kharghar 410210, Navi Mumbai, India	Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital	Bose, K (corresponding author), Tata Mem Hosp, ACTREC, Sect 22, Integrated Biophys & Struct Biol Lab, Kharghar 410210, Navi Mumbai, India.	kbose@actrec.gov.in			DBT; Department of Biotechnology (DBT), Government of India	DBT(Department of Biotechnology (DBT) India); Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India)	The authors thank Avani Solanki for help with protein purification and Pruthvi Raj Bejugam, Siddharth Gurdasani, and Nitu Singh for their intellectual inputs and critical feedback on the manuscript. The authors are grateful to Dr. Manoj K. Bhat (National Centre for Cell Science, Pune, India) for providing reagents and Dr. Sanjib Senapati, (Indian Institute of Technology, Madras, India) for help with MD simulations. The authors also acknowledge the facility provided by DBT-sponsored Distributed Information Sub Centre (DISC) of the Biotechnology Information System Network (BTISnet) at the Advanced Centre for Treatment, Research, and Education in Cancer, where in silico studies have been carried out. The project is funded by a grant from the Department of Biotechnology (DBT), Government of India.	Baldi A, 2008, PHARMACOGENOMICS, V9, P1069, DOI 10.2217/14622416.9.8.1069; Bejugam PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055416; Bhuiyan MS, 2009, CURR DRUG TARGETS, V10, P372, DOI 10.2174/138945009787846399; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; CALHOUN DB, 1983, BIOCHEMISTRY-US, V22, P1526, DOI 10.1021/bi00276a002; Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065; de Castro IP, 2011, MOL NEUROBIOL, V43, P80, DOI 10.1007/s12035-010-8150-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; EFTINK MR, 1981, ARCH BIOCHEM BIOPHYS, V209, P706, DOI 10.1016/0003-9861(81)90332-5; Gavathiotis E, 2012, NAT CHEM BIOL, V8, P639, DOI [10.1038/NCHEMBIO.995, 10.1038/nchembio.995]; Hasenbein S, 2010, J MOL BIOL, V397, P957, DOI 10.1016/j.jmb.2010.02.027; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Jiang JS, 2008, P NATL ACAD SCI USA, V105, P11939, DOI 10.1073/pnas.0805464105; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Krojer T, 2008, P NATL ACAD SCI USA, V105, P7702, DOI 10.1073/pnas.0803392105; Krojer T, 2010, NAT STRUCT MOL BIOL, V17, P844, DOI 10.1038/nsmb.1840; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, P443; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Liang JJ, 2006, PROTEIN SCI, V15, P1619, DOI 10.1110/ps.062216006; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Mauldin RV, 2013, NAT CHEM BIOL, V9, P90, DOI [10.1038/nchembio.1135, 10.1038/NCHEMBIO.1135]; Meltzer M, 2009, RES MICROBIOL, V160, P660, DOI 10.1016/j.resmic.2009.07.012; Merdanovic M, 2010, NAT STRUCT MOL BIOL, V17, P837, DOI 10.1038/nsmb.1839; Nam MK, 2006, EXP MOL MED, V38, P36, DOI 10.1038/emm.2006.5; Polur I, 2010, HISTOL HISTOPATHOL, V25, P599, DOI 10.14670/HH-25.599; Roy S, 2000, BIOCHEMISTRY-US, V39, P4603, DOI 10.1021/bi992328e; Singh N, 2011, ARCH BIOCHEM BIOPHYS, V516, P85, DOI 10.1016/j.abb.2011.10.007; Sohn J, 2007, CELL, V131, P572, DOI 10.1016/j.cell.2007.08.044; Sohn J, 2009, STRUCTURE, V17, P1411, DOI 10.1016/j.str.2009.07.017; Sohn J, 2009, MOL CELL, V33, P64, DOI 10.1016/j.molcel.2008.12.017; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; WANG CK, 1986, J MOL BIOL, V191, P509, DOI 10.1016/0022-2836(86)90145-2; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wrase R, 2011, P NATL ACAD SCI USA, V108, P10490, DOI 10.1073/pnas.1101084108; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhang XF, 2004, BIOCHEMISTRY-MOSCOW+, V69, P687, DOI 10.1023/B:BIRY.0000033743.09806.1a; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X; Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867	44	23	23	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3054	3066		10.1096/fj.13-227256	http://dx.doi.org/10.1096/fj.13-227256			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23608143				2022-12-28	WOS:000329877600013
J	Deschaseaux, F; Gaillard, J; Langonne, A; Chauveau, C; Naji, A; Bouacida, A; Rosset, P; Heymann, D; De Pinieux, G; Rouas-Freiss, N; Sensebe, L				Deschaseaux, Frederic; Gaillard, Julien; Langonne, Alain; Chauveau, Christophe; Naji, Abderrahim; Bouacida, Amina; Rosset, Philippe; Heymann, Dominique; De Pinieux, Gonzague; Rouas-Freiss, Nathalie; Sensebe, Luc			Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue	FASEB JOURNAL			English	Article						mesenchymal stem cells; osteoblasts; osteoclasts; osteogenesis; Indian Hedgehog	MESENCHYMAL STEM-CELLS; HLA-G; SKELETAL DEVELOPMENT; OSTEOBLASTIC DIFFERENTIATION; RANKL EXPRESSION; HEDGEHOG; PTHRP; IDENTIFICATION; INHIBITION; SECRETION	Bone-marrow mesenchymal stem cells (MSCs) are the origin of bone-forming cells with immunomodulation potential. HLA-G5 is among the generated immunosuppressive molecules. HLA-G proteins play a crucial role in promoting the acceptance of allografts. However, the mechanisms regulating the expression of HLA-G5 in human MSCs are unknown. We induced differentiation of MSCs and found that HLA-G5 was greatly up-regulated only in osteoblastic cells (+63% for mRNA). Growth plates and bone callus postfracture in adults showed that only bone-lining cells and mesenchymal progenitors were positive for HLA-G5. Use of gene silencing and dominant-negative factors revealed that HLA-G5 depends on the expression and function of the skeletogenesis master genes RUNX2 and DLX5. In addition, HLA-G5 could directly inhibit osteoclastogenesis by acting on monocytes through SHP1. However, in mature osteoblasts, the expression of HLA-G5 protein was greatly suppressed whereas the proosteoclastogenic factor, RANKL, was concomitantly increased. Down-regulation of HLA-G5 expression during the maturation of osteoblasts was due to binding of the repressor GLI3, a signal transducer of the Hedgehog pathway, to the GLI binding element within the HLA-G promoter. Our findings show that mesenchymal progenitors and osteoblastic cells specifically express HLA-G5 during osteogenesis, with a key role in bone homeostasis.	[Deschaseaux, Frederic; Bouacida, Amina; Sensebe, Luc] Univ Toulouse 3, CNRS, Stromalab Unite Mixte Rech UMR, Etab Francais Sang EFS Pyrenees Mediterranee, F-31062 Toulouse, France; [Deschaseaux, Frederic; Gaillard, Julien; Langonne, Alain; Sensebe, Luc] EFS Ctr Atlantique, Tours, France; [Gaillard, Julien; Bouacida, Amina] Univ Tours, Tours, France; [Chauveau, Christophe] Univ Lille Nord France, Boulogne Sur Mer, France; [Naji, Abderrahim; Rouas-Freiss, Nathalie] Inst Emerging Dis & Innovat Therapies IMETI, Serv Rech Hematoimmunol, Direct Sci Vivant DSV, Commissariat Energie Atom & Energies Alternat CEA, Paris, France; [Rosset, Philippe; De Pinieux, Gonzague] Ctr Hosp Univ CHU Trousseau, Tours, France; [Rosset, Philippe; Heymann, Dominique; De Pinieux, Gonzague] Univ Nantes, INSERM, Nantes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Tours; Universite de Lille - ISITE; Universite de Lille; CEA; UDICE-French Research Universities; Universite Paris Cite; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Deschaseaux, F (corresponding author), INSERM, U1031, STROMAlab, EFS PM,UMR UPS CNRS 5273, BP 84 225, F-31432 Toulouse 4, France.		Heymann, Dominique/AAC-6014-2019	Heymann, Dominique/0000-0001-7777-0669; Naji, Abderrahim/0000-0003-1168-974X	Agence Nationale de la Recherche Technologies pour la Sante et l'Autonomie, ATOS project [024-03]; European Commission [241879]	Agence Nationale de la Recherche Technologies pour la Sante et l'Autonomie, ATOS project(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre)	The research leading to these results received funding from the Agence Nationale de la Recherche Technologies pour la Sante et l'Autonomie, ATOS project (024-03; 2007-2010) and from the European Commission Seventh Framework Programme (241879; FP7/2007-2013), through the REBORNE project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai F, 2002, J EXP MED, V195, P1549, DOI 10.1084/jem.20011700; Bertaux K, 2005, J BONE MINER METAB, V23, P114, DOI 10.1007/s00774-004-0549-4; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cordonnier T, 2011, TISSUE ENG PART C-ME, V17, P249, DOI [10.1089/ten.tec.2010.0387, 10.1089/ten.TEC.2010.0387]; Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002; Dresner-Pollak R, 2004, GASTROENTEROLOGY, V127, P792, DOI 10.1053/j.gastro.2004.06.013; Ehlen Harald W. A., 2006, Birth Defects Research, V78, P267, DOI 10.1002/bdrc.20076; Jemtland R, 2003, BONE, V32, P611, DOI 10.1016/S8756-3282(03)00092-9; Johnston JJ, 2005, AM J HUM GENET, V76, P609, DOI 10.1086/429346; Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441-009-0832-8; Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LeMaoult J, 2003, TISSUE ANTIGENS, V62, P273, DOI 10.1034/j.1399-0039.2003.00143.x; Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006; Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003; Menier C, 2004, BLOOD, V104, P3153, DOI 10.1182/blood-2004-03-0809; Mercier FE, 2012, NAT REV IMMUNOL, V12, P49, DOI 10.1038/nri3132; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Morandi F, 2008, STEM CELLS, V26, P1275, DOI 10.1634/stemcells.2007-0878; Moreau P, 2009, J CELL MOL MED, V13, P2973, DOI 10.1111/j.1582-4934.2009.00800.x; Mori Y, 2008, J IMMUNOL, V181, P4742, DOI 10.4049/jimmunol.181.7.4742; Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452; Nasef A, 2007, TRANSPLANTATION, V84, P231, DOI 10.1097/01.tp.0000267918.07906.08; Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007; Olfa G, 2010, BONE, V46, P901, DOI 10.1016/j.bone.2009.12.027; Plaisant M, 2009, STEM CELLS, V27, P703, DOI 10.1634/stemcells.2008-0888; Rizzo R, 2008, CYTOTHERAPY, V10, P364, DOI 10.1080/14653240802105299; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Ruiz i Altaba A., 2007, CELL BIOL, V17, P438; Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002-9440(10)65116-4; van der Horst G, 2003, BONE, V33, P899, DOI 10.1016/j.bone.2003.07.004; Wu YL, 2008, AUTOIMMUNITY, V41, P183, DOI 10.1080/08916930701693180; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704	38	20	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2977	2987		10.1096/fj.13-227264	http://dx.doi.org/10.1096/fj.13-227264			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23592762				2022-12-28	WOS:000329877600006
J	Alt, J; Stathis, M; Rojas, C; Slusher, B				Alt, Jesse; Stathis, Marigo; Rojas, Camilo; Slusher, Barbara			Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme	FASEB JOURNAL			English	Article						Alzheimer's disease; prostate-specific membrane antigen	ACIDIC DIPEPTIDASE ACTIVITY; N-ACETYLASPARTYLGLUTAMATE; REACTION-MECHANISM; MEMBRANE ANTIGEN; INHIBITION; NAALADASE; NAAG; NEUROTRANSMITTER; NEUROPATHY; SUBSTRATE	Glutamate carboxypeptidase II (GCPII) is an exopeptidase that catalyzes the hydrolysis of N-acetylated aspartate-glutamate (NAAG) to N-acetyl aspartate (NAA) and glutamate. Consequently, GCPII inhibition has been of interest for the treatment of central and peripheral nervous system diseases associated with excess glutamate. Recently, it was reported that GCPII can also serve as an endopeptidase cleaving amyloid (A) peptides and that its inhibition could increase the risk of Alzheimer's disease by increasing brain A levels. This study aimed to corroborate and extend these new findings. We incubated A peptides (20 M) with human recombinant GCPII (300 ng/ml) and monitored the appearance of degradation products by mass spectrometry. A peptides remained intact after 18 h incubation with GCPII. Under the same experimental conditions, A(1-40) (20 M) was incubated with neprilysin (300 ng/ml), an endopeptidase known to hydrolyze A(1-40) and the expected cleavage products were observed. GCPII was confirmed active by catalyzing the complete hydrolysis of NAAG (100 M). We also studied the hydrolysis of [H-3]-NAAG (30 nM) catalyzed by GCPII (40 pM) in the presence of A peptides (picomolar to micromolar range). The addition of A peptides did not alter [H-3]-NAAG hydrolysis. We conclude that GCPII is not an amyloid peptide-degrading enzyme.Alt, J., Stathis, M., Rojas, C., Slusher. Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.	[Alt, Jesse; Stathis, Marigo; Rojas, Camilo; Slusher, Barbara] Johns Hopkins Univ, Sch Med, Brain Sci Inst, Neurotranslat Drug Discovery Program, Baltimore, MD 21205 USA; [Slusher, Barbara] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Slusher, Barbara] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Slusher, B (corresponding author), Johns Hopkins Univ, Sch Med, Brain Sci Inst, 855 North Wolfe St, Baltimore, MD 21205 USA.	bslusher@jhmi.edu			NCI NIH HHS [R01 CA161056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA161056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barinka C, 2012, CURR MED CHEM, V19, P856, DOI 10.2174/092986712799034888; Barinka C, 2002, J NEUROCHEM, V80, P477, DOI 10.1046/j.0022-3042.2001.00715.x; Berger UV, 1999, J COMP NEUROL, V415, P52, DOI 10.1002/(SICI)1096-9861(19991206)415:1<52::AID-CNE4>3.0.CO;2-K; Carozzi VA, 2010, NEUROTOX RES, V17, P380, DOI 10.1007/s12640-009-9114-1; Carpenter KJ, 2003, NEUROPEPTIDES, V37, P298, DOI 10.1016/j.npep.2003.08.001; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; Chen SR, 2002, J PHARMACOL EXP THER, V300, P662, DOI 10.1124/jpet.300.2.662; Devlin AM, 2000, HUM MOL GENET, V9, P2837, DOI 10.1093/hmg/9.19.2837; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Ferraris DV, 2012, CURR MED CHEM, V19, P1282; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; Ghosh A, 2004, J CELL BIOCHEM, V91, P528, DOI 10.1002/jcb.10661; Hlouchova K, 2012, CURR MED CHEM, V19, P1316, DOI 10.2174/092986712799462676; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Kim MJ, 2010, FASEB J, V24, P4491, DOI 10.1096/fj.09-148825; Klusak V, 2009, BIOCHEMISTRY-US, V48, P4126, DOI 10.1021/bi900220s; Long JB, 2005, EUR J PHARMACOL, V508, P115, DOI 10.1016/j.ejphar.2004.12.008; Mesters JR, 2006, EMBO J, V25, P1375, DOI 10.1038/sj.emboj.7600969; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Pavlicek J, 2012, CURR MED CHEM, V19, P1300, DOI 10.2174/092986712799462667; Peng XQ, 2010, EUR J PHARMACOL, V627, P156, DOI 10.1016/j.ejphar.2009.10.062; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; Rojas C, 2002, ANAL BIOCHEM, V310, P50, DOI 10.1016/S0003-2697(02)00286-5; SERVAL V, 1990, J NEUROCHEM, V55, P39, DOI 10.1111/j.1471-4159.1990.tb08818.x; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; SLUSHER BS, 1990, J BIOL CHEM, V265, P21297; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; van der Post JP, 2005, BRIT J CLIN PHARMACO, V60, P128, DOI 10.1111/j.1365-2125.2005.02396.x; Witkin JM, 2002, NEUROPHARMACOLOGY, V43, P348, DOI 10.1016/S0028-3908(02)00124-7; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Xi ZX, 2010, J NEUROCHEM, V112, P564, DOI 10.1111/j.1471-4159.2009.06478.x; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Zhang W, 2006, J NEUROL SCI, V247, P217, DOI 10.1016/j.jns.2006.05.052; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266	36	3	3	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2620	2625		10.1096/fj.12-225102	http://dx.doi.org/10.1096/fj.12-225102			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23525278	Green Published			2022-12-28	WOS:000328841000011
J	Lyssenko, NN; Nickel, M; Tang, CR; Phillips, MC				Lyssenko, Nicholas N.; Nickel, Margaret; Tang, Chongren; Phillips, Michael C.			Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability	FASEB JOURNAL			English	Article						macrophage reverse cholesterol transport; HDL quality; reconstituted HDL; discoidal HDL	REVERSE CHOLESTEROL TRANSPORT; APOA-I; PLASMA-MEMBRANE; CROSS-LINKING; CARDIOVASCULAR-DISEASE; TANGIER DISEASE; MESSENGER-RNA; HDL PARTICLES; ABCA1 GENE; EFFLUX	Nascent high-density lipoprotein (HDL) particles arise in different sizes. We have sought to uncover factors that control this size heterogeneity. Gel filtration, native PAGE, and protein cross-linking were used to analyze the size heterogeneity of nascent HDL produced by BHK-ABCA1, RAW 264.7, J774, and HepG2 cells under different levels of two factors considered as a ratio, the availability of apolipoprotein AI (apoAI) -accessible cell lipid, and concentration of extracellular lipid-free apoAI. Increases in the available cell lipid:apoAI ratio due to either elevated ATP-binding cassette transporter A1 (ABCA1) expression and activity or raised cell density (i.e., increasing numerator) shifted the production of nascent HDL from smaller particles with fewer apoAI molecules per particle and fewer molecules of choline-phospholipid and cholesterol per apoAI molecule to larger particles that contained more apoAI and more lipid per molecule of apoAI. A further shift to larger particles was observed in BHK-ABCA1 cells when the available cell lipid:apoAI ratio was raised still higher by decreasing the apoAI concentration (i.e., the denominator). These changes in nascent HDL biogenesis were reminiscent of the transition that occurs in the size composition of reconstituted HDL in response to an increasing initial lipid:apoAI molar ratio. Thus, the ratio of available cell lipid:apoAI is a fundamental cause of nascent HDL size heterogeneity, and rHDL formation is a good model of nascent HDL biogenesis.Lyssenko, N. N., Nickel, M., Tang, C., Phillips, M. C. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability.	[Lyssenko, Nicholas N.; Nickel, Margaret; Phillips, Michael C.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Gastroenterol Hepatol & Nutr,Lipid Res Grp, Philadelphia, PA 19104 USA; [Tang, Chongren] Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Washington; University of Washington Seattle	Phillips, MC (corresponding author), Childrens Hosp Philadelphia, Abramson Res Ctr Ste 1102,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu		Phillips, Michael/0000-0002-7147-8007	U.S. National Institutes of Health (NIH) [HL22633]; American Heart Association postdoctoral fellowship [10POST3630047]; NIH National Research Service Award individual postdoctoral fellowship [HL107065]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, F32HL107065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association postdoctoral fellowship(American Heart Association); NIH National Research Service Award individual postdoctoral fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank David Nguyen for radiolabeling apoAI and assistance with gas-liquid chromatography, Ginny Kellner-Weibel for assistance with gas-liquid chromatography, Debra K. Shivers and the Tissue Culture Core facility for assistance with cell culture, and Sissel Lund-Katz, Eric Alexander, and Palaniappan Sevugan Chetty for insightful discussions. This research was supported by U.S. National Institutes of Health (NIH) grant HL22633. N.N.L. was supported by an American Heart Association postdoctoral fellowship (10POST3630047) and an NIH National Research Service Award individual postdoctoral fellowship (HL107065).	Alexander ET, 2011, ARTERIOSCL THROM VAS, V31, P320, DOI 10.1161/ATVBAHA.110.216226; ASSMANN G, 1977, J CLIN INVEST, V60, P242, DOI 10.1172/JCI108761; Asztalos BF, 2007, J LIPID RES, V48, P592, DOI 10.1194/jlr.M600403-JLR200; Asztalos BF, 2001, ATHEROSCLEROSIS, V156, P217, DOI 10.1016/S0021-9150(00)00643-2; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; Besler C, 2012, EMBO MOL MED, V4, P251, DOI 10.1002/emmm.201200224; Bhat S, 2005, J BIOL CHEM, V280, P33015, DOI 10.1074/jbc.M505081200; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; Camont L, 2011, TRENDS MOL MED, V17, P594, DOI 10.1016/j.molmed.2011.05.013; Chisholm JW, 2002, J LIPID RES, V43, P36; Costet P, 2003, MOL CELL BIOL, V23, P7756, DOI 10.1128/MCB.23.21.7756-7766.2003; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; de la Llera-Moya M, 2010, ARTERIOSCL THROM VAS, V30, P796, DOI 10.1161/ATVBAHA.109.199158; Denis M, 2008, J BIOL CHEM, V283, P16178, DOI 10.1074/jbc.M709597200; Duong PT, 2006, J LIPID RES, V47, P832, DOI 10.1194/jlr.M500531-JLR200; EISENBERG S, 1984, J LIPID RES, V25, P1017; Faulkner LE, 2008, J LIPID RES, V49, P1322, DOI 10.1194/jlr.M800048-JLR200; FORTE TM, 1993, J LIPID RES, V34, P317; Gillotte KL, 1998, J LIPID RES, V39, P1918; GLOMSET JA, 1970, AM J CLIN NUTR, V23, P1129; Graversen JH, 2008, LIPIDS, V43, P467, DOI 10.1007/s11745-008-3169-2; Gu FF, 2010, J BIOL CHEM, V285, P4652, DOI 10.1074/jbc.M109.069914; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Hayashi M, 2005, J LIPID RES, V46, P1703, DOI 10.1194/jlr.M500092-JLR200; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kiss RS, 2003, J BIOL CHEM, V278, P10119, DOI 10.1074/jbc.M300137200; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Krimbou L, 2005, J LIPID RES, V46, P1668, DOI 10.1194/jlr.M500038-JLR200; Le Goff W, 2006, ARTERIOSCL THROM VAS, V26, P527, DOI 10.1161/01.ATV.0000201042.00725.84; Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c; Lin GR, 2000, ATHEROSCLEROSIS, V149, P359, DOI 10.1016/S0021-9150(99)00503-1; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Lund-Katz S, 2010, SUBCELL BIOCHEM, V51, P183, DOI 10.1007/978-90-481-8622-8_7; Lyssenko NN, 2012, BBA-MOL CELL BIOL L, V1821, P456, DOI 10.1016/j.bbalip.2011.07.020; Lyssenko NN, 2011, ARTERIOSCL THROM VAS, V31, P2700, DOI 10.1161/ATVBAHA.111.234906; Massey JB, 2008, BBA-MOL CELL BIOL L, V1781, P245, DOI 10.1016/j.bbalip.2008.03.003; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MILLER GJ, 1980, ANNU REV MED, V31, P97, DOI 10.1146/annurev.me.31.020180.000525; MILLER JCE, 1983, P NATL ACAD SCI-BIOL, V80, P1511, DOI 10.1073/pnas.80.6.1511; Negi S, 2010, J CLIN LIPIDOL, V4, P365, DOI 10.1016/j.jacl.2010.08.008; Oram JF, 2001, J BIOL CHEM, V276, P39898, DOI 10.1074/jbc.M106984200; Rader DJ, 2012, NAT MED, V18, P1344, DOI 10.1038/nm.2937; RITTER MC, 1977, J BIOL CHEM, V252, P1208; Rosenson RS, 2011, CLIN CHEM, V57, P392, DOI 10.1373/clinchem.2010.155333; Rothblat GH, 2010, CURR OPIN LIPIDOL, V21, P229, DOI 10.1097/MOL.0b013e328338472d; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCANU AM, 1982, CRC CR REV BIOCH MOL, V13, P109, DOI 10.3109/10409238209108711; Sezgin E, 2012, NAT PROTOC, V7, P1042, DOI 10.1038/nprot.2012.059; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Sontag TJ, 2012, J LIPID RES, V53, P951, DOI 10.1194/jlr.M021154; Sorci-Thomas MG, 2012, J LIPID RES, V53, P1890, DOI 10.1194/jlr.M026674; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; SWANEY JB, 1980, J BIOL CHEM, V255, P877; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; TALL AR, 1978, BIOCHIM BIOPHYS ACTA, V513, P185, DOI 10.1016/0005-2736(78)90172-4; Tian SM, 2002, BBA-PROTEINS PROTEOM, V1599, P56, DOI 10.1016/S1570-9639(02)00377-1; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Vaughan AM, 2006, J LIPID RES, V47, P2433, DOI 10.1194/jlr.M600218-JLR200; Vaughan AM, 2009, J LIPID RES, V50, P285, DOI 10.1194/jlr.M800366-JLR200; Vedhachalam C, 2007, J BIOL CHEM, V282, P25123, DOI 10.1074/jbc.M704590200; Vedhachalam C, 2010, J BIOL CHEM, V285, P31965, DOI 10.1074/jbc.M110.126292; Verghese PB, 2008, ARCH BIOCHEM BIOPHYS, V478, P161, DOI 10.1016/j.abb.2008.07.025; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4; ZORICH NL, 1987, BIOCHIM BIOPHYS ACTA, V919, P181, DOI 10.1016/0005-2760(87)90206-2	67	25	25	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2880	2892		10.1096/fj.12-216564	http://dx.doi.org/10.1096/fj.12-216564			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23543682	Green Published			2022-12-28	WOS:000328841000036
J	Sossey-Alaoui, K; Pluskota, E; Davuluri, G; Bialkowska, K; Das, M; Szpak, D; Lindner, DJ; Downs-Kelly, E; Thompson, CL; Plow, EF				Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao; Bialkowska, Katarzyna; Das, Mitali; Szpak, Dorota; Lindner, Daniel J.; Downs-Kelly, Erinn; Thompson, Cheryl L.; Plow, Edward F.			Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis	FASEB JOURNAL			English	Article						integrins; VEGF; VEGFR2; epithelial-to-mesenchymal-transition; tumor macrophages	INTEGRIN ACTIVATION; LEUKOCYTE ADHESION; GENE-EXPRESSION; INVASION; CELL; PROTEIN; WAVE3; RESISTANCE; MIGRATION; TALIN	The FERM domain containing protein Kindlin-3 has been recognized as a major regulator of integrin function in hematopoietic cells, but its role in neoplasia is totally unknown. We have examined the relationship between Kindlin-3 and breast cancer in mouse models and human tissues. Human breast tumors showed a approximate to 7-fold elevation in Kindlin-3 mRNA compared with nonneoplastic tissue by quantitative polymerase chain reaction. Kindlin-3 overexpression in a breast cancer cell line increased primary tumor growth and lung metastasis by 2.5- and 3-fold, respectively, when implanted into mice compared with cells expressing vector alone. Mechanistically, the Kindlin-3-overexpressing cells displayed a 2.2-fold increase in vascular endothelial growth factor (VEGF) secretion and enhanced 1 integrin activation. Increased VEGF secretion resulted from enhanced production of Twist, a transcription factor that promotes tumor angiogenesis. Knockdown of Twist diminished VEGF production, and knockdown of 1 integrins diminished Twist and VEGF production by Kindlin-3-overexpressing cells, while nontargeting small interfering RNA had no effect on expression of these gene products. Thus, Kindlin-3 influences breast cancer progression by influencing the crosstalk between 1 integrins and Twist to increase VEGF production. This signaling cascade enhances breast cancer cell invasion and tumor angiogenesis and metastasis.Sossey-Alaoui, K., Pluskota, E., Davuluri, G., Bialkowska, K., Das, M., Szpak, D., Lindner, D. J., Downs-Kelly, E., Thompson, C. L., Plow, E. F. Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis.	[Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao; Bialkowska, Katarzyna; Das, Mitali; Szpak, Dorota; Plow, Edward F.] Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; [Lindner, Daniel J.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA; [Downs-Kelly, Erinn] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44195 USA; [Thompson, Cheryl L.] Case Western Reserve Univ, Dept Family Med & Community Hlth, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Sossey-Alaoui, K (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.	sosseyk@ccf.org; plowe@ccf.org	Lindner, Daniel/ABB-5440-2020		National Heart, Lung, and Blood Institute (U.S. National Institutes of Health) [P01-HL-073311, R01-HL-096062]; Case Comprehensive Cancer Center [P30-CA-43703]; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096062, T32HL007914, P01HL073311] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (U.S. National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Brian McCue for technical assistance. This work was supported in part by National Heart, Lung, and Blood Institute (U.S. National Institutes of Health) grants P01-HL-073311 and R01-HL-096062 and Case Comprehensive Cancer Center grant P30-CA-43703.	Alexander NR, 2006, CANCER RES, V66, P3365, DOI 10.1158/0008-5472.CAN-05-3401; Bialkowska K, 2010, J BIOL CHEM, V285, P18640, DOI 10.1074/jbc.M109.085746; Brahme NN, 2012, CURR BIOL, V22, pR692, DOI 10.1016/j.cub.2012.07.049; Cance WG, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004021; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Desiniotis A, 2011, INT REV CEL MOL BIO, V289, P117, DOI 10.1016/B978-0-12-386039-2.00004-3; Dowling JJ, 2008, CIRC RES, V102, P423, DOI 10.1161/CIRCRESAHA.107.161489; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; JULIANO RL, 1993, SEMIN CANCER BIOL, V4, P277; Kulkarni S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042895; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Legate KR, 2009, J CELL SCI, V122, P187, DOI 10.1242/jcs.041624; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mahawithitwong P, 2013, INT J ONCOL, V42, P1360, DOI 10.3892/ijo.2013.1838; Malinin NL, 2010, BLOOD, V115, P4011, DOI 10.1182/blood-2009-10-239269; Malinin NL, 2009, NAT MED, V15, P313, DOI 10.1038/nm.1917; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Montanez E, 2008, GENE DEV, V22, P1325, DOI 10.1101/gad.469408; Moser M, 2008, NAT MED, V14, P325, DOI 10.1038/nm1722; Moser M, 2009, SCIENCE, V324, P895, DOI 10.1126/science.1163865; Moser M, 2009, NAT MED, V15, P300, DOI 10.1038/nm.1921; Plow EF, 2009, CURR OPIN HEMATOL, V16, P323, DOI 10.1097/MOH.0b013e32832ea389; Pluskota E, 2011, BLOOD, V117, P4978, DOI 10.1182/blood-2010-11-321182; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shen ZL, 2012, AM J SURG, V203, P222, DOI 10.1016/j.amjsurg.2011.06.050; Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012; Siegel DH, 2003, AM J HUM GENET, V73, P174, DOI 10.1086/376609; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Sossey-Alaoui K, 2011, INT J CANCER, V129, P1331, DOI 10.1002/ijc.25793; Sossey-Alaoui K, 2009, J BIOL CHEM, V284, P33019, DOI 10.1074/jbc.M109.034553; Svensson L, 2009, NAT MED, V15, P306, DOI 10.1038/nm.1931; Ussar S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000289; Varner Judith A., 1996, P69; Ye F, 2011, CURR OPIN HEMATOL, V18, P356, DOI 10.1097/MOH.0b013e3283497f09; Zhan J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050313	40	54	57	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2260	2271		10.1096/fj.13-244004	http://dx.doi.org/10.1096/fj.13-244004			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24469992	Green Published			2022-12-28	WOS:000335336000028
J	Welschoff, J; Matthey, M; Wenzel, D				Welschoff, Julia; Matthey, Michaela; Wenzel, Daniela			RGD peptides induce relaxation of pulmonary arteries and airways via beta 3-integrins	FASEB JOURNAL			English	Article						endothelial nitric oxide synthase; hypoxia; pulmonary vascular tone	ARG-GLY-ASP; SOLUBLE GUANYLATE-CYCLASE; SMOOTH-MUSCLE; POTASSIUM CHANNELS; K-V; ALPHA(V)BETA(3); INHIBITION; INTEGRINS; BINDING; RECEPTORS	Novel relaxants of pulmonary arteries and airways are of special interest to obtain insights into pulmonary signaling pathways and to develop treatment strategies for lung diseases. Herein, we demonstrate that Arg-Gly-Asp (RGD) peptides induce a dose-dependent relaxation of pulmonary arteries and airways in mouse. The relaxing effect was specific because it was strongly reduced using the control peptides RGE or RAD (P<0.001). Longer peptide sequences containing RGD and its flanking amino acids found in fibronectin showed a similar effect even at a 10-fold lower concentration. The relevance of RGD-induced pulmonary vasorelaxation was demonstrated in isometric force measurements, lung slices, and the isolated perfused lung model under normoxia and hypoxia and in vivo. As cell surface receptor we identified 3- but not 1-integrin subunits. Moreover, vasorelaxation by RGD peptides was strongly diminished after removal of the endothelium in endothelial nitric oxide synthase-deficient (eNOS(-/-) mice; P<0.01) and after pharmacological inhibition of the NO/sGC pathway (P<0.05). Additionally, several potassium channels like K-v, K-ir, and K-ATP played a role. In airways the response was mediated by K-v and K-Ca channels. Thus, RGD peptides are relaxants of pulmonary arteries and airways. These findings may help to establish novel therapeutic approaches for pulmonary hypertension and obstructive lung disease.Welschoff, J., Matthey, M., Wenzel, D. RGD peptides induce relaxation of pulmonary arteries and airways via 3-integrins.	[Welschoff, Julia; Matthey, Michaela; Wenzel, Daniela] Univ Bonn, Inst Physiol 1, D-53127 Bonn, Germany	University of Bonn	Wenzel, D (corresponding author), Univ Bonn, Inst Physiol 1, Sigmund Freud Str 25, D-53127 Bonn, Germany.	dwenzel@uni-bonn.de	Wenzel, Daniela/B-7613-2014	Wenzel, Daniela/0000-0003-1100-6363; Matthey, Michaela/0000-0002-1841-2906	BONFOR program of the University of Bonn; Ministry of Innovation, Science, Research, and Technology of the State of North Rhine, Westphalia, Germany	BONFOR program of the University of Bonn; Ministry of Innovation, Science, Research, and Technology of the State of North Rhine, Westphalia, Germany	The authors thank T. Baum for excellent technical assistance and A. Godecke (Heinrich-Heine-Universitat Dusseldorf, Dusseldorf, Germany) for providing eNOS<SUP>-/-</SUP> mice. The project was supported by the BONFOR program of the University of Bonn and a junior research group to D.W. funded by the Ministry of Innovation, Science, Research, and Technology of the State of North Rhine, Westphalia, Germany.	Arcangeli A, 2006, TRENDS CELL BIOL, V16, P631, DOI 10.1016/j.tcb.2006.10.003; Archer S, 2002, NEWS PHYSIOL SCI, V17, P131, DOI 10.1152/nips.01388.2002; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; Bhattacharya S, 2000, CIRC RES, V86, P456, DOI 10.1161/01.RES.86.4.456; Borron P, 1998, AM J PHYSIOL-LUNG C, V275, pL679, DOI 10.1152/ajplung.1998.275.4.L679; BOTNEY MD, 1992, AM J PATHOL, V140, P357; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; Burgel PR, 2011, EUR RESPIR REV, V20, P23, DOI 10.1183/09059180.00010410; Chan WL, 2001, AM J PHYSIOL-CELL PH, V280, pC593, DOI 10.1152/ajpcell.2001.280.3.C593; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; CURTIS TM, 1995, AM J PHYSIOL-LUNG C, V269, pL248, DOI 10.1152/ajplung.1995.269.2.L248; Dehart GW, 2008, P NATL ACAD SCI USA, V105, P7188, DOI 10.1073/pnas.0708044105; Dekkers BGJ, 2010, AM J RESP CRIT CARE, V181, P556, DOI 10.1164/rccm.200907-1065OC; Diez-Marques ML, 2006, CARDIOVASC RES, V69, P359, DOI 10.1016/j.cardiores.2005.10.011; Godecke A, 1998, CIRC RES, V82, P186; Hein TW, 2001, AM J PHYSIOL-HEART C, V281, pH2378, DOI 10.1152/ajpheart.2001.281.6.H2378; Herz K, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0257-5; Humbert M, 2004, J AM COLL CARDIOL, V43, p13S; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; Irvine JC, 2003, HYPERTENSION, V41, P1301, DOI 10.1161/01.HYP.0000072010.54901.DE; Kawaguchi M, 2001, BIOCHEM BIOPH RES CO, V288, P711, DOI 10.1006/bbrc.2001.5809; Kawasaki J, 2004, J BIOL CHEM, V279, P12959, DOI 10.1074/jbc.M313791200; Konig P, 2005, J HISTOCHEM CYTOCHEM, V53, P155, DOI 10.1369/jhc.4A6453.2005; Levine DJ, 2006, RESP CARE, V51, P368; Lipke DW, 1996, REGUL PEPTIDES, V63, P23, DOI 10.1016/0167-0115(96)00020-1; Malan D, 2010, DEVELOPMENT, V137, P993, DOI 10.1242/dev.045377; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203; Mogford JE, 1997, J CLIN INVEST, V100, P1647, DOI 10.1172/JCI119689; Mogford JE, 1996, CIRC RES, V79, P821, DOI 10.1161/01.RES.79.4.821; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NICOSIA RF, 1991, AM J PATHOL, V138, P829; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Platts SH, 1998, AM J PHYSIOL-HEART C, V275, pH1449; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; QIAO RL, 1995, AM J PHYSIOL-CELL PH, V269, pC110, DOI 10.1152/ajpcell.1995.269.1.C110; Reardon DA, 2011, FUTURE ONCOL, V7, P339, DOI [10.2217/fon.11.8, 10.2217/FON.11.8]; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; Sheppard D, 2003, PHYSIOL REV, V83, P673, DOI 10.1152/physrev.00033.2002; Singh B, 2000, AM J PHYSIOL-LUNG C, V278, pL217, DOI 10.1152/ajplung.2000.278.1.L217; Sweeney M, 2000, Respir Res, V1, P40, DOI 10.1186/rr11; Thirstrup S, 2000, RESP MED, V94, P328, DOI 10.1053/rmed.1999.0737; Tsikaris V, 2004, J PEPT SCI, V10, P589, DOI 10.1002/psc.603; Umesh A, 2006, J BIOL CHEM, V281, P34312, DOI 10.1074/jbc.M606765200; Wenzel D, 2006, CIRC RES, V98, P1203, DOI 10.1161/01.RES.0000219899.93384.ed; Wenzel D, 2013, P NATL ACAD SCI USA, V110, P18710, DOI 10.1073/pnas.1308130110; Wenzel D, 2012, HYPERTENSION, V59, P1256, DOI 10.1161/HYPERTENSIONAHA.111.188367; Wenzel D, 2012, PHARM RES-DORDR, V29, P1242, DOI 10.1007/s11095-011-0657-5; Wenzel D, 2009, HYPERTENSION, V54, P157, DOI 10.1161/HYPERTENSIONAHA.109.130468; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Zhao YJ, 1997, AM J PHYSIOL-HEART C, V272, pH904, DOI 10.1152/ajpheart.1997.272.2.H904	52	12	12	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2281	2292		10.1096/fj.13-246348	http://dx.doi.org/10.1096/fj.13-246348			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24500921				2022-12-28	WOS:000335336000030
J	Prunskaite-Hyyrylainen, R; Shan, JD; Railo, A; Heinonen, KM; Miinalainen, I; Yan, WY; Shen, BR; Perreault, C; Vainio, SJ				Prunskaite-Hyyrylainen, Renata; Shan, Jingdong; Railo, Antti; Heinonen, Krista M.; Miinalainen, Ilkka; Yan, Wenying; Shen, Bairong; Perreault, Claude; Vainio, Seppo J.			Wnt4, a pleiotropic signal for controlling cell polarity, basement membrane integrity, and antimullerian hormone expression during oocyte maturation in the female follicle	FASEB JOURNAL			English	Article						premature ovarian failure; sex determination; cell polarity; ovarian development	ANTI-MULLERIAN HORMONE; OVARIAN FAILURE; DUCT REGRESSION; NEST BREAKDOWN; PATHWAYS; MUTATION; PROLIFERATION; DEFICIENCY; GENES; FOXL2	Wnt4 is a key signal that channels the developmental fate of the indifferent mammalian gonad toward the ovary, but whether Wnt4 has later roles during ovary development remains unknown. To investigate this, we inactivated the Wnt4 gene by crossing Amhr2Cre and doxycycline-inducible Rosa(rtTA)-knock-in Cre mice with mice carrying a floxed Wnt4 allele and used a novel Wnt4(mCherry)-knock-in mouse. In these models, ovarian folliculogenesis was compromised, and female fertility was severely reduced, and Wnt4 deficiency eventually led to premature ovarian failure. These anomalies were associated with cell polarity defects in the follicle. Within the follicle, laminin and type IV collagen assembled ectopic basement membrane-like structures, the cell adherens junction components N-cadherin and beta-catenin lost their polarized expression pattern, and expression of the gap junction protein connexin 43 was reduced by similar to 30% when compared with that of the controls. Besides these changes, expression of antimullerian hormone (Amh) was inhibited in the absence of Wnt4 signaling in vivo. Consistent with this, Wnt4 signaling up-regulated Amh gene expression in KK1 cells in vitro. Thus, Wnt4 signaling is necessary during maturation of the ovarian follicles, where it coordinates expression of Amh, cell survival, and polarized organization of the follicular cells.-Prunskaite-Hyyrylainen, R., Shan, J., Railo, A., Heinonen, K. M., Miinalainen, I., Yan, W., Shen, B., Perreault, C., Vainio, S. J. Wnt4, a pleiotropic signal for controlling cell polarity, basement membrane integrity, and antimullerian hormone expression during oocyte maturation in the female follicle.	[Prunskaite-Hyyrylainen, Renata; Shan, Jingdong; Railo, Antti; Miinalainen, Ilkka; Yan, Wenying; Vainio, Seppo J.] Univ Oulu, Dept Med Biochem & Mol Biol, Inst Biomed, Oulu Ctr Cell Matrix Res, FIN-90220 Oulu, Finland; [Prunskaite-Hyyrylainen, Renata; Shan, Jingdong; Railo, Antti; Miinalainen, Ilkka; Yan, Wenying; Vainio, Seppo J.] Univ Oulu, Dev Biol Lab, Bioctr Oulu, FIN-90220 Oulu, Finland; [Heinonen, Krista M.; Perreault, Claude] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada; [Heinonen, Krista M.; Perreault, Claude] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Heinonen, Krista M.] Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ, Canada; [Yan, Wenying; Shen, Bairong] Soochow Univ, Ctr Syst Biol, Suzhou, Jiangsu, Peoples R China	University of Oulu; University of Oulu; Universite de Montreal; Universite de Montreal; University of Quebec; Institut national de la recherche scientifique (INRS); Soochow University - China	Vainio, SJ (corresponding author), Univ Oulu, Dept Med Biochem & Mol Biol, Dev Biol Lab, Aapistie 5,POB 5000, FIN-90220 Oulu, Finland.	seppo.vainio@oulu.fi	Yan, Wenying/G-9951-2017; Shen, Bairong/W-1254-2019; Yan, Wenying/N-7542-2014; Heinonen, Krista M/G-9769-2016; Shen, Bairong/E-6431-2012; Perreault, Claude/A-7220-2008	Yan, Wenying/0000-0001-5016-575X; Shen, Bairong/0000-0003-2899-1531; Yan, Wenying/0000-0001-5016-575X; Heinonen, Krista M/0000-0002-2410-4432; Shen, Bairong/0000-0003-2899-1531; Perreault, Claude/0000-0001-9453-7383; Miinalainen, Ilkka/0000-0002-3922-3442; Prunskaite-Hyyrylainen, Renata/0000-0001-5453-2983; Vainio, Seppo/0000-0001-9319-3566	Academy of Finland [206038, 121647, 250900, 260056]; Centre of Excellence grant of the Academy of Finland [251314]; Sigrid Juselius; Novonordisk; Finnish Cancer Research Foundations; European Community [FP7-HEALTH-F5-2012-INNOVATION-1 EURenOmics 305608]; Ministry of Education, China; Orion-Farmos Research Foundation; Jalmari and Rauha Ahokas Foundation; Novo Nordisk Fonden [NNF11OC1014597] Funding Source: researchfish	Academy of Finland(Academy of Finland); Centre of Excellence grant of the Academy of Finland; Sigrid Juselius(Sigrid Juselius Foundation); Novonordisk(Novo Nordisk); Finnish Cancer Research Foundations; European Community(European Commission); Ministry of Education, China(Ministry of Education, China); Orion-Farmos Research Foundation; Jalmari and Rauha Ahokas Foundation; Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank Dr. Richard R. Behringer (University of Texas M. D. Anderson Cancer Center, Houston, TX, USA) for his gift of the Amhr2-Cer-knock-in transgenic mice; H. Harkman, J. Kekolahti-Liias, J. Kujala, R. Vuento, T. Leinonen, and A. Viklund for excellent technical assistance; T. Jokela for taking part in the sampling of the Wnt4<SUP>W4mCh</SUP> specimens; H.-M. Lee and S. Murugan for analyzing the Amh biding sites; and Dr. H. Peltoketo, Dr. T. Pikkarainen, and I. Pietila for discussions and critical comments. This work was supported by the Academy of Finland (grants 206038, 121647, 250900 and 260056); Centre of Excellence grant 2012-2017 of the Academy of Finland (grant 251314), the Sigrid Juselius, Novonordisk, and Finnish Cancer Research Foundations; and the European Community's Seventh Framework Programme (FP7/2007-2013; grant FP7-HEALTH-F5-2012-INNOVATION-1 EURenOmics 305608). The work of W.Y. was supported by a grant from the Ministry of Education, China. The work of R.P.-H. was supported by the Orion-Farmos Research Foundation and the Jalmari and Rauha Ahokas Foundation.	Arora P, 2011, OBSTET GYNAECOL, V13, P67, DOI 10.1576/toag.13.2.67.27648; Biason-Lauber A, 2004, NEW ENGL J MED, V351, P792, DOI 10.1056/NEJMoa040533; Biason-Lauber A, 2007, HUM REPROD, V22, P224, DOI 10.1093/humrep/del360; Boyer A, 2010, FASEB J, V24, P3010, DOI 10.1096/fj.09-145789; Boyer A, 2010, TRENDS ENDOCRIN MET, V21, P25, DOI 10.1016/j.tem.2009.08.005; Caligioni C. S., 2009, CURR PROTOCOLS NEURO; Chen Y, 2007, ENDOCRINOLOGY, V148, P3580, DOI 10.1210/en.2007-0088; Chen Y, 2009, J ENDOCRINOL, V202, P407, DOI 10.1677/JOE-09-0109; Crisosto N, 2009, ENDOCRINE, V36, P339, DOI 10.1007/s12020-009-9227-6; Da Silva-Buttkus P, 2008, J CELL SCI, V121, P3890, DOI 10.1242/jcs.036400; Daley WP, 2012, DEVELOPMENT, V139, P411, DOI 10.1242/dev.075366; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; Heikkila M, 2005, ENDOCRINOLOGY, V146, P4016, DOI 10.1210/en.2005-0463; Heinonen KM, 2011, BLOOD, V118, P5163, DOI 10.1182/blood-2011-04-350553; Hsieh M, 2003, ENDOCRINOLOGY, V144, P4597, DOI 10.1210/en.2003-0048; IGUCHI T, 1990, BIOL REPROD, V43, P478, DOI 10.1095/biolreprod43.3.478; Irving-Rodgers HF, 2004, MATRIX BIOL, V23, P207, DOI 10.1016/j.matbio.2004.05.008; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Jeays-Ward K, 2003, DEVELOPMENT, V130, P3663, DOI 10.1242/dev.00591; Jorgez CJ, 2004, MOL ENDOCRINOL, V18, P953, DOI 10.1210/me.2003-0301; Kaku U, 2008, ENDOCR J, V55, P1043, DOI 10.1507/endocrj.K08E-102; Kevenaar ME, 2006, ENDOCRINOLOGY, V147, P3228, DOI 10.1210/en.2005-1588; Kicheva A, 2007, SCIENCE, V315, P521, DOI 10.1126/science.1135774; Kim Y, 2006, PLOS BIOL, V4, P1000, DOI 10.1371/journal.pbio.0040187; Kuo FT, 2011, ENDOCRINOLOGY, V152, P3917, DOI 10.1210/en.2010-0989; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mandel H, 2008, AM J HUM GENET, V82, P39, DOI 10.1016/j.ajhg.2007.08.005; Mora JM, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.096156; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Myers M, 2009, DEV BIOL, V334, P458, DOI 10.1016/j.ydbio.2009.08.001; Naillat F, 2010, HUM MOL GENET, V19, P1539, DOI 10.1093/hmg/ddq027; Peltoketo H, 2010, ENDOCRINOLOGY, V151, P1872, DOI 10.1210/en.2009-0966; Philibert P, 2008, J CLIN ENDOCR METAB, V93, P895, DOI 10.1210/jc.2007-2023; Philibert P, 2011, FERTIL STERIL, V95, P2683, DOI 10.1016/j.fertnstert.2011.01.152; Piltonen T, 2005, HUM REPROD, V20, P1820, DOI 10.1093/humrep/deh850; Railo A, 2008, EXP CELL RES, V314, P2389, DOI 10.1016/j.yexcr.2008.04.010; Railo A, 2009, EXP CELL RES, V315, P2690, DOI 10.1016/j.yexcr.2009.06.021; Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Schulte DM, 2007, GENE EXPR PATTERNS, V7, P72, DOI 10.1016/j.modgep.2006.05.009; Shan JD, 2010, DIFFERENTIATION, V79, P57, DOI 10.1016/j.diff.2009.08.006; Shan J, 2009, GENESIS, V47, P782, DOI 10.1002/dvg.20566; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Tingen C, 2009, MOL HUM REPROD, V15, P795, DOI 10.1093/molehr/gap073; Uda M, 2004, HUM MOL GENET, V13, P1171, DOI 10.1093/hmg/ddh124; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Veiga-Lopez A, 2012, FERTIL STERIL, V97, P748, DOI 10.1016/j.fertnstert.2011.12.028; Visser JA, 2012, NAT REV ENDOCRINOL, V8, P331, DOI 10.1038/nrendo.2011.224; Wang C, 2010, ENDOCRINOLOGY, V151, P2319, DOI 10.1210/en.2009-1489; Young JM, 2010, REPRODUCTION, V140, P489, DOI 10.1530/REP-10-0094	51	39	42	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1568	1581		10.1096/fj.13-233247	http://dx.doi.org/10.1096/fj.13-233247			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371124				2022-12-28	WOS:000335344300006
J	Cheruiyot, A; Lee, JA; Gao, FB; Ahmad, ST				Cheruiyot, Abigael; Lee, Jin-A; Gao, Fen-Biao; Ahmad, S. Tariq			Expression of mutant CHMP2B, an ESCRT-III component involved in frontotemporal dementia, causes eye deformities due to Notch misregulation in Drosophila	FASEB JOURNAL			English	Article						endosomal-lysosomal pathway; tumorigenesis	ENDOSOMAL ENTRY; MUTATIONS; PROTEIN; PATHWAY; VPS25; DEGENERATION; RECEPTOR; SCREEN; ABSENT	Endosomal sorting complexes required for transport (ESCRTs) mediate sorting of ubiquitinated membrane proteins into multivesicular bodies en route to lysosomes for degradation. A mutation in CHMP2B (CHMP2B(Intron5), an ESCRT-III component) that is associated with a hereditary form of frontotemporal dementia (FTD3) disrupts the endosomal-lysosomal pathway and causes accumulation of autophagosomes and multilamellar structures. We previously demonstrated that expression of CHMP2B(Intron5) in the Drosophila eye using GMR-Gal4 causes misregulation of the Toll receptor pathway. Here, we show that ectopic expression of CHMP2B(Intron5) using eyeless-Gal4 (ey>CHMP2B(Intron5)), a driver with different spatiotemporal expression attributes than GMR-Gal4 in the Drosophila eye, causes eye deformities when compared to expression of wild-type CHMP2B (CHMP2B(WT)) and the Drosophila homologue of CHMP2B (CG4618). In addition, ey>CHMP2B(Intron5) flies showed defects in photoreceptor cell patterning and phototactic behavior. Furthermore, ey>CHMP2B(Intron5) flies showed accumulation of Notch in enlarged endosomes and up-regulation of Notch activity. Partial loss of Notch activity in ey>CHMP2B(Intron5) flies significantly rescued eye deformities, photoreceptor patterning defect, and phototactic behavior defect, indicating that these defects are primarily due to Notch misregulation. These results demonstrate that CHMP2B(Intron5) preferentially affects different receptor signaling pathways in a cellular and developmental context-dependent manner.Cheruiyot, A., Lee, J-A., Gao, F-B., Ahmad, S. T. Expression of mutant CHMP2B, an ESCRT-III component involved in frontotemporal dementia, causes eye deformities due to Notch misregulation in Drosophila.	[Cheruiyot, Abigael; Ahmad, S. Tariq] Colby Coll, Dept Biol, Waterville, ME 04901 USA; [Lee, Jin-A] Hannam Univ, Coll Life Sci & Nanotechnol, Dept Biotechnol, Dajeon, South Korea; [Gao, Fen-Biao] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA	Colby College; Hannam University; University of Massachusetts System; University of Massachusetts Worcester	Ahmad, ST (corresponding author), Colby Coll, Dept Biol, 5720 Mayflower Hill Dr, Waterville, ME 04901 USA.	stahmad@colby.edu		Cheruiyot, Abigael/0000-0003-0612-6280	U.S. National Institutes of Health (NIH) [OD010949-10]; NIH [RO1 NS057553, 8 P20 GM103423-12]; National Center for Research Resources, INBRE [5 P20 RR016463-12]; National Institute of General Medical Sciences; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057553] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010949] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources, INBRE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank H. Householder, E. Hergenreder, L. Duff, and G. Lerner (Colby College) for technical assistance. The authors also thank the Bloomington Stock Center (Bloomington, IN, USA), the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA, USA) and the Drosophila Genomics Resource Center [Indiana University, Bloomington, IN, USA; supported by U.S. National Institutes of Health (NIH) grant OD010949-10] for providing the fly stocks, Notch antibody, and cDNA clones, respectively. This project was initiated at the Gladstone Institute of Neurological Disease with a support from the NIH (RO1 NS057553, F.-B.G.) and supported by grants from the National Center for Research Resources, INBRE (5 P20 RR016463-12), and the National Institute of General Medical Sciences (8 P20 GM103423-12) from the NIH to Colby College and Science Division Grant, Colby College (S.T.A.). The authors declare no conflicts of interest.	Ahmad ST, 2009, P NATL ACAD SCI USA, V106, P12168, DOI 10.1073/pnas.0903134106; Aoyama N, 2013, GENES GENET SYST, V88, P45, DOI 10.1266/ggs.88.45; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Belly A, 2010, J CELL SCI, V123, P2943, DOI 10.1242/jcs.068817; BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; Bonini NM, 1997, DEVELOPMENT, V124, P4819; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cox LE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009872; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Filimonenko M, 2007, J CELL BIOL, V179, P485, DOI 10.1083/jcb.200702115; Fortini ME, 2009, CURR OPIN GENET DEV, V19, P323, DOI 10.1016/j.gde.2009.04.005; Ghazi-Noori S, 2012, BRAIN, V135, P819, DOI 10.1093/brain/aws006; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; Henne WM, 2011, DEV CELL, V21, P77, DOI 10.1016/j.devcel.2011.05.015; Herz HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004165; Herz HM, 2006, DEVELOPMENT, V133, P1871, DOI 10.1242/dev.02356; Hurley JH, 2010, CRIT REV BIOCHEM MOL, V45, P463, DOI 10.3109/10409238.2010.502516; Isaacs AM, 2011, CURR ALZHEIMER RES, V8, P246; Kumar JP, 2001, CELL, V104, P687, DOI 10.1016/S0092-8674(01)00265-3; Kurata S, 2000, P NATL ACAD SCI USA, V97, P2117, DOI 10.1073/pnas.040556497; Lee JA, 2007, CURR BIOL, V17, P1561, DOI 10.1016/j.cub.2007.07.029; Lee JA, 2009, AUTOPHAGY, V5, P1070, DOI 10.4161/auto.5.7.9823; Lindquist SG, 2008, EUR J NEUROL, V15, P667, DOI 10.1111/j.1468-1331.2008.02144.x; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; Morrison HA, 2008, MOL BIOL CELL, V19, P4167, DOI 10.1091/mbc.E08-07-0716; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Parkinson N, 2006, NEUROLOGY, V67, P1074, DOI 10.1212/01.wnl.0000231510.89311.8b; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Riemensperger T, 2011, P NATL ACAD SCI USA, V108, P834, DOI 10.1073/pnas.1010930108; Saj A, 2010, DEV CELL, V18, P862, DOI 10.1016/j.devcel.2010.03.013; Saksena S, 2009, CELL, V136, P97, DOI 10.1016/j.cell.2008.11.013; Skibinski G, 2005, NAT GENET, V37, P806, DOI 10.1038/ng1609; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; Stuffers S, 2009, EXP CELL RES, V315, P1619, DOI 10.1016/j.yexcr.2008.10.013; Tanaka T, 2008, DEVELOPMENT, V135, P1107, DOI 10.1242/dev.017293; Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020; Urwin H, 2010, HUM MOL GENET, V19, P2228, DOI 10.1093/hmg/ddq100; Urwin H, 2009, BIOCHEM SOC T, V37, P208, DOI 10.1042/BST0370208; Vaccari T, 2005, DEV CELL, V9, P687, DOI 10.1016/j.devcel.2005.09.019; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Vaccari T, 2009, J CELL SCI, V122, P2413, DOI 10.1242/jcs.046391; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wolff T., 2007, CSH PROTOCOLS; Woodfield SE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056021	46	10	10	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					667	675		10.1096/fj.13-234138	http://dx.doi.org/10.1096/fj.13-234138			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24158394	Green Published			2022-12-28	WOS:000331072200014
J	Kim, HY; Yang, DH; Shin, SW; Kim, MY; Yoon, JH; Kim, S; Park, HC; Kang, DW; Min, D; Hur, MW; Choi, KY				Kim, Hyun-Yi; Yang, Dong-Hwa; Shin, Song-Weon; Kim, Mi-Yeon; Yoon, Jae-Hyun; Kim, Suhyun; Park, Hae-Chul; Kang, Dong Woo; Min, DoSik; Hur, Man-Wook; Choi, Kang-Yell			CXXC5 is a transcriptional activator of Flk-1 and mediates bone morphogenic protein-induced endothelial cell differentiation and vessel formation	FASEB JOURNAL			English	Article						HUVECs; mouse embryonic stem cells; caudal vein plex vessel formation	EMBRYONIC STEM-CELLS; SIGNAL-TRANSDUCTION; BINDING DOMAIN; VEGF; PATHWAY; ANGIOGENESIS; EXPRESSION; GENE; IDENTIFICATION; PROLIFERATION	CXXC5 is a member of a small subset of proteins containing CXXC-type zinc-finger domain. Here, we show that CXXC5 is a transcription factor activating Flk-1, a receptor for vascular endothelial growth factor. CXXC5 and Flk-1 were accmulated in nucli and membrane of mouse embryonic stem cells (mESCs), respectively, during their endothelial differentiation. CXXC5 overexpression induced Flk-1 transcription in both endothelium-differentiated mESCs and human umbilical vein endothelial cells (HUVECs). In vitro DNA binding assay showed direct interaction of CXXC5 on the Flk-1 promoter region, and mutation on its DNA-binding motif abolished transcriptional activity. We showed that bone morphorgeneic protein 4 (BMP4) induced CXXC5 transcription in the cells, and inhibitors of BMP signaling suppressed the CXXC5 induction and the consequent Flk-1 induction by BMP4 treatment. CXXC5 knockdown resulted in suppression of BMP4-induced stress fiber formation (56.8 +/- 1.3% decrease, P<0.05) and migration (54.6 +/- 1.9% decrease, P<0.05) in HUVECs. The in vivo roles of CXXC5 in BMP-signaling-specific vascular development and angiogenesis were shown by specific defect of caudal vein plex vessel formation (57.9 +/- 11.8% decrease, P<0.05) in cxxc5 morpholino-injected zebrafish embryos and by supression of BMP4-induced angigogensis in subcutaneously injected Matrigel plugs in CXXC5(-/-) mice. Overall, CXXC5 is a transcriptional activator for Flk-1, mediating BMP signaling for differentiation and migration of endothelial cell and vessel formation.Kim, H.-Y., Yang, D.-H., Shin, S.-W., Kim, M.-Y., Yoon, J.-H., Kim, S., Park, H.-C., Kang, D. W., Min, D., Hur, M.-W., Choi, K.-Y. CXXC5 is a transcriptional activator of Flk-1 and mediates bone morphogenic protein-induced endothelial cell differentiation and vessel formation.	[Kim, Hyun-Yi; Yang, Dong-Hwa; Shin, Song-Weon; Kim, Mi-Yeon; Kang, Dong Woo; Min, DoSik; Choi, Kang-Yell] Yonsei Univ, Coll Life Sci & Biotechnol, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea; [Kim, Hyun-Yi; Yang, Dong-Hwa; Shin, Song-Weon; Kim, Mi-Yeon; Choi, Kang-Yell] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 120749, South Korea; [Yoon, Jae-Hyun; Hur, Man-Wook] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 120749, South Korea; [Kim, Suhyun; Park, Hae-Chul] Korea Univ, Grad Sch Med, Ansan, South Korea; [Kang, Dong Woo; Min, DoSik] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea	Yonsei University; Yonsei University; Yonsei University; Yonsei University Health System; Korea University; Korea University Medicine (KU Medicine); Pusan National University	Choi, KY (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 120749, South Korea.	kychoi@yonsei.ac.kr		Kim, Suhyun/0000-0001-7425-1310; Hur, Man-Wook/0000-0002-3416-1334; Kim, Mi-Yeon/0000-0002-7929-865X	National Research Foundation (NRF); Ministry of Education, Science, and Technology (MEST) of Korea through the Translational Research Center for Protein Function Control [2010-00001919]; Midcareer Researcher Program [2012-010285]; Stem Cell Research Project [2010-0020235]; BK21 studentship from the NRF	National Research Foundation (NRF); Ministry of Education, Science, and Technology (MEST) of Korea through the Translational Research Center for Protein Function Control; Midcareer Researcher Program; Stem Cell Research Project; BK21 studentship from the NRF	This work was supported by grants from the National Research Foundation (NRF), funded by the Ministry of Education, Science, and Technology (MEST) of Korea through the Translational Research Center for Protein Function Control (2010-00001919), the Midcareer Researcher Program (2012-010285), and Stem Cell Research Project (2010-0020235); and S.W.S., H.Y.K., M.Y.K., and J.H.Y, were supported by a BK21 studentship from the NRF. The authors thank S. B. Lee for helpful discussions and for sharing unpublished work.	Andersson T, 2009, J BIOL CHEM, V284, P3672, DOI 10.1074/jbc.M808119200; Aras S, 2013, NUCLEIC ACIDS RES, V41, P2255, DOI 10.1093/nar/gks1454; Bai H, 2010, J CELL BIOCHEM, V109, P363, DOI 10.1002/jcb.22410; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Chappell JC, 2011, SEMIN CELL DEV BIOL, V22, P1005, DOI 10.1016/j.semcdb.2011.10.006; Cierpicki T, 2010, NAT STRUCT MOL BIOL, V17, P62, DOI 10.1038/nsmb.1714; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Goldman O, 2009, STEM CELLS, V27, P1750, DOI 10.1002/stem.100; Guo SC, 2010, BBA-REV CANCER, V1806, P108, DOI 10.1016/j.bbcan.2010.04.004; He C, 2005, BIOCHEM BIOPH RES CO, V329, P324, DOI 10.1016/j.bbrc.2005.01.133; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heinke J, 2008, CIRC RES, V103, P804, DOI 10.1161/CIRCRESAHA.108.178434; Jinn SW, 2005, DEVELOPMENT, V132, P5199, DOI 10.1242/dev.02087; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kelly MA, 2009, ARTERIOSCL THROM VAS, V29, P718, DOI 10.1161/ATVBAHA.109.184200; Kim MS, 2010, J BIOL CHEM, V285, P14585, DOI 10.1074/jbc.M109.094334; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lee JH, 2001, J BIOL CHEM, V276, P44669, DOI 10.1074/jbc.M107179200; Lee WJ, 2000, BIOCHEM J, V349, P821, DOI 10.1042/bj3490821; Lowery JW, 2010, CYTOKINE GROWTH F R, V21, P287, DOI 10.1016/j.cytogfr.2010.06.001; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Moreno-Miralles I, 2009, CURR OPIN HEMATOL, V16, P195, DOI 10.1097/MOH.0b013e32832a07d6; Munoz-Chapuli R, 2004, CELL MOL LIFE SCI, V61, P2224, DOI 10.1007/s00018-004-4070-7; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779; PASSANITI A, 1992, LAB INVEST, V67, P519; Pendino F, 2009, BLOOD, V113, P3172, DOI 10.1182/blood-2008-07-170035; Scott A, 2009, BIOCHEM SOC T, V37, P1184, DOI 10.1042/BST0371184; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suzuki Y, 2008, J BIOCHEM, V143, P199, DOI 10.1093/jb/mvm215; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105; Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293; Wiley DM, 2011, NAT CELL BIOL, V13, P686, DOI 10.1038/ncb2232; Xu C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1237; Yang DH, 2009, CIRC RES, V104, P372, DOI 10.1161/CIRCRESAHA.108.185405; Yue W, 2010, STEM CELLS DEV, V19, P1937, DOI 10.1089/scd.2010.0096; Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113; Zhang M, 2009, SCI CHINA SER C, V52, P528, DOI 10.1007/s11427-009-0083-7	47	25	28	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					615	626		10.1096/fj.13-236216	http://dx.doi.org/10.1096/fj.13-236216			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24136587				2022-12-28	WOS:000331072200010
J	Oyewole, AO; Wilmot, MC; Fowler, M; Birch-Machin, MA				Oyewole, Anne O.; Wilmot, Marie-Claire; Fowler, Mark; Birch-Machin, Mark A.			Comparing the effects of mitochondrial targeted and localized antioxidants with cellular antioxidants in human skin cells exposed to UVA and hydrogen peroxide	FASEB JOURNAL			English	Article						DNA damage; mitochondria; ultraviolet radiation; reactive oxygen species; ROS; Nrf2	IRON REGULATORY PROTEIN-1; INDUCED OXIDATIVE STRESS; ENDOPLASMIC-RETICULUM STRESS; FREE-RADICAL GENERATION; GREEN TEA POLYPHENOL; DNA-DAMAGE; DERMAL FIBROBLASTS; VISIBLE RADIATION; BETA-CAROTENE; HACAT CELLS	Skin cancer and aging are linked to increased cellular reactive oxygen species (ROS), particularly following exposure to ultraviolet A (UVA) in sunlight. As mitochondria are the main source of cellular ROS, this study compared the protective effects of mitochondria-targeted and -localized antioxidants (MitoQ and tiron, respectively) with cellular antioxidants against oxidative stress-induced [UVA and hydrogen peroxide (H2O2)] mitochondrial DNA (mtDNA) damage in human dermal fibroblasts. With the use of a long quantitative PCR assay, tiron (EC50 10 mM) was found to confer complete (100%) protection (P<0.001) against both UVA- and H2O2-induced mtDNA damage, whereas MitoQ (EC50 750 nM) provided less protection (17 and 32%, respectively; P<0.05). This particular protective effect of tiron was greater than a range of cellular antioxidants investigated. The nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway provides cellular protection against oxidative stress. An ELISA assay for the Nrf2 target gene heme oxygenase-1 (HO-1) and studies using Nrf2 small interfering RNA both indicated that tiron's mode of action was Nrf2 independent. The comet assay showed that tiron's protective effect against H2O2-induced nuclear DNA damage was greater than the cellular antioxidants and MitoQ (P<0.001). This study provides a platform to investigate molecules with similar structure to tiron as potent and clinically relevant antioxidants.Oyewole, A. O., Wilmot, M.-C., Fowler, M., Birch-Machin, M. A. Comparing the effects of mitochondrial targeted and localized antioxidants with cellular antioxidants in human skin cells exposed to UVA and hydrogen peroxide.	[Oyewole, Anne O.; Wilmot, Marie-Claire; Birch-Machin, Mark A.] Newcastle Univ, Sch Med, Inst Cellular Med, Dept Dermatol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Fowler, Mark] Unilever Res & Dev Colworth, Sharnbrook, Beds, England	Newcastle University - UK; Unilever	Birch-Machin, MA (corresponding author), Newcastle Univ, Sch Med, Inst Cellular Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	m.a.birch-machin@ncl.ac.uk			Biotechnology and Biological Sciences Research Council (BBSRC);  [Unilever]	Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); 	This work was supported by the Biotechnology and Biological Sciences Research Council (BBSRC; BBSRC CASE award with Unilever). The authors thank Dr. Jane Armstrong and Dr. Elaine Mutch (both Newcastle University) for their scientific expertise. The authors declare no conflicts of interest.	Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Aitken GR, 2007, CLIN EXP DERMATOL, V32, P722, DOI 10.1111/j.1365-2230.2007.02474.x; Armstrong JL, 2010, J BIOL CHEM, V285, P6091, DOI 10.1074/jbc.M109.014092; Aroun A, 2012, PHOTOCH PHOTOBIO SCI, V11, P118, DOI 10.1039/c1pp05204g; Atherton KM, 2009, BIOMARKERS, V14, P443, DOI 10.3109/13547500903137265; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Basu-Modak S, 2006, FREE RADICAL BIO MED, V41, P1197, DOI 10.1016/j.freeradbiomed.2006.06.008; Bergstrom P, 2011, NEUROPHARMACOLOGY, V60, P343, DOI 10.1016/j.neuropharm.2010.09.023; Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345; Berneburg M, 1997, PHOTOCHEM PHOTOBIOL, V66, P271, DOI 10.1111/j.1751-1097.1997.tb08654.x; Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x; Birch-Machin M, 2009, MUTAGENESIS, V24, P101; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Cantu D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007095; Chan WH, 2003, J CELL BIOCHEM, V90, P327, DOI 10.1002/jcb.10638; Corazzari M, 2007, BRIT J CANCER, V96, P1062, DOI 10.1038/sj.bjc.6603672; Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x; Diffey BL, 2002, METHODS, V28, P4, DOI 10.1016/S1046-2023(02)00204-9; Durham SE, 2003, BRIT J CANCER, V88, P90, DOI 10.1038/sj.bjc.6600773; Eicker J, 2003, PHOTOCH PHOTOBIO SCI, V2, P655, DOI 10.1039/b300808h; Fang Y, 2012, AUSTRALAS J DERMATOL, V53, P172, DOI 10.1111/j.1440-0960.2012.00912.x; Giordani A, 1998, PHOTOCHEM PHOTOBIOL, V68, P309, DOI 10.1111/j.1751-1097.1998.tb09686.x; Giordani A, 2000, PHOTOCHEM PHOTOBIOL, V72, P746, DOI 10.1562/0031-8655(2000)072<0746:IOIREB>2.0.CO;2; Heinrich U, 2003, J NUTR, V133, P98, DOI 10.1093/jn/133.1.98; Henderson JR, 2009, FREE RADICAL RES, V43, P796, DOI 10.1080/10715760903062895; Hirota A, 2011, EXP DERMATOL, V20, P664, DOI 10.1111/j.1600-0625.2011.01292.x; Hseu YC, 2012, FOOD CHEM TOXICOL, V50, P1245, DOI 10.1016/j.fct.2012.02.020; Huang XX, 2009, AM J PATHOL, V174, P1534, DOI 10.2353/ajpath.2009.080318; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; James AM, 2007, J BIOL CHEM, V282, P14708, DOI 10.1074/jbc.M611463200; Jian Z, 2011, J INVEST DERMATOL, V131, P1420, DOI 10.1038/jid.2011.56; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339; KRISHNA CM, 1992, ARCH BIOCHEM BIOPHYS, V294, P98, DOI 10.1016/0003-9861(92)90142-J; Krishnan KJ, 2006, J INVEST DERMATOL, V126, P408, DOI 10.1038/sj.jid.5700099; Krishnan KJ, 2004, J INVEST DERMATOL, V123, P1020, DOI 10.1111/j.0022-202X.2004.23457.x; Kruszewski M, 2003, MUTAT RES-FUND MOL M, V531, P81, DOI 10.1016/j.mrfmmm.2003.08.004; Li Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030186, 10.1371/journal.pone.0029003, 10.1371/journal.pone.0042558, 10.1371/journal.pone.0030835, 10.1371/journal.pone.0044441, 10.1371/journal.pone.0035543, 10.1371/journal.pone.0035122]; Liu Y, 2011, EUR J PHARMACOL, V650, P130, DOI 10.1016/j.ejphar.2010.10.009; Lloyd J. J., 2006, ULTRAVIOLET RAD MED, V6; Ma YS, 2009, BBA-GEN SUBJECTS, V1790, P1021, DOI 10.1016/j.bbagen.2009.04.012; Marrot L, 2008, PIGM CELL MELANOMA R, V21, P79, DOI 10.1111/j.1755-148X.2007.00424.x; McArdle F, 2005, FREE RADICAL BIO MED, V39, P651, DOI 10.1016/j.freeradbiomed.2005.04.010; McKinlay AF., 1987, CIE J, P83; Meewes C, 2001, FREE RADICAL BIO MED, V30, P238, DOI 10.1016/S0891-5849(00)00463-9; Morley N, 2005, PHOTODERMATOL PHOTO, V21, P15, DOI 10.1111/j.1600-0781.2005.00119.x; Morley N, 2003, J PHOTOCH PHOTOBIO B, V72, P55, DOI 10.1016/j.jphotobiol.2003.06.004; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Offord EA, 2002, FREE RADICAL BIO MED, V32, P1293, DOI 10.1016/S0891-5849(02)00831-6; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Passos JF, 2007, PLOS BIOL, V5, P1138, DOI 10.1371/journal.pbio.0050110; Pourzand C, 1999, P NATL ACAD SCI USA, V96, P6751, DOI 10.1073/pnas.96.12.6751; Pygmalion MJ, 2010, FREE RADICAL BIO MED, V49, P1629, DOI 10.1016/j.freeradbiomed.2010.08.009; Rizwan M, 2011, BRIT J DERMATOL, V164, P154, DOI 10.1111/j.1365-2133.2010.10057.x; Sakurai H, 2005, PHOTOCH PHOTOBIO SCI, V4, P715, DOI 10.1039/b417319h; Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019; Silveira LR, 2003, FREE RADICAL BIO MED, V35, P455, DOI 10.1016/S0891-5849(03)00271-5; Sood A, 2011, NAT NANOTECHNOL, V6, P824, DOI [10.1038/nnano.2011.188, 10.1038/NNANO.2011.188]; Stewart MS, 1996, J INVEST DERMATOL, V106, P1086, DOI 10.1111/1523-1747.ep12339344; Supinski G, 1999, J APPL PHYSIOL, V87, P2177, DOI 10.1152/jappl.1999.87.6.2177; Swalwell H, 2012, FREE RADICAL BIO MED, V52, P626, DOI 10.1016/j.freeradbiomed.2011.11.019; Talalay P, 2007, P NATL ACAD SCI USA, V104, P17500, DOI 10.1073/pnas.0708710104; Tobi SE, 2002, INT J CANCER, V102, P439, DOI 10.1002/ijc.10730; Tulah AS, 2013, MITOCHONDRION, V13, P444, DOI 10.1016/j.mito.2012.11.007; Ungvari Z, 2010, AM J PHYSIOL-HEART C, V299, pH18, DOI 10.1152/ajpheart.00260.2010; Wang N, 2012, DIGEST DIS SCI, V57, P1792, DOI 10.1007/s10620-012-2094-7; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yarian CS, 2006, MECH AGEING DEV, V127, P79, DOI 10.1016/j.mad.2005.09.028; Yiakouvaki A, 2006, J INVEST DERMATOL, V126, P2287, DOI 10.1038/sj.jid.5700373; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zhong JL, 2004, J INVEST DERMATOL, V123, P771, DOI 10.1111/j.0022-202X.2004.23419.x; Zhong JL, 2010, PHOTOCH PHOTOBIO SCI, V9, P18, DOI 10.1039/b9pp00068b	73	58	60	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					485	494		10.1096/fj.13-237008	http://dx.doi.org/10.1096/fj.13-237008			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24115050				2022-12-28	WOS:000333526100045
J	Sosa, LJ; Postma, NL; Estrada-Bernal, A; Hanna, M; Guo, R; Busciglio, J; Pfenninger, KH				Sosa, Lucas J.; Postma, Nienke L.; Estrada-Bernal, Adriana; Hanna, M.; Guo, R.; Busciglio, Jorge; Pfenninger, Karl H.			Dosage of amyloid precursor protein affects axonal contact guidance in Down syndrome	FASEB JOURNAL			English	Article						brain development; neurodevelopmental disorders	ALZHEIMERS-DISEASE; MOUSE MODEL; NEURITE OUTGROWTH; GROWTH CONES; RAT-BRAIN; INTERFERENCE REFLECTION; EXPRESSION PATTERN; MESSENGER-RNA; APP-BINDING; IN-VITRO	Amyloid precursor protein (APP), encoded on Hsa21, functions as a cell adhesion molecule (CAM) in axonal growth cones (GCs) of the developing brain. We show here that axonal GCs of human fetal Down syndrome (DS) neurons (and of a DS mouse model) overexpress APP protein relative to euploid controls. We investigated whether DS neurons generate an abnormal, APP-dependent GC phenotype in vitro. On laminin, which binds APP and 1 integrins (Itgb1), DS neurons formed enlarged and faster-advancing GCs compared to controls. On peptide matrices that bind APP only, but not on those binding exclusively Itgb1 or L1CAM, DS GCs were significantly enlarged (2.0-fold), formed increased close adhesions (1.8-fold), and advanced faster (1.4-fold). In assays involving alternating stripes of monospecific matrices, human control GCs exhibited no preference for any of the substrates, whereas DS GCs preferred the APP-binding matrix (cross-over decreased significantly from 48.2 to 27.2%). Reducing APP expression in DS GCs with siRNA normalized most measures of the phenotype, including substrate choice. These experiments show that human DS neurons exhibit an APP-dependent, abnormal GC phenotype characterized by increased adhesion and altered contact guidance. The results suggest that APP overexpression may perturb axonal pathfinding and circuit formation in developing DS brain.Sosa, L. J., Postma, N. L., Estrada-Bernal, A., Hanna, M., Guo, R., Busciglio, J., Pfenninger, K. H. Dosage of amyloid precursor protein affects axonal contact guidance in Down syndrome.	[Sosa, Lucas J.; Postma, Nienke L.; Estrada-Bernal, Adriana; Pfenninger, Karl H.] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA; [Sosa, Lucas J.; Postma, Nienke L.; Estrada-Bernal, Adriana; Pfenninger, Karl H.] Univ Colorado, Sch Med, Colorado Intellectual & Dev Disabil Res Ctr, Aurora, CO 80045 USA; [Guo, R.] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA; [Hanna, M.; Busciglio, Jorge] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA USA; [Hanna, M.; Busciglio, Jorge] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California Irvine; University of California System; University of California Irvine	Pfenninger, KH (corresponding author), Univ Colorado, Dept Pediat, Mailbox 8313,12800 E 19th Ave, Aurora, CO 80045 USA.	karl.pfenninger@ucdenver.edu		Sosa, Lucas/0000-0002-9153-7537	U.S. National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke [R01 NS061940]; Anna and John J. Sie Foundation (Denver, CO, USA); Linda Crnic Institute for Down Syndrome (Denver, CO, USA); Colorado Children's Hospital Research Institute (Aurora, CO, USA); NIH/National Institute of Child Health and Human Development [R01 HD38466]; University of California-Irvine Alzheimer's Disease Research Center [NIH AG16573, 2]; NIH/National Center for Advancing Translational Sciences Colorado Clinical Translation and Science Institute [UL1 TR000154]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038466] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG016573] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke; Anna and John J. Sie Foundation (Denver, CO, USA); Linda Crnic Institute for Down Syndrome (Denver, CO, USA); Colorado Children's Hospital Research Institute (Aurora, CO, USA); NIH/National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); University of California-Irvine Alzheimer's Disease Research Center; NIH/National Center for Advancing Translational Sciences Colorado Clinical Translation and Science Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Katheleen Gardiner for reviewing the manuscript and for many helpful discussions; Drs. Ken Maclean and Hua Jiang for their assistance with breeding and genotyping Ts65Dn mice; Dr. Martin Grumet (Rutgers W. M. Keck Center for Collaborative Neuroscience, Piscataway, NJ, USA) for the generous gift of eL1 recombinant protein; and Carmel Harberg for excellent assistance with the preparation of the manuscript. This research was supported by grants from the U.S. National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (R01 NS061940), the Anna and John J. Sie Foundation (Denver, CO, USA), the Linda Crnic Institute for Down Syndrome (Denver, CO, USA), and the Colorado Children's Hospital Research Institute (Aurora, CO, USA) to K. H. P.; NIH/National Institute of Child Health and Human Development (R01 HD38466) and University of California-Irvine Alzheimer's Disease Research Center (NIH AG16573, Project 2) to J. B.; and NIH/National Center for Advancing Translational Sciences Colorado Clinical Translation and Science Institute (UL1 TR000154). Contents are the authors' sole responsibility and do not necessarily represent official NIH views.	ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; ARAI H, 1994, BRAIN RES, V642, P132, DOI 10.1016/0006-8993(94)90914-8; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Caceres J, 1997, J CELL BIOCHEM, V65, P145, DOI 10.1002/(SICI)1097-4644(199705)65:2<145::AID-JCB2>3.0.CO;2-U; Cataldo AM, 2003, J NEUROSCI, V23, P6788; CLARRIS HJ, 1995, DEV BRAIN RES, V88, P87, DOI 10.1016/0165-3806(95)00083-P; Coulson EJ, 1997, BRAIN RES, V770, P72, DOI 10.1016/S0006-8993(97)00757-9; CURTIS ASG, 1964, J CELL BIOL, V20, P199, DOI 10.1083/jcb.20.2.199; Davisson M T, 1993, Prog Clin Biol Res, V384, P117; De Strooper B, 2000, J CELL SCI, V113, P1857; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; Edelstein A., 2010, CURR PROTOC MOL BIOL, P20, DOI [DOI 10.1002/0471142727.MB1420S92, 10.1002/0471142727.mb1420s92]; Engidawork E, 2001, AMINO ACIDS, V21, P331, DOI 10.1007/s007260170001; Griffin WST, 1998, NEUROBIOL AGING, V19, P401, DOI 10.1016/S0197-4580(98)00074-8; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haspel J, 2000, J NEUROBIOL, V42, P287, DOI 10.1002/(SICI)1097-4695(20000215)42:3<287::AID-NEU1>3.3.CO;2-O; Haydar TF, 2012, TRENDS NEUROSCI, V35, P81, DOI 10.1016/j.tins.2011.11.001; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hoe HS, 2009, J NEUROSCI, V29, P7459, DOI 10.1523/JNEUROSCI.4872-08.2009; Hunter CL, 2003, NEUROSCI RES, V45, P437, DOI 10.1016/S0168-0102(03)00005-1; IZZARD CS, 1976, J CELL SCI, V21, P129; KIBBEY MC, 1993, P NATL ACAD SCI USA, V90, P10150, DOI 10.1073/pnas.90.21.10150; Kim JM, 2005, EXP CELL RES, V304, P317, DOI 10.1016/j.yexcr.2004.11.009; Kirazov E, 2001, INT J DEV NEUROSCI, V19, P287, DOI 10.1016/S0736-5748(01)00012-0; Knoll B, 2007, NAT PROTOC, V2, P1216, DOI 10.1038/nprot.2007.157; Korte M, 2012, EXP BRAIN RES, V217, P435, DOI 10.1007/s00221-011-2894-6; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; LEMMON V, 1992, J NEUROSCI, V12, P818; Limozin L, 2009, CHEMPHYSCHEM, V10, P2752, DOI 10.1002/cphc.200900601; Lohse K, 1996, DEV BRAIN RES, V96, P83, DOI 10.1016/0165-3806(96)00076-4; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; Neve RL, 1996, MOL BRAIN RES, V39, P185, DOI 10.1016/0169-328X(96)00007-1; Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265; O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; PFENNINGER KH, 1981, J CELL BIOL, V89, P547, DOI 10.1083/jcb.89.3.547; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Rahman A.S., 2010, JOVE-J VIS EXP, P2384; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; Rice HC, 2013, BIOCHEMISTRY-US, V52, P3264, DOI 10.1021/bi400165f; Roberson ED, 2006, SCIENCE, V314, P781, DOI 10.1126/science.1132813; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; SALBAUM JM, 1994, J EXP ZOOL, V269, P116, DOI 10.1002/jez.1402690205; Salehi A, 2006, NEURON, V51, P29, DOI 10.1016/j.neuron.2006.05.022; SMALL DH, 1994, J NEUROSCI, V14, P2117; Song P., 2012, PLOS ONE, V7; Sosa LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064521; Spellman C, 2013, GENE, V512, P219, DOI 10.1016/j.gene.2012.10.051; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trazzi S, 2013, J BIOL CHEM, V288, P20817, DOI 10.1074/jbc.M113.451088; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VIELMETTER J, 1990, EXP BRAIN RES, V81, P283; Von Philipsborn AC, 2006, NAT PROTOC, V1, P1322, DOI 10.1038/nprot.2006.251; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007; Young-Pearse TL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-15	64	13	14	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					195	205		10.1096/fj.13-232686	http://dx.doi.org/10.1096/fj.13-232686			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24036883	Green Published, Green Submitted			2022-12-28	WOS:000333526100020
J	Weissmuller, T; Glover, LE; Fennimore, B; Curtis, VF; MacManus, CF; Ehrentraut, SF; Campbell, EL; Scully, M; Grove, BD; Colgan, SP				Weissmueller, Thomas; Glover, Louise E.; Fennimore, Blair; Curtis, Valerie F.; MacManus, Christopher F.; Ehrentraut, Stefan F.; Campbell, Eric L.; Scully, Melanie; Grove, Bryon D.; Colgan, Sean P.			HIF-dependent regulation of AKAP12 ( gravin) in the control of human vascular endothelial function	FASEB JOURNAL			English	Article						hypoxia-inducible factor; permeability; barrier function; angiogenesis	PROTEIN-KINASE-A; SIGNALING PATHWAYS; BARRIER FUNCTION; HYPOXIA; INDUCTION; ADENOSINE; ANGIOGENESIS; SSECKS/GRAVIN/AKAP12; INFLAMMATION; SUPPRESSION	Hypoxia has been widely implicated in many pathological conditions, including those associated with inflammation and tumorigenesis. A number of recent studies have implicated hypoxia in the control of vasculogenesis and permeability, the basis for which is not fully understood. Here we examine the transcriptional regulation of angiogenesis and permeability by hypoxia in endothelial cells. Guided by a global profiling approach in cultured endothelial cells, these studies revealed the selective induction of human gravin (protein kinase A anchoring protein 12) by hypoxia. Analysis of the cloned gravin promoter identified a functional hypoxia-responsive region including 2 binding sites for hypoxia-inducible factor (HIF). Site-directed mutagenesis identified the most distal HIF-binding site as essential for the induction of gravin by hypoxia. Further studies examining gravin gain and loss of function confirmed strong dependence of gravin in control of microvascular endothelial tube formation, wherein gravin functions as a braking system for angiogenesis. Additional studies in confluent endothelia revealed that gravin functionally couples to control endothelial barrier function in response to protein kinase A (PKA) agonists. Taken together, these results demonstrate transcriptional coordination of gravin by HIF-1 and amplified PKA-dependent endothelial responses. These findings provide an important link between hypoxia and metabolic conditions associated with inflammation and angiogenesis.Weissmuller, T., Glover, L. E., Fennimore, B., Curtis, V. F., MacManus, C. F., Ehrentraut, S. F., Campbell, E. L., Scully, M., Grove, B. D., Colgan, S. P. HIF-dependent regulation of AKAP12 (gravin) in the control of human vascular endothelial function.	[Weissmueller, Thomas; Glover, Louise E.; Fennimore, Blair; Curtis, Valerie F.; MacManus, Christopher F.; Ehrentraut, Stefan F.; Campbell, Eric L.; Scully, Melanie; Colgan, Sean P.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA; [Weissmueller, Thomas; Glover, Louise E.; Fennimore, Blair; Curtis, Valerie F.; MacManus, Christopher F.; Ehrentraut, Stefan F.; Campbell, Eric L.; Scully, Melanie; Colgan, Sean P.] Univ Colorado, Sch Med, Dept Immunol, Aurora, CO 80045 USA; [Weissmueller, Thomas; Glover, Louise E.; Fennimore, Blair; Curtis, Valerie F.; MacManus, Christopher F.; Ehrentraut, Stefan F.; Campbell, Eric L.; Scully, Melanie; Colgan, Sean P.] Univ Colorado, Sch Med, Mucosal Inflammat Program, Aurora, CO 80045 USA; [Weissmueller, Thomas] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Ehrentraut, Stefan F.] Univ Bonn, Dept Anesthesiol, Bonn, Germany; [Grove, Bryon D.] Univ N Dakota, Dept Anat & Cell Biol, Grand Forks, ND 58201 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Bonn; University of North Dakota Grand Forks	Colgan, SP (corresponding author), Univ Colorado, Mucosal Inflammat Program, 12700 E 19th Ave, Aurora, CO 80045 USA.	sean.colgan@ucdenver.edu	Campbell, Eric/N-5357-2015	Campbell, Eric/0000-0003-0744-6577; Ehrentraut, Stefan/0000-0001-5747-6737; Glover, Louise/0000-0001-9056-1810	U.S. National Institutes of Health [HL60569, DK50189, DK095491]; Crohn's and Colitis Foundation of America; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050189, R01DK050189, T32DK007038, R01DK095491, R37DK050189] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants HL60569, DK50189, and DK095491 and by funding from the Crohn's and Colitis Foundation of America. The authors declare no conflicts of interest.	Choi YK, 2007, J NEUROSCI, V27, P4472, DOI 10.1523/JNEUROSCI.5368-06.2007; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Colgan SP, 2012, ANNU REV PHYSIOL, V74, P153, DOI 10.1146/annurev-physiol-020911-153230; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Comerford KM, 2002, FASEB J, V16, P583, DOI 10.1096/fj.01-0739fje; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; Dormond O, 2003, THROMB HAEMOSTASIS, V90, P577, DOI 10.1160/TH03-03-0196; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Feoktistov I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.a5; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Gelman IH, 2012, CANCER METAST REV, V31, P493, DOI 10.1007/s10555-012-9360-1; Gelman Irwin H, 2010, Genes Cancer, V1, P1147, DOI 10.1177/1947601910392984; Glover LE, 2011, GASTROENTEROLOGY, V140, P1748, DOI 10.1053/j.gastro.2011.01.056; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hu JM, 2011, MOL CANCER RES, V9, P1520, DOI 10.1158/1541-7786.MCR-11-0090; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Kominsky DJ, 2010, J IMMUNOL, V184, P4062, DOI 10.4049/jimmunol.0903002; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Kwon HB, 2012, EXP MOL MED, V44, P225, DOI 10.3858/emm.2012.44.3.017; Lee HS, 2009, FEBS J, V276, P4622, DOI 10.1111/j.1742-4658.2009.07174.x; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Liu YZ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-105; Louis NA, 2005, FASEB J, V19, P950, DOI 10.1096/fj.04-3251com; MacManus CF, 2011, FASEB J, V25, P1856, DOI 10.1096/fj.10-170316; Ochoa CD, 2012, AM J PHYSIOL-LUNG C, V302, pL275, DOI [10.1152/ajplung.00215.2011., 10.1152/ajplung.00215.2011]; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL., 2011, COLD SPRING HARB SYM, V2011, P22; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; Thamotharan S, 2013, AM J PHYSIOL-ENDOC M, V304, pE583, DOI 10.1152/ajpendo.00513.2012; Troger J, 2012, BRIT J PHARMACOL, V166, P420, DOI 10.1111/j.1476-5381.2011.01796.x; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129; Yan XH, 2009, EXP CELL RES, V315, P1247, DOI 10.1016/j.yexcr.2008.12.026; You QH, 2010, INFLAMM RES, V59, P949, DOI 10.1007/s00011-010-0207-3; You QH, 2010, J SURG RES, V162, P110, DOI 10.1016/j.jss.2009.01.019; Zan LK, 2011, NEUROCHEM INT, V58, P872, DOI 10.1016/j.neuint.2011.02.014	38	16	16	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					256	264		10.1096/fj.13-238741	http://dx.doi.org/10.1096/fj.13-238741			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24029533	Green Published			2022-12-28	WOS:000333526100025
J	Neufeld, EF				Neufeld, Elizabeth F.			Unexpected Observations-A Tribute to Christian de Duve (1917-2013)	FASEB JOURNAL			English	Biographical-Item									Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Neufeld, EF (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, BSRB 310,615 Charles E Young Dr South, Los Angeles, CA 90095 USA.	eneufeld@mednet.ucla.edu							0	0	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4661	4663		10.1096/fj.13-1201ufm	http://dx.doi.org/10.1096/fj.13-1201ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24298016				2022-12-28	WOS:000329999000001
J	Roh, SE; Woo, JA; Lakshmana, MK; Uhlar, C; Ankala, V; Boggess, T; Liu, T; Hong, YH; Mook-Jung, I; Kim, SJ; Kang, DE				Roh, Seung-Eon; Woo, Jung A.; Lakshmana, Madepalli K.; Uhlar, Courtney; Ankala, Vinishaa; Boggess, Taylor; Liu, Tian; Hong, Yun-Hwa; Mook-Jung, Inhee; Kim, Sang Jeong; Kang, David E.			Mitochondrial dysfunction and calcium deregulation by the RanBP9-cofilin pathway	FASEB JOURNAL			English	Article						synapse; axonal transport; amyloid; MTT	AMYLOID PRECURSOR PROTEIN; BETA-INDUCED APOPTOSIS; ALZHEIMERS-DISEASE; CORTICAL-NEURONS; OXIDATIVE DAMAGE; PIVOTAL ROLE; MOUSE MODEL; CELL-DEATH; RANBP9; ACTIN	Mitochondrial dysfunction and synaptic damage are important features of Alzheimer's disease (AD) associated with amyloid beta (A beta) and tau. We reported previously that the scaffolding protein RanBP9, which is overall increased in brains of patients with AD and in mutant APP transgenic mice, simultaneously promotes A beta generation and focal adhesion disruption by accelerating the endocytosis of APP and beta 1-integrin, respectively. Moreover, RanBP9 induces neurodegeneration in vitro and in vivo and mediates A beta-induced neurotoxicity. Here we show in primary hippocampal neurons that RanBP9 potentiates A beta-induced reactive oxygen species (ROS) overproduction, apoptosis, and calcium deregulation. Analyses of calcium-handling measures demonstrate that RanBP9 selectively delays the clearance of cytosolic Ca2+ mediated by the mitochondrial calcium uniporter through a process involving the translocation of cofilin into mitochondria and oxidative mechanisms. Further, RanBP9 retards the anterograde axonal transport of mitochondria in primary neurons and decreases synaptic mitochondrial activity in brain. These data indicate that RanBP9, cofilin, and A beta mimic and potentiate each other to produce mitochondrial dysfunction, ROS overproduction, and calcium deregulation, which leads to neurodegenerative changes reminiscent of those seen in AD.	[Roh, Seung-Eon; Woo, Jung A.; Liu, Tian; Mook-Jung, Inhee; Kang, David E.] Seoul Natl Univ, Coll Med, World Class Univ Neurocyt Program, Seoul, South Korea; [Roh, Seung-Eon; Hong, Yun-Hwa; Kim, Sang Jeong] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul, South Korea; [Lakshmana, Madepalli K.] Torrey Pines Inst Mol Studies, Neurobiol Sect, Port St Lucie, FL USA; [Uhlar, Courtney; Ankala, Vinishaa; Boggess, Taylor; Kang, David E.] Univ S Florida, Dept Mol Med, Hlth Byrd Alzheimers Inst, Tampa, FL USA	Seoul National University (SNU); Seoul National University (SNU); Torrey Pines Institute for Molecular Studies, Florida; State University System of Florida; University of South Florida	Kang, DE (corresponding author), USF Hlth Byrd Inst, Dept Mol Med, 4001 E Fletcher Ave, Tampa, FL 33613 USA.	dkang@health.usf.edu	Liu, Tian/M-8684-2016; Kang, David E./E-5234-2012	Liu, Tian/0000-0003-3639-7321; Woo, Jung A/0000-0002-9194-1361; Kang, David E./0000-0002-7132-821X; Liu, Tian/0000-0002-6437-8892; Kim, Sang Jeong/0000-0001-8931-3713	U.S. National Institutes of Health/National Institute on Aging [1R01AG033055, 1K02AG031920]; World Class University-Neurocytomics Project from National Research Foundation of Korea (NRF-K); NRF-K [2011-0030737]; NATIONAL INSTITUTE ON AGING [R01AG033055, K02AG031920] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); World Class University-Neurocytomics Project from National Research Foundation of Korea (NRF-K); NRF-K; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Elisabetta Bianchi (Pasteur Institute, Paris, France) for the RanBP9 monoclonal antibody and Dr. Won Kyung Ho (Seoul National University, Seoul, Korea) for helpful discussions. This work was supported in part by U.S. National Institutes of Health/National Institute on Aging grants (1R01AG033055 and 1K02AG031920, D. E. K.), a World Class University-Neurocytomics Project grant from the National Research Foundation of Korea (NRF-K; D. E. K., I.M.-J.), and an NRF-K grant (S.J.K., 2011-0030737). The authors declare no conflicts of interest.	Berkova Z, 2003, CELL CALCIUM, V34, P55, DOI 10.1016/S0143-4160(03)00022-8; Bernstein BW, 2006, AM J PHYSIOL-CELL PH, V291, pC828, DOI 10.1152/ajpcell.00066.2006; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Bertrand SJ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-38; Bezprozvanny I, 2009, TRENDS MOL MED, V15, P89, DOI 10.1016/j.molmed.2009.01.001; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Brown M, 2009, MOD LANG QUART, V70, P1, DOI 10.1215/00267929-2008-025; Calkins MJ, 2011, BBA-MOL BASIS DIS, V1812, P507, DOI 10.1016/j.bbadis.2011.01.007; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Cichon J, 2012, J BIOL CHEM, V287, P3919, DOI 10.1074/jbc.M111.301911; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Davis RC, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-10; Distelmaier F, 2009, J MOL MED, V87, P515, DOI 10.1007/s00109-009-0452-5; Du H, 2010, P NATL ACAD SCI USA, V107, P18670, DOI 10.1073/pnas.1006586107; Eckert A, 2008, NEURODEGENER DIS, V5, P157, DOI 10.1159/000113689; GOODMAN Y, 1994, BRAIN RES, V654, P171, DOI 10.1016/0006-8993(94)91586-5; Gourlay CW, 2005, BIOCHEM SOC T, V33, P1260, DOI 10.1042/BST0331260; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Kang David E, 2011, Exp Neurobiol, V20, P67, DOI 10.5607/en.2011.20.2.67; Klamt F, 2009, NAT CELL BIOL, V11, P1241, DOI 10.1038/ncb1968; Kramer S, 2005, ONCOGENE, V24, P938, DOI 10.1038/sj.onc.1208257; Lakshmana MK, 2012, FASEB J, V26, P2072, DOI 10.1096/fj.11-196709; Lakshmana MK, 2010, FASEB J, V24, P119, DOI 10.1096/fj.09-136457; Lakshmana MK, 2009, J BIOL CHEM, V284, P11863, DOI 10.1074/jbc.M807345200; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Lee SH, 2012, J NEUROSCI, V32, P5953, DOI 10.1523/JNEUROSCI.0465-12.2012; Li YF, 2006, J BIOENERG BIOMEMBR, V38, P283, DOI 10.1007/s10863-006-9052-z; Liu T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.203; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; Moreira PI, 2001, BIOSCIENCE REP, V21, P789, DOI 10.1023/A:1015536808304; Nilsen J, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-74; Numakawa Y, 2006, J NEUROCHEM, V97, P1191, DOI 10.1111/j.1471-4159.2006.03827.x; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Palavicini JP, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.183; Pratico D, 2001, LIPIDS, V36, pS45, DOI 10.1007/s11745-001-0681-0; Salgo MG, 1996, ARCH BIOCHEM BIOPHYS, V333, P482, DOI 10.1006/abbi.1996.0418; Toescu EC, 2007, AGING CELL, V6, P265, DOI 10.1111/j.1474-9726.2007.00299.x; Wabnitz GH, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.36; Woo JA, 2012, CELL DEATH DIFFER, V19, P1413, DOI 10.1038/cdd.2012.14; Woo JA, 2012, FASEB J, V26, P1672, DOI 10.1096/fj.11-194423; Yan SD, 2005, INT J EXP PATHOL, V86, P161, DOI 10.1111/j.0959-9673.2005.00427.x; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106	44	25	25	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4776	4789		10.1096/fj.13-234765	http://dx.doi.org/10.1096/fj.13-234765			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23982146	Green Published			2022-12-28	WOS:000329999000013
J	Zhou, L; Zhao, XD; Han, YA; Lu, YY; Shang, YL; Liu, CH; Li, T; Jin, ZA; Fan, DM; Wu, KC				Zhou, Lin; Zhao, Xiaodi; Han, Yanan; Lu, Yuanyuan; Shang, Yulong; Liu, Changhao; Li, Ting; Jin, Zhian; Fan, Daiming; Wu, Kaichun			Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis	FASEB JOURNAL			English	Article						DNA methylation; metastasis	TUMOR-SUPPRESSOR; DNA METHYLATION; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; CELL-PROLIFERATION; CERVICAL-CANCER; DOWN-REGULATION; GENE; MICRORNAS; RUNX3	Epigenetic changes play significant roles in the development of cancer. UHRF1, as an epigenetic regulator, has been shown to be overexpressed and to coordinate tumor suppressor gene silencing in several cancers. However, the role and underlying mechanism of UHRF1 in gastric cancer (GC) progression remain largely unknown. In this study, we investigated the expression and function of UHRF1 in GC metastasis and explored its upstream regulatory mechanisms at the microRNA level. UHRF1 was overexpressed in GC tissues, especially in metastatic ones, and a high level of UHRF1 expression predicted poor survival. The down-regulation of UHRF1 suppressed GC invasion and metastasis in vitro and in vivo. We identified and verified miR-146a and miR-146b as direct upstream regulators of UHRF1. Furthermore, the restoration of miR-146a/b dramatically reduced the expression of UHRF1 through the direct targeting of its 3'-UTR, and this effect in turn reactivated the slit homologue 3 (Slit3), cadherin 4 (CDH4), and runt-related transcription factor 3 (RUNX3) genes via promoter demethylation. Finally, analyses of miR-146a/b and UHRF1 levels in human GC tissues revealed that miR-146a/b correlated inversely with UHRF1 expression. These findings describe a new mechanism for the regulation of UHRF1 and aberrant DNA hypermethylation in GC. The newly identified miR-146a/b/UHRF1 axis provides insight into the GC metastasis process, and targeting this novel axis represents a therapeutic approach to blocking GC metastasis.	Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China; Fourth Mil Med Univ, Xijing Hosp, Xijing Hosp Digest Dis, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Fan, DM (corresponding author), Xijing Hosp Digest Dis, State Key Lab Canc Biol, West Changle Rd, Xian 710032, Peoples R China.	daimingfan@fmmu.edu.cn; kaicwu@fmmu.edu.cn	liu, chang/HCI-5413-2022		National Natural Science Foundation of China [81272652, 81172290, 91129723, 81090270, 81090273, 81120108005]; National Key and Basic Research Development Program of China [2010CB529302, 2010CB529306]; National Municipal Science and Technology Project [2009ZX09103-667, 2009ZX09301-009-RC06]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key and Basic Research Development Program of China(National Basic Research Program of China); National Municipal Science and Technology Project	This study was supported by combined grants from the National Natural Science Foundation of China (81272652, 81172290, 91129723, 81090270, 81090273, and 81120108005), the National Key and Basic Research Development Program of China (2010CB529302 and 2010CB529306), and the National Municipal Science and Technology Project (2009ZX09103-667 and 2009ZX09301-009-RC06). The authors thank Zheng Chen, Guangbo Tang, Jianhua Dou, and Gui Ren (State Key Laboratory of Cancer Biology) for assistance in tissue sample collection. The authors report no conflicts of interest.	Alhosin M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-41; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bai FH, 2007, DIGEST DIS SCI, V52, P1571, DOI 10.1007/s10620-006-9570-x; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Chen Y, 2011, INT J CANCER, V129, P1586, DOI 10.1002/ijc.25831; Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009; Crnogorac-Jurcevic T, 2005, GASTROENTEROLOGY, V129, P1454, DOI 10.1053/j.gastro.2005.08.012; Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531; Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222; Du CP, 2011, CANCER LETT, V309, P54, DOI 10.1016/j.canlet.2011.05.016; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Gao DC, 2012, CANCER RES, V72, P4883, DOI 10.1158/0008-5472.CAN-12-1223; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gigek CO, 2012, EPIGENOMICS-UK, V4, P279, DOI [10.2217/EPI.12.22, 10.2217/epi.12.22]; Gonzalez CA, 2012, INT J CANCER, V130, P745, DOI 10.1002/ijc.26430; Hayashi Y., 2012, GUT; He LJ, 2009, CANCER LETT, V276, P88, DOI 10.1016/j.canlet.2008.10.044; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Hou ZB, 2012, MOL MED REP, V6, P501, DOI 10.3892/mmr.2012.946; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660; Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kogo R, 2011, CLIN CANCER RES, V17, P4277, DOI 10.1158/1078-0432.CCR-10-2866; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Li Q, 2011, EPIGENETICS-US, V6, P849, DOI 10.4161/epi.6.7.16314; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354; Lu XX, 2012, CANCER-AM CANCER SOC, V118, P5507, DOI 10.1002/cncr.27604; Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Osada H, 2007, CARCINOGENESIS, V28, P2, DOI 10.1093/carcin/bgl185; Packeisen J, 2002, J CLIN PATHOL, V55, P613, DOI 10.1136/jcp.55.8.613; Paik JH, 2011, CLIN CANCER RES, V17, P4761, DOI 10.1158/1078-0432.CCR-11-0494; Patnaik SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022379; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Tian RQ, 2011, J BIOL CHEM, V286, P25556, DOI 10.1074/jbc.M111.221564; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Unoki M, 2010, BRIT J CANCER, V103, P217, DOI 10.1038/sj.bjc.6605717; Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1; Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081; Wong KY, 2012, CARCINOGENESIS, V33, P1629, DOI 10.1093/carcin/bgs212; Xiao B, 2012, ONCOL REP, V27, P559, DOI 10.3892/or.2011.1514; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156	56	81	91	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4929	4939		10.1096/fj.13-233387	http://dx.doi.org/10.1096/fj.13-233387			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23982143				2022-12-28	WOS:000329999000027
J	van Diepen, HC; Ramkisoensing, A; Peirson, SN; Foster, RG; Meijer, JH				van Diepen, Hester C.; Ramkisoensing, Ashna; Peirson, Stuart N.; Foster, Russell G.; Meijer, Johanna H.			Irradiance encoding in the suprachiasmatic nuclei by rod and cone photoreceptors	FASEB JOURNAL			English	Article						circadian; melanopsin; light; electrophysiology	RETINAL GANGLION-CELLS; CIRCADIAN RESPONSES; LIGHT; MELANOPSIN; RAT; ILLUMINATION; NEURONS; BIPOLAR	Light information is transmitted to the central clock of the suprachiasmatic nuclei (SCN) for daily synchronization to the external solar cycle. Essential for synchronization is the capacity of SCN neurons to respond in a sustained and irradiance-dependent manner to light. Melanopsin has been considered to mediate this photosensory task of irradiance detection. By contrast, the contribution of the classical photoreceptors in irradiance encoding is less clear. Here we investigate the role of classical photoreceptors by in vivo electrophysiological responses in freely moving animals to specific wavelengths of light (UV, (max) 365 nm; blue, (max) 467 nm; and green, (max) 505 nm) in both melanopsin-deficient (Opn4(-/-)) mice and mice lacking rods and cones (rd/rd cl). Short- and long-wavelength light induced sustained irradiance-dependent responses in congenic wild-type mice (+19.6%). Unexpectedly, sustained responses to light persisted in Opn4(-/-) mice (+18.4%). These results provide unambiguous evidence that classical photoreceptors can transmit irradiance information to the SCN. In addition, at light intensities that would stimulate rod and cone photoreceptors, the SCN of rd/rd cl mice showed greatly reduced sustained responses to light (+7.8%). Collectively, our data demonstrate a role for classical photoreceptors in illuminance detection by the SCN.van Diepen, H. C., Ramkisoensing, A., Peirson, S. N., Foster, R. G., Meijer, J. H. Irradiance encoding in the suprachiasmatic nuclei by rod and cone photoreceptors.	[van Diepen, Hester C.; Ramkisoensing, Ashna; Meijer, Johanna H.] Leiden Univ, Med Ctr, Neurophysiol Lab, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; [Peirson, Stuart N.; Foster, Russell G.] Univ Oxford, Nuffield Lab Ophthalmol, Nuffield Dept Clin Neurosci, John Radcliffe Hosp, Oxford OX3 9DU, England	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Oxford	Meijer, JH (corresponding author), Leiden Univ, Med Ctr, POB 9600 Mailbox S5-P, NL-2300 RC Leiden, Netherlands.	russell.foster@eye.ox.ac.uk; j.h.meijer@lumc.nl		FOSTER, RUSSELL/0000-0001-6055-2067	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Sanne Verhoeve, Peter Stouten, Jan Janse, Sander van Berloo, Simona di Pretoro, Fred de Boer, and Ben van der Geest for assistance and technical support. The work leading to this paper was supported by a grant to R.G.F., S.N.P., and J.H.M. from the Wellcome Trust.	Aggelopoulos NC, 2000, J PHYSIOL-LONDON, V523, P211, DOI 10.1111/j.1469-7793.2000.t01-1-00211.x; Allen AE, 2011, J NEUROSCI, V31, P16833, DOI 10.1523/JNEUROSCI.2505-11.2011; Altimus CM, 2010, NAT NEUROSCI, V13, P1107, DOI 10.1038/nn.2617; Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Brown TM, 2011, J PHYSIOL-LONDON, V589, P1173, DOI 10.1113/jphysiol.2010.199877; Dacey DM, 2005, NATURE, V433, P749, DOI 10.1038/nature03387; Dkhissi-Benyahya O, 2007, NEURON, V53, P677, DOI 10.1016/j.neuron.2007.02.005; Do MTH, 2009, NATURE, V457, P281, DOI 10.1038/nature07682; Dollet A, 2010, CHRONOBIOL INT, V27, P768, DOI 10.3109/07420521003695704; Drouyer E, 2007, J NEUROSCI, V27, P9623, DOI 10.1523/JNEUROSCI.1391-07.2007; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Gooley JJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000741; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; Lucas RJ, 1999, ENDOCRINOLOGY, V140, P1520, DOI 10.1210/en.140.4.1520; Lupi D, 2008, NAT NEUROSCI, V11, P1068, DOI 10.1038/nn.2179; MEIJER JH, 1990, J BIOL RHYTHM, V5, P1, DOI 10.1177/074873049000500101; Meijer JH, 1998, J NEUROSCI, V18, P9078; MEIJER JH, 1986, BRAIN RES, V382, P109, DOI 10.1016/0006-8993(86)90117-4; MOORE RY, 1995, J COMP NEUROL, V352, P351, DOI 10.1002/cne.903520304; Mure LS, 2007, J BIOL RHYTHM, V22, P411, DOI 10.1177/0748730407306043; Nakamura TJ, 2004, NEUROSCI LETT, V371, P244, DOI 10.1016/j.neulet.2004.09.005; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Pang JJ, 2004, J PHYSIOL-LONDON, V558, P897, DOI 10.1113/jphysiol.2003.059543; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Schmidt TM, 2010, J NEUROSCI, V30, P16262, DOI 10.1523/JNEUROSCI.3656-10.2010; Sekaran S, 2003, CURR BIOL, V13, P1290, DOI 10.1016/S0960-9822(03)00510-4; TERMAN JS, 1980, BEHAV BRAIN RES, V1, P507, DOI 10.1016/S0166-4328(80)80083-0; van Oosterhout F, 2012, CURR BIOL, V22, P1397, DOI 10.1016/j.cub.2012.05.032; Weng S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054625; Wong KY, 2007, J PHYSIOL-LONDON, V582, P279, DOI 10.1113/jphysiol.2007.133751; Wong KY, 2012, J NEUROSCI, V32, P11478, DOI 10.1523/JNEUROSCI.1423-12.2012	35	42	43	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4204	4212		10.1096/fj.13-233098	http://dx.doi.org/10.1096/fj.13-233098			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23796782				2022-12-28	WOS:000329747100031
J	Tetreault, P; Beaudet, N; Perron, A; Belleville, K; Rene, A; Cavelier, F; Martinez, J; Stroh, T; Jacobi, AM; Rose, SD; Behlke, MA; Sarret, P				Tetreault, Pascal; Beaudet, Nicolas; Perron, Amelie; Belleville, Karine; Rene, Adeline; Cavelier, Florine; Martinez, Jean; Stroh, Thomas; Jacobi, Ashley M.; Rose, Scott D.; Behlke, Mark A.; Sarret, Philippe			Spinal NTS2 receptor activation reverses signs of neuropathic pain	FASEB JOURNAL			English	Article						GPCR; allodynia; incapacitance; weight-bearing deficits	PERIPHERAL-NERVE INJURY; ROSTRAL VENTROMEDIAL MEDULLA; NEUROTENSIN RECEPTORS; ANIMAL-MODELS; TONIC PAIN; RAT MODEL; PHARMACOLOGICAL CHARACTERIZATION; BURROWING BEHAVIOR; HIGHLY POTENT; CANCER PAIN	Management of painful peripheral neuropathies remains challenging, since patients with chronic pain respond poorly to the available pharmacopeia. In recent years, the G-protein-coupled receptor neurotensin (NT) type 2 (NTS2) emerged as an attractive target for treating transitory pain states. To date, however, there is no evidence for its role in the regulation of chronic peripheral neuropathies. Here, we found that NTS2 receptors were largely localized to primary afferent fibers and superficial dorsal horns. Changes in the time course of the gene expression profile of NT, NTS1, and NTS2 were observed over a 28-d period following the sciatic nerve constriction [chronic constriction injury (CCI) model]. We next determined the effects of central delivery of selective-NTS2 agonists to CCI-treated rats on both mechanical allodynia (evoked withdrawal responses) and weight-bearing deficits (discomfort and quality-of-life proxies). The NTS2 analogs JMV431, levocabastine, and -lactotensin were all effective in reducing ongoing tactile allodynia in CCI-treated rats. Likewise, amitriptyline, pregabalin, and morphine significantly attenuated CCI-induced mechanical hypersensitivity. NTS2 agonists were also efficient in reversing weight-bearing and postural deficits caused by nerve damage, unlike reference analgesics currently used in the clinic. Thus, NTS2 agonists may offer new treatment avenues for limiting pain associated with peripheral neuropathies and improve functional rehabilitation and well-being.Tetreault, P., Beaudet, N., Perron, A., Belleville, K., Rene, A., Cavelier, F., Martinez, J., Stroh, T., Jacobi, A. M., Rose, S. D., Behlke, M. A., Sarret, P. Spinal NTS2 receptor activation reverses signs of neuropathic pain.	[Tetreault, Pascal; Beaudet, Nicolas; Belleville, Karine; Sarret, Philippe] Univ Sherbrooke, Dept Physiol & Biophys, Fac Med & Hlth Sci, Sherbrooke, PQ J1H 5N4, Canada; [Perron, Amelie] Kyoto Univ, Inst Integrated Cell Mat Sci, Kyoto, Japan; [Rene, Adeline; Cavelier, Florine; Martinez, Jean] Univ Montpellier I, Inst Biomol Max Mousseron, Unite Mixte Rech Ctr Natl Rech Sci UMR CNRS 5247, Montpellier, France; [Rene, Adeline; Cavelier, Florine; Martinez, Jean] Univ Montpellier 2, Inst Biomol Max Mousseron, Unite Mixte Rech Ctr Natl Rech Sci UMR CNRS 5247, Montpellier, France; [Stroh, Thomas] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; [Jacobi, Ashley M.; Rose, Scott D.; Behlke, Mark A.] Integrated DNA Technol Inc, Coralville, IA USA	University of Sherbrooke; Kyoto University; Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; McGill University	Sarret, P (corresponding author), Univ Sherbrooke, Dept Physiol & Biophys, Fac Med & Hlth Sci, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada.	philippe.sarret@usherbrooke.ca	Martinez, Jean/R-9421-2019; Tétreault, Pascal/O-2583-2019; Cavelier, Florine/C-5659-2011; Tétreault, Pascal/F-1584-2016	Martinez, Jean/0000-0002-9267-4621; Tétreault, Pascal/0000-0001-9061-0635; Cavelier, Florine/0000-0001-5308-6416; Tétreault, Pascal/0000-0001-9061-0635; Behlke, Mark/0000-0002-4218-857X; Sarret, Philippe/0000-0002-7627-701X; Beaudet, Nicolas/0000-0003-2349-2362	Canadian Institutes of Health Research (CIHR) [MOP-74618]; Canada Research Chair in Neurophysiopharmacology of Chronic Pain; Fonds de Recherche du Quebec en Sante (FRQS); FRQS	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Neurophysiopharmacology of Chronic Pain; Fonds de Recherche du Quebec en Sante (FRQS); FRQS	This work is supported by a grant from the Canadian Institutes of Health Research (CIHR; MOP-74618; awarded to P. S.). P. S. is recipient of the Canada Research Chair in Neurophysiopharmacology of Chronic Pain, director of the Sherbrooke Neuroscience Centre, and member of the Fonds de Recherche du Quebec en Sante (FRQS)-funded Centre de Recherche Clinique Etienne Lebel. P. T. holds a doctoral scholarship from the FRQS.	ALRODHAN NRF, 1991, BRAIN RES, V557, P227, DOI 10.1016/0006-8993(91)90139-M; Andrews N, 2012, EUR J PAIN, V16, P485, DOI 10.1016/j.ejpain.2011.07.012; Apkarian AV, 2009, PROG NEUROBIOL, V87, P81, DOI 10.1016/j.pneurobio.2008.09.018; Attal Nadine, 2012, Continuum (Minneap Minn), V18, P161, DOI 10.1212/01.CON.0000411564.41709.2d; Backonja MM, 2004, J PAIN, V5, P491, DOI 10.1016/j.jpain.2004.09.001; Baliki M, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-18; BEHBEHANI MM, 1984, BRAIN RES, V324, P35, DOI 10.1016/0006-8993(84)90619-X; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Berrocoso E, 2011, EUR J PHARMACOL, V655, P46, DOI 10.1016/j.ejphar.2011.01.022; Boules M, 2009, BRAIN RES, V1294, P22, DOI 10.1016/j.brainres.2009.07.086; Boules M, 2011, BEHAV PHARMACOL, V22, P573, DOI 10.1097/FBP.0b013e3283474a3a; Boules M, 2010, BRAIN RES, V1308, P35, DOI 10.1016/j.brainres.2009.10.050; Bredeloux P, 2008, J MED CHEM, V51, P1610, DOI 10.1021/jm700925k; Brocco M, 2002, PHARMACOL BIOCHEM BE, V71, P667, DOI 10.1016/S0091-3057(01)00701-8; Buhler AV, 2008, PAIN, V135, P280, DOI 10.1016/j.pain.2007.06.010; Buhler AV, 2005, PAIN, V114, P285, DOI 10.1016/j.pain.2004.12.031; CLINESCHMIDT BV, 1979, EUR J PHARMACOL, V54, P129, DOI 10.1016/0014-2999(79)90415-1; CLINESCHMIDT BV, 1977, EUR J PHARMACOL, V46, P395, DOI 10.1016/0014-2999(77)90236-9; Davoody L, 2011, J PAIN, V12, P868, DOI 10.1016/j.jpain.2011.01.010; de Leon-Casasola O, 2011, PAIN MED, V12, pS100, DOI 10.1111/j.1526-4637.2011.01160.x; de Leon-Casasola OA, 2013, AM J MED, V126, pS3, DOI 10.1016/j.amjmed.2012.11.011; De Vry J, 2004, EUR J PHARMACOL, V491, P137, DOI 10.1016/j.ejphar.2004.03.051; Devulder J, 2005, CURR MED RES OPIN, V21, P1555, DOI 10.1185/030079905X65321; Ding HK, 2005, J PAIN, V6, P411, DOI 10.1016/j.jpain.2005.01.361; Dobner PR, 2006, PEPTIDES, V27, P2405, DOI 10.1016/j.peptides.2006.04.025; Dore-Savard L, 2008, MOL THER, V16, P1331, DOI 10.1038/mt.2008.98; Dore-Savard L, 2013, CLIN EXP METASTAS, V30, P225, DOI 10.1007/s10585-012-9530-0; Dowdall T, 2005, PHARMACOL BIOCHEM BE, V80, P93, DOI 10.1016/j.pbb.2004.10.016; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; DUBUC I, 1992, EUR J PHARMACOL, V219, P327, DOI 10.1016/0014-2999(92)90314-T; Dubuc I, 1999, EUR J PHARMACOL, V381, P9, DOI 10.1016/S0014-2999(99)00554-3; Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649; Feifel D, 2010, NEUROPHARMACOLOGY, V58, P195, DOI 10.1016/j.neuropharm.2009.07.001; Finnerup NB, 2010, PAIN, V150, P573, DOI 10.1016/j.pain.2010.06.019; Gilron I, 2006, CAN MED ASSOC J, V175, P265, DOI 10.1503/cmaj.060146; Goss James R, 2007, Expert Rev Neurother, V7, P487, DOI 10.1586/14737175.7.5.487; Guillemette A, 2012, EUR J PAIN, V16, P473, DOI 10.1016/j.ejpain.2011.07.008; Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X; Hughes FM, 2010, J MED CHEM, V53, P4623, DOI 10.1021/jm100092s; Jaggi AS, 2011, FUND CLIN PHARMACOL, V25, P1, DOI 10.1111/j.1472-8206.2009.00801.x; Jirkof P, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00165; Johansen JP, 2001, P NATL ACAD SCI USA, V98, P8077, DOI 10.1073/pnas.141218998; Kennedy JD, 2007, J MED CHEM, V50, P2547, DOI 10.1021/jm061023c; King T, 2009, NAT NEUROSCI, V12, P1364, DOI 10.1038/nn.2407; Kissin I, 2010, ANESTH ANALG, V110, P780, DOI 10.1213/ANE.0b013e3181cde882; Kleczkowska P, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-86; Kumar N, 2010, J NEUROCHEM, V113, P552, DOI 10.1111/j.1471-4159.2010.06625.x; Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231; LaBuda CJ, 2005, J NEUROSCI METH, V144, P175, DOI 10.1016/j.jneumeth.2004.11.008; LaCroix-Fralish ML, 2011, PAIN, V152, P1888, DOI 10.1016/j.pain.2011.04.014; Maeno H, 2004, BRAIN RES, V998, P122, DOI 10.1016/j.brainres.2003.11.039; Maj J, 1998, EUR J PHARMACOL, V351, P31, DOI 10.1016/S0014-2999(98)00297-0; Mao JR, 2012, TRENDS PHARMACOL SCI, V33, P568, DOI 10.1016/j.tips.2012.08.001; Mauderli AP, 2000, J NEUROSCI METH, V97, P19, DOI 10.1016/S0165-0270(00)00160-6; Mechanic JA, 2009, EUR NEUROPSYCHOPHARM, V19, P466, DOI 10.1016/j.euroneuro.2009.01.004; Moller KA, 2008, J NEUROSCI METH, V174, P1, DOI 10.1016/j.jneumeth.2008.06.017; Mogil JS, 2009, NAT REV NEUROSCI, V10, P283, DOI 10.1038/nrn2606; Mogil JS, 2004, PAIN, V112, P12, DOI 10.1016/j.pain.2004.09.028; Niikura K, 2008, NEUROSCI LETT, V435, P257, DOI 10.1016/j.neulet.2008.02.059; OSBAHR AJ, 1981, J PHARMACOL EXP THER, V217, P645; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Patrycja P. K., 2013, EUR J PHARM, V13, P00177; Perron A, 2006, BIOCHEM BIOPH RES CO, V343, P799, DOI 10.1016/j.bbrc.2006.03.047; Pettibone DJ, 2002, J PHARMACOL EXP THER, V300, P305, DOI 10.1124/jpet.300.1.305; Pradhan AAA, 2010, EUR J PAIN, V14, P503, DOI 10.1016/j.ejpain.2009.08.010; Rice ASC, 2008, PAIN, V139, P243, DOI 10.1016/j.pain.2008.08.017; Rossi GC, 2010, J PHARMACOL EXP THER, V334, P1075, DOI 10.1124/jpet.109.165282; Roussy G, 2008, J NEUROCHEM, V105, P1100, DOI 10.1111/j.1471-4159.2007.05205.x; Roussy G, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-38; Salon JA, 2011, PHARMACOL REV, V63, P901, DOI 10.1124/pr.110.003350; Sarhan S, 1997, PEPTIDES, V18, P1223, DOI 10.1016/S0196-9781(97)00145-9; Sarret P, 2005, J NEUROSCI, V25, P8188, DOI 10.1523/JNEUROSCI.0810-05.2005; Sarret P, 2003, J COMP NEUROL, V461, P483, DOI 10.1002/cne.10708; Sarret P, 2003, J COMP NEUROL, V461, P520, DOI 10.1002/cne.10718; SARRET P, 2003, HAND CHEM N, V20, P323; Smith DJ, 1997, J PHARMACOL EXP THER, V282, P899; Smith KE, 2012, BEHAV BRAIN RES, V232, P93, DOI 10.1016/j.bbr.2012.03.044; Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55; Stone LS, 2009, MOL INTERV, V9, P234, DOI 10.1124/mi.9.5.7; SUFKA KJ, 1994, PAIN, V58, P355, DOI 10.1016/0304-3959(94)90130-9; Sullivan MD, 2012, ARCH INTERN MED, V172, P433, DOI 10.1001/archinternmed.2011.2156; Tetreault P, 2011, PHYSIOL BEHAV, V104, P495, DOI 10.1016/j.physbeh.2011.05.015; Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947; Tyler BM, 1998, FEBS LETT, V421, P280, DOI 10.1016/S0014-5793(97)01575-5; Tyler-McMahon BM, 2000, EUR J PHARMACOL, V390, P107, DOI 10.1016/S0014-2999(99)00877-8; Ueda H, 2006, PHARMACOL THERAPEUT, V109, P57, DOI 10.1016/j.pharmthera.2005.06.003; Vachon P, 2004, CAN J VET RES, V68, P86; Wang LLX, 2003, ADV DRUG DELIVER REV, V55, P949, DOI 10.1016/S0169-409X(03)00098-X; Woolf CJ, 2010, NAT MED, V16, P1241, DOI 10.1038/nm.2230; Xiao HS, 2002, P NATL ACAD SCI USA, V99, P8360, DOI 10.1073/pnas.122231899; Xu B, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-15; Yamauchi R, 2003, LIFE SCI, V73, P1917, DOI 10.1016/S0024-3205(03)00546-0; Yang LA, 2004, EUR J NEUROSCI, V19, P871, DOI 10.1111/j.0953-816X.2004.03121.x; Zhang X, 1996, NEUROSCI RES, V25, P359	95	30	33	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3741	3752		10.1096/fj.12-225540	http://dx.doi.org/10.1096/fj.12-225540			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23756650				2022-12-28	WOS:000328840500032
J	Matsunaga, Y; Fukuyama, S; Okuno, T; Sasaki, F; Matsunobu, T; Asai, Y; Matsumoto, K; Saeki, K; Oike, M; Sadamura, Y; Machida, K; Nakanishi, Y; Kubo, M; Yokomizo, T; Inoue, H				Matsunaga, Yuko; Fukuyama, Satoru; Okuno, Toshiaki; Sasaki, Fumiyuki; Matsunobu, Takehiko; Asai, Yukari; Matsumoto, Koichiro; Saeki, Kazuko; Oike, Masahiro; Sadamura, Yukari; Machida, Kentaro; Nakanishi, Yoichi; Kubo, Masato; Yokomizo, Takehiko; Inoue, Hiromasa			Leukotriene B-4 receptor BLT2 negatively regulates allergic airway eosinophilia	FASEB JOURNAL			English	Article						asthma; CD4(+) T cell; interleukin-13; 12(S)-hydroxyheptadeca-5Z; 8E; 10E-trienoic acid	EXHALED BREATH CONDENSATE; T-CELL RECRUITMENT; MAST-CELLS; EXPERIMENTAL ASTHMA; HYPERRESPONSIVENESS; ANTAGONIST; ACTIVATION; RESPONSES; EXPRESSION; IL-13	Leukotriene B-4 (LTB4) has been implicated in the pathogenesis of allergic diseases. BLT2, a low-affinity LTB4 receptor, is activated by LTB4 and 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT). Although the high-affinity LTB4 receptor BLT1 has been shown to exert proinflammatory roles, the role of BLT2 in allergic inflammation has not been clarified. To study the function of BLT2 in development of asthma, we used mice model of ovalbumin (OVA)-induced allergic airway disease. The 12-HHT levels were elevated in bronchoalveolar lavage (BAL) fluids of OVA-sensitized/challenged wild-type mice. BLT2-deficient mice exhibited enhanced eosinophilia in BAL fluids after OVA exposure. Interleukin (IL)-13 levels in BAL fluids and IL-13-producing CD4(+) T cells in the lungs were elevated in BLT2-deficient mice compared to wild-type mice, whereas the levels of IL-4, IL-5, and interferon (IFN)- in BAL fluids and serum OVA-specific IgE were comparable. Transfection of BLT2-specific small interfering RNA enhanced IL-13 production in CD4(+) T cells in vitro. Expression of BLT2 mRNA in CD4(+) T cells was significantly reduced in patients with asthma compared to healthy control subjects. These findings indicate that BLT2 has a protective role in allergic airway inflammation and that diminished BLT2 expression in CD4(+) T cells may contribute to the pathophysiology of asthma.Matsunaga, Y., Fukuyama, S., Okuno, T., Sasaki, F., Matsunobu, T., Asai, Y., Matsumoto, K., Saeki, K., Oike, M., Sadamura, Y., Machida, K., Nakanishi, Y., Kubo, M., Yokomizo, T., Inoue, H. Leukotriene B-4 receptor BLT2 negatively regulates allergic airway eosinophilia.	[Matsunaga, Yuko; Fukuyama, Satoru; Asai, Yukari; Matsumoto, Koichiro; Nakanishi, Yoichi; Inoue, Hiromasa] Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka 812, Japan; [Okuno, Toshiaki; Sasaki, Fumiyuki; Matsunobu, Takehiko; Saeki, Kazuko; Yokomizo, Takehiko] Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Fukuoka 812, Japan; [Oike, Masahiro] Kyushu Univ, Grad Sch Med Sci, Dept Pharmacol, Fukuoka 812, Japan; [Okuno, Toshiaki; Yokomizo, Takehiko] Juntendo Univ, Sch Med, Dept Biochem, Tokyo 113, Japan; [Sadamura, Yukari; Machida, Kentaro; Inoue, Hiromasa] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pulm Med, Kagoshima 8908520, Japan; [Kubo, Masato] RIKEN Yokohama Inst, Res Ctr Allergy & Immunol, Lab Signal Network, Yokohama, Kanagawa, Japan; [Kubo, Masato] Tokyo Univ Sci, Res Inst Biol Sci, Div Biotechnol, Chiba, Japan	Kyushu University; Kyushu University; Kyushu University; Juntendo University; Kagoshima University; RIKEN; Tokyo University of Science	Inoue, H (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pulm Med, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	inoue-pulm@umin.net	Kubo, Masato/A-5918-2016; Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553	Japan Society for the Promotion of Science (JSPS); JSPS; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan; National Institute of Biomedical Innovation, Japan	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation, Japan(National Institute of Biomedical Innovation)	The authors thank Prof. Junichi Miyazaki (Osaka University, Osaka, Japan) for providing an expression vector pCXN2 and Ms. Ayako Hashizume, Ms. Makiko Kogo, and Ms. Asami Harumatsu for their technical assistance. This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), a Grant-in-Aid for Challenging Exploratory Research from JSPS, and a Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, and by the National Institute of Biomedical Innovation, Japan.	Aratake Y, 2012, FASEB J, V26, P4068, DOI 10.1096/fj.12-212050; Becker M, 2011, J IMMUNOL, V186, P7225, DOI 10.4049/jimmunol.1100676; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cho KJ, 2010, J IMMUNOL, V185, P6329, DOI 10.4049/jimmunol.1001213; Cho KJ, 2010, AM J RESP CELL MOL, V42, P294, DOI 10.1165/rcmb.2008-0445OC; Evans DJ, 1996, THORAX, V51, P1178, DOI 10.1136/thx.51.12.1178; Fish SC, 2005, J IMMUNOL, V174, P7716, DOI 10.4049/jimmunol.174.12.7716; GOETZL EJ, 1984, J CLIN IMMUNOL, V4, P79, DOI 10.1007/BF00915039; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Gronke L, 2008, PULM PHARMACOL THER, V21, P409, DOI 10.1016/j.pupt.2007.10.007; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273, DOI 10.1164/ajrccm.162.4.9912064; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Iizuka Y, 2010, FASEB J, V24, P4678, DOI 10.1096/fj.10-165050; Jaffe JS, 1996, AM J RESP CELL MOL, V15, P473, DOI 10.1165/ajrcmb.15.4.8879181; Kaur D, 2006, ALLERGY, V61, P1047, DOI 10.1111/j.1398-9995.2006.01139.x; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; Kita Y, 2005, ANAL BIOCHEM, V342, P134, DOI 10.1016/j.ab.2005.03.048; Kostikas K, 2005, CHEST, V127, P1553, DOI 10.1378/chest.127.5.1553; Kuniyeda K, 2007, J BIOL CHEM, V282, P3998, DOI 10.1074/jbc.M610540200; Lundeen KA, 2006, J IMMUNOL, V177, P3439, DOI 10.4049/jimmunol.177.5.3439; Matsumoto K, 2005, RESPIROLOGY, V10, P18, DOI 10.1111/j.1440-1843.2005.00647.x; Matsunaga Y, 2010, AM J RESP CRIT CARE, V181; Medoff BD, 2006, AM J PHYSIOL-LUNG C, V290, pL170, DOI 10.1152/ajplung.00212.2005; Meurs H, 2008, EUR RESPIR J, V32, P487, DOI 10.1183/09031936.00023608; Miki K, 2010, J PHARMACOL SCI, V113, P387, DOI 10.1254/jphs.10124FP; Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC; Montuschi P, 2003, THORAX, V58, P585, DOI 10.1136/thorax.58.7.585; Ohnishi Hiroshi, 2008, Allergol Int, V57, P291, DOI 10.2332/allergolint.08-RAI-0019; Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329; Richards I. M., 1991, ANN N Y ACAD SCI, V629, P428; Rockwell CE, 2010, CYTOKINE, V51, P12, DOI 10.1016/j.cyto.2010.03.018; SILBAUGH SA, 1992, EUR J PHARMACOL, V223, P57, DOI 10.1016/0014-2999(92)90818-O; Silkoff PE, 2001, CHEST, V119, P1049, DOI 10.1378/chest.119.4.1049; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Tager AM, 2003, PROSTAG LEUKOTR ESS, V69, P123, DOI 10.1016/S0952-3278(03)00073-5; Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217; Tsai M, 2005, CHEM IMMUNOL ALLERGY, V87, P179, DOI 10.1159/000087644; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WOLLERT PS, 1993, SURGERY, V114, P191; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Zuyderduyn S, 2008, EUR RESPIR J, V32, P265, DOI 10.1183/09031936.00051407	44	36	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3306	3314		10.1096/fj.12-217000	http://dx.doi.org/10.1096/fj.12-217000			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603839				2022-12-28	WOS:000329877600035
J	Davis, PM				Davis, Philip M.			Public accessibility of biomedical articles from PubMed Central reduces journal readership-retrospective cohort analysis	FASEB JOURNAL			English	Article						digital repositories; downloads; open access; scientific publishing	RANDOMIZED CONTROLLED-TRIAL; USAGE STATISTICS; OPEN ACCESS; CITATIONS; LIBRARIES	Does PubMed Centrala government-run digital archive of biomedical articlescompete with scientific society journals? A longitudinal, retrospective cohort analysis of 13,223 articles (5999 treatment, 7224 control) published in 14 society-run biomedical research journals in nutrition, experimental biology, physiology, and radiology between February 2008 and January 2011 reveals a 21.4% reduction in full-text hypertext markup language (HTML) article downloads and a 13.8% reduction in portable document format (PDF) article downloads from the journals' websites when U.S. National Institutes of Health-sponsored articles (treatment) become freely available from the PubMed Central repository. In addition, the effect of PubMed Central on reducing PDF article downloads is increasing over time, growing at a rate of 1.6% per year. There was no longitudinal effect for full-text HTML downloads. While PubMed Central may be providing complementary access to readers traditionally underserved by scientific journals, the loss of article readership from the journal website may weaken the ability of the journal to build communities of interest around research papers, impede the communication of news and events to scientific society members and journal readers, and reduce the perceived value of the journal to institutional subscribers.Davis, P. M. Public accessibility of biomedical articles from PubMed Central reduces journal readershipretrospective cohort analysis.	Phil Davis Consulting, Ithaca, NY 14850 USA		Davis, PM (corresponding author), Phil Davis Consulting, 432 Mitchell St, Ithaca, NY 14850 USA.	pmd8@cornell.edu	Davis, Philip M/A-5693-2009	Davis, Philip M/0000-0002-1893-5360	APS	APS	The author was solely responsible for the design and conduct of the study, collection and management of the data, data analysis and interpretation, preparation and submission of the manuscript, and can take responsibility for the integrity of the data and accuracy of the analysis. The author thanks the American Physiological Society (APS), the American Society for Nutrition (ASN), The Federation of American Societies for Experimental Biology (FASEB), and the Radiological Society of North America (RSNA) for their participation in the study. The study was supported by the APS.	Bennett L, 2012, POTENTIAL EFFECT MAK; BONATE PL, 2000, ANAL PRETEST POSTTES; Boukacem-Zeghmouri C, 2012, LEARN PUBL, V25, P271, DOI 10.1087/20120406; CIBER Research Ltd, 2012, PEER US STUD RAND CO; Cox L, 2011, LEARN PUBL, V24, P115, DOI 10.1087/20110206; Davis PM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a568; Davis PM, 2006, J AM SOC INF SCI TEC, V57, P1243, DOI 10.1002/asi.20405; Davis Philip M, 2012, Physiologist, V55, P163; Davis PM, 2011, FASEB J, V25, P2129, DOI 10.1096/fj.11-183988; Publishers Communication Group, 2011, J SUBSCRIPTIONS RENE, P3; Singer J.D., 2003, APPL LONGITUDINAL DA; Ware M., 2006, ALPSP SURVEY LIB FAC	12	9	9	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2536	2541		10.1096/fj.13-229922	http://dx.doi.org/10.1096/fj.13-229922			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23554455	Green Published, hybrid			2022-12-28	WOS:000328841000003
J	Mizushige, T; Sawashi, Y; Yamada, A; Kanamoto, R; Ohinata, K				Mizushige, Takafumi; Sawashi, Yurina; Yamada, Ayako; Kanamoto, Ryuhei; Ohinata, Kousaku			Characterization of Tyr-Leu-Gly, a novel anxiolytic-like peptide released from bovine alpha(S)-casein	FASEB JOURNAL			English	Article						gastrointestinal protease; neurotransmitter; tripeptide	DOPAMINE D-1; TRYPTIC HYDROLYSATE; GABA(A) RECEPTORS; ALPHA-CASOZEPINE; MILK ALPHA(S1)-CASEIN; SEROTONIN 5-HT1A; ADENOSINE A(2A); MICE; ANXIETY; RUBISCO	We found previously that dipeptide YL exhibits orally active anxiolytic activity comparable to diazepam. The YL sequence is often observed in the primary structure of natural food proteins. In the present study, we investigated whether YL and YL analogues are released from bovine (S)-casein by gastrointestinal proteases. YLG, corresponding to (S1)-casein (aa 91-93), was more effectively released from (S)-casein than YL by pepsin-pancreatin digestion, mimicking gastrointestinal enzymatic conditions. Using the synthetic model peptide, we determined that trypsin cleaved the N terminus of YLG, and elastase and carboxypeptidase contributed to cleave the C-terminus. YLG exhibited orally active anxiolytic-like activity in the elevated plus maze and open-field tests in mice. The anxiolytic-like activity of YLG was inhibited by WAY100135, SCH23390 or bicuculline, antagonists of serotonin 5-HT1A, dopamine D-1, and GABA(A) receptors, respectively; however, YLG had no affinity for these receptors. The pepsin-pancreatin digest of (S)-Casein also exhibited anxiolytic-like activity. Meanwhile, anxiolytic-like activity of -casozepine, an (S1)-casein-derived decapeptide with YL sequence in the N terminus, was blocked by WAY100135, SCH23390, or bicuculline, equally to YLG and YL; however, it was not detected in the pepsin-pancreatic digest. Taken together, we found that YLG is released after pepsin-pancreatic digestion of (S)-casein and exhibits potent anxiolytic-like activity via activation of serotonin, dopamine, and the GABA receptor system.Mizushige, T., Sawashi, Y., Yamada, A., Kanamoto, R., Ohinata, K. Characterization of Tyr-Leu-Gly, a novel anxiolytic-like peptide released from bovine (S)-casein.	[Mizushige, Takafumi; Sawashi, Yurina; Yamada, Ayako; Kanamoto, Ryuhei; Ohinata, Kousaku] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan; [Mizushige, Takafumi] Kyoto Univ, Ctr Promot Interdisciplinary Educ & Res C PIER, Res Unit Physiol Chem, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Ohinata, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan.	ohinata@kais.kyoto-u.ac.jp			Japanese Society for the Promotion of Science; Food Science Institute Foundation	Japanese Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Food Science Institute Foundation	This work was supported in part by Grants-in-Aid for Scientific Research (B) and Young Scientists (B) from the Japanese Society for the Promotion of Science to K.O. and T.M., and grants from the Food Science Institute Foundation to K.O. and T.M. The authors declare no conflicts of interest.	Cakir-Kiefer C, 2011, J AGR FOOD CHEM, V59, P11956, DOI 10.1021/jf202890e; Cakir-Kiefer C, 2011, J AGR FOOD CHEM, V59, P4464, DOI 10.1021/jf104089c; Chandra D, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-30; Guesdon B, 2006, PEPTIDES, V27, P1476, DOI 10.1016/j.peptides.2005.10.001; Hirata H, 2007, PEPTIDES, V28, P1998, DOI 10.1016/j.peptides.2007.07.024; Hou IC, 2011, J NEUROCHEM, V119, P785, DOI 10.1111/j.1471-4159.2011.07472.x; Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370; Kagebayashi T, 2012, MOL NUTR FOOD RES, V56, P1456, DOI 10.1002/mnfr.201200168; Kanegawa N, 2010, FEBS LETT, V584, P599, DOI 10.1016/j.febslet.2009.12.008; Kim JH, 2007, EUR J CLIN NUTR, V61, P536, DOI 10.1038/sj.ejcn.1602553; Leonardo ED, 2008, NEUROPSYCHOPHARMACOL, V33, P134, DOI 10.1038/sj.npp.1301569; Li Q, 2012, NEUROPHARMACOLOGY, V62, P474, DOI 10.1016/j.neuropharm.2011.09.002; Messaoudi M, 2005, EUR J NUTR, V44, P128, DOI 10.1007/s00394-004-0534-7; Messaoudi M, 2009, FUND CLIN PHARMACOL, V23, P323, DOI 10.1111/j.1472-8206.2009.00672.x; Miclo L, 2001, FASEB J, V15, P1780, DOI 10.1096/fj.00-0685fje; Miyamoto C, 2012, PROSTAG OTH LIPID M, V98, P17, DOI 10.1016/j.prostaglandins.2012.03.004; Oda A, 2012, J NEUROCHEM, V122, P356, DOI 10.1111/j.1471-4159.2012.07777.x; Ohinata K, 2007, BIOSCI BIOTECH BIOCH, V71, P2618, DOI 10.1271/bbb.70516; Olsen JV, 2004, MOL CELL PROTEOMICS, V3, P608, DOI 10.1074/mcp.T400003-MCP200; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; Short JL, 2006, NEUROPSYCHOPHARMACOL, V31, P525, DOI 10.1038/sj.npp.1300852; Suzuki C, 2011, FEBS LETT, V585, P2357, DOI 10.1016/j.febslet.2011.06.004; Takahashi H, 2011, BIOSCI BIOTECH BIOCH, V75, P1621, DOI 10.1271/bbb.110254; Wall PM, 2004, BEHAV BRAIN RES, V152, P67, DOI 10.1016/j.bbr.2003.09.035; Yang SZ, 2001, FEBS LETT, V509, P213, DOI 10.1016/S0014-5793(01)03042-3; Yu HS, 2007, PHARMACOL BIOCHEM BE, V87, P164, DOI 10.1016/j.pbb.2007.04.013; Zhao H, 2008, PEPTIDES, V29, P629, DOI 10.1016/j.peptides.2007.12.007; Zhao H, 2009, PROSTAG OTH LIPID M, V88, P68, DOI 10.1016/j.prostaglandins.2008.10.001	29	30	31	4	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2911	2917		10.1096/fj.12-225474	http://dx.doi.org/10.1096/fj.12-225474			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23580614				2022-12-28	WOS:000328841000039
J	Ohgita, T; Hayashi, N; Hama, S; Tsuchiya, H; Gotoh, N; Kogure, K				Ohgita, Takashi; Hayashi, Naoki; Hama, Susumu; Tsuchiya, Hiroyuki; Gotoh, Naomasa; Kogure, Kentaro			A novel effector secretion mechanism based on proton-motive force-dependent type III secretion apparatus rotation	FASEB JOURNAL			English	Article						Pseudomonas aeruginosa; flagellum; ATP synthase; PcrV; Strep tagII	BASAL BODY COMPLEX; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; PROTEIN EXPORT; FLAGELLA; HOOK; INJECTISOME; F-1-ATPASE	The type III secretion apparatus (T3SA) participates in the secretion of bacterial proteins called effectors, although the detailed mechanism of effector secretion remains unclear. T3SA and flagellum were shown to branch from a common ancestor and also show structural similarity. In addition, both T3SA-dependent effector secretion and flagellar rotation were reported to require proton-motive force (PMF) for activity. From these reports, we hypothesized that T3SA, like the flagellum, would rotate via PMF and that this rotation is responsible for effector secretion. To observe T3SA rotation, we constructed a novel observation system by modifying the tip of T3SA on bacterial cell membranes with an observation probe, which allowed documentation of T3SA rotation for the first time. T3SA rotation was stopped by the addition of a protonophore that decreases PMF. Moreover, increased viscosity of the observation medium inhibited both rotation of T3SA associated with beads and effector secretion. These results suggested that effector secretion would follow the PMF-dependent rotation of T3SA and could be inhibited by preventing T3SA rotation. Moreover, the motion-track analysis of bead rotation suggested that the T3SA needle might be flexible. Consequently, we propose a rotational secretion model as a novel effector secretion mechanism of T3SA.Ohgita, T., Hayashi, N., Hama, S., Tsuchiya, H., Gotoh, N., Kogure, K. A novel effector secretion mechanism based on proton-motive force-dependent type III secretion apparatus rotation.	[Ohgita, Takashi; Hama, Susumu; Tsuchiya, Hiroyuki; Kogure, Kentaro] Kyoto Pharmaceut Univ, Dept Biophys Chem, Kyoto 6078414, Japan; [Hayashi, Naoki; Gotoh, Naomasa] Kyoto Pharmaceut Univ, Dept Microbiol & Infect Control Sci, Kyoto 6078414, Japan	Kyoto Pharmaceutical University; Kyoto Pharmaceutical University	Kogure, K (corresponding author), Kyoto Pharmaceut Univ, Dept Biophys Chem, Yamashina Ku, Misasagi Nakauchicho 5, Kyoto 6078414, Japan.	kogure@mb.kyoto-phu.ac.jp		Hama, Susumu/0000-0002-2989-6168				AIZAWA S, 1985, J BACTERIOL, V161, P836, DOI 10.1128/JB.161.3.836-849.1985; Aizawa S, 2001, FEMS MICROBIOL LETT, V202, P157, DOI 10.1111/j.1574-6968.2001.tb10797.x; Caroline G, 2008, J BIOL CHEM, V283, P23940, DOI 10.1074/jbc.M803146200; Cornelis GR, 2006, NAT REV MICROBIOL, V4, P811, DOI 10.1038/nrmicro1526; DEPAMPHI.ML, 1971, J BACTERIOL, V105, P384, DOI 10.1128/JB.105.1.384-395.1971; Engel J, 2009, CURR OPIN MICROBIOL, V12, P61, DOI 10.1016/j.mib.2008.12.007; Gabel CV, 2003, P NATL ACAD SCI USA, V100, P8748, DOI 10.1073/pnas.1533395100; GONZALEZTELLO P, 1994, J CHEM ENG DATA, V39, P611, DOI 10.1021/je00015a050; Gophna U, 2003, GENE, V312, P151, DOI 10.1016/S0378-1119(03)00612-7; Hashimoto M, 2008, J MOL BIOL, V375, P367, DOI 10.1016/j.jmb.2007.09.046; Hauser AR, 2009, NAT REV MICROBIOL, V7, P654, DOI 10.1038/nrmicro2199; Ibuki T, 2011, NAT STRUCT MOL BIOL, V18, P277, DOI 10.1038/nsmb.1977; Imada K, 2007, P NATL ACAD SCI USA, V104, P485, DOI 10.1073/pnas.0608090104; Kinosita K, 1999, FASEB J, V13, pS201; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Lee PC, 2010, MOL MICROBIOL, V75, P924, DOI 10.1111/j.1365-2958.2009.07027.x; Magariyama Y, 2001, FEMS MICROBIOL LETT, V199, P125; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; Mueller CA, 2005, SCIENCE, V310, P674, DOI 10.1126/science.1118476; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogawa M, 2008, NAT REV MICROBIOL, V6, P11, DOI 10.1038/nrmicro1814; Okuda J, 2010, INFECT IMMUN, V78, P4511, DOI 10.1128/IAI.00428-10; Oster G, 2003, TRENDS CELL BIOL, V13, P114, DOI 10.1016/S0962-8924(03)00004-7; Rathinavelan T, 2010, BIOPHYS J, V98, P452, DOI 10.1016/j.bpj.2009.10.030; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; SHIOI J, 1980, J BACTERIOL, V144, P891, DOI 10.1128/JB.144.3.891-897.1980; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; Ueno H, 2005, P NATL ACAD SCI USA, V102, P1333, DOI 10.1073/pnas.0407857102; Wilharm G, 2004, INFECT IMMUN, V72, P4004, DOI 10.1128/IAI.72.7.4004-4009.2004; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	31	15	15	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2862	2872		10.1096/fj.13-229054	http://dx.doi.org/10.1096/fj.13-229054			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23515444				2022-12-28	WOS:000328841000034
J	Tsatsaronis, JA; Hollands, A; Cole, JN; Maamary, PG; Gillen, CM; Ben Zakour, NL; Kotb, M; Nizet, V; Beatson, SA; Walker, MJ; Sanderson-Smith, ML				Tsatsaronis, James A.; Hollands, Andrew; Cole, Jason N.; Maamary, Peter G.; Gillen, Christine M.; Ben Zakour, Nouri L.; Kotb, Malak; Nizet, Victor; Beatson, Scott A.; Walker, Mark J.; Sanderson-Smith, Martina L.			Streptococcal collagen-like protein A and general stress protein 24 are immunomodulating virulence factors of group A Streptococcus	FASEB JOURNAL			English	Article						systems biology; next-generation sequencing; innate immunity	ENTEROCOCCUS-FAECALIS; IN-VIVO; PLASMINOGEN BINDING; SEROTYPE M1; FACTOR-H; PYOGENES; EXPRESSION; SEQUENCE; SCL1; INFECTION	In Western countries, invasive infections caused by M1T1 serotype group A Streptococcus (GAS) are epidemiologically linked to mutations in the control of virulence regulatory 2-component operon (covRS). In indigenous communities and developing countries, severe GAS disease is associated with genetically diverse non-M1T1 GAS serotypes. Hypervirulent M1T1 covRS mutant strains arise through selection by human polymorphonuclear cells for increased expression of GAS virulence factors such as the DNase Sda1, which promotes neutrophil resistance. The GAS bacteremia isolate NS88.2 (emm 98.1) is a covS mutant that exhibits a hypervirulent phenotype and neutrophil resistance yet lacks the phage-encoded Sda1. Here, we have employed a comprehensive systems biology (genomic, transcriptomic, and proteomic) approach to identify NS88.2 virulence determinants that enhance neutrophil resistance in the non-M1T1 GAS genetic background. Using this approach, we have identified streptococcal collagen-like protein A and general stress protein 24 proteins as NS88.2 determinants that contribute to survival in whole blood and neutrophil resistance in non-M1T1 GAS. This study has revealed new factors that contribute to GAS pathogenicity that may play important roles in resisting innate immune defenses and the development of human invasive infectionsTsatsaronis, J. A., Hollands, A., Cole, J. N., Maamary, P. G., Gillen, C. M., Ben Zakour, N. L., Kotb, M., Nizet, V., Beatson, S. A. Walker, M. J., Sanderson-Smith, M. L. Streptococcal collagen-like protein A and general stress protein 24 are immunomodulating virulence factors of group A Streptococcus.	[Tsatsaronis, James A.; Sanderson-Smith, Martina L.] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW 2522, Australia; [Tsatsaronis, James A.; Sanderson-Smith, Martina L.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; [Hollands, Andrew; Cole, Jason N.; Nizet, Victor] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Hollands, Andrew; Cole, Jason N.; Maamary, Peter G.; Gillen, Christine M.; Ben Zakour, Nouri L.; Beatson, Scott A.; Walker, Mark J.] Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld, Australia; [Hollands, Andrew; Cole, Jason N.; Maamary, Peter G.; Gillen, Christine M.; Ben Zakour, Nouri L.; Beatson, Scott A.; Walker, Mark J.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia; [Kotb, Malak] Univ Cincinnati, Vet Affairs Med Ctr, Cincinnati, OH USA; [Kotb, Malak] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH USA	University of Wollongong; University of Wollongong; University of California System; University of California San Diego; University of Queensland; University of Queensland; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Sanderson-Smith, ML (corresponding author), Univ Wollongong, Sch Biol Sci, Illawarra Hlth & Med Res Inst, Wollongong, NSW 2522, Australia.	martina@uow.edu.au	Nizet, Victor/AAF-3190-2019; Sanderson-Smith, Martina/O-9387-2019; Beatson, Scott/B-6985-2013; Gillen, Christine M/A-2717-2014; ZAKOUR, Nouri L BEN/B-9338-2011; Walker, Mark J./F-6940-2011; Sanderson-Smith, Martina L/H-9614-2013	Beatson, Scott/0000-0002-1806-3283; ZAKOUR, Nouri L BEN/0000-0002-6949-1755; Sanderson-Smith, Martina L/0000-0002-6366-4993; Duplancic, Christine/0000-0002-1775-3055; Walker, Mark/0000-0001-7423-2769; Nizet, Victor/0000-0003-3847-0422	Australian National Health and Medical Research Council (NHMRC) fellowships; Australian Postgraduate Awards; Australian NHMRC [381413]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077780] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council (NHMRC) fellowships(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Awards(Australian Government); Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.L.S-S., M.J.W., A.H., J.N.C., and N.L.B Z are recipients of Australian National Health and Medical Research Council (NHMRC) fellowships. J.A.T. and P. G. M. are recipients of Australian Postgraduate Awards. Proteomic data analysis described in this work was supported by the use of the Australian Proteomics Computational Facility, funded by Australian NHMRC grant 381413. All other work described was funded by the Australian NHMRC.	Alikhan NF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-402; Aziz RK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-75; Aziz RK, 2008, EMERG INFECT DIS, V14, P1511, DOI 10.3201/eid1410.071660; Aziz RK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009798; Aziz RK, 2004, MOL MICROBIOL, V51, P123, DOI 10.1046/j.1365-2958.2003.03797.x; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Beres SB, 2006, P NATL ACAD SCI USA, V103, P7059, DOI 10.1073/pnas.0510279103; Bessen DE, 2002, INFECT IMMUN, V70, P1159, DOI 10.1128/IAI.70.3.1159-1167.2002; Buchanan JT, 2006, CURR BIOL, V16, P396, DOI 10.1016/j.cub.2005.12.039; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; Carver T, 2010, BIOINFORMATICS, V26, P676, DOI 10.1093/bioinformatics/btq010; Caswell CC, 2008, MOL MICROBIOL, V67, P584, DOI 10.1111/j.1365-2958.2007.06067.x; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Cole JN, 2011, NAT REV MICROBIOL, V9, P724, DOI 10.1038/nrmicro2648; Cole JN, 2010, MBIO, V1, DOI 10.1128/mBio.00191-10; Cook SM, 2012, MOL MICROBIOL, V86, P1052, DOI 10.1111/mmi.12037; Darling ACE, 2004, GENOME RES, V14, P1394, DOI 10.1101/gr.2289704; Delcher AL, 2007, BIOINFORMATICS, V23, P673, DOI 10.1093/bioinformatics/btm009; Garcia AF, 2010, MICROBIOL-SGM, V156, P3085, DOI 10.1099/mic.0.042614-0; Graham MR, 2006, AM J PATHOL, V169, P927, DOI 10.2353/ajpath.2006.060112; Graham MR, 2002, P NATL ACAD SCI USA, V99, P13855, DOI 10.1073/pnas.202353699; Green NM, 2005, J INFECT DIS, V192, P760, DOI 10.1086/430618; Han RL, 2006, MOL MICROBIOL, V61, P351, DOI 10.1111/j.1365-2958.2006.05237.x; Hassell M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-60; Hoe NP, 2007, FEMS MICROBIOL LETT, V277, P142, DOI 10.1111/j.1574-6968.2007.00955.x; Hollands A, 2010, J INFECT DIS, V202, P11, DOI 10.1086/653124; Hollands A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004102; Humtsoe JO, 2005, J BIOL CHEM, V280, P13848, DOI 10.1074/jbc.M410605200; Ikebe T, 2002, INFECT IMMUN, V70, P3227, DOI 10.1128/IAI.70.6.3227-3233.2002; Ikebe T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000832; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Kansal RG, 2010, J INFECT DIS, V201, P855, DOI 10.1086/651019; Kratovac Z, 2007, J BACTERIOL, V189, P1299, DOI 10.1128/JB.01301-06; Kurtz S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r12; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Maamary PG, 2010, J INNATE IMMUN, V2, P596, DOI 10.1159/000317640; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; Mora M, 2005, P NATL ACAD SCI USA, V102, P15641, DOI 10.1073/pnas.0507808102; Musser JM, 2009, J CLIN INVEST, V119, P2455, DOI 10.1172/JCI38095; Nannini EC, 2005, INFECT IMMUN, V73, P7772, DOI 10.1128/IAI.73.11.7772-7774.2005; Pahlman LI, 2007, J BIOL CHEM, V282, P24873, DOI 10.1074/jbc.M610015200; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Reuter M, 2010, J BIOL CHEM, V285, P38473, DOI 10.1074/jbc.M110.143727; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sanderson-Smith ML, 2008, FASEB J, V22, P2715, DOI 10.1096/fj.07-105643; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; Sharkawy A, 2002, CLIN INFECT DIS, V34, P454, DOI 10.1086/338466; Sumby P, 2005, J INFECT DIS, V192, P771, DOI 10.1086/432514; Sumby P, 2006, PLOS PATHOG, V2, P41, DOI 10.1371/journal.ppat.0020005; Teng F, 2005, J INFECT DIS, V191, P472, DOI 10.1086/427191; Vebo HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012489; Vebo HC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007660; Walker MJ, 2007, NAT MED, V13, P981, DOI 10.1038/nm1612; Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107; Zhang M, 2007, PROTEOMICS, V7, P1379, DOI 10.1002/pmic.200600578	61	10	11	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2633	2643		10.1096/fj.12-226662	http://dx.doi.org/10.1096/fj.12-226662			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23531597	Green Published, Green Submitted			2022-12-28	WOS:000328841000013
J	Ciencewicki, JM; Wang, XT; Marzec, J; Serra, ME; Bell, DA; Polack, FP; Kleeberger, SR				Ciencewicki, Jonathan M.; Wang, Xuting; Marzec, Jacqui; Elina Serra, M.; Bell, Douglas A.; Polack, Fernando P.; Kleeberger, Steven R.			A genetic model of differential susceptibility to human respiratory syncytial virus (RSV) infection	FASEB JOURNAL			English	Article						gene expression; infant lung disease; bronchiolitis; lymphoblastoid cell lines; MX1; HapMap	INFLUENZA-VIRUS; EXPRESSION; PROTEIN; RESISTANCE; INTERFERON; POLYMORPHISMS; INFANTS; SEVERITY; DISEASE; CELLS	Respiratory syncytial virus (RSV) is the primary cause of lower respiratory tract infection during childhood and causes severe symptoms in some patients, which may cause hospitalization and death. Mechanisms for differential responses to RSV are unknown. Our objective was to develop an in vitro model of RSV infection to evaluate interindividual variation in response to RSV and identify susceptibility genes. Populations of human-derived HapMap lymphoblastoid cell lines (LCLs) were infected with RSV. Compared with controls, RSV-G mRNA expression varied from similar to 1- to 400-fold between LCLs. Basal expression of a number of gene transcripts, including myxovirus (influenza virus) resistance 1 (MX1), significantly correlated with RSV-G expression in HapMap LCLs. Individuals in a case-control population of RSV-infected children who were homozygous (n=94) or heterozygous (n=172) for the predicted deleterious A allele in a missense G/A SNP in MX1 had significantly greater risk for developing severe RSV disease relative to those with the major allele (n=108) (chi(2)=5.305, P=0.021; OR: 1.750, 95% CI: 1.110, 2.758, P=0.021). We conclude that genetically diverse human LCLs enable identification of susceptibility genes (e.g., MX1) for RSV disease severity in children, providing insight for disease risk.-Ciencewicki, J. M., Wang, X., Marzec, J., Serra, M. E., Bell, D. A., Polack, F. P., Kleeberger, S. R. A genetic model of differential susceptibility to human respiratory syncytial virus (RSV) infection.	[Ciencewicki, Jonathan M.; Wang, Xuting; Marzec, Jacqui; Bell, Douglas A.; Kleeberger, Steven R.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA; [Elina Serra, M.; Polack, Fernando P.] Fdn INFANT, Buenos Aires, DF, Argentina; [Polack, Fernando P.] Vanderbilt Univ, Dept Pediat, Nashville, TN USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University	Ciencewicki, JM (corresponding author), NIEHS, Lab Resp Biol, 111 TW Alexander Dr,Bldg 101,MD D-201, Res Triangle Pk, NC 27709 USA.	ciencewickij@niehs.nih.gov	Bell, Douglas A/C-7687-2019; Kleeberger, Steven R/F-1807-2019	Bell, Douglas A/0000-0001-7700-0840; Kleeberger, Steven R/0000-0003-2948-8452; Serra, Maria Elina/0000-0002-0026-9072; Wang, Xuting/0000-0001-6781-8008	Director's Challenge Program; National Institutes of Health, National Institute of Environmental Health Sciences, U.S. Department of Health and Human Services; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES046008, ZIAES100557, ZIAES100475] Funding Source: NIH RePORTER	Director's Challenge Program; National Institutes of Health, National Institute of Environmental Health Sciences, U.S. Department of Health and Human Services; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported (in part) by a Director's Challenge Program and the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences, U.S. Department of Health and Human Services. The authors thank Dr. Patricio Acosta for all of his work to obtain the second population of RSV-infected children and his genotyping analyses. The authors also thank Dr. Michael Fessler and Dr. Donald Cook for thoughtful comments on the manuscript.	Anh DBT, 2006, AM J PHYSIOL-LUNG C, V291, pL426, DOI 10.1152/ajplung.00483.2005; Awomoyi AA, 2007, J IMMUNOL, V179, P3171, DOI 10.4049/jimmunol.179.5.3171; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Bucasas KL, 2013, PEDIATR INFECT DIS J, V32, pE68, DOI 10.1097/INF.0b013e318278b4b3; Cheung VG, 2003, NAT GENET, V33, P422, DOI 10.1038/ng1094; Cheung VG, 2006, GENOME RES, V16, P973, DOI 10.1101/gr.5320706; Choy E, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000287; Correa CR, 2004, AM J HUM GENET, V75, P885, DOI 10.1086/425221; Dermine M, 2012, J INTERF CYTOK RES, V32, P332, DOI 10.1089/jir.2011.0123; DeVincenzo JP, 2010, AM J RESP CRIT CARE, V182, P1305, DOI 10.1164/rccm.201002-0221OC; Diaz PV, 2012, PEDIATRICS, V130, pE804, DOI 10.1542/peds.2012-0160; DOMURAT F, 1985, J INFECT DIS, V152, P895, DOI 10.1093/infdis/152.5.895; Dyer KD, 2009, BLOOD, V114, P2649, DOI 10.1182/blood-2009-01-199497; Eisenhut M, 2006, CRIT CARE, V10, DOI 10.1186/cc4984; Gao S, 2011, IMMUNITY, V35, P514, DOI 10.1016/j.immuni.2011.07.012; Gentile DA, 2003, HUM IMMUNOL, V64, P338, DOI 10.1016/S0198-8859(02)00827-3; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Groskreutz DJ, 2006, J IMMUNOL, V176, P1733, DOI 10.4049/jimmunol.176.3.1733; HALLER O, 1995, J VIROL, V69, P2596, DOI 10.1128/JVI.69.4.2596-2601.1995; Harrod KS, 2003, AM J RESP CELL MOL, V28, P451, DOI 10.1165/rcmb.2002-0100OC; Inoue Y, 2007, J INFECT DIS, V195, P1618, DOI 10.1086/516790; ISAACS D, 1989, ARCH DIS CHILD, V64, P92, DOI 10.1136/adc.64.1.92; Jen KY, 2003, GENOME RES, V13, P2092, DOI 10.1101/gr.1240103; Kaan PM, 2003, AM J RESP CELL MOL, V28, P697, DOI 10.1165/rcmb.2002-0115OC; Klouwenberg PK, 2009, CRIT REV IMMUNOL, V29, P531, DOI 10.1615/CritRevImmunol.v29.i6.40; Laham FR, 2004, J INFECT DIS, V189, P2047, DOI 10.1086/383350; Lanari M, 2002, PEDIATR PULM, V33, P458, DOI 10.1002/ppul.10047; Lock EF, 2012, TOXICOL SCI, V126, P578, DOI 10.1093/toxsci/kfs023; Mella C, 2013, J INFECT DIS, V207, P564, DOI 10.1093/infdis/jis721; MEROLLA R, 1995, AM J RESP CRIT CARE, V152, P1358, DOI 10.1164/ajrccm.152.4.7551395; Min JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022070; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Paulus SC, 2007, CLIN IMMUNOL, V123, P252, DOI 10.1016/j.clim.2007.03.003; PAVLOVIC J, 1995, J VIROL, V69, P4506, DOI 10.1128/JVI.69.7.4506-4510.1995; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; Puthothu Beena, 2007, BMC Pulm Med, V7, P6, DOI 10.1186/1471-2466-7-6; Puthothu B, 2007, PEDIATR INFECT DIS J, V26, P1094, DOI 10.1097/INF.0b013e3181453579; Puthothu B, 2006, DIS MARKERS, V22, P303, DOI 10.1155/2006/865890; Puthothu Beena, 2006, Clin Mol Allergy, V4, P2; ROBERTS NJ, 1982, INFECT IMMUN, V35, P1142, DOI 10.1128/IAI.35.3.1142-1146.1982; Rohwedder A, 1998, J MED VIROL, V54, P320, DOI 10.1002/(SICI)1096-9071(199804)54:4&lt;320::AID-JMV13&gt;3.0.CO;2-J; Smirnov DA, 2009, NATURE, V459, P587, DOI 10.1038/nature07940; STAEHELI P, 1988, MOL CELL BIOL, V8, P4518, DOI 10.1128/MCB.8.10.4518; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; Stark JM, 2002, J MED VIROL, V67, P92, DOI 10.1002/jmv.2196; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Thomsen SF, 2008, PEDIATRICS, V121, P493, DOI 10.1542/peds.2007-1889; Torres JP, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-125; Tregoning JS, 2013, P NATL ACAD SCI USA, V110, P5576, DOI 10.1073/pnas.1214247110; Verhelst J, 2012, J VIROL, V86, P13445, DOI 10.1128/JVI.01682-12; von der Malsburg A, 2011, J BIOL CHEM, V286, P37858, DOI 10.1074/jbc.M111.249037; Wang XT, 2007, HUM MOL GENET, V16, P1188, DOI 10.1093/hmg/ddm066	52	21	22	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1947	1956		10.1096/fj.13-239855	http://dx.doi.org/10.1096/fj.13-239855			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24421397	Green Published			2022-12-28	WOS:000335344300038
J	Noel, SD; Abreu, AP; Xu, SY; Muyide, T; Gianetti, E; Tusset, C; Carroll, J; Latronico, AC; Seminara, SB; Carroll, RS; Kaiser, UB				Noel, Sekoni D.; Abreu, Ana Paula; Xu, Shuyun; Muyide, Titilayo; Gianetti, Elena; Tusset, Cintia; Carroll, Jessica; Latronico, Ana Claudia; Seminara, Stephanie B.; Carroll, Rona S.; Kaiser, Ursula B.			TACR3 mutations disrupt NK3R function through distinct mechanisms in GnRH-deficient patients	FASEB JOURNAL			English	Article						tachykinins; GPCR; hypogonadotropic hypogonadism; neurokinin B	CALCIUM-SENSING RECEPTOR; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; ACTIVITY-MODIFYING PROTEINS; 3RD INTRACELLULAR LOOP; 1ST EXTRACELLULAR LOOP; NEUROKININ B RECEPTOR; HUMAN SUBSTANCE-P; ARCUATE NUCLEUS; HORMONE SECRETION; QUALITY-CONTROL	Neurokinin B (NKB) and its G-protein-coupled receptor, NK3R, have been implicated in the neuroendocrine control of GnRH release; however, little is known about the structure-function relationship of this ligand-receptor pair. Moreover, loss-of-function NK3R mutations cause GnRH deficiency in humans. Using missense mutations in NK3R we previously identified in patients with GnRH deficiency, we demonstrate that Y256H and Y315C NK3R mutations in the fifth and sixth transmembrane domains (TM5 and TM6), resulted in reduced whole-cell (79.3 +/- 7.2%) or plasma membrane (67.3 +/- 7.3%) levels, respectively, compared with wild-type (WT) NK3R, with near complete loss of inositol phosphate (IP) signaling, implicating these domains in receptor trafficking, processing, and/or stability. We further demonstrate in a FRET-based assay that R295S NK3R, in the third intracellular loop (IL3), bound NKB but impaired dissociation of G(q)-protein subunits from the receptor compared with WT NK3R, which showed a 10.0 +/- 1.3% reduction in FRET ratios following ligand binding, indicating activation of G(q)-protein signaling. Interestingly, R295S NK3R, identified in the heterozygous state in a GnRH-deficient patient, also interfered with dissociation of G proteins and IP signaling from wild-type NK3R, indicative of dominant-negative effects. Collectively, our data illustrate roles for TM5 and TM6 in NK3R trafficking and ligand binding and for IL3 in NK3R signaling.-Noel, S. D., Abreu, A. P., Xu, S., Muyide, T., Gianetti, E., Tusset, C., Carroll, J., Latronico, A. C., Seminara, S. B., Carroll, R. S., Kaiser, U. B. TACR3 mutations disrupt NK3R function through distinct mechanisms in GnRH-deficient patients.	[Noel, Sekoni D.; Abreu, Ana Paula; Xu, Shuyun; Muyide, Titilayo; Carroll, Jessica; Carroll, Rona S.; Kaiser, Ursula B.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; [Noel, Sekoni D.; Abreu, Ana Paula; Xu, Shuyun; Muyide, Titilayo; Carroll, Jessica; Carroll, Rona S.; Kaiser, Ursula B.] Harvard Univ, Sch Med, Boston, MA USA; [Abreu, Ana Paula; Tusset, Cintia; Latronico, Ana Claudia] Univ Sao Paulo, Sch Med, Teaching Hosp, Dev Endocrinol Unit,Lab Hormones & Mol Genet, Sao Paulo, Brazil; [Gianetti, Elena; Seminara, Stephanie B.] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Universidade de Sao Paulo; Harvard University; Massachusetts General Hospital	Kaiser, UB (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA.	ukaiser@partners.org	Latronico, Ana Claudia/E-1198-2012; Latronico, Ana Claudia/AAC-5112-2019	Latronico, Ana Claudia/0000-0001-6782-693X; Latronico, Ana Claudia/0000-0001-6782-693X; /0000-0002-5505-0852	Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH [U54 HD028138]; Ruth L. Kirschstein National Research Service Postdoctoral Award [T32 DK007529-25]; NIH Fellowship [F05 HD072773-01];  [R01 HD019938];  [R01 HD019938-21S]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K24HD067388, P30HD018655, P50HD028138, F05HD072773, U54HD028138, R01HD019938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007529] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Ruth L. Kirschstein National Research Service Postdoctoral Award; NIH Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. John Gill and Dr. Ann-Marie Zavacki for helpful discussions. The authors also thank Drs. Bertil Hille (University of Washington School of Medicine, Seattle, WA, USA), Narasimhan Gautam (Washington University School of Medicine in St. Louis, St. Louis, MO, USA), Stephen Ikeda [National Institute on Alcohol Abuse and Alcoholism, Division of Clinical and Biological Research, U. S. National Institutes of Health (NIH), Bethesda, MD, USA] and Moritz Buneman (Philipps-Universtitaet Marburg, Marburg, Germany) for providing DNA constructs. This research was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, through cooperative agreement U54 HD028138 as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research (to U. B. K. and S. B. S.), by R01 HD019938 (to U. B. K.), by a T32 DK007529-25 Ruth L. Kirschstein National Research Service Postdoctoral Award (to S.D.N.), by a F05 HD072773-01 NIH Fellowship (to A. P. A.), and by R01 HD019938-21S1 (to J.C.). Author contributions: S.D.N., R. S. C., and U. B. K. designed the study; S.D.N, A. P. A, S. X, T. M., E. G., and J.C. performed experiments; S.D.N. collected and analyzed data; E. G., C. T., A. C. L., S. B. S., R. S. C., and U. B. K. provided materials and reagents; S.D.N. and U. B. K. wrote the manuscript; A. C. L., S. B. S., R. S. C., and U. B. K. gave technical support and conceptual advice. The authors declare no conflicts of interest.	Achour L, 2008, TRENDS PHARMACOL SCI, V29, P528, DOI 10.1016/j.tips.2008.07.009; Al-Salameh A, 2011, EUR J ENDOCRINOL, V165, P359, DOI 10.1530/EJE-11-0141; Amstalden M, 2010, J NEUROENDOCRINOL, V22, P1, DOI 10.1111/j.1365-2826.2009.01930.x; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bedecarrats GY, 2003, MOL CELL ENDOCRINOL, V205, P51, DOI 10.1016/S0303-7207(03)00201-6; Billings HJ, 2010, ENDOCRINOLOGY, V151, P3836, DOI 10.1210/en.2010-0174; Bouschet T, 2005, J CELL SCI, V118, P4709, DOI 10.1242/jcs.02598; Cezanne L, 2004, J BIOL CHEM, V279, P45057, DOI 10.1074/jbc.M404811200; CHANG MM, 1971, NATURE-NEW BIOL, V232, P86, DOI 10.1038/newbio232086a0; Chen SH, 2000, EMBO J, V19, P4265, DOI 10.1093/emboj/19.16.4265; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Conn PM, 2009, MOL CELL ENDOCRINOL, V299, P137, DOI 10.1016/j.mce.2008.10.051; Corander MP, 2010, J NEUROENDOCRINOL, V22, P181, DOI 10.1111/j.1365-2826.2009.01951.x; Dawson LA, 2010, CURR PHARM DESIGN, V16, P344, DOI 10.2174/138161210790170067; DORLEANSJUSTE P, 1986, EUR J PHARMACOL, V125, P37, DOI 10.1016/0014-2999(86)90081-6; Eghlidi DH, 2010, ENDOCRINOLOGY, V151, P3783, DOI 10.1210/en.2010-0198; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Francou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025614; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; Ganjiwale AD, 2011, J CHEM INF MODEL, V51, P2932, DOI 10.1021/ci2000264; Gardner TA, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0166; Gaskins GT, 2013, ENDOCRINOLOGY, V154, P3984, DOI 10.1210/en.2013-1479; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GETHER U, 1993, J BIOL CHEM, V268, P7893; Gianetti E, 2010, J CLIN ENDOCR METAB, V95, P2857, DOI 10.1210/jc.2009-2320; Glidewell-Kenney CA, 2013, MOL ENDOCRINOL, V27, P437, DOI 10.1210/me.2012-1271; Goodman RL, 2007, ENDOCRINOLOGY, V148, P5752, DOI 10.1210/en.2007-0961; GOW A, 1994, J NEUROSCI RES, V37, P574, DOI 10.1002/jnr.490370504; Guran T, 2009, J CLIN ENDOCR METAB, V94, P3633, DOI 10.1210/jc.2009-0551; Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006; Horwich A, 2002, J CLIN INVEST, V110, P1221, DOI 10.1172/JCI200216781; Janovick JA, 2009, MOL ENDOCRINOL, V23, P157, DOI 10.1210/me.2008-0384; Kallo I, 2012, J NEUROENDOCRINOL, V24, P464, DOI 10.1111/j.1365-2826.2011.02262.x; KANGAWA K, 1983, BIOCHEM BIOPH RES CO, V114, P533, DOI 10.1016/0006-291X(83)90813-6; Katritch V, 2013, ANNU REV PHARMACOL, V53, P531, DOI 10.1146/annurev-pharmtox-032112-135923; Khawaja AM, 1996, INT J BIOCHEM CELL B, V28, P721, DOI 10.1016/1357-2725(96)00017-9; Kinsey-Jones JS, 2012, ENDOCRINOLOGY, V153, P307, DOI 10.1210/en.2011-1641; Krajewski SJ, 2005, J COMP NEUROL, V489, P372, DOI 10.1002/cne.20626; Kung TT, 2004, PHARMACOL RES, V50, P611, DOI 10.1016/j.phrs.2004.07.002; Maya-Nunez Guadalupe, 2012, Subcell Biochem, V63, P263, DOI 10.1007/978-94-007-4765-4_14; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mizrachi D, 2004, MOL ENDOCRINOL, V18, P1768, DOI 10.1210/me.2003-0406; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Navarro VM, 2011, ENDOCRINOLOGY, V152, P4265, DOI 10.1210/en.2011-1143; Navarro VM, 2011, AM J PHYSIOL-ENDOC M, V300, pE202, DOI 10.1152/ajpendo.00517.2010; Navarro VM, 2009, J NEUROSCI, V29, P11859, DOI 10.1523/JNEUROSCI.1569-09.2009; NAWA H, 1984, LIFE SCI, V34, P1153, DOI 10.1016/0024-3205(84)90087-0; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Nordquist RE, 2008, PSYCHOPHARMACOLOGY, V198, P211, DOI 10.1007/s00213-008-1119-6; OSAKADA F, 1986, EUR J PHARMACOL, V120, P201, DOI 10.1016/0014-2999(86)90541-8; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Peeters MC, 2011, FASEB J, V25, P632, DOI 10.1096/fj.10-164319; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Pidasheva S, 2004, HUM MUTAT, V24, P107, DOI 10.1002/humu.20067; Punn A, 2012, J BIOL CHEM, V287, P8974, DOI 10.1074/jbc.M111.272161; Ramaswamy S, 2010, ENDOCRINOLOGY, V151, P4494, DOI 10.1210/en.2010-0223; Rance NE, 2010, BRAIN RES, V1364, P116, DOI 10.1016/j.brainres.2010.08.059; Rance NE, 2009, PEPTIDES, V30, P111, DOI 10.1016/j.peptides.2008.05.016; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Sandoval-Guzman T, 2004, BRAIN RES, V1026, P307, DOI 10.1016/j.brainres.2004.08.026; Schliefenbaum J., 2008, BIOPHYS J, V94, P665; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; Siffroi-Fernandez S, 2002, EUR J BIOCHEM, V269, P4930, DOI 10.1046/j.1432-1033.2002.03192.x; Simonsen KB, 2010, CURR OPIN DRUG DISC, V13, P379; Siuciak JA, 2007, PSYCHOPHARMACOLOGY, V194, P185, DOI 10.1007/s00213-007-0828-6; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; Tan CM, 2004, ANNU REV PHARMACOL, V44, P559, DOI 10.1146/annurev.pharmtox.44.101802.121558; Tao YX, 2006, PHARMACOL THERAPEUT, V111, P949, DOI 10.1016/j.pharmthera.2006.02.008; Thomas PD, 2003, NUCLEIC ACIDS RES, V31, P334, DOI 10.1093/nar/gkg115; Todman MG, 2005, NEUROSCIENCE, V132, P703, DOI 10.1016/j.neuroscience.2005.01.035; Topaloglu AK, 2009, NAT GENET, V41, P354, DOI 10.1038/ng.306; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Wacker JL, 2008, J BIOL CHEM, V283, P31068, DOI 10.1074/jbc.M805251200; Wakabayashi Y, 2010, J NEUROSCI, V30, P3124, DOI 10.1523/JNEUROSCI.5848-09.2010; Ward BK, 2006, CLIN ENDOCRINOL, V64, P580, DOI 10.1111/j.1365-2265.2006.02512.x; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yang JJ, 2012, ENDOCRINOLOGY, V153, P1498, DOI 10.1210/en.2011-1949; Young J, 2010, J CLIN ENDOCR METAB, V95, P2287, DOI 10.1210/jc.2009-2600; Zhang Y, 2009, PROTEINS, V77, P100, DOI 10.1002/prot.22588	87	9	9	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1924	1937		10.1096/fj.13-240630	http://dx.doi.org/10.1096/fj.13-240630			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24376026	Green Published			2022-12-28	WOS:000335344300036
J	Caron, AZ; He, XH; Mottawea, W; Seifert, EL; Jardine, K; Dewar-Darch, D; Cron, GO; Harper, ME; Stintzi, A; McBurney, MW				Caron, Annabelle Z.; He, Xiaohong; Mottawea, Walid; Seifert, Erin L.; Jardine, Karen; Dewar-Darch, Danielle; Cron, Greg O.; Harper, Mary-Ellen; Stintzi, Alain; McBurney, Michael W.			The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome	FASEB JOURNAL			English	Article						fatty liver; gut microbiota; high-fat diet	DIET-INDUCED OBESITY; GUT MICROBIOTA; HIGH-FAT; HOMEOSTASIS; EXPRESSION; STEATOSIS; DELETION	Type 2 diabetes, hepatic steatosis, and gut dysbiosis are pathophysiological consequences of obesity. Sirtuin (SIRT)-1 is a protein deacetylase implicated in the regulation of metabolic activity. We set out to determine whether the catalytic activity of SIRT1 plays a role in the development of metabolic syndrome, hepatic steatosis, and the distribution of gut microbiota. We challenged with a high-fat diet (HFD) a strain of mice homozygous for a Sirt1 allele carrying a point mutation that ablates the deacetylase activity of SIRT1. When compared to wild-type animals, mice lacking SIRT1 catalytic activity rapidly accumulated excessive hepatic lipid while fed the HFD, an effect evident within 2 wk of HFD feeding. Both white and brown adipose depots became hypertrophic, and the animals developed insulin resistance. The ratio of the major phyla of gut microbiota (Firmicutes and Bacteroidetes) increased rapidly in the SIRT1-deficient mice after HFD challenge. We conclude that the deacetylase activity of SIRT1 plays an important role in regulating glucose and hepatic lipid homeostasis. In addition, the composition of gut microbiota is influenced by both the animals' Sirt1 genotype and diet composition.Caron, A. Z., He, X., Mottawea, W., Seifert, E. L., Jardine, K., Dewar-Darch, D., Cron, G. O., Harper, M.-E., Stintzi, A., McBurney, M. W. The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome.	[Caron, Annabelle Z.; He, Xiaohong; Jardine, Karen; Dewar-Darch, Danielle; Cron, Greg O.; McBurney, Michael W.] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada; [Mottawea, Walid; Harper, Mary-Ellen; Stintzi, Alain; McBurney, Michael W.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L6, Canada; [Seifert, Erin L.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Jefferson University	McBurney, MW (corresponding author), Univ Ottawa, Ottawa Hosp, Res Inst, Program Canc Therapeut,Dept Med, Box 926,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	mmcburney@ohri.ca	Mottawea, Walid/K-6429-2018	Mottawea, Walid/0000-0003-1260-2140; Harper, Mary-Ellen/0000-0003-3864-5886; Cron, Greg/0000-0003-1117-9678	Canadian Institutes for Health Research	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank Dr. Manijeh Daneshmand for help with analysis of the histology. This work was supported by grants from the Canadian Institutes for Health Research.	Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cron G. O., 2013, P INT SOC MAG RESON, V21, P1522; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Le Roy T, 2013, GUT, V62, P1787, DOI 10.1136/gutjnl-2012-303816; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Li X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; McBurney Michael W, 2013, Genes Cancer, V4, P125, DOI 10.1177/1947601912474893; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Morris BJ, 2013, FREE RADICAL BIO MED, V56, P133, DOI 10.1016/j.freeradbiomed.2012.10.525; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Parks BW, 2013, CELL METAB, V17, P141, DOI 10.1016/j.cmet.2012.12.007; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Philp A, 2013, EXERC SPORT SCI REV, V41, P174, DOI 10.1097/JES.0b013e3182956803; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Purushotham A, 2012, MOL CELL BIOL, V32, P1226, DOI 10.1128/MCB.05988-11; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; SALMON DMW, 1985, INT J OBESITY, V9, P443; Seifert EL, 2012, FASEB J, V26, P555, DOI 10.1096/fj.11-193979; Sharma A, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00040; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Spencer MD, 2011, GASTROENTEROLOGY, V140, P976, DOI 10.1053/j.gastro.2010.11.049; Sundararajan A, 2007, BE J THEOR ECON, V7, DOI 10.1186/1471-2180-7-108; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Wang RH, 2010, INT J BIOL SCI, V6, P682; Yamakuchi M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00068; Ye Q., 2012, P INT SOC MAG RESON, V20, P1368	39	56	57	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1306	1316		10.1096/fj.13-243568	http://dx.doi.org/10.1096/fj.13-243568			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24297700				2022-12-28	WOS:000335324800023
J	Hindi, SM; Mishra, V; Bhatnagar, S; Tajrishi, MM; Ogura, Y; Yan, Z; Burkly, LC; Zheng, TS; Kumar, A				Hindi, Sajedah M.; Mishra, Vivek; Bhatnagar, Shephali; Tajrishi, Marjan M.; Ogura, Yuji; Yan, Zhen; Burkly, Linda C.; Zheng, Timothy S.; Kumar, Ashok			Regulatory circuitry of TWEAK-Fn14 system and PGC-1 alpha in skeletal muscle atrophy program	FASEB JOURNAL			English	Article						mitochondria; NF-B; denervation; ubiquitin-proteasome system; MuRF1; MAFBx; SP-1	DNA-DELETION MUTATIONS; TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; KAPPA-B ACTIVATION; PGC-1 COACTIVATORS; TARGETED ABLATION; PROTEIN; TRAF6; CONTRIBUTES; EXPRESSION; SARCOPENIA	Skeletal muscle wasting attributed to inactivity has significant adverse functional consequences. Accumulating evidence suggests that peroxisome proliferator-activated receptor coactivator 1 (PGC-1) and TNF-like weak inducer of apoptosis (TWEAK)-Fn14 system are key regulators of skeletal muscle mass in various catabolic states. While the activation of TWEAK-Fn14 signaling causes muscle wasting, PGC-1 preserves muscle mass in several conditions, including functional denervation and aging. However, it remains unknown whether there is any regulatory interaction between PGC-1 and TWEAK-Fn14 system during muscle atrophy. Here we demonstrate that TWEAK significantly reduces the levels of PGC-1 and mitochondrial content (approximate to 50%) in skeletal muscle. Levels of PGC-1 are significantly increased in skeletal muscle of TWEAK-knockout (KO) and Fn14-KO mice compared to wild-type mice on denervation. Transgenic (Tg) overexpression of PGC-1 inhibited progressive muscle wasting in TWEAK-Tg mice. PGC-1 inhibited the TWEAK-induced activation of NF-B (approximate to 50%) and dramatically reduced (approximate to 90%) the expression of atrogenes such as MAFbx and MuRF1. Intriguingly, muscle-specific overexpression of PGC-1 also prevented the inducible expression of Fn14 in denervated skeletal muscle. Collectively, our study demonstrates that TWEAK induces muscle atrophy through repressing the levels of PGC-1. Overexpression of PGC-1 not only blocks the TWEAK-induced atrophy program but also diminishes the expression of Fn14 in denervated skeletal muscle.Hindi, S. M., Mishra, V., Bhatnagar, S., Tajrishi, M. M., Ogura, Y., Yan, Z., Burkly, L. C., Zheng, T. S., Kumar, A. Regulatory circuitry of TWEAK-Fn14 system and PGC-1 in skeletal muscle atrophy program.	[Hindi, Sajedah M.; Mishra, Vivek; Bhatnagar, Shephali; Tajrishi, Marjan M.; Ogura, Yuji; Kumar, Ashok] Univ Louisville, Dept Anat Sci & Neurobiol, Sch Med, Louisville, KY 40202 USA; [Yan, Zhen] Univ Virginia, Robert M Berne Cardiovasc Res Ctr, Ctr Skeletal Muscle Res, Charlottesville, VA USA; [Burkly, Linda C.; Zheng, Timothy S.] Biogen Idec Inc, Cambridge, MA USA	University of Louisville; University of Virginia; Biogen	Kumar, A (corresponding author), Univ Louisville, Dept Anat Sci & Neurobiol, Sch Med, 500 South Preston St, Louisville, KY 40202 USA.	ashok.kumar@louisville.edu		Yan, Zhen/0000-0002-4826-9813; Kumar, Ashok/0000-0001-8571-2848	U.S. National Institutes of Health [R01AR059810, RO1AG029623]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059810, R01AR050429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG029623] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Dr. Avi Ashkenazi (Genentech, South San Francisco, CA, USA) for providing TWEAK-KO mice. This work was supported by U.S. National Institutes of Health grants R01AR059810 and RO1AG029623 to A. K. The authors declare no conflicts of interest. L. C. B. and T.S.Z are currently employees and stockholders in Biogen Idec. However, this does not alter the authors' adherence to all of the FASEB Journal policies on sharing data and materials.	Aiken J, 2002, ANN NY ACAD SCI, V959, P412, DOI 10.1111/j.1749-6632.2002.tb02111.x; Arany Z, 2008, CURR OPIN GENET DEV, V18, P426, DOI 10.1016/j.gde.2008.07.018; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Bhatnagar S, 2012, CURR MOL MED, V12, P3, DOI 10.2174/156652412798376107; Bhatnagar S, 2012, J CELL PHYSIOL, V227, P1042, DOI 10.1002/jcp.22821; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389; Brault JJ, 2010, J BIOL CHEM, V285, P19460, DOI 10.1074/jbc.M110.113092; Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Calvo JA, 2008, J APPL PHYSIOL, V104, P1304, DOI 10.1152/japplphysiol.01231.2007; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; COGGAN AR, 1992, J GERONTOL, V47, pB71, DOI 10.1093/geronj/47.3.B71; Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052; Dogra C, 2007, FASEB J, V21, P1857, DOI 10.1096/fj.06-7537com; Eisele PS, 2013, J BIOL CHEM, V288, P2246, DOI 10.1074/jbc.M112.375253; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Girgenrath M, 2006, EMBO J, V25, P5826, DOI 10.1038/sj.emboj.7601441; Glass DJ, 2010, CURR OPIN CLIN NUTR, V13, P225, DOI 10.1097/MCO.0b013e32833862df; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hagen JL, 2004, J GERONTOL A-BIOL, V59, P1099, DOI 10.1093/gerona/59.11.1099; Hindi SM, 2012, MOL CELL BIOL, V32, P4833, DOI 10.1128/MCB.00717-12; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Kandarian SC, 2002, EXERC SPORT SCI REV, V30, P111, DOI 10.1097/00003677-200207000-00004; Kerner J, 2001, AM J PHYSIOL-ENDOC M, V281, pE1054; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Li H, 2008, J MOL MED, V86, P1113, DOI 10.1007/s00109-008-0373-8; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lokireddy S, 2012, CELL METAB, V16, P613, DOI 10.1016/j.cmet.2012.10.005; Maecker H, 2005, CELL, V123, P931, DOI 10.1016/j.cell.2005.09.022; McKenzie D, 2002, EUR J BIOCHEM, V269, P2010, DOI 10.1046/j.1432-1033.2002.02867.x; Mittal A, 2010, J CELL BIOL, V188, P833, DOI 10.1083/jcb.200909117; Mourkioti F, 2006, J CLIN INVEST, V116, P2945, DOI 10.1172/JCI28721; Pastoris O, 2000, EXP GERONTOL, V35, P95, DOI 10.1016/S0531-5565(99)00077-7; Paul PK, 2012, MOL CELL BIOL, V32, P1248, DOI 10.1128/MCB.06351-11; Paul PK, 2010, J CELL BIOL, V191, P1395, DOI 10.1083/jcb.201006098; Peterson Courtney M, 2012, J Aging Res, V2012, P194821, DOI 10.1155/2012/194821; Romanello V, 2010, EMBO J, V29, P1774, DOI 10.1038/emboj.2010.60; Rowan SL, 2011, EXP GERONTOL, V46, P660, DOI 10.1016/j.exger.2011.03.005; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Sato S, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044-5040-3-18; Shi JR, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054054, 10.1371/journal.pone.0077651]; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Spate U, 2004, CURR OPIN CLIN NUTR, V7, P265, DOI 10.1097/01.mco.0000126344.88494.de; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Wende AR, 2007, J BIOL CHEM, V282, P36642, DOI 10.1074/jbc.M707006200; Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106; Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488; Wu CL, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016171, 10.1371/journal.pone.0022314]; Zheng TS, 2008, J LEUKOCYTE BIOL, V84, P338, DOI 10.1189/jlb.0308165	53	54	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1398	1411		10.1096/fj.13-242123	http://dx.doi.org/10.1096/fj.13-242123			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24327607	Green Published			2022-12-28	WOS:000335324800031
J	Kurashige, C; Hosono, K; Matsuda, H; Tsujikawa, K; Okamoto, H; Majima, M				Kurashige, Chie; Hosono, Kanako; Matsuda, Hiromi; Tsujikawa, Kazutake; Okamoto, Hirotsugu; Majima, Masataka			Roles of receptor activity-modifying protein 1 in angiogenesis and lymphangiogenesis during skin wound healing in mice	FASEB JOURNAL			English	Article						calcitonin gene-related peptide; CD31; VEGFR-3; macrophages; vascular endothelial growth factor	GENE-RELATED PEPTIDE; COUPLED RECEPTORS; SYSTEM; GROWTH; RAMPS; FACILITATION; MACROPHAGES; MECHANISMS; EXPRESSION; BIOLOGY	Receptor activity-modifying protein 1 (RAMP1) forms a complex with calcitonin receptor-like receptor (CLR) to produce the receptor for calcitonin gene-related peptide (CGRP). CGRP, a 37-aa neuropeptide, is widely distributed in neuronal tissues and exerts its biological effects via CLR/RAMP1; however, the pathophysiological roles of CLR/RAMP1 remain to be clarified. To study the functions of CLR/RAMP1, we generated RAMP1-knockout (RAMP1(-/-)) mice. Compared with those of wild-type (WT) mice, wound healing and wound-induced angiogenesis were significantly suppressed in RAMP1(-/-) mice, with reduced expression of vascular endothelial growth factor (VEGF)-A. Formation of the lymphatic vessels that drain interstitial fluids was also suppressed in RAMP1(-/-) mice, with reduced expression of VEGF-C and VEGFR-3 in wound granulation tissues. RAMP1 was expressed in endothelial cells (ECs) in the preexisting skin blood vessels, but was not observed in ECs in newly formed blood or lymphatic vessels. Macrophages in the wound granulation tissues expressed RAMP1 and produced substantial amounts of VEGF-C in response to CGRP in vitro. RAMP1(-/-) bone marrow chimeric mice showed delayed wound healing with reduced angiogenesis/lymphangiogenesis in wound granulation tissues. These findings suggest that RAMP1 plays a crucial role in wound healing and wound-induced angiogenesis and lymphangiogenesis and that it is a promising target for controlling angiogenesis and lymphangiogenesis.Kurashige, C., Hosono, K., Matsuda, H., Tsujikawa, K., Okamoto, H., Majima, M. Roles of receptor activity-modifying protein 1 in angiogenesis and lymphangiogenesis during skin wound healing in mice.	[Kurashige, Chie; Hosono, Kanako; Matsuda, Hiromi; Majima, Masataka] Kitasato Univ, Sch Med, Dept Pharmacol, Sagamihara, Kanagawa 2520374, Japan; [Kurashige, Chie; Matsuda, Hiromi; Okamoto, Hirotsugu] Kitasato Univ, Sch Med, Dept Anesthesiol, Sagamihara, Kanagawa 2520374, Japan; [Tsujikawa, Kazutake] Osaka Univ, Dept Immunol, Grad Sch Pharmaceut Sci, Suita, Osaka, Japan	Kitasato University; Kitasato University; Osaka University	Majima, M (corresponding author), Kitasato Univ, Sch Med, Sagamihara, Kanagawa 2520374, Japan.	mmajima@med.kitasato-u.ac.jp	Majima, Masataka/ABH-3063-2021		Integrative Research Program of the Graduate School of Medical Science at Kitasato University	Integrative Research Program of the Graduate School of Medical Science at Kitasato University	The authors thank Michiko Ogino, Kyoko Yoshikawa, Mieko Hamano, and Yoshihiro Nara for technical assistance. This study was supported by the Integrative Research Program of the Graduate School of Medical Science at Kitasato University. The authors declare no conflicts of interest.	Adams RH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001875; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Amano H, 2001, JPN J PHARMACOL, V87, P181, DOI 10.1254/jjp.87.181; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; Arai K, 2003, GUT, V52, P1242, DOI 10.1136/gut.52.9.1242; Archbold JK, 2011, TRENDS PHARMACOL SCI, V32, P591, DOI 10.1016/j.tips.2011.05.007; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Bell D, 1996, PHARMACOL REV, V48, P253; Boku K, 2001, GASTROENTEROLOGY, V120, P134, DOI 10.1053/gast.2001.20916; Brain SD, 1996, GEN PHARMACOL, V27, P607, DOI 10.1016/0306-3623(95)00125-5; BROWN M J, 1987, Journal of Cardiovascular Pharmacology, V10, pS82, DOI 10.1097/00005344-198710012-00011; Deng PY, 2005, PEPTIDES, V26, P1676, DOI 10.1016/j.peptides.2005.02.002; DENNIS T, 1989, J PHARMACOL EXP THER, V251, P718; Dunworth WP, 2009, ARTERIOSCL THROM VAS, V29, P650, DOI 10.1161/ATVBAHA.109.185066; Hay DL, 2008, PHARMACOL REV, V60, P143, DOI 10.1124/pr.108.00372; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; Kadmiel M, 2012, ADV EXP MED BIOL, V744, P49, DOI 10.1007/978-1-4614-2364-5_5; Kamoshita E, 2006, AM J PATHOL, V169, P1458, DOI 10.2353/ajpath.2006.051358; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Kataru RP, 2009, BLOOD, V113, P5650, DOI 10.1182/blood-2008-09-176776; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; Langenkamp E, 2009, CELL TISSUE RES, V335, P205, DOI 10.1007/s00441-008-0642-4; Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller G, 2002, SCIENCE, V296, P2121; Mishima T, 2011, AM J PHYSIOL-HEART C, V300, pH431, DOI 10.1152/ajpheart.00466.2010; Morfis M, 2003, TRENDS PHARMACOL SCI, V24, P596, DOI 10.1016/j.tips.2003.09.001; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Ohno T, 2008, GASTROENTEROLOGY, V134, P215, DOI 10.1053/j.gastro.2007.10.001; PREIBISZ JJ, 1993, AM J HYPERTENS, V6, P434, DOI 10.1093/ajh/6.5.434; QUIRION R, 1992, ANN NY ACAD SCI, V657, P88, DOI 10.1111/j.1749-6632.1992.tb22759.x; Saeki T, 2000, ALIMENT PHARM THERAP, V14, P135, DOI 10.1046/j.1365-2036.2000.014s1135.x; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Toda M, 2008, P NATL ACAD SCI USA, V105, P13550, DOI 10.1073/pnas.0800767105; Toda M, 2008, BIOMED PHARMACOTHER, V62, P352, DOI 10.1016/j.biopha.2008.02.003; Tsujikawa K, 2007, P NATL ACAD SCI USA, V104, P16702, DOI 10.1073/pnas.0705974104; Zen AA, 2009, BIOCHEM SOC T, V37, P1221, DOI 10.1042/BST0371221; Zheng SA, 2010, AM J PHYSIOL-CELL PH, V299, pC1485, DOI 10.1152/ajpcell.00173.2010	40	37	38	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1237	1247		10.1096/fj.13-238998	http://dx.doi.org/10.1096/fj.13-238998			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24308973				2022-12-28	WOS:000335324800018
J	Richter, K; Kiefer, KP; Grzesik, BA; Clauss, WG; Fronius, M				Richter, Katrin; Kiefer, Kevin P.; Grzesik, Benno A.; Clauss, Wolfgang G.; Fronius, Martin			Hydrostatic pressure activates ATP-sensitive K channels in lung epithelium by ATP release through pannexin and connexin hemichannels	FASEB JOURNAL			English	Article						mechanotransduction; Ussing chamber; stretch; transepithelial ion transport; Xenopus laevis	SULFONYLUREA RECEPTOR; SIGNAL-TRANSDUCTION; MECHANICAL FORCES; POTASSIUM CHANNEL; SODIUM-CHANNELS; ION-TRANSPORT; AIRWAY; STRESS; PATHWAYS; PROTEIN	Lungs of air-breathing vertebrates are constantly exposed to mechanical forces and therefore are suitable for investigation of mechanotransduction processes in nonexcitable cells and tissues. Freshly dissected Xenopus laevis lungs were used for transepithelial short-circuit current (I-SC) recordings and were exposed to increased hydrostatic pressure (HP; 5 cm fluid column, modified Ussing chamber). I-SC values obtained under HP (I-5cm) were normalized to values before HP (I-0cm) application (I-5cm/I-0cm). Under control conditions, HP decreased I-SC (I-5cm/I-0cm=0.84; n=68; P<0.0001). This effect was reversible and repeatable 30 times. Preincubation with ATP-sensitive K+ channel (K-ATP) inhibitors (HMR1098 and glibenclamide) prevented the decrease in I-SC (I-5cm/I-0cm: HMR1098=1.19, P<0.0001; glibenclamide=1.11, P<0.0001). Similar effects were observed with hemichannel inhibitors (I-5cm/I-0cm: meclofenamic acid=1.09, P<0.0001; probenecid=1.0, P<0.0001). The HP effect was accompanied by release of ATP (P<0.05), determined by luciferin-luciferase luminescence in perfusion solution from the luminal side of an Ussing chamber. ATP release was abrogated by both meclofenamic acid and probenecid. RT-PCR experiments revealed the expression of pannexin and connexin hemichannels and K-ATP subunit transcripts in X. laevis lung. These data show an activation of K-ATP in pulmonary epithelial cells in response to HP that is induced by ATP release through mechanosensitive pannexin and connexin hemichannels. These findings represent a novel mechanism of mechanotransduction in nonexcitable cells.Richter, K., Kiefer, K. P., Grzesik, B. A., Clauss, W. G., Fronius, M. Hydrostatic pressure activates ATP-sensitive K+ channels in lung epithelium by ATP release through pannexin and connexin hemichannels.	[Richter, Katrin; Kiefer, Kevin P.; Clauss, Wolfgang G.; Fronius, Martin] Univ Giessen, Inst Anim Physiol, D-35392 Giessen, Germany; [Grzesik, Benno A.] Univ Giessen, Dept Internal Med, D-35392 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Fronius, M (corresponding author), Univ Giessen, Inst Anim Physiol, Heinrich Buff Ring 26, D-35392 Giessen, Germany.	martin.fronius@bio.uni-giessen.de	Fronius, Martin/K-4118-2013	Richter, Katrin/0000-0002-2450-1083				Althaus M, 2007, FASEB J, V21, P2389, DOI 10.1096/fj.06-7694com; Bao L, 2004, FEBS LETT, V572, P65, DOI 10.1016/j.febslet.2004.07.009; Bardou O, 2009, AM J PHYSIOL-LUNG C, V296, pL145, DOI 10.1152/ajplung.90525.2008; Barth K, 2009, FEBS J, V276, P341, DOI 10.1111/j.1742-4658.2008.06795.x; Bell PD, 2003, P NATL ACAD SCI USA, V100, P4322, DOI 10.1073/pnas.0736323100; Bogdan R, 2008, PFLUG ARCH EUR J PHY, V456, P1109, DOI 10.1007/s00424-008-0486-5; Burke MA, 2008, CIRC RES, V102, P164, DOI 10.1161/CIRCRESAHA.107.165324; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; Burnstock G, 2012, PHARMACOL REV, V64, P834, DOI 10.1124/pr.111.005389; Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086; Cavanaugh KJ, 2001, AM J RESP CELL MOL, V25, P584, DOI 10.1165/ajrcmb.25.5.4486; Chatterjee S, 2006, MICROCIRCULATION, V13, P633, DOI 10.1080/10739680600930255; Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04-10-0912; D'hondt C, 2011, CELL SIGNAL, V23, P305, DOI 10.1016/j.cellsig.2010.07.018; de Boer TP, 2005, DIFFERENTIATION, V73, P330, DOI 10.1111/j.1432-0436.2005.00026.x; Dobbs LG, 2001, COMP BIOCHEM PHYS A, V129, P261, DOI 10.1016/S1095-6433(01)00322-1; Eckle T, 2013, FASEB J, V27, P3078, DOI 10.1096/fj.13-228551; Edwards YS, 2001, COMP BIOCHEM PHYS A, V129, P245, DOI 10.1016/S1095-6433(01)00321-X; FISCHER H, 1989, AM J PHYSIOL, V256, pC764, DOI 10.1152/ajpcell.1989.256.4.C764; Fitz J Gregory, 2007, Trans Am Clin Climatol Assoc, V118, P199; Fox JEM, 2002, BRIT J PHARMACOL, V135, P480, DOI 10.1038/sj.bjp.0704455; Fredberg JJ, 2006, ANNU REV PHYSIOL, V68, P507, DOI 10.1146/annurev.physiol.68.072304.114110; Fronius M, 2004, RESP PHYSIOL NEUROBI, V139, P133, DOI 10.1016/j.resp.2003.09.007; Fronius M., 2012, LUNG DIS SELECTED ST, P561; Fronius M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00146; Gogelein H, 2001, N-S ARCH PHARMACOL, V364, P33, DOI 10.1007/s002100000391; Gogelein H, 1998, J PHARMACOL EXP THER, V286, P1453; Gout Taras, 2012, Ann Thorac Med, V7, P115, DOI 10.4103/1817-1737.98842; Gribble FM, 1998, DIABETES, V47, P1412, DOI 10.2337/diabetes.47.9.1412; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; Hanner F, 2012, AM J PHYSIOL-RENAL, V303, pF1454, DOI 10.1152/ajprenal.00206.2011; Hollenhorst MI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/174306; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597; Kessler S, 2011, PFLUG ARCH EUR J PHY, V462, P419, DOI 10.1007/s00424-011-0980-z; Khakh BS, 2009, SCI AM, V301, P84, DOI 10.1038/scientificamerican1209-84; KIM KJ, 1990, RESP PHYSIOL, V81, P29, DOI 10.1016/0034-5687(90)90067-9; Knight MM, 2009, J ANAT, V214, P275, DOI 10.1111/j.1469-7580.2008.01021.x; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; KREBS HA, 1975, J EXP ZOOL, V194, P221, DOI 10.1002/jez.1401940115; Leroy C, 2004, AM J PHYSIOL-LUNG C, V286, pL1027, DOI 10.1152/ajplung.00249.2003; Li A, 2010, AM J PHYSIOL-CELL PH, V299, pC1308, DOI 10.1152/ajpcell.00333.2010; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667; Luckprom P, 2011, J PERIODONTAL RES, V46, P607, DOI 10.1111/j.1600-0765.2011.01379.x; Maina JN, 2000, ANAT REC, V261, P25; Maina JN, 2005, PHYSIOL REV, V85, P811, DOI 10.1152/physrev.00022.2004; MEBAN C, 1973, J ANAT, V114, P235; Mironov SL, 2000, BRAIN RES, V853, P60, DOI 10.1016/S0006-8993(99)02234-9; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; Okada SF, 2006, J BIOL CHEM, V281, P22992, DOI 10.1074/jbc.M603019200; Okada SF, 2013, AM J RESP CELL MOL, V49, P814, DOI 10.1165/rcmb.2012-0493OC; Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006; Power JHT, 1999, J EXP BIOL, V202, P2543; Prat AG, 1996, AM J PHYSIOL-CELL PH, V270, pC538, DOI 10.1152/ajpcell.1996.270.2.C538; Proks P, 2009, PROG BIOPHYS MOL BIO, V99, P7, DOI 10.1016/j.pbiomolbio.2008.10.002; Ramsingh R., 2011, AM J PHYSIOL-LUNG C, V4, P587; Ransford GA, 2009, AM J RESP CELL MOL, V41, P525, DOI 10.1165/rcmb.2008-0367OC; Reigada D, 2005, AM J PHYSIOL-CELL PH, V288, pC132, DOI 10.1152/ajpcell.00201.2004; Rooney SA, 2001, COMP BIOCHEM PHYS A, V129, P233, DOI 10.1016/S1095-6433(01)00320-8; Sakuma T, 1998, PHARMACOL TOXICOL, V83, P16, DOI 10.1111/j.1600-0773.1998.tb01436.x; Sesma JI, 2013, AM J PHYSIOL-CELL PH, V304, pC976, DOI 10.1152/ajpcell.00371.2012; Shestopalov VI, 2008, CELL MOL LIFE SCI, V65, P376, DOI 10.1007/s00018-007-7200-1; Silverman W, 2008, AM J PHYSIOL-CELL PH, V295, pC761, DOI 10.1152/ajpcell.00227.2008; Sridharan M, 2010, AM J PHYSIOL-HEART C, V299, pH1146, DOI 10.1152/ajpheart.00301.2010; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; VANWAGONER DR, 1993, CIRC RES, V72, P973, DOI 10.1161/01.RES.72.5.973; Wang J, 1997, PHARM RES-DORDR, V14, P1524, DOI 10.1023/A:1012113931332; Waza AA, 2012, EXP CELL RES, V318, P2559, DOI 10.1016/j.yexcr.2012.08.004; Wheeler A, 2008, MOL PHARMACOL, V74, P1333, DOI 10.1124/mol.108.048355; Wirtz HR, 2000, RESP PHYSIOL, V119, P1, DOI 10.1016/S0034-5687(99)00092-4; Zhang HX, 2011, J MOL CELL CARDIOL, V50, P552, DOI 10.1016/j.yjmcc.2010.12.011	72	18	20	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					45	55		10.1096/fj.13-229252	http://dx.doi.org/10.1096/fj.13-229252			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24048216				2022-12-28	WOS:000333526100007
J	Tannour-Louet, M; Lewis, SK; Louet, JF; Stewart, J; Addai, JB; Sahin, A; Vangapandu, HV; Lewis, AL; Dittmar, K; Pautler, RG; Zhang, LX; Smith, RG; Lamb, DJ				Tannour-Louet, Mounia; Lewis, Shaye K.; Louet, Jean-Francois; Stewart, Julie; Addai, Josephine B.; Sahin, Aysegul; Vangapandu, Hima V.; Lewis, Annisa L.; Dittmar, Kristin; Pautler, Robia G.; Zhang, Lixin; Smith, Roy G.; Lamb, Dolores J.			Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies	FASEB JOURNAL			English	Article						biomarkers; adjuvant therapy; RNAi; xenografts	DOSE PULSE CALCITRIOL; PHASE-II TRIAL; 24-HYDROXYLASE ACTIVITY; CANDIDATE ONCOGENE; OVARIAN-CANCER; D SYSTEM; CELLS; DEXAMETHASONE; CARCINOMAS; DOCETAXEL	A major limitation of exogenous vitamin D-3 administration for the treatment of prostate cancer is the marginal, if any, clinical efficacy. We dissected the basis for the resistance to the vitamin D-3 antitumor properties and specifically examined the effect of its major catabolic enzyme, CYP24A1, in prostate cancer. Local CYP24A1 expression levels and the effect of selective modulation were analyzed using tissue microarrays from needle core biopsy specimens and xenograft-bearing mouse models. CYP24A1 mRNA was elevated in malignant human prostate tissues compared to benign lesions. High CYP24A1 protein levels were seen in poorly differentiated and highly advanced stages of prostate cancer and correlated with parallel increase in the tumor proliferation rate. The use of CYP24A1 RNAi enhanced the cytostatic effects of vitamin D-3 in human prostate cancer cells. Remarkably, subcutaneous and orthotopic xenografts of prostate cancer cells harboring CYP24A1 shRNA resulted in a drastic reduction in tumor volume when mice were subjected to vitamin D-3 supplementation. CYP24A1 may be a predictive marker of vitamin D-3 clinical efficacy in patients with advanced prostate cancer. For those with up-regulated CYP24A1, combination therapy with RNAi targeting CYP24A1 could be considered to improve clinical responsiveness to vitamin D-3.Tannour-Louet, M., Lewis, S. K., Louet, J.-F., Stewart, J., Addai, J. B., Sahin, A., Vangapandu, H. V., Lewis, A. L., Dittmar, K., Pautler, R. G., Zhang, L., Smith, R. G., Lamb, D. J. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D-3-based therapies.	[Tannour-Louet, Mounia; Lewis, Shaye K.; Stewart, Julie; Addai, Josephine B.; Sahin, Aysegul; Vangapandu, Hima V.; Zhang, Lixin; Lamb, Dolores J.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; [Louet, Jean-Francois; Lamb, Dolores J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Pautler, Robia G.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Pautler, Robia G.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Pautler, Robia G.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Lamb, Dolores J.] Baylor Coll Med, Ctr Reprod Med, Houston, TX 77030 USA; [Lewis, Annisa L.] Weill Cornell Med Coll, Dept Pathol, Houston, TX USA; [Dittmar, Kristin] Weill Cornell Med Coll, Dept Radiol, Houston, TX USA; [Dittmar, Kristin] Methodist Hosp, Houston, TX 77030 USA; [Smith, Roy G.] Scripps Res Inst Florida, Dept Metab & Aging, Jupiter, FL USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Cornell University; Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston; Scripps Research Institute	Tannour-Louet, M (corresponding author), Baylor Coll Med, 1 Baylor Plaza, Houston, TX 77030 USA.	mounia.louet@gmail.com	Dittmar, Kristin/E-8815-2015; Zhang, Li/GWM-7501-2022; TANNOUR LOUET, Mounia/G-5413-2017; Mounia, TANNOUR LOUET/T-2622-2019	TANNOUR LOUET, Mounia/0000-0003-0614-063X; Mounia, TANNOUR LOUET/0000-0003-0614-063X; Louet, Jean-Francois/0000-0002-1626-7098; Vangapandu, Hima/0000-0003-4762-1990	U.S. Department of Defense, Prostate Cancer Research Program Idea Development Award [W81XWH-07-1-0022 PC061154]; William and Ella Owens Medical Research Foundation; Prostate Cancer Research Initiative; U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) [1C76HF02799-01-00]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK083014] Funding Source: NIH RePORTER	U.S. Department of Defense, Prostate Cancer Research Program Idea Development Award; William and Ella Owens Medical Research Foundation; Prostate Cancer Research Initiative; U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the U.S. Department of Defense, Prostate Cancer Research Program Idea Development Award W81XWH-07-1-0022 PC061154 to D.J.L.; a William and Ella Owens Medical Research Foundation grant to M. T. L. and D.J.L.; and a Prostate Cancer Research Initiative grant to D.J.L. The authors thank the Mouse Phenotype Core at Baylor College of Medicine, supported by the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) grant 1C76HF02799-01-00. The authors declare no conflicts of interest.	Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Anderson MG, 2006, CANCER CHEMOTH PHARM, V57, P234, DOI 10.1007/s00280-005-0059-7; Bareis P, 2001, BIOCHEM BIOPH RES CO, V285, P1012, DOI 10.1006/bbrc.2001.5289; Beer TM, 2004, CANCER EPIDEM BIOMAR, V13, P2225; Beer TM, 2007, J CLIN ONCOL, V25, P669, DOI 10.1200/JCO.2006.06.8197; Buffart TE, 2009, VIRCHOWS ARCH, V455, P213, DOI 10.1007/s00428-009-0814-y; Cross HS, 2005, J STEROID BIOCHEM, V97, P121, DOI 10.1016/j.jsbmb.2005.06.005; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Flaig TW, 2006, CANCER-AM CANCER SOC, V107, P266, DOI 10.1002/cncr.21982; Friedrich M, 2003, RECENT RES CANCER, V164, P239; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Liu G, 2003, CLIN CANCER RES, V9, P4077; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Mimori K, 2004, ANN ONCOL, V15, P236, DOI 10.1093/annonc/mdh056; Mitschele T, 2004, LAB INVEST, V84, P693, DOI 10.1038/labinvest.3700096; Parise RA, 2006, INT J CANCER, V119, P1819, DOI 10.1002/ijc.22058; Peehl DM, 2002, J UROLOGY, V168, P1583, DOI 10.1016/S0022-5347(05)64525-9; Schwartz GG, 2009, ANN EPIDEMIOL, V19, P96, DOI 10.1016/j.annepidem.2008.03.007; Schwartz GG, 2005, CLIN CANCER RES, V11, P8680, DOI 10.1158/1078-0432.CCR-05-1237; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tiffany NM, 2005, J UROLOGY, V174, P888, DOI 10.1097/01.ju.0000169261.42298.e6; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Trump DL, 2006, CANCER-AM CANCER SOC, V106, P2136, DOI 10.1002/cncr.21890; Weiss MM, 2003, J PATHOL, V200, P320, DOI 10.1002/path.1359	26	43	45	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					364	372		10.1096/fj.13-236109	http://dx.doi.org/10.1096/fj.13-236109			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24081904	Green Published			2022-12-28	WOS:000333526100034
J	Roy, S; Boiteux, C; Alijevic, O; Liang, CW; Berneche, S; Kellenberger, S				Roy, Sophie; Boiteux, Celine; Alijevic, Omar; Liang, Chungwen; Berneche, Simon; Kellenberger, Stephan			Molecular determinants of desensitization in an ENaC/degenerin channel	FASEB JOURNAL			English	Article						acid-sensing ion channel; channel gating; molecular dynamics; pH	ACID-SENSING ION-CHANNEL-1; EXTRACELLULAR DOMAIN; DEG/ENAC CHANNEL; SODIUM-CHANNEL; ION CHANNELS; ASIC1; LINKER; PORE; CONFORMATION; ACTIVATION	Epithelial Na+ channel (ENaC)/degenerin family members are involved in mechanosensation, blood pressure control, pain sensation, and the expression of fear. Several of these channel types display a form of desensitization that allows the channel to limit Na+ influx during prolonged stimulation. We used site-directed mutagenesis and chemical modification, functional analysis, and molecular dynamics simulations to investigate the role of the lower palm domain of the acid-sensing ion channel 1, a member of the ENaC/degenerin family. The lower palm domains of this trimeric channel are arranged around a central vestibule, at similar to 20 angstrom above the plasma membrane and are covalently linked to the transmembrane channel parts. We show that the lower palm domains approach one another during desensitization. Residues in the palm co-determine the pH dependence of desensitization, its kinetics, and the stability of the desensitized state. Mutations of palm residues impair desensitization by preventing the closing movement of the palm. Overexpression of desensitization-impaired channel mutants in central neurons allowed-in contrast to overexpression of wild type-a sustained signaling response to rapid pH fluctuations. We identify and describe here the function of an important regulatory domain that most likely has a conserved role in ENaC/degenerin channels.	[Roy, Sophie; Alijevic, Omar; Kellenberger, Stephan] Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; [Boiteux, Celine; Liang, Chungwen; Berneche, Simon] Univ Basel, Swiss Inst Bioinformat, Basel, Switzerland; [Boiteux, Celine; Liang, Chungwen; Berneche, Simon] Univ Basel, Biozentrum, Basel, Switzerland	University of Lausanne; Swiss Institute of Bioinformatics; University of Basel; University of Basel	Kellenberger, S (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	stephan.kellenberger@unil.ch		Kellenberger, Stephan/0000-0003-1755-6198	Swiss National Science Foundation [310030_135542, P3_139205]; Swiss National Supercomputing Center [s241]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Supercomputing Center	The authors thank Maxime Blanchard for the experiments with excised patches and Laurent Schild, Miguel van Bemmelen, Olivier Staub, Karolina Gwiazda, Gaetano Bonifacio, and Claudia Suenaga-Lelli for their comments on a previous version of the manuscript. This work was supported by grant 310030_135542 (S. K.) and professorship P3_139205 (S. B.) from the Swiss National Science Foundation, and Project s241 of the Swiss National Supercomputing Center (S.B).	Babini E, 2002, J BIOL CHEM, V277, P41597, DOI 10.1074/jbc.M205877200; Baconguis I, 2012, NATURE, V489, P400, DOI 10.1038/nature11375; Bargeton B, 2010, J BIOL CHEM, V285, P13816, DOI 10.1074/jbc.M109.086843; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Cushman KA, 2007, J GEN PHYSIOL, V129, P345, DOI 10.1085/jgp.200709757; Dawson RJP, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1917; Della Vecchia MC, 2013, J BIOL CHEM, V288, P5487, DOI 10.1074/jbc.M112.441964; Eastwood AL, 2012, PHYSIOLOGY, V27, P282, DOI 10.1152/physiol.00006.2012; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Gonzales EB, 2009, NATURE, V460, P599, DOI 10.1038/nature08218; Horisberger JD., 2004, NEPHRON PHYSIOL, V96, P37, DOI [10.1159/000076406, DOI 10.1159/000076406]; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Kashlan OB, 2011, J BIOL CHEM, V286, P649, DOI 10.1074/jbc.M110.167098; Li TB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1409; Li TB, 2010, J BIOL CHEM, V285, P31285, DOI 10.1074/jbc.M110.160382; Li TB, 2010, J BIOL CHEM, V285, P22706, DOI 10.1074/jbc.M110.134114; Li TB, 2009, J BIOL CHEM, V284, P4689, DOI 10.1074/jbc.M805302200; Liechti LA, 2010, J BIOL CHEM, V285, P16315, DOI 10.1074/jbc.M109.092015; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; O'Hagan R, 2005, NAT NEUROSCI, V8, P43, DOI 10.1038/nn1362; Paukert M, 2008, J BIOL CHEM, V283, P572, DOI 10.1074/jbc.M706811200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Schild L, 2010, BBA-MOL BASIS DIS, V1802, P1159, DOI 10.1016/j.bbadis.2010.06.014; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; Smart O. S., 1996, J MOL GRAPHICS, V14, P376, DOI [DOI 10.1016/S0263-7855(97)00009-X, 10.1016/S0263-7855119000009-21]; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Springauf A, 2011, J BIOL CHEM, V286, P24374, DOI 10.1074/jbc.M111.230797; Wemmie JA, 2013, NAT REV NEUROSCI, V14, P461, DOI 10.1038/nrn3529	31	28	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5034	5045		10.1096/fj.13-230680	http://dx.doi.org/10.1096/fj.13-230680			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24018065	Green Submitted			2022-12-28	WOS:000329999000036
J	Ackermann, MA; Patel, PD; Valenti, J; Takagi, Y; Homsher, E; Sellers, JR; Kontrogianni-Konstantopoulos, A				Ackermann, Maegen A.; Patel, Puja D.; Valenti, Jane; Takagi, Yasuharu; Homsher, Earl; Sellers, James R.; Kontrogianni-Konstantopoulos, Aikaterini			Loss of actomyosin regulation in distal arthrogryposis myopathy due to mutant myosin binding protein-C slow	FASEB JOURNAL			English	Article						actin; contractility; MYBPC1; skeletal muscle	RABBIT SKELETAL-MUSCLE; MYBP-C; CARDIAC MYOSIN; THICK FILAMENT; F-ACTIN; DOMAIN; MUTATIONS; ISOFORM; SITE; CONTRACTION	Myosin binding protein C (MyBP-C) is expressed in striated muscles, where it plays key roles in the modulation of actomyosin cross-bridges. Slow MyBP-C (sMyBP-C) consists of multiple variants sharing common domains but also containing unique segments within the NH2 and COOH termini. Two missense mutations in the NH2 terminus (W236R) and COOH terminus (Y856H) of sMyBP-C have been causally linked to the development of distal arthrogryposis-1 (DA-1), a severe skeletal muscle disorder. Using a combination of in vitro binding and motility assays, we show that the COOH terminus mediates binding of sMyBP-C to thick filaments, while the NH2 terminus modulates the formation of actomyosin cross-bridges in a variant-specific manner. Consistent with this, a recombinant NH2-terminal peptide that excludes residues 34-59 reduces the sliding velocity of actin filaments past myosin heads from 9.0 +/- 1.3 to 5.7 +/- 1.0 m/s at 0.1 M, while a recombinant peptide that excludes residues 21-59 fails to do so. Notably, the actomyosin regulatory properties of sMyBP-C are completely abolished by the presence of the DA-1 mutations. In summary, our studies are the first to show that the NH2 and COOH termini of sMyBP-C have distinct functions, which are regulated by differential splicing, and are compromized by the presence of missense point mutations linked to muscle disease.Ackermann, M. A., Patel, P. D., Valenti, J., Takagi, Y., Homsher, E., Sellers, J. R., Kontrogiannni-Konstantopoulos, A. Loss of actomyosin regulation in distal arthrogryposis myopathy due to mutant myosin binding protein-C slow.	[Ackermann, Maegen A.; Patel, Puja D.; Valenti, Jane; Kontrogianni-Konstantopoulos, Aikaterini] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Takagi, Yasuharu; Sellers, James R.] NHLBI, NIH, Bethesda, MD 20892 USA; [Homsher, Earl] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kontrogianni-Konstantopoulos, A (corresponding author), Univ Maryland, Sch Med, 108 N Greene St, Baltimore, MD 21201 USA.	akons001@umaryland.edu		Patel, Puja/0000-0002-7595-1340	U.S. National Institutes of Health (NIH) [R01-AR-52768]; NIH (intramural funds from National Heart, Lung, and Blood Institute); NIH [F32-AR-058079]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL001786, K99HL116778, ZIAHL006174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR058079, R01AR052768] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH (intramural funds from National Heart, Lung, and Blood Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This research has been supported by grants to A. K. K. from the U.S. National Institutes of Health (NIH; R01-AR-52768), to J.R.S from the NIH (intramural funds from National Heart, Lung, and Blood Institute), and to M. A. A. from the NIH (F32-AR-058079).	Ababou A, 2007, J BIOL CHEM, V282, P9204, DOI 10.1074/jbc.M610899200; Ackermann MA, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/636403; Ackermann MA, 2011, J PROTEOME RES, V10, P4547, DOI 10.1021/pr200355w; Ackermann MA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/652065; Ackermann MA, 2009, MOL BIOL CELL, V20, P2963, DOI 10.1091/mbc.E08-12-1251; Alyonycheva TN, 1997, J BIOL CHEM, V272, P20866, DOI 10.1074/jbc.272.33.20866; Borzok MA, 2007, J BIOL CHEM, V282, P32384, DOI 10.1074/jbc.M704089200; de Tombe PP, 2006, CIRC RES, V98, P1234, DOI 10.1161/01.RES.0000225873.63162.c4; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; Flashman E, 2007, BIOCHEM J, V401, P97, DOI 10.1042/BJ20060500; Gautel M, 1998, CIRC RES, V82, P124; Gilbert R, 1996, J CELL SCI, V109, P101; Gruen M, 1999, J MOL BIOL, V286, P933, DOI 10.1006/jmbi.1998.2522; Gurnett CA, 2010, HUM MOL GENET, V19, P1165, DOI 10.1093/hmg/ddp587; Harris SP, 2011, CIRC RES, V108, P751, DOI 10.1161/CIRCRESAHA.110.231670; HOMSHER E, 1993, ADV EXP MED BIOL, V332, P279; Homsher E, 1993, ADV EXP MED BIOL, V332, P289; James J, 2011, J BIOL CHEM, V286, P9913, DOI 10.1074/jbc.R110.171801; Jana SS, 2009, J BIOL CHEM, V284, P11563, DOI 10.1074/jbc.M806574200; Kensler RW, 2011, J STRUCT BIOL, V174, P44, DOI 10.1016/j.jsb.2010.12.003; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Markus B, 2012, HUM MUTAT, V33, P1435, DOI 10.1002/humu.22122; Martyn DA, 2004, J MOL CELL CARDIOL, V37, P813, DOI 10.1016/j.yjmcc.2004.07.005; McClellan G, 2004, J MOL CELL CARDIOL, V37, P823, DOI 10.1016/j.yjmcc.2004.05.023; MOOS C, 1978, J MOL BIOL, V124, P571, DOI 10.1016/0022-2836(78)90172-9; MOOS C, 1975, J MOL BIOL, V97, P1, DOI 10.1016/S0022-2836(75)80017-9; Oakley CE, 2007, INT J BIOCHEM CELL B, V39, P2161, DOI 10.1016/j.biocel.2006.12.008; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; Ratti J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.156646; Rybakova IN, 2011, J BIOL CHEM, V286, P2008, DOI 10.1074/jbc.M110.170605; Sellers J. R., 2001, CURR PROTOC CELL BIO, V13; SELLERS JR, 1991, J CELL SCI, P67; Shaffer JF, 2009, J BIOL CHEM, V284, P12318, DOI 10.1074/jbc.M808850200; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 2003, J MOL BIOL, V331, P713, DOI 10.1016/S0022-2836(03)00781-2; Vydyanath A, 2012, J MUSCLE RES CELL M, V33, P61, DOI 10.1007/s10974-012-9286-9; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; Welikson RE, 2002, J CELL SCI, V115, P3517; YASUDA M, 1995, J MOL CELL CARDIOL, V27, P2275, DOI 10.1016/S0022-2828(95)91731-4	41	27	27	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3217	3228		10.1096/fj.13-228882	http://dx.doi.org/10.1096/fj.13-228882			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23657818	Green Published			2022-12-28	WOS:000329877600027
J	Barcelona, PF; Jaldin-Fincati, JR; Sanchez, MC; Chiabrando, GA				Barcelona, Pablo F.; Jaldin-Fincati, Javier R.; Sanchez, Maria C.; Chiabrando, Gustavo A.			Activated alpha(2)-macroglobulin induces Muller glial cell migration by regulating MT1-MMP activity through LRP1	FASEB JOURNAL			English	Article						endocytosis; intracellular traffic; proteases; retina; retinopathies	RECEPTOR-RELATED PROTEIN-1; TYPE-1 MATRIX-METALLOPROTEINASE; FIBRILLARY ACIDIC PROTEIN; PREGNANCY ZONE PROTEIN; NERVE GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; RETINAL-DETACHMENT; IN-VITRO; 1-MATRIX METALLOPROTEINASE; PERICELLULAR PROTEOLYSIS	In retinal proliferative diseases, Muller glial cells (MGCs) acquire migratory abilities. However, the mechanisms that regulate this migration remain poorly understood. In addition, proliferative disorders associated with enhanced activities of matrix metalloprotease 2 (MMP-2) and MMP-9 also present increased levels of the protease inhibitor (2)-macroglobulin (M-2) and its receptor, the low-density lipoprotein receptor-related protein 1 (LRP1). In the present work, we investigated whether the protease activated form of M-2, M-2*, and LRP1 are involved with the MGC migratory process. By performing wound-scratch migration and zymography assays, we demonstrated that M-2* induced cell migration and proMMP-2 activation in the human Muller glial cell line, MIO-M1. This induction was blocked when LRP1 and MT1-MMP were knocked down with siRNA techniques. Using fluorescence microscopy and biochemical procedures, we found that M-2* induced an increase in LRP1 and MT1-MMP accumulation in early endosomes, followed by endocytic recycling and intracellular distribution of MT1-MMP toward cellular protrusions. Moreover, Rab11-dominant negative mutant abrogated MT1-MMP recycling pathway, cell migration, and proMMP-2 activation induced by M-2*. In conclusion, M-2*, through its receptor LRP1, induces cellular migration of Muller glial cells by a mechanism that involves MT1-MMP intracellular traffic to the plasma membrane by a Rab11-dependent recycling pathway.	[Barcelona, Pablo F.; Jaldin-Fincati, Javier R.; Sanchez, Maria C.; Chiabrando, Gustavo A.] Univ Nacl Cordoba, Dept Bioquim Clin, Fac Ciencias Quim, Ctr Invest Bioquim Clin & Inmunol Consejo Nacl In, RA-5000 Cordoba, Argentina	National University of Cordoba	Chiabrando, GA (corresponding author), Univ Nacl Cordoba, Dept Bioquim Clin, Fac Ciencias Quim, Ctr Invest Bioquim Clin & Inmunol Consejo Nacl In, Ciudad Univ, RA-5000 Cordoba, Argentina.	csanchez@fcq.unc.edu.ar; gustavo@fcq.unc.edu.ar	Barcelona, Pablo Federico/AAJ-8440-2020	Barcelona, Pablo/0000-0001-8248-2282; Jaldin-Fincati, Javier Roberto/0000-0002-9490-4785	Secretaria de Ciencia y Tecnologia de la Universidad Nacional de Cordoba (SECyTUNC) [214/10, 26/1169/08]; Fondo para la Investigacion Cientifica y Tecnologica (FONCyT): Prestamo BID Proyecto de Investigacion en Ciencia y Tecnolog a (PICT) [06-01207]; Proyecto de Investigacion en Ciencia y Tecnolog a Orientados (PICTO)-Glaxo [2012-0084]; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) Proyecto de Investigacion Plurianual (PIP) [112-200801-02067]	Secretaria de Ciencia y Tecnologia de la Universidad Nacional de Cordoba (SECyTUNC)(Secretaria de Ciencia y Tecnologia (SECYT)); Fondo para la Investigacion Cientifica y Tecnologica (FONCyT): Prestamo BID Proyecto de Investigacion en Ciencia y Tecnolog a (PICT); Proyecto de Investigacion en Ciencia y Tecnolog a Orientados (PICTO)-Glaxo; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) Proyecto de Investigacion Plurianual (PIP)	This work was supported in part by Secretaria de Ciencia y Tecnologia de la Universidad Nacional de Cordoba (SECyTUNC) grants 214/10 and 26/1169/08, Fondo para la Investigacion Cientifica y Tecnologica (FONCyT): Prestamo BID Proyecto de Investigacion en Ciencia y Tecnolog a (PICT) grant 06-01207, Proyecto de Investigacion en Ciencia y Tecnolog a Orientados (PICTO)-Glaxo grant 2012-0084, and Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) Proyecto de Investigacion Plurianual (PIP) grant 112-200801-02067. P. B. and J.J-F. are doctoral fellows of CONICET. M. C. S. and G. A. C. are members of the Research Career of CONICET. The authors thank Dr. Paul D. Hobson, native speaker, for revising the manuscript.	Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Bai YJ, 2011, INVEST OPHTH VIS SCI, V52, P5260, DOI 10.1167/iovs.10-6691; Barcelona PF, 2010, EXP EYE RES, V91, P264, DOI 10.1016/j.exer.2010.05.017; Barcelona PF, 2011, INVEST OPHTH VIS SCI, V52, P778, DOI 10.1167/iovs.10-5759; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Bonacci GR, 2007, ARCH BIOCHEM BIOPHYS, V460, P100, DOI 10.1016/j.abb.2007.01.004; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bull ND, 2008, INVEST OPHTH VIS SCI, V49, P3449, DOI 10.1167/iovs.08-1770; Caceres LC, 2010, J CELL BIOCHEM, V111, P607, DOI 10.1002/jcb.22737; Cao J, 2004, J BIOL CHEM, V279, P14129, DOI 10.1074/jbc.M312120200; Chiabrando G, 1997, PROTEIN EXPRES PURIF, V9, P399, DOI 10.1006/prep.1996.0680; Chiabrando GA, 2002, J NEUROSCI RES, V70, P57, DOI 10.1002/jnr.10369; CHU CT, 1994, LAB INVEST, V71, P792; Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090; Frittoli E, 2011, EUR J CELL BIOL, V90, P108, DOI 10.1016/j.ejcb.2010.04.007; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; Gonias SL, 2011, CURR PHARM DESIGN, V17, P1962; Gorovoy M, 2010, J LEUKOCYTE BIOL, V88, P769, DOI 10.1189/jlb.0410220; Guidry C, 2005, PROG RETIN EYE RES, V24, P75, DOI 10.1016/j.preteyeres.2004.07.001; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hollborn MR, 2004, LAB INVEST, V84, P963, DOI 10.1038/labinvest.3700121; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kim IB, 1998, EXP BRAIN RES, V121, P419, DOI 10.1007/s002210050476; Kimura H, 1999, INVEST OPHTH VIS SCI, V40, P524; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Laatsch A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029385; Lehti K, 2009, J CELL SCI, V122, P126, DOI 10.1242/jcs.035279; Lewis G, 1999, AM J OPHTHALMOL, V128, P165, DOI 10.1016/S0002-9394(99)00103-8; LEWIS GP, 1995, INVEST OPHTH VIS SCI, V36, P2404; Li XY, 2008, MOL BIOL CELL, V19, P3221, DOI 10.1091/mbc.E08-01-0016; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Limb GA, 2002, AM J PATHOL, V160, P1847, DOI 10.1016/S0002-9440(10)61131-5; Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864; Llorente-Cortes V, 2002, ARTERIOSCL THROM VAS, V22, P1905, DOI 10.1161/01.ATV.0000035391.46201.9A; Mantuano E, 2008, J BIOL CHEM, V283, P19904, DOI 10.1074/jbc.M801762200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Muratoglu SC, 2010, J BIOL CHEM, V285, P14308, DOI 10.1074/jbc.M109.046672; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; Noda K, 2003, INVEST OPHTH VIS SCI, V44, P2163, DOI 10.1167/iovs.02-0662; Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Ranganathan S, 2004, J BIOL CHEM, V279, P40536, DOI 10.1074/jbc.M407592200; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Romo P, 2011, ACTA OPHTHALMOL, V89, pe263, DOI 10.1111/j.1755-3768.2010.01968.x; Sanchez MC, 2007, EXP EYE RES, V85, P644, DOI 10.1016/j.exer.2007.07.018; Sanchez MC, 2006, EXP EYE RES, V83, P1378, DOI 10.1016/j.exer.2006.07.016; Sanchez MC, 2001, ARCH BIOCHEM BIOPHYS, V389, P218, DOI 10.1006/abbi.2001.2329; Schram K, 2011, ENDOCRINOLOGY, V152, P2037, DOI 10.1210/en.2010-1166; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Sethi CS, 2005, INVEST OPHTH VIS SCI, V46, P329, DOI 10.1167/iovs.03-0518; Shi Y, 2011, J NEUROSCI RES, V89, P544, DOI 10.1002/jnr.22576; Shi ZH, 2008, J BIOL CHEM, V283, P29156, DOI 10.1074/jbc.M802365200; Strongin AY, 2010, BBA-MOL CELL RES, V1803, P133, DOI 10.1016/j.bbamcr.2009.04.009; Tackenberg MA, 2009, MOL VIS, V15, P1886; Tang BL, 2009, CELL MOTIL CYTOSKEL, V66, P365, DOI 10.1002/cm.20376; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wang Y, 2002, CURR EYE RES, V24, P305, DOI 10.1076/ceyr.24.4.305.8408; Wickramasinghe RD, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-58; Williams KC, 2011, J BIOL CHEM, V286, P43405, DOI 10.1074/jbc.M111.297069; Xue LP, 2006, NEUROSCIENCE, V139, P723, DOI 10.1016/j.neuroscience.2005.12.032; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	65	28	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3181	3197		10.1096/fj.12-221598	http://dx.doi.org/10.1096/fj.12-221598			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23640058				2022-12-28	WOS:000329877600024
J	Elferich, J; Williamson, DM; Krishnamoorthy, B; Shinde, U				Elferich, Johannes; Williamson, Danielle M.; Krishnamoorthy, Bala; Shinde, Ujwal			Propeptides of eukaryotic proteases encode histidines to exploit organelle pH for regulation	FASEB JOURNAL			English	Article						secretory pathway; cathepsins	INTRAMOLECULAR CHAPERONE; PROPROTEIN CONVERTASE; CARBOXYL PROTEINASE; OCCLUDING LOOP; ACTIVATION; FURIN; IDENTIFICATION; EXPRESSION; SUBTILASES	Eukaryotic cells maintain strict control over protein secretion, in part by using the pH gradient maintained within their secretory pathway. How eukaryotic proteins evolved from prokaryotic orthologs to exploit the pH gradient for biological functions remains a fundamental question in cell biology. Our laboratory previously demonstrated that protein domains located within precursor proteins, propeptides, encode histidine-driven pH sensors to regulate organelle-specific activation of the eukaryotic proteases furin and proprotein convertase-1/3. Similar findings have been reported in other unrelated protease families. By analyzing >10,000 unique proteases within evolutionarily unrelated families, we show that eukaryotic propeptides are enriched in histidines compared with prokaryotic orthologs. On this basis, we hypothesize that eukaryotic proteins evolved to enrich histidines within their propeptides to exploit the tightly controlled pH gradient of the secretory pathway, thereby regulating activation within specific organelles. Enrichment of histidines in propeptides may therefore be used to predict the presence of pH sensors in other proteases or even protease substrates.	[Elferich, Johannes; Williamson, Danielle M.; Shinde, Ujwal] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; [Krishnamoorthy, Bala] Washington State Univ, Dept Math, Pullman, WA 99164 USA	Oregon Health & Science University; Washington State University	Shinde, U (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	shindeu@ohsu.edu	Krishnamoorthy, Bala/GVR-7967-2022	Elferich, Johannes/0000-0002-9911-706X	U.S. National Science Foundation [MCB0746589]; American Heart Foundation [12PRE11470005]; U.S. National Institutes of Health; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F30DK096752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM071338] Funding Source: NIH RePORTER; Div Of Molecular and Cellular Bioscience [0746589] Funding Source: National Science Foundation	U.S. National Science Foundation(National Science Foundation (NSF)); American Heart Foundation(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	This work was supported by the U.S. National Science Foundation (career award MCB0746589) and the American Heart Foundation (grant-in-aid to U.S.), the U.S. National Institutes of Health (training grant to D.M.W.), and the American Heart Association (predoctoral training grant 12PRE11470005 to J.E.).	Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Degnin C, 2004, MOL BIOL CELL, V15, P5012, DOI 10.1091/mbc.E04-08-0673; Dillon SL, 2012, J MOL BIOL, V423, P47, DOI 10.1016/j.jmb.2012.06.023; Embley TM, 2006, NATURE, V440, P623, DOI 10.1038/nature04546; Feliciangeli SF, 2006, J BIOL CHEM, V281, P16108, DOI 10.1074/jbc.M600760200; GUNKEL FA, 1989, EUR J BIOCHEM, V179, P185, DOI 10.1111/j.1432-1033.1989.tb14539.x; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Naghavi M, 2002, ATHEROSCLEROSIS, V164, P27, DOI 10.1016/S0021-9150(02)00018-7; Newcombe RG, 2006, STAT MED, V25, P543, DOI 10.1002/sim.2323; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; Oyama H, 2002, J BIOCHEM, V131, P757, DOI 10.1093/oxfordjournals.jbchem.a003162; Quraishi O, 1999, BIOCHEMISTRY-US, V38, P5017, DOI 10.1021/bi981950o; Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918; Seidah NG, 2012, NAT REV DRUG DISCOV, V11, P367, DOI 10.1038/nrd3699; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Shinde U, 2011, METHODS MOL BIOL, V768, P59, DOI 10.1007/978-1-61779-204-5_4; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Subbian E, 2005, J MOL BIOL, V347, P367, DOI 10.1016/j.jmb.2005.01.028; Tsiatsiani L, 2011, CELL DEATH DIFFER, V18, P1279, DOI 10.1038/cdd.2011.66; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81	29	1	1	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2939	2945		10.1096/fj.12-226886	http://dx.doi.org/10.1096/fj.12-226886			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23585398	Green Published			2022-12-28	WOS:000329877600002
J	Carlo, T; Kalwa, H; Levy, BD				Carlo, Troy; Kalwa, Hermann; Levy, Bruce D.			15-Epi-lipoxin A(4) inhibits human neutrophil superoxide anion generation by regulating polyisoprenyl diphosphate phosphatase 1	FASEB JOURNAL			English	Article						resolution; lipid mediators; inflammation; anti-inflammatory	PROTEIN-KINASE-C; FUNCTIONAL-CHARACTERIZATION; ACUTE-INFLAMMATION; PHOSPHOLIPASE-D; ACTIVATION; PHOSPHORYLATION; RESOLUTION	Regulation of leukocyte activation is critical to limit unintended tissue injury during acute inflammation. On neutrophil activation, polyisoprenyl diphosphate phosphatase 1 (PDP1) rapidly converts presqualene diphosphate to presqualene monophosphate to facilitate cell activation. Lipoxins are potent anti-inflammatory mediators for neutrophils, yet their counterregulatory signaling mechanisms remain to be determined. 15-Epi-lipoxin A(4) (15-epi-LXA(4)) blocked agonist-initiated association of the nicotinamide adenine dinucleotide phosphate oxidase components p47(PHOX) and p22(PHOX) in human neutrophils. 15-Epi-LXA(4) (0.1-100 nM) inhibited neutrophil superoxide anion (O-2(-)) generation in a concentration- and ALX/FPR2 receptor-dependent manner that was disrupted by PDP1-specific antibodies. In differentiated HL60 cells, a myeloid cell line, agonist-initiated O-2(-) generation was inhibited by PDP1 siRNA. Recombinant human PDP1 was directly phosphorylated in vitro by select protein kinase C (PKC) isoforms, including PKCII. When neutrophils were exposed to formyl-methionyl-leucyl-phenylalanine (fMLP), PKCII was rapidly phosphorylated and physically associated with PDP1. Agonist-initiated conversion of neutrophil presqualene diphosphate to presqualene monophosphate was blocked by PKCII inhibition. Neutrophil exposure to 15-epi-LXA(4) attenuated fMLP triggered PKCII phosphorylation and its interactions with PDP1. Together, these findings indicate that PDP1 serves an integral signaling role in neutrophil proinflammatory responses and as a target for counter-regulatory mediators.Carlo, T., Kalwa, H., Levy, B. D. 15-Epi-lipoxin A(4) inhibits human neutrophil superoxide anion generation by regulating polyisoprenyl diphosphate phosphatase 1.	[Carlo, Troy; Levy, Bruce D.] Brigham & Womens Hosp, Dept Internal Med, Pulm & Crit Care Med Div, Boston, MA 02115 USA; [Kalwa, Hermann] Brigham & Womens Hosp, Dept Internal Med, Cardiovasc Med Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Levy, BD (corresponding author), Brigham & Womens Hosp, Boston, MA 02115 USA.	blevy@partners.org	Kalwa, Hermann/ABG-2323-2021		U.S. National Heart, Lung, and Blood Institute [HL68669, HL090927]; American Heart Association [12SDG8900005]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090927, R01HL068669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM095467] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Roxanne Croze, Jack Y. Timmons, and Guangli Zhu for technical assistance. This work was supported in part by U.S. National Heart, Lung, and Blood Institute grants HL68669 and HL090927 and a Scientist Development grant from the American Heart Association (12SDG8900005). Author contributions: T. C. designed and performed research, analyzed data, and wrote the article; H. K. performed research and analyzed data; B. D. L. designed and performed research, analyzed data, and wrote the article. Conflicts of interest: B. D. L. is an inventor on patents assigned to Brigham and Women's Hospital and Partners HealthCare on the uses and clinical development of anti-inflammatory and proresolving lipid mediators.	Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bertram A, 2011, ARCH IMMUNOL THER EX, V59, P79, DOI 10.1007/s00005-011-0112-7; Bonnans C, 2006, J EXP MED, V203, P857, DOI 10.1084/jem.20052143; Carlo T, 2009, BIOCHEMISTRY-US, V48, P2997, DOI 10.1021/bi8020636; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Fukunaga K, 2006, J BIOL CHEM, V281, P9490, DOI 10.1074/jbc.M512970200; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Hilberath JN, 2011, FASEB J, V25, P1827, DOI 10.1096/fj.10-169896; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Jozsef L, 2002, P NATL ACAD SCI USA, V99, P13266, DOI 10.1073/pnas.202296999; Korchak HM, 2001, J BIOL CHEM, V276, P8910, DOI 10.1074/jbc.M008326200; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; LeCabec V, 1997, BLOOD, V89, P2113, DOI 10.1182/blood.V89.6.2113; Levy BD, 2005, BRIT J PHARMACOL, V146, P344, DOI 10.1038/sj.bjp.0706338; Levy BD, 1999, FASEB J, V13, P903, DOI 10.1096/fasebj.13.8.903; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Levy BD, 1997, NATURE, V389, P985, DOI 10.1038/40180; Miriyala S, 2010, J BIOL CHEM, V285, P13918, DOI 10.1074/jbc.M109.083931; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322	21	22	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2733	2741		10.1096/fj.12-223982	http://dx.doi.org/10.1096/fj.12-223982			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23568778	Green Published			2022-12-28	WOS:000328841000022
J	Linschooten, JO; Verhofstad, N; Gutzkow, K; Olsen, AK; Yauk, C; Oligschlager, Y; Brunborg, G; van Schooten, FJ; Godschalk, RWL				Linschooten, Joost O.; Verhofstad, Nicole; Gutzkow, Kristine; Olsen, Ann-Karin; Yauk, Carole; Oligschlager, Yvonne; Brunborg, Gunnar; van Schooten, Frederik J.; Godschalk, Roger W. L.			Paternal lifestyle as a potential source of germline mutations transmitted to offspring	FASEB JOURNAL			English	Article						MoBa; cigarette smoking; genomic instability	PARTICULATE AIR-POLLUTION; CIGARETTE-SMOKING; HERITABLE MUTATIONS; NORWEGIAN MOTHER; CHILDHOOD-CANCER; LINE MUTATIONS; TOBACCO-SMOKE; DNA-DAMAGE; RISK; COHORT	Paternal exposure to high levels of radioactivity causes heritable germline minisatellite mutations. However, the effect of more general paternal exposures, such as cigarette smoking, on germline mutations remains unexplored. We analyzed two of the most commonly used minisatellite loci (CEB1 and B6.7) to identify germline mutations in blood samples of complete mother-father-child triads from the Norwegian Mother and Child Cohort Study (MoBa). The presence of mutations was subsequently related to general lifestyle factors, including paternal smoking before the partner became pregnant. Paternally derived mutations at the B6.7 locus (mutation frequency 0.07) were not affected by lifestyle. In contrast, high gross yearly income as a general measure of a healthy lifestyle coincided with low-mutation frequencies at the CEB1 locus (P=0.047). Income was inversely related to smoking behavior, and paternally derived CEB1 mutations were dose dependently increased when the father smoked in the 6 mo before pregnancy, 0.21 vs. 0.05 in smoking and nonsmoking fathers, respectively (P=0.061). These results suggest that paternal lifestyle can affect the chance of heritable mutations in unstable repetitive DNA sequences. To our knowledge, this is the first study reporting an effect of lifestyle on germline minisatellite mutation frequencies in a human population with moderate paternal exposures.Linschooten, J. O., Verhofstad, N., Gutzkow, K., Olsen, A.-K., Yauk, C., Oligschlager, Y., Brunborg, G., van Schooten, F. J., Godschalk, R. W. L. Paternal lifestyle as a potential source of germline mutations transmitted to offspring.	[Linschooten, Joost O.; Verhofstad, Nicole; Oligschlager, Yvonne; van Schooten, Frederik J.; Godschalk, Roger W. L.] Maastricht Univ, Sch Nutr Metab & Toxicol, Dept Toxicol, Maastricht, Netherlands; [Gutzkow, Kristine; Olsen, Ann-Karin; Brunborg, Gunnar] Norwegian Inst Publ Hlth, Dept Chem & Radiat, Div Environm Med, Oslo, Norway; [Yauk, Carole] Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada	Maastricht University; Norwegian Institute of Public Health (NIPH); Carleton University	Godschalk, RWL (corresponding author), Sch Nutr Toxicol & Metab NUTRIM, Dept Toxicol, Univ Singel 50,POB 616, NL-6200 MD Maastricht, Netherlands.	r.godschalk@maastrichtuniversity.nl		Olsen, Ann-Karin/0000-0003-3982-5213; Yauk, Carole/0000-0002-6725-3454; Yauk, Carole/0000-0003-4919-876X	European Union (EU) [FOOD-CT-2005-016320]; Norwegian Ministry of Health; Ministry of Education and Research; U.S. National Institutes of Health (NIH)/National Instiute of Environmental Health Sciences [N01-ES-75558]; NIH/National Institute of Neurological Disorders and Stroke [UO1 NS 047537-01, UO1 NS 047537-06A1]; Norwegian Research Council/FUGE [151918/S10]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS047537] Funding Source: NIH RePORTER	European Union (EU)(CGIAREuropean Commission); Norwegian Ministry of Health; Ministry of Education and Research; U.S. National Institutes of Health (NIH)/National Instiute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Norwegian Research Council/FUGE(Research Council of Norway); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The Newborns and Genotoxic Exposure Risks (NewGeneris) study was funded by the European Union (EU contract FOOD-CT-2005-016320). The study population originated from the Norwegian Mother and Child Cohort Study (MoBa), which is supported by the Norwegian Ministry of Health and the Ministry of Education and Research, the U.S. National Institutes of Health (NIH)/National Instiute of Environmental Health Sciences (contract N01-ES-75558), NIH/National Institute of Neurological Disorders and Stroke (grants UO1 NS 047537-01 and UO1 NS 047537-06A1), and the Norwegian Research Council/FUGE (grant 151918/S10). The authors are grateful to all the participating families in Norway, who take part in this ongoing cohort study. The authors thank Dr. Elin Alsaker (Norwegian Institute of Public Health) for assisting in data analysis.	Anderson Diana, 2005, Toxicol Appl Pharmacol, V207, P506, DOI 10.1016/j.taap.2005.01.022; Boffetta P, 2000, ENVIRON HEALTH PERSP, V108, P73, DOI 10.2307/3454298; Bois P, 1999, CELL MOL LIFE SCI, V55, P1636, DOI 10.1007/s000180050402; Davies BG, 2007, BRIT J CANCER, V96, P1265, DOI 10.1038/sj.bjc.6603706; DeMarini DM, 2012, ENVIRON MOL MUTAGEN, V53, P166, DOI 10.1002/em.21685; Dubrova YE, 2003, SWISS MED WKLY, V133, P474; Dubrova YE, 1997, MUTAT RES-FUND MOL M, V381, P267; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; Dubrova YE, 2002, AM J HUM GENET, V71, P801, DOI 10.1086/342729; Dubrova YE, 2006, MUTAT RES-FUND MOL M, V602, P74, DOI 10.1016/j.mrfmmm.2006.08.001; Elshal MF, 2009, CLIN BIOCHEM, V42, P589, DOI 10.1016/j.clinbiochem.2008.11.012; Friedler G, 1996, PHARMACOL BIOCHEM BE, V55, P691, DOI 10.1016/S0091-3057(96)00286-9; Hurles M, 2012, NAT GENET, V44, P1174, DOI 10.1038/ng.2448; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; Kong A, 2012, NATURE, V488, P471, DOI 10.1038/nature11396; Laubenthal J, 2012, FASEB J, V26, P3946, DOI 10.1096/fj.11-201194; Magnus P, 2006, INT J EPIDEMIOL, V35, P1146, DOI 10.1093/ije/dyl170; Marchetti F, 2011, P NATL ACAD SCI USA, V108, P12811, DOI 10.1073/pnas.1106896108; O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989; Olsen AK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011349; Potts RJ, 1999, MUTAT RES-FUND MOL M, V423, P103, DOI 10.1016/S0027-5107(98)00242-5; Rehkopf DH, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-383; Robbins WA, 2005, CYTOGENET GENOME RES, V111, P371, DOI 10.1159/000086914; Ronningen KS, 2006, EUR J EPIDEMIOL, V21, P619, DOI 10.1007/s10654-006-9041-x; Secretan B, 2009, LANCET ONCOL, V10, P1033, DOI 10.1016/S1470-2045(09)70326-2; Sepaniak S, 2006, TOXICOLOGY, V223, P54, DOI 10.1016/j.tox.2006.03.001; Shi QH, 2001, MOL REPROD DEV, V59, P417, DOI 10.1002/mrd.1048; Singer TM, 2010, ENVIRON MOL MUTAGEN, V51, P919, DOI 10.1002/em.20613; Sipinen V, 2010, MUTAGENESIS, V25, P417, DOI 10.1093/mutage/geq024; Somers CM, 2004, SCIENCE, V304, P1008, DOI 10.1126/science.1095815; Sun JX, 2012, NAT GENET, V44, P1161, DOI 10.1038/ng.2398; Tamaki K, 1999, HUM MOL GENET, V8, P879, DOI 10.1093/hmg/8.5.879; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; Vergnaud G, 2000, GENOME RES, V10, P899, DOI 10.1101/gr.10.7.899; Verhofstad N, 2008, MUTAGENESIS, V23, P241, DOI 10.1093/mutage/gen022; Verhofstad N, 2011, TOXICOL SCI, V119, P218, DOI 10.1093/toxsci/kfq325; Yauk C, 1998, MUTAT RES-REV MUTAT, V411, P1, DOI 10.1016/S1383-5742(98)00003-9; Yauk C, 2008, P NATL ACAD SCI USA, V105, P605, DOI 10.1073/pnas.0705896105; Yauk CL, 2007, CANCER RES, V67, P5103, DOI 10.1158/0008-5472.CAN-07-0279; Yauk CL, 2004, MUTAT RES-REV MUTAT, V566, P169, DOI 10.1016/j.mrrev.2003.08.001; Yauk CL, 1996, P NATL ACAD SCI USA, V93, P12137, DOI 10.1073/pnas.93.22.12137; Yauk CL, 2012, MUTAT RES, V752, P6; ZHANG J, 1992, INT J EPIDEMIOL, V21, P273, DOI 10.1093/ije/21.2.273	44	40	40	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2873	2879		10.1096/fj.13-227694	http://dx.doi.org/10.1096/fj.13-227694			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23538710	Green Published			2022-12-28	WOS:000328841000035
J	Sharp, WW; Fang, YH; Han, M; Zhang, HJ; Hong, ZG; Banathy, A; Morrow, E; Ryan, JJ; Archer, SL				Sharp, Willard W.; Fang, Yong Hu; Han, Mei; Zhang, Hannah J.; Hong, Zhigang; Banathy, Alexandra; Morrow, Erik; Ryan, John J.; Archer, Stephen L.			Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia- reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission	FASEB JOURNAL			English	Article						Mdivi-1; reactive oxygen species; calcineurin; IR; cardiac arrest	CARDIAC-ARREST; FUSION; HEART; DEPHOSPHORYLATION; PHOSPHORYLATION	Mitochondrial fission, regulated by dynamin-related protein-1 (Drp1), is a newly recognized determinant of mitochondrial function, but its contribution to left ventricular (LV) impairment following ischemia-reperfusion (IR) injury is unknown. We report that Drp1 activation during IR results in LV dysfunction and that Drp1 inhibition is beneficial. In both isolated neonatal murine cardiomyocytes and adult rat hearts (Langendorff preparation) mitochondrial fragmentation and swelling occurred within 30 min of IR. Drp1-S637 (serine 637) dephosphorylation resulted in Drp1 mitochondrial translocation and increased mitochondrial fission. The Drp1 inhibitor Mdivi-1 preserved mitochondrial morphology, reduced cytosolic calcium, and prevented cell death. Drp1 siRNA similarly preserved mitochondrial morphology. In Langendorff hearts, Mdivi-1 reduced mitochondrial reactive oxygen species, improved LV developed pressure (92 +/- 5 vs. 28 +/- 10 mmHg, P<0.001), and lowered LV end diastolic pressure (10 +/- 1 vs. 86 +/- 13 mmHg, P<0.001) following IR. Mdivi-1 was protective if administered prior to or following ischemia. Because Drp1-S637 dephosphorylation is calcineurin sensitive, we assessed the effects of a calcineurin inhibitor, FK506. FK506 treatment prior to IR prevented Drp1-S637 dephosphorylation and preserved cardiac function. Likewise, therapeutic hypothermia (30 degrees C) inhibited Drp1-S637 dephosphorylation and preserved mitochondrial morphology and myocardial function. Drp1 inhibition is a novel strategy to improve myocardial function following IR.Sharp, W. S., Fang, Y. H., Han, M., Zhang, H. J., Hong, Z., Banathy, A., Morrow, E., Ryan, J. J., Archer, S. L. Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission.	[Sharp, Willard W.; Fang, Yong Hu; Han, Mei; Zhang, Hannah J.; Banathy, Alexandra] Univ Chicago, Dept Med, Sect Emergency Med, Chicago, IL 60637 USA; [Hong, Zhigang; Morrow, Erik; Ryan, John J.; Archer, Stephen L.] Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; [Archer, Stephen L.] Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	University of Chicago; University of Chicago; Queens University - Canada	Sharp, WW (corresponding author), Dept Med, Sect Emergency Med, 5841 S Maryland Ave,MC 5068, Chicago, IL 60637 USA.	wsharp@medicine.bsd.uchicago.edu	Sharp, Willard/AAB-9972-2020	Sharp, Willard/0000-0002-7175-3523; Banathy, Alexandra/0000-0002-8100-5238	U.S. National Institutes of Health (NIH) [NIH-K08-HL103901-02, NIH-RO1-HL071115]; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL103901, R01HL113003, R01HL071115] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Peter Toth for his assistance with confocal imaging. Funding was received from the U.S. National Institutes of Health (NIH), grants NIH-K08-HL103901-02 (W. W. S.) and NIH-RO1-HL071115 (S. L. A.), and from the American Heart Association (S.L.A.).	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Chang CR, 2010, ANN NY ACAD SCI, V1201, P34, DOI 10.1111/j.1749-6632.2010.05629.x; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen Y, 2011, CIRC RES, V109, P1327, DOI 10.1161/CIRCRESAHA.111.258723; Cho SG, 2010, AM J PHYSIOL-RENAL, V299, pF199, DOI 10.1152/ajprenal.00716.2009; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Cui M, 2010, J BIOL CHEM, V285, P11740, DOI 10.1074/jbc.M109.066662; EDOUTE Y, 1983, CIRC RES, V53, P663, DOI 10.1161/01.RES.53.5.663; Fang YH, 2012, J MOL MED, V90, P31, DOI 10.1007/s00109-011-0804-9; Givvimani S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032388; HENRY TD, 1990, CIRC RES, V67, P1453, DOI 10.1161/01.RES.67.6.1453; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hong ZG, 2006, CIRCULATION, V114, P1372, DOI 10.1161/CIRCULATIONAHA.106.641126; Hong ZG, 2013, CIRC RES, V112, P802, DOI 10.1161/CIRCRESAHA.111.300285; Jahani-Asl A, 2007, EMBO REP, V8, P912, DOI 10.1038/sj.embor.7401077; Kane LA, 2010, J MOL MED, V88, P971, DOI 10.1007/s00109-010-0674-6; Klouche K, 2002, CHEST, V122, P1006, DOI 10.1378/chest.122.3.1006; Marsboom G, 2012, CIRC RES, V110, P1484, DOI 10.1161/CIRCRESAHA.111.263848; NIEMINEN AL, 1992, TOXICOL APPL PHARM, V115, P147, DOI 10.1016/0041-008X(92)90317-L; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Otera H, 2010, J CELL BIOL, V191, P1141, DOI 10.1083/jcb.201007152; Papanicolaou KN, 2012, CIRC RES, V111, P1012, DOI 10.1161/CIRCRESAHA.112.274142; Papanicolaou KN, 2011, MOL CELL BIOL, V31, P1309, DOI 10.1128/MCB.00911-10; Park SW, 2011, INVEST OPHTH VIS SCI, V52, P2837, DOI 10.1167/iovs.09-5010; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Shao ZH, 2010, AM J PHYSIOL-HEART C, V298, pH2164, DOI 10.1152/ajpheart.00994.2009; Sorrell VL, 2011, J CARDIOVASC MAGN R, V13, DOI 10.1186/1532-429X-13-17; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Yeh ST, 2009, J MOL CELL CARDIOL, V47, P789, DOI 10.1016/j.yjmcc.2009.09.003; Zhang HJ, 2003, FASEB J, V17, P2293, DOI 10.1096/fj.03-0139fje; Zhao J, 2011, EMBO J, V30, P2762, DOI 10.1038/emboj.2011.198; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	37	238	253	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					316	326		10.1096/fj.12-226225	http://dx.doi.org/10.1096/fj.12-226225			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24076965	Green Published			2022-12-28	WOS:000333526100030
J	Kitamura, H; Kimura, S; Shimamoto, Y; Okabe, J; Ito, M; Miyamoto, T; Naoe, Y; Kikuguchi, C; Meek, B; Toda, C; Okamoto, S; Kanehira, K; Hase, K; Watarai, H; Ishizuka, M; El-Osta, A; Ohara, O; Miyoshi, I				Kitamura, Hiroshi; Kimura, Shunsuke; Shimamoto, Yoshinori; Okabe, Jun; Ito, Masatoshi; Miyamoto, Tomomi; Naoe, Yoshinori; Kikuguchi, Chisato; Meek, Bob; Toda, Chitoku; Okamoto, Shiki; Kanehira, Katsushi; Hase, Koji; Watarai, Hiroshi; Ishizuka, Mayumi; El-Osta, Assam; Ohara, Osamu; Miyoshi, Ichiro			Ubiquitin-specific protease 2-69 in macrophages potentially modulates metainflammation	FASEB JOURNAL			English	Article						diabetes; epigenetic control; aP2	N-TERMINAL SEQUENCES; DEUBIQUITINATING ENZYME; INSULIN-RESISTANCE; BACTERIAL LIPOPOLYSACCHARIDE; ATHEROSCLEROTIC PLAQUE; CELLULAR-LOCALIZATION; SIGNALING PATHWAYS; 3T3-L1 ADIPOCYTES; MMP-1 EXPRESSION; PROSTATE-CANCER	Macrophages play a critical role in chronic inflammation and metabolic diseases. We identified a longer splice variant of ubiquitin specific protease (USP) 2-69 as a novel molecule that modulates pathways implicated in metabolic disorders. Expression levels of aP2/FABP4 and PAI-1/SERPINE1 genes were increased by 4- and 1.8-fold, respectively, after short hairpin RNA-mediated knockdown (KD) of the USP2 gene, and such expression was alleviated by overexpression of USP2-69 in human myeloid cell lines. Supernatants derived from USP2-KD cells induced IL6 (similar to 6-fold) and SAA3 (similar to 15-fold) in 3T3-L1 adipocytes to suggest the anti-inflammatory properties of USP2. In addition, we observed a 30% decrease in the number of macrophages in mesenteric adipose tissue derived from USP2-69 transgenic mice fed a high-fat diet for 14 wk compared with that in their C57BL/6 littermates (P<0.01), which was consistent with a similar to 40% decrease in transcription of aP2 and PAI-1. The aP2 locus exhibited elevated chromatin accessibility (>2.1-fold), methylation of histone H3 lysine 4 (>4.5-fold), and acetylation of histone H4 (>2.5-fold) in USP2-KD cells. Transfection of isopeptidase-mutated USP2-69 did not alter chromatin conformation on the aP2 locus in USP2-KD cells. Our results suggest that USP2-69 suppresses meta-inflammatory molecules involved in the development of type-2 diabetes.	[Kitamura, Hiroshi; Miyamoto, Tomomi; Miyoshi, Ichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Comparat & Expt Med, Nagoya, Aichi 4678601, Japan; [Kimura, Shunsuke; Naoe, Yoshinori] Hokkaido Univ, Grad Sch Med Sci, Dept Funct Morphol, Lab Histol & Cytol, Sapporo, Hokkaido, Japan; [Ishizuka, Mayumi] Hokkaido Univ, Grad Sch Vet Med, Dept Environm Vet Sci, Toxicol Lab, Sapporo, Hokkaido, Japan; [Shimamoto, Yoshinori] Kitasato Univ, Sch Vet Med, Dept Vet Teaching Hosp, Towada, Aomori, Japan; [Okabe, Jun; El-Osta, Assam] Baker IDI Heart & Diabet Inst, Epigenet Human Hlth & Dis Lab, Melbourne, Vic, Australia; [Okabe, Jun; El-Osta, Assam] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic 3004, Australia; [Ito, Masatoshi; Kikuguchi, Chisato; Ohara, Osamu] RIKEN Res Ctr Allergy & Immunol, Lab Immunogen, Yokohama, Kanagawa, Japan; [Watarai, Hiroshi] RIKEN Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa, Japan; Natl Inst Longev Sci, Natl Ctr Geriatr & Gerontol, Immunol Sect, Dept Mech Aging, Obu, Japan; [Meek, Bob] St Antonius Hosp, Dept Med Microbiol & Immunol, Nieuwegein, Netherlands; [Toda, Chitoku; Okamoto, Shiki] Natl Inst Physiol Sci, Div Endocrinol & Metab, Okazaki, Aichi 444, Japan; [Kanehira, Katsushi] Natl Inst Anim Hlth, Viral Dis & Epidemiol Res Div, Tsukuba, Ibaraki 305, Japan; [Hase, Koji; Watarai, Hiroshi] Japanese Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Tokyo, Japan; [Hase, Koji] Univ Tokyo, Inst Med Sci, Div Mucosal Barriol, Int Res & Dev Ctr Mucosal Vaccines, Tokyo, Japan	Nagoya City University; Hokkaido University; Hokkaido University; Kitasato University; Baker Heart and Diabetes Institute; Monash University; RIKEN; RIKEN; National Center for Geriatrics & Gerontology; St. Antonius Hospital Utrecht; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; Japan Science & Technology Agency (JST); University of Tokyo	Kitamura, H (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Comparat & Expt Med, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	ktmr@med.nagoya-cu.ac.jp	Kimura, Shunsuke/D-7093-2012; Okamoto, Shiki/X-7274-2018; Meek, Bob/C-5042-2015; Ohara, Osamu/G-5448-2015	Kimura, Shunsuke/0000-0001-9408-2884; Okamoto, Shiki/0000-0002-2802-0527; Ohara, Osamu/0000-0002-3328-9571; El-Osta, Assam/0000-0003-2969-9137; El-Osta, Assam/0000-0001-7968-7375; Toda, Chitoku/0000-0002-1641-6217; Okabe, Jun/0000-0002-7196-0522	Japan Society for the Promotion of Science Kakenhi [21790334, 80312403]; Takeda Science Foundation; Ono Medical Research Foundation; Mochida Memorial Foundation; Suzuken Memorial Foundation; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Novartis Foundation; Nitto Foundation; AstraZeneca; Grants-in-Aid for Scientific Research [24117723] Funding Source: KAKEN	Japan Society for the Promotion of Science Kakenhi(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Ono Medical Research Foundation; Mochida Memorial Foundation; Suzuken Memorial Foundation; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Novartis Foundation(Novartis); Nitto Foundation; AstraZeneca(AstraZeneca); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Atsuo Kobayashi, Tomoko Yuasa, Tomoko Hasegawa, Saori Hayashi, Ryosuke Yashi, Dr. Mai Yamagishi, and Dr. Fumihiko Ishikawa at RIKEN, Prof. Toshihiko Iwanaga at Hokkaido University, and Satoshi Tanaka at Nippon Becton Dickinson Company for technical assistance. This study was supported by the Japan Society for the Promotion of Science Kakenhi (21790334 and 80312403), Takeda Science Foundation, Ono Medical Research Foundation, Mochida Memorial Foundation, Suzuken Memorial Foundation, Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care, Novartis Foundation, Nitto Foundation, and AstraZeneca.	Ashar HR, 2010, BBA-GENE REGUL MECH, V1799, P55, DOI 10.1016/j.bbagrm.2009.11.013; Bedard N, 2011, BIOL REPROD, V85, P594, DOI 10.1095/biolreprod.110.088542; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; De Taeye BM, 2006, J BIOL CHEM, V281, P32796, DOI 10.1074/jbc.M606214200; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Faesen AC, 2012, BIOCHEM SOC T, V40, P539, DOI 10.1042/BST20120004; Fasshauer M, 2004, J ENDOCRINOL, V181, P129, DOI 10.1677/joe.0.1810129; Furuhashi M, 2007, NATURE, V447, P959, DOI 10.1038/nature05844; Gewies A, 2003, CANCER RES, V63, P682; Gleissner CA, 2008, ARTERIOSCL THROM VAS, V28, P1920, DOI 10.1161/ATVBAHA.108.169417; Gousseva N, 2003, GENE EXPRESSION, V11, P163, DOI 10.3727/000000003108749053; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Han CY, 2007, DIABETES, V56, P2260, DOI 10.2337/db07-0218; Jacobi D, 2012, ADIPOCYTE, V1, P4, DOI 10.4161/adip.19036; Kitamura H, 2004, FEBS LETT, V578, P180, DOI 10.1016/j.febslet.2004.11.008; Kitamura H, 2002, J HISTOCHEM CYTOCHEM, V50, P245, DOI 10.1177/002215540205000212; Kitamura H., 2013, ADIPOCYTE IN PRESS; Kitamura H, 2008, PHYSIOL GENOMICS, V33, P121, DOI 10.1152/physiolgenomics.00095.2007; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; Lin SK, 2004, ARTHRITIS RHEUM-US, V50, P785, DOI 10.1002/art.20058; Mansilla S, 2008, ARTERIOSCL THROM VAS, V28, P1844, DOI 10.1161/ATVBAHA.108.171389; Mantovani A, 2009, ARTERIOSCL THROM VAS, V29, P1419, DOI 10.1161/ATVBAHA.108.180497; Mastaitis JW, 2005, DIABETES, V54, P952, DOI 10.2337/diabetes.54.4.952; Metzig M, 2011, INT J CANCER, V129, P607, DOI 10.1002/ijc.26124; Molusky MM, 2012, DIABETES, V61, P1025, DOI 10.2337/db11-0970; Newby AC, 2008, ARTERIOSCL THROM VAS, V28, P2108, DOI 10.1161/ATVBAHA.108.173898; Ng MCY, 2013, DIABETES, V62, P965, DOI 10.2337/db12-0266; Nicholas SB, 2005, KIDNEY INT, V67, P1297, DOI 10.1111/j.1523-1755.2005.00207.x; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Nio-Kobayashi J, 2010, J HISTOCHEM CYTOCHEM, V58, P741, DOI 10.1369/jhc.2010.956227; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627; Park KC, 2002, P NATL ACAD SCI USA, V99, P9733, DOI 10.1073/pnas.152011799; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Priolo C, 2006, CANCER RES, V66, P8625, DOI 10.1158/0008-5472.CAN-06-1374; Qin ZY, 2012, ATHEROSCLEROSIS, V221, P2, DOI 10.1016/j.atherosclerosis.2011.09.003; Ress C, 2010, EUR CYTOKINE NETW, V21, P65, DOI 10.1684/ecn.2009.0177; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Ruffieux-Daidie D, 2008, J AM SOC NEPHROL, V19, P2170, DOI 10.1681/ASN.2007101130; Samuvel DJ, 2011, ENDOCRINOLOGY, V152, P4662, DOI 10.1210/en.2011-1026; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Stienstra R, 2012, CELL METAB, V15, P10, DOI 10.1016/j.cmet.2011.10.011; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Talukdar S, 2012, NAT MED, V18, P1407, DOI 10.1038/nm.2885; Treeck O, 2008, BRIT J CANCER, V99, P1246, DOI 10.1038/sj.bjc.6604692; Villanueva CJ, 2010, IMMUNITY, V33, P647, DOI 10.1016/j.immuni.2010.11.017; Williams H, 2010, CARDIOVASC RES, V87, P137, DOI 10.1093/cvr/cvq042; Xu YZ, 2011, J BIOL CHEM, V286, P12839, DOI 10.1074/jbc.M110.185637	50	21	21	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4940	4953		10.1096/fj.13-233528	http://dx.doi.org/10.1096/fj.13-233528			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24005904				2022-12-28	WOS:000329999000028
J	Yu, HX; Segers, F; Sliedregt-Bol, K; Bot, I; Woltman, AM; Boross, P; Verbeek, S; Overkleeft, H; van der Marel, GA; van Kooten, C; van Berkel, TJC; Biessen, EAL				Yu, Haixiang; Segers, Filip; Sliedregt-Bol, Karen; Bot, Ilze; Woltman, Andrea M.; Boross, Peter; Verbeek, Sjef; Overkleeft, Herman; van der Marel, Gijs A.; van Kooten, Cees; van Berkel, Theo J. C.; Biessen, Erik A. L.			Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display	FASEB JOURNAL			English	Article						CD154; atherosclerosis; autoimmune diseases	SMOOTH-MUSCLE-CELLS; VASCULAR ENDOTHELIAL-CELLS; ACTIVATED T-CELLS; CD40-CD40 LIGAND; FUNCTIONAL CD40; NUCLEAR-FACTOR; GROWTH-FACTOR; K/BXN MOUSE; KAPPA-B; EXPRESSION	The CD40/CD40L dyad is deemed to play a central role in several inflammatory processes, including atherosclerosis. As CD40 is overexpressed in atherosclerotic lesions, it constitutes a promising candidate for targeted imaging approaches. Here we describe the design of a novel, selective peptide ligand for CD40 by phage display. A synthetic peptide corresponding with the phage insert NP31 displayed nanomolar affinity for CD40. Affinity was further enhanced by mutimeric presentation of NP31. An essential 11-mer peptide motif was identified by truncation and alanine scan studies. Enriched phage selectively bound human CD40 and homed to inflammatory joints in a murine model of rheumatoid arthritis. NP31 ablated VEGF and IL-6 transcriptional activation and partially inhibited IL-6 production by CD40L-activated endothelial cells. Notably, NP31 did not only alter the biodistribution profile of a streptavidin scaffold but also markedly increased accumulation of the carrier in atherosclerotic aortic lesions of aged ApoE(-/-) mice in a CD40-dependent manner. This potent and selective peptide ligand has potential for targeted imaging and drug delivery approaches in CD40-dependent inflammatory disorders such as atherosclerosis.Yu, H., Segers, F., Sliedregt-Bol, K., Bot, I., Woltman, A. M.(,) Boross, P., Verbeek, S., Overkleeft, H., van der Marel, G. A., van Kooten, C., van Berkel, T. J. C., Biessen, E. A. L. Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display.	[Yu, Haixiang; Segers, Filip; Bot, Ilze; van Berkel, Theo J. C.; Biessen, Erik A. L.] Leiden Univ, Div Biopharmaceut, Leiden Amsterdam Ctr Drug Res, Leiden, Netherlands; [Sliedregt-Bol, Karen; Overkleeft, Herman; van der Marel, Gijs A.] Leiden Univ, Dept Bioorgan Chem, Leiden, Netherlands; [Woltman, Andrea M.; van Kooten, Cees] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; [Boross, Peter; Verbeek, Sjef] Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Biessen, EAL (corresponding author), Univ Hosp Maastricht, Dept Pathol, Debeijelaan 25, NL-6229 HX Maastricht, Netherlands.	erik.biessen@mumc.nl	Boross, Peter/AAD-8928-2022; van Kooten, Cees/E-5694-2018; Van Berkel, Theo/ABD-7677-2021; Woltman, Andrea/GYV-2656-2022	van Kooten, Cees/0000-0002-6257-0899; Woltman, Andrea/0000-0001-9904-6751; Biessen, Erik/0000-0002-6454-8548; Bot, Ilze/0000-0002-1242-1959; Overkleeft, Herman/0000-0001-6976-7005	Netherlands Technology Foundation STW [LFA5952]; Netherlands Heart Foundation [2003T.201]; European Community [LSHM-CT-2003-503254]	Netherlands Technology Foundation STW(Technologiestichting STW); Netherlands Heart Foundation(Netherlands Heart Foundation); European Community(European Commission)	The authors gratefully acknowledge Prof. Dr. Esther Lutgens (Amsterdam Medical Center, Amsterdam, The Netherlands) for critical reading of the manuscript and for helpful suggestions. This study was financially supported by grant LFA5952 from The Netherlands Technology Foundation STW. This study was also supported by the generous grant 2003T.201 (EB) from The Netherlands Heart Foundation. The authors belong to the European Vascular Genomics Network (http://www.evgn.org), a Network of Excellence supported by the European Community's Sixth Framework Program for Research Priority 1 (Life Sciences, Genomics, and Biotechnology for Health; contract LSHM-CT-2003-503254).	ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Baccam M, 2003, J IMMUNOL, V170, P3099, DOI 10.4049/jimmunol.170.6.3099; Boross P, 2006, SPRINGER SEMIN IMMUN, V28, P339, DOI 10.1007/s00281-006-0049-9; Bruemmer D, 2001, AM J CARDIOL, V87, P21, DOI 10.1016/S0002-9149(00)01266-2; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Clark LB, 1996, ADV IMMUNOL, V63, P43; Ditzel HJ, 2004, TRENDS MOL MED, V10, P40, DOI 10.1016/j.molmed.2003.11.004; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Kyburz D, 2000, ARTHRITIS RHEUM, V43, P2571, DOI 10.1002/1529-0131(200011)43:11<2571::AID-ANR26>3.0.CO;2-4; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808; Molenaar TJM, 2002, BLOOD, V100, P3570, DOI 10.1182/blood-2002-02-0641; Molenaar TJM, 2002, VIROLOGY, V293, P182, DOI 10.1006/viro.2001.1254; Page A, 2012, AM J TRANSPLANT, V12, P115, DOI 10.1111/j.1600-6143.2011.03737.x; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Richards JL, 2003, EUR J BIOCHEM, V270, P2287, DOI 10.1046/j.1432-1033.2003.03596.x; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Schonbeck U, 2001, CIRC RES, V89, P1092, DOI 10.1161/hh2401.101272; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; van Kooten C, 2000, EXP NEPHROL, V8, P203; VanKooten C, 1996, ADV IMMUNOL, V61, P1; vanKooten C, 1997, KIDNEY INT, V51, P711, DOI 10.1038/ki.1997.102; Wang NZ, 2010, FASEB J, V24, P2178, DOI 10.1096/fj.09-136895; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; Yu HX, 2006, ARTERIOSCL THROM VAS, V26, P1531, DOI 10.1161/01.ATV.0000225286.30710.af; Zirlik A, 2007, ARTERIOSCL THROM VAS, V27, P1101, DOI 10.1161/ATVBAHA.107.140566	39	8	8	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4136	4146		10.1096/fj.12-224667	http://dx.doi.org/10.1096/fj.12-224667			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23896727				2022-12-28	WOS:000329747100025
J	Bagchi, M; Kim, LA; Boucher, J; Walshe, TE; Kahn, CR; D'Amore, PA				Bagchi, Mandrita; Kim, Leo A.; Boucher, Jeremie; Walshe, Tony E.; Kahn, C. Ronald; D'Amore, Patricia A.			Vascular endothelial growth factor is important for brown adipose tissue development and maintenance	FASEB JOURNAL			English	Article						sFlt1; apoptosis; mitochondria; proliferation	MESSENGER-RNA EXPRESSION; VEGF-A; ADIPOCYTE DIFFERENTIATION; ANGIOGENESIS; INSULIN; CELLS; FAT; GENE; IDENTIFICATION; ACTIVATION	Vascular endothelial growth factor (VEGF) is critical for angiogenesis, but also has pleiotropic effects on several nonvascular cells. Our aim was to investigate the role of VEGF in brown adipose tissue (BAT). We show that VEGF expression increases 2.5-fold during differentiation of cultured murine brown adipocytes and that VEGF receptor-2 is phosphorylated, indicating VEGF signaling. VEGF increased proliferation in brown preadipocytes in vitro by 70%, and blockade of VEGF signaling using anti-VEGFR2 antibody DC101 increased brown adipocyte apoptosis, as determined by cell number and activation of caspase 3. Systemic VEGF neutralization in mice, accomplished by adenoviral expression of soluble Flt1, resulted in 7-fold increase in brown adipocyte apoptosis, mitochondrial degeneration, and increased mitophagy compared to control mice expressing a null adenovirus. Absence of the heparan sulfate-binding VEGF isoforms, VEGF164 and VEGF188, resulted in abnormal BAT development in mice at E15.5, with fewer brown adipocytes and lower mitochondrial protein compared to wild-type littermates. These results suggest a role for VEGF in brown adipocytes and preadipocytes to promote survival, proliferation, and normal mitochondria and development.Bagchi, M., Kim, L A., Boucher, J., Walshe, T. E., Kahn, C. R., D'Amore, P. A. Vascular endothelial growth factor is important for brown adipose tissue development and maintenance.	[Bagchi, Mandrita; D'Amore, Patricia A.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Pathol, Boston, MA 02115 USA; [Kim, Leo A.; D'Amore, Patricia A.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Ophthalmol, Boston, MA 02115 USA; [Boucher, Jeremie; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02115 USA; [Bagchi, Mandrita; Kim, Leo A.; Walshe, Tony E.; D'Amore, Patricia A.] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute	D'Amore, PA (corresponding author), Massachusetts Eye & Ear, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	patricia_damore@meei.harvard.edu	D'Amore, Patricia A/G-5660-2017; Kim, Leo/Y-3323-2018; Walshe, Tony/AAJ-8833-2020; Kahn, Ronald/AAY-2435-2021; Boucher, Jeremie/G-6602-2015	D'Amore, Patricia A/0000-0001-9652-8974; Kim, Leo/0000-0001-9106-6416; Kahn, Ronald/0000-0002-7583-9228; 	U.S. National Institutes of Health [EY15435, K12-EY16335]; NATIONAL EYE INSTITUTE [K12EY016335, R01EY015435] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by U.S. National Institutes of Health grants EY15435 (to P. A. D.) and K12-EY16335 (to L. K.). The authors acknowledge Dhanesh Amarnani for his technical assistance in the sFlt1 experiments.	Asano A, 2001, MOL CELL ENDOCRINOL, V174, P71, DOI 10.1016/S0303-7207(00)00450-0; Asano A, 1997, BIOCHEM J, V328, P179, DOI 10.1042/bj3280179; BARNARD T, 1969, J ULTRA MOL STRUCT R, V29, P311, DOI 10.1016/S0022-5320(69)90109-9; Boucher J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001173; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; Bryan BA, 2008, MOL BIOL CELL, V19, P994, DOI 10.1091/mbc.E07-09-0856; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CIGOLINI M, 1986, J ANAT, V145, P207; Cinti S, 2007, ADIPOSE TISSUE ADIPO, P3, DOI [10.1007/978-1-59745-370-7_1, DOI 10.1007/978-1-59745-370-7_1]; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; Collins S, 2004, MOL ENDOCRINOL, V18, P2123, DOI 10.1210/me.2004-0193; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Cypess AM, 2010, CURR OPIN PEDIATR, V22, P478, DOI 10.1097/MOP.0b013e32833a8d6e; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; dela Paz NG, 2009, CELL TISSUE RES, V335, P5, DOI 10.1007/s00441-008-0706-5; Elias I, 2012, DIABETES, V61, P1801, DOI 10.2337/db11-0832; Farmer SR, 2008, GENE DEV, V22, P1269, DOI 10.1101/gad.1681308; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353; Fredriksson JM, 2005, FEBS LETT, V579, P5680, DOI 10.1016/j.febslet.2005.09.044; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; Guan FX, 2006, AM J PHYSIOL-RENAL, V291, pF422, DOI 10.1152/ajprenal.00448.2005; Halberg N, 2009, MOL CELL BIOL, V29, P4467, DOI 10.1128/MCB.00192-09; Jimenez M, 2002, FEBS LETT, V530, P37, DOI 10.1016/S0014-5793(02)03387-2; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005; Klein J, 2002, BIOESSAYS, V24, P382, DOI 10.1002/bies.10058; Korac A, 2008, HISTOL HISTOPATHOL, V23, P441, DOI 10.14670/HH-23.441; Kuhn A, 2002, J INVEST DERMATOL, V119, P1388, DOI 10.1046/j.1523-1747.2002.19647.x; Maharaj ASR, 2008, J EXP MED, V205, P491, DOI 10.1084/jem.20072041; Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462; Milosevic M., 2008, EMC 2008 14 EUR MICR, V3, P113; Miquerol L, 2000, DEVELOPMENT, V127, P3941; Miranda S, 2010, CELL SIGNAL, V22, P645, DOI 10.1016/j.cellsig.2009.11.019; Miyazawa-Hoshimoto S, 2005, AM J PHYSIOL-ENDOC M, V288, pE1128, DOI 10.1152/ajpendo.00003.2004; NAPOLITANO L, 1963, J CELL BIOL, V18, P663, DOI 10.1083/jcb.18.3.663; Nedergaard J, 2010, CELL METAB, V11, P268, DOI 10.1016/j.cmet.2010.03.007; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nieves BJ, 2009, BIOFACTORS, V35, P332, DOI 10.1002/biof.46; Nisoli E, 1997, CELL DEATH DIFFER, V4, P771, DOI 10.1038/sj.cdd.4400292; Patel-Hett S, 2011, INT J DEV BIOL, V55, P353, DOI 10.1387/ijdb.103213sp; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229; Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106; Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554; Seale P, 2009, DIABETES, V58, P1482, DOI 10.2337/db09-0622; Singh R, 2009, J CLIN INVEST, V119, P3329, DOI 10.1172/JCI39228; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Sun K, 2012, P NATL ACAD SCI USA, V109, P5874, DOI 10.1073/pnas.1200447109; Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200; Tonello C, 1999, FEBS LETT, V442, P167, DOI 10.1016/S0014-5793(98)01627-5; Xue Y, 2008, P NATL ACAD SCI USA, V105, P10167, DOI 10.1073/pnas.0802486105; Xue Y, 2009, CELL METAB, V9, P99, DOI 10.1016/j.cmet.2008.11.009; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zhang L, 2003, BIOCHEM BIOPH RES CO, V303, P1169, DOI 10.1016/S0006-291X(03)00495-9; Zhang QX, 1997, J SURG RES, V67, P147, DOI 10.1006/jsre.1996.4983	61	60	64	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3257	3271		10.1096/fj.12-221812	http://dx.doi.org/10.1096/fj.12-221812			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23682123	Bronze, Green Published			2022-12-28	WOS:000329877600031
J	Condello, S; Cao, LY; Matei, D				Condello, Salvatore; Cao, Liyun; Matei, Daniela			Tissue transglutaminase regulates beta-catenin signaling through a c-Src-dependent mechanism	FASEB JOURNAL			English	Article						EMT; Wnt signaling; beta-integrin; fibronectin	BREAST-CANCER CELLS; FACTOR-KAPPA-B; OVARIAN-CANCER; WNT/BETA-CATENIN; STEM-CELLS; TYROSINE PHOSPHORYLATION; COLORECTAL-CANCER; INDUCED APOPTOSIS; GENE-EXPRESSION; ACTIVATION	Tissue transglutaminase (TG2) is a multifunctional enzyme involved in protein cross-linking and cell adhesion to fibronectin (FN). In cancer, TG2 induces an epithelial to mesenchymal transition, contributing to metastasis. Because cadherins bind -catenin at cell-cell junctions, disruption of adherens junctions destabilizes cadherin-catenin complexes. The goal of the present study was to analyze whether and how TG2 interacts with and regulates -catenin signaling in ovarian cancer (OC) cells. We observed a significant correlation between TG2 and -catenin expression levels in OC cells and tumors. TG2 augmented Wnt/-catenin signaling, as evidenced by enhanced -catenin transcriptional activity, inducing transcription of target genes cyclin D1 and c-Myc. By promoting integrin-mediated cell adhesion to FN, TG2 physically associates with and recruits c-Src, which in turn phosphorylates -catenin at Tyr(654), releasing it from E-cadherin and rendering it available for transcriptional regulation. By interacting with FN and enhancing -catenin signaling, complexed TG2 stimulates OC cell proliferation. In summary, our data demonstrate that TG2 regulates -catenin expression and function in OC cells and define the c-Src-dependent mechanism through which this occurs.	[Condello, Salvatore; Cao, Liyun; Matei, Daniela] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Matei, Daniela] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Matei, Daniela] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; [Matei, Daniela] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Matei, Daniela] Indiana Univ Sch Med, Vet Affairs Roudebush Hosp, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Matei, D (corresponding author), Indiana Univ Simon Canc Ctr, 535 Barnhill Dr,RT 473, Indianapolis, IN 46202 USA.	salvcond@iupui.edu; dmatei@iupui.edu	Condello, Salvatore/ABB-6743-2021	Matei, Daniela/0000-0003-2169-5035; Condello, Salvatore/0000-0003-4979-3681	U.S. Department of Veterans Affairs; American Cancer Society; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs(US Department of Veterans Affairs); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Janusz Tucholski (University of Alabama, Birmingham, AL, USA), Dr. Harikrishna Nakshatri (Indiana University School of Medicine, Indianapolis, IN, USA), and Dr. Alexey M. Belkin (University of Maryland, Baltimore, MD, USA) for reagents; Dr. Susan Perkins for assistance with statistical analyses; and Dr. David Donner for helpful comments. This work was supported by the U.S. Department of Veterans Affairs through a merit award and the American Cancer Society through a research scholar grant (to D.M.).	Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Burkhalter RJ, 2011, J BIOL CHEM, V286, P23467, DOI 10.1074/jbc.M110.199539; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429; Cao LY, 2008, CARCINOGENESIS, V29, P1893, DOI 10.1093/carcin/bgn158; Chau WK, 2012, ONCOGENE, DOI 10.1038/onc.2012.290; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Chen X, 2010, ONCOTARGET, V1, P210, DOI 10.18632/oncotarget.127; Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057; Faverman L, 2008, FEBS LETT, V582, P1552, DOI 10.1016/j.febslet.2008.03.053; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; Hwang JY, 2008, CANCER RES, V68, P5849, DOI 10.1158/0008-5472.CAN-07-6130; Karni R, 2005, MOL CELL BIOL, V25, P5031, DOI 10.1128/MCB.25.12.5031-5039.2005; KASUGAI S, 1990, JPN J PHARMACOL, V52, P95, DOI 10.1254/jjp.52.95; Kumar A, 2011, PLOS ONE, V6; Li B, 2010, P NATL ACAD SCI USA, V107, P1408, DOI 10.1073/pnas.0907907107; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mangala LS, 2007, ONCOGENE, V26, P2459, DOI 10.1038/sj.onc.1210035; Mann AP, 2006, CANCER RES, V66, P8788, DOI 10.1158/0008-5472.CAN-06-1457; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; PINCUS JH, 1968, ARCH BIOCHEM BIOPHYS, V126, P44, DOI 10.1016/0003-9861(68)90557-2; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Satpathy M, 2009, J BIOL CHEM, V284, P15390, DOI 10.1074/jbc.M808331200; Satpathy N, 2007, CANCER RES, V67, P7194, DOI 10.1158/0008-5472.CAN-07-0307; Schmid S, 2011, INT J GYNECOL CANCER, V21, P975, DOI 10.1097/IGC.0b013e31821caa6f; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Shedden KA, 2005, CLIN CANCER RES, V11, P2123, DOI 10.1158/1078-0432.CCR-04-2061; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Usongo M, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-17; Verma A, 2008, CLIN CANCER RES, V14, P1997, DOI 10.1158/1078-0432.CCR-07-1533; Verma A, 2007, CURR CANCER DRUG TAR, V7, P559, DOI 10.2174/156800907781662275; Verma A, 2006, CANCER RES, V66, P10525, DOI 10.1158/0008-5472.CAN-06-2387; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wu R, 2001, CANCER RES, V61, P8247; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Yoshioka S, 2012, MOL CANCER RES, V10, P469, DOI 10.1158/1541-7786.MCR-11-0177; Zhang XL, 2010, NEOPLASMA, V57, P545, DOI 10.4149/neo_2010_06_545	51	33	34	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3100	3112		10.1096/fj.12-222620	http://dx.doi.org/10.1096/fj.12-222620			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23640056	Green Published			2022-12-28	WOS:000329877600017
J	Jiang, WX; Nakayama, Y; Sequeira, JM; Quadros, EV				Jiang, Wenxia; Nakayama, Yasumi; Sequeira, Jeffrey M.; Quadros, Edward V.			Mapping the functional domains of TCblR/CD320, the receptor for cellular uptake of transcobalamin-bound cobalamin	FASEB JOURNAL			English	Article						vitamin B-12; cytoplasmic domain; calcium-binding domain; LDLR-A; Hek293 cells; Qdots	DENSITY-LIPOPROTEIN RECEPTOR; LIGAND-BINDING DOMAIN; CYSTEINE-RICH REPEAT; MONOCLONAL-ANTIBODIES; VITAMIN B12; PROTEIN RAP; CELLS; 1ST; ENDOCYTOSIS; TRANSPORT	The membrane receptor TCblR/CD320 binds transcobalamin (TC) saturated with vitamin B-12 [cobalamin (Cbl)] and mediates cellular uptake of the vitamin. The specificity of TC for Cbl and of the receptor for TC-Cbl ensures efficient uptake of Cbl into cells. The high-affinity interaction of TCblR with TC-Cbl (K-a=10 nM(-1)) was investigated using deletions and mutations of amino acid sequences in TCblR. Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function. Deleting the cysteine-rich region (aa 95-141) that separates the two low-density lipoprotein receptor type A (LDLR-A) domains does not affect TC-Cbl binding (K-a = 19-24 nM(-1)). The two LDLR-A domains (aa 54-89 and 132-167) with the negatively charged acidic residues involved in Ca2+ binding are critical determinants of ligand binding. The cytoplasmic tail is apparently crucial for internalization of the ligand. Within this region, the RPLGLL motif and the PDZ binding motifs (QERL/KESL) appear to be involved in initiating and completing the process of ligand internalization. Mutations and deletions of these regions involved in binding and internalization of TC-Cbl are likely to produce the biochemical and clinical phenotype of Cbl deficiency.	[Jiang, Wenxia] Suny Downstate Med Ctr, Sch Grad Studies, Brooklyn, NY 11203 USA; [Nakayama, Yasumi; Sequeira, Jeffrey M.; Quadros, Edward V.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; [Quadros, Edward V.] Suny Downstate Med Ctr, Dept Cell Biol, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Quadros, EV (corresponding author), Suny Downstate Med Ctr, Box 20,450 Clarkson Ave, Brooklyn, NY 11203 USA.	edward.quadros@downstate.edu			U.S. National Institutes of Health [DK064732]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK064732, R01DK064732] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grant DK064732 (to E.V.Q.).	AMAGASAKI T, 1990, BLOOD, V76, P1380; Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; BIERI S, 1995, BIOCHEMISTRY-US, V34, P13059, DOI 10.1021/bi00040a017; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Bu GJ, 2001, INT REV CYTOL, V209, P79; CANNATA JJB, 1965, J BIOL CHEM, V240, P3249; COOPER BA, 1961, NATURE, V191, P393, DOI 10.1038/191393a0; DIGIROLAMO PM, 1975, ARCH BIOCHEM BIOPHYS, V168, P386, DOI 10.1016/0003-9861(75)90267-2; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fyfe JC, 2004, BLOOD, V103, P1573, DOI 10.1182/blood-2003-08-2852; HALL CA, 1984, J LAB CLIN MED, V103, P70; Jiang WX, 2011, DRUG DELIV, V18, P74, DOI 10.3109/10717544.2010.509745; Kurniawan ND, 2000, PROTEIN SCI, V9, P1282, DOI 10.1110/ps.9.7.1282; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Quadros EV, 2010, HUM MUTAT, V31, P924, DOI 10.1002/humu.21297; Quadros EV, 2009, BLOOD, V113, P186, DOI 10.1182/blood-2008-05-158949; Quadros EV, 2005, BIOCHEM BIOPH RES CO, V327, P1006, DOI 10.1016/j.bbrc.2004.12.103; Quadros EV, 1999, AM J PHYSIOL-GASTR L, V277, pG161, DOI 10.1152/ajpgi.1999.277.1.G161; QUADROS EV, 1994, ARCH BIOCHEM BIOPHYS, V308, P192, DOI 10.1006/abbi.1994.1027; Ratschmann R, 2009, MOL GENET METAB, V98, P285, DOI 10.1016/j.ymgme.2009.06.003; SENNETT C, 1981, ANNU REV BIOCHEM, V50, P1053, DOI 10.1146/annurev.bi.50.070181.005201; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WEISSBACH H, 1966, FED PROC, V25, P1649	27	13	13	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2988	2994		10.1096/fj.13-230185	http://dx.doi.org/10.1096/fj.13-230185			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603833	Green Published			2022-12-28	WOS:000329877600007
J	Cheshenko, N; Trepanier, JB; Stefanidou, M; Buckley, N; Gonzalez, P; Jacobs, W; Herold, BC				Cheshenko, Natalia; Trepanier, Janie B.; Stefanidou, Martha; Buckley, Niall; Gonzalez, Pablo; Jacobs, William; Herold, Betsy C.			HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression	FASEB JOURNAL			English	Article						glycoprotein B; glycoprotein D; miltefosine; genital herpes	HERPES-SIMPLEX-VIRUS; LEUKOCYTE PROTEASE INHIBITOR; GLYCOPROTEIN-B; KINASE-B; MILTEFOSINE; RECEPTOR; BINDING; PLAYS; EXPRESSION; INFECTION	HSV triggers intracellular calcium release to promote viral entry. We hypothesized that Akt signaling induces the calcium responses and contributes to HSV entry. Exposure of human cervical and primary genital tract epithelial, neuronal, or keratinocyte cells to HSV serotype 2 resulted in rapid phosphorylation of Akt. Silencing of Akt with small interfering RNA prevented the calcium responses, blocked viral entry, and inhibited plaque formation by 90% compared to control siRNA. Susceptibility to infection was partially restored if Akt was reintroduced into silenced cells with an Akt-expressing plasmid. HSV-2 variants deleted in glycoproteins B or D failed to induce Akt phosphorylation, and coimmunoprecipitation studies indicated that Akt interacts with glycoprotein B. Cell-surface expression of Akt was rapidly induced in response to HSV exposure. Miltefosine (50 M), a licensed drug that blocks Akt phosphorylation, inhibited HSV-induced calcium release, viral entry, and plaque formation following infection with acyclovir-sensitive and resistant clinical isolates. Miltefosine blocked amplification of HSV from explanted ganglia to epithelial cells; viral yields were significantly less in miltefosine compared to control-treated cocultures (P<0.01). Together, these findings identify a novel role for Akt in viral entry, link Akt and calcium signaling, and suggest a new target for HSV treatment and suppression.Cheshenko, N., Trepanier, J. B., Stefanidou, M., Buckley, N., Gonzalez, P., Jacobs, W., and Herold, B. C. HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.	[Cheshenko, Natalia; Herold, Betsy C.] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; [Cheshenko, Natalia; Trepanier, Janie B.; Stefanidou, Martha; Buckley, Niall; Gonzalez, Pablo; Jacobs, William; Herold, Betsy C.] Albert Einstein Coll Med, Dept Microbiol Immunol, Bronx, NY 10461 USA; [Jacobs, William] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Jacobs, William] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA; [Gonzalez, Pablo; Jacobs, William] Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; [Gonzalez, Pablo] Pontificia Univ Catolica Chile, Millennium Inst Immunol & Immunotherapy, Santiago, Chile	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Pontificia Universidad Catolica de Chile	Herold, BC (corresponding author), Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	betsy.herold@einstein.yu.edu	Cheshenko, Natalia/ABF-5896-2021; Gonzalez, Pablo/L-1973-2013	Gonzalez, Pablo/0000-0001-7709-6870; Jacobs, William/0000-0003-3321-3080; Herold, Betsy/0000-0001-9974-0786	U.S. National Institutes of Health (NIH) [AI-061679]; Center for AIDS Research at the Albert Einstein College of Medicine; Montefiore Medical Center [NIH AI-51519]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061679, R56AI061679, P30AI051519] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for AIDS Research at the Albert Einstein College of Medicine; Montefiore Medical Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Briana Nixon and Theodore Segarra for assistance with animal experiments, Prashant Desai (Johns Hopkins University, Baltimore, MD, USA) for the KVP26GFP virus and Greg Smith (Northwestern University, Evanston, IL, USA) for HSV-1 (F-GS2822). The authors also thank Yungtai Lo for statistical advice. The authors thank the Analytical Imaging Facility at Albert Einstein College of Medicine for assistance with confocal laser and E. A. Eugenin (Albert Einstein College of Medicine) for scientific advice. This work was supported in part by U.S. National Institutes of Health (NIH) grant AI-061679 and the Center for AIDS Research at the Albert Einstein College of Medicine and Montefiore Medical Center (NIH AI-51519).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Antinone SE, 2010, J VIROL, V84, P1504, DOI 10.1128/JVI.02029-09; Arii J, 2010, NATURE, V467, P859, DOI 10.1038/nature09420; Atanasiu D, 2007, P NATL ACAD SCI USA, V104, P18718, DOI 10.1073/pnas.0707452104; Atanasiu D, 2010, J VIROL, V84, P12292, DOI 10.1128/JVI.01700-10; Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151; Bender FC, 2003, J VIROL, V77, P9542, DOI 10.1128/JVI.77.17.9542-9552.2003; Benetti L, 2006, J VIROL, V80, P3341, DOI 10.1128/JVI.80.7.3341-3348.2006; Berridge MJ, 2009, BBA-MOL CELL RES, V1793, P933, DOI 10.1016/j.bbamcr.2008.10.005; Calleja V, 2009, PLOS BIOL, V7, P189, DOI 10.1371/journal.pbio.1000017; Carfi A, 2002, ACTA CRYSTALLOGR D, V58, P836, DOI 10.1107/S0907444902001270; Cheshenko N, 2003, J CELL BIOL, V163, P283, DOI 10.1083/jcb.200301084; Cheshenko N, 2002, J GEN VIROL, V83, P2247, DOI 10.1099/0022-1317-83-9-2247; Cheshenko N, 2007, MOL BIOL CELL, V18, P3119, DOI 10.1091/mbc.E07-01-0062; Chugh P, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-11; Connolly SA, 2005, J VIROL, V79, P1282, DOI 10.1128/JVI.79.2.1282-1295.2005; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; Desai P, 1998, J VIROL, V72, P7563, DOI 10.1128/JVI.72.9.7563-7568.1998; Fahey JV, 2002, J INFECT DIS, V185, P1606, DOI 10.1086/340512; Fakioglu E, 2008, J VIROL, V82, P9337, DOI 10.1128/JVI.00603-08; Fichorova RN, 1999, BIOL REPROD, V60, P508, DOI 10.1095/biolreprod60.2.508; Fichorova RN, 1997, BIOL REPROD, V57, P847, DOI 10.1095/biolreprod57.4.847; Garg R, 2012, VIROLOGY, V432, P271, DOI 10.1016/j.virol.2012.05.032; GERBER SI, 1995, VIROLOGY, V214, P29, DOI 10.1006/viro.1995.9957; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Heldwein EE, 2008, CELL MOL LIFE SCI, V65, P1653, DOI 10.1007/s00018-008-7570-z; Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Hwang JY, 2009, CELL CALCIUM, V45, P233, DOI 10.1016/j.ceca.2008.10.006; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; Koulen P, 2008, CELL PHYSIOL BIOCHEM, V21, P161, DOI 10.1159/000113758; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218; Oram RJ, 2000, J INFECT DIS, V181, P1458, DOI 10.1086/315387; Patterson RL, 2005, P NATL ACAD SCI USA, V102, P1357, DOI 10.1073/pnas.0409657102; Richardson PG, 2012, EXPERT OPIN DRUG MET, V8, P623, DOI 10.1517/17425255.2012.681376; Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011; Segarra TJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027675; Sindermann H, 2004, CLIN INFECT DIS, V39, P1520, DOI 10.1086/425359; Soroceanu L, 2008, NATURE, V455, P391, DOI 10.1038/nature07209; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tronstein E, 2011, JAMA-J AM MED ASSOC, V305, P1441, DOI 10.1001/jama.2011.420; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wagner MJ, 2011, J VIROL, V85, P2803, DOI 10.1128/JVI.01877-10; Wilson SS, 2009, EXPERT REV ANTI-INFE, V7, P559, DOI [10.1586/eri.09.34, 10.1586/ERI.09.34]; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263	50	60	63	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2584	2599		10.1096/fj.12-220285	http://dx.doi.org/10.1096/fj.12-220285			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23507869	Green Published			2022-12-28	WOS:000328841000008
J	Kim, TK; Kleszczynski, K; Janjetovic, Z; Sweatman, T; Lin, ZT; Li, W; Reiter, RJ; Fischer, TW; Slominski, AT				Kim, Tae-Kang; Kleszczynski, Konrad; Janjetovic, Zorica; Sweatman, Trevor; Lin, Zongtao; Li, Wei; Reiter, Russel J.; Fischer, Tobias W.; Slominski, Andrzej T.			Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway in human skin cells	FASEB JOURNAL			English	Article						keratinocytes; melanocytes; 6-hydroxymelatonin; AFMK; 5-methoxytryptamine	REACTIVE OXYGEN; INHIBITS PROLIFERATION; SEROTONINERGIC SYSTEM; VITILIGO PATHOGENESIS; HACAT KERATINOCYTES; AUTOIMMUNE-DISEASE; CALCIUM IMBALANCE; GENETIC-DEFECT; VITAMIN-D; EXPRESSION	Indolic and kynuric pathways of skin melatonin metabolism were monitored by liquid chromatography mass spectrometry in human keratinocytes, melanocytes, dermal fibroblasts, and melanoma cells. Production of 6-hydroxymelatonin [6(OH)M], N-1-acetyl-N-2-formyl-5-methoxykynuramine (AFMK) and 5-methoxytryptamine (5-MT) was detected in a cell type-dependent fashion. The major metabolites, 6(OH)M and AFMK, were produced in all cells. Thus, in immortalized epidermal (HaCaT) keratinocytes, 6(OH)M was the major product with V-max = 63.7 ng/10(6) cells and K-m = 10.2 M, with lower production of AFMK and 5-MT. Melanocytes, keratinocytes, and fibroblasts transformed melatonin primarily into 6(OH)M and AFMK. In melanoma cells, 6(OH)M and AFMK were produced endogenously, a process accelerated by exogenous melatonin in the case of AFMK. In addition, N-acetylserotonin was endogenously produced by normal and malignant melanocytes. Metabolites showed selective antiproliferative effects on human primary epidermal keratinocytes in vitro. In ex vivo human skin, both melatonin and AFMK-stimulated expression of involucrin and keratins-10 and keratins-14 in the epidermis, indicating their stimulatory role in building and maintaining the epidermal barrier. In summary, the metabolism of melatonin and its endogenous production is cell type-dependent and expressed in all three main cell populations of human skin. Furthermore, melatonin and its metabolite AFMK stimulate differentiation in human epidermis, indicating their key role in building the skin barrier.Kim, T.-K., Kleszczyski, K., Janjetovic, Z., Sweatman, T., Lin, Z., Li, W., Reiter, R. J., Fischer, T. W., Slominski, A. T. Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway in human skin cells.	[Kim, Tae-Kang; Janjetovic, Zorica; Slominski, Andrzej T.] Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; [Kim, Tae-Kang; Janjetovic, Zorica; Slominski, Andrzej T.] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Dept Lab Med, Memphis, TN 38163 USA; [Sweatman, Trevor] Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; [Lin, Zongtao; Li, Wei] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Slominski, Andrzej T.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; [Kleszczynski, Konrad; Fischer, Tobias W.] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Reiter, Russel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Lubeck; University of Texas System; University of Texas Health San Antonio	Slominski, AT (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 930 Madison Ave,RM525, Memphis, TN 38163 USA.	aslominski@uthsc.edu	Lin, Zongtao/GYU-9038-2022; Lin, Zongtao/J-3854-2019	Lin, Zongtao/0000-0002-6017-338X; Li, Wei/0000-0002-9522-4474; Slominski, Andrzej/0000-0001-8963-3995; Kleszczynski, Konrad/0000-0002-1311-263X	U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Muskuloskeletal and Skin Diseases [1R01AR056666-01A2]; University of Lubeck (Lubeck, Germany) [E22-2012]; University of Lubeck medical faculty; NIH [1S10RR026377-01, 1S10OD010678-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026377] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056666] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD010678] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Muskuloskeletal and Skin Diseases; University of Lubeck (Lubeck, Germany); University of Lubeck medical faculty; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This investigation was supported by U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Muskuloskeletal and Skin Diseases grant 1R01AR056666-01A2 (A. S.), University of Lubeck (Lubeck, Germany) research grant E22-2012 (K. K.), experimental dermatology funds from the University of Lubeck medical faculty (T. W. F.), and NIH grants 1S10RR026377-01 and 1S10OD010678-01 (W.L.).	Dubocovich ML, 2010, PHARMACOL REV, V62, P343, DOI 10.1124/pr.110.002832; Elias PM, 2010, AM J HUM BIOL, V22, P526, DOI 10.1002/ajhb.21043; Facciola G, 2001, EUR J CLIN PHARMACOL, V56, P881, DOI 10.1007/s002280000245; Fischer TW, 2006, INT J ONCOL, V29, P665; Fischer TW, 2008, EXP DERMATOL, V17, P713, DOI 10.1111/j.1600-0625.2008.00767.x; Fischer TW, 2006, FASEB J, V20, P1564, DOI 10.1096/fj.05-5227fje; Fischer TW, 2008, J PINEAL RES, V44, P1, DOI 10.1111/j.1600-079X.2007.00512.x; Fischer TW, 2006, J PINEAL RES, V40, P18, DOI 10.1111/j.1600-079X.2005.00273.x; Fischer TW, 2012, J PINEAL RES; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; Hardeland R, 2011, PROG NEUROBIOL, V93, P350, DOI 10.1016/j.pneurobio.2010.12.004; Hardeland R, 2009, J PINEAL RES, V47, P109, DOI 10.1111/j.1600-079X.2009.00701.x; Hipler UC, 2003, SKIN PHARMACOL APPL, V16, P379, DOI 10.1159/000072933; HIRATA F, 1974, J BIOL CHEM, V249, P1311; Iriti M, 2010, J PINEAL RES, V49, P101, DOI 10.1111/j.1600-079X.2010.00777.x; Janjetovic Z, 2010, J CELL PHYSIOL, V223, P36, DOI 10.1002/jcp.21992; Jockers R, 2008, BRIT J PHARMACOL, V154, P1182, DOI 10.1038/bjp.2008.184; Kleszczynski K, 2013, J PINEAL RES, V54, P89, DOI 10.1111/j.1600-079X.2012.01028.x; Kleszczynski K, 2012, ARCH DERMATOL RES, V304, P579, DOI 10.1007/s00403-012-1239-z; Kleszczynski K, 2011, DERM-ENDOCRINOL, V3, P27, DOI 10.4161/derm.3.1.14842; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Lanoix D, 2012, MOL CELL ENDOCRINOL, V348, P1, DOI 10.1016/j.mce.2011.08.025; Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Niu SD, 2010, J PINEAL RES, V49, P106, DOI 10.1111/j.1600-079X.2010.00771.x; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; ROGAWSKI MA, 1979, J NEUROCHEM, V32, P1219, DOI 10.1111/j.1471-4159.1979.tb11049.x; Schallreuter KU, 2008, EXP DERMATOL, V17, P139, DOI [10.1111/j.1600-0625.2007.00666_1.x, 10.1111/j.1600-0625.2007.00666.x]; Schallreuter KU, 2008, EXP DERMATOL, V17, P141, DOI 10.1111/j.1600-0625.2007.00666_2.x; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Semak I, 2005, BIOCHEMISTRY-US, V44, P9300, DOI 10.1021/bi050202d; Semak I, 2008, J PINEAL RES, V45, P515, DOI 10.1111/j.1600-079X.2008.00630.x; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; SLOMINSKI A, 1989, J ROY SOC MED, V82, P539, DOI 10.1177/014107688908200911; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; Slominski A, 2003, BBA-MOL BASIS DIS, V1639, P80, DOI 10.1016/S0925-4439(03)00124-8; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287; Slominski A, 2002, J INVEST DERMATOL, V119, P934, DOI 10.1046/j.1523-1747.2002.00156.x; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Slominski A, 2009, INT J CANCER, V124, P1470, DOI 10.1002/ijc.24005; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2012, INT J BIOCHEM CELL B, V44, P2003, DOI 10.1016/j.biocel.2012.07.027; Slominski AT, 2012, FASEB J, V26, P3901, DOI 10.1096/fj.12-208975; Slominski AT, 2011, J INVEST DERMATOL, V131, P1167, DOI 10.1038/jid.2010.425; Slominski AT, 2011, AM J PHYSIOL-CELL PH, V300, pC526, DOI 10.1152/ajpcell.00203.2010; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Stehle JH, 2011, J PINEAL RES, V51, P17, DOI 10.1111/j.1600-079X.2011.00856.x; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Yu H. L., 2020, ARXIV PREPRINT ARXIV	66	103	106	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2742	2755		10.1096/fj.12-224691	http://dx.doi.org/10.1096/fj.12-224691			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23620527	Green Published, Bronze			2022-12-28	WOS:000328841000023
J	Wortham, NC; Martinez, M; Gordiyenko, Y; Robinson, CV; Proud, CG				Wortham, Noel C.; Martinez, Magdalena; Gordiyenko, Yuliya; Robinson, Carol V.; Proud, Christopher G.			Analysis of the subunit organization of the eIF2B complex reveals new insights into its structure and regulation	FASEB JOURNAL			English	Article						protein synthesis; vanishing white matter	GUANINE-NUCLEOTIDE-EXCHANGE; INITIATION-FACTOR 2B; VANISHING WHITE-MATTER; TRANSLATION INITIATION; ALPHA-SUBUNIT; FACTOR-II; MACROMOLECULAR ASSEMBLIES; MASS-SPECTROMETRY; MESSENGER-RNA; LEUKOENCEPHALOPATHY	Eukaryotic initiation factor 2B (eIF2B) is the guanine nucleotide exchange factor for eIF2 and a critical regulator of protein synthesis, (e.g., as part of the integrated stress response). Certain mutations in the EIF2B genes cause leukoencephalopathy with vanishing white matter (VWM), an often serious neurological disorder. Comprising 5 subunits, -epsilon (eIF2B epsilon being the catalytic one), eIF2B has always been considered an epsilon heteropentamer. We have analyzed the subunit interactions within mammalian eIF2B by using a combination of mass spectrometry and in vivo studies of overexpressed complexes to gain further insight into the subunit arrangement of the complex. Our data reveal that eIF2B is actually decameric, a dimer of eIF2B(epsilon) tetramers stabilized by 2 copies of eIF2B. We also demonstrate a pivotal role for eIF2B in the formation of eIF2B(epsilon) tetramers. eIF2B(epsilon)(2) decamers show greater binding to eIF2 than to eIF2B(epsilon) tetramers, which may underlie the increased activity of the former. We examined the levels of eIF2B subunits in a panel of different mouse tissues and identified different levels of eIF2B subunits, particularly eIF2B, which implies heterogeneity in the cellular proportions of eIF2B(epsilon) and eIF2B(epsilon) complexes, with important implications for the regulation of translation in individual cell types.Wortham, N. C., Martinez, M., Gordiyenko, Y., Robinson, C. V., Proud, C. G. Analysis of the subunit organization of the eIF2B complex reveals new insights into its structure and regulation.	[Wortham, Noel C.; Martinez, Magdalena; Proud, Christopher G.] Univ Southampton, Ctr Biol Sci, Southampton SO17 1BJ, Hants, England; [Gordiyenko, Yuliya; Robinson, Carol V.] Univ Oxford, Dept Chem, Phys & Theoret Chem Lab, Oxford OX1 3QZ, England	University of Southampton; University of Oxford	Wortham, NC (corresponding author), Univ Southampton, Ctr Biol Sci, Life Sci Bldg 85,Highfield Campus, Southampton SO17 1BJ, Hants, England.	n.c.wortham@soton.ac.uk		Proud, Christopher/0000-0003-0704-6442; robinson, carol/0000-0001-7829-5505	UK Biotechnology and Biological Sciences Research Council [BB/J007706/1, BB/G008396/1]; Wellcome Trust program [088150/B/09/Z]; Biotechnology and Biological Sciences Research Council [BB/J007706/1, BB/G008396/1] Funding Source: researchfish; BBSRC [BB/J007706/1, BB/G008396/1] Funding Source: UKRI	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust program(Wellcome Trust); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank the members of the C.G.P. laboratory for useful discussions and assistance with cell harvesting, particularly Dr. J. Kenney for assistance with the mouse tissues; and Dr. G. Pavitt for useful discussions. This work was supported by grants BB/J007706/1 and BB/G008396/1 from the UK Biotechnology and Biological Sciences Research Council (to C.G.P.) and grant 088150/B/09/Z from the Wellcome Trust program (to C.V.R.).	BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; Chernushevich IV, 2004, ANAL CHEM, V76, P1754, DOI 10.1021/ac035406j; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; Cole MD, 2009, ONCOGENE, V28, P1169, DOI 10.1038/onc.2008.463; Craddock BL, 1996, BIOCHEM BIOPH RES CO, V220, P843, DOI 10.1006/bbrc.1996.0495; Dev K, 2010, MOL CELL BIOL, V30, P5218, DOI 10.1128/MCB.00265-10; Elsby R, 2011, J VIROL, V85, P9716, DOI 10.1128/JVI.05146-11; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Hernandez H, 2007, NAT PROTOC, V2, P715, DOI 10.1038/nprot.2007.73; Hiyama TB, 2009, J MOL BIOL, V392, P937, DOI 10.1016/j.jmb.2009.07.054; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; Kimball SR, 1998, J BIOL CHEM, V273, P12841, DOI 10.1074/jbc.273.21.12841; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; Li W, 2004, MOL CELL BIOL, V24, P3295, DOI 10.1128/MCB.24.8.3295-3306.2004; Liu R, 2011, HUM MUTAT, V32, P1036, DOI 10.1002/humu.21535; Pavitt GD, 2005, BIOCHEM SOC T, V33, P1487, DOI 10.1042/BST0331487; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Van der Knaap M. S., 2010, OMMBID 28, V28, P1, DOI [10.1036/ommbid.274, DOI 10.1036/OMMBID.274]; van der Knaap MS, 2002, ANN NEUROL, V51, P264, DOI 10.1002/ana.10112; van der Knaap MS, 2003, AM J HUM GENET, V73, P1199, DOI 10.1086/379524; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Wang XM, 2008, MOL CELL BIOL, V28, P1429, DOI 10.1128/MCB.01512-07; Wang XM, 2012, J BIOL CHEM, V287, P8263, DOI 10.1074/jbc.M111.331553; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williams DD, 2001, J BIOL CHEM, V276, P24697, DOI 10.1074/jbc.M011788200	34	44	45	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2225	2237		10.1096/fj.13-243329	http://dx.doi.org/10.1096/fj.13-243329			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24532666				2022-12-28	WOS:000335336000025
J	Yang, C; Xie, LY; Windle, JJ; Taylor, SM; Moran, RG				Yang, Chen; Xie, Lin-Ying; Windle, Jolene J.; Taylor, Shirley M.; Moran, Richard G.			Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure	FASEB JOURNAL			English	Article						knockout mice; transcription; translation; protein translocation and degradation; transcriptional interference	GAMMA-GLUTAMATE SYNTHETASE; TISSUE-SPECIFIC EXPRESSION; HUMAN LEUKEMIA SUBLINES; MULTIPLE TRANSCRIPTS; FOLIC-ACID; ANTIFOLATE; ORGANIZATION; RESISTANCE; MECHANISM; AUGMENTATION	The mouse is extensively used to model human folate metabolism and therapeutic outcomes with antifolates. However, the folylpoly--glutamate synthetase (fpgs) gene, whose product determines folate/antifolate intracellular retention and antifolate antitumor activity, displays a pronounced species difference. The human gene uses only a single promoter, whereas the mouse uses two: P2, akin to the human promoter, at low levels in most tissues; and P1, an upstream promoter used extensively in liver and kidney. We deleted the mouse P1 promoter through homologous recombination to study the dual-promoter mouse system and to create a mouse with a humanized fpgs gene structure. Despite the loss of the predominant fpgs mRNA species in liver and kidney (representing 95 and 75% of fpgs transcripts in these tissues, respectively), P1-knockout mice developed and reproduced normally. The survival of these mice was explained by increased P2 transcription due to relief of transcriptional interference, by a 3-fold more efficient translation of P2-derived than P1-derived transcripts, and by 2-fold higher stability of P2-derived FPGS. In combination, all 3 effects reinstated FPGS function, even in liver. By eliminating mouse P1, we created a mouse model that mimicked the human housekeeping pattern of fpgs gene expression.Yang, C., Xie, L.-Y., Windle, J. J., Taylor, S. M., Moran, R. G. Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure.	[Yang, Chen; Moran, Richard G.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Yang, Chen; Xie, Lin-Ying; Windle, Jolene J.; Taylor, Shirley M.; Moran, Richard G.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; [Windle, Jolene J.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA 23298 USA; [Taylor, Shirley M.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Massey Canc Ctr, 401 Coll St, Richmond, VA 23298 USA.	rmoran@vcu.edu		Windle, Jolene/0000-0001-6690-385X	U.S. National Institutes of Health (NIH) Cancer Center Support grant [P30 CA16059]; NIH [R01-CA39687]; NATIONAL CANCER INSTITUTE [R01CA039687, P30CA016059] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) Cancer Center Support grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors acknowledge the contributions of the Knockout and Transgenic Mouse Core and the Biological Macromolecule Core Laboratories of the Massey Cancer Center that were supported in part by U.S. National Institutes of Health (NIH) Cancer Center Support grant P30 CA16059. The authors also thank Prof. Michael Miles for helpful conversations. This research was supported in part by NIH grant R01-CA39687.	Alati T, 1996, CANCER RES, V56, P2331; Andreassi JL, 2002, BIOCHEMISTRY-US, V41, P226, DOI 10.1021/bi015644d; ANTONSSON B, 1990, ANAL BIOCHEM, V186, P8, DOI 10.1016/0003-2697(90)90563-O; Blakley R.L., 1969, N HOLLAND RES MONOGR, P1; Chattopadhyay S, 2007, MOL CANCER THER, V6, P404, DOI 10.1158/1535-7163.MCT-06-0343; Chave KJ, 2000, J BIOL CHEM, V275, P40365, DOI 10.1074/jbc.M007908200; Chen J, 2000, GENE, V242, P257, DOI 10.1016/S0378-1119(99)00507-7; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; Freemantle SJ, 1997, J BIOL CHEM, V272, P25373, DOI 10.1074/jbc.272.40.25373; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; Goldman ID, 2010, CURR OPIN INVEST DR, V11, P1409; Jansen G, 1999, J NATL CANCER I, V91, P2047, DOI 10.1093/jnci/91.23.2047A; Krug LM, 2003, CLIN CANCER RES, V9, P2072; Kuhnel JM, 2000, J CELL PHYSIOL, V184, P364, DOI 10.1002/1097-4652(200009)184:3<364::AID-JCP11>3.0.CO;2-N; Liani E, 2003, INT J CANCER, V103, P587, DOI 10.1002/ijc.10829; Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; OCONNOR BM, 1991, CANCER RES, V51, P3874; Racanelli AC, 2008, MOL CELL BIOL, V28, P836, DOI 10.1128/MCB.01088-07; RAY MS, 1993, J NATL CANCER I, V85, P1154, DOI 10.1093/jnci/85.14.1154; Roy K, 1997, J BIOL CHEM, V272, P5587, DOI 10.1074/jbc.272.9.5587; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; Said HM, 2000, AM J PHYSIOL-CELL PH, V279, pC1889, DOI 10.1152/ajpcell.2000.279.6.C1889; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Stark M, 2009, BLOOD, V113, P4362, DOI 10.1182/blood-2008-08-173799; TAYLOR SM, 1995, CANCER RES, V55, P6030; Turner FB, 1999, CANCER RES, V59, P6074; Turner FB, 2000, J BIOL CHEM, V275, P35960, DOI 10.1074/jbc.M005228200; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; Wang ES, 2003, LEUKEMIA LYMPHOMA, V44, P1027, DOI 10.1080/1042819031000077124; WILSON SD, 1982, CLIN CHEM, V28, P1198; Zhao RB, 2001, BIOCHEM PHARMACOL, V61, P857, DOI 10.1016/S0006-2952(01)00532-9	34	3	3	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					1998	2008		10.1096/fj.13-243261	http://dx.doi.org/10.1096/fj.13-243261			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24532667	Green Published			2022-12-28	WOS:000335336000005
J	Le Drean, G; Haure-Mirande, V; Ferrier, L; Bonnet, C; Hulin, P; de Coppet, P; Segain, JP				Le Drean, Gwenola; Haure-Mirande, Vianney; Ferrier, Laurent; Bonnet, Christian; Hulin, Philippe; de Coppet, Pierre; Segain, Jean-Pierre			Visceral adipose tissue and leptin increase colonic epithelial tight junction permeability via a RhoA-ROCK-dependent pathway	FASEB JOURNAL			English	Article						adipocytes; actin cytoskeleton; barrier; adipokines	HIGH-FAT DIET; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INTESTINAL PERMEABILITY; INDUCED OBESITY; ACTIN CYTOSKELETON; GUT MICROBIOTA; CELLS; BARRIER; PROTEIN	Proinflammatory cytokines produced by immune cells play a central role in the increased intestinal epithelial permeability during inflammation. Expansion of visceral adipose tissue (VAT) is currently considered a consequence of intestinal inflammation. Whether VAT per se plays a role in early modifications of intestinal barrier remains unknown. The aim of this study was to demonstrate the direct role of adipocytes in regulating paracellular permeability of colonic epithelial cells (CECs). We show in adult rats born with intrauterine growth retardation, a model of VAT hypertrophy, and in rats with VAT graft on the colon, that colonic permeability was increased without any inflammation. This effect was associated with altered expression of tight junction (TJ) proteins occludin and ZO-1. In coculture experiments, adipocytes decreased transepithelial resistance (TER) of Caco-2 CECs and induced a disorganization of ZO-1 on TJs. Intraperitoneal administration of leptin to lean rats increased colonic epithelial permeability and altered ZO-1 expression and organization. Treatment of HT29-19A CECs with leptin, but not adiponectin, dose-dependently decreased TER and altered TJ and F-actin cytoskeleton organization through a RhoA-ROCK-dependent pathway. Our data show that adipocytes and leptin directly alter TJ function in CECs and suggest that VAT could impair colonic epithelial barrier.Le Drean, G., Haure-Mirande, V., Ferrier, L., Bonnet, C., Hulin, P., de Coppet, P., Segain, J.-P. Visceral adipose tissue and leptin increase colonic epithelial tight junction permeability via a RhoA-ROCK-dependent pathway.	[Le Drean, Gwenola; Haure-Mirande, Vianney; Bonnet, Christian; de Coppet, Pierre; Segain, Jean-Pierre] Univ Nantes, INRA, UMR 1280, IMAD,CRNH, F-44093 Nantes, France; [Ferrier, Laurent] INRA, UMR ToxAlim 1331, Grp Neurogastroenterol & Nutr, F-31931 Toulouse, France; [Hulin, Philippe] Nantes Univ MicroPICell, Cellular & Tissular Imaging Core Facil, Nantes, France	INRAE; Nantes Universite; INRAE	Le Drean, G (corresponding author), Univ Nantes, INRA, UMR 1280, CHU Hotel Dieu, Pl Alexis Ricordeau, F-44093 Nantes, France.	gwenola.ledrean@univ-nantes.fr	Haure-Mirande, Jean-Vianney/AAS-9570-2020	Haure-Mirande, Jean-Vianney/0000-0002-5748-9666; Ferrier, Laurent/0000-0003-2981-7375	National League against Cancer (LNCC); French Nutrition Society (SFN); SanTDige; Institut National de la Recherche Agronomique (INRA); Region of Pays de la Loire	National League against Cancer (LNCC); French Nutrition Society (SFN); SanTDige; Institut National de la Recherche Agronomique (INRA); Region of Pays de la Loire(Region Pays de la Loire)	The authors thank Guillaume Poupeau for its surgical expertise and Prof. Dominique Darmaun for reviewing the manuscript. This work was funded by the National League against Cancer (LNCC), the French Nutrition Society (SFN), and SanTDige. V.H.-M. is a recipient of a doctoral fellowship from the Institut National de la Recherche Agronomique (INRA) and the Region of Pays de la Loire. The authors declare no conflicts of interest.	Ahima RS, 2006, OBESITY, V14, P242, DOI 10.1038/oby.2006.317; Aparicio T, 2005, GUT, V54, P1136, DOI 10.1136/gut.2004.060533; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; AUGERON C, 1984, CANCER RES, V44, P3961; Barrenetxe J, 2002, GUT, V50, P797, DOI 10.1136/gut.50.6.797; Batra A, 2009, INFLAMM BOWEL DIS, V15, P1897, DOI 10.1002/ibd.20937; Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; de La Serre CB, 2010, AM J PHYSIOL-GASTR L, V299, pG440, DOI 10.1152/ajpgi.00098.2010; Desreumaux P, 1999, GASTROENTEROLOGY, V117, P73, DOI 10.1016/S0016-5085(99)70552-4; Drew JE, 2007, AM J PHYSIOL-GASTR L, V293, pG682, DOI 10.1152/ajpgi.00231.2007; Drew JE, 2012, P NUTR SOC, V71, P175, DOI 10.1017/S0029665111003259; Ducroc R, 2005, DIABETES, V54, P348, DOI 10.2337/diabetes.54.2.348; El Homsi M, 2007, AM J PHYSIOL-GASTR L, V293, pG365, DOI 10.1152/ajpgi.00091.2007; Fanca-Berthon P, 2009, PEDIATR RES, V66, P47, DOI 10.1203/PDR.0b013e3181a2047e; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Ferrier L, 2006, AM J PATHOL, V168, P1148, DOI 10.2353/ajpath.2006.050617; Gambero A, 2007, INFLAMM BOWEL DIS, V13, P1357, DOI 10.1002/ibd.20222; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Guan HY, 2005, AM J PHYSIOL-ENDOC M, V288, pE663, DOI 10.1152/ajpendo.00461.2004; Gummesson A, 2011, OBESITY, V19, P2280, DOI 10.1038/oby.2011.251; Hardwick JCH, 2001, GASTROENTEROLOGY, V121, P79, DOI 10.1053/gast.2001.25490; Ivanov AI, 2010, AM J PATHOL, V177, P512, DOI 10.2353/ajpath.2010.100168; Karmiris K, 2006, INFLAMM BOWEL DIS, V12, P100, DOI 10.1097/01.MIB.0000200345.38837.46; Lalles JP, 2012, J NUTR BIOCHEM, V23, P1490, DOI 10.1016/j.jnutbio.2011.10.001; Lam YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034233; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Mckenzie JAG, 2007, J CELL PHYSIOL, V213, P221, DOI 10.1002/jcp.21114; Menard S, 2010, MUCOSAL IMMUNOL, V3, P247, DOI 10.1038/mi.2010.5; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Orozco-Solis R, 2009, PHYSIOL BEHAV, V96, P481, DOI 10.1016/j.physbeh.2008.11.016; Padidar S, 2011, DIGEST DIS SCI, V56, P1028, DOI 10.1007/s10620-010-1394-z; Rogers I, 2003, INT J OBESITY, V27, P755, DOI 10.1038/sj.ijo.0802316; Rouet-Benzineb R, 2004, J BIOL CHEM, V279, P16495, DOI 10.1074/jbc.M312999200; Segain JP, 2007, J IMMUNOL, V179, P901, DOI 10.4049/jimmunol.179.2.901; Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X; Thibault R, 2007, GASTROENTEROLOGY, V133, P1916, DOI 10.1053/j.gastro.2007.08.041; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193; Wang FJ, 2006, GASTROENTEROLOGY, V131, P1153, DOI 10.1053/j.gastro.2006.08.022; Waterland RA, 2006, J PEDIATR-US, V149, pS137, DOI 10.1016/j.jpeds.2006.06.064; Yamamoto K, 2005, GUT, V54, P789, DOI 10.1136/gut.2004.046516; Yang KP, 2008, FASEB J, V22, P2452, DOI 10.1096/fj.07-100735; Zeidan A, 2007, J PHARMACOL EXP THER, V322, P1110, DOI 10.1124/jpet.107.122440; Zilberfarb V, 1997, J CELL SCI, V110, P801; Zulian A, 2012, GUT, V61, P86, DOI 10.1136/gutjnl-2011-300391	48	45	45	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1059	1070		10.1096/fj.13-234203	http://dx.doi.org/10.1096/fj.13-234203			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24243887				2022-12-28	WOS:000335324800004
J	Subtil, FSB; Wilhelm, J; Bill, V; Westholt, N; Rudolph, S; Fischer, J; Scheel, S; Seay, U; Fournier, C; Taucher-Scholz, G; Scholz, M; Seeger, W; Engenhart-Cabillic, R; Rose, F; Dahm-Daphi, J; Hanze, J				Subtil, Florentine S. B.; Wilhelm, Jochen; Bill, Verena; Westholt, Niklas; Rudolph, Susann; Fischer, Julia; Scheel, Sebastian; Seay, Ulrike; Fournier, Claudia; Taucher-Scholz, Gisela; Scholz, Michael; Seeger, Werner; Engenhart-Cabillic, Rita; Rose, Frank; Dahm-Daphi, Jochen; Haenze, Joerg			Carbon ion radiotherapy of human lung cancer attenuates HIF-1 signaling and acts with considerably enhanced therapeutic efficiency	FASEB JOURNAL			English	Article						relative biological effectiveness; RBE; RNA silencing; angiogenesis; vascular endothelia growth factor; VEGF	FREE-RADICALS; CELL-LINES; IN-VIVO; HYPOXIA; IRRADIATION; ANGIOGENESIS; EXPRESSION; BIOLOGY; TUMORS; TRACK	Carbon ion irradiation is an emerging therapeutic option for various tumor entities. Radiation resistance of solid tumors toward photon irradiation is caused by attenuation of DNA damage in less oxygenated tumor areas and by increased hypoxia-inducible factor (HIF)-1 signaling. Carbon ion irradiation acts independently of oxygen; however, the role of HIF-1 is unclear. We analyzed the effect of HIF-1 signaling after carbon ions in comparison to photons by using biological equivalent radiation doses in a human non-small-cell cancer model. The studies were performed in cultured A549 and H1299 cell lines and in A549 xenografts. Knockdown of HIF-1 in vivo combined with photon irradiation delayed tumor growth (23 vs. 13 d; P<0.05). Photon irradiation induced HIF-1 and target genes, predominantly in oxygenated cells (1.6-fold; P<0.05), with subsequent enhanced tumor angiogenesis (1.7-fold; P<0.05). These effects were not observed after carbon ion irradiation. Micro-DNA array analysis indicated that photons, but not carbon ions, significantly induced components of the mTOR (mammalian target of rapamycin) pathway (gene set enrichment analysis; P<0.01) as relevant for HIF-1 induction. After carbon ion irradiation in vivo, we observed substantially decreased HIF-1 levels (8.9-fold; P<0.01) and drastically delayed tumor growth (P<0.01), an important finding that indicates a higher relative biological effectiveness (RBE) than anticipated from the cell survival data. Taken together, the evidence showed that carbon ions mediate an improved therapeutic effectiveness without tumor-promoting HIF-1 signaling.Subtil, F. S. B., Wilhelm, J., Bill, V., Westholt, N., Rudolph, S., Fischer, J., Scheel, S., Seay, U., Fournier, C., Taucher-Scholz, G., Scholz, M., Seeger, W., Engenhart-Cabillic, R., Rose, F., Dahm-Daphi, J., Hanze, J. Carbon ion radiotherapy of human lung cancer attenuates HIF-1 signaling and acts with considerably enhanced therapeutic efficiency.	[Subtil, Florentine S. B.; Bill, Verena; Westholt, Niklas; Rudolph, Susann; Fischer, Julia; Scheel, Sebastian; Engenhart-Cabillic, Rita; Rose, Frank] Univ Marburg, Dept Radiotherapy & Radiooncol, D-35033 Marburg, Germany; [Dahm-Daphi, Jochen] Univ Marburg, Inst Radiobiol & Mol Radiat Oncol, D-35033 Marburg, Germany; [Haenze, Joerg] Univ Marburg, Dept Urol & Pediat Urol, D-35033 Marburg, Germany; [Engenhart-Cabillic, Rita] Univ Giessen, Dept Radiotherapy, D-35390 Giessen, Germany; [Wilhelm, Jochen; Seay, Ulrike; Seeger, Werner] Univ Giessen & Marburg Lung Ctr UGMLC, German Ctr Lung Res, Giessen, Germany; [Fournier, Claudia; Taucher-Scholz, Gisela; Scholz, Michael] Helmholtzzentrum, Gesell Schwerionenforsch GSI, Darmstadt, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Justus Liebig University Giessen; Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research	Subtil, FSB (corresponding author), Univ Marburg, Dept Radiotherapy & Radiooncol, D-35033 Marburg, Germany.	florentine.subtil@staff.uni-marburg.de	Wilhelm, Jochen/AAX-4302-2021	Wilhelm, Jochen/0000-0001-5544-9647; Subtil, Florentine S.B./0000-0002-8525-5429; Hanze, Jorg/0000-0001-5424-7808; Scholz, Michael/0000-0002-6382-6737; Fournier, Claudia/0000-0002-1007-9934; Seeger, Werner/0000-0003-1946-0894	Deutsche Forschungsgemeinschaft [DFG-RO 2139/7-1]; University Medical Center Giessen and Marburg (UKGM); Verein fur Krebsforschung am Standort Giessen e.V.	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University Medical Center Giessen and Marburg (UKGM); Verein fur Krebsforschung am Standort Giessen e.V.	The authors thank Dr. Rory E. Morty for proofreading of the manuscript. The authors thank Florian Leinberger for his excellent technical assistance. Research in the authors' laboratories is supported by grants from the Deutsche Forschungsgemeinschaft (DFG-RO 2139/7-1), the University Medical Center Giessen and Marburg (UKGM), and by the Verein fur Krebsforschung am Standort Giessen e.V. The authors declare no conflicts of interest.	Aebersold DM, 2001, CANCER RES, V61, P2911; Anderson CS, 2010, SEMIN RADIAT ONCOL, V20, P186, DOI 10.1016/j.semradonc.2010.01.007; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; CARLSEN M, KEGG DB SET ANNOTATI; Choi N, 2001, LUNG CANCER, V31, P43, DOI 10.1016/S0169-5002(00)00156-2; Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324; Dellas K, 2008, STRAHLENTHER ONKOL, V184, P169, DOI 10.1007/s00066-008-1764-z; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Fokas E, 2010, INT J RADIAT ONCOL, V77, P1500, DOI 10.1016/j.ijrobp.2010.01.060; Furusawa Y, 2000, RADIAT RES, V154, P485, DOI 10.1667/0033-7587(2000)154[0485:IOAAHC]2.0.CO;2; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; Grutters JPC, 2010, RADIOTHER ONCOL, V95, P32, DOI 10.1016/j.radonc.2009.08.003; Hamada N, 2010, J RADIAT RES, V51, P365, DOI 10.1269/jrr.09137; Harada H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1786; Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200; Hattar K, 2013, CANCER IMMUNOL IMMUN, V62, P309, DOI 10.1007/s00262-012-1341-2; Heilmann J, 1996, INT J RADIAT ONCOL, V34, P599, DOI 10.1016/0360-3016(95)02112-4; Jiang Guo-Liang, 2012, Front Med, V6, P165, DOI 10.1007/s11684-012-0196-4; Kamlah F, 2009, CANCER GENE THER, V16, P195, DOI 10.1038/cgt.2008.71; Kamlah F, 2011, INT J RADIAT ONCOL, V80, P1541, DOI 10.1016/j.ijrobp.2011.03.033; Karger CP, 2013, INT J RADIAT ONCOL, V86, P450, DOI 10.1016/j.ijrobp.2013.01.019; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Kramer M, 2000, PHYS MED BIOL, V45, P3299, DOI 10.1088/0031-9155/45/11/313; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; Lu XG, 2008, CLIN ONCOL-UK, V20, P606, DOI 10.1016/j.clon.2008.07.001; Masunaga S, 2009, J CANCER RES CLIN, V135, P1109, DOI 10.1007/s00432-009-0552-1; Miyamoto T, 2007, J THORAC ONCOL, V2, P916, DOI 10.1097/JTO.0b013e3181560a68; Miyamoto T, 2007, INT J RADIAT ONCOL, V67, P750, DOI 10.1016/j.ijrobp.2006.10.006; Moeller B, 2006, BRIT J CANCER, V95, P1, DOI 10.1038/sj.bjc.6603201; Moeller BJ, 2004, CELL CYCLE, V3, P1107; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Nakano T, 2006, CLIN CANCER RES, V12, P2185, DOI 10.1158/1078-0432.CCR-05-1907; Ogata T, 2011, J RADIAT RES, V52, P374, DOI 10.1269/jrr.10102; *R DEV COR TEAM, 2007, LANG ENV STAT COMP; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Sonveaux P, 2003, CANCER RES, V63, P1012; Sowter HM, 2003, CANCER RES, V63, P6130; Sugane T, 2009, LUNG CANCER, V64, P45, DOI 10.1016/j.lungcan.2008.07.007; Takahashi A, 1998, CANCER LETT, V122, P181, DOI 10.1016/S0304-3835(97)00386-8; VAUPEL P, 1989, CANCER RES, V49, P6449; Weyrather WK, 1999, INT J RADIAT BIOL, V75, P1357, DOI 10.1080/095530099139232; Weyrather WK, 2004, RADIOTHER ONCOL, V73, pS161, DOI 10.1016/S0167-8140(04)80041-0	44	29	30	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1412	1421		10.1096/fj.13-242230	http://dx.doi.org/10.1096/fj.13-242230			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24347608				2022-12-28	WOS:000335324800032
J	Devalliere, J; Chang, WG; Andrejecsk, JW; Abrahimi, P; Cheng, CJ; Jane-wit, D; Saltzman, WM; Pober, JS				Devalliere, Julie; Chang, William G.; Andrejecsk, Jillian W.; Abrahimi, Parwiz; Cheng, Christopher J.; Jane-wit, Dan; Saltzman, W. Mark; Pober, Jordan S.			Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation	FASEB JOURNAL			English	Article						nanotechnology; neovascularization; controlled release; tissue engineering	PLGA-NANOPARTICLES; GENE DELIVERY; MYOCARDIAL-INFARCTION; ENDOCYTIC PATHWAYS; PROGENITOR CELLS; SKIN SUBSTITUTE; SIRNA DELIVERY; IN-VITRO; TISSUE; ANGIOGENESIS	Transplantation of endothelial cells (ECs) for therapeutic vascularization or tissue engineering is a promising method for increasing tissue perfusion. Here, we report on a new approach for enhanced EC transplantation using targeted nanoparticle transfection to deliver proangiogenic microRNA-132 (miR-132) to cultured ECs before their transplantation, thereby sensitizing cells to the effects of endogenous growth factors. We synthesized biodegradable PLGA polymer nanoparticles (NPs) that were loaded with miR-132 and coated with cyclic RGD (cRGD) peptides that target integrin v3 expressed on cultured human umbilical vein ECs (HUVECs), increasing NP uptake through clathrin-coated pits. Unlike previously reported NPs for miR delivery, these NPs slowly release RNA for several weeks. The endocytosed NPs remain in clathrin-coated vesicles from which they mediate intracellular delivery of siRNA or miRNA. Transfection of HUVECs with miR-132 enhances growth factor-induced proliferation and migration in 2D culture, producing a 1.8- and 5-fold increase, respectively. However, while the effects of conventional transfection were short-lived, NP transfection produced protein knockdown and biological effects that were significantly longer in duration (6 d). Transfection of HUVECs with miR-132 NP resulted in a 2-fold increase in the number of microvessels per square millimeter compared to lipid after transplantation into immunodeficient mice and led to a higher number of mural cell-invested vessels than control transfection. These data suggest that sustained delivery of miR-132 encapsulated in a targeted biodegradable polymer NP is a safe and efficient strategy to improve EC transplantation and vascularization.Devalliere, J., Chang, W. G., Andrejecsk, J. W., Abrahimi, P., Cheng, C. J., Jane-wit, D., Saltzman, W. M., Pober, J. S. Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation.	[Devalliere, Julie; Andrejecsk, Jillian W.; Cheng, Christopher J.; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT USA; [Devalliere, Julie; Abrahimi, Parwiz; Pober, Jordan S.] Yale Univ, Dept Immunobiol, New Haven, CT USA; [Chang, William G.; Jane-wit, Dan] Yale Univ, Dept Internal Med, New Haven, CT USA; [Cheng, Christopher J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA	Yale University; Yale University; Yale University; Yale University	Pober, JS (corresponding author), Dept Immunobiol, POB 208089, New Haven, CT 06520 USA.	jordan.pober@yale.edu		Chang, William/0000-0002-7707-9242	U.S. National Institutes of Health [HL108684, HL085416]; Clinical and Translational Science Award from the National Center for Advancing Translational Science [KL2-RR024138]; Paul and Daisy Soros Fellowship for New Americans; NATIONAL CANCER INSTITUTE [F32CA174247] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024138] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085416, T32HL007974, R21HL108684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI089704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Science Award from the National Center for Advancing Translational Science; Paul and Daisy Soros Fellowship for New Americans; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Gwen Arrington and Louise Benson (Yale School of Medicine, Yale University) for provision of HUVECs and Amos Brooks (Research Histology, Department of Pathology, Yale University) for immunohistochemistry. This work was supported by grants from the U.S. National Institutes of Health (HL108684 and HL085416). W. G. C. was supported by a Clinical and Translational Science Award (KL2-RR024138) from the National Center for Advancing Translational Science, and P. A. was supported by a Paul and Daisy Soros Fellowship for New Americans.	Anand S, 2011, CURR OPIN HEMATOL, V18, P171, DOI 10.1097/MOH.0b013e328345a180; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bramfeldt H, 2010, CURR MED CHEM, V17, P3944, DOI 10.2174/092986710793205327; Breunig M, 2007, P NATL ACAD SCI USA, V104, P14454, DOI 10.1073/pnas.0703882104; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Cartiera MS, 2009, BIOMATERIALS, V30, P2790, DOI 10.1016/j.biomaterials.2009.01.057; Chang W. G., 2013, CARDIOVASC RES, DOI 10.1093/cvr/cvt215; Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Conwell CC, 2008, MOL THER, V16, P370, DOI 10.1038/sj.mt.6300356; Costouros NG, 2002, J CELL BIOCHEM, P72, DOI 10.1002/jcb.10426; Danhier F, 2012, METHOD ENZYMOL, V508, P157, DOI 10.1016/B978-0-12-391860-4.00008-2; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; El-Sayed A, 2013, MOL THER, V21, P1118, DOI 10.1038/mt.2013.54; Enis DR, 2005, P NATL ACAD SCI USA, V102, P425, DOI 10.1073/pnas.0408357102; Fischer-Rasokat U, 2009, CIRC-HEART FAIL, V2, P417, DOI 10.1161/CIRCHEARTFAILURE.109.855023; Gibot L, 2010, TISSUE ENG PT A, V16, P3199, DOI [10.1089/ten.tea.2010.0189, 10.1089/ten.TEA.2010.0189]; Gomes RSM, 2013, ACS NANO, V7, P3362, DOI 10.1021/nn400171w; Gui LQ, 2009, TISSUE ENG PT A, V15, P2665, DOI [10.1089/ten.tea.2008.0526, 10.1089/ten.TEA.2008.0526]; Ilan N, 1998, J CELL SCI, V111, P3621; Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978-1-59745-178-9_2; Jain RK, 2005, NAT BIOTECHNOL, V23, P821, DOI 10.1038/nbt0705-821; Jay SM, 2008, FASEB J, V22, P2949, DOI 10.1096/fj.08-108803; Jay SM, 2010, BIOMATERIALS, V31, P3054, DOI 10.1016/j.biomaterials.2010.01.014; Jay SM, 2009, J CONTROL RELEASE, V134, P26, DOI 10.1016/j.jconrel.2008.10.019; Johnson PC, 2007, TISSUE ENG, V13, P2827, DOI 10.1089/ten.2007.0335; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Katare R, 2011, CIRC RES, V109, P894, DOI 10.1161/CIRCRESAHA.111.251546; Khazanov E, 2006, J GENE MED, V8, P998, DOI 10.1002/jgm.933; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Liu XQ, 2011, MOL PHARMACEUT, V8, P250, DOI 10.1021/mp100315q; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lunde K, 2006, NEW ENGL J MED, V355, P1199, DOI 10.1056/NEJMoa055706; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; Maier CL, 2010, MICROCIRCULATION, V17, P367, DOI 10.1111/j.1549-8719.2010.00038.x; Motlagh D, 2007, J BIOMED MATER RES A, V82A, P907, DOI 10.1002/jbm.a.31211; Murphy EJ, 2008, LIPIDS, V43, P105, DOI 10.1007/s11745-008-3156-7; Nimesh Surendra, 2012, Recent Pat DNA Gene Seq, V6, P91; Pollinger K, 2013, P NATL ACAD SCI USA, V110, P6115, DOI 10.1073/pnas.1220281110; Rosenzweig A, 2006, NEW ENGL J MED, V355, P1274, DOI 10.1056/NEJMe068172; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Shepherd BR, 2006, FASEB J, V20, P1739, DOI 10.1096/fj.05-5682fje; Stratman AN, 2010, BLOOD, V116, P4720, DOI 10.1182/blood-2010-05-286872; Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270; Szebeni J, 2011, ADV DRUG DELIVER REV, V63, P1020, DOI 10.1016/j.addr.2011.06.017; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Vercauteren D, 2010, MOL THER, V18, P561, DOI 10.1038/mt.2009.281; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]; Yigit M., 2011, CANCER RES, V72, P2952; Zhou J, 2012, BIOMATERIALS, V33, P583, DOI 10.1016/j.biomaterials.2011.09.061	56	64	65	0	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					908	922		10.1096/fj.13-238527	http://dx.doi.org/10.1096/fj.13-238527			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24221087	Green Published			2022-12-28	WOS:000331072200036
J	Reinhardt, S; Schuck, F; Grosgen, S; Riemenschneider, M; Hartmann, T; Postina, R; Grimm, M; Endres, K				Reinhardt, Sven; Schuck, Florian; Groesgen, Sven; Riemenschneider, Matthias; Hartmann, Tobias; Postina, Rolf; Grimm, Marcus; Endres, Kristina			Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease	FASEB JOURNAL			English	Article						APP processing; insulin signaling; ER stress; stress response; -secretase	ENDOPLASMIC-RETICULUM STRESS; AMYLOID PRECURSOR PROTEIN; ALPHA-SECRETASE ADAM10; BRAIN INSULIN-RESISTANCE; BOX-BINDING PROTEIN-1; ER STRESS; MESSENGER-RNA; BETA-SECRETASE; TRANSGENIC MICE; CELL-DEATH	In Alzheimer's disease (AD), disturbed homeostasis of the proteases competing for amyloid precursor protein processing has been reported: a disintegrin and metalloproteinase 10 (ADAM10), the physiological -secretase, is decreased in favor of the amyloid--generating enzyme BACE-1. To identify transcription factors that modulate the expression of either protease, we performed a screening approach: 48 transcription factors significantly interfered with ADAM10/BACE-1-promoter activity. One selective inducer of ADAM10 gene expression is the X-box binding protein-1 (XBP-1). This protein regulates the unfolded protein-response pathway. We demonstrate that particularly the spliced XBP-1 variant dose dependently regulates ADAM10 expression, which can be synergistically enhanced by 100 nM insulin. Analysis of 2 different transgenic mouse models (APP/PS1 and 5xFAD) revealed that at early time points in pathology XBP-1 metabolism is induced. This is accompanied by a 2-fold augmented ADAM10 amount as compared with nontransgenic littermates (P=0.011). Along with aging of the mice, the system is counterregulated, and XBP-1 together with ADAM10 expression level decreased to approximate to 50% as compared with control animals. Analyses of expression levels in human AD brains showed that ADAM10 mRNA correlated with active XBP-1 (r=0.3120), but expression did not reach levels of healthy age-matched controls, suggesting deregulation of XBP-1 signaling. Our results demonstrate that XBP-1 is a driver of ADAM10 gene expression and that disturbance of this pathway might contribute to development or progression of AD.Reinhardt, S., Schuck, F., Grosgen, S., Riemenschneider, M., Hartmann, T., Postina, R., Grimm, M., Endres, K. Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease.	[Reinhardt, Sven; Schuck, Florian; Endres, Kristina] Johannes Gutenberg Univ Mainz, Clin Res Grp, Dept Psychiat & Psychotherapy, D-55131 Mainz, Germany; [Postina, Rolf] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, D-55131 Mainz, Germany; [Groesgen, Sven; Hartmann, Tobias; Grimm, Marcus] Univ Saarland, Dept Neurodegenerat & Neurobiol, Deutsch Inst DemenzPravent DIDP, Homburg, Germany; [Riemenschneider, Matthias] Univ Saarland, Clin Psychiat & Psychotherapy, Homburg, Germany; [Hartmann, Tobias; Grimm, Marcus] Univ Saarland, Dept Expt Neurol, Homburg, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Saarland University; Saarland University; Saarland University	Endres, K (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Psychiat & Psychotherapy, Untere Zahlbacher Str 8, D-55131 Mainz, Germany.	kristina.endres@unimedizin-mainz.de	Endres, Kristina/K-4960-2015; Hartmann, Tobias/AAB-8297-2022; Grimm, Marcus O. W./F-8134-2011	Grimm, Marcus O. W./0000-0002-4160-6506; Hartmann, Tobias/0000-0001-7481-6430	German Federal Ministry of Education and Research (BMBF);  [FKZ01GS08130];  [01GS08125];  [01GS08129-5]	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); ; ; 	This work was supported by the German Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN) and FKZ01GS08130, 01GS08125, and 01GS08129-5. The authors kindly thank C. Haass (Ludwig Maximilian University, Munich, Germany) for providing APP antibody 6687 and C. Pietrzik (Johannes Gutenberg University Mainz, Mainz, Germany) for putting 5xFAD brain samples at their disposal. Author contributions: K. E. conceived the project and wrote the manuscript; S. R. performed cell culture experiments and analysis of mouse tissue and in vitro studies, analyzed the data, wrote the manuscript, and prepared the figures; M. G., T. H., and M. R. coordinated and designed the experiments with human samples; S. G. performed experiments with human samples and the fluorescent enzyme assay; S. G. and M. G. analyzed the respective data; F. S. and R. P. provided a critical evaluation of the experimental design and of the manuscript. The authors declare no conflicts of interest.	Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Augustin R, 2011, INT J ALZHEIMERS DIS, V2011; Augustin R, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-35; Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Bernales S, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00005; Bernstein HG, 2003, J NEUROCYTOL, V32, P153, DOI 10.1023/B:NEUR.0000005600.61844.a6; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Boissonneault V, 2009, J BIOL CHEM, V284, P1971, DOI 10.1074/jbc.M807530200; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Casas-Tinto S, 2011, HUM MOL GENET, V20, P2144, DOI 10.1093/hmg/ddr100; Castillo-Carranza DL, 2012, NEUROCHEM RES, V37, P1707, DOI 10.1007/s11064-012-0780-7; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Colciaghi F, 2002, MOL MED, V8, P67, DOI 10.1007/BF03402076; de la Monte SM, 2012, CURR ALZHEIMER RES, V9, P35; Duyckaerts C, 2008, ACTA NEUROPATHOL, V115, P5, DOI 10.1007/s00401-007-0312-8; Endres K, 2005, FEBS J, V272, P5808, DOI 10.1111/j.1742-4658.2005.04976.x; Endres K, 2012, EXP BRAIN RES, V217, P343, DOI 10.1007/s00221-011-2885-7; Fellgiebel A, 2009, J GERIATR PSYCH NEUR, V22, P3, DOI 10.1177/0891988708327810; Grimm M. O., 2011, INT J ALZHEIMERS DIS, V2011; Grimm MOW, 2013, INT J MOL SCI, V14, P5879, DOI 10.3390/ijms14035879; Guo FJ, 2010, CELL SIGNAL, V22, P1818, DOI 10.1016/j.cellsig.2010.07.006; Hayashi A, 2007, J BIOL CHEM, V282, P34525, DOI 10.1074/jbc.M704300200; Hebert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Hoozemans JJM, 2012, NEURODEGENER DIS, V10, P212, DOI 10.1159/000334536; Jorissen E, 2010, J NEUROSCI, V30, P4833, DOI 10.1523/JNEUROSCI.5221-09.2010; Kakiuchi C, 2003, NAT GENET, V35, P171, DOI 10.1038/ng1235; Kaneko M, 2010, J NEUROSCI, V30, P3924, DOI 10.1523/JNEUROSCI.2422-09.2010; Kim HJ, 2008, J NUTR BIOCHEM, V19, P754, DOI 10.1016/j.jnutbio.2007.09.009; Kogel D, 2012, NEUROBIOL AGING, V33, P2200, DOI 10.1016/j.neurobiolaging.2011.06.012; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Kuhn PH, 2010, EMBO J, V29, P3020, DOI 10.1038/emboj.2010.167; Lahiri DK, 2004, ANN NY ACAD SCI, V1030, P310, DOI 10.1196/annals.1329.039; Lammich S, 2010, J BIOL CHEM, V285, P15753, DOI 10.1074/jbc.M110.110742; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Liu SY, 2013, CNS NEUROSCI THER, V19, P229, DOI 10.1111/cns.12064; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; Maretzky T, 2008, J INVEST DERMATOL, V128, P1737, DOI 10.1038/sj.jid.5701242; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Mihailovich M, 2007, NUCLEIC ACIDS RES, V35, P2975, DOI 10.1093/nar/gkm191; Misiewicz M, 2013, J BIOL CHEM, V288, P20378, DOI 10.1074/jbc.M113.457242; Mohajeri MH, 2004, J NEURAL TRANSM, V111, P413, DOI 10.1007/s00702-003-0057-z; Nagashima Y, 2011, SCI REP-UK, V1, DOI 10.1038/srep00029; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nishitoh H, 2008, GENE DEV, V22, P1451, DOI 10.1101/gad.1640108; Nowak K, 2006, J NEUROCHEM, V96, P1696, DOI 10.1111/j.1471-4159.2006.03692.x; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Olsson A, 2003, EXP NEUROL, V183, P74, DOI 10.1016/S0014-4886(03)00027-X; Ozmen L, 2005, NEURODEGENER DIS, V2, P284, DOI 10.1159/000092314; Park SW, 2010, NAT MED, V16, P429, DOI 10.1038/nm.2099; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Prinzen C, 2005, FASEB J, V19, P1522, DOI 10.1096/fj.04-3619fje; Qi L, 2011, METHOD ENZYMOL, V490, P137, DOI 10.1016/B978-0-12-385114-7.00008-8; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Rzymski T, 2012, ONCOGENE, V31, P3621, DOI 10.1038/onc.2011.522; Sado M, 2009, BRAIN RES, V1257, P16, DOI 10.1016/j.brainres.2008.11.104; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Takahashi K, 2009, J NEUROCHEM, V109, P1324, DOI 10.1111/j.1471-4159.2009.06067.x; Talbot K, 2012, J CLIN INVEST, V122, P1316, DOI 10.1172/JCI59903; Tippmann F, 2009, FASEB J, V23, P1643, DOI 10.1096/fj.08-121392; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirosh B, 2006, J BIOL CHEM, V281, P5852, DOI 10.1074/jbc.M509061200; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Ueki K, 2011, NAT MED, V17, P246, DOI 10.1038/nm0311-246; Umeda T, 2011, J NEUROSCI RES, V89, P1031, DOI 10.1002/jnr.22640; Viana RJS, 2012, MOL NEUROBIOL, V46, P522, DOI 10.1007/s12035-012-8301-x; Wang Y, 2000, J BIOL CHEM, V275, P27013; Winnay JN, 2010, NAT MED, V16, P438, DOI 10.1038/nm.2121; Yamamoto K, 2004, J BIOCHEM, V136, P343, DOI 10.1093/jb/mvh122; Yanagitani K, 2009, MOL CELL, V34, P191, DOI 10.1016/j.molcel.2009.02.033; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zeng L, 2010, J IMMUNOL, V185, P2324, DOI 10.4049/jimmunol.0903052	85	70	71	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					978	997		10.1096/fj.13-234864	http://dx.doi.org/10.1096/fj.13-234864			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24165480				2022-12-28	WOS:000331072200042
J	Cheung, GYC; Kretschmer, D; Queck, SY; Joo, HS; Wang, R; Duong, AC; Nguyen, TH; Bach, THL; Porter, AR; DeLeo, FR; Peschel, A; Otto, M				Cheung, Gordon Y. C.; Kretschmer, Dorothee; Queck, Shu Y.; Joo, Hwang-Soo; Wang, Rong; Duong, Anthony C.; Nguyen, Thuan H.; Bach, Thanh-Huy L.; Porter, Adeline R.; DeLeo, Frank R.; Peschel, Andreas; Otto, Michael			Insight into structure-function relationship in phenol-soluble modulins using an alanine screen of the phenol-soluble modulin ( PSM) alpha 3 peptide	FASEB JOURNAL			English	Article						Staphylococcus aureus; toxins; neutrophils; hemolysis; inflammation; biofilm	STAPHYLOCOCCUS-AUREUS; VIRULENCE DETERMINANTS; ACTIVATES NEUTROPHILS; BIOFILM MATURATION; EPIDERMIDIS; INFECTIONS; MECHANISMS; SKIN	Phenol-soluble modulins (PSMs) are a family of peptides with multiple functions in staphylococcal pathogenesis. To gain insight into the structural features affecting PSM functions, we analyzed an alanine substitution library of PSM3, a strongly cytolytic and proinflammatory PSM of Staphylococcus aureus with a significant contribution to S. aureus virulence. Lysine residues were essential for both receptor-dependent proinflammatory and receptor-independent cytolytic activities. Both phenotypes also required additional structural features, with the C terminus being crucial for receptor activation. Biofilm formation was affected mostly by hydrophobic amino acid positions, suggesting that the capacity to disrupt hydrophobic interactions is responsible for the effect of PSMs on biofilm structure. Antimicrobial activity, absent from natural PSM3, could be created by the exchange of large hydrophobic side chains, indicating that PSM3 has evolved to exhibit cytolytic rather than antimicrobial activity. In addition to gaining insight into the structure-function relationship in PSMs, our study identifies nontoxic PSM3 derivatives for active vaccination strategies and lays the foundation for future efforts aimed to understand the biological role of PSM recognition by innate host defense.Cheung, G. Y., Kretschmer, D., Queck, S. Y., Joo, H.-S., Wang, R., Duong, A. C., Nguyen, T. H., Bach, T.-H., Porter, A. R., DeLeo, F. R., Peschel, A., Otto, M. Insight into structure-function relationship in phenol-soluble modulins using an alanine screen of the phenol-soluble modulin (PSM) 3 peptide.	[Cheung, Gordon Y. C.; Queck, Shu Y.; Joo, Hwang-Soo; Wang, Rong; Duong, Anthony C.; Nguyen, Thuan H.; Bach, Thanh-Huy L.; Otto, Michael] NIAID, Pathogen Mol Genet Sect, Lab Human Bacterial Pathogenesis, NIH, Bethesda, MD 20892 USA; [Kretschmer, Dorothee; Peschel, Andreas] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Cellular & Mol Microbiol Div, Tubingen, Germany; [Porter, Adeline R.; DeLeo, Frank R.] NIAID, Pathogen Host Cell Biol Sect, Lab Human Bacterial Pathogenesis, NIH, Hamilton, MT USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Eberhard Karls University of Tubingen; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Otto, M (corresponding author), NIAID, 9000 Rockville Pike,Bldg 33 1W10, Bethesda, MD 20892 USA.	motto@niaid.nih.gov		DeLeo, Frank/0000-0003-3150-2516; JOO, HWANG-SOO/0000-0003-4668-3225; Otto, Michael/0000-0002-2222-4115	Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH); German Research Foundation [SFB685, TRR34]; German Ministry of Education and Research; Interdisziplin res Zentrum fur Klinische Forschung (IZKF) Program of the Medical Faculty, University of Tubingen; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001079, ZIAAI000904] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH); German Research Foundation(German Research Foundation (DFG)); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Interdisziplin res Zentrum fur Klinische Forschung (IZKF) Program of the Medical Faculty, University of Tubingen; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Nele Nikola, Kevin Holmes, and David Stephany for technical help; Michael Dolan for PSM alpha 3 modeling; Francois Boulay (Commissariat a l'Energie Atomique, Grenoble, France) for FPR1 and FPR2-transfected cell lines; and Bas Surewaard for advice on the in vivo studies. This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH) (to M.O. and F. D.), and grants from the German Research Foundation (SFB685, TRR34), the German Ministry of Education and Research (SkinStaph, Menage), and the Interdisziplin res Zentrum fur Klinische Forschung (IZKF) Program of the Medical Faculty, University of Tubingen (to A.P.).	Cassat JE, 2013, CELL HOST MICROBE, V13, P759, DOI 10.1016/j.chom.2013.05.003; Chatterjee SS, 2013, NAT MED, V19, P364, DOI 10.1038/nm.3047; Cheung GYC, 2012, MICROBES INFECT, V14, P380, DOI 10.1016/j.micinf.2011.11.013; Cheung GYC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001133; Christophe T, 2001, J BIOL CHEM, V276, P21585, DOI 10.1074/jbc.M007769200; Cogen AL, 2010, J INVEST DERMATOL, V130, P192, DOI 10.1038/jid.2009.243; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; Geiger T, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003016; GLADSTONE GP, 1967, BRIT J EXP PATHOL, V48, P11; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Joo HS, 2011, J BIOL CHEM, V286, P8933, DOI 10.1074/jbc.M111.221382; Kennedy AD, 2010, J INFECT DIS, V202, P1050, DOI 10.1086/656043; Kobayashi SD, 2011, J INFECT DIS, V204, P937, DOI 10.1093/infdis/jir441; Kretschmer D, 2010, CELL HOST MICROBE, V7, P463, DOI 10.1016/j.chom.2010.05.012; Li M, 2009, P NATL ACAD SCI USA, V106, P5883, DOI 10.1073/pnas.0900743106; Lowy FD, 2003, J CLIN INVEST, V111, P1265, DOI 10.1172/JC1200318535; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Mehlin C, 1999, J EXP MED, V189, P907, DOI 10.1084/jem.189.6.907; MENZIES BE, 1994, INFECT IMMUN, V62, P1843, DOI 10.1128/IAI.62.5.1843-1847.1994; Otto M, 2008, BIODRUGS, V22, P27, DOI 10.2165/00063030-200822010-00003; Otto M, 2013, ANNU REV MED, V64, P175, DOI 10.1146/annurev-med-042711-140023; Periasamy Saravanan, 2012, Commun Integr Biol, V5, P275, DOI 10.4161/cib.19420; Periasamy S, 2012, P NATL ACAD SCI USA, V109, P1281, DOI 10.1073/pnas.1115006109; Pokorny A, 2002, BIOCHEMISTRY-US, V41, P11044, DOI 10.1021/bi020244r; Queck SY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000533; Rasigade J. P., 2013, PLOS ONE, V8; Rautenberg M, 2011, FASEB J, V25, P1254, DOI 10.1096/fj.10-175208; Schwartz K, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002744; Surewaard BGJ, 2013, CELL MICROBIOL, V15, P1427, DOI 10.1111/cmi.12130; Surewaard BGJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002606; Voyich JA, 2005, J IMMUNOL, V175, P3907, DOI 10.4049/jimmunol.175.6.3907; Voyich JM, 2006, J INFECT DIS, V194, P1761, DOI 10.1086/509506; Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656; Wang R, 2011, J CLIN INVEST, V121, P238, DOI 10.1172/JCI42520; Wardenburg JB, 2008, J EXP MED, V205, P287, DOI 10.1084/jem.20072208; WATSON DC, 1988, BIOCHEM J, V252, P87, DOI 10.1042/bj2520087; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578	39	47	49	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					153	161		10.1096/fj.13-232041	http://dx.doi.org/10.1096/fj.13-232041			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24008753	Green Published			2022-12-28	WOS:000333526100017
J	Ochala, J; Gokhin, DS; Iwamoto, H; Fowler, VM				Ochala, Julien; Gokhin, David S.; Iwamoto, Hiroyuki; Fowler, Velia M.			Pointed-end capping by tropomodulin modulates actomyosin crossbridge formation in skeletal muscle fibers	FASEB JOURNAL			English	Article						tropomyosin; thin-filament activation	X-RAY-DIFFRACTION; BETA-TROPOMYOSIN MUTATION; THIN-FILAMENTS; CALCIUM ACTIVATION; NEBULIN RULER; CONTRACTILE; PROTEINS; LENGTHS; FORCE; HEART	In skeletal muscle, thick and thin filaments are arranged in a myofibrillar lattice. Tropomodulin 1 (Tmod1) is a pointed-end capping and tropomyosin-binding protein that controls thin-filament assembly, stability, and lengths. It remains unknown whether Tmods have other functional roles, such as regulating muscle contractility. To investigate this, we recorded and analyzed the mechanical properties and X-ray diffraction patterns of single membrane-permeabilized skeletal muscle fibers from mice lacking Tmod1. Results show that absence of Tmod1 and its replacement by Tmod3 and Tmod4 may impair initial tropomyosin movement over actin subunits during thin-filament activation, thus reducing both the fraction of actomyosin crossbridges in the strongly bound state (-29%) and fiber force-generating capacity (-31%). Therefore, Tmods are novel regulators of actomyosin crossbridge formation and muscle contractility, and future investigations and models of skeletal muscle force production must incorporate Tmods.Ochala, J., Gokhin, D. S., Iwamoto, H., Fowler, V. M. Pointed-end capping by tropomodulin modulates actomyosin crossbridge formation in skeletal muscle fibers.	[Ochala, Julien] Kings Coll London, Sch Biomed Sci, Ctr Human & Aerosp Physiol Sci, London SE1 1UL, England; [Gokhin, David S.; Fowler, Velia M.] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA; [Iwamoto, Hiroyuki] Japan Synchrotron Radiat Res Inst, Nishinomiya, Hyogo, Japan	University of London; King's College London; Scripps Research Institute; Japan Synchrotron Radiation Research Institute	Ochala, J (corresponding author), Kings Coll London, Sch Biomed Sci, Ctr Human & Aerosp Physiol Sci, Rm 3-3,Shepherds House,Guys Campus, London SE1 1UL, England.	julien.ochala@kcl.ac.uk	Ochala, Julien/K-4120-2017	Ochala, Julien/0000-0002-6358-2920; Fowler, Velia/0000-0002-3161-8802	Swedish Research Council; National Heart, Lung, and Blood Institute at the U.S. National Institutes of Health (NIH) [R01-HL083464]; National Institute of Arthritis and Musculoskeletal and Skin Diseases at the NIH [P30-AR061303]; Muscular Dystrophy Association; NATIONAL EYE INSTITUTE [P30EY012598] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR061303] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); National Heart, Lung, and Blood Institute at the U.S. National Institutes of Health (NIH); National Institute of Arthritis and Musculoskeletal and Skin Diseases at the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by grants from the Swedish Research Council (to J.O.), a grant from the National Heart, Lung, and Blood Institute at the U.S. National Institutes of Health (NIH; R01-HL083464 to V. M. F), a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the NIH to the Imaging Core of the San Diego Skeletal Muscle Research Center (P30-AR061303 to V. M. F.), and a development grant from the Muscular Dystrophy Association (to D. S. G.). The X-ray experiments were performed under approval of the SPring-8 Proposal Review Committee (2011B1058). The authors thank Nancy E. Kim, Yvette Hedstrom, and Ann-Marie Gustafsson for excellent technical assistance. The authors declare no conflicts of interest.	Bang ML, 2009, FASEB J, V23, P4117, DOI 10.1096/fj.09-137729; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; Castillo A, 2009, BIOPHYS J, V96, P1856, DOI 10.1016/j.bpj.2008.10.053; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Fritz-Six KL, 2003, J CELL BIOL, V163, P1033, DOI 10.1083/jcb.200308164; Frontera WR, 1997, MUSCLE NERVE, V20, P948, DOI 10.1002/(SICI)1097-4598(199708)20:8<948::AID-MUS3>3.0.CO;2-6; Gokhin DS, 2013, NAT REV MOL CELL BIO, V14, P113, DOI 10.1038/nrm3510; Gokhin DS, 2012, AM J PHYSIOL-CELL PH, V302, pC555, DOI 10.1152/ajpcell.00299.2011; Gokhin DS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/103069; Gokhin DS, 2011, J CELL BIOL, V194, P105, DOI 10.1083/jcb.201011128; Gokhin DS, 2010, J CELL BIOL, V189, P95, DOI 10.1083/jcb.201001125; Iwamoto H, 2003, BIOPHYS J, V85, P2492, DOI 10.1016/S0006-3495(03)74672-4; Iwamoto H, 2002, J MOL BIOL, V317, P707, DOI 10.1006/jmbi.2002.5449; Iwamoto H, 2001, J MOL BIOL, V305, P863, DOI 10.1006/jmbi.2000.4334; Iwamoto H, 2009, J MOL BIOL, V390, P99, DOI 10.1016/j.jmb.2009.05.002; KNIGHT PJ, 1982, METHOD ENZYMOL, V85, P9; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; Lehman W, 2008, ADV EXP MED BIOL, V644, P95; Linari M, 2007, BIOPHYS J, V92, P2476, DOI 10.1529/biophysj.106.099549; Littlefield RS, 2008, SEMIN CELL DEV BIOL, V19, P511, DOI 10.1016/j.semcdb.2008.08.009; McKeown CR, 2008, CIRC RES, V103, P1241, DOI 10.1161/CIRCRESAHA.108.178749; Moss RL, 2004, CIRC RES, V94, P1290, DOI 10.1161/01.RES.0000127125.61647.4F; MOSS RL, 1979, J PHYSIOL-LONDON, V292, P177, DOI 10.1113/jphysiol.1979.sp012845; Mudry RE, 2003, J CELL BIOL, V162, P1057, DOI 10.1083/jcb.200305031; Ochala J, 2008, J PHYSIOL-LONDON, V586, P2993, DOI 10.1113/jphysiol.2008.153650; Ochala J, 2007, J PHYSIOL-LONDON, V581, P1283, DOI 10.1113/jphysiol.2007.129759; Ochala J, 2011, FASEB J, V25, P1903, DOI 10.1096/fj.10-176727; Ochala J, 2010, P NATL ACAD SCI USA, V107, P9807, DOI 10.1073/pnas.1001733107; Pappas CT, 2010, J CELL BIOL, V189, P859, DOI 10.1083/jcb.201001043; Regnier M, 1998, BIOPHYS J, V74, P2005, DOI 10.1016/S0006-3495(98)77907-X; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Yagi N, 2003, BIOPHYS J, V84, P1093, DOI 10.1016/S0006-3495(03)74925-X	32	12	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					408	415		10.1096/fj.13-239640	http://dx.doi.org/10.1096/fj.13-239640			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24072783	Green Published			2022-12-28	WOS:000333526100038
J	Seidl, MD; Nunes, F; Fels, B; Hildebrandt, I; Schmitz, W; Schulze-Osthoff, K; Muller, FU				Seidl, Matthias D.; Nunes, Frank; Fels, Benedikt; Hildebrandt, Iris; Schmitz, Wilhelm; Schulze-Osthoff, Klaus; Mueller, Frank U.			A novel intronic promoter of the Crem gene induces small ICER ( smICER) isoforms	FASEB JOURNAL			English	Article						transcription factors; cyclic AMP; cAMP; CREB; apoptosis; gene regulation	CAMP EARLY REPRESSOR; RESPONSE ELEMENT MODULATOR; TRANSCRIPTION FACTORS CREB; AMP EARLY REPRESSOR; BINDING-PROTEIN; CELL-PROLIFERATION; MESSENGER-RNA; FEEDBACK LOOP; BETA-CELLS; EXPRESSION	The transcription factors cAMP-responsive element binding protein (CREB) and cAMP-responsive element modulator (CREM) regulate gene transcription in response to elevated cAMP levels. The Crem isoform inducible cAMP early repressor (Icer) is transcribed by the internal promoter P2 as a critical regulator of multiple cellular processes. Here, we describe a novel inducible Crem isoform, small Icer (smIcer), regulated by a newly identified promoter (P6). ChIP revealed binding of CREB to P6 in human and mouse myocardium. P6 activity was induced by constitutively active CREB or stimulation of adenylyl cyclase. In mice, smIcer mRNA was ubiquitously expressed and transiently induced by -adrenoceptor stimulation e.g., in heart and lung. SmICER repressed both basal and cAMP-induced activities of P6 and P2 promoters. Stimulation of adenylyl cyclase induced P2 and P6 in cell type-specific manner. Alternative translational start sites resulted in three different smICER proteins, linked to increased apoptosis sensitivity. In conclusion, the Crem gene provides two distinct and mutually controlled mechanisms of a cAMP-dependent induction of transcriptional repressors. Our results suggest not only that smICER is a novel regulator of cAMP-mediated gene regulation, but also emphasize that biological effects that have been ascribed solely to ICER, should be revised with regard to smICER.Seidl, M. D., Nunes, F., Fels, B., Hildebrandt, I., Schmitz, W., Schulze-Osthoff, K., and Muller, F. U. A novel intronic promoter of the Crem gene induces small ICER (smICER) isoforms.	[Seidl, Matthias D.; Nunes, Frank; Fels, Benedikt; Hildebrandt, Iris; Schmitz, Wilhelm; Mueller, Frank U.] Univ Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany; [Schulze-Osthoff, Klaus] Univ Tubingen, Interfac Inst Biochem, Tubingen, Germany; [Schulze-Osthoff, Klaus] German Canc Consortium DKTK, Heidelberg, Germany; [Schulze-Osthoff, Klaus] German Canc Res Ctr, Heidelberg, Germany	University of Munster; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Seidl, MD (corresponding author), Univ Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48149 Munster, Germany.	seidl@uni-muenster.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720	Interdisziplinares Zentrum fur Klinische Forschung (IZKF) [Mu1/004/07, Mu1/014/11]; Deutsche Forschungsgemeinschaft (DFG) [Mu1376/11-1, SFB-685, SFB-773]	Interdisziplinares Zentrum fur Klinische Forschung (IZKF); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Melanie Voss and Andrea Walter for excellent technical assistance. This work was supported by the Interdisziplinares Zentrum fur Klinische Forschung (IZKF; Mu1/004/07, Mu1/014/11) and the Deutsche Forschungsgemeinschaft (DFG; Mu1376/11-1, SFB-685, SFB-773).	Behr R, 2000, MOL HUM REPROD, V6, P967, DOI 10.1093/molehr/6.11.967; Bieganska K, 2012, NEUROBIOL DIS, V45, P701, DOI 10.1016/j.nbd.2011.10.015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chakraborty K, 2009, J BIOL CHEM, V284, P21810, DOI 10.1074/jbc.M109.001180; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Ding B, 2005, P NATL ACAD SCI USA, V102, P14771, DOI 10.1073/pnas.0506489102; Favre D, 2011, DIABETOLOGIA, V54, P2337, DOI 10.1007/s00125-011-2165-x; Fitzgerald LR, 1996, J NEUROCHEM, V67, P490; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; FUJIMOTO T, 1994, J BIOCHEM-TOKYO, V115, P298, DOI 10.1093/oxfordjournals.jbchem.a124332; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; Gellersen B, 2002, MOL HUM REPROD, V8, P965, DOI 10.1093/molehr/8.11.965; Goodman RH, 2000, GENE DEV, V14, P1553; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Inada A, 2005, BIOCHEM BIOPH RES CO, V329, P925, DOI 10.1016/j.bbrc.2005.02.046; Inada A, 2004, MOL CELL BIOL, V24, P2831, DOI 10.1128/MCB.24.7.2831-2841.2004; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Klejman A, 2006, ACTA NEUROBIOL EXP, V66, P267; Lamas M, 1996, PHILOS T R SOC B, V351, P561, DOI 10.1098/rstb.1996.0055; Lamas M, 1997, MOL ENDOCRINOL, V11, P1425, DOI 10.1210/me.11.10.1425; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Mioduszewska B, 2008, J NEUROSCI RES, V86, P61, DOI 10.1002/jnr.21469; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Muller FU, 1998, FASEB J, V12, P1191; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Ohtsubo H, 2007, ARTERIOSCL THROM VAS, V27, P1549, DOI 10.1161/ATVBAHA.107.145011; OLESEN J, 1978, STROKE, V9, P344, DOI 10.1161/01.STR.9.4.344; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rauen T, 2011, J BIOL CHEM, V286, P32366, DOI 10.1074/jbc.M111.245811; Sanborn BM, 2000, ENDOCRINOLOGY, V141, P3921, DOI 10.1210/en.141.11.3921; Schulte JS, 2012, AM J PHYSIOL-HEART C, V302, pH1998, DOI 10.1152/ajpheart.00057.2011; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; Shanware NP, 2007, J BIOL CHEM, V282, P6283, DOI 10.1074/jbc.M610674200; Tomita H, 2003, CIRC RES, V93, P12, DOI 10.1161/01.RES.0000079794.57578.F1; Tyson-Capper AJ, 2005, J BIOL CHEM, V280, P34521, DOI 10.1074/jbc.M505344200; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Walker WH, 1996, TRENDS ENDOCRIN MET, V7, P133, DOI 10.1016/1043-2760(96)00035-5; Yan C, 2007, CIRC RES, V100, P510, DOI 10.1161/01.RES.0000259045.49371.9c	46	9	9	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					143	152		10.1096/fj.13-231977	http://dx.doi.org/10.1096/fj.13-231977			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24022402				2022-12-28	WOS:000333526100016
J	Li, XZ; Yu, Y; Funk, CD				Li, Xinzhi; Yu, Ying; Funk, Colin D.			Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4)	FASEB JOURNAL			English	Article						omega 3 polyunsaturated fatty acids; prostaglandin; inflammation; GPR120	PROLIFERATOR-ACTIVATED RECEPTORS; SIGNALING PATHWAYS; RESOLVIN D1; EICOSAPENTAENOIC ACID; GENE-TRANSCRIPTION; INSULIN-SECRETION; GPR120; INFLAMMATION; CELLS; EXPRESSION	Cyclooxygenase-2 (COX-2)-derived prostaglandins are implicated in numerous inflammatory disorders. The purpose of these studies was to examine previously unexplored interactions between COX-2 induction and docosahexaenoic acid (DHA) via the free fatty acid receptor 4 (FFA4) signaling pathway in murine RAW 264.7 cells and peritoneal macrophages challenged with lipopolysaccharide (LPS). DHA dose (IC50 = 18 mu M)- and time-dependently reduced COX-2 expression, without affecting COX-1. DHA (25 mu M for 24 h) decreased LPS-induced prostaglandin E-2 (PGE(2)) synthesis by 81%, primarily through reducing COX-2 (60%), as well as down-regulating microsomal prostaglandin E synthase-1 (46%), but independently of peroxisome proliferator-activated receptors. FFA4 knockdown abrogated DHA effects on COX-2 induction, PGE2 production, and interleukin 6 (IL-6) gene expression. In the presence of inhibitors of eicosanoid metabolism via COX-2, 12/15-lipoxygenase and CYP450s (rofecoxib (1 mu M), PD146176 (2 mu M), or MS-PPOH (20 mu M)), DHA was still effective in attenuating COX-2 induction. Moreover, Toll-like receptor 4 signaling via Akt/JNK phosphorylation and p65 nuclear translocation was repressed by DHA-activated FFA4 coupling with beta-arrestin 2, which was reversed by FFA4 knockdown. These data support DHA modulation of COX-2 expression and activity, in part, via FFA4, which provides a new mechanistic explanation for some of the anti-inflammatory effects of DHA.	[Li, Xinzhi; Funk, Colin D.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada; [Yu, Ying] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai, Peoples R China	Queens University - Canada; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Funk, CD (corresponding author), Queens Univ, Dept Biomed & Mol Sci, Botterell Hall,Rm 433,18 Stuart St, Kingston, ON K7L 3N6, Canada.	funkc@queensu.ca	Li, Xinzhi/X-2650-2019	Funk, Colin/0000-0001-7029-4233	Heart and Stroke Foundation of Ontario; Canadian Institutes for Health Research [CCI 117951]; National Natural Science Foundation of China [NSFC 81161120538]	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors thank Dr. A. Craig (Cancer Research Institute, Queen's University, Kingston, ON, Canada) for supplying RAW 264.7 cells. This work was supported by the Joint Health Research Initiative between the Canadian Institutes for Health Research and the National Natural Science Foundation of China (CCI 117951 and NSFC 81161120538). C. D. F. holds a Tier I Canada Research Chair in Molecular, Cellular, and Physiological Medicine and is the recipient of a Career Investigator Award from the Heart and Stroke Foundation of Ontario.	Bezugla Y, 2006, PROSTAG OTH LIPID M, V79, P93, DOI 10.1016/j.prostaglandins.2005.11.001; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Burns RN, 2010, BIOCHEM BIOPH RES CO, V396, P1030, DOI 10.1016/j.bbrc.2010.05.057; Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265; Cartoni C, 2010, J NEUROSCI, V30, P8376, DOI 10.1523/JNEUROSCI.0496-10.2010; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Funk CD, 2007, J CARDIOVASC PHARM, V50, P470, DOI 10.1097/FJC.0b013e318157f72d; Gotoh C, 2007, BIOCHEM BIOPH RES CO, V354, P591, DOI 10.1016/j.bbrc.2007.01.028; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Hui YQ, 2010, CIRCULATION, V121, P2654, DOI 10.1161/CIRCULATIONAHA.109.910687; Hwang D, 2001, FASEB J, V15, P2556, DOI 10.1096/fj.01-0432com; Ichimura A, 2012, NATURE, V483, P350, DOI 10.1038/nature10798; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kang YJ, 2006, J IMMUNOL, V177, P8111, DOI 10.4049/jimmunol.177.11.8111; Katsuma S, 2005, J BIOL CHEM, V280, P19507, DOI 10.1074/jbc.M412385200; Kebede MA, 2009, DIABETES OBES METAB, V11, P10, DOI 10.1111/j.1463-1326.2009.01114.x; Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Li H, 2005, KIDNEY INT, V67, P867, DOI 10.1111/j.1523-1755.2005.00151.x; Marszalek JR, 2005, ANNU REV CELL DEV BI, V21, P633, DOI 10.1146/annurev.cellbio.21.122303.120624; Massaro M, 2006, P NATL ACAD SCI USA, V103, P15184, DOI 10.1073/pnas.0510086103; Matsumura S, 2009, NEUROSCI LETT, V450, P186, DOI 10.1016/j.neulet.2008.11.056; Matsumura S, 2007, BIOMED RES-TOKYO, V28, P49, DOI 10.2220/biomedres.28.49; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Nguyen CA, 2012, CURR MED CHEM, V19, P28; Ni NC, 2011, J PHARMACOL EXP THER, V339, P768, DOI 10.1124/jpet.111.186031; Oh DY, 2011, CURR OPIN CLIN NUTR, V14, P322, DOI 10.1097/MCO.0b013e3283479230; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; Ringbom T, 2001, J NAT PROD, V64, P745, DOI 10.1021/np000620d; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Seta F, 2009, AM J PHYSIOL-REG I, V296, pR1751, DOI 10.1152/ajpregu.90985.2008; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; Smith WL, 2008, TRENDS BIOCHEM SCI, V33, P27, DOI 10.1016/j.tibs.2007.09.013; Smith WL, 2005, CURR OPIN CELL BIOL, V17, P174, DOI 10.1016/j.ceb.2005.02.005; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spite M, 2009, BRIT J PHARMACOL, V158, P1062, DOI 10.1111/j.1476-5381.2009.00234.x; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Wada M, 2007, J BIOL CHEM, V282, P22254, DOI 10.1074/jbc.M703169200; Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200; Weylandt KH, 2012, PROSTAG OTH LIPID M, V97, P73, DOI 10.1016/j.prostaglandins.2012.01.005; Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3; Yu Y., 2012, SCI TRANSL MED, V4; Zaibi MS, 2010, FEBS LETT, V584, P2381, DOI 10.1016/j.febslet.2010.04.027; ZHANG CL, 1992, THROMB RES, V65, P65	52	66	70	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4987	4997		10.1096/fj.13-235333	http://dx.doi.org/10.1096/fj.13-235333			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24005906				2022-12-28	WOS:000329999000032
J	Picchianti, M; Del Vecchio, M; Di Marcello, F; Biagini, M; Veggi, D; Norais, N; Rappuoli, R; Pizza, M; Balducci, E				Picchianti, Monica; Del Vecchio, Mariangela; Di Marcello, Federica; Biagini, Massimiliano; Veggi, Daniele; Norais, Nathalie; Rappuoli, Rino; Pizza, Mariagrazia; Balducci, Enrico			Auto ADP-ribosylation of NarE, a Neisseria meningitidis ADP-ribosyltransferase, regulates its catalytic activities	FASEB JOURNAL			English	Article						NAD; NAD-glycohydrolase; pathogenesis	GLYCOHYDROLASE ACTIVITY; NAD-BINDING; PROTEINS; HYDROXYLAMINE; GLYCATION; RIBOSE; TOXIN; SITE	NarE is an arginine-specific mono-ADP-ribosyltransferase identified in Neisseria meningitidis that requires the presence of iron in a structured cluster for its enzymatic activities. In this study, we show that NarE can perform auto-ADP-ribosylation. This automodification occurred in a time-and NAD-concentration-dependent manner; was inhibited by novobiocin, an ADP-ribosyltransferase inhibitor; and did not occur when NarE was heat inactivated. No reduction in incorporation was evidenced in the presence of high concentrations of ATP, GTP, ADP-ribose, or nicotinamide, which inhibits NAD-glycohydrolase, impeding the formation of free ADP-ribose. Based on the electrophoretic profile of NarE on auto-ADP-ribosylation and on the results of mutagenesis and mass spectrometry analysis, the auto-ADP-ribosylation appeared to be restricted to the addition of a single ADP-ribose. Chemical stability experiments showed that the ADP-ribosyl linkage was sensitive to hydroxylamine, which breaks ADP-ribose-arginine bonds. Site-directed mutagenesis suggested that the auto-ADP-ribosylation site occurred preferentially on the R-7 residue, which is located in the region I of the ADP-ribosyltransferase family. After auto-ADP-ribosylation, NarE showed a reduction in ADP-ribosyltransferase activity, while NAD-glycohydrolase activity was increased. Overall, our findings provide evidence for a novel intramolecular mechanism used by NarE to regulate its enzymatic activities.	[Picchianti, Monica; Del Vecchio, Mariangela; Di Marcello, Federica; Biagini, Massimiliano; Veggi, Daniele; Norais, Nathalie; Rappuoli, Rino; Pizza, Mariagrazia] Novartis Vaccines & Diagnost, Siena, Italy; [Picchianti, Monica] Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; [Balducci, Enrico] Univ Camerino, Sch Biosci & Biotechnol, I-62032 Camerino, Italy	Novartis; University of Siena; University of Camerino	Balducci, E (corresponding author), Ctr Ric Novartis Vaccines & Diagnost, Via Fiorentina 1, I-53100 Siena, Italy.	enrico.balducci@novartis.com		Balducci, Enrico/0000-0001-6147-9033	Novartis Vaccines and Diagnostics	Novartis Vaccines and Diagnostics	The authors thank Giorgio Corsi for his unstinting help with artwork; Elisabetta Soldaini for helpful discussion, valuable advice, and assistance; and Enrico Malito for the analysis of the 3D structure. The work was financially supported by Novartis Vaccines and Diagnostics.	Balducci E, 2005, ANAL BIOCHEM, V344, P278, DOI 10.1016/j.ab.2005.06.024; Balducci E, 2002, MOL CELL BIOCHEM, V233, P127, DOI 10.1023/A:1015562412828; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Bricker AL, 2005, INFECT IMMUN, V73, P6562, DOI 10.1128/IAI.73.10.6562-6566.2005; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; CERVANTESLAUREAN D, 1995, J BIOL CHEM, V270, P7929, DOI 10.1074/jbc.270.14.7929; Del Vecchio M, 2009, J BIOL CHEM, V284, P33040, DOI 10.1074/jbc.M109.057547; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; Fieldhouse RJ, 2008, TRENDS BIOCHEM SCI, V33, P546, DOI 10.1016/j.tibs.2008.08.003; GILL DM, 1991, METHOD ENZYMOL, V195, P267; Gunther F, 2012, 18 INT PATH NEISS C; Han MK, 1996, BIOCHEM J, V318, P903, DOI 10.1042/bj3180903; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; HSIA JA, 1985, J BIOL CHEM, V260, P6187; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; Jacobson EL, 1997, ADV EXP MED BIOL, V419, P371; JOHNSON AP, 1983, J CLIN PATHOL, V36, P213, DOI 10.1136/jcp.36.2.213; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; Koehler C, 2011, J BIOL CHEM, V286, P14842, DOI 10.1074/jbc.M110.193623; KREIMEYER A, 1985, BIOL CHEM H-S, V366, P537, DOI 10.1515/bchm3.1985.366.1.537; LIEBERMAN I, 1957, J BIOL CHEM, V225, P883; Masignani V, 2004, INT J MED MICROBIOL, V293, P471, DOI 10.1078/1438-4221-00296; Masignani V, 2003, MOL MICROBIOL, V50, P1055, DOI 10.1046/j.1365-2958.2003.03770.x; MEYER T, 1988, BIOL CHEM H-S, V369, P579, DOI 10.1515/bchm3.1988.369.2.579; MOSS J, 1983, J BIOL CHEM, V258, P6466; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; PEKALA PH, 1980, MOL CELL BIOCHEM, V31, P49, DOI 10.1007/BF00817890; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Rigby MR, 1996, J IMMUNOL, V156, P4259; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VANDENAKKER F, 1995, BIOCHEMISTRY-US, V34, P10996, DOI 10.1021/bi00035a005; Vogelsgesang M, 2006, BIOCHEMISTRY-US, V45, P1017, DOI 10.1021/bi052253g; Weng BY, 1999, J BIOL CHEM, V274, P31797, DOI 10.1074/jbc.274.45.31797; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V308, P31, DOI 10.1006/abbi.1994.1004; ZATMAN LJ, 1954, J BIOL CHEM, V209, P467	38	8	8	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4723	4730		10.1096/fj.13-229955	http://dx.doi.org/10.1096/fj.13-229955			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964075				2022-12-28	WOS:000329999000008
J	Sone, M; Oyama, K; Mohri, Y; Hayashi, R; Clevers, H; Nishimori, K				Sone, Mizuki; Oyama, Kazunori; Mohri, Yasuaki; Hayashi, Ryotaro; Clevers, Hans; Nishimori, Katsuhiko			LGR4 expressed in uterine epithelium is necessary for uterine gland development and contributes to decidualization in mice	FASEB JOURNAL			English	Article						Lif; Foxa2; Wnt signaling	LEUKEMIA INHIBITORY FACTOR; BLASTOCYST IMPLANTATION; WNT/BETA-CATENIN; INDIAN HEDGEHOG; MOUSE UTERUS; MESENCHYMAL INTERACTIONS; POSTNATAL-DEVELOPMENT; SIGNALING PATHWAY; STEM-CELLS; PROGESTERONE	In previous work we generated mice with a tissue specific ablation of a leucine-rich repeat containing G-protein-coupled receptor 4 (Lgr4) using the Keratin-5 (K5) Cre transgenic mouse strain (Lgr4(K5 KO)). Interestingly, the Lgr4(K5 KO) female mice were subfertile, and their embryos had impaired development. Notably, the contributions of uterine development to the subfertility phenotype were not elucidated in the previous report. In a readdress, the following study explores uterine aberration in Lgr4(K5 KO) female mice. Histological analysis revealed that the uteri of Lgr4(K5 KO) mice displayed altered epithelial differentiation characterized by a reduction in the number of uterine glands. Furthermore, Lgr4 deletion led to the reduced expression of morphoregulatory genes related to the Wnt signaling pathway. Additionally, the uteri of the Lgr4(K5 KO) mice lost the ability to undergo induced decidualization. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis and administration of recombinant leukemia inhibitory factor (LIF) demonstrated that the impaired decidualization in Lgr4(K5 KO) mice resulted from the decreased secretion of LIF concurrent with a reduction in uterine gland count. Thus, we propose that LGR4 contributes to uterine gland development, which supports decidualization during pregnancy.	[Sone, Mizuki; Oyama, Kazunori; Mohri, Yasuaki; Hayashi, Ryotaro; Nishimori, Katsuhiko] Tohoku Univ, Grad Sch Agr Sci, Mol Biol Lab, Sendai, Miyagi 9818555, Japan; [Clevers, Hans] Univ Med Ctr Utrecht, Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands	Tohoku University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center	Nishimori, K (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Mol Biol Lab, Aoba Ku, 1-1 Tsutsumidori Amamiyamachi, Sendai, Miyagi 9818555, Japan.	knishimori@m.tohoku.ac.jp			Japan Society for the Promotion of Science for Young Scientists [24112502]; Grants-in-Aid for Scientific Research [24112502] Funding Source: KAKEN	Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by Grants-in-Aid for Scientific Research on Innovative Areas (24112502) and Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (to Y.M. and K.O).	Aoki M, 2007, DEV BIOL, V301, P218, DOI 10.1016/j.ydbio.2006.08.018; BRANHAM WS, 1985, ENDOCRINOLOGY, V117, P2229, DOI 10.1210/endo-117-5-2229; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Cha JY, 2012, NAT MED, V18, P1754, DOI 10.1038/nm.3012; Chassot AA, 2008, HUM MOL GENET, V17, P1264, DOI 10.1093/hmg/ddn016; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen JR, 2000, ENDOCRINOLOGY, V141, P4365, DOI 10.1210/en.141.12.4365; Chen W, 2010, CELL TISSUE RES, V341, P441, DOI 10.1007/s00441-010-1013-5; Cooke PS, 2013, MOL HUM REPROD, V19, P547, DOI 10.1093/molehr/gat031; Daikoku T, 2011, DEV CELL, V21, P1014, DOI 10.1016/j.devcel.2011.09.010; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020; Dunlap KA, 2011, BIOL REPROD, V85, P386, DOI 10.1095/biolreprod.111.091769; Filant J, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.113.107631; FINN CA, 1972, BIOL REPROD, V7, P82, DOI 10.1093/biolreprod/7.1.82; Franco HL, 2011, FASEB J, V25, P1176, DOI 10.1096/fj.10-175349; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Gray CA, 2001, BIOL REPROD, V65, P1311, DOI 10.1095/biolreprod65.5.1311; Hayashi K, 2011, BIOL REPROD, V84, P308, DOI 10.1095/biolreprod.110.088161; Hoshii T, 2007, BIOL REPROD, V76, P303, DOI 10.1095/biolreprod.106.054619; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Jeong JW, 2009, ONCOGENE, V28, P31, DOI 10.1038/onc.2008.363; Jeong JW, 2010, BIOL REPROD, V83, P396, DOI 10.1095/biolreprod.109.083154; Kato S, 2007, FEBS LETT, V581, P4685, DOI 10.1016/j.febslet.2007.08.064; Kato S, 2006, NEPHRON EXP NEPHROL, V104, pE63, DOI 10.1159/000093999; Kubota K, 2010, CELL TISSUE RES, V340, P389, DOI 10.1007/s00441-010-0945-0; Lee K, 2006, NAT GENET, V38, P1204, DOI 10.1038/ng1874; Lee KY, 2007, TRENDS ENDOCRIN MET, V18, P234, DOI 10.1016/j.tem.2007.06.002; Lee KY, 2007, MOL CELL BIOL, V27, P5468, DOI 10.1128/MCB.00342-07; Lee KY, 2004, REPRODUCTION, V128, P679, DOI 10.1530/rep.1.00340; Li QX, 2007, J BIOL CHEM, V282, P31725, DOI 10.1074/jbc.M704723200; Li QX, 2013, ENDOCRINOLOGY, V154, P446, DOI 10.1210/en.2012-1585; Li XY, 2010, DEVELOPMENT, V137, P151, DOI 10.1242/dev.040659; Liu SJ, 2013, J BIOL CHEM, V288, P8794, DOI 10.1074/jbc.M112.436204; MARTIN L, 1973, J ENDOCRINOL, V57, P549, DOI 10.1677/joe.0.0570549; Matsumoto H, 2002, DEV BIOL, V245, P280, DOI 10.1006/dbio.2002.0645; Mendive F, 2006, DEV BIOL, V290, P421, DOI 10.1016/j.ydbio.2005.11.043; Mericskay M, 2004, DEVELOPMENT, V131, P2061, DOI 10.1242/dev.01090; Miller C, 1998, DEVELOPMENT, V125, P3201; Mohri Y, 2012, BIOSCI BIOTECH BIOCH, V76, P888, DOI 10.1271/bbb.110834; Mohri Y, 2011, DEV DYNAM, V240, P1626, DOI 10.1002/dvdy.22651; Mohri Y, 2010, FERTIL STERIL, V94, P2878, DOI 10.1016/j.fertnstert.2010.05.050; Mustata RC, 2011, EMBO REP, V12, P558, DOI 10.1038/embor.2011.52; Nallasamy S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002500; Nam JS, 2007, DEV BIOL, V311, P124, DOI 10.1016/j.ydbio.2007.08.023; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oyama K, 2011, SEX DEV, V5, P205, DOI 10.1159/000329476; Qian Y, 2013, DEVELOPMENT, V140, P1751, DOI 10.1242/dev.093641; Ramathal CY, 2010, SEMIN REPROD MED, V28, P17, DOI 10.1055/s-0029-1242989; RIDER V, 1985, J ENDOCRINOL, V104, P153, DOI 10.1677/joe.0.1040153; Shelton DN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040312; Song H, 2006, REPRODUCTION, V131, P341, DOI 10.1530/rep.1.00956; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Takamoto N, 2005, MOL ENDOCRINOL, V19, P2299, DOI 10.1210/me.2005-0019; Takamoto N, 2002, MOL ENDOCRINOL, V16, P2338, DOI 10.1210/me.2001-0154; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Thie M, 1996, INT J DEV BIOL, V40, P389; Tomizuka K, 2008, HUM MOL GENET, V17, P1278, DOI 10.1093/hmg/ddn036; Villacorte M, 2013, ONCOGENE, V32, P3477, DOI 10.1038/onc.2012.376; Wang Y, 2013, STEM CELLS, V31, P1921, DOI 10.1002/stem.1438	63	23	25	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4917	4928		10.1096/fj.13-232215	http://dx.doi.org/10.1096/fj.13-232215			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23975934				2022-12-28	WOS:000329999000026
J	Meir, YJJ; Lin, A; Huang, MF; Lin, JR; Weirauch, MT; Chou, HC; Lin, SJA; Wu, SCY				Meir, Yaa-Jyuhn James; Lin, Angelique; Huang, Meng-Fan; Lin, Jiao-Rung; Weirauch, Matthew T.; Chou, Hsiang-Chen; Lin, Siang-Jin Ashley; Wu, Sareina Chiung-Yuan			A versatile, highly efficient, and potentially safer piggyBac transposon system for mammalian genome manipulations	FASEB JOURNAL			English	Article						gene therapy; functional genomics; remobilization; induced pluripotent stem cell	CANCER GENE DISCOVERY; SLEEPING-BEAUTY; LENTIVIRAL VECTORS; MUTAGENESIS; TRANSFORMATION; SCREEN; LINES; TOL2; MOS1; TOOL	The piggyBac transposon is one of the most attractive nonviral tools for mammalian genome manipulations. Given that piggybac mobilizes in a cut-and-paste fashion, integrant remobilization could potentially damage the host genome. Here, we report a novel piggyBac transposon system with a series of recombinant transposases. We found that the transposition activity of wild-type (PBase) and hyperactive (hyPBase) piggyBac transposases can be significantly increased by peptide fusions in a cell-type dependent fashion, with the greatest change typically seen in mouse embryonic stem (ES) cells. The two most potent recombinant transposases, TPLGMH and ThyPLGMH, give a 9- and 7-fold increase, respectively, in the number of integrants in HEK293 compared with Myc-tagged PBase (MycPBase), and both display 4-fold increase in generating induced pluripotential stem cells. Interestingly, ThyPLGMH but not TPLGMH shows improved chromosomal excision activity (2.5-fold). This unique feature of TPLGMH provides the first evidence that integration activity of a transposase can be drastically improved without increasing its remobilization activity. Transposition catalyzed by ThyPLGMH is more random and occurs further from CpG islands than that catalyzed by MycPBase or TPLGMH. Our transposon system diversifies the mammalian genetic toolbox and provides a spectrum of piggyBac transposases that is better suited to different experimental purposes.Meir, Y.-J. J., Lin, A., Huang, M.-F., Lin, J.-R., Weirauch, M. T., Chou, H.-C., Lin, S.-J., Wu, S. C. A versatile, highly efficient, and potentially safer piggyBac transposon system for mammalian genome manipulations.	[Meir, Yaa-Jyuhn James; Chou, Hsiang-Chen; Lin, Siang-Jin Ashley] Chang Gung Univ, Dept Biomed Sci, Coll Med, Tao Yuan 333, Taiwan; [Lin, Angelique; Huang, Meng-Fan; Lin, Jiao-Rung; Wu, Sareina Chiung-Yuan] Chang Gung Univ, Inst Mol Med, Coll Med, Tao Yuan 333, Taiwan; [Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, CAGE, Cincinnati, OH 45229 USA; [Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA; [Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA	Chang Gung University; Chang Gung University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Wu, SCY (corresponding author), Chang Gung Univ, Inst Mol Med, Coll Med, Tao Yuan 333, Taiwan.	jmeir@mail.cgu.edu.tw; sareinaw@mail.cgu.edu.tw	Weirauch, Matthew/M-5459-2019	Wu, Sareina, Chiung-Yuan/0000-0002-6346-4406; Huang, Meng-Fan/0000-0001-5113-1746	National Science Council of Taiwan [NSC99-2320-B-182-010-MY3]; Chang Gung Memorial Hospital [CMRPD3A0011-3]; Molecular Medicine Research Center [EMRPD1B0171]; Healthy Aging Research Center of Chang Gung University [EMRPD1C0261]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Molecular Medicine Research Center; Healthy Aging Research Center of Chang Gung University	The authors thank Evan Snyder (Sanford Burnham Medical Research Institute, La Jolla, CA, USA) for providing C17.2. ATP1, pHAhyPBase, and the ES reporter cell line HPRT<SUP>PB-in2</SUP> were a kind gift of Allan Bradley (Wellcome Trust Sanger Institute, Hinxton, UK). This work is supported by the National Science Council of Taiwan (NSC99-2320-B-182-010-MY3), Chang Gung Memorial Hospital (CMRPD3A0011-3), and the Molecular Medicine Research Center (EMRPD1B0171) and Healthy Aging Research Center of Chang Gung University (EMRPD1C0261).	Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; Belay E, 2011, CURR GENE THER, V11, P406; Ben-Dor I, 2006, MOL THER, V14, P255, DOI 10.1016/j.ymthe.2006.02.010; Cadinanos J, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm446; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; Dupuy AJ, 2010, METHOD ENZYMOL, V477, P53, DOI 10.1016/S0076-6879(10)77004-X; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Gonzalez-Estevez C, 2003, P NATL ACAD SCI USA, V100, P14046, DOI 10.1073/pnas.2335980100; Grabundzija I, 2010, MOL THER, V18, P1200, DOI 10.1038/mt.2010.47; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; Hayes F, 2003, ANNU REV GENET, V37, P3, DOI 10.1146/annurev.genet.37.110801.142807; Hofherr SE, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017076, 10.1371/journal.pone.0023376]; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Keng VW, 2009, NAT BIOTECHNOL, V27, P264, DOI 10.1038/nbt.1526; Kettlun C, 2011, MOL THER, V19, P1636, DOI 10.1038/mt.2011.129; Lacoste A, 2009, CELL STEM CELL, V5, P332, DOI 10.1016/j.stem.2009.07.011; Madonna R, 2012, MOL BIOTECHNOL, V52, P193, DOI 10.1007/s12033-012-9504-0; Maragathavally KJ, 2006, FASEB J, V20, P1880, DOI 10.1096/fj.05-5485fje; Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343; Meir YJJ, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-28; Mitra R, 2008, EMBO J, V27, P1097, DOI 10.1038/emboj.2008.41; Nagy K, 2011, STEM CELL REV REP, V7, P693, DOI 10.1007/s12015-011-9239-5; OSBORNE BI, 1995, CURR OPIN CELL BIOL, V7, P406, DOI 10.1016/0955-0674(95)80097-2; Owens JB, 2012, NUCLEIC ACIDS RES, V40, P6978, DOI 10.1093/nar/gks309; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Qin JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010611; Rad R, 2010, SCIENCE, V330, P1104, DOI 10.1126/science.1193004; Sambrook J., 2001, MOL CLONING LAB MANU; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; Wang W, 2008, P NATL ACAD SCI USA, V105, P9290, DOI 10.1073/pnas.0801017105; Wilson MH, 2007, MOL THER, V15, P139, DOI 10.1038/sj.mt.6300028; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Wu SCY, 2006, P NATL ACAD SCI USA, V103, P15008, DOI 10.1073/pnas.0606979103; Yusa K, 2011, P NATL ACAD SCI USA, V108, P1531, DOI 10.1073/pnas.1008322108; Zayed H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024	40	13	17	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4429	4443		10.1096/fj.12-223586	http://dx.doi.org/10.1096/fj.12-223586			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23896728	Bronze			2022-12-28	WOS:000329937500011
J	Druppel, V; Kusche-Vihrog, K; Grossmann, C; Gekle, M; Kasprzak, B; Brand, E; Pavenstadt, H; Oberleithner, H; Kliche, K				Drueppel, Verena; Kusche-Vihrog, Kristina; Grossmann, Claudia; Gekle, Michael; Kasprzak, Bernd; Brand, Eva; Pavenstaedt, Hermann; Oberleithner, Hans; Kliche, Katrin			Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome	FASEB JOURNAL			English	Article						atomic force microscopy; endothelial function; epithelial sodium channel; ENaC; mechanical stiffness	NITRIC-OXIDE SYNTHASE; MINERALOCORTICOID RECEPTOR; VASCULAR ENDOTHELIUM; CARDIAC FIBROSIS; HEART-FAILURE; CYTOSKELETON; DYSFUNCTION	Aldosterone triggers the stiff endothelial cell syndrome (SECS), characterized by an up-regulation of epithelial sodium channels (ENaCs) and mechanical stiffening of the endothelial cell cortex accompanied by endothelial dysfunction. In vivo, aldosterone antagonism exerts sustained protection on the cardiovascular system. To illuminate the molecular mechanisms of this time-dependent effect, a study on endothelial cells in vitro and ex vivo was designed to investigate SECS over time. Endothelia (from human umbilical veins, bovine aortae, and explants of human arteries) were cultured in aldosterone-supplemented medium with or without the mineralocorticoid receptor (MR) antagonist spironolactone. MR expression, ENaC expression, cortical stiffness, and shear-mediated nitric oxide (NO) release were determined after 3 d (short term) and up to 24 d (long term). Over time, MR expression increased by 129%. ENaC expression and surface abundance increased by 32% and 42% (13.8 to 19.6 molecules per cell surface), paralleled by a 49% rise in stiffness. Spironolactone prevented this development and, after 3 wk of treatment, increased NO release by 50%. Thus, spironolactone improves endothelial function long-lastingly by preventing a time-dependent manifestation of SECS. This emphasizes the key role of vascular endothelium as a therapeutical target in cardiovascular disorders and might explain blood pressure independent actions of MR antagonism.Druppel, V., Kusche-Vihrog, K., Grossmann, C., Gekle, M., Kasprzak, B., Brand, E., Pavenstadt, H., Oberleithner, H., Kliche, K. Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome.	[Drueppel, Verena; Kusche-Vihrog, Kristina; Oberleithner, Hans] Univ Munster, Inst Physiol 2, D-48149 Munster, Germany; [Kasprzak, Bernd] Univ Munster, Dept Vasc Surg, D-48149 Munster, Germany; [Brand, Eva; Pavenstaedt, Hermann; Kliche, Katrin] Univ Munster, Dept Internal Med D, D-48149 Munster, Germany; [Grossmann, Claudia; Gekle, Michael] Univ Halle Wittenberg, Julius Bernstein Inst Physiol, D-06108 Halle, Germany	University of Munster; University of Munster; University of Munster; Martin Luther University Halle Wittenberg	Kliche, K (corresponding author), Dept Internal Med D, Albert Schweitzer Campus Gebaude A1, D-48149 Munster, Germany.	katrin.kliche@ukmuenster.de			Deutsche Forschungsgemeinschaft [GR 3415-1-2, GE 905/14-1, KU 1496/7-1, Br1589/8-2, OB 63/17-1, Koselleck-OB 63/18]; Innovative Medical Research of the University of Munster, Medical School [KL 211101, KU 120808]; Else-Kroner-Fresenius Stiftung [2010_A116]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Innovative Medical Research of the University of Munster, Medical School; Else-Kroner-Fresenius Stiftung	The authors thank COST Action TD1002 for supporting their networking activities, Marianne Wilhelmi and Barbara Windoffer for excellent technical assistance, and Mareike Herrmann for help with the ENaC qRT-PCR. This work was supported by the Deutsche Forschungsgemeinschaft (grants GR 3415-1-2; GE 905/14-1; KU 1496/7-1; Heisenberg professorship Br1589/8-2; OB 63/17-1 and Koselleck-OB 63/18); the fund Innovative Medical Research of the University of Munster, Medical School (grants KL 211101 and KU 120808); and the Else-Kroner-Fresenius Stiftung (grant 2010_A116). The authors declare no conflict of interest.	Barton M, 2010, PFLUG ARCH EUR J PHY, V460, P825, DOI 10.1007/s00424-010-0860-y; Benetos A, 1997, ARTERIOSCL THROM VAS, V17, P1152, DOI 10.1161/01.ATV.17.6.1152; Brandes RP, 2005, CARDIOVASC RES, V66, P286, DOI 10.1016/j.cardiores.2004.12.027; Briet M, 2013, J VASC RES, V50, P89, DOI 10.1159/000345243; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; Cat AND, 2012, CURR OPIN NEPHROL HY, V21, P147, DOI 10.1097/MNH.0b013e32834fb25b; de Magalhaes JP, 2012, FASEB J, V26, P4821, DOI 10.1096/fj.12-210872; Farquharson CAJ, 2000, CIRCULATION, V101, P594, DOI 10.1161/01.CIR.101.6.594; Fels J, 2010, PFLUG ARCH EUR J PHY, V460, P915, DOI 10.1007/s00424-010-0871-8; Hillebrand U, 2006, CARDIOVASC RES, V69, P916, DOI 10.1016/j.cardiores.2005.11.025; Iwashima F, 2008, ENDOCRINOLOGY, V149, P1009, DOI 10.1210/en.2007-0864; Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064; Johar S, 2006, FASEB J, V20, P1546, DOI 10.1096/fj.05-4642fje; Kasas S, 2005, CELL MOTIL CYTOSKEL, V62, P124, DOI 10.1002/cm.20086; KELM M, 1991, CARDIOVASC RES, V25, P831, DOI 10.1093/cvr/25.10.831; Kliche K., 2011, PFLUGERS ARCH; Krug AW, 2010, HYPERTENSION, V55, P1476, DOI 10.1161/HYPERTENSIONAHA.109.148783; Kusche-Vihrog K, 2008, PFLUG ARCH EUR J PHY, V455, P849, DOI 10.1007/s00424-007-0341-0; Kusche-Vihrog K, 2011, HYPERTENSION, V57, P231, DOI 10.1161/HYPERTENSIONAHA.110.163444; Lacolley P, 2001, J AM COLL CARDIOL, V37, P662, DOI 10.1016/S0735-1097(00)01129-3; Lang F, 2011, HYPERTENSION, V57, P146, DOI 10.1161/HYPERTENSIONAHA.110.164558; Loufrani L, 2008, MED BIOL ENG COMPUT, V46, P451, DOI 10.1007/s11517-008-0306-2; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; Mazzochi C, 2006, J BIOL CHEM, V281, P6528, DOI 10.1074/jbc.M509386200; Oberleithner H, 2009, P NATL ACAD SCI USA, V106, P2829, DOI 10.1073/pnas.0813069106; Oberleithner H, 2007, P NATL ACAD SCI USA, V104, P16281, DOI 10.1073/pnas.0707791104; Oberleithner H, 2010, KIDNEY INT, V77, P490, DOI 10.1038/ki.2009.490; Perez FR, 2009, HYPERTENSION, V53, P1000, DOI 10.1161/HYPERTENSIONAHA.108.128520; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 2001, CARDIOVASC DRUG THER, V15, P79, DOI 10.1023/A:1011119003788; SATO I, 1993, BIOCHEM BIOPH RES CO, V195, P1070, DOI 10.1006/bbrc.1993.2153; Soucy KG, 2006, J APPL PHYSIOL, V101, P1751, DOI 10.1152/japplphysiol.00138.2006; Stokes GS, 2009, CLIN INTERV AGING, V4, P379; Su YC, 2003, AM J PHYSIOL-CELL PH, V284, pC1542, DOI 10.1152/ajpcell.00248.2002; Takeda M, 2007, HYPERTENS RES, V30, P427, DOI 10.1291/hypres.30.427; Williams TA, 2006, ENDOCRINOLOGY, V147, P2496, DOI 10.1210/en.2005-1318; Zannad F, 2012, EUR HEART J, V33, P2782, DOI 10.1093/eurheartj/ehs257; Ziera T, 2009, FASEB J, V23, P3936, DOI 10.1096/fj.09-134759	38	57	58	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3652	3659		10.1096/fj.13-228312	http://dx.doi.org/10.1096/fj.13-228312			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729588				2022-12-28	WOS:000328840500024
J	Hoier, B; Prats, C; Qvortrup, K; Pilegaard, H; Bangsbo, J; Hellsten, Y				Hoier, Birgitte; Prats, Clara; Qvortrup, Klaus; Pilegaard, Henriette; Bangsbo, Jens; Hellsten, Ylva			Subcellular localization and mechanism of secretion of vascular endothelial growth factor in human skeletal muscle	FASEB JOURNAL			English	Article						transmission electron microscopy; confocal microscopy; microdialysis; exercise	VEGF EXPRESSION; ANGIOGENIC FACTORS; GENE-EXPRESSION; SINGLE BOUT; EXERCISE; PGC-1-ALPHA; CELLS; CAPILLARIZATION; DYSTROPHIN; PERICYTES	The subcellular distribution and secretion of vascular endothelial growth factor (VEGF) was examined in skeletal muscle of healthy humans. Skeletal muscle biopsies were obtained from m.v. lateralis before and after a 2 h bout of cycling exercise. VEGF localization was conducted on preparations of teased muscle fibers by transmission electron microscopy (TEM) and confocal microscopy (CM). Muscle interstitial fluid was sampled from microdialysis probes placed in the thigh muscle. TEM and CM analysis revealed two primary sites of localization of VEGF: in vesicles located in the subsarcolemmal regions and between the contractile elements within the muscle fibers; and in pericytes situated on the skeletal muscle capillaries. Quantitation of the subsarcolemmal density of VEGF vesicles, calculated on top of myonuclei, in the muscle fibers revealed a approximate to 50% increase (P<0.05) after exercise. The observation of more VEGF vesicles close to sarcolemma after exercise, combined with a 5-fold increase (P<0.05) in VEGF in the interstitial fluid, suggest that VEGF-containing vesicles redistribute to sarcolemma and that VEGF is secreted to the extracellular fluid. This study provides the first evidence in humans for a mechanism by which skeletal muscle fibers can control capillary growth by releasing VEGF from intracellular vesicles during contraction.Hoier, B., Prats, C., Qvortrup, K., Pilegaard, H., Bangsbo, J., Hellsten, Y. Subcellular localization and mechanism of secretion of vascular endothelial growth factor in human skeletal muscle.	[Hoier, Birgitte; Bangsbo, Jens; Hellsten, Ylva] Univ Copenhagen, Dept Nutr Exercise & Sport, DK-2100 Copenhagen, Denmark; [Prats, Clara; Qvortrup, Klaus] Univ Copenhagen, Dept Biomed Sci, Core Facil Integrated Microscopy, DK-2100 Copenhagen, Denmark; [Pilegaard, Henriette] Univ Copenhagen, Dept Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen	Hellsten, Y (corresponding author), Univ Copenhagen, Sect Integrat Physiol, Dept Nutr Exercise & Sport, Univ Pk 13, DK-2100 Copenhagen, Denmark.	yhellsten@ifi.ku.dk	Pilegaard, Henriette/M-2315-2014; Prats, Clara/F-5993-2014; Hoier, Birgitte/D-4395-2015; Bangsbo, Jens/A-7192-2015; Hellsten, Ylva/B-3420-2015	Pilegaard, Henriette/0000-0002-1071-0327; Prats, Clara/0000-0001-6465-3068; Hoier, Birgitte/0000-0002-2436-4314; Bangsbo, Jens/0000-0003-1305-9274; Hellsten, Ylva/0000-0002-2435-9558; Qvortrup, Klaus/0000-0001-8811-0260	Lundbeck; Lundbeck Foundation [R34-2009-3844] Funding Source: researchfish	Lundbeck(Lundbeck Corporation); Lundbeck Foundation(Lundbeckfonden)	The authors thank Gemma Kroos, Karina Olsen, Jens Jung Nielsen, Zhila Nikrozi, and Mary-Ann Gleie for their expert technical assistance. The study was funded by Lundbeck.	Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Breen EC, 1996, J APPL PHYSIOL, V81, P355, DOI 10.1152/jappl.1996.81.1.355; Chang HJ, 2006, INT J ONCOL, V28, P135; Egginton S, 2000, ADV EXP MED BIOL, V476, P81; Egginton S, 2009, PFLUG ARCH EUR J PHY, V457, P963, DOI 10.1007/s00424-008-0563-9; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Friedrich O, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001762; Gavin TP, 2007, ACTA PHYSIOL, V191, P139, DOI 10.1111/j.1748-1716.2007.01723.x; Gavin TP, 2004, J APPL PHYSIOL, V96, P19, DOI 10.1152/japplphysiol.00748.2003; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; HOFFMAN EP, 1987, NATURE, V330, P754, DOI 10.1038/330754a0; Hoffner L, 2003, J PHYSIOL-LONDON, V550, P217, DOI 10.1113/jphysiol.2002.037051; Hoier B, 2010, J PHYSIOL-LONDON, V588, P3833, DOI 10.1113/jphysiol.2010.190439; Hoier B., 2011, J PHYSL, V590, P596; Hoier B, 2010, AM J PHYSIOL-HEART C, V299, pH857, DOI 10.1152/ajpheart.00082.2010; Jensen L., 2004, Angiogenesis, V7, P255, DOI 10.1007/s10456-004-4184-4; Jensen L, 2004, AM J PHYSIOL-REG I, V287, pR397, DOI 10.1152/ajpregu.00071.2004; Jensen L, 2004, J PHYSIOL-LONDON, V557, P571, DOI 10.1113/jphysiol.2003.057711; Leick L, 2009, AM J PHYSIOL-ENDOC M, V297, pE92, DOI 10.1152/ajpendo.00076.2009; Lundby C, 2006, EUR J APPL PHYSIOL, V96, P363, DOI 10.1007/s00421-005-0085-5; Martell A.E., 1976, CRITICAL STABILITY C, V4; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nordsborg N, 2003, AM J PHYSIOL-REG I, V285, pR143, DOI 10.1152/ajpregu.00029.2003; Olesen J, 2010, PFLUG ARCH EUR J PHY, V460, P153, DOI 10.1007/s00424-010-0834-0; Olfert IM, 2010, AM J PHYSIOL-REG I, V299, pR1059, DOI 10.1152/ajpregu.00347.2010; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Radegran G, 1999, AM J PHYSIOL-HEART C, V276, pH1951, DOI 10.1152/ajpheart.1999.276.6.H1951; Rasbach KA, 2010, P NATL ACAD SCI USA, V107, P21866, DOI 10.1073/pnas.1016089107; Richardson RS, 1999, AM J PHYSIOL-HEART C, V277, pH2247, DOI 10.1152/ajpheart.1999.277.6.H2247; Rullman E, 2007, J APPL PHYSIOL, V102, P2346, DOI 10.1152/japplphysiol.00822.2006; Ryan NA, 2006, J APPL PHYSIOL, V100, P178, DOI 10.1152/japplphysiol.00827.2005; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; Tang K, 2004, PHYSIOL GENOMICS, V18, P63, DOI 10.1152/physiolgenomics.00023.2004; Wagner PD, 2011, BIOCHEM SOC T, V39, P1556, DOI 10.1042/BST20110646	36	44	45	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3496	3504		10.1096/fj.12-224618	http://dx.doi.org/10.1096/fj.12-224618			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23709615				2022-12-28	WOS:000328840500010
J	Jarlestedt, K; Rousset, CI; Stahlberg, A; Sourkova, H; Atkins, AL; Thornton, C; Barnum, SR; Wetsel, RA; Dragunow, M; Pekny, M; Mallard, C; Hagberg, H; Pekna, M				Jaerlestedt, Katarina; Rousset, Catherine I.; Stahlberg, Anders; Sourkova, Hana; Atkins, Alison L.; Thornton, Claire; Barnum, Scott R.; Wetsel, Rick A.; Dragunow, Mike; Pekny, Milos; Mallard, Carina; Hagberg, Henrik; Pekna, Marcela			Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxic-ischemic brain injury	FASEB JOURNAL			English	Article						behavioral deficit; mice	ANAPHYLATOXIN C3A; CEREBRAL INJURY; INFLAMMATION; EXPRESSION; PROTECTS; ACTIVATION; MECHANISMS; DEPLETION; IMMATURE; STROKE	Complement is an essential component of inflammation that plays a role in ischemic brain injury. Recent reports demonstrate novel functions of complement in normal and diseased CNS, such as regulation of neurogenesis and synapse elimination. Here, we examined the role of complement-derived peptide C3a in unilateral hypoxia-ischemia (HI), a model of neonatal HI encephalopathy. HI injury was induced at postnatal day 9 (P9), and loss of hippocampal tissue was determined on P31. We compared WT mice with transgenic mice expressing C3a under the control of glial fibrillary acidic protein promoter, which express biologically active C3a only in CNS and without the requirement of a priori complement activation. Further, we injected C3a peptide into the lateral cerebral ventricle of mice lacking the C3a receptor (C3aR) and WT mice and assessed HI-induced memory impairment 41 d later. We found that HI-induced tissue loss in C3a overexpressing mice was reduced by 50% compared with WT mice. C3a peptide injected 1 h after HI protected WT but not C3aR-deficient mice against HI-induced memory impairment. Thus, C3a acting through its canonical receptor ameliorates behavioral deficits after HI injury, and C3aR is a novel therapeutic target for the treatment of neonatal HI encephalopathy.Jarlestedt, K., Rousset, C. I., Stahlberg, A., Sourkova, H., Atkins, A. L., Thornton, C., Barnum, S. R., Wetsel, R. A., Dragunow, M., Pekny, M., Mallard, C., Hagberg, H., Pekna, M. Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxic-ischemic brain injury.	[Jaerlestedt, Katarina; Mallard, Carina; Hagberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Perinatal Ctr, SE-40530 Gothenburg, Sweden; [Stahlberg, Anders; Sourkova, Hana; Atkins, Alison L.; Pekny, Milos; Pekna, Marcela] Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, SE-40530 Gothenburg, Sweden; [Hagberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Obstet & Gynecol, SE-40530 Gothenburg, Sweden; [Rousset, Catherine I.; Thornton, Claire; Hagberg, Henrik] Kings Coll London, Ctr Developing Brain, London WC2R 2LS, England; [Barnum, Scott R.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Wetsel, Rick A.] Univ Texas Houston, Res Ctr Immunol & Autoimmune Dis, Inst Mol Med Prevent Human Dis, Houston, TX USA; [Dragunow, Mike] Univ Auckland, Dept Pharmacol, Auckland 1, New Zealand; [Dragunow, Mike] Univ Auckland, Natl Res Ctr Growth & Dev, Fac Med & Hlth Sci, Auckland 1, New Zealand	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of London; King's College London; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Health Science Center Houston; University of Auckland; University of Auckland	Pekna, M (corresponding author), Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, Box 440, SE-40530 Gothenburg, Sweden.	marcela.pekna@neuro.gu.se	Pekna, Marcela/AAM-3261-2021; Pekna, Marcela/AAM-3249-2021; Thornton, Claire/AAF-7481-2019	Pekna, Marcela/0000-0003-2734-8237; Pekna, Marcela/0000-0003-2734-8237; Thornton, Claire/0000-0001-7676-3272; Stahlberg, Anders/0000-0003-4243-0191; Mallard, Carina/0000-0001-8953-919X; Atkins, Alison/0000-0002-9673-8442; Hagberg, Henrik/0000-0003-3962-1448	Swedish Research Council [20116, 14185, 11548, 2642, 2367]; ALF Gothenburg [11267, 142821, 146051, 2863]; Stena Foundation; Magnus Bergvall Foundation; W. and M. Lundgren Foundation; Free Mason Foundation; Ahlen Foundation; Wellcome Trust; AFA Insurance; EU [036534, 237956, 279017, BM1002, 241778]; Swedish Stroke Foundation; Foundation Leducq; R. and T. Soderberg Foundation; E. Jacobson Foundation; R. and U. Amlov Foundation; New Zealand National Research Centre for Growth and Development; New Zealand Health Research Council; Action Medical Research [1764] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); ALF Gothenburg; Stena Foundation; Magnus Bergvall Foundation; W. and M. Lundgren Foundation; Free Mason Foundation; Ahlen Foundation; Wellcome Trust(Wellcome TrustEuropean Commission); AFA Insurance; EU(European Commission); Swedish Stroke Foundation; Foundation Leducq(Leducq Foundation); R. and T. Soderberg Foundation; E. Jacobson Foundation; R. and U. Amlov Foundation; New Zealand National Research Centre for Growth and Development; New Zealand Health Research Council(Health Research Council of New Zealand); Action Medical Research	This work was supported by the Swedish Research Council (20116, 14185, 11548, 2642, 2367); ALF Gothenburg (11267, 142821, 146051, 2863); the Stena Foundation; The Magnus Bergvall Foundation; the W. and M. Lundgren Foundation; The Free Mason Foundation; The Ahlen Foundation; Wellcome Trust; AFA Insurance; EU projects Neobrain (036534), EduGlia (237956), TargetBraIn (279017), and NanoNet COST Action (BM1002); the Swedish Stroke Foundation; Foundation Leducq; EU grant 241778; the R. and T. Soderberg Foundation; the E. Jacobson Foundation; the R. and U. Amlov Foundation; the New Zealand National Research Centre for Growth and Development; and the New Zealand Health Research Council.	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Bogestal YR, 2007, J NEUROSCI RES, V85, P2892, DOI 10.1002/jnr.21401; Boos L, 2005, NEUROSCI LETT, V387, P68, DOI 10.1016/j.neulet.2005.07.015; Boos L, 2004, J IMMUNOL, V173, P4708, DOI 10.4049/jimmunol.173.7.4708; Cowell RM, 2003, J NEUROSCI, V23, P9459; Ducruet AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038664; Figueroa E, 2005, NEUROSCI LETT, V380, P48, DOI 10.1016/j.neulet.2005.01.027; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; Grether JK, 1999, J PEDIATR-US, V134, P324, DOI 10.1016/S0022-3476(99)70458-0; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Hagberg H, 2012, ANN NEUROL, V71, P444, DOI 10.1002/ana.22620; Harhausen D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-15; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1333, DOI 10.1097/01.WCB.0000141559.17620.36; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Heese K, 1998, J NEUROCHEM, V70, P699; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Hulse RE, 2008, J NEUROSCI, V28, P12199, DOI 10.1523/JNEUROSCI.3856-08.2008; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Imm MD, 2002, NEUROSCI LETT, V325, P175, DOI 10.1016/S0304-3940(02)00271-9; Jarlestedt K, 2011, DEV NEUROSCI-BASEL, V33, P222, DOI 10.1159/000329710; Jauneau AC, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-8; Johnston MV, 2005, BRAIN PATHOL, V15, P234; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Lassiter HA, 2001, NEUROSCI LETT, V302, P37, DOI 10.1016/S0304-3940(01)01653-6; Lew SM, 1999, BRAIN RES BULL, V48, P325, DOI 10.1016/S0361-9230(99)00004-0; Madduri S, 2009, NEUROSCI RES, V65, P88, DOI 10.1016/j.neures.2009.06.003; MCRAE A, 1995, DEV BRAIN RES, V84, P245, DOI 10.1016/0165-3806(94)00177-2; Mocco J, 2006, CIRC RES, V99, P209, DOI 10.1161/01.RES.0000232544.90675.42; Morita H, 2006, NEUROSCI LETT, V409, P35, DOI 10.1016/j.neulet.2006.09.037; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Qiu L, 2007, J CEREBR BLOOD F MET, V27, P785, DOI 10.1038/sj.jcbfm.9600385; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Savman K, 1998, PEDIATR RES, V43, P746; Sheldon RA, 1998, BRAIN RES, V810, P114, DOI 10.1016/S0006-8993(98)00892-0; Shinjyo N, 2009, STEM CELLS, V27, P2824, DOI 10.1002/stem.225; Sonntag J, 1998, PEDIATR DEVEL PATHOL, V1, P131, DOI 10.1007/s100249900016; Stahlberg A, 2005, EXPERT REV MOL DIAGN, V5, P221, DOI 10.1586/14737159.5.2.221; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Ten VS, 2010, J NEUROSCI, V30, P2077, DOI 10.1523/JNEUROSCI.5249-09.2010; Ten VS, 2005, STROKE, V36, P2244, DOI 10.1161/01.STR.0000182237.20807.d0; van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022; Vasthare US, 1998, BRAIN RES BULL, V45, P413, DOI 10.1016/S0361-9230(97)00408-5; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	45	41	43	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3797	3804		10.1096/fj.13-230011	http://dx.doi.org/10.1096/fj.13-230011			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23737250				2022-12-28	WOS:000328840500037
J	Ku, BM; Kim, DS; Kim, KH; Yoo, BC; Kim, SH; Gong, YD; Kim, SY				Ku, Bo Mi; Kim, Dae-Seok; Kim, Kyung-Hee; Yoo, Byong Chul; Kim, Seok-Hyun; Gong, Young-Dae; Kim, Soo-Youl			Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma	FASEB JOURNAL			English	Article						kidney cancer; autophagy; protein cross-linking	CROSS-LINKING ENZYMES; TISSUE TRANSGLUTAMINASE; CANCER-CELLS; SURVIVAL; DISEASE; PROTEIN; PATHWAY; COMPLEX; ALPHA	Renal cell carcinoma (RCC), the predominant form of kidney cancer, is characterized by high resistance to radiation and chemotherapy. This study shows that expression of protein cross-linking enzyme transglutaminase 2 (TGase 2) is markedly increased in 7 renal cell carcinoma (RCC) cell lines in comparison to HEK293 and other cancer cell lines, such as NCI 60. However, the key role of TGase 2 in RCC was not clear. The down-regulation of TGase 2 was found to stabilize p53 expression, thereby inducing a 3- to 10-fold increase in apoptosis for 786-O, A498, CAKI-1, and ACHN cell lines by DAPI staining. MEF cells from TGase 2(-/-) mice showed stabilized p53 under apoptotic stress to compare to MEFs from wild-type mice. TGase 2 directly cross links the DNA binding domain of p53, leading to p53 depletion via autophagy in RCC. TGase 2 and p53 expression showed an inverse relationship in RCC cells. This finding implies that induced expression of TGase 2 promotes tumor cell survival through p53 depletion in RCC.Ku, B.M., Kim, D.-S. Kim, K.-H., Yoo, B.C., Kim, S.-H., Gong, Y.-D., Kim, S.-Y. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.	[Ku, Bo Mi; Kim, Dae-Seok; Kim, Seok-Hyun; Kim, Soo-Youl] Natl Canc Ctr, Div Canc Biol, Canc Cell & Mol Biol Branch, Goyang 410769, Gyeonggi Do, South Korea; [Kim, Kyung-Hee; Yoo, Byong Chul] Natl Canc Ctr, Colorectal Canc Branch, Div Translat & Clin Res 1, Res Inst, Goyang 410769, Gyeonggi Do, South Korea; [Gong, Young-Dae] Dongguk Univ, Ctr Innovat Drug Lib Res, Seoul, South Korea	National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); Dongguk University	Kim, SY (corresponding author), Natl Canc Ctr, Div Canc Biol, Canc Cell & Mol Biol Branch, 323 Ilsan Ro, Goyang 410769, Gyeonggi Do, South Korea.	kimsooyoul@gmail.com	Kim, Hyung-Kwan/R-8375-2019	Kim, Kyung-Hee/0000-0003-0214-0296	National Cancer Center in Korea [NCC1110011-2]; Bio and Medical Technology Development Program of the National Research Foundation (NRF); Korean government (MEST) [2012053532]	National Cancer Center in Korea; Bio and Medical Technology Development Program of the National Research Foundation (NRF)(National Research Foundation of Korea); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a research grant (NCC1110011-2) from the National Cancer Center in Korea to S.Y.K. and also partially supported by the Bio and Medical Technology Development Program of the National Research Foundation (NRF), funded by the Korean government (MEST; 2012053532). The authors declare no conflicts of interest.	Berglind H, 2008, CANCER BIOL THER, V7, P699, DOI 10.4161/cbt.7.5.5712; D'Eletto M, 2012, CELL DEATH DIFFER, V19, P1228, DOI 10.1038/cdd.2012.2; D'Eletto M, 2009, AUTOPHAGY, V5, P1145, DOI 10.4161/auto.5.8.10040; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Delhase M, 2012, P NATL ACAD SCI USA, V109, pE177, DOI 10.1073/pnas.1119296109; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hidaka H, 2012, ONCOTARGET, V3, P44; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Iismaa SE, 2009, PHYSIOL REV, V89, P991, DOI 10.1152/physrev.00044.2008; Jang GY, 2010, ONCOGENE, V29, P356, DOI 10.1038/onc.2009.342; Kawasaki T, 1999, ONCOL REP, V6, P329; Kim DS, 2011, ONCOGENE, V30, P4780, DOI 10.1038/onc.2011.183; Kim DS, 2006, CANCER RES, V66, P10936, DOI 10.1158/0008-5472.CAN-06-1521; Kim DS, 2010, BIOCHEM BIOPH RES CO, V403, P479, DOI 10.1016/j.bbrc.2010.11.063; Kim SJ, 2013, AMINO ACIDS, V44, P73, DOI 10.1007/s00726-011-1089-6; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lipworth L, 2006, J UROLOGY, V176, P2353, DOI 10.1016/j.juro.2006.07.130; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; Mehta K, 2010, BIOCHEM PHARMACOL, V80, P1921, DOI 10.1016/j.bcp.2010.06.029; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Park SS, 2006, J BIOL CHEM, V281, P34965, DOI 10.1074/jbc.M604150200; RABINOVITCH RA, 1994, J CLIN ONCOL, V12, P206, DOI 10.1200/JCO.1994.12.1.206	26	45	47	2	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3487	3495		10.1096/fj.12-224220	http://dx.doi.org/10.1096/fj.12-224220			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23704086				2022-12-28	WOS:000328840500009
J	Al-Qusairi, L; Prokic, I; Amoasii, L; Kretz, C; Messaddeq, N; Mandel, JL; Laporte, J				Al-Qusairi, Lama; Prokic, Ivana; Amoasii, Leonela; Kretz, Christine; Messaddeq, Nadia; Mandel, Jean-Louis; Laporte, Jocelyn			Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways	FASEB JOURNAL			English	Article						centronuclear myopathy; myotubular myopathy; atrophy; atrogene	HUMAN SKELETAL-MUSCLE; SIGNALING PATHWAYS; PHOSPHATASE; EXPRESSION; LIGASES; FAMILY; GROWTH; MAINTENANCE; ATROGIN-1; ENDOSOME	Mutations in the phosphoinositide phosphatase myotubularin (MTM1) results in X-linked myotubular/centronuclear myopathy (XLMTM), characterized by a severe decrease in muscle mass and strength in patients and murine models. However, the molecular mechanism involved in the muscle hypotrophy is unclear. Here we show that the IGF1R/Akt pathway is affected in Mtm1-deficient murine muscles, characterized by an increase in IGF1 receptor and Akt levels in both the presymptomatic and symptomatic phases. Moreover, up-regulation of atrogenes was observed in the presymptomatic phase of the myopathy, supporting overactivation of the ubiquitin-proteasome pathway. In parallel, the autophagy machinery was affected as indicated by the increase in the number of autophagosomes and of autophagy markers, such as LC3 and P62. However, phosphorylation of FOXO3a and mTOR were abnormal at late but not at early stages of the disease, suggesting that myotubularin acts both upstream in the IGF1R/Akt pathway and downstream on the balance between the autophagy and ubiquitin-proteasome pathways in vivo. Adeno-associated virus-mediated delivery of Mtm1 into Mtm1-null muscles rescued muscle mass and normalized the expression levels of IGF1 receptor, the ubiquitin-proteasome pathway, and autophagy markers. These data support the hypothesis that the unbalanced regulation of the ubiquitin proteasome pathway and the autophagy machinery is a primary cause of the XLMTM pathogenesis.Al-Qusairi, L., Prokic, I., Amoasii, L., Kretz, C., Messaddeq, N., Mandel, J.-L., Laporte, J. Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways.	[Al-Qusairi, Lama; Prokic, Ivana; Amoasii, Leonela; Kretz, Christine; Messaddeq, Nadia; Mandel, Jean-Louis; Laporte, Jocelyn] IGBMC, Dept Translat Med & Neurogenet, F-67404 Illkirch Graffenstaden, France; [Al-Qusairi, Lama; Prokic, Ivana; Amoasii, Leonela; Kretz, Christine; Messaddeq, Nadia; Mandel, Jean-Louis; Laporte, Jocelyn] INSERM, U964, Illkirch Graffenstaden, France; [Al-Qusairi, Lama; Prokic, Ivana; Amoasii, Leonela; Kretz, Christine; Messaddeq, Nadia; Mandel, Jean-Louis; Laporte, Jocelyn] CNRS, UMR 7104, Illkirch Graffenstaden, France; [Al-Qusairi, Lama; Prokic, Ivana; Amoasii, Leonela; Kretz, Christine; Messaddeq, Nadia; Mandel, Jean-Louis; Laporte, Jocelyn] Univ Strasbourg, Illkirch Graffenstaden, France; [Mandel, Jean-Louis] Coll France, Dept Human Genet, Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; PSL Research University Paris; College de France	Laporte, J (corresponding author), IGBMC, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, France.	jocelyn@igbmc.fr	laporte, jocelyn/J-7008-2012; Al-Qusairi/AAQ-6912-2021; laporte, jocelyn/O-4888-2019; Laporte, Jocelyn/H-6801-2016; Mandel, Jean Louis/Q-2668-2016	Al-Qusairi, Lama/0000-0002-2956-2811; Mandel, Jean Louis/0000-0002-0535-6589; Amoasii, Leonela/0000-0001-7960-2749	Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); University of Strasbourg (UdS); College de France; Agence Nationale de la Recherche (ANR); ERA-Net E-rare; Fondation pour la Recherche Medicale (FRM); Association Francaise contre les Myopathies (AFM); FRM; Association Paul Mandel	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); University of Strasbourg (UdS)(European Commission); College de France; Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); ERA-Net E-rare; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); FRM(Fondation pour la Recherche Medicale); Association Paul Mandel	The authors thank Pascale Koebel and Belinda S. Cowling [Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC), Illkirch, France] for production of AAV, Jean-Luc Weickert for the electron microscopy imaging, Josiane Hergueux for the semithin section preparation, Marie-France Champy (Institut Clinique de la Souris, Illkirch, France) for plasma IGF1 level and metabolic determinations, Jude Samulski (Gene Therapy Center, University of North Carolina, Chapel Hill, NC, USA) for the pXR1-AAV1 plasmid, and Ricardos Tabet (IGBMC, Illkirch, France) for primers of ribosomal RNA analysis. This work was supported by grants from the Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), University of Strasbourg (UdS), College de France, Agence Nationale de la Recherche (ANR), ERA-Net E-rare, Fondation pour la Recherche Medicale (FRM), and Association Francaise contre les Myopathies (AFM). L.A.-Q. was supported by a fellowship from FRM and by Association Paul Mandel.	Al-Qusairi L, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-26; Al-Qusairi L, 2009, P NATL ACAD SCI USA, V106, P18763, DOI 10.1073/pnas.0900705106; Amoasii L, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002965; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Buj-Bello A, 2002, P NATL ACAD SCI USA, V99, P15060, DOI 10.1073/pnas.212498399; Buj-Bello A, 2008, HUM MOL GENET, V17, P2132, DOI 10.1093/hmg/ddn112; Cao CH, 2008, MOL BIOL CELL, V19, P3334, DOI 10.1091/mbc.E08-04-0367; Cao C, 2007, TRAFFIC, V8, P1052, DOI 10.1111/j.1600-0854.2007.00586.x; Cebollero E, 2012, AUTOPHAGY, V8, P1868, DOI 10.4161/auto.22162; Cebollero E, 2012, CURR BIOL, V22, P1545, DOI 10.1016/j.cub.2012.06.029; Chambon C, 2010, P NATL ACAD SCI USA, V107, P14327, DOI 10.1073/pnas.1009536107; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cowling BS, 2012, PLOS GENET, V8, P31, DOI 10.1371/journal.pgen.1002595; Cowling BS, 2011, AM J PATHOL, V178, P2224, DOI 10.1016/j.ajpath.2011.01.054; Dowling JJ, 2010, HUM MOL GENET, V19, P2668, DOI 10.1093/hmg/ddq153; Dowling JJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000372; Fetalvero KM, 2013, MOL CELL BIOL, V33, P98, DOI 10.1128/MCB.01075-12; Fili N, 2006, P NATL ACAD SCI USA, V103, P15473, DOI 10.1073/pnas.0607040103; Gaugler M, 2011, J APPL PHYSIOL, V111, P192, DOI 10.1152/japplphysiol.00175.2011; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Glass DJ, 2010, CURR OPIN CLIN NUTR, V13, P225, DOI 10.1097/MCO.0b013e32833862df; Goldspink G, 2004, EXP GERONTOL, V39, P1433, DOI 10.1016/j.exger.2004.08.010; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Goodman CA, 2011, CELL SIGNAL, V23, P1896, DOI 10.1016/j.cellsig.2011.07.013; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hishiya A, 2006, EMBO J, V25, P554, DOI 10.1038/sj.emboj.7600945; Hnia K, 2012, TRENDS MOL MED, V18, P317, DOI 10.1016/j.molmed.2012.04.004; Hnia Karim, 2012, Adv Biol Regul, V52, P98; Hnia K, 2011, J CLIN INVEST, V121, P70, DOI 10.1172/JCI44021; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kaliman P, 2005, J BIOL CHEM, V280, P8016, DOI 10.1074/jbc.M412845200; Laporte J, 2003, HUM MOL GENET, V12, pR285, DOI 10.1093/hmg/ddg273; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Lecompte O, 2008, TRENDS BIOCHEM SCI, V33, P453, DOI 10.1016/j.tibs.2008.07.002; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; McCurdy CE, 2005, DIABETES, V54, P1349, DOI 10.2337/diabetes.54.5.1349; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pierson CR, 2012, HUM MOL GENET, V21, P811, DOI 10.1093/hmg/ddr512; Pierson CR, 2005, J NEUROPATH EXP NEUR, V64, P555, DOI 10.1097/01.jnen.0000171653.17213.2e; Razidlo GL, 2011, J BIOL CHEM, V286, P20005, DOI 10.1074/jbc.M110.197749; Robinson FL, 2006, TRENDS CELL BIOL, V16, P403, DOI 10.1016/j.tcb.2006.06.001; Romero NB, 2011, SEMIN PEDIATR NEUROL, V18, P250, DOI 10.1016/j.spen.2011.10.006; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2010, FEBS LETT, V584, P1411, DOI 10.1016/j.febslet.2010.01.056; Shen JH, 2009, NAT CELL BIOL, V11, P769, DOI 10.1038/ncb1884; Stephens TJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE688, DOI 10.1152/ajpendo.00101.2001; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tosch V, 2006, HUM MOL GENET, V15, P3098, DOI 10.1093/hmg/ddl250; Tosch V, 2010, NEUROMUSCULAR DISORD, V20, P375, DOI 10.1016/j.nmd.2010.03.015; Toussaint A, 2011, ACTA NEUROPATHOL, V121, P253, DOI 10.1007/s00401-010-0754-2; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; Vergne I, 2009, EMBO J, V28, P2244, DOI 10.1038/emboj.2009.159; Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	59	46	48	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3384	3394		10.1096/fj.12-220947	http://dx.doi.org/10.1096/fj.12-220947			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23695157				2022-12-28	WOS:000329877600043
J	Keszei, M; Detre, C; Castro, W; Magelky, E; O'Keeffe, M; Kis-Toth, K; Tsokos, GC; Wang, NH; Terhorst, C				Keszei, Marton; Detre, Cynthia; Castro, Wilson; Magelky, Erica; O'Keeffe, Michael; Kis-Toth, Katalin; Tsokos, George C.; Wang, Ninghai; Terhorst, Cox			Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1-isoform of the Slamf6 receptor	FASEB JOURNAL			English	Article						Ly108; SAP; systemic lupus erythematosus; OPN; T-FH	SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL; SUSCEPTIBILITY LOCUS; MURINE LUPUS; GENE; LY108; DISEASE; FAMILY; DIFFERENTIATION; POLYMORPHISMS	The costimulatory receptor Slamf6 partially controls lupus-related autoimmunity in congenic Sle1b mice; for instance, the presence of the protein isoform Slamf6-H1 in Sle1b.Slamf6-H1 mice mitigates disease. Here, we report that young Sle1b mice, but not Sle1b.Slamf6-H1 or B6 mice, contain a memory T-helper cell subset identified by ]mt]2-fold increase in expression of 17 genes, chief among which is Spp1, encoding the cytokine osteopontin (OPN). These T follicular helper (T-FH) cells, including OPN+ T-FH cells, expand concomitantly with severity of the disease. By contrast, Sle1b.Slamf6-H1 or Sle1b.SAP(-)/(-) mice do not develop autoantibodies and the number of T-FH cells is 5 times lower than in age-matched Sle1b mice. By comparing Sle1b and Sle1b.OPN-/(-) mice, we find that the lack of OPN expression impedes early autoantibody production. Furthermore, on the adoptive transfer of Sle1b.OPN-/(-) CD4(+) T cells into bm12 recipients autoantibody production and germinal center formation is reduced compared to recipients of Sle1b.OPN+/+ CD4(+) T cells. We propose a model in which OPN provides a survival signal for a precursor T-FH cell subset, which is a key factor in autoimmunity. Keszei, M., Detre, C., Castro, W., Magelky, E., O'Keeffe, M., Kis-Toth, K., Tsokos, G. C., Wang, N., Terhorst, C. Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1-isoform of the Slamf6 receptor.	[Keszei, Marton; Detre, Cynthia; Castro, Wilson; Magelky, Erica; O'Keeffe, Michael; Wang, Ninghai; Terhorst, Cox] Harvard Univ, Div Immunol, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Kis-Toth, Katalin; Tsokos, George C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Rheumatol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Terhorst, C (corresponding author), Harvard Univ, Ctr Life Sci, Sch Med, Div Immunol,Beth Israel Deaconess Med Ctr, Rm CLS 938,3 Blackfan Cir, Boston, MA 02115 USA.	cterhors@bidmc.harvard.edu	tsokos, george C/O-3360-2013; Keszei, Marton/F-3295-2014	tsokos, george C/0000-0001-9589-2360; Keszei, Marton/0000-0002-1158-2179; Castro, Wilson/0000-0002-9649-9883; Magelky, Erica/0000-0003-2393-0713	U.S. National Institutes of Health [PO1 AI-065687, RO1 DK-073339, 8UL1TR000170-05]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI065687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK073339] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Drs. Xuefang Xie and Shiva Gautam (Beth Israel Deaconess Medical Center) and Mick Correll (Dana-Farber Cancer Institute, Boston, MA, USA) for invaluable help with the gene-expression array experiments and the statistical analyses. The authors are grateful to Gongxian Liao and other members of the C.T. laboratory for discussions and for a critical review of the manuscript. This work was supported by grants from the U.S. National Institutes of Health to C.T. (PO1 AI-065687 and RO1 DK-073339) and to the Harvard Catalyst Statistics consulting service (8UL1TR000170-05).	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Calpe S, 2008, ADV IMMUNOL, V97, P177, DOI 10.1016/S0065-2776(08)00004-7; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Carlucci F, 2007, J IMMUNOL, V178, P2352, DOI 10.4049/jimmunol.178.4.2352; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; D'Alfonso S, 2005, ARTHRITIS RHEUM, V52, P539, DOI 10.1002/art.20808; Deenick EK, 2010, IMMUNITY, V33, P241, DOI 10.1016/j.immuni.2010.07.015; Dutta M, 2012, J IMMUNOL, V188, P3031, DOI 10.4049/jimmunol.1103226; Forton AC, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9025; Fraser CC, 2002, IMMUNOGENETICS, V53, P843, DOI 10.1007/s00251-001-0415-7; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Graham DSC, 2008, GENES IMMUN, V9, P93, DOI 10.1038/sj.gene.6364453; Guan HB, 2011, J IMMUNOL, V186, P6955, DOI 10.4049/jimmunol.1004043; Hur EM, 2007, NAT IMMUNOL, V8, P74, DOI 10.1038/ni1415; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kageyama R, 2012, IMMUNITY, V36, P986, DOI 10.1016/j.immuni.2012.05.016; Keszei M, 2011, J EXP MED, V208, P811, DOI 10.1084/jem.20101653; Keszei M, 2011, INT IMMUNOL, V23, P149, DOI 10.1093/intimm/dxq465; Kim JR, 2010, CLIN EXP IMMUNOL, V160, P348, DOI 10.1111/j.1365-2249.2010.04116.x; Kumar KR, 2006, SCIENCE, V312, P1665, DOI 10.1126/science.1125893; LAMPE MA, 1991, J IMMUNOL, V147, P2902; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886; Morel L, 2001, P NATL ACAD SCI USA, V98, P1787, DOI 10.1073/pnas.031336098; MORRIS SC, 1990, CLIN IMMUNOL IMMUNOP, V57, P263, DOI 10.1016/0090-1229(90)90040-W; Peck SR, 2000, IMMUNOGENETICS, V52, P63, DOI 10.1007/s002510000252; Qi H, 2008, NATURE, V455, P764, DOI 10.1038/nature07345; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Shimatani K, 2009, P NATL ACAD SCI USA, V106, P15807, DOI 10.1073/pnas.0908805106; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sobel ES, 2002, J IMMUNOL, V169, P2694, DOI 10.4049/jimmunol.169.5.2694; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359; Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555; Wandstrat AE, 2004, IMMUNITY, V21, P769, DOI 10.1016/j.immuni.2004.10.009; Wong EB, 2012, J IMMUNOL, V189, P5667, DOI 10.4049/jimmunol.1201661; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; You Y, 2010, J RHEUMATOL, V37, P2268, DOI 10.3899/jrheum.091390; Zhong MC, 2008, J BIOL CHEM, V283, P19255, DOI 10.1074/jbc.M800209200	41	20	24	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3123	3131		10.1096/fj.12-226951	http://dx.doi.org/10.1096/fj.12-226951			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23629864	Green Published			2022-12-28	WOS:000329877600019
J	Carr, SK; Chen, JH; Cooper, WN; Constancia, M; Yeo, GSH; Ozanne, SE				Carr, Sarah K.; Chen, Jian-Hua; Cooper, Wendy N.; Constancia, Miguel; Yeo, Giles S. H.; Ozanne, Susan E.			Maternal diet amplifies the hepatic aging trajectory of Cidea in male mice and leads to the development of fatty liver	FASEB JOURNAL			English	Article						developmental programming; maternal low protein; catch-up growth; lipid accumulation; epigenetic	POSTNATAL-GROWTH LEADS; LIFE-SPAN; PRENATAL EXPOSURE; DEFENSE CAPACITY; GENE-EXPRESSION; ADIPOSE-TISSUE; DNA-DAMAGE; EFFECTOR-A; RESTRICTION; PROTEIN	The importance of the early environment on long-term heath and life span is well documented. However, the molecular mechanisms mediating these effects remain poorly understood. Male offspring from a maternal protein restriction model, in which animals are exposed to a low-protein diet while in utero and then are cross-fostered to normally fed dams, demonstrate low birth weight, catch-up growth, and reduced life span (recuperated offspring). In the current study, we used microarray analysis to identify hepatic genes that changed with age. Cell death-inducing DNA fragmentation factor, subunit-like effector A (Cidea), a transcriptional coactivator that has been implicated in lipid accumulation demonstrated one of the largest age-associated increases in expression (200-fold, P<0.001). This increase was exaggerated approximate to 3-fold in recuperated offspring. These demonstrated increased hepatic lipid accumulation, higher levels of transcription factors important in lipid regulation, and greater oxidative stress. In vitro analysis revealed that Cidea expression was regulated by oxidative stress and DNA methylation. These findings suggest that maternal diet modulates the age-associated changes in Cidea expression through several mechanisms. This expression affects hepatic lipid metabolism in these animals and thus provides a mechanism by which maternal diet can contribute to the metabolic health and ultimately the life span of the offspring.Carr, S. K., Chen, J.-H., Cooper, W. N., Constancia, M., Yeo, G. S. H., Ozanne, S. E. Maternal diet amplifies the hepatic ageing trajectory of Cidea in male mice and leads to the development of fatty liver.	[Carr, Sarah K.; Chen, Jian-Hua; Cooper, Wendy N.; Constancia, Miguel; Yeo, Giles S. H.; Ozanne, Susan E.] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, MRC Metab Dis Unit, Metab Res Labs,Addenbrookes Hosp, Cambridge CB2 OQQ, England; [Constancia, Miguel] Univ Cambridge, Ctr Trophoblast Res, Cambridge CB2 OQQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Carr, SK (corresponding author), Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, MRC Metab Dis Unit, Metab Res Labs,Addenbrookes Hosp, Level 4,Box 289, Cambridge CB2 OQQ, England.	sb716@cam.ac.uk	Constancia, Miguel/F-6654-2013	Yeo, Giles See How/0000-0001-8823-3615; Ozanne, Susan/0000-0001-8753-5144; Constancia, Miguel/0000-0002-8976-1679	UK Biotechnology and Biological Science Research Council; BBSRC [BB/D01235X/1, BB/E002161/1, BB/D01235X/2] Funding Source: UKRI; MRC [MC_UU_12012/5, MC_UU_12012/1, MC_UU_12012/4, G0600717] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E002161/1, BB/D01235X/1, BB/D01235X/2] Funding Source: researchfish; British Heart Foundation [FS/09/029/27902] Funding Source: researchfish; Medical Research Council [MC_UU_12012/5/B, MC_UU_12012/1, MC_UU_12012/5, G0600717B, G0600717, MC_UU_12012/4] Funding Source: researchfish	UK Biotechnology and Biological Science Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the UK Biotechnology and Biological Science Research Council. S.E.O. is a British Heart Foundation Senior Fellow.	ANDERSON JM, 1972, J CLIN PATHOL, V25, P867, DOI 10.1136/jcp.25.10.867; Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7; Berends LM, 2013, INT J OBESITY, V37, P1051, DOI 10.1038/ijo.2012.196; Bruce KD, 2009, HEPATOLOGY, V50, P1796, DOI 10.1002/hep.23205; Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703; Chen JH, 2004, J BIOL CHEM, V279, P49439, DOI 10.1074/jbc.M409153200; Chen JH, 2010, CLIN SCI, V119, P373, DOI 10.1042/CS20100230; Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950; Cooper WN, 2012, FASEB J, V26, P1782, DOI 10.1096/fj.11-192708; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Glatz JFC, 2010, PHYSIOL REV, V90, P367, DOI 10.1152/physrev.00003.2009; Gong JY, 2009, CURR OPIN LIPIDOL, V20, P121, DOI 10.1097/MOL.0b013e328328d0bb; Haffner SM, 2006, OBESITY, V14, p121S, DOI 10.1038/oby.2006.291; HARRISON DE, 1984, P NATL ACAD SCI-BIOL, V81, P1835, DOI 10.1073/pnas.81.6.1835; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Kelder Bruce, 2007, Comp Hepatol, V6, P4, DOI 10.1186/1476-5926-6-4; Knebel B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031812; Li D, 2008, NUCLEIC ACIDS RES, V36, P330, DOI 10.1093/nar/gkm1028; Li YP, 2010, DIABETES, V59, P2400, DOI 10.2337/db10-0385; Medina-Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064; Nathanielsz PW, 2003, J PHYSIOL-LONDON, V548, P333, DOI 10.1113/jphysiol.2003.040527; Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050; Okamoto Y, 2002, HEPATOL RES, V23, P138, DOI 10.1016/S1386-6346(01)00172-3; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; Roseboom TJ, 2000, BRIT J HAEMATOL, V111, P112, DOI 10.1046/j.1365-2141.2000.02268.x; Strable MS, 2010, CRIT REV BIOCHEM MOL, V45, P199, DOI 10.3109/10409231003667500; Tarry-Adkins JL, 2008, FASEB J, V22, P2037, DOI 10.1096/fj.07-099523; Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796; Tarry-Adkins JL, 2013, FASEB J, V27, P379, DOI 10.1096/fj.12-218685; Toh SY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002890; Viswakarma N, 2007, J BIOL CHEM, V282, P18613, DOI 10.1074/jbc.M701983200; Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y; Zhou LK, 2012, HEPATOLOGY, V56, P95, DOI 10.1002/hep.25611; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	37	12	12	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2191	2201		10.1096/fj.13-242727	http://dx.doi.org/10.1096/fj.13-242727			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24481968				2022-12-28	WOS:000335336000022
J	Sun, XF; Terakawa, J; Clevers, H; Barker, N; Daikoku, T; Dey, SK				Sun, Xiaofei; Terakawa, Jumpei; Clevers, Hans; Barker, Nick; Daikoku, Takiko; Dey, Sudhansu K.			Ovarian LGR5 is critical for successful pregnancy	FASEB JOURNAL			English	Article						20-hydroxysteroid dehydrogenase; corpus luteum; progesterone	CONDITIONAL DELETION; STEM-CELLS; BLASTOCYST IMPLANTATION; EMBRYO IMPLANTATION; GROWTH-FACTORS; PROGESTERONE; RECEPTORS; UTERUS; EXPRESSION; GENES	Leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) is expressed in many organs, including female reproductive organs, and is a stem cell marker in the stomach and intestinal epithelium, hair follicles, and ovarian surface epithelium. Despite ongoing studies, the definitive physiological functions of Lgr5 remain unclear. We utilized mice with conditional deletion of Lgr5 (Lgr5(d/d)) in the female reproductive organs by progesterone receptor-Cre (Pgr(Cre)) to determine Lgr5's functions during pregnancy. Only 30% of plugged Lgr5(d/d) females delivered live pups, and their litter sizes were lower. We found that pregnancy failure in Lgr5(d/d) females was due to insufficient ovarian progesterone (P-4) secretion that compromised decidualization, terminating pregnancy. The drop in P-4 levels was reflected in elevated levels of P-4-metabolizing enzyme 20-hydroxysteroid dehydrogenase in corpora lutea (CL) inactivated of Lgr5. Of interest, P-4 supplementation rescued decidualization failure and supported pregnancy to full term in Lgr5(d/d) females. These results provide strong evidence that Lgr5 is critical to normal CL function, unveiling a new role of LGR5 in the ovary.Sun, X., Terakawa, J., Clevers, H., Barker, N., Daikoku, T., Dey, S. K. Ovarian LGR5 is critical for successful pregnancy.	[Sun, Xiaofei; Terakawa, Jumpei; Daikoku, Takiko; Dey, Sudhansu K.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Reprod Sci,Perinatal Inst, Cincinnati, OH USA; [Clevers, Hans] Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands; [Barker, Nick] Inst Med Biol, Adult Stem Cell Grp, Singapore, Singapore	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Dey, SK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Reprod Sci, MLC 7045,3333 Burnet Ave, Cincinnati, OH 45229 USA.	sk.dey@cchmc.org	Barker, Nick/AAE-9833-2021; Barker, Nick/AAS-2774-2020; Terakawa, Jumpei/AAF-1435-2020; Barker, Nick/A-5535-2011	Barker, Nick/0000-0003-3566-4475; Terakawa, Jumpei/0000-0002-7643-7976; 	U.S. National Institutes of Health [HD068524, PO1CA7783]; March of Dimes; Cincinnati Children's Hospital Medical Center Perinatal Institute pilot/feasibility grant; Lalor Foundation; Japan Society for the Promotion of Science - Kyoto University (Kyoto, Japan); Cincinnati Children's Hospital; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD068524] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [F32CA007783] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Cincinnati Children's Hospital Medical Center Perinatal Institute pilot/feasibility grant; Lalor Foundation; Japan Society for the Promotion of Science - Kyoto University (Kyoto, Japan); Cincinnati Children's Hospital; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Serenity Curtis for editing the manuscript and Amanda Bartos and Yingju Li for their help in immunostaining. Francesco DeMayo and John B. Lydon (Baylor College of Medicine, Houston, TX, USA) initially provided the Pgr-Cre mouse line. This work was supported in part by U.S. National Institutes of Health grants (HD068524 and PO1CA7783), grants from March of Dimes to S. K. D., and a Cincinnati Children's Hospital Medical Center Perinatal Institute pilot/feasibility grant to T. D. X. S. was supported by a Lalor Foundation postdoctoral fellowship. J.T. is supported by a Japan Society for the Promotion of Science postdoctoral fellowship sponsored by Kyoto University (Kyoto, Japan) and Cincinnati Children's Hospital.	Bachelot A, 2005, CURR TOP DEV BIOL, V68, P49, DOI 10.1016/S0070-2153(05)68003-9; Bao L, 2007, ENDOCRINOLOGY, V148, P2326, DOI 10.1210/en.2006-1643; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Birchmeier W, 2011, NATURE, V476, P287, DOI 10.1038/476287a; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Cha JY, 2012, NAT MED, V18, P1754, DOI 10.1038/nm.3012; Daikoku T, 2006, CANCER RES, V66, P2527, DOI 10.1158/0008-5472.CAN-05-4063; Daikoku T, 2013, MOL HUM REPROD, V19, P463, DOI 10.1093/molehr/gat016; Daikoku T, 2011, DEV CELL, V21, P1014, DOI 10.1016/j.devcel.2011.09.010; Daikoku T, 2011, GYNECOL ONCOL, V122, P424, DOI 10.1016/j.ygyno.2011.04.022; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Flesken-Nikitin A, 2013, NATURE, V495, P241, DOI 10.1038/nature11979; Garcia MI, 2009, DEV BIOL, V331, P58, DOI 10.1016/j.ydbio.2009.04.020; Grosdemouge Isabelle, 2003, Reprod Biol Endocrinol, V1, P12, DOI 10.1186/1477-7827-1-12; Hess AP, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P337; Hirota Y, 2010, J CLIN INVEST, V120, P803, DOI 10.1172/JCI40051; Hsieh M, 2005, BIOL REPROD, V73, P1135, DOI 10.1095/biolreprod.105.042739; Hsieh M, 2002, ENDOCRINOLOGY, V143, P898, DOI 10.1210/en.143.3.898; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Lee KY, 2007, MOL CELL BIOL, V27, P5468, DOI 10.1128/MCB.00342-07; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; Matsumoto H, 2002, DEV BIOL, V245, P280, DOI 10.1006/dbio.2002.0645; MCCORMACK JT, 1974, J ENDOCRINOL, V62, P101, DOI 10.1677/joe.0.0620101; Milligan SR, 1997, HUM REPROD, V12, P602; Morita H, 2004, MOL CELL BIOL, V24, P9736, DOI 10.1128/MCB.24.22.9736-9743.2004; Pangas SA, 2007, SEMIN REPROD MED, V25, P225, DOI 10.1055/s-2007-980216; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Paria BC, 2001, P NATL ACAD SCI USA, V98, P1047, DOI 10.1073/pnas.98.3.1047; SHARMA R, 1983, J ANAT, V137, P695; Sonderegger S, 2010, PLACENTA, V31, P839, DOI 10.1016/j.placenta.2010.07.011; Song HS, 2000, MOL ENDOCRINOL, V14, P1147, DOI 10.1210/me.14.8.1147; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Stocco C, 2007, ENDOCR REV, V28, P117, DOI 10.1210/er.2006-0022; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Sun XF, 2012, P NATL ACAD SCI USA, V109, P1145, DOI 10.1073/pnas.1118411109; Sun XF, 2009, ENDOCRINOLOGY, V150, P5065, DOI 10.1210/en.2009-0690; Tranguch S, 2007, J CLIN INVEST, V117, P1824, DOI 10.1172/JCI31622; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Schoore G, 2005, HISTOCHEM CELL BIOL, V124, P35, DOI 10.1007/s00418-005-0002-3; Wang DL, 2013, GENE DEV, V27, P1339, DOI 10.1101/gad.219360.113; Wang HB, 2006, NAT REV GENET, V7, P185, DOI 10.1038/nrg1808; Wang HB, 2004, NAT MED, V10, P1074, DOI 10.1038/nm1104	47	21	22	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2380	2389		10.1096/fj.13-248344	http://dx.doi.org/10.1096/fj.13-248344			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24469993	Green Published			2022-12-28	WOS:000335336000038
J	Thomas, MM; Wang, DC; D'Souza, DM; Krause, MP; Layne, AS; Criswell, DS; O'Neill, HM; Connor, MK; Anderson, JE; Kemp, BE; Steinberg, GR; Hawke, TJ				Thomas, Melissa M.; Wang, David C.; D'Souza, Donna M.; Krause, Matthew P.; Layne, Andrew S.; Criswell, David S.; O'Neill, Hayley M.; Connor, Michael K.; Anderson, Judy E.; Kemp, Bruce E.; Steinberg, Gregory R.; Hawke, Thomas J.			Muscle-specific AMPK beta 1 beta 2-null mice display a myopathy due to loss of capillary density in nonpostural muscles	FASEB JOURNAL			English	Article						necrosis; NO signaling; nitric oxide synthase	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; DEFICIENT SKELETAL-MUSCLE; GLUCOSE; MAINTENANCE; SARCOLEMMA; ISCHEMIA; NNOS; LIMB	AMP-activated protein kinase (AMPK) is a master regulator of metabolism. While muscle-specific AMPK 12 double-knockout (12M-KO) mice display alterations in metabolic and mitochondrial capacity, their severe exercise intolerance suggested a secondary contributor to the observed phenotype. We find that tibialis anterior (TA), but not soleus, muscles of sedentary 12M-KO mice display a significant myopathy (decreased myofiber areas, increased split and necrotic myofibers, and increased centrally nucleated myofibers. A mitochondrial- and fiber-type-specific etiology to the myopathy was ruled out. However, 12M-KO TA muscles displayed significant (P<0.05) increases in platelet aggregation and apoptosis within myofibers and surrounding interstitium (P<0.05). These changes correlated with a 45% decrease in capillary density (P<0.05). We hypothesized that the 12M-KO myopathy in resting muscle resulted from impaired AMPK-nNOS signaling, causing increased platelet aggregation, impaired vasodilation, and, ultimately, ischemic injury. Consistent with this hypothesis, AMPK-specific phosphorylation (Ser1446) of nNOS was decreased in 12M-KO compared to wild-type (WT) mice. The AMPK-nNOS relationship was further demonstrated by administration of 5-aminoimidazole-4-carboxamide 1--d-ribofuranoside (AICAR) to 12-MKO muscles and C2C12 myotubes. AICAR significantly increased nNOS phosphorylation and nitric oxide production (P<0.05) within minutes of administration in WT muscles and C2C12 myotubes but not in 12M-KO muscles. These findings highlight the importance of the AMPK-nNOS pathway in resting skeletal muscle.Thomas, M. M., Wang, D. C., D'Souza, D. M., Krause, M. P., Layne, A. S., Criswell, D. S., O'Neill, H. M., Connor, M. K., Anderson, J. E., Kemp, B. E., Steinberg, G. R., and Hawke, T. J. Muscle-specific AMPK 12-null mice display a myopathy due to loss of capillary density in nonpostural muscles.	[Thomas, Melissa M.; Wang, David C.; D'Souza, Donna M.; Krause, Matthew P.; Hawke, Thomas J.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada; [Steinberg, Gregory R.] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada; [Layne, Andrew S.; Criswell, David S.] Univ Florida, Ctr Exercise Sci, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [O'Neill, Hayley M.; Kemp, Bruce E.] Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [O'Neill, Hayley M.; Kemp, Bruce E.] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; [Connor, Michael K.; Hawke, Thomas J.] York Univ, Muscle Hlth Res Ctr, Toronto, ON M3J 2R7, Canada; [Anderson, Judy E.] Univ Manitoba, Dept Biol Sci, Winnipeg, MB, Canada	McMaster University; McMaster University; State University System of Florida; University of Florida; St. Vincent's Institute of Medical Research; University of Melbourne; University of Melbourne; York University - Canada; University of Manitoba	Hawke, TJ (corresponding author), McMaster Univ, Dept Pathol & Mol Med, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.	hawke@mcmaster.ca	Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Wang, David Chenhan/0000-0002-4754-9493; Steinberg, Gregory/0000-0001-5425-8275; Hawke, Thomas/0000-0003-4974-4820; O'Neill, Hayley/0000-0001-6812-6580	U.S. National Institute of Child Health and Human Development; Natural Science and Engineering Research Council of Canada; Canadian Institutes of Health Research (CIHR); Canadian Foundation for Innovation; Australian Research Council; Australian National Health and Medical Research Council; Victorian government's Operational Infrastructure Support program	U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Australian Research Council(Australian Research Council); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Victorian government's Operational Infrastructure Support program	The 10F5 antibody developed by C. Lucas was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the U.S. National Institute of Child Health and Human Development and maintained by the Department of Biology, University of Iowa (Iowa City, IA, USA). These studies were supported by grants and fellowships from the Natural Science and Engineering Research Council of Canada (T.J.H., G.R.S.) and the Canadian Institutes of Health Research (CIHR; T.J.H., G.R.S.), the Canadian Foundation for Innovation (T.J.H., G. R. S.), the Australian Research Council (B. E. K.), and the Australian National Health and Medical Research Council (B. E. K., G. R. S.). This work was supported, in part, by the Victorian government's Operational Infrastructure Support program (B. E. K.). G. R. S. holds a Canada Research Chair in Metabolism and Obesity. The authors also acknowledge the contributions of the Michael DeGroote Fellowship (M. M. T.), the Ontario Graduate Scholarship program (M. P. K.), and the Canadian Institutes of Health Research Banting and Best Doctoral Fellowship program (D. M. D.).	Asai A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000806; Baudouin-Brignole F, 1997, PLATELETS, V8, P391; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Copp SW, 2013, J PHYSIOL-LONDON, V591, P2885, DOI 10.1113/jphysiol.2013.251082; Crosbie RH, 2002, FASEB J, V16, P943, DOI 10.1096/fj.01-0327com; Dubowitz V, 2007, NEUROMUSCULAR DISORD, V17, P80, DOI 10.1016/j.nmd.2006.12.011; Dzamko N, 2010, J BIOL CHEM, V285, P115, DOI 10.1074/jbc.M109.056762; FOLKOW B, 1968, Microvascular Research, V1, P1, DOI 10.1016/0026-2862(68)90002-2; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; Hudlicka O, 2011, MLTJ-MUSCLE LIGAMENT, V1, P3; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Jorgensen SB, 2007, APPL PHYSIOL NUTR ME, V32, P904, DOI 10.1139/H07-079; Klein DK, 2007, AM J PHYSIOL-ENDOC M, V293, pE1242, DOI 10.1152/ajpendo.00382.2007; Kobayashi YM, 2008, NATURE, V456, P511, DOI 10.1038/nature07414; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Lantier L, 2010, FASEB J, V24, P3555, DOI 10.1096/fj.10-155994; Lee-Young RS, 2009, J BIOL CHEM, V284, P23925, DOI 10.1074/jbc.M109.021048; Lefer DJ, 1999, AM J PHYSIOL-HEART C, V276, pH1943, DOI 10.1152/ajpheart.1999.276.6.H1943; MCDONAGH PF, 1982, AM J PHYSIOL, V243, pH491, DOI 10.1152/ajpheart.1982.243.3.H491; Miller JD, 2005, J PHYSIOL-LONDON, V563, P925, DOI 10.1113/jphysiol.2004.076422; Mounier R, 2009, FASEB J, V23, P2264, DOI 10.1096/fj.08-119057; O'Neill HM, 2011, P NATL ACAD SCI USA, V108, P16092, DOI 10.1073/pnas.1105062108; Percival JM, 2010, J CLIN INVEST, V120, P816, DOI 10.1172/JCI40736; Percival JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003387; Planitzer G, 2001, CELL TISSUE RES, V306, P325, DOI 10.1007/s004410100449; Roberts CK, 1997, AM J PHYSIOL-ENDOC M, V273, pE220, DOI 10.1152/ajpendo.1997.273.1.E220; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Sewry CA, 2008, J MUSCLE RES CELL M, V29, P231, DOI 10.1007/s10974-008-9155-8; Shearer J, 2004, DIABETES, V53, P1429, DOI 10.2337/diabetes.53.6.1429; Shortreed KE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007293; Steinberg GR, 2010, J BIOL CHEM, V285, P37198, DOI 10.1074/jbc.M110.102434; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Stephens TJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE688, DOI 10.1152/ajpendo.00101.2001; Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004; Thomson M, 2007, AM J PHYSIOL-ENDOC M, V292, pE196, DOI 10.1152/ajpendo.00366.2006; Thomson DM, 2010, J APPL PHYSIOL, V108, P1775, DOI 10.1152/japplphysiol.01293.2009; Tousoulis D, 2012, CURR VASC PHARMACOL, V10, P4, DOI 10.2174/157016112798829760; Tymvios C, 2009, BRIT J PHARMACOL, V158, P1735, DOI 10.1111/j.1476-5381.2009.00408.x; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599; Zwetsloot KA, 2008, J PHYSIOL-LONDON, V586, P6021, DOI 10.1113/jphysiol.2008.159871	42	21	21	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2098	2107		10.1096/fj.13-238972	http://dx.doi.org/10.1096/fj.13-238972			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24522207	Green Published			2022-12-28	WOS:000335336000014
J	Chen, PW; Cescon, M; Megighian, A; Bonaldo, P				Chen, Peiwen; Cescon, Matilde; Megighian, Aram; Bonaldo, Paolo			Collagen VI regulates peripheral nerve myelination and function	FASEB JOURNAL			English	Article						extracellular matrix; peripheral nervous system; Schwann cells	SCHWANN-CELL DIFFERENTIATION; NEGATIVE REGULATOR; SIGNALING PATHWAY; DEFICIENCY; MICE; MECHANISMS; EXPRESSION; NEUROPATHY; MUTATIONS; KINASE	Collagen VI is an extracellular matrix protein with broad distribution in several tissues. Although Col6a1 is expressed by Schwann cells, the role of collagen VI in the peripheral nervous system (PNS) is yet unknown. Here we show that Schwann cells, but not axons, contribute to collagen VI deposition in peripheral nerves. By using Col6a1-null mice, in which collagen VI deposition is compromised, we demonstrate that lack of collagen VI leads to increased myelin thickness (P<0.001) along with 60-130% up-regulation in myelin-associated proteins and disorganized C fibers in the PNS. The hypermyelination of PNS in Col6a1(-/-) mice is supported by alterations of signaling pathways involved in myelination, including increase of P-FAK, P-AKT, P-ERK1, P-ERK2, and P-p38 (4.15, 1.67, 2.47, 3.34, and 2.60-fold, respectively) and reduction of vimentin (0.49-fold), P-JNK (0.74-fold), and P-c-Jun (0.50-fold). Pathologically, Col6a1(-/-) mice display an impairment of nerve conduction velocity and motor coordination (P<0.05), as well as a delayed response to acute pain stimuli (P<0.001), indicating that lack of collagen VI causes functional defects of peripheral nerves. Altogether, these results indicate that collagen VI is a critical component of PNS contributing to the structural integrity and proper function of peripheral nerves.Chen, P., Cescon, M., Megighian, A., Bonaldo, P. Collagen VI regulates peripheral nerve myelination and function.	[Chen, Peiwen; Cescon, Matilde; Bonaldo, Paolo] Univ Padua, Dept Mol Med, I-35131 Padua, Italy; [Megighian, Aram] Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy	University of Padua; University of Padua	Bonaldo, P (corresponding author), Univ Padua, Dept Mol Med, Via Ugo Bassi 58-B, I-35131 Padua, Italy.	bonaldo@bio.unipd.it	Cescon, Matilde/Y-3116-2019; Megighian, Aram/G-6478-2014; MEGIGHIAN, ARAM/I-8146-2019	Cescon, Matilde/0000-0001-7138-1857; Megighian, Aram/0000-0002-7971-5310; MEGIGHIAN, ARAM/0000-0002-7971-5310; Chen, Peiwen/0000-0002-8129-9328; Bonaldo, Paolo/0000-0002-9571-8140	Telethon Foundation [GGP10225, GGP11082]; Italian Ministry of Education, University, and Research [RBAP11Z3YA_003, 2008PB5S89_001, 2009YHX85_002]; University of Padova Strategic Projects; Cariparo Foundation	Telethon Foundation(Fondazione Telethon); Italian Ministry of Education, University, and Research(Ministry of Education, Universities and Research (MIUR)); University of Padova Strategic Projects; Cariparo Foundation(Fondazione Cariparo)	The authors are grateful to C. Colombelli, L. Nobbio, G. Vitale, and M. Filaferro for help with immunofluorescence and functional studies and M. L. Feltri for critical comments on the manuscript. The authors thank Alfonso Colombatti (Centro di Riferimento Oncologico di Aviano, Aviano, Italy), Elior Peles (Weizmann Institute of Science, Rehovot, Israel), James S. Trimmer (University of California, Davis, CA, USA), and Raimund Wagener (Universitat zu Koln, Cologne, Germany) for providing antibodies; P. Giusti and F. Papaleo for providing rotarod and hotplate equipment; and W. Giuriati for technical assistance. This work was supported by grants from the Telethon Foundation (GGP10225, GGP11082), Italian Ministry of Education, University, and Research (RBAP11Z3YA_003, 2008PB5S89_001, 2009YHX85_002), and University of Padova Strategic Projects. P.C. is supported by a fellowship from the Cariparo Foundation.	Allen JM, 2009, J BIOL CHEM, V284, P12020, DOI 10.1074/jbc.M806968200; Bolino A, 2004, J CELL BIOL, V167, P711, DOI 10.1083/jcb.200407010; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Bonnemann Carsten G, 2011, Handb Clin Neurol, V101, P81, DOI 10.1016/B978-0-08-045031-5.00005-0; Bradley JL, 2000, ACTA NEUROPATHOL, V99, P539, DOI 10.1007/s004010051158; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; Chance PF, 1999, ANN NY ACAD SCI, V883, P14, DOI 10.1111/j.1749-6632.1999.tb08562.x; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Cheng IH, 2011, NEUROSCIENCE, V183, P178, DOI 10.1016/j.neuroscience.2011.03.057; Cheng JS, 2009, NAT NEUROSCI, V12, P119, DOI 10.1038/nn.2240; Chernousov MA, 2006, J NEUROSCI, V26, P508, DOI 10.1523/JNEUROSCI.2544-05.2006; Chomiak T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007754; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; D'Mello R, 2008, BRIT J ANAESTH, V101, P8, DOI 10.1093/bja/aen088; Deodato F, 2002, NEUROMUSCULAR DISORD, V12, P392, DOI 10.1016/S0960-8966(01)00312-1; Doran B, 2006, P NATL ACAD SCI USA, V103, P7471, DOI 10.1073/pnas.0602057103; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; Feltri ML, 2002, J CELL BIOL, V156, P199, DOI 10.1083/jcb.200109021; Fragoso G, 2003, EXP NEUROL, V183, P34, DOI 10.1016/S0014-4886(03)00101-8; Gara SK, 2011, MATRIX BIOL, V30, P248, DOI 10.1016/j.matbio.2011.03.006; Gess B, 2011, J NEUROSCI, V31, P17180, DOI 10.1523/JNEUROSCI.3457-11.2011; Grove M, 2007, J CELL BIOL, V176, P277, DOI 10.1083/jcb.200609021; Haines JD, 2008, J MOL NEUROSCI, V35, P23, DOI 10.1007/s12031-007-9011-0; Harrisingh MC, 2004, EMBO J, V23, P3061, DOI 10.1038/sj.emboj.7600309; Hill R, 2009, J ANAT, V214, P219, DOI 10.1111/j.1469-7580.2008.01026.x; Hossain S, 2010, EXP NEUROL, V226, P47, DOI 10.1016/j.expneurol.2010.08.002; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Karkheiran S, 2013, HUM GENET, V132, P275, DOI 10.1007/s00439-012-1248-1; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; La Marca R, 2011, NAT NEUROSCI, V14, P857, DOI 10.1038/nn.2849; Lee HJ, 2009, EXP NEUROL, V216, P365, DOI 10.1016/j.expneurol.2008.12.009; Mirsky R, 1999, BRAIN PATHOL, V9, P293; Napoli I, 2012, NEURON, V73, P729, DOI 10.1016/j.neuron.2011.11.031; Newbern JM, 2011, NEURON, V69, P91, DOI 10.1016/j.neuron.2010.12.003; Nobbio L, 2009, J BIOL CHEM, V284, P23146, DOI 10.1074/jbc.M109.027128; Novak N, 2011, J CELL BIOL, V192, P243, DOI 10.1083/jcb.201010013; Ogata T, 2004, J NEUROSCI, V24, P6724, DOI 10.1523/JNEUROSCI.5520-03.2004; Parkinson DB, 2008, J CELL BIOL, V181, P625, DOI 10.1083/jcb.200803013; PELTONEN J, 1990, ANN NY ACAD SCI, V580, P501, DOI 10.1111/j.1749-6632.1990.tb17972.x; PELTONEN J, 1989, ANAL BIOCHEM, V178, P184, DOI 10.1016/0003-2697(89)90377-1; Pujol A, 2002, HUM MOL GENET, V11, P499, DOI 10.1093/hmg/11.5.499; Rasi K, 2010, J NEUROSCI, V30, P14490, DOI 10.1523/JNEUROSCI.2644-10.2010; Sander S, 1998, MUSCLE NERVE, V21, P217, DOI 10.1002/(SICI)1097-4598(199802)21:2<217::AID-MUS9>3.0.CO;2-E; Schnoor M, 2008, J IMMUNOL, V180, P5707, DOI 10.4049/jimmunol.180.8.5707; Triolo D, 2012, DEVELOPMENT, V139, P1359, DOI 10.1242/dev.072371; Vitale P, 2001, MECH DEVELOP, V102, P145, DOI 10.1016/S0925-4773(01)00303-3; Wallquist W, 2005, J NEUROSCI, V25, P3692, DOI 10.1523/JNEUROSCI.5225-04.2005; Warner LE, 1996, NEURON, V17, P451, DOI 10.1016/S0896-6273(00)80177-4; WAXMAN SG, 1980, MUSCLE NERVE, V3, P141, DOI 10.1002/mus.880030207; Webster H. D., 1993, PERIPHERAL NEUROPATH, P243; Wu LMN, 2012, CURR BIOL, V22, P1957, DOI 10.1016/j.cub.2012.08.025; Yang DP, 2012, J NEUROSCI, V32, P7158, DOI 10.1523/JNEUROSCI.5812-11.2012; Yang DR, 2005, J CELL BIOL, V168, P655, DOI 10.1083/jcb.200411158	56	46	48	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1145	1156		10.1096/fj.13-239533	http://dx.doi.org/10.1096/fj.13-239533			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24277578				2022-12-28	WOS:000335324800011
J	LaBarge, S; McDonald, M; Smith-Powell, L; Auwerx, J; Huss, JM				LaBarge, Samuel; McDonald, Marisa; Smith-Powell, Leslie; Auwerx, Johan; Huss, Janice M.			Estrogen-related receptor-alpha ( ERR alpha) deficiency in skeletal muscle impairs regeneration in response to injury	FASEB JOURNAL			English	Article						nuclear receptors; mitochondria; myogenic differentiation; gene expression; AMP-activated protein kinase	ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; MYOBLAST DIFFERENTIATION; TRANSCRIPTIONAL CONTROL; AMPK; GAMMA; METABOLISM; PGC-1-ALPHA; PHOSPHORYLATION	The estrogen-related receptor- (ERR) regulates mitochondrial biogenesis and glucose and fatty acid oxidation during differentiation in skeletal myocytes. However, whether ERR controls metabolic remodeling during skeletal muscle regeneration in vivo is unknown. We characterized the time course of skeletal muscle regeneration in wild-type (M-ERRWT) and muscle-specific ERR-/- (M-ERR-/-) mice after injury by intramuscular cardiotoxin injection. M-ERR-/- mice exhibited impaired regeneration characterized by smaller myofibers with increased centrally localized nuclei and reduced mitochondrial density and cytochrome oxidase and citrate synthase activities relative to M-ERRWT. Transcript levels of mitochondrial transcription factor A, nuclear respiratory factor-2a, and peroxisome proliferator-activated receptor (PPAR)- coactivator (PGC)-1, were downregulated in the M-ERR-/- muscles at the onset of myogenesis. Furthermore, coincident with delayed myofiber recovery, we observed reduced muscle ATP content (-45% vs.M-ERRWT) and enhanced AMP-activated protein kinase (AMPK) activation in M-ERR-/- muscle. We subsequently demonstrated that pharmacologic postinjury AMPK activation was sufficient to delay muscle regeneration in WT mice. AMPK activation induced ERR transcript expression in M-ERRWT muscle and in C2C12 myotubes through induction of the Esrra promoter, indicating that ERR may control gene regulation downstream of the AMPK pathway. Collectively, these results suggest that ERR deficiency during muscle regeneration impairs recovery of mitochondrial energetic capacity and perturbs AMPK activity, resulting in delayed myofiber repair.LaBarge, S., McDonald, M., Smith-Powell, L., Auwerx, J., Huss, J. M. Estrogen-related receptor- (ERR) deficiency in skeletal muscle impairs regeneration in response to injury.	[LaBarge, Samuel; McDonald, Marisa; Huss, Janice M.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet & Metab Dis Res, Duarte, CA 91010 USA; [LaBarge, Samuel; Huss, Janice M.] City Hope Natl Med Ctr, Beckman Res Inst, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA; [Smith-Powell, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA; [Auwerx, Johan] Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, Lausanne, Switzerland	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Huss, JM (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Diabet & Metab Dis Res, Leslie & Susan Gonda Goldschmied Bldg,Room 2132E3, Duarte, CA 91010 USA.	jhuss@coh.org	Auwerx, Johan/ABE-9307-2021	Auwerx, Johan/0000-0002-5065-5393	TEM-Office of Naval Research (ONR) [N00014-02-10958]; Public Health Service grant from the National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health (NIH; Bethesda MD, USA) [R01 DK074700]; Beckman Research Institute (City of Hope); Morgan and Helen Chu Graduate Student Fellowship; Ecole Polytechnique Federale de Lausanne; EU Ideas program [AdG-231138]; Swiss National Science Foundation [31003A-140780]; NIH [R01AG043930]; National Institute of Child Health and Human Development (NICHD), NIH; National Cancer Institute, NIH [P30CA33572]; NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG043930] Funding Source: NIH RePORTER	TEM-Office of Naval Research (ONR); Public Health Service grant from the National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health (NIH; Bethesda MD, USA); Beckman Research Institute (City of Hope); Morgan and Helen Chu Graduate Student Fellowship; Ecole Polytechnique Federale de Lausanne; EU Ideas program; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Child Health and Human Development (NICHD), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Brian Armstrong and Mariko Lee (Microscopy Core, City of Hope), Dr. Marcia Miller, Dr. Zhou Li, and Ricardo Zerda (Electron Microscopy Core, City of Hope; TEM-Office of Naval Research (ONR) grant N00014-02-10958), and the Animal Resources Center (Department of Comparative Medicine, City of Hope) for assistance; and Dr. Timothy Synold for his contribution to the HPLC assay methodology. This work was supported by Public Health Service grant R01 DK074700 (to J.H.) from the National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health (NIH; Bethesda MD, USA) and by the Beckman Research Institute (City of Hope) and the Morgan and Helen Chu Graduate Student Fellowship (to S.L.). J.A. is the Nestle Chair in Energy Metabolism, and his laboratory is supported by grants from the Ecole Polytechnique Federale de Lausanne, the EU Ideas program (AdG-231138), the Swiss National Science Foundation (31003A-140780), and NIH (R01AG043930). The Developmental Studies Hybridoma Bank was established under the auspices of the National Institute of Child Health and Human Development (NICHD), NIH, and is maintained by The University of Iowa Department of Biology (Iowa City, IA, USA). The Analytical Pharmacology Core is supported by grant P30CA33572 from the National Cancer Institute, NIH.	Bancroft JD, 2002, THEORY PRACTICE HIST, V5th; Bentzinger CF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008342; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chan AYM, 2004, J BIOL CHEM, V279, P32771, DOI 10.1074/jbc.M403528200; Ciciliot S, 2010, CURR PHARM DESIGN, V16, P906, DOI 10.2174/138161210790883453; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Duguez S, 2002, AM J PHYSIOL-ENDOC M, V282, pE802, DOI 10.1152/ajpendo.00343.2001; Durante PE, 2002, AM J PHYSIOL-ENDOC M, V283, pE178, DOI 10.1152/ajpendo.00404.2001; Figarola JL, 2013, INT J MOL MED, V31, P1166, DOI 10.3892/ijmm.2013.1313; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Hamai N, 1997, CELL STRUCT FUNCT, V22, P421, DOI 10.1247/csf.22.421; Hu XL, 2011, HYPERTENSION, V58, P696, DOI 10.1161/HYPERTENSIONAHA.111.174128; Huss JM, 2007, CELL METAB, V6, P25, DOI 10.1016/j.cmet.2007.06.005; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Liu DX, 2003, ENDOCRINOLOGY, V144, P4894, DOI 10.1210/en.2003-0432; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Lyons CN, 2004, BIOCHEM CELL BIOL, V82, P391, DOI 10.1139/O04-040; Mahlapuu M, 2004, AM J PHYSIOL-ENDOC M, V286, pE194, DOI 10.1152/ajpendo.00147.2003; Mascorro Jose A, 2007, Methods Mol Biol, V369, P19; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mounier R, 2009, FASEB J, V23, P2264, DOI 10.1096/fj.08-119057; Murray J, 2013, FASEB J, V27, P135, DOI 10.1096/fj.12-212290; Murray J, 2011, AM J PHYSIOL-CELL PH, V301, pC630, DOI 10.1152/ajpcell.00033.2011; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Niesler CU, 2007, EXP PHYSIOL, V92, P207, DOI 10.1113/expphysiol.2006.034736; Raney MA, 2008, J APPL PHYSIOL, V104, P1366, DOI 10.1152/japplphysiol.01282.2007; Rangwala SM, 2007, BIOCHEM BIOPH RES CO, V357, P231, DOI 10.1016/j.bbrc.2007.03.126; Remels AHV, 2010, MOL CELL ENDOCRINOL, V315, P113, DOI 10.1016/j.mce.2009.09.029; Scarpulla RC, 2012, BBA-GENE REGUL MECH, V1819, P1088, DOI 10.1016/j.bbagrm.2011.10.011; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Seth A, 2007, CELL METAB, V6, P236, DOI 10.1016/j.cmet.2007.08.004; Shao D, 2010, MITOCHONDRION, V10, P516, DOI 10.1016/j.mito.2010.05.012; Sonoda J, 2007, GENE DEV, V21, P1909, DOI 10.1101/gad.1553007; Vettor R, 2009, AM J PHYSIOL-ENDOC M, V297, pE987, DOI 10.1152/ajpendo.00229.2009; Vignaud A, 2005, TOXICON, V45, P789, DOI 10.1016/j.toxicon.2005.02.001; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; Wagatsuma A, 2011, MOL CELL BIOCHEM, V349, P139, DOI 10.1007/s11010-010-0668-2; Wallace GQ, 2009, ANNU REV PHYSIOL, V71, P37, DOI 10.1146/annurev.physiol.010908.163216; Wang SCM, 2010, MOL CELL ENDOCRINOL, V315, P146, DOI 10.1016/j.mce.2009.07.012; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Williamson DL, 2009, AM J PHYSIOL-ENDOC M, V297, pE304, DOI 10.1152/ajpendo.91007.2008; Witczak CA, 2008, CELL MOL LIFE SCI, V65, P3737, DOI 10.1007/s00018-008-8244-6; Yamamoto H, 2011, CELL, V147, P827, DOI 10.1016/j.cell.2011.10.017	51	43	45	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1082	1097		10.1096/fj.13-229211	http://dx.doi.org/10.1096/fj.13-229211			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24277576	Green Published			2022-12-28	WOS:000335324800006
J	Suzuki, N; Numakawa, T; Chou, J; Vega, S; Mizuniwa, C; Sekimoto, K; Adachi, N; Kunugi, H; Arikawa-Hirasawa, E; Yamada, Y; Akazawa, C				Suzuki, Nobuharu; Numakawa, Tadahiro; Chou, Joshua; de Vega, Susana; Mizuniwa, Chihiro; Sekimoto, Kaori; Adachi, Naoki; Kunugi, Hiroshi; Arikawa-Hirasawa, Eri; Yamada, Yoshihiko; Akazawa, Chihiro			Teneurin-4 promotes cellular protrusion formation and neurite outgrowth through focal adhesion kinase signaling	FASEB JOURNAL			English	Article						neuronal differentiation; cytoskeleton	FILOPODIA; GROWTH; CDC42; PAIR; REGULATOR; PROTEINS; FAMILY	Teneurin-4 (Ten-4), a transmembrane protein, is highly expressed in the central nervous system; however, its cellular and molecular function in neuronal differentiation remains unknown. In this study, we aimed to elucidate the function of Ten-4 in neurite outgrowth. Ten-4 expression was induced during neurite outgrowth of the neuroblastoma cell line Neuro-2a. Ten-4 protein was localized at the neurite growth cones. Knockdown of Ten-4 expression in Neuro-2a cells decreased the formation of the filopodia-like protrusions and the length of individual neurites. Conversely, overexpression of Ten-4 promoted filopodia-like protrusion formation. In addition, knockdown and overexpression of Ten-4 reduced and elevated the activation of focal adhesion kinase (FAK) and Rho-family small GTPases, Cdc42 and Rac1, key molecules for the membranous protrusion formation downstream of FAK, respectively. Inhibition of the activation of FAK and neural Wiskott-Aldrich syndrome protein (N-WASP), which is a downstream regulator of FAK and Cdc42, blocked protrusion formation by Ten-4 overexpression. Further, Ten-4 colocalized with phosphorylated FAK in the filopodia-like protrusion regions. Together, our findings show that Ten-4 is a novel positive regulator of cellular protrusion formation and neurite outgrowth through the FAK signaling pathway.Suzuki, N., Numakawa, T., Chou, J., de Vega, S., Mizuniwa, C., Sekimoto, K., Adachi, N., Kunugi, H., Arikawa-Hirasawa, E., Yamada, Y., Akazawa, C. Teneurin-4 promotes cellular protrusion formation and neurite outgrowth through focal adhesion kinase signaling.	[Suzuki, Nobuharu; Mizuniwa, Chihiro; Sekimoto, Kaori; Akazawa, Chihiro] Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Dept Biochem & Biophys, Tokyo 1138510, Japan; [Suzuki, Nobuharu; Chou, Joshua; de Vega, Susana; Yamada, Yoshihiko] Natl Inst Dent & Craniofacial Res, Lab Cell & Dev Biol, NIH, Bethesda, MD USA; [Numakawa, Tadahiro; Adachi, Naoki; Kunugi, Hiroshi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, Tokyo, Japan; [de Vega, Susana; Arikawa-Hirasawa, Eri] Juntendo Univ, Res Inst Dis Old Age, Fac Med, Tokyo, Japan; [de Vega, Susana; Arikawa-Hirasawa, Eri] Juntendo Univ, Dept Neurol, Fac Med, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Center for Neurology & Psychiatry - Japan; Juntendo University; Juntendo University	Akazawa, C (corresponding author), Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Dept Biochem & Biophys, Bunkyo Ku, 1-5-45 Yushima,Bldg 3, Tokyo 1138510, Japan.	c.akazawa.bb@tmd.ac.jp	de Vega, Susana/AAH-4775-2020; Kunugi, Hiroshi/ABC-5260-2021	Adachi, Naoki/0000-0002-4850-1467; Kunugi, Hiroshi/0000-0002-7209-3790	Intramural Research Program of the National Institute of Dental and Craniofacial Research, U.S. National Institutes of Health; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan [24300139]; MEXT Program for Strategic Research Foundation at Private Universities; MEXT [25860701]; Ministry of Health, Labor, and Welfare of Japan [23040101]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000485] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [25640019] Funding Source: KAKEN	Intramural Research Program of the National Institute of Dental and Craniofacial Research, U.S. National Institutes of Health; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT Program for Strategic Research Foundation at Private Universities; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dr. Yukiko Goda (RIKEN BSI, Wako, Japan) for her valuable suggestion. This work was supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research, U.S. National Institutes of Health (Y.Y.), a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (24300139; T.N.), the MEXT Program for Strategic Research Foundation at Private Universities 2011-2015 (S. V. and E. A-H.), a Grant-in-Aid for Young Scientists from MEXT (25860701; N.S.), and a Grant-in-Aid from the Ministry of Health, Labor, and Welfare of Japan (23040101; C. A.).	Chacon MR, 2012, DEVELOPMENT, V139, P3200, DOI 10.1242/dev.080564; Chacon MR, 2011, CELL ADHES MIGR, V5, P52, DOI 10.4161/cam.5.1.13681; Chen C, 2012, INT J BIOCHEM CELL B, V44, P447, DOI 10.1016/j.biocel.2011.11.022; Crespi A, 2012, J CELL SCI, V125, P4543, DOI 10.1242/jcs.106484; Detera-Wadleigh SD, 2007, PSYCHIAT GENET, V17, P274, DOI 10.1097/YPG.0b013e328133f352; Ginsberg SD, 2012, PHARMACOL BIOCHEM BE, V100, P705, DOI 10.1016/j.pbb.2011.09.015; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hong WZ, 2012, NATURE, V484, P201, DOI 10.1038/nature10926; Katz BZ, 2002, BBA-MOL CELL RES, V1592, P141, DOI 10.1016/S0167-4889(02)00308-7; Kuramoto K, 2009, J NEUROSCI RES, V87, P1794, DOI 10.1002/jnr.21997; Leamey CA, 2007, PLOS BIOL, V5, P2077, DOI 10.1371/journal.pbio.0050241; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Li H, 2006, MOL CELL NEUROSCI, V33, P136, DOI 10.1016/j.mcn.2006.06.012; Mahon K, 2010, NEUROSCI BIOBEHAV R, V34, P533, DOI 10.1016/j.neubiorev.2009.10.012; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Menna E, 2011, EUR J NEUROSCI, V34, P1655, DOI 10.1111/j.1460-9568.2011.07897.x; Minet AD, 1999, J CELL SCI, V112, P2019; Miyazaki H, 2007, BIOCHEM BIOPH RES CO, V361, P43, DOI 10.1016/j.bbrc.2007.06.170; Morck C, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-55; Mosca TJ, 2012, NATURE, V484, P237, DOI 10.1038/nature10923; Myers JP, 2012, J CELL SCI, V125, P2918, DOI 10.1242/jcs.100107; Rubin BP, 1999, DEV BIOL, V216, P195, DOI 10.1006/dbio.1999.9503; Rubin BP, 2002, DEVELOPMENT, V129, P4697; Seong JY, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1414; Shekarabi M, 2005, J NEUROSCI, V25, P3132, DOI 10.1523/JNEUROSCI.1920-04.2005; Silva JP, 2011, P NATL ACAD SCI USA, V108, P12113, DOI 10.1073/pnas.1019434108; Sklar P, 2011, NAT GENET, V43, P977, DOI 10.1038/ng.943; Suzuki N, 2012, J NEUROSCI, V32, P11586, DOI 10.1523/JNEUROSCI.2045-11.2012; Tanaka M, 2004, EMBO J, V23, P1075, DOI 10.1038/sj.emboj.7600128; Tucker RP, 2006, DEV BIOL, V290, P237, DOI 10.1016/j.ydbio.2005.11.038; Wu G, 1998, J NEUROCYTOL, V27, P1, DOI 10.1023/A:1006910001869; Young TR, 2013, J NEUROSCI, V33, P12490, DOI 10.1523/JNEUROSCI.4708-12.2013; Zheng LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022956	33	32	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1386	1397		10.1096/fj.13-241034	http://dx.doi.org/10.1096/fj.13-241034			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24344332	Green Published			2022-12-28	WOS:000335324800030
J	Gregor, M; Osmanagic-Myers, S; Burgstaller, G; Wolfram, M; Fischer, I; Walko, G; Resch, GP; Jorgl, A; Herrmann, H; Wiche, G				Gregor, Martin; Osmanagic-Myers, Selma; Burgstaller, Gerald; Wolfram, Michael; Fischer, Irmgard; Walko, Gernot; Resch, Guenter P.; Joergl, Almut; Herrmann, Harald; Wiche, Gerhard			Mechanosensing through focal adhesion-anchored intermediate filaments	FASEB JOURNAL			English	Article						vimentin; plectin; integrin activation; cell motility	MICE LACKING VIMENTIN; BRAIN TUMOR-CELLS; CULTURED-CELLS; OKADAIC ACID; ACTIN CYTOSKELETON; STRESS FIBERS; LIVING CELLS; CANCER-CELLS; PLECTIN; KINASE	Integrin-based mechanotransduction involves a complex focal adhesion (FA)-associated machinery that is able to detect and respond to forces exerted either through components of the extracellular matrix or the intracellular contractile actomyosin network. Here, we show a hitherto unrecognized regulatory role of vimentin intermediate filaments (IFs) in this process. By studying fibroblasts in which vimentin IFs were decoupled from FAs, either because of vimentin deficiency (V0) or loss of vimentin network anchorage due to deficiency in the cytolinker protein plectin (P0), we demonstrate attenuated activation of the major mechanosensor molecule FAK and its downstream targets Src, ERK1/2, and p38, as well as an up-regulation of the compensatory feedback loop acting on RhoA and myosin light chain. In line with these findings, we show strongly reduced FA turnover rates in P0 fibroblasts combined with impaired directional migration, formation of protrusions, and up-regulation of stretched high-affinity integrin complexes. By exploiting tension-independent conditions, we were able to mechanistically link these defects to diminished cytoskeletal tension in both P0 and V0 cells. Our data provide important new insights into molecular mechanisms underlying cytoskeleton-regulated mechanosensing, a feature that is fundamental for controlled cell movement and tumor progression.Gregor, M., Osmanagic-Myers, S., Burgstaller, G., Wolfram, M., Fischer, I., Walko, G., Resch, G. P., Jorgl, A., Herrmann, H., Wiche, G. Mechanosensing through focal adhesion-anchored intermediate filaments.	[Gregor, Martin; Osmanagic-Myers, Selma; Burgstaller, Gerald; Wolfram, Michael; Fischer, Irmgard; Walko, Gernot; Joergl, Almut; Wiche, Gerhard] Univ Vienna, Max F Perutz Labs, Dept Biochem & Cell Biol, A-1030 Vienna, Austria; [Resch, Guenter P.] Univ Vienna, Max F Perutz Labs, Elect Microscopy Campus Sci Support Facil, A-1030 Vienna, Austria; [Gregor, Martin] ASCR, Inst Mol Genet, Dept Transgen Models Dis, Prague, Czech Republic; [Herrmann, Harald] German Canc Res Ctr, Heidelberg, Germany	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Helmholtz Association; German Cancer Research Center (DKFZ)	Wiche, G (corresponding author), Univ Vienna, Max F Perutz Labs, Dept Biochem & Cell Biol, Dr Bohrgasse 9, A-1030 Vienna, Austria.	gerhard.wiche@univie.ac.at	Gregor, Martin/G-4411-2014; Osmanagic-Myers, Selma/AAI-8921-2020; Burgstaller, Gerald/M-6753-2019; WICHE, Gerhard/AAA-3227-2021	Gregor, Martin/0000-0001-6841-9527; Osmanagic-Myers, Selma/0000-0002-3834-1332; Walko, Gernot/0000-0002-8504-1738; Wiche, Gerhard/0000-0001-9550-5463	Austrian Science Research Fund [P20744-B11, I413-B09]; MEYS [7AMB13AT012, OP RDI CZ.1.05/1.1.00/02.0109 BIOCEV]; Austrian Science Fund (FWF) [T 584, I 1207, P 23729] Funding Source: researchfish	Austrian Science Research Fund(Austrian Science Fund (FWF)); MEYS; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The authors thank H. P. Erickson (Duke University Medical Center, Durham, NC, USA), M. Gimona (University of Salzburg, Salzburg, Austria), M. Schwartz (Scripps Research Institute, La Jolla, CA, USA), and P. Traub (University Bonn, Bonn, Germany) for generously providing materials, and A. J. Ridley, J. V. Small, and R. G. Valencia for sharing expertise. This work was supported by Austrian Science Research Fund grants P20744-B11 and I413-B09 (Multilocation DFG-Research Unit 1228 subproject). M.G. received support from MEYS (7AMB13AT012 and OP RDI CZ.1.05/1.1.00/02.0109 BIOCEV).	Abrahamsberg C, 2005, P NATL ACAD SCI USA, V102, P18449, DOI 10.1073/pnas.0505380102; Aikawa R, 2002, HYPERTENSION, V39, P233, DOI 10.1161/hy0202.102699; Andra K, 2003, J INVEST DERMATOL, V120, P189, DOI 10.1046/j.1523-1747.2003.12027.x; Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BERSHADSKY AD, 1987, CELL MOTIL CYTOSKEL, V8, P274, DOI 10.1002/cm.970080308; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; Burgstaller G, 2010, MOL BIOL CELL, V21, P3362, DOI 10.1091/mbc.E10-02-0094; Charras GT, 2002, BIOPHYS J, V82, P2970, DOI 10.1016/S0006-3495(02)75638-5; Cheng TJ, 1998, J CELL BIOCHEM, V71, P169; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Deguchi S, 2011, CYTOSKELETON, V68, P639, DOI 10.1002/cm.20541; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; Friedland JC, 2009, SCIENCE, V323, P642, DOI 10.1126/science.1168441; Garcia AJ, 1999, MOL BIOL CELL, V10, P785, DOI 10.1091/mbc.10.3.785; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; GIESE G, 1986, EUR J CELL BIOL, V40, P266; Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699; Henrion D, 1997, J CLIN INVEST, V100, P2909, DOI 10.1172/JCI119840; ILLC D, 1995, NATURE, V377, P539; INGBER DE, 1993, J CELL SCI, V104, P613; Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040; Ivaska J, 2011, ANNU REV CELL DEV BI, V27, P291, DOI 10.1146/annurev-cellbio-092910-154017; Katada K, 2012, J PROTEOMICS, V75, P1803, DOI 10.1016/j.jprot.2011.12.018; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kreplak L, 2009, J MOL BIOL, V385, P1043, DOI 10.1016/j.jmb.2008.10.095; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE WC, 1992, J CELL BIOCHEM, V49, P378, DOI 10.1002/jcb.240490408; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; McInroy L, 2011, EXP CELL RES, V317, P2468, DOI 10.1016/j.yexcr.2011.07.013; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meier M, 2009, J MOL BIOL, V390, P245, DOI 10.1016/j.jmb.2009.04.067; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Na S, 2008, P NATL ACAD SCI USA, V105, P6626, DOI 10.1073/pnas.0711704105; Na S, 2009, AM J PHYSIOL-CELL PH, V296, pC868, DOI 10.1152/ajpcell.00604.2008; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Osmanagic-Myers S, 2006, J CELL BIOL, V174, P557, DOI 10.1083/jcb.200605172; Prager-Khoutorsky M, 2011, NAT CELL BIOL, V13, P1457, DOI 10.1038/ncb2370; Qin Z, 2010, J BIOMECH, V43, P15, DOI 10.1016/j.jbiomech.2009.09.004; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Resch GP, 2010, METHOD CELL BIOL, V96, P529, DOI 10.1016/S0091-679X(10)96022-6; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; Rezniczek GA, 2007, J CELL BIOL, V176, P965, DOI 10.1083/jcb.200604179; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schober M, 2007, J CELL BIOL, V176, P667, DOI 10.1083/jcb.200608010; Schwartz MA, 2009, SCIENCE, V323, P588, DOI 10.1126/science.1169414; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; SMALL JV, 1978, J CELL SCI, V31, P393; Small JV, 1998, BBA-MOL CELL RES, V1404, P271, DOI 10.1016/S0167-4889(98)00080-9; Steinbock FA, 1999, BIOL CHEM, V380, P151, DOI 10.1515/BC.1999.023; Strnad P, 2001, CELL TISSUE RES, V306, P277, DOI 10.1007/s004410100455; Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002; Toivola DM, 2002, MOL BIOL CELL, V13, P1857, DOI 10.1091/mbc.01-12-0591; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wang N, 2002, J MUSCLE RES CELL M, V23, P535, DOI 10.1023/A:1023470709071; Wang N, 2000, AM J PHYSIOL-CELL PH, V279, pC188, DOI 10.1152/ajpcell.2000.279.1.C188; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wiche Gerhard, 2011, Bioarchitecture, V1, P14	65	112	113	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					715	729		10.1096/fj.13-231829	http://dx.doi.org/10.1096/fj.13-231829			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24347609				2022-12-28	WOS:000331072200019
J	Hutchinson, JL; Rajagopal, SP; Yuan, M; Norman, JE				Hutchinson, James L.; Rajagopal, Shalini P.; Yuan, Mei; Norman, Jane E.			Lipopolysaccharide promotes contraction of uterine myocytes via activation of Rho/ROCK signaling pathways	FASEB JOURNAL			English	Article						infection; labor; myometrium; preterm	NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; HUMAN MYOMETRIUM; PRETERM LABOR; KINASE; INTERLEUKIN-1-BETA; INHIBITOR; RECEPTORS; TERM	Myometrial contraction is a central feature of labor. Although a link between infection and preterm labor is widely accepted, surprisingly little is known about the mechanisms coupling infection-induced inflammation to myocyte contractile machinery. This study explores the myocyte response to pathogen-derived ligands in vitro. The pregnant human myometrial cell line PHM1-41 and primary cultured uterine myocytes responded to Toll-like receptor (TLR) ligands, including the bacterial wall component LPS, which at 100 ng/ml increased contraction of cells embedded within collagen gels over 72 h compared to PBS. LPS-treated myocytes secreted inflammatory mediators, including prostaglandin F2, the cytokines TNF- and IL-6, and a range of chemokines. The contractile response to LPS required TLR4 signaling and was independent of prostaglandin synthesis. Neutralizing TNF- had no effect on LPS-mediated contraction; however, the Rho-associated protein kinase (ROCK) inhibitors Y-27632 (10 M) and GSK-269962 (50 nM) both abrogated the contractile response. The finding of LPS-mediated contraction was supported by a 1.38 +/- 0.072-fold (mean +/- se) increase in myosin light-chain phosphorylation 48 h post-treatment, assessed by in-cell Western blot analysis. Together, these data suggest that, in addition to modulating the local inflammatory environment, pathogen-derived ligands may directly promote myometrial contractility via Rho/ROCK signaling, thus contributing to preterm labor-mediated preterm birth.Hutchinson, J. L., Rajagopal, S. P., Yuan, M., Norman, J. E. Lipopolysaccharide promotes contraction of uterine myocytes via activation of Rho/ROCK signaling pathways.	[Hutchinson, James L.; Rajagopal, Shalini P.; Yuan, Mei; Norman, Jane E.] Univ Edinburgh, MRC, Ctr Reprod Hlth, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Hutchinson, JL (corresponding author), Univ Edinburgh, MRC, Ctr Reprod Hlth, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	jlawrencehutchinson@gmail.com		Norman, Jane/0000-0001-6031-6953; Rajagopal, Shalini/0000-0002-7705-5523	UK Medical Research Council (MRC)-Centre for Reproductive Health (CRH); MRC; Action Medical Research [SP4275]; Medical Research Council [G1002033] Funding Source: researchfish; MRC [G1002033] Funding Source: UKRI	UK Medical Research Council (MRC)-Centre for Reproductive Health (CRH); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Action Medical Research; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Professor B. Sanborn (Colorado State University, Fort Collins, CO, USA) for her gift of PHM1-41 cells, Dr A. Henke (University Clinic Cologne, Cologne, Germany) for his gift of rat tail collagen, the Edinburgh Reproductive Tissues BioBank for providing myometrial samples, and Professor Philippa Saunders for supporting this work within the UK Medical Research Council (MRC)-Centre for Reproductive Health (CRH). This work was funded by an MRC career development fellowship to J.L.H. and an MRC Ph.D. studentship to S. P. R., and by grants from Action Medical Research (SP4275) and Tommy's.	Aguilar HN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009965; Alexander HA, 2012, REPROD SCI, V19, P43, DOI 10.1177/1933719111413297; Anderson L, 2009, REPROD SCI, V16, P1052, DOI 10.1177/1933719109340926; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Dallot E, 2003, BIOL REPROD, V68, P937, DOI 10.1095/biolreprod.102.008367; Elovitz MA, 2004, TRENDS ENDOCRIN MET, V15, P479, DOI 10.1016/j.tem.2004.10.009; Eude-Le Parco Isabelle, 2007, BMC Pregnancy Childbirth, V7 Suppl 1, pS11, DOI 10.1186/1471-2393-7-S1-S11; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Goupil E, 2010, J BIOL CHEM, V285, P25624, DOI 10.1074/jbc.M110.115196; Herschman HR, 2001, MED SCI SYMP SER, V16, P41; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Holmgren C, 2008, J REPROD IMMUNOL, V78, P134, DOI 10.1016/j.jri.2007.11.003; Huber M, 2006, EUR J IMMUNOL, V36, P701, DOI 10.1002/eji.200535593; Hudson CA, 2012, MOL HUM REPROD, V18, P265, DOI 10.1093/molehr/gar078; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Li LP, 2012, J IMMUNOL, V188, P4681, DOI 10.4049/jimmunol.1102628; Lorenz E, 2002, PEDIATR RES, V52, P373, DOI 10.1203/01.PDR.0000025342.83436.53; Monga M, 1996, BIOL REPROD, V55, P427, DOI 10.1095/biolreprod55.2.427; Norman JE, 1997, J REPROD FERTIL, V110, P249; Rinaldi SF, 2011, EXPERT REV CLIN IMMU, V7, P675, DOI [10.1586/ECI.11.58, 10.1586/eci.11.58]; ROMERO R, 1992, AM J REPROD IMMUNOL, V27, P117, DOI 10.1111/j.1600-0897.1992.tb00737.x; Sadowsky DW, 2006, AM J OBSTET GYNECOL, V195, P1578, DOI 10.1016/j.ajog.2006.06.072; Shmigol AV, 1998, J PHYSIOL-LONDON, V511, P803, DOI 10.1111/j.1469-7793.1998.803bg.x; Slater DM, 1999, MOL HUM REPROD, V5, P880, DOI 10.1093/molehr/5.9.880; Tahara M, 2005, AM J OBSTET GYNECOL, V192, P903, DOI 10.1016/j.ajog.2004.09.016; Tattersall M, 2008, REPRODUCTION, V135, P569, DOI 10.1530/REP-07-0461; Thomson AJ, 1999, HUM REPROD, V14, P229, DOI 10.1093/humrep/14.1.229; Tribe RM, 2003, BIOL REPROD, V68, P1842, DOI 10.1095/biolreprod.102.011403; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wei CY, 2006, MOL PHARMACOL, V69, P960, DOI 10.1124/mol.105.017368; Yarilina A, 2008, NAT IMMUNOL, V9, P378, DOI 10.1038/ni1576; Youssef RE, 2009, REPROD SCI, V16, P843, DOI 10.1177/1933719109336621	34	45	48	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					94	105		10.1096/fj.13-237040	http://dx.doi.org/10.1096/fj.13-237040			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24076962				2022-12-28	WOS:000333526100012
J	Marwarha, G; Berry, DC; Croniger, CM; Noy, N				Marwarha, Gurdeep; Berry, Daniel C.; Croniger, Colleen M.; Noy, Noa			The retinol esterifying enzyme LRAT supports cell signaling by retinol- binding protein and its receptor STRA6	FASEB JOURNAL			English	Article						vitamin A metabolism; JAK; STAT; cytokine receptors; insulin receptor; obesity	VITAMIN-A; INSULIN-RESISTANCE; ESTER BIOSYNTHESIS; RAT-LIVER; ACID; ACYLTRANSFERASE; ESTERIFICATION; HOMEOSTASIS; TRANSTHYRETIN; LECITHIN	Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP). At some tissues, holo-RBP is recognized by a plasma membrane receptor termed STRA6, which serves a dual role: it mediates transport of retinol from RBP into cells, and it functions as a cytokine receptor that, on binding holo-RBP, activates JAK2/STAT5 signaling. As STAT target genes include SOCS3, an inhibitor of insulin receptor, holo-RBP suppresses insulin responses in STRA6-expressing cells. We have shown previously that the two functions of STRA6 are interdependent. These observations suggest factors that regulate STRA6-mediated retinol transport may also control STRA6-mediated cell signaling. One such factor is retinol metabolism, which enables cellular uptake of retinol by maintaining an inward-directed concentration gradient. We show here that lecithin:retinol acyl transferase (LRAT), which catalyzes esterification of retinol to its storage species retinyl esters, is necessary for activation of the STRA6/JAK2/STAT5 cascade by holo-RBP. In accordance, LRAT-null mice are protected from holo-RBP-induced suppression of insulin responses. Hence, STRA6 signaling, which requires STRA6-mediated retinol transport, is supported by LRAT-catalyzed retinol metabolism. The observations demonstrate that STRA6 regulates key cellular processes by coupling circulating holo-RBP levels and intracellular retinol metabolism to cell signaling.Marwarha, G., Berry, D.C., Croniger, C.M., Noy, N. The retinol esterifying enzyme LRAT supports cell signaling by retinol-binding protein and its receptor STRA6.	[Marwarha, Gurdeep; Berry, Daniel C.; Noy, Noa] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Berry, Daniel C.; Croniger, Colleen M.; Noy, Noa] Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Noy, N (corresponding author), Case Western Reserve Univ, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	noa.noy@case.edu		MARWARHA, GURDEEP/0000-0001-5556-0003	U.S. National Institutes of Health (NIH) [RO1 DK088969]; NIH [DK59630]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U2CDK059630, R01DK088969, U24DK059630] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors are grateful to Krzysztof Palczewski (Case Western Reserve University) for sharing the Lrat-null mice and Lrat expression vector, Norbert Ghyselinck (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Strasbourg, France) for STRA6 antibodies, and Silke Vogel (Columbia University School of Physicians and Surgeons, New York, NY, USA) for the RBP expression construct. This work was supported by U.S. National Institutes of Health (NIH) grant RO1 DK088969. The Mouse Metabolic Phenotyping Center (MMPC) of Case Western Reserve University is supported by NIH grant DK59630.	Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Bellovino D, 1996, EXP CELL RES, V222, P77, DOI 10.1006/excr.1996.0010; Berry D. C., 2013, J BIOL CHEM; Berry DC, 2012, MOL CELL BIOL, V32, P3851, DOI 10.1128/MCB.00775-12; Berry DC, 2012, MOL CELL BIOL, V32, P3164, DOI 10.1128/MCB.00505-12; Berry DC, 2012, BBA-MOL CELL BIOL L, V1821, P168, DOI 10.1016/j.bbalip.2011.07.002; Berry DC, 2011, P NATL ACAD SCI USA, V108, P4340, DOI 10.1073/pnas.1011115108; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; D'Ambrosio DN, 2011, NUTRIENTS, V3, P63, DOI 10.3390/nu3010063; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Isken A, 2008, CELL METAB, V7, P258, DOI 10.1016/j.cmet.2008.01.009; Jiang WY, 2013, J BIOL CHEM, V288, P589, DOI 10.1074/jbc.M112.402883; Jiang WY, 2012, BBA-GEN SUBJECTS, V1820, P859, DOI 10.1016/j.bbagen.2012.03.016; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; Liu LM, 2005, J BIOL CHEM, V280, P40226, DOI 10.1074/jbc.M509643200; Mody N, 2008, AM J PHYSIOL-ENDOC M, V294, pE785, DOI 10.1152/ajpendo.00521.2007; NAPOLI JL, 1995, J STEROID BIOCHEM, V53, P497, DOI 10.1016/0960-0760(95)00096-I; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; ONG DE, 1988, J BIOL CHEM, V263, P5789; Orland MD, 2005, BBA-MOL CELL BIOL L, V1737, P76, DOI 10.1016/j.bbalip.2005.09.003; POSCH KC, 1992, J BIOL CHEM, V267, P19676; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RAZ A, 1969, J BIOL CHEM, V244, P3230; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200; Shih MYS, 2009, J BIOL CHEM, V284, P4292, DOI 10.1074/jbc.M807503200; SOPRANO DR, 1981, J BIOL CHEM, V256, P8256; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Wang CY, 2012, METHODS MOL BIOL, V821, P421, DOI 10.1007/978-1-61779-430-8_27; Wongsiriroj N, 2008, J BIOL CHEM, V283, P13510, DOI 10.1074/jbc.M800777200; Xie YS, 1998, PROTEIN EXPRES PURIF, V14, P31, DOI 10.1006/prep.1998.0944; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; YOST RW, 1988, J BIOL CHEM, V263, P18693	36	20	20	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					26	34		10.1096/fj.13-234310	http://dx.doi.org/10.1096/fj.13-234310			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24036882	Green Published			2022-12-28	WOS:000333526100005
J	Stura, EA; Visse, R; Cuniasse, P; Dive, V; Nagase, H				Stura, Enrico A.; Visse, Robert; Cuniasse, Philippe; Dive, Vincent; Nagase, Hideaki			Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain	FASEB JOURNAL			English	Article						matrix metalloproteinases; collagen; substrate binding; X-ray crystallography; extracellular matrix	C-TERMINAL DOMAIN; X-RAY-STRUCTURE; MATRIX METALLOPROTEINASES; BINDING; ACTIVATION; MECHANISM; SIZE; SEDIMENTATION; FLEXIBILITY; SPECIFICITY	Matrix metalloproteinase (MMP)-13 is one of the mammalian collagenases that play key roles in tissue remodelling and repair and in progression of diseases such as cancer, arthritis, atherosclerosis, and aneurysm. For collagenase to cleave triple helical collagens, the triple helical structure has to be locally unwound before hydrolysis, but this process is not well understood. We report crystal structures of catalytically inactive full-length human MMP-13(E223A) in complex with peptides of 14-26 aa derived from the cleaved prodomain during activation. Peptides are bound to the active site of the enzyme by forming an extended -strand with Glu(40) or Tyr(46) inserted into the S-1 specificity pocket. The structure of the N-terminal part of the peptides is variable and interacts with different parts of the catalytic domain. Those areas are designated substrate-dependent exosites, in that they accommodate different peptide structures, whereas the precise positioning of the substrate backbone is maintained in the active site. These modes of peptide-MMP-13 interactions have led us to propose how triple helical collagen strands fit into the active site cleft of the collagenase.Stura, E. A., Visse, R., Cuniasse, P., Dive, V., Nagase, H. Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain.	[Stura, Enrico A.; Cuniasse, Philippe; Dive, Vincent] Commissariat Energie Atom & Energies Alternat CEA, Serv Ingn Mol Prot, Gif Sur Yvette, France; [Visse, Robert; Nagase, Hideaki] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7FY, England	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Oxford	Nagase, H (corresponding author), Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Roosevelt Dr, Oxford OX3 7FY, England.	vincent.dive@cea.fr; hideaki.nagase@kennedy.ox.ac.uk	STURA, Enrico/A-2793-2010	STURA, Enrico/0000-0001-6718-2118	Wellcome Trust [075473]; Arthritis Research UK; U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Disease (NIH/NIAMS) [AR40994]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); Arthritis Research UK(Versus Arthritis); U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Disease (NIH/NIAMS); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Noriko Itoh for construction of the MMP-13(E223A) expression vector; Alan Lyons and Toyoko Nakamura for help in expressing and purifying the protein; Laura Vera for efforts with cryoprotection to improve data quality; the European Synchrotron Radiation Facility (ESRF; Grenoble, France) and Soleil for beam time; and Drs. Andrew McCarthy on line ID14-4, Max Nanao on line ID23-2; and Andrew Thomson on Proxima 1 for assistance with the synchrotron experiments. This work was supported by the Wellcome Trust (grant 075473), Arthritis Research UK, and the U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Disease (NIH/NIAMS; grant AR40994; R. V. and H.N.).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Bertini I, 2012, J AM CHEM SOC, V134, P2100, DOI 10.1021/ja208338j; Bertini I, 2006, ANGEW CHEM INT EDIT, V45, P7952, DOI 10.1002/anie.200603100; Bertini I, 2009, J BIOL CHEM, V284, P12821, DOI 10.1074/jbc.M809627200; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Cha HJ, 2002, J MOL BIOL, V320, P1065, DOI 10.1016/S0022-2836(02)00558-2; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; Elkins PA, 2002, ACTA CRYSTALLOGR D, V58, P1182, DOI 10.1107/S0907444902007849; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Erickson HP, 2009, BIOL PROCED ONLINE, V11, P32, DOI 10.1007/s12575-009-9008-x; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; Fulcher YG, 2011, BIOCHEMISTRY-US, V50, P9488, DOI 10.1021/bi2009807; Gall AL, 2001, J MOL BIOL, V307, P577, DOI 10.1006/jmbi.2001.4493; Goldring MB, 2012, THER ADV MUSCULOSKEL, V4, P269, DOI 10.1177/1759720X12448454; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; Hashimoto H, 2011, J BIOL CHEM, V286, P33236, DOI 10.1074/jbc.M111.264176; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; Igarashi Y, 2007, NUCLEIC ACIDS RES, V35, pD546, DOI 10.1093/nar/gkl813; Iyer S, 2006, J MOL BIOL, V362, P78, DOI 10.1016/j.jmb.2006.06.079; Johnson AR, 2007, J BIOL CHEM, V282, P27781, DOI 10.1074/jbc.M703286200; Jozic D, 2005, J BIOL CHEM, V280, P9578, DOI 10.1074/jbc.M411084200; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kollman JM, 2009, BIOCHEMISTRY-US, V48, P3877, DOI 10.1021/bi802205g; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Lu K. G., 2013, J MOL BIOL; Manka SW, 2012, P NATL ACAD SCI USA, V109, P12461, DOI 10.1073/pnas.1204991109; Maskos K, 2007, J MOL BIOL, V366, P1222, DOI 10.1016/j.jmb.2006.11.072; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Murphy G, 2008, MOL ASPECTS MED, V29, P290, DOI 10.1016/j.mam.2008.05.002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nagase H, 1997, BIOL CHEM, V378, P151; Nagase H, 2011, BIOL EXTRACELL MATR, P95, DOI 10.1007/978-3-642-16861-1_5; Nerenberg PS, 2008, J MOL BIOL, V382, P246, DOI 10.1016/j.jmb.2008.07.009; Newman J, 2004, ACTA CRYSTALLOGR D, V60, P610, DOI 10.1107/S0907444903029640; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Pendas AM, 2000, CLIN CHIM ACTA, V291, P137, DOI 10.1016/S0009-8981(99)00225-9; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; Robichaud TK, 2011, J BIOL CHEM, V286, P37535, DOI 10.1074/jbc.M111.273391; Salsas-Escat R, 2010, BIOCHEMISTRY-US, V49, P4147, DOI 10.1021/bi9021473; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stultz CM, 2002, J MOL BIOL, V319, P997, DOI 10.1016/S0022-2836(02)00421-7; STURA EA, 1999, PRACT APPROACH SER, V210, P177; Takaishi H, 2008, CURR PHARM BIOTECHNO, V9, P47, DOI 10.2174/138920108783497659; Tallant C, 2010, BBA-MOL CELL RES, V1803, P20, DOI 10.1016/j.bbamcr.2009.04.003; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Vera L., 2013, CRYST GROWTH DES, DOI 10.1021/cg301531f; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Woessner JF, 1998, BIOL EXTRAC, P1; Gomis-Ruth FX, 2008, CRIT REV BIOCHEM MOL, V43, P319, DOI 10.1080/10409230802376375 	62	26	28	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4395	4405		10.1096/fj.13-233601	http://dx.doi.org/10.1096/fj.13-233601			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23913860	Green Published			2022-12-28	WOS:000329937500008
J	Doherty, JE; Woodard, LE; Bear, AS; Foster, AE; Wilson, MH				Doherty, Joseph E.; Woodard, Lauren E.; Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.			An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression	FASEB JOURNAL			English	Article						piggyBac; inducible expression; gene transfer	IMMUNE-RESPONSE; MAMMALIAN-CELLS; FIREFLY LUCIFERASE; LIVER; DELIVERY; THERAPY; TETRACYCLINE; ACTIVATION; HEMOPHILIA; STRATEGIES	Transposons permit permanent cellular genome engineering in vivo. However, transgene expression falls rapidly postdelivery due to a variety of mechanisms, including immune responses. We hypothesized that delaying initial transgene expression would improve long-term transgene expression by using an engineered piggyBac transposon system that can regulate expression. We found that a 2-part nonviral Tet-KRAB inducible expression system repressed expression of a luciferase reporter in vitro. However, we also observed nonspecific promoter-independent repression. Thus, to achieve temporary transgene repression after gene delivery in vivo, we utilized a nonintegrating version of the repressor plasmid while the gene of interest was delivered in an integrating piggyBac transposon vector. When we delivered the luciferase transposon and repressor to immunocompetent mice by hydrodynamic injection, initial luciferase expression was repressed by 2 orders of magnitude. When luciferase expression was followed long term in vivo, we found that expression was increased >200-fold compared to mice that received only the luciferase transposon and piggyBac transposase. We found that repression of early transgene expression could prevent the priming of luciferase-specific T cells in vivo. Therefore, transient transgene repression postgene delivery is an effective strategy for inhibiting the antitransgene immune response and improving long-term expression in vivo without using immunosuppression.Doherty, J. E., Woodard, L. E., Bear, A. S., Foster, A. E., Wilson, M. H. An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.	[Doherty, Joseph E.; Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Med Scientist Training Program, Houston, TX 77030 USA; [Doherty, Joseph E.; Wilson, Matthew H.] Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; [Doherty, Joseph E.; Woodard, Lauren E.; Wilson, Matthew H.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Wilson, Matthew H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	Wilson, MH (corresponding author), Baylor Coll Med, 1 Baylor Plaza,MS BCM395,ABBR R704, Houston, TX 77030 USA.	mhwilson@bcm.edu	Wilson, Matthew H/K-3193-2013		U.S. National Institutes of Health (NIH) [T32GM007330]; NIH [T32DK064717, T32DK062706, T32DK060445, R01 DK093660]; U.S. Department of Veterans Affairs; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL092332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK060445, R01DK093660, T32DK062706, T32DK064717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007330] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	J.E.D. was supported by U.S. National Institutes of Health (NIH) Medical Scientist Training Program grant T32GM007330, and subsequently by NIH Cell and Gene Therapy Training grant T32DK064717 and the generous support of Bill and Mary Jo Robbins. L. E. W. was supported by NIH grant T32DK062706 and subsequently by NIH grant T32DK060445. M. H. W. was supported in part by a career development award from the U.S. Department of Veterans Affairs and NIH grant R01 DK093660. This work was also made possible by the generous support of Dr. and Mrs. Harold M. Selzman.	Abina MA, 1996, GENE THER, V3, P212; Arruda VR, 2009, MOL THER, V17, P1492, DOI 10.1038/mt.2009.150; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; Bell JB, 2007, NAT PROTOC, V2, P3153, DOI 10.1038/nprot.2007.471; Cerullo V, 2007, MOL THER, V15, P2080, DOI 10.1038/sj.mt.6300308; Chu QM, 2005, MOL THER, V12, P264, DOI 10.1016/j.ymthe.2005.04.007; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Doherty JE, 2012, HUM GENE THER, V23, P311, DOI 10.1089/hum.2011.138; Frka K, 2009, J BIOTECHNOL, V141, P8, DOI 10.1016/j.jbiotec.2009.02.013; Fujinami RS, 2006, CLIN MICROBIOL REV, V19, P80, DOI 10.1128/CMR.19.1.80-94.2006; Geurts AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6; Ginhoux F, 2004, MOL THER, V10, P279, DOI 10.1016/j.ymthe.2004.05.012; Gomez-Rodriguez J, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn523; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Goverdhana S, 2005, MOL THER, V12, P189, DOI 10.1016/j.ymthe.2005.03.022; Herweijer H, 2007, GENE THER, V14, P99, DOI 10.1038/sj.gt.3302891; Isenmann S, 2001, BRAIN RES, V892, P229, DOI 10.1016/S0006-8993(00)02957-7; Jeon YH, 2007, CANCER BIOL THER, V6, P781, DOI 10.4161/cbt.6.5.4005; Khanna A, 2000, J IMMUNOL, V164, P1346, DOI 10.4049/jimmunol.164.3.1346; Le Guiner C, 2007, CURR GENE THER, V7, P334; Limberis MP, 2009, GENE THER, V16, P441, DOI 10.1038/gt.2008.177; Limberis MP, 2010, MOL THER, V18, P143, DOI 10.1038/mt.2009.190; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; LoDuca PA, 2009, CURR GENE THER, V9, P104, DOI 10.2174/156652309787909490; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244; Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343; Mingozzi F, 2007, NAT MED, V13, P419, DOI 10.1038/nm1549; Morris JC, 2004, BLOOD, V103, P492, DOI 10.1182/blood-2003-07-2324; Nakazawa Y, 2013, J IMMUNOTHER, V36, P3, DOI 10.1097/CJI.0b013e3182791234; Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Pastore L, 1999, HUM GENE THER, V10, P1773, DOI 10.1089/10430349950017455; Racz Z, 2011, NUCLEIC ACID THER, V21, P215, DOI 10.1089/nat.2010.0248; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Saridey SK, 2009, MOL THER, V17, P2115, DOI 10.1038/mt.2009.234; Sebestyen MG, 2006, J GENE MED, V8, P852, DOI 10.1002/jgm.921; Seiler MP, 2007, CURR GENE THER, V7, P297, DOI 10.2174/156652307782151452; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; Suda T, 2007, GENE THER, V14, P129, DOI 10.1038/sj.gt.3302865; Suda T, 2007, MOL THER, V15, P2063, DOI 10.1038/sj.mt.6300314; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Vilaboa N, 2006, CURR GENE THER, V6, P421, DOI 10.2174/156652306777934829; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Woodard LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042666; Yen L, 2004, NATURE, V431, P471, DOI 10.1038/nature02844; Yusa K, 2011, P NATL ACAD SCI USA, V108, P1531, DOI 10.1073/pnas.1008322108; Zaldumbide A, 2008, GENE THER, V15, P239, DOI 10.1038/sj.gt.3303082	53	7	7	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3753	3762		10.1096/fj.13-232090	http://dx.doi.org/10.1096/fj.13-232090			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23752206	Green Published			2022-12-28	WOS:000328840500033
J	Bayer, SB; Maghzal, G; Stocker, R; Hampton, MB; Winterbourn, CC				Bayer, Simone B.; Maghzal, Ghassan; Stocker, Roland; Hampton, Mark B.; Winterbourn, Christine C.			Neutrophil-mediated oxidation of erythrocyte peroxiredoxin 2 as a potential marker of oxidative stress in inflammation	FASEB JOURNAL			English	Article						hydrogen peroxide; antioxidant defense; NADPH oxidase	CHRONIC GRANULOMATOUS-DISEASE; NADPH OXIDASE ACTIVITY; HYDROGEN-PEROXIDE; LIPOPOLYSACCHARIDE; BINDING; CD14; MYELOPEROXIDASE; AUTOXIDATION; PROTEIN; MODEL	Peroxiredoxin 2 (Prx2) is an abundant thiol protein in erythrocytes. It is oxidized readily on exposure to hydrogen peroxide (H2O2) and provides antioxidant protection by cycling between its reduced and disulfide-bonded forms. To test whether Prx2 oxidation could occur in pathological situations where neutrophils are activated, we exposed human erythrocytes to stimulated neutrophils and measured Prx2 oxidation by immunoblotting of nonreducing gels. With phorbol myristate acetate, lipopolysaccharide or Staphylococcus aureus Prx2 dimer increased from <5% to up to 100% depending on neutrophil number and incubation time. Studies with inhibitors and myeloperoxidase-deficient neutrophils showed that H2O2 generated by the neutrophil NADPH oxidase was responsible. Prx2 oxidation was detected at erythrocyte:neutrophil ratios found in blood and reversed over time as the oxidative burst subsided. Acidotic conditions also increased erythrocyte Prx2 oxidation. In a mouse model of endotoxemia induced by lipopolysaccharide, oxidized Prx2 increased transiently from <1 to 15%, then reverted to baseline by 24 h. No increase was seen in mice lacking NADPH oxidase activity. These results indicate that erythrocyte Prx2 scavenges H2O2 produced during inflammation. Oxidized erythrocyte Prx2 could be a sensitive real-time marker of systemic neutrophil activation and an early indicator of inflammation and oxidative stress.Bayer, S.B., Maghzal, G., Stocker, R., Hampton, M.B., Winterbourn, C.C. Neutrophil-mediated oxidation of erythrocyte peroxiredoxin 2 as a potential marker of oxidative stress in inflammation.	[Bayer, Simone B.; Hampton, Mark B.; Winterbourn, Christine C.] Univ Otago Christchurch, Ctr Free Rad Res, Christchurch, New Zealand; [Bayer, Simone B.; Hampton, Mark B.; Winterbourn, Christine C.] Univ Otago Christchurch, Gravida Natl Res Ctr Growth & Dev, Dept Pathol, Christchurch, New Zealand; [Maghzal, Ghassan; Stocker, Roland] Univ Sydney, Ctr Vasc Res, Sch Med Sci Pathol, Sydney, NSW 2006, Australia; [Maghzal, Ghassan; Stocker, Roland] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Maghzal, Ghassan; Stocker, Roland] Victor Chang Cardiac Res Inst, Vasc Biol Div, Darlinghurst, NSW, Australia	University of Otago; University of Otago; University of Sydney; University of Sydney; Victor Chang Cardiac Research Institute	Hampton, MB (corresponding author), Univ Otago Christchurch, Dept Pathol, POB 4345, Christchurch, New Zealand.	hampton@otago.ac.nz; christine.winterbourn@otago.ac.nz	Hampton, Mark B/A-8490-2008; Stocker, Roland/AAV-4489-2021; maghzal, ghassan/A-9692-2015	Hampton, Mark B/0000-0002-7349-3729; Bayer, Simone/0000-0002-5880-2095	Health Research Council of New Zealand; National Research Centre for Growth and Development of New Zealand; National Health and Medical Research Council of Australia; Australian Research Council; University of Otago	Health Research Council of New Zealand(Health Research Council of New Zealand); National Research Centre for Growth and Development of New Zealand; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); University of Otago	This work was supported by the Health Research Council of New Zealand, the National Research Centre for Growth and Development of New Zealand, the National Health and Medical Research Council of Australia, the Australian Research Council, and a University of Otago Scholarship (to S. B.). The authors declare no conflicts of interest. S. B. B. carried out most of the experimental work and contributed to experimental design and preparation of the manuscript; M. B. H. and C. C. W. contributed to experimental design, interpretation, and manuscript preparation; G. M. carried out the mouse studies; R. S. advised on the mouse studies and the preparation of the manuscript.	AGAR NS, 1986, J CLIN INVEST, V77, P319, DOI 10.1172/JCI112294; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; BROWN JM, 1989, AM J PHYSIOL, V256, pH584, DOI 10.1152/ajpheart.1989.256.2.H584; BROWN WD, 1969, J BIOL CHEM, V244, P6696; Burtis C. A., 2000, TIETZ FUNDAMENTALS C, P734; DeCoursey TE, 2005, CELL MOL LIFE SCI, V62, P2173, DOI 10.1007/s00018-005-5177-1; Green Jessie N., 2007, V412, P319, DOI 10.1007/978-1-59745-467-4_21; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hall A, 2009, FEBS J, V276, P2469, DOI 10.1111/j.1742-4658.2009.06985.x; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Johnson RM, 2005, FREE RADICAL BIO MED, V39, P1407, DOI 10.1016/j.freeradbiomed.2005.07.002; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; KETTLE AJ, 1994, J BIOL CHEM, V269, P17146; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Low FM, 2008, ANTIOXID REDOX SIGN, V10, P1621, DOI 10.1089/ars.2008.2081; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; Lundqvist H, 1996, J LEUKOCYTE BIOL, V59, P270, DOI 10.1002/jlb.59.2.270; MOORE RB, 1991, J BIOL CHEM, V266, P18964; Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x; Peskin AV, 2007, J BIOL CHEM, V282, P11885, DOI 10.1074/jbc.M700339200; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Remer KA, 2003, IMMUNOL LETT, V85, P75, DOI 10.1016/S0165-2478(02)00210-9; Rhee SG, 2011, ANTIOXID REDOX SIGN, V15, P781, DOI 10.1089/ars.2010.3393; Soler-Rodriguez AM, 2000, J IMMUNOL, V164, P2674, DOI 10.4049/jimmunol.164.5.2674; Stacey MM, 2009, FREE RADICAL BIO MED, V47, P1468, DOI 10.1016/j.freeradbiomed.2009.08.022; Troelstra A, 1999, J IMMUNOL, V162, P4220; Troelstra A, 1997, INFECT IMMUN, V65, P2272, DOI 10.1128/IAI.65.6.2272-2277.1997; VANASBECK BS, 1985, SCIENCE, V227, P756, DOI 10.1126/science.2982213; Wang YT, 2010, NAT MED, V16, P279, DOI 10.1038/nm.2092; WINTERBOURN CC, 1987, J CLIN INVEST, V80, P1486, DOI 10.1172/JCI113230; Winterbourn CC, 2013, ANTIOXID REDOX SIGN, V18, P642, DOI 10.1089/ars.2012.4827	32	31	33	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3315	3322		10.1096/fj.13-227298	http://dx.doi.org/10.1096/fj.13-227298			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603832				2022-12-28	WOS:000329877600036
J	van den Berg, SAA; Heemskerk, MM; Geerling, JJ; van Klinken, JB; Schaap, FG; Bijland, S; Berbee, JFP; van Harmelen, VJA; Pronk, ACM; Schreurs, M; Havekes, LM; Rensen, PCN; van Dijk, KW				van den Berg, Sjoerd A. A.; Heemskerk, Mattijs M.; Geerling, Janine J.; van Klinken, Jan-Bert; Schaap, Frank G.; Bijland, Silvia; Berbee, Jimmy F. P.; van Harmelen, Vanessa J. A.; Pronk, Amanda C. M.; Schreurs, Marijke; Havekes, Louis M.; Rensen, Patrick C. N.; van Dijk, Ko Willems			Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake	FASEB JOURNAL			English	Article						APOA5; central nervous system; hyperphagia; triglyceride metabolism	CENTRAL-NERVOUS-SYSTEM; DENSITY LIPOPROTEIN-TRIGLYCERIDE; LDL-RECEPTOR; RICH LIPOPROTEINS; GENE-EXPRESSION; LIPID DROPLETS; EARLY PHASE; APOC-III; IN-VITRO; BLOOD	Mutations in apolipoprotein A5 (APOA5) have been associated with hypertriglyceridemia in humans and mice. This has been attributed to a stimulating role for APOA5 in lipoprotein lipase-mediated triglyceride hydrolysis and hepatic clearance of lipoprotein remnant particles. However, because of the low APOA5 plasma abundance, we investigated an additional signaling role for APOA5 in high-fat diet (HFD)-induced obesity. Wild-type (WT) and Apoa5(-/-) mice fed a chow diet showed no difference in body weight or 24-h food intake (Apoa5(-/-), 4.5 +/- 0.6 g; WT, 4.2 +/- 0.5 g), while Apoa5(-/-) mice fed an HFD ate more in 24 h (Apoa5(-/-), 2.8 +/- 0.4 g; WT, 2.5 +/- 0.3 g, P<0.05) and became more obese than WT mice. Also, intravenous injection of APOA5-loaded VLDL-like particles lowered food intake (VLDL control, 0.26 +/- 0.04 g; VLDL+APOA5, 0.11 +/- 0.07 g, P<0.01). In addition, the HFD-induced hyperphagia of Apoa5(-/-) mice was prevented by adenovirus-mediated hepatic overexpression of APOA5. Finally, intracerebroventricular injection of APOA5 reduced food intake compared to injection of the same mouse with artificial cerebral spinal fluid (0.40 +/- 0.11 g; APOA5, 0.23 +/- 0.08 g, P<0.01). These data indicate that the increased HFD-induced obesity of Apoa5(-/-) mice as compared to WT mice is at least partly explained by hyperphagia and that APOA5 plays a role in the central regulation of food intake.Van den Berg, S. A. A., Heemskerk, M. M., Geerling, J. J., van Klinken, J.-B., Schaap, F. G., Bijland, S., Berbee, J. F. P., van Harmelen, V. J. A., Pronk, A. C. M., Schreurs, M., Havekes, L. M., Rensen, P. C. N., van Dijk, K. W. Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake.	[van den Berg, Sjoerd A. A.; Heemskerk, Mattijs M.; van Klinken, Jan-Bert; Bijland, Silvia; van Harmelen, Vanessa J. A.; Pronk, Amanda C. M.; van Dijk, Ko Willems] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands; [van den Berg, Sjoerd A. A.; Heemskerk, Mattijs M.; Geerling, Janine J.; van Klinken, Jan-Bert; Berbee, Jimmy F. P.; van Harmelen, Vanessa J. A.; Pronk, Amanda C. M.; Havekes, Louis M.; Rensen, Patrick C. N.; van Dijk, Ko Willems] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, NL-2300 RC Leiden, Netherlands; [Geerling, Janine J.; Berbee, Jimmy F. P.; Havekes, Louis M.; Rensen, Patrick C. N.; van Dijk, Ko Willems] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands; [Schaap, Frank G.] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands; [Berbee, Jimmy F. P.] Univ Patras, Sch Med, Dept Med, Pharmacol Unit, Rion, Greece; [Schreurs, Marijke] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Mol Genet Grp,Med Biol Div, Groningen, Netherlands; [Havekes, Louis M.] Dutch Org Tech Sci Res TNO Qual Life, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Patras; University of Groningen	Heemskerk, MM (corresponding author), Leiden Univ, Med Ctr, Rm S03-46,POB 9600,Albinusdreef 2,S4-P, NL-2300 RC Leiden, Netherlands.	m.m.heemskerk@lumc.nl	Rensen, Patrick C.N./D-7176-2018; van Dijk, Ko Willems/AAT-4681-2021; van den Berg, Sjoerd A/R-9541-2018; van Dijk, Ko Willems/A-1798-2008	Rensen, Patrick C.N./0000-0002-8455-4988; van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394; Schaap, Frank/0000-0002-1597-572X; van den Berg, Sjoerd/0000-0001-8967-376X; van Harmelen, Vanessa/0000-0003-0111-9858; van den Berg, Sjoerd/0000-0001-5937-7505	Center of Medical Systems Biology (CMSB); Netherlands Consortium for Systems Biology (NCSB); Netherlands Diabetes Foundation [DFN2007.00.010]; Netherlands Heart Foundation [2009T038]	Center of Medical Systems Biology (CMSB); Netherlands Consortium for Systems Biology (NCSB); Netherlands Diabetes Foundation; Netherlands Heart Foundation(Netherlands Heart Foundation)	This work was supported by grants from the Center of Medical Systems Biology (CMSB), the Netherlands Consortium for Systems Biology (NCSB) established by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO), and the Netherlands Diabetes Foundation (DFN2007.00.010 to P.C.N.R.). P.C.N.R. is an established investigator of the Netherlands Heart Foundation (grant 2009T038). Furthermore, the authors thank Rick Havinga (University Medical Center Groningen, Groningen, The Netherlands) for surgical and analytical assistance.	Austin MA, 2000, CIRCULATION, V101, P2777, DOI 10.1161/01.CIR.101.24.2777; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Candela P, 2008, ENDOTHELIUM-J ENDOTH, V15, P254, DOI 10.1080/10623320802487759; Chan DC, 2006, ARTERIOSCL THROM VAS, V26, P590, DOI 10.1161/01.ATV.0000203519.25116.54; Chan DC, 2004, CLIN SCI, V107, P233, DOI 10.1042/CS20040109; Chen ES, 2010, LIPIDS, V45, P511, DOI 10.1007/s11745-010-3426-z; Coomans CP, 2011, DIABETES, V60, P3132, DOI 10.2337/db10-1100; Coomans CP, 2011, J LIPID RES, V52, P1712, DOI 10.1194/jlr.M015396; Corella D, 2007, J MOL MED-JMM, V85, P119, DOI 10.1007/s00109-006-0147-0; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; Demeester N, 2000, J LIPID RES, V41, P963; Dhurandhar NV, 2002, J NUTR, V132, P3155, DOI 10.1093/jn/131.10.3155; Dichlberger A, 2007, J LIPID RES, V48, P1451, DOI 10.1194/jlr.C600026-JLR200; Forte TM, 2009, J LIPID RES, V50, pS150, DOI 10.1194/jlr.R800050-JLR200; Fox PT, 2002, NAT REV NEUROSCI, V3, P319, DOI 10.1038/nrn789; FUJIMOTO K, 1993, J CLIN INVEST, V91, P1830, DOI 10.1172/JCI116395; Genoux A, 2005, ARTERIOSCL THROM VAS, V25, P1186, DOI 10.1161/01.ATV.0000163841.85333.83; Gerritsen G, 2005, J LIPID RES, V46, P1466, DOI 10.1194/jlr.M400479-JLR200; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Glatzle J, 2004, AM J PHYSIOL-REG I, V287, pR354, DOI 10.1152/ajpregu.00705.2003; Gotoh K, 2006, AM J PHYSIOL-REG I, V290, pR202, DOI 10.1152/ajpregu.00502.2005; Grosskopf I, 2005, ARTERIOSCL THROM VAS, V25, P2573, DOI 10.1161/01.ATV.0000186189.26141.12; Guardiola M, 2012, NUTR METAB CARDIOVAS, V22, P756, DOI 10.1016/j.numecd.2010.12.003; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847; Hishida A, 2012, ENDOCR J, V59, P589, DOI 10.1507/endocrj.EJ11-0310; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Horvatovich K, 2011, INT J PEDIATR OBES, V6, pE318, DOI 10.3109/17477166.2010.490268; Ishihara M, 2005, J LIPID RES, V46, P2015, DOI 10.1194/jlr.D500018-JLR200; Karagiannides I, 2008, FEBS J, V275, P4796, DOI 10.1111/j.1742-4658.2008.06619.x; Kim JY, 2006, J AM COLL NUTR, V25, P340, DOI 10.1080/07315724.2006.10719544; Koch S, 2001, J LIPID RES, V42, P1143; Lichtenstein L, 2007, ARTERIOSCL THROM VAS, V27, P2420, DOI 10.1161/ATVBAHA.107.151894; McNay DEG, 2012, J CLIN INVEST, V122, P142, DOI 10.1172/JCI43134; Merkel M, 2005, J CLIN INVEST, V115, P2694, DOI 10.1172/JCI26712; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; Mooradian AD, 2009, NAT CLIN PRACT ENDOC, V5, P150, DOI 10.1038/ncpendmet1066; Moreno-Luna R, 2007, J CLIN ENDOCR METAB, V92, P2280, DOI 10.1210/jc.2006-1802; Morgan K, 2004, J BIOL CHEM, V279, P31139, DOI 10.1074/jbc.M400458200; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mullier A, 2010, J COMP NEUROL, V518, P943, DOI 10.1002/cne.22273; Nelbach L, 2008, J LIPID RES, V49, P572, DOI 10.1194/jlr.M700281-JLR200; O'Brien PJ, 2005, CLIN CHEM, V51, P351, DOI 10.1373/clinchem.2004.040824; OKUMURA T, 1994, GASTROENTEROLOGY, V107, P1861, DOI 10.1016/0016-5085(94)90833-8; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; PERONNET F, 1991, CAN J SPORT SCI, V16, P23; Ponten F, 2011, J INTERN MED, V270, P428, DOI 10.1111/j.1365-2796.2011.02427.x; Pruneta-Deloche V, 2005, ATHEROSCLEROSIS, V181, P403, DOI 10.1016/j.atherosclerosis.2005.01.034; Rensen PCN, 1997, J LIPID RES, V38, P1070; Sanchez-Moreno C, 2011, J NUTR, V141, P380, DOI 10.3945/jn.110.130344; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; Schaap FG, 2006, J LIPID RES, V47, P2333, DOI 10.1194/jlr.M500533-JLR200; Schreyer SA, 2002, AM J PHYSIOL-ENDOC M, V282, pE207, DOI 10.1152/ajpendo.2002.282.1.E207; Schutzer SE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010980; Schwinkendorf DR, 2011, INT J OBESITY, V35, P336, DOI 10.1038/ijo.2010.159; Shen L, 2008, DIABETES, V57, P2092, DOI 10.2337/db08-0291; Shimogori T, 2010, NAT NEUROSCI, V13, P767, DOI 10.1038/nn.2545; Shu X, 2008, J LIPID RES, V49, P1670, DOI 10.1194/jlr.M800111-JLR200; Shu X, 2010, BBA-MOL CELL BIOL L, V1801, P605, DOI 10.1016/j.bbalip.2010.02.004; Smith CE, 2010, OBESITY, V18, P327, DOI 10.1038/oby.2009.216; So PW, 2005, INT J OBESITY, V29, P603, DOI 10.1038/sj.ijo.0802917; Tiller G, 2009, ENDOCRINOLOGY, V150, P5373, DOI 10.1210/en.2009-0488; van der Hoogt CC, 2006, BBA-MOL CELL BIOL L, V1761, P213, DOI 10.1016/j.bbalip.2006.01.002; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; van Dijk TH, 2003, ANAL BIOCHEM, V322, P1, DOI 10.1016/j.ab.2003.07.008; von Eckardstein A, 2009, CURR OPIN LIPIDOL, V20, P197, DOI 10.1097/MOL.0b013e32832afd63; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; Whigham LD, 2006, AM J PHYSIOL-REG I, V290, pR190, DOI 10.1152/ajpregu.00479.2005; Wolfgang MJ, 2006, J BIOL CHEM, V281, P37265, DOI 10.1074/jbc.R600016200; Yang L, 2012, J LIPID RES, V53, P1245, DOI 10.1194/jlr.R024117; Zheng XY, 2012, BIOL CHEM, V393, P161, DOI 10.1515/hsz-2011-0259; Ziotopoulou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE838, DOI 10.1152/ajpendo.2000.279.4.E838	72	10	10	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3354	3362		10.1096/fj.12-225367	http://dx.doi.org/10.1096/fj.12-225367			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23650188				2022-12-28	WOS:000329877600040
J	Lee, ST; Gong, SP; Yum, KE; Lee, EJ; Lee, CH; Choi, JH; Kim, DY; Han, H; Kim, KS; Hysolli, E; Ahn, JY; Park, IH; Han, JY; Jeong, JW; Lim, JM				Lee, Seung Tae; Gong, Seung Pyo; Yum, Kyung Eun; Lee, Eun Ju; Lee, Chae Hyun; Choi, Jun Hee; Kim, Dae Yong; Han, Hojae; Kim, Kye-Seong; Hysolli, Eriona; Ahn, Ji Yeon; Park, In-Hyun; Han, Jae Yong; Jeong, Jae-Wook; Lim, Jeong Mook			Transformation of somatic cells into stem cell-like cells under a stromal niche	FASEB JOURNAL			English	Article						genetic and cellular plasticity; colony-forming fibroblasts; reprogramming; pluripotency; microenvironment	FIBROBLASTS; PLURIPOTENCY; INDUCTION; CANCER; TISSUE; POLYPLOIDY; DERIVATION; APOPTOSIS; P53	To study the genomic plasticity of somatic cells without ectopic genetic manipulation, we cultured mouse fibroblasts with ovarian cells, embryonic fibroblasts of different strains, and parthenogenetic embryonic stem cells (ESCs). Of 41 trials, cell aggregation resembling nascent ESC colony from inner cell mass was detected in 9 cases (22%), and 6 cases (67%) yielded fibroblast-derived colonies with ESC morphology. Cells used in coculture provided the critical (P=0.0061) inducing factor for the aggregation. These colony-forming fibroblasts (CFFs) showed similar characteristics to those in ESCs and induced pluripotent stem cells (iPSCs), including pluripotency gene expression, in vitro differentiation, and teratoma formation. Furthermore, CFFs produced somatic chimera, although none showed germline chimerism. CFFs had a tetraploid-like karyotype, and their imprinting patterns differed from parthenogenetic ESCs, thereby confirming their nongermline transmissibility. We observed dysregulation of cell cycle-related proteins, as well as both homologous and heterologous recombination of genomic single-nucleotide polymorphisms in CFFs. Our observations provide information on somatic cell plasticity, resulting in stemness or tumorigenesis, regardless of colony-forming cell progenitors in the fibroblast population. The plasticity of somatic genomes under environmental influences, as well as acquisition of pluripotency by cell fusion, is also implicated.Lee, S. T., Gong, S. P., Yum, K. E., Lee, E. J., Lee, C. H., Choi, J. H., Kim, D. Y., Han, H., Kim, K.-S., Hysolli, E., Ahn, J. Y., Park, I.-H., Han, J. Y., Jeong, J.-W., Lim, J. M. Transformation of somatic cells into stem cell-like cells under a stromal niche.	[Lee, Seung Tae; Gong, Seung Pyo; Yum, Kyung Eun; Lee, Eun Ju; Lee, Chae Hyun; Choi, Jun Hee; Han, Jae Yong; Lim, Jeong Mook] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151742, South Korea; [Yum, Kyung Eun; Lee, Chae Hyun; Choi, Jun Hee; Ahn, Ji Yeon; Han, Jae Yong; Lim, Jeong Mook] Seoul Natl Univ, WCU Biomodulat Program, Seoul 151742, South Korea; [Kim, Dae Yong; Han, Hojae] Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; [Lee, Seung Tae] Kangwon Natl Univ, Dept Anim Biotechnol, Chunchon, South Korea; [Gong, Seung Pyo] Pukyong Natl Univ, Dept Marine Biomat & Aquaculture, Pusan, South Korea; [Lee, Eun Ju] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul 110744, South Korea; [Ahn, Ji Yeon] Seoul Natl Univ Hosp, Canc Res Inst, Seoul 110744, South Korea; [Kim, Kye-Seong] Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul 133791, South Korea; [Hysolli, Eriona; Park, In-Hyun] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Jeong, Jae-Wook] Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Kangwon National University; Pukyong National University; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Hanyang University; Yale University; Michigan State University; Michigan State University College of Human Medicine	Lim, JM (corresponding author), Seoul Natl Univ, WCU Biomodulat Program, Seoul 151742, South Korea.	limjm@snu.ac.kr	Han, Ho Jae/M-1476-2016	Han, Ho Jae/0000-0002-0657-1766; Gong, Seung Pyo/0000-0002-9358-9568; Lee, Seung Tae/0000-0002-8952-3881	World Class University (WCU) Biomodulation Program (Seoul, Korea) [R31-2008-000-10056-0]; Ministry of Education, Science, and Technology, Republic of Korea [20120006091]; Charles Hood Foundation	World Class University (WCU) Biomodulation Program (Seoul, Korea); Ministry of Education, Science, and Technology, Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); Charles Hood Foundation	The authors acknowledge the support from the World Class University (WCU) Biomodulation Program (Seoul, Korea; grant R31-2008-000-10056-0). This study was supported by a grant from the Ministry of Education, Science, and Technology, Republic of Korea (20120006091). I.-H. P. is supported by the Charles Hood Foundation. The authors thank Prof. Yu-Kyung Oh (College of Pharmacology, Seoul National University, Seoul, Korea), Prof. Sung-Gil Chi (Department of Bioscience, Korea University, Seoul, Korea), Prof. Gene Lee (College of Dentistry, Seoul National University), Prof. Dong-Sup Lee (College of Medicine, Seoul National University), and Prof. Jae-Bum Kim (College of Natural Science, Seoul National University) for their contributions of material and technical support and manuscript preparation. The authors greatly appreciate Prof. Dong-Soon Lee for consultation on cytogenetics.	Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1; Bissell MJ, 2008, P NATL ACAD SCI USA, V105, P15637, DOI 10.1073/pnas.0808457105; BOUISSOU H, 1986, B ACAD NAT MED PARIS, V170, P189; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cho HJ, 2010, BLOOD, V116, P386, DOI 10.1182/blood-2010-02-269589; Choi JK, 2012, J POULT SCI, V49, P196, DOI 10.2141/jpsa.010091; Collas P, 2006, STEM CELL REV, V2, P309, DOI 10.1007/BF02698058; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Eyden B, 2004, ULTRASTRUCT PATHOL, V28, P307, DOI 10.1080/019131290882204; Gentric G, 2012, CLIN RES HEPATOL GAS, V36, P29, DOI 10.1016/j.clinre.2011.05.011; Gong SP, 2010, FERTIL STERIL, V93, P2594, DOI 10.1016/j.fertnstert.2009.12.053; Hall B, 2007, INT J HEMATOL, V86, P8, DOI 10.1532/IJH97.06230; Harlow CR, 2002, MOL CELL ENDOCRINOL, V187, P23, DOI 10.1016/S0303-7207(01)00702-X; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hubner K, 2003, SCIENCE, V300, P1251, DOI 10.1126/science.1083452; Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864; Kieusseian A, 2012, DEVELOPMENT, V139, P3521, DOI 10.1242/dev.079210; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Kim JW, 2012, CANCER RES, V72, P3187, DOI 10.1158/0008-5472.CAN-12-0534; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Lee ST, 2012, BIOMATERIALS, V33, P8934, DOI 10.1016/j.biomaterials.2012.08.062; Lee ST, 2010, BIOMATERIALS, V31, P1219, DOI 10.1016/j.biomaterials.2009.10.054; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rajasingh J, 2008, CIRC RES, V102, pE107, DOI 10.1161/CIRCRESAHA.108.176115; Robinton DA, 2012, NATURE, V481, P295, DOI 10.1038/nature10761; Schauer IG, 2011, NEOPLASIA, V13, P393, DOI 10.1593/neo.101720; Shono T, 2002, CANCER RES, V62, P1069; Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang K, 1999, P NATL ACAD SCI USA, V96, P10016, DOI 10.1073/pnas.96.18.10016; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Wang XL, 2006, STEM CELLS, V24, P482, DOI 10.1634/stemcells.2005-0219; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang GC, 2012, STEM CELLS DEV, V21, P955, DOI 10.1089/scd.2011.0649; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	41	8	8	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2644	2656		10.1096/fj.12-223065	http://dx.doi.org/10.1096/fj.12-223065			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23580613	Green Published			2022-12-28	WOS:000328841000014
J	Sedlak, F; Sacha, P; Blechova, M; Brezinova, A; Safarik, M; Sebestik, J; Konvalinka, J				Sedlak, Frantisek; Sacha, Pavel; Blechova, Miroslava; Brezinova, Anna; Safarik, Martin; Sebestik, Jaroslav; Konvalinka, Jan			Glutamate carboxypeptidase II does not process amyloid-beta peptide	FASEB JOURNAL			English	Article						PSMA; Alzheimer's disease; disaggregation; exopeptidase; substrate specificity; depsipeptide	CLEARANCE	The accumulation of amyloid- (A) peptide is thought to be a major causative mechanism of Alzheimer's disease. A accumulation could be caused by dysregulated processing of amyloid precursor protein, yielding excessive amounts of A, and/or by inefficient proteolytic degradation of the peptide itself. Several proteases have been described as A degradation enzymes, most notably metalloendopeptidases, aspartic endopeptidases, and some exopeptidases. Recently a report suggested that another metallopeptidase, glutamate carboxypeptidase II (GCPII), can also cleave A. GCPII is a zinc exopeptidase that cleaves glutamate from N-acetyl-l-aspartyl-l-glutamate in the central nervous system and from pteroylpoly--glutamate in the jejunum. GCPII has been proposed as a promising therapeutic target for disorders caused by glutamate neurotoxicity. However, an A-degrading activity of GCPII would compromise potential pharmaceutical use of GCPII inhibitors, because the enzyme inhibition might lead to increased A levels and consequently to Alzheimer's disease. Therefore, we analyzed the reported A-degrading activity of GCPII using highly purified recombinant enzyme and synthetic A. We did not detect any A degradation activity of GCPII or its homologue even under prolonged incubation at a high enzyme to substrate ratio. These results are in good agreement with the current detailed structural understanding of the substrate specificity and enzyme-ligand interactions of GCPII.Sedlak, F., Sacha, P., Blechova, M., Bezinova, A., Safaik, M., Sebestik, J., Konvalinka, J. Glutamate carboxypeptidase II does not process amyloid- peptide.	[Sedlak, Frantisek; Sacha, Pavel; Blechova, Miroslava; Brezinova, Anna; Safarik, Martin; Sebestik, Jaroslav; Konvalinka, Jan] Gilead Sci, Prague, Czech Republic; [Sedlak, Frantisek; Sacha, Pavel; Blechova, Miroslava; Brezinova, Anna; Safarik, Martin; Sebestik, Jaroslav; Konvalinka, Jan] Acad Sci Czech Republ, Res Ctr, IOCB, Prague, Czech Republic; [Sacha, Pavel; Konvalinka, Jan] Charles Univ Prague, Fac Sci, Dept Biochem, Prague, Czech Republic	Gilead Sciences; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Charles University Prague	Konvalinka, J (corresponding author), Inst Organ Chem & Biochem, Flemingovo 2, Prague 16610 6, Czech Republic.	konval@uochb.cas.cz	Konvalinka, Jan/G-7518-2014; Sebestik, Jaroslav/C-9166-2012; Sedlak, Frantisek/T-1788-2019; Sedlak, Frantisek/H-1420-2014; Sacha, Pavel/G-9729-2014	Sebestik, Jaroslav/0000-0002-0614-2064; Sacha, Pavel/0000-0001-6198-9826; Sedlak, Frantisek/0000-0002-5565-8462; Konvalinka, Jan/0000-0003-0695-9266	Grant Agency of the Czech Republic [P304/12/0847]	Grant Agency of the Czech Republic(Grant Agency of the Czech Republic)	The authors thank Tomas Knedlik for the GCPII activity determination by radioenzymatic assay and Radko Soucek for skillful amino acid analysis of A beta<INF>1-42</INF> samples. This research was funded by grant P304/12/0847 from the Grant Agency of the Czech Republic.	Barinka C, 2004, EUR J BIOCHEM, V271, P2782, DOI 10.1111/j.1432-1033.2004.04209.x; Barinka C, 2012, CURR MED CHEM, V19, P856, DOI 10.2174/092986712799034888; Barinka C, 2002, J NEUROCHEM, V80, P477, DOI 10.1046/j.0022-3042.2001.00715.x; Barinka C, 2008, J MOL BIOL, V376, P1438, DOI 10.1016/j.jmb.2007.12.066; Carpino LA, 2004, TETRAHEDRON LETT, V45, P7519, DOI 10.1016/j.tetlet.2004.07.162; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Hamazaki H, 1996, FEBS LETT, V396, P139, DOI 10.1016/0014-5793(96)01087-3; Hlouchova K, 2012, CURR MED CHEM, V19, P1316, DOI 10.2174/092986712799462676; Hlouchova K., 2012, PROTEINASES DRUG TAR, P63; Hlouchova K, 2007, J NEUROCHEM, V101, P682, DOI 10.1111/j.1471-4159.2006.04341.x; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; Kim MJ, 2010, FASEB J, V24, P4491, DOI 10.1096/fj.09-148825; Klusak V, 2009, BIOCHEMISTRY-US, V48, P4126, DOI 10.1021/bi900220s; Numata K, 2010, BIOCHEMISTRY-US, V49, P3254, DOI 10.1021/bi902134p; O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613; O'Nuallain B, 2006, METHOD ENZYMOL, V413, P34, DOI 10.1016/S0076-6879(06)13003-7; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Plechanovova A, 2011, J MED CHEM, V54, P7535, DOI 10.1021/jm200807m; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Selkoe DJ, 2001, ALZHEIMER'S DISEASE, P421, DOI 10.1002/0470846453.ch38; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Thies W, 2011, ALZHEIMERS DEMENT, V7, P175, DOI [10.1016/j.jalz.2011.02.004, 10.1016/j.jalz.2011.02.002]; Tykvart J, 2012, PROTEIN EXPRES PURIF, V82, P106, DOI 10.1016/j.pep.2011.11.016; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; Wang YJ, 2006, DRUG DISCOV TODAY, V11, P931, DOI 10.1016/j.drudis.2006.08.004; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Yamin R, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-33; Yoo C, 2010, FEBS LETT, V584, P4157, DOI 10.1016/j.febslet.2010.08.048; Zagorski MG, 1999, METHOD ENZYMOL, V309, P189	31	3	3	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2626	2632		10.1096/fj.12-225094	http://dx.doi.org/10.1096/fj.12-225094			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23525279				2022-12-28	WOS:000328841000012
J	Gouspillou, G; Sgarioto, N; Kapchinsky, S; Purves-Smith, F; Norris, B; Pion, CH; Barbat-Artigas, S; Lemieux, F; Taivassalo, T; Morais, JA; Aubertin-Leheudre, M; Hepple, RT				Gouspillou, Gilles; Sgarioto, Nicolas; Kapchinsky, Sophia; Purves-Smith, Fennigje; Norris, Brandon; Pion, Charlotte H.; Barbat-Artigas, Sebastien; Lemieux, Francois; Taivassalo, Tanja; Morais, Jose A.; Aubertin-Leheudre, Mylene; Hepple, Russell T.			Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans	FASEB JOURNAL			English	Article						reactive oxygen species; sarcopenia; aging; mitophagy	HUMAN SKELETAL-MUSCLE; LYSOSOMAL AXIS THEORY; OXIDATIVE CAPACITY; DEGENERATIVE DISEASES; DNA MUTATIONS; IN-VIVO; AGE; APOPTOSIS; PORE; ACCUMULATION	Mitochondrial dysfunction is implicated in skeletal muscle atrophy and dysfunction with aging, with strong support for an increased mitochondrial-mediated apoptosis in sedentary rodent models. Whether this applies to aged human muscle is unknown, nor is it clear whether these changes are caused by sedentary behavior. Thus, we examined mitochondrial function [respiration, reactive oxygen species (ROS) emission, and calcium retention capacity (CRC)] in permeabilized myofibers obtained from vastus lateralis muscle biopsies of healthy physically active young (23.7 +/- 2.7 yr; mean +/- sd) and older (71.2 +/- 4.9 yr) men. Although mitochondrial ROS and maximal respiratory capacity were unaffected, the acceptor control ratio was reduced by 18% with aging, suggesting mild uncoupling of oxidative phosphorylation. CRC was reduced by 50% with aging, indicating sensitization of the mitochondrial permeability transition pore (mPTP) to apoptosis. Consistent with the mPTP sensitization, older muscles showed a 3-fold greater fraction of endonuclease G (a mitochondrial proapoptotic factor)-positive myonuclei. Aged muscles also had lower mitophagic potential, based on a 43% reduction in Parkin to the voltage-dependent anion channel (VDAC) protein ratio. Collectively, these results show that mitochondrial-mediated apoptotic signaling is increased in older human muscle and suggest that accumulation of dysfunctional mitochondria with exaggerated apoptotic sensitivity is due to impaired mitophagy.-Gouspillou, G., Sgarioto, N., Kapchinsky, S., Purves-Smith, F., Norris, B., Pion, C. H., Barbat-Artigas, S., Lemieux, F., Taivassalo, T., Morais, J. A., Aubertin-Leheudre, M., Hepple, R. T. Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans.	[Gouspillou, Gilles; Sgarioto, Nicolas; Norris, Brandon; Morais, Jose A.; Hepple, Russell T.] McGill Univ, McGill Univ Hlth Ctr, Montreal, PQ, Canada; [Kapchinsky, Sophia; Purves-Smith, Fennigje; Taivassalo, Tanja; Hepple, Russell T.] McGill Univ, Dept Kinesiol, Montreal, PQ, Canada; [Hepple, Russell T.] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; [Gouspillou, Gilles; Pion, Charlotte H.; Barbat-Artigas, Sebastien; Lemieux, Francois; Aubertin-Leheudre, Mylene] Univ Quebec, Dept Kinanthropol, Montreal, PQ H3C 3P8, Canada	McGill University; McGill University; McGill University; University of Quebec; University of Quebec Montreal	Hepple, RT (corresponding author), Royal Victoria Hosp, Dept Crit Care Med, 687 Pine Ave W, Montreal, PQ H3A 1A, Canada.	russell.hepple@mcgill.ca		Gouspillou, Gilles/0000-0002-8543-3619; Hepple, Russell/0000-0003-3640-486X	Canadian Institutes of Health Research [MOP125986, MOP119583]; Quebec Network for Research on Aging; Canadian Foundation for Innovation; Fonds de Recherche du Quebec-Sante; McGill University Health Center	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Quebec Network for Research on Aging; Canadian Foundation for Innovation(Canada Foundation for Innovation); Fonds de Recherche du Quebec-Sante(Fonds de la Recherche en Sante du Quebec); McGill University Health Center	Operating funds were provided for this project from the Canadian Institutes of Health Research (MOP125986 and MOP119583 to R.T.H.) and a pilot grant from the Quebec Network for Research on Aging (to M.A.-L. and R.T.H.). R.T.H. was also supported by a Leaders Opportunity Fund from the Canadian Foundation for Innovation and a Chercheurs Boursiers Senior Award from the Fonds de Recherche du Quebec-Sante. G.G. was supported by a postdoctoral fellowship from the McGill University Health Center.	Amara CE, 2007, P NATL ACAD SCI USA, V104, P1057, DOI 10.1073/pnas.0610131104; Brenner C, 2012, CIRC RES, V111, P1237, DOI 10.1161/CIRCRESAHA.112.265942; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Capel F, 2005, MECH AGEING DEV, V126, P505, DOI 10.1016/j.mad.2004.11.001; Chabi B, 2008, AGING CELL, V7, P2, DOI 10.1111/j.1474-9726.2007.00347.x; Conley KE, 2000, J PHYSIOL-LONDON, V526, P203, DOI 10.1111/j.1469-7793.2000.t01-1-00203.x; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Ghosh S, 2011, DIABETES, V60, P2051, DOI 10.2337/db11-0121; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Gouspillou G, 2014, AGING CELL, V13, P39, DOI 10.1111/acel.12147; Gouspillou G, 2010, BBA-BIOENERGETICS, V1797, P143, DOI 10.1016/j.bbabio.2009.09.004; Hafner AV, 2010, AGING-US, V2, P914, DOI 10.18632/aging.100252; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Hanson BJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1281, DOI 10.1177/002215540205001001; Hepple RT, 2011, SARCOPENIA-AGE-RELATED MUSCLE WASTING AND WEAKNESS: MECHANISMS AND TREATMENTS, P135, DOI 10.1007/978-90-481-9713-2_7; Hiona A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011468; Hutter E, 2007, AGING CELL, V6, P245, DOI 10.1111/j.1474-9726.2007.00282.x; Hunter SK, 1999, J APPL PHYSIOL, V86, P1858, DOI 10.1152/jappl.1999.86.6.1858; Hernandez-Alvarez MI, 2010, DIABETES CARE, V33, P645, DOI 10.2337/dc09-1305; Joseph AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069327; Joseph AM, 2012, AGING CELL, V11, P801, DOI 10.1111/j.1474-9726.2012.00844.x; Karakelides H, 2010, DIABETES, V59, P89, DOI 10.2337/db09-0591; Konopka AR, 2014, J GERONTOL A-BIOL, V69, P371, DOI 10.1093/gerona/glt107; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61; Leeuwenburgh C, 2005, AM J PHYSIOL-REG I, V288, pR1288, DOI 10.1152/ajpregu.00576.2004; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; Mansouri A, 2006, MECH AGEING DEV, V127, P298, DOI 10.1016/j.mad.2005.11.004; Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005; Marzetti E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032829; Marzetti E, 2010, BBA-GEN SUBJECTS, V1800, P235, DOI 10.1016/j.bbagen.2009.05.007; Narayanan N, 1996, AM J PHYSIOL-CELL PH, V271, pC1032, DOI 10.1152/ajpcell.1996.271.4.C1032; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Nauratil M, 2008, EXP CELL RES, V314, P164, DOI 10.1016/j.yexcr.2007.09.013; Picard M, 2008, AM J PHYSIOL-REG I, V295, pR659, DOI 10.1152/ajpregu.90357.2008; Picard M, 2012, AM J PHYSIOL-CELL PH, V302, pC629, DOI 10.1152/ajpcell.00368.2011; Picard M, 2011, AGING CELL, V10, P1047, DOI 10.1111/j.1474-9726.2011.00745.x; Picard M, 2011, J PHYSIOL-LONDON, V589, P4413, DOI 10.1113/jphysiol.2011.212712; Picard Martin, 2010, Aging Cell, V9, P1032, DOI 10.1111/j.1474-9726.2010.00628.x; Piquereau J, 2013, AUTOPHAGY, V9, P1837, DOI 10.4161/auto.26502; Purves-Smith FM, 2012, EXP GERONTOL, V47, P913, DOI 10.1016/j.exger.2012.07.013; Rasmussen UF, 2003, PFLUG ARCH EUR J PHY, V446, P270, DOI 10.1007/s00424-003-1022-2; Rowan SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029082; Rowan SL, 2011, EXP GERONTOL, V46, P660, DOI 10.1016/j.exger.2011.03.005; Russ DW, 2004, SPORTS MED, V34, P221, DOI 10.2165/00007256-200434040-00002; Safdar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010778; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Selman C, 2003, BIOGERONTOLOGY, V4, P141, DOI 10.1023/A:1024149923693; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Sun Y, 2012, J BIOL CHEM, V287, P40652, DOI 10.1074/jbc.M112.419721; Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282; Terman A, 2004, EXP GERONTOL, V39, P701, DOI 10.1016/j.exger.2004.01.005; Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598; Tonkonogi M, 2000, J PHYSIOL-LONDON, V528, P379, DOI 10.1111/j.1469-7793.2000.00379.x; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779; Varanyuwatana P, 2012, MITOCHONDRION, V12, P120, DOI 10.1016/j.mito.2011.04.006; Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Whitman SA, 2005, PFLUG ARCH EUR J PHY, V450, P437, DOI 10.1007/s00424-005-1473-8; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028	66	126	128	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1621	1633		10.1096/fj.13-242750	http://dx.doi.org/10.1096/fj.13-242750			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371120				2022-12-28	WOS:000335344300011
J	You, ZP; Al Kindi, H; Abdul-Karim, A; Barrette, PO; Schwertani, A				You, Zhipeng; Al Kindi, Hamood; Abdul-Karim, Ahmad; Barrette, Piere-Olivier; Schwertani, Adel			Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice	FASEB JOURNAL			English	Article						UT; heart; ob; ob	SMOOTH-MUSCLE-CELLS; PERFUSED RAT PANCREAS; MILDLY OXIDIZED LDL; CONFOCAL MICROSCOPY; DIABETES-MELLITUS; NUCLEAR-MEMBRANES; INSULIN-RELEASE; MOUSE HEART; HYPERTENSION; ATHEROSCLEROSIS	The metabolic syndrome is defined by the presence of hyperlipidemia, obesity, hypertension, and diabetes. The syndrome is associated with significant cardiovascular morbidity and mortality. The aim of the present study was to determine the role of the vasoactive peptide urotensin II (UII) in the pathogenesis of the metabolic syndrome. We used obese mice (ob/ob) to determine the effect of UII receptor (UT) blockage on the different facets of the metabolic syndrome with special emphasis on cardiac function. Our data demonstrate a significant increase in UII and UT expression in the myocardium of obese mice accompanied by a significant decrease in sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) expression, as well as intracellular Na+ and Ca2+ compared with wild-type mice (P<0.05). Treatment of ob/ob mice with the UII receptor antagonist SB657510 significantly improved glucose levels, blood pressure, hyperlipidemia, expression of myocardial SERCA2a, intracellular Na+ and Ca2+ and cardiac function in association with a decrease in weight gain, and mammalian target of rapamycin (mTOR) and sodium/hydrogen exchanger 1 (NHE-1) protein expression compared with vehicle (P<0.05). These findings demonstrate an important role for UII in the pathogenesis of the metabolic syndrome and suggest that the use of UT receptor antagonists may provide a new therapeutic tool for the treatment of this syndrome.You, Z., Al Kindi, H., Abdul-Karim, A., Barrette, P.-O., Schwertani, A. Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice.	[You, Zhipeng; Abdul-Karim, Ahmad; Barrette, Piere-Olivier; Schwertani, Adel] McGill Univ, Ctr Hlth, Div Cardiol, Montreal, PQ H3G 1A4, Canada; [Al Kindi, Hamood] McGill Univ, Ctr Hlth, Div Cardiac Surg, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	Schwertani, A (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Ste C9-166,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	adel.schwertani@mcgill.ca			Canadian Institute of Health Research; Heart and Stroke Foundation of Quebec	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Quebec	This work was supported by the Canadian Institute of Health Research and the Heart and Stroke Foundation of Quebec. The authors thank GlaxoSmithKline for providing SB657510. The authors declare no conflicts of interest.	Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Ban Y, 2009, J ATHEROSCLER THROMB, V16, P179, DOI 10.5551/jat.E608; Barrette Pierre-Olivier, 2012, Front Endocrinol (Lausanne), V3, P165, DOI 10.3389/fendo.2012.00165; Belke DD, 2004, DIABETES, V53, P3201, DOI 10.2337/diabetes.53.12.3201; Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533; Bkaily G, 2004, CAN J PHYSIOL PHARM, V82, P805, DOI 10.1139/Y04-119; Bkaily G, 1997, MOL CELL BIOCHEM, V172, P171, DOI 10.1023/A:1006840228104; Bkaily G, 1999, METHOD ENZYMOL, V307, P119; Bkaily G, 2006, CAN J PHYSIOL PHARM, V84, P431, DOI 10.1139/Y06-002; Bkaily G, 2009, CAN J PHYSIOL PHARM, V87, P108, DOI 10.1139/Y08-115; Bouchentouf M, 2011, CYTOKINE, V56, P732, DOI 10.1016/j.cyto.2011.09.023; Bouchentouf M, 2010, CELL TRANSPLANT, V19, P369, DOI 10.3727/096368909X484266; Cheung BMY, 2004, J HYPERTENS, V22, P1341, DOI 10.1097/01.hjh.0000125452.28861.f1; Conlon JM, 1996, J EXP ZOOL, V275, P226, DOI 10.1002/(SICI)1097-010X(19960601/15)275:2/3<226::AID-JEZ14>3.3.CO;2-Y; Coulouarn Y, 1999, FEBS LETT, V457, P28, DOI 10.1016/S0014-5793(99)01003-0; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Grundy SM, 1999, AM J CARDIOL, V83, p25F; Gruson D, 2010, J CLIN HYPERTENS, V12, P653, DOI 10.1111/j.1751-7176.2010.00336.x; Harris GS, 2007, PEPTIDES, V28, P1483, DOI 10.1016/j.peptides.2007.04.018; Hileeto D, 2002, DIABETES-METAB RES, V18, P386, DOI 10.1002/dmrr.322; Hillier C, 2001, CIRCULATION, V103, P1378, DOI 10.1161/01.CIR.103.10.1378; Hinton RB, 2008, AM J PHYSIOL-HEART C, V294, pH2480, DOI 10.1152/ajpheart.91431.2007; Hirose T, 2009, PEPTIDES, V30, P1124, DOI 10.1016/j.peptides.2009.02.009; Iglarz M, 2003, HYPERTENSION, V42, P737, DOI 10.1161/01.HYP.0000083511.91817.B1; Karmazyn M, 2013, J MOL CELL CARDIOL, V61, P77, DOI 10.1016/j.yjmcc.2013.02.006; Kato K, 2010, J CARDIOVASC PHARM, V55, P191, DOI 10.1097/FJC.0b013e3181cf0074; Kiss RS, 2011, PEPTIDES, V32, P956, DOI 10.1016/j.peptides.2011.02.016; Kurtz TW, 2005, ARTERIOSCL THROM VAS, V25, P478, DOI 10.1161/01.ATV.0000153088.15433.8f; Kylin E., 1923, ZENTRALBLATT INNERE, V44, P105, DOI DOI 10.1002/(SICI)1096-9136(199807)15:7<539::; Lim M, 2004, CIRCULATION, V109, P1212, DOI 10.1161/01.CIR.0000121326.69153.98; Maddaford TG, 2010, AM J PHYSIOL-HEART C, V298, pH360, DOI 10.1152/ajpheart.00932.2009; Matsushita M, 2001, J HYPERTENS, V19, P2185, DOI 10.1097/00004872-200112000-00011; Nothacker HP, 1999, NAT CELL BIOL, V1, P383, DOI 10.1038/14081; Ong KL, 2006, PEPTIDES, V27, P1659, DOI 10.1016/j.peptides.2006.02.008; Pakala R, 2008, CARDIOVASC REVASCULA, V9, P166, DOI 10.1016/j.carrev.2008.02.001; Papadopoulos P, 2009, ATHEROSCLEROSIS, V204, P395, DOI 10.1016/j.atherosclerosis.2008.10.044; PEARSON D, 1980, P NATL ACAD SCI-BIOL, V77, P5021, DOI 10.1073/pnas.77.8.5021; Ross B, 2010, AM J PHYSIOL-REG I, V298, pR1156, DOI 10.1152/ajpregu.00706.2009; Russell FD, 2004, J PHARMACOL EXP THER, V310, P209, DOI 10.1124/jpet.104.065425; Saez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030968; Silvestre R, 2004, EUR J ENDOCRINOL, V151, P803, DOI 10.1530/eje.0.1510803; Silvestre RA, 2001, HORM METAB RES, V33, P379, DOI 10.1055/s-2001-15414; Srinivasan K, 2007, INDIAN J MED RES, V125, P451; Sun Hong-xia, 2002, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V24, P223; Totsune K, 2003, CLIN SCI, V104, P1, DOI 10.1042/CS20020271; VAGUE J, 1947, PRESSE MED, V55, P339; Wang HX, 2009, REGUL PEPTIDES, V154, P85, DOI 10.1016/j.regpep.2009.01.004; Watanabe T, 2001, CIRCULATION, V103, P1440, DOI 10.1161/01.CIR.103.10.1440; Watanabe T, 2001, CIRCULATION, V104, P16, DOI 10.1161/hc2601.092848; Watanabe T, 2006, HYPERTENS RES, V29, P375, DOI 10.1291/hypres.29.375; Watanabe T, 2006, HYPERTENS RES, V29, P821, DOI 10.1291/hypres.29.821; Wenyi Z, 2003, DIABETOLOGIA, V46, P972, DOI 10.1007/s00125-003-1145-1; Wold LE, 2006, FREE RADICAL BIO MED, V40, P1419, DOI 10.1016/j.freeradbiomed.2005.12.009; You ZP, 2012, ARTERIOSCL THROM VAS, V32, P1809, DOI 10.1161/ATVBAHA.112.252973; Zhu Fang, 2002, Zhonghua Yi Xue Za Zhi, V82, P1473	56	13	14	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1210	1220		10.1096/fj.13-236471	http://dx.doi.org/10.1096/fj.13-236471			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24297699				2022-12-28	WOS:000335324800016
J	Hikiji, H; Endo, D; Horie, K; Harayama, T; Akahoshi, N; Igarashi, H; Kihara, Y; Yanagida, K; Takeda, J; Koji, T; Shimizu, T; Ishii, S				Hikiji, Hisako; Endo, Daisuke; Horie, Kyoji; Harayama, Takeshi; Akahoshi, Noriyuki; Igarashi, Hidemitsu; Kihara, Yasuyuki; Yanagida, Keisuke; Takeda, Junji; Koji, Takehiko; Shimizu, Takao; Ishii, Satoshi			TDAG8 activation inhibits osteoclastic bone resorption	FASEB JOURNAL			English	Article						proton-sensing receptor; GPR65; Rho; cell morphology; T-cell death-associated gene 8	PROTEIN-COUPLED RECEPTOR; INDUCED THYMOCYTE APOPTOSIS; EXTRACELLULAR ACIDIFICATION; CATION CHANNELS; GENE 8; OSTEOPOROSIS; ACID; MICE; LOCALIZATION; OVARIECTOMY	Although the roles of acids in bone metabolism are well characterized, the function of proton-sensing receptors in bone metabolism remains to be explored. In this study, we evaluated the role of proton-sensing receptor T-cell death-associated gene 8 (TDAG8) in osteoclastic activity during bone loss after ovariectomy. Through observations of bone mineral content, we found that pathological bone resorption was significantly exacerbated in mice homozygous for a gene trap mutation in the Tdag8 gene. Furthermore, osteoclasts from the homozygous mutant mice resorbed calcium in vitro more than the osteoclasts from the heterozygous mice did. Impaired osteoclast formation under acidic conditions was ameliorated in cultures of bone marrow cells by Tdag8 gene mutation. Extracellular acidification changed the cell morphology of osteoclasts via the TDAG8-Rho signaling pathway. These results suggest that the enhancement of TDAG8 function represents a new strategy for preventing bone resorption diseases, such as osteoporosis.Hikiji, H., Endo, D., Horie, K., Harayama, T., Akahoshi, N., Igarashi, H., Kihara, Y., Yanagida, K., Takeda, J., Koji, T., Shimizu, T., Satoshi, I. TDAG8 activation inhibits osteoclastic bone resorption.	[Hikiji, Hisako; Harayama, Takeshi; Kihara, Yasuyuki; Yanagida, Keisuke; Shimizu, Takao; Ishii, Satoshi] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan; [Endo, Daisuke; Koji, Takehiko] Nagasaki Univ, Grad Sch Biomed Sci, Dept Histol & Cell Biol, Nagasaki 852, Japan; [Horie, Kyoji; Takeda, Junji] Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Osaka, Japan; [Akahoshi, Noriyuki; Igarashi, Hidemitsu; Ishii, Satoshi] Akita Univ, Grad Sch Med, Dept Immunol, Akita 0108543, Japan	University of Tokyo; Nagasaki University; Osaka University; Akita University	Ishii, S (corresponding author), Akita Univ, Grad Sch Med, Dept Immunol, 1-1-1 Hondo, Akita 0108543, Japan.	satishii@med.akita-u.ac.jp	Harayama, Takeshi/AAD-8852-2022; Shimizu, Takao/AAV-7052-2021; Kihara, Yasuyuki/C-8801-2011	Harayama, Takeshi/0000-0003-2255-4197; Kihara, Yasuyuki/0000-0001-7462-3006; Horie, Kyoji/0000-0001-9036-8180	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Health and Labor Sciences research grant for the research on allergic disease and immunology from the Ministry of Health, Labor, and Welfare of Japan; Ministry of Health, Labor, and Welfare of Japan; Grants-in-Aid for Scientific Research [23390467, 25116703] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Health and Labor Sciences research grant for the research on allergic disease and immunology from the Ministry of Health, Labor, and Welfare of Japan; Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank K. Ohori, C. Kanokoda, and S. Kondo for technical assistance and all the members of their laboratory (Department of Biochemistry and Molecular Biology, University of Tokyo) for support and valuable suggestions. This work was supported in part by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to T. S., S. I., and H. H.), a Health and Labor Sciences research grant for the research on allergic disease and immunology from the Ministry of Health, Labor, and Welfare of Japan (to S. I.), and a grant to the Respiratory Failure Research Group from the Ministry of Health, Labor, and Welfare of Japan (to S. I.). The authors declare no conflicts of interest.	ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; Biel M, 2009, PHYSIOL REV, V89, P847, DOI 10.1152/physrev.00029.2008; Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307; Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.e04-12-1117; Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200; Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010-0006; Hikiji H, 2004, J CLIN INVEST, V114, P85, DOI 10.1172/JC1200420504; Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003; Horie K, 2003, MOL CELL BIOL, V23, P9189, DOI 10.1128/MCB.23.24.9189-9207.2003; Horne WC, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P221, DOI 10.1016/B978-0-12-373884-4.00031-8; Ihara Y, 2010, P NATL ACAD SCI USA, V107, P17309, DOI 10.1073/pnas.1001165107; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; Iwai K, 2007, J BONE MINER RES, V22, P1612, DOI 10.1359/JBMR.070612; KOJI T, 1993, ENDOCRINOLOGY, V132, P382, DOI 10.1210/en.132.1.382; Kottyan LC, 2009, BLOOD, V114, P2774, DOI 10.1182/blood-2009-05-220681; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; MacLean C, 2008, ANN INTERN MED, V148, P197, DOI 10.7326/0003-4819-148-3-200802050-00198; Mogi C, 2009, J IMMUNOL, V182, P3243, DOI 10.4049/jimmunol.0803466; MORSE A, 1945, J DENT RES, V24, P143, DOI 10.1177/00220345450240030501; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195; Osako MK, 2010, CIRC RES, V107, P466, DOI 10.1161/CIRCRESAHA.110.216846; Pereverzev A, 2008, BONE, V42, P150, DOI 10.1016/j.bone.2007.08.044; Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964; Radu CG, 2006, MOL CELL BIOL, V26, P668, DOI 10.1128/MCB.26.2.668-677.2006; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seuwen K, 2006, J RECEPT SIG TRANSD, V26, P599, DOI 10.1080/10799890600932220; Shibata K, 2000, HISTOCHEM CELL BIOL, V113, P153, DOI 10.1007/s004180050434; Tosa N, 2003, INT IMMUNOL, V15, P741, DOI 10.1093/intimm/dxg070; Turner RT, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P855, DOI 10.1016/B978-0-12-373884-4.00057-4; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Usui M, 2004, P NATL ACAD SCI USA, V101, P6653, DOI 10.1073/pnas.0303093101; Vaananen HK, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P193, DOI 10.1016/B978-0-12-373884-4.00030-6; Vennekens R, 2008, CURR PHARM DESIGN, V14, P18; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Yang DQ, 2012, J BONE MINER RES, V27, P1695, DOI 10.1002/jbmr.1623; Yang MH, 2006, J BIOL CHEM, V281, P23598, DOI 10.1074/jbc.M602191200; YOSHII A, 1995, J HISTOCHEM CYTOCHEM, V43, P321, DOI 10.1177/43.3.7532657	44	25	26	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					871	879		10.1096/fj.13-233106	http://dx.doi.org/10.1096/fj.13-233106			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24221084				2022-12-28	WOS:000331072200032
J	El Osta, M; Liu, ML; Adada, M; Senkal, CE; Idkowiak-Baldys, J; Obeid, LM; Clarke, CJ; Hannun, YA				El Osta, Mohamad; Liu, Mengling; Adada, Mohamad; Senkal, Can E.; Idkowiak-Baldys, Jolanta; Obeid, Lina M.; Clarke, Christopher J.; Hannun, Yusuf A.			Sustained PKC beta II activity confers oncogenic properties in a phospholipase D-and mTOR-dependent manner	FASEB JOURNAL			English	Article						protein kinase C; proliferation; migration	PROTEIN-KINASE-C; P70 S6 KINASE; BREAST-CANCER CELLS; RECYCLING ENDOSOMES; PERINUCLEAR REGION; PLASMA-MEMBRANE; SEQUESTRATION; PHOSPHORYLATION; ENZASTAURIN; MECHANISMS	Protein kinase C (PKC) is a family of serine/threonine kinases implicated in a variety of physiological processes. We have shown previously that sustained activation of the classical PKC and PKCII induces their phospholipase D (PLD)-dependent internalization and translocation to a subset of the recycling endosomes defined by the presence of PKC and PLD (the pericentrion), which results in significant differences in phosphorylation of PKC substrates. Here, we have investigated the biological consequences of sustained PKC activity and the involvement of PLD in this process. We find that sustained activation of PKC results in activation of the mammalian target of rapamycin (mTOR)/S6 kinase pathway in a PLD- and endocytosis-dependent manner, with both pharmacologic inhibitors and siRNA implicating the PLD2 isoform. Notably, dysregulated overexpression of PKCII in A549 lung cancer cells was necessary for the enhanced proliferation and migration of these cancer cells. Inhibition of PKCII with enzastaurin reduced A549 cell proliferation by >60% (48 h) and migration by >50%. These biological effects also required both PLD activity and mTOR function, with both the PLD inhibitor FIPI and rapamycin reducing cell growth by >50%. Reciprocally, forced overexpression of wild-type PKCII, but not an F666D mutant that cannot interact with PLD, was sufficient to enhance cell growth and increase migration of noncancerous HEK cells; indeed, both properties were almost doubled when compared to vector control and PKC-F666D-overexpressing cells. Notably, this condition was also dependent on both PLD and mTOR activity. In summary, these data define a PKC-driven oncogenic signaling pathway that requires both PLD and mTOR, and suggest that inhibitors of PLD or mTOR would be beneficial in cancers where PKC overexpression is a contributing or driving factor.El Osta, M., Liu, M. Adada, M., Senkal, C. E., Idkowiak-Baldys, J., Obeid, L. M., Clarke, C. J., Hannun, Y. A. Sustained PKCII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.	[El Osta, Mohamad; Idkowiak-Baldys, Jolanta] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Liu, Mengling; Adada, Mohamad; Senkal, Can E.; Obeid, Lina M.; Clarke, Christopher J.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Obeid, Lina M.] Northport Vet Affairs Med Ctr, Northport, NY USA	Medical University of South Carolina; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hannun, YA (corresponding author), SUNY Stony Brook, Stony Brook Canc Ctr, 100 Nicolls Rd, Stony Brook, NY 11794 USA.	yusuf.hannun@stonybrook.edu		obeid, lina/0000-0002-0734-0847; Adada, Mohamad/0000-0002-2988-2081; Liu, Mengling/0000-0003-1309-0087	U.S. National Institutes of Health [HL43707]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health grant HL43707.	Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Becker KP, 2005, CELL MOL LIFE SCI, V62, P1448, DOI 10.1007/s00018-005-4531-7; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; Blobe GC, 1996, CANCER SURV, V27, P213; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Chen YB, 2008, EXPERT OPIN INV DRUG, V17, P939, DOI 10.1517/13543784.17.6.939 ; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Courage C, 1997, INT J CANCER, V73, P763, DOI 10.1002/(SICI)1097-0215(19971127)73:5<763::AID-IJC25>3.0.CO;2-5; El-Osta MA, 2011, J BIOL CHEM, V286, P19340, DOI 10.1074/jbc.M110.152330; Fan QW, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000014; Fasolo A, 2012, CURR PHARM DESIGN, V18, P2766, DOI 10.2174/138161212800626210; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Flinn RJ, 2010, MOL BIOL CELL, V21, P833, DOI 10.1091/mbc.E09-09-0756; Ghobrial IM, 2011, AM J HEMATOL, V86, P573, DOI 10.1002/ajh.22048; Gomez-Cambronero J, 2012, SCI WORLD J, V10, P1356; Gullberg M, 2003, CURR OPIN BIOTECH, V14, P82, DOI 10.1016/S0958-1669(02)00011-3; Gunawardane RN, 2005, CANCER RES, V65, P11572, DOI 10.1158/0008-5472.CAN-05-1196; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hu TH, 2005, BIOCHEM BIOPH RES CO, V333, P750, DOI 10.1016/j.bbrc.2005.05.184; Hu TH, 2004, J BIOL CHEM, V279, P35702, DOI 10.1074/jbc.M402372200; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Husseinzadeh HD, 2011, CURR CLIN PHARMACOL, V6, P214, DOI 10.2174/157488411797189433; Idkowiak-Baldys J, 2006, J BIOL CHEM, V281, P22321, DOI 10.1074/jbc.M512540200; Idkowiak-Baldys J, 2009, J BIOL CHEM, V284, P22322, DOI 10.1074/jbc.M109.026765; Ip CKM, 2011, ONCOGENE, V30, P2420, DOI 10.1038/onc.2010.615; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lavieri RR, 2010, J MED CHEM, V53, P6706, DOI 10.1021/jm100814g; Lewis JA, 2009, BIOORG MED CHEM LETT, V19, P1916, DOI 10.1016/j.bmcl.2009.02.057; Li L, 2010, J BIOL CHEM, V285, P19705, DOI 10.1074/jbc.C110.102483; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; Nazarewicz R. R., 2011, J BIOL CHEM, V286, P2866; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Peng X, 2012, ACTA PHYSIOL, V204, P219, DOI 10.1111/j.1748-1716.2011.02298.x; Proud CG, 1997, BIOCHEM J, V328, P329; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Su W, 2009, MOL PHARMACOL, V75, P437, DOI 10.1124/mol.108.053298; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Vansteenkiste J, 2012, ONCOLOGY-BASEL, V82, P25, DOI 10.1159/000335268; Wells A, 2000, ADV CANCER RES, V78, P31; Winter JN, 2010, AM J PHYSIOL-CELL PH, V299, pC335, DOI 10.1152/ajpcell.00039.2010; Yoon MS, 2011, J CELL BIOL, V195, P435, DOI 10.1083/jcb.201107033; Yoon MS, 2011, J BIOL CHEM, V286, P29568, DOI 10.1074/jbc.M111.262816; Zhou HY, 2011, CURR PROTEIN PEPT SC, V12, P30	50	8	8	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					495	505		10.1096/fj.13-230557	http://dx.doi.org/10.1096/fj.13-230557			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24121461	Green Published			2022-12-28	WOS:000333526100046
J	Khanal, P; Kim, G; Lim, SC; Yun, HJ; Lee, KY; Choi, HK; Choi, HS				Khanal, Prem; Kim, Garam; Lim, Sung-Chul; Yun, Hyo-Jeong; Lee, Kwang Youl; Choi, Hoo-Kyun; Choi, Hong Seok			Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer	FASEB JOURNAL			English	Article						cis; trans isomerase; histone methyltransferases; ubiquitination; H3K9me3; H3K4me3	HISTONE METHYLATION; ALZHEIMERS-DISEASE; CELL-CYCLE; PHOSPHORYLATION; CHROMATIN; METHYLTRANSFERASES; OVEREXPRESSION; TARGET; G9A; HETEROCHROMATIN	Pin1, a conserved eukaryotic peptidyl-prolyl cis/trans isomerase, has profound effects on numerous key-signaling molecules, and its deregulation contributes to disease, particularly cancer. Although Pin1-mediated prolyl isomerization of protein servers as a regulatory switch in signaling pathways, the significance of proline isomerase activity in chromatin modifying complex remains unclear. Here, we identify Pin1 as a key negative regulator for suppressor of variegation 3-9 homologue 1 (SUV39H1) stability, a major methyltransferase responsible for histone H3 trimethylation on Lys9 (H3K9me3). Pin1 interacts with SUV39H1 in a phosphorylation-dependent manner and promotes ubiquitination-mediated degradation of SUV39H1. Consequently, Pin1 reduces SUV39H1 abundance and suppresses SUV39H1 ability to induce H3K9me3. In contrast, depletion of Pin1 in cancer cells leads to elevated SUV39H1 expression, which subsequently increases H3K9me3, inhibiting tumorigenecity of cancer cells. In a xenograft model with 4T1 metastatic mouse breast carcinoma cells, Pin1 overexpression increases tumor growth, whereas SUV39H1 overexpression abrogates it. In human breast cancer patients, immunohistochemical staining shows that Pin1 levels are negatively correlated with SUV39H1 as well as H3K9me3 levels. Thus, Pin1-mediated reduction of SUV39H1 stability contributes to convey oncogenic signals for aggressiveness of human breast cancer, suggesting that Pin1 may be a promising drug target for anticancer therapy.Khanal, P., Kim, G., Lim, S.-C., Yun, H.-J., Lee, K. Y., Choi, H.-K., Choi, H. S. Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.	[Khanal, Prem; Kim, Garam; Yun, Hyo-Jeong; Choi, Hoo-Kyun; Choi, Hong Seok] Chosun Univ, Coll Pharm, Kwangju 501759, South Korea; [Lim, Sung-Chul] Chosun Univ, Dept Pathol, Sch Med, Kwangju 501759, South Korea; [Lee, Kwang Youl] Chonnam Natl Univ, Coll Pharm, Kwangju, South Korea	Chosun University; Chosun University; Chonnam National University	Choi, HS (corresponding author), Chosun Univ, Coll Pharm, Kwangju 501759, South Korea.	chs@chosun.ac.kr			Ministry of Health and Welfare, Republic of Korea [A111800]	Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This study was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A111800).	Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Aagaard L, 2000, J CELL SCI, V113, P817; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brenkman AB, 2008, CANCER RES, V68, P7597, DOI 10.1158/0008-5472.CAN-08-1059; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Ding QQ, 2008, CANCER RES, V68, P6109, DOI 10.1158/0008-5472.CAN-08-0579; Esnault S, 2006, J IMMUNOL, V177, P6999, DOI 10.4049/jimmunol.177.10.6999; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Khanal P, 2012, ONCOGENE, V31, P3845, DOI 10.1038/onc.2011.548; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lee TH, 2011, MOL CELL, V42, P147, DOI 10.1016/j.molcel.2011.03.005; Lee TH, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001906; Leey NY, 2009, CARCINOGENESIS, V30, P671, DOI 10.1093/carcin/bgp027; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mal AK, 2006, EMBO J, V25, P3323, DOI 10.1038/sj.emboj.7601229; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pani E, 2008, BBA-MOL CELL RES, V1783, P1121, DOI 10.1016/j.bbamcr.2008.02.020; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rangasamy V, 2012, P NATL ACAD SCI USA, V109, P8149, DOI 10.1073/pnas.1200804109; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rustighi A, 2009, NAT CELL BIOL, V11, P133, DOI 10.1038/ncb1822; Ryo A, 2006, J BIOL CHEM, V281, P4117, DOI 10.1074/jbc.M507026200; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Stanya KJ, 2008, J CELL BIOL, V183, P49, DOI 10.1083/jcb.200806172; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Takahashi K, 2008, CELL MOL LIFE SCI, V65, P359, DOI 10.1007/s00018-007-7270-0; Takahashi K, 2007, ONCOGENE, V26, P3835, DOI 10.1038/sj.onc.1210153; Tun-Kyi A, 2011, NAT IMMUNOL, V12, P733, DOI 10.1038/ni.2069; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yang YJ, 2010, NUCLEIC ACIDS RES, V38, P382, DOI 10.1093/nar/gkp991; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	53	27	28	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4606	4618		10.1096/fj.13-236851	http://dx.doi.org/10.1096/fj.13-236851			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23934277	Bronze			2022-12-28	WOS:000329937500026
J	Steinke, K; Sachse, F; Ettischer, N; Strutz-Seebohm, N; Henrion, U; Rohrbeck, M; Klosowski, R; Wolters, D; Brunner, S; Franz, WM; Pott, L; Munoz, C; Kandolf, R; Schulze-Bahr, E; Lang, F; Klingel, K; Seebohm, G				Steinke, Katja; Sachse, Frank; Ettischer, Nicole; Strutz-Seebohm, Nathalie; Henrion, Ulrike; Rohrbeck, Matthias; Klosowski, Rafael; Wolters, Dirk; Brunner, Stefan; Franz, Wolfgang-Michael; Pott, Lutz; Munoz, Carlos; Kandolf, Reinhard; Schulze-Bahr, Eric; Lang, Florian; Klingel, Karin; Seebohm, Guiscard			Coxsackie virus B3 modulates cardiac ion channels	FASEB JOURNAL			English	Article						CVB3; trafficking; arrhythmias; myocarditis	RHINOVIRUS 3C PROTEASE; LONG-QT SYNDROME; TORSADE-DE-POINTES; VENTRICULAR-TACHYCARDIA; UNIDIRECTIONAL BLOCK; POTASSIUM CHANNELS; ANTIVIRAL ACTIVITY; VULNERABLE WINDOW; GENE-EXPRESSION; COMMON-CAUSE	Infections with coxsackieviruses of type B (CVBs), which are known to induce severe forms of acute and chronic myocarditis, are often accompanied by ventricular arrhythmias and sudden cardiac death. The mechanisms underlying the development of virus-induced, life-threatening arrhythmias, which are phenotypically similar to those observed in patients having functionally impaired cardiac ion channels, remain, however, enigmatic. In the present study, we show, for the first time, modulating time-dependent effects of CVB3 on the cardiac ion channels KCNQ1, hERG1, and Ca(v)1.2 in heterologous expression. Channel protein abundance in cellular plasma membrane and patterns of their subcellular distribution were altered in infected murine hearts. The antiviral compound AG7088 did not prevent these effects on channels. In silico analyses of infected human myocytes suggest pronounced alterations of electrical and calcium signaling and increased risk of arrhythmogenesis. These modifications are attenuated by the common Asian polymorphism KCNQ1 P448R, a genetic determinant preventing coxsackievirus-induced effects in vitro. This study provides a previously unknown explanation for the development of arrhythmias in enteroviral myocarditis, which will help to develop therapeutic strategies for arrhythmia treatment.Steinke, K., Sachse, F., Ettischer, N., Strutz-Seebohm, N., Henrion, U., Rohrbeck, M., Klosowski, R., Wolters, D., Brunner, S., Franz, W.-M., Pott, L., Munoz, C., Kandolf, R., Schulze-Bahr, E., Lang, F., Klingel, K., Seebohm, G. Coxsackievirus B3 modulates cardiac ion channels.	[Steinke, Katja; Strutz-Seebohm, Nathalie; Henrion, Ulrike; Rohrbeck, Matthias; Schulze-Bahr, Eric; Seebohm, Guiscard] Univ Hosp Munster, Inst Genet Heart Dis IfGH, Dept Cardiovasc Med, Munster, Germany; [Steinke, Katja; Brunner, Stefan] Ruhr Univ Bochum, Dept Biochem 1, Cat Channel Grp, Bochum, Germany; [Klosowski, Rafael; Wolters, Dirk] Ruhr Univ Bochum, Dept Analyt Chem, Bochum, Germany; [Pott, Lutz] Ruhr Univ Bochum, Dept Cellular Physiol, Bochum, Germany; [Sachse, Frank; Kandolf, Reinhard] Univ Utah, Nora Eccles Cardiovasc Res & Training Inst, Salt Lake City, UT USA; [Sachse, Frank; Kandolf, Reinhard] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; [Ettischer, Nicole; Klingel, Karin] Univ Hosp Tuebingen, Dept Mol Pathol, Tubingen, Germany; [Henrion, Ulrike; Munoz, Carlos; Lang, Florian] Univ Tubingen, Dept Physiol 1, Tubingen, Germany; [Franz, Wolfgang-Michael] Univ Munich, Dept Internal Med 1, Munich, Germany	University of Munster; Ruhr University Bochum; Ruhr University Bochum; Ruhr University Bochum; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; University of Munich	Seebohm, G (corresponding author), Inst Genet Herzerkrankungen IfGH, Abt Myozellulare Elektrophysiol, Albert Schweitzer Campus 1 Gebaude D3, D-48149 Munster, Germany.	guiscard.seebohm@ukmuenster.de		Sachse, Frank/0000-0003-4987-705X; Pott, Lutz/0000-0002-4000-4132	Deutsche Forschungsgemeinschaft [SE1077/3, SFB-TR19]; Interdisziplinares Zentrurn fur Klinische Forschung (IZKF) Minister [IZKF-Seel-012-13]; Federal Ministry of Education and Research [01EZ0817]; Research School of the Ruhr University Bochum; Richard A. and Nora Eccles Fund for Cardiovascular Research	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisziplinares Zentrurn fur Klinische Forschung (IZKF) Minister; Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Research School of the Ruhr University Bochum; Richard A. and Nora Eccles Fund for Cardiovascular Research	The authors thank Ilaria Piccini for performing the qRT-PCR of endogenous SSGK1 transcripts and Stephanie Nolte and Sandra Bundschuh for technical assistance. This work was funded by the Deutsche Forschungsgemeinschaft (SE1077/3 to G.S. and K.K.; SFB-TR19 to KK, R.K., and F.L.), the Interdisziplinares Zentrurn fur Klinische Forschung (IZKF) Minister (IZKF-Seel-012-13), the Federal Ministry of Education and Research (01EZ0817 to K.K. and R.K.), the Research School of the Ruhr University Bochum, and the Richard A. and Nora Eccles Fund for Cardiovascular Research (to F.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the German animal welfare act, which is based on the directive of the European parliament and of the council on the protection of animals used for scientific purposes. This study conforms to the Baden-Wuerttemberg State guidelines for animal welfare. The protocol was approved by the Committee on the Ethics of Animal Experiments of Baden-Wuerttemberg State authorities. All efforts were made to minimize suffering. The authors declare no conflicts of interest.	Ackerman MJ, 2003, MAYO CLIN PROC, V78, P1479, DOI 10.4065/78.12.1479; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Badorff C, 2001, HEART, V86, P489, DOI 10.1136/heart.86.5.489; Bowles NE, 2003, J AM COLL CARDIOL, V42, P466, DOI 10.1016/S0735-1097(03)00648-X; Carthy CM, 1998, J VIROL, V72, P7669, DOI 10.1128/JVI.72.9.7669-7675.1998; Chen CCH, 2006, MOL BIOL CELL, V17, P1286, DOI 10.1091/mbc.E05-08-0787; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Collier JM, 2003, BIRTH DEFECTS RES A, V67, P488, DOI 10.1002/bdra.10073; Cunningham R, 2000, ANN EMERG MED, V35, P618, DOI 10.1016/S0196-0644(00)70037-0; Daley AJ, 1998, J PAEDIATR CHILD H, V34, P196, DOI 10.1046/j.1440-1754.1998.00176.x; Dragovich PS, 1998, J MED CHEM, V41, P2806, DOI 10.1021/jm980068d; Dutton JR, 2009, DEV DYNAM, V238, P1412, DOI 10.1002/dvdy.21932; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; Feuer R, 2005, J NEUROSCI, V25, P2434, DOI 10.1523/JNEUROSCI.4517-04.2005; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Huber S, 2004, VIRAL IMMUNOL, V17, P358, DOI 10.1089/vim.2004.17.358; KANDOLF R, 1987, P NATL ACAD SCI USA, V84, P6272, DOI 10.1073/pnas.84.17.6272; KANDOLF R, 1985, P NATL ACAD SCI USA, V82, P4818, DOI 10.1073/pnas.82.14.4818; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Klingel K, 1998, LAB INVEST, V78, P1227; Koo SH, 2006, BRIT J CLIN PHARMACO, V61, P301, DOI 10.1111/j.1365-2125.2005.02545.x; Lang F, 2003, CELL PHYSIOL BIOCHEM, V13, P41, DOI 10.1159/000070248; Lang F, 2001, Sci STKE, V2001, pre17, DOI 10.1126/stke.2001.108.re17; Leonard EG, 2004, PEDIATR INFECT DIS J, V23, P665, DOI 10.1097/01.inf.0000132280.36984.a9; Leong Louis E.-C., 2002, P187; Levander OA, 1997, BIOL TRACE ELEM RES, V56, P5, DOI 10.1007/BF02778980; Lin JY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-103; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; Mena I, 2000, VIROLOGY, V271, P276, DOI 10.1006/viro.2000.0332; MOSS AJ, 1982, MOD CONC CARDIOV DIS, V51, P85; Nerbonne JM, 2005, PHYSIOL REV, V85, P1205, DOI 10.1152/physrev.00002.2005; Patick AK, 1999, ANTIMICROB AGENTS CH, V43, P2444, DOI 10.1128/AAC.43.10.2444; PRESS WH, 1992, NUMERICAL RECIPES; Qu ZL, 2006, BIOPHYS J, V91, P793, DOI 10.1529/biophysj.106.080945; QUAN WL, 1990, CIRC RES, V66, P367, DOI 10.1161/01.RES.66.2.367; Sachse FB, 2008, ANN BIOMED ENG, V36, P41, DOI 10.1007/s10439-007-9405-8; Salerno F, 2011, INT J CARDIOL, V147, P468, DOI 10.1016/j.ijcard.2011.01.019; Sano H, 2008, BIOCHEM J, V411, P89, DOI 10.1042/BJ20071318; SARELI P, 1987, CLIN CARDIOL, V10, P361, DOI 10.1002/clc.4960100514; SATO Y, 1989, JPN HEART J, V30, P935; Schuck S, 2007, TRAFFIC, V8, P47, DOI 10.1111/j.1600-0854.2006.00506.x; Seebohm G, 2007, CIRC RES, V100, P686, DOI 10.1161/01.RES.0000260250.83824.8f; Seebohm G, 2008, CIRC RES, V103, P1451, DOI 10.1161/CIRCRESAHA.108.177360; Shah SS, 1998, PEDIATR CARDIOL, V19, P185, DOI 10.1007/s002469900277; Sharma D, 2004, J MOL CELL CARDIOL, V37, P79, DOI 10.1016/j.yjmcc.2004.03.015; SHAW RM, 1995, J CARDIOVASC ELECTR, V6, P115, DOI 10.1111/j.1540-8167.1995.tb00763.x; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Strutz-Seebohm N, 2009, CHANNELS, V3, P88, DOI 10.4161/chan.3.2.8086; TAI YT, 1992, CARDIOLOGY, V80, P339, DOI 10.1159/000175023; Ten Tusscher KHWJ, 2006, PHYS MED BIOL, V51, P6141, DOI 10.1088/0031-9155/51/23/014; Terasaki F, 1990, Heart Vessels Suppl, V5, P45; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Wessely R, 1998, CIRCULATION, V98, P450, DOI 10.1161/01.CIR.98.5.450; Westenskow P, 2004, CIRCULATION, V109, P1834, DOI 10.1161/01.CIR.0000125524.34234.13; Wetzel U, 2003, HERZ, V28, P583, DOI 10.1007/s00059-003-2492-x; Witherell G, 2000, Curr Opin Investig Drugs, V1, P297; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C	59	18	19	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4108	4121		10.1096/fj.13-230193	http://dx.doi.org/10.1096/fj.13-230193			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825229				2022-12-28	WOS:000329747100023
J	Xie, GX; Zhong, W; Li, HK; Li, Q; Qiu, YP; Zheng, XJ; Chen, HY; Zhao, XQ; Zhang, SC; Zhou, ZX; Zeisel, SH; Jia, W				Xie, Guoxiang; Zhong, Wei; Li, Houkai; Li, Qiong; Qiu, Yunping; Zheng, Xiaojiao; Chen, Huiyuan; Zhao, Xueqing; Zhang, Shucha; Zhou, Zhanxiang; Zeisel, Steven H.; Jia, Wei			Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption	FASEB JOURNAL			English	Article						gastrointestinal tract; liver; blood; ultraperformance liquid chromatography mass spectrometry; metabolomics	GUT MICROBIOTA; LIVER; ALCOHOL; CHOLESTEROL; CONJUGATION; HOMEOSTASIS; RECEPTOR; GROWTH; COA	Our understanding of the bile acid metabolism is limited by the fact that previous analyses have primarily focused on a selected few circulating bile acids; the bile acid profiles of the liver and gastrointestinal tract pools are rarely investigated. Here, we determined how chronic ethanol consumption altered the bile acids in multiple body compartments (liver, gastrointestinal tract, and serum) of rats. Rats were fed a modified Lieber-DeCarli liquid diet with 38% of calories as ethanol (the amount equivalent of 4-5 drinks in humans). While conjugated bile acids predominated in the liver (98.3%), duodenum (97.8%), and ileum (89.7%), unconjugated bile acids comprised the largest proportion of measured bile acids in serum (81.2%), the cecum (97.7%), and the rectum (97.5%). In particular, taurine-conjugated bile acids were significantly decreased in the liver and gastrointestinal tract of ethanol-treated rats, while unconjugated and glycine-conjugated species increased. Ethanol consumption caused increased expression of genes involved in bile acid biosynthesis, efflux transport, and reduced expression of genes regulating bile acid influx transport in the liver. These results provide an improved understanding of the systemic modulations of bile acid metabolism in mammals through the gut-liver axis.Xie, G., Zhong, W., Li, H., Li, Q., Qiu, Y., Zheng, X., Chen, H., Zhao, X., Zhang, S., Zhou, Z., Zeisel, S. H., Jia, W. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption.	[Xie, Guoxiang; Zhong, Wei; Li, Houkai; Li, Qiong; Qiu, Yunping; Zheng, Xiaojiao; Chen, Huiyuan; Zhao, Xueqing; Zhou, Zhanxiang] Univ North Carolina Greensboro, Ctr Translat Biomed Res, Kannapolis, NC USA; [Xie, Guoxiang; Jia, Wei] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Ctr Translat Med, Shanghai 200030, Peoples R China; [Xie, Guoxiang; Jia, Wei] Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA; [Zhang, Shucha; Zeisel, Steven H.] Univ North Carolina Chapel Hill, Inst Nutr Res, Kannapolis, NC USA	University of North Carolina; University of North Carolina Greensboro; Shanghai Jiao Tong University; Cancer Research Center of Hawaii; University of Hawaii System; University of North Carolina; University of North Carolina Chapel Hill	Jia, W (corresponding author), Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA.	z_zhou@uncg.edu; wjia@cc.hawaii.edu	Jia, Wei/AAN-5102-2020; Qiu, Yunping/AAO-5200-2021; li, houkai/S-6785-2019; chen, hui/HDO-2955-2022; Li, Qiong/I-4114-2013; Xie, Guoxiang/F-3022-2016	Jia, Wei/0000-0002-3739-8994; li, houkai/0000-0003-2846-7895; Xie, Guoxiang/0000-0002-0951-4150; Qiu, Yunping/0000-0003-1039-5264	U.S. National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism [R01 AA020212]; NATIONAL CANCER INSTITUTE [P30CA071789] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020212] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was financially supported by U.S. National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism grant R01 AA020212.	Chiang John Y. L., 1998, Frontiers in Bioscience, V3, pD176; Chu FF, 2004, CANCER RES, V64, P962, DOI 10.1158/0008-5472.CAN-03-2272; Claus SP, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.56; Corrao G, 1997, J STUD ALCOHOL, V58, P486, DOI 10.15288/jsa.1997.58.486; Dumas ME, 2006, P NATL ACAD SCI USA, V103, P12511, DOI 10.1073/pnas.0601056103; DUPONT J, 1974, LIPIDS, V9, P294, DOI 10.1007/BF02532210; FALANY CN, 1994, J BIOL CHEM, V269, P19375; HARDISON WGM, 1977, AM J PHYSIOL, V232, pE75, DOI 10.1152/ajpendo.1977.232.1.E75; HEPNER GW, 1973, J CLIN INVEST, V52, P433, DOI 10.1172/JCI107200; Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007-JLR200; IGA T, 1982, BIOCHEM PHARMACOL, V31, P205; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Queipo-Ortuno MI, 2012, AM J CLIN NUTR, V95, P1323, DOI 10.3945/ajcn.111.027847; Delgado-Villa MJ, 2009, J STUD ALCOHOL DRUGS, V70, P615, DOI 10.15288/jsad.2009.70.615; KILLENBERG PG, 1978, J BIOL CHEM, V253, P1005; Kim I, 2007, J LIPID RES, V48, P2664, DOI 10.1194/jlr.M700330-JLR200; Martin FPJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100153; MIDTVEDT T, 1974, AM J CLIN NUTR, V27, P1341, DOI 10.1093/ajcn/27.11.1341; Miyata M, 2011, J PHARMACOL EXP THER, V336, P188, DOI 10.1124/jpet.110.171736; Mutlu EA, 2012, AM J PHYSIOL-GASTR L, V302, pG966, DOI 10.1152/ajpgi.00380.2011; Niemela O, 2007, CLIN CHIM ACTA, V377, P39, DOI 10.1016/j.cca.2006.08.035; Oliva L, 1998, ALCOHOL CLIN EXP RES, V22, P1538; Purohit V, 2008, ALCOHOL, V42, P349, DOI 10.1016/j.alcohol.2008.03.131; REDDY BS, 1981, CANCER RES, V41, P3766; Reschly EJ, 2008, J LIPID RES, V49, P1577, DOI 10.1194/jlr.M800138-JLR200; Ridlon JM, 2006, J LIPID RES, V47, P241, DOI 10.1194/jlr.R500013-JLR200; Robben J., 1987, FRONTIERS MICROBIOLO, P241, DOI [10.1007/978-94-009-3353-8_25, DOI 10.1007/978-94-009-3353-8_25]; Shi XL, 2012, J BIOL CHEM, V287, P6336, DOI 10.1074/jbc.M111.312199; Swann JR, 2011, P NATL ACAD SCI USA, V108, P4523, DOI 10.1073/pnas.1006734107; Vlahcevic ZR, 1996, HEPATOLOGY TXB LIVER, V1, P376; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Wei J, 2009, J DIGEST DIS, V10, P85, DOI 10.1111/j.1751-2980.2009.00369.x; WOSTMANN BS, 1973, J NUTR, V103, P982, DOI 10.1093/jn/103.7.982; Zhong W, 2012, AM J PATHOL, V180, P998, DOI 10.1016/j.ajpath.2011.11.017	34	120	123	5	56	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3583	3593		10.1096/fj.13-231860	http://dx.doi.org/10.1096/fj.13-231860			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23709616	Green Submitted, Green Published			2022-12-28	WOS:000328840500018
J	Boycott, HE; Dallas, ML; Elies, J; Pettinger, L; Boyle, JP; Scragg, JL; Gamper, N; Peers, C				Boycott, Hannah E.; Dallas, Mark L.; Elies, Jacobo; Pettinger, Louisa; Boyle, John P.; Scragg, Jason L.; Gamper, Nikita; Peers, Chris			Carbon monoxide inhibition of Cav3.2 T-type Ca2+ channels reveals tonic modulation by thioredoxin	FASEB JOURNAL			English	Article						heme oxygenase 1; gasotransmitter; redox modulation; patch clamp	HEME OXYGENASE-1/CARBON MONOXIDE; GATED CALCIUM-CHANNELS; SENSORY NEURONS; REDOX MODULATION; ION CHANNELS; EXPRESSION; RAT; PROLIFERATION; PATHWAY; PHARMACOLOGY	T-type Ca2+ channels play diverse roles in tissues such as sensory neurons, vascular smooth muscle, and cancers, where increased expression of the cytoprotective enzyme, heme oxygenase-1 (HO-1) is often found. Here, we report regulation of T-type Ca2+ channels by carbon monoxide (CO) a HO-1 by-product. CO (applied as CORM-2) caused a concentration-dependent, poorly reversible inhibition of all T-type channel isoforms (Cav3.1-3.3, IC50 approximate to 3 M) expressed in HEK293 cells, and native T-type channels in NG108-15 cells and primary rat sensory neurons. No recognized CO-sensitive signaling pathway could account for the CO inhibition of Cav3.2. Instead, CO sensitivity was mediated by an extracellular redox-sensitive site, which was also highly sensitive to thioredoxin (Trx). Trx depletion (using auranofin, 2-5 M) reduced Cav3.2 currents and their CO sensitivity by >50% but increased sensitivity to dithiothreitol approximate to 3-fold. By contrast, Cav3.1 and Cav3.3 channels, and their sensitivity to CO, were unaffected in identical experiments. Our data propose a novel signaling pathway in which Trx acts as a tonic, endogenous regulator of Cav3.2 channels, while HO-1-derived CO disrupts this regulation, causing channel inhibition. CO modulation of T-type channels has widespread implications for diverse physiological and pathophysiological mechanisms, such as excitability, contractility, and proliferation.Boycott, H. E., Dallas, M. L., Elies, J., Pettinger, L., Boyle, J. P., Scragg, J. L., Gamper, N., Peers, C. Carbon monoxide inhibition of Cav3.2 T-type Ca2+ channels reveals tonic modulation by thioredoxin.	[Boycott, Hannah E.; Dallas, Mark L.; Elies, Jacobo; Boyle, John P.; Scragg, Jason L.; Gamper, Nikita; Peers, Chris] Univ Leeds, Fac Med & Hlth, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England; [Pettinger, Louisa] Univ Leeds, Fac Biol Sci, Leeds, W Yorkshire, England	University of Leeds; University of Leeds	Peers, C (corresponding author), Univ Leeds, Fac Med & Hlth, LIGHT, Div Cardiovasc & Diabet Res, Clarendon Way, Leeds, W Yorkshire, England.	c.s.peers@leeds.ac.uk	Boyle, John/N-4868-2016; Dallas, Mark/Q-6117-2019; Elies, Jacobo/K-7684-2017; Dallas, Mark L/A-6654-2013	Dallas, Mark/0000-0002-5190-0522; Elies, Jacobo/0000-0002-2518-8412; Peers, Chris/0000-0002-8354-346X; Gamper, Nikita/0000-0001-5806-0207	Alzheimer's Research UK; UK Medical Research Council; British Heart Foundation; MRC [G1002183] Funding Source: UKRI; British Heart Foundation [PG/11/84/29146, PG/09/013/26885, FS/12/42/29585, FS/10/010/28169] Funding Source: researchfish; Medical Research Council [G1002183] Funding Source: researchfish	Alzheimer's Research UK(Alzheimer's Research UK (ARUK)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors are most grateful to Dr. E. Perez-Reyes (University of Virginia, Charlottesville, VA, USA) for provision of T-type channel expressing HEK293 cells, and Dr. Ian Wood (University of Leeds) for NG108-15 cells. This work was supported by Alzheimer's Research UK, the UK Medical Research Council, and the British Heart Foundation.	Al-Owais MMA, 2012, J BIOL CHEM, V287, P24754, DOI 10.1074/jbc.M112.357012; Bachnoff N, 2011, FREE RADICAL BIO MED, V50, P1355, DOI 10.1016/j.freeradbiomed.2011.02.026; Banerjee R, 2012, J BIOL CHEM, V287, P4397, DOI 10.1074/jbc.R111.287995; Cain SM, 2010, CHANNELS, V4, P475, DOI 10.4161/chan.4.6.14106; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Chang TJ, 2008, AM J PHYSIOL-HEART C, V295, pH999, DOI 10.1152/ajpheart.01289.2007; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Dallas ML, 2008, NEUROREPORT, V19, P345, DOI 10.1097/WNR.0b013e3282f51045; Dallas ML, 2011, FASEB J, V25, P1519, DOI 10.1096/fj.10-173450; Ding YY, 2006, FEBS J, V273, P5333, DOI 10.1111/j.1742-4658.2006.05526.x; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Durante W, 2006, J CELL MOL MED, V10, P672, DOI 10.1111/j.1582-4934.2006.tb00427.x; Fearon IM, 2000, PFLUG ARCH EUR J PHY, V441, P181, DOI 10.1007/s004240000424; Gray LS, 2006, CELL CALCIUM, V40, P115, DOI 10.1016/j.ceca.2006.04.014; Iftinca MC, 2009, TRENDS PHARMACOL SCI, V30, P32, DOI 10.1016/j.tips.2008.10.004; Joksovic PM, 2006, J PHYSIOL-LONDON, V574, P415, DOI 10.1113/jphysiol.2006.110395; Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659; Kang HW, 2006, J BIOL CHEM, V281, P4823, DOI 10.1074/jbc.M510197200; Karmazinova M, 2010, PFLUG ARCH EUR J PHY, V460, P1015, DOI 10.1007/s00424-010-0874-5; Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053; Kuga T, 1996, CIRC RES, V79, P14, DOI 10.1161/01.RES.79.1.14; Kuo IYT, 2011, J PHYSIOL-LONDON, V589, P783, DOI 10.1113/jphysiol.2010.199497; Linley JE, 2008, J NEUROSCI, V28, P11240, DOI 10.1523/JNEUROSCI.2297-08.2008; Lipskaia L, 2009, PFLUG ARCH EUR J PHY, V457, P673, DOI 10.1007/s00424-007-0428-7; Liu BY, 2010, J CLIN INVEST, V120, P1240, DOI 10.1172/JCI41084; Magnusson S, 2000, NEUROSCIENCE, V95, P821; McGivern JG, 2006, DRUG DISCOV TODAY, V11, P245, DOI 10.1016/S1359-6446(05)03662-7; Miwa K, 2005, CIRC J, V69, P291, DOI 10.1253/circj.69.291; Nelson MT, 2007, J NEUROSCI, V27, P12577, DOI 10.1523/JNEUROSCI.2206-07.2007; Nelson MT, 2007, J NEUROSCI, V27, P8250, DOI 10.1523/JNEUROSCI.1800-07.2007; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; PEERS C, 1990, J PHYSIOL-LONDON, V421, P293, DOI 10.1113/jphysiol.1990.sp017945; Peers C, 2011, EXP PHYSIOL, V96, P836, DOI 10.1113/expphysiol.2011.059063; Peng J, 2001, NEUROPEPTIDES, V35, P297, DOI 10.1054/npep.2001.0880; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; RICHARD S, 1992, BIOCHIM BIOPHYS ACTA, V1160, P95, DOI 10.1016/0167-4838(92)90042-C; Rodman DM, 2005, CIRC RES, V96, P864, DOI 10.1161/01.RES.0000163066.07472.ff; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Scragg JL, 2008, J BIOL CHEM, V283, P24412, DOI 10.1074/jbc.M803037200; Steiner AA, 2001, BRIT J PHARMACOL, V132, P1673, DOI 10.1038/sj.bjp.0704014; Taylor JT, 2008, WORLD J GASTROENTERO, V14, P4984, DOI 10.3748/wjg.14.4984; Todorovic SM, 2011, BRIT J PHARMACOL, V163, P484, DOI 10.1111/j.1476-5381.2011.01256.x; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; Tzeng BH, 2012, CARDIOVASC RES, V96, P533, DOI 10.1093/cvr/cvs257; Was H, 2010, CURR DRUG TARGETS, V11, P1551, DOI 10.2174/1389450111009011551; Wilkinson WJ, 2011, J PHYSIOL-LONDON, V589, P3055, DOI 10.1113/jphysiol.2011.206706; Wu LY, 2005, PHARMACOL REV, V57, P585, DOI 10.1124/pr.57.4.3; Xu SZ, 2008, NATURE, V451, P69, DOI 10.1038/nature06414	51	27	29	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3395	3407		10.1096/fj.13-227249	http://dx.doi.org/10.1096/fj.13-227249			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23671274				2022-12-28	WOS:000329877600044
J	Langie, SAS; Achterfeldt, S; Gorniak, JP; Halley-Hogg, KJA; Oxley, D; van Schooten, FJ; Godschalk, RWL; McKay, JA; Mathers, JC				Langie, Sabine A. S.; Achterfeldt, Sebastian; Gorniak, Joanna P.; Halley-Hogg, Kirstin J. A.; Oxley, David; van Schooten, Frederik J.; Godschalk, Roger W. L.; McKay, Jill A.; Mathers, John C.			Maternal folate depletion and high-fat feeding from weaning affects DNA methylation and DNA repair in brain of adult offspring	FASEB JOURNAL			English	Article						epigenetics; base excision repair; developmental origin	OXIDATIVE STRESS; EPIGENETIC CHANGES; EXCISION-REPAIR; ALZHEIMERS-DISEASE; GENE-EXPRESSION; ACID TRANSPORT; DEFICIENT DIET; FOLIC-ACID; DAMAGE; COLON	The mechanisms through which environmental and dietary factors modulate DNA repair are still unclear but may include dysregulation of gene expression due to altered epigenetic markings. In a mouse model, we investigated the effect of maternal folate depletion during pregnancy and lactation, and high-fat feeding from weaning, on base excision repair (BER) and DNA methylation and expression of selected BER-related genes in the brain of adult offspring. While folate depletion did not affect BER activity of the mothers, BER increased in the offspring at weaning (P=0.052). In the long term, as observed in 6-mo-old offspring, the double insult, i.e., maternal low-folate supply and high-fat feeding from weaning, decreased BER activity significantly in the cortex, cerebellum, hippocampus, and subcortical regions (P0.017). This fall in BER activity was associated with small changes in methylation or expression of BER-related genes. Maternal folate depletion led to slightly increased oxidative DNA damage levels in subcortical regions of adult offspring, which may increase sensitivity to oxidative stress and predispose to neurological disorders. In summary, our data suggest that low-folate supply during early life may leave an epigenetic mark that can predispose the offspring to further dietary insults, causing adverse effects during adult life.Langie, S. A. S., Achterfeldt, S., Gorniak, J. P., Halley-Hogg, K. J. A., Oxley, D., van Schooten, F. J., Godschalk, R. W. L., McKay, J. A., Mathers, J. C. Maternal folate depletion and high-fat feeding from weaning affects DNA methylation and DNA repair in brain of adult offspring.	[Langie, Sabine A. S.; Achterfeldt, Sebastian; Gorniak, Joanna P.; Halley-Hogg, Kirstin J. A.; McKay, Jill A.; Mathers, John C.] Newcastle Univ, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Langie, Sabine A. S.; Achterfeldt, Sebastian; Gorniak, Joanna P.; Halley-Hogg, Kirstin J. A.; Mathers, John C.] Newcastle Univ, Ctr Brain Ageing & Vital, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [McKay, Jill A.] Newcastle Univ, Human Nutr Res Ctr, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Oxley, David] Babraham Inst, Prote Grp, Cambridge, England; [van Schooten, Frederik J.; Godschalk, Roger W. L.] Maastricht Univ, Dept Toxicol, Maastricht, Netherlands	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Maastricht University	Langie, SAS (corresponding author), Flemisch Inst Technol Res VITO, Environm Risk & Hlth Unit, Boeretang 200, B-2400 Mol, Belgium.	sabine.langie@gmail.com	Langie, Sabine A/Q-2917-2017	Langie, Sabine A/0000-0003-3288-7331; McKay, Jill Ann/0000-0002-2711-0301; Mathers, John/0000-0003-3406-3002	Lifelong Health and Wellbeing cross council initiative by the UK Medical Research Council; Biotechnology and Biological Sciences Research Council (BBSRC); Engineering and Physical Sciences Research Council; Economic and Social Research Council; BBSRC [BB/G007993/1]; Biotechnology and Biological Sciences Research Council [BB/G007993/1] Funding Source: researchfish; Medical Research Council [G0700718] Funding Source: researchfish	Lifelong Health and Wellbeing cross council initiative by the UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Hoffmann-La Roche (Basel, Switzerland) for supplying Ro 19-8022. Further thanks goes to Adele Kitching and Julie Wallace (Comparative Biology Centre, Newcastle University) for care of the animals, and Dr Long Xie and Sofia Lisanti for help with animal care and dissections. The Centre for Brain Aging and Vitality is funded through the Lifelong Health and Wellbeing cross council initiative by the UK Medical Research Council, Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council, and Economic and Social Research Council. The project was also funded by the BBSRC (BB/G007993/1). The authors declare no conflicts of interest.	Bagnyukova TV, 2008, BRAIN RES, V1237, P44, DOI 10.1016/j.brainres.2008.07.073; Basten GP, 2006, BRIT J CANCER, V94, P1942, DOI 10.1038/sj.bjc.6603197; Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; BRANDA RF, 1993, CANCER RES, V53, P5401; Chen KH, 2000, CARCINOGENESIS, V21, P1017, DOI 10.1093/carcin/21.5.1017; Choi SW, 1998, GUT, V43, P93, DOI 10.1136/gut.43.1.93; Chouliaras L, 2010, PROG NEUROBIOL, V90, P498, DOI 10.1016/j.pneurobio.2010.01.002; Collins AR, 2012, EUR J NUTR, V51, P261, DOI 10.1007/s00394-012-0318-4; Collins AR, 2000, FREE RADICAL RES, V32, P333, DOI 10.1080/10715760000300331; Dhikav V, 2011, DRUG AGING, V28, P1, DOI 10.2165/11586390-000000000-00000; Dobosy JR, 2008, PROSTATE, V68, P1187, DOI 10.1002/pros.20782; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Dudley KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021662; Duthie SJ, 2011, J INHERIT METAB DIS, V34, P101, DOI 10.1007/s10545-010-9128-0; Duthie SJ, 2010, CANCER PREV RES, V3, P92, DOI 10.1158/1940-6207.CAPR-09-0231; Gallou-Kabani C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014398; Godschalk RWL, 1998, CARCINOGENESIS, V19, P819, DOI 10.1093/carcin/19.5.819; Gordon L, 2012, GENOME RES, V22, P1395, DOI 10.1101/gr.136598.111; Guintivano J, 2013, EPIGENETICS-US, V8, P290, DOI 10.4161/epi.23924; Hamilton JA, 2007, J MOL NEUROSCI, V33, P12, DOI 10.1007/s12031-007-0050-3; Hegde ML, 2012, MECH AGEING DEV, V133, P157, DOI 10.1016/j.mad.2012.01.005; HIETANEN E, 1990, INT J CANCER, V46, P640, DOI 10.1002/ijc.2910460415; Hsiao PJ, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-82; Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204; JENNINGS E, 1995, MED HYPOTHESES, V45, P297, DOI 10.1016/0306-9877(95)90121-3; Kimura Y, 2012, AM J CLIN NUTR, V95, P1209, DOI 10.3945/ajcn.111.030817; Langie SAS, 2011, MUTAGENESIS, V26, P461, DOI 10.1093/mutage/ger005; Langie SAS, 2010, MUTAT RES-GEN TOX EN, V695, P75, DOI 10.1016/j.mrgentox.2009.12.005; Lillycrop KA, 2011, INT J OBESITY, V35, P72, DOI 10.1038/ijo.2010.122; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; Mathers JC, 2007, CURR CANCER DRUG TAR, V7, P425; Mattson MP, 2003, AGEING RES REV, V2, P329, DOI 10.1016/S1568-1637(03)00013-8; Mckay JA, 2011, ACTA PHYSIOL, V202, P103, DOI 10.1111/j.1748-1716.2011.02278.x; McKay JA, 2011, MOL NUTR FOOD RES, V55, P1717, DOI 10.1002/mnfr.201100150; Mehler MF, 2008, PROG NEUROBIOL, V86, P305, DOI 10.1016/j.pneurobio.2008.10.001; Mitchell RW, 2011, PROSTAG LEUKOTR ESS, V85, P293, DOI 10.1016/j.plefa.2011.04.007; Munzel M, 2011, ANGEW CHEM INT EDIT, V50, P6460, DOI 10.1002/anie.201101547; Nabel CS, 2011, SCIENCE, V333, P1229, DOI 10.1126/science.1211917; Ochoa JJ, 2011, FREE RADICAL BIO MED, V50, P1053, DOI 10.1016/j.freeradbiomed.2011.02.004; Palou M, 2011, BRIT J NUTR, V106, P769, DOI 10.1017/S0007114511000973; Parra P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013005; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Sadakane K, 2006, FOOD CHEM TOXICOL, V44, P1372, DOI 10.1016/j.fct.2006.03.002; Sibani S, 2002, CARCINOGENESIS, V23, P61, DOI 10.1093/carcin/23.1.61; Slim RM, 1996, J AM COLL NUTR, V15, P289; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1055, DOI 10.1152/ajpendo.00554.2001; Starlard-Davenport A, 2010, WORLD REV NUTR DIET, V101, P123, DOI 10.1159/000314517; Strakovsky RS, 2011, J PHYSIOL-LONDON, V589, P2707, DOI 10.1113/jphysiol.2010.203950; Unnikrishnan A, 2011, FREE RADICAL BIO MED, V50, P270, DOI 10.1016/j.freeradbiomed.2010.11.003; van den Hove DLA, 2012, CURR ALZHEIMER RES, V9, P545; Vogel U, 2003, FREE RADICAL RES, V37, P947, DOI 10.1080/1071576031000150779; Vucetic Z, 2010, ENDOCRINOLOGY, V151, P4756, DOI 10.1210/en.2010-0505; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Zawia NH, 2009, FREE RADICAL BIO MED, V46, P1241, DOI 10.1016/j.freeradbiomed.2009.02.006	56	56	57	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3323	3334		10.1096/fj.12-224121	http://dx.doi.org/10.1096/fj.12-224121			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23603834				2022-12-28	WOS:000329877600037
J	Schmidt, EM; Schmid, E; Munzer, P; Hermann, A; Eyrich, AK; Russo, A; Walker, B; Gu, SC; vom Hagen, JM; Faggio, C; Schaller, M; Foller, M; Schols, L; Gawaz, M; Borst, O; Storch, A; Stournaras, C; Lang, F				Schmidt, Eva-Maria; Schmid, Evi; Muenzer, Patrick; Hermann, Andreas; Eyrich, Ann-Kathrin; Russo, Antonella; Walker, Britta; Gu, Shuchen; vom Hagen, Jennifer Mueller; Faggio, Caterina; Schaller, Martin; Foeller, Michael; Schoels, Ludger; Gawaz, Meinrad; Borst, Oliver; Storch, Alexander; Stournaras, Christos; Lang, Florian			Chorein sensitivity of cytoskeletal organization and degranulation of platelets	FASEB JOURNAL			English	Article						chorea-acanthocytosis; PI3K; VAMP8; aggregation	GRANULE EXOCYTOSIS; CORTICAL ACTIN; CELL-DEATH; KINASE; PROTEIN; APOPTOSIS; GENE; PHOSPHORYLATION; DYNAMICS; BAD	Chorea-acanthocytosis (ChAc), a lethal disease caused by defective chorein, is characterized by neurodegeneration and erythrocyte acanthocytosis. The functional significance of chorein in other cell types remained ill-defined. The present study revealed chorein expression in blood platelets. As compared to platelets from healthy volunteers, platelets from patients with ChAc displayed a 47% increased globular/filamentous actin ratio, indicating actin depolymerization. Moreover, phosphoinositide-3-kinase subunit p85 phosphorylation, p21 protein-activated kinase (PAK1) phosphorylation, as well as vesicle-associated membrane protein 8 (VAMP8) expression were significantly reduced in platelets from patients with ChAc (by 17, 22, and 39%, respectively) and in megakaryocytic (MEG-01) cells following chorein silencing (by 16, 54, and 11%, respectively). Activation-induced platelet secretion from dense granules (ATP release) and granules (P-selectin exposure) were significantly less (by 55% after stimulation with 1 g/ml CRP and by 33% after stimulation with 5 M TRAP, respectively) in ChAc platelets than in control platelets. Furthermore, platelet aggregation following stimulation with different platelet agonists was significantly impaired. These observations reveal a completely novel function of chorein, i.e., regulation of secretion and aggregation of blood platelets.Schmidt, E.-M., Schmid, E., Munzer, P., Hermann, A., Eyrich, A.-K., Russo, A., Walker, B., Gu, S., Muller vom Hagen, J., Faggio, C., Schaller, M., Foller, M., Schols, L., Gawaz, M., Borst, O., Storch, A., Stournaras, C., Lang, F. Chorein sensitivity of cytoskeletal organization and degranulation of platelets.	[Schmidt, Eva-Maria; Schmid, Evi; Muenzer, Patrick; Eyrich, Ann-Kathrin; Russo, Antonella; Walker, Britta; Gu, Shuchen; Foeller, Michael; Borst, Oliver; Stournaras, Christos; Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; [Schmidt, Eva-Maria] Univ Tubingen, Dept Med Psychol & Behav Neurobiol, D-72076 Tubingen, Germany; [vom Hagen, Jennifer Mueller; Schoels, Ludger] Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; [vom Hagen, Jennifer Mueller; Schoels, Ludger] Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; [Schaller, Martin] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; [Gawaz, Meinrad; Borst, Oliver] Univ Tubingen, Dept Cardiol & Cardiovasc Med, D-72076 Tubingen, Germany; [Hermann, Andreas; Storch, Alexander] Tech Univ Dresden, Dept Neurol, Div Neurodegenerat Dis, Dresden, Germany; [Hermann, Andreas; Storch, Alexander] German Ctr Neurodegenerat Dis DZNE Dresden, Dresden, Germany; [Russo, Antonella; Faggio, Caterina] Univ Messina, Dept Biol & Environm Sci, Messina, Italy; [Schoels, Ludger] DZNE, Tubingen, Germany; [Stournaras, Christos] Univ Crete, Sch Med, Dept Biochem, Iraklion, Greece	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Technische Universitat Dresden; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Technische Universitat Dresden; University of Messina; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Crete	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Schöls, Ludger/ABB-2482-2021; Hermann, Andreas/D-4213-2017	Schöls, Ludger/0000-0001-7774-5025; Hermann, Andreas/0000-0002-7364-7791; Munzer, Patrick/0000-0001-5357-038X; Borst, Oliver/0000-0003-4002-4085; faggio, caterina/0000-0002-0066-2421	Deutsche Forschungsgemeinschaft [KFO 274, GRK 1302, SFB 773, LA 315/13-3]; Neuroacanthocytosis Advocacy (London, UK); Bundesministerium fur Bildung und Forschung under the frame of E-Rare-2; ERA-Net for Research on Rare Diseases; Carl-Zeiss-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Neuroacanthocytosis Advocacy (London, UK); Bundesministerium fur Bildung und Forschung under the frame of E-Rare-2(Federal Ministry of Education & Research (BMBF)); ERA-Net for Research on Rare Diseases; Carl-Zeiss-Stiftung	The authors thank all of the patients and their families, as well as the healthy control subjects, for participation. The authors acknowledge the meticulous preparation of the manuscript by Tanja Loch and Lejla Subasic. This study was supported by the Carl-Zeiss-Stiftung; the Deutsche Forschungsgemeinschaft, KFO 274, GRK 1302, SFB 773, LA 315/13-3; the Neuroacanthocytosis Advocacy (London, UK); and the Bundesministerium fur Bildung und Forschung under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases.	Barzilai A, 2010, APOPTOSIS, V15, P1371, DOI 10.1007/s10495-010-0501-0; Borst O, 2012, CIRC RES, V111, P1297, DOI 10.1161/CIRCRESAHA.112.276444; Borst O, 2012, BLOOD, V119, P251, DOI 10.1182/blood-2011-06-359976; Castro-Castro A, 2011, EMBO J, V30, P3913, DOI 10.1038/emboj.2011.310; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Daub K, 2006, FASEB J, V20, P2559, DOI 10.1096/fj.06-6265fje; De Franceschi L, 2011, BLOOD, V118, P5652, DOI 10.1182/blood-2011-05-355339; Dobson-Stone C, 2004, ANN NEUROL, V56, P299, DOI 10.1002/ana.20200; Dobson-Stone C, 2002, EUR J HUM GENET, V10, P773, DOI 10.1038/sj.ejhg.5200866; Dobson-Stone C, 1993, GENEREVIEWS; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Eliyahu E, 2005, REPRODUCTION, V129, P161, DOI 10.1530/rep.1.00424; European Molecular Biology Laboratory-European Bioinformatics Institute, 2011, INTACT DAT; Eylenstein A, 2011, FASEB J, V25, P2012, DOI 10.1096/fj.10-178210; Fawaz NA, 2012, EUR J HAEMATOL, V88, P350, DOI 10.1111/j.1600-0609.2011.01739.x; Foller M, 2012, FASEB J, V26, P1526, DOI 10.1096/fj.11-198317; Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196; Gilio K, 2009, J BIOL CHEM, V284, P33750, DOI 10.1074/jbc.M109.048439; Graham GJ, 2009, BLOOD, V114, P1083, DOI 10.1182/blood-2009-03-210211; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Ip CKM, 2011, ONCOGENE, V30, P2420, DOI 10.1038/onc.2010.615; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Keller H, 2002, EXP CELL RES, V277, P161, DOI 10.1006/excr.2002.5552; Kondkar AA, 2010, J THROMB HAEMOST, V8, P369, DOI 10.1111/j.1538-7836.2009.03700.x; Kreis P, 2008, J NEUROCHEM, V106, P1184, DOI 10.1111/j.1471-4159.2008.05474.x; Kurano Y, 2007, BIOCHEM BIOPH RES CO, V353, P431, DOI 10.1016/j.bbrc.2006.12.059; Lian LR, 2005, BLOOD, V106, P110, DOI 10.1182/blood-2004-05-2005; Malacombe M, 2006, BBA-MOL CELL RES, V1763, P1175, DOI 10.1016/j.bbamcr.2006.09.004; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Massberg S, 2003, FASEB J, V17, P397, DOI 10.1096/f.03-0464.fje; Mitchell T, 2008, AM J PHYSIOL-CELL PH, V295, pC1354, DOI 10.1152/ajpcell.00239.2008; Onabajo OO, 2008, J IMMUNOL, V180, P6685, DOI 10.4049/jimmunol.180.10.6685; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Papakonstanti EA, 2008, FEBS LETT, V582, P2120, DOI 10.1016/j.febslet.2008.02.064; Papakonstanti EA, 2002, MOL BIOL CELL, V13, P2946, DOI 10.1091/mbc.02-01-0599; Papakonstanti EA, 2007, METHOD ENZYMOL, V428, P227, DOI 10.1016/S0076-6879(07)28012-7; Polgar J, 2002, BLOOD, V100, P1081, DOI 10.1182/blood.V100.3.1081; Polzien L, 2011, J BIOL CHEM, V286, P17934, DOI 10.1074/jbc.M110.177345; Ren QS, 2007, MOL BIOL CELL, V18, P24, DOI 10.1091/mbc.E06-09-0785; Romaniuk MA, 2012, FASEB J, V26, P2788, DOI 10.1096/fj.11-197541; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Saiki S, 2007, MOVEMENT DISORD, V22, P848, DOI 10.1002/mds.21437; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Stefani IC, 2012, CURR ALZHEIMER RES, V9, P373; Taylor JM, 2013, NEUROCHEM INT, V62, P803, DOI 10.1016/j.neuint.2012.12.016; Tomiyasu A, 2011, AM J MED GENET B, V156B, P620, DOI 10.1002/ajmg.b.31206; Ueno S, 2001, NAT GENET, V28, P121, DOI 10.1038/88825; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wu CG, 2007, PROTEOMICS, V7, P1775, DOI 10.1002/pmic.200601006; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	54	36	37	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2799	2806		10.1096/fj.13-229286	http://dx.doi.org/10.1096/fj.13-229286			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23568775				2022-12-28	WOS:000328841000028
J	Kiss, G; Konrad, C; Doczi, J; Starkov, AA; Kawamata, H; Manfredi, G; Zhang, SF; Gibson, GE; Beal, MF; Adam-Vizi, V; Chinopoulos, C				Kiss, Gergely; Konrad, Csaba; Doczi, Judit; Starkov, Anatoly A.; Kawamata, Hibiki; Manfredi, Giovanni; Zhang, Steven F.; Gibson, Gary E.; Beal, M. Flint; Adam-Vizi, Vera; Chinopoulos, Christos			The negative impact of alpha-ketoglutarate dehydrogenase complex deficiency on matrix substrate-level phosphorylation	FASEB JOURNAL			English	Article						succinyl-CoA ligase; adenine nucleotide translocase; F-0-F-1 ATP synthase; reversal potential	ADENINE-NUCLEOTIDE TRANSLOCASE; ENERGY-YIELDING OXIDATION; SUCCINYL-COA SYNTHETASES; ACID-CYCLE METABOLITES; GUINEA-PIG HEART; MITOCHONDRIAL DYSFUNCTION; ANAEROBIC METABOLISM; PYRIDINE NUCLEOTIDE; HYDROGEN-PEROXIDE; ATP DEPLETION	A decline in alpha-ketoglutarate dehydrogenase complex (KGDHC) activity has been associated with neurodegeneration. Provision of succinyl-CoA by KGDHC is essential for generation of matrix ATP (or GTP) by substrate-level phosphorylation catalyzed by succinyl-CoA ligase. Here, we demonstrate ATP consumption in respiration-impaired isolated and in situ neuronal somal mitochondria from transgenic mice with a deficiency of either dihydrolipoyl succinyltransferase (DLST) or dihydrolipoyl dehydrogenase (DLD) that exhibit a 20-48% decrease in KGDHC activity. Import of ATP into the mitochondrial matrix of transgenic mice was attributed to a shift in the reversal potential of the adenine nucleotide translocase toward more negative values due to diminished matrix substrate-level phosphorylation, which causes the translocase to reverse prematurely. Immunoreactivity of all three subunits of succinyl-CoA ligase and maximal enzymatic activity were unaffected in transgenic mice as compared to wild-type littermates. Therefore, decreased matrix substrate-level phosphorylation was due to diminished provision of succinyl-CoA. These results were corroborated further by the finding that mitochondria from wild-type mice respiring on substrates supporting substrate-level phosphorylation exhibited similar to 30% higher ADP-ATP exchange rates compared to those obtained from DLST-/- or DLD-/- littermates. We propose that KGDHC-associated pathologies are a consequence of the inability of respiration-impaired mitochondria to rely on "in-house" mitochondrial ATP reserves.-Kiss, G., Konrad, C., Doczi, J., Starkov, A. A., Kawamata, H., Manfredi, G., Zhang, S. F., Gibson, G. E., Beal, M. F., Adam-Vizi, V., Chinopoulos, C. The negative impact of alpha-ketoglutarate dehydrogenase complex deficiency on matrix substrate-level phosphorylation.	[Kiss, Gergely; Konrad, Csaba; Doczi, Judit; Adam-Vizi, Vera; Chinopoulos, Christos] Semmelweis Univ, Dept Med Biochem, H-1094 Budapest, Hungary; [Starkov, Anatoly A.; Kawamata, Hibiki; Manfredi, Giovanni; Zhang, Steven F.; Beal, M. Flint; Chinopoulos, Christos] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Gibson, Gary E.] Cornell Univ, Coll Med, Burke Med Res Inst, Dept Neurol & Neurosci,Weill Cornell Med Coll, White Plains, NY 10605 USA	Semmelweis University; Cornell University; Cornell University	Chinopoulos, C (corresponding author), Semmelweis Univ, Dept Med Biochem, Tuzolto St 37-47, H-1094 Budapest, Hungary.	chinopoulos.christos@eok.sote.hu	Starkov, Anatoly/B-2688-2012	Starkov, Anatoly/0000-0002-1334-4828; Chinopoulos, Christos/0000-0003-0183-4149	U.S. National Institutes of Health (NIH) [P01 AG014930]; NIH/National Institute of Neurological Disease and Stroke [F31 NS054554]; NIH [1R21NS065396, R01 GM088999]; Orszagos Tudomanyos Kutatasi Alapprogram (OTKA); Magyar Tudomanyos Akademia (MTA); MTA-SE Lendulet Neurobiochemistry Research Division [95003]; OTKA NNF [78905]; OTKA [NNF2 85658, K 100918]; Egeszsegugyi Tudomanyos Tanacs ETT [55160]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS054554, R21NS065396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014930] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Neurological Disease and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Orszagos Tudomanyos Kutatasi Alapprogram (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Magyar Tudomanyos Akademia (MTA); MTA-SE Lendulet Neurobiochemistry Research Division; OTKA NNF; OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Egeszsegugyi Tudomanyos Tanacs ETT; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U.S. National Institutes of Health (NIH) grant P01 AG014930 to G.E.G., A.A.S.. and M.F.B.; NIH/National Institute of Neurological Disease and Stroke grant F31 NS054554 to H.K.; NIH grant 1R21NS065396 to A.A.S.; NIH grant R01 GM088999 to G.M.; grants from the Orszagos Tudomanyos Kutatasi Alapprogram (OTKA), Magyar Tudomanyos Akademia (MTA) to V.A.-V.; and grants MTA-SE Lendulet Neurobiochemistry Research Division 95003, OTKA NNF 78905, OTKA NNF2 85658, OTKA K 100918, and Egeszsegugyi Tudomanyos Tanacs ETT 55160 to C.C. The authors thank Katalin Zolde for excellent technical assistance. The authors declare no conflicts of interest.	AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Alarcon C, 2002, DIABETES, V51, P2496, DOI 10.2337/diabetes.51.8.2496; ALEXANDRE A, 1978, P NATL ACAD SCI USA, V75, P5296, DOI 10.1073/pnas.75.11.5296; Alves TC, 2012, METHODS MOL BIOL, V810, P281, DOI 10.1007/978-1-61779-382-0_18; Atamna H, 2004, P NATL ACAD SCI USA, V101, P11153, DOI 10.1073/pnas.0404349101; Atamna H, 2001, J BIOL CHEM, V276, P48410, DOI 10.1074/jbc.M108362200; Browne SE, 2002, INT REV NEUROBIOL, V53, P243; Bubber P, 2005, ANN NEUROL, V57, P695, DOI 10.1002/ana.20474; Bubber P, 2011, EUR NEUROPSYCHOPHARM, V21, P254, DOI 10.1016/j.euroneuro.2010.10.007; Calingasan NY, 2008, NEUROSCIENCE, V153, P986, DOI 10.1016/j.neuroscience.2008.02.071; CHANCE B, 1960, NATURE, V185, P666, DOI 10.1038/185666a0; CHICK WL, 1968, AM J PHYSIOL, V215, P1107, DOI 10.1152/ajplegacy.1968.215.5.1107; Chinopoulos C, 2004, J NEUROCHEM, V91, P471, DOI 10.1111/j.1471-4159.2004.02732.x; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; Chinopoulos C, 2013, J NEUROSCI RES, V91, P1030, DOI 10.1002/jnr.23196; Chinopoulos C, 2011, J NEUROSCI RES, V89, P1897, DOI 10.1002/jnr.22659; Chinopoulos C, 2011, FEBS LETT, V585, P1255, DOI 10.1016/j.febslet.2011.04.004; Chinopoulos C, 2011, FEBS J, V278, P1112, DOI 10.1111/j.1742-4658.2011.08026.x; Chinopoulos C, 2010, FASEB J, V24, P2405, DOI 10.1096/fj.09-149898; Chinopoulos C, 2009, BIOPHYS J, V96, P2490, DOI 10.1016/j.bpj.2008.12.3915; Cooper AJL, 2012, NEUROCHEM RES, V37, P2439, DOI 10.1007/s11064-012-0803-4; Demin OV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P634; Dumont M, 2009, FREE RADICAL BIO MED, V47, P1019, DOI 10.1016/j.freeradbiomed.2009.07.008; Dunkley PR, 2008, NAT PROTOC, V3, P1718, DOI 10.1038/nprot.2008.171; Gerencser AA, 2012, J PHYSIOL-LONDON, V590, P2845, DOI 10.1113/jphysiol.2012.228387; Gibson GE, 2010, BBA-MOL BASIS DIS, V1802, P122, DOI 10.1016/j.bbadis.2009.08.010; Gibson GE, 2000, NEUROCHEM INT, V36, P97, DOI 10.1016/S0197-0186(99)00114-X; HUNTER FE, 1949, J BIOL CHEM, V177, P361; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; Johnson MT, 1997, P NATL ACAD SCI USA, V94, P14512, DOI 10.1073/pnas.94.26.14512; KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S; Kanamori T, 2003, EMBO J, V22, P2913, DOI 10.1093/emboj/cdg299; Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011; Klivenyi P, 2004, J NEUROCHEM, V88, P1352, DOI 10.1046/j.1471-4159.2003.02263.x; Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200; Martell A. E., 1974, CRITICAL STABILITY C; MCMILLIN JB, 1988, MOL CELL BIOCHEM, V81, P121; Metelkin E, 2009, FEBS J, V276, P6942, DOI 10.1111/j.1742-4658.2009.07394.x; NICHOLLS DG, 1977, EUR J BIOCHEM, V75, P601, DOI 10.1111/j.1432-1033.1977.tb11560.x; Nilsen LH, 2011, J NEUROSCI RES, V89, P1997, DOI 10.1002/jnr.22606; PENNEY DG, 1970, BIOCHEM J, V118, P221, DOI 10.1042/bj1180221; PETRONILLI V, 1988, BIOCHIM BIOPHYS ACTA, V932, P306, DOI 10.1016/0005-2728(88)90167-3; PEUHKURINEN KJ, 1983, AM J PHYSIOL, V244, pH281, DOI 10.1152/ajpheart.1983.244.2.H281; Phillips D, 2009, BIOCHEMISTRY-US, V48, P7140, DOI 10.1021/bi900725c; PISARENKO O, 1987, BIOMED BIOCHIM ACTA, V46, pS568; PISARENKO O, 1988, BIOCHIM BIOPHYS ACTA, V934, P55, DOI 10.1016/0005-2728(88)90119-3; PISARENKO OI, 1985, BASIC RES CARDIOL, V80, P126, DOI 10.1007/BF01910459; PORPACZY Z, 1983, BIOCHIM BIOPHYS ACTA, V749, P172, DOI 10.1016/0167-4838(83)90249-2; RANDALL HM, 1966, AM J PHYSIOL, V211, P493, DOI 10.1152/ajplegacy.1966.211.2.493; ROUSLIN W, 1986, AM J PHYSIOL, V250, pH503, DOI 10.1152/ajpheart.1986.250.3.H503; ROUSLIN W, 1990, AM J PHYSIOL, V259, pH1759, DOI 10.1152/ajpheart.1990.259.6.H1759; SANADI DR, 1963, BIOCHEMISTRY-US, V2, P523, DOI 10.1021/bi00903a023; SANBORN T, 1979, AM J PHYSIOL, V237, pH535, DOI 10.1152/ajpheart.1979.237.5.H535; Sheu KFR, 1999, ANN NY ACAD SCI, V893, P61; Shi QL, 2009, J NEUROCHEM, V109, P214, DOI 10.1111/j.1471-4159.2009.05955.x; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TAEGTMEYER H, 1978, CIRC RES, V43, P808, DOI 10.1161/01.RES.43.5.808; TAEGTMEYER H, 1977, J BIOL CHEM, V252, P5010; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; Tretter L, 2000, J NEUROSCI, V20, P8972; Tretter L, 2007, J NEUROCHEM, V103, P1864, DOI 10.1111/j.1471-4159.2007.04891.x; Watt IN, 2010, P NATL ACAD SCI USA, V107, P16823, DOI 10.1073/pnas.1011099107; Weinberg JM, 2000, AM J PHYSIOL-RENAL, V279, pF927, DOI 10.1152/ajprenal.2000.279.5.F927; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826; WILSON MA, 1970, BIOCHIM BIOPHYS ACTA, V216, P54, DOI 10.1016/0005-2728(70)90158-1; WISNIEWSKI E, 1993, J BIOL CHEM, V268, P9343; Yang LC, 2009, NEUROBIOL DIS, V36, P320, DOI 10.1016/j.nbd.2009.07.023; Zacharias NM, 2012, J AM CHEM SOC, V134, P934, DOI 10.1021/ja2040865	72	41	43	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2392	2406		10.1096/fj.12-220202	http://dx.doi.org/10.1096/fj.12-220202			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23475850	Green Published			2022-12-28	WOS:000319667600027
J	Sachse, CC; Kim, YH; Agsten, M; Huth, T; Alzheimer, C; Kovacs, DM; Kim, DY				Sachse, Carolyn C.; Kim, Young Hye; Agsten, Marianne; Huth, Tobias; Alzheimer, Christian; Kovacs, Dora M.; Kim, Doo Yeon			BACE1 and presenilin/gamma-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels	FASEB JOURNAL			English	Article						MinK; MiRP; Alzheimer's disease; KCNQ1	BETA-SECRETASE; ALZHEIMERS-DISEASE; I-KS; TARGETED DISRUPTION; MEDIATED CLEAVAGE; SODIUM-CHANNELS; ALPHA-SECRETASE; UP-REGULATION; MINK; ENZYME	BACE1 and presenilin (PS)/gamma-secretase play a major role in Alzheimer's disease pathogenesis by regulating amyloid-beta peptide generation. We recently showed that these secretases also regulate the processing of voltage-gated sodium channel auxiliary beta-subunits and thereby modulate membrane excitability. Here, we report that KCNE1 and KCNE2, auxiliary subunits of voltage-gated potassium channels, undergo sequential cleavage mediated by either alpha-secretase and PS/gamma-secretase or BACE1 and PS/gamma-secretase in cells. Elevated alpha-secretase or BACE1 activities increased C-terminal fragment (CTF) levels of KCNE1 and 2 in human embryonic kidney (HEK293T) and rat neuroblastoma (B104) cells. KCNE-CTFs were then further processed by PS/gamma-secretase to KCNE intracellular domains. These KCNE cleavages were specifically blocked by chemical inhibitors of the secretases in the same cell models. We also verified our results in mouse cardiomyocytes and cultured primary neurons. Endogenous KCNE1- and KCNE2-CTF levels increased by 2- to 4-fold on PS/gamma-secretase inhibition or BACE1 overexpression in these cells. Furthermore, the elevated BACE1 activity increased KCNE1 processing and shifted KCNE1/KCNQ1 channel activation curve to more positive potentials in HEK cells. KCNE1/KCNQ1 channel is a cardiac potassium channel complex, and the positive shift would lead to a decrease in membrane repolarization during cardiac action potential. Together, these results clearly showed that KCNE1 and KCNE2 cleavages are regulated by BACE1 and PS/gamma-secretase activities under physiological conditions. Our results also suggest a functional role of KCNE cleavage in regulating voltage-gated potassium channels.-Sachse, C. C., Kim, Y. H., Agsten, M., Huth, T., Alzheimer, C., Kovacs, D. M., and Kim, D. Y. BACE1 and presenilin/gamma-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels.	[Sachse, Carolyn C.; Kim, Young Hye; Kovacs, Dora M.; Kim, Doo Yeon] Harvard Univ, MassGen Inst Neurodegenerat Dis, Massachusetts Gen Hosp, Neurobiol Dis Lab,Genet & Aging Res Unit,Med Sch, Charlestown, MA USA; [Kim, Young Hye] Korea Basic Sci Inst, Div Mass Spectrometry Res, Ochang, South Korea; [Agsten, Marianne; Huth, Tobias; Alzheimer, Christian] Univ Erlangen Nurnberg, Inst Physiol & Pathophysiol, D-91054 Erlangen, Germany	Harvard University; Massachusetts General Hospital; Korea Basic Science Institute (KBSI); University of Erlangen Nuremberg	Kim, DY (corresponding author), Massachusetts Gen Hosp, Genet & Aging Res Unit, 114 16th St, Charlestown, MA 02129 USA.	dkim@helix.mgh.harvard.edu		Huth, Tobias/0000-0002-6414-8923	Cure Alzheimer's fund; U.S. National Institutes of Health/National Institute on Aging; Dr. Ernst und Anita Bauer-Stiftung; Johannes und Frieda Marohn-Stiftung; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014713, P01AG015379, R21AG031483] Funding Source: NIH RePORTER	Cure Alzheimer's fund; U.S. National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Dr. Ernst und Anita Bauer-Stiftung; Johannes und Frieda Marohn-Stiftung; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Stephanie Hartmann (University of Erlangen-Nurnberg) for her contribution in revising this manuscript and Dr. Jordan Tang (University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA) for BACE1 inhibitor <INF>D</INF>R9. This work is supported by grants from the Cure Alzheimer's fund to D.Y.K, the U.S. National Institutes of Health/National Institute on Aging to D.M.K and D.Y.K., the Dr. Ernst und Anita Bauer-Stiftung to S.H., and the Johannes und Frieda Marohn-Stiftung to T.H. and C.A.	Angulo E, 2004, J NEUROCHEM, V91, P547, DOI 10.1111/j.1471-4159.2004.02771.x; Assal F, 2002, CURR OPIN NEUROL, V15, P445, DOI 10.1097/00019052-200208000-00007; Balasubramaniam R, 2003, J PHYSIOL-LONDON, V552, P535, DOI 10.1113/jphysiol.2003.048249; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Carey BW, 2007, BIOCHEM J, V401, P121, DOI 10.1042/BJ20060847; Clancy SM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006330; Cole SL, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-22; de Leon M J, 1995, Neuroimaging Clin N Am, V5, P1; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Haapasalo A, 2007, J BIOL CHEM, V282, P9063, DOI 10.1074/jbc.M611324200; Haapasalo A, 2011, J ALZHEIMERS DIS, V25, P3, DOI 10.3233/JAD-2011-101065; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hu XY, 2010, J NEUROSCI, V30, P8819, DOI 10.1523/JNEUROSCI.1334-10.2010; Huth T, 2011, PFLUG ARCH EUR J PHY, V461, P355, DOI 10.1007/s00424-010-0913-2; Huth T, 2009, NEUROBIOL DIS, V33, P282, DOI 10.1016/j.nbd.2008.10.015; Kim DY, 2007, NAT CELL BIOL, V9, P755, DOI 10.1038/ncb1602; Kim DY, 2011, J BIOL CHEM, V286, P8106, DOI 10.1074/jbc.M110.134692; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kovacs DM, 2010, NEUROSCI LETT, V486, P68, DOI 10.1016/j.neulet.2010.08.048; Larner AJ, 2010, NEUROMOL MED, V12, P71, DOI 10.1007/s12017-009-8076-z; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Li Y, 2006, NEUROSCIENTIST, V12, P199, DOI 10.1177/1073858406287717; McCrossan ZA, 2003, J NEUROSCI, V23, P8077; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; McCrossan ZA, 2009, J MEMBRANE BIOL, V228, P1, DOI 10.1007/s00232-009-9154-8; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Pannaccione A, 2007, MOL PHARMACOL, V72, P665, DOI 10.1124/mol.107.034868; Pongs O, 2010, PHYSIOL REV, V90, P755, DOI 10.1152/physrev.00020.2009; Rossner S, 2001, J NEUROSCI RES, V64, P437; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Shepherd C, 2009, ACTA NEUROPATHOL, V118, P37, DOI 10.1007/s00401-009-0521-4; Temple J, 2005, CIRC RES, V97, P62, DOI 10.1161/01.RES.0000173047.42236.88; Thomas G, 2007, J PHYSIOL-LONDON, V578, P99, DOI 10.1113/jphysiol.2006.118133; Tinel N, 2000, FEBS LETT, V480, P137, DOI 10.1016/S0014-5793(00)01918-9; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; Vassar R, 2009, J NEUROSCI, V29, P12787, DOI 10.1523/JNEUROSCI.3657-09.2009; Velliquette RA, 2005, J NEUROSCI, V25, P10874, DOI 10.1523/JNEUROSCI.2350-05.2005; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Wolfe MS, 2008, CURR ALZHEIMER RES, V5, P158, DOI 10.2174/156720508783954767; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	48	30	32	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2458	2467		10.1096/fj.12-214056	http://dx.doi.org/10.1096/fj.12-214056			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23504710	Green Published			2022-12-28	WOS:000319667600033
J	Nunes, PM; Wright, AJ; Veltien, A; van Asten, JJA; Tack, CJ; Jones, JG; Heerschap, A				Nunes, Patricia M.; Wright, Alan J.; Veltien, Andor; van Asten, Jack J. A.; Tack, Cees J.; Jones, John G.; Heerschap, Arend			Dietary lipids do not contribute to the higher hepatic triglyceride levels of fructose- compared to glucose-fed mice	FASEB JOURNAL			English	Article						in vivo hepatic lipid metabolism; magnetic resonance spectroscopy; de novo lipogenesis	FATTY LIVER-DISEASE; DE-NOVO LIPOGENESIS; INSULIN-RESISTANCE; MAGNETIC-RESONANCE; LIPOPROTEIN OVERPRODUCTION; SWEETENED BEVERAGES; RATS; CONSUMPTION; METABOLISM; HAMSTER	Fructose consumption has been associated with the surge in obesity and dyslipidemia. This may be mediated by the fructose effects on hepatic lipids and ATP levels. Fructose metabolism provides carbons for de novo lipogenesis (DNL) and stimulates enterocyte secretion of apoB48. Thus, fructose-induced hepatic triglyceride (HTG) accumulation can be attributed to both DNL stimulation and dietary lipid absorption. The aim of this study was to assess the effects of fructose diet on HTG and ATP content and the contributions of dietary lipids and DNL to HTG. Measurements were performed in vivo in mice by magnetic resonance imaging (MRI) and novel magnetic resonance spectroscopy (MRS) approaches. Abdominal adipose tissue volume and intramyocellular lipid levels were comparable between 8-wk fructose- and glucose-fed mice. HTG levels were approximate to 1.5-fold higher in fructose-fed than in glucose-fed mice (P<0.05). Metabolic flux analysis by C-13 and H-2 MRS showed that this was not due to dietary lipid absorption, but due to DNL stimulation. The contribution of oral lipids to HTG was, after 5 h, 1.60 +/- 0.23% for fructose and 2.16 +/- 0.35% for glucose diets (P=0.26), whereas that of DNL was higher in fructose than in glucose diets (2.55 +/- 0.51 vs.1.13 +/- 0.24%, P=0.01). Hepatic energy status, assessed by P-31 MRS, was similar for fructose- and glucose-fed mice. Fructose-induced HTG accumulation is better explained by DNL and not by dietary lipid uptake, while not compromising ATP homeostasis.Nunes, P. M., Wright, A. J., Veltien, A., van Asten, J. J. A., Tack, C. J., Jones, J. G., Heerschap, A. Dietary lipids do not contribute to the higher hepatic triglyceride levels of fructose- compared to glucose-fed mice.	[Nunes, Patricia M.; Wright, Alan J.; Veltien, Andor; van Asten, Jack J. A.; Heerschap, Arend] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6525 ED Nijmegen, Netherlands; [Tack, Cees J.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands; [Jones, John G.] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal	Radboud University Nijmegen; Radboud University Nijmegen; Universidade de Coimbra	Nunes, PM (corresponding author), Natl Inst Med Res, Dept Physiol & Metab, Mill Hill, London NW7 1AA, England.	pnunes@nimr.mrc.ac.uk	van Asten, Jack/C-6559-2013; Jones, John/A-8684-2010; Veltien, Andor/E-2834-2016; Tack, Cees J/A-2368-2014; Heerschap, Arend/G-5228-2010	van Asten, Jack/0000-0002-2135-5682; Jones, John/0000-0002-3745-3885; Veltien, Andor/0000-0002-8090-5445; Nunes, Patricia/0000-0003-4740-8268	project PREDICCt [01C-104]; Dutch Heart Foundation; Dutch Diabetes Research Foundation; Dutch Kidney Foundation; Portuguese Foundation of Science and Technology project [PTDC/SAU-MET/111398/2009]	project PREDICCt; Dutch Heart Foundation(Netherlands Heart Foundation); Dutch Diabetes Research Foundation; Dutch Kidney Foundation; Portuguese Foundation of Science and Technology project	This research was performed within the framework of the Netherlands Center for Translational Molecular Medicine (CTMM; http://www.ctmm.nl), project PREDICCt (grant 01C-104), and supported by the Dutch Heart Foundation, Dutch Diabetes Research Foundation, and Dutch Kidney Foundation. Additional support was obtained from the Portuguese Foundation of Science and Technology project PTDC/SAU-MET/111398/2009.	Abdelmalek MF, 2012, HEPATOLOGY, V56, P952, DOI 10.1002/hep.25741; Abdelmalek MF, 2010, HEPATOLOGY, V51, P1961, DOI 10.1002/hep.23535; Assy N, 2008, CAN J GASTROENTEROL, V22, P811, DOI 10.1155/2008/810961; Bray George A, 2010, J Diabetes Sci Technol, V4, P1003; Chemlik M., 2012, P INT SOC MAG RESON, V20, P1704; Delgado TC, 2009, NMR BIOMED, V22, P310, DOI 10.1002/nbm.1327; Elliott SS, 2002, AM J CLIN NUTR, V76, P911, DOI 10.1093/ajcn/76.5.911; FOLCH J, 1957, J BIOL CHEM, V226, P497; Griffiths JR, 1980, BIOCHEM SOC T, V8, P641, DOI 10.1042/bst0080641; Haidari M, 2002, J BIOL CHEM, V277, P31646, DOI 10.1074/jbc.M200544200; Hellerstein MK, 1996, ANNU REV NUTR, V16, P523, DOI 10.1146/annurev.nu.16.070196.002515; HIGUCHI K, 1992, J LIPID RES, V33, P1753; Jones JG, 2001, MAGN RESON MED, V45, P156, DOI 10.1002/1522-2594(200101)45:1<156::AID-MRM1020>3.0.CO;2-Z; Jonkers R. A., 2013, DIABETOLOGIA, V56; Jonkers RAM, 2012, MAGN RESON MED, V68, P997, DOI 10.1002/mrm.23321; KasimKarakas SE, 1996, J LAB CLIN MED, V128, P208, DOI 10.1016/S0022-2143(96)90013-X; Koo HY, 2008, BBA-MOL BASIS DIS, V1782, P341, DOI 10.1016/j.bbadis.2008.02.007; Le KA, 2009, AM J CLIN NUTR, V89, P1760, DOI 10.3945/ajcn.2008.27336; Lewis GF, 2005, ENDOCRINOLOGY, V146, P247, DOI 10.1210/en.2004-1143; MOON RB, 1973, J BIOL CHEM, V248, P7276; Naressi A, 2001, MAGN RESON MATER PHY, V12, P141, DOI 10.1016/S1352-8661(01)00111-9; Nunes PM, 2012, AM J PHYSIOL-ENDOC M, V303, pE71, DOI 10.1152/ajpendo.00597.2011; Ouyang X, 2008, J HEPATOL, V48, P993, DOI 10.1016/j.jhep.2008.02.011; Pfeuffer J, 1999, MAGNET RESON MED, V41, P1077, DOI 10.1002/(SICI)1522-2594(199906)41:6<1077::AID-MRM1>3.0.CO;2-#; RIZKALLA SW, 1992, MOL CELL BIOCHEM, V109, P127, DOI 10.1007/BF00229766; Roglans N, 2007, HEPATOLOGY, V45, P778, DOI 10.1002/hep.21499; Sevastianova K, 2010, RADIOLOGY, V256, P466, DOI 10.1148/radiol.10091351; Sock ETN, 2010, BRIT J NUTR, V103, P939, DOI 10.1017/S0007114509992819; STAEWEN RS, 1990, INVEST RADIOL, V25, P559, DOI 10.1097/00004424-199005000-00015; Stanhope KL, 2009, J CLIN INVEST, V119, P1322, DOI 10.1172/JCI37385; Swarbrick MM, 2008, BRIT J NUTR, V100, P947, DOI 10.1017/S0007114508968252; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; Tappy L, 2010, PHYSIOL REV, V90, P23, DOI 10.1152/physrev.00019.2009; Teff KL, 2009, J CLIN ENDOCR METAB, V94, P1562, DOI 10.1210/jc.2008-2192; THORBURN AW, 1989, AM J CLIN NUTR, V49, P1155, DOI 10.1093/ajcn/49.6.1155; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Vila L, 2011, J NUTR BIOCHEM, V22, P741, DOI 10.1016/j.jnutbio.2010.06.005	37	24	24	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					1988	1997		10.1096/fj.13-241208	http://dx.doi.org/10.1096/fj.13-241208			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24500922				2022-12-28	WOS:000335336000004
J	Seijkens, T; Hoeksema, MA; Beckers, L; Smeets, E; Meiler, S; Levels, J; Tjwa, M; de Winther, MPJ; Lutgens, E				Seijkens, Tom; Hoeksema, Marten A.; Beckers, Linda; Smeets, Esther; Meiler, Svenja; Levels, Johannes; Tjwa, Marc; de Winther, Menno P. J.; Lutgens, Esther			Hypercholesterolemia-induced priming of hematopoietic stem and progenitor cells aggravates atherosclerosis	FASEB JOURNAL			English	Article						lipoproteins; inflammation	PROLIFERATION; MONOCYTOSIS; DISEASE; ACCUMULATION; MAINTENANCE; INFECTION; SUBSETS; LESSONS; LESIONS; MICE	Modulation of hematopoietic stem and progenitor cells (HSPCs) determines immune cell function. In this study, we investigated how hypercholesterolemia affects HSPC biology and atherosclerosis. Hypercholesterolemia induced loss of HSPC quiescence, characterized by increased proliferation and expression of cyclin B-1, C-1, and D-1, and a decreased expression of Rb, resulting in a 3.6- fold increase in the number of HSPCs in hypercholesterolemic Ldlr(-/-) mice. Competitive bone marrow (BM) transplantations showed that a hypercholesterolemic BM microenvironment activates HSPCs and skews their development toward myeloid lineages. Conversely, hypercholesterolemia-primed HSPCs acquired an enhanced propensity to generate myeloid cells, especially granulocytes and Ly6C(high) monocytes, even in a normocholesterolemic BM microenvironment. In conformity, macrophages differentiated from hypercholesterolemia-primed HSPCs produced 17.0% more TNF-, 21.3% more IL-6, and 10.5% more MCP1 than did their normocholesterolemic counterparts. Hypercholesterolemia-induced priming of HSPCs generated leukocytes that more readily migrated into the artery, which resulted in a 2.1-fold increase in atherosclerotic plaque size. In addition, these plaques had a more advanced phenotype and exhibited a 1.2-fold increase in macrophages and 1.8-fold increase in granulocytes. These results identify hypercholesterolemia-induced activation and priming of HSPCs as a novel pathway in the development of atherosclerosis. Inhibition of this proinflammatory differentiation pathway on the HSPC level has the potential to reduce atherosclerosis.Seijkens, T., Hoeksema, M. A., Beckers, L., Smeets, E., Meiler, S., Levels, J., Tjwa, M., de Winther, M. P. J., Lutgens, E. Hypercholesterolemia-induced priming of hematopoietic stem and progenitor cells aggravates atherosclerosis.	[Seijkens, Tom; Hoeksema, Marten A.; Beckers, Linda; Smeets, Esther; Meiler, Svenja; de Winther, Menno P. J.; Lutgens, Esther] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 CZ Amsterdam, Netherlands; [Levels, Johannes] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1105 CZ Amsterdam, Netherlands; [Tjwa, Marc] Goethe Univ Frankfurt, Inst Transfus Med, Lab Vasc Hematol Angiogenesis, D-60054 Frankfurt, Germany; [Lutgens, Esther] Univ Munich, Inst Cardiovasc Prevent IPEK, Munich, Germany	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Goethe University Frankfurt; University of Munich	Lutgens, E (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 15, NL-1105 CZ Amsterdam, Netherlands.	e.lutgens@amc.uva.nl	Lutgens, Esther/E-2919-2010	Lutgens, Esther/0000-0002-2609-5744; Seijkens, Tom/0000-0001-6370-1267; Hoeksema, Marten/0000-0001-5981-121X; de Winther, Menno/0000-0002-4038-6636	Dutch Heart Foundation; Netherlands Organization for Scientific Research (NOW); Academisch Medisch Centrum (AMC); Humboldt Foundation; Deutsche Forschungsgemeinschaft [DFG809, SFB 1054]; Netherlands CardioVascular Research Initiative [CVON2011-19]	Dutch Heart Foundation(Netherlands Heart Foundation); Netherlands Organization for Scientific Research (NOW)(Netherlands Organization for Scientific Research (NWO)); Academisch Medisch Centrum (AMC); Humboldt Foundation(Alexander von Humboldt Foundation); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Netherlands CardioVascular Research Initiative	This study was supported by the Dutch Heart Foundation (Dr. E. Dekker grant to T. S.; Dr. E. Dekker Established Investigator grant to E. L. and M.P.J.D.W.), the Netherlands Organization for Scientific Research (NOW; Vidi grant to E. L.; Vici grant to E. L.), the Academisch Medisch Centrum (AMC; fellowship to E. L. and M.P.J.D.W.), the Humboldt Foundation (Sofja Kovalevskaja grant to E. L.), and the Deutsche Forschungsgemeinschaft (DFG809 and SFB 1054 to E. L.). The authors acknowledge the support from the Netherlands CardioVascular Research Initiative (participants: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences) for the GENIUS project Generating the Best Evidence-Based Pharmaceutical Targets for Atherosclerosis (CVON2011-19).	Arbel Y, 2012, ATHEROSCLEROSIS, V225, P456, DOI 10.1016/j.atherosclerosis.2012.09.009; Baldridge MT, 2011, TRENDS IMMUNOL, V32, P57, DOI 10.1016/j.it.2010.12.003; BARLOW CW, 1990, CARDIOVASC DRUG THER, V4, P1389, DOI 10.1007/BF02018267; Coller BS, 2005, ARTERIOSCL THROM VAS, V25, P658, DOI 10.1161/01.ATV.0000156877.94472.a5; Cortez M, 2013, INFLAMMATION, V36, P379, DOI 10.1007/s10753-012-9557-z; Daria D, 2008, BLOOD, V111, P1894, DOI 10.1182/blood-2007-02-071746; Davis R, 2012, CELL CYCLE, V11, P109, DOI 10.4161/cc.11.1.18473; Drechsler M, 2010, CIRCULATION, V122, P1837, DOI 10.1161/CIRCULATIONAHA.110.961714; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; FELDMAN DL, 1991, ARTERIOSCLER THROMB, V11, P985, DOI 10.1161/01.ATV.11.4.985; Feng Y., 2012, PLOS ONE, V11; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P1275, DOI 10.1056/NEJM197406062902302; Kanters E, 2004, BLOOD, V103, P934, DOI 10.1182/blood-2003-05-1450; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; King KY, 2011, NAT REV IMMUNOL, V11, P685, DOI 10.1038/nri3062; Kiseleva EP, 2003, B EXP BIOL MED+, V135, P475, DOI 10.1023/A:1024923611004; Kolb-Maurer A, 2004, FEMS IMMUNOL MED MIC, V40, P147, DOI 10.1016/S0928-8244(03)00305-5; Lievens D, 2010, BLOOD, V116, P4317, DOI 10.1182/blood-2010-01-261206; Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293; Matsumoto A, 2013, BBA-GEN SUBJECTS, V1830, P2335, DOI 10.1016/j.bbagen.2012.07.004; Murphy AJ, 2011, J CLIN INVEST, V121, P4138, DOI 10.1172/JCI57559; Niu HT, 2013, BLOOD, V121, P1986, DOI 10.1182/blood-2012-05-433755; Oduro KA, 2012, BLOOD, V120, P2203, DOI 10.1182/blood-2011-11-391342; OLIVARES R, 1993, AM J EPIDEMIOL, V137, P49, DOI 10.1093/oxfordjournals.aje.a116601; Pronk CJH, 2011, J EXP MED, V208, P1563, DOI 10.1084/jem.20110752; Schuettpelz LG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00204; Soehnlein O, 2013, TRENDS ENDOCRIN MET, V24, P129, DOI 10.1016/j.tem.2012.10.008; Soehnlein O, 2009, J CELL MOL MED, V13, P4293, DOI 10.1111/j.1582-4934.2009.00965.x; Spann NJ, 2012, CELL, V151, P138, DOI 10.1016/j.cell.2012.06.054; Sweetnam PM, 1997, AM J EPIDEMIOL, V145, P416; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Takizawa H, 2012, BLOOD, V119, P2991, DOI 10.1182/blood-2011-12-380113; Tjwa M, 2009, J CLIN INVEST, V119, P1008, DOI 10.1172/JCI36010; Tolani S, 2013, ATHEROSCLEROSIS, V229, P79, DOI 10.1016/j.atherosclerosis.2013.03.031; Ueda Y, 2005, J EXP MED, V201, P1771, DOI 10.1084/jem.20041419; Ueda Y, 2009, J IMMUNOL, V182, P6477, DOI 10.4049/jimmunol.0803961; Viatour P, 2008, CELL STEM CELL, V3, P416, DOI 10.1016/j.stem.2008.07.009; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415; Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538; Yvan-Charvet L, 2010, SCIENCE, V328, P1689, DOI 10.1126/science.1189731	41	79	82	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2202	2213		10.1096/fj.13-243105	http://dx.doi.org/10.1096/fj.13-243105			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24481967				2022-12-28	WOS:000335336000023
J	Schroder-Heurich, B; Wieland, B; Lavin, MF; Schindler, D; Dork, T				Schroeder-Heurich, Bianca; Wieland, Britta; Lavin, Martin F.; Schindler, Detlev; Doerk, Thilo			Protective role of RAD50 on chromatin bridges during abnormal cytokinesis	FASEB JOURNAL			English	Article						Aurora B; DNA damage; MRN complex; anaphase bridges; mitosis	STRAND BREAK REPAIR; HOMOLOGY-DIRECTED REPAIR; DNA-REPAIR; METAPHASE CHROMOSOME; ANAPHASE BRIDGES; HUMAN MRE11; HISTONE H3; COMPLEX; BINDING; PATHWAY	Faithful chromosome segregation is required for preserving genomic integrity. Failure of this process may entail chromatin bridges preventing normal cytokinesis. To test whether RAD50, a protein normally involved in DNA double-strand break repair, is involved in abnormal cytokinesis and formation of chromatin bridges, we used immunocytochemical and protein interaction assays. RAD50 localizes to chromatin bridges during aberrant cytokinesis and subsequent stages of the cell cycle, either decorating the entire bridge or focally accumulating at the midbody zone. Ionizing radiation led to an approximate to 4-fold increase in the rate of chromatin bridges in an ataxia telangiectatica mutated (ATM)-dependent manner in human RAD50-proficient fibroblasts but not in RAD50-deficient cells. Cells with a RAD50-positive chromatin bridge were able to continue cell cycling and to progress through S phase (44%), whereas RAD50 knockdown caused a deficiency in chromatin bridges as well as an approximate to 4-fold prolonged duration of mitosis. RAD50 colocalized and directly interacted with Aurora B kinase and phospho-histone H3, and Aurora B kinase inhibition led to a deficiency in RAD50-positive bridges. Based on these observations, we propose that RAD50 is a crucial factor for the stabilization and shielding of chromatin bridges. Our study provides evidence for a hitherto unknown role of RAD50 in abnormal cytokinesis.Schroder-Heurich, B., Wieland, B., Lavin, M. F., Schindler, D., Dork, T. Protective role of RAD50 on chromatin bridges during abnormal cytokinesis.	[Schroeder-Heurich, Bianca; Wieland, Britta; Doerk, Thilo] Hannover Med Sch, Gynaecol Res Unit, D-30625 Hannover, Germany; [Lavin, Martin F.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Lavin, Martin F.] Univ Queensland, Clin Res Ctr, Herston, Qld, Australia; [Schindler, Detlev] Univ Wurzburg, Inst Human Genet, Wurzburg, Germany	Hannover Medical School; QIMR Berghofer Medical Research Institute; University of Queensland; University of Wurzburg	Schroder-Heurich, B (corresponding author), Hannover Med Sch, Gynaecol Res Unit OE 6411, Carl Neuberg Str 1, D-30625 Hannover, Germany.	schroeder-heurich.bianca@mh-hannover.de	Lavin, Martin F/F-5961-2014; Dörk, Thilo/J-8620-2012	Lavin, Martin F/0000-0002-5940-4769; Dörk, Thilo/0000-0002-9458-0282; Schroder-Heurich, Bianca/0000-0002-5996-2373				Acilan C, 2007, GENE CHROMOSOME CANC, V46, P522, DOI 10.1002/gcc.20425; Anderson DE, 2001, J BIOL CHEM, V276, P37027, DOI 10.1074/jbc.M106179200; Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777; Chapman JR, 2008, EMBO REP, V9, P795, DOI 10.1038/embor.2008.103; Chen CT, 2009, CELL, V136, P397, DOI 10.1016/j.cell.2009.01.028; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Gatei M, 2011, J BIOL CHEM, V286, P31542, DOI 10.1074/jbc.M111.258152; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goodarzi AA, 2009, BIOCHEM SOC T, V37, P569, DOI 10.1042/BST0370569; Hari FJ, 2010, EMBO REP, V11, P387, DOI 10.1038/embor.2010.30; Harvey SH, 2002, GENOME BIOL, V3; Hirano T, 2006, NAT REV MOL CELL BIO, V7, P311, DOI 10.1038/nrm1909; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Huang HM, 2008, CANCER RES, V68, P3724, DOI 10.1158/0008-5472.CAN-08-0479; Kinoshita E, 2009, CHROMOSOME RES, V17, P277, DOI 10.1007/s10577-008-9018-6; Laulier C, 2011, NUCLEIC ACIDS RES, V39, P5935, DOI 10.1093/nar/gkr187; Lichten M, 2005, NAT STRUCT MOL BIOL, V12, P392, DOI 10.1038/nsmb0505-392; Losada A, 2001, BIOESSAYS, V23, P924, DOI 10.1002/bies.1133; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; McAleenan A, 2013, NATURE, V493, P250, DOI 10.1038/nature11630; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Norden C, 2006, CELL, V125, P85, DOI 10.1016/j.cell.2006.01.045; Olive PL, 1998, RADIAT RES, V150, pS42, DOI 10.2307/3579807; Pfeiffer P, 2004, CYTOGENET GENOME RES, V104, P7, DOI 10.1159/000077460; Rozier L, 2013, MOL CELL, V49, P1097, DOI 10.1016/j.molcel.2013.01.023; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Tamulevicius P, 2007, RADIAT RES, V167, P1, DOI 10.1667/RR0751.1; Tittel-Elmer M, 2012, MOL CELL, V48, P98, DOI 10.1016/j.molcel.2012.07.004; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; van der Linden E, 2009, NUCLEIC ACIDS RES, V37, P1580, DOI 10.1093/nar/gkn1072; Vinciguerra P, 2010, J CLIN INVEST, V120, P3834, DOI 10.1172/JCI43391; Waltes R, 2009, AM J HUM GENET, V84, P605, DOI 10.1016/j.ajhg.2009.04.010; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Williams GJ, 2010, DNA REPAIR, V9, P1299, DOI 10.1016/j.dnarep.2010.10.001; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	42	7	8	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1331	1341		10.1096/fj.13-236984	http://dx.doi.org/10.1096/fj.13-236984			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24344331				2022-12-28	WOS:000335324800025
J	Ruedel, A; Stark, K; Kaufmann, S; Bauer, R; Reinders, J; Rovensky, J; Blazickova, S; Oefner, PJ; Bosserhoff, AK				Ruedel, Anke; Stark, Klaus; Kaufmann, Simone; Bauer, Richard; Reinders, Joerg; Rovensky, Jozef; Blazickova, Stanislava; Oefner, Peter J.; Bosserhoff, Anja K.			N-cadherin promoter polymorphisms and risk of osteoarthritis	FASEB JOURNAL			English	Article						genetic association study; CDH2; hnRNP K; rs11564299	GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; TRANSCRIPTION FACTOR; EXPRESSION; SUSCEPTIBILITY; MIGRATION; TISSUE; CELLS; GENE; IDENTIFICATION	Osteoarthritis (OA) is the most common form of arthritis. It is characterized by cartilage destruction and bone remodeling, mediated in part by synovial fibroblasts (SFs). Given the functional significance of cadherins in these cells, we aimed at determining the role of genetic variants of N-cadherin (CDH2) in OA of the knee and hip. Six single-nucleotide polymorphisms in the genomic region of the CDH2 gene were genotyped in 312 patients with OA and 259 healthy control subjects. Gene expression of CDH2 was analyzed by qRT-PCR. Liquid chromatography-mass spectrometry was used to identify a transcription factor isolated by DNA pulldown. Its potential for binding to gene variants was examined by electrophoretic mobility shift assay, enzyme-linked immunosorbent assay, and chromatin immunoprecipitation. Genetic analysis identified a polymorphism located in the CDH2 promoter region to be associated with risk of OA. The minor allele of rs11564299 had a protective effect against OA. Compared to carriers of the major allele, carriers of the minor allele of rs11564299 displayed increased N-cadherin levels in SFs. Based on in silico analysis, the minor allele was predicted to generate a novel transcription factor binding site, Direct-binding assays and mass spectrometric analysis identified hnRNP K as binding selectively to the minor allele. In summary, a CDH2 promoter polymorphism influences the risk of OA, and hnRNP K was found to be involved in the regulation of elevated N-cadherin expression in patients with OA carrying the minor allele of rs11564299.Ruedel, A., Stark, K., Kaufmann, S., Bauer, R., Reinders, J., Rovensky, J., Blaikova, S., Oefner, P. J., Bosserhoff, A. K. N-cadherin promoter polymorphisms and risk of osteoarthritis.	[Ruedel, Anke; Kaufmann, Simone; Bosserhoff, Anja K.] Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; [Stark, Klaus] Univ Regensburg, Dept Internal Med 2, D-93053 Regensburg, Germany; [Stark, Klaus] Univ Regensburg, Dept Genet Epidemiol, D-93053 Regensburg, Germany; [Reinders, Joerg; Oefner, Peter J.] Univ Regensburg, Inst Funct Genom, D-93053 Regensburg, Germany; [Bauer, Richard] Univ Hosp Regensburg, Dept Oral & Maxillofacial Surg, Regensburg, Germany; [Rovensky, Jozef; Blazickova, Stanislava] Natl Inst Rheumat Dis, Piestany, Slovakia	University of Regensburg; University of Regensburg; University of Regensburg; University of Regensburg; University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Stark, Klaus/L-7367-2013; Bosserhoff, Anja/GNH-4801-2022	Stark, Klaus/0000-0002-7832-1942; Bosserhoff, Anja/0000-0001-8147-394X; Reinders, Joerg/0000-0003-1025-7849	Deutsche Forschungsgemeinschaft (DFG) [FOR 696]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Rainer Straub (Internal Medicine I, University Hospital of Regensburg) for supplying the research material and for helpful discussions. This study was supported by Deutsche Forschungsgemeinschaft (DFG) grant FOR 696 to A.K.B. and K.S.	Agarwal SK, 2008, ARTHRITIS RHEUM-US, V58, P1044, DOI 10.1002/art.23369; [Anonymous], 2012, LANCET; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Becker SF, 2012, ARCH BIOCHEM BIOPHYS, V524, P30, DOI 10.1016/j.abb.2012.02.013; Benotmane AM, 1997, ANAL BIOCHEM, V250, P181, DOI 10.1006/abio.1997.2231; Bijsterbosch J, 2013, OSTEOARTHR CARTILAGE, V21, P565, DOI 10.1016/j.joca.2013.01.011; Blindt R, 2004, CARDIOVASC RES, V62, P212, DOI 10.1016/j.cardiores.2004.01.004; Chang SK, 2011, P NATL ACAD SCI USA, V108, P8402, DOI 10.1073/pnas.1019437108; Collinet C, 2013, PROG MOL BIOL TRANSL, V116, P25, DOI 10.1016/B978-0-12-394311-8.00002-9; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Evangelou E, 2013, ANN RHEUM DIS; Evangelou E, 2011, ANN RHEUM DIS, V70, P349, DOI 10.1136/ard.2010.132787; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gonzalez A, 2013, OSTEOARTHR CARTILAGE, V21, P1443, DOI 10.1016/j.joca.2013.07.001; GRUNWALD GB, 1982, J CELL SCI, V55, P69; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Ivanov AI, 2013, INT REV CEL MOL BIO, V303, P27, DOI 10.1016/B978-0-12-407697-6.00002-7; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kiel DP, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S14; Ku CS, 2010, J HUM GENET, V55, P195, DOI 10.1038/jhg.2010.19; Kuphal S, 2006, ONCOGENE, V25, P248, DOI 10.1038/sj.onc.1209054; Lee DM, 2007, SCIENCE, V315, P1006, DOI 10.1126/science.1137306; Li G, 2001, CANCER RES, V61, P3819; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Miller LE, 2000, FASEB J, V14, P2097, DOI 10.1096/fj.99-1082com; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Panoutsopoulou K., 2013, J MED GENET, DOI 10.1136/jmedgenet-2013-101754; Peglion F, 2012, CELL ADHES MIGR, V6, P327, DOI 10.4161/cam.20855; PENGUE G, 1993, FEBS LETT, V321, P233, DOI 10.1016/0014-5793(93)80115-B; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Schubert T, 2009, INT J IMMUNOPATH PH, V22, P715, DOI 10.1177/039463200902200317; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirasawa S, 2004, HUM MOL GENET, V13, P2221, DOI 10.1093/hmg/ddh245; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; Waldron-Lynch F, 2001, GENES IMMUN, V2, P82, DOI 10.1038/sj.gene.6363738; Wenke AK, 2009, FEBS J, V276, P2494, DOI 10.1111/j.1742-4658.2009.06973.x; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864	38	14	15	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					683	691		10.1096/fj.13-238295	http://dx.doi.org/10.1096/fj.13-238295			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24148886	Green Submitted			2022-12-28	WOS:000331072200016
J	Yuan, YM; Li, MY; Hong, N; Hong, YH				Yuan, Yongming; Li, Mingyou; Hong, Ni; Hong, Yunhan			Correlative light and electron microscopic analyses of mitochondrial distribution in blastomeres of early fish embryos	FASEB JOURNAL			English	Article						medaka; Tom20; localization; fluorescent protein; out membrane	STEM-CELLS; DRUG SELECTION; IN-VITRO; MEDAKA; ESTABLISHMENT; PRESERVATION; FLUORESCENCE; ZEBRAFISH; PROTEINS; IMPORT	Early embryos of vertebrates undergo remarkable dynamic molecular events, such as embryonic gradient, cellular polarity, and asymmetry necessary for cell fate decisions. Correlative light and electron microscopy (CLEM) is a powerful tool to investigate rare or dynamic molecular events and has been developed for relatively small cells in culture and tissues but is not yet available for large cells of early development stage embryos. Here we report the capability of CLEM in blastomeres of medaka fish by using the mitochondria detection system. A short N-terminal signal peptide of the mitochondrial protein Tom20 was linked to green fluorescent protein (GFP), resulting in a fusion protein termed Tom20:GFP. The subcellular location of Tom20:GFP in medaka blastomeres reveals the lack of mitochondrial distribution in pseudopodia as well as inconspicuous redistribution during divisions. Blastomeres, after sample preparation procedures including high-pressure freezing and freeze substitution, are able to preserve fluorescence, antigenicity, and fine structures, which allows for precise correlation between the Tom20:GFP fluorescence and mitochondria on merged light and electron micrographs. Furthermore, nanogold immunostaining for Tom20:GFP and endogenous Tom20 revealed their specific localization on the mitochondrial outer membrane. Our results extend the CLEM approach to early development stage embryos of a vertebrate.Yuan, Y., Li, M., Hong, N., Hong, Y. Correlative light and electron microscopic analyses of mitochondrial distribution in blastomeres of early fish embryos.	[Yuan, Yongming; Li, Mingyou; Hong, Ni; Hong, Yunhan] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; [Li, Mingyou; Hong, Yunhan] Shanghai Ocean Univ, Coll Fisheries & Life Sci, Shanghai, Peoples R China	National University of Singapore; Shanghai Ocean University	Hong, YH (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbshyh@nus.edu.sg	Hong, Ni/Y-6114-2018; Yuan, Yongming/H-7240-2016; Hong, Yunhan/D-4197-2009	Hong, Ni/0000-0002-9404-3110; Yuan, Yongming/0000-0002-2057-2204; Li, Mingyou/0000-0002-8729-7964	National Research Foundation Singapore [NRF-CRP7-2010-03]	National Research Foundation Singapore(National Research Foundation, Singapore)	The authors thank J. R. Deng for fish breeding and C. M. Foong for laboratory management. This work was supported by the National Research Foundation Singapore (NRF-CRP7-2010-03). Author contributions: Y.Y. and Y.H. designed the experiment and prepared the manuscript; Y.Y., M.L., and N.H. performed the research work. The authors declare no conflicts of interest.	Arismendi-Morillo G, 2012, ULTRASTRUCT PATHOL, V36, P409, DOI 10.3109/01913123.2012.694582; Brown E, 2009, SEMIN CELL DEV BIOL, V20, P910, DOI 10.1016/j.semcdb.2009.07.006; Endo T, 2010, BBA-MOL CELL RES, V1803, P706, DOI 10.1016/j.bbamcr.2009.11.007; GARRIS DR, 1984, GYNECOL OBSTET INVES, V17, P10, DOI 10.1159/000299116; Giepmans BNG, 2008, HISTOCHEM CELL BIOL, V130, P211, DOI 10.1007/s00418-008-0460-5; He WZ, 2008, NATURE, V455, P542, DOI 10.1038/nature07255; Herpin A, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-3; Hong N, 2013, STEM CELLS DEV, V22, DOI 10.1089/scd.2012.0144; Hong N, 2012, STEM CELLS DEV, V21, P2333, DOI 10.1089/scd.2011.0630; Hong N, 2010, CELL MOL LIFE SCI, V67, P1189, DOI 10.1007/s00018-009-0247-4; Hong YH, 1998, P NATL ACAD SCI USA, V95, P3679, DOI 10.1073/pnas.95.7.3679; Hong YH, 2004, P NATL ACAD SCI USA, V101, P8011, DOI 10.1073/pnas.0308668101; Hong YH, 2004, TRANSGENIC RES, V13, P41, DOI 10.1023/B:TRAG.0000017172.71391.fa; Hong YH, 1996, MOL MAR BIOL BIOTECH, V5, P93; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; Kukulski W, 2011, J CELL BIOL, V192, P111, DOI 10.1083/jcb.201009037; Li MY, 2009, MECH DEVELOP, V126, P366, DOI 10.1016/j.mod.2009.02.004; Liu LX, 2009, GENE EXPR PATTERNS, V9, P541, DOI 10.1016/j.gep.2009.06.008; MCDONALD K, 1993, MICROSC RES TECHNIQ, V24, P465, DOI 10.1002/jemt.1070240603; Muller-Reichert T, 2007, METHOD CELL BIOL, V79, P101, DOI 10.1016/S0091-679X(06)79004-5; Nebenfuhr A, 2000, PLANT PHYSIOL, V124, P135, DOI 10.1104/pp.124.1.135; Nixon SJ, 2009, TRAFFIC, V10, P131, DOI 10.1111/j.1600-0854.2008.00859.x; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Shu XK, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001041; van Rijnsoever C, 2008, NAT METHODS, V5, P973, DOI 10.1038/nmeth.1263; Vanhecke D, 2008, METHOD CELL BIOL, V88, P151, DOI 10.1016/S0091-679X(08)00409-3; Waizenegger T, 2003, J BIOL CHEM, V278, P42064, DOI 10.1074/jbc.M305736200; Wittbrodt J, 2002, NAT REV GENET, V3, P53, DOI 10.1038/nrg704; Yamano K, 2011, NAT CELL BIOL, V13, P1026, DOI 10.1038/ncb2334; Yi MS, 2010, NAT PROTOC, V5, P1418, DOI 10.1038/nprot.2010.104; Yi MS, 2010, SCI CHINA LIFE SCI, V53, P426, DOI 10.1007/s11427-010-0079-3; Yi MS, 2009, SCIENCE, V326, P430, DOI 10.1126/science.1175151; Zhao HB, 2012, ANAL CHEM, V84, P987, DOI 10.1021/ac202541t	35	9	9	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					577	585		10.1096/fj.13-233635	http://dx.doi.org/10.1096/fj.13-233635			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24136588				2022-12-28	WOS:000331072200006
J	Delaine-Smith, RM; Sittichokechaiwut, A; Reilly, GC				Delaine-Smith, Robin M.; Sittichokechaiwut, Anuphan; Reilly, Gwendolen C.			Primary cilia respond to fluid shear stress and mediate flow-induced calcium deposition in osteoblasts	FASEB JOURNAL			English	Article						mechanotransduction; oscillatory fluid flow; osteogenesis; extracellular matrix	STEM-CELL DIFFERENTIATION; BONE-CELLS; MATRIX PRODUCTION; OSTEOCYTES; MECHANOTRANSDUCTION; POLYCYSTIN-1; POLARIS	Bone turnover in vivo is regulated by mechanical forces such as shear stress originating from interstitial oscillatory fluid flow (OFF), and bone cells in vitro respond to mechanical loading. However, the mechanisms by which bone cells sense mechanical forces, resulting in increased mineral deposition, are not well understood. The aim of this study was to investigate the role of the primary cilium in mechanosensing by osteoblasts. MLO-A5 murine osteoblasts were cultured in monolayer and subjected to two different OFF regimens: 5 short (2 h daily) bouts of OFF followed by morphological analysis of primary cilia; or exposure to chloral hydrate to damage or remove primary cilia and 2 short bouts (2 h on consecutive days) of OFF. Primary cilia were shorter and there were fewer cilia per cell after exposure to periods of OFF compared with static controls. Damage or removal of primary cilia inhibited OFF-induced PGE(2) release into the medium and mineral deposition, assayed by Alizarin red staining. We conclude that primary cilia are important mediators of OFF-induced mineral deposition, which has relevance for the design of bone tissue engineering strategies and may inform clinical treatments of bone disorders causes by load-deficiency.Delaine-Smith, R. M., Sittichokechaiwut, A., Reilly, G. C. Primary cilia respond to fluid shear stress and mediate flow-induced calcium deposition in osteoblasts.	[Delaine-Smith, Robin M.; Reilly, Gwendolen C.] Univ Sheffield, Dept Mat Sci & Engn, Kroto Res Inst, Sheffield, S Yorkshire, England; [Sittichokechaiwut, Anuphan] Naresuan Univ, Periodontol Sect, Dept Prevent Dent, Phitsanulok, Thailand	University of Sheffield; Naresuan University	Delaine-Smith, RM (corresponding author), Queen Mary Univ London, Sch Engn & Mat Sci, Mile End Rd, London E1 4NS, England.	r.delaine-smith@qmul.ac.uk	Sittichokechaiwut, Anuphan/GRS-0477-2022; Reilly, Gwendolen C./C-3456-2009	Reilly, Gwendolen C./0000-0003-1456-1071	Engineering and Physical Sciences Research Council (EPSRC); University of Sheffield Women Academic Returners Programme; University of Sheffield Excellence Exchange Scheme; Royal Thai Government	Engineering and Physical Sciences Research Council (EPSRC)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); University of Sheffield Women Academic Returners Programme; University of Sheffield Excellence Exchange Scheme; Royal Thai Government	The authors thank the Engineering and Physical Sciences Research Council (EPSRC) and the University of Sheffield Women Academic Returners Programme for funding provided to G. R. for R.M.D.-S. Part of the imaging was performed at the Kroto Research Institute Confocal Imaging Facility. Prof. Lynda Bonewald (University of Missouri, Kansas City, MO, USA) kindly provided the MLO-A5 cells. Preliminary data (not shown) were gathered and technical training was undertaken by A. S. at Stanford University (Stanford, CA, USA) in the laboratory of Dr. Christopher Jacobs with funding from the University of Sheffield Excellence Exchange Scheme and the Royal Thai Government. The authors also thank Dr. Jacobs (currently at Columbia University, New York, NY, USA) for helpful discussions. G. R. is currently a member of the Insigneo Institute for In Silico Medicine (University of Sheffield). The authors declare no conflicts of interest.	Abdul-Majeed S, 2012, CELL MOL LIFE SCI, V69, P165, DOI 10.1007/s00018-011-0744-0; Abdul-Majeed S, 2011, HYPERTENSION, V58, P325, DOI 10.1161/HYPERTENSIONAHA.111.172080; Besschetnova TY, 2010, CURR BIOL, V20, P182, DOI 10.1016/j.cub.2009.11.072; Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004; Delaine-Smith RM, 2012, EUR CELLS MATER, V24, P162, DOI 10.22203/eCM.v024a12; Delaine-Smith Robin M, 2012, Muscles Ligaments Tendons J, V2, P169; Delaine-Smith RM, 2011, VITAM HORM, V87, P417, DOI 10.1016/B978-0-12-386015-6.00039-1; Donahue TLH, 2003, J BIOMECH, V36, P1363, DOI 10.1016/S0021-9290(03)00118-0; Donnelly E, 2010, J ORTHOP RES, V28, P77, DOI 10.1002/jor.20946; Farnum CE, 2009, METHOD CELL BIOL, V94, P117, DOI 10.1016/S0091-679X(08)94006-1; Felgner H, 1996, J CELL SCI, V109, P509; Gardner K, 2011, J ORTHOP RES, V29, P582, DOI 10.1002/jor.21271; Geiger RC, 2009, AM J RESP CELL MOL, V40, P76, DOI 10.1165/rcmb.2007-0307OC; Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235; Hoey DA, 2012, J BIOMECH, V45, P17, DOI 10.1016/j.jbiomech.2011.08.008; Hoey DA, 2011, BIOCHEM BIOPH RES CO, V412, P182, DOI 10.1016/j.bbrc.2011.07.072; Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087; Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021-9290(98)00114-6; Jensen CG, 2004, CELL BIOL INT, V28, P101, DOI 10.1016/j.cellbi.2003.11.007; Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622; Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09-148007; Lee KL, 2010, CLIN REV BONE MINER, V8, P201, DOI 10.1007/s12018-010-9078-y; Leucht P, 2013, MED ENG PHYS, V35, P392, DOI 10.1016/j.medengphy.2012.06.005; Liedert Astrid, 2008, V1, P253; Liu W, 2003, AM J PHYSIOL-RENAL, V285, pF998, DOI 10.1152/ajprenal.00067.2003; Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104; Malone AMD, 2007, AM J PHYSIOL-CELL PH, V292, pC1830, DOI 10.1152/ajpcell.00352.2005; Masyuk AI, 2008, AM J PHYSIOL-GASTR L, V295, pG725, DOI 10.1152/ajpgi.90265.2008; McGlashan SR, 2006, J HISTOCHEM CYTOCHEM, V54, P1005, DOI 10.1369/jhc.5A6866.2006; McGlashan SR, 2010, CELL BIOL INT, V34, P441, DOI 10.1042/CBI20090094; MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028; Morris HL, 2010, P I MECH ENG H, V224, P1509, DOI 10.1243/09544119JEIM751; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006; Pitaval A, 2010, J CELL BIOL, V191, P303, DOI 10.1083/jcb.201004003; Ponik SM, 2007, J CELL BIOCHEM, V100, P794, DOI 10.1002/jcb.21089; Potter DR, 2008, CIRC RES, V102, P770, DOI 10.1161/CIRCRESAHA.107.160226; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232-002-1042-4; Prodromou NV, 2012, J CELL SCI, V125, P4297, DOI 10.1242/jcs.100545; Qiu N, 2012, J CELL SCI, V125, P1945, DOI 10.1242/jcs.095893; Reilly GC, 2003, BIORHEOLOGY, V40, P591; Reilly GC, 2010, J BIOMECH, V43, P55, DOI 10.1016/j.jbiomech.2009.09.009; Rydholm S, 2010, AM J PHYSIOL-RENAL, V298, pF1096, DOI 10.1152/ajprenal.00657.2009; Satir P, 2010, J CELL SCI, V123, P499, DOI 10.1242/jcs.050377; Sittichockechaiwut A, 2009, BONE, V44, P822, DOI 10.1016/j.bone.2008.12.027; Sittichokechaiwut A, 2010, EUR CELLS MATER, V20, P45; Temiyasathit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033368; Tummala P, 2010, CELL MOL BIOENG, V3, P207, DOI 10.1007/s12195-010-0127-x; Wann AKT, 2012, CELL MOL LIFE SCI, V69, P2967, DOI 10.1007/s00018-012-0980-y; Wann AKT, 2012, FASEB J, V26, P1663, DOI 10.1096/fj.11-193649; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Xiao ZS, 2011, FASEB J, V25, P2418, DOI 10.1096/fj.10-180299; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Yoder BK, 2002, AM J PHYSIOL-RENAL, V282, pF541, DOI 10.1152/ajprenal.00273.2001; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200	59	57	63	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					430	439		10.1096/fj.13-231894	http://dx.doi.org/10.1096/fj.13-231894			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24097311	Green Published, Green Accepted			2022-12-28	WOS:000333526100040
J	Sugatani, J; Sadamitsu, S; Yamaguchi, M; Yamazaki, Y; Higa, R; Hattori, Y; Uchida, T; Ikari, A; Sugiyama, W; Watanabe, T; Ishii, S; Miwa, M; Shimizu, T				Sugatani, Junko; Sadamitsu, Satoshi; Yamaguchi, Masahiko; Yamazaki, Yasuhiro; Higa, Ryoko; Hattori, Yoshiki; Uchida, Takahiro; Ikari, Akira; Sugiyama, Wataru; Watanabe, Tatsuo; Ishii, Satoshi; Miwa, Masao; Shimizu, Takao			Antiobese function of platelet-activating factor: increased adiposity in platelet-activating factor receptor- deficient mice with age	FASEB JOURNAL			English	Article						(1); (3)-adrenergic receptor; uncoupling protein 1; UCP1; brown adipocytes; brown adipose tissue macrophages; thermogenesis	BROWN ADIPOCYTES; FACTOR PAF; ADAPTIVE THERMOGENESIS; LIPID MEDIATORS; ADULT HUMANS; TISSUE; OBESITY; METABOLISM; EXPRESSION; FAT	Platelet-activating factor receptor (PAFR)-deficient mice developed a more severe obese state characterized by higher body mass (approximate to 25%) and epididymal fat mass (approximate to 55%) with age than that of wild-type (WT) littermates. PAFR-deficient mice did not show changes in the expression of critical genes involved in anabolic and catabolic metabolism in adipose, liver, and muscle tissues between 6 and 36 wk. However, a 38-81% reduction in (3)/(1)-adrenergic receptor (AR) and uncoupling protein 1 (UCP1) mRNA and protein levels was observed in the interscapular brown adipose tissue (BAT) of PAFR-deficient mice. Whereas a single injection of the (3)-adrenergic agonist, CL-316,243 (25 g/kg) increased temperatures in the brown fat and rectums of WT mice, this increase in temperature was markedly suppressed in PAFR-deficient mice. Acetyl-CoA:lyso-platelet-activating factor (PAF) acetyltransferase, which is involved in PAF biosynthesis, and the PAF receptor were predominantly localized in BAT macrophages, whereas brown adipocytes possessed the enzyme and functional PAF receptors. The stimulation of brown adipocytes by PAF induced the expression of (3)-AR mRNA and protein (1.5- and 1.9-fold, respectively), but not that of UCP1. These results indicate that obesity in PAFR-deficient mice resulted from impaired BAT activity and suggest that the antiobese function of PAF occurs through (3)-AR/UCP1 expression in BAT.Sugatani, J., Sadamitsu, S., Yamaguchi, M., Yamazaki, Y., Higa, R., Hattori, Y., Uchida, T., Ikari, A., Sugiyama, W., Watanabe, T., Ishii, S., Miwa, M., Shimizu, T. Antiobese function of platelet-activating factor: increased adiposity in platelet-activating factor receptor-deficient mice with age.	[Sugatani, Junko; Sadamitsu, Satoshi; Yamaguchi, Masahiko; Yamazaki, Yasuhiro; Higa, Ryoko; Hattori, Yoshiki; Uchida, Takahiro; Ikari, Akira; Miwa, Masao] Univ Shizuoka, Sch Pharmaceut Sci, Dept Pharmacobiochem, Suruga Ku, Shizuoka 4228526, Japan; [Sugatani, Junko; Watanabe, Tatsuo] Univ Shizuoka, Sch Pharmaceut Sci, Global Ctr Excellence Innovat Human Hlth Sci, Suruga Ku, Shizuoka 4228526, Japan; [Sugiyama, Wataru; Watanabe, Tatsuo] Univ Shizuoka, Sch Food & Nutr Sci, Suruga Ku, Shizuoka 4228526, Japan; [Ishii, Satoshi] Akita Univ, Grad Sch Med, Dept Immunol, Akita 010, Japan; [Shimizu, Takao] Natl Ctr Global Hlth & Med, Dept Lipid Signaling, Tokyo, Japan	University of Shizuoka; University of Shizuoka; University of Shizuoka; Akita University; National Center for Global Health & Medicine - Japan	Sugatani, J (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Pharmacobiochem, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	sugatani@u-shizuoka-ken.ac.jp	Shimizu, Takao/AAV-7052-2021	Higa, Ryoko/0000-0002-6720-7677	global Center of Excellence program; Ministry of Education, Culture, Sports, Science and Technology, Japan [21590170, 22590068]; Grants-in-Aid for Scientific Research [25116703] Funding Source: KAKEN	global Center of Excellence program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors gratefully acknowledge Masaki Imanishi, Kengo Yasuda, and Kouki Hiramoto for excellent technical assistance. This work was supported in part by the global Center of Excellence program and grants-in-aid for scientific research (21590170 and 22590068) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Bamshad M, 1999, AM J PHYSIOL-REG I, V276, pR1569, DOI 10.1152/ajpregu.1999.276.6.R1569; BLANK ML, 1981, LIFE SCI, V29, P769, DOI 10.1016/0024-3205(81)90031-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; FEVE B, 1992, J BIOL CHEM, V267, P15909; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Gettys TW, 1997, INT J OBESITY, V21, P865, DOI 10.1038/sj.ijo.0800479; Harayama T, 2008, J BIOL CHEM, V283, P11097, DOI 10.1074/jbc.M708909200; Hikiji H, 2004, J CLIN INVEST, V114, P85, DOI 10.1172/JC1200420504; Inokuma K, 2006, AM J PHYSIOL-ENDOC M, V290, pE1014, DOI 10.1152/ajpendo.00105.2005; Irie Y, 1999, BIOCHEM BIOPH RES CO, V255, P221, DOI 10.1006/bbrc.1998.9999; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Large V, 2004, DIABETES METAB, V30, P294, DOI 10.1016/S1262-3636(07)70121-0; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Mattsson CL, 2011, AM J PHYSIOL-ENDOC M, V301, pE1108, DOI 10.1152/ajpendo.00085.2011; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Samra JS, 2000, P NUTR SOC, V59, P441, DOI 10.1017/S0029665100000604; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Shindou H, 2000, BIOCHEM BIOPH RES CO, V271, P812, DOI 10.1006/bbrc.2000.2723; SUGATANI J, 1989, FASEB J, V3, P65, DOI 10.1096/fasebj.3.1.2910739; Sugatani J, 2006, DRUG METAB DISPOS, V34, P1677, DOI 10.1124/dmd.106.010645; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; TOKUMURA A, 1987, BIOCHEM BIOPH RES CO, V145, P415, DOI 10.1016/0006-291X(87)91338-6; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Viengchareun S, 2001, AM J PHYSIOL-ENDOC M, V280, pE640, DOI 10.1152/ajpendo.2001.280.4.E640; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; YAMAZAKI R, 1994, BIOCHEM PHARMACOL, V47, P995, DOI 10.1016/0006-2952(94)90410-3; YASUDA K, 1986, BIOCHEM BIOPH RES CO, V138, P1231, DOI 10.1016/S0006-291X(86)80414-4; Zingaretti MC, 2009, FASEB J, V23, P3113, DOI 10.1096/fj.09-133546	39	17	17	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					440	452		10.1096/fj.13-233262	http://dx.doi.org/10.1096/fj.13-233262			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24100020				2022-12-28	WOS:000333526100041
J	Aydin, H; Smrke, BM; Lee, JE				Aydin, Halil; Smrke, Brianna M.; Lee, Jeffrey E.			Structural characterization of a fusion glycoprotein from a retrovirus that undergoes a hybrid 2-step entry mechanism	FASEB JOURNAL			English	Article						ASLV; TM; helix dipole moment; HTLV-1	EBOLA-VIRUS GLYCOPROTEIN; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; INDUCED CONFORMATIONAL-CHANGES; ALPHA-HELIX DIPOLE; AVIAN-SARCOMA; LOW-PH; ENVELOPE GLYCOPROTEIN; RECEPTOR-BINDING; CRYSTAL-STRUCTURE; INFLUENZA HEMAGGLUTININ	Entry of enveloped viruses into host cells is mediated by their surface envelope glycoproteins (Env). On the surface of the virus, Env is in a metastable, prefusion state, primed to catalyze the fusion of the viral and host membranes. An external trigger is needed to promote the drastic conformational changes necessary for the fusion subunit to fold into the low-energy, 6-helix bundle. These triggers typically facilitate pH-independent entry at the plasma membrane or pH-dependent entry in a low-pH endosomal compartment. The alpha-retrovirus avian sarcoma leukosis virus (ASLV) has a rare, 2-step entry mechanism with both pH-dependent and pH-independent features. Here, we present the 2.0-angstrom-resolution crystal structure of the ASLV transmembrane (TM) fusion protein. Our structural and biophysical studies indicated that unlike other pH-dependent or pH-independent viral TMs, the ASLV fusion subunit is stable irrespective of pH. Two histidine residues (His490 and His492) in the chain reversal region confer stability at low pH. A structural comparison of class I viral fusion proteins suggests that the presence of a positive charge, either a histidine or arginine amino acid, stabilizes a helical dipole moment and is a signature of fusion proteins active at low pH. The structure now reveals key residues and features that explain its 2-step mechanism, and we discuss the implications of the ASLV TM structure in the context of general mechanisms required for membrane fusion.	[Aydin, Halil; Smrke, Brianna M.; Lee, Jeffrey E.] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto	Lee, JE (corresponding author), 1 Kings Coll Cir,Rm 6316, Toronto, ON M5S 1A8, Canada.	jeff.lee@utoronto.ca			University of Toronto startup funds; Canada Research Chair in Structural Virology; Canadian Institutes of Health Research (CIHR) [MOP-115066]; New Investigator award [MSH-113554]; University of Toronto graduate fellowship; Ontario Genomics Institute Summer Research Fellowship; Canadian Society for Immunology Summer Internship Award	University of Toronto startup funds; Canada Research Chair in Structural Virology; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); New Investigator award; University of Toronto graduate fellowship; Ontario Genomics Institute Summer Research Fellowship; Canadian Society for Immunology Summer Internship Award	The research was supported in part by University of Toronto startup funds, a Canada Research Chair in Structural Virology, a Canadian Institutes of Health Research (CIHR) open operating grant (MOP-115066), and a New Investigator award (MSH-113554) to J.E.L. H. A. was supported by a University of Toronto graduate fellowship, and B. M. S. was funded by an Ontario Genomics Institute Summer Research Fellowship and Canadian Society for Immunology Summer Internship Award. The authors thank the Molecular Structure and Function program at the Hospital for Sick Children Research Institute (Toronto, ON, Canada) for generous access to a circular dichroism spectropolarimeter, and Aiping Dong, Dr. Aled Edwards, and Dr. Cheryl Arrowsmith (Structural Genomics Consortium, Toronto, ON, Canada) for access to the X-ray diffraction facility. ASLV TM crystal structure and structure factors have been deposited into the Protein Data Bank (accession code 4JPR).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Babel AR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000171; Barnard RJO, 2006, VIROLOGY, V344, P25, DOI 10.1016/j.virol.2005.09.021; Barnard RJO, 2004, J VIROL, V78, P10433, DOI 10.1128/JVI.78.19.10433-10441.2004; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BenTal N, 1996, BIOPHYS J, V71, P3046, DOI 10.1016/S0006-3495(96)79498-5; Bentz J, 2000, BIOPHYS J, V78, P886, DOI 10.1016/S0006-3495(00)76646-X; Bosshard HR, 2004, J MOL RECOGNIT, V17, P1, DOI 10.1002/jmr.657; Brown JH, 1996, PROTEINS, V26, P134; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Cote M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033734; Damico R, 1999, J VIROL, V73, P3087, DOI 10.1128/JVI.73.4.3087-3094.1999; Delos SE, 2005, J VIROL, V79, P3488, DOI 10.1128/JVI.79.6.3488-3499.2005; Delos SE, 2010, J VIROL, V84, P5687, DOI 10.1128/JVI.02583-09; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; Duquerroy S, 2005, VIROLOGY, V335, P276, DOI 10.1016/j.virol.2005.02.022; Earp LJ, 2003, J VIROL, V77, P3058, DOI 10.1128/JVI.77.5.3058-3066.2003; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Felder CE, 2007, NUCLEIC ACIDS RES, V35, pW512, DOI 10.1093/nar/gkm307; Gallaher WR, 1996, CELL, V85, P477, DOI 10.1016/S0092-8674(00)81248-9; GILBERT JM, 1995, J VIROL, V69, P7410, DOI 10.1128/JVI.69.12.7410-7415.1995; Harrison JS, 2012, BIOCHEMISTRY-US, V51, P2515, DOI 10.1021/bi3000353; Harrison JS, 2011, PROTEIN SCI, V20, P1587, DOI 10.1002/pro.688; Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Igonet S, 2011, P NATL ACAD SCI USA, V108, P19967, DOI 10.1073/pnas.1108910108; Kaletsky RL, 2007, J VIROL, V81, P13378, DOI 10.1128/JVI.01170-07; Kampmann T, 2006, STRUCTURE, V14, P1481, DOI 10.1016/j.str.2006.07.011; Katritzky AR, 2009, J MED CHEM, V52, P7631, DOI 10.1021/jm900450n; Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326; Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319; Koellhoffer JF, 2012, BIOCHEMISTRY-US, V51, P7665, DOI 10.1021/bi300976m; Lamb D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001268; Lee JE, 2008, NATURE, V454, P177, DOI 10.1038/nature07082; Lee KK, 2010, EMBO J, V29, P1299, DOI 10.1038/emboj.2010.13; Li KJ, 2007, VIROLOGY, V361, P149, DOI 10.1016/j.virol.2006.11.013; Liu K, 2008, J MED CHEM, V51, P7843, DOI 10.1021/jm800869t; Maerz AL, 2000, J VIROL, V74, P6614, DOI 10.1128/JVI.74.14.6614-6621.2000; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; Mason JM, 2004, CHEMBIOCHEM, V5, P170, DOI 10.1002/cbic.200300781; Matsuyama S, 2004, J VIROL, V78, P8201, DOI 10.1128/JVI.78.15.8201-8209.2004; MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Melikyan GB, 2004, J VIROL, V78, P3753, DOI 10.1128/JVI.78.7.3753-3762.2004; Morizono K, 2011, CURR OPIN VIROL, V1, P13, DOI 10.1016/j.coviro.2011.05.001; Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7; Netter RC, 2004, J VIROL, V78, P13430, DOI 10.1128/JVI.78.24.13430-13439.2004; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Plemper RK, 2011, CURR OPIN VIROL, V1, P92, DOI 10.1016/j.coviro.2011.06.002; Prevost M, 1996, J MOL BIOL, V260, P99, DOI 10.1006/jmbi.1996.0384; Quirin K, 2008, VIROLOGY, V378, P21, DOI 10.1016/j.virol.2008.04.046; Rojek JM, 2008, J VIROL, V82, P1505, DOI 10.1128/JVI.01331-07; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006; Sengupta D, 2005, STRUCTURE, V13, P849, DOI 10.1016/j.str.2005.03.010; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Smith JG, 2004, J VIROL, V78, P1403, DOI 10.1128/JVI.78.3.1403-1410.2004; Wallin M, 2004, EMBO J, V23, P54, DOI 10.1038/sj.emboj.7600012; Wang HT, 2009, ANTIMICROB AGENTS CH, V53, P4987, DOI 10.1128/AAC.00670-09; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Yaddanapudi K, 2006, FASEB J, V20, P2519, DOI 10.1096/fj.06-6151com	74	12	12	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5059	5071		10.1096/fj.13-232371	http://dx.doi.org/10.1096/fj.13-232371			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24036886	Green Published			2022-12-28	WOS:000329999000038
J	Ghionzoli, M; Repele, A; Sartiani, L; Costanzi, G; Parenti, A; Spinelli, V; David, AL; Garriboli, M; Totonelli, G; Tian, J; Andreadis, ST; Cerbai, E; Mugelli, A; Messineo, A; Pierro, A; Eaton, S; De Coppi, P				Ghionzoli, Marco; Repele, Andrea; Sartiani, Laura; Costanzi, Giulia; Parenti, Astrid; Spinelli, Valentina; David, Anna L.; Garriboli, Massimo; Totonelli, Giorgia; Tian, Jun; Andreadis, Stelios T.; Cerbai, Elisabetta; Mugelli, Alessandro; Messineo, Antonio; Pierro, Agostino; Eaton, Simon; De Coppi, Paolo			Human amniotic fluid stem cell differentiation along smooth muscle lineage	FASEB JOURNAL			English	Article						tissue engineering; myogenic; regenerative medicine; fetal cells; multipotent	PROGENITOR CELLS; BONE-MARROW; ACTIN EXPRESSION; BLOOD-VESSELS; TGF-BETA; IN-VITRO; CONTRACTION; BLADDER; CHANNELS; DERIVATION	Functional smooth muscle engineering requires isolation and expansion of smooth muscle cells (SMCs), and this process is particularly challenging for visceral smooth muscle tissue where progenitor cells have not been clearly identified. Herein we showed for the first time that efficient SMCs can be obtained from human amniotic fluid stem cells (hAFSCs). Clonal lines were generated from c-kit(+) hAFSCs. Differentiation toward SM lineage (SMhAFSCs) was obtained using a medium conditioned by PDGF-BB and TGF-beta 1. Molecular assays revealed higher level of alpha smooth muscle actin (alpha-SMA), desmin, calponin, and smoothelin in SMhAFSCs when compared to hAFSCs. Ultrastructural analysis demonstrated that SMhAFSCs also presented in the cytoplasm increased intermediate filaments, dense bodies, and glycogen deposits like SMCs. SMhAFSC metabolism evaluated via mass spectrometry showed higher glucose oxidation and an enhanced response to mitogenic stimuli in comparison to hAFSCs. Patch clamp of transduced hAFSCs with lentiviral vectors encoding ZsGreen under the control of the alpha-SMA promoter was performed demonstrating that SMhAFSCs retained a smooth muscle cell-like electro-physiological fingerprint. Eventually SMhAFSCs contractility was evident both at single cell level and on a collagen gel. In conclusion, we showed here that hAFSCs under selective culture conditions are able to give rise to functional SMCs.	[Ghionzoli, Marco; Repele, Andrea; Costanzi, Giulia; Garriboli, Massimo; Totonelli, Giorgia; Pierro, Agostino; Eaton, Simon; De Coppi, Paolo] UCL, Inst Child Hlth, Surg Unit, London, England; [David, Anna L.] UCL, Inst Womens Hlth, Prenatal Cell & Gene Therapy Grp, London, England; [Ghionzoli, Marco; Repele, Andrea; Costanzi, Giulia; Garriboli, Massimo; Totonelli, Giorgia; Pierro, Agostino; Eaton, Simon; De Coppi, Paolo] Great Ormond St Hosp Sick Children, London, England; [Sartiani, Laura; Parenti, Astrid; Spinelli, Valentina; Cerbai, Elisabetta; Mugelli, Alessandro] Univ Florence, Dept Pharmacol, Florence, Italy; [Ghionzoli, Marco; Messineo, Antonio] Univ Florence, Dept Pediat Surg, Florence, Italy; [Tian, Jun; Andreadis, Stelios T.] SUNY Buffalo, Dept Chem & Biol Engn, Buffalo, NY 14260 USA	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Florence; University of Florence; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	De Coppi, P (corresponding author), UCL Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	p.decoppi@ucl.ac.uk	Cerbai, Elisabetta/J-2663-2013; Sartiani, Laura/ABF-5576-2020; Totonelli, Giorgia/AAH-9253-2019; Sartiani, Laura/M-1364-2015; Garriboli, Massimo/AFN-3851-2022	Cerbai, Elisabetta/0000-0001-7839-1361; Sartiani, Laura/0000-0002-4208-0913; Sartiani, Laura/0000-0002-4208-0913; Garriboli, Massimo/0000-0001-5377-3849; David, Anna/0000-0002-0199-6140; De Coppi, Paolo/0000-0002-1659-0207; spinelli, valentina/0000-0002-4910-0243; Parenti, Astrid/0000-0002-7980-6853; messineo, antonio/0000-0002-9789-843X; Ghionzoli, Marco/0000-0002-3128-737X; Eaton, Simon/0000-0003-0892-9204; spinelli, valentina/0000-0001-6083-6983	Fondazione Citta della Speranza; Fondazione Meyer Firenze; Ministero dell'Istruzione; dell'Universita e delle Ricerca (Rome, Italy); Great Osmond Street Hospital (GOSH) Charity (London, UK); GOSH Charity; University College London/University College London Hospitals from the UK Department of Health National Institute for Health Research Biomedical Research Centre; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086582] Funding Source: NIH RePORTER	Fondazione Citta della Speranza; Fondazione Meyer Firenze; Ministero dell'Istruzione(Ministry of Education, Universities and Research (MIUR)); dell'Universita e delle Ricerca (Rome, Italy); Great Osmond Street Hospital (GOSH) Charity (London, UK); GOSH Charity; University College London/University College London Hospitals from the UK Department of Health National Institute for Health Research Biomedical Research Centre; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Bertrand Vernay for assistance with time lapse microscopy, Ayad Eddaoudi for his valuable help in cell sorting, Dr. Sara Paccosi and Dr. Claudia Musilli for their support with cell cultures, and Dr. Pedro Lei and Dr. Waseem Qasim for their support with transduction. This work has been supported by Fondazione Citta della Speranza, Fondazione Meyer Firenze, Ministero dell'Istruzione, dell'Universita e delle Ricerca (Rome, Italy; PRIN 2010-11), and the Great Osmond Street Hospital (GOSH) Charity (London, UK). P. D. C. is supported by the GOSH Charity. A. L. D. is supported at University College London/University College London Hospitals by funding from the UK Department of Health National Institute for Health Research Biomedical Research Centre's funding scheme.	Aikawa M, 1997, CIRCULATION, V96, P82; Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140-6736(06)68438-9; Badylak SF, 2012, LANCET, V379, P943, DOI 10.1016/S0140-6736(12)60073-7; Beamish JA, 2010, TISSUE ENG PART B-RE, V16, P467, DOI [10.1089/ten.teb.2009.0630, 10.1089/ten.TEB.2009.0630]; Bollini S, 2011, STEM CELLS DEV, V20, P1985, DOI 10.1089/scd.2010.0424; Bonnet P, 2008, STEM CELLS DEV, V17, P1131, DOI 10.1089/scd.2007.0219; Coco DP, 2009, AM J SURG PATHOL, V33, P1795, DOI 10.1097/PAS.0b013e3181b76477; Crescioli C, 2005, J CLIN ENDOCR METAB, V90, P962, DOI 10.1210/jc.2004-1496; De Coppi P, 2007, J UROLOGY, V177, P369, DOI 10.1016/j.juro.2006.09.103; De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274; DELAFOSSE B, 1994, AM J PHYSIOL-ENDOC M, V267, pE775, DOI 10.1152/ajpendo.1994.267.5.E775; Ehrlich HP, 2000, J CELL PHYSIOL, V182, P303, DOI 10.1002/(SICI)1097-4652(200002)182:2<303::AID-JCP20>3.0.CO;2-H; Gabella G, 2002, RES PRO CEL, V38, P1; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Huang HR, 2006, BIOCHEM BIOPH RES CO, V351, P321, DOI 10.1016/j.bbrc.2006.09.171; Huber A, 2012, J TISSUE ENG REGEN M, V6, P505, DOI 10.1002/term.451; Huet E, 2008, FASEB J, V22, P1144, DOI 10.1096/fj.07-8748com; Jeon ES, 2006, J CELL SCI, V119, P4994, DOI 10.1242/jcs.03281; Kanematsu A, 2005, AM J PATHOL, V166, P565, DOI 10.1016/S0002-9440(10)62278-X; Kashiwakura Y, 2003, CIRCULATION, V107, P2078, DOI 10.1161/01.CIR.0000070082.64414.B5; Kinner B, 2002, EXP CELL RES, V278, P72, DOI 10.1006/excr.2002.5561; Kurpinski K, 2010, STEM CELLS, V28, P734, DOI 10.1002/stem.319; Lin HK, 2004, J UROLOGY, V171, P1348, DOI 10.1097/01.ju.0000108800.47594.8b; Liu JY, 2008, CARDIOVASC RES, V79, P24, DOI 10.1093/cvr/cvn059; Liu JY, 2007, CARDIOVASC RES, V75, P618, DOI 10.1016/j.cardiores.2007.04.018; Liu JY, 2010, TISSUE ENG PT A, V16, P2553, DOI [10.1089/ten.tea.2009.0833, 10.1089/ten.TEA.2009.0833]; Majesky MW, 2007, ARTERIOSCL THROM VAS, V27, P1248, DOI 10.1161/ATVBAHA.107.141069; Majesky MW, 2011, CIRC RES, V108, P365, DOI 10.1161/CIRCRESAHA.110.223800; Merkulova-Rainon T, 2012, CARDIOVASC RES, V95, P205, DOI 10.1093/cvr/cvs097; Miano JM, 2002, RES PRO CEL, V38, P39; Mistry DK, 1998, BRIT J PHARMACOL, V124, P1131, DOI 10.1038/sj.bjp.0701940; Nakase Y, 2008, J THORAC CARDIOV SUR, V136, P850, DOI 10.1016/j.jtcvs.2008.05.027; Narita Y, 2008, CELL TISSUE RES, V333, P449, DOI 10.1007/s00441-008-0654-0; Oishi K, 2002, J PHYSIOL-LONDON, V540, P139, DOI 10.1113/jphysiol.2001.013278; Peng HF, 2011, TISSUE ENG PT A, V17, P981, DOI [10.1089/ten.tea.2010.0109, 10.1089/ten.TEA.2010.0109]; Pozzobon M, 2010, PEDIATR SURG INT, V26, P3, DOI 10.1007/s00383-009-2478-8; Rodriguez LV, 2006, P NATL ACAD SCI USA, V103, P12167, DOI 10.1073/pnas.0604850103; Sala FG, 2009, J SURG RES, V156, P205, DOI 10.1016/j.jss.2009.03.062; Sartiani L, 2007, STEM CELLS, V25, P1136, DOI 10.1634/stemcells.2006-0466; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Sinha S, 2004, AM J PHYSIOL-CELL PH, V287, pC1560, DOI 10.1152/ajpcell.00221.2004; Sinha S, 2006, STEM CELLS, V24, P1678, DOI 10.1634/stemcells.2006-0002; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; Snetkov VA, 1998, PEDIATR RES, V43, P548, DOI 10.1203/00006450-199804000-00019; Teramoto N, 2006, J PHYSIOL-LONDON, V572, P617, DOI 10.1113/jphysiol.2006.105973; THYBERG J, 1995, CELL TISSUE RES, V281, P421; Tian H, 2010, BIOMATERIALS, V31, P870, DOI 10.1016/j.biomaterials.2009.10.001; van Eys GJ, 2007, TRENDS CARDIOVAS MED, V17, P26, DOI 10.1016/j.tcm.2006.11.001; vanderLoop FTL, 1996, J CELL BIOL, V134, P401, DOI 10.1083/jcb.134.2.401; Wade GR, 1999, AM J PHYSIOL-GASTR L, V277, pG885, DOI 10.1152/ajpgi.1999.277.4.G885; Wang AJ, 2012, CELLS TISSUES ORGANS, V195, P5, DOI 10.1159/000331412; Wang C., TISSUE ENG A, V16, P1201; Wang Q, 1996, AM J PHYSIOL-CELL PH, V271, pC1725, DOI 10.1152/ajpcell.1996.271.5.C1725; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Xiao QZ, 2007, AM J PHYSIOL-CELL PH, V292, pC342, DOI 10.1152/ajpcell.00341.2006; Xie CQ, 2007, ARTERIOSCL THROM VAS, V27, pE311, DOI 10.1161/ATVBAHA.107.154260; Xie CQ, 2009, STEM CELLS DEV, V18, P741, DOI 10.1089/scd.2008.0179; Yang Y, 1999, DEVELOPMENT, V126, P3027	59	26	27	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4853	4865		10.1096/fj.12-218578	http://dx.doi.org/10.1096/fj.12-218578			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23995291	Green Published			2022-12-28	WOS:000329999000020
J	Kola, B; Wittman, G; Bodnar, I; Amin, F; Lim, CT; Olah, M; Christ-Crain, M; Lolli, F; van Thuijl, H; Leontiou, CA; Fuzesi, T; Dalino, P; Isidori, AM; Harvey-White, J; Kunos, G; Nagy, GM; Grossman, AB; Fekete, C; Korbonits, M				Kola, Blerina; Wittman, Gabor; Bodnar, Ibolya; Amin, Faisal; Lim, Chung Thong; Olah, Mark; Christ-Crain, Mirjam; Lolli, Francesca; van Thuijl, Hinke; Leontiou, Chrysanthia A.; Fuezesi, Tamas; Dalino, Paolo; Isidori, Andrea M.; Harvey-White, Judith; Kunos, George; Nagy, Gyoergy M.; Grossman, Ashley B.; Fekete, Csaba; Korbonits, Marta			The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release	FASEB JOURNAL			English	Article						cannabinoids; rimonabant; CB1 knockout	ACTIVATED PROTEIN-KINASE; MESSENGER-RNA EXPRESSION; FOOD-INTAKE; ENDOCANNABINOID SYSTEM; CARDIOMETABOLIC RISK; CARDIAC DYSFUNCTION; OXIDATIVE STRESS; ADIPOSE-TISSUE; RIMONABANT; OBESITY	This study aimed to investigate whether the growth hormone release and metabolic effects of ghrelin on AMPK activity of peripheral tissues are mediated by cannabinoid receptor type 1 (CB1) and the central nervous system. CB1-knockout (KO) and/or wild-type mice were injected peripherally or intracerebroventricularly with ghrelin and CB1 antagonist rimonabant to study tissue AMPK activity and gene expression (transcription factors SREBP1c, transmembrane protein FAS, enzyme PEPCK, and protein HSL). Growth hormone levels were studied both in vivo and in vitro. Peripherally administered ghrelin in liver, heart, and adipose tissue AMPK activity cannot be observed in CB1-KO or CB1 antagonist-treated mice. Intracerebroventricular ghrelin treatment can influence peripheral AMPK activity. This effect is abolished in CB1-KO mice and by intracerebroventricular rimonabant treatment, suggesting that central CB1 receptors also participate in the signaling pathway that mediates the effects of ghrelin on peripheral tissues. Interestingly, in vivo or in vitro growth hormone release is intact in response to ghrelin in CB1-KO animals. Our data suggest that the metabolic effects of ghrelin on AMPK in peripheral tissues are abolished by the lack of functional CB1 receptor via direct peripheral effect and partially through the central nervous system, thus supporting the existence of a possible ghrelin-cannabinoid-CB1-AMPK pathway.	[Kola, Blerina; Amin, Faisal; Lim, Chung Thong; Christ-Crain, Mirjam; Lolli, Francesca; van Thuijl, Hinke; Leontiou, Chrysanthia A.; Dalino, Paolo; Grossman, Ashley B.; Korbonits, Marta] Queen Mary Univ London, Barts & London Med Sch, Ctr Endocrinol, London, England; [Wittman, Gabor; Fuezesi, Tamas; Fekete, Csaba] Hungarian Acad Sci, Inst Expt Med, Dept Endocrine Neurobiol, Budapest, Hungary; [Wittman, Gabor; Fekete, Csaba] Tufts Med Ctr, Div Endocrinol Diabet Metab & Mol Med, Dept Med, Boston, MA USA; [Bodnar, Ibolya; Olah, Mark; Nagy, Gyoergy M.] Semmelweis Univ, Fac Med, Dept Human Morphol & Dev Biol, H-1085 Budapest, Hungary; [Dalino, Paolo] Osped Niguarda Ca Granda, Endocrinol Unit, Milan, Italy; [Isidori, Andrea M.] Univ Roma La Sapienza, Dept Med Pathophysiol, I-00185 Rome, Italy; [Harvey-White, Judith; Kunos, George] NIAAA, Lab Physiol Studies, NIH, Bethesda, MD USA; [Grossman, Ashley B.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England	University of London; Queen Mary University London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Tufts Medical Center; Semmelweis University; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Sapienza University Rome; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Oxford	Korbonits, M (corresponding author), Barts & London Queen Marys Sch Med & Dent, Dept Endocrinol, Charterhouse Sq, London EC1M 6BQ, England.	m.korbonits@qmul.ac.uk	Isidori, Andrea/AAL-3249-2020; Isidori, Andrea M./F-3062-2010	Isidori, Andrea/0000-0002-9037-5417; Isidori, Andrea M./0000-0002-9037-5417; Christ-Crain, Mirjam/0000-0002-6336-0965; Korbonits, Marta/0000-0002-4101-9432; Fekete, Csaba/0000-0002-8206-562X	Wellcome Trust Project Grant; Seventh EU Research Framework Program [Health-F2-2010-259772]; Lendulet Award of the Hungarian Academy of Sciences; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000350] Funding Source: NIH RePORTER	Wellcome Trust Project Grant(Wellcome Trust); Seventh EU Research Framework Program; Lendulet Award of the Hungarian Academy of Sciences; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The study was supported by a Wellcome Trust Project Grant, the Seventh EU Research Framework Program (Health-F2-2010-259772), and a Lendulet Award of the Hungarian Academy of Sciences.	Al-Massadi O, 2010, J NEUROENDOCRINOL, V22, P1127, DOI 10.1111/j.1365-2826.2010.02065.x; Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Andrews ZB, 2011, PEPTIDES, V32, P2248, DOI 10.1016/j.peptides.2011.05.014; Arnone M, 1997, PSYCHOPHARMACOLOGY, V132, P104, DOI 10.1007/s002130050326; Baran K, 2002, DIABETES, V51, P152, DOI 10.2337/diabetes.51.1.152; Buettner C, 2008, NAT MED, V14, P667, DOI 10.1038/nm1775; Claret M, 2007, J CLIN INVEST, V117, P2325, DOI 10.1172/JCI31516; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; D'Eon TM, 2008, DIABETES, V57, P1262, DOI 10.2337/db07-1186; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Dieguez C, 2011, NEUROENDOCRINOLOGY, V94, P1, DOI 10.1159/000328122; Fekete C, 2004, ENDOCRINOLOGY, V145, P4816, DOI 10.1210/en.2004-0476; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Herling AW, 2008, ENDOCRINOLOGY, V149, P2557, DOI 10.1210/en.2007-1515; Jbilo O, 2005, FASEB J, V19, P1567, DOI 10.1096/fj.04-3177fje; Kim MS, 2004, NAT MED, V10, P727, DOI 10.1038/nm1061; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; Kola B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001797; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; Kola B, 2009, J ENDOCRINOL, V202, P191, DOI 10.1677/JOE-09-0056; Korbonits M, 2004, FRONT NEUROENDOCRIN, V25, P27, DOI 10.1016/j.yfrne.2004.03.002; Kubota N, 2007, CELL METAB, V6, P55, DOI 10.1016/j.cmet.2007.06.003; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Lindqvist A, 2007, REGUL PEPTIDES, V142, P24, DOI 10.1016/j.regpep.2007.01.007; Matias I, 2006, J CLIN ENDOCR METAB, V91, P3171, DOI 10.1210/jc.2005-2679; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Morris DG, 2003, J CLIN ENDOCR METAB, V88, P6080, DOI 10.1210/jc.2002-022048; Mukhopadhyay P, 2010, CARDIOVASC RES, V85, P773, DOI 10.1093/cvr/cvp369; Niyuhire F, 2007, J PHARMACOL EXP THER, V322, P1067, DOI 10.1124/jpet.107.119594; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Osei-Hyiaman D, 2008, J CLIN INVEST, V118, P3160, DOI 10.1172/JCI34827; Perez-Tilve D, 2011, FASEB J, V25, P2814, DOI 10.1096/fj.11-183632; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; Poirier B, 2005, DIABETES OBES METAB, V7, P65, DOI 10.1111/j.1463-1326.2004.00374.x; Rajesh M, 2012, DIABETES, V61, P716, DOI 10.2337/db11-0477; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sangiao-Alvarellos S, 2009, ENDOCRINOLOGY, V150, P4562, DOI 10.1210/en.2009-0482; Sato T, 2012, J BIOCHEM, V151, P119, DOI 10.1093/jb/mvr134; Shearman LP, 2008, EUR J PHARMACOL, V579, P215, DOI 10.1016/j.ejphar.2007.10.033; Slavic S, 2013, J MOL MED, V91, P811, DOI 10.1007/s00109-013-1034-0; Sugamura K, 2009, CIRCULATION, V119, P28, DOI 10.1161/CIRCULATIONAHA.108.811992; Tam J, 2012, CELL METAB, V16, P167, DOI 10.1016/j.cmet.2012.07.002; Tam J, 2010, J CLIN INVEST, V120, P2953, DOI 10.1172/JCI42551; Tedesco L, 2008, DIABETES, V57, P2028, DOI 10.2337/db07-1623; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Tiyerili V, 2010, BASIC RES CARDIOL, V105, P465, DOI 10.1007/s00395-010-0090-7; Trillou CR, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI 10.1152/ajpregu.00545.2002; Trillou CR, 2004, INT J OBESITY, V28, P640, DOI 10.1038/sj.ijo.0802583; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Tsubone T, 2005, REGUL PEPTIDES, V130, P97, DOI 10.1016/j.regpep.2005.04.004; Weekers F, 2000, ENDOCRINOLOGY, V141, P3993, DOI 10.1210/en.141.11.3993; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540	56	18	20	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5112	5121		10.1096/fj.13-232918	http://dx.doi.org/10.1096/fj.13-232918			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23982145	Green Published			2022-12-28	WOS:000329999000043
J	Rodgers, BD				Rodgers, Buel D.			When is education a disservice?	FASEB JOURNAL			English	Article						Ph.D job market; Ph.D. training; mentoring	SPONSORSHIP	A surplus of Ph.D. graduates and cuts in funding risks the future of science. In fact, several recent surveys indicate that the Ph.D. job market in relevant science fields is in a state of contracture, yet many universities continue to maintain or even expand Ph.D. programs. An assessment of job advertisements in the journal Science supports the survey conclusions and suggests that advertising for tenure-track faculty positions as well as postdoctoral opportunities have both significantly declined since the 2008 financial collapse, leaving few opportunities for recent Ph.D. graduates in traditional career tracks. Incentives to expand Ph.D. programs continue to influence university administration despite their detrimental effects on students and possibly to the field. Active mentoring, however, could help establish less-is-more programs that benefit students and universities while maintaining the necessary stream of trainees critical to the future of science. Such programs would also require significant changes to university administration that may be unpopular, but are likely inevitable.	Washington State Univ, Dept Anim Sci, Washington Ctr Muscle Biol, Pullman, WA 99164 USA	Washington State University	Rodgers, BD (corresponding author), Washington State Univ, Dept Anim Sci, Washington Ctr Muscle Biol, Pullman, WA 99164 USA.	danrodgers@wsu.edu	Rodgers, Dan/AAA-5343-2020	Rodgers, Buel/0000-0003-0751-1105	Division Of Integrative Organismal Systems [1147275] Funding Source: National Science Foundation	Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Association of American Universities, 2010, AAU MEMB POL; CAMERON SW, 1981, J HIGH EDUC, V52, P369, DOI 10.2307/1981284; Clark RA, 2000, TEACH PSYCHOL, V27, P262, DOI 10.1207/S15328023TOP2704_04; CRONANHILLIX T, 1986, TEACH PSYCHOL, V13, P123, DOI 10.1207/s15328023top1303_5; Cyranoski D, 2011, NATURE, V472, P276, DOI 10.1038/472276a; Johnson W. B., 2003, GETTING MENTORED GRA; Johnson W. B., 2016, BEING MENTOR GUIDE H, V2nd; McCook A, 2011, NATURE, V472, P280, DOI 10.1038/472280a; National Science Foundation, 2013, WEBCASPAR DAT; National Science Foundation, 2012, SCI ENG IND 2012; Powell K., 2012, SCIENCECAREERS, P992; RESKIN BF, 1979, SOCIOL EDUC, V52, P129, DOI 10.2307/2112319; Scott M. E., 1992, J HUMANISTIC ED DEV, V30, P167; Stephan P, 2012, NATURE, V484, P29, DOI 10.1038/484029a; Van Eck Peluchette J., 2000, J SOC PSYCHOL, V140, P549; Vastag B., 2012, WASH POST; Wilson R., 2013, CHRON HIGHER EDUC	17	2	2	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4678	4681		10.1096/fj.13-235762	http://dx.doi.org/10.1096/fj.13-235762			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23975933				2022-12-28	WOS:000329999000003
J	Conte, ML; Maat, SL; Omary, MB				Conte, Marisa L.; Maat, Stacy L.; Omary, M. Bishr			Increased co-first authorships in biamedical and clinical publications: a call for recognition	FASEB JOURNAL			English	Article						coauthors; joint first authorship; citations		There has been a dramatic increase in the number and percentage of publications in biomedical and clinical journals in which two or more coauthors claim first authorship, with a change in some journals from no joint first authorship in 1990 to co-first authorship of >30% of all research publications in 2012. As biomedical and clinical research become increasingly complex and team-driven, and given the importance attributed to first authorship by grant reviewers and promotion and tenure committees, the time is ripe for journals, bibliographic databases, and authors to highlight equal first author contributions of published original research.Conte, M. L., Maat, S. L., Omary, M. B. Increased co-first authorships in biomedical and clinical publications: a call for recognition.	[Conte, Marisa L.] Univ Michigan, Sch Med, Taubman Hlth Sci Lib, Ann Arbor, MI 48109 USA; [Maat, Stacy L.] Univ Michigan, Sch Med, Sch Informat, Ann Arbor, MI 48109 USA; [Omary, M. Bishr] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Omary, M. Bishr] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Omary, MB (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 7720 Med Sci 2,1301 E Catherine St, Ann Arbor, MI 48109 USA.	mbishr@umich.edu		Omary, Bishr/0000-0002-8624-2347; Conte, Marisa/0000-0001-7377-163X				Bunton SA, 2007, ACAD MED, V82, P281, DOI 10.1097/ACM.0b013e3180307e87; Druss BG, 2005, AM J MED, V118, P658, DOI 10.1016/j.amjmed.2005.02.015; Dubnansky E, 2012, GASTROENTEROLOGY, V143, P879, DOI 10.1053/j.gastro.2012.08.009; Kennedy D, 2003, SCIENCE, V301, P733, DOI 10.1126/science.301.5634.733; Mavis B, 2003, ACAD MED, V78, P757, DOI 10.1097/00001888-200307000-00020; O'Brien T, 2013, ACAD MED, V88, P156, DOI 10.1097/ACM.0b013e31827c0e34	6	26	26	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3902	3904		10.1096/fj.13-235630	http://dx.doi.org/10.1096/fj.13-235630			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23839935	Green Submitted			2022-12-28	WOS:000329747100005
J	Kirkby, NS; Chan, MV; Lundberg, MH; Massey, KA; Edmands, WMB; MacKenzie, LS; Holmes, E; Nicolaou, A; Warner, TD; Mitchell, JA				Kirkby, Nicholas S.; Chan, Melissa V.; Lundberg, Martina H.; Massey, Karen A.; Edmands, William M. B.; MacKenzie, Louise S.; Holmes, Elaine; Nicolaou, Anna; Warner, Timothy D.; Mitchell, Jane A.			Aspirin-triggered 15-epi-lipoxin A(4) predicts cyclooxygenase-2 in the lungs of LPS-treated mice hut not in the circulation: implications for a clinical test	FASEB JOURNAL			English	Article						15-HETE; COX-2 biomarker; vascular inflammation; nonsteroidal anti-inflammatory drugs	ARACHIDONIC-ACID; GENE DISRUPTION; INFLAMMATION; INHIBITION; 5-LIPOXYGENASE; PROSTACYCLIN; EICOSANOIDS; THROMBOXANE; LIPOXINS; SYNTHASE	Inhibition of cyclooxygenase (COX)-2 increases cardiovascular deaths. Identifying a biomarker of COX-2 is desirable but difficult, since COX-1 and COX-2 ordinarily catalyze formation of an identical product, prostaglandin H-2. When acetylated by aspirin, however, COX-2 (but not COX-1) can form 15(R)-HETE, which is metabolized to aspirin-triggered lipoxin (ATL), 15-epi-lipoxin A(4). Here we have used COX-1- and COX-2-knockout mice to establish whether plasma ATL could be used as a biomarker of vascular COX-2 in vivo. Vascular COX-2 was low but increased by LPS (10 mg/kg; i.p). Aspirin (10 mg/kg; i.v.) inhibited COX-1, measured as blood thromboxane and COX-2, measured as lung PGE(2). Aspirin also increased the levels of ATL in the lungs of LPS-treated wild-type C57Bl6 mice (vehicle: 25.5 +/- 9.3 ng/ml; 100 mg/kg: 112.0 +/- 7.4 ng/ml; P<0.05). Despite this, ATL was unchanged in plasma after LPS and aspirin. This was true in wild-type as well as COX-1(-/-) and COX-2(-/-) mice. Thus, in mice in which COX-2 has been induced by LPS treatment, aspirin triggers detectable 15-epi-lipoxin A(4) in lung tissue, but not in plasma. This important study is the first to demonstrate that while ATL can be measured in tissue, plasma ATL is not a biomarker of vascular COX-2 expression.Kirkby, N. S., Chan, M. V., Lundberg, M. H., Massey, K. A., Edmands, W. M. B., MacKenzie, L. S., Holmes, E., Nicolaou, A., Warner, T. D., Mitchell, J. A. Aspirin-triggered 15-epi-lipoxin A(4) predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test.	[Kirkby, Nicholas S.; Lundberg, Martina H.; Edmands, William M. B.; MacKenzie, Louise S.; Holmes, Elaine; Mitchell, Jane A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Kirkby, Nicholas S.; Chan, Melissa V.; Lundberg, Martina H.; Warner, Timothy D.] Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London, England; [Massey, Karen A.; Nicolaou, Anna] Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England; [MacKenzie, Louise S.] Univ Hertfordshire, Sch Life & Med Sci, Hatfield AL10 9AB, Herts, England	Imperial College London; University of London; Queen Mary University London; University of Bradford; University of Hertfordshire	Kirkby, NS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	n.kirkby@imperial.ac.uk; j.a.mitchell@imperial.ac.uk	Nicolaou, Anna/D-4025-2018; Holmes, Elaine/A-2189-2015; Warner, Timothy D/A-1980-2009; Holmes, Elaine/ABE-6606-2020; Mackenzie, Louise/AAY-7585-2020; Slingsby, Martina H/B-1476-2015	Nicolaou, Anna/0000-0002-1314-413X; Warner, Timothy D/0000-0003-3988-4408; Holmes, Elaine/0000-0002-0556-8389; Mackenzie, Louise/0000-0003-4271-379X; Lundberg, Martina H/0000-0001-6369-3041; Chan, Melissa/0000-0003-2154-1386; Slingsby, Martina H/0000-0002-2620-7582; Kirkby, Nicholas/0000-0003-3509-8549	Wellcome Trust [0852551Z108/Z]; British Heart Foundation	Wellcome Trust(Wellcome TrustEuropean Commission); British Heart Foundation(British Heart Foundation)	This research was supported by a program grant from the Wellcome Trust (0852551Z108/Z) and a pilot study grant from the British Heart Foundation. The authors declare no conflicts of interest.	Armstrong PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020062; Botting RM, 2010, PHARMACOL REP, V62, P518, DOI 10.1016/S1734-1140(10)70308-X; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; Fiorucci S, 2003, BRIT J PHARMACOL, V139, P1351, DOI 10.1038/sj.bjp.0705356; Flavahan NA, 2007, TRENDS PHARMACOL SCI, V28, P106, DOI 10.1016/j.tips.2007.01.003; FRIDOVICH SE, 1981, J BIOL CHEM, V256, P260; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kirkby NS, 2012, P NATL ACAD SCI USA, V109, P17597, DOI 10.1073/pnas.1209192109; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Liu B, 2012, EXP PHYSIOL, V97, P895, DOI 10.1113/expphysiol.2011.063784; Massey K. A., 2012, FREE RADIC BIOL MED; McGettigan P, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001098; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; Paul-Clark MJ, 2004, J EXP MED, V200, P69, DOI 10.1084/jem.20040566; Planaguma A, 2010, MUCOSAL IMMUNOL, V3, P270, DOI 10.1038/mi.2009.141; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; Smith JP, 2012, HYPERTENSION, V59, P719, DOI 10.1161/HYPERTENSIONAHA.111.181404; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Ye YM, 2008, J IMMUNOL, V181, P3515, DOI 10.4049/jimmunol.181.5.3515	26	14	15	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3938	3946		10.1096/fj.12-215533	http://dx.doi.org/10.1096/fj.12-215533			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23792301	Green Published			2022-12-28	WOS:000329747100009
J	Leinster, DA; Colom, B; Whiteford, JR; Ennis, DP; Lockley, M; McNeish, IA; Aurrand-Lions, M; Chavakis, T; Imhof, BA; Balkwill, FR; Nourshargh, S				Leinster, David A.; Colom, Bartomeu; Whiteford, James R.; Ennis, Darren P.; Lockley, Michelle; McNeish, Iain A.; Aurrand-Lions, Michel; Chavakis, Triantafyllos; Imhof, Beat A.; Balkwill, Frances R.; Nourshargh, Sussan			Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer	FASEB JOURNAL			English	Article						pericytes; angiogenesis; vascular development; immune cell infiltrate	JAM-C; TRANSENDOTHELIAL MIGRATION; MOUSE MODEL; EXPRESSION; ANGIOGENESIS; METASTASIS; PERICYTES; NETWORK; GROWTH	Junctional adhesion molecule C (JAM-C) is a transmembrane protein with significant roles in regulation of endothelial cell (EC) functions, including immune cell recruitment and angiogenesis. As these responses are important in promoting tumor growth, the role of EC JAM-C in tumor development was investigated using the ID8 syngeneic model of ovarian cancer. Within 10-15 wk, intraperitoneally injected ID8 cells form multiple tumor deposits and ascites that resemble human high-grade serous ovarian cancer. Compared to wild-type mice, survival in this model was increased in EC JAM-C knockouts (KOs; 88 vs. 96 d, P=0.04) and reduced in EC JAM-C transgenics (88 vs. 78.5 d, P=0.03), mice deficient in or overexpressing EC JAM-C, respectively. While tumor growth was significantly reduced in EC JAM-C KOs (87% inhibition at 10 wk, P<0.0005), this was not associated with alterations in tumor vessel density or immune cell infiltration. However, tumor microvessels from EC JAM-C-deficient mice exhibited reduced pericyte coverage and increased vascular leakage, suggesting a role for EC JAM-C in the development of functional tumor vessels. These findings provide evidence for a role for EC JAM-C in tumor growth and aggressiveness as well as recruitment of pericytes to newly formed blood vessels in a model of ovarian cancer.Leinster, D. A., Colom, B., Whiteford, J. R., Ennis, D. P., Lockley, M., McNeish, I. A., Aurrand-Lions, M., Chavakis, T., Imhof, B. A., Balkwill, F. R., Nourshargh, S. Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.	[Leinster, David A.; Colom, Bartomeu; Whiteford, James R.; Nourshargh, Sussan] Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England; [Ennis, Darren P.; Lockley, Michelle; McNeish, Iain A.; Balkwill, Frances R.] Queen Mary Univ London, Barts Canc Inst, Barts & London Sch Med & Dent, London EC1M 6BQ, England; [Aurrand-Lions, Michel] Aix Marseille Univ, Ctr Rech Cancerol Marseille, INSERM, Inst Paoli Calmettes,UMR 1068, Marseille, France; [Chavakis, Triantafyllos] Tech Univ Dresden, Dresden, Germany; [Imhof, Beat A.] Ctr Med Univ Geneva, Geneva, Switzerland	University of London; Queen Mary University London; University of London; Queen Mary University London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Technische Universitat Dresden; University of Geneva	Nourshargh, S (corresponding author), Queen Mary Univ London, Ctr Microvasc Res, William Harvey Res Inst, Barts & London Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.	s.nourshargh@qmul.ac.uk	Aurrand-Lions, Michel/O-9953-2016; Chavakis, Triantafyllos/ABE-8845-2020; Colom, Bartomeu/AAA-7539-2019	Aurrand-Lions, Michel/0000-0002-8361-3034; Colom, Bartomeu/0000-0001-6256-6462; Whiteford, James/0000-0002-8967-7389; Balkwill, Frances/0000-0002-5587-9759; lockley, michelle/0000-0002-9281-5789; McNeish, Iain/0000-0002-9387-7586; Nourshargh, Sussan/0000-0001-5677-1806	Wellcome Trust [088407/Z/09/Z, 081172/Z/06/Z, 098291/Z/12/Z]; Deutsche Forschungsgemeinschaft; European Research Council; Arthritis Research-UK [19207]; MRC [G0501974] Funding Source: UKRI; Cancer Research UK [16354, 13034] Funding Source: researchfish; Medical Research Council [G0501974] Funding Source: researchfish; Versus Arthritis [19207] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); Arthritis Research-UK(Versus Arthritis); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Versus Arthritis(Versus Arthritis)	The present work was funded by the Wellcome Trust (project grant 088407/Z/09/Z, programme grant 081172/Z/06/Z, and senior investigator award 098291/Z/12/Z to S.N.). T.C. was funded by the Deutsche Forschungsgemeinschaft and the European Research Council. J.R.W. was funded by Arthritis Research-UK (grant 19207).	Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2005, J IMMUNOL, V174, P6406, DOI 10.4049/jimmunol.174.10.6406; Baker M, 2012, NAT PROTOC, V7, P89, DOI 10.1038/nprot.2011.435; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bradfield PF, 2007, ARTERIOSCL THROM VAS, V27, P2104, DOI 10.1161/ATVBAHA.107.147694; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Colom B, 2012, FASEB J, V26, P1064, DOI 10.1096/fj.11-196220; Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024; Falcon BL, 2011, AM J PATHOL, V178, P2920, DOI 10.1016/j.ajpath.2011.02.019; Garson K, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-39; Imhof BA, 2007, J PATHOL, V212, P198, DOI 10.1002/path.2163; Keiper T, 2005, FASEB J, V19, P2078, DOI 10.1096/fj.05-4196fje; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Lamagna C, 2005, CANCER RES, V65, P5703, DOI 10.1158/0008-5472.CAN-04-4012; Langer HF, 2011, CANCER RES, V71, P4096, DOI 10.1158/0008-5472.CAN-10-2794; Leinster DA, 2012, J PATHOL, V227, P136, DOI 10.1002/path.4002; Murakami M, 2010, CANCER RES, V70, P1759, DOI 10.1158/0008-5472.CAN-09-1703; Nourshargh S, 2006, J LEUKOCYTE BIOL, V80, P714, DOI 10.1189/jlb.1105645; Ody C, 2007, LEUKEMIA, V21, P1285, DOI 10.1038/sj.leu.2404689; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Palmer G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2223; Rabquer BJ, 2010, J IMMUNOL, V185, P1777, DOI 10.4049/jimmunol.1000556; Reynolds LE, 2010, NATURE, V465, P813, DOI 10.1038/nature09106; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Scheiermann C, 2007, SCIENCE, V318, P1472, DOI 10.1126/science.1149276; Scheiermann C, 2009, ARTERIOSCL THROM VAS, V29, P1509, DOI 10.1161/ATVBAHA.109.187559; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tenan M, 2010, GLIA, V58, P524, DOI 10.1002/glia.20941; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Voisin MB, 2010, AM J PATHOL, V176, P482, DOI 10.2353/ajpath.2010.090510; Vonlaufen A, 2006, J PATHOL, V209, P540, DOI 10.1002/path.2007; Woodfin A, 2011, NAT IMMUNOL, V12, P761, DOI 10.1038/ni.2062; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	37	15	15	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4244	4253		10.1096/fj.13-230441	http://dx.doi.org/10.1096/fj.13-230441			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825230	Green Published			2022-12-28	WOS:000329747100034
J	Mamidi, R; Michael, JJ; Muthuchamy, M; Chandra, M				Mamidi, Ranganath; Michael, John Jeshurun; Muthuchamy, Mariappan; Chandra, Murali			Interplay between the overlapping ends of tropomyosin and the N terminus of cardiac troponin T affects tropomyosin states on actin	FASEB JOURNAL			English	Article						myofilament Ca2+ sensitivity; thin-filament activation; calcium-activated tension; molecular swivel; myofilament cooperativity	ACTOMYOSIN ATPASE ACTIVITY; THIN FILAMENT REGULATION; ALPHA-TROPOMYOSIN; MUSCLE CONTRACTILITY; DETACHMENT KINETICS; ISOFORMS MODULATE; CARBOXY-TERMINUS; STRIATED-MUSCLE; TRANSGENIC MICE; TAIL DOMAIN	The functional significance of the molecular swivel at the head-to-tail overlapping ends of contiguous tropomyosin (Tm) dimers in striated muscle is unknown. Contractile measurements were made in muscle fibers from transgenic (TG) mouse hearts that expressed a mutant -Tm (Tm-H276N). We also reconstituted mouse cardiac troponin T (McTnT) N-terminal deletion mutants, McTnT(1-44) and McTnT(45-74), into muscle fibers from Tm-H276N. For controls, we used the wild-type (WT) McTnT because altered effects could be correlated with the mutant forms of McTnT. Tm-H276N slowed crossbridge (XB) detachment rate (g) by 19%. McTnT(1-44) attenuated Ca2+-activated maximal tension against Tm-WT (36%) and Tm-H276N (38%), but sped g only against Tm-H276N by 35%. The rate of tension redevelopment decreased (17%) only in McTnT(1-44) + Tm-H276N fibers. McTnT(45-74) attenuated tension (19%) and myofilament Ca2+ sensitivity (pCa(50)=5.93 vs. 6.00 in the control fibers) against Tm-H276N, but not against Tm-WT background. Thus, altered XB cycling kinetics decreased the fraction of strongly bound XBs in McTnT(1-44) + Tm-H276N fibers, whereas diminished thin-filament cooperativity attenuated tension in McTnT(45-74) + Tm-H276N fibers. In summary, our study is the first to show that the interplay between the N terminus of cTnT and the overlapping ends of contiguous Tm effectuates different states of Tm on the actin filament. Mamidi, R., Michael, J. J., Muthuchamy, M., Chandra, M. Interplay between the overlapping ends of tropomyosin and the N terminus of cardiac troponin T affects tropomyosin states on actin.	[Mamidi, Ranganath; Michael, John Jeshurun; Chandra, Murali] Washington State Univ, Dept Integrat Physiol & Neurosci, Coll Vet Med, Pullman, WA 99164 USA; [Muthuchamy, Mariappan] Texas A&M Hlth Sci Ctr Coll Med, Dept Syst Biol Translat Med, Cardiovasc Res Inst, Div Lymphat Biol, College Stn, TX USA	Washington State University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Chandra, M (corresponding author), Washington State Univ, Dept Integrat Physiol & Neurosci, 251 Vet Biomed Res Bldg, Pullman, WA 99164 USA.	murali@vetmed.wsu.edu	Michael, John Jeshurun/AAP-5970-2020		U.S. National Heart, Lung, and Blood Institute [R01-HL-075643, R01-HL-80526]; Poncin fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080526, R01HL075643] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Poncin fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Sri Lakshmi Mallampalli for excellent technical assistance. This work was funded by U.S. National Heart, Lung, and Blood Institute grants R01-HL-075643 (M. C.) and R01-HL-80526 (M. M.) and by a Poncin fellowship (R. M.). The authors declare no conflicts of interest.	Bach CTT, 2010, CELL ADHES MIGR, V4, P226, DOI 10.4161/cam.4.2.10888; Borovikov YS, 2011, BIOCHEM BIOPH RES CO, V411, P496, DOI 10.1016/j.bbrc.2011.06.138; Borovikov YS, 2009, ARCH BIOCHEM BIOPHYS, V489, P20, DOI 10.1016/j.abb.2009.07.018; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; Brown JH, 2005, ADV PROTEIN CHEM, V71, P121, DOI 10.1016/S0065-3233(04)71004-9; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Chandra M, 2006, BIOPHYS J, V90, P2867, DOI 10.1529/biophysj.105.076950; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; Chandra M, 2007, AM J PHYSIOL-REG I, V293, pR1595, DOI 10.1152/ajpregu.00157.2007; Chandra M, 2009, J BIOL CHEM, V284, P30889, DOI 10.1074/jbc.M109.049718; DETOMBE PP, 1995, CIRC RES, V76, P734, DOI 10.1161/01.RES.76.5.734; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Gaffin RD, 2004, J PHYSIOL-LONDON, V561, P777, DOI 10.1113/jphysiol.2004.070631; Gaffin RD, 2004, J PHYSIOL-LONDON, V556, P531, DOI 10.1113/jphysiol.2003.058487; Gollapudi SK, 2013, J MOL BIOL, V425, P1565, DOI 10.1016/j.jmb.2013.01.028; Gollapudi SK, 2012, BIOPHYS J, V103, P940, DOI 10.1016/j.bpj.2012.07.035; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Gunning P, 2008, ADV EXP MED BIOL, V644, P293; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; Holmes KC, 2008, J MUSCLE RES CELL M, V29, P213, DOI 10.1007/s10974-008-9157-6; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Li XC, 2011, BIOPHYS J, V100, P1005, DOI 10.1016/j.bpj.2010.12.3697; Mamidi R, 2013, J PHYSIOL-LONDON, V591, P1217, DOI 10.1113/jphysiol.2012.243394; Mamidi R, 2012, ARCH BIOCHEM BIOPHYS, V525, P1, DOI 10.1016/j.abb.2012.05.024; Maytum R, 2002, J BIOL CHEM, V277, P29774, DOI 10.1074/jbc.M201761200; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Michael JJ, 2013, AM J PHYSIOL-HEART C, V304, pH253, DOI 10.1152/ajpheart.00572.2012; Montgomery DE, 2001, J PHYSIOL-LONDON, V536, P583, DOI 10.1111/j.1469-7793.2001.0583c.xd; Moss RL, 2004, CIRC RES, V94, P1290, DOI 10.1161/01.RES.0000127125.61647.4F; Murakami K, 2008, P NATL ACAD SCI USA, V105, P7200, DOI 10.1073/pnas.0801950105; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; PAN BS, 1991, J BIOL CHEM, V266, P12432; PATO MD, 1981, J BIOL CHEM, V256, P602; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; Razumova MV, 2000, BIOPHYS J, V78, P3120, DOI 10.1016/S0006-3495(00)76849-4; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Smith DA, 2003, BIOPHYS J, V84, P3168, DOI 10.1016/S0006-3495(03)70041-1; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; UENO H, 1976, J BIOCHEM, V80, P283, DOI 10.1093/oxfordjournals.jbchem.a131275	47	13	13	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3848	3859		10.1096/fj.13-232363	http://dx.doi.org/10.1096/fj.13-232363			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23748972	Green Published			2022-12-28	WOS:000328840500042
J	Meng, JH; Wang, JF; Lawrence, GW; Dolly, JO				Meng, Jianghui; Wang, Jiafu; Lawrence, Gary W.; Dolly, J. Oliver			Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons	FASEB JOURNAL			English	Article						amphiphysin; AP2; clathrin; dynamin; large dense-core vesicles; small clear synaptic vesicles	DEPENDENT BULK ENDOCYTOSIS; CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLES; SYNAPTOTAGMIN-I; NERVE-TERMINALS; PROTEIN-RECEPTOR; DYNAMIN ISOFORMS; SENSORY NEURONS; HIGH-AFFINITY; TOXIN	Proteins responsible for basal and stimulated endocytosis in nerves containing small clear synaptic vesicles (SCSVs) or large dense-core vesicles (LDCVs) are revealed herein, using probes that exploit surface-exposed vesicle proteins as acceptors for internalization. Basal uptake of botulinum neurotoxins (BoNTs) by both SCSV-releasing cerebellar granule neurons (CGNs) and LDCV-enriched trigeminal ganglionic neurons (TGNs) was found to require protein acceptors and acidic compartments. In addition, dynamin, clathrin, adaptor protein complex-2 (AP2), and amphiphysin contribute to the depolarization-evoked entry. For fast recycling of SCSVs, knockdown and knockout strategies demonstrated that CGNs use predominantly dynamin 1, whereas isoform 2 and, to a smaller extent, isoform 3 support a less rapid mode of stimulated endocytosis. Accordingly, proximity ligation assay confirmed that dynamin 1 and 2 colocalize with amphiphysin 1 in CGNs, and the latter copurified with both dynamins from cell extracts. In contrast, LDCV-releasing TGNs preferentially employ dynamins 2 and 3 and amphiphysin 1 for evoked endocytosis and lack the fast phase. Hence, stimulation recruits dynamin, clathrin, AP2, and amphiphysin to augment BoNT internalization, and neurons match endocytosis mediators to the different demands for locally recycling SCSVs or replenishing distally synthesized LDCVs.	[Meng, Jianghui; Wang, Jiafu; Lawrence, Gary W.; Dolly, J. Oliver] Dublin City Univ, Int Ctr Neurotherapeut, Dublin 9, Ireland	Dublin City University	Dolly, JO (corresponding author), Dublin City Univ, Int Ctr Neurotherapeut, Dublin 9, Ireland.	oliver.dolly@dcu.ie	Wang, Jiafu/AAX-9388-2020; Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020; Meng, Jianghui/H-4302-2014	Wang, Jiafu/0000-0002-3654-4400; Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; Meng, Jianghui/0000-0002-3107-4200	Science Foundation Ireland; Allergan Inc. (Irvine, CA, USA); Neuroscience Section of the Programme for Research in Third Level Institutions (PRTLI); European Regional Development Fund (ERDF) of the European Union	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Allergan Inc. (Irvine, CA, USA)(AbbVieAllergan); Neuroscience Section of the Programme for Research in Third Level Institutions (PRTLI); European Regional Development Fund (ERDF) of the European Union	This research is funded by a Principle Investigator Award (to J.O.D.) from Science Foundation Ireland, in part by Allergan Inc. (Irvine, CA, USA) and under the Neuroscience Section of the Programme for Research in Third Level Institutions (PRTLI) Cycle 4. The PRTLI is cofunded through the European Regional Development Fund (ERDF), part of the European Union Structural Funds Programme 2007-2013. The authors thank Pietro De Camilli (Yale University, New Haven, CT, USA) for providing dynamin 1 heterozygous mice and Dr. Shawn M. Ferguson (Yale University) for suggestions on breeding and genotyping. The authors are also grateful to Dr. Y. Zhu (Northwestern University, Evanston, IL, USA) for providing the SypHluorin construct.	Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Artalejo CR, 2002, P NATL ACAD SCI USA, V99, P6358, DOI 10.1073/pnas.082658499; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Binz T, 2009, J NEUROCHEM, V109, P1584, DOI 10.1111/j.1471-4159.2009.06093.x; BLACK JD, 1986, J CELL BIOL, V103, P521, DOI 10.1083/jcb.103.2.521; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Chai Q, 2006, NATURE, V444, P1096, DOI 10.1038/nature05411; Cheung G, 2012, J NEUROSCI, V32, P6014, DOI 10.1523/JNEUROSCI.6305-11.2012; Chung C, 2010, J NEUROSCI, V30, P1363, DOI 10.1523/JNEUROSCI.3427-09.2010; Clayton EL, 2010, NAT NEUROSCI, V13, P845, DOI 10.1038/nn.2571; Clayton EL, 2009, J NEUROCHEM, V111, P901, DOI 10.1111/j.1471-4159.2009.06384.x; Clayton EL, 2009, J NEUROSCI, V29, P7706, DOI 10.1523/JNEUROSCI.1976-09.2009; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Couesnon A, 2009, CELL MICROBIOL, V11, P289, DOI 10.1111/j.1462-5822.2008.01253.x; Davletov B, 2005, TRENDS NEUROSCI, V28, P446, DOI 10.1016/j.tins.2005.06.001; Deinhardt K, 2006, J CELL BIOL, V174, P459, DOI 10.1083/jcb.200508170; Dodick DW, 2010, HEADACHE, V50, P921, DOI 10.1111/j.1526-4610.2010.01678.x; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Dolly JO, 2011, FEBS J, V278, P4454, DOI 10.1111/j.1742-4658.2011.08205.x; DOLLY JO, 1984, NATURE, V307, P457, DOI 10.1038/307457a0; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Dong M, 2007, J CELL BIOL, V179, P1511, DOI 10.1083/jcb.200707184; Dong M, 2008, MOL BIOL CELL, V19, P5226, DOI 10.1091/mbc.E08-07-0765; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Ferguson SM, 2007, SCIENCE, V316, P570, DOI 10.1126/science.1140621; Ferguson SM, 2012, NAT REV MOL CELL BIO, V13, P75, DOI 10.1038/nrm3266; Fischer A, 2009, P NATL ACAD SCI USA, V106, P1330, DOI 10.1073/pnas.0812839106; Fu ZJ, 2009, BIOCHEMISTRY-US, V48, P5631, DOI 10.1021/bi9002138; Granseth B, 2006, NEURON, V51, P773, DOI 10.1016/j.neuron.2006.08.029; Harper CB, 2011, J BIOL CHEM, V286, P35966, DOI 10.1074/jbc.M111.283879; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Hesse S, 1995, NEUROSCI LETT, V201, P37, DOI 10.1016/0304-3940(94)12124-9; Jackson JL, 2012, JAMA-J AM MED ASSOC, V307, P1736, DOI 10.1001/jama.2012.505; Jin RS, 2006, NATURE, V444, P1092, DOI 10.1038/nature05387; Kasprowicz J, 2008, J CELL BIOL, V182, P1007, DOI 10.1083/jcb.200804162; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Mahrhold S, 2006, FEBS LETT, V580, P2011, DOI 10.1016/j.febslet.2006.02.074; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Meng JH, 2007, J CELL SCI, V120, P2864, DOI 10.1242/jcs.012211; Meng JH, 2009, J NEUROSCI, V29, P4981, DOI 10.1523/JNEUROSCI.5490-08.2009; Montal M, 2010, ANNU REV BIOCHEM, V79, P591, DOI 10.1146/annurev.biochem.051908.125345; Newell-Litwa K, 2007, J CELL SCI, V120, P531, DOI 10.1242/jcs.03365; Partoens P, 1998, J CELL SCI, V111, P681; Peng LS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002008; Raimondi A, 2011, NEURON, V70, P1100, DOI 10.1016/j.neuron.2011.04.031; Restani L, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003087; Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200; Rummel A, 2009, J NEUROCHEM, V110, P1942, DOI 10.1111/j.1471-4159.2009.06298.x; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; Voglmaier SM, 2006, NEURON, V51, P71, DOI 10.1016/j.neuron.2006.05.027; von Kleist L, 2011, CELL, V146, P471, DOI 10.1016/j.cell.2011.06.025; Wang JF, 2008, J BIOL CHEM, V283, P16993, DOI 10.1074/jbc.M710442200; Wang JF, 2012, BIOCHEM J, V444, P59, DOI 10.1042/BJ20120100; Wang JF, 2011, J BIOL CHEM, V286, P6375, DOI 10.1074/jbc.M110.181784; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Yao J, 2010, J NEUROSCI, V30, P5569, DOI 10.1523/JNEUROSCI.4781-09.2010; Yao J, 2012, NAT NEUROSCI, V15, P243, DOI 10.1038/nn.3013; Yiangou Yiangos, 2011, J Pain Res, V4, P347, DOI 10.2147/JPR.S25189; Yowler BC, 2002, J BIOL CHEM, V277, P32815, DOI 10.1074/jbc.M205258200; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhu YL, 2009, NEURON, V61, P397, DOI 10.1016/j.neuron.2008.12.024	73	15	15	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3167	3180		10.1096/fj.13-228973	http://dx.doi.org/10.1096/fj.13-228973			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23640057				2022-12-28	WOS:000329877600023
J	Pederson, T				Pederson, Thoru			Turning on a Dime: The 75th Anniversary of America's March Against Polio	FASEB JOURNAL			English	Article									Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, 364 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						ROBBINS FC, 1952, J IMMUNOL, V69, P673; WELLER TH, 1952, J IMMUNOL, V69, P645	2	3	3	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2533	2535		10.1096/fj.13-0702ufm	http://dx.doi.org/10.1096/fj.13-0702ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23824205				2022-12-28	WOS:000328841000002
J	Valdez, DJ; Nieto, PS; Diaz, NM; Garbarino-Pico, E; Guido, ME				Valdez, Diego J.; Nieto, Paula S.; Diaz, Nicolas M.; Garbarino-Pico, Eduardo; Guido, Mario E.			Differential regulation of feeding rhythms through a multiple-photoreceptor system in an avian model of blindness	FASEB JOURNAL			English	Article						phototransduction; inner retina; pineal gland	CHICK PINEAL CELLS; HEREDITARY RETINAL DEGENERATION; EXTRARETINAL LIGHT PERCEPTION; ISLAND RED CHICKEN; PHOTOENDOCRINE TRANSDUCTION; BRAIN PHOTORECEPTORS; NON-CONE; NON-ROD; GUANYLATE-CYCLASE; GANGLION-CELLS	All organisms have evolved photodetection systems to synchronize their physiology and behavior with the external light-dark (LD) cycles. In nonmammalian vertebrates, the retina, the pineal organ, and the deep brain can be photoreceptive. Inner retinal photoreceptors transmit photic information to the brain and regulate diverse nonvisual tasks. We previously reported that even after preventing extraretinal photoreception, blind GUCY1* chickens lacking functional visual photoreceptors could perceive light that modulates physiology and behavior. Here we investigated the contribution of different photoreceptive system components (retinal/pineal and deep brain photoreceptors) to the photic entrainment of feeding rhythms. Wild-type (WT) and GUCY1* birds with head occlusion to avoid extraocular light detection synchronized their feeding rhythms to a LD cycle with light >12 lux, whereas at lower intensities blind birds free-ran with a period of >24 h. When released to constant light, both WT and blind chickens became arrhythmic; however, after head occlusion, GUCY1* birds free-ran with a 24.5-h period. In enucleated birds, brain illumination synchronized feeding rhythms, but in pinealectomized birds only responses to high-intensity light (800 lux) were observed, revealing functional deep brain photoreceptors. In chickens, a multiple photoreceptive system, including retinal and extraretinal photoreceptors, differentially contributes to the synchronization of circadian feeding behavior.Valdez, D. J., Nieto, P. S., Diaz, N. M., Garbarino-Pico, E., Guido, M. E. Differential regulation of feeding rhythms through a multiple-photoreceptor system in an avian model of blindness.	[Valdez, Diego J.; Nieto, Paula S.; Diaz, Nicolas M.; Garbarino-Pico, Eduardo; Guido, Mario E.] Univ Nacl Cordoba, Consejo Nacl Invest Cient Tecn CONICET, Fac Ciencias Quim, Ctr Invest Quim Biol Cordoba CIQUIBIC,Dept Quim B, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Guido, ME (corresponding author), Univ Nacl Cordoba, CONICET, Fac Ciencias Quim, CIQUIBIC,Dept Quim Biol, Haya de la Torre S-N,Ciudad Univ, RA-5000 Cordoba, Argentina.	mguido@fcq.unc.edu.ar		Valdez, Diego Javier/0000-0002-4467-6761; Garbarino Pico, Eduardo/0000-0002-2931-2038	Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT; PICT) [967, 898, 647]; Consejo Nacional de Investigaciones Cientificas y Tecnicas de la Republica Argentina (CONICET); Ministerio de Ciencia y Tecnologia de la Provincia de Cordoba (MinCyT-Cba); Secretaria de Ciencia y Tecnica-Universidad Nacional de Cordoba (SeCyT-UNC)	Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT; PICT); Consejo Nacional de Investigaciones Cientificas y Tecnicas de la Republica Argentina (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Ministerio de Ciencia y Tecnologia de la Provincia de Cordoba (MinCyT-Cba); Secretaria de Ciencia y Tecnica-Universidad Nacional de Cordoba (SeCyT-UNC)(Secretaria de Ciencia y Tecnologia (SECYT))	The authors are grateful to Dr. Horacio de la Iglesia for critical reading of this manuscript. This work was supported by Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT; PICT 2004 no. 967, PICT 2006 no. 898, PICT Bicentenario 2010 no. 647), Consejo Nacional de Investigaciones Cientificas y Tecnicas de la Republica Argentina (CONICET), Ministerio de Ciencia y Tecnologia de la Provincia de Cordoba (MinCyT-Cba), and Secretaria de Ciencia y Tecnica-Universidad Nacional de Cordoba (SeCyT-UNC).	Bailey MJ, 2004, INVEST OPHTH VIS SCI, V45, P769, DOI 10.1167/iovs.03-1125; Bellingham J, 2002, CELL TISSUE RES, V309, P57, DOI 10.1007/s00441-002-0573-4; BENOIT J, 1964, ANN NY ACAD SCI, V117, P204, DOI 10.1111/j.1749-6632.1964.tb48175.x; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Brandstatter R, 2003, J NEUROENDOCRINOL, V15, P398, DOI 10.1046/j.1365-2826.2003.01003.x; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; Cantwell EL, 2006, J COMP NEUROL, V496, P97, DOI 10.1002/cne.20935; Chaurasia SS, 2005, J NEUROCHEM, V92, P158, DOI 10.1111/j.1471-4159.2004.02874.x; CHENG KM, 1980, POULTRY SCI, V59, P2179, DOI 10.3382/ps.0592179; Contin MA, 2006, FASEB J, V20, P2648, DOI 10.1096/fj.06-6133fje; Contin MA, 2010, INVEST OPHTH VIS SCI, V51, P5491, DOI 10.1167/iovs.10-5643; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; Do MTH, 2010, PHYSIOL REV, V90, P1547, DOI 10.1152/physrev.00013.2010; Drivenes O, 2003, J COMP NEUROL, V456, P84, DOI 10.1002/cne.10523; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Farber DB, 1997, CURR OPIN NEUROBIOL, V7, P666, DOI 10.1016/S0959-4388(97)80087-6; Foster RG, 2002, PROG RETIN EYE RES, V21, P507, DOI 10.1016/S1350-9462(02)00036-8; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; GASTON S, 1968, SCIENCE, V160, P1125, DOI 10.1126/science.160.3832.1125; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Guido ME, 2010, PROG NEUROBIOL, V92, P484, DOI 10.1016/j.pneurobio.2010.08.005; Guido ME, 2002, NEUROCHEM RES, V27, P1473, DOI 10.1023/A:1021696321391; Hackett SJ, 2008, SCIENCE, V320, P1763, DOI 10.1126/science.1157704; Halford S, 2009, CURR BIOL, V19, P1396, DOI 10.1016/j.cub.2009.06.066; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Holthues H, 2005, BIOCHEM BIOPH RES CO, V326, P160, DOI 10.1016/j.bbrc.2004.11.022; Isoldi MC, 2005, P NATL ACAD SCI USA, V102, P1217, DOI 10.1073/pnas.0409252102; Jenkins A, 2003, CURR BIOL, V13, P1269, DOI 10.1016/S0960-9822(03)00509-8; Kang SW, 2010, NEUROSCIENCE, V170, P200, DOI 10.1016/j.neuroscience.2010.06.082; Kumbalasiri T, 2005, EXP EYE RES, V81, P368, DOI 10.1016/j.exer.2005.05.004; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Matsushita A, 2000, CELL TISSUE RES, V299, P245, DOI 10.1007/s004419900145; McGoogan J. M., 1999, AM J PHYSIOL, V77, P1418; MCMILLAN JP, 1975, J COMP PHYSIOL, V102, P257, DOI 10.1007/BF01464360; MCMILLAN JP, 1975, J COMP PHYSIOL, V102, P263, DOI 10.1007/BF01464361; Melyan Z, 2005, NATURE, V433, P741, DOI 10.1038/nature03344; MENAKER M, 1968, P NATL ACAD SCI USA, V60, P146, DOI 10.1073/pnas.60.1.146; MENAKER M, 1968, P NATL ACAD SCI USA, V59, P414, DOI 10.1073/pnas.59.2.414; MENAKER M, 1976, PHOTOCHEM PHOTOBIOL, V23, P299, DOI 10.1111/j.1751-1097.1976.tb07251.x; MENAKER M, 1971, BIOL REPROD, V4, P295, DOI 10.1093/biolreprod/4.3.295; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Nakane Y, 2010, CELL TISSUE RES, V342, P341, DOI 10.1007/s00441-010-1073-6; Nakane Y, 2010, P NATL ACAD SCI USA, V107, P15264, DOI 10.1073/pnas.1006393107; NYCE J, 1977, PHOTOCHEM PHOTOBIOL, V25, P529, DOI 10.1111/j.1751-1097.1977.tb09123.x; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Peirson S, 2006, NEURON, V49, P331, DOI 10.1016/j.neuron.2006.01.006; Potter LR, 2011, CELL SIGNAL, V23, P1921, DOI 10.1016/j.cellsig.2011.09.001; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Qiu XD, 2005, NATURE, V433, P745, DOI 10.1038/nature03345; Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271; Semple-Rowland SL, 1999, MOL VIS, V5; Semple-Rowland SL, 2001, MOL BRAIN RES, V97, P51, DOI 10.1016/S0169-328X(01)00297-2; Semple-Rowland SL, 1999, EXP EYE RES, V69, P579, DOI 10.1006/exer.1999.0743; Sernagor E, 2005, CURR BIOL, V15, pR556, DOI 10.1016/j.cub.2005.07.004; ULSHAFER RJ, 1985, EXP EYE RES, V40, P865, DOI 10.1016/0014-4835(85)90131-9; ULSHAFER RJ, 1984, EXP EYE RES, V39, P125, DOI 10.1016/0014-4835(84)90003-4; Underwood Herbert, 2001, Handbook of Behavioral Neurobiology, V12, P111; Valdez DJ, 2009, FASEB J, V23, P1186, DOI 10.1096/fj.08-117085; Venkataraman V, 1998, FEBS LETT, V427, P69, DOI 10.1016/S0014-5793(98)00396-2; Verra DM, 2011, INVEST OPHTH VIS SCI, V52, P5111, DOI 10.1167/iovs.11-75301; Wada Y, 2000, J COMP NEUROL, V428, P138, DOI 10.1002/1096-9861(20001204)428:1<138::AID-CNE9>3.0.CO;2-N; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X; ZATZ M, 1989, BRAIN RES, V501, P46, DOI 10.1016/0006-8993(89)91025-1	68	10	10	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2702	2712		10.1096/fj.12-222885	http://dx.doi.org/10.1096/fj.12-222885			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23585397				2022-12-28	WOS:000328841000019
J	Saligrama, N; Case, LK; Krementsov, DN; Teuscher, C				Saligrama, Naresha; Case, Laure K.; Krementsov, Dimitry N.; Teuscher, Cory			Histamine H-2 receptor signaling x environment interactions determine susceptibility to experimental allergic encephalomyelitis	FASEB JOURNAL			English	Article						pertussis toxin; multiple sclerosis; effector T-cell response; CD4 T cells	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PERTUSSIS TOXIN; T-CELLS; PHARMACOLOGICAL CHARACTERIZATION; CYTOKINE PRODUCTION; MULTIPLE-SCLEROSIS; DENDRITIC CELLS; CYCLIC-AMP; CLONAL EXPANSION; IMMUNE-RESPONSE	Histamine and its receptors are important in both multiple sclerosis and experimental allergic encephalomyelitis (EAE). C57BL/6J (B6) mice deficient for the histamine H-2 receptor (H2RKO) are less susceptible to EAE and exhibit blunted Th1 responses. However, whether decreased antigen-specific T-cell effector responses in H2RKO mice were due to a lack of H2R signaling in CD4(+) T cells or antigen-presenting cells has remained unclear. We generated transgenic mice expressing H2R specifically in T cells on the H2RKO background, and, using wild-type B6 and H2RKO mice as controls, induced EAE either in the presence or absence of the ancillary adjuvant pertussis toxin (PTX), which models the effects of infectious inflammatory stimuli on autoimmune disease. We monitored the mice for clinical signs of EAE and neuropathology, as well as effector T-cell responses using flow cytometry. EAE severity and neuropathology in H2RKO mice expressing H2R exclusively in T cells become equal to those in wild-type B6 mice only when PTX is used to elicit disease. EAE complementation was associated with frequencies of CD4(+)IFN-gamma(+) and CD4(+)IL-17(+) cells that are equal to or greater than those in wild-type B6, respectively. Thus, the regulation of encephalitogenic T-cell responses and EAE susceptibility by H2R signaling in CD4(+) T cells is dependent on gene x environment interactions.-Saligrama, N., Case, L. K., Krementsov, D. N., Teuscher, C. Histamine H-2 receptor signaling x environment interactions determine susceptibility to experimental allergic encephalomyelitis.	[Saligrama, Naresha; Case, Laure K.; Krementsov, Dimitry N.; Teuscher, Cory] Univ Vermont, Dept Med, Burlington, VT 05405 USA; [Teuscher, Cory] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Teuscher, C (corresponding author), Univ Vermont, Immunobiol Program, C331 Given Med Bldg, Burlington, VT 05405 USA.	c.teuscher@uvm.edu	Krementsov, Dimitry/Y-8288-2019	Krementsov, Dimitry/0000-0003-2709-7466; Saligrama, Naresha/0000-0003-2526-7150	U.S. National Institute of Health [NS061014, AI041747, NS060901, NS036526, NS069628]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061014, R01NS036526, R01NS060901, R01NS069628] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank the University of Vermont transgenic/knockout facility, Dr. Mercedes R. Rincon, and Dr. John Dodge for their help in generating the H2RKO-dlck<SUP>Hrh2</SUP>Tg mice; Drs. Rachael M. Hannah and Adrian D. Bonev, (Department of Pharmacology, University of Vermont) for technical assistance with Ca<SUP>2+</SUP> imaging; and Suzanne Newberry and Dr. Alan K. Howe (Department of Pharmacology, University of Vermont) for their design and completion of the in vitro PKA activity assay. This work was supported by the U.S. National Institute of Health (grants NS061014, AI041747, NS060901, NS036526, and NS069628 to C.T.). The authors declare no conflicts of interest.	Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; ALGADI M, 1985, BRIT J PHARMACOL, V85, P877, DOI 10.1111/j.1476-5381.1985.tb11087.x; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; BATZRI S, 1978, BIOCHIM BIOPHYS ACTA, V541, P181, DOI 10.1016/0304-4165(78)90391-4; BenNun A, 1997, P ASSOC AM PHYSICIAN, V109, P120; Biswas S, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-57; Blankenhorn EP, 2000, J IMMUNOL, V164, P3420, DOI 10.4049/jimmunol.164.6.3420; Burnette W N, 1997, Behring Inst Mitt, P434; Caldwell GB, 2012, J CELL BIOCHEM, V113, P39, DOI 10.1002/jcb.23325; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; CHEW CS, 1986, BIOCHIM BIOPHYS ACTA, V888, P116, DOI 10.1016/0167-4889(86)90077-7; CHEW CS, 1980, AM J PHYSIOL, V238, pG312, DOI 10.1152/ajpgi.1980.238.4.G312; CORUZZI G, 1993, N-S ARCH PHARMACOL, V348, P77, DOI 10.1007/BF00168540; Denkinger CM, 2007, CELL IMMUNOL, V246, P46, DOI 10.1016/j.cellimm.2007.05.004; Dy M, 2004, CYTOKINE GROWTH F R, V15, P393, DOI 10.1016/j.cytogfr.2004.06.003; Elliott KA, 2001, INT IMMUNOPHARMACOL, V1, P1923, DOI 10.1016/S1567-5769(01)00117-5; Emerson MR, 2002, NEUROREPORT, V13, P1407, DOI 10.1097/00001756-200208070-00012; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Fletcher JM, 2010, CLIN EXP IMMUNOL, V162, P1, DOI 10.1111/j.1365-2249.2010.04143.x; Frei R, 2013, J ALLERGY CLIN IMMUN, V132, P194, DOI 10.1016/j.jaci.2013.01.013; FUKUSHIMA Y, 1995, BIOCHEM J, V310, P553, DOI 10.1042/bj3100553; Fumagalli F, 2004, ALLERGY, V59, P74, DOI 10.1111/j.1398-9995.2004.00573.x; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P5937, DOI 10.1073/pnas.88.13.5937a; GRAY LS, 1989, J IMMUNOL, V142, P1631; GRUND VR, 1975, J PHARMACOL EXP THER, V195, P176; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Hart PH, 1997, IMMUNOLOGY, V91, P601, DOI 10.1046/j.1365-2567.1997.00284.x; Higuchi M, 2000, NEUROSCIENCE, V99, P721, DOI 10.1016/S0306-4522(00)00230-X; Hill SJ, 1997, PHARMACOL REV, V49, P253; HILL SJ, 1990, PHARMACOL REV, V42, P45; Hofstetter HH, 2002, J IMMUNOL, V169, P117, DOI 10.4049/jimmunol.169.1.117; Hornquist CE, 1997, J IMMUNOL, V158, P1068; Hou WQ, 2003, J IMMUNOL, V170, P1728, DOI 10.4049/jimmunol.170.4.1728; Huang TT, 2003, INT IMMUNOL, V15, P1359, DOI 10.1093/intimm/dxg135; Idzko M, 2002, J ALLERGY CLIN IMMUN, V109, P839, DOI 10.1067/mai.2002.124044; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, INT ARCH ALLERGY IMM, V124, P190, DOI 10.1159/000053707; Krementsov DN, 2013, MULT SCLER J, V19, P1684, DOI 10.1177/1352458513506954; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Lattin J, 2007, J LEUKOCYTE BIOL, V82, P16, DOI 10.1189/jlb.0107051; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; LEURS R, 1994, BRIT J PHARMACOL, V112, P847, DOI 10.1111/j.1476-5381.1994.tb13157.x; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Loniewski K, 2008, MOL IMMUNOL, V45, P2312, DOI 10.1016/j.molimm.2007.11.012; MacGlashan Donald Jr., 2003, Journal of Allergy and Clinical Immunology, V112, pS53, DOI 10.1016/S0091-6749(03)01877-3; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; McGlade JP, 2007, J IMMUNOL, V178, P2794, DOI 10.4049/jimmunol.178.5.2794; MERRILL JE, 1987, INT ARCH ALLER A IMM, V82, P195, DOI 10.1159/000234186; MITSUHASHI M, 1989, J BIOL CHEM, V264, P18356; Munoz JJ, 1985, PERTUSSIS TOXIN, P1; Murphey C, 2011, CELL IMMUNOL, V267, P50, DOI 10.1016/j.cellimm.2010.11.003; Noubade R, 2007, J CLIN INVEST, V117, P3507, DOI 10.1172/JCI32792; Noubade R, 2011, BLOOD, V118, P3290, DOI 10.1182/blood-2011-02-336552; Ohman L, 2002, GUT, V51, P392, DOI 10.1136/gut.51.3.392; Ohman L, 2000, SCAND J IMMUNOL, V52, P80; Omata N, 2002, J IMMUNOL, V169, P4861, DOI 10.4049/jimmunol.169.9.4861; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Parsons ME, 2006, BRIT J PHARMACOL, V147, pS127, DOI 10.1038/sj.bjp.0706440; Pedotti R, 2003, P NATL ACAD SCI USA, V100, P1867, DOI 10.1073/pnas.252777399; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Ryan M, 1998, INT IMMUNOL, V10, P651, DOI 10.1093/intimm/10.5.651; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; Shayo C, 1997, MOL PHARMACOL, V51, P983, DOI 10.1124/mol.51.6.983; Shive CL, 2000, EUR J IMMUNOL, V30, P2422, DOI 10.1002/1521-4141(2000)30:8<2422::AID-IMMU2422>3.0.CO;2-H; Spach KM, 2009, J IMMUNOL, V182, P7776, DOI 10.4049/jimmunol.0900142; Teuscher C, 2004, AM J PATHOL, V165, P1593, DOI 10.1016/S0002-9440(10)63416-5; Teuscher C, 2004, AM J PATHOL, V164, P883, DOI 10.1016/S0002-9440(10)63176-8; TOLONE G, 1982, EXPERIENTIA, V38, P966, DOI 10.1007/BF01953681; TRAIFFORT E, 1992, J NEUROCHEM, V59, P290, DOI 10.1111/j.1471-4159.1992.tb08903.x; TUOMISTO L, 1983, AGENTS ACTIONS, V13, P255, DOI 10.1007/BF01967346; Wakatsuki A, 2003, EUR J IMMUNOL, V33, P1859, DOI 10.1002/eji.200323675; Wang LD, 1997, AM J PHYSIOL-CELL PH, V273, pC2037, DOI 10.1152/ajpcell.1997.273.6.C2037; Yokoyama H, 2001, BRAIN DEV-JPN, V23, P542, DOI 10.1016/S0387-7604(01)00261-3; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434	80	4	4	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1898	1909		10.1096/fj.13-239939	http://dx.doi.org/10.1096/fj.13-239939			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371118	Green Published			2022-12-28	WOS:000335344300034
J	Sonkar, VK; Kulkarni, PP; Dash, D				Sonkar, Vijay K.; Kulkarni, Paresh P.; Dash, Debabrata			Amyloid beta peptide stimulates platelet activation through RhoA-dependent modulation of actomyosin organization	FASEB JOURNAL			English	Article						mitochondrial respiration; clot retraction; myosin light chain; platelet adhesion; thromboembolism	ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MITOCHONDRIAL DYSFUNCTION; GRAPHENE OXIDE; CORE PROTEIN; KINASE-C; TAU; MECHANISMS; NEURONS; STORAGE	Platelets contribute to 95% of circulating amyloid precursor protein in the body and have widely been employed as a "peripheral" model of neurons in Alzheimer's disease. We sought to analyze the effects of amyloid beta (A beta) on platelets and to understand the underlying molecular mechanism. The A beta active fragment containing amino acid sequence 25-35 (A beta(25-35); 10-20 mu M) was found to induce strong aggregation of human platelets, granule release, and integrin activation, similar to that elicited by physiological agonists. Platelets exposed to A beta(25-35) retracted fibrin clot and displayed augmented adhesion to collagen under arterial shear, reflective of a switch to prothrombotic phenotype. Exposure of platelets to A beta peptide (20 mu M) resulted in a 4.2- and 2.3-fold increase in phosphorylation of myosin light chain (MLC) and MLC phosphatase, respectively, which was reversed by Y27632, an inhibitor of Rho-associated coiled-coil protein kinase (ROCK). A beta(25-35)-induced platelet aggregation and clot retraction were also significantly attenuated by Y27632. Consistent with these findings, A beta(25-35) elicited a significant rise in the level of RhoA-GTP in platelets. Platelets pretreated with reverse-sequenced A beta fragment (A beta(35-25)) and untreated resting platelets served as controls. We conclude that A beta induces cellular activation through RhoA-dependent modulation of actomyosin, and hence, RhoA could be a potential therapeutic target in Alzheimer's disease and cerebral amyloid angiopathy.-Sonkar, V. K., Kulkarni, P. P., Dash, D. Amyloid beta peptide stimulates platelet activation through RhoA-dependent modulation of actomyosin organization.	[Sonkar, Vijay K.; Kulkarni, Paresh P.; Dash, Debabrata] Banaras Hindu Univ, Inst Med Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India	Banaras Hindu University (BHU)	Dash, D (corresponding author), Banaras Hindu Univ, Inst Med Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.	ddass@satyam.net.in	Kulkarni, Paresh P/AAB-3190-2019; DASH, DEBABRATA/AAF-1837-2020	Kulkarni, Paresh P/0000-0002-9108-0485; 	Department of Science and Technology (DST); Department of Biotechnology (DBT), Government of India; Indian Council of Medical Research (ICMR); Council of Scientific and Industrial Research (CSIR); Tata Innovation Fellowship from the DBT; ICMR; Institute of Medical Sciences (IMS), Banaras Hindu University (BHU)	Department of Science and Technology (DST)(Department of Science & Technology (India)); Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India); Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR)); Council of Scientific and Industrial Research (CSIR)(Council of Scientific & Industrial Research (CSIR) - India); Tata Innovation Fellowship from the DBT; ICMR(Indian Council of Medical Research (ICMR)); Institute of Medical Sciences (IMS), Banaras Hindu University (BHU)	This research was supported by grants received by D. D. from the Department of Science and Technology (DST) and the Department of Biotechnology (DBT), Government of India; the Indian Council of Medical Research (ICMR); and the Council of Scientific and Industrial Research (CSIR). D. D. thankfully acknowledges a Tata Innovation Fellowship grant received from the DBT. V. K. S. is the recipient of a research fellowship from ICMR. P. P. K. was supported by residency program of the Institute of Medical Sciences (IMS), Banaras Hindu University (BHU). The authors declare no conflicts of interest. The authors sincerely thank Dr. Mohan Kumar (Department of Pathology, IMS, BHU) for helping with the lung histology study.	Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; BUSH AI, 1990, J BIOL CHEM, V265, P15977; Caccamo A, 2010, J BIOL CHEM, V285, P13107, DOI 10.1074/jbc.M110.100420; Casoli T, 2008, MECH AGEING DEV, V129, P154, DOI 10.1016/j.mad.2007.11.004; Chacon PJ, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-14; Chauhan AK, 2006, J EXP MED, V203, P767, DOI 10.1084/jem.20051732; Davis J, 1999, AMYLOID, V6, P157, DOI 10.3109/13506129909007321; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; Deane R, 2004, STROKE, V35, P2628, DOI 10.1161/01.STR.0000143452.85382.d1; Di Luca M, 2000, EUR J PHARMACOL, V405, P277, DOI 10.1016/S0014-2999(00)00559-8; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; Gnaiger E, 2000, LIFE IN THE COLD, P431; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; KILKSON H, 1984, BLOOD, V64, P406; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Nayak MK, 2011, THROMB HAEMOSTASIS, V106, P624, DOI 10.1160/TH11-03-0178; Pleines I, 2012, BLOOD, V119, P1054, DOI 10.1182/blood-2011-08-372193; Roher AE, 2009, ALZHEIMERS DEMENT, V5, P18, DOI 10.1016/j.jalz.2008.10.004; Saller F, 2008, CURR SIGNAL TRANSD T, V3, P22; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Setiadi H, 2003, J CELL BIOL, V163, P1385, DOI 10.1083/jcb.200307178; SHATTIL SJ, 1987, BLOOD, V70, P307; Shen MY, 2008, EUR J PHARMACOL, V588, P259, DOI 10.1016/j.ejphar.2008.04.040; Shen MY, 2008, PHARMACOL RES, V57, P151, DOI 10.1016/j.phrs.2008.01.004; Shrivastava S, 2009, ACS NANO, V3, P1357, DOI 10.1021/nn900277t; Singh SK, 2012, ACS NANO, V6, P2731, DOI 10.1021/nn300172t; Singh SK, 2011, ACS NANO, V5, P4987, DOI 10.1021/nn201092p; Sjovall F, 2013, MITOCHONDRION, V13, P7, DOI 10.1016/j.mito.2012.11.001; Skovronsky DM, 2001, J BIOL CHEM, V276, P17036, DOI 10.1074/jbc.M006285200; Smith CCT, 1997, NEUROSCI LETT, V235, P157, DOI 10.1016/S0304-3940(97)00738-6; Tang K, 2006, J NEUROL SCI, V240, P53, DOI 10.1016/j.jns.2005.09.002; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Williamson R, 2002, J NEUROSCI, V22, P10, DOI 10.1523/JNEUROSCI.22-01-00010.2002; Xu J, 2001, J CEREBR BLOOD F MET, V21, P702, DOI 10.1097/00004647-200106000-00008; Zamolodchikov D, 2012, BLOOD, V119, P3342, DOI 10.1182/blood-2011-11-389668	35	46	47	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1819	1829		10.1096/fj.13-243691	http://dx.doi.org/10.1096/fj.13-243691			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24421399				2022-12-28	WOS:000335344300027
J	Esser, D; Mars, M; Oosterink, E; Stalmach, A; Muller, M; Afman, LA				Esser, Diederik; Mars, Monica; Oosterink, Els; Stalmach, Angelique; Muller, Michael; Afman, Lydia A.			Dark chocolate consumption improves leukocyte adhesion factors and vascular function in overweight men	FASEB JOURNAL			English	Article						flow mediated dilation; augmentation index; high-fat challenge; cardiovascular disease	FLAVANOL-RICH COCOA; ENDOTHELIAL FUNCTION; MEDIATED VASODILATATION; CARDIOVASCULAR HEALTH; POSTPRANDIAL LIPEMIA; REPEATED EXPOSURE; PREDICTION; MORTALITY; EVENTS; ARTERY	Flavanol-enriched chocolate consumption increases endothelium-dependent vasodilation. Most research so far has focused on flow-mediated dilation (FMD) only; the effects on other factors relevant to endothelial health, such as inflammation and leukocyte adhesion, have hardly been addressed. We investigated whether consumption of regular dark chocolate also affects other markers of endothelial health, and whether chocolate enrichment with flavanols has additional benefits. In a randomized double-blind crossover study, the effects of acute and of 4 wk daily consumption of high flavanol chocolate (HFC) and normal flavanol chocolate (NFC) on FMD, augmentation index (AIX), leukocyte count, plasma cytokines, and leukocyte cell surface molecules in overweight men (age 45-70 yr) were investigated. Sensory profiles and motivation scores to eat chocolate were also collected. Findings showed that a 4 wk chocolate intake increased FMD by 1%, which was paralleled by a decreased AIX of 1%, decreased leukocyte cell count, decreased plasma sICAM1 and sICAM3, and decreased leukocyte adhesion marker expression (P<0.05 for time effect), with no difference between HFC and NFC consumption. Flavanol enrichment did affect taste and negatively affected motivation to consume chocolate. This study provides new insights on how chocolate affects endothelial health by demonstrating that chocolate consumption, besides improving vascular function, also lowers the adherence capacity of leukocytes in the circulation.Esser, D., Mars, M., Oosterink, E., Stalmach, A., Muller, M., Afman, L.A. Dark chocolate consumption improves leukocyte adhesion factors and vascular function in overweight men.	[Esser, Diederik; Mars, Monica; Oosterink, Els; Muller, Michael; Afman, Lydia A.] Top Inst Food & Nutr, Wageningen, Netherlands; [Esser, Diederik; Mars, Monica; Oosterink, Els; Muller, Michael; Afman, Lydia A.] Wageningen Univ, Div Human Nutr, NL-6703 HD Wageningen, Netherlands; [Stalmach, Angelique] Univ Glasgow, Ctr Populat & Hlth Sci, Glasgow, Lanark, Scotland	Top Institute Food & Nutrition; Wageningen University & Research; University of Glasgow	Afman, LA (corresponding author), Wageningen Univ, Div Human Nutr, Bomenweg 2, NL-6703 HD Wageningen, Netherlands.	lydia.afman@wur.nl	Mars, Monica/O-4423-2014; Muller, Michael/B-5795-2008; Stalmach, Angelique/B-3250-2009; Muller, Michael/M-5724-2019	Mars, Monica/0000-0003-2010-1039; Muller, Michael/0000-0002-5930-9905; Stalmach, Angelique/0000-0003-4491-654X; Muller, Michael/0000-0002-5930-9905	Top Institute Food and Nutrition [A-1004]	Top Institute Food and Nutrition	The authors thank Casper Schalkwijk, Jos op't Roodt, Iris Smaardijk, Jeske Hageman, Tessa Romijn, Anneke Flipse and Edith van den Bergh for their help and technical assistance. This study was funded by Top Institute Food and Nutrition (A-1004). The chocolate used in this study was donated by Barry Callebaut (Lebbeke, Belgium). The authors declare no conflicts of interest.	Alipour A, 2008, ATHEROSCLEROSIS SUPP, V9, P39, DOI 10.1016/j.atherosclerosissup.2008.05.007; Alipour A, 2007, BIOCHEM SOC T, V35, P466, DOI 10.1042/BST0350466; Arts ICW, 2002, METHODS IN POLYPHENOL ANALYSIS, P214; Balzer J, 2008, J AM COLL CARDIOL, V51, P2141, DOI 10.1016/j.jacc.2008.01.059; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Esser D, 2013, J NUTR, V143, P843, DOI 10.3945/jn.113.174540; Esser D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053474; Faridi Z, 2008, AM J CLIN NUTR, V88, P58, DOI 10.1093/ajcn/88.1.58; Farouque HMO, 2006, CLIN SCI, V111, P71, DOI 10.1042/CS20060048; Grassi D, 2012, HYPERTENSION, V60, P827, DOI 10.1161/HYPERTENSIONAHA.112.193995; Hartaigh BO, 2012, ATHEROSCLEROSIS, V224, P161, DOI 10.1016/j.atherosclerosis.2012.04.012; Heiss C, 2007, J CARDIOVASC PHARM, V49, P74, DOI 10.1097/FJC.0b013e31802d0001; Hetherington MM, 2002, APPETITE, V38, P19, DOI 10.1006/appe.2001.0442; Hooper L, 2012, AM J CLIN NUTR, V95, P740, DOI 10.3945/ajcn.111.023457; Inaba Y, 2010, INT J CARDIOVAS IMAG, V26, P631, DOI 10.1007/s10554-010-9616-1; Jalil AMM, 2008, MOLECULES, V13, P2190, DOI 10.3390/molecules13092190; Katz DL, 2011, ANTIOXID REDOX SIGN, V15, P2779, DOI 10.1089/ars.2010.3697; Langer S, 2011, J AGR FOOD CHEM, V59, P8435, DOI 10.1021/jf201398t; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Lesschaeve I, 2005, AM J CLIN NUTR, V81, p330S, DOI 10.1093/ajcn/81.1.330S; Li CR, 2010, ATHEROSCLEROSIS, V209, P545, DOI 10.1016/j.atherosclerosis.2009.09.029; Monagas M, 2009, AM J CLIN NUTR, V90, P1144, DOI 10.3945/ajcn.2009.27716; Muniyappa R, 2008, AM J CLIN NUTR, V88, P1685, DOI 10.3945/ajcn.2008.26457; Robbins RJ, 2009, J CHROMATOGR A, V1216, P4831, DOI 10.1016/j.chroma.2009.04.006; Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103; Steffen Y, 2005, BIOCHEM BIOPH RES CO, V331, P1277, DOI 10.1016/j.bbrc.2005.04.035; Steffen Y, 2007, BIOCHEM BIOPH RES CO, V359, P828, DOI 10.1016/j.bbrc.2007.05.200; Stein LJ, 2003, APPETITE, V40, P119, DOI 10.1016/S0195-6663(02)00173-3; Ting HJ, 2007, CIRC RES, V100, P381, DOI 10.1161/01.RES.0000258023.76515.a3; Torres-Moreno M, 2012, J SCI FOOD AGR, V92, P404, DOI 10.1002/jsfa.4592; van Bussel BCT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058576; van Oostrom AJHHM, 2004, ATHEROSCLEROSIS, V177, P175, DOI 10.1016/j.atherosclerosis.2004.07.004; Vlachopoulos C, 2010, EUR HEART J, V31, P1865, DOI 10.1093/eurheartj/ehq024; Wang-Polagruto JF, 2006, J CARDIOVASC PHARM, V47, pS177, DOI 10.1097/00005344-200606001-00013	34	42	42	3	54	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1464	1473		10.1096/fj.13-239384	http://dx.doi.org/10.1096/fj.13-239384			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24302679				2022-12-28	WOS:000335324800037
J	Levit, A; Nowak, S; Peters, M; Wiener, A; Meyerhof, W; Behrens, M; Niv, MY				Levit, Anat; Nowak, Stefanie; Peters, Maximilian; Wiener, Ayana; Meyerhof, Wolfgang; Behrens, Maik; Niv, Masha Y.			The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14	FASEB JOURNAL			English	Article						GPCRs; cross-reactivity; drug repositioning; multispecificity	AIRWAY SMOOTH-MUSCLE; POTASSIUM CHANNELS; IDENTIFICATION; MEDICATIONS; GLIMEPIRIDE; DISCOVERY; COMPONENT; DOCKING; TARGETS; T2R38	Bitter taste receptors (TAS2Rs) mediate aversive response to toxic food, which is often bitter. These G-protein-coupled receptors are also expressed in extraoral tissues, and emerge as novel targets for therapeutic indications such as asthma and infection. Our goal was to identify ligands of the broadly tuned TAS2R14 among clinical drugs. Molecular properties of known human bitter taste receptor TAS2R14 agonists were incorporated into pharmacophore- and shape-based models and used to computationally predict additional ligands. Predictions were tested by calcium imaging of TAS2R14-transfected HEK293 cells. In vitro testing of the virtual screening predictions resulted in 30-80% success rates, and 15 clinical drugs were found to activate the TAS2R14. hERG potassium channel, which is predominantly expressed in the heart, emerged as a common off-target of bitter drugs. Despite immense chemical diversity of known TAS2R14 ligands, novel ligands and previously unknown polypharmacology of drugs were unraveled by in vitro screening of computational predictions. This enables rational repurposing of traditional and standard drugs for bitter taste signaling modulation for therapeutic indications.Levit, A., Nowak, S., Peters, M., Wiener, A., Meyerhof, W., Behrens, M., Niv, M. Y. The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14.	[Levit, Anat; Wiener, Ayana; Niv, Masha Y.] Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Robert H Smith Fac Agr Food & Environm, IL-76100 Rehovot, Israel; [Levit, Anat; Wiener, Ayana; Niv, Masha Y.] Hebrew Univ Jerusalem, Fritz Haber Ctr Mol Dynam, Jerusalem, Israel; [Peters, Maximilian] Hebrew Univ Jerusalem, Dept Med Neurobiol, Inst Med Res Israel Canada, Jerusalem, Israel; [Nowak, Stefanie; Meyerhof, Wolfgang; Behrens, Maik] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, Nuthetal, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Niv, MY (corresponding author), Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Robert H Smith Fac Agr Food & Environm, POB 12, IL-76100 Rehovot, Israel.	masha.niv@mail.huji.ac.il	Niv, Masha/AAL-1123-2020; Behrens, Maik/B-6753-2016; Peters, Maximilian/AAA-3509-2020	Behrens, Maik/0000-0003-2082-8860; Niv, Masha/0000-0001-8275-8795	Deutsche Forschungsgemeinschaft grant [ME 1024/8-1]; Israel Science Foundation	Deutsche Forschungsgemeinschaft grant(German Research Foundation (DFG)); Israel Science Foundation(Israel Science Foundation)	This work was supported by a Deutsche Forschungsgemeinschaft grant (ME 1024/8-1) to W.M., M.B., M.Y.N. and an Israel Science Foundation grant to M.Y.N. The authors thank Dr. Elite Levin for helpful discussions and OpenEye Scientific Software for free academic license of their software.	An SS, 2012, AM J PHYSIOL-LUNG C, V303, pL304, DOI 10.1152/ajplung.00126.2012; Ayenew Zelalem, 2009, Recent Pat Drug Deliv Formul, V3, P26; Barnum D, 1996, J CHEM INF COMP SCI, V36, P563, DOI 10.1021/ci950273r; Barra J, 1999, Pharm Acta Helv, V74, P37, DOI 10.1016/S0031-6865(99)00013-8; Behrens M, 2004, BIOCHEM BIOPH RES CO, V319, P479, DOI 10.1016/j.bbrc.2004.05.019; Behrens M, 2011, PHYSIOL BEHAV, V105, P4, DOI 10.1016/j.physbeh.2011.02.010; Behrens M, 2010, RESULTS PROBL CELL D, V52, P87, DOI 10.1007/978-3-642-14426-4_8; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; Bolton E., 2008, ANN REPORTS COMPUTAT, V4; Bordon Y, 2012, NAT REV IMMUNOL, V12, DOI 10.1038/nri3332; Born S, 2013, J NEUROSCI, V33, P201, DOI 10.1523/JNEUROSCI.3248-12.2013; Briscoe VJ, 2010, EXPERT OPIN DRUG MET, V6, P225, DOI 10.1517/17425250903512955; Brockhoff A, 2010, P NATL ACAD SCI USA, V107, P11110, DOI 10.1073/pnas.0913862107; Bufe B, 2002, NAT GENET, V32, P397, DOI 10.1038/ng1014; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen XK, 2011, SCIENCE, V333, P1262, DOI 10.1126/science.1204076; Cho MJ, 2004, J AGR FOOD CHEM, V52, P5895, DOI 10.1021/jf0495035; Clark AA, 2012, FASEB J, V26, P4827, DOI 10.1096/fj.12-215087; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Dorkhan M, 2007, VASC HEALTH RISK MAN, V3, P721; Dotson CD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003974; Drew MGB, 1998, J AGR FOOD CHEM, V46, P3016, DOI 10.1021/jf980095c; Drewnowski A, 2000, AM J CLIN NUTR, V72, P1424; Foster SR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064579; Gerthoffer WT, 2013, CURR OPIN PHARMACOL, V13, P324, DOI 10.1016/j.coph.2013.04.002; Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365; Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x; Intelmann D, 2009, CHEMOSENS PERCEPT, V2, P118, DOI 10.1007/s12078-009-9049-1; Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277; Janssen S, 2013, TRENDS ENDOCRIN MET, V24, P92, DOI 10.1016/j.tem.2012.11.006; Jonsson MKB, 2012, J MOL CELL CARDIOL, V53, P369, DOI 10.1016/j.yjmcc.2012.06.011; Karaman R, 2013, J MOL MODEL, V19, P2399, DOI 10.1007/s00894-013-1780-5; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Kim HO, 2006, J AGR FOOD CHEM, V54, P10102, DOI 10.1021/jf062422j; Kinnamon SC, 2012, ACTA PHYSIOL, V204, P158, DOI 10.1111/j.1748-1716.2011.02308.x; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Kruger DM, 2010, CHEMMEDCHEM, V5, P148, DOI 10.1002/cmdc.200900314; Kubinyi H., 2006, COMPUTER APPL PHARM, P377, DOI DOI 10.1002/0470037237; Lee RJ, 2013, AM J RHINOL ALLERGY, V27, P283, DOI 10.2500/ajra.2013.27.3911; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Levit Anat, 2012, Methods Mol Biol, V914, P179, DOI 10.1007/978-1-62703-023-6_11; Levit A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027990; Ley JP, 2008, CHEMOSENS PERCEPT, V1, P58, DOI 10.1007/s12078-008-9008-2; Ley JP, 2012, J AGR FOOD CHEM, V60, P6303, DOI 10.1021/jf301335z; Li F, 2013, MOL HUM REPROD, V19, P349, DOI 10.1093/molehr/gat009; Liggett SB, 2013, EXPERT OPIN THER TAR, V17, P721, DOI 10.1517/14728222.2013.782395; Lin XY, 2012, J MED CHEM, V55, P5749, DOI 10.1021/jm300338m; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lombardino JG, 2004, NAT REV DRUG DISCOV, V3, P853, DOI 10.1038/nrd1523; Lounkine E, 2012, NATURE, V486, P361, DOI 10.1038/nature11159; Maniruzzaman M, 2014, DRUG DEV IND PHARM, V40, P145, DOI 10.3109/03639045.2013.804833; Mattes RD, 2011, PHYSIOL BEHAV, V104, P624, DOI 10.1016/j.physbeh.2011.05.002; Mennella JA, 2008, CLIN THER, V30, P2120, DOI 10.1016/j.clinthera.2008.11.018; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Muchmore SW, 2008, J CHEM INF MODEL, V48, P941, DOI 10.1021/ci7004498; Murgueitio Manuela S, 2012, Drug Discov Today Technol, V9, pe219, DOI 10.1016/j.ddtec.2012.07.009; Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004; Ohmoto M, 2006, CHEM SENSES, V31, P739, DOI 10.1093/chemse/bjl016; Ripphausen P, 2010, J MED CHEM, V53, P8461, DOI 10.1021/jm101020z; Rodgers S, 2006, J CHEM INF MODEL, V46, P569, DOI 10.1021/ci0504418; Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t; ROGERS DJ, 1960, SCIENCE, V132, P1115, DOI 10.1126/science.132.3434.1115; Roland WSU, 2011, J AGR FOOD CHEM, V59, P11764, DOI 10.1021/jf202816u; Schiffman SS, 2000, PHYSIOL BEHAV, V69, P413, DOI 10.1016/S0031-9384(99)00262-0; Shapiro TA, 2001, CANCER EPIDEM BIOMAR, V10, P501; Slack JP, 2010, CURR BIOL, V20, P1104, DOI 10.1016/j.cub.2010.04.043; Sohi H, 2004, DRUG DEV IND PHARM, V30, P429, DOI 10.1081/DDC-120037477; Stumpfe D, 2012, J MED CHEM, V55, P2932, DOI 10.1021/jm201706b; Tizzano M, 2013, PHYSIOLOGY, V28, P51, DOI 10.1152/physiol.00035.2012; Triballeau N, 2005, J MED CHEM, V48, P2534, DOI 10.1021/jm049092j; Ueda T, 2003, J NEUROSCI, V23, P7376; Urban J, 2013, ANGEW CHEM INT EDIT, V52, P1553, DOI 10.1002/anie.201208450; Viswanathan VK, 2013, GUT MICROBES, V4, P91, DOI 10.4161/gmic.23776; Wiener A, 2012, NUCLEIC ACIDS RES, V40, pD413, DOI 10.1093/nar/gkr755; Wu KK, 2000, CIRCULATION, V102, P2022, DOI 10.1161/01.CIR.102.17.2022; Wu SV, 2005, PHYSIOL GENOMICS, V22, P139, DOI 10.1152/physiolgenomics.00030.2005; Xu J, 2013, MOL HUM REPROD, V19, P17, DOI 10.1093/molehr/gas040; Yarmolinsky DA, 2009, CELL, V139, P234, DOI 10.1016/j.cell.2009.10.001; Zhou PZ, 2011, ACTA PHARMACOL SIN, V32, P781, DOI 10.1038/aps.2011.70	79	73	75	7	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1181	1197		10.1096/fj.13-242594	http://dx.doi.org/10.1096/fj.13-242594			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24285091				2022-12-28	WOS:000335324800014
J	Weissmann, G				Weissmann, Gerald			Stephen E. Malawista (1934-2013): Infection and Rheumatic Disease	FASEB JOURNAL			English	Biographical-Item							LYME ARTHRITIS		NYU, Sch Med, New York, NY 10012 USA	New York University	Weissmann, G (corresponding author), NYU, Sch Med, New York, NY 10012 USA.	gerald.weissmann@med.nyu.edu	Weissmann, Gerald/N-5273-2015	Weissmann, Gerald/0000-0002-4285-4552				HARDIN JA, 1984, YALE J BIOL MED, V57, P589; HARRIS ED, 1983, NEW ENGL J MED, V308, P773, DOI 10.1056/NEJM198303313081309; Mendelsohn D., 2002, NEW YORK REV BOOKS; Rosenstein ED, 2004, INFLAMMATION, V28, P311, DOI 10.1007/s10753-004-6641-z; RUDOLPH SA, 1977, P NATL ACAD SCI USA, V74, P3404, DOI 10.1073/pnas.74.8.3404; Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202; Scher JU, 2012, ARTHRITIS RHEUM-US, V64, P3083, DOI 10.1002/art.34539; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; Svartz N, 1975, Rheumatology, V6, P322; SVARTZ N, 1954, OTOLARYNGOL S, V116, P284	11	0	0	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					521	523		10.1096/fj.14-0201ufm	http://dx.doi.org/10.1096/fj.14-0201ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24482449				2022-12-28	WOS:000331072200001
J	Besedovsky, L; Born, J; Lange, T				Besedovsky, Luciana; Born, Jan; Lange, Tanja			Endogenous glucocorticoid receptor signaling drives rhythmic changes in human T-cell subset numbers and the expression of the chemokine receptor CXCR4	FASEB JOURNAL			English	Article						circadian rhythm; cortisol; CXCL12	BONE-MARROW; CUSHINGS-SYNDROME; LYMPHOCYTE SUBPOPULATIONS; CORTICOSTEROID ACTION; CIRCADIAN-RHYTHMS; PERIPHERAL-BLOOD; IMMUNE-SYSTEM; RAT-BRAIN; RU-486; CORTISOL	In humans, numbers of circulating naive T cells strongly decline in the morning, which was suggested to be mediated by cortisol, inducing a CXCR4 up-regulation with a subsequent extravasation of the cells. As a systematic evaluation of this assumption is lacking, we investigated in two human placebo-controlled studies the effects of the glucocorticoid receptor (GR) antagonist mifepristone (200 mg orally at 23:00) and of suppressing endogenous cortisol with metyrapone (1 g orally at 04:00) on temporal changes in CXCR4 expression and numbers of different T-cell subsets using flow cytometry. Mifepristone attenuated, and metyrapone completely blocked, the morning increase in CXCR4 expression on naive T cells. In parallel, both substances also hindered the decline in naive T-cell numbers with this effect, however, being less apparent after mifepristone. We identified, and confirmed in additional in vitro studies, a partial agonistic GR effect of mifepristone at night (i.e., between 02:00 and 03:30) that could explain the lower antagonistic efficacy of the substance on CXCR4 expression and naive T-cell counts. CXCR4 expression emerged to be a most sensitive marker of GR signaling. Our studies jointly show that endogenous cortisol, specifically via GR activation, causes the morning increase in CXCR4 expression and the subsequent extravasation of naive T cells, thus revealing an important immunological function of the morning cortisol rise. Besedovsky, L., Born, J., Lange, T. Endogenous glucocorticoid receptor signaling drives rhythmic changes in human T-cell subset numbers and the expression of the chemokine receptor CXCR4.	[Besedovsky, Luciana; Born, Jan; Lange, Tanja] Univ Tubingen, Dept Med Psychol & Behav Neurobiol, Tubingen, Germany; [Besedovsky, Luciana; Lange, Tanja] Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany; [Lange, Tanja] Univ Lubeck, Dept Internal Med 1, D-23538 Lubeck, Germany	Eberhard Karls University of Tubingen; University of Lubeck; University of Lubeck	Lange, T (corresponding author), Univ Lubeck, Dept Neuroendocrinol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	lange@uni-luebeck.de	Born, Jan/K-2596-2016; Lange, Tanja/Z-1688-2018	Born, Jan/0000-0002-1847-6248; Lange, Tanja/0000-0001-8309-2112	University of Lubeck [H02-2012]; Deutsche Forschungsgemeinde [SFB 654]	University of Lubeck; Deutsche Forschungsgemeinde	The authors thank Boris von Niessen and Christian Krumrey for technical assistance. This work was supported by a grant from the University of Lubeck (H02-2012) to T.L. and by a grant from the Deutsche Forschungsgemeinde (SFB 654: Plasticity and Sleep).	Ackermann K, 2012, SLEEP, V35, P933, DOI 10.5665/sleep.1954; Bai ZB, 2009, J IMMUNOL, V182, P1287, DOI 10.4049/jimmunol.182.3.1287; Bartholome B, 2004, FASEB J, V18, P70, DOI 10.1096/fj.03-0328com; Baus E, 2001, STEROIDS, V66, P39, DOI 10.1016/S0039-128X(00)00137-9; BERTAGNA X, 1988, CLIN ENDOCRINOL, V28, P537, DOI 10.1111/j.1365-2265.1988.tb03688.x; BERTAGNA X, 1994, J CLIN ENDOCR METAB, V78, P375, DOI 10.1210/jc.78.2.375; Besedovsky L, 2012, BRAIN BEHAV IMMUN, V26, P1116, DOI 10.1016/j.bbi.2012.07.016; Besedovsky L, 2012, PFLUG ARCH EUR J PHY, V463, P121, DOI 10.1007/s00424-011-1044-0; Born J, 1997, J IMMUNOL, V158, P4454; Castinetti F, 2012, CURR OPIN ENDOCRINOL, V19, P295, DOI 10.1097/MED.0b013e32835430bf; Caulfield J, 2002, IMMUNOLOGY, V105, P155, DOI 10.1046/j.0019-2805.2001.01359.x; Cermakian N, 2013, CHRONOBIOL INT, V30, P870, DOI 10.3109/07420528.2013.782315; Cole SW, 1999, J IMMUNOL, V162, P1392; COX JH, 1982, CELL IMMUNOL, V66, P407, DOI 10.1016/0008-8749(82)90190-3; Curnow SJ, 2004, J IMMUNOL, V172, P7154, DOI 10.4049/jimmunol.172.11.7154; Di Rosa F, 2005, TRENDS IMMUNOL, V26, P360, DOI 10.1016/j.it.2005.04.011; Di Rosa F, 2009, IMMUNOL CELL BIOL, V87, P20, DOI 10.1038/icb.2008.84; Dimitrov S, 2009, BLOOD, V113, P5134, DOI 10.1182/blood-2008-11-190769; FAUCI AS, 1980, CELL IMMUNOL, V49, P43, DOI 10.1016/0008-8749(80)90054-4; FAUCI AS, 1975, IMMUNOLOGY, V28, P669; Feelders RA, 2013, J CLIN ENDOCR METAB, V98, P425, DOI 10.1210/jc.2012-3126; Feuerer M, 2003, NAT MED, V9, P1151, DOI 10.1038/nm914; Fryer CJ, 2000, J BIOL CHEM, V275, P17771, DOI 10.1074/jbc.M908729199; GAILLARD RC, 1984, P NATL ACAD SCI-BIOL, V81, P3879, DOI 10.1073/pnas.81.12.3879; GARREL DR, 1995, J CLIN ENDOCR METAB, V80, P379, DOI 10.1210/jc.80.2.379; Ghosh MC, 2009, BLOOD, V113, P575, DOI 10.1182/blood-2008-04-151803; GOWER DB, 1974, J STEROID BIOCHEM, V5, P501, DOI 10.1016/0022-4731(74)90051-X; Johanssen S, 2007, EUR J ENDOCRINOL, V157, P561, DOI 10.1530/EJE-07-0458; Kalman BA, 2002, ENDOCRINOLOGY, V143, P4184, DOI 10.1210/en.2002-220375; KAWATE T, 1981, J IMMUNOL, V126, P1364; Kollet O, 2013, LEUKEMIA, V27, P2006, DOI 10.1038/leu.2013.154; LAUE L, 1988, J CLIN ENDOCR METAB, V66, P290, DOI 10.1210/jcem-66-2-290; LAUE L, 1990, J CLIN ENDOCR METAB, V71, P1474, DOI 10.1210/jcem-71-6-1474; Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215; Mazo IB, 2005, IMMUNITY, V22, P259, DOI 10.1016/j.immuni.2005.01.008; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; MILLER AH, 1994, ENDOCRINOLOGY, V135, P1934, DOI 10.1210/en.135.5.1934; Morgan FH, 2013, PHARMACOTHERAPY, V33, P319, DOI 10.1002/phar.1202; Okutsu M, 2005, AM J PHYSIOL-REG I, V288, pR591, DOI 10.1152/ajpregu.00438.2004; OTTAWAY CA, 1992, BRAIN BEHAV IMMUN, V6, P97, DOI 10.1016/0889-1591(92)90011-C; Pelegri C, 2003, AM J PHYSIOL-CELL PH, V284, pC67, DOI 10.1152/ajpcell.00084.2002; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Rigel DF, 2010, J PHARMACOL EXP THER, V334, P232, DOI 10.1124/jpet.110.167148; Rimmele U, 2013, NEUROPSYCHOPHARMACOL, V38, P884, DOI 10.1038/npp.2012.254; SACKSTEIN R, 1995, J INVEST MED, V43, P68; Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386; Stefanski V, 2003, J NEUROIMMUNOL, V138, P17, DOI 10.1016/S0165-5728(03)00076-6; Stephenson RP, 1997, BRIT J PHARMACOL, V120, P106, DOI 10.1111/j.1476-5381.1997.tb06784.x; THOMSON SP, 1980, CLIN IMMUNOL IMMUNOP, V17, P506, DOI 10.1016/0090-1229(80)90146-4; Trifonova ST, 2013, CHRONOBIOL INT, V30, P669, DOI 10.3109/07420528.2013.775654; Wang JB, 1998, J LEUKOCYTE BIOL, V64, P642, DOI 10.1002/jlb.64.5.642; Zhang SM, 2007, STEROIDS, V72, P600, DOI 10.1016/j.steroids.2007.03.012	53	53	54	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					67	75		10.1096/fj.13-237958	http://dx.doi.org/10.1096/fj.13-237958			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24051033	hybrid			2022-12-28	WOS:000333526100009
J	Kaneti, G; Sarig, H; Marjieh, I; Fadia, Z; Mor, A				Kaneti, Galoz; Sarig, Hadar; Marjieh, Ibrahim; Fadia, Zaknoon; Mor, Amram			Simultaneous breakdown of multiple antibiotic resistance mechanisms in S. aureus	FASEB JOURNAL			English	Article						host defense peptides; peptidomimetics; OAK; oxacillin; membrane potential; synergy	OLIGO-ACYL-LYSYL; STAPHYLOCOCCUS-AUREUS; CAPSULE POLYSACCHARIDE; BETA-LACTAMS; DAPTOMYCIN; OXACILLIN; RESPONSES; SUSCEPTIBILITY; COMBINATIONS; INHIBITORS	In previous studies, the oligo-acyl-lysyl (OAK) C12(omega 7)K-beta(12) added to cultures of gram-positive bacteria exerted a bacteriostatic activity that was associated with membrane depolarization, even at high concentrations. Here, we report that multidrug-resistant Staphylococcus aureus strains, unlike other gram-positive species, have reverted to the sensitive phenotype when exposed to subminimal inhibitory concentrations (sub-MICs) of the OAK, thereby increasing antibiotics potency by up to 3 orders of magnitude. Such chemosensitization was achieved using either cytoplasm or cell-wall targeting antibiotics. Moreover, eventual emergence of resistance to antibiotics was significantly delayed. Using the mouse peritonitis-sepsis model, we show that on single-dose administration of oxacillin and OAK combinations, death induced by a lethal staphylococcal infection was prevented in a synergistic manner, thereby supporting the likelihood for synergism to persist under in vivo conditions. Toward illuminating the molecular basis for these observations, we present data arguing that sub-MIC OAK interactions with the plasma membrane can inhibit proton-dependent signal transduction responsible for expression and export of resistance factors, as demonstrated for beta-lactamase and PBP2a. Collectively, the data reveal a potentially useful approach for overcoming antibiotic resistance and for preventing resistance from emerging as readily as when bacteria are exposed to an antibiotic alone.	[Kaneti, Galoz; Sarig, Hadar; Marjieh, Ibrahim; Fadia, Zaknoon; Mor, Amram] Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.	amor@tx.technion.ac.il			Israel Science Foundation [909/12]; Russell Berrie Nanotechnology Institute (Technion)	Israel Science Foundation(Israel Science Foundation); Russell Berrie Nanotechnology Institute (Technion)	This work was supported by the Israel Science Foundation (grant 909/12) and by the Russell Berrie Nanotechnology Institute (Technion).	ANTHONY E. E., 1931, SCIENCE, V73, P319, DOI 10.1126/science.73.1890.319; Arede P, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002816; BELLOMO G, 1991, CELL CALCIUM, V12, P335, DOI 10.1016/0143-4160(91)90049-K; Campos MA, 2004, INFECT IMMUN, V72, P7107, DOI 10.1128/IAI.72.12.7107-7114.2004; Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200; Dhand A, 2011, CLIN INFECT DIS, V53, P158, DOI 10.1093/cid/cir340; Ejim L, 2011, NAT CHEM BIOL, V7, P348, DOI [10.1038/NCHEMBIO.559, 10.1038/nchembio.559]; Epand RF, 2009, BIOPHYS J, V97, P2250, DOI 10.1016/j.bpj.2009.08.006; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fournier B, 2005, CLIN MICROBIOL REV, V18, P521, DOI 10.1128/CMR.18.3.521-540.2005; Gao W, 2013, J INFECT DIS, V207, P929, DOI 10.1093/infdis/jis772; Garrigos C, 2012, ANTIMICROB AGENTS CH, V56, P3806, DOI 10.1128/AAC.00127-12; Goldberg K, 2013, FASEB J, V27, P3818, DOI 10.1096/fj.13-227942; Held-Kuznetsov V, 2009, FASEB J, V23, P4299, DOI 10.1096/fj.09-136358; Jana S, 2006, APPL MICROBIOL BIOT, V70, P140, DOI 10.1007/s00253-005-0279-0; Jenkins RE, 2012, J ANTIMICROB CHEMOTH, V67, P1405, DOI 10.1093/jac/dks071; Klitgaard JK, 2008, J ANTIMICROB CHEMOTH, V62, P1215, DOI 10.1093/jac/dkn417; Kobayashi SD, 2011, NAT MED, V17, P168, DOI 10.1038/nm0211-168; Kwon DH, 2007, ANTIMICROB AGENTS CH, V51, P2070, DOI 10.1128/AAC.01472-06; Leonard SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042103; Lin GR, 2010, ANTIMICROB AGENTS CH, V54, P2201, DOI 10.1128/AAC.01143-09; Livne L, 2010, FASEB J, V24, P5092, DOI 10.1096/fj.10-167809; Llobet E, 2008, MICROBIOL-SGM, V154, P3877, DOI 10.1099/mic.0.2008/022301-0; Makobongo MO, 2012, ANTIMICROB AGENTS CH, V56, P378, DOI 10.1128/AAC.00689-11; Mayer ML, 2010, ADV M C M, P195, DOI 10.1079/9781845936570.0195; McDougal LK, 2003, J CLIN MICROBIOL, V41, P5113, DOI 10.1128/JCM.41.11.5113-5120.2003; Mor A, 2010, ADV M C M, P100, DOI 10.1079/9781845936570.0100; NIEMINEN AL, 1990, BIOCHEM BIOPH RES CO, V167, P600, DOI 10.1016/0006-291X(90)92067-A; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; Oliveira DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023287; Patel D, 2010, ANTIMICROB AGENTS CH, V54, P5070, DOI 10.1128/AAC.01058-10; Perez-Vazquez M, 2009, J ANTIMICROB CHEMOTH, V63, P21, DOI 10.1093/jac/dkn430; Pietiainen M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-429; Poole K, 2005, J ANTIMICROB CHEMOTH, V56, P20, DOI 10.1093/jac/dki171; Radzishevsky IS, 2008, CHEM BIOL, V15, P354, DOI 10.1016/j.chembiol.2008.03.006; Rand KH, 2004, ANTIMICROB AGENTS CH, V48, P2871, DOI 10.1128/AAC.48.8.2871-2875.2004; Rotem S, 2008, FASEB J, V22, P2652, DOI 10.1096/fj.07-105015; Rotem S, 2009, BBA-BIOMEMBRANES, V1788, P1582, DOI 10.1016/j.bbamem.2008.10.020; Morones-Ramirez JR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006276; Sarig H, 2011, FASEB J, V25, P3336, DOI 10.1096/fj.11-183764; Sarig H, 2011, ANTIMICROB AGENTS CH, V55, P688, DOI 10.1128/AAC.00666-10; Sarig H, 2010, FASEB J, V24, P1904, DOI 10.1096/fj.09-149427; Stavri M, 2007, J ANTIMICROB CHEMOTH, V59, P1247, DOI 10.1093/jac/dkl460; Strahl H, 2010, P NATL ACAD SCI USA, V107, P12281, DOI 10.1073/pnas.1005485107; Szweda P, 2012, APPL MICROBIOL BIOT, V96, P1157, DOI 10.1007/s00253-012-4484-3; Therien AG, 2012, ANTIMICROB AGENTS CH, V56, P4662, DOI 10.1128/AAC.00726-12; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; Wilke MS, 2004, J BIOL CHEM, V279, P47278, DOI 10.1074/jbc.M407054200; Yang SJ, 2010, ANTIMICROB AGENTS CH, V54, P3161, DOI 10.1128/AAC.00487-10; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134; Yuan J, 2011, J MOL BIOL, V406, P730, DOI 10.1016/j.jmb.2011.01.014; Zaknoon F, 2012, ANTIMICROB AGENTS CH, V56, P4827, DOI 10.1128/AAC.00511-12; Zaknoon F, 2011, ANTIMICROB AGENTS CH, V55, P3803, DOI 10.1128/AAC.00129-11	53	15	15	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4834	4843		10.1096/fj.13-237610	http://dx.doi.org/10.1096/fj.13-237610			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23970798				2022-12-28	WOS:000329999000018
J	Chen, PK; Chang, BI; Kuo, CH; Chen, PS; Cho, CF; Chang, CF; Shi, GY; Wu, HL				Chen, Po-Ku; Chang, Bi-Ing; Kuo, Cheng-Hsiang; Chen, Pin-Shern; Cho, Chia-Fong; Chang, Chuan-Fa; Shi, Guey-Yueh; Wu, Hua-Lin			Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis	FASEB JOURNAL			English	Article						cell migration; pericellular proteolysis; lipid raft; endothelial cells	PROTEIN-C ACTIVATION; ENDOTHELIAL-CELL MIGRATION; HUMAN KERATINOCYTES; SIGNALING PATHWAYS; BINDING-SITE; LIPID RAFTS; EXPRESSION; MEMBRANE; POLARIZATION; MICRODOMAINS	Urokinase-type plasminogen activator (uPA) activates plasminogen (Plg) through a major pericellular proteolytic system involved in cell migration and angiogenesis; however, the Plg receptor that participates in uPA-mediated Plg activation has not yet been identified. In this study, we demonstrated that thrombomodulin (TM), a type I transmembrane glycoprotein, is a novel Plg receptor that plays a role in pericellular proteolysis and cell migration. Plg activation at the cell surface and the extent of its cell migration- and invasion-promoting effect are cellular TM expression dependent. Direct binding of Plg and the recombinant TM extracellular domain, with a K-D of 0.1-0.3 M, was determined through surface plasmon resonance analysis. Colocalization of TM, Plg, and the uPA receptor within plasma membrane lipid rafts, at the leading edge of migrating endothelial cells, was demonstrated and was also shown to overlap with areas of major pericellular proteolysis. Moreover, the roles of TM and Plg in neoangiogenesis were demonstrated in vivo through the skin wound-healing model. In conclusion, we propose that TM is a novel Plg receptor that regulates uPA/uPA receptor-mediated Plg activation and pericellular proteolysis within lipid rafts at the leading edge of migrating cells during angiogenesis.Chen, P.-K., Chang, B.-I., Kuo, C.-H., Chen, P.-S., Cho, C.-F., Chang, C.-F., Shi, G.-Y., Wu, H.-L. Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis.	[Chen, Po-Ku; Chang, Bi-Ing; Kuo, Cheng-Hsiang; Chen, Pin-Shern; Cho, Chia-Fong; Shi, Guey-Yueh; Wu, Hua-Lin] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 701, Taiwan; [Chen, Po-Ku; Kuo, Cheng-Hsiang; Cho, Chia-Fong] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan; [Chen, Po-Ku; Chang, Chuan-Fa] Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan 701, Taiwan; [Chang, Bi-Ing; Kuo, Cheng-Hsiang; Chen, Pin-Shern; Shi, Guey-Yueh; Wu, Hua-Lin] Natl Cheng Kung Univ, Cardiovasc Res Ctr, Tainan 701, Taiwan; [Shi, Guey-Yueh; Wu, Hua-Lin] Natl Cheng Kung Univ, Ctr Biosci & Biotechnol, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Wu, HL (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, 1 Univ Rd, Tainan 701, Taiwan.	gyshi@mail.ncku.edu.tw; halnwu@mail.ncku.edu.tw	Kuo, Cheng-Hsiang/GRJ-7463-2022; Chang, Chuan-Fa/F-8660-2011	Kuo, Cheng-Hsiang/0000-0002-4885-9020; Chang, Chuan-Fa/0000-0003-2404-1248	National Science Council, Executive Yuan, Taipei, Taiwan [NSC 99-2320-B-006-008-MY3, NSC 99-2628-B-006-003-MY3, NSC 100-2325-B-006-003-MY3]; National Cheng Kung University Aim for the Top University Plan grant from the Ministry of Education, Taiwan	National Science Council, Executive Yuan, Taipei, Taiwan(Ministry of Science and Technology, Taiwan); National Cheng Kung University Aim for the Top University Plan grant from the Ministry of Education, Taiwan	This work was supported by National Science Council, Executive Yuan, Taipei, Taiwan grants NSC 99-2320-B-006-008-MY3, NSC 99-2628-B-006-003-MY3, and NSC 100-2325-B-006-003-MY3 and by a National Cheng Kung University Aim for the Top University Plan grant from the Ministry of Education, Taiwan. P.-K.C. designed and performed the study and wrote the paper; G.-Y.S. and H.-L. W. designed the study, wrote the paper, and supervised the research; B.-I.C. performed the ELISA assay; C.-H. K. performed immunofluorescence microscopy; P.-S.C. and C.-F. Cho contributed vital reagents and analytical tools; C. F. Chang performed the SPR assay. The authors declare no conflicts of interest.	Andronicos NM, 2010, BLOOD, V115, P1319, DOI 10.1182/blood-2008-11-188938; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Bae JS, 2007, P NATL ACAD SCI USA, V104, P2867, DOI 10.1073/pnas.0611493104; BOFFA MC, 1984, REV FR TRANSFUS IMMU, V27, P807, DOI 10.1016/S0338-4535(84)80133-6; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Castellino FJ, 2005, THROMB HAEMOSTASIS, V93, P647, DOI 10.1160/TH04-12-0842; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1975, THROMB DIATH HAEMOST, V34, P403, DOI 10.1055/s-0038-1651399; CONWAY EM, 1992, BLOOD, V80, P1254; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Das R, 2007, BLOOD, V110, P3763, DOI 10.1182/blood-2007-03-079392; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Drew AF, 2001, BLOOD, V97, P3691, DOI 10.1182/blood.V97.12.3691; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Han HS, 2000, FIBRINOLYSIS PROTEOL, V14, P221, DOI 10.1054/fipr.2000.0059; Hsu YY, 2012, FASEB J, V26, P3440, DOI 10.1096/fj.12-204917; Katoh SY, 2009, EXP CELL RES, V315, P2818, DOI 10.1016/j.yexcr.2009.07.008; Kindzelskii AL, 2004, HISTOCHEM CELL BIOL, V121, P299, DOI 10.1007/s00418-004-0639-3; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; Kinney CM, 2008, AM J PHYSIOL-CELL PH, V294, pC241, DOI 10.1152/ajpcell.00187.2007; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Ledesma MD, 2003, BRAIN RES, V987, P107, DOI 10.1016/S0006-8993(03)03296-7; Li YH, 2006, THROMB HAEMOSTASIS, V95, P128, DOI 10.1160/TH05-06-0415; Lishko V. K., 2004, BLOOD, V104, P719; Lund LR, 2006, EMBO J, V25, P2686, DOI 10.1038/sj.emboj.7601173; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; MCCACHREN SS, 1991, BLOOD, V78, P3128; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Moon JJ, 2005, J CELL PHYSIOL, V203, P166, DOI 10.1002/jcp.20220; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Oh CW, 2003, J THROMB HAEMOST, V1, P1683, DOI 10.1046/j.1538-7836.2003.00182.x; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; Peterson JJ, 1999, AM J PATHOL, V155, P1569, DOI 10.1016/S0002-9440(10)65473-9; RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Senet P, 1997, ARCH DERMATOL RES, V289, P151, DOI 10.1007/s004030050171; Shi CS, 2008, BLOOD, V112, P3661, DOI 10.1182/blood-2008-03-142760; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; SOFF GA, 1991, BLOOD, V77, P515; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; Wang H, 2006, CANCER RES, V66, P7211, DOI 10.1158/0008-5472.CAN-05-4331; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5	49	13	13	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4520	4531		10.1096/fj.13-227561	http://dx.doi.org/10.1096/fj.13-227561			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23943648				2022-12-28	WOS:000329937500019
J	Wayakanon, K; Thornhill, MH; Douglas, CWI; Lewis, AL; Warren, NJ; Pinnock, A; Armes, SP; Battaglia, G; Murdoch, C				Wayakanon, Kornchanok; Thornhill, Martin H.; Douglas, C. W. Ian; Lewis, Andrew L.; Warren, Nicholas J.; Pinnock, Abigail; Armes, Steven P.; Battaglia, Giuseppe; Murdoch, Craig			Polymersome-mediated intracellular delivery of antibiotics to treat Porphyromonas gingivalis-infected oral epithelial cells	FASEB JOURNAL			English	Article						periodontal disease; antimicrobial chemotherapy; nanotechnology	ZWITTERIONIC DIBLOCK COPOLYMER; IN-VITRO; PERIODONTAL-DISEASES; INVASION; VESICLES; PH; BACTERIA; BINDING; DRUG; ENCAPSULATION	The gram-negative anaerobe Porphyromonas gingivalis colonizes the gingival crevice and is etiologically associated with periodontal disease that can lead to alveolar bone damage and resorption, promoting tooth loss. Although susceptible to antibiotics, P. gingivalis can evade antibiotic killing by residing within gingival keratinocytes. This provides a reservoir of organisms that may recolonize the gingival crevice once antibiotic therapy is complete. Polymersomes are nanosized amphiphilic block copolymer vesicles that can encapsulate drugs. Cells internalize polymersomes by endocytosis into early endosomes, where they are disassembled by the low pH, causing intracellular release of their drug load. In this study, polymersomes were used as vehicles to deliver antibiotics in an attempt to kill intracellular P. gingivalis within monolayers of keratinocytes and organotypic oral mucosal models. Polymersome-encapsulated metronidazole or doxycycline, free metronidazole, or doxycycline, or polymersomes alone as controls, were used, and the number of surviving intracellular P. gingivalis was quantified after host cell lysis. Polymersome-encapsulated metronidazole or doxycycline significantly (P<0.05) reduced the number of intracellular P. gingivalis in both monolayer and organotypic cultures compared to free antibiotic or polymersome alone controls. Polymersomes are effective delivery vehicles for antibiotics that do not normally gain entry to host cells. This approach could be used to treat recurrent periodontitis or other diseases caused by intracellular-dwelling organisms.Wayakanon, K., Thornhill, M. H., Douglas, C. W. I., Lewis, A. L., Warren, N. J., Pinnock, A., Armes, S. P., Battaglia, G., Murdoch, C. Polymersome-mediated intracellular delivery of antibiotics to treat Porphyromonas gingivalis-infected oral epithelial cells.	[Wayakanon, Kornchanok; Thornhill, Martin H.; Pinnock, Abigail; Battaglia, Giuseppe; Murdoch, Craig] Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Med & Surg, Sheffield S10 2TA, S Yorkshire, England; [Douglas, C. W. Ian] Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Pathol, Sheffield S10 2TA, S Yorkshire, England; [Warren, Nicholas J.; Armes, Steven P.] Univ Sheffield, Dept Chem, Sheffield S10 2TA, S Yorkshire, England; [Battaglia, Giuseppe] UCL, Dept Chem, London, England; [Lewis, Andrew L.] Biocompatibles UK Ltd, Farnham, Surrey, England	University of Sheffield; University of Sheffield; University of Sheffield; University of London; University College London; Biocompatibles International PLC	Murdoch, C (corresponding author), Univ Sheffield, Sch Clin Dent, Unit Oral & Maxillofacial Med & Surg, Sheffield S10 2TA, S Yorkshire, England.	g.battaglia@ucl.ac.uk; c.murdoch@sheffield.ac.uk	Warren, Nicholas/AAE-9388-2021; Battaglia, Giuseppe/I-2142-2013; Warren, Nicholas J/I-1588-2013	Warren, Nicholas/0000-0002-8298-1417; Battaglia, Giuseppe/0000-0003-3349-6770; Warren, Nicholas J/0000-0002-8298-1417; Thornhill, Martin/0000-0003-0681-4083; Armes, Steven/0000-0002-8289-6351; Murdoch, Craig/0000-0001-9724-122X; Lewis, Andrew/0000-0001-5779-5631	Oral and Dental Research Trust, UK; Biocompatibles UK Ltd.; Government of Thailand	Oral and Dental Research Trust, UK; Biocompatibles UK Ltd.; Government of Thailand	This work was supported by funding from the Oral and Dental Research Trust, UK (K. W., C. M.) and Biocompatibles UK Ltd. (G. B., A. L. L.). K. W. was the recipient of a Ph.D. scholarship from the Government of Thailand.	Ahmed F, 2006, J CONTROL RELEASE, V116, P150, DOI 10.1016/j.jconrel.2006.07.012; Ahmed F, 2006, MOL PHARMACEUT, V3, P340, DOI 10.1021/mp050103u; Andrian E, 2004, INFECT IMMUN, V72, P4689, DOI 10.1128/IAI.72.8.4689-4698.2004; Belton CM, 1999, CELL MICROBIOL, V1, P215, DOI 10.1046/j.1462-5822.1999.00022.x; Blanazs A, 2011, J AM CHEM SOC, V133, P16581, DOI 10.1021/ja206301a; Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574-6968.2012.02579.x; Canton I, 2013, FASEB J, V27, P98, DOI 10.1096/fj.12-212183; Canton I, 2012, CHEM SOC REV, V41, P2718, DOI 10.1039/c2cs15309b; Chen T, 2004, MICROB PATHOGENESIS, V36, P205, DOI 10.1016/j.micpath.2003.12.001; Christian DA, 2009, EUR J PHARM BIOPHARM, V71, P463, DOI 10.1016/j.ejpb.2008.09.025; Colley HE, 2011, BRIT J CANCER, V105, P1582, DOI 10.1038/bjc.2011.403; Dickinson BC, 2011, MOL ORAL MICROBIOL, V26, P210, DOI 10.1111/j.2041-1014.2011.00609.x; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; Dorn BR, 2000, FEMS MICROBIOL LETT, V187, P139, DOI 10.1016/S0378-1097(00)00191-9; Du JZ, 2005, J AM CHEM SOC, V127, P17982, DOI 10.1021/ja056514l; GEISOW MJ, 1984, EXP CELL RES, V150, P36, DOI 10.1016/0014-4827(84)90699-2; Giacomelli C, 2006, BIOMACROMOLECULES, V7, P817, DOI 10.1021/bm0508921; Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873; Hearnden V, 2009, PHARM RES-DORDR, V26, P1718, DOI 10.1007/s11095-009-9882-6; Hirsch R, 2012, J PERIODONTAL RES, V47, P137, DOI 10.1111/j.1600-0765.2011.01418.x; Holt SC, 2005, PERIODONTOL 2000, V38, P72, DOI 10.1111/j.1600-0757.2005.00113.x; ISOGAI E, 1992, ARCH ORAL BIOL, V37, P667, DOI 10.1016/0003-9969(92)90130-Z; JENSEN RL, 1974, J PERIODONTOL, V45, P786, DOI 10.1902/jop.1974.45.11.786; Kim Younghoon, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P4350; Kim YH, 2009, J CONTROL RELEASE, V134, P132, DOI 10.1016/j.jconrel.2008.10.020; LAMONT RJ, 1995, INFECT IMMUN, V63, P3878, DOI 10.1128/IAI.63.10.3878-3885.1995; LAMONT RJ, 1992, ORAL MICROBIOL IMMUN, V7, P364, DOI 10.1111/j.1399-302X.1992.tb00637.x; Lomas H, 2008, FARADAY DISCUSS, V139, P143, DOI 10.1039/b717431d; Lomas H, 2010, MACROMOL BIOSCI, V10, P513, DOI 10.1002/mabi.201000083; LoPresti C, 2011, ACS NANO, V5, P1775, DOI 10.1021/nn102455z; Madianos PN, 1996, INFECT IMMUN, V64, P660, DOI 10.1128/IAI.64.2.660-664.1996; Massignani M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010459; Massignani M, 2009, SMALL, V5, P2424, DOI 10.1002/smll.200900578; Mombelli A, 2004, INT DENT J, V54, P3, DOI 10.1111/j.1875-595X.2004.tb00246.x; Mombelli A, 2012, FRONT ORAL BIOL, V15, P133, DOI 10.1159/000329676; Murdoch C, 2010, NANOMEDICINE-UK, V5, P1025, DOI 10.2217/NNM.10.97; Nakagawa I, 2005, MICROBES INFECT, V7, P157, DOI 10.1016/j.micinf.2004.10.007; Nakhjiri SF, 2001, FEMS MICROBIOL LETT, V200, P145, DOI 10.1111/j.1574-6968.2001.tb10706.x; Njoroge T, 1997, INFECT IMMUN, V65, P1980, DOI 10.1128/IAI.65.5.1980-1984.1997; Poulet PP, 1999, J CLIN PERIODONTOL, V26, P261, DOI 10.1034/j.1600-051X.1999.260411.x; Shen L, 2008, LANGMUIR, V24, P10019, DOI 10.1021/la801190z; Suwannakul S, 2010, MICROBIOL-SGM, V156, P3052, DOI 10.1099/mic.0.038075-0; Tsuda K, 2008, CELL STRUCT FUNCT, V33, P123, DOI 10.1247/csf.08012; Umeda JE, 2006, ORAL MICROBIOL IMMUN, V21, P415, DOI 10.1111/j.1399-302X.2006.00312.x; VanWinkelhoff AJ, 1996, PERIODONTOL 2000, V10, P45; Wang LG, 2012, ANGEW CHEM INT EDIT, V51, P11122, DOI 10.1002/anie.201204169; Weinmann Stephen B, 2011, J Int Acad Periodontol, V13, P31; Yadev NR, 2011, MICROB PATHOGENESIS, V50, P278, DOI 10.1016/j.micpath.2010.11.009; Yilmaz O, 2003, MICROBIOL-SGM, V149, P2417, DOI 10.1099/mic.0.26483-0; Yilmaz O, 2002, CELL MICROBIOL, V4, P305, DOI 10.1046/j.1462-5822.2002.00192.x; Yuan LH, 2007, FEMS IMMUNOL MED MIC, V51, P388, DOI 10.1111/j.1574-695X.2007.00326.x	51	50	51	4	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4455	4465		10.1096/fj.12-225219	http://dx.doi.org/10.1096/fj.12-225219			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23921377				2022-12-28	WOS:000329937500013
J	Harmancey, R; Vasquez, HG; Guthrie, PH; Taegtmeyer, H				Harmancey, Romain; Vasquez, Hernan G.; Guthrie, Patrick H.; Taegtmeyer, Heinrich			Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart	FASEB JOURNAL			English	Article						high-sucrose diet; myocardial metabolism; type 2 diabetes; cardiac function; uncoupling proteins	ACUTE MYOCARDIAL-INFARCTION; ACTIVATED RECEPTOR-ALPHA; UNCOUPLING PROTEIN-3; DIABETES-MELLITUS; SKELETAL-MUSCLE; REPERFUSION; SUBSTRATE; ISCHEMIA; GLUCOSE; UCP3	Diabetic patients with acute myocardial infarction are more likely to die than nondiabetic patients. In the present study we examined the effect of insulin resistance on myocardial ischemia tolerance. Hearts of rats, rendered insulin resistant by high-sucrose feeding, were subjected to ischemia/reperfusion ex vivo. Cardiac power of control hearts from chow-fed rats recovered to 93%, while insulin-resistant hearts recovered only to 80% (P<0.001 vs. control). Unexpectedly, impaired contractile recovery did not result from an impairment of glucose oxidation (576 +/- 36 vs. 593 +/- 42 nmol/min/g dry weight; not significant), but from a failure to increase and to sustain oxidation of the long-chain fatty acid oleate on reperfusion (1878 +/- 56 vs. 2070 +/- 67 nmol/min/g dry weight; P<0.05). This phenomenon was due to a reduced ability to transport oleate into mitochondria and associated with a 38-58% decrease in the mitochondrial uncoupling protein 3 (UCP3) levels. Contractile function was rescued by replacing oleate with a medium-chain fatty acid or by restoring UCP3 levels with 24 h of food withdrawal. Lastly, the knockdown of UCP3 in rat L6 myocytes also decreased oleate oxidation by 13-18% following ischemia. Together the results expose UCP3 as a critical regulator of long-chain fatty acid oxidation in the stressed heart postischemia and identify octanoate as an intervention by which myocardial metabolism can be manipulated to improve function of the insulin-resistant heart.Harmancey, R., Vasquez, H. G., Guthrie, P. H., Taegtmeyer, H. Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart.	[Harmancey, Romain; Vasquez, Hernan G.; Guthrie, Patrick H.; Taegtmeyer, Heinrich] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Cardiol, Univ Texas Med Sch Houston, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Taegtmeyer, H (corresponding author), Univ Texas Med Sch Houston, 6431 Fannin,MSB 1-246, Houston, TX 77030 USA.	heinrich.taegtmeyer@uth.tmc.edu			U.S. National Institutes of Health (NIH) [R01-HL-061483]; NIH [P30 DK-079638]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Roxy Tate for editorial assistance. This work was supported by U.S. National Institutes of Health (NIH) grant R01-HL-061483 to H.T. The Mouse Metabolism Core at the Baylor College of Medicine Diabetes Research Center (Houston, TX, USA) is supported by NIH grant P30 DK-079638.	Adel W, 2010, INT J ANGIOL, V19, pE78, DOI 10.1055/s-0031-1278373; Almdal T, 2004, ARCH INTERN MED, V164, P1422, DOI 10.1001/archinte.164.13.1422; Arikawa E, 2007, DIABETES, V56, P1410, DOI 10.2337/db06-0655; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Bezaire V, 2007, FASEB J, V21, P312, DOI 10.1096/fj.06-6966rev; Boudina S, 2007, CIRCULATION, V115, P3213, DOI 10.1161/CIRCULATIONAHA.106.679597; Boudina S, 2012, DIABETES, V61, P3260, DOI 10.2337/db12-0063; Bugger H, 2008, DIABETES, V57, P2924, DOI 10.2337/db08-0079; Cook SA, 2010, EUR HEART J, V31, P100, DOI 10.1093/eurheartj/ehp396; Gerber LK, 2006, AM J PHYSIOL-CELL PH, V291, pC1198, DOI 10.1152/ajpcell.00246.2006; Goodwin GW, 1998, AM J PHYSIOL-HEART C, V274, pH1239, DOI 10.1152/ajpheart.1998.274.4.H1239; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Harjai KJ, 2003, AM J CARDIOL, V91, P1041, DOI 10.1016/S0002-9149(03)00145-0; Harmancey R, 2012, FASEB J, V26, P3118, DOI 10.1096/fj.12-208991; Harmancey R, 2010, J LIPID RES, V51, P1380, DOI 10.1194/jlr.M001230; Hidaka S, 1999, DIABETES, V48, P430, DOI 10.2337/diabetes.48.2.430; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hirota Morihiko, 2006, Journal of Toxicological Sciences, V31, P149, DOI 10.2131/jts.31.149; Hue L, 2009, AM J PHYSIOL-ENDOC M, V297, pE578, DOI 10.1152/ajpendo.00093.2009; Iozzo P, 2002, DIABETES, V51, P3020, DOI 10.2337/diabetes.51.10.3020; Lockridge JB, 2008, J LIPID RES, V49, P1395, DOI 10.1194/jlr.M700517-JLR200; Longnus SL, 2001, AM J PHYSIOL-HEART C, V281, pH1561, DOI 10.1152/ajpheart.2001.281.4.H1561; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Mak KH, 2000, J AM COLL CARDIOL, V35, P563, DOI 10.1016/S0735-1097(99)00628-2; Marso SP, 2007, AM J CARDIOL, V100, P206, DOI 10.1016/j.amjcard.2007.02.080; Meldrum KK, 2001, J SURG RES, V99, P288, DOI 10.1006/jsre.2001.6201; MORROW RJ, 1973, P SOC EXP BIOL MED, V142, P223; Murray AJ, 2005, DIABETES, V54, P3496, DOI 10.2337/diabetes.54.12.3496; Ozcan C, 2013, AM J PHYSIOL-HEART C, V304, pH1192, DOI 10.1152/ajpheart.00592.2012; SADDIK M, 1992, J BIOL CHEM, V267, P3825; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schrauwen P, 2001, DIABETES, V50, P2870, DOI 10.2337/diabetes.50.12.2870; Seifert EL, 2008, J BIOL CHEM, V283, P25124, DOI 10.1074/jbc.M803871200; Sena S, 2009, J MOL CELL CARDIOL, V46, P910, DOI 10.1016/j.yjmcc.2009.02.014; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; Witteles RM, 2008, J AM COLL CARDIOL, V51, P93, DOI 10.1016/j.jacc.2007.10.021; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com; Zhu Y, 2013, MOL ENDOCRINOL, V27, P172, DOI 10.1210/me.2012-1210	39	43	46	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3966	3978		10.1096/fj.13-234914	http://dx.doi.org/10.1096/fj.13-234914			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825227	Green Published			2022-12-28	WOS:000329747100012
J	Tran, T; Teoh, CM; Tam, JKC; Qiao, YK; Chin, CY; Chong, OK; Stewart, AG; Harris, T; Wong, WSF; Guan, SP; Leung, BP; Gerthoffer, WT; Unruh, H; Halayko, AJ				Thai Tran; Teoh, Chun Ming; Tam, John Kit Chung; Qiao, Yongkang; Chin, Chin Yein; Chong, Oi Khuan; Stewart, Alastair G.; Harris, Trudi; Wong, Wai Shiu Fred; Guan, Shou Ping; Leung, Bernard P.; Gerthoffer, William T.; Unruh, Helmut; Halayko, Andrew J.			Laminin drives survival signals to promote a contractile smooth muscle phenotype and airway hyperreactivity	FASEB JOURNAL			English	Article						apoptosis; phenotype plasticity; integrin	EXTRACELLULAR-MATRIX; ASTHMA; EXPRESSION; CELLS; PROLIFERATION; MATURATION; KINASE; MODEL; YIGSR; WALL	Increased airway smooth muscle (ASM) mass is believed to underlie the relatively fixed airway hyperresponsiveness (AHR) in asthma. Developments of therapeutic approaches to reverse airway remodeling are impeded by our lack of insight on the mechanisms behind the increase in mass of contractile ASM cells. Increased expression of laminin, an extracellular matrix protein, is associated with asthma. Our studies investigate the role of laminin-induced ASM survival signals in the development of increased ASM and AHR. Antagonizing laminin integrin binding using the laminin-selective competing peptide, YIGSR, and mimicking laminin with exogenous 2-chain laminin, we show that laminin is both necessary and sufficient to induce ASM cell survival, concomitant with the induction of ASM contractile phenotype. Using siRNA, we show that the laminin-binding integrin 71 mediates this process. Moreover, in laminin-211-deficient mice, allergen-induced AHR was not observed. Notably, ASM cells from asthmatic airways express a higher abundance of intracellular cell survival proteins, consistent with a role for reduced rates of cell apoptosis in development of ASM hyperplasia. Targeting the laminin-integrin 71 signaling pathway may offer new avenues for the development of therapies to reduce the increase in mass of contractile phenotype ASM cells that underlie AHR in asthma.Tran, T., Teoh, C. M., Tam, J. K. C., Qiao, Y., Chin, C. Y., Chong, O. K., Stewart, A. G., Harris, T., Wong, W. S. F., Guan, S. P., Leung, B. P., Gerthoffer, W. T., Unruh, H., and Halayko, A. J. Laminin drives survival signals to promote a contractile smooth muscle phenotype and airway hyperreactivity.	[Thai Tran; Teoh, Chun Ming; Qiao, Yongkang; Chin, Chin Yein; Chong, Oi Khuan; Leung, Bernard P.] Natl Univ Singapore, Dept Physiol, Singapore 117597, Singapore; [Thai Tran; Wong, Wai Shiu Fred; Guan, Shou Ping; Leung, Bernard P.] Natl Univ Singapore, Program Immunol, Inst Life Sci, Singapore 117597, Singapore; [Tam, John Kit Chung] Natl Univ Singapore, Dept Surg, Singapore 117597, Singapore; [Wong, Wai Shiu Fred; Guan, Shou Ping] Natl Univ Singapore, Dept Pharmacol, Singapore 117597, Singapore; [Stewart, Alastair G.; Harris, Trudi] Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; [Gerthoffer, William T.] Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL USA; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada; [Unruh, Helmut; Halayko, Andrew J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada; [Unruh, Helmut; Halayko, Andrew J.] Univ Manitoba, Sect Resp Dis, Winnipeg, MB, Canada; [Halayko, Andrew J.] Manitoba Inst Child Hlth, Biol Breathing Grp, Winnipeg, MB, Canada	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; University of Melbourne; University of South Alabama; University of Manitoba; University of Manitoba; University of Manitoba	Tran, T (corresponding author), Natl Univ Singapore, Dept Physiol, Block MD9,2 Med Dr, Singapore 117597, Singapore.	tran_thai@nuhs.edu.sg	Tam, John/B-6048-2012; Leung, Bernard PuiLam/O-2409-2013	Leung, Bernard PuiLam/0000-0002-1119-4934; TRAN, Thai/0000-0002-8662-3676; stewart, alastair/0000-0002-2271-5942; Wong, Wai Shiu Fred/0000-0001-7010-3759; Halayko, Andrew/0000-0002-7865-4552; Gerthoffer, William/0000-0001-5154-4962	Singapore Ministry of Education's Academic Research Fund [T13-0702-P26]; Singapore Deputy President (Research and Technology) startup grant; Canada Research Chairs Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG006000] Funding Source: NIH RePORTER	Singapore Ministry of Education's Academic Research Fund; Singapore Deputy President (Research and Technology) startup grant; Canada Research Chairs Program(Canada Research Chairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Ms. Karol McNeill and Ms. Tie Khee Chan (TUNEL assay) for excellent technical assistance. This study received financial support from the Singapore Ministry of Education's Academic Research Fund (T13-0702-P26), as well as support from a Singapore Deputy President (Research and Technology) startup grant to T.T. A.J.H. is supported through the Canada Research Chairs Program.	Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; Bao Z, 2009, AM J RESP CRIT CARE, V179, P657, DOI 10.1164/rccm.200809-1516OC; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bentley JK, 2009, AM J PHYSIOL-LUNG C, V296, pL176, DOI 10.1152/ajplung.90376.2008; Dekkers BGJ, 2007, AM J PHYSIOL-LUNG C, V292, pL1405, DOI 10.1152/ajplung.00331.2006; Dekkers BGJ, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-170; Deng H, 2010, AM J RESP CELL MOL, V42, P744, DOI 10.1165/rcmb.2009-0037OC; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; Halayko AJ, 2004, AM J RESP CELL MOL, V31, P266, DOI 10.1165/rcmb.2003-0272OC; Herszberg B, 2006, J ALLERGY CLIN IMMUN, V118, P382, DOI 10.1016/j.jaci.2006.03.044; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; Kaur D, 2010, CLIN EXP ALLERGY, V40, P279, DOI 10.1111/j.1365-2222.2009.03423.x; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Pullan S, 1996, J CELL SCI, V109, P631; Ramos-Barbon D, 2005, J CLIN INVEST, V115, P1580, DOI 10.1172/JCI19711; Robinson PJ, 1996, PEDIATR PULM, V22, P248, DOI 10.1002/(SICI)1099-0496(199610)22:4<248::AID-PPUL4>3.0.CO;2-I; Sharma P, 2008, AM J PHYSIOL-LUNG C, V294, pL57, DOI 10.1152/ajplung.00378.2007; Stewart AG, 2004, EUR RESPIR J, V24, P515, DOI 10.1183/09031936.04.00067404; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tran T, 2007, AM J RESP CELL MOL, V37, P668, DOI 10.1165/rcmb.2007-0165OC; Tran T, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-117; Ward JE, 2008, EUR RESPIR J, V32, P362, DOI 10.1183/09031936.00119307	22	16	18	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3991	4003		10.1096/fj.12-221341	http://dx.doi.org/10.1096/fj.12-221341			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23756649	Green Published			2022-12-28	WOS:000329747100014
J	Cozzi, R; Zerbini, F; Assfalg, M; D'Onofrio, M; Biagini, M; Martinelli, M; Nuccitelli, A; Norais, N; Telford, JL; Maione, D; Rinaudo, CD				Cozzi, Roberta; Zerbini, Francesca; Assfalg, Michael; D'Onofrio, Mariapina; Biagini, Massimiliano; Martinelli, Manuele; Nuccitelli, Annalisa; Norais, Nathalie; Telford, John L.; Maione, Domenico; Rinaudo, C. Daniela			Group B Streptococcus pilus sortase regulation: a single mutation in the lid region induces pilin protein polymerization in vitro	FASEB JOURNAL			English	Article						transpeptidation; backbone protein; limited proteolysis; thermal stability; NMR spectroscopy	CELL-WALL; STAPHYLOCOCCUS-AUREUS; SURFACE-PROTEINS; CRYSTAL-STRUCTURES; IDENTIFICATION; INVOLVEMENT; CATALYSIS; INSIGHTS; VACCINE; ANCHOR	Gram-positive bacteria build pili on their cell surface via a class C sortase-catalyzed transpeptidation mechanism from pilin protein substrates. Despite the availability of several crystal structures, pilus-related C sortases remain poorly characterized to date, and their mechanisms of transpeptidation and regulation need to be further investigated. The available 3-dimensional structures of these enzymes reveal a typical sortase fold, except for the presence of a unique feature represented by an N-terminal highly flexible loop known as the lid. This region interacts with the residues composing the catalytic triad and covers the active site, thus maintaining the enzyme in an autoinhibited state and preventing the accessibility to the substrate. It is believed that enzyme activation may occur only after lid displacement from the catalytic domain. In this work, we provide the first direct evidence of the regulatory role of the lid, demonstrating that it is possible to obtain in vitro an efficient polymerization of pilin subunits using an active C sortase lid mutant carrying a single residue mutation in the lid region. Moreover, biochemical analyses of this recombinant mutant reveal that the lid confers thermodynamic and proteolytic stability to the enzyme.	[Cozzi, Roberta; Zerbini, Francesca; Biagini, Massimiliano; Martinelli, Manuele; Nuccitelli, Annalisa; Norais, Nathalie; Telford, John L.; Maione, Domenico; Rinaudo, C. Daniela] Novartis Vaccines & Diagnost, I-53100 Siena, Italy; [Assfalg, Michael; D'Onofrio, Mariapina] Univ Verona, Dept Biotechnol, Nucl Magnet Resonance Lab, I-37100 Verona, Italy	Novartis; University of Verona	Maione, D (corresponding author), Novartis Vaccines & Diagnost, Via Fiorentina 1, I-53100 Siena, Italy.	domenico.maione@novartis.com	Telford, John Laird/ABG-8144-2020	Assfalg, Michael/0000-0001-9331-3169; martinelli, manuele/0000-0002-9371-076X; D'ONOFRIO, Mariapina/0000-0002-8699-0847	University of Verona; Novartis Vaccines and Diagnostics (Siena, Italy)	University of Verona; Novartis Vaccines and Diagnostics (Siena, Italy)	This work was supported by the Joint Research Project 2010 between the University of Verona and Novartis Vaccines and Diagnostics (Siena, Italy). The authors thank Prof. Henriette Molinari for helpful discussions.	Budzik JM, 2008, J BIOL CHEM, V283, P36676, DOI 10.1074/jbc.M806796200; Cozzi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049048; Cozzi R, 2012, FASEB J, V26, P2008, DOI 10.1096/fj.11-196378; Cozzi R, 2011, FASEB J, V25, P1874, DOI 10.1096/fj.10-174797; Dramsi S, 2006, MOL MICROBIOL, V60, P1401, DOI 10.1111/j.1365-2958.2006.05190.x; Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027; Hendrickx APA, 2011, NAT REV MICROBIOL, V9, P166, DOI 10.1038/nrmicro2520; Hung TT, 2004, MOL MICROBIOL, V53, P251, DOI 10.1111/j.1365-2958.2004.04117.x; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; Kang HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023367; Khare B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022995; Khare B, 2011, J MOL BIOL, V414, P563, DOI 10.1016/j.jmb.2011.10.017; Klock Heath E., 2009, V498, P91, DOI 10.1007/978-1-59745-196-3_6; Lu GW, 2011, PROTEINS, V79, P2764, DOI 10.1002/prot.23093; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Mandlik A, 2008, TRENDS MICROBIOL, V16, P33, DOI 10.1016/j.tim.2007.10.010; Manetti AGO, 2007, MOL MICROBIOL, V64, P968, DOI 10.1111/j.1365-2958.2007.05704.x; Manzano C, 2009, BIOCHEMISTRY-US, V48, P10549, DOI 10.1021/bi901261y; Manzano C, 2008, STRUCTURE, V16, P1838, DOI 10.1016/j.str.2008.10.007; Margarit I, 2009, J INFECT DIS, V199, P108, DOI 10.1086/595564; Marraffini LA, 2006, MICROBIOL MOL BIOL R, V70, P192, DOI 10.1128/MMBR.70.1.192-221.2006; Marraffini LA, 2004, J BIOL CHEM, V279, P37763, DOI 10.1074/jbc.M405282200; Necchi F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025300; Neiers F, 2009, J MOL BIOL, V393, P704, DOI 10.1016/j.jmb.2009.08.058; Nobbs AH, 2008, INFECT IMMUN, V76, P3550, DOI 10.1128/IAI.01613-07; Nuccitelli A, 2011, P NATL ACAD SCI USA, V108, P10278, DOI 10.1073/pnas.1106590108; Persson K, 2011, ACTA CRYSTALLOGR D, V67, P212, DOI 10.1107/S0907444911004215; Pezzicoli A, 2008, J INFECT DIS, V198, P890, DOI 10.1086/591182; Rinaudo CD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009216; Rosini R, 2006, MOL MICROBIOL, V61, P126, DOI 10.1111/j.1365-2958.2006.05225.x; Schneewind O, 2012, PHILOS T R SOC B, V367, P1123, DOI 10.1098/rstb.2011.0210; Sendi P, 2008, INFECTION, V36, P100, DOI 10.1007/s15010-007-7251-0; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; Spirig T, 2011, MOL MICROBIOL, V82, P1044, DOI 10.1111/j.1365-2958.2011.07887.x; Telford JL, 2006, NAT REV MICROBIOL, V4, P509, DOI 10.1038/nrmicro1443; Ton-That H, 2004, BBA-MOL CELL RES, V1694, P269, DOI 10.1016/j.bbamcr.2004.04.014; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Vengadesan K, 2011, J MOL BIOL, V407, P731, DOI 10.1016/j.jmb.2011.02.024; Wu CG, 2012, J BACTERIOL, V194, P2531, DOI 10.1128/JB.00093-12; Zong YN, 2004, J BIOL CHEM, V279, P31383, DOI 10.1074/jbc.M401374200	41	10	10	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3144	3154		10.1096/fj.13-227793	http://dx.doi.org/10.1096/fj.13-227793			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23631841				2022-12-28	WOS:000329877600021
J	Sroubek, J; Krishnan, Y; McDonald, TV				Sroubek, Jakub; Krishnan, Yamini; McDonald, Thomas V.			Sequence and structure-specific elements of HERG mRNA determine channel synthesis and trafficking efficiency	FASEB JOURNAL			English	Article						codon-usage; KCNH2; LQTS; SNP; protein translation	LONG QT SYNDROME; SECONDARY STRUCTURE; PROTEIN-KINASE; SYNONYMOUS MUTATIONS; ESCHERICHIA-COLI; GC-CONTENT; CODON; TRANSLATION; POLYMORPHISM; MECHANISMS	Human ether-a-gogo-related gene (HERG) encodes a potassium channel that is highly susceptible to deleterious mutations resulting in susceptibility to fatal cardiac arrhythmias. Most mutations adversely affect HERG channel assembly and trafficking. Why the channel is so vulnerable to missense mutations is not well understood. Since nothing is known of how mRNA structural elements factor in channel processing, we synthesized a codon-modified HERG cDNA (HERG-CM) where the codons were synonymously changed to reduce GC content, secondary structure, and rare codon usage. HERG-CM produced typical I-Kr-like currents; however, channel synthesis and processing were markedly different. Translation efficiency was reduced for HERG-CM, as determined by heterologous expression, in vitro translation, and polysomal profiling. Trafficking efficiency to the cell surface was greatly enhanced, as assayed by immunofluorescence, subcellular fractionation, and surface labeling. Chimeras of HERG-NT/CM indicated that trafficking efficiency was largely dependent on 5 sequences, while translation efficiency involved multiple areas. These results suggest that HERG translation and trafficking rates are independently governed by noncoding information in various regions of the mRNA molecule. Noncoding information embedded within the mRNA may play a role in the pathogenesis of hereditary arrhythmia syndromes and could provide an avenue for targeted therapeutics.	[Sroubek, Jakub; Krishnan, Yamini; McDonald, Thomas V.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY USA; [McDonald, Thomas V.] Albert Einstein Coll Med, Dept Med, Wilf Family Cardiovasc Res Ctr, Bronx, NY USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	McDonald, TV (corresponding author), 1300 Morris Pk Ave,Forchheimer G35, Bronx, NY 10461 USA.	tom.mcdonald@einstein.yu.edu			U.S. National Institutes of Health/National Heart, Lung, and Blood Institute [F30HL096279, R01HL077929]; American Heart Association [11GRNT5480008]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL096279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. Charles Rubin, John Warner, and Umadas Maitra for thoughtful discussion and advice. This work was supported in part by grants from the U.S. National Institutes of Health/National Heart, Lung, and Blood Institute (F30HL096279 to Y.K. and R01HL077929 to T. V. M.) and the American Heart Association (11GRNT5480008 to T.V.M.).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Anderson CL, 2006, CIRCULATION, V113, P365, DOI 10.1161/CIRCULATIONAHA.105.570200; Banasavadi-Siddegowda YK, 2011, J BIOL CHEM, V286, P43071, DOI 10.1074/jbc.M111.269993; Barc Julien, 2011, J Am Coll Cardiol, V57, P40, DOI 10.1016/j.jacc.2010.08.621; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartoszewski RA, 2010, J BIOL CHEM, V285, P28741, DOI 10.1074/jbc.M110.154575; Bernardi G, 2000, GENE, V241, P3, DOI 10.1016/S0378-1119(99)00485-0; Buchan JR, 2007, BIOL CELL, V99, P475, DOI 10.1042/BC20070037; Capon F, 2004, HUM MOL GENET, V13, P2361, DOI 10.1093/hmg/ddh273; Chen J, 2009, AM J PHYSIOL-HEART C, V296, pH1244, DOI 10.1152/ajpheart.01252.2008; Crotti L, 2005, CIRCULATION, V112, P1251, DOI 10.1161/CIRCULATIONAHA.105.549071; Delisle BP, 2005, MOL PHARMACOL, V68, P233, DOI 10.1124/mol.105.012914; Delisle BP, 2003, J BIOL CHEM, V278, P35749, DOI 10.1074/jbc.M305787200; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fraser CS, 2009, PROG MOL BIOL TRANSL, V90, P1, DOI 10.1016/S1877-1173(09)90001-1; Fullerton SM, 2001, MOL BIOL EVOL, V18, P1139, DOI 10.1093/oxfordjournals.molbev.a003886; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Goldenberg I, 2008, J AM COLL CARDIOL, V51, P2291, DOI 10.1016/j.jacc.2008.02.068; Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188; Handa V, 2003, NUCLEIC ACIDS RES, V31, P6243, DOI 10.1093/nar/gkg818; Hurt CM, 2000, J BIOL CHEM, V275, P35424, DOI 10.1074/jbc.M006241200; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Komar AA, 1999, FEBS LETT, V462, P387, DOI 10.1016/S0014-5793(99)01566-5; Komar AA, 2009, TRENDS BIOCHEM SCI, V34, P16, DOI 10.1016/j.tibs.2008.10.002; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Krishnan Y, 2012, BBA-MOL CELL RES, V1823, P1273, DOI 10.1016/j.bbamcr.2012.05.012; Kudla G, 2006, PLOS BIOL, V4, P933, DOI 10.1371/journal.pbio.0040180; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Li Y, 2008, J MEMBRANE BIOL, V223, P107, DOI 10.1007/s00232-008-9118-4; Lu JL, 2008, J MOL BIOL, V384, P73, DOI 10.1016/j.jmb.2008.08.089; Mahoney SJ, 2009, PROG MOL BIOL TRANSL, V90, P53, DOI 10.1016/S1877-1173(09)90002-3; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Merchant SS, 2007, SCIENCE, V318, P245, DOI 10.1126/science.1143609; Moss AJ, 2005, J CLIN INVEST, V115, P2018, DOI 10.1172/JCI25537; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Pager CT, 2009, PROG MOL BIOL TRANSL, V90, P187, DOI 10.1016/S1877-1173(09)90005-9; Rasband W., 2006, IMAGEJ; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Romiguier J, 2010, GENOME RES, V20, P1001, DOI 10.1101/gr.104372.109; Saenen JB, 2008, J MOL CELL CARDIOL, V44, P633, DOI 10.1016/j.yjmcc.2008.01.006; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051; Saunders R, 2010, NUCLEIC ACIDS RES, V38, P6719, DOI 10.1093/nar/gkq495; Schulze-Bahr E, 2008, PROG BIOPHYS MOL BIO, V98, P289, DOI 10.1016/j.pbiomolbio.2009.01.008; Schwartz PJ, 2006, J INTERN MED, V259, P39, DOI 10.1111/j.1365-2796.2005.01583.x; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; Takyar S, 2005, CELL, V120, P49, DOI 10.1016/j.cell.2004.11.042; Thomas D, 2003, CARDIOVASC RES, V60, P235, DOI 10.1016/j.cardiores.2003.08.002; VARENNE S, 1984, J MOL BIOL, V180, P549, DOI 10.1016/0022-2836(84)90027-5; Walker VE, 2007, J BIOL CHEM, V282, P23509, DOI 10.1074/jbc.M701006200; Walker VE, 2010, J BIOL CHEM, V285, P3319, DOI 10.1074/jbc.M109.024000; Wan Y, 2011, NAT REV GENET, V12, P641, DOI 10.1038/nrg3049; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wen JD, 2008, NATURE, V452, P598, DOI 10.1038/nature06716; Zhang G, 2009, NAT STRUCT MOL BIOL, V16, P274, DOI 10.1038/nsmb.1554; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zumwalt M, 2007, RNA BIOL, V4, P93, DOI 10.4161/rna.4.2.5039	67	5	6	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3039	3053		10.1096/fj.12-227009	http://dx.doi.org/10.1096/fj.12-227009			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23608144	Green Published			2022-12-28	WOS:000329877600012
J	Huang, JY; Simcox, J; Mitchell, TC; Jones, D; Cox, J; Luo, B; Cooksey, RC; Boros, LG; McClain, DA				Huang, Jingyu; Simcox, Judith; Mitchell, T. Creighton; Jones, Deborah; Cox, James; Luo, Bai; Cooksey, Robert C.; Boros, Laszlo G.; McClain, Donald A.			Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice	FASEB JOURNAL			English	Article						AMPK; insulin signaling; acetylation	HEREDITARY HEMOCHROMATOSIS; MOUSE MODEL; INSULIN-RESISTANCE; OXIDATIVE STRESS; CELL APOPTOSIS; METABOLISM; ACETYLATION; HEPCIDIN; P53; DEACETYLATION	Excess iron is associated with hepatic damage and diabetes in humans, although the detailed molecular mechanisms are not known. To investigate how iron regulates glucose homeostasis, we fed C57BL/6J male mice with high-iron (HI) diets (2 or 20 g Fe/kg chow). Mice fed an HI diet exhibited elevated AMP-activated protein kinase (AMPK) activity and impaired insulin signaling in skeletal muscle and liver. Consistent with the increased AMPK activity, glucose uptake was enhanced in mice fed an HI diet. The effects of improved glucose tolerance induced by HI feeding were abolished in transgenic mice with expression of muscle specific dominant-negative AMPK. Glucose output was suppressed in the liver of wild-type mice fed an HI diet, due to decreased expression of gluconeogenic genes and decreased substrate (lactate) from peripheral glycolysis. Iron activated AMPK by increasing deacetylase and decreasing LKB1 acetylation, in turn stimulating the phosphorylation of LKB1 and AMPK. The effects of HI diet were abrogated by treatment of the mice with N-acetyl cysteine, suggesting a redox-dependent mechanism for increasing deacetylase activity. In addition, tissue from iron-fed mice exhibited an elevated AMP/ATP ratio, further contributing to AMPK activation. In summary, a diet high in iron improves glucose tolerance by activating AMPK through mechanisms that include deacetylation.Huang J., Simcox, J., Mitchell, T. C., Jones, D., Cox, J., Luo, B., Cooksey, R. C., Boros, L. G., McClain, D. A. Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice.	[Huang, Jingyu; Simcox, Judith; Mitchell, T. Creighton; Jones, Deborah; Cox, James; Luo, Bai; Cooksey, Robert C.; McClain, Donald A.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA; [Huang, Jingyu; Simcox, Judith; Mitchell, T. Creighton; Jones, Deborah; Cox, James; Luo, Bai; Cooksey, Robert C.; McClain, Donald A.] Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT USA; [Cooksey, Robert C.; McClain, Donald A.] Vet Affairs Med Ctr, Res Serv, Salt Lake City, UT 84148 USA; [Boros, Laszlo G.] Sidmap LLC, Los Angeles, CA USA; [Boros, Laszlo G.] Harbor UCLA Med Ctr, Dept Pediat, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute	McClain, DA (corresponding author), Div Endocrinol, 30 N 2030 East, Salt Lake City, UT 84132 USA.	donald.mcclain@hsc.utah.edu		McClain, Don/0000-0002-3310-2359; Simcox, Judith/0000-0001-7350-6342	U.S. National Institutes of Health [RO1DK081842, 1T32DK091317]; Research Service of the U.S. Department of Veterans Affairs; Marilyn Jane Robinson Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081842, T32DK091317] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001140] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Service of the U.S. Department of Veterans Affairs(US Department of Veterans Affairs); Marilyn Jane Robinson Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Dr. Morris Birnbaum (University of Pennsylvania, Philadelphia, PA, USA) for the AMPK-DN mice. This work was supported by the U.S. National Institutes of Health (RO1DK081842, D.M.; 1T32DK091317, J.S.), the Research Service of the U.S. Department of Veterans Affairs, and the Marilyn Jane Robinson Foundation.	Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Cooksey RC, 2004, ENDOCRINOLOGY, V145, P5305, DOI 10.1210/en.2004-0392; Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348; Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978; Fryer LGD, 2002, FEBS LETT, V531, P189, DOI 10.1016/S0014-5793(02)03501-9; Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421; Hatunic M, 2010, METABOLISM, V59, P380, DOI 10.1016/j.metabol.2009.08.006; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Huang JH, 2007, J BIOL CHEM, V282, P37501, DOI 10.1074/jbc.M703625200; Huang JY, 2011, DIABETES, V60, P80, DOI 10.2337/db10-0593; Huberman A, 2002, ANAL BIOCHEM, V307, P375, DOI 10.1016/S0003-2697(02)00047-7; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Joitihan HA, 2008, MOL MED, V14, P98, DOI 10.2119/2007-00114.Jouihan; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kume S, 2006, FREE RADICAL BIO MED, V40, P2175, DOI 10.1016/j.freeradbiomed.2006.02.014; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Lebeau A, 2002, EUR J CLIN INVEST, V32, P603, DOI 10.1046/j.1365-2362.2002.01026.x; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Lu JY, 2011, CELL, V146, P968, DOI 10.1016/j.cell.2011.07.044; McClain DA, 2006, DIABETOLOGIA, V49, P1661, DOI 10.1007/s00125-006-0200-0; Nemeth E, 2005, BLOOD, V105, P1803, DOI 10.1182/blood-2004-08-3042; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Pietrangelo A, 2010, GASTROENTEROLOGY, V139, P393, DOI 10.1053/j.gastro.2010.06.013; Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271; QUAIL EA, 1995, FEBS LETT, V359, P126, DOI 10.1016/0014-5793(95)00023-3; Rajpathak SN, 2009, DIABETES OBES METAB, V11, P472, DOI 10.1111/j.1463-1326.2008.00985.x; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Sullivan JL, 2007, EXP BIOL MED, V232, P1014, DOI 10.3181/0703-MR-54; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	38	43	45	2	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2845	2854		10.1096/fj.12-216929	http://dx.doi.org/10.1096/fj.12-216929			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23515442	Green Published			2022-12-28	WOS:000328841000032
J	DiPatrizio, NV; Joslin, A; Jung, KM; Piomelli, D				DiPatrizio, Nicholas V.; Joslin, Alexandra; Jung, Kwang-Mook; Piomelli, Daniele			Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats	FASEB JOURNAL			English	Article						2-arachidonoyl-sn-glycerol; anandamide; taste; lipids	CANNABINOID CB1 RECEPTORS; LINOLEIC-ACID; CORN-OIL; CARDIOMETABOLIC RISK; OROSENSORY DETECTION; ENERGY-BALANCE; ADIPOSE-TISSUE; NEURAL-CONTROL; FEMALE RATS; OBESITY	Dietary fat exerts a potent stimulatory effect on feeding. This effect is mediated, at least in part, by a cephalic mechanism that involves recruitment of the vagus nerve and subsequent activation of endocannabinoid signaling in the gut. Here, we used a sham-feeding protocol in rats to identify fatty-acid constituents of dietary fat that might be responsible for triggering small-intestinal endocannabinoid signaling. Sham feeding rats with a corn oil emulsion increased endocannabinoid levels in jejunum, relative to animals that received either mineral oil (which contains no fatty acids) or no oil. Sham-feeding emulsions containing oleic acid (18:1) or linoleic acid (18:2) caused, on average, a nearly 2-fold accumulation of jejunal endocannabinoids, whereas emulsions containing stearic acid (18:0) or linolenic acid (18:3) had no such effect. In a 2-bottle-choice sham-feeding test, rats displayed strong preference for emulsions containing 18:2, which was blocked by pretreatment with the peripherally restricted CB1 cannabinoid receptor antagonists, AM6546 and URB447. Our results suggest that oral exposure to the monoenoic and dienoic fatty acid component of dietary fat selectively initiates endocannabinoid mobilization in the gut, and that this local signaling event is essential for fat preference.	[DiPatrizio, Nicholas V.; Joslin, Alexandra; Jung, Kwang-Mook; Piomelli, Daniele] Univ Calif Irvine, Sch Med, Dept Anat & Neurobiol, Irvine, CA 92697 USA; [Piomelli, Daniele] Univ Calif Irvine, Sch Med, Dept Pharmacol, Irvine, CA 92697 USA; [Piomelli, Daniele] Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; [Piomelli, Daniele] Ist Italiano Tecnol, Unit Drug Discovery & Dev, Genoa, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Istituto Italiano di Tecnologia - IIT	Piomelli, D (corresponding author), Univ Calif Irvine, Sch Med, Gillespie Neurosci Res Facil 3103, Irvine, CA 92697 USA.	piomelli@uci.edu	DiPatrizio, NIcholas/AAV-1865-2021; Jung, Kwang-Mook/F-1035-2018	DiPatrizio, NIcholas/0000-0001-8423-0695; Jung, Kwang-Mook/0000-0003-4096-6953	U.S. National Institutes of Health [DK073955]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073955] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Joe Gancayco, Conor Murray, Paul Coh, David Grigoryan, James Lim, and Dr. Miki Igarashi for help with experiments. This work was supported by U.S. National Institutes of Health grant DK073955 (to D.P.).	Alvheim AR, 2012, OBESITY, V20, P1984, DOI 10.1038/oby.2012.38; Astarita G, 2009, J CHROMATOGR B, V877, P2755, DOI 10.1016/j.jchromb.2009.01.008; Bluher M, 2006, DIABETES, V55, P3053, DOI 10.2337/db06-0812; Cartoni C, 2010, J NEUROSCI, V30, P8376, DOI 10.1523/JNEUROSCI.0496-10.2010; Cote M, 2007, INT J OBESITY, V31, P692, DOI 10.1038/sj.ijo.0803539; DAYTON S, 1966, J LIPID RES, V7, P103; DiPatrizio NV, 2008, AM J PHYSIOL-REG I, V295, pR1409, DOI 10.1152/ajpregu.90484.2008; DiPatrizio NV, 2008, J NEUROSCI, V28, P9702, DOI 10.1523/JNEUROSCI.1171-08.2008; DiPatrizio NV, 2012, TRENDS NEUROSCI, V35, P403, DOI 10.1016/j.tins.2012.04.006; DiPatrizio NV, 2011, P NATL ACAD SCI USA, V108, P12904, DOI 10.1073/pnas.1104675108; Engeli S, 2005, DIABETES, V54, P2838, DOI 10.2337/diabetes.54.10.2838; Gaillard D, 2008, FASEB J, V22, P1458, DOI 10.1096/fj.07-8415com; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Greenberg D, 1996, PSYCHOSOM MED, V58, P559, DOI 10.1097/00006842-199611000-00004; Grill HJ, 2006, OBESITY, V14, P216, DOI 10.1038/oby.2006.312; HAMILTON RB, 1984, J COMP NEUROL, V222, P560, DOI 10.1002/cne.902220408; HAMOSH M, 1977, LAB INVEST, V37, P603; HAMOSH M, 1990, NUTRITION, V6, P421; HAMOSH M, 1973, J CLIN INVEST, V52, P88, DOI 10.1172/JCI107177; Izzo AA, 2009, BRIT J PHARMACOL, V158, P451, DOI 10.1111/j.1476-5381.2009.00183.x; Jarbe TUC, 2005, BEHAV PHARMACOL, V16, P373; Kawai T, 2003, AM J PHYSIOL-REG I, V285, pR447, DOI 10.1152/ajpregu.00729.2002; Kelley AE, 2004, NEUROSCI BIOBEHAV R, V27, P765, DOI 10.1016/j.neubiorev.2003.11.015; Laugerette F, 2005, J CLIN INVEST, V115, P3177, DOI 10.1172/JCI25299; Liang NC, 2006, AM J PHYSIOL-REG I, V291, pR1236, DOI 10.1152/ajpregu.00226.2006; Liu P, 2011, J NEUROSCI, V31, P8634, DOI 10.1523/JNEUROSCI.6273-10.2011; LoVerme J, 2009, BIOORG MED CHEM LETT, V19, P639, DOI 10.1016/j.bmcl.2008.12.059; Mahler SV, 2007, NEUROPSYCHOPHARMACOL, V32, P2267, DOI 10.1038/sj.npp.1301376; Martin C, 2011, PHYSIOL BEHAV, V105, P36, DOI 10.1016/j.physbeh.2011.02.029; Matias I, 2007, TRENDS ENDOCRIN MET, V18, P27, DOI 10.1016/j.tem.2006.11.006; Matias I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042399; MINDELL S, 1990, PHYSIOL BEHAV, V48, P283, DOI 10.1016/0031-9384(90)90314-T; Moreau R. A., 2011, Vegetable oils in food technology: composition, properties and uses, P273; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Pittman D, 2007, BRAIN RES, V1151, P74, DOI 10.1016/j.brainres.2007.03.027; Saitou K, 2009, PHYSIOL BEHAV, V96, P142, DOI 10.1016/j.physbeh.2008.09.014; Sclafani A, 2007, AM J PHYSIOL-REG I, V293, pR1823, DOI 10.1152/ajpregu.00211.2007; Smith G P, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0806ds04; SMITH GP, 1991, BRAIN RES BULL, V27, P379, DOI 10.1016/0361-9230(91)90128-7; Smith KS, 2011, P NATL ACAD SCI USA, V108, pE255, DOI 10.1073/pnas.1101920108; Stratford JM, 2006, PHYSIOL BEHAV, V89, P311, DOI 10.1016/j.physbeh.2006.06.009; Sykaras AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042373; Tam J, 2010, J CLIN INVEST, V120, P2953, DOI 10.1172/JCI42551; Treesukosol Y, 2010, AM J PHYSIOL-REG I, V299, pR1050, DOI 10.1152/ajpregu.00763.2009; Wu Q, 2012, NATURE, V483, P594, DOI 10.1038/nature10899; Yoneda T, 2007, PHYSIOL BEHAV, V91, P304, DOI 10.1016/j.physbeh.2007.03.006; Yoneda T, 2009, PHYSIOL BEHAV, V96, P735, DOI 10.1016/j.physbeh.2009.01.010; Yoshida R, 2010, P NATL ACAD SCI USA, V107, P935, DOI 10.1073/pnas.0912048107; Yu WZ, 1999, PHARMACOL BIOCHEM BE, V64, P573, DOI 10.1016/S0091-3057(99)00124-0	49	54	54	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2513	2520		10.1096/fj.13-227587	http://dx.doi.org/10.1096/fj.13-227587			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23463697	Green Published, Green Submitted			2022-12-28	WOS:000319667600039
J	Holmquist, E; Okroj, M; Nodin, B; Jirstrom, K; Blom, AM				Holmquist, Emelie; Okroj, Marcin; Nodin, Bjorn; Jirstrom, Karin; Blom, Anna M.			Sushi domain-containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase	FASEB JOURNAL			English	Article						innate immunity; CCP domain	SARCOMA-ASSOCIATED HERPESVIRUS; C4B-BINDING PROTEIN; PLASMA-PROTEINS; SYSTEM; PURIFICATION; EXPRESSION	Recently discovered Sushi domain-containing protein 4 (SUSD4) contains several Sushi or complement control protein domains; therefore, we hypothesized that it may act as complement inhibitor. Two isoforms of human SUSD4, fused to the Fc part of human IgG, were recombinantly expressed in Chinese hamster ovary (CHO) cells. The secreted soluble isoform of SUSD4 (SUSD4b) inhibited the classical and lectin complement pathways by 50% at a concentration of 0.5 mu M. This effect was due to the fact that 1 mu M SUSD4b inhibited the formation of the classical C3 convertase by 90%. The membrane-bound isoform (SUSD4a) inhibited the classical and alternative complement pathways when expressed on the surface of CHO cells but not when expressed as a soluble, truncated protein. In all functional studies, we used known complement inhibitors as positive controls, while Coxsackie adenovirus receptor, which has no effect on complement, expressed with Fc tag, was a negative control. We also studied the mRNA expression of both isoforms of SUSD4 in a panel of human tissues using quantitative PCR and primarily found SUSD4a in esophagus and brain, while SUSD4b was highly expressed in esophagus, ovary, and heart. Overall, our results show that SUSD4 is a novel complement inhibitor with restricted expression.-Holmquist, E., Okroj, M., Nodin, B., Jirstrom, K. Blom, A. M. Sushi domain-containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase.	[Holmquist, Emelie; Okroj, Marcin; Blom, Anna M.] Lund Univ, Dept Lab Med, Div Med Prot Chem, S-20502 Malmo, Sweden; [Nodin, Bjorn; Jirstrom, Karin] Lund Univ, Div Pathol, Dept Clin Sci, Lund, Sweden	Lund University; Lund University	Blom, AM (corresponding author), Lund Univ, Dept Lab Med Malmo, Skane Univ Hosp, Wallenberg Lab, Inga Maria Nilssons Gata 53, S-20502 Malmo, Sweden.	anna.blom@med.lu.se	Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022	Blom, Anna/0000-0002-1348-1734; 	Cancerfonden, Swedish Research Council [K2012-66X-14928-09-5, K2010-80X-21514-01-4]; National Board of Health and Welfare; Foundation of Osterlund; Foundation of Crafoord; Foundation of Greta and Johan Kock; Foundation of Thelma Zoega; Foundation of Tore Nilsson; Foundation of King Gustav V's 80th anniversary; Skane University Hospital	Cancerfonden, Swedish Research Council(Swedish Research Council); National Board of Health and Welfare; Foundation of Osterlund; Foundation of Crafoord; Foundation of Greta and Johan Kock; Foundation of Thelma Zoega; Foundation of Tore Nilsson; Foundation of King Gustav V's 80th anniversary; Skane University Hospital	This work was supported by the Cancerfonden, Swedish Research Council (K2012-66X-14928-09-5 and K2010-80X-21514-01-4), National Board of Health and Welfare and the Foundations of Osterlund, Crafoord, Greta and Johan Kock, Thelma Zoega, Tore Nilsson, King Gustav V's 80th anniversary, Knut and Alice Wallenberg, and Inga-Britt and Arne Lundberg, as well as a grant from the Skane University Hospital.	Cardone J, 2011, CLIN EXP IMMUNOL, V164, P301, DOI 10.1111/j.1365-2249.2011.04400.x; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; FEARON DT, 1975, NEW ENGL J MED, V292, P937, DOI 10.1056/NEJM197505012921802; FRYNS JP, 1987, J MED GENET, V24, P271, DOI 10.1136/jmg.24.5.271; Happonen KE, 2009, J IMMUNOL, V182, P1518, DOI 10.4049/jimmunol.182.3.1518; Kemper C, 2010, ANNU REV IMMUNOL, V28, P131, DOI 10.1146/annurev-immunol-030409-101250; LAURELL CB, 1983, J CHROMATOGR, V278, P53, DOI 10.1016/S0378-4347(00)84755-6; Lundwall A, 2002, MOL HUM REPROD, V8, P805, DOI 10.1093/molehr/8.9.805; Mark L, 2004, J BIOL CHEM, V279, P45093, DOI 10.1074/jbc.M407558200; Nilsson SC, 2011, MOL IMMUNOL, V48, P1611, DOI 10.1016/j.molimm.2011.04.004; Nodin B, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-14; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Okroj M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047245; Okroj M, 2012, J BIOL CHEM, V287, P20100, DOI 10.1074/jbc.M111.324913; Okroj M, 2009, J BIOL CHEM, V284, P505, DOI 10.1074/jbc.M806669200; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Shaffer LG, 2007, GENET MED, V9, P607, DOI 10.1097/GIM.0b013e3181484b49; Spiller OB, 2006, J VIROL, V80, P4068, DOI 10.1128/JVI.80.8.4068-4078.2006; Spiller OB, 2003, J BIOL CHEM, V278, P9283, DOI 10.1074/jbc.M211579200; Spiller OB, 2003, J VIROL, V77, P592, DOI 10.1128/JVI.77.1.592-599.2003; Sun SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026838; TENNER AJ, 1981, J IMMUNOL, V127, P648; Thurman JM, 2011, LAB INVEST, V91, P4, DOI 10.1038/labinvest.2010.173; Tu ZD, 2010, AM J PATHOL, V176, P2378, DOI 10.2353/ajpath.2010.091036; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620	27	23	25	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2355	2366		10.1096/fj.12-222042	http://dx.doi.org/10.1096/fj.12-222042			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23482636				2022-12-28	WOS:000319667600024
J	Hagmann, H; Kuczkowski, A; Ruehl, M; Lamkemeyer, T; Brodesser, S; Horke, S; Dryer, S; Schermer, B; Benzing, T; Brinkkoetter, PT				Hagmann, Henning; Kuczkowski, Alexander; Ruehl, Michael; Lamkemeyer, Tobias; Brodesser, Susanne; Horke, Sven; Dryer, Stuart; Schermer, Bernhard; Benzing, Thomas; Brinkkoetter, Paul Thomas			Breaking the chain at the membrane: paraoxonase 2 counteracts lipid peroxidation at the plasma membrane	FASEB JOURNAL			English	Article						atherosclerosis; arylesterase; oxidative stress; inflammation	LOW-DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; ATHEROSCLEROSIS; DEFICIENCY; EXPRESSION; PRODUCTS; GENE; PHOSPHOLIPIDS; INFLAMMATION; MECHANISMS	Lipid peroxidation through electrophilic molecules of extracellular origin is involved in the pathogenesis of many inflammatory conditions. To counteract free radical actions at the plasma membrane, cells host a variety of antioxidative enzymes. Here we analyzed localization, membrane topology, and trafficking of PON2 a member of the paraoxonase family of 3 enzymatically active proteins (PON1-3) found to have antiatherogenic properties. Immunohistochemistry localized PON2 to the villous tip of human intestinal epithelial cells. Employing membrane preparations, surface biotinylation experiments, and mutational analyses in HEK 293T and HeLa cells, we demonstrate that PON2 is a type II transmembrane protein. A hydrophobic stretch in the N terminus was identified as single transmembrane domain of PON2. The enzymatically active domain faced the extracellular compartment, where it suppressed lipid peroxidation (P < 0.05) and regulated the glucosylceramide content, as demonstrated by mass spectrometry (P < 0.05). PON2 translocation to the plasma membrane was dependent on intracellular calcium responses and could be induced to > 10-fold as compared to baseline (P=0.0001) by oxidative stress. Taken together, these data identify the paraoxonase protein PON2 as a type II transmembrane protein, which is dynamically translocated to the plasma membrane in response to oxidative stress to counteract lipid peroxidation.-Hagmann, H., Kuczkowski, A., Ruehl, M., Lamkemeyer, T., Brodesser, S., Horke, S., Dryer, S., Schermer, B., Benzing, T., Brinkkoetter, P. T. Breaking the chain at the membrane: paraoxonase 2 counteracts lipid peroxidation at the plasma membrane.	[Hagmann, Henning; Kuczkowski, Alexander; Ruehl, Michael; Schermer, Bernhard; Benzing, Thomas; Brinkkoetter, Paul Thomas] Univ Cologne, Dept Internal Med 2, D-50937 Cologne, Germany; [Hagmann, Henning; Kuczkowski, Alexander; Ruehl, Michael; Schermer, Bernhard; Benzing, Thomas; Brinkkoetter, Paul Thomas] Univ Cologne, Ctr Mol Med Cologne, D-50937 Cologne, Germany; [Lamkemeyer, Tobias; Brodesser, Susanne; Schermer, Bernhard; Benzing, Thomas] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50937 Cologne, Germany; [Brodesser, Susanne] Univ Cologne, Inst Med Microbiol Immunol & Hyg, D-50937 Cologne, Germany; [Schermer, Bernhard; Benzing, Thomas] Univ Cologne, D-50937 Cologne, Germany; [Horke, Sven] Univ Hosp Mainz, Inst Pharmacol, Mainz, Germany; [Dryer, Stuart] Univ Houston, Dept Biol & Biochem, Houston, TX USA	University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; University Hospital Mainz; University of Houston System; University of Houston	Brinkkoetter, PT (corresponding author), Univ Cologne, Dept Internal Med 2, Kerpener Str 62, D-50937 Cologne, Germany.	thomas.benzing@uk-koeln.de; paul.brinkkoetter@uk-koeln.de	Schermer, Bernhard/E-9972-2014; Benzing, Thomas/X-5476-2019	Schermer, Bernhard/0000-0002-5194-9000; 	Marga und Walter Boll-Stiftung [HH 210-05-11]; Deutsche Forschungsgemeinschaft [BR2955/4-1, SCHE1562, SFB832, SFB572, SFB635, SFB829]; Koln Fortune Program of the University of Cologne	Marga und Walter Boll-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Koln Fortune Program of the University of Cologne	The authors thank Angelika Koeser for technical support. This study was funded by the Marga und Walter Boll-Stiftung (HH 210-05-11). P.T.B. received funding from the Deutsche Forschungsgemeinschaft (BR2955/4-1) and Koln Fortune Program of the University of Cologne. B.S. obtained funding from the Deutsche Forschungsgemeinschaft (SCHE1562 and SFB832). T.B. received funding from the Deutsche Forschungsgemeinschaft (SFB572, SFB635, and SFB829).	Altenhofer S, 2010, J BIOL CHEM, V285, P24398, DOI 10.1074/jbc.M110.118604; Aviram M, 2004, FREE RADICAL BIO MED, V37, P1304, DOI 10.1016/j.freeradbiomed.2004.06.030; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; Aviram Michael, 2008, V477, P259, DOI 10.1007/978-1-60327-517-0_20; Barros GP, 2012, INT J GEOPHYS, V2012, DOI [10.1155/2012/459497, 10.5402/2012/137289]; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Devarajan A, 2011, ANTIOXID REDOX SIGN, V14, P341, DOI 10.1089/ars.2010.3430; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goswami B, 2009, CLIN CHIM ACTA, V410, P1, DOI 10.1016/j.cca.2009.09.025; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; Horke S, 2007, CIRCULATION, V115, P2055, DOI 10.1161/CIRCULATIONAHA.106.681700; Horke S, 2010, BIOCHEM J, V426, P73, DOI 10.1042/BJ20091414; Jarerattanachat V, 2013, J PHYS CHEM B, V117, P8490, DOI 10.1021/jp4040612; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; Kumagai T, 2004, J BIOL CHEM, V279, P48389, DOI 10.1074/jbc.M409935200; KUNIMOTO M, 1981, BIOCHIM BIOPHYS ACTA, V646, P169, DOI 10.1016/0005-2736(81)90284-4; Levy E, 2007, AM J PHYSIOL-GASTR L, V293, pG1252, DOI 10.1152/ajpgi.00369.2007; Mackness B, 2006, ARTERIOSCL THROM VAS, V26, P1545, DOI 10.1161/01.ATV.0000222924.62641.aa; Mackness B, 2010, IUBMB LIFE, V62, P480, DOI 10.1002/iub.347; MACKNESS MI, 1985, COMP BIOCHEM PHYS B, V82, P675, DOI 10.1016/0305-0491(85)90506-1; Minoguchi K, 2006, EUR RESPIR J, V28, P378, DOI 10.1183/09031936.06.00084905; Mochizuki H, 1998, GENE, V213, P149, DOI 10.1016/S0378-1119(98)00193-0; Musiek ES, 2006, J NEUROCHEM, V97, P1301, DOI 10.1111/j.1471-4159.2006.03797.x; Musiek ES, 2005, BRAIN PATHOL, V15, P149; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Ng CJ, 2006, J BIOL CHEM, V281, P29491, DOI 10.1074/jbc.M605379200; Ng CJ, 2001, J BIOL CHEM, V276, P44444, DOI 10.1074/jbc.M105660200; Ng DS, 2008, CARDIOVASC PATHOL, V17, P226, DOI 10.1016/j.carpath.2007.10.001; Patel BP, 2007, INTEGR CANCER THER, V6, P365, DOI 10.1177/1534735407309760; Patel M, 2008, J NEUROCHEM, V104, P264, DOI 10.1111/j.1471-4159.2007.04974.x; Powers SK, 2008, PHYSIOL REV, V88, P1243, DOI 10.1152/physrev.00031.2007; PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225; Quintanar-Escorza MA, 2010, TOXICOL IN VITRO, V24, P1338, DOI 10.1016/j.tiv.2010.05.002; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Ravandi A, 2004, LIPIDS, V39, P97, DOI 10.1007/s11745-004-1207-5; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rosenblat M, 2009, J LIPID RES, V50, P870, DOI 10.1194/jlr.M800550-JLR200; Schindler J, 2006, J NEURAL TRANSM, V113, P995, DOI 10.1007/s00702-006-0508-4; Schwamb J, 2012, BLOOD, V120, P3978, DOI 10.1182/blood-2012-05-431783; Signorelli P, 2002, METHOD ENZYMOL, V345, P275; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; Teiber JF, 2004, J LIPID RES, V45, P2260, DOI 10.1194/jlr.M400213-JLR200; Tsao SM, 2007, NUTR CANCER, V59, P8, DOI 10.1080/01635580701365043; Volkel W, 2006, NEUROCHEM INT, V48, P679, DOI 10.1016/j.neuint.2005.12.003; Waddington EI, 2003, ATHEROSCLEROSIS, V167, P111, DOI 10.1016/S0021-9150(02)00391-X; Wang W., 2001, IN VITRO MUTAGENESIS, P37; Witte I, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.91; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wong-Ekkabut J, 2007, BIOPHYS J, V93, P4225, DOI 10.1529/biophysj.107.112565; Yang Y, 2012, FREE RADICAL BIO MED, V53, P437, DOI 10.1016/j.freeradbiomed.2012.05.015; Young O, 2010, HEAD NECK-J SCI SPEC, V32, P750, DOI 10.1002/hed.21247	52	46	50	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1769	1779		10.1096/fj.13-240309	http://dx.doi.org/10.1096/fj.13-240309			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24421402				2022-12-28	WOS:000335344300023
J	Fortin, J; Boehm, U; Weinstein, MB; Graff, JM; Bernard, DJ				Fortin, Jerome; Boehm, Ulrich; Weinstein, Michael B.; Graff, Jonathan M.; Bernard, Daniel J.			Follicle-stimulating hormone synthesis and fertility are intact in mice lacking SMAD3 DNA binding activity and SMAD2 in gonadotrope cells	FASEB JOURNAL			English	Article						pituitary; reproduction; activin; knockout	BETA-SUBUNIT TRANSCRIPTION; BONE MORPHOGENETIC PROTEIN-2; MESSENGER-RIBONUCLEIC-ACID; REGULATES EXPRESSION; TARGETED DISRUPTION; LUTEINIZING-HORMONE; SECONDARY SURGE; GENE-EXPRESSION; RU486 BLOCKS; A INDUCTION	The activin/inhibin system regulates follicle-stimulating hormone (FSH) synthesis and release by pituitary gonadotrope cells in mammals. In vitro cell line data suggest that activins stimulate FSH -subunit (Fshb) transcription via complexes containing the receptor-regulated SMAD proteins SMAD2 and SMAD3. Here, we used a Cre-loxP approach to determine the necessity for SMAD2 and/or SMAD3 in FSH synthesis in vivo. Surprisingly, mice with conditional mutations in both Smad2 and Smad3 specifically in gonadotrope cells are fertile and produce FSH at quantitatively normal levels. Notably, however, we discovered that the recombined Smad3 allele produces a transcript that encodes the entirety of the SMAD3 C-terminal Mad homology 2 (MH2) domain. This protein behaves similarly to full-length SMAD3 in Fshb transcriptional assays. As the truncated protein lacks the N-terminal Mad homology 1 (MH1) domain, these results show that SMAD3 DNA-binding activity as well as SMAD2 are dispensable for normal FSH synthesis in vivo. Furthermore, the observation that deletion of proximal exons does not remove all SMAD3 function may facilitate interpretation of divergent phenotypes previously described in different Smad3 knockout mouse lines.Fortin, J., Boehm, U., Weinstein, M. B., Graff, J. M., Bernard, D. J. Follicle-stimulating hormone synthesis and fertility are intact in mice lacking SMAD3 DNA binding activity and SMAD2 in gonadotrope cells.	[Fortin, Jerome; Bernard, Daniel J.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; [Boehm, Ulrich] Univ Saarland, Dept Pharmacol & Toxicol, Sch Med, Homburg, Germany; [Weinstein, Michael B.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; [Graff, Jonathan M.] Univ Texas Southwestern, Dept Dev Biol, Dallas, TX USA	McGill University; Saarland University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Fortin, J (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Promenade Sir William Osler,Rm 1315, Montreal, PQ H3G 1Y6, Canada.	jerome.fortin@mail.mcgill.ca; daniel.bernard@mcgill.ca		Bernard, Daniel/0000-0001-5365-5586	Canadian Institutes of Health Research (CIHR); CIHR [MOP-89991]; DFG [BO1743/2]; U.S. National Institutes of Health National Institute of Child Health and Human Development [U54-HD28934]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); DFG(German Research Foundation (DFG)); U.S. National Institutes of Health National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors acknowledge Xiang Zhou for help with the ovariectomy procedures and Ken McDonald for assistance with FACS. J.F. was supported by a Doctoral Research Award from the Canadian Institutes of Health Research (CIHR). This work was funded by CIHR operating grant MOP-89991 (to D.J.B). D.J.B. is a Senior Research Scholar of the Fonds de la Recherche en Sante de Quebec. U. B. is funded by DFG BO1743/2. The University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core is supported by the U.S. National Institutes of Health National Institute of Child Health and Human Development (Specialized Cooperative Centers Program in Reproduction Research) grant U54-HD28934.	Bernard DJ, 2010, FERTIL STERIL, V93, P2465, DOI 10.1016/j.fertnstert.2010.03.034; Bernard DJ, 2004, MOL ENDOCRINOL, V18, P606, DOI 10.1210/me.2003-0264; Besecke LM, 1996, ENDOCRINOLOGY, V137, P3667, DOI 10.1210/en.137.9.3667; Besson-Fournier C, 2012, BLOOD, V120, P431, DOI 10.1182/blood-2012-02-411470; Bilezikjian LM, 2004, MOL CELL ENDOCRINOL, V225, P29, DOI 10.1016/j.mce.2004.02.010; Bilezikjian LM, 2012, MOL CELL ENDOCRINOL, V359, P43, DOI 10.1016/j.mce.2012.01.025; Blount AL, 2009, J BIOL CHEM, V284, P7631, DOI 10.1074/jbc.M806676200; Caligioni CS, 2009, CURR PROTOC NEUROSCI; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; CORRIGAN AZ, 1991, ENDOCRINOLOGY, V128, P1682, DOI 10.1210/endo-128-3-1682; Coss D, 2005, MOL ENDOCRINOL, V19, P2610, DOI 10.1210/me.2005-0047; DALKIN AC, 1993, ENDOCRINOLOGY, V132, P1297, DOI 10.1210/en.132.3.1297; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dupont J, 2003, BIOL REPROD, V68, P1877, DOI 10.1095/biolreprod.102.012005; Fortin J., 2013, ENDOCR REV, V34, pOR04; Fortin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059058; Ho CC, 2010, ENDOCRINOLOGY, V151, P3445, DOI 10.1210/en.2010-0071; Ho CC, 2009, BIOL REPROD, V81, P133, DOI 10.1095/biolreprod.108.074211; HOAK DC, 1980, P NATL ACAD SCI-BIOL, V77, P4953, DOI 10.1073/pnas.77.8.4953; Hoivik EA, 2011, ENDOCRINOLOGY, V152, P2100, DOI 10.1210/en.2010-1305; Huang HJ, 2001, ENDOCRINOLOGY, V142, P2275, DOI 10.1210/en.142.6.2275; Itman C, 2011, ENDOCRINOLOGY, V152, P2076, DOI 10.1210/en.2010-1453; Justice NJ, 2011, MOL ENDOCRINOL, V25, P1404, DOI 10.1210/me.2011-0093; Kim S, 2011, N KOREAN REV, V7, P3; KIRK SE, 1994, ENDOCRINOLOGY, V135, P876, DOI 10.1210/en.135.3.876; KNOX KL, 1992, BIOL REPROD, V46, P220, DOI 10.1095/biolreprod46.2.220; Knox KL, 1996, ENDOCRINOLOGY, V137, P1226, DOI 10.1210/en.137.4.1226; KNOX KL, 1993, ENDOCRINOLOGY, V133, P277, DOI 10.1210/en.133.1.277; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Lamba P, 2006, J MOL ENDOCRINOL, V36, P201, DOI 10.1677/jme.1.01961; Lamba P, 2008, ENDOCRINOLOGY, V149, P3095, DOI 10.1210/en.2007-0425; Lamba P, 2010, ENDOCRINOLOGY, V151, P5456, DOI 10.1210/en.2010-0605; Lamba P, 2009, MOL ENDOCRINOL, V23, P1001, DOI 10.1210/me.2008-0324; Lee KB, 2007, J MOL ENDOCRINOL, V38, P315, DOI 10.1677/jme.1.02196; Li QL, 2008, MOL CELL BIOL, V28, P7001, DOI 10.1128/MCB.00732-08; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; Liu Y, 2004, GENESIS, V40, P118, DOI 10.1002/gene.20072; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; Marshall J C, 1993, Trans Am Clin Climatol Assoc, V104, P31; Nicol L, 2008, J ENDOCRINOL, V196, P497, DOI 10.1677/jOE-07-0542; Otsuka F, 2002, ENDOCRINOLOGY, V143, P4938, DOI 10.1210/en.2002-220929; Pangas SA, 2000, TRENDS ENDOCRIN MET, V11, P309, DOI 10.1016/S1043-2760(00)00294-0; Rejon CA, 2013, CELL SIGNAL, V25, P1403, DOI 10.1016/j.cellsig.2013.03.002; Safwat N, 2005, ENDOCRINOLOGY, V146, P4814, DOI 10.1210/en.2005-0457; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Suszko MI, 2008, MOL CELL ENDOCRINOL, V281, P27, DOI 10.1016/j.mce.2007.10.003; Suszko MI, 2005, MOL ENDOCRINOL, V19, P1849, DOI 10.1210/me.2004-0475; Suszko MI, 2003, MOL ENDOCRINOL, V17, P318, DOI 10.1210/me.2002-0081; Szabo M, 1996, ENDOCRINOLOGY, V137, P85, DOI 10.1210/en.137.1.85; Thackray VG, 2010, MOL CELL ENDOCRINOL, V314, P192, DOI 10.1016/j.mce.2009.09.003; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Tomic D, 2004, MOL ENDOCRINOL, V18, P2224, DOI 10.1210/me.2003-0414; Tomic D, 2002, BIOL REPROD, V66, P917, DOI 10.1095/biolreprod66.4.917; Tran S, 2013, MOL ENDOCRINOL, V27, P407, DOI 10.1210/me.2012-1286; Tran S, 2011, MOL ENDOCRINOL, V25, P1170, DOI 10.1210/me.2010-0480; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Wang Y, 2008, ENDOCRINOLOGY, V149, P5577, DOI 10.1210/en.2008-0220; Wang Y, 2012, CELL SIGNAL, V24, P1632, DOI 10.1016/j.cellsig.2012.04.006; Wang Y, 2010, J MOL ENDOCRINOL, V44, P349, DOI 10.1677/JME-09-0142; Wen S, 2008, ENDOCRINOLOGY, V149, P2701, DOI 10.1210/en.2007-1502; Wen SP, 2010, P NATL ACAD SCI USA, V107, P16372, DOI 10.1073/pnas.1000423107; Woodruff TK, 1996, ENDOCRINOLOGY, V137, P5463, DOI 10.1210/en.137.12.5463; Wu S, 2010, ENDOCRINOLOGY, V151, P1142, DOI 10.1210/en.2009-0598; Xu R, 2003, J ANDROL, V24, P192; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Ye P, 2013, J CLIN INVEST, V123, P2317, DOI 10.1172/JCI67356; YING SY, 1988, ENDOCR REV, V9, P267, DOI 10.1210/edrv-9-2-267; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	73	23	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1474	1485		10.1096/fj.13-237818	http://dx.doi.org/10.1096/fj.13-237818			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24308975	Green Published			2022-12-28	WOS:000335324800038
J	Garrison, HH; Deschamps, AM				Garrison, Howard H.; Deschamps, Anne M.			NIH research funding and early career physician scientists: continuing challenges in the 21st century	FASEB JOURNAL			English	Article						science policy; workforce; training	MEDICINE	Physician scientists (researchers with either M.D. or M.D.-Ph.D. degrees) have the unique potential to combine clinical perspectives with scientific insight, and their participation in biomedical research has long been an important topic for policymakers and educators. Given the recent changes in the research environment, an update and extension of earlier studies of this population was needed. Our findings show that physician scientists are less likely to take a major role in biomedical research than they were in the past. The number of physician scientists receiving postdoctoral research training and career development awards is at an all-time low. Physician scientists today, on average, receive their first major research award (R01 equivalent) at a later age than in the 1980s. The number of first-time R01-equivalent awards to physicians is at the same level as it was 30 yr ago, but physicians now represent a smaller percentage of the grant recipients. The long-term decline in the number of physicians entering research careers was temporarily halted during the period of substantial U.S. National Institutes of Health (NIH) budget growth (1998-2003). These gains are lost, however, in the subsequent years when NIH budgets failed to keep pace with rising costs. Garrison, H. H., Deschamps, A. M. NIH research funding and early career physician scientists: continuing challenges in the 21st century.	[Garrison, Howard H.; Deschamps, Anne M.] Federat Amer Soc Expt Biol, Off Publ Affairs, Bethesda, MD 20814 USA		Garrison, HH (corresponding author), Federat Amer Soc Expt Biol, Off Publ Affairs, 9650 Rockville Pike, Bethesda, MD 20814 USA.	hgarrison@faseb.org		Garrison, Howard/0000-0001-9455-3527	Doris Duke Charitable Foundation; Burroughs Wellcome Fund	Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Burroughs Wellcome Fund(Burroughs Wellcome Fund)	Funding for this project came from the Doris Duke Charitable Foundation and the Burroughs Wellcome Fund. The authors declare no conflicts of interest. A. M. D. and H. H. G. had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. A. M. D. collected and analyzed the data and contributed to the writing of the manuscript. H. H. G. analyzed the data and wrote the manuscript. The authors are grateful to Dr. Richard Galbraith, Dr. John Schreiber, and Dr. Francis Miller for their comments and suggestions on earlier versions of this paper.	Andriole DA, 2010, ACAD MED, V85, P1250, DOI 10.1097/ACM.0b013e3181e10159; Center for the Study of Education Policy, 2013, GRAP ANN COMP DAT ST; Dickler HB, 2007, JAMA-J AM MED ASSOC, V297, P2496, DOI 10.1001/jama.297.22.2496; Fang D, 2004, ANAL BRIEF, V4, P1; Federation of American Societies for Experimental Biology, 2014, SEQ CUTS BIOM RES; Garrison H. H., 2014, PHYS SCI ASSESSING W; GILL GN, 1984, AM SCHOLAR, V53, P353; Heinig SJ, 2007, NEW ENGL J MED, V357, P1042, DOI 10.1056/NEJMsb071774; Jeffe DB, 2011, ACAD MED, V86, P953, DOI 10.1097/ACM.0b013e31822225c5; MOODY FG, 1987, AM J SURG, V153, P337, DOI 10.1016/0002-9610(87)90572-1; National Institutes of Health, 2012, BIOM RES WORKF WORK; National Institutes of Health NIH Data Book, 2013, NEW NIH INV R01 EQ I; National Research Council of the National Academies, 2005, BRIDG IND FOST IND N; Pharmaceutical Research and Manufacturers of America, 2013, BIOPH RES IND 2013 P; Rockey S., 2013, DOES YOUR ACAD TRAIN; Rosenberg LE, 1999, J CLIN INVEST, V103, P1621, DOI 10.1172/JCI7304; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Schafer S., 2009, VANISHING PHYS SCI, P17; Teitelbaum MS, 2008, SCIENCE, V321, P644, DOI 10.1126/science.1160272; Their S., 1980, CLIN RES, V28, P85; U. S. National Institutes of Health, 2013, NIH DAT BOOK R01 EQ; U.S. National Institutes of Health, 2013, HIST C APPR; U. S. National Institutes of Health Advisory Committee to the Director, 2012, DIV BIOM RES WORKF W; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; Youngclaus JA., 2013, PHYS ED DEBT COST AT; Zemlo TR, 2000, FASEB J, V14, P221, DOI 10.1096/fasebj.14.2.221	26	108	108	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1049	1058		10.1096/fj.13-241687	http://dx.doi.org/10.1096/fj.13-241687			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24297696	hybrid, Green Published			2022-12-28	WOS:000335324800003
J	Masschelein, E; Van Thienen, R; D'Hulst, G; Hespel, P; Thomis, M; Deldicque, L				Masschelein, Evi; Van Thienen, Ruud; D'Hulst, Gommaar; Hespel, Peter; Thomis, Martine; Deldicque, Louise			Acute environmental hypoxia induces LC3 lipidation in a genotype-dependent manner	FASEB JOURNAL			English	Article						exercise; p62; autophagy; monozygotic twin design	HUMAN SKELETAL-MUSCLE; UNFOLDED PROTEIN RESPONSE; HIGH-ALTITUDE; RESISTANCE EXERCISE; HYPOBARIC HYPOXIA; UBIQUITIN LIGASES; MOUNT EVEREST; ADAPTATION; ATROPHY; AUTOPHAGY	Hypoxia-induced muscle wasting is a phenomenon often described with prolonged stays at high altitude, which has been attributed to altered protein metabolism. We hypothesized that acute normobaric hypoxia would induce a negative net protein balance by repressing anabolic and activating proteolytic signaling pathways at rest and postexercise and that those changes could be partially genetically determined. Eleven monozygotic twins participated in an experimental trial in normoxia and hypoxia (10.7% O-2). Muscle biopsy samples were obtained before and after a 20-min moderate cycling exercise. In hypoxia at rest, autophagic flux was increased, as indicated by an increased microtubule-associated protein 1 light chain 3 type II/I (LC3-II/I) ratio (+25%) and LC3-II expression (+60%) and decreased p62/SQSTM1 expression (-25%; P<0.05), whereas exercise reversed those changes to a level similar to that with normoxia except for p62/SQSTM1, which was further decreased (P<0.05). Hypoxia also increased Bnip3 (+34%) and MAFbx (+18%) mRNA levels as well as REDD1 expression (+439%) and AMP-activated protein kinase phosphorylation (+22%; P<0.05). Among the molecular responses to hypoxia and/or exercise, high monozygotic similarity was found for REDD1, LC3-II, and LC3-II/I (P<0.05). Our results indicate that environmental hypoxia modulates protein metabolism at rest and after moderate exercise by primarily increasing markers of protein breakdown and, more specifically, markers of the autophagy-lysosomal system, with a modest genetic contribution.Masschelein, E., Van Thienen, R., D'Hulst, G., Hespel, P., Thomis, M., Deldicque, L. Acute environmental hypoxia induces LC3 lipidation in a genotype-dependent manner.	[Masschelein, Evi; Van Thienen, Ruud; D'Hulst, Gommaar; Hespel, Peter; Deldicque, Louise] Katholieke Univ Leuven, Dept Kinesiol, Exercise Physiol Res Grp, B-3001 Louvain, Belgium; [Thomis, Martine] Katholieke Univ Leuven, Dept Kinesiol, Phys Act Sports & Hlth Res Grp, B-3001 Louvain, Belgium	KU Leuven; KU Leuven	Deldicque, L (corresponding author), Katholieke Univ Leuven, Dept Kinesiol, Exercise Physiol Res Grp, Tervuursevest 101, B-3001 Louvain, Belgium.	louise.deldicque@faber.kuleuven.be	D'Hulst, Gommaar/AAM-6546-2020	D'Hulst, Gommaar/0000-0001-5737-8627; Deldicque, Louise/0000-0003-3393-5278; Hespel, Peter/0000-0003-1283-2229; D'Hulst, Gommaar/0000-0002-5259-5777; Thomis, Martine/0000-0001-9093-2191	KU Leuven [OT/09/033]; Fonds voor Wetenschappelijk Onderzoek-Vlaanderen [G.0706.09, KAN.1.5.100.10N]	KU Leuven(KU Leuven); Fonds voor Wetenschappelijk Onderzoek-Vlaanderen(FWO)	The authors thank Monique Ramaekers for skillful technical assistance during the experiments. The participation of the subjects is also gratefully acknowledged. Support for this study was provided by KU Leuven (research grant OT/09/033) and by the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (grants G.0706.09 and KAN.1.5.100.10N). The authors declare no conflicts of interest.	Amirouche A, 2009, ENDOCRINOLOGY, V150, P286, DOI 10.1210/en.2008-0959; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Baldi Simonetta, 2010, Int J Chron Obstruct Pulmon Dis, V5, P29; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; BASERGA R, 1991, J CELL SCI, V98, P433; Beall CM, 2006, INTEGR COMP BIOL, V46, P18, DOI 10.1093/icb/icj004; Beall CM, 2007, P NATL ACAD SCI USA, V104, P8655, DOI 10.1073/pnas.0701985104; Bigham A., 2010, PLOS GENET, V6; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389; BOUCHARD C, 1990, ACTA GENET MED GEMEL, V39, P85, DOI 10.1017/S0001566000005596; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chaillou T., 2013, ACTA PHYSL OXF, DOI 10.1111/apha.12110; Chaillou T, 2012, AM J PHYSIOL-REG I, V302, pR643, DOI 10.1152/ajpregu.00262.2011; Chaudhary P, 2012, MOL CELL BIOCHEM, V364, P101, DOI 10.1007/s11010-011-1210-x; Ciciliot S, 2010, CURR PHARM DESIGN, V16, P906, DOI 10.2174/138161210790883453; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; D'Hulst G, 2013, ACTA PHYSIOL, V208, P251, DOI 10.1111/apha.12086; Deldicque L, 2010, EUR J APPL PHYSIOL, V108, P791, DOI 10.1007/s00421-009-1289-x; Egan B, 2010, J PHYSIOL-LONDON, V588, P1779, DOI 10.1113/jphysiol.2010.188011; Etheridge T, 2011, AM J PHYSIOL-ENDOC M, V301, pE697, DOI 10.1152/ajpendo.00276.2011; Favier FB, 2010, AM J PHYSIOL-REG I, V298, pR1659, DOI 10.1152/ajpregu.00550.2009; Ferrari M, 2004, CAN J APPL PHYSIOL, V29, P463, DOI 10.1139/h04-031; Garvey JF, 2009, EUR RESPIR J, V33, P1195, DOI 10.1183/09031936.00111208; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Grocott M, 2007, CRIT CARE, V11, DOI 10.1186/cc5142; Grocott MPW, 2009, NEW ENGL J MED, V360, P140, DOI 10.1056/NEJMoa0801581; Grocott M, 2008, HIGH ALT MED BIOL, V9, P123, DOI 10.1089/ham.2008.1012; Hayot M, 2011, MOL CELL ENDOCRINOL, V332, P38, DOI 10.1016/j.mce.2010.09.008; Hoppeler H, 2001, J EXP BIOL, V204, P3133; HOPPELER H, 1990, INT J SPORTS MED, V11, pS3, DOI 10.1055/s-2007-1024846; Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1; Imoberdorf R, 2006, MED SCI SPORT EXER, V38, P1082, DOI 10.1249/01.mss.0000222836.66391.35; Jamart C, 2012, EUR J APPL PHYSIOL, V112, P3173, DOI 10.1007/s00421-011-2287-3; Jamart C, 2011, MUSCLE NERVE, V43, P708, DOI 10.1002/mus.21949; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Koning M, 2011, TISSUE ENG PT A, V17, P1747, DOI 10.1089/ten.tea.2010.0624; Koumenis C, 2007, METHOD ENZYMOL, V435, P275, DOI 10.1016/S0076-6879(07)35014-3; Koumenis C, 2006, MOL CANCER RES, V4, P423, DOI 10.1158/1541-7786.MCR-06-0150; LACEY RJ, 1993, J ENDOCRINOL, V138, P555, DOI 10.1677/joe.0.1380555; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Macaluso F, 2012, J MUSCLE RES CELL M, V33, P187, DOI 10.1007/s10974-012-9302-0; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Martin DS, 2010, EXP PHYSIOL, V95, P463, DOI 10.1113/expphysiol.2009.047589; MARTINELLI M, 1990, EXPERIENTIA, V46, P672, DOI 10.1007/BF01939930; NICHOLSON AN, 1988, SLEEP, V11, P354, DOI 10.1093/sleep/11.4.354; Pooja Chaudhary, 2012, Al Ameen Journal of Medical Sciences, V5, P355; PREEDY VR, 1989, BIOCHEM J, V257, P519, DOI 10.1042/bj2570519; PREEDY VR, 1985, BIOCHEM J, V228, P179, DOI 10.1042/bj2280179; Rennie M. J., 1983, PROG CLIN BIOL RES, V136, P317; Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253; Schols AMWJ, 2005, AM J CLIN NUTR, V82, P53, DOI 10.1093/ajcn/82.1.53; Simonson TS, 2010, SCIENCE, V329, P72, DOI 10.1126/science.1189406; Sriwijitkamol A, 2007, DIABETES, V56, P836, DOI 10.2337/db06-1119; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482; Thomis MAI, 1998, MED SCI SPORT EXER, V30, P724, DOI 10.1097/00005768-199805000-00013; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vigano A, 2008, PROTEOMICS, V8, P4668, DOI 10.1002/pmic.200800232; Vincent B, 2010, J APPL PHYSIOL, V109, P564, DOI 10.1152/japplphysiol.01007.2009; Westerterp-Plantenga MS, 1999, J APPL PHYSIOL, V87, P391, DOI 10.1152/jappl.1999.87.1.391; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	65	36	39	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					1022	1034		10.1096/fj.13-239863	http://dx.doi.org/10.1096/fj.13-239863			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24200883	Green Accepted			2022-12-28	WOS:000331072200045
J	Zulueta, A; Caretti, A; Signorelli, P; Dall'Olio, F; Trinchera, M				Zulueta, Aida; Caretti, Anna; Signorelli, Paola; Dall'Olio, Fabio; Trinchera, Marco			Transcriptional control of the B3GALT5 gene by a retroviral promoter and methylation of distant regulatory elements	FASEB JOURNAL			English	Article						hepatocyte nuclear factor 1; colon cancer; type 1 chain carbohydrates; transposon	SIALYL-LEWIS-X; DNA METHYLATION; BETA-1,3-GALACTOSYLTRANSFERASE BETA-3GAL-T5; CELL-ADHESION; CANCER; EXPRESSION; ANTIGEN; ENHANCERS; CHAIN; CDX2	We focused on transcription factors and epigenetic marks that regulate the B3GALT5 gene through its retroviral long terminal repeat (LTR) promoter. We compared the expression levels of the B3GALT5 LTR transcript, quantitated by competitive RT-PCR, with those of the candidate transcription factors HNF1/ and Cdx1/2, determined by Western blot analysis, in colon cancer biopsies, various cell lines, and cell models serving as controls. We found that HNF1/ were easily detected, irrespective of the amount of LTR transcript expressed by the source, whereas Cdx1/2 were undetectable, and no sample lacking HNF1/ expressed the LTR transcript. On transfection in proper host cells, both HNF1 and HNF1 provided detectable LTR transcript, whereas shRNA-mediated silencing of HNF1 impaired transcription. Treating cells with 5-aza-2-deoxycytidine (5AZA) strongly reduced expression, without affecting HNF1/, despite the lack of CpG islands in the LTR and proximal sequences. By electrophoresis mobility shift and luciferase reporter assays, the LTR promoter binding and activity did not correlate with the amounts of LTR transcript expressed in the cells and depended on the levels of the transcription factors. We conclude that HNF1/ are necessary but insufficient to activate and regulate B3GALT5 LTR transcription, which depends on unknown regulatory elements that are active when methylated and located outside of and far from the LTR promoter.Zulueta, A., Caretti, A., Signorelli, P., Dall'Olio, F., Trinchera, M. Transcriptional control of the B3GALT5 gene by a retroviral promoter and methylation of distant regulatory elements.	[Zulueta, Aida; Caretti, Anna; Signorelli, Paola] Univ Milan, San Paolo Hosp, Dept Hlth Sci, Milan, Italy; [Dall'Olio, Fabio] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy; [Trinchera, Marco] Univ Insubria, Dept Med Clin & Expt DMCS, I-21100 Varese, Italy	San Paolo-Polo Universitaria Hospital; University of Milan; University of Bologna; University of Insubria	Trinchera, M (corresponding author), Univ Insubria, Via JH Dunant 5, I-21100 Varese, Italy.	marco.trinchera@uninsubria.it	CARETTI, ANNA/L-3557-2019; Caretti, Anna/O-8958-2017; Zulueta, Aida/AHH-9389-2022	CARETTI, ANNA/0000-0001-6140-6969; Caretti, Anna/0000-0001-6140-6969; Zulueta, Aida/0000-0001-8295-6847; signorelli, paola/0000-0003-2368-2393	Ph.D. Program in Molecular Medicine of the University of Milan	Ph.D. Program in Molecular Medicine of the University of Milan	A.Z. was supported by the Ph.D. Program in Molecular Medicine of the University of Milan.	Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21; Aran D, 2013, CELL, V154, P11, DOI 10.1016/j.cell.2013.06.018; Caretti A, 2012, INT J BIOCHEM CELL B, V44, P84, DOI 10.1016/j.biocel.2011.09.010; Caretti A, 2010, CELL PHYSIOL BIOCHEM, V26, P831, DOI 10.1159/000323992; D'Angelo A, 2010, DEVELOPMENT, V137, P1573, DOI 10.1242/dev.044420; Duffy MJ, 2010, ANN ONCOL, V21, P441, DOI 10.1093/annonc/mdp332; Dunn CA, 2005, GENE, V364, P2, DOI 10.1016/j.gene.2005.05.045; Dunn CA, 2003, P NATL ACAD SCI USA, V100, P12841, DOI 10.1073/pnas.2134464100; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Isshiki S, 2003, J BIOL CHEM, V278, P36611, DOI 10.1074/jbc.M302681200; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Kheradpour P, 2013, GENOME RES, V23, P800, DOI 10.1101/gr.144899.112; Kikuchi R, 2010, KIDNEY INT, V78, P569, DOI 10.1038/ki.2010.176; Kulis M, 2013, BIOCH BIOPHYS ACTA; Laubli H, 2010, SEMIN CANCER BIOL, V20, P169, DOI 10.1016/j.semcancer.2010.04.005; Mare L, 2004, EUR J BIOCHEM, V271, P186, DOI 10.1046/j.1432-1033.2003.03919.x; Mare L, 2007, J BIOL CHEM, V282, P49, DOI 10.1074/jbc.M606666200; Mare L, 2013, INT J BIOCHEM CELL B, V45, P792, DOI 10.1016/j.biocel.2013.01.004; Pilozzi E, 2004, J PATHOL, V204, P289, DOI 10.1002/path.1641; Pontoglio M, 2000, J AM SOC NEPHROL, V11, pS140; Rebollo R, 2012, ANNU REV GENET, V46, P21, DOI 10.1146/annurev-genet-110711-155621; Salvini R, 2001, J BIOL CHEM, V276, P3564, DOI 10.1074/jbc.M006662200; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Trinchera M, 2011, INT J BIOCHEM CELL B, V43, P130, DOI 10.1016/j.biocel.2010.10.004; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; WU GD, 1994, J BIOL CHEM, V269, P17080	32	14	14	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					946	955		10.1096/fj.13-236273	http://dx.doi.org/10.1096/fj.13-236273			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24128890	Green Submitted			2022-12-28	WOS:000331072200039
J	Wilson, SL; Guilbert, M; Sule-Suso, J; Torbet, J; Jeannesson, P; Sockalingum, GD; Yang, Y				Wilson, Samantha L.; Guilbert, Marie; Sule-Suso, Josep; Torbet, Jim; Jeannesson, Pierre; Sockalingum, Ganesh D.; Yang, Ying			A microscopic and macroscopic study of aging collagen on its molecular structure, mechanical properties, and cellular response	FASEB JOURNAL			English	Article						AGEs; fibrillogenesis; fiber alignment; contraction; elastic modulus	GLYCATION END-PRODUCTS; HUMAN-SKIN FIBROBLASTS; AGE-RELATED-CHANGES; I COLLAGEN; DIAMAGNETIC ANISOTROPY; INDENTATION TECHNIQUE; HYDROGELS; MODEL; DIFFERENTIATION; CARBAMYLATION	During aging, collagen structure changes, detrimentally affecting tissues' biophysical and biomechanical properties due to an accumulation of advanced glycation end-products (AGEs). In this investigation, we conducted a parallel study of microscopic and macroscopic properties of different-aged collagens from newborn to 2-yr-old rats, to examine the effect of aging on fibrillogenesis, mechanical and contractile properties of reconstituted hydrogels from these collagens seeded with or without fibroblasts. In addition to fibrillogenesis of collagen under the conventional conditions, some fibrillogenesis was conducted alongside a 12-T magnetic field, and gelation rate and AGE content were measured. A nondestructive indentation technique and optical coherence tomography were used to determine the elastic modulus and dimensional changes, respectively. It was revealed that in comparison to younger specimens, older collagens exhibited higher viscosity, faster gelation rates, and a higher AGE-specific fluorescence. Exceptionally, only young collagens formed highly aligned fibrils under magnetic fields. The youngest collagen demonstrated a higher elastic modulus and contraction in comparison to the older collagen. We conclude that aging changes collagen monomer structure, which considerably affects the fibrillogenesis process, the architecture of the resulting collagen fibers and the global network, and the macroscopic properties of the formed constructs.Wilson, S. L., Guilbert, M., Sule-Suso, J., Torbet, J., Jeannesson, P., Sockalingum, G. D., Yang, Y. A microscopic and macroscopic study of aging collagen on its molecular structure, mechanical properties, and cellular response.	[Wilson, Samantha L.; Sule-Suso, Josep; Yang, Ying] Keele Univ, Inst Sci & Technol Med, Stoke On Trent ST4 7QB, Staffs, England; [Guilbert, Marie; Jeannesson, Pierre; Sockalingum, Ganesh D.] Univ Reims, Unite Matrice Extracellulaire & Dynam Cellulaire, Equipe Med Dynam Intracellulaire & Architecture N, Unite Format & Rech UFR Pharm,CNRS, Reims, France; [Sule-Suso, Josep] Univ Hosp North Staffordshire, Ctr Canc, Stoke On Trent, Staffs, England; [Torbet, Jim] CNRS, Consortium Rech Emergence Technol Avancees CRETA, Grenoble, France	Keele University; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS)	Yang, Y (corresponding author), Keele Univ, Inst Sci & Technol Med, Stoke On Trent ST4 7QB, Staffs, England.	y.yang@keele.ac.uk		Yang, Ying/0000-0002-1362-6040	Engineering and Physical Sciences Research Council (EPSRC; Swindon, UK) [EP/F/500491/1]; Alliance bilateral program (Egide and British Council); exchange program in EuroMagNET II (Grenoble, France); Region Champagne-Ardenne, France; Engineering and Physical Sciences Research Council [EP/I017801/1] Funding Source: researchfish; EPSRC [EP/I017801/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council (EPSRC; Swindon, UK)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Alliance bilateral program (Egide and British Council); exchange program in EuroMagNET II (Grenoble, France); Region Champagne-Ardenne, France(Region Grand-Est); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	The corneal specimens from Birmingham and Midland Eye Centre (UK) are highly appreciated. Funding from the Engineering and Physical Sciences Research Council (EPSRC; Swindon, UK) Doctoral Training Centre (DTC) in Regenerative Medicine (grant EP/F/500491/1), Alliance bilateral program (Egide and British Council) and the exchange program in EuroMagNET II (Grenoble, France) are gratefully acknowledged. M. G. is a recipient of a fellowship from the Region Champagne-Ardenne, France. The authors thank the Consortium de Recherche pour l'Emergence de Technologies Avancees (CRETA)/Centre National de la Recherche Scientifique (CNRS) laboratory (Grenoble, France) for the use of their magnet and for technical help. Special thanks to Mr. S. J. Wilson and associates at KMF Precision Sheet Metal Ltd. (Newcastle, UK) for the kind donation of the specimen clamping apparatus.	Ahearne M, 2008, BRIT J OPHTHALMOL, V92, P268, DOI 10.1136/bjo.2007.130104; Ahearne M, 2007, ANN BIOMED ENG, V35, P1608, DOI 10.1007/s10439-007-9323-9; Ahearne M, 2010, TISSUE ENG PART C-ME, V16, P319, DOI 10.1089/ten.TEC.2008.0650; Ahearne M, 2010, EXP EYE RES, V91, P584, DOI 10.1016/j.exer.2010.07.013; Bailey A. J., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P529; Bailey AJ, 1999, P INDIAN AS-CHEM SCI, V111, P57; Bartling B, 2009, FASEB J, V23, P1510, DOI 10.1096/fj.08-122648; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BELLMUNT MJ, 1995, BBA-MOL BASIS DIS, V1272, P53, DOI 10.1016/0925-4439(95)00069-G; Brown RA, 2006, BIOTECHNOL INTELL UN, P7; Bruel A, 1996, ATHEROSCLEROSIS, V127, P155, DOI 10.1016/S0021-9150(96)05947-3; Charest JL, 2007, BIOMATERIALS, V28, P2202, DOI 10.1016/j.biomaterials.2007.01.020; Damodarasamy M, 2010, J GERONTOL A-BIOL, V65, P209, DOI 10.1093/gerona/glp202; DANIELSEN CC, 1987, MECH AGEING DEV, V40, P9, DOI 10.1016/0047-6374(87)90030-3; Garnotel R, 2000, J IMMUNOL, V164, P5928, DOI 10.4049/jimmunol.164.11.5928; GUIDRY C, 1985, J CELL SCI, V79, P67; Guo C, 2007, BIOMATERIALS, V28, P1105, DOI 10.1016/j.biomaterials.2006.10.010; HAAR JL, 1971, ANAT REC, V170, P199, DOI 10.1002/ar.1091700206; Haus JM, 2007, J APPL PHYSIOL, V103, P2068, DOI 10.1152/japplphysiol.00670.2007; Isobe Y, 2012, MATERIALS, V5, P501, DOI 10.3390/ma5030501; Jaisson S, 2006, CHEM BIOL, V13, P149, DOI 10.1016/j.chembiol.2005.11.005; Jiang ST, 2000, KIDNEY INT, V57, P1539, DOI 10.1046/j.1523-1755.2000.00998.x; Kollias N, 1998, J INVEST DERMATOL, V111, P776, DOI 10.1046/j.1523-1747.1998.00377.x; Lingelbach LB, 2000, J NUTR, V130, P1247, DOI 10.1093/jn/130.5.1247; Liu KK, 2001, J PHYS D APPL PHYS, V34, pL91, DOI 10.1088/0022-3727/34/15/102; MAYS PK, 1991, BIOCHEM J, V276, P307, DOI 10.1042/bj2760307; Mikulikova K, 2008, PHYSIOL RES, V57, P89, DOI 10.33549/physiolres.931093; Mikulikova K, 2007, J CHROMATOGR A, V1155, P125, DOI 10.1016/j.chroma.2007.01.020; Miyahara T., 1982, J GERONTOL, V37; Mocan E., 2011, CURIERUL MED, V2, P3; Newman S, 1997, BIOPOLYMERS, V41, P337, DOI 10.1002/(SICI)1097-0282(199703)41:3<337::AID-BIP9>3.0.CO;2-T; Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064; PAULING L, 1979, P NATL ACAD SCI USA, V76, P2293, DOI 10.1073/pnas.76.5.2293; Pia de la Maza M., 2012, J DIABETES MELLIT, V02, P221, DOI DOI 10.4236/JDM.2012.22035; REISER KM, 1991, P SOC EXP BIOL MED, V196, P17; RUBIN AL, 1963, SCIENCE, V139, P37, DOI 10.1126/science.139.3549.37; Said G, 2012, INT J ONCOL, V40, P1797, DOI 10.3892/ijo.2012.1393; Schulze C, 2012, CLIN PLAST SURG, V39, P9, DOI 10.1016/j.cps.2011.09.008; Semba RD, 2010, J GERONTOL A-BIOL, V65, P963, DOI 10.1093/gerona/glq074; SILVER FH, 1980, J BIOL CHEM, V255, P9427; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; STEVEN FS, 1967, BIOCHEM J, V104, P534, DOI 10.1042/bj1040534; Torbet J., 1984, BIOCH J, V219; Torbet J, 2007, BIOMATERIALS, V28, P4268, DOI 10.1016/j.biomaterials.2007.05.024; Trappe S, 2003, J PHYSIOL-LONDON, V552, P47, DOI 10.1113/jphysiol.2003.044966; Willems NMBK, 2010, CALCIFIED TISSUE INT, V86, P307, DOI 10.1007/s00223-010-9339-2; Wilson SL, 2012, ADV FUNCT MATER, V22, P3641, DOI 10.1002/adfm.201200655; WORCESTER DL, 1978, P NATL ACAD SCI USA, V75, P5475, DOI 10.1073/pnas.75.11.5475; Yang Y, 2007, J R SOC INTERFACE, V4, P1169, DOI 10.1098/rsif.2007.1044	49	22	22	1	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					14	25		10.1096/fj.13-227579	http://dx.doi.org/10.1096/fj.13-227579			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24025727	Green Published			2022-12-28	WOS:000333526100004
J	La Sala, MS; Hurtado, MD; Brown, AR; Bohorquez, DV; Liddle, RA; Herzog, H; Zolotukhin, S; Dotson, CD				La Sala, Michael S.; Hurtado, Maria D.; Brown, Alicia R.; Bohorquez, Diego V.; Liddle, Rodger A.; Herzog, Herbert; Zolotukhin, Sergei; Dotson, Cedrick D.			Modulation of taste responsiveness by the satiation hormone peptide YY	FASEB JOURNAL			English	Article						endocrine signaling; hormonal signaling; fat intake; behavior; gustation	GASTRIC BYPASS-SURGERY; SWEET TASTE; NEUROPEPTIDE-Y; WEIGHT-LOSS; PANCREATIC-POLYPEPTIDE; STRAIN DIFFERENCES; FLAVOR PREFERENCE; LEPTIN LEVELS; FOOD-INTAKE; OBESE RATS	It has been hypothesized that the peripheral taste system may be modulated in the context of an animal's metabolic state. One purported mechanism for this phenomenon is that circulating gastrointestinal peptides modulate the functioning of the peripheral gustatory system. Recent evidence suggests endocrine signaling in the oral cavity can influence food intake (FI) and satiety. We hypothesized that these hormones may be affecting FI by influencing taste perception. We used immunohistochemistry along with genetic knockout models and the specific reconstitution of peptide YY (PYY) in saliva using gene therapy protocols to identify a role for PYY signaling in taste. We show that PYY is expressed in subsets of taste cells in murine taste buds. We also show, using brief-access testing with PYY knockouts, that PYY signaling modulates responsiveness to bitter-tasting stimuli, as well as to lipid emulsions. We show that salivary PYY augmentation, via viral vector therapy, rescues behavioral responsiveness to a lipid emulsion but not to bitter stimuli and that this response is likely mediated via activation of Y2 receptors localized apically in taste cells. Our findings suggest distinct functions for PYY produced locally in taste cells vs. that circulating systemically.	[La Sala, Michael S.; Hurtado, Maria D.; Zolotukhin, Sergei] Univ Florida, Dept Pediat, Coll Med, Gainesville, FL 32611 USA; [Brown, Alicia R.; Dotson, Cedrick D.] Univ Florida, Dept Neurosci, Coll Med, Gainesville, FL 32611 USA; [Dotson, Cedrick D.] Univ Florida, Dept Psychiat, Coll Med, Div Addict Med, Gainesville, FL 32611 USA; [Dotson, Cedrick D.] Univ Florida, Ctr Smell & Taste, Gainesville, FL 32611 USA; [Bohorquez, Diego V.; Liddle, Rodger A.] Duke Univ, Dept Med, Durham, NC USA; [Bohorquez, Diego V.; Liddle, Rodger A.] Vet Affairs Med Ctr, Durham, NC USA; [Herzog, Herbert] Garvan Inst Med Res, Sydney, NSW, Australia	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Garvan Institute of Medical Research	Dotson, CD (corresponding author), Univ Florida, McKnight Brain Inst, Dept Neurosci, 1149 Newell Dr,Box 100244, Gainesville, FL 32611 USA.	c.dotson@mbi.ufl.edu	Brown, Alicia/C-6478-2008; Herzog, Herbert/B-8294-2008	Brown, Alicia/0000-0001-6602-7917; , Herbert/0000-0002-1713-1029; Dotson, Cedrick/0000-0003-0992-1191	U.S. National Institutes of Health [P30-DC010763, R01-DK62302, R01-DC012819]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK098796, F32DK094704, R01DK091946, R01DK062302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC012819, P30DC010763] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002230] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Megan Doheny for assistance in data collection and Andres Acosta for technical assistance. This work was supported by the U.S. National Institutes of Health, grants P30-DC010763 and R01-DK62302 (to S.Z.) and R01-DC012819 (to C.D.D).	Acosta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026137; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Boey D, 2006, DIABETOLOGIA, V49, P1360, DOI 10.1007/s00125-006-0237-0; Bohorquez DV, 2011, J MOL HISTOL, V42, P3, DOI 10.1007/s10735-010-9302-6; Bueter M, 2011, PHYSIOL BEHAV, V104, P709, DOI 10.1016/j.physbeh.2011.07.025; Chen CH, 1997, NEUROGASTROENT MOTIL, V9, P109, DOI 10.1046/j.1365-2982.1997.d01-26.x; Chen K, 2010, BRAIN RES, V1325, P53, DOI 10.1016/j.brainres.2010.02.026; Dotson CD, 2005, PHYSIOL BEHAV, V85, P655, DOI 10.1016/j.physbeh.2005.06.010; Dotson CD, 2005, CHEM SENSES, V30, P593, DOI 10.1093/chemse/bji053; Dotson CD, 2004, CHEM SENSES, V29, P489, DOI 10.1093/chemse/bjh051; Dramane G, 2011, CURR MED CHEM, V18, P3417, DOI 10.2174/092986711796504655; Dvoryanchikov G, 2009, J COMP NEUROL, V517, P1, DOI 10.1002/cne.22152; Ekblad E, 2002, PEPTIDES, V23, P251, DOI 10.1016/S0196-9781(01)00601-5; Elson AET, 2010, FASEB J, V24, P3960, DOI 10.1096/fj.10-158105; Gilbertson TA, 1998, ANN NY ACAD SCI, V855, P165, DOI 10.1111/j.1749-6632.1998.tb10560.x; Glendinning JI, 2008, PHYSIOL BEHAV, V95, P476, DOI 10.1016/j.physbeh.2008.07.017; Hajnal A, 2010, AM J PHYSIOL-GASTR L, V299, pG967, DOI 10.1152/ajpgi.00070.2010; HARTEL S, 1988, HISTOCHEMISTRY, V89, P151, DOI 10.1007/BF00489918; Hastings JA, 2001, BRAIN RES, V890, P32, DOI 10.1016/S0006-8993(00)02874-2; Hofer D, 1999, HISTOCHEM CELL BIOL, V112, P79, DOI 10.1007/s004180050394; Horio N, 2010, J PHARMACOL SCI, V112, P8, DOI 10.1254/jphs.09R07FM; Hurtado MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046358; Jyotaki M, 2010, ENDOCR J, V57, P467, DOI 10.1507/endocrj.K10E-095; Katano H, 2006, GENE THER, V13, P594, DOI 10.1038/sj.gt.3302691; Kawai K, 2000, P NATL ACAD SCI USA, V97, P11044, DOI 10.1073/pnas.190066697; le Roux CW, 2011, AM J PHYSIOL-REG I, V301, pR1057, DOI 10.1152/ajpregu.00139.2011; LEIBOWITZ SF, 1991, PEPTIDES, V12, P1251, DOI 10.1016/0196-9781(91)90203-2; Martin B, 2009, ANN NY ACAD SCI, V1170, P98, DOI 10.1111/j.1749-6632.2009.03920.x; Michel MC, 2008, N-S ARCH PHARMACOL, V377, P205, DOI 10.1007/s00210-008-0280-0; Michel MC, 1998, PHARMACOL REV, V50, P143; Michlig S, 2007, J COMP NEUROL, V502, P1003, DOI 10.1002/cne.21354; Miras AD, 2010, CURR OPIN GASTROEN, V26, P140, DOI 10.1097/MOG.0b013e328333e94a; Morimoto R, 2008, NUTRITION, V24, P878, DOI 10.1016/j.nut.2008.06.011; Nakamura Y, 2008, DIABETES, V57, P2661, DOI 10.2337/db07-1103; Nelson TM, 2003, CHEM SENSES, V28, P695, DOI 10.1093/chemse/bjg062; Nguyen AD, 2011, CURR OPIN ENDOCRINOL, V18, P56, DOI 10.1097/MED.0b013e3283422f0a; Olbers T, 2006, ANN SURG, V244, P715, DOI 10.1097/01.sla.0000218085.25902.f8; Padley F., 1986, LIPID HDB, P88; Panek-Scarborough LM, 2012, PHYSIOL BEHAV, V105, P1242, DOI 10.1016/j.physbeh.2012.01.001; Sclafani A, 2007, PHYSIOL BEHAV, V90, P602, DOI 10.1016/j.physbeh.2006.11.012; Shigemura N, 2004, ENDOCRINOLOGY, V145, P839, DOI 10.1210/en.2003-0602; Shin AC, 2011, AM J PHYSIOL-REG I, V301, pR1267, DOI 10.1152/ajpregu.00314.2011; Shin YK, 2008, J NEUROCHEM, V106, P455, DOI 10.1111/j.1471-4159.2008.05397.x; Smith BK, 2001, AM J PHYSIOL-REG I, V281, pR596, DOI 10.1152/ajpregu.2001.281.2.R596; Smith JC, 2001, APPETITE, V36, P93, DOI 10.1006/appe.2000.0372; Stefanie B., 2013, BIOL CHEM, V394, P921; Stewart JE, 2011, PROG LIPID RES, V50, P225, DOI 10.1016/j.plipres.2011.02.002; Stewart JE, 2010, BRIT J NUTR, V104, P145, DOI 10.1017/S0007114510000267; Tichansky DS, 2011, SURG ENDOSC, V25, P1176, DOI 10.1007/s00464-010-1335-0; Umabiki M, 2010, TOHOKU J EXP MED, V220, P267, DOI 10.1620/tjem.220.267; Vona-Davis LC, 2007, CURR TOP MED CHEM, V7, P1710, DOI 10.2174/156802607782340966; Zhang L, 2011, PHARMACOL THERAPEUT, V131, P91, DOI 10.1016/j.pharmthera.2011.03.011; Zhang XJ, 2011, ACTA HISTOCHEM, V113, P663, DOI 10.1016/j.acthis.2010.09.007; Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7	55	35	35	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5022	5033		10.1096/fj.13-228064	http://dx.doi.org/10.1096/fj.13-228064			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24043261	Green Published			2022-12-28	WOS:000329999000035
J	Kai, AKL; Lam, AKM; Chen, YX; Tai, ACP; Zhang, XM; Lai, AKW; Yeung, PKK; Tam, S; Wang, J; Lam, KS; Vanhoutte, PM; Bos, JL; Chung, SSM; Xu, AM; Chung, SK				Kai, Alan K. L.; Lam, Amy K. M.; Chen, Yingxian; Tai, Andrew C. P.; Zhang, Xinmei; Lai, Angela K. W.; Yeung, Patrick K. K.; Tam, Sidney; Wang, Jian; Lam, Karen S.; Vanhoutte, Paul M.; Bos, Johannes L.; Chung, Stephen S. M.; Xu, Aimin; Chung, Sookja K.			Exchange protein activated by cAMP 1 (Epac1)-deficien mice develop beta-cell dysfunction and metabolic syndrome	FASEB JOURNAL			English	Article						glucose-stimulated insulin secretion; glucose transporter type 2; hyperglycemia; high-fat-diet-induced obesity; multiple low-dose streptozotocin-induced diabetes	GLUCAGON-LIKE PEPTIDE-1; INSULIN-RESISTANCE; CYCLIC-AMP; EXPRESSION; RECEPTOR; EXENDIN-4; APOPTOSIS; EPAC; DIFFERENTIATION; ABNORMALITIES	Previously, exchange protein directly activated by cAMP 2 (Epac2) and PKA were known to play a role in glucose-stimulated insulin secretion (GSIS) by pancreatic cells. The present study shows that Epac1 mRNA is also expressed by cells. Therefore, we generated mice and embryonic stem (ES) cells with deletion of the Epac1 gene to define its role in -cell biology and metabolism. The homozygous Epac1-knockout (Epac1(-/-)) mice developed impaired glucose tolerance and GSIS with deranged islet cytoarchitecture, which was confirmed by isolated islets from adult Epac1(-/-) mice. Moreover, Epac1(-/-) mice developed more severe hyperglycemia with increased -cell apoptosis and insulitis after multiple low-dose streptozotocin (MLDS; 40 mg/kg) treatment than Epac1(+/+) mice. Interestingly, Epac1(-/-) mice also showed metabolic defects, including increased respiratory exchange ratio (RER) and plasma triglyceride (TG), and more severe diet-induced obesity with insulin resistance, which may contributed to -cell dysfunction. However, islets differentiated from Epac1(-/-) ES cells showed insulin secretion defect, reduced Glut2 and PDX-1 expression, and abolished GLP-1-stimulated PCNA induction, suggesting a role of Epac1 in -cell function. The current study provides in vitro and in vivo evidence that Epac1 has an important role in GSIS of cells and phenotype resembling metabolic syndrome. Kai, A. K. L., Lam, A. K. M., Chen, Y., Tai, A. C. P., Zhang, X., Lai, A. K. W., Yeung, P. K. K., Tam, S., Wang, J., Lam, K. S., Vanhoutte, P. M., Bos, J. L., Chung, S. S. M., Xu, A., Chung, S. K. Exchange protein activated by cAMP 1 (Epac1)-deficient mice develop -cell dysfunction and metabolic syndrome.	[Kai, Alan K. L.; Lam, Amy K. M.; Chen, Yingxian; Tai, Andrew C. P.; Lai, Angela K. W.; Yeung, Patrick K. K.; Chung, Sookja K.] Univ Hong Kong, Dept Anat, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Zhang, Xinmei; Lam, Karen S.; Xu, Aimin] Univ Hong Kong, Dept Med, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Tam, Sidney] Univ Hong Kong, Clin Biochem Unit, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Vanhoutte, Paul M.] Univ Hong Kong, Dept Pharmacol, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Lam, Karen S.; Vanhoutte, Paul M.; Xu, Aimin; Chung, Sookja K.] Univ Hong Kong, Res Ctr Heart Brain Hormone & Healthy Aging, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Wang, Jian] Forth Mil Med Univ, Xian, Peoples R China; [Bos, Johannes L.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Chung, Stephen S. M.] United Int Coll, Div Sci & Technol, Zhuhai, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Air Force Military Medical University; Utrecht University; Utrecht University Medical Center; Beijing Normal University - Hong Kong Baptist University United International College	Chung, SK (corresponding author), Dept Anat, 1-F,Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	skchung@hkucc.hku.hk	; Chen, Christina Yingxian/O-5676-2016	Tai, Andrew Chi Pang/0000-0002-9120-7562; Chen, Christina Yingxian/0000-0002-8013-1515	Hong Kong General Research Fund; Merck external grant ( [36689]	Hong Kong General Research Fund; Merck external grant (	This work was supported by funding from a Hong Kong General Research Fund grant to S.K.C. (principal investigator) and Merck external grant (IISP ID 36689) to S.E.C. (principal investigator) and K.S.L. (coinvestigator).	Aston-Mourney K, 2008, DIABETOLOGIA, V51, P540, DOI 10.1007/s00125-008-0930-2; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; Bock T, 2003, DIABETES, V52, P1716, DOI 10.2337/diabetes.52.7.1716; Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Conarello SL, 2003, P NATL ACAD SCI USA, V100, P6825, DOI 10.1073/pnas.0631828100; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Doyle ME, 2007, PHARMACOL THERAPEUT, V113, P546, DOI 10.1016/j.pharmthera.2006.11.007; Esni F, 1999, J CELL BIOL, V144, P325, DOI 10.1083/jcb.144.2.325; Green EA, 1998, IMMUNITY, V9, P733, DOI 10.1016/S1074-7613(00)80670-6; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Harrity T, 2006, DIABETES, V55, P240, DOI 10.2337/diabetes.55.01.06.db05-0648; Ho HTB, 2000, MOL CELL BIOL, V20, P5840, DOI 10.1128/MCB.20.16.5840-5846.2000; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; Jorns A, 1996, VIRCHOWS ARCH, V428, P177; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Koh G, 2005, ARCH BIOCHEM BIOPHYS, V438, P70, DOI 10.1016/j.abb.2005.03.018; Kwon G, 2004, J BIOL CHEM, V279, P8938, DOI 10.1074/jbc.M310330200; Leech CA, 2000, BIOCHEM BIOPH RES CO, V278, P44; Li DS, 2009, NAT PROTOC, V4, P1649, DOI 10.1038/nprot.2009.150; Li H, 2010, ACTA PHARMACOL SIN, V31, P570, DOI 10.1038/aps.2010.38; Li YZ, 2003, J BIOL CHEM, V278, P471, DOI 10.1074/jbc.M209423200; Liu MJ, 2010, J MOL MED, V88, P351, DOI 10.1007/s00109-009-0571-z; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Morioka T, 2007, J CLIN INVEST, V117, P2860, DOI 10.1172/JCI30910; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Movassat J, 2002, J CLIN ENDOCR METAB, V87, P4775, DOI 10.1210/jc.2002-020137; OBrien BA, 1996, J PATHOL, V178, P176; Okada T, 2007, P NATL ACAD SCI USA, V104, P8977, DOI 10.1073/pnas.0608703104; Overton HA, 2008, BRIT J PHARMACOL, V153, pS76, DOI 10.1038/sj.bjp.0707529; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; PILKIS SJ, 1988, ADV SEC MESS PHOSPH, V22, P175; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reimer MK, 2002, DIABETES, V51, pS138, DOI 10.2337/diabetes.51.2007.S138; Schroeder IS, 2006, NAT PROTOC, V1, P495, DOI 10.1038/nprot.2006.71; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; Ueno H, 2001, GENOMICS, V78, P91, DOI 10.1006/geno.2001.6641; von Herrath M, 2007, NAT REV IMMUNOL, V7, P988, DOI 10.1038/nri2192; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yan JB, 2013, MOL CELL BIOL, V33, P918, DOI 10.1128/MCB.01227-12; Zhao AZ, 2005, CURR TOP DEV BIOL, V67, P207, DOI 10.1016/S0070-2153(05)67006-8	45	45	47	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4122	4135		10.1096/fj.13-230433	http://dx.doi.org/10.1096/fj.13-230433			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825225				2022-12-28	WOS:000329747100024
J	Li, SH; Guo, J; Wu, J; Sun, Z; Han, MH; Shan, SW; Deng, ZQ; Yang, BB; Weisel, RD; Li, RK				Li, Shu-Hong; Guo, Jian; Wu, Jun; Sun, Zhuo; Han, Mihan; Shan, Sze Wan; Deng, Zhaoqun; Yang, Burton B.; Weisel, Richard D.; Li, Ren-Ke			miR-17 targets tissue inhibitor of metalloproteinase 1 and 2 to modulate cardiac matrix remodeling	FASEB JOURNAL			English	Article						TIMP1; TIMP2; MMP; myocardial infarction	RANDOMIZED PHASE-1 TRIAL; MYOCARDIAL-INFARCTION; ISCHEMIC CARDIOMYOPATHY; HEART-FAILURE; BONE-MARROW; STEM-CELLS; MICRORNAS; MICE; EXPRESSION; DEFICIENCY	We aimed to investigate the role of miR-17 in cardiac matrix remodeling following myocardial infarction (MI). Using real-time PCR, we quantified endogenous miR-17 in infarcted mouse hearts. Compared with related microRNAs, miR-17 was up-regulated most dramatically: 3.7-fold and 2.4-fold in the infarct region 3 and 7 d post-MI, respectively, and 2.4-fold in the border zone at d 3 compared to sham control (P<0.01). Chimeric luciferase reporter constructs were cloned for miR-17 target validation. miR-17 targeted the 3-UTR of TIMP2 and the protein coding region of TIMP1. The miR-17 mimic decreased TIMP2 (P<0.01) and TIMP1 (P<0.05) protein expression compared with the scrambled control. Inhibition of endogenous miR-17 by in vivo antagomir delivery enhanced TIMP2 (P<0.01) and TIMP1 (P<0.05) protein expression compared to the mismatch group, decreased MMP9 activity (P<0.05), reduced infarct size as early as 7 d post-MI (P<0.05), and improved cardiac function (fractional shortening and fractional area contraction, P<0.05) at d 21 and 28 post-MI. Transgenic mice overexpressing miR-17 in the heart confirmed the deleterious role of miR-17 in matrix modulation. Our study suggests that miR-17 participates in the regulation of cardiac matrix remodeling and provides a novel therapeutic approach using miR-17 inhibitors to prevent remodeling and heart failure after MI.Li, S.-H., Guo, J., Wu, J., Sun, Z., Han, M., Shan, S. W., Deng, Z., Yang, B. B., Weisel, R. D., Li, R.-K. miR-17 targets tissue inhibitor of metalloproteinase 1 and 2 to modulate cardiac matrix remodeling.	[Li, Shu-Hong; Guo, Jian; Wu, Jun; Sun, Zhuo; Han, Mihan; Weisel, Richard D.; Li, Ren-Ke] Univ Toronto, Div Cardiovasc Surg, Toronto, ON, Canada; [Li, Shu-Hong; Guo, Jian; Wu, Jun; Sun, Zhuo; Han, Mihan; Weisel, Richard D.; Li, Ren-Ke] Univ Toronto, Toronto Gen Res Inst, Univ Hlth Network, Toronto, ON, Canada; [Li, Shu-Hong; Guo, Jian; Wu, Jun; Sun, Zhuo; Han, Mihan; Weisel, Richard D.; Li, Ren-Ke] Univ Toronto, Dept Surg, Div Cardiac Surg, Toronto, ON, Canada; [Shan, Sze Wan; Deng, Zhaoqun; Yang, Burton B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Li, RK (corresponding author), Univ Hlth Network, MaRS Ctr, Toronto Med Discovery Tower,Rm 3-702,101 Coll St, Toronto, ON M5G 1L7, Canada.	renkeli@uhnres.utoronto.ca		Li, Ren-Ke/0000-0002-2584-060X; SHAN, SW/0000-0001-6876-9914	Canadian Institutes of Health Research [MOP102535, MOP111171]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the Canadian Institutes of Health Research (MOP102535 to R.K.L. and MOP111171 to B.B.Y.). R.K.L. holds a Canada Research Chair in Cardiac Regeneration. The authors thank Kelly Davis for editing the manuscript. The authors declare no conflicts of interest.	Angoulvant D, 2009, J THORAC CARDIOV SUR, V137, P471, DOI 10.1016/j.jtcvs.2008.08.031; Assmus B, 2013, JAMA-J AM MED ASSOC, V309, P1622, DOI 10.1001/jama.2013.3527; Bolli R, 2011, LANCET, V378, P1847, DOI 10.1016/S0140-6736(11)61590-0; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Creemers EEJM, 2003, AM J PHYSIOL-HEART C, V284, pH364, DOI 10.1152/ajpheart.00511.2002; Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812; Duisters RF, 2009, CIRC RES, V104, P170, DOI 10.1161/CIRCRESAHA.108.182535; Fazel S, 2005, J THORAC CARDIOV SUR, V130, P1310, DOI 10.1016/j.jtcvs.2005.07.012; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Fedak PWM, 2003, J THORAC CARDIOV SUR, V126, P797, DOI 10.1016/S0022-5223(03)00398-2; Felkin LE, 2006, J HEART LUNG TRANSPL, V25, P1413, DOI 10.1016/j.healun.2006.09.006; Fichtlscherer S, 2010, CIRC RES, V107, P677, DOI 10.1161/CIRCRESAHA.109.215566; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hare JM, 2012, JAMA-J AM MED ASSOC, V308, P2369, DOI 10.1001/jama.2012.25321; Ikonomidis JS, 2005, AM J PHYSIOL-HEART C, V288, pH149, DOI 10.1152/ajpheart.00370.2004; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Jugdutt BI, 2009, NEW ENGL J MED, V360, P1567, DOI 10.1056/NEJMcibr0810801; Kandalam V, 2010, CIRC RES, V106, P796, DOI 10.1161/CIRCRESAHA.109.209189; Li YY, 1998, CIRCULATION, V98, P1728, DOI 10.1161/01.CIR.98.17.1728; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Tian H, 2007, J MOL CELL CARDIOL, V43, P733, DOI 10.1016/j.yjmcc.2007.09.003; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; Van Rooij E, 2007, PHYSIOL GENOMICS, V31, P365, DOI 10.1152/physiolgenomics.00206.2007; Vanhoutte D, 2006, CARDIOVASC RES, V69, P604, DOI 10.1016/j.cardiores.2005.10.002; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Webb CS, 2006, CIRCULATION, V114, P1020, DOI 10.1161/CIRCULATIONAHA.105.600353	28	25	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4254	4265		10.1096/fj.13-231688	http://dx.doi.org/10.1096/fj.13-231688			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825222	Bronze			2022-12-28	WOS:000329747100035
J	Cansby, E; Amrutkar, M; Holm, LM; Nerstedt, A; Reyahi, A; Stenfeldt, E; Boren, J; Carlsson, P; Smith, U; Zierath, JR; Mahlapuu, M				Cansby, Emmelie; Amrutkar, Manoj; Holm, Louise Manneras; Nerstedt, Annika; Reyahi, Azadeh; Stenfeldt, Elin; Boren, Jan; Carlsson, Peter; Smith, Ulf; Zierath, Juleen R.; Mahlapuu, Margit			Increased expression of STK25 leads to impaired glucose utilization and insulin sensitivity in mice challenged with a high-fat diet	FASEB JOURNAL			English	Article						serine /threonine; protein kinase 25; type 2 diabetes; metabolic balance	ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; MITOCHONDRIAL DYSFUNCTION; CHEMICAL ANOXIA; DOWN-REGULATION; RESISTANCE; LIVER; MUSCLE; GOLGI; METABOLISM	Partial depletion of serine/threonine protein kinase 25 (STK25), a member of the Ste20 superfamily of kinases, increases lipid oxidation and glucose uptake in rodent myoblasts. Here we show that transgenic mice overexpressing STK25, when challenged with a high-fat diet, develop reduced glucose tolerance and insulin sensitivity compared to wild-type siblings, as evidenced by impairment in glucose and insulin tolerance tests as well as in euglycemic-hyperinsulinemic clamp studies. The fasting plasma insulin concentration was elevated in Stk25 transgenic mice compared to wild-type littermates (4.9 +/- 0.8 vs. 2.6 +/- 0.4 ng/ml after 17 wk on high-fat diet, P<0.05). Overexpression of STK25 decreased energy expenditure during the dark phase of observation (P<0.05), despite increased spontaneous activity. The oxidative capacity of skeletal muscle of transgenic carriers was reduced, as evidenced by altered expression of Cpt1, Acox1, and ACC. Hepatic triglycerides and glycogen were elevated (1.6- and 1.4-fold, respectively; P<0.05) and expression of key enzymes regulating lipogenesis (Fasn), glycogen synthesis (Gck), and gluconeogenesis (G6pc, Fbp1) was increased in the liver of the transgenic mice. Our findings suggest that overexpression of STK25 in conditions of excess dietary fuels associates with a shift in the metabolic balance in peripheral tissues from lipid oxidation to storage, leading to a systemic insulin resistance.Cansby, E., Amrutkar, M., Manneras Holm, L., Nerstedt, A., Reyahi, A., Stenfeldt, E., Boren, J., Carlsson, P., Smith, U., Zierath, J.R., Mahlapuu, M. Increased expression of STK25 leads to impaired glucose utilization and insulin sensitivity in mice challenged with a high-fat diet.	[Cansby, Emmelie; Amrutkar, Manoj; Nerstedt, Annika; Smith, Ulf; Mahlapuu, Margit] Univ Gothenburg, Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden; [Stenfeldt, Elin; Boren, Jan] Univ Gothenburg, Wallenberg Lab, Dept Mol & Clin Med, SE-41345 Gothenburg, Sweden; [Reyahi, Azadeh; Carlsson, Peter] Univ Gothenburg, Dept Cell & Mol Biol, SE-41345 Gothenburg, Sweden; [Holm, Louise Manneras; Zierath, Juleen R.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; Karolinska Institutet	Mahlapuu, M (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Ctr Excellence Cardiovasc & Metabol Res, Lundberg Lab Diabet Res,Dept Mol & Clin Med, Bla Straket 5, SE-41345 Gothenburg, Sweden.	margit.mahlapuu@gu.se	Carlsson, Peter/B-5551-2008; AMRUTKAR, MANOJ/I-4975-2014; Amrutkar, Manoj/J-2848-2019	Carlsson, Peter/0000-0001-6535-5927; AMRUTKAR, MANOJ/0000-0002-1868-0249; Amrutkar, Manoj/0000-0002-1868-0249; Mahlapuu, Margit/0000-0001-8740-8874; Zierath, Juleen/0000-0001-6891-7497	Swedish Research Council; European Foundation for the Study of Diabetes/Lilly; European Foundation for the Study of Diabetes and Novo Nordisk Partnership for Diabetes Research in Europe; Novo Nordisk Foundation; Diabetes Wellness Network Sweden; Diabetesfonden; P. and A. Hedlunds Foundation; M. Bergvall Foundation; Novo Nordisk Fonden [NNF13OC0004973] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); European Foundation for the Study of Diabetes/Lilly(Eli Lilly); European Foundation for the Study of Diabetes and Novo Nordisk Partnership for Diabetes Research in Europe; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Diabetes Wellness Network Sweden; Diabetesfonden; P. and A. Hedlunds Foundation; M. Bergvall Foundation; Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank Dr. M. Bjornholm (Karolinska Institutet, Stockholm, Sweden) for valuable comments during the preparation of this manuscript, and Dr. Marcus Stahlman (Wallenberg Laboratory, Sahlgrenska Academy, Gothenburg, Sweden) for assistance with lipid extractions. DEXA measurements and indirect calorimetry measurements were performed by the Center for Physiology and Bio-Imaging (CPI), University of Gothenburg (Gothenburg, Sweden). This work was supported by grants from the Swedish Research Council, the European Foundation for the Study of Diabetes/Lilly research grant, the European Foundation for the Study of Diabetes and Novo Nordisk Partnership for Diabetes Research in Europe, the Novo Nordisk Foundation, the Diabetes Wellness Network Sweden, the Diabetesfonden, the P. and A. Hedlunds Foundation, and the M. Bergvall Foundation. The authors declare no conflicts of interest.	Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; Bruce CR, 2009, DIABETES, V58, P550, DOI 10.2337/db08-1078; Carling D, 2005, BIOCHIMIE, V87, P87, DOI 10.1016/j.biochi.2004.10.017; CHANG AY, 1970, DIABETOLOGIA, V6, P274, DOI 10.1007/BF01212238; Chibalin AV, 2008, CELL, V132, P375, DOI 10.1016/j.cell.2007.12.035; Choi CS, 2007, P NATL ACAD SCI USA, V104, P16480, DOI 10.1073/pnas.0706794104; CLORE JN, 1992, J CLIN ENDOCR METAB, V74, P660, DOI 10.1210/jc.74.3.660; D'Adamo E, 2010, DIABETES CARE, V33, P1817, DOI 10.2337/dc10-0284; DeFronzo RA, 2009, DIABETES CARE, V32, pS157, DOI 10.2337/dc09-S302; ELMAGHRABI MR, 1988, P NATL ACAD SCI USA, V85, P8430, DOI 10.1073/pnas.85.22.8430; Fidalgo M, 2010, J CELL SCI, V123, P1274, DOI 10.1242/jcs.061341; Gastaldelli A, 2007, GASTROENTEROLOGY, V133, P496, DOI 10.1053/j.gastro.2007.04.068; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Homan R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; Jin ES, 2007, DIABETES, V56, P777, DOI 10.2337/db06-0717; Kleiber M., 1932, HILGARDIA, V6, P39; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Matsuki T, 2010, CELL, V143, P826, DOI 10.1016/j.cell.2010.10.029; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nerstedt A, 2012, DIABETOLOGIA, V55, P1797, DOI 10.1007/s00125-012-2511-7; Nerstedt A, 2010, DIABETOLOGIA, V53, P2406, DOI 10.1007/s00125-010-1856-z; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nogueira E, 2008, J BIOL CHEM, V283, P16248, DOI 10.1074/jbc.M709724200; Noland RC, 2007, AM J PHYSIOL-ENDOC M, V293, pE986, DOI 10.1152/ajpendo.00399.2006; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Pombo CM, 2007, FRONT BIOSCI-LANDMRK, V12, P850, DOI 10.2741/2107; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Ryysy L, 2000, DIABETES, V49, P749, DOI 10.2337/diabetes.49.5.749; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; SCHWERZMANN K, 1989, P NATL ACAD SCI USA, V86, P1583, DOI 10.1073/pnas.86.5.1583; SEIDMAN I, 1967, BIOCHIM BIOPHYS ACTA, V146, P600, DOI 10.1016/0005-2744(67)90249-5; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; Song SM, 2001, AM J PHYSIOL-ENDOC M, V281, pE275, DOI 10.1152/ajpendo.2001.281.2.E275; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VAISHNAVA H, 1970, DIABETOLOGIA, V6, P21, DOI 10.1007/BF00425887; VALLANCEOWEN J, 1952, J CLIN PATHOL, V5, P42, DOI 10.1136/jcp.5.1.42; Voss K, 2007, NEUROGENETICS, V8, P249, DOI 10.1007/s10048-007-0098-9; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Yu XX, 2001, AM J PHYSIOL-REG I, V281, pR1553, DOI 10.1152/ajpregu.2001.281.5.R1553	47	32	33	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3660	3671		10.1096/fj.13-228494	http://dx.doi.org/10.1096/fj.13-228494			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729594				2022-12-28	WOS:000328840500025
J	Chen, JR; Zhang, J; Lazarenko, OP; Cao, JJ; Blackburn, ML; Badger, TM; Ronis, MJJ				Chen, Jin-Ran; Zhang, Jian; Lazarenko, Oxana P.; Cao, Jay J.; Blackburn, Michael L.; Badger, Thomas M.; Ronis, Martin J. J.			Soy protein isolates prevent loss of bone quantity associated with obesity in rats through regulation of insulin signaling in osteoblasts	FASEB JOURNAL			English	Article						high-fat diet; free fatty acid; isoflavone; osteocalcin	VOLUNTARY WEIGHT-LOSS; MINERAL DENSITY; DIETARY PHYTOESTROGENS; FAT; MASS; INHIBITION; ISOFLAVONE; CELL; INTERVENTION; ACQUISITION	In both rodents and humans, excessive consumption of a typical Western diet high in saturated fats and cholesterol is known to result in disruption of energy metabolism and development of obesity and insulin resistance. However, how these high-fat, energy-dense diets affect bone development, morphology, and modeling is poorly understood. Here we show that male weanling rats fed a high-fat (HF) diet containing 45% fat and 0.5% cholesterol made with casein (HF-Cas) for 6 wk displayed a significant increase in bone marrow adiposity and insulin resistance. Substitution of casein with soy protein isolate (SPI) in the HF diet (HF-SPI) prevented these effects. Maintenance of bone quantity in the SPI-fed rats was associated with increased undercarboxylated osteocalcin secretion and altered JNK/IRS1/Akt insulin signaling in osteoblasts. The HF-Cas group had significantly greater serum nonesterified free fatty acid (NEFA) concentrations than controls, whereas the HF-SPI prevented this increase. In vitro treatment of osteoblasts or mesenchymal stromal ST2 cells with NEFAs significantly decreased insulin signaling. An isoflavone mixture similar to that found in serum of HF-SPI rats significantly increased in vitro osteoblast proliferation and blocked significantly reduced NEFA-induced insulin resistance. Finally, insulin/IGF1 was able to increase both osteoblast activity and differentiation in a set of in vitro studies. These results suggest that high-fat feeding may disrupt bone development and modeling; high concentrations of NEFAs and insulin resistance occurring with high fat intake are mediators of reduced osteoblast activity and differentiation; diets high in soy protein may help prevent high dietary fat-induced bone impairments; and the molecular mechanisms underlying the SPI-protective effects involve isoflavone-induced normalization of insulin signaling in bone.Chen, J.-R., Zhang, J., Lazarenko, O. P., Cao, J. J., Blackburn, M. L., Badger, T. M., Ronis, M. J. J. Soy protein isolates prevent loss of bone quantity associated with obesity in rats through regulation of insulin signaling in osteoblasts.	[Chen, Jin-Ran; Zhang, Jian; Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.; Ronis, Martin J. J.] Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; [Chen, Jin-Ran; Zhang, Jian; Badger, Thomas M.; Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; [Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; [Cao, Jay J.] USDA ARS, Grand Forks Human Nutr Res Ctr, Grand Forks, ND 58202 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; United States Department of Agriculture (USDA)	Chen, JR (corresponding author), Arkansas Childrens Nutr Ctr, 15 Childrens Way,Slot 512-20B, Little Rock, AR 72202 USA.	chenjinran@uams.edu			U.S. Department of Agriculture (USDA)/Agricultural Research Service (ARS) [CRIS 6251-51000-003, CRIS 5450-51000-046-00D]	U.S. Department of Agriculture (USDA)/Agricultural Research Service (ARS)(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	This work was supported in part by U.S. Department of Agriculture (USDA)/Agricultural Research Service (ARS) grant CRIS 6251-51000-003 to the Arkansas Children's Nutrition Center and CRIS 5450-51000-046-00D to the Grand Forks Human Nutrition Research Center (J.J.C.).	Badger TM, 2008, EXP BIOL MED, V233, P1242, DOI 10.3181/0802-RM-60; Baile CA, 2011, ANN NY ACAD SCI, V1215, P40, DOI 10.1111/j.1749-6632.2010.05845.x; Bhathena SJ, 2002, AM J CLIN NUTR, V76, P1191, DOI 10.1093/ajcn/76.6.1191; Blake C, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-28; Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006-1006; Cao JJ, 2009, BONE, V44, P1097, DOI 10.1016/j.bone.2009.02.017; Cederroth CR, 2008, DIABETES, V57, P1176, DOI 10.2337/db07-0630; Chan ME, 2012, FASEB J, V26, P4855, DOI 10.1096/fj.12-209841; Chao D, 2000, J AM GERIATR SOC, V48, P753, DOI 10.1111/j.1532-5415.2000.tb04749.x; Chen JR, 2008, EXP BIOL MED, V233, P1348, DOI 10.3181/0802-RM-63; Chen JR, 2012, FASEB J, V26, P1131, DOI 10.1096/fj.11-197822; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; Chen JR, 2010, J BONE MINER RES, V25, P1117, DOI 10.1002/jbmr.7; Chen JR, 2009, J NUTR, V139, P1839, DOI 10.3945/jn.109.109041; Chen JR, 2009, J BONE MINER RES, V24, P221, DOI 10.1359/JBMR.081011; Chen XW, 2003, J NUTR BIOCHEM, V14, P342, DOI 10.1016/S0955-2863(03)00056-1; Cimino CO, 1999, CLIN CHIM ACTA, V287, P69, DOI 10.1016/S0009-8981(99)00124-2; Clemens TL, 2011, J BONE MINER RES, V26, P677, DOI 10.1002/jbmr.321; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; Davies JH, 2005, ARCH DIS CHILD, V90, P373, DOI 10.1136/adc.2004.053553; Elbaz A, 2010, J CELL MOL MED, V14, P982, DOI 10.1111/j.1582-4934.2009.00751.x; Fazeli PK, 2013, J CLIN ENDOCR METAB, V98, P935, DOI 10.1210/jc.2012-3634; Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002; Grundy SM, 2004, J CLIN ENDOCR METAB, V89, P2595, DOI 10.1210/jc.2004-0372; Gu LW, 2005, J AGR FOOD CHEM, V53, P6858, DOI 10.1021/jf050802j; He JN, 2006, BONE, V38, P826, DOI 10.1016/j.bone.2005.11.021; Holzer RG, 2011, CELL, V147, P173, DOI 10.1016/j.cell.2011.08.034; JENSEN LB, 1994, J BONE MINER RES, V9, P459; Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008; Kim MS, 2005, J MED FOOD, V8, P439, DOI 10.1089/jmf.2005.8.439; Nagata C, 2002, OSTEOPOROSIS INT, V13, P200, DOI 10.1007/s001980200014; Nolan CJ, 2006, DIABETES, V55, pS16, DOI 10.2337/db06-S003; Palacios C, 2006, CRIT REV FOOD SCI, V46, P621, DOI 10.1080/10408390500466174; Pollock NK, 2011, J PEDIATR-US, V158, P727, DOI 10.1016/j.jpeds.2010.11.052; Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198-007-0492-z; Ronis MJ, 2009, J NUTR, V139, P1431, DOI 10.3945/jn.109.107029; Schwartz AV, 2012, J BONE MINER RES, V27, P619, DOI 10.1002/jbmr.1483; Shea MK, 2009, AM J CLIN NUTR, V90, P1230, DOI 10.3945/ajcn.2009.28151; Solinas G, 2006, P NATL ACAD SCI USA, V103, P16454, DOI 10.1073/pnas.0607626103; Spallarossa P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015583; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Taylor ED, 2006, PEDIATRICS, V117, P2167, DOI 10.1542/peds.2005-1832; Torre-Villalvazo I, 2009, J NUTR, V139, P2237, DOI 10.3945/jn.109.109769; Villareal DT, 2011, NEW ENGL J MED, V364, P1218, DOI 10.1056/NEJMoa1008234; Watkins BA, 2005, J NUTR BIOCHEM, V16, P479, DOI 10.1016/j.jnutbio.2005.01.019; Wu J, 2004, METABOLISM, V53, P942, DOI 10.1016/j.metabol.2004.01.019; Zhang JT, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030355, 10.1371/journal.pone.0041657]	49	32	34	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3514	3523		10.1096/fj.12-226464	http://dx.doi.org/10.1096/fj.12-226464			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23776073				2022-12-28	WOS:000328840500012
J	Liu, BY; Escalera, J; Balakrishna, S; Fan, L; Caceres, AI; Robinson, E; Sui, AW; McKay, MC; McAlexander, MA; Herrick, CA; Jordt, SE				Liu, Boyi; Escalera, Jasmine; Balakrishna, Shrilatha; Fan, Lu; Caceres, Ana I.; Robinson, Eve; Sui, Aiwei; McKay, M. Craig; McAlexander, M. Allen; Herrick, Christina A.; Jordt, Sven E.			TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis	FASEB JOURNAL			English	Article						pruritis; sensory neurons; TRP channels	ITCH-ASSOCIATED RESPONSE; POTENTIAL ANKYRIN 1; P-INDUCED ITCH; SUBSTANCE-P; ATOPIC-DERMATITIS; NEUROKININ-1 RECEPTOR; TRPV1 ANTAGONIST; NERVE-FIBERS; MURINE MODEL; CRUCIAL ROLE	Allergic contact dermatitis is a common skin disease associated with inflammation and persistent pruritus. Transient receptor potential (TRP) ion channels in skin-innervating sensory neurons mediate acute inflammatory and pruritic responses following exogenous stimulation and may contribute to allergic responses. Genetic ablation or pharmacological inhibition of TRPA1, but not TRPV1, inhibited skin edema, keratinocyte hyperplasia, nerve growth, leukocyte infiltration, and antihistamine-resistant scratching behavior in mice exposed to the haptens, oxazolone and urushiol, the contact allergen of poison ivy. Hapten-challenged skin of TRPA1-deficient mice contained diminished levels of inflammatory cytokines, nerve growth factor, and endogenous pruritogens, such as substance P (SP) and serotonin. TRPA1-deficient sensory neurons were defective in SP signaling, and SP-induced scratching behavior was abolished in Trpa1(-/-) mice. SP receptor antagonists, such as aprepitant inhibited both hapten-induced cutaneous inflammation and scratching behavior. These findings support a central role for TRPA1 and SP in the integration of immune and neuronal mechanisms leading to chronic inflammatory responses and pruritus associated with contact dermatitis.Liu, B., Escalera, J., Balakrishna, S., Fan, L., Caceres, A. I., Robinson, E., Sui, A., McKay, M. C., McAlexander, M. A., Herrick, C. A., Jordt, S. E. TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis.	[Liu, Boyi; Escalera, Jasmine; Balakrishna, Shrilatha; Fan, Lu; Caceres, Ana I.; Sui, Aiwei; Jordt, Sven E.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; [Robinson, Eve; Herrick, Christina A.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [McKay, M. Craig] GlaxoSmithKline, Biol Reagents & Assay Dev, Res Triangle Pk, NC USA; [McAlexander, M. Allen] GlaxoSmithKline, Resp Therapy Area, King Of Prussia, PA USA	Yale University; Yale University; GlaxoSmithKline; GlaxoSmithKline	Jordt, SE (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.	sven.jordt@yale.edu	Liu, Boyi/J-5396-2014; Jordt, Sven-Eric/ABE-6517-2020; Caceres, Ana I/E-5542-2012	Jordt, Sven-Eric/0000-0001-6171-5622; Caceres, Ana I/0000-0001-7219-8851	U.S. National Institute of Environmental Health Sciences [R01 ES015056, U01 ES015674, F31 ES015932]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F31ES015932, U01ES015674, R01ES015056] Funding Source: NIH RePORTER	U.S. National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors are grateful to David Julius (University of California, San Francisco, CA, USA) for Trpa1<SUP>-/-</SUP> mice, and to Jaime Garcia-Anoveros (Northwestern University, Chicago, IL, USA) for mouse TRPA1 cDNA. This work was funded by grants from the U.S. National Institute of Environmental Health Sciences (awards R01 ES015056 and U01 ES015674 to S.E.J. and predoctoral fellowship F31 ES015932 to J.E.). S.E.J. is serving on the scientific advisory board of, and has equity interest in, Hydra Biosciences (Cambridge, MA, USA), a biotechnology company developing TRP channel inhibitors. Authors affiliated with GlaxoSmithKline may have equity interest in GlaxoSmithKline.	Andoh T, 1998, J PHARMACOL EXP THER, V286, P1140; Andoh T, 2001, J INVEST DERMATOL, V117, P1621, DOI 10.1046/j.0022-202x.2001.01585.x; Andoh T, 2007, J INVEST DERMATOL, V127, P2042, DOI 10.1038/sj.jid.5700810; Atoyan R, 2009, J INVEST DERMATOL, V129, P2312, DOI 10.1038/jid.2009.58; Banvolgyi A, 2005, J NEUROIMMUNOL, V169, P86, DOI 10.1016/j.jneuroim.2005.08.012; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Beresford L, 2004, IMMUNOLOGY, V111, P118, DOI 10.1111/j.1365-2567.2004.01786.x; Bessac BF, 2009, FASEB J, V23, P1102, DOI 10.1096/fj.08-117812; Buddenkotte J, 2010, ALLERGY, V65, P805, DOI 10.1111/j.1398-9995.2010.01995.x; Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106; Carlton SM, 1996, BRAIN RES, V734, P103, DOI 10.1016/S0006-8993(96)00619-1; DUNN IS, 1982, CELL IMMUNOL, V68, P377, DOI 10.1016/0008-8749(82)90122-8; Duval A, 2009, NEW ENGL J MED, V361, P1415, DOI 10.1056/NEJMc0906670; Dux M, 1996, INFLAMM RES, V45, P10, DOI 10.1007/BF02263498; EKBLOM A, 1993, SKIN PHARMACOL, V6, P215; El-Nour H, 2006, IMMUNOPHARM IMMUNOT, V28, P621, DOI 10.1080/08923970601067136; El-Nour H, 2007, ACTA DERM-VENEREOL, V87, P390, DOI 10.2340/00015555-0288; Fernandes ES, 2013, FASEB J, V27, P1664, DOI 10.1096/fj.12-221218; FJELLNER B, 1981, ACTA DERM-VENEREOL, V61, P245; Gladman AC, 2006, WILD ENVIRON MED, V17, P120, DOI 10.1580/PR31-05.1; Grabbe S, 1996, J CLIN INVEST, V98, P1158, DOI 10.1172/JCI118899; Hesketh PJ, 2008, NEW ENGL J MED, V358, P2482, DOI 10.1056/NEJMra0706547; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; Hox V, 2013, AM J RESP CRIT CARE, V187, P486, DOI 10.1164/rccm.201208-1358OC; Imamachi N, 2009, P NATL ACAD SCI USA, V106, P11330, DOI 10.1073/pnas.0905605106; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johnson KR, 2003, GENOMICS, V81, P6, DOI 10.1016/S0888-7543(02)00013-7; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kinkelin I, 2000, CELL TISSUE RES, V302, P31, DOI 10.1007/s004410000202; KURAISHI Y, 1995, EUR J PHARMACOL, V275, P229, DOI 10.1016/0014-2999(94)00780-B; LaMotte RH, 2011, EXP DERMATOL, V20, P778, DOI 10.1111/j.1600-0625.2011.01367.x; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Li HS, 1998, EUR J NEUROSCI, V10, P1292, DOI 10.1046/j.1460-9568.1998.00140.x; Liang JX, 2011, NEUROSCI LETT, V492, P175, DOI 10.1016/j.neulet.2011.02.009; Liu T, 2012, NEUROSCI BULL, V28, P145, DOI 10.1007/s12264-012-1207-9; Man MQ, 2008, J INVEST DERMATOL, V128, P79, DOI 10.1038/sj.jid.5701011; McQueen DS, 2007, BRIT J PHARMACOL, V151, P278, DOI 10.1038/sj.bjp.0707216; Mir O, 2011, NEW ENGL J MED, V364, P487, DOI 10.1056/NEJMc1013027; Neisius U, 2002, J AM ACAD DERMATOL, V47, P28, DOI 10.1067/mjd.2002.120462; Niwa Y, 2003, BRIT J DERMATOL, V149, P248, DOI 10.1046/j.1365-2133.2003.05417.x; Nojima H, 2003, J PHARMACOL EXP THER, V306, P245, DOI 10.1124/jpet.103.049239; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Raap U, 2011, CURR OPIN ALLERGY CL, V11, P420, DOI 10.1097/ACI.0b013e32834a41c2; RATZLAFF RE, 1992, J NEUROIMMUNOL, V41, P89, DOI 10.1016/0165-5728(92)90199-U; Roosterman D, 2006, PHYSIOL REV, V86, P1309, DOI 10.1152/physrev.00026.2005; Rukwied R, 1999, EXP DERMATOL, V8, P39, DOI 10.1111/j.1600-0625.1999.tb00346.x; Scholzen TE, 2001, J IMMUNOL, V166, P1285, DOI 10.4049/jimmunol.166.2.1285; Shiba T, 2012, TOXICOL APPL PHARM, V264, P370, DOI 10.1016/j.taap.2012.08.012; Shim WS, 2007, J NEUROSCI, V27, P2331, DOI 10.1523/JNEUROSCI.4643-06.2007; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Stander S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010968; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; SUNDELIN JB, 1992, EUR J BIOCHEM, V203, P625, DOI 10.1111/j.1432-1033.1992.tb16592.x; Tang HB, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-42; Tang HB, 2008, NEUROPHARMACOLOGY, V55, P1405, DOI 10.1016/j.neuropharm.2008.08.037; Togashi Y, 2002, EUR J PHARMACOL, V435, P259, DOI 10.1016/S0014-2999(01)01588-6; Trentin PG, 2006, EXP BIOL MED, V231, P1146; Trevisani M, 2007, P NATL ACAD SCI USA, V104, P13519, DOI 10.1073/pnas.0705923104; Tsukumo Y, 2010, J PHARMACOL SCI, V113, P255, DOI 10.1254/jphs.10050FP; Vincenzi B, 2010, NEW ENGL J MED, V363, P397, DOI 10.1056/NEJMc1003937; von Banchet GS, 1999, NEUROSCI LETT, V274, P175, DOI 10.1016/S0304-3940(99)00719-3; Wakabayashi T, 2005, IMMUNOL CELL BIOL, V83, P18, DOI 10.1111/j.1440-1711.2005.01310.x; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; Willis DN, 2011, FASEB J, V25, P4434, DOI 10.1096/fj.11-188383; Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789; Yun JW, 2011, J INVEST DERMATOL, V131, P1576, DOI 10.1038/jid.2011.87; Yun JW, 2011, J DERMATOL SCI, V62, P8, DOI 10.1016/j.jdermsci.2010.10.014	68	150	156	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3549	3563		10.1096/fj.13-229948	http://dx.doi.org/10.1096/fj.13-229948			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23722916	Green Published			2022-12-28	WOS:000328840500015
J	Durham, AL; McLaren, A; Hayes, BP; Caramori, G; Clayton, CL; Barnes, PJ; Chung, KF; Adcock, IM				Durham, Andrew L.; McLaren, Alistair; Hayes, Brian P.; Caramori, Gaetano; Clayton, Chris L.; Barnes, Peter J.; Chung, K. Fan; Adcock, Ian M.			Regulation of Wnt4 in chronic obstructive pulmonary disease	FASEB JOURNAL			English	Article						inflammation; proliferation; epithelial cells	OXIDATIVE STRESS; HISTONE DEACETYLASE; BETA-CATENIN; GENE-EXPRESSION; COPD; INFLAMMATION; MOUSE; LUNG; ACTIVATION; INHIBITOR	Chronic obstructive pulmonary disease (COPD) is associated with persistent inflammation and oxidative stress in susceptible individuals. Using microarray analysis of bronchial biopsy samples from patients with COPD and controls, we identified Wnt4 as being up-regulated in COPD. Analysis of bronchial biopsy samples showed a very strong correlation between Wnt4 and IL8 gene expression, suggesting that Wnt4 plays a role in chronic lung inflammation. In vitro, Wnt4 induced proliferation and inflammation in human epithelial cells (BEAS-2B) and normal primary human bronchial epithelial cells in a concentration-dependent manner. This effect was enhanced in the presence of interleukin-1 beta (IL-1 beta) as a result of activation of the p38 and c-Jun NH2-terminal kinase mitogen-activated protein kinase pathways. Hydrogen peroxide, but not proinflammatory stimuli, up-regulated Wnt4 expression in epithelial cells. In monocytic THP-1 and primary airway smooth muscle cells, Wnt4 induced inflammation and enhanced the inflammatory response to lipopolysaccharide and IL-1 beta but did not induce proliferation. In addition, these other cell types did not have enhanced Wnt4 expression in response to hydrogen peroxide. Our results indicate that airway epithelial activation, due to oxidative stress, may lead to Wnt4 induction. Wnt4, in turn, acts through the noncanonical pathway to activate epithelial cell remodeling and IL8 gene expression, leading to neutrophil infiltration and inflammation.-Durham, A. L., McLaren, A., Hayes, B. P., Caramori, G., Clayton, C. L., Barnes, P. J., Chung, K. F., Adcock, I. M. Regulation of Wnt4 in chronic obstructive pulmonary disease.	[Durham, Andrew L.; Barnes, Peter J.; Chung, K. Fan; Adcock, Ian M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London, England; [McLaren, Alistair; Clayton, Chris L.] GlaxoSmithKline Res, Core Discovery Technol Grp, Resp Ctr Excellence Drug Discovery, Stevenage, Herts, England; [Hayes, Brian P.] GlaxoSmithKline Res, Allergy & Inflammat Grp, Resp Ctr Excellence Drug Discovery, Stevenage, Herts, England; [Caramori, Gaetano] Univ Ferrara, Sect Resp Dis, Ctr Studio Malattie Infiammatorie Cron Vie Aeree, Dept Med Sci, I-44100 Ferrara, Italy	Imperial College London; GlaxoSmithKline; GlaxoSmithKline; University of Ferrara	Durham, AL (corresponding author), Natl Heart & Lung Inst, Airways Dis Sect, Dovehouse St, London SW3 6LY, England.	a.durham@imperial.ac.uk	Chung, Kian Fan/B-1872-2012; Caramori, Gaetano/AAS-8611-2020; Adcock, Ian/L-3217-2019; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Caramori, Gaetano/0000-0002-9807-327X; Chung, Kian Fan/0000-0001-7101-1426; Adcock, Ian/0000-0003-2101-8843; Barnes, Peter/0000-0002-5122-4018; Durham, Andrew/0000-0003-2372-4688	Medical Research Council; Wellcome Trust; GlaxoSmithKline; Medical Research Council [G0801056B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0509-10080, NF-SI-0611-10148] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); GlaxoSmithKline(GlaxoSmithKline); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The in vivo mouse model work was performed by Colin J. Clarke and Cornelis H. C. Wiegman. This work was funded by the Medical Research Council and Wellcome Trust and by an unrestricted research grant from GlaxoSmithKline.	Baarsma HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025450; Barnes PJ, 2011, AM J RESP CRIT CARE, V184, P866, DOI 10.1164/rccm.201108-1436ED; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 2000, CHEST, V117, P10; Barnes PJ, 2006, CHEST, V129, P151, DOI 10.1378/chest.129.1.151; Bernard P, 2008, BIOL CELL, V100, P167, DOI 10.1042/BC20070072; Bowler Russell P, 2004, COPD, V1, P255, DOI 10.1081/COPD-200027031; Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cohen ED, 2009, J CLIN INVEST, V119, P2538, DOI 10.1172/JCI38079; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; de Boer WI, 2006, AM J CLIN PATHOL, V125, P184, DOI 10.1039/W1AXKGT7UA37X257; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Ezzie ME, 2012, THORAX, V67, P122, DOI 10.1136/thoraxjnl-2011-200089; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Groves AM, 2012, AM J RESP CELL MOL, V47, P776, DOI 10.1165/rcmb.2011-0433OC; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; Heinonen KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019279; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2001, FASEB J, V15, pA473; Jourdan M, 2007, BRIT J HAEMATOL, V138, P160, DOI 10.1111/j.1365-2141.2007.06629.x; Kim D, 2007, ONCOGENE, V26, P4571, DOI 10.1038/sj.onc.1210230; Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284; KIRKHAM P, 2006, PHARMACOL THERAPEUT, V111, P776; Konigshoff M, 2010, AM J RESP CELL MOL, V42, P21, DOI 10.1165/rcmb.2008-0485TR; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Lapperre TS, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-85; Lara E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-170; Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037; Li Y, 2012, REPROD SCI, V19, P1232, DOI 10.1177/1933719112447126; Liu CF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010382; Llinas L, 2011, PULM PHARMACOL THER, V24, P32, DOI 10.1016/j.pupt.2010.10.010; Luppi F, 2007, AM J RESP CRIT CARE, V175, P527, DOI 10.1164/rccm.200612-1821ED; Lyons JP, 2004, EXP CELL RES, V298, P369, DOI 10.1016/j.yexcr.2004.04.036; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; Mandel H, 2008, AM J HUM GENET, V82, P39, DOI 10.1016/j.ajhg.2007.08.005; Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456-005-5612-9; Morello S, 2006, J IMMUNOL, V177, P7173, DOI 10.4049/jimmunol.177.10.7173; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Osafune K, 2006, DEVELOPMENT, V133, P151, DOI 10.1242/dev.02174; Perry MM, 2011, AM J RESP CELL MOL, V45, P746, DOI 10.1165/rcmb.2010-0304OC; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Postma Dirkje S, 2006, Proc Am Thorac Soc, V3, P434, DOI 10.1513/pats.200601-006AW; Qiu WM, 2011, BIOCHEM BIOPH RES CO, V413, P98, DOI 10.1016/j.bbrc.2011.08.061; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Renda T, 2008, EUR RESPIR J, V31, P62, DOI 10.1183/09031936.00036707; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; Soriano JB, 2008, EUR RESPIR J, V32, P1426, DOI 10.1183/09031936.00138108; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tilley AE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022798; Triantaphyllopoulos K, 2011, AM J PHYSIOL-LUNG C, V300, pL691, DOI 10.1152/ajplung.00252.2010; Ushijima H, 2012, BIOCHEM BIOPH RES CO, V423, P679, DOI 10.1016/j.bbrc.2012.06.013; Voynow JA, 2009, AM J RESP CELL MOL, V41, P107, DOI 10.1165/rcmb.2008-0381OC; Wang R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014793; Williams AS, 2007, J PHARMACOL EXP THER, V322, P351, DOI 10.1124/jpet.107.121624; Zeskind Julie E, 2008, Proc Am Thorac Soc, V5, P834, DOI 10.1513/pats.200807-074TH	66	27	27	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2367	2381		10.1096/fj.12-217083	http://dx.doi.org/10.1096/fj.12-217083			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23463699	Green Published, Green Submitted			2022-12-28	WOS:000319667600025
J	Gunning, AP; Kirby, AR; Fuell, C; Pin, C; Tailford, LE; Juge, N				Gunning, A. Patrick; Kirby, Andrew R.; Fuell, Christine; Pin, Carmen; Tailford, Louise E.; Juge, Nathalie			Mining the "glycocode"-exploring the spatial distribution of glycans in gastrointestinal mucin using force spectroscopy	FASEB JOURNAL			English	Article						atomic force microscopy; lectin-carbohydrate interaction; adhesion; molecular recognition	PORCINE SUBMAXILLARY MUCIN; TN-ANTIGEN FORM; O-GLYCANS; PEANUT AGGLUTININ; INTESTINAL-TRACT; MUCUS LAYERS; SIALIC ACIDS; MICROSCOPY; RECOGNITION; LECTINS	Mucins are the main components of the gastrointestinal mucus layer. Mucin glycosylation is critical to most intermolecular and intercellular interactions. However, due to the highly complex and heterogeneous mucin glycan structures, the encoded biological information remains largely encrypted. Here we have developed a methodology based on force spectroscopy to identify biologically accessible glycoepitopes in purified porcine gastric mucin (pPGM) and purified porcine jejunal mucin (pPJM). The binding specificity of lectins Ricinus communis agglutinin I (RCA), peanut (Arachis hypogaea) agglutinin (PNA), Maackia amurensis lectin II (MALII), and Ulex europaeus agglutinin I (UEA) was utilized in force spectroscopy measurements to quantify the affinity and spatial distribution of their cognate sugars at the molecular scale. Binding energy of 4, 1.6, and 26 aJ was determined on pPGM for RCA, PNA, and UEA. Binding was abolished by competition with free ligands, demonstrating the validity of the affinity data. The distributions of the nearest binding site separations estimated the number of binding sites in a 200-nm mucin segment to be 4 for RCA, PNA, and UEA, and 1.8 for MALII. Binding site separations were affected by partial defucosylation of pPGM. Furthermore, we showed that this new approach can resolve differences between gastric and jejunum mucins.-Gunning, A. P., Kirby, A. R., Fuell, C., Pin, C., Tailford L. E., Juge, N. Mining the "glycocode"-exploring the spatial distribution of glycans in gastrointestinal mucin using force spectroscopy.	[Gunning, A. Patrick; Kirby, Andrew R.; Fuell, Christine; Pin, Carmen; Tailford, Louise E.; Juge, Nathalie] Inst Food Res, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Juge, N (corresponding author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	nathalie.juge@ifr.ac.uk	pin, carmen/C-8959-2014	Juge, Nathalie/0000-0001-8515-1315	BBSRC Institute Strategic Programme, Gut Health and Food Safety [BB/J004529/1]; Biotechnology and Biological Sciences Research Council [BBS/E/F/00044406, BBS/E/F/00044452, BB/K019554/1] Funding Source: researchfish; BBSRC [BB/K019554/1, BBS/E/F/00044406, BBS/E/F/00044452] Funding Source: UKRI	BBSRC Institute Strategic Programme, Gut Health and Food Safety; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank the UK Biotechnology and Biological Sciences Research Council (BBSRC). This research was partly funded by the BBSRC Institute Strategic Programme BB/J004529/1, Gut Health and Food Safety. The authors thank Mark Philo [Institute for Food Research (IFR) Metabolomics Department] as well as Mike Naldrett and Gerhard Saalbach (John Innes Centre Proteomics Facility, Norwich Research Park, Norwich, UK) for their technical support with mass spectrometry, and Emmanuelle Crost and Neil Rigby for help with mucin purification. The authors also thank Jack Dainty (IFR Bioinformatics and Statistics group) for assistance with statistical analysis and Gary Barker for assistance with the binding modeling theory and implementation. The authors are grateful to Vic Morris (IFR) for his critical review of the manuscript.	Adams EL, 2004, CARBOHYD RES, V339, P579, DOI 10.1016/j.carres.2003.11.023; Baos SC, 2012, BIOPHYS J, V102, P176, DOI 10.1016/j.bpj.2011.08.058; Borgert A, 2012, ACS CHEM BIOL, V7, P1031, DOI 10.1021/cb300076s; Brown D, 1994, MODELS BIOL MATH STA; Butt HJ, 1999, LANGMUIR, V15, P2559, DOI 10.1021/la981503+; Ceroni A, 2007, SOURCE CODE BIOL MED, V2, DOI 10.1186/1751-0473-2-3; Ceroni A, 2008, J PROTEOME RES, V7, P1650, DOI 10.1021/pr7008252; CHEN YX, 1995, GLYCOCONJUGATE J, V12, P55, DOI 10.1007/BF00731869; Dam TK, 2007, J BIOL CHEM, V282, P28256, DOI 10.1074/jbc.M704677200; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; Gunning AP, 2008, FASEB J, V22, P2331, DOI 10.1096/fj.07-100578; Hinterdorfer P, 2006, NAT METHODS, V3, P347, DOI 10.1038/NMETH871; Hinterdorfer P, 2002, COLLOID SURFACE B, V23, P115, DOI 10.1016/S0927-7765(01)00256-9; Hong ZN, 2005, BIOMACROMOLECULES, V6, P3458, DOI 10.1021/bm0505843; Jeffers F, 2010, CARBOHYD RES, V345, P1486, DOI 10.1016/j.carres.2010.05.012; Johansson MEV, 2011, CELL MOL LIFE SCI, V68, P3635, DOI 10.1007/s00018-011-0822-3; Johansson MEV, 2011, P NATL ACAD SCI USA, V108, P4659, DOI 10.1073/pnas.1006451107; Jonckheere N, 2010, BIOCHIMIE, V92, P1, DOI 10.1016/j.biochi.2009.09.018; Juge N, 2012, TRENDS MICROBIOL, V20, P30, DOI 10.1016/j.tim.2011.10.001; Khoo KH, 2010, METHOD ENZYMOL, V478, P3, DOI 10.1016/S0076-6879(10)78001-0; Kilcoyne M, 2012, ANAL CHEM, V84, P3330, DOI 10.1021/ac203404n; MARTINEZMENARGUEZ JA, 1992, HISTOCHEM J, V24, P207, DOI 10.1007/BF01046790; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; MILLER RS, 1981, GASTROENTEROLOGY, V81, P759; Moran AP, 2011, GUT, V60, P1412, DOI 10.1136/gut.2010.212704; Morris V. J., 2009, ATOMIC FORCE MICROSC; Oxley D., 2004, PURIFYING PROTEINS P, P579; Pierres A, 2001, BIOPHYS J, V81, P25, DOI 10.1016/S0006-3495(01)75677-9; Robbe C, 2004, BIOCHEM J, V384, P307, DOI 10.1042/BJ20040605; Robbe C, 2003, ELECTROPHORESIS, V24, P611, DOI 10.1002/elps.200390071; Robbe-Masselot C, 2009, GLYCOCONJUGATE J, V26, P397, DOI 10.1007/s10719-008-9186-9; Round AN, 2004, J STRUCT BIOL, V145, P246, DOI 10.1016/j.jsb.2003.10.029; Round AN, 2002, BIOPHYS J, V83, P1661, DOI 10.1016/S0006-3495(02)73934-9; Round AN, 2007, GLYCOBIOLOGY, V17, P578, DOI 10.1093/glycob/cwm027; Round AN, 2012, BIOMACROMOLECULES, V13, P3253, DOI 10.1021/bm301024x; Sharma V, 1998, GLYCOBIOLOGY, V8, P1007, DOI 10.1093/glycob/8.10.1007; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Sletmoen M, 2009, BIOPOLYMERS, V91, P719, DOI 10.1002/bip.21213; Wang YF, 2011, FEBS LETT, V585, P3927, DOI 10.1016/j.febslet.2011.10.035; Yakubov GE, 2007, BIOMACROMOLECULES, V8, P3791, DOI 10.1021/bm700721c; YAO K, 1989, ANAL BIOCHEM, V179, P332, DOI 10.1016/0003-2697(89)90138-3; Zhu R, 2010, NAT NANOTECHNOL, V5, P788, DOI 10.1038/nnano.2010.212; Znamenskaya Y, 2012, J PHYS CHEM B, V116, P5047, DOI 10.1021/jp212495t	45	25	25	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2342	2354		10.1096/fj.12-221416	http://dx.doi.org/10.1096/fj.12-221416			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23493619	hybrid, Green Published			2022-12-28	WOS:000319667600023
J	Annoura, T; van Schaijk, BCL; Ploemen, IHJ; Sajid, M; Lin, JW; Vos, MW; Dinmohamed, AG; Inaoka, DK; Rijpma, SR; van Gemert, GJ; Chevalley-Maurel, S; Kielbasa, SM; Scheltinga, F; Franke-Fayard, B; Klop, O; Hermsen, CC; Kita, K; Gego, A; Franetich, JF; Mazier, D; Hoffman, SL; Janse, CJ; Sauerwein, RW; Khan, SM				Annoura, Takeshi; van Schaijk, Ben C. L.; Ploemen, Ivo H. J.; Sajid, Mohammed; Lin, Jing-wen; Vos, Martijn W.; Dinmohamed, Avinash G.; Inaoka, Daniel K.; Rijpma, Sanna R.; van Gemert, Geert-Jan; Chevalley-Maurel, Severine; Kielbasa, Szymon M.; Scheltinga, Fay; Franke-Fayard, Blandine; Klop, Onny; Hermsen, Cornelus C.; Kita, Kiyoshi; Gego, Audrey; Franetich, Jean-Francois; Mazier, Dominique; Hoffman, Stephen L.; Janse, Chris J.; Sauerwein, Robert W.; Khan, Shahid M.			Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development	FASEB JOURNAL			English	Article						malaria; s48; 45; liver; genetically attenuated; B9	HIGH-EFFICIENCY TRANSFECTION; MALARIA PARASITE; FALCIPARUM; SPOROZOITES; SURFACE; IDENTIFICATION; HEPATOCYTES; ATTENUATION; SELECTION; PFS48/45	The 10 Plasmodium 6-Cys proteins have critical roles throughout parasite development and are targets for antimalaria vaccination strategies. We analyzed the conserved 6-cysteine domain of this family and show that only the last 4 positionally conserved cysteine residues are diagnostic for this domain and identified 4 additional 6-Cys family-related proteins. Two of these, sequestrin and B9, are critical to Plasmodium liver-stage development. RT-PCR and immunofluorescence assays show that B9 is translationally repressed in sporozoites and is expressed after hepatocyte invasion where it localizes to the parasite plasma membrane. Mutants lacking B9 expression in the rodent malaria parasites P. berghei and P. yoelii and the human parasite P. falciparum developmentally arrest in hepatocytes. P. berghei mutants arrest in the livers of BALB/c (100%) and C57BL6 mice (>99.9%), and in cultures of Huh7 human-hepatoma cell line. Similarly, P. falciparum mutants while fully infectious to primary human hepatocytes abort development 3 d after infection. This growth arrest is associated with a compromised parasitophorous vacuole membrane a phenotype similar to, but distinct from, mutants lacking the 6-Cys sporozoite proteins P52 and P36. Our results show that 6-Cys proteins have critical but distinct roles in establishment and maintenance of a parasitophorous vacuole and subsequent liver-stage developmentAnnoura, T., van Schaijk, B. C. L., Ploemen, I. H. J., Sajid, M., Lin, J.-W., Vos, M. W., Dinmohamed, A. G., Inaoka, D. K., Rijpma, S. R., van Gemert, G.-J., Chevalley-Maurel, S., Kiebasa, S. M., Scheltinga, F., Franke-Fayard, B., Klop, O. Hermsen, C. C., Kita, K., Gego, A., Franetich, J.-F., Mazier, D., Hoffman, S. L., Janse, C. J., Sauerwein, R. W., Khan, S. M. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development.	[Annoura, Takeshi; Sajid, Mohammed; Lin, Jing-wen; Dinmohamed, Avinash G.; Chevalley-Maurel, Severine; Franke-Fayard, Blandine; Klop, Onny; Janse, Chris J.; Khan, Shahid M.] Leiden Univ, Med Ctr, Dept Parasitol, Leiden Malaria Res Grp, NL-2333 ZA Leiden, Netherlands; [Kielbasa, Szymon M.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, NL-2333 ZA Leiden, Netherlands; [van Schaijk, Ben C. L.; Ploemen, Ivo H. J.; Vos, Martijn W.; van Gemert, Geert-Jan; Scheltinga, Fay; Hermsen, Cornelus C.; Sauerwein, Robert W.] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6525 ED Nijmegen, Netherlands; [Rijpma, Sanna R.] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, NL-6525 ED Nijmegen, Netherlands; [Inaoka, Daniel K.; Kita, Kiyoshi] Univ Tokyo, Grad Sch Med, Dept Biomed Chem, Tokyo, Japan; [Gego, Audrey; Franetich, Jean-Francois; Mazier, Dominique] INSERM, Paris, France; [Gego, Audrey; Franetich, Jean-Francois; Mazier, Dominique] Univ Paris 06, Paris, France; [Mazier, Dominique] Grp Hosp Pitie Salpetriere, AP HP, Serv Parasitol Mycol, F-75634 Paris, France; [Hoffman, Stephen L.] Sanaria Inc, Rockville, MD USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen; University of Tokyo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Sanaria Inc.	Khan, SM (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Leiden Malaria Res Grp, NL-2333 ZA Leiden, Netherlands.	s.m.khan@lumc.nl	Sauerwein, Robert/C-8519-2013; Kiełbasa, Szymon/G-1636-2018; Hermsen, C.C./L-4368-2015; Dinmohamed, Avinash/N-3648-2018; Inaoka, Daniel Ken/GMX-4344-2022; Rijpma, Sanna R./P-8720-2015; Franetich, Jean-François/GZA-9674-2022; Kiełbasa, Szymon M./K-2792-2019; Annoura, Takeshi/AAS-7911-2021	Kiełbasa, Szymon/0000-0003-2805-6535; Dinmohamed, Avinash/0000-0002-4767-6716; Inaoka, Daniel Ken/0000-0002-9791-927X; Rijpma, Sanna R./0000-0002-1593-424X; Kita, Kiyoshi/0000-0002-0426-4308; Janse, Chris J/0000-0002-6410-6205; Khan, Shahid/0000-0002-0533-4670; Lin, Jing-wen/0000-0003-3338-8788; , Blandine/0000-0001-6041-4182	Top Institute Pharma (Leiden, The Netherlands) [T4-102]	Top Institute Pharma (Leiden, The Netherlands)(Netherlands Government)	The authors thank Marga van de Vegte-Bolmer, Jolanda Klaassen, Astrid Pouwelsen, Laura Pelser-Posthumus, Jacqueline Kuhnen, Jai Ramesar, and Michel Mulder for excellent technical support. Confocal microscopy was performed at the Microscopic Imaging Centre (Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands). The authors thank Prof. Volker Heussler (Institute of Cell Biology, University of Bern, Bern, Switzerland), Prof. Kai Matuschewski (Max Planck Institute for Infection Biology, Berlin, Germany), Prof. Anthony A. Holder (Medical Research Council National Institute for Medical Research, Mill Hill, London, UK), Prof. Masao Yuda (Mie University, School of Medicine, Tsu, Japan), and Prof. Maria Mota (Insituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal) for kindly providing us with the anti-P. berghei antibodies against EXP1, UIS4, MSP1, CSP, and HSP70, respectively, and Dr. Ed Remarque (Biomedical Primate Research Centre, Rijswijk, The Netherlands) for the P. falciparum MSP1-19. This study was funded by Top Institute Pharma (Leiden, The Netherlands) project T4-102.	Annoura Takeshi, 2013, Methods Mol Biol, V923, P429; Annoura T, 2012, VACCINE, V30, P2662, DOI 10.1016/j.vaccine.2012.02.010; Arredondo SA, 2012, P NATL ACAD SCI USA, V109, P6692, DOI 10.1073/pnas.1204363109; CARTER R, 1995, MOL BIOCHEM PARASIT, V71, P203, DOI 10.1016/0166-6851(94)00054-Q; Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006; Ecker A, 2008, MOL MICROBIOL, V70, P209, DOI 10.1111/j.1365-2958.2008.06407.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548; Eswar N., 2007, CURR PROTOC PROTEIN, V50; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gerloff DL, 2005, P NATL ACAD SCI USA, V102, P13598, DOI 10.1073/pnas.0502378102; Gilson PR, 2006, MOL CELL PROTEOMICS, V5, P1286, DOI 10.1074/mcp.M600035-MCP200; Gomes-Santos CSS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002046; Graewe S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002224; GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Helm S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013653; Ifediba T, 1981, NATURE, V294, P364, DOI 10.1038/294364a0; Ishino T, 2005, MOL MICROBIOL, V58, P1264, DOI 10.1111/j.1365-2958.2005.04801.x; Janse CJ, 2006, NAT PROTOC, V1, P346, DOI 10.1038/nprot.2006.53; Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007; Kaiser K, 2003, J EXP MED, V197, P1045, DOI 10.1084/jem.20022100; Khan SM, 2012, CURR OPIN BIOTECH, V23, P908, DOI 10.1016/j.copbio.2012.04.003; Labaied M, 2007, INFECT IMMUN, V75, P3758, DOI 10.1128/IAI.00225-07; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lasonder E, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000195; Le Roch KG, 2004, GENOME RES, V14, P2308, DOI 10.1101/gr.2523904; Lin JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029289; Lindner SE, 2013, MOL CELL PROTEOMICS, V12, P1127, DOI 10.1074/mcp.M112.024505; Lingelbach K, 1998, J CELL SCI, V111, P1467; Mair GR, 2006, SCIENCE, V313, P667, DOI 10.1126/science.1125129; Mair GR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000767; Molina-Cruz A, 2013, SCIENCE, V340, P984, DOI 10.1126/science.1235264; Mueller AK, 2005, P NATL ACAD SCI USA, V102, P3022, DOI 10.1073/pnas.0408442102; Orito Y, 2013, MOL MICROBIOL, V87, P66, DOI 10.1111/mmi.12083; Plattner F, 2008, ANNU REV MICROBIOL, V62, P471, DOI 10.1146/annurev.micro.62.081307.162802; Ploemen IHJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050772; Ploemen IHJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007881; PONNUDURAI T, 1986, PARASITOLOGY, V93, P263, DOI 10.1017/S003118200005143X; Ramachandran S, 2011, PROTEINS, V79, P261, DOI 10.1002/prot.22879; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; RENIA L, 1988, J IMMUNOL METHODS, V112, P201, DOI 10.1016/0022-1759(88)90358-4; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; Sanders PR, 2005, J BIOL CHEM, V280, P40169, DOI 10.1074/jbc.M509631200; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; Sturm A, 2006, SCIENCE, V313, P1287, DOI 10.1126/science.1129720; Templeton TJ, 1999, MOL BIOCHEM PARASIT, V101, P223, DOI 10.1016/S0166-6851(99)00066-3; Thompson J, 2001, MOL BIOCHEM PARASIT, V118, P147, DOI 10.1016/S0166-6851(01)00377-2; Tonkin ML, 2013, J BIOL CHEM, V288, P12805, DOI 10.1074/jbc.M113.455667; van Dijk MR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000853; van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; van Schaijk BCL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015121; van Schaijk BCL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003549; VanBuskirk KM, 2009, P NATL ACAD SCI USA, V106, P13004, DOI 10.1073/pnas.0906387106; VERHAVE JP, 1988, PARASITE IMMUNOL, V10, P17, DOI 10.1111/j.1365-3024.1988.tb00200.x; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Zhang M, 2010, J EXP MED, V207, P1, DOI 10.1084/jem.20091975	59	57	58	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2158	2170		10.1096/fj.13-241570	http://dx.doi.org/10.1096/fj.13-241570			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24509910				2022-12-28	WOS:000335336000019
J	Hornburger, MC; Mayer, BA; Leonhardt, S; Willer, EA; Zahler, S; Beyerle, A; Rajalingam, K; Vollmar, AM; Furst, R				Hornburger, Michael C.; Mayer, Bettina A.; Leonhardt, Stefanie; Willer, Elisabeth A.; Zahler, Stefan; Beyerle, Andrea; Rajalingam, Krishnaraj; Vollmar, Angelika M.; Fuerst, Robert			A novel role for inhibitor of apoptosis (IAP) proteins as regulators of endothelial barrier function by mediating RhoA activation	FASEB JOURNAL			English	Article						inflammation; permeability; small RhoA GTPases	NF-KAPPA-B; ACUTE LUNG INJURY; CASPASE INHIBITION; CELL-MIGRATION; INFLAMMATION; CANCER; XIAP; MECHANISMS; THROMBIN; HYPERPERMEABILITY	Inhibitor of apoptosis (IAP) proteins, such as XIAP or cIAP1/2, are important regulators of apoptosis in cancer cells, and IAP antagonists are currently evaluated as antitumor agents. Beyond their function in cancer cells, this study demonstrates a novel role of IAPs as regulators of vascular endothelial permeability. Two structurally different IAP antagonists, ABT and Smac085, as well as silencing of IAPs, reduced the thrombin receptor-activating peptide (TRAP)-induced barrier dysfunction in human endothelial cells as assessed by measuring macromolecular permeability or transendothelial electrical resistance. ABT diminished thrombin-evoked stress fiber formation, activation of myosin light chain 2, and disassembly of adherens junctions independent of calcium signaling, protein kinase C, and mitogen-activated protein kinases. Interestingly, ABT and silencing of IAPs, in particular XIAP, reduced the TRAP-evoked RhoA activation, whereas Rac1 was not affected. XIAP and, to a lesser extent, cIAP1 were found to directly interact with RhoA independently of the RhoA activation status. Under cell-free conditions, XIAP did not induce an ubiquitination of RhoA. In summary, our work discloses IAPs as crucial regulators of endothelial permeability and suggests IAP inhibition as interesting approach for the prevention of endothelial barrier dysfunction.-Hornburger, M. C., Mayer, B. A., Leonhardt, S., Willer, E. A., Zahler, S., Beyerle, A., Rajalingam, K., Vollmar, A. M., Furst, R. A novel role for inhibitor of apoptosis (IAP) proteins as regulators of endothelial barrier function by mediating RhoA activation.	[Hornburger, Michael C.; Beyerle, Andrea; Fuerst, Robert] Goethe Univ Frankfurt, Inst Pharmaceut Biol, Bioctr, D-60438 Frankfurt, Germany; [Rajalingam, Krishnaraj] Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60438 Frankfurt, Germany; [Hornburger, Michael C.; Mayer, Bettina A.; Leonhardt, Stefanie; Willer, Elisabeth A.; Zahler, Stefan; Vollmar, Angelika M.] Univ Munich, Ctr Drug Res, Dept Pharm, Munich, Germany	Goethe University Frankfurt; Goethe University Frankfurt; University of Munich	Furst, R (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Biol, Bioctr, Max von Laue Str 9, D-60438 Frankfurt, Germany.	fuerst@em.uni-frankfurt.de		Furst, Robert/0000-0002-9926-7578; Zahler, Stefan/0000-0002-5140-7287				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Bubik MF, 2012, J MOL CELL CARDIOL, V52, P196, DOI 10.1016/j.yjmcc.2011.10.020; Damgaard RB, 2013, EMBO MOL MED, V5, P1278, DOI 10.1002/emmm.201303090; Feltham R, 2011, J BIOL CHEM, V286, P17015, DOI 10.1074/jbc.M111.222919; Foley JF, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003938; Furst R, 2008, MOL PHARMACOL, V74, P1, DOI 10.1124/mol.108.045773; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Kearney CJ, 2013, J BIOL CHEM, V288, P4878, DOI 10.1074/jbc.M112.422410; Kim KM, 2012, J CELL PHYSIOL, V227, P1701, DOI 10.1002/jcp.22894; Kipnis E, 2004, SHOCK, V21, P444, DOI 10.1097/00024382-200405000-00008; Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112; Lampugnani MG, 2007, THROMB RES, V120, pS1, DOI 10.1016/S0049-3848(07)70124-X; Liu JY, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176982; Mayer BA, 2011, ARTERIOSCL THROM VAS, V31, P2240, DOI 10.1161/ATVBAHA.111.234294; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Nakatani Y, 2013, BIOCHEM J, V450, P629, DOI 10.1042/BJ20121702; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Oberoi-Khanuja Tripat Kaur, 2012, Small GTPases, V3, P131, DOI 10.4161/sgtp.19988; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Vandenabeele P, 2012, NAT REV IMMUNOL, V12, P833, DOI 10.1038/nri3325; Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016; Varfolomeev E, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001878; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Welty-Wolf KE, 2002, THROMB HAEMOSTASIS, V88, P17; Willer EA, 2012, J MOL CELL CARDIOL, V53, P567, DOI 10.1016/j.yjmcc.2012.07.002	33	17	17	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1938	1946		10.1096/fj.13-235754	http://dx.doi.org/10.1096/fj.13-235754			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24371121				2022-12-28	WOS:000335344300037
J	Buffa, P; Romano, C; Pandini, A; Massimino, M; Tirro, E; Di Raimondo, F; Manzella, L; Fraternali, F; Vigneri, PG				Buffa, Pietro; Romano, Chiara; Pandini, Alessandro; Massimino, Michele; Tirro, Elena; Di Raimondo, Francesco; Manzella, Livia; Fraternali, Franca; Vigneri, Paolo G.			BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein	FASEB JOURNAL			English	Article						CML; molecular dynamics; mutations; resistance; TKIs	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; IMATINIB RESISTANCE; PHILADELPHIA-CHROMOSOME; DASATINIB BMS-354825; T315I MUTANT; C-ABL; MUTATION; AP24534; DOMAIN	Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen bonds with ponatinib. We therefore introduced mutations in each of these residues, either preserving or altering their physicochemical properties. We found that E286, M318, I360, and D381 are dispensable for ABL and BCR-ABL protein stability but are critical for preserving catalytic activity. Indeed, only a conservative I360T substitution retained kinase proficiency and transforming potential. Molecular dynamics simulations of BCR-ABL(I360T) revealed differences in both helix C dynamics and protein-correlated motions, consistent with a modified ATP-binding pocket. Nevertheless, this mutant remained sensitive to ponatinib, imatinib, and dasatinib. These results suggest that changes in the 4 BCR-ABL residues described here would be selected against by a lack of kinase activity or by maintained responsiveness to TKIs. Notably, amino acids equivalent to those identified in BCR-ABL are conserved in 51% of human tyrosine kinases. Hence, these residues may represent an appealing target for the design of pharmacological compounds that would inhibit additional oncogenic tyrosine kinases while avoiding the emergence of resistance due to point mutations.Buffa, P., Romano, C., Pandini. A., Massimino, M., Tirr, E., Di Raimondo, F., Manzella, L., Fraternali. F., Vigneri, P. G. BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.	[Buffa, Pietro; Pandini, Alessandro; Fraternali, Franca] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Romano, Chiara; Massimino, Michele; Tirro, Elena; Di Raimondo, Francesco; Manzella, Livia; Vigneri, Paolo G.] Univ Catania, Dept Clin & Mol Biomed, I-95124 Catania, Italy; [Vigneri, Paolo G.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy	University of London; King's College London; University of Catania; Istituto Superiore di Sanita (ISS)	Vigneri, PG (corresponding author), Univ Catania, Dept Clin & Mol Biomed, Via Androne 85, I-95124 Catania, Italy.	franca.fraternali@kcl.ac.uk; pvigneri@libero.it	Fraternali, Franca/D-4410-2011; Tirrò, Elena/AAQ-8085-2020; VIGNERI, Paolo/K-8504-2016; Di Raimondo, Francesco/K-7965-2016; Pandini, Alessandro/F-9854-2012; Fraternali, Franca/C-8912-2009	Tirrò, Elena/0000-0001-8012-5134; VIGNERI, Paolo/0000-0002-5943-6066; Massimino, Michele/0000-0001-5896-8573; Romano, Chiara/0000-0002-2586-8266; Di Raimondo, Francesco/0000-0002-7749-0293; Pandini, Alessandro/0000-0002-4158-233X; MANZELLA, Livia/0000-0002-9908-6443; Fraternali, Franca/0000-0002-3143-6574	Associazione Italiana per la Ricerca sul Cancro (AIRC); Biotechnology and Biological Sciences Research Council [BB/I023291/1, BB/H018409/1]; AIRC-Marie Curie fellowship; BBSRC [BB/H018409/1, BB/I023291/1] Funding Source: UKRI	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); AIRC-Marie Curie fellowship(Fondazione AIRC per la ricerca sul cancro); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Maria Stella Pennisi, Stefania Stella, and Silvia Rita Vitale for critical reading of the manuscript. This work was supported by an investigator grant to P.G.V. from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and by funding from the Biotechnology and Biological Sciences Research Council (BB/I023291/1 and BB/H018409/1 to A.P. and F.F.). P.B. is the recipient of an AIRC-Marie Curie fellowship.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Aleksandrov A, 2010, J BIOL CHEM, V285, P13807, DOI 10.1074/jbc.M110.109660; Aloisi A, 2006, BLOOD, V107, P1591, DOI 10.1182/blood-2005-05-2123; Apperley JF, 2007, LANCET ONCOL, V8, P1018, DOI 10.1016/S1470-2045(07)70342-X; Azam M, 2008, NAT STRUCT MOL BIOL, V15, P1109, DOI 10.1038/nsmb.1486; Baccarani M, 2009, J CLIN ONCOL, V27, P6041, DOI 10.1200/JCO.2009.25.0779; Barf T, 2012, J MED CHEM, V55, P6243, DOI 10.1021/jm3003203; Barrett CP, 2004, ACTA CRYSTALLOGR D, V60, P2280, DOI 10.1107/S0907444904019171; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Cortes J, 2009, BLOOD, V114, P267; Cortes JE, 2012, NEW ENGL J MED, V367, P2075, DOI 10.1056/NEJMoa1205127; Cowan-Jacob SW, 2007, ACTA CRYSTALLOGR D, V63, P80, DOI 10.1107/S0907444906047287; De Falco V, 2013, J CLIN ENDOCR METAB, V98, pE811, DOI 10.1210/jc.2012-2672; Dixit A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002179; Dixit A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000487; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Ernst T, 2012, SEMIN ONCOL, V39, P58, DOI 10.1053/j.seminoncol.2011.11.002; Gibbons DL, 2012, CANCER-AM CANCER SOC, V118, P293, DOI 10.1002/cncr.26225; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; Guo T, 2007, CLIN CANCER RES, V13, P4874, DOI 10.1158/1078-0432.CCR-07-0484; Huang WS, 2010, J MED CHEM, V53, P4701, DOI 10.1021/jm100395q; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jabbour E, 2012, AM J HEMATOL, V87, P1038, DOI 10.1002/ajh.23282; Jabbour E, 2011, CANCER-AM CANCER SOC, V117, P1800, DOI 10.1002/cncr.25717; Jabbour E, 2009, BLOOD, V114, P2037, DOI 10.1182/blood-2009-01-197715; Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kantarjian HM, 2006, ANN INTERN MED, V145, P913, DOI 10.7326/0003-4819-145-12-200612190-00008; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lee TS, 2008, CANCER-AM CANCER SOC, V112, P1744, DOI 10.1002/cncr.23355; Lee TS, 2009, RECENT PAT ANTI-CANC, V4, P164, DOI 10.2174/157489209788452867; Lee TS, 2008, MOL CANCER THER, V7, P3834, DOI 10.1158/1535-7163.MCT-08-0482; Levinson NM, 2006, PLOS BIOL, V4, P753, DOI 10.1371/journal.pbio.0040144; Lin YL, 2013, P NATL ACAD SCI USA, V110, P1664, DOI 10.1073/pnas.1214330110; Lovera S, 2012, J AM CHEM SOC, V134, P2496, DOI 10.1021/ja210751t; Manley PW, 2002, EUR J CANCER, V38, pS19, DOI 10.1016/S0959-8049(02)80599-8; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Nagar B, 2002, CANCER RES, V62, P4236; Nicolini FE, 2013, HAEMATOLOGICA, V98, P1510, DOI 10.3324/haematol.2012.080234; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028; Pandini A, 2012, FASEB J, V26, P868, DOI 10.1096/fj.11-190868; Preyer M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017020; Pricl S, 2005, MOL CANCER THER, V4, P1167, DOI 10.1158/1535-7163.MCT-05-0101; Quintas-Cardama A, 2008, CLIN CANCER RES, V14, P4392, DOI 10.1158/1078-0432.CCR-08-0117; Quintas-Cardama A, 2009, NAT REV CLIN ONCOL, V6, P535, DOI 10.1038/nrclinonc.2009.112; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shah Neil P, 2011, Clin Adv Hematol Oncol, V9, P925; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shan YB, 2009, P NATL ACAD SCI USA, V106, P139, DOI 10.1073/pnas.0811223106; Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938; Steinbrecher T, 2012, J CHEM THEORY COMPUT, V8, P4405, DOI 10.1021/ct300613v; Tokarski JS, 2006, CANCER RES, V66, P5790, DOI 10.1158/0008-5472.CAN-05-4187; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Verkhivker GA, 2007, BIOPOLYMERS, V85, P333, DOI 10.1002/bip.20656; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Zhou TJ, 2007, CHEM BIOL DRUG DES, V70, P171, DOI 10.1111/j.1747-0285.2007.00556.x; Zhou TJ, 2011, CHEM BIOL DRUG DES, V77, P1, DOI 10.1111/j.1747-0285.2010.01054.x	67	26	26	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1221	1236		10.1096/fj.13-236992	http://dx.doi.org/10.1096/fj.13-236992			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24297701	Green Submitted			2022-12-28	WOS:000335324800017
J	Pushpavalli, SNCVL; Sarkar, A; Bag, I; Hunt, CR; Ramaiah, MJ; Pandita, TK; Bhadra, U; Pal-Bhadra, M				Pushpavalli, Sreerangam N. C. V. L.; Sarkar, Arpita; Bag, Indira; Hunt, Clayton R.; Ramaiah, M. Janaki; Pandita, Tej K.; Bhadra, Utpal; Pal-Bhadra, Manika			Argonaute-1 functions as a mitotic regulator by controlling Cyclin B during Drosophila early embryogenesis	FASEB JOURNAL			English	Article						p53; miR-317; grp; cdk1; Ago-1	RNA INTERFERENCE; GENE; DNA; MITOSIS; HETEROCHROMATIN; LOCALIZATION; INACTIVATION; MICROTUBULE; BIOGENESIS; DIVISION	The role of Ago-1 in microRNA (miRNA) biogenesis has been thoroughly studied, but little is known about its involvement in mitotic cell cycle progression. In this study, we established evidence of the regulatory role of Ago-1 in cell cycle control in association with the G(2)/M cyclin, cyclin B. Immunostaining of early embryos revealed that the maternal effect gene Ago-1 is essential for proper chromosome segregation, mitotic cell division, and spindle fiber assembly during early embryonic development. Ago-1 mutation resulted in the up-regulation of cyclin B-Cdk1 activity and down-regulation of p53, grp, mei-41, and wee1. The increased expression of cyclin B in Ago-1 mutants caused less stable microtubules and probably does not produce enough force to push the nuclei to the cortex, resulting in a decreased number of pole cells. The role of cyclin B in mitotic defects was further confirmed by suppressing the defects in the presence of one mutant copy of cyclin B. We identified involvement of 2 novel embryonic miRNAsmiR-981 and miR-317for spatiotemporal regulation of cyclin B. In summary, our results demonstrate that the haploinsufficiency of maternal Ago-1 disrupts mitotic chromosome segregation and spindle fiber assembly via miRNA-guided control during early embryogenesis in Drosophila. The increased expression of cyclin B-Cdk1 and decreased activity of the Cdk1 inhibitor and cell cycle checkpoint proteins (mei-41 and grp) in Ago-1 mutant embryos allow the nuclei to enter into mitosis prematurely, even before completion of DNA replication. Thus, our results have established a novel role of Ago-1 as a regulator of the cell cycle.Pushpavalli, S. N. C. V. L., Sarkar, A., Bag, I., Hunt C. R., Ramaiah, M. J., Pandita, T. K., Bhadra, U., Pal-Bhadra, M. Argonaute-1 functions as a mitotic regulator by controlling Cyclin B during Drosophila early embryogenesis.	[Pushpavalli, Sreerangam N. C. V. L.; Bhadra, Utpal] Ctr Cellular & Mol Biol, Funct Genom & Gene Silencing Grp, Hyderabad 500007, Andhra Pradesh, India; [Pushpavalli, Sreerangam N. C. V. L.; Sarkar, Arpita; Bag, Indira; Ramaiah, M. Janaki; Pal-Bhadra, Manika] Indian Inst Chem Technol, Ctr Chem Biol, Hyderabad 500607, Andhra Pradesh, India; [Hunt, Clayton R.; Pandita, Tej K.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); University of Texas System; University of Texas Southwestern Medical Center Dallas	Pal-Bhadra, M (corresponding author), Indian Inst Chem Technol, Ctr Chem Biol, Uppal Rd, Hyderabad 500607, Andhra Pradesh, India.	manikapb@gmail.com	RAMAIAH, JANAKI/AAL-9074-2020; Pandita, Tej K/AAM-9188-2020	Ramaiah, Janaki/0000-0003-1814-2819; Sarkar, Arpita/0000-0001-5061-2505	Wellcome Trust (UK) [GAP 0158, GAP0065]; India Department of Biotechnology (DBT) [GAP326]; NATIONAL CANCER INSTITUTE [R01CA154320, R01CA129537] Funding Source: NIH RePORTER	Wellcome Trust (UK)(Wellcome Trust); India Department of Biotechnology (DBT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Jim Birchler (University of Missouri, Columbia, MO, USA, W. E. Theurkauf (State University of New York, Stony Brook, NY, USA), G. Cavalli (Institute of Human Genetics, Montpellier, France), Stephen Cohen (European Molecular Biology Laboratory, Heidelberg, Germany) for the fly stocks, J. Raff (University of Cambridge, Cambridge, UK) for the centrosomin antibody, and P. Devender for maintenance of Drosophila culture. This work was supported by Wellcome Trust (UK) grants GAP 0158 to M.B.P. and GAP0065 to U.B. and by India Department of Biotechnology (DBT) grant GAP326 to M.B.P.	Azzam G, 2012, DEV BIOL, V365, P384, DOI 10.1016/j.ydbio.2012.03.005; Boutla A, 2003, NUCLEIC ACIDS RES, V31, P4973, DOI 10.1093/nar/gkg707; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chivukula RR, 2008, TRENDS BIOCHEM SCI, V33, P474, DOI 10.1016/j.tibs.2008.06.008; Czech B, 2009, MOL CELL, V36, P445, DOI 10.1016/j.molcel.2009.09.028; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Deshpande G, 2005, GENE DEV, V19, P1680, DOI 10.1101/gad.1316805; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; Durand-Dubief M, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-2; Easow G, 2007, RNA, V13, P1198, DOI 10.1261/rna.563707; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Huang V, 2012, NUCLEIC ACIDS RES, V40, P1695, DOI 10.1093/nar/gkr934; Ji JY, 2002, GENETICS, V162, P1179; Kataoka Y, 2001, GENES CELLS, V6, P313, DOI 10.1046/j.1365-2443.2001.00427.x; Kellogg DR, 2003, J CELL SCI, V116, P4883, DOI 10.1242/jcs.00908; Koesters R, 1999, GENOMICS, V61, P210, DOI 10.1006/geno.1999.5951; Lennox KA, 2011, GENE THER, V18, P1111, DOI 10.1038/gt.2011.100; Li XM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000876; O'Dor E, 2006, DEV BIOL, V290, P312, DOI 10.1016/j.ydbio.2005.11.015; O'Farrell PH, 2004, CURR BIOL, V14, pR35, DOI 10.1016/j.cub.2003.12.022; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Price D, 2000, GENETICS, V155, P159; Pushpavalli SNCVL, 2012, CHROMOSOME RES, V20, P333, DOI 10.1007/s10577-012-9279-y; Ruby JG, 2007, GENOME RES, V17, P1850, DOI 10.1101/gr.6597907; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Stiffler LA, 1999, DEVELOPMENT, V126, P5505; Stoica C, 2006, J BIOL CHEM, V281, P37646, DOI 10.1074/jbc.M604476200; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; SULLIVAN W, 1993, MOL BIOL CELL, V4, P885, DOI 10.1091/mbc.4.9.885; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tram U., 2002, ENCY LIFE SCI; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yang LL, 2007, DEVELOPMENT, V134, P4265, DOI 10.1242/dev.009159; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	43	23	24	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					655	666		10.1096/fj.13-231167	http://dx.doi.org/10.1096/fj.13-231167			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24165481	Green Published			2022-12-28	WOS:000331072200013
J	Lamming, DW; Demirkan, G; Boylan, JM; Mihaylova, MM; Peng, T; Ferreira, J; Neretti, N; Salomon, A; Sabatini, DM; Gruppuso, PA				Lamming, Dudley W.; Demirkan, Gokhan; Boylan, Joan M.; Mihaylova, Maria M.; Peng, Tao; Ferreira, Jonathan; Neretti, Nicola; Salomon, Arthur; Sabatini, David M.; Gruppuso, Philip A.			Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2)	FASEB JOURNAL			English	Article						gene expression; proteomics; liver; metabolism; signal transduction	EXTENDS LIFE-SPAN; PHOSPHORYLATION; INHIBITION; EXPRESSION; LIVER; P38; IDENTIFICATION; STIMULATION; GLUCOKINASE; LIPOGENESIS	The mechanistic target of rapamycin (mTOR) exists in two complexes that regulate diverse cellular processes. mTOR complex 1 (mTORC1), the canonical target of rapamycin, has been well studied, whereas the physiological role of mTORC2 remains relatively uncharacterized. In mice in which the mTORC2 component Rictor is deleted in liver [Rictor-knockout (RKO) mice], we used genomic and phosphoproteomic analyses to characterize the role of hepatic mTORC2 in vivo. Overnight food withdrawal followed by refeeding was used to activate mTOR signaling. Rapamycin was administered before refeeding to specify mTORC2-mediated events. Hepatic mTORC2 regulated a complex gene expression and post-translational network that affects intermediary metabolism, ribosomal biogenesis, and proteasomal biogenesis. Nearly all changes in genes related to intermediary metabolic regulation were replicated in cultured fetal hepatocytes, indicating a cell-autonomous effect of mTORC2 signaling. Phosphoproteomic profiling identified mTORC2-related signaling to 144 proteins, among which were metabolic enzymes and regulators. A reduction of p38 MAPK signaling in the RKO mice represents a link between our phosphoproteomic and gene expression results. We conclude that hepatic mTORC2 exerts a broad spectrum of biological effects under physiological conditions. Our findings provide a context for the development of targeted therapies to modulate mTORC2 signaling.Lamming, D. W., Demirkan, G., Boylan, J. M., Mihaylova, M. M., Peng, T., Ferreira, J., Neretti, N., Salomon, A., Sabatini, D. M., Gruppuso, P. A. Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2).	[Lamming, Dudley W.; Mihaylova, Maria M.; Peng, Tao; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Lamming, Dudley W.; Mihaylova, Maria M.; Peng, Tao; Sabatini, David M.] MIT, Dept Biol, Cambridge, MA USA; [Lamming, Dudley W.; Mihaylova, Maria M.; Peng, Tao; Sabatini, David M.] MIT, Howard Hughes Med Inst, Cambridge, MA USA; [Lamming, Dudley W.; Mihaylova, Maria M.; Peng, Tao; Sabatini, David M.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Lamming, Dudley W.; Mihaylova, Maria M.; Peng, Tao; Sabatini, David M.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Demirkan, Gokhan; Ferreira, Jonathan; Neretti, Nicola; Salomon, Arthur; Gruppuso, Philip A.] Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA; [Boylan, Joan M.; Gruppuso, Philip A.] Brown Univ, Dept Pediat, Providence, RI 02912 USA; [Demirkan, Gokhan; Boylan, Joan M.; Gruppuso, Philip A.] Brown Univ, Rhode Isl Hosp, Dept Pediat, Providence, RI 02903 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Brown University; Brown University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Div Pediat Endocrinol, 593 Eddy St, Providence, RI 02903 USA.	philip_gruppuso@brown.edu	Mihaylova, Maria M./ACZ-4949-2022; Lamming, Dudley/O-7191-2015	Mihaylova, Maria M./0000-0002-2725-767X; Lamming, Dudley/0000-0002-0079-4467; /0000-0002-1446-7256; Neretti, Nicola/0000-0002-9552-1663	NIH [AG041765]; Damon Runyon Foundation; Julie Martin Mid-Career Award in Aging Research from the American Federation of Aging Research (AFAR); U.S. National Institute on Aging (NIA) [R01 AI083636]; U.S. National Institutes of Health (NIH)/NIA [K25 AG028753]; U.S. National Institute of Child Health and Human Development (NICHD) [R01 HD024455]; NSF/EPSCoR [1004057]; Rhode Island Science and Technology Advisory Council grant; Division of Biology and Medicine at Brown University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR020923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R00AG041765, K25AG028753, K99AG041765] Funding Source: NIH RePORTER; Office Of The Director [1004057] Funding Source: National Science Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Foundation; Julie Martin Mid-Career Award in Aging Research from the American Federation of Aging Research (AFAR); U.S. National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); U.S. National Institutes of Health (NIH)/NIA; U.S. National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NSF/EPSCoR; Rhode Island Science and Technology Advisory Council grant; Division of Biology and Medicine at Brown University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Office Of The Director(National Science Foundation (NSF)NSF - Office of the Director (OD))	The authors thank all the members of the D. M. S. and P. A. G. laboratories for their insightful comments and suggestions. The XBP1 S61 antibody was the kind gift of Umut Ozcan (Boston Children's Hospital, Boston, MA, USA), and the XBP1 and MKK4 antibodies were the kind gifts of Yuxiong Feng and Sandhya Sanduja (laboratory of Piyush Gupta, Whitehead Institute, Cambridge, MA, USA). The total STAT1 antibody was the kind gift of Christine Patterson (laboratory of Harvey Lodish, Whitehead Institute). The Rictor conditional-knockout mice were the generous gift of Mark Magnuson (Vanderbilt University Medical Center, Nashville, TN, USA). The authors thank Tom DiCesare (Whitehead Institute, Cambridge, MA, USA) for assistance with graphic design. D. W. L. is supported by an NIH K99/R00 Pathway to Independence Award (AG041765). M. M. is supported by a fellowship from the Damon Runyon Foundation. This project was funded in part by a Julie Martin Mid-Career Award in Aging Research from the American Federation of Aging Research (AFAR) to D. M. S., by U.S. National Institute on Aging (NIA) grant R01 AI083636 to A. S., by a Mentored Quantitative Research Development Award from the U.S. National Institutes of Health (NIH)/NIA K25 AG028753 to N.N., and by U.S. National Institute of Child Health and Human Development (NICHD) grant R01 HD024455 to P. A. G. This research is based in part on work conducted in the Rhode Island National Science Foundation (NSF)/Experimental Program to Stimulate Competitive Research (EPSCoR) Proteomics Shared Resource Facility, which is supported in part by NSF/EPSCoR grant 1004057, NIH grant S10 RR020923, a Rhode Island Science and Technology Advisory Council grant, and the Division of Biology and Medicine at Brown University. D. M. S. is an investigator at the Howard Hughes Medical Institute.	Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Beausoleil SA, 2006, NAT BIOTECHNOL, V24, P1285, DOI 10.1038/nbt1240; Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cho KW, 2011, MOL CELL BIOL, V31, P450, DOI 10.1128/MCB.00459-10; Chun J, 2003, J BIOCHEM, V133, P103, DOI 10.1093/jb/mvg010; Clavel S, 2010, MOL CELL BIOL, V30, P470, DOI 10.1128/MCB.00666-09; Cohen SE, 2007, J BIOL CHEM, V282, P23672, DOI 10.1074/jbc.M704053200; Crespo JL, 2005, PLANT PHYSIOL, V139, P1736, DOI 10.1104/pp.105.070847; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Demirkan G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021729; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Elias JE, 2010, METHODS MOL BIOL, V604, P55, DOI 10.1007/978-1-60761-444-9_5; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Festuccia WT, 2010, AM J PHYSIOL-REG I, V299, pR159, DOI 10.1152/ajpregu.00821.2009; Ficarro SB, 2005, RAPID COMMUN MASS SP, V19, P57, DOI 10.1002/rcm.1746; Giubellino A, 2013, ENDOCRINOLOGY, V154, P646, DOI 10.1210/en.2012-1854; Gruppuso PA, 2011, CELL CYCLE, V10, P1050, DOI 10.4161/cc.10.7.15230; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Haeusler RA, 2010, J BIOL CHEM, V285, P35245, DOI 10.1074/jbc.C110.175851; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Hu HY, 2007, GENOMICS, V90, P421, DOI 10.1016/j.ygeno.2007.07.003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135; Laplante M, 2006, DIABETES, V55, P2771, DOI 10.2337/db06-0551; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee J, 2011, NAT MED, V17, P1251, DOI 10.1038/nm.2449; Mihaylova MM, 2011, CELL, V145, P607, DOI 10.1016/j.cell.2011.03.043; Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586; Payne VA, 2005, DIABETES, V54, P1949, DOI 10.2337/diabetes.54.7.1949; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Robida-Stubbs S, 2012, CELL METAB, V15, P713, DOI 10.1016/j.cmet.2012.04.007; Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; Steinbaugh MJ, 2012, AM J PHYSIOL-ENDOC M, V303, pE488, DOI 10.1152/ajpendo.00110.2012; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Tonner P, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-412; Willems L, 2012, LEUKEMIA, V26, P1195, DOI 10.1038/leu.2011.339; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Yu KB, 2010, PROTEOMICS, V10, P2113, DOI 10.1002/pmic.200900159; Yuan MS, 2012, J BIOL CHEM, V287, P29579, DOI 10.1074/jbc.M112.386854; Zhang YX, 2008, HEPATOLOGY, V48, P289, DOI 10.1002/hep.22342; Zhou HY, 2012, CHIN J CANCER, V31, P8, DOI 10.5732/cjc.011.10281	51	60	61	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					300	315		10.1096/fj.13-237743	http://dx.doi.org/10.1096/fj.13-237743			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24072782	Green Published			2022-12-28	WOS:000333526100029
J	Xu, Y; Her, CT				Xu, Yang; Her, Chengtao			VBP1 facilitates proteasome and autophagy-mediated degradation of MutS homologue hMSH4	FASEB JOURNAL			English	Article						ubiquitination; VHL; p97; DSB repair	VON-HIPPEL-LINDAU; CEREVISIAE MSH5 GENE; DOUBLE-STRAND BREAKS; DNA MISMATCH-REPAIR; MAMMALIAN MEIOSIS; AAA-ATPASE; UBIQUITIN LIGASES; BINDING-PROTEIN; CROSSING-OVER; COMPLEX	Ubiquitination is an important mechanism for the regulation of diverse cellular functions, including proteolysis and DNA repair. The human MutS family protein hMSH4 functions in meiotic recombinational DNA double-strand break (DSB) repair. It was previously observed that hMSH4 interacts with the von Hippel-Lindau binding protein 1 (VBP1), a partner of the VHL ubiquitin E3 ligase as well as a subunit of the prefoldin complex. In this study we address how ubiquitination regulates the homeostasis of hMSH4 in the human embryonic kidney cell line HEK293T. We demonstrate that VBP1 targets hMSH4 for degradation and identify a new VBP1 binding partner, p97, an AAA(+) ATPase involved in protein degradation and DNA damage response. VBP1, VHL, and p97 coexist in the hMSH4 immunocomplex and regulate the polyubiquitination of hMSH4. Furthermore, the results of this study demonstrate that VBP1 acts together with p97 to regulate hMSH4 degradation. Overall, this study has revealed a molecular mechanism by which VBP1 controls the levels of hMSH4 by ubiquitination in mitotic cells. Such a mechanism may be important for controlling the role of hMSH4 in regulating homologous recombination and nonhomologous DNA end joining-mediated DSB repair in human cells.	[Xu, Yang; Her, Chengtao] Washington State Univ, Coll Vet Med, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Her, CT (corresponding author), Washington State Univ, Coll Vet Med, Sch Mol Biosci, Mail Drop 64-7520, Pullman, WA 99164 USA.	cher@wsu.edu	Xu, Yang/H-6154-2013		U.S. Public Health Service from the U.S. National Institute of General Medical Sciences [GM084353]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084353] Funding Source: NIH RePORTER	U.S. Public Health Service from the U.S. National Institute of General Medical Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank K.-L. Lim (National Neuroscience Institute, Singapore), K. Ramadan (University of Zurich-Vetsuisse, Zurich, Switzerland), and M. Matsumoto (Kyushu University, Fukuoka, Japan) for providing reagents, L. Chu for preparation of the HEK293T whole-cell extracts, and other members of the C. H. laboratory for helpful discussions. This work was supported in part by U.S. Public Health Service grant GM084353 (C. H.) from the U.S. National Institute of General Medical Sciences.	Acs K, 2011, NAT STRUCT MOL BIOL, V18, P1345, DOI 10.1038/nsmb.2188; Alexandru G, 2008, CELL, V134, P804, DOI 10.1016/j.cell.2008.06.048; Bocher T, 1999, CANCER RES, V59, P816; Brinke A, 1997, GENOMICS, V45, P105, DOI 10.1006/geno.1997.4902; Chu YL, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-51; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Delgehyr N, 2012, P NATL ACAD SCI USA, V109, P5729, DOI 10.1073/pnas.1108537109; den Besten W, 2012, NAT STRUCT MOL BIOL, V19, P511, DOI 10.1038/nsmb.2269; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Franz A, 2011, MOL CELL, V44, P85, DOI 10.1016/j.molcel.2011.08.028; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Handel MA, 2010, NAT REV GENET, V11, P124, DOI 10.1038/nrg2723; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Her C, 1998, GENOMICS, V52, P50, DOI 10.1006/geno.1998.5374; Her C, 2003, CANCER RES, V63, P865; Her C, 2007, FRONT BIOSCI-LANDMRK, V12, P905, DOI 10.2741/2112; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hotton SK, 2008, ANNU REV PLANT BIOL, V59, P467, DOI 10.1146/annurev.arplant.58.032806.104011; Hua ZH, 2011, ANNU REV PLANT BIOL, V62, P299, DOI 10.1146/annurev-arplant-042809-112256; Jentsch S, 2007, TRENDS BIOCHEM SCI, V32, P6, DOI 10.1016/j.tibs.2006.11.005; Jin LY, 2008, CELL, V133, P653, DOI 10.1016/j.cell.2008.04.012; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020; Kneitz B, 2000, GENE DEV, V14, P1085; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Lee TH, 2006, DNA REPAIR, V5, P32, DOI 10.1016/j.dnarep.2005.07.004; Lenzi ML, 2005, AM J HUM GENET, V76, P112, DOI 10.1086/427268; Lim KL, 2011, NEUROBIOL DIS, V43, P9, DOI 10.1016/j.nbd.2010.08.001; Long J, 2008, J BIOL CHEM, V283, P5427, DOI 10.1074/jbc.M704973200; McClellan AJ, 2005, CELL, V121, P739, DOI 10.1016/j.cell.2005.03.024; Meerang M, 2011, NAT CELL BIOL, V13, P1376, DOI 10.1038/ncb2367; Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407; Miyazawa M, 2011, J BIOL CHEM, V286, P19191, DOI 10.1074/jbc.M110.216259; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mousnier A, 2007, P NATL ACAD SCI USA, V104, P13615, DOI 10.1073/pnas.0705162104; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Neyton S, 2004, MOL HUM REPROD, V10, P917, DOI 10.1093/molehr/gah123; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; Raman M, 2011, MOL CELL, V44, P72, DOI 10.1016/j.molcel.2011.06.036; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Saeki Y, 2009, EMBO J, V28, P359, DOI 10.1038/emboj.2008.305; Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386; Santucci-Darmanin S, 2000, FASEB J, V14, P1539, DOI 10.1096/fj.14.11.1539; Santucci-Darmanin S, 2002, HUM MOL GENET, V11, P1697, DOI 10.1093/hmg/11.15.1697; Snowden T, 2004, MOL CELL, V15, P437, DOI 10.1016/j.molcel.2004.06.040; Snowden T, 2008, J BIOL CHEM, V283, P145, DOI 10.1074/jbc.M704060200; Tan JMM, 2008, HUM MOL GENET, V17, P431, DOI 10.1093/hmg/ddm320; Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014; Tsuchiya H, 1996, CANCER RES, V56, P2881; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Vo AT, 2005, EMBO REP, V6, P438, DOI 10.1038/sj.embor.7400392; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; Wooten MW, 2008, J BIOL CHEM, V283, P6783, DOI 10.1074/jbc.M709496200; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2006, J STRUCT BIOL, V156, P29, DOI 10.1016/j.jsb.2006.01.005; Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780; Yi W, 2005, BIOCHEM BIOPH RES CO, V332, P524, DOI 10.1016/j.bbrc.2005.04.154; Zalevsky J, 1999, GENETICS, V153, P1271	65	14	14	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4799	4810		10.1096/fj.13-235127	http://dx.doi.org/10.1096/fj.13-235127			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964080	Green Published			2022-12-28	WOS:000329999000015
J	Verollet, C; Gallois, A; Dacquin, R; Lastrucci, C; Pandruvada, SNM; Ortega, N; Poincloux, R; Behar, A; Cougoule, C; Lowell, C; Al Saati, T; Jurdic, P; Maridonneau-Parini, I				Verollet, Christel; Gallois, Anne; Dacquin, Romain; Lastrucci, Claire; Pandruvada, Subramanya N. M.; Ortega, Nathalie; Poincloux, Renaud; Behar, Annie; Cougoule, Celine; Lowell, Clifford; Al Saati, Talal; Jurdic, Pierre; Maridonneau-Parini, Isabelle			Hck contributes to bone homeostasis by controlling the recruitment of osteoclast precursors	FASEB JOURNAL			English	Article						osteopetrosis; cell migration; podosomes; Src tyrosine kinases	PROTEIN-TYROSINE KINASE; 3-DIMENSIONAL MIGRATION; ACTIN REORGANIZATION; MACROPHAGE FUSION; GENE HCK; SRC; PODOSOME; EXPRESSION; DIFFERENTIATION; OSTEOPETROSIS	In osteoclasts, Src controls podosome organization and bone degradation, which leads to an osteopetrotic phenotype in src(-/-) mice. Since this phenotype was even more severe in src(-/-)hck(-/-) mice, we examined the individual contribution of Hck in bone homeostasis. Compared to wt mice, hck(-/-) mice exhibited an osteopetrotic phenotype characterized by an increased density of trabecular bone and decreased bone degradation, although osteoclastogenesis was not impaired. Podosome organization and matrix degradation were found to be defective in hck(-/-) osteoclast precursors (preosteoclast) but were normal in mature hck(-/-) osteoclasts, probably through compensation by Src, which was specifically overexpressed in mature osteoclasts. As a consequence of podosome defects, the 3-dimensional migration of hck(-/-) preosteoclasts was strongly affected in vitro. In vivo, this translated by altered bone homing of preosteoclasts in hck(-/-) mice: in metatarsals of 1-wk-old mice, when bone formation strongly depends on the recruitment of these cells, reduced numbers of osteoclasts and abnormal developing trabecular bone were observed. This phenotype was still detectable in adults. In summmary, Hck is one of the very few effectors of preosteoclast recruitment described to date and thereby plays a critical role in bone remodeling.Verollet, C., Gallois, A., Dacquin, R., Lastrucci, C., Pandruvada, S. M. N., Ortega, N., Poincloux, R., Behar, A., Cougoule, C., Lowell, C., Al Saati, T., Jurdic, P., Maridonneau-Parini, I. Hck contributes to bone homeostasis by controlling the recruitment of osteoclast precursors.	[Verollet, Christel; Lastrucci, Claire; Ortega, Nathalie; Poincloux, Renaud; Behar, Annie; Cougoule, Celine; Maridonneau-Parini, Isabelle] IPBS, UMR 5089, CNRS, Toulouse, France; [Verollet, Christel; Lastrucci, Claire; Ortega, Nathalie; Poincloux, Renaud; Behar, Annie; Cougoule, Celine; Maridonneau-Parini, Isabelle] Univ Toulouse, F-31077 Toulouse, France; [Verollet, Christel; Lastrucci, Claire; Ortega, Nathalie; Poincloux, Renaud; Behar, Annie; Cougoule, Celine; Maridonneau-Parini, Isabelle] UPS, Toulouse, France; [Gallois, Anne] NYU, Inst Canc, Langone Med Ctr, New York, NY USA; [Dacquin, Romain; Pandruvada, Subramanya N. M.; Jurdic, Pierre] Univ Lyon 1, UMR 5242, Inst Genom Fonct Lyon, Lyon, France; [Dacquin, Romain; Pandruvada, Subramanya N. M.; Jurdic, Pierre] Ecole Normale Super Lyon, CNRS, F-69364 Lyon, France; [Lowell, Clifford] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Al Saati, Talal] CHU Purpan, Unite Inst Natl Sante & Rech Med INSERM, CREFRE, UPS,US006,Serv Histopathol, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; New York University; NYU Langone Medical Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); University of California System; University of California San Francisco; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Maridonneau-Parini, I (corresponding author), Univ Toulouse, UPS, IPBS, F-31077 Toulouse, France.	isabelle.maridonneau-parini@ipbs.fr	Poincloux, Renaud/AAD-4746-2019; pandruvada, subramanya/AAA-3072-2019; COUGOULE, Céline/ABB-4180-2021; Ortega, Nathalie/C-3382-2019; Pandruvada, Subramanya/E-4373-2012; Maridonneau-Parini, Isabelle/F-1985-2011	Poincloux, Renaud/0000-0003-2884-1744; Pandruvada, Subramanya/0000-0001-9568-7666; Maridonneau-Parini, Isabelle/0000-0003-0189-0976; Verollet, Christel/0000-0002-1079-9085	Sidaction; Institut National de la Sante et de la Recherche Medicale (INSERM); Fondation pour la Recherche Medicale (FRM) [DEQ20051205752]; Universite Lyon 1; French Ministry of Research; Association pour la Recherche sur le Cancer (ARC); Societe Francaise de Rhumatologie (SFR); ARC [8505, 2010-120-1877]; Agence Nationale de la Recherche (ANR) [2010-01301]; FRM [DEQ20110421312]; Region Midi-Pyrenees (Platform TRI); Tarkinaid [HEALTH-F4-2011-282095]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065495, R01AI068150] Funding Source: NIH RePORTER	Sidaction; Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Universite Lyon 1; French Ministry of Research(Ministry of Research, FranceEuropean Commission); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Societe Francaise de Rhumatologie (SFR); ARC(Australian Research Council); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); FRM(Fondation pour la Recherche Medicale); Region Midi-Pyrenees (Platform TRI)(Region Occitanie); Tarkinaid; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors acknowledge F.-X. Frenois of the Imag'In platform for scanning of histology slides; T.K. van den Berg and G.C. Lugo-Villarino for critical reading of the manuscript. C.V. was supported by a fellowship from Sidaction; R.D. by a fellowship from Institut National de la Sante et de la Recherche Medicale (INSERM); S.P. by the Fondation pour la Recherche Medicale (FRM; DEQ20051205752) and Universite Lyon 1; A.G. by grants from the French Ministry of Research, the Association pour la Recherche sur le Cancer (ARC), and the Societe Francaise de Rhumatologie (SFR).This work was supported in part by ARC 8505 (Platform TRI) and 2010-120-1877 (P.J.), Agence Nationale de la Recherche (ANR) 2010-01301 (I.M.P.), FRM DEQ20110421312 (I.M.P.), Region Midi-Pyrenees (Platform TRI), and Tarkinaid FP7-2007-2013 under grant agreement HEALTH-F4-2011-282095 (I.M.P).	Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627; BLAVIER L, 1995, J CELL SCI, V108, P3649; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Byeon SE, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/512926; Carreno S, 2002, J BIOL CHEM, V277, P21007, DOI 10.1074/jbc.M201212200; Cougoule C, 2005, TRAFFIC, V6, P682, DOI 10.1111/j.1600-0854.2005.00307.x; Cougoule C, 2012, EUR J CELL BIOL, V91, P938, DOI 10.1016/j.ejcb.2012.07.002; Cougoule C, 2010, BLOOD, V115, P1444, DOI 10.1182/blood-2009-04-218735; Dacquin R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026627; Daino K, 2009, INT J CANCER, V125, P612, DOI 10.1002/ijc.24392; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07-03-0227; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Everts V, 2009, BBA-MOL BASIS DIS, V1792, P757, DOI 10.1016/j.bbadis.2009.05.004; Gallois A, 2009, M S-MED SCI, V25, P259, DOI 10.1051/medsci/2009253259; Gartland A, 2009, AM J PATHOL, V175, P2668, DOI 10.2353/ajpath.2009.090185; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Guiet R, 2008, EUR J CELL BIOL, V87, P527, DOI 10.1016/j.ejcb.2008.03.008; Guiet R, 2012, J BIOL CHEM, V287, P13051, DOI 10.1074/jbc.M111.307124; Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975; Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010-0006; Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105-2896.2005.00335.x; Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008; Kim HS, 2012, CELL SIGNAL, V24, P1306, DOI 10.1016/j.cellsig.2012.02.014; Kim HJ, 2010, J CELL BIOCHEM, V111, P1107, DOI 10.1002/jcb.22841; Kim HJ, 2009, P NATL ACAD SCI USA, V106, P2325, DOI 10.1073/pnas.0806963106; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kotani M, 2013, J IMMUNOL, V190, P605, DOI 10.4049/jimmunol.1201345; Labernadie A, 2010, P NATL ACAD SCI USA, V107, P21016, DOI 10.1073/pnas.1007835107; LEE ER, 1995, J HISTOCHEM CYTOCHEM, V43, P525, DOI 10.1177/43.5.7730591; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, BLOOD, V87, P1780; Luo Y, 2009, BIOCHEMISTRY-US, V48, P1838, DOI 10.1021/bi8020789; Luxenburg C, 2006, EUR J CELL BIOL, V85, P203, DOI 10.1016/j.ejcb.2005.11.002; Luxenburg C, 2006, J CELL SCI, V119, P4878, DOI 10.1242/jcs.03271; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68; Mugniery E, 2012, HUM MOL GENET, V21, P2503, DOI 10.1093/hmg/dds065; Oikawa T, 2012, J CELL BIOL, V197, P553, DOI 10.1083/jcb.201111116; Ortega N, 2005, MOL BIOL CELL, V16, P3028, DOI 10.1091/mbc.E04-12-1119; Ortega N, 2003, ANN NY ACAD SCI, V995, P109, DOI 10.1111/j.1749-6632.2003.tb03214.x; Ortega N, 2010, DIS MODEL MECH, V3, P224, DOI 10.1242/dmm.004226; Pandruvada SNM, 2010, INT J CANCER, V126, P2319, DOI 10.1002/ijc.24920; Poincloux R, 2006, EUR J CELL BIOL, V85, P327, DOI 10.1016/j.ejcb.2005.09.012; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749-6632.2011.06283.x; Van Goethem E, 2010, J IMMUNOL, V184, P1049, DOI 10.4049/jimmunol.0902223; Verollet C, 2011, EUR J IMMUNOL, V41, P2805, DOI 10.1002/eji.201141538; Verollet C, 2010, J IMMUNOL, V184, P7030, DOI 10.4049/jimmunol.0903345; Vignery Agnes, 2008, V475, P149, DOI 10.1007/978-1-59745-250-2_9; Villeneuve C, 2005, J LIPID RES, V46, P475, DOI 10.1194/jlr.M400308-JLR200; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Winograd-Katz SE, 2011, EUR J CELL BIOL, V90, P143, DOI 10.1016/j.ejcb.2010.07.006; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	60	16	16	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3608	3618		10.1096/fj.13-232736	http://dx.doi.org/10.1096/fj.13-232736			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23742809	Green Published			2022-12-28	WOS:000328840500020
J	Liu, H; Zhao, B; Chen, YC; You, DW; Liu, R; Rong, MQ; Ji, WZ; Zheng, P; Lai, R				Liu, Huan; Zhao, Bo; Chen, Yongchang; You, Dewen; Liu, Rui; Rong, Mingqiang; Ji, Weizhi; Zheng, Ping; Lai, Ren			Multiple coagulation factor deficiency protein 2 contains the ability to support stem cell self-renewal	FASEB JOURNAL			English	Article						MCFD2; pluripotency	HUMAN EMBRYONIC STEM; RECEPTOR COMPLEX; FACTOR-VIII; PLURIPOTENCY; MAINTENANCE; GENE; DIFFERENTIATION; ACTIVATION; EXPRESSION; PATHWAYS	Defects in multiple coagulation factor deficiency protein 2 (MCFD2) are a cause of factor V and factor VIII combined deficiency type 2 (F5F8D). MCFD2 was also suggested to play an important role as an autocrine/paracrine factor in maintaining neural stem cell potential. The current work provided direct evidence that both amphibian and human MCFD2 can maintain stem cell pluripotency or stemness of rhesus monkey embryonic stem cells (rESCs) as basic fibroblast growth factor 2 (FGF-2) does. In most cases, MCFD2 had identical effects on stem cells as FGF-2. We investigated the possible mechanism of MCFD2 to support stem cell pluripotency by highlighting the effects of MCFD2 and FGF-2 on several signaling pathways in rESCs, namely MAPK, TGF-, Wnt, and Akt, and 3 core transcriptional factors (Oct4, Nanog, and Sox2). In addition, some features of signaling pathways (MAPK and Akt), which are different from human embryonic stem cells (hESCs) and mouse embryonic stem cells (mESCs), are found in rESCs, indicating that primate ESCs have unique signaling mechanisms. These results may shed light on the biological roles of MCFD2, the conserved protein family distributed in both vertebrates and invertebrates. The ability to support stem cell self-renewal may be the general function of the conserved protein family.Liu, H., Zhao, B., Chen, Y., You, D., Liu, R., Rong, M., Ji, W., Zheng, P., Lai, R. Multiple coagulation factor deficiency protein 2 contains the ability to support stem cell self-renewal.	[Liu, Huan; You, Dewen; Liu, Rui; Rong, Mingqiang; Lai, Ren] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China; [Zhao, Bo; Zheng, Ping] Chinese Acad Sci, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China; [Chen, Yongchang; Ji, Weizhi] Chinese Acad Sci, Kunming Inst Zool, Kunming Primate Res Ctr, Kunming, Yunnan, Peoples R China; [Zhao, Bo; Chen, Yongchang] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Ji, WZ (corresponding author), Kunming Inst Zool, 32 Jiaochangdonglu, Kunming 650223, Yunnan, Peoples R China.	wji@mail.kiz.ac.cn; rlai@mail.kiz.ac.cn		Zhao, Bo/0000-0002-1000-8239; zheng, ping/0000-0003-0402-5507	China Ministry of Science and Technology [2010CB529800]; Chinese National Natural Science Foundation [31070701, 31000962, 31025025]; China Ministry of Agriculture [2009ZX08009-159B]; Chinese Academy of Sciences [KSCX2-EW-J-23, KSCX2-EW-R-11]; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences; Yunnan Province	China Ministry of Science and Technology(Ministry of Science and Technology, China); Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); China Ministry of Agriculture(Ministry of Agriculture & Rural Affairs); Chinese Academy of Sciences(Chinese Academy of Sciences); Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences; Yunnan Province	This work was supported by the China Ministry of Science and Technology (2010CB529800), the Chinese National Natural Science Foundation (31070701, 31000962, 31025025), the China Ministry of Agriculture (2009ZX08009-159B), the Chinese Academy of Sciences (KSCX2-EW-J-23, KSCX2-EW-R-11), and the Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province. The authors declare no conflict of interests.	Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brimble SN, 2004, STEM CELLS DEV, V13, P585, DOI 10.1089/scd.2004.13.585; DEKA N, 1988, GENE, V71, P123, DOI 10.1016/0378-1119(88)90084-4; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8; Han XH, 2011, J BIOL CHEM, V286, P10649, DOI 10.1074/jbc.M110.169391; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Li WL, 2009, CELL STEM CELL, V4, P16, DOI 10.1016/j.stem.2008.11.014; Mohanty D, 2005, AM J HEMATOL, V79, P262, DOI 10.1002/ajh.20397; Nyfeler B, 2006, TRAFFIC, V7, P1473, DOI 10.1111/j.1600-0854.2006.00483.x; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Takahashi K, 2005, BIOCHEM SOC T, V33, P1522, DOI 10.1042/BST0331522; Toda H, 2003, J BIOL CHEM, V278, P35491, DOI 10.1074/jbc.M305342200; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; You DW, 2009, J BIOL CHEM, V284, P22079, DOI 10.1074/jbc.M109.013276; Zhang B, 2005, J BIOL CHEM, V280, P25881, DOI 10.1074/jbc.M502160200; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153; Zhang B, 2009, BRIT J HAEMATOL, V145, P15, DOI 10.1111/j.1365-2141.2008.07559.x; Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267	26	5	6	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3298	3305		10.1096/fj.13-228825	http://dx.doi.org/10.1096/fj.13-228825			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23660967				2022-12-28	WOS:000329877600034
J	Tinnes, S; Ringwald, J; Haas, CA				Tinnes, Stefanie; Ringwald, Julia; Haas, Carola A.			TIMP-1 inhibits the proteolytic processing of Reelin in experimental epilepsy	FASEB JOURNAL			English	Article						hippocampus; dispersion; kainate; metalloprotease; organotypic slice cultures	GRANULE CELL DISPERSION; TISSUE INHIBITOR; GENE-EXPRESSION; SECRETED REELIN; KAINIC ACID; PROTEIN; NEURONS; METALLOPROTEINASES-1; ACTIVATION; MOLECULES	Temporal lobe epilepsy is frequently associated with granule cell dispersion (GCD), an abnormal widening of the granule cell layer in the dentate gyrus. There is increasing evidence that a loss and the functional inactivation of the positional signal Reelin is involved in GCD formation. Reelin is synthesized and released by Cajal-Retzius cells and interneurons, and its function depends on proteolytic cleavage after secretion. Epileptic conditions impair Reelin processing by inhibition of matrix metalloprotease (MMP) activity and cause the extracellular accumulation of unprocessed Reelin. Here we investigated how epileptic conditions inhibit MMP activity. We used kainate (KA) treatment of organotypic hippocampal slice cultures as an epilepsy model and found a significant increase of tissue inhibitor of metalloproteases 1 (TIMP-1) levels and strongly enhanced TIMP-1 immunolabeling in hippocampal neurons. Functional inhibition of TIMP-1 prevented the KA-induced impairment of Reelin cleavage indicating that TIMP-1 inhibits MMP activity. Moreover, application of recombinant TIMP-1 alone was sufficient to impair Reelin processing and to induce GCD, similar to that observed after KA treatment. In summary, we present evidence that epileptic conditions inhibit MMP activity by up-regulation of endogenous TIMP-1, which in turn leads to extracellular accumulation of uncleaved and inactive Reelin and thereby to GCD.Tinnes, S., Ringwald, J., Haas, C. A. TIMP-1 inhibits the proteolytic processing of Reelin in experimental epilepsy.	[Tinnes, Stefanie; Ringwald, Julia] Univ Freiburg, Dept Neurosurg, D-79106 Freiburg, Germany; [Haas, Carola A.] Univ Freiburg, Bernstein Ctr Freiburg, D-79106 Freiburg, Germany	University of Freiburg; University of Freiburg	Haas, CA (corresponding author), Univ Clin Freiburg, Dept Neurosurg, Breisacher Str 64, D-79106 Freiburg, Germany.	carola.haas@uniklinik-freiburg.de			Deutsche Forschungsgemeinschaft (DFG) [Transregio SFB TR3]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank J. Gerlach for critical reading of the manuscript and S. Huber and A. Djie-Maletz for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (DFG; Transregio SFB TR3).	Alcantara S, 1998, J NEUROSCI, V18, P7779; Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x; Botella-Lopez A, 2006, P NATL ACAD SCI USA, V103, P5573, DOI 10.1073/pnas.0601279103; Cooper JA, 2008, TRENDS NEUROSCI, V31, P113, DOI 10.1016/j.tins.2007.12.003; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; de Rouvroit CL, 1999, EXP NEUROL, V156, P214, DOI 10.1006/exnr.1998.7007; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; Fatemi SH, 2001, NEUROREPORT, V12, P3209, DOI 10.1097/00001756-200110290-00014; Frotscher M, 2010, TRENDS NEUROSCI, V33, P407, DOI 10.1016/j.tins.2010.06.001; Gorter JA, 2007, EPILEPSIA, V48, P53, DOI 10.1111/j.1528-1167.2007.01290.x; Haas CA, 2002, J NEUROSCI, V22, P5797; Haas CA, 2010, EXP BRAIN RES, V200, P141, DOI 10.1007/s00221-009-1948-5; Heinrich C, 2006, J NEUROSCI, V26, P4701, DOI 10.1523/JNEUROSCI.5516-05.2006; Hisanaga A, 2012, FEBS LETT, V586, P3349, DOI 10.1016/j.febslet.2012.07.017; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Ignatova N, 2004, NEUROBIOL DIS, V15, P326, DOI 10.1016/j.nbd.2003.11.008; Impagnatiello F, 1998, P NATL ACAD SCI USA, V95, P15718, DOI 10.1073/pnas.95.26.15718; Jaworski J, 1999, J BIOL CHEM, V274, P28106, DOI 10.1074/jbc.274.40.28106; Jossin Y, 2004, J NEUROSCI, V24, P514, DOI 10.1523/JNEUROSCI.3408-03.2004; Jossin Y, 2007, J NEUROSCI, V27, P4243, DOI 10.1523/JNEUROSCI.0023-07.2007; Jourquin J, 2003, EUR J NEUROSCI, V18, P1507, DOI 10.1046/j.1460-9568.2003.02876.x; Krstic D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047793; Kubo K, 2002, NEUROSCI RES, V43, P381, DOI 10.1016/S0168-0102(02)00068-8; Lugli Giovanni, 2003, BMC Biochem, V4, P9, DOI 10.1186/1471-2091-4-9; Lukasiuk K, 2003, EUR J NEUROSCI, V17, P271, DOI 10.1046/j.1460-9568.2003.02461.x; Lukasiuk K, 2011, EPILEPSY RES, V96, P191, DOI 10.1016/j.eplepsyres.2011.08.002; Mannello F, 2001, APOPTOSIS, V6, P479, DOI 10.1023/A:1012493808790; Motti D, 2010, EUR J NEUROSCI, V32, P1364, DOI 10.1111/j.1460-9568.2010.07403.x; Muller MC, 2009, EXP NEUROL, V216, P390, DOI 10.1016/j.expneurol.2008.12.029; Nakano Y, 2007, J BIOL CHEM, V282, P20544, DOI 10.1074/jbc.M702300200; Pesold C, 1998, P NATL ACAD SCI USA, V95, P3221, DOI 10.1073/pnas.95.6.3221; Ramos-Moreno T, 2006, EUR J NEUROSCI, V23, P401, DOI 10.1111/j.1460-9568.2005.04567.x; Rivera S, 1997, J NEUROSCI, V17, P4223; Sbai O, 2008, MOL CELL NEUROSCI, V39, P549, DOI 10.1016/j.mcn.2008.08.004; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Tinnes S, 2011, FASEB J, V25, P1002, DOI 10.1096/fj.10-168294; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Utsunomiya-Tate N, 2000, P NATL ACAD SCI USA, V97, P9729, DOI 10.1073/pnas.160272497; Wright JW, 2009, NEURAL PLAST, V2009, DOI 10.1155/2009/579382; Yasui N, 2011, J BIOL CHEM, V286, P35247, DOI 10.1074/jbc.M111.242719; Zhang JW, 1998, EUR J NEUROSCI, V10, P3358, DOI 10.1046/j.1460-9568.1998.00347.x	42	26	26	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2542	2552		10.1096/fj.12-224899	http://dx.doi.org/10.1096/fj.12-224899			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23493620				2022-12-28	WOS:000328841000004
J	Wilkars, W; Wollberg, J; Mohr, E; Han, M; Chetkovich, DM; Bahring, R; Bender, RA				Wilkars, Wiebke; Wollberg, Jessica; Mohr, Evita; Han, Mieri; Chetkovich, Dane M.; Baehring, Robert; Bender, Roland A.			Nedd4-2 regulates surface expression and may affect N-glycosylation of hyperpolarization-activated cyclic nucleotide-gated (HCN)-1 channels	FASEB JOURNAL			English	Article						ion channel; trafficking; TRIP8b; ubiquitination	CARDIAC-PACEMAKER CHANNELS; UBIQUITIN LIGASE NEDD4-2; TEMPORAL-LOBE EPILEPSY; HCN CHANNELS; POTASSIUM CHANNEL; ION CHANNELS; LINKED GLYCOSYLATION; DEPENDENT REGULATION; SODIUM-CHANNELS; PROTEIN	HCN channels are important regulators of neuronal excitability. The proper function of these channels is governed by various mechanisms, including post-translational modifications of channel subunits. Here, we provide evidence that ubiquitination via a ubiquitin ligase, neuronal precursor cell expressed developmentally downregulated (Nedd)-4-2, is involved in the regulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. We identified a PY motif (L/PPxY), the characteristic binding motif for Nedd4-2 in the C terminus of the HCN1 subunit, and showed that HCN1 and Nedd4-2 interacted both in vivo (rat hippocampus, neocortex, and cerebellum) and in vitro [human embryonic kidney 293 (HEK293) cells], resulting in increased HCN1 ubiquitination. Elimination of the PY motif reduced, but did not abolish, Nedd4-2 binding, which further involved a stretch of approximate to 100 aa downstream in the HCN1 C terminus. Coexpression of Nedd4-2 and HCN1 drastically reduced the HCN1-mediated h-current amplitude (85-92%) in Xenopus laevis oocytes and reduced surface expression (34%) of HCN1 channels in HEK293 cells, thereby opposing effects of tetratricopeptide repeat-containing Rab8b interacting protein (TRIP8b)-(1a-4), an auxiliary subunit that promotes HCN1 surface expression. Regulation may further include N-glycosylation of HCN1 channels, which is significantly enhanced by TRIP8b(1a-4), but may be reduced by Nedd4-2. Taken together, our data indicate that Nedd4-2 plays an important role in the regulation of HCN1 trafficking and may compete with TRIP8b(1a-4) in this process.Wilkars, W., Wollberg, J., Mohr, E., Han, M., Chetkovich, D. M., Bahring, R., Bender, R. A. Nedd4-2 regulates surface expression and may affect N-glycosylation of hyperpolarization-activated cyclic nucleotide-gated (HCN)-1 channels.	[Wilkars, Wiebke; Mohr, Evita; Han, Mieri; Bender, Roland A.] Univ Hamburg, Med Ctr, Inst Neuroanat, D-20246 Hamburg, Germany; [Wollberg, Jessica; Baehring, Robert] Univ Hamburg, Med Ctr, Inst Cellular & Integrat Physiol, D-20246 Hamburg, Germany; [Chetkovich, Dane M.] Northwestern Univ, Feinberg Sch Med, Davee Dept Neurol & Clin Neurosci, Chicago, IL 60611 USA; [Chetkovich, Dane M.] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA	University of Hamburg; University of Hamburg; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bender, RA (corresponding author), Univ Hamburg, Med Ctr, Inst Neuroanat, Martinistr 52, D-20246 Hamburg, Germany.	rbender@uke.uni-hamburg.de	Chetkovich, Dane/AAV-5457-2021	Bahring, Robert/0000-0002-0406-5958	Deutsche Forschungsgemeinschaft (DFG) [BE4107/2-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Telse Kock and Christiane Schroder-Birkner for excellent technical assistance. This study was supported by Deutsche Forschungsgemeinschaft (DFG; grant: BE4107/2-1).	Albesa M, 2011, J MOL CELL CARDIOL, V51, P90, DOI 10.1016/j.yjmcc.2011.03.015; Baruscotti M, 2010, PFLUG ARCH EUR J PHY, V460, P405, DOI 10.1007/s00424-010-0810-8; Bender RA, 2007, J NEUROSCI, V27, P4697, DOI 10.1523/JNEUROSCI.4699-06.2007; Bender RA, 2008, PROG NEUROBIOL, V86, P129, DOI 10.1016/j.pneurobio.2008.09.007; Bongiorno D, 2011, CHANNELS, V5, P79, DOI 10.4161/chan.5.1.13967; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brewster A, 2002, J NEUROSCI, V22, P4591, DOI 10.1523/JNEUROSCI.22-11-04591.2002; Brewster AL, 2007, CEREB CORTEX, V17, P702, DOI 10.1093/cercor/bhk021; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; Ekberg J, 2007, J BIOL CHEM, V282, P12135, DOI 10.1074/jbc.M609385200; Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200; Gasser A, 2010, J BIOL CHEM, V285, P26149, DOI 10.1074/jbc.M109.098681; Gravante B, 2004, J BIOL CHEM, V279, P43847, DOI 10.1074/jbc.M401598200; Guo J, 2012, J BIOL CHEM, V287, P33132, DOI 10.1074/jbc.M112.389643; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Han Y, 2011, J BIOL CHEM, V286, P20823, DOI 10.1074/jbc.M111.236125; Hardel N, 2008, CARDIOVASC RES, V79, P52, DOI 10.1093/cvr/cvn062; He YW, 2008, J BIOL CHEM, V283, P24000, DOI 10.1074/jbc.M803361200; Hegle AP, 2010, AM J PHYSIOL-CELL PH, V298, pC1066, DOI 10.1152/ajpcell.00389.2009; Herrmann S, 2012, BRIT J PHARMACOL, V166, P501, DOI 10.1111/j.1476-5381.2011.01798.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Jespersen T, 2007, CARDIOVASC RES, V74, P64, DOI 10.1016/j.cardiores.2007.01.008; Jung S, 2010, J NEUROSCI, V30, P6678, DOI 10.1523/JNEUROSCI.1290-10.2010; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Lamothe SM, 2013, J BIOL CHEM, V288, P15075, DOI 10.1074/jbc.M113.453670; Lewis AS, 2011, J NEUROSCI, V31, P7424, DOI 10.1523/JNEUROSCI.0936-11.2011; Lewis AS, 2011, MOL CELL NEUROSCI, V46, P357, DOI 10.1016/j.mcn.2010.11.007; Lewis AS, 2010, CHANNELS, V4, P215, DOI 10.4161/chan.4.3.11630; Lewis AS, 2009, J NEUROSCI, V29, P6250, DOI 10.1523/JNEUROSCI.0856-09.2009; Lorincz A, 2002, NAT NEUROSCI, V5, P1185, DOI 10.1038/nn962; McClelland S, 2011, ANN NEUROL, V70, P454, DOI 10.1002/ana.22479; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Pian P, 2006, J GEN PHYSIOL, V128, P593, DOI 10.1085/jgp.200609648; Piskorowski R, 2011, NEURON, V70, P495, DOI 10.1016/j.neuron.2011.03.023; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Rotin D, 2011, PFLUG ARCH EUR J PHY, V461, P1, DOI 10.1007/s00424-010-0893-2; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Rougier JS, 2005, AM J PHYSIOL-CELL PH, V288, pC692, DOI 10.1152/ajpcell.00460.2004; Santoro B, 2004, J NEUROSCI, V24, P10750, DOI 10.1523/JNEUROSCI.3300-04.2004; Santoro B, 2011, J NEUROSCI, V31, P4074, DOI 10.1523/JNEUROSCI.5707-10.2011; Santoro B, 2009, NEURON, V62, P802, DOI 10.1016/j.neuron.2009.05.009; Schafer MKE, 2010, FEBS LETT, V584, P4475, DOI 10.1016/j.febslet.2010.10.011; Schuetz F, 2008, AM J PHYSIOL-CELL PH, V295, pC73, DOI 10.1152/ajpcell.00146.2008; Shin M, 2008, NEUROBIOL DIS, V32, P26, DOI 10.1016/j.nbd.2008.06.013; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tyrrell L, 2001, J NEUROSCI, V21, P9629, DOI 10.1523/JNEUROSCI.21-24-09629.2001; Wang J, 2002, NEURON, V36, P451, DOI 10.1016/S0896-6273(02)00968-6; Wegierski T, 2006, EMBO J, V25, P5659, DOI 10.1038/sj.emboj.7601429; Whitaker GM, 2007, J BIOL CHEM, V282, P22900, DOI 10.1074/jbc.M610978200; Wilkars W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032181; Yang B, 2010, CELL DEATH DIFFER, V17, P68, DOI 10.1038/cdd.2009.84; Yi JJ, 2005, NEURON, V47, P629, DOI 10.1016/j.neuron.2005.07.008; Zha QQ, 2008, J NEUROCHEM, V105, P68, DOI 10.1111/j.1471-4159.2007.05110.x; Zhang Y, 1999, J MEMBRANE BIOL, V171, P195, DOI 10.1007/s002329900571; Zolles G, 2006, NEURON, V52, P1027, DOI 10.1016/j.neuron.2006.12.005; Zolles G, 2009, NEURON, V62, P814, DOI 10.1016/j.neuron.2009.05.008; Zong XG, 2005, J BIOL CHEM, V280, P34224, DOI 10.1074/jbc.M506544200	65	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2177	2190		10.1096/fj.13-242032	http://dx.doi.org/10.1096/fj.13-242032			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24451387				2022-12-28	WOS:000335336000021
J	Liu, GL; Zhang, FF; Wang, RX; London, L; London, SD				Liu, Guangliang; Zhang, Fangfang; Wang, Ruixue; London, Lucille; London, Steven D.			Protective MCMV immunity by vaccination of the salivary gland via Wharton's duct: replication-deficient recombinant adenovirus expressing individual MCMV genes elicits protection similar to that of MCMV	FASEB JOURNAL			English	Article						vaccine development; mucosal immunity; inflammation	TRANSGENE EXPRESSION; AQUAPORIN-1 CDNA; PAROTID-GLANDS; MUCOSAL; VECTOR; IMMUNIZATION; INDUCTION; INFECTION; PROTEIN; MODEL	Salivary glands, a major component of the mucosal immune system, confer antigen-specific immunity to mucosally acquired pathogens. We investigated whether a physiological route of inoculation and a subunit vaccine approach elicited MCMV-specific and protective immunity. Mice were inoculated by retrograde perfusion of the submandibular salivary glands via Wharton's duct with tcMCMV or MCMV proteins focused to the salivary gland via replication-deficient adenovirus expressing individual MCMV genes (gB, gH, IE1; controls: saline and replication deficient adenovirus without MCMV inserts). Mice were evaluated for MCMV-specific antibodies, T-cell responses, germinal center formation, and protection against a lethal MCMV challenge. Retrograde perfusion with tcMCMV or adenovirus expressed MCMV proteins induced a 2- to 6-fold increase in systemic and mucosal MCMV-specific antibodies, a 3- to 6-fold increase in GC marker expression, and protection against a lethal systemic challenge, as evidenced by up to 80% increased survival, decreased splenic pathology, and decreased viral titers from 10(6) pfu to undetectable levels. Thus, a focused salivary gland immunization via a physiological route with a protein antigen induced systemic and mucosal protective immune responses. Therefore, salivary gland immunization can serve as an alternative mucosal route for administering vaccines, which is directly applicable for use in humans.-Liu, G., Zhang, F., Wang, R., London, L., London, S. D. Protective MCMV immunity by vaccination of the salivary gland via Wharton's duct: replication-deficient recombinant adenovirus expressing individual MCMV genes elicits protection similar to that of MCMV.	[Liu, Guangliang; Zhang, Fangfang; Wang, Ruixue; London, Lucille; London, Steven D.] SUNY Stony Brook, Sch Dent Med, Dept Oral Biol & Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	London, SD (corresponding author), SUNY Stony Brook, Sch Dent Med, Dept Oral Biol & Pathol, Stony Brook, NY 11794 USA.	steven.london@stonybrook.edu	Zhang, Fang/HHN-2153-2022		U.S. National Institutes of Health/National Institute of Dental and Craniofacial Research [1R01 DE016652]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016652] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Dr. Changyu Zheng (National Institute of Dental and Craniofacial Research, U.S. National Institutes of Health, Bethesda, MD, USA) for providing training in the salivary gland cannulation technique. The authors also thank Drs. John D. Shanley and Carol A. Wu (University of Connecticut, Storrs, CT, USA) for providing recombinant adenovirus vectors and cell lines. This project was supported by U.S. National Institutes of Health/National Institute of Dental and Craniofacial Research grant 1R01 DE016652 (S.D.L.). The work described in this manuscript has not been previously published and is not being considered concurrently by another publication. All authors concur with this submission. The authors declare no conflicts of interest.	Acosta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026137; Adriaansen J, 2011, HUM GENE THER, V22, P84, DOI 10.1089/hum.2010.097; Amerongen AVN, 2002, ORAL DIS, V8, P12, DOI 10.1034/j.1601-0825.2002.1o816.x; Baum B J, 2000, Adv Dent Res, V14, P84; Baum BJ, 2004, TRENDS MOL MED, V10, P585, DOI 10.1016/j.molmed.2004.10.003; Baum BJ, 2012, P NATL ACAD SCI USA, V109, P19403, DOI 10.1073/pnas.1210662109; Benihoud K, 1999, CURR OPIN BIOTECH, V10, P440, DOI 10.1016/S0958-1669(99)00007-5; Bohm V, 2008, MED MICROBIOL IMMUN, V197, P135, DOI 10.1007/s00430-008-0092-3; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P141, DOI 10.1016/S0167-5699(98)01413-3; Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001; Brune W, 2001, Curr Protoc Immunol, VChapter 19, DOI 10.1002/0471142735.im1907s43; Gao R, 2011, GENE THER, V18, P38, DOI 10.1038/gt.2010.128; Grewal JS, 2011, FASEB J, V25, P1680, DOI 10.1096/fj.10-174656; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Kasman LM, 2009, ORAL DIS, V15, P587, DOI 10.1111/j.1601-0825.2009.01600.x; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Kuriki Y., 2011, JOVE-J VIS EXP, V14, P3074; Liu GL, 2009, J VIROL, V83, P6963, DOI 10.1128/JVI.00284-09; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Massie B, 1998, J VIROL, V72, P2289, DOI 10.1128/JVI.72.3.2289-2296.1998; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Ogorelkova M., 2003, METHOD MOL BIOL, V246, P15; Omnell K A, 1983, Dentomaxillofac Radiol, V12, P13; Perez P, 2011, ORAL DIS, V17, P476, DOI 10.1111/j.1601-0825.2010.01775.x; Pilgrim MJ, 2007, EXP MOL PATHOL, V82, P269, DOI 10.1016/j.yexmp.2006.12.010; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Samuni Y, 2011, BBA-MOL BASIS DIS, V1812, P1515, DOI 10.1016/j.bbadis.2011.06.014; SCHMIDT NJ, 1976, J CLIN MICROBIOL, V4, P61; Shanley JD, 2005, VACCINE, V23, P996, DOI 10.1016/j.vaccine.2004.07.041; Shanley JD, 2003, VACCINE, V21, P2632, DOI 10.1016/S0264-410X(03)00037-9; Takahashi I, 2009, CURR OPIN IMMUNOL, V21, P352, DOI 10.1016/j.coi.2009.04.002; Tarlinton D, 2008, CURR OPIN IMMUNOL, V20, P162, DOI 10.1016/j.coi.2008.03.016; Tucker SN, 2004, VACCINE, V22, P2500, DOI 10.1016/j.vaccine.2003.12.034; Voutetakis A, 2004, J CELL PHYSIOL, V199, P1, DOI 10.1002/jcp.10429; Voutetakis A, 2010, GENE THER, V17, P50, DOI 10.1038/gt.2009.123; Voutetakis A, 2008, HUM GENE THER, V19, P1401, DOI [10.1089/hum.2008.034, 10.1089/hgt.2008.034]; Woodrow KA, 2012, ANNU REV BIOMED ENG, V14, P17, DOI 10.1146/annurev-bioeng-071811-150054; Zheng C, 2012, ORAL DIS, V18, P477, DOI 10.1111/j.1601-0825.2011.01895.x; Zheng C, 2011, ORAL DIS, V17, P77, DOI 10.1111/j.1601-0825.2010.01707.x; Zheng CY, 2012, HUM GENE THER METHOD, V23, P169, DOI 10.1089/hgtb.2011.175; Zheng CY, 2011, CLIN CANCER RES, V17, P2842, DOI 10.1158/1078-0432.CCR-10-2982; Zheng CY, 2010, J GENE MED, V12, P3, DOI 10.1002/jgm.1416; Zufferey R, 2004, GENE THER, V11, P1425, DOI 10.1038/sj.gt.3302321	43	6	6	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1698	1710		10.1096/fj.13-244178	http://dx.doi.org/10.1096/fj.13-244178			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24391133	Green Published			2022-12-28	WOS:000335344300017
J	Sakellariou, GK; Davis, CS; Shi, Y; Ivannikov, MV; Zhang, YQ; Vasilaki, A; Macleod, GT; Richardson, A; Van Remmen, H; Jackson, MJ; McArdle, A; Brooks, SV				Sakellariou, Giorgos K.; Davis, Carol S.; Shi, Yun; Ivannikov, Maxim V.; Zhang, Yiqiang; Vasilaki, Aphrodite; Macleod, Gregory T.; Richardson, Arlan; Van Remmen, Holly; Jackson, Malcolm J.; McArdle, Anne; Brooks, Susan V.			Neuron-specific expression of CuZnSOD prevents the loss of muscle mass and function that occurs in homozygous CuZnSOD-knockout mice	FASEB JOURNAL			English	Article						SOD1; heat-shock protein; neuromuscular junction; oxidative stress	SKELETAL-MUSCLE; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; NEUROMUSCULAR-JUNCTION; AGE; MITOCHONDRIAL; DAMAGE; GENERATION; ATROPHY; LEADS	Deletion of copper-zinc superoxide dismutase (CuZnSOD) in Sod1(-/-) mice leads to accelerated loss of muscle mass and force during aging, but the losses do not occur with muscle-specific deletion of CuZnSOD. To determine the role of motor neurons in the muscle decline, we generated transgenic Sod1(-/-) mice in which CuZnSOD was expressed under control of the synapsin 1 promoter (SynTgSod1(-/-) mice). SynTgSod1(-/-) mice expressed CuZnSOD in brain, spinal cord, and peripheral nerve, but not in other tissues. Sciatic nerve CuZnSOD content in SynTgSod1(-/-) mice was similar to 20% that of control mice, but no reduction in muscle mass or isometric force was observed in SynTgSod1(-/-) mice compared with control animals, whereas muscles of age-matched Sod1(-/-) mice displayed 30-40% reductions in mass and force. In addition, increased oxidative damage and adaptations in stress responses observed in muscles of Sod1(-/-) mice were absent in SynTgSod1(-/-) mice, and degeneration of neuromuscular junction (NMJ) structure and function occurred in Sod1(-/-) mice but not in SynTgSod1(-/-) mice. Our data demonstrate that specific CuZnSOD expression in neurons is sufficient to preserve NMJ and skeletal muscle structure and function in Sod1(-/-) mice and suggest that redox homeostasis in motor neurons plays a key role in initiating sarcopenia during aging.-Sakellariou, G. K., Davis, C. S., Shi, Y., Ivannikov, M. V., Zhang, Y., Vasilaki, A., Macleod, G. T., Richardson, A., Van Remmen, H., Jackson, M. J., McArdle, A., Brooks, S. V. Neuron-specific expression of CuZnSOD prevents the loss of muscle mass and function that occurs in homozygous CuZnSOD-knockout mice.	[Sakellariou, Giorgos K.; Vasilaki, Aphrodite; Jackson, Malcolm J.; McArdle, Anne] Univ Liverpool, Arthrit Res UK Ctr Integrated Res Musculoskeletal, Dept Musculoskeletal Biol, Med Res Council,Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England; [Davis, Carol S.; Brooks, Susan V.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Shi, Yun; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Ivannikov, Maxim V.; Zhang, Yiqiang; Macleod, Gregory T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA; [Shi, Yun; Ivannikov, Maxim V.; Zhang, Yiqiang; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA; [Van Remmen, Holly] South Texas Vet Hlth Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Liverpool; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center	Brooks, SV (corresponding author), Univ Michigan, 2029 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	svbrooks@umich.edu	Zhang, Yiqiang/AAA-3143-2019	Jackson, Malcolm/0000-0003-3683-8297; Vasilaki, Aphrodite/0000-0002-5652-0895; Macleod, Gregory/0000-0003-3782-6968; Brooks, Susan/0000-0003-1954-967X	U. S. National Institute on Aging/National Institutes of Health [AG-020591, T32 AG021890]; BBSRC [BB/K003860/1, BB/I004076/1] Funding Source: UKRI; MRC [MR/K006312/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/K003860/1, BB/I004076/1] Funding Source: researchfish; Medical Research Council [MR/K006312/1] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020591, T32AG021890] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002595] Funding Source: NIH RePORTER	U. S. National Institute on Aging/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Teresa M. Evans, Lauren K. Wood, Anne Erickson, and Jose Gomez for technical assistance. This work was supported by U. S. National Institute on Aging/National Institutes of Health grants AG-020591 and T32 AG021890 (to M.V.I.).	Broome CS, 2006, FASEB J, V20, P1549, DOI 10.1096/fj.05-4935fje; Butikofer L, 2011, FASEB J, V25, P4378, DOI 10.1096/fj.11-191262; CAMPBELL MJ, 1973, J NEUROL NEUROSUR PS, V36, P174, DOI 10.1136/jnnp.36.2.174; Chai RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028090; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Evans WJ, 2010, AM J CLIN NUTR, V91, p1123S, DOI 10.3945/ajcn.2010.28608A; Fischer LR, 2011, BRAIN, V134, P196, DOI 10.1093/brain/awq314; Flood DG, 1999, AM J PATHOL, V155, P663, DOI 10.1016/S0002-9440(10)65162-0; Gems D, 2009, CELL CYCLE, V8, P1681, DOI 10.4161/cc.8.11.8595; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Jang YC, 2010, FASEB J, V24, P1376, DOI 10.1096/fj.09-146308; Kaja S, 2007, EUR J NEUROSCI, V25, P2009, DOI 10.1111/j.1460-9568.2007.05438.x; Kulakowski SA, 2011, J APPL PHYSIOL, V111, P844, DOI 10.1152/japplphysiol.00070.2011; Larkin LM, 2011, AM J PHYSIOL-REG I, V301, pR1400, DOI 10.1152/ajpregu.00093.2011; Larsson JE, 1998, ACTA ANAESTH SCAND, V42, P987, DOI 10.1111/j.1399-6576.1998.tb05360.x; LARSSON L, 1983, ACTA PHYSIOL SCAND, V117, P469, DOI 10.1111/j.1748-1716.1983.tb00024.x; Larsson L, 2001, INT J SPORT NUTR EXE, V11, pS28, DOI 10.1123/ijsnem.11.s1.s28; LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11; Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Muller FL, 2007, AM J PHYSIOL-REG I, V293, pR1159, DOI 10.1152/ajpregu.00767.2006; Muller FL, 2006, FREE RADICAL BIO MED, V40, P1993, DOI 10.1016/j.freeradbiomed.2006.01.036; Palomero J, 2013, AM J PHYSIOL-REG I, V305, pR351, DOI 10.1152/ajpregu.00530.2012; Perez V. I., 2009, BIOCHIM BIOPHYS ACTA, V1790, P628; Porter M. M., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P129; Reid MB, 2002, ANN NY ACAD SCI, V959, P108, DOI 10.1111/j.1749-6632.2002.tb02087.x; Rowan SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029082; Sakellariou GK, 2011, AGING CELL, V10, P749, DOI 10.1111/j.1474-9726.2011.00709.x; Sakellariou GK, 2013, ANTIOXID REDOX SIGN, V18, P603, DOI 10.1089/ars.2012.4623; Samuel MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046663; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Vasilaki A, 2006, AGING CELL, V5, P109, DOI 10.1111/j.1474-9726.2006.00198.x; Vasilaki A, 2007, PROTEOM CLIN APPL, V1, P362, DOI 10.1002/prca.200600702; Vasilaki A, 2010, AGING CELL, V9, P979, DOI 10.1111/j.1474-9726.2010.00635.x; Ward WF, 2005, J GERONTOL A-BIOL, V60, P847, DOI 10.1093/gerona/60.7.847; Zhang YQ, 2013, FASEB J, V27, P3536, DOI 10.1096/fj.13-228130	37	65	65	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1666	1681		10.1096/fj.13-240390	http://dx.doi.org/10.1096/fj.13-240390			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24378874	Green Published, Green Submitted			2022-12-28	WOS:000335344300015
J	Alkhori, L; Ost, A; Alenius, M				Alkhori, Liza; Oest, Anita; Alenius, Mattias			The corepressor Atrophin specifies odorant receptor expression in Drosophila	FASEB JOURNAL			English	Article						neuronal differentiation; epigenetic; HDAC; olfactory system; Notch	OLFACTORY SENSE-ORGANS; TRANSCRIPTIONAL REPRESSION; NEGATIVE REGULATION; PRONEURAL GENE; REPEAT; FAMILY; DRPLA	In both insects and vertebrates, each olfactory sensory neuron (OSN) expresses one odorant receptor (OR) from a large genomic repertoire. How a receptor is specified is a tantalizing question addressing fundamental aspects of cell differentiation. Here, we demonstrate that the corepressor Atrophin (Atro) segregates OR gene expression between OSN classes in Drosophila. We show that the knockdown of Atro result in either loss or gain of a broad set of ORs. Each OR phenotypic group correlated with one of two opposing Notch fates, Notch responding, Nba (N-on), and nonresponding, Nab (N-off) OSNs. Our data show that Atro segregates ORs expressed in the Nba OSN classes and helps establish the Nab fate during OSN development. Consistent with a role in recruiting histone deacetylates, immunohistochemistry revealed that Atro regulates global histone 3 acetylation (H3ac) in OSNs and requires Hdac3 to segregate OR gene expression. We further found that Nba OSN classes exhibit variable but higher H3ac levels than the Nab OSNs. Together, these data suggest that Atro determines the level of H3ac, which ensures correct OR gene expression within the Nba OSNs. We propose a mechanism by which a single corepressor can specify a large number of neuron classes.Alkhori, L., ost, A., Alenius, M. The corepressor Atrophin specifies odorant receptor expression in Drosophila.	[Alkhori, Liza; Alenius, Mattias] Linkoping Univ, Dept Clin & Expt Med, S-58183 Linkoping, Sweden; [Oest, Anita] Max Planck Inst Immunobiol & Epigenet, Freiburg, Germany	Linkoping University; Max Planck Society	Alenius, M (corresponding author), Linkoping Univ, Dept Clin & Expt Med, S-58183 Linkoping, Sweden.	mattias.alenius@liu.se						Bai L, 2009, J NEUROSCI, V29, P12940, DOI 10.1523/JNEUROSCI.3525-09.2009; Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022; Charroux B, 2006, DEV BIOL, V291, P278, DOI 10.1016/j.ydbio.2005.12.012; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Endo K, 2007, NAT NEUROSCI, V10, P153, DOI 10.1038/nn1832; Endo K, 2012, NAT NEUROSCI, V15, P224, DOI 10.1038/nn.2998; Fishilevich E, 2005, CURR BIOL, V15, P1548, DOI 10.1016/j.cub.2005.07.066; Flici H, 2011, DEVELOPMENT, V138, P4167, DOI 10.1242/dev.070391; Fuss SH, 2009, MOL CELL NEUROSCI, V41, P101, DOI 10.1016/j.mcn.2009.02.014; Goulding SE, 2000, NEURON, V25, P69, DOI 10.1016/S0896-6273(00)80872-7; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Gupta BP, 1997, GENES CELLS, V2, P225, DOI 10.1046/j.1365-2443.1997.d01-312.x; Haecker A, 2007, PLOS BIOL, V5, P1298, DOI 10.1371/journal.pbio.0050145; Jafari S, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001280; Knutson SK, 2008, EMBO J, V27, P1017, DOI 10.1038/emboj.2008.51; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Martinez CA, 2008, MOL CELL BIOL, V28, P2792, DOI 10.1128/MCB.01203-07; McGuire Sean E, 2004, Sci STKE, V2004, ppl6, DOI 10.1126/stke.2202004pl6; Miller CJ, 2010, GENETICS, V186, P79, DOI 10.1534/genetics.110.117622; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; Shen Y, 2009, CELL MOL LIFE SCI, V66, P437, DOI 10.1007/s00018-008-8403-9; Sim CK, 2012, GENE DEV, V26, P2483, DOI 10.1101/gad.201665.112; Wang L, 2008, EMBO REP, V9, P555, DOI 10.1038/embor.2008.67; Wang Lei, 2008, Nucl Recept Signal, V6, pe009, DOI 10.1621/nrs.06009; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4	29	14	14	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1355	1364		10.1096/fj.13-240325	http://dx.doi.org/10.1096/fj.13-240325			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24334704				2022-12-28	WOS:000335324800027
J	Pisanti, S; Picardi, P; Ciaglia, E; Margarucci, L; Ronca, R; Giacomini, A; Malfitano, AM; Casapullo, A; Laezza, C; Gazzerro, P; Bifulco, M				Pisanti, Simona; Picardi, Paola; Ciaglia, Elena; Margarucci, Luigi; Ronca, Roberto; Giacomini, Arianna; Malfitano, Anna Maria; Casapullo, Agostino; Laezza, Chiara; Gazzerro, Patrizia; Bifulco, Maurizio			Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation	FASEB JOURNAL			English	Article						mevalonate pathway; cancer progression; endothelial cells; AMP-mimetic	CANCER CELL-GROWTH; PROTEIN-KINASE; ENDOTHELIAL-CELLS; APOPTOSIS; PROLIFERATION; ANGIOGENESIS; EXPRESSION; N-6-ISOPENTENYLADENOSINE; INHIBITION; METFORMIN	N6-isopentenyladenosine (iPA), an end product of the mevalonate pathway with an isopentenyl chain, is already known to exert a suppressor effect against various tumors. In this work, we investigated whether iPA also directly interferes with the angiogenic process, which is fundamental to tumor growth and progression. To this end, using human umbilical vein endothelial cells (HUVECs) as a suitable in vitro model of angiogenesis, we evaluated their viability, proliferation, migration, invasion, tube formation in response to iPA, and molecular mechanisms involved. Data were corroborated in mice by using a gel plug assay. iPA dose- and time-dependently inhibited all the neoangiogenesis stages, with an IC50 of 0.98 M. We demonstrated for the first time, by liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS), that iPA was monophosphorylated into 5-iPA-monophosphate (iPAMP) by the adenosine kinase (ADK) inside the cells. iPAMP is the active form that inhibits angiogenesis through the direct activation of AMP-kinase (AMPK). Indeed, all effects were completely reversed by pretreatment with 5-iodotubercidin (5-Itu), an ADK inhibitor. The isoprenoid intermediate isopentenyl pyrophosphate (IPP), which shares the isopentenyl moiety with iPA, was ineffective in the inhibition of angiogenesis, thus showing that the iPA structure is specific for the observed effects. In conclusion, iPA is a novel AMPK activator and could represent a useful tool for the treatment of diseases where excessive neoangiogenesis is the underlying pathology. Pisanti, S., Picardi, P., Ciaglia, E., Margarucci, L., Ronca, R., Giacomini, A., Malfitano, A. M., Casapullo, A., Laezza, C., Gazzerro, P., Bifulco, M. Anti-angiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end-product, mediated by AMPK activation.	[Pisanti, Simona; Picardi, Paola; Ciaglia, Elena; Malfitano, Anna Maria; Bifulco, Maurizio] Univ Salerno, Dept Med & Surg, I-84084 Salerno, Italy; [Pisanti, Simona; Picardi, Paola; Ciaglia, Elena; Margarucci, Luigi; Malfitano, Anna Maria; Casapullo, Agostino; Gazzerro, Patrizia; Bifulco, Maurizio] Univ Salerno, Dept Pharm, I-84084 Salerno, Italy; [Ronca, Roberto; Giacomini, Arianna] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Laezza, Chiara] CNR, Inst Endocrinol & Expt Oncol IEOS, I-80125 Naples, Italy	University of Salerno; University of Salerno; University of Brescia; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Pisanti, S (corresponding author), Univ Salerno, Via Giovanni Paolo 2, I-84084 Salerno, Italy.	spisanti@unisa.it; maubiful@unisa.it	Giacomini, Arianna/K-4437-2016; Ronca, Roberto/AAC-6470-2022; laez, chi/AAW-4437-2020; Pisanti, Simona/J-3521-2012; Ciaglia, E/AAA-7924-2019; Giacomini, Arianna/U-6854-2019; CASAPULLO, Agostino/B-4236-2011	Giacomini, Arianna/0000-0002-9984-9033; Ronca, Roberto/0000-0001-8979-7068; Pisanti, Simona/0000-0003-1383-7929; Ciaglia, E/0000-0002-8035-4583; Bifulco, Maurizio/0000-0002-1771-4531; CASAPULLO, Agostino/0000-0002-2310-9426; Malfitano, Anna Maria/0000-0002-6193-2835	Associazione Educazione e Ricerca Medica Salernitana (ERMES); Associazione Italiana per la Ricerca sul Cancro [AIRC-IG 13312]; Fondazione Italiana per la Ricerca sul Cancro (FIRC)	Associazione Educazione e Ricerca Medica Salernitana (ERMES); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Fondazione Italiana per la Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Educazione e Ricerca Medica Salernitana (ERMES) and by Associazione Italiana per la Ricerca sul Cancro (AIRC-IG 13312 to M.B.). E.C. and A.G. were supported by a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC). The authors declare no conflicts of interest.	Auchampach JA, 2007, CIRC RES, V101, P1075, DOI 10.1161/CIRCRESAHA.107.165761; Bifulco M, 2008, ANTI-CANCER AGENT ME, V8, P200, DOI 10.2174/187152008783497028; Bucci M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057801; BURNS DM, 1976, CANCER BIOCHEM BIOPH, V1, P269; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chen MB, 2011, J CELL PHYSIOL, V226, P1915, DOI 10.1002/jcp.22522; Chen MB, 2011, CELL BIOCHEM BIOPHYS, V60, P311, DOI 10.1007/s12013-011-9153-0; Ciaglia E, 2013, J LEUKOCYTE BIOL, V94, P1207, DOI 10.1189/jlb.0413190; Coltrini D, 2013, ANGIOGENESIS, V16, P469, DOI 10.1007/s10456-012-9324-7; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; DIVEKAR AY, 1974, MOL PHARMACOL, V10, P529; Esfahanian N, 2012, MOL MED REP, V5, P1068, DOI 10.3892/mmr.2012.753; Ewart MA, 2008, ARTERIOSCL THROM VAS, V28, P2255, DOI 10.1161/ATVBAHA.108.175919; FAUST JR, 1991, J BIOL CHEM, V266, P9961; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Gaskin FS, 2009, MICROCIRCULATION, V16, P167, DOI 10.1080/10739680802355897; Goransson O, 2007, J BIOL CHEM, V282, P32549, DOI 10.1074/jbc.M706536200; Golovko A, 2000, GENE, V258, P85, DOI 10.1016/S0378-1119(00)00421-2; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Kanellis J, 2006, IMMUNOL CELL BIOL, V84, P6, DOI 10.1111/j.1440-1711.2005.01388.x; Laezza C, 1997, EXP CELL RES, V234, P178, DOI 10.1006/excr.1997.3610; Laezza C, 2006, FASEB J, V20, P412, DOI 10.1096/fj.05-4044lsf; Laezza C, 2010, MOL CARCINOGEN, V49, P892, DOI 10.1002/mc.20666; Laezza C, 2009, INT J CANCER, V124, P1322, DOI 10.1002/ijc.24056; Laezza C, 2008, ENDOCR-RELAT CANCER, V15, P965, DOI 10.1677/ERC-08-0030; Laezza C, 2008, J MOL MED, V86, P1341, DOI 10.1007/s00109-008-0396-1; Laezza C, 2006, FEBS LETT, V580, P6076, DOI 10.1016/j.febslet.2006.09.074; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee CW, 2012, CANCER RES, V72, P4394, DOI 10.1158/0008-5472.CAN-12-0429; Lee DH, 2012, CELL SIGNAL, V24, P2216, DOI 10.1016/j.cellsig.2012.07.019; Liu XM, 2011, AM J PHYSIOL-HEART C, V300, pH84, DOI 10.1152/ajpheart.00749.2010; Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Morizane Y, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199398; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Peyton KJ, 2012, J PHARMACOL EXP THER, V342, P827, DOI 10.1124/jpet.112.194712; Pisanti S, 2011, BLOOD, V117, P5541, DOI 10.1182/blood-2010-09-307355; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Reihill JA, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-9; Ronca R, 2013, J PATHOL, V230, P228, DOI 10.1002/path.4181; Ruscica M, 2011, J ENDOCRINOL INVEST, V34, pE362, DOI 10.3275/7803; Sanli T., 2013, CANCER BIOL THER, DOI [10.4161/cbt.26726, DOI 10.4161/CBT. 26726]; Santoro A, 2009, INT J CANCER, V125, P996, DOI 10.1002/ijc.24483; Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671; Sinclair CJD, 2001, BRIT J PHARMACOL, V134, P1037, DOI 10.1038/sj.bjp.0704349; Spinola M, 2007, INT J CANCER, V120, P2744, DOI 10.1002/ijc.22601; Stahmann N, 2010, J BIOL CHEM, V285, P10638, DOI 10.1074/jbc.M110.108688; Su KH, 2012, J CELL PHYSIOL, V227, P3053, DOI 10.1002/jcp.23052; Theodoropoulou S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052852; Theodoropoulou S, 2010, FASEB J, V24, P2620, DOI 10.1096/fj.09-152546; Vakana E, 2011, BLOOD, V118, P6399, DOI 10.1182/blood-2011-01-332783; Yung MMH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-327; Zheng QY, 2012, BIOCHEM BIOPH RES CO, V419, P741, DOI 10.1016/j.bbrc.2012.02.093; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zou MH, 2008, CLIN EXP PHARMACOL P, V35, P535, DOI 10.1111/j.1440-1681.2007.04851.x	58	29	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1132	1144		10.1096/fj.13-238238	http://dx.doi.org/10.1096/fj.13-238238			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24265487				2022-12-28	WOS:000335324800010
J	Wegener, JW; Loga, F; Stegner, D; Nieswandt, B; Hofmann, F				Wegener, Joerg W.; Loga, Florian; Stegner, David; Nieswandt, Bernhard; Hofmann, Franz			Phospholipase D1 is involved in alpha(1)-adrenergic contraction of murine vascular smooth muscle	FASEB JOURNAL			English	Article						blood pressure; intracellular signaling; Ca(V)1; 2 Ca2+ channel; U46619	PROTEIN-KINASE-C; RECEPTOR STIMULATION; ALPHA; ACTIVATION; RELAXATION; CHANNELS; ARTERIES; SUBSET; CELLS	(1)-Adrenergic stimulation increases blood vessel tone in mammals. This process involves a number of intracellular signaling pathways that include signaling via phospholipase C, diacylglycerol (DAG), and protein kinase C. So far, it is not certain whether signaling via phospholipase D (PLD) and PLD-derived DAG is involved in this process. We asked whether PLD participates in the (1)-adrenergic-mediated signaling in vascular smooth muscle. (1)-Adrenergic-induced contraction was assessed by myography of isolated aortic rings and by pressure recordings using the hindlimb perfusion model in mice. The effects of the PLD inhibitor 1-butanol (IC50 0.15 vol%) and the inactive congener 2-butanol were comparatively studied. Inhibition of PLD by 1-butanol reduced specifically the (1)-adrenergic-induced contraction and the (1)-adrenergic-induced pressure increase by 10 and 40% of the maximum, respectively. 1-Butanol did not influence the aortic contractions induced by high extracellular potassium, by the thromboxane analog U46619, or by a phorbol ester. The effects of 1-butanol were absent in mice that lack PLD1 (Pld1(-/-) mice) or that selectively lack the Ca(V)1.2 channel in smooth muscle (sm-Ca(V)1.2(-/-) mice) but still present in the heterozygous control mice. (1)-Adrenergic contraction of vascular smooth muscle involves activation of PLD1, which controls a portion of the (1)-adrenergic-induced Ca(V)1.2 channel activity.Wegener, J. W., Loga, F., Stegner, D., Nieswandt, B., Hofmann, F. Phospholipase D1 is involved in (1)-adrenergic contraction of murine vascular smooth muscle.	[Wegener, Joerg W.; Loga, Florian; Hofmann, Franz] Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; [Stegner, David; Nieswandt, Bernhard] Univ Wurzburg, Lehrstuhl Expt Biomed, Univ Klinikum Wurzburg, D-97070 Wurzburg, Germany; [Stegner, David; Nieswandt, Bernhard] Univ Wurzburg, Rudolf Virchow Zentrum, Deutsch Forsch Gemeinschaft DFG Forsch Zentrum Ex, D-97070 Wurzburg, Germany	Technical University of Munich; University of Wurzburg; University of Wurzburg	Wegener, JW (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	joerg.wegener@mytum.de	Stegner, David/AAA-4948-2019	Stegner, David/0000-0003-1059-9865; Wegener, Jorg/0000-0002-8129-1537	Deutsche Forschungsgemeinschaft [For 923, WE2650/4-1, Ni556/8-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Theodora Kernel for excellent technical assistance. This study was supported by the Deutsche Forschungsgemeinschaft (For 923, WE2650/4-1 to J.W.W. and Ni556/8-1 to B.N.).	Aittaleb M, 2010, MOL PHARMACOL, V77, P111, DOI 10.1124/mol.109.061234; Balboa MA, 1998, MOL PHARMACOL, V53, P221, DOI 10.1124/mol.53.2.221; Becker KP, 2005, CELL MOL LIFE SCI, V62, P1448, DOI 10.1007/s00018-005-4531-7; Becker KP, 2004, J BIOL CHEM, V279, P28251, DOI 10.1074/jbc.M400770200; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; Docherty JR, 2010, CELL MOL LIFE SCI, V67, P405, DOI 10.1007/s00018-009-0174-4; Elvers M, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000551; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; Hu TH, 2005, BIOCHEM BIOPH RES CO, V327, P1047, DOI 10.1016/j.bbrc.2004.12.117; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Huster M, 2010, FASEB J, V24, P2651, DOI 10.1096/fj.09-149856; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Klein J, 2005, J NEUROCHEM, V94, P1473, DOI 10.1111/j.1471-4159.2005.03315.x; Kurz T, 1999, CARDIOVASC RES, V42, P48, DOI 10.1016/S0008-6363(98)00298-3; Loga F, 2013, CARDIOVASC RES, V100, P280, DOI 10.1093/cvr/cvt176; Meng W, 1998, AM J PHYSIOL-HEART C, V274, pH411, DOI 10.1152/ajpheart.1998.274.2.H411; Mier K, 2002, CARDIOVASC RES, V54, P133, DOI 10.1016/S0008-6363(01)00566-1; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; Mueed I, 2005, BRIT J PHARMACOL, V146, P972, DOI 10.1038/sj.bjp.0706398; Murthy KS, 2006, ANNU REV PHYSIOL, V68, P345, DOI 10.1146/annurev.physiol.68.040504.094707; Muthalif MM, 2000, J PHARMACOL EXP THER, V293, P268; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; Salamanca DA, 2005, BIOCHEM PHARMACOL, V70, P1537, DOI 10.1016/j.bcp.2005.07.017; Sang RL, 2007, CHEM BIOL DRUG DES, V69, P240, DOI 10.1111/j.1747-0285.2007.00502.x; Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Taves J, 2008, ARCH BIOCHEM BIOPHYS, V477, P60, DOI 10.1016/j.abb.2008.05.007; Vorland M, 2008, PLATELETS, V19, P582, DOI 10.1080/09537100802454992; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005; Wier WG, 2004, REV PHYSIOL BIOCH P, V150, P91, DOI 10.1007/s10254-003-0019-8; Yamamoto Y, 2001, EUR J PHARMACOL, V424, P131, DOI 10.1016/S0014-2999(01)01134-7	31	1	1	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1044	1048		10.1096/fj.13-237925	http://dx.doi.org/10.1096/fj.13-237925			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24253251				2022-12-28	WOS:000335324800002
J	Ruisanchez, E; Dancs, P; Kerek, M; Nemeth, T; Farago, B; Balogh, A; Patil, R; Jennings, BL; Liliom, K; Malik, KU; Smrcka, AV; Tigyi, G; Benyo, Z				Ruisanchez, Eva; Dancs, Peter; Kerek, Margit; Nemeth, Tamas; Farago, Bernadett; Balogh, Andrea; Patil, Renukadevi; Jennings, Brett L.; Liliom, Karoly; Malik, Kafait U.; Smrcka, Alan V.; Tigyi, Gabor; Benyo, Zoltan			Lysophosphatidic acid induces vasodilation mediated by LPA(1) receptors, phospholipase C, and endothelial nitric oxide synthase	FASEB JOURNAL			English	Article						LPA; vasorelaxation; endothelium; eNOS; phospholipase C	CRUDE SOYBEAN LECITHIN; SPHINGOSINE 1-PHOSPHATE; GENE-EXPRESSION; SIGNALING PATHWAYS; CA2+ INFLUX; CELL DEATH; IN-VITRO; ACTIVATION; EPSILON; AUTOTAXIN	Lysophosphatidic acid (LPA) has been implicated as a mediator of several cardiovascular functions, but its potential involvement in the control of vascular tone is obscure. Here, we show that both LPA (18:1) and VPC31143 (a synthetic agonist of LPA(1-3) receptors) relax intact mouse thoracic aorta with similar E-max values (53.9 and 51.9% of phenylephrine-induced precontraction), although the EC50 of LPA- and VPC31143-induced vasorelaxations were different (400 vs. 15 nM, respectively). Mechanical removal of the endothelium or genetic deletion of endothelial nitric oxide synthase (eNOS) not only diminished vasorelaxation by LPA or VPC31143 but converted it to vasoconstriction. Freshly isolated mouse aortic endothelial cells expressed LPA(1), LPA(2), LPA(4) and LPA(5) transcripts. The LPA(1,3) antagonist Ki16425, the LPA(1) antagonist AM095, and the genetic deletion of LPA(1), but not that of LPA(2), abolished LPA-induced vasorelaxation. Inhibition of the phosphoinositide 3 kinase-protein kinase B/Akt pathway by wortmannin or MK-2206 failed to influence the effect of LPA. However, pharmacological inhibition of phospholipase C (PLC) by U73122 or edelfosine, but not genetic deletion of PLC epsilon, abolished LPA-induced vasorelaxation and indicated that a PLC enzyme, other than PLC epsilon, mediates the response. In summary, the present study identifies LPA as an endothelium-dependent vasodilator substance acting via LPA(1), PLC, and eNOS.Ruisanchez, E., Dancs, P., Kerek, M., Nemeth, T., Farago, B., Balogh, A., Patil, R., Jennings, B. L., Liliom, K., Malik, K. U., Smrcka, A. V., Tigyi, G., Benyo, Z. Lysophosphatidic acid induces vasodilation mediated by LPA(1) receptors, phospholipase C, and endothelial nitric oxide synthase.	[Ruisanchez, Eva; Dancs, Peter; Kerek, Margit; Nemeth, Tamas; Farago, Bernadett; Benyo, Zoltan] Semmelweis Univ, Inst Human Physiol & Clin Expt Res, H-1446 Budapest, Hungary; [Balogh, Andrea; Patil, Renukadevi; Tigyi, Gabor] Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN USA; [Jennings, Brett L.; Malik, Kafait U.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN USA; [Liliom, Karoly] Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Budapest, Hungary; [Smrcka, Alan V.] Univ Rochester, Sch Med, Dept Physiol & Pharmacol, Rochester, NY USA	Semmelweis University; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; University of Rochester	Benyo, Z (corresponding author), Semmelweis Univ, Inst Human Physiol & Clin Expt Res, POB 448, H-1446 Budapest, Hungary.	gtigyi@uthsc.edu; benyo.zoltan@med.semmelweis-univ.hu	Liliom, Karoly/A-6563-2011	Liliom, Karoly/0000-0002-7177-6872; Benyo, Zoltan/0000-0001-6015-0359	Hungarian National Innovation Office [OMFB-00770/2009]; Hungarian Scientific Research Fund [OTKA K-101775]; U.S. National Institutes of Health/National Cancer Institute [NCI CA-092160]; NATIONAL CANCER INSTITUTE [R01CA092160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053536] Funding Source: NIH RePORTER	Hungarian National Innovation Office; Hungarian Scientific Research Fund(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); U.S. National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are grateful to Andras Kiss (2nd Department of Pathology, Semmelweis University, Budapest, Hungary) for providing anticlaudin-5 antibody as well as to Bernadett Balazs, Ibolya Balog, Laszlo Hricisak, Eva Kormoci, Peter Mukli, Gergely Balazs Szabo and Judit Tolgyesi for expert secretarial and technical assistance. This study was supported by grants from the Hungarian National Innovation Office (OMFB-00770/2009), the Hungarian Scientific Research Fund (OTKA K-101775) and the U.S. National Institutes of Health/National Cancer Institute (NCI CA-092160) to Z.B. and to G. T., respectively.	Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Alexander JS, 1998, AM J PHYSIOL-HEART C, V274, pH115, DOI 10.1152/ajpheart.1998.274.1.H115; Amerongen GPV, 2000, ARTERIOSCL THROM VAS, V20, pE127, DOI 10.1161/01.ATV.20.12.e127; Bai ZB, 2013, J IMMUNOL, V190, P2036, DOI 10.4049/jimmunol.1202025; Blaho VA, 2011, CHEM REV, V111, P6299, DOI 10.1021/cr200273u; Brault S, 2007, AM J PHYSIOL-REG I, V292, pR1174, DOI 10.1152/ajpregu.00619.2006; Caner H, 2000, ACTA NEUROCHIR, V142, P455, DOI 10.1007/s007010050457; Chappell D, 2009, CIRC RES, V104, P1313, DOI 10.1161/CIRCRESAHA.108.187831; Chen CG, 2012, ATHEROSCLEROSIS, V222, P74, DOI 10.1016/j.atherosclerosis.2012.02.010; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Choi JW, 2013, BBA-MOL CELL BIOL L, V1831, P20, DOI 10.1016/j.bbalip.2012.07.015; Citro S, 2007, P NATL ACAD SCI USA, V104, P15543, DOI 10.1073/pnas.0702943104; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Dusaban SS, 2013, P NATL ACAD SCI USA, V110, P3609, DOI 10.1073/pnas.1217355110; Garrido JM, 2012, ANN VASC SURG, V26, P549, DOI 10.1016/j.avsg.2012.01.005; Gupte R, 2011, CHEMMEDCHEM, V6, P922, DOI 10.1002/cmdc.201000425; Gustin C, 2008, ARTERIOSCL THROM VAS, V28, P491, DOI 10.1161/ATVBAHA.107.158642; Hains MD, 2006, MOL PHARMACOL, V69, P2068, DOI 10.1124/mol.105.017921; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Horvath B, 2005, J CARDIOVASC PHARM, V45, P225, DOI 10.1097/01.fjc.0000154377.90069.b9; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kim EK, 2008, EXP MOL MED, V40, P445, DOI 10.3858/emm.2008.40.4.445; Kou RQ, 2002, BIOCHEMISTRY-US, V41, P4982, DOI 10.1021/bi016017r; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee Yu-We, 2006, Taiwania, V51, P11; LIAW L, 1993, ARTERIOSCLER THROMB, V13, P985, DOI 10.1161/01.ATV.13.7.985; McQuarrie E. B., 1960, U. S. Patent, Patent No. 2931818; Michel T, 2010, PFLUG ARCH EUR J PHY, V459, P807, DOI 10.1007/s00424-009-0765-9; Minnear FL, 2001, AM J PHYSIOL-LUNG C, V281, pL1337, DOI 10.1152/ajplung.2001.281.6.L1337; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Moolenaar WH, 2011, NAT REV MOL CELL BIO, V12, P674, DOI 10.1038/nrm3188; Muniyappa R, 2007, ENDOCR REV, V28, P463, DOI 10.1210/er.2007-0006; Mutoh T, 2012, BRIT J PHARMACOL, V165, P829, DOI 10.1111/j.1476-5381.2011.01622.x; Nakanaga K, 2010, J BIOCHEM, V148, P13, DOI 10.1093/jb/mvq052; Neidlinger NA, 2006, J BIOL CHEM, V281, P775, DOI 10.1074/jbc.M505790200; Niioka T., 2013, J CARDIOVASC PHARM, DOI 10.1097/FJC.0000000000000013; Ohata H, 2001, CIRC RES, V88, P925, DOI 10.1161/hh0901.090300; Ohata H, 2011, EXP PHYSIOL, V96, P468, DOI 10.1113/expphysiol.2011.056416; Palmetshofer A, 1999, THROMB HAEMOSTASIS, V82, P1532; Pamuklar Z, 2009, J BIOL CHEM, V284, P7385, DOI 10.1074/jbc.M807820200; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Rizza C, 1999, LAB INVEST, V79, P1227; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Sakai N, 2013, FASEB J, V27, P1830, DOI 10.1096/fj.12-219378; Sandow SL, 2009, AM J PHYSIOL-HEART C, V297, pH1, DOI 10.1152/ajpheart.00042.2009; Sarker MH, 2010, MICROCIRCULATION, V17, P39, DOI 10.1111/j.1549-8719.2010.00001.x; Schober A, 2012, BRIT J PHARMACOL, V167, P465, DOI 10.1111/j.1476-5381.2012.02021.x; Schulze C, 1997, J NEUROCHEM, V68, P991; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; Shibata K, 2011, J CARDIOVASC PHARM, V57, P604, DOI 10.1097/FJC.0b013e3182144174; Shimizu Hideki, 2005, Brain Tumor Pathol, V22, P59, DOI 10.1007/s10014-005-0190-5; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Smrcka AV, 2012, CELL SIGNAL, V24, P1333, DOI 10.1016/j.cellsig.2012.01.009; Smyth SS, 2008, BBA-MOL CELL BIOL L, V1781, P563, DOI 10.1016/j.bbalip.2008.05.008; Swaney JS, 2011, J PHARMACOL EXP THER, V336, P693, DOI 10.1124/jpet.110.175901; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; Tigyi G, 2010, BRIT J PHARMACOL, V161, P241, DOI 10.1111/j.1476-5381.2010.00815.x; TOKUMURA A, 1978, LIPIDS, V13, P468, DOI 10.1007/BF02533615; TOKUMURA A, 1995, RES COMMUN MOL PATH, V90, P96; TOKUMURA A, 1978, AGR BIOL CHEM TOKYO, V42, P515, DOI 10.1080/00021369.1978.10863013; TOKUMURA A, 1978, LIPIDS, V13, P572, DOI 10.1007/BF02533598; Ueda H, 2006, PHARMACOL THERAPEUT, V109, P57, DOI 10.1016/j.pharmthera.2005.06.003; Wang H, 2005, CIRC RES, V97, P1305, DOI 10.1161/01.RES.0000196578.15385.bb; Xiang SY, 2013, BBA-MOL CELL BIOL L, V1831, P213, DOI 10.1016/j.bbalip.2012.09.004; Yakubu MA, 1997, AM J PHYSIOL-REG I, V273, pR703, DOI 10.1152/ajpregu.1997.273.2.R703; Yanagida K, 2013, BBA-MOL CELL BIOL L, V1831, P33, DOI 10.1016/j.bbalip.2012.08.003; Yin F, 2005, INVEST OPHTH VIS SCI, V46, P1927, DOI 10.1167/iovs.04-1256; Zhang YF, 2012, J IMMUNOL, V189, P3914, DOI 10.4049/jimmunol.1201604; Zhou Z, 2011, CELL METAB, V13, P592, DOI 10.1016/j.cmet.2011.02.016	73	18	18	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					880	890		10.1096/fj.13-234997	http://dx.doi.org/10.1096/fj.13-234997			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24249637	Green Published			2022-12-28	WOS:000331072200033
J	Ritz, SA; Antle, DM; Cote, J; Deroy, K; Fraleigh, N; Messing, K; Parent, L; St-Pierre, J; Vaillancourt, C; Mergler, D				Ritz, Stacey A.; Antle, David M.; Cote, Julie; Deroy, Kathy; Fraleigh, Nya; Messing, Karen; Parent, Lise; St-Pierre, Joey; Vaillancourt, Cathy; Mergler, Donna			First steps for integrating sex and gender considerations into basic experimental biomedical research	FASEB JOURNAL			English	Article						transformed cell lines; primary cell cultures; animal models	HEALTH; MALES; TESTOSTERONE; SUPPRESSION; DIMORPHISM; HORMONES; MICE	In recent decades there has been an increasing recognition of the need to account for sex and gender in biology and medicine, in order to develop a more comprehensive understanding of biological phenomena and to address gaps in medical knowledge that have arisen due to a generally masculine bias in research. We have noted that as basic experimental biomedical researchers, we face unique challenges to the incorporation of sex and gender in our work, and that these have remained largely unarticulated, misunderstood, and unaddressed in the literature. Here, we describe some of the specific challenges to the incorporation of sex and gender considerations in research involving cell cultures and laboratory animals. In our view, the mainstreaming of sex and gender considerations in basic biomedical research depends on an approach that will allow scientists to address these issues in ways that do not undermine our ability to pursue our fundamental scientific interests. To that end, we suggest a number of strategies that allow basic experimental researchers to feasibly and meaningfully take sex and gender into account in their work. Ritz, S.A., Antle, D. M., Cote, J., Deroy, K., Fraleigh, N., Messing, K., Parent, L., St-Pierre, J., Vaillancourt, C., Mergler, D. First steps for integrating sex and gender considerations into basic experimental biomedical research.	[Ritz, Stacey A.] Northern Ontario Sch Med, Div Med Sci, Sudbury, ON, Canada; [Ritz, Stacey A.; Cote, Julie; Messing, Karen; Parent, Lise; Vaillancourt, Cathy; Mergler, Donna] Univ Quebec, Ctr Rech Interdisciplinaire Biol Sante Soc & Envi, Montreal, PQ H3C 3P8, Canada; [Messing, Karen; Mergler, Donna] Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada; [Antle, David M.; Cote, Julie] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada; [Deroy, Kathy; St-Pierre, Joey; Vaillancourt, Cathy] Univ Quebec, Inst Armand Frappier, Inst Natl Rech Sci, Laval, PQ, Canada; [Fraleigh, Nya] Laurentian Univ, Dept Biol, Sudbury, ON P3E 2C6, Canada; [Parent, Lise] Univ Quebec, Tele Univ, Montreal, PQ, Canada	Northern Ontario School of Medicine; University of Quebec; University of Quebec Montreal; University of Quebec; University of Quebec Montreal; McGill University; University of Quebec; Institut national de la recherche scientifique (INRS); Laurentian University; University of Quebec; University of Quebec Montreal	Ritz, SA (corresponding author), Laurentian Univ, Northern Ontario Sch Med, East Campus,935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.	sritz@nosm.ca		Messing, Karen/0000-0001-6657-0725; Vaillancourt, Cathy/0000-0003-0543-6244	CIHR Institute of Gender and Health [GTA92108]	CIHR Institute of Gender and Health(Canadian Institutes of Health Research (CIHR))	The authors thank Marie-Eve Rioux-Pelletier, coordinator of the Canadian Institute of Health Research (CIHR) Team in Gender, Environment, and Health, for invaluable administrative support. The authors also thank all members and associates of the CIHR Team in Gender, Environment, and Health for conversations that have helped them to elucidate these ideas, and to Dr. Deboleena Roy, who offered intellectually generous and constructive critiques on the original version of this manuscript. Financial support for the CIHR Team in Gender, Environment, and Health was provided by an Emerging Team grant from the CIHR Institute of Gender and Health (GTA92108).	American Type Culture Collection, 2013, PROD SHEET HCC827 AT; American Type Culture Collection, 2013, PROD SHEET A549 ATCC; Barrett ELB, 2011, AGING CELL, V10, P913, DOI 10.1111/j.1474-9726.2011.00741.x; Baylis C, 2012, J GERONTOL A-BIOL, V67, P1365, DOI 10.1093/gerona/gls171; Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002; Campesi Ilaria, 2012, Handb Exp Pharmacol, P265, DOI 10.1007/978-3-642-30726-3_13; Canadian Institutes of Health Research Institute of Gender and Health, 2012, WHAT DIFF SEX GEND M; CHAMPLIN AK, 1971, J REPROD FERTIL, V27, P233, DOI 10.1530/jrf.0.0270233; Connell R., 2021, GENDER WORLD PERSPEC, V4; DELPHY C, 1993, WOMEN STUD INT FORUM, V16, P1, DOI 10.1016/0277-5395(93)90076-L; Demyanets Svitlana, 2012, Handb Exp Pharmacol, P443, DOI 10.1007/978-3-642-30726-3_20; Durdiakova J, 2011, ACTA NEUROBIOL EXP, V71, P434; Epstein S., 2004, BODY SOC THOUSAND OA, V10, P183, DOI DOI 10.1177/1357034X04042942; Fairweather D, 2013, CURR PROB CARDIOLOGY, V38, P7, DOI 10.1016/j.cpcardiol.2012.07.003; Fausto-Sterling A, 2005, SIGNS, V30, P1491, DOI 10.1086/424932; Fausto-Sterling A., 2012, SEX GENDER BIOL SOCI; Fine C., 2010, DELUSIONS GENDER OUR; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Gendered Innovations in Science Health & Medicine Engineering and Environment, 2011, AN RES DES HLTH BIOM; Gendered Innovations Project, 2011, GEND INN SCI HLTH ME; Green KK, 2011, ANIM BEHAV, V81, P901, DOI 10.1016/j.anbehav.2011.01.033; Haig D, 2004, ARCH SEX BEHAV, V33, P87, DOI 10.1023/B:ASEB.0000014323.56281.0d; Hostinar C. E., 2013, PSYCHOL B; Kalueff AV, 2006, BEHAV PROCESS, V71, P8, DOI 10.1016/j.beproc.2005.09.004; Klein Sabra L, 2012, Handb Exp Pharmacol, P499, DOI 10.1007/978-3-642-30726-3_22; Klein SL, 2012, ENDOCRINOLOGY, V153, P2544, DOI 10.1210/en.2011-2120; Krause DN, 2006, J APPL PHYSIOL, V101, P1252, DOI 10.1152/japplphysiol.01095.2005; KRAVDAL O, 1995, INT J EPIDEMIOL, V24, P477, DOI 10.1093/ije/24.3.477; Krieger N, 2003, INT J EPIDEMIOL, V32, P652, DOI 10.1093/ije/dyg156; Libert C, 2010, NAT REV IMMUNOL, V10, P594, DOI 10.1038/nri2815; Ma WD, 1998, BIOL REPROD, V59, P1317, DOI 10.1095/biolreprod59.6.1317; Magkos F, 2010, NUTRITION, V26, P686, DOI 10.1016/j.nut.2009.10.013; Manole MD, 2011, CURR PHARM DESIGN, V17, P3854; MARTIN E, 1991, SIGNS, V16, P485, DOI 10.1086/494680; Martocchia A, 2011, CURR TOP MED CHEM, V11, P1668; McCombe PA, 2009, CURR MOL MED, V9, P1058, DOI 10.2174/156652409789839116; Oliffe J.L., 2012, DESIGNING CONDUCTING; Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013; Petersen A., 1998, UNMASKING MASCULINE; Regitz-Zagrosek V, 2013, HYPERTENSION, V61, P270, DOI 10.1161/HYPERTENSIONAHA.111.189233; Rogers L. J., 2011, GENDER SCI DIFFERENC, P27; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Sharman Z, 2012, SOC SCI MED, V74, P1812, DOI 10.1016/j.socscimed.2011.08.039; Spoletini Ilaria, 2012, Handb Exp Pharmacol, P91, DOI 10.1007/978-3-642-30726-3_5; van Anders SM, 2012, HORM BEHAV, V61, P31, DOI 10.1016/j.yhbeh.2011.09.012; Verthelyi D, 2001, INT IMMUNOPHARMACOL, V1, P983, DOI 10.1016/S1567-5769(01)00044-3; Vina J, 2011, CURR PHARM DESIGN, V17, P3959, DOI 10.2174/138161211798764942; Walker PL, 1998, AM J PHYS ANTHROPOL, V106, P255, DOI 10.1002/(SICI)1096-8644(199806)106:2<255::AID-AJPA11>3.3.CO;2-F; Waxman DJ, 2006, MOL ENDOCRINOL, V20, P2613, DOI 10.1210/me.2006-0007; Wilder RL, 2002, ANN NY ACAD SCI, V966, P13, DOI 10.1111/j.1749-6632.2002.tb04197.x; Wizeman T.M., 2001, EXPLORING BIOL CONTR; Zucker I, 2010, NATURE, V465, P690, DOI 10.1038/465690a	52	63	64	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					4	13		10.1096/fj.13-233395	http://dx.doi.org/10.1096/fj.13-233395			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24056086	Green Accepted			2022-12-28	WOS:000333526100003
J	Gyimesi, M; Pires, RH; Billington, N; Sarlos, K; Kocsis, ZS; Modos, K; Kellermayer, MSZ; Kovacs, M				Gyimesi, Mate; Pires, Ricardo H.; Billington, Neil; Sarlos, Kata; Kocsis, Zsuzsa S.; Modos, Karoly; Kellermayer, Miklos S. Z.; Kovacs, Mihaly			Visualization of human Bloom's syndrome helicase molecules bound to homologous recombination intermediates	FASEB JOURNAL			English	Article						DNA repair; oligomerization; structure; electron microscopy; atomic force microscopy	TOPOISOMERASE-III-ALPHA; ATOMIC-FORCE MICROSCOPY; BLM HELICASE; COLI UVRD; D-LOOPS; DNA; MECHANISM; TRANSLOCATION; SUBSTRATE; MONOMERS	Homologous recombination (HR) is a key process in the repair of double-stranded DNA breaks (DSBs) that can initiate cancer or cell death. Human Bloom's syndrome RecQ-family DNA helicase (BLM) exerts complex activities to promote DSB repair while avoiding illegitimate HR. The oligomeric assembly state of BLM has been a key unresolved aspect of its activities. In this study we assessed the structure and oligomeric state of BLM, in the absence and presence of key HR-intermediate DNA structures, by using single-molecule visualization (electron microscopic and atomic force microscopic single-particle analysis) and solution biophysical (dynamic light scattering, kinetic and equilibrium binding) techniques. Besides full-length BLM, we used a previously characterized truncated construct (BLM642-1290) as a monomeric control. Contrary to previous models proposing a ring-forming oligomer, we found the majority of BLM molecules to be monomeric in all examined conditions. However, BLM showed a tendency to form dimers when bound to branched HR intermediates. Our results suggest that HR activities requiring single-stranded DNA translocation are performed by monomeric BLM, while complex DNA structures encountered and dissolved by BLM in later stages of HR induce partial oligomerization of the helicase.	[Gyimesi, Mate; Sarlos, Kata; Kocsis, Zsuzsa S.; Kovacs, Mihaly] Eotvos Lorand Univ, Dept Biochem, Hungarian Acad Sci, ELTE MTA,Momentum Motor Enzymol Res Grp, H-1117 Budapest, Hungary; [Pires, Ricardo H.; Modos, Karoly; Kellermayer, Miklos S. Z.] Semmelweis Univ, Dept Biophys & Radiat Biol, H-1085 Budapest, Hungary; [Billington, Neil] NHLBI, Lab Mol Physiol, Bethesda, MD 20892 USA	Eotvos Lorand University; Hungarian Academy of Sciences; Semmelweis University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kovacs, M (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany P S 1-c, H-1117 Budapest, Hungary.	kovacsm@elte.hu	Kovacs, Mihaly/A-6841-2011; Gyimesi, Mate/I-2639-2017	Kellermayer, Miklos/0000-0002-5553-6553; Billington, Neil/0000-0003-2306-0228; Horvath-Sarlos, Kata/0000-0003-3813-0209; Kovacs, Mihaly/0000-0002-1200-4741; Kocsis, Zsuzsa/0000-0002-4336-3325; Gyimesi, Mate/0000-0002-7195-1925	Norway grants [NNF2-85613]; Hungarian Scientific Research Fund [K71915, NK81950]; TAMOP [4.2.1/B-09/1/KMR-2010-0003]; Human Frontier Science Program [RGY0072/2010]; Momentum Program of the Hungarian Academy of Sciences [LP2011-006/2011]; European Union; European Social Fund	Norway grants; Hungarian Scientific Research Fund(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); TAMOP; Human Frontier Science Program(Human Frontier Science Program); Momentum Program of the Hungarian Academy of Sciences; European Union(European Commission); European Social Fund(European Social Fund (ESF))	The authors thank The Electron Microscopy Core Facility of the U. S. National Heart, Lung, and Blood Institute for the use of electron microscopy facilities. This work was supported by Norway grants (NNF2-85613 to M. K.); the Hungarian Scientific Research Fund (K71915 and NK81950 to M. K.); TAMOP (4.2.1/B-09/1/KMR-2010-0003 to M. K.); the Human Frontier Science Program (RGY0072/2010 to M. K.); and the Momentum Program of the Hungarian Academy of Sciences (LP2011-006/2011 to M. K.). M. K. is a Bolyai Fellow of the Hungarian Academy of Sciences. M. G. is a Marie Curie Fellow. This research was realized in the frames of TAMOP 4.2.4. A/2-11-1-2012-0001, National Excellence Program: elaborating and operating an inland student and researcher personal support system. The project was subsidized by the European Union and cofinanced by the European Social Fund.	Bachrati CZ, 2006, NUCLEIC ACIDS RES, V34, P2269, DOI 10.1093/nar/gkl258; Beresten SF, 1999, PROTEIN EXPRES PURIF, V17, P239, DOI 10.1006/prep.1999.1135; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; BRYAN RK, 1990, FUND THEOR, V39, P221; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Bugreev DV, 2009, J BIOL CHEM, V284, P26349, DOI 10.1074/jbc.M109.029371; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; Compton SA, 2008, J BIOL CHEM, V283, P24478, DOI 10.1074/jbc.M803370200; Doherty KM, 2005, J BIOL CHEM, V280, P29494, DOI 10.1074/jbc.M500653200; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Forget AL, 2012, NATURE, V482, P423, DOI 10.1038/nature10782; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Gyimesi M, 2010, NUCLEIC ACIDS RES, V38, P4404, DOI 10.1093/nar/gkq145; Hoo CM, 2008, J NANOPART RES, V10, P89, DOI 10.1007/s11051-008-9435-7; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kim YM, 2010, NUCLEIC ACIDS RES, V38, P7764, DOI 10.1093/nar/gkq586; Lodish H., 2004, MOL BIOL CELL; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATLOCK DL, BIOCHEMISTRY, V49, P2097; Mazina OM, 2012, J BIOL CHEM, V287, P11820, DOI 10.1074/jbc.M112.341347; Muzzolini L, 2007, PLOS BIOL, V5, P157, DOI 10.1371/journal.pbio.0050020; Niedziela-Majka A, 2007, J BIOL CHEM, V282, P27076, DOI 10.1074/jbc.M704399200; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811; Plank JL, 2006, P NATL ACAD SCI USA, V103, P11118, DOI 10.1073/pnas.0604873103; Ralf C, 2006, J BIOL CHEM, V281, P22839, DOI 10.1074/jbc.M604268200; Sambrook J., 2001, MOL CLONING; Shi C, 2009, BBA-GEN SUBJECTS, V1790, P1, DOI 10.1016/j.bbagen.2008.10.003; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Vindigni A, 2009, HFSP J, V3, P153, DOI 10.2976/1.3079540; Wang HD, 2002, BIOPHYS J, V83, P3619, DOI 10.1016/S0006-3495(02)75362-9; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Xu YN, 2012, NUCLEIC ACIDS RES, V40, P9802, DOI 10.1093/nar/gks728	40	11	11	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4954	4964		10.1096/fj.13-234088	http://dx.doi.org/10.1096/fj.13-234088			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24005907	Green Published			2022-12-28	WOS:000329999000029
J	Campolo, M; Esposito, E; Ahmad, A; Di Paola, R; Wallace, JL; Cuzzocrea, S				Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Wallace, John L.; Cuzzocrea, Salvatore			A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury	FASEB JOURNAL			English	Article						inflammation; apoptosis; central nervous system; motor recovery; nonsteroidal anti-inflammatory drug	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; NITRIC-OXIDE; INFLAMMATORY RESPONSE; SIGNALING MOLECULE; OXIDATIVE STRESS; MOUSE MODEL; RAT; EXPRESSION; APOPTOSIS	Spinal cord trauma causes loss of motor function that is in part due to the ensuing inflammatory response. Hydrogen sulfide (H2S) is a potent, endogenous anti-inflammatory and neuroprotective substance that has been explored for use in the design of novel nonsteroidal anti-inflammatory drugs. In the current study, we evaluated the potential beneficial effects of ATB-346 [2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester], an H2S-releasing derivative of naproxen, in a murine model of spinal cord injury (SCI). SCI was induced in mice by spinal cord compression, produced through the application of vascular clips to the dura via a T5 to T8 laminectomy. ATB-346, naproxen (both at 30 mol/kg), or vehicle was orally administered to the mice 1 and 6 h after SCI and once daily thereafter for 10 d. Motor function [Basso Mouse Scale (BMS) of locomotion] improved gradually in the mice treated with naproxen. However, those treated with ATB-346 exhibited a significantly more rapid and sustained recovery of motor function, achieving greater than double the increase in locomotion score of the naproxen group by the 10th day of treatment. ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI. Again, the effects of ATB-346 were superior to those of naproxen for several parameters. These results showed marked beneficial effects of an H2S-releasing derivative of naproxen in an animal model of SCI, significantly enhancing recovery of motor function, possibly by reducing the secondary inflammation and tissue injury that characterizes this model. The combination of inhibition of cyclooxygenase and delivery of H2S may offer a promising alternative to existing therapies for traumatic injury.Campolo, M., Esposito, E., Ahmad, A., Di Paola, R., Wallace, J. L., Cuzzocrea, A. Hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury.	[Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, Messina, Italy; [Wallace, John L.] Univ Calgary, Inflammat Res Network, Calgary, AB T2N 4N1, Canada; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Sch Med, Manchester Biomed Res Ctr, Manchester M13 9WL, Lancs, England	University of Messina; University of Calgary; University of Manchester	Wallace, JL (corresponding author), Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada.	altapharm@hotmail.com	Campolo, Michela/K-6432-2016; di paola, rosanna/U-4356-2019; Wallace, John/AAL-3763-2021	di paola, rosanna/0000-0001-6725-8581; Esposito, Emanuela/0000-0002-2663-6387; Ahmad, Akbar/0000-0003-1841-9670; Cuzzocrea, Salvatore/0000-0001-6131-3690; Campolo, Michela/0000-0002-5124-3876	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank Carmelo La Spada for excellent technical assistance during this study, Caterina Cutrona for secretarial assistance, and Valentina Malvagni for editorial assistance with the manuscript. This work was supported by a grant from the Canadian Institutes of Health Research (to J.L.W.). J.L.W. is a founder and shareholder of Antibe Therapeutics, Inc.	Abe K, 1996, J NEUROSCI, V16, P1066; Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blackler R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035196; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Chu QJ, 2013, J SURG RES, V183, P330, DOI 10.1016/j.jss.2012.12.003; Chvatal SA, 2008, BIOMATERIALS, V29, P1967, DOI 10.1016/j.biomaterials.2008.01.002; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Finnerup NB, 2001, SPINAL CORD, V39, P256, DOI 10.1038/sj.sc.3101161; Fiorucci S, 2007, BRIT J PHARMACOL, V150, P996, DOI 10.1038/sj.bjp.0707193; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Geng B, 2004, BIOCHEM BIOPH RES CO, V313, P362, DOI 10.1016/j.bbrc.2003.11.130; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2008, SHOCK, V30, P142, DOI 10.1097/SHK.0b013e31815dd381; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; Gong QH, 2010, PHARMACOL BIOCHEM BE, V96, P52, DOI 10.1016/j.pbb.2010.04.006; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Kimura H, 2005, ANTIOXID REDOX SIGN, V7, P778, DOI 10.1089/ars.2005.7.778; Kimura H, 2012, ANTIOXID REDOX SIGN, V17, P45, DOI 10.1089/ars.2011.4345; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014; Lin H, 2006, ANN NEUROL, V60, P399, DOI 10.1002/ana.20965; Liu KL, 2006, J AGR FOOD CHEM, V54, P3472, DOI 10.1021/jf060043k; Malaspina A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-500; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Pedersen MO, 2009, BIOFACTORS, V35, P315, DOI 10.1002/biof.44; Resnick DK, 2004, NEUROREPORT, V15, P837, DOI 10.1097/00001756-200404090-00020; Schmitt Caroline, 2006, Spine J, V6, P113, DOI 10.1016/j.spinee.2005.05.379; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tan BH, 2010, NEUROCHEM INT, V56, P3, DOI 10.1016/j.neuint.2009.08.008; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Wallace J. L., 2008, United States Patent Application, Patent No. [WO/2008/009127, 2008009127]; Wallace JL, 2007, FASEB J, V21, P4070, DOI 10.1096/fj.07-8669com; Wallace JL, 2007, TRENDS PHARMACOL SCI, V28, P501, DOI 10.1016/j.tips.2007.09.003; Wallace JL, 2007, GASTROENTEROLOGY, V132, P261, DOI 10.1053/j.gastro.2006.11.042; Wallace JL, 2010, BRIT J PHARMACOL, V159, P1236, DOI 10.1111/j.1476-5381.2009.00611.x; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yip PK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-6; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	61	34	37	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4489	4499		10.1096/fj.13-234716	http://dx.doi.org/10.1096/fj.13-234716			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23901068				2022-12-28	WOS:000329937500016
J	Giri, A; Bajpai, S; Trenton, N; Jayatilaka, H; Longmore, GD; Wirtz, D				Giri, Anjil; Bajpai, Saumendra; Trenton, Nicholaus; Jayatilaka, Hasini; Longmore, Gregory D.; Wirtz, Denis			The Arp2/3 complex mediates multigeneration dendritic protrusions for efficient 3-dimensional cancer cell migration	FASEB JOURNAL			English	Article						3D environment; collagen I matrix; matrix deformation	N-WASP; CORTACTIN; ACTIVATION; LAMELLIPODIA; INVADOPODIA; COLLAGEN; PROTEIN; GTPASES; ROLES; CYTOSKELETON	Arp2/3 is a protein complex that nucleates actin filament assembly in the lamellipodium in adherent cells crawling on planar 2-dimensional (2D) substrates. However, in physiopathological situations, cell migration typically occurs within a 3-dimensional (3D) environment, and little is known about the role of Arp2/3 and associated proteins in 3D cell migration. Using time resolved live-cell imaging and HT1080, a fibrosarcoma cell line commonly used to study cell migration, we find that the Arp2/3 complex and associated proteins N-WASP, WAVE1, cortactin, and Cdc42 regulate 3D cell migration. We report that this regulation is caused by formation of multigeneration dendritic protrusions, which mediate traction forces on the surrounding matrix and effective cell migration. The primary protrusions emanating directly from the cell body and prolonging the nucleus forms independent of Arp2/3 and dependent on focal adhesion proteins FAK, talin, and p130Cas. The Arp2/3 complex, N-WASP, WAVE1, cortactin, and Cdc42 regulate the secondary protrusions branching off from the primary protrusions. In 3D matrices, fibrosarcoma cells as well as migrating breast, pancreatic, and prostate cancer cells do not display lamellipodial structures. This study characterizes the unique topology of protrusions made by cells in a 3D matrix and show that these dendritic protrusions play a critical role in 3D cell motility and matrix deformation. The relative contribution of these proteins to 3D migration is significantly different from their role in 2D migration.Giri, A., Bajpai, S., Trenton, N., Jayatilaka, H., Longmore, G. D., Wirtz, D. The Arp2/3 complex mediates multigeneration dendritic protrusions for efficient 3-dimensional cancer cell migration.	[Giri, Anjil; Bajpai, Saumendra; Trenton, Nicholaus; Jayatilaka, Hasini; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Giri, Anjil; Bajpai, Saumendra; Longmore, Gregory D.; Wirtz, Denis] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Longmore, Gregory D.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Longmore, Gregory D.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Longmore, Gregory D.] Washington Univ, Sch Med, Bridging Res Imaging Genom & High Throughput BRIG, St Louis, MO 63110 USA	Johns Hopkins University; Johns Hopkins University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Wirtz, D (corresponding author), Johns Hopkins Univ, 3400 North Charles St,Croft Hall, Baltimore, MD 21218 USA.	glongmor@dom.wustl.edu; wirtz@jhu.edu	Bajpai, Saumendra/B-8120-2014	Bajpai, Saumendra/0000-0002-9397-2102	U.S. National Institutes of Health (NIH) [GM084204, CA143868, CA85839]; NATIONAL CANCER INSTITUTE [R01CA085839, U54CA143868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084204] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health (NIH) grants GM084204, CA143868, and CA85839. D.W. acknowledges fruitful discussions with Dr. Sean X. Sun (Johns Hopkins Physical Sciences-Oncology Center, Johns Hopkins University). A.G. and D.W. designed the experiments; A.G., S.B.K., NT., H.J., and D.W. conducted the experiments and analyzed the data; A.G. and D.W. wrote the article; A.G., D.W., and G.D.L. edited the article. The authors declare no conflicts of interest.	Bloom RJ, 2008, BIOPHYS J, V95, P4077, DOI 10.1529/biophysj.108.132738; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Christiansen DL, 2000, MATRIX BIOL, V19, P409, DOI 10.1016/S0945-053X(00)00089-5; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Fraley SI, 2011, NAT CELL BIOL, V13, P5, DOI 10.1038/ncb0111-5; Fraley SI, 2010, NAT CELL BIOL, V12, P598, DOI 10.1038/ncb2062; Friedl P, 2009, CANCER METAST REV, V28, P129, DOI 10.1007/s10555-008-9174-3; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Grinnell F, 2003, MOL BIOL CELL, V14, P384, DOI 10.1091/mbc.E02-08-0493; Huttenlocher A., 2011, COLD SPRING HARBOR P, V3; Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103; Khatau SB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00488; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Konstantopoulos K, 2013, BIOPHYS J, V104, P279, DOI 10.1016/j.bpj.2012.12.016; Kowalski JR, 2005, J CELL SCI, V118, P79, DOI 10.1242/jcs.01586; Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Raub CB, 2007, BIOPHYS J, V92, P2212, DOI 10.1529/biophysj.106.097998; Rhee S, 2007, P NATL ACAD SCI USA, V104, P5425, DOI 10.1073/pnas.0608030104; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Shakir MA, 2008, GENETICS, V179, P1957, DOI 10.1534/genetics.108.088963; Suraneni P, 2012, J CELL BIOL, V197, P239, DOI 10.1083/jcb.201112113; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vignjevic D, 2003, J CELL BIOL, V160, P951, DOI 10.1083/jcb.200208059; Weaver AM, 2008, CURR BIOL, V18, pR362, DOI 10.1016/j.cub.2008.02.028; Weaver AM, 2003, CURR OPIN CELL BIOL, V15, P23, DOI 10.1016/S0955-0674(02)00015-7; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wu CY, 2012, CELL, V148, P973, DOI 10.1016/j.cell.2011.12.034; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317; Yu XZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030605; Zhou XM, 2008, GENE DEV, V22, P1231, DOI 10.1101/gad.1643308	45	48	49	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4089	4099		10.1096/fj.12-224352	http://dx.doi.org/10.1096/fj.12-224352			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23796785	Green Published			2022-12-28	WOS:000329747100021
J	Gu, W; Fukuda, T; Isaji, T; Hashimoto, H; Wang, YQ; Gu, JG				Gu, Wei; Fukuda, Tomohiko; Isaji, Tomoya; Hashimoto, Hirokazu; Wang, Yuqin; Gu, Jianguo			alpha 1,6-Fucosylation regulates neurite formation via the activin/phospho-Smad2 pathway in PC12 cells: the implicated dual effects of Fut8 for TGF-beta/activin-mediated signaling	FASEB JOURNAL			English	Article						N-glycosylation; glycosyltransferase; cell differentiation	GROWTH-FACTOR-BETA; CORE FUCOSYLATION; ALPHA-1,6-FUCOSYL-TRANSFERASE-DEFICIENT MICE; ALPHA-3-BETA-1 INTEGRIN; N-ACETYLGLUCOSAMINE; NERVOUS-SYSTEM; EXPRESSION; PHENOTYPE; FUCOSE; DIFFERENTIATION	It is well known that 1,6-fucosyltransferase (Fut8) and its products, 1,6-fucosylated N-glycans, are highly expressed in brain tissue. Recently, we reported that Fut8-knockout mice exhibited multiple behavioral abnormalities with a schizophrenia-like phenotype, suggesting that 1,6-fucosylation plays important roles in the brain and neuron system. In the present study, we screened several neural cell lines and found that PC12 cells express the highest levels of 1,6-fucosylation. The knockdown (KD) of Fut8 promoted a significant enhancement of neurite formation and induction of neurofilament expression. Surprisingly, the levels of phospho-Smad2 were greatly increased in the KD cells. Finally, we found that the activin-mediated signal pathway was essential for these changes in KD cells. Exogenous activin, not TGF-1, induced neurite outgrowth and phospho-Smad2. In addition, the 1,6-fucosylation level on the activin receptors was greatly decreased in KD cells, while the total expression level was unchanged, suggesting that 1,6-fucosylation negatively regulated activin-mediated signaling. Furthermore, inhibition of activin receptor-mediated signaling or restoration of Fut8 expression rescued cell morphology and phospho-Smad2 levels, which were enhanced in KD cells. Considering the fact that 1,6-fucosylation is important for TGF--mediated signaling, the results of this study strongly suggest that Fut8 plays a dual role in TGF-/activin-mediated signaling.Gu, W., Fukuda, T., Isaji, T., Hashimoto, H., Wang, Y., Gu, J. 1,6-Fucosylation regulates neurite formation via the activin/phospho-Smad2 pathway in PC12 cells: the implicated dual effects of Fut8 for TGF-/activin-mediated signaling.	[Gu, Wei; Fukuda, Tomohiko; Isaji, Tomoya; Hashimoto, Hirokazu; Wang, Yuqin; Gu, Jianguo] Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Inst Mol Biomembrane & Glycobiol, Sendai, Miyagi 9818558, Japan	Tohoku Medical & Pharmaceutical University	Gu, JG (corresponding author), Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Inst Mol Biomembrane & Glycobiol, Aoba Ku, 4-4-1 Komatsushima, Sendai, Miyagi 9818558, Japan.	jgu@tohoku-pharm.ac.jp	Isaji, Tomoya/ABC-9285-2021; Gu, Jianguo/ABC-9257-2020		Japan Society for the Promotion of Science [21370059, 23651196]; Ministry of Education, Culture, Sports, Science, and Technology of Japan [23110002, 24590087]; Mizutani Foundation for Glycoscience; Grants-in-Aid for Scientific Research [24570169] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Mizutani Foundation for Glycoscience; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was partly supported by grants-in-aid for scientific cesearch (21370059 to J.G.) and challenging exploratory research (23651196 to J.G.) from the Japan Society for the Promotion of Science; by a grant from the Scientific Research on Innovative Areas (23110002 to J.G.; 24590087 to T.F.) and the Strategic Research Foundation grant-aided Project for Private Universities from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and by the Mizutani Foundation for Glycoscience. The authors acknowledge James L. McDonald of Scientific Editorial Services for editing this manuscript.	Abe K, 1996, BRAIN RES, V723, P206, DOI 10.1016/0006-8993(96)00253-3; ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; Bao YL, 2005, J ENDOCRINOL, V184, P493, DOI 10.1677/joe.1.05978; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Buss A, 2008, SPINAL CORD, V46, P364, DOI 10.1038/sj.sc.3102148; Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dow AL, 2005, J NEUROSCI, V25, P4908, DOI 10.1523/JNEUROSCI.5155-04.2005; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Finnson Kenneth W, 2012, Front Biosci (Schol Ed), V4, P251; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; Fukuda T, 2011, J BIOL CHEM, V286, P18434, DOI 10.1074/jbc.M110.172536; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; Hagedorn HG, 2001, INT J ONCOL, V18, P669; Heupel K, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-25; Isaji T, 2009, J BIOL CHEM, V284, P12207, DOI 10.1074/jbc.M807920200; Ishikawa M, 2010, J BIOL CHEM, V285, P32734, DOI 10.1074/jbc.M110.118745; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; Krieglstein K, 2011, TRENDS NEUROSCI, V34, P421, DOI 10.1016/j.tins.2011.06.002; Li WZ, 2006, GLYCOBIOLOGY, V16, P1007, DOI 10.1093/glycob/cwl023; Li WZ, 2012, J BIOL CHEM, V287, P2500, DOI 10.1074/jbc.M111.303123; Lutz M, 2004, EUR J BIOCHEM, V271, P920, DOI 10.1111/j.1432-1033.2004.03994.x; Pinho SS, 2011, CELL MOL LIFE SCI, V68, P1011, DOI 10.1007/s00018-010-0595-0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Wang XC, 2006, J BIOL CHEM, V281, P2572, DOI 10.1074/jbc.M510893200; Wang XC, 2006, METHOD ENZYMOL, V417, P11, DOI 10.1016/S0076-6879(06)17002-0; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; WILSON JR, 1976, BIOCHEM BIOPH RES CO, V72, P909, DOI 10.1016/S0006-291X(76)80218-5; Zhao YY, 2006, J BIOL CHEM, V281, P38343, DOI 10.1074/jbc.M608764200; Zheng F, 2009, MOL PSYCHIATR, V14, P332, DOI 10.1038/sj.mp.4002131	35	23	24	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3947	3958		10.1096/fj.12-225805	http://dx.doi.org/10.1096/fj.12-225805			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23796784				2022-12-28	WOS:000329747100010
J	Zhang, Y; Jiang, G; Sauler, M; Lee, PJ				Zhang, Yi; Jiang, Ge; Sauler, Maor; Lee, Patty J.			Lung endothelial HO-1 targeting in vivo using lentiviral miRNA regulates apoptosis and autophagy during oxidant injury	FASEB JOURNAL			English	Article						cell death; VE-cadherin; heat-shock protein	HEME OXYGENASE-1; CONFERS SUSCEPTIBILITY; GENE-TRANSCRIPTION; PROTECTIVE ROLE; CELL-DEATH; EXPRESSION; FISSION; FUSION; SIRNA; RNAS	The lung endothelium is a major target for inflammatory and oxidative stress. Heme oxygenase-1 (HO-1) induction is a crucial defense mechanism during oxidant challenges, such as hyperoxia. The role of lung endothelial HO-1during hyperoxia in vivo is not well defined. We engineered lentiviral vectors with microRNA (miRNA) sequences controlled by vascular endothelium cadherin (VE-cad) to study the specific role of lung endothelial HO-1. Wild-type (WT) murine lung endothelial cells (MLECs) or WT mice were treated with lentivirus and exposed to hyperoxia (95% oxygen). We detected HO-1 knockdown (approximate to 55%) specifically in the lung endothelium. MLECs and lungs showed approximately a 2-fold increase in apoptosis and ROS generation after HO-1 silencing. We also demonstrate for the first time that silencing endothelial HO-1 has the same effect on lung injury and survival as silencing HO-1 in multiple lung cell types and that HO-1 regulates caspase 3 activation and autophagy in endothelium during hyperoxia. These studies demonstrate the utility of endothelial-targeted gene silencing in vivo using lentiviral miRNA constructs to assess gene function and that endothelial HO-1 is an important determinant of survival during hyperoxia.Zhang, Y., Jiang, G., Sauler, M., Lee, P. J. Lung endothelial HO-1 targeting in vivo using lentiviral miRNA regulates apoptosis and autophagy during oxidant injury.	[Zhang, Yi; Sauler, Maor; Lee, Patty J.] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT 06520 USA; [Jiang, Ge] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai, Peoples R China	Yale University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Lee, PJ (corresponding author), Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu			U.S. National Institutes of Health [HL 071595, HL 090660, FAMRI 82384]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090660, R01HL071595] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	P.J.L. was supported by U.S. National Institutes of Health grants HL 071595, HL 090660, and FAMRI 82384. The authors thank Dr. Robert Homer (Department of Pathology, Yale University School of Medicine) for his assistance with describing pathology methodology.	Agarwal A, 2000, J AM SOC NEPHROL, V11, P965, DOI 10.1681/ASN.V115965; Banerjee P, 2012, J BIOL CHEM, V287, P32113, DOI 10.1074/jbc.M112.393140; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao JA, 2011, HUM GENE THER, V22, P271, DOI 10.1089/hum.2010.059; Carchman EH, 2011, HEPATOLOGY, V53, P2053, DOI 10.1002/hep.24324; Constantin M, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/859235; Dib M, 2009, AM J PHYSIOL-LUNG C, V297, pL687, DOI 10.1152/ajplung.90509.2008; Dorn Ii G. W., 2013, CIRC J, V77, P1370; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Jin Y, 2012, AUTOPHAGY, V8, P426, DOI 10.4161/auto.19258; Joza S, 2012, AM J PATHOL, V181, P2003, DOI 10.1016/j.ajpath.2012.08.037; Kawamoto S, 2011, TISSUE ENG PT A, V17, P1605, DOI 10.1089/ten.tea.2010.0447; Ke BB, 2009, HUM GENE THER, V20, P1133, DOI 10.1089/hum.2009.049; Kim HP, 2008, AUTOPHAGY, V4, P887, DOI 10.4161/auto.6767; Kissler S, 2006, NAT GENET, V38, P479, DOI 10.1038/ng1766; Kosmider B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026059; Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034; Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Lian XM, 2005, J IMMUNOL, V174, P7250, DOI 10.4049/jimmunol.174.11.7250; Liu K, 2012, J CARDIOVASC PHARM T, V17, P395, DOI 10.1177/1074248412442002; Liu RL, 2012, CELL BIOL INT, V36, P863, DOI 10.1042/CBI20110662; Lo S, 2013, ANN SURG, V257, P352, DOI 10.1097/SLA.0b013e318269d0e2; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mattart L, 2012, CELL SIGNAL, V24, P199, DOI 10.1016/j.cellsig.2011.09.002; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Morse D, 2003, AM J PHYSIOL-LUNG C, V285, pL250, DOI 10.1152/ajplung.00387.2002; Novak I, 2012, ANTIOXID REDOX SIGN, V17, P794, DOI 10.1089/ars.2011.4407; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Park F, 2007, PHYSIOL GENOMICS, V31, P159, DOI 10.1152/physiolgenomics.00069.2007; Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859; Pushparaj PN, 2008, J DENT RES, V87, P992, DOI 10.1177/154405910808701109; Raval CM, 2010, CURR DRUG TARGETS, V11, P1532; Ryter SW, 2013, CURR PHARM DESIGN, V19, P2747; Sass G, 2012, Z GASTROENTEROL, V50, P34, DOI 10.1055/s-0031-1282046; Schmeckpeper J, 2009, DIFFERENTIATION, V78, P169, DOI 10.1016/j.diff.2009.01.002; Scott JR, 2005, CRIT CARE MED, V33, P2563, DOI 10.1097/01.CCM.0000186765.61268.FC; Shen XD, 2012, AM J TRANSPLANT, V12, P1730, DOI 10.1111/j.1600-6143.2012.04021.x; Siner JM, 2007, FASEB J, V21, P1422, DOI 10.1096/fj.06-6661com; Snove O, 2006, NAT METHODS, V3, P689, DOI 10.1038/NMETH927; Sun MW, 2013, CARDIOVASC RES, V97, P686, DOI 10.1093/cvr/cvs423; Tanimoto T, 2009, FREE RADICAL BIO MED, V46, P1119, DOI 10.1016/j.freeradbiomed.2009.01.017; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Unuma K, 2013, HEPATOL RES, V43, P91, DOI 10.1111/j.1872-034X.2012.01049.x; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Zhang J, 2013, J SURG RES, V182, pE79, DOI 10.1016/j.jss.2012.11.014; Zhang XC, 2005, J IMMUNOL, V175, P4834, DOI 10.4049/jimmunol.175.8.4834; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC; Zhang XC, 2002, AM J PHYSIOL-LUNG C, V283, pL815, DOI 10.1152/ajplung.00485.2001; Zhang XC, 2006, FASEB J, V20, P2156, DOI 10.1096/fj.06-5668fje; Zungu M, 2011, CIRC J, V75, P2513, DOI 10.1253/circj.CJ-11-0967	58	41	42	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4041	4058		10.1096/fj.13-231225	http://dx.doi.org/10.1096/fj.13-231225			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23771928	Bronze, Green Published			2022-12-28	WOS:000329747100018
J	Zhao, HL; Yoshida, A; Xiao, W; Ologunde, R; O'Dea, KP; Takata, M; Tralau-Stewart, C; George, AJT; Ma, DQ				Zhao, Hailin; Yoshida, Akira; Xiao, Wei; Ologunde, Rele; O'Dea, Kieran P.; Takata, Masao; Tralau-Stewart, Catherine; George, Andrew J. T.; Ma, Daqing			Xenon treatment attenuates early renal allograft injury associated with prolonged hypothermic storage in rats	FASEB JOURNAL			English	Article						acute rejection; renoprotection	ISCHEMIA-REPERFUSION INJURY; DELAYED GRAFT FUNCTION; KIDNEY-TRANSPLANTATION; HEME OXYGENASE-1; ACUTE REJECTION; ISCHEMIA/REPERFUSION INJURY; NEONATAL ASPHYXIA; ANESTHESIA; SURVIVAL; MECHANISMS	Prolonged hypothermic storage elicits severe ischemia-reperfusion injury (IRI) to renal grafts, contributing to delayed graft function (DGF) and episodes of acute immune rejection and shortened graft survival. Organoprotective strategies are therefore needed for improving long-term transplant outcome. The aim of this study is to investigate the renoprotective effect of xenon on early allograft injury associated with prolonged hypothermic storage. Xenon exposure enhanced the expression of heat-shock protein 70 (HSP-70) and heme oxygenase 1 (HO-1) and promoted cell survival after hypothermia-hypoxia insult in human proximal tubular (HK-2) cells, which was abolished by HSP-70 or HO-1 siRNA. In the brown Norway to Lewis rat renal transplantation, xenon administered to donor or recipient decreased the renal tubular cell death, inflammation, and MHC II expression, while delayed graft function (DGF) was therefore reduced. Pathological changes associated with acute rejection, including T-cell, macrophage, and fibroblast infiltration, were also decreased with xenon treatment. Donors or recipients treated with xenon in combination with cyclosporin A had prolonged renal allograft survival. Xenon protects allografts against delayed graft function, attenuates acute immune rejection, and enhances graft survival after prolonged hypothermic storage. Furthermore, xenon works additively with cyclosporin A to preserve post-transplant renal function.Zhao, H., Yoshida, A., Xiao, W., Ologunde, R., O'Dea, K. P., Takata, M., Tralau-Stewart, C., George, A. J. T., Ma, D. Xenon treatment attenuates early renal allograft injury associated with prolonged hypothermic storage in rats.	[Zhao, Hailin; Yoshida, Akira; Xiao, Wei; Ologunde, Rele; O'Dea, Kieran P.; Takata, Masao; Ma, Daqing] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Sect Anaesthet Pain Med & Intens Care, Fac Med,Chelsea & Westminster Hosp, London, England; [Xiao, Wei] Capital Med Univ, Dept Anaesthesiol, Xuanwu Hosp, Beijing, Peoples R China; [Tralau-Stewart, Catherine] Univ London Imperial Coll Sci Technol & Med, Ctr Drug Discovery, Dept Med, London, England; [George, Andrew J. T.] Univ London Imperial Coll Sci Technol & Med, Sect Mol Immunol, Dept Med, Hammersmith Hosp, London, England	Imperial College London; Capital Medical University; Imperial College London; Imperial College London	Ma, DQ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Sect Anaesthet Pain Med & Intens Care, Fac Med,Chelsea & Westminster Hosp, London, England.	d.ma@imperial.ac.uk	Ma, Daqing/GLT-2735-2022	Ma, Daqing/0000-0003-1235-0537; George, Andrew/0000-0002-2866-0241; Ologunde, Rele/0000-0002-1203-8327; Ma, Daqing/0000-0002-0688-2097; Yoshida, Akira/0000-0003-3590-1637	British Medical Research Council (MRC) Developmental Pathway Funding Scheme (DPFS) program [G802392]; MRC [G0802392] Funding Source: UKRI; Medical Research Council [G0802392] Funding Source: researchfish	British Medical Research Council (MRC) Developmental Pathway Funding Scheme (DPFS) program; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the British Medical Research Council (MRC) Developmental Pathway Funding Scheme (DPFS) program (project grant G802392). The authors declare no conflicts of interest.	Abraini JH, 2005, ANN NY ACAD SCI, V1053, P289, DOI 10.1196/annals.1344.025; Asderakis A, 2001, TRANSPLANTATION, V72, P674, DOI 10.1097/00007890-200108270-00020; Bilolo KK, 2003, TRANSPLANTATION, V75, P1881, DOI 10.1097/01.TP.0000064710.78335.D3; Blydt-Hansen TD, 2003, J AM SOC NEPHROL, V14, P745, DOI 10.1097/01.ASN.0000050760.87113.25; Cornell LD, 2008, ANNU REV PATHOL-MECH, V3, P189, DOI 10.1146/annurev.pathmechdis.3.121806.151508; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Hariharan S, 2002, KIDNEY INT, V62, P311, DOI 10.1046/j.1523-1755.2002.00424.x; Jevnikar AM, 2008, CLIN J AM SOC NEPHRO, V3, pS56, DOI 10.2215/CJN.03040707; Jurewicz M, 2010, J IMMUNOL, V184, P2939, DOI 10.4049/jimmunol.0901889; Kruger B, 2009, P NATL ACAD SCI USA, V106, P3390, DOI 10.1073/pnas.0810169106; Kuboki S, 2007, AM J PHYSIOL-GASTR L, V292, pG1141, DOI 10.1152/ajpgi.00491.2006; Kumar S, 2009, J AM SOC NEPHROL, V20, P2412, DOI 10.1681/ASN.2008080868; LACHMANN B, 1990, LANCET, V335, P1413; Lepore DA, 2001, CELL STRESS CHAPERON, V6, P93, DOI 10.1379/1466-1268(2001)006<0093:ROPSAH>2.0.CO;2; Li C, 2009, NAT REV NEPHROL, V5, P513, DOI 10.1038/nrneph.2009.113; Lockwood GG, 2006, ANESTHESIOLOGY, V104, P458, DOI 10.1097/00000542-200603000-00012; Lu CY, 1999, KIDNEY INT, V55, P2157, DOI 10.1046/j.1523-1755.1999.00491.x; Lynch C, 2000, ANESTHESIOLOGY, V92, P865, DOI 10.1097/00000542-200003000-00031; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2009, J AM SOC NEPHROL, V20, P713, DOI 10.1681/ASN.2008070712; Ma DQ, 2006, J CEREBR BLOOD F MET, V26, P199, DOI 10.1038/sj.jcbfm.9600184; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P378, DOI 10.1111/j.1600-6143.2004.00332.x; Mikhalski D, 2008, TRANSPLANTATION, V85, pS3, DOI 10.1097/TP.0b013e318169c29e; Moeller S, 2002, NEPHROL DIAL TRANSPL, V17, P2071, DOI 10.1093/ndt/17.12.2071; Pagel PS, 2010, J CARDIOTHOR VASC AN, V24, P143, DOI 10.1053/j.jvca.2009.03.016; Perico N, 2004, LANCET, V364, P1814, DOI 10.1016/S0140-6736(04)17406-0; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Rawat S, 2010, ANESTH ANALG, V110, P101, DOI 10.1213/ANE.0b013e3181be0e17; Sanders RD, 2004, BRIT MED BULL, V71, P115, DOI 10.1093/bmb/ldh034; Sheikh SZ, 2011, J IMMUNOL, V186, P5506, DOI 10.4049/jimmunol.1002433; Siedlecki A, 2011, AM J TRANSPLANT, V11, P2279, DOI 10.1111/j.1600-6143.2011.03754.x; Tantravahi J, 2007, ANNU REV MED, V58, P369, DOI 10.1146/annurev.med.58.061705.145143; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Wu HL, 2007, J CLIN INVEST, V117, P2847, DOI 10.1172/JCI31008; Wu HL, 2010, J AM SOC NEPHROL, V21, P1878, DOI 10.1681/ASN.2009101048	40	26	28	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4076	4088		10.1096/fj.13-232173	http://dx.doi.org/10.1096/fj.13-232173			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23759444	Bronze			2022-12-28	WOS:000329747100020
J	Putti, S; Calandra, P; Rossi, N; Scarabino, D; Deidda, G; Tocchini-Valentini, GP				Putti, Sabrina; Calandra, Patrizia; Rossi, Nicoletta; Scarabino, Daniela; Deidda, Giancarlo; Tocchini-Valentini, Glauco P.			Highly efficient, in vivo optimized, archaeal endonuclease for controlled RNA splicing in mammalian cells	FASEB JOURNAL			English	Article						bulge-helix-bulge; Methanocaldococcus jannaschii	MESSENGER-RNA; HNRNP A1; EVOLUTION; SELECTION; SEQUENCE; COMPLEX; IDENTIFICATION; ENZYME; M9	ARCHAEA-ExPRESs is an mRNA modification technology that makes use of components derived from the Archaeon Methanocaldococcus jannaschii, namely the tRNA splicing endonuclease (MJ-EndA) and its natural substrate, the bulge-helix-bulge (BHB) structure (1). These components can perform both cis- and trans-splicing in cellular and animal models and may provide a convenient way to modulate gene expression using components independent of cellular regulatory networks. To use MJ-EndA in stable expression mammalian systems, we developed variants characterized by high efficiency and sustainable in vivo activity. The MJ-EndA variants were created by the introduction of proper localization signals followed by mutagenesis and direct selection in mammalian cells. Of note, enzyme selection used an in vivo selection method based on puromycin resistance conferred to cells by BHB-mediated intron splicing from an out-of-frame puromycin N-acetyl transferase (PAC) gene. This approach yielded several endonuclease variants, the best of which showed 40-fold higher activity compared to the parental enzyme and stable processing of 30% of the target mRNA. Notably, these variants showed complete compatibility with long-term expression in mammalian cells, suggesting that they may be usefully applied in functional genomics and genetically modified animal models.Putti, S., Calandra, P., Rossi, N., Scarabino, D., Deidda, G., Tocchini-Valentini, G. P. Highly efficient, in vivo optimized, archaeal endonuclease for controlled RNA splicing in mammalian cells.	[Putti, Sabrina; Calandra, Patrizia; Rossi, Nicoletta; Scarabino, Daniela; Deidda, Giancarlo; Tocchini-Valentini, Glauco P.] European Mouse Mutant Arch, Ist Biol Cellulare & Neurobiol, CNR, Monterotondo, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR)	Deidda, G (corresponding author), European Mouse Mutant Arch, Ist Biol Cellulare & Neurobiol, Via E Ramarini 32, I-00015 Monterotondo Scalo Rome, Italy.	giancarlo.deidda@cnr.it	Scarabino, Daniela/AAX-5959-2020; Scarabino, Daniela/AAB-3837-2019; putti, sabrina/H-2574-2019	Scarabino, Daniela/0000-0002-5565-6379; putti, sabrina/0000-0003-3335-043X; DEIDDA, GIANCARLO/0000-0002-0828-5800	Italian Ministry of Research; European Union	Italian Ministry of Research(Ministry of Education, Universities and Research (MIUR)); European Union(European Commission)	The authors thank G. Di Franco for technical assistance and A. Ferrara and T. Cuccurullo for help with the manuscript. This work was supported by Italian Ministry of Research grants (FIRB Idee Progettuali 2005, CNR Progetto d'Interesse Strategico Invecchiamento 2012-2014) and European Union Framework Programme 7 (EUCOMMTools, PHENOSCALE contracts). The authors declare no conflicts of interest.	BURKE JM, 1993, FASEB J, V7, P106, DOI 10.1096/fasebj.7.1.8422956; Calvin K, 2008, BIOCHEMISTRY-US, V47, P13659, DOI 10.1021/bi801141q; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; Deidda G, 2003, NAT BIOTECHNOL, V21, P1499, DOI 10.1038/nbt908; Deidda G, 2010, FASEB J, V24, P2976, DOI 10.1096/fj.10-154658; Diener JL, 1998, MOL CELL, V1, P883, DOI 10.1016/S1097-2765(00)80087-8; Garcia-Blanco MA, 2003, NAT BIOTECHNOL, V21, P1448, DOI 10.1038/nbt1203-1448; Honey S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e24; Iijima M, 2006, FEBS LETT, V580, P1365, DOI 10.1016/j.febslet.2006.01.058; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Labrou NE, 2010, CURR PROTEIN PEPT SC, V11, P91, DOI 10.2174/138920310790274617; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; Michael M., 1995, CELL, V83, P415; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paushkin SV, 2004, CELL, V117, P311, DOI 10.1016/S0092-8674(04)00342-3; Popow J, 2011, SCIENCE, V331, P760, DOI 10.1126/science.1197847	20	2	2	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3466	3477		10.1096/fj.13-231993	http://dx.doi.org/10.1096/fj.13-231993			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23682120				2022-12-28	WOS:000328840500007
J	Biggar, KK; Kotani, E; Furusawa, T; Storey, KB				Biggar, Kyle K.; Kotani, Eiji; Furusawa, Toshiharu; Storey, Kenneth B.			Expression of freeze-responsive proteins, Fr10 and Li16, from freeze-tolerant frogs enhances freezing survival of BmN insect cells	FASEB JOURNAL			English	Article						cryobiology; silkworm	RANA-SYLVATICA; WOOD FROG; ANTIFREEZE PROTEIN; UP-REGULATION; GENE; STRESS; INHIBITION; EXPOSURE; SERVER	To date, two novel freeze-responsive proteins, Fr10 and Li16, have been discovered in the wood frog, Rana sylvatica, and likely support freezing survival. Although previous studies have established tissue distribution of each protein, there have been no studies that explore their functional consequences in intolerant cells. To assess the ability of Fr10 and Li16 to confer freeze tolerance, we transfected each protein into a freeze-intolerant silkworm cell line (BmN). Selected controls were the transfection of an unrelated protein (CAT) and a no-transfection sample. Li16 and Fr10 showed 1.8 +/- 0.1- and 1.7 +/- 0.2-fold, respectively, greater survival after freezing at -6 degrees C for 1 h than did transfection controls. To investigate how these novel proteins protect cells from freezing damage, protein structures were predicted from primary amino acid sequences. Analysis of the structures indicated that Fr10 is a secreted protein and may be a new type IV antifreeze protein, whereas Li16 may have intracellular membrane associated functions. This study shows that freezing protection can be provided to intolerant cells by the overexpression of transfected Li16 and Fr10 frog proteins. Results from this study will provide new insights into adapting intolerant cells for medical organ cryoprotection using a natural vertebrate model of tolerance.Biggar, K. K., Kotani, E., Furusawa, T., Storey, K. B. Expression of freeze-responsive proteins, Fr10 and Li16, from freeze-tolerant frogs enhances freezing survival of BmN insect cells.	[Biggar, Kyle K.; Storey, Kenneth B.] Carleton Univ, Inst Biochem, Ottawa, ON K1S 5B6, Canada; [Biggar, Kyle K.] Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada; [Kotani, Eiji] Kyoto Inst Technol, Grad Sch Sci & Technol, Kyoto 606, Japan; [Furusawa, Toshiharu] Kinugasa Res Fdn Text Sci, Kyoto, Japan	Carleton University; Carleton University; Kyoto Institute of Technology	Storey, KB (corresponding author), Carleton Univ, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada.	kenneth_storey@carleton.ca			Natural Sciences and Engineering Research Council (NSERC) of Canada [6793]; NSERC	Natural Sciences and Engineering Research Council (NSERC) of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	The authors thank J. M. Storey for editorial review of the manuscript. This work was supported by a Discovery grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada (grant 6793). K. B. S. holds the Canada Research Chair in Molecular Physiology, and K. K. B. held an NSERC postgraduate fellowship.	BRASSEUR R, 1992, PROTEINS, V13, P246, DOI 10.1002/prot.340130307; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; Cai Q, 1997, AM J PHYSIOL-REG I, V272, pR1480, DOI 10.1152/ajpregu.1997.272.5.R1480; Cai QY, 1997, GENE, V198, P305, DOI 10.1016/S0378-1119(97)00332-6; Cai QY, 1997, BBA-GENE STRUCT EXPR, V1353, P69, DOI 10.1016/S0167-4781(97)00057-2; De Croos JNA, 2004, J BIOENERG BIOMEMBR, V36, P229, DOI 10.1023/B:JOBB.0000031974.35812.c9; Deng GJ, 1997, FEBS LETT, V402, P17, DOI 10.1016/S0014-5793(96)01466-4; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Heng BC, 2006, J BIOMED SCI, V13, P433, DOI 10.1007/s11373-005-9051-9; Hobbs RS, 2008, TRANSGENIC RES, V17, P33, DOI 10.1007/s11248-007-9128-5; Horton P, 2007, NUCLEIC ACIDS RES, V35, pW585, DOI 10.1093/nar/gkm259; Kostal V, 2012, P NATL ACAD SCI USA, V109, P3270, DOI 10.1073/pnas.1119986109; Kotani E, 2003, GENE, V320, P67, DOI 10.1016/S0378-1119(03)00811-4; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lomize MA, 2012, NUCLEIC ACIDS RES, V40, pD370, DOI 10.1093/nar/gkr703; McNally JD, 2002, FASEB J, V16, P902, DOI 10.1096/fj.02-0017fje; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Roufayel R, 2011, J EXP ZOOL PART A, V315A, P487, DOI 10.1002/jez.696; STOREY KB, 1992, ANNU REV PHYSIOL, V54, P619, DOI 10.1146/annurev.physiol.54.1.619; Storey KB, 2004, LIFE IN THE FROZEN STATE, P243, DOI 10.1201/9780203647073.ch7; STOREY KB, 1988, PHYSIOL REV, V68, P27, DOI 10.1152/physrev.1988.68.1.27; Sullivan KJ, 2012, CRYOBIOLOGY, V64, P192, DOI 10.1016/j.cryobiol.2012.01.008; Uemura M, 2006, PHYSIOL PLANTARUM, V126, P81, DOI 10.1111/j.1399-3054.2005.00594.x; Wallis JG, 1997, PLANT MOL BIOL, V35, P323, DOI 10.1023/A:1005886210159; Xu D, 2012, PROTEINS, V80, P1715, DOI 10.1002/prot.24065; Yu SO, 2010, CRYOBIOLOGY, V61, P327, DOI 10.1016/j.cryobiol.2010.10.158; Zhang SH, 2007, Z NATURFORSCH C, V62, P583	29	10	12	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3376	3383		10.1096/fj.13-230573	http://dx.doi.org/10.1096/fj.13-230573			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23657819				2022-12-28	WOS:000329877600042
J	Kourtzelis, I; Rafail, S; DeAngelis, RA; Foukas, PG; Ricklin, D; Lambris, JD				Kourtzelis, Ioannis; Rafail, Stavros; DeAngelis, Robert A.; Foukas, Periklis G.; Ricklin, Daniel; Lambris, John D.			Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation	FASEB JOURNAL			English	Article						C5a anaphylatoxin; immune cells; compstatin; C3; polypropylene	FOREIGN-BODY RESPONSE; C5A; HEMODIALYSIS; MEMBRANES; IMMUNE; MODEL; BIOCOMPATIBILITY; COMPSTATIN; NEUTROPHIL; PROTEINS	Although complement is a known contributor to biomaterial-induced complications, pathological implications and therapeutic options remain to be explored. Here we investigated the involvement of complement in the inflammatory response to polypropylene meshes commonly used for hernia repair. In vitro assays revealed deposition of complement activation fragments on the mesh after incubation in plasma. Moreover, significant mesh-induced complement and granulocyte activation was observed in plasma and leukocyte preparations, respectively. Pretreatment of plasma with the complement inhibitor compstatin reduced opsonization >2-fold, and compstatin and a C5a receptor antagonist (C5aRa) impaired granulocyte activation by 50 and 67%, respectively. We established a clinically relevant mouse model of implantation and could confirm deposition of C3 activation fragments on mesh implants in vivo using immunofluorescence. In meshes extracted after subcutaneous or peritoneal implantation, the amount of immune cell infiltrate in mice deficient in key complement components (C3, C5aR), or treated with C5aRa, was approximately half of that observed in wild-type littermates or mice treated with inactive C5aRa, respectively. Our data suggest that implantation of a widely used surgical mesh triggers the formation of an inflammatory cell microenvironment at the implant site through complement activation, and indicates a path for the therapeutic modulation of implant-related complications.Kourtzelis, I., Rafail, S., DeAngelis, R. A., Foukas, P. G., Ricklin, D., Lambris, J. D. Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation.	[Kourtzelis, Ioannis; Rafail, Stavros; DeAngelis, Robert A.; Ricklin, Daniel; Lambris, John D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Foukas, Periklis G.] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Pathol 2, GR-11527 Athens, Greece	University of Pennsylvania; Athens Medical School; National & Kapodistrian University of Athens; University Hospital Attikon	Lambris, JD (corresponding author), Univ Penn, Dept Pathol & Lab Med, 422 Curie Blvd, Philadelphia, PA 19104 USA.	lambris@upenn.edu	Foukas, Periklis/AAA-4034-2020; Kourtzelis, Ioannis/G-1767-2012; Lambris, John/Q-5633-2018	Kourtzelis, Ioannis/0000-0002-7292-5745; Lambris, John/0000-0002-9370-5776; Kourtzelis, Ioannis/0000-0003-3006-8885	U.S. National Institutes of Health [AI068730, AI030040, EY020633, GM097747, DE021685, AI097805]; NATIONAL EYE INSTITUTE [R01EY020633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI097805, R01AI030040, N01AI030040, P01AI068730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE021685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097747] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the U.S. National Institutes of Health: AI068730, AI030040, EY020633, GM097747, and DE021685 (J.D.L.) and AI097805 (D. R.). J.D.L. and D. R. are the inventors of patents describing compstatin analogs and their clinical use. J.D.L. is the founder of Amyndas Pharmaceuticals, which develops complement-targeted therapeutics. The authors thank Dr. Stergios Rafail (General Regional Hospital George Papanikolaou, Thessaloniki, Greece) for providing the mesh polypropylene biomaterials, Dr. Hongchang Qu (University of Pennsylvania, Philadelphia, PA, USA) for synthesis of complement inhibitors, and Dr. Deborah McClellan for her help in editing the manuscript. D. R. and J.D.L. shared the supervision of this work.	Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; Andersson J, 2005, BIOMATERIALS, V26, P1477, DOI 10.1016/j.biomaterials.2004.05.011; Andersson J, 2002, J IMMUNOL, V168, P5786, DOI 10.4049/jimmunol.168.11.5786; Asarias JR, 2011, J INVEST SURG, V24, P87, DOI 10.3109/08941939.2010.548904; BOHLER J, 1991, AM J NEPHROL, V11, P479, DOI 10.1159/000168363; Bray BL, 2003, NAT REV DRUG DISCOV, V2, P587, DOI 10.1038/nrd1133; Cazander G, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/534291; de Vroege R, 1997, PERFUSION-UK, V12, P369, DOI 10.1177/026765919701200605; DeAngelis RA, 2012, IMMUNOBIOLOGY, V217, P1097, DOI 10.1016/j.imbio.2012.07.012; Ekdahl KN, 2011, ADV DRUG DELIVER REV, V63, P1042, DOI 10.1016/j.addr.2011.06.012; Engberg AE, 2011, J BIOMED MATER RES A, V97A, P74, DOI 10.1002/jbm.a.33030; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Higgins DM, 2009, AM J PATHOL, V175, P161, DOI 10.2353/ajpath.2009.080962; Huebsch N, 2009, NATURE, V462, P426, DOI 10.1038/nature08601; Hussain MA, 1998, J BIOMATER APPL, V12, P300, DOI 10.1177/088532829801200403; Kao WYJ, 1999, BIOMATERIALS, V20, P2213, DOI 10.1016/S0142-9612(99)00152-0; Kourtzelis I, 2010, BLOOD, V116, P631, DOI 10.1182/blood-2010-01-264051; Labow RS, 2001, J CELL PHYSIOL, V186, P95, DOI 10.1002/1097-4652(200101)186:1<95::AID-JCP1008>3.0.CO;2-0; Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388; Lhotta K, 1998, KIDNEY INT, V53, P1044; Mackenzie PJ, 2007, CAN J OPHTHALMOL, V42, P227, DOI 10.3129/canjophthalmol.i07-032; Manthey HD, 2011, FASEB J, V25, P2447, DOI 10.1096/fj.10-174284; Mares J, 2009, KIDNEY INT, V76, P404, DOI 10.1038/ki.2009.138; Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006; MCLEOD BC, 1983, TRANSFUSION, V23, P143, DOI 10.1046/j.1537-2995.1983.23283172853.x; McNally AK, 2011, ADV EXP MED BIOL, V713, P97, DOI 10.1007/978-94-007-0763-4_7; Morais JM, 2010, AAPS J, V12, P188, DOI 10.1208/s12248-010-9175-3; Nielsen EW, 2007, MOL IMMUNOL, V44, P1819, DOI 10.1016/j.molimm.2006.10.003; Nilsson B, 2007, MOL IMMUNOL, V44, P82, DOI 10.1016/j.molimm.2006.06.020; Nilsson B, 2010, TRENDS IMMUNOL, V31, P32, DOI 10.1016/j.it.2009.09.005; Nilsson PH, 2013, BIOMATERIALS, V34, P985, DOI 10.1016/j.biomaterials.2012.10.040; Nilsson UR, 2001, MOL IMMUNOL, V38, P151, DOI 10.1016/S0161-5890(01)00039-6; Oikonomopoulou K, 2012, SEMIN IMMUNOPATHOL, V34, P151, DOI 10.1007/s00281-011-0280-x; Patel JD, 2007, J BIOMED MATER RES A, V80A, P381, DOI 10.1002/jbm.a.30907; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; Qu HC, 2013, IMMUNOBIOLOGY, V218, P496, DOI 10.1016/j.imbio.2012.06.003; Qu HC, 2011, MOL IMMUNOL, V48, P481, DOI 10.1016/j.molimm.2010.10.004; Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20; Ricklin D, 2013, J IMMUNOL, V190, P3839, DOI 10.4049/jimmunol.1203200; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rosch R, 2003, EUR SURG RES, V35, P161, DOI 10.1159/000070045; Sahu A, 1996, J IMMUNOL, V157, P884; Schachtrupp A, 2003, BRIT J SURG, V90, P114, DOI 10.1002/bjs.4023; Schneider R L, 1987, Quintessence Dent Technol, V11, P93; Sonmez K, 2009, B-ENT, V5, P149; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Thomas SN, 2011, BIOMATERIALS, V32, P2194, DOI 10.1016/j.biomaterials.2010.11.037; Wu YQ, 2011, J IMMUNOL, V186, P4269, DOI 10.4049/jimmunol.1003802; Xia Z, 2006, BIOMED MATER, V1, pR1, DOI 10.1088/1748-6041/1/1/R01	50	24	26	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2768	2776		10.1096/fj.12-225888	http://dx.doi.org/10.1096/fj.12-225888			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23558338	Green Published			2022-12-28	WOS:000328841000025
J	Das, S; Sarkar, A; Ryan, KA; Fox, S; Berger, AH; Juncadella, IJ; Bimczok, D; Smythies, LE; Harris, PR; Ravichandran, KS; Crowe, SE; Smith, PD; Ernst, PB				Das, Soumita; Sarkar, Arup; Ryan, Kieran A.; Fox, Sarah; Berger, Alice H.; Juncadella, Ignacio J.; Bimczok, Diane; Smythies, Lesley E.; Harris, Paul R.; Ravichandran, Kodi S.; Crowe, Sheila E.; Smith, Phillip D.; Ernst, Peter B.			Brain angiogenesis inhibitor 1 is expressed by gastric phagocytes during infection with Helicobacter pylori and mediates the recognition and engulfment of human apoptotic gastric epithelial cells	FASEB JOURNAL			English	Article						efferocytosis; mucosal immunity; stomach; bacteria; gastritis	PHOSPHATIDYLSERINE RECEPTOR; CYTOKINE PRODUCTION; CORPSE CLEARANCE; STEM-CELLS; DIFFERENTIATION; MACROPHAGES; DISEASE; SYSTEM; IDENTIFICATION; HOMEOSTASIS	After Helicobacter pylori infection in humans, gastric epithelial cells (GECs) undergo apoptosis due to stimulation by the bacteria or inflammatory cytokines. In this study, we assessed the expression and function of brain angiogenesis inhibitor 1 (BAI1) in the engulfment of apoptotic GECs using human tissue and cells. After induction of apoptosis by H. pylori or camptothecin, there was a 5-fold increase in the binding of apoptotic GECs to THP-1 cells or peripheral blood monocyte-derived macrophages as assayed by confocal microscopy or conventional and imaging flow cytometry. Binding was impaired 95% by pretreating apoptotic cells with annexin V, underscoring the requirement for phosphatidylserine recognition. The phosphatidylserine receptor BAI1 was expressed in human gastric biopsy specimens and gastric phagocytes. To confirm the role of BAI1 in apoptotic cell clearance, the functional domain of BAI1 was used as a competitive inhibitor or BAI1 expression was inhibited by small interfering RNA. Both approaches decreased binding and engulfment >40%. Exposing THP-1 cells to apoptotic cells inhibited IL-6 production from 1340 to <364 pg/ml; however, this decrease was independent of phagocytosis. We conclude that recognition of apoptotic cells by BAI1 contributes to their clearance in the human gastric mucosa and this is associated with anti-inflammatory effects.Das, S., Sarkar, A., Ryan, K. A., Fox, S., Berger, A. H., Juncadella, I. J., Bimczok, D., Smythies, L. E., Harris, P. R., Ravichandran, K. S., Crowe, S. E., Smith, P. D., Ernst, P. B. Brain angiogenesis inhibitor 1 is expressed by gastric phagocytes during infection with Helicobacter pylori and mediates the recognition and engulfment of human apoptotic gastric epithelial cells.	[Das, Soumita; Sarkar, Arup; Fox, Sarah; Ernst, Peter B.] Univ Calif San Diego, Dept Pathol, Div Comparat Pathol & Med, San Diego, CA 92093 USA; [Crowe, Sheila E.] Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA; [Ryan, Kieran A.] Natl Univ Ireland Univ Coll Cork, Dept Microbiol, Cork, Ireland; [Ryan, Kieran A.] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland; [Berger, Alice H.] Broad Inst Massachusetts Inst Technol & Harvard U, Canc Program, Cambridge, MA USA; [Berger, Alice H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Juncadella, Ignacio J.; Ravichandran, Kodi S.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; [Juncadella, Ignacio J.; Ravichandran, Kodi S.] Univ Virginia, Beirne Carter Ctr Immunol, Charlottesville, VA USA; [Bimczok, Diane; Smythies, Lesley E.; Smith, Phillip D.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Bimczok, Diane; Smythies, Lesley E.; Smith, Phillip D.] Univ Alabama Birmingham, Dept Gastroenterol, Birmingham, AL USA; [Harris, Paul R.] Pontificia Univ Catolica Chile, Sch Med, Unit Gastroenterol & Nutr, Div Pediat, Santiago, Chile	University of California System; University of California San Diego; University of California System; University of California San Diego; University College Cork; University College Cork; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; University of Virginia; University of Virginia; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Pontificia Universidad Catolica de Chile	Ernst, PB (corresponding author), Univ Calif San Diego, Dept Pathol, Div Comparat Pathol & Med, MC 0063, San Diego, CA 92093 USA.	pernst@ucsd.edu	Sarkar, Arup/V-3277-2018	Sarkar, Arup/0000-0002-5030-2782; Ernst, Peter/0000-0001-7777-1813; Ravichandran, Kodi/0000-0001-9049-1410	U.S. National Institutes of Health [AI079145, DK084063, AI070491, DK61769, DK54495, DK84063, AI83539, RR20136]; University of Alabama at Birmingham Mucosal HIV and Immunobiology Center (Center for Clinical and Translational Science and Immunology, Autoimmunity and Transplantation Pilot Program) [DK64400]; Research Service of the Veterans Administration; University of Virginia Digestive Health Research Center Immunology and Cell Isolation Core and Morphology/Imaging Core [DK67629]; UCSD Neuroscience Microscopy Shared Facility [P30 NS047101]; UCSD Moores Cancer Center Biorepository Tissue Technology Shared Resources [2P30 CA023100]; UCSD Digestive Diseases Research Development Center [DK80506]; NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR020136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007496, R21AI083539, U01AI070491, R01AI079145, R56AI079145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061769, R24DK080506, K01DK097144, P30DK067629, R01DK084063, R24DK064400, R01DK054495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Alabama at Birmingham Mucosal HIV and Immunobiology Center (Center for Clinical and Translational Science and Immunology, Autoimmunity and Transplantation Pilot Program); Research Service of the Veterans Administration; University of Virginia Digestive Health Research Center Immunology and Cell Isolation Core and Morphology/Imaging Core; UCSD Neuroscience Microscopy Shared Facility; UCSD Moores Cancer Center Biorepository Tissue Technology Shared Resources; UCSD Digestive Diseases Research Development Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Amber Ablack for technical assistance in the maintenance of AGS cells and H. pylori strains; Drs. Scott Vandenberg and Donald Pizzo [University of California, San Diego (UCSD) histology core facility] for the immunohistochemical analysis; Joanne Lannigan, William Ross, Mike Solga, and Elizabeth Wiznerowicz (University of Virginia) for technical assistance; and the University of Texas Medical Branch Protein Biosynthesis and Biomarker Core Laboratory (Galveston, TX, USA) for protein purification. This work was supported by U.S. National Institutes of Health grants AI079145, DK084063, and AI070491 (to P.B.E.), DK61769 (to S.E.C.), and DK54495, DK84063, AI83539, and RR20136; as well as grants to the University of Alabama at Birmingham Mucosal HIV and Immunobiology Center (Center for Clinical and Translational Science and Immunology, Autoimmunity and Transplantation Pilot Program; DK64400), the Research Service of the Veterans Administration (to P.D.S.), the University of Virginia Digestive Health Research Center Immunology and Cell Isolation Core and Morphology/Imaging Core (DK67629), the UCSD Neuroscience Microscopy Shared Facility (P30 NS047101), the UCSD Moores Cancer Center Biorepository Tissue Technology Shared Resources (2P30 CA023100), and the UCSD Digestive Diseases Research Development Center (DK80506). The authors declare no conflict of interest.	Ariel A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00004; Bhattacharyya A, 2009, GASTROENTEROLOGY, V136, P2258, DOI 10.1053/j.gastro.2009.02.014; Bimczok D, 2010, MUCOSAL IMMUNOL, V3, P260, DOI 10.1038/mi.2010.10; Bimczok D, 2013, J IMMUNOL, V190, P6626, DOI 10.4049/jimmunol.1203330; Brown S, 2002, NATURE, V418, P200, DOI 10.1038/nature00811; Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668; Das S, 2011, P NATL ACAD SCI USA, V108, P2136, DOI 10.1073/pnas.1014775108; Ding SZ, 2004, GASTROENTEROLOGY, V127, P845, DOI 10.1053/j.gastro.2004.06.017; Elliott MR, 2010, J CELL BIOL, V189, P1059, DOI 10.1083/jcb.201004096; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Fadok VA, 1998, BIOCHEM SOC T, V26, P653, DOI 10.1042/bst0260653; Fan XJ, 1998, J EXP MED, V187, P1659, DOI 10.1084/jem.187.10.1659; Fleeton MN, 2004, J EXP MED, V200, P235, DOI 10.1084/jem.20041132; Giles KM, 2001, J IMMUNOL, V167, P976, DOI 10.4049/jimmunol.167.2.976; Gomez CP, 2012, J IMMUNOL, V189, P2203, DOI 10.4049/jimmunol.1103021; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Henson PM, 2013, J CLIN INVEST, V123, P2773, DOI 10.1172/JCI69344; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Hume DA, 2008, MUCOSAL IMMUNOL, V1, P432, DOI 10.1038/mi.2008.36; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; IWANAGA T, 1993, GASTROENTEROLOGY, V105, P1089, DOI 10.1016/0016-5085(93)90953-A; Jones NL, 1997, AM J PATHOL, V151, P1695; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; Kjeken R, 2004, MOL BIOL CELL, V15, P345, DOI 10.1091/mbc.e03-05-0334; Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Laine L, 2008, GASTROENTEROLOGY, V135, P41, DOI 10.1053/j.gastro.2008.05.030; Laskay T, 2003, TRENDS MICROBIOL, V11, P210, DOI 10.1016/S0966-842X(03)00075-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucas M, 2006, J IMMUNOL, V177, P4047, DOI 10.4049/jimmunol.177.6.4047; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Marchiando A. M., 2011, GASTROENTEROLOGY, V140; Miksa M, 2009, J IMMUNOL METHODS, V342, P71, DOI 10.1016/j.jim.2008.11.019; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; Park D, 2009, CURR BIOL, V19, P346, DOI 10.1016/j.cub.2009.01.042; Park SY, 2008, CELL DEATH DIFFER, V15, P192, DOI 10.1038/sj.cdd.4402242; Rescigno M, 2011, TRENDS IMMUNOL, V32, P256, DOI 10.1016/j.it.2011.04.003; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; Ryan KA, 2004, INFECT IMMUN, V72, P2123, DOI 10.1128/IAI.72.4.2123-2130.2004; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Su LP, 2009, GASTROENTEROLOGY, V136, P551, DOI 10.1053/j.gastro.2008.10.081; Toda S, 2012, MOL CELL BIOL, V32, P118, DOI 10.1128/MCB.05993-11; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Vidrich A, 2003, CURR OPIN GASTROEN, V19, P583, DOI 10.1097/00001574-200311000-00012; Yamaoka Y, 2010, NAT REV GASTRO HEPAT, V7, P629, DOI 10.1038/nrgastro.2010.154; Yen TH, 2006, STEM CELL REV, V2, P203, DOI 10.1007/s12015-006-0048-1; Zhou ZH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02271	53	26	27	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2214	2224		10.1096/fj.13-243238	http://dx.doi.org/10.1096/fj.13-243238			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24509909	Green Published			2022-12-28	WOS:000335336000024
J	Galvao, J; Davis, B; Tilley, M; Normando, E; Duchen, MR; Cordeiro, MF				Galvao, Joana; Davis, Benjamin; Tilley, Mark; Normando, Eduardo; Duchen, Michael R.; Cordeiro, M. Francesca			Unexpected low-dose toxicity of the universal solvent DMSO	FASEB JOURNAL			English	Article						neuronal apoptosis; retina; DARC; toxicity; AIF	APOPTOSIS-INDUCING FACTOR; MITOCHONDRIAL PERMEABILITY TRANSITION; POLYMERASE-1-DEPENDENT CELL-DEATH; POLY(ADP-RIBOSE) PAR POLYMER; DIMETHYL-SULFOXIDE DMSO; PHOSPHATIDYLSERINE EXTERNALIZATION; MOLECULAR-MECHANISMS; AIF; ACTIVATION; DIMETHYLSULFOXIDE	Dimethyl sulfoxide (DMSO) is an important aprotic solvent that can solubilize a wide variety of otherwise poorly soluble polar and nonpolar molecules. This, coupled with its apparent low toxicity at concentrations <10%, has led to its ubiquitous use and widespread application. Here, we demonstrate that DMSO induces retinal apoptosis in vivo at low concentrations (5 l intravitreally dosed DMSO in rat from a stock concentration of 1, 2, 4, and 8% v/v). Toxicity was confirmed in vitro in a retinal neuronal cell line, at DMSO concentrations >1% (v/v), using annexin V, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and AlamarBlue cell viability assays. DMSO concentrations >10% (v/v) have recently been reported to cause cellular toxicity through plasma membrane pore formation. Here, we show the mechanism by which low concentrations (2-4% DMSO) induce caspase-3 independent neuronal death that involves apoptosis-inducing factor (AIF) translocation from mitochondria to the nucleus and poly-(ADP-ribose)-polymerase (PARP) activation. These results highlight safety concerns of using low concentrations of DMSO as a solvent for in vivo administration and in biological assays. We recommend that methods other than DMSO are employed for solubilizing drugs but, where no alternative exists, researchers compute absolute DMSO final concentrations and include an untreated control group in addition to DMSO vehicle control to check for solvent toxicity.Galvao, J., Davis, B., Tilley, M., Normando, E., Duchen, M. R., Cordeiro, M. F. Unexpected low-dose toxicity of the universal solvent DMSO.	[Galvao, Joana; Davis, Benjamin; Tilley, Mark; Normando, Eduardo; Cordeiro, M. Francesca] UCL, Inst Ophthalmol, Glaucoma & Retinal Neurodegenerat Res Grp, London EC1V 9EL, England; [Duchen, Michael R.] UCL, Dept Cell & Dev Biol, London EC1V 9EL, England; [Duchen, Michael R.] UCL, UK Parkinsons Dis Consortium, Inst Neurol, London EC1V 9EL, England; [Normando, Eduardo; Cordeiro, M. Francesca] Univ London Imperial Coll Sci Technol & Med, Western Eye Hosp, London, England	University of London; University College London; University of London; University College London; University of London; University College London; Imperial College London	Cordeiro, MF (corresponding author), UCL, Inst Ophthalmol, Glaucoma & Retinal Neurodegenerat Res Grp, London EC1V 9EL, England.	m.cordeiro@ucl.ac.uk	duchen, michael/A-2116-2009	duchen, michael/0000-0003-2548-4294; Normando, Eduardo Maria/0000-0002-5774-8082; Tilley, Mark/0000-0002-0571-522X; Cordeiro, Maria Francesca/0000-0001-8663-6525; Davis, Benjamin/0000-0001-6121-1635	Foundation for Science and Technology, Portugal (FCT) [SFRH/BD/47947/2008]; Fonds Europeen de Developpement Regional (FEDER)	Foundation for Science and Technology, Portugal (FCT)(Portuguese Foundation for Science and Technology); Fonds Europeen de Developpement Regional (FEDER)(European Commission)	This study was supported by Foundation for Science and Technology, Portugal (FCT Fellowship SFRH/BD/47947/2008) and Fonds Europeen de Developpement Regional (FEDER). The authors thank Dr. Lisa Turner for proofreading; Dr. Will Kotiadis, Dr. Ronan Astin, and Dr. Goncalo Pereira for help using the mitochondrial respiration electrode; and Dr. Antonio Francisco Ambrosio and Dr. Ana Raquel Santiago for general advice. Conflict of interest: M.F.C. has a patent application.	Abeti R, 2012, NEUROCHEM RES, V37, P2589, DOI 10.1007/s11064-012-0895-x; Aita K, 2005, EXP MOL PATHOL, V79, P265, DOI 10.1016/j.yexmp.2005.07.001; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Andrabi SA, 2008, ANN NY ACAD SCI, V1147, P233, DOI 10.1196/annals.1427.014; Austin JW, 2008, J NEUROTRAUM, V25, P411, DOI 10.1089/neu.2007.0436; Avila MY, 2002, INVEST OPHTH VIS SCI, V43, P3021; Avila MY, 2002, INVEST OPHTH VIS SCI, V43, P1897; Balaiya S., 2013, INVEST OPHTH VIS SCI, V53, P4315; Banic B, 2011, CELL MOL BIOL LETT, V16, P328, DOI 10.2478/s11658-011-0007-y; Bizrah M., 2012, INVEST OPHTHALMOL VI, V53; BROWN HM, 1990, PFLUG ARCH EUR J PHY, V415, P395, DOI 10.1007/BF00373615; Burugula B, 2011, INVEST OPHTH VIS SCI, V52, P4263, DOI 10.1167/iovs.10-7103; Cao XG, 2007, INVEST OPHTH VIS SCI, V48, P3714, DOI 10.1167/iovs.06-1304; Clerc P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034465; Cordeiro MF, 2004, P NATL ACAD SCI USA, V101, P13352, DOI 10.1073/pnas.0405479101; DANIELS SA, 1990, GRAEF ARCH CLIN EXP, V228, P513, DOI 10.1007/BF00918482; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; de Menorval MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041733; Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432; Duchen MR, 2012, PFLUG ARCH EUR J PHY, V464, P111, DOI 10.1007/s00424-012-1112-0; Ekwall B., 1990, SHORT TERM TOXICITY, P75, DOI DOI 10.1155/2014/180549; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Er E, 2006, BBA-BIOENERGETICS, V1757, P1301, DOI 10.1016/j.bbabio.2006.05.032; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Gregory MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017659; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; Hanslick JL, 2009, NEUROBIOL DIS, V34, P1, DOI 10.1016/j.nbd.2008.11.006; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hill R. V., 1973, ANN NY ACAD SCI, V243, P485; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Huang Y, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-78; Ju KR, 2006, BRAIN RES, V1122, P209, DOI 10.1016/j.brainres.2006.09.022; Julien C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040020; Koiri RK, 2011, LEUKEMIA RES, V35, P950, DOI 10.1016/j.leukres.2010.12.029; Konno T, 2007, LIFE SCI, V80, P1115, DOI 10.1016/j.lfs.2006.11.053; Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2; Kumi-Diaka J, 2000, BIOL CELL, V92, P115, DOI 10.1016/S0248-4900(00)89019-X; Lee SH, 2013, CELL DEATH DIFFER, V20, P64, DOI 10.1038/cdd.2012.93; Li B, 2000, EXP EYE RES, V70, P755, DOI 10.1006/exer.2000.0843; Li Y., 2012, INT J MOL SCI, V11, P2109; Lin Yang J, 2011, IN VIVO, V2011, P1; Liu B, 2013, INVEST OPHTH VIS SCI, V54, P1061, DOI 10.1167/iovs.12-10142; Liu J, 2001, INT IMMUNOPHARMACOL, V1, P63, DOI 10.1016/S1567-5769(00)00016-3; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Luke J, 2010, CURR EYE RES, V35, P1090, DOI 10.3109/02713683.2010.512408; Mirnikjoo B, 2009, J BIOL CHEM, V284, P22512, DOI 10.1074/jbc.C109.022913; Mirnikjoo B, 2009, J BIOL CHEM, V284, P6918, DOI 10.1074/jbc.M805288200; Modesitt SC, 2010, GYNECOL ONCOL, V119, P351, DOI 10.1016/j.ygyno.2010.06.030; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Norberg E, 2010, BIOCHEM BIOPH RES CO, V396, P95, DOI 10.1016/j.bbrc.2010.02.163; Notman R, 2006, J AM CHEM SOC, V128, P13982, DOI 10.1021/ja063363t; Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003; Pelzel HR, 2012, INVEST OPHTH VIS SCI, V53, P1428, DOI 10.1167/iovs.11-8872; Pelzel HR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-62; Perche O, 2007, INVEST OPHTH VIS SCI, V48, P2753, DOI 10.1167/iovs.06-1258; Pina Y, 2011, CLIN OPHTHALMOL, V5, P337, DOI 10.2147/OPTH.S16172; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Qi WD, 2008, HEARING RES, V236, P52, DOI 10.1016/j.heares.2007.12.002; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rojas JC, 2008, BRAIN RES, V1215, P208, DOI 10.1016/j.brainres.2008.04.001; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Sankpal UT, 2012, PROSTATE, V72, P1648, DOI 10.1002/pros.22518; Santiago AR, 2007, NEUROBIOL DIS, V25, P464, DOI 10.1016/j.nbd.2006.10.023; Sun C, 2013, INT J MOL SCI, V14, P850, DOI 10.3390/ijms14010850; Sun HH, 2012, NEUROSCIENCE, V223, P114, DOI 10.1016/j.neuroscience.2012.07.026; SZMANT HH, 1975, ANN NY ACAD SCI, V243, P20, DOI 10.1111/j.1749-6632.1975.tb25340.x; Teng BT, 2011, J PHYSIOL-LONDON, V589, P3349, DOI 10.1113/jphysiol.2011.209619; Tsai TI, 2009, DOC OPHTHALMOL, V119, P199, DOI 10.1007/s10633-009-9191-8; Van Bergen NJ, 2009, INVEST OPHTH VIS SCI, V50, P4267, DOI 10.1167/iovs.09-3484; van Wijk SJL, 2005, FREE RADICAL BIO MED, V39, P81, DOI 10.1016/j.freeadbiomed.2005.03.021; Vieira H, 2003, IUBMB LIFE, V55, P613, DOI 10.1080/15216540310001639652; Vondracek J, 2006, LEUKEMIA RES, V30, P81, DOI 10.1016/j.leukres.2005.05.016; Wang XC, 2007, NAT CELL BIOL, V9, P541, DOI 10.1038/ncb1574; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wang YF, 2009, EXP NEUROL, V218, P193, DOI 10.1016/j.expneurol.2009.03.020; Wang YF, 2009, J NEUROCHEM, V110, P687, DOI 10.1111/j.1471-4159.2009.06167.x; Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; YU ZW, 1994, BIOSCIENCE REP, V14, P259, DOI 10.1007/BF01199051; Zacharias LC, 2011, J OCUL PHARMACOL TH, V27, P143, DOI 10.1089/jop.2010.0143	81	378	388	10	154	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1317	1330		10.1096/fj.13-235440	http://dx.doi.org/10.1096/fj.13-235440			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24327606				2022-12-28	WOS:000335324800024
J	Shi, J; Birnbaumer, L; Large, WA; Albert, AP				Shi, Jian; Birnbaumer, Lutz; Large, William A.; Albert, Anthony P.			Myristoylated alanine-rich C kinase substrate coordinates native TRPC1 channel activation by phosphatidylinositol 4,5-bisphosphate and protein kinase C in vascular smooth muscle	FASEB JOURNAL			English	Article						Ca2+ signaling; calmodulin; transgenic	MARCKS PROTEIN; CATION CHANNEL; ANGIOTENSIN-II; CALMODULIN; INHIBITION; PIP2; PKC; ENDOTHELIN-1; SECRETION; CELLS	Canonical transient receptor potential 1 (TRPC1) Ca2+-permeable cation channels contribute to vascular tone and blood vessel remodeling and represent potential therapeutic targets for cardiovascular disease. Protein kinase C (PKC) and phosphatidylinositol 4,5-bisphosphate [PI(4,5)P-2] are obligatory for native TRPC1 channel activation in vascular smooth muscle cells (VSMCs) but how PKC and PI(4,5)P-2 act together to induce channel gating remains unresolved. The present study reveals that myristoylated alanine-rich C kinase substrate (MARCKS) protein coordinates activation of TRPC1 channels by PKC and PI(4,5)P-2. TRPC1 channels and MARCKS form signaling complexes with PI(4,5)P-2 bound to MARCKS; in this configuration TRPC1 channels are closed. Activators of TRPC1 channels induce PKC phosphorylation of TRPC1 proteins, which causes dissociation of TRPC1 subunits from MARCKS and release of PI(4,5)P-2 from MARCKS; PI(4,5)P-2 subsequently binds to TRPC1 subunits to induce channel opening. Calmodulin acting at, or upstream of, MARCKS is also required for TRPC1 channel opening through a similar gating mechanism involving PKC and PI(4,5)P-2. These novel findings show that MARCKS coordinates native TRPC1 channel activation in VSMCs by acting as a reversible PI(4,5)P-2 buffer, which is regulated by PKC-mediated TRPC1 phosphorylation. Moreover, our data provide evidence that PI(4,5)P-2 is a gating ligand of TRPC1 channels.Shi, J., Birnbaumer, L., Large, W. A., and Albert, A. P. Myristoylated alanine-rich C kinase substrate coordinates native TRPC1 channel activation by phosphatidylinositol 4,5-bisphosphate and protein kinase C in vascular smooth muscle.	[Shi, Jian; Large, William A.; Albert, Anthony P.] Univ London, Dept Pharmacol & Cell Physiol, Div Biomed Sci, London SW17 0RE, England; [Birnbaumer, Lutz] NIEHS, Neurobiol Lab, Res Triangle Pk, NC 27709 USA	University of London; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Albert, AP (corresponding author), Univ London, Div Biomed Sci, Cranmer Terrace, London SW17 0RE, England.	aalbert@sgul.ac.uk		Albert, Anthony/0000-0002-3596-9634	UK Biotechnology and Biological Sciences Research Council [BB/J007226/1]; Intramural Research Program of the U.S. National Institutes of Health [z01-ES-101684]; BBSRC [BB/J007226/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/J007226/1] Funding Source: researchfish; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES101643, ZIAES101684, Z01ES101684] Funding Source: NIH RePORTER	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Intramural Research Program of the U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the UK Biotechnology and Biological Sciences Research Council (BB/J007226/1 to A. P. A.) and by the Intramural Research Program of the U.S. National Institutes of Health (project z01-ES-101684 to L.B.).	Abramowitz J, 2009, FASEB J, V23, P297, DOI 10.1096/fj.08-119495; Albert AP, 2008, J PHYSIOL-LONDON, V586, P3087, DOI 10.1113/jphysiol.2008.153676; Albert AP, 2006, BRIT J PHARMACOL, V148, P1001, DOI 10.1038/sj.bjp.0706797; Albert AP, 2011, ADV EXP MED BIOL, V704, P391, DOI 10.1007/978-94-007-0265-3_22; Alli AA, 2012, AM J PHYSIOL-RENAL, V303, pF800, DOI 10.1152/ajprenal.00703.2011; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Beech DJ, 2013, CIRC J, V77, P570, DOI 10.1253/circj.CJ-13-0154; Damera G, 2010, EXP LUNG RES, V36, P75, DOI 10.3109/01902140903131200; Dietrich A, 2007, PFLUG ARCH EUR J PHY, V455, P465, DOI 10.1007/s00424-007-0314-3; Dietrich A, 2010, THROMB HAEMOSTASIS, V103, P262, DOI 10.1160/TH09-08-0517; Foster WM, 2010, AM J PHYSIOL-LUNG C, V299, pL345, DOI 10.1152/ajplung.00067.2010; Gallant C, 2005, J CELL SCI, V118, P3595, DOI 10.1242/jcs.02493; Gambhir A, 2004, BIOPHYS J, V86, P2188, DOI 10.1016/S0006-3495(04)74278-2; Gonzalez-Cobos JC, 2010, FRONT BIOSCI-LANDMRK, V15, P1023, DOI 10.2741/3660; Hardie RC, 2012, SCIENCE, V338, P260, DOI 10.1126/science.1222376; House SJ, 2008, PFLUG ARCH EUR J PHY, V456, P769, DOI 10.1007/s00424-008-0491-8; Huang JH, 2010, CURR BIOL, V20, P189, DOI 10.1016/j.cub.2009.12.019; Inoue R. J., 2010, PHARMACOL THERAPEUT, V123, P371; Ju M, 2010, J PHYSIOL-LONDON, V588, P1419, DOI 10.1113/jphysiol.2009.185256; Kwon Y, 2007, MOL CELL, V25, P491, DOI 10.1016/j.molcel.2007.01.021; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McLaughlin S, 2005, BIOCHEM SOC SYMP, V72, P189, DOI 10.1042/bss0720189; Peppiatt-Wildman CM, 2007, J PHYSIOL-LONDON, V580, P755, DOI 10.1113/jphysiol.2006.126656; Saleh SN, 2006, J PHYSIOL-LONDON, V577, P479, DOI 10.1113/jphysiol.2006.119305; Saleh SN, 2008, J PHYSIOL-LONDON, V586, P2463, DOI 10.1113/jphysiol.2008.152157; Saleh SN, 2009, J PHYSIOL-LONDON, V587, P5361, DOI 10.1113/jphysiol.2009.180331; Saleh SN, 2009, J PHYSIOL-LONDON, V587, P531, DOI 10.1113/jphysiol.2008.166678; Shi J, 2012, BRIT J PHARMACOL, V166, P2161, DOI 10.1111/j.1476-5381.2012.01937.x; Shi J, 2010, J PHYSIOL-LONDON, V588, P3671, DOI 10.1113/jphysiol.2010.194621; Shi J, 2012, FASEB J, V26, P409, DOI 10.1096/fj.11-185611; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Suh B.-C., 2005, ANNU REV BIOPHYS, V37, P175; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Zhu M. X., 2005, PFLUGERS ARCH, V451, P101	36	24	25	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					244	255		10.1096/fj.13-238022	http://dx.doi.org/10.1096/fj.13-238022			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24022404	Green Published			2022-12-28	WOS:000333526100024
J	Carbone, JW; Margolis, LM; McClung, JP; Cao, JJ; Murphy, NE; Sauter, ER; Combs, GF; Young, AJ; Pasiakos, SM				Carbone, John W.; Margolis, Lee M.; McClung, James P.; Cao, Jay J.; Murphy, Nancy E.; Sauter, Edward R.; Combs, Gerald F., Jr.; Young, Andrew J.; Pasiakos, Stefan M.			Effects of energy deficit, dietary protein, and feeding on intracellular regulators of skeletal muscle proteolysis	FASEB JOURNAL			English	Article						ubiquitin proteasome; caspase-3; negative energy balance; high-protein diets	GASTRIC-CANCER PATIENTS; FAT-FREE MASS; ENDURANCE EXERCISE; CATABOLIC CONDITIONS; GENE-EXPRESSION; WEIGHT-LOSS; PROTEASOME; RESPONSES; PATHWAY; SUPPLEMENTATION	This study was undertaken to characterize the ubiquitin proteasome system (UPS) response to varied dietary protein intake, energy deficit (ED), and consumption of a mixed meal. A randomized, controlled trial of 39 adults consuming protein at 0.8 (recommended dietary allowance [RDA]), 1.6 (2x-RDA), or 2.4 (3x-RDA) g.kg(-1).d(-1) for 31 d. A 10-d weight maintenance (WM) period was followed by 21 d of 40% ED. Ubiquitin (Ub)-mediated proteolysis and associated gene expression were assessed in the postabsorptive (fasted) and postprandial (fed; 480 kcal, 20 g protein) states after WM and ED by using muscle biopsies, fluorescence-based assays, immunoblot analysis, and real-time qRT-PCR. In the assessment of UPS responses to varied protein intakes, ED, and feeding, the RDA, WM, and fasted measures served as appropriate controls. ED resulted in the up-regulation of UPS-associated gene expression, as mRNA expression of the atrogenes muscle RING finger-1 (MuRF1) and atrogin-1 were 1.2- and 1.3-fold higher (P<0.05) for ED than for WM. However, mixed-meal consumption attenuated UPS-mediated proteolysis, independent of energy status or dietary protein, as the activities of the 26S proteasome subunits beta 1, beta 2, and beta 5 were lower (P<0.05) for fed than for fasted. Muscle protein ubiquitylation was also 45% lower (P<0.05) for fed than for fasted, regardless of dietary protein and energy manipulations. Independent of habitual protein intake and despite increased MuRF1 and atrogin-1 mRNA expression during ED, consuming a protein-containing mixed meal attenuates Ub-mediated proteolysis.	[Carbone, John W.] Eastern Michigan Univ, Sch Hlth Sci, Ypsilanti, MI 48197 USA; [Margolis, Lee M.; McClung, James P.; Murphy, Nancy E.; Young, Andrew J.; Pasiakos, Stefan M.] US Army Res Inst Environm Med, Mil Nutr Div, Natick, MA 01760 USA; [Cao, Jay J.; Sauter, Edward R.; Combs, Gerald F., Jr.] ARS, Grand Forks Human Nutr Res Ctr, USDA, Grand Forks, ND USA; [Sauter, Edward R.] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA	Eastern Michigan University; United States Department of Defense; United States Army; United States Department of Agriculture (USDA); University of North Dakota Grand Forks	Pasiakos, SM (corresponding author), US Army Res Inst Environm Med, Mil Nutr Div, 15 Kansas St,Bldg 42, Natick, MA 01760 USA.	stefan.pasiakos@us.army.mil	Pasiakos, Stefan M/E-6295-2014; McClung, James P/A-1989-2009	Pasiakos, Stefan M/0000-0002-5378-5820; , Lee/0000-0002-0652-1304; Margolis, Lee/0000-0003-1697-825X	U.S. Army Medical Research and Material Command (USAMRMC); USDA, Agricultural Research Service (ARS); Eastern Michigan University College of Health and Human Services; Dairy Research Institute; USDA; USAMRMC; USDA, ARS [58-1950-7-707]	U.S. Army Medical Research and Material Command (USAMRMC)(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); USDA, Agricultural Research Service (ARS)(United States Department of Agriculture (USDA)USDA Agricultural Research Service); Eastern Michigan University College of Health and Human Services; Dairy Research Institute; USDA(United States Department of Agriculture (USDA)); USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); USDA, ARS(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	The authors thank the volunteers who participated in this research experiment and LuAnn Johnson [U.S. Department of Agriculture (USDA) Grand Forks Human Nutrition Research Center, Grand Forks, SD, USA] for significant contributions to the data analysis. The study was supported by the U.S. Army Medical Research and Material Command (USAMRMC); the USDA, Agricultural Research Service (ARS); and the Eastern Michigan University College of Health and Human Services. S. M. P. reported that his institution received a grant from the Dairy Research Institute for work outside this publication. E. R. S. reported that his institution received a grant and travel support from the USDA for work associated with this publication. E. R. S. is a consultant for Halo Health, has received royalties for book editorship, and has been granted a patent. J.P.M. reported that his institution received a grant from the USAMRMC for work outside this publication. The other authors report no conflicts of interest. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U. S. Army or the U. S. Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement of approval of the products or services of these organizations. This material is based on work supported by the USDA, ARS, under agreement 58-1950-7-707. Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA. This trial is registered at ClinicalTrials.gov (http://www.clinicaltrials.gov) as number NCT01292395.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; [Anonymous], 2005, DIET REF INT EN CARB; Bolster DR, 2005, AM J PHYSIOL-ENDOC M, V289, pE678, DOI 10.1152/ajpendo.00060.2005; Bossola M, 2003, ANN SURG, V237, P384, DOI 10.1097/00000658-200303000-00013; Bossola M, 2001, AM J PHYSIOL-REG I, V280, pR1518, DOI 10.1152/ajpregu.2001.280.5.R1518; Burnham K.P., 2002, MODEL SELECTION MULT, VSecond edition; Carbone JW, 2012, ADV NUTR, V3, P119, DOI 10.3945/an.111.001792; Chaston TB, 2007, INT J OBESITY, V31, P743, DOI 10.1038/sj.ijo.0803483; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; KASCH FW, 1976, J APPL PHYSIOL, V40, P982, DOI 10.1152/jappl.1976.40.6.982; Kumari R, 2011, BIOCHEM BIOPH RES CO, V412, P644, DOI 10.1016/j.bbrc.2011.08.017; Lunn WR, 2012, MED SCI SPORT EXER, V44, P682, DOI 10.1249/MSS.0b013e3182364162; Pasiakos SM, 2013, FASEB J, V27, P3837, DOI 10.1096/fj.13-230227; Pasiakos SM, 2011, AM J CLIN NUTR, V94, P809, DOI 10.3945/ajcn.111.017061; Pasiakos SM, 2010, INT J SPORT NUTR EXE, V20, P282, DOI 10.1123/ijsnem.20.4.282; Pasiakos SM, 2010, J NUTR, V140, P745, DOI 10.3945/jn.109.118372; Raina N, 2004, AM J PHYSIOL-ENDOC M, V286, pE481, DOI 10.1152/ajpendo.00355.2003; Raina N, 2003, CYTOKINE, V22, P180, DOI 10.1016/S1043-4666(03)00105-4; ROZA AM, 1984, AM J CLIN NUTR, V40, P168, DOI 10.1093/ajcn/40.1.168; Salem M, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-328; Schakman O, 2012, AM J PHYSIOL-ENDOC M, V303, pE729, DOI 10.1152/ajpendo.00060.2012; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; Vary T C, 1998, Curr Opin Clin Nutr Metab Care, V1, P217, DOI 10.1097/00075197-199803000-00013; Weinheimer EM, 2010, NUTR REV, V68, P375, DOI 10.1111/j.1753-4887.2010.00298.x; Williams A, 1999, SURGERY, V126, P744, DOI 10.1067/msy.2099.99888; Wohlgemuth SE, 2011, REJUV RES, V14, P315, DOI 10.1089/rej.2010.1132; Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007; Workeneh BT, 2006, J AM SOC NEPHROL, V17, P3233, DOI 10.1681/ASN.2006020131; Wycherley TP, 2012, AM J CLIN NUTR, V96, P1281, DOI 10.3945/ajcn.112.044321	36	32	32	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5104	5111		10.1096/fj.13-239228	http://dx.doi.org/10.1096/fj.13-239228			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23965841				2022-12-28	WOS:000329999000042
J	Thomsen, C; Grundevik, P; Elias, P; Stahlberg, A; Aman, P				Thomsen, Christer; Grundevik, Pernilla; Elias, Per; Stahlberg, Anders; Aman, Pierre			A conserved N-terminal motif is required for complex formation between FUS, EWSR1, TAF15 and their oncogenic fusion proteins	FASEB JOURNAL			English	Article						neurodegenerative diseases; tumor biology; neuropathology	AMYOTROPHIC-LATERAL-SCLEROSIS; EWINGS-SARCOMA PROTEIN; B-LYMPHOCYTE DEVELOPMENT; CELL-FREE FORMATION; MYXOID LIPOSARCOMA; BINDING PROTEIN; ARGININE METHYLATION; FAMILY ONCOPROTEINS; NUCLEAR IMPORT; DNA-DAMAGE	The three FET (FUS, EWSR1, and TAF15) family RNA binding proteins are expressed in all tissues and almost all cell types. The disordered N-terminal parts are always present in FET fusion oncoproteins of sarcomas and leukemia. Mutations in FUS and TAF15 cause aggregation of FET proteins in neurological disorders. Here we used recombinant proteins in pulldown experiments and mass spectrometry to identify major interaction partners of the FET N-terminal parts. We report that FUS, EWSR1, and TAF15 form homo-and heterocomplexes as major binding partners and identify an evolutionarily conserved N-terminal motif (FETBM1) that is required for this interaction. The binding is RNA and DNA independent and robust up to 1 M of NaCl. The localization of FETBM1 and its target sequences supports a simple model for FET protein aggregation as reported in neurological disorders such as amyotrophic lateral sclerosis, frontotemporal dementia, and essential tremor. The FETBM1 localization also explains the binding of normal full-length FET proteins to their oncogenic fusion proteins.	[Thomsen, Christer; Grundevik, Pernilla; Stahlberg, Anders; Aman, Pierre] Univ Gothenburg, Sahlgrenska Acad, Dept Pathol, Sahlgrenska Canc Ctr,Inst Biomed, S-40530 Gothenburg, Sweden; [Elias, Per] Univ Gothenburg, Sahlgrenska Acad, Dept Med Biochem & Cell Biol, Inst Biomed, S-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Aman, P (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Pathol, Sahlgrenska Canc Ctr,Inst Biomed, Box 425, S-40530 Gothenburg, Sweden.	pierre.aman@llcr.med.gu.se		Stahlberg, Anders/0000-0003-4243-0191; Aman, Pierre/0000-0002-1482-8875	Swedish Cancer Society; Assar Gabrielssons Research Foundation; Johan Jansson Foundation for Cancer Research; Social-styrelsen; Swedish Society for Medical Research; Swedish Children's Cancer Society; BioCARE National Strategic Research Program at University of Gothenburg; Wilhelm and Martina Lundgren Foundation for Scientific Research; Swedish Research Council [2367]; Swedish Foundation for Strategic Research	Swedish Cancer Society(Swedish Cancer Society); Assar Gabrielssons Research Foundation; Johan Jansson Foundation for Cancer Research; Social-styrelsen; Swedish Society for Medical Research; Swedish Children's Cancer Society; BioCARE National Strategic Research Program at University of Gothenburg; Wilhelm and Martina Lundgren Foundation for Scientific Research; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research)	This work was supported by grants from the Swedish Cancer Society, Assar Gabrielssons Research Foundation, Johan Jansson Foundation for Cancer Research, Social-styrelsen, Swedish Society for Medical Research, Swedish Children's Cancer Society, BioCARE National Strategic Research Program at University of Gothenburg, Wilhelm and Martina Lundgren Foundation for Scientific Research, the Swedish Research Council (2367), and the Swedish Foundation for Strategic Research. The protein interactions from this publication have been submitted to the International Molecular Exchange (IMEx) Consortium (http://www.imexconsortium.org) through IntAct [pmid: 22121220] and assigned the identifier IM-21252.	AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Andersson MK, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-37; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Belyanskaya LL, 2003, EXP CELL RES, V288, P374, DOI 10.1016/S0014-4827(03)00221-0; Belyanskaya LL, 2001, J BIOL CHEM, V276, P18681, DOI 10.1074/jbc.M011446200; Bento C, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-89; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Blechingberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046251; Couthouis J, 2012, HUM MOL GENET, V21, P2899, DOI 10.1093/hmg/dds116; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dinkel H, 2012, NUCLEIC ACIDS RES, V40, pD242, DOI 10.1093/nar/gkr1064; Dormann D, 2012, EMBO J, V31, P4258, DOI 10.1038/emboj.2012.261; Dormann D, 2010, EMBO J, V29, P2841, DOI 10.1038/emboj.2010.143; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Embree LJ, 2009, CANCER RES, V69, P4363, DOI 10.1158/0008-5472.CAN-08-3229; Fujii R, 2005, J CELL SCI, V118, P5755, DOI 10.1242/jcs.02692; Gardiner M, 2008, BIOCHEM J, V415, P297, DOI 10.1042/BJ20081135; Goransson M, 2002, EXP CELL RES, V278, P125, DOI 10.1006/excr.2002.5566; Goransson M, 2009, ONCOGENE, V28, P270, DOI 10.1038/onc.2008.378; Han TNW, 2012, CELL, V149, P768, DOI 10.1016/j.cell.2012.04.016; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Hoell JI, 2011, NAT STRUCT MOL BIOL, V18, P1428, DOI 10.1038/nsmb.2163; Kato M, 2012, CELL, V149, P753, DOI 10.1016/j.cell.2012.04.017; Klevernic IV, 2009, BIOCHEM J, V418, P625, DOI 10.1042/BJ20082097; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066; Lagier-Tourenne C, 2012, NAT NEUROSCI, V15, P1488, DOI 10.1038/nn.3230; Lagier-Tourenne C, 2010, HUM MOL GENET, V19, pR46, DOI 10.1093/hmg/ddq137; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Law Warren J., 2006, Briefings in Functional Genomics & Proteomics, V5, P8, DOI 10.1093/bfgp/ell015; Lee JW, 2005, STEM CELLS, V23, P738, DOI 10.1634/stemcells.2004-0375; Lee KAW, 2007, CELL RES, V17, P286, DOI 10.1038/cr.2007.22; Li HJ, 2007, J CLIN INVEST, V117, P1314, DOI 10.1172/JCI31222; Mitchell JC, 2013, ACTA NEUROPATHOL, V125, P273, DOI 10.1007/s00401-012-1043-z; Morlando M, 2012, EMBO J, V31, P4502, DOI 10.1038/emboj.2012.319; Munoz DG, 2009, ACTA NEUROPATHOL, V118, P617, DOI 10.1007/s00401-009-0598-9; Neumann M, 2011, BRAIN, V134, P2595, DOI 10.1093/brain/awr201; Ng KP, 2007, P NATL ACAD SCI USA, V104, P479, DOI 10.1073/pnas.0607007104; Pahlich S, 2009, J PROTEOME RES, V8, P4455, DOI 10.1021/pr900235t; Paronetto MP, 2011, MOL CELL, V43, P353, DOI 10.1016/j.molcel.2011.05.035; Papadopoulos JS, 2007, BIOINFORMATICS, V23, P1073, DOI 10.1093/bioinformatics/btm076; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Riggi N, 2007, J PATHOL, V213, P4, DOI 10.1002/path.2209; Spahn L, 2003, ONCOGENE, V22, P6819, DOI 10.1038/sj.onc.1206810; Tan AY, 2012, P NATL ACAD SCI USA, V109, P6030, DOI 10.1073/pnas.1203028109; Tan AY, 2009, J MOL CELL BIOL, V1, P82, DOI 10.1093/jmcb/mjp025; Thelin-Jarnum S, 2002, INT J CANCER, V97, P446, DOI 10.1002/ijc.1632; Thomas GR, 2002, CANCER BIOL THER, V1, P428, DOI 10.4161/cbt.1.4.23; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942; Woulfe J, 2010, BRAIN PATHOL, V20, P589, DOI 10.1111/j.1750-3639.2009.00337.x; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Zinszner H, 1997, J CELL SCI, V110, P1741	55	19	19	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4965	4974		10.1096/fj.13-234435	http://dx.doi.org/10.1096/fj.13-234435			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23975937				2022-12-28	WOS:000329999000030
J	Guha, S; Baltazar, GC; Coffey, EE; Tu, LA; Lim, JC; Beckel, JM; Patel, S; Eysteinsson, T; Lu, WN; O'Brien-Jenkins, A; Laties, AM; Mitchell, CH				Guha, Sonia; Baltazar, Gabriel C.; Coffey, Erin E.; Tu, Leigh-Anne; Lim, Jason C.; Beckel, Jonathan M.; Patel, Shaun; Eysteinsson, Thor; Lu, Wennan; O'Brien-Jenkins, Ann; Laties, Alan M.; Mitchell, Claire H.			Lysosomal alkalinization, lipid oxidation, and reduced phagosome clearance triggered by activation of the P2X7 receptor	FASEB JOURNAL			English	Article						lipofuscin; autophagy; retinal degeneration; purinergic signaling	RETINAL-PIGMENT EPITHELIUM; CULTURED HUMAN; RPE CELLS; RELEASE; STIMULATION; ATP; PH; ACCUMULATION; DEGRADATION; MODULATION	Lysosomal enzymes function optimally at low pH; as accumulation of waste material contributes to cell aging and disease, dysregulation of lysosomal pH may represent an early step in several pathologies. Here, we demonstrate that stimulation of the P2X7 receptor (P2X7R) for ATP alkalinizes lysosomes in cultured human retinal pigmented epithelial (RPE) cells and impairs lysosomal function. P2X7R stimulation did not kill RPE cells but alkalinized lysosomes by 0.3 U. Receptor stimulation also elevated cytoplasmic Ca2+; Ca2+ influx was necessary but not sufficient for lysosomal alkalinization. P2X7R stimulation decreased access to the active site of cathepsin D. Interestingly, lysosomal alkalinization was accompanied by a rise in lipid oxidation that was prevented by P2X7R antagonism. Likewise, the autofluorescence of phagocytosed photoreceptor outer segments increased by lysosomal alkalinization was restored 73% by a P2X7R antagonist. Together, this suggests that endogenous autostimulation of the P2X7R may oxidize lipids and impede clearance. The P2X7R was expressed on apical and basolateral membranes of mouse RPE; mRNA expression of P2X7R and extracellular ATP marker NTPDase1 was raised in RPE tissue from the ABCA4(-/-) mouse model of Stargardt's retinal degeneration. In summary, P2X7R stimulation raises lysosomal pH and impedes lysosomal function, suggesting a possible role for overstimulation in diseases of accumulation.Guha, S., Baltazar G. C., Coffey, E. E., Tu, L.-A., Lim, J. C., Beckel, J. M., Patel, S., Eysteinsson, T., Lu, W., O'Brien-Jenkins, A., Laties, A. M., Mitchell, C. H. Lysosomal alkalinization, lipid oxidation, and reduced phagosome clearance triggered by activation of the P2X7 receptor.	[Guha, Sonia; Baltazar, Gabriel C.; Coffey, Erin E.; Tu, Leigh-Anne; Lim, Jason C.; Beckel, Jonathan M.; Lu, Wennan; O'Brien-Jenkins, Ann; Mitchell, Claire H.] Univ Penn, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Laties, Alan M.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; [Patel, Shaun; Mitchell, Claire H.] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; [Eysteinsson, Thor] Univ Iceland, Dept Physiol, Reykjavik, Iceland	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Iceland	Mitchell, CH (corresponding author), Univ Penn, Dept Anat & Cell Biol, 440 Levy Bldg,240 S 40th St, Philadelphia, PA 19104 USA.	chm@exchange.upenn.edu	Beckel, Jonathan/A-6758-2008; Eysteinsson, Thor/L-3069-2015	Beckel, Jonathan/0000-0003-1390-2292; Guha, Sonia/0000-0002-7585-8381; Eysteinsson, Thor/0000-0002-9748-5854	U.S. National Institutes of Health (NIH) [EY013434, EY015537, EY017045, EY001583]; Jody Sack Fund; Paul and Evanina Bell Mackall Foundation Trust; Research to Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY001583, R01EY013434, R24EY017045, R01EY015537] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jody Sack Fund; Paul and Evanina Bell Mackall Foundation Trust; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work is supported by grants from the U.S. National Institutes of Health (NIH) EY013434 and EY015537 (C. H. M.), EY017045 (A. M. L.), Vision Research Core grant EY001583 (C. H. M. and A. M. L.), Research to Prevent Blindness (A. M. L.), the Jody Sack Fund (W. L.), and the Paul and Evanina Bell Mackall Foundation Trust (A. M. L.). The authors thank Kathleen Boesze-Battaglia for help with the photoreceptor purification, Bruce Shenker (University of Pennsylvania School of Dental Medicine Flow Cytometry facility) for help with flow cytometry, and Gabriel Travis (Jules Stein Eye Institute, University of California, Los Angeles, CA, USA) for providing the ABCA4<SUP>-/-</SUP> mice. C. H. M. and A. M. L. are listed as inventors on intellectual property covering some of the data presented here. Preliminary versions of some of this material have appeared in abstract form (40-42).	Baltazar GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049635; BOESZEBATTAGLIA K, 1992, INVEST OPHTH VIS SCI, V33, P484; Chen CS, 2000, J BIOCHEM BIOPH METH, V42, P137, DOI 10.1016/S0165-022X(00)00048-8; Chiozzi P, 1996, BIOCHEM BIOPH RES CO, V218, P176, DOI 10.1006/bbrc.1996.0031; Cotrina ML, 2009, PURINERG SIGNAL, V5, P223, DOI 10.1007/s11302-009-9138-2; del Puerto A, 2012, J CELL SCI, V125, P176, DOI 10.1242/jcs.091736; Drummen GPC, 2002, FREE RADICAL BIO MED, V33, P473, DOI 10.1016/S0891-5849(02)00848-1; Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059; Guha S, 2011, FASEB J, V25; Guha S, 2012, J NEUROCHEM, V122, P823, DOI 10.1111/j.1471-4159.2012.07804.x; Hoppe G, 2004, CELL MOL LIFE SCI, V61, P1664, DOI 10.1007/s00018-004-4080-5; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Jiang LL, 2012, J CELL SCI, V125, P5479, DOI 10.1242/jcs.110072; Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006; Kawai A, 2007, AUTOPHAGY, V3, P154, DOI 10.4161/auto.3634; Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014; Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675; Liu J, 2012, AM J PHYSIOL-CELL PH, V303, pC160, DOI 10.1152/ajpcell.00278.2011; Lu W, 2007, J PHARMACOL EXP THER, V323, P157, DOI 10.1124/jpet.107.124545; Mahon GJ, 2004, CURR EYE RES, V28, P277, DOI 10.1076/ceyr.28.4.277.27835; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Mitchell C. H., 2012, INVEST OPHTH VIS SCI, V53, P3703; Mitchell CH, 2008, PURINERG SIGNAL, V4, P101, DOI 10.1007/s11302-007-9054-2; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pavan B, 2006, BIOCHEM BIOPH RES CO, V350, P169, DOI 10.1016/j.bbrc.2006.09.015; Peters S, 2006, OPHTHAL RES, V38, P83, DOI 10.1159/000090268; Reigada D, 2005, AM J PHYSIOL-CELL PH, V289, pC617, DOI 10.1152/ajpcell.00542.2004; Reigada David, 2006, Purinergic Signal, V2, P499, DOI 10.1007/s11302-005-3980-7; Reigada D, 2006, J PHYSIOL-LONDON, V575, P707, DOI 10.1113/jphysiol.2006.114439; Ryter SW, 2012, ANNU REV PHYSIOL, V74, P377, DOI 10.1146/annurev-physiol-020911-153348; Skaper SD, 2010, FASEB J, V24, P337, DOI 10.1096/fj.09-138883; Sperlagh B, 2006, PROG NEUROBIOL, V78, P327, DOI 10.1016/j.pneurobio.2006.03.007; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Takenouchi T, 2009, J IMMUNOL, V182, P2051, DOI 10.4049/jimmunol.0802577; Tu LA, 2010, INVEST OPHTH VIS SCI, V51; Vessey KA, 2012, PLOS ONE, V7, P290, DOI 10.1371/journal.pone.0029990; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Weisman GA, 2012, MOL NEUROBIOL, V46, P96, DOI 10.1007/s12035-012-8263-z; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P1522, DOI 10.1167/iovs.10-6172; Zois CE, 2011, AUTOPHAGY, V7, P1371, DOI 10.4161/auto.7.11.16664	42	63	65	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4500	4509		10.1096/fj.13-236166	http://dx.doi.org/10.1096/fj.13-236166			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23964074	Green Published			2022-12-28	WOS:000329937500017
J	Joanisse, S; Gillen, JB; Bellamy, LM; McKay, BR; Tarnopolsky, MA; Gibala, MJ; Parise, G				Joanisse, Sophie; Gillen, Jenna B.; Bellamy, Leeann M.; McKay, Bryon R.; Tarnopolsky, Mark A.; Gibala, Martin. J.; Parise, Gianni			Evidence for the contribution of muscle stem cells to nonhypertrophic skeletal muscle remodeling in humans	FASEB JOURNAL			English	Article						satellite cells; Pax7; aerobic interval training	DIGITORUM LONGUS MUSCLE; SATELLITE CELL; MOLECULAR RESPONSES; MYONUCLEAR ADDITION; GAMMA-IRRADIATION; FIBER TYPES; LOW-VOLUME; OLDER MEN; HYPERTROPHY; ENDURANCE	The purpose of this study was to explore the possible role of muscle stem cells, also referred to as satellite cells (SCs), in adaptation and remodeling following a nonhypertrophic stimulus in humans. Muscle biopsies were obtained from the vastus lateralis of previously untrained women (n=15; age: 27 +/- 8 yr, BMI: 29 +/- 6 kg/m(2)) before and after 6 wk of aerobic interval training. The fiber type-specific SC response to training was analyzed using immunofluorescent microscopy of muscle cross sections. Following training, the number of SCs associated with fibers expressing myosin heavy-chain type I and II isoforms (hybrid fibers) increased (pre: 0.062 +/- 0.035 SC/hybrid fiber; post: 0.38 +/- 0.063 SC/hybrid fiber; P<0.01). In addition, there was a greater number of MyoD(+)/Pax7(-) SCs, indicative of differentiating SCs, associated with hybrid fibers (0.18 +/- 0.096 MyoD(+)/Pax7(-) SC/hybrid fiber) compared to type I (0.015 +/- 0.00615 MyoD(+)/Pax7(-) SC/type I fiber) or II (0.012 +/- 0.00454 MyoD(+)/Pax7(-) SC/type II fiber) fibers (P<0.05). There was also a training-induced increase in the number of hybrid fibers containing centrally located nuclei (15.1%) compared to either type I (3.4%) or II fibers (3.6%) (P<0.01). These data are consistent with the hypothesis that SCs contribute to the remodeling of muscle fibers even in the absence of hypertrophy.Joanisse, S., Gillen, J. B., Bellamy, L. M., McKay, B. R., Tarnopolsky, M. A., Gibala, M. J., Parise, G. Evidence for the contribution of muscle stem cells to nonhypertrophic skeletal muscle remodeling in humans.	[Joanisse, Sophie; Gillen, Jenna B.; Bellamy, Leeann M.; McKay, Bryon R.; Gibala, Martin. J.; Parise, Gianni] McMaster Univ, Dept Kinesiol, Hamilton, ON L8S 4L8, Canada; [Tarnopolsky, Mark A.] McMaster Univ, Dept Pediat & Med, Hamilton, ON L8S 4L8, Canada; [Parise, Gianni] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University; McMaster University	Parise, G (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON L8S 4L8, Canada.	pariseg@mcmaster.ca		Joanisse, Sophie/0000-0001-9983-9401	U.S. National Institute of Child Health and Human Development	U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The Pax7 hybridoma cells, developed by Dr. A. Kawakami, and the A4.951 hybridoma cells, developed by Dr. H. Blau, were obtained from the Developmental Studies Hybridoma Bank (DSHB) developed under the auspices of the U.S. National Institute of Child Health and Human Development and maintained by The University of Iowa Department of Biology (Iowa City, IA, USA). Contributions: G. P., M.J.G, J.B.G., and S.J. conceived and designed the experiments, M. A. T., J.B.G, and B. R. M collected the data, S.J., L. M. B., B. R. M, and G. P. analyzed the data; S.J. and G. P. prepared the manuscript. S.J., G. P., J.B.G., M.J.G., L. M. B., B. R. M., and M. A. T. edited the manuscript. All authors approved the final version of the manuscript for publication. The current study was completed at McMaster University (Hamilton, ON, Canada).	Adams GR, 2002, AM J PHYSIOL-CELL PH, V283, pC1182, DOI 10.1152/ajpcell.00173.2002; Allen DL, 1999, MUSCLE NERVE, V22, P1350, DOI 10.1002/(SICI)1097-4598(199910)22:10<1350::AID-MUS3>3.0.CO;2-8; Bouchla A, 2011, J CARDIOPULM REHABIL, V31, P47, DOI 10.1097/HCR.0b013e3181e174d7; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; Charifi N, 2003, MUSCLE NERVE, V28, P87, DOI 10.1002/mus.10394; Conjard A, 1998, PFLUG ARCH EUR J PHY, V436, P962, DOI 10.1007/s004240050730; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846; Demirel HA, 1999, J APPL PHYSIOL, V86, P1002, DOI 10.1152/jappl.1999.86.3.1002; Gibala M, 2009, APPL PHYSIOL NUTR ME, V34, P428, DOI 10.1139/H09-046; Gibala MJ, 2006, J PHYSIOL-LONDON, V575, P901, DOI 10.1113/jphysiol.2006.112094; Gibala MJ, 2012, J PHYSIOL-LONDON, V590, P1077, DOI 10.1113/jphysiol.2011.224725; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; Kadi F, 2004, MUSCLE NERVE, V29, P120, DOI 10.1002/mus.10510; Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012; Kurosaka M, 2012, ACTA PHYSIOL, V205, P159, DOI 10.1111/j.1748-1716.2011.02381.x; Little JP, 2010, J PHYSIOL-LONDON, V588, P1011, DOI 10.1113/jphysiol.2009.181743; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McCarthy JJ, 2007, J APPL PHYSIOL, V103, P1100, DOI 10.1152/japplphysiol.00101.2007a; McCarthy JJ, 2011, DEVELOPMENT, V138, P3657, DOI 10.1242/dev.068858; McKay BR, 2013, AM J PHYSIOL-CELL PH, V304, pC717, DOI 10.1152/ajpcell.00305.2012; McKay BR, 2012, FASEB J, V26, P2509, DOI 10.1096/fj.11-198663; Mckay BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006027; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; O'Connor RS, 2007, J APPL PHYSIOL, V103, P1107, DOI 10.1152/japplphysiol.00502.2007; Petrella JK, 2008, J APPL PHYSIOL, V104, P1736, DOI 10.1152/japplphysiol.01215.2007; Petrella JK, 2006, AM J PHYSIOL-ENDOC M, V291, pE937, DOI 10.1152/ajpendo.00190.2006; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7; Putnam CT, 1999, J APPL PHYSIOL, V86, P40, DOI 10.1152/jappl.1999.86.1.40; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; ROSENBLATT JD, 1993, PFLUG ARCH EUR J PHY, V423, P255, DOI 10.1007/BF00374404; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; Ross A, 2001, SPORTS MED, V31, P1063, DOI 10.2165/00007256-200131150-00003; Roth SM, 2001, J GERONTOL A-BIOL, V56, pB240, DOI 10.1093/gerona/56.6.B240; Rudnicki MA, 2008, COLD SH Q B, V73, P323, DOI 10.1101/sqb.2008.73.064; SCHULTZ E, 1985, MUSCLE NERVE, V8, P217, DOI 10.1002/mus.880080307; Snijders T, 2011, MUSCLE NERVE, V43, P393, DOI 10.1002/mus.21891; Tajbakhsh S, 2003, CURR OPIN GENET DEV, V13, P413, DOI 10.1016/S0959-437X(03)00090-X; Tarnopolsky MA, 2011, MUSCLE NERVE, V43, P717, DOI 10.1002/mus.21945; Ten Broek RW, 2010, J CELL PHYSIOL, V224, P7, DOI 10.1002/jcp.22127; Verdijk LB, 2009, J GERONTOL A-BIOL, V64, P332, DOI 10.1093/gerona/gln050; Verney J, 2008, MUSCLE NERVE, V38, P1147, DOI 10.1002/mus.21054; WHALEN RG, 1985, J EXP BIOL, V115, P43; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226	44	58	60	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4596	4605		10.1096/fj.13-229799	http://dx.doi.org/10.1096/fj.13-229799			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23928822	Green Published			2022-12-28	WOS:000329937500025
J	Beraldo, FH; Soares, IN; Goncalves, DF; Fan, J; Thomas, AA; Santos, TG; Mohammad, AH; Roffe, M; Calder, MD; Nikolova, S; Hajj, GN; Guimaraes, AL; Massensini, AR; Welch, I; Betts, DH; Gros, R; Drangova, M; Watson, AJ; Bartha, R; Prado, VF; Martins, VR; Prado, MAM				Beraldo, Flavio H.; Soares, Iaci N.; Goncalves, Daniela F.; Fan, Jue; Thomas, Anu A.; Santos, Tiago G.; Mohammad, Amro H.; Roffe, Martin; Calder, Michele D.; Nikolova, Simona; Hajj, Glaucia N.; Guimaraes, Andre L.; Massensini, Andre R.; Welch, Ian; Betts, Dean H.; Gros, Robert; Drangova, Maria; Watson, Andrew J.; Bartha, Robert; Prado, Vania F.; Martins, Vilma R.; Prado, Marco A. M.			Stress-inducible phosphoprotein 1 has unique cochaperone activity during development and regulates cellular response to ischemia via the prion protein	FASEB JOURNAL			English	Article						Hsp90; stroke; maternal-effect gene; Hsp70; prion protein	CEREBRAL-ARTERY OCCLUSION; DNA-DAMAGE; HEAT-SHOCK; MICE DEFICIENT; HSP90; CHAPERONE; STI1; CELLS; GENE; HEAT-SHOCK-PROTEIN-90	Stress-inducible phosphoprotein 1 (STI1) is part of the chaperone machinery, but it also functions as an extracellular ligand for the prion protein. However, the physiological relevance of these STI1 activities in vivo is unknown. Here, we show that in the absence of embryonic STI1, several Hsp90 client proteins are decreased by 50%, although Hsp90 levels are unaffected. Mutant STI1 mice showed increased caspase-3 activation and 50% impairment in cellular proliferation. Moreover, placental disruption and lack of cellular viability were linked to embryonic death by E10.5 in STI1-mutant mice. Rescue of embryonic lethality in these mutants, by transgenic expression of the STI1 gene, supported a unique role for STI1 during embryonic development. The response of STI1 haploinsufficient mice to cellular stress seemed compromised, and mutant mice showed increased vulnerability to ischemic insult. At the cellular level, ischemia increased the secretion of STI1 from wild-type astrocytes by 3-fold, whereas STI1 haploinsufficient mice secreted half as much STI1. Interesting, extracellular STI1 prevented ischemia-mediated neuronal death in a prion protein-dependent way. Our study reveals essential roles for intracellular and extracellular STI1 in cellular resilience.Beraldo, F. H., Soares, I. N., Goncalves, D. F., Fan, J., Thomas, A. A., Santos, T. G., Mohammad, A. H., Roffe, M., Calder, M. D., Nikolova, S., Hajj, G. N., Guimaraes, A. N., Massensini, A. R., Welch, I., Betts, D. H., Gros, R., Drangova, M., Watson, A. J., Bartha, R., Prado, V. F., Martins, V. R., and Prado, M. A. M. Stress-inducible phosphoprotein 1 has unique cochaperone activity during development and regulates cellular response to ischemia via the prion protein.	[Beraldo, Flavio H.; Soares, Iaci N.; Goncalves, Daniela F.; Fan, Jue; Thomas, Anu A.; Mohammad, Amro H.; Nikolova, Simona; Guimaraes, Andre L.; Gros, Robert; Drangova, Maria; Bartha, Robert; Prado, Vania F.; Prado, Marco A. M.] Univ Western Ontario, Robarts Res Inst, London, ON, Canada; [Beraldo, Flavio H.; Thomas, Anu A.; Calder, Michele D.; Betts, Dean H.; Gros, Robert; Watson, Andrew J.; Prado, Vania F.; Prado, Marco A. M.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Soares, Iaci N.; Mohammad, Amro H.; Prado, Vania F.; Prado, Marco A. M.] Univ Western Ontario, Dept Anat & Cell Biol, London, ON, Canada; [Calder, Michele D.; Watson, Andrew J.] Univ Western Ontario, Dept Obstet & Gynaecol, London, ON, Canada; [Welch, Ian] Univ Western Ontario, Anim Care Serv, London, ON, Canada; [Welch, Ian] Univ Western Ontario, Veterinarian Serv, London, ON, Canada; [Drangova, Maria; Bartha, Robert] Univ Western Ontario, Dept Med Biophys, London, ON, Canada; [Soares, Iaci N.] Univ Fed Minas Gerais, Program Mol Med, Belo Horizonte, MG, Brazil; [Goncalves, Daniela F.; Massensini, Andre R.] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil; [Santos, Tiago G.; Roffe, Martin; Hajj, Glaucia N.; Martins, Vilma R.] AC Camargo Canc Ctr, Int Res Ctr, Dept Mol & Cell Biol, Sao Paulo, Brazil; [Santos, Tiago G.; Roffe, Martin; Hajj, Glaucia N.; Martins, Vilma R.] Natl Inst Translat Neurosci, Sao Paulo, Brazil; [Calder, Michele D.; Betts, Dean H.; Watson, Andrew J.] Lawson Hlth Res Inst, Childrens Hlth Res Inst, London, ON, Canada; [Guimaraes, Andre L.] Univ Montes Claros, Montes Claros, MG, Brazil	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; A.C.Camargo Cancer Center; Western University (University of Western Ontario)	Prado, MAM (corresponding author), John P Robarts Res Inst, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.	vmartins@cipe.accamargo.org.br; mprado@robarts.ca	Prado, Marco Antonio Maximo/K-7638-2013; Roffe, Martin/S-1124-2019; Santos, Tiago/F-2387-2012; Hajj, Glaucia N M/I-8176-2015; Betts, Dean H/B-7414-2015; Gros, Robert/A-3010-2009; Martins, Vilma R/E-2547-2012; dos Santos, Tiago Goss/A-1538-2019; Gros, Robert/AAV-2237-2020; Massensini, Andre/C-7697-2015; Guimarães, André Luiz Sena/D-8122-2011; Roffé, Martín/I-1864-2013; Watson, Andrew J/A-5636-2015; Prado, Vania Ferreira/K-7630-2013; Martins, Vilma/N-5446-2019; Santos, Tiago Goss/AAQ-4272-2020; Bartha, Robert/K-3611-2013; Drangova, Maria/J-3123-2012	Prado, Marco Antonio Maximo/0000-0002-3028-5778; Roffe, Martin/0000-0001-7247-3067; Santos, Tiago/0000-0001-6641-7413; Hajj, Glaucia N M/0000-0003-2342-7384; Betts, Dean H/0000-0002-5528-9142; Gros, Robert/0000-0002-3667-8011; Martins, Vilma R/0000-0002-2909-8502; dos Santos, Tiago Goss/0000-0001-6641-7413; Gros, Robert/0000-0002-3667-8011; Massensini, Andre/0000-0002-1508-3801; Guimarães, André Luiz Sena/0000-0002-3162-3206; Roffé, Martín/0000-0001-7247-3067; Watson, Andrew J/0000-0002-2344-3061; Prado, Vania Ferreira/0000-0003-4994-6393; Santos, Tiago Goss/0000-0001-6641-7413; Bartha, Robert/0000-0002-7118-9096; Drangova, Maria/0000-0003-1856-9038; Mohammad, Amro/0000-0001-7230-9195	Canadian Institute of Health Research [MOP 93651, MOP 126000]; PrioNet-Canada; Canadian Foundation for Innovation; Ontario Research Fund; Alzheimer's Association; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo, Brazil); Department of Foreign Affairs and International Trade (Canada); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brazil); Ontario Graduate Scholarship Program; FAPESP; CNPq; Heart and Stroke Foundation of Canada	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); PrioNet-Canada; Canadian Foundation for Innovation(Canada Foundation for Innovation); Ontario Research Fund; Alzheimer's Association(Alzheimer's Association); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo, Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Department of Foreign Affairs and International Trade (Canada); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Ontario Graduate Scholarship Program(Ontario Graduate Scholarship); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	The authors thank Joy Dunmore-Buyze for micro-CT sample preparation and image acquisition and Sanda Raulic and Weiyan Wen for help with mouse colonies. The authors also thank Dr. Gerald Kidder (University of Western Ontario) for help with data analysis and interpretation. This work was supported by grants from the Canadian Institute of Health Research (MOP 93651 and MOP 126000, M.A.M.P., R.B., and V.F.P), PrioNet-Canada (M. A. M. P., R. B. and V. F. P.), Canadian Foundation for Innovation (M. A. M. P., V. F. P., and R. G.), Ontario Research Fund (M. A. M. P., V. F. P., and R. G.), the Alzheimer's Association (M. A. M. P., V. R. M., and V. F. P.), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil; V. R. M.), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo, Brazil; V. R. M.). F.H.B. and I.N.S. received fellowships from the Department of Foreign Affairs and International Trade (Canada). I.N.S. and D. F. G. received a fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brazil). A. H. M. received a fellowship from the Ontario Graduate Scholarship Program; T. G. S. and M. R. received a fellowship from FAPESP; A.L.G. received a fellowship from CNPq. R.G. and M. D. are supported by awards from the Heart and Stroke Foundation of Canada.	Arantes C, 2009, GLIA, V57, P1439, DOI 10.1002/glia.20861; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Badea CT, 2008, PHYS MED BIOL, V53, pR319, DOI 10.1088/0031-9155/53/19/R01; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Beraldo FH, 2010, J BIOL CHEM, V285, P36542, DOI 10.1074/jbc.M110.157263; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Caetano FA, 2008, J NEUROSCI, V28, P6691, DOI 10.1523/JNEUROSCI.1701-08.2008; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Daniel S, 2008, BBA-MOL CELL RES, V1783, P1003, DOI 10.1016/j.bbamcr.2008.01.014; De Maio A, 2011, CELL STRESS CHAPERON, V16, P235, DOI 10.1007/s12192-010-0236-4; Degenhardt K, 2010, CIRC-CARDIOVASC IMAG, V3, P314, DOI 10.1161/CIRCIMAGING.109.918482; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Erlich RB, 2007, GLIA, V55, P1690, DOI 10.1002/glia.20579; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Gangaraju VK, 2011, NAT GENET, V43, P153, DOI 10.1038/ng.743; Grad I, 2006, MOL CELL BIOL, V26, P8976, DOI 10.1128/MCB.00734-06; Guillot-Sestier MV, 2009, J BIOL CHEM, V284, P35973, DOI 10.1074/jbc.M109.051086; Guzman MS, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001194; Ha K, 2011, MOL CANCER THER, V10, P1194, DOI 10.1158/1535-7163.MCT-11-0094; Hajj G. N., 2013, CELL MOL LIFE SCI, DOI 10.1007/s00018-013-1328-y; Imai T, 2011, P NATL ACAD SCI USA, V108, P16363, DOI 10.1073/pnas.1108372108; Lee CT, 2012, EMBO J, V31, P1518, DOI 10.1038/emboj.2012.37; Lima FRS, 2007, J NEUROCHEM, V103, P2164, DOI 10.1111/j.1471-4159.2007.04904.x; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Luo JS, 2003, J BIOL CHEM, V278, P50908, DOI 10.1074/jbc.M307637200; Martins-Silva C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017611; Matkovich SJ, 2006, CIRC RES, V99, P996, DOI 10.1161/01.RES.0000247932.71270.2c; McLennan NF, 2004, AM J PATHOL, V165, P227, DOI 10.1016/S0002-9440(10)63291-9; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Mitsios N, 2007, J NEUROSCI RES, V85, P602, DOI 10.1002/jnr.21142; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Oda T, 2007, BLOOD, V109, P5016, DOI 10.1182/blood-2006-08-038638; Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pimienta G, 2011, MOL PHARMACEUT, V8, P2252, DOI 10.1021/mp200346y; Prado VF, 2006, NEURON, V51, P601, DOI 10.1016/j.neuron.2006.08.005; Quanz M, 2012, J BIOL CHEM, V287, P8803, DOI 10.1074/jbc.M111.320887; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Santos TG, 2013, J NEUROCHEM, V124, P210, DOI 10.1111/jnc.12091; Santos TG, 2011, STEM CELLS, V29, P1126, DOI 10.1002/stem.664; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schmid AB, 2012, EMBO J, V31, P1506, DOI 10.1038/emboj.2011.472; Shah M, 2002, J BIOL CHEM, V277, P45662, DOI 10.1074/jbc.M205935200; Sharma K, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014654; Shyu WC, 2005, J NEUROSCI, V25, P8967, DOI 10.1523/JNEUROSCI.1115-05.2005; Song HO, 2009, J MOL BIOL, V390, P604, DOI 10.1016/j.jmb.2009.05.035; Southworth DR, 2011, MOL CELL, V42, P771, DOI 10.1016/j.molcel.2011.04.023; Specchia V, 2010, NATURE, V463, P662, DOI 10.1038/nature08739; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tsai CL, 2012, CELL REP, V2, P283, DOI 10.1016/j.celrep.2012.07.002; Voss AK, 2000, DEVELOPMENT, V127, P1; Wang TH, 2010, MOL CELL PROTEOMICS, V9, P1873, DOI 10.1074/mcp.M110.000802; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024; Zhao RM, 2007, ADV EXP MED BIOL, V594, P27	62	60	60	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3594	3607		10.1096/fj.13-232280	http://dx.doi.org/10.1096/fj.13-232280			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729591				2022-12-28	WOS:000328840500019
J	Gonzalez-Montalban, N; Lee, YJ; Makarava, N; Savtchenko, R; Baskakov, IV				Gonzalez-Montalban, Nuria; Lee, Young Jin; Makarava, Natallia; Savtchenko, Regina; Baskakov, Ilia V.			Changes in prion replication environment cause prion strain mutation	FASEB JOURNAL			English	Article						protein misfolding cyclic amplification; neurodegenerative diseases; protein misfolding; amyloid; conformational stability; proteinase K digestion	SCRAPIE AGENT; MOUSE SCRAPIE; PROTEIN; TRANSMISSION; SELECTION; CONFORMATION; COFACTOR; HAMSTERS	Interspecies prion transmission often leads to stable changes in physical and biological features of prion strains, a phenomenon referred to as a strain mutation. It remains unknown whether changes in the replication environment in the absence of changes in PrP primary structure can be a source of strain mutations. To approach this question, RNA content was altered in the course of amplification of hamster strains in serial protein misfolding cyclic amplification (sPMCAb). On adaptation to an RNA-depleted environment and then readaptation to an environment containing RNA, strain 263K gave rise to a novel PrPSc conformation referred to as 263K(R+), which is characterized by very low conformational stability, high sensitivity to proteolytic digestion, and a replication rate of 10(6)-fold/PMCAb round, which exceeded that of 263K by almost 10(4)-fold. A series of PMCAb experiments revealed that 263K(R+) was lacking in brain-derived 263K material, but emerged de novo as a result of changes in RNA content. A similar transformation was also observed for strain Hyper, suggesting that this phenomenon was not limited to 263K. The current work demonstrates that dramatic PrPSc transformations can be induced by changes in the prion replication environment and without changes in PrP primary structure.Gonzalez-Montalban, N., Jin Lee, Y., Makarava, N., Savtchenko, R., Baskakov, I. V. Changes in prion replication environment cause prion strain mutation.	[Gonzalez-Montalban, Nuria; Lee, Young Jin; Makarava, Natallia; Savtchenko, Regina; Baskakov, Ilia V.] Univ Maryland, Sch Med, Ctr Biomed Engn & Technol, Baltimore, MD 21201 USA; [Gonzalez-Montalban, Nuria; Lee, Young Jin; Makarava, Natallia; Savtchenko, Regina; Baskakov, Ilia V.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Baskakov, IV (corresponding author), Univ Maryland, Sch Med, 725 W Lombard St, Baltimore, MD 21201 USA.	baskakov@umaryland.edu	Lee, Young Jin/K-9635-2019; Lee, Young Jin/AAF-6189-2019	Lee, Young Jin/0000-0002-2325-5271; 	U.S. National Institutes of Health [NS045585, NS074998]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045585, R56NS074998, R01NS074998] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Robert Rohwer for assistance in conducting bioassays and Pamela Wright for editing the manuscript. This work was supported by U.S. National Institutes of Health grants NS045585 and NS074998 to I.V.B.	Angers RC, 2010, SCIENCE, V328, P1154, DOI 10.1126/science.1187107; Ayers JI, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001317; Bartz JC, 2000, J VIROL, V74, P5542, DOI 10.1128/JVI.74.12.5542-5547.2000; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; Colby DW, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000736; Colby DW, 2009, P NATL ACAD SCI USA, V106, P20417, DOI 10.1073/pnas.0910350106; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; Cosseddu GM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002370; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; Deleault NR, 2012, P NATL ACAD SCI USA, V109, pE1938, DOI 10.1073/pnas.1206999109; Deleault NR, 2012, P NATL ACAD SCI USA, V109, P8546, DOI 10.1073/pnas.1204498109; Deleault NR, 2010, BIOCHEMISTRY-US, V49, P3928, DOI 10.1021/bi100370b; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Ghaemmaghami S, 2013, AM J PATHOL, V182, P866, DOI 10.1016/j.ajpath.2012.11.038; Ghaemmaghami S, 2011, J MOL BIOL, V413, P527, DOI 10.1016/j.jmb.2011.07.021; Ghaemmaghami S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000673; Giles K, 2010, ANN NEUROL, V68, P151, DOI 10.1002/ana.22104; Gonzalez-Montalban N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041210; Gonzalez-Montalban N, 2011, BIOCHEMISTRY-US, V50, P7933, DOI 10.1021/bi200950v; Gonzalez-Montalban N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001277; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; Klingeborn M, 2011, P NATL ACAD SCI USA, V108, pE1244, DOI 10.1073/pnas.1111255108; Legname G, 2005, P NATL ACAD SCI USA, V102, P2168, DOI 10.1073/pnas.0409079102; Legname G, 2006, P NATL ACAD SCI USA, V103, P19105, DOI 10.1073/pnas.0608970103; Li JL, 2010, SCIENCE, V327, P869, DOI 10.1126/science.1183218; Makarava N, 2011, PLOS PATHOG, V7; Makarava N, 2013, J BIOL CHEM, V288, P33, DOI 10.1074/jbc.M112.419531; Makarava N, 2012, J BIOL CHEM, V287, P30205, DOI 10.1074/jbc.M112.392985; Makarava N, 2012, PRION, V6, P252, DOI 10.4161/pri.19930; Makarava N, 2012, J NEUROSCI, V32, P7345, DOI 10.1523/JNEUROSCI.6351-11.2012; Makarava N, 2010, ACTA NEUROPATHOL, V119, P177, DOI 10.1007/s00401-009-0633-x; Makarava N, 2009, J BIOL CHEM, V284, P14386, DOI 10.1074/jbc.M900533200; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Piro JR, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002001; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Saa P, 2012, J VIROL, V86, P10494, DOI 10.1128/JVI.01286-12; Safar JG, 2005, J VIROL, V79, P10796, DOI 10.1128/JVI.79.16.10796-10806.2005; Sajnani G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002547; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748	43	32	33	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3702	3710		10.1096/fj.13-230466	http://dx.doi.org/10.1096/fj.13-230466			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23729586	Green Published			2022-12-28	WOS:000328840500028
J	Konrad, FM; Neudeck, G; Vollmer, I; Ngamsri, KC; Thiel, M; Reutershan, J				Konrad, Franziska M.; Neudeck, Gianna; Vollmer, Irene; Ngamsri, Kristian C.; Thiel, Manfred; Reutershan, Joerg			Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A(2A) dependent	FASEB JOURNAL			English	Article						neutrophils; migration; oxidative burst; phosphodiesterase inhibitor; PTX	ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; NECROSIS-FACTOR-ALPHA; PHOSPHODIESTERASE INHIBITION; NEUTROPHIL ACTIVATION; DOUBLE-BLIND; SEQUESTRATION; PERMEABILITY; LISOFYLLINE; MIGRATION	Pentoxifylline (PTX) has been shown to exert anti-inflammatory effects in experimental acute lung injury. However, results in humans were controversial. Recent in vitro studies suggested that the adenosine receptor A(2A) may be required for PTX to be effective. Therefore, we studied the association between A(2A) and PTX in a murine model of LPS-induced pulmonary inflammation. PTX treatment (10 mg/kg) reduced cellular influx (by 40%), microvascular permeability (30%), and the release of chemotactic cytokines into the alveolar space (TNF- 60%, IL-6 60%, and CXCL2/3 53%, respectively). These protective effects were abolished completely in A(2A)(-/-) mice and in wild-type mice that had been treated with the selective A(2A) antagonist (1 mg/kg), but effects were not different in mice with altered adenosine levels. In vitro transmigration assays revealed a pivotal role of the endothelium in PTX-mediated PMN migration, with a reduction of 50% (2 mM PTX). This effect was also A(2A) dependent. Further, oxidative burst of human PMNs was A(2A)-dependently reduced by 53% after PTX treatment. In summary, PTX exhibits its anti-inflammatory effects in LPS-induced lung injury through an A(2A)-dependent pathway. These results will help to better understand previous conflicting data on PTX in inflammation and will direct further studies to consider the predominant role of A(2A).Konrad, F. M., Neudeck, G., Vollmer, I., Ngamsri, K. C., Thiel, M., Reutershan, J. Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A(2A) dependent.	[Konrad, Franziska M.; Neudeck, Gianna; Vollmer, Irene; Ngamsri, Kristian C.; Reutershan, Joerg] Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Tubingen, Germany; [Thiel, Manfred] Univ Med Ctr, Dept Anesthesiol, Mannheim, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ruprecht Karls University Heidelberg	Reutershan, J (corresponding author), Univ Tubingen, Dept Anesthesiol & Intens Care Med, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	joerg.reutershan@uni-tuebingen.de			German Research Foundation [RE 1683/3-1]	German Research Foundation(German Research Foundation (DFG))	This work was supported by German Research Foundation grant RE 1683/3-1 (to J.R.).	Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bursten SL, 1996, CRIT CARE MED, V24, P1129, DOI 10.1097/00003246-199607000-00011; Bursten SL, 1998, J PHARMACOL EXP THER, V284, P337; Cepkova Magda, 2006, J Intensive Care Med, V21, P119, DOI 10.1177/0885066606287045; Coimbra R, 2006, J TRAUMA, V60, P115, DOI 10.1097/01.ta.0000200075.12489.74; Coimbra R, 2004, J TRAUMA, V57, P1157, DOI 10.1097/01.TA.0000151261.28640.F7; Costantini TW, 2010, IMMUNOPHARM IMMUNOT, V32, P82, DOI 10.3109/08923970903183557; de Campos T, 2008, PANCREAS, V37, P42, DOI 10.1097/MPA.0b013e3181612d19; de Oliveira IS, 2008, CLINICS, V63, P77, DOI 10.1590/S1807-59322008000100014; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Ege T, 2004, THORAC CARDIOV SURG, V52, P10, DOI 10.1055/s-2004-815798; El-Lakkany N, 2011, EXP PARASITOL, V129, P152, DOI 10.1016/j.exppara.2011.06.015; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; George CLS, 1999, AM J PHYSIOL-LUNG C, V276, pL776, DOI 10.1152/ajplung.1999.276.5.L776; Grenz A, 2008, PLOS MED, V5, P968, DOI 10.1371/journal.pmed.0050137; Haddad JJ, 2002, J PHARMACOL EXP THER, V300, P559, DOI 10.1124/jpet.300.2.559; HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962; Konrad FM, 2012, AM J PHYSIOL-LUNG C, V303, pL425, DOI 10.1152/ajplung.00387.2011; Korhonen K, 2004, PEDIATR RES, V56, P901, DOI 10.1203/01.PDR.0000145256.19073.E4; Kreth S, 2010, SHOCK, V34, P10, DOI 10.1097/SHK.0b013e3181cdc3e2; KUDOH I, 1995, ANESTHESIOLOGY, V82, P531, DOI 10.1097/00000542-199502000-00023; Kudoh I, 2001, CRIT CARE MED, V29, P1621, DOI 10.1097/00003246-200108000-00020; Lall RN, 2006, J AM COLL SURGEONS, V202, P10, DOI 10.1016/j.jamcollsurg.2005.07.018; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158; Mazar J, 2005, ANESTHESIOLOGY, V102, P1174, DOI 10.1097/00000542-200506000-00017; Michetti C, 2003, J SURG RES, V115, P92, DOI 10.1016/S0022-4804(03)00219-1; Miyazaki H, 1999, ANESTHESIOLOGY, V90, P1650, DOI 10.1097/00000542-199906000-00022; MORIUCHI H, 1995, CRIT CARE MED, V23, P357, DOI 10.1097/00003246-199502000-00023; Ngamsri KC, 2010, J IMMUNOL, V185, P4374, DOI 10.4049/jimmunol.1000433; Olson TS, 2002, AM J PHYSIOL-REG I, V282, pR1245, DOI 10.1152/ajpregu.00540.2001; PORTER JM, 1982, AM HEART J, V104, P66, DOI 10.1016/0002-8703(82)90642-1; Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC; Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004; Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Reutershan J, 2007, AM J RESP CRIT CARE, V175, P1027, DOI 10.1164/rccm.200612-1822OC; Reyes G, 2011, MOL MEMBR BIOL, V28, P412, DOI 10.3109/09687688.2011.604861; Rhee CK, 2009, CRIT CARE, V13, DOI 10.1186/cc8149; RICE GC, 1994, P NATL ACAD SCI USA, V91, P3857, DOI 10.1073/pnas.91.9.3857; Schick MA, 2012, J PHYSIOL-LONDON, V590, P2693, DOI 10.1113/jphysiol.2012.232116; Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5; Schulte G, 2004, ACTA PHYSIOL SCAND, V182, P133, DOI 10.1111/j.1365-201X.2004.01350.x; Spindler V, 2011, AM J PATHOL, V178, P2424, DOI 10.1016/j.ajpath.2011.01.014; STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364; Wagner R, 2010, AM J PHYSIOL-LUNG C, V299, pL502, DOI 10.1152/ajplung.00083.2010; Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WELSH CH, 1988, AM REV RESPIR DIS, V138, P1106, DOI 10.1164/ajrccm/138.5.1106; Wiedemann HP, 2002, CRIT CARE MED, V30, P1; Zeni F, 1996, CRIT CARE MED, V24, P207, DOI 10.1097/00003246-199602000-00005; Zhang J-Y, 2011, PLOS ONE, V6	53	28	28	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3524	3535		10.1096/fj.13-228122	http://dx.doi.org/10.1096/fj.13-228122			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23699177				2022-12-28	WOS:000328840500013
J	Burk, RF; Olson, GE; Hill, KE; Winfrey, VP; Motley, AK; Kurokawa, S				Burk, Raymond F.; Olson, Gary E.; Hill, Kristina E.; Winfrey, Virginia P.; Motley, Amy K.; Kurokawa, Suguru			Maternal-fetal transfer of selenium in the mouse	FASEB JOURNAL			English	Article						selenoprotein P; apolipoprotein E receptor-2; glutathione peroxidase-3; visceral yolk sac; placenta	APOLIPOPROTEIN-E RECEPTOR-2; SELENOPROTEIN P SEPP1; NEUROLOGICAL DYSFUNCTION; BASEMENT-MEMBRANES; DELETION; KIDNEY; MICE; MAINTENANCE; ENDOCYTOSIS; MEGALIN	Selenoprotein P (Sepp1) is taken up by receptor-mediated endocytosis for its selenium. The other extracellular selenoprotein, glutathione peroxidase-3 (Gpx3), has not been shown to transport selenium. Mice with genetic alterations of Sepp1, the Sepp1 receptors apolipoprotein E receptor-2 (apoER2) and megalin, and Gpx3 were used to investigate maternal-fetal selenium transfer. Immunocytochemistry (ICC) showed receptor-independent uptake of Sepp1 and Gpx3 in the same vesicles of d-13 visceral yolk sac cells, suggesting uptake by pinocytosis. ICC also showed apoER2-mediated uptake of maternal Sepp1 in the d-18 placenta. Thus, two selenoprotein-dependent maternal-fetal selenium transfer mechanisms were identified. Selenium was quantified in d-18 fetuses with the mechanisms disrupted. Maternal Sepp1 deletion, which lowers maternal whole-body selenium, decreased fetal selenium under selenium-adequate conditions but deletion of fetal apoER2 did not. Fetal apoER2 deletion did decrease fetal selenium, by 51%, under selenium-deficient conditions, verifying function of the placental Sepp1-apoER2 mechanism. Maternal Gpx3 deletion decreased fetal selenium, by 13%, but only under selenium-deficient conditions. These findings indicate that the selenoprotein uptake mechanisms ensure selenium transfer to the fetus under selenium-deficient conditions. The failure of their disruptions (apoER2 deletion, Gpx3 deletion) to affect fetal selenium under selenium-adequate conditions indicates the existence of an additional maternal-fetal selenium transfer mechanism.Burk, R. F., Olson, G. E., Hill, K. E., Winfrey, V. P., Motley, A. K., and Kurokawa, S. Maternal-fetal transfer of selenium in the mouse.	[Burk, Raymond F.; Hill, Kristina E.; Winfrey, Virginia P.; Motley, Amy K.; Kurokawa, Suguru] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA; [Olson, Gary E.; Winfrey, Virginia P.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University	Burk, RF (corresponding author), Vanderbilt Univ Sch Med, 1030C Med Res Bldg 4, Nashville, TN 37232 USA.	raymond.burk@vanderbilt.edu			U.S. National Institutes of Health [R37 ES02497, R01 DK82813, P30 ES00267, P30 DK58404]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082813, P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002497, P30ES000267] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors are grateful to Lori M. Austin, Teri D. Stevenson, Kristin V. Bradshaw (deceased), and Michelle L. Chatterton for animal husbandry. Dr. Takeshi Naruse (Kaketsuken, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan) kindly provided the hybridoma that produced 9S4, the monoclonal antibody to Sepp1. Dr. Daniel Biemesderfer (Yale University, New Haven, CT, USA) provided the antibody to megalin, and Dr. Joachim Herz (University of Texas Southwestern Medical School, Dallas, TX, USA) provided the antibody to apoER2 and the megalin<SUP>+/-</SUP> mouse strain. These studies were supported by U.S. National Institutes of Health grants R37 ES02497, R01 DK82813, P30 ES00267, and P30 DK58404. The authors declare no conflicts of interest.	Anan Y, 2009, LIFE SCI, V84, P888, DOI 10.1016/j.lfs.2009.03.023; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Burk RF, 2007, J NEUROSCI, V27, P6207, DOI 10.1523/JNEUROSCI.1153-07.2007; Burk RF, 2006, BBA-GEN SUBJECTS, V1760, P1789, DOI 10.1016/j.bbagen.2006.08.010; Burk RF, 2011, AM J PHYSIOL-GASTR L, V301, pG32, DOI 10.1152/ajpgi.00064.2011; Burk RF, 2009, BBA-GEN SUBJECTS, V1790, P1441, DOI 10.1016/j.bbagen.2009.03.026; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; Hill KE, 2007, J BIOL CHEM, V282, P10972, DOI 10.1074/jbc.M700436200; Hill KE, 2012, J BIOL CHEM, V287, P40414, DOI 10.1074/jbc.M112.421404; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kurokawa S, 2012, J BIOL CHEM, V287, P28717, DOI 10.1074/jbc.M112.383521; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Ma SG, 2002, J BIOL CHEM, V277, P12749, DOI 10.1074/jbc.M111462200; Miyauchi S, 2006, PLACENTA, V27, P550, DOI 10.1016/j.placenta.2005.05.004; Olson GE, 2008, J BIOL CHEM, V283, P6854, DOI 10.1074/jbc.M709945200; Olson GE, 2007, J BIOL CHEM, V282, P12290, DOI 10.1074/jbc.M611403200; Olson GE, 2010, AM J PHYSIOL-RENAL, V298, pF1244, DOI 10.1152/ajprenal.00662.2009; SAHALI D, 1992, AM J PATHOL, V140, P33; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Trotter JH, 2011, J NEUROSCI, V31, P14413, DOI 10.1523/JNEUROSCI.3135-11.2011; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Zou ZY, 2004, J BIOL CHEM, V279, P34302, DOI 10.1074/jbc.M405608200	24	56	56	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3249	3256		10.1096/fj.13-231852	http://dx.doi.org/10.1096/fj.13-231852			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23651543	Green Published			2022-12-28	WOS:000329877600030
J	Haselkorn, R				Haselkorn, Robert			Hard to Swallow: Do Foods Containing "Genetically Modified Organisms" (GMOs) Need Warning Labels?	FASEB JOURNAL			English	Editorial Material									Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Haselkorn, R (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 East 58th St, Chicago, IL 60637 USA.	rh01@uchicago.edu						Committee on Scientific Evaluation of the Introduction of Genetically Modified Microorganisms and Plants into the Environment National Research Council, 1989, FIELD TEST GEN MOD O; Strom S, 2013, NY TIMES; Zhang ZC, 2011, P NATL ACAD SCI USA, V108, P18737, DOI 10.1073/pnas.1110552108	3	0	0	0	41	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2531	2532		10.1096/fj.13-0701ufm	http://dx.doi.org/10.1096/fj.13-0701ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23824204				2022-12-28	WOS:000328841000001
J	Pavlov, TS; Ilatovskaya, DV; Levchenko, V; Li, LJ; Ecelbarger, CM; Staruschenko, A				Pavlov, Tengis S.; Ilatovskaya, Daria V.; Levchenko, Vladislav; Li, Lijun; Ecelbarger, Carolyn M.; Staruschenko, Alexander			Regulation of ENaC in mice lacking renal insulin receptors in the collecting duct	FASEB JOURNAL			English	Article						kidney; aldosterone-sensitive distal nephron; mTOR	EPITHELIAL SODIUM-CHANNEL; BLOOD-PRESSURE; NA+ CHANNEL; CELL-LINE; A6 CELLS; PHOSPHOINOSITIDE 3-KINASE; HORMONAL-REGULATION; TRANSPORT; ALDOSTERONE; KIDNEY	The epithelial sodium channel (ENaC) is one of the central effectors involved in regulation of salt and water homeostasis in the kidney. To study mechanisms of ENaC regulation, we generated knockout mice lacking the insulin receptor (InsR KO) specifically in the collecting duct principal cells. Single-channel analysis in freshly isolated split-open tubules demonstrated that the InsR-KO mice have significantly lower ENaC activity compared to their wild-type (C57BL/6J) littermates when animals were fed either normal or sodium-deficient diets. Immunohistochemical and Western blot assays demonstrated no significant changes in expression of ENaC subunits in InsR-KO mice compared to wild-type littermates. Insulin treatment caused greater ENaC activity in split-open tubules isolated from wild-type mice but did not have this effect in the InsR-KO mice. Thus, these results suggest that insulin increases ENaC activity via its own receptor affecting the channel open probability. To further determine the mechanism of the action of insulin on ENaC, we used mouse mpkCCD(c14) principal cells. Insulin significantly augmented amiloride-sensitive transepithelial flux in these cells. Pretreatment of the mpkCCD(c14) cells with phosphatidylinositol 3-kinase (LY294002; 10 M) or mTOR (PP242; 100 nM) inhibitors precluded this effect. This study provides new information about the importance of insulin receptors expressed in collecting duct principal cells for ENaC activity.Pavlov, T. S., Ilatovskaya, D. V., Levchenko, V., Li, L., Ecelbarger, C. M., Staruschenko, A. Regulation of ENaC in mice lacking renal insulin receptors in the collecting duct.	[Pavlov, Tengis S.; Ilatovskaya, Daria V.; Levchenko, Vladislav; Staruschenko, Alexander] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Li, Lijun; Ecelbarger, Carolyn M.] Georgetown Univ, Med Ctr, Dept Med, Div Endocrinol & Metab, Washington, DC 20007 USA	Medical College of Wisconsin; Georgetown University	Staruschenko, A (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ecelbarc@georgetown.edu; staruschenko@mcw.edu		Ilatovskaya, Daria/0000-0003-4832-4170; Staruschenko, Alexander/0000-0002-5190-8356	American Diabetes Association [1-10-BS-168]; American Heart Association [10POST4140109, 13SDG14220012]; U.S. National Institutes of Health [DK082507, HL108880]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082507] Funding Source: NIH RePORTER	American Diabetes Association(American Diabetes Association); American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Glen Slocum and Christine Duris (Medical College of Wisconsin) are recognized for excellent technical assistance with immunohistochemistry experiments. The authors also thank Dr. Oleg Palygin (Medical College of Wisconsin) for his invaluable help with electrophysiological experiments. This work was supported by American Diabetes Association grant 1-10-BS-168 (to A. S.), American Heart Association grants 10POST4140109 and 13SDG14220012 (to T. S. P.), and U.S. National Institutes of Health grants DK082507 (to C. M. E.) and HL108880 (to A.S.).	Baquero AF, 2011, AM J PHYSIOL-CELL PH, V300, pC860, DOI 10.1152/ajpcell.00318.2010; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Blazer-Yost BL, 2005, PFLUG ARCH EUR J PHY, V450, P75, DOI 10.1007/s00424-004-1371-5; Blazer-Yost BL, 2003, AM J PHYSIOL-CELL PH, V284, pC1645, DOI 10.1152/ajpcell.00372.2002; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Frindt G, 2012, AM J PHYSIOL-RENAL, V302, pF1227, DOI 10.1152/ajprenal.00675.2011; Ge YQ, 2006, AM J PHYSIOL-RENAL, V291, pF1274, DOI 10.1152/ajprenal.00190.2006; Gonzalez-Rodriguez E, 2007, KIDNEY INT, V71, P116, DOI 10.1038/sj.ki.5002018; Guan YF, 2005, NAT MED, V11, P861, DOI 10.1038/nm1278; Hills CE, 2006, CELL PHYSIOL BIOCHEM, V18, P337, DOI 10.1159/000097611; Holzman JL, 2007, AM J PHYSIOL-RENAL, V292, pF1219, DOI 10.1152/ajprenal.00214.2006; Ilatovskaya DV, 2013, AM J PHYSIOL-CELL PH, V304, pC102, DOI 10.1152/ajpcell.00231.2012; Ilatovskaya DV, 2011, FASEB J, V25, P2688, DOI 10.1096/fj.10-167262; ITO O, 1994, AM J PHYSIOL, V267, pF265, DOI 10.1152/ajprenal.1994.267.2.F265; KIRCHNER KA, 1988, AM J PHYSIOL, V255, pF1206, DOI 10.1152/ajprenal.1988.255.6.F1206; KOTCHEN TA, 1991, AM J PHYSIOL, V261, pE692, DOI 10.1152/ajpendo.1991.261.6.E692; Lastra G, 2010, NAT REV CARDIOL, V7, P577, DOI 10.1038/nrcardio.2010.123; Levchenko V, 2010, J CELL PHYSIOL, V223, P252, DOI 10.1002/jcp.22033; Li GL, 2005, ENDOCRINOLOGY, V146, P4690, DOI 10.1210/en.2005-0505; Li LJ, 2013, AM J PHYSIOL-RENAL, V304, pF279, DOI 10.1152/ajprenal.00161.2012; Li LJ, 2012, AM J PHYSIOL-REG I, V303, pR505, DOI 10.1152/ajpregu.00033.2012; Lu M, 2011, J BIOL CHEM, V286, P30647, DOI 10.1074/jbc.M111.257592; Lu M, 2010, J AM SOC NEPHROL, V21, P811, DOI 10.1681/ASN.2009111168; Mamenko M, 2012, J BIOL CHEM, V287, P660, DOI 10.1074/jbc.M111.298919; Manhiani MM, 2012, HYPERTENSION, V59, P421, DOI 10.1161/HYPERTENSIONAHA.111.185215; Mansley MK, 2010, BRIT J PHARMACOL, V161, P1778, DOI 10.1111/j.1476-5381.2010.01003.x; Mansley MK, 2010, BRIT J PHARMACOL, V161, P571, DOI 10.1111/j.1476-5381.2010.00898.x; MARUNAKA Y, 1992, AM J PHYSIOL, V263, pF392, DOI 10.1152/ajprenal.1992.263.3.F392; Pavlov TS, 2011, AM J PHYSIOL-RENAL, V301, pF672, DOI 10.1152/ajprenal.00597.2010; Pavlov TS, 2010, PPAR RES, V2010, DOI 10.1155/2010/703735; Pavlov TS, 2010, J AM SOC NEPHROL, V21, P833, DOI 10.1681/ASN.2009080885; Pochynyuk O, 2010, FASEB J, V24, P2056, DOI 10.1096/fj.09-151506; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; Record RD, 1996, AM J PHYSIOL-CELL PH, V271, pC1079, DOI 10.1152/ajpcell.1996.271.4.C1079; Shane MA, 2006, GEN COMP ENDOCR, V147, P85, DOI 10.1016/j.ygcen.2005.11.010; Song J, 2006, AM J PHYSIOL-RENAL, V290, pF1055, DOI 10.1152/ajprenal.00108.2005; Staruschenko A, 2007, J AM SOC NEPHROL, V18, P1652, DOI 10.1681/ASN.2007010020; Staruschenko A, 2012, COMPR PHYSIOL, V2, P1541, DOI 10.1002/cphy.c110052; Sun P, 2010, J AM SOC NEPHROL, V21, P1667, DOI 10.1681/ASN.2009111110; Tallini NY, 2002, AM J PHYSIOL-CELL PH, V283, pC1171, DOI 10.1152/ajpcell.00606.2001; Tiwari S, 2008, PHARMACOL RES, V57, P383, DOI 10.1016/j.phrs.2008.03.013; Tiwari S, 2008, P NATL ACAD SCI USA, V105, P6469, DOI 10.1073/pnas.0711283105; Tiwari S, 2007, AM J PHYSIOL-RENAL, V293, pF974, DOI 10.1152/ajprenal.00149.2007; Tiwari S, 2007, AM J PHYSIOL-RENAL, V293, pF178, DOI 10.1152/ajprenal.00447.2006; Vigneri R, 2010, ACTA DIABETOL, V47, P271, DOI 10.1007/s00592-010-0215-3; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Wang J, 2008, AM J PHYSIOL-RENAL, V295, pF843, DOI 10.1152/ajprenal.90348.2008; Zhang YH, 2005, AM J PHYSIOL-CELL PH, V288, pC141, DOI 10.1152/ajpcell.00343.2004	52	34	36	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2723	2732		10.1096/fj.12-223792	http://dx.doi.org/10.1096/fj.12-223792			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23558339	Green Published			2022-12-28	WOS:000328841000021
J	Stralberg, F; Henning, P; Gjertsson, I; Kindlund, B; Souza, PPC; Persson, E; Abrahamson, M; Kasprzykowski, F; Grubb, A; Lerner, UH				Stralberg, Fredrik; Henning, Petra; Gjertsson, Inger; Kindlund, Bert; Souza, Pedro P. C.; Persson, Emma; Abrahamson, Magnus; Kasprzykowski, Franciszek; Grubb, Anders; Lerner, Ulf H.			Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling	FASEB JOURNAL			English	Article						cystatin C; osteoclasts; Nfatc1; c-Fos	HUMAN CYSTATIN-C; NF-KAPPA-B; BONE-RESORPTION; RECEPTOR-ACTIVATOR; IDENTIFICATION; EXPRESSION; OSTEOIMMUNOLOGY; DIFFERENTIATION; PURIFICATION; PROGENITOR	The cysteine proteinase inhibitor cystatin C inhibited RANKL-stimulated osteoclast formation in mouse bone marrow macrophage cultures, an effect associated with decreased mRNA expression of Acp5, Calcr, Ctsk, Mmp9, Itgb3, and Atp6i, without effect on proliferation or apoptosis. The effects were concentration dependent with half-maximal inhibition at 0.3 M. Cystatin C also inhibited osteoclast formation when RANKL-stimulated osteoclasts were cultured on bone, leading to decreased formation of resorption pits. RANKL-stimulated cells retained characteristics of phagocytotic macrophages when cotreated with cystatin C. Three other cysteine proteinase inhibitors, cystatin D, Z-RLVG-CHN2 (IC50 0.1 M), and E-64 (IC50 3 M), also inhibited osteoclast formation in RANKL-stimulated macrophages. In addition, cystatin C, Z-RLVG-CHN2, and E-64 inhibited osteoclastic differentiation of RANKL-stimulated CD14(+) human monocytes. The effect by cystatin C on differentiation of bone marrow macrophages was exerted at an early stage after RANKL stimulation and was associated with early (4 h) inhibition of c-Fos expression and decreased protein and nuclear translocation of c-Fos. Subsequently, p52, p65, IB, and Nfatc1 mRNA were decreased. Cystatin C was internalized in osteoclast progenitors, a process requiring RANKL stimulation. These data show that cystatin C inhibits osteoclast differentiation and formation by interfering intracellularly with signaling pathways downstream RANK. Stralberg, F., Henning, P., Gjertsson, I., Kindlund, B-., Souza, P. P. C., Persson, E., Abrahamson, M., Kasprzykowski, F., Grubb, A., Lerner, U. H. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.	[Stralberg, Fredrik; Souza, Pedro P. C.; Persson, Emma; Lerner, Ulf H.] Umea Univ, Dept Mol Periodontol, SE-90187 Umea, Sweden; [Henning, Petra; Kindlund, Bert; Lerner, Ulf H.] Univ Gothenburg, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden; [Gjertsson, Inger] Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; [Abrahamson, Magnus; Grubb, Anders] Lund Univ, Dept Lab Med, Div Clin Chem & Pharmacol, Lund, Sweden; [Kasprzykowski, Franciszek] Univ Gdansk, Inst Chem, PL-80952 Gdansk, Poland	Umea University; University of Gothenburg; University of Gothenburg; Lund University; Fahrenheit Universities; University of Gdansk	Lerner, UH (corresponding author), Umea Univ, Dept Mol Periodontol, SE-90187 Umea, Sweden.	ulf.lerner@odont.umu.se	Souza, Pedro/GZH-1275-2022; Abrahamson, Magnus/CAG-9507-2022; Souza, Pedro Paulo Chaves/G-3801-2011	Souza, Pedro Paulo Chaves/0000-0001-7266-6061; Henning, Petra/0000-0002-9330-6265; Lerner, Ulf/0000-0002-3579-1960; Grubb, Anders/0000-0002-0125-3662	Swedish Research Council for Medicine [84138-32, 05196]; Swedish Rheumatism Association; Royal 80 Year Fund of King Gustav V; County Council of Vasterbotten; Medical Faculty of Umea University; Combine; Lundberg Foundation; ALF/LUA grants from the Sahlgrenska University Hospital; Amgen	Swedish Research Council for Medicine; Swedish Rheumatism Association; Royal 80 Year Fund of King Gustav V; County Council of Vasterbotten; Medical Faculty of Umea University; Combine; Lundberg Foundation(European Commission); ALF/LUA grants from the Sahlgrenska University Hospital; Amgen(Amgen)	Primer and probe sequences and plasmid standards for real-time PCR quantification of the titin gene were kindly provided by Dr. Anne Galy (Genethon, Evry, France). Plasmids pCMV Delta R8.74 and pMD.G2 were produced by the Plasmid Factory, GmBH&Co. KG (Bielefeld, Germany). This work was supported by the Swedish Research Council for Medicine (U. H. L., 84138-32; A. G., 05196), the Swedish Rheumatism Association, the Royal 80 Year Fund of King Gustav V, the County Council of Vasterbotten, the Medical Faculty of Umea University, Combine, the Lundberg Foundation, and ALF/LUA grants from the Sahlgrenska University Hospital. U. H. L. and A. G. initiated the project; F. S., P. H., and U. H. L. conceived and designed the experiments; F. S. performed most of the experiments and analyses; P. H. and I. G. made the lentivirus constructs; P. H. and B. K. performed the experiments with the human cells, the RANK overexpression experiments, the reporter gene assays and the translocation experiments; P. P. C. S. and E. P. assisted in the WB analyses; M. A., F. K., and A. G. synthesized the peptides and the recombinant proteins; F. S. and U. H. L. made the initial draft of the manuscript. Conflicts of interest: U. H. L. has received lecture fees from Amgen. A. G., F. K., and U. H. L. are founders of a biotechnology company. All other authors report no conflicts of interest.	ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Backlund A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3298; BALBIN M, 1994, J BIOL CHEM, V269, P23156; Bengtsson E, 2005, ATHEROSCLEROSIS, V180, P45, DOI 10.1016/j.athersclerosis.2004.12.025; BJORCK L, 1990, J VIROL, V64, P941; Blair HC, 2000, J CELL BIOCHEM, V78, P627, DOI 10.1002/1097-4644(20000915)78:4<627::AID-JCB12>3.0.CO;2-3; Bokarewa M, 2007, J RHEUMATOL, V34, P1293; Brage M, 2004, BONE, V34, P412, DOI 10.1016/j.bone.2003.11.018; Brage M, 2005, CALCIFIED TISSUE INT, V76, P439, DOI 10.1007/s00223-004-0043-y; Brillard-Bourdet M, 1998, BIOCHEM J, V331, P239, DOI 10.1042/bj3310239; Choi SJ, 1999, J BIOL CHEM, V274, P27747, DOI 10.1074/jbc.274.39.27747; Conaway HH, 2009, FASEB J, V23, P3526, DOI 10.1096/fj.09-132548; Cornwall GA, 2003, MOL CELL ENDOCRINOL, V200, P1, DOI 10.1016/S0303-7207(02)00408-2; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; Ekstrom U, 2008, FEBS J, V275, P4571, DOI 10.1111/j.1742-4658.2008.06600.x; Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859; Gjertsson I, 2009, MOL THER, V17, P632, DOI 10.1038/mt.2009.299; Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE-07-0338; Granholm S, 2013, BONE, V52, P83, DOI 10.1016/j.bone.2012.09.019; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Grubb AO, 2001, ADV CLIN CHEM, V35, P63, DOI 10.1016/S0065-2423(01)35015-1; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P523, DOI 10.1080/00021369.1978.10863014; Hiltke TR, 1999, J DENT RES, V78, P1401, DOI 10.1177/00220345990780080501; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Johansson L, 2000, BONE, V26, P451, DOI 10.1016/S8756-3282(00)00261-1; Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Lee FYI, 2005, J BIOL CHEM, V280, P29929, DOI 10.1074/jbc.M414600200; LERNER UH, 1992, J BONE MINER RES, V7, P433; Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007-0038; Olsson T, 2004, NEUROSCIENCE, V128, P65, DOI 10.1016/j.neuroscience.2004.06.024; Palmqvist P, 2006, J BIOL CHEM, V281, P2414, DOI 10.1074/jbc.M510160200; Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130; Rassam M, 2004, PHYTOCHEMISTRY, V65, P19, DOI 10.1016/j.phytochem.2003.09.019; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Schwab AM, 2005, ENDOCRINOLOGY, V146, P4349, DOI 10.1210/en.2005-0601; Sokol JP, 2004, MOL CANCER RES, V2, P183; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Wallin H, 2010, BIOCHIMIE, V92, P1625, DOI 10.1016/j.biochi.2010.08.011; Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007	48	24	29	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2687	2701		10.1096/fj.12-211748	http://dx.doi.org/10.1096/fj.12-211748			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23572233				2022-12-28	WOS:000328841000018
J	Wang, XH; Grace, PM; Pham, MN; Cheng, K; Strand, KA; Smith, C; Li, J; Watkins, LR; Yin, H				Wang, Xiaohui; Grace, Peter M.; Pham, Michael N.; Cheng, Kui; Strand, Keith A.; Smith, Christina; Li, Jing; Watkins, Linda R.; Yin, Hang			Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain	FASEB JOURNAL			English	Article						inflammation; innate immune; microglia; drug repositioning	PREGNANE-X RECEPTOR; INNATE IMMUNE-RESPONSES; NITRIC-OXIDE; BINDING; MD-2; SYSTEM; BRAIN; INFLAMMATION; PENETRATION; RECOGNITION	Rifampin has been used for the treatment of bacterial infections for many years. Clinically, rifampin has been found to possess immunomodulatory effects. However, the molecular target responsible for the immunosuppressive effects of rifampin is not known. Herein, we show that rifampin binds to myeloid differentiation protein 2 (MD-2), the key coreceptor for innate immune TLR4. Rifampin blocked TLR4 signaling induced by LPS, including NF-B activation and the overproduction of proinflammatory mediators nitric oxide, interleukin 1, and tumor necrosis factor in mouse microglia BV-2 cells and macrophage RAW 264.7 cells. Rifampin's inhibition of TLR4 signaling was also observed in immunocompetent rat primary macrophage, microglia, and astrocytes. Further, we show that rifampin (75 or 100 mg/kg b.i.d. for 3 d, intraperitoneal) suppressed allodynia induced by chronic constriction injury of the sciatic nerve and suppressed nerve injury-induced activation of microglia. Our findings indicate that MD-2 is a important target of rifampin in its inhibition of innate immune function and contributes to its clinically observed immune-suppressive effect. The results also suggest that rifampin may be repositioned as an agent for the treatment of neuropathic pain.Wang, X., Grace, P. M., Pham, M. N., Cheng, K., Strand, K. A., Smith, C., Li, J., Watkins, L. R., Yin, H. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain.	[Wang, Xiaohui; Pham, Michael N.; Cheng, Kui; Smith, Christina; Yin, Hang] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Wang, Xiaohui; Pham, Michael N.; Cheng, Kui; Smith, Christina; Yin, Hang] Univ Colorado, BioFrontiers Inst, Boulder, CO 80309 USA; [Wang, Xiaohui; Grace, Peter M.; Strand, Keith A.; Watkins, Linda R.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Wang, Xiaohui; Grace, Peter M.; Strand, Keith A.; Watkins, Linda R.] Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA; [Li, Jing] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol, Beijing 100730, Peoples R China	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Yin, H (corresponding author), 596 Univ Colorado Boulder, Boulder, CO 80309 USA.	hubert.yin@colorado.edu	Wang, Xiaohui/B-8126-2011; Smith, Christina/GXG-6941-2022; YIN, HANG/O-2097-2014; Grace, Peter/I-5507-2013	Wang, Xiaohui/0000-0002-3415-5612; YIN, HANG/0000-0002-9762-4818; Strand, Keith/0000-0001-8885-0162; Grace, Peter/0000-0002-8999-1220; Li, Jing/0000-0003-2504-1629; Boville (Smith), Christina/0000-0002-2577-9343	U.S. National Institutes of Health [GM101279, RR025780, DA029119, DA024044, DA023132]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM101279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA024044, R01DA023132] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by U.S. National Institutes of Health grants GM101279, RR025780, DA029119, DA024044, and DA023132. The authors thank Yingning Zhang, Thomas A. Cochran, and Wanyu Sun for the help with primary cell isolation and rat TNF-alpha ELISA.	Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Barochia A, 2011, EXPERT OPIN DRUG MET, V7, P479, DOI 10.1517/17425255.2011.558190; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bettoni I, 2008, GLIA, V56, P1312, DOI 10.1002/glia.20699; Bi W, 2011, BRAIN RES, V1395, P12, DOI 10.1016/j.brainres.2011.04.019; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Buchanan MM, 2010, J NEUROCHEM, V114, P13, DOI 10.1111/j.1471-4159.2010.06736.x; Calvo M, 2012, LANCET NEUROL, V11, P629, DOI 10.1016/S1474-4422(12)70134-5; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Cheng J, 2010, J PHARMACOL EXP THER, V335, P32, DOI 10.1124/jpet.110.170225; Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a; Dolgin E, 2011, NAT MED, V17, P1027, DOI 10.1038/nm0911-1027; EULE H, 1974, TUBERCLE, V55, P81, DOI 10.1016/0041-3879(74)90069-5; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; Grace PM, 2011, BRAIN BEHAV IMMUN, V25, P1322, DOI 10.1016/j.bbi.2011.04.003; Gradisar H, 2007, J LEUKOCYTE BIOL, V82, P968, DOI 10.1189/jlb.1206727; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Harrison C, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3076; Hutchinson MR, 2008, EUR J NEUROSCI, V28, P20, DOI 10.1111/j.1460-9568.2008.06321.x; Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135; Kim SK, 2009, KOREAN J PHYSIOL PHA, V13, P475, DOI 10.4196/kjpp.2009.13.6.475; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kodama S, 2011, J BIOL CHEM, V286, P3570, DOI 10.1074/jbc.M110.179812; Kuronuma K, 2009, J BIOL CHEM, V284, P25488, DOI 10.1074/jbc.M109.040832; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, P954, DOI DOI 10.1007/978-0-387-46312-4; Li TG, 2005, AM J PHYSIOL-GASTR L, V288, pG74, DOI 10.1152/ajpgi.00258.2004; Loeffler A M, 1999, Pediatr Infect Dis J, V18, P631, DOI 10.1097/00006454-199907000-00012; MARIJA MG, 1971, LANCET, V2, P930; Milligan ED, 2004, EUR J NEUROSCI, V20, P2294, DOI 10.1111/j.1460-9568.2004.03709.x; Milligan ED, 2001, J NEUROSCI, V21, P2808, DOI 10.1523/JNEUROSCI.21-08-02808.2001; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; MINDERMANN T, 1993, J ANTIMICROB CHEMOTH, V31, P731, DOI 10.1093/jac/31.5.731; Mindermann T, 1998, ANTIMICROB AGENTS CH, V42, P2626, DOI 10.1128/AAC.42.10.2626; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; NAU R, 1994, ANTIMICROB AGENTS CH, V38, P1186, DOI 10.1128/AAC.38.5.1186; Nau R, 2010, CLIN MICROBIOL REV, V23, P858, DOI 10.1128/CMR.00007-10; Nicotra L, 2012, EXP NEUROL, V234, P316, DOI 10.1016/j.expneurol.2011.09.038; NILSSON BS, 1971, LANCET, V2, P374; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Pahlevan AA, 2002, J ANTIMICROB CHEMOTH, V49, P531, DOI 10.1093/jac/49.3.531; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Park SH, 2012, BIOCHEM BIOPH RES CO, V419, P735, DOI 10.1016/j.bbrc.2012.02.091; Park SH, 2012, PHARMACOL THERAPEUT, V133, P291, DOI 10.1016/j.pharmthera.2011.11.001; Resman N, 2008, FEBS LETT, V582, P3929, DOI 10.1016/j.febslet.2008.10.037; Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Savas U, 2000, DRUG METAB DISPOS, V28, P529; Shichita T, 2012, J NEUROCHEM, V123, P29, DOI 10.1111/j.1471-4159.2012.07941.x; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tanga FY, 2005, P NATL ACAD SCI USA, V102, P5856, DOI 10.1073/pnas.0501634102; Treutwein B, 1999, PERCEPT PSYCHOPHYS, V61, P87, DOI 10.3758/BF03211951; TSAI MJ, 1973, P NATL ACAD SCI USA, V70, P2072, DOI 10.1073/pnas.70.7.2072; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Wang XH, 2012, P NATL ACAD SCI USA, V109, P6325, DOI 10.1073/pnas.1200130109; WEHRLI W, 1968, P NATL ACAD SCI USA, V61, P667, DOI 10.1073/pnas.61.2.667; Yan JE, 2012, NEUROSCI LETT, V526, P54, DOI 10.1016/j.neulet.2012.08.012; Yao AH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591298; Yuhas Y, 2006, ANTIMICROB AGENTS CH, V50, P396, DOI 10.1128/AAC.50.1.396-398.2006; Zhou C, 2006, J CLIN INVEST, V116, P2280, DOI 10.1172/JCI26283; Ziglam HM, 2004, J CHEMOTHERAPY, V16, P357, DOI 10.1179/joc.2004.16.4.357; Zimmer SM, 2008, J BIOL CHEM, V283, P27916, DOI 10.1074/jbc.M802826200	63	50	53	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2713	2722		10.1096/fj.12-222992	http://dx.doi.org/10.1096/fj.12-222992			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23568774	Green Published			2022-12-28	WOS:000328841000020
J	Gao, S; Lu, L; Bai, Y; Zhang, P; Song, WB; Duan, CM				Gao, Shan; Lu, Ling; Bai, Yan; Zhang, Peng; Song, Weibo; Duan, Cunming			Structural and functional analysis of amphioxus HIF alpha reveals ancient features of the HIF alpha family	FASEB JOURNAL			English	Article						transactivation domain; oxygen-dependent degradation; cephalochordate; nuclear localization signal	HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; FACTOR-I; GENE-EXPRESSION; MESENCHYMAL TRANSITION; NUCLEAR TRANSLOCATION; PROLYL HYDROXYLATION; DNA-BINDING; GROWTH; OXYGEN	Hypoxia-inducible factors (HIFs) are master regulators of the transcriptional response to hypoxia. To gain insight into the structural and functional evolution of the HIF family, we characterized the HIF alpha gene from amphioxus, an invertebrate chordate, and identified several alternatively spliced HIF alpha isoforms. Whereas HIF alpha Ia, the full-length isoform, contained a complete oxygen-dependent degradation (ODD) domain, the isoforms Ib, Ic, and Id had 1 or 2 deletions in the ODD domain. When tagged with GFP and tested in mammalian cells, the amphioxus HIF alpha Ia protein level increased in response to hypoxia or CoCl2 treatment, whereas HIF alpha Ib, Ic, and Id showed reduced or no hypoxia regulation. Deletion of the ODD sequence in HIF alpha Ia up-regulated the HIF alpha Ia levels under normoxia. Gene expression analysis revealed HIF alpha Ic to be the predominant isoform in embryos and larvae, whereas isoform Ia was the most abundant form in the adult stage. The expression levels of Ib and Id were very low. Hypoxia treatment of adults had no effect on the mRNA levels of these HIF alpha isoforms. Functional analyses in mammalian cells showed all 4 HIF alpha isoforms capable of entering the nucleus and activating hypoxia response element-dependent reporter gene expression. The functional nuclear location signal (NLS) mapped to 3 clusters of basic residues. (775)KKARL functioned as the primary NLS, but (KRK)-K-737 and (KK)-K-754 also contributed to the nuclear localization. All amphioxus HIF alpha isoforms had 2 functional transactivation domains (TADs). Its C-terminal transactivation (C-TAD) shared high sequence identity with the human HIF-1 alpha and HIF-2 alpha C-TAD. This domain contained a conserved asparagine, and its mutation resulted in an increase in transcriptional activity. These findings reveal many ancient features of the HIF alpha family and provide novel insights into the evolution of the HIF alpha family.-Gao, S., Lu, L., Bai, Y., Zhang, P., Song, W., Duan, C. Structural and functional analysis of amphioxus HIF alpha reveals ancient features of the HIF alpha family.	[Gao, Shan; Bai, Yan; Zhang, Peng; Duan, Cunming] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; [Gao, Shan; Song, Weibo] Ocean Univ China, Sch Med & Pharm, Minist Educ, Inst Evolut & Marine Biodivers, Qingdao, Peoples R China; [Lu, Ling] Ocean Univ China, Sch Med & Pharm, Minist Educ, Key Lab Marine Drugs, Qingdao, Peoples R China	University of Michigan System; University of Michigan; Ocean University of China; Ocean University of China	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu	Zhang, Peng/I-3757-2018		U.S. National Science Foundation [IOB-0543018, IOS-1051034]; Division Of Integrative Organismal Systems [1051034] Funding Source: National Science Foundation	U.S. National Science Foundation(National Science Foundation (NSF)); Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	The authors thank Dr. Xungang Tan (Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China) for providing animals for the gene expression analysis; Drs. Yinlong Qiu, Ya Yang, and Wenfeng Qian (University of Michigan) for advice on the phylogenetic analysis; Dr. Jie Huang (Ocean University of China) for help with the tree computation; Dr. Eric Huang, (U.S. National Cancer Institute) for providing the pANRT construct; and Mr. Nicholas Silva (University of Michigan) for proofreading the manuscript. This work was supported by U.S. National Science Foundation grants IOB-0543018 and IOS-1051034 to C.D.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Barriga EH, 2013, J CELL BIOL, V201, P759, DOI 10.1083/jcb.201212100; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Dehal P, 2005, PLOS BIOL, V3, P1700, DOI 10.1371/journal.pbio.0030314; Dunwoodie SL, 2009, DEV CELL, V17, P755, DOI 10.1016/j.devcel.2009.11.008; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldser D, 1999, CANCER RES, V59, P3915; Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Han WQ, 2013, BBA-MOL CELL RES, V1833, P1454, DOI 10.1016/j.bbamcr.2013.02.029; Heidbreder M, 2003, FASEB J, V17, P1541, DOI 10.1096/fj.02-0963fje; Holland LZ, 2008, GENOME RES, V18, P1380; Holland LZ, 2010, INTEGR COMP BIOL, V50, P17, DOI 10.1093/icb/icq039; Holland LZ, 2004, CELL MOL LIFE SCI, V61, P2290, DOI 10.1007/s00018-004-4075-2; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kajimura S, 2006, MOL CELL BIOL, V26, P1142, DOI 10.1128/MCB.26.3.1142-1155.2006; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamei H, 2011, DEVELOPMENT, V138, P777, DOI 10.1242/dev.056853; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Li QF, 2006, CELL RES, V16, P548, DOI 10.1038/sj.cr.7310072; Loenarz C, 2011, EMBO REP, V12, P63, DOI 10.1038/embor.2010.170; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Pasanen A, 2010, INT J BIOCHEM CELL B, V42, P1189, DOI 10.1016/j.biocel.2010.04.008; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Pocock R, 2008, NAT NEUROSCI, V11, P894, DOI 10.1038/nn.2152; Prabhakar NR, 2012, PHYSIOL REV, V92, P967, DOI 10.1152/physrev.00030.2011; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Putnam NH, 2008, NATURE, V453, P1064, DOI 10.1038/nature06967; Ren HX, 2010, P NATL ACAD SCI USA, V107, P5857, DOI 10.1073/pnas.0909570107; Romero NM, 2008, MOL CELL BIOL, V28, P3410, DOI 10.1128/MCB.01027-07; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shay JES, 2012, SEMIN CELL DEV BIOL, V23, P389, DOI 10.1016/j.semcdb.2012.04.004; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Williams M, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-64; Zhang P, 2012, AM J PHYSIOL-REG I, V303, pR1165, DOI 10.1152/ajpregu.00340.2012	50	11	12	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1880	1890		10.1096/fj.12-220152	http://dx.doi.org/10.1096/fj.12-220152			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24174425	Green Submitted, Green Published			2022-12-28	WOS:000335344300032
J	Esteva-Font, C; Jin, BJ; Verkman, AS				Esteva-Font, Cristina; Jin, Byung-Ju; Verkman, A. S.			Aquaporin-1 gene deletion reduces breast tumor growth and lung metastasis in tumor-producing MMTV-PyVT mice	FASEB JOURNAL			English	Article						AQP1; water channel; endothelia	WATER PERMEABILITY; CELL-MIGRATION; MOUSE MODEL; CANCER MODEL; INHIBITION; PROLIFERATION; ANGIOGENESIS; EXPRESSION; TETRAETHYLAMMONIUM; INVOLVEMENT	Aquaporin 1 (AQP1) is a plasma membrane water-transporting protein expressed strongly in tumor microvascular endothelia. We previously reported impaired angiogenesis in implanted tumors in AQP1-deficient mice and reduced migration of AQP1-deficient endothelial cells in vitro. Here, we investigated the consequences of AQP1 deficiency in mice that spontaneously develop well-differentiated, luminal-type breast adenomas with lung metastases [mouse mammary tumor virus-driven polyoma virus middle T oncogene (MMTV-PyVT)]. AQP1(+/+) MMTV-PyVT mice developed large breast tumors with total tumor mass 3.5 +/- 0.5 g and volume 265 +/- 36 mm(3) (se, 11 mice) at age 98 d. Tumor mass (1.6 +/- 0.2 g) and volume (131 +/- 15 mm(3), 12 mice) were greatly reduced in AQP1(-/-) MMTV-PyVT mice (P<0.005). CD31 immunofluorescence showed abnormal microvascular anatomy in tumors of AQP1(-/-) MMTV-PyVT mice, with reduced vessel density. HIF-1 expression was increased in tumors in AQP1(-/-) MMTV-PyVT mice. The number of lung metastases (5 +/- 1/mouse) was much lower than in AQP1(+/+) MMTV-PyVT mice (31 +/- 8/mouse, P<0.005). These results implicate AQP1 as an important determinant of tumor angiogenesis and, hence, as a potential drug target for adjuvant therapy of solid tumors.Esteva-Font, C., Jin, B.-J., Verkman, A. S. Aquaporin-1 gene deletion reduces breast tumor growth and lung metastasis in tumor-producing MMTV-PyVT mice.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, 1246 Hlth Sci East Tower, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu			U.S. National Institutes of Health [DK35124, EY13574, DK72517, EB00415]; Fulbright Program; Ministry of Education, Culture, and Sports of Spain; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, P30DK072517, R37DK035124] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fulbright Program; Ministry of Education, Culture, and Sports of Spain; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Liman Qian for help in mouse breeding and genotyping analysis. This study was supported by grants DK35124, EY13574, DK72517, and EB00415 from the U.S. National Institutes of Health. C.E.-F. was supported by a grant from the Fulbright Program and the Ministry of Education, Culture, and Sports of Spain.	Abreu-Rodriguez I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028385; Almholt K, 2008, MOL CANCER THER, V7, P2758, DOI 10.1158/1535-7163.MCT-08-0251; Auguste KI, 2007, FASEB J, V21, P108, DOI 10.1096/fj.06-6848com; Brooks HL, 2000, MOL PHARMACOL, V57, P1021; Carbrey Jennifer M, 2009, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-540-79885-9_1; Endo M, 1999, MICROVASC RES, V58, P89, DOI 10.1006/mvre.1999.2158; Fraisl P, 2013, EXP CELL RES, V319, P1331, DOI 10.1016/j.yexcr.2013.02.010; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; Gonzalez R. C., 2004, DIGITAL IMAGING PROC; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara-Chikuma M, 2008, MOL CELL BIOL, V28, P326, DOI 10.1128/MCB.01482-07; Hu J, 2006, FASEB J, V20, P1892, DOI 10.1096/fj.06-5930fje; Kaneko K, 2008, MICROVASC RES, V75, P297, DOI 10.1016/j.mvr.2007.12.003; Lam J. B., 2009, PLOS ONE, V4, P1; Levin MH, 2006, INVEST OPHTH VIS SCI, V47, P4365, DOI 10.1167/iovs.06-0335; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; Martin MD, 2008, CANCER RES, V68, P6251, DOI 10.1158/0008-5472.CAN-08-0537; Migliati E, 2009, MOL PHARMACOL, V76, P105, DOI 10.1124/mol.108.053744; Mobasheri A, 2005, INT J ONCOL, V26, P1149; Mosbasheri A, 2004, AM J PHYSIOL-CELL PH, V286, pC529, DOI 10.1152/ajpcell.00408.2003; Nicchia GP, 2013, J MOL MED, V91, P613, DOI 10.1007/s00109-012-0977-x; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5; Papadopoulos MC, 2012, LANCET NEUROL, V11, P535, DOI 10.1016/S1474-4422(12)70133-3; Ribatti D, 2014, BBA-GEN SUBJECTS, V1840, P1550, DOI 10.1016/j.bbagen.2013.09.025; Ruiz-Ederra J, 2007, INVEST OPHTH VIS SCI, V48, P4802, DOI 10.1167/iovs.07-0537; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Seeliger D, 2013, ACS CHEM BIOL, V8, P249, DOI 10.1021/cb300153z; Sogaard R, 2008, PFLUG ARCH EUR J PHY, V456, P285, DOI 10.1007/s00424-007-0392-2; Thiagarajah JR, 2002, J BIOL CHEM, V277, P19139, DOI 10.1074/jbc.M202071200; Verkman AS, 2008, J MOL MED, V86, P523, DOI 10.1007/s00109-008-0303-9; Verkman AS, 2006, KIDNEY INT, V69, P1120, DOI 10.1038/sj.ki.5000226; Yang BX, 2006, FEBS LETT, V580, P6679, DOI 10.1016/j.febslet.2006.11.025; Yokomori H, 2011, LIVER INT, V31, P1554, DOI 10.1111/j.1478-3231.2011.02610.x; Zhang D, 2002, J GEN PHYSIOL, V119, P561, DOI 10.1085/jgp.20028597	40	57	60	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1446	1453		10.1096/fj.13-245621	http://dx.doi.org/10.1096/fj.13-245621			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24334548	Green Published			2022-12-28	WOS:000335324800035
J	Holtzhausen, A; Golzio, C; How, T; Lee, YH; Schiemann, WP; Katsanis, N; Blobe, GC				Holtzhausen, Alisha; Golzio, Christelle; How, Tam; Lee, Yong-Hun; Schiemann, William P.; Katsanis, Nicholas; Blobe, Gerard C.			Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development	FASEB JOURNAL			English	Article						TGF-; tumorigenesis; invasion; dorsoventral axis	GROWTH-FACTOR-BETA; TGF-BETA; II RECEPTOR; ENDOTHELIAL-CELLS; ZEBRAFISH EMBRYO; UP-REGULATION; TUMOR; TRANSDUCTION; MECHANISM; ACTIVIN	The bone morphogenetic protein (BMP) signaling pathways have important roles in embryonic development and cellular homeostasis, with aberrant BMP signaling resulting in a broad spectrum of human disease. We report that BMPs unexpectedly signal through the canonical transforming growth factor (TGF-)-responsive Smad2 and Smad3. BMP-induced Smad2/3 signaling occurs preferentially in embryonic cells and transformed cells. BMPs signal to Smad2/3 by stimulating complex formation between the BMP-binding TGF- superfamily receptors, activin receptor-like kinase (ALK)3/6, and the Smad2/3 phosphorylating receptors ALK5/7. BMP signaling through Smad2 mediates, in part, dorsoventral axis patterning in zebrafish embryos, whereas BMP signaling through Smad3 facilitates cancer cell invasion. Consistent with increased BMP-mediated Smad2/3 signaling during cancer progression, Smad1/5 and Smad 2/3 signaling converge in human cancer specimens. Thus, the signaling mechanisms used by BMPs and TGF- superfamily receptors are broader than previously appreciated.Holtzhausen, A., Golzio, C., How, T., Lee, Y.-H., Schiemann, W. P., Katsanis, N., Blobe, G. C. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development.	[Holtzhausen, Alisha; Blobe, Gerard C.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Golzio, Christelle; Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC 27708 USA; [How, Tam; Blobe, Gerard C.] Duke Univ, Dept Med, Durham, NC 27708 USA; [Lee, Yong-Hun; Schiemann, William P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Duke University; Duke University; Duke University; Case Western Reserve University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, 450 Res Dr,LSRC B354,Box 91004, Durham, NC 27708 USA.	gerard.blobe@duke.edu	Blobe, Gerard/AAJ-5945-2020; Holtzhausen, Alisha/AAR-3606-2021	Blobe, Gerard/0000-0002-4274-8901; Holtzhausen, Alisha/0000-0003-3604-7401; Katsanis, Nicholas/0000-0002-2480-0171; Golzio, Christelle/0000-0002-4420-3921	U.S. National Institutes of Health [R01-CA136786]; Komen for the Cure grant [SAC100002]; American Heart Association [AHA-11POST7160006]; Center of Human Disease Modeling; NATIONAL CANCER INSTITUTE [R01CA129359, R01CA136786, P30CA014236] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen for the Cure grant; American Heart Association(American Heart Association); Center of Human Disease Modeling; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Drs. Paul Yu (Massachusetts General Hospital, Boston, MA, USA), Fred Miller (Wayne State University, Detroit, MI, USA), and Harold Moses (Vanderbilt University, Nashville, TN, USA) for reagents, Kyu Seo Kim (Duke University) for help with cloning and in vitro transcription, and Brad Gersh and Alok Tewari (Duke University) for data processing and analysis. This work was supported in part by U.S. National Institutes of Health grant R01-CA136786 (to G.C.B.), Komen for the Cure grant SAC100002 (to G.C.B.), American Heart Association grant AHA-11POST7160006 (to C.G.) and seed funding from the Center of Human Disease Modeling. N.K. is a Distinguished Brumley Professor. The authors declare no conflicts of interest.	Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Boergermann JH, 2010, INT J BIOCHEM CELL B, V42, P1802, DOI 10.1016/j.biocel.2010.07.018; Bueno L, 2008, EUR J CANCER, V44, P142, DOI 10.1016/j.ejca.2007.10.008; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Corradini E, 2009, CYTOKINE GROWTH F R, V20, P389, DOI 10.1016/j.cytogfr.2009.10.008; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192-08; Deng HY, 2009, CANCER LETT, V281, P220, DOI 10.1016/j.canlet.2009.02.046; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dick A, 2000, DEVELOPMENT, V127, P343; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Ehrlich M, 2012, FEBS LETT, V586, P1885, DOI 10.1016/j.febslet.2012.01.040; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Gordon KJ, 2009, CARCINOGENESIS, V30, P238, DOI 10.1093/carcin/bgn274; GRAINGER DJ, 1995, CLIN CHIM ACTA, V235, P11, DOI 10.1016/0009-8981(94)05995-4; Heinecke K, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-59; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herrera B, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-20; Hild M, 1999, DEVELOPMENT, V126, P2149; Hsu MY, 2008, LAB INVEST, V88, P842, DOI 10.1038/labinvest.2008.55; Imai Y, 2001, GENESIS, V30, P160, DOI 10.1002/gene.1055; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Ishibashi O, 2010, J CELL PHYSIOL, V222, P465, DOI 10.1002/jcp.21968; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kropf J, 1997, CLIN CHEM, V43, P1965; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu IM, 2009, EMBO J, V28, P88, DOI 10.1038/emboj.2008.266; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Pangas SA, 2008, MOL CELL BIOL, V28, P248, DOI 10.1128/MCB.01404-07; Schmid B, 2000, DEVELOPMENT, V127, P957; Sebald W, 2004, BIOL CHEM, V385, P697, DOI 10.1515/BC.2004.086; Star GP, 2010, MICROVASC RES, V80, P349, DOI 10.1016/j.mvr.2010.05.010; Stewart A, 2010, J CELL PHYSIOL, V223, P658, DOI 10.1002/jcp.22064; Sugimoto H, 2007, FASEB J, V21, P256, DOI 10.1096/fj.06-6837com; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Uemura M, 2005, MOL BIOL CELL, V16, P4214, DOI 10.1091/mbc.E05-02-0149; Upton PD, 2009, J BIOL CHEM, V284, P15794, DOI 10.1074/jbc.M109.002881; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xia Y, 2010, J AM SOC NEPHROL, V21, P666, DOI 10.1681/ASN.2009050511; Yu PB, 2005, J BIOL CHEM, V280, P24443, DOI 10.1074/jbc.M502825200	55	70	70	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1248	1267		10.1096/fj.13-239178	http://dx.doi.org/10.1096/fj.13-239178			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24308972	Green Published			2022-12-28	WOS:000335324800019
J	Zhang, J; Li, Y; Shan, K; Wang, LL; Qiu, W; Lu, YL; Zhao, D; Zhu, GQ; He, FX; Wang, YW				Zhang, Jing; Li, Yan; Shan, Kai; Wang, Lulu; Qiu, Wen; Lu, Yanlai; Zhao, Dan; Zhu, Ganqian; He, Fengxia; Wang, Yingwei			Sublytic C5b-9 induces IL-6 and TGF-beta 1 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C/EBP beta acetylation	FASEB JOURNAL			English	Article						transcription factor; post-translational modification; renal inflammation; renal pathology	MEMBRANE ATTACK COMPLEX; BINDING PROTEIN-BETA; FACTOR-KAPPA-B; IGA NEPHROPATHY; MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS; TRANSCRIPTIONAL COACTIVATOR; AMELIORATES PROTEINURIA; PROMOTER-BINDING; GENE-EXPRESSION; TH17 CELLS	CCAAT/enhancer-binding protein (C/EBP)-enhanced IL-6 and TGF-1 promoter activity and p300-mediated C/EBP acetylation were involved in up-regulation of IL-6 and TGF-1 expression in GMCs attacked by sublytic C5b-9. In detail, the elements of C/EBP binding to rat IL-6 and TGF-1 promoter and 3 acetylated sites of rat C/EBP protein were first revealed. Furthermore, silencing the p300 or C/EBP gene in rat kidney significantly reduced the production of IL-6 and TGF-1 and renal lesions in Thy-1N rats. Together, these data indicate that the mechanism of IL-6 and TGF-1 production in renal tissue of Thy-1N rats is associated with sublytic C5b-9 up-regulated p300 and p300-mediated C/EBP acetylation as well as C/EBP-activated IL-6 and TGF-1 genes.Zhang, J., Li, Y., Shan, K., Wang, L., Qiu, W., Lu, Y., Zhao, D., Zhu, G., He, F., Wang, Y. Sublytic C5b-9 induces IL-6 and TGF-1 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C/EBP acetylation.	[Zhang, Jing; Li, Yan; Shan, Kai; Wang, Lulu; Qiu, Wen; Lu, Yanlai; Zhao, Dan; Zhu, Ganqian; He, Fengxia; Wang, Yingwei] Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University	Wang, YW (corresponding author), Nanjing Med Univ, Dept Microbiol & Immunol, Hanzhong Rd 140, Nanjing 210029, Jiangsu, Peoples R China.	wangyw1508@njmu.edu.cn	Shan, Kai/GSJ-6217-2022	Li, Yan/0000-0003-0420-4222; He, Fengxia/0000-0002-1695-3127	National Natural Science Foundations of China [81072402, 31000396, 81273333]; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions; Technology Development Foundation of Nanjing Medical University; Collaborative Innovation Center of Nanjing Medical University [JX21831802/005]	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions; Technology Development Foundation of Nanjing Medical University; Collaborative Innovation Center of Nanjing Medical University	The authors thank Professor Feng Lin (Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH, USA) for reviewing the manuscript. The study was supported by grants from the National Natural Science Foundations of China (81072402, 31000396, and 81273333), by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions, by a grant from the Technology Development Foundation of Nanjing Medical University, and by a grant from the Collaborative Innovation Center of Nanjing Medical University (JX21831802/005).	Abraham S, 2009, J INTERF CYTOK RES, V29, P1, DOI 10.1089/jir.2008.0036; Brandt J, 1996, KIDNEY INT, V49, P335, DOI 10.1038/ki.1996.50; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Chen JH, 2011, EPIGENETICS-US, V6, P957, DOI 10.4161/epi.6.8.16065; Chen YW, 2007, EUR J IMMUNOL, V37, P167, DOI 10.1002/eji.200636285; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; Cybulsky AV, 2005, AM J PHYSIOL-RENAL, V289, pF593, DOI 10.1152/ajprenal.00066.2005; Darvill AM, 2006, J LAB CLIN MED, V147, P301, DOI 10.1016/j.lab.2006.02.001; Gao L, 2006, CLIN EXP IMMUNOL, V144, P326, DOI 10.1111/j.1365-2249.2006.03069.x; Gao L, 2009, CELL PROLIFERAT, V42, P83, DOI 10.1111/j.1365-2184.2008.00575.x; He T, 2011, J BIOL CHEM, V286, P14137, DOI 10.1074/jbc.M110.176289; Ikezumi Y, 2000, KIDNEY INT, V58, P100, DOI 10.1046/j.1523-1755.2000.00145.x; Ikezumi Y, 2004, KIDNEY INT, V66, P1036, DOI 10.1111/j.1523-1755.2004.00852.x; Ikezumi Y, 2002, KIDNEY INT, V61, P1339, DOI 10.1046/j.1523-1755.2002.00259.x; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Jin JL, 2013, J BIOL CHEM, V288, P14451, DOI 10.1074/jbc.M113.460840; Kitzler TM, 2012, BBA-MOL CELL RES, V1823, P1007, DOI 10.1016/j.bbamcr.2012.03.001; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lee S, 2010, J BIOL CHEM, V285, P21399, DOI 10.1074/jbc.M110.128413; Lin FJ, 2012, SCAND J CLIN LAB INV, V72, P221, DOI 10.3109/00365513.2011.652158; Liu CY, 2004, CYTOKINE, V27, P93, DOI 10.1016/j.cyto.2004.02.003; Liu LS, 2012, J BIOL CHEM, V287, P16410, DOI 10.1074/jbc.M111.319566; Liu X, 2008, NATURE, V451, P846, DOI 10.1038/nature06546; Lu J, 2005, CYTOKINE, V31, P46, DOI 10.1016/j.cyto.2005.03.001; Matsumoto K, 2002, NEPHRON, V91, P243, DOI 10.1159/000058399; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Nangaku Masaomi, 2005, Clin Exp Nephrol, V9, P183, DOI 10.1007/s10157-005-0357-8; Niculescu F, 2001, IMMUNOL RES, V24, P191, DOI 10.1385/IR:24:2:191; Park I, 2013, J CELL BIOL, V202, P295, DOI 10.1083/jcb.201210099; Qiu W, 2012, J PATHOL, V226, P619, DOI 10.1002/path.3011; Qiu W, 2009, EUR J IMMUNOL, V39, P3251, DOI 10.1002/eji.200939264; Sato T, 1999, J AM SOC NEPHROL, V10, P1242; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Spooner CJ, 2007, MOL IMMUNOL, V44, P1384, DOI 10.1016/j.molimm.2006.05.004; Stangou M, 2008, SCAND J UROL NEPHROL, V42, P373, DOI 10.1080/00365590801943241; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Suana AJ, 2011, J PHARMACOL EXP THER, V337, P411, DOI 10.1124/jpet.110.176222; Sugaru E, 2005, AM J PHYSIOL-RENAL, V289, pF998, DOI 10.1152/ajprenal.00065.2005; Tramontini NL, 2002, INFLAMMATION, V26, P311, DOI 10.1023/A:1021420903355; Tsukada J, 2011, CYTOKINE, V54, P6, DOI 10.1016/j.cyto.2010.12.019; Tumlin JA, 2007, CLIN J AM SOC NEPHRO, V2, P1054, DOI 10.2215/CJN.04351206; Turnberg D, 2005, CURR OPIN NEPHROL HY, V14, P223, DOI 10.1097/01.mnh.0000165887.75501.24; Wang H, 2008, CLIN EXP IMMUNOL, V152, P559, DOI 10.1111/j.1365-2249.2008.03654.x; Wang HT, 2007, J BIOL CHEM, V282, P24679, DOI 10.1074/jbc.M705066200; Wang YW, 2006, LIFE SCI, V79, P182, DOI 10.1016/j.lfs.2005.12.053; Xu JH, 2006, CELL TISSUE RES, V326, P159, DOI 10.1007/s00441-006-0214-4; YAMAMOTO T, 1987, J IMMUNOL, V138, P3758; YAMAMOTO T, 1987, KIDNEY INT, V32, P514, DOI 10.1038/ki.1987.240; Zhou XR, 2007, IMMUNOLOGY, V122, P476, DOI 10.1111/j.1365-2567.2007.02674.x; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	52	45	55	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1511	1525		10.1096/fj.13-242693	http://dx.doi.org/10.1096/fj.13-242693			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24344329				2022-12-28	WOS:000335324800041
J	Orecchia, A; Mettouchi, A; Uva, P; Simon, GC; Arcelli, D; Avitabile, S; Ragone, G; Meneguzzi, G; Pfenninger, KH; Zambruno, G; Failla, CM				Orecchia, Angela; Mettouchi, Amel; Uva, Paolo; Simon, Glenn C.; Arcelli, Diego; Avitabile, Simona; Ragone, Gianluca; Meneguzzi, Guerrino; Pfenninger, Karl H.; Zambruno, Giovanna; Failla, Cristina Maria			Endothelial cell adhesion to soluble vascular endothelial growth factor receptor-1 triggers a cell dynamic and angiogenic phenotype	FASEB JOURNAL			English	Article						integrin alpha 5 beta 1; cell migration; vessel formation	PROTEIN-KINASE-C; EXTRACELLULAR-MATRIX; CROSS-TALK; INTEGRIN; MARCKS; G-ALPHA(13); RADIXIN; RHO; ALPHA(5)BETA(1); ACTIVATION	The aim of this study was to identify the molecular signals produced in human endothelial cells (ECs) by the interaction of 51 integrin with soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) present in the extracellular matrix. We generated a gene expression profile of ECs adhering to sVEGFR-1 or to fibronectin, the classic extracellular matrix ligand for 51 integrin or in a nonadhering condition. Several biological pathways were differently modulated, 3 protein kinase C substrates [adducin, myristoylated alanine-rich protein kinase C substrate (MARCKS), and radixin] were differently expressed and phosphorylated when cells adhering to sVEGFR-1 were compared with those adhering to fibronectin. Rac1 activation and G(13) protein involvement through the interaction with radixin were also detected after attachment to sVEGFR-1, and these responses depended on active VEGFR-2 signaling. On sVEGFR-1, ECs exhibited a motile phenotype that was consistent with the abundant presence of MARCKS, a stabilizer of dynamic adhesions. Moreover, ECs silenced for radixin expression no longer responded to the proangiogenic VEGFR-1-derived peptide 12. We propose that the presence of sVEGFR-1 in the EC microenvironment directs 51 integrin signaling to generate a dynamic, motile phenotype. Our findings also provide new insights into the mechanism of action of proangiogenic peptide 12, relevant to a therapeutic perspective.Orecchia, A., Mettouchi, A., Uva, P., Simon, G.C., Areclli, D., Avitabile, S., Ragone, G., Meneguzzi, G., Pfenninger, K.H., Zambruno, G., Failla, C.M. Endothelial cell adhesion to soluble vascular endothelial growth factor receptor-1 triggers a cell dynamic and angiogenic phenotype.	[Orecchia, Angela; Avitabile, Simona; Zambruno, Giovanna; Failla, Cristina Maria] Ist Ricovero & Cura Carattere Sci IRCCS, Ist Dermopat Immacolata, Mol & Cell Biol Lab, Rome, Italy; [Arcelli, Diego; Ragone, Gianluca] Ist Ricovero & Cura Carattere Sci IRCCS, Ist Dermopat Immacolata, Mol Oncol Lab, Rome, Italy; [Mettouchi, Amel; Meneguzzi, Guerrino] Fac Med Nice, INSERM, U634, F-06034 Nice, France; [Uva, Paolo] Ctr Adv Studies Res & Dev Sardinia CRS4, Bioinformat Lab, Cagliari, Italy; [Simon, Glenn C.; Pfenninger, Karl H.] Univ Colorado, Dept Pediat, Aurora, CO USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Colorado System; University of Colorado Anschutz Medical Campus	Failla, CM (corresponding author), IDI IRCCS, Mol & Cell Biol Lab, Via Monti Creta 104, I-00167 Rome, Italy.	c.failla@idi.it	Uva, Paolo/A-2877-2011; Zambruno, Giavanna/K-2933-2018; Failla, Cristina M./AAA-2881-2019	Uva, Paolo/0000-0002-9524-8492; METTOUCHI, Amel/0000-0003-1453-6482; Meneguzzi, Guerrino/0000-0002-1609-6540; Failla, Cristina/0000-0001-5991-8914; Zambruno, Giovanna/0000-0002-1295-056X	Agence Nationale de la Recherche [ANR-05135AS]; Centre National de la Recherche Scientifique; Italian Ministry of Health (Ricerca Corrente); Institut National de la Sante et de la Recherche Medicale fellowship	Agence Nationale de la Recherche(French National Research Agency (ANR)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Italian Ministry of Health (Ricerca Corrente)(Ministry of Health, Italy); Institut National de la Sante et de la Recherche Medicale fellowship	The authors thank Mauro Helmer Citterich for technical support in microarray hybridization and Maurizio Inzillo and Daniele Bartoloni for artwork. This work was supported by an Institut National de la Sante et de la Recherche Medicale fellowship to A.O. in the years 2007-2009, grants from the Agence Nationale de la Recherche (ANR-05135AS) and the Centre National de la Recherche Scientifique to A.M., and grants from the Italian Ministry of Health (Ricerca Corrente).	Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Chappell JC, 2009, DEV CELL, V17, P377, DOI 10.1016/j.devcel.2009.07.011; Disatnik MH, 2004, J CELL SCI, V117, P4469, DOI 10.1242/jcs.01309; Estrada-Bernal A, 2009, J CELL SCI, V122, P2300, DOI 10.1242/jcs.047860; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fryer BH, 2005, CANCER LETT, V229, P13, DOI 10.1016/j.canlet.2004.12.009; Gatlin JC, 2006, MOL BIOL CELL, V17, P5115, DOI 10.1091/mbc.E05-12-1183; Gentleman R., 2011, GENEFILTER METHODS F; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; IZZARD CS, 1976, J CELL SCI, V21, P129; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Kalwa H, 2011, J BIOL CHEM, V286, P2320, DOI 10.1074/jbc.M110.196022; Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114; Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647; Kearney JB, 2004, BLOOD, V103, P4527, DOI 10.1182/blood-2003-07-2315; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Liu GQ, 2005, J BIOL CHEM, V280, P39042, DOI 10.1074/jbc.M504341200; Liu GQ, 2009, ANGIOGENESIS, V12, P1, DOI 10.1007/s10456-008-9123-3; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Orecchia A, 2003, J CELL SCI, V116, P3479, DOI 10.1242/jcs.00673; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ruppel KM, 2005, P NATL ACAD SCI USA, V102, P8281, DOI 10.1073/pnas.0503326102; Shan DD, 2006, DEV CELL, V10, P707, DOI 10.1016/j.devcel.2006.03.014; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Soro S, 2008, BLOOD, V111, P3479, DOI 10.1182/blood-2007-03-077537; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanjore H, 2008, DEV DYNAM, V237, P75, DOI 10.1002/dvdy.21385; Taverna D, 2001, CANCER RES, V61, P5255; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; Wu J. M., 2011, GCRMA BACKGROUND ADJ; YANG JT, 1993, DEVELOPMENT, V119, P1093; Zhao Y, 2000, AM J PHYSIOL-CELL PH, V279, pC1611, DOI 10.1152/ajpcell.2000.279.5.C1611	50	13	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					692	704		10.1096/fj.12-225771	http://dx.doi.org/10.1096/fj.12-225771			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24174428				2022-12-28	WOS:000331072200017
J	Cheung, HNM; Dunbar, C; Morotz, GM; Cheng, WH; Chan, HYE; Miller, CCJ; Lau, KF				Cheung, Hei Nga Maggie; Dunbar, Charlotte; Morotz, Gabor M.; Cheng, Wai Hang; Chan, Ho Yin Edwin; Miller, Christopher C. J.; Lau, Kwok-Fai			FE65 interacts with ADP-ribosylation factor 6 to promote neurite outgrowth	FASEB JOURNAL			English	Article						ARF6; amyloid-; A4 precursor protein-binding family B member 1; neurons; Rac1	AMYLOID PRECURSOR PROTEIN; RECEPTOR-RELATED PROTEIN; PHOSPHOTYROSINE-BINDING DOMAIN; ADAPTER PROTEIN; NUCLEAR TRANSLOCATION; DOWNSTREAM ACTIVATION; DEPENDENT ACTIVATION; APOE RECEPTOR; GROWTH CONES; AXON GROWTH	FE65 is an adaptor protein that binds to the amyloid precursor protein (APP). As such, FE65 has been implicated in the pathogenesis of Alzheimer's disease. In addition, evidence suggests that FE65 is involved in brain development. It is generally believed that FE65 participates in these processes by recruiting various interacting partners to form functional complexes. Here, we show that via its first phosphotyrosine binding (PTB) domain, FE65 binds to the small GTPase ADP-ribosylation factor 6 (ARF6). FE65 preferentially binds to ARF6-GDP, and they colocalize in neuronal growth cones. Interestingly, FE65 stimulates the activation of both ARF6 and its downstream GTPase Rac1, a regulator of actin dynamics, and functions in growth cones to stimulate neurite outgrowth. We show that transfection of FE65 and/or ARF6 promotes whereas small interfering RNA knockdown of FE65 or ARF6 inhibits neurite outgrowth in cultured neurons as compared to the mock-transfected control cells. Moreover, knockdown of ARF6 attenuates FE65 stimulation of neurite outgrowth and defective neurite outgrowth seen in FE65-deficient neurons is partially corrected by ARF6 overexpression. Notably, the stimulatory effect of FE65 and ARF6 on neurite outgrowth is abrogated either by dominant-negative Rac1 or knockdown of Rac1. Thus, we identify FE65 as a novel regulator of neurite outgrowth via controlling ARF6-Rac1 signaling.Cheung, H. N., Dunbar, C., Morotz, G. M., Cheng, W. H., Chan, H. Y., Miller, C. C., Lau, K.-.F. FE65 interacts with ADP-ribosylation factor 6 to promote neurite outgrowth.	[Cheung, Hei Nga Maggie; Cheng, Wai Hang; Chan, Ho Yin Edwin; Lau, Kwok-Fai] Chinese Univ Hong Kong, Sch Life Sci, Shatin, Hong Kong, Peoples R China; [Dunbar, Charlotte; Morotz, Gabor M.; Miller, Christopher C. J.] Kings Coll London, Inst Psychiat, Ctr Neurodegenerat Res, Dept Neurosci, London, England	Chinese University of Hong Kong; University of London; King's College London	Lau, KF (corresponding author), Chinese Univ Hong Kong, Sch Life Sci, Shatin, Hong Kong, Peoples R China.	kflau@cuhk.edu.hk	Chan, Edwin/A-9478-2011; Mórotz, Gábor Miklós/C-7979-2013	Chan, Edwin/0000-0003-4307-474X; Mórotz, Gábor Miklós/0000-0003-4223-7009; Lau, Kwok-Fai/0000-0002-0193-1152; Cheng, Wai Hang/0000-0002-3408-9184; Miller, Christopher/0000-0002-5130-1845	Research Grant Council Hong Kong [CUHK467712]; CUHK Direct Grant Scheme [2030443]; United College Endowment Fund [CA11156, CA11188]; Wellcome Trust; Medical Research Council (UK); Alzheimer's Research UK; BBSRC [BB/L019299/1] Funding Source: UKRI; MRC [G0501573] Funding Source: UKRI; Alzheimers Research UK [ARUK-PhD2012-1] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [BB/L019299/1] Funding Source: researchfish; Medical Research Council [G0501573] Funding Source: researchfish	Research Grant Council Hong Kong(Hong Kong Research Grants Council); CUHK Direct Grant Scheme; United College Endowment Fund; Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimer's Research UK(Alzheimer's Research UK (ARUK)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by funds from the Research Grant Council Hong Kong (CUHK467712); the CUHK Direct Grant Scheme (2030443); United College Endowment Fund (CA11156 and CA11188); Wellcome Trust; Medical Research Council (UK); and Alzheimer's Research UK. The authors thank Ka Ming Vincent Tam for technical assistance.	Albertinazzi C, 2003, MOL BIOL CELL, V14, P1295, DOI 10.1091/mbc.E02-07-0406; Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Balasubramanian N, 2007, NAT CELL BIOL, V9, P1381, DOI 10.1038/ncb1657; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Bryan B, 2004, J BIOL CHEM, V279, P45824, DOI 10.1074/jbc.M406216200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen LH, 2012, J BIOL CHEM, V287, P26104, DOI 10.1074/jbc.M112.360206; Chen PW, 2013, J BIOL CHEM, V288, P5849, DOI 10.1074/jbc.M112.415778; Chow WNV, 2012, BIOCHEM J, V443, P681, DOI 10.1042/BJ20112175; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; De Curtis I, 2008, DEV NEUROSCI-BASEL, V30, P47, DOI 10.1159/000109851; Dent EW, 2007, NAT CELL BIOL, V9, P1347, DOI 10.1038/ncb1654; Dumanis SB, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-9; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Eva R, 2012, J NEUROSCI, V32, P10352, DOI 10.1523/JNEUROSCI.1409-12.2012; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Flynn KC, 2012, NEURON, V76, P1091, DOI 10.1016/j.neuron.2012.09.038; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; Guenette S, 2006, EMBO J, V25, P420, DOI 10.1038/sj.emboj.7600926; Hao CY, 2011, BIOCHEM J, V436, P631, DOI 10.1042/BJ20110145; Hernandez-Deviez DJ, 2004, MOL BIOL CELL, V15, P111, DOI 10.1091/mbc.E03-06-0410; Hoe HS, 2006, J BIOL CHEM, V281, P24521, DOI 10.1074/jbc.M600728200; Hoe HS, 2009, J NEUROSCI, V29, P7459, DOI 10.1523/JNEUROSCI.4872-08.2009; Jaworski J, 2007, EUR J CELL BIOL, V86, P513, DOI 10.1016/j.ejcb.2007.04.007; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Kesavapany S, 2002, NEUROSCIENCE, V115, P951, DOI 10.1016/S0306-4522(02)00422-0; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Lau KF, 2000, NEUROREPORT, V11, P3607, DOI 10.1097/00001756-200011090-00041; Lau KF, 2008, J BIOL CHEM, V283, P34728, DOI 10.1074/jbc.M801874200; Leemhuis J, 2010, J NEUROSCI, V30, P14759, DOI 10.1523/JNEUROSCI.4036-10.2010; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Lu W, 2013, CURR BIOL, V23, P1018, DOI 10.1016/j.cub.2013.04.050; Lundquist EA, 2003, CURR OPIN NEUROBIOL, V13, P384, DOI 10.1016/s0959-4388(03)00071-0; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Ma QH, 2008, NAT CELL BIOL, V10, P283, DOI 10.1038/ncb1690; Ma Z, 2007, CURR BIOL, V17, P722, DOI 10.1016/j.cub.2007.03.014; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; May V, 2002, J NEUROSCI, V22, P6980; McLoughlin DM, 1998, BIOCHEM SOC T, V26, P497, DOI 10.1042/bst0260497; McLoughlin DM, 1996, FEBS LETT, V397, P197; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Minopoli G, 2012, IUBMB LIFE, V64, P936, DOI 10.1002/iub.1094; Mo J, 2012, BIOCHEM BIOPH RES CO, V422, P250, DOI 10.1016/j.bbrc.2012.04.136; Monteleon CL, 2012, MOL BIOL CELL, V23, P4495, DOI 10.1091/mbc.E12-03-0246; Montenegro-Venegas C, 2010, MOL BIOL CELL, V21, P3518, DOI 10.1091/mbc.E09-08-0709; Mulvihill MM, 2011, BIOCHEMISTRY-US, V50, P6208, DOI 10.1021/bi200508f; Myers KR, 2008, TRENDS CELL BIOL, V18, P184, DOI 10.1016/j.tcb.2008.02.002; Nakaya T, 2008, J BIOL CHEM, V283, P19119, DOI 10.1074/jbc.M801827200; Nekhoroshkova E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004647; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; Pasqualato S, 2001, EMBO REP, V2, P234, DOI 10.1093/embo-reports/kve043; Perez RG, 1997, J NEUROSCI, V17, P9407; Perkinton MS, 2004, J BIOL CHEM, V279, P22084, DOI 10.1074/jbc.M311479200; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Radhakrishna H, 1999, J CELL SCI, V112, P855; Rama N, 2012, J BIOL CHEM, V287, P30014, DOI 10.1074/jbc.M111.324780; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sannerud R, 2011, P NATL ACAD SCI USA, V108, pE559, DOI 10.1073/pnas.1100745108; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Schweitzer JK, 2011, SEMIN CELL DEV BIOL, V22, P39, DOI 10.1016/j.semcdb.2010.09.002; Sepp KJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000111; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Stante M, 2009, P NATL ACAD SCI USA, V106, P5093, DOI 10.1073/pnas.0810869106; Stiles TL, 2013, J CELL SCI, V126, P209, DOI 10.1242/jcs.113191; Tahirovic S, 2010, J NEUROSCI, V30, P6930, DOI 10.1523/JNEUROSCI.5395-09.2010; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Tsai SC, 1998, J BIOL CHEM, V273, P20697, DOI 10.1074/jbc.273.33.20697; Tudor EL, 2010, NEUROSCIENCE, V167, P774, DOI 10.1016/j.neuroscience.2010.02.035; Tudor EL, 2005, J BIOL CHEM, V280, P34735, DOI 10.1074/jbc.M506216200; Turner AJ, 2011, EMBO REP, V12, P180, DOI 10.1038/embor.2011.25; Uhlik MT, 2005, J MOL BIOL, V345, P1, DOI 10.1016/j.jmb.2004.10.038; Vagnoni A, 2012, HUM MOL GENET, V21, P2845, DOI 10.1093/hmg/dds109; Wang BP, 2004, J NEUROSCI RES, V75, P12, DOI 10.1002/jnr.10834; Wang PL, 2011, NEUROREPORT, V22, P716, DOI 10.1097/WNR.0b013e32834aca9d; Wang Y, 2009, LEARN MEMORY, V16, P537, DOI 10.1101/lm.1499309; Williams KL, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-24; YAMADA KM, 1970, P NATL ACAD SCI USA, V66, P1206, DOI 10.1073/pnas.66.4.1206; Yamazaki T, 1997, J NEUROSCI, V17, P1004; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128	91	30	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					337	349		10.1096/fj.13-232694	http://dx.doi.org/10.1096/fj.13-232694			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24056087	Green Accepted			2022-12-28	WOS:000333526100032
J	Liao, GX; van Driel, B; Magelky, E; O'Keeffe, MS; Malefyt, RD; Engel, P; Herzog, RW; Mizoguchi, E; Bhan, AK; Terhorst, C				Liao, Gongxian; van Driel, Boaz; Magelky, Erica; O'Keeffe, Michael S.; Malefyt, Rene de Waal; Engel, Pablo; Herzog, Roland W.; Mizoguchi, Emiko; Bhan, Atul K.; Terhorst, Cox			Glucocorticoid-induced TNF receptor family- related protein ligand regulates the migration of monocytes to the inflamed intestine	FASEB JOURNAL			English	Article						GITR-L; TNFSF18; macrophage; experimental colitis	CD4(+) T-CELLS; SPLENIC RESERVOIR; DENDRITIC CELLS; BONE-MARROW; GITR; EXPRESSION; COLITIS; RECRUITMENT; MACROPHAGES; ENGAGEMENT	Glucocorticoid-induced TNF receptor family-related protein (GITR) regulates the function of both T cells and antigen-presenting cells (APCs), while the function of GITR ligand (GITR-L) is largely unknown. Here we evaluate the role of GITR-L, whose expression is restricted to APCs, in the development of enterocolitis. On injecting naive CD4(+) T cells, GITR-L(-/-)Rag(-/-) mice develop a markedly milder colitis than Rag(-/-) mice, which correlates with a 50% reduction of Ly6C(+)CD11b(+)MHCII(+) macrophages in the lamina propria and mesenteric lymph nodes. The same result was observed in CD40-induced acute colitis and during peritonitis, suggesting an altered monocyte migration. In line with these observations, the number of nondifferentiated monocytes was approximately 3-fold higher in the spleen of GITR-L(-/-)Rag(-/-) mice than in Rag(-/-) mice after CD40 induction. Consistent with the dynamic change in the formation of an active angiotensin II type 1 receptor (AT1) dimer in GITR-L-/- splenic monocytes during intestinal inflammation, the migratory capability of splenic monocytes from GITR-L-deficient mice was impaired in an in vitro transwell migration assay. Conversely, GITR-L reduces the number of splenic Ly6C(hi) monocytes, concomitantly with an increase in AT1 dimers. We conclude that GITR-L regulates the number of proinflammatory macrophages in sites of inflammation by controlling the egress of monocytes from the splenic reservoir.Liao, G., van Driel, B., Magelky, E., O'Keeffe, M. S., de Waal Malefyt, R., Engel, P., Herzog, R. W., Mizoguchi, E., Bhan, A. K., Terhorst, C. Glucocorticoid-induced TNF receptor family-related protein ligand regulates the migration of monocytes to the inflamed intestine.	[Liao, Gongxian; van Driel, Boaz; Magelky, Erica; O'Keeffe, Michael S.; Terhorst, Cox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Beth Israel Deaconess Med Ctr,Div Immunol, Boston, MA 02115 USA; [Mizoguchi, Emiko] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA 02115 USA; [Bhan, Atul K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Malefyt, Rene de Waal] Merck Res Labs, Biol Discovery, Palo Alto, CA USA; [Engel, Pablo] Univ Barcelona, Sch Med, Dept Cell Biol Immunol & Neurosci, Immunol Unit, Barcelona, Spain; [Herzog, Roland W.] Univ Florida, Dept Pediat, Gainesville, FL USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Merck & Company; University of Barcelona; State University System of Florida; University of Florida	Liao, GX (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, 3 Blackfan Circle,CLS 928, Boston, MA 02115 USA.	gliao@bidmc.harvard.edu; cterhors@bidmc.harvard.edu	Engel, Pablo/R-5907-2019	Engel, Pablo/0000-0001-8410-252X; Magelky, Erica/0000-0003-2393-0713; de Waal Malefyt, Rene/0000-0002-2663-383X	U.S. National Institutes of Health [R01 DK-52510, P01 HL078810, 5T32DK007760, P30 DK-43351]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007760, P30DK043351, R01DK052510] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank members of the C. T. laboratory for helpful discussions and the Beth Israel Deaconess Medical Center histology core for processing colon tissue slides with H&E staining. This work was sponsored by the U.S. National Institutes of Health (R01 DK-52510 to C. T., P01 HL078810 to C. T. and R. H., 5T32DK007760 to G. L., and P30 DK-43351 to A. B., C. T., and E. M.). The authors declare no conflicts of interest.	AbdAlla S, 2004, CELL, V119, P343, DOI 10.1016/j.cell.2004.10.006; Azuma M, 2010, CRIT REV IMMUNOL, V30, P547, DOI 10.1615/CritRevImmunol.v30.i6.40; Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Carrier Y, 2012, EUR J IMMUNOL, V42, P1393, DOI 10.1002/eji.201142162; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Griseri T, 2012, IMMUNITY, V37, P1116, DOI 10.1016/j.immuni.2012.08.025; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Kintscher U, 2001, HYPERTENSION, V37, P587, DOI 10.1161/01.HYP.37.2.587; Kurotaki D, 2011, J IMMUNOL, V186, P2229, DOI 10.4049/jimmunol.1001345; Lacal PM, 2013, J PHARMACOL EXP THER, V347, P164, DOI 10.1124/jpet.113.207605; Leuschner F, 2010, CIRC RES, V107, P1364, DOI 10.1161/CIRCRESAHA.110.227454; Liao GX, 2012, GASTROENTEROLOGY, V142, P582, DOI 10.1053/j.gastro.2011.11.031; Liao GX, 2010, INT IMMUNOL, V22, P259, DOI 10.1093/intimm/dxq001; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Liu K, 2010, IMMUNOL REV, V234, P45, DOI 10.1111/j.0105-2896.2009.00879.x; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nardelli B, 2006, ENDOCRINOLOGY, V147, P70, DOI 10.1210/en.2005-0518; Rivollier A, 2012, J EXP MED, V209, P139, DOI 10.1084/jem.20101387; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Santucci L, 2007, GUT, V56, P52, DOI 10.1136/gut.2006.091181; Segal BH, 2002, J LEUKOCYTE BIOL, V71, P410; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Siddiqui KRR, 2010, IMMUNITY, V32, P557, DOI 10.1016/j.immuni.2010.03.017; Simpson SJ, 1997, EUR J IMMUNOL, V27, P17, DOI 10.1002/eji.1830270104; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; van Driel B, 2012, GASTROENTEROLOGY, V143, P1544, DOI 10.1053/j.gastro.2012.08.042; van Olffen RW, 2009, J IMMUNOL, V182, P7490, DOI 10.4049/jimmunol.0802751; Varol C, 2009, IMMUNITY, V31, P502, DOI 10.1016/j.immuni.2009.06.025; Williams MR, 2011, TRENDS IMMUNOL, V32, P461, DOI 10.1016/j.it.2011.06.009	38	10	11	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					474	484		10.1096/fj.13-236505	http://dx.doi.org/10.1096/fj.13-236505			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24107315	Green Published			2022-12-28	WOS:000333526100044
J	Pryce, G; Visintin, C; Ramagopalan, SV; Al-Izki, S; De Faveri, LE; Nuamah, RA; Mein, CA; Montpetit, A; Hardcastle, AJ; Kooij, G; de Vries, HE; Amor, S; Thomas, SA; Ledent, C; Marsicano, G; Lutz, B; Thompson, AJ; Selwood, DL; Giovannoni, G; Baker, D				Pryce, Gareth; Visintin, Cristina; Ramagopalan, Sreeram V.; Al-Izki, Sarah; De Faveri, Lia E.; Nuamah, Rosamond A.; Mein, Charles A.; Montpetit, Alexandre; Hardcastle, Alison J.; Kooij, Gijs; de Vries, Helga E.; Amor, Sandra; Thomas, Sarah A.; Ledent, Catherine; Marsicano, Giovanni; Lutz, Beat; Thompson, Alan J.; Selwood, David L.; Giovannoni, Gavin; Baker, David			Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists	FASEB JOURNAL			English	Article						drug transporters; experimental autoimmune encephalomyelitis; genomics; multidrug resistance transporters; therapeutics	ANTIHYPERALGESIC PROPERTIES; CANNABIMIMETIC PROPERTIES; SMOKED CANNABIS; MICE DEFICIENT; EXPRESSION; NEURODEGENERATION; SUBPOPULATION; TRANSPORT; NEURONS	The purpose of this study was the generation of central nervous system (CNS)-excluded cannabinoid receptor agonists to test the hypothesis that inhibition of spasticity, due to CNS autoimmunity, could be controlled by affecting neurotransmission within the periphery. Procedures included identification of chemicals and modeling to predict the mode of exclusion; induction and control of spasticity in the ABH mouse model of multiple sclerosis; conditional deletion of CB1 receptor in peripheral nerves; side-effect profiling to demonstrate the mechanism of CNS-exclusion via drug pumps; genome-wide association study in N2(129xABH) backcross to map polymorphic cannabinoid drug pump; and sequencing and detection of cannabinoid drug-pump activity in human brain endothelial cell lines. Three drugs (CT3, SAB378 and SAD448) were identified that control spasticity via action on the peripheral nerve CB1 receptor. These were peripherally restricted via drug pumps that limit the CNS side effects (hypothermia) of cannabinoids to increase the therapeutic window. A cannabinoid drug pump is polymorphic and functionally lacking in many laboratory (C57BL/6, 129, CD-1) mice used for transgenesis, pharmacology, and toxicology studies. This phenotype was mapped and controlled by 1-3 genetic loci. ABCC1 within a cluster showing linkage is a cannabinoid CNS-drug pump. Global and conditional CB1 receptor-knockout mice were used as controls. In summary, CNS-excluded CB1 receptor agonists are a novel class of therapeutic agent for spasticity.Pryce, G., Visintin, C., Ramagopalan, S. V., Al-Izki, S., De Faveri, L. E., Nuamah, R. A., Mein, C. A., Montpetit, A., Hardcastle, A. J., Kooij, G., de Vries, H. E., Amor, S., Thomas, S. A., Ledent, C., Marsicano, G., Lutz, B., Thompson, A. J., Selwood, D. L., Giovannoni, G., Baker, D. Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.	[Pryce, Gareth; Ramagopalan, Sreeram V.; Al-Izki, Sarah; Amor, Sandra; Giovannoni, Gavin; Baker, David] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England; [De Faveri, Lia E.; Nuamah, Rosamond A.; Mein, Charles A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Genome Ctr, London E1 2AT, England; [Pryce, Gareth; Visintin, Cristina; Thompson, Alan J.; Giovannoni, Gavin; Baker, David] UCL, Inst Neurol, London, England; [Visintin, Cristina; Selwood, David L.] UCL, Wolfson Inst Biomed Res, London, England; [Hardcastle, Alison J.] UCL, Inst Ophthalmol, London, England; [Montpetit, Alexandre] McGill Univ, Montreal, PQ, Canada; [Montpetit, Alexandre] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Kooij, Gijs; de Vries, Helga E.; Amor, Sandra] Free Univ Amsterdam, Vrije Univ Med Ctr, Amsterdam, Netherlands; [Thomas, Sarah A.] Kings Coll London, Inst Pharmaceut Sci, London WC2R 2LS, England; [Ledent, Catherine] Free Univ Brussels, Inst Interdisciplinary Res Human & Mol Biol, Brussels, Belgium; [Marsicano, Giovanni] Univ Bordeaux, Neuroctr Magendie, INSERM, Bordeaux, France; [Lutz, Beat] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, D-55122 Mainz, Germany	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; University College London; University of London; University College London; University of London; University College London; McGill University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of London; King's College London; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Johannes Gutenberg University of Mainz	Baker, D (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England.	david.baker@qmul.ac.uk	Marsicano, Giovanni/I-9603-2016; Lutz, Beat/AFK-6229-2022; Kooij, Gijs/AAA-4268-2020; Thompson, Alan J/C-2654-2008; Lutz, Beat/AAG-4538-2022; Thomas, Sarah/C-6796-2009	Thompson, Alan J/0000-0002-4333-8496; Thomas, Sarah/0000-0002-0053-0154; De Faveri, Lia/0000-0002-6685-8806; Mein, Charles/0000-0003-0811-9658; Marsicano, Giovanni/0000-0003-3804-1951; Hardcastle, Alison/0000-0002-0038-6770; Selwood, David/0000-0002-6817-5064; Kooij, Gijs/0000-0002-9488-2918	Atlantic Ventures Inc.; MRC [MC_PC_13037] Funding Source: UKRI	Atlantic Ventures Inc.; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank the Multiple Sclerosis Society of Great Britain and Northern Ireland, Aims2Cure, the Brain Research Trust, and the Barts and the London Charity. Atlantic Ventures Inc. in part funded spasticity studies involving CT3. Some authors (D. B., G. P., A.J.T., and G. G.) are named inventors on a patent relating to the use of CT3, but receive no financial reward from this.	AdamWorrall J., 2007, Patent, Patent No. [WO2007006732, 2007006732]; Agarwal N, 2007, NAT NEUROSCI, V10, P870, DOI 10.1038/nn1916; Al-Izki S, 2012, MULT SCLER RELAT DIS, V1, P29, DOI 10.1016/j.msard.2011.09.001; Al-Izki S, 2011, MULT SCLER J, V17, P939, DOI 10.1177/1352458511400476; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Baker D, 2012, MULT SCLER RELAT DIS, V1, P64, DOI 10.1016/j.msard.2011.11.001; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Bonhomme-Faivre L, 2008, ADDICT BIOL, V13, P295, DOI 10.1111/j.1369-1600.2008.00096.x; Brain C. T., 2003, Patent, Patent No. [03066603, WO03066603]; Burstein SH, 2004, LIFE SCI, V75, P1513, DOI 10.1016/j.lfs.2004.04.010; Carl SM, 2010, MOL PHARMACEUT, V7, P1057, DOI 10.1021/mp900178j; Chia R, 2005, NAT GENET, V37, P1181, DOI 10.1038/ng1665; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Corey-Bloom J, 2012, CAN MED ASSOC J, V184, P1143, DOI 10.1503/cmaj.110837; Dyson A, 2005, PAIN, V116, P129, DOI 10.1016/j.pain.2005.03.037; Dziadulewicz EK, 2007, J MED CHEM, V50, P3851, DOI 10.1021/jm070317a; Hendrikse NH, 1998, BRIT J PHARMACOL, V124, P1413, DOI 10.1038/sj.bjp.0701979; Hiragata S, 2007, UROLOGY, V70, P202, DOI 10.1016/j.urology.2007.02.069; Holland ML, 2007, BRIT J PHARMACOL, V152, P815, DOI 10.1038/sj.bjp.0707467; Holland ML, 2008, EUR J PHARMACOL, V591, P128, DOI 10.1016/j.ejphar.2008.06.079; Holland ML, 2006, BIOCHEM PHARMACOL, V71, P1146, DOI 10.1016/j.bcp.2005.12.033; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Huestis MA, 2007, PSYCHOPHARMACOLOGY, V194, P505, DOI 10.1007/s00213-007-0861-5; Karst M, 2007, J PHARMACOL EXP THER, V322, P420, DOI 10.1124/jpet.107.124214; Katona I., 2006, ANNU REV NEUROSCI, V35, P529; Keane TM, 2011, NATURE, V477, P289, DOI 10.1038/nature10413; Kheder Ammar, 2012, Pract Neurol, V12, P289, DOI 10.1136/practneurol-2011-000155; Kooij G, 2010, J AUTOIMMUN, V34, P416, DOI 10.1016/j.jaut.2009.10.006; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lankas GR, 1997, TOXICOL APPL PHARM, V143, P357, DOI 10.1006/taap.1996.8086; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Loscher Wolfgang, 2005, NeuroRx, V2, P86, DOI 10.1007/BF03206645; Maresz K, 2007, NAT MED, V13, P492, DOI 10.1038/nm1561; Martin BR, 2006, J PHARMACOL EXP THER, V318, P1230, DOI 10.1124/jpet.106.104109; Musumeci G, 2011, NEUROBIOL DIS, V43, P669, DOI 10.1016/j.nbd.2011.05.018; Nielsen JB, 2007, ACTA PHYSIOL, V189, P171, DOI 10.1111/j.1748-1716.2006.01652.x; Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468-1331.2010.03328.x; Omura S, 2008, INT J ANTIMICROB AG, V31, P91, DOI 10.1016/j.ijantimicag.2007.08.023; Pawarode A, 2007, CANCER CHEMOTH PHARM, V60, P179, DOI 10.1007/s00280-006-0357-8; Pippert TR, 2001, J BIOCHEM MOL TOXIC, V15, P83, DOI 10.1002/jbt.3; Pryce G, 2007, BRIT J PHARMACOL, V150, P519, DOI 10.1038/sj.bjp.0707003; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; Rawls SM, 2002, J PHARMACOL EXP THER, V301, P963, DOI 10.1124/jpet.301.3.963; Rishton GM, 2006, CURR OPIN DRUG DISC, V9, P303; Vann RE, 2007, J PHARMACOL EXP THER, V320, P678, DOI 10.1124/jpet.106.111625; Varvel SA, 2005, J PHARMACOL EXP THER, V314, P329, DOI 10.1124/jpet.104.080739; Wilkinson JD, 2003, J PHARM PHARMACOL, V55, P1687, DOI 10.1211/0022357022304; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; Zajicek J. P., 2012, J NEUROL NEUROSUR PS, V83, P1125; Zhou L, 2002, FEBS LETT, V523, P68, DOI 10.1016/S0014-5793(02)02936-8	50	23	23	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					117	130		10.1096/fj.13-239442	http://dx.doi.org/10.1096/fj.13-239442			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24121462				2022-12-28	WOS:000333526100014
J	Spadaro, M; Montone, M; Arigoni, M; Cantarella, D; Forni, G; Pericle, F; Pascolo, S; Calogero, RA; Cavallo, F				Spadaro, Michela; Montone, Monica; Arigoni, Maddalena; Cantarella, Daniela; Forni, Guido; Pericle, Federica; Pascolo, Steve; Calogero, Raffaele A.; Cavallo, Federica			Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4	FASEB JOURNAL			English	Article						alarmins; pattern recognition receptors	TALACTOFERRIN ALPHA; CYTOKINE PRODUCTION; ORAL TALACTOFERRIN; GENE-EXPRESSION; NATURAL-KILLER; MESSENGER-RNA; BIOCONDUCTOR; INDUCTION; IMMUNITY; PROTEIN	Lactoferrin, a key component of innate immunity, is a cationic monomeric 80-kDa glycoprotein of the transferrin superfamily. Recombinant human lactoferrin, known as talactoferrin (TLF), induces a distinct functional maturation program in human dendritic cells (DCs) derived from peripheral blood monocytes. However, the receptors and molecular mechanisms involved in this induction have not been fully determined. By exploiting genome-wide transcription profiling of immature DCs, TNF-- and IL-1-matured DCs (m-DCs), and TLF-matured DCs (TLF-DCs), we have detected a set of transcripts specific for m-DCs and one specific for TLF-DCs. Functional network reconstruction highlighted, as expected, the association of m-DC maturation with IL-1, TNF-, and NF-B, whereas TLF-DC maturation was associated with ERK and NF-B. This involvement of ERK and NF-B transduction factors suggests direct involvement of Toll-like receptors (TLRs) in TLF-induced maturation. We have used MyD88 inhibition and siRNA silencing TLRs on human DCs and mouse TLR-2-knockout cells, to show that TLF triggers the maturation of both human and mouse DCs through TLR-2 and TLR-4.Spadaro, M., Montone, M., Arigoni, M., Cantarella, D., Forni, G., Pericle, F., Pascolo, S., Calogero, R. A., Cavallo, F. Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4.	[Spadaro, Michela; Montone, Monica; Arigoni, Maddalena; Forni, Guido; Calogero, Raffaele A.; Cavallo, Federica] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Cantarella, Daniela] Univ Turin, Lab Funct Genom, Oncogen Ctr, Inst Canc Res & Treatment,Sch Med, I-10126 Turin, Italy; [Pericle, Federica] Univ Texas El Paso, Ctr Res Entrepreneurship & Innovat Enterprise, El Paso, TX 79968 USA; [Pascolo, Steve] Univ Zurich Hosp, Dept Oncol, CH-8091 Zurich, Switzerland	University of Turin; University of Turin; University of Texas System; University of Texas El Paso; University of Zurich; University Zurich Hospital	Cavallo, F (corresponding author), Univ Turin, Dept Mol Biotechnol & Hlth Sci, Ctr Mol Biotechnol, Via Nizza 52, I-10126 Turin, Italy.	federica.cavallo@unito.it	Spadaro, Michela/F-1399-2016; Calogero, Raffaele/K-9428-2019; Cavallo, Federica/C-5666-2011	Calogero, Raffaele/0000-0002-2848-628X; Arigoni, Maddalena/0000-0003-4629-3841; Spadaro, Michela/0000-0001-7544-8879; CANTARELLA, DANIELA/0000-0001-6135-2032; MONTONE, MONICA/0000-0001-7907-4333; Cavallo, Federica/0000-0003-4571-1060	Italian Association for Cancer Research (AIRC) [IG 5377]; Fondazione Ricerca Molinette (FRM) Onlus; University of Torino; Regione Piemonte; Agennix, Inc. (Houston, TX, USA)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Ricerca Molinette (FRM) Onlus; University of Torino; Regione Piemonte(Regione Piemonte); Agennix, Inc. (Houston, TX, USA)	This study was supported by grants from the Italian Association for Cancer Research (AIRC; IG 5377), the Fondazione Ricerca Molinette (FRM) Onlus, the University of Torino, the Regione Piemonte, and by research funding from Agennix, Inc. (Houston, TX, USA).	Actor JK, 2009, CURR PHARM DESIGN, V15, P1956, DOI 10.2174/138161209788453202; Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Ando K, 2010, FEBS J, V277, P2051, DOI 10.1111/j.1742-4658.2010.07620.x; Baker EN, 2009, BIOCHIMIE, V91, P3, DOI 10.1016/j.biochi.2008.05.006; Barton GM, 2009, NAT REV IMMUNOL, V9, P535, DOI 10.1038/nri2587; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bournazou I, 2009, J CLIN INVEST, V119, P20, DOI 10.1172/JCI36226; Castiello L, 2011, CANCER IMMUNOL IMMUN, V60, P457, DOI 10.1007/s00262-010-0954-6; Collins CA, 2008, DEV BIOL, V324, P55, DOI 10.1016/j.ydbio.2008.08.034; Cumberbatch M, 2003, CLIN EXP IMMUNOL, V132, P352, DOI 10.1046/j.1365-2249.2003.02146.x; Curran CS, 2006, CELL IMMUNOL, V242, P23, DOI 10.1016/j.cellimm.2006.08.006; De la Rosa G, 2008, J IMMUNOL, V180, P6868, DOI 10.4049/jimmunol.180.10.6868; Dietz AB, 2000, BIOCHEM BIOPH RES CO, V275, P731, DOI 10.1006/bbrc.2000.3372; Fan Jie, 2010, Open Crit Care Med J, V2, P1; GAHR M, 1991, J LEUKOCYTE BIOL, V49, P427, DOI 10.1002/jlb.49.5.427; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giermasz AS, 2009, CANCER IMMUNOL IMMUN, V58, P1329, DOI 10.1007/s00262-008-0648-5; Gonzalez-Chavez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020; Haversen L, 2002, CELL IMMUNOL, V220, P83, DOI 10.1016/S0008-8749(03)00006-6; Hayes TG, 2010, INVEST NEW DRUG, V28, P156, DOI 10.1007/s10637-009-9233-9; Hayes TG, 2006, INVEST NEW DRUG, V24, P233, DOI 10.1007/s10637-005-3690-6; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jagannathan M, 2009, J IMMUNOL, V183, P7461, DOI 10.4049/jimmunol.0901517; Joffre O, 2009, IMMUNOL REV, V227, P234, DOI 10.1111/j.1600-065X.2008.00718.x; Jonasch E, 2008, CANCER-AM CANCER SOC, V113, P72, DOI 10.1002/cncr.23519; Kalinski P, 2009, FUTURE ONCOL, V5, P379, DOI [10.2217/fon.09.6, 10.2217/FON.09.6]; Kelly RJ, 2010, EXPERT OPIN BIOL TH, V10, P1379, DOI 10.1517/14712598.2010.512914; Legrand D, 2010, BIOMETALS, V23, P365, DOI 10.1007/s10534-010-9297-1; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Mehra A, 2003, BIOTECHNOL BIOENG, V84, P822, DOI 10.1002/bit.10860; Morris A, 2001, BREAST CANCER RES TR, V67, P71, DOI 10.1023/A:1010649303056; NISHIYA K, 1982, J IMMUNOL, V129, P2519; Ostuni R, 2010, CELL MOL LIFE SCI, V67, P4109, DOI 10.1007/s00018-010-0464-x; Puddu P, 2010, BIOMETALS, V23, P387, DOI 10.1007/s10534-010-9307-3; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; Shebl FM, 2010, CANCER EPIDEM BIOMAR, V19, P978, DOI 10.1158/1055-9965.EPI-10-0064; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Spadaro M, 2008, FASEB J, V22, P2747, DOI 10.1096/fj.07-098038; Spadaro M, 2007, CANCER RES, V67, P6425, DOI 10.1158/0008-5472.CAN-06-4080; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; Varadhachary A, 2004, INT J CANCER, V111, P398, DOI 10.1002/ijc.20271; Vesela R, 2011, CELL IMMUNOL, V271, P78, DOI 10.1016/j.cellimm.2011.06.006; Von Heydebreck A., 2004, COLLECTION BIOSTAT R; Watts C, 2010, CURR OPIN IMMUNOL, V22, P124, DOI 10.1016/j.coi.2009.12.005; Yang D, 2009, TRENDS IMMUNOL, V30, P531, DOI 10.1016/j.it.2009.07.004	51	27	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					416	429		10.1096/fj.13-229591	http://dx.doi.org/10.1096/fj.13-229591			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24088817				2022-12-28	WOS:000333526100039
J	Yang, J; Zheng, W; Wang, Q; Lara, C; Hussein, S; Chen, XZ				Yang, Jungwoo; Zheng, Wang; Wang, Qian; Lara, Carlos; Hussein, Shaimaa; Chen, Xing-Zhen			Translational up-regulation of polycystic kidney disease protein PKD2 by endoplasmic reticulum stress	FASEB JOURNAL			English	Article						ADPKD; P-eIF2 alpha; uORF	ACTIVATION; PERK; RNA; DEPHOSPHORYLATION; PHOSPHORYLATION; PROLIFERATION; DEGRADATION; EIF2-ALPHA; MECHANISMS; ISCHEMIA	Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 or PKD2, and it affects over 10 million people worldwide. It is characterized by cyst formation in the kidney, liver and pancreas. Dosage changes in PKD1/PKD2 are important in ADPKD pathogenesis; therefore, their expression and function has to be strictly regulated. However, how they are regulated remain poorly understood. Recent studies have linked PKD2 regulation to endoplasmic reticulum (ER) stress that is implicated in neuronal, cardiac, and renal diseases. One major ER stress downstream is phosphorylation of eukaryotic initiation factor eIF2 alpha by kinase PERK, which attenuates global protein translation and enhances translation of selected proteins. Here, we showed in several mammalian cell lines that PKD2 protein expression is upregulated by different stresses that all increase phosphorylated eIF2 alpha (P-eIF2 alpha). Increasing P-eIF2 alpha by overexpression or inhibiting the phosphatase activity resulted in increased PKD2. PCR and polysome-binding assays showed that ER stress does not affect the PKD2 mRNA level but increase its binding with ribosomes, indicating that P-eIF2 alpha translationally up-regulates PKD2. By mutation analysis, we found that the upstream open reading frame (uORF) in the 5'-untrans-lated region of PKD2 mRNA represses PKD2 translation. Thus, ER stress and P-eIF2 alpha translationally upregulates PKD2 through bypassing the inhibitory uORF.	[Yang, Jungwoo; Zheng, Wang; Wang, Qian; Lara, Carlos; Hussein, Shaimaa; Chen, Xing-Zhen] Univ Alberta, Fac Med & Dent, Dept Physiol, Membrane Prot Dis Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Chen, XZ (corresponding author), Univ Alberta, Fac Med & Dent, Dept Physiol, Membrane Prot Dis Res Grp, 7-29 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	xzchen@ualberta.ca	Hussein, Shaimaa/HHZ-5533-2022	Hussein, Shaimaa/0000-0003-0849-9670	Canadian Institutes of Health Research; Kidney Foundation of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Kidney Foundation of Canada	The authors thank Dr. David Ron (New York University, New York, NY, USA) for providing Myc-tagged PERK, eIF2 alpha, eIF2 alpha-S51A, and Flag-tagged Gadd34 plasmids, and PERK<SUP>+/+</SUP> and PERK<SUP>-/-</SUP> MEF cells. PKD2<SUP>+/+</SUP> and PKD2<SUP>-/-</SUP> MCD cells were kindly provided by Dr. Guanqing Wu (Vanderbilt University, Nashville, TN, USA). This work was supported by grants from the Canadian Institutes of Health Research and Kidney Foundation of Canada (to X.Z.C.). X.Z.C. is a Senior Scholar of Alberta Innovates-Health Solutions.	Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chapin HC, 2010, J CELL BIOL, V191, P701, DOI 10.1083/jcb.201006173; Cybulsky AV, 2010, KIDNEY INT, V77, P187, DOI 10.1038/ki.2009.389; Dey S, 2010, J BIOL CHEM, V285, P33165, DOI 10.1074/jbc.M110.167213; Dickhout JG, 2011, CIRC RES, V108, P629, DOI 10.1161/CIRCRESAHA.110.226803; Dickhout JG, 2009, ANTIOXID REDOX SIGN, V11, P2341, DOI [10.1089/ars.2009.2705, 10.1089/ARS.2009.2705]; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Ghosh HS, 2011, SCI REP-UK, V1, DOI 10.1038/srep00150; Grimm DH, 2006, J BIOL CHEM, V281, P137, DOI 10.1074/jbc.M507845200; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harris PC, 2010, J AM SOC NEPHROL, V21, P1073, DOI 10.1681/ASN.2010030328; Inagi R, 2009, NEPHRON EXP NEPHROL, V112, pE1, DOI 10.1159/000210573; Kim I, 2009, J AM SOC NEPHROL, V20, P2556, DOI 10.1681/ASN.2009030271; Kitamura M, 2008, AM J PHYSIOL-RENAL, V295, pF323, DOI 10.1152/ajprenal.00050.2008; Kurbegovic A, 2010, HUM MOL GENET, V19, P1174, DOI 10.1093/hmg/ddp588; Lass A, 2007, ARCH BIOCHEM BIOPHYS, V462, P62, DOI 10.1016/j.abb.2007.04.010; Lee YY, 2009, J BIOL CHEM, V284, P6661, DOI 10.1074/jbc.M806735200; Liang GQ, 2008, HUM MOL GENET, V17, P3254, DOI 10.1093/hmg/ddn221; Liang GQ, 2008, HUM MOL GENET, V17, P1109, DOI 10.1093/hmg/ddm383; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marciniak SJ, 2006, J CELL BIOL, V172, P201, DOI 10.1083/jcb.200508099; Matsui Y, 2008, AUTOPHAGY, V4, P409, DOI 10.4161/auto.5638; McEwen E, 2005, J BIOL CHEM, V280, P16925, DOI 10.1074/jbc.M412882200; Montie HL, 2005, BBA-MOL BASIS DIS, V1741, P314, DOI 10.1016/j.bbadis.2005.04.007; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Obara T, 2006, J AM SOC NEPHROL, V17, P2706, DOI 10.1681/ASN.2006040412; Palam LR, 2011, J BIOL CHEM, V286, P10939, DOI 10.1074/jbc.M110.216093; Park EY, 2009, J BIOL CHEM, V284, P7214, DOI 10.1074/jbc.M805890200; Prasad S, 2009, AM J PATHOL, V175, P1493, DOI 10.2353/ajpath.2009.090227; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rutkowski DT, 2007, TRENDS BIOCHEM SCI, V32, P469, DOI 10.1016/j.tibs.2007.09.003; Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900; Sammarco MC, 2005, ANAL BIOCHEM, V346, P210, DOI 10.1016/j.ab.2005.08.033; Serra AL, 2010, NEW ENGL J MED, V363, P820, DOI 10.1056/NEJMoa0907419; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Torres VE, 2012, NEW ENGL J MED, V367, P2407, DOI 10.1056/NEJMoa1205511; Tran U, 2010, DEVELOPMENT, V137, P1107, DOI 10.1242/dev.046045; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Walz G, 2010, NEW ENGL J MED, V363, P830, DOI 10.1056/NEJMoa1003491; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Wegierski T, 2009, EMBO J, V28, P490, DOI 10.1038/emboj.2008.307; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Wu YL, 2006, HUM MOL GENET, V15, P3280, DOI 10.1093/hmg/ddl404; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhao Y, 2002, NEPHROL DIAL TRANSPL, V17, P2138, DOI 10.1093/ndt/17.12.2138	55	9	9	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4998	5009		10.1096/fj.13-236075	http://dx.doi.org/10.1096/fj.13-236075			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23985800				2022-12-28	WOS:000329999000033
J	Coura, RS; Cressant, A; Xia, J; de Chaumont, F; Olivo-Marin, JC; Pelloux, Y; Dalley, JW; Granon, S				Coura, Renata S.; Cressant, Arnaud; Xia, Jing; de Chaumont, Fabrice; Olivo-Marin, Jean Christophe; Pelloux, Yann; Dalley, Jeffrey W.; Granon, Sylvie			Nonaggressive and adapted social cognition is controlled by the interplay between noradrenergic and nicotinic receptor mechanisms in the prefrontal cortex	FASEB JOURNAL			English	Article						norepinephine; decision making; dopamine; 5-HT	ACETYLCHOLINE-RECEPTOR; LOCUS-COERULEUS; MODULATION; MOUSE; NOREPINEPHRINE; ATTENTION; RELEASE; EXPRESSION; MODEL; BRAIN	Social animals establish flexible behaviors and integrated decision-making processes to adapt to social environments. Such behaviors are impaired in all major neuropsychiatric disorders and depend on the prefrontal cortex (PFC). We previously showed that nicotinic acetylcholine receptors (nAChRs) and norepinephrine (NE) in the PFC are necessary for mice to show adapted social cognition. Here, we investigated how the cholinergic and NE systems converge within the PFC to modulate social behavior. We used a social interaction task (SIT) in C57BL/6 mice and mice lacking 2*nAChRs (2(-/-) mice), making use of dedicated software to analyze >20 social sequences and pinpoint social decisions. We performed specific PFC NE depletions before SIT and measured monoamines and acetylcholine (ACh) levels in limbic corticostriatal circuitry. After PFC-NE depletion, C57BL/6 mice exhibited impoverished and more rigid social behavior and were 6-fold more aggressive than sham-lesioned animals, whereas 2(-/-) mice showed unimpaired social behavior. Our biochemical measures suggest a critical involvement of DA in SIT. In addition, we show that the balance between basal levels of monoamines and of ACh modulates aggressiveness and this modulation requires functional 2*nAChRs. These findings demonstrate the critical interplay between prefrontal NE and nAChRs for the development of adapted and nonaggressive social cognition.Coura, R. S., Cressant, A., Xia, J., de Chaumont, F., Olivo-Marin, J. C., Pelloux, Y., Dalley, J. W., Granon, S. Nonaggressive and adapted social cognition is controlled by the interplay between noradrenergic and nicotinic receptor mechanisms in the prefrontal cortex.	[Coura, Renata S.; Cressant, Arnaud; Granon, Sylvie] Univ Paris 11, Ctr Neurosci Paris Sud, UMR 8195, F-91405 Orsay, France; [Xia, Jing; Pelloux, Yann; Dalley, Jeffrey W.] Univ Cambridge, Addenbrookes Hosp, Behav & Clin Neurosci Inst, Cambridge CB2 2QQ, England; [Xia, Jing; Pelloux, Yann; Dalley, Jeffrey W.] Univ Cambridge, Addenbrookes Hosp, Dept Psychol, Cambridge CB2 2QQ, England; [Dalley, Jeffrey W.] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England; [de Chaumont, Fabrice; Olivo-Marin, Jean Christophe] Inst Pasteur, CNRS, Unite Anal Images Quantitat, Unite Rech Assoc 2582, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite Jean Monnet; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Granon, S (corresponding author), Univ Paris 11, Ctr Neurosci Paris Sud, UMR 8195, F-91405 Orsay, France.	sylvie.granon@u-psud.fr	Olivo-Marin, Jean-Christophe/K-4428-2015; Granon, Sylvie/J-9224-2019	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; Pelloux, Yann/0000-0001-8262-9969; Granon, sylvie/0000-0001-9384-3119; de Chaumont, Fabrice/0000-0001-7613-7204; Dalley, Jeffrey/0000-0002-2282-3660	Centre National de la Recherche Scientifique, an Agence pour la Recherche; chaire d'excellence from Paris Sud University; Welcome Trust; Medical Research Council; Behavioral and Clinical Neuroscience Institute at Cambridge University; Medical Research Council [G0001354, G0001354B, G1000183B] Funding Source: researchfish	Centre National de la Recherche Scientifique, an Agence pour la Recherche; chaire d'excellence from Paris Sud University; Welcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Behavioral and Clinical Neuroscience Institute at Cambridge University; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was partly supported by the Centre National de la Recherche Scientifique, an Agence pour la Recherche grant (to S. G. and J.C.O.-M.) and a chaire d'excellence from Paris Sud University (to S. G.). This work was partly supported by the Welcome Trust and Medical Research Council in support of the Behavioral and Clinical Neuroscience Institute at Cambridge University. The authors thank Jean-Antoine Girault, Denis Herve, and David Belin for the revision and for enriching discussions. The authors declare no conflicts of interest. Author contributions: R. C. and A. C. performed and analyzed experiments; J.X. performed neurochemical analysis; R. C. conducted statistical analyses and wrote the manuscript; Y.P. participated in the biochemical analyses; F. D. C and J.C.O.-M. created the tracking and analysis methods for automatical behavior analysis; J.D. and J.C.O.-M. wrote the manuscript; S. G. conceived the project, conducted statistical analysis and wrote the manuscript.	Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.biopsych.2004.08.019; Aston-Jones G, 1999, BIOL PSYCHIAT, V46, P1309, DOI 10.1016/S0006-3223(99)00140-7; Audet MC, 2010, INT J NEUROPSYCHOPH, V13, P361, DOI 10.1017/S1461145709990174; Avale ME, 2008, P NATL ACAD SCI USA, V105, P15991, DOI 10.1073/pnas.0807635105; Avale ME, 2011, FASEB J, V25, P2145, DOI 10.1096/fj.10-178558; Azam L, 2006, MOL PHARMACOL, V70, P967, DOI 10.1124/mol.106.024513; Bouret S, 2005, TRENDS NEUROSCI, V28, P574, DOI 10.1016/j.tins.2005.09.002; Bourgeois JP, 2012, CEREB CORTEX, V22, P1007, DOI 10.1093/cercor/bhr159; Briand LA, 2007, PROG NEUROBIOL, V83, P69, DOI 10.1016/j.pneurobio.2007.06.007; Briley M S, 1977, Int Rev Neurobiol, V20, P31, DOI 10.1016/S0074-7742(08)60650-9; Cambon K, 2010, NEUROSCIENCE, V171, P840, DOI 10.1016/j.neuroscience.2010.09.015; Chabout J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029401; Chan WK, 2007, NEUROPHARMACOLOGY, V52, P1641, DOI 10.1016/j.neuropharm.2007.03.008; Changeux JP, 2010, ANNU REV PHARMACOL, V50, P1, DOI 10.1146/annurev.pharmtox.010909.105741; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Coura RD, 2012, PSYCHOPHARMACOLOGY, V221, P1, DOI 10.1007/s00213-011-2596-6; Crawley Jacqueline N., 2007, WHATS WRONG MY MOUSE; CROWCROFT PETER, 1963, PROC ZOOL SOC LONDON, V140, P517; Cusi AM, 2012, J PSYCHIATR NEUROSCI, V37, P154, DOI 10.1503/jpn.100179; Dalley JW, 2004, NEUROSCI BIOBEHAV R, V28, P771, DOI 10.1016/j.neubiorev.2004.09.006; Dalley JW, 2002, NEUROPSYCHOPHARMACOL, V26, P716, DOI 10.1016/S0893-133X(01)00412-2; Dalley JW, 2001, J NEUROSCI, V21, P4908, DOI 10.1523/JNEUROSCI.21-13-04908.2001; Dayan P, 2006, NETWORK-COMP NEURAL, V17, P335, DOI 10.1080/09548980601004024; de Chaumont F, 2012, NAT METHODS, V9, P410, DOI [10.1038/NMETH.1924, 10.1038/nmeth.1924]; Dreher JC, 2009, P NATL ACAD SCI USA, V106, P617, DOI 10.1073/pnas.0805517106; Fett AKJ, 2011, NEUROSCI BIOBEHAV R, V35, P573, DOI 10.1016/j.neubiorev.2010.07.001; Franberg O, 2012, SYNAPSE, V66, P650, DOI 10.1002/syn.21551; Gallistel CR, 2004, J EXP PSYCHOL ANIM B, V30, P3, DOI 10.1037/0097-7403.30.1.3; Gamo NJ, 2011, BEHAV NEUROSCI, V125, P282, DOI 10.1037/a0023165; Giammanco M, 2005, MED SCI MONITOR, V11, pRA136; GOLANI I, 1993, BEHAV BRAIN RES, V53, P21, DOI 10.1016/S0166-4328(05)80263-3; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; Granon S, 2003, P NATL ACAD SCI USA, V100, P9596, DOI 10.1073/pnas.1533498100; GRANON S, 1995, PSYCHOPHARMACOLOGY, V119, P139, DOI 10.1007/BF02246154; Granon S, 2006, ACTA PAEDIATR, V95, P645, DOI 10.1080/08035250600719747; Grant S, 2009, ELECTRONIC PORTFOLIOS: PERSONAL INFORMATION, PERSONAL DEVELOPMENT AND PERSONAL VALUES, P83; Guillem K, 2011, SCIENCE, V333, P888, DOI 10.1126/science.1207079; Hasler G, 2010, WORLD PSYCHIATRY, V9, P155; Jamain S, 2008, P NATL ACAD SCI USA, V105, P1710, DOI 10.1073/pnas.0711555105; King HM, 2012, PSYCHONEUROENDOCRINO, V37, P396, DOI 10.1016/j.psyneuen.2011.07.010; Kohls G, 2009, DEVELOPMENTAL SCI, V12, P614, DOI 10.1111/j.1467-7687.2009.00816.x; Layne JE, 2003, J EXP BIOL, V206, P4425, DOI 10.1242/jeb.00661; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; Li XH, 2002, ANESTHESIOLOGY, V96, P1450, DOI 10.1097/00000542-200206000-00026; Livingstone PD, 2009, BIOCHEM PHARMACOL, V78, P744, DOI 10.1016/j.bcp.2009.06.004; Lucas-Meunier E, 2003, PFLUG ARCH EUR J PHY, V446, P17, DOI 10.1007/s00424-002-0999-2; Maloku E, 2011, NEUROPSYCHOPHARMACOL, V36, P1366, DOI 10.1038/npp.2011.21; Mansvelder HD, 2006, PSYCHOPHARMACOLOGY, V184, P292, DOI 10.1007/s00213-005-0070-z; Marshall DL, 1997, J NEUROCHEM, V68, P1511; Martin-Ruiz CM, 2003, BIOL PSYCHIAT, V54, P1222, DOI 10.1016/S0006-3223(03)00348-2; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; Maubourguet N, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000229; McGaughy J, 2008, NEUROSCIENCE, V153, P63, DOI 10.1016/j.neuroscience.2008.01.064; Moret Chantal, 2011, Neuropsychiatr Dis Treat, V7, P9, DOI 10.2147/NDT.S19619; Morice E, 2007, NEUROPSYCHOPHARMACOL, V32, P2108, DOI 10.1038/sj.npp.1301354; Nutt D, 2007, J PSYCHOPHARMACOL, V21, P461, DOI 10.1177/0269881106069938; O'Connell LA, 2012, SCIENCE, V336, P1154, DOI 10.1126/science.1218889; O'Leary KT, 2006, NEUROPHARMACOLOGY, V50, P81, DOI 10.1016/j.neuropharm.2005.08.013; O'Leary KT, 2003, J NEUROCHEM, V84, P952, DOI 10.1046/j.1471-4159.2003.01575.x; O'Leary OF, 2007, EUR NEUROPSYCHOPHARM, V17, P215, DOI 10.1016/j.euroneuro.2006.06.012; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Robbins TW, 1998, ANN NY ACAD SCI, V846, P222, DOI 10.1111/j.1749-6632.1998.tb09740.x; RORABACHER DB, 1991, ANAL CHEM, V63, P139, DOI 10.1021/ac00002a010; Scarr E, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00055; Schliebs R, 2011, BEHAV BRAIN RES, V221, P555, DOI 10.1016/j.bbr.2010.11.058; Serreau P, 2011, BEHAV BRAIN RES, V225, P151, DOI 10.1016/j.bbr.2011.07.016; Siever LJ, 2004, AM J PSYCHIAT, V161, P398, DOI 10.1176/appi.ajp.161.3.398; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Siuta MA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000393; Tait DS, 2007, EUR J NEUROSCI, V25, P3719, DOI 10.1111/j.1460-9568.2007.05612.x; Taly A, 2009, NAT REV DRUG DISCOV, V8, P733, DOI 10.1038/nrd2927; TANDON R, 1989, ARCH GEN PSYCHIAT, V46, P745; TOTH E, 1992, NEUROCHEM RES, V17, P265, DOI 10.1007/BF00966669; Ventura R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003044; Vizi ES, 1999, BRAIN RES REV, V30, P219, DOI 10.1016/S0165-0173(99)00016-8; Yamamoto K, 2004, PROG NEURO-PSYCHOPH, V28, P913, DOI 10.1016/j.pnpbp.2004.05.033; Yu AJ, 2005, NEURON, V46, P681, DOI 10.1016/j.neuron.2005.04.026; Zhou FM, 2001, NAT NEUROSCI, V4, P1224, DOI 10.1038/nn769	81	26	26	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4343	4354		10.1096/fj.13-231084	http://dx.doi.org/10.1096/fj.13-231084			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23882123	Green Published, hybrid			2022-12-28	WOS:000329937500003
J	Plieskatt, JL; Deenonpoe, R; Mulvenna, JP; Krause, L; Sripa, B; Bethony, JM; Brindley, PJ				Plieskatt, Jordan L.; Deenonpoe, Raksawan; Mulvenna, Jason P.; Krause, Lutz; Sripa, Banchob; Bethony, Jeffrey M.; Brindley, Paul J.			Infection with the carcinogenic liver fluke Opisthorchis viverrini modifies intestinal and biliary microbiome	FASEB JOURNAL			English	Article						opisthorchiasis; microbiota; neglected tropical disease; infection-related cancer; cholangiocarcinoma	16S RIBOSOMAL-RNA; HELICOBACTER-PYLORI; GUT MICROBIOTA; GENE-EXPRESSION; GASTRIC-CANCER; BILE-ACID; HIGH-RISK; CHOLANGIOCARCINOMA; INFLAMMATION; DIAGNOSIS	Opisthorchis viverrini is a fish-borne trematode endemic in East Asia. Following ingestion, the flukes locate to the biliary tree where chronic infection frequently leads to cholangiocarcinoma (CCA). The mechanisms by which O. viverrini infection culminates in CCA remain unknown. An unexplored aspect is its influence on the host microbiome. In the hamster, infection with this pathogen reliably leads to CCA. Genomic DNAs of microbiota from colorectal contents and bile of hamsters and from whole O. viverrini were examined in this model of fluke-induced CCA. Microbial communities were characterized by high-throughput sequencing of variable regions 7-9 of prokaryotic 16S ribosomal DNA. Of approximate to 1 million sequences, 536,009 with useable reads were assignable to 29,776 operational taxonomy units (OTUs) and, in turn, to 20 phyla and 273 genera of Bacteria or Archaea. Microbial community analyses revealed that fluke infection perturbed the gastrointestinal tract microbiome, increasing Lachnospiraceae, Ruminococcaceae, and Lactobacillaceae, while decreasing Porphyromonadaceae, Erysipelotrichaceae, and Eubacteriaceae (P0.05). More than 60 OTUs were detected in the biliary system, which confirmed bacteriobilia and a noteworthy community of microbes associated with the parasites. The fluke-associated microorganisms included potential pathogens from the Enterobacteriaceae and Listeriaceae and others, including Cyanobacteria and Deinococci, usually found in external environments. Given that opisthorchiasis is distinguished from other helminth infections by a robust inflammatory phenotype with conspicuously elevated IL-6, and that inflammation of the biliary system leads to periductal fibrosis, which is a precursor of CCA, the flukes and their microbiota may together drive this distinctive immune response.Plieskatt, J. L., Raksawan, D., Mulvenna, J. P., Krause, L., Sripa, B., Bethony, J. M., Brindley, P. J. Infection with the carcinogenic liver fluke Opisthorchis viverrini modifies intestinal and biliary microbiome.	[Plieskatt, Jordan L.; Bethony, Jeffrey M.; Brindley, Paul J.] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA; [Plieskatt, Jordan L.; Bethony, Jeffrey M.; Brindley, Paul J.] George Washington Univ, Sch Med & Hlth Sci, Res Ctr Neglected Trop Dis Poverty, Washington, DC 20052 USA; [Deenonpoe, Raksawan; Sripa, Banchob] Khon Kaen Univ, Dept Pathol, Trop Dis Res Lab, Fac Med, Khon Kaen, Thailand; [Mulvenna, Jason P.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Krause, Lutz] Queensland Inst Med Res, Bioinformat Lab, Brisbane, Qld 4006, Australia	George Washington University; George Washington University; Khon Kaen University; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute	Bethony, JM (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.	jbethony@gwu.edu; pbrindley@gwu.edu	Krause, Lutz/M-7305-2015; Mulvenna, Jason/H-7110-2014	Krause, Lutz/0000-0003-3806-0845; Mulvenna, Jason/0000-0003-3521-8061; Brindley, Paul J./0000-0003-1765-0002; Plieskatt, Jordan/0000-0002-2333-7234; Sripa, Banchob/0000-0001-8899-5919	U.S. National Cancer Institute (NCI) [R01CA155297, R01CA164719]; U.S. National Institute of Allergy and Infectious Disease (NIAID) [P50AI098639]; National Health and Medical Research Council of Australia (NHMRC); Dr. Cyrus and Myrtle Katzen Cancer Research Center at George Washington University (Washington, DC, USA); NATIONAL CANCER INSTITUTE [R01CA164719, R01CA155297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI098639] Funding Source: NIH RePORTER	U.S. National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Dr. Cyrus and Myrtle Katzen Cancer Research Center at George Washington University (Washington, DC, USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Dr. Steven Zeichner for discussions that led to this study and Drs. Victoria Mann and Gabriel Rinaldi for comments on the manuscript. SeqWright, Inc. (Houston, TX, USA) provided bioinformatics advice after performing the pyrosequencing. This work was partially supported by U.S. National Cancer Institute (NCI) grants R01CA155297 to J.M.B. and P.J.B and R01CA164719 to J.P.M. and P.J.B and by U.S. National Institute of Allergy and Infectious Disease (NIAID) grant P50AI098639 to B. S., J.M.B., and P.J.B. J.P.M. is the recipient of a fellowship from the National Health and Medical Research Council of Australia (NHMRC), and P.J.B. and J.M.B. were supported by the Dr. Cyrus and Myrtle Katzen Cancer Research Center at George Washington University (Washington, DC, USA) The contents of the article are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID, NCI, U. S. National Institutes of Health, or NHMRC.	Adams DH, 2006, NAT REV IMMUNOL, V6, P244, DOI 10.1038/nri1784; Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Angiuoli SV, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-356; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; BHAMARAPRAVATI N, 1978, AM J TROP MED HYG, V27, P787, DOI 10.4269/ajtmh.1978.27.787; Blechacz B, 2011, NAT REV GASTRO HEPAT, V8, P512, DOI 10.1038/nrgastro.2011.131; Blekher L, 2000, J CLIN MICROBIOL, V38, P3036, DOI 10.1128/JCM.38.8.3036-3038.2000; Boonyanugomol W, 2012, HPB, V14, P177, DOI 10.1111/j.1477-2574.2011.00423.x; BOUVARD V, 2009, LANCET ONCOL, V10, P321, DOI [DOI 10.1016/S1470-2045(09)70096-8, 10.1016/s1470-2045(09)70096-8]; Broadhurst M. J., 2012, PLOS PATHOG, V8; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carpenter HA, 1998, MAYO CLIN PROC, V73, P473; CHANGBUMRUNG S, 1990, Journal of the Medical Association of Thailand, V73, P81; Chen XM, 2005, J IMMUNOL, V175, P7447, DOI 10.4049/jimmunol.175.11.7447; Cox MM, 2005, NAT REV MICROBIOL, V3, P882, DOI 10.1038/nrmicro1264; CSENDES A, 1975, AM J SURG, V129, P629, DOI 10.1016/0002-9610(75)90334-7; de Martel C, 2010, GASTROEN CLIN BIOL, V34, P173, DOI 10.1016/j.gcb.2010.01.008; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225; Dourado MN, 2012, GENET MOL BIOL, V35, P142, DOI 10.1590/S1415-47572012005000017; Duboc H, 2013, GUT, V62, P531, DOI 10.1136/gutjnl-2012-302578; Eckburg PB, 2003, INFECT IMMUN, V71, P591, DOI 10.1128/IAI.71.2.591-596.2003; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Emerson D, 2010, ANNU REV MICROBIOL, V64, P561, DOI 10.1146/annurev.micro.112408.134208; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Fukata M, 2008, ONCOGENE, V27, P234, DOI 10.1038/sj.onc.1210908; GENDREL D, 1994, CLIN INFECT DIS, V18, P103, DOI 10.1093/clinids/18.1.103; Hamady M, 2009, GENOME RES, V19, P1141, DOI 10.1101/gr.085464.108; HASWELLELKINS MR, 1994, INT J CANCER, V59, P505, DOI 10.1002/ijc.2910590412; Hayes KS, 2010, SCIENCE, V328, P1391, DOI 10.1126/science.1187703; Horz H. P., 2011, J ORAL MICROBIOL, DOI 10.3402/jom.v3i0.5940; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Pharmaceuticals, 2012, IARC MONOGR EVAL CAR, V100, P1; Islam KBMS, 2011, GASTROENTEROLOGY, V141, P1773, DOI 10.1053/j.gastro.2011.07.046; Jensen S, 2010, FEMS MICROBIOL ECOL, V74, P523, DOI 10.1111/j.1574-6941.2010.00981.x; Jinawath N, 2006, HEPATOLOGY, V44, P1025, DOI 10.1002/hep.21330; Johnson Christopher, 2012, Transl Gastrointest Cancer, V1, P58; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; Laha T, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-189; Lange M, 2005, APPL MICROBIOL BIOT, V66, P465, DOI 10.1007/s00253-004-1790-4; Lupp C, 2007, CELL HOST MICROBE, V2, P204, DOI 10.1016/j.chom.2007.08.002; Lvova MN, 2012, PARASITOL INT, V61, P167, DOI 10.1016/j.parint.2011.08.005; Mahlen SD, 2011, CLIN MICROBIOL REV, V24, P755, DOI 10.1128/CMR.00017-11; Mairiang E, 2012, PARASITOL INT, V61, P208, DOI 10.1016/j.parint.2011.07.009; Maurice CF, 2013, CELL, V152, P39, DOI 10.1016/j.cell.2012.10.052; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; Nossa CW, 2010, WORLD J GASTROENTERO, V16, P4135, DOI 10.3748/wjg.v16.i33.4135; O'Hara SP, 2013, J HEPATOL, V58, P575, DOI 10.1016/j.jhep.2012.10.011; O'Hara SP, 2011, J BIOL CHEM, V286, P30352, DOI 10.1074/jbc.M111.269464; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peterfreund GL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046966; Que YA, 2011, NAT REV CARDIOL, V8, P322, DOI 10.1038/nrcardio.2011.43; Razumilava N, 2013, CLIN GASTROENTEROL H, V11, P13, DOI 10.1016/j.cgh.2012.09.009; Robinson MW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002042; Rook GAW, 2012, CLIN REV ALLERG IMMU, V42, P5, DOI 10.1007/s12016-011-8285-8; Ryan MP, 2010, J HOSP INFECT, V75, P153, DOI 10.1016/j.jhin.2010.03.007; Satarug S, 1998, CARCINOGENESIS, V19, P485, DOI 10.1093/carcin/19.3.485; SAUTER C, 1995, LANCET, V346, P1433, DOI 10.1016/S0140-6736(95)92451-5; Schloissnig S, 2013, NATURE, V493, P45, DOI 10.1038/nature11711; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Sithithaworn P, 2012, PARASITOL INT, V61, P10, DOI 10.1016/j.parint.2011.08.014; Sripa B, 2012, TRENDS PARASITOL, V28, P395, DOI 10.1016/j.pt.2012.07.006; Sripa B, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001654; Sripa B, 2011, ACTA TROP, V120, pS158, DOI 10.1016/j.actatropica.2010.07.006; Sripa B, 2009, HEPATOLOGY, V50, P1273, DOI 10.1002/hep.23134; Stauffer JK, 2012, HEPATOLOGY, V56, P1567, DOI 10.1002/hep.25674; Syal G, 2012, AM J PHYSIOL-GASTR L, V303, pG1077, DOI 10.1152/ajpgi.00227.2012; Tajiri T, 2008, WORLD J GASTROENTERO, V14, P3000, DOI 10.3748/wjg.14.3000; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tlaskalova-Hogenova H, 2011, CELL MOL IMMUNOL, V8, P110, DOI 10.1038/cmi.2010.67; Valero MA, 2006, ACTA TROP, V100, P17, DOI 10.1016/j.actatropica.2006.09.002; Virgin HW, 2011, CELL, V147, P44, DOI 10.1016/j.cell.2011.09.009; Walk ST, 2010, INFLAMM BOWEL DIS, V16, P1841, DOI 10.1002/ibd.21299; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Weinstock JV, 2012, NATURE, V491, P183, DOI 10.1038/491183a; White J, 2011, ROUTL FILM GUIDEBOOK, P1; Winter SE, 2013, SCIENCE, V339, P708, DOI 10.1126/science.1232467; Wonkchalee O, 2012, PARASITOL RES, V110, P1213, DOI 10.1007/s00436-011-2616-9; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10	82	101	104	0	52	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4572	4584		10.1096/fj.13-232751	http://dx.doi.org/10.1096/fj.13-232751			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23925654	Green Published			2022-12-28	WOS:000329937500023
J	Zandi-Nejad, K; Takakura, A; Jurewicz, M; Chandraker, AK; Offermanns, S; Mount, D; Abdi, R				Zandi-Nejad, Kambiz; Takakura, Ayumi; Jurewicz, Mollie; Chandraker, Anil K.; Offermanns, Stefan; Mount, David; Abdi, Reza			The role of HCA2 (GPR109A) in regulating macrophage function	FASEB JOURNAL			English	Article						nicotinic acid; inflammation; PUMA-G; HM74A	TUMOR-NECROSIS-FACTOR; NICOTINIC-ACID; CYCLIC-AMP; MOLECULAR-IDENTIFICATION; RHEUMATOID-ARTHRITIS; ADENYLATE-CYCLASE; IFN-GAMMA; PUMA-G; EXPRESSION; RECEPTORS	We investigated the novel role of HCA2 (GPR109A) and its ligand nicotinic acid in regulating macrophage function. Hca2 expression in the RAW264.7 murine macrophage cell line is strongly induced by LPS treatment and correlates with the expression of TNF-. Treatment with 300 M nicotinic acid (reported EC50 3 M, peak plasma concentration 50-300 M), significantly inhibited TNF-, IL-6, IL-12p40, and IL-1 production (P<0.05) in LPS (1 ng/ml)-stimulated wild-type murine bone marrow-derived macrophages (BMMs) but failed to do so in Hca2(-/-) BMMs. Treatment with nicotinic acid reduced nuclear factor B (NF-B) activation levels by 43% (P<0.03) in wild-type BMMs 6 h after LPS stimulation but not in Hca2(-/-) BMMs. Nicotinic acid significantly inhibited wild-type BMM chemotaxis (P<0.001), but had no effect on the chemotaxis of Hca2(-/-) BMMs. A significant increase in low-density lipoprotein uptake by both wild-type (P<0.006) and Hca2(-/-) BMMs (P<0.03) in response to LPS was observed, which was significantly suppressed by nicotinic acid in wild-type BMMs (P<0.04) but not in Hca2(-/-) BMMs. Our results suggest that the nicotinic acid-HCA2 axis is a novel negative regulator of macrophage activation.Zandi-Nejad, K., Takakura, A., Jurewicz, M., Chandraker, A. K., Offermanns, S., Mount, D., Abdi, R. The role of HCA2 (GPR109A) in regulating macrophage function.	[Zandi-Nejad, Kambiz] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA; [Zandi-Nejad, Kambiz; Jurewicz, Mollie; Chandraker, Anil K.; Abdi, Reza] Harvard Univ, Sch Med, Boston, MA USA; [Takakura, Ayumi; Mount, David] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; [Jurewicz, Mollie; Chandraker, Anil K.; Abdi, Reza] Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA; [Offermanns, Stefan] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Max Planck Society	Zandi-Nejad, K (corresponding author), Div Nephrol, 330 Brookline Ave,E RN 304, Boston, MA 02215 USA.	kzandi@bidmc.harvard.edu	Chandraker, Anil/L-3908-2019; Offermanns, Stefan/L-3313-2017	Jurewicz, Mollie/0000-0001-8482-3060; Offermanns, Stefan/0000-0001-8676-6805	Genzyme Renal Innovation Program (GRIP) grant from Genzyme (Cambridge, MA, USA); American Heart Association; U.S. National Institutes of Health [DK070756, DK57708, RO1-AI091930-01A 1]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057708, P01DK070756] Funding Source: NIH RePORTER	Genzyme Renal Innovation Program (GRIP) grant from Genzyme (Cambridge, MA, USA); American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported, in part, by a Genzyme Renal Innovation Program (GRIP) grant from Genzyme (Cambridge, MA, USA) (K.Z.-N.), a Scientist Development grant from the American Heart Association (A. T.), and U.S. National Institutes of Health grants DK070756 and DK57708 (D. M.), and RO1-AI091930-01A 1 (R. A.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, American Heart Association, or Genzyme.	Agarwal N, 2009, NATURE, V460, P98, DOI 10.1038/nature08123; AKTORIES K, 1980, FEBS LETT, V115, P11, DOI 10.1016/0014-5793(80)80715-0; AKTORIES K, 1980, N-S ARCH PHARMACOL, V312, P167, DOI 10.1007/BF00569726; Amichay D, 1996, J IMMUNOL, V157, P4511; BARATH P, 1990, AM J CARDIOL, V65, P297, DOI 10.1016/0002-9149(90)90291-8; Benyo Z, 2005, J CLIN INVEST, V115, P3634, DOI 10.1172/JCI23626; BUTCHER RW, 1968, J BIOL CHEM, V243, P1705; CARLSON LA, 1968, ACTA MED SCAND, V183, P423; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075; Deane KD, 2010, ARTHRITIS RHEUM-US, V62, P3161, DOI 10.1002/art.27638; Digby JE, 2012, ARTERIOSCL THROM VAS, V32, P669, DOI 10.1161/ATVBAHA.111.241836; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FUNK JL, 1993, ATHEROSCLEROSIS, V98, P67, DOI 10.1016/0021-9150(93)90224-I; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; Hertz AL, 2009, P NATL ACAD SCI USA, V106, P21978, DOI 10.1073/pnas.0911684106; HOTZ W, 1983, ADV LIPID RES, V20, P195; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; Kamisato S, 1997, J BIOCHEM-TOKYO, V121, P862; Kirii H, 2003, ARTERIOSCL THROM VAS, V23, P656, DOI 10.1161/01.ATV.0000064374.15232.C3; Kobayashi T, 2010, J PERIODONTOL, V81, P650, DOI 10.1902/jop.2010.090688; Kruth HS, 2002, J BIOL CHEM, V277, P34573, DOI 10.1074/jbc.M205059200; Kwon WY, 2011, CRIT CARE MED, V39, P328, DOI 10.1097/CCM.0b013e3181feeae4; Lauring B, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003877; Lee TS, 1999, ARTERIOSCL THROM VAS, V19, P734, DOI 10.1161/01.ATV.19.3.734; Lukasova M, 2011, J CLIN INVEST, V121, P1163, DOI 10.1172/JCI41651; Martin WJ, 2009, ARTHRITIS RHEUM-US, V60, P281, DOI 10.1002/art.24185; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Mohammad MK, 2006, INT IMMUNOL, V18, P1101, DOI 10.1093/intimm/dxl045; Mount DB, 2006, RHEUM DIS CLIN N AM, V32, P313, DOI 10.1016/j.rdc.2006.02.006; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Offermanns S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004445; Offermanns S, 2011, PHARMACOL REV, V63, P269, DOI 10.1124/pr.110.003301; Pessler F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2435; Rossi AG, 1998, J IMMUNOL, V160, P3562; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Schaub A, 2001, EUR J IMMUNOL, V31, P3714, DOI 10.1002/1521-4141(200112)31:12<3714::AID-IMMU3714>3.0.CO;2-1; SEINO Y, 1994, CYTOKINE, V6, P87, DOI 10.1016/1043-4666(94)90013-2; Serezani CH, 2008, AM J RESP CELL MOL, V39, P127, DOI 10.1165/rcmb.2008-0091TR; Seymour RM, 2001, IMA J MATH APPL MED, V18, P159; Soga T, 2003, BIOCHEM BIOPH RES CO, V303, P364, DOI 10.1016/S0006-291X(03)00342-5; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; TIPPING PG, 1993, AM J PATHOL, V142, P1721; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Wall EA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000202; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200; Yasuda T, 2007, J ATHEROSCLER THROMB, V14, P192, DOI 10.5551/jat.E502; Yurkovetsky ZR, 2007, CLIN CANCER RES, V13, P2422, DOI 10.1158/1078-0432.CCR-06-1805	50	76	78	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4366	4374		10.1096/fj.12-223933	http://dx.doi.org/10.1096/fj.12-223933			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23882124	Green Published			2022-12-28	WOS:000329937500005
J	Lopez-Montero, I; Lopez-Navajas, P; Mingorance, J; Rivas, G; Velez, M; Vicente, M; Monroy, F				Lopez-Montero, Ivan; Lopez-Navajas, Pilar; Mingorance, Jesus; Rivas, German; Velez, Marisela; Vicente, Miguel; Monroy, Francisco			Intrinsic disorder of the bacterial cell division protein ZipA: coil-to-brush conformational transition	FASEB JOURNAL			English	Article						E; coli; Langmuir monolayers; polymer theory	AIR-WATER; UNSTRUCTURED PROTEINS; RHEOLOGICAL PROPERTIES; DILATATIONAL RHEOLOGY; ADSORPTION-KINETICS; SURFACE RHEOLOGY; RING STRUCTURE; FTSZ; INTERFACES; MEMBRANE	The full-length ZipA protein from Escherichia coli, one of the essential elements of the cell division machinery, was studied in a surface model built as adsorbed monolayers. The interplay between lateral packing and molecular conformation was probed using a combined methodology based on the scaling analysis of the surface pressure isotherms and ellipsometry measurements of the monolayer thickness. The observed behavior is compatible with the one expected for an intrinsically disordered and highly flexible protein that is preferentially structured in a random coil conformation. At low grafting densities, ZipA coils organize in a mushroom-like regime, whereas a coil-to-brush transition occurs on increasing lateral packing. The structural results suggest a functional scenario in which ZipA acts as a flexible tether anchoring bacterial proto-ring elements to the membrane during the earlier stages of division.Lopez-Montero, I., Lopez-Navajas, P., Mingorance, J., Rivas, G., Velez, M., Vicente, M., Monroy, F. Intrinsic disorder of the bacterial cell division protein ZipA: coil-to-brush conformational transition.	[Lopez-Montero, Ivan; Monroy, Francisco] Univ Complutense, Dept Quim Fis 1, E-28040 Madrid, Spain; [Lopez-Navajas, Pilar; Rivas, German] CSIC, CIB, Madrid, Spain; [Mingorance, Jesus] Hosp Univ La Paz, IdiPaz, Madrid, Spain; [Velez, Marisela] CSIC, Inst Catalisis & Petr Quim, Madrid, Spain; [Velez, Marisela] CSIC, Fac Ciencias, Inst Madrileno Estudios Avanzados Nanociencia IMD, Madrid, Spain; [Vicente, Miguel] CSIC, CNB, Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hospital Universitario La Paz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP); Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Monroy, F (corresponding author), Univ Complutense Madrid, Dept Quim Fis 1 1, Ciudad Univ S-N, E-28040 Madrid, Spain.	monroy@quim.ucm.es	López-Montero, Iván/A-5263-2017; Monroy, Francisco/N-2763-2013; Rivas, German/AAG-7458-2022; Rivas, German/AFL-7528-2022; Mingorance, Jesus/B-7562-2009; Velez, Marisela/F-2900-2013	López-Montero, Iván/0000-0001-8131-6063; Monroy, Francisco/0000-0001-6455-3083; Rivas, German/0000-0003-3450-7478; Rivas, German/0000-0003-3450-7478; Mingorance, Jesus/0000-0001-6173-5711; Velez, Marisela/0000-0002-9424-510X	Ministerio de Economia y Competitividad of Spain [FIS2012-35723, FIS2009-14650-C02-01, BIO2008-04478-C03, BIO2011-28941-C03-01, BIO2011-28941-C03-02, CSD2007-0010]; Comunidad de Madrid (CAM) [S2005MAT-0283, S2009MAT-1507, S2006-BIO-0260]; European Commission [DIVINOCELL FP7 HEALTH-F3-2009-223431]; Human Frontier Science Program [HFSP-RGP0050/2010]; Juan de la Cierva program (Ministerio de Economia y Competitividad); Research Consortium on Nanobiomaterials (NOBIMAT); Research Consortium on Nanobiomaterials (CAM); Programa de Formacion de Personal Investigador (FPI-CAM)	Ministerio de Economia y Competitividad of Spain(Spanish Government); Comunidad de Madrid (CAM)(Comunidad de Madrid); European Commission(European CommissionEuropean Commission Joint Research Centre); Human Frontier Science Program(Human Frontier Science Program); Juan de la Cierva program (Ministerio de Economia y Competitividad); Research Consortium on Nanobiomaterials (NOBIMAT); Research Consortium on Nanobiomaterials (CAM); Programa de Formacion de Personal Investigador (FPI-CAM)	This work was partially financed under grants from the Ministerio de Economia y Competitividad of Spain (FIS2012-35723 and FIS2009-14650-C02-01 to F. M.; BIO2008-04478-C03 to M. Vi., G. R., and M.Ve.; BIO2011-28941-C03-01 to M. Vi.; BIO2011-28941-C03-02 to G. R.; and Consolider Ingenio en Nanociencia Molecular CSD2007-0010 to F. M. and M. V.); Comunidad de Madrid (CAM; S2005MAT-0283 and S2009MAT-1507 to F. M. and M. V., and S2006-BIO-0260 to M. Vi., G. R., and J.M.); the European Commission (DIVINOCELL FP7 HEALTH-F3-2009-223431 to M. Vi., G. R., and M.Ve.); and the Human Frontier Science Program (HFSP-RGP0050/2010 to M. Vi. and G. R.). I. L.-M. was partially supported by the Juan de la Cierva program (Ministerio de Economia y Competitividad) and the Research Consortium on Nanobiomaterials (NOBIMAT; CAM). P.L.-N. thanks Programa de Formacion de Personal Investigador (FPI-CAM) for financial support. The authors thank the facility Centro de Asistencia a la Investigacion Infrarrojo-Raman-Correlador (Universidad Complutense) for BAM time.	Adamson AW., 1990, PHYS CHEM SURFACES, V5th; Azzam R. M. A., 1992, ELLIPSOMETRY POLARIZ; Benjamins J, 1996, COLLOID SURFACE A, V114, P245, DOI 10.1016/0927-7757(96)03533-9; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Colby R.H., 2003, POLYM PHYS; De Gennes P.-G., 1979, SCALING CONCEPTS POL; Dunker A. K., 2000, BIOCHEMISTRY-US, V41, P6573; Dunker A. K., 2008, CURR OPIN STRUC BIOL, V18, P1; Dunker AK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-S2-S1; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Erickson HP, 2010, MICROBIOL MOL BIOL R, V74, P504, DOI 10.1128/MMBR.00021-10; Erickson HP, 2001, CURR OPIN CELL BIOL, V13, P55, DOI 10.1016/S0955-0674(00)00174-5; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Gorter E., 1941, ANNU REV BIOCHEM, V10, P619; GRAHAM DE, 1980, J COLLOID INTERF SCI, V76, P227, DOI 10.1016/0021-9797(80)90289-1; Gsponer J, 2008, SCIENCE, V322, P1365, DOI 10.1126/science.1163581; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; Hernandez-Rocamora VM, 2012, J BIOL CHEM, V287, P30097, DOI 10.1074/jbc.M112.388959; Hoh JH, 1998, PROTEINS, V32, P223, DOI 10.1002/(SICI)1097-0134(19980801)32:2<223::AID-PROT8>3.0.CO;2-L; Indiana University Center for Computational Biology and Bioinformatics/Temple University Center for Information Science and Technology, 2012, DAT PROT DIS DISPROT; Jonnes R. A. L., 1999, POLYM SURFACES INTER; KAWAGUCHI M, 1993, PROG POLYM SCI, V18, P341, DOI 10.1016/0079-6700(93)90029-C; Langevin D, 2010, CURR OPIN COLLOID IN, V15, P283, DOI 10.1016/j.cocis.2010.02.002; Langmuir I, 1939, CHEM REV, V24, P181, DOI 10.1021/cr60078a002; Liu Z, 1999, MOL MICROBIOL, V31, P1853, DOI 10.1046/j.1365-2958.1999.01322.x; Lopez-Montero I, 2013, BBA-BIOMEMBRANES, V1828, P687, DOI 10.1016/j.bbamem.2012.11.003; Lopez-Montero I, 2008, LANGMUIR, V24, P4065, DOI 10.1021/la703350s; Lopez-Montero I, 2012, LANGMUIR, V28, P4744, DOI 10.1021/la204742b; Lopez-Montero I, 2010, CHEM PHYS LIPIDS, V163, P56, DOI 10.1016/j.chemphyslip.2009.10.002; Maldonado-Valderrama J, 2005, J PHYS CHEM B, V109, P17608, DOI 10.1021/jp050927r; Maldonado-Valderrama J, 2003, LANGMUIR, V19, P8436, DOI 10.1021/la034242z; Martos A, 2010, BIOCHEMISTRY-US, V49, P10780, DOI 10.1021/bi101495x; Mateos-Gil P, 2012, BBA-BIOMEMBRANES, V1818, P806, DOI 10.1016/j.bbamem.2011.12.012; Miller R, 1998, NAHRUNG, V42, P225, DOI 10.1002/(SICI)1521-3803(199808)42:03/04&lt;225::AID-FOOD225&gt;3.3.CO;2-Y; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; Minton AP, 2010, ANAL BIOCHEM, V397, P247, DOI 10.1016/j.ab.2009.10.023; Mobius D., 1998, STUDIES INTERFACE SC, V7; Monroy F, 1998, PHYS REV E, V58, P7629, DOI 10.1103/PhysRevE.58.7629; Monroy F, 2007, ADV COLLOID INTERFAC, V134-35, P175, DOI 10.1016/j.cis.2007.04.023; Mosyak L, 2000, EMBO J, V19, P3179, DOI 10.1093/emboj/19.13.3179; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P9146, DOI 10.1021/bi0009690; MURAMATSU N, 1988, P NATL ACAD SCI USA, V85, P2984, DOI 10.1073/pnas.85.9.2984; Murray BS, 2002, CURR OPIN COLLOID IN, V7, P426, DOI 10.1016/S1359-0294(02)00077-8; Murray BS, 1996, LANGMUIR, V12, P5973, DOI 10.1021/la960748o; Namba K, 2001, GENES CELLS, V6, P1, DOI 10.1046/j.1365-2443.2001.00384.x; Netz RR, 2003, PHYS REP, V380, P1, DOI 10.1016/S0370-1573(03)00118-2; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; Ohashi T, 2002, J BACTERIOL, V184, P4313, DOI 10.1128/JB.184.15.4313-4315.2002; Ohashi T, 2007, PROTEIN SCI, V16, P1429, DOI 10.1110/ps.072845607; Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P1989, DOI 10.1021/bi047993o; Orbulescu J, 2010, LANGMUIR, V26, P3268, DOI 10.1021/la903033x; Osawa M, 2008, SCIENCE, V320, P792, DOI 10.1126/science.1154520; Pazos M, 2013, J BIOL CHEM, V288, P3219, DOI 10.1074/jbc.M112.434944; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Postel C, 2003, J COLLOID INTERF SCI, V266, P74, DOI 10.1016/S0021-9797(03)00571-X; Renault A, 1999, BIOPHYS J, V76, P1580, DOI 10.1016/S0006-3495(99)77317-0; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; Rueda S, 2003, J BACTERIOL, V185, P3344, DOI 10.1128/JB.185.11.3344-3351.2003; Russev SC, 2000, COLLOID SURFACE B, V19, P89, DOI 10.1016/S0927-7765(99)00167-8; Sankaranarayanan K, 2010, J PHYS CHEM B, V114, P8067, DOI 10.1021/jp100896b; Sarkis J, 2011, J BIOL CHEM, V286, P30481, DOI 10.1074/jbc.M111.243881; Sickmeier M, 2007, NUCLEIC ACIDS RES, V35, pD786, DOI 10.1093/nar/gkl893; Skoog K, 2012, BIOCHEMISTRY-US, V51, P1407, DOI 10.1021/bi2015647; Small DM, 2009, J LIPID RES, V50, pS329, DOI 10.1194/jlr.R800083-JLR200; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; TAUNTON HJ, 1988, NATURE, V332, P712, DOI 10.1038/332712a0; Tompa P, 2005, TRENDS BIOCHEM SCI, V30, P484, DOI 10.1016/j.tibs.2005.07.008; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tompa P, 2012, TRENDS BIOCHEM SCI, V37, P509, DOI 10.1016/j.tibs.2012.08.004; Tompa P, 2012, NAT CHEM BIOL, V8, P597, DOI 10.1038/nchembio.1009; Tompa P, 2011, CURR OPIN STRUC BIOL, V21, P419, DOI 10.1016/j.sbi.2011.03.012; Uversky VN, 2008, SCIENCE, V322, P1340, DOI 10.1126/science.1167453; Uversky VN, 2013, BBA-PROTEINS PROTEOM, V1834, P932, DOI 10.1016/j.bbapap.2012.12.008; Uversky VN, 2012, CURR PROTEIN PEPT SC, V13, P2; Uversky VN, 2011, INT J BIOCHEM CELL B, V43, P1090, DOI 10.1016/j.biocel.2011.04.001; Uversky VN, 2010, BBA-PROTEINS PROTEOM, V1804, P1231, DOI 10.1016/j.bbapap.2010.01.017; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vicente M, 2006, J BACTERIOL, V188, P19, DOI 10.1128/JB.188.1.19-27.2006; Voros J, 2004, BIOPHYS J, V87, P553, DOI 10.1529/biophysj.103.030072; Wang KH, 2011, LANGMUIR, V27, P7595, DOI 10.1021/la201496j; Wang LB, 2004, J LIPID RES, V45, P1704, DOI 10.1194/jlr.M400106-JLR200; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Williams A, 1996, COLLOID SURFACE A, V114, P267, DOI 10.1016/0927-7757(96)03534-0; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xie HB, 2007, J PROTEOME RES, V6, P1882, DOI 10.1021/pr060392u	88	17	17	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3363	3375		10.1096/fj.12-224337	http://dx.doi.org/10.1096/fj.12-224337			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23660966				2022-12-28	WOS:000329877600041
J	Sioud, M; Skorstad, G; Mobergslien, A; Sboe-Larssen, S				Sioud, Mouldy; Skorstad, Gjertrud; Mobergslien, Anne; Sboe-Larssen, Stein			A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells	FASEB JOURNAL			English	Article						cancer vaccines; phage display; siRNA; cross presentation	POTENT ANTITUMOR IMMUNITY; REGULATORY T-CELLS; CANCER-CELLS; RECEPTOR; DELIVERY; EXPRESSION; RESPONSES; DEC-205; PROTEIN; TRANSPLANTATION	Dendritic cells (DCs) initiate host immune responses by presenting captured antigens to naive T cells. Hence, DC-binding peptides may be used for antigen targeting to boost naive and memory immune responses. By biopanning peptide phage libraries on human monocyte-derived DCs, we identified novel DC-binding peptides. One of the selected phages, displaying the NW peptide (NWYLPWLGTNDW), bound DCs with high affinity, and its binding was inhibited by the corresponding synthetic peptide. Antigenic peptides or proteins conjugated to the NW peptide bound to DCs and were internalized without negative effects on DC phenotype and function. Ex vivo targeted delivery of CMV-pp65 peptides to DCs via the NW peptide increased T-cell responses in HLA-A2(+)/CMV+ donors compared to untargeted peptides (P<0.001). Stimulation of CD45RO-depleted peripheral blood mononuclear cells from CMV- donors with the NW-pp65 fusion peptides expanded pp65-specific precursor T cells. Moreover, the NW peptide mediated small interfering RNA delivery to DCs, and a significant gene silencing was obtained. Collectively, the data reveal that proteins and nucleic acids can be directed to DCs through the NW peptide, enabling effective uptake and functional effects such as T-cell activation in the context of MHC class I and II molecules.Sioud, M., Skorstad, G., Mobergslien, A., SaebOe-Larssen, S. A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells.	[Sioud, Mouldy; Skorstad, Gjertrud; Mobergslien, Anne] Univ Oslo, Radium Hosp, Dept Immunol, N-0310 Oslo, Norway; [Sboe-Larssen, Stein] Univ Oslo, Radium Hosp, Dept Cell Therapy, N-0310 Oslo, Norway	University of Oslo; University of Oslo	Sioud, M (corresponding author), Univ Oslo, Radium Hosp, Dept Immunol, N-0310 Oslo, Norway.	mosioud@medisin.uio.no			Norwegian Cancer Society; Gene Therapy Program at the Norwegian Radium Hospital	Norwegian Cancer Society(Norwegian Cancer Society); Gene Therapy Program at the Norwegian Radium Hospital	This work was supported in part by the Norwegian Cancer Society and the Gene Therapy Program at the Norwegian Radium Hospital to M. S. The authors thank Dr. Sebastian Patzke for helping with confocal microscopy and Dr. Anne Dybwad for critical reading of the manuscript.	Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Birkholz K, 2010, BLOOD, V116, P2277, DOI 10.1182/blood-2010-02-268425; Bozzacco L, 2007, P NATL ACAD SCI USA, V104, P1289, DOI 10.1073/pnas.0610383104; Costantini TW, 2012, PEPTIDES, V38, P94, DOI 10.1016/j.peptides.2012.08.015; DYBWAD A, 1993, EUR J IMMUNOL, V23, P3189, DOI 10.1002/eji.1830231222; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FALCIABOOTH NJ, 2010, J IMMUNOL, V184, P4317; Flatekval GF, 2009, IMMUNOLOGY, V128, pe837, DOI 10.1111/j.1365-2567.2009.03093.x; Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571; Goffinet C, 2006, FASEB J, V20, P500, DOI 10.1096/fj.05-4651fje; Hangalapura BN, 2011, CANCER RES, V71, P5827, DOI 10.1158/0008-5472.CAN-11-0804; Hansen MH, 2001, MOL MED, V7, P230, DOI 10.1007/BF03401842; He LZ, 2007, J IMMUNOL, V178, P6259, DOI 10.4049/jimmunol.178.10.6259; Jedema I, 2011, HAEMATOL-HEMATOL J, V96, P1204, DOI 10.3324/haematol.2010.039099; Johnson TS, 2008, CLIN CANCER RES, V14, P8169, DOI 10.1158/1078-0432.CCR-08-1474; Kato M, 2006, INT IMMUNOL, V18, P857, DOI 10.1093/intimm/dxl022; Kretz-Rommel A, 2007, J IMMUNOTHER, V30, P715, DOI 10.1097/CJI.0b013e318135472c; Kurts C, 2010, NAT REV IMMUNOL, V10, P403, DOI 10.1038/nri2780; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Leiriao P, 2012, EUR J IMMUNOL, V42, P2042, DOI 10.1002/eji.201142166; Liu Y, 2006, J IMMUNOL, V177, P8440, DOI 10.4049/jimmunol.177.12.8440; Luo H, 2011, FASEB J, V25, P1; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007; Patel N, 2012, AM J TRANSPLANT, V12, P539, DOI 10.1111/j.1600-6143.2011.03837.x; Pira GL, 2004, INT IMMUNOL, V16, P635, DOI 10.1093/intimm/dxh065; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Sant AJ, 2012, J EXP MED, V209, P1391, DOI 10.1084/jem.20121517; Serre K, 1998, J IMMUNOL, V161, P6059; Shadidi M, 2003, DRUG RESIST UPDATE, V6, P363, DOI 10.1016/j.drup.2003.11.002; Shadidi M, 2002, FASEB J, V16, P256, DOI 10.1096/fj.02-0280fje; Sioud M, 2012, BIOCONJUGATE CHEM, V23, P1040, DOI 10.1021/bc300050j; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; Tacken PJ, 2011, SEMIN IMMUNOL, V23, P12, DOI 10.1016/j.smim.2011.01.001; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Trivedi D, 2005, BLOOD, V105, P2793, DOI 10.1182/blood-2003-05-1433; Tsuji T, 2011, J IMMUNOL, V186, P1218, DOI 10.4049/jimmunol.1000808; Wang XF, 2007, CANCER RES, V67, P3337, DOI 10.1158/0008-5472.CAN-06-2480; Wei HF, 2009, CLIN CANCER RES, V15, P4612, DOI 10.1158/1078-0432.CCR-08-3321; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996; Yao JX, 2008, CLIN INFECT DIS, V46, pE96, DOI 10.1086/587749	44	18	22	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3272	3283		10.1096/fj.12-224758	http://dx.doi.org/10.1096/fj.12-224758			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23671272				2022-12-28	WOS:000329877600032
J	Klosen, P; Sebert, ME; Rasri, K; Laran-Chich, MP; Simonneaux, V				Klosen, Paul; Sebert, Marie-Emilie; Rasri, Kamontip; Laran-Chich, Marie-Pierre; Simonneaux, Valerie			TSH restores a summer phenotype in photoinhibited mammals via the RF-amides RFRP3 and kisspeptin	FASEB JOURNAL			English	Article						seasonal rhythms; reproduction; body weight; melatonin; tancyte; deiodinase 2; somatostatin	RFAMIDE-RELATED PEPTIDE-3; MT1 MELATONIN RECEPTOR; SEASONAL BODY-WEIGHT; PARS TUBERALIS; DJUNGARIAN HAMSTER; GENE-EXPRESSION; PHOTOPERIODIC REGULATION; PHODOPUS-SUNGORUS; BINDING SITES; FOOD-INTAKE	In mammals, melatonin is the pivotal messenger synchronizing biological functions, notably reproductive activity, with annual daylength changes. Recently, two major findings clarified melatonin's mode of action. First, melatonin controls the production of thyroid stimulating hormone (TSH) by the pars tuberalis of the adenohypophysis. This TSH regulates local thyroid hormone availability in the mediobasal hypothalamus. Second, the RF-amides kisspeptin and RFRP-3, recently discovered regulators of the gonadotropic axis, are involved in the melatonin control of reproduction. This study aims to establish a mechanistic link between the melatonin-driven TSH and the RF-amide control of reproduction. We treated short-day-adapted male Djungarian and Syrian hamsters with a chronic central infusion of TSH. In both hamster species, the central administration of 5 mIU/d TSH for 4 to 6 wk restored the summer phenotype of both testicular activity and kisspeptin and RFRP expression. Vehicle treated hamsters remain sexually inactive. Furthermore, the TSH treatment increased the body weight of lean short-day-adapted Djungarian hamsters and reduced hypothalamic somatostatin expression to the summer phenotype. In summary, our study demonstrates the pivotal role of melatonin-driven TSH for the seasonal regulation of reproduction and body weight, and uncovers the neuropeptides relaying this signal within the hypothalamus.Klosen, P., Sebert, M.-E., Rasri, K., Laran-Chich, M.-P., Simonneaux, V. TSH restores a summer phenotype in photoinhibited mammals via the RF-amides RFRP3 and kisspeptin.	[Klosen, Paul; Sebert, Marie-Emilie; Laran-Chich, Marie-Pierre; Simonneaux, Valerie] Univ Strasbourg, CNRS, Unite Propres Rech UPR 3212, Dept Neurobiol Rythmes,Inst Neurosci Cellulaires, F-67084 Strasbourg, France; [Rasri, Kamontip] Thammasat Univ, Dept Preclin Sci, Fac Med, Rangsit, Thailand	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Thammasat University	Simonneaux, V (corresponding author), Univ Strasbourg, CNRS, Inst Neurosci Cellulaires & Integrat, UPR3212, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	simonneaux@inci-cnrs.unistra.fr		Klosen, Paul/0000-0001-9724-5044	Agence Nationale de la Recherche (ANR) FrenchKiss [BLAN-07-0056]; Centre National de la Recherche Scientifique	Agence Nationale de la Recherche (ANR) FrenchKiss(French National Research Agency (ANR)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS))	The authors thank Dr. Jens Mikkelsen (Neurobiology Research Unit, Copenhagen University Hospital, Copenhagen, Denmark) for plasma testosterone assay; Prof. Veerle Darras (Laboratory of Comparative Endocrinology, Leuven, Belgium) for tissue T3 assay; and Dr. Dominique Ciocca for animal care and technical assistance. Animal study was conducted at the Animal Resource and Experimentation Platform/Chronobiotron (TGIR, UMS 3415 Unistra/CNRS). This work was supported in part by the Agence Nationale de la Recherche (ANR) FrenchKiss (BLAN-07-0056) and the Centre National de la Recherche Scientifique.	Ancel C, 2012, ENDOCRINOLOGY, V153, P1352, DOI 10.1210/en.2011-1622; Ansel L, 2010, J BIOL RHYTHM, V25, P81, DOI 10.1177/0748730410361918; Baker JR, 1932, P R SOC LOND B-CONTA, V110, P313, DOI 10.1098/rspb.1932.0027; Barrett P, 2005, ENDOCRINOLOGY, V146, P1930, DOI 10.1210/en.2004-1452; Barrett P, 2007, ENDOCRINOLOGY, V148, P3608, DOI 10.1210/en.2007-0316; Barrett P, 2012, J PINEAL RES, V52, P376, DOI 10.1111/j.1600-079X.2011.00963.x; Bentley GE, 2010, BRAIN RES, V1364, P62, DOI 10.1016/j.brainres.2010.10.001; BITTMAN EL, 1983, ENDOCRINOLOGY, V113, P2276, DOI 10.1210/endo-113-6-2276; BOCKERS TM, 1995, J NEUROENDOCRINOL, V7, P607, DOI 10.1111/j.1365-2826.1995.tb00798.x; Clarke IJ, 2008, ENDOCRINOLOGY, V149, P5811, DOI 10.1210/en.2008-0575; Clarke IJ, 2009, PEPTIDES, V30, P154, DOI 10.1016/j.peptides.2008.08.022; COOK CB, 1992, ENDOCRINOLOGY, V130, P1077, DOI 10.1210/en.130.2.1077; Dardente H, 2008, J NEUROENDOCRINOL, V20, P1252, DOI 10.1111/j.1365-2826.2008.01784.x; Dardente H, 2003, J NEUROENDOCRINOL, V15, P778, DOI 10.1046/j.1365-2826.2003.01060.x; Dardente H, 2010, CURR BIOL, V20, P2193, DOI 10.1016/j.cub.2010.10.048; Ebling FJP, 2008, J NEUROENDOCRINOL, V20, P827, DOI 10.1111/j.1365-2826.2008.01721.x; FIGALA J, 1973, OECOLOGIA, V12, P89, DOI 10.1007/BF00345511; Gofflot F, 2007, CELL, V131, P405, DOI 10.1016/j.cell.2007.09.012; Greives TJ, 2008, J NEUROENDOCRINOL, V20, P1339, DOI 10.1111/j.1365-2826.2008.01790.x; Greives TJ, 2007, ENDOCRINOLOGY, V148, P1158, DOI 10.1210/en.2006-1249; Hanon EA, 2010, J NEUROENDOCRINOL, V22, P51, DOI 10.1111/j.1365-2826.2009.01937.x; Hanon EA, 2008, CURR BIOL, V18, P1147, DOI 10.1016/j.cub.2008.06.076; Herwig A, 2012, J NEUROENDOCRINOL, V24, P991, DOI 10.1111/j.1365-2826.2012.02324.x; HOFFMAN RA, 1965, SCIENCE, V148, P1609, DOI 10.1126/science.148.3677.1609; Janati A, 2013, J NEUROENDOCRINOL, V25, P402, DOI 10.1111/jne.12015; Jethwa PH, 2007, ENDOCRINOLOGY, V148, P4044, DOI 10.1210/en.2007-0038; Klosen P, 2002, J HISTOCHEM CYTOCHEM, V50, P1647, DOI 10.1177/002215540205001209; KLOSEN P, 1993, J HISTOCHEM CYTOCHEM, V41, P455, DOI 10.1177/41.3.8429209; Kriegsfeld LJ, 2006, P NATL ACAD SCI USA, V103, P2410, DOI 10.1073/pnas.0511003103; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; LERCHL A, 1995, GEN COMP ENDOCR, V98, P129, DOI 10.1006/gcen.1995.1053; MASSONPEVET M, 1994, CELL TISSUE RES, V278, P97, DOI 10.1007/s004410050196; MAYWOOD ES, 1995, ENDOCRINOLOGY, V136, P144, DOI 10.1210/en.136.1.144; Mikkelsen JD, 2009, REGUL PEPTIDES, V152, P95, DOI 10.1016/j.regpep.2008.10.001; Mikkelsen JD, 2009, PEPTIDES, V30, P26, DOI 10.1016/j.peptides.2008.09.004; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; Murphy M, 2012, ENDOCRINOLOGY, V153, P101, DOI 10.1210/en.2011-1249; Nakao N, 2008, NATURE, V452, P317, DOI 10.1038/nature06738; Pinilla L, 2012, PHYSIOL REV, V92, P1235, DOI 10.1152/physrev.00037.2010; Rasri K, 2008, NEUROSCIENCE, V157, P174, DOI 10.1016/j.neuroscience.2008.08.058; Revel FG, 2008, ENDOCRINOLOGY, V149, P902, DOI 10.1210/en.2007-0848; Revel FG, 2006, CURR BIOL, V16, P1730, DOI 10.1016/j.cub.2006.07.025; Reyns GE, 2003, GEN COMP ENDOCR, V134, P80, DOI 10.1016/S0016-6480(03)00220-X; Rizwan MZ, 2012, ENDOCRINOLOGY, V153, P3770, DOI 10.1210/en.2012-1133; Ross AW, 2004, ENDOCRINOLOGY, V145, P13, DOI 10.1210/en.2003-0838; Simonneaux Valerie, 2012, Front Endocrinol (Lausanne), V3, P168, DOI 10.3389/fendo.2012.00168; Simonneaux V, 2009, PEPTIDES, V30, P146, DOI 10.1016/j.peptides.2008.06.006; Tsutsui K, 2012, GEN COMP ENDOCR, V177, P305, DOI 10.1016/j.ygcen.2012.02.013; Ubuka T, 2012, ENDOCRINOLOGY, V153, P373, DOI 10.1210/en.2011-1110; VANECEK J, 1987, BRAIN RES, V435, P359, DOI 10.1016/0006-8993(87)91625-8; Wallis K, 2010, MOL ENDOCRINOL, V24, P1904, DOI 10.1210/me.2010-0175; WEAVER DR, 1989, J NEUROSCI, V9, P2581; WITTKOWSKI W, 1988, CELL TISSUE RES, V251, P183, DOI 10.1007/BF00215463; Yasuo S, 2007, ENDOCRINOLOGY, V148, P4385, DOI 10.1210/en.2007-0497	54	77	82	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2677	2686		10.1096/fj.13-229559	http://dx.doi.org/10.1096/fj.13-229559			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23538709				2022-12-28	WOS:000328841000017
J	Marchal, JA; Lopez, GJ; Peran, M; Comino, A; Delgado, JR; Garcia-Garcia, JA; Conde, V; Aranda, FM; Rivas, C; Esteban, M; Garcia, MA				Marchal, Juan A.; Lopez, Gabriel J.; Peran, Macarena; Comino, Ana; Delgado, Juan R.; Garcia-Garcia, Javier A.; Conde, Veronica; Aranda, Fernando M.; Rivas, Carmen; Esteban, Mariano; Garcia, Maria A.			The impact of PKR activation: from neurodegeneration to cancer	FASEB JOURNAL			English	Review						protein kinase R; apoptosis; protein kinase R modulators	DEPENDENT PROTEIN-KINASE; RNA-BINDING PROTEIN; NF-KAPPA-B; MILD COGNITIVE IMPAIRMENT; TUMOR-SUPPRESSOR FUNCTION; FACTOR 2-ALPHA KINASES; NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; INDUCED APOPTOSIS; METHIONINE AMINOPEPTIDASE-2	An inverse association between cancer and neurodegeneration is plausible because these biological processes share several genes and signaling pathways. Whereas uncontrolled cell proliferation and decreased apoptotic cell death governs cancer, excessive apoptosis contributes to neurodegeneration. Protein kinase R (PKR), an interferon-inducible double-stranded RNA protein kinase, is involved in both diseases. PKR activation blocks global protein synthesis through eIF2 phosphorylation, leading to cell death in response to a variety of cellular stresses. However, PKR also has the dual role of activating the nuclear factor -B pathway, promoting cell proliferation. Whereas PKR is recognized for its negative effects on neurodegenerative diseases, in part, inducing high level of apoptosis, the role of PKR activation in cancer remains controversial. In general, PKR is considered to have a tumor suppressor function, and some clinical data show a correlation between suppressed or inactivated PKR and a poor prognosis for several cancers. However, other studies show high PKR expression and activation levels in various cancers, suggesting that PKR might contribute to neoplastic progression. Understanding the cellular factors and signals involved in the regulation of PKR in these age-related diseases is relevant and may have important clinical implications. The present review highlights the current knowledge on the role of PKR in neurodegeneration and cancer, with special emphasis on its regulation and clinical implications.Marchal, J. A., Lopez, G. J., Peran, M., Comino, A., Delgado, J. R., Garcia-Garcia, J. A., Conde, V., Aranda, F. M., Rivas, C., Esteban, M., Garcia, M. A. The impact of PKR activation: from neurodegeneration to cancer.	[Marchal, Juan A.; Peran, Macarena] Univ Granada, Ctr Biomed Res, Biopathol & Regenerat Med Inst IBIMER, Granada, Spain; [Marchal, Juan A.] Univ Granada, Dept Human Anat & Embryol, Fac Med, Granada, Spain; [Lopez, Gabriel J.] Complejo Hosp Torrecardenas, Serv Cirugia, Almeria, Spain; [Peran, Macarena] Univ Jaen, Dept Hlth Sci, Jaen, Spain; [Comino, Ana; Aranda, Fernando M.; Garcia, Maria A.] Virgen de las Nieves Univ Hosp, Expt Surg Res Unit, Granada, Spain; [Delgado, Juan R.; Garcia-Garcia, Javier A.; Conde, Veronica; Garcia, Maria A.] Virgen de las Nieves Univ Hosp, Dept Oncol, Granada, Spain; [Rivas, Carmen; Esteban, Mariano] CSIC, Ctr Nacl Biotecnol, Dept Biol Mol & Celular, Madrid, Spain; [Rivas, Carmen] Univ Santiago de Compostela, Inst Invest Sanitarias IDIS, Ctr Invest Med Mol CIMUS, Santiago De Compostela, Spain	University of Granada; University of Granada; Hospital Torrecardenas; Universidad de Jaen; Hospital Universitario Virgen de las Nieves; Hospital Universitario Virgen de las Nieves; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Universidade de Santiago de Compostela	Garcia, MA (corresponding author), Univ Hosp Virgen de las Nieves, Azpitarte Sn, E-18012 Granada, Spain.	mangelgarcia@ugr.es	Garcia, Maria Angel MA/I-5116-2016; Peran, Macarena/I-5225-2016; Esteban, Mariano/ABG-5375-2020; Marchal, Juan Antonio/M-4305-2014; Rivas, Carmen/L-3162-2017; Rivas, Carmen/AAB-6278-2019	Garcia, Maria Angel MA/0000-0003-2003-3769; Peran, Macarena/0000-0001-7562-2347; Esteban, Mariano/0000-0003-0846-2827; Marchal, Juan Antonio/0000-0002-4996-8261; Rivas, Carmen/0000-0002-0518-7199; Rivas, Carmen/0000-0002-0518-7199	Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria) fund; Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional (FEDER) fund [CP08/00063, PI10/02295]	Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria) fund; Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional (FEDER) fund	The authors gratefully acknowledge technicians from the Experimental Surgery Research Unit (Virgen de las Nieves University Hospital) for supporting our work with equipment. This work was supported in part by grants from the Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria, Fondo Europeo de Desarrollo Regional (FEDER) funds, projects CP08/00063 and PI10/02295). The authors report no conflicts of interest.	Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Andre ND, 2007, CANCER LETT, V258, P118, DOI 10.1016/j.canlet.2007.08.021; Garcia MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023887; Marchal JA, 2013, DRUG DES DEV THER, V7, P1301, DOI 10.2147/DDDT.S51354; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Bando Y, 2005, NEUROCHEM INT, V46, P11, DOI 10.1016/j.neuint.2004.07.005; Bannwarth S, 2006, J MOL BIOL, V355, P898, DOI 10.1016/j.jmb.2005.11.026; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; Barbosa C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003529; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bennett RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046040; Blalock WL, 2011, LEUKEMIA, V25, P236, DOI 10.1038/leu.2010.264; Blalock WL, 2010, J CELL PHYSIOL, V223, P572, DOI 10.1002/jcp.22092; Bose A, 2011, BRAIN PATHOL, V21, P189, DOI 10.1111/j.1750-3639.2010.00437.x; Brochier C, 2013, J NEUROSCI, V33, P8621, DOI 10.1523/JNEUROSCI.5214-12.2013; Buizza L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.13; Carvalho BM, 2013, OBESITY, V21, P2452, DOI 10.1002/oby.20410; Carvalho MA, 2012, ENDOCRINOLOGY, V153, P5261, DOI 10.1210/en.2012-1400; Chan CT, 2012, P NATL ACAD SCI USA, V109, pE2476, DOI 10.1073/pnas.1205459109; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; Chen HM, 2008, EUR J NEUROSCI, V28, P2003, DOI 10.1111/j.1460-9568.2008.06491.x; Cheng X, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.42; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clerzius G, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-96; Couturier J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-72; Couturier J, 2012, CURR ALZHEIMER RES, V9, P344, DOI 10.2174/156720512800107582; Couturier J, 2010, J BIOL CHEM, V285, P1272, DOI 10.1074/jbc.M109.041954; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Damjanac M, 2009, J CELL MOL MED, V13, P1823, DOI 10.1111/j.1582-4934.2009.00688.x; Daniels SM, 2012, MICROBIOL MOL BIOL R, V76, P652, DOI 10.1128/MMBR.00012-12; Datta B, 2006, ARCH BIOCHEM BIOPHYS, V452, P138, DOI 10.1016/j.abb.2006.06.009; Dey M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041; Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Driver Jane A, 2012, BMJ, V344, pe1442, DOI 10.1136/bmj.e1442; Dumurgier J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053587; Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009; Fujiwara T, 2012, BIOCHEM BIOPH RES CO, V427, P100, DOI 10.1016/j.bbrc.2012.09.017; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Garcia MA, 2006, EMBO J, V25, P4284, DOI 10.1038/sj.emboj.7601302; Gaub P, 2010, CELL DEATH DIFFER, V17, P1392, DOI 10.1038/cdd.2009.216; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2004, MOL CELL BIOL, V24, P4502, DOI 10.1128/MCB.24.10.4502-4512.2004; Gil J, 2002, FEBS LETT, V529, P249, DOI 10.1016/S0014-5793(02)03348-3; Gil J, 2000, BIOCHEMISTRY-US, V39, P16016, DOI 10.1021/bi001754t; Guo CC, 2013, J THORAC ONCOL, V8, P301, DOI 10.1097/JTO.0b013e318282def7; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; He Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024855; He Y, 2013, EUR J IMMUNOL, V43, P1147, DOI 10.1002/eji.201243187; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hiasa Y, 2003, AM J GASTROENTEROL, V98, P2528, DOI 10.1016/S0002-9270(03)01696-4; Hii SI, 2004, INT J CANCER, V109, P329, DOI 10.1002/ijc.11714; Hong LZ, 2010, NEUROSCI BULL, V26, P232, DOI 10.1007/s12264-010-1111-0; Hugon J, 2009, EXPERT REV NEUROTHER, V9, P1455, DOI [10.1586/ern.09.92, 10.1586/ERN.09.92]; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Joshi M, 2013, BIOCHIMIE, V95, P1980, DOI 10.1016/j.biochi.2013.07.030; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kotipatruni RR, 2011, NEUROCHEM RES, V36, P2063, DOI 10.1007/s11064-011-0530-2; Kunkeaw N, 2013, ONCOGENE, V32, P3722, DOI 10.1038/onc.2012.382; Kwon HC, 2005, JPN J CLIN ONCOL, V35, P545, DOI 10.1093/jjco/hyi146; Lanni C, 2012, FREE RADICAL BIO MED, V52, P1727, DOI 10.1016/j.freeradbiomed.2012.02.034; Lanni C, 2010, J ALZHEIMERS DIS, V20, P97, DOI 10.3233/JAD-2010-1347; Lee JE, 2011, NEUROTOXICOLOGY, V32, P702, DOI 10.1016/j.neuro.2011.08.004; Lee K, 2011, RNA, V17, P1076, DOI 10.1261/rna.2701111; Liu XF, 2013, BLOOD, V121, P3364, DOI 10.1182/blood-2012-09-456400; Liu YH, 2012, MOL BIOL CELL, V23, P4506, DOI 10.1091/mbc.E12-05-0362; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Lu B, 2012, NATURE, V488, P670, DOI 10.1038/nature11290; Marques JT, 2008, J INTERF CYTOK RES, V28, P469, DOI 10.1089/jir.2007.0006; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Morel M, 2009, NEUROBIOL DIS, V36, P151, DOI 10.1016/j.nbd.2009.07.004; Morel M, 2009, J CELL MOL MED, V13, P1476, DOI 10.1111/j.1582-4934.2009.00849.x; Mounir Z, 2010, FUTURE ONCOL, V6, P643, DOI 10.2217/FON.10.45; Mounir Z, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000389; Mouton-Liger F, 2012, BBA-MOL BASIS DIS, V1822, P885, DOI 10.1016/j.bbadis.2012.01.009; Mouton-Liger F, 2012, BIOL PSYCHIAT, V71, P829, DOI 10.1016/j.biopsych.2011.11.031; Nag S, 2013, J BIOMED RES, V27, P254, DOI 10.7555/JBR.27.20130030; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Okumura F, 2013, J BIOL CHEM, V288, P2839, DOI 10.1074/jbc.M112.401851; Ong CL, 2005, J VIROL, V79, P12763, DOI 10.1128/JVI.79.20.12763-12772.2005; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Paccalin M, 2006, DEMENT GERIATR COGN, V22, P320, DOI 10.1159/000095562; Page G, 2006, NEUROSCIENCE, V139, P1343, DOI 10.1016/j.neuroscience.2006.01.047; Pang QS, 2003, J BIOL CHEM, V278, P41709, DOI 10.1074/jbc.M301392200; Pang QS, 2002, J BIOL CHEM, V277, P49638, DOI 10.1074/jbc.M209386200; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Paquet C, 2012, BRAIN PATHOL, V22, P219, DOI 10.1111/j.1750-3639.2011.00520.x; Pataer A, 2010, CLIN CANCER RES, V16, P5522, DOI 10.1158/1078-0432.CCR-10-0753; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Patel S, 2012, BIOCHEMISTRY-US, V51, P9312, DOI 10.1021/bi300935p; Peel AL, 2004, J NEUROPATH EXP NEUR, V63, P97, DOI 10.1093/jnen/63.2.97; Peel AL, 2001, HUM MOL GENET, V10, P1531, DOI 10.1093/hmg/10.15.1531; Peidis P, 2011, CELL DEATH DIFFER, V18, P145, DOI 10.1038/cdd.2010.76; Peters GA, 2009, P NATL ACAD SCI USA, V106, P10696, DOI 10.1073/pnas.0900735106; Pindel A, 2011, J INTERF CYTOK RES, V31, P59, DOI 10.1089/jir.2010.0099; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Prasad S, 2012, PREV MED, V54, pS29, DOI 10.1016/j.ypmed.2011.11.011; Raven JF, 2008, J BIOL CHEM, V283, P3097, DOI 10.1074/jbc.M709677200; Roe CM, 2010, NEUROLOGY, V74, P106, DOI 10.1212/WNL.0b013e3181c91873; Roh MS, 2005, PATHOL INT, V55, P688, DOI 10.1111/j.1440-1827.2005.01892.x; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Ruuska M, 2012, ARTHRITIS RHEUM-US, V64, P772, DOI 10.1002/art.33391; Saito Yoshimasa, 2012, Frontiers in Genetics, V3, P194, DOI 10.3389/fgene.2012.00194; Sanghvi VR, 2011, J VIROL, V85, P12614, DOI 10.1128/JVI.05240-11; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Selvakumar P, 2004, BIOCHEM BIOPH RES CO, V322, P1012, DOI 10.1016/j.bbrc.2004.08.021; Selvakumar P, 2004, CLIN CANCER RES, V10, P2771, DOI 10.1158/1078-0432.CCR-03-0218; Sendoel A, 2010, NATURE, V465, P577, DOI 10.1038/nature09141; Serrano J, 2010, ONCOGENE, V29, P2165, DOI 10.1038/onc.2009.503; Shimada A, 1998, CANCER RES, V58, P4434; Singh M, 2012, J CELL BIOCHEM, V113, P2754, DOI 10.1002/jcb.24152; Singh M, 2011, BIOCHEMISTRY-US, V50, P4550, DOI 10.1021/bi200104h; Singh M, 2009, J MOL BIOL, V385, P457, DOI 10.1016/j.jmb.2008.10.068; Stanga S, 2012, CURR ALZHEIMER RES, V9, P1191, DOI 10.2174/156720512804142886; Stern E, 2013, J NEUROSCI, V33, P2517, DOI 10.1523/JNEUROSCI.2322-12.2013; Suen KC, 2003, J BIOL CHEM, V278, P49819, DOI 10.1074/jbc.M306503200; Sunico CR, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-29; Tan MS, 2012, NEUROSCI LETT, V516, P226, DOI 10.1016/j.neulet.2012.03.093; Terada T, 2000, HUM PATHOL, V31, P817, DOI 10.1053/hupa.2000.8443; Terada W, 2000, LIVER, V20, P450, DOI 10.1034/j.1600-0676.2000.020006450.x; Thinnes FP, 2012, MOL GENET METAB, V106, P502, DOI 10.1016/j.ymgme.2012.06.004; Thotala DK, 2012, CELL DEATH DIFFER, V19, P387, DOI 10.1038/cdd.2011.94; Tucker LA, 2008, ONCOGENE, V27, P3967, DOI 10.1038/onc.2008.14; Uo T, 2009, J NEUROSCI, V29, P2824, DOI 10.1523/JNEUROSCI.6186-08.2009; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xu M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047721; Yang Xiang-Jiao, 2013, F1000Prime Rep, V5, P45, DOI 10.12703/P5-45; Yarchoan M, 2013, J NEUROL SCI, V333, P9, DOI 10.1016/j.jns.2013.05.028; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102; Zhao MJ, 2002, J BIOL CHEM, V277, P44539, DOI 10.1074/jbc.M208408200; Zhou XY, 2010, NEUROSCI LETT, V468, P320, DOI 10.1016/j.neulet.2009.11.024; Zhu PJ, 2011, CELL, V147, P1384, DOI 10.1016/j.cell.2011.11.029	137	78	81	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					1965	1974		10.1096/fj.13-248294	http://dx.doi.org/10.1096/fj.13-248294			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24522206				2022-12-28	WOS:000335336000002
J	McColl, B; Kao, BR; Lourthai, P; Chan, K; Wardan, H; Roosjen, M; Delagneau, O; Gearing, LJ; Blewitt, ME; Svasti, S; Fucharoen, S; Vadolas, J				McColl, Bradley; Kao, Betty R.; Lourthai, Preeyachan; Chan, Kasey; Wardan, Hady; Roosjen, Mark; Delagneau, Orane; Gearing, Linden J.; Blewitt, Marnie E.; Svasti, Saovaros; Fucharoen, Suthat; Vadolas, Jim			An in vivo model for analysis of developmental erythropoiesis and globin gene regulation	FASEB JOURNAL			English	Article						hemoglobin switching; BAC transgenics; epigenetics; chromatin modification	YEAST ARTIFICIAL CHROMOSOME; FETAL-HEMOGLOBIN LEVELS; HUMAN GAMMA-GLOBIN; MOUSE MODEL; NUCLEAR RECEPTORS; BCL11A; LOCUS; EXPRESSION; DECITABINE; PROMOTERS	Expression of fetal -globin in adulthood ameliorates symptoms of -hemoglobinopathies by compensating for the mutant -globin. Reactivation of the silenced -globin gene is therefore of substantial clinical interest. To study the regulation of -globin expression, we created the GG mice, which carry an intact 183-kb human -globin locus modified to express enhanced green fluorescent protein (eGFP) from the G-globin promoter. GG embryos express eGFP first in the yolk sac blood islands and then in the aorta-gonad mesonephros and the fetal liver, the sites of normal embryonic hematopoiesis. eGFP expression in erythroid cells peaks at E9.5 and then is rapidly silenced (>95%) and maintained at low levels into adulthood, demonstrating appropriate developmental regulation of the human -globin locus. In vitro knockdown of the epigenetic regulator DNA methyltransferase-1 in GG primary erythroid cells increases the proportion of eGFP(+) cells in culture from 41.9 to 74.1%. Furthermore, eGFP fluorescence is induced >3-fold after treatment of erythroid precursors with epigenetic drugs known to induce -globin expression, demonstrating the suitability of the G-globin eGFP reporter for evaluation of -globin inducers. The GG mouse model is therefore a valuable model system for genetic and pharmacologic studies of the regulation of the -globin locus and for discovery of novel therapies for the -hemoglobinopathies.McColl, B., Kao, B. R., Lourthai, P., Chan, K., Wardan, H., Roosjen, M., Delagneau, O., Gearing, L. J., Blewitt, M. E., Svasti, S., Fucharoen, S., Vadolas, J. An in vivo model for analysis of developmental erythropoiesis and globin gene regulation.	[McColl, Bradley; Kao, Betty R.; Lourthai, Preeyachan; Chan, Kasey; Wardan, Hady; Roosjen, Mark; Delagneau, Orane; Vadolas, Jim] Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Grp, Parkville, Vic 3052, Australia; [Kao, Betty R.; Vadolas, Jim] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Gearing, Linden J.; Blewitt, Marnie E.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Gearing, Linden J.; Blewitt, Marnie E.] Univ Melbourne, Dept Genet, Melbourne, Vic, Australia; [Lourthai, Preeyachan] Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand; [Lourthai, Preeyachan; Svasti, Saovaros; Fucharoen, Suthat] Mahidol Univ, Inst Mol Biosci, Thalassemia Res Ctr, Nakhon Pathom, Thailand; [Blewitt, Marnie E.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Mol Med, Parkville, Vic 3050, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; Mahidol University; Mahidol University; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Vadolas, J (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Grp, Flemington Rd, Parkville, Vic 3052, Australia.	jim.vadolas@mcri.edu.au	Svasti, Saovaros/AAH-6111-2020	Kao, Betty/0000-0003-0202-8018; Blewitt, Marnie/0000-0002-2984-1474; Gearing, Linden/0000-0003-3508-3056; Vadolas, Jim/0000-0002-3072-3512	National Health and Medical Research Council; Murdoch Childrens Research Institute; Victorian Government; Thalassaemia Australia; Thalassaemia Society of New South Wales; Greek Conference, a Research Chair grant from the Thailand National Science and Technology Development Agency (NSTDA); Mahidol University; Medical Scholars Program, Mahidol University	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Murdoch Childrens Research Institute; Victorian Government; Thalassaemia Australia; Thalassaemia Society of New South Wales; Greek Conference, a Research Chair grant from the Thailand National Science and Technology Development Agency (NSTDA); Mahidol University; Medical Scholars Program, Mahidol University	The authors thank Chelsea Dunn for assistance with the preparation of figures. This work was supported by the National Health and Medical Research Council, the Murdoch Childrens Research Institute, the Victorian Government's Operational Infrastructure Support Program, Thalassaemia Australia, the Thalassaemia Society of New South Wales, the Greek Conference, a Research Chair grant from the Thailand National Science and Technology Development Agency (NSTDA), and Mahidol University. P. L. was supported by the Medical Scholars Program, Mahidol University. P. L. was a Ph.D. candidate at Mahidol University; this work was submitted in partial fulfilment of the Ph.D. requirements.	Akpan I, 2010, EXP HEMATOL, V38, P989, DOI 10.1016/j.exphem.2010.08.001; Amaya M, 2013, BLOOD, V121, P3493, DOI 10.1182/blood-2012-11-466227; Banzon V, 2011, EXP HEMATOL, V39, P26, DOI 10.1016/j.exphem.2010.10.003; Baron MH, 2012, BLOOD, V119, P4828, DOI 10.1182/blood-2012-01-153486; Bauer DE, 2012, BLOOD, V120, P2945, DOI 10.1182/blood-2012-06-292078; Borg J, 2010, NAT GENET, V42, P801, DOI 10.1038/ng.630; Chan KSK, 2012, FASEB J, V26, P1736, DOI 10.1096/fj.11-199356; Costa FC, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003155; Cui SAY, 2011, MOL CELL BIOL, V31, P3298, DOI 10.1128/MCB.05310-11; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; Fraser ST, 2010, METHOD ENZYMOL, V476, P403, DOI 10.1016/S0076-6879(10)76022-5; Fucharoen S, 2013, BRIT J HAEMATOL, V161, P587, DOI 10.1111/bjh.12304; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; Harju-Baker S, 2008, MOL CELL BIOL, V28, P3101, DOI 10.1128/MCB.01858-07; Jamsai D, 2005, GENOMICS, V85, P453, DOI 10.1016/j.ygeno.2004.11.016; Jamsai D, 2006, GENOMICS, V88, P309, DOI 10.1016/j.ygeno.2006.03.009; Kaufman RM, 1999, BLOOD, V94, P3178, DOI 10.1182/blood.V94.9.3178.421k23_3178_3184; Kingsley PD, 2006, BLOOD, V107, P1665, DOI 10.1182/blood-2005-08-3097; Lavelle D, 2006, BLOOD CELL MOL DIS, V36, P269, DOI 10.1016/j.bcmd.2006.01.004; Lavelle D, 2012, BLOOD, V119, P1240, DOI 10.1182/blood-2011-08-371690; Lettre G, 2008, P NATL ACAD SCI USA, V105, P11869, DOI 10.1073/pnas.0804799105; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Mabaera R, 2007, BLOOD, V110, P1343, DOI 10.1182/blood-2007-01-068635; MAVILIO F, 1983, P NATL ACAD SCI-BIOL, V80, P6907, DOI 10.1073/pnas.80.22.6907; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; McGrath KE, 2003, BLOOD, V101, P1669, DOI 10.1182/blood-2002-08-2531; Menzel S, 2007, NAT GENET, V39, P1197, DOI 10.1038/ng2108; Olivieri NF, 2011, BLOOD, V118, P2708, DOI 10.1182/blood-2011-03-341909; Papadopoulos P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051272; Perrine SP, 2010, ANN NY ACAD SCI, V1202, P158, DOI 10.1111/j.1749-6632.2010.05593.x; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips JD, 2007, BLOOD, V109, P2618, DOI 10.1182/blood-2006-06-022848; Porcu S, 1997, BLOOD, V90, P4602, DOI 10.1182/blood.V90.11.4602.4602_4602_4609; Sankaran VG, 2010, BRIT J HAEMATOL, V149, P181, DOI 10.1111/j.1365-2141.2010.08105.x; Sedgewick AE, 2008, BLOOD CELL MOL DIS, V41, P255, DOI 10.1016/j.bcmd.2008.06.007; Shi LH, 2013, NAT MED, V19, P291, DOI 10.1038/nm.3101; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Tanabe O, 2007, EMBO J, V26, P2295, DOI 10.1038/sj.emboj.7601676; Thein SL, 2007, P NATL ACAD SCI USA, V104, P11346, DOI 10.1073/pnas.0611393104; THORPE SJ, 1994, BRIT J HAEMATOL, V87, P125, DOI 10.1111/j.1365-2141.1994.tb04881.x; Uda M, 2008, P NATL ACAD SCI USA, V105, P1620, DOI 10.1073/pnas.0711566105; Vadolas J, 2006, J BIOL CHEM, V281, P7399, DOI 10.1074/jbc.M512931200; Vadolas J, 2005, BBA-GENE STRUCT EXPR, V1728, P150, DOI 10.1016/j.bbaexp.2005.02.008; Vadolas J, 2004, HUM MOL GENET, V13, P223, DOI 10.1093/hmg/ddh023; van Dijk TB, 2010, BLOOD, V116, P4349, DOI 10.1182/blood-2010-03-274399; Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048; Wilber A, 2011, BLOOD, V117, P3945, DOI 10.1182/blood-2010-11-316893; Xu J, 2013, P NATL ACAD SCI USA, V110, P6518, DOI 10.1073/pnas.1303976110; Xu J, 2010, GENE DEV, V24, P783, DOI 10.1101/gad.1897310	51	9	9	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2306	2317		10.1096/fj.13-246637	http://dx.doi.org/10.1096/fj.13-246637			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24443374				2022-12-28	WOS:000335336000032
J	Chen, JL; Walton, KL; Winbanks, CE; Murphy, KT; Thomson, RE; Makanji, Y; Qian, HW; Lynch, GS; Harrison, CA; Gregorevic, P				Chen, Justin L.; Walton, Kelly L.; Winbanks, Catherine E.; Murphy, Kate T.; Thomson, Rachel E.; Makanji, Yogeshwar; Qian, Hongwei; Lynch, Gordon S.; Harrison, Craig A.; Gregorevic, Paul			Elevated expression of activins promotes muscle wasting and cachexia	FASEB JOURNAL			English	Article						adeno-associated virus; atrophy; myostatin	INHIBIN-DEFICIENT MICE; CANCER CACHEXIA; TREATMENT OPTIONS; SKELETAL-MUSCLES; MYOSTATIN; ATROPHY; PATHWAY; PROTEIN; MECHANISMS; REGULATOR	In models of cancer cachexia, inhibiting type IIB activin receptors (ActRIIBs) reverse muscle wasting and prolongs survival, even with continued tumor growth. ActRIIB mediates signaling of numerous TGF-beta proteins; of these, we demonstrate that activins are the most potent negative regulators of muscle mass. To determine whether activin signaling in the absence of tumor-derived factors induces cachexia, we used recombinant serotype 6 adeno-associated virus (rAAV6) vectors to increase circulating activin A levels in C57BL/6 mice. While mice injected with control vector gained similar to 10% of their starting body mass (3.8 +/- 0.4 g) over 10 wk, mice injected with increasing doses of rAAV6:activin A exhibited weight loss in a dose-dependent manner, to a maximum of -12.4% (-4.2 +/- 1.1 g). These reductions in body mass in rAAV6:activin-injected mice correlated inversely with elevated serum activin A levels (7- to 24-fold). Mechanistically, we show that activin A reduces muscle mass and function by stimulating the ActRIIB pathway, leading to deleterious consequences, including increased transcription of atrophy-related ubiquitin ligases, decreased Akt/mTOR-mediated protein synthesis, and a profibrotic response. Critically, we demonstrate that the muscle wasting and fibrosis that ensues in response to excessive activin levels is fully reversible. These findings highlight the therapeutic potential of targeting activins in cachexia.-Chen, J. L., Walton, K. L., Winbanks, C. E., Murphy, K. T., Thomson, R. E., Makanji, Y., Qian, H., Lynch, G. S., Harrison, C. A., Gregorevic, P. Elevated expression of activins promotes muscle wasting and cachexia.	[Chen, Justin L.; Winbanks, Catherine E.; Thomson, Rachel E.; Qian, Hongwei; Gregorevic, Paul] Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia; [Chen, Justin L.; Walton, Kelly L.; Makanji, Yogeshwar; Harrison, Craig A.] Prince Henrys Inst, Clayton, Vic, Australia; [Chen, Justin L.; Harrison, Craig A.; Gregorevic, Paul] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia; [Murphy, Kate T.; Lynch, Gordon S.; Gregorevic, Paul] Univ Melbourne, Dept Physiol, Melbourne, Vic, Australia; [Gregorevic, Paul] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA	Baker Heart and Diabetes Institute; Prince Henry's Institute of Medical Research; Monash University; University of Melbourne; University of Washington; University of Washington Seattle	Gregorevic, P (corresponding author), Baker IDI Heart & Diabet Inst, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	paul.gregorevic@bakeridi.edu.au	Gregorevic, Paul/AAH-6040-2021; Lynch, Gordon/G-9553-2015; Walton, Kelly/ABF-7282-2020	Gregorevic, Paul/0000-0002-7418-8945; Lynch, Gordon/0000-0001-9220-9810; Walton, Kelly/0000-0003-0627-2958; Harrison, Craig/0000-0003-1059-3682; Murphy, Kate/0000-0003-1993-4367	National Health and Medical Research Council (NH&MRC) of Australia [526648, 566820, 1006488]; NHMRC [1046782, 1013533, 1023178]; Pfizer Australia; Operational Infrastructure Support Program of the Victorian government	National Health and Medical Research Council (NH&MRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Pfizer Australia(PfizerPfizer Australia); Operational Infrastructure Support Program of the Victorian government	The authors thank Drs. Jonathan Davey and Kevin Watt (Division of Cell Signaling and Metabolism, Baker IDI Heart and Diabetes Institute) and Emily Kelly, Karen Chan, and Enid Prusyers (Prince Henry's Institute) for technical assistance; David de Kretser and Susan Hayward (Monash Institute of Medical Research, Melbourne, VIC, Australia) for assistance with the activin ELISAs; Drs. Mark Ziemann, Ross Lazarus, and Assam El-Osta (Division of Diabetic Complications, Baker IDI Heart and Diabetes Institute) for support with bioinformatics analyses; and Prof. Mark A. Febbraio (Division of Cell Signaling and Metabolism, Baker IDI Heart and Diabetes Institute) for technical advice and assistance concerning measurement of animals' body composition. The human cancer cell lines were a gift from Assoc. Prof. Guiying Nie and Dr. Colin Clyne (Prince Henry's Institute). Myostatin-null mice were a gift of Prof. Se-Jin Lee (Johns Hopkins University, Baltimore, MD, USA). This work was supported by grant funding (526648, 566820, 1006488) from the National Health and Medical Research Council (NH&MRC) of Australia. P.G., C.A.H., and K.T.M. are supported by Career Development Fellowships (1046782, 1013533, and 1023178) from the NH&MRC. P.G. was previously supported by a senior research fellowship, sponsored by Pfizer Australia. The Baker IDI Heart and Diabetes Institute and Prince Henry's Institute are supported in part by the Operational Infrastructure Support Program of the Victorian government. Author contributions: J.L.C., K.L.W., C.A.H. and P.G. designed the research; J.L.C., K.L., K.T.M., R.E.T., Y.M., and H.Q. performed the experimental work; C.E.W., G.S.L., C.A.H., and P.G. contributed reagents and analytical tools and technical advice; J.L.C., C.E.W., K.T.M., and P.G. analyzed the data; J.L.C., G.S.L., C.A.H., and P.G. wrote the manuscript. The authors declare no conflicts of interest.	Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Blanco G, 2001, HUM MOL GENET, V10, P9, DOI 10.1093/hmg/10.1.9; Blankinship MJ, 2004, MOL THER, V10, P671, DOI 10.1016/j.ymthe.2004.07.016; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Carson JA, 2010, EXERC SPORT SCI REV, V38, P168, DOI 10.1097/JES.0b013e3181f44f11; Clavel S, 2010, MOL CELL BIOL, V30, P470, DOI 10.1128/MCB.00666-09; Fearon K, 2013, NAT REV CLIN ONCOL, V10, P90, DOI 10.1038/nrclinonc.2012.209; Harada K, 1996, J CLIN ENDOCR METAB, V81, P2125, DOI 10.1210/jc.81.6.2125; Harrison CA, 2011, GROWTH FACTORS, V29, P174, DOI 10.3109/08977194.2011.608666; Hu XL, 2011, ARTERIOSCL THROM VAS, V31, P1540, DOI 10.1161/ATVBAHA.110.222638; Kawase T, 2009, CELL, V136, P535, DOI 10.1016/j.cell.2008.12.002; Knight PG, 1996, J ENDOCRINOL, V148, P267, DOI 10.1677/joe.0.1480267; Kumar A, 2012, CURR OPIN CLIN NUTR, V15, P233, DOI 10.1097/MCO.0b013e328351c3fc; Lee SJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-2; Leto G, 2006, CLIN EXP METASTAS, V23, P117, DOI 10.1007/s10585-006-9010-5; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Li QL, 2007, MOL HUM REPROD, V13, P675, DOI 10.1093/molehr/gam055; Ludlow H, 2009, CLIN ENDOCRINOL, V71, P867, DOI 10.1111/j.1365-2265.2009.03567.x; Makanji Y, 2011, ENDOCRINOLOGY, V152, P3758, DOI 10.1210/en.2011-1052; Mansilla F, 2008, J CELL BIOCHEM, V105, P847, DOI 10.1002/jcb.21880; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Mittal A, 2010, J CELL BIOL, V188, P833, DOI 10.1083/jcb.200909117; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Rahimov F, 2011, PHYSIOL GENOMICS, V43, P398, DOI 10.1152/physiolgenomics.00223.2010; Ruegg MA, 2011, ANNU REV PHARMACOL, V51, P373, DOI 10.1146/annurev-pharmtox-010510-100537; Schertzer JD, 2006, AM J PHYSIOL-ENDOC M, V291, pE499, DOI 10.1152/ajpendo.00101.2006; Suzuki N, 2007, J CLIN INVEST, V117, P2468, DOI 10.1172/JCI30654; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Walton KL, 2009, J BIOL CHEM, V284, P9311, DOI 10.1074/jbc.M808763200; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; Winbanks CE, 2012, J CELL BIOL, V197, P997, DOI 10.1083/jcb.201109091; Winbanks CE, 2011, J BIOL CHEM, V286, P13805, DOI 10.1074/jbc.M110.192625; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; Wu Q, 2006, FRONT BIOSCI-LANDMRK, V11, P2714, DOI 10.2741/2001; Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	42	132	136	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1711	1723		10.1096/fj.13-245894	http://dx.doi.org/10.1096/fj.13-245894			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24378873				2022-12-28	WOS:000335344300018
J	Roebrock, K; Sunderkotter, C; Munck, NA; Wolf, M; Nippe, N; Barczyk, K; Varga, G; Vogl, T; Roth, J; Ehrchen, J				Roebrock, Kirsten; Sunderkoetter, Cord; Muenck, Niels-Arne; Wolf, Marc; Nippe, Nadine; Barczyk, Katarzyna; Varga, Georg; Vogl, Thomas; Roth, Johannes; Ehrchen, Jan			Epidermal expression of I-TAC (Cxcl11) instructs adaptive Th2-type immunity	FASEB JOURNAL			English	Article						leishmaniasis; keratinocytes	LEISHMANIA-MAJOR INFECTION; SUSCEPTIBLE BALB/C MICE; ANTIGEN-PRESENTING CELLS; HUMAN EPITHELIAL-CELLS; DENDRITIC CELLS; T-CELLS; GENE-EXPRESSION; TH2 RESPONSE; CHEMOKINE; INFLAMMATION	To decipher early promoters of the local microenvironment for Th2-type immunity, we wanted to identify gene patterns that were induced by Leishmania major in the infected skin of susceptible, Th2-prone BALB/c, but not of resistant, Th1-prone C57BL/6 mice. We found a marked up-regulation of the chemokine I-TAC (Cxcl11) during the first 2 d of infection in the epidermis of susceptible but not of resistant mice. Accordingly, local injection of I-TAC (2x1 mu g) in resistant mice on the first day of infection resulted in a Th2-driven, sustained deterioration of disease and dramatically enhanced parasite levels. On the cellular level, I-TAC decreased IL-12 production by dendritic cells (DCs) in skin-draining lymph nodes and by DCs in vitro. Thus, we demonstrate for the first time that epidermis-derived I-TAC triggers a sustained Th2-response that determines the outcome of a complex immunological process.-Roebrock, K., Sunderkotter, C., Munck, N-A., Wolf, M., Nippe, N., Barczyk, K., Varga, G., Vogl, T., Roth, J., Ehrchen, J. Epidermal expression of I-TAC (Cxcl11) instructs adaptive Th2-type immunity.	[Roebrock, Kirsten; Muenck, Niels-Arne; Wolf, Marc; Nippe, Nadine; Barczyk, Katarzyna; Vogl, Thomas; Roth, Johannes; Ehrchen, Jan] Univ Munster, Inst Immunol, D-48149 Munster, Germany; [Sunderkoetter, Cord; Ehrchen, Jan] Univ Munster, Dept Dermatol, D-48149 Munster, Germany; [Varga, Georg] Univ Munster, Dept Pediat Rheumatol & Immunol, D-48149 Munster, Germany; [Roebrock, Kirsten; Sunderkoetter, Cord; Muenck, Niels-Arne; Vogl, Thomas; Roth, Johannes; Ehrchen, Jan] Interdisciplinary Ctr Clin Res, Munster, Germany	University of Munster; University of Munster; University of Munster	Ehrchen, J (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 58, D-48149 Munster, Germany.	jan.ehrchen@ukmuenster.de		Sunderkotter, Cord/0000-0002-2929-145X; Munck, Niels-Arne/0000-0002-1875-8894	Deutsche Forschungsgemeinschaft (DFG) [EH 397/1-1, SU 193/3-2]; German Ministry of Research (BMBF) [01KI07100]; IZKF, University of Munster [Eh2/019/11, Sun2/019/07]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Ministry of Research (BMBF)(Federal Ministry of Education & Research (BMBF)); IZKF, University of Munster	The authors thank Eva Nattkemper, Claudia Sole, and Ulla Nordhues for excellent technical assistance. The authors thank Toni Weinhage for help with the cytometric bead assay. The PRISM T 7000 device was made available by the service and technology platform Integrated Functional Genomics (IFG) of the Interdisciplinary Center for Clinical Research (IZKF) of the University of Munster. This work was funded by Deutsche Forschungsgemeinschaft (DFG; EH 397/1-1 and SU 193/3-2), the German Ministry of Research (BMBF; 01KI07100), and the IZKF, University of Munster (Eh2/019/11, Sun2/019/07).	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Antoniazi S, 2004, INFECT IMMUN, V72, P5168, DOI 10.1128/IAI.72.9.5168-5174.2004; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Barbi J, 2008, J IMMUNOL, V181, P4613, DOI 10.4049/jimmunol.181.7.4613; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Braun MC, 2000, J IMMUNOL, V164, P3009, DOI 10.4049/jimmunol.164.6.3009; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; Corthay A, 2006, SCAND J IMMUNOL, V64, P93, DOI 10.1111/j.1365-3083.2006.01782.x; Cox JH, 2008, J BIOL CHEM, V283, P19389, DOI 10.1074/jbc.M800266200; de Jong EC, 1999, J LEUKOCYTE BIOL, V66, P201, DOI 10.1002/jlb.66.2.201; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Ehrchen J, 2001, J ENDOCRINOL, V169, P87, DOI 10.1677/joe.0.1690087; Ehrchen J, 2007, FASEB J, V21, P3208, DOI 10.1096/fj.06-7261com; Ehrchen JM, 2008, INFECT IMMUN, V76, P4241, DOI 10.1128/IAI.01714-07; Ehrchen JM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000871; Filippi C, 2003, J EXP MED, V198, P201, DOI 10.1084/jem.20021893; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Humphreys NE, 2008, J IMMUNOL, V180, P2443, DOI 10.4049/jimmunol.180.4.2443; Iezzi G, 2006, J IMMUNOL, V177, P1250, DOI 10.4049/jimmunol.177.2.1250; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kanda N, 2007, EUR J IMMUNOL, V37, P338, DOI 10.1002/eji.200636420; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Katzman SD, 2008, J CLIN INVEST, V118, P801, DOI 10.1172/JCI33174; Lindell DM, 2008, EUR J IMMUNOL, V38, P2168, DOI 10.1002/eji.200838155; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Matte C, 2002, J INFECT DIS, V185, P673, DOI 10.1086/339260; Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11; Muller K, 2001, MED MICROBIOL IMMUN, V190, P73; Nabors GS, 1995, PARASITE IMMUNOL, V17, P569, DOI 10.1111/j.1365-3024.1995.tb01000.x; Newberry RD, 2001, J IMMUNOL, V166, P4465, DOI 10.4049/jimmunol.166.7.4465; Nigg AP, 2007, J IMMUNOL, V178, P7251, DOI 10.4049/jimmunol.178.11.7251; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Petkovic V, 2004, J LEUKOCYTE BIOL, V76, P701, DOI 10.1189/jlb.1103570; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; SUNDERKOTTER C, 1993, J IMMUNOL, V151, P4891; Tacchini-Cottier F, 2000, J IMMUNOL, V165, P2628, DOI 10.4049/jimmunol.165.5.2628; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Vester B, 1999, INFECT IMMUN, V67, P3155, DOI 10.1128/IAI.67.6.3155-3159.1999; von Stebut E, 2003, J EXP MED, V198, P191, DOI 10.1084/jem.20030159; von Stebut E, 2007, EXP DERMATOL, V16, P340, DOI 10.1111/j.1600-0625.2007.00554.x; Westphal G, 2002, METHOD ENZYMOL, V356, P80; Whelan M, 2000, J IMMUNOL, V164, P6453, DOI 10.4049/jimmunol.164.12.6453; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x	55	10	12	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1724	1734		10.1096/fj.13-233593	http://dx.doi.org/10.1096/fj.13-233593			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24398292				2022-12-28	WOS:000335344300019
J	Gansler, J; Preissner, KT; Fischer, S				Gansler, Julia; Preissner, Klaus T.; Fischer, Silvia			Influence of proinflammatory stimuli on the expression of vascular ribonuclease 1 in endothelial cells	FASEB JOURNAL			English	Article						extracellular RNA; tumor necrosis factor; vascular homeostasis	EXTRACELLULAR RNA; PANCREATIC RIBONUCLEASE; HISTONE DEACETYLASES; SERUM RIBONUCLEASE; CANCER; INFLAMMATION; CYTOKINES; PROTEIN; PROCOAGULANT; PERMEABILITY	Extracellular RNA (eRNA) released under injury or pathological conditions has been identified as a yet unrecognized vascular alarm signal to induce procoagulant, permeability-promoting, and proinflammatory activities. eRNA-induced functions were largely prevented by administration of RNase1 as a natural blood vessel-protective antagonist of eRNA. The aim of this study was to investigate the inflammatory regulation of endothelial cell RNase1, which is partly stored in Weibel-Palade bodies of these cells. Long-term treatment of human umbilical vein endothelial cells (HUVECs) with inflammatory agents like tumor necrosis factor (TNF-) or interleukin 1 (IL-1), but not with eRNA, significantly decreased the release (34 +/- 5%; 34 +/- 7% of control) as well as the cellular expression (19.5 +/- 5%; 33 +/- 8% of control) of RNase1. Down-regulation of RNase1 by TNF- stimulation or RNase1 siRNA knockdown increased the permeability of HUVEC monolayers, demonstrated by dearrangement of VE-cadherins at cell-cell borders. Mechanistically, cytokine-induced decrease of RNase1 expression did not involve the nuclear factor B (NFB) signaling pathway but epigenic modifications. Since inhibition of histone deacetylases resulted in recovery of RNase1 expression and secretion after cytokine treatment, an acetylation-dependent process of RNase1 regulation is proposed. These results indicate that cytokine-mediated down-regulation of RNase1 in endothelial cells may aggravate eRNA-induced inflammatory activities and thereby disturbs the vascular homeostasis of the extracellular RNA/RNase system.Gansler, J., Preissner, K. T., Fischer, S. Influence of proinflammatory stimuli on the expression of vascular ribonuclease 1 in endothelial cells.	[Gansler, Julia; Preissner, Klaus T.; Fischer, Silvia] Univ Giessen, Sch Med, Inst Biochem, D-35392 Giessen, Germany	Justus Liebig University Giessen	Fischer, S (corresponding author), Univ Giessen, Sch Med, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	silvia.fischer@biochemie.med.uni-giessen.de	Fischer, Silvia/ABG-3104-2021		Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany) [SFB547, SPP1190, FI 543/2-1]; Excellence Cluster Cardiopulmonary System (ECCPS);  [IRTG-1566 (PROMISE)]	Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany)(German Research Foundation (DFG)); Excellence Cluster Cardiopulmonary System (ECCPS)(German Research Foundation (DFG)); 	The authors thank Jessica Schneider and Barbel Fuhler for their skilful technical assistance. Funding was obtained from the Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany), including SFB547, SPP1190, FI 543/2-1, the Excellence Cluster Cardiopulmonary System (ECCPS), and IRTG-1566 (PROMISE). The authors declare no conflicts of interest.	BARDON A, 1976, CLIN CHIM ACTA, V67, P231, DOI 10.1016/0009-8981(76)90331-4; Barrabes S, 2007, GLYCOBIOLOGY, V17, P388, DOI 10.1093/glycob/cwm002; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Fischer S, 2007, BLOOD, V110, P2457, DOI 10.1182/blood-2006-08-040691; Fischer S, 2013, CANCER RES, V73, P5080, DOI 10.1158/0008-5472.CAN-12-4657; Fischer S, 2012, THROMB HAEMOSTASIS, V108, P730, DOI 10.1160/TH12-03-0186; Fischer S, 2011, THROMB HAEMOSTASIS, V105, P345, DOI 10.1160/TH10-06-0345; Fischer S, 2009, FASEB J, V23, P2100, DOI 10.1096/fj.08-121608; Friedl J, 2002, BLOOD, V100, P1334, DOI 10.1182/blood.V100.4.1334.h81602001334_1334_1339; Futami J, 1997, DNA CELL BIOL, V16, P413, DOI 10.1089/dna.1997.16.413; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; Grabiec AM, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3137; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kannemeier C, 2007, P NATL ACAD SCI USA, V104, P6388, DOI 10.1073/pnas.0608647104; Kawabata Tomoko, 2010, Arthritis Res Ther, V12, pR133, DOI 10.1186/ar3071; Landre JBP, 2002, J CELL BIOCHEM, V86, P540, DOI 10.1002/jcb.10234; Petaja J, 2011, THROMB RES, V127, pS34, DOI 10.1016/S0049-3848(10)70153-5; REDDI KK, 1976, P NATL ACAD SCI USA, V73, P2308, DOI 10.1073/pnas.73.7.2308; Rugeles MT, 2003, AIDS, V17, P481, DOI 10.1097/00002030-200303070-00002; SENO M, 1994, BBA-GENE STRUCT EXPR, V1218, P466, DOI 10.1016/0167-4781(94)90208-9; Shakespear MR, 2011, TRENDS IMMUNOL, V32, P335, DOI 10.1016/j.it.2011.04.001; SHEID B, 1977, CANCER, V39, P2204, DOI 10.1002/1097-0142(197705)39:5<2204::AID-CNCR2820390539>3.0.CO;2-Y; Sohn RH, 2005, BLOOD, V105, P3910, DOI 10.1182/blood-2004-03-0928; Sorrentino S, 2010, FEBS LETT, V584, P2194, DOI 10.1016/j.febslet.2010.04.018; SZNAJD J, 1981, COR VASA, V23, P241; WEICKMANN JL, 1984, CANCER RES, V44, P1682; ZIMMERMAN SB, 1965, ANAL BIOCHEM, V10, P444, DOI 10.1016/0003-2697(65)90313-1	31	21	21	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					752	760		10.1096/fj.13-238600	http://dx.doi.org/10.1096/fj.13-238600			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24174426				2022-12-28	WOS:000331072200022
J	Haque, S; Yan, XJ; Rosen, L; McCormick, S; Chiorazzi, N; Mongini, PKA				Haque, Shabirul; Yan, Xiao Jie; Rosen, Lisa; McCormick, Steven; Chiorazzi, Nicholas; Mongini, Patricia K. A.			Effects of prostaglandin E-2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion	FASEB JOURNAL			English	Article						B lymphocyte; TP53; eicosanoid; inflammation; lymphoma	NF-KAPPA-B; SINGLE-STRANDED-DNA; PROTEIN-KINASE; SOMATIC HYPERMUTATION; GENE HYPERMUTATION; SJOGRENS-SYNDROME; POLYMERASE-ETA; A-T; MUTATIONS; ACTIVATION	Within T-cell-dependent germinal centers, p53 gene transcription is repressed by Bcl-6 and is thus less vulnerable to mutation. Malignant lymphomas within inflamed extranodal sites exhibit a relatively high incidence of p53 mutations. The latter might originate from normal B-cell clones manifesting activation-induced cytosine deaminase (AID) and up-regulated p53 following T-cell-independent (TI) stimulation. We here examine p53 gene transcription in such TI clones, with a focus on modulatory effects of prostaglandin E-2 (PGE(2)), and evaluate progeny for p53 mutations. Resting IgM(+)IgD(+)CD27(-) B cells from human tonsils were labeled with CFSE and stimulated in vitro with complement-coated antigen surrogate, IL-4, and BAFF +/- exogenous PGE(2) (50 nM) or an analog specific for the EP2 PGE(2) receptor. We use flow cytometry to measure p53 and AID protein within variably divided blasts, qRT-PCR of p53 mRNA from cultures with or without actinomycin D to monitor mRNA transcription/stability, and single-cell p53 RT-PCR/sequencing to assess progeny for p53 mutations. We report that EP2 signaling triggers increased p53 gene transcriptional activity in AID(+) cycling blasts (P<0.01). Progeny exhibit p53 mutations at a frequency (8.5x10(-4)) greater than the baseline error rate (<0.8x10(-4)). We conclude that, devoid of the repressive influences of Bcl-6, dividing B lymphoblasts in inflamed tissues should display heightened p53 transcription and increased risk of p53 mutagenesis.Haque, S., Yan, X. J., Rosen, L., McCormick, S., Chiorazzi, N., Mongini, P. K. A. Effects of prostaglandin E-2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion.	[Haque, Shabirul; Yan, Xiao Jie; Rosen, Lisa; Chiorazzi, Nicholas; Mongini, Patricia K. A.] Feinstein Inst Med Res, North Shore Long Isl Jewish LIJ Hlth Syst, Manhasset, NY 11030 USA; [McCormick, Steven] New York Eye & Ear Infirm, Dept Pathol, New York, NY 10003 USA; [Chiorazzi, Nicholas; Mongini, Patricia K. A.] Hofstra North Shore LIJ, Sch Med, Dept Mol Med, Hempstead, NY USA	Northwell Health; New York Eye & Ear Infirmary of Mount Sinai; Hofstra University	Mongini, PKA (corresponding author), Feinstein Inst Med Res, Karches Ctr CLL Res, Lab Cell Biol B, 350 Community Dr, Manhasset, NY 11030 USA.	pmongini@nshs.edu	haque, shabirul/AAB-9136-2022	haque, shabirul/0000-0002-6721-0630	Karches Foundation; Prince Family Foundation; Marks Foundation; U.S. National Institutes of Health (NIH) [R21 AR061653, NIH M01]; General Clinical Research Center [RR01853]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR061653] Funding Source: NIH RePORTER	Karches Foundation; Prince Family Foundation; Marks Foundation; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by funds from The Karches Foundation, The Prince Family Foundation, and The Marks Foundation; U.S. National Institutes of Health (NIH) grant R21 AR061653 (to P.K.A.M.), and NIH M01 General Clinical Research Center grant RR01853. The authors thank Hyunjoo Lee and Jennifer Nieto for their skilled technical assistance; Herb Borrero for cell sorting; and Dr. Carlo Callissano for early help with single-cell RT-PCR. The authors also thank Dr. Betty Diamond and Dr. Michael Brunda for reviewing the manuscript and Dr. Thomas MacCarthy for helping to implement the web- based SHMTool (http://scb.aecom.yu.edu/shmtool). The authors declare no conflicts of interest.	Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Abdouh M, 2001, J BIOL CHEM, V276, P4382, DOI 10.1074/jbc.M004559200; Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Azzam GA, 2011, CELL CYCLE, V10, P1352, DOI 10.4161/cc.10.9.15344; Bachl J, 2001, J IMMUNOL, V166, P5051, DOI 10.4049/jimmunol.166.8.5051; BALDINI L, 1994, BLOOD, V84, P270; BASICZANINOVIC T, 1995, MOL CARCINOGEN, V14, P214, DOI 10.1002/mc.2940140311; Bende RJ, 2009, HAEMATOL-HEMATOL J, V94, P1109, DOI 10.3324/haematol.2009.005983; Benoit V, 2006, ONCOGENE, V25, P5708, DOI 10.1038/sj.onc.1209579; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Berger M, 2001, J BIOL CHEM, V276, P3785, DOI 10.1074/jbc.M008879200; BHATIA KG, 1992, CANCER RES, V52, P4273; Bhattacharya P, 2008, EUR J IMMUNOL, V38, P227, DOI 10.1002/eji.200737664; Carvajal LA, 2013, EMBO REP, V14, P414, DOI 10.1038/embor.2013.25; Casabonne D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052808; Cerutti A, 2012, EUR J IMMUNOL, V42, P1956, DOI 10.1002/eji.201242594; Chahwan R, 2012, SEMIN IMMUNOL, V24, P293, DOI 10.1016/j.smim.2012.05.005; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Choi EM, 2009, BBA-MOL CELL RES, V1793, P1354, DOI 10.1016/j.bbamcr.2009.05.006; Das P, 2007, CANCER-AM CANCER SOC, V109, P2323, DOI 10.1002/cncr.22680; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; de Moraes E, 2007, INT J CANCER, V121, P929, DOI 10.1002/ijc.22899; de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P1314; Delbos F, 2007, J EXP MED, V204, P17, DOI 10.1084/jem.20062131; Dorner T, 1998, EUR J IMMUNOL, V28, P3384; DU MQ, 1995, BLOOD, V86, P4587, DOI 10.1182/blood.V86.12.4587.bloodjournal86124587; Dumais N, 2002, J IMMUNOL, V168, P274, DOI 10.4049/jimmunol.168.1.274; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Fedyk ER, 1996, P NATL ACAD SCI USA, V93, P10978, DOI 10.1073/pnas.93.20.10978; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; Frank AK, 2011, MOL CELL BIOL, V31, P1201, DOI 10.1128/MCB.01136-10; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gao N, 2010, J BIOL CHEM, V285, P28097, DOI 10.1074/jbc.M110.116566; Gostissa M, 2013, P NATL ACAD SCI USA, V110, P2934, DOI 10.1073/pnas.1222570110; Groom J, 2002, J CLIN INVEST, V109, P59, DOI 10.1172/JCI200214121; Gudkov Andrei V, 2011, Genes Cancer, V2, P503, DOI 10.1177/1947601911409747; Herlands RA, 2008, IMMUNITY, V29, P249, DOI 10.1016/j.immuni.2008.06.009; Hsu MC, 2006, P NATL ACAD SCI USA, V103, P5905, DOI 10.1073/pnas.0601502103; Huang CX, 2013, NAT IMMUNOL, V14, P380, DOI 10.1038/ni.2543; Huang SK, 2012, FASEB J, V26, P3703, DOI 10.1096/fj.11-203323; Iwahashi H, 2000, J IMMUNOL, V164, P5403, DOI 10.4049/jimmunol.164.10.5403; Jeong BS, 2010, FASEB J, V24, P1347, DOI 10.1096/fj.09-146001; Khoury Marie P, 2011, Genes Cancer, V2, P453, DOI 10.1177/1947601911408893; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Klein RD, 2005, CANCER RES, V65, P1808, DOI 10.1158/0008-5472.CAN-04-3567; KOCIALKOWSKI S, 1995, BRIT J HAEMATOL, V89, P55, DOI 10.1111/j.1365-2141.1995.tb08911.x; Kramata P, 2005, CANCER RES, V65, P3577, DOI 10.1158/0008-5472.CAN-04-4537; Landgren O, 2007, BLOOD, V109, P2198, DOI 10.1182/blood-2006-08-044008; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee H, 2012, J IMMUNOL, V188, P6093, DOI 10.4049/jimmunol.1103037; Lee H, 2010, J IMMUNOL, V185, P5300, DOI 10.4049/jimmunol.1000574; Lens D, 1997, BLOOD, V89, P2015, DOI 10.1182/blood.V89.6.2015; Li SY, 2013, MOL IMMUNOL, V53, P214, DOI 10.1016/j.molimm.2012.08.009; Liu H, 2007, MOL CELL BIOL, V27, P8480, DOI 10.1128/MCB.01126-07; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; Liu XH, 2005, J BIOL CHEM, V280, P3817, DOI 10.1074/jbc.M406577200; MacCarthy T, 2009, P NATL ACAD SCI USA, V106, P8629, DOI 10.1073/pnas.0903803106; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028; Martomo SA, 2005, P NATL ACAD SCI USA, V102, P8656, DOI 10.1073/pnas.0501852102; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mongini PKA, 2006, J IMMUNOL, V176, P6736, DOI 10.4049/jimmunol.176.11.6736; Mongini PKA, 2005, J IMMUNOL, V175, P6143, DOI 10.4049/jimmunol.175.9.6143; Murphy SH, 2011, P NATL ACAD SCI USA, V108, P17117, DOI 10.1073/pnas.1114420108; Naderi EH, 2011, NEOPLASIA, V13, P653, DOI 10.1593/neo.11542; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Park SW, 2012, AM J PHYSIOL-GASTR L, V303, pG657, DOI 10.1152/ajpgi.00529.2011; Peng HZ, 1996, AM J PATHOL, V148, P643; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Rowh MAW, 2011, ONCOGENE, V30, P4757, DOI 10.1038/onc.2011.191; Royer B, 1997, BLOOD, V90, P766, DOI 10.1182/blood.V90.2.766; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Saldana-Meyer R, 2011, EPIGENETICS-US, V6, P1068, DOI 10.4161/epi.6.9.16683; Saxena A, 2004, J CLIN PATHOL, V57, P1258, DOI 10.1136/jcp.2004.018416; Schmidt NW, 2006, J LEUKOCYTE BIOL, V79, P852, DOI 10.1189/jlb.0705402; Schonhoff CM, 2008, HEPATOLOGY, V47, P1309, DOI 10.1002/hep.22162; Shen HM, 2009, J EXP MED, V206, P1057, DOI 10.1084/jem.20082678; Shick L, 1997, CELL GROWTH DIFFER, V8, P121; Shim M, 2010, J BIOL CHEM, V285, P16206, DOI 10.1074/jbc.M109.078576; Slatter TL, 2010, CELL DEATH DIFFER, V17, P540, DOI 10.1038/cdd.2009.136; SMELAND EB, 1988, EUR J IMMUNOL, V18, P1847, DOI 10.1002/eji.1830181131; Steinert D, 2009, AM J PHYSIOL-CELL PH, V296, pC75, DOI 10.1152/ajpcell.00024.2008; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sweet RA, 2011, P NATL ACAD SCI USA, V108, P7932, DOI 10.1073/pnas.1018571108; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; Takahashi P, 2011, APOPTOSIS, V16, P950, DOI 10.1007/s10495-011-0623-z; Takakuwa T, 2000, JPN J CANCER RES, V91, P280, DOI 10.1111/j.1349-7006.2000.tb00942.x; Tapinos NI, 1999, ARTHRITIS RHEUM-US, V42, P1466, DOI 10.1002/1529-0131(199907)42:7<1466::AID-ANR21>3.0.CO;2-L; Vilborg A, 2009, P NATL ACAD SCI USA, V106, P15756, DOI 10.1073/pnas.0900862106; Wang P, 2010, J BIOL CHEM, V285, P24793, DOI 10.1074/jbc.M110.110320; Ward JM, 1999, LAB INVEST, V79, P3; Wilson TM, 2005, J EXP MED, V201, P637, DOI 10.1084/jem.20042066; Wright BE, 2011, CARCINOGENESIS, V32, P1559, DOI 10.1093/carcin/bgr177; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu XS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015549; Xia DR, 2012, NAT MED, V18, P224, DOI 10.1038/nm.2608; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Young KH, 2008, BLOOD, V112, P3088, DOI 10.1182/blood-2008-01-129783; Zainuddin N, 2011, LEUKEMIA RES, V35, P272, DOI 10.1016/j.leukres.2010.08.023; Zhang SZ, 2011, FASEB J, V25, P2387, DOI 10.1096/fj.10-175299; Zheng SJ, 2005, DIABETES, V54, P1423, DOI 10.2337/diabetes.54.5.1423; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhu F, 2010, CANCER RES, V70, P5851, DOI 10.1158/0008-5472.CAN-09-4646; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001; Zou TT, 2006, J BIOL CHEM, V281, P19387, DOI 10.1074/jbc.M602344200	116	6	7	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					627	643		10.1096/fj.13-237792	http://dx.doi.org/10.1096/fj.13-237792			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24145719	Green Published			2022-12-28	WOS:000331072200011
J	Penaloza, CG; Estevez, B; Han, DM; Norouzi, M; Lockshin, RA; Zakeri, Z				Penaloza, Carlos G.; Estevez, Brian; Han, Dinah M.; Norouzi, Melissa; Lockshin, Richard A.; Zakeri, Zahra			Sex-dependent regulation of cytochrome P450 family members Cyp1a1, Cyp2e1, and Cyp7b1 by methylation of DNA	FASEB JOURNAL			English	Article						gender; sexual dimorphism; estrogen; 17-estradiol; 5-aza-2-deoxycytidine; sodium bisulfite; X-ist	GENDER-RELATED DIFFERENCES; METHYLTRANSFERASES DNMT3A; BOVINE BLASTOCYSTS; GENE-EXPRESSION; HORMONES; DISEASE; CELLS	Sexual differences are only partially attributable to hormones. Cultured male or female cells, even from embryos before sexual differentiation, differ in gene expression and sensitivity to toxins, and these differences persist in isolated primary cells. Male and female cells from Swiss Webster CWF mice manifest sex-distinct patterns of DNA methylation for X-ist and for cytochrome P450 (CYP; family members 1a1, 2e1m, and 7b1. Dnmt3l is differentially expressed but not differentially methylated, and Gapdh is neither differentially methylated nor expressed. CYP family genes differ in expression in whole tissue homogenates and cell cultures, with female Cyp expression 2- to 355-fold higher and Dnmt3l 12- to 32-fold higher in males. DNA methylation in the promoters of these genes is sex dimorphic; reducing methylation differences reduces to 1- to 6-fold differences in the expression of these genes. Stress or estradiol alters both methylation and gene expression. We conclude that different methylation patterns partially explain the sex-based differences in expression of CYP family members and X-ist, which potentially leads to inborn differences between males and females and their different responses to chronic and acute changes. Sex-differential methylation may have medical effects.Penaloza, C.G., Estevez, B., Han, D.M., Norouzi, M., Lockshin, R.A., Zakeri, Z. Sex-dependent regulation of cytochrome P450 family members Cyp1a1, Cyp2e1, and Cyp7b1 by methylation of DNA.	[Penaloza, Carlos G.; Estevez, Brian; Han, Dinah M.; Norouzi, Melissa; Lockshin, Richard A.; Zakeri, Zahra] CUNY Queens Coll, Flushing, NY 11367 USA; [Penaloza, Carlos G.; Estevez, Brian; Han, Dinah M.; Norouzi, Melissa; Lockshin, Richard A.; Zakeri, Zahra] CUNY, Grad Ctr, Flushing, NY USA	City University of New York (CUNY) System; Queens College NY (CUNY); City University of New York (CUNY) System	Zakeri, Z (corresponding author), CUNY Queens Coll, 65-30 Kissena Blvd,NSB E143, Flushing, NY 11367 USA.	zahra_zakeri@hotmail.com		Estevez, Brian/0000-0002-1863-7224	U.S. National Institutes of Health/National Institute of General Medical Sciences [T 34 GM070387]; Professional Staff Congress-City University of New York; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM070387] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Professional Staff Congress-City University of New York; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by funding from the U.S. National Institutes of Health/National Institute of General Medical Sciences (Minority Access to Research Careers-Undergraduate Student Training in Academic Research) grant T 34 GM070387, and by a Professional Staff Congress-City University of New York award to Z.F.Z.	Bermejo-Alvarez P, 2008, PHYSIOL GENOMICS, V32, P264, DOI 10.1152/physiolgenomics.00234.2007; Bermejo-Alvarez P, 2010, P NATL ACAD SCI USA, V107, P3394, DOI 10.1073/pnas.0913843107; Bhadhprasit W, 2011, DRUG METAB DISPOS, V39, P490, DOI 10.1124/dmd.110.035980; Bourc'his D, 2008, MOL CELL ENDOCRINOL, V282, P87, DOI 10.1016/j.mce.2007.11.025; Bryant DN, 2010, NEUROSCIENCE, V170, P1261, DOI 10.1016/j.neuroscience.2010.08.019; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Cheng YW, 2007, ENVIRON MOL MUTAGEN, V48, P14, DOI 10.1002/em.20270; Conerly M, 2010, DIS MODEL MECH, V3, P290, DOI 10.1242/dmm.004812; Dewing P, 2003, MOL BRAIN RES, V118, P82, DOI 10.1016/S0169-328X(03)00339-5; Gebert C, 2009, GENOMICS, V94, P63, DOI 10.1016/j.ygeno.2009.03.004; Giltay EJ, 1999, ANN NY ACAD SCI, V876, P340, DOI 10.1111/j.1749-6632.1999.tb07658.x; Hazelhoff MH, 2012, INT J MOL SCI, V13, P10523, DOI 10.3390/ijms130810523; Jeng SR, 2012, GEN COMP ENDOCR, V175, P163, DOI 10.1016/j.ygcen.2011.11.005; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KALIN MF, 1990, STEROIDS, V55, P330, DOI 10.1016/0039-128X(90)90058-J; Kolodkin MH, 2011, J NEUROENDOCRINOL, V23, P577, DOI 10.1111/j.1365-2826.2011.02147.x; Kouzmenko A, 2010, EPIGENOMICS-UK, V2, P765, DOI 10.2217/EPI.10.58; La Salle S, 2004, DEV BIOL, V268, P403, DOI 10.1016/j.ydbio.2003.12.031; Le Goff G, 2006, INSECT BIOCHEM MOLEC, V36, P674, DOI 10.1016/j.ibmb.2006.05.009; Lockshin MD, 2001, J APPL PHYSIOL, V91, P2366, DOI 10.1152/jappl.2001.91.5.2366; Lockshin MD, 2006, ORTHOP CLIN N AM, V37, P629, DOI 10.1016/j.ocl.2006.08.002; Macak-Safranko Z, 2011, EXP TOXICOL PATHOL, V63, P345, DOI 10.1016/j.etp.2010.02.009; Mollerup S, 1999, CANCER RES, V59, P3317; Ng Martin K C, 2007, Heart Lung Circ, V16, P185, DOI 10.1016/j.hlc.2007.02.108; Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Penaloza C, 2009, FASEB J, V23, P1869, DOI 10.1096/fj.08-119388; Qin HH, 2013, AUSTRALAS J DERMATOL, V54, P90, DOI 10.1111/j.1440-0960.2012.00968.x; Roughton K, 2012, EUR J NEUROSCI, V36, P2763, DOI 10.1111/j.1460-9568.2012.08197.x; Selmi C., 2012, AUTOIMMUN REV, V11, P6; Torcia MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039853; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; Vanselow J, 2011, GEN COMP ENDOCR, V170, P475, DOI 10.1016/j.ygcen.2010.11.003; Voskuhl Rhonda, 2011, Biol Sex Differ, V2, P1, DOI 10.1186/2042-6410-2-1; Wang FF, 2010, HYPERTENSION, V55, P1172, DOI 10.1161/HYPERTENSIONAHA.110.150839; Wu L, 2012, J HUM HYPERTENS, V26, P731, DOI 10.1038/jhh.2011.96; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	37	35	37	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					966	977		10.1096/fj.13-233320	http://dx.doi.org/10.1096/fj.13-233320			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24161885	Green Published			2022-12-28	WOS:000331072200041
J	Billings, SE; Pierzchalski, K; Tjaden, NEB; Pang, XY; Trainor, PA; Kane, MA; Moise, AR				Billings, Sara E.; Pierzchalski, Keely; Tjaden, Naomi E. Butler; Pang, Xiao-Yan; Trainor, Paul A.; Kane, Maureen A.; Moise, Alexander R.			The retinaldehyde reductase DHRS3 is essential for preventing the formation of excess retinoic acid during embryonic development	FASEB JOURNAL			English	Article						development; metabolism; nuclear receptors; retinoid; vitamin A	SHORT-CHAIN DEHYDROGENASE/REDUCTASE; VITAMIN-A; RESPONSE ELEMENT; GENE-EXPRESSION; TARGETED DISRUPTION; METABOLIZING ENZYME; CERVICAL-VERTEBRAE; IN-VIVO; HINDBRAIN; HEART	Oxidation of retinol via retinaldehyde results in the formation of the essential morphogen all-trans-retinoic acid (ATRA). Previous studies have identified critical roles in the regulation of embryonic ATRA levels for retinol, retinaldehyde, and ATRA-oxidizing enzymes; however, the contribution of retinaldehyde reductases to ATRA metabolism is not completely understood. Herein, we investigate the role of the retinaldehyde reductase Dhrs3 in embryonic retinoid metabolism using a Dhrs3-deficient mouse. Lack of DHRS3 leads to a 40% increase in the levels of ATRA and a 60% and 55% decrease in the levels of retinol and retinyl esters, respectively, in Dhrs3(-/-) embryos compared to wild-type littermates. Furthermore, accumulation of excess ATRA is accompanied by a compensatory 30-50% reduction in the expression of ATRA synthetic genes and a 120% increase in the expression of the ATRA catabolic enzyme Cyp26a1 in Dhrs3(-/-) embryos vs. controls. Excess ATRA also leads to alterations (40-80%) in the expression of several developmentally important ATRA target genes. Consequently, Dhrs3(-/-) embryos die late in gestation and display defects in cardiac outflow tract formation, atrial and ventricular septation, skeletal development, and palatogenesis. These data demonstrate that the reduction of retinaldehyde by DHRS3 is critical for preventing formation of excess ATRA during embryonic development.	[Billings, Sara E.; Pang, Xiao-Yan; Moise, Alexander R.] Univ Kansas, Sch Pharm, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; [Pierzchalski, Keely; Kane, Maureen A.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Tjaden, Naomi E. Butler; Trainor, Paul A.] Stowers Inst Med Res, Kansas City, MO USA; [Tjaden, Naomi E. Butler; Trainor, Paul A.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA	University of Kansas; University System of Maryland; University of Maryland Baltimore; Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center	Moise, AR (corresponding author), Univ Kansas, Sch Pharm, Dept Pharmacol & Toxicol, 5060 Malott Hall,1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.	alexmoise@ku.edu	Tjaden, Naomi/GVU-6515-2022; AR, Moise/P-2474-2019; Moise, Alexander R/C-9498-2009	AR, Moise/0000-0003-2307-6035; Moise, Alexander R/0000-0003-2307-6035; Trainor, Paul/0000-0003-2774-3624; Pierzchalski, Keely/0000-0002-2456-0382	University of Kansas School of Pharmacy; U.S. National Center for Research Resources (NCRR); National Institute of General Medical Sciences (NIGMS) [5P20RR017708-10, 8 P20 GM103420-10]; University of Kansas Center for Research; University of Maryland School of Pharmacy; U.S. National Instittue of Allergy and Infectious Diseases [HHSN272202000046C]; Stowers Institute for Medical Research; National Institute for Dental and Craniofacial Research [DE016082]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD077260] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103420] Funding Source: NIH RePORTER	University of Kansas School of Pharmacy; U.S. National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); University of Kansas Center for Research; University of Maryland School of Pharmacy; U.S. National Instittue of Allergy and Infectious Diseases; Stowers Institute for Medical Research; National Institute for Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. Joseph Napoli, Rick Dobrowsky and Jeff Staudinger for valuable suggestions. The authors thank Dr. Janet Rossant (University of Toronto, the Hospital for Sick Children, Toronto, ON, Canada) for the gift of the RARE-LacZ reporter mice and Dr. Fred de Sauvage (Genentech, South San Francisco, CA, USA) and Lexicon Pharmaceuticals (The Woodlands, TX, USA) for sharing the Dhrs3<SUP>-/-</SUP> strain. The authors also thank Dr. David Moore, Ms. Heather Shinogle and Dr. Jennifer Hueston for help with microscopy and the use of a dissecting microscope. This work was supported by new faculty startup funds from the University of Kansas School of Pharmacy (A. R. M.); by grants from the U.S. National Center for Research Resources (NCRR) and National Institute of General Medical Sciences (NIGMS; 5P20RR017708-10 and 8 P20 GM103420-10; A. R. M.); by an award from the General Research Fund from the University of Kansas Center for Research (A. R. M.); by new faculty startup funds from the University of Maryland School of Pharmacy (M. A. K.) and U.S. National Instittue of Allergy and Infectious Diseases contract HHSN272202000046C (M. A. K.); and by the Stowers Institute for Medical Research and the National Institute for Dental and Craniofacial Research (DE016082; P.A.T.).	ABBOTT BD, 1989, TERATOLOGY, V40, P533, DOI 10.1002/tera.1420400602; Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Ackermans MMG, 2011, NUTR REV, V69, P613, DOI 10.1111/j.1753-4887.2011.00425.x; Ashique AM, 2012, GENESIS, V50, P415, DOI 10.1002/dvg.22002; Cerignoli F, 2002, CANCER RES, V62, P1196; Clagett-Dame M, 2011, NUTRIENTS, V3, P385, DOI 10.3390/nu3040385; COHLAN SQ, 1953, SCIENCE, V117, P535, DOI 10.1126/science.117.3046.535; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; CONDIE BG, 1993, DEVELOPMENT, V119, P579; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; Costaridis P, 1996, DEV DYNAM, V205, P41; Cunningham TJ, 2011, DEV DYNAM, V240, P1142, DOI 10.1002/dvdy.22583; DAVIS LA, 1981, TERATOLOGY, V24, P139, DOI 10.1002/tera.1420240205; Deisenroth C, 2011, J BIOL CHEM, V286, P28343, DOI 10.1074/jbc.M111.254227; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Dupe V, 2003, P NATL ACAD SCI USA, V100, P14036, DOI 10.1073/pnas.2336223100; Dupe V, 1997, DEVELOPMENT, V124, P399; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; Farjo KM, 2011, DEV BIOL, V357, P347, DOI 10.1016/j.ydbio.2011.07.011; Feng L, 2010, DEV BIOL, V338, P1, DOI 10.1016/j.ydbio.2009.10.029; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; GARDINER DM, 1995, DEVELOPMENT, V121, P1731; Guris DL, 2006, DEV CELL, V10, P81, DOI 10.1016/j.devcel.2005.12.002; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Inman K. E., 2010, HEART DEV REGENERATI, V1, P417; Irie T, 2002, COMP BIOCHEM PHYS B, V131, P209, DOI 10.1016/S1096-4959(01)00496-1; Kam RKT, 2010, INT J DEV BIOL, V54, P1355, DOI 10.1387/ijdb.092984rk; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kane MA, 2008, ANAL BIOCHEM, V378, P71, DOI 10.1016/j.ab.2008.03.038; Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f; Kane MA, 2010, METHODS MOL BIOL, V652, P1, DOI 10.1007/978-1-60327-325-1_1; Kastner P, 1997, DEVELOPMENT, V124, P313; KAUR S, 1992, J EXP ZOOL, V264, P323, DOI 10.1002/jez.1402640311; Kedishvili NY, 2013, J LIPID RES, V54, P1744, DOI 10.1194/jlr.R037028; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Keyte A, 2012, DIFFERENTIATION, V84, DOI 10.1016/j.diff.2012.04.005; Kiefer FW, 2012, NAT MED, V18, P918, DOI 10.1038/nm.2757; Kim YK, 2011, FASEB J, V25, P1641, DOI 10.1096/fj.10-175448; Kirschner RD, 2010, CELL CYCLE, V9, P2177, DOI 10.4161/cc.9.11.11844; Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kolodzinska A, 2013, KARDIOL POL, V71, P447, DOI 10.5603/KP.2013.0090; Kumar S, 2012, BBA-MOL CELL BIOL L, V1821, P198, DOI 10.1016/j.bbalip.2011.04.004; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Levi L, 2012, AM J PHYSIOL-ENDOC M, V302, pE626, DOI 10.1152/ajpendo.00310.2011; Li Y, 2008, BRIT J CANCER, V98, P1380, DOI 10.1038/sj.bjc.6604320; Lin SC, 2010, P NATL ACAD SCI USA, V107, P9234, DOI 10.1073/pnas.0910430107; Loudig O, 2000, MOL ENDOCRINOL, V14, P1483, DOI 10.1210/me.14.9.1483; Maclean G, 2009, DEV DYNAM, V238, P732, DOI 10.1002/dvdy.21878; MCLAIN K, 1992, MECH DEVELOP, V39, P3, DOI 10.1016/0925-4773(92)90021-B; Moise AR, 2010, FASEB J, V24, P1261, DOI 10.1096/fj.09-147207; Moise AR, 2005, J BIOL CHEM, V280, P27815, DOI 10.1074/jbc.M503520200; Moise AR, 2004, J BIOL CHEM, V279, P50230, DOI 10.1074/jbc.M409130200; Mou C, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001028; Nagy A., 2003, MANIPULATING MOUSE E; Nakajima Y, 1996, CARDIOVASC RES, V31, pE77; Napoli JL, 2012, BBA-MOL CELL BIOL L, V1821, P152, DOI 10.1016/j.bbalip.2011.05.004; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; O'Byrne SM, 2013, J LIPID RES, V54, P1731, DOI 10.1194/jlr.R037648; Okano J, 2012, DEV DYNAM, V241, P1744, DOI 10.1002/dvdy.23862; Papaioannou VE, 2005, MOUSE PHENOTYPES HDB; Pennimpede T, 2010, BIRTH DEFECTS RES A, V88, P883, DOI 10.1002/bdra.20709; Penniston KL, 2006, AM J CLIN NUTR, V83, P191; Porte S, 2013, CHEM-BIOL INTERACT, V202, P186, DOI 10.1016/j.cbi.2012.11.014; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; Reeves PG, 1997, J NUTR, V127, pS838; Rhinn M, 2012, DEVELOPMENT, V139, P843, DOI 10.1242/dev.065938; Rhinn M, 2011, P NATL ACAD SCI USA, V108, P16687, DOI 10.1073/pnas.1103877108; Ribes V, 2007, DEV BIOL, V303, P66, DOI 10.1016/j.ydbio.2006.10.032; Rinne T, 2007, CELL CYCLE, V6, P262, DOI 10.4161/cc.6.3.3796; Rochette-Egly Cecile, 2009, Nucl Recept Signal, V7, pe005, DOI 10.1621/nrs.07005; Ross AC, 2011, ANNU REV NUTR, V31, P65, DOI 10.1146/annurev-nutr-072610-145127; Ross AC, 2010, METHODS MOL BIOL, V652, P295, DOI 10.1007/978-1-60327-325-1_17; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Ryckebusch L, 2008, P NATL ACAD SCI USA, V105, P2913, DOI 10.1073/pnas.0712344105; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Sandell LL, 2007, GENE DEV, V21, P1113, DOI 10.1101/gad.1533407; Sandell LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030698; Savolainen SM, 2009, TOXICOL PATHOL, V37, P395, DOI 10.1177/0192623309335060; Shimizu H, 2007, BIRTH DEFECTS RES A, V79, P465, DOI 10.1002/bdra.20358; Sirbu IO, 2008, DEV DYNAM, V237, P1627, DOI 10.1002/dvdy.21570; Smeenk L, 2008, NUCLEIC ACIDS RES, V36, P3639, DOI 10.1093/nar/gkn232; Spiegler E., 2011, BIOCHIM BIOPHYS ACTA, V1821, P88; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Szatmari I, 2006, J EXP MED, V203, P2351, DOI 10.1084/jem.20060141; Tahayato A, 2003, GENE EXPR PATTERNS, V3, P449, DOI 10.1016/S1567-133X(03)00066-8; Tang T, 2010, NAT BIOTECHNOL, V28, P749, DOI 10.1038/nbt.1644; Uehara M, 2007, DEV BIOL, V302, P399, DOI 10.1016/j.ydbio.2006.09.045; White RJ, 2008, DEV DYNAM, V237, P2775, DOI 10.1002/dvdy.21695; Williams SS, 2004, PHYSIOL GENOMICS, V19, P184, DOI 10.1152/physiolgenomics.00136.2004; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Wong YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045725; Yashiro K, 2004, DEV CELL, V6, P411, DOI 10.1016/S1534-5807(04)00062-0; YASUI H, 1995, CIRCULATION, V91, P2478, DOI 10.1161/01.CIR.91.9.2478; Yasui H, 1997, TERATOLOGY, V55, P353; Zhang M, 2007, FASEB J, V21, P2886, DOI 10.1096/fj.06-7964com; Zhang Y, 2010, GENE, V464, P32, DOI 10.1016/j.gene.2010.05.004; Zhang YX, 2003, DEV DYNAM, V226, P618, DOI 10.1002/dvdy.10267; Zhou HQ, 2010, CELL CYCLE, V9, P2709; Ziouzenkova O, 2007, NAT MED, V13, P695, DOI 10.1038/nm1587; Zolfaghari R, 2012, AM J PHYSIOL-GASTR L, V303, pG578, DOI 10.1152/ajpgi.00234.2012; Zolfaghari R, 2009, ARCH BIOCHEM BIOPHYS, V489, P1, DOI 10.1016/j.abb.2009.08.001	106	75	76	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4877	4889		10.1096/fj.13-227967	http://dx.doi.org/10.1096/fj.13-227967			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24005908	Green Published			2022-12-28	WOS:000329999000022
J	Madec, AM; Cassel, R; Dubois, S; Ducreux, S; Vial, G; Chauvin, MA; Mesnier, A; Chikh, K; Bosco, D; Rieusset, J; Van Coppenolle, F; Thivolet, C				Madec, Anne-Marie; Cassel, Romeo; Dubois, Severine; Ducreux, Sylvie; Vial, Guillaume; Chauvin, Marie-Agnes; Mesnier, Aurelia; Chikh, Karim; Bosco, Domenico; Rieusset, Jennifer; Van Coppenolle, Fabien; Thivolet, Charles			Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway	FASEB JOURNAL			English	Article						diabetes; human pancreatic; beta-cells; RAS; AT1R inhibitor; ER stress; calcium homeostasis; PLC-IP3-calcium pathway	ENDOPLASMIC-RETICULUM STRESS; PANCREATIC BETA-CELLS; OXIDATIVE STRESS; INSULIN-SECRETION; PPAR-GAMMA; DYSFUNCTION; ANTAGONISM; MECHANISMS; INHIBITORS; ISOFORMS	As shown in a large clinical prospective trial, inhibition of the renin-angiotensin system (RAS) can delay the onset of type 2 diabetes in high-risk individuals. We evaluated the beneficial effects of RAS inhibition on beta-cell function under glucotoxic conditions. Human islets from 13 donors were cultured in 5.5 mM (controls) or 16.7 mM glucose [high glucose (HG)] for 4 d with or without losartan (5 mu M), a selective AT1R blocker, and/or U73122 (2 mu M), a selective PLC inhibitor, during the last 2 d. HG induced RAS activation with overexpression of AT1R (P<0.05) and angiotensinogen (P<0.001) mRNAs. HG increased endoplasmic reticulum (ER) stress markers (P<0.001) such as GRP78, sXBP1, and ATF4 mRNAs and Grp78 protein levels (P<0.01). HG also decreased reticular calcium concentration (P<0.0001) and modified protein expressions of ER calcium pumps with reduction of SERCA2b (P<0.01) and increase of IP3R2 (P<0.05). Losartan prevented these deleterious effects and was associated with improved insulin secretion despite HG exposure. AT1R activation triggers the PLC-IP3-calcium pathway. Losartan prevented the increase of PLC beta 1 and gamma 1 protein levels induced by HG (P<0.05). U73122 reproduced all the protective effects of losartan. AT1R blockade protects human islets from the deleterious effects of glucose through inhibition of the PLC-IP3-calcium pathway.	[Madec, Anne-Marie; Cassel, Romeo; Dubois, Severine; Vial, Guillaume; Chauvin, Marie-Agnes; Mesnier, Aurelia; Chikh, Karim; Rieusset, Jennifer; Thivolet, Charles] Univ Lyon 1, INSERM, U1060, Lyon Sud Med Fac, F-69921 Oullins, France; [Ducreux, Sylvie; Van Coppenolle, Fabien] Univ Lyon 1, INSERM, U1060, Rockefeller Med Fac, F-69365 Lyon, France; [Bosco, Domenico] Univ Hosp Geneva, Cell Isolat & Transplantat Ctr, Geneva, Switzerland; [Thivolet, Charles] Univ Lyon 1, HCL, Dept Endocrinol & Diabet, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Geneva; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Madec, AM (corresponding author), Univ Lyon 1, INSERM, U1060, Inra 1235,Lyon Sud Med Fac, 165 Chemin Grand Revoyet,BP 12, F-69921 Oullins, France.	anne-marie.coquelet-madec@univ-lyon1.fr	Rieusset, Jennifer/F-1595-2018; DUCREUX, SYLVIE/D-6257-2013	Rieusset, Jennifer/0000-0002-1587-2253; DUCREUX, SYLVIE/0000-0003-3207-9537; Vial, Guillaume/0000-0002-7333-8526; CHIKH, Karim/0000-0002-1217-4193; Bosco, Domenico/0000-0003-3453-9613; BERGER, Marie-Agnes/0000-0003-4189-6029	Juvenile Diabetes Research Foundation (JDRF) from Geneva University Hospital [31-2008-413]; INSERM; University Claude Bernard Lyon (UCBL); Centaure Transplantation Research Network	Juvenile Diabetes Research Foundation (JDRF) from Geneva University Hospital; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University Claude Bernard Lyon (UCBL); Centaure Transplantation Research Network	Human islets were provided through Juvenile Diabetes Research Foundation (JDRF) award 31-2008-413 [European Consortium for Islet Transplantation (ECIT) Islet for Basic Research program] from Geneva University Hospital and from the cell isolation laboratory at Grenoble University Hospital (Grenoble, France). The authors thank the genomic platform of INSERM 1060-Cardiovasculaire, Metabolisme, Diabetologie, et Nutrition (CARMEN). This work was supported by grants from both INSERM and University Claude Bernard Lyon (UCBL) and Centaure Transplantation Research Network. The authors declare no conflicts of interest.	Back SH, 2012, ANNU REV BIOCHEM, V81, P767, DOI 10.1146/annurev-biochem-072909-095555; Bensellam M, 2012, MOL CELL ENDOCRINOL, V364, P1, DOI 10.1016/j.mce.2012.08.003; Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601; Brini M, 2009, PHYSIOL REV, V89, P1341, DOI 10.1152/physrev.00032.2008; Chu KY, 2007, ANTIOXID REDOX SIGN, V9, P869, DOI 10.1089/ars.2007.1590; Chu KY, 2009, CURR PROTEIN PEPT SC, V10, P75, DOI 10.2174/138920309787315176; Chu KY, 2006, DIABETES, V55, P367, DOI 10.2337/diabetes.55.02.06.db05-1022; Del Guerra S, 2005, DIABETES, V54, P727, DOI 10.2337/diabetes.54.3.727; Dubois S, 2010, J MOL ENDOCRINOL, V45, P99, DOI 10.1677/JME-10-0020; Ducreux S, 2006, BIOCHEM J, V395, P259, DOI 10.1042/BJ20051282; Fiume R, 2012, FASEB J, V26, P203, DOI 10.1096/fj.11-186510; Geng DF, 2012, INT J CARDIOL, V155, P236, DOI 10.1016/j.ijcard.2010.10.011; Gillespie EL, 2005, DIABETES CARE, V28, P2261, DOI 10.2337/diacare.28.9.2261; Henriksen EJ, 2007, AM J PHYSIOL-REG I, V293, pR974, DOI 10.1152/ajpregu.00147.2007; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hunyady L, 2006, MOL ENDOCRINOL, V20, P953, DOI 10.1210/me.2004-0536; Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0; Kono T, 2012, MOL ENDOCRINOL, V26, P257, DOI 10.1210/me.2011-1181; Lau T, 2004, DIABETOLOGIA, V47, P240, DOI 10.1007/s00125-003-1295-1; Lee B, 1999, ENDOCRINOLOGY, V140, P2173, DOI 10.1210/en.140.5.2173; Lee YY, 2010, BIOCHEM BIOPH RES CO, V397, P735, DOI 10.1016/j.bbrc.2010.06.022; Liu M, 2005, J BIOL CHEM, V280, P13209, DOI 10.1074/jbc.C400475200; Luciani DS, 2009, DIABETES, V58, P422, DOI 10.2337/db07-1762; Lupi R, 2006, EUR J ENDOCRINOL, V154, P355, DOI 10.1530/eje.1.02086; McMurray JJ, 2010, NEW ENGL J MED, V362, P1477, DOI 10.1056/NEJMoa1001121; Mekahli D, 2011, COLD SPRING HARB PER, V3, P1; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Poitout V, 2008, ENDOCR REV, V29, P351, DOI 10.1210/er.2007-0023; Ramracheya RD, 2006, DIABETOLOGIA, V49, P321, DOI 10.1007/s00125-005-0101-7; Ravier MA, 2011, DIABETES, V60, P2533, DOI 10.2337/db10-1543; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tikellis C, 2004, DIABETES, V53, P989, DOI 10.2337/diabetes.53.4.989; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; Yamazaki H, 2010, J NUTR SCI VITAMINOL, V56, P1, DOI 10.3177/jnsv.56.1	36	23	25	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5122	5130		10.1096/fj.13-234104	http://dx.doi.org/10.1096/fj.13-234104			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24008754				2022-12-28	WOS:000329999000044
J	Roy, A; Fields, WC; Rocha-Resende, C; Resende, RR; Guatimosim, S; Prado, VF; Gros, R; Prado, MAM				Roy, Ashbeel; Fields, William C.; Rocha-Resende, Cibele; Resende, Rodrigo R.; Guatimosim, Silvia; Prado, Vania F.; Gros, Robert; Prado, Marco A. M.			Cardiomyocyte-secreted acetylcholine is required for maintenance of homeostasis in the heart	FASEB JOURNAL			English	Article						cardiac remodeling; VAChT; choline acetyltransferase; parasympathetic activity; cardiac hypertrophy; autonomic function	COUPLED-RECEPTOR KINASE-5; CARDIAC-HYPERTROPHY; CHOLINERGIC SYSTEM; GENE-EXPRESSION; CELLS; LYMPHOCYTES; TRANSPORTER; MYOCYTES; FAILURE; SIGNALS	Heart activity and long-term function are regulated by the sympathetic and parasympathetic branches of the nervous system. Parasympathetic neurons have received increased attention recently because acetylcholine (ACh) has been shown to play protective roles in heart disease. However, parasympathetic innervation is sparse in the heart, raising the question of how cholinergic signaling regulates cardiomyocytes. We hypothesized that non-neuronal secretion of ACh from cardiomyocytes plays a role in cholinergic regulation of cardiac activity. To test this possibility, we eliminated secretion of ACh exclusively from cardiomyocytes by targeting the vesicular acetylcholine transporter (VAChT). We find that lack of cardiomyocyte-secreted ACh disturbs the regulation of cardiac activity and causes cardiomyocyte remodeling. Mutant mice present normal hemodynamic parameters under nonstressful conditions; however, following exercise, their heart rate response is increased. Moreover, hearts from mutant mice present increased oxidative stress, altered calcium signaling, remodeling, and hypertrophy. Hence, without cardiomyocyte-derived ACh secretion, hearts from mutant mice show signs of imbalanced autonomic activity consistent with decreased cholinergic drive. These unexpected results suggest that cardiomyocyte-derived ACh is required for maintenance of cardiac homeostasis and regulates critical signaling pathways necessary to maintain normal heart activity. We propose that this non-neuronal source of ACh boosts parasympathetic cholinergic signaling to counterbalance sympathetic activity regulating multiple aspects of heart physiology.	[Roy, Ashbeel; Fields, William C.; Prado, Vania F.; Gros, Robert; Prado, Marco A. M.] Univ Western Ontario, Robarts Res Inst, London, ON, Canada; [Roy, Ashbeel; Prado, Vania F.; Gros, Robert; Prado, Marco A. M.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Fields, William C.] Univ Western Ontario, Grad Program Neurosci, London, ON, Canada; [Prado, Vania F.; Prado, Marco A. M.] Univ Western Ontario, Dept Anat & Cell Biol, London, ON, Canada; [Gros, Robert] Univ Western Ontario, Dept Med, London, ON, Canada; [Rocha-Resende, Cibele; Guatimosim, Silvia] Univ Fed Minas Gerais, Inst Biol Sci, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil; [Resende, Rodrigo R.] Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Gros, R (corresponding author), Robarts Res Inst, 100 Perth Dr, London, ON N6A 5K8, Canada.	rgros@robarts.ca; mprado@robarts.ca	Gros, Robert/AAV-2237-2020; Rocha-Resende, Cibele/CAF-4462-2022; Prado, Marco Antonio Maximo/K-7638-2013; Prado, Vania Ferreira/K-7630-2013; Rocha-Resende, Cibele/CAI-0845-2022; Gros, Robert/A-3010-2009; Guatimosim, Silvia/AAN-7441-2021	Gros, Robert/0000-0002-3667-8011; Prado, Marco Antonio Maximo/0000-0002-3028-5778; Prado, Vania Ferreira/0000-0003-4994-6393; Gros, Robert/0000-0002-3667-8011; Guatimosim, Silvia/0000-0001-8386-3722; Rocha-Resende, Cibele/0000-0002-5109-0654	Heart and Stroke Foundation of Ontario [NA6656, G-13-0002843]; Canadian Institutes for Health Research [MOP-82756, MOP-89919]; Canadian Foundation for Innovation; Ontario Research Fund; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG; Brazil); U.S. National Institutes of Health from the Fogarty International Center [R03TW008425]; Ontario Graduate Scholarship; New Investigator Award from the Heart and Stroke Foundation of Canada; FOGARTY INTERNATIONAL CENTER [R03TW008425] Funding Source: NIH RePORTER	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Ontario Research Fund; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG; Brazil)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); U.S. National Institutes of Health from the Fogarty International Center; Ontario Graduate Scholarship(Ontario Graduate Scholarship); New Investigator Award from the Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	The authors thank Dr. R. Jane Rylett (University of Western Ontario, London, ON, Canada) for kindly providing the CHT1 antibody and Drs. Dale Laird and Qingping Feng (University of Western Ontario) for their insightful comments regarding the manuscript. This work was supported by the Heart and Stroke Foundation of Ontario (grants NA6656 and G-13-0002843), the Canadian Institutes for Health Research (grants MOP-82756 and MOP-89919), the Canadian Foundation for Innovation, the Ontario Research Fund, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil), Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG; Brazil), and the U.S. National Institutes of Health (grant R03TW008425 from the Fogarty International Center to S. G.). A. R. is supported by an Ontario Graduate Scholarship. R. G. was supported by a New Investigator Award from the Heart and Stroke Foundation of Canada.	Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Amin JK, 2001, J MOL CELL CARDIOL, V33, P131, DOI 10.1006/jmcc.2000.1285; Assini JM, 2013, J LIPID RES, V54, P711, DOI 10.1194/jlr.M032631; Beraldo F. H., 2013, FASEB J, V27, DOI [10.1096/fj.13-232280, DOI 10.1096/FJ.13-232280]; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Canaani J, 2010, NEUROSCI MED, V1, P43, DOI [10.4236/nm.2010.12007, 01, DOI 10.4236/NM.2010.12007,01, 10.4236/nm.2010.12007, DOI 10.4236/NM.2010.12007]; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; de Castro BM, 2009, MOL CELL BIOL, V29, P5238, DOI 10.1128/MCB.00245-09; Ferlito M, 2010, J MOL CELL CARDIOL, V49, P791, DOI 10.1016/j.yjmcc.2010.08.020; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Fujii T, 2001, JPN J PHARMACOL, V85, P11, DOI 10.1254/jjp.85.11; Gold JI, 2012, CIRC RES, V111, P1048, DOI 10.1161/CIRCRESAHA.112.273367; Guatimosim S, 2008, CELL CALCIUM, V44, P230, DOI 10.1016/j.ceca.2007.11.016; Guzman MS, 2013, J NEUROCHEM, V124, P658, DOI 10.1111/jnc.12128; Guzman MS, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001194; Hoover DB, 2004, CARDIOVASC RES, V62, P112, DOI 10.1016/j.cardiores.2004.01.012; Kanazawa H, 2010, J CLIN INVEST, V120, P408, DOI 10.1172/JCI39778; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kawano H, 2003, HEART VESSELS, V18, P32, DOI 10.1007/s003800300005; Kawashima K, 2000, PHARMACOL THERAPEUT, V86, P29, DOI 10.1016/S0163-7258(99)00071-6; Lara A, 2010, MOL CELL BIOL, V30, P1746, DOI 10.1128/MCB.00996-09; Lau JK, 2013, CANCER RES, V73, P1328, DOI 10.1158/0008-5472.CAN-12-3190; Levy MN, 1997, BAILLIERE CLIN NEUR, V6, P227; Lorke DE, 2011, J APPL TOXICOL, V31, P515, DOI 10.1002/jat.1589; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; Martini JS, 2008, P NATL ACAD SCI USA, V105, P12457, DOI 10.1073/pnas.0803153105; Martins-Silva C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017611; Misgeld T, 2002, NEURON, V36, P635, DOI 10.1016/S0896-6273(02)01020-6; Parsons SM, 2000, FASEB J, V14, P2423, DOI 10.1096/fj.00-0203rev; Prado MAM, 2002, NEUROCHEM INT, V41, P291, DOI 10.1016/S0197-0186(02)00044-X; Prado VF, 2013, BIOCHEM J, V450, P265, DOI 10.1042/BJ20121662; Rana OR, 2010, AUTON NEUROSCI-BASIC, V156, P82, DOI 10.1016/j.autneu.2010.04.011; Ribeiro FM, 2003, J NEUROCHEM, V87, P136, DOI 10.1046/j.1471-4159.2003.01974.x; Rocha-Resende C, 2012, J MOL CELL CARDIOL, V53, P206, DOI 10.1016/j.yjmcc.2012.05.003; Rodriguez-Diaz R, 2011, NAT MED, V17, P888, DOI 10.1038/nm.2371; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Roy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039997; Sailaja BS, 2012, P NATL ACAD SCI USA, V109, pE3687, DOI 10.1073/pnas.1209990110; Shaked I, 2009, IMMUNITY, V31, P965, DOI 10.1016/j.immuni.2009.09.019; Stacy RC, 2005, J NEUROSCI, V25, P9347, DOI 10.1523/JNEUROSCI.1800-05.2005; Thum T, 2007, CIRCULATION, V116, P258, DOI 10.1161/CIRCULATIONAHA.107.687947; Ucar A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2090; Waypa GB, 2002, CIRC RES, V91, P719, DOI 10.1161/01.RES.0000036751.04896.F1; Wessler I, 1998, PHARMACOL THERAPEUT, V77, P59, DOI 10.1016/S0163-7258(97)00085-5	47	61	62	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5072	5082		10.1096/fj.13-238279	http://dx.doi.org/10.1096/fj.13-238279			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	24018063	Green Published			2022-12-28	WOS:000329999000039
J	Schwarz, A; von Reumont, BM; Erhart, J; Chagas, AC; Ribeiro, JMC; Kotsyfakis, M				Schwarz, Alexandra; von Reumont, Bjoern M.; Erhart, Jan; Chagas, Andrezza C.; Ribeiro, Jose M. C.; Kotsyfakis, Michalis			De novo Ixodes ricinus salivary gland transcriptome analysis using two next-generation sequencing methodologies	FASEB JOURNAL			English	Article						high-throughput annotation; molecular evolution; cDNA; public database; tick life stages; tick feeding	TICK-BORNE ENCEPHALITIS; GEOGRAPHICAL-DISTRIBUTION; EVOLUTION; PROTEIN; EXPRESSION; SCAPULARIS; ABUNDANCE; CDNA; SIALOTRANSCRIPTOME; CONSTRUCTION	Tick salivary gland (SG) proteins possess powerful pharmacologic properties that facilitate tick feeding and pathogen transmission. For the first time, SG transcriptomes of Ixodes ricinus, an important disease vector for humans and animals, were analyzed using next-generation sequencing. SGs were collected from different tick life stages fed on various animal species, including cofeeding of nymphs and adults on the same host. Four cDNA samples were sequenced, discriminating tick SG transcriptomes of early-and late-feeding nymphs or adults. In total, 441,381,454 pyrosequencing reads and 67,703,183 Illumina reads were assembled into 272,220 contigs, of which 34,560 extensively annotated coding sequences are disclosed; 8686 coding sequences were submitted to GenBank. Overall, 13% of contigs were classified as secreted proteins that showed significant differences in the transcript representation among the 4 SG samples, including high numbers of sample-specific transcripts. Detailed phylogenetic reconstructions of two relatively abundant SG-secreted protein families demonstrated how this study improves our understanding of the molecular evolution of hematophagy in arthropods. Our data significantly increase the available genomic information for I. ricinus and form a solid basis for future tick genome/transcriptome assemblies and the functional analysis of effectors that mediate the feeding physiology and parasite-vector interaction of I. ricinus.	[Schwarz, Alexandra; Erhart, Jan; Ribeiro, Jose M. C.; Kotsyfakis, Michalis] AS CR, Inst Parasitol, Ctr Biol, Lab Genom & Prote Dis Vectors,Vvi, Ceske Budejovice 37005, Czech Republic; [von Reumont, Bjoern M.] Nat Hist Museum, Dept Life Sci, London SW7 5BD, England; [Chagas, Andrezza C.; Ribeiro, Jose M. C.] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA	Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; Natural History Museum London; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ribeiro, JMC (corresponding author), AS CR, Inst Parasitol, Ctr Biol, Lab Genom & Prote Dis Vectors,Vvi, Branisovska 31, Ceske Budejovice 37005, Czech Republic.	alexandraschwarz@arcor.de	Ribeiro, Jose/J-7011-2015; Kotsyfakis, Michail/G-9525-2014; von Reumont, Bjoern M/Q-7065-2018	Kotsyfakis, Michail/0000-0002-7526-1876; von Reumont, Bjoern M/0000-0002-7462-8226; Ribeiro, Jose/0000-0002-9107-0818	Grant Agency of the Czech Republic (GACR) [P502/12/2409]; Academy of Sciences of the Czech Republic [Z60220518]; 7th Framework Program of the European Union [PIRG07-GA-2010-268177]; Alexander von Humboldt Foundation; German Research Foundation [DFG] [WA-530/34, RE-3454/1-1]; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH; USA); Academy of Sciences of the Czech Republic; European Molecular Biology Organization [EMBO] [482-2012]; National Grid Infrastructure MetaCentrum, provided under the program Projects of Large Infrastructure for Research, Development, and Innovations [LM2010005]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000810] Funding Source: NIH RePORTER	Grant Agency of the Czech Republic (GACR)(Grant Agency of the Czech Republic); Academy of Sciences of the Czech Republic(Czech Academy of Sciences); 7th Framework Program of the European Union(European Commission); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); German Research Foundation [DFG](German Research Foundation (DFG)); Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH; USA); Academy of Sciences of the Czech Republic(Czech Academy of Sciences); European Molecular Biology Organization [EMBO](European Molecular Biology Organization (EMBO)); National Grid Infrastructure MetaCentrum, provided under the program Projects of Large Infrastructure for Research, Development, and Innovations; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Grant Agency of the Czech Republic (GACR; grant P502/12/2409), the Academy of Sciences of the Czech Republic (grant Z60220518), and the 7th Framework Program of the European Union (Marie Curie Reintegration grant PIRG07-GA-2010-268177). A. S. was funded by the Alexander von Humboldt Foundation (Feodor Lynen Research Fellowship), and B. M. V. R. received financial support from the German Research Foundation [DFG; grants WA-530/34 at the Zoologisches Forschungsmuseum Alexander Koenig (ZFMK; Bonn, Germany) and RE-3454/1-1 at the Natural History Museum (London, UK)]. J.M.C.R. was supported by the Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH; USA). M. K. received support from the Academy of Sciences of the Czech Republic (Jan Evangelista Purkyne Fellowship) and the European Molecular Biology Organization [EMBO; Application Short Term Fellowship (ASTF) 482-2012]. The authors thank Petr Kopacek and his research group for the supply of dissection equipment, James J. Valdes and Brenda Rae Marshall (Division of Intramural Research Program Support Staff, NIAID) for English language editing of this manuscript, and the reviewers of this article for their constructive comments. The authors further thank Tomas Skalicky for his bioinformatics support using the MetaCentrum Virtual Organization (Czech Republic). The access to computing and storage facilities owned by parties and projects contributing to the National Grid Infrastructure MetaCentrum, provided under the program Projects of Large Infrastructure for Research, Development, and Innovations (LM2010005) is highly appreciated. The authors are also grateful to Andrea Gocke (National Center for Biotechnology Information, USA) for helping with sequence submission. Because A. C. C. and J. M. C. R. are government employees and this is a government work, the work is in the public domain in the United States. Notwithstanding any other agreements, the NIH reserves the right to provide the work to PubMedCentral for display and use by the public, and PubMedCentral may tag or modify the work consistent with its customary practices. Rights can be established outside of the United States subject to a government use license.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Alim MA, 2012, INSECT BIOCHEM MOLEC, V42, P925, DOI 10.1016/j.ibmb.2012.09.005; Anatriello E, 2010, BMC GENOMICS, V11; Andersen JF, 2004, BIOCHEMISTRY-US, V43, P6987, DOI 10.1021/bi049655t; Batista IFC, 2010, ARCH BIOCHEM BIOPHYS, V493, P151, DOI 10.1016/j.abb.2009.10.009; Batista IFC, 2008, TOXICON, V51, P823, DOI 10.1016/j.toxicon.2007.12.011; Bellgard MI, 2012, INT J PARASITOL, V42, P161, DOI 10.1016/j.ijpara.2011.11.006; Birol I, 2009, BIOINFORMATICS, V25, P2872, DOI 10.1093/bioinformatics/btp367; Chmelar J, 2012, J PROTEOMICS, V75, P3842, DOI 10.1016/j.jprot.2012.04.026; Chmelar J, 2011, BLOOD, V117, P736, DOI 10.1182/blood-2010-06-293241; Chmelar J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-233; Dai SX, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-4; Das S, 2001, J INFECT DIS, V184, P1056, DOI 10.1086/323351; Donohue KV, 2009, J INSECT PHYSIOL, V55, P909, DOI 10.1016/j.jinsphys.2009.05.019; Florin-Christensen M, 2009, FRONT BIOSCI-LANDMRK, V14, P3064, DOI 10.2741/3435; Francischetti IMB, 2005, INSECT BIOCHEM MOLEC, V35, P1142, DOI 10.1016/j.ibmb.2005.05.007; Francischetti IMB, 2011, J PROTEOMICS, V74, P2892, DOI 10.1016/j.jprot.2011.07.015; Francischetti IMB, 2009, FRONT BIOSCI-LANDMRK, V14, P2051, DOI 10.2741/3363; Garcia C, 2012, GENETICS, V192, P161, DOI 10.1534/genetics.112.142687; Islam MK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000497; Jaenson TGT, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-8; Karim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028525; Katoh K, 2008, BRIEF BIOINFORM, V9, P286, DOI 10.1093/bib/bbn013; Kiszewski AE, 2001, ANNU REV ENTOMOL, V46, P167, DOI 10.1146/annurev.ento.46.1.167; Kotsyfakis M, 2010, MOL MICROBIOL, V77, P456, DOI 10.1111/j.1365-2958.2010.07220.x; Mans BJ, 2008, INSECT BIOCHEM MOLEC, V38, P22, DOI 10.1016/j.ibmb.2007.09.002; Mans BJ, 2008, INSECT BIOCHEM MOLEC, V38, P42, DOI 10.1016/j.ibmb.2007.09.003; Mans BJ, 2004, INSECT BIOCHEM MOLEC, V34, P1, DOI 10.1016/j.ibmb.2003.09.002; Mansfield KL, 2009, J GEN VIROL, V90, P1781, DOI 10.1099/vir.0.011437-0; Medlock JM, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-1; Narasimhan S, 2002, INSECT MOL BIOL, V11, P641, DOI 10.1046/j.1365-2583.2002.00375.x; Paesen GC, 2009, J MOL BIOL, V389, P734, DOI 10.1016/j.jmb.2009.04.045; Pareek CS, 2011, J APPL GENET, V52, P413, DOI 10.1007/s13353-011-0057-x; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; Pei JM, 2008, NUCLEIC ACIDS RES, V36, P2295, DOI 10.1093/nar/gkn072; Porter R, 2013, MED VET ENTOMOL, V27, P237, DOI 10.1111/j.1365-2915.2012.01047.x; Randolph SE, 2010, EUROSURVEILLANCE, V15, P24; Reddy MK, 2002, MOL BIOTECHNOL, V22, P223, DOI 10.1385/MB:22:3:223; Reed DH, 2003, CONSERV BIOL, V17, P230, DOI 10.1046/j.1523-1739.2003.01236.x; Ribeiro JMC, 2006, INSECT BIOCHEM MOLEC, V36, P111, DOI 10.1016/j.ibmb.2005.11.005; Ribeiro JMC, 2012, INSECT BIOCHEM MOLEC, V42, P332, DOI 10.1016/j.ibmb.2012.01.003; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schuijt TJ, 2011, CELL HOST MICROBE, V10, P136, DOI 10.1016/j.chom.2011.06.010; Schwarz A, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-268; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; Simpson JT, 2009, GENOME RES, V19, P1117, DOI 10.1101/gr.089532.108; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Stanek G, 2009, WIEN KLIN WOCHENSCHR, V121, P673, DOI 10.1007/s00508-009-1281-9; TOUTOUNGI LN, 1995, EXP APPL ACAROL, V19, P233, DOI 10.1007/BF00130826; Vijay N, 2013, MOL ECOL, V22, P620, DOI 10.1111/mec.12014; Wang H, 2001, MED VET ENTOMOL, V15, P403, DOI 10.1046/j.0269-283x.2001.00328.x; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851	53	70	91	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4745	4756		10.1096/fj.13-232140	http://dx.doi.org/10.1096/fj.13-232140			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964076	Green Published			2022-12-28	WOS:000329999000010
J	Lira, VA; Okutsu, M; Zhang, M; Greene, NP; Laker, RC; Breen, DS; Hoehn, KL; Yan, Z				Lira, Vitor A.; Okutsu, Mitsuharu; Zhang, Mei; Greene, Nicholas P.; Laker, Rhianna C.; Breen, David S.; Hoehn, Kyle L.; Yan, Zhen			Autophagy is required for exercise training-induced skeletal muscle adaptation and improvement of physical performance	FASEB JOURNAL			English	Article						voluntary wheel running; mitophagy; Bnip3; mitochondrial biogenesis; angiogenesis	FIBER-TYPE TRANSFORMATION; MITOCHONDRIAL BIOGENESIS; PROTEIN-KINASE; PGC-1-ALPHA; ANGIOGENESIS; GLUCOSE; MITOPHAGY; INSULIN; DISEASE; RISK	Pathological and physiological stimuli, including acute exercise, activate autophagy; however, it is unknown whether exercise training alters basal levels of autophagy and whether autophagy is required for skeletal muscle adaptation to training. We observed greater autophagy flux (i.e., a combination of increased LC3-II/LC3-I ratio and LC3-II levels and reduced p62 protein content indicating a higher rate of initiation and resolution of autophagic events), autophagy protein expression (i.e., Atg6/Beclin1, Atg7, and Atg8/LC3) and mitophagy protein Bnip3 expression in tonic, oxidative muscle compared to muscles of either mixed fiber types or of predominant glycolytic fibers in mice. Long-term voluntary running (4 wk) resulted in increased basal autophagy flux and expression of autophagy proteins and Bnip3 in parallel to mitochondrial biogenesis in plantaris muscle with mixed fiber types. Conversely, exercise training promoted autophagy protein expression with no significant increases of autophagy flux and mitochondrial biogenesis in the oxidative soleus muscle. We also observed increased basal autophagy flux and Bnip3 content without increases in autophagy protein expression in the plantaris muscle of sedentary muscle-specific Pgc-1 transgenic mice, a genetic model of augmented mitochondrial biogenesis. These findings reveal that endurance exercise training-induced increases in basal autophagy, including mitophagy, only take place if an enhanced oxidative phenotype is achieved. However, autophagy protein expression is mainly dictated by contractile activity independently of enhancements in oxidative phenotype. Exercise-trained mice heterozygous for the critical autophagy protein Atg6 showed attenuated increases of basal autophagy flux, mitochondrial content, and angiogenesis in skeletal muscle, along with impaired improvement of endurance capacity. These results demonstrate that increased basal autophagy is required for endurance exercise training-induced skeletal muscle adaptation and improvement of physical performance.Lira, V. A., Okutsu, M., Zhang, M., Greene, N. P., Laker, R. C., Breen, D. S., Hoehn, K. L., Yan, Z. Autophagy is required for exercise training-induced skeletal muscle adaptation and improvement of physical performance.	[Lira, Vitor A.; Okutsu, Mitsuharu; Zhang, Mei; Greene, Nicholas P.; Laker, Rhianna C.; Yan, Zhen] Univ Virginia, Dept Med, Charlottesville, VA 22908 USA; [Breen, David S.; Hoehn, Kyle L.; Yan, Zhen] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; [Yan, Zhen] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Lira, Vitor A.; Okutsu, Mitsuharu; Zhang, Mei; Greene, Nicholas P.; Laker, Rhianna C.; Yan, Zhen] Univ Virginia, Ctr Skeletal Muscle Res, Robert M Berne Cardiovasc Res Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Yan, Z (corresponding author), Univ Virginia, Sch Med, 409 Ln Rd,MR4-6041A, Charlottesville, VA 22908 USA.	zhen.yan@virginia.edu	Lira, Vitor/AAN-3403-2021; Greene, Nicholas/A-6076-2013; Greene, Nicholas/G-7399-2015	Lira, Vitor/0000-0002-3162-3804; Greene, Nicholas/0000-0002-9504-9362; Yan, Zhen/0000-0002-4826-9813; Greene, Nicholas/0000-0001-9621-2005; Hoehn, Kyle/0000-0002-0214-3238	U.S. National Institutes of Health (NIH) [AR050429]; American Diabetes Association research award [7-06-RA-165]; American Physiological Society postdoctoral fellowship in physiological genomics; NIH training grant [T32HL07284]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050429] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association research award(American Diabetes Association); American Physiological Society postdoctoral fellowship in physiological genomics; NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Beth Levine (University of Texas Southwestern Medical Center, Dallas, TX, USA) for her generosity in providing Atg6-deficient mice and Dr. Ira G. Shulman for insightful comments on the manuscript. The study was supported by U.S. National Institutes of Health (NIH) grant AR050429 and American Diabetes Association research award 7-06-RA-165 (Z.Y.), an American Physiological Society postdoctoral fellowship in physiological genomics (V.A.L.), and NIH training grant T32HL07284 (N.P.G.).	Akimoto T, 2004, AM J PHYSIOL-CELL PH, V287, pC1311, DOI 10.1152/ajpcell.00248.2004; Band M, 2009, FASEB J, V23, P2327, DOI 10.1096/fj.08-122978; Bouchard C, 2001, MED SCI SPORT EXER, V33, pS446, DOI 10.1097/00005768-200106001-00013; Buchman AS, 2012, NEUROLOGY, V78, P1323, DOI 10.1212/WNL.0b013e3182535d35; Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012; Colditz GA, 1997, CANCER CAUSE CONTROL, V8, P649, DOI 10.1023/A:1018458700185; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399; EISENBERG HA, 1994, J APPL PHYSIOL, V76, P859, DOI 10.1152/jappl.1994.76.2.859; Geng TY, 2010, AM J PHYSIOL-CELL PH, V298, pC572, DOI 10.1152/ajpcell.00481.2009; Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010; Grumati P, 2011, AUTOPHAGY, V7, P1415, DOI 10.4161/auto.7.12.17877; He CC, 2012, NATURE, V481, P511, DOI 10.1038/nature10758; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Janssen I, 2000, J APPL PHYSIOL, V89, P465, DOI 10.1152/jappl.2000.89.2.465; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KATZ LD, 1983, DIABETES, V32, P675, DOI 10.2337/diabetes.32.7.675; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li P, 2006, AM J PHYSIOL-CELL PH, V290, pC1461, DOI 10.1152/ajpcell.00532.2005; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lira VA, 2010, J PHYSIOL-LONDON, V588, P3551, DOI 10.1113/jphysiol.2010.194035; Lira VA, 2010, AM J PHYSIOL-ENDOC M, V299, pE145, DOI 10.1152/ajpendo.00755.2009; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; Masiero E, 2010, AUTOPHAGY, V6, P307, DOI 10.4161/auto.6.2.11137; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nielsen J, 2010, AM J PHYSIOL-ENDOC M, V299, pE1053, DOI 10.1152/ajpendo.00324.2010; Pogozelski AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007934; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Quinsay MN, 2010, AUTOPHAGY, V6, P855, DOI 10.4161/auto.6.7.13005; Raben N, 2008, HUM MOL GENET, V17, P3897, DOI 10.1093/hmg/ddn292; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Romanello V, 2010, EMBO J, V29, P1774, DOI 10.1038/emboj.2010.60; Schiaffino S, 2011, PHYSIOL REV, V91, P1447, DOI 10.1152/physrev.00031.2010; Smuder A. J., J APPL PHYSL, V111, P1190; Waters RE, 2004, AM J PHYSIOL-CELL PH, V287, pC1342, DOI 10.1152/ajpcell.00247.2004; Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106; Wohlgemuth SE, 2010, EXP GERONTOL, V45, P138, DOI 10.1016/j.exger.2009.11.002; Yamada E, 2012, CELL REP, V1, P557, DOI 10.1016/j.celrep.2012.03.014; Yan Z, 2011, J APPL PHYSIOL, V110, P264, DOI 10.1152/japplphysiol.00993.2010; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16	44	280	306	4	54	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4184	4193		10.1096/fj.13-228486	http://dx.doi.org/10.1096/fj.13-228486			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23825228	Green Published			2022-12-28	WOS:000329747100029
J	Urano, Y; Ochiai, S; Noguchi, N				Urano, Yasuomi; Ochiai, Sachika; Noguchi, Noriko			Suppression of amyloid-beta production by 24S-hydroxycholesterol via inhibition of intracellular amyloid precursor protein trafficking	FASEB JOURNAL			English	Article						oxysterol; vesicular transport; ER stress; Alzheimer's disease	ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; LIPID RAFTS; DEMENTED PATIENTS; GAMMA-SECRETASE; ER STRESS; CHOLESTEROL; BRAIN; PRESENILIN-1; PATHWAY	Cholesterol can be converted to 24S-hydroxycholesterol (24SOHC) by neuronal cholesterol 24-hydroxylase. In mouse models of Alzheimer's disease (AD), increasing 24SOHC levels reduced AD pathology. However, mechanisms underlying the effects of 24SOHC on amyloid- (A) production have remained unclear. Here we report that 24SOHC treatment reduces A production and increases endoplasmic reticulum (ER)-resident immature amyloid precursor protein (APP) levels in human neuroblastoma SH-SY5Y cells and CHO cells stably expressing human APP. Treatment with 1-10 M 24SOHC (equivalent to the concentrations detected in human brain homogenates) diminished A production (IC50=4.6 M for A(40)) without affecting secretase activities. To evaluate the intracellular APP transport, we established an in vitro vesicle formation assay. We found that APP budding via COPII vesicles was diminished by 70% in 24SOHC-treated cells. The proteomics and immunoblotting analysis revealed that 24SOHC induced the expression of glucose-regulated protein 78 (GRP78), an ER chaperone, through unfolded protein response pathways, and enhanced the formation of the APP/GRP78 complex. Knockdown of GRP78 diminished the inhibitory effects of 24SOHC on A production. These results suggest that 24SOHC down-regulates APP trafficking via enhancement of the complex formation of APP with up-regulated GRP78 in the ER, resulting in suppression of A production.Urano, Y., Ochiai, S., Noguchi, N. Suppression of amyloid- production by 24S-hydroxycholesterovia inhibition of intracellular amyloid precursor protein trafficking.	[Urano, Yasuomi; Ochiai, Sachika; Noguchi, Noriko] Doshisha Univ, Dept Med Life Syst, Fac Med & Life Sci, Kyoto 6100394, Japan	Doshisha University	Urano, Y (corresponding author), Doshisha Univ, Dept Med Life Syst, Fac Med & Life Sci, 1-3 Miyakodani, Kyoto 6100394, Japan.	yurano@mail.doshisha.ac.jp		Urano, Yasuomi/0000-0002-4901-1937	Takeda Science Foundation; Ministry of Education, Sports, Science, and Technology in Japan [21800075, 23700428]; Grants-in-Aid for Scientific Research [25830041] Funding Source: KAKEN	Takeda Science Foundation(Takeda Science Foundation (TSF)); Ministry of Education, Sports, Science, and Technology in Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dr. Edward Koo (University of California-San Diego, La Jolla, CA, USA) and Drs. Yasuo Ihara and Satoru Funamoto (Doshisha University, Kyoto, Japan) for providing reagents. The authors also thank Rie Yasuda, Maya Suetsugu, and Fumika Onoue for research support. This work was supported in part by the Takeda Science Foundation to Y.U. and a grant-in-aid for Research Activity Start-Up 21800075 and Young Scientists (B) 23700428 to Y.U. from the Ministry of Education, Sports, Science, and Technology in Japan.	Barrett PJ, 2012, SCIENCE, V336, P1168, DOI 10.1126/science.1219988; Bretillon L, 2000, NEUROSCI LETT, V293, P87, DOI 10.1016/S0304-3940(00)01466-X; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Bryleva EY, 2010, P NATL ACAD SCI USA, V107, P3081, DOI 10.1073/pnas.0913828107; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Halford RW, 2009, P NATL ACAD SCI USA, V106, P3502, DOI 10.1073/pnas.0813349106; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200; Hiltunen M, 2006, J BIOL CHEM, V281, P32240, DOI 10.1074/jbc.M603106200; Hoshino T, 2007, BIOCHEM J, V402, P581, DOI 10.1042/BJ20061318; Hudry E, 2010, MOL THER, V18, P44, DOI 10.1038/mt.2009.175; Huttunen HJ, 2007, J BIOL CHEM, V282, P28285, DOI 10.1074/jbc.M702951200; Huttunen HJ, 2009, FASEB J, V23, P3819, DOI 10.1096/fj.09-134999; Jeitner TM, 2011, CURR MED CHEM, V18, P1515; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kolsch H, 2004, NEUROSCI LETT, V368, P303, DOI 10.1016/j.neulet.2004.07.031; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kudo T, 2006, BIOCHEM BIOPH RES CO, V344, P525, DOI 10.1016/j.bbrc.2006.03.173; Lutjohann D, 2000, J LIPID RES, V41, P195; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Maulik M, 2013, MOL NEUROBIOL, V47, P37, DOI 10.1007/s12035-012-8337-y; Prasanthi JRP, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-1; Radhakrishnan A, 2007, P NATL ACAD SCI USA, V104, P6511, DOI 10.1073/pnas.0700899104; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859; Salminen A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-41; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Stensballe A, 2001, PROTEOMICS, V1, P955, DOI 10.1002/1615-9861(200108)1:8<955::AID-PROT955>3.0.CO;2-P; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Treiman M, 2002, TRENDS CARDIOVAS MED, V12, P57, DOI 10.1016/S1050-1738(01)00147-5; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Urano Y, 2008, P NATL ACAD SCI USA, V105, P16513, DOI 10.1073/pnas.0807450105; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-4; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Yamanaka K, 2011, J BIOL CHEM, V286, P24666, DOI 10.1074/jbc.M111.236273; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zuliani G, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-121	47	51	52	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					4305	4315		10.1096/fj.13-231456	http://dx.doi.org/10.1096/fj.13-231456			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	23839932				2022-12-28	WOS:000329747100039
J	Moh, MC; Lorenzini, PA; Gullo, C; Schwarz, H				Moh, Mei Chung; Lorenzini, Paolo Alberto; Gullo, Charles; Schwarz, Herbert			Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling	FASEB JOURNAL			English	Article						TNFR1; THP-1 cells; monocytes	TNF RECEPTOR; HUMAN 4-1BB; MONOCYTE ACTIVATION; FAMILY; TRANSDUCTION; MEMBRANE; MEMBERS; CELLS; PROLIFERATION; STABILIZATION	Reverse signaling through CD137 ligand (CD137L) potently activates monocytes. However, the underlying mechanism is not well elucidated. This study provides evidence that tumor necrosis factor receptor 1 (TNFR1) acts as a coreceptor for CD137L and mediates CD137L signaling. CD137L colocalizes with TNFR1 on the plasma membrane and binds directly to TNFR1 via its extracellular domain. Using the human monocytic THP-1 cell line, we demonstrate that engagement of CD137L by recombinant CD137 protein promotes cell adhesion, apoptosis, expression of CD14, and production of IL-8 and tumor necrosis factor (TNF). Concomitantly, the expression of TNFR1 protein is down-regulated in response to CD137L activation, due to enhanced extracellular release and internalization of TNFR1. Activation of TNFR1 by TNF protein additively augments CD137L-induced IL-8 expression. Conversely, inhibition of TNFR1 activity by a TNFR1-neutralizing antibody inhibits CD137L-mediated cell adhesion, cell death, CD14 expression, and IL-8 production. Taken together, these data show that TNFR1 associates with CD137L and is required for CD137L reverse signaling.Moh, M. C., Lorenzini, P. A., Gullo, C., Schwarz, H. Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling.	[Moh, Mei Chung; Lorenzini, Paolo Alberto; Schwarz, Herbert] Duke Natl Univ Singapore Grad Med Sch, Dept Physiol, Singapore, Singapore; [Moh, Mei Chung; Lorenzini, Paolo Alberto; Schwarz, Herbert] Duke Natl Univ Singapore Grad Med Sch, Program Immunol, Singapore, Singapore; [Gullo, Charles] Duke Natl Univ Singapore Grad Med Sch, Dept Med Educ Res & Evaluat, Singapore, Singapore; [Gullo, Charles] Natl Univ Singapore, Dept Microbiol, Singapore 117456, Singapore; [Schwarz, Herbert] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore	National University of Singapore; National University of Singapore	Schwarz, H (corresponding author), Natl Univ Singapore, Dept Physiol, Ctr Life Sci, 03-05,28 Med Dr, Singapore 117456, Singapore.	phssh@nus.edu.sg	Gullo, Charles A/X-9938-2019	Gullo, Charles A/0000-0002-4221-0087	Singapore Agency for Science, Technology, and Research (A*STAR)-Hungary National Office for Research and Technology (NKTH) [10/1/21/24/637]	Singapore Agency for Science, Technology, and Research (A*STAR)-Hungary National Office for Research and Technology (NKTH)	This study was supported by a Singapore Agency for Science, Technology, and Research (A*STAR)-Hungary National Office for Research and Technology (NKTH) joint grant (10/1/21/24/637).	ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Benslimane N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043070; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1997, FEBS LETT, V417, P301, DOI 10.1016/S0014-5793(97)01306-9; D'Alessio A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2; Domonkos A, 2001, EUR CYTOKINE NETW, V12, P411; Drenkard D, 2007, FASEB J, V21, P456, DOI 10.1096/fj.05-4739com; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; Gullo C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010845; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Ho WT, 2013, CANCER RES, V73, P652, DOI 10.1158/0008-5472.CAN-12-3849; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jones SJ, 1999, J IMMUNOL, V162, P1042; Ju SW, 2009, INT IMMUNOL, V21, P1135, DOI 10.1093/intimm/dxp077; Kang YJ, 2007, NAT IMMUNOL, V8, P601, DOI 10.1038/ni1471; Kim J.D., 2011, IMMUNE NETW, V11, P216, DOI DOI 10.4110/IN.2011.11.4.216; Kwajah MMS, 2010, EUR J IMMUNOL, V40, P1938, DOI 10.1002/eji.200940105; Langstein J, 2000, BIOCHEM BIOPH RES CO, V273, P117, DOI 10.1006/bbrc.2000.2889; Langstein J, 1999, BLOOD, V94, P3161, DOI 10.1182/blood.V94.9.3161.421k31_3161_3168; Langstein J, 1999, J LEUKOCYTE BIOL, V65, P829, DOI 10.1002/jlb.65.6.829; Langstein J, 1998, J IMMUNOL, V160, P2488; Mitoma H, 2008, ARTHRITIS RHEUM-US, V58, P1248, DOI 10.1002/art.23447; MOSSELMANS R, 1988, J IMMUNOL, V141, P3096; Prive GG, 2007, METHODS, V41, P388, DOI 10.1016/j.ymeth.2007.01.007; Saito K, 2004, J BIOL CHEM, V279, P13555, DOI 10.1074/jbc.M303791200; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schwarz H, 2005, J LEUKOCYTE BIOL, V77, P281, DOI 10.1189/jlb.0904558; SCHWARZ H, 1995, BLOOD, V85, P1043, DOI 10.1182/blood.V85.4.1043.bloodjournal8541043; Shao Z, 2011, J LEUKOCYTE BIOL, V89, P21, DOI 10.1189/jlb.0510315; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Wen T, 2002, J IMMUNOL, V168, P4897, DOI 10.4049/jimmunol.168.10.4897; Won EY, 2010, J BIOL CHEM, V285, P9202, DOI 10.1074/jbc.M109.084442	38	13	13	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2957	2966		10.1096/fj.12-225250	http://dx.doi.org/10.1096/fj.12-225250			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23620528	Bronze			2022-12-28	WOS:000329877600004
J	Pinto, V; Pinho, MJ; Soares-da-Silva, P				Pinto, Vanda; Pinho, Maria Joao; Soares-da-Silva, Patricio			Renal amino acid transport systems and essential hypertension	FASEB JOURNAL			English	Review						kidney; dopamine; nitric oxide; blood pressure	LYSINURIC PROTEIN INTOLERANCE; MEDULLARY BLOOD-FLOW; L-DOPA UPTAKE; L-ARGININE; OXIDATIVE STRESS; NITRIC-OXIDE; FUNCTIONAL-CHARACTERIZATION; DOPAMINERGIC SYSTEM; CL-/HCO3-EXCHANGER; MOLECULAR-CLONING	Several clinical and animal studies suggest that "blood pressure goes with the kidney," that is, a normotensive recipient of a kidney genetically programmed for hypertension will develop hypertension. Intrarenal dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport. The candidate transport systems for L-DOPA, the source for dopamine, include the sodium-dependent systems B-0, B-0,B-+, and y(+)L, and the sodium-independent systems L (LAT1 and LAT2) and b(0,+). Renal LAT2 is overexpressed in the prehypertensive spontaneously hypertensive rat (SHR), which might contribute to enhanced L-DOPA uptake in the proximal tubule and increased dopamine production, as an attempt to overcome the defect in D-1 receptor function. On the other hand, it has been recently reported that impaired arginine transport contributes to low renal nitric oxide bioavailability observed in the SHR renal medulla. Here we review the importance of renal amino acid transporters in the kidney and highlight pathophysiological changes in the expression and regulation of these transporters in essential hypertension. The study of the regulation of renal amino acid transporters may help to define the underlying mechanisms predisposing individuals to an increased risk for development of hypertension.Pinto, V., Pinho, M. J., Soares-da-Silva, P. Renal amino acid transport systems and essential hypertension.	[Pinto, Vanda; Pinho, Maria Joao; Soares-da-Silva, Patricio] Univ Porto, Dept Pharmacol & Therapeut, Fac Med, P-4200319 Oporto, Portugal; [Pinto, Vanda] Univ Porto, Inst Mol & Cell Biol IBMC, P-4200319 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Soares-da-Silva, P (corresponding author), Univ Porto, Dept Pharmacol & Therapeut, Fac Med, P-4200319 Oporto, Portugal.	pss@med.up.pt	Soares-da-Silva, Patricio/A-6704-2015	Soares-da-Silva, Patricio/0000-0002-2446-5078; Pinto, Vanda/0000-0001-9979-1663; Pinho, Maria Joao/0000-0001-8173-0379	Fundacao para a Ciencia e a Tecnologia; Programa Operacional Ciencia e Inovacao (POCI); Fundo Europeu de Desenvolvimento Regional (FEDER); Programa Comunitario de Apoio [PIC/IC/83204/2007]	Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Programa Operacional Ciencia e Inovacao (POCI)(Portuguese Foundation for Science and Technology); Fundo Europeu de Desenvolvimento Regional (FEDER)(European Commission); Programa Comunitario de Apoio	This work was supported by Fundacao para a Ciencia e a Tecnologia, Programa Operacional Ciencia e Inovacao (POCI), Fundo Europeu de Desenvolvimento Regional (FEDER), and Programa Comunitario de Apoio (PIC/IC/83204/2007). The authors declare no conflicts of interest.	Agostinho P, 1997, FASEB J, V11, P154, DOI 10.1096/fasebj.11.2.9039958; Avissar NE, 2001, AM J PHYSIOL-CELL PH, V281, pC963, DOI 10.1152/ajpcell.2001.281.3.C963; Bauch C, 2003, J BIOL CHEM, V278, P1316, DOI 10.1074/jbc.M210449200; BIANCHI G, 1974, CLIN SCI MOL MED, V47, P435, DOI 10.1042/cs0470435; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Broer S, 2008, PHYSIOL REV, V88, P249, DOI 10.1152/physrev.00018.2006; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; Cowley AW, 1997, AM J PHYSIOL-REG I, V273, pR1, DOI 10.1152/ajpregu.1997.273.1.R1; DAHL LK, 1974, CIRC RES, V34, P94, DOI 10.1161/01.RES.34.1.94; Danilczyk U, 2006, NATURE, V444, P1088, DOI 10.1038/nature05475; Dave MH, 2004, J PHYSIOL-LONDON, V558, P597, DOI 10.1113/jphysiol.2004.065037; DEFEO ML, 1987, CLIN EXP HYPERTENS A, V9, P2049, DOI 10.3109/10641968709159074; DESJEUX JF, 1980, J CLIN INVEST, V65, P1382, DOI 10.1172/JCI109802; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; Eslami B, 2006, TOHOKU J EXP MED, V208, P25, DOI 10.1620/tjem.208.25; Fleck C, 2003, AMINO ACIDS, V24, P347, DOI 10.1007/s00726-002-0316-6; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Furesz TC, 1997, PLACENTA, V18, P649, DOI 10.1016/S0143-4004(97)90006-0; Gomes P., 2008, CARDIOVASCULAR HORMO, P251; Grisk O, 2001, NEWS PHYSIOL SCI, V16, P262; Haddy FJ, 2006, LIFE SCI, V79, P1585, DOI 10.1016/j.lfs.2006.05.017; Hediger MA, 1999, AM J PHYSIOL-RENAL, V277, pF487, DOI 10.1152/ajprenal.1999.277.4.F487; HELLER J, 1993, PFLUG ARCH EUR J PHY, V425, P208, DOI 10.1007/BF00374168; Hussain T, 2003, EXP BIOL MED, V228, P134, DOI 10.1177/153537020322800202; JOSE PA, 1992, J AM SOC NEPHROL, V2, P1265; Kakoki M, 2002, HYPERTENSION, V39, P287, DOI 10.1161/hy0202.102700; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405; Kowalczuk S, 2005, BIOCHEM J, V386, P417, DOI 10.1042/BJ20050100; LEVY D, 1990, NEW ENGL J MED, V0322; Lo M, 2002, PHYSIOL GENOMICS, V8, P15, DOI 10.1152/physiolgenomics.00057.2001; Malakauskas SM, 2007, AM J PHYSIOL-RENAL, V292, pF533, DOI 10.1152/ajprenal.00325.2006; MATTSON DL, 1994, AM J PHYSIOL, V266, pH1918, DOI 10.1152/ajpheart.1994.266.5.H1918; Melk A, 2005, KIDNEY INT, V68, P2667, DOI 10.1111/j.1523-1755.2005.00738.x; Mendes Ribeiro Antonio Claudio, 2004, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V2, P123; Miyata N, 1999, HYPERTENSION, V33, P446, DOI 10.1161/01.HYP.33.1.446; Morris SM, 2009, BRIT J PHARMACOL, V157, P922, DOI 10.1111/j.1476-5381.2009.00278.x; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NAKANISHI K, 1995, AM J PHYSIOL-REG I, V268, pR317, DOI 10.1152/ajpregu.1995.268.2.R317; NISHI A, 1992, ACTA PHYSIOL SCAND, V144, P263, DOI 10.1111/j.1748-1716.1992.tb09295.x; Ortiz PA, 2001, HYPERTENSION, V38, P621, DOI 10.1161/hy09t1.093361; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; Parks LD, 2002, AM J PHYSIOL-RENAL, V283, pF1208, DOI 10.1152/ajprenal.00021.2002; Pedrosa R, 2008, HYPERTENSION, V51, P1332, DOI 10.1161/HYPERTENSIONAHA.107.102434; PESTANA M, 1994, BRIT J PHARMACOL, V112, P417, DOI 10.1111/j.1476-5381.1994.tb13088.x; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Pinho M., 2009, J EPITHELIAL BIOL PH, V2, P36; Pinho MJ, 2007, MOL CELL BIOCHEM, V306, P9, DOI 10.1007/s11010-007-9548-9; Pinho MJ, 2007, AM J PHYSIOL-REG I, V293, pR538, DOI 10.1152/ajpregu.00906.2006; Pinho MJ, 2007, AM J PHYSIOL-RENAL, V292, pF1452, DOI 10.1152/ajprenal.00465.2006; Pinho MJ, 2004, KIDNEY INT, V66, P216, DOI 10.1111/j.1523-1755.2004.00722.x; Pinho MJ, 2003, HYPERTENSION, V42, P613, DOI 10.1161/01.HYP.0000091822.00166.B1; Pinto V, 2011, MECH AGEING DEV, V132, P298, DOI 10.1016/j.mad.2011.06.003; Pinto V, 2010, BIOCHEM BIOPH RES CO, V398, P553, DOI 10.1016/j.bbrc.2010.06.117; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; Quan H, 2004, MOL CELL BIOL, V24, P4166, DOI 10.1128/MCB.24.10.4166-4173.2004; Racasan S, 2004, HYPERTENSION, V44, P83, DOI 10.1161/01.HYP.0000133251.40322.20; RAJANTIE J, 1981, J CLIN INVEST, V67, P1078, DOI 10.1172/JCI110120; Rajapakse NW, 2012, AM J PHYSIOL-RENAL, V302, pF1554, DOI 10.1152/ajprenal.00084.2011; Romeo E, 2006, AM J PHYSIOL-RENAL, V290, pF376, DOI 10.1152/ajprenal.00286.2005; Schlaich MP, 2004, CIRCULATION, V110, P3680, DOI 10.1161/01.CIR.0000149748.79945.52; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Seol SY, 2008, BIOCHEM BIOPH RES CO, V374, P714, DOI 10.1016/j.bbrc.2008.07.094; Silva E, 2007, AM J PHYSIOL-REG I, V293, pR1764, DOI 10.1152/ajpregu.00425.2007; Simao S, 2008, BRIT J PHARMACOL, V153, P1445, DOI 10.1038/bjp.2008.16; Simao S, 2008, MOL CELL BIOCHEM, V315, P31, DOI 10.1007/s11010-008-9785-6; Simao S, 2011, J CELL BIOCHEM, V112, P3660, DOI 10.1002/jcb.23299; Singer D, 2011, CHANNELS, V5, P408, DOI 10.4161/chan.5.5.16470; Singer D, 2009, J BIOL CHEM, V284, P19953, DOI 10.1074/jbc.M109.011171; Soares-da-Silva P, 2004, AM J PHYSIOL-RENAL, V287, pF252, DOI 10.1152/ajprenal.00030.2004; SOARESDASILVA P, 1991, ACTA PHYSIOL SCAND, V143, P287, DOI 10.1111/j.1748-1716.1991.tb09234.x; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Storey BT, 2005, INT J CANCER, V117, P387, DOI 10.1002/ijc.21169; Takanaga H, 2005, J BIOL CHEM, V280, P8974, DOI 10.1074/jbc.M413027200; Taler SJ, 2008, PRIMARY CARE, V35, P489, DOI 10.1016/j.pop.2008.06.001; Tanner LM, 2007, J INHERIT METAB DIS, V30, P716, DOI 10.1007/s10545-007-0558-2; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Uchiyama T, 2005, FEBS LETT, V579, P2499, DOI 10.1016/j.febslet.2005.03.065; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Verrey F, 2005, ANNU REV PHYSIOL, V67, P557, DOI 10.1146/annurev.physiol.67.031103.153949; Verrey F, 2009, PFLUG ARCH EUR J PHY, V458, P53, DOI 10.1007/s00424-009-0638-2; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; Wu F, 2000, AM J PHYSIOL-REG I, V278, pR1506, DOI 10.1152/ajpregu.2000.278.6.R1506; Yasuhara A, 2008, CIRCULATION, V118, P2146, DOI 10.1161/CIRCULATIONAHA.108.787259; Yoon YH, 2008, DNA CELL BIOL, V27, P559, DOI 10.1089/dna.2008.0755; Zeng CY, 2007, CLIN SCI, V112, P583, DOI 10.1042/CS20070018; Zeng CY, 2011, HYPERTENSION, V57, P11, DOI 10.1161/HYPERTENSIONAHA.110.157727; Zeng CY, 2004, PHYSIOL GENOMICS, V19, P233, DOI 10.1152/physiolgenomics.00127.2004; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang Q, 2013, AM J PHYSIOL-RENAL, V304, pF326, DOI 10.1152/ajprenal.00501.2012; Zheng Hui-Zhen, 2000, Shengli Xuebao, V52, P323	98	31	32	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					2927	2938		10.1096/fj.12-224998	http://dx.doi.org/10.1096/fj.12-224998			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23616567				2022-12-28	WOS:000329877600001
J	Cohen, B; Martinelli, GP; Raphan, T; Schaffner, A; Xiang, YQ; Holstein, GR; Yakushin, SB				Cohen, Bernard; Martinelli, Giorgio P.; Raphan, Theodore; Schaffner, Adam; Xiang, Yongqing; Holstein, Gay R.; Yakushin, Sergei B.			The vasovagal response of the rat: its relation to the vestibulosympathetic reflex and to Mayer waves	FASEB JOURNAL			English	Article						blood pressure; heart rate; sinusoidal galvanic vestibular stimulation; linear acceleration; faints; otolith system	SYMPATHETIC-NERVE ACTIVITY; GALVANIC VESTIBULAR STIMULATION; DIFFERENTIAL-DELAY EQUATION; BLOOD-PRESSURE WAVES; ARTERIAL-PRESSURE; HEART-RATE; LINEAR ACCELERATION; BAROREFLEX CONTROL; SQUIRREL-MONKEY; SYNCOPE	Vasovagal responses (VVRs) are characterized by transient drops in blood pressure (BP) and heart rate (HR) and increased amplitude of low-frequency oscillations in the Mayer wave frequency range. Typical VVRs were induced in anesthetized, male, Long-Evans rats by sinusoidal galvanic vestibular stimulation (sGVS). VVRs were also produced by single sinusoids that transiently increased BP and HR, by 70-90 degrees nose-up tilts, and by 60 degrees tilts of the gravitoinertial acceleration vector using translation while rotating (TWR). The average power of the BP signal in the Mayer wave range increased substantially when tilts were >70 degrees (0.91 g), i.e., when linear accelerations in the x-z plane were 0.9-1.0 g. The standard deviations of the wavelet-filtered BP signals during tilt and TWR overlaid when they were normalized to 1 g. Thus, the amplitudes of the Mayer waves coded the magnitude of the linear acceleration 1 g acting on the head and body, and the average power in this frequency range was associated with the generation of VVRs. These data show that VVRs are a natural outcome of stimulation of the vestibulosympathetic reflex and are not a disease. The results also demonstrate the usefulness of the rat as a small animal model for studying human VVRs.Cohen, B., Martinelli, G. P., Raphan, T., Schaffner, A., Xiang, Y., Holstein, G. R., Yakushin, S. B. The vasovagal response of the rat: its relation to the vestibulosympathetic reflex and to Mayer waves.	[Cohen, Bernard; Martinelli, Giorgio P.; Schaffner, Adam; Holstein, Gay R.; Yakushin, Sergei B.] Icahn Sch Med Mt Sinai, Dept Neurol, Brooklyn, NY USA; [Holstein, Gay R.] Icahn Sch Med Mt Sinai, Dept Neurosci, Brooklyn, NY USA; [Raphan, Theodore; Xiang, Yongqing] CUNY Brooklyn Coll, Dept Comp & Informat Sci, Brooklyn, NY 11210 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Brooklyn College (CUNY)	Yakushin, SB (corresponding author), Mt Sinai Sch Med, Box 1135,1 Gustave Levy Pl, New York, NY 10029 USA.	bernard.cohen@mssm.edu			U.S. National Institutes of Health [DC12573, DC008846, AG035389, DC004996, DC05204]; NATIONAL INSTITUTE ON AGING [R21AG035389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC012573, R01DC008846, P30DC005204, R01DC004996] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by U.S. National Institutes of Health grants DC12573, DC008846, AG035389, DC004996, and DC05204. The authors thank Kathleen Crosby for editorial assistance and Dmitri Ogorodnikov for technical assistance.	Abbiw-Jackson RM, 1998, J MATH BIOL, V37, P203, DOI 10.1007/s002850050126; Alboni P, 2000, EUROPACE, V2, P172, DOI 10.1053/eupc.1999.0088; Alboni P, 2007, EUROPACE, V9, P83, DOI 10.1093/europace/eul179; Bent LR, 2006, EXP BRAIN RES, V174, P701, DOI 10.1007/s00221-006-0515-6; Burattini R, 2004, EXP PHYSIOL, V89, P397, DOI 10.1113/expphysiol.2003.027094; Burgess DE, 1997, AM J PHYSIOL-REG I, V273, pR1878, DOI 10.1152/ajpregu.1997.273.6.R1878; Card JP, 2006, J COMP NEUROL, V499, P840, DOI 10.1002/cne.21140; Cavalcanti S, 1996, IEEE T BIO-MED ENG, V43, P982, DOI 10.1109/10.536899; Chapuis B, 2004, J PHYSIOL-LONDON, V559, P639, DOI 10.1113/jphysiol.2004.065474; Cohen Bernard, 2012, Front Neurol, V3, P148, DOI 10.3389/fneur.2012.00148; Cohen Bernard, 2011, Front Neurol, V2, P90, DOI 10.3389/fneur.2011.00090; Cohen B, 2011, EXP BRAIN RES, V210, P45, DOI 10.1007/s00221-011-2604-4; Connolly SJ, 2003, JAMA-J AM MED ASSOC, V289, P2224, DOI 10.1001/jama.289.17.2224; COURJON JH, 1987, EXP BRAIN RES, V66, P41; Cui J, 2001, AM J PHYSIOL-REG I, V281, pR625, DOI 10.1152/ajpregu.2001.281.2.R625; Cui JA, 1999, NEUROSCI LETT, V267, P181, DOI 10.1016/S0304-3940(99)00360-2; DEBOER RW, 1987, AM J PHYSIOL, V253, pH680, DOI 10.1152/ajpheart.1987.253.3.H680; El Sayed K, 2012, EXP BRAIN RES, V221, P427, DOI 10.1007/s00221-012-3185-6; ELGHOZI JL, 1991, CLIN EXP PHARMACOL P, V18, P735, DOI 10.1111/j.1440-1681.1991.tb01391.x; GOLDBERG JM, 1984, J NEUROPHYSIOL, V51, P1236, DOI 10.1152/jn.1984.51.6.1236; GOLDBERG JM, 1982, BRAIN RES, V252, P156, DOI 10.1016/0006-8993(82)90990-8; Grewal T, 2012, EXP BRAIN RES, V220, P101, DOI 10.1007/s00221-012-3118-4; Guild SJ, 2001, AM J PHYSIOL-REG I, V281, pR206, DOI 10.1152/ajpregu.2001.281.1.R206; GUYTON AC, 1952, AM J PHYSIOL, V170, P601, DOI 10.1152/ajplegacy.1952.170.3.601; GUYTON AC, 1951, AM J PHYSIOL, V165, P158, DOI 10.1152/ajplegacy.1951.165.1.158; Hammam E, 2012, EXP BRAIN RES, V219, P441, DOI 10.1007/s00221-012-3090-z; Hammam E, 2011, EXP BRAIN RES, V213, P507, DOI 10.1007/s00221-011-2800-2; Hammer PE, 2005, AM J PHYSIOL-REG I, V288, pR1637, DOI 10.1152/ajpregu.00050.2004; Holstein Gay R, 2012, Front Neurol, V3, P4, DOI 10.3389/fneur.2012.00004; James C, 2010, AUTON NEUROSCI-BASIC, V158, P127, DOI 10.1016/j.autneu.2010.07.005; James C, 2010, EXP BRAIN RES, V202, P291, DOI 10.1007/s00221-009-2131-8; Julien C, 2006, CARDIOVASC RES, V70, P12, DOI 10.1016/j.cardiores.2005.11.008; KAMINSKI RJ, 1970, AM J PHYSIOL, V219, P1768, DOI 10.1152/ajplegacy.1970.219.6.1768; Kitney R I, 1979, J Biomed Eng, V1, P89, DOI 10.1016/0141-5425(79)90063-3; LEVISON WH, 1966, CIRC RES, V18, P673, DOI 10.1161/01.RES.18.6.673; Lewis T, 1932, BRIT MED J, V1932, P873, DOI 10.1136/bmj.1.3723.873; MADWED JB, 1989, AM J PHYSIOL, V256, pH1573, DOI 10.1152/ajpheart.1989.256.6.H1573; Malpas SC, 1999, AM J PHYSIOL-REG I, V276, pR1311, DOI 10.1152/ajpregu.1999.276.5.R1311; Malpas SC, 1998, AM J PHYSIOL-REG I, V274, pR1283, DOI 10.1152/ajpregu.1998.274.5.R1283; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; Marrone A, 1999, PHYSICA A, V271, P458, DOI 10.1016/S0378-4371(99)00243-5; Maruta J, 2005, EXP BRAIN RES, V163, P273, DOI 10.1007/s00221-004-2178-5; Mayer S, 1876, SITZUNGSBERICHT MATH, V74, P281; Myers CW, 2001, AUTON NEUROSCI-BASIC, V91, P62, DOI 10.1016/S1566-0702(01)00289-2; Nowak JA, 2009, AM J PHYSIOL-HEART C, V296, pH171, DOI 10.1152/ajpheart.00963.2008; Ottesen JT, 1997, J MATH BIOL, V36, P41, DOI 10.1007/s002850050089; PREISS G, 1974, AM J PHYSIOL, V226, P724, DOI 10.1152/ajplegacy.1974.226.3.724; Prudham D, 1981, Age Ageing, V10, P141; Ringwood JV, 2001, AM J PHYSIOL-REG I, V280, pR1105, DOI 10.1152/ajpregu.2001.280.4.R1105; Seydnejad SR, 2001, IEEE ENG MED BIOL, V20, P92, DOI 10.1109/51.917729; Strang G., 1996, WAVELETS FILTER BANK; Sumner GL, 2010, J CARDIOVASC ELECTR, V21, P1375, DOI 10.1111/j.1540-8167.2010.01848.x; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; Traube, 1865, CENTRALBL MED WISS B, V3, P881; Vielle B, 2005, J MATH BIOL, V50, P595, DOI 10.1007/s00285-004-0305-3; WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566, DOI 10.1152/jappl.1993.74.5.2566; Yates BJ, 2000, EXP BRAIN RES, V130, P151, DOI 10.1007/s002219900238	57	15	15	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2564	2572		10.1096/fj.12-226381	http://dx.doi.org/10.1096/fj.12-226381			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23504712	Green Published, Bronze			2022-12-28	WOS:000328841000006
J	Pederson, T				Pederson, Thoru			Life, Redrawn: A Memoir of Carl R. Woese (1928-2012)	FASEB JOURNAL			English	Biographical-Item									Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Cell & Dev Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Cell & Dev Dynam, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						PEDERSON T, PUBLICATION LIST	1	4	4	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1285	1287		10.1096/fj.13-0401ufm	http://dx.doi.org/10.1096/fj.13-0401ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23547106				2022-12-28	WOS:000316940800001
J	Bavelloni, A; Piazzi, M; Faenza, I; Raffini, M; D'Angelo, A; Cattini, L; Cocco, L; Blalock, WL				Bavelloni, Alberto; Piazzi, Manuela; Faenza, Irene; Raffini, Mirco; D'Angelo, Antonietta; Cattini, Luca; Cocco, Lucio; Blalock, William L.			Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia	FASEB JOURNAL			English	Article						SRp20; SRSF3; mass spectrometry; phosphorylation; proteomics; signal transduction	PROTEIN-KINASE-B; INDUCED GRANULOCYTIC DIFFERENTIATION; SERINE-THREONINE KINASE; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; PHOSPHOINOSITIDE 3-KINASE; HL-60 CELLS; SPLICING FACTORS; PHOSPHORYLATION; EXPRESSION	The AKT/PKB kinase is essential for cell survival, proliferation, and differentiation; however, aberrant AKT activation leads to the aggressiveness and drug resistance of many human neoplasias. In the human acute promyelocytic leukemia cell line NB4, nuclear AKT activity increases during all-trans retinoic acid (ATRA)-mediated differentiation. As nuclear AKT activity is associated with differentiation, we sought to identify the nuclear substrates of AKT that were phosphorylated after ATRA treatment. A proteomics-based search for nuclear substrates of AKT in ATRA-treated NB4 cells was undertaken by using 2D-electrophoresis/mass spectrometry (MS) in combination with an anti-AKT phospho-substrate antibody. Western blot analysis, an in vitro kinase assay, and/or site-directed mutagenesis were performed to further characterize the MS findings. MS analysis revealed prohibitin (PHB)-2, a multifunctional protein involved in cell cycle progression and the suppression of oxidative stress, to be a putative nuclear substrate of AKT. Follow-up studies confirmed that AKT phosphorylates PHB2 on Ser-91 and that forced expression of the PHB2(S91A) mutant results in a rapid loss of viability and apoptotic cell death. Activation of nuclear AKT during ATRA-mediated differentiation results in the phosphorylation of several proteins, including PHB2, which may serve to coordinate nuclear-mitochondrial events during differentiation.Bavelloni, A., Piazzi, M., Faenza, I., Raffini, M., D'Angelo, A., Cattini, L., Cocco, L., Blalock, W. L. Prohibitin 2 represents a novel nuclear AKT substrate during all-trans-retinoic acid-induced differentiation of acute promyelocytic leukemia cells.	[Bavelloni, Alberto; Blalock, William L.] Rizzoli Orthoped Inst, Struttura Complessa SC Lab Musculoskeletal Cell B, Bologna, Italy; [Bavelloni, Alberto; Raffini, Mirco; D'Angelo, Antonietta; Cattini, Luca] Rizzoli Orthoped Inst, Ramses Lab, Bologna, Italy; [Piazzi, Manuela; Faenza, Irene; Cocco, Lucio] Univ Bologna, Dept Biomed Sci, Cell Signaling Lab, Bologna, Italy; [Blalock, William L.] Natl Res Council CNR Italy, IGM, Bologna, Italy	IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	Blalock, WL (corresponding author), CNR, IGM, Rizzoli Orthoped Inst, Via Barbiano 1-10, I-40136 Bologna, Italy.	william.blalock@cnr.it	Piazzi, Manuela/AAD-5016-2020; Cocco, Lucio/AAI-2206-2020; Faenza, Irene/AAC-4606-2022; Bavelloni, Alberto/E-5726-2019; Blalock, William L/C-6959-2019; Piazzi, Manuela/K-2147-2016	Piazzi, Manuela/0000-0002-9072-2757; Cocco, Lucio/0000-0002-9206-8277; Faenza, Irene/0000-0002-5227-3567; Bavelloni, Alberto/0000-0002-6467-1431; Blalock, William L/0000-0002-8045-4840; Piazzi, Manuela/0000-0002-9072-2757	5 x 1000 (2011-2012) fund; Italian MIUR-FIRB (Minister of University and Scientific Research-Fund for Basic Research Investments) Human ProteomeNet; MUIR-FIRB; Italian MUIR-PRIN (Programma di Ricerca di Rilevante Interesse Nazionale)	5 x 1000 (2011-2012) fund; Italian MIUR-FIRB (Minister of University and Scientific Research-Fund for Basic Research Investments) Human ProteomeNet(Ministry of Education, Universities and Research (MIUR)); MUIR-FIRB; Italian MUIR-PRIN (Programma di Ricerca di Rilevante Interesse Nazionale)	The authors thank Dr. D. Pinetti and A. Valmori for technical assistance. The Cassa di Risparmio di Modena (CARISMO) purchased the Chip-Cube-QTOF Instrumentation (Agilent). This work was supported by the "5 x 1000 (2011-2012)" fund to the SC Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopedic Institute; the Italian MIUR-FIRB (Minister of University and Scientific Research-Fund for Basic Research Investments) Human ProteomeNet, MUIR-FIRB 2010, and the Italian MUIR-PRIN (Programma di Ricerca di Rilevante Interesse Nazionale) (to L.C.). The authors declare no conflicts of interest.	Bartholomeusz C, 2012, EXPERT OPIN THER TAR, V16, P121, DOI 10.1517/14728222.2011.644788; Baudhuin LM, 2003, FASEB J, V17, P341, DOI 10.1096/fj.03-0302fje; Bavelloni A, 2006, PROTEOMICS, V6, P5725, DOI 10.1002/pmic.200600318; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bertagnolo V, 1999, CANCER RES, V59, P542; Blalock WL, 2011, LEUKEMIA, V25, P236, DOI 10.1038/leu.2010.264; Blalock WL, 2014, J CELL PHYSIOL, V229, P1047, DOI 10.1002/jcp.24529; Braccini L., 2012, Advances in Biological Regulation, V52, P389, DOI 10.1016/j.jbior.2012.04.002; Capitani S, 2000, EUR J HISTOCHEM, V44, P61; Collins SJ, 2008, CURR OPIN HEMATOL, V15, P346, DOI 10.1097/MOH.0b013e3283007edf; Crean JK, 2006, FASEB J, V20, P1712, DOI 10.1096/fj.05-5010fje; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GOLOMB HM, 1976, ARCH INTERN MED, V136, P825, DOI 10.1001/archinte.136.7.825; Gupta K, 2012, LEUKEMIA, V26, P1277, DOI 10.1038/leu.2012.2; Han EKH, 2008, ANTICANCER RES, V28, P957; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jia R, 2010, INT J BIOL SCI, V6, P806; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kim Eun Kyoung, 2012, Adv Biol Regul, V52, P88; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kurokawa K, 2014, ONCOGENE, V33, P1407, DOI 10.1038/onc.2013.86; Lee SB, 2010, J BIOL CHEM, V285, P29457, DOI 10.1074/jbc.M110.131367; Liu J, 2012, ONKOLOGIE, V35, P335, DOI 10.1159/000338941; Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martelli AM, 2011, LEUKEMIA, V25, P1064, DOI 10.1038/leu.2011.46; Martelli AM, 2012, BBA-MOL CELL RES, V1823, P2168, DOI 10.1016/j.bbamcr.2012.08.017; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Matkovic K, 2006, LEUKEMIA, V20, P941, DOI 10.1038/sj.leu.2404204; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McCubrey James A, 2012, Adv Biol Regul, V52, P249; Mishra S, 2006, J CELL MOL MED, V10, P353, DOI 10.1111/j.1582-4934.2006.tb00404.x; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Ozes ON, 1999, NATURE, V401, P82; Piazzi M, 2013, MOL CELL PROTEOMICS, V12, P2220, DOI 10.1074/mcp.M113.029686; Pitha-Rowe I, 2003, LEUKEMIA, V17, P1723, DOI 10.1038/sj.leu.2403065; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296; Strub GM, 2011, FASEB J, V25, P600, DOI 10.1096/fj.10-167502; Sun LG, 2004, J CELL SCI, V117, P3021, DOI 10.1242/jcs.01142; Sun LG, 2011, CELL SIGNAL, V23, P1686, DOI 10.1016/j.cellsig.2011.06.005; Tallman MS, 2009, BLOOD, V114, P5126, DOI 10.1182/blood-2009-07-216457; Teittinen KJ, 2012, LEUKEMIA RES, V36, P232, DOI 10.1016/j.leukres.2011.06.038; Theiss AL, 2007, FASEB J, V21, P197, DOI 10.1096/fj.06-6801com; Toker Alex, 2012, Adv Biol Regul, V52, P78; Weinstein-Oppenheimer C, 2000, LEUKEMIA, V14, P1921, DOI 10.1038/sj.leu.2401926; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	62	22	22	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2009	2019		10.1096/fj.13-244368	http://dx.doi.org/10.1096/fj.13-244368			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24522204				2022-12-28	WOS:000335336000006
J	Kilander, MBC; Petersen, J; Andressen, KW; Ganji, RS; Levy, FO; Schuster, J; Dahl, N; Bryja, V; Schulte, G				Kilander, Michaela B. C.; Petersen, Julian; Andressen, Kjetil Wessel; Ganji, Ranjani Sri; Levy, Finn Olav; Schuster, Jens; Dahl, Niklas; Bryja, Vitezslav; Schulte, Gunnar			Disheveled regulates precoupling of heterotrimeric G proteins to Frizzled 6	FASEB JOURNAL			English	Article						GPCR; WNT-5A; GNAI1; GNAQ	COUPLED-RECEPTOR ACTIVATION; F9 TERATOCARCINOMA CELLS; C-TERMINAL REGION; LIVING CELLS; ADRENERGIC-RECEPTOR; SIGNALING PATHWAYS; WNT/BETA-CATENIN; PLASMA-MEMBRANE; RAT FRIZZLED-1; WNT	Frizzleds (FZDs) are classified as G-protein-coupling receptors, but how signals are initiated and specified through heterotrimeric G proteins is unknown. FZD(6) regulates convergent extension movements, and its C-terminal Arg511Cys mutation causes nail dysplasia in humans. We investigated the functional relationship between FZD(6), Disheveled (DVL), and heterotrimeric G proteins. Live cell imaging combined with fluorescence recovery after photobleaching (FRAP) revealed that inactive human FZD(6) precouples to G(i1) and G(q) but not to G(oA),G(s), and G(12) proteins. G-protein coupling is measured as a 10-20% reduction in the mobile fraction of fluorescently tagged G proteins on chemical receptor surface cross-linking. The FZD(6) Arg511Cys mutation is incapable of G-protein precoupling, even though it still binds DVL. Using both FRAP and Forster resonance energy transfer (FRET) technology, we showed that the FZD(6)-G(i1) and FZD-G(q) complexes dissociate on WNT-5A stimulation. Most important, G-protein precoupling of FZD(6) and WNT-5A-induced signaling to extracellular signal-regulated kinase1/2 were impaired by DVL knockdown or overexpression, arguing for a strict dependence of FZD(6)-G-protein coupling on DVL levels and identifying DVL as a master regulator of FZD/G-protein signaling. In summary, we propose a mechanistic connection between DVL and G proteins integrating WNT, FZD, G-protein, and DVL function.Kilander, M. B. C., Petersen, J., Andressen, K. W., Ganji, R. S. Levy, F. O., Schuster, J., Dahl N., Bryja, V., Schulte, G. Disheveled regulates precoupling of heterotrimeric G proteins to Frizzled 6.	[Kilander, Michaela B. C.; Petersen, Julian; Schulte, Gunnar] Karolinska Inst, Sect Receptor Biol & Signaling, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; [Andressen, Kjetil Wessel; Levy, Finn Olav] Univ Oslo, Inst Clin Med, Dept Pharmacol, Oslo, Norway; [Andressen, Kjetil Wessel; Levy, Finn Olav] Oslo Univ Hosp, Oslo, Norway; [Andressen, Kjetil Wessel; Levy, Finn Olav] Univ Oslo, Fac Med, KG Jebsen Cardiac Res Ctr, Oslo, Norway; [Andressen, Kjetil Wessel; Levy, Finn Olav] Univ Oslo, Fac Med, Ctr Heart Failure Res, Oslo, Norway; [Ganji, Ranjani Sri; Bryja, Vitezslav; Schulte, Gunnar] Masaryk Univ, Fac Sci, Inst Expt Biol, CS-61137 Brno, Czech Republic; [Schuster, Jens; Dahl, Niklas] Uppsala Univ, Dept Immunol Genet & Pathol, Biomedicinskt Ctr BMC, Uppsala, Sweden; [Bryja, Vitezslav] Acad Sci Czech Republic, Inst Biophys, Dept Cytokinet, Prague, Czech Republic	Karolinska Institutet; University of Oslo; University of Oslo; University of Oslo; University of Oslo; Masaryk University Brno; Uppsala University; Czech Academy of Sciences	Schulte, G (corresponding author), Karolinska Inst, Sect Receptor Biol & Signaling, Dept Physiol & Pharmacol, Nanna Svartz Vag 2, S-17177 Stockholm, Sweden.	gunnar.schulte@ki.se	Ganji, Ranjani/AGD-5702-2022; Bryja, Vítězslav/P-4217-2019; Bryja, Vít?zslav/H-1925-2014; Schuster, Jens/D-2005-2010; Petersen, Julian/ABE-6060-2021	Bryja, Vítězslav/0000-0002-9136-5085; Bryja, Vít?zslav/0000-0002-9136-5085; Schuster, Jens/0000-0002-4383-9880; Petersen, Julian/0000-0002-7444-0610; Schulte, Gunnar/0000-0002-2700-7013; Andressen, Kjetil Wessel/0000-0003-1094-1501; Kilander, Michaela/0000-0001-5166-4614	Karolinska Institutet; Swedish Research Council [K2008-68P-20810-01-4, K2008-333 68X-20805-01-4, K2012-67X-20805-05-3]; Swedish Cancer Society [CAN 2008/539, 2011/690]; Knut and Alice Wallenberg Foundation [KAW2008.0149]; Board of Doctoral Education at Karolinska Institutet; Engkvist's Foundations; Foundation Lars Hiertas Minne; Swedish Royal Academy of Sciences/Foundation Hierta-Retzius Fond; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Czech Science Foundation [204/09/H058, 204/09/0498, 13-32990S]; Ministry of Education, Youth and Sports of The Czech Republic [MSM0021622430]; Program KI-MU - European Social Fund [CZ.1.07/2.3.00/20.0180]; state budget of the Czech Republic	Karolinska Institutet(Karolinska Institutet); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Board of Doctoral Education at Karolinska Institutet; Engkvist's Foundations; Foundation Lars Hiertas Minne; Swedish Royal Academy of Sciences/Foundation Hierta-Retzius Fond; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Czech Science Foundation(Grant Agency of the Czech Republic); Ministry of Education, Youth and Sports of The Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Program KI-MU - European Social Fund; state budget of the Czech Republic	The authors thank Madelon M. Maurice (University Medical Center, Utrecht, The Netherlands), Robert J. Lefkowitz (Duke University Medical Center, Durham, NC, USA), Randall T. Moon (University of Washington School of Medicine, Seattle, WA, USA), Jyrki Kukkonen (Turku University Hospital, Turku, Finland), Mark Rasenick (University of Chicago, Chicago, IL, USA), Nevin A. Lambert (Georgia Health Sciences University, Augusta, GA, USA), and Zsolt Lenkei (Ecole Superieure de Physique et Chimie Industrielle-Paristech, Paris, France) for reagents. The work was supported by grants from Karolinska Institutet, the Swedish Research Council (K2008-68P-20810-01-4, K2008-333 68X-20805-01-4, and K2012-67X-20805-05-3), the Swedish Cancer Society (CAN 2008/539, 2011/690), the Knut and Alice Wallenberg Foundation (KAW2008.0149), the Board of Doctoral Education at Karolinska Institutet (to M. B. C. K. and J. P.), Engkvist's Foundations, Foundation Lars Hiertas Minne, Swedish Royal Academy of Sciences/Foundation Hierta-Retzius Fond, the Swedish Foundation for International Cooperation in Research and Higher Education (STINT), the Czech Science Foundation (204/09/H058, 204/09/0498, and 13-32990S), the Ministry of Education, Youth and Sports of The Czech Republic (MSM0021622430), and the Program KI-MU (CZ.1.07/2.3.00/20.0180), cofinanced by the European Social Fund and the state budget of the Czech Republic. The authors declare no conflicts of interest.	Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Ayoub Mohammed Akli, 2012, Front Endocrinol (Lausanne), V3, P82, DOI 10.3389/fendo.2012.00082; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Bikkavilli RK, 2008, J CELL SCI, V121, P234, DOI 10.1242/jcs.021964; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Bryja V, 2008, EMBO REP, V9, P1244, DOI 10.1038/embor.2008.193; Cui CY, 2013, J INVEST DERMATOL, V133, P1990, DOI 10.1038/jid.2013.84; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103; Dijksterhuis JP, 2014, BRIT J PHARMACOL, V171, P1195, DOI 10.1111/bph.12364; Frojmark AS, 2011, AM J HUM GENET, V88, P852, DOI 10.1016/j.ajhg.2011.05.013; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Gayen S, 2013, MOLECULES, V18, P8579, DOI 10.3390/molecules18078579; Halleskog C, 2013, CELL SIGNAL, V25, P822, DOI 10.1016/j.cellsig.2012.12.006; Halleskog C, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-111; Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870; Hein P, 2009, N-S ARCH PHARMACOL, V379, P435, DOI 10.1007/s00210-008-0383-7; Katanaev V. L., 2009, NAT PREC; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kilander MBC, 2011, ACTA PHYSIOL, V203, P363, DOI 10.1111/j.1748-1716.2011.02324.x; Kilander MBC, 2011, CELL SIGNAL, V23, P550, DOI 10.1016/j.cellsig.2010.11.004; Koval A, 2011, BIOCHEM PHARMACOL, V82, P1311, DOI 10.1016/j.bcp.2011.06.005; Koval A, 2011, BIOCHEM J, V433, P435, DOI 10.1042/BJ20101878; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Lohse MJ, 2012, PHARMACOL REV, V64, P299, DOI 10.1124/pr.110.004309; Malbon CC, 2011, BIOCHEM J, V434, P575; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Malbon Craig C, 2011, Biochem J, V433, pe3, DOI 10.1042/BJ20102111; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Philip F, 2007, J BIOL CHEM, V282, P19203, DOI 10.1074/jbc.M701558200; Qin K, 2008, FASEB J, V22, P2920, DOI 10.1096/fj.08-105775; Qin K, 2011, NAT CHEM BIOL, V7, P740, DOI [10.1038/nchembio.642, 10.1038/NCHEMBIO.642]; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Schulte G, 2007, TRENDS PHARMACOL SCI, V28, P518, DOI 10.1016/j.tips.2007.09.001; Schulte G, 2010, PHARMACOL REV, V62, P632, DOI 10.1124/pr.110.002931; Schwarz-Romond T, 2005, J CELL SCI, V118, P5269, DOI 10.1242/jcs.02646; Schwarz-Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Simons M, 2009, NAT CELL BIOL, V11, P286, DOI 10.1038/ncb1836; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Tauriello DVF, 2012, P NATL ACAD SCI USA, V109, pE812, DOI 10.1073/pnas.1114802109; Vasquez C, 1999, J NEUROSCI, V19, P9271; Wang C, 2013, NATURE, V497, P338, DOI 10.1038/nature12167; Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 2008, TRENDS PHARMACOL SCI, V29, P616, DOI 10.1016/j.tips.2008.08.006; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352	63	42	42	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2293	2305		10.1096/fj.13-246363	http://dx.doi.org/10.1096/fj.13-246363			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24500924				2022-12-28	WOS:000335336000031
J	Takasawa, K; Kashimada, K; Pelosi, E; Takagi, M; Morio, T; Asahara, H; Schlessinger, D; Mizutani, S; Koopman, P				Takasawa, Kei; Kashimada, Kenichi; Pelosi, Emanuele; Takagi, Masatoshi; Morio, Tomohiro; Asahara, Hiroshi; Schlessinger, David; Mizutani, Shuki; Koopman, Peter			FOXL2 transcriptionally represses Sf1 expression by antagonizing WT1 during ovarian development in mice	FASEB JOURNAL			English	Article						sex determination; reproduction; LHX9	STEROIDOGENIC FACTOR-I; SEX DETERMINATION; NUCLEAR RECEPTOR; GONADAL DEVELOPMENT; FOLLICLE DEVELOPMENT; GENE-EXPRESSION; GRANULOSA-CELLS; MOUSE; FACTOR-1; PROMOTER	Steroidogenic factor 1 (SF1; Ad4BP/NR5A1) plays key roles in gonadal development. Initially, the Sf1 gene is expressed in mouse fetal gonads of both sexes, but later is up-regulated in testes and down-regulated in ovaries. While Sf1 expression is activated and maintained by Wilms tumor 1 (WT1) and LIM homeobox 9 (LHX9), the mechanism of sex-specific regulation remains unclear. We hypothesized that Sf1 is repressed by the transcription factor Forkhead box L2 (FOXL2) during ovarian development. In an in vitro system (TM3 cells), up-regulation of Sf1 by the WT1 splice variant WT1-KTS was antagonized by FOXL2, as determined by quantitative RT-PCR. Using reporter assays, we localized the Sf1 proximal promoter region involved in this antagonism to a 674-bp interval. A conserved FOXL2 binding site was identified in this interval by in vitro chromatin immunoprecipitation. Introducing mutations into this site abolished negative regulation by FOXL2 in reporter assays. Finally, in Foxl2-null mice, Sf1 expression was increased 2-fold relative to wild-type XX fetal gonads. Our results support the hypothesis that FOXL2 negatively regulates Sf1 expression by antagonizing WT1-KTS during early ovarian development in mice.Takasawa, K., Kashimada, K., Pelosi, E., Takagi, M., Morio, T., Asahara, H., Schlessinger, D., Mizutani, S., Koopman, P. FOXL2 transcriptionally represses Sf1 expression by antagonizing WT1 during ovarian development in mice.	[Takasawa, Kei; Kashimada, Kenichi; Takagi, Masatoshi; Morio, Tomohiro; Mizutani, Shuki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo 1138510, Japan; [Asahara, Hiroshi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Syst BioMed, Bunkyo Ku, Tokyo 1138510, Japan; [Pelosi, Emanuele; Schlessinger, David] NIA, Intramural Res Program, Genet Lab, US Natl Inst Hlth Biomed Res Ctr, Baltimore, MD 21224 USA; [Koopman, Peter] Univ Queensland, Inst Mol Biosci, Div Mol Genet & Dev, Brisbane, Qld, Australia	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Queensland	Kashimada, K (corresponding author), Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo 1138510, Japan.	kkashimada.ped@tmd.ac.jp	Koopman, Peter A/C-9416-2009; Pelosi, Emanuele/D-2015-2017	Koopman, Peter A/0000-0001-6939-0914; Pelosi, Emanuele/0000-0003-1890-9821; Morio, Tomohiro/0000-0002-9259-1025; Takasawa, Kei/0000-0001-6947-4034; Kashimada, Kenichi/0000-0003-2505-5932	Intramural Research Program of the U.S. National Institutes of Health, National Institute on Aging; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [23249071]; Japan Society for the Promotion of Science (JSPS) KAKENHI grant [24115707]; Japan Science and Technology Agency (JST) Core Research for Evolutionary Science and Technology (CREST) [24591503]; NATIONAL INSTITUTE ON AGING [ZIAAG000647] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23249071, 24591503] Funding Source: KAKEN	Intramural Research Program of the U.S. National Institutes of Health, National Institute on Aging; Ministry of Education, Culture, Sports, Science, and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS) KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Science and Technology Agency (JST) Core Research for Evolutionary Science and Technology (CREST); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dagmar Wilhelm (Monash University, Melbourne, VIC, Australia) for critical reading of the manuscript and Atsushi Kubo (Tokyo Medical and Dental University) for technical support. This research was supported, in part, by the Intramural Research Program of the U.S. National Institutes of Health, National Institute on Aging, for E.P. and D.S.; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Grants-in-Aid for Scientific Research (KAKENHI) grant 23249071, Japan Society for the Promotion of Science (JSPS) KAKENHI grant 24115707, and Japan Science and Technology Agency (JST) Core Research for Evolutionary Science and Technology (CREST), for H.A.; and KAKENHI (C) grant 24591503, for K.K.	Barrionuevo F, 2009, DEV BIOL, V327, P301, DOI 10.1016/j.ydbio.2008.12.011; Benayoun BA, 2008, HUM MOL GENET, V17, P3118, DOI 10.1093/hmg/ddn209; Beverdam A, 2003, CYTOGENET GENOME RES, V101, P242, DOI 10.1159/000074344; Beverdam A, 2006, HUM MOL GENET, V15, P417, DOI 10.1093/hmg/ddi463; Caburet S, 2012, MOL CELL ENDOCRINOL, V356, P55, DOI 10.1016/j.mce.2011.06.019; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Garcia-Ortiz JE, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-36; Gao LY, 2011, BIOL REPROD, V84, P422, DOI 10.1095/biolreprod.110.084590; Georges A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025463; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Jeyasuria P, 2004, MOL ENDOCRINOL, V18, P1610, DOI 10.1210/me.2003-0404; Kashimada K, 2011, FASEB J, V25, P3561, DOI 10.1096/fj.11-184333; Kashimada K, 2011, ENDOCRINOLOGY, V152, P272, DOI 10.1210/en.2010-0636; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; McFarlane L, 2013, SEX DEV, V7, P207, DOI 10.1159/000348677; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Ottolenghi C, 2007, HUM MOL GENET, V16, P2795, DOI 10.1093/hmg/ddm235; Pailhoux E, 2001, NAT GENET, V29, P453, DOI 10.1038/ng769; Park M, 2010, MOL ENDOCRINOL, V24, P1024, DOI 10.1210/me.2009-0375; Pelusi C, 2008, BIOL REPROD, V79, P1074, DOI 10.1095/biolreprod.108.069435; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Schepers G, 2003, J BIOL CHEM, V278, P28101, DOI 10.1074/jbc.M304067200; Schmidt D, 2004, DEVELOPMENT, V131, P933, DOI 10.1242/dev.00969; Sekido R, 2008, NATURE, V453, P930, DOI 10.1038/nature06944; Shen JHC, 2002, MOL ENDOCRINOL, V16, P529, DOI 10.1210/me.16.3.529; Svingen T, 2009, SEX DEV, V3, P194, DOI 10.1159/000228720; Uda M, 2004, HUM MOL GENET, V13, P1171, DOI 10.1093/hmg/ddh124; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wang DS, 2007, MOL ENDOCRINOL, V21, P712, DOI 10.1210/me.2006-0248; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Wilhelm D, 2009, MECH DEVELOP, V126, P324, DOI 10.1016/j.mod.2009.02.006; Wilson MJ, 2005, J BIOL CHEM, V280, P5917, DOI 10.1074/jbc.M412806200; Woodson KG, 1997, MOL ENDOCRINOL, V11, P117, DOI 10.1210/me.11.2.117	40	37	40	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2020	2028		10.1096/fj.13-246108	http://dx.doi.org/10.1096/fj.13-246108			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24451388	Green Published, Bronze			2022-12-28	WOS:000335336000007
J	Van Audenhove, I; Boucherie, C; Pieters, L; Zwaenepoel, O; Vanloo, B; Martens, E; Verbrugge, C; Hassanzadeh-Ghassabeh, G; Vandekerckhove, J; Cornelissen, M; De Ganck, A; Gettemans, J				Van Audenhove, Isabel; Boucherie, Ciska; Pieters, Leen; Zwaenepoel, Olivier; Vanloo, Berlinda; Martens, Evelien; Verbrugge, Charlotte; Hassanzadeh-Ghassabeh, Gholamreza; Vandekerckhove, Joel; Cornelissen, Maria; De Ganck, Ariane; Gettemans, Jan			Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization	FASEB JOURNAL			English	Article						heavy-chain only antibodies; cytoskeletal protein modulation; invasive protrusions; oncotargets	SQUAMOUS-CELL CARCINOMAS; EXTRACELLULAR-MATRIX DEGRADATION; N-WASP; ACTIN POLYMERIZATION; ARP2/3 COMPLEX; IN-VITRO; F-ACTIN; PROMOTES; INVASIVENESS; MEMBRANE	Invadopodia are actin-rich protrusions arising through the orchestrated regulation of precursor assembly, stabilization, and maturation, endowing cancer cells with invasive properties. Using nanobodies (antigen-binding domains of Camelid heavy-chain antibodies) as perturbators of intracellular functions and/or protein domains at the level of the endogenous protein, we examined the specific contribution of fascin and cortactin during invadopodium formation in MDA-MB-231 breast and PC-3 prostate cancer cells. A nanobody (K-d similar to 35 nM, 1:1 stoichiometry) that disrupts fascin F-actin bundling emphasizes the importance of stable actin bundles in invadopodium array organization and turnover, matrix degradation, and cancer cell invasion. Cortactin-SH3 dependent WIP recruitment toward the plasma membrane was specifically inhibited by a cortactin nanobody (K-d similar to 75 nM, 1:1 stoichiometry). This functional domain is shown to be important for formation of properly organized invadopodia, MMP-9 secretion, matrix degradation, and cancer cell invasion. Notably, using a subcellular delocalization strategy to trigger protein loss of function, we uncovered a fascin-bundling-independent role in MMP-9 secretion. Hence, we demonstrate that nanobodies enable high resolution protein function mapping in cells.-Van Audenhove, I., Boucherie, C., Pieters, L., Zwaenepoel, O., Vanloo, B., Martens, E., Verbrugge, C., Hassanzadeh-Ghassabeh, G., Vandekerckhove, J., Cornelissen, M., De Ganck, A., Gettemans, J. Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization.	[Van Audenhove, Isabel; Boucherie, Ciska; Zwaenepoel, Olivier; Vanloo, Berlinda; Martens, Evelien; Verbrugge, Charlotte; Vandekerckhove, Joel; De Ganck, Ariane; Gettemans, Jan] Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; [Pieters, Leen; Cornelissen, Maria] Univ Ghent, Dept Basic Med Sci, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; [Hassanzadeh-Ghassabeh, Gholamreza] VIB, Nanobody Serv Facil, Brussels, Belgium	Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB)	Gettemans, J (corresponding author), Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.gettemans@ugent.be			Research Foundation Flanders [Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen]; League against Cancer (Stichting tegen Kanker, Belgium), Ghent University (BOF-GOA); Interuniversity Attraction Poles Programme of the Belgian State, Federal Office for Scientific, Technical and Cultural Affairs [IUAP P7/13]; FWO-Flanders	Research Foundation Flanders [Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen]; League against Cancer (Stichting tegen Kanker, Belgium), Ghent University (BOF-GOA); Interuniversity Attraction Poles Programme of the Belgian State, Federal Office for Scientific, Technical and Cultural Affairs; FWO-Flanders(FWO)	The authors thank Prof. Dr. Marleen Van Troys for advice on confocal microscopy experimental methodology and live-cell imaging techniques, as well as Dr. Isabelle Maridonneau Parini (Institut de Pharmacologie et de Biologie Structural, University of Toulouse, Toulouse, France) for the gift of LifeAct-mCherry and Prof. Roberto Dominguez (Department of Physiology, University of Pennsylvania, Philadelphia, PA, USA) for the gift of pTYB12 vector. The authors thank Prof. Janis Burkhardt (Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA) for the gift of full-length HS1 cDNA and the cDNA of the HS1 SH3 domain in GST-expression vectors, Prof. Laura Machesky (Beatson Institute for Cancer Research, Glasgow, UK) for the gift of pEGFP-C1 WASP, and Prof. Werner Muller-Esterl (Institut fur Biochemie II, Johann Wolfgang Goethe Universitat, Frankfurt, Germany) for the gift of pEGFP-N1 Dynamin II. This work was supported by grants from the Research Foundation Flanders [Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen], the League against Cancer (Stichting tegen Kanker, Belgium), Ghent University (BOF-GOA), and the Interuniversity Attraction Poles Programme of the Belgian State, Federal Office for Scientific, Technical and Cultural Affairs (IUAP P7/13). I.V.A. is supported by the FWO-Flanders.	Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; Al-Alwan M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027339; Alam H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-32; Aratyn YS, 2007, MOL BIOL CELL, V18, P3928, DOI 10.1091/mbc.E07-04-0346; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Banon-Rodriguez I, 2011, EUR J CELL BIOL, V90, P213, DOI 10.1016/j.ejcb.2010.09.001; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; De Clercq S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078108; De Clercq S, 2013, CELL MOL LIFE SCI, V70, P909, DOI 10.1007/s00018-012-1169-0; Delanote V, 2010, FASEB J, V24, P105, DOI 10.1096/fj.09-134304; Gibcus JH, 2008, BRIT J CANCER, V98, P950, DOI 10.1038/sj.bjc.6604246; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hashimoto Y, 2005, INT J BIOCHEM CELL B, V37, P1787, DOI 10.1016/j.biocel.2005.05.004; Jansen S, 2011, J BIOL CHEM, V286, P30087, DOI 10.1074/jbc.M111.251439; Jawhari AU, 2003, AM J PATHOL, V162, P69, DOI 10.1016/S0002-9440(10)63799-6; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Kirkbride KC, 2011, CELL ADHES MIGR, V5, P187, DOI 10.4161/cam.5.2.14773; Lai FPL, 2009, MOL BIOL CELL, V20, P3209, DOI 10.1091/mbc.E08-12-1180; Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mayer BJ, 2001, J CELL SCI, V114, P1253; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Onodera M, 2009, LAB INVEST, V89, P1261, DOI 10.1038/labinvest.2009.89; Ortiz CM, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-41; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Rodrigo JP, 2009, J PATHOL, V217, P516, DOI 10.1002/path.2462; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; Rutka JT, 2008, NEOPLASIA, V10, P149, DOI 10.1593/neo.07909; Schoumacher M, 2011, EUR J CELL BIOL, V90, P93, DOI 10.1016/j.ejcb.2010.05.010; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Van Audenhove I, 2013, CYTOSKELETON, V70, P604, DOI 10.1002/cm.21122; van den Abbeele A, 2007, CANCER LETT, V255, P57, DOI 10.1016/j.canlet.2007.03.023; Van den Abbeele A, 2010, CELL MOL LIFE SCI, V67, P1519, DOI 10.1007/s00018-010-0266-1; van Rossum AGSH, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-15; Vignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb BA, 2007, EUR J CELL BIOL, V86, P189, DOI 10.1016/j.ejcb.2007.01.003; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Xie JJ, 2010, AM J PATHOL, V176, P939, DOI 10.2353/ajpath.2010.090118; Xie JJ, 2005, BIOCHEM BIOPH RES CO, V337, P355, DOI 10.1016/j.bbrc.2005.09.055; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; Yang SY, 2013, J BIOL CHEM, V288, P274, DOI 10.1074/jbc.M112.427971; Zanet J, 2012, J CELL BIOL, V197, P477, DOI 10.1083/jcb.201110135	59	49	49	0	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1805	1818		10.1096/fj.13-242537	http://dx.doi.org/10.1096/fj.13-242537			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24414419				2022-12-28	WOS:000335344300026
J	Hu, ZY; Crump, SM; Anand, M; Kant, R; Levi, R; Abbott, GW				Hu, Zhaoyang; Crump, Shawn M.; Anand, Marie; Kant, Ritu; Levi, Roberto; Abbott, Geoffrey W.			Kcne3 deletion initiates extracardiac arrhythmogenesis in mice	FASEB JOURNAL			English	Article						long-QT syndrome; subunit; potassium channel	NOREPINEPHRINE RELEASE; GENETIC-BASIS; HEART; ALDOSTERONE; ARRHYTHMIAS; DISRUPTION; EXPRESSION; MUTATION; RECEPTOR; SUBUNIT	Mutations in the human KCNE3 potassium channel ancillary subunit gene are associated with life-threatening ventricular arrhythmias. Most genes underlying inherited cardiac arrhythmias, including KCNE3, are not exclusively expressed in the heart, suggesting potentially complex disease etiologies. Here we investigated mechanisms of KCNE3-linked arrhythmogenesis in Kcne3(-/-) mice using real-time qPCR, echo- and electrocardiography, ventricular myocyte patch-clamp, coronary artery ligation/reperfusion, blood analysis, cardiac synaptosome exocytosis, microarray and pathway analysis, and multitissue histology. Kcne3 transcript was undetectable in adult mouse atria, ventricles, and adrenal glands, but Kcne3(-/-) mice exhibited 2.3-fold elevated serum aldosterone (P=0.003) and differentially expressed gene networks consistent with an adrenal-targeted autoimmune response. Furthermore, 8/8 Kcne3(-/-) mice vs. 0/8 Kcne3(+/+) mice exhibited an activated-lymphocyte adrenal infiltration (P=0.0002). Kcne3 deletion also caused aldosterone-dependent ventricular repolarization delay (19.6% mean QT(c) prolongation in females; P<0.05) and aldosterone-dependent predisposition to postischemia arrhythmogenesis. Thus, 5/11 Kcne3(-/-) mice vs. 0/10 Kcne3(+/+) mice exhibited sustained ventricular tachycardia during reperfusion (P<0.05). Kcne3 deletion is therefore arrhythmogenic by a novel mechanism in which secondary hyperaldosteronism, associated with an adrenal-specific lymphocyte infiltration, impairs ventricular repolarization. The findings highlight the importance of considering extracardiac pathogenesis when investigating arrhythmogenic mechanisms, even in inherited, monogenic channelopathies.Hu, Z., Crump, S. M., Anand, M., Kant, R., Levi, R., Abbott, G. W. Kcne3 deletion initiates extracardiac arrhythmogenesis in mice.	[Hu, Zhaoyang; Crump, Shawn M.; Anand, Marie; Kant, Ritu; Abbott, Geoffrey W.] Univ Calif Irvine, Sch Med, Bioelect Lab, Irvine, CA 92697 USA; [Hu, Zhaoyang; Crump, Shawn M.; Anand, Marie; Kant, Ritu; Abbott, Geoffrey W.] Univ Calif Irvine, Sch Med, Dept Pharmacol, Irvine, CA 92697 USA; [Hu, Zhaoyang; Crump, Shawn M.; Anand, Marie; Kant, Ritu; Abbott, Geoffrey W.] Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; [Levi, Roberto] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Cornell University	Abbott, GW (corresponding author), Univ Calif Irvine, Sch Med, Dept Pharmacol, 360 Med Surge 2, Irvine, CA 92697 USA.	abbottg@uci.edu			U.S. National Institutes of Health-National Heart, Lung and Blood Institute [HL079275, HL034215]; University of California-Irvine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275, R01HL034215] Funding Source: NIH RePORTER	U.S. National Institutes of Health-National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); University of California-Irvine(University of California System); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Vikram Kanda for expert technical assistance. The authors are grateful for financial support from the U.S. National Institutes of Health-National Heart, Lung and Blood Institute (HL079275 to G. W. A.; HL034215 to R. L.) and University of California-Irvine setup funds (to G.W.A.).	Abbott GW, 2013, EXPERT REV CLIN PHAR, V6, P49, DOI [10.1586/ECP.12.76, 10.1586/ecp.12.76]; Abi-Char J, 2007, J PHYSIOL-LONDON, V582, P1205, DOI 10.1113/jphysiol.2007.134809; Arrighi I, 2001, P NATL ACAD SCI USA, V98, P8792, DOI 10.1073/pnas.141233398; Belladonna ML, 2002, J IMMUNOL, V168, P5448, DOI 10.4049/jimmunol.168.11.5448; Benitah JP, 2001, J PHYSIOL-LONDON, V537, P151, DOI 10.1111/j.1469-7793.2001.0151k.x; Delpon E, 2008, CIRC-ARRHYTHMIA ELEC, V1, P209, DOI 10.1161/CIRCEP.107.748103; Gao XR, 2007, J CARD FAIL, V13, P170, DOI 10.1016/j.cardfail.2006.11.015; George AL, 2013, J CLIN INVEST, V123, P75, DOI 10.1172/JCI62928; Goldman AM, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000289; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; KAUDEWITZ P, 1986, J INVEST DERMATOL, V86, P350, DOI 10.1111/1523-1747.ep12285562; Koyama M, 2003, MOL PHARMACOL, V63, P378, DOI 10.1124/mol.63.2.378; Mackins CJ, 2006, J CLIN INVEST, V116, P1063, DOI 10.1172/JCI25713; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; McGee B, 1996, J RHEUMATOL, V23, P36; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Nakajima T, 2012, CIRC J, V76, P2763, DOI 10.1253/circj.CJ-12-0551; Napolitano C, 2012, PEDIATR CARDIOL, V33, P980, DOI 10.1007/s00246-012-0287-7; Ohno S, 2009, HUM MUTAT, V30, P557, DOI 10.1002/humu.20834; Ouvrard-Pascaud A, 2005, CIRCULATION, V111, P3025, DOI 10.1161/CIRCULATIONAHA.104.503706; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Preston P, 2010, J BIOL CHEM, V285, P7165, DOI 10.1074/jbc.M109.047829; Roden DM, 1996, AM J CARDIOL, V78, P12, DOI 10.1016/S0002-9149(96)00448-1; Roepke TK, 2008, FASEB J, V22, P3648, DOI 10.1096/fj.08-110171; Roepke TK, 2011, FASEB J, V25, P727, DOI 10.1096/fj.10-173682; Sole L, 2013, CHANNELS, V7, P85, DOI 10.4161/chan.23258; Wei JF, 2010, CLIN CARDIOL, V33, P572, DOI 10.1002/clc.20762	27	17	17	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					935	945		10.1096/fj.13-241828	http://dx.doi.org/10.1096/fj.13-241828			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24225147	Green Published, Green Submitted			2022-12-28	WOS:000331072200038
J	Pierdominici, M; Barbati, C; Vomero, M; Locatelli, SL; Carlo-Stella, C; Ortona, E; Malorni, W				Pierdominici, Marina; Barbati, Cristiana; Vomero, Marta; Locatelli, Silvia L.; Carlo-Stella, Carmelo; Ortona, Elena; Malorni, Walter			Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders	FASEB JOURNAL			English	Review						cancer; lymphocytes; Hodgkin's lymphoma; non-Hodgkin's lymphoma; cell fate	CHRONIC LYMPHOCYTIC-LEUKEMIA; TP53 TUMOR-SUPPRESSOR; BECLIN 1 EXPRESSION; CELL-DEATH; MAMMALIAN TARGET; THERAPEUTIC TARGETS; INDUCED APOPTOSIS; T-LYMPHOCYTES; MTOR PATHWAY; GENE ATG5	Autophagy represents a key mechanism of cytoprotection that can be activated by a variety of extracellular and intracellular stresses and allows the cell to sequester cytoplasmic components and damaged organelles, delivering them to lysosomes for degradation and recycling. However, the autophagy process has also been associated with the death of the cell. It has been demonstrated to be constitutive in some instances and inducible in others, and the idea that it could represent a pathogenetic determinant as well as a possible prognostic tool and a therapeutic target in a plethora of human diseases has recently been considered. Among these, cancer represents a major one. In this review, we recapitulate the critical implications of autophagy in the pathogenesis, progression, and treatment of lymphoproliferative disorders. Leukemias and lymphomas, in fact, represent paradigmatic human diseases in which advances have recently been made in this respect.Pierdominici, M., Barbati, C., Vomero, M., Locatelli, S. L., Carlo-Stella, C., Ortona, E., Malorni, W. Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.	[Pierdominici, Marina; Barbati, Cristiana; Vomero, Marta; Ortona, Elena] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; [Malorni, Walter] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy; [Barbati, Cristiana] Ist San Raffaele, Sulmona, Italy; [Locatelli, Silvia L.; Carlo-Stella, Carmelo] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Dept Hematol & Oncol, Rozzano, Italy; [Locatelli, Silvia L.; Carlo-Stella, Carmelo] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy; [Ortona, Elena; Malorni, Walter] San Raffaele Pisana, IRCCS, Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); IRCCS Humanitas Research Hospital; University of Milan; IRCCS San Raffaele Pisana	Malorni, W (corresponding author), Ist Super Sanita, Dept Therapeut Res & Med Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	Locatelli, Silvia Laura/ABH-9461-2020; Locatelli, Silvia Laura/D-7293-2018; Carlo-Stella, Carmelo/B-3805-2010; Vomero, Marta/AAC-6074-2022; Malorni, Walter/G-5874-2016; Pierdominici, Marina/J-6436-2016; ortona, elena/J-6395-2016	Locatelli, Silvia Laura/0000-0001-7948-0788; Locatelli, Silvia Laura/0000-0001-7948-0788; Carlo-Stella, Carmelo/0000-0003-3144-0124; Vomero, Marta/0000-0001-9744-5628; malorni, walter/0000-0002-1223-7000; Pierdominici, Marina/0000-0002-6372-3754; ortona, elena/0000-0001-9845-8105	Italian Ministry of Health (Ricerca Finalizzata); Italian Association for Cancer Research [9998, 11505]	Italian Ministry of Health (Ricerca Finalizzata)(Ministry of Health, Italy); Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	The authors apologize to all colleagues whose work may not have been cited for space reasons. This work was supported in part by grants from the Italian Ministry of Health (Ricerca Finalizzata 2010) and the Italian Association for Cancer Research (9998 and 11505).	Alessandri C, 2012, FASEB J, V26, P4722, DOI 10.1096/fj.12-206060; Altman BJ, 2012, FEBS J, V279, P2598, DOI 10.1111/j.1742-4658.2012.08651.x; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amrein L, 2011, LEUKEMIA RES, V35, P99, DOI 10.1016/j.leukres.2010.05.029; Arsov I, 2011, J IMMUNOL, V186, P2201, DOI 10.4049/jimmunol.1002223; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105; Benhamron S, 2011, EUR J IMMUNOL, V41, P2390, DOI 10.1002/eji.201041336; Bouabdallah K, 2013, CURR OPIN ONCOL, V25, pS1, DOI 10.1097/CCO.0b013e32835de8ee; Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Cao Q, 2008, INT J BIOCHEM CELL B, V40, P272, DOI 10.1016/j.biocel.2007.07.020; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Copeland A, 2012, CURR OPIN ONCOL, V24, P466, DOI 10.1097/CCO.0b013e32835689a3; Dal Col J, 2008, BLOOD, V111, P5142, DOI 10.1182/blood-2007-07-103481; Del Principe D, 2013, CURR MOL MED, V13, P499; Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146; Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; Fernandez D, 2006, ARTHRITIS RHEUM-US, V54, P2983, DOI 10.1002/art.22085; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foster JG, 2012, PHARMACOL REV, V64, P1027, DOI 10.1124/pr.110.004051; Fulda S, 2009, APOPTOSIS, V14, P409, DOI 10.1007/s10495-008-0306-6; Georgakis GV, 2006, BRIT J HAEMATOL, V132, P503, DOI 10.1111/j.1365-2141.2005.05881.x; Gerland LM, 2004, EXP GERONTOL, V39, P789, DOI 10.1016/j.exger.2004.01.013; GESER A, 1989, AM J EPIDEMIOL, V129, P740, DOI 10.1093/oxfordjournals.aje.a115189; Guidetti A, 2012, BRIT J HAEMATOL, V158, P108, DOI 10.1111/j.1365-2141.2012.09139.x; Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200; He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001; Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood-2010-02-271171; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Huang JJ, 2011, HUM PATHOL, V42, P1459, DOI 10.1016/j.humpath.2010.12.014; Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784; Hubbard VM, 2010, J IMMUNOL, V185, P7349, DOI 10.4049/jimmunol.1000576; Iqbal J, 2009, LEUKEMIA, V23, P1139, DOI 10.1038/leu.2009.3; Ishdorj G, 2012, LEUKEMIA LYMPHOMA, V53, P26, DOI 10.3109/10428194.2011.604752; Jaffe ES, 2009, HEMATOL-AM SOC HEMAT, V2009, P523, DOI DOI 10.1182/ASHEDUCATI0N-2009.1.523; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jia W, 2011, J IMMUNOL, V186, P5313, DOI 10.4049/jimmunol.1002404; Kirschbaum MH, 2012, LEUKEMIA LYMPHOMA, V53, P259, DOI 10.3109/10428194.2011.608448; Kovacs JR, 2012, CELL DEATH DIFFER, V19, P144, DOI 10.1038/cdd.2011.78; Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671; Kuppers R, 2012, J CLIN INVEST, V122, P3439, DOI [10.1172/JCI6124.5, 10.1172/JCI61245]; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; Leseux L, 2008, BLOOD, V111, P285, DOI 10.1182/blood-2007-04-085092; Leseux L, 2006, BLOOD, V108, P4156, DOI 10.1182/blood-2006-05-026203; Leslie LA, 2013, LEUKEMIA LYMPHOMA, V54, P2365, DOI 10.3109/10428194.2013.780288; Li CY, 2006, J IMMUNOL, V177, P5163, DOI 10.4049/jimmunol.177.8.5163; Lista P, 2011, J CELL MOL MED, V15, P1443, DOI 10.1111/j.1582-4934.2011.01293.x; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Marconi M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.389; Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309; McLeod IX, 2012, IMMUNOL REV, V249, P195, DOI 10.1111/j.1600-065X.2012.01143.x; Meadows SA, 2012, BLOOD, V119, P1897, DOI 10.1182/blood-2011-10-386763; Miller BC, 2008, AUTOPHAGY, V4, P309, DOI 10.4161/auto.5474; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nicotra G, 2010, MODERN PATHOL, V23, P937, DOI 10.1038/modpathol.2010.80; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524; Pierdominici M, 2011, CURR PHARM DESIGN, V17, P3888, DOI 10.2174/138161211798357809; Powell JD, 2010, IMMUNITY, V33, P301, DOI 10.1016/j.immuni.2010.09.002; Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303; Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143; Puissant A, 2010, CELL CYCLE, V9, P3470, DOI 10.4161/cc.9.17.13048; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rathmell JC, 2012, IMMUNOL REV, V249, P5, DOI 10.1111/j.1600-065X.2012.01158.x; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; Rosich L, 2013, AUTOPHAGY, V9, P115, DOI 10.4161/auto.22483; Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823; Sawas A, 2011, CURR OPIN HEMATOL, V18, P280, DOI 10.1097/MOH.0b013e328347786d; Shankland KR, 2012, LANCET, V380, P848, DOI 10.1016/S0140-6736(12)60605-9; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827; Shi WY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.13; Sommermann TG, 2012, AUTOPHAGY, V8, P265, DOI 10.4161/auto.8.2.18763; Sosa MS, 2013, ADV EXP MED BIOL, V734, P73, DOI 10.1007/978-1-4614-1445-2_5; Stephenson LM, 2009, AUTOPHAGY, V5, P625, DOI 10.4161/auto.5.5.8133; Swat W, 2006, BLOOD, V107, P2415, DOI 10.1182/blood-2005-08-3300; Tagawa H, 2013, CANCER SCI, V104, P801, DOI 10.1111/cas.12160; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Teachey DT, 2009, BRIT J HAEMATOL, V145, P569, DOI 10.1111/j.1365-2141.2009.07657.x; Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639; Watanabe K, 2008, BIOCHEM BIOPH RES CO, V374, P274, DOI 10.1016/j.bbrc.2008.07.013; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Witzig TE, 2010, HEMATOL-AM SOC HEMAT, P265, DOI 10.1182/asheducation-2010.1.265; Xu-Monette ZY, 2012, AUTOPHAGY, V8, P842, DOI 10.4161/auto.19703; Xu-Monette ZY, 2012, BLOOD, V119, P3668, DOI 10.1182/blood-2011-11-366062; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Younes A, 2011, ONCOLOGIST, V16, P730, DOI 10.1634/theoncologist.2010-0318; Yu K, 2010, CANCER RES, V70, P621, DOI 10.1158/0008-5472.CAN-09-2340; Zhang YJ, 2011, DRUG DISCOV TODAY, V16, P325, DOI 10.1016/j.drudis.2011.02.008; Zhao WL, 2010, LEUKEMIA, V24, P13, DOI 10.1038/leu.2009.223	97	20	21	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					524	535		10.1096/fj.13-235655	http://dx.doi.org/10.1096/fj.13-235655			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24196588				2022-12-28	WOS:000331072200002
J	Rius, B; Titos, E; Moran-Salvador, E; Lopez-Vicario, C; Garcia-Alonso, V; Gonzalez-Periz, A; Arroyo, V; Claria, J				Rius, Bibiana; Titos, Esther; Moran-Salvador, Eva; Lopez-Vicario, Cristina; Garcia-Alonso, Veronica; Gonzalez-Periz, Ana; Arroyo, Vicente; Claria, Joan			Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis	FASEB JOURNAL			English	Article						inflammation; anti-inflammatory mediators; macrophages; NAFLD; weight loss	FATTY LIVER-DISEASE; LIPID MEDIATORS; WEIGHT-LOSS; METABOLIC SYNDROME; INFLAMMATION; OMEGA-3-FATTY-ACIDS; MECHANISMS; MICRORNAS; THERAPY; PROMOTE	Insulin resistance and nonalcoholic steatohepatitis (NASH), characterized by hepatic steatosis combined with inflammation, are major sequelae of obesity. Currently, lifestyle modification (i.e., weight loss) is the first-line therapy for NASH. However, weight loss resolves steatosis but not inflammation. In this study, we tested the ability of resolvin D1 (RvD1), an anti-inflammatory and proresolving molecule, to promote the resolution initiated by calorie restriction in obese mice with NASH. Calorie restriction reduced adipose and liver weight (-56 and -13%, respectively; P<0.001), serum leptin and resistin levels, hepatic steatosis, and insulin resistance. In addition to these, mice receiving RvD1 during the dietary intervention showed increased adiponectin expression at both the mRNA and protein levels and reduced liver macrophage infiltration (-15%, P<0.01). Moreover, RvD1 skewed macrophages from an M1- to an M2-like anti-inflammatory phenotype, induced a specific hepatic miRNA signature (i.e., miR-219-5p and miR-199a-5p), and reduced inflammatory adipokine mRNA and protein expression and macrophage innate immune response. In precision-cut liver slices (PCLSs), which override the influence of circulating factors, RvD1 attenuated hypoxia-induced mRNA and protein expression of COX-2, IL-1, IL-6, and CCR7. Of note, RvD1 anti-inflammatory actions were absent in macrophage-depleted PCLSs. In summary, RvD1 acts as a facilitator of the hepatic resolution process by reducing the inflammatory component of obesity-induced NASH.Rius, B., Titos, E., Moran-Salvador, E., Lopez-Vicario, C., Garcia-Alonso, V., Gonzalez-Periz, A., Arroyo, V., Claria, J. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis.	[Rius, Bibiana; Titos, Esther; Moran-Salvador, Eva; Lopez-Vicario, Cristina; Garcia-Alonso, Veronica; Gonzalez-Periz, Ana; Claria, Joan] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Esther Koplowitz Ctr, Dept Biochem & Mol Genet, E-08036 Barcelona, Spain; [Arroyo, Vicente] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Esther Koplowitz Ctr, Liver Unit, Barcelona 08036, Spain; [Titos, Esther; Gonzalez-Periz, Ana; Arroyo, Vicente; Claria, Joan] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain; [Claria, Joan] Univ Barcelona, Dept Physiol Sci 1, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona	Claria, J (corresponding author), Hosp Clin Barcelona, Dept Biochem & Mol Genet, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Arroyo, Vicente/F-9189-2015; Titos, Esther/AAA-5394-2019; Claria, Joan/M-7772-2019	Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Lopez-Vicario, Cristina/0000-0002-6609-8501; Claria, Joan/0000-0003-4333-7749	Ministerio de Economia y Competitividad [SAF 12/32789]; Instituto de Salud Carlos III; Ministerio de Ciencia e Innovacion (MICINN) [AP2007-02004, BES-2010-034193]; CIBERehd; IDIBAPS	Ministerio de Economia y Competitividad(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); CIBERehd; IDIBAPS	The authors thank the Bioinformatics Unit of the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) for technical help. This work was supported by Ministerio de Economia y Competitividad (SAF 12/32789). Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III. The authors' laboratory is a Consolidated Research Group recognized by the Generalitat de Catalunya (2009SGR1484). This study was conducted at the Esther Koplowitz Center (Barcelona, Spain) and was supported by Ministerio de Ciencia e Innovacion (MICINN) grants AP2007-02004 (to E. M-S.) and BES-2010-034193 (to V. G.-A). E. T. and A. G.-P. had contracts with CIBERehd. C. L.-V. was supported by IDIBAPS.	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Aron-Wisnewsky J, 2012, J HEPATOL, V56, P225, DOI 10.1016/j.jhep.2011.04.022; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Capristo E, 2005, Eur Rev Med Pharmacol Sci, V9, P265; Claria J, 2013, AM J PHYSIOL-CELL PH, V304, pC1141, DOI 10.1152/ajpcell.00351.2012; Claria J, 2012, J IMMUNOL, V189, P2597, DOI 10.4049/jimmunol.1201272; Fredman G, 2012, SCI REP-UK, V2, DOI 10.1038/srep00639; Gonsalves CS, 2010, J IMMUNOL, V184, P3878, DOI 10.4049/jimmunol.0902594; Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje; Gonzalez-Periz A, 2009, FASEB J, V23, P1946, DOI 10.1096/fj.08-125674; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Harrison SA, 2007, GUT, V56, P1760, DOI 10.1136/gut.2006.112094; Hellmann J, 2011, FASEB J, V25, P2399, DOI 10.1096/fj.10-178657; Huang MA, 2005, AM J GASTROENTEROL, V100, P1072, DOI 10.1111/j.1572-0241.2005.41334.x; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Jou J, 2008, SEMIN LIVER DIS, V28, P370, DOI 10.1055/s-0028-1091981; Klassen LW, 2008, BIOCHEM PHARMACOL, V76, P426, DOI 10.1016/j.bcp.2008.05.012; Kosteli A, 2010, J CLIN INVEST, V120, P3466, DOI 10.1172/JCI42845; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Lopez-Vicario C., 2013, GUT, DOI 10.1136/gutjnl-2012-303179; Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968; Masterton GS, 2010, ALIMENT PHARM THER, V31, P679, DOI 10.1111/j.1365-2036.2010.04230.x; Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018; Promrat K, 2010, HEPATOLOGY, V51, P121, DOI 10.1002/hep.23276; Recchiuti A, 2011, FASEB J, V25, P544, DOI 10.1096/fj.10-169599; Rius B, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00257; Roderburg C, 2011, HEPATOLOGY, V53, P209, DOI 10.1002/hep.23922; Sackmann-Sala L, 2012, OBESITY, V20, P101, DOI 10.1038/oby.2011.235; Sanyal AJ, 2005, NAT CLIN PRACT GASTR, V2, P46, DOI 10.1038/ncpgasthep0084; Schnitger AKD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027435; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Szabo G, 2012, J HEPATOL, V57, P462, DOI 10.1016/j.jhep.2012.01.030; Tilg H, 2006, GASTROENTEROLOGY, V131, P934, DOI 10.1053/j.gastro.2006.05.054; Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Torres DM, 2008, GASTROENTEROLOGY, V134, P1682, DOI 10.1053/j.gastro.2008.02.077; Xydakis AM, 2004, J CLIN ENDOCR METAB, V89, P2697, DOI 10.1210/jc.2003-031826; Zelber-Sagi S, 2012, J HEPATOL, V56, P1145, DOI 10.1016/j.jhep.2011.12.011; Zivkovic AM, 2007, AM J CLIN NUTR, V86, P285, DOI 10.1093/ajcn/86.2.285	42	69	71	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					836	848		10.1096/fj.13-235614	http://dx.doi.org/10.1096/fj.13-235614			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24249635				2022-12-28	WOS:000331072200029
J	Wang, W; Mutka, AL; Zmrzljak, UP; Rozman, D; Tanila, H; Gylling, H; Remes, AM; Huttunen, HJ; Ikonen, E				Wang, Wei; Mutka, Aino-Liisa; Zmrzljak, Ursula Prosenc; Rozman, Damjana; Tanila, Heikki; Gylling, Helena; Remes, Anne M.; Huttunen, Henri J.; Ikonen, Elina			Amyloid precursor protein alpha- and beta-cleaved ectodomains exert opposing control of cholesterol homeostasis via SREBP2	FASEB JOURNAL			English	Article						LDL uptake; APP processing	ALZHEIMERS-DISEASE; SURROGATE MARKERS; SITE-1 PROTEASE; LIPID RAFTS; APP; METABOLISM; TRANSPORT; ABSORPTION; PRESENILIN; SECRETASE	Amyloid precursor protein (APP) is ubiquitously expressed. Studies in neuronal cells have implicated APP or its fragments as negative regulators of cholesterol metabolism. In the current study, APP acted, via its -cleavage, as a positive regulator of sterol regulatory element-binding protein-2 (SREBP2) signaling in human astrocytic cells (U251MG), hepatic cells (HepG2), and primary fibroblasts, leading to an approximate 30% increase in SRE-dependent gene expression and, consequently, enhanced cholesterol biosynthesis and LDL receptor levels. This effect was mediated via the secretory ectodomain APPs. The -cleaved ectodomain, in turn, repressed SRE-dependent gene expression by up to approximate to 30%. This resulted in decreased cholesterol synthesis and LDL receptor content, establishing a physiological feedback loop in cholesterol-loaded cells, where APP undergoes preferential -cleavage. Patients with familial Alzheimer's disease had decreased circulating lathosterol, reflecting hepatic cholesterol synthesis, and their fibroblasts had reduced LDL receptor content, which was alleviated by decreasing -cleavage. These results show that APP regulates cholesterol metabolism in cells relevant for whole-body cholesterol balance and reveal that APP - and -cleavages produce opposing paracrine regulators of SREBP2 signaling.Wang, W., Mutka, A.-L., Zmrzljak, U. P., Tanila, D. R. H., Gylling, H., Remes, A. M., Huttunen, H. J., Ikonen, E. Amyloid precursor protein - and -cleaved ectodomains exert opposing control of cholesterol homeostasis via SREBP2.	[Wang, Wei; Mutka, Aino-Liisa; Ikonen, Elina] Univ Helsinki, Inst Biomed, FI-00014 Helsinki, Finland; [Gylling, Helena] Univ Helsinki, Dept Med, Div Internal Med, FI-00014 Helsinki, Finland; [Huttunen, Henri J.] Univ Helsinki, Ctr Neurosci, FI-00014 Helsinki, Finland; [Wang, Wei; Ikonen, Elina] Minerva Fdn, Inst Med Res, Helsinki, Finland; [Zmrzljak, Ursula Prosenc; Rozman, Damjana] Univ Ljubljana, Fac Med, Inst Biochem, Ctr Funct Genom & Biochips, Ljubljana, Slovenia; [Tanila, Heikki] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Kuopio, Finland; [Remes, Anne M.] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland; [Remes, Anne M.] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Ljubljana; University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland	Ikonen, E (corresponding author), Univ Helsinki, Inst Biomed, Haartmaninkatu 8, FI-00014 Helsinki, Finland.	elina.ikonen@helsinki.fi		Ikonen, Elina/0000-0001-8382-1135; Huttunen, Henri/0000-0002-9867-4438; Rozman, Damjana/0000-0002-6501-2163; Prosenc Zmrzljak, Ursula/0000-0002-9034-790X	Academy of Finland [123743, 131313, 131489, 126889, 218066, 218081]; Sigrid Juselius Foundation; Jenny and Antti Wihuri Foundation; Maire Taponen Foundation; Finnish Medical Foundation; Biocentrum Helsinki; Slovenian Research Agency [J1-9438, P1-0104]; Slovenian Research Agency	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Jenny and Antti Wihuri Foundation; Maire Taponen Foundation; Finnish Medical Foundation; Biocentrum Helsinki; Slovenian Research Agency(Slovenian Research Agency - Slovenia); Slovenian Research Agency(Slovenian Research Agency - Slovenia)	The authors thank Petra Makinen and Mikko Hiltunen (Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Finland) for help with APP Western blot analyses and ELISA; Anna Uro, Pipsa Kaipainen, and Hennariikka Koivisto for technical assistance; Dennis Selkoe (Harvard Medical School Center for Neurological Diseases, Brigham and Women's Hospital, Boston, MA, USA), Frederic Checler (Institut de Pharmacologie Moleculaire et Cellularie, Centre National de la Recherche Scientifique, Valbonne, France), and Timothy Levine (University College London, London, UK) for the plasmids; and Pentti Tienari for discussions and comments on the manuscript. This study was financially supported by the Academy of Finland (grants 123743, 131313, 131489, 126889, 218066, and 218081), the Sigrid Juselius Foundation, the Jenny and Antti Wihuri Foundation, the Maire Taponen Foundation, the Finnish Medical Foundation, Biocentrum Helsinki, and Slovenian Research Agency grants J1-9438 and P1-0104. U.P.Z. was funded as young researcher by the Slovenian Research Agency. H.J.H. is an employee and share-holder of Hermo Pharma, Ltd. (Helsinki, Finland).	Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burns M, 2003, J NEUROSCI, V23, P5645; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Du XM, 2006, MOL BIOL CELL, V17, P2735, DOI 10.1091/mbc.E05-11-1094; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Feng XR, 2006, GENE, V371, P68, DOI 10.1016/j.gene.2005.11.006; Fink M, 2005, ENDOCRINOLOGY, V146, P5321, DOI 10.1210/en.2005-0781; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Gong JS, 2002, J NEUROSCI RES, V70, P438, DOI 10.1002/jnr.10347; Grimm MOW, 2008, J BIOL CHEM, V283, P11302, DOI 10.1074/jbc.M801520200; Grimm MOW, 2005, NAT CELL BIOL, V7, P1118, DOI 10.1038/ncb1313; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821; Jager S, 2009, J NEUROCHEM, V111, P1369, DOI 10.1111/j.1471-4159.2009.06420.x; Jiang Y, 2010, P NATL ACAD SCI USA, V107, P1630, DOI 10.1073/pnas.0908953107; Jimenez S, 2011, J BIOL CHEM, V286, P18414, DOI 10.1074/jbc.M110.209718; Kolsch H., 1801, BIOCHIM BIOPHYS ACTA, V1801, P945; Li HM, 2010, P NATL ACAD SCI USA, V107, P17362, DOI 10.1073/pnas.1012568107; Liu Q, 2007, NEURON, V56, P66, DOI 10.1016/j.neuron.2007.08.008; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marquer C, 2011, FASEB J, V25, P1295, DOI 10.1096/fj.10-168633; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Miettinen TA, 2011, NUTR METAB CARDIOVAS, V21, P765, DOI 10.1016/j.numecd.2011.05.005; MIETTINEN TA, 1990, AM J EPIDEMIOL, V131, P20, DOI 10.1093/oxfordjournals.aje.a115479; Mohamed A, 2012, J NEUROSCI, V32, P6490, DOI 10.1523/JNEUROSCI.0630-12.2012; Muller UC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006288; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002; Pierrot N, 2013, EMBO MOL MED, V5, P608, DOI 10.1002/emmm.201202215; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; Rosen C, 2012, NEUROMOL MED, V14, P65, DOI 10.1007/s12017-012-8171-4; Rovelet-Lecrux A, 2007, J NEUROL NEUROSUR PS, V78, P1158, DOI 10.1136/jnnp.2006.113514; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Simonen P, 2008, ATHEROSCLEROSIS, V197, P883, DOI 10.1016/j.atherosclerosis.2007.08.003; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tamboli IY, 2008, J NEUROSCI, V28, P12097, DOI 10.1523/JNEUROSCI.2635-08.2008; THINAKARAN G, 1995, J NEUROSCI, V15, P6314; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; van der Wulp MYM, 2013, MOL CELL ENDOCRINOL, V368, P1, DOI 10.1016/j.mce.2012.06.007; Wang P, 2005, J NEUROSCI, V25, P1219, DOI 10.1523/JNEUROSCI.4660-04.2005; Weyer SW, 2011, EMBO J, V30, P2266, DOI 10.1038/emboj.2011.119; Xiong HQ, 2008, NEUROBIOL DIS, V29, P422, DOI 10.1016/j.nbd.2007.10.005; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007	55	16	16	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					849	860		10.1096/fj.13-239301	http://dx.doi.org/10.1096/fj.13-239301			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24249638				2022-12-28	WOS:000331072200030
J	Wu, T; Vander Kooi, C; Shah, P; Charnigo, R; Huang, C; Smyth, SS; Morris, AJ				Wu, Tao; Vander Kooi, Craig; Shah, Pritom; Charnigo, Richard; Huang, Cai; Smyth, Susan S.; Morris, Andrew J.			Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration	FASEB JOURNAL			English	Article						lysophospholipase; lysophosphatidic acid; cell motility; cell adhesion	ACID LPA RECEPTORS; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPASE-D; CRYSTAL-STRUCTURE; METASTASIS; ACTIVATION; EXPRESSION; INHIBITOR; DYNAMICS; MOTILITY	Autotaxin (ATX) is a secreted lysophospholipase D (lysoPLD) that binds to integrin adhesion receptors. We dissected the roles of integrin binding and lysoPLD activity in stimulation of human breast cancer and mouse aortic vascular smooth muscle cell migration by ATX. We compared effects of wild-type human ATX, catalytically inactive ATX, an integrin binding-defective ATX variant with wild-type lysoPLD activity, the isolated ATX integrin binding N-terminal domain, and a potent ATX selective lysoPLD inhibitor on cell migration using transwell and single-cell tracking assays. Stimulation of transwell migration was reduced (18 or 27% of control, respectively) but not ablated by inactivation of integrin binding or inhibition of lysoPLD activity. The N-terminal domain increased transwell migration (30% of control). ATX lysoPLD activity and integrin binding were necessary for a 3.8-fold increase in the fraction of migrating breast cancer cell step velocities >0.7 m/min. ATX increased the persistent directionality of single-cell migration 2-fold. This effect was lysoPLD activity independent and recapitulated by the integrin binding N-terminal domain. Integrin binding enables uptake and intracellular sequestration of ATX, which redistributes to the front of migrating cells. ATX binding to integrins and lysoPLD activity therefore cooperate to promote rapid persistent directional cell migration.Wu, T., Kooi, C. V., Shah, P., Charnigo, R., Huang, C., Smyth, S. S., Morris, A. J. Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration.	[Wu, Tao; Smyth, Susan S.; Morris, Andrew J.] Univ Kentucky, Gill Heart Inst, Div Cardiovasc Med, Lexington, KY 40536 USA; [Vander Kooi, Craig] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; [Huang, Cai] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; [Charnigo, Richard] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY 40536 USA; [Shah, Pritom] UCL, Wolfson Inst Biomed Res, Canc Res Technol Discovery Labs, London, England; [Smyth, Susan S.; Morris, Andrew J.] Dept Vet Affairs Med Ctr, Lexington, KY USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of London; University College London; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	Smyth, SS (corresponding author), Univ Kentucky, 741 South Limestone St, Lexington, KY 40536 USA.	a.j.morris@uky.edu; susansmyth@uky.edu			U.S. National Institutes of Health; U.S. Department of Veterans Affairs; American Heart Association; NATIONAL CANCER INSTITUTE [P30CA177558] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024598, S10RR026884] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094155, P20GM103527, R01GM050388] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001014, I01BX001984] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); American Heart Association(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by grants from the U.S. National Institutes of Health and the U.S. Department of Veterans Affairs to A.J.M. and S. S. S. T. W. was the recipient of an American Heart Association postdoctoral fellowship. This material is also based on work supported in part by resources at the Lexington Veterans Affairs Medical Center. The authors are grateful to Manjula Sunkara, Fanmuyi Yang, and Frederick Onono for their contributions to the project.	Albers HMHG, 2012, CHEM REV, V112, P2593, DOI 10.1021/cr2003213; Albers HMHG, 2010, P NATL ACAD SCI USA, V107, P7257, DOI 10.1073/pnas.1001529107; Alemayehu M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056174; Bai ZB, 2013, J IMMUNOL, V190, P2036, DOI 10.4049/jimmunol.1202025; Bridgewater RE, 2012, J CELL SCI, V125, P3695, DOI 10.1242/jcs.095810; David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741; Delorme-Walker VD, 2011, J CELL BIOL, V193, P1289, DOI 10.1083/jcb.201010059; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fulkerson Z, 2011, J BIOL CHEM, V286, P34654, DOI 10.1074/jbc.M111.276725; Gierse J, 2010, J PHARMACOL EXP THER, V334, P310, DOI 10.1124/jpet.110.165845; Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002; Hausmann J, 2011, NAT STRUCT MOL BIOL, V18, P198, DOI 10.1038/nsmb.1980; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Huttenlocher A, 2005, NAT CELL BIOL, V7, P336, DOI 10.1038/ncb0405-336; Kanda H, 2008, NAT IMMUNOL, V9, P415, DOI 10.1038/ni1573; Kato K, 2012, P NATL ACAD SCI USA, V109, P16876, DOI 10.1073/pnas.1208017109; Li X, 2013, J CELL SCI, V126, P2617, DOI 10.1242/jcs.117044; Lin ME, 2010, PROSTAG OTH LIPID M, V91, P130, DOI 10.1016/j.prostaglandins.2009.02.002; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Moolenaar WH, 2011, NAT REV MOL CELL BIO, V12, P674, DOI 10.1038/nrm3188; Morris AJ, 2013, J LIPID RES, V54, P1153, DOI 10.1194/jlr.E037887; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nishimasu H, 2011, NAT STRUCT MOL BIOL, V18, P205, DOI 10.1038/nsmb.1998; Pamuklar Z, 2009, J BIOL CHEM, V284, P7385, DOI 10.1074/jbc.M807820200; Panchatcharam M, 2013, ARTERIOSCL THROM VAS, V33, P52, DOI 10.1161/ATVBAHA.112.300527; Price JT, 1999, CANCER RES, V59, P5475; Salous AK, 2013, J LIPID RES, V54, P2775, DOI 10.1194/jlr.M039685; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Wu Z. Y., 2011, PLOS ONE, V6; Yuelling LM, 2008, BBA-MOL CELL BIOL L, V1781, P525, DOI 10.1016/j.bbalip.2008.04.009; Yukiura H, 2011, J BIOL CHEM, V286, P43972, DOI 10.1074/jbc.M111.301093	36	31	31	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					861	870		10.1096/fj.13-232868	http://dx.doi.org/10.1096/fj.13-232868			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24277575	Green Published			2022-12-28	WOS:000331072200031
J	Haenzi, B; Bonny, O; Masson, R; Lienhard, S; Dey, JH; Kuro-o, M; Hynes, NE				Haenzi, Barbara; Bonny, Olivier; Masson, Regis; Lienhard, Susanne; Dey, Julien H.; Kuro-o, Makoto; Hynes, Nancy E.			Loss of Memo, a novel FGFR regulator, results in reduced lifespan	FASEB JOURNAL			English	Article						vitamin D; 1; 25-dihydroxyvitamin D-3; 1; 25(OH)(2)D; calcium; mineral homeostasis; kidney; insulin sensitivity	KLOTHO; ABLATION; HYPERPHOSPHATEMIA; PHOSPHATE; RECEPTOR	Memo is a widely expressed 33-kDa protein required for heregulin (HRG)-, epidermal growth factor (EGF)-, and fibroblast growth factor (FGF)-induced cell motility. Studies in mouse embryonic fibroblasts, wild-type or knockout for Memo, were performed to further investigate the role of Memo downstream of FGFR. We demonstrated that Memo associates with the FGFR signalosome and is necessary for optimal activation of signaling. To uncover Memo's physiological role, Memo conditional-knockout mice were generated. These animals showed a reduced life span, increased insulin sensitivity, small stature, graying hair, alopecia, kyphosis, loss of subcutaneous fat, and loss of spermatozoa in the epididymis. Memo-knockout mice also have elevated serum levels of active vitamin D, 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D), and calcium compared to control littermates expressing Memo. In summary, the results from in vivo and in vitro models support the hypothesis that Memo is a novel regulator of FGFR signaling with a role in controlling 1,25(OH)(2)D production and normal calcium homeostasis.Haenzi, B., Bonny, O., Masson, R., Lienhard, S., Dey, J. H., Kuro-o, M., Hynes, N. E. Loss of Memo, a novel FGFR regulator, results in reduced lifespan.	[Haenzi, Barbara; Masson, Regis; Lienhard, Susanne; Dey, Julien H.; Hynes, Nancy E.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Haenzi, Barbara; Dey, Julien H.; Hynes, Nancy E.] Univ Basel, Basel, Switzerland; [Bonny, Olivier] Univ Lausanne, Dept Pharmacol & Toxicol, Lausanne, Switzerland; [Kuro-o, Makoto] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	Friedrich Miescher Institute for Biomedical Research; University of Basel; University of Lausanne; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	nancy.hynes@fmi.ch		bonny, olivier/0000-0003-4123-4279	Swiss National Fond [SNF 31003A-121574]; European Molecular Biology Organization (EMBO) [ASTF 332-2208]; Swiss National Foundation [PP00P3-133648]; Transfog FP6 IP [LSHC-CT-2004-503438]; Friedrich Miescher Institute for Biochemical Research	Swiss National Fond(Swiss National Science Foundation (SNSF)); European Molecular Biology Organization (EMBO)(European Molecular Biology Organization (EMBO)); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Transfog FP6 IP; Friedrich Miescher Institute for Biochemical Research	The authors thank Gwen MacDonald, Simon Woehrle, and other members of the N.E.H. laboratory for inspiring discussions; Debby Hynx, Dmitri Firsov, and Candice Stoudmann for technical advice and help; and Jurg Biber (University of Zurich, Zurich, Switzerland) for the anti-NaPi2a antibody. The work of B. H. was partially supported by the Swiss National Fond (SNF 31003A-121574) and a European Molecular Biology Organization (EMBO) short-term fellowship (ASTF 332-2208). O.B. is supported by a Swiss National Foundation professorship (PP00P3-133648). The work of R. M. was partially supported by Transfog FP6 IP (LSHC-CT-2004-503438). The laboratory of N.E.H. is supported by the Friedrich Miescher Institute for Biochemical Research. The authors declare no conflicts of interest.	Andrukhova O, 2012, BONE, V51, P621, DOI 10.1016/j.bone.2012.05.015; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Biber J, 2007, NAT PROTOC, V2, P1356, DOI 10.1038/nprot.2007.156; Bibert S, 2009, AM J PHYSIOL-RENAL, V297, pF612, DOI 10.1152/ajprenal.00139.2009; Bryant MR, 2009, GLIA, V57, P935, DOI 10.1002/glia.20818; de Groot T, 2008, KIDNEY INT, V74, P1241, DOI 10.1038/ki.2008.320; DeLuca HF, 2004, AM J CLIN NUTR, V80, p1689S, DOI 10.1093/ajcn/80.6.1689S; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Guo CY, 2002, GENESIS, V32, P8, DOI 10.1002/gene.10021; Hesse M, 2007, MATRIX BIOL, V26, P75, DOI 10.1016/j.matbio.2006.10.003; Hu MC, 2010, FASEB J, V24, P3438, DOI 10.1096/fj.10-154765; Kuro-o M, 2010, MECH AGEING DEV, V131, P270, DOI 10.1016/j.mad.2010.02.008; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Lengner CJ, 2004, J CELL PHYSIOL, V200, P327, DOI 10.1002/jcp.20118; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Meira M, 2009, J CELL SCI, V122, P787, DOI 10.1242/jcs.032094; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Prie D, 2010, CLIN J AM SOC NEPHRO, V5, P1717, DOI 10.2215/CJN.02680310; Schlatter ID, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032501; Schonig K, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf134; Segawa H, 2007, AM J PHYSIOL-RENAL, V292, pF769, DOI 10.1152/ajprenal.00248.2006; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107	26	16	17	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					327	336		10.1096/fj.13-228320	http://dx.doi.org/10.1096/fj.13-228320			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24056085				2022-12-28	WOS:000333526100031
J	Ding, DQ; Xi, P; Zhou, JZ; Wang, M; Cong, YS				Ding, Deqiang; Xi, Peng; Zhou, Junzhi; Wang, Miao; Cong, Yu-Sheng			Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kappa B-dependent transcription	FASEB JOURNAL			English	Article						hTERT; cell invasion; matrix metalloproteinase	CANCER; CELLS; PROLIFERATION; PROTEIN; TERT; METALLOPROTEINASES; ASSOCIATION; PROGRESSION; SUBUNIT; HTR	Telomerase plays a pivotal role in the pathology of aging and cancer by controlling telomere length and integrity. However, accumulating evidence indicates that telomerase reverse transcriptase may have fundamental biological functions independent of its enzymatic activity in telomere maintenance. In this study, the ectopic expression of human telomerase reverse transcriptase (hTERT) and its catalytic mutant hTERT K626A induced cancer cell invasion accompanied by the up-regulation of the metalloproteinases (MMPs) MMP1, -3, -9, and -10. Both hTERT and hTERT K626A induced MMP9 mRNA expression and promoter activity in an NF-B-dependent manner. hTERT and hTERT K626A also regulated the expression of several NF-B target genes in cancer cell lines. Furthermore, both hTERT and hTERT K626A interacted with NF-B p65 and increased NF-B p65 nuclear accumulation and DNA binding. A mammalian 1-hybrid assay showed a functional interplay between hTERT and NF-B p65 that may mediate NF-B-dependent transcription activation in cells. Together, these data reveal a telomere-independent role for telomerase as a transcriptional modulator of the NF-B signaling pathway and a possible contributor to cancer development and progression.Ding, D., Xi, P., Zhou, J., Wang, M., Cong, Y.-S. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-B-dependent transcription.	[Ding, Deqiang; Zhou, Junzhi; Wang, Miao; Cong, Yu-Sheng] Hangzhou Normal Univ, Inst Aging Res, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Ding, Deqiang; Xi, Peng; Zhou, Junzhi] Beijing Normal Univ, Coll Life Sci, Key Lab Cell Proliferat & Regulat Biol, Minist Educ,Inst Cell Biol, Beijing 100875, Peoples R China	Hangzhou Normal University; Beijing Normal University	Cong, YS (corresponding author), Hangzhou Normal Univ, Inst Aging Res, Sch Med, Hangzhou, Zhejiang, Peoples R China.	yscong@hznu.edu.cn	Xi, Peng/A-9768-2012	Xi, Peng/0000-0001-6626-4840; Ding, Deqiang/0000-0002-7959-5654	National Basic Research Program of China [2012CB911203]; National Natural Science Foundation of China [31071200, 31171320]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by grants from the National Basic Research Program of China (2012CB911203) and the National Natural Science Foundation of China (31071200, 31171320).	Akiyama M, 2003, CANCER RES, V63, P18; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blasco MA, 2003, EUR J CELL BIOL, V82, P441, DOI 10.1078/0171-9335-00335; Buhmeida Abdelbaset, 2009, J Gastrointest Cancer, V40, P91, DOI 10.1007/s12029-009-9091-x; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 2008, CELL RES, V18, P725, DOI 10.1038/cr.2008.74; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Kamat AA, 2006, CLIN CANCER RES, V12, P1707, DOI 10.1158/1078-0432.CCR-05-2338; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lee J, 2008, ONCOGENE, V27, P3754, DOI 10.1038/sj.onc.1211037; Li YF, 2012, HUM REPROD, V27, P2096, DOI 10.1093/humrep/des110; Liu Z, 2012, ONCOGENE; Maida Y, 2009, NATURE, V461, P230, DOI 10.1038/nature08283; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Okamoto N, 2011, P NATL ACAD SCI USA, V108, P20388, DOI 10.1073/pnas.1015171108; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Pytliak M, 2012, ONKOLOGIE, V35, P49, DOI 10.1159/000336304; Qiu Q, 2004, MOL HUM REPROD, V10, P677, DOI 10.1093/molehr/gah088; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Sharma NK, 2012, NUCLEIC ACIDS RES, V40, P712, DOI 10.1093/nar/gkr758; Shay JW, 2011, SEMIN CANCER BIOL, V21, P349, DOI 10.1016/j.semcancer.2011.10.001; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Wan FY, 2010, CELL RES, V20, P24, DOI 10.1038/cr.2009.137; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wright WE, 1996, DEV GENET, V18, P173; Zhou LL, 2009, BIOCHEM BIOPH RES CO, V386, P739, DOI 10.1016/j.bbrc.2009.06.116	38	91	94	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4375	4383		10.1096/fj.13-230904	http://dx.doi.org/10.1096/fj.13-230904			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23884427				2022-12-28	WOS:000329937500006
J	Hammerling, U				Hammerling, Ulrich			The Centennial of Vitamin A: A Century of Research in Retinoids and Carotenoids	FASEB JOURNAL			English	Article							RECEPTOR; DIET		[Hammerling, Ulrich] Sloan Kettering Inst Canc Res, Program Immunol, New York, NY 10065 USA; [Hammerling, Ulrich] Weill Cornell Med Coll, Program Immunol & Microbial Pathogenesis, Weill Cornell Grad Sch Biomed Sci, New York, NY USA	Memorial Sloan Kettering Cancer Center; Cornell University	Hammerling, U (corresponding author), Sloan Kettering Inst Canc Res, Program Immunol, 1275 York Ave, New York, NY 10065 USA.	hammerlu@mskcc.org			Sloan-Kettering Institute	Sloan-Kettering Institute	The author thanks Sloan-Kettering Institute for generous financial support. The author is indebted to Jochen Buck, Donald Fischman, and Lonny Levin for valuable insights into the topic and to Lorraine Gudas for academic support.	Acin-Perez R, 2010, FASEB J, V24, P5033, DOI 10.1096/fj.10-166934; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; Funk C, 1911, J PHYSIOL-LONDON, V43, P395; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; Hopkins F., 1929, COMMUNICATION; Karrer P., 1937, COMMUNICATION; McCollum EV, 1913, J BIOL CHEM, V15, P167; Moran NA, 2010, SCIENCE, V328, P624, DOI 10.1126/science.1187113; Osborne TB, 1913, J BIOL CHEM, V15, P311; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SOMMER A, 1980, LANCET, V1, P557; Sourkes T.L, 2009, B HIST CHEM, V34, P32; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Wald G, 1933, NATURE, V132, P316, DOI 10.1038/132316a0; Willstatter R, 1907, LIEBIGS ANN CHEM, V355, P1; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	17	3	3	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2013	27	10					3887	3890		10.1096/fj.13-1001ufm	http://dx.doi.org/10.1096/fj.13-1001ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	290IC	24082007				2022-12-28	WOS:000329747100001
J	Manzoni, C; Lewis, PA				Manzoni, Claudia; Lewis, Patrick A.			Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies	FASEB JOURNAL			English	Article						Parkinson's disease; LRRK2; GBA	CHAPERONE-MEDIATED AUTOPHAGY; ALPHA-SYNUCLEIN; LRRK2; MUTATIONS; ATP13A2; PARKINSONISM; ACCUMULATION; LEADS; NEUROPATHOLOGY; MACROAUTOPHAGY	The past decade has witnessed huge advances in our understanding of the genetics underlying Parkinson's disease. Identifying commonalities in the biological function of genes linked to Parkinson's provides an opportunity to elucidate pathways that lead to neuronal degeneration and eventually to disease. We propose that the genetic forms of Parkinson's disease largely associated with -synuclein-positive neuropathology (SNCA, LRRK2, and GBA) are brought together by involvement in the autophagy/lysosomal pathway and that this represents a unifying pathway to disease in these cases.Manzoni, C., Lewis, P. A. Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies.	[Manzoni, Claudia; Lewis, Patrick A.] UCL Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England; [Lewis, Patrick A.] Univ Reading, Sch Pharm, Reading, Berks, England	University of London; University College London; University of Reading	Lewis, PA (corresponding author), UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1N 3BG, England.	c.manzoni@ucl.ac.uk; patrick.lewis@ucl.ac.uk	Lewis, Patrick A./C-3674-2009; manzoni, claudia/F-4831-2014	Lewis, Patrick/0000-0003-4537-0489	Michael J. Fox Foundation; Parkinson's UK [F1002]; Rosetrees Trust; Wellcome Trust/Medical Research Council (MRC) [WT089698]; Medical Research Council [MC_G1000735] Funding Source: researchfish; Parkinson&quot;s UK [F-1002] Funding Source: researchfish; MRC [MC_G1000735] Funding Source: UKRI	Michael J. Fox Foundation; Parkinson's UK(Parkinson's UK); Rosetrees Trust(Rosetrees Trust); Wellcome Trust/Medical Research Council (MRC); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Parkinson&quot;s UK(Parkinson&apos;s UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors acknowledge generous research support from the Michael J. Fox Foundation and Parkinson's UK. P.A.L. is a Parkinson's UK research fellow (grant F1002). C.M. is funded by the Rosetrees Trust. This work was supported in part by the Wellcome Trust/Medical Research Council (MRC) Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium (UKPDC), whose members are from the University College London Institute of Neurology (London, UK), the University of Sheffield (Sheffield, UK), and the MRC Protein Phosphorylation Unit at the University of Dundee (Dundee, UK).	Ahmed I, 2012, J NEUROSCI, V32, P16503, DOI 10.1523/JNEUROSCI.0209-12.2012; Alegre-Abarrategui J, 2009, HUM MOL GENET, V18, P4022, DOI 10.1093/hmg/ddp346; Alvarez-Erviti L, 2010, ARCH NEUROL-CHICAGO, V67, P1464, DOI 10.1001/archneurol.2010.198; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; Bras J, 2012, HUM MOL GENET, V21, P2646, DOI 10.1093/hmg/dds089; Burre J, 2012, J NEUROSCI, V32, P15227, DOI 10.1523/JNEUROSCI.3545-12.2012; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Chu YP, 2009, NEUROBIOL DIS, V35, P385, DOI 10.1016/j.nbd.2009.05.023; Cookson MR, 2010, NAT REV NEUROSCI, V11, P791, DOI 10.1038/nrn2935; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Cullen V, 2011, ANN NEUROL, V69, P940, DOI 10.1002/ana.22400; Deas E, 2011, BBA-MOL CELL RES, V1813, P623, DOI 10.1016/j.bbamcr.2010.08.007; Dehay B, 2012, P NATL ACAD SCI USA, V109, P9611, DOI 10.1073/pnas.1112368109; Doherty KM, 2013, JAMA NEUROL, V4, P1; Friedman LG, 2012, J NEUROSCI, V32, P7585, DOI 10.1523/JNEUROSCI.5809-11.2012; Gomez-Suaga P, 2012, HUM MOL GENET, V21, P511, DOI 10.1093/hmg/ddr481; Houlden H, 2012, ACTA NEUROPATHOL, V124, P325, DOI 10.1007/s00401-012-1013-5; Kahle PJ, 2009, FREE RADICAL BIO MED, V47, P1354, DOI 10.1016/j.freeradbiomed.2009.08.003; Lashuel HA, 2013, NAT REV NEUROSCI, V14, P38, DOI 10.1038/nrn3406; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Lichtenthaler SF, 2011, J NEUROCHEM, V117, P779, DOI 10.1111/j.1471-4159.2011.07248.x; Lin X, 2009, NEURON, V64, P807, DOI 10.1016/j.neuron.2009.11.006; MacLeod DA, 2013, NEURON, V77, P425, DOI 10.1016/j.neuron.2012.11.033; Mazzulli JR, 2011, CELL, V146, P37, DOI 10.1016/j.cell.2011.06.001; Nair U, 2011, CELL, V146, P290, DOI 10.1016/j.cell.2011.06.022; Orenstein SJ, 2013, NAT NEUROSCI, V16, P394, DOI 10.1038/nn.3350; Park JS, 2011, HUM MUTAT, V32, P956, DOI 10.1002/humu.21527; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Schultheis PJ, 2013, HUM MOL GENET, V22, P2067, DOI 10.1093/hmg/ddt057; Sidransky E, 2012, LANCET NEUROL, V11, P986, DOI 10.1016/S1474-4422(12)70190-4; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Thomas KJ, 2011, HUM MOL GENET, V20, P40, DOI 10.1093/hmg/ddq430; Tofaris GK, 2012, MOVEMENT DISORD, V27, P1364, DOI 10.1002/mds.25136; Tong YR, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-2; Usenovic M, 2012, J NEUROSCI, V32, P4240, DOI 10.1523/JNEUROSCI.5575-11.2012; Vilarino-Guell C, 2011, AM J HUM GENET, V89, P162, DOI 10.1016/j.ajhg.2011.06.001; Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200; Winslow AR, 2010, J CELL BIOL, V190, P1023, DOI 10.1083/jcb.201003122; Yap TL, 2011, J BIOL CHEM, V286, P28080, DOI 10.1074/jbc.M111.237859; Yeger-Lotem E, 2009, NAT GENET, V41, P316, DOI 10.1038/ng.337; Young MM, 2013, J LIPID RES, V54, P5, DOI 10.1194/jlr.R031278; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005; Zimprich A, 2011, AM J HUM GENET, V89, P168, DOI 10.1016/j.ajhg.2011.06.008	44	49	50	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3424	3429		10.1096/fj.12-223842	http://dx.doi.org/10.1096/fj.12-223842			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23682122	Green Published, Green Accepted			2022-12-28	WOS:000328840500002
J	Steen, RG; Dager, SR				Steen, R. Grant; Dager, Stephen R.			Evaluating the evidence for evidence-based medicine: are randomized clinical trials less flawed than other forms of peer-reviewed medical research?	FASEB JOURNAL			English	Article						study design; prospective study; retrospective study; meta-analysis; meta-analytic review	PRIMARY PREVENTION; GOLD STANDARD; LIMITATIONS; METAANALYSIS; QUALITY; BIASES; ASSOCIATION; STATISTICS; EQUIPOISE; STATEMENT	Evidence-based medicine considers randomized clinical trials (RCTs) to be the strongest form of evidence for clinical decision making. To test the hypothesis that RCTs have fewer methodological flaws than non-RCTs, limitations of 17,591 RCTs and 39,029 non-RCTs were characterized. Panels of experts assembled to write meta-analyses evaluated this literature to determine which articles should be included in 316 meta-analytic reviews. Overall, 38.7% of RCTs evaluated were excluded from review for an identified flaw. Commonly identified flaws in RCTs were as follows: insufficient data provided to evaluate the study (9.6% of 17,591 RCTs); inadequate randomization (9.0%); inadequate blinding (4.9%); and duplicative publication (4.4%). Overall, 20.2% of all published medical research has an identified methodological flaw, with RCTs having as many limitations as non-RCTs.Steen, R. G., Dager, S. R. Evaluating the evidence for evidence-based medicine: are randomized clinical trials less flawed than other forms of peer-reviewed medical research?	[Steen, R. Grant] MediCC Med Commun Consultants LLC, Chapel Hill, NC USA; [Dager, Stephen R.] Univ Washington, Sch Med, Dept Radiol & Bioengn, Seattle, WA USA	University of Washington; University of Washington Seattle	Steen, RG (corresponding author), MediCC, 103 Van Doren Pl, Chapel Hill, NC 27517 USA.	g_steen_medicc@yahoo.com		Steen, R. Grant/0000-0003-3386-6575				Aliu O, 2012, PLAST RECONSTR SURG, V129, P989, DOI 10.1097/PRS.0b013e31824ecd61; Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Bain BJ, 2011, J CLIN PATHOL, V64, P373, DOI 10.1136/jcp.2010.080820; Berwanger O, 2009, J CLIN EPIDEMIOL, V62, P387, DOI 10.1016/j.jclinepi.2008.05.013; Can OS, 2011, EUR J ANAESTH, V28, P485, DOI 10.1097/EJA.0b013e32833fb96f; Chen Y., 2010, PLOS ONE, V5; Cleophas TJ, 2000, CLIN CHEM LAB MED, V38, P1217, DOI 10.1515/CCLM.2000.192; Devisch I, 2009, J EVAL CLIN PRACT, V15, P950, DOI 10.1111/j.1365-2753.2009.01232.x; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; Felson DT, 2004, ARTHRITIS RES THER, V6, P117, DOI 10.1186/ar1189; Ferraris VA, 2003, ANN THORAC SURG, V76, P4, DOI 10.1016/S0003-4975(03)00430-2; Fries JF, 2004, ARTHRITIS RES THER, V6, pR250, DOI 10.1186/ar1170; Grossman J, 2005, PERSPECT BIOL MED, V48, P516, DOI 10.1353/pbm.2005.0092; Ho PM, 2008, CIRCULATION, V118, P1675, DOI 10.1161/CIRCULATIONAHA.107.721357; Johnson SA, 2010, JAMA-J AM MED ASSOC, V303, P438, DOI 10.1001/jama.2010.43; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 2001, J CLIN EPIDEMIOL, V54, P541, DOI 10.1016/S0895-4356(00)00347-4; Kaul S, 2010, J AM COLL CARDIOL, V55, P415, DOI 10.1016/j.jacc.2009.06.065; Kim JS, 2011, INT DENT J, V61, P163, DOI 10.1111/j.1875-595X.2011.00037.x; Kurichi JE, 2006, J AM COLL SURGEONS, V202, P476, DOI 10.1016/j.jamcollsurg.2005.11.018; Lee CM, 2004, ANN PHARMACOTHER, V38, P1412, DOI 10.1345/aph.1D493; Lewin S, 2012, PLOS MED, V9; Makhinson M, 2012, J NERV MENT DIS, V200, P76, DOI 10.1097/NMD.0b013e31823e62cd; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Parsons NR, 2011, J BONE JOINT SURG BR, V93B, P1154, DOI 10.1302/0301-620X.93B9.27193; Pincus T, 2004, RHEUM DIS CLIN N AM, V30, P701, DOI 10.1016/j.rdc.2004.08.002; Smith GCS, 2003, BRIT MED J, V327, P1459, DOI 10.1136/bmj.327.7429.1459; Song F, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14080; Tejani AM, 2012, CAN MED ASSOC J, V184, P791, DOI 10.1503/cmaj.112-2036; Tonelli M, 2011, CAN MED ASSOC J, V183, pE1189, DOI 10.1503/cmaj.101280; Tonelli MR, 2009, J EVAL CLIN PRACT, V15, P955, DOI 10.1111/j.1365-2753.2009.01244.x; Wu SQ, 2011, THESCIENTIFICWORLDJO, V11, P2106, DOI 10.1100/2011/139494; Yazici Hasan, 2007, Bull NYU Hosp Jt Dis, V65, P132; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	36	8	8	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3430	3436		10.1096/fj.13-230714	http://dx.doi.org/10.1096/fj.13-230714			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23695156	Bronze			2022-12-28	WOS:000328840500003
J	Ueda, Y; Makino, A; Murase-Tamada, K; Sakai, S; Inaba, T; Hullin-Matsuda, F; Kobayashi, T				Ueda, Yoshibumi; Makino, Asami; Murase-Tamada, Kotono; Sakai, Shota; Inaba, Takehiko; Hullin-Matsuda, Francoise; Kobayashi, Toshihide			Sphingomyelin regulates the transbilayer movement of diacylglycerol in the plasma membrane of Madin-Darby canine kidney cells	FASEB JOURNAL			English	Article						lipid probe; C1AB domain; ceramides; flip-flop	PROTEIN-KINASE-C; PHOSPHOLIPASE-C; QUANTITATIVE-ANALYSIS; PHOSPHATASE ENZYMES; LIPID-METABOLISM; GOLGI-APPARATUS; MODEL MEMBRANES; PHASE-DIAGRAM; MDCK CELLS; CHOLESTEROL	Diacylglycerol (DAG) is a key component in lipid metabolism and signaling. Previous model membrane studies using DAG analogs suggest their rapid membrane transbilayer movement. However, little is known about the DAG distribution and dynamics in cell membranes. Using live-cell fluorescence microscopy, we monitored the transbilayer movement of DAG with the yellow fluorescent protein-tagged C1AB domain from protein kinase C- (EYFP-C1AB), which selectively binds DAG. When HeLa cells were treated with Bacillus cereus phospholipase C (Bc-PLC) to produce DAG on the outer leaflet of the plasma membrane, intracellularly expressed EYFP-C1AB probe accumulated at the plasma membrane, indicating the transbilayer movement of the outer leaflet DAG to the inner leaflet. This Bc-PLC-induced translocation of EYFP-C1AB probe to the plasma membrane was not observed in the sphingolipid-enriched plasma membrane of Madin-Darby canine kidney cells, but was recovered after cell treatment with sphingomyelinase or preincubation with an inhibitor of sphingolipid biosynthesis. The inhibitory effect of sphingomyelin (SM) on the transbilayer movement of DAG was reproduced in model membranes using a fluorescent short-chain DAG analog. These results demonstrate that the SM content on the outer leaflet regulates the transbilayer movement of DAG in the plasma membrane, thus providing new insights into the dynamics of DAG in cell pathophysiology.Ueda, Y., Makino, A., Murase-Tamada, K., Sakai, S., Inaba, T., Hullin-Matsuda, F., Kobayashi, T. Sphingomyelin regulates the transbilayer movement of diacylglycerol in the plasma membrane of Madin-Darby canine kidney cells.	[Ueda, Yoshibumi; Makino, Asami; Murase-Tamada, Kotono; Sakai, Shota; Inaba, Takehiko; Hullin-Matsuda, Francoise; Kobayashi, Toshihide] Rikagaku Kenkyujo RIKEN, Lipid Biol Lab, Wako, Saitama, Japan; [Hullin-Matsuda, Francoise; Kobayashi, Toshihide] Univ Lyon 1, INSERM, U1060, F-69622 Villeurbanne, France	RIKEN; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Kobayashi, T (corresponding author), RIKEN, Lipid Biol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kobayasi@riken.jp	KOBAYASHI, TOSHIHIDE/S-8313-2019; Hullin-Matsuda, Françoise/N-3880-2017; Ueda, Yoshibumi/AHA-4956-2022; Kobayashi, Toshihide/B-6298-2015	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Hullin-Matsuda, Françoise/0000-0002-6042-2841; Ueda, Yoshibumi/0000-0003-1500-3469; Kobayashi, Toshihide/0000-0002-4811-7270; Inaba, Takehiko/0000-0002-8770-4662	Lipid Dynamics Program of RIKEN; Ministry of Education, Culture, Sports, Science, and Technology of Japan [22390018, 24657143, 23790115]; Naito Foundation; Japan Society for the Promotion of Science for Young Scientists [05J04184]; Grants-in-Aid for Scientific Research [24657143] Funding Source: KAKEN	Lipid Dynamics Program of RIKEN; Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors are grateful to Drs. T. Hayakawa and P. Greimel for their comments on the model membrane study and Drs. T. Okazaki and S. Mitsutake for the discussion on SMS2. The authors thank Dr. M. Sato (University of Tokyo, Tokyo, Japan) for the cDNA clone of C1AB, and Dr. K. Kim for his help during the purification of the DAG probe from insect cells. In addition, the authors express special grateful thoughts to Dr R. E. Pagano, who passed away September 22, 2010, not only for providing the cDNA tool during this work, but for all the fruitful contributions to the field of membrane lipid trafficking that he inspired. The authors also thank the members of the T. K. laboratory for critically reading the manuscript. This work was supported by the Lipid Dynamics Program of RIKEN, Grants-in-Aid for Scientific Research 22390018, 24657143 (to T. K.) and 23790115 (to A. M.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and the Naito Foundation (to T. K.). Y. U. was the recipient of a research fellowship of the Japan Society for the Promotion of Science for Young Scientists (05J04184).	Abe M, 2012, MOL CELL BIOL, V32, P1396, DOI 10.1128/MCB.06113-11; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; Arora A, 2004, BIOCHEM BIOPH RES CO, V318, P920, DOI 10.1016/j.bbrc.2004.04.118; Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Carman GM, 2006, TRENDS BIOCHEM SCI, V31, P694, DOI 10.1016/j.tibs.2006.10.003; Cerbon J, 2003, BIOCHEM J, V373, P917, DOI 10.1042/BJ20021732; Contreras F. -Xabier, 2009, V462, P155, DOI 10.1007/978-1-60327-115-8_10; Contreras FX, 2003, J BIOL CHEM, V278, P37169, DOI 10.1074/jbc.M303206200; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; DEKRUYFF B, 1973, BIOCHIM BIOPHYS ACTA, V307, P1, DOI 10.1016/0005-2736(73)90020-5; Ding T, 2008, J LIPID RES, V49, P376, DOI 10.1194/jlr.M700401-JLR200; Fox TE, 2007, J BIOL CHEM, V282, P12450, DOI 10.1074/jbc.M700082200; Fujita A, 2009, P NATL ACAD SCI USA, V106, P9256, DOI 10.1073/pnas.0900216106; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; GANONG BR, 1984, BIOCHEMISTRY-US, V23, P4977, DOI 10.1021/bi00316a023; Gerl MJ, 2012, J CELL BIOL, V196, P213, DOI 10.1083/jcb.201108175; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hailemariam TK, 2008, ARTERIOSCL THROM VAS, V28, P1519, DOI 10.1161/ATVBAHA.108.168682; Holland WL, 2007, NUTR REV, V65, pS39, DOI 10.1301/nr.2007.jun.S39-S46; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Ishitsuka R, 2011, J LIPID RES, V52, P2084, DOI 10.1194/jlr.D018184; Kates M, 1986, TECHNIQUES LIPIDOLOG, V3; KAWATO S, 1978, BIOCHEMISTRY-US, V17, P5026, DOI 10.1021/bi00616a026; Kiyokawa E, 2005, J BIOL CHEM, V280, P24072, DOI 10.1074/jbc.M502244200; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; KOBAYASHI T, 1992, NATURE, V359, P647, DOI 10.1038/359647a0; Kol MA, 2003, BIOCHEMISTRY-US, V42, P231, DOI 10.1021/bi0268403; KOYNOVA RD, 1985, FEBS LETT, V187, P65, DOI 10.1016/0014-5793(85)81215-1; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; KUTCHAI H, 1983, BIOCHIM BIOPHYS ACTA, V736, P137, DOI 10.1016/0005-2736(83)90277-8; LEWIS RNAH, 1987, BIOCHEMISTRY-US, V26, P6118, DOI 10.1021/bi00393a026; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Manmontri B, 2008, J LIPID RES, V49, P1056, DOI 10.1194/jlr.M800013-JLR200; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; Marsh D., 2013, HDB LIPID BILAYERS, DOI 10.1201/9781420088335-8; MATEO CR, 1995, BIOPHYS J, V68, P978, DOI 10.1016/S0006-3495(95)80273-0; MAUCO G, 1984, BIOCHEM J, V224, P933, DOI 10.1042/bj2240933; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Meshulam T, 2006, BIOCHEMISTRY-US, V45, P2882, DOI 10.1021/bi051999b; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Murate M, 2010, BIOCHEMISTRY-US, V49, P4732, DOI 10.1021/bi100007u; Naylor CE, 1998, NAT STRUCT BIOL, V5, P738, DOI 10.1038/1447; Newton AC, 2009, J LIPID RES, V50, pS266, DOI 10.1194/jlr.R800064-JLR200; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ogushi F, 2012, CHEM PHYS LETT, V522, P96, DOI 10.1016/j.cplett.2011.11.057; OTNAESS AB, 1977, EUR J BIOCHEM, V79, P459, DOI 10.1111/j.1432-1033.1977.tb11828.x; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; Paris L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2575; Ramoni C, 2001, J IMMUNOL, V167, P2642, DOI 10.4049/jimmunol.167.5.2642; Reue K, 2008, J LIPID RES, V49, P2493, DOI 10.1194/jlr.R800019-JLR200; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rothblat GH, 1999, J LIPID RES, V40, P781; Sakurai J, 2004, J BIOCHEM, V136, P569, DOI 10.1093/jb/mvh161; Sampaio JL, 2011, P NATL ACAD SCI USA, V108, P1903, DOI 10.1073/pnas.1019267108; Shaner RL, 2009, J LIPID RES, V50, P1692, DOI 10.1194/jlr.D800051-JLR200; Shogomori H, 2008, BBA-GEN SUBJECTS, V1780, P612, DOI 10.1016/j.bbagen.2007.09.001; SRIPADA PK, 1987, J LIPID RES, V28, P710; Tafesse FG, 2007, J BIOL CHEM, V282, P17537, DOI 10.1074/jbc.M702423200; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Vieu C, 1996, J LIPID RES, V37, P1153; Villani M, 2008, BIOCHEM J, V414, P31, DOI 10.1042/BJ20071240; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; VOS JP, 1995, FEBS LETT, V368, P393, DOI 10.1016/0014-5793(95)00695-6; Wuttke A, 2013, FASEB J, V27, P1610, DOI 10.1096/fj.12-221499; Yeang C, 2008, BBA-MOL CELL BIOL L, V1781, P610, DOI 10.1016/j.bbalip.2008.07.002; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zambon AC, 2000, AM J PHYSIOL-RENAL, V279, pF1045, DOI 10.1152/ajprenal.2000.279.6.F1045	81	19	19	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3284	3297		10.1096/fj.12-226548	http://dx.doi.org/10.1096/fj.12-226548			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23682124	Bronze			2022-12-28	WOS:000329877600033
J	Roberts, BM; Ahn, B; Smuder, AJ; Al-Rajhi, M; Gill, LC; Beharry, AW; Powers, SK; Fuller, DD; Ferreira, LF; Judge, AR				Roberts, Brandon M.; Ahn, Bumsoo; Smuder, Ashley J.; Al-Rajhi, Monsour; Gill, Luther C.; Beharry, Adam W.; Powers, Scott K.; Fuller, David D.; Ferreira, Leonardo F.; Judge, Andrew R.			Diaphragm and ventilatory dysfunction during cancer cachexia	FASEB JOURNAL			English	Article						C-26; respiratory muscles; muscle function; single fiber; limb muscle	MYOSIN HEAVY-CHAIN; SKELETAL-MUSCLE ATROPHY; MOTOR UNIT RECRUITMENT; KAPPA-B; SHORTENING VELOCITY; FORCE; ACTIVATION; EXPRESSION; PROTEIN; CONTRACTION	Cancer cachexia is characterized by a continuous loss of locomotor skeletal muscle mass, which causes profound muscle weakness. If this atrophy and weakness also occurs in diaphragm muscle, it could lead to respiratory failure, which is a major cause of death in patients with cancer. Thus, the purpose of the current study was to determine whether colon-26 (C-26) cancer cachexia causes diaphragm muscle fiber atrophy and weakness and compromises ventilation. All diaphragm muscle fiber types were significantly atrophied in C-26 mice compared to controls, and the atrophy-related genes, atrogin-1 and MuRF1, significantly increased. Maximum isometric specific force of diaphragm strips, absolute maximal calcium activated force, and maximal specific calcium-activated force of permeabilized diaphragm fibers were all significantly decreased in C-26 mice compared to controls. Further, isotonic contractile properties of the diaphragm were affected to an even greater extent than isometric function. Ventilation measurements demonstrated that C-26 mice have a significantly lower tidal volume compared to controls under basal conditions and, unlike control mice, an inability to increase breathing frequency, tidal volume, and, thus, minute ventilation in response to a respiratory challenge. These data demonstrate that C-26 cancer cachexia causes profound respiratory muscle atrophy and weakness and ventilatory dysfunction.Roberts, B. M., Ahn, B., Smuder, A. J., Al-Rajhi, M., Gill, L. C., Beharry, A. W., Powers, S. K., Fuller, D. D., Ferreira, L. F., Judge, A. R. Diaphragm and ventilatory dysfunction during cancer cachexia.	[Roberts, Brandon M.; Gill, Luther C.; Beharry, Adam W.; Fuller, David D.; Judge, Andrew R.] Univ Florida, Dept Phys Therapy, Gainesville, FL 32611 USA; [Ahn, Bumsoo; Smuder, Ashley J.; Al-Rajhi, Monsour; Powers, Scott K.; Ferreira, Leonardo F.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Judge, AR (corresponding author), Univ Florida, Dept Phys Therapy, 1275 Ctr Dr,HPNP Bldg 1142, Gainesville, FL 32611 USA.	arjudge@phhp.ufl.edu	Roberts, Brandon M/AAG-4266-2021; Ahn, Bumsoo/GNP-7749-2022; Roberts, Brandon/H-4504-2019; Ahn, Bumsoo/AAK-3818-2021	Roberts, Brandon M/0000-0003-0395-6967; Ahn, Bumsoo/0000-0002-2743-7099; Ferreira, Leonardo/0000-0001-6581-5882	Bankhead Coley Cancer Research Program [09BN-09]; U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR060209]; U.S. National Institute of Neurological Disorders and Stroke [R01 NS080180]; U.S. National Heart, Lung, and Blood Institute [R01HL087839, R00HL098453]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087839, T32HL105355, R00HL098453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER	Bankhead Coley Cancer Research Program; U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); U.S. National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by Bankhead Coley Cancer Research Program grant 09BN-09 and U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01AR060209 (to A.R.J.); U.S. National Institute of Neurological Disorders and Stroke grant R01 NS080180 (to D. D. F.); and U.S. National Heart, Lung, and Blood Institute grants R01HL087839 (to S. K. P.) and R00HL098453 (to L.F.F.).	Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004; Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Azoulay E, 2004, MEDICINE, V83, P360, DOI 10.1097/01.md.0000145370.63676.fb; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bonetto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022538; Bottinelli R, 1996, J PHYSIOL-LONDON, V495, P573, DOI 10.1113/jphysiol.1996.sp021617; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; BROOKS SV, 1990, J APPL PHYSIOL, V68, P1282, DOI 10.1152/jappl.1990.68.3.1282; Bullimore SR, 2010, CAN J PHYSIOL PHARM, V88, P937, DOI [10.1139/y10-068, 10.1139/Y10-068]; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Campbell K, 1997, BIOPHYS J, V72, P254, DOI 10.1016/S0006-3495(97)78664-8; Campbell KS, 2003, AM J PHYSIOL-HEART C, V285, pH2857, DOI 10.1152/ajpheart.00295.2003; Campbell KS, 2002, BIOPHYS J, V82, P929, DOI 10.1016/S0006-3495(02)75454-4; CLAFLIN DR, 1985, J PHYSIOL-LONDON, V359, P357, DOI 10.1113/jphysiol.1985.sp015589; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Cosper PF, 2012, INT J CANCER, V130, P2722, DOI 10.1002/ijc.26298; Costelli P, 2001, BRIT J CANCER, V84, P946, DOI 10.1054/bjoc.2001.1696; DeRuisseau LR, 2009, P NATL ACAD SCI USA, V106, P9419, DOI 10.1073/pnas.0902534106; Diffee GM, 2002, AM J PHYSIOL-CELL PH, V283, pC1376, DOI 10.1152/ajpcell.00154.2002; DRORBAUGH JE, 1955, PEDIATRICS, V16, P81; Edman K A, 1988, Adv Exp Med Biol, V226, P643; Eley HL, 2008, BRIT J CANCER, V98, P443, DOI 10.1038/sj.bjc.6604150; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033; Feathers LSB, 2003, J PAIN SYMPTOM MANAG, V25, P305, DOI 10.1016/S0885-3924(03)00048-4; Ferreira LF, 2012, J APPL PHYSIOL, V112, P1538, DOI 10.1152/japplphysiol.01269.2011; Ferreira LF, 2011, MED SCI SPORT EXER, V43, P1025, DOI 10.1249/MSS.0b013e3182019a78; Ferreira LF, 2010, AM J PHYSIOL-CELL PH, V299, pC552, DOI 10.1152/ajpcell.00065.2010; Fouladiun M, 2007, CLIN CANCER RES, V13, P6379, DOI 10.1158/1078-0432.CCR-07-1147; Frimel TN, 2005, MUSCLE NERVE, V32, P605, DOI 10.1002/mus.20398; Fuller DD, 2008, EXP NEUROL, V211, P97, DOI 10.1016/j.expneurol.2008.01.013; Gilliver SF, 2011, EXP PHYSIOL, V96, P171, DOI 10.1113/expphysiol.2010.054239; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Hardin BJ, 2008, J APPL PHYSIOL, V104, P694, DOI 10.1152/japplphysiol.00898.2007; Johannigman JA, 1997, SURGERY, V122, P737, DOI 10.1016/S0039-6060(97)90081-7; Judge AR, 2007, AM J PHYSIOL-CELL PH, V292, pC372, DOI 10.1152/ajpcell.00293.2006; Kravitz RM, 2009, PEDIATRICS, V123, pS231, DOI 10.1542/peds.2008-2952G; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Mantilla CB, 2011, RESP PHYSIOL NEUROBI, V179, P57, DOI 10.1016/j.resp.2011.06.028; Miller SE, 1997, SURGERY, V122, P740; Mintzopoulos D., 2011, P INT SOC MAG RESON, V19, P1138; Moreno-Gonzalez A, 2007, J PHYSIOL-LONDON, V579, P313, DOI 10.1113/jphysiol.2006.124164; Moss RL, 2010, J GEN PHYSIOL, V136, P21, DOI 10.1085/jgp.201010471; MOSS RL, 1982, J MUSCLE RES CELL M, V3, P295, DOI 10.1007/BF00713039; Murphy KT, 2012, DIS MODEL MECH, V5, P533, DOI 10.1242/dmm.008839; Murphy KT, 2011, AM J PHYSIOL-REG I, V301, pR716, DOI 10.1152/ajpregu.00121.2011; Powers SK, 2002, J APPL PHYSIOL, V92, P1851, DOI 10.1152/japplphysiol.00881.2001; Qiu K, 2012, MOL THER, V20, P21, DOI 10.1038/mt.2011.214; Reed SA, 2012, FASEB J, V26, P987, DOI 10.1096/fj.11-189977; Ripamonti C, 2002, SUPPORT CARE CANCER, V10, P204, DOI 10.1007/s005200100296; Sandhu MS, 2009, RESP PHYSIOL NEUROBI, V169, P94, DOI 10.1016/j.resp.2009.06.014; Schmitt TL, 2007, J MOL MED, V85, P647, DOI 10.1007/s00109-007-0177-2; SEGAL SS, 1986, AM J PHYSIOL, V250, pC474, DOI 10.1152/ajpcell.1986.250.3.C474; Senf SM, 2008, FASEB J, V22, P3836, DOI 10.1096/fj.08-110163; Sieck GC, 1997, EUR RESPIR J, V10, P2147, DOI 10.1183/09031936.97.10092147; SIECK GC, 1989, J APPL PHYSIOL, V66, P2539, DOI 10.1152/jappl.1989.66.6.2539; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; TESSITORE L, 1993, ARCH BIOCHEM BIOPHYS, V306, P52, DOI 10.1006/abbi.1993.1479; Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011	60	61	64	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2600	2610		10.1096/fj.12-222844	http://dx.doi.org/10.1096/fj.12-222844			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23515443	Green Published			2022-12-28	WOS:000328841000009
J	Wu, YH; Lo, HF; Chen, SH; Chen, HW				Wu, Yi-Hung; Lo, Hsiao-Fan; Chen, Sih-Han; Chen, Hungwen			Caspase-14 suppresses GCM1 acetylation and inhibits placental cell differentiation	FASEB JOURNAL			English	Article						syncytiotrophoblast; cell-cell fusion; CBP	NF-KAPPA-B; TROPHOBLAST DIFFERENTIATION; GENE-TRANSCRIPTION; CLEAVAGE SITE; IN-VITRO; EXPRESSION; PURIFICATION; DEGRADATION; ACTIVATION; TARGETS	Glial cell missing 1 (GCM1) transcription factor regulates placental cell fusion into the syncytiotrophoblast. Caspase-14 is proteolytically activated to mediate filaggrin processing during keratinocyte differentiation. Interestingly, altered expression of nonactivated caspase-14 proenzyme is associated with tumorigenesis and diabetic retinopathy, suggesting that caspase-14 may perform physiological functions independently of its protease activity. Here, we performed tandem affinity purification coupled with mass spectrometry analysis to identify caspase-14 proenzyme as a GCM1-interacting protein that suppresses GCM1 activity and syncytiotrophoblast differentiation. Immunohistochemistry revealed that caspase-14 and GCM1 colocalize to placental cytotrophoblast cells at 8 wk of gestation and syncytiotrophoblast layer at term. Further, we demonstrated that caspase-14 mRNA level is decreased by 40% in placental BeWo cells treated with forskolin (FSK). To the contrary, stimulation of GCM1-regulated placental cell fusion and human chorionic gonadotropin (hCG) expression by FSK is enhanced by caspase-14 knockdown. Indeed, GCM1 protein level is increased by 40% in the caspase-14-knockdown BeWo cells. Because GCM1 is stabilized by acetylation, we subsequently showed that caspase-14 impedes the interaction between GCM1 and cAMP response element-binding protein (CREB)-binding protein (CBP) to suppress CBP-mediated acetylation and transcriptional coactivation of GCM1. Therefore, caspase-14 can suppress placental cell differentiation through down-regulation of GCM1 activity.Wu, Y.-H., Lo, H.-F., Chen, S.-H., Chen, H. Caspase-14 suppresses GCM1 acetylation and inhibits placental cell differentiation.	[Wu, Yi-Hung; Lo, Hsiao-Fan; Chen, Sih-Han; Chen, Hungwen] Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 10764, Taiwan; [Chen, Hungwen] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	National Taiwan University; Academia Sinica - Taiwan	Chen, HW (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	hwchen@gate.sinica.edu.tw			National Science Council [99-2311-B-001-019, 1002311-B-001-010]; Academia Sinica, Taiwan	National Science Council(Ministry of Science and Technology, Taiwan); Academia Sinica, Taiwan(Academia Sinica - Taiwan)	This work was supported by grants (to H.C.) from the National Science Council (grants 99-2311-B-001-019 and 1002311-B-001-010) and Academia Sinica, Taiwan. The authors thank Dr. Shu-Yu Lin for technical assistance in acquiring and analyzing the LTQ-Orbitrap data. The authors also thank Drs. Mei-Leng Cheong and Ching-Wen Chang for establishing primary culture of cytotrophoblast cells.	Al-Shabrawey M, 2012, MOL VIS, V18, P1895; Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11; Ballaun C, 2008, BIOCHEM BIOPH RES CO, V371, P261, DOI 10.1016/j.bbrc.2008.04.050; Chang CW, 2005, MOL CELL BIOL, V25, P8401, DOI 10.1128/MCB.25.19.8401-8414.2005; Chang M, 2008, BIOL REPROD, V78, P841, DOI 10.1095/biolreprod.107.065599; Chen HW, 2000, BIOCHEMISTRY-US, V39, P1675, DOI 10.1021/bi991786k; Chiang MH, 2009, J BIOL CHEM, V284, P17411, DOI 10.1074/jbc.M109.016170; Chien AJ, 2002, BIOCHEM BIOPH RES CO, V296, P911, DOI 10.1016/S0006-291X(02)02015-6; Choul-Li S, 2010, BIOCHEM J, V426, P229, DOI 10.1042/BJ20090877; Chuang HC, 2006, NUCLEIC ACIDS RES, V34, P1459, DOI 10.1093/nar/gkl048; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; GHERSA P, 1994, J BIOL CHEM, V269, P29129; Gloeckner CJ, 2007, PROTEOMICS, V7, P4228, DOI 10.1002/pmic.200700038; Guha M, 2010, ONCOGENE, V29, P1280, DOI 10.1038/onc.2009.428; Hibino T, 2010, J CELL BIOCHEM, V109, P487, DOI 10.1002/jcb.22425; Hoste E, 2011, J INVEST DERMATOL, V131, P2233, DOI 10.1038/jid.2011.153; Kam DWR, 2005, REPROD BIOMED ONLINE, V11, P236; Kashif M, 2011, DEVELOPMENT, V138, P2235, DOI 10.1242/dev.059105; Keay SD, 2004, BJOG-INT J OBSTET GY, V111, P1218, DOI 10.1111/j.1471-0528.2004.00412.x; Keryer G, 1998, J CELL SCI, V111, P995; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Koenig U, 2005, BIOCHEM BIOPH RES CO, V335, P309, DOI 10.1016/j.bbrc.2005.07.072; Krajewska M, 2005, CLIN CANCER RES, V11, P5462, DOI 10.1158/1078-0432.CCR-04-2527; Liang CY, 2010, BIOL REPROD, V83, P387, DOI 10.1095/biolreprod.110.083915; Lin FY, 2011, NUCLEIC ACIDS RES, V39, P848, DOI 10.1093/nar/gkq838; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; Park K, 2006, BIOCHEM BIOPH RES CO, V347, P941, DOI 10.1016/j.bbrc.2006.06.156; Pistritto G, 2002, CELL DEATH DIFFER, V9, P995, DOI 10.1038/sj.cdd.4401061; Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Wang LJ, 2012, MOL CELL BIOL, V32, P3707, DOI 10.1128/MCB.00223-12; White LJ, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-98; Yamamoto M, 2012, J BIOL CHEM, V287, P32825, DOI 10.1074/jbc.M112.357467; Yang CS, 2005, J BIOL CHEM, V280, P10083, DOI 10.1074/jbc.M413986200; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200	35	7	9	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2013	27	7					2818	2828		10.1096/fj.12-224279	http://dx.doi.org/10.1096/fj.12-224279			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277TA	23580611				2022-12-28	WOS:000328841000030
J	Hu, RX; Pan, WC; Fedulov, AV; Jester, W; Jones, MR; Weiss, ST; Panettieri, RA; Tantisira, K; Lu, Q				Hu, Ruoxi; Pan, Wenchi; Fedulov, Alexey V.; Jester, William; Jones, Matthew R.; Weiss, Scott T.; Panettieri, Reynold A., Jr.; Tantisira, Kelan; Lu, Quan			MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway	FASEB JOURNAL			English	Article						asthma; miR-10a; PIK3CA	DNA-SYNTHESIS; PHOSPHOINOSITIDE 3-KINASE; ERK ACTIVATION; EXPRESSION; MIR-10A; GROWTH; TIME; IDENTIFICATION; PHENOTYPE; CDC6	Airway smooth muscle (ASM) cells play important physiological roles in the lung, and abnormal proliferation of ASM directly contributes to the airway remodeling during development of lung diseases such as asthma. MicroRNAs are small yet versatile gene tuners that regulate a variety of cellular processes, including cell growth and proliferation; however, little is known about the precise role of microRNAs in the proliferation of the ASM. Here we report that a specific microRNA (miR-10a) controls ASM proliferation through directly inhibiting the phosphoinositide 3-kinase (PI3K) pathway. Next-generation sequencing identified miR-10a as the most abundant microRNA expressed in primary human airway smooth muscle (HASM) cells, accounting for > 20% of all small RNA reads. Overexpression of miR-10a reduced mitogen-induced HASM proliferation by approximate to 50%, whereas inhibition of miR-10a increased HASM proliferation by approximate to 40%. Microarray profiling of HASM cells expressing miR-10a mimics identified 52 significantly down-regulated genes as potential targets of miR-10a, including the catalytic subunit of PI3K (PIK3CA), the central component of the PI3K pathway. MiR-10a directly suppresses PIK3CA expression by targeting the 3-untranslated region (3-UTR) of the gene. Inhibition of PIK3CA by miR-10a reduced V-akt murine thymoma viral oncogene homolog 1 (AKT) phosphorylation and blunted the expression of cyclins and cyclin-dependent kinases that are required for HASM proliferation. Together, our study identifies a novel microRNA-mediated regulatory mechanism for PI3K signaling and ASM proliferation and further suggests miR-10a as a potential therapeutic target for lung diseases whose etiology resides in abnormal ASM proliferation.Hu, R., Pan, W., Fedulov, A. V., Jester, W., Jones, M. R., Weiss, S. T., Panettieri, R. A., Jr., Tantisira, K., Lu, Q. MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway.	[Hu, Ruoxi; Pan, Wenchi; Lu, Quan] Harvard Univ, Program Mol & Integrat Physiol Sci, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Hu, Ruoxi; Pan, Wenchi; Lu, Quan] Harvard Univ, Dept Genet & Complex Dis, Sch Publ Hlth, Boston, MA 02115 USA; [Fedulov, Alexey V.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Jester, William; Panettieri, Reynold A., Jr.] Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; [Jones, Matthew R.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; [Tantisira, Kelan] Harvard Univ, Channing Div Network Med, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Pennsylvania; Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Lu, Q (corresponding author), Harvard Univ, Program Mol & Integrat Physiol Sci, Sch Publ Hlth, 665 Huntington Ave,Room I-305, Boston, MA 02115 USA.	qlu@hsph.harvard.edu	panettieri, reynold/AAG-9485-2019	Jester Jr., William/0000-0002-2872-6095; Pan, Wen-Chi/0000-0002-0588-8083	U.S. National Institutes of Health (NIH) [R01 HL114769, U01 HL065899]; NIH [P01 HL114471, P30 ES013508]; Canadian Institute of Health Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, P01HL114471, R01HL104053, R01HL114769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by U.S. National Institutes of Health (NIH) grants R01 HL114769 (Q.L.) and U01 HL065899 (S.T.W., Q.L., and K.T.). R.A.P. received support from NIH grants P01 HL114471 and P30 ES013508. R.H. was supported by a fellowship from the Canadian Institute of Health Research.	Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bryant A, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-8; Chiba Y, 2009, AM J RESP CRIT CARE, V180, P713, DOI 10.1164/rccm.200903-0325OC; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fang Y, 2010, P NATL ACAD SCI USA, V107, P13450, DOI 10.1073/pnas.1002120107; Fernandes DJ, 2001, CLIN EXP PHARMACOL P, V28, P619, DOI 10.1046/j.1440-1681.1999.03494.x; Foley NH, 2011, CELL DEATH DIFFER, V18, P1089, DOI 10.1038/cdd.2010.172; HE L, 2004, NAT REV GENET, V5, P522; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Hoppe R, 2013, EUR J CANCER, V49, P3598, DOI 10.1016/j.ejca.2013.07.145; Hsu SH, 2012, J CLIN INVEST, V122, P2871, DOI 10.1172/JCI63539; Huang HR, 2010, J BIOL CHEM, V285, P9383, DOI [10.1074/jbc.M110.101543, 10.1074/jbc.M109.095612]; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jiang XF, 2012, FASEB J, V26, P1995, DOI 10.1096/fj.11-193870; Karpova AY, 1997, AM J PHYSIOL-LUNG C, V272, pL558, DOI 10.1152/ajplung.1997.272.3.L558; Kohler CU, 2013, BIOCHEM BIOPH RES CO, V438, P48, DOI 10.1016/j.bbrc.2013.07.021; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Krymskaya VP, 2001, AM J PHYSIOL-LUNG C, V280, pL1009, DOI 10.1152/ajplung.2001.280.5.L1009; Kuhn AR, 2010, AM J RESP CELL MOL, V42, P506, DOI 10.1165/rcmb.2009-0123OC; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lund AH, 2010, CELL DEATH DIFFER, V17, P209, DOI 10.1038/cdd.2009.58; Martin JG, 2003, RESP PHYSIOL NEUROBI, V137, P251, DOI 10.1016/S1569-9048(03)00151-4; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Meseguer S, 2011, J BIOL CHEM, V286, P4150, DOI 10.1074/jbc.M110.167817; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Neganova I, 2011, STEM CELLS, V29, P651, DOI 10.1002/stem.620; Orsini MJ, 1999, AM J PHYSIOL-LUNG C, V277, pL479, DOI 10.1152/ajplung.1999.277.3.L479; Page K, 1999, AM J RESP CELL MOL, V20, P1294, DOI 10.1165/ajrcmb.20.6.3597; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Panettieri RA, 2008, AM J RESP CRIT CARE, V177, P248, DOI 10.1164/rccm.200708-1217PP; Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689; Perry MM, 2014, AM J RESP CELL MOL, V50, P7, DOI 10.1165/rcmb.2013-0067OC; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Roman-Gomez J, 2006, CLIN CANCER RES, V12, P4845, DOI 10.1158/1078-0432.CCR-05-2592; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Stadthagen G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003913; Stewart AG, 2001, PULM PHARMACOL THER, V14, P255, DOI 10.1006/pupt.2001.0290; Takahashi H, 2012, NAT IMMUNOL, V13, P587, DOI 10.1038/ni.2286; Volpe MV, 1997, HISTOCHEM CELL BIOL, V108, P495, DOI 10.1007/s004180050190; Walker TR, 1998, MOL PHARMACOL, V54, P1007, DOI 10.1124/mol.54.6.1007; Wang WCH, 2011, P NATL ACAD SCI USA, V108, P6246, DOI 10.1073/pnas.1101439108; Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Xue XC, 2011, J IMMUNOL, V187, P5879, DOI 10.4049/jimmunol.1100535	53	64	70	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2347	2357		10.1096/fj.13-247247	http://dx.doi.org/10.1096/fj.13-247247			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24522205	Green Published			2022-12-28	WOS:000335336000035
J	MacIntyre, DA; Lee, YS; Migale, R; Herbert, BR; Waddington, SN; Peebles, D; Hagberg, H; Johnson, MR; Bennett, PR				MacIntyre, David A.; Lee, Yun S.; Migale, Roberta; Herbert, Bronwen R.; Waddington, Simon N.; Peebles, Donald; Hagberg, Henrik; Johnson, Mark R.; Bennett, Phillip R.			Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice	FASEB JOURNAL			English	Article						NFkB; infection; myometrium; progesterone	NF-KAPPA-B; HUMAN MYOMETRIAL CELLS; HUMAN OXYTOCIN RECEPTOR; HUMAN UTERINE MYOCYTES; PROGESTERONE-RECEPTOR; MECHANICAL STRETCH; GENE-EXPRESSION; TRANSCRIPTION FACTOR; HUMAN PARTURITION; AIRWAY INFLAMMATION	Activation of uterine inflammatory pathways leads to preterm labor (PTL), associated with high rates of neonatal mortality and morbidity. The transcription factors nuclear factor B (NFB) and activator protein 1 (AP-1) regulate key proinflammatory and procontractile genes involved in normal labor and PTL. Here we show that NFB activation normally occurs in the mouse myometrium at gestation day E18, prior to labor, whereas AP-1 and JNK activation occurs at labor onset. Where labor was induced using the progesterone receptor antagonist RU486, NFkB and AP-1/JNK activation both occurred at the time of labor (20 h compared to 60 h in DMSO-treated controls). Using an LPS (Escherichia coli: serotype O111)-induced PTL model that selectively activates AP-1 but not NFkB, we show that myometrial AP-1 activation drives production of cytokines (Il-6, Il-8, and Il-1), metalloproteinases (Mmp3 and Mmp10), and procontractile proteins (Cox-2 and Cx43) resulting in PTL after 7 h. Protein levels of CX43 and IL-1, and IL-1 cleavage, were increased following LPS-induced activation of AP-1. Inhibition of JNK by SP600125 (30 mg/kg) delayed PTL by 6 h (7.5 vs. 13.5 h P<0.05). Our data reveal that NFB activation is not a functional requirement for infection/inflammation-induced preterm labor and that AP-1 activation is sufficient to drive inflammatory pathways that cause PTL.MacIntyre, D. A., Lee, Y. S., Migale, R., Herbert, B. R., Waddington, S. N., Peebles, D., Hagberg, H., Johnson, M. R., Bennett, P. R. Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice.	[MacIntyre, David A.; Lee, Yun S.; Migale, Roberta; Herbert, Bronwen R.; Johnson, Mark R.; Bennett, Phillip R.] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Imperial Coll Parturit Res Grp, London W12 0NN, England; [Waddington, Simon N.] UCL, Gene Transfer Technol Grp, London, England; [Peebles, Donald] UCL, Inst Womens Hlth, Ctr Perinatal Brain Protect & Repair, London, England; [Waddington, Simon N.] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa; [Hagberg, Henrik] Univ Gothenburg, Perinatal Ctr, Dept Clin Sci, Gothenburg, Sweden; [Hagberg, Henrik] Kings Coll London, Ctr Developing Brain, London WC2R 2LS, England; [Johnson, Mark R.] Chelsea & Westminster Hosp, London, England	Imperial College London; University of London; University College London; University of London; University College London; University of Witwatersrand; University of Gothenburg; University of London; King's College London; Imperial College London	MacIntyre, DA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Imperial Coll Parturit Res Grp, Hammersmith Campus, London W12 0NN, England.	d.macintyre@imperial.ac.uk	MacIntyre, David A/D-9267-2012; Waddington, Simon/G-3778-2011; Migale, Roberta/I-3834-2019	Waddington, Simon/0000-0003-4970-4730; Migale, Roberta/0000-0001-8424-1060; MacIntyre, David/0000-0002-4186-5567; Bennett, Phillip/0000-0002-6253-4919; Hagberg, Henrik/0000-0003-3962-1448	Wellcome Trust [DSRR_P24225]; Arthur Haffenden Fund	Wellcome Trust(Wellcome TrustEuropean Commission); Arthur Haffenden Fund	This work was supported by the Wellcome Trust, grant DSRR_P24225, and the Arthur Haffenden Fund.	Agrawal V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063990; Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; AURON PE, 1987, J IMMUNOL, V138, P1447; Belt AR, 1999, AM J OBSTET GYNECOL, V181, P359, DOI 10.1016/S0002-9378(99)70562-4; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bisits AM, 2005, PLOS COMPUT BIOL, V1, P132, DOI 10.1371/journal.pcbi.0010019; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Condon JC, 2006, MOL ENDOCRINOL, V20, P764, DOI 10.1210/me.2005-0242; Condon JC, 2004, P NATL ACAD SCI USA, V101, P4978, DOI 10.1073/pnas.0401124101; Dudley DJ, 1996, BIOL REPROD, V55, P992, DOI 10.1095/biolreprod55.5.992; FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592; Geimonen E, 1996, J BIOL CHEM, V271, P23667, DOI 10.1074/jbc.271.39.23667; Geimonen E, 1998, J CLIN ENDOCR METAB, V83, P1177, DOI 10.1210/jc.83.4.1177; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hutchinson JL, 2014, FASEB J, V28, P94, DOI 10.1096/fj.13-237040; Imada K, 2002, BIOL PHARM BULL, V25, P1223, DOI 10.1248/bpb.25.1223; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Keelan JA, 1999, AM J OBSTET GYNECOL, V181, P1530, DOI 10.1016/S0002-9378(99)70400-X; Khanjani S, 2011, J CELL MOL MED, V15, P809, DOI 10.1111/j.1582-4934.2010.01069.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Lee Y, 2012, J CELL MOL MED, V16, P2487, DOI 10.1111/j.1582-4934.2012.01567.x; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034707; LIMJUCO G, 1986, P NATL ACAD SCI USA, V83, P3972, DOI 10.1073/pnas.83.11.3972; Lindstrom TM, 2005, REPRODUCTION, V130, P569, DOI 10.1530/rep.1.00197; Loudon JAZ, 2004, MOL HUM REPROD, V10, P895, DOI 10.1093/molehr/gah112; MacIntyre D. A., 2007, FETAL MATERNAL MED R, V18, P333; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924; Mitchell JA, 2005, ENDOCRINOLOGY, V146, P2048, DOI 10.1210/en.2004-1066; Mohan AR, 2007, ENDOCRINOLOGY, V148, P1850, DOI 10.1210/en.2006-1289; Nath P, 2005, EUR J PHARMACOL, V506, P273, DOI 10.1016/j.ejphar.2004.11.040; Olson DM, 2003, BEST PRACT RES CL OB, V17, P717, DOI 10.1016/S1521-6934(03)00069-5; Pieber D, 2001, EUR J PHARMACOL, V427, P7, DOI 10.1016/S0014-2999(01)01189-X; PIERSANTI M, 1995, ENDOCRINOLOGY, V136, P3571, DOI 10.1210/en.136.8.3571; Pirianov G, 2009, ENDOCRINOLOGY, V150, P699, DOI 10.1210/en.2008-1178; Ramirez-Alcantara V, 2009, AM J PHYSIOL-GASTR L, V297, pG990, DOI 10.1152/ajpgi.00219.2009; Romero R, 2007, SEMIN REPROD MED, V25, P21, DOI 10.1055/s-2006-956773; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Slater DM, 1999, MOL HUM REPROD, V5, P880, DOI 10.1093/molehr/5.9.880; Soloff MS, 2004, ENDOCRINOLOGY, V145, P1248, DOI 10.1210/en.2003-1310; Sooranna SR, 2004, MOL HUM REPROD, V10, P109, DOI 10.1093/molehr/gah021; Terzidou V, 2005, J CLIN ENDOCR METAB, V90, P237, DOI 10.1210/jc.2004-0277; Terzidou V, 2006, J CLIN ENDOCR METAB, V91, P2317, DOI 10.1210/jc.2005-2649; Thomson AJ, 1999, HUM REPROD, V14, P229, DOI 10.1093/humrep/14.1.229; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wewers MD, 1999, J IMMUNOL, V162, P4858; Williams AS, 2007, J PHARMACOL EXP THER, V322, P351, DOI 10.1124/jpet.107.121624; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	52	80	82	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2358	2368		10.1096/fj.13-247783	http://dx.doi.org/10.1096/fj.13-247783			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24497579				2022-12-28	WOS:000335336000036
J	Bruzzone, A; Sauliere, A; Finana, F; Senard, JM; Luthy, I; Gales, C				Bruzzone, Ariana; Sauliere, Aude; Finana, Frederic; Senard, Jean-Michel; Luethy, Isabel; Gales, Celine			Dosage-dependent regulation of cell proliferation and adhesion through dual beta(2)-adrenergic receptor/cAMP signals	FASEB JOURNAL			English	Article						MCF-10A human breast cell line; Epac; PKA; signaling compartmentalization	BETA-ADRENERGIC-RECEPTORS; BREAST-CANCER CELLS; CYCLIC-AMP ANALOGS; BETA-2-ADRENERGIC RECEPTOR; CHOLESTEROL DEPLETION; ADENYLATE-CYCLASE; CARDIAC MYOCYTES; MAMMARY-GLAND; LIPID RAFTS; CAMP	The role of -adrenergic receptors (-ARs) remains controversial in normal and tumor breast. Herein we explore the cAMP signaling involved in -AR-dependent control of proliferation and adhesion of nontumor human breast cell line MCF-10A. Low concentrations of a -agonist, isoproterenol (ISO), promote cell adhesion (87.5% cells remaining adherent to the plastic dishes following specific detachment vs. 35.0% in control, P<0.001), while increasing concentrations further engages an additional 36% inhibition of Erk1/2 phosphorylation (p-Erk1/2)-dependent cell proliferation (P<0.01). Isoproterenol dose response on cell adhesion was fitted to a 2-site curve (EC50(1): 16.5 +/- 11.5 fM, EC50(2): 4.08 +/- 3.09 nM), while ISO significantly inhibited p-Erk1/2 according to a 1-site model (EC50: 0.25 +/- 0.13 nM). Using -AR-selective agonist/antagonists and cAMP analogs/inhibitors, we identified a dosage-dependent signaling in which low ISO concentrations target a (2)-AR population localized in raft microdomains and stimulate a G(s)/cAMP/Epac/adhesion-signaling module, while higher concentrations engage a concomitant activation of another (2)-AR population outside rafts and inhibit the proliferation by a G(s)/cAMP/PKA-dependent signaling module. Our data provide a new molecular basis for the dose-dependent switch of -AR signaling. This study also sheds light on a new cAMP pathway core mechanism with a single receptor triggering dual cAMP signaling controlled by PKA or Epac but with different cellular outputs.Bruzzone, A., Sauliere, A., Finana, F., Senard, J.-M., Luthy, I., Gales, C. Dosage-dependent regulation of cell proliferation and adhesion through dual (2)-adrenergic receptor/cAMP signals.	[Bruzzone, Ariana; Luethy, Isabel] Consejo Nacl Invest Cient & Tecn CONICET, Inst Biol & Med Expt, Buenos Aires, DF, Argentina; [Sauliere, Aude; Senard, Jean-Michel; Gales, Celine] Univ Toulouse 3, Inst Natl Sante & Rech Med, Inst Malad Metab & Cardiovasc, F-31062 Toulouse, France; [Finana, Frederic] Inst Rech Pierre Fabre, Dept Cellular & Mol Biol, Castres, France; [Senard, Jean-Michel] Toulouse Univ Hosp, Dept Clin Pharmacol, Toulouse, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Gales, C (corresponding author), Inst Malad Metab & Cardiovasc, INSERM, U1048, I2MC, 1 Ave Jean Poulhes,BP84225, F-31432 Toulouse 4, France.	celine.gales@inserm.fr		Senard, Jean-Michel/0000-0001-7679-1281; GALES, Celine/0000-0002-4938-1583	Ministerio de Ciencia, Tecnologia e Innovacion Productiva (MINCyT)/EcosSud Argentina/Francia; Proyecto de Investigacion en Ciencia y Tecnologia (PICT) Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT); Proyecto de Investigacion Plurianual (692-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Fundacion Roemmers; Fundacion Bunge y Born Argentina	Ministerio de Ciencia, Tecnologia e Innovacion Productiva (MINCyT)/EcosSud Argentina/Francia; Proyecto de Investigacion en Ciencia y Tecnologia (PICT) Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT); Proyecto de Investigacion Plurianual (692-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Fundacion Roemmers; Fundacion Bunge y Born Argentina	This paper is dedicated to the memory of the authors' friend and colleague Dr. Herve Paris, who was the mentor of this work and passed away suddenly during its completion. This work was supported by a grant from the Ministerio de Ciencia, Tecnologia e Innovacion Productiva (MINCyT)/EcosSud Argentina/Francia, Proyecto de Investigacion en Ciencia y Tecnologia (PICT) 2011#103 Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) and Proyecto de Investigacion Plurianual (PIP 2010-2012#692-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), and Fundacion Roemmers. A. B. was a recipient of an Oster fellowship from Fundacion Bunge y Born Argentina. The authors especially thank Sabrina Copsel, Lucia Gargiulo, Carlos Davio, Lauriane Onfroy, Colette Denis, and Marie-Helene Seguelas for their invaluable technical help, Silvio Gutkind (U.S. National Institutes of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, USA) and Omar Coso [Facultad de Ciencias Exactas y Naturales (FCEN)-Instituto de Fisiologica, Biologia Molecular y Neurociencias (IFIBYNE), Universidad de Buenos Aires-CONICET, Buenos Aires, Argentina] for generously providing PKI and N-Epac encoding vectors, and Lucrecia Calvo for critical reading of the manuscript.	Agarwal SR, 2011, J MOL CELL CARDIOL, V50, P500, DOI 10.1016/j.yjmcc.2010.11.015; Almahariq M, 2013, MOL PHARMACOL, V83, P122, DOI 10.1124/mol.112.080689; Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; Barron TI, 2012, THER ADV MED ONCOL, V4, P113, DOI 10.1177/1758834012439738; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Brock M, 2007, BRAIN RES, V1145, P1, DOI 10.1016/j.brainres.2007.01.119; Carie AE, 2007, ONCOGENE, V26, P3777, DOI 10.1038/sj.onc.1210172; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen L, 2008, J BIOL CHEM, V283, P13799, DOI 10.1074/jbc.M800555200; Cheng XD, 2008, ACTA BIOCH BIOPH SIN, V40, P651, DOI 10.1111/j.1745-7270.2008.00438.x; Cooper DMF, 2005, BIOCHEM SOC T, V33, P1319, DOI 10.1042/BST0331319; Daly CJ, 2011, TRENDS PHARMACOL SCI, V32, P219, DOI 10.1016/j.tips.2011.02.008; De Arcangelis V, 2010, MOL PHARMACOL, V78, P340, DOI 10.1124/mol.110.064444; Dodge-Kafka KL, 2005, NATURE, V437, P574, DOI 10.1038/nature03966; DRAOUI A, 1991, ANTICANCER RES, V11, P677; Eid AH, 2012, CELL PHYSIOL BIOCHEM, V30, P247, DOI 10.1159/000339061; Enserink JM, 2004, J BIOL CHEM, V279, P44889, DOI 10.1074/jbc.M404599200; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Grandoch M, 2009, BRIT J CANCER, V101, P2038, DOI 10.1038/sj.bjc.6605439; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Hochbaum D, 2003, J BIOL CHEM, V278, P33738, DOI 10.1074/jbc.M305208200; Honegger KJ, 2006, P NATL ACAD SCI USA, V103, P803, DOI 10.1073/pnas.0503562103; Houslay MD, 2010, TRENDS BIOCHEM SCI, V35, P91, DOI 10.1016/j.tibs.2009.09.007; Inderwies T, 2003, DOMEST ANIM ENDOCRIN, V24, P123, DOI 10.1016/S0739-7240(02)00211-4; Kassel KM, 2008, AM J PHYSIOL-LUNG C, V294, pL131, DOI 10.1152/ajplung.00381.2007; Kiermayer S, 2005, MOL BIOL CELL, V16, P5639, DOI 10.1091/mbc.E05-05-0432; Kim MO, 2012, BBA-GEN SUBJECTS, V1820, P1636, DOI 10.1016/j.bbagen.2012.05.008; Leitinger B, 2002, J CELL SCI, V115, P963; Li DM, 2011, BREAST CANCER RES TR, V128, P7, DOI 10.1007/s10549-011-1499-x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lorenowicz MJ, 2006, J LEUKOCYTE BIOL, V80, P1542, DOI 10.1189/jlb.0506357; Mantovani G, 2008, EXP CELL RES, V314, P123, DOI 10.1016/j.yexcr.2007.08.024; MARCHETTI B, 1990, ENDOCRINOLOGY, V126, P565, DOI 10.1210/endo-126-1-565; Mouat MF, 2003, J NUTR BIOCHEM, V14, P74, DOI 10.1016/S0955-2863(02)00250-4; Nedvetsky PI, 2012, MOL BIOL CELL, V23, P2973, DOI 10.1091/mbc.E12-02-0078; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Pinero CP, 2012, BRIT J PHARMACOL, V166, P721, DOI 10.1111/j.1476-5381.2011.01791.x; Pontier SM, 2008, J BIOL CHEM, V283, P24659, DOI 10.1074/jbc.M800778200; Powe DG, 2011, BREAST CANCER RES TR, V130, P457, DOI 10.1007/s10549-011-1371-z; Powe DG, 2010, ONCOTARGET, V1, P628, DOI 10.18632/oncotarget.197; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Re G, 1996, PHARMACOL RES, V33, P255, DOI 10.1006/phrs.1996.0036; Rivas M, 2003, MOL CELL ENDOCRINOL, V213, P31, DOI 10.1016/j.mce.2003.10.029; Sauliere A, 2012, NAT CHEM BIOL, V8, P622, DOI [10.1038/NCHEMBIO.961, 10.1038/nchembio.961]; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Slotkin TA, 2000, BREAST CANCER RES TR, V60, P153, DOI 10.1023/A:1006338232150; Spina A, 2012, BIORESEARCH OPEN ACC, V1, P324, DOI 10.1089/biores.2012.0270; Sun YT, 2007, EMBO J, V26, P53, DOI 10.1038/sj.emboj.7601502; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; TAGLIAFERRI P, 1988, CANCER RES, V48, P1642; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Toll L, 2011, J PHARMACOL EXP THER, V336, P524, DOI 10.1124/jpet.110.173971; TORTORA G, 1988, BLOOD, V71, P230; VANDEWALLE B, 1990, J CANCER RES CLIN, V116, P303, DOI 10.1007/BF01612908; WELLNER RB, 1988, BIOCHEM PHARMACOL, V37, P3035, DOI 10.1016/0006-2952(88)90293-6; Wu CY, 2010, AM J PHYSIOL-CELL PH, V298, pC1151, DOI 10.1152/ajpcell.00382.2009; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Zaccolo M, 2005, BIOCHEM SOC T, V33, P1323, DOI 10.1042/BST0331323; Zocher M, 2012, P NATL ACAD SCI USA, V109, pE3463, DOI 10.1073/pnas.1210373109	63	28	28	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1342	1354		10.1096/fj.13-239285	http://dx.doi.org/10.1096/fj.13-239285			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24308976				2022-12-28	WOS:000335324800026
J	Julian, CG; Yang, IV; Browne, VA; Vargas, E; Rodriguez, C; Pedersen, BS; Moore, LG; Schwartz, DA				Julian, Colleen G.; Yang, Ivana V.; Browne, Vaughn A.; Vargas, Enrique; Rodriguez, Carmelo; Pedersen, Brent S.; Moore, Lorna G.; Schwartz, David A.			Inhibition of peroxisome proliferator-activated receptor gamma: a potential link between chronic maternal hypoxia and impaired fetal growth	FASEB JOURNAL			English	Article						PPAR; intrauterine growth restriction	ARTERY BLOOD-FLOW; HIGH-ALTITUDE; BIRTH-WEIGHT; DRUG TARGET; EXPRESSION; PREGNANCY; PREECLAMPSIA; TROPHOBLAST; REDUCTIONS; GLUCOSE	Chronic exposure to hypoxia raises the risk of pregnancy disorders characterized by maternal vascular dysfunction and diminished fetal growth. In an effort to identify novel pathways for these hypoxia-related effects, we assessed gene expression profiles of peripheral blood mononuclear cells (PBMCs) obtained from 43 female, high-altitude or sea-level residents in the nonpregnant state or during pregnancy (20 or 36 wk). Hypoxia-related fetal growth restriction becomes apparent between 25 and 29 wk of gestation and continues until delivery. Our sampling strategy was designed to capture changes occurring before (20 wk) and during (36 wk) the time frame of slowed fetal growth. PBMC gene expression profiles were generated using human gene expression microarrays and compared between altitudes. Biological pathways were identified using pathway analysis. Modest transcriptional differences were observed between altitudes in the nonpregnant state. Of the genes that were differentially expressed at high altitude vs. sea level during pregnancy (20 wk: 59 probes mapped to 41 genes; 36 wk: 985 probes mapped to 700 genes), several are of pathological relevance for fetal growth restriction. In particular, transcriptional changes were consistent with the negative regulation of peroxisome proliferator-activated receptor (PPAR) at high altitude; such effects were accompanied by reduced birth weight (P <0.05) and head circumference (P <0.01) at high altitude vs. sea level. Our findings indicate that chronic exposure to hypoxia during pregnancy alters maternal gene expression patterns in general and, in particular, expression of key genes involved in metabolic homeostasis that have been proposed to play a role in the pathophysiology of fetal growth restriction.Julian, C. G., Yang, I. V., Browne, V. A., Vargas, E., Rodriguez, C., Pedersen, B. S., Moore, L. G., Schwartz, D. A. Inhibition of peroxisome proliferator-activated receptor : a potential link between chronic maternal hypoxia and impaired fetal growth.	[Julian, Colleen G.] Univ Colorado, Div Biomed Informat & Personalized Med, Denver, CO 80202 USA; [Yang, Ivana V.; Pedersen, Brent S.; Schwartz, David A.] Univ Colorado, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO USA; [Browne, Vaughn A.] Univ Colorado, Dept Emergency Med, Denver, CO 80202 USA; [Moore, Lorna G.] Univ Colorado, Dept Obstet & Gynecol, Denver, CO 80202 USA; [Vargas, Enrique] Bolivian Inst High Altitude Biol, La Paz, Bolivia; [Rodriguez, Carmelo] Clin Sirani, Santa Cruz, Bolivia	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Julian, CG (corresponding author), Univ Colorado Denver, Dept Med, 12700 E 19th Ave,Mailstop 8611, Aurora, CO 80045 USA.	colleen.julian@ucdenver.edu	Yang, Ivana V/P-3059-2018	Yang, Ivana V/0000-0002-1018-489X	U.S. National Institutes of Health (NIH) Building Interdisciplinary Research Careers Women's Health grant [5 K12 HD057022-07];  [NIH-HL079647];  [NIH-HL095393];  [NIH-HL101715];  [NIH-ES18181]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD057022] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095393, R01HL079647, RC2HL101715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) Building Interdisciplinary Research Careers Women's Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors acknowledge all the women who participated in this project. Their appreciation is also extended to physicians and technical staff at the Bolivian Institute of High Altitude Biology and Clinica Sirani for assistance with the conduct of this project. Finally, the authors thank Dr. Megan Wilson, Corrine Hennessy, and Beth Davidson for assistance with data acquisition and analysis. C.G.J. is supported by a U.S. National Institutes of Health (NIH) Building Interdisciplinary Research Careers Women's Health grant (5 K12 HD057022-07). Support for data collection and analysis was obtained from grants NIH-HL079647 (L.G.M.), NIH-HL095393 (D.A.S.), NIH-HL101715 (D.A.S.), and NIH-ES18181 (D.A.S.).	Arngrimsson R, 1997, AM J HUM GENET, V61, P354, DOI 10.1086/514843; Barker DJP, 1999, ANN MED, V31, P3, DOI 10.1080/07853890.1999.11904392; Baumann MU, 2007, AM J PHYSIOL-CELL PH, V293, pC477, DOI 10.1152/ajpcell.00075.2007; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigham A., 2010, PLOS GENET, V6; Bigham A. W., 2012, AM SOC HUM GEN ANN M; Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920; Bull Todd M, 2007, Proc Am Thorac Soc, V4, P117, DOI 10.1513/pats.200605-128JG; Caniggia I, 2002, PLACENTA, V23, pS47, DOI 10.1053/plac.2002.0815; CAPELESS EL, 1991, AM J OBSTET GYNECOL, V165, P883, DOI 10.1016/0002-9378(91)90432-Q; Davila RD, 2010, REPROD SCI, V17, P861, DOI 10.1177/1933719110372418; Davila RD, 2011, REPROD SCI, V18, P79, DOI 10.1177/1933719110380061; Diaz M, 2012, J CLIN ENDOCR METAB, V97, pE1468, DOI 10.1210/jc.2012-1064; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Gilbert WM, 2003, AM J OBSTET GYNECOL, V188, P1596, DOI 10.1067/mob.2003.384; Guo YF, 2008, ACTA BIOCH BIOPH SIN, V40, P426, DOI 10.1111/j.1745-7270.2008.00418.x; Holdsworth-Carson SJ, 2010, PLACENTA, V31, P222, DOI 10.1016/j.placenta.2009.12.009; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jozkowicz A, 2000, ACTA BIOCHIM POL, V47, P1147, DOI 10.18388/abp.2000_3967; Julian CG, 2008, AM J PHYSIOL-REG I, V295, pR906, DOI 10.1152/ajpregu.00164.2008; Julian CG, 2007, ARCH DIS CHILD-FETAL, V92, P372, DOI 10.1136/adc.2006.109579; Julian CG, 2009, AM J PHYSIOL-REG I, V296, pR1564, DOI 10.1152/ajpregu.90945.2008; Keyes LE, 2003, PEDIATR RES, V54, P20, DOI 10.1203/01.PDR.0000069846.64389.DC; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Krampl E, 2000, ULTRASOUND OBST GYN, V16, P9, DOI 10.1046/j.1469-0705.2000.00156.x; Krampl E, 2001, BRIT J OBSTET GYNAEC, V108, P254, DOI 10.1016/S0306-5456(00)00072-3; Krampl ER, 2001, ULTRASOUND OBST GYN, V18, P578, DOI 10.1046/j.0960-7692.2001.00579.x; Laros R, 2003, AM J OBSTET GYNECOL, V188, P1599; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Li X, 2007, NEPHROL DIAL TRANSPL, V22, P1041, DOI 10.1093/ndt/gfl766; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCarthy FP, 2013, BRIT J PHARMACOL, V168, P1074, DOI 10.1111/bph.12069; McCarthy FP, 2011, HYPERTENSION, V58, P882, DOI 10.1161/HYPERTENSIONAHA.111.179440; McCarthy FP, 2011, HYPERTENSION, V58, P280, DOI 10.1161/HYPERTENSIONAHA.111.172627; Moore LG, 2004, PLACENTA, V25, pS60, DOI 10.1016/j.placenta.2004.01.008; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Palmer SK, 1999, AM J OBSTET GYNECOL, V180, P1161, DOI 10.1016/S0002-9378(99)70611-3; Parast MM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008055; PIJNENBORG R, 1980, PLACENTA, V1, P3, DOI 10.1016/S0143-4004(80)80012-9; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rodie VA, 2005, J SOC GYNECOL INVEST, V12, P320, DOI 10.1016/j.jsgi.2005.03.004; Savvidou MD, 2001, HYPERTENSION, V38, P1289, DOI 10.1161/hy1201.097305; Schaiff WT, 2000, J CLIN ENDOCR METAB, V85, P3874, DOI 10.1210/jc.85.10.3874; Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949; Shriver Mark D., 2005, Human Genomics, V2, P81; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sozio MS, 2011, AM J PHYSIOL-GASTR L, V301, pG739, DOI [10.1152/ajpgi.00432.2010, 10.1152/ajpgi.00161.2011]; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; van Patot MT, 2003, PLACENTA, V24, P326, DOI 10.1053/plac.2002.0899; Villar K., 2003, ECLAMPSIA PREECLAMPS, P189; Waite LL, 2005, J CLIN ENDOCR METAB, V90, P620, DOI 10.1210/jc.2004-0849; Walker JJ, 2000, LANCET, V356, P1260, DOI 10.1016/S0140-6736(00)02800-2; Weix J, 2012, ARTHRITIS RHEUM-US, V64, P2095, DOI 10.1002/art.34375; Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010; WITTER FR, 1991, EARLY HUM DEV, V25, P181, DOI 10.1016/0378-3782(91)90114-I; Zamudio S, 2006, PLACENTA, V27, P49, DOI 10.1016/j.placenta.2004.12.010; Zamudio S, 2007, AM J PATHOL, V170, P2171, DOI 10.2353/ajpath.2007.061185; Zamudio S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008551; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012	60	9	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1268	1279		10.1096/fj.13-239749	http://dx.doi.org/10.1096/fj.13-239749			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24307415	Green Published			2022-12-28	WOS:000335324800020
J	Deshpande, DA; Yan, HD; Kong, KC; Tiegs, BC; Morgan, SJ; Pera, T; Panettieri, RA; Eckhart, AD; Penn, RB				Deshpande, Deepak A.; Yan, Huandong; Kong, Kok-Choi; Tiegs, Brian C.; Morgan, Sarah J.; Pera, Tonio; Panettieri, Reynold A.; Eckhart, Andrea D.; Penn, Raymond B.			Exploiting functional domains of GRK2/3 to alter the competitive balance of pro- and anticontractile signaling in airway smooth muscle	FASEB JOURNAL			English	Article						asthma; -agonist; bronchodilation; desensitization; G-protein-coupled receptor	ADRENERGIC-RECEPTOR KINASE; PROTEIN-COUPLED RECEPTORS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; DESENSITIZATION; SPECIFICITY; INHIBITION; ACTIVATION; MECHANISM	To clarify the potential utility of targeting GRK2/3-mediated desensitization as a means of manipulating airway smooth muscle (ASM) contractile state, we assessed the specificity of GRK2/3 regulation of procontractile and relaxant G-protein-coupled receptors in ASM. Functional domains of GRK2/3 were stably expressed, or siRNA-mediated GRK2/3 knockdown was performed, in human ASM cultures, and agonist-induced signaling was assessed. Regulation of contraction of murine tracheal rings expressing GRK2 C terminus was also assessed. GRK2/3 knockdown or expression of the GRK2 C terminus caused a significant (approximate to 30-90%) increase in maximal -agonist and histamine [phosphoinositide (PI) hydrolysis] signaling, without affecting the calculated EC50. GRK2 C-terminal expression did not affect signaling by methacholine, thrombin, or LTD4. Expression of the GRK2 N terminus or kinase-dead holo-GRK2 diminished (approximate to 30-70%) both PI hydrolysis and Ca2+ mobilization by every G(q)-coupled receptor examined. Under conditions of GRK2 C-terminal expression, -agonist inhibition of methacholine-stimulated PI hydrolysis was greater. Finally, transgenic expression of the GRK2 C terminus in murine ASM enabled approximate to 30-50% greater -agonist-mediated relaxation of methacholine-induced contraction. Collectively these data demonstrate the relative selectivity of GRKs for the (2)AR in ASM and the ability to exploit GRK2/3 functional domains to render ASM hyporesponsive to contractile agents while increasing responsiveness to bronchodilating -agonist.Deshpande, D. A., Yan, H., Kong, K.-C., Tiegs, B. C., Morgan, S. J., Pera, T., Panettieri, R. A., Eckhart, A. D., Penn, R. B. Exploiting functional domains of GRK2/3 to alter the competitive balance of pro- and anticontractile signaling in airway smooth muscle.	[Deshpande, Deepak A.; Yan, Huandong; Morgan, Sarah J.; Penn, Raymond B.] Univ Maryland, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA; [Kong, Kok-Choi; Penn, Raymond B.] Wake Forest Univ Hlth Sci, Dept Internal Med, Winston Salem, NC USA; [Tiegs, Brian C.; Pera, Tonio; Eckhart, Andrea D.; Penn, Raymond B.] Thomas Jefferson Univ, Jane & Leonard Korman Lung Ctr, Ctr Translat Med, Dept Med, Philadelphia, PA 19107 USA; [Panettieri, Reynold A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University System of Maryland; University of Maryland Baltimore; Wake Forest University; Wake Forest University School of Medicine; Jefferson University; University of Pennsylvania	Penn, RB (corresponding author), Thomas Jefferson Univ, Dept Med, Room 317,Coll Bldg,1025 Walnut St, Philadelphia, PA 19107 USA.	raymond.penn@jefferson.edu	panettieri, reynold/AAG-9485-2019		U.S. National Institutes of Health [HL58506, AG041265, HL087560]; U.S. National Institute of Arthritis and Musculoskeletal and Skin Disease [T32 AR07592]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL104119, R01HL058506, R00HL087560, P01HL114471, R29HL058506, K99HL087560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG041265] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Institute of Arthritis and Musculoskeletal and Skin Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was funded by U.S. National Institutes of Health grants HL58506 (R. B. P.) and AG041265 and HL087560 (D. A. D.). S.J.M. is supported by U.S. National Institute of Arthritis and Musculoskeletal and Skin Disease grant T32 AR07592.	Abisheganaden J, 1998, AM J MED, V104, P494; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Billington CK, 2005, BIOCHEMISTRY-US, V44, P14595, DOI 10.1021/bi0510734; Bond D, 2008, BIOL PROCED ONLINE, V10, P20, DOI 10.1251/bpo139; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; Cohn HI, 2008, AM J PHYSIOL-HEART C, V295, pH1695, DOI 10.1152/ajpheart.00564.2008; Deshpande DA, 2007, FASEB J, V21, P2335, DOI 10.1096/fj.06-8060com; Deshpande DA, 2006, CELL SIGNAL, V18, P2105, DOI 10.1016/j.cellsig.2006.04.008; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Finney PA, 2000, J CLIN INVEST, V106, P125, DOI 10.1172/JCI8374; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Gros R, 2000, HYPERTENSION, V35, P38, DOI 10.1161/01.HYP.35.1.38; Guo MH, 2005, BIOCHEMISTRY-US, V44, P13771, DOI 10.1021/bi051255y; HAUCK RW, 1999, AM J PHYSIOL, V277, P22; ISHII K, 1994, J BIOL CHEM, V269, P1125; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KIM CM, 1993, J BIOL CHEM, V268, P15412; Koch WJ, 1999, TRENDS CARDIOVAS MED, V9, P77, DOI 10.1016/S1050-1738(99)00009-2; KONG GH, 1994, J BIOL CHEM, V269, P13084; Kong KC, 2008, BIOCHEMISTRY-US, V47, P9279, DOI 10.1021/bi801056w; Kong KC, 2006, FASEB J, V20, P1558, DOI 10.1096/fj.05-5622fje; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Luo JS, 2008, MOL PHARMACOL, V74, P338, DOI 10.1124/mol.107.044750; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Naik S, 2005, J BIOL CHEM, V280, P8722, DOI 10.1074/jbc.M413014200; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Penn RB, 2008, N-S ARCH PHARMACOL, V378, P149, DOI 10.1007/s00210-008-0263-1; Penn RB, 1998, AM J RESP CELL MOL, V19, P338, DOI 10.1165/ajrcmb.19.2.3025; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Penn RB, 1998, HANDBK PHYS, V1, P125; Peters SP, 1999, AM J MED, V107, P283; Struckmann N, 2003, MOL PHARMACOL, V64, P1444, DOI 10.1124/mol.64.6.1444; Tilley SL, 2003, AM J PHYSIOL-LUNG C, V284, pL599, DOI 10.1152/ajplung.00324.2002; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026	44	16	17	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					956	965		10.1096/fj.13-240226	http://dx.doi.org/10.1096/fj.13-240226			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24132623	Green Published			2022-12-28	WOS:000331072200040
J	Corum, DG; Tsichlis, PN; Muise-Helmericks, RC				Corum, Daniel G.; Tsichlis, Philip N.; Muise-Helmericks, Robin C.			AKT3 controls mitochondrial biogenesis and autophagy via regulation of the major nuclear export protein CRM-1	FASEB JOURNAL			English	Article						angiogenesis; endothelial cells; mitophagy	KINASE-B-GAMMA; PATHOLOGICAL ANGIOGENESIS; VASCULAR DEVELOPMENT; ENDOTHELIAL-CELLS; ENERGY-METABOLISM; PGC-1-ALPHA; ISOFORMS; SURVIVAL; GROWTH; MICE	Our previous work has shown that Akt3 is required for mitochondrial biogenesis in primary human endothelial cells (ECs) and in Akt3-null mice; Akt3 affects subcellular localization of peroxisome proliferator-activated receptor coactivator-1 (PGC-1), the master regulator of mitochondrial biogenesis. The purpose of this study is to determine the mechanism by which Akt3 controls the subcellular distribution of PGC-1 and to explore the effect on mitochondrial biogenesis and turnover during angiogenesis. Here we use standard biochemical analyses and Akt3-knockdown strategies to show that Akt3 controls the stabilization of chromosome maintenance region-1 (CRM-1), the major nuclear export receptor. Site-directed mutagenesis and association analyses show that PGC-1 nuclear export is CRM-1 dependent. Akt3 knockdown and CRM-1 overexpression cause 3-fold reductions in PGC-1 target gene expression, compared to control levels. Akt3 inhibition causes autophagy, as measured by autophagosome formation, in a CRM-1-dependent, Akt1/mTOR-independent pathway. In vivo, Akt3-null and heterozygous mice show dose-dependent decreases in angiogenesis compared to wild-type littermates (approximate to 5- and 2.5-fold decreases, respectively), as assessed by Matrigel plug assays. This correlates with an approximate to 1.5-fold decrease in mitochondrial Cox IV expression. Our studies suggest that Akt3 is a regulator of mitochondrial dynamics in the vasculature via regulation of CRM-1-dependent nuclear export.Corum, D. G., Tsichlis, P. N., Muise-Helmericks, R. C. AKT3 controls mitochondrial biogenesis and autophagy via regulation of the major nuclear export protein CRM-1.	[Corum, Daniel G.; Muise-Helmericks, Robin C.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA; [Corum, Daniel G.; Muise-Helmericks, Robin C.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Tsichlis, Philip N.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA	Medical University of South Carolina; Medical University of South Carolina; Tufts Medical Center	Muise-Helmericks, RC (corresponding author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, 173 Ashley Ave,BSB654, Charleston, SC 29425 USA.	musehelm@musc.edu			U.S. National Heart, Blood and Lung Institute [HL084565, 2T32HL007260-36]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084565, T32HL007260] Funding Source: NIH RePORTER	U.S. National Heart, Blood and Lung Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Yong Gong for help with Matrigel assays, Amy Phelps [Center of Biomedical Research Excellence (COBRE) Histology Core Facility, Medical University of South Carolina] for help with sectioning, and C. Beeson and R. Schnellman for their helpful suggestions. This work was supported in part by U.S. National Heart, Blood and Lung Institute grants HL084565 (to R. M. H.) and 2T32HL007260-36 (to D.G.C.).	Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Bell EL, 2011, MOL CELL, V42, P561, DOI 10.1016/j.molcel.2011.05.008; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; CAIN AJ, 1948, Q J MICROSC SCI, V89, P229; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang JS, 2010, J BIOL CHEM, V285, P18039, DOI 10.1074/jbc.M109.083121; Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cozzone D, 2008, DIABETOLOGIA, V51, P512, DOI 10.1007/s00125-007-0913-8; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Ding L, 2012, CELL METAB, V15, P861, DOI 10.1016/j.cmet.2012.04.020; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Endersby R, 2011, CANCER RES, V71, P4106, DOI 10.1158/0008-5472.CAN-10-3597; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fieber CB, 2006, EXP CELL RES, V312, P1164, DOI 10.1016/j.yexcr.2006.01.022; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gentile C, 2013, DEV BIOL, V373, P163, DOI 10.1016/j.ydbio.2012.10.020; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003; Guttler T, 2011, EMBO J, V30, P3457, DOI 10.1038/emboj.2011.287; Haigis MC, 2012, CANCER RES, V72, P2468, DOI 10.1158/0008-5472.CAN-11-3633; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Hutten S, 2007, TRENDS CELL BIOL, V17, P193, DOI 10.1016/j.tcb.2007.02.003; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051; Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695; Koseoglu S, 2007, CANCER BIOL THER, V6, P755, DOI 10.4161/cbt.6.5.3995; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Larrivee B, 2009, CIRC RES, V104, P428, DOI 10.1161/CIRCRESAHA.108.188144; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013; Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Liu M, 2013, J MOL CELL CARDIOL, V54, P25, DOI 10.1016/j.yjmcc.2012.10.011; Mao CC, 2007, J IMMUNOL, V178, P5443, DOI 10.4049/jimmunol.178.9.5443; Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm; Maroulakou IG, 2008, J CELL PHYSIOL, V217, P468, DOI 10.1002/jcp.21518; Papaioannou V. E., 2005, MOUSE PHENOTYPES HDB; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Saji M, 2005, BIOCHEM BIOPH RES CO, V332, P167, DOI 10.1016/j.bbrc.2005.04.109; Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Tal R, 2007, J BIOL CHEM, V282, P5617, DOI 10.1074/jbc.M605940200; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Wareski P, 2009, J BIOL CHEM, V284, P21379, DOI 10.1074/jbc.M109.018911; Wright GL, 2008, FASEB J, V22, P3264, DOI 10.1096/fj.08-106468; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028	58	27	28	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2014	28	1					395	407		10.1096/fj.13-235382	http://dx.doi.org/10.1096/fj.13-235382			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AD8OS	24081905	Green Published			2022-12-28	WOS:000333526100037
J	Kuliawat, R; Klein, L; Gong, ZW; Nicoletta-Gentile, M; Nemkal, A; Cui, LG; Bastie, C; Su, K; Huffman, D; Surana, M; Barzilai, N; Fleischer, N; Muzumdar, R				Kuliawat, Regina; Klein, Laura; Gong, Zhenwei; Nicoletta-Gentile, Marianna; Nemkal, Anjana; Cui, Lingguang; Bastie, Claire; Su, Kai; Huffman, Derek; Surana, Manju; Barzilai, Nir; Fleischer, Norman; Muzumdar, Radhika			Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the beta cell	FASEB JOURNAL			English	Article						hyperglycemic clamps; pancreatic islets; diabetes	NADH SHUTTLE SYSTEM; ALZHEIMERS-DISEASE; NEUROPROTECTIVE FACTOR; PHOSPHATE DEHYDROGENASE; MEMORY IMPAIRMENT; GLUCOKINASE GENE; PEPTIDE; ACTIVATION; MITOCHONDRIAL; DEATH	Humanin (HN) is a 24-aa polypeptide that offers protection from Alzheimer's disease and myocardial infarction, increases insulin sensitivity, improves survival of beta cells, and delays onset of diabetes. Here we examined the acute effects of HN on insulin secretion and potential mechanisms through which they are mediated. Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine beta cell line (beta TC3) in vitro. Sprague-Dawley rats (3 mo old) that received HNGF6A required a significantly higher glucose infusion rate and demonstrated higher insulin levels during hyperglycemic clamps compared to saline controls. In vitro, compared to scrambled peptide controls, HNGF6A increased GSIS in isolated islets from both normal and diabetic mice as well as in beta TC3 cells. Effects of HNGF6A on GSIS were dose dependent, K-ATP channel independent, and associated with enhanced glucose metabolism. These findings demonstrate that HNGF6A increases GSIS in whole animals, from isolated islets and from cells in culture, which suggests a direct effect on the beta cell. The glucose-dependent effects on insulin secretion along with the established effects on insulin action suggest potential for HN and its analogs in the treatment of diabetes.	[Klein, Laura; Gong, Zhenwei; Nicoletta-Gentile, Marianna; Nemkal, Anjana; Cui, Lingguang; Su, Kai; Muzumdar, Radhika] Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA; [Kuliawat, Regina] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; [Bastie, Claire; Huffman, Derek; Surana, Manju; Barzilai, Nir; Fleischer, Norman] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Bastie, Claire] Warwick Med Sch, Div Metab & Vasc Hlth, Coventry, W Midlands, England	Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Warwick	Muzumdar, R (corresponding author), Albert Einstein Coll Med, Dept Pediat, Golding Bldg 705,1300 Morris Pk Ave, Bronx, NY 10461 USA.	radhika.muzumdar@einstein.yu.edu	Muzumdar, Radhika/D-9860-2014	Bastie, Claire/0000-0001-8178-4748	U.S. National Institutes of Health [K08-AG-027462, K08-AG-027462-03S1, R01-AG-035114, P30-AG-038072, R01-AG-618381, K99/R00, AG-037574]; Core laboratories of the Albert Einstein Diabetes Research and Training Center [DK 20541]; Einstein Nathan Shock Center, Cellular and Tissue Aging Core [P30-AG-038072]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081412, P30DK020541, P60DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG038072, K08AG027462, K99AG037574, R01AG035114] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Core laboratories of the Albert Einstein Diabetes Research and Training Center; Einstein Nathan Shock Center, Cellular and Tissue Aging Core; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Natalia V. Cheshenko (Department of Pediatrics, Albert Einstein College of Medicine) for assistance with determination of intracellular calcium concentrations. This work was supported by grants from the U.S. National Institutes of Health, K08-AG-027462, K08-AG-027462-03S1, and R01-AG-035114 to R. H. M.; P30-AG-038072 to R. K.; R01-AG-618381 and P30-AG-038072 to N.B.; K99/R00 award AG-037574 to D. M. H.; and by the Core laboratories of the Albert Einstein Diabetes Research and Training Center (DK 20541) and Einstein Nathan Shock Center, Cellular and Tissue Aging Core P30-AG-038072. Disclosure: N.B. is a consultant and a shareholder of CoHBar.	Arakawa T, 2011, CURR MED CHEM, V18, P5554, DOI 10.2174/092986711798347261; Arakawa T, 2006, J PEPT SCI, V12, P639, DOI 10.1002/psc.773; Cheshenko N, 2003, J CELL BIOL, V163, P283, DOI 10.1083/jcb.200301084; Cline GW, 2011, DIABETES METAB J, V35, P458, DOI 10.4093/dmj.2011.35.5.458; Cunningham BA, 2003, BIOCHEM J, V369, P173, DOI 10.1042/BJ20021196; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; Doliba NM, 2012, AM J PHYSIOL-ENDOC M, V302, pE87, DOI 10.1152/ajpendo.00218.2011; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Eto K, 1999, J BIOL CHEM, V274, P25386, DOI 10.1074/jbc.274.36.25386; Fleischer N, 1998, DIABETES, V47, P1419, DOI 10.2337/diabetes.47.9.1419; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; Gong ZW, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/320482; Harada M, 2004, BIOCHEM BIOPH RES CO, V324, P255, DOI 10.1016/j.bbrc.2004.09.046; Hashimoto Y, 2005, LIFE SCI, V77, P3092, DOI 10.1016/j.lfs.2005.03.031; Hashimoto Y, 2003, J NEUROCHEM, V84, P864, DOI 10.1046/j.1471-4159.2003.01585.x; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hashimoto Yuichi, 2004, Eur J Neurosci, V19, P2356, DOI 10.1111/j.0953-816X.2004.03298.x; Hashimoto Y, 2009, MOL BIOL CELL, V20, P2864, DOI 10.1091/mbc.E09-02-0168; Henquin JC, 2002, DIABETES, V51, pS60, DOI 10.2337/diabetes.51.2007.S60; Hoang PT, 2010, METABOLISM, V59, P343, DOI 10.1016/j.metabol.2009.08.001; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Ishihara H, 1996, DIABETES, V45, P1238, DOI 10.2337/diabetes.45.9.1238; Jensen MV, 2008, AM J PHYSIOL-ENDOC M, V295, pE1287, DOI 10.1152/ajpendo.90604.2008; Jung SS, 2003, J NEUROCHEM, V84, P266, DOI 10.1046/j.1471-4159.2003.01524.x; Kinasiewicz A, 2004, PHYSIOL RES, V53, P327; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; MacDonald MJ, 2000, ARCH BIOCHEM BIOPHYS, V384, P143, DOI 10.1006/abbi.2000.2107; Mamiya T, 2001, BRIT J PHARMACOL, V134, P1597, DOI 10.1038/sj.bjp.0704429; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Matschinsky FM, 2011, HANDB EXP PHARMACOL, V203, P357, DOI 10.1007/978-3-642-17214-4_15; Maximov V, 2002, MED HYPOTHESES, V59, P670, DOI 10.1016/S0306-9877(02)00223-2; Muzumdar RH, 2010, ARTERIOSCL THROM VAS, V30, P1940, DOI 10.1161/ATVBAHA.110.205997; Muzumdar RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006334; Niikura T, 2006, CURR NEUROPHARMACOL, V4, P139, DOI 10.2174/157015906776359577; Nurse P, 2003, NATURE, V424, P883, DOI 10.1038/424883a; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; Sponne I, 2004, MOL CELL NEUROSCI, V25, P95, DOI 10.1016/j.mcn.2003.09.017; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Tajima H, 2002, NEUROSCI LETT, V324, P227, DOI 10.1016/S0304-3940(02)00199-4; Tajima H, 2005, J NEUROSCI RES, V79, P714, DOI 10.1002/jnr.20391; Terashita K, 2003, J NEUROCHEM, V85, P1521, DOI 10.1046/j.1471-4159.2003.01797.x; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Tinoco AD, 2011, BIOCHEMISTRY-US, V50, P7447, DOI 10.1021/bi200417k; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Xu XS, 2006, STROKE, V37, P2613, DOI 10.1161/01.STR.0000242772.94277.1f; Yamagishi Y, 2003, PEPTIDES, V24, P585, DOI 10.1016/S0196-9781(03)00106-2; Yoshida S, 2010, BIOCHEM BIOPH RES CO, V402, P280, DOI 10.1016/j.bbrc.2010.10.015	50	46	51	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4890	4898		10.1096/fj.13-231092	http://dx.doi.org/10.1096/fj.13-231092			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23995290	Green Published			2022-12-28	WOS:000329999000023
J	Goldberg, K; Sarig, H; Zaknoon, F; Epand, RF; Epand, RM; Mor, A				Goldberg, Keren; Sarig, Hadar; Zaknoon, Fadia; Epand, Raquel F.; Epand, Richard M.; Mor, Amram			Sensitization of gram-negative bacteria by targeting the membrane potential	FASEB JOURNAL			English	Article						proton motive force; host defense peptides; oligo-acyl-lysyl; peptidomimetics; synergy	ACYL-LYSINE OLIGOMERS; ESCHERICHIA-COLI; MULTIDRUG-RESISTANCE; ANTIMICROBIAL PEPTIDES; EFFLUX PUMP; PSEUDOMONAS-AERUGINOSA; ANTIBACTERIAL PEPTIDES; STAPHYLOCOCCUS-AUREUS; CYTOPLASMIC MEMBRANE; ANTIBIOTICS	Toward generating new tools for fighting multidrug-resistant (MDR) bacteria, we assessed the ability of a membrane-active peptide to sensitize gram-negative bacteria to various antibiotics. The mechanism for affecting inner and/or outer membrane functions was assessed by complementary biophysical methods (SPR, DSC, ITC). The implication of efflux pumps was examined using Acr-AB mutants, as tested with representative antibiotics, host defense peptides, and synthetic mimics. The ability to affect disease course systemically was compared for a single therapy and combination therapy, using the mouse thigh-infection model. The data show that potent antibiotic action can be provoked in vitro and in vivo, by a treatment combining two antibacterial compounds whose individual inefficiency against gram-negative bacteria stems from their efflux. Thus, at subminimal inhibitory concentrations, the lipopeptide-like sequence, N(7)dodecenoyl-lysyl-[lysyl-aminododecanoyl-lysyl]-amide (designated C12(7)K-(12)), has, nonetheless, rapidly achieved a transient membrane depolarization, which deprived bacteria of the proton-motive force required for active efflux. Consequently, bacteria became significantly sensitive to intracellular targeting antibiotics. Collectively, these findings suggest a potentially useful approach for expanding the antibiotics sensitivity spectrum of MDR gram-negative bacteria to include efflux substrates.Goldberg, K., Sarig, H., Zaknoon, F., Epand, R. F., Epand, R. M., Mor, A. Sensitization of gram-negative bacteria by targeting the membrane potential.	[Goldberg, Keren; Sarig, Hadar; Zaknoon, Fadia; Mor, Amram] Technion Israel Inst Technol, Dept Biotechnol & Food Engn, Haifa, Israel; [Epand, Raquel F.; Epand, Richard M.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada	Technion Israel Institute of Technology; McMaster University	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Biotechnol & Food Engn, Haifa, Israel.	amor@tx.technion.ac.il	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558	Israel Science Foundation [909/12]; Russell Berrie Nanotechnology Institute at the Technion; Canadian Institutes of Health Research [MOP 86608]	Israel Science Foundation(Israel Science Foundation); Russell Berrie Nanotechnology Institute at the Technion; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by Israel Science Foundation (grant 909/12), by the Russell Berrie Nanotechnology Institute at the Technion, and by the Canadian Institutes of Health Research (grant MOP 86608). The authors are grateful to Colette F. Quinn (TA Instruments, Newcastle, DE, USA) for her help in running samples in the nano-ITC.	Acar JF, 2000, MED CLIN N AM, V84, P1391, DOI 10.1016/S0025-7125(05)70294-7; Aires JR, 2005, J BACTERIOL, V187, P1923, DOI 10.1128/JB.187.6.1923-1929.2005; Aminov RI, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00134; Bolintineanu D, 2010, PEPTIDES, V31, P1, DOI 10.1016/j.peptides.2009.11.010; Butler MS, 2011, J ANTIBIOT, V64, P413, DOI 10.1038/ja.2011.44; Choi S, 2009, P NATL ACAD SCI USA, V106, P6968, DOI 10.1073/pnas.0811818106; Daugelavicius R, 2000, ANTIMICROB AGENTS CH, V44, P2969, DOI 10.1128/AAC.44.11.2969-2978.2000; Ejim L, 2011, NAT CHEM BIOL, V7, P348, DOI [10.1038/NCHEMBIO.559, 10.1038/nchembio.559]; Epand RF, 2011, CELL MOL LIFE SCI, V68, P2177, DOI 10.1007/s00018-011-0711-9; Epand RF, 2010, ANTIMICROB AGENTS CH, V54, P3708, DOI 10.1128/AAC.00380-10; Epand RF, 2009, BIOPHYS J, V97, P2250, DOI 10.1016/j.bpj.2009.08.006; Epand RM, 2008, J AM CHEM SOC, V130, P14346, DOI 10.1021/ja8062327; Epand RM, 2011, J PEPT SCI, V17, P298, DOI 10.1002/psc.1319; Gaidukov L, 2003, BIOCHEMISTRY-US, V42, P12866, DOI 10.1021/bi034514x; HANCOCK REW, 1984, ANNU REV MICROBIOL, V38, P237, DOI 10.1146/annurev.mi.38.100184.001321; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; Koo SP, 1997, INFECT IMMUN, V65, P4795, DOI 10.1128/IAI.65.11.4795-4800.1997; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; Livne L, 2010, FASEB J, V24, P5092, DOI 10.1096/fj.10-167809; Livne L, 2009, CHEM BIOL, V16, P1250, DOI 10.1016/j.chembiol.2009.11.012; Mangoni ML, 2008, J BIOL CHEM, V283, P22907, DOI 10.1074/jbc.M800495200; Martinac B, 2008, PHYSIOL REV, V88, P1449, DOI 10.1152/physrev.00005.2008; Nikaido H, 2009, ANNU REV BIOCHEM, V78, P119, DOI 10.1146/annurev.biochem.78.082907.145923; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Qian CD, 2012, ANTIMICROB AGENTS CH, V56, P1458, DOI 10.1128/AAC.05580-11; Radzishevsky IS, 2008, CHEM BIOL, V15, P354, DOI 10.1016/j.chembiol.2008.03.006; Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309; Rieg S, 2009, INT J ANTIMICROB AG, V33, P174, DOI 10.1016/j.ijantimicag.2008.07.032; Rotem S, 2008, FASEB J, V22, P2652, DOI 10.1096/fj.07-105015; Sakoulas G, 2012, ANTIMICROB AGENTS CH, V56, P838, DOI 10.1128/AAC.05551-11; Sarig H, 2011, FASEB J, V25, P3336, DOI 10.1096/fj.11-183764; Sarig H, 2011, ANTIMICROB AGENTS CH, V55, P688, DOI 10.1128/AAC.00666-10; Sarig H, 2010, FASEB J, V24, P1904, DOI 10.1096/fj.09-149427; Schiffelers RM, 2001, J PHARMACOL EXP THER, V298, P369; Schumacher A, 2007, J ANTIMICROB CHEMOTH, V59, P1261, DOI 10.1093/jac/dkl380; Seeger MA, 2008, CURR DRUG TARGETS, V9, P729, DOI 10.2174/138945008785747789; Shafer WM, 1998, P NATL ACAD SCI USA, V95, P1829, DOI 10.1073/pnas.95.4.1829; Silverman JA, 2003, ANTIMICROB AGENTS CH, V47, P2538, DOI 10.1128/AAC.47.8.2538-2544.2003; Spellberg B, 2004, CLIN INFECT DIS, V38, P1279, DOI 10.1086/420937; Steenbergen JN, 2009, J ANTIMICROB CHEMOTH, V64, P1130, DOI 10.1093/jac/dkp346; Strahl H, 2010, P NATL ACAD SCI USA, V107, P12281, DOI 10.1073/pnas.1005485107; Torres JA, 2007, EXPERT REV ANTI-INFE, V5, P833, DOI 10.1586/14787210.5.5.833; Ulvatne H, 2001, J ANTIMICROB CHEMOTH, V48, P203, DOI 10.1093/jac/48.2.203; VAARA M, 1983, NATURE, V303, P526, DOI 10.1038/303526a0; Vaara M, 2008, ANTIMICROB AGENTS CH, V52, P3229, DOI 10.1128/AAC.00405-08; Viveiros M, 2008, INT J ANTIMICROB AG, V31, P458, DOI 10.1016/j.ijantimicag.2007.12.015; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000	52	41	41	1	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3818	3826		10.1096/fj.13-227942	http://dx.doi.org/10.1096/fj.13-227942			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23733749				2022-12-28	WOS:000328840500039
J	Shahnazari, M; Chu, V; Wronski, TJ; Nissenson, RA; Halloran, BP				Shahnazari, Mohammad; Chu, Vivian; Wronski, Thomas J.; Nissenson, Robert A.; Halloran, Bernard P.			CXCL12/CXCR4 signaling in the osteoblast regulates the mesenchymal stem cell and osteoclast lineage populations	FASEB JOURNAL			English	Article						bone; chemokine; skeletal homeostasis	CHEMOKINE RECEPTOR CXCR4; BONE-FORMATION; MICE LACKING; EXPRESSION; DIFFERENTIATION; MAINTENANCE; PROMOTES; SURVIVAL; RANKL; SDF-1	The chemokine CXCL12 and its receptor CXCR4 play a key role in regulation of hematopoietic stem cells and cell migratory function during morphogenesis. Osteoblasts express both the ligand and the receptor, but little is known about the role of CXCL12-CXCR4 signaling in maintaining skeletal homeostasis. Using Cre-Lox technology to delete CXCR4 in mature osteoblasts in mice, we show here a significant decrease in bone mass and alterations in cancellous bone structure. CXCR4 gene ablation increased the number of colony-forming units (CFU), CFU-positive for alkaline phosphatase (CFU-AP(+)), and mineralizing nodules in bone marrow stromal cell (BMSC) cultures. The adipocyte precursor population decreased in BMSCs harvested from the KO animals. The nonadherent population of BMSCs harvested from the long bone diaphysis of KO animals formed more osteoclasts, a finding that was associated with increased circulatory levels of pyridinoline, a marker of bone resorption. Our data show that osteoblast-specific CXCR4 deletion has profound effects on the mesenchymal stem cell pool and allocation to the osteoblastic and adipocytic cell lineages. They also show that CXCL12/CXCR4 signaling in the mature osteoblast can feedback to regulate the osteoclast precursor pool size and play a multifunctional role in regulating bone formation and resorption.Shahnazari, M., Chu, V., Wronski, T. J., Nissenson, R. A., Halloran, B. P. CXCL12/CXCR4 signaling in the osteoblast regulates the mesenchymal stem cell and osteoclast lineage populations.	[Shahnazari, Mohammad; Chu, Vivian; Nissenson, Robert A.; Halloran, Bernard P.] Vet Affairs Med Ctr, Div Endocrinol, San Francisco, CA 94123 USA; [Shahnazari, Mohammad; Nissenson, Robert A.; Halloran, Bernard P.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Wronski, Thomas J.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; State University System of Florida; University of Florida	Halloran, BP (corresponding author), Vet Affairs Med Ctr, Div Endocrinol, 4150 Clement St, San Francisco, CA 94123 USA.	bernard.halloran@ucsf.edu	Shahnazari, Mohammad Reza/AAU-8573-2020	Shahnazari, Mohammad Reza/0000-0001-8647-5426	U.S. Department of Veterans Affairs Merit Review program; Northern California Institute for Research and Education; Veterans Affairs [I01BX001496] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs Merit Review program(US Department of Veterans Affairs); Northern California Institute for Research and Education; Veterans Affairs(US Department of Veterans Affairs)	The CXCR4<SUP>wt/f</SUP> mice were kindly provided by Dr. Yong-Rui Zou (Department of Microbiology, Columbia University College of Physicians and Surgeons, New York, NY, USA). The authors are grateful to Alicia Leeper and Alyssa Williams (University of Florida, Gainesville, FL, USA) for technical assistance with bone histomorphometry. Funds for these studies were provided by the U.S. Department of Veterans Affairs Merit Review program and the Northern California Institute for Research and Education.	Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270; Cao JJ, 2005, J BONE MINER RES, V20, P1659, DOI 10.1359/JBMR.050503; Christopher MJ, 2009, BLOOD, V114, P1331, DOI 10.1182/blood-2008-10-184754; Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251; De Klerck B, 2005, ARTHRITIS RES THER, V7, pR1208, DOI 10.1186/ar1806; Diamond P, 2009, J BONE MINER RES, V24, P1150, DOI [10.1359/jbmr.090210, 10.1359/JBMR.090210]; Hoggatt J, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt54; Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105; Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226; Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Kostenuik PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE1133; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nagasawa T, 2011, TRENDS IMMUNOL, V32, P315, DOI 10.1016/j.it.2011.03.009; Nie YC, 2004, J EXP MED, V200, P1145, DOI 10.1084/jem.20041185; Ono N, 2012, J CELL PHYSIOL, V227, P408, DOI 10.1002/jcp.22986; PARFITT AM, 1988, CALCIFIED TISSUE INT, V42, P284, DOI 10.1007/BF02556360; Parikka V, 2001, ENDOCRINOLOGY, V142, P5371, DOI 10.1210/en.142.12.5371; Peng J, 2008, ENDOCRINOLOGY, V149, P1329, DOI 10.1210/en.2007-0235; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Shinohara K, 2011, J ORTHOP RES, V29, P1064, DOI 10.1002/jor.21374; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021; Zhu W, 2007, J BIOL CHEM, V282, P18676, DOI 10.1074/jbc.M610232200; Zhu W, 2011, J BIOL CHEM, V286, P26794, DOI 10.1074/jbc.M111.250985	27	50	51	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2013	27	9					3505	3513		10.1096/fj.12-225763	http://dx.doi.org/10.1096/fj.12-225763			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	277SV	23704087				2022-12-28	WOS:000328840500011
J	Leelaram, MN; Bhat, AG; Godbole, AA; Bhat, RS; Manjunath, R; Nagaraja, V				Leelaram, Majety Naga; Bhat, Anuradha Gopal; Godbole, Adwait Anand; Bhat, Rajeshwari Subray; Manjunath, Ramanathapuram; Nagaraja, Valakunja			Type IA topoisomerase inhibition by clamp closure	FASEB JOURNAL			English	Article						DNA cleavage-religation; enzyme-DNA heterocatenane; monoclonal antibody; mycobacteria	MYCOBACTERIAL DNA GYRASE; MONOCLONAL-ANTIBODY; SMEGMATIS; ENZYME; MECHANISM; CLEAVAGE; TUBERCULOSIS; SEQUENCE; POISONS; BINDING	Bacterial DNA topoisomerase I (topoI) catalyzes relaxation of negatively supercoiled DNA. The enzyme alters DNA topology through protein-operated DNA gate, switching between open and closed conformations during its reaction. We describe the mechanism of inhibition of Mycobacterium smegmatis and Mycobacterium tuberculosis topoI by monoclonal antibodies (mAbs) that bind with high affinity and inhibit at 10-50 nM concentration. Unlike other inhibitors of topoisomerases, the mAbs inhibited several steps of relaxation reaction, namely DNA binding, cleavage, strand passage, and enzyme-DNA dissociation. The enhanced religation of the cleaved DNA in presence of the mAb indicated closing of the enzyme DNA gate. The formation of enzyme-DNA heterocatenane in the presence of the mAbs as a result of closing the gate could be inferred by the salt resistance of the complex, visualized by atomic force microscopy and confirmed by fluorescence measurements. Locking the enzyme-DNA complex as a closed clamp restricted the movements of the DNA gate, affecting all of the major steps of the relaxation reaction. Enzyme trapped on DNA in closed clamp conformation formed roadblock for the elongating DNA polymerase. The unusual multistep inhibition of mycobacterial topoisomerases may facilitate lead molecule development, and the mAbs would also serve as valuable tools to probe the enzyme mechanism.	[Leelaram, Majety Naga; Bhat, Anuradha Gopal; Godbole, Adwait Anand; Bhat, Rajeshwari Subray; Nagaraja, Valakunja] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; [Manjunath, Ramanathapuram] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; [Nagaraja, Valakunja] Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Nagaraja, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	vraj@mcbl.iisc.ernet.in	Godbole, Adwait/AAM-5736-2021; Godbole, Adwait/V-5526-2018	Majety, Naga Leelaram/0000-0003-2884-4654	Centre of Excellence from the Department of Biotechnology, Government of India	Centre of Excellence from the Department of Biotechnology, Government of India	The authors thank H. K. Majumder (Indian Institute of Chemical Biology) for the kinetoplast DNA; S. Chatterjee and T. K. Kundu (Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India) for atomic force microscopy; the Molecular Biophysics Unit, of the Indian Institute of Science for fluorescence spectrometery; and N. S. Srilatha for surface plasmon resonance spectroscopy. P. Tare is acknowledged for primer extension experiments and T. Bhowmick for discussions. Technical assistance was provided by S. M. Hegde and B. Mallick. Members of the V.N. laboratory are thanked for the reagents, discussions, and critical reading of the manuscript. This work is supported by Centre of Excellence grant in tuberculosis research (to V.N.) from the Department of Biotechnology, Government of India. V. N. is a J. C. Bose Fellow of Department of Science and Technology, Government of India.	BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; Bhaduri T, 1998, NUCLEIC ACIDS RES, V26, P1668, DOI 10.1093/nar/26.7.1668; Bhaduri T, 1998, J BIOL CHEM, V273, P13925, DOI 10.1074/jbc.273.22.13925; Bhat AG, 2009, J MOL BIOL, V393, P788, DOI 10.1016/j.jmb.2009.08.064; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; CARROLL SB, 1982, P NATL ACAD SCI-BIOL, V79, P7233, DOI 10.1073/pnas.79.23.7233; Changela A, 2001, NATURE, V411, P1077, DOI 10.1038/35082615; Chen A Y, 1994, Adv Pharmacol, V29B, P245; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Cheng BK, 2007, J ANTIMICROB CHEMOTH, V59, P640, DOI 10.1093/jac/dkl556; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Drlica K, 2008, ANTIMICROB AGENTS CH, V52, P385, DOI 10.1128/AAC.01617-06; Feinberg H, 1999, NAT STRUCT BIOL, V6, P918; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; Godbole AA, 2012, ARCH BIOCHEM BIOPHYS, V528, P197, DOI 10.1016/j.abb.2012.10.004; GUILHOT C, 1994, J BACTERIOL, V176, P535, DOI 10.1128/JB.176.2.535-539.1994; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; Jain P, 2006, J MOL BIOL, V357, P1409, DOI 10.1016/j.jmb.2006.01.079; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Leelaram MN, 2012, FEBS J, V279, P55, DOI 10.1111/j.1742-4658.2011.08398.x; Leelaram MN, 2010, J IMMUNOL METHODS, V357, P26, DOI 10.1016/j.jim.2010.03.008; Leelaram MN, 2009, TUBERCULOSIS, V89, P256, DOI 10.1016/j.tube.2009.05.004; Li ZY, 2001, MOL CELL, V7, P301, DOI 10.1016/S1097-2765(01)00178-2; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Manjunatha UH, 2005, NUCLEIC ACIDS RES, V33, P3085, DOI 10.1093/nar/gki622; Manjunatha UH, 2001, EUR J BIOCHEM, V268, P2038, DOI 10.1046/j.1432-1327.2001.02077.x; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 2010, BIOCHEMISTRY-US, V49, P9722, DOI 10.1021/bi100907m; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; Nagaraja V, 2002, CURR PHARM DESIGN, V8, P1995, DOI 10.2174/1381612023393567; Nitiss John L, 2002, Curr Opin Investig Drugs, V3, P1512; ORLOWSKI R, 1990, VIROLOGY, V176, P638, DOI 10.1016/0042-6822(90)90036-Q; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sikder D, 2001, J MOL BIOL, V312, P347, DOI 10.1006/jmbi.2001.4942; Unniraman S, 2002, J BACTERIOL, V184, P5449, DOI 10.1128/JB.184.19.5449-5456.2002; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100	45	16	16	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3030	3038		10.1096/fj.12-226118	http://dx.doi.org/10.1096/fj.12-226118			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23612788				2022-12-28	WOS:000329877600011
J	Ramkhelawon, B; Rivas, D; Lehoux, S				Ramkhelawon, Bhama; Rivas, Daniel; Lehoux, Stephanie			Shear stress activates extracellular signal-regulated kinase 1/2 via the angiotensin II type 1 receptor	FASEB JOURNAL			English	Article						endothelial cells; mechanotransduction; caveolin-1; endosomes; receptor internalization	PROTEIN-KINASE; 1A RECEPTOR; INTERNALIZATION; ENDOCYTOSIS; PHOSPHORYLATION; MEMBRANE; CAVEOLAE; BINDING; AT(1); RAB5	Mechanical factors such as strain, pressure, and shear stress are key regulators of cell function, but the molecular mechanisms underlying the detection and responses to such stimuli are poorly understood. Whether the angiotensin II (AngII) AT1 receptor (AT1R) transduces shear stress in endothelial cells (ECs) is unknown. We exposed human umbilical cord endothelial cells (HUVECs) to a shear stress of 0 (control) or 15 dyn/cm(2) for 5 or 10 min. The colocalization of AT1R with caveolin-1 (Cav1), endosomal markers Rab5, EEA1, and Rab7, and lysosomal marker Lamp-1 increased in shear stimulated cells, detected by immunocytochemistry. Shear stress reduced labeling of wild-type mouse ECs (18 +/- 3% of unsheared control, P<0.01) but not Cav1(-/-) ECs (90 +/- 10%) with fluorescent AngII, confirming that internalization of AT1R requires Cav1. Shear stress activated ERK1/2 2-fold (P<0.01), which was prevented by the AT1R blocker losartan. NADPH oxidase inhibition with apocynin prevented both the colocalization of AT1R with Cav1 and the induction of ERK1/2 by shear stress. Moreover, shear-dependent ERK1/2 activation was minimal in CHO cells expressing an AT1Ra mutant that does not internalize, compared with cells expressing wild-type AT1Ra (P<0.05). Hence, AT1R may be an important transducer of shear stress-dependent activation of ERK1/2.	[Ramkhelawon, Bhama] Paris Cardiovasc Res Ctr, Paris, France; [Rivas, Daniel; Lehoux, Stephanie] McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Lady Davis Institute; McGill University	Lehoux, S (corresponding author), McGill Univ, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	stephanie.lehoux@mcgill.ca			Canada Foundation for Innovation; Canada Research Chairs; Canadian Institutes of Health Research (CIHR)	Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Canada Research Chairs(Canada Research ChairsCGIAR); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This work is supported by the Canada Foundation for Innovation, the Canada Research Chairs, and the Canadian Institutes of Health Research (CIHR). The authors thank David Simon for his technical contribution to this work.	ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; Bao XP, 2001, AM J PHYSIOL-HEART C, V281, pH22, DOI 10.1152/ajpheart.2001.281.1.H22; BIANCHI C, 1986, ENDOCRINOLOGY, V119, P1873, DOI 10.1210/endo-119-4-1873; Boyd NL, 2003, AM J PHYSIOL-HEART C, V285, pH1113, DOI 10.1152/ajpheart.00302.2003; CARO CG, 1969, NATURE, V223, P1159, DOI 10.1038/2231159a0; Castier Y, 2005, CIRC RES, V97, P533, DOI 10.1161/01.RES.0000181759.63239.21; Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; de Gasparo M, 2000, PHARMACOL REV, V52, P415; de Toledo M, 2003, MOL BIOL CELL, V14, P4846, DOI 10.1091/mbc.E03-04-0254; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Gould GW, 2009, NAT REV MOL CELL BIO, V10, P287, DOI 10.1038/nrm2652; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hilenski LL, 2004, ARTERIOSCL THROM VAS, V24, P677, DOI 10.1161/01.ATV.0000112024.13727.2c; Horiuchi M, 2012, CLIN SCI, V123, P193, DOI 10.1042/CS20110677; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Kimura T, 2006, J BIOL CHEM, V281, P10598, DOI 10.1074/jbc.M510531200; Kippenberger S, 2005, J BIOL CHEM, V280, P3060, DOI 10.1074/jbc.M409590200; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; Kule CE, 2004, REGUL PEPTIDES, V120, P141, DOI 10.1016/j.regpep.2004.03.001; Lehoux S, 2006, J INTERN MED, V259, P381, DOI 10.1111/j.1365-2796.2006.01624.x; Lemarie CA, 2010, J MOL CELL CARDIOL, V48, P433, DOI 10.1016/j.yjmcc.2009.09.018; Li HW, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2943286; Lopez-Ilasaca M, 2003, MOL BIOL CELL, V14, P5038, DOI 10.1091/mbc.E03-06-0383; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; Miserey-Lenkei S, 2001, MOL ENDOCRINOL, V15, P294, DOI 10.1210/me.15.2.294; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Niwa K, 2006, FREE RADICAL RES, V40, P167, DOI 10.1080/10715760500474287; Oshita A, 2006, HYPERTENSION, V48, P671, DOI 10.1161/01.HYP.0000238141.99816.47; Park H, 2000, AM J PHYSIOL-HEART C, V278, pH1285, DOI 10.1152/ajpheart.2000.278.4.H1285; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Pilecka I, 2011, EXP CELL RES, V317, P1093, DOI 10.1016/j.yexcr.2011.02.002; Ramkhelawon B, 2009, CIRC RES, V105, P869, DOI 10.1161/CIRCRESAHA.109.204040; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Rodman JS, 2000, J CELL SCI, V113, P183; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Shigenaga A, 2008, HYPERTENSION, V52, P672, DOI 10.1161/HYPERTENSIONAHA.108.117341; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Tarbell JM, 2010, CARDIOVASC RES, V87, P320, DOI 10.1093/cvr/cvq146; Thomas WG, 1999, REGUL PEPTIDES, V79, P9, DOI 10.1016/S0167-0115(98)00140-2; Thomas WG, 1998, MOL ENDOCRINOL, V12, P1513, DOI 10.1210/me.12.10.1513; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; ULLIAN ME, 1990, J BIOL CHEM, V265, P195; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; Yasuda N, 2008, EMBO REP, V9, P179, DOI 10.1038/sj.embor.7401157; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang YL, 2009, AM J PHYSIOL-CELL PH, V296, pC1391, DOI 10.1152/ajpcell.00549.2008; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	59	18	19	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2013	27	8					3008	3016		10.1096/fj.12-222299	http://dx.doi.org/10.1096/fj.12-222299			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292BT	23585396				2022-12-28	WOS:000329877600009
